

دریافت نسخه رایگان نرم افزار


مدیریت مطب  
اکسیر

کلیک کنید! <



بهترین نرم افزار مطب





Enhanced  
**DIGITAL  
VERSION**  
Included

# THE **HARRIET LANE** HANDBOOK

THE JOHNS HOPKINS HOSPITAL

CAMILLE C. **ANDERSON**  
SUNAINA **KAPOOR**  
TIFFANY E. **MARK**



ELSEVIER

**TWENTY-THIRD**  
EDITION

Any screen.  
Any time.  
Anywhere.

Activate the eBook version  
of this title at no additional charge.



Elsevier eBooks+ gives you the power to browse, search, and customize your content, make notes and highlights, and have content read aloud.

Unlock your eBook today.

1. Visit <http://ebooks.health.elsevier.com/>
2. Log in or Sign up
3. Scratch box below to reveal your code
4. Type your access code into the “Redeem Access Code” box
5. Click “Redeem”

It's that easy!

Place Peel Off  
Sticker Here

For technical assistance:  
email [textbookscom.support@elsevier.com](mailto:textbookscom.support@elsevier.com)  
call 1-800-545-2522 (inside the US)  
call +44 1 865 844 640 (outside the US)

Use of the current edition of the electronic version of this book (eBook) is subject to the terms of the nontransferable, limited license granted on <http://ebooks.health.elsevier.com/>. Access to the eBook is limited to the first individual who redeems the PIN, located on the inside cover of this book, at <http://ebooks.health.elsevier.com/> and may not be transferred to another party by resale, lending, or other means.

## PEDIATRIC PARAMETERS AND EQUIPMENT

	Premie	Newborn	6 mo	1 yr	2-3 yr	4-6 yr	7-10 yr	11-15 yr	>16 yr
WT (kg)	1-3	2-4	6-8	10	12-16	20-25	25-35	40-50	>50
BAG VALVE MASK	Infant	Infant	Small child	Small child	Child	Child	Child/small adult	Adult	Adult
NASAL AIRWAY (Fr)	12	12	14-16	14-16	14-18	14-18	16-20	18-22	22-36
ORAL AIRWAY	Infant 50 mm	Small 60 mm	Small 60 mm	Small 60 mm	Small 70 mm	Small 70-80 mm	Med 80-90 mm	Med 90 mm	Med 90 mm
BLADE	MIL 0	MIL 0	MIL 1	MIL 1, MAC 2	MIL 1, MAC 2	MIL 2, MAC 2	MIL 2, MAC 2	MIL 2, MAC 3	MIL 2, MAC 3
ETT	2.5-3.0	3.0-3.5	3.5	4.0	4.0-4.5	4.5-5.0	5.5-6.0	6.0-6.5	7.0-8.0
LMA	1	1	1.5	2	2	2.5	2.5-3	3	4
GLIDESCOPE	1	1 or 2	2	2	3	3	3	3 or 4	3 or 4
IV CATH (ga)	22-24	22-24	20-24	20-24	18-22	18-22	18-22	18-20	18-20
CVL (Fr)	3	3-4	4	4-5	4-5	5	5	7	7
NGT/OGT (Fr)	5	5-8	8	10	10-12	12-14	12-14	14-18	14-18
CHEST TUBE (Fr)	10-12	10-12	12-18	16-20	16-24	20-28	20-32	28-38	28-42
FOLEY (Fr)	6	8	8	8	8	8	8	10	12

### ESTIMATED BLOOD PRESSURE BY AGE

Measurement	50 <sup>th</sup> %	5 <sup>th</sup> %
Systolic BP [Diastolic BP is usually 2/3 systolic BP]	$90 + (\text{age} \times 2)$	60 (neonate); 70 (1 mo-1 yr) $70 + (\text{age} \times 2)$ (for 2-10 yr) 90 (>10 yr)
MAP	$55 + (\text{age} \times 1.5)$	$40 + (\text{age} \times 1.5)$

### NORMAL VITAL SIGNS BY AGE

Age	Heart Rate (beats/min)	Blood Pressure (mmHg)	Respiratory Rate (breaths/min)
Premie	120-170	55-75/35-45 (gestational age approximates normal MAP)	40-70
0-3 mo	100-150	65-85/45-55	35-55
3-6 mo	90-120	70-90/50-65	30-45
6-12 mo	80-120	80-100/55-65	25-40
1-3 yr	70-110	90-105/55-70	20-30
3-6 yr	65-110	95-110/60-75	20-25
6-12 yr	60-95	100-120/60-75	14-22
>12 yr	55-85	110-135/65-85	12-18

### ENDOTRACHEAL TUBE FORMULAS

Uncuffed ETT size: $\text{age (years)} / 4 + 4$ ; Cuffed ETT size: $\text{age (years)} / 4 + 3$
ETT depth (from lip to mid-trachea): $\text{ETT internal diameter (size)} \times 3$

### GLASGOW COMA SCALE

Activity	Score	Child/Adult	Score	Infant
Eye opening	4	Spontaneous	4	Spontaneous
	3	To speech	3	To speech/sound
	2	To pain	2	To painful stimuli
	1	None	1	None
Verbal	5	Oriented	5	Coos/babbles
	4	Confused	4	Irritable cry
	3	Inappropriate	3	Cries to pain
	2	Incomprehensible	2	Moans to pain
	1	None	1	None
Motor	6	Obeys commands	6	Normal spontaneous movement
	5	Localizes to pain	5	Withdraws to touch
	4	Withdraws to pain	4	Withdraws to pain
	3	Abnormal flexion	3	Abnormal flexion (decorticate)
	2	Abnormal extension	2	Abnormal extension (decerebrate)
	1	None (flaccid)	1	None (flaccid)

*Adapted from Hunt EA, Nelson-McMillan K, Levin A, O'Brien C, McNamara L, Hutchins L. The Johns Hopkins Children's Center Kids Kard, 2021.*

## RESUSCITATION MEDICATIONS

<b>Adenosine</b> Supraventricular tachycardia	<b>0.1 mg/kg IV/IO RAPID BOLUS (over 1-2 sec), Flush with 10 mL normal saline</b> May repeat at 0.2 mg/kg IV/IO, then 0.3 mg/kg IV/IO after 2 min Max first dose 6 mg, max subsequent dose 12 mg Administer using a 3-way stopcock attached to a 10 mL NS flush Prolonged asystole may occur following administration
<b>Amiodarone</b> Ventricular tachycardia Ventricular fibrillation	<b>5 mg/kg IV/IO</b> No Pulse: Push Undiluted Pulse: Dilute and give over 20-60 minutes Max first dose 300 mg, max subsequent dose 150 mg Max total dose 15 mg/kg/24 hours OR 2200 mg/24 hours Strongly consider pretreating with IV calcium in patients with a pulse to prevent hypotension. Monitor for hypotension after administration
<b>Atropine</b> Bradycardia (increased vagal tone) Primary AV block	<b>0.02 mg/kg IV/IO/IM, 0.04–0.06 mg/kg ETT</b> Max single dose 0.5 mg Repeat once in 5 minutes if needed to max total dose 1 mg. Max total dose 3 mg used in adults. 1 mg/mL concentration recommended for IM or ETT use
<b>Calcium chloride (10% elemental calcium)</b> Hypocalcemia Hyperkalemia Hypermagnesemia Calcium channel blocker overdose	<b>20 mg/kg IV/IO</b> Max dose 1 gram May administer peripherally during an arrest
<b>Calcium gluconate (10% elemental calcium)</b> Hypocalcemia Hyperkalemia Hypermagnesemia Calcium channel blocker overdose	<b>60 mg/kg IV/IO</b> Max dose 3 grams
<b>Dextrose</b> Hypoglycemia	<b>Weight-Based Dosing: 0.5–1 gram/kg</b> <b>Volume-Based Dosing (“Rule of 50”):</b> <b>&lt;5 kg: 10% dextrose 5-10 mL/kg IV/IO</b> <b>5-44 kg: 25% dextrose 2-4 mL/kg IV/IO</b> <b>≥45 kg: 50% dextrose 1-2 mL/kg IV/IO</b> <b>Max single dose 25 grams = 50 mL</b>
<b>Epinephrine</b> Pulseless arrest Bradycardia (symptomatic) Anaphylaxis	<b>0.01 mg/kg IV/IO (0.1 mg/mL) every 3–5 min (max single dose 1 mg)</b> <b>0.1 mg/kg ETT (1 mg/mL) every 3–5 min (max single dose 2.5 mg)</b> <b>Anaphylaxis:</b> <b>0.01 mg/kg IM (1 mg/mL) in thigh every 5-15 min PRN; max single dose 0.5 mg</b> <b>Standardized/Autoinjector:</b> <b>&lt;7.5 kg: no autoinjector, see above</b> <b>7.5 to &lt;15 kg: 0.1 mg IM</b> <b>15 to &lt;30 kg: 0.15 mg IM</b> <b>≥30 kg: 0.3 mg IM</b>
<b>Hydrocortisone</b> Adrenal Crisis/Insufficiency	<b>2 mg/kg IV/IM/IO</b> Max dose 100 mg
<b>Insulin (Regular or Aspart)</b> Hyperkalemia	<b>0.1 units/kg IV/IO with 0.5 gram/kg of dextrose</b> Max dose 5 units Doses less than 5 units require dilution. Consider using a 1 unit/mL dilution.
<b>Lidocaine</b> Antiarrhythmic	<b>1 mg/kg IV/IO, 2-3 mg/kg ETT</b> Max single dose 100 mg May repeat every 5 min to max total dose 3 mg/kg
<b>Magnesium sulfate</b> Torsades de pointes Hypomagnesemia	<b>50 mg/kg IV/IO</b> No Pulse: Dilution recommended; infusion rate dependent on indication Pulse: Dilute and give over 20-60 minutes Max single dose 2 grams Monitor for hypotension/bradycardia

**Naloxone**  
Opioid overdose  
Coma

**Respiratory Depression: 0.001-0.005 mg/kg/dose IV/IO/IM/SUBQ (max 0.1 mg first dose, may titrate to effect)**  
**Full Reversal/Arrest Dose: 0.1 mg/kg IV/IO/IM/SUBQ (max dose 2 mg)**  
ETT dose 2–3 times IV dose, IN dose up to 8 mg. May give every 2 min PRN

**Sodium Bicarbonate**  
**(8.4% = 1 mEq/mL)**

Administer only with clear indication:  
Metabolic acidosis  
Hyperkalemia  
Tricyclic antidepressant overdose

**1 mEq/kg IV/IO**  
≥10kg: Administer undiluted 1 mEq/mL product  
<10kg: Dilute 8.4% sodium bicarbonate 1:1 with sterile water to a final concentration of 4.2% = 0.5 mEq/mL  
Hyperkalemia: Max single dose 50 mEq

ETT Meds (NAVEL: naloxone, atropine, vasopressin, epinephrine, lidocaine)—dilute meds to 5 mL with NS, follow with positive-pressure ventilation.

*Adapted from Hunt EA, Nelson-McMillan K, Levin A, O'Brien C, McNamara L, Hutchins L. The Johns Hopkins Children's Center Kids Kard, 2021; and the American Heart Association. PALS Pocket Card, 2020.*

## IV Infusions\*

Medication	Dose (mCg/kg/min)	Dilution in 100 mL in a	
		Compatible IV Fluid	IV Infusion Rate
Alprostadil (prostaglandin E <sub>1</sub> )	0.05–0.1	0.3 mg/kg	1 mL/hr = 0.05 mCg/kg/min
Amiodarone	5–15	6 mg/kg	1 mL/hr = 1 mCg/kg/min
DOBUTamine	2–20	6 mg/kg	1 mL/hr = 1 mCg/kg/min
DOPamine	5–20	6 mg/kg	1 mL/hr = 1 mCg/kg/min
EPINEPHrine	0.05-2	0.6 mg/kg	1 mL/hr = 0.1 mCg/kg/min
Lidocaine, post resuscitation	20–50	6 mg/kg	1 mL/hr = 1 mCg/kg/min
Phenylephrine	0.1–2, up to 5 in severe circumstances	0.3 mg/kg	1 mL/hr = 0.05 mCg/kg/min
Terbutaline	0.1–4 (up to 10 has been used)	0.6 mg/kg	1 mL/hr = 0.1 mCg/kg/min
Vasopressin (pressor)	0.17–8 milliunits/kg/min	6 units/kg	1 mL/hr = 1 milliunit/kg/min

\*Standardized concentrations and use of smart infusion pumps are recommended when available. For additional information, see Larsen GY, Park HB et. al. Standard drug concentrations and smart-pump technology reduce continuous-medication-infusion errors in pediatric patients. *Pediatrics*. 2005;116(1):e21-e25.

Special thanks to LeAnn McNamara, PharmD for her expert guidance with IV infusion and resuscitation medication guidelines.

This page intentionally left blank

A MANUAL FOR PEDIATRIC HOUSE OFFICERS

---

TWENTY-THIRD  
EDITION

THE  
**HARRIET**  
**LANE**  
HANDBOOK



**JOHNS HOPKINS**  
CHILDREN'S CENTER

This page intentionally left blank

A MANUAL FOR PEDIATRIC HOUSE OFFICERS

---

TWENTY-THIRD  
EDITION

THE  
HARRIET  
LANE  
HANDBOOK

THE HARRIET LANE HOUSE STAFF AT  
THE CHARLOTTE R. BLOOMBERG CHILDREN'S CENTER OF  
THE JOHNS HOPKINS HOSPITAL

**EDITORS**

**CAMILLE C. ANDERSON, MD**

**SUNAINA KAPOOR, MD, MPH**

**TIFFANY E. MARK, MD**



Elsevier  
1600 John F. Kennedy Blvd.  
Ste 1800  
Philadelphia, PA 19103-2899

THE HARRIET LANE HANDBOOK,  
TWENTY-THIRD EDITION  
INTERNATIONAL EDITION

ISBN: 978-0-323-87698-8

ISBN: 978-0-323-87880-7

**Copyright © 2024 by Elsevier Inc. All rights reserved.**

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: [www.elsevier.com/permissions](http://www.elsevier.com/permissions).

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

### Notice

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by Elsevier, authors, editors or contributors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Previous editions copyrighted 2021, 2018, 2015, 2012, 2009, 2005, 2002, 2000, 1996, 1993, 1991, 1987, 1984, 1981, 1978, 1975, 1972, and 1969.

*Senior Content Strategist:* Marybeth Thiel  
*Senior Content Development Manager:* Meghan Andress  
*Publishing Services Manager:* Julie Eddy  
*Senior Project Manager:* Cindy Thoms  
*Design Direction:* Patrick Ferguson

Printed in India



Last digit is the print number: 9 8 7 6 5 4 3 2 1

### **To our families**

Bill and Robin Anderson, thank you for encouraging me to dream big and pursue a life that brings me meaning and joy. You have helped me every step of the way and I love you more than I can say. Tess Anderson, you inspire me every day with your unending well of kindness and generosity – thank you for being a wonderful sister. Jordan Perry, you make all hard things seem possible; I couldn't have done this without you. To the friends who have supported me like family, thank you for being on this journey with me.

Atul and Nupur Kapoor, thank you for the endless sacrifices, constant support, and unconditional love that allowed me to live out my dreams – I owe it all to you. Anirudh Arun, thank you for being the most caring and supportive husband – I cherish our journey of becoming physicians, life partners, and parents together. Ankit Kapoor, thank you for always challenging me to be the best sister, daughter, and doctor I can be. Sheela Kapoor, thank you for being my biggest cheerleader, my fund of virtue, and my rock – I miss you dearly. Mowgli and Meeko, you bring us endless joy. And finally, to my son Ishaan, this is all for you – you are the bright star in our future.

Charlie and Elizabeth Mark, thank you for being my greatest source of encouragement in pursuing my dreams of becoming a medical doctor. I would not be where I am today without your unwavering support all these years. To my brother, Patrick Mark, thank you for being the greatest and most caring older brother, always showing me the importance of family and love. To my extended family and friends, thank you for all the encouragement, kind words, laughter, and joy throughout my life – you all have made this journey possible.

### **To our patients and their families**

Thank you for teaching us and for trusting in us. You have made us pediatricians.

### **To our residents**

Your tireless advocacy and care for our patients inspires us constantly. Thank you for all of the sacrifices you have made.

### **To the wonderful pediatricians who trained us, especially**

Nicole Shilkofski

### **To the Children's Center leaders we have learned from**

Margaret Moon, Tina Cheng, and George Dover

### **To the frontline providers of the COVID-19 pandemic**

Thank you for your bravery in a time of uncertainty.

# Preface

*“Why this child? Why this disease? Why now?”*

—**Barton Childs, MD**

*The Harriet Lane Handbook* was first developed in 1953 after Harrison Spencer (chief resident in 1950–1951) suggested that residents should write a pocket-sized “pearl book.” As recounted by Henry Seidel, the first editor of *The Harriet Lane Handbook*, “Six of us began without funds and without [the] supervision of our elders, meeting sporadically around a table in the library of the Harriet Lane Home.” The product of their efforts was a concise yet comprehensive handbook that became an indispensable tool for the residents of the Harriet Lane Home. Ultimately, Robert Cooke (department chief, 1956–1974) realized the potential of the Handbook and the fifth edition was published for widespread distribution by Year Book. Since that time, the handbook has been regularly updated and rigorously revised to reflect the most up-to-date information and available clinical guidelines. It has grown from a humble Hopkins resident “pearl book” to become a nationally and internationally respected clinical resource. Now translated into many languages, the handbook is still intended as an easy-to-use manual to help pediatricians provide current and comprehensive pediatric care.

Today, *The Harriet Lane Handbook* continues to be updated and revised by house officers for house officers. Recognizing the limit to what can be included in a pocket guide, additional information has been placed online and for use via mobile applications. The online-only content includes references, expanded text, and additional tables, figures, and images.

In addition to including the most up-to-date guidelines, practice parameters, and references, we will highlight some of the most important improvements in the twenty-third edition of *The Harriet Lane Handbook*:

The **Traumatic Injuries** chapter now contains a detailed description of considerations for the primary survey, as well as emergent labs.

The **Neurology** chapter has been reorganized into emergent and chronic or progressive diagnoses and includes a new section on functional neurologic disorders.

The **Analgesia and Procedural Sedation** chapter has a new section detailing the evaluation of pain in children with significant neurological impairment.

The **Infectious Disease** chapter now includes a summary of parasitic and fungal infections.

The **Cardiology and Rheumatology** chapters now include information on diagnosis and management of multisystem inflammatory syndrome in children (MIS-C).

The **Biostatistics** chapter has been restructured to reflect principles of practicing evidence based medicine (EBM).

The **Development, Behavior, and Developmental Disability** chapter now includes information about adverse childhood experiences.

Also new to *The Harriet Lane Handbook* this year are supplemental Harriet Lane Audio Companion Case Files. These audio files adopt a case-based interview format with content experts in order to take a more conversational and discussion-based approach into important topics within pediatrics (see Audio P.1).

*The Harriet Lane Handbook*, designed for pediatric house staff, was made possible by the extraordinary efforts of this year's Johns Hopkins Harriet Lane Pediatric Residency Program senior resident class. It has been an honor to watch these fine doctors mature and refine their skills since internship. They have balanced their busy work schedules and personal lives while authoring the chapters that follow. We are grateful to each of them, along with their faculty advisors, who selflessly dedicated their time to improve the quality and content of this publication. The high quality of this handbook is representative of our residents, who are the heart and soul of our department.

	<b>Chapter</b>	<b>Author</b>	<b>Faculty Advisor</b>
1	Emergency and Critical Care Management	Tai Kyung S. Hairston, MD LeAnn McNamara, PharmD	Justin M. Jeffers, MD, MEHP Nicole Shilkofski, MD, MEd
2	Traumatic Injuries	Radhika Ghodasara, MD	Jennifer F. Anders, MD Paul D. Sponseller, MD, MBA
3	Toxicology	Sophie Crinion, MD	Elizabeth Hines, MD
4	Procedures	Maite E. Del Valle Rolón, MD	Thuy Ngo, DO, MEd
5	Adolescent Medicine	Amitte Rosenfeld, MD Yasamin Ege Sanii, MD	Rachel H. Alinsky, MD, MPH Renata Arrington Sanders, MD, MPH, ScM
6	Analgesia and Procedural Sedation	Alexander Jaksic, MD Divya Madhusudhan, MD	Rajeev Wadia, MD
7	Cardiology	Alexander Tang, MD James Ting, MD	Caridad M. de la Uz, MD William Ravekes, MD W. Reid Thompson III, MD
8	Dermatology	Katherine Cummings, MD Allison Haley, MD	Bernard Cohen, MD
9	Development, Behavior, and Developmental Disability	Brenna M. Beck, MD, MEd Christle Nwora, MD	Harolyn Belcher, MD
10	Endocrinology	Rashmi Pashankar, MD	Kristin Arcara, MD
11	Fluids and Electrolytes	Joniqua Ceasar, MD	Leonard S. Feldman, MD
12	Gastroenterology	Elshaddai Ephrem, MD	Darla Shores, MD, PhD
13	Genetics: Metabolism and Conditions with Distinctive Appearance	Jacqueline Wood, MD, MA	Joann Bodurtha, MD, MPH Ada Hamosh, MD, MPH
14	Hematology	Joan Park, MD	James F. Casella, MD Courtney Elizabeth Lawrence, MD, MS Emily S. Rao, MD, MA, MS
15	Immunology and Allergy	Samantha Leong, MD, PhD	Robert Wood, MD
16	Immunophylaxis	Lindsay Sheets, MD, MPH	Pranita D. Tamma, MD, MHS
17	Microbiology and Infectious Disease	Amali Gunawardana, MD Ashley Wallace Wu, MD	Alice Jenh Hsu, PharmD Sanjay K. Jain, MD John McAteer, DO, MPH Nadine Peart, MD Erica Prochaska, MD
18	Neonatology	Elizabeth Lee, MD	Maureen M. Gilmore, MD

19	Nephrology	Ryan Handoko, MD	Jeffrey Fadrowski, MD, MHS Cozumel Pruette, MD, MHS, MS
20	Neurology	Hannah E. Edelman MD, PhD Maera J. Stratton, MD	Matthew J. Elrick, MD, PhD Eric H. Kossoff, MD Christopher Oakley, MD Lisa R Sun, MD
21	Nutrition and Growth	Audrey Companiony Hopkins, MD	Darla Shores, MD, PhD Jennifer Thompson, MS, RD, CSP, LDN
22	Oncology	Lawrence Gersz MD, MBA Rebecca Xi, MD	Nicole Arwood, PharmD Stacy Cooper, MD
23	Palliative Care	Sapna Desai, MD	Melanie L. Brown, MD, MSE Matt Norvell, MDiv, BCC
24	Psychiatry	Jelina Marie V. Castillo, MD, MPH	Nadia Zaim, MD
25	Pulmonology and Sleep Medicine	Saskia Groenewald, MD	Laura M. Sterni, MD
26	Radiology	Urveel Mukesh Shah, MD	Emily A. Dunn, MD
27	Rheumatology	Emma Vaimberg, MD	Ekemini Akan Ogbu, MD, MSc
28	Blood Chemistry and Body Fluids	Camille C. Anderson, MD	Nadia Ayala-Lopez, PhD Lori Sokoll, PhD
29	Biostatistics and Evidence-Based Medicine	Michael R. Rose, MD, MPH	Leonard S. Feldman, MD
30	Drug Dosages	Carlton K.K. Lee, PharmD, MPH	
31	Drugs in Kidney Failure	Elizabeth A.S. Goswami, PharmD Katherine Hapgood, PharmD	Carlton K.K. Lee, PharmD, MPH

**HARRIET LANE AUDIO COMPANION CASE FILE AUTHORS**

<b>Audio Case File</b>	<b>Associated Chapter</b>	<b>Author(s)</b>	<b>Content Expert</b>
P.1 Introduction to Audio Case Files		Camille C. Anderson, MD, Sunaina Kapoor, MD, MPH, and Tiffany E. Mark, MD	
1.1 Advocacy, gun violence, and healthcare utilization	Emergency and Critical Care Management	Rachel Darko, MD	Katherine E. Hoops, MD, MPH
3.1 Pediatric ingestions, workup, and management	Toxicology	Zainab Khan, MD	Roselyn Appenteng, MD
5.1 An interactive walk through the HEADSS assessment, and next steps	Adolescent Medicine	Andrea Silvas, MD	Errol Fields, MD, PhD, MPH
6.1 Medications for analgesia and sedation	Analgesia and Procedural Sedation	Matthew Kosasih, MD	Sapna Kudchadkar, MD, PhD
7.1 Auscultation and heart sounds	Cardiology	Kyla Cordrey, MD Rebecca Dyer, MD	W. Reid Thompson III, MD
7.2 Tetralogy of Fallot: Review of the congenital heart disease and accompanying cardiac surgeries	Cardiology	Fred Lam, MD	W. Reid Thompson III, MD
12.1 A framework for gastrointestinal bleeding by age	Gastroenterology	Kaysha Henry, MD, MPH	Steven Miller, MD
13.1 Newborn screening	Genetics: Metabolism and Conditions With Distinctive Appearance	Nadav Weinstock, MD, PhD	Shira G. Ziegler, MD, PhD

14.1 Hemophilia & Efficizumab	Hematology	Anna Bitners, MD	Courtney Lawrence, MD
17.1 Resistance mechanisms in Gramnegative rods	Microbiology and Infectious Disease	Ashley Wallace Wu, MD and Amali Gunawardana, MD	John McAteer, DO, MPH
18.1 Ventilation strategies in the neonatal ICU	Neonatology	Megan Gates, MD	Kartikeya Makker, MBBS
20.1 Seizure mimics: an age-based approach	Neurology	Maria Molinaro, MD Molly Himmelrich, MD Alexander Testino, MD	Eric H. Kossoff, MD
21.1 Pediatric food insecurity	Nutrition and Growth	Edward Corty, MD	Melissa Lutz, MD
22.1 Initial presentation and workup of acute lymphoblastic leukemia	Oncology	Katelyn Williams, MD Nathaniel J. Silvestri, MD	Michelle Hudspeth, MD
23.1 End of life decision making in the adolescent palliative care patient	Palliative Care	Juliet Joseph, MD	Emily Johnson, CRNP
27.1 A systematic approach to differentiating the various childhood arthritic conditions	Rheumatology	Tolulope Fatola, MD	Julia F. Shalen, MD
29.1 Evidence based medicine: A discussion on race-based clinical practice guidelines	Biostatistics and Evidence-Based Medicine	Rafi Faria, MD Cecilia Di Caprio, MD	Marquita Genies, MD, MPH

The Formulary is complete, concise, and up-to-date thanks to the tireless efforts of Carlton K.K. Lee, PharmD, MPH. With each edition, he carefully updates, revises, and improves the section. His herculean efforts make the Formulary one of the most useful and cited pediatric drug reference texts available.

We are grateful and humbled to have the opportunity to build on the great work of the preceding editors: Drs. Henry Seidel, Harrison Spencer, William Friedman, Robert Haslam, Jerry Winkelstein, Herbert Swick, Dennis Headings, Kenneth Schuberth, Basil Zitelli, Jeffery Biller, Andrew Yeager, Cynthia Cole, Peter Rowe, Mary Greene, Kevin Johnson, Michael Barone, George Siberry, Robert Iannone, Veronica Gunn, Christian Nechyba, Jason Robertson, Nicole Shilkofski, Jason Custer, Rachel Rau, Megan Tschudy, Kristin Arcara, Jamie Flerlage, Branden Engorn, Helen Hughes, Lauren Kahl, Keith Kleinman, Lauren McDaniel, and Matthew Molloy. Many of these previous editors continue to make important contributions to the education of the Harriet Lane house staff, none more than Dr. Nicole Shilkofski, our residency program director. Her dedication to the residents and to educating future pediatricians impresses us constantly. As recent editors, Drs. Keith Kleinman, Lauren McDaniel, and Matthew Molloy also have been instrumental in helping us to navigate this process. We are honored to follow in their footsteps.

An undertaking of this magnitude could not have been accomplished without the support and dedication of some extraordinary people. First, we would like to thank Dr. Nicole Shilkofski, our residency program director, and our associate residency program directors: Drs. Jeffrey Fadrowski, Marquita Genies, Cozumel Pruette, and Nakiya Showell. Thank you for entrusting us with the opportunity to serve as chief residents and *The Harriet Lane*

*Handbook* editors. We would also like to offer special thanks to our program coordinators: Kathy Mainhart and Yinka Omosule, invaluable assets to our program. We are so appreciative of your support and without you, we would be lost. And finally, thank you to our Department Director, Dr. Margaret Moon, for your tireless leadership of the Children’s Center.

<b>Residents</b>	<b>Interns</b>
Saher Ali	Ricci Allen
Halei Benefield	Danielle Amundsen
Anna Bitners	Sarah Benett
Kyla Cordrey	Alec Berman
Edward Corty	David Berman
Rachel Darko	Rikiara Brown
Ian Drummond	
Rebecca Dryer	Carolei Bryan
Tolulope Fatola	Amber Bulna
Devki Gami	Cecilia Di Caprio
Megan Gates	Chizorbam Diribe
Ross Gilbert	Sarah Ehrenberg
Jillian Heckman	Rafi Faria
Laura Henderson	Whitney Fidelis
Kaysha Henry	Jeanette Freeman
Molly Himmelrich	Elena Georges
Zainab Khan	Rachel Gilbert
Andrew Kleist	Dana Goplerud
Matthew Kosasih	Adrienne Johnson
Jacqueline Kruglyakova	Juliet Joseph
Fred Lam	Adam Ketchum
Vianca Masucci	Andrew Koltun
Maria Molinaro	Chiara Pandolfi de Rinaldis
Teresa Oszkinis	Zaw Phyo
Roshni Patel	Megan Rescigno
Kristen Penberthy	
Mallika Rajamani	Claire Rhee
Maneesha Sakhuja	Harper Robinson
Nisha Shah	Sarika Sachdeva
Andrea Silvas	Raquel Sofia Sandoval
Nathaniel Silvestri	Vincent Shieh
William Squiers	Rohan Soman
Alexander Testino	Anthony Spellman
Nadav Weinstock	Melissa Trofa
Katelyn Williams	Sarah Vogel
	Priscilla Yong

**Camille C. Anderson**  
**Sunaina Kapoor**  
**Tiffany E. Mark**

# Contents

## **PART I Pediatric Acute Care**

- 1** Emergency and Critical Care Management, 3  
*Tai Kyung Hairston, MD and LeAnn McNamara, PharmD*
- 2** Traumatic Injuries, 36  
*Radhika Ghodasara, MD*
- 3** Toxicology, 66  
*Sophie Crinion, MD*
- 4** Procedures, 75  
*Maite E. Del Valle Rolón, MD*

## **PART II Diagnostic and Therapeutic Information**

- 5** Adolescent Medicine, 115  
*Yasamin Ege Sanii, MD and Amitte Rosenfeld, MD*
- 6** Analgesia and Procedural Sedation, 151  
*Alexander James Jaksic, MD and Divya Madhusudhan, MD*
- 7** Cardiology, 172  
*Alexander Tang, MD and James Ting, MD*
- 8** Dermatology, 209  
*Allison Haley, MD and Katherine Cummings, MD*
- 9** Development, Behavior, and Developmental Disability, 236  
*Brenna M. Beck, MD, MEd and Christle Nwora, MD*
- 10** Endocrinology, 261  
*Rashmi Pashankar, MD*
- 11** Fluids and Electrolytes, 294  
*Joniqua Ceasar, MD*
- 12** Gastroenterology, 318  
*Elshaddai Ephrem, MD*
- 13** Genetics: Metabolism and Conditions With Distinctive Appearance, 336  
*Jacqueline Wood, MD, MA*
- 14** Hematology, 365  
*Joan Park, MD*
- 15** Immunology and Allergy, 408  
*Samantha E. Leong, MD, PhD*
- 16** Immunoprophylaxis, 423  
*Lindsay Sheets, MD, MPH*
- 17** Microbiology and Infectious Disease, 454  
*Amali Gunawardana, MD and Ashley Wallace, Wu, MD*

- 18** Neonatology, 503  
*Elizabeth Lee, MD*
- 19** Nephrology, 529  
*Ryan Handoko, MD*
- 20** Neurology, 570  
*Hannah E. Edelman, MD, PhD and Maera J. Stratton, MD*
- 21** Nutrition and Growth, 594  
*Audrey Companiony Hopkins, MD*
- 22** Oncology, 618  
*Lawrence Gersz, MD, MBA and Rebecca Xi, MD*
- 23** Palliative Care, 640  
*Sapna Desai, MD*
- 24** Psychiatry, 648  
*Jelina Marie V. Castillo, MD, MPH*
- 25** Pulmonology and Sleep Medicine, 663  
*Saskia Groenewald, MD*
- 26** Radiology, 687  
*Urveel Mukesh Shah, MD*
- 27** Rheumatology, 710  
*Emma Vaimberg, MD*

**PART III Reference**

- 28** Blood Chemistry and Body Fluids, 735  
*Camille C. Anderson, MD*
- 29** Biostatistics and Evidence-Based Medicine, 746  
*Michael R. Rose, MD, MPH*

**PART IV Formulary**

- 30** Drug Dosages, 761  
*Carlton K.K. Lee, PharmD, MPH*
- 31** Drugs in Kidney Failure, 1196  
*Elizabeth A.S. Goswami, PharmD and Katherine Hapgood, PharmD*

Index, 1209

# PART I

## PEDIATRIC ACUTE CARE



This page intentionally left blank

# Chapter 1

## Emergency and Critical Care Management

*Tai Kyung Hairston, MD and LeAnn McNamara, PharmD*

 See additional content online.

 **Audio Case File 1.1** Advocacy, gun violence, and healthcare utilization

This chapter is presented in accordance with the universal acronym **C-A-B** (compressions/circulation, airway, breathing) to emphasize the reduction of “no blood flow” time.<sup>1-3</sup> However, given the high prevalence of asphyxial cardiac arrest in the pediatric population, ventilation remains fundamental to the resuscitation of the critically ill child.<sup>4</sup> This chapter functions as a guide to caring for “sick” children, spanning the principles of resuscitation and stabilization, as well as management of the most common pediatric medical emergencies.

### I. APPROACH TO THE UNRESPONSIVE CHILD

#### A. Circulation<sup>1-3,5-11</sup>

1. Assessment
  - a. **Pulse:** Spend no more than **10 seconds** assessing pulse. Assess brachial pulse in infants, carotid or femoral pulse in children.
  - b. **Perfusion:** Check for pallor, mottling, or cyanosis. Capillary refill time >2 seconds is delayed and <1 to 2 seconds or “flash” may indicate warm shock.
  - c. **Rate:** Bradycardia **<60 beats/min** with **poor perfusion** requires immediate cardiopulmonary resuscitation (CPR). Tachycardia **>220 beats/min** suggests pathologic tachyarrhythmia.
  - d. **Rhythm:** Attach patient to defibrillator or continuous electrocardiography. In arrest, check rhythm every 2 minutes with minimal interruptions in chest compressions (e.g., during compressor change).
  - e. **Blood pressure (BP):** Hypotension in a pediatric patient is a **late** manifestation of circulatory compromise.
  - f. **Urine output:** Normal output is 1.5 to 2 mL/kg/hr in infants and young children and 1 mL/kg/hr in older children.
2. Management: Initiate CPR immediately if patient is pulseless or bradycardic (<60 beats/min) with poor perfusion.
  - a. **Chest compressions:** See [Box 1.1](#) for an outline of the five components of **high-quality CPR**.

**BOX 1.1****FIVE COMPONENTS OF HIGH-QUALITY CARDIOPULMONARY RESUSCITATION**

- “Push fast”: Target rate of **100–120 compressions/min.**
- “Push hard”: Target depth of **at least  $\frac{1}{3}$  anteroposterior diameter of chest.**
  - Place step stool at side of bed to assist compressor.
  - Slide backboard under patient or place on hard surface.
  - Use the compression technique that achieves the best results.
    - Consider two-handed, one-handed, two-finger, or two-thumb-encircling hands techniques.
  - Aim for 1 fingerbreadth below intermammary line in infants, 2 fingerbreadths in prepubertal children, and the lower half of the sternum in adolescents.
- Allow **full chest recoil** between compressions.
- **Minimize interruptions** in chest compressions.
  - Rotate compressor every 2 min or sooner if fatigued.
  - Check cardiac rhythm at time of compressor change.
- Avoid excessive ventilation.
  - If no advanced airway (endotracheal tube, laryngeal mask airway, tracheostomy) secured, perform **30:2 compression-ventilation ratio** (with single rescuer or for any adolescent/adult) or **15:2 ratio** (in an infant/child only if 2 rescuers present).
  - If advanced airway secured, give **one breath every 2–3 sec (20–30/min)** with continuous compressions.
  - Ventilation volume should produce no more than minimal, visible chest rise.

- b. **Monitoring:** Continuous capnography and invasive hemodynamic monitoring may guide effectiveness of chest compressions.
- (1) Target **end-tidal CO<sub>2</sub> (EtCO<sub>2</sub>) >20 mmHg.** If consistently less than 20 mmHg, improve compressions and assess for excessive ventilation.
  - (2) Abrupt and sustained rise in EtCO<sub>2</sub> is often observed just prior to clinical return of spontaneous circulation (ROSC).
  - (3) If a patient has an indwelling arterial catheter, assess waveform for feedback to evaluate chest compressions. Target **diastolic BP >25 mmHg** in infants and **>30 mmHg** in children.
- c. **Defibrillation:** Shockable arrest rhythms include **ventricular fibrillation** and **pulseless ventricular tachycardia.** Nonshockable arrest rhythms include asystole, pulseless electrical activity, and bradycardia with poor perfusion.
- (1) Use age- and size-appropriate pads as recommended per manufacturer.
  - (2) Initial shock dose is **2 J/kg**, second dose is **4 J/kg**, subsequent doses are **≥4 J/kg (maximum 10 J/kg or adult maximum dose).**
- d. **Cardioversion:** A synchronized electrical shock delivered for hemodynamically **unstable** patients with **tachyarrhythmias** (i.e., supraventricular tachycardia, atrial flutter, ventricular tachycardia) and **palpable pulses.**
- (1) Initial dose is **0.5 to 1 J/kg.** Increase to **2 J/kg** if ineffective, repeating doses if necessary. Reevaluate diagnosis if rhythm does not convert to sinus.

- (2) Consultation with a pediatric cardiologist is recommended for elective cardioversion for stable patients with tachyarrhythmias.
- e. Resuscitation
- (1) **Access:** Place intraosseous access immediately if in arrest or if intravenous (IV) access difficult.
- (a) If previously established, central access is preferred for drug administration.
- (b) Endotracheal tube (ETT) drug administration is acceptable if required. Naloxone, atropine, vasopressin, epinephrine, and lidocaine (NAVEL) can be administered via endotracheal route.
- (2) **Pharmacotherapy:** See [Table 1.1](#) detailing medications for pediatric resuscitation. If actual body weight is unavailable, use length-based habitus-modified (e.g., Mercy method, PAWPER tape) estimation methods, parental estimates, or length-based (e.g., Broselow tape) estimation methods, in order of accuracy.
- (a) For nonshockable rhythms, early epinephrine administration after CPR initiation (within 5 minutes) is recommended.
- (3) **Fluids:** Administer isotonic crystalloid for treatment of shock even if BP is normal.
- (a) Administer up to 60 mL/kg of isotonic crystalloid in 20 mL/kg increments in nonneonates during the first 20 minutes until perfusion improves. Frequently reassess for hepatomegaly, pulmonary crackles, and respiratory distress.
- (b) Special consideration for **cardiogenic shock:**
- (i) Administer an initial fluid bolus of 5 to 10 mL/kg over 10 to 20 minutes if cardiac insufficiency suspected or unknown (consider in neonate).
- (ii) Be prepared to support oxygenation and ventilation in case of pulmonary edema.
- (c) Special consideration for **septic shock:** Specific goals of therapy include ScvO<sub>2</sub> (central venous saturation) ≥70%, adequate BP, normalized heart rate (HR), and appropriate end-organ perfusion.
- (i) Administer balanced fluid in 10 mL/kg or 20 mL/kg aliquots with frequent reassessment. Lactated Ringer's solution (LR) preferred.
- f. **Extracorporeal-CPR (E-CPR):** Rapid deployment of venoarterial (VA) or venovenous (VV) extracorporeal membrane oxygenation (ECMO) to artificially provide oxygenation, ventilation, and circulation as a means of CPR for in-hospital arrest refractory to conventional interventions. Contraindications are limited but may include extremes of prematurity or low birth weight, lethal chromosomal abnormalities, uncontrollable

TABLE 1.1

PEDIATRIC RESUSCITATION MEDICATIONS<sup>5,7,13,19</sup>

Medication	Indication	Dosing	Mechanism	Side Effects
Adenosine	SVT secondary to AV node reentry or accessory pathways	Initial: 0.1 mg/kg IV (max 6 mg) Sec: 0.2 mg/kg IV (max 12 mg) Third: 0.3 mg/kg IV (max 12 mg) Wait 2 min between doses Administer with three-way stopcock rapid push/flush technique	Purine nucleoside blocks AV node conduction	Brief period of asystole (10–15 sec)
Amiodarone	Shock-refractory VF or pVT, refractory SVT	5 mg/kg (max 300 mg) IV/IO No pulse: Push undiluted dose Pulse: Dilute and run over 20–60 min Repeat dosing: 5 mg/kg (max 150 mg) up to 15 mg/kg total Infusion: 5–15 mCg/kg/min (max 15 mg/kg/day or 2200 mg/day)	Potassium-channel blockade suppresses AV node, prolongs QT and QRS	Risk of polymorphic VT, hypotension, decreased cardiac contractility
Atropine	Bradycardia from increased vagal tone, cholinergic drug toxicity, second- and third-degree AV block	0.02 mg/kg IV/IO/IM (min 0.1 mg/dose, max 0.5 mg/dose; larger doses may be needed for organophosphate poisoning) or 0.04–0.06 mg/kg ET Repeat dosing: May repeat once after 5 min; max total dose 1 mg (child). Max total dose 3 mg used in adults.	Cholinergic blockade accelerates atrial pacemakers, enhances AV conduction	Tachycardia, risk of myocardial ischemia, paradoxical bradycardia with lower than minimal dosing
Calcium chloride	Hypocalcemia, hyperkalemia, hypermagnesemia, calcium channel blocker overdose	20 mg/kg (max 1 g) IV/IO Administer over 5 min Consider calcium gluconate in nonarrest if access is peripheral only	Binds myocardial troponin to increase cardiac contractility	Risk of myocardial necrosis, severe tissue injury with peripheral infiltration
Dextrose	Documented hypoglycemia	0.5–1 g/kg IV/IO Newborn: 5–10 mL/kg D <sub>10</sub> W Infants, children: 2–4 mL/kg D <sub>25</sub> W Adolescents: 1–2 mL/kg D <sub>50</sub> W	Restores energy metabolite	Risk of poor neurologic outcomes in setting of hyperglycemia

Epinephrine	Asystole, PEA, VF, pVT, diastolic hypotension, bradycardia	Bolus: 0.01 mg/kg IV/IO (0.1 mg/mL; max 1 mg) or 0.1 mg/kg ET (1 mg/mL; max 2.5 mg) Repeat dosing: Bolus every 3–5 min as needed Infusion: 0.05–2 mCg/kg/min	$\alpha$ -agonism increases aortic diastolic pressure and coronary perfusion	Tachycardia, ectopy, tachyarrhythmias, hypertension
Lidocaine	Shock-refractory VF or pVT (second-line after amiodarone)	Bolus: 1 mg/kg (max 100 mg) IV/IO, 2–3 mg/kg ET Repeat dosing: 1 mg/kg (max 100 mg) every 5 min up to 3 mg/kg in first hr Infusion: 20–50 mCg/kg/min	Sodium-channel blockade decreases automaticity	Myocardial depression, altered mental status, seizures, muscle twitching
Magnesium sulfate	Torsades de pointes, hypomagnesemia	50 mg/kg (max 2 g) IV/IO No pulse: Dilution recommended; infusion rate dependent on indication Pulse: Dilute and administer over 20–60 min	Calcium antagonist depresses abnormal secondary depolarizations and AV node conduction	Hypotension, bradycardia
Naloxone	Opioid overdose	Full reversal: 0.1 mg/kg/dose (max 2 mg/dose) IV/IO/IM/SUBQ, 0.2 mg/kg to 1 mg/kg/dose ET, or 2–8 mg IN (use full applicator available) Repeat dosing: every 2 min as needed	Opioid antagonist reverses opioid-induced respiratory depression, sedation, analgesia, and hypotension	Rapid withdrawal, agitation, pain, pulmonary edema
Procainamide	Refractory SVT, atrial flutter, atrial fibrillation, VT	Load: 15 mg/kg IV/IO, infuse over 30–60 min Infusion: 20–80 mCg/kg/min (max 2 g/24 hr)	Sodium-channel blockade prolongs effective refractory period, depresses conduction velocity	Proarrhythmic, polymorphic VT, hypotension
Sodium bicarbonate	Routine use in arrest is <b>not</b> recommended; hyperkalemia, arrhythmias in tricyclic overdose	1 mEq/kg IV/IO Hyperkalemia: Max single dose 50 mEq	Buffers acidosis by binding hydrogen ions to improve myocardial function, reduce SVR and inhibit defibrillation	May impair tissue oxygen delivery, hypokalemia, hypocalcemia, hypernatremia, impaired cardiac function

AV, Atrioventricular;  $D_{10}W$ , dextrose 10% in water; ET, endotracheal; HR, heart rate; ICP, intracranial pressure; IM, intramuscular; IO, intraosseous; IV, intravenous; IN, intranasal; mCg, microgram; PEA, pulseless electrical activity; pVT, pulseless ventricular tachycardia; SUBQ, subcutaneous; SVR, systemic vascular resistance; SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia.

hemorrhage, or irreversible brain damage. Should not be offered if likely to be futile.

- g. **Post—cardiac arrest care:** Postresuscitation care optimizes oxygenation and perfusion, preserves organ function, and maintains blood glucose levels.
- (1) Obtain chest x-ray to verify ET tube placement, arterial blood gas to correct acid/base disturbances, hemoglobin and hematocrit to assess need for transfusion.
  - (2) Maintain oxygen saturation between 94% and 99% and PaCO<sub>2</sub> between 35 and 45 mmHg or appropriate to the patient's underlying condition.
  - (3) Monitor core temperature continuously and prevent/treat fever to reduce metabolic demand.
    - (a) For comatose patients after out-of-hospital cardiac arrest, either maintenance of normothermia or controlled therapeutic hypothermia may be reasonable.
  - (4) Maintain systolic blood pressure >5th percentile for age.
  - (5) Continuous electroencephalography (EEG) is recommended for the detection of seizures following cardiac arrest in patients with persistent encephalopathy.
  - (6) It is recommended that pediatric cardiac arrest survivors be evaluated for rehabilitation services.

## **B. Airway and Breathing<sup>1,7,8,13-19</sup>**

### 1. Assessment

- a. **Airway patency:** Perform head tilt and chin lift or jaw thrust to open airway. Avoid overextension in infants.
- b. **Spontaneous respirations:** Assess spontaneous patient effort.
  - (1) If the patient is breathing regularly, place the patient in **recovery position** (turn onto side).
  - (2) If the patient has a palpable pulse but inadequate breathing, give 1 rescue breath every 2 to 3 seconds (20–30 breaths/min).
  - (3) When performing CPR in infants and children with an advanced airway, target a respiratory rate range of 1 breath every 2 to 3 seconds (20–30 breaths/min), accounting for age and clinical condition. Rates exceeding this may compromise hemodynamics.
- c. **Adequacy of respiration:** Evaluate for symmetric chest rise. Auscultate for equal breath sounds with good aeration.
- d. **Distress:** Recognize tachypnea, grunting, flaring, retractions, stridor, or wheeze. Infants may exhibit head bobbing.

### 2. Securing airway

- a. **Bag-Valve-Mask ventilation (BVM):** May be used indefinitely if ventilating effectively.
  - (1) Avoid pushing mask down, which can obstruct airway. Bring face into mask.

- (2) Consider **oropharyngeal** airway in the **unconscious** patient with obstruction. Correct size will extend from corner of mouth to mandibular angle.
  - (3) Consider **nasopharyngeal** airway in the **conscious** (gag reflex intact) or unconscious patient with obstruction. Correct size will extend from tip of nose to tragus of ear.
  - (4) Cricoid pressure (Sellick maneuver) may be used to minimize gastric inflation and aspiration. Avoid excess pressure leading to tracheal obstruction.
- b. **Laryngeal mask airway (LMA):** Supraglottic airway placed blindly. Useful to emergently secure access to a difficult airway.
- (1) Use manufacturer-specific weight-based mask size estimation systems or the combined width of the patient's index, middle, and ring fingers to estimate mask size.
  - (2) Continuous chest compressions can be performed once LMA is placed.
- c. **Endotracheal intubation:** Rapid sequence intubation is indicated in patients presenting with (presumed) full stomach. Immediately sequential sedation and neuromuscular blockade help to avert the need for positive pressure ventilation, minimizing aspiration risk.
- (1) **Preparation:** Always have a secondary plan to manage the airway if intubation is unsuccessful.
    - (a) **Preoxygenation:** Deliver 100% oxygen via a nonrebreather mask for at least 3 minutes. Children have higher oxygen consumption than adults and can rapidly become hypoxemic.
    - (b) **Equipment:** Collect monitoring, suctioning, and oxygen delivery equipment.
      - (i) If available, quantitative **EtCO<sub>2</sub>** is recommended as primary method to confirm ventilation.
      - (ii) Place suction catheter at head of bed. Set suction device from **−80 mmHg to −120 mmHg**.
      - (iii) Consider nasogastric tube for stomach decompression. See [Chapter 4](#) for placement.
    - (c) **Airway supplies:** Use cuffed ETTs over uncuffed ETTs for intubating infants and children. When a cuffed ETT is used, attention should be paid to ETT size, position, and cuff inflation pressure (<20–25 cm H<sub>2</sub>O).
      - (i) If available, use a length-based estimator (e.g., Broselow tape) of ETT size and laryngoscope blade size.
      - (ii) To estimate age-based ETT size (internal diameter) for patients 2 to 10 years:

Cuffed ETT(mm) = (age in years/4) + 3.5

Uncuffed ETT(mm) = (age in years/4) + 4.0

(iii) To approximate depth of insertion:

Depth(cm) = ETT size × 3

(iv) Choose laryngoscope blade type and size based on patient age and airway.

(v) Straight (i.e., Miller) blades are typically reserved for children <2 years age or difficult airways.

(a) Miller #00-1 for premature to 2 months age

(b) Miller #1 for 3 months to 3 years age

(c) Miller #2 for >3 years age

(vi) Curved (i.e., Mac) laryngoscope blades are often more effective for children >2 years age.

(a) Mac #2 for >2 years age

(b) Mac #3 for >8 years age

(d) **Pharmacology:** See [Table 1.2](#) for rapid sequence intubation medications.

(e) **Positioning:** Place patient in “sniffing” position with neck slightly extended to align the airway.

(i) Infants and toddlers may require towel roll beneath **shoulders** due to large occiput.

(ii) Children and adolescents may require towel roll beneath **neck**.

(2) **Procedure:** Advanced airways should be placed by experienced healthcare providers with appropriate training.

(a) Routine use of cricoid pressure is not recommended during endotracheal intubation of pediatric patients.

(b) Confirm placement by detecting EtCO<sub>2</sub>, observing chest wall movement, auscultating for symmetric breath sounds, and monitoring oxygen saturation. Evaluate placement via chest radiograph.

(3) **Failure:** Acute respiratory failure in an intubated patient may signify **D**isplacement of the ETT, **O**bstruction, **P**neumothorax, or **E**quipment failure (**DOPE**).

d. **Surgical airway:** Consider needle or surgical cricothyrotomy if BVM, endotracheal intubation, and LMA fail. If available, consult emergently with difficult airway specialists (pediatric anesthesiologist, intensivist, and/or otolaryngologist).

3. Oxygenation and ventilation

a. Oxygen delivery systems:

(1) Low-flow systems (e.g., nasal cannula, simple face mask) **do not meet** the inspiratory flow demand of the patient. Delivery of set fraction of inspired oxygen (FiO<sub>2</sub>) is difficult due to room air mixing.

**TABLE 1.2****RAPID SEQUENCE INTUBATION MEDICATIONS** <sup>13,17-19,22</sup>

Medication	Benefit	Indication	Dosing	Side Effects
<b>1. ADJUNCTS</b>				
Atropine	Prevent bradycardia associated with laryngoscope insertion, decrease oral secretions	Bradycardia in any patient, infants <1 year, children 1–5 years receiving succinylcholine, children >5 years receiving a second dose of succinylcholine	0.02 mg/kg IV/IO/IM (max 0.5 mg)	Tachycardia, pupil dilation
Glycopyrrolate	Decrease oral secretions, prevent bradycardia; may cause less tachycardia than atropine, preserves pupillary exam in trauma	Hypersalivation	0.004–0.01 mg/kg IV/IM/IO (max 0.1 mg)	Tachycardia
Lidocaine	Blunts rise in ICP associated with laryngoscopy	Elevated ICP, shock, arrhythmia, and status asthmaticus	1 mg/kg IV/IO (max 100 mg)	Myocardial depression, altered mental status, seizures, muscle twitching
<b>2. INDUCTION AGENTS</b>				
Etomidate (sedative)	Minimal cardiovascular side effects, minimally decreases ICP	Multitrauma patient at risk for increased ICP and hypotension Caution in patients with adrenal suppression; avoid in septic shock	0.3 mg/kg IV/IO (max 20 mg)	Suppresses adrenal corticosteroid synthesis, vomiting, myoclonus, lowers seizure threshold
Fentanyl (analgesic, sedative)	Minimal cardiovascular effect	Shock	1–5 mCg/kg slow IV/IM push (max 100 mCg)	Chest wall rigidity, bradycardia, respiratory depression
Ketamine (sedative, analgesic)	Catecholamine release causes bronchodilation, abates bradycardia associated with laryngoscope insertion, increases HR and SVR, produces a “dissociative amnesia”	Status asthmaticus, shock and hypotensive patients Caution in patients at risk for elevated ICP or glaucoma history	1–2 mg/kg IV/IO (max 150 mg) 4–6 mg/kg IM	Vomiting, laryngospasm, hypersalivation, emergence reactions (hallucinations)

*Continued*

TABLE 1.2

RAPID SEQUENCE INTUBATION MEDICATIONS<sup>13,17-19,22</sup>—CONT'D

Medication	Benefit	Indication	Dosing	Side Effects
Midazolam (sedative, amnestic, anxiolytic)	Minimal cardiovascular effect	Mild shock	0.05–0.1 mg/kg IV/IM/IO (max single dose 6–10 mg depending on age (see Formulary))	Dose-dependent respiratory depression, hypotension
Propofol (sedative)	Ultra-short acting	Avoid in shock or patients who require maintenance of CPP	2 mg/kg IV	Hypotension, myocardial depression, metabolic acidosis; may cause paradoxical hypertension in children
<b>3. NEUROMUSCULAR BLOCKADE</b>				
Succinylcholine (depolarizing)	Rapid-onset, short-acting neuromuscular blockade agent, reversible with acetylcholinesterase inhibitor	Role limited due to adverse events Contraindicated in neuromuscular disease, myopathies, spinal cord injury, crush injury, burns, renal insufficiency	IV: ≤2 years: 2 mg/kg >2 years: 1 mg/kg (30–60 sec onset, 4–6 min duration) IM: 3–4 mg/kg (3–4 min onset, 10–30 min duration) Max dose: 150 mg/dose IM	Hyperkalemia, trigger of malignant hyperthermia, masseter spasm, bradycardia, muscle fasciculations, increased intracranial, intraocular, and intra gastric pressure
Rocuronium (nondepolarizing)	Minimal cardiovascular effect, reversible with sugammadex	Caution in patients with difficult airway	1.2 mg/kg IV/IM/IO (30–90 sec onset, 30–45 min duration) Max dose: 100 mg	Prolonged duration in hepatic failure
Vecuronium (nondepolarizing)	Minimal cardiovascular effect, reversible with sugammadex	Caution in patients with difficult airway	0.15–0.2 mg/kg IV/IO (1–3 min onset, 30–40 min duration) Max dose: 10 mg	Prolonged duration in hepatic failure, longer time to paralysis than rocuronium

CPP, Cerebral perfusion pressure; HR, heart rate; ICP, intracranial pressure; IM, intramuscular; IV, intravenous; IO, intraosseous; mCg, microgram; RSI, rapid sequence intubation; SVR, systemic vascular resistance.

- (2) High-flow systems (e.g., nonrebreather, oxygen hood) **do meet** the inspiratory flow demand of the patient. Measurable  $\text{FiO}_2$  is delivered.
- (3) High-flow nasal cannula (**HFNC**):
  - (a) High-flow, noninvasive respiratory support provides a heated and humidified air-oxygen mixture that may improve gas exchange by providing airway-distending pressure.
  - (b) Optimal and maximal flow rates are unknown. Consensus supports a maximum flow rate of up to **2 L/kg/min** or 12 L/min for infants and toddlers, 30 L/min for children, and up to 50 L/min for adolescents and adults.
- b. Noninvasive positive pressure ventilation (**NIPPV**):
  - (1) **CPAP**: Delivery of a continuous, distending positive airway pressure independent of patient inspiratory effort.
  - (2) **BiPAP**: Pressure-limited ventilatory mode in which the clinician sets an inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP).
    - (a) EPAP is started at 4 to 5  $\text{cmH}_2\text{O}$  and increased to a maximum of 8 to 12  $\text{cmH}_2\text{O}$ .
    - (b) Set 4 to 6  $\text{cmH}_2\text{O}$  of pressure support, or the difference between IPAP and EPAP.
    - (c) Consider setting a “backup rate,” or respiratory rate just shy of the spontaneous respiratory rate to be delivered in case of apnea.
- c. Mechanical ventilation:
  - (1) **Parameters**:
    - (a) Rate: Number of mechanical breaths delivered per minute
    - (b)  $\text{FiO}_2$ : Fraction of oxygen in inspired gas
    - (c) PIP: Peak inspiratory pressure attained during respiratory cycle
    - (d) Positive end-expiratory pressure (PEEP): Distending pressure that increases functional residual capacity (FRC), or volume of gas at the end of exhalation
    - (e) Mean airway pressure ( $P_{\text{aw}}$ ): Average airway pressure over entire respiratory cycle, which correlates to mean alveolar volume
    - (f) Tidal volume ( $V_T$ ): Volume of gas delivered during inspiration
    - (g) Time: May indicate a function of time spent in inspiration ( $T_i$ ), in high pressure ( $T_{\text{high}}$ ), or in low pressure ( $T_{\text{low}}$ )
  - (2) Modes of ventilation:
    - (a) **Controlled ventilation**: Ventilation is completely mechanical with no spontaneous ventilation efforts expected from the patient.

- (i) Pressure-controlled ventilation (**PCV**): A preset respiratory rate and  $T_i$  deliver a pressure-limited breath (the set pressure is maintained during inspiration).  $V_T$  is determined by the preset pressure as well as lung compliance and resistance.
  - (ii) Volume-controlled ventilation (**VCV**): A preset respiratory rate and  $T_i$  deliver a preset  $V_T$ .
  - (b) Intermittent mandatory ventilation (**IMV**): Allows the patient to breathe spontaneously between a preset number of (mandatory) mechanical breaths
    - (i) Synchronized IMV (**SIMV**): If patient initiates spontaneous breath, mandatory breath is synchronized with patient effort rather than spaced evenly over each minute.
    - (ii) If spontaneous breathing rate is less than mandatory rate, some mandatory breaths will be delivered in the absence of patient effort.
    - (iii) Delivered breaths may be volume regulated or pressure limited.
  - (c) Airway-pressure-release ventilation (**APRV**): Most of the respiratory cycle is spent at a high distending pressure (a functionally high CPAP phase) with intermittent, short release to a low pressure for a brief ventilation phase. Spontaneous breathing can be superimposed at any point in the cycle.
  - (d) **Support ventilation**: Mechanical breaths support patient-initiated breaths, but no mandatory breaths are provided.
    - (i) Pressure support (**PS**): Delivers a preset amount of pressure to assist spontaneous respiratory effort
    - (ii) Often used in combination with other modes of ventilation to support spontaneous breaths greater than preset respiratory rates
  - (e) High-frequency oscillatory ventilation (**HFOV**): Gas flow pressurizes the system to the preset  $P_{aw}$  while a piston moves backward and forward to force and withdraw a small  $V_T$  (that approximates anatomic dead space) into the lungs at rates exceeding normal respiratory rates.
- (3) **Management**: The three subdivisions of mechanical ventilatory support are the acute (lung recruitment), maintenance (lung recovery), and weaning phases.
- (a) **Acute**: See [Table 1.3](#) for ventilation parameter initial settings and titration effects.
  - (b) **Maintenance**: To avoid volutrauma, barotrauma, or oxygen toxicity, maintain  $V_T$  at 4–6 mL/kg, PIP <35 cmH<sub>2</sub>O, and  $FiO_2 \leq 60\%$ .

**TABLE 1.3****MECHANICAL VENTILATION PARAMETER SETTINGS AND EFFECTS**<sup>13,16,19</sup>

Parameter	Initial Setting	Effect of ↑ on PaCO <sub>2</sub>	Effect of ↑ on PaO <sub>2</sub>
PIP	≤28 cmH <sub>2</sub> O or ≤29–32 cmH <sub>2</sub> O for reduced chest wall compliance	↓↓	↑
PEEP	3–5 cmH <sub>2</sub> O	↑	↑↑
V <sub>T</sub>	5–8 mL/kg or 3–6 mL/kg for poorly compliant lungs	↓↓	↑
Rate	Normal rate for age	↓↓	Minimal ↑
I:E ratio	(33%) 1:2 (67%)	No change	↑
FiO <sub>2</sub>	<50% and/or to maintain PaO <sub>2</sub> between 80 and 100 mmHg and SpO <sub>2</sub> ≥95%	No change	↑↑

**HIGH-FREQUENCY VENTILATION PARAMETERS**

Amplitude (ΔP)	Set to produce a visible wiggling motion to the level of the lower abdomen	↓	No change
Frequency (Hz)	Range from 3–20 Hz (180–1200 breaths per min)	↑↑	↓
P <sub>aw</sub>	5 cmH <sub>2</sub> O > P <sub>aw</sub> of previous conventional ventilation	Minimal ↓	↑

FiO<sub>2</sub>, Fraction of inspired oxygen; I:E, inspiratory to expiratory; Hz, hertz; P<sub>aw</sub>, mean airway pressure; PaCO<sub>2</sub>, partial pressure of carbon dioxide (arterial); PaO<sub>2</sub>, partial pressure of oxygen (arterial); PEEP, positive end-expiratory pressure; PIP, peak inspiratory pressure; V<sub>T</sub>, tidal volume.

**(c) Weaning:**

- (i) Assess daily for clinical signs of readiness, such as spontaneous breathing efforts.
- (ii) Standard indices indicating readiness include FiO<sub>2</sub> <50%, PEEP of 5 cmH<sub>2</sub>O, PIP <20 cmH<sub>2</sub>O, normalized rate for age, and absence of hypercapnia or acidosis.
- (iii) The general approach combines gradual weaning of parameters and reliance on pressure-support modes.

**(d) Extubation:**

- (i) Provide humidified inspired oxygen after extubation.
- (ii) In case of uncuffed tube or the absence of an air leak at delivered pressure <30 cmH<sub>2</sub>O, consider 24 hours of dexamethasone (airway edema dosing) to prevent postextubation stridor.

**II. MANAGEMENT OF SHOCK**<sup>3,5,7,12,13</sup>**A. Definition: Physiologic state characterized by inadequate oxygen and nutrient delivery to meet tissue demands**

1. **Compensated:** Perfusion to vital organs is maintained by compensatory mechanisms.
  - a. Tachycardia is often the first and most sensitive vital sign change.

- b. Blood flow is redirected from nonvital organs and tissues to vital organs by a selective increase in systemic vascular resistance (SVR), resulting in reduced peripheral perfusion and decreased urine volume.
  - c. Cardiac contractility increases to maintain cardiac output.
  - d. Increased venous smooth muscle tone improves preload and stroke volume.
2. **Decompensated:** Perfusion to vital organs is compromised. Denoted by **hypotension**, poor perfusion, oliguria/anuria, and altered mental status.

**B. Etiology: Categorized into four basic types:**

1. **Hypovolemic:** Inadequate fluid intake, increased fluid losses (hemorrhage, gastroenteritis, burns). Assess for tachycardia, narrow pulse pressure, delayed capillary refill, cool extremities.
2. **Cardiogenic:** Congenital heart disease, myocarditis, cardiomyopathy, arrhythmia. Assess for increased respiratory effort from pulmonary edema, hepatomegaly, jugular venous distention, and cyanosis.
3. **Distributive:** Sepsis, anaphylaxis, neurogenic (e.g., high cervical spine injury)
  - a. Assess for tachycardia, fever, and petechial, purpuric, or urticarial rash.
  - b. Warm septic shock is characterized by bounding peripheral pulses, flash capillary refill, and wide pulse pressure.
  - c. Cold septic shock is characterized by decreased peripheral pulses, delayed capillary refill, and narrow pulse pressure.
  - d. Neurogenic shock is characterized by hypotension with a wide pulse pressure, normal HR or bradycardia, and hypothermia.
4. **Obstructive:** Tension pneumothorax, cardiac tamponade, pulmonary embolism, ductal-dependent congenital cardiac abnormalities
  - a. Early clinical presentation is indistinguishable from hypovolemic shock. Progression of shock leads to signs and symptoms similar to cardiogenic shock.
  - b. Cardiac tamponade is characterized by muffled heart sounds and pulsus paradoxus.
  - c. Ductal-dependent lesions may be characterized by higher preductal versus postductal BP or arterial oxygen saturation.

**C. Management**

1. Administer 100% supplemental oxygen initially regardless of oxygen saturation to optimize oxygen delivery. Once perfusion restored, titrate as able to avoid adverse effects from hyperoxia.
2. See [Table 1.4](#) for type- and etiology-specific pathophysiology and management of shock.
3. See [Table 1.5](#) for vasoactive agents to support cardiac output. Vasoactive agents affect SVR (vasodilators and vasoconstrictors), cardiac contractility (inotropes), or HR (chronotropes). Some agents increase blood flow via contractility and vasodilation (inodilators) or increase perfusion pressure via contractility and vasoconstriction (inoconstrictors).

TABLE 1.4

PATHOPHYSIOLOGY AND MANAGEMENT OF SHOCK<sup>3,5</sup>

Type	HR	Preload	Contractility	SVR	Management
Hypovolemic	↑	↓↓	Normal or ↑	↑	Rapid administration of isotonic crystalloids Replace blood loss with 10 mL/kg PRBC boluses Consider colloids if response is poor to crystalloids and loss of protein-containing fluids is suspected
Distributive	↑ or ↓	Normal or ↓	Normal or ↓	↓ (may progress to ↑)	Administer isotonic crystalloids to expand intravascular volume Support with vasopressors if fluid-refractory
Septic	↑	↓↓	Normal or ↓	↓	<b>Within 1st hour:</b> Administer fluid boluses (balanced/buffered crystalloid preferred) and broad-spectrum antibiotics, and consider stress-dose hydrocortisone <b>Warm:</b> Support with norepinephrine <b>Cold:</b> Support with epinephrine
Neurogenic	Normal or ↓	↓↓	Normal	↓↓	Position patient flat or head-down Administer a trial of isotonic crystalloid therapy If fluid-refractory, support with norepinephrine or epinephrine Maintain normothermia
Cardiogenic	↑	↑	↓↓	↑	Consider cautious administration (10–20 min) of isotonic crystalloid (5–10 mL/kg); stop if fluid overload develops Support with inodilator milrinone Decrease metabolic demand with oxygen therapy, ventilatory support, and antipyretics
Obstructive	↑	±	Normal	↑	Correct underlying cause Start prostaglandin E <sub>1</sub> if ductal-dependent lesion suspected Consider cautious administration (10–20 min) of isotonic crystalloid (5–10 mL/kg); stop if fluid overload develops

HR, Heart rate; PRBC, packed red blood cell; SVR, systemic vascular resistance.

**TABLE 1.5**  
**MEDICATIONS TO SUPPORT CARDIAC OUTPUT**<sup>5,7,13</sup>

Medication	Dose	Mechanism	Comments
Dobutamine	2–20 mCg/kg/min	Selective $\beta_1$ agonist	Inotrope May predispose to arrhythmia Indicated for normotensive, poorly perfused shock
Dopamine	5–20 mCg/kg/min	Direct dopamine receptor agonist, indirect $\beta$ and $\alpha$ agonist (stimulates norepinephrine release), direct $\alpha$ agonist at high dose (>15 mCg/kg/min)	Low to moderate dose: inotrope, chronotrope, splanchnic vasodilator High dose: vasopressor Indicated for shock with poor contractility and/or low SVR and cold septic shock if epinephrine unavailable
Epinephrine	0.05–2 mCg/kg/min	$\beta_1$ and $\beta_2$ agonist at low dose (<0.3 mCg/kg/min), $\alpha_1$ agonist at high dose (>0.3 mCg/kg/min)	Low dose: inotrope, chronotrope, vasodilator High dose: vasopressor Indicated for hypotensive shock with marked circulatory instability and cold septic shock
Milrinone	Loading: 50 mCg/kg over 15 min, then 0.25–0.75 mCg/kg/min	Type III phosphodiesterase-inhibitor	Inodilator Improves cardiac output with little effect on heart rate Indicated for normotensive shock with myocardial dysfunction and cold septic shock refractory to epinephrine
Norepinephrine	0.05–2.5 mCg/kg/min	$\alpha_1$ and $\beta_1$ agonist	Vasoconstrictor, mild inotrope Indicated for shock with low SVR (warm septic, anaphylactic, spinal) and cold shock refractory to epinephrine if diastolic BP low
Phenylephrine	Loading: 5–20 mCg/kg/dose (max 500 mCg), then 0.1–2 mCg/kg/min	Pure $\alpha_1$ agonist	Vasoconstrictor Rapid increase in BP may cause reflex bradycardia
Vasopressin (ADH)	0.17–8 milliUnits/kg/min	Vasopressin receptor agonist	Vasoconstrictor Consider for cardiac arrest, refractory hypotension in septic shock and GI hemorrhage

ADH, Antidiuretic hormone; BP, blood pressure; GI, gastrointestinal; mCg, microgram; NO, nitric oxide; SVR, systemic vascular resistance.

- a. Use epinephrine or norepinephrine for fluid-refractory septic shock as initial vasoactive infusion (or dopamine if these are unavailable) and consider the addition of stress-dose steroids.
- b. For hemorrhagic shock following trauma, administer blood products when available instead of crystalloid.

### III. MANAGEMENT OF COMMON EMERGENCIES

#### A. Anaphylaxis<sup>20</sup>

1. **Definition:** Severe, systemic hypersensitivity reaction. Usually rapid in onset and characterized by compromise in airway, breathing, and/or circulation. May involve multiple organ systems, including the following:
  - a. **Cutaneous/mucosal** (80% to 90%): Flushing, urticaria, pruritis, angioedema
  - b. **Respiratory** (70%): Laryngeal edema, bronchospasm, dyspnea, wheezing, stridor, hypoxemia
  - c. **Gastrointestinal** (45%): Vomiting, diarrhea, nausea, crampy abdominal pain
  - d. **Circulatory** (45%): Tachycardia, hypotension, syncope
2. **Management:**
  - a. **Stop exposure** to precipitating antigen.
  - b. While performing A-B-Cs, immediately give intramuscular (**IM**) **epinephrine** into midanterolateral thigh.
    - (1) For child, administer **0.01 mg/kg of 1 mg/mL solution** up to a max dose of 0.3 mg/dose. For adult-sized patients, first administer **0.2 to 0.5 mg of 1 mg/mL solution**, increasing as necessary up to max single dose of 0.5 mg.
    - (2) Autoinjector dosing: 7.5 to <15 kg use **0.1 mg**, 15 to <30 kg use **0.15 mg**, ≥30 kg use **0.3 mg**.
    - (3) Repeat dosing every 5 to 15 minutes as needed.
  - c. Provide oxygen and ventilatory assistance. Consider early endotracheal intubation.
  - d. Obtain IV access. For management of shock, resuscitate with 20 mL/kg isotonic crystalloid fluid boluses and vasoactive agents as needed.
  - e. Place patient in Trendelenburg position (head 30 degrees below feet).
  - f. Consider adjuvant pharmacologic agents:
    - (1) **Histamine receptor antagonist:** Diphenhydramine (H1-antagonism) and famotidine (H2-antagonism)
    - (2) **Corticosteroid:** Methylprednisolone or dexamethasone
    - (3) **Inhaled β<sub>2</sub> agonist:** Albuterol
  - g. Symptoms may recur (“biphasic anaphylaxis”) up to 72 hours after initial recovery.
    - (1) Observe for a minimum of 4 to 10 hours for late-phase symptoms.

- (2) Discharge with an epinephrine autoinjector and an anaphylaxis action plan.

## B. Upper Airway Obstruction

### 1. Epiglottitis<sup>21-22</sup>

- a. **Definition:** Life-threatening, rapidly progressive inflammation (usually infectious) of the supraglottic region
  - (1) Most often affects children between 1 and 8 years but may occur at any age
  - (2) May be caused by infection, thermal injury, caustic ingestion, or foreign body
  - (3) Most common infectious organisms include *Haemophilus influenzae* (unvaccinated), *Streptococcus pneumoniae*, group A streptococci, and *Staphylococcus aureus*.
  - (4) Patients often present febrile, toxic-appearing, and tripod in respiratory distress. Drooling, dysphagia, and inspiratory stridor are common. Barky cough is absent.
- b. **Management:** Avoid *any agitation* of the child prior to securing airway to prevent impending complete obstruction.
  - (1) Allow child to assume a position of comfort. Unobtrusively provide blow-by oxygen. Monitor with pulse oximetry.
  - (2) To secure airway, emergently consult difficult airway personnel (pediatric anesthesiologist, intensivist, and/or otolaryngologist).
    - (a) If unstable (unresponsive, cyanotic, bradycardic), emergently intubate.
    - (b) If stable with high suspicion, escort patient to OR for laryngoscopy and intubation under general anesthesia. Equipment for tracheotomy should be readily available.
    - (c) If stable with moderate or low suspicion, obtain lateral neck radiograph to assess for “thumb sign” of an inflamed epiglottis.
  - (3) Initiate broad-spectrum antibiotic therapy (e.g., vancomycin and ceftriaxone).

### 2. Croup<sup>23-24</sup>

- a. **Definition:** Common respiratory illness of the larynx, trachea, and bronchi.
  - (1) Most common in infants aged 6 to 36 months
  - (2) 75% of infections are caused by parainfluenza virus.
  - (3) Patients present with fever, barking cough, inspiratory stridor, and increased work of breathing, often worse at night.
- b. **Management:**
  - (1) Administer oxygen to children with hypoxemia or severe respiratory distress. Consider humidified air, although current consensus suggests it is ineffective for mild to moderate disease.

- (2) If **no stridor at rest**, give dexamethasone. Consider nebulized budesonide in patients vomiting or who lack IV access.
  - (3) If **stridor at rest**, give dexamethasone and nebulized racemic epinephrine. Observe for 2 to 4 hours given short duration of action of nebulized epinephrine.
  - (4) Indications for hospitalization include >1 racemic epinephrine nebulization required, atypical age (<6 months), severe respiratory distress, or dehydration.
  - (5) Consider heliox (helium and oxygen mixture) to improve turbulent airflow in moderate to severe croup, although benefit is controversial.
3. Foreign body aspiration<sup>1,22,25</sup>
- a. **Definition:** Acute airway obstruction from aspiration of an organic (e.g., nuts, seeds, grapes, hot dogs) or inorganic (e.g., coins, pins, beads, balloons, small toy parts) foreign body
    - (1) Male children younger than 3 years of age are most susceptible.
    - (2) Patients (<40%) present with classic triad of paroxysmal cough, wheezing, and decreased air entry. Other manifestations include cyanosis, fever, stridor, and persistent pneumonia or notably may be asymptomatic.
    - (3) The most common location is the right main bronchus (45% to 57%), then left main bronchus (18% to 40%), and trachea (10% to 17%).
  - b. **Management:** Care is taken to avoid converting a partial airway obstruction into complete obstruction.
    - (1) If **not** breathing (no cough or sound):
      - (a) Infant: Deliver repeated cycles of 5 back blows followed by 5 chest compressions until object is expelled or victim becomes unresponsive.
      - (b) Child: Perform subdiaphragmatic abdominal thrusts (Heimlich maneuver) until object is expelled or victim becomes unresponsive.
      - (c) Patients should be taken to the OR for emergent removal under direct laryngoscopy and bronchoscopy.
    - (2) If **breathing** (forcefully coughing, phonating):
      - (a) Obtain posteroanterior chest (including neck) radiograph to screen for radiopaque body or mediastinal shift. Consider inspiratory and expiratory films (or bilateral lateral decubitus in young patients) to assess for air trapping. A normal chest radiograph does not rule out foreign body.
      - (b) If clinical concern is high, consider urgent bronchoscopy or laryngoscopy.
    - (3) If patient becomes **unresponsive**: initiate CPR immediately.
      - (a) After 30 chest compressions, open airway and remove foreign body if visible. Do **not** perform blind sweep.

- (b) Attempt to give two breaths and continue with cycles of chest compressions and ventilations until object expelled.

### C. Status Asthmaticus<sup>26-31</sup>

1. **Definition:** Inflammatory airflow obstruction secondary to triad of airway edema, bronchoconstriction, and hyperresponsiveness
2. **Examination:** Assess breathlessness, speech, alertness, respiratory rate, accessory muscle use, wheezing, HR, pulsus paradoxus, peak expiratory flow, SpO<sub>2</sub>, and pCO<sub>2</sub>.
3. **Management:**
  - a. Provide oxygen to achieve SpO<sub>2</sub> ≥90%. If hypoxemia not readily corrected with supplemental oxygen, consider pneumothorax, pneumonia, methemoglobinemia, or other process.
  - b. See [Table 1.6](#) for pharmacologic agents used in acute asthma exacerbations. Consider using Pediatric Asthma Score to recognize exacerbation severity and guide treatment ([Table 1.7](#)).

**TABLE 1.6**

**STATUS ASTHMATICUS MEDICATIONS<sup>26-30</sup>**

Medication	Dose	Comments
<b>SHORT-ACTING β<sub>2</sub> AGONIST</b>		
Albuterol	<p><b>Mild to moderate:</b> Administer up to 3 doses in the first hour</p> <p>MDI: 4–8 puffs (90 mCg/puff) Q20 min–4 hr</p> <p>Nebulizer: 0.15 mg/kg (min 2.5 mg, max 5 mg) Q20 min–4 hr</p> <p><b>Severe:</b> Continuous nebulization: 0.5 mg/kg/hr (max 30 mg/hr)</p>	Inhaler (with spacer) is preferred delivery method given equal or greater efficacy, fewer side effects, and shorter length of stay
<b>ANTICHOLINERGICS</b>		
Ipratropium bromide	<p>Administer Q20 min for 3 doses with albuterol</p> <p>MDI: 4–8 puffs (17 mCg/puff)</p> <p>Nebulizer: 0.25–0.5 mg</p>	No additional benefit shown in inpatient setting
<b>SYSTEMIC CORTICOSTEROIDS</b>		
Dexamethasone	<b>Mild to moderate:</b> 0.6 mg/kg/day PO/IV/IM for 1–2 days (max 16 mg/day)	Equally as efficacious as prednisone or prednisolone with fewer side effects, better compliance and palatability
Prednisone, prednisolone	<b>Mild to severe:</b> 2 mg/kg/day PO for 5–7 days (max 60 mg/day)	Taper if course ≥7 days or bounce back from recent exacerbation
Methylprednisolone	<p><b>Severe:</b></p> <p>Loading: 2 mg/kg IV (max 80 mg)</p> <p>Maintenance: 2 mg/kg/day IV divided Q6–12 hr (max &lt;12 years 60 mg/day, ≥12 years 80 mg/day)</p>	No known advantage in severe exacerbations for higher dosing or IV administration over oral therapy, provided normal GI transit and absorption

**INJECTED  $\beta_2$  AGONIST**

Epinephrine	0.01 mg/kg of 1 mg/mL IM (max 0.5 mg) Q15–20 min for up to 3 doses	Consider for severe exacerbation with minimal air entry Consider quickly accessed autoinjector
Terbutaline	SUBQ: 0.01 mg/kg (max 0.25 mg/dose) Q20 min for up to 3 doses, then as needed Q2–6 hr IV load: 4–10 mCg/kg IV IV continuous: 0.2–5 mCg/kg/min (doses as high as 10 mCg/kg/min have been used)	Consider for severe exacerbation with minimal air entry IV administration may decrease the need for mechanical ventilation

**ADJUNCT THERAPIES**

Magnesium sulfate	25–75 mg/kg/dose IV (max 2 g), infuse over 20 min	Smooth muscle relaxant May cause hypotension; consider simultaneous fluid bolus Reduces hospitalization rates in severe exacerbations
Ketamine	1–2 mg/kg IV load followed by 1 mg/kg/hr infusion, titrated to effect	Used as a sympathomimetic adjuvant in effort to avoid endotracheal intubation Preferred induction-sedative agent for endotracheal intubation in asthma
Aminophylline	6 mg/kg IV load over 20 min followed by 0.5–1.2 mg/kg/hr infusion (age-dependent, see formulary)	Use limited to severe exacerbations refractory to traditional interventions May improve lung function and oxygen saturation but is associated with greater length of stay and time to symptom improvement
Heliox	Optimal helium-oxygen ratio unknown, most commonly 70:30 or 80:20 mixture	Low density gas that promotes laminar airflow and improves $\beta_2$ agonist delivery to distal airways Useful in severe or very severe exacerbations
Inhaled anesthetics (e.g., halothane, isoflurane, sevoflurane)	Consultation with pediatric anesthesiologist recommended	Rescue therapy for intubated patients with life-threatening exacerbation Associated with prolonged length of stay and increased cost Isoflurane may cause hypotension Sevoflurane may cause renal tubular injury, hepatotoxicity, neuropathy

*GI*, Gastrointestinal; *IM*, intramuscular; *IV*, intravenous; *mCg*, microgram; *MDI*, metered-dose inhaler; *PO*, by mouth; *SUBQ*, subcutaneous.

TABLE 1.7

## PEDIATRIC ASTHMA SCORE

Examination Component	1	2	3
Respiratory rate			
1–4 yr	≤34	35–39	≥40
4–6 yr	≤30	31–35	≥36
6–10 yr	≤26	27–30	≥31
>12 yr	≤23	24–27	≥28
O <sub>2</sub> requirement	>95% on room air	90%–95% on room air	<90% on room air or any oxygen
Retractions	None or intercostal	Intercostal and substernal	Intercostal, substernal, and supraclavicular
Work of breathing (count to 10)	Speaks in sentences, coos and babbles	Speaks in partial sentences, short cry	Speaks in single words/short phrases, grunting
Auscultation	Normal breath sounds to end-expiratory wheezes only	Expiratory wheezing	Inspiratory and expiratory wheezing to diminished breath sounds

Data from Nievas IF, Anand KJ. Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit. *J Pediatr Pharmacol Ther.* 2013;18(2):88–104. <https://doi.org/10.5863/1551-6776-18.2.88>

## c. Ventilation interventions:

- (1) Normalizing pCO<sub>2</sub> can be a sign of impending respiratory failure.
- (2) NIPPV (e.g., BiPAP) may be used in patients with impending respiratory failure to avoid intubation but requires a cooperative patient with spontaneous respirations.
- (3) Intubation should be approached cautiously given the risk of worsening air-trapping and difficulty in managing the transition from extremely negative to positive pressure ventilation.
  - (a) Indications include severe airway obstruction, markedly increased work of breathing, refractory hypoxemia, and impending respiratory arrest.
  - (b) Ventilation strategies include slower rates with prolonged expiratory phase, minimal end-expiratory pressures, and short inspiratory times to minimize hyperinflation and air trapping.
- (4) Consider inhaled anesthetics or ECMO as rescue therapies.

D. Pulmonary Hypertensive Crisis<sup>13,32</sup>

## 1. Definition:

- a. Pulmonary hypertension (PH) is defined as resting elevated mean pulmonary artery pressure (PAP) ≥**25 mmHg** in children >3 months of age.

- b. A **pulmonary hypertensive crisis** is a sudden increase in PAP and pulmonary vascular resistance (PVR) that causes acute right-sided heart failure.
  - (1) May be triggered by pain, anxiety, tracheal suctioning, hypoxia, acidosis, or respiratory illness. Most commonly described after cardiac surgery or in the setting of rapid withdrawal of PH-specific therapies.
  - (2) Patients present with systemic hypotension, oxygen desaturation (if atrial or ventricular communication present), and decreased EtCO<sub>2</sub> on capnography (reduced pulmonary blood flow).
  - (3) Assess for increased intensity of systolic murmur (worsening tricuspid regurgitation) and increased hepatomegaly.
- 2. **Management:** Timely consultation with providers with expertise in managing PH is recommended.
  - a. Implement efforts to keep patient calm. Consider opiates, sedatives, and neuromuscular blockade to reduce stress response, especially postoperatively. Avoid agents that decrease SVR.
  - b. Oxygen is a pulmonary vasodilator and should be administered to treat hypoxemia. Avoid acute hypercarbia and acidosis, which abruptly increase PVR. Consider brief hyperventilation or sodium bicarbonate infusions.
  - c. Diuretics treat congestive symptoms. Avoid excessive reduction in intravascular volume leading to decreased cardiac output.
  - d. NIPPV may improve oxygenation, treat hypoventilation, and reduce work of breathing. Weigh benefits against increasing patient anxiety and delaying mechanical ventilation.
  - e. PH-specific pharmacologic therapies aim to induce pulmonary vasodilation, support the right ventricle, and maintain cardiac output.
    - (1) **Inhaled pulmonary vasodilators:** Nitric oxide
      - (a) Indicated to reduce need for ECMO in patients with an oxygen index >25
      - (b) Rapid withdrawal of low doses may cause rebound PH. Gradually decrease dose when weaning.
      - (c) Monitor for methemoglobinemia.
    - (2) **Synthetic prostacyclin analogs** (epoprostenol [Flolan], treprostinil, iloprost):
      - (a) Administered by continuous IV or subcutaneous route. Iloprost is inhaled.
    - (3) **Phosphodiesterase type-5 inhibitors:** Sildenafil, tadalafil
      - (a) Often used to prevent rebound PH associated with cessation of nitric oxide
      - (b) Monitor for acute hypotension or hypoxemia secondary to increased alveolar-arterial gradient.

- (4) **Endothelin receptor antagonist:** Bosentan
- f. Consider ECMO or emergent atrial septostomy in case of failed medical management.

## E. Hypertensive Crisis<sup>13,33</sup>

### 1. Definition:

- a. For normal BP values based on age and height, see [Chapter 19](#).
- b. **Hypertensive emergency:** Acutely elevated BP (usually significantly >99th percentile for age and gender) with evidence of end-organ damage
  - (1) Most commonly secondary to renal disease, catecholamine-producing tumors, endocrine syndromes, toxidromes, medication withdrawal, or elevated intracranial pressure (ICP)
  - (2) Presents with encephalopathy (e.g., headaches, vomiting, seizures, altered mental status), vision disturbance, congestive heart failure (e.g., dyspnea, peripheral edema, gallop rhythm), and acute kidney injury
- c. **Hypertensive urgency:** Acutely elevated BP (usually >5 mmHg greater than the 99th percentile for age and gender) without evidence of end-organ damage
  - (1) Most commonly primary hypertension in children >7 years age, followed by renal disease
  - (2) Present with minor complaints (e.g., headaches, nausea)

### 2. Management:

- a. Rule out increased ICP before instituting antihypertensive treatment given critical need to maintain cerebral perfusion.
- b. Goal is to reduce BP by  $\leq 25\%$  in the **first 8 hours**, then gradual normalization over the next **24 to 48 hours**.
- c. See [Table 1.8](#) for hypertensive emergency and urgency medications.

## F. Pulmonary Embolism<sup>34</sup>

1. **Definition:** Acute obstruction of the pulmonary artery or one of its branches by material that originated downstream.
  - a. Risk factors include central venous catheters, OCPs, cancer, immobility, infection, nephrotic syndrome, inflammatory conditions (lupus, IBD), recent surgery, preexisting DVT, and inherited thrombophilia syndromes.
  - b. The classic triad of symptoms (pleuritic chest pain, shortness of breath, and hemoptysis) may not always be seen in children, who may only present with persistent tachypnea.
  - c. Massive PE, defined as an embolus that completely obstructs pulmonary blood flow, can present with hemodynamic instability and sudden death.
  - d. Assess for signs of respiratory distress.
  - e. Diagnosis with CT-PA has high sensitivity and specificity. Evaluation may also include EKG, echocardiogram, CXR, or V/Q scan.

TABLE 1.8

HYPERTENSIVE CRISIS MEDICATIONS<sup>13,33</sup>

Drug	Dose	Pharmacokinetics	Mechanism	Side Effects
<b>PARENTERAL THERAPY</b>				
Esmolol	Bolus: 100–500 mCg/kg Infusion: 25–250 mCg/kg/min (max 1000 mCg/kg/min)	Onset: Immediate Duration: 10–30 min	$\beta_1$ blocker	Bradycardia, bronchospasm (at high doses)
Hydralazine	0.1–0.2 mg/kg/dose IV/IM (max 2 mg/kg/dose or 20 mg) Q4–6 hr PRN	Onset: 5–30 min Duration: 1–4 hr	Direct arteriole vasodilator	Reflex tachycardia, flushing, lupus-like syndrome
Labetalol	Bolus: 0.2–1 mg/kg (max 40 mg) Infusion: 0.25–1 mg/kg/hr (max 3 mg/kg/hr)	Onset: 2–5 min Duration: 2–12 hr	$\beta_1$ , $\beta_2$ , and $\alpha_1$ blocker	Hyperkalemia, bronchospasm; caution in liver failure due to prolonged duration of action
Nicardipine	Start at 0.5–1 mCg/kg/min (max 5 mCg/kg/min or 15 mg/hr)	Onset: 5–15 min Duration: 4–6 hr	Calcium channel blocker	Reflex tachycardia
Nitroprusside	0.3–4 mCg/kg/min (max 10 mCg/kg/min)	Onset: 30 sec to 2 min Duration: 1–10 min	Arterial and venous vasodilation via NO	Cyanide toxicity
<b>ENTERAL THERAPY</b>				
Captopril	0.3–0.5 mg/kg (max 6 mg/kg/day or 450 mg/24 hr)	Onset: 15–30 min Duration: 2–6 hr	ACE inhibitor; lowers blood pressure without causing tachycardia	Hyperkalemia, neutropenia, angioedema, cough; contraindicated in bilateral renal artery stenosis or solitary kidney
Clonidine	1–10 mCg/kg/dose Q6–8 hr (max 25 mCg/kg/24 hr up to 0.8 mg/24 hr)	Onset: 30–60 min Duration: 6–10 hr	Central $\alpha$ agonist	Bradycardia, rebound hypertension, sedation
Nifedipine	0.1–0.25 mg/kg/dose Q4–6 hr PO/SL (max 10 mg/dose, 1–2 mg/kg/24 hr)	Onset: 15–30 min Duration: 4–6 hr	Calcium channel blocker	Precipitous hypotension, reflex tachycardia

ACE, Angiotensin-converting enzyme; IM, intramuscular; IV, intravenous; mCg, microgram; NO, nitric oxide; PO, oral; PRN, as needed; SL, sublingual.

- (1) Normal D-dimer does not rule out PE.
- (2) EKG can show right heart strain and/or atrial enlargement, sinus tachycardia, right axis deviation, RBBB, and ST-T segment changes as well as the classic S1-Q3-T3 pattern. Normal EKG does not rule out PE.

## 2. **Management:**

- a. Initiate anticoagulation with unfractionated heparin or low-molecular-weight heparin (see Formulary for dosing and monitoring).
- b. Medical thrombolysis using tissue plasminogen activator (alteplase) is indicated in PE with any hemodynamic instability.
- c. Surgical interventions such as thrombolysis, thrombectomy, or embolectomy are indicated in massive PE when medical thrombolysis is contraindicated.

## G. **Hypercyanotic Crisis (“Tet Spell”)**<sup>22,35</sup>

1. **Definition:** Cyanotic emergency secondary to an acute worsening of a preexisting right ventricular outflow tract obstruction (e.g., in a patient with tetralogy of Fallot) that prevents pulmonary blood flow and induces a right-to-left intracardiac shunt.
  - a. Peak incidence occurs between 2 and 4 months of age.
  - b. Usually occurs in the morning after crying, feeding, or defecation.
  - c. Patients present with extreme cyanosis, hyperpnea, tachypnea, and agitation.
2. **Management:** Follow stepwise approach, escalating if spell is not broken.
  - a. Make every effort to calm the child. Allow parent to comfort. Consider oral sucrose analgesia (e.g., Sweet-Ease).
  - b. Bring knees to chest in infants or encourage squatting in older children to increase SVR and decrease shunting.
  - c. Administer 100% oxygen **if patient tolerates**, although effect is limited given absence of effective pulmonary blood flow.
  - d. For stepwise pharmacologic abortive management, see [Table 1.9](#).
  - e. Consider isotonic crystalloid resuscitation (5 to 10 mL/kg boluses) to ensure adequate preload if patient is dehydrated.
  - f. Treat acidosis with sodium bicarbonate.
  - g. For refractory spells, consider general anesthesia and emergent surgery for palliation with a systemic to pulmonary shunt or full repair.

## H. **Altered Level of Consciousness**<sup>22,36</sup>

1. **Definition:** A spectrum of impaired consciousness spanning confusion, disorientation, agitation, stupor, lethargy, and coma.
  - a. Fluctuations in level of consciousness are common and progression may occur rapidly.
  - b. **Coma:** Refers to an unarousable state
  - c. **Lethargy:** Refers to a depressed consciousness resembling sleep from which a patient can be aroused but immediately returns to depressed state

TABLE 1.9

HYPERCYANOTIC CRISIS ABORTIVE MEDICATIONS<sup>22,35</sup>

Medication	Dose	Comment
Ketamine	1–2 mg/kg IM or IV, administer IV dose over 60 sec	Sedating, increases SVR
Morphine	0.05–0.2 mg/kg IM, SUBQ or IV; do <i>not</i> wait for IV access	Calms agitation, suppresses hyperpnea Monitor for respiratory depression
Phenylephrine	5–20 mCg/kg IV bolus Max single dose 200 mCg	$\alpha$ Agonist, increases SVR
Propranolol	0.15–0.25 mg/kg, via slow IV push Max initial dose 1 mg	$\beta$ Blockade decreases heart rate, promoting ventricular filling Monitor for hypotension

IM, Intramuscular; IV, intravenous; SUBQ, subcutaneous; SVR, systemic vascular resistance.

- d. **Stupor:** Refers to a state of depressed response to external stimuli but not totally asleep
- e. Standard descriptors of level of responsiveness include:
  - (1) The **Glasgow Coma Scale** (and modified scale for infants): See [Table 1.10](#) to score level of responsiveness.
  - (2) **AVPU** mnemonic: Graded as **A** if alert, **V** if responsive to verbal stimulation, **P** if responsive to painful stimulation, or **U** if unresponsive

TABLE 1.10

COMA SCALES<sup>20</sup>

Grading	Glasgow Coma Scale	Modified Coma Scale for Infants
<b>EYE OPENING</b>		
4	Spontaneous	Spontaneous
3	To speech	To speech
2	To pain	To pain
1	None	None
<b>VERBAL</b>		
5	Oriented	Coos or babbles
4	Confused	Irritable
3	Inappropriate words	Cries to pain
2	Nonspecific sounds	Moans to pain
1	None	None
<b>MOTOR</b>		
6	Follows commands	Normal, spontaneous movements
5	Localizes pain	Withdraws to touch
4	Withdraws to pain	Withdraws to pain
3	Abnormal flexion	Abnormal flexion
2	Abnormal extension	Abnormal extension
1	None	None

Data from Shaw KN, Bachur RG. *Fleisher & Ludwig's Textbook of Pediatric Emergency Medicine*. 7th ed. Lippincott Williams & Wilkins; 2016.

- f. Broad differential considerations include **D**rugs, **I**nfection, **M**etabolic, and **S**tructural causes (DIMS).
  - g. See [Table 1.11](#) for common etiologies and targeted workup recommendations.
2. **Management:** Stabilize initially. Further management is aimed at correcting underlying etiology.
- a. **Airway, Breathing, Circulation:**
    - (1) Administer supplemental oxygen to patients presenting with seizure or with signs of shock, regardless of pulse oximetry reading.

**TABLE 1.11****ETIOLOGIES AND TARGETED EVALUATION OF ALTERED LEVEL OF CONSCIOUSNESS**

Category	Etiologies	Workup
Drugs	Opiates (e.g., oxycodone, fentanyl, heroin) Sympathomimetics (e.g., cocaine, MDMA) Anticholinergics (e.g., diphenhydramine, TCAs) Cholinergics (e.g., organophosphates) Serotonin syndrome (e.g., SSRIs, dextromethorphan)	Urine toxicology screen Acetaminophen level ASA level Ethanol level ECG Blood gas Serum chemistry
Infection	Systemic sepsis Meningitis Encephalitis Abscess	Blood culture Complete blood count Urine analysis and culture CSF analysis and culture (if indicated)
Metabolic	Hypoglycemia Electrolyte abnormalities (e.g., hypernatremia/ hyponatremia) Uremic encephalopathy Hyperammonemic encephalopathy Diabetic ketoacidosis Inborn error of metabolism Hepatic failure Renal failure	Blood gas Lactate Glucose Electrolytes Liver enzymes Renal function Ammonia Serum amino acids Urine organic acids Acylcarnitine profile Coagulation studies Serum/urine osmolarity
Structural	Space-occupying lesions (e.g., tumor, blood, abscess, cyst, cerebral edema secondary to trauma) Obstructions to cerebral blood flow (e.g., thrombus, vasculitis)	Head CT or MRI
Other	Anoxia Hypothermia/hyperthermia Seizure/postictal state Psychiatric/psychogenic	EEG

ASA, Acetylsalicylic acid (aspirin); CSF, cerebral spinal fluid; CT, computed tomography; ECG, electrocardiogram; EEG, electroencephalogram; MDMA, 3,4-Methylenedioxymethamphetamine (ecstasy); MRI, magnetic resonance imaging; SSRI, selective serotonin reuptake inhibitor; TCAs, tricyclic antidepressants.

Data from Krmpotic K. A clinical approach to altered level of consciousness in the pediatric patient. *Austin Pediatr.* 2016;3(5):1046.

- (2) Intubation is indicated in patients unable to protect their airway.
  - (3) Consider delaying administration of atropine unless necessary secondary to the loss of pupillary light reflex.
  - (4) Avoid hypercarbia, maintaining PaCO<sub>2</sub> in normal range. Prophylactic hyperventilation is not recommended.
- b. **Dextrose:** Correct hypoglycemia immediately with a 5 to 10 mL/kg bolus of 10% dextrose or 2 to 4 mL/kg of 25% dextrose. After bolus, start a continuous infusion of dextrose-containing fluids to avoid recurrent hypoglycemia.
- c. **Imaging:** Request emergency head computed tomography (CT) if patient stable for transport. Consult with neurosurgical team if indicated.
- d. **Hyponatremia:** Often asymptomatic unless sodium decreases rapidly or becomes severe (i.e., <125 mmol/L)
- (1) Treat **symptomatic** hyponatremia immediately with a 3 to 5 mL/kg bolus of 3% hypertonic saline over 15 to 30 minutes until seizure activity ceases or serum sodium level is >125 mmol/L.
  - (2) See [Chapter 11](#) for subsequent, slow correction of asymptomatic hyponatremia.
- e. **Infection:** If presentation concerning for severe sepsis, treat empirically with broad-spectrum antibiotics (e.g., ceftriaxone and vancomycin) within the first hour. Include antiviral therapy (e.g., acyclovir) if viral encephalitis is suspected. Lumbar puncture should be performed only if there is no clinical suspicion of increased ICP and the patient is stable.
- f. **Ingestion:** General management includes decreasing absorption, altering metabolism, and enhancing elimination.
- (1) Contact the regional poison control center for specific treatment recommendations.
  - (2) See [Chapter 3](#) for toxicology management.
- g. **Naloxone:** If patients have a definite pulse but abnormal breathing or only gasping, administer opioid antagonist (full reversal: 0.1 mg/kg/dose IV/IM/subcutaneous [SUBQ], max 2 mg/dose) if opioid ingestion is suspected. Repeat dosing every 2 to 3 minutes. Short duration of action may necessitate multiple doses.
- (1) For patients in respiratory arrest, rescue breathing or bag-mask ventilation should be initiated.
  - (2) For patients in cardiac arrest, in the absence of proven benefit from the use of naloxone, standard resuscitative measures should take priority over naloxone administration, with a focus on high-quality CPR.
- h. **Thiamine:** Consider administration prior to glucose for patients with eating disorders, chronic disease, or alcoholism to prevent Wernicke encephalopathy.
- i. If patient is an infant or toddler, consider evaluation for inborn error of metabolism, hepatic failure, renal failure, or nonaccidental trauma.

**I. Status Epilepticus<sup>37-38</sup>**

1. **Definition:** Prolonged seizure (clinical or electrographic) or recurrent seizure activity without return to baseline lasting **5 minutes** or more
  - a. Common acute etiologies: Febrile seizures, metabolic disturbances, sepsis, head trauma, stroke/hemorrhage, drug toxicity, inadequate antiepileptic therapy, hypoxia, hypertensive encephalopathy, autoimmune encephalitis
  - b. Common chronic etiologies: Preexisting epilepsy, tumor, stroke, inborn error of metabolism, ethanol abuse
2. **Management:** Timely administration of anticonvulsant therapy is associated with a greater likelihood of seizure termination and better neurologic outcomes. See [Table 1.12](#) for timed evaluation and treatment outline.

**J. Increased Intracranial Pressure<sup>39-41</sup>**

1. **Definition:** An increase in the volume of an intracranial component (brain, blood, or cerebrospinal fluid) within the fixed volume of the skull that exceeds the limits of compensation, generally accepted as a sustained increase  $\geq 20$  mmHg
  - a. Intricately related to cerebral perfusion via the following equation:

$$\text{Cerebral perfusion pressure (CPP)} = \text{Mean arterial pressure (MAP)} - \text{ICP}$$

**TABLE 1.12****STATUS EPILEPTICUS TREATMENT GUIDELINE<sup>37-38</sup>****IMMEDIATE APPROACH (0–5 MIN)****Management:**

Protect airway, intubate if needed

Assess vitals

Bedside fingerstick blood glucose

Establish peripheral IV access: Administer emergent AED, fluid resuscitation, nutrient resuscitation (thiamine, dextrose)

Labs: laboratory blood glucose, CBC, BMP, calcium, magnesium, antiseizure medication drug levels

Medication	Dose	Comment
Diazepam	0.15–0.2 mg/kg IV (max 10 mg/dose) 2–5 years: 0.5 mg/kg PR (max 20 mg/dose) 6–11 years: 0.3 mg/kg PR (max 20 mg/dose) $\geq 12$ years: 0.2 mg/kg PR (max 20 mg/dose) May repeat dose once in 5 min	Monitor for hypotension, respiratory depression
Lorazepam	0.1 mg/kg IV (max 4 mg/dose) May repeat dose once in 5–10 min	Monitor for hypotension, respiratory depression
Midazolam	0.2 mg/kg IV/IM/IN 0.5 mg/kg buccal Max: 10 mg all forms Single dose recommended	Monitor for hypotension, respiratory depression

**URGENT APPROACH (5–15 MIN)****Management:**

- Secondary AED control therapy
- Initiate vasopressor support if indicated
- Neurological examination
- CT if indicated
- Labs: Liver function tests, coagulation studies, toxicology screen, inborn error of metabolism screening
- Neurologic consultation

Medication	Dose	Comment
Fosphenytoin	20 mg PE/kg IV/IM (max 1500 mg PE/dose) May give additional 10 mg PE/kg repeat dose	Monitor for arrhythmia, hypotension Max administration rate 150 mg PE/min or 2 mg PE/kg/min
Levetiracetam	60 mg/kg IV (max 4500 mg/dose)	Minimal drug interactions Not hepatically metabolized
Phenobarbital	15–20 mg/kg IV (max 1000 mg/dose) May give additional 5–10 mg/kg repeat dose	Monitor for hypotension, respiratory depression
Phenytoin	20 mg/kg IV (max 1500 mg/dose) May give additional 10 mg/kg repeat dose	Monitor for arrhythmia, hypotension, purple glove syndrome
Valproic acid	20–40 mg/kg IV May give additional 20 mg/kg repeat dose (max 3000 mg/dose)	Use with caution in TBI Rarely used in children <2 years due to risk of fatal hepatotoxicity (see Formulary) Monitor for hyperammonemia, pancreatitis, hepatotoxicity, thrombocytopenia

**REFRACTORY APPROACH (15–60 MIN)****Management:**

- Refractory AED control therapy
- Continuous EEG monitoring if indicated
- MRI if indicated
- Lumbar puncture if indicated
- Consider broad-spectrum antibiotics and antivirals if indicated
- Intracranial pressure monitoring if indicated
- Urinary catheter

Medication	Dose	Comment
Midazolam (continuous infusion)	Load: 0.2 mg/kg Infusion: 0.05–2 mg/kg/hr Breakthrough: 0.1–0.2 mg/kg bolus	Tachyphylaxis with prolonged use Monitor for respiratory depression, hypotension
Pentobarbital	Load: 5–15 mg/kg Infusion: 0.5–5 mg/kg/hr Breakthrough: 5 mg/kg bolus	Monitor for hypotension, respiratory depression, cardiac depression, paralytic ileus
Propofol	Load: 1–2 mg/kg Infusion: 20–65 mcg/kg/min Breakthrough: 1 mg/kg bolus	Monitor for hypotension, respiratory depression, cardiac failure, rhabdomyolysis, metabolic acidosis, renal failure, hypertriglyceridemia, pancreatitis (propofol-related infusion syndrome)

*AED*, Antiepileptic drug; *BMP*, basic metabolic panel; *CBC*, complete blood count; *CT*, computed tomography; *EEG*, electroencephalogram; *IM*, intramuscular; *IN*, intranasal; *IV*, intravenous; *mcg*, microgram; *PE*, phenytoin equivalent; *PR*, per rectum; *TBI*, traumatic brain injury.

- b. Most commonly caused by brain trauma, tumors, or intracranial infections
  - c. Patients present with headache, diplopia, nausea, vomiting, or decreased level of consciousness.
  - d. Assess for signs of trauma, ataxia, pupillary asymmetry, papilledema, cranial nerve dysfunction, bulging fontanelle, or abnormal posturing.
    - (1) Foramen magnum herniation: Hypertension, bradycardia, irregular respirations (Cushing triad)
    - (2) Transtentorial herniation: Ipsilateral pupillary dilation, contralateral hemiparesis
  - e. Evaluation may include infectious studies, electrolytes, toxicology screen, and stat CT head. Lumbar puncture is contraindicated due to herniation risk if cause is obstructive.
2. **Management:** Adequate CPP (**>40 mmHg**) is critical to overcome the resistance of increased ICP.
- a. Stabilize initially as per resuscitation guidelines.
    - (1) Maintain normal oxygenation and ventilation to treat increased metabolic demand and avoid hypercarbia-related cerebral vasodilation.
    - (2) Consider hyperventilation (EtCO<sub>2</sub> target between 25 and 30) for patients with **active** evidence of herniation. Prophylactic hyperventilation is otherwise not recommended.
    - (3) Support MAP with adequate isotonic fluid resuscitation and vasoactive agents.
  - b. Consultation with neurosurgical team is recommended and required immediately if evidence of herniation is present.
  - c. Administer **mannitol** (0.5 to 1 g/kg) and/or **hypertonic saline** (5 to 10 mL/kg of 3% hypertonic saline) in case of acute neurologic deterioration or cerebral herniation.
    - (1) Continuous infusions of 3% hypertonic saline (0.1 to 1.0 mL/kg/hr) may be titrated as necessary to maintain ICP less than 20 mmHg.
    - (2) Rapid osmotic diuresis from mannitol may cause hypovolemia and hypotension, especially in polytrauma patients.
  - d. Request **noncontrast head CT** to evaluate for emergent surgical pathology.
  - e. Treat acute seizure activity given the associated increased cerebral metabolic rate and subsequent increased cerebral blood flow. Consider prophylactic antiseizure therapy (e.g., phenytoin, levetiracetam) if transport or delayed definitive care is anticipated.
  - f. Sedation and analgesia prevent increases in ICP related to pain and agitation, although benefit is balanced with risk of hypotension and alteration of neurologic exam.
  - g. Avoid secondary brain injury by maintaining neuroprotective parameters: Maintain head midline and elevated at 30 degrees, normoglycemia, normonatremia, normothermia, and correct acidosis.

- h. If elevated ICP is refractory to medical management, consider draining an existing ventriculoperitoneal shunt or acute neurosurgical intervention (external ventricular drain or decompressive craniectomy).
- i. For elevated ICP refractory to medical and surgical management, consider barbiturate coma.

#### IV. CRITICAL CARE REFERENCE DATA

1. Minute ventilation ( $V_E$ ):

$$V_E = \text{Respiratory rate} \times \text{Tidal volume } (V_T)$$

2. Alveolar gas equation:

$$P_{AO_2} = [FiO_2(P_{atm} - PH_2O)] - (P_aCO_2 / R)$$

- a.  $P_{AO_2}$  = Alveolar partial pressure of oxygen
  - b.  $FiO_2$  = Inspired fraction of oxygen (0.21 at room air)
  - c.  $P_{atm}$  = Atmospheric pressure (760 mmHg at sea level; adjust for high altitude)
  - d.  $PH_2O$  = Water vapor pressure (47 mmHg)
  - e.  $P_aCO_2$  = Arteriolar partial pressure of carbon dioxide (measured via arterial blood gas)
  - f.  $R$  = Respiratory quotient (0.8;  $CO_2$  produced/ $O_2$  consumed)
3. Alveolar-arterial oxygen gradient (A-a gradient):

$$A - a \text{ gradient} = P_{AO_2} - P_aO_2$$

- a.  $P_{AO_2}$  = Alveolar partial pressure of oxygen (estimated from alveolar gas equation)
  - b.  $P_aO_2$  = Arteriolar partial pressure of oxygen (measured via arterial blood gas)
  - c. Normal gradient is 20 to 65 mmHg on 100% oxygen or 5 to 20 mmHg on room air.
  - d. The A-a gradient is increased in hypoventilation, diffusion limitations, pulmonary blood-flow shunts, and ventilation/blood flow (V/Q) mismatch.
4. Oxygenation index (OI):

$$OI = P_{aw} \times FiO_2 \times 100 / P_aO_2$$

- a.  $P_{aw}$  (mmHg) = Mean airway pressure
- b.  $OI > 40$  in hypoxemic respiratory failure is historically considered an indication for extracorporeal life support.

#### REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Berg MD, Schexnayder SM, Chameides L, et al. Part 13: Pediatric basic life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation*. 2010;122(18 suppl 3):S862–S875.
2. Atkins DL, Berger S, Duff JP, et al. Part 11: Pediatric basic life support and cardiopulmonary resuscitation quality: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation*. 2015;132(18 suppl 2):S519–S525.
3. De Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric advanced life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation*. 2015;132(18 suppl 2):S526–S542.
4. Atkins DL, de Caen AR, Berger S, et al. 2017 American Heart Association focused update on pediatric basic life support and cardiopulmonary resuscitation quality: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation*. 2018;137:e1–e6.
5. *Pediatric Advanced Life Support Provider Manual*. American Heart Association, Subcommittee on Pediatric Resuscitation; 2020.
6. Raymond TT, Cunnyngham CB, Thompson MT, et al. Outcomes among neonates, infants, and children after extracorporeal cardiopulmonary resuscitation for refractory in hospital pediatric cardiac arrest: a report from the National Registry of Cardiopulmonary Resuscitation. *Pediatr Crit Care Med*. 2010;11(3):362–371.
7. Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric advanced life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation*. 2010;122(18 suppl 3):S876–S908.
8. Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation*. 2020;142(16\_suppl\_2):S469–S523. <https://doi.org/10.1161/CIR.0000000000000901>
9. Meaney PA, Bobrow BJ, Mancini ME, et al. Cardiopulmonary resuscitation quality: improving cardiac resuscitation outcomes both inside and outside the hospital: a consensus statement from the American Heart Association. *Circulation*. 2013;128:417–435.
10. Berg RA, Sutton RM, Reeder RW, et al. Association between diastolic blood pressure during pediatric in-hospital cardiopulmonary resuscitation and survival. *Circulation*. 2018;137(17):1784–1795.
11. Wells M, Goldstein LN, Bentley A. The accuracy of emergency weight estimation systems in children—a systematic review and meta-analysis. *Int J Emerg Med*. 2017;10:29.
12. Weiss SL, Peters MJ, Alhazzani W, et al. Executive summary: Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. *Pediatr Crit Care Med*. 2020;21(2):186–195. <https://doi.org/10.1097/PCC.0000000000002197>. <https://www.narcis.nl/publication/RecordID/oai:repository.ubn.ru.nl:2066%2F220773>
13. Nichols DG, Shaffner DH. *Rogers Textbook of Pediatric Intensive Care*. 5th ed. Lippincott Williams & Wilkins; 2016.

14. Daugherty RJ, Nadkarni V, Brenn BR. Endotracheal tube size estimation for children with pathological short stature. *Pediatr Emerg Care*. 2006;22(11):710–717.
15. Mikalsen IB, Davis P, Øymar K. High flow nasal cannula in children: a literature review. *Scand J Trauma Resusc Emerg Med*. 2016;24:93.
16. Davis PJ, Cladis FP. *Smith's Anesthesia for Infants and Children*. 10th ed. Elsevier; 2022.
17. Mittiga M, Rinderknecht A, Kerrey B. A Modern and Practical Review of Rapid-Sequence Intubation in Pediatric Emergencies. *Clinical Pediatric Emergency Medicine*. 2015;16(3),172–185.
18. Deleted in proofs.
19. Zimmerman JJ, Rotta AT. *Fuhrman & Zimmerman's Pediatric Critical Care*. 6th ed. Elsevier; 2021.
20. Cardona V, Ansotegui IJ, Ebisawa M, et al. World Allergy Organization Anaphylaxis Guidance 2020. *World Allergy Organ J*. 2020;13(10):100472. <https://doi.org/10.1016/j.waojou.2020.100472>
21. Leboulanger N, Garabedian EN. Airway management in pediatric head and neck infections. *Infect Disord Drug Targets*. 2012;12(4):256–260.
22. Shaw KN, Bachur RG. *Fleisher & Ludwig's Textbook of Pediatric Emergency Medicine*. 7th ed. Lippincott Williams & Wilkins; 2016.
23. Petrocheilou A, Tanou K, Kalampouka E, et al. Viral croup: diagnosis and a treatment algorithm. *Pediatr Pulmonol*. 2014;49(5):421–429.
24. Smith DK, McDermott AJ, Sullivan JF. Croup: diagnosis and management. *Am Fam Physician*. 2018;97(9):575–580.
25. Singh H, Parakh A. Tracheobronchial foreign body aspiration in children. *Clin Pediatr (Phila)*. 2014;53(5):415–419.
26. National Asthma Education and Prevention Program. *Expert Panel Report III: Guidelines for the Diagnosis and Management of Asthma*. National Heart, Lung and Blood Institute; 2007.
27. Jones BP, Fleming GM, Otilio JK, et al. Pediatric acute asthma exacerbations: evaluation and management from emergency department to intensive care unit. *J Asthma*. 2016;53(6):607–617.
28. Dalabih AR, Bondi SA, Harris ZL, et al. Aminophylline infusion for status asthmaticus in the pediatric critical care unit setting is independently associated with increased length of stay and time for symptom improvement. *Pulm Pharmacol Ther*. 2014;27(1):57–61.
29. Wong JJ, Lee JH, Turner D, et al. A review of the use of adjunctive therapies in severe acute asthma exacerbation in critically ill children. *Expert Rev Respir Med*. 2014;8(4):423–441.
30. Doymaz S, Schneider J, Sagy M. Early administration of terbutaline in severe pediatric asthma may reduce incidence of acute respiratory failure. *Ann Allergy Asthma Immunol*. 2014;112(3):207–210.
31. Kelly CS, Andersen CL, Pestian JP, et al. Improved outcomes for hospitalized asthmatic children using a clinical pathway. *Ann Allergy Asthma Immunol*. 2000;84(5):509–516. [https://doi.org/10.1016/S1081-1206\(10\)62514-8](https://doi.org/10.1016/S1081-1206(10)62514-8)
32. Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. *Circulation*. 2015;132(21):2037–2099.
33. Raina R, Mahajan Z, Sharma Z, et al. Hypertensive crisis in pediatric patients: an overview. *Front Pediatr*. 2020;Oct 20;8:588911.
34. Ramiz S, Rajpurkar M. Pulmonary embolism in children. *Pediatr Clin North Am*. 2018;65(3):495–507. <https://doi.org/10.1016/j.pcl.2018.02.002>. <https://www.sciencedirect.com/science/article/pii/S0031395518300245>

35. Park MK. *Park's Pediatric Cardiology for Practitioners*. 7th ed. Elsevier; 2021.
36. Krmpotic K. A clinical approach to altered level of consciousness in the pediatric patient. *Austin Pediatr*. 2016;3(5):1046.
37. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. *Neurocrit Care*. 2012;17(1):3–23.
38. Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. *Epilepsy Curr*. 2016;16(1):48–61.
39. Pitfield AF, Carroll AB, Kissoon N. Emergency management of increased intracranial pressure. *Pediatr Emerg Care*. 2012;28(2):200–204.
40. Kochanek P, Tasker R, Bell M, Adelson P, et al. Management of Pediatric Severe Traumatic Brain Injury: 2019 Consensus and Guidelines-Based Algorithm for First and Second Tier Therapies. *Pediatric Critical Care Medicine* 20(3):p 269-279, March 2019. <https://doi.org/10.1097/PCC.0000000000001737>
41. Stevens RD, Shoykhet M, Cadena R. Emergency neurological life support: intracranial hypertension and herniation. *Neurocrit Care*. 2015;23(suppl 2):S76–S82.

# Chapter 2

## Traumatic Injuries

*Radhika Ghodasara, MD*

 See additional content online.

### I. COMPONENTS OF THE TRAUMA ASSESSMENT

#### A. Primary Survey

1. The primary survey involves assessment of ABCDE: Airway, Breathing, Circulation, Disability, Exposure.<sup>1</sup>
  - a. **Airway:**
    - (1) Can the patient maintain their own airway? Consider their neurologic status.
    - (2) Is the airway patent? Is there an upper airway obstruction or stridor?
    - (3) Do they have a head/neck injury that would make endotracheal intubation difficult? Will they need a surgical airway?
    - (4) Ensure C-spine stability when assessing and managing a patient's airway.
    - (5) Have backup—call anesthesia or an intensivist for difficult airways.
  - b. **Breathing:**
    - (1) Does the patient have an intervenable process (e.g., hemorrhagic, obstructive, compressive) affecting oxygenation/ventilation that can be addressed with rapid procedural intervention (such as a medical airway, needle decompression, or a chest tube)?
    - (2) If the patient is not breathing on their own, is the bag-valve-mask ventilation technique being optimized until a more secure airway is placed? Confirm a good mask seal, appropriate patient positioning, appropriate respiratory rate and volume for age/size, equal chest rise, and end-tidal CO<sub>2</sub> monitoring.
  - c. **Circulation:**
    - (1) Is the patient actively hemorrhaging? Identify and control external bleeding quickly.
    - (2) Does the patient show signs of pericardial tamponade (e.g. distended neck veins, distant heart sounds, and decreased pulse pressure)?
    - (3) Assess for shock: hypotension, tachycardia, altered mental status, and decreased urine output. Does the patient have

access? Place two large-bore IVs. If intravenous access is difficult or limited, promptly consider intraosseous (IO) access.

- (4) Are pulses strong or thready? Check centrally (carotid, femoral, brachial) and distally (radial, pedal). Is their skin warm or cool? Assess capillary refill.
- (5) What are the vital signs? Tachycardia may be the only abnormal vital sign in early shock.
- (6) Consider the need for fluid resuscitation and/or blood product administration. Cases of severe hemorrhage may benefit from early activation of massive transfusion protocols.
- (7) Large-volume resuscitation is not a substitute for prompt control of external hemorrhage in the injured patient.

d. **Disability:**

- (1) What is the patient's neurologic status? Assess pupil size, symmetry, reactivity.
- (2) Calculate Glasgow Coma Score (see [Chapter 1](#)): "intubate when less than 8"; motor score may identify spinal cord injury.
- (3) What was the mechanism of the traumatic injury? (e.g., high-speed motor vehicle collision with traumatic brain injury or house fire with significant burns)
- (4) Does the patient need fast-acting pain control and/or sedation? Consider risk of respiratory depression with opioids. Confirm medical history and drug allergies when possible.

e. **Exposure:**

- (1) Expose skin completely for thorough evaluation. Remove injurious debris and clothing.
- (2) Could there have been a medication overdose or drug intoxication associated with the trauma?

2. Note: The Advanced Trauma Life Support algorithm developed by the American College of Surgeons continues to support prioritizing the rapid assessment and treatment of life-threatening airway and breathing problems ahead of circulation problems (ABC). For nontraumatic cardiorespiratory arrest, the circulation, airway, and breathing (CAB) sequence is currently in use by the American Heart Association as part of the Pediatric Advanced Life Support algorithm (see [Chapter 1](#)).

## **B. Secondary Survey (Fig. 2.1)**

### **C. Labs/Workup to Consider in the Emergent Setting**

1. Critical care labs: Hemoglobin, blood gas, lactate, glucose, electrolytes
2. Coagulation studies (PT, aPTT, INR, fibrinogen): especially for operative planning
3. Type and screen/cross: Preparing crossmatched blood is important for anticipated surgical intervention. Emergency blood release may be needed in cases of severe hemorrhage.




FIGURE 2.1

Trauma secondary survey.

4. Lactate: If level is elevated, consider poor tissue perfusion, organ/vascular injury, internal hemorrhage.
5. Urinalysis: Hematuria may indicate kidney, urinary tract, or pelvic injury.
6. Creatinine and BUN (acute kidney injury); liver transaminases (direct liver trauma or shock liver); lipase (traumatic pancreatitis)
7. CBC: Initial hemoglobin can be normal in acute hemorrhage.
8. Pregnancy test: Obtain for all females of child-bearing age.


## II. HEAD AND NECK TRAUMA

### A. Head Imaging

1. PECARN algorithm developed by the Pediatric Emergency Care Applied Research Network ([Fig. 2.2](#))<sup>2</sup>
  - a. A well-validated, pediatric clinical decision aid that predicts need for computed tomography (CT) head imaging after pediatric head injury by assessing risk factors
  - b. Allows providers to identify pediatric patients at very low risk of clinically important traumatic brain injuries (ciTBI)
  - c. CT imaging carries known risks of lethal radiation-induced malignancy, which is higher in children than adults (the risk decreases with age).
  - d. Only applies to children with GCS scores  $\geq 14$ .
2. If signs of traumatic brain injury on CT, consider consultation with pediatric intensivists, neurosurgery, and/or trauma surgery.
  - a. For management of increased intracranial pressure, see [Chapter 1](#).

### B. Cervical Spine and Neck Imaging

1. There are currently no unified protocols or clinical guidelines for pediatric cervical spine clearance after blunt trauma.<sup>3</sup>
2. Based on Pediatric Emergency Care Applied Research Network (PECARN) C-spine criteria,<sup>3</sup> consider obtaining imaging if any of the following are present in a pediatric patient:
  - a. Altered mental status
  - b. Focal neurologic deficits
  - c. Complaint of neck pain
  - d. Torticollis
  - e. Substantial injury to the torso
  - f. Predisposing condition
  - g. High-risk motor vehicle crash
  - h. Diving accident
3. Of note, many institutions alternatively or adjunctly use NEXUS criteria for clinical C-spine clearance, though it is not validated in children  $\leq 8$  years.<sup>3</sup>



**FIGURE 2.2**

PECARN algorithm for identifying children at very low risk of clinically important traumatic brain injury (ciTBI).<sup>2</sup>

The criteria state that if any of the below are present, imaging is indicated<sup>4,5</sup>:

- a. Midline cervical tenderness
  - b. Altered level of alertness
  - c. Evidence of intoxication
  - d. Neurologic deficit
  - e. Presence of a painful distracting injury
4. Unlike the NEXUS criteria, the PECARN criteria include consideration of mechanism of injury and suggest that cervical spine imaging should be considered even in those who cooperate and are pain free if a high-risk mechanism of injury exists.
  5. Recent guidelines by the Pediatric Cervical Spine Clearance Working Group Algorithm<sup>6</sup> additionally highlight the following factors:
    - a. When clinical C-spine clearance is not possible, the preferred imaging modality for children who are  $\leq 3$  years old is radiography (see Chapter 26).
    - b. Clinical clearance can be done regardless of mechanism of injury in a child who is  $\geq 3$  years old if they are asymptomatic with normal mental status and normal physical examination.
    - c. Clinical clearance cannot be performed if the child or their parent reports persistent neck pain, abnormal head posture, or difficulty in neck movement.
  6. Other clinical considerations<sup>7</sup>:
    - a. Evaluate carefully children who display marking from seatbelt restraints in a motor vehicle collision, as this may indicate that extreme flexion of the cervical spine has occurred.
    - b. It should be stressed that the subsequent development of neck tenderness is an important diagnostic sign. Parents should always be encouraged to return to care if pain develops later or the child develops reluctance to move their neck.

### C. Specific Imaging Studies

1. A C-spine x-ray with minimum of two views (lateral, anteroposterior, and/or odontoid views) has 90% sensitivity in identifying bony cervical spine injury.<sup>8</sup>
2. Consider CT scan if there is high level of concern for a cervical vertebrae fracture and plain radiographs are inconclusive.<sup>9</sup>
3. Consider magnetic resonance imaging (MRI) scan for further evaluation of ligamentous and cervical spinal cord injury.<sup>9,10</sup>
4. 30%–40% of children with traumatic myelopathy have SCIWORA (spinal cord injury without radiographic abnormality)—clinical symptoms of traumatic myelopathy with no radiographic or CT features of spinal fracture or instability. MRI should be considered in these cases.<sup>11</sup>
  - a. SCIWORA is most common in children 8 years of age and under.

5. If signs of spinal column or vascular injury on imaging, consider consultation by trauma, vascular, spine, and/or head and neck surgeon.

### III. CONCUSSION

#### A. Concussion Evaluation

1. Concussions can encompass a constellation of symptoms following traumatic head injury, thought to result from neurometabolic dysfunction rather than structural injury. They are typically associated with normal structural neuroimaging findings. Most concussion symptoms clinically resolve in 1 to 3 weeks.<sup>12</sup>
2. Concussion symptoms can be physical, cognitive, emotional, or related to sleep:<sup>13</sup>
  - a. Headache
  - b. Feeling foggy, fatigued
  - c. Confusion, difficulty focusing
  - d. Photophobia, phonophobia
  - e. Forgetfulness
  - f. Nausea ± vomiting
3. Patients with symptoms lasting more than 3 weeks, worsening symptoms, or history of multiple concussions may benefit from a more detailed, longitudinal assessment by a medical provider (pediatrician, neurologist, sports medicine specialist, concussion specialist).<sup>13</sup>
4. The Centers for Disease Control and Prevention (CDC) HEADS UP website is a valuable resource center grounded in an education campaign focused on increasing awareness of concussion among children to prevent and reduce adverse outcomes.<sup>14</sup>
5. The CDC's Acute Concussion Evaluation (ACE) is a tool that can be used in multiple settings, including the clinic and emergency department. The form provides a thorough definition of what a concussion is and signs/symptoms for which to assess. There is also an ACE care plan for patients to help guide their recovery.<sup>14</sup>
6. CDC's HEADS UP resource links for patients and providers:
  - a. General website: <https://www.cdc.gov/headsup>
  - b. ACE Forms and Work/School Care Plans: <https://www.cdc.gov/headsup/providers/tools.html>

#### B. Return-to-School and Return-to-Play Guidelines (Table 2.1)

1. The overarching goal is to allow healing from injury and prevent cumulative brain trauma.

### IV. INTRATHORACIC, ABDOMINAL, AND PELVIC TRAUMA<sup>16</sup>

#### A. Assessment and Management Pearls

1. See Fig. 2.1 for physical exam findings during the secondary survey.
2. Tension pneumothorax or massive hemothorax

TABLE 2.1

## RETURN-TO-PLAY AND RETURN-TO-SCHOOL FOR CONCUSSION

Return-to-School Guidelines <sup>13</sup>	Return-to-Play Guidelines <sup>15</sup>
<ul style="list-style-type: none"> <li>• If symptoms affect concentration or if unable to tolerate stimulation for more than 30 minutes without symptoms, encourage rest with light mental activities, so long as symptoms are not provoked or worsened. Minimize computer use, texting/phone use, television, and video games.</li> <li>• If able to tolerate stimulation for minimum of 30–45 min without symptoms, consider returning to learning with modifications—see below.</li> <li>• Students should be performing at their academic baseline before returning to sports, full physical activity, or other extracurricular activities.</li> <li>• Most students with a concussion will recover within 3 weeks.</li> <li>• For students with symptoms lasting longer than 3 weeks, consider further medical management and accommodations</li> </ul> <p><b>Suggested school modifications:</b></p> <ul style="list-style-type: none"> <li>• Shortened school days</li> <li>• Frequent breaks during classes</li> <li>• Extra time to complete assignments</li> <li>• Decreased homework load</li> <li>• No significant examinations or standardized testing at this time</li> <li>• Consider 504 Plan and/or Individualized Education Plan (IEP)</li> </ul>	<p>6 gradual steps to help safely return an athlete to play:</p> <ul style="list-style-type: none"> <li>• Steps should not be completed in one day but instead over days, weeks, or months as tolerated by the individual.</li> <li>• Move to the next level of activity only if no new/worsening symptoms are experienced.</li> <li>• If symptoms return/worsen, patients should stop activities and notify a medical provider for clinical reevaluation.</li> <li>• After rest and resolution of symptoms, patients should resume play at the previous tolerated step of the return to play guidelines.</li> </ul> <p><b>Step 1:</b> Back to regular activities (such as school)</p> <p><b>Step 2:</b> Light aerobic activity</p> <ul style="list-style-type: none"> <li>• 5–10 minutes of walking, light jogging, light stationary biking</li> <li>• No weightlifting</li> </ul> <p><b>Step 3:</b> Moderate activity</p> <ul style="list-style-type: none"> <li>• Incorporating more head or body movement</li> <li>• Moderate jogging, brief running, moderate-intensity stationary biking, moderate-intensity weightlifting (reduced time and/or reduced weight from typical routine)</li> </ul> <p><b>Step 4:</b> Heavy noncontact activity</p> <ul style="list-style-type: none"> <li>• Sprinting/running, high-intensity stationary biking, regular weightlifting routine, noncontact sport-specific drills</li> </ul> <p><b>Step 5:</b> Full contact in controlled practice</p> <p><b>Step 6:</b> Full contact in competition/game play</p>


- a. Symptoms: Respiratory distress, unequal/abnormal breath sounds, hypotension, tachycardia, altered mental status
  - b. Iatrogenic causes: Positive-pressure-related barotrauma, procedures (subclavian or internal jugular central line placement), following CPR
  - c. Traumatic causes: Penetrating or blunt trauma, rib fractures
  - d. Emergent treatment: Immediate needle decompression (tension pneumothorax), chest tube placement (pneumothorax, hemothorax), volume resuscitation/blood transfusion (hemothorax)
3. Cardiac tamponade
- a. Symptoms: Chest pain, difficulty breathing, muffled/distant heart sounds, tachycardia, hypotension, altered mental status, electrical alternans on ECG/cardiac telemetry
  - b. Emergent treatment: Pericardiocentesis, volume resuscitation

4. Aortic dissection
  - a. Symptoms: Severe chest/abdominal pain, shortness of breath, loss of consciousness, stroke symptoms, pulse differential between arms or between arms and legs, poor distal perfusion, leg pain, difficulty walking
  - b. More stable patients can be considered for inotropy-reducing treatment ( $\beta$ -blockers) and endovascular repair.
  - c. Transfer should be initiated to the nearest trauma center if indicated and possible.
  - d. Hemodynamically unstable patients with concern for dissection should be taken to the operating room for laparotomy/thoracotomy.
5. Rib fractures and flail chest
  - a. Patients with multiple acute rib fractures typically warrant admission to a pediatric trauma center for:
    - (1) Pain control to improve respiratory function
    - (2) Age-appropriate pulmonary physiotherapy to prevent atelectasis
  - b. Splinting rib fractures with external devices can worsen ventilatory compromise and should be avoided.
  - c. Patients with rib fractures who require tube thoracostomy to relieve pneumo- or hemothorax should have tubes placed at sites separate from the areas of fracture.
  - d. Children younger than 3 years of age with rib fractures and without a history of high-force trauma warrant evaluation for possible child abuse.
  - e. Children with flail chest (which occurs when the chest wall loses stability as the result of multiple rib fractures) should receive respiratory support. Those with respiratory distress or failure should be intubated and receive positive-pressure ventilation for adequate oxygenation and ventilation as well as to optimally expand and internally splint the injured segments.
  - f. Due to more compliant chest walls, more kinetic energy can be transmitted to the intrathoracic structures without thoracic bony injury in children. For this reason, pulmonary contusion without rib fracture occurs more often in children than adults. Significant force is required to produce thoracic bony injury in children.
6. Abdominal injury (vascular, bowel or other organ) requiring surgery
  - a. PECARN rule for blunt abdominal trauma
    - (1) A pediatric patient with all of the below patient history and physical examination findings (without laboratory or ultrasonographic information) has a very low risk for intra-abdominal injury (IAI) requiring acute intervention (99% sensitivity in internal and external retrospective validation studies).<sup>17,18</sup>
      - (a) No evidence of abdominal wall trauma or seatbelt sign
      - (b) Glasgow Coma Scale score greater than 13
      - (c) No abdominal tenderness
      - (d) No evidence of thoracic wall trauma

- (e) No complaints of abdominal pain
  - (f) No decreased breath sounds
  - (g) No vomiting
- b. Peritonitis (severe pain, abdominal wall guarding/rigidity, avoidance of motion, flexed hips to relieve abdominal wall tension, hypoactive-to-absent bowel sounds, distention) can indicate intra-abdominal vascular or organ/bowel injury.
- (1) Peritonitis due to intra-abdominal hemorrhage may take several hours to develop.
- c. “Seatbelt sign” (bruising/visible injury in the distribution of a seatbelt restraint) is a significant predictive factor for surgical abdominal injury after blunt trauma (sensitivity 70.6%, specificity 82.4%).<sup>19</sup>
- d. Emergency laparotomy is the accepted standard of care in patients with a penetrating torso injury who are hemodynamically unstable and have a clinical indication for exploratory laparotomy, such as evisceration or gastrointestinal bleeding.
7. Unstable pelvic fracture
- a. Place a pelvic stabilization device.
  - b. Can be associated with pelvic organ injury, internal bleeding, and/or urinary tract injury

## B. Imaging Studies to Consider

1. Ultrasound—FAST (focused assessment with sonography in trauma) exam
  - a. May identify free fluid early and guide need for further imaging, observation, or surgery
  - b. In a 2017 randomized trial of 925 hemodynamically stable children comparing standard trauma workup or standard workup plus FAST, there was no difference in the proportion obtaining CT, missed intra-abdominal injury (IAI), length of stay, or cost.<sup>20</sup>
  - c. In a 2021 systematic review and meta-analysis of hemodynamically stable pediatric patients presenting with blunt abdominal trauma, the FAST exam had a pooled sensitivity of 35% and specificity of 96% for IAI.<sup>21</sup>
    - (1) A positive FAST examination result means that IAI is likely and could warrant CT imaging.
    - (2) A negative examination result alone cannot preclude further diagnostic workup (e.g., CT scan, serial FAST exams).
    - (3) See [Fig. 2.3](#) for an algorithm that incorporates the FAST exam and other findings to identify patients at very low risk for IAI.<sup>22</sup>
2. Radiographs
  - a. Chest x-ray: Evaluate for rib fracture, pneumothorax/hemothorax, pulmonary contusion, pneumomediastinum.
  - b. Abdominal and pelvic x-rays: Evaluate for free air, fluid, pelvic fracture.

**FIGURE 2.3**

Workup of intra-abdominal injury (IAI) in pediatric blunt abdominal trauma.<sup>22</sup>

### 3. Abdominal/pelvic CT with IV contrast:

- CT is the gold standard for diagnosis of IAI; however, radiographs should be obtained first if there is concern for additional injuries that would compromise clinical stability.
- CT is commonly used to rule out IAI in children, despite associated cost and radiation exposure. The Pediatric Surgery Research Collaborative developed a clinical prediction rule to identify children at very low risk for IAI after blunt abdominal trauma, for whom a CT scan of the abdomen could be avoided. (Fig. 2.3).<sup>22</sup>
  - The algorithm includes 5 clinical factors associated with IAI in the order of availability: reported abdominal pain, abnormal abdominal exam, abnormal chest x-ray, AST >200 U/L, and abnormal pancreatic enzymes.
- In stable patients with blunt abdominal trauma, CT with routine oral contrast is not necessarily indicated, whereas IV contrast should be used to help to identify visceral, vascular, or bowel injury.
- For penetrating abdominal trauma (gunshot wounds, impalement, stab wounds), triple contrast (oral, rectal, IV) CT can be used to

identify peritoneal penetration or intra-abdominal organ injury in stable patients.

- e. If gross hematuria or urinalysis with microscopic hematuria  $\geq 50$  RBCs per high-powered field, the patient may have genitourinary tract trauma. Consider CT pelvis with/without IV contrast or serial urinalyses/physical exams in consultation with surgery or urology.
4. If any workup is positive for thoracic or abdominal trauma, immediate consultation with nearest pediatric trauma center/surgeon is indicated if not available on site.

## V. LIMB AND LONG BONE TRAUMA<sup>16</sup>

### A. Assessment and Management Pearls

1. See [Fig. 2.1](#) for physical exam findings during the secondary assessment.
2. Children are difficult to examine, especially when they are in pain. A painful orthopedic injury can distract from other internal injury.
3. Neurovascular assessment:
  - a. Choose motor/sensory tests that are easy to perform quickly.
  - b. Use Doppler to aid in identifying pulses and monitoring for compartment syndrome.
4. Bleeding
  - a. Consider arterial bleed if absent pulses and cool extremity with bleeding.
  - b. Consider venous bleed if persistent pulse with bleeding.
  - c. Obtain time of tourniquet placement if done in prehospital setting.
5. Compartment syndrome:
  - a. Circumferential, constrictive swelling leads to vascular and nerve compromise.
  - b. Can develop soon after significant trauma—especially in crush injuries, burns, animal bites/stings, vascular injuries of limbs, long bone fractures, limb gunshot wounds
  - c. Symptoms include pain (especially out of proportion to apparent injury or with passive extension), paresthesias, pallor, pulselessness (if unable to palpate pulse, use Doppler), paresis
6. If signs/symptoms of compartment syndrome or fracture, immediate consultation with an orthopedic surgeon is recommended.
7. Consider need for tetanus prophylaxis. Refer to [Chapter 16](#) for details.

### B. Imaging

1. Children's bones are less densely calcified, have thickened periosteum, and have growth plates, all of which increase their vulnerability to fractures.
2. Consider obtaining radiographs if bony point tenderness or deformity, decreased sensation, decreased range of motion, or overlying skin discoloration.
3. Radiographs with anterior-posterior (AP) and lateral views  $\pm$  oblique and including areas above and below the suspected area of injury are recommended.

### C. Traumatic Fractures in Children

1. Physeal or Salter-Harris fractures: Fractures involving growth plates (see [Chapter 26](#))
2. Plastic fractures: Pliability of bones in response to compressive and transverse forces
  - a. Torus or buckle fracture: Compression injury with buckled cortex
  - b. Greenstick fracture: Fracture on one side of the diaphysis with cortex intact on other side of diaphysis
  - c. Bowing or bending fractures
3. Avulsion fractures: Tendon or ligament dislodging a bone fragment—these are more common among adolescents participating in sports.
4. Dislocations in children are relatively unusual, generally related to major trauma, and associated with fractures. This is due to stronger ligaments with comparatively less bony strength.
  - a. Subluxation of the radial head or “nursemaid elbow” reduction can often be done by an emergency provider. Most other dislocations should be referred to orthopedic surgery.
5. See [Chapter 4](#) for basic splinting and musculoskeletal procedures.

### D. Fractures Requiring Urgent Orthopedic Surgeon Consultation

1. Open fractures
2. Unacceptably displaced fractures
3. Fractures with associated neurovascular compromise (consider emergent reduction to improve neurovascular status if orthopedic surgery is not available on site)
4. Significant growth plate or joint injuries
5. Complete or displaced fractures of the long bones of the extremities
6. Pelvic fractures (other than minor avulsions)
7. Spinal fractures
8. Dislocations of major joints other than the shoulder

### E. Fractures That Are Appropriate to Manage Acutely With Outpatient Referral to Orthopedics (Table 2.2)

## VI. DENTAL TRAUMA

### A. Components of a Tooth (Fig. 2.4)

### B. Differences Between Primary and Permanent Teeth (Fig. 2.5)

1. Primary teeth appear 6 months to 3 years of age, are relatively smaller, thinner, and whiter; the roots are shorter and the front teeth have a smooth biting surface.
2. Permanent teeth appear 6 years to 21 years of age, relatively larger with a longer root; front teeth have a ridged biting surface.

### C. Dental Injuries

1. Avulsion<sup>23</sup>
  - a. Complete displacement of the tooth and its root from the bony alveolar socket

TABLE 2.2

## COMMON PEDIATRIC ORTHOPEDIC INJURIES AND MANAGEMENT

Injury	ED Management	Follow-Up
Clavicle fracture without tenting or displacement (if present, orthopedic surgery consultation required)	Sling	Primary care provider in 2 weeks
Acromioclavicular joint separation	Sling	Orthopedics within 1 week
Proximal humerus fracture without deformity, displacement, or neurovascular injury	Sling	Orthopedics within 1 week
Distal radius or ulna fracture without deformity, displacement, or neurovascular injury	Volar splint	Orthopedics within 1 week
Salter-Harris Type 1—Distal radius	Volar splint	Orthopedics within 1 week
Salter-Harris Type 1—Distal fibula	Posterior splint, crutches	Orthopedics within 1 week
Distal radius buckle fracture without deformity, displacement, or neurovascular injury	Volar splint	Orthopedics within 1 week
Phalanx fractures without displacement or open deformity	Splint/buddy tape	Primary care provider in 2 weeks





FIGURE 2.4

Normal anatomy of a tooth.<sup>16</sup>

- b. If a primary tooth, reimplantation should not be attempted and outpatient dental follow-up is appropriate.
- c. If a permanent tooth, this is a dental emergency. If possible and safe, immediate reimplantation should occur within 60 minutes to maximize tooth and periodontal ligament viability.



**FIGURE 2.5**

Development from primary to permanent teeth by location. (Modified from American Dental Association. <https://www.mouthhealthy.org>)

- (1) Good prognosis is very much dependent on early actions and reimplantation at the place of accident or during emergency care management.
- d. For a permanent tooth, reimplantation should always be attempted. If reimplantation is not possible, place the tooth in a suitable storage medium (in descending order of preference: milk, Hank's balanced salt solution, expectorated saliva, saline) and refer to a dentist emergently for reimplantation and splinting.
  - (1) Situations when reimplantation is not indicated: primary tooth avulsion, severe caries or periodontal disease, an uncooperative patient, risk of choking, severe cognitive impairment, sedation, immunosuppression, severe cardiac conditions, unstable patient
- e. Reimplantation steps:
  - (1) Pick up the avulsed tooth by the crown and avoid touching the root.
  - (2) Wash the tooth and alveolar socket with sterile saline, removing clotted blood if necessary.

- (3) Administer local anesthesia (without a vasoconstrictor) into the gum if necessary.
- (4) Insert the root into the alveolar socket with concave part facing the tongue, and apply slight manual pressure.
- (5) Ask the patient to bite on gauze or cloth to hold it in position.
- (6) The patient should be seen by a dentist or dental professional emergently for splinting and follow-up care.

## 2. Luxation<sup>24</sup>

- a. Luxation injuries result from physical displacement of tooth within the alveolar socket itself. Luxation can be associated with tearing of the periodontal ligament or injury to the alveolar bone.
  - (1) Luxation injuries are the most common traumatic dental injuries in the primary dentition.
- b. Primary tooth:
  - (1) If tooth is loose and there is an increased risk of aspiration, the tooth may be extracted by using firm pressure with gauze.
  - (2) If tooth is not loose, it may need repositioning and splinting.
  - (3) In both situations, refer to a dentist for evaluation within 48 hours.
- c. Permanent tooth:
  - (1) Immediate dental evaluation required if significant tooth mobility; otherwise, outpatient evaluation within 48 hours is appropriate

## 3. Subluxation<sup>24</sup>

- a. Subluxation is characterized by tooth injury with minor mobility but without displacement.
- b. Regardless of whether permanent or primary tooth, outpatient dental follow-up, ideally within 48 hours, is needed to rule out root fracture.

## 4. Tooth fracture<sup>24</sup>

- a. Classify the fracture per involvement of enamel, dentin, and pulp.
- b. For management guidelines, see [Table 2.3](#).

### D. Anticipatory Guidance Following Dental Trauma

1. Avoid contact sports until cleared by a dentist

**TABLE 2.3**

**TOOTH FRACTURE TYPES AND FOLLOW-UP RECOMMENDATIONS<sup>26</sup>**

Fracture Type	Follow-Up Recommendations
Enamel fracture	Dental evaluation outpatient for possible binding of tooth fragment, if available
Enamel-dentin fracture	Dental evaluation 48–72 hr to place a dressing of calcium hydroxide to prevent injury to the pulp
Enamel-dentin-pulp fracture	Immediate dental evaluation within 48 hr
Alveolar ridge fracture	Emergent dental evaluation

2. Analgesics as needed for pain control (e.g., acetaminophen, ibuprofen, cold compresses)
3. Soft diet
4. Use a soft toothbrush, if able to brush teeth.
5. Regular follow-up with a dentist

## VII. OPHTHALMOLOGIC TRAUMA<sup>16</sup>

### A. Chemical Injury to the Eye

1. Immediate and continued irrigation of eyes with water, isotonic saline, or lactated Ringer's solution is necessary.
2. Consult with Poison Control.
  - a. Call (800) 222-1222—will route to local center.
  - b. Available 24 hours a day
3. Determine if substance is an acid or alkali. Alkali solutions tend to be more damaging because they penetrate more deeply.
  - a. Obtain a baseline pH by touching Litmus paper to the conjunctiva. This is a crude but practical way to determine the type of substance if otherwise unknown.
    - (1) Consider acidic substance if pH <7, and alkali if >7.4.
    - (2) Continue irrigation for a minimum of 20 minutes or until 2 liters of fluid have been used to irrigate the eye(s).
    - (3) Evert the eyelid and continue lavage.
    - (4) Remeasure pH every 15 to 30 minutes until pH becomes neutral (7.0 to 7.4). Normalization of pH for most eye exposures typically takes 30 to 60 minutes.
4. Measure and trend visual acuity if possible.
5. Urgent ophthalmologic evaluation should be considered in cases with severe vision changes or vision loss, uncontrolled pain, significant mucosal injury, or persistent pH abnormality despite diligent irrigation.
6. In the United States, injury from chemical ocular burns occurs most often in residential settings, with preschool-aged children being the most common victims.<sup>16</sup>

### B. Ruptured Globe

1. A ruptured globe is caused by laceration or puncture of the cornea and/or sclera following projectile or blunt trauma.
2. Warrants emergent ophthalmology consultation.
3. Key physical exam findings include teardrop-shaped pupil pointing toward perforation, hyphema (hemorrhage in the anterior chamber), subconjunctival hemorrhage, severe pain, decreased visual acuity, edema.
  - a. When hyphema is present, sickle cell trait is a significant risk factor for complications including secondary hemorrhage, increased intraocular pressure, and permanent visual impairment in children.<sup>25</sup>

4. Stop the exam and place a rigid eye shield. Do not instill eye drops.
5. Elevate the head of the bed.
6. Keep patient as calm as possible and control symptoms (e.g., antiemetics and pain control) to avoid increased globe pressure and further extrusion of vitreous/aqueous humor.
7. Administer appropriate antibiotics.

### C. Corneal Abrasion

1. Symptoms: Red eye with tearing, intense pain, resistance to eye opening, photophobia, foreign body sensation
2. Consider application of topical anesthetic before examination, which can support diagnosis if providing immediate relief.
  - a. Although topical anesthetic eye drops may be used during the initial examination, they should not be regularly used or prescribed for the treatment of corneal abrasion pain due to risk of patient misuse or complications. Repeat application of an ocular anesthetic can delay or compromise healing and increase infection risk.
3. Evert eyelids to look for retained foreign body; irrigate eye if necessary.
4. Apply fluorescein staining and examine with Wood's lamp. Focal uptake indicates abrasion.
  - a. Staining should be deferred until the eye examination is complete and an open globe is excluded.
5. Treatment: Artificial tears and/or ophthalmic ointment for lubrication, topical ophthalmic antibiotic ointment, oral analgesics or ophthalmic NSAIDs, ophthalmologic follow-up as indicated, ± patching depending on severity or patient cooperation.
6. Consider ophthalmologic consultation in the ED if concern for larger corneal abrasions associated with vision changes, corneal laceration, ulceration, embedded foreign body, or prolonged healing (i.e., symptoms not improving after several days).

### D. Eyelid Glued Shut due to Cyanoacrylate (Superglue)

1. Can consider trimming eyelashes as needed with blunt-tip scissors. Do not try to force eyes open.
2. Consider ophthalmology consultation, especially in the case of glue bonding to the eye.
3. The use of around-the-clock eye/mucosa-safe oil-based ointments can help accelerate dissolution of the glue bonds. Can cover eye with gauze or a patch to prevent the patient from touching it.
4. Consider consultation with ophthalmology if a few days of ointment is unsuccessful.
5. A 2017 report by physicians at the University of Alabama at Birmingham Hospital discusses the Jameson muscle hook technique, which has been successfully used there without complications to safely relieve eyelid adhesions due to cyanoacrylate glue without the use of general anesthesia in pediatric and adult patients.<sup>26</sup>

- a. With this method, topical anesthetic is applied through an explored opening in the eye. Then, a Jameson muscle hook is inserted into an opening between the eyelids and pulled parallel to the lid margins through the site of adhesion, while counter pressure is applied against the direction of the hook.

### **E. Eyelid Laceration**

1. Do not initiate closure of an eyelid laceration prior to excluding injury to the globe or foreign body.
  - a. Ocular injury (i.e., open globe, traumatic hyphema, corneal abrasion) may accompany eyelid laceration in up to two-thirds of cases.
2. Consult with ophthalmology if full-thickness lacerations (exposed adipose tissue), laceration through the lid margin, lacerations involving lacrimal canaliculi (medial third of the upper/lower lids), ptosis (unequal lifting of lids with upward gaze would suggest this), or other concerning symptoms.
3. Lacerations to the eyelid should be repaired within 24 hours of injury to prevent scarring and promote appropriate alignment of the eyelid tissues.
4. Superficial, simple lacerations that are horizontal, follow the skin lines, and involve less than 25% of the lid will usually heal well without suturing. Providers can use antibiotic ointment or adhesive surgical tape (i.e., Steri-strips) to approximate wound edges.

### **F. Orbital Floor Fractures**

1. This injury is usually caused by blunt trauma. The weakest area of the orbital bones is the orbital floor/maxillary roof.
2. For children, the most common mechanisms of orbital fracture injury are falls, being struck by a ball, and physical assaults.
3. Key physical exam findings include eyelid swelling, ecchymosis, exophthalmos, ptosis, diplopia, anesthesia of the cheek (involvement of infraorbital nerve), and restricted extraocular eye movements (intraocular muscle entrapment).
4. Often associated with significant traumatic injury. Evaluate for other globe injuries (including retinal trauma, ruptured globe, hyphema) and intracranial injuries/bleeds.
  - a. Injury to the globe is commonly associated with an orbital fracture (29% to 50% of patients, depending upon the setting).
5. In addition to ophthalmology, consider consultation with plastic surgery and/or head and neck surgery.
6. CT imaging should be performed for a patient with periorbital trauma and any of the following findings:
  - a. Evidence of a fracture on physical examination
  - b. Limitation of extraocular movement
  - c. Decreased visual acuity

- d. Severe pain
- e. Inadequate examination (usually because of soft tissue swelling)
- f. Altered mental status

### G. Other Instances Requiring Ophthalmologic Consultation

1. Traumatic iritis is associated with blunt trauma and may present as painful red eye, pupillary constriction, and photophobia, often with delayed presentation of symptoms (24 to 72 hours) after trauma.
2. Sudden loss of vision could suggest retrobulbar hemorrhage or retinal detachment.

2

## VIII. ANIMAL BITES<sup>16</sup>

### A. Risk of Infection and Antibiotic Prophylaxis

1. Risk factors include:
  - a. Underlying immunosuppression (including diabetes) or asplenia
  - b. Bite involving the hand, foot, genitalia, or joint surface
  - c. Bite in an extremity with underlying venous and/or lymphatic compromise
  - d. Bite near or in a prosthetic joint or vascular graft
  - e. Crush injury or puncture wound
  - f. Cat bite (given propensity for deep puncture wounds)
  - g. Human bite
  - h. Delayed presentation ( $\geq 12$  hours after a bite on the extremities and  $\geq 24$  hours after a bite on the face)
2. Antibiotic prophylaxis is suggested for:
  - a. Patients with risk factors above
  - b. Lacerations undergoing primary closure
  - c. Wounds requiring surgical repair
3. Empiric antibiotic treatment ([Table 2.4](#))
  - a. Consider IV antibiotics if patient is critically ill or unable to tolerate PO intake.
  - b. Tetanus postexposure prophylaxis: See [Chapter 16](#).
  - c. Rabies postexposure prophylaxis: See [Chapter 16](#).

**TABLE 2.4**

#### ANTIBIOTIC MANAGEMENT OF ANIMAL AND HUMAN BITES

Type of Bite	Organisms	Treatment
Animal bite	<i>Staphylococcus aureus</i> , <i>Streptococci</i> , oral anaerobes, <i>Pasteurella</i> , <i>Capnocytophaga canimorsus</i>	<ul style="list-style-type: none"> <li>• Amoxicillin/clavulanate for 5 days</li> <li>• TMP/SMX and clindamycin, if allergy to penicillin</li> </ul>
Human bite	<i>Streptococcus viridans</i> , <i>S. aureus</i> , oral anaerobes, <i>Eikenella corrodens</i>	<ul style="list-style-type: none"> <li>• Amoxicillin/clavulanate for 5 days</li> <li>• Clindamycin and ciprofloxacin, if allergy to penicillin</li> </ul>

**B. Physical Exam Assessment**

1. Evaluate wounds carefully for foreign material.
2. Neurovascular assessment should be routinely performed in areas distal to the wounds.
3. The median time to showing symptoms of infection following a dog bite is approximately 24 hours; the median time following a cat bite is typically shorter—approximately 12 hours.

**C. Imaging**


1. Imaging is not necessary for most clinically uninfected, superficial bites.
2. Deep bite wounds, including those near joints, warrant radiographs to evaluate for evidence of foreign bodies (such as embedded teeth), fracture, or joint disruption.


**D. Decision to Suture and Infection Risk**

1. Avoidance of primary closure is generally preferred unless wound is present on the face (cosmetic importance and has a lower rate of infection relative to other areas).
2. Wounds left open to heal by secondary intention should be debrided, irrigated copiously, dressed, and evaluated daily for signs of infection.
3. Lacerations closed primarily should be clinically uninfected and ideally <24 hours old (facial lacerations) or <12 hours old (sites other than the face). Meticulous debridement and irrigation should be performed prior to closure.
4. Bite wounds should not be closed with tissue adhesive glue (e.g., Dermabond) due to increased infection risk.
5. Surgical consultation (i.e. plastic, orthopedic, otolaryngology, ophthalmology) warranted in:
  - a. Large/complex wounds
  - b. Wounds that involve tendons, joints, deep fascia, major vasculature, or bones
  - c. Deep infection (abscess, necrotizing soft tissue infection, septic arthritis, osteomyelitis)
  - d. Infection associated with neurovascular compromise
  - e. Presence of crepitus
  - f. Rapidly progressive infection

**IX. BURNS<sup>27,28</sup>****A. First Aid and Emergency Management**

1. See [Fig. 2.6](#) for an algorithmic approach to burn evaluation in the emergency setting.
2. Triaging burn severity
  - a. Estimate of the total body surface area (TBSA) of burns (see [Fig. 2.7](#) for modified Lund-Browder chart)
    - (1) Only include partial- and full-thickness burns in this calculation (exclude superficial burns).

**FIGURE 2.6**Initial burn management.<sup>28</sup>



Age	<1 yr	1 yr	5 yr	10 yr	15 yr	Adult
A Front or back of head	9.5	8.5	6.5	5.5	4.5	3.5
B Front or back of thigh	2.75	3.25	4	4.25	4.5	4.75
C Front or back of leg	2.5	2.5	2.75	3	3.25	3.5

**FIGURE 2.7**

Burn assessment (modified Lund-Browder chart). All numbers are percentages. Only include partial and full thickness burns in calculation. (Modified from Barkin RM, Rosen P. *Emergency Pediatrics: A Guide to Ambulatory Care*. 6th ed. Mosby; 2003.)

- (2) The hand of the person who is burned (palm and adducted 5 fingers) is approximately 1% of the TBSA; this can be an easier way to measure TBSA of burns in the emergent setting
  - b. Determine the depth of the burn (see [Table 2.5](#)).
3. Burns that should prompt consideration of elective/early intubation

TABLE 2.5

## BURN CLASSIFICATION

Wound Depth	Layer Involved	Clinical Findings
Superficial	Epidermis	<ul style="list-style-type: none"> <li>• Dry, painful, erythematous (like a sunburn)</li> </ul>
Partial thickness	Dermis	<ul style="list-style-type: none"> <li>• Moist, painful, erythematous</li> <li>• Blistering, blanching</li> <li>• Disruption of nails, hair, sebaceous glands</li> </ul>
Full thickness	Subcutaneous, fascia, muscle, bone	<ul style="list-style-type: none"> <li>• Pale, charred, waxy, leathery</li> <li>• Insensate (nerve endings burned)</li> <li>• No bleeding or blanching (capillary bed burned)</li> </ul>

- a. Signs of smoke inhalational injury (e.g., singed nasal hairs, soot at the nares, oropharyngeal erythema)
  - b. Early onset stridor
  - c. Severe burns of face and/or mouth
  - d. Signs of worsening oxygenation/ventilation
4. Fluids
- a. See Fig. 2.8 for fluid resuscitation guide in patients with burns.
    - (1) Fluid resuscitation should be considered a dynamic process guided by frequent reassessments as opposed to an absolute volume, to prevent over- or under-resuscitation.
  - b. Consider central venous access for burns greater than 25% TBSA.
  - c. Withhold potassium from IV fluids for the first 48 hours (release of potassium from damaged tissues).




FIGURE 2.8

Formulaic fluid resuscitation for pediatric burn patients. <sup>16,28</sup>

- d. Foley catheter placement is recommended to monitor urine output during fluid resuscitation phase.
5. Analgesia
  - a. Consider conscious/procedural sedation versus general anesthesia for cases requiring significant debridement.
  - b. Children with major burns typically require opioid analgesics for pain relief.
  - c. Most burn centers use morphine for wound care pain. Fentanyl may be a safer choice for initial pain management for patients whose cardiovascular status is unstable.
  - d. Acetaminophen and NSAIDs alone or in combination with opioids for less severe burns.
6. Indications for transfer to a burn center
  - a. Partial-thickness (second-degree) burns  $\geq 10\%$  TBSA burn
  - b. Any significant burn to the face, hands, feet, genitalia, perineum, or major joints
  - c. Full-thickness (third-degree) burns
  - d. Electrical burns, including lightning injury
  - e. Chemical burns
  - f. Inhalation injury
  - g. Any child with burns and traumatic injury (i.e., fractures) in whom the burn injury poses the greatest risk of morbidity or mortality
  - h. Burns in children with preexisting conditions that could complicate management, prolong recovery, or affect mortality.
    - (1) Children requiring social, emotional, or rehabilitative factors
    - (2) Burned children in hospitals without qualified personnel and equipment for the care of children
7. Risk of shock
  - a. Immediately following the burn injury, vasoactive mediators (cytokines, prostaglandins, oxygen radicals) are released from damaged tissue, causing increased capillary permeability and risk of distributive shock.
  - b. Patients with large burns ( $\geq 15\%$  TBSA for young children and  $\geq 20\%$  for older children and adolescents) often develop systemic inflammatory responses.
  - c. Tissue damage and release of cell contents can cause electrolyte shifts and cardiac arrhythmia. For patients with 40% TBSA or more, myocardial depression can occur.
8. Criteria for admission to a local hospital for observation, intravenous fluid administration, and pain management include:
  - a. Children with 5%–10% TBSA burn (depending upon parental capability and social circumstances)
  - b. Full thickness burn 2%–5% TBSA, if local pediatric surgical expertise is available
  - c. Circumferential burn
  - d. Medical problem predisposing to infection
  - e. Concern for nonaccidental trauma or unsafe home environment

9. Wound evaluation and care
  - a. Debridement
    - (1) Debridement of devitalized tissue (including ruptured blisters) decreases the risk of infection.
    - (2) The depth of burn wounds can be determined with better accuracy when the wound bed is inspected directly.
    - (3) Initial debridement can usually be accomplished with sterile saline-soaked gauze.
    - (4) Experts generally recommend that large blisters and those that are painful (regardless of size) be removed.
  - b. Wound dressing
    - (1) For patients who are being rapidly transferred to a burn unit, burns should be covered with dry, sterile dressings. Moist dressings, ointments, or creams should not be applied because they can hinder initial wound assessment and care at the burn center.
    - (2) Superficial burns (epidermal and superficial partial-thickness burns) are generally managed with topical antimicrobial agents with an overlying dressing.
      - (a) A moist wound environment should be maintained for optimal healing.
      - (b) For optimum effect and pain relief, the dressing should maintain maximum contact with the wound without adhering to it. It should be easy to apply and remove.
  - c. Management of less severe burns (superficial and partial thickness)
    - (1) Clean with warm saline or mild soap and water.
    - (2) For superficial burns (including sunburns), application of nonperfumed moisturizing cream or ointment is typically all that is required, without need for a topical antibiotic or dressing.
    - (3) Sloughed or necrotic skin, including ruptured blisters, should be debrided before applying a dressing.
    - (4) For partial-thickness burns, apply topical antibacterial agent such as bacitracin (requires daily dressing changes) or silver-impregnated dressings (dressing can be left in place until follow-up) and cover with nonadherent dressing.
    - (5) Follow-up inspections of burn wounds should occur the day after injury (to adjust pain medications and to assess the patient's/family's competence performing dressing changes). Subsequent follow-up can then be done on a weekly basis until wound epithelialization occurs.

### **B. Other Special Considerations With Burns**

1. Circumferential burns rapidly begin to contract and can lead to compartment syndrome.
2. Children involved in a house/building fire or fire in an enclosed space are at risk for carbon monoxide and cyanide poisoning; consider empiric use of appropriate therapy (e.g. hyperoxygenation or hydroxocobalamin).

3. For patients with electrical burns from exposure to high voltage (>1000 V) or lightning:
  - a. May have associated conditions such as cardiac arrhythmias—consider cardiac monitoring for 48 hours
  - b. Risk of fractures, compartment syndromes, and rhabdomyolysis/myoglobinuria (with related renal injury)
  - c. Increased risk of compression spine fractures or spinal cord injury due to tetany
4. Household outlets are 120 to 240 V, and household electrical burns rarely cause serious injuries or cardiac arrhythmias.<sup>27</sup>
  - a. Mobile babies, toddlers, and young children can chew on or bite electrical cords that are plugged into an outlet. Electrical burn from this can lead to significant mouth/facial injury.
5. Tetanus prophylaxis is warranted with burns. Refer to [Chapter 16](#) for details.
6. See [Section X](#) for signs of nonaccidental traumatic burns.

## X. NONACCIDENTAL TRAUMA<sup>16</sup>

### A. Physical Abuse

1. Red flags in history
  - a. History is inconsistent with age, pattern, or severity of the injury.
  - b. History is inconsistent with child's physical or developmental capabilities.
  - c. Inconsistent/incomplete/vague/changing explanations for significant injury
  - d. Delay in presentation
  - e. Different witnesses provide different explanations.
2. Red flags in physical exam
  - a. Bruises
    - (1) In protected areas—chest, abdomen, back, buttocks
    - (2) Multiple
    - (3) In various stages of healing
    - (4) Do not fit history or developmental stage of child
    - (5) In unusual places (e.g., postauricular, neck, inner aspect of arms)
    - (6) Consistent with slap of hand or pinch
  - b. Burns
    - (1) Scald burns that have a sharply demarcated edge
    - (2) Burns in the distinct shape of an object
    - (3) Small circular burns matching a cigarette or cigar tip
    - (4) Burns on the perineal area with sparing of inguinal/flexural creases, matching a “dip-in” pattern (child dipped into scalding water)
    - (5) Multiple burns in various places
    - (6) Stocking/glove distribution burns

- (7) Symmetrically burned palms/soles, buttocks, and/or lower legs; mirror image burns of extremities
  - c. Frenulum tears
  - d. Loop marks from cord or cable
  - e. Welts
  - f. Bites
  - g. See [Figs. 2.9 through 2.12](#) (color plates) and [eFigs. 2.1 through 2.4](#) for examples.
3. Imaging guidelines<sup>29-31</sup>
- a. Skeletal survey
    - (1) In children less than 2 years of age, use a skeletal survey to evaluate for bony injury. This includes frontal and lateral views of the skull, lateral views of the cervical spine and thoracolumbosacral spine, and single frontal views of the long bones, hands, feet, chest, and abdomen.
    - (2) In children greater than 5 years of age, targeted imaging to the area(s) of suspected injury is usually appropriate. The utility of screening with skeletal survey diminishes after 5 years of age.
    - (3) In children 2 to 5 years of age, decisions about type of imaging are open to clinical judgement.
    - (4) Do not use “babygrams” (i.e., whole-body x-rays) because of the high rate of false negatives.
    - (5) Follow-up skeletal survey approximately 2 weeks after the initial examination should be performed when abnormal or equivocal findings are found on initial study or to identify fractures missed on initial survey.
    - (6) Fractures associated with child abuse include posterior rib fractures, bucket handle and metaphyseal corner fractures, spine and scapula fractures, and skull fractures.
  - b. Head CT without contrast if:
    - (1) Less than 6 months of age with suspected abuse
    - (2) Neurological changes, altered mental status
    - (3) Significant facial injuries concerning for abuse
  - c. Additional imaging/consultation
    - (1) Ophthalmologic evaluation for retinal hemorrhages
    - (2) MRI may identify lesions/injury not detected by CT.
4. What to do if child abuse is suspected:
- a. Medical stabilization is the immediate goal; prevention of further injuries is the long-term goal.
  - b. All healthcare providers are mandated by law to report suspected child maltreatment to the local police and/or child welfare agency.
  - c. The professional who makes a report is immune from any civil or criminal liability.
  - d. Consider consultation of local child injury/abuse specialist.



**eFIGURE 2.1**

Bite mark outlining the dental arch. (Modified from Zitelli BJ, McIntire SC, Nowalk, AJ. *Atlas of Pediatric Physical Diagnosis*. 7th ed. Elsevier; 2018.)




**eFIGURE 2.2**

Cigarette burn appearing as a circular punched-out lesion. (Modified from Zitelli BJ, McIntire SC, Nowalk, AJ. *Atlas of Pediatric Physical Diagnosis*. 7th ed. Elsevier; 2018.)

**eFIGURE 2.3**

Loop marks from a cord or cable. (Modified from Zitelli BJ, McIntire SC, Nowalk, AJ. *Atlas of Pediatric Physical Diagnosis*. 7th ed. Elsevier; 2018.)

**eFIGURE 2.4**

Multiple parallel lines equally distributed due to a slap from a hand. (Modified from Zitelli BJ, McIntire SC, Nowalk, AJ. *Atlas of Pediatric Physical Diagnosis*. 7th ed. Elsevier; 2018.)

- e. It is important to obtain a workup to rule out medical causes of injuries (bleeding disorder, osteogenesis imperfecta).
5. Carefully and legibly document the following:
- a. Reported and suspected history and mechanisms of injury
  - b. Any history given by the victim in their own words (use quotation marks)
  - c. Information provided by other providers or services
  - d. Physical examination findings, including photos or drawings of injuries and details of dimensions, color, shape, and texture. Consider early use of police crime laboratory photography to document injuries. If taking photos, start with full patient, then part of patient, then zoomed into wound, and then take a separate photo of wrist identification band.

## **B. Sexual Abuse<sup>32</sup>**

1. What to do if sexual abuse is suspected:
- a. Sexual abuse evaluations are best performed in a nonemergency setting, such as a child abuse advocacy center.
  - b. Urgent evaluation is necessary under the following circumstances and typically occurs in an emergency setting:
    - (1) The alleged abuse occurred within 72 to 96 hours, depending upon jurisdiction.
    - (2) There are genital or anal injuries that require treatment.
    - (3) There is obvious forensic evidence on the patient's clothes or body that must be collected.
    - (4) There is danger of continued abuse or reprisal by the alleged perpetrator.
    - (5) The victim has reported homicidal or suicidal ideation.
  - c. Avoid re-traumatizing the patient with invasive exams unless medically necessary. Keep in mind that most genital examinations are normal in cases of sexual abuse.
2. The medical evaluation of childhood sexual abuse has several immediate goals:
- a. Identify injuries or other conditions that require treatment.
  - b. Screen for, empirically treat, and/or diagnose sexually transmitted infections (STIs).
  - c. Evaluate for and, if possible/desired, reduce the risk of pregnancy.
  - d. Document findings of potential forensic value.
3. STI testing
- a. In adolescents, recommended for all patients presenting with concern for sexual abuse
  - b. In prepubertal children presenting with concern for sexual abuse, consider testing if any of the below factors are met:
    - (1) Penetration of the vagina or anus
    - (2) Abuse by a stranger

- (3) Abuse by a perpetrator known to be infected with an STI or at high risk of being infected (IV drug use, sex trafficking concerns, multiple sexual partners)
  - (4) Child with sibling or another household member with STI
  - (5) Child living in an area with high rate of STI in the community
  - (6) Signs/symptoms of an STI
  - (7) Has already been diagnosed with one STI
- c. Tests include:
- (1) Serum: HIV, syphilis
  - (2) Specimen cultures for gonorrhea/chlamydia/trichomonas, which can be collected from the penis, vagina, anus, and pharynx
- d. Consider the need for postexposure HIV prophylaxis (see [Chapter 17](#)).

## REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Henry S. ATLS Advanced Trauma Life Support 10th Edition Student Course Manual. *ACS American College of Surgeons*. 2018.
2. Kuppermann N, Holmes JF, Dayan PS, et al. Identification of children at very low risk of clinically-important brain injuries after head trauma: a prospective cohort study. *Lancet*. 2009;374(9696):1160–1170. [https://doi.org/10.1016/S0140-6736\(09\)61558-0](https://doi.org/10.1016/S0140-6736(09)61558-0)
3. Leonard JC, Browne LR, Ahmad FA, et al. Cervical spine injury risk factors in children with blunt trauma. *Pediatrics*. 2019. <https://doi.org/10.1542/peds.2018-3221>
4. Hoffman JR, Mower WR, Wolfson AB, et al. Validity of a set of clinical criteria to rule out injury to the cervical spine in patients with blunt trauma. *N Engl J Med*. 2000;343(2):94–99. <https://doi.org/10.1056/NEJM200007133430203>
5. Viccellio P, Simon H, Pressman B, et al. A prospective multicenter study of cervical spine injury in children. *Pediatrics*. 2001;108(2):E20. <https://doi.org/10.1542/peds.108.2.e20>
6. Herman MJ, Brown KO, Sponseller PD, et al. Pediatric cervical spine clearance: a consensus statement and algorithm from the pediatric cervical spine clearance working group. *J Bone Jt Surg*. 2019;101(1):e1. <https://doi.org/10.2106/jbjs.18.00217>
7. Maxwell MJ, Jardine AD. Paediatric cervical spine injury but NEXUS negative. *Emerg Med J*. 2007;24(9):676. <https://doi.org/10.1136/emj.2007.046912>
8. Nigrovic LE, Rogers AJ, Adelgais KM, et al. Utility of plain radiographs in detecting traumatic injuries of the cervical spine in children. *Pediatr Emerg Care*. 2012;28(5):426–432. <https://doi.org/10.1097/PEC.0b013e3182531911>
9. Flynn JM, Closkey RF, Mahboubi S, Dormans JP. Role of magnetic resonance imaging in the assessment of pediatric cervical spine injuries. *J Pediatr Orthop*. 22(5):573–577. <http://www.ncbi.nlm.nih.gov/pubmed/12198456>
10. Henry M, Riesenburger RI, Kryzanski J, et al. A retrospective comparison of CT and MRI in detecting pediatric cervical spine injury. *Childs Nerv Syst*. 2013;29(8):1333–1338. <https://doi.org/10.1007/s00381-013-2092-x>
11. Yeste K, Barton EA, Cleveland CA, et al. Spinal cord injury without radiological abnormality. *American Academy of Physical Medicine and Rehabilitation*. 2013 December. <https://now.aapmr.org/spinal-cord-injury-without-radiological-abnormality/>
12. Gioia GA, Collins M, Isquith PK. Improving identification and diagnosis of mild traumatic brain injury with evidence: psychometric support for the acute concussion evaluation. *J Head Trauma Rehabil*. 2008;23(4):230–242. <https://doi.org/10.1097/01.HTR.0000327255.38881.ca>
13. Halstead ME, McAvoy K, Devore CD, et al. Returning to learning following a concussion. *Pediatrics*. 2013;132(5):948–957. <https://doi.org/10.1542/peds.2013-2867>
14. Centers for Disease Control and Prevention. *Heads Up*. Atlanta, GA: National Center for Injury Prevention and Control; 2021. <https://www.cdc.gov/headsup>
15. Centers for Disease Control and Prevention. *Heads Up Returning to Sports and Activities*. National Center for Injury Prevention and Control; 2019. [https://www.cdc.gov/headsup/basics/return\\_to\\_sports.html](https://www.cdc.gov/headsup/basics/return_to_sports.html)
16. Fleisher GR, Ludwig S. *Textbook of Pediatric Emergency Medicine*. 8th ed. Lippincott Williams & Wilkins; 2020.
17. Springer E, Frazier SB, Arnold DH, Vukovic AA. External validation of a clinical prediction rule for very low risk pediatric blunt abdominal trauma. *Am J Emerg Med*. 2018 Nov. <https://doi.org/10.1016/j.ajem.2018.11.031>

18. Holmes J, Lillis K, Monroe D, et al. Identifying children at very low risk of clinically important blunt abdominal injuries. *Ann Emerg Med*. 2013;62(2):107–116. <https://doi.org/10.1016/j.annemergmed.2012.11.009>
19. Drucker NA, McDuffie L, Groh E, et al. Physical examination is the best predictor of the need for abdominal surgery in children following motor vehicle collision. *J Emerg Med*. 2018;54(1):1–7. <https://doi.org/10.1016/j.jemermed.2017.08.008>
20. Holmes JF, Kelley KM, Wootton-Gorges SL, et al. Effect of abdominal ultrasound on clinical care, outcomes, and resource use among children with blunt torso trauma: a randomized clinical trial. *JAMA*. 2017;317(22):2290–2296. <https://doi.org/10.1001/jama.2017.6322>
21. Liang T, Roseman E, Gao M, et al. The utility of the focused assessment with sonography in trauma examination in pediatric blunt abdominal trauma: a systematic review and meta-analysis. *Pediatr Emerg Care*. 2021 Feb. <https://doi.org/10.1097/pec.0000000000001755>
22. Streck CJ, Vogel AM, Zhang J, et al. Pediatric Surgery Research Collaborative. Identifying children at very low risk for blunt intra-abdominal injury in whom CT of the abdomen can be avoided safely. *J Am Coll Surg*. 2017;224(4):449–458e3. <https://doi.org/10.1016/j.jamcollsurg.2016.12.041>
23. Fouad AF, Abbott PV, Tsilingaridis G, et al. International Association of Dental Traumatology guidelines for the management of traumatic dental injuries: 2. Avulsion of permanent teeth. *Dent Traumatol*. 2020;36:331–342. <https://doi.org/10.1111/edt.12573>
24. Bourguignon C, Cohenca N, Lauridsen E, et al. International Association of Dental Traumatology Guidelines for the management of traumatic dental injuries: 1. Fractures and luxations. *Dent Traumatol*. 2020;36(4):314–330. <https://doi.org/10.1111/edt.12578>
25. Nasrullah A, Kerr NC. Sickle cell trait as a risk factor for secondary hemorrhage in children with traumatic hyphema. *Am J Ophthalmol*. 1997 Jun. [https://doi.org/10.1016/s0002-9394\(14\)71127-4](https://doi.org/10.1016/s0002-9394(14)71127-4)
26. Jijelava K, Le H, Parker J, Yee J. Getting hooked: a simple technique for the treatment of adhesive injuries to the eyelids. *J Emerg Med*. 2017. <https://doi.org/10.1016/j.jemermed.2016.09.013>
27. Smith ML. Pediatric burns: management of thermal, electrical, and chemical burns and burn-like dermatologic conditions. *Pediatr Ann*. 2000;29(6):367–378. <https://doi.org/10.3928/0090-4481-20000601-10>
28. Strobel AM, Fey R. Emergency care of pediatric burns. *Emerg Med Clin North Am*. 2018;36(2):441–458. <https://doi.org/10.1016/j.emc.2017.12.011>
29. Wootton-Gorges SL, Soares BP, Widmann RF, et al. ACR appropriateness criteria® suspected physical abuse-child. *J Am Coll Radiol*. 2017;14(5S):S338–S349. <https://doi.org/10.1016/j.jacr.2017.01.036>
30. Rubin DM, Christian CW, Bilaniuk LT, et al. Diagnostic imaging of child abuse. *Pediatrics*. 2009;123(5):1382–1386. <https://doi.org/10.1542/peds.111.6.1382>
31. Berkowitz CD. Physical abuse of children. *N Engl J Med*. 2017;376(17):1659–1666. <https://doi:10.1056/NEJMcp1701446>
32. Kellogg N, American Academy of Pediatrics Committee on Child Abuse and Neglect. The evaluation of sexual abuse in children. *Pediatrics*. 2005;116(2):506–512. <https://doi.org/10.1542/peds.2005-1336>



**FIGURE 2.9**

Frenulum tear due to direct blow to the face. (Modified from Zitelli BJ, McIntire SC, Nowalk, AJ. *Atlas of Pediatric Physical Diagnosis*. 7th ed. Elsevier; 2018.)



**FIGURE 2.10**

Postauricular bruising. (Modified from Zitelli BJ, McIntire SC, Nowalk, AJ. *Atlas of Pediatric Physical Diagnosis*. 7th ed. Elsevier; 2018.)



**FIGURE 2.11**

Petechial lesions due to choking. (Modified from Zitelli BJ, McIntire SC, Nowalk, AJ. *Atlas of Pediatric Physical Diagnosis*. 7th ed. Elsevier; 2018.)



**FIGURE 2.12**

Pinch marks signified by two small bruises separated by clear space. (Modified from Zitelli BJ, McIntire SC, Nowalk, AJ. *Atlas of Pediatric Physical Diagnosis*. 7th ed. Elsevier; 2018.)

# Chapter 3

## Toxicology

*Sophie Crinion, MD*

 See additional content online.

 **Audio Case File 3.1** Pediatric ingestions, workup, and management

**Whenever ingestion is suspected, contact local poison control at 1-800-222-1222.**

Each year the American Association of Poison Control Centers records about 1.2 million childhood poisoning exposures. Of these exposures, 75% occur in children younger than the age of 6 years. Exposures in young children are often unintentional, whereas adolescents are more likely to have intentional ingestions.<sup>1</sup>

### I. INITIAL EVALUATION

When to suspect ingestion: always, but especially with altered mental status or seizure. Begin the evaluation with an assessment of circulation, airway and breathing, and manage accordingly.<sup>2</sup>

#### A. History

Keep in mind that history may be inaccurate and provide supportive care and treatment in accordance with clinical condition and toxidrome.<sup>2</sup>

##### 1. Exposure history

Obtain history from witnesses and/or close contacts: Route, timing, and number of exposures (acute, chronic, or repeated ingestion), prior treatments or decontamination efforts.

##### 2. Substance identification and quantity ingested

Attempt to identify exact name of substance(s) ingested, including product name, active ingredients, possible contaminants, expiration date, concentration, and dose. Attempt to estimate the missing volume of liquid or the number of missing pills from a container. Poison control can assist with pill identification.<sup>2,3</sup>

##### 3. Environmental information

Accessible items in the house or garage, open containers, spilled tablets, household members taking medications, other caregivers, herbs, or other complementary medicines<sup>2,3</sup>

#### B. Workup and Laboratory Investigation

1. **Electrocardiogram (ECG):** Several medications will cause ECG changes, including QTc and QRS prolongation.

##### 2. Blood tests

a. Venous blood gas, blood glucose, and serum electrolytes

- b. Individual drug levels such as acetaminophen, aspirin, and ethanol are helpful general screenings in an acute, unknown ingestion.
- c. Acetaminophen levels are especially important to test in suicidal ingestions. Many medications for pain or upper respiratory symptoms contain acetaminophen.

### 3. Urine toxicology screens

- a. Basic screens include amphetamines, cocaine, opiates, phencyclidine (PCP), and tetrahydrocannabinol (THC).
- b. Positive results are presumptive only; must be confirmed by gas chromatography/mass spectrometry<sup>4</sup>

## C. Clinical Diagnostic Aids: Table With Clinical Signs and Possible Intoxicants (eTable 3.1)

## II. TOXIDROMES

See [Table 3.1](#).

## III. INGESTIONS AND ANTIDOTES

See [Table 3.2](#).

### A. Decontamination

#### 1. Activated charcoal<sup>5</sup>

- a. Most effective when used within first hour after ingestion but can be given after first hour, especially for sustained-release preparations
- b. Should be given PO to an awake and alert patient. Nasogastric (NG) tube should be used only if a patient is intubated due to risk of aspiration.
- c. Substances not absorbed by charcoal: Iron, alcohols, lithium
- d. Contraindications: Unprotected airway, caustic ingestion, disrupted gastrointestinal tract, concern for aspiration

#### 2. Whole bowel irrigation

- a. Indicated for evacuation of substances not bound to activated charcoal, such as iron, lead-containing foreign bodies, fatal sustained-release products, drug packing
- b. Use a polyethylene glycol electrolyte solution preparation to irrigate the bowel. Recommended rates: 9 months to 6 years (500 mL/hr), 6 to 12 years (1000 mL/hr), more than 12 years (1500 to 2000 mL/hr). Often will need two NG tubes and pumps to maintain these rates.<sup>6</sup>

### B. Enhanced Removal

- 1. Hemodialysis or exchange transfusions may be indicated to remove a drug/toxin.
- 2. Ingestions that may require enhanced removal therapies: Salicylate, lithium, methanol, ethylene glycol, metformin-associated lactic acidosis, valproate, theophylline

eTABLE 3.1

## CLINICAL DIAGNOSTIC AIDS

Clinical Sign	Intoxicant
<b>VITAL SIGNS</b>	
Hypothermia	Alcohol, $\beta$ -blockers, barbiturates, carbamazepine, carbon monoxide, clonidine, ethanol, hypoglycemics, opioids, phenothiazines, sedative-hypnotics
Hyperpyrexia	Amphetamines, anticholinergics, antihistamines, $\beta$ -blockers, caffeine, cocaine, dinitrophenol, isoniazid, monoamine oxidase inhibitors (MAOIs), phencyclidine, phenothiazines, salicylates, sympathomimetics, selective serotonin reuptake inhibitors (SSRIs), theophylline, thyroxine, tricyclic antidepressants (TCAs)
Bradypnea	Acetone, alcohol, botulinum toxin, clonidine, ethanol, ibuprofen, opioids, nicotine, sedative-hypnotics
Tachypnea	Amphetamines, barbiturates, carbon monoxide, cyanide, ethylene glycol, isopropanol, methanol, salicylates <i>Direct pulmonary insult:</i> Hydrocarbons, organophosphates, salicylates
Bradycardia	$\alpha$ 1-Agonists, alcohols, $\beta$ -blockers, calcium channel blockers, central $\alpha$ 2-agonist (clonidine), digoxin, opioids, organophosphates, plants (lily of the valley, foxglove, oleander), sedative-hypnotics
Tachycardia	Amphetamines, anticholinergics, antihistamines, cocaine, cyclic antidepressants, cyanide, iron, phencyclidine, salicylates, sympathomimetics, theophylline, TCAs, thyroxine
Hypotension	$\alpha$ 2-Agonists, angiotensin-converting enzyme (ACE) inhibitors, barbiturates, carbon monoxide, cyanide, iron, methemoglobinemia, opioids, phenothiazine, sedative-hypnotics, TCAs <i>Profound hypotension:</i> $\beta$ -blockers, calcium channel blockers, clonidine, cyclic antidepressants, digoxin, imidazolines, nitrites, quinidine, propoxyphene, theophylline
Hypertension	Amphetamines, anticholinergics, antihistamines, clonidine, cocaine, cyclic antidepressants (early after ingestion), diet pills, ephedrine, MAOIs, nicotine, over-the-counter cold remedies, phencyclidine, phenylpropanolamine, sympathomimetics, TCAs <i>Delayed hypertension:</i> Thyroxine
Hypoxia	Oxidizing agents
<b>NEUROMUSCULAR</b>	
Nervous system instability	<i>Insidious onset:</i> Acetaminophen, benzocaine, opioids <i>Abrupt onset:</i> Lidocaine, monocyclic or tricyclic antidepressants, phenothiazines, theophylline <i>Delayed onset:</i> Atropine, diphenoxylate <i>Transient instability:</i> Hydrocarbons
Depression and excitation	Clonidine, imidazolines, phencyclidine
Ataxia	Alcohol, anticonvulsants, barbiturates, carbon monoxide, heavy metals, hydrocarbons, solvents, sedative-hypnotics
Chvostek/Trousseau signs	Ethylene glycol, hydrofluoric acid—induced hypocalcemia, phosphate-induced hypocalcemia from Fleet enema

Coma	Alcohol, anesthetics, anticholinergics (antihistamines, antidepressants, phenothiazines, atropinics, over-the-counter sleep preparations), anticonvulsants, baclofen, barbiturates, benzodiazepines, bromide, carbon monoxide, chloral hydrate, clonidine, cyanide, cyclic antidepressants, $\gamma$ -hydroxybutyrate (GHB), hydrocarbons, hypoglycemics, inhalants, insulin, lithium, opioids, organophosphate insecticides, phenothiazines, salicylates, sedative-hypnotics, tetrahydrozoline, theophylline
Delirium, psychosis	Alcohol, anticholinergics (including cold remedies), cocaine, heavy metals, heroin, lysergic acid diethylamide (LSD), marijuana, mescaline, methaqualone, peyote, phencyclidine, phenothiazines, steroids, sympathomimetics
Miosis	Barbiturates, clonidine, ethanol, opioids, organophosphates, phencyclidine, phenothiazines, muscarinic mushrooms
Mydriasis	Amphetamines, antidepressants, antihistamines, atropinics, barbiturates (if comatose), botulism, cocaine, glutethimide, LSD, marijuana, methanol, phencyclidine
Nystagmus	Barbiturates, carbamazepine, diphenylhydantoin, ethanol, glutethimide, MAOIs, phencyclidine (both vertical and horizontal), sedative-hypnotics
Paralysis	Botulism, heavy metals, nicotine, paralytic shellfish poisoning, plants (poison hemlock), organophosphates (i.e., pesticides, nerve agents)
Seizures	Ammonium fluoride, amphetamines, anticholinergics, antidepressants, antihistamines, atropine, $\beta$ -blockers, boric acid, bupropion, caffeine, camphor, carbamates, carbamazepine, carbon monoxide, chlorinated insecticides, cocaine, cyclic antidepressants, diethyltoluamide, ergotamine, ethanol, GHB, <i>Gyromitra</i> mushrooms, hydrocarbons, hypoglycemics, ibuprofen, imidazolines, isoniazid, lead, lidocaine, lindane, lithium, LSD, meperidine, nicotine, opioids, organophosphate insecticides, phencyclidine, phenothiazines, phenylpropanolamine, phenytoin, physostigmine, plants (water hemlock), propoxyphene, salicylates, strychnine, theophylline

**CARDIOVASCULAR**

Hypoperfusion	Calcium channel blockers, iron
Wide QRS complex	Carbamazepine, chloroquine, Class IA antidysrhythmics, Class IC antidysrhythmics, cocaine, diphenhydramine, TCAs

**ELECTROLYTES**

Anion gap metabolic acidosis	Acetaminophen, carbon monoxide, chronic toluene, cyanide, dinitrophenol, ethylene glycol, ibuprofen, iron, isoniazid, lactate, methanol, metformin, paraldehyde, phenformin, salicylates
Electrolyte disturbances	Diuretics, salicylates, theophylline
Hypoglycemia	Alcohol, $\beta$ -blockers, hypoglycemics, insulin, salicylates
Serum osmol gap	Acetone, ethanol, ethylene glycol, isopropyl alcohol, methanol, propylene glycol

eTABLE 3.1

**CLINICAL DIAGNOSTIC AIDS—CONT'D**

Clinical Sign	Intoxicant
<b>SKIN</b>	
Cyanosis unresponsive to oxygen	Aniline dyes, benzocaine, nitrites, nitrobenzene, phenazopyridine, phenacetin
Flushing	Alcohol, antihistamines, atropinics, boric acid, carbon monoxide, cyanide, disulfiram
Jaundice	Acetaminophen, carbon tetrachloride, heavy metals (iron, phosphorus, arsenic), naphthalene, phenothiazines, plants (mushrooms, fava beans)
<b>ODORS</b>	
Acetone	Acetone, isopropyl alcohol, phenol, salicylates
Alcohol	Ethanol
Bitter almond	Cyanide
Garlic	Heavy metal (arsenic, phosphorus, thallium), organophosphates
Hydrocarbons	Hydrocarbons (gasoline, turpentine, etc.)
Oil of wintergreen	Salicylates
Pear	Chloral hydrate
Violets	Turpentine
<b>RADIOLOGY</b>	
Small opacities on radiograph	Halogenated toxins, heavy metals, iron, lithium, densely packaged products

TABLE 3.1

## TOXIDROMES

Drug Class	Temp	HR	RR	BP	Pupils	Skin	Mental Status	Other Signs	Causative Agents
Anticholinergic “Mad as a hatter, red as a beet, blind as a bat, hot as a hare, dry as a bone” <sup>a</sup>	↑	↑	↑/nl	↑/nl	Dilated	Dry, flushed	Delirium, psychosis, paranoia	Urinary retention, decreased bowel sounds, thirst, garbled speech	Antihistamines, atropine, antipsychotics, phenothiazines, scopolamine, TCAs
Cholinergic “SLUDGE, Killer Bs” <sup>a</sup>	nl	↓	↑ (bronchospasm)	↓/nl	Constricted	Sweaty	Depressed, confused	Salivation, lacrimation, urination, defecation, emesis Liquid nicotine can cause fasciculations and paralysis.	Organophosphates, pesticides, nerve agents, tobacco, liquid nicotine
Opioids	↓/nl	↓/nl	↓ (hypoventilation)	↓/nl	Constricted	No change	Sedated		Morphine, fentanyl, oxycodone, methadone
Sympathomimetics	↑/nl	↑	↑/nl	↑	Dilated	Sweaty	Agitated	At risk for seizures, coronary vasospasm	Amphetamines, cocaine
Sedative/hypnotics “Coma with normal vitals”	nl	nl	↓/nl	↓/nl	Normal	No change	Depressed		Benzodiazepines, barbiturates, ethanol
Serotonergic	↑	↑	↑	↑/nl	Dilated	Flushed	Confusion	Shivering, muscle rigidity, at risk for seizures, hyperreflexia and clonus of lower extremities	SSRIs, SNRIs, MAOIs, trazadone, dextromethorphan, LSD, TCAs, MDMA (ecstasy)

<sup>a</sup>The “mad as a hatter” mnemonic references delirium, flushed skin, mydriasis, hyperpyrexia, and dry skin/urinary retention seen in the anticholinergic toxidrome. The “SLUDGE” mnemonic references salivation, lacrimation, urination, diaphoresis, gastrointestinal distress (including diarrhea), and emesis seen in the cholinergic toxidrome. The “Killer Bs” mnemonic references bronchospasm, bronchorrhea, and bradycardia seen in the cholinergic toxidrome.

↑ refers to increased or elevated vital sign, ↓ refers to decreased or depressed vital sign, *nl* refers to vital sign within normal limits.

*BP*, Blood pressure; *HR*, heart rate; *LSD*, lysergic acid diethylamide; *MAOIs*, monoamine oxidase inhibitors; *MDMA*, 3,4-methylenedioxymethamphetamine; *RR*, respiratory rate; *SNRIs*, serotonin and norepinephrine reuptake inhibitors; *SSRIs*, selective serotonin reuptake inhibitors; *TCAs*, tricyclic antidepressants; *Temp*, temperature.

TABLE 3.2

## COMMONLY INGESTED AGENTS

Ingested Agent	Signs and Symptoms	Antidote <sup>a</sup>
Acetaminophen	See Section IV.	
Amphetamines	See sympathomimetics toxidrome in Table 3.1.	Supportive care Benzodiazepines for agitation
Anticholinergics	See anticholinergic toxidrome in Table 3.1.	Physostigmine
Anticholinesterase inhibitors (carbamates, donepezil)	See cholinergic toxidrome in Table 3.1.	Atropine
Antihistamines	See anticholinergic toxidrome in Table 3.1; paradoxical CNS stimulation, dizziness, seizures, prolonged QT	Supportive care
Button batteries	Electrical injury and necrosis in esophagus and surrounding tissues	Location: Esophagus: EMERGENT ENDOSCOPIC/SURGICAL REMOVAL Stomach/beyond stomach: Consult GI
Benzodiazepines	See sedative/hypnotic toxidrome in Table 3.1.	Flumazenil
β-Blockers	Bradycardia, hypotension, AV conduction block, bronchospasm, hypoglycemia	Glucagon See insulin/dextrose treatment in calcium channel blockers below. High-dose pressors
Household bleach (small volume)	Oral irritation	Supportive care
Calcium channel blockers	Bradycardia, hypotension, AV conduction block, pulmonary edema, hyperglycemia	Calcium chloride (10%) Calcium gluconate (10%) Glucagon High-dose insulin/dextrose <sup>12</sup> : 1 unit/kg bolus → infuse at 1–10 unit/kg/hr; give with D <sub>25</sub> W at 0.5 g/kg/hr. Monitor BG frequently. High-dose pressors
Clonidine	Symptoms resemble an opioid toxidrome. CNS depression, coma, lethargy, hypothermia, miosis, bradycardia, profound hypotension, respiratory depression	Naloxone Supportive care
Cocaine	See sympathomimetics toxidrome in Table 3.1.	Supportive care
Detergent pods	Vomiting, sedation, aspiration, respiratory distress	Supportive care
Ecstasy	Hallucinations, teeth grinding, hyperthermia, hyponatremia, seizures	Supportive care
Ethanol	See sedative/hypnotic toxidrome in Table 3.1. Hypoglycemia in young children	Supportive care

Ethylene glycol/ methanol	Similar to ethanol; additionally, blurry or double vision (methanol), renal failure/hypocalcemia (ethylene glycol), osmol gap with severe anion gap metabolic acidosis	Fomepizole Ethanol (only to be used as second-line agent when fomepizole unavailable; risk of inappropriate dosing, CNS depression, aspiration, and hypoglycemia) Consider dialysis.
Iron	Vomiting, diarrhea, hypotension, lethargy, anion gap metabolic acidosis, cardiogenic shock, renal failure	Deferoxamine
Lead	See Section V.	
Nicotine	Vomiting and see cholinergic toxidrome in <a href="#">Table 3.1</a>	Supportive care
NSAIDs	Nausea, vomiting, epigastric pain, headache, gastrointestinal hemorrhage, renal failure	Supportive care
Opioids	See opioid toxidrome in <a href="#">Table 3.1</a> .	Naloxone
Organophosphates	See cholinergic toxidrome in <a href="#">Table 3.1</a> .	Atropine Pralidoxime
Salicylates	Gastrointestinal upset, tinnitus, tachypnea, hyperpyrexia, dizziness, lethargy, dysarthria, seizure, coma, cerebral edema	Sodium bicarbonate: 1–2 mEq/kg IV push, followed by D <sub>5</sub> W + 140 mEq/L NaHCO <sub>3</sub> and 20 mEq/L KCl at 1.5× maintenance fluid rate with goal serum pH 7.45–7.55 Consider dialysis.
Serotonergic agents	See serotonergic toxidrome in <a href="#">Table 3.1</a> .	Benzodiazepines (first-line) Cyproheptadine
Sulfonylureas	Hypoglycemia, dizziness, agitation, confusion, tachycardia, diaphoresis	Food (if able) Dextrose: 0.5–1 g/kg (2–4 mL/kg of D <sub>25</sub> W) <i>After euglycemia achieved:</i> Octreotide: 1–1.25 mCg/kg SQ Q6–12 hr (max. dose 50 mCg) if rebound hypoglycemia
Synthetic cannabinoids	Agitation, altered sensorium, tachycardia, hypertension, vomiting, mydriasis, hypokalemia	Supportive care
TCA's	Tachycardia, seizures, delirium, widened QRS possibly leading to ventricular arrhythmias, hypotension	<i>For wide QRS complex:</i> Sodium bicarbonate: 1–2 mEq/kg IV push, followed by D <sub>5</sub> W + 140 mEq/L NaHCO <sub>3</sub> and 20 mEq/L KCl at 1.5× maintenance fluid rate with goal serum pH 7.45–7.55
Warfarin	Bleeding	Phytonadione/vitamin K <sub>1</sub>

<sup>a</sup>See Formulary for dosing recommendations.

BG, Blood glucose; CNS, central nervous system; KCl, potassium chloride; NaHCO<sub>3</sub>, sodium bicarbonate; NSAIDs, nonsteroidal antiinflammatory drugs; TCA, tricyclic antidepressant.

Data from Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report. *Clin Toxicol.* 2021;59(12):1282–1501.

### C. Other Considerations

1. Many ingestions are managed primarily with supportive care of any associated toxic effects, such as hypotension or hyperpyrexia.
2. Seizures: First-line agents are benzodiazepines. Barbiturates or propofol should be considered as second-line agents. Phenytoin has no role in the treatment of toxin-induced seizures.<sup>7</sup>
3. Patients with severe poisoning and refractory cardiorespiratory failure after ingestion are potential extracorporeal membrane oxygenation (ECMO) candidates because the toxic effects are transient.

## IV. ACETAMINOPHEN OVERDOSE<sup>8</sup>

NAPQI metabolite is hepatotoxic.

### A. Four Phases of Intoxication

1. **Phase 1 (first 24 hours):** Nonspecific symptoms such as nausea, malaise, vomiting
2. **Phase 2 (24 to 72 hours):** Above symptoms resolve; right upper quadrant pain, hepatomegaly, and increasing transaminases develop
3. **Phase 3 (72 to 96 hours):** Return of nonspecific symptoms as well as evidence of liver failure (increased prothrombin time, lactate, phosphate), renal failure, and encephalopathy
4. **Phase 4 (4 days to 2 weeks):** Recovery or death


### B. Treatment Criteria

1. **Serum acetaminophen** concentration above the possible toxicity line on the Rumack-Matthew nomogram after single acute ingestion (Fig. 3.1)
2. **History of ingesting more than 200 mg/kg or 10 g** (whichever is less) and serum concentration not available or time of ingestion not known
3. **If time of ingestion is unknown or multiple/chronic ingestion**, check acetaminophen level and AST. Treat if either is elevated.

### C. Antidote: *N*-Acetylcysteine (See Formulary in Chapter 30)

1. **PO:** 140 mg/kg loading dose (max 15 g/dose) followed by 70 mg/kg/dose (max 7.5 g/dose) Q4 hours continue treatment until transaminases and INR have peaked and are decreasing substantially towards normal. Repeat dose if vomiting occurs within 1 hour of administration.
2. **Intravenous (IV):** 150 mg/kg *N*-acetylcysteine IV loading dose (max 15 g/dose) over 60 minutes, followed by 50 mg/kg/dose (max 5 g/dose) over 4 hours, followed by 100 mg/kg/dose (max 10 g/dose) over 16 hours for a total infusion time of 21 hours. Some patients may require more than 21 hours of *N*-acetylcysteine administration. See Formulary for weight-based drug dilution volumes.
3. **Liver failure:** Continue the 100 mg/kg over 16 hours infusion until resolution of encephalopathy, AST less than 1000 units/L, and INR less than 2.

### D. Consider Referral to Liver Transplant Center if Patient Meets King's College Criteria



**FIGURE 3.1**

Rumack-Matthew nomogram. Semilogarithmic plot of plasma acetaminophen levels versus time. This nomogram is valid for use after single acute ingestions of acetaminophen. The need for treatment cannot be extrapolated based on a level before 4 hr. (Data from *Pediatrics* 1975;55:871, and Micromedex.)

## V. LEAD POISONING<sup>9</sup>

### A. Definition

Centers for Disease Control and Prevention (CDC) defines a reference level of 3.5  $\mu\text{g}/\text{dL}$  to identify children with elevated blood lead levels (BLLs).<sup>10</sup>

### B. Sources of Exposure

Paint, dust, soil, drinking water, cosmetics, cookware, toys, caregivers with occupations and/or hobbies using lead-containing materials or substances, and bullets if in joint spaces or pleura

### C. Overview of Symptoms by Blood Lead Level

1. **BLL  $\geq 40$   $\mu\text{g/dL}$ :** Irritability, vomiting, abdominal pain, constipation, anorexia
2. **BLL  $\geq 70$   $\mu\text{g/dL}$ :** Lethargy, seizure, and coma. **Note:** Children may be asymptomatic with lead levels greater than 100  $\mu\text{g/dL}$ .

### D. Management

1. See [Tables 3.3 and 3.4](#) for general management and repeat testing guidelines.
2. Chelation therapy<sup>2</sup>
  - a. Asymptomatic children with BLL 45 to 69 mCg/dL  
**Succimer:** 1050 mg/m<sup>2</sup>/day PO divided Q8 hours  $\times$  5 days, then 700 mg/m<sup>2</sup>/day divided Q12 hours  $\times$  14 days. See Formulary for more details.
  - b. Asymptomatic children with BLL  $\geq 70$  mCg/dL
    - (1) **Succimer:** Per above dosing
    - (2) **Edetate (EDTA) calcium disodium:** 1000 mg/m<sup>2</sup> (max dose 2 to 3 g) as 24-hour IV infusion  $\times$  5 days. Begin 2 hours after first dose of succimer. Monitor renal function closely.  
**Warning:** Do not mistake edetate disodium for edetate calcium disodium. Edetate *calcium* disodium is the correct medicine used for the treatment of lead poisoning.
  - c. Symptomatic children unable to take PO (e.g., lead encephalopathy, seizure)

**TABLE 3.3**
**MANAGEMENT OF LEAD POISONING<sup>11</sup>**

Blood Lead Level (BLL)	Recommended Guidelines (See <a href="#">Table 3.4</a> for Repeat Testing Guidelines.)
3.5–19 $\mu\text{g/dL}$	<ol style="list-style-type: none"> <li>1. Obtain detailed environmental exposure history to assess for possible sources.</li> <li>2. Provide education about reducing environmental lead.</li> <li>3. Consider CBC, iron studies, and multivitamin with iron supplementation.</li> <li>4. Environmental investigation may be available based on local resources.</li> </ol>
10–19 $\mu\text{g/dL}$	<ol style="list-style-type: none"> <li>1. As above for BLL 5–9 <math>\mu\text{g/dL}</math></li> <li>2. Environmental investigation may be available based on local resources.</li> </ol>
20–44 $\mu\text{g/dL}$	<ol style="list-style-type: none"> <li>1. As above for BLL 5–9 <math>\mu\text{g/dL}</math></li> <li>2. Environmental investigation</li> <li>3. Iron level, complete blood cell count (CBC), abdominal radiography with bowel decontamination if indicated</li> <li>4. Complete exam, including neurodevelopmental assessment</li> </ol>
45–69 $\mu\text{g/dL}$	<ol style="list-style-type: none"> <li>1. As above for BLL 20–44 <math>\mu\text{g/dL}</math></li> <li>2. Administer oral chelation therapy, consider hospitalization.</li> </ol>
$\geq 70$ $\mu\text{g/dL}$	<ol style="list-style-type: none"> <li>1. Hospitalize and commence chelation therapy.</li> <li>2. Contact local poison control.</li> </ol>

**TABLE 3.4**  
**REPEAT BLOOD LEAD TESTING GUIDELINES<sup>11</sup>**

If Screening BLL Is: ( $\mu\text{g/dL}$ )	Time Frame of Confirmation of Screening BLL	Follow-Up Testing (After Confirmatory Testing)	Later Follow-Up Testing After BLL Declining
>3.5–9	3 months	3 months	6–9 months
10–19	1 month <sup>a</sup>	1–3 months	3–6 months
20–44	2 weeks <sup>a</sup>	2 weeks–1 month	1–3 months
>45	48 hours	As soon as possible	As soon as possible

<sup>a</sup>Per provider discretion.

BLL, Blood lead level.

- (1) **Dimercaprol (BAL):** 450 mg/m<sup>2</sup>/day IM divided Q4 hours  $\times$  3 to 5 days (number of days based on clinical course). Do not give to patients with peanut allergy. Do not use concomitantly with iron, as BAL-iron complex is a potent emetic. Use with caution in patients with G6PD deficiency, as it may cause hemolysis.
- (2) **Edetate (EDTA) calcium disodium:** 1500 mg/m<sup>2</sup> (maximum dose 2 to 3 g) as 24-hour IV continuous infusion  $\times$  5 days. Begin 4 hours after first dose of BAL.

## VI. WEB RESOURCES

- American Association of Poison Control Centers: <http://www.aapcc.org/>
- American Academy of Clinical Toxicology: <http://www.clintox.org/index.cfm>
- Centers for Disease Control and Prevention, Section on Environmental Health: <http://www.cdc.gov/nceh>

## REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report. *Clin Toxicol (Phila)*. 2021;59(12):1282–1501. <https://doi.org/10.1080/15563650.2021.1989785>. PMID: 34890263.
2. Nelson LS, Hoffman RS, Howland MA, et al. *Goldfrank's Toxicologic Emergencies*. 11th ed. McGraw-Hill; 2019.
3. Wang G, Dart RC, Rumack BH. Poisoning. In: Bunik M, Hay WW, Levin MJ, Abzug MJ, eds. *Current Diagnosis and Treatment: Pediatrics*, 26e. McGraw-Hill; 2022. Accessed September 06, 2022. <https://accessmedicine.mhmedical.com/content.aspx?bookid=3163&sectionid=266216633>
4. Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. *Mayo Clin Proc*. 2008;83(1):66–76.
5. Fleisher GR, Ludwig S, eds. *Textbook of Pediatric Emergency Medicine*. 7th ed. Lippincott Williams & Wilkins; 2016.
6. Thanacoody R, Caravati EM, Troutman B, et al. Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients. *Clin Toxicol (Phila)*. 2015;53(1):5.
7. Chen HY, Albertson TE, Olson KR. Treatment of drug-induced seizures. *Br J Clin Pharmacol*. 2016;81(3):412–419.
8. Theobald JL, Kostic MA. Poisoning. In: Kleigman RM, St Geme JW, et al., eds. *Nelson Textbook of Pediatrics* 21st ed. Philadelphia: Elsevier 77: 490–510.
9. Advisory Committee on Childhood Lead Poisoning Prevention of the Centers for Disease Control and Prevention. *Low Level Lead Exposure Harms Children: A Renewed Call for Primary Prevention*; January 2012. [http://www.cdc.gov/nceh/lead/ACCLPP/Final\\_Document\\_030712.pdf](http://www.cdc.gov/nceh/lead/ACCLPP/Final_Document_030712.pdf)
10. *Blood Lead Levels in Children*. (2022 August 29). Centers for Disease Control and Prevention. Retrieved 2022 September 15 from <https://www.cdc.gov/nceh/lead/prevention/blood-lead-levels.htm>.
11. *Recommended Actions Based on Blood Lead Level*. (2022 September 8). Centers for Disease Control and Prevention. Retrieved 2022 September 15 from <https://www.cdc.gov/nceh/lead/advisory/acclpp/actions-blls.htm>.
12. Engebretsen KM, Kaczmarek KM, Morgan J, Holger JS. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. *Clin Toxicol*. 2011;49(4):277–283.

# Chapter 4

## Procedures

*Maite E. Del Valle Rolón, MD*

 See additional content online.

### I. GENERAL GUIDELINES

#### A. Consent

Before any procedure is performed, it is crucial to obtain informed consent from the parent or guardian by explaining the procedure, the indications, and any risks involved; answer questions; and discuss possible alternatives. Obtaining consent should not impede lifesaving, emergent procedures.

#### B. Documentation

**It is important that the physician performing the procedure document the informed consent process.** Include the date, time, additional providers present (if applicable), brief summary of the consent conversation, the diagnosis, recommended procedure, specific risks and benefits, and alternative treatments. It is equally important to document if a patient refuses a procedure and that the risks associated with refusal were discussed.

#### C. Risks

1. All invasive procedures involve pain, risk for infection and bleeding, and potential injury to neighboring structures.
2. Sedation and analgesia should be planned, and the risks of such explained to the parent and/or patient as appropriate. (See [Chapter 6](#) and the AAP Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures.<sup>1</sup>)
3. Universal precautions and proper sterile technique should be followed for all patient contact that exposes the healthcare provider to bodily fluids.

#### D. Attending to the Needs of a Fearful Child<sup>2</sup>

Children represent a vulnerable population in that they often lack the capacity to understand why a potentially uncomfortable procedure is being performed. All efforts should be made to provide information about the procedure to the child at an age-appropriate level. Utilize child life specialists as able.

1. **Observe:** Monitor how child reacts when you enter the room. If they are visibly fearful, you should take some time for them to get used to your presence.
2. **Engage:** Talk about an unrelated subject to get their attention. When possible, allow the child to touch medical equipment. Mimic parts of the exam on toys or others so that the child can see the exam before experiencing it.

3. **Monitor:** If your initial interaction was not successful, step back and try a different approach.

## II. ULTRASOUND FOR PROCEDURES<sup>2a</sup>

### A. Introduction to Ultrasound

Ultrasound has become an increasingly important bedside diagnostic and procedural aid, and it can improve visualization of subcutaneous structures during procedures.

### B. Ultrasound Basics

#### 1. Probe selection

- a. Linear transducers use higher frequencies than curvilinear or phased-array transducers to produce higher-resolution images near the body's surface and are primarily used for procedures in pediatrics. A wide area of contact at the skin surface facilitates needle placement in procedures. Linear transducers have poor resolution of deep structures in the body.
- b. Curvilinear transducers use low to midrange frequencies and permit deep structure visualization. Though they provide a wide area of skin contact to facilitate procedures near concave and convex surfaces, larger curvilinear probes are difficult to use in small children.
- c. There are a variety of other probes (i.e., phased-array, microconvex, intracavitary) that generate sector-shaped images but are predominantly used for diagnostic purposes.

#### 2. Image optimization

- a. Ensure adequate contact by using enough ultrasound gel and applying comfortable pressure on the skin.
- b. Gain: Measure of image brightness, which is used for optimizing images and reducing artifact
- c. Frequency: Increase to improve image resolution of shallow structures. Decrease to improve imaging of deep structures.
- d. Depth: Adjust to visualize structure of interest and at least a centimeter of tissue below that structure.

## III. NEUROLOGIC PROCEDURES: LUMBAR PUNCTURE<sup>3-5</sup>

### A. Indications

Examination of spinal fluid for suspected infection, inflammatory disorder, malignancy, instillation of intrathecal chemotherapy, diagnosis of subarachnoid hemorrhage, or measurement of opening pressure

### B. Complications

Local pain, apnea due to positioning, headache, bleeding, infection, subarachnoid epidermal cyst, ocular muscle palsy, epidural CSF leak, spinal hematoma, and/or brainstem herniation

### C. Cautions and Contraindications

1. Increased intracranial pressure (ICP): Before lumbar puncture (LP), perform a funduscopic examination. Presence of papilledema, retinal hemorrhage, or clinical suspicion of increased ICP should prompt further evaluation and may be a contraindication to the procedure. A sudden


drop in spinal canal fluid pressure by rapid release of cerebrospinal fluid (CSF) may cause fatal herniation. Computed tomography (CT) may be indicated before LP if there is suspected intracranial bleeding, focal mass lesion, or increased ICP. A normal CT scan does not rule out increased ICP but usually excludes conditions that may put the patient at risk for herniation. Decision to obtain CT should not delay appropriate antibiotic therapy, if indicated.

2. Bleeding diathesis: Platelet count greater than  $50,000/\text{mm}^3$  is desirable before LP, and correction of any clotting factor deficiencies can minimize the risk for bleeding and subsequent cord or nerve root compression.
3. Overlying skin infection may result in inoculation of CSF with organisms.
4. A mass or evidence of trauma to lumbar vertebrae
5. LP should be deferred in unstable patients, and appropriate therapy should be initiated, including antibiotics, if indicated.

4

#### D. Procedure

1. Apply local anesthetic cream if sufficient time is available.
2. Position child (Fig. 4.1) in either the sitting position or lateral recumbent position, with hips, knees, and neck flexed. Keep shoulders and hips aligned to avoid rotating the spine. *Do not* compromise a small infant's cardiorespiratory status with positioning.
3. Locate the desired intervertebral space (either L3 to L4 or L4 to L5) by drawing an imaginary line between the top of the iliac crests. Alternatively, ultrasound can be used to mark the intervertebral space (see Section XI [online content]).
4. Prepare the skin in a sterile fashion. Drape conservatively to make monitoring the infant possible. Use a 20- to 22-gauge spinal needle with stylet (1.5, 2.5, or 3.5 inch, depending on the size of the child). A smaller-gauge needle will decrease the incidence of spinal headache and CSF leak.
5. Overlying skin and interspinous tissue can be anesthetized with 1% lidocaine using a 25-gauge needle.
6. Puncture the skin in the midline just caudad to the palpated spinous process, angling slightly cephalad toward the umbilicus. Advance several millimeters at a time, and withdraw stylet frequently to check for CSF flow. **Needle may be advanced without the stylet once it is completely through the skin.** In small infants, one may *not* feel a change in resistance or "pop" as the dura is penetrated.
7. If resistance is met initially and the needle cannot be advanced, withdraw needle to just under the skin surface and redirect the angle of the needle slightly.
8. Send CSF for appropriate studies. In general, send the first tube for culture and Gram stain, the second tube for measurement of glucose and protein levels, and the last tube for cell count and differential. Additional tubes can be collected for viral cultures, polymerase chain reaction (PCR), or CSF metabolic studies, if indicated. If subarachnoid hemorrhage or traumatic tap is suspected, send the first and fourth tubes



**FIGURE 4.1**

Lumbar puncture site. (A) Infant placed in sitting position. (B) Infant placed in lateral (recumbent) position. (From Dieckmann R, Fiser D, Selbst S. *Pediatric Emergency and Critical Care Procedures*. Mosby; 1997.)

for cell count, and ask the laboratory to examine the CSF for xanthochromia.

9. Accurate measurement of CSF pressure can be made only with the patient lying quietly on their side in an unflexed position. It is not a reliable measurement in the sitting position. Once the free flow of spinal fluid is

obtained, attach the manometer and measure CSF pressure. Opening pressure is recorded when the CSF level is steady.

**E. A video on lumbar punctures is available on the *New England Journal of Medicine's* website**

## IV. OTOLARYNGOLOGIC PROCEDURES

### A. Cerumen Impaction Removal<sup>6,7</sup>

1. **Indications:** Symptomatic (decreased hearing, pain) and/or assessment of the ear. Clinicians should *not* routinely disimpact asymptomatic patients whose ears can be adequately assessed.
2. **Complications:** Allergic reaction to cerumenolytics, trauma, earache, dizziness, nystagmus, retention of water, tympanic membrane perforation
3. **Procedures**
  - a. **Cerumenolytics**
    - (1) There is no high-quality evidence suggesting that one cerumenolytic is more effective than another. Water and saline are equally as effective as cerumenolytics. Hydrogen peroxide has reduced efficacy.
  - b. **Irrigation**
    - (1) Direct visualization is not necessary.
    - (2) Irrigation of the ear canal with a large syringe containing lukewarm water is equally effective as a commercial mechanical jet irrigator.
    - (3) Place a small bucket (e.g., emesis bin) under the patient's ear to collect water.
    - (4) Straighten the ear as much as possible by lifting the auricle up and posteriorly. Gently apply a continuous stream upward in the canal.
    - (5) Note that irrigation is contraindicated in patients with tympanostomy tubes or perforated tympanic membranes
  - c. **Manual removal/instrumentation**
    - (1) Most useful for cerumen removal in the outer one-third of the ear
    - (2) Direct visualization is essential and an uncooperative patient may render manual removal impossible.
    - (3) Tools include curettes (plastic or metal), spoons, alligator forceps. Do not attempt to break through the cerumen. Advance the loop of the curette behind the cerumen and retrieve.
  - d. **A video on cerumen removal is available on the *New England Journal of Medicine's* website.**

### B. Foreign Body Removal From Ear<sup>3,8</sup>

1. **Indications:** Retained foreign body in the external auditory canal
2. **Contraindications:** Urgent referral to an otolaryngologist **prior** to attempted removal is indicated if object is a button battery or penetrating the ear canal (e.g., pencil, cotton-tipped swab).
3. **Complications:** External auditory canal trauma (most common), perforation of the tympanic membrane, retained foreign object, ossicular disruption

**4. Procedure:**

- a. Insects should be killed with mineral oil, ethanol, or lidocaine prior to attempted removal.
- b. Irrigation is useful for hard objects resistant to grasping that are nonocclusive. It is contraindicated for removal of vegetables/legumes (increases swelling) and button batteries (enhances current flow)
- c. Instrumentation is most successful for irregularly shaped objects that are graspable.
- d. Studies suggest that referral to ENT should be made after a single provider fails to remove the foreign body.

**5. A video on [removal of foreign bodies from the ear and nose](#) is available on the *New England Journal of Medicine's* website.****C. Foreign Body Removal From Nose<sup>9,10,3</sup>**

1. **Indications:** Retained foreign body in the nasal cavity. Button batteries and magnets attached to the nasal septum require emergent removal.
2. **Contraindications:** Most nasal foreign bodies do not require subspecialty referral. Consider otolaryngology referral for posterior objects, button batteries, penetrating injuries, and unsuccessful initial attempts.
3. **Complications:** Epistaxis, perforation of cribriform plate, aspiration, mucosal injury, rhinosinusitis, retained foreign object (which may lead to necrosis of septum and mucosa).
4. **Procedure:** Topical lidocaine, a vasoconstrictor (e.g., crushed ice or spray), may be used to minimize bleeding and edema.
  - a. **Self-removal:** The easiest and least invasive method. Typically, only effective for patients older than 3 years. Instruct the patient to occlude the unobstructed nostril and blow their nose.
  - b. **Parent kiss:** Provides up to a 60% successful removal rate.
    - (1) Instruct the caregiver to place their lips around the patient's lips (similar to a "mouth-to-mouth" resuscitation breath) and occlude the uninvolved nostril with one finger.
    - (2) Quickly and forcefully exhale one puff into the child's mouth. This maneuver often expels the foreign body.
  - c. **High-flow oxygen:** Best for foreign bodies that *completely* occlude the anterior nasal cavity. Place suction tubing into the unobstructed nostril while the child's mouth is closed. Deliver 10 to 15 L/min of oxygen flow through the tubing.
  - d. **Instrumentation:** Best for foreign bodies that are *nonocclusive*.
    - (1) Equipment: alligator forceps, right-angle hook, Foley catheter (5 to 8 Fr) or Katz extractor, irrigating devices
    - (2) Use alligator forceps to extract compressible objects that have rough surfaces.
    - (3) Use a right-angle hook for smooth objects that cannot be easily grasped.
    - (4) Use a Foley catheter for small, round objects (e.g., marble). Lubricate the catheter, advance the uninflated catheter past the object, inflate the catheter balloon, and withdraw the catheter and the object.

## D. Management of Epistaxis<sup>9,11</sup>

1. **Indications:** Simple nosebleed. Most cases of epistaxis in children have a benign etiology. Referral to an otolaryngologist is indicated for uncontrollable bleeding, posterior epistaxis, hemodynamic instability, or anatomic abnormalities (e.g., tumors, polyps). See Chapter 14 for management of epistaxis in patients with hemophilia, von Willebrand disease, immune thrombocytopenia, or other bleeding disorders.
2. **Complications:** Persistent bleeding, swallowing blood, toxic shock syndrome (from packing material), septal hematomas/abscesses from traumatic packing, sinusitis
3. **Procedure:** The child should sit upright and bent forward at the waist to minimize swallowing blood. Remove blood clots, which promote fibrinolysis.
  - a. **Direct compression:** Instruct the child or parent to compress the nasal alae against the septus with two fingers for 5–15 minutes. Most simple bleeds will clot after 5 to 10 minutes.
  - b. **Topical vasoconstriction:** Use oxymetazoline-soaked cotton pledgets or gauze. Phenylephrine is associated with morbidity when used topically and should be avoided in patients younger than 6 years of age. However, if bleeding is refractory to other interventions, the minimum dose of phenylephrine needed to cease bleeding should be used. Use a squirt bottle or apply the vasoconstrictor on a piece of cotton, applying direct pressure on the nose for 5 to 10 minutes.
  - c. **Nasal packing**
    - (1) Apply topical anesthetic on a cotton pledget and insert into the nasal cavity. Remove after 5–10 minutes.
    - (2) Rub antibiotic ointment into a quarter-inch × 72-inch gauze ribbon. Using a nasal speculum or forceps, pack the nasal cavity by grasping the gauze ribbon approximately 6 inches from its end and placing the packing as far back as possible. Ensure that the free end protrudes from the nose and secure with tape.
    - (3) Maintain packing for 72 hours. If bleeding persists after 72 hours, packing should be replaced and the child referred to an otolaryngologist.

## V. CARDIOVASCULAR PROCEDURES

### A. Vagal Maneuvers for Supraventricular Tachycardia (SVT)<sup>12-14</sup>

1. **Indications:** Supraventricular tachycardia, 2:1 atrioventricular (AV) block, evaluation of cardiac murmurs
2. **Contraindications:** Carotid sinus massage is to be avoided in patients with prior stroke within the past 3 months, significant carotid stenosis or bruit, or any history of ventricular arrhythmia.
3. **Complications:** Typically transient (resolve within seconds to minutes) and include prolonged sinus pause, hypertension (increased intrathoracic pressure), hypotension (decreased venous return/decrease in intrathoracic pressure on exhalation)

**4. Procedure:**

- a. **Cold stimulus to the face:** Briefly place an icepack or washcloth soaked in ice water on the forehead or bridge of the nose. The ice should not be applied for longer than 30 seconds to avoid frostbite.
- b. **Valsalva maneuver:** Place the patient in supine position and instruct to exhale forcefully against a closed glottis. The strain should be maintained for 10 to 15 seconds before resuming normal breathing.
- c. **Modified Valsalva maneuver:** Place the patient in a semirecumbent position (45-degree angle) and apply standard Valsalva strain. Immediately reposition supine with 15 seconds of passive leg raise at a 45-degree angle. (This has greater success rate at restoring sinus rhythm than standard Valsalva.)
- d. **Carotid sinus massage:** Place the patient in a supine position with neck extension. Apply steady pressure for 5 to 10 seconds to **one** carotid sinus (inferior to the angle of the mandible where pulsation is detected). If unsuccessful, wait 1 to 2 minutes and repeat on the contralateral side.
- e. **See Chapter 1 for further management of SVT.**

**B. Heelstick and Fingerstick<sup>15</sup>**

1. **Indications:** Blood sampling in infants, obtaining point-of-care whole blood samples such as serum glucose
2. **Complications:** Infection, bleeding, osteomyelitis
3. **Procedure:**
  - a. Warm heel or finger.
  - b. Clean with alcohol.
  - c. Using a lancet, puncture heel on the lateral aspect (avoiding the posterior area) or finger on the distal palmar lateral pad.
  - d. Wipe away the first drop of blood, and then collect the sample using a capillary tube or container.
  - e. Alternate between squeezing blood from the leg toward the heel (or from the hand toward the finger) and then releasing the pressure for several seconds.

**C. Peripheral Intravenous Access<sup>15</sup>**

1. **Indications:** Blood sampling and access to peripheral venous circulation to deliver fluid, medications, or blood products
2. **Complications:** Thrombosis, infection
3. **Procedure:**
  - a. Apply tourniquet around the extremity proximal to chosen site.
  - b. Prepare site with alcohol or chlorhexidine.
  - c. Insert IV catheter, bevel up, at an angle almost parallel to the skin, advancing until a *flash* of blood is seen in the catheter hub. Advance the plastic catheter only, remove the needle, and secure the catheter.
  - d. After removing tourniquet, attach a syringe and apply gentle negative pressure to withdraw blood for serum sampling. Then, attach T connector filled with saline to the catheter, flush with normal saline (NS) to ensure patency of the IV line.

#### 4. **Ultrasound-guided procedure:**

- a. With linear ultrasound probe, identify a vein that does not appear to be prohibitively tortuous or stenotic. Perform this by sliding the probe along the course of the vessel and identifying its direction and branching. The saphenous veins in the calves, veins in the forearms, antecubital areas, inside of the upper arms, and external jugular veins are areas where ultrasound guidance can help. An ideal vessel appears less than 1 cm below the skin surface. Deeper vessels are prone to through-and-through perforation of the vessel. Infiltration around deeper vessels is also a risk, as a shorter length of catheter resides in the vessel after insertion.
- b. Prepare the site, and in the case of limb vessels, place a tourniquet proximal to the insertion site.
- c. Under ultrasound visualization, insert the needle into the skin at a shallow (usually <30 degrees) angle to the skin at the midline of the probe near where it contacts the skin. With the probe visualizing the vessel transversely, slowly advance the needle and follow the tip of the needle by sliding the probe away from you. Advance the ultrasound probe until the needle punctures the vessel wall.
- d. Proceed with cannulation of the vessel and secure the intravenous catheter per standard procedure.

5. **Infiltration and extravasation**<sup>16</sup>: This is a common injury secondary to fluid infusion into subcutaneous tissues around the venipuncture site and typically occurs due to puncture of the vein or if the catheter slips out of the vein. The difference between infiltration and extravasation is the type of fluid that has leaked (nonvesicant vs. vesicant). Infiltrations are generally benign, although they can still inflict damage via exertion of mechanical forces on surrounding structures. Extravasation due to a vesicant can cause blistering and burns, leading to necrosis of the tissue. To determine if infiltration/extravasation has occurred, firmly occlude the vein 1 to 2 inches proximal to the insertion site. Continued infusion without resistance indicates infiltration. Immediately stop the infusion. Refer to institutional policy for guidelines regarding application of medication (e.g., hyaluronidase, phentolamine, nitroglycerin ointment). Elevate the affected limb to reduce swelling; apply a warm compress for 10 to 15 minutes; encourage movement of the affected arm. Reevaluate the site every 8 hours.

6. **A video on [peripheral IV placement](#) is available on the *New England Journal of Medicine's* website.**


7. **A video on [ultrasound-guided peripheral IV placement](#) is available on the *New England Journal of Medicine's* website.**

#### **D. External Jugular Puncture and Catheterization (See Section XI [Online Content])**

#### **E. Radial Artery Puncture and Catheterization**<sup>3,4,15</sup>

1. **Indications:** Arterial blood sampling or frequent blood gas and continuous blood pressure monitoring in an intensive care setting


2. **Complications:** Infection, bleeding, occlusion of artery by hematoma or thrombosis, ischemia if ulnar circulation is inadequate
3. **Procedure:**
  - a. Before the procedure, test adequacy of ulnar blood flow with the Allen test: Clench the hand while simultaneously compressing ulnar and radial arteries. The hand will blanch. Release pressure from the ulnar artery and observe the flushing response. Procedure is safe to perform if the entire hand flushes.
  - b. Locate the radial pulse. It is optional to infiltrate the area over the point of maximal impulse with lidocaine. Avoid infusion into the vessel by aspirating before infusing. Prepare the site in a sterile fashion.
  - c. Puncture: Insert a butterfly needle attached to a syringe at a 30- to 60-degree angle over the point of maximal impulse. Blood should flow freely into the syringe in a pulsatile fashion. Suction may be required for plastic tubes. Once the sample is obtained, apply firm, constant pressure for 5 minutes and then place a pressure dressing on the puncture site.
  - d. Catheter placement: Secure the patient's hand to an arm board. Leave the fingers exposed to observe any color changes. Prepare the wrist with sterile technique and infiltrate over the point of maximal impulse with 1% lidocaine. Insert an IV catheter with its needle at a 30-degree angle to the horizontal until a flash of blood is seen in the catheter hub. Advance the plastic catheter and remove the needle. Alternatively, pass the needle and catheter through the artery to transfix it, and then withdraw the needle. Very slowly, withdraw the catheter until free flow of blood is noted, then advance the catheter and secure in place using sutures or tape. Seldinger technique (Fig. 4.2) using a guidewire can also be used. Apply a sterile dressing and infuse heparinized isotonic fluid (per institutional protocol) at a minimum of 1 mL/hr. A pressure transducer may be attached to monitor blood pressure.
  - e. Suggested size of arterial catheters based on weight:
    - (1) Infant (<10 kg): 24 Gauge
    - (2) Child (10 to 40 kg): 22 Gauge
    - (3) Adolescent (>40 kg): 20 Gauge
4. **Ultrasound-guided procedure:**
  - a. Use the linear probe. After the sterile field has been prepped, apply gel to the probe and place within a sterile cover. Place the ultrasound probe transverse to the artery on the radial, posterior tibial, or dorsalis pedis pulse. Identify the artery, which will appear pulsatile with some compression. Once the artery has been identified, center the probe over the vessel (Fig. 4.3). Insert the needle into the skin at a 45-degree angle at the midline of the probe near where it contacts the skin. With the probe visualizing the vessel transversely, slowly advance the needle and follow the tip of the needle by sliding the probe away. Advance the ultrasound probe until the needle punctures

**FIGURE 4.2**


Seldinger technique. (A) Guidewire is placed through introducer needle into lumen of vessel. (B) Catheter is advanced into vessel lumen along guidewire. (C) Hub of catheter is secured to skin with suture. (Modified from Fuhrman B, Zimmerman J. *Pediatric Critical Care*. 4th ed. Mosby; 2011.)

the vessel wall. Proceed with the rest of the procedure after vessel puncture, as described previously.

5. **Videos on [arterial puncture](#) and [radial artery catheterization](#) are available on the *New England Journal of Medicine's* website.**

**FIGURE 4.3**

Ultrasound transverse view of radial artery. In the left image, the radial artery is seen in cross section with veins on either side. On the right image, pressure has been applied and the veins are collapsed while the artery remains patent. A, Artery; V, vein. (From Weiner MM, Geldard P, Mittnacht AJC. Ultrasound guided vascular access: a comprehensive review. *J Cardiothorac Vasc Anesth.* 2013;27[2]:345–360.)

**FIGURE 4.4**

Intraosseous needle placement using standard anterior tibial approach. Insertion point is in the midline on medial flat surface of anterior tibia, 1 to 3 cm (2 fingerbreadths) below tibial tuberosity. (From Dieckmann R, Fiser D, Selbst S. *Pediatric Emergency and Critical Care Procedures.* Mosby; 1997.)

6. A video on [ultrasound-guided radial artery catheterization](#) is available on the *New England Journal of Medicine's* website.

#### F. Intraosseous (IO) Access<sup>3,4,17</sup> (Fig. 4.4)

1. **Indications:** Obtain emergency access in children during life-threatening situations. This is very useful during cardiopulmonary arrest, shock, burns, and life-threatening status epilepticus. Any crystalloid, blood product, or drug that may be infused into a peripheral vein may also be infused into the IO space. The IO needle should be removed once adequate vascular access has been established. Insertion of IO needle into fractured bones should be avoided.

**2. Complications:**

- a. Extravasation of fluid from incomplete or through-and-through cortex penetration, infection, bleeding, osteomyelitis, compartment syndrome, fat embolism, fracture, epiphyseal injury.
- b. Frequency of complications increases with prolonged infusions.

**3. Sites of entry (in order of preference):**

- a. Anteromedial surface of the proximal tibia, 1 to 2 cm below and slightly medial to the tibial tuberosity on the flat part of the bone
- b. Distal femur 3 cm above the lateral condyle in the midline
- c. Medial surface of the distal tibia 1 to 2 cm above the medial malleolus (may be a more effective site in older children than the distal femur)
- d. Proximal humerus, 2 cm below the acromion process into the greater tubercle with the arm held in adduction and internal rotation
- e. Anterosuperior iliac spine at a 90-degree angle to the long axis of the body


**4. Procedure:**

- a. Prepare the selected site in a sterile fashion.
- b. If the child is conscious, anesthetize the puncture site down to the periosteum with 1% lidocaine (optional in emergent situations).
- c. Choose between a manual IO or drill-powered IO insertion device:
  - (1) For manual IO needle: Insert a 15-gauge (for all children) or 18-gauge (for infants and neonates) IO needle perpendicular to the skin at an angle away from the epiphyseal plate, and advance to the periosteum. With a boring rotary motion, penetrate through the cortex until there is a decrease in resistance, indicating that you have reached the marrow. The needle should stand firmly without support. Secure the needle carefully.
  - (2) For drill-powered IO needle: Enter skin with the needle perpendicular to the skin, as with the manual needle, and press the needle until you meet the periosteum. Then apply easy pressure while gently depressing the drill trigger until you feel a decrease in resistance. Remove the drill while holding the needle steady to ensure stability prior to securing the needle. Use an EZ-IO AD 15-mm needle (pink hub) for patients 3 to 39 kg and a 25-mm needle (blue hub) for patients 40 kg and greater.
- d. Remove the stylet and attempt to aspirate marrow. (Note that it is not necessary to aspirate marrow.) Flush with crystalloid solution. Observe for fluid extravasation. Marrow can be sent to determine glucose levels, chemistries, blood types and crossmatches, hemoglobin levels, blood gas analyses, and cultures. Note that sending serum laboratory tests from IO aspirates is institution-dependent.
- e. Secure the IO needle. Attach standard IV tubing. Increased pressure (through pressure bag or push) may be necessary for infusion. There is a high risk for obstruction if continuous high-pressure fluids are not flushed through the IO needle.

5. A video on IO catheter placement is available on the *New England Journal of Medicine's* website.

### G. Umbilical Artery and Umbilical Vein Catheterization<sup>3,18</sup>

1. **Indications:** Vascular access (via umbilical vein [UV]), blood pressure monitoring (via umbilical artery [UA]), or blood gas monitoring (via UA) in critically ill neonates
2. **Complications:** Infection; bleeding; perforation of vessel; thrombosis with distal embolization, ischemia or infarction of lower extremities, bowel, or kidney; arrhythmia if catheter is in the heart; air embolus
3. **Contraindications:** Omphalitis, peritonitis, possible/confirmed necrotizing enterocolitis, intestinal hypoperfusion
4. **Line placement:**
  - a. Umbilical arterial catheter (UAC) line: Low line vs. high line
    - (1) Low line: Tip of catheter should lie just above the aortic bifurcation between L3 and L4.
    - (2) High line: Tip of catheter should be above the diaphragm between T6 and T9. A high line has fewer complications and lesser need for replacement than a low line.
  - b. Umbilical venous catheter (UVC) lines should be placed in the inferior vena cava above the level of the ductus venosus and the hepatic veins and below the level of the right atrium.
  - c. Catheter length: Determine the length of catheter required using either a standardized graph based on shoulder-umbilical length or the following birth weight (BW) regression formula:
    - (1) UAC high line (cm) =  $(3 \times \text{BW [kg]}) + 9$
    - (2) UVC length (cm) =  $0.5 \times \text{UAC high line (cm)} + 1$
5. **Procedure for UAC line (Fig. 4.5):**
  - a. Determine the length of the catheter to be inserted for either high (T6 to T9) or low (L3 to L4) position.
  - b. Restrain infant. Maintain the infant's temperature during the procedure. Prepare and drape the umbilical cord and adjacent skin using sterile technique.
  - c. Flush the catheter with sterile saline solution before insertion. Ensure that there are no air bubbles in the catheter or attached syringe.
  - d. Tie sterile umbilical tape around the base of the cord, tight enough to prevent bleeding. Cut through the cord horizontally about 1.5 to 2 cm from the skin.
  - e. Identify the one large, thin-walled UV and two smaller, thick-walled arteries. Use one tip of open, curved forceps to gently probe and dilate one artery. Then use both points of closed forceps and dilate artery by allowing forceps to open gently.
  - f. Grasp the catheter 1 cm from its tip with toothless forceps and insert the catheter into the lumen of the artery. Aim the tip toward the feet and gently advance the catheter to the desired distance. *Do not force.*

**FIGURE 4.5**

Placement of umbilical arterial catheter. (A) Dilating lumen of umbilical artery. (B) Insertion of umbilical artery catheter. (From Dieckmann R, Fiser D, Selbst S. *Pediatric Emergency and Critical Care Procedures*. Mosby; 1997.)

- If resistance is encountered, try loosening umbilical tape, applying steady and gentle pressure, or manipulating the angle of the umbilical cord to the skin. Often the catheter cannot be advanced because of the creation of a “false luminal tract.” There should be good blood return when the catheter enters the iliac artery.
- g. Confirm catheter tip position with x-ray or ultrasound. Secure catheter with a suture through the cord, a marker tape, and a tape bridge. The catheter may be pulled back but *not* advanced once the sterile field is broken.
  - h. Observe for complications: Blanching or cyanosis of lower extremities, perforation, thrombosis, embolism, or infection. If any complications occur, the catheter should be removed.
  - i. Use isotonic fluids containing heparin per institutional policy. Never use hypotonic fluids in the UA.

6. **Procedure for UVC line (see Fig. 4.5):**
  - a. Determine the desired length and follow steps “5a” through “5d” for UA catheter placement.
  - b. Isolate the thin-walled UV, clear thrombi with forceps, and insert catheter, aiming the tip toward the right shoulder. Gently advance the catheter to the desired distance. *Do not force*. If resistance is encountered, try loosening the umbilical tape, applying steady and gentle pressure, or manipulating the angle of the umbilical cord to the skin. Resistance is commonly met at the abdominal wall and again at the portal system. *Do not* infuse anything into the liver.
  - c. Confirm catheter tip position with x-ray or ultrasound. Secure catheter with a suture through the cord, a marker tape, and a tape bridge. The catheter may be pulled back but *not* advanced once the sterile field is broken.
7. **A video on UVC/UAC line placement is available on the *New England Journal of Medicine's* website.**

## VI. PULMONARY PROCEDURES

### A. Use of Metered-Dose Inhalers and Spacers<sup>9</sup>

1. **Indications:** Delivery of medication to distal airways in the lungs
2. **Complications:** Failure of medication delivery. **Note** that there are risks associated with the medication rather than the delivery method.
3. **Procedure:**
  - a. Shake the inhaler, remove the cap, and attach it to the spacer device.
  - b. Instruct the child to exhale completely.
  - c. Place the mouthpiece of the spacer into the patient’s mouth and instruct the child to make a complete seal with the lips. Alternatively, a spacer with a mask can be placed over the child’s mouth if they are unable to make a seal with their lips.
  - d. Spray 1 puff from the inhaler into the spacer and instruct the patient to breathe slowly and deeply. Older children should hold a single large breath for 10 seconds; younger children can take 4 to 5 breaths.
  - e. Wait 1 minute and repeat as indicated.

### B. Needle Cricothyrotomy<sup>9,19</sup>

1. **Indications:** When an emergency airway is required and the clinician is unable to use bag-valve-mask (BVM) ventilation or secure an orotracheal or nasotracheal airway. Common indications include facial fractures, blood or vomitus in the airway, airway obstruction (e.g., foreign body, tumor, edema from trauma).
2. **Contraindications:** Relative contraindications include inability to locate landmarks, laryngotracheal damage, coagulopathy, bleeding dyscrasia, laryngeal fracture or tracheal transection.
3. **Complications:** Bleeding, hypoxia, pneumothorax, esophageal laceration, vocal cord injury, posterior tracheal wall perforation, infection

#### 4. Procedure:

- a. Immobilize the larynx with the nondominant hand and identify the cricothyroid membrane. This is located by palpating the laryngeal prominence at midline of the thyroid cartilage and then moving distally 1 to 2 cm to a small depression. This depression overlies the cricothyroid membrane.
- b. Insert a 12- to 14-gauge angio-catheter caudally at a 30- to 45-degree angle through the cricothyroid membrane. Attach a 3-mL syringe with saline, aspirating as the needle is inserted. Advance until air is aspirated into the syringe.
- c. Advance the catheter over the needle and remove the needle. Attach a 3.0 endotracheal tube (ETT) adapter to the angio-catheter and then attach an oxygen source that can deliver roughly 30 psi. Alternatively, a bag-valve device can be connected using a 7.0 ETT adapter and a 3-mL syringe with plunger removed.
- d. Intermittent ventilation can be achieved by cutting a small hole in the oxygen tubing and covering the hole in the tubing. Allow for expiration by uncovering the hole for 2 to 9 seconds.

#### C. Needle Thoracostomy<sup>3,20</sup>

1. **Indications:** Evacuation of a tension pneumothorax
2. **Complications:** Infection; bleeding; pneumothorax; hemothorax; pulmonary contusion or laceration; puncture of diaphragm, spleen, or liver; or bronchopleural fistula
3. **Procedure:**
  - a. Prepare and drape the skin as clean as possible, with goal of sterility.
  - b. Insert a large-bore angio-catheter (14- to 22-gauge, based on patient size and likely depth of the chest wall) into the anterior second intercostal space in the midclavicular line. Insert needle over superior aspect of rib margin to avoid neurovascular structures. If the angio-catheter permits, a 3- to 10-mL syringe with 1 to 2 mL of saline can be connected to it. Aspirating the syringe while inserting the IV will pull air bubbles through the saline if an air collection exists. A rush of bubbles signifies successful access.
  - c. When pleural space is entered, withdraw needle and attach a three-way stopcock and syringe to the catheter, and aspirate air. The stopcock is used to stop air flow through the catheter when sufficient evacuation has been performed.
  - d. Subsequent insertion of a chest tube is necessary for ongoing release of air. It is advised not to completely evacuate chest prior to placement of chest tube to avoid pleural injury.
4. **A video on [needle decompression of spontaneous pneumothorax](#) is available on the *New England Journal of Medicine's* website.**

#### D. Bag-Valve-Mask Ventilation<sup>21,22</sup>

1. **Indication:** Respiratory failure, apnea
2. **Contraindication:** Complete upper airway obstruction
3. **Complications:** Gastric distention

**4. Procedure:**

- a. Child's head should be positioned so that nose and mouth are pointing toward the ceiling. A shoulder roll may be needed to improve position. If cervical spine injury is suspected, do not move the neck.
- b. Place mask on patient's face. For effective BVM ventilation, the mask must fit properly (covering the patient's mouth and nose).
- c. Use the E-C clamp technique. For the "E" use the little, ring, and middle fingers to lift the jaw. The thumb and index finger form the "C" to hold the mask to the face, forming a seal between the mask and the face.
- d. Two-person BVM ventilation is more effective. One rescuer will do the E-C clamp technique with both hands while the other person compresses the ventilation bag.

**E. Endotracheal intubation: Please refer to Chapter 1****VII. GASTROINTESTINAL PROCEDURES****A. Nasogastric Tube Placement<sup>3,9,23</sup>**

1. **Indications:** Enteral nutrition, administration of medications, treatment of ileus or obstruction, gastric decompression, gastric lavage
2. **Contraindications:** Esophageal stricture, esophageal varices, severe midface trauma (cribriform plate disruption), bleeding diatheses, alkaline ingestion
3. **Complications:** Malposition, coiling of tube, esophageal perforation, pneumothorax, aspiration
4. **Procedure:**
  - a. Approximate the length of 5- to 18-Fr tube insertion by positioning the tube from the nares or mouth to the ear, then to the mid-xyphoid-umbilicus. Mark this length on the tube with marker.
  - b. The patient should be sitting as upright as possible. The head should be tilted toward the chest.
  - c. Lubricate the tube and insert the tube through the nose. Advance the tube to the length mark, asking the patient to swallow while the tube is inserted. It may be helpful to provide a cup of water with a straw.
  - d. Confirm placement of the tube with a radiograph of the lower chest/upper abdomen. Ensure that the tube is located distal to the carina, crosses the diaphragm, and rests in a central position in the gastric region. The tube should not cross the midline. Additional confirmation can be obtained by testing the pH of aspirated contents. A pH <4 confirms proper positioning. Alternatively, insert a small amount of air (20 to 30 mL) through the tube while listening to the gastric area with a stethoscope.
  - e. Secure the tube.

**B. Gastrostomy Tube Replacement<sup>3,9,24</sup>**

1. **Indications:** Dislodged, blocked, or replacement of gastrostomy tube (G-tube) or gastrostomy button.

2. **Complications:** Perforation, bleeding, pneumoperitoneum, creation of “false tract” particularly if tube is newly placed. **Note** that misplacement and associated complications are rare for children with a mature G-tube tract undergoing tube replacement in a pediatric emergency room.
3. **Relative contraindications:** Tube has been displaced for 24 hours or more, tube was placed less than one month ago, suspicion of peritonitis
4. **Procedure:**
  - a. Deflate balloon completely with a syringe and pull the tube out steadily.
  - b. Insert new tube in the stoma and inflate balloon fully with water. Gently tug on the tube to assess whether the balloon is inflated. Secure the tube.
  - c. Confirm intragastric placement by aspirating gastric contents.
  - d. If replacement tube is not immediately available, a Foley catheter of similar size may be placed using the method above to maintain tract patency.
  - e. If the G-tube tract is too constricted for placement of G-tube, consider upsizing with Foley catheter serial dilation.
5. **A video on [gastrostomy tube exchange](#) is available on the *New England Journal of Medicine*'s website.**

## VIII. GENITOURINARY PROCEDURES

### A. Urinary Bladder Catheterization<sup>9,25</sup>

1. **Indications:** To obtain urine for urinalysis and sterile culture, to accurately monitor hydration status, and bladder decompression
2. **Complications:** Hematuria, infection, trauma to urethra or bladder, intravesical knot of catheter (rarely occurs)
3. **Contraindications:** Pelvic fractures, known trauma to the urethra, or blood at the meatus
4. **Catheter selection:** 6 Fr for newborns, 6 to 8 Fr for infants, 8 to 10 Fr for prepubertal females, and up to 12 Fr for adolescents
5. **Procedure:**
  - a. For collection of urinalysis and/or urine culture, the infant/child should not have voided within 1 hour of procedure.
  - b. Prepare the urethral opening using sterile technique.
  - c. In males, apply gentle traction to the penis to straighten the urethra. In uncircumcised male infants, expose the meatus with gentle retraction of the foreskin. The foreskin must be retracted only far enough to visualize the meatus.
  - d. In females, the urethral orifice may be difficult to visualize but is usually immediately superoanterior to the vaginal orifice.
  - e. Gently insert a lubricated catheter into the urethra. Slowly advance catheter until resistance is met at the external sphincter. Continued pressure will overcome this resistance, and the catheter will enter the bladder. Only a few centimeters of advancement are required to reach


the bladder in females. In males, insert a few centimeters longer than the shaft of the penis.

- f. Carefully remove the catheter once specimen is obtained, and cleanse skin of iodine.
- g. If indwelling Foley catheter is inserted, inflate balloon with sterile water or saline as indicated on bulb, then connect catheter to drainage tubing attached to urine drainage bag. Secure catheter tubing to inner thigh.

6. **Videos on catheterization of the male urethra and catheterization of the female urethra are available on the *New England Journal of Medicine's* website.**

**B. Suprapubic Bladder Aspiration<sup>3,4</sup>**

1. **Indications:** To obtain urine in a sterile manner for urinalysis and culture in children younger than 2 years (avoid in children with genitourinary tract anomalies, coagulopathy, or intestinal obstruction), bladder decompression. This bypasses distal urethra, thereby minimizing risk for contamination.
2. **Complications:** Infection (cellulitis), hematuria (usually microscopic), intestinal perforation
3. **Procedure** (Fig. 4.6):
  - a. Anterior rectal pressure in females or gentle penile pressure in males may be used to prevent urination during the procedure. Child should not have voided within 1 hour of procedure.
  - b. Restrain child in the supine, frog leg position. Prepare suprapubic area in a sterile fashion.
  - c. The site for puncture is 1 to 2 cm above the symphysis pubis in the midline. Use a syringe with a 22-gauge, 1.5-inch needle, and puncture at a 10- to 20-degree angle to the perpendicular, aiming slightly caudad.
  - d. Ultrasound guidance:
    - (1) Ultrasound can be used to visualize the urinary bladder for this procedure as follows: Use the curvilinear or linear probe depending on the size of the child. Apply the probe in transverse position in the midline of the lower abdomen, positioning it to locate the bladder. The bladder is a midline structure with a dark center and bright margins. The shape of the bladder is usually rounded; however, it can appear spherical, pyramidal, or even cuboidal (Fig. 4.7).
    - (2) The bladder may be empty as well with no dark cavity. If no clear structure, give fluids and reassess in 30 minutes. This technique can also be used in the evaluation of anuric patients, to differentiate between decreased urine production and urinary retention. This is also useful in the case of patients with a urinary catheter as the catheter is usually visible. If it is visualized and the bladder also has urine around it, the catheter is likely malfunctioning.

**FIGURE 4.6**

Landmarks for suprapubic bladder aspiration. (Modified from Dieckmann R, Fiser D, Selbst S. *Pediatric Emergency and Critical Care Procedures*. Mosby; 1997.)



**FIGURE 4.7**

Ultrasound of bladder. In this transverse midline view of the pelvis the bladder appears black (anechoic) and cuboid in the midline. This is the typical appearance of a full bladder on ultrasound, although the shape may vary. (From Leeson K, Leeson B. Pediatric ultrasound: applications in the emergency department. *Emerg Med Clin North Am.* 2013;31[3]:809–829.)

- (3) Aspiration can be performed after marking the site with ultrasound, proceeding with preparing and draping the patient, and proceeding to puncture.
- e. **Gently exert suction as the needle is advanced until urine enters syringe.** The needle should not be advanced more than 3 cm. Aspirate urine with gentle suction.
- f. Remove needle, cleanse skin of iodine, and apply a sterile bandage.
4. **A video of suprapubic bladder aspiration is available on the *New England Journal of Medicine's* website.**

## IX. MUSCULOSKELETAL PROCEDURES

### A. Basic Splinting<sup>3</sup>

1. **Indications:** To provide short-term stabilization of limb injuries while accommodating swelling associated with acute injuries
2. **Complications:** Pressure sores, dermatitis, neurovascular impairment
3. **Procedure:**
  - a. Determine style of splint needed (see [Section IX.B](#)).
  - b. Measure and cut fiberglass or plaster to appropriate length. If using plaster, upper-extremity splints require 8 to 10 layers and lower-extremity splints require 12 to 14 layers.

- c. Pad extremity with copious cotton roll padding, taking care to overlap each turn by 50%. In prepackaged fiberglass splints, additional padding is not generally required. Bony prominences may require additional padding. Place cotton between digits if they are in a splint.
- d. Immerse plaster slabs into room temperature water until bubbling stops. Smooth out wet plaster slab, avoiding any wrinkles. Fiberglass splints will harden when exposed to air.
- e. Position splint over extremity and mold to desired contour. Wrap with an elastic bandage to hold molded splint onto extremity in position of function, overlapping each turn by 50%. Continue to hold desired form of splint upon extremity until fully hardened.
- f. **NOTE:** Plaster and fiberglass become warm while drying. Using warm water will decrease drying time. This may result in inadequate time to mold splint. Turn edge of the splint back on itself to produce a smooth surface. Take care to cover the sharp edges of fiberglass.
- g. Use crutches or slings as indicated.
- h. The need for orthopedic referral should be individually assessed.
  - i. Emergent orthopedic referral may be required, including when there is concern for neurovascular compromise or compartment syndrome of the affected extremity.

#### 4. Postsplint care:


- a. Standard rest, ice, and elevation of affected extremity should be performed.
- b. Avoid weight bearing on splinted extremity.
- c. Do not get splint wet. Splints can be wrapped in water-resistant items such as a plastic bag or a specially designed splint bag to allow for showering. Use a hair dryer in instances where the splint has accidentally gotten wet.
- d. Do not stick items such as a pen or clothes hanger to scratch inside the splint.
- e. If areas in or distal to the splint develop numbness, tingling, or increased pain; turn blue or pale; or become swollen, patient should loosen the elastic bandage of the splint. Instruct to seek immediate medical care if this does not quickly (<30 minutes) resolve these symptoms.

#### 5. A video on [basic splinting techniques](#) is available on the *New England Journal of Medicine's* website.

### B. Selected Splints and Indications (Fig. 4.8)

#### 1. Long arm posterior splint

- a. **Indications:** Immobilization of elbow and forearm injuries
- b. **Procedure:** Elbow flexed at 90 degrees, forearm in neutral position, slight dorsiflexion of the wrist. Splint extends from palmar crease of the hand to mid upper arm along the ulnar side of the forearm and the posterior aspect of the humerus. Width should be semicircumferential.



**FIGURE 4.8**

Selected splint types. Light purple layer is stockinette, white layer is cotton roll, dark purple layer is the splint. (A) Long arm posterior splint. (B) Sugar tong forearm splint. (C) Ulnar gutter splint. (D) Thumb spica splint. (E) Volar splint. (F) Posterior ankle splint. (G) Ankle stirrup splint.

## 2. Sugar tong forearm splint

- a. **Indications:** For distal radius and wrist fractures; to immobilize the elbow and minimize pronation and supination
- b. **Procedure:** Elbow flexed at 90 degrees, forearm in neutral position, and slight dorsiflexion of the wrist. Splint extends from palmar crease along volar aspect of forearm, around elbow, and dorsally to the metacarpals. Fingers and thumb remain free. Width should support arm on both sides but not overlap.

## 3. Ulnar gutter splint

- a. **Indications:** Nonrotated fourth or fifth (boxer) metacarpal metaphyseal fracture with less than 20 degrees of angulation, uncomplicated fourth and fifth phalangeal fracture.
- b. Assess for rotation, displacement (especially Salter I type fracture), angulation, and joint stability before splinting.
- c. **Procedure:** Elbow in neutral position, wrist in slight dorsiflexion, metacarpophalangeal (MP) joint at 60 to 90 degrees, interphalangeal (IP) joint at 20 degrees. Apply splint in U shape from the tip of the fifth digit to 3 cm distal to the volar crease of the elbow. Splint should be wide enough to enclose the fourth and fifth digits.

## 4. Thumb spica splint

- a. **Indications:** Nonrotated, nonangulated, nonarticular fractures of the thumb metacarpal or phalanx, ulnar collateral ligament injury (gamekeeper's or skier's thumb), scaphoid fracture, or suspected scaphoid fracture (pain in anatomic snuff box)
- b. **Procedure:** Wrist in slight dorsiflexion, thumb in some flexion and abduction, IP joint in slight flexion. Apply splint in U shape along radial side of forearm extending from tip of thumb to mid-forearm. Mold the splint along the long axis of the thumb so that thumb position is maintained. This will result in a spiral configuration along the forearm with maintained apposition of the index finger and thumb.

## 5. Volar splint

- a. **Indications:** Wrist immobilization for wrist sprains, strains, or certain uncomplicated fractures
- b. **Procedure:** Wrist in slight dorsiflexion. Apply splint on palmar surface from the MP joint to 2 to 3 cm distal to the volar crease of the elbow. It is useful to curve the splint to allow the MP joint to rest at an 80- to 90-degree angle.

## 6. Posterior ankle splint

- a. **Indications:** Immobilization of ankle sprains and fractures of the foot, ankle, and distal tibia and/or fibula
- b. **Procedure:** Place patient in prone position with ipsilateral knee flexed at 90 degrees and affected ankle held in flexion at 90 degrees. Splint should extend from base of toes to upper portion of the calf. Width should match that of the foot. An ankle stirrup (sugar tong) splint can be added to increase stability for ankle fractures.

## 7. Ankle stirrup splint

- a. **Indications:** Immobilization of the ankle

- b. **Procedure:** Ankle held in flexion at 90 degrees. Splint extends in U-shaped fashion from fibular head underneath the ankle to just below the knee. Width should be one-half of the narrowest circumference of the lower leg and not overlapping. May be used alone or in combination with (placed after) posterior ankle splint.

### C. Radial Head Subluxation (Nursemaid's Elbow) Reduction<sup>26,27</sup>

1. **Presentation:** Commonly occurs in children aged 1 to 4 years with a history of inability to use an arm after it was pulled. Child presents with affected arm held at the side in pronation, with elbow slightly flexed.
2. **Caution:** Rule out a fracture clinically before doing procedure. Consider radiograph if mechanism of injury or history is atypical or if exam is concerning for fracture (e.g., swelling, bruising, tenderness).
3. **Procedure:**
  - a. Two most common techniques include hyperpronation (HP) and traditional supination-flexion (SF) maneuvers. Meta-analyses of randomized trials evaluating the two techniques favor HP for both efficacy and pain tolerance.
  - b. Support the elbow with one hand and place your thumb laterally over the radial head at the elbow applying pressure medially. With your other hand, grasp the child's hand in a handshake position or at the wrist.
  - c. HP method: Forcefully pronate the wrist. You may feel a click as reduction occurs.
  - d. SF method: Quickly and deliberately supinate and externally rotate the forearm, and simultaneously flex the elbow.
  - e. Most children will begin to use the arm within 15 minutes, some immediately after reduction. If reduction occurs after a prolonged period of subluxation, it may take the child longer to recover use of the arm. In this case, the arm should be immobilized with a posterior splint.
  - f. If procedure is unsuccessful, consider obtaining a radiograph. Maneuver may be repeated if needed.
4. **A video on [reduction of nursemaid's elbow](#) is available on the *New England Journal of Medicine's* website.**

### D. Finger/Toe Dislocation Reduction<sup>3</sup>

1. **Indications:** IP and MP/metatarsophalangeal dislocations
2. **Complications:** Fracture of phalanges, entrapment of neurovascular structures
3. **Cautions:** Volar dislocations and dorsal dislocations with interposition of the volar plate or entrapment of the metacarpal/metatarsal head often cannot be performed using closed reduction.
4. **Procedure:**
  - a. Assess for neurovascular compromise in the affected digit. Perform radiographs to evaluate for possible fracture.
  - b. Consider procedural sedation or a digital block prior to procedure.
  - c. Grasp the digit proximal to the fracture to allow for stabilization.

- d. Grasp the tip of the distal digit and apply longitudinal traction, with the joint typically slipping into place.
- e. Alternatively, grasp the distal phalanx and mildly hyperextend to accentuate the deformity while applying longitudinal traction.
- f. After reduction, again evaluate neurovascular status and obtain radiographs to ensure proper position and to further evaluate for fracture.
- g. Immobilize the joint using a padded splint using full extension for distal IP joints and 20 to 30 degrees of flexion for proximal IP joints.



### E. Knee Arthrocentesis<sup>3</sup>

1. **Indications:** Evaluation of fluid for the diagnosis of disease, including infectious, inflammatory, and crystalline disease, and removal of fluid for relief of pain and/or functional limitation
2. **Contraindications:** Bleeding diathesis, local fracture, overlying skin infection
3. **Complications:** Pain, bleeding, infection
4. **Procedure:**
  - a. Place child supine on exam table with knee in slight flexion, with use of a padded roll underneath the knee for support, if unable to slightly flex.
  - b. The lateral or medial approach can be made, with the lateral approach preferred to avoid the vastus medialis muscle.
  - c. The puncture point should be at the posterior margin of the patella in both cases.
  - d. Prepare the overlying skin in a sterile fashion, and once cleaned, numb the area using 1% lidocaine with a small-gauge needle. Then, using an 18-gauge needle attached to a syringe, puncture the skin at a 10- to 20-degree downward angle, and advance under continuous syringe suction until fluid is withdrawn, indicating entry into the joint space.
  - e. In large effusions, several syringes may be needed for complete fluid removal if so desired, and the needle may have to be redirected to access pockets of fluid.
  - f. Upon completion, withdraw the needle and cover the wound with a sterile gauze dressing.
  - g. Synovial fluid can then be sent for studies as indicated.
5. **A video on [knee arthrocentesis](#) is available on the *New England Journal of Medicine's* website.**

### F. Hematoma Blocks<sup>28</sup>

1. **Indications:** Analgesia for closed fracture of the extremity that requires manipulation or closed reduction. It can be an adjunct or an alternative when procedural sedation is not possible or is impractical.
2. **Contraindications:** Allergic reactions to local anesthetic agents, open fracture, cellulitis overlying fracture site, presence of a neurologic or vascular deficit

3. **Complications:** Rare, but include compartment syndrome, local anesthetic toxicity (circumoral and tongue numbness, dizziness, tinnitus, and visual disturbances), and osteomyelitis
4. **Procedure:**
  - a. Perform using aseptic technique.
  - b. Draw up the local anesthetic solution into a syringe with a 22- or 23-gauge, 2-inch-long needle. Bupivacaine is desired and can be used alone or mixed with lidocaine in a 50:50 ratio. (See [Chapter 6](#) for dosage maximum.)
  - c. Apply a wheal of 1% lidocaine subcutaneously over the fracture site. Wait 1 to 2 minutes for the anesthetic to take effect.
  - d. Slowly insert and advance the needle attached to the local anesthetic solution through the skin wheal and aimed at the fracture site. C-arm fluoroscopy can aid fracture/hematoma localization. Slowly advance the needle.
    - (1) Aspirate with the syringe to **ensure there is no free flow of blood**, which indicates that the needle is within a blood vessel. If there is free blood flow, do not inject the local anesthetic solution.
    - (2) A flash, without flow, of blood indicates entry of the tip of the needle into the hematoma.
    - (3) Redirect needle if you strike bone or if no flash of blood is returned.
  - e. Once flash, without flow, is obtained, slowly inject the local anesthetic solution into the hematoma.
  - f. Reposition the needle to different areas within the hematoma and inject small amounts of the local anesthetic into each area. This distributes the local anesthetic solution to increase the efficacy of the hematoma block and minimizes the risk of intravascular injection of the entire dose of local anesthetic.
  - g. Withdraw the needle, apply a bandage to the skin puncture site, and await analgesia.

## X. SKIN/DERMATOLOGIC PROCEDURES

### A. Immunization and Medication Administration<sup>9,29</sup>

**NOTE:** Please see Chapters 16 and 30 for relevant vaccines and medications and their appropriate administration routes.

#### 1. Subcutaneous injections

- a. **Indications:** Immunizations and medications
- b. **Complications:** Bleeding, infection, allergic reaction, lipohypertrophy, or lipoatrophy after repeated injections
- c. **Procedure:**
  - (1) Locate injection site: Upper outer arm or outer aspect of upper thigh.
  - (2) Cleanse skin with alcohol.


- (3) Insert  $\frac{5}{8}$ -inch, 23- or 25-gauge needle into subcutaneous layer at a 45-degree angle to the skin. Aspirate for blood; if none present, inject medication/immunization.

## 2. Intramuscular (IM) injections

- a. **Indications:** Immunizations and medications
- b. **Complications:** Bleeding, infection, allergic reaction, nerve injury
- c. **Cautions:**
  - (1) Avoid IM injections in a child with a bleeding disorder or thrombocytopenia.
  - (2) Maximum volume to be injected is 0.5 mL in a small infant, 1 mL in an older infant, 2 mL in a school-aged child, and 3 mL in an adolescent.
- d. **Procedure:**
  - (1) Locate injection site: Anterolateral upper thigh in smaller child or outer aspect of upper arm (deltoid) in older one. The dorsal gluteal region is less commonly used because of risk for nerve or vascular injury. To find the ventral gluteal site, form a triangle by placing your index finger on the anterior iliac spine and your middle finger on the most superior aspect of the iliac crest. The injection should occur in the middle of the triangle formed by the two fingers and the iliac crest.
  - (2) Cleanse skin with alcohol.
  - (3) Isolate the muscle by spreading the skin tight. Insert a 1-inch, 22- or 25-gauge needle until hub is flush with skin surface. The needle should be perpendicular to the skin. Aspirate for blood; if none present, inject medication.

## B. Basic Laceration Repair<sup>3,9</sup>

1. **Wound irrigation<sup>30,31</sup>:** Numerous studies, including a large Cochrane review, conclude that there is no difference in the infection rates of wounds irrigated with either tap water or sterile NS. The volume of irrigation depends on the location and size of the wound; 100 mL per 1 cm of laceration is a good approximation for relatively uncontaminated wounds.
2. **Suturing:**
  - a. Basic suturing technique (Fig. 4.9):
    - (1) Simple interrupted: Basic closure of most uncomplicated wounds
    - (2) Horizontal mattress: Provides eversion of wound edges
    - (3) Vertical mattress: For added strength in areas of thick skin or areas of skin movement; provides eversion of wound edges
    - (4) Running intradermal: For cosmetic closures
    - (5) Deep dermal: For bringing together deeper portions of wounds with dissolving sutures to allow improved approximation and closure of superficial surfaces
  - b. **Procedure:**
    - (1) See Tables 4.1 to 4.3 for sutures material, size, and time for removal.<sup>32</sup>



**FIGURE 4.9**

Suture techniques. (A) Simple interrupted. (B) Vertical mattress. (C) Horizontal mattress. (D) Deep dermal. (Modified from Srivastava D, Taylor RS. Suturing technique and other closure materials. In: Robinson JK, Hanke CW, Siegel DM, et al., eds. *Surgery of the Skin*. 3rd ed. Elsevier; 2015:193–213.)

- (2) **NOTE:** Lacerations of the face, lips, hands, genitalia, mouth, or periorbital area may require consultation with a specialist. Ideally, lacerations at increased risk for infection (areas with

**TABLE 4.1****GUIDELINES FOR SUTURE MATERIAL, SIZE, AND REMOVAL<sup>32</sup>**

Body Region	Nonabsorbable	Absorbable	Duration (Days)
Scalp	5-0 or 4-0	4-0	5-7
Face	6-0	5-0	3-5
Eyelid	7-0 or 6-0	—	3-5
Eyebrow	6-0 or 5-0	5-0	3-5
Trunk	5-0 or 4-0	3-0	5-7
Extremities	5-0 or 4-0	4-0	7-10
Joint surface	4-0	—	10-14
Hand	5-0	5-0	7
Foot sole	4-0 or 3-0	4-0	7-10

**TABLE 4.2****CHARACTERISTICS OF COMMON ABSORBABLE SUTURES<sup>32</sup>**

Material	Type	Tensile Strength	Absorption Time (Weeks)	Uses
Vicryl	Braided	75% at 14 days 50% at 21 days 5% at 30 days	8-10	Subcutaneous closure, vessel ligation
Vicryl rapide	Braided	50% at 5 days 0 at 14 days	6	Mucosa, dermis
Surgical gut plain	Twisted	Poor at 7-10 days	6-8	Subcutaneous closure
Surgical gut chromic	Twisted	Poor at 21-23 days	8-10	Subcutaneous closure
Monocryl	Monofilament	60%-70% at 7 days 30%-40% at 14 days	13-17	Subcuticular

**TABLE 4.3****CHARACTERISTICS OF COMMON NONABSORBABLE SUTURES<sup>32</sup>**

Material	Type	Tensile Strength
<b>NYLON (USED FOR SKIN CLOSURE)</b>		
Ethilon	Monofilament	20% per year
Dermalon	Monofilament	20% per year
Surgilon	Braided	Good
Nurolon	Braided	Good
<b>POLYPROPYLENE (USED FOR SCALP, EYEBROWS)</b>		
Prolene	Monofilament	Permanent
Surgilene	Monofilament	Permanent

poor blood supply, contamination, or crush injury) should be sutured within 6 hours of injury. Clean wounds in cosmetically important areas may be closed up to 24 hours after injury in the absence of significant contamination or devitalization. In

general, bite wounds should not be sutured except in areas of high cosmetic importance (face) or if significant gaping is present. These wounds can be closed loosely to aid in healing by secondary intention. The longer sutures are left in place, the greater potential for scarring and infection. Sutures in cosmetically sensitive areas should be removed as soon as possible. Sutures in high tension areas (e.g., extensor surfaces) should stay in longer.

- (3) Prepare child for procedure with appropriate sedation, analgesia, and restraint. Utilize Child Life Specialist or age-appropriate distraction.
- (4) Anesthetize the wound with topical anesthetic or with lidocaine mixed with bicarbonate (with or without epinephrine) by injecting the anesthetic into the subcutaneous tissues (see [Chapter 6](#)).
- (5) Copiously irrigate the wound as per above. This is the most important step in preventing infection.
- (6) Prepare and drape the patient for a sterile procedure.
- (7) Debride the wound when indicated. Probe for foreign bodies as indicated. Consider obtaining a radiograph if a radiopaque foreign body is suspected.
- (8) Select suture type for indicated wound closure (see [Tables 4.1 to 4.3](#)).
- (9) Match layers of injured tissues. Carefully match the depth of the bite taken on each side of the wound when suturing. Take equal bites from both wound edges. Apply slight thumb pressure on the wound edge as the needle is entering the opposite side. Pull the sutures to approximate wound edges but not too tightly, to avoid tissue necrosis. In delicate areas, sutures should be approximately 2 mm apart and 2 mm from the wound edge. Larger bites are acceptable where cosmesis is less important.<sup>3</sup>
- (10) When suturing is complete, apply topical antibiotic and sterile dressing. If laceration is in proximity of a joint, splinting of the affected area to limit mobility often speeds healing and prevents wound dehiscence.
- (11) For active children, keep the wound covered until sutures are removed.
- (12) Check wounds at 48 to 72 hours in cases where tissue is of questionable viability, if wound was packed, or for patients prescribed prophylactic antibiotics. Change dressing at checkup.
- (13) For hand lacerations, close skin only; do not use subcutaneous stitches. Elevate and immobilize the hand. Consider consulting a hand or plastics specialist.
- (14) Consider the need for tetanus prophylaxis (see [Chapter 16](#)).

- c. **Wound care at home:**
    - (1) Keep the wound dry and clean for the initial 24 hours. The child may shower and dry the wound after.
    - (2) Avoid swimming or bathing until sutures are removed.
    - (3) Wear sunscreen to minimize pigment changes.
    - (4) Counsel on signs of wound infection and dehiscence.
    - (5) Return for suture removal as indicated.
  - d. **A video on [basic laceration repair](#) is available on the *New England Journal of Medicine's* website.**
3. **Skin staples**<sup>33</sup>
- a. **Indications:**
    - (1) Best for scalp, trunk, extremity lacerations
    - (2) More rapid application than sutures, but can be more painful to remove
    - (3) Lower rates of wound infection
  - b. **Contraindications:**
    - (1) Not for areas that require meticulous cosmesis
    - (2) Avoid in patients who require magnetic resonance imaging (MRI) or CT.
  - c. **Procedure:**
    - (1) Apply topical anesthetic, as above. Injection of lidocaine is not routinely used when using staples.
    - (2) Clean and irrigate wound, as with suturing.
    - (3) Appose wound edges, press stapler firmly against skin at center of apposed edges, and staple.
    - (4) Apply antibiotic ointment and sterile bandage.
    - (5) Leave in place for the same length of time as sutures (see [Table 4.1](#))
    - (6) To remove, use dedicated staple remover.
4. **Tissue adhesives**<sup>3,34</sup>
- a. **Indications:**
    - (1) For use with superficial lacerations with clean edges
    - (2) Excellent cosmetic results, ease of application, and reduced patient anxiety
    - (3) Lower rates of wound infection
  - b. **Contraindications:**
    - (1) Not for use in areas under large amounts of tension (e.g., hands, joints)
    - (2) Use caution with areas near the eye or over areas with hair such as the eyebrow.
  - c. **Procedure:**
    - (1) Use pressure to achieve hemostasis and clean the wound as explained previously.
    - (2) Hold together wound edges.
    - (3) Apply adhesive dropwise along the wound surface. Avoid applying adhesive to the inside of the wound. Hold in place for 20 to 30 seconds.


- (4) If the wound is misaligned, remove the adhesive with forceps and reapply. Petroleum jelly or similar substance can aid in removal of skin adhesive.
- (5) Adhesive will slough off after 5 to 10 days.
- (6) Antibiotic ointments or other creams/lotions should not be applied to the adhesive, as this can cause premature loosening of the glue and subsequent wound dehiscence.
- (7) No need to return for removal.

#### 5. **Hair apposition technique**<sup>35,36</sup>

- a. **Indication:** Linear lacerations of the scalp
- b. **Contraindications:** It does not provide hemostasis, so it is not recommended for bleeding wounds.
- c. **Procedure:**
  - (1) Separate a few strands of hair on each side of the wound (parallel).
  - (2) Cross the strands once and add tissue adhesive where the strands cross.
  - (3) No need to return for removal

### C. **Incision and Drainage (I&D) of Abscess**<sup>3</sup>

1. **Indications:** Diagnostic and therapeutic drainage of soft tissue abscess
2. **Complications:** Inadequate abscess drainage, local tissue injury, pain, scar formation, and, in rare cases, fistula formation. Consider specialized surgical evaluation for abscesses in cosmetically or anatomically sensitive areas (the face, neck, breast, or anogenital region) or for recurrent and multiple interconnected abscesses.
3. **Ultrasound identification:** Ultrasound imaging can be used to differentiate cellulitis from abscess.
  - a. Use a linear probe; place the probe over the area of interest, and scan it systematically such that the entire area of interest is examined.
  - b. Cellulitis characteristics on ultrasound:
    - (1) Increased edema; tissue may appear slightly darker and will have distorted, indistinct margins
    - (2) Areas may have a “cobblestone” appearance caused by edema (Fig. 4.10).
  - c. Abscess characteristics on ultrasound:
    - (1) Dark fluid collection distinct from surrounding tissue (see Fig. 4.10)
    - (2) Often round or oval
    - (3) Doppler can help to distinguish between lymph nodes and fluid collections.
4. **Procedure:**
  - a. Consider procedural sedation based upon the child’s expected tolerance of the procedure and the location/size/complexity of the abscess.



**FIGURE 4.10**

Ultrasound characteristics of soft tissue cellulitis and *abscess*. (A) Cellulitis characterized by bright (hyperechoic) tissue due to edema and inflammation in the tissue. (B) This image demonstrates the classic “cobblestone” appearance which is a later ultrasound finding in cellulitis.



**FIGURE 4.10, cont'd**

(C) A black (anechoic) rounded structure is noted in the soft tissue, which is characteristic of a soft tissue abscess. Some abscesses may appear dark gray depending on the characteristics of the fluid within the abscess. (From Leeson K, Leeson B. Pediatric ultrasound: applications in the emergency department. *Emerg Med Clin North Am.* 2013;31[3]:809–829.)

- b. Apply topical anesthetic cream to the abscess to numb the superficial epidermis (see [Chapter 6](#)).
- c. Prepare the overlying skin in a sterile fashion and, once cleaned, numb the area using 1% lidocaine and a small-gauge needle, performing first a circumferential field block of the abscess area followed by direct injection to the planned incision site.
- d. Make a simple linear incision over the total length of the abscess down to the superficial fascia using a scalpel blade, cutting parallel to the natural crease of the skin.
- e. Using a hemostat, bluntly widen and undermine the incision to break up any septations or loculated fluid collections. Vigorously irrigate the wound using sterile saline to improve removal of purulent material.
- f. If desired, introduce a sterile packing strip into the wound using a hemostat, making sure to fill in an outside-to-inside pattern without overfilling. Leave a 2- to 3-cm tail outside the wound to facilitate removal and cover the wound with an absorbent dressing. Packing material should be removed in 1 to 2 days with a minimum of daily dressing changes until healed.
- g. Consider starting antibiotics that cover staphylococcus and streptococcal species per local guidelines and resistance patterns.

Consider obtaining Gram stain, culture, and susceptibility testing of purulent fluid.

5. **A video on I&D of Abscesses is available on the *New England Journal of Medicine's* website.**

#### D. Tuberculin Skin Test Placement<sup>37</sup>

1. **Indications:** Concern for exposure to tuberculosis
2. **Contraindications:** History of severe reactions to prior placements (e.g., necrosis, anaphylactic shock, ulcerations). **Note** that there is no contraindication for any other individuals including infants, children, pregnant women, or persons who have been vaccinated with *Bacillus Calmette-Guérin* (BCG). Vaccination with live viruses may interfere with the tuberculin skin test (TST), so the test should be done either the same day as the vaccination or at least 1 month after administration of the vaccine.
3. **Complications:** Pain, necrosis
4. **Procedure:** Inject 0.1 mL of tuberculin purified protein derivative (PPD) with a tuberculin syringe (bevel up) into the forearm at a 5- to 15-degree angle. It is an intradermal injection. The injection should produce a pale elevation of the skin 6 to 10 mm in diameter.
5. **Follow-up:** A TST should be read between 48 and 72 hours after administration. The reaction is measured across the forearm (perpendicular to the long axis) in millimeters of induration (palpable, raised, hardened area or swelling). Do not measure erythema.
6. **Interpretation:** See [Chapter 17](#).

#### E. Tick Removal<sup>38,39</sup>

1. **Indications:** Visualization of tick. Urgent removal is essential, as the risk of Lyme disease transmission significantly increases after 24 hours of attachment.
2. **Complications:** Retention of tick fragments (particularly mouthparts), infection, granuloma formation
3. **Procedure:**
  - a. Use clean, fine-tipped tweezers to grasp the tick at the skin surface. Lift up firmly, applying steady pressure and without a twisting motion. Do not squeeze the body of the tick, because its fluid may leak infectious material.
  - b. Clean the bite area with rubbing alcohol or soap and water.

## REFERENCES

A complete list of references can be found online.

## XI. ONLINE CONTENT

### A. Ultrasound-Guided Lumbar Puncture

1. Use the linear probe. Before preparing the patient, obtain a transverse view of the spine perpendicular to its axis. In the transverse view, identify the anatomic midline by locating the spinous process. The periosteum of the spinous process will appear as a hyperechoic, rounded structure with dark, posterior shadowing. Center the spinous process in the middle of the probe and mark a line in a cephalad-caudad direction on the patient's back to identify the midline (eFig. 4.1).
2. Rotate the probe 90 degrees to obtain a longitudinal view (probe parallel to the spine). Identify the vertebral bodies and an intervertebral space above or below L4. Mark a line on either side of the skin correlating with the space (eFig. 4.2).
3. The intersection of the marks identifies the area to be punctured. The crosshairs formed by the marks should leave the actual insertion site clean (eFig. 4.3).
4. The procedure should progress with no further movement of the patient. Preparation and draping should proceed from this point to completion of the procedure.


### B. External Jugular Puncture and Catheterization<sup>3</sup>

1. **Indications:** Blood sampling in patients with inadequate peripheral vascular access or during resuscitation
2. **Complications:** Infection, bleeding, pneumothorax
3. **Procedure:** (eFig. 4.4)
  - a. Restrain patient securely with head turned 45 degrees to the contralateral side of cannulation. Position with towel roll under shoulders or with head over side of bed to extend neck and accentuate the posterior margin of the sternocleidomastoid muscle on the side of venipuncture. Place patient in the 15- to 20-degree Trendelenburg position.
  - b. Prepare area in a sterile fashion.
  - c. The external jugular vein will distend if its most proximal segment is occluded or if the child cries. The vein runs from the angle of the mandible to the posterior border of the lower third of the sternocleidomastoid muscle.



**eFIGURE 4.1**


Transverse ultrasound view of the lumbar spine. The spinous process is labeled in this ultrasound image of the lumbar spine, marking the anatomic midline for a lumbar puncture. A marking line should be drawn in the cephalad-caudad direction on the skin over the spinous processes. (From Marin J. Novel applications in pediatric emergency ultrasound. *Clin Pediatr Emerg Med.* 2011;12[1]:53–64.)

**eFIGURE 4.2**

Longitudinal ultrasound view of the spine. The spinous processes are visualized as hyperechoic (bright) lines with posterior shadowing. In between the rounded spinous process is the interspinous space, which should be marked with a line for the procedure. (From Marin J. Novel applications in pediatric emergency ultrasound. *Clin Pediatr Emerg Med*. 2011;12[1]:53–64.)

**eFIGURE 4.3**

Lumbar area marked for lumbar puncture. The lines from ultrasound markings should make a cross as seen in this image. Ideally there will be an area free of marking in the center where the actual puncture site will be. (From Strony R. Ultrasound-assisted lumbar puncture in obese patients. *Crit Care Clin*. 2010;26[4]:661–664.)

**eFIGURE 4.4**

External jugular catheterization. (From Dieckmann R, Fiser D, Selbst S. *Illustrated Textbook of Pediatric Emergency and Critical Care Procedures*. Mosby; 1997.)

## REFERENCES

1. Coté CJ, Wilson S. Guidelines for monitoring and management of pediatric patients before, during, and after sedation for diagnostic and therapeutic procedures: update 2019. *Pediatrics*. 2019;143(6).
2. Kraus BA, Krauss BS. Managing the frightened child. *Ann Emerg Med*. 2019;74(1):30–35.
- 2a. Pediatric Emergency Critical Care and Ultrasound. Cambridge University Press; 2014. DOI: <https://doi.org/10.1017/CBO9780511903755>
3. Mittiga MR, Ruddy RM. Procedures. In: Shaw KN, Bachur RG, eds. *Fleisher & Ludwig's Textbook of Pediatric Emergency Medicine*. 7th ed. Lippincott Williams & Wilkins; 2016.
4. Dieckmann R, Fiser D, Selbst S. *Illustrated Textbook of Pediatric Emergency and Critical Care Procedures*. Mosby; 1997.
5. Guerrero P. Lumbar puncture. In: Sherman SC, Weber JM, Schindlbeck MA, Rahul G, eds. *Clinical Emergency Medicine*. McGraw Hill; 2014. <https://accessemergencymedicine.mhmedical.com/content.aspx?bookid=991&sectionid=55139110>.


6. Schwartz SR, Magit AE, Rosenfeld RM, et al. Clinical practice guideline (update): earwax (cerumen impaction). *Otolaryngol Head Neck Surg*. 2017;156(suppl 1).
7. Horton GA, Simpson MTW, Beyea MM, Beyea JA. Cerumen management: an updated clinical review and evidence-based approach for primary care physicians. *J Prim Care Community Health*. January. 2020. <https://doi.org/10.1177/2150132720904181>
8. Shih M, Brock L, Liu Y-C C. Pediatric aural foreign body extraction: comparison of efficacies among clinical settings and retrieval methods. *Otolaryngology—Head and Neck Surgery*. 2021;164(3):662–666. <https://doi.org/10.1177/0194599820953130>
9. Goodman DM. *Current Procedures: Pediatrics*. McGraw-Hill; 2007.
10. Wilson JL. Primary care removal of fishhooks, rings, and foreign bodies from the ear, nose, and superficial eye and conjunctiva. *Primary Care: Clinics in Office Practice*. Accessed December 12, 2021. Published October 7, 2021. <https://www.sciencedirect.com/science/article/pii/S0095454321015955>
11. Béquignon E, Teissier N, Gauthier A, et al. Emergency department care of childhood epistaxis. *Emerg Med J*. 2017;34(8):543.
12. Campbell M, Buitrago SR. BET 2: Ice water immersion, other vagal manoeuvres or adenosine for SVT in children. *Emerg Med J*. 2017;34(1):58–60.
13. Appelboom A, Reuben A, Mann C, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial. *Lancet*. 2015;386(10005):1747.
14. Pasquier M, Clair M, Pruvot E, et al. Carotid sinus massage. *N Engl J Med*. 2017;377(15):e21.
15. Barone MA. Pediatric procedures. In: *Oski's Pediatrics: Principles and Practice*. Lippincott Williams & Wilkins; 2006:2671–2687.
16. Amjad I, Murphy T, Nylander-Housholder L, et al. A new approach to management of intravenous infiltration in pediatric patients: pathophysiology, classification, and treatment. *J Infus Nurse*. 2011;34(4):242–249.
17. Morrison C, Disma N. Intraosseous access in children. New applications of an ancient technique. *Trends in Anaesthesia and Critical Care*. 2018;21:21–26. <https://doi.org/10.1016/j.tacc.2018.04.004>
18. Gomella T, Eyal FG, Bany-Mohammed F, eds. *Gomella's Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs*. 8th ed. McGraw Hill; 2020. <https://accesspediatrics.mhmedical.com/content.aspx?bookid=2762&sectionid=234452059>
19. Bribriescio A, Patterson GA. Cricothyroid approach for emergency access to the airway. *Thorac Surg Clin*. 2018;28(3):435–440. <https://doi.org/10.1016/j.thorsurg.2018.04.009>
20. Reed RC, Waters BL, Siebert JR. Complications of percutaneous thoracostomy in neonates and infants. *J Perinatol*. 2016;36(4):296–299. <https://doi.org/10.1038/jp.2015.190>
21. Davidovic L, LaCovey D, Pitetti RD. Comparison of 1- versus 2-person bag-valve-mask techniques for manikin ventilation of infants and children. *Ann Emerg Med*. 2005;46:37–42.
22. *Pediatric Advanced Life Support: Provider Manual*. American Heart Association; 2020.
23. Irving SY, Lyman B, Northington L, et al. Nasogastric tube placement and verification in children. *Nutr Clin Pract*. 2014;29(3):267–276.

24. Showalter CD, Kerrey B, Spellman-Kennebeck S. Gastrostomy tube replacement in a pediatric ED: frequency of complications and impact of confirmatory imaging. *Am J Emerg Med.* 2012;30(8):1501–1506.
25. Faase MA, Maizels M. Catheterization of the urethra in girls. *N Engl J Med.* 2014;371(19):1849.
26. Bexkens R, Washburn FJ, Eygendaal D, et al. Effectiveness of reduction maneuvers in the treatment of nursemaid's elbow: a systematic review and meta-analysis. *Am J Emerg Med.* 2017;35(1):159–163.
27. Aylor M, Anderson JDM, Vanderford P, Halsey M, Lai S, Braner DAV. Reduction of pulled elbow. *New England Journal of Medicine.* 2014;371(21). <https://doi.org/10.1056/nejmvcm1211809>
28. Graham TP. Hematoma blocks. In: Reichman EF, ed. *Reichman's Emergency Medicine Procedures.* 3rd ed. McGraw-Hill; 2019.
29. Centers for Disease Control and Prevention. Vaccine administration. <https://www.cdc.gov/vaccines/pubs/pinkbook/vac-admin.html>
30. Fernandez R, Griffiths R. Water for wound cleaning. *Cochrane Database Syst Rev.* 2012;2:CD003861.
31. Weiss EA, Oldham G, Lin M, Foster T, Quinn JV. Water is a safe and effective alternative to sterile normal saline for wound irrigation prior to suturing: a prospective, double-blind, randomized, controlled clinical trial. *BMJ Open.* 2013;3(1).
32. Maas CS. Sutures and needles. In: *Wound Management and Suturing Manual.* American Academy of Facial Plastic & Reconstructive Surgery; 2001:27–28.
33. McNamara R, DeAngelis M. Laceration repair with sutures, staples, and wound closure tapes. In: King C, Henretig FM, eds. *Textbook of Pediatric Emergency Procedures.* 2nd ed. Lippincott Williams & Wilkins; 2008:1034.
34. Adl H, Henkelman E, Goldman RD. Topical skin adhesives for laceration repair in children. *Can Fam Phys.* 2021;67(4):260–262. <https://doi.org/10.46747/cfp.6704260>
35. Ong ME, Chan YH, Teo J, et al. Hair apposition technique for scalp laceration repair: a randomized controlled trial comparing physicians and nurses (HAT 2 study). *Am J Emerg Med.* 2008;26(4):433–438.
36. Hock MO, Ooi SB, Saw SM, Lim SH. A randomized controlled trial comparing the hair apposition technique with tissue glue to standard suturing in scalp lacerations (HAT study). *Ann Emerg Med.* 2002 Jul;40(1):19–26. PMID: 12085068. <https://doi.org/10.1067/mem.2002.125928>
37. Centers for Disease Control and Prevention. *Fact sheets: Tuberculin Skin Testing;* 2020. <https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm>
38. Centers for Disease Control and Prevention. *Tick Removal;* 2021. [https://www.cdc.gov/ticks/removing\\_a\\_tick.html](https://www.cdc.gov/ticks/removing_a_tick.html)
39. Krass L, Amin D. Tick removal. In: Reichman EF, ed. *Reichman's Emergency Medicine Procedures.* 3rd ed. McGraw Hill; 2018. Accessed December 13, 2021. <https://accessemergencymedicine.mhmedical.com/content.aspx?bookid=2498&sectionid=201295372>

This page intentionally left blank

# PART II

## DIAGNOSTIC AND THERAPEUTIC INFORMATION



This page intentionally left blank

# Chapter 5

## Adolescent Medicine

*Yasamin Ege Sanii, MD and Amitte Rosenfeld, MD*

 See additional content online.

 **Audio Case File 5.1** An interactive walk through the HEADSSS assessment, and next steps

### I. THEORY OF ADOLESCENCE/INTRODUCTION

Adolescence is defined by both an age range, typically encompassing ages 10 to 25, as well as a life stage consisting of rapid physical, psychological, and social growth and development.<sup>1</sup> Adolescence is a foundational time that lays groundwork for future identity, health, and well-being. Progression through adolescence is characterized by cognitive, psychosocial, and emotional development, which help adolescents to establish their identity and autonomy.<sup>2</sup> See [eTable 5.1](#) for detailed psychosocial development by age. The goal of adolescence is to gain independence and develop a secure identity, spanning a period of legal and medical dependency and independence.<sup>2</sup> The health habits and behaviors formed during this time can have long-lasting impact on future health status and well-being.<sup>3</sup> Helping adolescents effectively navigate these changes and junctures enables safe and supported growth and development.

### II. STRUCTURAL FACTORS IMPACTING ADOLESCENTS AND THEIR HEALTH

Structural factors have significant impact on the health and well-being of adolescents. Adverse childhood experiences have been associated with chronic health problems, mental illness, and substance use issues in adulthood<sup>4</sup> (see [Chapter 9](#) for further discussion). Consideration and integration of these issues into care for adolescence is essential to providing effective care.

#### A. Examples

This is not meant to be an exhaustive list, but rather a starting point for discussion of selected factors. For further information please see References.

##### 1. Racism<sup>5</sup>

- a. Institutional: Education, environmental/location, legal (police-instigated violence, juvenile justice system)
- b. Personally mediated: Explicit/implicit bias, interpersonal relationships
- c. Internalized: Stereotypes, stereotype threat

eTABLE 5.1

## PSYCHOSOCIAL DEVELOPMENT OF ADOLESCENTS

Task	Early Adolescence (10–13 Years)	Middle Adolescence (14–16 Years)	Late Adolescence (>17 Years)
Independence	Less interest in parental activities Wide mood swings	Peak of parental conflicts	Reacceptance of parental advice and values
Body image	Preoccupation with self and pubertal changes Uncertainty about appearance	General acceptance of body Concern over making body more attractive	Acceptance of pubertal changes
Peers	Intense relationships with same-sex friend(s)	Peak of peer involvement Conformity with peer values Increased sexual activity and experimentation	Peer group less important More time spent in sharing intimate relationships
Identity	Increased cognition Increased fantasy world Increasing sexual attractions Idealistic vocational goals Increased need for privacy Lack of impulse control	Increased scope of feelings Increased intellectual ability Feeling of omnipotence Risk-taking behavior Emerging sexual identity	Practical, realistic vocational goals Refinement of moral, religious, and sexual values Ability to compromise and to set limits Sexual identity becomes more secure

From Joffe A. Introduction to adolescent medicine. In: McMillan JA, DeAngelis CD, Feigan RD, et al, eds. *Oski's Pediatrics Principles and Practice*. 4th ed. Lippincott Williams, & Wilkins; 2006.

2. **Environmental/neighborhood disparities:** Lack of outdoor spaces, clean air and water, exposure to environmental toxins, exposure to trauma and violence
3. **Documentation status and immigration:** Limited access to services and higher education, concerns for family separation
4. **Reproductive justice:** Restriction of services based on geography, insurance status

### B. Role Clinicians Can Play<sup>5</sup>

1. **Individual patient interactions/relationships:** Clinicians can work to create a culturally safe space for patients and their families by examining their own biases and employing a patient- and family-centered and evidence-based approach to care for all patients. Additionally, strategies can be used such as “Raising Resisters”<sup>6</sup> to provide anticipatory guidance to support patients and families in resisting internalized messages of racism and instead promote positive and value-based identity formation.
2. **Community engagement and advocacy:** Clinicians can work with their local communities, governments, and community-based organizations to advocate for systems and policies that reduce inequity and improve access, thereby reducing exposure to adverse childhood experiences and optimizing outcomes for youth.

## III. CONFIDENTIALITY

Confidentiality is a crucial component of adolescent healthcare because adolescents report that they may be delayed in seeking care, preferentially seek care at sites offering confidential care and information shared on sensitive topics may be limited.<sup>7,8</sup> Begin integrating one-on-one time between the provider and patient into adolescent visits as early as age 11 to provide teens with regular opportunities to discuss concerns and sensitive topics in an open manner.<sup>9</sup> This time also provides the foundation for their transition to adulthood, helping them learn how to talk to their doctor on their own and take responsibility for their health. Providers should be aware of barriers to confidentiality related to consent laws and billing/explanation of benefits by insurance companies.<sup>10</sup>

### A. Consent Laws

All states within the United States, including the District of Columbia, allow minors to consent to sexually transmitted infection (STI) services (diagnosis and treatment), although some states have a minimum age to consent. No states explicitly prohibit minors' consent to pre-exposure prophylaxis (PrEP), although it is often not explicitly addressed.<sup>11</sup> Laws surrounding consent to HIV testing and treatment, contraception, abortion, mental health/substance use disorder treatment, and other healthcare services vary by state. Current information on consent laws by state can be found at the Guttmacher Institute's website (<https://www.guttmacher.org/state-policy/explore/overview-minors-consent-law>).<sup>12</sup>

### B. Breach of Confidentiality

Confidentiality must be breached if the adolescent is at risk of harming themselves or others (e.g., suicidal or homicidal ideation). Parents/guardians

should be informed if there is concern for self-harm and for safety concerns, patients should be taken to an emergency room, and/or police should be called. Providers should familiarize themselves with the “duty to warn” (harm to others) laws in their jurisdiction—the responsibility of a provider to warn an identifiable third party of a potential threat of harm to their health.<sup>13</sup> Cases of child abuse or neglect must be reported to child protective services. The definition of statutory rape and reporting laws vary by state, with minimum age to consent to sexual activity ranging from 16 to 18 years old. Current information on reporting laws by state can be found at the Rape, Abuse & Incest National Network’s website (<https://rainn.org/public-policy-action>).<sup>14</sup> See Chapter 2 for more information on evaluation and management of suspected sexual abuse. When confidentiality must be breached, special care must be taken to maintain the physician-patient relationship with the adolescent to the extent possible. This can be done by involving the adolescent in the conversation by offering choices about what exactly is shared and how it is shared (e.g., with whom, by whom) so that they are part of the decision-making process. It is also helpful to share with adolescents at the beginning of the confidential component of their visits the reasons that would necessitate breaking confidentiality so that it does not come as a surprise if concerns do arise.

### C. Documentation and Billing

Confidentiality can be inadvertently breached if providers are not careful about documentation and do not have sufficient understanding of who has access. In the United States, the 21st Century Cures Act necessitates open notes, but providers can choose to keep notes on sensitive topics confidential. Providers in the United States should explore with their own hospital and/or legal counsel how to do this. Other providers should explore local laws and regulations to be able to share with patients what can and cannot be kept confidential. In some places insurance disclosures such as “Explanations of Benefits” may also inadvertently breach confidentiality.<sup>10</sup> Providers should be aware of the local regulations around what will be sent to the primary insurance holder. Government-funded and other programs outside of insurance such as US Title X services and local health departments can be possible solutions to overcome this barrier.

## IV. HEALTH MAINTENANCE ELEMENTS UNIQUE TO THE ADOLESCENT PATIENT

### A. History (HEADSSS Assessment) and Screenings<sup>15</sup>

Medical history should include all areas typically covered; however, there are some areas that require specific focus during adolescence. Most of the well visit is often spent exploring the psychosocial aspects of an adolescent’s health. HEADSSS is a useful mnemonic to remember these essential components.

1. **H—Home:** Household composition, family dynamics and relationships, recent changes, housing stability

2. **E—Education/employment:** School performance and attendance, goals for the future, after-school job or other work history, vocational training programs
  - a. See [Chapter 9](#) for more information on learning disabilities
3. **E—Eating**
  - a. Body image and dieting
  - b. Eating disorders (see [Chapter 24](#) for more information)
  - c. Obesity and weight management in adolescence (see [Chapter 21](#) for more information)
    - (1) Developing lifelong habits and new independence in decision making around lifestyle. Overweight in adolescence is a predictor of lifelong morbidity and mortality.<sup>16</sup>
    - (2) Family practices around food: who does the shopping/cooking, what (if any) responsibility the adolescent holds, how often do they eat out, do they eat all together or separately, where do people eat in the home (e.g., at a table vs. in front of the TV)
    - (3) Lipid and diabetes mellitus (DM) screening recommendations ([Table 5.1](#))
  - d. Food security: Can use validated two-item survey (“often true” or “sometimes true” is a positive screen vs. “never true”)<sup>17</sup>:
    - (1) Within the past 12 months we worried whether our food would run out before we got money to buy more.
    - (2) Within the past 12 months the food we bought just didn’t last and we didn’t have money to get more.
4. **A—Activities:**
  - a. Social media<sup>18</sup>: Explore how social media is used and for what quantity of time.
    - (1) Benefits: Communication and engagement
    - (2) Risks of excessive/inappropriate use: Impaired sleep, attention, and learning; obesity; depression; viewing of unsuitable content; decrease in caregiver-child interactions; compromised privacy; meeting high-risk sexual partners or sexual predators, sexting, and cyberbullying
    - (3) Guidance for teens and families: [https://downloads.aap.org/AAP/PDF/Bright%20Futures/BF4\\_HealthySocialMedia.pdf](https://downloads.aap.org/AAP/PDF/Bright%20Futures/BF4_HealthySocialMedia.pdf)
    - (4) American Academy of Pediatrics (AAP) Family Media Use Plan: <https://www.healthychildren.org/MediaUsePlan>
  - b. Screen time: Provide guidance on limiting use.
  - c. Physical activity: Goal of at least 60 minutes of moderate to vigorous physical activity daily.<sup>19</sup> Work with adolescents and their families to identify safe and creative ways they can achieve this while acknowledging limitations and inequities in access to safe outdoor space.
  - d. Hobbies and interests
  - e. Sleep
5. **D—Drugs** (Substance use: tobacco, EtOH, illicit substances, prescription drugs not prescribed to the individual)

TABLE 5.1

## PREVENTATIVE HEALTH LABS AND PROCEDURES

Preventative Health Topic	Recommendations and Further References
Immunizations	See Chapter 16
Cholesterol <sup>98,9</sup>	Once between ages 9 and 11 and again between 17 and 21
Diabetes <sup>99</sup>	Screen with A1c, fasting plasma glucose, or oral glucose tolerance test for adolescents with: <ol style="list-style-type: none"> <li>1. BMI <math>\geq</math>85% for age and sex AND</li> <li>2. One or more risk factors, such as family history, acanthosis nigricans, HTN, HLD, PCOS, or other signs of or conditions associated with insulin resistance</li> </ol> If normal, repeat at minimum every 3 years or sooner based on changes in risk profile.
Blood pressure <sup>100</sup>	See Chapter 19. BP should be checked annually in all adolescents and at every healthcare encounter if they have obesity or are taking medications known to increase BP, have renal disease, a history of aortic arch obstruction or coarctation, or DM. <sup>103</sup>
Sexual health	See Section V.
Cervical cancer <sup>101,102</sup>	<ol style="list-style-type: none"> <li>1. &lt;21 years old: no screening</li> <li>2. Aged 21–29 years: Cytology alone every 3 years</li> <li>3. Immunocompromised (living with or without HIV): screening within 1 year of first insertional sexual activity. Annually for 3 years, then every 3 years (cytology only)</li> </ol> Recommended screening intervals and follow-up depend on patient's risk of CIN3+ based on combination of pap smear results, and past history. Web-based decision tool can be found at <a href="https://app.asccp.org/">https://app.asccp.org/</a>
Infectious diseases <sup>9</sup>	<ol style="list-style-type: none"> <li>1. HIV: Universal screening beginning at age 15: See Section V for details based on risk.</li> <li>2. <i>N. gonorrhoeae</i> and <i>C. trachomatis</i>: See Section V for recommendations and discussion.</li> <li>3. Hepatitis C Virus (HCV)<sup>104</sup>:           <ul style="list-style-type: none"> <li>• Universal screening for age 18+</li> <li>• Screening for all adolescents (regardless of age) who have ever injected or used intranasal drugs, have a history of incarceration, with HIV infection and/or prior to starting PrEP</li> </ul> </li> </ol>

A lack of evidence has led to variability in guidelines for topics such as screening for dyslipidemia, iron-deficiency anemia, diabetes, and tuberculosis. The recommendations in this table are largely based on the AAP,<sup>9</sup> CDC, U.S. Preventive Services Task Force (USPSTF),<sup>98</sup> and the American College of Obstetricians and Gynecologists (ACOG).

### a. Epidemiology

- (1) In 2021 almost half of 12th graders in the United States reported using alcohol in the last year, and a similar number reported using illicit drugs in their lifetime, with cannabis being by far the most frequent.<sup>20</sup>
- (2) Roughly a third of 12th graders in the United States reported vaping nicotine in the past year, down from a peak of 40% in 2019.<sup>20</sup>

(3) Substance use during adolescence increases likelihood of developing a substance use disorder (SUD) later, with greater risk conferred with earlier use.<sup>22</sup>

b. **Screening, brief intervention, and referral to treatment (SBIRT):** The AAP and SAMHSA recommend universal screening as part of routine healthcare. This can be done wherever and whenever adolescents receive medical care.<sup>23</sup>

(1) **Screening:** Must be done with a validated tool. Start by asking how many days adolescent has used any alcohol, marijuana, or anything else to get high in the past 12 months, followed by risk stratification/brief assessment using a validated tool specifically designed for adolescents. May require comprehensive assessment if problem suggested (see below).<sup>22</sup>

(a) Validated self-report tools are generally considered to be a credible method for screening and found to corroborate with other sources of information, making other methods such as urine drug testing unnecessary.

(b) Tools (*a few examples, many others available*): Screening to Brief Intervention (S2BI)<sup>24</sup> and Brief Screener for Tobacco, Alcohol and other Drugs (BSTAD)<sup>25</sup> are available online through the National Institute on Drug Abuse (NIDA)<sup>26</sup> (<https://nida.nih.gov/nidamed-medical-health-professionals/screening-tools-resources/screening-tools-adolescent-substance-use>). CRAFFT<sup>27</sup> (Box 5.1) can be used after positive initial screen to “any use” question and identifies potentially problematic behavior associated with the substance use, as well as calculates the probability that the patient has a substance use disorder.

(c) Important to also screen for co-occurring mental health disorders (see Chapter 24)

(2) **Brief Intervention:** Counseling based on risk stratification; motivational interviewing as appropriate

### BOX 5.1

#### CRAFFT QUESTIONNAIRE

**C**—Have you ever ridden in a **CAR** driven by someone (or yourself) who was “high” or had been using alcohol or drugs?

**R**—Do you ever use alcohol or drugs to **RELAX**, feel better about yourself, or fit in?

**A**—Do you ever use alcohol/drugs while you are **ALONE**?

**F**—Do your family or **FRIENDS** ever tell you that you should cut down on your drinking or drug use?

**F**—Do you ever **FORGET** things you did while using alcohol or drugs?

**T**—Have you gotten into **TROUBLE** while you were using alcohol or drugs?

**NOTE:** Answering yes to two or more questions is a positive screen.

From Gephart H: Rating scales, questionnaires, and behavior checklists. In ADHD Complex: Practicing Mental Health in Primary Care. Philadelphia, Elsevier, 2019, pp 1–7.

- (a) Low risk (abstinent): Reinforce decisions with praise and provide anticipatory guidance regarding riding in a car with a driver under the influence.
  - (b) Yes to “Car” question: Counsel and encourage safety plan.
  - (c) Substance use without an SUD: Advise cessation of substance use, educate regarding health risks of continued use, and praise personal attributes.
  - (d) Mild to moderate SUD: Conduct in-depth assessment using motivational interviewing (MI) (see [eTable 5.2](#)). MI is a counseling technique aimed at helping a patient identify their goals and values and use these to strengthen their motivation for change.
  - (e) Severe SUD: In-depth assessment and MI as above plus referral to treatment (see IV.A.5.d.(3))
- (3) **Referral to Treatment** (see IV.A.5.d.(3))
- c. Peer and family use/exposure
  - d. Substance use disorders
    - (1) **Epidemiology:** In the United States, in 2020 an estimated 6.3% of adolescents aged 12 to 17 and 24.4% aged 18 to 25 met criteria for an SUD in the past year based on DSM-5 criteria.<sup>28</sup>
    - (2) **Diagnosis:** DSM-5 defines substance use disorders with the same criteria for all substances: A pattern of continued use and clinically/functionally significant impairment with  $\geq 2$  of the symptoms in [Table 5.2](#)
    - (3) **Treatment and referral**<sup>22</sup>
      - (a) Spectrum of service levels: Outpatient services to intensive outpatient/partial hospital to residential/inpatient services and medically managed intensive inpatient services
      - (b) Utilize multidimensional assessment for a holistic, biopsychosocial approach to service planning and treatment<sup>29,22</sup>
      - (c) Medication for addiction treatment<sup>30</sup>: For opioid use disorder, buprenorphine is FDA approved for ages 16+ but is often used off-label for younger ages; naltrexone is FDA approved for ages 18+, and methadone is approved for 18 and up, with limited accessibility in certain circumstances for <18 years old. Medications for other SUDs such as with alcohol and tobacco/nicotine are largely approved for 18+, though may be used off-label.
    - (4) HCV screening (see [Table 5.1](#))

## 6. S—Sexuality and gender

- a. Terminology and definitions ([Table 5.3](#)): While gender and sexuality are often conflated, they are independent components of identity, each with multiple subcomponents. Gender identity is a person’s intrinsic sense of self, as male, female, or other gender.<sup>31</sup> Sexuality is how one relates to others sexually. There are three components of sexual orientation: identity, behavior, and attraction.

**eTABLE 5.2****TAKING A SUBSTANCE USE HISTORY**

*Comprehensive assessments are often conducted using a formal instrument in a structured interview format lasting 45 minutes to an hour for diagnostic purposes. Below are questions that can be used to gather an initial substance use history in the primary care setting.*

History of use	<ul style="list-style-type: none"> <li>• Which substances have been used ever?</li> </ul> <p>For each:</p> <ul style="list-style-type: none"> <li>• Age of first use?</li> <li>• Length and pattern of use?</li> <li>• Date of most recent use?</li> </ul>
Current use	<ul style="list-style-type: none"> <li>• What substances are used currently?</li> <li>• How much and how frequently?</li> <li>• Mode of ingestion?</li> <li>• Triggers for use? How does it make you feel?</li> </ul>
Dependence	<ul style="list-style-type: none"> <li>• History of withdrawal?</li> <li>• Requiring more of substance to achieve same effect?</li> <li>• When you stop using how do you feel?</li> <li>• Do you have cravings to use?</li> </ul>
Negative consequences	<ul style="list-style-type: none"> <li>• Impact on physical and emotional health</li> <li>• Social: School problems, loss of employment, cessation of hobbies/activities</li> <li>• Risky behaviors</li> <li>• Legal involvement</li> </ul>
Risk evaluation	<ul style="list-style-type: none"> <li>• Have you ever injected drugs? If so, cleaning equipment? Sharing equipment?</li> <li>• Have you ever exchanged sex for drugs or money?</li> <li>• Do you use alone?</li> <li>• Have you ever overdosed?</li> <li>• Have you ever witnessed anyone else overdosing?</li> <li>• Do you have a naloxone kit? Do you know how to use it?</li> </ul>
Social environment	<ul style="list-style-type: none"> <li>• Use among family and/or peers?</li> <li>• Family history of substance use disorder?</li> <li>• Home environment?</li> </ul>
Cessation and treatment	<ul style="list-style-type: none"> <li>• Have you ever tried to cut down or quit? Were you successful?</li> <li>• Longest period of abstinence? What triggered a relapse?</li> <li>• Have you ever been in treatment? What type? When?</li> <li>• Have you ever been on medications as part of treatment?</li> <li>• What are your current goals (abstinence, reduction in use, harm reduction)?</li> </ul>
Strength/resources	<ul style="list-style-type: none"> <li>• Family or other community supports</li> <li>• Coping skills</li> <li>• Motivation/readiness for treatment</li> </ul>

Adapted from Center for Substance Abuse Treatment. Screening and Assessing Adolescents for Substance Use Disorders. Treatment Improvement Protocol (TIP) Series, No. 31. HHS Publication No. (SMA) 12-4079. Substance Abuse and Mental Health Services Administration; 1998. *Revised 2012.*

**TABLE 5.2****DSM-5 CRITERIA FOR SUBSTANCE USE DISORDERS (SUD)<sup>a</sup>**

Category	Criteria
Impaired control	<ul style="list-style-type: none"> <li>• Using more or longer than intended</li> <li>• Persistent desire or unsuccessful attempts to cut down or quit</li> <li>• Excessive time spent obtaining, using, or recovering from substances</li> <li>• Intense desire to use or cravings</li> </ul>
Social impairment	<ul style="list-style-type: none"> <li>• Failure to fulfill academic, work, or home responsibilities</li> <li>• Use causing or exacerbating interpersonal problems</li> <li>• Giving up or reducing important social, occupational, or recreational activities because of use</li> </ul>
Risky use	<ul style="list-style-type: none"> <li>• Recurrent substance use in physically hazardous situations</li> <li>• Continued use despite physical or psychological problems due to use</li> </ul>
Pharmacologic criteria <sup>b</sup>	<ul style="list-style-type: none"> <li>• Tolerance (diminished effect of same dose, needing higher dose to achieve effect)</li> <li>• Withdrawal symptoms with cessation of substance use</li> </ul>

<sup>a</sup>No longer separated into substance dependence and abuse (DSM-IV); all categorized as substance use disorder.

<sup>b</sup>If medication is being taken only as prescribed, then tolerance and withdrawal do not count toward SUD diagnosis.

≥2 = positive for SUD; 2-3 = mild SUD; 4-5 = moderate SUD; 6+ = severe SUD.

Data from American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-5)*. American Psychiatric Publishing; 2013.

**TABLE 5.3****GENDER AND SEXUALITY TERMINOLOGY AND DEFINITIONS**

Term	Definition
Gender identity	A person's internal sense of self and how they fit into the world, from the perspective of gender
Gender expression	The outward manner in which an individual expresses or displays their gender. This may include choices in clothing and hairstyle, or speech and mannerisms. This may differ from gender identity.
Sex assigned at birth	Based on assessment of external genitalia, as well as chromosomes and gonads
Sexual orientation	There are three components: identity, behavior, and attraction; not directly related to gender identity. The sexual orientation of transgender people should be defined by the individual.
Transgender	An individual whose gender identity differs from the sex assigned at birth
Cisgender	An individual whose gender identity is the same as the sex assigned at birth
Gender diverse	Includes individuals whose gender identity and/or role does not conform to a binary understanding of gender as limited to the categories of man or woman, male or female. May be more complex, fluid, multifaceted, or otherwise less clearly defined than a transgender person
Gender dysphoria	Discomfort or distress caused by discrepancy between a person's gender identity and sex assigned at birth. DSM-5 criteria recommend a diagnosis occur after 6 months of continuous incongruence. For prepubescent children, defined by DSM-5 as a marked incongruence between one's experienced/expressed gender and assigned gender. <sup>95</sup>

Adapted from World Professional Association for Transgender Health<sup>34</sup> and UCSF Transgender Care.<sup>96</sup> Others as referenced in table.

- (1) One teaching tool to assist with this concept can be found at <https://genderbread.org> and <https://thegenderbook.com>.
- b. Taking a sexual history: Should be done as part of routine healthcare. Employ a patient-centered, nonjudgmental approach, keeping in mind potential histories of trauma or abuse. The “Five Ps” approach is outlined below.<sup>32</sup> See <https://www.cdc.gov/std/treatment/sexualhistory.htm> for full list of questions and example script.
  - (1) **P**artners: Number of lifetime and current partners
  - (2) **P**ractices: Type of sexual contact, parts of body involved, history of exchanging sex for needs
  - (3) **P**rotection from STIs: Knowledge of contraception and STI prevention
  - (4) **P**ast History of STIs: Prior testing for STIs/HIV
  - (5) **P**regnancy Intention: Reproductive life plan and prior pregnancies and/or abortions
  - (6) Additionally inquire about history of nonconsensual intimate physical contact or sex and performance or function concerns
- c. Development of identity and behaviors during adolescence
  - (1) The AAP recommends routinely asking about sexual orientation and gender identity during adolescent visits as sexual identity emerges during adolescence.<sup>33</sup> It is important to provide a safe environment for adolescents to discuss questions about their sexual identity and behavior and to ask questions about sexual activities regardless of sexual orientation, and keep information that they are not ready to share confidential.
  - (2) Mirror language used by adolescents for body parts and for their identified gender and sexual orientation or behaviors. This is particularly important for lesbian, gay, bisexual, transgender (LGBT), and other gender diverse youth. Terms used by adolescents may not match what the provider expects based on reported activity or sexual orientation.
- d. Considerations for transgender and gender-diverse adolescents
  - (1) Several societies put out standards of care, which can be used to guide management:
    - (a) The World Professional Association for Transgender Health (WPATH) standards of care<sup>34</sup>: <https://www.wpath.org/publications/soc>
    - (b) UCSF Health Considerations for Gender Non-Conforming Children and Transgender Adolescents<sup>35</sup>: <https://transcare.ucsf.edu/guidelines/youth>
    - (c) Endocrine Society Clinical Practice Guideline<sup>36</sup>
  - (2) Gender affirmation: [Table 5.4](#)
  - (3) Timing: Timing of treatment interventions is based on clinical evaluation, including age and pubertal status, input from the patient and their family, and shared decision making. Interventions range from fully reversible to partially irreversible to fully irreversible. It is recommended that these be carried out in a

TABLE 5.4

## GENDER AFFIRMATION FOR TRANSGENDER AND GENDER-DIVERSE YOUTH

Type	Components	Reversibility and Timeline
Social	<ul style="list-style-type: none"> <li>Changes to name, pronoun, clothing, or appearance (e.g., binders, stand-to-pee devices, silicone breasts)</li> <li>Parental support and education to create a safe environment for the child</li> </ul>	Reversible; all ages; familial support of social transition for transgender children has been associated with better mental health outcomes. <sup>97</sup>
Legal	Legally changing name and gender identifier	Reversible; all ages
Medical	<p>Pubertal suppression: GnRH analogue (e.g., leuprolide and histrelin)</p> <p>Hormone therapy: for example, estradiol, progesterone, testosterone, spironolactone</p>	<p>Reversible; starting at Tanner stage II (recommended that adolescent experience the onset of puberty in order to make informed decision about pubertal delay); can relieve distress of pubertal development and can provide time to explore gender identity further</p> <p>Partially irreversible; sufficient mental capacity to give informed consent (generally by the age of 16 years). Treatment can be considered as early as age 13.5 to 14 years.</p>
Surgical	For example, gonadectomy, hysterectomy, mastectomy, and genital surgery	Irreversible; typically not recommended until age of majority

Adapted from Rafferty et al,<sup>37</sup> World Professional Association for Transgender Health,<sup>34</sup> and Olson-Kennedy et al.<sup>35</sup>

staged approach, prioritizing reversible interventions earlier.<sup>34,37</sup> See Table 5.4 for more details.

- (4) Fertility and family planning: It is important to discuss with adolescents and their families who are considering gender affirmation interventions how these may impact future sexual function, fertility, and family planning. Fertility preservation options should be offered early in the process.<sup>37</sup>
- (5) Family acceptance is an important protective factor for the mental health and well-being of transgender and gender-diverse youth.<sup>38</sup> Clinicians can support and facilitate these relationships through open conversations and providing resources such as<sup>37</sup>:
  - (a) The Family Acceptance Project: <https://familyproject.sfsu.edu>
  - (b) Parents, Families & Friends of Lesbians and Gays (PFLAG): <https://community.pflag.org>
  - (c) The Parents Project: <https://www.theparentsproject.com>

## 7. S—Suicide/depression (see Chapter 24 for further details)

- a. History of depression or other mental health problems
- b. Current or prior suicidal thoughts or attempts or other self-harming or injurious behavior
- c. Screening: PHQ-A<sup>39</sup> is a validated depression screening tool for adolescents. Screening tools also exist for other mental health disorders such as anxiety (GAD7),<sup>40</sup> although they are not specific to

adolescents: [https://www.aacap.org/AACAP/Families\\_and\\_Youth/Resource\\_Centers/Depression\\_Resource\\_Center/Resources\\_for\\_Clinicians\\_Depression.aspx](https://www.aacap.org/AACAP/Families_and_Youth/Resource_Centers/Depression_Resource_Center/Resources_for_Clinicians_Depression.aspx)

- d. National disasters, such as pandemics, can impact mental health. Isolation has been associated with negative health outcomes,<sup>41</sup> and the COVID-19 pandemic specifically has resulted in higher rates of a range of mental health concerns including anxiety, depression, eating disorders, and substance use.<sup>42</sup>
- e. Sociocontextual factors: Social determinants of health, racism (see Section II for more in-depth discussion)



## 8. **S—Safety**

- a. Screening for history of ACEs/trauma (see [Chapter 9](#) for more details)
- b. Feeling unsafe at home, school, or in the community
- c. Bullying
- d. Guns or other weapons at home or access to them
- e. Interactions with police/police-instigated violence and police brutality<sup>43</sup>
  - (1) Significant racial disparities: Black youth experience nearly ninefold-more encounters with police compared with White counterparts and are more likely to experience use of force and injury.
  - (2) Police exposures are associated with adverse health outcomes for Black youth, including increased rates of adverse mental health, sexual risk behaviors, and substance use.
- f. Fighting, arrests, gang membership


## 9. **Other aspects of medical history with relevance during adolescence:**

- a. Review of symptoms: STI symptoms, obstructive sleep apnea symptoms (see [Chapter 25](#)), sleep (how much, sleep hygiene habits)
- b. Menstrual history
  - (1) Age of menarche, last menstrual period (LMP), frequency/regularity, quality, duration, associated symptoms and severity (missing school/work, requiring medication, etc.)
  - (2) Menarche for majority will occur between ages 11 and 15; lack of menarche by age 16 is defined as primary amenorrhea and warrants further workup.<sup>45</sup> Clinical consideration of overall course of growth and development also important
  - (3) See [Chapter 10](#) for more regarding expected pubertal development timing and concern for polycystic ovary syndrome (PCOS).
- c. Medications: Any over-the-counter supplements, protein powders, weight loss meds, etc.

## **B. Physical Examination Elements Unique to the Adolescent**<sup>46,47</sup>

- 1. Conducting a trauma-informed examination<sup>48</sup>
  - a. Definition: Incorporating awareness of known or potential history of trauma into the physical exam: intentional use of clinical language,

- modesty draping and professional touch, and prioritizing patient autonomy whenever possible
- b. Screen all patients for history of trauma prior to any sensitive exam.
  - c. Language: Use clinical rather than colloquial language. Verbally walk patient through entire exam prior to starting.
  - d. Optimize patient autonomy during the exam whenever possible. This can include strategies (based on patient comfort and desire) such as self-swabbing for STI screening (see Section V.A for more details), self-insertion of the speculum, keeping the head of the table up during a pelvic exam, or others determined through shared decision making.<sup>49</sup>
2. **Dentition and gums:** Caries, enamel defects from tobacco use, and enamel erosion from induced vomiting
  3. **Skin:** Acne (see [Chapter 8](#) for treatment guidelines), hirsutism, atypical nevi, acanthosis nigricans, rashes, evidence of cutting, piercings, and tattoos
  4. **Thyroid:** Size, nodules. Hypo-/hyperthyroidism can affect puberty.
  5. **Breasts:**
    - a. Female normal breast development: Tanner staging, also known as Sexual Maturity Rating ([Fig. 5.1A](#)), masses (most commonly fibrocystic changes and fibroadenomas in females, or gynecomastia in males), breast asymmetry (common occurrence in adolescence; more pronounced between Tanner pubertal stages 2 and 4)
    - b. Physiologic gynecomastia in males:
      - (1) Epidemiology: Generally, occurs in middle to late stages of puberty (usually peaks in Tanner pubertal stage 3); occurs in 50% of boys (50% unilateral, 50% bilateral)
      - (2) Etiology: Breast growth stimulated by estradiol
      - (3) Clinical course: Regression usually occurs over a 2-year period.
      - (4) Physical examination: Firm glandular tissue in a concentric mass beneath the areola/nipple is consistent with physiologic gynecomastia. A testicular examination should also be performed.
      - (5) Differential diagnosis: Nonphysiologic gynecomastia. Common causes include medication or substance use (particularly cannabis), primary or secondary hypogonadism, cirrhosis, hyperthyroidism, tumors, and pseudogynecomastia (excess adipose tissue on exam).
      - (6) Red flags: Symptom duration over 2 years, nipple discharge, skin changes, breast masses, and coincident testicular abnormalities
      - (7) Treatment: Often no treatment is necessary. Severe or nonregressing cases may warrant referral to pediatric surgeon, endocrinologist, or oncologist, depending on suspected etiology.
  6. **Genitalia:** For both male and female genital examinations, in addition to trauma-informed guidance discussed previously, a chaperone should be present (parent, guardian, or family member not included), an explanation should occur before the examination, and findings should be

**FIGURE 5.1**

Tanner stages of puberty. (A) Breast development in females. (B) Pubic hair development in males and females. (C) Male genital development. (Modified from Rodgers A, Salkind J. *Crash Course: Paediatrics*. 5th ed. Elsevier; 2019. Figure 7.3 with data from Emmanuel M, Bokor BR. Tanner Stages. [Updated December 15, 2021]. In: *StatPearls*. StatPearls Publishing; 2022. <https://www.ncbi.nlm.nih.gov/books/NBK470280/>)

discussed. Tanner staging should be done separately for genitalia and pubic hair to identify issues with the hypothalamic-pituitary-gonadal (HPG) vs. hypothalamic-pituitary-adrenal (HPA) axis.

a. **Male**<sup>50</sup>

- (1) Tanner staging of genital development: Fig. 5.1C
- (2) Tanner staging of pubic hair development: Fig. 5.1B
- (3) Assess for signs of STIs (rashes, warts, ulcers, erosions, discharge), inguinal hernias, masses, hydroceles, varicoceles, and evidence of trauma. If there are symptoms of proctitis with

history of receptive anal intercourse (e.g., rectal pain, rectal bleeding, or tenesmus), a digital rectal examination should be performed.

b. **Female**<sup>51,52</sup>

- (1) Tanner staging of pubic hair development: see [Fig. 5.1B](#)
- (2) Assess for signs of STIs (rashes, warts, ulcers, erosions, discharge), discharge suggestive of candidiasis or bacterial vaginosis, and evidence of trauma.
- (3) Speculum exams are not routinely recommended for healthy asymptomatic women.<sup>53</sup> Indications for bimanual exam or speculum exam include:
  - (a) Vaginal discharge with or without lower abdominal or pelvic pain (assess cervix for mucopurulent discharge, friability, large ectropion, foreign body, or cervical motion tenderness)
  - (b) Menstrual disorders (amenorrhea, abnormal vaginal bleeding, or dysmenorrhea refractory to medical therapy)
  - (c) Pap smear (see [Table 5.1](#))

- c. For suspected or reported sexual abuse or rape, refer to a specialized center if not appropriately trained and equipped to document evidence of trauma and collect forensic specimens.

NOTE: See [Chapter 10](#) for information about precocious and delayed puberty.

## V. SEXUAL HEALTH

### A. Sexually Transmitted Infection Screening Guidelines by Sexual Behaviors<sup>15,52-55</sup>

1. **All adolescents over age 13:** The CDC recommends universal screening for HIV (via HIV 1/2 antigen/antibody test) at least once using an opt-out approach, or more frequently based on risk factors.
2. **Receptive vaginal intercourse:**
  - a. **With one lifetime partner:** Screen once with HIV 1/2 antigen/antibody test; self- or provider-collected vaginal NAAT for gonorrhea and chlamydia (routine screening recommended annually in sexually active women under age 25), can add trichomonas in high-prevalence settings.
    - (1) *Vaginal swab* is the preferred method to screen for gonorrhea and chlamydia; self-collected specimens may have higher patient acceptability. Vaginal swabs are as sensitive and specific as cervical swabs, and both are more accurate than urine samples.<sup>56-58</sup>
  - b. **With risk factors (new partner, multiple partners, partner with STI, incarceration, transactional sex):** Screen for syphilis and trichomonas in high-prevalence settings, HIV testing when being evaluated for other STIs, continued gonorrhea and chlamydia testing annually in women >25 years old. Repeat testing 3 months after treatment of

- gonorrhea or chlamydia due to high risk for re-infection. Repeat as indicated by sexual risk.
3. **Penetrative penile intercourse:**
    - a. **With one lifetime partner:** Screen once with HIV 1/2 antigen/antibody test. Insufficient evidence on gonorrhea and chlamydia urine NAAT screening benefits; consider in high-risk clinical settings (adolescent clinics, sexual health clinic).
    - b. **With risk factors (new partner, multiple partners, partner with STI, incarceration, transactional sex):** HIV testing whenever being evaluated for STIs, rapid plasma reagin (RPR), and NAAT for gonorrhea and chlamydia in high-risk clinical settings. Repeat as indicated by sexual risk.
  4. **Receptive anal intercourse:** HIV testing indicated if unknown status or previously negative and patient or their partner has had more than one sex partner since last test; RPR annually, and gonorrhea and chlamydia NAAT (test swab of rectum) are recommended if receptive intercourse in the last year.
    - a. Consider 3- to 6-month interval STI testing for those at increased risk (e.g., new sexual partner without a condom).
  5. **Oral intercourse:** Gonorrhea NAAT (test swab of pharynx) if receptive oral intercourse in the last year, pharyngeal chlamydia screening not recommended. If positive for pharyngeal gonorrhea, should return in 7 to 10 days for test of cure. If still positive, should complete culture before re-treating.
  6. **Pregnant women:** Screenings at first prenatal visit include HIV, hepatitis B (HBsAg), hepatitis C, syphilis (RPR), HIV, gonorrhea, and chlamydia.
    - a. If positive gonorrhea or chlamydia, recommend test of cure 4 weeks after treatment with repeat screening 3 months after and during the third trimester.
    - b. Repeat testing with patients at high risk for infection, including cisgender women with current or recent injection-drug use, STI during pregnancy, multiple sex partners during pregnancy, or new sexual partner during pregnancy.
      - (1) Repeat syphilis screen (RPR) at 28 weeks' gestation.
      - (2) Repeat HIV screen in third trimester (preferably before 36 weeks' gestation).
      - (3) Repeat hepatitis B testing should be completed at time of admission to the hospital for delivery.
  7. **Transgender/gender diverse:** Given the diversity of transgender persons regarding patterns of sexual behavior, hormone use, and surgery, clinicians should assess STI risk based on the patient's sexual behaviors and current anatomy (the latter of which should guide method of NAAT testing, if indicated).
  8. **Correctional facilities recommended screenings via opt-out approach:**
    - a. Women less than or equal to 35 years old: gonorrhea, chlamydia, and trichomonas

- b. Men less than or equal to 30 years old: gonorrhea and chlamydia
  - c. Syphilis testing in high-prevalence locations
  - d. All people should receive HIV and hepatitis A, B, and C screening.
9. **Concern for recent exposure to STI:**
- a. Fourth-generation HIV 1/2 antigen/antibody tests detect acute infection within 10 to 14 days. If there is concern for acute or early HIV exposure, consider an HIV RNA nucleic acid test.<sup>59</sup>
  - b. Screen with RPR, gonorrhea, and chlamydia NAT (method of testing as described earlier by sexual behavior), and vaginal trichomonas NAT as indicated.
  - c. Consider HSV PCR testing in individuals presenting for STI evaluation with genital lesion(s). There is no role for HSV antibody testing.
10. **Persons living with HIV:** Screen at initial visit and at least annually with RPR, gonorrhea and chlamydia NAAT (screening at anatomic site of exposure), and vaginal trichomonas NAAT as indicated. Hepatitis B screening at initial diagnosis, hepatitis C screening at initial diagnosis, and annually thereafter. Screen more frequently if indicated by sexual risk behaviors.

## **B. Sexually Transmitted Infection Evaluation and Management (Tables 5.5 to 5.7)<sup>52</sup>**

1. **HIV:** See [Chapter 17](#) for information on diagnosis and treatment of HIV, Pre-exposure prophylaxis (PrEP), and postexposure prophylaxis (PEP). PrEP should be initiated in the primary care setting, when possible.
2. **Syphilis<sup>52</sup>**
  - a. Etiology: *Treponema pallidum*
  - b. Early syphilis (within 1 year of initial infection)
    - (1) Primary syphilis (chancre): Firm, usually painless sore(s) or ulcer(s) develop at the site of initial infection (genital, rectal, or oral). Chancres typically develop within 3 weeks of infection and heal 3 to 6 weeks after development in the absence of treatment.
    - (2) Secondary syphilis: Within weeks to months after a chancre appears, patients may develop body rash involving palms and soles, mucocutaneous lesions, lymphadenopathy, constitutional symptoms, and/or early neurosyphilis (e.g., meningitis or ocular syphilis).
    - (3) Early latent syphilis: Asymptomatic stage
    - (4) Late syphilis (over 1 year after initial infection)
      - (a) Late latent syphilis: Asymptomatic stage
      - (b) Tertiary syphilis: Organ involvement may progress to cardiovascular syphilis (e.g., aortitis), late neurosyphilis (e.g., tabes dorsalis or paresis), or gummatous syphilis.
  - c. Diagnosis: Testing algorithm varies by laboratory and typically includes a nontreponemal test (RPR or Venereal Disease Research Laboratory [VDRL] test) and a treponemal test (e.g., fluorescent

TABLE 5.5

SEXUALLY TRANSMITTED AND GENITOURINARY INFECTIONS: GUIDELINES FOR MANAGEMENT<sup>a,52</sup>

Infection	Clinical Diagnosis	Empiric Therapy <sup>a</sup>	Comments
Chlamydia infections	Uncomplicated infection of the cervix, urethra, or rectum	Doxycycline 100 mg PO 2×/day for 7 days <i>Alt regimen:</i> Azithromycin <i>OR</i> levofloxacin	<ul style="list-style-type: none"> <li>• Consider empiric treatment for gonococcal infection in patient at high risk for gonorrhea.</li> <li>• Repeat test in 3 months due to high rates of reinfection.</li> </ul>
	Lymphogranuloma venereum (LGV)	Doxycycline 100 mg PO 2×/day for 21 days <i>Alt regimen:</i> Azithromycin <i>OR</i> erythromycin	
Gonorrhea infections	Uncomplicated infection of the cervix, urethra, or rectum of adolescents <150 kg	Ceftriaxone 500 mg IM once <i>Alt for cephalosporin allergy:</i> Gentamicin PLUS azithromycin <i>If ceftriaxone administration not available:</i> Cefixime	<ul style="list-style-type: none"> <li>• Empiric treatment for chlamydia should be provided if chlamydia cannot be excluded with doxycycline 100 mg orally 2×/day for 7 days.</li> <li>• Repeat test in 3 months due to high rates of reinfection.</li> </ul>
	Infection of the pharynx in adolescents <150 kg	Ceftriaxone 500 mg IM once	
	Infection of cervix, urethra, rectum, or pharynx of adolescents >150 kg	Ceftriaxone 1 gm IM once	<ul style="list-style-type: none"> <li>• Test of cure at 7–14 days</li> </ul>
	Disseminated gonococcal infections	Ceftriaxone 1 gm IV/IM daily <i>Alt regimen:</i> Cefotaxime <i>OR</i> ceftizoxime	
Epididymitis	Acute epididymitis most likely caused by gonorrhea and chlamydia	Ceftriaxone 500 mg IM once PLUS doxycycline 100 mg PO 2×/day for 10 days	<ul style="list-style-type: none"> <li>• Can switch to oral therapy 24–48 hr after clinical improvement. Total course: 7 days</li> </ul>
	Acute epididymitis most likely caused by gonorrhea, chlamydia, or enteric organisms (men who practice insertive anal sex)	Ceftriaxone 500 mg IM once PLUS levofloxacin 500 mg PO 1×/day for 10 days	

Continued

TABLE 5.5

SEXUALLY TRANSMITTED AND GENITOURINARY INFECTIONS: GUIDELINES FOR MANAGEMENT<sup>a,52</sup>—CONT'D

Infection	Clinical Diagnosis	Empiric Therapy <sup>a</sup>	Comments
	Acute epididymitis caused by enteric organisms only	Levofloxacin 500 mg PO 1×/day for 10 days	
Pelvic inflammatory disease (PID)	Parenteral treatment	Ceftriaxone 1 gm IV Q24 hr <i>PLUS</i> doxycycline 100 mg PO or IV Q12 hr <i>PLUS</i> metronidazole 500 mg PO or IV Q12 hr <i>Alt regimen:</i> Cefotetan <i>PLUS</i> doxycycline <i>OR</i> Cefoxitin <i>PLUS</i> doxycycline	<ul style="list-style-type: none"> <li>• Can transition to oral therapy 24–48 hr after clinical improvement.</li> <li>• If tubo-ovarian abscess present, should be observed &gt;24 hr.</li> </ul>
	IM or oral treatment	Ceftriaxone 500 mg IM once <i>PLUS</i> doxycycline 100 mg PO 2×/day for 14 days <i>PLUS</i> metronidazole 500 mg PO 2×/day for 14 days <i>OR</i> Cefoxitin <i>PLUS</i> probenecid <i>PLUS</i> doxycycline <i>PLUS</i> metronidazole	
Nongonococcal urethritis (NGU)	Initial	Doxycycline 100 mg PO 2×/day for 7 days <i>Alt regimen:</i> Azithromycin	
	Persistent NGU test for <i>Mycoplasma genitalium</i> (NAAT) and resistance	<i>Refer to treatment for Mycoplasma genitalium below.</i>	

<i>Mycoplasma genitalium</i>	Persistent urethritis, cervicitis, or PID despite appropriate treatment	<p><i>Macrolide sensitive:</i> Doxycycline 100 mg PO 2×/day for 7 days, <i>FOLLOWED BY:</i> Azithromycin 1 gm PO once, <i>FOLLOWED BY:</i> Azithromycin 500 mg PO 1×/day for 3 days (2.5 gm total) <i>Macrolide resistant OR unable to complete resistance testing:</i> Doxycycline 100 mg PO 2×/day for 7 days, <i>FOLLOWED BY:</i> Moxifloxacin 400 mg PO 1×/day for 7 days</p>	
Syphilis	Primary, secondary, or early latent syphilis	Benzathine penicillin G 2.4 million units IM once (single dose)	Dosing applies to pregnant patients and patients with HIV.
	Late latent syphilis	Benzathine penicillin G 7.2 million units total, 3 doses of 2.4 million units IM each at 1-week intervals	Dosing applies to pregnant patients and patients with HIV.
<i>Trichomonas vaginalis</i>	Men with nongonococcal urethritis, test for trichomonas in men who have penile-vaginal intercourse in high-prevalence areas	Metronidazole 2 gm PO once <i>Alt regimen:</i> Tinidazole	
	Women, see <a href="#">Table 5.6</a>	Metronidazole 500 mg PO 2×/day for 7 days <i>Alt regimen:</i> Tinidazole	Molecular diagnostic options more sensitive than wet mount. Repeat test in 3 months due to high rates of reinfection.
Herpes (genital, nonneonatal)	First clinical episode genital herpes	Acyclovir 400 mg PO 3×/day for 7–10 days OR famciclovir 250 mg PO 3×/day for 7–10 days OR valacyclovir 1 gm PO 2×/day for 7–10 days	
	Suppressive therapy for recurrent genital herpes	Acyclovir 400 mg PO 2×/day OR valacyclovir 500 mg PO 1×/day OR valacyclovir 1 gm PO 1×/day OR famciclovir 250 mg PO 2×/day	Suppressive therapy can be offered in patients with severe recurrent HSV-2 infections; suppression also effective for less frequent recurrences and decreases transmission of HSV-2 to partner.

Continued

TABLE 5.5

SEXUALLY TRANSMITTED AND GENITOURINARY INFECTIONS: GUIDELINES FOR MANAGEMENT<sup>a,52</sup>—CONT'D

Infection	Clinical Diagnosis	Empiric Therapy <sup>a</sup>	Comments
	Episode therapy for recurrent genital herpes	Acyclovir 800 mg PO 2×/day for 5 days <i>Alt regimen:</i> Alternative dosing of acyclovir, famciclovir, or valacyclovir	<ul style="list-style-type: none"> <li>• HSV-1 genital herpes is much less likely to result in recurrence, rapid decrease in shedding during first year of infection. Minimal data on suppressive therapy, should be reserved for those with frequent recurrences.</li> <li>• Low concern for adverse events or antiviral resistance.</li> </ul>

<sup>a</sup>For dosing for children aged ≤8 years or weighing less than 45 kg, for dosing of alternative regimens, or for details on treatment in pregnancy or patients who are HIV positive, please refer to the CDC Treatment Guidelines, 2021: <https://www.cdc.gov/std/treatment-guidelines/wall-chart.pdf>. Partner notification and treatment are recommended for most sexually transmitted infections. Patients treated for a sexually transmitted infection should refrain from all sexual activity for 7 days posttreatment.

*Alt*, Alternative; *IM*, intramuscular; *IV*, intravenous; *PO*, per os.

TABLE 5.6

DIAGNOSTIC FEATURES AND MANAGEMENT OF VAGINAL INFECTIONS<sup>52</sup>

	No Infection/Physiologic Leukorrhea	Vulvovaginal Candidiasis	Trichomoniasis	Bacterial Vaginosis <sup>a</sup>
Etiology	—	<i>Candida albicans</i> and other candida species	<i>Trichomonas vaginalis</i>	High concentration of anaerobic bacteria: <i>Gardnerella vaginalis</i> , <i>Prevotella</i> , <i>Mobiluncus</i> , etc.
Typical symptoms	None	Pruritus, vaginal soreness, dyspareunia, external dysuria, ↑ discharge	Malodorous frothy discharge, vulvar irritation	Malodorous, ↑ discharge
Discharge amount	Variable; usually scant	Scant to moderate	Profuse	Moderate
Discharge color	Clear or white	White	Yellow-green	Usually white or gray
Discharge consistency	Heterogenous	Clumped; adherent plaques	Homogenous	Homogenous, low viscosity (milk consistency)
Vulvar/vaginal inflammation	No	Yes	Yes, may see strawberry-appearance cervix on pelvic exam	No
pH of vaginal fluid <sup>b</sup>	Usually <4.5	Usually <4.5	Usually >5.0	Usually >4.5
Amine (“fishy”) odor with 10% potassium hydroxide (KOH)	None	None, but KOH helps with visualization of yeast	May be present	Present, positive “whiff-amine” test
Microscopy <sup>c</sup>	Normal epithelial cells; <i>Lactobacillus</i> predominates	Leukocytes, epithelial cells, yeast, mycelia, or pseudomycelia in 40%–80% of cases	Leukocytes; motile trichomonads wet mount with low sensitivity of 44%–68%, sensitivity decreases 21% within 1 hour after collection	Clue cells, few leukocytes; <i>Lactobacillus</i> outnumbered by profuse mixed flora (nearly always including <i>G. vaginalis</i> plus anaerobes)

Continued

TABLE 5.6

DIAGNOSTIC FEATURES AND MANAGEMENT OF VAGINAL INFECTIONS<sup>52</sup>—CONT'D

	No Infection/Physiologic Leukorrhea	Vulvovaginal Candidiasis	Trichomoniasis	Bacterial Vaginosis <sup>a</sup>
Usual treatment	None	Fluconazole 150 mg PO once <i>OR</i> intravaginal azole cream	Metronidazole 500 mg PO 2×/ day for 7 days <i>OR</i> tinidazole 2 gm PO once	Metronidazole 500 mg PO 2×/day for 7 days <i>OR</i> metronidazole gel 0.75% 5 gm intravaginally daily for 5 days <i>OR</i> clindamycin cream 2% 5 gm intravaginally daily for 7 days

<sup>a</sup>Despite more sensitive and specific laboratory tests, cost and practicality make the Amsel criteria the best in-office method to diagnose bacterial vaginosis (BV). To diagnose BV, at least three criteria must be present: (1) homogenous, thin, gray/white discharge; (2) vaginal pH >4.5; (3) positive whiff-amine test; (4) clue cells on wet mount.

<sup>b</sup>pH determination is not useful if blood is present.

<sup>c</sup>To detect fungal elements, vaginal fluid is mixed with 10% KOH before microscopic examination; to examine for other features, fluid is mixed with saline.

TABLE 5.7

DIAGNOSTIC FEATURES AND MANAGEMENT OF GENITAL ULCERS AND WARTS<sup>52</sup>

Infection	Clinical Presentation	Presumptive Diagnosis	Definitive Diagnosis	Treatment/Management of Sex Partners
Genital herpes	Grouped vesicles, painful shallow ulcers to mild clinical manifestation (redness, pain, excoriations); HSV-2 more common cause of genital lesions	HSV virologic testing by NAAT or culture from active lesion. HSV NAAT 90%–100% sensitive and very specific. Previously used cytologic detection of cellular changes in HSV is less sensitive and specific (Tzanck preparation)	HSV NAAT or culture HSV PCR should be used in systemic or CNS HSV infections.	No known cure. Prompt initiation of therapy shortens duration of first episode. For severe recurrent disease, initiate therapy at start of prodrome or within 1 day. Transmission can occur during asymptomatic periods. See Table 5.5.
Chancroid	Etiology: <i>Haemophilus ducreyi</i> Painful and deep genital ulcer(s); tender, suppurative inguinal adenopathy	Clinical presentation of genital ulcer and, if present, regional lymphadenopathy No evidence of <i>Treponema pallidum</i> (syphilis) on dark-field microscopy or NAAT of ulcer exudate/fluid, serologic syphilis testing negative 7–14 days after symptom onset; negative HSV NAAT or culture of ulcer exudate/fluid	Use of special media (not widely available in United States); no FDA-cleared NAAT for <i>H. ducreyi</i> in the United States	Azithromycin 1 gm PO once OR ceftriaxone 250 mg IM once OR ciprofloxacin 500 mg PO 2×/day for 3 days OR erythromycin base 500 mg PO 3×/day for 7 days Partners should be examined and treated, regardless of whether symptoms are present, or if they have had sex within 10 days preceding onset of patient's symptoms. Reexamine in 3–7 days, symptoms should improve within 3 days of treatment, objective improvement of ulcer within 7 days. Larger ulcers may take longer to heal, may take longer to heal if concomitant with HIV or if lesion is under foreskin in uncircumcised patient.
Primary syphilis (chancre)	Indurated, well-defined, usually single painless ulcer or chancre; nontender inguinal adenopathy	Nontreponemal serologic test: VDRL, RPR, or STS	Treponemal serologic test: FTA-ABS, dark-field microscopy or direct fluorescent antibody tests of lesion exudates or tissue	Parenteral penicillin G (see Table 5.5 for preparation[s], dosage, and length of treatment)

Continued

TABLE 5.7

DIAGNOSTIC FEATURES AND MANAGEMENT OF GENITAL ULCERS AND WARTS<sup>52</sup>—CONT'D

Infection	Clinical Presentation	Presumptive Diagnosis	Definitive Diagnosis	Treatment/Management of Sex Partners
HPV infection (anogenital warts)	Soft, fleshy, flat, papular, or pedunculated, painless growths, painless most often around vaginal introitus, under foreskin in uncircumcised men, shaft of the penis or intra-anal area; no inguinal adenopathy	Typical clinical presentation and visual inspection	Can complete biopsy for atypical lesions, immunocompromised patients, or those who do not respond to therapy	Treatment does not eradicate infection. <ol style="list-style-type: none"> <li><b>Patient-administered therapies include:</b> Podofilox gel <i>OR</i> imiquimod cream <i>OR</i> sinecatechins ointment</li> <li><b>Clinician-applied therapies include:</b> Cryotherapy with liquid nitrogen or cryoprobe <i>OR</i> surgical removal <i>OR</i> trichloroacetic acid (TCA) or bichloroacetic acid (BCA)               <ul style="list-style-type: none"> <li>HPV that causes genital warts (most often strains 6 and 11) typically not the same as HPV that causes cancer.</li> <li>Due to period of communicability being unknown, current and future partners should be informed.</li> <li>Previous partners can be evaluated for STIs; however, typically no HPV testing necessary, should be made aware that they may have contracted HPV even if asymptomatic.</li> </ul> </li> </ol>

**NOTE:** Chancroid, lymphogranuloma venereum (LGV), and granuloma inguinale should be considered in the differential diagnosis of genital ulcers if the clinical presentation is atypical and tests for herpes and syphilis are negative. *EIA*, Enzyme immunoassay; *FTA-ABS*, fluorescent treponemal antibody absorbed; *HPV*, human papillomavirus; *HSV*, herpes simplex virus; *IM*, intramuscular; *RPR*, rapid plasma reagin; *STS*, serologic test for syphilis; *TP-PA*, *T. pallidum* passive particle agglutination assay; *VDRL*, Venereal Disease Research Laboratory.

treponemal antibody absorbed [FTA-ABS] test, enzyme immunoassay) for confirmation.

- d. Treatment: See [Table 5.5](#). Clinical and serologic evaluation should be performed 6 and 12 months after treatment to ensure a fourfold reduction in nontreponemal titers or seroreversion. Monitor for Jarisch-Herxheimer reaction (fever, headache, and myalgias) within 24 hours of treatment.
- e. Partner treatment: Partners with sexual contact within 90 days of a patient's diagnosis should be treated presumptively for early syphilis, even if serologic testing is negative. Partners with sexual contact over 90 days prior to diagnosis should be treated presumptively for early syphilis if serologic results are not immediately available or opportunity for follow-up is uncertain. If serologic test results are available and negative, treatment is not necessary. If serologic tests are positive, treatment should be based on clinical and serologic evaluation and syphilis stage.
- f. See [Chapter 17](#) for information on neonatal syphilis and interpretation of maternal and neonatal syphilis testing.

### 3. Chlamydia and gonorrhea<sup>52</sup>

- a. Etiology: *Chlamydia trachomatis* and *Neisseria gonorrhoeae*
- b. Clinical manifestations: Urethritis, cervicitis, pharyngitis, proctitis, epididymitis, prostatitis, pelvic inflammatory disease. Other manifestations include:
  - (1) Lymphogranuloma venereum (LGV): Lymphoproliferative reaction caused by *C. trachomatis* serovars L1 to L3 that most frequently presents as proctitis and lymphadenopathy in patients who have receptive anal intercourse or are HIV positive
  - (2) Disseminated gonococcal infection: Bacteremic spread of *N. gonorrhoeae* results in septic arthritis or arthritis-dermatitis syndrome (polyarthralgia, tenosynovitis, and dermatitis). May also involve CNS or cardiovascular system manifestations. In addition to urogenital, rectal, and pharyngeal NAAT, workup should include blood, synovial, or CSF cultures, as applicable.
- c. Diagnosis: Site-specific NAAT, including urogenital (urine NAAT in males, urine or vaginal NAAT in females [see Section II.A.2.b]), pharyngeal, and rectal
- d. Treatment: See [Table 5.5](#). In order to prevent re-infection, patients should be advised to abstain from sexual intercourse for 7 days after a single-dose therapy (standard gonorrhea treatment) or until completion of a 7-day regimen (standard chlamydia treatment), until resolution of symptoms and until all sexual partners have been treated.
- e. Partner treatment: Partners should be treated if they had sexual contact with the patient 60 days preceding onset of symptoms or are the last sexual contact of the patient. For partners for whom providers are concerned about access to prompt clinical evaluation and

treatment, expedited partner therapy may be an option depending on local and state laws.

4. **Pelvic inflammatory disease (PID):** Acute infection of the female upper genital tract, may include tubo-ovarian abscess (TOA)<sup>52</sup>
  - a. Etiology: Often polymicrobial in nature; however, *N. gonorrhoeae* and *C. trachomatis* are the most identified pathogens, followed by *Mycoplasma genitalium*
  - b. Differential diagnosis: Endometriosis, ovarian cyst, ovarian torsion, ectopic pregnancy, acute appendicitis, inflammatory bowel disease (IBD), pyelonephritis, dysmenorrhea, septic/threatened abortion
  - c. Workup: Pelvic and bimanual examination, gonorrhea/chlamydia and HIV testing, human chorionic gonadotropin (hCG), wet preparation, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and urinalysis/urine culture if clinically indicated. Consider testing for *M. genitalium* in persistent PID despite appropriate treatment. Consider a complete blood cell count (CBC) with differential and pelvic ultrasound if the patient is ill appearing, has an adnexal mass on bimanual examination, or is not improving after antibiotics.
  - d. Minimum diagnostic criteria: Uterine, adnexal, or cervical motion tenderness without other identifiable causes. One or more of the following additional criteria enhances specificity: fever (>38.3°C), mucopurulent vaginal or cervical discharge, cervical friability, leukocytes on saline microscopy, increased ESR or CRP, laboratory documentation of chlamydial or gonorrhea infection.
  - e. Treatment: See [Table 5.5](#).
  - f. Hospital admission criteria: Cannot exclude acute surgical abdomen, presence of TOA, pregnancy, immunodeficiency, severe illness, inability to tolerate or follow outpatient oral regimen, failure to respond to appropriate outpatient therapy, or follow-up cannot be ensured
5. **Trichomoniasis**<sup>52</sup>
  - a. Etiology: *Trichomonas vaginalis*
  - b. Clinical manifestations: See [Table 5.6](#).
  - c. Diagnosis and treatment: See [Table 5.6](#). Patients should be advised to abstain from sexual intercourse until they and their partners have completed therapy and symptoms have resolved.
  - d. Follow-up: Women treated for trichomoniasis should be retested 3 months after treatment due to high rates of reinfection.
  - e. Partner treatment: Partners should be treated to prevent reinfection.
6. ***Mycoplasma genitalium***<sup>52</sup>
  - a. Etiology: *M. genitalium*
  - b. Clinical manifestations: Persistent urethritis, cervicitis, or PID despite appropriate treatment
  - c. Diagnosis: FDA-cleared NAAT of *M. genitalium* for urine and urethral, penile meatal, endocervical, and vaginal swab samples. Due to high rates of macrolide resistance, if resistance testing is available, it should be completed to guide therapy.

d. Treatment: See [Table 5.5](#).

## 7. Vaginal infections, genital ulcers, and warts

- a. Diagnostic features of vaginal infections (see [Table 5.6](#)) can assist in differentiating normal vaginal discharge from bacterial vaginosis, trichomoniasis, and yeast vaginitis.
- b. Diagnostic features of genital lesions, as well as management of warts and ulcers, are presented in [Table 5.7](#).

## C. Contraception<sup>60,61</sup>


### 1. Special considerations in adolescents:

- a. Approximately 40% to 50% of adolescents in the United States have had penile-vaginal sexual intercourse, and nearly half of adolescent pregnancies are unplanned.<sup>62-64</sup>
- b. Barriers to contraception may include confidentiality concerns (e.g., fear of parental disclosure), fear of pelvic examination, and fear of medication side effects.
- c. **Long-acting reversible contraception (LARC)** methods have well-established safety and efficacy and are first-line contraceptive methods according to the ACOG and the AAP. Adherence and continuation rates of LARC methods in adolescents are superior to short-acting contraceptives. To avoid a delay in initiation, quick-start methods should be considered for most adolescents.<sup>65</sup>
- d. Providers should pay special attention to informed consent, confidentiality, parental involvement, insurance coverage, and cost. If an adolescent does not have or does not want to use their insurance coverage, refer to a clinic with Title X or other public funding (<https://www.hhs.gov/opa/>).
- e. Counseling should include discussion of the need for barrier method to prevent STIs.

### 2. Method comparison ([Fig. 5.2](#))<sup>66</sup>

### 3. Contraception selection and initiation:

- a. **Selecting a contraceptive method:** Refer to the CDC Medical Eligibility Criteria ([https://www.cdc.gov/reproductivehealth/contraception/pdf/summary-chart-us-medical-eligibility-criteria\\_508tagged.pdf](https://www.cdc.gov/reproductivehealth/contraception/pdf/summary-chart-us-medical-eligibility-criteria_508tagged.pdf)) for relative and absolute contraindications for each hormonal contraceptive method and the CDC's Selected Practice Recommendations (<https://www.cdc.gov/reproductivehealth/contraception/mmwr/spr/summary.html>) for minimum requirements to start each method.
  - (1) To start a hormonal method, the basic medical history should include assessment of clotting risk, blood pressure, pregnancy status, migraines with aura, family history, and any other pertinent medical comorbidities.
  - (2) Combined hormonal contraception (contraception that includes estrogen) is associated with a small increase in risk for thrombosis, including deep venous thrombosis, myocardial infarction, and stroke.<sup>67</sup> The risk is higher in women who smoke



**CONDOMS SHOULD ALWAYS BE USED TO REDUCE THE RISK OF SEXUALLY TRANSMITTED INFECTIONS**

Other Methods of Contraception

**Lactational Amenorrhea Method:** LAM is a highly effective, temporary method of contraception.

**Emergency Contraception:** Emergency contraceptive pills or a copper IUD after unprotected intercourse substantially reduces risk of pregnancy.

**FIGURE 5.2**

Comparing effectiveness and side effects of family planning methods. (From Centers for Disease Control and Prevention. U.S. selected practice recommendations for contraceptive use, 2016. *MMWR Recomm Rep.* 2016;65[4];1-66. Patient-friendly chart per U.S. Food & Drug Administration available at: <https://www.fda.gov/consumers/free-publications-women/birth-control-chart>)

more than 15 cigarettes a day, women over 35 years old, women with history of migraine with aura, and women with other risk factors for cardiovascular disease.

(3) To support adherence and continuation, use a patient-centered approach, review method effectiveness, and provide anticipatory guidance regarding side effects of each method when assisting an adolescent in selecting a new contraceptive method.


- b. **Quick start (Fig. 5.3):** Starting a method of contraception on the day of the visit (not waiting until a new menstrual cycle begins) should be considered for most adolescents. Can be used for all methods, including LARC, if there is reasonable certainty that the patient is not pregnant (Box 5.2). A urine pregnancy test should be performed when using this approach, and patients should be advised to use a second form of birth control for 7 days.<sup>68</sup>

5

#### 4. **Specific contraceptive methods:**

NOTE: Contraceptive methods are described in order of effectiveness.

- a. **Subdermal implant:** Progestin-only LARC, 4-cm rod inserted into the upper arm. Newer model (Nexplanon) is radio-opaque. FDA approved for 3 years; studies show efficacy for up to 5 years.<sup>69</sup> Minimal or no effect on bone density; can cause irregular bleeding, mood swings, depressed mood, headache, or acne.<sup>70</sup> Return to fertility is rapid after removal. May be less effective for women who are overweight or obese. The most effective form of birth control
- (1) Efficacy: Number of expected pregnancies per 100 women is less than 1.<sup>71</sup>
- (2) Persistent irregular bleeding is the most common complaint resulting in implant removal, but continuation rates among adolescents remain high.<sup>72</sup> As opposed to levonorgestrel IUD, bleeding changes persist throughout duration of use. The bleeding pattern in the first 3 months of use is predictive of future bleeding. Important to provide pre-insertion anticipatory guidance. Consider postinsertion management of bleeding with NSAIDs or combined OCPs.<sup>66,73</sup>
- b. **Intrauterine device (IUD)<sup>65</sup>:** LARC inserted into the uterus through the cervix. Safe to use among adolescents, may be inserted without difficulty in most adolescents and nulliparous women. Rate of expulsion is between 0.05% and 8%, typically occurs within the first 3 months. Does not increase risk of infertility; baseline fertility returns rapidly after removal. Previously thought that risk of pelvic infection was increased with placement; however, recent reviews do not support this and demonstrate similar risks of PID in women with asymptomatic gonorrhea or chlamydia regardless of IUD insertion.<sup>74</sup> Women should be tested for STIs on day of insertion depending on their risk factors. Insertion should not be delayed for test results; treatment can occur without IUD removal.<sup>75</sup>

**FIGURE 5.3**

Algorithm for quick start initiation of contraception (<https://www.aafp.org/afp/2006/0701/p105.html>).

<sup>a</sup>Pregnancy tests may take 2 to 3 weeks after sex to be accurate.

<sup>b</sup>Consider pregnancy test at second depot medroxyprogesterone acetate (DMPA [Depo-Provera]) injection if quick start regimen was used and patient failed 4-week follow-up visit. (Lesnewski R, Prine L. Initiating hormonal contraception. *Am Fam Physician*. 2006;74[1]:105–112. PMID: 16848384.)

**BOX 5.2****HOW TO BE REASONABLY CERTAIN THAT A WOMAN IS NOT PREGNANT**

If the patient has no symptoms or signs of pregnancy and meets any of the following criteria:

1. Is  $\leq 7$  days after the start of normal menses
2. Has not had sexual intercourse since the start of last normal menses
3. Has been correctly and consistently using a reliable method of contraception
4. Is  $\leq 7$  days after spontaneous or induced abortion
5. Is within 4 weeks postpartum
6. Is fully or nearly fully breastfeeding, amenorrheic, and  $< 6$  months postpartum

Adapted from Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. *MMWR Recomm Rep.* 2016;65(4):1–66.

- (1) Efficacy: Among the most effective forms of birth control. Number of expected pregnancies per 100 women is less than 1.<sup>71</sup>
  - (2) Types of IUDs
    - (a) Copper (Paragard): Hormone-free, FDA approved for 10 years of use, although data support potential efficacy for an additional 1 to 2 years.<sup>65,76</sup>
    - (b) Progestin-containing (levonorgestrel): There are four types with differing amounts of progestin. Mirena is FDA approved for 5 years; data support an additional 2 years.<sup>65,69</sup> Kyleena is FDA approved for 5 years. Liletta is FDA approved for 4 years; data support an additional year.<sup>65,77</sup> Skyla is FDA approved for 3 years.
  - (3) Side Effects: Changes in bleeding patterns are common in the first months of use. Copper IUD may cause heavier menses and cramping. Many women using the levonorgestrel IUD will have a decrease in bleeding over time or amenorrhea.<sup>70</sup> First-line treatment for bleeding and spotting is NSAIDs.<sup>78</sup> Bleeding concerns that are not associated with device insertion should be evaluated for other etiologies.
- c. **Depot medroxyprogesterone acetate (DMPA [Depo-Provera]) injection**<sup>67,74</sup>: Progestin-only, IM injection every 13 weeks or subcutaneous injection every 12 to 14 weeks. Delayed return to fertility (9 to 18 months).<sup>79</sup> Menstrual irregularity is common but often resolves after several cycles. Other side effects include headaches, abdominal pain, and weight gain.<sup>86</sup> Average weight gain within 1 year is  $< 2$  kg, increase of weight by 5% within 6 months is associated with continued excessive weight gain and patients should be counseled appropriately.<sup>80,81</sup>
- (1) Efficacy: Number of expected pregnancies per 100 women is 6.
  - (2) Patient should be encouraged to receive adequate calcium and vitamin D due to association with decrease in bone mineral density.

(3) In 2004 an FDA black box warning was issued on DMPA, stating it should not be used for longer than 2 consecutive years, unless other forms of birth control are inadequate due to bone mineral density concerns. However, further studies have shown that bone density substantially, if not completely returns after discontinuation. Therefore, risk of potential loss of bone mineral density should be weighed against the need for effective contraception in the context of each adolescent.<sup>68</sup>

d. **Combined hormonal methods:** Combined estrogen-progestin-containing methods of contraception have similar efficacy with 9% failure rate if used correctly. They may result in side effects of breast tenderness, nausea, and headache, symptoms that usually improve with time.<sup>70</sup> These estrogen-containing methods are medically contraindicated in patients 35 years or older who smoke 15 or more cigarettes per day or have a history of stroke, thrombosis, cardiovascular disease, hypertension, migraine with aura, breast cancer, valvular heart disease, or certain forms of liver disease.<sup>75</sup>

(1) **Combined hormonal oral contraceptive pills (OCPs):** Combination of estrogen and progestin taken daily. “Low-dose” (35 mcg or less of ethinyl estradiol) pills are the recommended dosing for adolescents. First-line treatment for dysmenorrhea and endometriosis as combined hormonal OCPs make menstruation lighter, shorter, and more regular and decrease pain.<sup>79</sup> Newer formulations exist, known as extended-cycle regimens, which reduce the number of menstrual cycles per year.

(a) The first pill should be taken either on the day of the visit (quick start) or between the first and seventh day after the start of the menstrual period (most commonly Sunday).

(b) Some pill packs have 28 pills; others have 21 pills. When the 28-day pack is empty, immediately start taking pills from a new pack. When the 21-day pack is empty, wait 1 week (7 days), then begin taking pills from a new pack.

(c) If a pill is missed, it should be taken as soon as remembered, even if it means taking two pills in 1 day. If two or more pills are missed, two pills should be taken daily until back on schedule and a backup method should be used for 7 days.

(2) **Transdermal (patch) contraceptive:** Apply one patch for 3 weeks, then remove for 1 week for withdrawal bleed. Place on abdomen, upper torso, upper outer arm, or buttocks. Greater exposure to estrogen than with other methods; may have more estrogen-related side effects. There may be a greater risk for thromboembolism compared to OCPs, though the data are not clear.<sup>82</sup> May be less effective in obese women

(3) **Vaginal ring:** Flexible latex-free ring. Placed in vagina for 3 weeks, removed for 1 week for withdrawal bleeding. May be used continuously (avoiding week of menses) by replacing with a new ring every 4 weeks (or the same day every month) to help reduce

pelvic pain and dysmenorrhea. May be removed for up to 3 hours (not recommended in adolescents). Requires user comfort with insertion and removal<sup>70</sup>

- e. **Progestin-only pills:** Can be used for those with contraindications to estrogen-containing formulations. Require daily use and are more sensitive to timing (should be taken at same time each day); have no pill-free interval. Considered less effective than combined hormonal methods. Irregular bleeding is a common adverse effect. Norethindrone is a commonly used progestin-only pill; however, a new formulation, Drospirenone, has also been approved. Drospirenone has a higher dose of hormone and, though there are limited data at this time, is thought to be more effective than norethindrone. Drospirenone has anti-mineralocorticoid effects similar to spironolactone and therefore a theoretical possibility of causing hyperkalemia, though data are still limited.<sup>79,80</sup>
  - f. **Barrier methods:** Require placement prior to sexual intercourse. Include cervical sponge, cervical cap, cervical shield, diaphragm (these methods are used in conjunction with spermicide), as well as female and male condoms. Male condom is the most used birth control among adolescents with a failure rate of 18% with typical use.<sup>66,70</sup> Use latex condoms only with water-based lubricants; oil-based lubricants are not recommended due to increased breakage.<sup>81</sup> While barrier methods are less effective than other methods of contraception, their use should still be emphasized for prevention of STIs. For patient education materials on how to properly use a condom, please visit <https://www.cdc.gov/condomeffectiveness/external-condom-use.html>.
  - g. **Fertility awareness-based methods of pregnancy prevention:** Involves following a woman's menstrual cycle to help prevent pregnancy. Many smartphone apps are available for use.
  - h. **Other forms of nonhormonal birth control:** Spermicide is a gel, foam, cream, or suppository applied to vagina prior to sexual intercourse. Most spermicides contain nonoxynol-9, a detergent that works by damaging a sperm's body and flagella, making it immobile and inactive. Spermicide has a failure rate of 28%. Side effects include allergic reaction, irritation, and UTI.<sup>70</sup> A pH-regulating gel, Phexxi, was approved in 2020. This gel of lactic acid must be applied prior to intercourse and maintains a lower vaginal pH even when alkaline sperm is present, immobilizing sperm. Initial studies demonstrate 86.3% effectiveness with side effects of vulvovaginal burning, pruritus, UTI, BV, and mycotic infection. However, rates of UTI, BV, and yeast infections were reduced from baseline data, demonstrating it may protect for vulvovaginal infections.<sup>83</sup>
5. **Emergency contraception (EC)**<sup>84</sup>: Used to prevent pregnancy following unprotected sex (including sexual assault) or a recent possible failure of another method of contraception. A patient-friendly handout on forms of emergency contraception, efficacy, and how to obtain EC is available

at <https://beyondthepill.ucsf.edu/sites/beyondthepill.ucsf.edu/files/EC-English-043019.pdf>

- a. Mechanism: Hormonal methods work by delaying ovulation. Copper IUD inhibits fertilization by affecting sperm viability and function. Recent studies demonstrate that hormonal IUDs may also be used for emergency contraception.<sup>85</sup> All methods are only effective before implantation takes place and will not disrupt an implanted pregnancy.
- b. Efficacy<sup>86</sup>: Copper or hormonal IUDs are the most effective method, with failure rates less than 0.1% if inserted within 5 days, but require a clinic visit for insertion.<sup>87</sup> Ulipristal is the next most effective but requires a prescription and is less effective in women over 195 pounds. Levonorgestrel is the next most effective and is available over the counter. The Yuzpe regimen is the least effective with at least 75% efficacy and has the most side effects.<sup>88</sup>
- c. Timing: Hormonal methods are most effective when given as soon as possible. Efficacy declines linearly with time, but there is efficacy up to 120 hours after intercourse. Ulipristal and an IUD maintain high efficacy when taken up to 120 hours after intercourse.
- d. Pregnancy should be excluded based on history, physical exam, or pregnancy testing before prescribing ulipristal or placing an IUD, as they may adversely affect an established pregnancy.
- e. Methods:
  - (1) Progestin only: Levonorgestrel. Take 1.5 mg orally once within 72 hours of coitus. Only method offered over the counter without prescription
  - (2) Antiprogestins: Ulipristal. Take 30 mg orally once as soon as possible, but at least within 120 hr. Mifepristone is an alternative agent used in some countries as EC but is not available in the United States. Provider prescription required
  - (3) Ethinyl estradiol plus levonorgestrel (Yuzpe regimen): Patients take multiple OCPs from packets designed for 28-day use. Take equivalent of 100 mCg of ethinyl estradiol plus 500 mCg of levonorgestrel. Twelve hours later, take the same dose.
  - (4) Copper or hormonal IUD may be inserted within 120 hours of coitus to prevent pregnancy from occurring.
- f. General recommendations<sup>89-91</sup>:
  - (1) Counseling about EC should be a routine part of anticipatory guidance for all female and male adolescents. Advance prescriptions should be considered for all adolescents.
  - (2) Antiemetics can be used to prevent nausea and should be used prophylactically in the Yuzpe regimen.
  - (3) May be combined with other ongoing methods of birth control
  - (4) OCPs may be started immediately after progestin-only or combined hormonal EC dosing has been completed. DMPA may be given the same day.

- (5) Patient should abstain from sexual intercourse or use barrier contraception for 7 days (14 if using ulipristal) or until next menses, whichever comes first.
- (6) Scheduled follow-up is not required after use of EC. However, women whose menses are delayed by a week or more, or have any signs of pregnancy (e.g., irregular menses, abdominal cramping), should be evaluated clinically or have a pregnancy test.

6. **Follow-up recommendations for contraception:** Two or three visits per year to monitor compliance, blood pressure, side effects, and satisfaction with chosen birth control option

#### D. Pregnancy<sup>92,93</sup>

If pregnancy is suspected in an adolescent patient, take a sexual history and explore how the patient feels about a possible pregnancy in order to guide the rest of the visit.

1. **Diagnosis:**
  - a. Perform urine hCG testing to diagnose the pregnancy. False-positives and false-negatives are possible; repeat urine testing or quantitative serum hCG testing may be indicated.
  - b. If pregnancy is diagnosed, estimate the gestational age using the LMP. Confirm with a brief exam of uterine size. When in doubt, arrange an ultrasound and obstetric consultation promptly, as gestational age will affect counseling options.
  - c. Share the diagnosis with the patient privately. Encourage them to involve a parent or legal guardian and facilitate the discussion, if necessary. Be familiar with local confidentiality laws, which vary by state. State-specific information can be found at <https://www.plannedparenthoodaction.org/abortion-access-tool/US>
  - d. Review the patient's medications to ensure they are safe for pregnancy. Start patient on prenatal vitamin if not taking and review general pregnancy recommendations for diet, exercise, and abstinence from substance use.
2. **Prenatal testing:** All pregnant adolescents should be tested for HIV, syphilis, hepatitis B, hepatitis C, chlamydia, and gonorrhea at the first prenatal visit. If an infection is suspected or if there may be a delay in obstetric care, the pediatrician should perform the testing.<sup>52</sup>
3. **Options counseling:** Counsel the adolescent on the importance of making a timely decision. The options depend on gestational age but may include continuing the pregnancy and raising the infant, continuing the pregnancy and making an adoption plan, or terminating the pregnancy. If a pediatrician has personal limitations in offering a discussion of all three options, they should make a prompt referral to a colleague or consultant. Medical and surgical abortion may be available depending on the gestational age of the pregnancy, coexisting medical conditions, and state laws. Medical abortion is generally available under 9 weeks of gestation; surgical abortion is generally available under 20 to 24 weeks of gestation.

4. **Complications:** First-trimester complications include ectopic pregnancy and spontaneous abortion; immediate obstetric referral may be indicated for abdominal pain and/or vaginal bleeding in the pregnant patient.

## VI. TRANSITIONING ADOLESCENTS INTO ADULT CARE<sup>94</sup>

All adolescents, particularly those with special healthcare needs or chronic conditions, benefit from careful attention to the process of transitioning to an adult model of care. Transition planning should routinely occur during well visits and should start at age 12. Resources for how to approach and organize the transition process, including guidance on transition readiness and planning, are available at <https://www.gottransition.org/>. See Chapter 9 for discussion of transition to adult care for youth with developmental disorders and disabilities.

## VII. WEB RESOURCES

### A. Websites for Clinicians

- Centers for Disease Control and Prevention (CDC) on contraception: <http://www.cdc.gov/reproductivehealth/unintendedpregnancy/contraception.htm>
- CDC on sexually transmitted infections (STI): <https://www.cdc.gov/std/life-stages-populations/adolescents-youngadults.htm>
- CDC Wall Chart, Quick Reference for STI Treatment: <https://www.cdc.gov/std/treatment-guidelines/wall-chart.pdf>
- Society for Adolescent Health and Medicine: <http://www.adolescenthealth.org>

### B. Websites for Patients

- Drug abuse: <http://www.teens.drugabuse.gov>
- Sexual health: <http://www.plannedparenthood.org/>, <http://www.bedsider.org>
- CDC resources for Lesbian, Gay, Bisexual, & Transgender (LGBT) youth: <https://www.cdc.gov/lgbthealth/youth-resources.htm>

## REFERENCES

A complete list of references can be found online.

## REFERENCES

1. World Health Organization. Adolescent health. Updated 2021. Accessed December 1, 2021. [https://www.who.int/health-topics/adolescent-health#tab=tab\\_1](https://www.who.int/health-topics/adolescent-health#tab=tab_1)
2. Sanders RA. Adolescent psychosocial, social, and cognitive development. *Pediatr Rev*. 2013;34(8):354–359.
3. Sawyer SM, Afifi RA, Bearinger LH, et al. Adolescence: a foundation for future health. *Lancet*. 2012;379(9826):1630–1640. Accessed December 1, 2021. <https://www.sciencedirect.com/science/article/pii/S0140673612600725>. [https://doi.org/10.1016/S0140-6736\(12\)60072-5](https://doi.org/10.1016/S0140-6736(12)60072-5)
4. Centers for Disease Control and Prevention. Preventing adverse childhood experiences. Updated 2021 Accessed December 1, 2021. <https://www.cdc.gov/violenceprevention/aces/fastfact.html>
5. Trent M, Dooley DG, Dougé J. The impact of racism on child and adolescent health. *Pediatrics*. 2019;144(2). Accessed December 1, 2021. <https://doi.org/10.1542/peds.2019-1765>
6. Ward JV. Raising resisters: the role of truth telling in the psychological development of African American girls. In: Leadbeater BJ, Way N, eds. *Urban Girls: Resisting Stereotypes, Creating Identities*. NYU Press; 1996:85–99.
7. Cheng TL, Savageau JA, Sattler AL, DeWitt TG. Confidentiality in health care: a survey of knowledge, perceptions, and attitudes among high school students. *JAMA*. 1993;269(11):1404–1407. <https://doi.org/10.1001/jama.1993.03500110072038>
8. Ford CA, English A. Limiting confidentiality of adolescent health services: what are the risks? *JAMA*. 2002;288(6):752–753. Accessed December 2, 2021. <https://doi.org/10.1001/jama.288.6.752>
9. 2021 recommendations for preventive pediatric health care. *Pediatrics (Evanston)*. 2021;147(3):e2020049776. <https://www.ncbi.nlm.nih.gov/pubmed/33593848>. <https://doi.org/10.1542/peds.2020-049776>
10. Tebb KP, Sedlander E, Pica G, et al. *Protecting Adolescent Confidentiality under Health Care Reform: The Special Case Regarding Explanations of Benefits (EOBs)*. San Francisco: Philip R. Lee Institute of Health Policy and Division of Adolescent and Young Adult Medicine, Department of Pediatrics, University of California; 2014.
11. Tanner MR. Preexposure prophylaxis for prevention of HIV acquisition among adolescents: clinical considerations, 2020. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*; 2020:69. Accessed December 1, 2021. <https://www.cdc.gov/mmwr/volumes/69/rr/rr6903a1.htm>. <https://doi.org/10.15585/mmwr.rr6903a1>
12. An overview of consent to reproductive health services by young People. Guttmacher Institute. Updated 2021. Accessed December 1, 2021. <https://www.guttmacher.org/state-policy/explore/overview-minors-consent-law>
13. Duty to Warn. Updated 2021. Accessed December 14, 2021. <https://www.cdc.gov/std/treatment/duty-to-warn.htm>
14. Public policy and action: laws in your state. Rape Abuse Incest National Network. Updated 2021. Accessed December 1, 2021. <https://rainn.org/public-policy-action>
15. Goldenring JM, Rosen DS. Getting into adolescent heads: an essential update. *Contemp Pediatr*. 2004;21(1):64–90.
16. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents—a follow-up of the Harvard growth

- study of 1922 to 1935. *N Engl J Med*. 327(19):1350–1355. <https://agris.fao.org/agris-search/search.do?recordID=US201301763810>
17. Hager ER, Quigg AM, Black MM, et al. Development and validity of a 2-item screen to identify families at risk for food insecurity. *Pediatrics (Evanston)*. 2010;126(1):e26–e32. <https://www.ncbi.nlm.nih.gov/pubmed/20595453>. <https://doi.org/10.1542/peds.2009-3146>
  18. Reid Chassiakos YL, Radesky J, Christakis D, Moreno MA, Cross C. Council on Communications and Media. Children and adolescents and digital media. *Pediatrics*. 2016;138(5):e20162593.
  19. Olson RD, Piercy KL, Troiano RP, et al. *Physical Activity Guidelines for Americans*. U.S. Department of Health and Human Services; 2018.
  20. Abuse, National Institute on Drug. *Monitoring the Future Survey 2020*. National Institute on Drug Abuse Web site; Updated 2020. Accessed Dec 1, 2021 <https://www.drugabuse.gov/drug-topics/trends-statistics/monitoring-future>
  21. Abuse, National Institute on Drug. *Stats & Trends in Teen Drug Use with Interactive Chart*. NIDA for Teens Web site; Updated 2019. Accessed Dec 1, 2021 <https://teens.drugabuse.gov/teachers/stats-trends-teen-drug-use>
  22. Ries RK, Fiellin DA, Miller SC, Saitz R. *The ASAM Principles of Addiction Medicine*. Wolters Kluwer; 2014. [https://ebookcentral.proquest.com/lib/\[SITE\\_ID\]/detail.action?docID=2035664](https://ebookcentral.proquest.com/lib/[SITE_ID]/detail.action?docID=2035664)
  23. Levy SJL, Williams JF. Substance use screening, brief intervention, and referral to treatment. *Pediatrics (Evanston)*. 2016;138(1):e20161211. <https://www.ncbi.nlm.nih.gov/pubmed/27325634>. <https://doi.org/10.1542/peds.2016-1211>
  24. Levy S, Weiss R, Sherritt L, et al. An electronic screen for triaging adolescent substance use by risk levels. *JAMA Pediatr*. 2014;168(9):822–828. <https://doi.org/10.1001/jamapediatrics.2014.774>
  25. Kelly SM, Gryczynski J, Mitchell SG, Kirk A, O’Grady KE, Schwartz RP. Validity of brief screening instrument for adolescent tobacco, alcohol, and drug use. *Pediatrics (Evanston)*. 2014;133(5):819–826. <https://www.ncbi.nlm.nih.gov/pubmed/24753528>. <https://doi.org/10.1542/peds.2013-2346>
  26. National Institute on Drug Abuse. *Screening Tools for Adolescent Substance Use*; Updated 2019. Accessed Dec 1, 2021 <https://www.drugabuse.gov/nidamed-medical-health-professionals/screening-tools-resources/screening-tools-adolescent-substance-use>
  27. Knight JR, Shrier LA, Bravender TD, Farrell M, Vander Bilt J, Shaffer HJ. A new brief screen for adolescent substance abuse. *Arch Pediatr Adolesc Med*. 1999;153(6):591–596. <https://doi.org/10.1001/archpedi.153.6.591>
  28. *Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health*. Center for Behavioral Health Statistics and Quality; 2020.
  29. *ASAM Criteria*. American Society of Addiction Medicine Web Site; Updated 2021. Accessed Dec 1, 2021 <https://www.asam.org/asam-criteria>
  30. Committee on Substance Use and Prevention. Medication-assisted treatment of adolescents with opioid use disorders. *Pediatrics (Evanston)*. 2016;138(3):e20161893. <https://www.ncbi.nlm.nih.gov/pubmed/27550978>. <https://doi.org/10.1542/peds.2016-1893>
  31. Killermann S. *The Genderbread Person v4.0*. *The Genderbread Person Web Site*; Updated 2017. Accessed Dec 3, 2021 <https://www.genderbread.org/>
  32. *A Guide to Taking a Sexual History*. Centers for Disease Control and Prevention; 2021. Accessed Dec 1, 2021 <https://www.cdc.gov/std/treatment/sexualhistory.htm>

33. Rafferty J, Section on Lesbian, Gay, Bisexual, and Transgender Health and Wellness, Yogman M, et al. Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. *Pediatrics*. 2018;142(4):e20182162. Accessed Dec 14, 2021. <https://doi.org/10.1542/peds.2018-2162>
34. World Professional Association for Transgender Health. *Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People*. 2012 [7th version].
35. Olson-Kennedy J, Rosenthal SM, Hastings J, Wesp L, University of California—San Francisco. *Health Considerations for Gender Non-conforming Children and Transgender Adolescents*; 2016. <https://transcare.ucsf.edu/guidelines/youth>
36. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2017;102(11):2869–3903.
37. Rafferty JR, Donaldson AA, Forcier M. Primary care considerations for transgender and gender-diverse youth. *Pediatr Rev*. 2020;41(9):437–454. <https://doi.org/10.1542/pir.2018-0194>. <https://search.proquest.com/docview/2439635257>
38. Ryan C, Russell ST, Huebner D, Diaz R, Sanchez J. Family acceptance in adolescence and the health of LGBT young adults. *J Child Adolesc*. 2010;23(4):205–213. <https://api.istex.fr/ark:/67375/WNG-WWKSHG4W-W/fulltext.pdf>. <https://doi.org/10.1111/j.1744-6171.2010.00246.x>
39. Johnson JG, Harris ES, Spitzer RL, Williams JBW. The patient health questionnaire for adolescents: Validation of an instrument for the assessment of mental disorders among adolescent primary care patients. *J Adolesc Health*. 2002;30(3):196–204. [https://doi.org/10.1016/S1054-139X\(01\)00333-0](https://doi.org/10.1016/S1054-139X(01)00333-0)
40. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092–1097.
41. Loades ME, Chatburn E, Higson-Sweeney N, et al. Rapid systematic review: the impact of social isolation and loneliness on the mental health of children and adolescents in the context of COVID-19. *J Am Acad Child Adolesc Psychiatry*. 2020;59(11):1218–1239.e3. <https://doi.org/10.1016/j.jaac.2020.05.009>
42. How the Pandemic Has Impacted Teen Mental Health. 2021P
43. Jindal M, Mistry KB, Trent M, McRae A, Thornton RLJ. Police exposures and the health and well-being of black youth in the US: a systematic review. *JAMA Pediatr*. 2021. <https://doi.org/10.1001/jamapediatrics.2021.2929>
44. Deleted in proofs.
45. Emans SJ, Laufer MR. *Emans, Laufer, Goldstein's Pediatric and Adolescent Gynecology*. Wolters Kluwer Health; 2012. <https://books.google.com/books?id=pdNh7ieMJzQC>
46. Joffe A. Introduction to adolescent medicine. In: McMillan JA, DeAngelis CD, Feigan RD et al., et al., eds. *Oski's Pediatrics: Principles and Practice*. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006:546–557.
47. Neinstein LS, et al. *Adolescent Health Care: A Practical Guide*. Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007.
48. Caring for patients who have experienced trauma: ACOG committee opinion, number 825. *Obstet Gynecol*. 2021;137(4):e94–e99. <https://www.ncbi.nlm.nih.gov/pubmed/33759830>. <https://doi.org/10.1097/AOG.0000000000004326>

49. Bates CK, Carroll N, Potter J. The challenging pelvic examination. *J Gen Intern Med*. 2011;26(6):651–657. <https://link.springer.com/article/10.1007/s11606-010-1610-8>. <https://doi.org/10.1007/s11606-010-1610-8>
50. Marcell AV, et al., et al. Male adolescent sexual and reproductive health care. *Pediatrics*. 2011;128(6):e1658–e1676.
51. Kaskowitz A, Quint E. A practical overview of managing adolescent gynecologic conditions in the pediatric office. *Pediatr Rev*. 2014;35(9):371–381.
52. Committee opinion no 534. Well-woman visit. *Obstet Gynecol*. 2012;120(2, Part 1):421–424. <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00006250-201208000-00041>. <https://doi.org/10.1097/AOG.0b013e3182680517>
53. ACOG committee opinion no. 754. The utility of and indications for routine pelvic examination. *Obstet Gynecol*. 2018;132(4):e174–e180. <https://doi.org/10.1097/AOG.0000000000002895>. <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00006250-201810000-00060>
54. Emmanuel PJ, Martinez J, Committee on Pediatric AIDS. American academy of pediatrics. adolescents and HIV infection: the pediatrician's role in promoting routine testing. *Pediatrics*. 2011;128(5):1023–1029.
55. Workowski K, Bachmann L, Chan P, et al. *Sexually Transmitted Infections Treatment Guidelines, 2021*. U.S. Department of Health and Human Services Centers for Disease Control and Prevention; 2021:1–135.
56. Papp JR, Schachter J, Gaydos C, Van Der Pol B. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae—2014. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*. 2014;63(No. RR-02).
57. U.S. Preventive Services Task Force. *Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement*. US Preventive Services Task Force; 2019.
58. U.S. Preventive Services Task Force. *Screening for chlamydia and Gonorrhea: US Preventive Services Task Force Recommendation Statement*. US Preventive Services Task Force; 2021.
59. Centers for Disease Control and Prevention. *Quick Reference Guide: Recommended Laboratory HIV Testing Algorithm for Serum or Plasma Specimens*; 2018. <https://stacks.cdc.gov/view/cdc/50872>
60. Upadhyia KK. Contraception for adolescents. *Pediatr Rev*. 2013;34(9):384–394.
61. Zurawin RK, Ayensu-Coker L. Innovations in contraception: a review. *Clin Obstet Gynecol*. 2007;50(2):425–439.
62. Kann L, McManus T, Harris WA, et al. Youth risk behavior surveillance—United States, 2017. *MMWR Surveill Summ*. 2018;67(No. SS-8):1–114.
63. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. *Contraception*. 2011;84(5):478–485.
64. Fang J, Husman C, DeSilva L, Chang R, Peralta L. Evaluation of self-collected vaginal swab, first void urine, and endocervical swab specimens for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in adolescent females. *J Pediatr Adolescent Gynecol*. 2008;21(6). <https://pubmed.ncbi.nlm.nih.gov/19064231/>
65. Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group. The American College of Obstetricians and Gynecologists. Adolescents and long-acting reversible contraception: implants and intrauterine devices. Committee opinion no. 735. *Obstet Gynecol*. 2018;131:e130–e139.

66. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*. 2016;65(4):1–66.
67. Centers for Disease Control and Prevention. *Contraceptive Guidance for Healthcare Providers*. US Medical Eligibility Criteria for Contraceptive Use, Combined Hormonal Contraceptives; 2016. <https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/appendixd.html>
68. Depot medroxyprogesterone acetate and bone effects. Committee opinion No. 602. American College of Obstetricians and Gynecologists. *Obstet Gynecol*. 2014;123:1398–1402.
69. McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. *Am J Obstet Gynecol*. 2017;216:586.e1–e6.
70. Berwald N, Cheng S, Augenbraun M, Abu-Lawi K, Lucchesi M, Zehtabchi S. Self-administered vaginal swabs are a feasible alternative to physician-assisted cervical swabs for sexually transmitted infection screening in the emergency department. *Acad Emerg Med*. 2009;16(3). <https://onlinelibrary.wiley.com/doi/10.1111/j.1553-2712.2009.00359.x>
71. Abma JC, Martinez GM. *Sexual Activity and Contraceptive Use Among Teenagers in the United States, 2011–2015*. U.S. Department of Health and Human Services Centers for Disease Control and Prevention; 2017:1–22.
72. Diedrich JT, Klein DA, Peipert JF. Long-acting reversible contraception in adolescents: a systematic review and meta-analysis. *Am J Obstet Gynecol*. 2017;216(4):364.e1–364.e12.
73. Ramdhan RC, Simonds E, Wilson C, Loukas MOR, Shane Tubbs R. Complications of subcutaneous contraception: a review. *Cureus*. 2018;10(1).
74. Trussell J. Contraceptive Failure in the United States. *Epub*. 2011;83(5):397–404.
75. Weisberg E, Hickey M, Palmer D, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in implanon users. *Hum Reprod*. 2009;24(8):1852–1861.
76. Wu JP, Pickle S. Extended use of the intrauterine device: a literature review and recommendations for clinical practice. *Contraception*. 2014;89:495–503.
77. Creinin MD, Jansen R, Starr RM, et al. Lovenorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system. *Contraception*. 2016;94:353–356.
78. Godfrey EM, et al. Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review. *Contraception*. 2013;87:549–566.
79. Schwallie PCAJ. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. *Contraception*. 1974;10(2).
80. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*. 2016;65(3):1–103, 2016.
81. Slynd (drospirenone tablets). *US FDA Approved Product Information*; Updated 2019. Accessed December 9, 2021 [www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/211367s000lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211367s000lbl.pdf)
82. Tepper NK, et al. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. *Contraception*. 2017;95(2):130–139.
83. Bird ST, Pepe SR, Etminan M, Liu X, Brophy JM, Delaney JA. The association between drospirenone and hyperkalemia: a comparative-safety study. *BMC Clin Pharmacol*. 2011.

84. on Adolescence C. Emergency contraception. *Pediatrics*. 2012;130(6):1174–1182.
85. Steiner M, Piedrahita C, Glover L, Joanis C, Spruyt A, Foldes R. The impact of lubricants on latex condoms during vaginal intercourse. *Int J STD AIDS*. 1994;5(1).
86. Glasier A. Emergency contraception: clinical outcomes. *Contraception*. 2013;309–313.
87. Thomas MA, Chappell BT, Maximos B, Culwell KR, Dart C, Howard B. A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial. *Contracept X*. 2020.
88. Turok DK, Gero A, Simmons RG, et al. Levonorgestrel vs. copper intrauterine devices for emergency contraception. *N Engl J Med*. 2021;384(4):335–344.
89. Haeger KO, Lamme J, Cleland K. State of emergency contraception in the U.S., 2018. *Contracept Reprod Med*. 2018;57(6).
90. Trussell J, Rodríguez G, Ellertson C. New estimates of the effectiveness of the yuzpe regimen of emergency contraception. *Contraception*. 1998;57(6).
91. Emergency contraception. *Practice Bulletin*. 2015;152.
92. Trussell J. Contraceptive failure in the United States. *Contraception*. 2011;83:397.
93. Hornberger LL, AAP Committee on Adolescence. Diagnosis of pregnancy and providing counseling options for the adolescent patient. *Pediatrics*. 2017;140(3):e2017227.
94. American Academy of Pediatrics. Clinical Report—Supporting the health care transition from adolescence to adulthood in the medical home. *Pediatrics*. 2011;128(1):182–200.
95. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. American Psychiatric Publishing; 2013.
96. Deutsch MB. *Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People*. San Francisco: University of California; 2016.
97. Olsen KR, Durwood L, DeMueles M, McLaughlin KA. Mental health of transgender children who are supported in their identities. *Pediatrics*. 2016;137(3):e20153223.
98. *The Primary Care Clinician's Source for Prevention Recommendations*. United States Preventive Services Task Force; 2021.
99. 2. Classification and diagnosis of diabetes: standards of medical care in Diabetes—2021. *Diabetes Care*. 2021;44(1):S15–S33. <https://search.proquest.com/docview/2486191610>. <https://doi.org/10.2337/dc21-S002>
100. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*. 2017;140(3):e20171904. <https://doi.org/10.1542/peds.2017-3035>. *Pediatrics (Evanston)*. 2017;140(6) <https://www.ncbi.nlm.nih.gov/pubmed/29192011>
101. American College of Obstetricians and Gynecologists. *Updated Cervical Cancer Screening Guidelines*; Updated 2021. Accessed Dec 2, 2021 <https://www.acog.org/en/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines>
102. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. *J Lower Genital Tract Dis*. 2020;24(2):102.

- 
103. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Subcommittee on screening and management of high blood pressure in children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*. 2017;140(3):e20171904. <https://doi.org/10.1542/peds.2017-1904>
  104. Infectious Disease Society of America, American Association for the Study of Liver Diseases. *HCV Testing and Linkage to Care*. Updated 2021. Accessed December 1, 2021. <https://www.hcvguidelines.org/evaluate/testing-and-linkage>

# Chapter 6

## Analgesia and Procedural Sedation

*Alexander James Jaksic, MD and  
Divya Madhusudhan, MD*

 See additional content online.

 **Audio Case File 6.1** Medications for analgesia and sedation

### I. TYPES OF PAIN

#### A. Definition

1. Pain can be defined as “An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage.”<sup>1</sup>
2. Pain can be classified as nociceptive or neuropathic.

#### B. Types of Pain: [Table 6.1](#)

### II. PAIN ASSESSMENT

#### A. Infant<sup>5</sup>

1. **Physiologic response**
  - a. Characterized by oxygen desaturation, crying, diaphoresis, flushing or pallor, and increases in blood pressure, heart rate, and respiratory rate
  - b. Seen primarily in acute pain; can subside with continuing/chronic pain
2. **Behavioral response**
  - a. Observe characteristics and duration of cry, facial expressions, visual tracking, body movements, and response to stimuli.
  - b. Neonatal Infant Pain Scale (NIPS): Behavioral assessment tool for the preterm neonate and full-term neonate up to 6 weeks after birth.
  - c. FLACC scale ([Table 6.2](#)): Measures and evaluates pain interventions by quantifying pain behaviors, including **F**acial expression, **L**eg movement, **A**ctivity, **C**ry, and **C**onsolability, with scores ranging from 0 to 10.<sup>6</sup> The Revised FLACC scale (r-FLACC) is reliable in children with cognitive impairment.<sup>7</sup>

#### B. Preschooler

1. In addition to physiologic and behavioral responses, the **FACES** pain scale revised (FPS-R) can be used to assess pain intensity in children as young as 3 years of age by having the patient point to the image on the scale that best characterizes their pain ([Fig. 6.1](#)).

**TABLE 6.1****TYPES OF PAIN**

Category <sup>2-4</sup>	Mechanism/Role	Common Clinical Features
Nociceptive	<p>An adaptive (protective) pain. Sensed by functional pain receptors (nociceptors) that respond to thermal, mechanical, or chemical stimuli (inflammation/tissue injury). Associated with physiologic processes and behaviors intended to benefit the affected individual.</p> <ul style="list-style-type: none"> <li>• Somatic pain: Injury to bones, joints, muscles, skin</li> <li>• Visceral pain: Pain from organs (bladder, bowel, ovaries/testes)</li> </ul>	<ul style="list-style-type: none"> <li>• Somatic: More easily localized. Stabbing, sharp, aching, throbbing, squeezing, “pressure-like”</li> <li>• Visceral: Poorly localized. Deep, diffuse. Dull, “gnawing,” crampy, achy</li> </ul>
Neuropathic/dysfunctional	<p>A maladaptive pain that provides no clear protective benefit. It is thought to be caused by damage to, or dysfunction of, sensory nerves. Can result from uncontrolled chronic nociceptive pain.</p> <ul style="list-style-type: none"> <li>• Neuropathic pain—Pain due to nerve injury. Commonly caused by compression, surgical transection, ischemia, or infiltration of nerve (i.e., neuropathy, neuromas, trigeminal and postherpetic neuralgia) or uncontrolled chronic pain.</li> <li>• Dysfunctional pain—Pain without known neurologic etiology. Related to abnormal processing of signals (i.e., fibromyalgia, irritable bowel syndrome, interstitial cystitis).</li> </ul>	<ul style="list-style-type: none"> <li>• Burning, shooting, shock-like, pins/needles, tingling</li> <li>• Frequently difficult to describe for patients</li> </ul>

**C. School-Age and Adolescent**

1. Evaluate physiologic and behavioral responses; ask about description, location, and character of pain. Starting at the age of 7 years, children can use the standard subjective pain rating scale, in which 0 is no pain and 10 is the worst pain ever experienced.


**D. Children With Significant Neurological Impairment (SNI)<sup>4</sup>**

1. Pain is often underrecognized and undertreated in children with SNI.
2. The behavioral responses to pain in children with SNI can be quite similar or disparate from pain responses in children without SNI. Having meaningful input from a consistent care provider who is familiar with the child’s baseline behaviors and responses to painful and nonpainful (such as hunger) stimuli is crucial.
3. Identifying observable pain behaviors in children with SNI: [Table 6.3](#)

**TABLE 6.2****FLACC PAIN ASSESSMENT TOOL**

<b>FACE</b>
0—No particular expression or smile 1—Occasional grimace or frown, withdrawn, disinterested 2—Frequent to constant frown, quivering chin, clenched jaw
<b>LEGS</b>
0—Normal position or relaxed 1—Uneasy, restless, tense 2—Kicking or legs drawn up
<b>ACTIVITY</b>
0—Lying quietly, normal position, moves easily 1—Squirming, shifting back and forth, tense 2—Arched, rigid, or jerking
<b>CRY</b>
0—No cry (awake or asleep) 1—Moans or whimpers, occasional complaint 2—Crying steadily, screams or sobs, frequent complaints
<b>CONSOLABILITY</b>
0—Content, relaxed 1—Reassured by occasional touching, hugging, or being talked to; distractible 2—Difficult to console or comfort

Modified from Manworren R, Hynan L. Clinical validation of FLACC: preverbal patient pain scale. *Pediatr Nurs.* 2003;29:140–146.

**FIGURE 6.1**

Wong-Baker FACES pain rating scale. (From Wong-Baker FACES Foundation. Wong-Baker FACES pain rating scale. 2016. Retrieved with permission from <http://www.WongBakerFACES.org>. Originally published in *Whaley & Wong's Nursing Care of Infants and Children*. Elsevier.)

- Pain assessment tools that incorporate the input of a parent or longitudinal caregiver such as the r-FLACC scale can be of great benefit to better identify and quantify pain and determine response to interventions provided.

**TABLE 6.3****OBSERVABLE PAIN BEHAVIORS IN CHILDREN WITH SNI**

Category	Examples
Vocalization	Crying, moaning, gasping, sharp intake of breaths
Facial Reaction	Grimacing, squinting, frowning, teeth grinding/clenched
Interaction	Inconsolable, withdrawn, seeking comfort
Sleep	Disturbed sleep, increased or decreased sleep
Activity/Tone	Increased baseline movement/tone, restless/fidgety, startles easily, pulls away when touched, twists or turns, posturing [arching/stiffening], resists motion
Physiologic	Tachycardia, shivering, color change/pallor, tears
Atypical Features	Breath holding, withdrawn/lack of facial expression, laughter, self-injurious behavior

From Hauer J, Houtrow AJ. Pain assessment and treatment in children with significant impairment of the central nervous system. Section on Hospice & Palliative Medicine Council on Children with Disabilities. *Pediatrics*. 2017 Jun.

- a. Like the FLACC, the r-FLACC scale is a 5-item pain assessment tool with a score ranging from 0 to 10. Constructed to allow parents to individualize by adding behaviors specific to their child, which can be particularly beneficial for children with atypical pain behaviors
- b. Sample r-FLACC scale<sup>8</sup> (Table 6.4)
  - (1) The descriptors in italics are validated in children with SNI.<sup>8</sup>
  - (2) Review descriptors in each category with family; assess if there are better indicators of pain in their child and incorporate them into the appropriate category.
  - (3) Observe child for 1–2 minutes (longer if asleep) with their legs/body uncovered. Observe activity or reposition child, if possible, to assess for tenseness and tone. Initiate consoling interventions if needed.

**III. ANALGESICS<sup>5</sup>****A. Medications to Avoid in Children**

1. Combined analgesics
  - a. Danger of acetaminophen toxicity when using combined opioid-acetaminophen products (oxycodone or hydrocodone with acetaminophen)
  - b. **Preferable to prescribe opioids and acetaminophen separately**
2. Codeine
  - a. **Not recommended for use in children**
  - b. Five percent of the population show ultra-rapid metabolism of codeine to morphine (the active metabolite), which can lead to dangerously high levels. This is especially unsafe after tonsillectomy and adenoidectomy (T&A) performed for sleep apnea.<sup>9</sup>
  - c. Little to no analgesic effect in newborns and approximately 10% of the US population.<sup>10</sup>

TABLE 6.4

R-FLACC SCALE<sup>a</sup>

Category	0	1	2
Face	<ul style="list-style-type: none"> <li>No particular expression or smile</li> </ul>	<ul style="list-style-type: none"> <li>Occasional grimace/frown; withdrawn or disinterested</li> </ul>	<ul style="list-style-type: none"> <li>Consistent grimace or frown; frequent/constant quivering chin, clenched jaw</li> <li><i>Distressed-looking face; expression of fright or panic</i></li> </ul> <p>Individual Behavior:</p>
Legs	<ul style="list-style-type: none"> <li>Normal position or relaxed</li> <li><i>Usual tone and motion to limbs</i></li> </ul>	<ul style="list-style-type: none"> <li>Uneasy, restless, tense</li> <li><i>Occasional tremors</i></li> </ul>	<ul style="list-style-type: none"> <li>Kicking, or legs drawn up</li> <li><i>Marked increase in spasticity, constant tremors or jerking</i></li> </ul> <p>Individual Behavior:</p>
Activity	<ul style="list-style-type: none"> <li>Lying quietly, normal position, moves easily</li> <li><i>Regular, rhythmic respirations</i></li> </ul>	<ul style="list-style-type: none"> <li>Squirming, shifting back and forth</li> <li><i>Tense or guarded movements; mildly agitated (head back and forth, aggression); shallow, splinting respirations, intermittent sighs</i></li> </ul>	<ul style="list-style-type: none"> <li>Arched, rigid or jerking</li> <li><i>Severe agitation; head banging; shivering (not rigors); breath holding, gasping or sharp intake of breaths, severe splinting</i></li> </ul> <p>Individual Behavior:</p>
Cry	<ul style="list-style-type: none"> <li>No cry/verbalization</li> </ul>	<ul style="list-style-type: none"> <li>Moans or whimpers; occasional complaint</li> <li><i>Occasional verbal outburst or grunt</i></li> </ul>	<ul style="list-style-type: none"> <li>Crying steadily, screams or sobs, frequent complaints</li> <li><i>Repeated outbursts, constant grunting</i></li> </ul> <p>Individual Behavior:</p>
Consolability	<ul style="list-style-type: none"> <li>Content and relaxed</li> </ul>	<ul style="list-style-type: none"> <li>Reassured by occasional touching, hugging or being talked to. Distractible</li> </ul>	<ul style="list-style-type: none"> <li>Difficult to console or comfort</li> <li><i>Pushing away caregiver, resisting care/comfort measures</i></li> </ul> <p>Individual Behavior:</p>

<sup>a</sup>Italicized text in above table indicates the additional or revised aspects of the r-FLACC scale compared to the FLACC scale.

3. Meperidine
  - a. Not recommended for use in children due to risk of neurotoxicity (agitation, tremors, myoclonus, and seizures), especially when renal dysfunction is present.<sup>11</sup>
  - b. Contraindicated in patients receiving monoamine oxidase (MAO) inhibitors.
4. Tramadol
  - a. Opioid pain reliever, with additional effects on nonopioid receptors.
  - b. May be overmetabolized to an active opiate metabolite, resulting in potentially fatal respiratory depression.
  - c. In 2017 the FDA issued its strongest warning against use in children; therefore, administration is considered off label.<sup>12</sup>

### B. Nonopioid Analgesics

Weak analgesics with antipyretic activity are commonly used to manage mild to moderate pain of nonvisceral origin. Can be administered alone or in combination with opioids.

1. **Acetaminophen (by mouth [PO]/per rectum [PR]/intravenous [IV]):** Weak analgesic with no antiinflammatory activity, platelet inhibition, or gastrointestinal (GI) irritation. Hepatotoxicity can occur with high doses.
2. **Aspirin (PO/PR):** Associated with platelet inhibition and GI irritation. Avoid use as analgesia in children due to risk of Reye syndrome.
3. **Nonsteroidal antiinflammatory drugs (NSAIDs):** Ibuprofen (PO/IV), ketorolac (IV/intramuscular [IM]/PO/intranasal [IN]), naproxen (PO), diclofenac (PO/IV), and celecoxib (PO)
  - a. Use with extreme caution in children less than 6 months of age due to concern for adverse GI effects and risk of renal failure.
  - b. Especially useful for sickle cell disease and pain of bony, rheumatic, or inflammatory etiology.
  - c. Concurrent histamine-2-receptor blocker or proton pump inhibitor is recommended with prolonged use given GI side effects.
  - d. Other adverse effects include interference with platelet aggregation, hepatitis, bronchoconstriction, hypersensitivity reactions, and azotemia. Avoid in patients with severe renal disease, dehydration, or heart failure.

**NOTE:** Ketorolac is a potent analgesic. Limit duration of therapy to less than 5 days to minimize renal toxicity.

### C. Opioids (Table 6.5)

Produce analgesia by binding to  $\mu$  receptors in the brain and spinal cord.

1. **Side effects:** Pruritus, nausea, vomiting, constipation, urine retention, sedation, respiratory depression and hypotension. Prescribe a bowel regimen when prescribing opioids.
2. **Patients with renal failure**
  - a. **Morphine:** Avoid use. Decreased excretion of the active metabolite may result in respiratory depression.
  - b. **Preferred choices:** Fentanyl, remifentanyl, methadone, hydromorphone, oxycodone

TABLE 6.5

## COMMONLY USED OPIOIDS

Drug	Morphine Equivalence Ratio	Onset (min)	Duration (hr)	Side Effects	Comments
Fentanyl	80–100	IV: 1–2	0.5–1	Pruritus Bradycardia <b>Chest wall rigidity with doses &gt;5 mCg/kg</b> (but can occur at all doses); treat with naloxone or neuromuscular blockade.	Risk of cardiovascular instability is lower than other opioids, making it relatively safer in hypovolemia, congenital heart disease, or head trauma. Respiratory depressant effect much longer (4 hr) than analgesic effect Most commonly used opioid for short, painful procedures, but transdermal route is more effective in chronic pain <sup>a</sup>
Hydromorphone	4–7	IV/SQ: 5–10 PO: 30–60	3–4		Less sedation, nausea, and pruritus than morphine
Methadone	0.25–1 <sup>b</sup>	IV: 5–10 PO: 30–60	4–24		Initial dose may produce analgesia for 3–4 hr; duration of action is increased with repeated dosing. Useful for neuropathic pain and opioid weaning due to unique mechanism of NMDA blockade
Morphine	1	IV: 5–10 IM/SQ: 10–30 PO: 30–60	IV: 3–4 IM/SQ/PO: 4–5	Seizures in neonates Can cause significant histamine release	Available in sustained-release form for chronic pain
Oxycodone	1.5	30–60	3–4		Available in sustained-release form for chronic pain

<sup>a</sup>Removing a transdermal fentanyl patch does not stop opioid uptake from the skin; fentanyl will continue to be absorbed for 12–24 hours after patch removal (fentanyl 25 mCg patch administers 25 mCg/hr of fentanyl).

<sup>b</sup>Morphine-to-methadone conversion in the tolerant/dependent patient is variable. Consider starting at the lowest conversion ratio: 0.25.

IM, Intramuscular; IV, intravenous; mCg, microgram; PO, by mouth; SQ, subcutaneous.

Data from Yaster M, Cote C, Krane E, et al. *Pediatric Pain Management and Sedation Handbook*. Mosby; 1997:29–50.

3. Long-acting opioids, such as extended-release tablets, transdermal patches, and PO methadone, are not recommended for acute pain management.
4. Although opioids are essential for the treatment of moderate to severe pain, a thoughtful approach is recommended with the quantity that is dispensed, as studies have shown that over 50% of opioid doses dispensed are not consumed.<sup>13</sup> There is need for further research to develop evidence-based opioid prescribing guidelines for treating acute pain in children.

#### D. Local Anesthetics<sup>14–17</sup>

Administered topically or subcutaneously to surround peripheral nerves (peripheral block) or centrally (epidural/spinal block). Temporarily block nerve conduction at the sodium channel.

1. **For all local anesthetics, 1% solution = 1 g/100 mL = 10 mg/mL**
2. **Topical local anesthetics (Table 6.6)<sup>17</sup>**
3. **Injectable local anesthetics (Table 6.7):**
  - a. Subcutaneous infiltration of the skin at the site: Used for painful procedures such as wound closure or lumbar puncture
  - b. Use of a 27- to 30-gauge needle, alkalization, warming the solution to 37°C to 42°C, and a slow injection can reduce stinging from injection. Alkalinize by adding 1 mL (1 mEq [milliequivalent]) sodium bicarbonate to 9 mL lidocaine (or 29 mL bupivacaine).
  - c. To enhance efficacy and duration, add epinephrine (5 to 10 mCg of epinephrine to 1 mL of local anesthetic) to decrease vascular uptake. **Never use local anesthetics with epinephrine in areas supplied by end arteries (e.g., pinna, fingers, toes, nasal tip, penis).**
  - d. **Maximum volume (mL) = (maximum mg/kg dose × weight in kg)/(% solution × 10).** See Table 6.7 for maximum doses.
  - e. **Toxicity:** Central nervous system (CNS) and cardiac toxicity are of greatest concern. CNS symptoms are seen before cardiovascular collapse. Calculate the maximum volume of the local anesthetic and always draw up less than that. Bupivacaine is associated with more severe cardiac toxicity than lidocaine.
    - (1) Progression of symptoms: Perioral numbness → dizziness → auditory disturbances → muscular twitching → loss of consciousness → seizures → coma → respiratory arrest → cardiovascular collapse
    - (2) Summary of American Society of Regional Anesthesia and Pain Medicine (ASRA) Checklist for Treatment of Local Anesthetic Systemic Toxicity (LAST) (Fig. 6.2)<sup>18</sup>
    - (3) If concerned for systemic toxicity, contact an anesthesiologist and call Poison Control (1-800-222-1222).

#### E. Nonpharmacologic Measures of Pain Relief<sup>19,20</sup>

1. **Sucrose for neonates (Sweet-Ease):**
  - a. Indications: Painful minor procedures (heel lance, venipuncture, and intramuscular injection) in neonates and infants. Has not been shown to be effective for relief of circumcision pain. Strongest evidence for

TABLE 6.6

## COMMONLY USED TOPICAL LOCAL ANESTHETICS

	Components	Indications	Peak Effect	Duration <sup>a</sup>	Cautions
EMLA	Lidocaine 2.5% Prilocaine 2.5%	Intact skin only Venipuncture, circumcision, LP, abscess drainage, BMA	60 min	90 min	Methemoglobinemia: Not for use in patients predisposed to methemoglobinemia (e.g. G6PD deficiency) Infants <3 months of age: Use sparingly (up to 1 g is safe)
LMX	Lidocaine 4%	Same as EMLA	30 min	60 min	Same as EMLA
LET	Lidocaine 4% Epinephrine 0.1% Tetracaine 0.5% Can be mixed with cellulose to create a gel	Safe for nonintact skin/lacerations Can be used to attain hemostasis with simple lacerations	30 min	45 min	Vasoconstriction: Contraindicated in areas supplied by end arteries (e.g., pinna, nose, penis, digits) Avoid contact with mucous membranes Not for use in contaminated wounds
Viscous lidocaine	Lidocaine 2% (May be mixed with aluminum/magnesium hydroxide/simethicone [Maalox] and diphenhydramine in a 1:1:1 ratio for palatability when administered orally)	Safe for nonintact skin Mucous membranes (e.g., urethral catheter placement, mucositis)	10 min	30 min	Overuse can lead to life-threatening toxicity Not to be used for teething

<sup>a</sup>Approximate.

BMA, Bone marrow aspiration; EMLA, eutectic mixture of local anesthetics; G6PD, glucose-6-phosphate dehydrogenase; LP, lumbar puncture; min, minutes.

Data from Krauss B, Green SM. Sedation and analgesia for procedures in children. *N Engl J Med*. 2000;342:938–945; Zempsky W, Cravero J. Relief of pain and anxiety in pediatric patients in emergency medical systems. *Pediatrics*. 2004;114:1348–1356.


**TABLE 6.7**  
**COMMONLY USED INJECTABLE LOCAL ANESTHETICS**

Agent	Concentration (%) <sup>a</sup>	Max Dose (mg/kg)	Onset (min)	Duration (hr)
Lidocaine	0.5–2	5	3	0.5–2
Lidocaine with epinephrine	0.5–2	7	3	1–3
Bupivacaine	0.25–0.75	2.5	15	2–4
Bupivacaine with epinephrine	0.25–0.75	3	15	4–8
Bupivacaine with lidocaine mixture	Variable	<sup>b</sup>	3–15	0.5–4

<sup>a</sup>1% solution = 10 mg/mL.

<sup>b</sup> $[(\text{mg/kg used of bupivacaine})/2.5 \text{ mg/kg} \times 100] + [(\text{mg/kg used of lidocaine})/5 \text{ mg/kg} \times 100]$ . **Toxicity occurs when the sum is >100%.**

Data from St Germain BA. The management of pain in the emergency department. *Pediatr Clin North Am.* 2000;47:651–679; Yaster M, Cote C, Krane E, et al. *Pediatric Pain Management and Sedation Handbook* Mosby; 1997:51–72.



**FIGURE 6.2**

Checklist for Treatment of Local Anesthetic Systemic Toxicity (LAST). (From American Society of Regional Anesthesia and Pain Medicine. Local Anesthetic Systemic Toxicity Checklist. 2020. [https://www.asra.com/images/default-source/asra-products/local-anesthetic-systemic-toxicity-rgb.jpg?sfvrsn=61e2f4b3\\_3](https://www.asra.com/images/default-source/asra-products/local-anesthetic-systemic-toxicity-rgb.jpg?sfvrsn=61e2f4b3_3))

infants less than 1 month old,<sup>19</sup> but additional evidence suggests efficacy up to 12 months.<sup>20</sup>

- b. Procedure: Administer up to 2 mL of 24% sucrose into the infant's mouth by syringe or from a nipple/pacifier ~2 minutes before the procedure. Effective doses in very low-birth-weight infants may be as low as 0.05 to 0.1 mL.
  - c. An additional dose may be administered within a relatively short period of time for multiple procedures, but it should not be administered more than twice in 1 hour.
  - d. Use with other age-appropriate nonpharmacologic measures.
  - e. Avoid if patient is unable to appropriately feed by mouth or cannot safely handle oral secretions.
2. **Other:** Parental presence/holding, distraction with toys, child life specialists, guided meditation/coping skills, virtual reality simulations, hot or cold packs.

#### IV. PATIENT-CONTROLLED ANALGESIA (PCA)

##### A. Definition

1. PCA enables a patient to receive a limited number of small bolus doses of an analgesic with or without a continuous (basal) infusion on an as-needed basis. In children younger than 6 years old or with physical/mental disability, a family member, caregiver, or nurse may administer bolus doses.
2. Practitioner specifies: Dose, minimum time period between doses (lockouts), basal infusion rate, maximum dose per hour.

##### B. Indications

1. Moderate to severe pain of acute or chronic nature. Commonly used in sickle cell disease, postsurgery, posttrauma, burns, and cancer
2. Useful for preemptive pain management (e.g., dressing changes)

##### C. Routes of Administration

1. IV
2. Epidural: This route should be prescribed and managed by an anesthesiologist.

##### D. Agents (Table 6.8)

**TABLE 6.8**

**ORDERS FOR PATIENT-CONTROLLED ANALGESIA**

Drug	Basal Rate (mCg/kg/hr)	Bolus Dose (mCg/kg)	Lockout Period (min)	Boluses (hr)	Max Dose (mCg/kg/hr)
Morphine	10–30	10–30	6–10	4–6	100–150
Hydromorphone	3–5	3–5	6–10	4–6	15–20
Fentanyl	0.5–1	0.5–1	6–10	2–3	2–4

mCg, Microgram.

Data from Yaster M, Cote C, Krane E, et al. *Pediatric Pain Management and Sedation Handbook* Mosby; 1997:100.

### E. Adjuvants

1. Low-dose **naloxone** (Narcan) infusion reduces incidence of pruritus and nausea associated with narcotic administration.
2. Low-dose **ketamine** infusion is an analgesic with a narcotic sparing effect. It is especially helpful in chemotherapy-induced mucositis, visceral pain, and neuropathic pain. Its mechanism of action is by N-methyl-D-aspartate (NMDA) blockade. May be used with, or as an alternative to, methadone.

### F. Side Effects of Opioid Patient-Controlled Analgesia

1. Please refer to III. Analgesics; C. Opioids; 2. Side Effects

## V. OPIOID TAPERING

### A. Indications

1. Because of the development of dependence and potential for withdrawal, a tapering schedule is required if the patient has received frequent opioid analgesics for >5 days.

### B. Withdrawal

1. See [Box 18.1](#) for symptoms of opioid withdrawal.
2. Onset of signs and symptoms: 6 to 12 hours after the last dose of morphine and 36 to 48 hours after the last dose of methadone
3. Duration: 7 to 14 days, with a peak intensity reached within 2 to 4 days

### C. Recommendations for Tapering

1. **Conversion:** All drugs should be converted to a single equianalgesic member of that group (see [Table 6.5](#)).
2. **PCA wean:** Drug dosing should be changed from continuous/intermittent IV infusion to PO basal/bolus therapy. If the patient is on PCA, once the first PO dose is administered, the PCA basal infusion should be stopped 30 to 60 minutes later. PCA bolus doses should be continued but reduced by 25% to 50%. If no further bolus doses are administered in the next 6 hours, the PCA should be discontinued. If the patient continues to experience pain, consider increasing scheduled PO dose, administering a rescue one-time PO bolus dose, or adding an adjuvant analgesic (e.g., NSAID).
3. **Slow dose decrease:** During an intermittent IV/PO wean, the total daily dose should be decreased by 10% to 20% of the original dose every 1 to 2 days (e.g., to taper a morphine dose of 40 mg/day, decrease the daily dose by 4 to 8 mg every 1 to 2 days).
4. **Oral regimen:** If not done previously, IV dosing should be converted to equivalent PO administration 1 to 2 days before discharge, and titration should be continued as outlined previously.
5. **Adjunctive therapy:**
  - a. **Clonidine** in combination with an opioid decreases the length of time needed for opioid weaning in neonatal abstinence syndrome, with few short-term side effects. Long-term safety has yet to be thoroughly

investigated, but follow-up after 1 year on motor, cognitive, and language scores showed no difference in those treated with clonidine.<sup>21,22</sup>

- b. PO and transdermal clonidine have a potential role for sedation, analgesia, and iatrogenic drug withdrawal in critically ill children, but current reports are retrospective or small clinical trials with significant heterogeneity in dosing, so further research is necessary. Transdermal dosing should not be used in children aged <1 year due to altered skin absorption.<sup>23</sup>
- c. Studies have shown efficacy of  $\alpha_2$ -adrenergic agonists in treating opioid withdrawal and reducing doses of methadone, but the duration of treatment was longer with  $\alpha_2$ -adrenergic agonists, and there were fewer adverse effects with methadone.<sup>24</sup>
- d. **Dexmedetomidine** is an  $\alpha_2$ -adrenoreceptor agonist, which produces sedation and mild analgesia, with minimal to no respiratory depression. Administered as a continuous infusion, it has been shown to reduce opioid requirements and facilitate opioid weaning.

## 6. Examples

- a. See eBox 6.1 for example of opioid wean.

## VI. PROCEDURAL SEDATION<sup>5,14–17,25–27</sup>

### A. Definitions

1. **Mild sedation (anxiolysis):** Intent is anxiolysis with maintenance of consciousness.
2. **Moderate sedation:** Formerly known as *conscious sedation*. A controlled state of depressed consciousness during which airway reflexes and patency are maintained. Patient responds appropriately to age-appropriate commands (e.g., “Open your eyes”) and light touch. This level of sedation often obtained with a combination of a low-dose sedative-hypnotic and an analgesic.
3. **Deep sedation:** A controlled state of depressed consciousness during which *airway reflexes and patency may not be maintained*, though cardiovascular function is usually maintained. The child will have purposeful response to repeated or painful stimulation. In practice, deep sedation is required for most painful procedures in children. This level of sedation may be achieved with propofol or a combination of a sedative-hypnotic and an analgesic agent.
4. **Dissociative sedation:** Unique state of sedation achieved with ketamine characterized by a deep level of depressed consciousness and analgesia. Airway reflexes and patency are generally maintained; however, excessive oral secretions may become problematic, occasionally resulting in micro-aspiration or laryngospasm.

### B. Preparation

1. The patient should be **NPO** (nothing by mouth) for solids and liquids (Table 6.9).<sup>25</sup> Per American Society of Anesthesiologists (ASA) and American Academy of Pediatrics (AAP) guidelines, children receiving

**eBOX 6.1**

**EXAMPLES OF OPIOID TAPERING**

Patient on morphine patient-controlled analgesia (PCA) to be converted to oral (PO) morphine with home weaning.

For example: morphine PCA basal rate = 2 mg/hr, average bolus rate = 0.5 mg/hr

Step 1: Calculate daily dose: basal + bolus =  $(2 \text{ mg/hr} \times 24 \text{ hr}) + (0.5 \text{ mg/hr} \times 24 \text{ hr}) = 60 \text{ mg}$  intravenous (IV) morphine

Step 2: Convert according to drug potency: morphine IV/morphine oral = approx. 3:1 potency;  $3 \times 60 \text{ mg} = 180 \text{ mg}$  PO morphine

Step 3: Prescribe 90 mg BID or 60 mg TID; wean 10%–20% of original dose (30 mg) every 1–2 days

*BID*, Twice daily; *IV*, intravenous; *mg*, milligram; *PCA*, patient-controlled analgesia; *PO*, by mouth; *TID*, three times daily.

Data from Yaster M, Cote C, Krane E, et al. *Pediatric Pain Management and Sedation Handbook*. Mosby; 1997:29–50.

**TABLE 6.9****FASTING RECOMMENDATIONS FOR ANESTHESIA**

Food Type	Minimum Fasting Period (hr)
Clear liquids	2
Breast milk	4
Nonhuman milk, formula	6
Solids	8


Data from *Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration: Application to Healthy Patients Undergoing Elective Procedures*. A report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and Use of Pharmacological Agents to Reduce the Risk of Pulmonary Aspiration. <https://anesthesiology.pubs.asahq.org/article.aspx?articleid=1933410>

moderate sedation for elective procedures should follow the same fasting guidelines as those for general anesthesia.<sup>26,28</sup> For urgent/emergent sedation when children are not NPO, the risks of sedation and possible aspiration must be balanced against the benefits of performing the procedure promptly. Recent studies suggest that NPO status for liquids and solids may not be statistically associated with aspiration, although studies are limited because aspiration is a relatively uncommon complication.<sup>29</sup>


## 2. Focused patient history:

- a. Allergies, medications, and any history of a previous reaction to anesthesia or sedation
- b. Assess for the possibility of an adverse airway event occurring with sedation (e.g., hypoxemia, hypercarbia, inability to mask ventilate). This can occur from: (1) mechanical airway obstruction (micrognathia, tonsillar and/or adenoid hypertrophy, large tongue, history of snoring, presence of noisy breathing, diagnosis of obstructive sleep apnea, obesity, presence of a craniofacial syndrome), (2) lung disease (history of prematurity, chronic lung disease, asthma), or (3) presence of a recent upper respiratory infection (URI). A history of a URI increases the risk of laryngospasm and/or bronchospasm; therefore, one must weigh the risks/benefits of providing sedation after a recent URI versus need for immediate interventional procedure. For elective procedures requiring sedation, it is best to wait 2 to 4 weeks after resolution of illness to reduce the risk of an adverse event.<sup>30</sup>
  - (1) There is currently insufficient data regarding how long to wait after symptomatic COVID-19 infection before undergoing an elective procedure.
- c. Assess aspiration risk (neuromuscular disease, esophageal disease, altered mental status, obesity, pregnancy).
- d. Presence of kidney/liver disease (may prolong sedative effect) and cardiac disease (potential for hemodynamic instability with sedative administration)

3. **Physical examination:** Specific attention to mouth opening and neck extension. Use the Mallampati classification system to assess the airway for likelihood of difficult direct laryngoscopy and intubation (Fig. 6.3).
4. **Determine ASA Physical Status Classification** (Table 6.10): Class I and II patients are generally good candidates for mild, moderate, or deep sedation outside of the operating room.<sup>26</sup>
5. **Always have an emergency plan ready:**
  - a. Make sure qualified backup personnel and equipment are close by.




Grade I



Grade II



Grade III



Grade IV

**FIGURE 6.3**

Mallampati classification system.

TABLE 6.10

## ASA PHYSICAL STATUS CLASSIFICATION

Class I	A normally healthy patient
Class II	A patient with mild systemic disease (e.g., controlled reactive airway disease)
Class III	A patient with severe systemic disease (e.g., a child who is actively wheezing)
Class IV	A patient with severe systemic disease that is a constant threat to life (e.g., a child with status asthmaticus)
Class V	A moribund patient who is not expected to survive without the operation (e.g., a patient with severe cardiomyopathy requiring heart transplantation)
Class VI	A declared brain-dead patient whose organs are being removed for donor purposes

- b. Complications most often occur 5 to 10 minutes after administration of IV medication and immediately after a procedure is completed (when the stimuli associated with the procedure are removed).<sup>16</sup>
6. **Personnel:** Two providers are required. One provider should perform the procedure, and a separate provider should monitor the patient during sedation and recovery.
7. **Ensure IV access** prior to induction by flushing with saline. Subcutaneous infiltration of a sedative can cause unpredictable or prolonged sedation.
8. **Have airway/intubation equipment immediately available** (see [Chapter 1](#)).
9. **Emergency medications:** Always have emergency medications for rapid sequence intubation and CPR immediately available.
10. **Reversal agents** should be readily available (naloxone, flumazenil).

### C. Monitoring<sup>31</sup>

1. **Vital signs:** Baseline vital signs should be obtained. The following should be monitored throughout sedation:
  - a. Oxygenation: Continuous pulse oximetry with variable pitch pulse tone and audible low threshold alarm
  - b. Circulation: Continuous EKG, with arterial blood pressure and heart rate evaluated at least every 5 minutes
  - c. Ventilation: Frequent evaluation of respiratory rate and airway patency (via direct visualization and auscultation) during any sedation, and continuous capnography (end-tidal carbon dioxide [CO<sub>2</sub>]) during moderate or deep sedation
    - (1) Unrecognized apnea is often followed by desaturation within 1 to 2 minutes when not receiving supplemental oxygenation. Administration of supplemental oxygen can further delay recognition of apnea because the onset of desaturation may occur more than 2 minutes after apnea.

## D. Pharmacologic Agents

1. **Goal of procedural sedation:** The administration of medications to provide appropriate levels of analgesia, sedation, and anxiolysis so that the procedure can occur without the need to secure the airway.
2. **CNS, cardiovascular, and respiratory depression** may always occur; occurs more commonly when combining sedative drugs and/or opioids, or with rapid drug administration. It is always best to titrate medications to the desired level of sedation.
3. **Common sedative/hypnotic agents (Box 6.1).** Also see [Table 6.5](#) and [Table 6.11](#) for more information on opioids, barbiturates, and benzodiazepines.

### BOX 6.1

#### PROPERTIES OF COMMON SEDATIVE/HYPNOTIC AGENTS

##### Sedating Antihistamines (Diphenhydramine, Hydroxyzine)

- Mild sedative-hypnotics with antiemetic and antipruritic properties; used for sedation and treatment of opioid side effects
- No anxiolytic or analgesic effects

##### Barbiturates

- Contraindicated in patients with porphyria
- Suitable only for nonpainful procedures
- Not reversible with flumazenil
- Narrower margin of safety than benzodiazepines
- No anxiolytic or analgesic effects

##### Benzodiazepines

- Reversible with flumazenil
- Anxiolytic effects; no analgesic effects

##### Opioids

- Reversible with naloxone
- Analgesic effects; no anxiolytic effects

##### Ketamine<sup>5,15–19</sup>

- Causes potent dissociative amnesia and analgesia
- Nystagmus indicates likely therapeutic effect
- Vocalizations/movement may occur even with adequate sedation
- Onset: IV, 0.5–2 min; IM, 5–10 min; PO/PR, 20–45 min
- Duration: IV, 20–60 min; IM, 30–90 min; PO/PR, 60–120+ min
- **CNS effects:** Emergence delirium with auditory, visual, and tactile hallucinations
- **Cardiovascular effects:** Inhibits catecholamine reuptake, thereby causing increased HR, BP, SVR, and PVR. Rarely causes hemodynamic instability; however, in catecholamine-deplete patients (e.g., shock) it can cause direct myocardial depression and hypotension.
- **Respiratory effects:** Bronchodilation (useful in patients with asthma), increased secretions (can result in laryngospasm), maintenance of ventilatory response to hypoxia, relative maintenance of airway reflexes

**BOX 6.1—CONT'D**

- **Other effects:** Increased muscle tone, myoclonic jerks, nausea, emesis
- **Contraindications:** Hypertension and preexisting psychotic disorders
  - Controversy exists on its safety in patients with elevated ICP or IOP. Evidence suggesting ketamine elevates intracranial pressure or causes harm in these patients is limited.

**Propofol**

- For deep sedation or general anesthesia
- Administered as single or multiple IV boluses ± infusion
- Rapid onset and brief recovery (5–15 min) with bolus administration
- Can have antiemetic and euphoric effects
- **Caution:** Respiratory depression, apnea, hypotension
- No analgesic effects

**Dexmedetomidine**<sup>32-36</sup>

- $\alpha_2$  agonist
- Sedative, anxiolytic, and analgesic effects
- Administration
  - IV: load over 10 min followed by infusion
  - Intranasal: administered via drops or atomizer, no IV access required, plasma levels theoretically equal to IV dose
- Slower onset of action compared to other IV sedative-hypnotics
- Favorable due to low risk of respiratory depression, decreased irritability/agitation during recovery
- Can cause hypotension (with initial bolus), hypertension (with high doses, multiple boluses), and bradycardia (avoid in patients on atrioventricular nodal blocking medications)

Data from Yaster M, Cote C, Krane E, et al. *Pediatric Pain Management and Sedation Handbook* Mosby; 1997:376–382; St Germain BA. The management of pain in the emergency department. *Pediatr Clin North Am.* 2000;47:651–679; Cote CJ, Lerman J, Todres ID, et al. *A Practice of Anesthesia for Infants and Children.* WB Saunders; 2001.

4. Reversal agents:
  - a. Naloxone: Opioid antagonist. See [Box 6.2](#) for naloxone administration protocol.
  - b. Flumazenil: Benzodiazepine antagonist.

**E. Discharge Criteria**<sup>26</sup>

1. The patient can maintain a patent airway without requiring supplemental oxygen. There should also be no compromise in cardiovascular function.
2. The patient should be easily arousable with intact protective airway reflexes (swallow, cough, and gag).
3. The patient should have the ability to talk and sit up unaided (if age appropriate). Alternatively, for very young or intellectually disabled children, the goal is to return to their presedation level of responsiveness.
4. Ensure ability to maintain adequate hydration (i.e., the patient can tolerate enteral fluids).

TABLE 6.11

COMMONLY USED BENZODIAZEPINES<sup>a</sup> AND BARBITURATES

Drug Class	Duration of Action	Drug	Route	Onset (min)	Duration (hr)	Comments
Benzodiazepines	Short	Midazolam (Versed)	IV	1–3	1–2	Has rapid and predictable onset of action, short recovery time
			IM/IN	5–10		Causes amnesia
			PO/PR	10–30		Results in mild depression of hypoxic ventilatory drive
	Intermediate	Diazepam (Valium)	IV (painful)	1–6	0.25–1	Poor choice for procedural sedation
			PR	7–15		Excellent for muscle relaxation or prolonged sedation
			PO	30–60		Pain on IV injection
	Long	Lorazepam (Ativan)	IV	1–5	3–4	Poor choice for procedural sedation
IM			10–20	Ideal for prolonged anxiolysis, seizure treatment		
PO			30–60			
Barbiturates	Short	Methohexital	PR <sup>b</sup>	5–10	0.5–1.5	PR form used as sedative for nonpainful procedure
	Intermediate	Pentobarbital	IV	1–10	1–4	Predictable sedation and immobility for nonpainful procedures
			IM	5–15	2–4	Minimal respiratory depression when used alone
			PO/PR	15–60	2–4	Associated with slow wake up and agitation

<sup>a</sup>Use IV solution for PO, PR, and IN administration. Rectal diazepam gel (Diastat) is also available.

<sup>b</sup>IV administration produces general anesthesia; only PR should be used for sedation.

IM, Intramuscular; IN, intranasal; IV, intravenous; min, minute; PO, by mouth; PR, per rectum.

Data from Yaster M, Cote C, Krane E, et al. *Pediatric Pain Management and Sedation Handbook* Mosby; 1997:345–374; St Germain BA. The management of pain in the emergency department. *Pediatr Clin North Am*. 2000;47:651–679; Cote CJ, Lerman J, Todres ID, et al. *A Practice of Anesthesia for Infants and Children*. WB Saunders; 2001.

**BOX 6.2****NALOXONE (NARCAN) ADMINISTRATION<sup>a</sup>****Indications: Patients Requiring Naloxone (Narcan) Usually Meet All the Following Criteria**

- Shallow respirations or respiratory rate <8 breaths/min<sup>b</sup>
- Pinpoint pupils
- Unresponsive to physical stimulation

**Procedure**

1. **Stop opioid administration** (as well as other sedative drugs), assess **ABCs** (**A**irway, **B**reathing, **C**irculation), and **call for help**.
2. **Dilute naloxone:**
  - a. If child >40 kg: Mix 0.4 mg (1 ampule) of naloxone with 9 mL of normal saline (final concentration 0.04 mg/mL = 40 mCg/mL).
  - b. If child <40 kg: Mix 0.4 mg (1 ampule) of naloxone with 9 mL of normal saline to make a concentration of 40 mCg/mL (as above). **Then, repeat dilution** by mixing 1 mL of the 40 mCg/mL solution with 9 mL of normal saline for final concentration of 4 mCg/mL.
3. **Administer and observe response:** Administer dilute naloxone *slowly* (1–2 mCg/kg/dose IV over 2 minutes). Observe patient response.
4. **Titrate to effect:** Within 1–2 minutes, patient should open eyes and respond. If not, continue until a total dose of 10 mCg/kg is given. If no response is obtained, evaluate for other cause of sedation/respiratory depression.
5. **Discontinue naloxone administration:** Discontinue naloxone as soon as patient responds (e.g., takes deep breaths when directed).
6. **Caution:** Another dose of naloxone may be required within 30 min of first dose (duration of action of naloxone is shorter than that of most opioids).
7. **Monitor patient:** Assign a staff member to monitor sedation/respiratory status and remind patient to take deep breaths as necessary.
8. **Alternative analgesia:** Provide nonopioids for pain relief. Resume opioid administration at half the original dose when the patient is easily aroused, and respiratory rate is >9 breaths/min.

<sup>a</sup>Naloxone administration for patients being treated for pain. Higher doses may be necessary for patients found in the community or those with signs of cardiopulmonary failure. Please see Formulary for additional dosing.

<sup>b</sup>Respiratory rates that require naloxone vary according to infant's/child's usual rate.

Modified from McCaffery M, Pasero C. *Pain: Clinical Manual*. Mosby; 1999:269–270.

**F. Examples of Sedation Protocols (Table 6.12 and eTable 6.1)**

eTABLE 6.1

## SUGGESTED ANALGESIA AND SEDATION PROTOCOLS

Pain Threshold	Procedure	Suggested Choices
Nonpainful	CT/MRI/EEG/ECHO	Midazolam <sup>a</sup> Dexmedetomidine <sup>b,c</sup>
Mild	Phlebotomy/IV	EMLA
	LP	EMLA ( $\pm$ midazolam), lidocaine
	Pelvic exam	Midazolam
	Minor laceration, well vascularized	LET
	Minor laceration, not well vascularized	Lidocaine
Moderate	BM aspiration	EMLA ( $\pm$ midazolam)
	Arthrocentesis	Lidocaine (local) for cooperative child or ketamine for uncooperative child
	Fracture reduction	Ketamine
	Major laceration	Ketamine or fentanyl + midazolam
	Burn debridement	Ketamine or fentanyl + midazolam
	Dentistry	Dexmedetomidine <sup>b,c</sup> Dexmedetomidine + fentanyl
	Venous cannulation	Dexmedetomidine <sup>b,c</sup> Dexmedetomidine + fentanyl
	Long procedures (>30 min)	Consider general anesthesia
Severe	Fracture reduction	Ketamine
	Long procedures (>30 min)	Consider general anesthesia

<sup>a</sup>Consult with neurologist prior to administering a benzodiazepine for sedation during EEG.

<sup>b</sup>Kost S, Roy A. Procedural sedation and analgesia in the pediatric emergency department: a review of sedative pharmacology. *Clin Pediatr Emerg Med.* 2010;11:233.

<sup>c</sup>Lewis J, Bailey CR. Intranasal dexmedetomidine for sedation in children; a review. *J Perioper Pract.* 2020 Jun;30(6):170–175. <https://doi.org/10.1177/1750458919854885>. Epub 2019 Jun 27. PMID: 31246159.

BM, Bone marrow; CT, computed tomography; ECHO, echocardiogram; EEG, electroencephalogram; EMLA, eutectic mixture of local anesthetics; LP, lumbar puncture; LET, lidocaine, epinephrine, tetracaine; MRI, magnetic resonance imaging.

Modified from Yaster M, Cote C, Krane E, et al. *Pediatric Pain Management and Sedation Handbook* Mosby; 1997:551–552.

**TABLE 6.12****EXAMPLES OF SEDATION PROTOCOLS**

Protocol/Doses	Comments
Ketamine × 1–3 doses	Lowest rates of adverse events when ketamine used alone <sup>a</sup>
Ketamine + midazolam + atropine (“ketazolam”)	Atropine = antisialagogue Midazolam = counters emergence delirium
Ketamine × 1–3 doses Midazolam × 1 dose Atropine × 1 dose	Can be given IM or IV. If giving IM, combine all 3 agents in 1 syringe (using the smallest volume possible, preferably <3 mL total).
Midazolam + fentanyl	High likelihood of respiratory depression
Midazolam × 3 doses PRN Fentanyl × 3 doses PRN	Give fentanyl no more frequently than every 3 min Risk of rigid chest—give no faster than 1 mCg/kg/min
Dexmedetomidine	Can be given IN or IV Risk of hypotension, hypertension, and bradycardia with bolus

<sup>a</sup>Green SM, Roback MG, Krauss B, et al. Predictors of emesis and recovery agitation with emergency department ketamine sedation: an individual-patient data meta-analysis of 8,282 children. *Ann Emerg Med.* 2009;54:171–180.

IM, Intramuscular; IN, intranasal; IV, intravenous; mCg, microgram; PRN, as needed.

Modified from Yaster M, Cote C, Krane E, et al. *Pediatric Pain Management and Sedation Handbook*. Mosby; 1997.

**VII. WEB RESOURCES**

- International Association for the Study of Pain: <http://childpain.org/>
- American Pain Society: <https://painmed.org/>
- American Society of Anesthesiologists: <http://www.asahq.org/>

**REFERENCES**

A complete list of references can be found online.

## REFERENCES

1. International Association for the Study of Pain. IASP taxonomy. <https://www.iasp-pain.org/Taxonomy>
2. Woolf CJ. What is this thing called pain? *J Clin Invest*. 2010;120(11):3742–3744. <https://doi.org/10.1172/JCI45178>
3. Walters ET. Adaptive mechanisms driving maladaptive pain: how chronic ongoing activity in primary nociceptors can enhance evolutionary fitness after severe injury. *Philos Trans R Soc Lond B Biol Sci*. 2019;374(1785):20190277. PMID: 31544606; PMCID: PMC6790390. <https://doi.org/10.1098/rstb.2019.0277>
4. Hauer J, Houtrow AJ. Pain assessment and treatment in children with significant impairment of the central nervous system. Section on Hospice & Palliative Medicine Council on Children with Disabilities. *Pediatrics*. 2017;139(6):e20171002. <https://doi.org/10.1542/peds.2017-1002>
5. Yaster M, Cote C, Krane E, et al. *Pediatric Pain Management and Sedation Handbook*. Mosby; 1997.
6. Manworren R, Hynan L. Clinical validation of FLACC: preverbal patient pain scale. *Pediatr Nurs*. 2003;29:140–146.
7. Malviya S, Voepel-Lewis T. The revised FLACC observational pain tool: improved reliability and validity for pain assessment in children with cognitive impairment. *Paediatr Anaesth*. 2006;16:258–265.
8. Malviya S, Voepel-Lewis T, Burke C, et al. The revised FLACC Observational Pain Tool: improved reliability and validity for pain assessment in children with cognitive impairment. *Pediatric Anesthesia*. 2006;16:258–265.
9. FDA Drug Safety Communication. Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/ or adenoidectomy. Published February 2013. <https://www.fda.gov/media/85072/download>
10. Wong C, Lau E, Palozzi L, Campbell F. Pain management in children: part 2a transition from codeine to morphine for moderate to severe pain in children. *Can Pharm J (Ott)*. 2012;145(6):276–279. e1. <https://doi.org/10.3821/145.6.cpj276>
11. Benner KW, Durham SH. Meperidine restriction in a pediatric hospital. *J Pediatr Pharmacol Ther*. 2011;16(3):185–190.
12. Jenco M. FDA issues warning on tramadol use in those under age 17. *AAP News*. 2015;22.
13. Monitto CL, Hsu A, Gao S, et al. Opioid prescribing for the treatment of acute pain in children on hospital discharge. *Anesth Analg*. 2017;125:2113.
14. Yaster M, Maxwell LG. Pediatric regional anesthesia. *Anesthesiology*. 1989;70:324–338.
15. St Germain BA. The management of pain in the emergency department. *Pediatr Clin North Am*. 2000;47:651–679.
16. Krauss B, Green S. Procedural sedation and analgesia in children. *Lancet*. 2006;367:766–780.
17. Fein J, Zempsky W, Cravero J. Relief of pain and anxiety in pediatric patients in emergency medical systems. *Pediatrics*. 2012;130(5):e1391–e1405. <https://doi.org/10.1542/peds.2012-2536>
18. Neal JM, Neal EJ, Weinberg GL. American Society of Regional Anesthesia and Pain Medicine Local Anesthetic Systemic Toxicity checklist: 2020 version. *Reg Anesth Pain Med*. 2021;46:81–82.
19. Stevens B, Yamada J, Ohlsson A, et al. Sucrose for analgesia in newborn infants undergoing painful procedures. *Cochrane Database Syst Rev*. 2016;7:CD001069. <https://doi.org/10.1002/14651858.CD001069.pub5>

20. Kassab M, Foster JP, Foureur M, Fowler C. Sweet-tasting solutions for needle-related procedural pain in infants one month to one year of age. *Cochrane Database Syst Rev*. 2012;12:CD008411. <https://doi.org/10.1002/14651858.CD008411.pub2>
21. Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. *Pediatrics*. 2009;123:e849–e856.
22. Bada HS, Sithisarn T, Gibson J, et al. Morphine versus clonidine for neonatal abstinence syndrome. *Pediatrics*. 2015;135:e383.
23. Capino AC, Miller JL, Johnson PN. Clonidine for sedation and analgesia and withdrawal in critically ill infants and children. *Pharmacotherapy*. 2016;36:1290–1299. <https://doi.org/10.1002/phar.1850>
24. Gowing L, Farrell M, Ali R, White JM. Alpha-adrenergic agonists for the management of opioid withdrawal. *Cochrane Database Syst Rev*. 2016;5:CD002024. <https://doi.org/10.1002/14651858.CD002024.pub5>
25. Coté CJ, Lerman J, Anderson B. *A Practice of Anesthesia for Infants and Children*. 6th ed. Elsevier; 2019.
26. Coté C, Wilson S. Guidelines for monitoring and management of pediatric patients before, during, and after sedation for diagnostic and therapeutic procedures: update 2019. *Pediatrics*. 2019:e20191000. <https://doi.org/10.1542/peds.2019-1000>
27. Practice guidelines for sedation and analgesia by non-anesthesiologists. *Anesthesiology*. 2002;96:1004–1017.
28. Practice guidelines for moderate procedural sedation and analgesia 2018. *Anesthesiology*. 2018;128(3):437–479. <https://doi.org/10.1097/aln.0000000000002043>
29. Beach ML, Cohen DM, Gallagher SM, et al. Major adverse events and relationship to nil per os status in pediatric sedation/anesthesia outside the operating room: a report of the pediatric sedation research consortium. *Anesthesiology*. 2016;124(1):80–88.
30. Mallory MD, Travers C, McCracken CE, et al. Upper respiratory infections and airway adverse events in pediatric procedural sedation. *Pediatrics*. 2017:140.
31. American Society of Anesthesiologists. Standards for basic anesthetic monitoring. Published Dec 13, 2020. From <https://www.asahq.org/standards-and-guidelines/standards-for-basic-anesthetic-monitoring>
32. Sulton C, McCracken C, Simon HK, et al. Pediatric procedural sedation using dexmedetomidine: a report from the Pediatric Sedation Research Consortium. *Hosp Pediatr*. 2016;6:536.
33. Mason KP, Zurakowski D, Zgleszewski S, et al. Incidence and predictors of hypertension during high-dose dexmedetomidine sedation for pediatric MRI. *Paediatr Anaesth*. 2010;20:516.
34. Berkenbosch JW, Tobias JD. Development of bradycardia during sedation with dexmedetomidine in an infant concurrently receiving digoxin. *Pediatr Crit Care Med*. 2003;4:203.
35. Hammer GB, Drover DR, Cao H, et al. The effects of dexmedetomidine on cardiac electrophysiology in children. *Anesth Analg*. 2008;106:7.
36. Lewis J, Bailey CR. Intranasal dexmedetomidine for sedation in children; a review. *J Perioper Pract*. 2020 Jun;30(6):170–175. Epub 2019 Jun 27. PMID: 31246159. <https://doi.org/10.1177/1750458919854885>

# Chapter 7

## Cardiology

*Alexander Tang, MD and James Ting, MD*

 See additional content online.

 **Audio Case File 7.1** Auscultation and heart sounds

 **Audio Case File 7.2** Tetralogy of Fallot: Review of the congenital heart disease and accompanying cardiac surgeries

### I. PHYSICAL EXAMINATION

#### A. Heart Rate

Refer to the first page of this book for normal heart rate (HR) by age.

#### B. Blood Pressure

1. Blood pressure (BP):

See [Chapter 19](#) for normal BP values by age.

2. **Mean arterial pressure (MAP)**

a.  $\text{MAP} = \text{diastolic pressure} + 1/3 \text{ pulse pressure}$  OR  $\text{MAP} = 1/3 \text{ systolic pressure} + 2/3 \text{ diastolic pressure}$

b. Preterm infants and newborns: Normal MAP = gestational age in weeks

3. Abnormalities in BP

a. Four-limb BP measurements can be used to assess for coarctation of the aorta.

b. Pulsus paradoxus: Exaggeration of the normal drop in systolic blood pressure (SBP) with inspiration. Determine SBP at the end of exhalation and during inhalation; difference >10 mmHg, consider pericardial effusion, tamponade, pericarditis, severe asthma, or restrictive cardiomyopathies.

4. Hypertension (HTN)

a. See [Chapter 1](#) for management of acute HTN.

b. See [Chapter 19](#) for screening, workup, and management of chronic HTN.

#### C. Heart Sounds

1. **S<sub>1</sub>**: Associated with closure of mitral and tricuspid valves; heard best at the apex or left lower sternal border (LLSB)

2. **S<sub>2</sub>**: Associated with closure of pulmonary and aortic valves; heard best at the left upper sternal border (LUSB) and has normal physiologic splitting that increases with inspiration

3. **S<sub>3</sub>**: Heard best at the apex or LLSB

4. **S<sub>4</sub>**: Heard at the apex

#### D. Systolic and Diastolic Sounds

See [Box 7.1](#) for abnormal heart sounds.<sup>1</sup>

## E. Murmurs

Clinical characteristics are summarized in [Table 7.1](#).<sup>1</sup>

1. **Grading of heart murmurs:** Intensified by states of higher cardiac output (e.g., anemia, anxiety, fever, exercise)<sup>1</sup>
  - a. Grade I: Barely audible
  - b. Grade II: Murmur softer than heart sounds, but audible
  - c. Grade III: Murmur moderately loud, equally loud as heart sounds, not accompanied by a thrill
  - d. Grade IV: Murmur louder than heart sounds, associated with a thrill
  - e. Grade V: Audible with a stethoscope barely on the chest
  - f. Grade VI: Audible with a stethoscope off the chest
2. Benign heart murmurs<sup>2</sup>:
  - a. Caused by a disturbance of the laminar flow of blood; frequently produced as the diameter of the blood's pathway decreases and velocity increases
  - b. Present in >80% of children sometime during childhood, most commonly beginning at age 3 to 4 years
  - c. Accentuated in high-output states, especially with fever and anemia
  - d. Normal electrocardiogram (ECG) and radiographic findings

**NOTE:** ECG and chest radiograph are not routinely used, nor are they cost-effective screening tools for distinguishing benign from pathologic murmurs.

### BOX 7.1

#### SUMMARY OF ABNORMAL HEART SOUNDS

- **Widely split S<sub>1</sub>:** Ebstein anomaly, RBBB
- **Widely split and fixed S<sub>2</sub>:** Right ventricular volume overload (e.g., ASD, PAPVR), pressure overload (e.g., PS), electrical delay in RV contraction (e.g., RBBB), early aortic closure (e.g., MR), occasionally heard in normal child
- **Narrowly split S<sub>2</sub>:** Pulmonary hypertension, AS, delay in LV contraction (e.g., LBBB), occasionally heard in normal child
- **Single S<sub>2</sub>:** Pulmonary hypertension, one semilunar valve (e.g., pulmonary atresia, aortic atresia, truncus arteriosus), P<sub>2</sub> not audible (e.g., TGA, TOF, severe PS), severe AS, occasionally heard in normal child
- **Paradoxically split S<sub>2</sub>:** Severe AS, LBBB, Wolff-Parkinson-White syndrome (type B)
- **Abnormal intensity of P<sub>2</sub>:** Increased P<sub>2</sub> (e.g., pulmonary hypertension), decreased P<sub>2</sub> (e.g., severe PS, TOF, TS)
- **S<sub>3</sub>:** Occasionally heard in healthy children or adults or may indicate dilated ventricles (e.g., large VSD, CHF)
- **S<sub>4</sub>:** Always pathologic, indicative of decreased ventricular compliance
- **Ejection click:** Heard with stenosis of the semilunar valves, dilated great arteries in the setting of pulmonary or systemic HTN, idiopathic dilation of the PA, TOF, persistent truncus arteriosus
- **Midsystolic click:** Heard at the apex in mitral valve prolapse
- **Diastolic opening snap:** Rare in children; associated with TS/MS

AS, Aortic stenosis; ASD, atrial septal defect; CHF, congestive heart failure; LBBB, left bundle-branch block; LV, left ventricle; MR, mitral regurgitation; MS, mitral stenosis; PA, pulmonary artery; PAPVR, partial anomalous pulmonary venous return; PS, pulmonic stenosis; RBBB, right bundle-branch block; RV, right ventricular; TGA, transposition of the great arteries; TOF, tetralogy of fallot; TS, tricuspid stenosis; VSD, ventricular septal defect.

Modified from Park MK. *Pediatric Cardiology for Practitioners*. 5th ed. Elsevier; 2008:25.

TABLE 7.1

## COMMON INNOCENT HEART MURMURS

Type (Timing)	Description of Murmur	Age Group
Classic vibratory murmur (Still murmur; systolic)	Maximal at LMSB or between LLSB and apex Grade 2–3/6 in intensity Low-frequency vibratory, twanging string, groaning, squeaking, or musical	3–6 years; occasionally in infancy
Pulmonary ejection murmur (systolic)	Maximal at LUSB Early to midsystolic Grade 1–3/6 in intensity Blowing in quality	8–14 years
Pulmonary flow murmur of newborn (systolic)	Maximal at LUSB Transmits well to left and right chest, axilla, and back Grade 1–2/6 in intensity	Premature and full- term newborns Usually disappears by 3–6 months
Venous hum (continuous)	Maximal at right (or left) supraclavicular and infraclavicular areas Grade 1–3/6 in intensity Inaudible in supine position Intensity changes with rotation of head and disappears with compression of jugular vein	3–6 years
Carotid bruit (systolic)	Right supraclavicular area over carotids Grade 2–3/6 in intensity Occasional thrill over carotid	Any age

LLSB, Left lower sternal border; LMSB, left middle sternal border; LUSB, left upper sternal border.

From Park MK. *Pediatric Cardiology for Practitioners*. 5th ed. Elsevier; 2008:36.

3. **A murmur is more likely to be pathologic when one or more of the following are present:** Symptoms (e.g., chest pain, dyspnea with exertion, syncope with exertion); cyanosis; a systolic murmur that is loud (grade  $\geq 3/6$ ), harsh, pansystolic, or long in duration; diastolic murmur; abnormal heart sounds; presence of a click; abnormally strong or weak pulses<sup>1,2</sup>
4. Systolic and diastolic heart murmurs (Box 7.2)

## II. ELECTROCARDIOGRAPHY

### A. Basic Electrocardiography Principles

1. Lead placement (Fig. 7.1)
2. ECG complexes
  - a. P wave: Represents atrial depolarization
  - b. QRS complex: Represents ventricular depolarization
  - c. T wave: Represents ventricular repolarization
  - d. U wave: May follow the T wave and represents late phases of ventricular repolarization

**BOX 7.2****SYSTOLIC AND DIASTOLIC HEART MURMURS****RUSB**

Aortic valve stenosis (supravalvular, subvalvular)

*Aortic regurgitation*

**LUSB**

Pulmonary valve stenosis

Atrial septal defect

Pulmonary ejection murmur, innocent

Pulmonary flow murmur of newborn

Pulmonary artery stenosis

Aortic stenosis

Coarctation of the aorta

Patent ductus arteriosus

Partial anomalous pulmonary venous return (PAPVR)

Total anomalous pulmonary venous return (TAPVR)

*Pulmonary regurgitation*

**LLSB**

Ventricular septal defect, including atrioventricular septal defect

Vibratory innocent murmur (Still murmur)

HOCM (IHSS)

Tricuspid regurgitation

Tetralogy of Fallot

*Tricuspid stenosis*

**Apex**

Mitral regurgitation

Vibratory innocent murmur (Still murmur)

Mitral valve prolapse

Aortic stenosis

HOCM (IHSS)

*Mitral stenosis*

Murmurs listed by the location at which they are best heard. *Diastolic murmurs are in italics.*


*HOCM*, Hypertrophic obstructive cardiomyopathy; *IHSS*, idiopathic hypertrophic subaortic stenosis; *LLSB*, left lower sternal border; *LUSB*, left upper sternal border; *RUSB*, right upper sternal border.

From Park MK. *Pediatric Cardiology for Practitioners*. 5th ed. Elsevier; 2008:30.

### 3. Systematic approach for evaluating ECGs (Table 7.2 shows normal ECG parameters)<sup>1,3</sup>:

#### a. Rate

- (1) Standardization: Paper speed is 25 mm/sec. One small square = 1 mm = 0.04 second. One large square = 5 mm = 0.2 second. Amplitude standard: 10 mm = 1 mV
- (2) Calculation: HR (beats/min) = 60 divided by the average R-R interval in seconds, or 300 divided by the number of large boxes between 2 R waves (1 large box = 300 bpm, 2 large boxes = 150 bpm) (Fig. 7.2)



**FIGURE 7.1**

(A) Hexaxial reference system. (B) Horizontal reference system. (Modified from Park MK, Guntheroth WG. *How to Read Pediatric ECGs*. 4th ed. Elsevier; 2006:3.)

b. **Rhythm**

- (1) Sinus rhythm: Every QRS complex is preceded by a P wave and normal P-wave axis (upright P in leads I and aVF).
- (2) There is normal respiratory variation of the R-R interval without morphologic changes of the P wave or QRS complex.

c. **Axis:** The direction of the QRS in leads I and aVF should be observed, the quadrant determined, and comparison made with age-matched normal values (Fig. 7.3 and Table 7.2).

d. **Intervals** (PR, QRS, QTc)

- (1) See Table 7.2 for normal PR and QRS intervals.
- (2) The QTc is calculated using the Bazett formula:  

$$\text{QTc} = \text{QT (sec) measured} / \sqrt{\text{R-R}}$$
 (use the shortest R-R interval on the ECG measured in lead II or V<sub>5</sub>).
- (3) The QT interval (in seconds) is measured from the beginning of the QRS complex to the end of the T wave. Divide this value by the square root of the preceding R-R interval (also measured in seconds) to obtain the QTc.
- (4) **Normal values for QTc are:**
  - (a) 0.44 second is the 97th percentile for infants 3 to 4 days old.<sup>4</sup>
  - (b) ≤0.45 second in all males aged >1 week and in prepubescent females
  - (c) ≤0.46 second for postpubescent females

e. **P-wave size and shape:** A normal P wave duration should be <0.09 second (2.5 small boxes) in children and <0.07 second (2 small boxes) in infants. Normal P wave amplitude (height) is <0.3 mV (3 mm or 3 small boxes in height, with normal standardization).

f. **R-wave progression:** In general, there is a normal increase in R-wave size and a decrease in S-wave size from leads V<sub>1</sub> to V<sub>6</sub> (with dominant S waves in the right precordial leads V<sub>1</sub>, V<sub>2</sub> and dominant R waves in the left precordial leads V<sub>4</sub>, V<sub>5</sub>, representing dominance of left

TABLE 7.2


## NORMAL PEDIATRIC ELECTROCARDIOGRAM PARAMETERS

Age	Heart Rate (bpm)	QRS Axis <sup>a</sup>	PR Interval (sec) <sup>b</sup>	QRS Duration (sec) <sup>b</sup>	Lead V <sub>1</sub>			Lead V <sub>6</sub>		
					R-Wave Amplitude (mm) <sup>b</sup>	S-Wave Amplitude (mm) <sup>b</sup>	R/S Ratio	R-Wave Amplitude (mm) <sup>b</sup>	S-Wave Amplitude (mm) <sup>b</sup>	R/S Ratio
0–7 days	95–160 (125)	+30 to +180 (+110)	0.10 (0.12)	0.05 (0.07)	13 (24)	7 (18)	1.5	5 (15)	3 (10)	2
1–3 weeks	105–180 (145)	+30 to +180 (+110)	0.10 (0.12)	0.05 (0.07)	13 (24)	7 (18)	1.5	5 (15)	3 (10)	2
1–6 months	110–180 (145)	+10 to +125 (+70)	0.10 (0.14)	0.055 (0.075)	10 (19)	5 (15)	1.5	13 (22)	3 (9)	4
6–12 months	110–170 (135)	+10 to +125 (+60)	0.10 (0.14)	0.055 (0.075)	10 (20)	7 (18)	1.2	13 (23)	2 (7)	6
1–3 years	90–150 (120)	+10 to +125 (+60)	0.11 (0.14)	0.055 (0.075)	9 (18)	8 (21)	0.8	13 (23)	2 (7)	20
4–5 years	72–135 (108)	+20 to +120 (+60)	0.13 (0.17)	0.06 (0.075)	8 (16)	11 (23)	0.65	15 (26)	2 (5)	20
6–8 years	65–135 (100)	+20 to +120 (+60)	0.13 (0.17)	0.06 (0.075)	8 (16)	11 (23)	0.65	15 (26)	2 (5)	20
9–11 years	65–130 (90)	+20 to +120 (+60)	0.15 (0.18)	0.06 (0.085)	5 (12)	12 (25)	0.5	17 (26)	1 (4)	20
12–16 years	60–120 (85)	+20 to +120 (+60)	0.15 (0.19)	0.07 (0.085)	4 (10)	11 (22)	0.3	14 (23)	1 (4)	10
>16 years	60–100 (80)	+30 to +105 (+50)	0.15 (0.21)	0.08 (0.10)	3 (14)	10 (23)	0.3	10 (21)	1 (13)	9


<sup>a</sup>Normal range and (mean).

<sup>b</sup>Mean and (98th percentile).

Data from Park MK, Salamat M. *Pediatric Cardiology for Practitioners*. 7th ed. St Louis: Elsevier; 2021; and Davignon A, et al. Normal ECG standards for infants and children. *Pediatr Cardiol*. 1979;1:123–131.


**FIGURE 7.2**

Calculation of approximate heart rate.

**FIGURE 7.3**

Location of quadrants of the mean QRS axis from leads I and aVF. (From Park MK, Guntheroth WG. *How to Read Pediatric ECGs*. 4th ed. Elsevier; 2006:17.)

- ventricular forces. However, newborns and infants have a normal dominance of the right ventricle and therefore larger R waves in  $V_1, V_2$ , and smaller R waves in  $V_5, V_6$ .
- g. **Q waves:** Normal Q waves are usually  $<0.04$  second in duration and  $<25\%$  of the total QRS amplitude. Normal Q waves are  $\leq 5.5$  mm deep in the left precordial leads  $V_4, V_5$  and aVF in children  $>3$  years of age, and  $\leq 6$  mm deep in lead III for children age  $<3$  years. Q waves of  $>0.04$  second duration are likely pathologic. Excessively deep Q waves in III,  $V_5$ , and  $V_6$  may indicate left ventricular hypertrophy.
- h. **ST-segment (Fig. 7.4):** ST-segment elevation or depression of  $>1$  mm in two contiguous limb leads and  $>2$  mm in two contiguous precordial leads ( $V_1-V_6$ ) is consistent with myocardial ischemia or injury. Diffuse ST elevation of  $<1$  mm in the limb leads and  $<2$  mm in the precordial leads may indicate early repolarization, which is a normal variant.
- i. **T wave:**
- (1) Inverted T waves in  $V_1$  and  $V_2$  can be normal in children up to adolescence (Table 7.3).
  - (2) Tall, peaked T waves may be seen in hyperkalemia. A normal T wave is less than one-half the amplitude of its corresponding R wave.<sup>1,3</sup>
  - (3) Flat or low T waves may be seen in hypokalemia, hypothyroidism, normal newborns, myocardial/pericardial ischemia, and inflammation.

**FIGURE 7.4**

Nonpathologic (nonischemic) and pathologic (ischemic) *ST* and *T* changes. (A) Characteristic nonischemic *ST*-segment alteration called *J*-depression (note that *ST* slope is upward), B to C. Ischemic or pathologic *ST*-segment alterations: (B) downward slope of *ST* segment; (C) horizontal segment is sustained. (From Park MK, Guntheroth WG. *How to Read Pediatric ECGs*. 4th ed. Elsevier; 2006:107.)

**TABLE 7.3****NORMAL T-WAVE AXIS**

Age	V <sub>1</sub> , V <sub>2</sub>	AVF	I, V <sub>5</sub> , V <sub>6</sub>
Birth to 1 day	±	+	±
1–4 days	±	+	+
4 days to adolescent	–	+	+
Adolescent to adult	+	+	+

+, *T* wave positive; –, *T* wave negative; ±, *T* wave normally either positive or negative.

j. **Hypertrophy/enlargement**

- (1) Atrial enlargement: *P* wave duration exceeding these norms may indicate left atrial enlargement. *P* wave amplitude greater than 3 mm may indicate right atrial enlargement (Fig. 7.5).
- (2) Ventricular hypertrophy: Diagnosed by *QRS* axis, voltage, and *R/S* ratio (Box 7.3; see also Table 7.4).

**B. ECG Abnormalities**


1. **Nonventricular arrhythmias** (Table 7.4; Fig. 7.6)<sup>5</sup>
2. **Ventricular arrhythmias** (Table 7.5; Fig. 7.7)
3. **Nonventricular conduction disturbances** (Table 7.6; Fig. 7.8)<sup>6</sup>
4. **Ventricular conduction disturbances** (Table 7.7)

**C. ECG Findings Secondary to Electrolyte Disturbances, Medications, and Systemic Illnesses** (Table 7.8)<sup>5,7</sup>

**D. Long QT**

1. **Diagnosis:**

- a. In general, normal QTc is similar in males and females from 6 months until late adolescence (0.37 to 0.44). In newborns and small infants, the upper limit is 0.47 in the first week and 0.45 in the first 6 months.
- b. In adults, prolonged QTc is generally >0.45 second in males and >0.46 second in females after adolescence.
- c. In ~10% of cases, patients may have a normal baseline QTc. Patients may also have a family history of long QT associated with

**FIGURE 7.5**

Criteria for atrial enlargement (From Park MK, Guntheroth WG: *How to Read Pediatric ECGs*, 4th ed. Philadelphia, Mosby, 2006.)

**BOX 7.3****VENTRICULAR HYPERTROPHY CRITERIA****Right Ventricular Hypertrophy (RVH) Criteria**

Must have at least one of the following:

- Upright T wave in lead  $V_1$  after 3 days of age to adolescence
- Presence of Q wave in  $V_1$  (QR or QRS pattern)
- Increased right and anterior QRS voltage (with normal QRS duration):
  - R in lead  $V_1$ ,  $V_2$ , or aVR  $>98$ th percentile for age
  - S in lead  $V_6$ ,  $>98$ th percentile for age
- Right ventricular strain (associated with inverted T wave in  $V_1$  with tall R wave)

**Left Ventricular Hypertrophy (LVH) Criteria**

- Left ventricular strain (associated with inverted T wave in leads  $V_6$ , I, and/or aVF)
- Left axis deviation (LAD) for patient's age
- Volume overload (associated with Q wave  $>5$  mm and tall T waves in  $V_5$  or  $V_6$ )
- Increased QRS voltage in left leads (with normal QRS duration):
  - R in lead  $V_6$  (and I, aVL,  $V_5$ ),  $>98$ th percentile for age
  - S in lead  $V_1$ ,  $>98$ th percentile for age

TABLE 7.4

## NONVENTRICULAR ARRHYTHMIAS

Name/Description	Cause	Treatment
<b>SINUS</b>		
<b>Tachycardia</b>		
Normal sinus rhythm with HR >95th percentile for age (usually infants: <220 beats/min and children: <180 beats/min)	Hypovolemia, shock, anemia, sepsis, fever, anxiety, CHF, PE, myocardial disease, drugs (e.g., $\beta$ -agonists, albuterol, caffeine, atropine)	Address underlying cause.
<b>Bradycardia</b>		
Normal sinus rhythm with HR <5th percentile for age	Normal (especially in athletic individuals), increased ICP, hypoxia, hyperkalemia, hypercalcemia, vagal stimulation, hypothyroidism, hypothermia, drugs (e.g., opioids, digoxin, $\beta$ -blockers), long QT	Address underlying cause; if symptomatic, refer to inside back cover for bradycardia algorithm.
<b>SUPRAVENTRICULAR<sup>a</sup></b>		
<b>Premature Atrial Contraction (PAC)</b>		
Narrow QRS complex; ectopic focus in atria with abnormal P-wave morphology	Digitalis toxicity, medications (e.g., caffeine, theophylline, sympathomimetics), normal variant	Treat digitalis toxicity; otherwise no treatment needed
<b>Atrial Flutter</b>		
Atrial rate 240–360 beats/min; characteristic saw-tooth or flutter pattern with variable ventricular response rate and normal QRS complex	Dilated atria, previous intra-atrial surgery, valvular or ischemic heart disease, idiopathic in newborns	Synchronized cardioversion or overdrive pacing; treat underlying cause
<b>Atrial Fibrillation</b>		
Irregular; atrial rate 350–600 beats/min, yielding characteristic fibrillatory pattern (no discrete P waves) and irregular ventricular response rate of about 110–150 beats/min with normal QRS complex	Those listed previously for atrial flutter (except idiopathic), alcohol exposure, familial	Synchronized cardioversion; then may need anticoagulation based on stroke risk


**SVT**

Sudden run of three or more consecutive premature supraventricular beats at >220 beats/min (infant) or >180 beats/min (child), with narrow QRS complex and absent/abnormal P wave; either sustained (>30 sec) or non-sustained	Wolff-Parkinson-White syndrome, idiopathic, may be seen in congenital heart disease (e.g., Ebstein anomaly, single ventricle)	Vagal maneuvers, adenosine; if unstable, need immediate synchronized cardioversion (0.5 J/kg up to 1 J/kg); consult cardiologist; refer to the back of the book for tachycardia with poor perfusion and tachycardia with adequate perfusion algorithms
I. <i>AV Reentrant</i> : Presence of accessory bypass pathway, in conjunction with AV node, establishes cyclic pattern of reentry independent of SA node; most common cause of nonsinus tachycardia in children (see Wolff-Parkinson-White syndrome, <a href="#">Table 7.7</a> )		
II. <i>Junctional</i> : Automatic focus; simultaneous depolarization of atria and ventricles yields invisible P wave or retrograde P wave	Cardiac surgery, idiopathic	Adjust for clinical situation; consult Cardiology
III. <i>Ectopic atrial tachycardia</i> : Rapid firing of ectopic focus in atrium	Idiopathic	AV nodal blockade, ablation

**NODAL ESCAPE/JUNCTIONAL RHYTHM**

Abnormal rhythm driven by AV node impulse, giving normal QRS complex and invisible P wave (buried in preceding QRS or T wave) or retrograde P wave (negative in lead II, positive in aVR); seen in sinus bradycardia	Common after surgery of atria	Often requires no treatment; if rate is slow enough, may require pacemaker
--	-------------------------------	--

<sup>a</sup>Abnormal rhythm resulting from ectopic focus in atria or AV node, or from accessory conduction pathways. Characterized by different P-wave shape and abnormal P-wave axis. QRS morphology usually normal. See [Fig. 7.6](#).<sup>6</sup> AV, Atrioventricular; CHF, congestive heart failure; HR, heart rate; ICP, intracranial pressure; PE, pulmonary embolism; SA, sinoatrial; SVT, supraventricular tachycardia.


**FIGURE 7.6**

Supraventricular arrhythmias. *P*, Premature atrial contraction. (From Park MK, Guntheroth WG. *How to Read Pediatric ECGs*. 4th ed. Elsevier; 2006:129.)

**TABLE 7.5****VENTRICULAR ARRHYTHMIAS**

Name/Description	Cause	Treatment
<b>PREMATURE VENTRICULAR CONTRACTION (PVC)</b>		
<p>Ectopic ventricular focus causing early depolarization. Abnormally wide QRS complex appears prematurely, usually with full compensatory pause. May be unifocal or multifocal</p> <p><b>Bigeminy:</b> Alternating normal and abnormal QRS complexes</p> <p><b>Trigeminy:</b> Two normal QRS complexes followed by an abnormal one</p> <p><b>Couplet:</b> Two consecutive PVCs</p>	<p>Myocarditis, myocardial injury, cardiomyopathy, long QT, congenital and acquired heart disease, drugs (catecholamines, theophylline, caffeine, anesthetics), MVP, anxiety, hypokalemia, hypoxia, hypomagnesemia; can be normal variant</p>	<p>None; more worrisome if associated with underlying heart disease or syncope, if worse with activity, or if they are multiform (especially couplets); address underlying cause; rule out structural heart disease</p>
<b>VENTRICULAR TACHYCARDIA</b>		
<p>Series of three or more PVCs at rapid rate (120–250 beats/min), with wide QRS complex and dissociated, retrograde, or no P wave</p>	<p>See causes of PVCs (70% have underlying cause)</p>	<p>Refer to front of book for tachycardia with poor perfusion and tachycardia with adequate perfusion algorithms</p>
<b>VENTRICULAR FIBRILLATION</b>		
<p>Depolarization of ventricles in uncoordinated asynchronous pattern, yielding abnormal QRS complexes of varying size and morphology with irregular, rapid rate; rare in children</p>	<p>Myocarditis, MI, postoperative state, digitalis or quinidine toxicity, catecholamines, severe hypoxia, electrolyte disturbances, long QT</p>	<p>Requires immediate defibrillation; refer to back of book for asystole and pulseless arrest algorithm</p>

*MI*, Myocardial infarction; *MVP*, mitral valve prolapse.

**FIGURE 7.7**


Ventricular arrhythmias. *RR*, R-R interval. (From Park MK, Guntheroth WG. *How to Read Pediatric ECGs*. 4th ed. Elsevier; 2006:138.)

**TABLE 7.6****NONVENTRICULAR CONDUCTION DISTURBANCES**

Name/Description <sup>a</sup>	Cause	Treatment
<b>FIRST-DEGREE HEART BLOCK</b>		
Abnormal but asymptomatic delay in conduction through AV node, yielding prolongation of PR interval	Acute rheumatic fever, tickborne (e.g., Lyme) disease, connective tissue disease, congenital heart disease, cardiomyopathy, digitalis toxicity, postoperative state, normal children	No specific treatment except to address the underlying cause
<b>SECOND-DEGREE HEART BLOCK: MOBITZ TYPE I (WENCKEBACH)</b>		
Progressive lengthening of PR interval until a QRS complex is not conducted; common finding in asymptomatic teenagers	Myocarditis, cardiomyopathy, congenital heart disease, postoperative state, MI, toxicity (digitalis, $\beta$ -blocker), normal children, Lyme disease, lupus	Address underlying cause, or none needed
<b>SECOND-DEGREE HEART BLOCK: MOBITZ TYPE II</b>		
Loss of conduction to ventricle without lengthening of the PR interval; may progress to complete heart block	Same as for Mobitz type I	Address underlying cause; may need pacemaker
<b>THIRD-DEGREE (COMPLETE) HEART BLOCK</b>		
Complete dissociation of atrial and ventricular conduction, with atrial rate faster than ventricular rate; P wave and PP interval regular; RR interval regular and much slower	Congenital due to maternal lupus or other connective tissue disease. Acquired due to same causes as Mobitz type I.	If bradycardic and symptomatic, consider pacing; refer to back of the book for bradycardia algorithm

<sup>a</sup>High-degree AV block: Conduction of atrial impulse at regular intervals, yielding 2:1 block (two atrial impulses for each ventricular response), 3:1 block, etc.

AV, Atrioventricular; MI, myocardial infarction.

**FIGURE 7.8**

Conduction blocks. P, P wave. (From Park MK, Guntheroth WG. *How to Read Pediatric ECGs*. 4th ed. Elsevier; 2006:141.)

**TABLE 7.7****VENTRICULAR CONDUCTION DISTURBANCES**

Name/Description	Criteria	Causes/Treatment
<b>RIGHT BUNDLE-BRANCH BLOCK (RBBB)</b>		
Delayed right bundle conduction prolongs RV depolarization time, leading to wide QRS	<ol style="list-style-type: none"> <li>1. Prolonged or wide QRS with terminal slurred R' (M-shaped RSR' or RR') in V<sub>1</sub>, V<sub>2</sub>, aVR</li> <li>2. Wide and slurred S wave in leads I and V<sub>6</sub></li> </ol>	ASD, surgery with right ventriculotomy, occasionally seen in normal children
<b>LEFT BUNDLE-BRANCH BLOCK (LBBB)</b>		
Delayed left bundle conduction prolongs septal and LV depolarization time, leading to wide QRS with loss of usual septal signal; there is still a predominance of left ventricle forces; rare in children	<ol style="list-style-type: none"> <li>1. Wide negative QRS complex in lead V<sub>1</sub> with loss of septal R wave</li> <li>2. Wide R or RR' complex in lead V<sub>6</sub> with loss of septal Q wave</li> </ol>	Hypertension, ischemic or valvular heart disease, cardiomyopathy
<b>WOLFF-PARKINSON-WHITE (WPW)</b>		
Atrial impulse transmitted via anomalous conduction pathway to ventricles, bypassing AV node and normal ventricular conduction system; leads to early and prolonged depolarization of ventricles; bypass pathway is a predisposing condition for SVT	<ol style="list-style-type: none"> <li>1. Shortened PR interval</li> <li>2. Delta wave</li> <li>3. Wide QRS</li> </ol>	Acute management of SVT if necessary, as previously described; consider ablation of accessory pathway if recurrent SVT; all patients need Cardiology referral

ASD, Atrial septal defect; LV, left ventricle; RV, right ventricle; SVT, supraventricular tachycardia.

**TABLE 7.8****SYSTEMIC EFFECTS ON ELECTROCARDIOGRAM**

	Short QT	Long QT-U	Prolonged QRS	ST-T Changes	Sinus Tachycardia	Sinus Bradycardia	AV Block	Ventricular Tachycardia	Miscellaneous
<b>CHEMISTRY</b>									
Hyperkalemia			X	X			X	X	Low-voltage P waves; peaked T waves
Hypokalemia		X		X					
Hypercalcemia	X					X	X	X	
Hypocalcemia		X			X		X		
Hypermagnesemia							X		
Hypomagnesemia		X							
<b>DRUGS</b>									
Digitalis	X			X		T	X	T	
Phenothiazines		T						T	
Phenytoin	X								
Propranolol	X					X	X		
Tricyclic antidepressants		T	T	T	T		T	T	
Verapamil						X	X		

*Continued*

TABLE 7.8

## SYSTEMIC EFFECTS ON ELECTROCARDIOGRAM—CONT'D

	Short QT	Long QT-U	Prolonged QRS	ST-T Changes	Sinus Tachycardia	Sinus Bradycardia	AV Block	Ventricular Tachycardia	Miscellaneous
<b>MISCELLANEOUS</b>									
CNS injury		X		X	X	X	X		
Friedreich ataxia				X	X			X	Atrial flutter, SVT
Duchenne muscular dystrophy				X	X			X	Atrial flutter, SVT
Myotonic dystrophy			X	X		X	X		SVT
Collagen vascular disease				X			X	X	
Hypothyroidism						X	X		Low voltage
Hyperthyroidism			X	X	X		X		SVT
Lyme disease							X		
Maternal lupus							X		

CNS, Central nervous system; T, present only with drug toxicity; X, present.

Data from Garson A Jr. *The Electrocardiogram in Infants and Children: A Systematic Approach* Lea & Febiger; 1983:172; and Walsh EP, Alexander ME, Cecchin F. Electrocardiography and introduction to electrophysiologic techniques. In: Keane JF, Lock JE, Fyler DC, eds. *Nadas' Pediatric Cardiology*. Elsevier; 2006:168.

unexplained syncope, seizure, SIDS, or cardiac arrest, with or without prolongation of QTc on ECG at baseline.

- d. Treadmill exercise testing and QT prolonging medications may prolong the QTc and may induce arrhythmias.
2. **Complications:** Associated with ventricular arrhythmias (torsades de pointes), syncope, and sudden death
3. **Management:**
  - a. Congenital long QT:  $\beta$ -blockers and/or defibrillators and avoidance of QT-prolonging medications; rarely requires cardiac sympathetic denervation or cardiac pacemakers
  - b. Acquired long QT: Treatment of arrhythmias, discontinuation of precipitating drugs, and correction of metabolic abnormalities

### E. Hyperkalemia

ECG changes dependent on the serum potassium ( $K^+$ ) level; however, the ECG may be normal with serum  $K^+$  levels between 2.5 and 6 mEq/L

1. **Serum  $K^+$  <2.5 mEq/L:** Depressed ST segment, biphasic T wave, prominent U wave
2. **Serum  $K^+$  >6 mEq/L:** Tall T wave
3. **Serum  $K^+$  >7.5 mEq/L:** Long PR interval, wide QRS, tall T wave
4. **Serum  $K^+$  >9 mEq/L:** Absent P wave, sinusoidal

## III. CONGENITAL HEART DISEASE

### A. Pulse Oximetry Screening for Critical Congenital Heart Disease

1. **To be done as late as possible but before discharge from nursery, preferably >24 hours of life, due to decreased false-positive rate.**  
Recommended to use the right hand and one foot, either in parallel or direct sequence
2. **The screening result would be considered positive if:**
  - a. Any oxygen saturation measures <90%
  - b. Oxygen saturation <95% in both extremities on three measures, each separated by 1 hour
  - c. There is a >3% absolute difference in oxygen saturation between the right hand and foot on three measures, each separated by 1 hour

### B. Common Syndromes Associated With Cardiac Lesions (Table 7.9)

### C. Acyanotic Lesions (Table 7.10)

### D. Cyanotic Lesions (Table 7.11)

A hyperoxia test is used to evaluate the etiology of cyanosis in neonates. A baseline arterial blood gas (ABG) with saturation at  $F_{iO_2} = 0.21$  is obtained. Then the infant is placed in an oxygen hood at  $F_{iO_2} = 1$  for a minimum of 10 minutes, and the ABG is repeated. In cardiac disease, there will not be a significant change in  $PaO_2$  following the oxygen challenge test. A  $PaO_2$  of >200 after exposure to  $F_{iO_2}$  of 1.0 is considered normal, and >150 indicates pulmonary rather than cardiac disease. **NOTE:** Pulse oximetry is not useful for following changes in oxygenation once saturation has reached 100% (approximately a  $PaO_2$  of >90 mmHg).<sup>8-17</sup> See eTable 7.1 for interpretation of oxygen challenge test (hyperoxia test). Hyperoxia test is not commonly performed anymore to known adverse effects of hyperoxemia and alkalosis.

eTABLE 7.1

## INTERPRETATION OF OXYGEN CHALLENGE TEST (HYPEROXIA TEST)

Condition	FiO <sub>2</sub> = 0.21	FiO <sub>2</sub> = 1.00	
	PaO <sub>2</sub> (% Saturation)	PaO <sub>2</sub> (% Saturation)	PaCO <sub>2</sub>
Normal	70 (95)	>200 (100)	35
Pulmonary disease	50 (85)	>150 (100)	50
Neurologic disease	50 (85)	>150 (100)	50
Methemoglobinemia	70 (85)	>200 (85)	35
Cardiac disease			
• Separate circulation <sup>a</sup>	<40 (<75)	<50 (<85)	35
• Restricted PBF <sup>b</sup>	<40 (<75)	<50 (<85)	35
• Complete mixing without restricted PBF <sup>c</sup>	50 (85)	<150 (<100)	35
Persistent pulmonary hypertension		<i>Preductal</i>	<i>Postductal</i>
R to L shunt via PDA only	70 (95)	<40 (<75)	Variable
R to L shunt via PDA and PFO	<40 (<75)	<40 (<75)	Variable

<sup>a</sup>D-Transposition of the great arteries (D-TGA) with intact ventricular septum.

<sup>b</sup>Tricuspid atresia with pulmonary stenosis or atresia, pulmonary atresia or critical pulmonary stenosis with intact ventricular septum, or tetralogy of Fallot.

<sup>c</sup>Truncus arteriosus, total anomalous pulmonary venous return, single ventricle, hypoplastic left heart syndrome, D-TGA with ventricular septal defect, tricuspid atresia without pulmonary stenosis or atresia.

FiO<sub>2</sub>, Fraction of inspired oxygen; PBF, pulmonary blood flow; PFO, patent foramen ovale.

From Lees MH. Cyanosis of the newborn infant: recognition and clinical evaluation. *J Pediatr.* 1970;77:484; Kitterman JA. Cyanosis in the newborn infant. *Pediatr Rev.* 1982;4:13; and Jones RW, Baumer JH, Joseph MC, et al. Arterial oxygen tension and response to oxygen breathing in differential diagnosis of heart disease in infancy. *Arch Dis Child.* 1976;51:667–673.

TABLE 7.9

## MAJOR SYNDROMES ASSOCIATED WITH CARDIAC DEFECTS

Syndrome	Dominant Cardiac Defect
CHARGE	TOF, truncus arteriosus, aortic arch abnormalities
DiGeorge	Aortic arch anomalies, TOF, truncus arteriosus, VSD, PDA
Trisomy 21	Atrioventricular septal defect, VSD
Marfan	Aortic root dilation, mitral valve prolapse
Loeys-Dietz	Aortic root dilation with higher risk of rupture at smaller dimensions
Noonan	Supravalvular pulmonic stenosis, LVH
Turner	COA, bicuspid aortic valve, aortic root dilation as a teenager
Williams	Supravalvular aortic stenosis, pulmonary artery stenosis
FAS	Occasional: VSD, PDA, ASD, TOF
IDM	TGA, VSD, COA, cardiomyopathy
VATER/VACTERL	VSD
VCFS	Truncus arteriosus, TOF, pulmonary atresia with VSD, TGA, interrupted aortic arch

ASD, Atrial septal defect; CHARGE, a syndrome of associated defects including Coloboma of the eye, Heart anomaly, choanal Atresia, Restriction of growth and development, and Genital and Ear anomalies; COA, coarctation of aorta; FAS, fetal alcohol syndrome; IDM, infant of diabetic mother; LVH, left ventricular hypertrophy; PDA, patent ductus arteriosus; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; VATER/VACTERL, association of Vertebral anomalies, Anal atresia, Cardiac anomalies, Tracheoesophageal fistula, Renal/radial anomalies, Limb defects; VCFS, velocardiofacial syndrome; VSD, ventricular septal defect.

From Park MK. *Pediatric Cardiology for Practitioners*. 5th ed. Elsevier; 2008:10–12.

## IV. ACQUIRED HEART DISEASE

## A. Myocardial Infarction (MI) in Children (Box 7.4; Fig. 7.9)

## B. Endocarditis

## 1. Common causative organisms noted in Nationwide Inpatient Sample Database (2000–2010):

- In children with underlying heart disease, viridans streptococci are the most common organisms (33%), with other streptococci making up 17%. *Staphylococcus aureus* is the second most common (28%), with other staphylococcus species making up 7%. Gram-negative bacilli (5%) and polymicrobial infections (11%) make up the remaining cases.
- In children without underlying heart disease, *S. aureus* is the most common organism (47%), with other staphylococcus species making up 6%. Viridans streptococci are the second most common (18%), with other streptococci making up 10%. Gram-negative bacilli (8%) and polymicrobial infections (12%) make up the remaining cases.<sup>14</sup>
- In neonates and immunocompromised children, fungi and HACEK organisms (*Haemophilus*, *Actinobacillus*, *Cardiobacterium*, *Eikenella*, and *Kingella*) are more common, accounting for 17% to 30% of cases.<sup>15</sup>

**TABLE 7.10****ACYANOTIC CONGENITAL HEART DISEASE**

Lesion Type	Examination Findings	ECG Findings	Chest Radiograph Findings
Ventricular septal defect (VSD)	2–5/6 holosystolic or early systolic murmur, loudest at the LLSB, ± systolic thrill ± apical diastolic rumble with large shunt With large VSD and pulmonary hypertension, S <sub>2</sub> may be narrow	Small VSD: Normal Medium VSD: LVH ± LAE Large VSD: BVH ± LAE, pure RVH	May show cardiomegaly and increased PVMs, depending on amount of left-to-right shunting
Atrial septal defect (ASD)	Wide, fixed split S <sub>2</sub> with grade 2–3/6 SEM at the LUSB May have mid-diastolic rumble at LLSB	Small ASD: Normal Large ASD: RAD and mild RVH or RBBB with RSR' in V <sub>1</sub>	May show cardiomegaly with increased PVMs if hemodynamically significant ASD
Patent ductus arteriosus (PDA)	40%–60% in VLBW infants 1–4/6 continuous “machinery” murmur loudest at LUSB Wide pulse pressure	Small–moderate PDA: Normal or LVH Large PDA: BVH	May have cardiomegaly and increased PVMs, depending on size of shunt
Atrioventricular septal defects	Most occur in Down syndrome Hyperactive precordium with systolic thrill at LLSB and loud S <sub>1</sub> ± grade 3–4/6 holosystolic regurgitant murmur along LLSB ± systolic murmur of MR at apex ± mid-diastolic rumble at LLSB or at apex ± gallop rhythm	Superior QRS axis RVH and LVH may be present	Cardiomegaly with increased PVMs
Pulmonary stenosis (PS)	Ejection click at LUSB with valvular PS; click intensity varies with respiration, decreasing with inspiration and increasing with expiration S <sub>2</sub> may split widely with P <sub>2</sub> diminished in intensity SEM (2–5/6) ± thrill at LUSB with radiation to back and sides	Mild PS: Normal Moderate PS: RAD and RVH Severe PS: RAE and RVH with strain	Normal heart size with normal to decreased PVMs

Aortic stenosis (AS)	Systolic thrill at RUSB, suprasternal notch, or over carotids Ejection click that does not vary with respiration if valvular AS. Harsh SEM (2–4/6) at second RICS or third LICS, with radiation to neck and apex ± early diastolic decrescendo murmur due to AR Narrow pulse pressure, if severe stenosis	Mild AS: Normal Moderate–severe AS: LVH ± strain	Usually normal
Coarctation of aorta may present as: 1. Infant in CHF 2. Child with HTN 3. Child with murmur	Male/female ratio of 2:1 2–3/6 SEM at LUSB, radiating to left interscapular area Bicuspid valve is often associated, so may have systolic ejection click at apex and RUSB BP in lower extremities will be lower than in upper extremities Pulse oximetry discrepancy of >5% between upper and lower extremities is also suggestive of coarctation	<i>In infancy:</i> RVH or RBBB <i>In older children:</i> LVH	Marked cardiomegaly and pulmonary venous congestion Rib notching from collateral circulation usually not seen in children younger than 5 years because collaterals not yet established

AR, Aortic regurgitation; ASD, atrial septal defect; BP, blood pressure; BVH, biventricular hypertrophy; CDG, congenital disorders of glycosylation; CHD, congenital heart disease; CHF, congestive heart failure; HTN, hypertension; LAE, left atrial enlargement; LICS, left intercostal space; LLSB, left lower sternal border; LUSB, left upper sternal border; LVH, left ventricular hypertrophy; MR, mitral regurgitation; PVM, pulmonary vascular markings; RAD, right axis deviation; RAE, right atrial enlargement; RBBB, right bundle-branch block; RICS, right intercostal space; RUSB, right upper sternal border; RVH, right ventricular hypertrophy; SEM, systolic ejection murmur; VLBW, very low birth weight (i.e., <1500 g); VSD, ventricular septal defect.

TABLE 7.11

## CYANOTIC CONGENITAL HEART DISEASE

Lesion	Examination Findings	ECG Findings	Chest Radiograph Findings
<p>Tetralogy of Fallot:</p> <ol style="list-style-type: none"> <li>1. Large VSD</li> <li>2. RVOT obstruction</li> <li>3. RVH</li> <li>4. Overriding aorta</li> </ol> <p>Degree of RVOT obstruction will determine whether there is clinical cyanosis; if PS is mild, there will be a left-to-right shunt, and child will be acyanotic; increased obstruction leads to increased right-to-left shunting across VSD, and child will be cyanotic</p>	<p>Loud SEM at LMSB and LUSB and a loud, single <math>S_2 \pm</math> thrill at LMSB and LLSB</p> <p><i>Tet spells:</i> Occur in young infants; as RVOT obstruction increases or systemic resistance decreases, right-to-left shunting across VSD occurs; may present with tachypnea, increasing cyanosis, and decreasing murmur</p>	RAD and RVH	Boot-shaped heart with normal heart size $\pm$ decreased PVMs
Transposition of great arteries	Nonspecific; extreme cyanosis; loud, single $S_2$ ; no murmur unless there is associated VSD or PS	RAD and RVH (due to RV acting as systemic ventricle); after 3 days of age, upright T wave in $V_1$ may be only abnormality	Classic finding: "egg on a string" with cardiomegaly; possible increased PVMs
Tricuspid atresia (absent tricuspid valve and hypoplastic RV and PA; must have ASD, PDA, or VSD to survive)	Single $S_2$ + grade 2–3/6 systolic regurgitation murmur at LLSB if VSD is present. Occasional PDA murmur	Superior QRS axis; RAE or CAE and LVH	Normal or slightly enlarged heart size; may have boot-shaped heart

Total anomalous pulmonary venous return:  
Instead of draining into LA, pulmonary veins  
drain into the following locations (must  
have ASD or PFO for survival):

*Supracardiac (most common):* SVC

*Cardiac:* Coronary sinus or RA

*Subdiaphragmatic:* IVC, portal vein, ductus  
venosus, or hepatic vein

*Mixed type*

Hyperactive RV impulse, quadruple rhythm, S<sub>2</sub>  
fixed and widely split, 2–3/6 SEM at LUSB, and  
mid-diastolic rumble at LLSB

RAD, RVH (RSR' in V<sub>1</sub>); may see RAE

Cardiomegaly and increased PVMs;  
classic finding is  
“snowman in a snowstorm,” but this  
is rarely seen until after age  
4 months

## OTHER

Cyanotic CHDs that each occur at a  
frequency of <1% include pulmonary  
atresia, Ebstein anomaly, truncus  
arteriosus, single ventricle, and double  
outlet right ventricle

*ASD*, Atrial septal defect; *CAE*, common atrial enlargement; *CHDs*, congenital heart diseases; *ECG*, electrocardiogram; *IVC*, inferior vena cava; *LA*, left atrium; *LLSB*, left lower sternal border; *LMSB*, left midsternal border; *LUSB*, left upper sternal border; *LVH*, left ventricular hypertrophy; *PA*, pulmonary artery; *PDA*, patent ductus arteriosus; *PFO*, patent foramen ovale; *PVM*, pulmonary vascular markings; *PS*, pulmonary stenosis; *RA*, right atrium; *RAD*, right-axis deviation; *RAE*, right atrial enlargement; *RV*, right ventricle; *RVH*, right ventricular hypertrophy; *RVOT*, right ventricular outflow tract; *SEM*, systolic ejection murmur; *SVC*, superior vena cava; *VSD*, ventricular septal defect.

**BOX 7.4****MYOCARDIAL INFARCTION IN CHILDREN**<sup>18,19</sup>**Etiologies**

Anomalous origin of coronary artery  
 Kawasaki disease  
 Congenital heart disease  
 Dilated cardiomyopathy  
 Severe hypertension  
 SLE  
 Myocarditis  
 Drug ingestion (cocaine, adrenergic drugs)


**Diagnosis**

**ECG findings**<sup>20,21</sup>: See Fig. 7.9.

**History and Exam**: See Fig. 7.13.

**Biomarkers**

Troponin I, CK-MB nonspecific for ischemic injury in children

**FIGURE 7.9**

Sequential changes during myocardial infarction. (From Park MK, Guntheroth WG. *How to Read Pediatric ECGs*. 4th ed. Elsevier; 2006:115.)

2. **Presentation:** Heart murmur, recurrent fever, splenomegaly, petechiae, fatigue, Osler nodes (tender nodules at the fingertips), Janeway lesions (painless hemorrhagic areas on the palms or soles), splinter hemorrhages, Roth spots (retinal hemorrhages)

### 3. **Diagnosis**—Duke criteria:

- a. Pathologic criteria:
  - (1) Direct evidence of endocarditis based upon histologic findings
  - (2) Gram stain positive or cultures of specimens
- b. Clinical criteria: 1 major criterion and 1 minor OR 3 minor criteria:
  - (1) Major: Persistently positive blood cultures (2 sets 12 hours apart), positive echocardiogram for vegetations, new regurgitant murmur, single positive blood culture for *Coxiella burnetii*
  - (2) Minor: Fever, predisposing valvular condition (prosthetic heart valve, valve lesion OR intravenous drug user [IVDU]), vascular phenomenon (e.g., emboli), immunologic phenomenon (e.g., Roth spots, Osler nodes), positive blood cultures that do not meet major criteria

4. Management: Daily blood cultures while febrile; support heart failure symptoms with diuretics, digoxin, etc.

### C. Bacterial Endocarditis Prophylaxis

See [Box 7.5](#) for cardiac conditions that meet criteria for prophylaxis.<sup>16</sup>

1. **All dental procedures** that involve treatment of gingival tissue, the periapical region of the teeth, or oral mucosal perforation
2. **Invasive procedures** that involve incision or biopsy of respiratory mucosa, such as tonsillectomy and adenoidectomy
3. **Not recommended** for genitourinary or gastrointestinal tract procedures; solely for bacterial endocarditis prevention
4. **Treatment:** Amoxicillin is preferred PO; ampicillin if unable to take PO; cephalexin if allergic to penicillins<sup>16</sup>

### D. Myocardial Disease

1. **Dilated cardiomyopathy:** End result of myocardial damage leading to atrial and ventricular dilation with decreased systolic contractile function of the ventricles
  - a. Treatment: Management of congestive heart failure (CHF) (digoxin, diuretics, vasodilation, angiotensin-converting enzyme [ACE] inhibitors)
  - b. Anticoagulants should be considered to decrease the risk of thrombus formation. Cardiac transplant may eventually be required.

#### BOX 7.5

##### CARDIAC CONDITIONS FOR WHICH ANTIBIOTIC PROPHYLAXIS IS RECOMMENDED

- Prosthetic cardiac valve
- Previous bacterial endocarditis
- Congenital heart disease (CHD)—Limited to the following conditions:
  - Unrepaired cyanotic defect, including palliative shunts and conduits
  - Completely repaired CHD with prosthetic material/device (placed by surgery or catheterization), during first 6 months after procedure
  - Repaired CHD with residual defects at or adjacent to the site of prosthetic patch or device (which inhibits endothelialization)
  - Cardiac transplantation patients who develop cardiac valvulopathy

Data from Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation*. 2007;116(15):1736–1754.

2. **Hypertrophic obstructive cardiomyopathy (HOCM):** Abnormality of myocardial cells leading to significant ventricular hypertrophy (usually left ventricle) with small to normal ventricular dimensions. Increased contractile function, impaired filling secondary to stiff ventricles. Most common type is asymmetrical septal hypertrophy with (HOCM) or without left ventricular outflow obstruction. There is a 4% to 6% incidence of sudden death in children and adolescents.
  - a. Treatment: Moderate restriction of physical activity, negative inotropes ( $\beta$ -blocker, calcium channel blocker) to help improve filling, and maintenance of adequate hydration. If at increased risk for sudden death, may consider implantable defibrillator. If symptomatic with subaortic obstruction, may benefit from myectomy
  - b. Additional management: HOCM is a preload-dependent lesion; therefore patient may benefit from higher rates of fluid administration. Avoid inotropes, tachycardia, and afterload reduction.
3. **Restrictive cardiomyopathy:** Myocardial or endocardial disease (usually infiltrative or fibrotic) resulting in stiff ventricular walls with restriction of diastolic filling but normal contractile function. Results in atrial enlargement. Associated with a high mortality rate. Very rare in children. Treatment is supportive with diuretics, anticoagulants, calcium channel blockers, a pacemaker for heart block, and cardiac transplantation, if severe.
4. **Myocarditis:** Inflammation of myocardial tissue
  - a. Etiology:
    - (1) Infectious: Viral (coxsackie virus, echovirus, adenovirus), bacterial, rickettsial, fungal, parasitic
    - (2) Other: Immune-mediated disease (Kawasaki disease, acute rheumatic fever), collagen vascular disease, toxin-induced
  - b. Presentation: Symptoms can be nonspecific, including fatigue, shortness of breath, emesis. Exam includes signs of CHF, soft systolic murmur, arrhythmia.
  - c. Testing:
    - (1) Imaging: ECG: Low QRS voltages throughout (<5 mm), ST-segment and T-wave changes (e.g., decreased T-wave amplitude), prolongation of QT interval, arrhythmias (especially premature contractions, first- or second-degree AV block); echo shows enlarged chambers and impaired LV function
    - (2) Labs: CK, troponin
  - d. Treatment: Bed rest, diuretics, inotropes (dopamine, dobutamine, milrinone), digoxin, gamma globulin, ACE inhibitors, possibly steroids
  - e. May require ventricular assist device and/or heart transplantation (~20% to 25% of cases)

## E. Pericardial Disease

1. **Pericarditis:** Inflammation of visceral and parietal layers of pericardium. It is often self-limited.
  - a. Presentation: Chest pain (often pleuritic in nature), fever, tachycardia, distant heart sounds, friction rub
  - b. EKG: Diffuse ST-segment elevation in almost all leads (representing inflammation of adjacent myocardium); PR-segment depression

- c. **Treatment:** Address underlying condition and provide symptomatic treatment with rest, analgesia, and antiinflammatory drugs
2. **Pericardial effusion:** Accumulation of excess fluid in pericardial sac
  - a. **Etiology:** Acute pericarditis, serous effusion from increased hydrostatic pressure (CHF), decreased plasma oncotic pressure, increased capillary permeability
  - b. **Presentation:** Can be asymptomatic, chest or abdominal pain, muffled heart sounds, dullness to percussion, vital sign instability from cardiac compression (e.g., hypotension)
  - c. **EKG:** Decreased QRS voltage, electrical alternans
  - d. **Treatment:** Address underlying condition. Observe if asymptomatic; use pericardiocentesis if there is sudden increase in volume or hemodynamic compromise. Nonsteroidal antiinflammatory drugs (NSAIDs) or steroids may be of benefit, depending on etiology.
3. **Cardiac tamponade:** Accumulation of pericardial fluid under high pressure causing compression of cardiac chambers, limiting filling, and decreasing stroke volume and cardiac output
  - a. **Etiology:** Same as pericardial effusion
  - b. **Presentation:** Dyspnea, fatigue, signs of CHF (jugular venous distension, hepatomegaly, edema, tachypnea/rales), pulsus paradoxus
  - c. **EKG:** Same as pericardial effusion
  - d. **Echocardiogram:** RV collapse in early diastole, RA/LA collapse in end diastole and early systole
  - e. **Treatment** is pericardiocentesis with temporary catheter left in place if necessary; pericardial window or stripping, if it is a recurrent condition


## F. Kawasaki Disease<sup>17</sup>

Acute febrile vasculitis of unknown etiology, which is common in children aged <8 years and is the leading cause of acquired childhood heart disease (in the form of coronary artery dilation/aneurysm) in developed countries

1. **Etiology:** Unknown; thought to be immune regulated in response to infectious agents or environmental toxins
2. **Diagnosis:**
  - a. Complete/typical Kawasaki disease (KD): Based on clinical criteria. These include high fever lasting 5 days or more, plus at least four of the following five criteria below. If at least four of the below criteria are present, the diagnosis of KD can be made with 4 days of fever.
    - (1) Bilateral, painless, bulbar, limbic-sparing conjunctival injection without exudate
    - (2) Erythematous mouth and pharynx, strawberry tongue, or red, cracked lips
    - (3) Polymorphous exanthem (may be morbilliform, maculopapular, or scarlatiniform)
    - (4) Swelling of hands and feet with erythema of palms and soles
    - (5) Cervical lymphadenopathy (>1.5 cm in diameter), usually single and unilateral
  - b. Incomplete/atypical Kawasaki disease: A suspicion of KD with fewer than four of the diagnostic criteria present. Laboratory criteria and echocardiogram are assessed to support the diagnosis. There is no

difference in the risk of developing coronary artery lesions between complete KD and incomplete KD.<sup>22</sup>

- (1) More often seen in infants. Incomplete KD should be considered in any infant <6 months with fever of 7 days or greater duration with or without clinical criteria, and in patients of any age with unexplained fever of 5 or more days with two or three clinical criteria of KD. Baseline echocardiogram should be strongly considered for any infant <6 months with fever of 7 days or greater duration, even in the absence of clinical or laboratory criteria.
  - (2) See [Fig. 7.10](#) for evaluation of incomplete Kawasaki disease.
  - (3) Supplemental laboratory criteria: Albumin  $\leq 3.0$  g/dL, anemia for age, elevation of alanine aminotransferase, platelets after 7 days  $\geq 450,000/\text{mm}^3$ , white blood cell count  $\geq 15,000/\text{mm}^3$ , and urine white blood cells/hpf  $\geq 10$  (non-catheterized specimen)
3. **Other clinical findings:** Often associated with extreme irritability, abdominal pain, diarrhea, vomiting. Also seen are arthritis and arthralgia, hepatic enlargement, jaundice, acute acalculous distention of the gallbladder, carditis
  4. **Laboratory findings:** Leukocytosis with left shift, neutrophils with vacuoles or toxic granules, elevated C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) (seen acutely), thrombocytosis, normocytic and normochromic anemia, sterile pyuria (33%), increased transaminases (40%), hyperbilirubinemia (10%)
  5. **Subacute phase (11 to 25 days after onset of illness):** Resolution of fever, rash, and lymphadenopathy. Often, desquamation of the fingertips or toes and thrombocytosis occur. Cardiovascular complications: If untreated, 20% to 25% develop coronary artery aneurysms and dilation in subacute phase (peak prevalence occurs about 2 to 4 weeks after onset of disease; rarely appears after 6 weeks) and are at risk for coronary thrombosis acutely and coronary stenosis chronically. Carditis; aortic, mitral, and tricuspid regurgitation; pericardial effusion; CHF; MI; left ventricular dysfunction; and ECG changes may also occur.
  6. **Convalescent phase:** ESR, CRP, and platelet count return to normal. Those with coronary artery abnormalities are at increased risk for MI, arrhythmias, and sudden death.
  7. **Management** (see also [eTable 7.2](#))<sup>17</sup>
    - a. Intravenous immunoglobulin (IVIG)
      - (1) Shown to reduce incidence of coronary artery dilation to <3% and decrease duration of fever, if given in the first 10 days of illness. Current recommended regimen is a single dose of IVIG, 2 g/kg over 10 to 12 hours.<sup>17</sup>
      - (2) Can be given to children after 10th day of fever if ESR or CRP elevated with persistent fever
      - (3) Approximately 10% of patients treated with IVIG fail to respond (persistent or recurrent fever  $\geq 36$  hours after IVIG completion). Re-treat with second dose.<sup>17</sup>
    - b. Aspirin is recommended for both its antiinflammatory and antiplatelet effects. In the United States, high-dose aspirin (80 to 100 mg/kg/day divided in four doses) is recommended until 48 to 72 hours after



**FIGURE 7.10**

Evaluation of incomplete Kawasaki disease. (From Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. *Circulation* 2017; Mar 29.)

defervescence. Some centers use moderate-dose aspirin (30 to 50 mg/kg/day), as there is no evidence to suggest either dosing is superior, and because of the increased potential for adverse effects with the higher dosing. This is given in addition to IVIG. Low-dose aspirin (3 to 5 mg/kg/day as a single daily dose) is continued for 6 to 8 weeks or until platelet count and ESR are normal (if there are no coronary artery abnormalities). Aspirin may be continued indefinitely, if coronary artery abnormalities persist. Concomitant use of ibuprofen antagonizes the antiplatelet effect of aspirin and, as such, should be avoided in patients with coronary artery aneurysms taking aspirin for its platelet-inhibiting effects.<sup>17</sup>

- c. High-dose pulse glucocorticoids (usually intravenous methylprednisolone) or infliximab are sometimes used for IVIG-resistant patients.<sup>17</sup>

**eTABLE 7.2****GUIDELINES FOR TREATMENT AND FOLLOW-UP OF CHILDREN WITH KAWASAKI DISEASE**

Risk Level	Pharmacologic Therapy	Physical Activity	Follow-Up and Diagnostic Testing	Invasive Testing
I. No coronary artery changes at any stage of illness	None beyond initial 6–8 weeks	No restrictions beyond initial 6–8 weeks	Counsel on cardiovascular risk factors every 5 years	None recommended
II. Transient coronary artery ectasia that resolves by 8 weeks after disease onset	None beyond initial 6–8 weeks	No restrictions beyond initial 6–8 weeks	Counsel on cardiovascular risk factors every 3–5 years	None recommended
III. Small-to-medium solitary coronary artery aneurysm	3–5 mg/kg/day aspirin, at least until aneurysm resolves	For patients in first decade of life, no restriction beyond initial 6–8 weeks; during the second decade of life, physical activity guided by stress testing every 2 years; avoid competitive contact and high-impact sports while on antiplatelet therapy	Annual follow-up with echocardiogram and electrocardiogram	Angiography, if stress testing or echocardiography suggests stenosis
IV. One or more large, >6 mm, aneurysms and coronary arteries with multiple small-to-medium aneurysms, without obstruction	Long-term aspirin (3–5 mg/kg/day) and warfarin or LMWH for patients with giant aneurysms	Annual stress testing guides physical activity; avoid competitive contact and high-impact sports while on anticoagulant therapy	Echocardiogram and electrocardiogram at 6-month intervals, annual stress testing, atherosclerosis risk factor counseling at each visit	Cardiac catheterization 6–12 months after acute illness with additional testing if ischemia noted or testing inconclusive
V. Coronary artery obstruction	Long-term aspirin (3–5 mg/kg/day); warfarin or LMWH if giant aneurysm persists; consider use of $\beta$ -blockers to reduce myocardial work	Contact sports, isometrics, and weight training should be avoided; other physical activity recommendations guided by outcome of stress testing or myocardial perfusion scan	Echocardiogram and electrocardiogram at 6-month intervals, annual Holter and stress testing	Cardiac catheterization 6–12 months after acute illness to aid in selecting therapeutic options, additional testing if ischemia noted

LMWH, Low-molecular-weight heparin.

- d. Follow-up: Serial echocardiography is recommended to assess coronary arteries and left ventricular function (at time of diagnosis, at 2 weeks, at 6 to 8 weeks, and at 12 months [optional]). More frequent intervals and long-term follow-up are recommended if abnormalities are seen on echocardiography. A higher baseline z-score of the coronary arteries on echocardiogram is strongly associated with worse cardiac outcomes.<sup>17</sup> Cardiac catheterization may be necessary.
- e. Follow up with a pediatric cardiologist depending on presence of coronary aneurysms and z-score of aneurysm (see eTable 7.2).

### G. Multisystem Inflammatory Syndrome in Children

Please see Chapter 27 for a full discussion of multisystem inflammatory syndrome in children (MIS-C). The cardiac monitoring for MIS-C is discussed here. Cardiac dysfunction is a principal concern in the management of MIS-C. In various case series, the reported incidence of cardiac dysfunction in patients with MIS-C has ranged from 35% to 100%.<sup>23</sup> As there are still relatively few data for MIS-C and practice varies from center to center, these are general principles surrounding the cardiac monitoring for patients with suspected MIS-C.

1. **Lab monitoring:** B-type natriuretic peptide and troponin levels should be obtained at baseline, and if elevated, should be monitored serially and as clinically indicated.
2. **ECG:** At minimum, a baseline 12-lead ECG is indicated in patients with suspected MIS-C, and serial ECGs every 1–2 days is suggested. Should there be concern for significant abnormality, namely AV block (in two studies, first-degree AV block occurred in approximately 20% of hospitalized patients with MIS-C<sup>24,25</sup>), telemetry should be considered. Similarly, if there is any concern for hemodynamic instability, continuous cardiac monitoring should be strongly considered.
3. **Echocardiography:** All patients with suspected MIS-C should have a baseline echocardiogram to assess for ventricular function, valvar function, coronary artery dimensions, presence of effusion, or other abnormalities. Timing of repeat echocardiogram will depend on the presence and degree of abnormality noted on baseline echocardiogram. Typically, if the baseline echocardiogram is abnormal, echocardiogram will be repeated while inpatient as clinically indicated. Namely, if there are coronary artery changes, current recommendations are to repeat an echocardiogram every 2 to 3 days until the size is stable, then determine frequency based upon the Kawasaki disease guidelines. If the baseline echocardiogram is within normal limits, a repeat can be done in 1 to 2 weeks and can be done outpatient.
4. **Outpatient follow-up:** Current expert opinion frameworks based on initial data and Kawasaki disease guidelines recommend outpatient follow-up for at least one year after the acute episode of illness with an echocardiogram and ECG at all appointments. Cardiac enzymes should be repeated if not normalized at discharge. If arrhythmia or AV block is noted at any point, a Holter monitor should be considered. Recommendations also depend upon the presence or absence of ventricular dysfunction of coronary artery change, as these factors may warrant more frequent follow-up. Proposed timing of these follow-up evaluations are as follows:

**BOX 7.6****GUIDELINES FOR DIAGNOSIS OF INITIAL ATTACK OF RHEUMATIC FEVER (JONES CRITERIA)**

Major Manifestations	Minor Manifestations
Carditis Polyarthritides Chorea Erythema marginatum Subcutaneous nodules	Clinical findings: Arthralgia Fever Laboratory findings: Elevated acute-phase reactants (erythrocyte sedimentation rate, C-reactive protein) Prolonged PR interval

**Plus Supporting Evidence of Antecedent Group A Streptococcal Infection**

- Positive throat culture or rapid streptococcal antigen test
- Elevated or rising streptococcal antibody titer

**NOTE:** If supported by evidence of preceding group A streptococcal infection, the presence of two major manifestations or of one major and two minor manifestations indicates a high probability of acute rheumatic fever.

- 1–2 weeks
  - 4–6 weeks
  - A cardiac MRI can be considered at the 3-month follow-up if there is a history of ventricular dysfunction or significantly elevated cardiac enzymes.
  - 9–12 months<sup>23,24</sup>
5. **Activity restriction:** Current practice for activity restriction following MIS-C is based upon guidelines for return to sport participation following acute myocarditis. In those guidelines, restriction for 3 to 6 months following diagnosis is recommended due to myocardial involvement. Additionally, subsequent preparticipation screening may be prudent to ensure the safety of return to athletic activity.<sup>23</sup>

**H. Rheumatic Heart Disease**

- Etiology:** Believed to be an immunologically mediated, delayed sequela of group A streptococcal pharyngitis
- Clinical findings:** History of streptococcal pharyngitis 1 to 5 weeks before onset of symptoms. Often with pallor, malaise, easy fatigability
- Diagnosis:** Jones criteria (Box 7.6)
- Management:** Penicillin, bed rest, salicylates, supportive management of CHF (if present) with diuretics, digoxin, morphine


**V. IMAGING****A. Chest Radiograph (Fig. 7.11)****B. Echocardiography (eTable 7.3)****VI. PROCEDURES****A. Cardiac Surgery (Fig. 7.12, Table 7.12)****B. Cardiac Catheterization<sup>9,10</sup> (Table 7.13)**

- Relatively common complications to be aware of: Arrhythmias (SVT, AV block, bradycardia, etc.), vascular complications (thrombosis, decreased/absent pulses), intervention-related (balloon rupture, etc.), bleeding


eTABLE 7.3

## ECHOCARDIOGRAMS

	Transthoracic Echocardiogram (TTE)	Transesophageal Echocardiogram (TEE)
Approach	Transducer placed on chest externally	Transducer on end of modified endoscope to view heart from esophagus
Pros	Does not require general anesthesia Simpler to perform than TEE	Better views in obese patients Good for intraoperative use Better visualization of small lesions/ vegetations
Cons	Limited views in certain patients (uncooperative, obese, suspected endocarditis)	Requires general anesthesia More difficult to perform

**FIGURE 7.11**

Radiological contours of the heart. *AO*, Aorta; *IVC*, inferior vena cava; *LA*, left atrium; *LAA*, left atrial appendage; *LPA*, left pulmonary artery; *LV*, left ventricle; *PA*, pulmonary artery; *RA*, right atrium; *RPA*, right pulmonary artery; *RV*, right ventricle; *SVC*, superior vena cava.

**FIGURE 7.12**

Schematic diagram of cardiac shunts, including the modified Blalock-Taussig-Thomas (*BTT*), Sano modification, bidirectional Glenn, and Fontan shunts.

2. Other less common complications: Myocardial/vessel staining, cardiac perforation, cardiac tamponade, air embolus, infection, allergic reaction, cardiac arrest, and death

**TABLE 7.12**  
**CARDIAC SURGERIES<sup>30</sup>**

Intervention	Indication	Procedure
Palliative systemic-to-pulmonary artery shunts (e.g., Blalock-Taussig-Thomas shunt)	Lesions with impaired pulmonary perfusion (TOF, HLHS, tricuspid atresia, pulmonary atresia)	Shunt created to increase pulmonary blood flow
Norwood procedure, stage 1 (neonatal period)	HLHS	MPA anastomosis to aorta with arch reconstruction Modified BTTS or Sano performed to provide pulmonary blood flow ASD created for decompression of left atrium Expected oxygen saturation 75%–85%
Bidirectional Glenn shunt or hemi-Fontan (3–6 months)	HLHS Intermediate step between Norwood 1 and Fontan	Bidirectional Glenn shunt or hemi-Fontan to reduce volume overload of single right ventricle Expected oxygen saturation 80%–85%
Fontan procedure	Functionally single ventricle (tricuspid atresia, HLHS)	Anastomosis of right atria and/or IVC to pulmonary arteries, separates systemic and pulmonary circulations Expected oxygen saturation >92%
Modified Fontan	Single ventricle	Completely separates systemic and pulmonary circulations Expected oxygen saturations >92%
Arterial switch	TGA	Connects aorta to LV and PA to RV, reconnects coronary arteries to aorta Normal oxygen saturations
Ross procedure (“switch procedure”)	Aortic stenosis	Pulmonary valve used to replace diseased aortic valve, pulmonary valve replaced by homograft, avoids long-term anticoagulation Normal oxygen saturations

ASD, Atrial septal defect; BTTS, Blalock-Taussig-Thomas shunt; HLHS, hypoplastic left heart syndrome; LV, left ventricle; MPA, main pulmonary artery; PA, pulmonary artery; RV, right ventricle; TAPVR, total anomalous pulmonary venous return; TGA, transposition of great arteries; TOF, tetralogy of Fallot.

## VII. COMMON CARDIAC COMPLAINTS

### A. Nontraumatic Chest Pain<sup>18</sup>

#### 1. Etiologies

##### a. Life-threatening causes

- (1) Cardiac: Congenital heart disease (CHD) with left ventricular outflow tract obstruction, coronary artery abnormality, pericarditis, myocarditis, dilated cardiomyopathy, aortic root dissection; cardiac etiologies are rare in children (prevalence <6%)<sup>26</sup>

TABLE 7.13

## CARDIAC CATHETERIZATION

Intervention	Indication	Procedure
Diagnostic catheter	Pre- or postcardiac procedure, monitoring progression of disease severity	Measurement of flow and pressures within different parts of the heart and large vessels
Patent ductus arteriosus (PDA) stent	Duct-dependent cyanotic lesions	Stent placed within PDA to allow mixing of blood between aorta and pulmonary artery
Balloon atrial septostomy	Common: TGA, HLHS with restrictive atrial septum Less common: tricuspid/mitral/aortic/pulmonary atresia, TAPVR	Opening between left and right atria created to allow mixing of blood between systemic and pulmonary systems
Device closure of ASD	ASD	Placement of device within atrial septal defect to close connection between right and left atria
Balloon valvuloplasty	Common: aortic or pulmonary valve stenosis	Inflation of balloon within valve to enlarge opening to reduce narrowing
Transcatheter valve replacement	Aortic/pulmonary/mitral/tricuspid valve stenosis or regurgitation	Placement of new valve within old valve to replace functionality to either improve stenosis or regurgitation
Catheter ablation	Certain arrhythmias, including pre-excitation, atrial ectopic tachycardia	Utilization of energy to scar tissue to limit production of ectopic beats or aberrant pathways

ASD, Atrial septal defect; BTTS, Blalock-Taussig-Thomas shunt; HLHS, hypoplastic left heart syndrome; LV, left ventricle; MPA, main pulmonary artery; PA, pulmonary artery; RV, right ventricle; TAPVR, total anomalous pulmonary venous return; TGA, transposition of great arteries; TOF, tetralogy of Fallot.

(2) Noncardiac: Pneumothorax, pulmonary embolism, pulmonary HTN, acute chest syndrome

b. Common, noncardiac causes (94% to 99% patients):  
Musculoskeletal (costochondritis), respiratory (asthma, pneumonia, pleuritic), gastrointestinal (gastroesophageal reflux disease [GERD]), psychiatric (panic attack, hyperventilation syndrome)

2. **When to consider referral to cardiologist:** Symptoms that suggest cardiac etiology (palpitations, syncope with exertion, and decreased exercise tolerance), ECG changes, new murmur

## B. Syncope<sup>19</sup>


### 1. Etiologies

a. Cardiac etiologies:

(1) Electrical disturbances: Long QT syndrome, Brugada syndrome, congenital short QT syndrome, catecholaminergic polymorphic ventricular tachycardia

(2) Structural heart disease: Hypertrophic cardiomyopathy, coronary artery anomalies, valvular aortic stenosis, dilated cardiomyopathy, acute myocarditis, pulmonary HTN

b. Noncardiac etiologies<sup>19</sup>:



**FIGURE 7.13**

Algorithm for the evaluation of nontraumatic chest pain. *ABCs*, Airway, breathing, and circulation; *EKG*, electrocardiogram; *PALS*, pediatric advanced life support; *PE*, pulmonary embolism; *PMH*, past medical history.

- (1) Common: Vasovagal syncope (50% pediatric syncope), breath-holding spells, orthostatic hypotension
- (2) Life-threatening: Heat illness/stroke, anaphylaxis, toxic ingestion, hypoglycemia

2. **When to consider referral to cardiologist:**
  - a. History: Congenital/acquired heart disease, syncope with exertion, associated chest pain or palpitations
  - b. Family history: Early sudden cardiac death, arrhythmia, cardiomyopathy
  - c. Evaluation: Abnormal cardiac exam or abnormal ECG

## VIII. EXERCISE RECOMMENDATIONS FOR PATIENTS WITH CONGENITAL HEART DISEASE

See eTable 7.4 for exercise recommendations for patients with CHD.<sup>27</sup>

## IX. LIPID MONITORING RECOMMENDATIONS

### A. Screening of Children and Adolescents<sup>28</sup>

1. **Universal screening:** Children 9 to 11 years old (prior to onset of puberty) and at 17 to 21 years
2. **Targeted screening:** 2 to 8 years old and 12 to 16 years old with risk factors:
  - a. Moderate or high-risk medical condition: History of prematurity, very low birth weight, CHD (repaired or unrepaired), recurrent urinary tract infections, renal or urologic malformations, family history of congenital renal disease, solid organ transplant, malignancy or bone marrow transplant, treatment with drugs known to raise BP, other systemic illness associated with HTN (e.g., neurofibromatosis, tuberous sclerosis), evidence of elevated intracranial pressure
  - b. Other cardiovascular risk factors, including diabetes, HTN, body mass index  $\geq 95$ th percentile, cigarette use
  - c. Family history of early cardiovascular disease (CVD) or severe hypercholesterolemia:
    - (1) Parent or grandparent who at  $<55$  years old (males) or  $<65$  years old (females) suffered an MI or sudden death, underwent a coronary artery procedure, or who had evidence of coronary atherosclerosis, peripheral vascular disease, or cerebrovascular disease.
    - (2) Parent with total cholesterol  $\geq 240$  mg/dL or known dyslipidemia

### B. Goals for Lipid Levels in Childhood<sup>28</sup>

1. **Total cholesterol**
  - a. Acceptable ( $<170$  mg/dL): No additional testing.
  - b. Borderline (170 to 199 mg/dL): Dietary or other lifestyle modifications. Could repeat testing in 1 year.
  - c. High ( $\geq 200$  mg/dL): Repeat and average values. If persistently  $\geq 200$ , obtain lipoprotein analysis. Could consider pharmacotherapy.
2. **Low-density lipoprotein (LDL) cholesterol**
  - a. Acceptable ( $<110$  mg/dL)
  - b. Borderline (110 to 129 mg/dL)
  - c. High ( $\geq 130$  mg/dL)

eTABLE 7.4

**EXERCISE RECOMMENDATIONS FOR CONGENITAL HEART DISEASE AND SPORTS ALLOWED FOR SOME SPECIFIC CARDIAC LESIONS<sup>27</sup>**

Diagnosis		Sports Allowed	
Small ASD or VSD		No restriction	
Mild aortic stenosis		No restriction	
MVP (without other risk factors)		No restriction	
Moderate aortic stenosis		IA, IB, IIA	
Mild LV dysfunction		IA, IB, IC	
Moderate LV dysfunction		IA only	
Long QT syndrome		IA only	
Hypertrophic cardiomyopathy		None (or IA only)	
Severe aortic stenosis		None	

Sports Classification	Moderate Dynamic (B)		
	Low Dynamic (A)	Moderate Dynamic (B)	High Dynamic (C)
I. Low static	Billiards Bowling Golf Riflery	Baseball/softball Table tennis Volleyball Fencing	Racket sports Cross-country skiing Field hockey <sup>a</sup> Race walking Running (long distance) Soccer <sup>a</sup>
II. Moderate static	Archery Auto racing <sup>a,b</sup> Diving <sup>a,b</sup> Equestrian <sup>a,b</sup> Motorcycling <sup>a,b</sup>	Fencing Field events (jumping) Figure skating <sup>a</sup> Football (American) <sup>a</sup> Surfing Rugby <sup>a</sup> Running (sprint) Synchronized swimming <sup>b</sup>	Basketball <sup>a</sup> Ice hockey <sup>a</sup> Cross-country skiing (skating technique) Swimming Lacrosse <sup>a</sup> Running (middle distance) Team handball
III. High static	Bobsledding Field events Gymnastics <sup>a,b</sup> Rock climbing Sailing Windsurfing <sup>a,b</sup> Waterskiing <sup>a,b</sup> Weight-lifting <sup>a,b</sup>	Bodybuilding <sup>a,b</sup> Downhill skiing <sup>a,b</sup> Skateboarding <sup>a,b</sup>	Boxing/wrestling <sup>a</sup> Martial arts <sup>a</sup> Rowing Speed skating Cycling <sup>a,b</sup>

<sup>a</sup>Danger of bodily collision.<sup>b</sup>Increased risk if syncope occurs.

ASD, Atrial septal defect; LV, left ventricular; MVP, mitral valve prolapse; VSD, ventricular septal defect.

Data from Maron BJ, Zipes DP. 36th Bethesda Conference: Eligibility recommendations for competitive athletes with cardiovascular abnormalities. *J Am Coll Cardiol.* 2005;45(8):1318–1321; and Committee on Sports Medicine and Fitness, American Academy of Pediatrics. Medical conditions affecting sports participation. *Pediatrics.* 2001;107(5):1205–1209.

## X. CARDIOVASCULAR SCREENING

### A. Sports<sup>29,30</sup>

There is no established or mandated preparticipation sports screening. There is a recommended history and physical examination screening from the AHA.<sup>29</sup> Routine ECGs are not required unless there is suspicion of underlying cardiac disease (see eBox 7.1).

### B. Attention-Deficit/Hyperactivity Disorder (ADHD)<sup>31</sup>

1. Obtain a good patient and family history as well as physical examination.
2. There is no increased risk of sudden cardiac death in children without cardiac disease taking ADHD medications. There is no consensus on universal ECG screening. ECGs should be obtained in those who screen with positive answers on history, in cases of polypharmacy, in those with tachycardia while on medications, and in those with a history of significant cardiac disease. If a patient has significant heart disease or concern for cardiac disease, have patient evaluated by a pediatric cardiologist.

## XI. WEB RESOURCES

- Cove Point Foundation: Congenital Heart Disease: <http://www.pted.org>
- MurmurQuiz: <https://murmurquiz.org>

## REFERENCES

A complete list of references can be found online.

**eBOX 7.1****THE 12-ELEMENT AMERICAN HEART ASSOCIATION RECOMMENDATIONS FOR PARTICIPATION: CARDIOVASCULAR SCREENING OF COMPETITIVE ATHLETES****Medical History<sup>a</sup>****Personal History**

1. Exertional chest pain/discomfort
2. Unexplained syncope/near syncope<sup>b</sup>
3. Excessive exertional and unexplained dyspnea/fatigue, associated with exercise
4. Prior recognition of a heart murmur
5. Elevated systemic blood pressure

**Family History**

1. Premature death (sudden and unexpected, or otherwise) before age 50 years due to heart disease, in  $\geq 1$  relative
2. Disability from heart disease in a close relative  $< 50$  years of age
3. Specific knowledge of certain cardiac conditions in family members: Hypertrophic or dilated cardiomyopathy, long-QT syndrome or other ion channelopathies, Marfan syndrome, or clinically important arrhythmias

**Physical Examination**

1. Heart murmur<sup>c</sup>
2. Femoral pulses to exclude aortic coarctation
3. Physical stigmata of Marfan syndrome
4. Brachial artery blood pressure (sitting position)<sup>d</sup>

<sup>a</sup>Parental verification is recommended for high-school and middle-school athletes.

<sup>b</sup>Judged not to be neurocardiogenic (vasovagal); of particular concern when related to exertion.

<sup>c</sup>Auscultation should be performed in both supine and standing positions (or with Valsalva maneuver), specifically to identify murmurs of dynamic left ventricular outflow tract obstruction.

<sup>d</sup>Preferably taken in both arms.

From Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. *Circulation*. 2007;115:1643–1655.

## REFERENCES

1. Park MK, Salamat, M. *Pediatric Cardiology for Practitioners*. 7th ed. Elsevier; 2021.
2. Sapin SO. Recognizing normal heart murmurs: a logic-based mnemonic. *Pediatrics*. 1997;99:616–619.
3. Davignon A, Rautaharju P, Boisselle E, et al. Normal ECG standards for infants and children. *Pediatr Cardiol*. 1979;1:123–131.
4. Schwartz PJ, Stramba-Badiale M, Segantini A, et al. Prolongation of the QT interval and the sudden infant death syndrome. *N Engl J Med*. 1998;338:1709–1714.
5. Garson A Jr. *The Electrocardiogram in Infants and Children: A Systematic Approach*. Lea & Febiger; 1983.
6. Park MK, Guntheroth WG. *How to Read Pediatric ECGs*. 4th ed. Mosby; 2006.
7. Walsh EP. Cardiac arrhythmias. In: Fyler DC, Nadas A, eds. *Pediatric Cardiology*. Hanley & Belfus; 1992:384.
8. Colan SD, Parness IA, Spevak PJ, et al. Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. *J Am Coll Cardiol*. 1992;19:619–629.
9. Stanger P, Heymann MA, Tarnoff H, et al. Complications of cardiac catheterization of neonates, infants, and children. *Circulation*. 1974;50:595–608.
10. Vitiello R, McCrindle BW, Nykanen D, et al. Complications associated with pediatric cardiac catheterization. *J Am Coll Cardiol*. 1998;32(5):1433–1440.
11. Lees MH. Cyanosis of the newborn infant: recognition and clinical evaluation. *J Pediatr*. 1970;77:484–498.
12. Kitterman JA. Cyanosis in the newborn infant. *Pediatr Rev*. 1982;4:13–24.
13. Jones RW, Baumer JH, Joseph MC, et al. Arterial oxygen tension and response to oxygen breathing in differential diagnosis of heart disease in infancy. *Arch Dis Child*. 1976;51:667–673.
14. Gupta S, Sakhuja A, McGrath E, Asmar B. Trends, microbiology, and outcomes of infective endocarditis in children during 2000-2010 in the United States. *Congenit Heart Dis*. 2017 Mar;12(2):196–201.
15. Park MK, Salamat M. *Park's Pediatric Cardiology for Practitioners*. 7th ed. Vol. 19. Elsevier/Saunders; 2021:264–281.
16. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guidelines from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation*. 2007;116:1736–1754.
17. McCrindle BW, Rowley AH, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. *Circulation*. 2017;135:e927–e999.
18. Friedman KG, Alexander ME. Chest pain and syncope in children: a practical approach to the diagnosis of cardiac disease. *J Pediatr*. 2013;163:896–901.
19. Massin M, Bourgiuignont A, Coremans C, et al. Syncope in pediatric patients presenting to an emergency department. *J Pediatr*. 2004;145:223–228.
20. Towbin JA, Bricker JT, Garson A Jr. Electrocardiographic criteria for diagnosis of acute myocardial infarction in childhood. *Am J Cardiol*. 1992;69:1545–1548.
21. Hirsch R, Landt Y, Porter S, et al. Cardiac troponin I in pediatrics: normal values and potential use in assessment of cardiac injury. *J Pediatr*. 1997;130:872–877.

22. Cho MA, Choi YJ, Jung JW. Affects of “age at diagnosis” on coronary artery lesions in patients with incomplete kawasaki disease. *Korean Circ J*. 2010;40(6):283–287.
23. Sperotto F, Friedman KG, Son MBF, et al. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. *Eur J Pediatr*. 2021;180:307–322.
24. Dionne A, Mah DY, Son MBF, et al. Block in children with multisystem inflammatory syndrome. *Pediatrics*. 2020;146(5):e2020009704.
25. Choi NH, Fremed M, Starc T, et al. MIS-C and cardiac conduction abnormalities. *Pediatrics*. 2020;146(6).
26. Reddy SV, Singh HR. Chest pain in children and adolescents. *Pediatr Rev*. 2010;31:e1–e9.
27. Maron BJ, Zipes DP. Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities. *J Am Coll Cardiol*. 2005;45:1318–1321.
28. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics*. 2011;128(suppl 5):S213–S256.
29. Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. *Circulation*. 2007;115:1643–1655.
30. Maron BJ, Levin BD, Washington RL, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities task force 2: Preparticipation screening for cardiovascular disease in competitive athletes. *Circulation*. 2015;132(22):e267–72.
31. Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. *Pediatrics*. 2008;122:451.

# Chapter 8

## Dermatology

*Allison Haley, MD and Katherine Cummings, MD*

 See additional content online.

### I. EVALUATION AND CLINICAL DESCRIPTIONS OF SKIN FINDINGS

#### A. Primary Skin Lesions

1. **Macule:** Small, flat, well-circumscribed discolored lesion (<1 cm)
2. **Patch:** Large macule ( $\geq 1$  cm)
3. **Papule:** Small, elevated, firm, well-circumscribed superficial lesion (<1 cm)
4. **Plaque:** Large papule ( $\geq 1$  cm)
5. **Pustule:** Small, well-circumscribed elevation of skin containing purulent material (<1 cm)
6. **Vesicle:** Small, well-circumscribed elevation of skin containing serous fluid (<1 cm)
7. **Bulla:** Large vesicle ( $\geq 1$  cm)
8. **Wheal:** Transient, raised, well-circumscribed lesion with erythematous periphery and central pallor
9. **Nodule:** Soft or firm lesion in dermis or subcutaneous fat ( $\geq 1$  cm)
10. **Tumor/mass:** Solid, firm lesion (typically  $\geq 2$  cm)

#### B. Secondary Skin Lesions

1. **Scale:** Small, thin plates (scales) shedding from the surface of the skin
2. **Crust:** Solidified exudative material from erosions or ruptured vesicles/pustules
3. **Erosion:** Loss of the most superficial layers of the epidermis from friction, pressure, or inflammation that heals without scarring
4. **Ulcer:** Full-thickness loss of the epidermis and at least a part of the dermis, with clearly defined edges, that heals with scarring
5. **Fissure:** Linear or wedge-shaped epidermal tear that reaches into the dermis and may be associated with inflammation and pain
6. **Excoriation:** Any loss of substance of the skin secondary to scratching
7. **Lichenification:** Thickening of the epidermis with accentuated skin lines, secondary to chronic inflammation and/or scratching
8. **Scar:** Formation of new connective tissue after full-thickness injury to skin, leaving permanent change in skin

#### C. Shapes and Arrangements

1. **Linear:** Distributed along a line
2. **Dermatomal:** Following a dermatome
3. **Filiform:** Thread-like

4. **Serpiginous:** Wavy, coiled, serpentine pattern
5. **Annular:** Ring-like configuration
6. **Nummular/discoid:** Disk-like, coin-shaped lesion
7. **Targetoid:** Resembling a bull's-eye target with central erythema surrounded by pale edema with a peripheral border of erythema
8. **Clustered:** Lesions in a group
9. **Herpetiform:** Clustered vesicular lesions on erythematous bases (herpes simplex pattern)
10. **Reticulated:** Net or lacey distribution
11. **Geographic:** Resembling outlines on a map such as a continent
12. **Morbilliform:** Eruption of erythematous to dusky coalescing macules with interspersed healthy skin

## II. VASCULAR ANOMALIES<sup>1</sup>

### A. Vascular Tumors

1. Infantile hemangiomas (Fig. 8.1, Color Plates)<sup>2,3</sup>
  - a. **Pathogenesis:** Benign vascular tumor with rapid proliferation followed by spontaneous involution. Most present before 4 weeks of age. Undergo rapid growth between 1 and 2 months of age, with 80% of size reached by 3 months. Most begin to regress between 6 and 12 months of age, with the majority of tumor regression occurring by 4 years of age. 50% to 70% resolve completely.
  - b. **Clinical presentation:** Newborns may demonstrate pale macules with overlying or surrounding, thread-like telangiectasias that later develop into hemangiomas. May be superficial, deep, or mixed. Pattern may be focal (neat round lesions) or segmental (following embryologic segments). After involution, can have residual skin changes including scarring and atrophy
  - c. Indicators that should prompt consideration for early treatment:
    - (1) Potential for life-threatening complications: Airway hemangiomas, liver hemangiomas (associated with high-output heart failure and severe hypothyroidism), and profuse bleeding from an ulcerated hemangioma
    - (2) Risk of functional impairment: Interference with the development of vision (if near eye) and interference with feeding (if near mouth)
    - (3) Ulceration: Most common complication (5% to 21%). Can be extremely painful and usually scars; risk greatest in large hemangiomas and those located in skin creases, particularly the diaper area
    - (4) Associated structural anomalies: PHACES syndrome (**P**osterior cranial fossa malformations, large segmental facial **H**emangiomas, **A**rterial lesions, **C**ardiovascular anomalies [aortic anomalies], **E**ye anomalies, **S**ternal cleft anomalies/supraumbilical raphes<sup>4</sup>) and LUMBAR syndrome (**L**ower body hemangioma, **U**rogenital anomalies, **U**lceration, **M**yelopathy,

- Bony deformities, Anorectal malformations, Arterial anomalies, Renal anomalies)**
- (5) Potential for disfigurement: Risk of permanent scarring or distortion of anatomic landmarks
- d. **Diagnosis:** Usually diagnosed clinically. Atypical clinical findings, growth pattern, and equivocal imaging should prompt tissue biopsy to exclude other neoplasms or unusual vascular malformations. See [Table 8.1](#) for indications to order imaging.
- (1) Consult the free International Society Study of Vascular Anomalies (ISSVA) classification online for characterization and differentiation between benign and aggressive vascular tumors
- e. **Treatment:**
- (1) Most are uncomplicated and can be observed with watchful waiting. Photo documentation is used to follow the growth and regression process.
  - (2) If an infantile hemangioma is identified as high risk, the child should be evaluated by a hemangioma specialist promptly, as there is a narrow window of opportunity in which to intervene and prevent poor outcomes.
  - (3)  $\beta$ -adrenergic blockers such as propranolol are considered first-line therapy for complicated infantile hemangiomas and should be initiated under supervision of a pediatric dermatologist or experienced practitioner.<sup>5</sup> While patients should be clinically screened for cardiac disease, EKG and/or echocardiogram are not required unless there is clinical concern. Contraindications include: reactive airways, sinus bradycardia, decompensated heart failure, greater than first-degree heart block, hypotension, hypoglycemia, hypersensitivity to propranolol. Off-label use of selective  $\beta$ -blockers may be considered in certain patients. Duration should be at least 6 months and up to 12 months of age.<sup>6</sup>



**TABLE 8.1**

**INDICATIONS TO OBTAIN IMAGING OF INFANTILE HEMANGIOMAS**

Indication	Imaging Modality
1. Diagnosis of infantile hemangiomas (IH) is uncertain (e.g., atypical appearance or behavior)	Ultrasound with Doppler
2. Five or more cutaneous IH	Abdominal ultrasound with Doppler (screen for hepatic IH)
3. Associated structural abnormalities (e.g., PHACE syndrome or LUMBAR syndrome) are suspected	<ol style="list-style-type: none"> <li>1. If PHACE syndrome is suspected, MRI/MRA head/neck with and without contrast; echocardiography</li> <li>2. If LUMBAR syndrome is suspected, spinal ultrasound and abdominal ultrasound with Doppler are initial screen, with MRI likely to follow</li> <li>3. May wish to consult with hemangioma specialist on exact imaging to be ordered</li> </ol>

From Krowchuk D, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. *Pediatrics*. 2019;143(1):1–28.

- (4) Corticosteroids are considered second line. Similar efficacy to propranolol in a prospective, randomized, investigator-blinded trial, but propranolol is better tolerated and with fewer severe side effects.<sup>7</sup>
  - (5) Topical timolol is effective in superficial, uncomplicated hemangiomas (recommend 0.5% gel forming solution).
  - (6) Ulcerated hemangiomas may respond to pulsed dye laser therapy or topical or systemic steroids.
2. Pyogenic granuloma (lobular capillary hemangioma) (Fig. 8.2, Color Plates)
- a. **Clinical presentation:** Benign vascular tumor, appears as small (usually 3 to 10 mm but occasionally much larger), bright red papule that grows over several weeks to months into sessile or pedunculated papule with a “collarette,” scale, or crust. Can bleed profusely with minor trauma and can ulcerate. Rarely spontaneously regresses. Seen in all ages; average age of diagnosis 6 months to 10 years. Located on head and neck, sometimes in oral mucosa but can be at any skin site and often misdiagnosed as hemangiomas
  - b. **Treatment:** Usually required, given frequent bleeding and ulceration. Options include shave excision or curettage with cautery of base, surgical excision, carbon dioxide laser excision, or pulsed dye laser therapy. For most cases, shave and cautery are quick, safe, low risk, and can be performed quickly with local anesthesia. Small, intact lesions may respond to topical timolol therapy.

### B. Vascular Malformations

Include capillary (port-wine stains and salmon patch/stork bite/angel kiss), lymphatic, venous, and arteriovenous malformations

NOTE: For a comparison of vascular malformations to vascular tumors, please see eTable 8.1.<sup>8</sup>

## III. INFECTIONS

### A. Viral

1. Warts
  - a. **Pathogenesis:** Human papillomaviruses (HPVs) of the epithelium or mucus membrane
  - b. **Clinical presentation:**
    - (1) Common warts: Skin-colored, rough, minimally scaly papules and nodules found most commonly on the hands, although can occur anywhere. Can be solitary or multiple, range from a few millimeters to several centimeters, may form large plaques or a confluent linear pattern secondary to autoinoculation. Sometimes persistent in immunocompromised patients and persistence may be a marker for underlying immunodeficiency.
    - (2) Flat warts: Flesh to brown/yellow-colored, smooth, flat-topped papules commonly found over the hands, arms, and face. Usually <2 mm in diameter and often present in clusters

**eTABLE 8.1****DIFFERENTIATING VASCULAR TUMORS AND VASCULAR MALFORMATIONS**

Vascular tumor (infantile hemangioma, pyogenic granuloma, kaposiform hemangioendothelioma, tufted angioma, other tumors)	Vascular malformation (venous, arterial, AVM, capillary, lymphatic, combination lesions)
<ul style="list-style-type: none"> <li>• Usually not present at birth</li> <li>• Dynamic</li> <li>• Regressing</li> <li>• Proliferative</li> </ul>	<ul style="list-style-type: none"> <li>• Often present at birth</li> <li>• Static</li> <li>• Persistent</li> <li>• Non-proliferative</li> </ul>

*AVM*, Arteriovenous malformation.

Adapted from McInerney T, Cohen BA, Rozell-Shannon L. Commentary: Vascular birthmarks in infants: importance of treating the 10%. *AAP Publications: AAP News*. Accessed February 2023. <https://publications.aap.org/aapnews/news/8474/Commentary-Vascular-birthmarks-in-infants?autologincheck=redirected>

- (3) Plantar warts: Occur on soles of feet as inward-growing, hyperkeratotic plaques and papules. Trauma on weight-bearing surfaces results in small black dots (petechiae from thrombosed vessels on the surface of the wart). Can be painful
  - c. **Diagnosis:** Clinical diagnosis; using a magnifier may help confirm clinical diagnosis
  - d. **Treatment<sup>9</sup>:**
    - (1) Spontaneous resolution occurs in greater than 75% of warts in otherwise healthy individuals within 3 years. No specific treatment clearly better than placebo, except possibly topical salicylic acid. Cryotherapy is sometimes combined with salicylic acid, but the efficacy of this combination has not been proven.
    - (2) Keratolytics (topical salicylates): Particularly effective in combination with adhesive tape occlusion. Response may take 4 to 6 months.
    - (3) Intralesional bleomycin, topical or intralesional fluorouracil, laser therapy, topical sensitizers, and imiquimod have been used for refractory warts, but the efficacy has not been proven. Destructive techniques, *Candida* antigen, cantharidin, or “beetle juice” are not clearly more effective than placebo. Additionally, destructive techniques can be painful and cause scarring, particularly on the digits. These options are not routinely recommended in children.
2. Molluscum contagiosum (Fig. 8.3, Color Plates)
    - a. **Pathogenesis:** Large DNA poxvirus. Spread by skin-to-skin contact
    - b. **Clinical presentation:** Dome-shaped, often umbilicated, translucent to white papules that range from 1 mm to 1 cm. Occur anywhere but only rarely on palms and soles, most commonly on the trunk and intertriginous areas. Can occur in the genital area and lower abdomen when obtained as a sexually transmitted infection in sexually active adolescents and autoinoculation in younger children. May be pruritic and can be surrounded by erythema, resembling eczema. The surrounding red, scaly reaction is referred to as “the beginning of the end” (see Treatment).
    - c. **Diagnosis:** Clinical diagnosis; magnifier can be used to distinguish from warts and other papular lesions
    - d. **Treatment:** Most spontaneously resolve within 6 to 18 months and do not require intervention other than monitoring for secondary bacterial infection. Surrounding eczematous changes may indicate an immunologic reaction and serve as a harbinger of regression. Treatment may cause scarring and may not be more effective than placebo. For symptomatic lesions curettage, topical irritants and sensitizers, and cantharidin may be an option. Recurrences are common.
  3. Herpes simplex virus
    - a. **Pathogenesis:** Either HSV-1 or HSV-2 may be implicated, regardless of lesion location. During the initial outbreak, oral lesions last 2 to


3 weeks, whereas genital lesions may last 2 to 6 weeks. Recurrent episodes are usually much shorter.

- b. **Clinical presentation (Fig. 8.5, Color Plates):** Symptoms include prodrome of tingling, itching, or burning followed by painful vesicles on erythematous base that may last 7 to 10 days, break open, and crust prior to healing; flu-like symptoms; dehydration (gingivostomatitis); dysuria (genital); ophthalmologic symptoms (keratitis). May be triggered by stress, illness, sun exposure, and menstruation. The first outbreak is typically the worst.
  - c. **Intrauterine HSV skin findings:** Recent case series show that cutaneous manifestation of HSV acquired in utero includes erosions, ulcerations, crusted papules or plaques, calcinosis cutis, excoriations, macules (erythematous, scarring with hypopigmented or hyperpigmented lesions), cutaneous atrophy, contractures, and bruising in addition to vesicles with erythematous base.
  - d. **Diagnosis:** Diagnosed clinically and, in many centers, with viral DNA PCR (more sensitive than culture). To culture a lesion, clean with alcohol, un-roof lesion with sterile needle or wooden side of cotton swab, collect vesicular fluid on sterile swab, and send in viral transport medium.
  - e. **Treatment:** Acyclovir or valacyclovir for 7 to 14 days (see Formulary for dosing). For children with herpetic gingivostomatitis, antiviral therapy should be initiated within 72 to 96 hours of onset if they are unable to drink or have significant pain. Valacyclovir is generally preferred as it is more bioavailable than acyclovir and, as a result, is dosed less frequently. See infectious disease chapter for more details on neonatal HSV.
4. Erythema infectiosum (“fifth disease”)
- a. **Pathogenesis:** Parvovirus B19
  - b. **Clinical presentation:** Pediatric presentation of nonspecific febrile illness with headache, coryza, and gastrointestinal complaints. Two to five days after onset of symptoms, the classic malar rash with “slapped cheek” appearance erupts, followed by a reticular rash to the trunk several days later. Associated signs and symptoms include arthralgias (more common in adults) and a transient aplastic crisis, which may be more of a problem in patients with hemoglobinopathies and pregnant women.
  - c. **Diagnosis:** Clinical diagnosis, serum IgM, or serum DNA PCR
  - d. **Treatment:** Supportive care. Avoid people who are pregnant as virus can cause hydrops fetalis.
5. Pityriasis rosea (PR, Figs. 8.9 and 8.10, Color Plates)
- a. **Pathogenesis:** Possible viral etiology (HHV-6, -7) as some cases are preceded by a prodrome of headache and malaise. No association with bacterial or fungal organisms has been found.
  - b. **Clinical presentation:** Classically presents with a “herald” patch, a single salmon-colored oval patch 2 to 5 cm in diameter, with central clearing. In the following days, similar but smaller oval patches

- appear, usually on the trunk and proximal extremities. On the back, the confluence of patches may appear in a “Christmas tree” pattern. The rash usually spreads from top down or centrifugally. In young children, lesions more often involve the scalp, face, and groin and can spare the trunk. Symptoms resolve in 4 weeks to several months.
- c. **Diagnosis:** Clinical diagnosis, but KOH scrapings to differentiate from tinea may be necessary. In sexually active patients, testing is recommended to rule out secondary syphilis, which may mimic the rash of PR.
  - d. **Treatment:** Will self-resolve without treatment. Symptomatic therapy with topical medium-potency steroids may reduce pruritis.
6. Roseola infantum (Fig. 8.11, Color Plates)
- a. **Pathogenesis:** Human herpesvirus 6 (HHV-6, less commonly HHV-7)
  - b. **Clinical presentation:** Typically diagnosed in children <2 years old with peak 7 to 13 months. Febrile phase of 3 to 5 days of high fever (often >40°C), viremia, and irritability. As febrile phase resolves, patients develop a morbilliform rash on neck and trunk that spreads centripetally to face and extremities for 1 to 2 days.
  - c. **Diagnosis:** Clinical diagnosis
  - d. **Treatment:** Self-resolving
7. Hand, foot, and mouth disease
- a. **Pathogenesis:** Most commonly coxsackievirus A serotypes
  - b. **Clinical presentation:** Oral lesions on the tongue, buccal mucosa, and palate that initially are 1- to 5-mm erythematous macules and evolve to vesicles and ulcers with a thin erythematous halo. Erythematous, nonpruritic 1- to 10-mm macules, papules, and/or vesicles on the palms and soles. Typically resolve in 3 to 4 days. Usually nontender, unless caused by coxsackie A6 (may be associated with high fevers, widespread lesions, longer duration [12 days], palmar and plantar desquamation, and nail dystrophy)
  - c. **Diagnosis:** Clinical diagnosis. Most infections are now caused by coxsackie A6, and the rash tends to be worse in areas with normal skin trauma (face, extremities, diaper area). Moreover, lesions may be dramatic in areas with irritated skin such as in patches of eczema.
  - d. **Treatment:** Supportive care
8. Reactive erythema (Fig. 8.4; Figs. 8.5 to 8.11, Color Plates)
- a. **Pathogenesis:** Represent cutaneous reaction patterns triggered by endogenous and environmental factors (e.g., viral infections, drug reactions, immunizations)
  - b. **Clinical presentation:** Group of disorders characterized by erythematous patches, plaques, and nodules that vary in size, shape, and distribution and may develop purpura, urticarial plaques, and erythema multiforme-like lesions

## B. Parasitic

1. Scabies (Figs. 8.12 to 8.14, Color Plates)



**FIGURE 8.4**

Reactive erythema. (Modified from Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:206.)

- a. **Pathogenesis:** Caused by the mite *Sarcoptes scabiei*. Spread by skin-to-skin contact and through fomites. Can live for 2 days away from a human host. Female mites burrow and lay eggs under the skin.
  - b. **Clinical presentation:** Initial lesion is a small, erythematous papule that is easy to overlook. Can have burrows (elongated, edematous papulovesicles, often with a pustule at the advancing border) that are pathognomonic. Most commonly located in interdigital webs, wrist folds, elbows, axilla, genitals, buttocks, and belt line but can become widely disseminated. In temperate climates, the face and scalp are usually spared. In young infants, the palms and soles are also commonly involved. Burrows are most dramatic in patients who are unable to scratch (e.g., infants). An immunologically mediated disseminated eczematous (Id) eruption results in generalized severe pruritus, especially at night. Can become nodular, particularly in intertriginous areas, or be susceptible to superinfection due to frequent excoriations. Immunosuppressed patients may develop diffuse, scaly, crusted eruption and lack pruritus and may progress to “crusted scabies” or infection with very high numbers of mites, requiring more intensive topical and oral therapy.
  - c. **Treatment<sup>10</sup>:**
    - (1) Permethrin cream: 5% cream applied to skin from neck down in normal hosts, including under fingernails and toenails. Rinse off after 8 to 14 hours. Can repeat in 7 to 10 days
    - (2) Ivermectin (off-label use): Single 200 mcg/kg dose; can repeat in 2 weeks. Efficacy comparable to permethrin cream. May be the best choice for immunodeficient patients for whom total body application may be difficult but is not considered first line for pregnant patients or children weighing less than 15 kg
    - (3) Spinosad: 0.9% topical suspension, approved for treatment of scabies in adults and children 4 years of age and older. This treatment was approved in 2021, and its efficacy compared to prior treatments has not been well established.
    - (4) Environment: Mites cannot live away from human skin for more than 2 to 3 days. Launder clothing and sheets. Bag and seal stuffed animals and pillows for 2 to 3 days. Consider treatment of close contacts.
2. Head lice: Pediculosis capitis
- a. **Pathogenesis:** Caused by *Pediculus humanus capitis*. Female louse lays eggs (nits) on the base of the hair shaft, which hatch into nymphs that mature to adult lice in 1 week. Transmission occurs through direct contact with the head of a person with lice, and transmission through towels, brushes, or hats is controversial. Lice do not fly or jump.
  - b. **Clinical diagnosis:** Should be suspected in child with scalp pruritus or persistent pyoderma around hairline. Diagnosis is confirmed by visualization of live lice, best done by using a fine-toothed nit comb through wet hair.

- c. **Treatment:** First-line treatment is topical pediculicides (permethrin, topical ivermectin, malathion, benzyl alcohol, topical dimethicone). Wet combing with a fine-toothed nit comb is an alternative for infants or patients who prefer to avoid medication. There is concern that lice are becoming resistant to topical permethrin and malathion; however, the most common cause of persistent head lice is poor adherence to treatment and continued exposure to other infected individuals. If resistance, independent from reinfection, is suspected, then oral ivermectin can be used.

### C. Fungal (Figs. 8.15 to 8.19, Color Plates)

1. Tinea capitis (Fig. 8.15, Color Plates)
  - a. **Pathogenesis:** Mostly caused by fungi of the genus *Trichophyton* in North America (95%), less commonly *Microsporum* (5% or less), and spread through direct contact and fomites
  - b. **Epidemiology:** Usually occurs in young children, with higher incidence in type 4 hair follicles
  - c. **Clinical presentation:**
    - (1) Black dot: Most common. Slowly growing, minimally scaly patches, sometimes erythematous but often with little or no inflammation until later in the course. These areas develop alopecia, and black dots are visible on scalp where hair has broken.
    - (2) Gray patch (“seborrheic dermatitis type”): Erythematous, scaling, well-demarcated patches that grow centrifugally. Hair breaks off a few millimeters above the scalp and takes on a gray/frosted appearance.
    - (3) Kerion (Fig. 8.16, Color Plates): Complication of tinea capitis or tinea corporis. Type IV hypersensitivity to fungus. Raised, boggy/spongy lesions, often tender and covered with purulent exudate. Most commonly occurs months after primary infection
    - (4) All can be associated with posterior cervical lymphadenopathy.
    - (5) Secondary infection usually from *Staphylococcus aureus* may be associated with tender pustules requiring treatment with oral antibiotic.
  - c. **Diagnosis:** Can be made clinically, but since oral antifungal therapy is indicated, tinea capitis should be confirmed by direct microscopic exam of a potassium hydroxide (KOH) preparation of the proximal ends of hairs, gently and painlessly scraped from the affected area. Cultures should be obtained on all patients by using a sterile toothbrush or cotton swab. The scale can be scraped directly into a sterile plastic cup and/or the cotton swab tips can be broken off and placed into the sterile plastic cups.
  - d. **Treatment<sup>11</sup>:** (Intent for Clinical Review submitted by Section of Dermatology (SOD) of American Academy of Pediatrics (AAP)) Always requires systemic therapy. First-line therapy includes oral griseofulvin for 10 to 12 weeks (which should be taken with fatty foods for improved absorption) or terbinafine for 6 weeks (see

Formulary for dosing). Most experts consider terbinafine superior to griseofulvin for *T. tonsurans* because of its shorter duration of therapy and superior effectiveness. The FDA recommends baseline and follow-up hepatic function testing in children taking terbinafine, though most clinicians forego laboratory testing in healthy children without history of liver disease if treatment is 6 weeks or less.

Though not FDA approved for tinea capitis, fluconazole at 6 mg/kg/day (max 400 mg/day) for 6 weeks is recommended by the AAP Red Book as an alternative treatment of tinea capitis in children younger than 2 years old.<sup>12</sup> All family members, particularly other children, should be examined carefully for subtle infection. Selenium sulfide 2.5% shampoo may shorten the period of shedding of fungal organisms and reduce risk of infection of unaffected family members. Off-label treatment with itraconazole 5 to 6 mg/kg/day for 6 weeks (comes in liquid formulation as well, which makes it easier to use in infants and toddlers). For kerion, can use high-potency topical steroid for 1 to 2 weeks at same time that start oral therapy but if severe maybe 1 to 2 weeks of oral steroid; treat secondary bacterial infection with 1 to 2 weeks of oral antibiotic.

2. Tinea corporis and pedis<sup>11</sup> (Figs. 8.17 and 8.18, Color Plates)
  - a. **Pathogenesis:** Spread through direct contact and fomites, especially in sports with close contact (e.g., tinea gladiatorum)
  - b. **Clinical presentation:** Pruritic, erythematous, annular patch or plaque with central clearing and a scaly raised border. Typically affects hair-free skin, but any skin can be affected
  - c. **Diagnosis:** Usually diagnosed clinically, but a KOH preparation or fungal culture can be used to help guide diagnosis and treatment. If widespread and considering oral therapy, send fungal culture to confirm diagnosis.
  - d. **Treatment:** Topical antifungals (terbinafine, miconazole, clotrimazole, ketoconazole) through 1 to 2 weeks past lesion resolution. Widespread eruption may require oral antifungals.
3. Tinea (pityriasis) versicolor (Fig. 8.19, Color Plates)
  - a. **Pathogenesis:** Caused by *Malassezia*. Exacerbated by hot/humid weather, hyperhidrosis, topical skin oil use. Most people are colonized with *Malassezia*, but only a small number are prone to develop clinical lesions. Not associated with poor hygiene. Not contagious
  - b. **Clinical presentation:** Well-demarcated, minimally scaly, hypopigmented macules or patches. Hypopigmented areas tend to be more prominent in the summer because affected areas do not tan. Lesions often have a fine scale that may be noted following gentle rubbing and can be mildly pruritic but are usually asymptomatic.
  - c. **Diagnosis:** KOH microscopy reveals pseudohyphae and yeast cells that appear like “spaghetti and meatballs.”
  - d. **Treatment:** Topical antifungal shampoos and/or creams (miconazole, oxiconazole, ketoconazole) or selenium sulfide are effective. Given the risk of hepatotoxicity, oral azole antifungals are reserved for

resistant or widespread disease. Oral terbinafine is not effective. Pigmentation changes may take months to resolve despite successful treatment.

4. Id reaction
  - a. **Pathogenesis:** Possible delayed-type hypersensitivity response to fungal antigens, also referred to as “autoeczematization” or “dermatophytid reaction”
  - b. **Clinical presentation:** A new onset pruritic, papular, vesicular rash in a patient with tinea pedis, tinea manuum, tinea cruris, tinea corporis, or tinea capitis. Typically occurs after treatment of the dermatophyte has been initiated. Often presents as patient or caregiver concern for allergy to the antifungal treatment
  - c. **Diagnosis:** Clinical
  - d. **Treatment:** Continue treatment for underlying dermatophyte. Topical corticosteroids or other antipruritic treatment may be used.

#### D. Bacterial

1. Impetigo
  - a. **Pathogenesis:** Contagious bacterial infection of the skin, most commonly caused by *Staphylococcus aureus* (99% MSSA), with a minority of cases caused by Group A *Streptococcus*
  - b. **Clinical presentation:**
    - (1) Nonbullous impetigo: Papules that evolve into erythematous pustules or vesicles that break and form thick, honey-colored crusts and plaques. Commonly overlying any break to skin barrier. Primarily face and extremities
    - (2) Bullous impetigo: Painless vesicles that evolve into flaccid bullae and crusted patches with undermined border. Seen more in infants and young children. Caused by *Staphylococcus aureus* exfoliative toxin A
  - c. **Diagnosis:** Clinical diagnosis
  - d. **Treatment:** When impetigo is contained to a small area, topical mupirocin may be used for 5 days. When the infection is widespread, an oral antibiotic such as cephalexin should be used for 7 days. Consider broader coverage if MRSA is suspected, although MSSA accounts for most infections.
2. Staph scalded skin syndrome
  - a. **Pathogenesis:** *Staphylococcus aureus* infections of the skin with hematogenous dissemination of exfoliative toxin A or B to the epidermis
  - b. **Clinical presentation:** Typical presentation is Ritter disease (generalized exfoliation) in a 3- to 7-day-old infant who initially is febrile and irritable with conjunctivitis and perioral erythema. In addition to newborns, this presentation is seen in young children who do not have antibodies to the toxin and often do not clear the toxin-antibody complex quickly due to decreased renal excretion. It may also occur in older children and adults with renal failure who cannot

clear the toxin/antibody complex. One to two days after the prodromal onset, patient develops diffuse erythema, fragile, flaccid bullae, and erosions that are Nikolsky positive (mild rubbing of skin causes skin to slough off) in areas of mechanical stress such as intertriginous areas. Lesions are not scarring as they are intraepidermal. Older children tend to have a localized bullous impetigo with tender scarlatiniform eruption. Infants and toddlers usually have a combination of the presentations seen in neonates and older children followed 7 to 10 days later by white to brown thick flaking and desquamation of the entire body, especially hands, feet, face, and neck.

- c. **Diagnosis:** Typically clinically. However, cultures should be obtained from any potential source site of infection, if there is a primary site of infection. If there is no primary site of infection, look for sites of colonization such as the medial canthi, nares, or umbilical stump in newborns.
  - d. **Treatment:** Nearly all cases are MSSA, with an increasing number being clindamycin resistant. First-line treatment may include oral penicillinase-resistant beta-lactams such as first- or second-generation cephalosporins. Vancomycin should be considered in patients who fail to respond to treatment and/or in areas with a high prevalence of MRSA. Management should also include supportive care with topical emollients and close monitoring of fluid and electrolyte status.
3. Scarlet fever (Fig. 8.20, Color Plates)
- a. **Pathogenesis:** Exotoxin-mediated response to a *Streptococcus pyogenes* infection, typically pharyngitis
  - b. **Clinical presentation:** Sandpaper-like, coarse, erythematous, blanching rash that originates in the groin and axilla, then spreads to the trunk, then extremities but spares the palms and soles. May have Pastia lines (pink/red lines in skin creases). Associated with pharyngitis, circumoral pallor, and a strawberry tongue
  - c. **Diagnosis:** Clinical diagnosis. May benefit from rapid strep test and throat culture
  - d. **Treatment:** No additional treatment aside from treating the patient's *Strep* pharyngitis. Failing to correctly diagnose and treat increases risk of patient developing rheumatic fever.
4. Cellulitis: See Chapter 17.

#### IV. HAIR LOSS (FIG. 8.22, COLOR PLATES )

##### A. Telogen Effluvium

1. **Pathogenesis:** Most common cause of diffuse hair loss. Telogen is the resting phase of hair growth that typically lasts 3 months, followed by hair shedding. Normally, 10% of hairs are in resting phase. Acute events (such as infection, fever, anesthesia, certain medications) can trigger premature telogen that results in a larger number of hairs shed 3 months later.

2. **Clinical presentation:** Diffuse hair thinning 3 months after a stressful event (major illnesses or surgery, pregnancy, severe weight loss)
3. **Treatment:** Self-limited. Regrowth usually occurs over several months.

### B. Alopecia Areata

1. **Clinical presentation:** Chronic inflammatory (probably autoimmune) disease that starts with well-circumscribed small bald patches and normal-appearing underlying skin. New lesions may demonstrate subtle erythema and be pruritic. Bald patches may enlarge to involve large areas of the scalp or other hair-bearing areas. Many experience good hair regrowth within 1 to 2 years, although most will relapse. A minority progress to total loss of all scalp (alopecia totalis) and/or body hair (alopecia universalis).
2. **Diagnosis:** Usually clinical diagnosis, but examination with magnification will show yellow dots, black dots, and exclamation point hairs. If diagnosis is unclear, a skin biopsy can also be obtained to confirm diagnosis.
3. **Treatment**<sup>13</sup>: First-line therapy is topical steroids. Referral to dermatology is warranted for consideration of other treatments. No evidence-based data that any therapy is better than placebo. Older children, adolescents, and young adults with long-standing localized areas of hair loss have the best prognosis. New agents including JAK inhibitors show promise for treatment of resistant and/or persistent alopecia areata.

### C. Traction Alopecia (Fig. 8.22, Color Plates)

1. **Pathogenesis:** Hairstyles that apply tension for long periods of time
2. **Clinical presentation:** Noninflammatory linear areas of hair loss at margins of hairline, part line, or scattered regions, depending on hairstyling procedures used
3. **Treatment:** Avoidance of styling products or styles that result in traction. If traction remains for long periods, condition may progress to permanent scarring hair loss.

### D. Trichotillomania and Hair Pulling

1. **Pathogenesis:** Alopecia due to compulsive urge to pull out one's own hair, resulting in irregular areas of incomplete hair loss. Mainly on the scalp; can involve eyebrows and eyelashes. Onset is usually after age 10 and should be distinguished from hair twirling/pulling in younger children that resolves without treatment in most cases.
2. **Clinical presentation:** Characterized by hair of differing lengths; area of hair loss can be unusual in shape
3. **Treatment:** Behavioral modification and consider psychiatric evaluation (can be associated with anxiety, depression, and obsessive-compulsive disorder)

## V. ACNE VULGARIS

### A. Pathogenetic Factors

Follicular hyperkeratinization, increased sebum production, *Cutibacterium acnes* (formerly *Propionibacterium acnes*) proliferation, and inflammation

## B. Risk Factors

Androgens, family history, stress, and medications such as topical and oral steroids, antidepressants, antiepileptics, cyclosporin, B vitamins. No strong evidence that dietary habits affect acne

## C. Clinical Presentation

### 1. Noninflammatory lesions

- Closed comedone (whitehead): Accumulation of sebum and keratinous material, resulting in white/skin-colored papules without surrounding erythema
- Open comedone (blackhead): Dilated follicles filled with keratinocytes, oils, and melanin

- Inflammatory lesions:** Papules, pustules, nodules, and cysts with evidence of surrounding inflammation. Typically appear later in the course of acne. Nodulocystic presentations are more likely to lead to hyperpigmentation and/or permanent scarring.

## D. Treatment<sup>14-16</sup> (Table 8.2)

Topical minocycline foam, topical clascoterone (anti-androgen for males and females), encapsulated benzoyl peroxide and tretinoin, topical trifarotene (a fourth-generation retinoid approved for face and trunk)

- Skin care:** Gentle nonabrasive cleaning. Avoid picking or popping lesions. Vigorous scrubbing and abrasive cleaners can worsen acne.
- Topical first-line therapies:** Recommended for mild to moderate acne

**TABLE 8.2**

### PEDIATRIC TREATMENT RECOMMENDATION FOR MILD, MODERATE, AND SEVERE ACNE

Acne Classification	Initial Treatment	Inadequate Response
Mild	Benzoyl peroxide (BPO) or topical retinoid <b>OR Topical combination therapy:</b> BPO + Antibiotic or retinoid + BPO or retinoid + Antibiotic + BPO	Add BPO or retinoid if not already prescribed <b>OR</b> change topical retinoid concentration, type, and/or formulation <b>OR</b> change topical combination therapy.
Moderate	<i>Topical combination therapy:</i> Retinoid + BPO or retinoid + BPO + Antibiotic <b>OR</b> Oral antibiotic + Topical retinoid + BPO or Topical retinoid + Topical antibiotic + BPO	Change topical retinoid concentration, type, and/or formulation and/or change topical combination therapy <b>OR</b> add or change oral antibiotic. Consider oral isotretinoin (dermatology referral). Females: Consider hormonal therapy.
Severe	<i>Combination therapy:</i> Oral antibiotic + Topical retinoid + BPO ± Topical antibiotic	Consider changing oral antibiotic <b>AND</b> consider oral isotretinoin. Females: Consider hormonal therapy. Strongly consider referral to dermatology.

Topical fixed-combination prescriptions available.

Data from Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. *Pediatrics*. 2013;131:S163–S186.

- a. Retinoids (eTable 8.2)
    - (1) Normalize follicular keratinization and decrease inflammation
    - (2) A pea-sized amount should be applied to cover the entire face (not spot treatment). Avoid eyes, creases of nose. Start two to three times weekly, titrate to nightly as tolerated. Can take 2 months to see effect
    - (3) Risks: Cause irritation and dryness of skin. Retinoids should be used at night because they can cause photosensitivity and decreased effectiveness when exposed to sunlight. Use daily SPF sunscreen. This class should not be used during pregnancy.
    - (4) Three topical retinoids (tretinoin, adapalene, and tazarotene) are available by prescription in the United States. Adapalene 0.1% gel has been approved for over-the-counter (OTC) use with significant efficacy.<sup>17</sup>
  - b. Benzoyl peroxide (BPO)
    - (1) Oxidizing agent with antibacterial and mild comedolytic properties
    - (2) Washes may be most convenient formulation, as they can be used in the shower.
    - (3) Recommend daily use, typically in the morning.
    - (4) Risks: Can bleach hair, clothing, towels, and sheets
  - c. Salicylic acid: Topical comedolytic agent that may be found in OTC face washes and serves as an alternative to a topical retinoid
3. **Topical antimicrobials:**
- a. Azelaic acid: Antimicrobial, comedolytic, and antiinflammatory. Recommended by the American Academy of Dermatology (AAD) for the treatment of postinflammatory dyspigmentation Available in a 15% gel and a 20% cream (more efficacious)<sup>18</sup>
  - b. Erythromycin and clindamycin: Avoid topical antibiotics as monotherapy. Topical BPO should be concurrently used to optimize efficacy and avoid bacterial resistance.
  - c. New topicals undergoing review are clascoterone and minocycline foam.
4. **Oral antibiotics (eTable 8.3):** Recommended for moderate to severe inflammatory acne that is resistant to topical treatment. These medications should be used with BPO or topical retinoid. Do not use as monotherapy. Limit to 3 months to minimize bacterial resistance.
- a.  $\geq 8$  years old: Doxycycline or minocycline
  - b.  $< 8$  years old, pregnancy, or tetracycline allergy: Azithromycin, erythromycin, or trimethoprim/sulfamethoxazole
  - c. Erythromycin should be used with care due to increased risk of resistance. The AAD recommends reserving trimethoprim/sulfamethoxazole for patients who have failed other treatments or are unable to tolerate tetracyclines and macrolides.
5. **Hormonal therapy:** Reduces sebum production and androgen levels. Good option for pubertal females who have sudden onset of moderate to

**eTABLE 8.2****FORMULATIONS AND CONCENTRATIONS OF TOPICAL RETINOIDS**

Retinoid	Vehicle <sup>a</sup>	Strength (%)
TRETINOIN Pregnancy Category C	Cream	0.025, 0.05, 0.1
	Gel	0.01, 0.025
	Gel (micronized)	0.05
	Microsphere gel	0.04, 0.1
	Polymerized cream	0.025
	Polymerized gel	0.025
ADAPALENE Pregnancy Category C	Cream	0.1
	Gel	0.1, 0.3
	Solution	0.1
	Lotion	0.1
TAZAROTENE Pregnancy Category X	Gel	0.05, 0.1
	Cream	0.05, 0.1

<sup>a</sup>Numerous generic retinoids are available.

Data from Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. *Pediatrics*. 2013;131:S163–S186, Table 4.

**eFIGURE 8.1**

Café-au-lait spot. (From Cohen BA. Disorders in pigmentation. In: *Pediatric Dermatology*. 5th ed. Saunders Elsevier; 2022:157–179.)

**eTABLE 8.3****FIRST-LINE ORAL ANTIBIOTICS USED FOR TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS**

Antibiotic	Potential Adverse Effects	Comments
DOXYCYCLINE	Pill esophagitis; photosensitivity; staining of forming tooth enamel (<8 years of age); vaginal candidiasis	Take with large glass of water and maintain upward position ~1 hr; optimize photoprotection; avoid in children without permanent teeth
MINOCYCLINE (Immediate release)	Cutaneous and/or mucosal hyperpigmentation; DHS (systemic, within first 1–2 months); LLS; SJS; vestibular toxicity (within first few days); staining of forming tooth enamel (<8 years of age); vaginal candidiasis	Can be taken with meals; warn patient about dizziness/vertigo; avoid in children without permanent teeth; monitor for pigmentary changes on skin
MINOCYCLINE (Extended release)	Same as above although above side effects reported predominantly with immediate release formulations; lower incidence of acute vestibular side effects with weight-based dosing	Less accumulation of drug over time due to pharmacokinetic properties of extended release formulation; may correlate with decreased hyperpigmentation

*DHS*, Drug hypersensitivity syndrome; *LLS*, lupus-like syndrome; *SJS*, Stevens-Johnson syndrome.

Modified from Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. *Pediatrics*. 2013;131:S163–S186, Table 5.

severe hormonal acne (often on lower face, jawline) and have not responded to conventional first-line therapies. Should not be used as monotherapy. Combination oral contraceptives (see [Chapter 5](#) for additional information) or spironolactone (antiandrogen)

6. **Oral isotretinoin:** Reserved for patients with severe nodular, cystic, or scarring acne who do not respond to traditional therapy or who cannot be weaned from oral antibiotics. Should be managed by a dermatologist. Most patients have complete resolution of their acne after 16 to 20 weeks of use.
  - a. Side effects:
    - (1) Teratogenicity: Patients and physicians are mandated by the FDA to comply with the iPledge program to eliminate fetal exposure to isotretinoin. Female patients with child-bearing potential must use two forms of birth control with routine pregnancy testing.
    - (2) Hepatotoxicity, hyperlipidemia, and bone marrow suppression, a complete blood cell count, fasting lipid profile, and liver function tests should be obtained before initiation of therapy and repeated at 4 and 8 weeks.

## VI. COMMON NEONATAL DERMATOLOGIC CONDITIONS (FIG. 8.21; FIGS. 8.23 TO 8.30, COLOR PLATES)

### A. Erythema Toxicum Neonatorum (Fig. 8.23, Color Plates)

1. **Clinical presentation:** Most common rash of full-term infants; incidence declines with lower birth weight and prematurity. Appears as small erythematous macules and papules that evolve into pustules on erythematous bases. Rash most often occurs by 24 to 48 hours of life but can be present at birth or emerge as late as 2 to 3 weeks.
2. **Course:** Self-limited, resolves within 5 to 7 days; recurrences possible

### B. Transient Neonatal Pustular Melanosis (Figs. 8.24 to 8.25, Color Plates)


1. **Clinical presentation:** More commonly affects full-term infants with darker pigmentation. At birth, appears as small pustules on nonerythematous bases that rupture and leave erythematous/hyperpigmented macules with a collarette of scale
2. **Course:** Self-limited macules fade over weeks to months.

### C. Miliaria (Heat Rash) (Fig. 8.26, Color Plates)

1. **Clinical presentation:** Common newborn rash associated with warmer climates, incubator use, or occlusion with clothes/dressings. Appears as small erythematous papules or pustules usually on face, scalp, or intertriginous areas
2. **Course:** Rash resolves when infant is placed in cooler environment or tight clothing/dressings are removed.

### D. Milia (Fig. 8.27, Color Plates)

1. **Clinical presentation:** Common newborn lesions. Appears as 1- to 3-mm white/yellow papules, frequently found on nose and face; due to retention of keratin and sebaceous materials in pilosebaceous follicles



**FIGURE 8.21**

Evaluation of neonatal rashes. (Modified from Cohen BA. *Atlas of Pediatric Dermatology*. 5th ed. Elsevier Limited; 2021.)

2. **Course:** Self-limited, resolves within first few weeks to few months of life

### E. Neonatal Acne (Fig. 8.28, Color Plates)

1. **Clinical presentation:** Seen in 20% of infants. Appears as inflammatory papules or pustules without comedones, usually on face and scalp. Secondary to effect of maternal and endogenous androgens on infant's sebaceous glands
2. **Course:** Peaks around 1 month, resolves within a few months, usually without intervention. Does not increase risk of acne as an adolescent

### F. Seborrheic Dermatitis (Figs. 8.29 to 8.30, Color Plates)

1. **Clinical presentation:** Erythematous plaques with greasy yellow scales. Located in areas rich with sebaceous glands, such as scalp, cheeks, ears, eyebrows, intertriginous areas, diaper area. Unknown etiology. Can be seen in newborns, more commonly in infants aged 1 to 4 months. Can also be seen in older patients, particularly adolescents with chronic medical conditions
2. **Course:** Self-limited and resolves within a few weeks to months
3. **Treatment:** Can remove scales on scalp with an emollient (e.g., mineral or olive oil, or petroleum jelly) and a soft brush/fine comb. In more severe cases, antifungal shampoos or low-potency topical steroid can shorten the course, although no shampoos are FDA approved for children less than 2 years of age.

### G. Congenital Dermal Melanocytosis

1. **Clinical presentation:** Most common pigmented lesion of newborns, usually seen in babies with darker skin tone. Appear as blue/gray macules without definite disappearance of dermal melanocytes. Can be mistaken for child abuse; thus accurate documentation at newborn and well-child visits is important
2. **Course:** Spots typically fade within first few years of life, with majority resolved or much improved by age 10 years.
3. **Other types:** Nevus of Ota involves the skin innervated by the first and second divisions of the trigeminal nerve and can cause neurocutaneous melanosis with up to 10% of patients developing sensorineural hearing loss or glaucoma ipsilateral to the skin lesion. Nevus of Ito involves the skin innervated by the posterior supraclavicular and lateral brachio-cutaneous nerves.

### H. Diaper Dermatitis<sup>19</sup>

1. **Clinical presentation:** Irritant contact dermatitis characterized by erythematous eruption on buttocks and genital areas with exclusion of other potential causes. Most commonly associated with increased loose stools from viral gastroenteritis, antibiotics, and other gastrointestinal disorders. Rarely associated with diaper candidiasis, characterized by a red, raised papular rash with small pustules at the periphery (Fig. 8.31). Tends to involve the skin prominences and spares the protected skin creases<sup>19</sup>

2. **Treatment:** Frequent diaper changes, air exposure, adequate drying, gentle cleaning, and judicious use of topical barrier preparations. If persistent, can use low-potency topical steroid until cleared no more than twice daily. For candidiasis, treatment with topical nystatin, miconazole, or clotrimazole is sufficient. Combination steroid/antifungal creams should be avoided due to steroid-related side effects and association with persistent fungal infections.<sup>20</sup>

## VII. AUTOIMMUNE AND ALLERGIC DERMATOLOGIC CONDITIONS (FIGS. 8.32 TO 8.38, COLOR PLATES)

### A. Contact Dermatitis

1. Irritant dermatitis: Exposure to physical, chemical, or mechanical irritants to the skin. Common irritants include frequent hand washing, hot water, lip-licking, thumb-sucking, and exposure to chemicals, paints, or certain foods like citrus fruits.
2. Allergic dermatitis
  - a. **Pathogenesis:** Immune reaction to an environmental trigger that comes into contact with the skin. After initial sensitization period of 7 to 10 days in susceptible individuals, an allergic response occurs with subsequent exposures.
  - b. **Common allergens:** *Toxicodendron* spp. (poison ivy, oak, sumac), nickel, cobalt, gold, dyes, fragrances, formaldehyde, latex, and acetophenone azine (found in shin guards and other sports equipment)
  - c. Dermatitis that can progress to chronic scaling, lichenification, and pigment changes. Poison ivy (Fig. 8.32, Color Plates): Exposure to urushiol causes streaks of erythematous papules, pustules, and vesicles. Highly pruritic, can become edematous, especially if rash is on face or genitals. In extreme cases, anaphylaxis can occur.
  - d. **Diagnosis:** Careful history taking and recognition of unusual shapes and locations suggesting an “outside job” allow for clinical diagnosis. Patch testing may also be helpful when trigger cannot be identified.
  - e. **Treatment:**
    - (1) Remove causative agent. Moisturize with ointment like Vaseline or Aquaphor twice per day. Use antihistamine and/or oatmeal baths as needed for itching, sedation, and sleeping, though they do not directly impact the rash.
    - (2) Mild/moderate: Topical steroids twice a day for 1 week, then daily for 1 to 2 weeks
    - (3) Widespread/severe: Systemic steroids for 2 to 3 weeks, with taper. There is no role for short courses of steroids because eruption will flare when drug is stopped.
    - (4) For poison ivy contact, remove clothing and wash skin with mild soap and water as soon as possible.

**B. Atopic Dermatitis (Eczema) (Figs. 8.33 to 8.36, Color Plates)**

1. **Pathogenesis:** Due to inadequate skin barrier function from combination of genetic and environmental factors, resulting in transepidermal water loss and immunologically mediated inflammatory reaction. Can be associated with elevated serum IgE
2. **Epidemiology<sup>21</sup>:** Affects up to 20% of children in the United States, the vast majority with onset before age 5 years. Other comorbidities may follow, including asthma, allergic rhinitis, and food allergies. Eczema resolves or improves in over 75% of patients by adulthood.
3. **Clinical presentation:** Dry, pruritic skin with acute changes, including erythema, vesicles, crusting, and chronic changes, including scaling, postinflammatory hypo- or hyperpigmentation (eFigs. 8.1 and 8.2), and lichenification
  - a. Infantile form: Erythematous, scaly lesions on the cheeks, scalp, and extensor surfaces. Covered areas (especially the diaper area) are usually spared.
  - b. Childhood form: Lichenified plaques in flexural areas
  - c. Adolescence: More localized and lichenified skin changes. Predominantly on skin flexures, hands, and feet
4. **Treatment<sup>21</sup>:** See Chapter 15.
  - a. Lifestyle: Avoiding triggers (products with alcohol, fragrances, astringents, sweat, allergens, and excessive bathing). Avoid scratching (eczema is the “itch that rashes”).
  - b. Bathing: Should be less than 5 minutes in lukewarm water with a gentle bar soap and no washcloth or scrubbing. Skin should be patted dry (not rubbed) and followed by rapid application of an emollient (“soak and smear”).
  - c. To reduce the risk of secondary infection, consider diluted bleach baths once or twice a week (mix  $\frac{1}{4}$  cup of bleach in full tub of lukewarm water and soak for 10 minutes, then rinse off with fresh water).
  - d. Skin hydration: Frequent use of bland emollients with minimal water content (Vaseline or Aquaphor). Avoid lotions, as they have high water and low oil content, which worsens dry skin. Consider “wet dressings” in severe cases to increase absorption of medication and moisturization. After bathing, apply steroid ointment, then moisturizer, prior to clothing child in warm, damp pajamas. Follow with second layer of dry pajamas and remove after several hours or overnight.
  - e. Oral antihistamines: There is little evidence that antihistamines improve skin lesions in atopic dermatitis. Nonsedating antihistamines can be used for environmental allergies and hives. Sedating antihistamines may be of transient benefit for sedation at bedtime.
  - f. Treatment for inflammation:
    - (1) **Mild disease: Topical steroids<sup>22</sup>** (Table 8.3): Low- and medium-potency steroid ointments once or twice daily for 7 days during a flare. Severe flares may require a high-potency steroid for a longer duration of therapy, followed by a taper to a low-potency

**eFIGURE 8.2**

Postinflammatory hyperpigmentation. (From Cohen BA. Disorders in pigmentation. In: *Pediatric Dermatology*. 4th ed. Saunders Elsevier; 2013:48–68.)

TABLE 8.3

## RELATIVE POTENCIES OF TOPICAL CORTICOSTEROIDS

Class	Drug	Vehicle(s)	Strength (%)
I. VERY HIGH POTENCY	Augmented betamethasone dipropionate	Ointment	0.05
	Clobetasol propionate	Cream, foam, ointment	0.05
	Diflorasone diacetate	Ointment	0.05
	Halobetasol propionate	Cream, ointment	0.05
II. HIGH POTENCY	Amcinonide	Cream, lotion, ointment	0.1
	Augmented betamethasone dipropionate	Cream	0.05
	Betamethasone propionate	Cream, foam, ointment, solution	0.05
	Desoximetasone	Cream, ointment, gel	0.25 (C,O), 0.05 (G)
	Diflorasone diacetate	Cream	0.05
	Fluocinonide	Cream, gel, ointment, solution	0.05
	Halcinonide	Cream, ointment	0.1
	Mometasone furoate	Ointment	0.1
	Triamcinolone acetonide	Cream, ointment	0.5
	III–IV. MEDIUM POTENCY	Betamethasone valerate	Cream, foam, lotion, ointment
Clocortolone pivalate		Cream	0.1
Desoximetasone		Cream	0.05
Fluocinolone acetonide, Flurandrenolide		Cream, ointment	0.025 (C), 0.05 (O)
Fluticasone propionate		Cream, ointment	0.05 (C), 0.005 (O)
Triamcinolone acetonide, Mometasone furoate		Cream	0.1
V. LOWER-MEDIUM POTENCY	Hydrocortisone butyrate	Cream, ointment, solution	0.1
	Hydrocortisone probutate, Prednicarbate	Cream	0.1
	Hydrocortisone valerate	Cream, ointment	0.2
VI. LOW POTENCY	Alclometasone dipropionate	Cream, ointment	0.05
	Desonide	Cream, gel, foam, ointment	0.05
	Fluocinonide acetonide	Cream, solution	0.01
VII. LOWEST POTENCY	Dexamethasone	Cream	0.1
	Hydrocortisone	Cream, lotion	0.25
		Cream, ointment	0.5
		Cream, solution	1
Hydrocortisone acetate	Cream, ointment	0.5–1	

C, Cream; G, gel; O, ointment.

Modified from Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. Section 2. Management and treatment of atopic dermatitis with topical therapies. *J Am Acad Dermatol.* 2014;71(1):116–132, Table 5.

steroid. Use of topical steroids in areas where skin is thin (groin, axilla, face, under breasts) should generally be avoided. Short durations of low-potency steroids may be used as needed in these areas. Ointments can be applied over steroid. Avoid overuse of steroids, as this can lead to chronic hyperpigmentation or hypopigmentation. Ensure that long-term eczema patients have frequent breaks from daily steroid use, such as week on and week off. Nonsteroidal topical agents may be used in sensitive areas; see below.

- (2) **Moderate disease: Crisaborole** is a topical PDE4 inhibitor approved for mild to moderate eczema, with preliminary studies of the 2% ointment showing improvement in the majority of clinical signs and symptoms, particularly pruritus.<sup>23</sup> Topical calcineurin inhibitors (**tacrolimus ointment, pimecrolimus cream**) are second-line therapies that should only be used in consultation with a dermatologist due to FDA “black box” warnings on these medications for theoretical increased risk of cancer, although there are no data to confirm, and long-term safety studies are pending.<sup>24,25</sup>
- (3) **Severe disease: Phototherapy** with narrowband UVB light is a treatment option for older children and adolescents. Low-dose **methotrexate** is a consideration before cyclosporine. For many dermatologists, low-dose oral methotrexate is the first oral option for severe disease unresponsive to aggressive topical therapy. Oral **cyclosporine** is only used in severe cases of older children and adolescents who have failed other treatments due to concern for renal compromise. **Dupilumab** is an IL-4 receptor  $\alpha$  antagonist prescribed for refractory cases, starting at age six. A number of new agents, including topical and oral JAK and interleukin inhibitors, are in clinical trials.



## 5. Complications<sup>26</sup>:

- Bacterial superinfection: Usually *S. aureus*, sometimes group A *Streptococcus*. Depending on extent of infection, treat with topical mupirocin or systemic antibiotics.
- Eczema herpeticum superinfection with herpes simplex virus can cause severe systemic infection. Presents as vesiculopustular lesions with central punched-out erosions that do not respond to oral antibiotics. Must be treated systemically with acyclovir or valacyclovir. Should be evaluated by ophthalmologist if there is concern for eye involvement.
- Many children with eczema can develop decreased quality of life such as problems with sleeping due to discomfort and bullying due to scarring and disfigurement.

## C. Papular Urticaria (Fig. 8.37, Color Plates)

- Pathogenesis:** Type IV hypersensitivity reaction to fleas, mosquitos, or bedbugs; also known as insect bite–induced hypersensitivity (IBIH)

2. **Clinical presentation/epidemiology:** Summarized by the SCRATCH principles<sup>27</sup>
  - a. **Symmetric eruption:** Exposed areas and scalp commonly affected. Sparing diaper region, palms, and soles
  - b. **Cluster:** Appear as “meal clusters” or “breakfast, lunch, and dinner,” which are linear or triangular groupings of lesions. Associated with bedbugs and fleas
  - c. **Rover not required:** A remote animal exposure or lack of pet at home does not rule out IBIH.
  - d. **Age:** Tends to peak by age 2. Not seen in newborn period. Most tend to develop tolerance by age 10.
  - e. **Target lesions:** Especially in darkly pigmented patients. **Time:** Emphasize chronic nature of eruption and need for patience and watchful waiting.
  - f. **Confused pediatrician/parent:** Diagnosis often met with disbelief by parent and/or referring pediatrician
  - g. **Household:** Because of the nature of the hypersensitivity, usually only affects one family member in the household
3. **Management (3 Ps):**
  - a. **Prevention:** Wear protective clothing, use insect repellent when outside (AAP guidelines recommend up to 30% DEET- or 12% picaridin-containing repellents), launder bedding and mattress pads for bedbugs, and maximize flea control for pets.
  - b. **Pruritis control:** Topical steroids or antihistamines may be of some benefit.
  - c. **Patience:** Can be frustrating because of its persistent, recurrent nature. Assure patients that their symptoms will resolve and they will eventually develop tolerance.

## **D. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis**

### **1. Pathogenesis:**

Severe mucocutaneous reaction with partial to full epidermal necrosis due to keratinocyte necrosis. Stevens-Johnson syndrome (SJS) has less than 10% involvement of body surface area (BSA), whereas toxic epidermal necrolysis (TEN) has greater than 30% BSA involvement. BSA involvement between 10% to 30% is termed SJS/TEN. Overall mortality for pediatric patients is less than 8%. Commonly caused by medications initiated in previous 8 weeks, including sulfonamide antibiotics, lamotrigine, carbamazepine, phenobarbital, and several oncologic drugs. May also be caused by *Mycoplasma pneumoniae* infections. Nearly one-third of cases have no identified trigger.

### **2. Clinical presentation:**

Fever and flu-like prodrome for 1 to 3 days prior to mucocutaneous lesions. Ophthalmologic and oropharyngeal symptoms are often first sites of mucosal involvement. Urogenital mucosal involvement seen in two-thirds of patients may lead to urinary retention and have significant long-term anatomic changes in female patients. Epidermal lesions are described as exquisitely tender (with pain out of proportion), ill-defined, coalescing macules and

patches of erythema with central purple-to-black areas. Lesions typically start on face and trunk then spread in a symmetric distribution sparing the scalp, palms, and soles. Bullae form with disease progression. Then, the epidermis sloughs with positive Nikolsky and Asboe-Hansen (lateral expansion of bullae with pressure) signs. Acute phase may last 8 to 12 days with reepithelization requiring up to four weeks.

### 3. **Diagnosis:**

Although usually not necessary, clinical diagnosis may be confirmed with a skin biopsy. Additional workup includes Complete blood count (CBC), comprehensive metabolic panel (CMP), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), bacterial and fungal cultures, *M. pneumoniae* PCR, and Chest x-ray (CXR).

### 4. **Treatment:**

Remove offending agent, supportive care, and close monitoring of all organ systems in the inpatient/ICU setting. There is controversy regarding IVIG and single dose of tumor necrosis factor alpha (TNF-alpha) inhibitor early in course. Systemic steroids probably should not be used.

### 5. **Complications:**

At risk for serious complications, including secondary bacterial infections (*Staphylococcus aureus* and *Pseudomonas aeruginosa*), septic shock, pneumonia, acute respiratory distress syndrome (ARDS), and epithelial necrosis of the GI tract. Most common complication in children is corneal scarring and dry eye.

## VIII. NAIL DISORDERS<sup>28</sup>

1. Acquired nail disorders
  - a. Paronychia: Red, tender, purulent swelling of proximal or lateral nail folds (eFigs. 8.3 and 8.4)
    - (1) Acute form: Caused by bacterial invasion after trauma to cuticle
      - (a) Clinical features: Exquisite pain, sudden swelling, and abscess formation around one nail
2. Congenital/hereditary nail disorders
  - a. Isolated nail disorders (eFigs. 8.5 and 8.6)
    - (1) Congenital nail dystrophy: Clubbing and spooning (koilonychia), may be autosomal dominant with no other anomalies

## IX. DISORDERS OF PIGMENTATION<sup>29</sup>

1. Hyperpigmentation
  - a. Congenital melanocytic nevi (CMN): Melanocytic nevi that are either present at birth or appear within the first few months of life in 1% to 3% of neonates<sup>30</sup>
    - (1) Appearance: Black or tan with irregular borders and often dark terminal hairs
    - (2) Risks:
      - (a) Melanoma—At least 5% of large CMN greater than 20 cm with 70% of this cohort having cancerous transformation by 10 years

**eFIGURE 8.3**

Acute paronychia. (From Cohen BA. Disorders of the hair and nails. In: *Pediatric Dermatology*. 5th ed. Saunders Elsevier; 2022:2229–259.)

**eFIGURE 8.4**

Chronic paronychia. (From Cohen BA. Disorders of the hair and nails. In: *Pediatric Dermatology*. 4th ed. Saunders Elsevier; 2013:211–239.)

**eFIGURE 8.5**

Koilonychia. (From Cohen BA. Disorders of the hair and nails. In: *Pediatric Dermatology*. 5th ed. Saunders Elsevier; 2022:227–259.)

**eFIGURE 8.6**

Congenital ingrown nails. (From Cohen BA. Disorders of the hair and nails. In: *Pediatric Dermatology*. 4th ed. Saunders Elsevier; 2013:211–239.)

of age.<sup>31</sup> The presence of approximately 20 satellite nevi (smaller congenital nevi) also increases risk of melanoma.

(b) Neurocutaneous melanosis—Children with large, multiple, satellite nevi, or lesions over the spine are at risk for leptomeningeal involvement with symptoms that may include hydrocephalus and seizures that may require evaluation by gadolinium contrast MRI.<sup>32,33</sup>

- b. Epidermal melanosis: Most lesions appear tan or light brown
    - (1) Café-au-lait spots (eFig. 8.1): Discrete tan macules that appear at birth or during childhood in 10% to 20% of normal individuals, sizes vary from freckles to patches, may involve any site on skin. May be diagnostic marker for neurofibromatosis type 1 ( $\geq 6$  lesions, each greater than 5 mm in diameter in prepubertal, or greater than 15 mm in postpubertal child) or other syndromes
2. Hypopigmentation and depigmentation
- a. Localized hypopigmentation
    - (1) Hypopigmented macules (eFig. 8.7)
      - (a) Epidemiology: 0.1% to 0.5% of normal newborns have a single hypopigmented macule, but it may be a marker for tuberous sclerosis as 70% to 90% of those affected have such macules on the trunk at birth.
3. Dyspigmentation
- a. Blaschkoid dyspigmentation<sup>34</sup>: Congenital hypopigmentation and hyperpigmentation along the lines of Blaschko (eFig. 8.8)
    - (1) Patterns of hyper- or hypopigmentation: Whorl shape on trunk, V shape on the back, waves on the vertex scalp

## X. RASHES OF UNKNOWN OR INFLAMMATORY ETIOLOGY


1. Pityriasis lichenoides et varioliformis acuta (PLEVA) and pityriasis lichenoides chronica (PLC)
- a. **Pathogenesis:** Spectrum of rare disorders known as the “pityriasis lichenoides” separated into acute and chronic forms. Pathogenesis theorized to involve T-cell dyscrasia and abnormal immune response to viral, bacterial, or protozoal infection
  - b. **Presentation:** Typically affects children and young adults. PLEVA is an acute eruption of multiple erythematous macules, papules, and/or vesicles, which can become hemorrhagic or necrotic, affecting any cutaneous surface but without mucosal involvement. Lesions resolve over a few weeks, but new lesions develop as prior lesions fade. The rash may be asymptomatic, pruritic, or painful and last from a few weeks to 2 years. Some patients can go on to develop PLC, which is described as a more gradual development of red-brown papules that relapses and remits over months to years. In both conditions, hyper- or hypopigmentation commonly persists after resolution of lesions, but scarring may or may not occur.



∞

**eFIGURE 8.7**

Congenital hypopigmented macule. (From Cohen BA. Disorders in pigmentation. In: *Pediatric Dermatology*. 5th ed. Saunders Elsevier; 2022:157–179.)

**eFIGURE 8.8**

Blaschkoid dyspigmentation. (From Cohen BA. Disorders in pigmentation. In: *Pediatric Dermatology*. 5th ed. Saunders Elsevier; 2022:157–179.)

- c. **Diagnosis:** Skin biopsy is required to confirm diagnosis with typical histopathologic findings. Immunohistochemistry may reveal CD8+ T-cell inflammatory infiltrate.
  - d. **Treatment:** Usually benign and self-limiting and does not require treatment. If lesions are widespread, debilitating, or scarring, first-line therapies include systemic antibiotics and topical corticosteroids. Limited treatment data exist due to rarity of disorder and lack of clinical trials. Resistant cases may respond to phototherapy.
2. Confluent and reticulated papillomatosis (CARP) (Fig. 8.38, Color Plates)
- a. **Pathogenesis:** Unknown, but possibly related to disordered keratinization resulting in hyperproliferation. Reports also link CARP to *Malassezia* infection
  - b. **Presentation:** Hyperpigmented, scaly macules and/or papillomatous papules that coalesce into patches in a reticular pattern. Lesions are typically most prominent in the intermammary, interscapular, neck, and axillary regions, and spare the mucosa. The rash can be mildly pruritic but is usually asymptomatic and can persist for up to 3 years if not treated.
  - c. **Diagnosis:** Clinical diagnosis, but KOH scraping to rule out tinea may be necessary. Skin biopsy can be helpful, but there are no diagnostic histologic findings for CARP.
  - d. **Treatment:** Systemic antibiotic therapy with doxycycline or minocycline is the mainstay of treatment. Benefits are attributed to the antiinflammatory properties, rather than antibacterial, as no specific bacterial cause has been identified.
3. Giannotti-Crosti syndrome, or popular acrodermatitis of childhood
- a. **Pathogenesis:** Possibly related to viral illness such as Epstein-Barr virus (most common trigger in the United States) or hepatitis B (most common trigger in Europe). There may be an association with IgE-mediated immunity and atopy.
  - b. **Presentation:** Occurs primarily in children younger than 5 years old. Acute eruption of papules and vesicles involving the extensor surfaces of arms, legs, and feet, with involvement of face and buttocks. The trunk is relatively spared, and the mucosa is not involved. The lesions are flat-topped and typically either skin colored, pink, or brown. Symptoms of pruritis are variable. Occasionally, hemorrhagic lesions can occur, and Koebner phenomenon has been observed. Patients may experience concomitant malaise, fever, and diarrhea.
  - c. **Diagnosis:** Clinical diagnosis, but skin biopsy may be used to exclude other diagnoses
  - d. **Treatment:** Self-limited disease that resolves within 2 months. Antipruritic topical creams may be used for symptomatic relief but do not alter duration of disease.

#### H. Autoimmune Bullous Diseases: See Section XI, Online Content.

### REFERENCES

A complete list of references can be found online.

**XI. ONLINE CONTENT****A. Autoimmune and Allergic Lesions**1. **Autoimmune** bullous diseases

- a. Very rare in children but should be considered if bullous lesions do not respond to standard therapy. Suspicion for any of the following should warrant referral to a dermatologist for diagnosis and management.
- b. **Pemphigus vulgaris** (eFig. 8.9):
  - (1) Pathogenesis: IgG autoantibodies to epidermal adhesion molecules, which interrupt integrity of epidermis and/or mucosa and result in extensive blister formation
  - (2) Clinical presentation: Flaccid bullae that start in the mouth and spread to face, scalp, trunk, extremities, and other mucosal membranes. Positive Nikolsky sign. Ruptured blisters are painful and prone to secondary infection. Can lead to impaired oral intake if there is significant oral mucosal involvement
  - (3) Treatment: Systemic glucocorticoids, rituximab, and/or intravenous immunoglobulin

**eFIGURE 8.9**

Pemphigus vulgaris. (From Cohen BA. *Dermatology Image Atlas*; 2001. <http://www.dermatlas.org/>)

## REFERENCES

1. ISSVA classification for vascular anomalies. International society for the study of vascular anomalies. <http://www.issva.org/UserFiles/file/ISSVA-Classification-2018.pdf>
2. Darrow D, Greene A, Mancini A, Nopper A. Diagnosis and management of infantile hemangioma. *Pediatrics*. 2015;136:e1060.
3. Krowchuk D, et al. Clinical practice guideline for the management of infantile hemangiomas. *Pediatrics*. 2019;143(1):1–28.
4. Hartemink DA, Chiu YE, Drolet BA, et al. PHACES syndrome: a review. *Int J Pediatr Otorhinolaryngol*. 2009;73:181–187.
5. FDA. Pierre Fabre Pharmaceuticals. *Hemangeol*. 2014. [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/205410s000lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205410s000lbl.pdf)
6. Baselga E, Dembowska-Baginska B, Przewratil P, et al. Efficacy of propranolol between 6 and 12 months of age in high-risk infantile hemangioma. *Pediatrics*. 2018;142(3):e20173866.
7. Bauman NM, McCarter RJ, Guzzetta PC, et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial. *JAMA Otolaryngol Head Neck Surg*. 2014;140(4):323–330.
8. McInerny T, Cohen BA, Rozell-Shannon L. Commentary: Vascular birthmarks in infants: importance of treating the 10%. *AAP Publications: AAP News*. Accessed February 2023. <https://publications.aap.org/aapnews/news/8474/Commentary-Vascular-birthmarks-in-infants?autologincheck=redirected>
9. Kwok CS, Gibbs S, Bennett C. Topical treatment for cutaneous warts. *Cochrane Database Syst Rev*. 2012;9:CD001781.
10. Hicks MI, Elston DM. Scabies. *Dermatol Ther*. 2009;22:279–292.
11. Andrews MD, Burns M. Common tinea infections in children. *Am Fam Physician*. 2008;77:1415–1420.
12. Tinea capitis. In: *The Red Book*. 32nd ed. American Academy of Pediatrics; <https://publications.aap.org/redbook/book/347/chapter/5757153/Tinea-Capitis-Ringworm-of-the-Scalp>. Accessed January 29, 2023.
13. Alkhalifah A, Alsantali A, Wang E, et al. Alopecia areata update: part II. Treatment. *J Am Acad Dermatol*. 2010;62:191–202.
14. Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. *Pediatrics*. 2006;118:1188–1199.
15. Archer CB, Cohen SN, Baron SE. Guidance on the diagnosis and clinical management of acne. *Clin Exp Dermatol*. 2012;37(suppl 1):1–6.
16. Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. *Pediatrics*. 2013;131(suppl 3):S163–S186.
17. Kawshima M, Harada S, Loesche C, Miyachi Y. Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded controlled study. *J Dermatol Sci*. 2008;49(3):241.
18. Graupe K, Cunliffe WJ, Gollnick HP, Zaumseil RP. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. *Cutis*. 1996;57(suppl 1):20.
19. Pogacar MS, Maver U, Varda NM, Micetc-Turk D. Diagnosis and management of diaper dermatitis in infants with emphasis on skin microbiota in the diaper area. *Int J Dermatol*. 2018;57:265–275.
20. Alston S, Cohen B, Braun M. Persistent and recurrent tinea corporis in children treated with combination antifungal/corticosteroid agents. *Pediatrics*. 2003;111:201.

21. McAleer MA, Flohr C, Irvine AD. Management of difficult and severe eczema in childhood. *BMJ*. 2012;345:e4770.
22. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. Section 2. Management and treatment of atopic dermatitis with topical therapies. *J Am Acad Dermatol*. 2014;71(1):116–132.
23. Stein Gold LF, Spelman L, Spellman MC, Hughes MH, Zane LT. A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. *J Drugs Dermatol*. 2015;14(12):1394.
24. Patel TS, Greer SC, Skinner Jr RB. Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. *Am J Clin Dermatol*. 2007;8:189–194.
25. Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ, American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American academy of dermatology association task force. *J Am Acad Dermatol*. 2006;54(5):818.
26. Boquniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. *J Allergy Clin Immunol*. 2010;125:4–13.
27. Hernandez RG, Cohen BA. Insect bite-induced hypersensitivity and the SCRATCH principles: a new approach to papular urticaria. *Pediatrics*. 2006;118:e189–e196.
28. Cohen BA. Disorders of the hair and nails. In: *Pediatric Dermatology*. 5th ed. Elsevier; 2022:227–259.
29. Cohen BA. Disorders in pigmentation. In: *Pediatric Dermatology*. 5th ed. Elsevier; 2022:157–179.
30. Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestation status using updated classification and nomenclature. *J Pediatr*. 2012;161(2):240–245.
31. Marghoob AA. Congenital melanocytic nevi. Evaluation and management. *Dermatol Clin*. 2002;20:607.
32. Marghoob AA. Number of satellite nevi as a correlate for neurocutaneous melanocytosis in patients with large congenital melanocytic nevi. *JAMA Arch Dermatol* (1960–2012). 2012;140(2):171–175.
33. Di Rocco F, Sabatino G, Koutzoglou M, Battaglia D, Caldarelli M, Tamburrini G. Neurocutaneous melanosis. *Childs Nerv Syst*. 2004;20(1):23.
34. Cohen J, Shahrokh K, Cohen B. Analysis of 36 cases of Blaschkoid dyspigmentation: reading between the lines of Blaschko. *Pediatr Dermatol*. 2014;31(4):471–476.



**FIGURE 8.1**

Infantile hemangioma. (From Cohen BA. *Atlas of Pediatric Dermatology*. 3rd ed. Mosby; 2005:126.)



**FIGURE 8.2**

Pyogenic granuloma. (From Cohen BA. *Dermatology Image Atlas*; 2001. <http://www.dermatlas.org/>)



**FIGURE 8.3**

Molluscum contagiosum. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:131.)




**FIGURE 8.5**

Herpetic gingivostomatitis. (Modified from Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:106.)



**FIGURE 8.6**

Herpes zoster. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:110.)



**FIGURE 8.7**

Varicella. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:108.)



**FIGURE 8.8**

Measles. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:175.)



**FIGURE 8.9**

Pityriasis rosea. (From Cohen BA. *Atlas of Pediatric Dermatology*. 5th ed. Elsevier Limited; 2021.)



**FIGURE 8.10**

Pityriasis rosea. (From Cohen BA. *Atlas of Pediatric Dermatology*. 5th ed. Elsevier Limited; 2021.)



**FIGURE 8.11**

Roseola. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:177.)



**FIGURE 8.12**

Scabies; finger webbing. (From Cohen BA. *Atlas of Pediatric Dermatology*. 3rd ed. Mosby; 2005:126.)



**FIGURE 8.13**

Scabies. (From Cohen BA. *Atlas of Pediatric Dermatology*. 5th ed. Elsevier Limited; 2021.)



**FIGURE 8.14**

Scabies. (From Cohen BA. *Atlas of Pediatric Dermatology*. 5th ed. Elsevier Limited; 2021.)



**FIGURE 8.15**

Tinea capitis. (From Cohen BA. *Atlas of Pediatric Dermatology*. 3rd ed. Mosby; 1993.)



**FIGURE 8.16**

Kerion. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:218c.)



**FIGURE 8.17**

Tinea corporis. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:96.)



**FIGURE 8.18**

Tinea pedis. (From Cohen BA. *Dermatology Image Atlas*; 2001. <http://www.dermatlas.org/>)



**FIGURE 8.19**

Tinea versicolor. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:99.)



**FIGURE 8.20**

Scarlet fever. (From Cohen BA. *Dermatology Image Atlas*; 2001. <http://www.dermatlas.org/>)



**FIGURE 8.22**

Traction alopecia. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:220.)



**FIGURE 8.23**

Erythema toxicum neonatorum. (From Cohen BA. *Pediatric Dermatology*. 2nd ed. Mosby; 1999:18.)



**FIGURE 8.24**

Transient neonatal pustular melanosis. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:20.)



**FIGURE 8.25**

Hyperpigmentation from resolving transient neonatal pustular melanosis. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:20.)



**FIGURE 8.26**

Miliaria rubra. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:21.)



**FIGURE 8.27**

Milia. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:22.)



**FIGURE 8.28**

Neonatal acne. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:22.)



**FIGURE 8.29**

Seborrheic dermatitis. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:32.)



**FIGURE 8.30**

Seborrheic dermatitis. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:32.)




**FIGURE 8.31**

Diaper candidiasis. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:33.)



**FIGURE 8.32**

Poison ivy. (From Cohen BA. *Dermatology Image Atlas*; 2001. <http://www.dermatlas.org/>)



**FIGURE 8.33**

Infantile eczema. (From Cohen BA. *Atlas of Pediatric Dermatology*. 3rd ed. Mosby; 2005:79.)




**FIGURE 8.34**

Nummular eczema. (From Cohen BA. *Atlas of Pediatric Dermatology*. 3rd ed. Mosby; 2005:80.)



**FIGURE 8.35**

Follicular eczema. (From Cohen BA. *Atlas of Pediatric Dermatology*. 4th ed. Elsevier Limited; 2013:83.)




**FIGURE 8.36**

Childhood eczema with lesion in suprapubic area. (From Cohen BA. *Atlas of Pediatric Dermatology*. 3rd ed. Mosby; 2005.)



**FIGURE 8.37**

Papular urticaria from insect bite. (From Cohen BA. *Atlas of Pediatric Dermatology*. 5th ed. China: Elsevier Limited; 2021.)



**FIGURE 8.38**

Confluent reticulated papillomatosis. (From Cohen BA. *Atlas of Pediatric Dermatology*. 5th ed. Elsevier Limited; 2021.)

# Chapter 9

## Development, Behavior, and Developmental Disability

*Brenna M. Beck, MD, MEd and Christle Nwora, MD*

 See additional content online.

### I. DEVELOPMENTAL DEFINITIONS<sup>1,2</sup>

#### A. Developmental Streams

1. **Gross motor skills:** Descriptions of posture and locomotion that involve the use of large proximal core muscle groups in the upper and lower extremities. Examples of gross motor skills include walking, running, and jumping.
2. **Fine motor skills:** Upper extremity distal muscle coordination and hand manipulative abilities and hand-eye coordination. Examples of fine motor skills include picking up small objects between the thumb and index finger (pincer grasp).
3. **Visual-motor problem-solving skills:** Integrated set of fine motor, eye-hand coordination, and cognitive skills. These require an intact motor substrate and a given level of nonverbal cognitive ability. Examples of visual-motor problem-solving skills include solving a puzzle or drawing shapes.
4. **Language:** The ability to understand and communicate with another person. This is the best predictor of intellectual performance in the absence of a communication disorder or significant hearing loss.
5. **Personal-social skills:** Communicative in origin; represent the cumulative use of language comprehension and expression and problem-solving skills to interact with others. Examples may include reciprocal play, sharing, and eye contact.
6. **Adaptive skills:** Skills concerned with self-help or activities of daily living. Examples of adaptive skills include toileting and brushing teeth.

#### B. Developmental Quotient

1. **A calculation that reflects the rate of development** in any given stream; represents the percentage of normal development present at the time of testing

$$\text{Developmental quotient (DQ)} = \frac{\text{Developmental age (DA)}}{\text{Chronological age (CA)}} \times 100\%$$

2. **Two separate developmental assessments** over time are more predictive of later abilities than a single assessment.<sup>2</sup>

3. In contrast to developmental quotient (DQ), intelligence quotient (IQ) **has greater statistical reliability and validity**. Biases may occur in IQ test results, which may be attributable to culture and environment.

### C. Abnormal Development

1. **Delay:** Performance significantly below average in a given area of development. May occur in a single stream or several streams (“global developmental delay”)
2. **Deviancy:** Atypical development within a single stream, such as developmental milestones occurring out of sequence. Deviancy does not necessarily imply abnormality but should alert one to the possibility that problems may exist. *Example:* An infant who rolls at an early age may have abnormally increased tone.
3. **Dissociation:** A substantial difference in the rate of development between two or more streams. *Example:* Increased motor delay relative to cognition seen in some children with cerebral palsy (CP)
4. **Two separate developmental assessments** over time are more predictive of later abilities than a single assessment.

9

## II. GUIDELINES FOR NORMAL DEVELOPMENT AND BEHAVIOR

### A. Developmental Milestones

Developmental assessment is based on the premise that milestone acquisition occurs at a specific rate in an orderly and sequential manner: See [Table 9.1](#)

**B. Age-Appropriate Behavioral Issues in Infancy and Early Childhood: See [Table 9.2](#)**

## III. DEVELOPMENTAL SCREENING AND EVALUATION OF DEVELOPMENTAL DISORDERS

### A. Developmental Screening and Screening Guidelines

1. **Developmental *surveillance* should be included in every well child visit, and any concerns should be addressed immediately with formal screening.** This includes direct observation of the child and eliciting and attending to the parent’s concerns.
2. **Standardized developmental *screening* should be administered at 9-month, 18-month, and 30-month well child visits,** in the absence of developmental concerns. If a 30-month visit is not possible, this screening can be done at the 24-month visit.
3. See full American Academy of Pediatrics (AAP) guideline for developmental screening algorithm.<sup>3</sup>

**B. Commonly Used Developmental Screening and Assessment Tools: See [Table 9.3](#)**

**C. Identification of Developmental “Red Flags”: See [Table 9.4](#)**

### D. Evaluation of Abnormal Development

1. Referral to developmental and appropriate specialists
2. Referral to early intervention services for children aged 0 to 3 years (see [Section V](#))

TABLE 9.1

## DEVELOPMENTAL MILESTONES

Age	Social/Emotional Milestones	Language/Communication Milestones	Cognitive Milestones (learning, thinking, problem-solving)	Movement/Physical Development Milestones
2 months	Calms down when spoken to or picked up; looks at your face; seems happy to see you when you walk up to her; smiles when you talk to or smile at her	Makes sounds other than crying; reacts to loud sounds	Watches you as you move; looks at a toy for several seconds	Holds head up while on tummy; Moves both arms and both legs; Opens hands briefly
4 months	Smiles on his own to get your attention; chuckles (not yet a full laugh) when you try to make him laugh; looks at you, moves, or makes sounds to get or keep your attention	Makes cooing sounds (“ooo”, “aahh”); makes sounds back when you talk to him; turns head toward the sound of your voice	If hungry, opens mouth when he sees breast or bottle; looks at her hands with interest	Holds head steady without support when you are holding him; holds a toy when you put it in his hand; uses his arm to swing at toys; brings hands to mouth; pushes up onto elbows-forearms when on tummy
6 months	Knows familiar people; likes to look at self in a mirror; laughs	Takes turns making sounds with you; blows “raspberries” (sticks tongue out and blows); makes squealing noises	Puts things in her mouth to explore them; reaches to grab a toy she wants; closes lips to show she doesn’t want more food	Rolls from tummy to back; ushes up with straight arms when on tummy; leans on hands to support herself when sitting
9 months	Is shy, clingy, or fearful around strangers; shows several facial expressions, like happy, sad, angry, and surprised; looks when you call her name; reacts when you leave (looks, reaches for you, or cries); smiles or laughs when you play peek-a-boo	Makes a lot of different sounds like “mamamama” and “bababababa”; lifts arms up to be picked up	Looks for objects when dropped out of sight (like his spoon or toy); bangs two things together	Gets to a sitting position by herself; moves things from one hand to her other hand; uses fingers to “rake” food towards himself; sits without support

12 months	Plays games with you, like pat-a-cake	Waves “bye-bye”; calls a parent “mama” or “dada” or another special name; understands “no” (pauses briefly or stops when you say it)	Puts something in a container, like a block in a cup; looks for things he sees you hide, like a toy under a blanket	Pulls up to stand; walks, holding on to furniture; drinks from a cup without a lid, as you hold it; picks things up between thumb and pointer finger, like small bits of food
15 months	Copies other children while playing, like taking toys out of a container when another child does; shows you an object she likes; claps when excited; hugs stuffed doll or other toy; shows you affection (hugs, cuddles, or kisses you)	Tries to say one or two words besides “mama” or “dada,” like “ba” for ball or “da” for dog; looks at a familiar object when you name it; follows directions given with both a gesture and words (for example, he gives you a toy when you hold out your hand and say, “Give me the toy.”); points to ask for something or to get help	Tries to use things the right way, like a phone, cup, or book; stacks at least two small objects, like blocks	Takes a few steps on his own; uses fingers to feed herself some food
18 months	Moves away from you, but looks to make sure you are close by; points to show you something interesting; puts hands out for you to wash them; looks at a few pages in a book with you; helps you dress him by pushing arm through sleeve or lifting up foot	Tries to say three or more words besides “mama” or “dada”; follows one-step directions without any gestures, like giving you the toy when you say, “Give it to me.”	Copies you doing chores, like sweeping with a broom; plays with toys in a simple way, like pushing a toy car	Walks without holding on to anyone or anything; scribbles; drinks from a cup without a lid and may spill sometimes; feeds himself with his fingers; tries to use a spoon; climbs on and off a couch or chair without help

*Continued*

TABLE 9.1

## DEVELOPMENTAL MILESTONES—CONT'D

Age	Social/Emotional Milestones	Language/Communication Milestones	Cognitive Milestones (learning, thinking, problem-solving)	Movement/Physical Development Milestones
24 months	Notices when others are hurt or upset, like pausing or looking sad when someone is crying; looks at your face to see how to react in a new situation	Points to things in a book when you ask, like “Where is the bear?”; says at least two words together, like “More milk,”; points to at least two body parts when you ask him to show you; uses more gestures than just waving and pointing, like blowing a kiss or nodding yes	Holds something in one hand while using the other hand (for example, holding a container and taking the lid off); tries to use switches, knobs, or buttons on a toy; plays with more than one toy at the same time, like putting toy food on a toy plate	Kicks a ball; runs; walks (not climbs) up a few stairs with or without help; eats with a spoon
30 months	Plays next to other children and sometimes plays with them; shows you what she can do by saying, “Look at me!”; follows simple routines when told, like helping to pick up toys when you say, “It’s clean-up time.”	Says about 50 words; says two or more words together, with one action word, like “Doggie run”; names things in a book when you point and ask, “What is this?”; says words like “I,” “me,” or “we”	Uses things to pretend, like feeding a block to a doll as if it were food; shows simple problem-solving skills, like standing on a small stool to reach something; follows two-step instructions like “Put the toy down and close the door.”; shows he knows at least one color, like pointing to a red crayon when you ask, “Which one is red?”	Uses hands to twist things, like turning doorknobs or unscrewing lids; takes some clothes off by himself, like loose pants or an open jacket; jumps off the ground with both feet; turns book pages, one at a time, when you read to her

3 years	Calms down within 10 minutes after you leave her, like at a childcare drop off; notices other children and joins them to play	Talks with you in conversation using at least two back-and-forth exchanges; asks “who,” “what,” “where,” or “why” questions, like “Where is mommy/daddy?”; says what action is happening in a picture or book when asked, like “running,” “eating,” or “playing”; says first name, when asked; talks well enough for others to understand, most of the time	Draws a circle, when you show him how; avoids touching hot objects, like a stove, when you warn her	Strings items together, like large beads or macaroni; puts on some clothes by himself, like loose pants or a jacket; uses a fork
4 years	Pretends to be something else during play (teacher, superhero, dog); asks to go play with children if none are around, like “Can I play with Alex?”; comforts others who are hurt or sad, like hugging a crying friend; avoids danger, like not jumping from tall heights at the playground; likes to be a “helper”; changes behavior based on where she is (place of worship, library, playground)	Says sentences with four or more words; says some words from a song, story, or nursery rhyme; talks about at least one thing that happened during her day, like “I played soccer.”; answers simple questions like “what is a coat for?” or “What is a crayon for?”	Names a few colors of items; tells what comes next in a well-known story; draws a person with three or more body parts	Catches a large ball most of the time; serves herself food or pours water, with adult supervision; unbuttons some buttons; holds crayon or pencil between fingers and thumb (not a fist)

*Continued*

TABLE 9.1

## DEVELOPMENTAL MILESTONES—CONT'D

Age	Social/Emotional Milestones	Language/Communication Milestones	Cognitive Milestones (learning, thinking, problem-solving)	Movement/Physical Development Milestones
5 years	Follows rules or takes turns when playing games with other children; sings, dances, or acts for you; does simple chores at home, like matching socks or clearing the table after eating	Tells a story she heard or made up with at least two events (for example, a ball was stuck in a tree and a firefighter saved it); answers simple questions about a book or story after you read or tell it to him; keeps a conversation going with more than three back-and-forth exchanges; uses or recognizes simple rhymes (bat-cat, ball-tall)	Counts to 10; names some numbers between 1 and 5 when you point to them; uses words about time, like “yesterday,” “tomorrow,” “morning,” or “night”; pays attention for 5 to 10 minutes during activities (for example, during story time or making arts and crafts – but screen time does not count); writes some letters in her name; names some letters when you point to them	Buttons some buttons; hops on one foot

CDC Developmental Milestones. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. Last Reviewed: Dec 29, 2022. Available at [cdc.gov/ncddd/actearly/milestones/index.html](https://www.cdc.gov/ncddd/actearly/milestones/index.html). Jennifer M. Zubler, Lisa D. Wiggins, Michelle M. Macias, Toni M. Whitaker, Judith S. Shaw, Jane K. Squires, Julie A. Pajek, Rebecca B. Wolf, Karnesha S. Slaughter, Amber S. Broughton, Krysta L. Gerndt, Bethany J. Mlodoch, Paul H. Lipkin; Evidence-Informed Milestones for Developmental Surveillance Tools. *Pediatrics* March 2022; 149 (3): e2021052138. 10.1542/peds.2021-052138.

TABLE 9.2

## AGE-APPROPRIATE BEHAVIORAL ISSUES IN INFANCY AND EARLY CHILDHOOD

Age	Behavioral Issue	Symptoms	Guidance
1–3 months	Colic	Paroxysms of fussiness/ crying, $\geq 3$ per day, $\geq 3$ days/week, may pull knees up to chest, pass flatus	Crying usually peaks at 6 weeks and resolves by 3 –4 months. Prevent overstimulation; swaddle infant; use white noise, swing, or car rides to soothe. Avoid medication and formula changes. Encourage breaks for the primary caregiver.
3–4 months	Trained night feeding	Night awakening	Comfort quietly, avoid reinforcing behavior (i.e., avoid night feeds). Do not play at night. Introducing cereal or solid food does not reduce awakening. Develop a consistent bedtime routine. Place baby in bed while drowsy and not fully asleep.
9 months	Stranger anxiety/ separation anxiety	Distress when separated from parent or approached by a stranger	Use a transitional object (e.g., special toy, blanket). Use routine or ritual to separate from parent. May continue until 24 months but can reduce in intensity
	Developmental night waking	Separation anxiety at night	Keep lights off. Avoid picking child up or feeding. May reassure verbally at regular intervals or place a transitional object in crib
12 months	Aggression	Biting, hitting, kicking in frustration	Say “no” with negative facial cues. Begin time out (1 minute/year of age). No eye contact or interaction, place in a nonstimulating location. May restrain child gently until cooperation is achieved
	Need for limit setting	Exploration of environment, danger of injury	Avoid punishing exploration or poor judgment. Emphasize childproofing and distraction.
18 months	Temper tantrums	Occur with frustration, attention-seeking rage, negativity/refusal	Try to determine cause, react appropriately (i.e., help child who is frustrated, ignore attention-seeking behavior). Make sure child is in a safe location.

Continued

TABLE 9.2

## AGE-APPROPRIATE BEHAVIORAL ISSUES IN INFANCY AND EARLY CHILDHOOD—CONT'D

Age	Behavioral Issue	Symptoms	Guidance
24 months	Toilet training	Child needs to demonstrate readiness: shows interest, neurologic maturity (i.e., recognizes urge to urinate or defecate), ability to walk to bathroom and undress self, desire to please/imitate parents, increasing periods of daytime dryness	Age range for toilet training is usually 2–4 years. Give guidance early; may introduce potty seat but avoid pressure or punishment for accidents. Wait until the child is ready. Expect some periods of regression, especially with stressors.
24–36 months	New sibling	Regression, aggressive behavior	Allow for special time with parent, 10–20 min daily of one-on-one time exclusively devoted to the older sibling(s). Child chooses activity with parent. No interruptions. May not be taken away as punishment
36 months	Nightmares	Awakens crying, may or may not complain of bad dream	Reassure child, explain that he or she had a bad dream. Leave bedroom door open, use a nightlight, demonstrate there are no monsters under the bed. Discuss dream the following day. Avoid scary movies or television shows.
	Night terrors	Agitation, screaming 1–2 hours after going to bed. Child may have eyes open but not respond to parent. May occur at same time each night	May be familial, not volitional. <i>Prevention:</i> For several nights, awaken child 15 min before terrors typically occur. Avoid overtiredness. <i>Acute:</i> Be calm; speak in soft, soothing, repetitive tones; help child return to sleep. Protect child against injury.

From Dixon SD, Stein MT. *Encounters With Children: Pediatric Behavior and Development*. Mosby; 2000.

3. Medical evaluation as outlined in [Tables 9.5 through 9.7](#)
4. Genetic evaluation ([Table 9.8](#)) is warranted for all children with developmental delay or intellectual disability (ID) if the cause is not known (e.g., previous traumatic brain injury or neurologic insult).

TABLE 9.3

## DEVELOPMENTAL SCREENING TESTS BY DIAGNOSIS

Diagnosis Evaluated	Screening Test	Age	Completed by	Comments	Weblink
Cognitive and motor development	Ages and Stages Questionnaire (ASQ)	4–60 months	Parent	Increased time efficiency (can fill out while waiting) Documents milestones that are difficult to assess in the office	<a href="https://www.agesandstages.com">https://www.agesandstages.com</a>
Developmental and behavioral problems	Parents' Evaluation of Developmental Status (PEDS)	0–8 years	Parent	May also be useful as a surveillance tool	<a href="https://www.pedstest.com">https://www.pedstest.com</a>
Language, problem-solving development	Capute Scales: Clinical Linguistic and Auditory Milestone Scale (CLAMS), Clinical Adaptive Test (CAT)	3–36 months	Clinician	Give quantitative DQs for language (CLAMS) and visual-motor/problem-solving (CAT) abilities	<a href="https://brookespublishing.com/product/the-capute-scales/">https://brookespublishing.com/product/the-capute-scales/</a>
Autism spectrum disorders	Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F)	16–30 months	Parent	Positive screens require clinician follow-up	<a href="https://mchatscreen.com/">https://mchatscreen.com/</a>
	Communication and Symbolic Behavior Scales and Developmental Profile (CSBS DP; Infant-Toddler Checklist)	6–24 months	Parent	The Infant Toddler Checklist is a one-page questionnaire that is part of a larger standardized screening tool (CSBS DP) Can be used in patients as young as 6 months	<a href="https://www.brookespublishing.com/checklist.pdf">https://www.brookespublishing.com/checklist.pdf</a>
	Childhood Autism Screening Test (CAST)	4–11 years	Parent	Only screening tool evaluated in preschool population	<a href="https://www.autismresearchcentre.com/tests/childhood-autism-spectrum-test-cast/">https://www.autismresearchcentre.com/tests/childhood-autism-spectrum-test-cast/</a>

Modified from American Academy of Pediatrics. Identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening. *Pediatrics*. 2006;118:405–420; American Academy of Pediatrics. Identification and evaluation of children with autism spectrum disorders. *Pediatrics*. 2007;120:1183–1215; Robins DL, Casagrande K, Barton M, et al. Validation of the Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F). *Pediatrics*. 2014;133:37–45.

**TABLE 9.4****DEVELOPMENTAL “RED FLAGS”**

Age of Patient	“Red Flag” Symptom
Any age	Loss of previously obtained developmental skills Parental or professional concerns about vision, including: vision fixing, following an object, or a confirmed visual impairment Hearing loss Persistently low muscle tone or floppiness Asymmetry of movements or other features suggestive of cerebral palsy, such as increased muscle tone Head circumference above the 99.6th percentile, below 0.4th percentile, or has crossed two major percentile lines (up or down)
5 months (corrected for gestation)	Not able to hold object placed in hand
6 months (corrected for gestation)	Not reaching for objects
12 months	Unable to sit unsupported
18 months	Not walking in male patients Not pointing at objects to share interest with others
24 months	Not walking in female patients
30 months and older	Unable to run Persistent toe walking

From Bellman M, Byrne O, Sege R. Developmental assessment of children. *BMJ*. 2013;346:31–36.

**TABLE 9.5****DEVELOPMENTAL EVALUATION: PERTINENT HISTORY AND PHYSICAL**

Prenatal and birth history	Prenatal genetic screening Perception of fetal movement Pregnancy complications Toxins/teratogens Gestational age Birthweight Days in hospital/NICU admission Newborn screen results
Past medical problems	Trauma Infection Medication
Developmental history	Timing of milestone achievement Delayed skills Loss of skills (regression)
Behavioral history	Social skills Eye contact Affection Hyperactivity, impulsivity, inattention, distractibility Self-regulation Perseveration Worries/avoidance Stereotypies, peculiar habits

**TABLE 9.5**  
**DEVELOPMENTAL EVALUATION: PERTINENT HISTORY AND PHYSICAL—CONT'D**

Educational history	Need for special services Grade retention Established educational plans
Family history	History of developmental disabilities, ADHD, seizures, tics, stillbirths, neonatal death, congenital malformations, mental illness, or recurrent miscarriages Family members who were late talkers or walkers Family member school performance Family pedigree (see <a href="#">Chapter 13</a> )
General exam	Height, weight, and head circumference Dysmorphic features or features with distinctive appearance Cardiac murmurs Midline defects Hepatosplenomegaly Skin exam
Age-directed neuro exam	Cranial nerves Tone and strength Postural reactions ( <a href="#">eTable 9.1</a> ) Functional abilities Reflexes (including primitive reflexes for infants [ <a href="#">Table 9.6</a> ])
In-clinic activities/tests	Goodenough—Harris Draw-a-Person Test Gesell figures ( <a href="#">eFig. 9.1</a> ): Ask the child to copy various shapes. Gesell block skills ( <a href="#">eFig. 9.2</a> ): Ask the child to reproduce block structures as built by the examiner.

**TABLE 9.6**  
**PRIMITIVE REFLEXES**

Primitive Reflexes	Elicitation	Response	Timing
Moro reflex (“embrace” response) of fingers, wrists, and elbows	<i>Supine:</i> Sudden neck extension; allow head to fall back about 3 cm	Extension, adduction, and then abduction of UEs, with semiflexion	Present at birth; disappears by 3–6 months
Galant reflex (GR)	<i>Prone suspension:</i> Stroking paravertebral area from thoracic to sacral region	Produces truncal incurvature with concavity toward stimulated side	Present at birth; disappears by 2–6 months
Asymmetrical tonic neck reflex (ATNR, “fencer” response)	<i>Supine:</i> Rotate head laterally about 45–90 degrees	Relative extension of limbs on chin side and flexion on occiput side	Present at birth; disappears by 4–9 months

*Continued*

TABLE 9.6

## PRIMITIVE REFLEXES—CONT'D

Primitive Reflexes	Elicitation	Response	Timing
Symmetrical tonic neck reflex (STNR, “cat” reflex)	<i>Sitting:</i> Head extension/flexion	Extension of UEs and flexion of LEs/flexion of UEs and LE extension	Appears at 5 months; not present in most normal children; disappears by 8–9 months
Tonic labyrinthine supine (TLS)	<i>Supine:</i> Extension of the neck (alters relation of the labyrinths)	Tonic extension of trunk and LEs, shoulder retraction and adduction, usually with elbow flexion	Present at birth; disappears by 6–9 months
Tonic labyrinthine prone (TLP)	<i>Prone:</i> Flexion of the neck	Active flexion of trunk with protraction of shoulders	Present at birth; disappears by 6–9 months
Positive support reflex (PSR)	<i>Vertical suspension:</i> Bouncing hallucal areas on firm surface	<i>Neonatal:</i> momentary LE extension followed by flexion <i>Mature:</i> extension of LEs and support of body weight	Present at birth; disappears by 2–4 months Appears by 6 months
Stepping reflex (SR, walking reflex)	<i>Vertical suspension:</i> Hallucal stimulation	Stepping gait	Disappears by 2–3 months
Crossed extension reflex (CER)	<i>Prone:</i> Hallucal stimulation of LE in full extension	Initial flexion, adduction, then extension of contralateral limb	Present at birth; disappears by 9 months
Plantar grasp	Stimulation of hallucal areas	Plantar flexion grasp	Present at birth; disappears by 9 months
Palmar grasp	Stimulation of palm	Palmar grasp	Present at birth; disappears by 9 months
Lower extremity placing (LEP)	<i>Vertical suspension:</i> Rubbing tibia or dorsum of foot against edge of tabletop	Initial flexion, then extension, then placing of LE on tabletop	Appears at 1 day
Upper extremity placing (UEP)	Rubbing lateral surface of forearm along edge of tabletop from elbow to wrist to dorsal hand	Flexion, extension, then placing of hand on tabletop	Appears at 3 months
Downward thrust (DT)	<i>Vertical suspension:</i> Thrusting LEs downward	Full extension of LEs	Appears at 3 months

LE, Lower extremity; UE, upper extremity.

TABLE 9.7

**DEVELOPMENTAL EVALUATION: INITIAL LABS AND OTHER STUDIES**

Hearing screening	Formal audiologic testing is indicated for all children with global developmental delay or any delay in communication or language
Neuroimaging	Consider if abnormal neurologic exam, concern about head circumference growth velocity, or global developmental delay present
Electroencephalogram	Consider if history of or concern for seizure disorder
Laboratory studies	Consider CBC, CMP, lead level, CK, TSH based on history and exam Confirm newborn screen results

CBC, Complete blood count; CK, creatine kinase; CMP, complete metabolic panel; TSH, thyroid stimulating hormone.

TABLE 9.8

**DEVELOPMENTAL EVALUATION: GENETIC WORKUP**

Chromosomal microarray (CMA)	Considered first-tier diagnostic test in <i>all</i> children with GDD/ID <sup>33</sup>
Fragile X testing	Should be performed in all boys <i>and</i> girls with GDD/ID of unknown cause. Of boys with GDD/ID of unknown cause, 2%–3% will have fragile X syndrome, as will 1%–2% of girls.
Testing for X-linked conditions	Consider genetic testing for X-linked genes in boys with GDD/ID after negative CMA and negative fragile X testing. Should be specifically in those patients whose pedigree is suggestive of an X-linked condition

The tests discussed above do not require referral to a genetic specialist and can be ordered by the patient's pediatrician as a part of the evaluation of global developmental delay/intellectual disability (GDD/ID). If unrevealing and severe DD/ID present, refer to genetic specialist for consideration of additional testing such as metabolic testing or whole exome sequencing.


From Moeschler JB, Shevell M. Comprehensive evaluation of the child with intellectual disability or global developmental delays. *Pediatrics*. 2014;134(3):e903–e918.

**IV. SPECIFIC DISORDERS OF DEVELOPMENT****A. Overview**


1. Mental and/or physical impairment(s) that cause significant limitations in functioning
2. **Developmental diagnosis** is a functional description; identification of an etiology is important to further inform treatment, prognosis, comorbidities, and future risk.
3. Individuals with disabilities represent 12%–30% of the US population. They are a heterogeneous group that unfortunately are four times more likely to report fair to poor health when compared to those without a disability. Disability is categorized as a vulnerable population with health disparities.<sup>4-6</sup>
  - a. Many children with disabilities also hold other marginalized identities, which means that providers must be cognizant of resource gaps and be intentional in addressing disparities.<sup>7,8</sup>

15 months  
18 months  
2 years  
2½ years

Imitates scribble  
Scribbles spontaneously  
Imitates stroke  
Differentiates horizontal and vertical stroke




3 yr




4 yr




4½ yr




5 yr




6 yr




6 yr




7 yr



8 yr




9 yr



11 yr

**eFIGURE 9.1**

Gesell figures. (From Illingsworth RS. *The Development of the Infant and Young Child, Normal and Abnormal*. 5th ed. Williams & Wilkins; 1972:229–232; Cattell P. *The Measurement of Intelligence of Infants and Young Children*. Psychological Corporation; 1960:97–261.)

**eFIGURE 9.2**

Gesell block skills. (From Capute AJ, Accardo PJ. *The Pediatrician and the Developmentally Disabled Child: A Clinical Textbook on Mental Retardation*. University Park Press; 1979:122.)

**eTABLE 9.1****POSTURAL REACTIONS**

Postural Reaction	Age of Appearance	Description	Importance
Head righting	6 weeks—3 months	Lifts chin from tabletop in prone position	Necessary for adequate head control and sitting
Landau response	2—3 months	Extension of head, then trunk and legs when held prone	Early measure of developing trunk control
Derotational righting	4—5 months	Following passive or active head turning, body rotates to follow direction of head	Prerequisite to independent rolling
Anterior propping	4—5 months	Arm extension anteriorly in supported sitting	Necessary for tripod sitting
Parachute	5—6 months	Arm extension when falling	Facial protection when falling
Lateral propping	6—7 months	Arm extension laterally in protective response	Allows independent sitting
Posterior propping	8—10 months	Arm extension posteriorly	Allows pivoting in sitting

Modified from Milani-Comparetti A, Gidoni EA. Routine developmental examination in normal and retarded children. *Dev Med Child Neurol.* 1967;9:631–638; Capute AJ. Early neuromotor reflexes in infancy. *Pediatr Ann.* 1986;15:217–218, 221–223, 226; Capute AJ, Palmer FB, Shapiro BK, et al. Primitive reflex profile: a quantitation of primitive reflexes in infancy. *Dev Med Child Neurol.* 1984;26:375–383; Palmer FB, Capute AJ. Developmental disabilities. In: Oski FA, ed. *Principles and Practice of Pediatrics.* JB Lippincott; 1994.

4. School- and home-based interventions for developmental disorders (see Section V)

## B. Intellectual Disability (ID)

### 1. Definition and epidemiology

- a. Deficits in general cognitive and intellectual (problem-solving) and adaptive abilities
- b. Affects approximately 1% of population<sup>9</sup>
- c. Some communities prefer person-centered language (person with a disability), and others prefer identity-first language (disabled person). Adapt the use to the individual and family's preference.

### 2. Clinical presentation

- a. Delay in milestones (motor, language, social)
- b. Academic difficulty
- c. Identifiable features of known associated genetic syndrome (e.g., trisomy 21, fragile X, Rett syndrome)

### 3. Diagnosis

- a. Diagnostic criteria: (1) deficits in cognitive functioning, (2) deficits in adaptive functioning, (3) onset of these deficits during developmental period (before 18 years of age)
- b. Deficits in adaptive functioning must be in one or more domains of activities of daily living (ADLs).
- c. ID is further categorized as mild, moderate, severe, or profound (eTable 9.2).

### 4. Interventions/treatment

Support, employment, and recreational programs through resources such as are available through local programs: The Arc (<https://www.thearc.org>), Parents' Place (<https://www.ppmid.org/>), or the Parent Center Hub (<https://www.parentcenterhub.org>)

## C. Communication Disorders

### 1. Definition

- a. Deficits in communication, language, or speech
- b. Important to note that children who learn multiple languages may present with language differences that are not necessarily a language disorder<sup>10,11</sup>
- c. Can be subdivided into:
  - (1) Receptive/expressive language disorder
  - (2) Speech sound disorder
  - (3) Childhood-onset fluency disorder (stuttering)
  - (4) Social pragmatic communication disorder
- d. Differential diagnosis includes ID, hearing loss, significant motor impairment, or severe mental health difficulties.

### 2. Interventions/treatment

- a. Referrals to speech-language pathology (SLP), audiology

## D. Learning Disability<sup>9</sup>

### 1. Definition

A heterogenous group of deficits in an individual's ability to perceive and process information efficiently and accurately

**eTABLE 9.2****SEVERITY LEVELS FOR INTELLECTUAL DISABILITY (INTELLECTUAL DEVELOPMENTAL DISORDER)**

Severity Level	Conceptual Domain	Social Domain	Practical Domain
Mild	For preschool children, there may be no obvious conceptual differences. For school-aged children and adults, there are difficulties in learning academic skills involving reading, writing, arithmetic, time, or money, with support needed in one or more areas to meet age-related expectations. In adults, abstract thinking, executive function (i.e., planning, strategizing, priority setting, and cognitive flexibility), and short-term memory, as well as functional use of academic skills (e.g., reading, money management) are impaired. There is a somewhat concrete approach to problems and solutions compared with age mates.	Compared with typically developing age mates, the individual is immature in social interactions. For example, there may be difficulty in accurately perceiving peers' social cues. Communication, conversation, and language are more concrete or immature than expected for age. There may be difficulties regulating emotion and behavior in age-appropriate fashion; these difficulties are noticed by peers in social situations. There is limited understanding of risk in social situations; social judgment is immature for age, and the person is at risk of being manipulated by others (gullibility).	The individual may function age-appropriately in personal care. Individuals need some support with complex daily living tasks in comparison to peers. In adulthood, supports typically involve grocery shopping, transportation, home and child-care organizing, nutritious food preparation, and banking and money management. Recreational skills resemble those of age-mates, although judgment related to well-being and organization around recreation requires support. In adulthood, competitive employment is often seen in jobs that do not emphasize conceptual skills. Individuals generally need support to make health care decisions and legal decisions, and to learn to perform a skilled vocation competently. Support is typically needed to raise a family.
Moderate	All through development, the individual's conceptual skills lag markedly behind those of peers. For preschoolers, language and preacademic skills may develop slowly. For school-aged children, progress in reading, writing, mathematics, and understanding of	The individual shows marked differences from peers in social and communicative behavior across development. Spoken language is typically a primary tool for social communication, but is much less complex than that of peers. Capacity for relationships is	The individual can care for personal needs involving eating, dressing, elimination, and hygiene as an adult, although an extended period of teaching and time is needed for the individual to become independent in these areas, and reminders may be needed. Similarly,

time and money occurs slowly across the school years, and is markedly limited compared with that of peers. For adults, academic skill development is typically at an elementary level, and support is required for all use of academic skills in work and personal life. Ongoing assistance on a daily basis is needed to complete conceptual tasks of day-to-day life, and others may take over these responsibilities fully for the individual.

evident in ties to family and friends, and the individual may have successful friendships across life and sometimes romantic relations in adulthood. However, individuals may not perceive or interpret social cues accurately. Social judgment and decision-making abilities are limited, and caretakers must assist the person with life decisions. Friendships with typically developing peers are often affected by communication or social limitations. Significant social and communicative support is needed in work settings for success.

participation in all household tasks can be achieved by adulthood, although an extended period of teaching is needed, and ongoing supports will typically occur for adult-level performance. Independent employment in jobs that require limited conceptual and communication skills can be achieved, but considerable support from coworkers, supervisors, and others is needed to manage social expectations, job complexities, and ancillary responsibilities such as scheduling, transportation, health benefits, and money management. A variety of recreational skills can be developed. These typically require additional supports and learning opportunities over an extended period of time. Maladaptive behavior is present in a significant minority and causes social problems.

Severe	Attainment of conceptual skills is limited. The individual generally has little understanding of written language or of concepts involving numbers, quantity, time, and money. Caretakers provide extensive support for problem solving throughout life.	Spoken language is quite limited in terms of vocabulary and grammar. Speech may be single words or phrases, and may be supplemented through augmentative means. Speech and communication are focused on the here and now within everyday events. Language is used for social communication more than for explication. Individuals understand simple speech and	The individual requires support for all activities of daily living, including meals, bathing, and elimination. The individual requires supervision at all times. The individual cannot make responsible decisions regarding well-being of self or others. In adulthood, participation in tasks at home, recreation, and work requires ongoing support and assistance. Skill acquisition in all
--------	--	--	--



eTABLE 9.2

**SEVERITY LEVELS FOR INTELLECTUAL DISABILITY (INTELLECTUAL DEVELOPMENTAL DISORDER)—CONT'D**

Severity Level	Conceptual Domain	Social Domain	Practical Domain
		gestural communication. Relationships with family members and familiar others are a source of pleasure and help.	domains involves long-term teaching and ongoing support. Maladaptive behavior, including self-injury, is present in a significant minority.
Profound	Conceptual skills generally involve the physical world rather than symbolic processes. The individual may use objects in goal-directed fashion for self-care, work, and recreation. Certain visuospatial skills (e.g., matching and sorting based on physical characteristics) may be acquired. However, co-occurring motor and sensory impairments may prevent functional use of objects.	The individual has very limited understanding of symbolic communication in speech or gesture. He or she may understand some simple instructions or gestures. The individual expresses his or her own desires and emotions largely through nonverbal, nonsymbolic communication. The individual enjoys relationships with well-known family members, caretakers, and familiar others, and initiates and responds to social interactions through gestural and emotional cues. Co-occurring sensory and physical impairments may prevent many social activities.	The individual is dependent on others for all aspects of daily physical care, health, and safety, although he or she may be able to participate in some of these activities as well. Individuals without severe physical impairments may assist with some daily work at home, like carrying dishes to the table. Simple actions With objects may be the basis of participation in some vocational activities with high levels of ongoing support. Recreational activities may involve, for example, enjoyment in listening to music, watching movies, going out for walks, or participating in water activities, all with the support of others. Co-occurring physical and sensory impairments are frequent barriers to participation (beyond watching) in home, recreational, and vocational activities. Maladaptive behavior is present in a significant minority.

eTABLE 9.3

## TYPES OF ALTERNATIVE AND AUGMENTATIVE COMMUNICATION (AAC)

Type of AAC	Description	Formats	Access Method
Low-tech AAC	Generally paper-based supports Messages represented by gestures, symbols/photos, objects, words, phrases, or spelling with letters	Basic signs, pencil/paper (writing), eye pointing board, communication board or book, Velcro/magnet/pull-off messages	Direct selection with upper extremities/ stylus/laser pointer/head-stick/ mouth-stick/eye pointing Indirect selection with partner assisted scanning
Mid-tech AAC	Generally non—computer-based devices with recordable/digitized speech Messages represented by symbols/photos, words, phrases No spelling options; device can't blend letters together to make a spoken word May require physical dexterity to change pages Generally, more limited vocabulary possibilities as compared to high-tech AAC	Single button with single message or multiple messages to scan through Multilevel devices with changeable paper overlay Single level device with nonchanging vocabulary overlay	Direct selection with fingers/hand// stylus/laser pointer/head-stick/ mouth-stick Indirect selection with switch scanning
High-tech AAC	Computer-based devices with synthesized or digitized speech Messages could be represented by symbols, photos, words, phrases, or spelling Over 40 different picture-based vocabulary setups are available on the market, to match to patients' language and access needs	Tablet/smartphone/smart watch with AAC application Dedicated speech generating devices, talking word processor Nondedicated/integrated devices with computer access options	Direct selection with fingers/hand/ stylus/laser pointer/head-stick/ mouth-stick/eye pointing/mouse Indirect selection with switch scanning

From personal communication with Tooley, Lauren, MS, CCC-SLP, Kennedy Krieger Institute, and from *Augmentative and Alternative Communication*. American Speech-Language-Hearing Association, [https://www.asha.org/PRPSpecificTopic.aspx?folderid=8589942773&section=Key\\_Issues](https://www.asha.org/PRPSpecificTopic.aspx?folderid=8589942773&section=Key_Issues)

## 2. Diagnosis

- a. Achievement on standardized tests that is substantially below expected for age, schooling and level of intelligence in one or more of the following areas: basic reading skills, reading comprehension, reading fluency skills, oral expression, listening comprehension, written expression, mathematic calculation, and mathematic problem solving
- b. There is no alternative diagnosis such as sensory impairment or ID

## 3. Intervention/treatment

- a. School-based services through IEP and 504 plans tailored to specific learning needs
- b. It is important to address the stigma associated with labeling a child as having a learning disability. This stigma may prevent families from engaging in care that can benefit the child.
- c. Black, non-Hispanic, and Hispanic children and children from other marginalized racial populations are less likely to be identified as having a learning disability than White, non-Hispanic children and are comparatively underrepresented in special education.<sup>12</sup> Ensure that all families know the resources that are available to them.
- d. Resources for families
  - (1) <https://www.idaamerica.org/>
  - (2) <https://www.nclld.org/>
  - (3) International Dyslexia Association <https://dyslexiaida.org/>
  - (4) <https://espanol.ninds.nih.gov/es/trastornos/problemas-de-aprendizaje>
  - (5) <https://catalog.ninds.nih.gov/>

## E. Cerebral Palsy (CP)

### 1. Definition and epidemiology

- a. A group of disorders of the development of movement and posture attributed to *nonprogressive* disturbances that occurred in the developing fetal or infant brain<sup>13,14</sup>
- b. Prevalence: 2 to 3/1000 live births<sup>2</sup>
- c. Disparities: Black children have an increase in prevalence of CP compared to White children, and this disparity was found only in children with greater functional limitations.<sup>4</sup> Following adjustment of socioeconomic status and perinatal factors, there was a paradoxical decreased risk of CP in Black children, indicating the influence of these factors on CP and their independent association in pregnant Black women.

### 2. Clinical presentation

- a. Delayed motor development, abnormal tone, atypical postures, persistent primitive reflexes past 6 months
- b. History of known or suspected brain injury
- c. Manifestations may change with brain maturation and development.

### 3. Diagnosis

- a. Classification is based on physiologic and topographic characteristics as well as severity (Table 9.9).<sup>15</sup>

TABLE 9.9

CLINICAL CLASSIFICATION OF CEREBRAL PALSY<sup>15</sup>

Type	Pattern of Involvement
<b>I. SPASTIC (INCREASED TONE, CLASPED KNIFE, CLONUS, FURTHER CLASSIFIED BY DISTRIBUTION)</b>	
Bilateral spasticity	Diplegia (legs primarily affected) Quadriplegia (all four extremities impaired; legs worse than arms)
Unilateral spasticity	Hemiplegia (ipsilateral arm and leg; arm worse than leg) Monoplegia (one extremity, usually upper; probably reflects a mild hemiplegia)
<b>II. DYSKINETIC (LEAD-PIPE OR CANDLE-WAX RIGIDITY, VARIABLE TONE, ± CLONUS)</b>	
Dystonic	Complex disorders often reflecting basal ganglia pathology, resulting in involuntary and uncontrolled movements. May be focal or generalized.
Choreoathetoid	
<b>III. OTHER</b>	
Ataxic	Movement and tone disorders often reflecting cerebellar origin
Hypotonic	Usually related to diffuse, often severe cerebral and/or cerebellar cortical dysfunction. May be axial, appendicular, or generalized
Rigid	Muscle contraction, seen in rare neurogenetic diseases

From Graham HK, Rosenbaum P, et al. Cerebral palsy. *Nat Rev Disease Primers*. 2016;2(15082).

- b. Brain imaging should be obtained with MRI; abnormal in 70%–90% of individuals with CP<sup>16</sup>

#### 4. Interventions/Treatment

- a. Baseline and ongoing medical subspecialty care, including developmental pediatrics, neurology, orthopedics, and neurosurgery
- b. Interdisciplinary team involvement (see [Section V](#))
- c. Equipment to promote mobility and communication, including augmentative and alternative communication—any form of communication other than oral speech ([eTable 9.3](#))<sup>17</sup>
  - (1) Augmentative communication: Communication supports/methods used by individuals who have some speech but limited use of their speech
  - (2) Alternative communication: Communication supports/methods used by individuals who have no speech
- d. Pharmacotherapy for spasticity (e.g., botulinum toxin injections, baclofen), dyskinesia, hypersalivation (e.g., glycopyrrolate, scopolamine patch)<sup>47</sup>
- e. In carefully selected patients: intrathecal baclofen, selective dorsal rhizotomy, deep brain stimulation<sup>48</sup>

#### F. Autism Spectrum Disorder (ASD)

##### 1. Definitions and epidemiology

- a. Encompasses previously named disorders of autistic disorder (autism), Asperger syndrome, childhood disintegrative disorder, and pervasive developmental disorder not otherwise specified (PDD-NOS)

- b. Increasing prevalence; 1 in 54 children in the United States had ASD in 2018<sup>18,19</sup>
- c. Almost five times more common in males than females<sup>18</sup>

## 2. Screening

- a. Formal screening for ASD recommended at the 18- and 24-month visits (see AAP practice guidelines for more detailed recommendations)<sup>20</sup>
- b. Recommendations upheld by the AAP despite a U.S. Preventive Services Task Force (USPSTF) draft recommendation statement citing insufficient evidence for screening.<sup>21,22</sup>
- c. Evaluate using screening tools such as **Modified Checklist for Autism in Toddlers (M-CHAT-R/F)** and **Childhood Autism Screening Test (CAST)** (see [Table 9.3](#)).
- d. There are racial and ethnic differences in the evaluation and diagnoses of ASD. Black and Hispanic children with ASD are noted to receive evaluations later than White children with ASD.<sup>23</sup>

## 3. Diagnosis

- a. Symptoms vary by age, developmental level, language ability, and supports in place.
- b. Diagnostic criteria include<sup>9</sup>:
  - (1) **Impaired social communication and interaction**  
*Examples:* Lack of joint attention behaviors (e.g., showing toys, pointing for showing), diminished eye contact, no sharing of emotions, lack of imitation
  - (2) **Restricted repetitive patterns of behavior, interests, or activities**  
*Examples:* Simple motor stereotypies (hand flapping, finger flicking), repetitive use of objects (spinning coins, lining up toys), repetitive speech (echolalia), resistance to change, unusual sensory responses
  - (3) Presentation in early childhood and significant limitation of functioning

## 4. Interventions/treatment

- a. Applied behavior analysis (ABA)  
A treatment approach for young children with ASD is called applied behavior analysis (ABA). ABA has become widely accepted among healthcare professionals and is used in many schools and treatment clinics. ABA encourages positive behaviors and discourages negative behaviors while the child's progress is carefully tracked and measured.<sup>49</sup>
- b. Educational interventions, visual supports, naturalistic developmental behavioral interventions (integrating behavioral and child-responsive strategies to teach developmentally appropriate skills in a more natural and interactive setting)<sup>21,22</sup>
- c. Referral to SLP, OT/sensory-based interventions
- d. Family resources
  - (1) <https://www.autismspeaks.org/technology-and-autism>

- (2) <https://www.autism-society.org/living-with-autism/treatment-options/>
- (3) <https://www.nichd.nih.gov/health/topics/autism/conditioninfo/treatments>
- (4) <https://www.autismspeaks.org/tool-kit/atnair-p-parents-guide-applied-behavior-analysis>

## G. Attention Deficit/Hyperactivity Disorder (ADHD): See Chapter 24

# V. LONGITUDINAL CARE OF CHILDREN WITH DEVELOPMENTAL DISORDERS AND DISABILITIES

## A. Interdisciplinary Involvement

1. Neurodevelopmental pediatrician, child neurologist, developmental/behavioral pediatrician, other medical subspecialties as indicated (e.g., orthopedics for CP can be very important)
2. Genetic counseling for families of children with a genetic condition
3. Psychologists for formal testing, counseling
4. Mental health support: People with disabilities reported approximately five times more mentally unhealthy days than those in the general population.<sup>24,25</sup>
5. Rehabilitation and therapists, including physical therapy (PT), occupational therapy (OT), and SLP
6. Educators and the school system
7. Community and parent advocacy organizations

## B. Relevant Laws and Regulation

1. The **Individuals with Disabilities Education Act (IDEA)** sets forth regulations in the following areas for states that receive federal funding<sup>26,27</sup>:
  - a. Entitles all children with qualifying disabilities to a free and appropriate public education in the least restrictive environment
  - b. **Early intervention services:** Infants and toddlers younger than 3 years may be referred for evaluation to receive developmental service. Eligibility criteria vary by state; see The National Early Childhood Technical Assistance Center (<https://www.ectacenter.org>) for details.
  - c. **Qualifying disabilities:** Children aged 3 to 21 years with autism spectrum disorder, ID, specific learning disability (LD), hearing or visual impairment, speech or language impairment, orthopedic impairment, traumatic brain injury, emotional disturbance, or other health impairment are eligible.
  - d. **Individualized education program (IEP):** Written statement that includes a child's current capabilities, goals and how they will be measured, and services required. A comprehensive team is needed to develop and implement the IEP.
  - e. **Transition services:** School systems must provide transition services that prepare students for postsecondary activities, and IEPs must include a statement of transition service needs starting no later than

age 14. The student must be included in the IEP process starting at age 14.

- f. **Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Act (ADA):** Prohibits discrimination against individuals with any disability, more broadly defined as an impairment that limits function.<sup>29</sup> A Section 504 Plan can also be used to get reasonable accommodations for a child who has a disability but who does not meet criteria for special education and related services; for example, a quiet setting or extra time for testing, mobility assistance for a child who uses a wheelchair

### C. Head Start and Early Head Start

Programs instituted by the federal government to promote school readiness of low-income children aged 3 to 5 years (Head Start) and younger than 3 years (Early Head Start) within their communities<sup>28</sup>

## VI. TRANSITIONS FROM PEDIATRIC TO ADULT CARE FOR YOUTH WITH DEVELOPMENTAL DISABILITIES

### A. The Need

Research reveals health disparities between adults with developmental disabilities and those without. Disparities include:

1. Increased ED utilization
2. Lack of identified adult provider
3. Worse self-perception of health<sup>30</sup>

### B. The Role of the Pediatric Provider

1. AAP Consensus Statement on Transitions<sup>31,32</sup>
  - a. Identify a health professional as point person to work with the youth and family on transition process.
  - b. **Create healthcare transition plan by age 14** with the youth and family.  
**NOTE:** If a child's disability leaves them without capacity to make their own healthcare decisions, then parents must have court documents signed by two different physicians to have continued healthcare proxy (allowing parent to continue medical decision-making) established for after the child turns 18. This process should start before the child has turned 18 to avoid a lapse in the parent's ability to act as proxy for their child.
  - c. Apply same guidelines for primary and preventive care for all adolescents and young adults.
  - d. Ensure affordable, continuous insurance coverage.

### C. Transition Domains

1. Transitions for young adults with disabilities occur across many domains of life and warrant support from an interdisciplinary team (Table 9.10).

**TABLE 9.10****TRANSITION DOMAINS FOR YOUTH WITH DEVELOPMENTAL DISORDERS AND DISABILITIES**

Transition Domain	Common Issues	Necessary Support Personnel/Services
Physical/emotional health	Difficulty identifying adult providers, retained in pediatric care, lost to follow-up, increased ED usage, insurance difficulties	Pediatrician, adult PCP, subspecialists
Education/employment	Education services through IDEA end at 21 years old. Subsequent difficulty finding and engaging in postsecondary education and/or employment opportunities	Educational team members (teachers, therapists), vocational rehab specialists, college counselors, postsecondary education programs
Legal/financial	Difficulties with issues of SSI, guardianship, conservatorship	Attorney, legal counsel, family advocate
Housing/transportation	Access to accessible housing and transportation, development and ongoing support of skills needs for independent living	Life skills courses, group homes, independent living supports/aides, resources through state departments of disability and the U.S. Department of Housing and Urban Development, state mobility services
Leisure pursuits/respite care	Decreased structure of leisure pursuits with termination of school services at 21, increased burden on caregivers	Day programs, social engagement programs (e.g., Best Buddies, Special Olympics), respite care services for caregivers
Sexuality	Romantic and sexual relationships, vulnerability, reproductive rights, contraception, parenthood, access to appropriate screening and healthcare	Education team members (sexual education while in school), family members; OB/gyn providers, adult healthcare providers

*ED*, Emergency department; *IDEA*, Individuals with Disabilities Education Act; *OB/Gyn*, obstetrician/gynecologist; *PCP*, primary care physician; *SSI*, supplemental security income.

9

## VII. SOCIAL DETERMINANTS OF HEALTH AND ADVERSITY SIGNIFICANTLY IMPACT CHILD DEVELOPMENT, ATTAINMENT OF DEVELOPMENTAL MILESTONES, AND/OR LONG-TERM HEALTH

### A. Social Determinants of Health (SDOHs)

1. Definitions and epidemiology
  - a. SDOHs are the conditions in which people are born, grow, work, live, and age, and the wider set of forces and systems shaping the conditions of daily life.<sup>34</sup>
2. Five key domains<sup>35</sup>:
  - a. Economic stability (e.g., poverty and food insufficiency)

- b. Education (e.g., high school graduate and early childhood education)
  - c. Social and community context (e.g., concerns about immigration status and social support)
  - d. Health and healthcare (e.g., health insurance status and access to a healthcare provider)
  - e. Neighborhood and built environment (e.g., neighborhood crime and quality of housing)
3. The role of the pediatric provider
    - a. Considering SDOHs among children and youth is critical given that the physical, social, and emotional capabilities that develop early in life provide the foundation for life course health and well-being.<sup>36</sup>
    - b. Screening for SDOHs has benefits such as improving diagnostic algorithms, identifying children and youth in need of more support, improving patient-provider relationships, and collecting data for epidemiological purposes.<sup>33</sup>
    - c. Referral to clinic, community, or state resources when appropriate

## **B. Adverse Childhood Experiences (ACEs)**

1. Definitions and epidemiology<sup>3</sup>
  - a. All ACE questions refer to occurrences in the first 18 years of life. Studies indicate more than two-thirds of the population have experienced at least one ACE. The initial ACEs study only addressed those listed below, but there are likely many more ACEs that influence development and long-term health outcomes.
    - (1) Abuse
      - (a) Emotional abuse
      - (b) Physical abuse
      - (c) Sexual abuse
    - (2) Household challenges
      - (a) Mother treated violently
      - (b) Substance abuse in the household
      - (c) Mental illness in the household
      - (d) Parental separation or divorce
      - (e) Incarcerated household member
    - (3) Neglect
      - (a) Emotional neglect
      - (b) Physical neglect
    - (4) The Philadelphia ACE Project expanded the survey to include community adversity, factors that also impact development and long-term health.<sup>38,39</sup>
      - (a) Experience of bullying
      - (b) Discrimination
      - (c) Witnessing violence
      - (d) Being in the foster care system
      - (e) Living through adverse neighborhood experiences or adverse community environments (the “other ACEs”)

2. Mechanism by which ACEs influence health and well-being throughout the life span
  - a. There is a dose-response relationship between ACEs and long-term negative physical and mental health outcomes in adults.
  - b. Childhood ACEs may lead to toxic stress (see [section 4a](#)) and impact multiple biologic indices (e.g., brain development, immune function, stress response system, epigenetics).
3. Role of the pediatric provider
  - a. Screening for ACEs and toxic stress with referral to resources and support can prevent long-term negative health outcomes throughout the life span.
  - b. Supportive adult relationships are protective against toxic stress.<sup>40</sup>
    - (1) Pediatricians have unique opportunity to support parent-child relationships.
4. Resources
  - a. Safe Environment for Every Kid (<https://www.seekwellbeing.org>)
    - (1) Stress
      - (a) Definitions and epidemiology
        - (i) **Positive stress:** Helps to guide growth
        - (ii) **Tolerable stress:** Not helpful, but will not cause damage
        - (iii) **Toxic stress:** Overcomes the child's undeveloped coping mechanisms and leads to long-term impairment and illness<sup>40</sup>
          - (a) Results when a child experiences strong, frequent, or prolonged activation of the stress response systems in absence of protection from a supportive adult
          - (b) Healthy brain development can be disrupted or impaired by prolonged, pathologic stress response with significant long-term implications for learning, behavior, health, and adult functioning.<sup>41</sup>
        - (iv) **Traumatic stress:** The physical and emotional responses of a child to events that threaten the life or physical integrity of the child or of someone critically important to the child (e.g., parent, sibling). *Examples:* natural disaster, assault
          - (a) There is a dose-response relationship to traumatic stress over time.
      - (b) The role of the pediatric provider
        - (i) Screening
        - (ii) **Referral to effective treatments for children who have experienced trauma**
          - (a) Trauma-focused cognitive-behavioral therapy<sup>42</sup>
          - (b) Parent-child interactive therapy<sup>43</sup>
      - (c) Resources
        - (i) National Child Traumatic Stress Network (<https://www.NCTSN.org>)

- (2) Resilience
  - (a) Definitions and epidemiology
    - (i) Resilience: The process by which a child moves through a traumatic event, using various protective factors for support, and returning to a “baseline” in terms of an emotional and physiologic response to the stressor<sup>44</sup>
  - (b) Protective factors<sup>45</sup>
    - (i) Cognitive capacity
    - (ii) Healthy attachment relationships (especially with parents and caregivers)
    - (iii) Motivation and ability to learn and engage with the environment
    - (iv) Ability to regulate emotions and behavior
    - (v) Supportive environmental systems, including education, cultural beliefs, and faith-based communities
  - (c) Resources
    - (i) Relational Health Framework: strengths-based approach to identifying and building safe, stable and nurturing relationships as a critical public health measure to promote resilience and counter toxic stress. <https://www.aap.org/en/patient-care/early-childhood/early-relational-health/>
    - (ii) Protective Factors Framework: [www.cssp.org/our-work/projects/protective-factors-framework/](http://www.cssp.org/our-work/projects/protective-factors-framework/)
    - (iii) Strengthening Families: <https://www.strengtheningfamiliesprogram.org>
    - (iv) The AAP Resilience Project: <https://www.aap.org/en/patient-care/trauma-treatment-and-resilience/>
    - (v) Healthy Children: <https://www.healthychildren.org>

### **E. Relationship Between Adversity and Resilience**

1. Traumatic event occurs (e.g., as broad as abuse to failing a test) → stress is experienced, which elicits emotional and physiologic responses → support is received (e.g., reassurance, identification of own internal strengths, connection with adult or social supports) → stability is reobtained and the individual is more skilled in identifying and using their own internal skills while maintaining awareness of and access to external supports. When the next traumatic event occurs, the individual draws on past experiences of support and stabilizes again.

### **F. Diversity and Equity in Adversity and Resilience**

1. **Childhood adversity is common across all socioeconomic demographics.**
2. Certain populations have **increased risk of ACEs due to SDOHs and systemic barriers**<sup>46</sup>:
  - a. Lower socioeconomic status
  - b. Racial minorities or multiracial individuals
  - c. Sexual minorities

## VII. WEB RESOURCES

- Autism Speaks: <https://www.autismspeaks.org>
- Bright Futures: <https://www.brightfutures.org>
- Cerebral Palsy Foundation: <https://yourcpf.org>
- Disability Programs and Services: <https://www.dol.gov/odep/topics/disability.htm>
- Got Transition: <https://www.gottransition.org>
- Individuals With Disabilities Education Act (IDEA): <https://idea.ed.gov>
- Intellectual Disability: <https://aidd.org>
- National Center for Learning Disabilities: <https://www.nclld.org>
- National Early Childhood Technical Assistance Center: <https://www.ectacenter.org>
- Reach Out and Read: <https://www.reachoutandread.org>

## REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Capute AJ, Shapiro BK, Palmer FB. Spectrum of developmental disabilities: continuum of motor dysfunction. *Orthop Clin North Am.* 1981;12:3–22.
2. Capute A, Accardo P. *Developmental Disabilities in Infancy and Childhood.* 2nd ed. Paul H. Brooks Publishing Co; 1996.
3. American Academy of Pediatrics. Identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening. *Pediatrics.* 2006;118:405–420.
4. Dabney KW, Ziegler R, Holmes L. Health and healthcare disparities in children with cerebral palsy. In: Miller F, Bachrach S, Lennon N, O’Neil M, eds. *Cerebral Palsy.* Springer, Cham. [https://doi.org/10.1007/978-3-319-50592-3\\_210-1](https://doi.org/10.1007/978-3-319-50592-3_210-1)
5. Zablotsky B, Black LI, Maenner MJ, et al. Prevalence and trends of developmental disabilities among children in the United States: 2009–2017. *Pediatrics.* 2019;144(4):e20190811. <https://doi.org/10.1542/peds.2019-0811>
6. Zablotsky B, Black LI. Prevalence of children aged 3–17 years with developmental disabilities, by urbanicity: United States, 2015–2018. *Natl Health Stat Report.* 2020;(139):1–7.
7. Berg KL, Shiu CS, Feinstein RT, Acharya K, MeDrano J, Msall ME. Children with developmental disabilities experience higher levels of adversity. *Res Dev Disabil.* 2019 Jun;89:105–113. <https://doi.org/10.1016/j.ridd.2019.03.011>. Epub 2019 Apr 8 30974258.
8. Santiago AM, Berg KA, Leroux J. Assessing the impact of neighborhood conditions on neurodevelopmental disorders during childhood. *Int J Environ Res Public Health.* 2021;18(17):9041. <https://doi.org/10.3390/ijerph18179041>
9. Shapiro BK, Gallico RP. Learning disabilities. *Pediatr Clin North Am.* 1993;40:491–505.
10. Psychiatric Association American. *Diagnostic and Statistical Manual of Mental Disorders: Text Revision.* 5th ed. APA; 2013.
11. Prezas RF, Jo AA. Differentiating language difference and language disorder: information for working with English language learners in the schools. *J Hum Serv Train Res Pract.* 2017;2(1):article 2.
12. Morgan PL, Farkas G, Hillemeier MM, et al. Minorities are disproportionately underrepresented in special education: longitudinal evidence across five disability conditions. *Educ Res.* 2015;44(5):278–292. <https://doi.org/10.3102/0013189X15591157>
13. Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy April 2006. *Dev Med Child Neurol Suppl.* 2007;109:8–14.
14. Colver A, Fairhurst C, Pharoah PO. Cerebral palsy. *Lancet.* 2014;383:1240–1249.
15. Liptak GS, Murphy NA. Council on Children with Disabilities. Providing a primary care medical home for children and youth with cerebral palsy. *Pediatrics.* 2011;128:e1321–e1329.
16. Hoon AH. Neuroimaging in cerebral palsy: patterns of brain dysgenesis and injury. *J Child Neurol.* 2005;20:936–939.
17. Chazin KT, Ledford JR, Pak NS. A Systematic Review of Augmented Input Interventions and Exploratory Analysis of Moderators. *Am J Speech Lang Pathol.* 2021 May 18;30(3):1210–1223. [https://doi.org/10.1044/2020\\_AJSLP-20-00102](https://doi.org/10.1044/2020_AJSLP-20-00102). Epub 2021 Mar 31 33789063. PMID: 33789063.
18. Johnson CP, Myers SM, American Academy of Pediatrics. Identification and evaluation of children with autism spectrum disorders. *Pediatrics.* 2007;120:1183–1215. Reaffirmed in AAP publications reaffirmed or retired. *Pediatrics.* 2014;134:e1520.

19. Baio J, Wiggins L, Christensen DL, et al. Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 Sites, United States, 2014. *MMWR Surveill Summ.* 2018;67(No. SS-6):1–23.
20. Hassink G. *AAP Statement on U.S. preventive services task force draft recommendation on autism screening*; 2015. <https://www.aap.org/en-us/about-the-aap/aap-press-room/pages/AAP-Statement-on-U-S-Preventive-Services-Task-Force-Draft-Recommendation-Statement-on-Autism-Screening.aspx>
21. Schreibman L, Dawson G, Stahmer AC, et al. Naturalistic developmental behavioral interventions: empirically validated treatments for autism spectrum disorder. *J Autism Dev Disord.* 2015;45(8):2411–2428.
22. Myers SM, Johnson CP. American academy of pediatrics council on children with disabilities. management of children with autism spectrum disorders. *Pediatrics.* 2007;120:1162–1182.
23. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2010. *MMWR Morb Mortal Wkly Rep.* 2014;63:1–21.
24. Centers for Disease Control and Prevention. *Spotlight On: Racial and Ethnic Differences in Children Identified with Autism Spectrum Disorders*; 2019. Accessed June 1, 2021. <https://www.cdc.gov/ncbddd/autism/addm-community-report/differences-in-children.html>
25. Blick MA, Franklin MD, Ellsworth DW, et al. The double burden: health disparities among people of color living with disabilities. Ohio Disability and Health Program; 2015. [https://nisonger.osu.edu/sites/default/files/u4/the\\_double\\_burden\\_health\\_disparities\\_among\\_people\\_of\\_color\\_living\\_with\\_disabilities.pdf](https://nisonger.osu.edu/sites/default/files/u4/the_double_burden_health_disparities_among_people_of_color_living_with_disabilities.pdf)
26. Individuals with Disability Education Improvement Act of 2004, Pub. L. No. 108-445.
27. Lipkin PH, Okamoto J. Council on children with disabilities and council on school health. the individuals with disabilities education act (IDEA) for children with special educational needs. *Pediatrics.* 2015;136(6):e1650–e1662.
28. Improving Head Start for School Readiness Act of 2007, Pub. L. No. 110-134.
29. United States. Department of Health, Education, and Welfare. Office for Civil Rights. *Section 504 of the Rehabilitation act of 1973: Fact Sheet: Handicapped Persons Rights Under Federal law.* Dept. of Health, Education, and Welfare, Office of the Secretary, Office for Civil Rights; 1978. Revised June 2006.
30. Oswald DP, Gilles DL, Cannady MS, et al. Youth with special health care needs: transition to adult health care services. *Matern Child Health J.* 2013;17(10):1744–1752. <https://doi.org/10.1007/s10995-012-1192-7>
31. American Academy of Pediatrics, American Academy of Family Physicians, American College of Physicians—American Society of Internal Medicine. A consensus statement on health care transitions for young adults with special health care needs. *Pediatrics.* 2002;110(6 pt 2):1304–1306.
32. American Academy of Pediatrics Clinical Report. Supporting the health care transition from adolescence to adulthood in the medical home. *Pediatrics.* 2018;142(5).
33. Moeschler JB, Shevell M, Committee on Genetics. Comprehensive evaluation of the child with intellectual disability or global developmental delays. *Pediatrics.* 2014;134:e903–e918.
34. World Health Organization. *Social determinants of health*; 2008. Accessed May 1, 2021. [https://www.who.int/social\\_determinants/sdh\\_definition/en/](https://www.who.int/social_determinants/sdh_definition/en/)

35. Services USDoHH. *Social determinants of health*; 2014. Accessed May 1, 2021. <https://www.healthypeople.gov/2020/topics-objectives/topic/social-determinants-of-health>
36. Lu MC, Halfon N. Racial and ethnic disparities in birth outcomes: a life-course perspective. *Matern Child Health J*. 2003;7(1):13–30.
37. Gottlieb L, Fichtenberg C, Adler N. Screening for social determinants of health. *JAMA*. 2016;316(23):2552.
38. Felitti VJ, Anda RF, Nordenberg D, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. *Am J Prev Med*. 1998;14(4):245–258.
39. The Philadelphia ACE Project. *Philadelphia ACE Project*. <https://www.philadelphiaaces.org/philadelphia-ace-survey>
40. Center on the Developing Child at Harvard University. Key concepts: toxic stress. Accessed May 2, 2021. [http://developingchild.harvard.edu/topics/science\\_of\\_early\\_childhood/toxic\\_stress\\_response](http://developingchild.harvard.edu/topics/science_of_early_childhood/toxic_stress_response)
41. Shonkoff JP, Garner AS. American Academy of Pediatrics Committee on Psychosocial Aspects of Child and Family Health; Committee on Early Childhood, Adoption, and Dependent Care; Section on Developmental and Behavioral Pediatrics. The lifelong effects of early childhood adversity and toxic stress. *Pediatrics*. 2012;129(1):e232–e246. Accessed May 1, 2021. <http://pediatrics.aappublications.org/content/129/1/e232.full>
42. Child Welfare Information Gateway. Trauma-focused cognitive behavioral therapy for children affected by sexual abuse or trauma. Accessed May 29, 2014. <http://www.childwelfare.gov/pubs/trauma/trauma.pdf>
43. Child Welfare Information Gateway. Parent-child interaction therapy with at-risk families. Accessed May 29, 2014. [https://www.childwelfare.gov/pubpdfs/f\\_interactbulletin.pdf](https://www.childwelfare.gov/pubpdfs/f_interactbulletin.pdf)
44. AAP. The Resilience Project. Accessed May 2, 2021. <https://www.aap.org/en/patient-care/trauma-treatment-and-resilience/>
45. Center for the Study of Social Policy. The protective factors framework. Accessed May 2, 2021. <http://www.cssp.org/reform/strengthening-families/thebasics/protective-factors>
46. Giano Z, Wheeler DL, Hubach RD. The frequencies and disparities of adverse childhood experiences in the U.S. *BMC Public Health*. 2020;20:1327. <https://doi.org/10.1186/s12889-020-09411-z>
47. Reilly M, Liuzzo K, Blackmer AB. Pharmacological management of spasticity in children with cerebral palsy. *Journal of Pediatric Health Care*. 2020;34(5):495–509.
48. Kudva A, Abraham ME, Gold J, Patel NA, Gendreau JL, Herschman Y, Mammis A. Intrathecal baclofen, selective dorsal rhizotomy, and extracorporeal shockwave therapy for the treatment of spasticity in cerebral palsy: a systematic review. *Neurosurgical Review*. 44:3209–3228.
49. Gitimoghaddam M, Chichkine N, McArthur L, Sangha SS, Symington V. Applied behavior analysis in children and youth with autism spectrum disorders: a scoping review. *Perspectives on Behavior Science*. 45:521–557.

# Chapter 10

## Endocrinology

*Rashmi Pashankar, MD*

 See additional content online.

### I. DIABETES

#### A. Diagnosis of Diabetes Mellitus<sup>1-3</sup>

Diagnostic criteria (must meet one of four):

1. Symptoms of diabetes (polyuria, polydipsia, weight loss, frequent yeast infections) and random blood glucose (BG)  $\geq 200$  mg/dL
2. Fasting plasma glucose (FPG = no caloric intake for at least 8 hours)  $\geq 126$  mg/dL
3. Oral glucose tolerance test (OGTT) with a 2-hour postload plasma glucose of  $\geq 200$  mg/dL
4. Hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>)  $\geq 6.5\%$  obtained via laboratory testing (POCT HbA<sub>1c</sub> is nondiagnostic)

**NOTE:** In the absence of symptoms of hyperglycemia, FPG or OGTT should be repeated on another day.

#### B. Definition of Increased Risk (Prediabetes)

1. FPG 100 to 125 mg/dL
2. 2-hour post-OGTT BG 140 to 199 mg/dL
3. HbA<sub>1c</sub> 5.7% to 6.4%

#### C. Interpreting Hemoglobin A<sub>1c</sub><sup>1,2</sup>

1. Estimates average BG for the past 3 months
2. HbA<sub>1c</sub> of 6% approximately equals an average BG of 130 mg/dL; each additional 1%  $\approx$  30 mg/dL more
3. Unreliable in patients with abnormal red cell life span or morphology (e.g., sickle cell disease, spherocytosis)
4. Although there are limited data supporting HbA<sub>1c</sub> for diagnosing type 2 diabetes in children and adolescents, the American Diabetes Association continues to recommend HbA<sub>1c</sub> for diagnosis of type 2 diabetes in this population.

#### D. Etiology: Distinguishing Between Types of Diabetes Mellitus<sup>1,2</sup>

1. Type 1 (T1DM) versus T2DM (most common types, polygenic; [Table 10.1](#))
2. Other forms of diabetes<sup>4,5</sup>
  - a. Monogenic diabetes: 1% to 2% of diabetes mellitus (DM). Due to single-gene mutations, typically relating to insulin production or release. Identifying gene can have clinical significance.

TABLE 10.1

## CHARACTERISTICS SUGGESTIVE OF TYPE 1 VERSUS TYPE 2 DIABETES

Characteristic	Type 1	Type 2
Onset	As early as 1-year-old through adulthood	Usually postpubertal
Polydipsia and polyuria	Present for days to weeks	Absent or present for weeks to months
Weight	Weight loss	Obese (although weight loss is common in presentation with severe hyperglycemia)
Other physical findings		Acanthosis nigricans
Family history	Autoimmune diseases	Type 2 diabetes
Ketoacidosis	More common (1/3 at onset)	Less common (6% at onset)
Lab characteristics	Autoantibodies common; C-peptide generally should be unmeasurable >2 years after diagnosis	Autoantibodies less common, but sometimes present

- (1) Suspect if autosomal dominant inheritance pattern of early-onset (<25 years) DM, insulin independence, absent T2DM phenotype (nonobese), or preservation of C-peptide
- (2) Many well-described subtypes; some, such as MODY1 and MODY3 (due to mutations in transcription factors for insulin production) responsive to treatment with sulfonylureas
- b. Neonatal diabetes (NDM): Defined as DM onset <6 months of age
  - (1) Rare: 1:160,000 to 260,000 live births, typically a de novo mutation
  - (2) May be transient (50% recur) or permanent
  - (3) Subset respond to sulfonylureas
- c. Cystic fibrosis–related diabetes (CFRD): OGTT rather than HbA<sub>1c</sub> is the recommended screening test.
- d. Other causes of DM: Diseases of exocrine pancreas due to pancreatitis, trauma, infection, invasive disease (e.g., hemochromatosis)

### E. Screening for Type 2 Diabetes Mellitus<sup>1,6</sup>

1. **Whom to screen:** Children who are overweight (body mass index [BMI] >85th percentile) *and* have one or more of the following risk factors:
  - a. Maternal history of diabetes or gestational diabetes mellitus during child's gestation
  - b. Family history of T2DM in a first- or second-degree relative
  - c. Race/ethnicity: African American, Native American, Hispanic, Asian, or Pacific Islander
  - d. Signs associated with insulin resistance (acanthosis nigricans, hypertension, dyslipidemia, polycystic ovarian syndrome, or small-for-gestational-age birth weight)

2. **How to screen:** Fasting plasma glucose, OGTT, or HbA<sub>1c</sub>
3. **When to screen:** Begin at the age of 10 years or at the onset of puberty (whichever occurs first) and repeat at a minimum of every 3 years or more often if BMI is increasing.

#### F. Additional Testing in New-Onset Diabetes

1. **Diabetes autoantibodies<sup>1,2</sup>:** Recommended for all children with suspected T2DM or whose diabetes type is unclear
  - a. Includes islet cell autoantibodies (ICAs) and antibodies to GAD (GAD65), insulin, tyrosine phosphatases IA-2, IA-2 $\beta$ , and  $\beta$ -cell–specific zinc transporter 8 (ZnT8)
  - b. Confirmation of diagnosis of T1DM if 2 or more antibodies are present, though about 5% of T1DM will not have measurable ICAs, and some children with T2DM will have measurable ICAs
2. **Screening for autoimmune diseases in T1DM<sup>6</sup>:**
  - a. Thyroid disease (present in 17% to 30% of patients with T1DM): Screen with TSH when clinically well and consider screening for thyroid antibodies. If TSH normal, recheck every 1 to 2 years or sooner if symptoms develop.
  - b. Celiac disease (present in 1.6% to 16.4% of patients with T1DM): Screen with tissue transglutaminase (TTG) IgA antibody and total IgA. Repeat within 2 years of diabetes diagnosis and again after 5 years. Repeat more frequently if there are symptoms or a first-degree relative with celiac disease.

#### G. Management of Diabetes<sup>6-8</sup>

1. **Diabetes medications FDA approved for children:**
  - a. Insulin: See [Tables 10.2 and 10.3](#) for calculations. Insulin doses are subsequently adjusted based on actual blood sugars.
  - b. Metformin: FDA approved in children  $\geq 10$  years old with type 2 diabetes, though sometimes used off label in younger children. Main side effects are gastrointestinal (GI) and are often transient. Extended-release option is available for patients with GI side effects.
  - c. Glucagon-like peptide 1 (GLP-1) agonists (currently only liraglutide and exenatide): FDA approved in children  $\geq 10$  years old with T2DM. Main side effects include GI effects, pancreatitis, and hypoglycemia. Avoid if there is a family history of medullary thyroid cancer or personal history of pancreatitis.
2. **T1DM management:** The majority of children with T1DM should be treated with intensive insulin regimens via multiple daily injections, a continuous subcutaneous infusion via insulin pump, or an automated insulin delivery system.
3. **T2DM management:**
  - a. Lifestyle modification therapy (nutrition and physical activity) and metformin should be initiated at time of diagnosis.
  - b. Insulin therapy should be initiated if distinction between T1DM and T2DM is unclear, when HbA<sub>1c</sub>  $\geq 8.5\%$ , when random BG  $\geq 250$ , in presence of diabetic ketoacidosis (DKA), or when patient with known

**TABLE 10.2**  
**SUBCUTANEOUS INSULIN DOSING**

	Insulin	Dose Calculation	Sample Calculation for 24-kg Child	Dose
Total daily dose		0.5–1 unit/kg/day	$0.75 \times 24 = 18$ units/day	18 units
Basal	Glargine	1/2 daily total	$1/2 \times 18 \text{ units} = 9$	9 units daily
	<i>OR</i> Detemir	1/2 daily total $\div$ BID	$1/2 \times 18 \text{ units} = 9$	4.5 units BID
Carbohydrate coverage ratio	Lispro, aspart	$500 \div$ daily total	$500 \div 18 = 28$	1 unit: 28 g carbohydrate
	<i>OR</i> Regular	$450 \div$ daily total	$450 \div 18 = 25$	1 unit: 25 g carbohydrate
Correction factor	Lispro, aspart	$1800 \div$ daily total	$1800 \div 18 = 100$	1 unit expected to drop BG by 100 mg/dL
	<i>OR</i> Regular	$1500 \div$ daily total	$1500 \div 18 = 83$	1 unit expected to drop BG by 83 mg/dL

T2DM is not meeting glycemic target with metformin and lifestyle modification alone. **NOTE:** If significant hyperglycemia (BG >600) or ketosis is present, patient should be evaluated for DKA or hyperosmolar hyperglycemic state

- c. Consider addition of GLP-1 agonist therapy if glycemic targets are not met with metformin alone, or combined therapy with metformin and insulin.

**TABLE 10.3**  
**TYPES OF INSULIN PREPARATIONS AND SUGGESTED ACTION PROFILES FOR SUBCUTANEOUS ADMINISTRATION<sup>54</sup>**

Insulin <sup>a</sup>	Onset	Peak	Effective Duration
Ultra-rapid-acting analog (faster aspart, lispro-aabc)	5–10 min	1–3 hr	3–5 hr
Rapid-acting (lispro, aspart, glulisine)	10–20 min	1–3 hr	3–5 hr
Short-acting (regular)	30–60 min	2–4 hr	5–8 hr
Intermediate acting (NPH)	2–4 hr	4–12 hr	12–24 hr
Long-acting			
Glargine	2–4 hr	8–12 hr	22–24 hr
Detemir	1–2 hr	4–7 hr	20–24 hr
Degludec	30–90 min	No peak	>42 hr

**NOTE:** Be aware that there are stronger concentrations of various types of insulin available (e.g., U-500 regular insulin, which is 5 times more concentrated than U-100 regular insulin; U-300 insulin glargine). There are also premixed combinations of rapid or short AND intermediate acting insulin (e.g., 70% NPH/30% regular [Humulin 70/30]).

<sup>a</sup>Assuming 0.1–0.2 U/kg per injection. Onset and duration vary significantly by injection site.

*NPH*, Neutral protamine Hagedorn.

Modified from The American Diabetes Association. *Practical Insulin: A Handbook for Prescribing Providers*. 2nd ed. American Diabetes Association; 2007.

#### 4. **Goals of therapy:**

- a. HbA<sub>1c</sub> <7% (individualized to avoid excessive hypoglycemia)
  - b. Assessment and management of complications: hypertension, dyslipidemia, nephropathy, retinopathy, neuropathy in all types of diabetes; additionally for obstructive sleep apnea, nonalcoholic fatty liver disease, and polycystic ovarian syndrome in type 2 diabetes
5. Interdisciplinary care team should include mental health provider and medical nutrition therapy with initial education and annual update. Regularly assess for eating disorders, disease-related coping, depression, and psychosocial stressors impacting diabetes management.

### H. **Diabetes Management Devices**<sup>9</sup>

1. Technology is rapidly changing, but general principles are described below.
2. **Insulin pumps:** Contain rapid-acting insulin only and provide basal and bolus insulin. Doses can be programmed to vary throughout the day. Settings consist of:
  - a. Basal rate—continuous insulin infusion
  - b. Carbohydrate coverage—insulin-to-carbohydrate ratio
  - c. Hyperglycemia correction—based on correction factor and target blood glucose

**NOTE:** There is risk for DKA with interruptions in insulin delivery (e.g., pump malfunction) given lack of long-acting insulin.

3. **Continuous glucose monitors (CGMs):** Measure glucose concentration in interstitial fluid continuously and provide alerts for high and low glucose levels.
4. **Automated insulin delivery systems:** Use of continuous glucose monitor data and algorithms to automate insulin delivery to reduce hyperglycemia and hypoglycemia and increase time in target range.

### I. **Monitoring**<sup>6,8-10</sup>

#### 1. **Glycemic control:**

- a. Assessment of blood glucose using glucometer or CGM
    - (1) Multiple times daily (e.g., before meals/snacks, at bedtime, prior to exercise, with symptoms of hypoglycemia, after treating for hypoglycemia, before driving)
    - (2) CGM metrics over most recent 14 or more days: time in range (70–180 mg/dL), time below target (<70 and <54 mg/dL) and time above target (>180 mg/dL)
  - b. HbA<sub>1c</sub> every 3 months
2. Urine ketones should be checked with persistent hyperglycemia, any illness (regardless of blood glucose level), or with nausea/vomiting.
3. **Associated conditions or complications:** See [Table 10.4](#).

### J. **Diabetic Emergencies**<sup>11,12</sup>

#### 1. **Diabetic ketoacidosis (DKA)**

- a. Definition: Hyperglycemia (or euglycemia in a patient with known diabetes), ketonemia, ketonuria, and metabolic acidosis (pH <7.30, bicarbonate <15 mEq/L)


TABLE 10.4

SCREENING FOR DIABETES-ASSOCIATED CONDITIONS AND COMPLICATIONS<sup>6,10</sup>

Type of Condition or Complication	Screening Test	Frequency
Hypertension	Blood pressure measurement	At every visit
Hyperlipidemia	Lipid profile	At diagnosis, then yearly if T2DM or T1DM, age 9–11 years and overweight or LDL>100; every 3 years if low-density lipoprotein (LDL) <100 mg/dL
Retinopathy	Dilated eye examination or retinal photography	T1DM: every 2 years after 3–5 years of diabetes, provided age >10 years T2DM: at diagnosis, yearly
Diabetic nephropathy	Random spot urine microalbumin-to-creatinine ratio	T1DM: yearly after 5 years of diabetes, provided age >10 years T2DM: at diagnosis, yearly
Neuropathy	Foot exam	T1DM: yearly after 5 years of diabetes, provided ≥ age 10 T2DM: at diagnosis, yearly
Nonalcoholic steatohepatitis (NASH)	ALT, AST	T2DM: at diagnosis, yearly
Obstructive sleep apnea (OSA)	Review of symptoms	T2DM: at every visit
Polycystic ovary syndrome (PCOS)	Menstrual history ± lab evaluation	T2DM: at every visit

ALT, Alanine amino transferase; AST, aspartate amino transferase; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

- b. BG reflects hydration status, pH reflects DKA severity
  - c. Symptoms: Nausea, emesis, abdominal pain, fruity breath, altered mental status, Kussmaul respirations
  - d. Precipitating factors: New-onset DM, known diabetes with missed insulin doses, insulin pump/infusion site malfunction, or physiologic stress due to acute illness
  - e. Management: See Fig. 10.1. Because the fluid and electrolyte requirements vary greatly from patient to patient, guidelines are only a starting point, and therapy must be individualized based on patient characteristics. **NOTE:** Initial insulin administration may cause transient worsening of the acidosis as potassium is driven into cells in exchange for hydrogen ions.
  - f. Cerebral edema: Most severe complication of DKA. Overly aggressive hydration and rapid correction of hyperglycemia may play a role in its development. Risk factors include severe acidosis, evidence of renal insufficiency, young age and new onset, use of bicarbonate.
  - g. Once DKA is resolved, transition to subcutaneous (SQ) insulin. See Tables 10.2 and 10.3 for calculations or resume home insulin doses.
2. **Hyperosmolar hyperglycemic state (HHS)**
- a. Definition: Extreme hyperglycemia (BG >600 mg/dL) and hyperosmolarity (>320 mOsm/kg), **without significant ketosis or acidosis**

**FIGURE 10.1**

Management of diabetic ketoacidosis. (Modified from Cooke DW, Plotnick L. Management of diabetic ketoacidosis in children and adolescents. *Pediatr Rev.* 2008;29:431–436.)

- b. Characteristics: Gradually increasing polyuria and polydipsia leading to profound dehydration, altered consciousness
- c. Management:
  - (1) Fluids: Fluids alone will decrease BG due to dilution, promotion of glucosuria, and increased glucose uptake with improved circulation. Fluid replacement should be more rapid than in DKA with goal of gradual decline in serum sodium (about 0.5 mEq/dL/hr) and osmolality. Bolus  $\geq 20$  cc/kg 0.9% saline and repeat until perfusion improved. Then start maintenance fluids plus deficit replacement over 24 to 48 hours using 0.45% to 0.75% saline (if perfusion inadequate, consider isotonic fluids). Urine output should also be replaced.
  - (2) Insulin therapy: Start insulin (0.025 to 0.05 unit/kg/hr) when BG no longer declining at least 50 mg/dL/hr with fluids alone. Titrate insulin to decrease BG by 75 to 100 mg/dL/hr.
  - (3) Electrolytes: Potassium, phosphate, and magnesium deficits greater than in DKA; monitor every 2 to 4 hours. Start potassium replacement with 40 mEq/L once K  $< 5$  mEq/L.

## II. THYROID GLAND<sup>13-15</sup>

### A. Thyroid Tests<sup>14,16,17</sup>

1. **Normal thyroid function values:** See reference values for age (Table 10.5). Preterm infants have different ranges (Table 10.6).

**TABLE 10.5**

**AGE-BASED NORMAL VALUES FOR ROUTINE THYROID FUNCTION TESTS**

Test	Age	Normal Range	
TSH (mIU/L)	Birth–6 days	0.70–15.2	
	1 week–3 months	0.72–11.0	
	3 months–12 months	0.73–8.35	
	1–5 years	0.70–5.97	
	6–10 years	0.60–4.84	
	>10 years	0.45–4.50	
Free T <sub>4</sub> (ng/dL)	Birth–3 days	0.66–2.71	
	4–30 days	0.83–3.09	
	31 days–12 months	0.48–2.34	
	13 months–5 years	0.85–1.75	
	6–10 years	0.90–1.67	
	11–19 years	0.93–1.60	
	>19 years	0.82–1.77	
Total T <sub>4</sub> (mCg/dL)	<1 month	Male	Female
	1–23 months	4.5–17.2	4.5–17.2
	2–12 years	5.9–13.9	5.9–13.9
	13–20 years	5.7–11.6	5.7–11.6
	>20 years	5.1–10.3	5.3–11.7
		4.9–0.5	5.1–11.9

**NOTE:** If age-specific reference ranges are provided by the laboratory that is running the assay, please refer to those ranges.

T<sub>4</sub>, Thyroxine; TSH, thyroid stimulating hormone.

TSH and Free T<sub>4</sub> reference ranges from Labcorp; Total T<sub>4</sub> reference range from Quest Diagnostics.

**TABLE 10.6****MEAN TSH AND T<sub>4</sub> OF PRETERM AND TERM INFANTS 0–28 DAYS**

Age ± SD	Cord (Day 0)	Day 7	Day 14	Day 28
<b>T<sub>4</sub> (mCg/dL)</b>				
23–27 <sup>a</sup>	5.44 ± 2.02	4.04 ± 1.79	4.74 ± 2.56	6.14 ± 2.33
28–30	6.29 ± 2.02	6.29 ± 2.10	6.60 ± 2.25	7.46 ± 2.33
31–34	7.61 ± 2.25	9.40 ± 3.42	9.09 ± 3.57	8.94 ± 2.95
>37	9.17 ± 1.94	12.67 ± 2.87	10.72 ± 1.40	9.71 ± 2.18
<b>FT<sub>4</sub> (ng/dL)</b>				
23–27	1.28 ± 0.41	1.47 ± 0.56	1.45 ± 0.51	1.50 ± 0.43
28–30	1.45 ± 0.43	1.82 ± 0.66	1.65 ± 0.44	1.71 ± 0.43
31–34	1.49 ± 0.33	2.14 ± 0.57	1.96 ± 0.43	1.88 ± 0.46
>37	1.41 ± 0.39	2.70 ± 0.57	2.03 ± 0.28	1.65 ± 0.34
<b>TSH (mIU/L)</b>				
23–27 <sup>b</sup>	2.1	2.2	2.4	2.6
28–30 <sup>b</sup>	3.4	3.1	2.8	2.5
31–34	7.90 ± 5.20	3.60 ± 4.80	3.80 ± 9.30	3.50 ± 3.40
>37	6.70 ± 4.80	2.60 ± 1.80	2.50 ± 2.00	1.80 ± 0.90

<sup>a</sup>Weeks gestational age.

<sup>b</sup>Standard deviations unavailable in Kaluarachchi et al. reference. Percentile graphs present in reference.

FT<sub>4</sub>, Free thyroxine; T<sub>4</sub>, thyroxine; TSH, thyroid stimulating hormone.

Data modified from Williams FL, Simpson J, Delahunty C, et al. Collaboration from The Scottish Preterm Thyroid Group: Developmental trends in cord and postpartum serum thyroid hormones in preterm infants. *J Clin Endocrinol Metab.* 2004;89:5314–5320; Kaluarachchi DC, Allen DB, Eickhoff JC, Dawe SJ, Baker MW. Thyroid-stimulating hormone reference ranges for preterm infants. *Pediatrics.* 2019 Aug;144(2):e20190290. Epub 2019 Jul 16. PMID: 31311840. doi: 10.1542/peds.2019-0290

10

2. **Interpretation of abnormal thyroid function values:** See [Table 10.7](#).

3. **Imaging studies:**

- Thyroid ultrasound: Most useful in assessing thyroid nodules for features suspicious for malignancy
- Thyroid uptake scan: Measures uptake of technetium (<sup>99m</sup>Tc) pertechnetate or radioactive iodine by metabolically active thyroid tissue, helping to identify etiology of hyperthyroidism

**TABLE 10.7****THYROID FUNCTION TESTS: INTERPRETATION**

Disorder	TSH	T <sub>4</sub>	Free T <sub>4</sub>
Primary hyperthyroidism	L	H	High N to H
Primary hypothyroidism	H	L	L
Hypothalamic/pituitary hypothyroidism	L, N, H <sup>a</sup>	L	L
TBG deficiency	N	L	N
Euthyroid sick syndrome	L, N, H <sup>a</sup>	L	L to low N
TSH adenoma or pituitary resistance	N to H	H	H
Subclinical hypothyroidism <sup>b</sup>	H	N	N

<sup>a</sup>Can be normal, low, or slightly high.

<sup>b</sup>Treatment may not be necessary.

H, High; L, low; N, normal; T<sub>4</sub>, thyroxine; TBG, thyroxine-binding globulin; TSH, thyroid stimulating hormone.

## B. Hypothyroidism

1. **Types of hypothyroidism:** Can be either congenital or acquired and either primary or central. See [Table 10.8](#) for details on identification and management.
2. **Subclinical hypothyroidism and obesity<sup>18</sup>:** Moderate elevations in thyroid stimulating hormone (TSH [4 to 10 mIU/L]), with normal or slightly elevated triiodothyronine (T<sub>3</sub>) and thyroxine (T<sub>4</sub>), are seen in 10% to 23% of obese children. There does not appear to be a benefit to treating these individuals. Values tend to normalize with weight loss. Could consider testing for thyroid antibodies to further clarify whether there is true thyroid dysfunction.
3. **Newborn screening for hypothyroidism<sup>15-20</sup>:** Mandated in all 50 states. Measures a combination of TSH and T<sub>4</sub>, based on the particular state's algorithm; 1:25 abnormal tests are confirmed. Congenital hypothyroidism has prevalence of 1:3000 to 1:4000 US infants. If abnormal results are found, clinicians should follow recommendations of the American College of Medical Genetics ACT Sheets and Algorithm for confirmation testing.

## C. Hyperthyroidism

1. **General features:**
  - a. Epidemiology: Prevalence increases with age, rare before adolescence; female-to-male predominance
  - b. Etiology: Most common cause is Graves disease, followed by subacute thyroiditis. Less common causes are Hashitoxicosis, autonomously functioning thyroid nodule, factitious hyperthyroidism (intake of exogenous hormone), TSH-secreting pituitary tumor (rare), and pituitary resistance to thyroid hormone. See [Table 10.9](#) for comparison of Graves disease and Hashimoto thyroiditis.
  - c. Laboratory findings: See [Table 10.7](#). Further tests include TSH receptor–stimulating antibody, thyroid stimulating immunoglobulin (TSI), antithyroglobulin and antimicrosomal (thyroid peroxidase) antibodies.
2. **Thyroid storm<sup>21</sup>:**
  - a. Presentation: Acute onset of hyperthermia, tachycardia, and restlessness. May progress to delirium, coma, and death
  - b. Treatment: Admission to ICU. Emergent pediatric endocrinology consultation recommended. Therapy aimed at relieving symptoms (propranolol) and reducing peripheral conversion of T<sub>4</sub> to T<sub>3</sub> (hydrocortisone), thyroid hormone production (antithyroid drugs), release of hormone from thyroid gland (potassium iodide), and reabsorption from enterohepatic circulation (cholestyramine)
3. **Neonatal thyrotoxicosis:**
  - a. Presentation: Microcephaly, frontal bossing, intrauterine growth restriction (IUGR), tachycardia, systolic hypertension leading to widened pulse pressure, irritability, failure to thrive, exophthalmos, goiter, flushing, vomiting, diarrhea, jaundice, thrombocytopenia, and cardiac failure or arrhythmias. Onset from immediately after birth to weeks

TABLE 10.8

HYPOTHYROIDISM<sup>55,56</sup>

Clinical Symptoms	Onset	Etiology	Management	Follow-up
<b>PRIMARY/CONGENITAL</b>				
Large fontanelles, lethargy, constipation, hoarse cry, hypotonia, hypothermia, jaundice. Most often picked up on newborn screen.	Symptoms usually develop by 2 weeks; almost always by 6 weeks.  Some infants may be relatively asymptomatic if not caused by absence of thyroid gland.	<b>Primary:</b> Defect of fetal thyroid development most common. Other causes include TSH receptor mutation or thyroid dyshormonogenesis.  <b>OR Central:</b> Deficiency of TSH or thyrotropin-releasing hormone (TRH).	Replacement with L-thyroxine once newborn screen is positive, pending results of confirmatory testing. <sup>a</sup> Goal T <sub>4</sub> in upper half of normal range. In primary hypothyroidism, TSH should be kept in normal range for age.	Monitor T <sub>4</sub> and TSH 1–2 weeks after initiation and then every 2 weeks until TSH normalizes. Once levels are adequate follow per schedule listed below. Treated patients are still at risk for developmental delay.
<b>ACQUIRED</b>				
Growth deceleration, coarse brittle hair, dry skin, delayed tooth eruption, cold intolerance.	Can occur as early as 2 years old.	<b>Primary:</b> Can be caused by Hashimoto thyroiditis (diagnosis supported by + antithyroglobulin or antimicrosomal antibodies), head/neck radiation.  <b>OR Central:</b> Caused by pituitary/hypothalamic insults including brain tumor.	Replacement with L-thyroxine. <sup>a</sup> Targets for TSH and T <sub>4</sub> same as for congenital hypothyroidism above.	Follow every 1–3 months during the first 12 months, every 2–4 months until 3 years, and then every 3–12 months until growth complete. Follow 4–6 weeks after any dose change.

**NOTE:** Thyroid hormone levels in premature infants are lower than those seen in full-term infants. Furthermore, the TSH surge seen at approximately 24 hours of age in full-term babies does not appear in preterm infants. In this population, lower levels are associated with increased illness; however, the effect of replacement therapy remains controversial.

<sup>a</sup>Because of the risk of inducing adrenal crisis if adrenocorticotrophic hormone (ACTH) deficiency is present, the treatment of central hypothyroidism *should not be* started until normal ACTH/cortisol function is documented. L-thyroxine, Levothyroxine; TSH, thyroid stimulating hormone.

**TABLE 10.9**  
**HYPERTHYROIDISM**

Presentation	Distinguishing Imaging/Lab Findings	Management
<b>GRAVES DISEASE</b>		
Typical symptoms of hyperthyroidism plus diffuse goiter, eye symptoms, localized dermopathy, and lymphoid hyperplasia	TSH is often undetectable. ↑ <sup>99m</sup> Tc-pertechnate uptake. Positive TSI.	First-line treatment in children is methimazole. Radioactive iodine ( <sup>131</sup> I) or surgical thyroidectomy are options for initial treatment or refractory cases. Follow symptoms, T <sub>4</sub> , and TSH levels.
<b>HASHIMOTO THYROIDITIS</b>		
± Initial hyperthyroidism, followed by eventual thyroid burnout and hypothyroidism	Often low but detectable TSH and less significant increase in T <sub>4</sub> . ↓ <sup>99m</sup> Tc-pertechnate uptake. Significant elevation of thyroglobulin and/or microsomal antibody.	Hyperthyroid phase is usually self-limited; patient may eventually need thyroid replacement therapy. Propranolol if symptomatic during hyperthyroid phase.

<sup>99m</sup>Tc, Technetium; T<sub>4</sub>, thyroxine; TSH, thyroid stimulating hormone; TSI, thyroid stimulating immunoglobulin.

- b. Etiology: Occurs exclusively in infants born to mothers with Graves disease. Caused by transplacental passage of maternal TSI. Occasionally, mothers are unaware they have Graves. Even if a mother has received definitive treatment (thyroidectomy or radiation therapy), passage of TSI remains possible.
- c. Treatment and monitoring: Propranolol for symptom control. Methimazole to lower thyroxine levels. Digoxin may be indicated for heart failure. Disease usually resolves by 6 months of age.

### III. PARATHYROID GLAND AND VITAMIN D<sup>22-24</sup>

#### A. Parathyroid Hormone Function

1. Increases serum calcium by increasing bone resorption
2. Increases calcium and magnesium reuptake and phosphorus excretion in the kidney
3. Increases 25-hydroxy vitamin D conversion to 1,25-dihydroxy vitamin D in order to increase calcium absorption in the intestine

#### B. Distinguishing Between Abnormalities Related to Parathyroid Hormone and Vitamin D

See [Table 10.10](#).

#### C. Vitamin D Supplementation

Please see [Chapter 21](#) for additional information.

### IV. ADRENAL GLAND<sup>25-29</sup>

#### A. Adrenal Insufficiency

##### 1. Causes of adrenal insufficiency:

- a. Impaired steroidogenesis, as in congenital adrenal hyperplasia

TABLE 10.10

## DISTINGUISHING BETWEEN DISORDERS OF PARATHYROID GLANDS AND VITAMIN D REGULATION

	Hypoparathyroidism	Hyperparathyroidism	PTH Resistance/ Pseudo-Hypoparathyroidism	Vitamin D Deficiency
PTH	↓ or inappropriately normal in the setting of hypocalcemia	↑	↑	-/↑
1,25-D	↓	↑	↓	—
25-OHD	—	-/↓	—	↓
Calcium	↓	↑	↓	-/↓
Phosphorus	↑	↓	↑	-/↓
Alkaline phosphate	-/↓	-/↑	↑	↑
Common causes	DiGeorge, autoimmune (APS), iatrogenic	Primary: Adenoma, hyperplasia Secondary: Renal failure, rickets	Genetic mutations	Nutritional deficiency
First-line Rx	Calcium, calcitriol	Hydration with normal saline, surgical resection	Calcitriol	Vitamin D +/- calcium

1,25-D, 1,25 Dihydroxy vitamin D; 25-OHD, 25-hydroxy vitamin D; APS, autoimmune polyendocrine syndrome; MEN, multiple endocrine neoplasia; PTH, parathyroid hormone; Rx, treatment.

- b. Adrenal destruction or dysfunction as in primary adrenal insufficiency (AI) (Addison disease), autoimmune polyendocrine syndrome, or adrenoleukodystrophy
  - c. Secondary AI caused by impaired circulating adrenocorticotrophic hormone (ACTH) due to hypothalamic or pituitary pathology
  - d. Acquired insufficiency secondary to long-term corticosteroid use leading to HPA suppression. **NOTE:** This is the most common cause seen in clinical practice and may also occur in setting of chronic high-dose inhaled corticosteroids.
2. **Laboratory findings in adrenal insufficiency:**
    - a. In primary AI, there is deficient mineralocorticoid and glucocorticoid production. In central AI, there is only deficient glucocorticoid production, and mineralocorticoid production is normal.
    - b. Primary AI: Elevated ACTH, elevated plasma renin activity, low cortisol, low aldosterone, hypoglycemia, hyponatremia, hyperkalemia
    - c. Central AI: Normal/low ACTH, normal plasma renin activity (no impairment of mineralocorticoid function), low cortisol, normal aldosterone, hyponatremia, hypoglycemia
    - d. In infants with congenital adrenal hyperplasia (CAH), 17-hydroxyprogesterone (17-OHP) is increased (see [Table 10.11](#) for normal values by age).
  3. **Diagnosis of adrenal insufficiency:**
    - a. Initial screening with AM cortisol level, which may be drawn concomitantly with an ACTH level
    - b. See [Table 10.12](#) for interpretation of AM cortisol results.
    - c. Plasma ACTH elevation >100 pg/mL with concomitant hypocortisolemia <10 mCg/dL is consistent with glucocorticoid deficiency due to primary AI.
    - d. Standard dose ACTH stimulation test is used to confirm diagnosis.
  4. **ACTH stimulation test:**
    - a. In brief, with ACTH deficiency or prolonged adrenal suppression, there is an inadequate rise in cortisol after a single ACTH dose.
    - b. See [Box 10.1](#) for interpretation of ACTH stimulation test.
  5. **Congenital adrenal hyperplasia (CAH):**
    - a. See [Fig. 10.2](#).
    - b. Group of autosomal recessive disorders characterized by a defect in one of the enzymes required in the synthesis of adrenal hormones
    - c. The enzymatic defect results in impaired synthesis of adrenal steroids beyond the enzymatic block and overproduction of the precursors before the block.
    - d. 21-hydroxylase deficiency accounts for 90% of cases.
    - e. Most common cause of ambiguous genitalia in females
  6. **Diagnosis of CAH on newborn screen:**
    - a. The test measures 17-OHP and is 2% specific, resulting in a 98% false-positive rate due to artificial elevations from prematurity, sickness, stress.<sup>27</sup>

**TABLE 10.11****17-HYDROXYPROGESTERONE, SERUM**

Age	Baseline (ng/dL)
Premature (31–35 weeks)	≤405
Term infants (3 days)	<420
1–11 months	≤147
1 year	≤139
2–5 years	≤134
6 years	≤137
7 years	≤145
8 years	≤154
9 years	≤166
10 years	≤180
11 years	≤196
12 years	≤213
13 years	≤233
14 years	≤254
15 years	19–279
16 years	23–300
17 years	26–325
Males, Tanner II–III	12–130
Females, Tanner II–III	18–220
Males, Tanner IV–V	51–190
Females, Tanner IV–V	36–200
Male (18–30 years)	32–307
Adult female	
Follicular phase	23–102
Midcycle phase	67–349
Luteal phase	139–431

Reference ranges from Quest Diagnostics LC/MS assay (liquid chromatography/tandem mass spectroscopy).

For preterm infants or infants born small for gestational age, see Olgemöller B, Roscher AA, Liebl B, et al. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. *J Clin Endocrinol Metab.* 2003;88:5790–5794.

**TABLE 10.12****CORTISOL, 8 A.M.**

Interpretation	Cortisol (mCg/dL)
Suggestive of adrenal insufficiency	<5
Indeterminate	5–14
Adrenal insufficiency unlikely	>14

- b. If 17-OHP is 40 to 100 ng/mL, repeat test.
- c. If 17-OHP is higher than 100 ng/mL, obtain electrolytes and serum 17-OHP. If evidence of hyperkalemia or hyponatremia, initiate treatment with hydrocortisone.
- d. In complete enzyme deficiency, adrenal crisis in untreated patients occurs at 1 to 2 weeks of age due to salt wasting.

**BOX 10.1****PERFORMANCE AND INTERPRETATION OF ACTH STIMULATION TEST****Standard Dose ACTH Stimulation Test**

Obtain initial baseline cortisol level


Give 250 mCg IV ACTH

Measure cortisol at 30 min

Measure cortisol at 60 min

**Interpretation of Results**

Cutoff for adequate cortisol response is highly variable depending on cortisol assay used and may be anywhere between 12.7 and 17.5 mCg/dL for both primary and central adrenal insufficiency. Cortisol reference ranges should be verified with the individual lab running the assay.

**FIGURE 10.2**

Biosynthetic pathway for steroid hormones.

**7. Diagnosis of CAH outside of newborn period:**

- Suspect partial enzyme deficiency if evidence of androgen excess (premature adrenarche, hirsutism, irregular menses, acne, advanced bone age).
- Morning 17-OHP levels may be elevated.
- Diagnosis may require an ACTH stimulation test. A significant rise in the 17-OHP level 60 minutes after ACTH injection is diagnostic. Cortisol response may be decreased.

**8. Addison disease<sup>30</sup>:**

- Primary AI due to autoimmune destruction of the adrenal glands

- b. In children, it may be part of autoimmune polyendocrine syndrome type 1 (APS-1), which also includes hypoparathyroidism and chronic mucocutaneous candidiasis.
- c. Individuals with autoimmune Addison disease should also be screened for other endocrinopathies (T1DM, celiac disease, hypothyroidism, hypoparathyroidism).
9. **Treatment of adrenal insufficiency:**
- a. See [Table 10.13](#) for relative steroid potencies.
- b. See [Table 10.14](#) for maintenance glucocorticoid and mineralocorticoid dosing.

**TABLE 10.13****POTENCY OF VARIOUS THERAPEUTIC STEROIDS<sup>a</sup>**

Steroid	Glucocorticoid Effect <sup>b</sup> (in mg of Cortisol per mg of Steroid)	Mineralocorticoid Effect <sup>c</sup> (in mg of Cortisol per mg of Steroid)
Cortisol (hydrocortisone)	1	1
Cortisone acetate (oral)	0.8	0.8
Cortisone acetate (intramuscular)	0.8	0.8
Prednisone	4	0.25
Prednisolone	4	0.25
Methylprednisolone	5	0.4
β-Methasone	25	0
Triamcinolone	5	0
Dexamethasone	30	0
9α-Fluorocortisone (fludrocortisone)	15	200
Deoxycorticosterone acetate	0	20
Aldosterone	0.3	200–1000

<sup>a</sup>Set relative to potency of cortisol.

<sup>b</sup>To determine cortisol equivalent of a given steroid dose, multiply dose of steroid by corresponding number in column for glucocorticoid or mineralocorticoid effect. To determine dose of a given steroid based on desired cortisol dose, divide desired hydrocortisone dose by corresponding number in the column.

<sup>c</sup>Total physiologic replacement for salt retention is usually 0.1 mg fludrocortisone, regardless of patient size.

Modified from Sperling MA. *Pediatric Endocrinology*. 3rd ed. Elsevier; 2008:476.

**TABLE 10.14****MAINTENANCE DOSING STEROIDS**

Adrenal Hormone	Dose
Glucocorticoid dosing	1. PO hydrocortisone 6–18 mg/m <sup>2</sup> /day ÷ TID OR 2. PO prednisone 1.5–3.5 mg/m <sup>2</sup> /day ÷ BID
Mineralocorticoid dosing <sup>a</sup>	1. PO fludrocortisone acetate 0.1 mg/m <sup>2</sup> /day OR 2. If unable to take PO: IV hydrocortisone 50 mg/m <sup>2</sup> /day <sup>b</sup> PLUS 3. Infants require an additional 1–2 g (17–34 mEq) of sodium supplementation daily

<sup>a</sup>Required in salt-losing forms of adrenal insufficiency.

<sup>b</sup>Synthetic steroids (e.g., prednisone, dexamethasone) do not have sufficient mineralocorticoid effect.

- c. Typically, lower doses are required for central AI, intermediate doses for primary AI, and higher doses for CAH in order to suppress excess androgen production.
10. **Stress dosing of steroids:**
- Hydrocortisone and cortisone are the only glucocorticoids that provide the necessary mineralocorticoid effects;** prednisone and dexamethasone do not.
  - See [Table 10.15](#) for calculation of moderate and major stress dose steroid calculations.
  - See [Box 10.2](#) for rapid approximation of steroid dosing in the setting of acute adrenal crisis.
11. **Indications for stress dosing of steroids:**
- “Stress” is defined as systemic infection, febrile illness, diarrheal illness, trauma/fracture, burns, or surgery.
  - Stress glucocorticoids should be given to patients:
    - With known primary or secondary AI
    - Following discontinuation of exogenous steroid (given for greater than 2 weeks at doses greater than physiologic replacement) until there is recovery of endogenous cortisol production (consider the need for 8 a.m. cortisol or ACTH stimulation test)
  - Consider for hypotension refractory to fluid resuscitation in patients with suspicion for AI (even if not clinically diagnosed).

## B. Adrenal Cortex Hormone Excess<sup>29</sup>

- Causes:**
  - Hypercortisolism (Cushing syndrome):

**TABLE 10.15**

### STRESS DOSING STEROIDS

Degree of Stress	Dose
Moderate stress (minor illness, fever)	1. PO hydrocortisone 30–50 mg/m <sup>2</sup> /day ÷ TID OR 2. PO prednisone 6–10 mg/m <sup>2</sup> /day ÷ BID
Severe stress (surgery, severe illness, compensated shock)	1. IV bolus of hydrocortisone 50 mg/m <sup>2</sup> then 50–100 mg/m <sup>2</sup> /day IV as continuous infusion or divided Q6 hr OR 2. IM injection of 25 mg/m <sup>2</sup> /dose Q6 hr

### BOX 10.2

#### RAPID APPROXIMATION OF STRESS DOSE STEROID REQUIREMENT

- Infant:** 25 mg hydrocortisone  
**Small child:** 50 mg hydrocortisone  
**Large child/adolescent:** 100 mg hydrocortisone

- (1) Exogenous steroid use
  - (2) Excess cortisol secretion from the adrenals
  - (3) Excess ACTH production from ectopic ACTH-producing tumor
  - (4) Excess ACTH production from a pituitary tumor (known as Cushing *disease*)
- b. Hyperaldosteronism:
- (1) Benign tumor of adrenal cortex (Conn syndrome)
  - (2) Overproduction by both adrenal glands (idiopathic hyperaldosteronism)
  - (3) Rarely glucocorticoid remediable aldosteronism
  - (4) Less common in children than hypercortisolism
  - (5) Lab findings include hypokalemia and hypernatremia

## 2. **Diagnosis of Cushing syndrome<sup>31</sup>:**

- a. Step 1: Demonstrate hypercortisolism with two separate measurements. Multiple screening tests are available; specificity increases when they are used in combination:
- (1) 24-hour urine cortisol (>90 mCg/24 hours consistent with hypercortisolism)
  - (2) Midnight salivary cortisol level (>0.13 mCg/dL consistent with hypercortisolism)
  - (3) Overnight low-dose dexamethasone suppression test: Give 1 mg dexamethasone at 11 p.m. followed by an 8 a.m. serum cortisol the next morning (normal suppression <1.8 mCg/dL).
- b. Step 2: Determine etiology of hypercortisolism (ACTH-dependent vs. independent)
- (1) Obtain plasma ACTH between 11 p.m. and 1 a.m.: >23 pg/mL in a patient with hypercortisolism (as diagnosed above) indicates ACTH dependency (Cushing disease vs. ectopic tumor).
  - (2) If cause is Cushing disease (ACTH-dependent), ACTH level will be >100× elevated.
  - (3) In ACTH-independent Cushing syndrome, level will be <5 pg/mL.

## C. **Adrenal Medulla Hormone Excess: Pheochromocytoma<sup>32-34</sup>**

### 1. **Clinical findings:**

- a. Extreme, sustained elevations in blood pressure (accounts for <1% of pediatric hypertension)
- b. Associated with syndromes: multiple endocrine neoplasia (MEN) IIa and IIb, von Hippel-Lindau, neurofibromatosis (NF) 1, familial paraganglioma syndrome

### 2. **Diagnosis:**

- a. Urine metanephrines (see [eTable 10.1](#) for age-specific normal values)
- b. Plasma metanephrines (see [eTable 10.2](#) for age-specific normal values)

**eTABLE 10.1****CATECHOLAMINES,<sup>a</sup> URINE**

Compound	3–8 Years	9–12 Years	13–17 Years	Adults	
Dopamine (mCg/24 hr)	80–378	51–474	51–645	52–480	
Epinephrine (mCg/24 hr)	1–7	≤8	≤11	2–14	
Norepinephrine (mCg/24 hr)	5–41	5–50	12–88	15–100	
Homovanillic acid (mg/24 hr)	0.5–6.7	1.1–6.8	1.4–7.2	1.6–7.5	
Vanillylmandelic acid (mg/24 hr)	≤2.3	≤3.4	≤3.9	≤6.0	
	3 Months–4 Years	5–9 Years	10–13 Years	14–17 Years	18–29 Years
Metanephrines (mCg/24 hr)	25–117	11–139	51–275	40–189	25–222
Normetanephrines (mCg/24 hr)	54–249	31–398	67–503	69–531	40–412

<sup>a</sup>Catecholamines are elevated in a variety of tumors, including neuroblastoma, ganglioneuroma, ganglioblastoma, and pheochromocytoma.

Data from JHH Laboratories.

**eTABLE 10.2****CATECHOLAMINES, PLASMA**

	Supine (pg/mL)	Sitting (pg/mL)
<b>EPINEPHRINE</b>		
3–15 years	≤464	Not determined
Adult	≤50	≤95
<b>NOREPINEPHRINE</b>		
3–15 years	≤1251	Not determined
Adult	112–658	217–1109
<b>DOPAMINE</b>		
3–15 years	≤60	Not determined
Adult	≤30	≤30

Data from Blondell R, Foster MB, Dave KC. Disorders of puberty. *Am Family Phys.* 1999;60:209–218; and JHH Laboratories.

## V. DISORDERS OF SODIUM AND WATER REGULATION<sup>35</sup>

**A. Distinguishing Between Disorders of Sodium and Water Regulation: See Table 10.16**

**B. Correction of Hypo- and Hypernatremia: See Chapter 11**

**C. Conducting a Water Deprivation Test**

1. Begin test after a 24-hour period of adequate hydration and stable weight.
2. Obtain a baseline weight after bladder emptying, as well as baseline urine and blood osmolality and electrolytes.
3. Restrict fluids (consider max 7 hours, 4 hours for infants).
4. Measure body weight and urine—specific gravity and volume hourly.
5. If urine specific gravity  $\geq 1.014$ , or weight loss approaching 5%, terminate test and obtain urine and blood for osmolality and electrolytes.

**D. Interpretation of Water Deprivation Test Results: See Table 10.17**

**E. Differentiating Between Central Versus Nephrogenic Causes of Diabetes Insipidus**

1. Administer vasopressin subcutaneously at end of water deprivation test. Assess urine output, urine specific gravity, and water intake.

**TABLE 10.16**

### DIFFERENTIATING BETWEEN DISORDERS OF SODIUM AND WATER REGULATION

	SIADH	Cerebral Salt Wasting	DI
Serum Na <sup>+</sup>	<135 mEq/L	<135 mEq/L	>145 mEq/L <sup>a</sup>
Serum Osm	<280 mOsm/kg	<280 mOsm/kg	>300 mOsm/kg <sup>a</sup>
Urine Na <sup>+</sup>	>40 mEq/L	>40 mEq/L	<40 mEq/L <sup>b</sup>
Urine Osm	>100 mOsm/kg (inappropriately concentrated)	>100 mOsm/kg (inappropriately concentrated)	<300 mOsm/kg (inappropriately dilute)
Volume status	Euvolemia	Hypovolemia	Hypovolemia
Urine output	Decreased	Increased	Increased
Other lab findings	High vasopressin	Low vasopressin	Central: low vasopressin (<0.5 pg/mL) Nephrogenic: high vasopressin
Causes	Nausea, CNS and pulmonary pathology, surgery, certain medications	CNS disorders, hypersecretion of atrial natriuretic peptide	Central: ↓ADH secretion from posterior pituitary Nephrogenic: ADH resistance at the nephron collecting duct
Treatment	Fluid restriction and correction of underlying cause Treatment with sodium will cause diuresis	Replacement of urine volume with IV solutions ± salt replacement	Central: Intranasal desmopressin acetate (DDAVP) Nephrogenic: Access to free water, salt restriction, consider thiazide diuretics, indomethacin

<sup>a</sup>Normal serum sodium and osmolality can be seen in compensated diabetes insipidus, and water deprivation test should be performed if clinical suspicion is high.

<sup>b</sup>Urine sodium generally low in diabetes insipidus; however, this depends on solute intake.

ADH, Antidiuretic hormone; CNS, central nervous system; DI, diabetes insipidus; IV, intravenous; Na<sup>+</sup>, sodium; Osm, osmolality; SIADH, syndrome of inappropriate ADH secretion.

**TABLE 10.17****RESULTS OF WATER DEPRIVATION TEST IN NORMAL VERSUS CENTRAL/NEPHROGENIC DIABETES INSIPIDUS**

	Normal (Psychogenic Polydipsia)	Central/ Nephrogenic DI
Urine volume	Decreased	No change
Weight loss	No change	≤5%
Urine osmolality (mOsm/L)	500–1400 (>1000 generally excludes diagnosis of DI)	<150
Plasma osmolality (mOsm/L)	288–291	>290
Urine specific gravity	≥1.010	<1.005
Urine: plasma osmolality ratio	>2	<2

DI, Diabetes insipidus.

- See [Table 10.18](#) for interpretation of vasopressin test.

**VI. GROWTH<sup>35-37</sup>****A. Assessing Height**

- Mid-parental height and target height range:**
  - Mid-parental height for boys: (Paternal height + maternal height + 5 in or 13 cm)/2
  - Mid-parental height for girls: (Paternal height + maternal height – 5 in or 13 cm)/2
  - Target height range: Mid-parental height ± 2 SD (1 SD = 2 in or 5 cm)
- Determining average growth velocity:** See [Table 10.19](#).
- See [eFigs. 10.1 and 10.2](#) for normal growth velocity curves for American females and males, respectively.

**TABLE 10.18****RESULTS OF VASOPRESSIN ADMINISTRATION IN EVALUATION OF DIABETES INSIPIDUS**


	Psychogenic Polydipsia	Central <sup>a</sup>	Nephrogenic
Urine volume	↓	↓	No change
Urine specific gravity	≥1.010	≥1.010	No change
Oral fluid intake	No change	↓	No change

<sup>a</sup>In central diabetes insipidus, urine osmolality increases by 200% or more in response to vasopressin administration.


**TABLE 10.19****ESTIMATED GROWTH VELOCITY IN CHILDREN BASED ON AGE**

Age	Growth
Birth to 1 year old	25 cm/year
1 year old to 4 years old	10 cm/year
4 years old to 8 years old	5 cm/year
8 years old to 12 years old	5 cm/year <sup>a</sup>

<sup>a</sup>Rates may be considerably higher at later end of this age range when individuals have entered their pubertal growth spurt.

**eFIGURE 10.1**

Height velocity by age for American girls. (From Kelly A, Winer KK, Kalkwarf H, et al. Age-based reference ranges for annual height velocity in US children. *J Clin Endocrinol Metab.* 2014;99:2104.)

**eFIGURE 10.2**

Height velocity by age for American boys. (From Kelly A, Winer KK, Kalkwarf H, et al. Age-based reference ranges for annual height velocity in US children. *J Clin Endocrinol Metab.* 2014;99:2104.)

## B. Short Stature

### 1. Definition:

- a. Short stature is height  $<2$  SD below mean or  $<3$ rd percentile for age and sex.
- b. Growth failure is defined as height  $<2$  SD below mid-parental height or height velocity  $<10$ th percentile for age resulting in a downward trend crossing height percentiles.
- c. Majority of children with short stature are healthy; true growth failure is typically pathologic and requires evaluation.

### 2. Determining etiology:

- a. See [Table 10.20](#) for approach to differentiating between pathologic and nonpathologic causes of short stature.
- b. Bone age is determined by radiographs of left wrist and hand.
- c. See [Fig. 10.3](#) for initial workup.
- d. A more extensive workup can be guided by history and physical exam and could include:
  - (1) TTG and IgA (celiac disease)
  - (2) CBC with differential (anemia, malignancy, inflammation)
  - (3) CRP/ESR (inflammation, infection)
  - (4) CMP (renal/liver disorders, malnutrition, calcium disorders)
  - (5) TSH, free  $T_4$  (hypothyroidism)
  - (6) Karyotype or targeted gene testing (Turner syndrome, SHOX mutation)
  - (7) IGF1, IGFBP-3 [proxy measurements for growth hormone (GH)]; IGFBP-3 has a higher specificity in children  $<10$ ); see [Table 10.21](#) and [eTable 10.3](#) for normal values of IGF-1 and IGFBP-3, respectively.

### 3. Indications for growth hormone use<sup>38</sup>:

- The FDA has approved growth hormone for:
- a. Growth hormone deficiency

**TABLE 10.20**

**PATHOLOGIC VERSUS NONPATHOLOGIC CAUSES OF SHORT STATURE**


	Familial Short Stature	Constitutional Growth Delay	Pathologic Causes (e.g., Endocrine, Genetic)
Growth velocity	Normal	Normal	Decreased
Onset of puberty	Normal	Delayed	Depends on cause
Family history	Short stature	Delayed puberty	+/-
Bone age	Normal	Delayed	Usually delayed (may be normal in genetic causes)
Eventual adult height	Short, near mid-parental height	Normal	Depends on cause

**eTABLE 10.3****INSULIN-LIKE GROWTH FACTOR—BINDING PROTEIN-3 (IGFBP-3)<sup>a</sup>**

Age	mg/L	Tanner Stage	Female (mg/L)	Male (mg/L)
0–7 days	≤0.7	Tanner I	1.2–6.4	1.4–5.2
8–15 days	0.5–1.4	Tanner II	2.8–6.9	2.3–6.3
16 days–1 year	0.7–3.6	Tanner III	3.9–9.4	3.2–8.9
2 years	0.8–3.9	Tanner IV	3.3–8.1	3.7–8.7
3 years	0.9–4.3	Tanner V	2.7–9.1	2.6–8.6
4 years	1.0–4.7			
5 years	1.1–5.2			
6 years	1.3–5.6			
7 years	1.4–6.1			
8 years	1.6–6.5			
9 years	1.8–7.1			
10 years	2.1–7.7			
11 years	2.4–8.4			
12 years	2.7–8.9			
13 years	3.1–9.5			
14 years	3.3–10.0			
15 years	3.5–10.0			
16 years	3.4–9.5			
17 years	3.2–8.7			
18 years	3.1–7.9			
19 years	2.9–7.3			
Adults continue to vary by age				

<sup>a</sup>Levels below the 5th percentile suggest growth hormone deficiency. This test may have greater discrimination than the IGF-1 test in younger patients.

Data from Quest Diagnostics immunochemiluminometric assay (ICMA).

**FIGURE 10.3**

Differential diagnosis of short stature.

**TABLE 10.21****INSULIN-LIKE GROWTH FACTOR 1<sup>a</sup>**

Age (Years)	Male (ng/mL)	Females (ng/mL)
<1	14–142	17–185
1–1.9	12–134	15–175
2–2.9	12–135	16–179
3–3.9	30–155	38–214
4–4.9	28–181	34–238
5–5.9	31–214	37–272
6–6.9	38–253	45–316
7–7.9	48–298	58–367
8–8.9	62–347	76–424
9–9.9	80–398	99–483
10–10.9	100–449	125–541
11–11.9	123–497	152–593
12–12.9	146–541	178–636
13–13.9	168–576	200–664
14–14.9	187–599	214–673
15–15.9	201–609	218–659
16–16.9	209–602	208–619
17–17.9	207–576	185–551

<sup>a</sup>A clearly normal IGF-1 level argues against growth hormone (GH) deficiency, except in young children in whom there is considerable overlap between normal levels and those with GH deficiency.

Reference ranges from Quest Diagnostics LC/MS (liquid chromatography/tandem mass spectrometry) assay.

- b. Children born small-for-gestational-age (SGA) who, between 2 and 4 years of age, have shown inadequate catchup growth or evidence of normal growth velocity with height <2.5 SD below mean
- c. Chronic kidney disease
- d. Turner syndrome, Noonan syndrome, Prader-Willi syndrome
- e. Short stature homeobox containing gene (SHOX) deficiency
- f. Children with idiopathic short stature (height <2.25 SD below mean and unlikely to attain normal adult height)

## VII. SEXUAL DEVELOPMENT<sup>39-45</sup>

### A. Puberty

1. For normal pubertal stages, see [Chapter 5](#).
2. For definitions of precocious and delayed puberty, see [Table 10.22](#).

### B. Lab Evaluation

1. LH, FSH, estradiol, and testosterone (free and total): see [Tables 10.23 through 10.27](#) for normal values. **NOTE:** Early in puberty, LH production peaks overnight and is lower during the day, so consider obtaining levels in the early morning.
2. Gonadotropin (GnRH) stimulation test<sup>46</sup>:

**TABLE 10.22****DEFINITIONS OF PRECOCIOUS AND DELAYED SEXUAL MATURATION**

	<b>Females</b>	<b>Males</b>
Precocious	Before age 8 years: Thelarche (may be benign or progressive as seen in precocious puberty) Adrenarche (may be isolated or a feature of precocious puberty)	Before age 9 years: Testicular enlargement Adrenarche (may be isolated or a feature of precocious puberty)
Delayed	No thelarche by 13 years or >5 years between thelarche and menarche  Primary amenorrhea: No menarche by age 16 years in the presence of secondary sexual characteristics, or no menarche and no secondary sexual characteristics by age 14 years	No testicular enlargement by 14 years

**TABLE 10.23****LUTEINIZING HORMONE**

<b>Age</b>	<b>Males (mIU/mL)</b>	<b>Females (mIU/mL)</b>
0–2 years	Not established	Not established
3–7 years	≤0.26	≤0.26
8–9 years	≤0.46	≤0.69
10–11 years	≤3.13	≤4.38
12–14 years	0.23–4.41	0.04–10.80
15–17 years	0.29–4.77	0.97–14.70
<b>Tanner Stages</b>	<b>Males (mIU/mL)</b>	<b>Females (mIU/mL)</b>
I	≤0.52	≤0.15
II	≤1.76	≤2.91
III	≤4.06	≤7.01
IV–V	0.06–4.77	0.10–14.70

Data from Quest Diagnostics immunoassay. For more information, see <https://www.questdiagnostics.com>.

**TABLE 10.24****FOLLICLE-STIMULATING HORMONE**

<b>Age</b>	<b>Male (mIU/mL)</b>	<b>Female (mIU/mL)</b>
0–4 years	Not established	Not established
5–9 years	0.21–4.33	0.72–5.33
10–13 years	0.53–4.92	0.87–9.16
14–17 years	0.85–8.74	0.64–10.98

Data from Quest Diagnostics immunoassay. For more information, see <https://www.questdiagnostics.com>.

**TABLE 10.25****ESTRADIOL<sup>a</sup>**

Age	Level (pg/mL)
Prepubertal children	<25
Males	6–44
Females	
Luteal phase	26–165
Follicular phase	None detected–266
Midcycle	118–355
Adult females on OCP	None detected–102

<sup>a</sup>Normal infants have elevated estradiol at birth, which decreases to prepubertal values during the first week of life. Estradiol levels increase again between age 1 and 2 months and return to prepubertal values by age 6–12 months. OCP, Oral contraceptive pill.

Data from JHH Laboratories.

**TABLE 10.26****TESTOSTERONE, TOTAL SERUM<sup>a</sup>**

Age	Male (ng/dL)	Female (ng/dL)
Cord blood	17–61	16–44
1–10 days	≤187	≤24
1–3 months	72–344	≤17
3–5 months	≤201	≤12
5–7 months	≤59	≤13
7–12 months	≤16	≤11
1–5.9 years	≤5	≤8
6–7.9 years	≤25	≤20
8–10.9 years	≤42	≤35
11–11.9 years	≤260	≤40
12–13.9 years	≤420	≤40
14–17.9 years	≤1000	≤40
≥18 (adult)	250–1100	2–45
<b>TANNER STAGE</b>		
Stage I	≤5	≤8
Stage II	≤167	≤24
Stage III	21–719	≤28
Stage IV	25–912	≤31
Stage V	110–975	≤33

<sup>a</sup>Normal testosterone/dihydrotestosterone (T/DHT) ratio is <18 in adults and older children and <10 in neonates. A T/DHT ratio >20 suggests 5- $\alpha$ -reductase deficiency or androgen insensitivity syndrome.

Data from Quest Diagnostics LC/MS (liquid chromatography/tandem mass spectrometry) assay.

**TABLE 10.27****TESTOSTERONE, FREE**

Age	Male (pg/mL)	Female (pg/mL)
1–11 years	≤1.3	≤1.5
12–13 years	≤64.0	≤1.5
14–17 years	4.0–100.0	≤3.6
18–69 years	46.0–224.0	0.2–5.0

Data from Quest Diagnostics LC/MS (liquid chromatography/tandem mass spectrometry) assay.

- a. Purpose: To evaluate for biochemical evidence of puberty when LH, FSH, and sex hormone testing is inconclusive.
  - b. Method: Give GnRH analog (leuprolide) SQ, and measure LH and FSH levels at 0 and 60 minutes.
  - c. Interpretation: Prepubertal children should show no or minimal increase in LH and FSH in response to GnRH. A rise of LH to >3.3 to 5.0 IU/L is evidence of central puberty.
3. **Delayed puberty**<sup>41,45,47</sup>: See Fig. 10.4 for information on evaluation and management of delayed puberty.
  4. **Precocious puberty**<sup>42,47</sup>: See Fig. 10.5 for information on evaluation and management of precocious puberty.

### C. Polycystic Ovarian Syndrome<sup>48</sup>

#### 1. Clinical features in adolescents:

- a. Diagnostic criteria (must have features of both):
  - (1) Hyperandrogenism: Either clinical or biochemical
    - (a) Clinical: Hirsutism, acne, male pattern alopecia
    - (b) Biochemical characteristics: Elevated androgens including DHEA-S (see Table 10.28 for normal values), free or total testosterone
  - (2) Menstrual abnormalities: Amenorrhea or oligomenorrhea (chronic anovulation)


**NOTE:** Appearance of multiple ovarian cysts is a diagnostic criterion for adults, but not for adolescents, as this can be a normal finding in adolescent females.

- b. Common cause of female infertility
  - c. Often LH>FSH, but this is not required for diagnosis
  - d. Chronic anovulation and unopposed estrogen exposure increase risk for endometrial cancer.
  - e. Associated with insulin resistance and increased risk of type 2 diabetes
- #### 2. Management:
- a. Combined oral contraceptives: First-line for management of menstrual abnormalities and hirsutism/acne. Increases SHBG (thus decreasing free testosterone), which may result in increased insulin sensitivity and restoration of ovulation
  - b. Anti-androgen therapy, such as spironolactone, to treat hirsutism
  - c. Weight reduction and other lifestyle changes
  - d. Metformin: Can be considered as possible treatment if goal is to treat insulin resistance


### D. Ambiguous Genitalia<sup>49</sup>

#### 1. Clinical findings in a neonate suspicious for ambiguous genitalia:

- a. Apparent female with clitoromegaly (length >1 cm or width >6 mm in term infant), inguinal or labial mass, or posterior labial fusion
- b. Micropenis (stretched penile length that is  $-2.5$  SD below mean for age; see Table 10.29 for normal values)

**FIGURE 10.4**

An approach to the child presenting with delayed puberty. *CNS*, Central nervous system; *FSH*, follicle-stimulating hormone; *IGF1*, insulin-like growth factor 1; *LH*, luteinizing hormone; *MRI*, magnetic resonance imaging. (From Klein DA, Emerick JE, Sylvester JE, Vogt KS. Disorders of puberty. An approach to diagnosis and management. *Am Fam Physician*. 2017;96[9]:590–599.)

**FIGURE 10.5**

An approach to the child presenting with early puberty. *DHEA-S*, Dehydroepiandrosterone sulfate; *FSH*, follicle-stimulating hormone; *LH*, luteinizing hormone; *MRI*, magnetic resonance imaging. (Reprinted with permission from Disorders of Puberty: An Approach to Diagnosis and Management, November 1, 2017, Vol 96, No 9, American Family Physician Copyright © 2017 American Academy of Family Physicians. All rights reserved.)

- c. Nonpalpable gonads in an apparent male
- d. Hypospadias associated with separation of scrotal sacs or undescended testis
- e. Discordance between prenatal karyotype and genital appearance

## 2. Etiology:

- a. Due to undervirilization of male genitalia or virilization of female genitalia
- b. Most common cause is CAH
- c. Other causes by male versus female karyotype:
  - (1) 46,XY karyotype: Testicular regression, androgen insensitivity, testosterone biosynthesis disorders, rare forms of CAH, absence of SRY

**TABLE 10.28****DEHYDROEPIANDROSTERONE SULFATE (DHEA-S)**

Age	Male (mCg/dL)	Female (mCg/dL)
<1 months	≤316	15–261
1–6 months	≤58	≤74
7–11 months	≤26	≤26
1–3 years	≤15	≤22
4–6 years	≤27	≤34
7–9 years	≤91	≤92
10–13 years	≤138	≤148
14–17 years	38–340	37–307
<b>TANNER STAGES (AGES 7–17)</b>		
I	≤49	≤46
II	≤81	15–133
III	22–126	42–126
IV	33–177	42–241
V	110–370	45–320

Data from Quest Diagnostics assay. For more information see <https://www.questdiagnostics.com>.

**TABLE 10.29****MEAN STRETCHED PENILE LENGTH (CM)<sup>a</sup>**

Age	Mean ± SD	– 2.5 SD
<b>BIRTH</b>		
30 weeks' gestation	2.5 ± 0.4	1.5
34 weeks' gestation	3.0 ± 0.4	2.0
Full term	3.5 ± 0.4	2.5
0–5 months	3.9 ± 0.8	1.9
6–12 months	4.3 ± 0.8	2.3
1–2 years	4.7 ± 0.8	2.6
2–3 years	5.1 ± 0.9	2.9
3–4 years	5.5 ± 0.9	3.3
4–5 years	5.7 ± 0.9	3.5
5–6 years	6.0 ± 0.9	3.8
6–7 years	6.1 ± 0.9	3.9
7–8 years	6.2 ± 1.0	3.7
8–9 years	6.3 ± 1.0	3.8
9–10 years	6.3 ± 1.0	3.8
10–11 years	6.4 ± 1.1	3.7
Adult	13.3 ± 1.6	9.3

<sup>a</sup>Measured from the pubic ramus to the tip of the glans while traction is applied along the length of the phallus to the point of increased resistance.

SD, Standard deviation.

Data from Feldman KW, Smith DW. Fetal phallic growth and penile standards for newborn male infants. *J Pediatr*. 1975;86:395.

- (2) 46,XX karyotype: SRY+, classical (21-hydroxylase deficiency) or more rare forms of CAH
- (3) Other: Sex chromosome mosaicism (e.g., 46,XY/46,xx, 46,XY/45,XO)

### 3. Evaluation:

- a. Labs: Timing of collection is important.
  - (1) Initial testing (within first 24–48 hours of life): LH, FSH, testosterone, dihydrotestosterone (DHT, see [eTable 10.4](#)), anti-müllerian hormone (AMH) and expedited determination of sex chromosomes (ask that resulting lab rush results of sex chromosomes)
  - (2) After 36 hours of life: 17-hydroxyprogesterone
  - (3) Daily electrolytes until salt-wasting CAH is ruled out
  - (4) Further testing as needed to evaluate for more rare forms of CAH: DHEA, 17-hydroxypregnenolone, 11-deoxycortisol, cortisol, ACTH
- b. Imaging: Options include genitogram (contrast study of the urogenital sinus and internal duct structures) or voiding cystourethrogram (VCUG), pelvic and abdominal ultrasound, and pelvic magnetic resonance imaging (MRI) to evaluate internal anatomy.
- c. Care should be taken to avoid premature gender/sex designation, completion of birth certificate, and naming of infant.

## E. Cryptorchidism<sup>50</sup>

### 1. Epidemiology and clinical course:

- a. Can be present at birth (congenital) or after birth (acquired). Congenital rate is 1% to 4.6% of males born >2.5 kg.
- b. Increased risk with preterm birth or low birth weight.
- c. About  $\frac{1}{3}$  to  $\frac{1}{2}$  of cryptorchid testicles descend spontaneously, usually by age 3 months.
- d. Neoplasm more common in males with cryptorchidism and may occur in contralateral testis; early orchidopexy decreases risk of malignancy.
- e. Males with bilateral cryptorchidism have higher risk for reduced fertility.
- f. There is a higher risk of testicular torsion prior to repair.

### 2. Evaluation:

- a. Providers should palpate testes for quality and position in all males at each well child visit.
- b. Any phenotypic male newborn with bilateral, *nonpalpable* testes should undergo evaluation for CAH with karyotype and hormonal profile.
- c. In those without CAH, distinguish between cryptorchidism and anorchia (absent testes) with serum müllerian inhibiting substance and consider additional hormone testing (inhibin B, FSH, LH, and testosterone).

**eTABLE 10.4****DIHYDROTESTOSTERONE**

<b>Age</b>	<b>Males (ng/dL)</b>	<b>Females (ng/dL)</b>
Cord blood	<2–8	<2–5
1–6 months	12–85	<5
Prepubertal	<5	<5
Tanner stage II–III	3–33	5–19
Tanner stage IV–V	22–75	3–30

Data from Quest Diagnostics RIA (radioimmunoassay).

**eTABLE 10.5****ANDROSTENEDIONE, SERUM**

Age	Males (ng/dL)	Females (ng/dL)
Premature (31–35 weeks)	≤480	≤480
Full-term infants	≤290	≤290
1–12 months	6–78	6–78
1–4 years	5–51	5–51
5–9 years	6–115	6–115
10–13 years	12–221	12–221
14–17 years	22–225	22–225
Tanner stage II–III	17–82	43–180
Tanner stage IV–V	57–150	73–220
Adult male (18–30 years)	50–220	
Female follicular phase		35–250
Female luteal phase		30–235

Data from Quest Diagnostics LC/MS (liquid chromatography/tandem mass spectrometry) analysis.

3. **Treatment:** Observe for 6 months, at which time if testis remains undescended, referral to specialist recommended. Orchidopexy between 6 and 18 months of age recommended.

## VIII. NEONATAL HYPOGLYCEMIA EVALUATION<sup>51,52</sup>

### A. Definition

1. Serum glucose level insufficient to meet metabolic requirements. For practical purposes, value is defined as a point-of-care glucose (POCG) <45 to 50 mg/dL within first 48 hours of life and <70 mg/dL beyond this period.

**NOTE:** Bedside glucometer is a convenient tool to screen for hypoglycemia but can be inaccurate by 10 to 15 mg/dL when in the range of hypoglycemia. STAT plasma glucose must be sent to establish diagnosis of hypoglycemia.

### B. Treatment Goals

1. For neonates with suspected congenital hypoglycemia disorder and infants/children with confirmed hypoglycemia disorder, maintain plasma glucose >70 mg/dL.
2. For high-risk neonates without a suspected congenital hypoglycemia disorder, maintain plasma glucose >45 to 50 mg/dL for those <48 hours of age and >60 mg/dL for those aged >48 hours.

### C. Management

See [Chapter 18](#).

### D. Further Workup

1. If serum glucose is consistently <70 mg/dL after 48 hours of life, at the time of hypoglycemia (serum glucose <45 to 50 mg/dL via glucometer), obtain STAT serum glucose, insulin, growth hormone, cortisol, free fatty acids, and  $\beta$ -hydroxybutyrate.
2. Consider **glucagon stimulation test:** Administer glucagon and obtain serum glucose levels Q10 min  $\times$ 4. Repeat growth hormone and cortisol levels 30 minutes after documented hypoglycemia.

### E. Interpretation of Results

1. A rise in glucose  $\geq$ 30 mg/dL on glucagon stimulation test, along with elevated plasma insulin levels >2  $\mu$ U/mL (absence of detectable insulin does not rule out hyperinsulinism, as insulin may be present below the lower limit of detection of the assay), low serum levels of free fatty acids (<1.5 mmol/L) and  $\beta$ -hydroxybutyrate (<2 mmol/L), and a persistent glucose requirement >8 mg/kg/min suggests a diagnosis of hyperinsulinemia.
2. Hypoglycemia with midline defects and micropenis in a male suggest hypopituitarism, supported by low serum levels of growth hormone and cortisol at the time of hypoglycemia.

### F. Hyperinsulinemia

1. Hyperinsulinemia is the most common cause of neonatal hypoglycemia beyond the first 7 days of life and may be congenital or transient.

2. Congenital hyperinsulinism can be caused by dominant or recessive mutations in genes responsible for regulating insulin secretion from pancreatic  $\beta$  cells.
3. Transient hyperinsulinemia is commonly seen in infants of diabetic mothers and less commonly in the setting of perinatal asphyxia and intrauterine growth restriction.
4. Long-term management of persistent hyperinsulinism includes diazoxide, which inhibits pancreatic secretion of insulin by keeping  $\beta$ -cell ATP-sensitive potassium channels open; however, it has been rarely associated with pulmonary hypertension (black box warning<sup>53</sup>).

## IX. ADDITIONAL NORMAL VALUES

Normal values may differ among laboratories because of variation in technique and type of assay used.

See the following tables for normal values:

eTable 10.1, Catecholamines, urine

eTable 10.2, Catecholamines, plasma

eTable 10.3, Insulin-like growth factor–binding protein

eTable 10.4, DHT

eTable 10.5, Androstenedione, serum

## X. WEB RESOURCES

- **Children with Diabetes** (<https://www.childrenwithdiabetes.com>)
- **American Diabetes Association** (<https://www.diabetes.org>)
- **International Society for Pediatric and Adolescent Diabetes** (<https://www.ispad.org>)
- **Pediatric Endocrine Society** (<https://www.lwpes.org>)
- **The Endocrine Society** (<https://www.endocrine.org>)
- **American Thyroid Association** (<https://www.thyroid.org>)

## REFERENCES

A complete list of references can be found online.

## REFERENCES

1. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. *Diabetes Care*. 2022;44(suppl 1):S17–S38.
2. Mayer-Davis EJ, Kahkoska AR, Jefferies C, et al. ISPAD Clinical Practice Consensus Guidelines 2018: definition, epidemiology, and classification of diabetes in children and adolescents. *Pediatr Diabetes*. 2018;19(suppl 27):7–19.
3. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. *Diabetes Care*. 2009;32:1327–1334.
4. Hattersley AT, Greeley SAW, Polak M, et al. ISPAD clinical practice consensus guidelines 2018: the diagnosis and management of monogenic diabetes in children and adolescents. *Pediatr Diabetes*. 2018;19(suppl 27):47–63.
5. Steck AK, Winter WE. Review on monogenic diabetes. *Curr Opin Endocrinol Diabetes Obes*. 2011;18:252–258.
6. American Diabetes Association. Children and adolescents: standards of medical care in diabetes—2022. *Diabetes Care*. 2022;45(suppl 1):S208–S231.
7. Zeitler P, Arslanian S, Fu J, et al. ISPAD clinical practice consensus guidelines 2018: type 2 diabetes in youth. *Pediatr Diabetes*. 2018;19(suppl 27):28–46.
8. Copeland KC, Silverstein J, Moore KR, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. *Pediatrics*. 2013;131:364–382.
9. American Diabetes Association. Diabetes technology: standards of medical care in diabetes—2022. *Diabetes Care*. 2022;45(suppl 1):S97–S112.
10. American Diabetes Association. Retinopathy, neuropathy and foot care: standards of medical care in diabetes—2022. *Diabetes Care*. 2022;45(suppl 1):S185–S194.
11. Cooke DW, Plotnick L. Management of diabetic ketoacidosis in children and adolescents. *Pediatr Rev*. 2008;29:431–436.
12. Wolfsdorg JI, Glaser N, Agus M, et al. ISPAD clinical practice consensus guidelines 2018: diabetic ketoacidosis and hyperglycemic hyperosmolar state. *Pediatr Diabetes*. 2018;19(suppl 27):155–177.
13. Fisher DA. The thyroid. In: Rudolph CD, Rudolph AM, Lister GE, et al., eds. *Rudolph's Pediatrics*, McGraw-Hill; 2011.
14. Fisher DA. Thyroid function and dysfunction in premature infants. *Pediatr Endocrinol Rev*. 2007;4:317–328.
15. Büyükgebiz A. Newborn screening for congenital hypothyroidism. *J Pediatr Endocrinol Metab*. 2006;19:1291–1298.
16. Lem AJ, de Rijke YB, van Toor H, et al. Serum thyroid hormone levels in healthy children from birth to adulthood and in short children born small for gestational age. *J Clin Endocrinol Metab*. 2012;97:3170–3178.
17. Williams FL, Simpson J, Delahunty C, et al. Developmental trends in cord and postpartum serum thyroid hormones in preterm infants. *J Clin Endocrinol Metab*. 2004;89:5314–5320.
18. Reinehr T. Thyroid function in the nutritionally obese child and adolescent. *Curr Opin Pediatr*. 2011;23:415–420.
19. Kaluarachchi DC, Allen DB, Eickhoff JC, Dawe SJ, Baker MW. Thyroid-stimulating hormone reference ranges for preterm infants. *Pediatrics*. 2019;144(2):e20190290. <https://doi.org/10.1542/peds.2019-0290>. Epub 2019 Jul 16. PMID: 31311840
20. Screening for congenital hypothyroidism: US Preventative Services Task Force reaffirmation recommendation. *Ann Fam Med*. 2008;6:166.

21. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. *Thyroid*. 2016;26(10):1343–1421.
22. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab*. 2010;96:53–58.
23. Greer FR. Defining vitamin D deficiency in children: beyond 25-OH vitamin D serum concentrations. *Pediatrics*. 2009;124:1471–1473.
24. Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. *Pediatrics*. 2008;122:398–417.
25. Stewart PM. The adrenal cortex. In: Melmed S, Polonsky KS, Reed Larsen P, et al., eds. *Williams Textbook of Endocrinology*. Saunders; 2011.
26. American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics. Technical report: congenital adrenal hyperplasia. *Pediatrics*. 2000;106:1511–1518.
27. Autal Z, Zhou P. Congenital adrenal hyperplasia: diagnosis, evaluation, and management. *Pediatr Rev*. 2009;30:e49–e57.
28. Autal Z, Zhou P. Addison disease. *Pediatr Rev*. 2009;30:491–493.
29. Stratakis CA. Cushing syndrome in pediatrics. *Endocrinol Metab Clin North Am*. 2012;41:793–803.
30. Auron M, Nouhad R. Adrenal insufficiency. *Pediatr Rev*. 2015;36(3):92–103.
31. Klein J, Vugin P, Hyman S. Cushing syndrome. *Pediatr Rev*. 2014;35(9):405–407.
32. Edmonds S, Fein DM, Gurtman A. Pheochromocytoma. *Pediatr Rev*. 2011;32:308–310.
33. Lenders JW, Pacak K, Walther MM, et al. Biomedical diagnosis of pheochromocytoma: which test is best? *JAMA*. 2002;287:1427–1434.
34. Weise M, Merke DP, Pacak K, et al. Utility of plasma free metanephrines for detecting childhood pheochromocytoma. *J Clin Endocrinol Metab*. 2002;87:1955–1960.
35. Robinson AG, Verbalis JG. Posterior pituitary. In: Melmed S, Polonsky KS, Reed Larsen P, et al., eds. *Williams Textbook of Endocrinology*. Saunders; 2011.
36. Plotnick L, Miller R. Growth, growth hormone, and pituitary disorders. In: McMillan J, ed. *Oski's Pediatrics: Principles and Practice*. Lippincott Williams & Wilkins; 2006:2084–2092.
37. MacGillivray MH. The basics for the diagnosis and management of short stature: a pediatric endocrinologist's approach. *Pediatr Ann*. 2000;29:570–575.
38. Rose S, Cook D, et al. Growth hormone therapy guidelines: clinical and managed care perspectives. *Am J Pharm Benefits*. 2014;6(5):e134–e146.
39. Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. *Lancet*. 2007;370:685–697.
40. Styne DM. New aspects in the diagnosis and treatment of pubertal disorders. *Pediatr Clin North Am*. 1997;44:505–529.
41. Kaplowitz PB. Delayed puberty. *Pediatr Rev*. 2010;31:189–195.
42. Carel JC, Leger J. Clinical practice. Precocious puberty. *N Engl J Med*. 2008;358:2366–2377.
43. American Academy of Pediatrics. Committee on Genetics, Sections on Endocrinology and Urology. Evaluation of newborn with developmental anomalies of the external genitalia. *Pediatrics*. 2000;106:138–142.
44. Blondell R, Foster MB, Dave KC. Disorders of puberty. *Am Fam Physician*. 1999;60:209–218.

45. Master-Hunter T, Heiman DL. Amenorrhea: evaluation and treatment. *Am Fam Physician*. 2006;73:1374–1382.
46. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics*. 2009;123:e752–e762.
47. Klein DA, Emerick JE, Sylvester JE, Vogt KS. Disorders of puberty: an approach to diagnosis and management. *Am Fam Physician*. 2017;96(9):590–599.
48. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2013;98(12):4565–4592.
49. Mcann-Crosby B. Ambiguous genitalia: evaluation and management in the newborn. *NeoReviews*. 2017;17(3):e144–e153.
50. Kolon TF, Herndon CDA, Baker LA, et al. *Evaluation and Treatment of Cryptorchidism*. American Urological Association Guideline; 2014.
51. Fourtner SH, Stanley CA. Genetic and nongenetic forms of hyperinsulinism in neonates. *NeoReviews*. 2004;5(9):e370–e376.
52. Thompon-Branch A, Havranek T. Neonatal hypoglycemia. *Pediatr Rev*. 2017;38(4):147–157.
53. Timlin MR, Black AB, Delaney HM, et al. Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. *Pediatr Cardiol*. 2017;38(6):1247–1250.
54. Danne T, Phillip M, Buckingham BA, et al. ISPAD Clinical Practice Consensus Guidelines 2018: insulin treatment in children and adolescents with diabetes. *Pediatr Diabetes*. 2018;19(suppl 27):115–135.
55. Jonklass J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. *Thyroid*. 2014;24(12):1670–1751.
56. Leger J, Olivieri A, Donaldson M, et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. *J Clin Endocrinol Metab*. 2014;99(2):363–384.

# Chapter 11

## Fluids and Electrolytes

*Joniqua Ceasar, MD*

 See additional content online.

### I. INTRODUCTION

Intravenous fluids (IVFs) should be thought of as a medication by those who prescribe them. Since the late 1950s, IVF choice has been largely guided by Holliday and Segar's estimations of sodium requirements. Using the electrolyte composition of human milk, they calculated that the average child requires 3 mEq sodium (Na) and 2 mEq potassium (K) per 100 to 120 mL water (H<sub>2</sub>O).<sup>1</sup> According to their calculation, basic solute needs can be met by administering  $\frac{1}{4}$  normal saline (NS), a hypotonic fluid. While this estimation led to a long-standing tradition in pediatric maintenance IVF (MIVF) therapy, evidence published over the past few decades culminated in new American Academy of Pediatrics (AAP) guidelines recommending isotonic fluids as the maintenance fluid of choice for the majority of hospitalized children.<sup>2</sup>

### II. FLUID RESUSCITATION

#### A. Calculating Maintenance Fluid Volume

The Holliday-Segar method (Table 11.1 and Box 11.1) is the most widely used method to approximate maintenance fluid volume. This method estimates caloric expenditure in fixed-weight categories and assumes the average patient will require 100 mL of water for each 100 calories metabolized, with approximately 100 kcal burned per kg.<sup>1</sup> There is no evidence for a maximum rate, but experts recommend a maximum of 120 mL/hr in absence of any cardiac, hepatic, or renal pathology.<sup>3-4</sup> If concern exists, the maintenance fluid rate should be lowered to avoid volume overload.

**NOTE:** The Holliday-Segar method is not suitable for neonates <14 days old, because it generally overestimates fluid needs in neonates. (See Chapter 18 for neonatal fluid management.)

#### B. Calculating Fluid Loss

1. Total body water (TBW) is equal to 60% of a child's weight in kg (75% in infants).<sup>5</sup>

$$\text{EQUATION 11.1: } \text{TBW}^a = \text{weight (kg)} \times 0.6$$

<sup>a</sup>TBW uses preillness weight; 1 L water = 1 kg water

TABLE 11.1

## HOLLIDAY-SEGAR METHOD

Body Weight	Fluid Volume	
	mL/kg/day	mL/kg/hr
First 10 kg	100	≈ 4
Second 10 kg	50	≈ 2
Each additional kg	20	≈ 1

## BOX 11.1

## HOLLIDAY-SEGAR METHOD

Example: Determine the correct fluid rate for an 8-year-old child weighing 25 kg:

First 10 kg:	$4 \text{ mL/kg/hr} \times 10 \text{ kg} = 40 \text{ mL/hr}$	$100 \text{ mL/kg/day} \times 10 \text{ kg} = 1000 \text{ mL/day}$
Second 10 kg:	$2 \text{ mL/kg/hr} \times 10 \text{ kg} = 20 \text{ mL/hr}$	$50 \text{ mL/kg/day} \times 10 \text{ kg} = 500 \text{ mL/day}$
Each additional 1 kg:	$1 \text{ mL/kg/hr} \times 5 \text{ kg} = 5 \text{ mL/hr}$	$20 \text{ mL/kg/day} \times 5 \text{ kg} = 100 \text{ mL/day}$
	Answer: 65 mL/hr	Answer: 1600 mL/day

- In a euvolemic child, 60% of TBW resides in the intracellular compartment (where potassium [K] concentration is 140 mEq/L and sodium [Na] is negligible), and 40% of TBW is in the extracellular compartment (where Na concentration is ~140 mEq/L and K is negligible).<sup>6-8</sup>
- The most precise method of assessing fluid deficit uses weight loss:

**EQUATION 11.2:** Fluid deficit (L) = preillness weight (kg) – illness weight (kg)

- Clinical assessment: If weight loss is not known, clinical observation may be used to approximate the percentage of dehydration (Table 11.2).<sup>9,10</sup>

**EQUATION 11.3:** % Dehydration<sup>a</sup> =  $\frac{\text{fluid deficit}^b}{\text{preillness weight}} \times 100\%$

<sup>a</sup>1% dehydration = 10 mL/kg of fluid deficit;

<sup>b</sup>1 L of water = 1 kg of water

- In a healthy child, insensible fluid volume loss is approximated as  $\frac{1}{3}$  of the Holliday-Segar MIVF per day. **NOTE:** This calculation is based on fluid requirements of healthy children. Many hospitalized children have increased insensible losses (e.g., secondary to fever or

**TABLE 11.2**  
**CLINICAL OBSERVATIONS IN DEHYDRATION**

	Older Child		
	3% (30 mL/kg)	6% (60 mL/kg)	9% (90 mL/kg)
	Infant		
	5% (50 mL/kg)	10% (100 mL/kg)	15% (150 mL/kg)
Dehydration classification	Mild	Moderate	Severe
Mental status	Alert		Lethargic/obtunded
Fontanelle	Flat	Soft	Sunken
Eyes	Normal	Deep set	Sunken
Tears	Present	Reduced	None
Buccal mucosa/lips	Normal/dry	Dry	Parched/cracked
Pulse rate	Normal	Slightly increased	Increased
Skin (touch)	Normal	Dry	Clammy
Skin turgor	Normal	Decreased	Tenting
Capillary refill	Normal	≈ 3–5 seconds	>5 seconds
Pulse quality	Normal	Weak	Feeble/impalpable
Urine output	Normal/mild oliguria	Mild oliguria	Severe oliguria/anuria

Data from Kliegman R, Geme SJ, eds. *Nelson Textbook of Pediatrics*. 21st ed. Elsevier; 2020; McMillan JA, DeAngelis CD, Feigin RD, Jones MD. *Oski's Pediatrics: Principles and Practice*. 4th ed. Saunders; 2006.

increased respiratory rate) that must be factored into fluid determinations.

### C. Maintenance Fluid Choice in Hospitalized Children

Based on a growing body of evidence, the AAP recommends isotonic fluid as the most appropriate MIVF therapy for the vast majority of hospitalized children between the ages of 28 days and 18 years.<sup>2</sup> Neonates under 28 days of age should receive hypotonic fluids (e.g. D5 1/2 normal saline).<sup>11</sup>

1. See [Table 11.3](#) for isotonic fluid options.
2. Various disease states can lead to an increased secretion of antidiuretic hormone (ADH), which promotes the retention of free water, leading to hyponatremia.<sup>11,12</sup> See [Box 11.2](#) for examples.
3. Exceptions exist in certain patient populations, such as children with neurosurgical disorders, congenital or acquired cardiac disease, hepatic disease, cancer, acute kidney injury, chronic kidney disease, nephrotic syndrome, diabetes insipidus, and voluminous watery diarrhea or severe burns.<sup>2</sup>
4. See [Tables 11.3](#) and [11.4](#) for electrolyte composition of various parenteral and enteral fluid replacement options.
5. Unless hyperkalemia is present or the child is in renal failure, maintenance potassium requirements (20 mEq/L of fluid) should be given.<sup>14</sup> Do not add potassium (K<sup>+</sup>) to fluids until urine output has been established.<sup>15,16</sup>

TABLE 11.3

## COMPOSITION OF FREQUENTLY USED PARENTERAL REHYDRATION FLUIDS

	D% CHO (g/100 mL)	Protein <sup>a</sup> (g/100 mL)	Cal/L	Na <sup>2+</sup> (mEq/L)	K <sup>+</sup> (mEq/L)	Cl <sup>-</sup> (mEq/L)	HCO <sub>3</sub> <sup>-b</sup> (mEq/L)	Mg <sup>2+</sup>	Ca <sup>2+</sup> (mEq/L)	mOsm/L
<b>HYPOTONIC</b>										
D <sub>5</sub> W	5	—	170	—	—	—	—	—	—	252
D <sub>10</sub> W	10	—	340	—	—	—	—	—	—	505
D <sub>5</sub> 1/4 NS (0.225% NaCl)	5	—	170	38.5	—	38.5	—	—	—	329
1/2 NS (0.45% NaCl)	—	—	—	77	—	77	—	—	—	154
<b>ISOTONIC</b>										
Lactated Ringer's	0–10	—	0–340	130	4	109	28	—	3	273
Plasmalyte	—	—	—	140	5	98	27	3	—	294
Bicarbonated Ringer's	0–10	—	0–340	147	4	155.5	—	—	≈ 4	—
NS (0.9% NaCl)	—	—	—	154	—	154	—	—	—	308
<b>HYPERTONIC</b>										
2% NaCl	—	—	—	342	—	342	—	—	—	684
3% NaCl	—	—	—	513	—	513	—	—	—	1027
8.4% sodium bicarbonate (1 mEq/mL)	—	—	—	1000	—	—	1000	—	—	2000
<b>COLLOID</b>										
Albumin 25% (salt poor)	—	25	1000	100–160	—	<120	—	—	—	300
Intralipid <sup>c</sup>	2.25	—	1100	2.5	0.5	4.0	—	—	—	258–284

<sup>a</sup>Protein or amino acid equivalent.<sup>b</sup>Bicarbonate or equivalent (citrate, acetate, lactate).<sup>c</sup>Values are approximate; may vary from lot to lot. Also contains <1.2% egg phosphatides.CHO, Carbohydrate; HCO<sub>3</sub><sup>-</sup>, bicarbonate; NS, normal saline.

**BOX 11.2****CLINICAL SETTING OF INCREASED ADH RELEASE IN CHILDREN<sup>9,29</sup>**

<b>Hemodynamic Stimuli for ADH Release (Decreased Effective Volume)</b>	<b>Nonosmotic and Nonhemodynamic Stimuli for ADH Release</b>
Hypovolemia	CNS disturbances (infection, brain tumors, head injury, thrombosis)
Nephrosis	Pulmonary disease (pneumonia, asthma, bronchiolitis, PPV)
Cirrhosis	Cancer
Congestive heart failure	Medications/drugs (Ecstasy, AEDs, cytoxan, vincristine, opiates, TCAs, SSRIs)
Hypoaldosteronism	GI disturbances (nausea and emesis)
Hypotension	Pain or stress
Hypoalbuminemia	Postoperative state

*AEDs*, antiepileptic drugs; *CNS*, central nervous system; *PPV*, positive pressure ventilation; *SSRIs*, selective serotonin reuptake inhibitors; *TCAs*, tricyclic antidepressants.

**D. Volume Replacement Strategy<sup>9,15,16</sup>**

1. Volume resuscitation and deficit replacement should generally be completed over 24 hours.
2. See [Table 11.5](#) for a three-phase approach to fluid replacement.
3. Children with isonatremic hypovolemia can be repleted with isotonic fluid per AAP recommendations.<sup>2</sup> See [Box 11.3](#) for sample calculations in isonatremic hypovolemia.
4. If ongoing losses can be measured directly, they should be replaced 1:1 concurrently with maintenance fluid administration. If the losses cannot be measured, an estimate of 10 mL/kg body weight for each watery stool and 2 mL/kg body weight for each episode of emesis should be administered.<sup>5</sup> See [Table 11.6](#) for electrolyte composition of certain bodily fluids.
5. Oral intake is the preferred method for repletion and maintenance, if possible.

**III. FLUID REMOVAL****A. Diuretics**

1. Please see [Chapter 19](#) for commonly used diuretics.
2. Maintenance fluids and diuretics should not be administered concurrently except in the following clinical scenarios:
  - a. Needing to provide dextrose-containing fluids when there is also a concern for volume overload
  - b. Treatment for hypercalcemia or hyperkalemia

TABLE 11.4

## COMPOSITION OF ORAL REHYDRATION FLUIDS

	D% CHO (g/100 mL)	Na <sup>2+</sup> (mEq/L)	K <sup>+</sup> (mEq/L)	Cl <sup>-</sup> (mEq/L)	HCO <sub>3</sub> <sup>-a</sup> (mEq/L)	Ca <sup>2+</sup> (mEq/L)	mOsm/L
<b>ORAL FLUIDS</b>							
Pedialyte	2.5	45	20	35	30	—	250
WHO solution	2	90	20	80	30	—	311
Rehydralyte	2.5	75	20	65	30	—	305
<b>COMMONLY CONSUMED FLUIDS (NOT RECOMMENDED FOR ORAL REHYDRATION)<sup>b</sup></b>							
Apple juice	12	0.4	44	45	—	—	730
Coca-Cola	10.8	5.2	—	—	13.4	—	650
Gatorade	5.9	36	10	—	—	—	377
Ginger ale	9	3.5	0.1	—	3.6	—	565
Milk	4.9	22	36	28	30	—	260
Orange juice	10.4	0.2	49	—	50	—	654
Powerade	5.8	18	2.7	—	—	—	264

<sup>a</sup>Bicarbonate or equivalent (citrate, acetate, lactate).

<sup>b</sup>Electrolyte values are approximate. Data will vary by brand.

CHO, Carbohydrate; HCO<sub>3</sub><sup>-</sup>, bicarbonate; WHO, World Health Organization.

Data from McMillan JA, DeAngelis CD, Feigin RD, Jones MD. *Oski's Pediatrics: Principles and Practice*. 4th ed. Saunders; 2006., and USDA website <https://fdc.nal.usda.gov/index.html>.

**TABLE 11.5**  
**VOLUME REPLACEMENT STRATEGY**

Phase I	Phase II	Phase III
<b>Initial Stabilization</b>	<b>Deficit Repletion, Maintenance Volume, and Ongoing Losses</b>	<b>Recovery and Ongoing Losses</b>
Rapid fluid resuscitation with isotonic fluid <sup>a</sup> 20 mL/kg represents only a 2% volume replacement	Replace half of the remaining deficit over the first 8 hr (this includes any fluid given in the initial stabilization phase). Replace the second half of deficit over the following 16 hr, making sure to also include maintenance fluid volume during this time.	Continue maintenance fluid administration, taking ongoing losses into consideration.

<sup>a</sup>Should be used in patients in need of rapid volume expansion.

See [Box 11.3](#) for sample calculation.

**BOX 11.3****SAMPLE CALCULATIONS: ISONATREMIC DEHYDRATION**

Example: A 15-kg (pre-illness weight) child with 10% dehydration and normal serum sodium

Requirement	Formula	Sample Calculation
Maintenance fluid requirements	Holliday–Segar formula	$(100 \text{ mL/kg/day} \times 10 \text{ kg}) + (50 \text{ mL/kg/day} \times 5 \text{ kg}) = 1250 \text{ mL/24 hr} = 52 \text{ mL/hr}$
Fluid deficit	<a href="#">Eq. 11.2</a> or <a href="#">Eq. 11.3</a>	$10 \text{ mL/kg} \times 15 \text{ kg} \times 10\% = 1500 \text{ mL}$

**FLUID REPLACEMENT RATE OVER 24 HR**

$\frac{1}{2}$  fluid deficit replaced in first 8 hr  $750 \text{ mL/8 hr} = 94 \text{ mL/hr} + 52 \text{ mL/hr maintenance} = 146 \text{ mL/hr}$

$\frac{1}{2}$  fluid deficit replaced over 16 hr  $750 \text{ mL/16 hr} = 47 \text{ mL/hr} + 52 \text{ mL/hr maintenance} = 99 \text{ mL/hr}$

**NOTE:** If patient received an initial 20 mL/kg bolus (300 mL):  $1500 \text{ mL} - 300 \text{ mL} = 1200 \text{ mL}$

$\frac{1}{2}$  fluid deficit in first 8 hr:  $600 \text{ mL/8 hr} = 75 \text{ mL} + 52 \text{ mL/hr maintenance} = 127 \text{ mL/hr}$

$\frac{1}{2}$  fluid deficit over next 16 hr:  $600 \text{ mL/16 hr} = 38 \text{ mL/hr} + 52 \text{ mL/hr maintenance} = 90 \text{ mL/hr}$

- c. Treatment for tubular toxins (e.g., rhabdomyolysis or nephrotoxic chemotherapy administration) when there is also a concern for volume overload

**B. Indications for Acute Dialysis: Please refer to [Chapter 19, Section IX](#).**

**IV. ELECTROLYTE MANAGEMENT**

See [Chapter 28](#) for age-specific normal values of electrolytes.

TABLE 11.6

## ELECTROLYTE COMPOSITION OF VARIOUS FLUIDS

Source of Fluid	Na <sup>+</sup> (mEq/L)	K <sup>+</sup> (mEq/L)	Cl <sup>-</sup> (mEq/L)
Gastric	20–80	5–20	100–150
Pancreatic	120–140	5–15	90–120
Small bowel	100–140	5–15	90–130
Bile	120–140	5–15	80–120
Ileostomy	45–135	3–15	20–115
Diarrhea	10–90	10–80	10–110
Skin with burns <sup>a</sup>	140	5	110
Sweat			
Normal	10–30	3–10	10–35
Cystic fibrosis <sup>b</sup>	50–130	5–25	50–110

<sup>a</sup>3–5 g/dL of protein may be lost in fluid from burn wounds.

<sup>b</sup>Replacement fluid dependent on sodium content.

Modified from Kliegman RM, Stanton B, St. Gene J, et al. *Nelson Textbook of Pediatrics*. 19th ed. Saunders; 2011.

### A. Serum Osmolality and Tonicity<sup>2,9,17</sup>

1. Fluids can be expressed in terms of their tonicity and their osmolality.
2. Serum osmolality (normally maintained at 285 to 295 mOsm/kg) is a measure of both permeable and nonpermeable solutes and is calculated using the following equation:

$$\text{EQUATION 11.4: Osmolality} = 2 \text{ Na} + \frac{\text{glucose (mg/dL)}}{18} + \frac{\text{BUN (mg/dL)}}{2.8}$$

3. Osmolality is measured as osmoles per weight (kg) versus osmolarity, which is measured as osmoles per volume (L).
4. Tonicity is effective osmolality. It is the net force on water across a semipermeable membrane (e.g., the cell membrane) based on the osmotic pressures. It is relative and determined largely by sodium content. Substances that flow freely across membranes, such as urea, are ineffective osmoles and influence osmolality but not tonicity.

### B. Sodium

The equations within this section are **theoretical** and are not validated. They offer a starting point for calculation of electrolyte abnormalities, but clinical context is **ALWAYS** of the utmost importance and frequent monitoring is necessary. **Children with neurosurgical disorders, cardiac disease, hepatic disease, cancer, kidney disease, diabetes insipidus, and severe burns may require consultation with subspecialists before fluid choice and volume is administered.** When correcting dysnatremias, frequent lab monitoring (~2 to 4 hours) is indicated with adjustment of fluid type and rate as needed.

1. **Hyponatremia:** Excess Na loss (Na <135 mEq/L)
  - a. Clinical manifestations and differential diagnosis (Table 11.7)

TABLE 11.7

HYPONATREMIA<sup>7,14,9</sup>

## CLINICAL MANIFESTATIONS

Related to rate of change: Nausea, headache, muscle cramps, weakness, confusion, apnea, lethargy, seizure, coma, hypothermia, depressed DTRs

## ETIOLOGIES

## Hypovolemic

## Renal Losses

Salt-wasting nephropathy  
Diuretic use  
Juvenile nephronophthisis  
Hypoaldosteronism (CAH, pseudohypoaldosteronism, UTI/obstruction)  
Cerebral salt-wasting syndrome  
Postobstructive diuresis  
ATN (polyuric phase)

## Extrarenal Losses

GI losses  
Skin losses  
Third spacing  
Cystic fibrosis

## Euvolemic

SIADH (see Chapter 10)  
Excess salt-free infusions  
Desmopressin acetate  
Water intoxication  
Hypothyroidism  
Sepsis  
Primary polydipsia<sup>a</sup>  
Malnutrition<sup>a</sup>

## Hypervolemic

Nephrotic syndrome  
Hypoalbuminemia  
Heart failure  
Cirrhosis  
Renal failure  
Glucocorticoid deficiency

## LABORATORY DATA

↑ Urine Na (>20 mEq/L)	↓ Urine Na (<20 mEq/L)	↓ Urine volume	↓ Urine Na <sup>b</sup> (<20 mEq/L)
↑ Urine volume		↑ Specific gravity	
↓ Specific gravity	↓ Urine volume	↑ Urine osmolality (>100 mOsm/L)	↓ Urine volume
↓ Urine osmolality <sup>c</sup> (<100 mOsm/L)	↑ Specific gravity		
	↑ Urine osmolality (>100 mOsm/L)		

## MANAGEMENT

Replace losses (see hypovolemic hyponatremia)

Restrict fluids  
Address the underlying cause

<sup>a</sup>Urine osmolality is <100 mOsm/L.

<sup>b</sup>Urine Na may be appropriate for the level of Na intake in patients with SIADH and water intoxication.

<sup>c</sup>Minimum possible urine osmolality = 50 mOsm/kg.

ATN, Acute tubular necrosis; CAH, congenital adrenal hyperplasia; DTR, deep tendon reflex; GI, gastrointestinal; SIADH, syndrome of inappropriate antidiuretic hormone secretion; UTI, urinary tract infection.

b. Causes of pseudohyponatremia:

(1) Increased serum osmolality:

(a) Hyperglycemia: Na decreased 1.6 mEq/L for each 100 mg/dL rise in glucose. The fluid shifts that cause the hyponatremia will partially correct on their own as the hyperglycemia normalizes.

(2) Normal serum osmolality:

(a) Hyperlipidemia: Na artificially decreased by  $0.002 \times \text{lipid (mg/dL)}$

(b) Hyperproteinemia: Na artificially decreased by  $0.25 \times [\text{protein (g/dL)} - 8]$

## c. Management

- (1) The traditional equation used to calculate the excess sodium deficit in hyponatremia is:

**EQUATION 11.5<sup>3</sup>:**

$$\text{Na deficit (mEq)}^a = [\text{Desired Na (mEq/L)} - \text{Serum Na (mEq/L)}] \times \text{TBW (L)}$$

<sup>a</sup>This represents the *excess sodium deficit* in hyponatremic dehydration. It must be added to the daily sodium requirement for hospitalized patients of **~ 14 mEq/100 mL fluid given.**

- (2) Hyponatremia should be corrected **by no more than 10 to 12 mEq per 24 hr** to avoid rapid change of serum sodium, which can cause osmotic demyelination syndrome.<sup>8,16,18</sup>
- (3) Witnessed onset of hyponatremia over the course of hours does not pose as great of a risk and can be corrected in a similar amount of time to that in which it developed.<sup>9</sup>
- (4) If central nervous system (CNS) symptoms are present, hypertonic saline (HTS) should be administered over 3 to 4 hours to correct the hyponatremia by ~5 mEq/L.<sup>7,8,14</sup> Use Eq. 11.7 to determine rate of HTS.
- (5) To determine the sodium content of the fluid necessary for repletion:

**EQUATION 11.6:** Na content (mEq/L) =

$$\frac{\text{Na deficit} + (14 \text{ mEq}/100\text{mL} \times \text{maintenance fluid volume [mL]})}{\text{volume deficit}^a}$$

<sup>a</sup>Use daily maintenance volume requirements if euvolemic.

- (6) Once the fluid type is determined, the starting rate can be calculated using the following:

**EQUATION 11.7:**

$$\text{Fluid rate (mL/hour)} = \frac{\text{Na deficit (mEq)} \times 1000 \text{ mL}}{\text{infusate Na (mEq)} \times \text{hours IVF will run in a day}}$$

- (7) See [Boxes 11.4 and 11.5](#) for sample calculations in hyponatremic dehydration.

2. **Hypernatremia:** Excess free water loss (Na >145 mEq/L)

- a. Clinical manifestations and differential diagnosis ([Table 11.8](#))
- b. Management:

- (1) Hypernatremic hypovolemia occurs in scenarios in which free water is either unavailable/restricted or there is excessive loss of solute-free water (see [Table 11.8](#)).

**BOX 11.4****SAMPLE CALCULATIONS: HYPONATREMIC DEHYDRATION**

Example: A 15-kg (pre-illness weight) child with 10% dehydration and serum sodium 125 mEq/L without central nervous system symptoms

Requirement	Formula	Sample Calculation
Maintenance fluid requirements	Holliday-Segar formula	$(100 \text{ mL/kg/d} \times 10 \text{ kg}) + (50 \text{ mL/kg/d} \times 5 \text{ kg}) = 1250 \text{ mL/24 hr} = 52 \text{ mL/hr}$
Fluid deficit	Eq. 11.2 or Eq. 11.3	$10 \text{ mL/kg} \times 15 \text{ kg} \times 10\% = 1500 \text{ mL}$

**FLUID REPLACEMENT RATE OVER 24 HRS**

$1500 \text{ mL/24 hr} = 63 \text{ mL/hr} + 52 \text{ mL/hr maintenance} = 115 \text{ mL/hr}$

**CALCULATIONS FOR FLUID SELECTION**

Maintenance sodium requirements	3 mEq per 100 mL of maintenance fluid	$3 \text{ mEq} \times (1250 \text{ mL}/100 \text{ mL}) = 38 \text{ mEq Na}^+$
Isotonic sodium deficit	8–10 mEq Na <sup>+</sup> per each 100 mL of fluid deficit	$10 \text{ mEq} \times (1500 \text{ mL}/100 \text{ mL}) = 150 \text{ mEq Na}^+$
Sodium deficit	Eq. 11.5	$(135 \text{ mEq} - 125 \text{ mEq}) \times 9 = 90 \text{ mEq Na}^+$
Total sodium content	Eq. 11.6	$90 \text{ mEq} + (14 \text{ mEq}/100 \text{ mL} \times 1250 \text{ mL}) = 265 \text{ mEq}$
Sodium required per L	Divide total sodium by fluid deficit in L	$265 \text{ mEq}/1.5 \text{ L} = 177 \text{ mEq}$

**BOX 11.5****SAMPLE CALCULATIONS: SEVERE SYMPTOMATIC HYPONATREMIC DEHYDRATION****Initial Fluid Replacement for Neurologic Stabilization**

Example: A 15-kg (pre-illness weight) child with altered mental status and serum sodium 110 mEq/L

Fluid to be used: 3% hypertonic saline (HTS)

Requirement	Formula	Sample Calculation
Sodium deficit	Eq. 11.5	$5 \text{ mEq/L} \times 9 = 45 \text{ mEq Na}^+$
Rate of administration	Eq. 11.7	$[(45 \text{ mEq} \times 1000 \text{ mL}) / 513 \text{ mEq} \times 4 \text{ hr}] = 22 \text{ mL/hr of 3\% HTS}$

**TABLE 11.8****HYPERNATREMIA**<sup>7,6,9</sup>**CLINICAL MANIFESTATIONS**

With hypernatremic hypovolemia, there is better preservation of intravascular volume compared to hypovolemic hyponatremia. Lethargy, weakness, altered mental status, irritability, coma, and seizures. High-pitched cry, thrombosis, brain hemorrhage, muscle cramps, hyperpnea, and respiratory failure.

**ETIOLOGIES****Low Urine Osmolality****Elevated Urine Osmolality**<sup>a,b</sup>

	↓ Urine Na (<20 mEq/L)	↑ Urine Na (>20 mEq/L)
Diabetes insipidus (central and nephrogenic) (see Chapters 10 and 19)	GI losses Skin losses Respiratory	Exogenous Na <sup>+</sup> (meds, infant formula) Mineralocorticoid excess (e.g., hyperaldosteronism)
Postobstructive diuresis	Increased insensible losses	
CKD	Adipsia	
Diuretic use		
Polyuric phase of ATN		

**MANAGEMENT**

Timeline of onset can mirror timeline for correction.

<sup>a</sup>>1000 mOsm/kg in extrarenal water loss.

<sup>b</sup>This cause of hypernatremia is usually secondary to free water loss; therefore the fractional excretion of sodium may be decreased or normal.

ATN, Acute tubular necrosis; CKD, chronic kidney disease; GI, gastrointestinal; Na, sodium.

- (2) Hypernatremia is dangerous because of complications from potential treatment sequelae, the most serious of which is cerebral edema.<sup>6,9</sup>
- (3) Plan to correct the serum Na by no more than 10 mEq/24 hr and correct the free water deficit over 48 hours to minimize the risk of cerebral edema.<sup>6,12,13,19</sup>
- (4) As with hyponatremia, witnessed onset of hypernatremia over the course of hours can be corrected rapidly; this is because the brain has not had time to produce idiogenic osmoles to adapt to the change in osmolality.<sup>9,13</sup>
- (5) Expert opinion recommends starting with D5 1/2 NS.<sup>19</sup> However, the sodium and fluid needs can also be calculated.
- (6) The free water deficit is as follows:

**EQUATION 11.8**<sup>4,6</sup>:

$$\text{FWD (mL)} = \text{TBW (mL)} \times \left[ 1 - \frac{\text{Desired Na (mEq/L)}}{\text{Serum Na (mEq/L)}} \right]^a$$

<sup>a</sup>The difference in desired and serum Na should be no more than 10 mEq/L/day.

- (7) The FWD is used to calculate the solute fluid deficit (SFD) (i.e., the amount of fluid that contains electrolytes).

**EQUATION 11.9:**  $SFD = \text{Fluid deficit}^a - FWD$

<sup>a</sup>See [eq. 11.2](#) for fluid deficit calculations.

(8) Despite the hypernatremia, there is also a Na deficit that should be accounted for:

**EQUATION 11.10:**

$$\text{Na required (mEq)} = [\text{SFD (mL)} + \text{maintenance fluid volume (mL)}] \times \frac{14 \text{ mEq}}{100 \text{ mL}}$$

(9) The amount of sodium is then divided by the total fluid deficit in addition to the maintenance fluid volume. This will help approximate the fluid tonicity required.

**EQUATION 11.11:**

$$\text{Na content of fluid (mEq/L)} = \frac{\text{Na required (mEq)}}{\text{Fluid deficit (L)} + \text{maintenance fluid volume (L)}}$$

(10) See [Box 11.6](#) for sample calculations in hypernatremic dehydration.

### BOX 11.6

#### SAMPLE CALCULATIONS: HYPERNATREMIC DEHYDRATION

Example: A 15-kg (pre-illness weight) child with 10% dehydration and serum sodium 155 mEq/L

Requirement	Formula	Sample Calculation
Maintenance fluid requirements	Holliday-Segar formula	$(100 \text{ mL/kg/d} \times 10 \text{ kg}) + (50 \text{ mL/kg/d} \times 5 \text{ kg}) = 1250 \text{ mL/24 hr} = 52 \text{ mL/hr}$
Total fluid deficit	<a href="#">Eq. 11.2</a> or <a href="#">Eq. 11.3</a>	$10 \text{ mL/kg} \times 15 \text{ kg} \times 10\% = 1500 \text{ mL}$
<b>Fluid Replacement Rate Over 24 hrs</b>		
$1500 \text{ mL/24 hr} = 63 \text{ mL/hr} + 52 \text{ mL/hr maintenance} = 115 \text{ mL/hr}$		
<b>Calculations for Fluid Selection</b>		
Free water deficit	<a href="#">Eq. 11.8</a>	$9000 \text{ mL} \times [1 - (145 \text{ mEq/L} / 155 \text{ mEq/L})] = 585 \text{ mL} (\sim 600)$
Solute fluid deficit	<a href="#">Eq. 11.9</a>	$1500 \text{ mL} - 600 \text{ mL} = 900 \text{ mL}$
Total sodium required	<a href="#">Eq. 11.10</a>	$(900 \text{ mL} + 1250 \text{ mL}) \times 14 \text{ mEq} / 100 \text{ mL} = 300 \text{ mEq Na}^+$
Na content of fluid	<a href="#">Eq. 11.11</a>	$300 \text{ mEq} / (1.25 + 1.5 \text{ L}) = 110 \text{ mEq/L Na}$

(11) If the fluid necessary contains >154 mEq of Na, then the following equation can be used to make a 1L bag at the desired tonicity<sup>19</sup>:

**EQUATION 11.12:**

$$\text{mL of 3\% saline} = 1000 \text{ mL} \times \frac{\text{desired Na (mEq/L)} - 154 \text{ (mEq/L)}}{513 \text{ (mEq/L)} - \text{desired Na (mEq/L)}}$$

(12) This equation can also be used to calculate rate to run HTS with NS bolus in a severely hypernatremic child. See [Box 11.7](#).

3. Calculations pertaining to dysnatremias can be double-checked using the following equation:

**EQUATION 11.13<sup>4-6</sup>:**

$$\frac{\text{Change in Serum Na}}{1\text{L of parenteral fluid administration}} = \frac{(\text{Infusate Na} + \text{Infusate K}) - \text{Serum Na}}{\text{TBW} + 1}$$

**BOX 11.7**

**SAMPLE CALCULATIONS: SEVERE HYPERNATREMIC DEHYDRATION**

**Initial Fluid Resuscitation Strategy to Avoid Rapid Sodium Correction When Serum Na<sup>+</sup> >175 mEq/L<sup>16</sup>**

Example: A 3-kg (pre-illness weight) breastfed neonate appearing severely dehydrated with serum sodium 185 mEq/L and hemodynamic instability.

Resuscitation with normal saline (NS) may drop the serum Na<sup>+</sup> too quickly. Plan to simultaneously run NS and 3% hypertonic saline (HTS), given rapidly together (i.e., over 5 minutes), to effectively give resuscitation fluid with a concentration no more than 15 mEq/L below the child's serum Na<sup>+</sup>. Repeat the boluses as needed to achieve hemodynamic stability.

Requirement	Formula	Sample Calculation
Ideal bolus fluid concentration	Serum sodium (in mEq/L) – 15 mEq/L	185 mEq/L – 15 mEq/L = 170 mEq/L
mL of HTS required per L of NS	<a href="#">Eq. 11.12</a>	1000 mL × (170 mEq/L – 154 mEq/L) / (513 mEq/L – 170 mEq/L) = 47 mL
Bolus NS amount in mL	20 mL/kg × wt (in kg)	20 mL/kg × 3 kg = 60 mL
Bolus amount HTS in mL	mL HTS required per L of NS × NS bolus amount (in mL) / 1000 mL	47 mL × 60 mL / 1000 mL = 2.8 mL

**C. Potassium****1. Hypokalemia**

- a. Clinical manifestations and differential diagnosis ([Table 11.9](#))
- b. The transtubular potassium gradient (TTKG) can help differentiate between etiologies of hypokalemia, as noted in [Table 11.9](#):

**EQUATION 11.14<sup>9</sup>:**

$$\text{TTKG}^a = \frac{[\text{K}]_{\text{urine}}}{[\text{K}]_{\text{plasma}}} \times \left( \frac{\text{plasma osmolality}}{\text{urine osmolality}} \right)$$

<sup>a</sup>The urine osmolality must be greater than the serum osmolality for the calculation to be valid.

- c. Management: Potassium infusion rates generally should not exceed 1 mEq/kg/hr.<sup>3</sup>

**2. Hyperkalemia**

- a. Clinical manifestations and differential diagnosis ([Table 11.10](#))
- b. Management ([Fig. 11.1](#))

**D. Calcium****1. Hypocalcemia**

- a. Clinical manifestations and differential diagnosis ([Table 11.11](#))
- b. Special considerations:
  - (1) Albumin readily binds serum calcium. Correction for albumin:  $\Delta$  of 1 g/dL changes the total serum calcium in the same direction by 0.8 mg/dL.
  - (2) pH: Acidosis increases ionized calcium.
  - (3) Symptoms of hypocalcemia refractory to calcium supplementation may be caused by hypomagnesemia.
  - (4) Significant hyperphosphatemia should be corrected before the correction of hypocalcemia because renal calculi or soft-tissue calcification may occur if total  $[\text{Ca}^{2+}] \times [\text{PO}_4^{3-}] \geq 70$ .<sup>9</sup>

**2. Hypercalcemia:** [Table 11.11](#)**E. Magnesium**

1. Hypomagnesemia: [Table 11.12](#)
2. Hypermagnesemia: [Table 11.12](#)

**F. Phosphate**

1. Hypophosphatemia: [Table 11.13](#)
2. Hyperphosphatemia: [Table 11.13](#)

**V. ALGORITHM FOR EVALUATING ACID-BASE DISTURBANCES<sup>9,20,21</sup>****A. Determine the pH.**

The body does not fully compensate for primary acid-base disorders; therefore the primary disturbance will shift the pH away from 7.40. See [Chapter 28](#) for normal bicarbonate values by age.

TABLE 11.9

HYPOKALEMIA<sup>9,28</sup>

## CLINICAL MANIFESTATIONS

Manifest at levels <2.5 mEq/L. Skeletal muscle weakness or ascending paralysis, muscle cramps, ileus, urinary retention, and cardiac arrhythmias. Electrocardiogram (ECG) changes: delayed depolarization, flat T waves, depressed ST segment, and U waves.

## ETIOLOGIES

## Decreased Stores

## Metabolic Alkalosis

Hypertensive	Normotensive	Metabolic Acidosis	No Change in Serum pH	Extrarenal	Normal Stores <sup>a</sup>
Renovascular disease	Gitelman syndrome	RTA (type I and II)	Meds (amphotericin, cisplatin,	Skin losses	Acute metabolic alkalosis
Excess renin	Bartter syndrome	DKA	aminoglycosides, penicillin or penicillin	GI losses/laxative	Hyperinsulinemia
Cushing syndrome	Hypoparathyroidism	Ureterosigmoidostomy	derivatives, diuretics)	abuse/enema abuse	Leukocytosis (if sample sits at room
CAH	Cystic fibrosis	Fanconi syndrome	Interstitial nephritis	Clay ingestion	temperature)
Adrenal adenoma	EAST syndrome			Kayexalate	Meds (adrenergic agonists, theophylline,
Licorice ingestion	Loop and thiazide			Malnutrition/anorexia	toluene, cesium chloride,
Liddle syndrome	diuretics			nervosa	hydroxychloroquine, barium)
	Emesis				Familial hypokalemic periodic paralysis
<b>LABORATORY DATA</b>					
TTKG >4				TTKG ≤4	~Urine K <sup>+</sup>
<b>MANAGEMENT</b>					
Acute		Calculate deficit and replace with potassium acetate or potassium chloride. Enteral replacement is safer when feasible. Follow K <sup>+</sup> closely. IV replacement generally should not exceed 1 mEq/kg given over 1 hr.			
Chronic		Determine daily requirement and replace with potassium chloride or potassium gluconate.			

<sup>a</sup>Blood pressure may vary.

CAH, Congenital adrenal hyperplasia; DKA, diabetic ketoacidosis; GI, gastrointestinal; K<sup>+</sup>, potassium; RTA, renal tubular acidosis; EAST, epilepsy, ataxia, sensorineural hearing loss, and tubulopathy; TTKG, transtubular potassium gradient.

**TABLE 11.10**  
**HYPERKALEMIA<sup>9</sup>****CLINICAL MANIFESTATIONS**

Skeletal muscle weakness, fasciculations, paresthesias, and ascending paralysis. The typical ECG progression with increasing serum  $K^+$  values:

1. Peaked T waves
2. Prolonged PR and widening of QRS
3. Loss of P waves
4. ST segment depression with further widening of QRS
5. Bradycardia, atrioventricular (AV) block, ventricular arrhythmias, torsades de pointes, and cardiac arrest

**ETIOLOGIES**

Increased Total Body $K^+$		Intracellular Shifts (No Change in Total Body $K^+$ )
Increased Urine $K^+$	Decreased Urine $K^+$	
Transfusion with aged blood	Renal failure	Tumor lysis syndrome
Exogenous $K^+$	Hypoaldosteronism	Leukocytosis ( $>200 \times 10^3/\mu\text{L}$ )
Spitzer syndrome	Aldosterone insensitivity	Thrombocytosis ( $>750 \times 10^3/\mu\text{L}$ ) <sup>a</sup>
	↓ Insulin causing hyperglycemia and/or DKA	Metabolic acidosis <sup>b</sup>
	Congenital adrenal hyperplasia	Blood drawing (hemolyzed sample)
	Type IV RTA	Rhabdomyolysis/crush injury
	Meds: ACE inhibitors, angiotensin II blockers, $K^+$ -sparing diuretics, calcineurin inhibitors, NSAIDs, heparin, TMX, drospirenone	Malignant hyperthermia
		Theophylline intoxication

**MANAGEMENT**

See Fig. 11.1.

<sup>a</sup>For every platelet increase of 100,000/ $\mu\text{L}$ , there is a 0.15 mEq/L increase in serum  $K^+$ .

<sup>b</sup>For every 0.1-unit reduction in arterial pH, there is approximately a 0.2–0.4 mEq/L increase in plasma  $K^+$ .

ACE, Angiotensin-converting enzyme; DKA, diabetic ketoacidosis; ECG, electrocardiogram;  $K^+$ , potassium; NSAIDs, nonsteroidal antiinflammatory drugs; RTA, renal tubular acidosis; TMX, trimethoprim.


1. Acidemia (pH < 7.35):
  - a. Respiratory acidosis:  $\text{PCO}_2 > 45$  mmHg
  - b. Metabolic acidosis: Arterial  $\text{HCO}_3^- < 20$  mmol/L
2. Alkalemia (pH > 7.45):
  - a. Respiratory alkalosis:  $\text{PCO}_2 < 35$  mmHg
  - b. Metabolic alkalosis: Arterial  $\text{HCO}_3^- > 28$  mmol/L

**B. Calculate the anion gap (AG).**

1. **AG:** Represents anions other than bicarbonate and chloride required to balance the positive charge of Na. Normal: 12 mEq/L  $\pm$  2 mEq/L

$$\text{EQUATION 11.15: } \text{AG} = \text{Na}^+ - (\text{Cl}^- + \text{HCO}_3^-)$$

2. The majority of unmeasured anions contributing to the AG in normal individuals are albumin and phosphate. Correcting the AG for albumin concentration increases the utility of the traditional method.<sup>22</sup>

**FIGURE 11.1**

Algorithm for hyperkalemia. *CRM*, Cardiorespiratory monitor; *ECG*, electrocardiogram.

**EQUATION 11.16:** Corrected AG =

$$\text{Observed AG} + 2.5 \times (\text{Normal albumin} - \text{measured albumin})$$

AG > 15: Anion gap metabolic acidosis (AGMA)

AG < 12: Nonelevated anion gap metabolic acidosis (NAGAMA)

AG > 20 mEq/L: Primary AGMA regardless of the pH or serum  $\text{HCO}_3^-$  concentration

### C. Calculate the delta gap (DG).<sup>20</sup>

If there is an AGMA, calculating the DG will help to determine if there is another, concurrent metabolic abnormality:

TABLE 11.11

## HYPOCALCEMIA AND HYPERCALCEMIA

Hypocalcemia	Hypercalcemia
<b>CLINICAL MANIFESTATIONS</b>	
Signs and symptoms: Tetany, neuromuscular irritability with weakness, paresthesias, fatigue, cramping, altered mental status, seizures, laryngospasm, and cardiac arrhythmias	Signs and symptoms: Weakness, irritability, lethargy, seizures, coma, abdominal cramping, anorexia, nausea, vomiting, polyuria, polydipsia, renal calculi, and pancreatitis
Physical exam:	
<ul style="list-style-type: none"> <li>• Trousseau sign (carpopedal spasm after arterial occlusion of an extremity for 3 minutes)</li> <li>• Chvostek sign (muscle twitching on percussion of the facial nerve)</li> </ul>	
ECG changes: Prolonged QT interval	ECG changes: Shortened QT interval
<b>ETIOLOGIES</b>	
Hypoparathyroidism	Hyperparathyroidism
Vitamin D deficiency	Vitamin D intoxication
Hyperphosphatemia	Excessive exogenous calcium administration
Pancreatitis	Malignancy
Malabsorption (malnutrition)	Prolonged immobilization
Drugs (anticonvulsants, cimetidine, aminoglycosides, calcium channel blockers)	Thiazide diuretics
Hypomagnesemia/hypermagnesemia	Subcutaneous fat necrosis
Maternal hyperparathyroidism (in neonates)	Williams syndrome
Ethylene glycol ingestion	Granulomatous disease (e.g., sarcoidosis)
Calcitriol (activated vitamin D) insufficiency	Hyperthyroidism
Tumor lysis syndrome	Milk-alkali syndrome
<b>MANAGEMENT</b>	
Acute	Consider IV replacement (calcium gluconate or calcium chloride [central access preferred])
Chronic	Consider use of oral supplements of calcium carbonate, calcium gluconate, calcium glubionate, or calcium lactate
	Increase UOP and $\text{Ca}^{2+}$ excretion:
	1. If the glomerular filtration rate and blood pressure are stable, give NS with maintenance $\text{K}^+$ at 2–3 times the maintenance rate
	2. Diuresis with furosemide
	Consider hemodialysis for severe or refractory cases.
	Consider steroids in malignancy, granulomatous disease, and vitamin D toxicity to decrease vitamin D and $\text{Ca}^{2+}$ absorption
	Severe or persistently elevated $\text{Ca}^{2+}$ : Consider calcitonin or bisphosphonate

$\text{Ca}^{2+}$ , Calcium; ECG, electrocardiogram; UOP, urine output.

**EQUATION 11.17:**  $\text{DG} = (\text{AG} - 12) - (24 - \text{HCO}_3^-)$

DG > 6: combined AGMA and metabolic alkalosis

DG < -6: combined AGMA and NAGMA

**TABLE 11.12****HYPOMAGNESEMIA AND HYPERMAGNESEMIA<sup>9</sup>**

Hypomagnesemia	Hypermagnesemia
<b>CLINICAL MANIFESTATIONS</b>	
Prominent manifestations may be caused by concurrent hypocalcemia (see <a href="#">Table 11.11</a> ) Typically occur at levels <0.7 mg/dL: Anorexia, nausea, weakness, malaise, depression, nonspecific psychiatric symptoms, hyperreflexia, ECG changes: flattening of T wave and lengthening of ST segment	Typically occur at levels >4.5 mg/dL: Hypotonia, hyporeflexia, paralysis, lethargy, confusion, hypotension, and prolonged QT, QRS, and PR intervals. Respiratory failure and cardiac arrest at >15 mg/dL

**ETIOLOGIES**

GI Disorders	Genetic	Medications	Miscellaneous	Renal Failure and Excessive Administration
Diarrhea	Gitelman syndrome	Amphotericin	Decreased intake	Status asthmaticus
Malabsorption diseases	Bartter syndrome	Cisplatin	Hungry bone syndrome	eclampsia/preeclampsia, cathartics, enemas, phosphate binders, laxatives, lithium ingestions, milk-alkali syndrome
Short bowel	EAST syndrome	Cyclosporine	Exchange transfusion	
Malnutrition	AD hypoparathyroidism	Loop and thiazide diuretics	Diabetes mellitus	
Pancreatitis	Mitochondrial disorders	Mannitol	Steatorrhea	
	Miscellaneous disorders	Pentamidine	Hyperaldosteronism	

**MANAGEMENT**

Acute	IV magnesium sulfate	Stop supplemental Mg <sup>2+</sup>
Chronic	PO magnesium oxide or magnesium sulfate	Diuresis Ca <sup>2+</sup> supplements, such as calcium chloride (central access preferred) or calcium gluconate

AD, Autosomal dominant; Ca<sup>2+</sup>, calcium; EAST, epilepsy, ataxia, sensorineural hearing loss, and tubulopathy; ECG, electrocardiogram; GI, gastrointestinal; IV, intravenous; Mg<sup>2+</sup>, magnesium; PO, by mouth.

**D. Calculate the osmolal gap.**

**EQUATION 11.18:** Serum osmolal gap = calculated serum osmolality  
– laboratory measured osmolality

TABLE 11.13

HYPOPHOSPHATEMIA AND HYPERPHOSPHATEMIA<sup>9</sup>

Hypophosphatemia	Hyperphosphatemia
<b>CLINICAL MANIFESTATIONS</b>	
Symptomatic only at very low levels (<1 mg/dL)	Symptoms of resulting hypocalcemia and systemic calcification (i.e., deposition of phosphorus-calcium salts in tissues)
Acute: rhabdomyolysis, tremor, paresthesias, irritability, confusion, hemolysis, delirium, seizure, myocardial depression, and coma	
Chronic: Rickets, proximal muscle weakness	
<b>ETIOLOGIES</b>	
Refeeding syndrome	Tumor lysis syndrome
Insulin	Rhabdomyolysis
BMT	DKA/lactic acidosis
Hungry bone syndrome	Hemolysis
Decreased intake	Renal failure
Antacids	Hypoparathyroidism
Glucocorticoids	Hyperthyroidism
Rickets	Excessive intake (enemas/laxatives and cow's milk)
Hyperparathyroidism	Vitamin D intoxication
Increased renal losses (e.g., renal tubular defects, diuretic use)	Familial tumoral calcinosis
McCune-Albright syndrome	Acromegaly
Epidermal nevus syndrome	
Fanconi syndrome	
Metabolic acidosis/respiratory alkalosis	
Glycosuria	
Volume expansion	
Sepsis	
<b>MANAGEMENT</b>	
Acute	IV potassium phosphate or sodium phosphate
Chronic	PO potassium phosphate or sodium phosphate
	Restrict dietary phosphate. Phosphate binders (calcium carbonate, aluminum hydroxide)

BMT, Bone marrow transplant; DKA, diabetic ketoacidosis. IV, intravenous; PO, by mouth.

1. There is always a difference (<6) between calculated osmolality and measured osmolality.<sup>24</sup>
2. A markedly elevated osmolar gap (>10) in the setting of an AG acidosis is highly suggestive of acute methanol or ethylene glycol intoxication.<sup>25-27</sup>

### E. Calculate expected compensatory response (Table 11.14).

1. Pure **respiratory** acidosis (or alkalosis): 10 mmHg rise (fall) in PaCO<sub>2</sub> results in an average 0.08 fall (rise) in pH.
2. Pure **metabolic** acidosis (or alkalosis): 10 mEq/L fall (rise) in HCO<sub>3</sub><sup>-</sup> results in an average 0.15 fall (rise) in pH.

TABLE 11.14

CALCULATION OF EXPECTED COMPENSATORY RESPONSE<sup>20,9</sup>

Disturbance	Primary Change	Expected Compensatory Response
Acute respiratory acidosis	↑PaCO <sub>2</sub>	↑HCO <sub>3</sub> <sup>-</sup> by 1 mEq/L for each 10 mmHg rise in PaCO <sub>2</sub>
Acute respiratory alkalosis	↓PaCO <sub>2</sub>	↓HCO <sub>3</sub> <sup>-</sup> by 2 mEq/L for each 10 mmHg fall in PaCO <sub>2</sub>
Chronic respiratory acidosis	↑PaCO <sub>2</sub>	↑HCO <sub>3</sub> <sup>-</sup> by 4 mEq/L for each 10 mmHg rise in PaCO <sub>2</sub>
Chronic respiratory alkalosis	↓PaCO <sub>2</sub>	↓HCO <sub>3</sub> <sup>-</sup> by 4 mEq/L for each 10 mmHg fall in PaCO <sub>2</sub>
Metabolic acidosis	↓HCO <sub>3</sub> <sup>-</sup>	PaCO <sub>2</sub> = 1.5 × [HCO <sub>3</sub> <sup>-</sup> ] + 8 ± 2
Metabolic alkalosis	↑HCO <sub>3</sub> <sup>-</sup>	↑PaCO <sub>2</sub> by 7 mmHg for each 10 mEq/L rise in HCO <sub>3</sub> <sup>-</sup>

**F. Determine the likely etiology.**

Check for appropriate compensation. See [Box 11.8](#) for helpful mnemonics.


**G. If there is not appropriate compensation, consider an additional acid-base derangement (Fig. 11.2).****BOX 11.8****MNEMONICS FOR METABOLIC ACIDOSIS ETIOLOGIES****Anion Gap Metabolic Acidosis**

**M**ethanol  
**U**remia  
**D**iabetic ketoacidosis (or starvation ketosis)  
**P**araldehyde, propylene glycol  
**I**soniazid, iron, some IEMs  
**L**actic acidosis (D and L)  
**E**thanol, ethylene glycol  
**R**habdomyolysis  
**S**alicylates (aspirin)  
**G**lycols (ethylene and propylene)  
**O**xoproline  
**L**-lactate  
**D**-lactate  
**M**ethanol  
**A**spirin  
**R**enal failure  
**K**etoacidosis

**Non–Anion Gap Metabolic Acidosis**

**D**iarrhea  
**U**reteral diversion  
**R**enal tubular acidosis  
**H**yperalimentation  
**A**ddison's disease, **A**cetazolamide,  
**A**mmonium chloride  
**M**iscellaneous: amphotericin B,  
cholestyramine

*IEM*, Inborn error of metabolism.

**FIGURE 11.2**

(A and B) Etiology of acid-base disturbances. *BPD*, Bronchopulmonary dysplasia; *CAH*, congenital adrenal hyperplasia; *CNS*, central nervous system; *COPD*, chronic obstructive pulmonary disease; *EAST*, epilepsy, ataxia, sensorineural hearing loss, and tubulopathy; *NSAID*, nonsteroidal antiinflammatory drug.




FIGURE 11.2, cont'd

## REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Holliday MA, Segar WE. The maintenance need for water in parenteral fluid therapy. *Pediatrics*. 1957;19(5):823–832. <https://doi.org/10.1542/peds.102.2.399>
2. Feld LG, Neuspiel DR, Foster BA, et al. Maintenance. Clinical practice guideline: maintenance intravenous fluids in children. *Pediatrics*. 2018;142(6).
3. The Children's Hospital of Philadelphia. *Continuous IV fluid administration clinical pathway - inpatient*. 2014. Accessed December 16, 2021. <https://www.chop.edu/clinical-pathway/fluid-administration-continuous-iv-clinical-pathway>
4. Intravenous fluid therapy - childrenscolorado.org. (n.d.). Accessed December 16, 2021. <https://www.childrenscolorado.org/49e72a/globalassets/healthcare-professionals/clinical-pathways/intravenous-fluid-therapy.pdf>
5. Powers KS. Dehydration: isotremic, hyponatremic, and hypernatremic recognition and management. *Pediatr Rev*. 2015;36:274–285.
6. Adrogue H, Madias N. Hypernatremia. *N Engl J Med*. 2000;342(20):1493–1499.
7. Adrogue HJ. Aiding fluid prescription for the dysnatremias. *Intensive Care Med*. 1997;23:309–316.
8. Adrogue H, Madias N. Hyponatremia. *N Engl J Med*. 2000;342:1581–1589. <https://doi.org/10.1056/NEJM200005253422107>
9. Kliegman R, Geme SJ, eds. *Nelson Textbook of Pediatrics*. 21st ed. Elsevier; 2020.
10. McMillan JA, DeAngelis CD, Feigin RD, Jones MD. *Oski's Pediatrics: Principles and Practice*. 4th ed. Saunders; 2006.
11. Hall AM, Ayus JC, Moritz ML. How salty are your fluids? Pediatric maintenance IV fluid prescribing practices among hospitalists. *Front Pediatr*. 2020;7. <https://doi.org/10.3389/fped.2019.00549>
12. Moritz ML, Ayus JC. Prevention of hospital-acquired hyponatremia: a case for using isotonic saline. *Pediatrics*. 2003;111(2):227–230. <https://doi.org/10.1542/peds.111.2.227>
13. Jospe N, Forbes G. Back to basics: fluids and electrolytes—clinical aspects. *Pediatr Rev Acad Pediatr*. 1996;17(11):395–403. <https://doi.org/10.1542/pir.17-11-395>
14. Roberts KB. Fluid and electrolytes: parenteral fluid therapy. *Pediatr Rev*. 2001;22(11):380–387. <https://doi.org/10.1542/pir.22-11-380>
15. Finberg L. Dehydration in infancy and childhood. *Pediatr Rev*. 2002;23(8):277–282. <https://doi.org/10.1542/pir.23-8-277>
16. Foster BA, Tom D, Hill V. Hypotonic versus isotonic fluids in hospitalized children: a systematic review and meta-analysis. *J Pediatr*. 2014;165(1):163–169. <https://doi.org/10.1016/j.jpeds.2014.01.040>
17. Centor R. *The Hospitalist's Role in the Perioperative Management of Hyponatremia*. Society of hospitalist medicine learning portal. Published 2018. <https://www.shmlearningportal.org/content/perioperative-management-hyponatremia>
18. Ranger AM, Chaudhary N, Avery M, Fraser D. Central pontine and extrapontine myelinolysis in children: a review of 76 patients. *J Child Neurol*. 2012;27(8):1027–1037. <https://doi.org/10.1177/0883073812445908>
19. Moritz ML, Ayus JC. Intravenous fluid management for the acutely ill child. *Curr Opin Pediatr*. 2011;23(2):186–193. <https://doi.org/10.1097/MOP.0b013e3283440fd9>
20. Schwaderer AL, Schwartz GJ. Treating hypernatremic dehydration. *Pediatr Rev*. 2005;26(4):148–150. <https://doi.org/10.1542/pir.26-4-148>
21. Haber RJ. A practical approach to acid-base disorders. *Conf Rev*. 1991;155:146–151.

22. Carmody JB, Norwood VF. A clinical approach to paediatric acid-base disorders. *Postgrad Med J*. 2012;88(1037):143–151. <https://doi.org/10.1136/postgradmedj-2011-130191>
23. Fleisher G, Ludwig SHF. In: *Textbook of Pediatric Emergency Medicine*. 7th ed. Williams & Wilkins; 2016.
24. Figge J, Jabor A, Kazda AFA. Anion gap and hypoalbuminemia. *J Crit Care Med*. 1998;26(11):1807–1810.
25. Schrier RW, ed. *Renal and Electrolyte Disorders*. 8th ed. Wolters Kluwer; 2018.
26. Bhagat CI, Garcia-Webb P, Fletcher E, Beilby JP. Calculated vs measured plasma osmolalities revisited. *Clin Chem*. 1984;30(10):1703–1705.
27. Pursell RA, Pudek M, Brubacher J, Abu-Laban RB. Derivation and validation of a formula to calculate the contribution of ethanol to the osmolal gap. *Ann Emerg Med*. 2001;38(6):653–659. <https://doi.org/10.1067/mem.2001.119455>
28. Garrard A, Sollee DR, Butterfield RC, Johannsen L, Wood A, Bertholf RL. Validation of a pre-existing formula to calculate the contribution of ethanol to the osmolar gap. *Clin Toxicol*. 2012;50(7):562–566. <https://doi.org/10.3109/15563650.2012.704039>
29. Lynd LD, Richardson KJ, Pursell RA. An evaluation of the osmole gap as a screening test for toxic alcohol poisoning. *BMC Emerg Med*. 2008;8:1–10. <https://doi.org/10.1186/1471-227X-8-15>

# Chapter 12

## Gastroenterology

*Elshaddai Ephrem, MD*

 See additional content online.

 **Audio Case File 12.1** A framework for gastrointestinal bleeding by age

### I. GASTROINTESTINAL EMERGENCIES

#### A. Gastrointestinal Bleeding

1. **Presentation:** Blood loss from the gastrointestinal (GI) tract occurs in four ways: hematemesis, hematochezia, melena, and occult bleeding.
2. **Differential diagnosis of GI bleeding:** [Table 12.1](#)
3. **Diagnosis/management:**
  - a. Assess airway, breathing, circulation, and hemodynamic stability.
  - b. Perform full physical exam and verify bleeding with rectal examination and testing of stool or emesis for occult blood. Notable exam findings include abdominal tenderness, guarding, rebound, hepatosplenomegaly, perianal skin tags, or fissures.
  - c. Obtain baseline laboratory tests: Complete blood cell count (CBC), coagulation studies, type and screen, reticulocyte count, complete metabolic panel (CMP), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), and assess for disseminated intravascular coagulation (D dimer, fibrinogen).
  - d. If concerned for hemodynamic instability, begin initial fluid resuscitation. Consider transfusion if there is continued bleeding, symptomatic anemia, and/or a hematocrit level <21%. Initiate intravenous (IV) proton pump inhibitor (PPI).
  - e. Further evaluation and therapy based on the assessment and site of bleeding:
    - (1) Upper GI bleeding: Consider esophagogastroduodenoscopy (EGD) and testing for *Helicobacter pylori*.<sup>1</sup> Gastric lavage via nasogastric (NG) tube or administration of IV erythromycin may increase visibility and diagnostic yield.<sup>2-3</sup>
    - (2) Lower GI bleeding: Consider abdominal radiograph, upper GI study ( $\pm$  small bowel follow-through), air-contrast barium enema, colonoscopy, Meckel scan, tagged red cell scan, computed tomography (CT), and magnetic resonance enterography (MRE). Consider stool cultures, stool ova and parasites, *Clostridium difficile* toxin, and stool calprotectin.

TABLE 12.1

## DIFFERENTIAL DIAGNOSIS OF GASTROINTESTINAL BLEEDING

Age	Upper Gastrointestinal Tract	Lower Gastrointestinal Tract
Newborns (0–30 days)	Swallowed maternal blood Gastritis NGT placement trauma	Necrotizing enterocolitis Malrotation with midgut volvulus Anal fissure Hirschsprung disease Food protein–induced allergic proctocolitis (FPIAP)
Infant (30 days–1 year)	Gastritis Esophagitis Peptic ulcer disease Pyloric stenosis Varices	Anal fissure Allergic proctocolitis Intussusception Meckel diverticulum Lymphonodular hyperplasia Intestinal duplication Infectious colitis Hirschsprung disease FPIAP (milk allergy)
Preschool (1–5 years)	Gastritis Esophagitis Peptic ulcer disease Esophageal varices Epistaxis Mallory-Weiss tear Foreign body ingestion	Juvenile polyps Lymphonodular hyperplasia Meckel diverticulum Hemolytic-uremic syndrome Henoch-Schönlein purpura Infectious colitis Anal fissure
School age and adolescence	Esophageal varices Peptic ulcer disease Epistaxis Gastritis Mallory-Weiss tear Drugs (NSAIDs, corticosteroids, alcohol)	Inflammatory bowel disease Infectious colitis Juvenile polyps Anal fissure Hemorrhoids

Modified from Baker RD, Baker SS. *Pediatrics in Review*. October 2021;42(10):546–557. <https://doi.org/10.1542/pir.2020-000554>

## B. Acute Abdomen<sup>4</sup>

- Definition:** Severe abdominal pain that may require emergency surgical intervention
- Differential diagnosis:** Table 12.2
- Diagnosis:**
  - History:** Course and characterization of the pain, emesis, melena, hematochezia, diet, stool history, fever, travel history, menstrual history, vaginal/testicular symptoms, urinary symptoms, respiratory symptoms, and recent surgeries
  - Physical exam:** Rashes, arthritis, and jaundice. Abdominal tenderness on palpation, rebound/guarding, rigidity, masses, distention, or abnormal bowel sounds, rectal examination with stool hemoccult testing, pelvic examination (discharge, masses, adnexal/cervical motion tenderness), and genital examinations

TABLE 12.2

## ACUTE ABDOMINAL PAIN

Gastrointestinal source	Appendicitis, pancreatitis, intussusception, malrotation with volvulus, inflammatory bowel disease, gastritis, bowel obstruction, mesenteric lymphadenitis, irritable bowel syndrome, abscess, hepatitis, perforated ulcer, Meckel diverticulitis, cholecystitis, choledocholithiasis, constipation, gastroenteritis, abdominal trauma, mesenteric ischemia, and abdominal migraine
Renal source	Urinary tract infection, pyelonephritis, and nephrolithiasis
Genitourinary source	Ectopic pregnancy, ovarian cyst/torsion, pelvic inflammatory disease, and testicular torsion
Oncologic source	Wilms tumor, neuroblastoma, rhabdomyosarcoma, and lymphoma
Other sources	Henoch-Schönlein purpura, pneumonia, sickle cell anemia, diabetic ketoacidosis, cannabinoid hyperemesis syndrome, juvenile rheumatoid arthritis, and incarcerated hernia

- c. **Labs:** CBC, CMP, coagulation studies, lactate, type and screen, urinalysis, amylase, lipase, gonorrhea/chlamydia testing,  $\beta$ -human chorionic gonadotropin ( $\beta$ -hCG), ESR, and CRP
  - d. **Imaging:** Two-view abdominal radiographs to assess for obstruction, constipation, free air, gallstones, and kidney stones. Consider chest radiograph to evaluate for pneumonia, abdominal/pelvic ultrasonography, and abdominal CT with contrast or magnetic resonance imaging (MRI).
4. **Management:** Ensure patient is NPO and begin IV hydration. Consider nasogastric decompression, serial abdominal examinations, surgical/gynecologic/GI evaluation, pain control, and antibiotics as indicated.

## II. CONDITIONS OF THE GASTROINTESTINAL TRACT

## A. Vomiting

1. **Definition:** Forceful oral expulsion of gastric contents can be bilious or nonbilious.
2. **Differential diagnosis:** [Table 12.3](#)
3. **Diagnosis:**
  - a. **History:** Diet, medications, drugs, timing (acute vs. chronic), exposures, character (bilious, bloody, projectile) and associated symptoms. Pay special attention to vomiting **without** concomitant diarrhea.
  - b. **Physical exam:** HEENT and neurologic exam with specific attention to mucus membranes, skin and dentition, as well as a thorough abdominal exam
  - c. **Labs:** Although not always necessary, consider CMP, CBC, UA,  $\beta$ -hCG, and lipase. Urine drug screen if suspect drug abuse.
  - d. **Imaging:** Plain abdominal radiograph with upright view (to rule out obstruction or free air), abdominal ultrasound (US), upper GI series. Consider neurologic imaging if indicated.

TABLE 12.3

## DIFFERENTIAL DIAGNOSIS OF VOMITING

Age	Typically Nonbilious	Typically Bilious
Newborn and infant (0 days—1 year)	Overfeeding, physiologic reflux, milk protein sensitivity, pyloric stenosis, necrotizing enterocolitis, metabolic disorder, infection (GU, respiratory, GI), esophageal/intestinal atresia/stenosis, and Hirschsprung disease	Malrotation ± volvulus, intestinal atresia/stenosis, intussusception, pancreatitis
Preschool (1—5 years)	Cyclic vomiting, infectious (GI, GU), toxin ingestion, diabetic ketoacidosis (DKA), CNS mass effect, eosinophilic esophagitis, post-tussive, peptic disease, and appendicitis	Malrotation, intussusception, incarcerated hernia, pancreatitis, intestinal dysmotility
School age and adolescence	Eating disorders, pregnancy, CNS mass effect, eosinophilic esophagitis, DKA, peptic disease, cyclic vomiting, toxins/drugs of abuse, infectious (GU, GI), and appendicitis	Peritoneal adhesions, malrotation, incarcerated hernia, pancreatitis, and intestinal dysmotility

CNS, Central nervous system; DKA, diabetic ketoacidosis; GI, gastrointestinal; GU, genitourinary.

- Management:** Hydration. Gastric decompression if GI obstruction suspected. Antiemetic therapy can be used in the acute setting; avoid chronic use (see Chapter 22 for discussion of antiemetic therapy). Consider surgical consultation if the vomiting is bilious.

## B. Gastrointestinal Reflux Disease<sup>5</sup>

- Definition:** Gastroesophageal reflux (GER) is physiologic passage of gastric contents into the esophagus, and gastroesophageal reflux disease (GERD) is defined as troublesome symptoms or complications of GER.
- Differential diagnosis:** Dysmotility including achalasia, gastroparesis, ileus, and obstruction. Inflammatory conditions such as esophagitis, gastritis/dyspepsia, peptic ulcer disease. Anatomic abnormalities such as Zenker diverticulum, tracheoesophageal fistula, vascular ring, pyloric stenosis. Functional disorders including abdominal migraines and cyclical vomiting syndrome. Food allergies/intolerance in infants
- Diagnosis:**
  - History:** Recurrent regurgitation, choking, vomiting, heartburn, chest pain, dysphagia, stridor or wheezing, cough, recurrent aspiration pneumonia, dental erosions, and sleep disturbances. In infants, GERD may present as irritability, weight loss, feeding refusal, or Sandifer syndrome. History is typically sufficient for diagnosis and to initiate management.
  - Testing:** Esophageal pH monitoring and esophageal impedance monitoring if diagnosis unclear<sup>6</sup>

#### 4. Management:

- a. **Lifestyle:** A prone or left-sided sleeping position and elevation of head of bed may improve GER symptoms in older children, but current studies for infants have been inconclusive. Infants up to 12 months should continue to sleep supine—risk of sleep-related infant death far outweighs benefit of prone or lateral sleeping in GERD. After feeds, infants should be kept upright and a trial of smaller more frequent feeds may be beneficial. Avoidance of secondhand smoke exposure.
- b. **Diet:** Milk-thickening agents can be beneficial for symptom relief. If severe and unresponsive to conservative management, consider 2- to 4-week trial of extensively hydrolyzed protein formula in infants or elimination of cow's milk in maternal diet to eliminate milk protein sensitivity as a cause of unexplained vomiting.
- c. **Pharmacotherapy:** Medication is not recommended for “happy spitters” or infants with uncomplicated GER. Both PPIs and H<sub>2</sub> receptor antagonists (H<sub>2</sub>Ras) are effective in relieving symptoms and promoting mucosal healing.<sup>7</sup> There is insufficient evidence to support routine use of prokinetic therapies (metoclopramide and erythromycin).

### C. Eosinophilic Esophagitis<sup>8,9</sup> (EOE)

1. **Definition:** A chronic, immune/antigen-mediated disease characterized by symptoms of esophageal dysfunction with  $\geq 15$  eosinophils/high-power field (hpf) on esophageal biopsy
2. **Diagnosis:**
  - a. **History:** Dysphagia, food impaction, chest pain, food refusal or intolerance, GER symptoms, emesis, abdominal pain, and failure to thrive. Majority of patients with EoE have concurrent atopic disorder.
  - b. **Diagnosis:** EGD with esophageal biopsies demonstrating at least 15 eos/hpf on histology with chronic symptoms of esophageal dysfunction. Must evaluate for other causes or contributions to esophageal eosinophilia. Importantly histologic evidence without clinical correlation is not diagnostic. Per the AGREE conference, a PPI trial is no longer needed for diagnosis. Consider obtaining allergy testing (see [Chapter 15](#)).
3. **Management<sup>10</sup>:**
  - a. **Dietary therapy:** 6-food elimination diet (milk, wheat, eggs, soy, peanuts/tree nuts, seafood), elemental diet, or targeted elimination diet determined by allergy testing
  - b. **Pharmacotherapy:** Topical swallowed steroids delivered via inhaler or budesonide are preferred as first-line therapy to induce remission with limited side effects (6- to 8-week course of fluticasone). PPI therapy can also be trialed for initial treatment. Systemic steroids for short-term use (e.g., dysphagia leading to dehydration or weight loss). No current evidence to support routine use of biologics
  - c. **Complications:** Symptomatic strictures requiring esophageal dilation

## D. Celiac Disease<sup>11</sup>

1. **Definition:** An immune-mediated inflammatory enteropathy caused by sensitivity to dietary gluten and related proteins (wheat, barley, and rye) in genetically susceptible individuals
2. **Diagnosis:**
  - a. **History:** Presentation can be variable, and some patients are asymptomatic. Most common symptoms include diarrhea, vomiting, abdominal pain, constipation, distention, and failure to thrive. Non-GI symptoms include rash (dermatitis herpetiformis), osteoporosis, short stature, delayed puberty, and iron deficiency anemia that is resistant to oral iron. Increased occurrence in children with autoimmune disorders, Down syndrome, Turner syndrome, William syndrome, immunoglobulin A (IgA) deficiency, and in first-degree relatives of those with celiac disease
  - b. **Labs:** First-line screening is IgA antibody to human recombinant tissue transglutaminase (TTG) and serum IgA. If known selective IgA deficiency with symptoms suggestive of celiac disease, testing with TTG IgG is recommended after 3 years of age.<sup>12</sup> CBC, iron studies, hepatic function panel, thyroid tests, calcium, and vitamin D are recommended. Additional antibody testing may be necessary for inconclusive clinical scenarios.
  - c. **Procedures:** Biopsy is “gold standard” for diagnosis. Intestinal biopsies showing villous atrophy supports diagnosis. Results dependent on adequate consumption of gluten prior to testing; ensure 6 to 8 weeks of gluten ingestion prior to endoscopy.
3. **Management:** Lifetime gluten-free diet. Annual screening with TTG is recommended to monitor adherence to diet.
4. **Complications:** More often seen in adulthood but at risk for vitamin deficiencies and other autoimmune disorders. Higher risk of non-Hodgkin lymphoma, specifically enteropathy-associated T-cell lymphoma.

## E. Inflammatory Bowel Disease<sup>13,14</sup>

1. **Classification:**
  - a. **Crohn disease:** Transmural inflammatory process affecting any segment of the GI tract, most commonly terminal ileum. Commonly presents with abdominal pain, weight loss, diarrhea, and poor growth
  - b. **Ulcerative colitis (UC):** Chronic, relapsing, inflammatory disease of the colon and rectum. Commonly presents with rectal bleeding and diarrhea
2. **Diagnosis:**
  - a. **History:** Abdominal pain, weight loss, diarrhea, lethargy, nausea, vomiting, malnutrition, psychiatric symptoms, arthropathy, and rashes. Family history, exposure to infectious agents, or antibiotic treatment.
  - b. **Physical exam:** Stomatitis, perianal skin tags, fissures, and fistulas. Assessment of hydration and nutritional status. Fever, orthostasis,

tachycardia, abdominal tenderness, distention, or masses suggest moderate to severe disease and need for hospitalization.

- c. **Labs:** CBC, CMP, ESR, CRP. Fecal calprotectin has been shown to be elevated in inflammatory bowel disease (IBD) and may serve as a sensitive, noninvasive test.<sup>15</sup> IBD often associated with anemia, hypoalbuminemia, thrombocytosis, and elevated inflammatory markers. Stool studies to exclude infectious process are necessary.
  - d. **Imaging:** MRE is the preferred imaging modality for diagnosis of pediatric IBD due to high diagnostic accuracy and no radiation exposure. CT and fluoroscopy are other alternative strategies if MRE unavailable.
  - e. **Procedures:** Diagnostic endoscopy with biopsies used to confirm diagnosis
3. **Management**<sup>16-19</sup>:
- a. **Induction of remission:**
    - (1) Crohn: Exclusive enteral formula-based nutrition (80%–100% caloric need by liquid formula), 5-aminosalicylates, antitumor necrosis factor (TNF) agents, and, if indicated, antibiotics or surgery. Corticosteroids can be used if necessary. Novel dietary options such as Crohn disease exclusion diet, specific carbohydrate diet (SCD), or any other low complex SCDs may be possible therapeutic options.<sup>20,21</sup>
    - (2) UC: Corticosteroids, 5-aminosalicylates, TNF agents, and if indicated, antibiotics or surgery. Therapy guided by severity of illness
  - b. **Maintenance of remission:** Immunosuppression includes thiopurines, methotrexate, cyclosporine, tacrolimus, and anti-TNF monoclonal antibodies. Avoid prolonged steroid use.
  - c. **Other:** Surgical intervention indicated only after medical management has failed in both Crohn disease and UC. In Crohn disease, surgery is indicated for localized disease (strictures), abscess, or disease refractory to medical management.

## F. Constipation<sup>22,23</sup>

Normal stooling patterns by age: Infants 0 to 3 months, 2 to 3 bowel movements/day (breastfed infants may stool after every feed or go 5 to 7 days with no stool); 6 to 12 months, 1.8/day; 1 to 3 years, 1.4/day; >3 years, 1/day. If an exclusively breastfed <1 month old is not stooling regularly, it may be a sign of insufficient milk intake; monitor weight gain.

### 1. Definitions:

- a. **Constipation:** Delay or difficulty in defecation for 2 or more weeks. Functional causes of constipation are the most common. History and physical exam are often sufficient for diagnosis.
  - (1) Functional: Consider Rome IV Criteria (eTable 12.1).
  - (2) Nonfunctional: See Table 12.4 for differential diagnosis.

**eTABLE 12.1****ROME CRITERIA FOR FUNCTIONAL CONSTIPATION**

In the absence of organic pathology, must include two or more of the following occurring at least once per week for a minimum of 1 month with insufficient criteria for a diagnosis of irritable bowel syndrome:

1.  $\leq 2$  defecations in the toilet per week in child of developmental age of at least 4 years
2. At least 1 episode of fecal incontinence per week (after toilet training)
3. History of retentive posturing or excessive volitional stool retention
4. History of painful or hard bowel movements
5. Presence of a large fecal mass in the rectum
6. History of large-diameter stools that can obstruct the toilet

Modified from Constipation Guideline Committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Evaluation and treatment of constipation in infants and children: Evidence-Based Recommendations from ESPGHAN and NASPGHAN. *J Pediatr Gastroenterol Nutr.* 2014;58(2):261 and Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional disorders: children and adolescents. *Gastroenterology.* 2016;S0016-5085(16)00181-5.

TABLE 12.4

DIFFERENTIAL DIAGNOSIS OF CONSTIPATION<sup>a</sup>

Anatomic malformations	Anal stenosis, anterior displaced anus, imperforate anus, and pelvic mass (e.g., sacral teratoma)
Metabolic and gastrointestinal	Cystic fibrosis, diabetes mellitus, gluten enteropathy, hypercalcemia, hypokalemia, hypothyroidism, and multiple endocrine neoplasia type 2B
Neuropathic conditions	Neurofibromatosis, spinal cord abnormalities, spinal cord trauma, static encephalopathy, and tethered cord
Intestinal nerve or muscle disorders	Hirschsprung disease, intestinal neuronal dysplasia, visceral myopathies, and visceral neuropathies
Abnormal abdominal musculature	Down syndrome, gastroschisis, and prune belly
Connective tissue disorders	Ehlers-Danlos syndrome, scleroderma, and systemic lupus erythematosus
Drugs	Antacids, anticholinergics, antidepressants, antihypertensives, opiates, phenobarbital, sucralfate, and sympathomimetics
Other	Botulism, cow's milk protein intolerance, heavy metal ingestion (lead), and vitamin D intoxication

<sup>a</sup>Functional constipation remains the most common cause.

Constipation Guideline Committee of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Evaluation and treatment of constipation in infants and children: Evidence-Based Recommendations from ESPGHAN and NASPGHAN. *J Pediatr Gastroenterol Nutr.* 2014;58(2):258–274.

## 2. Diagnosis:

- a. **History:** Age of onset, toilet training experience, frequency/consistency/size of stools, pain or bleeding with defecation, presence of abdominal pain, soiling of underwear, stool-withholding behavior, change in appetite, abdominal distention, allergies, dietary history, medications, developmental history, psychosocial history. Refer to Bristol Stool Form Scale for classification of stool history (Fig. 12.1). Delayed meconium, poor weight gain or weight loss, anorexia, nausea, vomiting, and family history (e.g., thyroid disorders, cystic fibrosis) would warrant further evaluation for nonfunctional causes.
- b. **Physical exam:** External perineum, perianal examination. Fecal impaction may be palpated on abdominal or digital rectal examination. Plain abdominal single view radiography can be considered when physical examination is unreliable.

## 3. Management of functional constipation: Box 12.1 and eTable 12.2

- a. **Disimpaction:**
  - (1) Oral/nasogastric approach: Polyethylene glycol (PEG) solutions are effective for initial disimpaction. May also use other osmotic laxatives: magnesium citrate, lactulose
  - (2) Rectal approach: Saline or mineral oil enemas effective. Avoid enemas in infants; glycerin suppositories may be used in infants less than 1 year.
- b. **Maintenance therapy** (usually 3 to 12 months): Goal is to prevent recurrence.

**eTABLE 12.2****PHARMACOLOGIC MANAGEMENT OF CONSTIPATION****OSMOTIC LAXATIVE**

Polyethylene glycol (PEG)—oral	First-line for disimpaction and maintenance Mixed as 17 g/8 oz of water, juice, or other liquid	>3 years of age: 1–1.5 g/kg per day for 3 days, may be continued for up to a week. A large daily dose of up to 100 g/day for 1–2 days, lower doses for longer periods, up to 12 wk, have been used.
Lactulose—oral	If PEG not available, best and safest alternative (if >1 year of age)	1 mL/kg, twice a day, for up to 12 wk, then tapered over 4 wk
Magnesium citrate—oral		4 mL/kg per day—generally given on 2 consecutive evenings
Sodium phosphate—oral/enema	Risk of acute phosphate nephropathy Should not be used in children <2 years	>12 yr: 4.5 oz enema on 2–3 consecutive evenings 5–11 yr: 2.25 oz on 2–3 consecutive evenings 2–4 yr: 1 oz on 2–3 consecutive evenings
Glycerin—suppository/enema	Suppository may be used in infants <1 year old	

**STIMULANT LAXATIVES**

Bisacodyl—oral/enema/suppository		1–2 suppositories per day for 2–3 consecutive evenings, may be repeated in 1–2 wk
Senna—oral		

**STOOL SOFTENERS**

Mineral oil—oral/enema		>12 yr: 4.5 oz on 2–3 consecutive evenings 2–11 yr: 2.25 oz on 2–3 consecutive evenings
Sodium docusate—oral/enema		

Modified from Colombo JM, Wassom MC, Rosen JM. Constipation and encopresis in childhood. *Pediatr Rev.* 2015;36(9):392–401.

Type 1		Separate hard lumps, like nuts (hard to pass)
Type 2		Sausage-shaped but lumpy
Type 3		Like a sausage but with cracks on the surface
Type 4		Like a sausage or snake, smooth and soft
Type 5		Soft blobs with clear-cut edges
Type 6		Fluffy pieces with ragged edges, a mushy stool
Type 7		Watery, no solid pieces. Entirely liquid

**FIGURE 12.1**

Bristol Stool Form Scale. (From *Campbell-Walsh-Wein Urology*. 12th ed. Elsevier; 2020, Fig. 36.1.)

- (1) **Dietary changes:** Evidence supporting dietary intervention is weak; however, increased intake of fruits, vegetables, whole grains, and fluids other than milk is recommended.
  - (2) **Behavioral modifications:** Regular toilet habits with positive reinforcement. Referral to a mental health specialist for motivational or behavioral concerns if soiling an issue
  - (3) **Medications: Daily PEG.** Lactulose as second-line treatment. The use of stimulant laxatives and stool softeners may also be considered. Discontinue therapy gradually only after return of regular bowel movements with good evacuation. Evidence does not support use of probiotics.
- c. **Special considerations in infants aged <1 year:** 2 to 4 oz of 100% fruit juice (e.g., prune or pear) recommended in younger infants. Glycerin suppositories may be useful. While use is off label, PEG is routinely used in children <1 year of age. Avoid mineral oil, stimulant laxatives, and phosphate enemas.

**BOX 12.1****MANAGEMENT OF CONSTIPATION****HOME CLEANOUT INSTRUCTIONS**

Step 1: Take a stimulant laxative (bisacodyl, senna) with 8 oz of liquid, as per dosing instructions below.

Step 2: Drink polyethylene glycol (PEG). Mix with water or another clear non-carbonated liquid. Drink full amount in 2 hr. See below for dosing instructions.

Step 3: 1–2 hr after finishing PEG, should begin passing formed/thick brown stool. The stool should become thinner, and clearer stooling continues.

Step 4: If not stooling or passing very thick stools 4 hr after the PEG is finished, drink 1 capful of PEG in 8 oz of liquid every hour until stools are clear.

Step 5: Cleanout is finished when stool is mostly clear with very little sand-like material mixed in. Proceed to maintenance instructions below.

**DOSING INSTRUCTIONS**

<b>Weight</b>	<b>Polyethylene Glycol (PEG) Dose</b>	<b>Stimulant Laxative Recommendation</b>
8–10 kg	Mix 2.5 capfuls of PEG in 8 oz of clear drink	<2 years old: No stimulant laxative use
10.1–15 kg	Mix 3.5 capfuls of PEG in 16 oz of clear drink	2 years to <3 years old: Chewable senna (chocolate squares) <sup>a</sup>
15.1–20 kg	Mix 5 capfuls of PEG in 20 oz of clear drink	≥3 years old: Oral chewable senna (chocolate squares)
20.1–25 kg	Mix 6 capfuls of PEG in 24 oz of clear drink	until child can swallow pills, then oral bisacodyl laxative
25.1–30 kg	Mix 7 capfuls of PEG in 28 oz of clear drink	
30.1–40 kg	Mix 9.5 capfuls of PEG in 40 oz of clear drink	
40.1–50 kg	Mix 12 capfuls of PEG in 48 oz of clear drink	
50.1 kg or more	Mix 14 capfuls of PEG in 56 oz of clear drink	

**DAILY MAINTENANCE THERAPY**

The day after colon cleanse, the patient should begin taking maintenance daily PEG for continued management of constipation.

Advise patient/family to mix PEG in clear noncarbonated drink or water at least once daily. See formulary for dosing. Advise to drink the entire solution in 30 min or less for it to work well. It is best to give the PEG after school and before dinner. Do not give PEG right before bedtime.

The goal of daily maintenance PEG is for the child to have 1 or 2 soft and easily passable bowel movements every day.

Advise to have child to sit on the toilet after every meal or whenever they feel the need to stool.

<sup>a</sup> See Formulary for dosing recommendations.

Modified from handout given to patients who visit the Johns Hopkins Children's Center Pediatric Chronic Constipation Center, as an example of constipation management; variations are found at other institutions.

**G. Diarrhea<sup>24</sup>**

1. **Definition:** Acute diarrhea is more than three loose or watery stools per day. Chronic diarrhea is diarrhea lasting more than 2 to 4 weeks.
2. **Pathogenesis:** It can be infectious or malabsorptive with an osmotic or secretory mechanism.
  - a. **Osmotic diarrhea:** Water is drawn into intestinal lumen by maldigested osmotic compounds, as seen in celiac disease, pancreatic disease, or lactose intolerance. Stool volume depends on diet and decreases with fasting (stool osmolar gap  $\geq 100$  mOsm/kg).
  - b. **Secretory diarrhea:** Water accompanies secreted or unabsorbed electrolytes into the intestinal lumen (e.g., excessive secretion of chloride ions caused by cholera toxin). Stool volume is increased and does not vary with diet (stool osmolar gap  $< 50$  mOsm/kg).
  - c. Stool osmolar gap: The standard value is 290 mOsm/kg.<sup>25</sup>

Stool osmolar gap =

$$\text{Stool Osm} - \{2 \times [\text{stool (Na) mEq / L} + \text{stool (K) mEq / L}]\}$$

3. **Differential diagnosis:** [Table 12.5](#)
4. **Diagnosis:**
  - a. **History:** Acute vs. chronic, travel history, recent antibiotic use, and immune status
  - b. **Labs:** CMP, CBC, stool hemocult testing, stool culture, *C. difficile* toxin, ova and parasites, and viral antigens (see [Chapter 17](#) for common bacterial and viral pathogens)

**TABLE 12.5****DIFFERENTIAL DIAGNOSIS OF COMMON CAUSES OF DIARRHEA**

Diagnosis	Major Clinical Features
Infectious colitis (viral, bacterial, protozoal)	Blood or mucous in stool, possible exposure history (e.g., travel)
Lactose malabsorption	Bloating, flatulence, abdominal pain, and elevated breath hydrogen concentration postlactose ingestion
Small bowel bacterial overgrowth	Abdominal discomfort and increased risk if ileocecal valve removed
Irritable bowel syndrome	Constipation and/or diarrhea and absence of laboratory or imaging findings
Allergic enteropathy	Growth failure, hypoalbuminemia, anemia, and may have elevated serum IgE
Hirschsprung disease	Distended abdomen, abnormal barium enema, absent ganglion cells on rectal biopsy
Cystic fibrosis	Decreased fecal elastase, steatorrhea, and poor growth
IBD and celiac disease	See <a href="#">Sections III.D and III.E</a>
Other: Hyperthyroidism, UTI, and encopresis	Dependent on etiology

*IBD*, Inflammatory bowel disease; *IgE*, immunoglobulin E; *UTI*, urinary tract infection.

Modified from Zella GC, Israel EJ. Chronic diarrhea in children. *Pediatr Rev.* 2012;33(5):207–218.

### 5. Management:

- a. **Oral rehydration therapy (ORT)**<sup>26</sup>: Enteral hydration has proven superior in reducing the length of hospital stay and adverse events.<sup>21</sup> Parenteral hydration is indicated in severe dehydration, hemodynamic instability, or failure of ORT.
- b. **Diet**: Restart regular diet as soon as tolerated.
- c. **Pharmacotherapy**: No supporting evidence for use of nonspecific antidiarrheal agents, antimotility agents (e.g., loperamide), antisecretory drugs, and toxin binders (e.g., cholestyramine). Consider evidence-based antimicrobial therapy for infectious diarrhea (see Chapter 17). If malabsorptive (e.g., celiac disease or IBD), therapy should be tailored to disease process.
- d. **Probiotics**<sup>27-29</sup>: Evidence supporting use of probiotics is limited; however, their efficacy has been demonstrated in the following circumstances: antibiotic-associated diarrhea, *C. difficile* diarrhea (severe recurrent disease only), hepatic encephalopathy, the prevention of atopic dermatitis, and possibly preventing necrotizing enterocolitis in premature infants.

## III. CONDITIONS OF THE LIVER

### A. Liver Laboratory Studies: Table 12.6

1. **Synthetic/metabolic function**: Albumin, prealbumin, international normalized ratio (INR), activated partial thromboplastin time (aPTT), gamma-glutamyl transferase (GGT), cholesterol levels, bilirubin, and ammonia
2. **Liver cell injury**: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase
3. **Biliary system**: Bilirubin (total and direct), urobilinogen, GGT, and alkaline phosphatase

### B. Acute Liver Failure<sup>30,31</sup>

1. **Definition**: Laboratory evidence of liver injury with no known history of chronic liver disease, the presence of coagulopathy not corrected by vitamin K administration, and an INR >1.5 if patient has encephalopathy or >2.0 if patient does not have encephalopathy
2. **Differential diagnosis**: Table 12.7
3. **Diagnosis**:
  - a. **History**: Fatigue, nausea, vomiting, irritability, confusion, drowsiness, skin changes, medications, ingestion, illicit drug use, family history, developmental delay, transfusion history
  - b. **Physical exam**: Neurologic status, skin exam, hepatosplenomegaly, nutritional status, growth, bruising, petechiae. Slit lamp exam if concern for Wilson disease. Findings of chronic liver disease include clubbing, palmar erythema, cutaneous xanthoma, ascites, and prominent abdominal vessels.

**TABLE 12.6****LIVER LABORATORY TESTS**

Enzyme	Source	Increased	Decreased	Comments
AST/ALT	Liver, heart, skeletal muscle, pancreas, RBCs, and kidney	Hepatocellular injury, rhabdomyolysis, muscular dystrophy, hemolysis, and liver cancer	Vitamin B6 deficiency and uremia	ALT more specific than AST for liver, AST > ALT in hemolysis
Alkaline phosphatase	Osteoblasts, liver, small intestine, kidney, and placenta	Hepatocellular injury, bone growth, disease, trauma, pregnancy, and familial	Low phosphate, Wilson disease, zinc deficiency, hypothyroidism, and pernicious anemia	Highest in cholestatic conditions; must be differentiated from bone source
GGT	Renal tubules, bile ducts, pancreas, small intestine, and brain	Cholestasis, newborn period, and induced by drugs	Estrogen therapy, artificially low in hyperbilirubinemia	Not found in bone, increased in 90% of primary liver disease, specific for hepatobiliary disease in nonpregnant patient
Ammonia	Bowel flora and protein metabolism	Hepatic disease secondary to urea cycle dysfunction, hemodialysis, valproic acid therapy, urea cycle enzyme deficiency, organic acidemia, and carnitine deficiency		Converted to urea in liver

AST/ALT, Aspartate aminotransferase/alanine aminotransferase; GGT,  $\gamma$ -glutamyl transpeptidase; RBCs, red blood cells.

TABLE 12.7

## DIFFERENTIAL DIAGNOSIS OF ACUTE LIVER FAILURE

Infection	Herpes simplex virus, hepatitis A, hepatitis B, adenovirus, cytomegalovirus, Epstein-Barr virus, enterovirus, human herpes virus 6, parvovirus B19, and dengue fever
Vascular	Budd-Chiari syndrome, portal vein thrombosis, venoocclusive disease, and ischemic hepatitis
Inherited/metabolic	Wilson disease, mitochondrial, tyrosinemia, galactosemia, hemochromatosis, fatty acid oxidation defect, and iron storage disease
Immune dysregulation	Natural killer cell dysfunction (hemophagocytic lymphohistiocytosis), autoimmune, and macrophage activation syndrome
Drugs/toxins	Acetaminophen, anticonvulsants, antimicrobials, chemotherapy, aflatoxins, herbal and dietary supplements
Other	Idiopathic and cancer/leukemia

- c. **Labs:** Liver synthetic/metabolic function, liver cell injury, and biliary system tests (see earlier). BMP, magnesium, phosphorus, CBC with peripheral smear, reticulocyte count, ammonia, lipase. Factors V, VII (depleted first in ALF), VIII, and fibrinogen. A urine toxicology screen and a serum acetaminophen level should be obtained (see Chapter 3). Viral hepatitis studies, autoantibodies, and evaluation for metabolic syndromes must be considered.

**NOTE:** See Chapter 17 for interpretation of serologic markers of hepatitis B.

- d. **Imaging:** Abdominal US with Doppler flow. Consider head CT scan to exclude hemorrhage/edema and chest radiography.
- e. **Procedures:** Liver biopsy
- f. **Management:** Evaluate for underlying cause. Consider intensive care unit (ICU) level care with close monitoring of mental status, fluid balance, metabolic disturbances, hepatorenal syndrome, sepsis, and coagulopathies. Cerebral edema is life-threatening and may require intracranial pressure monitoring. Consider liver transplant when indicated.

### C. Nonalcoholic Fatty Liver Disease<sup>32</sup>

- Definition:** Chronic liver disease from excessive fat accumulation in the liver, often secondary to insulin resistance and obesity. Most common liver disease in children in the United States
- Diagnosis:** Screen between 9 and 11 years for obese children and overweight children with risk factors. ALT is the recommended test. If ALT persistently elevated >2 times upper limit of normal for >3 months, further evaluation is warranted. Must exclude alternative etiologies
- Management:** Extensive lifestyle modifications, well-balanced healthy diet. No medications have proven benefit. Bariatric surgery can be considered if severe comorbidities. Screen for diabetes and other comorbid conditions.

### D. Hyperbilirubinemia<sup>33-35</sup>

- Definition:** Bilirubin is the product of hemoglobin metabolism. There are two forms: direct (conjugated) and indirect (unconjugated). Hyperbilirubinemia is usually the result of increased hemoglobin load, reduced hepatic uptake, reduced hepatic conjugation, or decreased excretion. Direct hyperbilirubinemia is defined as a direct bilirubin >20% of the total bilirubin or a direct bilirubin of >2 mg/dL.
- Differential diagnosis:** [Table 12.8](#)
- Management:** Dependent upon etiology. Evaluation and diagnosis should be guided by history; however, liver laboratory studies (see earlier) and ultrasounds are warranted in many patients. Refer to [Chapter 18](#) for evaluation and treatment of neonatal hyperbilirubinemia.

**TABLE 12.8**
**DIFFERENTIAL DIAGNOSIS OF HYPERBILIRUBINEMIA**
**INDIRECT HYPERBILIRUBINEMIA**

Transient neonatal jaundice	Breast milk jaundice and physiologic jaundice Polycythemia and reabsorption of extravascular blood
Hemolytic disorders	Autoimmune disease, blood group incompatibility, hemoglobinopathies, microangiopathies, red cell enzyme deficiencies, and red cell membrane disorders
Enterohepatic recirculation	Cystic fibrosis, Hirschsprung disease, ileal atresia, and pyloric stenosis
Disorders of bilirubin metabolism	Acidosis, Crigler-Najjar syndrome, Gilbert syndrome, hypothyroidism, and hypoxia
Miscellaneous	Dehydration, drugs, hypoalbuminemia, sepsis, and panhypopituitarism

**DIRECT HYPERBILIRUBINEMIA**

Biliary obstruction	Biliary atresia, choledochal cyst, fibrosing pancreatitis, gallstones or biliary sludge, inspissated bile syndrome, neoplasm, and primary sclerosing cholangitis
Infection	Cholangitis, cytomegalovirus, adenovirus, enterovirus, Epstein-Barr virus, herpes simplex virus, histoplasmosis, human immunodeficiency virus, leptospirosis, liver abscess, sepsis, syphilis, rubella, toxocariasis, toxoplasmosis, tuberculosis, urinary tract infection, varicella-zoster virus, and viral hepatitis
Genetic/metabolic disorders	$\alpha$ 1-Antitrypsin deficiency, Alagille syndrome, Caroli disease, cystic fibrosis, Dubin-Johnson syndrome, galactokinase deficiency, galactosemia, glycogen storage disease, hereditary fructose intolerance, hypothyroidism, Niemann-Pick disease, progressive familial intrahepatic cholestasis (PFIC), Rotor syndrome, tyrosinemia, and Wilson disease
Chromosomal abnormalities	Trisomy 18, trisomy 21, and Turner syndrome
Drugs	Acetaminophen, aspirin, erythromycin, ethanol, iron, isoniazid, methotrexate, parenteral nutrition, oxacillin, rifampin, steroids, sulfonamides, tetracycline, and vitamin A
Miscellaneous	Neonatal hepatitis syndrome, parenteral alimentation, and Reye syndrome

## IV. PANCREATITIS<sup>36-38</sup>

**Definition:** Inflammatory disease of the pancreas

### A. Acute Pancreatitis<sup>39</sup>

#### 1. Diagnosis:

- a. **History:** Abdominal pain, irritability, epigastric tenderness, nausea and vomiting. Multiple etiologies (Table 12.9). Per INSPPIRE criteria, diagnosis of acute pancreatitis requires at least two of the following:
  - (1) Abdominal pain compatible with acute pancreatitis
  - (2) Serum amylase and/or lipase values >3 times upper limit of normal
  - (3) Imaging findings consistent with acute pancreatitis
- b. **Labs:** CMP, GGT, CBC, amylase, lipase, calcium, and triglycerides
- c. **Imaging:** Transabdominal US recommended. CT or MRI reserved for more complicated cases depending on etiology

**TABLE 12.9**

#### CONDITIONS ASSOCIATED WITH ACUTE PANCREATITIS

SYSTEMIC DISEASES	
Infections	Coxsackie, CMV, cryptosporidium, EBV, hepatitis, influenza A or B, leptospirosis, mycoplasma, mumps, rubella, typhoid fever, and varicella
Inflammatory and vasculitic disorders	Collagen vascular diseases, hemolytic uremic syndrome, Henoch-Schönlein purpura, IBD, and Kawasaki disease
Sepsis/peritonitis/shock	
IDIOPATHIC (UP TO 25% OF CASES)	
MECHANICAL/STRUCTURAL	
Trauma	Blunt trauma, child abuse, and ERCP
Anatomic anomalies	Annular pancreas, choledochal cyst, pancreatic divisum, stenosis, and other
Obstruction	Parasites, stones, and tumors
METABOLIC AND TOXIC FACTORS	
Drugs/toxins	Salicylates, cytotoxic drugs (l-asparaginase), corticosteroids, chlorothiazides, furosemide, oral contraceptives (estrogen), tetracyclines, sulfonamides, valproic acid, azathioprine, and 6-mercaptopurine
Cystic fibrosis	
Diabetes mellitus	
Hypercalcemia	
Hyperlipidemia	
Hypothermia	
Malnutrition	
Organic acidemia	
Renal disease	

CMV, Cytomegalovirus; EBV, Epstein-Barr virus; ERCP, endoscopic retrograde cholangiopancreatography; IBD, inflammatory bowel disease.

**TABLE 12.10****PROPOSED ETIOLOGIES OF CHRONIC PANCREATITIS IN CHILDHOOD**

Calcific	Cystic fibrosis, hereditary pancreatitis (e.g., PRSS1 and SPINK1 mutations), hypercalcemia, hyperlipidemia, idiopathic, and juvenile tropical pancreatitis
Obstructive (noncalcific)	Congenital anomalies, idiopathic fibrosing pancreatitis, renal disease, sclerosing cholangitis, sphincter of Oddi dysfunction, and trauma

Modified from Robertson MA. Pancreatitis. In: Walker WA et al, eds. *Pediatric Gastrointestinal Disease*. 3rd ed. BC Decker; 2000:1321–1344; Werlin SL. Pancreatitis. In: McMillan JA et al, eds. *Oski's Pediatrics*. Lippincott Williams & Wilkins; 2006:2010–2012.

**2. Management:**

- a. **Analgesia:** Acetaminophen or NSAIDs as first-line therapy; opiates for refractory pain
- b. **Nutrition:** Aggressive IV fluid hydration within initial 48 hours. Early enteral feeding recommended (within 72 hours of presentation and hemodynamically stable) and associated with shorter hospitalization and decreases comorbidity
- c. **Complications:** Multiorgan dysfunction, shock, pseudocysts, fluid collections, and necrosis. Antibiotics reserved for infected necrosis. Surgical consult as indicated

**B. Chronic Pancreatitis<sup>40,41</sup>****1. Diagnosis:**

- a. **History:** Abdominal pain consistent with pancreatic origin, pancreatic insufficiency; plus consistent imaging findings or biopsy with histopathologic features. Must be distinguished from acute recurrent pancreatitis (ARP), which is defined as at least two distinct episodes of pancreatitis with complete resolution of pain or normalization of laboratory levels
- b. **Labs:** Same as acute pancreatitis. Normal amylase/lipase does not exclude diagnosis of chronic pancreatitis or ARP. Fecal elastase to screen for exocrine function and fat-soluble vitamins assessment. Consider genetic testing.
- c. **Imaging:** Repeat imaging recommended with US and/or MRCP

**NOTE:** See [Table 12.10](#) for proposed etiologies of chronic pancreatitis in childhood.

2. **Management:** (For acute exacerbations) same as management of acute pancreatitis. Maintenance to focus on nonmedication strategies, adequate nutrition for growth, nonopioids, and planned opioids

**V. WEB RESOURCES**

- North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition: <https://www.naspgan.org>
- Children's Digestive Health Information for Kids and Parents: <https://www.gikids.org>

- Celiac Disease Foundation: <https://clinical.celiac.org>
- Rome Foundation for Diagnosis and Treatment of Functional Gastrointestinal Disorders: <https://www.theromefoundation.org>
- Crohn's & Colitis Foundation: <https://www.crohnscolitisfoundation.org>

## REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of helicobacter pylori in children and adolescents (update 2016). *J Pediatr Gastroenterol Nutr.* 2017;64(6):991–1003.
2. Romano C, Oliva S, Martellosi S, et al. Pediatric gastrointestinal bleeding: Perspectives from the Italian Society of pediatric Gastroenterology. *World J Gastroenterol.* 2017;23(8):1328–1337.
3. Osman D, Djibré M, Da Silva D, et al. Management by the intensivist of gastrointestinal bleeding in adults and children. *Ann Intensive Care.* 2012;2:46.
4. Reust CE, Williams A. Recurrent abdominal pain in children. *Am Fam Physician.* 2018;97(12):785–793.
5. Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastroenterol Nutr.* 2018;66(3):516–554.
6. Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. *Am J Gastroenterol.* 2007;102(3):668–685.
7. Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. *Dig Dis Sci.* 2008;53(2):385–393.
8. Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. *United European Gastroenterol J.* 2017;5(3):335–358.
9. Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE conference. *Gastroenterology.* 2018;155(4):1022–1033.
10. Papadopoulou A, Koletzko S, Heuschkel R, et al. Management guidelines of eosinophilic esophagitis in childhood. *J Pediatr Gastroenterol Nutr.* 2014;58(1):107–118.
11. Hill ID, Fasano A, Guandalini S, et al. NASPGHAN clinical report on the diagnosis and treatment of gluten-related disorders. *J Pediatr Gastroenterol Nutr.* 2016;63(1):156–165.
12. Hill ID, Dirks MH, Liptak GS, et al. North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr.* 2005;40(1):1–19.
13. Beattie RM, Croft NM, Fell JM, Afzal NA, Heuschkel RB. Inflammatory bowel disease. *Arch Dis Child.* 2006;91(5):426–432.
14. Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. *J Pediatr Gastroenterol Nutr.* 2007;44(5):653–674.
15. Joishy M, Davies I, Ahmed M, et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* 2009;48(1):48–54.
16. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. *J Pediatr Gastroenterol Nutr.* 2014;58(6):795–806.

17. Baldwin KR, Kaplan JL. Medical management of pediatric inflammatory bowel disease. *Semin Pediatr Surg.* 2017;26(6):360–366.
18. Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. *JAMA Pediatr.* 2015;169(11):1053–1060.
19. Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. *J Pediatr Gastroenterol Nutr.* 2012;55(3):340–361.
20. Scarallo L, Lionetti P. Dietary management in pediatric patients with Crohn's disease. *Nutrients.* 2021;13(5):1611. <https://doi.org/10.3390/nu13051611>
21. Suskind DL, Wahbeh G, Gregory N, Vendettuoli H, Christie D. Nutritional therapy in pediatric Crohn disease: the specific carbohydrate diet. *J Pediatr Gastroenterol Nutr.* 2014;58(1):87–91.
22. Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. *J Pediatr Gastroenterol Nutr.* 2014;58(2):258–274.
23. Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional disorders: children and adolescents. *Gastroenterology.* 2016;S0016–5085(16):00181–00185.
24. Zella GC, Israel EJ. Chronic diarrhea in children. *Pediatr Rev.* 2012;33(5):207–217.
25. Thomas PD, Forbes A, Green J, et al. Guidelines for the investigation of chronic diarrhoea, 2nd ed. *Gut.* 2003;52(suppl 5). v1–15.
26. King CK, Glass R, Bresee JS, Duggan C. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. *MMWR Recomm Rep (Morb Mortal Wkly Rep).* 2003;52(RR-16):1–16.
27. Preidis GA, Weizman AV, Kashyap PC, Morgan RL. AGA Technical review on the role of probiotics in the management of gastrointestinal disorders. *Gastroenterology.* 2020;159(2):708–738. e4. doi: 10.1053/j.gastro.2020.05.060. Epub 2020 Jun 9. PMID: 32531292; PMCID: PMC8018518.
28. Michail S, Sylvester F, Fuchs G, Issenman R. Clinical efficacy of probiotics: review of the evidence with focus on children. *J Pediatr Gastroenterol Nutr.* 2006;43(4):550–557.
29. Shane AL, Deshpande GC, Merenstein D. Improved neonatal outcomes with probiotics. *JAMA Pediatr.* 2013;167(10):885–886.
30. Bucuvalas J, Yazigi N, Squires Jr RH. Acute liver failure in children. *Clin Liver Dis.* 2006;10(1):149–168 (vii).
31. Devictor D, Tissieres P, Afanetti M, Debray D. Acute liver failure in children. *Clin Res Hepatol Gastroenterol.* 2011;35(6–7):430–437.
32. Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). *J Pediatr Gastroenterol Nutr.* 2017;64(2):319–334.
33. Brumbaugh D, Mack C. Conjugated hyperbilirubinemia in children. *Pediatr Rev.* 2012;33(7):291–302.
34. Fawaz R, Baumann U, Ekong U, Fischler B, Hadzic N, et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastroenterol Nutr.* 2017;64(1):154–168.

35. Pan DH, Rivas Y. Jaundice: newborn to age 2 months. *Pediatr Rev.* 2017;38(11):499–510.
36. Lowe ME. Pancreatitis in childhood. *Curr Gastroenterol Rep.* 2004;6(3):240–246.
37. Nydegger A, Couper RT, Oliver MR. Childhood pancreatitis. *J Gastroenterol Hepatol.* 2006;21(3):499–509.
38. Srinath AI, Lowe ME. Pediatric pancreatitis. *Pediatr Rev.* 2013;34(2):79–90.
39. Abu-El-Haija M, Kumar S, Quiros JA, Balakrishnan K, Barth B, et al. Management of acute pancreatitis in the pediatric population: a clinical report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition pancreas committee. *J Pediatr Gastroenterol Nutr.* 2018;66(1):159–176.
40. Gariépy CE, Heyman MB, Lowe ME, et al. Causal evaluation of acute recurrent and chronic pancreatitis in children: consensus from the INSPPIRE group. *J Pediatr Gastroenterol Nutr.* 2017;64(1):95–103.
41. Abu-El-Haija M, Uc A, Werlin SL, et al. Nutritional considerations in pediatric pancreatitis: a position paper from the NASPHAN pancreas committee and ESPHAN cystic fibrosis/pancreas working group. *J Pediatr Gastroenterol Nutr.* 2018;67(1):131–143.

# Chapter 13

## Genetics: Metabolism and Conditions With Distinctive Appearance

*Jacqueline Wood, MD, MA \**

 See additional content online.

 **Audio Case File 13.1** Newborn screening

### I. METABOLISM<sup>1-8</sup>

#### A. Clinical Presentation of Metabolic Disease (Box 13.1)


1. Metabolic disease can be conceptualized into broad categories ([Table 13.1](#)).
2. When a particular diagnosis is considered, a complete patient history, including details of conception, pregnancy, prenatal screening and diagnostic studies, delivery, postnatal growth, development, and a three-generation family history in the form of a pedigree ([eFig. 13.1](#)) should accompany a comprehensive physical examination. The family history may be remarkable for close relatives who died of similar presentations (may be mistaken for “sepsis” or “SIDS”).
3. A high index of suspicion is required, as routine investigations may be unrevealing. Be especially vigilant in a full-term baby presenting with “sepsis” who has no risk factors.

#### **BOX 13.1**

##### **WHEN TO SUSPECT METABOLIC DISEASE<sup>1-3</sup>**

Overwhelming illness in the neonatal period  
Vomiting  
Acute acidosis, anion gap  
Massive ketosis  
Hypoglycemia  
Coagulopathy  
Coma  
Seizures, especially myoclonic  
Hypotonia  
Unusual odor of urine  
Extensive dermatosis  
Neutropenia, thrombocytopenia, or pancytopenia  
Family history of siblings dying early

\*The author would like to give special thanks to Shira G. Ziegler, MD PhD.



	male		index case/proband		monozygotic twins
	female		multiple males n=1,2,...		dizygotic twins
	sex unknown		affected		obligate carrier
	deceased female		pregnancy		stillbirth
	a/presymptomatic		SB		spontaneous abortion (SAB)
	broken union		termination of pregnancy (TOP)		
	consanguinity				
	adopted				
	in				
	out				

- A&W = alive and well
- Generations designated by Roman numerals
- Conditions listed below symbols

**eFIGURE 13.1**  
Pedigree construction.


**TABLE 13.1****BROAD CLASSIFICATION OF METABOLIC DISEASE<sup>1-6</sup>**

<p><b>Intoxication Disorders</b> Toxic accumulation of small molecules upstream of a defective enzyme. Tend to present early in life with nonspecific symptoms that may include recurrent vomiting, irritability, lethargy progressing to coma, organ dysfunction. Symptoms may wax and wane with intercurrent illness.</p>	<p>See <a href="#">Table 13.2</a>. Acidosis algorithm (<a href="#">Fig. 13.1</a>) Hyperammonemia algorithm (<a href="#">Fig. 13.2</a>)</p>
<p><b>Disorders of Reduced Fasting Tolerance</b> Disorders in the body's ability to tolerate fasting, with early onset of hypoglycemia. Can present in infancy or later when trying to sleep through the night, including morning symptoms or seizures. Look for laboratory abnormalities and symptoms not usually found in typical fasting.</p>	<p>See <a href="#">Table 13.3</a>. Hypoglycemia algorithm (<a href="#">Fig. 13.3</a>)</p>
<p><b>Disorders of Complex Molecules</b> These disorders have a broad phenotypic spectrum and typical biochemical screening can be unrevealing. Features can be present at birth and/or slowly progressive affecting multiple organ systems. Often enzymatic and/or broad molecular genetic testing is needed.</p>	<p>See <a href="#">Table 13.4</a>.</p>
<p><b>Mitochondrial Disorders</b> Defect in energy production through the electron transport chain. There is a broad spectrum of clinical manifestations, often involving high-energy organs including brain, muscle, and/or heart.</p>	<p>See <a href="#">Table 13.5</a>.</p>
<p><b>Neurotransmitter Disorders</b> Defect in neurotransmission which can present around birth with severe infantile epileptic encephalopathy, or later with parkinsonism-dystonia or, neurodevelopmental or psychiatric disorders.</p>	<p>See <a href="#">Table 13.6</a>.</p>

4. Routine newborn screening (see [Section II](#)) is meant to detect many metabolic disorders before onset of clinical symptoms, but the conditions screened vary by state and not all countries screen, so clinical suspicion should remain high if clinical picture is concerning.

## B. Evaluation


1. **Initial laboratory tests:** Comprehensive metabolic panel, blood glucose, venous blood gas (VBG), ammonia (beware false-positives from prolonged tourniquet time, struggling children, lack of ice, or sample delay), complete blood cell count with differential, urinalysis
2. **Subsequent evaluation for metabolic disease:**
  - a. Consult a geneticist.
  - b. A basic metabolic workup includes plasma amino acids (PAA), urine organic acids (UOA), acylcarnitine profile, quantitative (free and total) plasma carnitine, lactate/pyruvate ratio. Further specialized biochemical testing is available.
3. **Additional labs given specific circumstances:**
  - a. **Metabolic acidosis:** Ammonia, lactate,  $\beta$ -hydroxybutyrate, acetoacetate, UOA, urinalysis with urine pH, acylcarnitine profile, quantitative (free and total) plasma carnitine ([Fig. 13.1](#))



**FIGURE 13.1**

Evaluation of metabolic acidosis with increased anion gap. (From Burton B. Inborn errors of metabolism in infancy: a guide to diagnosis. *Pediatrics*. 1998;102:E69.)

- b. **Hyperammonemia:** VBG, UOA, PAA, acylcarnitine profile, urine orotic acid (Fig. 13.2)
- c. **Hypoglycemia:** Samples at time of hypoglycemia—glucose, insulin, growth hormone, cortisol, free fatty acids,  $\beta$ -hydroxybutyrate (see Chapter 10). Cortisol, fasting and postprandial lactate, urine ketones, creatine kinase, acylcarnitine profile, PAA, UOA (Fig. 13.3)
- d. **Neonatal seizures:** Cerebrospinal fluid (CSF) amino acids and PAA, CSF/serum glucose ratio, serum and CSF neurotransmitters, CSF and plasma lactate, plasma very-long-chain fatty acids, UOA, serum uric acid, urine sulfites. Consider trial of pyridoxine.

**FIGURE 13.2**


Evaluation of hyperammonemia. Indicates inappropriately low urinary ketones in the setting of symptomatic hypoglycemia. *HMG-CoA*, Hydroxymethylglutaryl-CoA; *MCAD*, medium-chain acyl-CoA dehydrogenase; *VLCAD*, very-long-chain acyl-CoA dehydrogenase. Whole exome sequencing can detect only single gene defects.

### C. Categories of Metabolic Disorders

1. **Intoxication disorders** (Table 13.2)
2. **Disorders of reduced fasting tolerance** (Table 13.3)
3. **Disorders of complex molecules** (Table 13.4)
4. **Mitochondrial disorders** (Table 13.5)
5. **Neurotransmitter disorders** (Table 13.6)

### D. Management of Metabolic Crisis

1. Specific acute management available in Tables 13.2–13.6

**FIGURE 13.3**

Evaluation of hypoglycemia. (Modified from Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. *Pediatrics*. 1998;102:E69; Cox GF. Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy. *Prog Pediatr Cardiol*. 2007;24:15–25.)

2. A general guiding principle is to provide hydration and enough glucose to meet the patient's caloric needs to stop catabolism.
  - a. Use D10% + electrolytes for age at 1.5 to 2 times maintenance rate.
  - b. Use caution in mitochondrial disorders (and do not use D10 in pyruvate dehydrogenase deficiency), because this may enhance lactic acidosis. If uncertain, measure lactate and acid-base status regularly.
3. For unknown/suspected metabolic disease, treatment should *not* be delayed during workup.

TABLE 13.2

INTOXICATION DISORDERS<sup>1-6</sup>

Disorders With Selected Examples	Etiology, Clinical Presentation	Acute Management <sup>a</sup>	Chronic Management <sup>a</sup>	Diagnostic Testing <sup>a</sup>
<b>Urea Cycle Disorders</b> OTC Deficiency CPS I Deficiency Citrullinemia	Unable to metabolize proteins to energy Acute intoxication episodes of hyperammonemia, ± respiratory alkalosis	<b>Reversal of Catabolism</b> Bolus if dehydration D10 + ¼ NS to NS at 1.5–2× maintenance <b>Stop Intake of Offending Agents</b> Stop protein intake (NPO). Resume within 24–48 hr to prevent deficiencies of essential nutrients <b>Toxin Removal</b> Removal of ammonia via sodium benzoate + sodium phenylacetate (Ammonul) with arginine IV or dialysis as indicated for ammonia >250 µmol/L	Protein-restricted diet Ammonia scavengers (e.g., sodium phenylbutyrate) Arginine supplementation (dependent on defect)	PAA Urine orotic acid Molecular testing OTC deficiency (most common, X-linked) and CPS I deficiency are not picked up on newborn screening
<b>Organic Acidemias</b> Propionic acidemia Methylmalonic acidemia Isovaleric acidemia	Unable to metabolize certain amino acids and fats Acute intoxication episodes of hyperammonemia with metabolic acidosis Bone marrow suppression, cardiomyopathy	<b>Reversal of Catabolism</b> , as above <b>Stop Intake of Offending Agents</b> , as above <b>Toxin Removal</b> Carnitine in propionic, methylmalonic, and isovaleric acidemia Glycine in isovaleric acidemia Bicarbonate if pH <7.1	Formula that restricts certain amino acids Carnitine	Acylcarnitine profile Quantitative (free and total) carnitine PAA UOA Molecular testing
Maple syrup urine disease	Unable to metabolize branched-chain amino acids (BCAAs) Acute intoxication with high leucine leads to intracranial edema and coma Inappropriate urinary ketones	<b>Reversal of Catabolism</b> , as above <b>Stop Intake of Offending Agents</b> Stop protein from food and continue BCAA-free formula, valine, and isoleucine <b>Toxin Removal</b> Dialysis in extreme situations	Diet and formula that restricts BCAAs Supplementation with isoleucine and valine	PAA UOA Molecular testing

<b>Aminoacidopathies</b> Phenylketonuria (PKU) Tyrosinemia (HT)	Unable to metabolize phenylalanine (PKU) or phenylalanine and tyrosine (HT) PKU: intellectual disability if untreated HT: liver failure, vomiting, pain crisis, hyponatremia, Fanconi syndrome	<b>Supportive.</b> Dextrose-based fluids are safe for use <b>HT:</b> Pain control and hydration during pain crisis	PKU: Phenylalanine-restricted diet; sapropterin effective in some HT: Tyrosine- and phenylalanine-restricted diet; Nitisinone	PAA HT: UOA for succinylacetone Molecular testing
<b>Carbohydrate Disorders</b> Galactosemia Hereditary fructose intolerance (HFI)	Unable to metabolize galactose (galactosemia) or fructose (HFI) Vomiting, diarrhea, liver failure, renal failure Galactosemia: risk of <i>Escherichia coli</i> sepsis	<b>Supportive.</b> Dextrose-based fluids are safe for use	Galactosemia: Avoidance of galactose (and lactose); soy-based formulas HFI: Avoidance of fructose (and sucrose)	Urine reducing substances Galactosemia: erythrocyte gal-1-phosphate, galactose-1-phosphate uridylyltransferase activity Molecular testing
<b>Metal Disorders</b> Menkes Wilson disease hemochromatosis	Defects in the uptake or excretion of metals Liver disease + neurologic involvement (Menkes, Wilson) + cardiomyopathy (hemochromatosis)	<b>Chelation therapy</b>	Wilson: Copper avoidance, copper chelation Menkes: Copper supplementation Hemochromatosis: Phlebotomy, iron chelation	Serum copper Ceruloplasmin Iron Ferritin Transferrin Molecular testing

<sup>a</sup>Management and testing should be in partnership with a genetics physician, as comprehensive details are beyond the scope of this resource.

CPS, Carbamoyl phosphate synthetase; D10, dextrose 10%; IV, intravenous; NPO, nil per os; NS, normal saline; OTC, ornithine transcarbamylase; PAA, plasma amino acids; UOA, urine organic acids.

TABLE 13.3

DISORDERS OF REDUCED FASTING TOLERANCE<sup>1-7,33</sup>

Disorders With Selected Examples	Etiology, Clinical Presentation	Acute Management <sup>a</sup>	Chronic Management <sup>a</sup>	Diagnostic Testing <sup>a</sup>
<b>Fatty Acid Oxidation (FAO) Disorders</b> VLCAD deficiency LCHAD deficiency MCAD deficiency	Disorders of fat metabolism Hypoketotic hypoglycemia in fasting. Can also present with rhabdomyolysis, cardiomyopathy, liver disease	<b>Reversal of Fasting State</b> Bolus glucose if hypoglycemia D10 + 1/2 NS to NS at 1–1.5× maintenance <b>Stop Intake of Offending Agents</b> No IV lipids or long chain fats	Avoid prolonged fasting and supplement carbohydrates during illness; consider overnight feeds or uncooked cornstarch as needed for hypoglycemia. For VLCAD and LCHAD, maintain low-fat diet and supplement with medium-chain triglycerides or triheptanoin.	Acylcarnitine profile Quantitative (free and total) carnitine UOA Urine acylglycines
<b>Glycogen Storage Disorders</b> GSD 1a, 1b GSD II GSD III GSD IV GSD V GSD VI GSD IX	Multisystem disorders resulting from defects in the synthesis and catabolism of glycogen <i>Hepatic glycogenoses</i> (GSD Ia [von Gierke], GSD VI, GSD IX): Hepatomegaly, fasting ketotic hypoglycemia, ± hyperlipidemia, uremia, lactic acidosis <i>Muscle glycogenoses</i> (GSD V [McArdle], GSD II [Pompe]): Skeletal and cardiac muscle involvement resulting in fatigue, elevations in creatine kinase <i>Mixed</i> (GSD III [Cori], GSD IV): Fasting ketotic hypoglycemia with myopathy	<b>Reversal of Fasting State</b> , as above	Prevent long periods of fasting with use of cornstarch. GSD II (Pompe): Enzyme replacement	Glucose Lactate Uric acid Lipid panel Transaminases CK Electrocardiogram Echocardiogram Enzyme activity Molecular testing

<sup>a</sup>Management and testing should be in partnership with a genetics physician, as comprehensive details are beyond the scope of this resource.

CK, Creatine kinase; D10, dextrose 10%; GSD, glycogen storage disease; IV, intravenous; LCHAD, long-chain L-3 hydroxyacyl-CoA dehydrogenase; MCAD, medium-chain acyl-CoA dehydrogenase; NS, normal saline; UOA, urine organic acids; VLCAD, very-long-chain acyl-CoA dehydrogenase.

TABLE 13.4

DISORDERS OF COMPLEX MOLECULES<sup>1-6</sup>

Disorders With Selected Examples	Etiology, Clinical Presentation	Management <sup>a</sup>	Diagnostic Testing <sup>a</sup>
<b>Mucopolysaccharidoses</b>	Chronic, progressive, multisystem disorders from glycosaminoglycan accumulation	Acute management is supportive Stem cell transplantation: MPS I	Skeletal survey for dysostosis multiplex Urine glycosaminoglycans
MPS I (Hurler)	Coarse facial features and organomegaly: MPS I Hurler, MPS II Hunter, MPS III Sanfillipo	Enzyme replacement: MPS I, MPS II, MPS IV, MPS VI	Urine oligosaccharides
MPS II (Hunter)			Enzyme activity
MPS III (Sanfilippo)	Developmental delay: MPS III Sanfilippo		Molecular testing
MPS IV (Morquio)			
MPS VI (Maroteaux-Lamy)	Skeletal dysplasia: MPS IV Morquio		
<b>Sphingolipidoses</b>	Impaired degradation of sphingolipids	Acute management is supportive	Urine oligosaccharides
Gaucher	Progressive psychomotor slowing and neurologic problems (e.g., epilepsy, ataxia, and spasticity), hepatosplenomegaly	Enzyme replacement: Gaucher, Fabry	Enzyme activity
Niemann-Pick Type A, B		Stem cell transplant: Krabbe	Molecular testing
Tay-Sachs	Normal intellect: Gaucher (+ bone crises), Niemann-Pick B (+ lung disease), Fabry (+ acroparesthasias, renal or cardiac disease)	Substrate reduction with miglustat or eliglustat: Gaucher	
Krabbe			
Fabry			
<b>Sterol Synthesis Disorders</b>	Multisystem disorders with dysmorphic features and variable skeletal dysplasia	Acute: Adrenal insufficiency may be present Chronic: Consider cholesterol supplementation and/or simvastatin for some disorders	Plasma sterols Serum cholesterol Molecular testing
Smith-Lemli-Opitz	Abnormal peroxisome function or synthesis	Acute: Stress dose corticosteroids if adrenal insufficiency Chronic: Stem cell transplant for X-linked adrenoleukodystrophy	Very-long-chain fatty acids including phytanic and pristanic
Greenberg dysplasia			
<b>Peroxisomal Disorders</b>	Neurologic abnormalities such as hypotonia, encephalopathy, seizures, ocular findings		Pipecolic acids
Zellweger	Dysmorphic facial features: Zellweger		Erythrocyte plasmalogen
Rhizomelic chondrodysplasia punctata (RCDP)			
X-linked adrenoleukodystrophy	Rhizomelia: RCDP		Molecular testing
	Leukodystrophy: X-linked adrenoleukodystrophy		

<sup>a</sup>Management and testing should be in partnership with a genetics physician because comprehensive details are beyond the scope of this resource.

MPS, Mucopolysaccharidosis.

**TABLE 13.5****MITOCHONDRIAL DISORDERS<sup>1-6</sup>**

Disorders With Selected Examples	Clinical Presentation	Management <sup>a</sup>	Diagnostic Testing <sup>a</sup>
<b>Mitochondrial Disorders</b> MELAS MERRF Leigh Kearns-Sayre	Multisystemic disease which can include lactic acidosis, muscle weakness, cardiomyopathy, ataxia, ophthalmoplegia, neuropathy, chronic diarrhea	Acute: For MELAS, IV arginine may abort a neurologic crisis Chronic: Cocktail of antioxidants, vitamins, and cofactors	Serum and CSF lactate and pyruvate Plasma and CSF amino acids UOA Brain imaging Molecular testing Muscle biopsy

<sup>a</sup>Management and testing should be in partnership with a genetics physician, as comprehensive details are beyond the scope of this resource.

*CSF*, Cerebrospinal fluid; *IV*, intravenous; *MELAS*, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; *MERRF*, myoclonic epilepsy with ragged red fibers; *UOA*, urine organic acids.

**TABLE 13.6****NEUROTRANSMITTER DISORDERS<sup>1-6,10</sup>**

Disorders With Selected Examples	Clinical Presentation	Management <sup>a</sup>	Diagnostic Testing <sup>a</sup>
<b>Neurotransmitter Disorders</b> Nonketotic hyperglycinemia (NKH) Sulfite oxidase deficiency B6-dependent seizures GABA receptor mutations or metabolism defects	Infantile epileptic encephalopathy	Acute: Consider trial of pyridoxine ± folinic acid Attenuated NKH: Administration of sodium benzoate and blockade of overstimulated NMDA receptors	CSF neurotransmitters CSF glucose Urine sulfite PAA UOA Molecular testing
<b>Dopamine Disorders</b> Dopa-responsive dystonia Tyrosine hydroxylase deficiency	Dystonia, dyskinesia	Dopamine	CSF biogenic amines

<sup>a</sup>Management and testing should be in partnership with a genetics physician, as comprehensive details are beyond the scope of this resource.

*CSF*, Cerebrospinal fluid; *GABA*,  $\gamma$ -aminobutyric acid; *PAA*, plasma amino acid; *UOA*, urine organic acid.

**E. Commonly Used Medications**

1. Carnitine 50 mg/kg/dose intravenous (IV) every 6 hours when ill, or 100 mg/kg/day orally (PO) divided every 8 hours when well. For dosing in primary carnitine deficiency, see Formulary.
2. Sodium phenylacetate (10%) + sodium benzoate (10%) (Ammonul) should be combined with arginine HCl in a 25 to 35 mL/kg 10% dextrose solution and administered through a central venous catheter to treat acute hyperammonemia in a urea cycle patient. Administration through a central venous catheter is preferred, however this medication can be administered peripherally.

- a. For a child less than 20 kg, the dose is 250 mg/kg sodium phenylacetate and 250 mg/kg sodium benzoate.
  - b. For a child greater than 20 kg, the dose is 5.5 g/m<sup>2</sup> sodium phenylacetate and 5.5 g/m<sup>2</sup> sodium benzoate.
  - c. The dose of arginine HCl is 200 to 600 mg/kg for a child <20 kg, or 4–12 g/m<sup>2</sup> for a child or adult >20 kg, depending on the diagnosis.
    - (1) 200 mg/kg or 4 g/m<sup>2</sup> for carbamylphosphate synthase (CPS) deficiency and ornithine transcarbamylase (OTC) deficiency.
    - (2) 600 mg/kg or 12 g/m<sup>2</sup> for citrullinemia and argininosuccinate lyase (ASL) deficiency.
  - d. Administer as a loading dose over 90 to 120 minutes, followed by an equivalent dose as a maintenance infusion over 24 hours.
3. Arginine HCl for MELAS stroke-like episode: Treatment for MELAS is generally supportive. During the acute stroke-like episode, a bolus of intravenous arginine (500 mg/kg for children or 10 g/m<sup>2</sup> body surface area for adults) within three hours of symptom onset is recommended followed by the administration of a similar dosage of intravenous arginine as a continuous infusion over 24 hours for the next three to five days.<sup>10</sup> (MELAS: mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes)
  4. Sodium benzoate for nonketotic hyperglycinemia (NKH): Patients with attenuated NKH require a lower dose (200–550 mg/kg/day). For older children and adults, consider dosing based on body surface area (e.g., for attenuated NKH start at 5.5 g/m<sup>2</sup> BSA). Patients with severe NKH require a higher dose (550–750 mg/kg/day); for adults, maximum 16.5 g/m<sup>2</sup>/day<sup>10</sup>

## II. NEWBORN METABOLIC SCREENING<sup>7</sup>

### A. Timing

1. First screen should be performed within the first 48 to 72 hours of life (at least 24 hours after initiation of feeding).
2. Second screen (requested in some states) should be performed after 7 days of age.
3. Preterm infants: Perform initial screen at birth (to collect sample before transfusions), another at age 48 to 72 hours, a third at age 7 days, and a final at age 28 days or before discharge (whichever comes first).

### B. Abnormal Result

1. Requires immediate follow-up and confirmatory testing; consult a geneticist
2. ACT Sheets and Confirmatory Algorithms are available for more information on how to proceed with specific abnormalities: [https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/ACT\\_Sheets\\_and\\_Algorithms.aspx](https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/ACT_Sheets_and_Algorithms.aspx) (search ACT sheets).

### C. Results Affected by Transfusion

**NOTE:** Repeat newborn metabolic screen 3 months after last transfusion.

1. Biotinidase enzyme activity
2. Galactose-1-phosphate uridylyltransferase (GALT) activity
3. Hemoglobinopathy evaluation

**III. DYSMORPHOLOGY<sup>7,11-14</sup>****A. History**

Pertinent history includes pregnancy course, prenatal exposures, type of conception (natural or assisted), perinatal history, developmental milestones, and review of systems.

**B. Family History**

1. Three-generation pedigree focused on both medical and developmental histories (see [eFig. 13.1](#)).
2. Helpful mnemonics include:
  - a. SIDE mnemonic<sup>15</sup>: Anything SIMILAR in the family? Anything INHERITED through the family? Any premature, unexplained DEATHS? Any EXTRAORDINARY events?
  - b. SCREEN mnemonic<sup>16</sup>: SOME CONCERNS about conditions running in the family? REPRODUCTION—any issues with pregnancy infertility, or birth defects? EARLY disease, death, or disability? ETHNICITY? NONGENETIC—any other risk factors?
  - c. Rule of Too/Two<sup>13</sup>:
    - (1) Too: tall? short? many? few? early? young? different?
    - (2) Two: cancers? generations? in the family? birth defects?
3. **Patterns of inheritance:** See [Online Content](#) for discussion of different patterns of inheritance.

**C. Physical Examination**

1. **Major anomalies:** Structural anomalies that are found in less than 5% of the population and may cause significant cosmetic or functional impairment, often requiring medical or surgical management.
2. **Minor anomalies<sup>11,12,14,17</sup>:** Structural anomalies that are found in greater than 5% of the population with little or no cosmetic or functional significance to the patient.
3. Examples of major and minor anomalies ([Table 13.7](#)). Three or more minor anomalies may be a nonspecific indicator of occult or major anomaly.

**D. Workup: Tailor to individual patient and existing information, including effective chart review, prior genetic testing, and genetic testing in the family**

1. **Imaging to evaluate for major anomalies**
  - a. Head ultrasound (US) or brain magnetic resonance imaging (MRI)
  - b. Echocardiogram
  - c. Complete abdominal US
  - d. Skeletal survey with radiographs composed of: AP views of skull, chest/ribs, upper extremities and hands, lower extremities and feet; lateral views of skull, complete spine, chest, and odontoid view
2. **Dilated eye exam**
3. **Hearing evaluation**

TABLE 13.7

EXAMPLES OF DYSMORPHOLOGY EXAM FINDINGS<sup>11-14,17</sup>

	Major Anomalies	Minor Anomalies
General	Growth <3rd percentile	Short or tall stature
Head	Structural brain abnormalities (e.g., holoprosencephaly, schizencephaly), craniosynostosis	Asymmetric head shape, micrognathia, prominent metopic ridge, widows peak
Eyes	Anophthalmia, cataracts, coloboma	Palpebral fissures, epicanthal folds, hypertelorism or hypotelorism, telecanthus, epicanthus, ptosis
Ears, nose, throat	Cleft lip/palate, tracheal-esophageal fistula	Periauricular pits/tags, overfolded helix, everted ears, low-set ears, microtia, abnormal nasal bridge, branchial cleft cysts
Chest/lungs	Congenital diaphragmatic hernia, situs inversus	Inverted nipples, accessory nipples, pectus excavatum or carinatum
Heart	Congenital heart defects (e.g., tetralogy of Fallot, coarctation of aorta, atrial or ventricular septal defects)	Patent ductus arteriosus, valvular abnormalities
Abdomen	Omphalocele, gastroschisis, intestinal atresia	Umbilical hernia
Genitourinary	Ambiguous genitalia, horseshoe kidney	Hypogonadism, pelvic kidney, shawl scrotum, labial hypoplasia
Musculoskeletal	Skeletal dysplasia, spina bifida	Clubfeet, bowing, syndactyly of two digits, postaxial polydactyly, 5th finger clinodactyly, hypoplastic nails, short metacarpals or metatarsals
Skin	Cutis aplasia	Striae, café-au-lait spots, atypical skin creases, transverse palmar crease, nevus simplex, congenital dermal melanocytosis


4. **Genetic testing:** See Fig. 13.4 and Table 13.8. The patient should be referred to genetics for a dysmorphology evaluation and appropriate testing.

#### IV. PATTERNS OF GENETIC CONDITIONS WITH DISTINCTIVE APPEARANCE<sup>11,14</sup>

This section is not comprehensive; it covers some common reasons to seek a genetics consult. These conditions will often be managed by a multidisciplinary team.

##### A. Cardiac Conditions

1. **Congenital heart disease:** Investigation for co-occurring anomalies with abdominal US. Chromosome microarray testing indicated, including for 22q11 deletion syndrome (Table 13.9).



**FIGURE 13.4**

Etiologies of dysmorphic features.<sup>29</sup> <sup>a</sup>Whole exome sequencing can only reliably detect single base pair changes and insertions/deletions of less than 20 base pairs.

2. **Cardiomyopathy:** Can be from inborn errors of metabolism, channelopathies, mutations in genes important for sarcomere and desmosome production/function, or other single gene disorders.
3. **Long QT disorders:** Many single gene disorders

## B. Ciliopathies

1. **Nonmotile ciliopathies:** Defects in primary (nonmotile) ciliary function. Cystic renal disease, brain malformations (molar tooth sign), retinal degeneration, congenital hepatic fibrosis, polydactyly, skeletal dysplasia, obesity. **Examples:** Cystic kidneys as a result of heritable polycystic kidney disease; neurodevelopmental ciliopathies such as Joubert syndrome or Bardet-Biedl syndrome
2. **Primary ciliary dyskinesias:** Defects in motile cilia. Recurrent respiratory infections (chronic sinopulmonary disease), infertility, situs inversus. **Examples:** More than 45 genes known to cause primary ciliary dyskinesia. When situs inversus is present, it is referred to as Kartagener syndrome.
3. **Evaluation:** Evaluation for potentially affected organ systems, including abdominal US, echocardiogram, brain MRI, and complete retinal evaluation with ophthalmology. Skeletal survey if limb defects. CMP to evaluate kidney and liver function. Unless a specific disorder is suspected, broad genetic testing is appropriate.

**TABLE 13.8****DIAGNOSTIC GENETIC TESTING AND CLINICAL CONSIDERATIONS**

Genetic Testing Technology	Description of Technology	Turnaround Time	Able to Detect	Specific Indications
Karyotype	Systematically arranged photomicrograph of chromosomes	1–2 weeks	Aneuploidy, larger deletions/duplications ( $\geq 5$ kb), translocation or balanced rearrangements	Indicated for suspected aneuploidy, recurrent miscarriage, looking for a balanced translocation
Fluorescence in situ hybridization (FISH)	Mapping a segment of DNA by molecular hybridization of a fluorescent probe	<1 week	Presence or absence of a specific site or chromosome	Not indicated, except in family studies and for rapid diagnosis of a suspected trisomy <sup>32</sup>
Microarray (a.k.a. Array CGH, SNP or oligochromosomal microarray)	Comparative genome hybridization using a high-density SNP profile or oligos (short segments of DNA) across the genome	2–4 weeks	Genomic gains or losses (copy number variation [CNV]), regions of homozygosity (consanguinity). Incidental findings unrelated to phenotype	First-line cytogenetic test for all patients with unexplained global developmental delay, intellectual disability, autism, and/or congenital anomalies
Single gene testing	Nucleotide-by-nucleotide Sanger sequencing of a single gene	~1 month	Mutations in specific gene of interest	Indicated when there is a strong clinical suspicion of a specific single gene disorder
Targeted mutation analysis	Detection of previously identified familial mutation or common population mutation	<1 month	Whether the patient has (or does not have) only the specific mutation tested	Confirmation of clinical diagnosis, presymptomatic genetic diagnosis, identification of carrier status, preimplantation genetic diagnosis, prenatal testing
Repeat expansion testing	Southern blot or triplet-repeat primed PCR	<1 month	The quantity of repeats in the specific gene tested	Indicated when there is a strong clinical suspicion of a triplet repeat disorder
Methylation analysis	Methylation multiplex ligation-dependent probe amplification	<1 month	Whether the region tested has normal or abnormal methylation	Indicated when there is a strong clinical suspicion of a specific methylation defect (e.g., Prader-Willi)

*Continued*

**TABLE 13.8****DIAGNOSTIC GENETIC TESTING AND CLINICAL CONSIDERATIONS—CONT'D**

<b>Genetic Testing Technology</b>	<b>Description of Technology</b>	<b>Turnaround Time</b>	<b>Able to Detect</b>	<b>Specific Indications</b>
Next-generation sequencing (multiple gene panels)	Massively parallel sequencing of specific genes	1–2 months	Simultaneously identifies if there are any variants in multiple genes of interest	Used for syndromes with heterogeneity (mutations in different genes can cause the same phenotype, or the phenotypes are hard to distinguish clinically)
Whole exome sequencing (WES)	Massively parallel sequencing of almost all exons	2–6 months	Simultaneously identifies if there are any variants in the coding portions of genes that match the patient's phenotype. Incidental findings unrelated to phenotype	More comprehensive genomic test indicated in an otherwise negative workup, or when cost-benefit ratio of more targeted testing is in favor of WES
Whole genome sequencing (WGS)	Massively parallel sequencing of entire genome	Variable	More uniform coverage of exonic, intronic, and splice site mutations. Incidental findings unrelated to phenotype	Not widely clinically available; used mostly in research studies

*CGH*, Comparative genomic hybridization; *DNA*, deoxyribonucleic acid; *Kb*, kilobases; *PCR*, polymerase chain reaction; *SNP*, single nucleotide polymorphism.

TABLE 13.9

GENETIC SYNDROMES ASSOCIATED WITH CARDIAC DEFECTS<sup>11</sup>

Genetic Syndrome	Cardiac Defect	Other Features	Diagnostic Evaluation
Noonan syndrome <sup>a</sup>	Pulmonary valve stenosis, hypertrophic cardiomyopathy	Short stature, broad neck, lymphatic dysplasia, low ears and hypertelorism, coagulation defects	“RASopathy” gene panel including <i>PTPN11</i>
Williams syndrome (7q11.23 deletion) <sup>a</sup>	Supravalvular aortic stenosis	Periorbital fullness, broad nasal tip, large ears, thick lips, small teeth, hypercalcemia, renal artery stenosis, connective tissue abnormalities, overfriendliness	Microarray
Holt-Oram syndrome	ASD	Upper limb malformation, cardiac conduction disease	<i>TBX5</i> sequencing
Down syndrome <sup>a</sup>	VSD, AV canal defect	(See Section V)	Karyotype
Turner syndrome <sup>a</sup>	Coarctation of aorta	(See Section V)	Karyotype
22q11.2 Deletion syndrome <sup>a</sup>	Tetralogy of Fallot, interrupted aortic arch, VSD	(See Section V)	Microarray

<sup>a</sup>Published clinical management guidelines available.<sup>20</sup>

ASD, Atrial septal defect; AV, atrioventricular; VSD, ventricular septal defect.

### C. Cleft Lip and Palate (CLP)

1. Can be isolated or part of a syndrome
2. **Risk factors:** Maternal smoking, heavy alcohol use, systemic corticosteroid use, folic acid and cobalamin deficiency<sup>18</sup>
3. Submucosal clefts may be indicated by a bifid uvula.
4. **Evaluation:** Children can have difficulties with feeding, speech, and hearing (chronic otitis or hearing loss as part of a syndrome). If not an isolated anomaly, may need further workup with ophthalmology and echocardiogram.
5. **Examples:** Autosomal dominant inheritance seen in Van der Woude syndrome (associated with lip pits) and Stickler syndrome (can have retinal detachment, hearing loss)

### D. Connective Tissue Disorders

1. Consider when a patient has velvety skin, hyperextensible joints, abnormal scarring, poor healing, striae, pectus deformities, tall stature, myopia, lens dislocations, arachnodactyly
2. **Evaluation:** Some connective tissue disorders are associated with dilated aorta (echocardiogram), dysplastic vessels, or fragility of lens/retina (ophthalmology evaluation).

3. **Examples:** Dilated aorta with characteristic physical features in Marfan syndrome; vascular fragility in vascular Ehlers-Danlos (type IV); isolated hyperextensibility of joints in hypermobile Ehlers-Danlos (type III)

### E. Developmental Delay, Intellectual Disability

1. All children should be offered genetic evaluation.
2. See [Chapter 9](#) for information on evaluation.

**Examples:** Microarray is first tier test because it can detect microdeletion and microduplication syndromes, such as 1p36 deletion syndrome. *FMR1* repeat testing can detect fragile X syndrome and heterozygous females, who can also have developmental delays. The American College of Medical Genetics (ACMG) is currently reviewing the possibility of starting with whole exome sequencing (WES). If whole genome sequencing becomes the clinical standard, then chromosome microarray and even fragile X testing will no longer be indicated.

### F. Deafness, Hard of Hearing

1. Approximately 60% of hearing loss is genetic. It can be syndromic or nonsyndromic.
2. Consider perinatal infectious causes (e.g., cytomegalovirus).
3. **Evaluation:** Consider connexin 26 and 30 gene testing as first step if nonsyndromic and/or broad gene panel testing. Individualize inner ear/brain imaging. Ophthalmology assessment, ECG, and renal US should be considered for those with negative connexin testing.
4. **Examples:** Approximately half of nonsyndromic hearing loss is from *GJB2* (encodes connexin 26) gene mutations. Syndromic causes include Usher syndrome, which can also have gradual vision loss.

### G. Hypotonia

1. **Central:** Abnormalities of brain function, normal strength or axial weakness, preserved/persistent newborn reflexes, normal CK, normal muscle bulk
  - a. **Evaluation:** CK to differentiate. Evaluate for causes such as hypothyroidism (TSH); evaluate brain structure and function with MRI and EEG.
  - b. **Examples:** Prader-Willi syndrome, peroxisomal disorders, many others
2. **Peripheral:** Alert, profound weakness that is often appendicular, absent reflexes, feeding difficulties, normal or increased CK
  - a. **Evaluation:** Evaluate for causes such as hypothyroidism (TSH) or mitochondrial disease (lactate/pyruvate). Electromyography (EMG) to determine if muscle or nerve affected. Consider that cardiac muscle could be affected (echocardiogram).
  - b. **Examples:** Spinal muscular atrophy (now included in newborn screening), myotonic dystrophy, muscular dystrophies

### H. Limb and Stature Conditions

1. Can be defects in collagen formation, bone formation, or remodeling
2. **Evaluation:** Radiographic skeletal survey of all bones to localize dysplasia. Some conditions, including achondroplasia, can have narrowing at the

foramen magnum or cervical instability (flexion/extension C-spine films). There can be a risk of central or peripheral sleep apneas (sleep study). Karyotype for females with short stature to evaluate for Turner syndrome. Unless a specific condition is suspected, broad genetic testing is appropriate.

3. **Examples:** Rhizomelic limb shortening and narrow foramen magnum seen in achondroplasia. Cervical instability seen in *COL2A1* gene mutations (spondyloepiphyseal dysplasia congenita, Stickler syndrome). The presence of multiple congenital joint contractures is called arthrogryposis, which is seen in many conditions. Fractures can be seen in osteogenesis imperfecta and hypophosphatasia.

### I. Liver Disease

1. Liver failure and/or direct and indirect hyperbilirubinemia can be a manifestation of a metabolic condition or the result of a genetic syndrome.
2. **Evaluation:** Metabolic workup, including PAA, UOA, urine succinylacetone, very-long-chain fatty acids, urine-reducing substances. Some syndromes have ocular features (ophthalmology evaluation). Unless a specific condition is suspected, broad genetic testing is appropriate.
3. **Examples:** Cholestasis found in progressive familial intrahepatic cholestasis (type 1, 2, and 3). Liver dysfunction can be seen in tyrosinemia. Indirect/unconjugated hyperbilirubinemia can be seen in Gilbert and Crigler-Najjar syndromes.

### J. Oncologic Conditions<sup>19</sup>

1. Approximately 10% of pediatric oncology patients have a heritable cancer predisposition syndrome or germline mutation. This puts them and affected family members at risk for certain cancers and may affect their individualized treatments.
2. Obtain a thorough family history with specific cancer diagnoses and age of diagnosis.
3. **Evaluation:** Many cancers warrant referral. Genetic testing is tailored to each specific diagnosis. Examples include myelodysplastic syndrome, medulloblastoma, atypical teratoid rhabdoid tumor, sarcomas, pituitary blastoma, and many more.
4. **Examples:** Early onset of cancers in Li-Fraumeni syndrome (especially sarcoma) and von Hippel-Lindau syndrome (especially hemangioblastoma)

### K. Overgrowth

1. Generalized overgrowth can result in macrosomia at birth or height and/or head circumference greater than the 98th percentile.
2. Hemihypertrophy may be the result of mosaicism from somatic changes.
3. Be aware that certain overgrowth syndromes have associated cancer risks and may require routine monitoring (e.g., abdominal US screening in Beckwith-Wiedemann syndrome).

4. **Evaluation:** Condition-specific genetic testing based on exam findings; may require skin biopsy. In some conditions, internal organs can be affected (echocardiogram, ECG, renal US).
5. **Examples:** Generalized overgrowth with developmental delays can be the result of Sotos syndrome, Beckwith-Wiedemann syndrome, or others. Segmental overgrowth/hemihypertrophy can result from somatic *PIK3CA* mutations affecting the brain (MCAP syndrome) or a limb (Klippel-Trénaunay syndrome).

#### L. Conditions Associated With Seizures

1. Consider genetics, especially with positive family history, intractable epilepsy, infantile onset, developmental regression, intellectual disability, dysmorphic features, autism, or brain malformations.
2. Can be the result of metabolic conditions or syndromic conditions
3. Increased recurrence risk in families even if no genetic cause identified
4. **Evaluation:** Consideration of microarray, epilepsy panels, or whole exome sequencing (particularly if dysmorphic features present); consider biochemical testing for inborn errors of metabolism; physical exam with Wood's lamp for cutaneous manifestations (e.g., hypopigmented macules).
5. **Examples:** Sodium channel defects (*SCN1A* mutations) can lead to a broad spectrum of seizures. Accompanying dermatologic findings can be characteristic for neurocutaneous conditions, including neurofibromatosis type 1 and tuberous sclerosis.

#### M. Skin Pigmentation Alterations

1. Can be the result of post-zygotic mosaicism. As a result, genetic variants may only be detectable in affected skin and not in blood.
2. Skin and the central nervous system are derived from the same neural crest lineage; many skin pigmentation anomalies have associated central nervous system abnormalities, including malformations or seizures. Often referred to as neurocutaneous conditions.
3. **Evaluation:** Examination with a Wood's lamp, ophthalmology evaluation
4. **Examples:** Multiple café-au-lait macules seen in neurofibromatosis type 1 and Legius syndrome. Genetic mosaicism in skin can lead to a pigmentation pattern called hypomelanosis of Ito.

#### N. Vascular Anomalies

1. Can involve arterial, vascular, and lymphatic systems. Can be caused by germline pathogenic variants or postzygotic somatic mutations (mosaicism). Some are associated with segmental overgrowth.
2. Vascular syndromes can cause clinically significant arteriovenous malformations and arteriovenous fistulas in the skin, internal organs, and brain/spine.
3. **Evaluation:** Examine mucosal membranes. Some conditions require evaluation for intraorgan arteriovenous malformations with abdominal US and/or MRI/magnetic resonance angiography (MRA) of brain and spine. Several conditions are autosomal dominant—obtain family history for vascular lesions.

4. **Examples:** Autosomal dominant history of multiple capillary malformations could be from *RASA1* mutations. Port-wine stains seen in Sturge-Weber syndrome. Telangiectasias on lips, nose, and hands seen in hereditary hemorrhagic telangiectasia

## V. ETIOLOGIES OF DYSMORPHIC FEATURES (FIG. 13.4)<sup>11,14,29</sup>

### A. Aneuploidy

Abnormal number of chromosomes

1. Aneuploidy syndromes are most commonly due to maternal nondisjunction and more rarely due to chromosomal translocation or mosaicism. Risk increases with maternal age.
2. The evaluation for aneuploidy often begins prenatally with a first trimester screen (nuchal translucency, nasal bone, free  $\beta$ -human chorionic gonadotropin [ $\beta$ -hCG], PAPP-A) or circulating cell-free fetal DNA analysis showing increased risk.
3. Prenatal diagnostic testing options include chorionic villus sampling in the first trimester or amniocentesis during or after the second trimester.
4. Fluorescence in situ hybridization (FISH) may be performed in the first 24 to 48 hours of life to indicate number of chromosomes but will not determine the morphology of the chromosomes (e.g., if a translocation is present). Therefore karyotype analysis is still indicated in aneuploidy syndromes, both to provide a diagnosis and to provide accurate genetic counseling.
5. **Specific aneuploidy syndromes:**
  - a. **Down syndrome (Trisomy 21):**
    - (1) **Features:** Hypotonia and characteristic facial features (brachycephaly, epicanthal folds, flat nasal bridge, upward-slanting palpebral fissures, Brushfield spots, small mouth and ears), excess skin at the nape of the neck, single transverse palmar crease, short fifth finger with clinodactyly, wide gap between the first and second toes. Intellectual disability present in all, but severity is variable.
    - (2) Full health supervision guidelines from the American Academy of Pediatrics (AAP) are available (see [Section VII](#)).
    - (3) In brief: In addition to karyotype, neonates should have echocardiogram to assess for congenital heart disease, ophthalmologic evaluation to assess for cataracts, hearing screen, complete blood count (CBC) to assess for transient myeloproliferative disease, thyroid studies to assess for hypothyroidism, and referral to early intervention services. Annual thyroid studies, CBC (add ferritin and CRP for any child at risk of iron deficiency), hearing and vision assessments. Cervical spine x-ray at age 3 years if asymptomatic (sooner imaging with immediate neurosurgical referral if symptomatic). Monitor for signs of obstructive sleep apnea and neurologic dysfunction.

- b. **Edwards syndrome (Trisomy 18):**
- (1) **Features:** Intrauterine growth restriction and polyhydramnios, small for gestational age at birth, clenched hands with overlapping fingers, hypoplastic nails, short sternum, prominent occiput, low-set and structurally abnormal ears, micrognathia, rocker-bottom feet, congenital heart disease, cystic and horseshoe kidneys, seizures, hypertonia, significant developmental and cognitive impairments
  - (2) Ninety percent die before 1 year of life.
- c. **Patau syndrome (Trisomy 13):**
- (1) **Features:** Defects of forebrain development (holoprosencephaly), severe developmental disability, low-set malformed ears, cleft lip and palate (CLP), microphthalmia, aplasia cutis congenita, polydactyly (most frequently of the postaxial type), narrow hyperconvex nails, apneic spells, cryptorchidism, congenital heart defects
  - (2) Ninety-five percent die before 6 months of life.
- d. **Turner syndrome (45, X):**
- (1) **Features:** Short stature, gonadal dysgenesis with amenorrhea and lack of a pubertal growth spurt, broad chest with hypoplastic or inverted nipples, webbed neck. The diagnosis should be considered prenatally in a female fetus with hydrops, increased nuchal translucency, cystic hygroma, or lymphedema. Intelligence is usually normal, but patients are at risk for cognitive, behavioral, and social disabilities.
  - (2) Full health supervision guidelines from the AAP are available (see [Section VII](#)).
  - (3) In brief: Obtain baseline echocardiogram, renal US, ophthalmology and audiology evaluations. Routine thyroid testing, biochemical liver tests, Hemoglobin A<sub>1c</sub>, vitamin D, TTG and immunoglobulin A (IgA), audiology, skin examinations, bone mineral density, and skeletal assessments.
- e. **Klinefelter syndrome (47, XXY; 48, XXYY; 48, XXXY; and 49, XXXXY):**
- (1) **Features:** Primary hypogonadism, which may present in infancy with hypospadias or cryptorchidism or in adolescence/adulthood with infertility, gynecomastia, and small testes. Children may have expressive language delay.
  - (2) There is an increased risk of breast carcinoma in 47, XXY.
  - (3) Testosterone therapy is indicated at puberty for hypergonadotropic hypogonadism.

## B. Copy Number Variation (Deletions and Duplications)

Partial loss or additional copies of genetic material on part of a chromosome

1. **22q11 Deletion syndrome (velocardiofacial syndrome, DiGeorge syndrome)**
  - a. **Features:** Congenital heart disease (tetralogy of Fallot, interrupted aortic arch, ventricular septal defect [VSD], and truncus arteriosus most common), palatal abnormalities (velopharyngeal incompetence,

cleft palate), characteristic facial features in approximately two-thirds, developmental delays, learning disabilities, immunodeficiency, hypocalcemia, feeding problems, renal anomalies, hearing loss, laryngotracheoesophageal anomalies, growth hormone deficiency, autoimmune disorders, seizures (with or without hypocalcemia), and psychiatric disorders

- b. **Diagnostic evaluation:** Microarray; FISH is no longer recommended. Assessments should include serum calcium, absolute lymphocyte count, B- and T-cell subsets, renal US, chest x-ray, cardiac examination, and echocardiogram
- c. **Health supervision:** Hold live vaccines until immune function is assessed.

## 2. **5p– syndrome (cri-du-chat syndrome)**

- a. **Features:** High-pitched cry, delayed development, intellectual disability, microcephaly, low birth weight, hypotonia, hypertelorism, low-set ears, small jaw, round face, congenital heart disease (VSD, atrial septal defect [ASD], PDA)
- b. **Diagnostic evaluation:** Can be detected on karyotype or microarray

## 3. **1p36 Deletion syndrome**

- a. **Features:** Developmental delay, intellectual disability, delayed growth, hypotonia, seizures, speech delay, hearing and vision impairment, microcephaly, low ears with thick helices, congenital heart disease (structural defects or cardiomyopathy)
- b. **Diagnostic evaluation:** Microarray

## C. Disorders of Methylation/Epigenetics

Heritable changes that affect gene activity and expression

### 1. **Prader-Willi syndrome**

- a. **Features:** Severe hypotonia and feeding difficulties in infancy, followed by an insatiable appetite in later infancy or early childhood. Developmental delays in motor and language abilities. All affected individuals have some degree of intellectual/learning disability. Short stature is common; males and females have hypogonadism, and in most, infertility.
- b. **Diagnostic evaluation:** Results from missing *paternally* contributed region. Methylation testing can detect almost all individuals—whether due to abnormal paternal-specific imprinting, a paternal deletion, or maternal uniparental disomy within the Prader-Willi/Angelman critical region of 15q. Follow up with further molecular testing.
- c. **Health supervision:** Full health supervision guidelines from the AAP are available (see [Section VII](#)). Monitor for feeding difficulties in infancy and close supervision beginning in childhood to prevent obesity. Evaluate for and treat hypothyroidism, sleep apnea (central and obstructive), central adrenal insufficiency,<sup>21</sup> and cryptorchidism.
- d. **Treatment:** Growth hormone can be beneficial, and hormone replacement therapy can aid in sexual development.

## 2. Angelman syndrome

- a. **Features:** Happy demeanor, hand-flapping, and fascination with water. Severe developmental delay, intellectual disability, severe speech impairment, gait ataxia, tremulous limbs, hypotonia, microcephaly, and seizures
- b. **Diagnostic evaluation:** Results from missing *maternally* contributed region. Methylation testing can detect almost all individuals—whether due to abnormal maternal-specific imprinting, a maternal deletion, or paternal uniparental disomy within the Prader-Willi/Angelman critical region of 15q. Some individuals can be detected through *UBE3A* sequence analysis.
- c. **Health supervision:** Monitor for seizures, behavior problems, feeding issues, sleep disturbance, scoliosis, strabismus, constipation, and gastroesophageal reflux disease.
- d. **Treatment:** Antiepileptic drugs for seizures; be careful not to overtreat, because Angelman syndrome also associated with movement abnormalities (*avoid* carbamazepine, vigabatrin, and tiagabine).<sup>22</sup> Speech therapy with a focus on nonverbal communication. Sedatives for nighttime wakefulness.

## 3. Classic Rett syndrome: X-linked condition present only in females because pathogenic *MECP2* variants are most often lethal in males who have only one X chromosome. Males who do survive with *MECP2* mutations have presentation different from Rett syndrome that often includes neonatal encephalopathy.

- a. **Features:** Neurodevelopmental syndrome that presents after 6 to 18 months of typical development with acquired microcephaly, then developmental stagnation, followed by rapid regression. Gait ataxia or inability to ambulate; repetitive, stereotypical handwringing; fits of screaming or inconsolable crying; episodic breathing abnormalities (sighing, apnea, or hyperpnea); tremors; and generalized tonic-clonic seizures
- b. **Diagnostic evaluation:** Molecular testing of *MECP2*
- c. **Health supervision:** Regular ECG to evaluate QT interval,<sup>23</sup> monitor for scoliosis

## D. Repeat Expansion

Pathogenic expansion of trinucleotide repeats during DNA replication

### 1. Fragile X syndrome

- a. Most common cause of inherited intellectual disability
- b. **Features:** Males have relative macrocephaly and prominent ears. Postpubertal macroorchidism and tall stature that slows in adolescence. Females have a range of intellectual disability due to the degree of inactivation of the affected X chromosome. Female premutation carriers (55 to 200 repeats) can develop primary ovarian insufficiency; males with 55 to 200 repeats can develop a tremor/ataxia phenotype.

- c. **Diagnostic evaluation:** Repeat expansion testing of *FMR1* gene to assess number of CGG trinucleotide repeats (typically >200 in fragile X syndrome).
  - d. **Health supervision:** Full health supervision guidelines from the AAP are available (see [Section VII](#)). Symptom and supportive psychopharmacologic medications
2. Other examples include Huntington disease (CAG repeats), myotonic dystrophy (CTG repeats), and Friedrich ataxia (GAA repeats).

## E. Mendelian/Single Gene Disorders

Mutation in a single gene causing a disorder

### 1. Marfan syndrome

- a. **Features:** Myopia, ectopia lentis, aortic dilatation with predisposition to rupture, mitral valve prolapse, pneumothorax, bone overgrowth and joint laxity, pectus carinatum or excavatum, scoliosis, pes planus
- b. **Diagnostic evaluation:** Clinical diagnosis based on the revised Ghent criteria (a “systemic score” system based on clinical features that can support a diagnosis if score is greater than or equal to 7). Sequencing of *FBN1* gene
- c. **Health supervision:** Annual ophthalmologic examination; annual echocardiography; intermittent surveillance of the entire aorta with computed tomography (CT) or MRA scans beginning in young adulthood. Avoid contact sports, competitive sports, isometric exercise. Full health supervision guidelines from the AAP are available (see [Section VII](#)).
- d. **Treatment:**  $\beta$ -blocker (atenolol) and/or an angiotensin-II type 1 receptor blocker (losartan) is current standard of care. Valve-sparing surgery to replace aortic root when diameter exceeds  $\sim 4.5$  cm in adults (or if rates of aortic dilation exceed  $\sim 0.5$  cm/year) and significant aortic regurgitation is present.<sup>24</sup>

### 2. Ehlers-Danlos syndrome (EDS)

- a. **Features:** Smooth, velvety, hyperextensible skin, widened scars, poor healing, easy bruising, joint hypermobility with recurrent dislocations, chronic joint or limb pain, and a positive family history. The vascular-type EDS is distinct and involves translucent skin, characteristic facies (pinched nose), as well as risk for arterial, intestinal, and uterine fragility or rupture.
- b. **Diagnostic evaluation:** Clinical evaluation and family history. There are more than thirteen types; for classical and vascular types, echocardiogram and DNA testing. Vascular type additionally needs CT/MRA imaging of head to pelvis. Joint hypermobility can be scored with Beighton criteria. No known genetic cause of hypermobile type, which is most common
- c. **Treatment:** Physical therapy to improve joint stability, low-resistance exercise, and pain medications as needed; treat gastroesophageal reflux. Vascular EDS requires management in a clinic specializing in connective tissue disorders.

### 3. Achondroplasia

- a. **Features:** Short arms and legs (due to rhizomelia or shortening of the most proximal extremity segments: humerus and femur); bowing of the lower legs; large head with characteristic facial features including frontal bossing and midface retrusion. Infantile hypotonia is typical, followed by delayed motor development. Gibbus deformity of the thoracolumbar spine leads to exaggerated lumbar lordosis. Rarely, children have hydrocephalus and restrictive pulmonary disease. Stenosis at the foramen magnum in infancy increases the risk of death; lumbar spinal stenosis may present in childhood but is more common in adulthood. Intelligence and life span are usually normal. Average adult height for males and females is approximately 4 feet.
- b. **Diagnostic evaluation:** Clinical diagnosis based on characteristic physical exam. *FGFR3* mutation testing available if diagnostic uncertainty
- c. **Health supervision:** Full health supervision guidelines from the AAP are available (see [Section VII](#)). In brief: Use standard growth charts for achondroplasia. Baseline head CT including cervicomedullary junction in infancy, and precautions against uncontrolled head movement or neck manipulation. Monitor for signs of obstructive sleep apnea, middle ear complications (e.g., otitis media), or spinal stenosis (more common in adults). New treatments available and in clinical trials

### F. Teratogen Exposure (Table 13.10)

### G. In utero Forces<sup>25</sup>

1. Uterine compression:
  - a. Can be intrinsic (oligohydramnios, multiple fetuses, uterine deformities) or extrinsic (small pelvis)
  - b. Results in deformations, including craniofacial (plagiocephaly, flattened facies, crumpled ear, craniosynostosis), extremities (dislocated hips, equinovarus or calcaneovalgus feet, tibial bowing, contractures), torticollis, lung hypoplasia, scoliosis
2. Abnormal fetal muscular tone or posture can result in hyperextended knees, dislocated hips, contractures.
3. Placental compromise
4. Amniotic bands

## VI. CONSENT AND DISCLOSURE OF GENETIC TESTING

### A. Ethics of Genetic Testing in Pediatrics

Genetic testing in pediatric patients poses unique challenges given that children require proxies (most often parents) to give consent for testing. Several publications and statements have been released about genetic testing in children, including the “Ethical Issues with Genetic Testing in Pediatrics” statement made by the AAP.<sup>26</sup> Important considerations include:

**TABLE 13.10**  
**SELECTED TERATOGENS**<sup>11,30-31</sup>

Exposure	Features
Intrauterine infections	See <a href="#">Chapter 17</a>
Intrauterine substance exposure	Alcohol: Fetal alcohol spectrum disorder: microcephaly, small palpebral fissures with epicanthal folds, low nasal bridge with upturned nose, smooth philtrum and thin vermilion border, small chin, developmental delay, intellectual disability Cocaine: IUGR, developmental delay, learning disabilities, attention and behavioral challenges, occasional congenital anomalies
Intrauterine medication exposure <i>See Formulary for drug-specific information on risk in pregnancy.</i>	Phenytoin: Fetal hydantoin syndrome: growth deficiency, hypertelorism, flat nasal bridge, cleft lip and palate, long philtrum and thin bowed upper lip, digitalized thumbs, hypoplasia of distal phalanges Warfarin: Nasal hypoplasia, epiphyseal stippling, hypoplastic distal phalanges, Peters anomaly, brain malformations Valproate: High forehead, broad nasal bridge, small mouth and chin, cardiac defects, long/thin phalanges, developmental delay Retinoic acid: Microtia, depressed nasal bridge, hypertelorism, cardiac defects, brain malformations, intellectual disability ACE inhibitors: Oligohydramnios, renal tubular dysgenesis, poor ossification of calvaria, cardiac defects, brain malformations Methotrexate: Microcephaly, growth restriction, hypoplasia of skull bones, micrognathia, low-set ears, mesomelia, syndactyly
Maternal medical conditions	Diabetes mellitus: Polyhydramnios, macrosomia; variety of congenital anomalies including spina bifida, heart defects, skeletal anomalies, urinary/reproductive system anomalies Uncontrolled maternal PKU: Microcephaly, IUGR, hypertonia, cardiac defects, intellectual disability
Environmental exposures	High lead levels: Miscarriage, intrauterine growth restriction, learning and behavior problems High levels of radiation: Miscarriage, microcephaly, developmental delay; exposure of less than 5 rads (125 pelvic x-rays) not associated with increased risk of birth defects

This is not a comprehensive listing. Patient-oriented resource for exposures during pregnancy and breastfeeding: <https://mothertobaby.org>.<sup>31</sup>

ACE, Angiotensin-converting enzyme; IUGR, intrauterine growth restriction; PKU, phenylketonuria.

1. Testing and screening of a pediatric patient should be in his/her best interest and provide clear benefits.
2. If testing is performed for the interests of parents or other family members, it should not be to the detriment of the child.
3. Treatment and/or follow-up must be available after testing is sent.
4. Carrier testing or screening in children and adolescents is not broadly supported.
5. Predictive testing for late-onset disorders is discouraged until a patient is able to make an autonomous decision; in these cases, extensive pre-test counseling is recommended.

## B. Informed Consent

Pretest counseling and informed consent are important prior to sending any genome-wide testing, and documentation of informed consent is recommended. Possible results from genetic testing include:

1. Positive: A causative/related variant is found.
2. Negative: Either no causative/related variant is present, *or* the available technology or scope of the test methodology was unable to detect the causative/related variant. A negative result does not guarantee the condition does not have a genetic etiology.
3. Variant(s) of uncertain significance: Variants for which the meaning is uncertain (could be variants without clinical significance or related to the patient's presentation but not previously reported)
4. Incidental or secondary finding(s): Variants anticipated to affect the patient's health that are unrelated to the indication for sending the test (and may be an adult-onset condition)
5. Discovery that parents are blood relatives and/or nonmaternity/nonpaternity

## C. Professional Disclosure of Familial Genetic Information

Pretest counseling should include the discussion that genetic testing may have implications for family members. With regard to disclosure of genetic testing results to at-risk family members when a patient or family member chooses not to disclose, the provider must weigh the duty to respect privacy and autonomy of the patient with the duty to prevent harm in another identifiable person. The ethical and legal duties of the physician are not well defined. The American Society of Human Genetics released a statement on professional disclosure of familial genetic information, which outlines "exceptional circumstances," which if all are present, disclosure may be permissible: (1) attempts to encourage disclosure by the patient have failed, (2) harm is "highly likely" to occur, (3) the harm is "serious and foreseeable," (4) either the disease is preventable/treatable or early monitoring will reduce risks, (5) the at-risk relative(s) are identifiable, and (6) the harm of failure to disclose outweighs the harm that may result from disclosure.<sup>27</sup>

## D. Disclosure of Incidental Findings

Patients are sometimes given the option to be informed of any incidental or secondary findings when they pursue genetic testing, but in general, it is recommended that incidental findings should be reported when there is strong evidence of benefit to the patient. The minimal list of reportable incidental findings may be found in the ACMG March 2013 statement and related updates.<sup>28</sup>

## VII. WEB RESOURCES

### A. Specific Genetic Disorders

- Genetics Home Reference: <https://ghr.nlm.nih.gov/> (patient-friendly information)
- GeneReviews: <https://www.genereviews.org> (expert-authored clinical descriptions including diagnosis and management recommendations)

- National Organization for Rare Disorders: <https://www.rarediseases.org>
- Online Mendelian Inheritance in Man (OMIM): <https://omim.org> (curated primary literature, can be used to search for clinical features to build a differential)

### **B. Guidelines for Genetic Conditions**

- Newborn screening ACT Sheets and Confirmatory Algorithms: [https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/ACT\\_Sheets\\_and\\_Algorithms.aspx](https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/ACT_Sheets_and_Algorithms.aspx)

### **C. Molecular Testing Resources**

- Concert Genetics: <https://www.concertgenetics.com>
- Genetics Testing Registry: <https://www.ncbi.nlm.nih.gov/gtr>

### **D. Teratogen Evaluation**

- LactMed: Drugs and lactation database available through the U.S. National Library of Medicine. <https://www.ncbi.nlm.nih.gov/books/NBK501922/?report=classic>
- Patient-oriented information on exposures during pregnancy: <https://www.mothersbaby.org><sup>31</sup>

## **REFERENCES**

A complete list of references can be found online.

**VIII. ONLINE CONTENT****A. Patterns of Inheritance****1. Autosomal dominant:**

- a. Disease manifestation with a variant in one allele of a gene; the other allele is normal.
- b. It can appear in multiple generations.
- c. An affected individual has a 50% risk of passing on the variant with *each* pregnancy.

**2. Autosomal recessive:**

- a. Disease manifestation requiring variants in both alleles of the gene
- b. There can be multiple affected individuals in the same generation.
- c. An affected couple (each being a carrier) has a 25% chance of having an affected child, a 25% chance of having an *unaffected* child, and a 50% chance of producing a carrier of the condition with *each* pregnancy.

**3. X-linked:**

- a. Because females have two X chromosomes and males have only one X chromosome, males are more commonly and more severely affected by X-linked conditions. Females can be unaffected or have a spectrum of manifestations. In carrier females, lyonization is the process of silencing one X chromosome in each cell and “unfavorable lyonization” can result in a large proportion of cells that inactivated the normal X chromosome, and as a result clinical features are present.
- b. Females have a 50% chance of passing on an affected X to each male or female child. Males will pass on the affected X to all female children and will have *unaffected* sons.

**4. Mitochondrial:**

- a. Classically a matrilineal inheritance pattern, caused by mitochondrial DNA inherited from one’s mother that contributes to mitochondrial function. Sons will be affected but cannot pass the condition on to their offspring.
- b. There may be significant phenotypic variability due to “heteroplasmy,” in which the relative proportion of affected and unaffected mitochondria may change as cells divide.
- c. Mitochondrial disease is currently known to be caused either by variants in mitochondrial DNA or by recessive variants in nuclear genes that code for proteins that function in the mitochondria.

**5. Genomic imprinting and uniparental disomy:**

- a. The two alleles of a gene may be functionally equivalent but may be expressed or silenced depending on the parent of origin of the chromosome. This is due to the presence of epigenetic machinery influencing the expression of genes and resulting in different methylation patterns.

- b. Uniparental disomy is a rare occurrence in which offspring have inherited both copies of a chromosome from one parent. There are two types: (1) Uniparental isodisomy is an error in meiosis II, in which the offspring receives two identical copies of a chromosome from one parent. This can result in autosomal recessive disorders because any variant on one parental allele could be present on both alleles of their offspring. (2) Uniparental heterodisomy is an error in meiosis I, in which the offspring receives both copies of a single parent's chromosome. This can result in disorders of imprinting because only one parent contributed to the epigenetic pattern of that chromosome.

## REFERENCES

1. Hoffman GF, Zschocke J, Nyhan WL. *Inherited Metabolic Diseases: A Clinical Approach*. 2nd ed. Springer; 2017.
2. Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. *Pediatrics*. 1998;102(6):E69.
3. Zschocke J, Hoffman GF. *Vademecum Metabolicum*. 5th ed. Milupa Metabolics; 2021.
4. Blau N, Duran M, Gibson K, et al. *Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Disease*. Springer; 2014.
5. Saudubray JM, Baumgartner MR, Garcia-Cazorla A, et al. *Inborn Metabolic Diseases: Diagnosis and Treatment*. 7th ed. Springer; 2022.
6. Sarafoglou K, Hoffman G, Roth K. *Pediatric Endocrinology and Inborn Errors of Metabolism*. 2nd ed. McGraw-Hill; 2017.
7. Seidel HM, Rosenstein B, Pathak A, et al. *Primary Care of the Newborn*. 4th ed. Mosby; 2006.
8. Cox GF. Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy. *Prog Pediatr Cardiol*. 2007;24(1):15–25.
9. Koenig MK, Emrick L, Karau A, et al. Recommendations for the management of strokelike episodes in patients with mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes. *JAMA Neurol*. 2016;73(5):591–594.
10. Van Hove, J.L.K., Coughlin, C., II, Swanson, M., et al. Nonketotic Hyperglycinemia. 2002 Nov 14 [Updated 2019 May 23]. In: Adam, M.P., Everman, D.B., Mirzaa, G.M., et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1357/>
11. Jones KL, Jones MC, del Campo M. *Smith's Recognizable Patterns of Human Malformation*. 8th ed. Saunders; 2021.
12. Gripp KW, Slavotinek AM, Hall JG, et al. *Handbook of Physical Measurements*. 3rd ed. Oxford University Press; 2013.
13. Saul RA. *Medical Genetics in Pediatric Practice*. American Academy of Pediatrics; 2013.
14. Firth HV, Hurst JA. *Oxford Desk Reference: Clinical Genetics and Genomics*. 2nd ed. Oxford University Press; 2017.
15. Smith T, Bodurtha J, Hodgson N, et al. *Family matters—dealing with DNA Legacies: Integrating Genetics, Genetic Counseling and Hospice and Palliative Care (TH342)*. AAHPM Abstracts; 2015.

16. Trotter TL, Martin HM. Family history in pediatric primary care. *Pediatrics*. 2007;120(suppl 2):S60–S65.
17. Hoyme HE. Minor anomalies: diagnostic clues to aberrant human morphogenesis. *Genetica*. 1993;89:307–315.
18. Kohli SS, Kohli VS. A comprehensive review of the genetic basis of cleft lip and palate. *J Oral Maxillofac Pathol*. 2012;16(1):64–72.
19. Jongmans MC, Loeffen JL, Waander E, et al. Recognition of genetic predisposition in pediatric cancer patients: an easy-to-use selection tool. *Eur J Med Genet*. 2016;59(3):116–125.
20. Bassett, A.S., McDonald-McGim, D.M., Derriendt, K., et al. Practical guidelines for managing patients with 22q11.2 deletion syndrome. *J Pediatr*. 2011;159(2):332–339.
21. Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. *Prader-Willi Syndrome*; 1998. Last update 2017. GeneReviews. <http://www.ncbi.nlm.nih.gov/books/NBK1330/>
22. Dagli AI, Mathews J, Williams CA. *Angelman Syndrome*; 1998. Last update 2017. GeneReviews. <http://www.ncbi.nlm.nih.gov/books/NBK1144/>
23. Christodoulou J, Gladys H. *MECP2-Related Disorders*; 2001. Last update 2019. GeneReviews. <http://www.ncbi.nlm.nih.gov/books/NBK1497/>
24. Dietz H. *FBN-1 Related Marfan Syndrome*; 2001. Last update 2017. GeneReviews. <https://www.ncbi.nlm.nih.gov/books/NBK1335/>
25. Marc Dante KJ, Kliegman RM, Schuh A. *Nelson Essentials of Pediatrics*. 9th ed. Elsevier; 2022.
26. American Academy of Pediatrics, Committee on Bioethics. Ethical issues with genetic testing in pediatrics. *Pediatrics*. 2001;107(6):1451–1455.
27. The American Society of Human Genetics Social Issues subcommittee on familial disclosure: professional disclosure of familial genetic information. *Am J Hum Genet*. 1998;62:474–483.
28. Green RC, Berg JS, Grody WW, et al. American College of Medical Genetics and Genomics (ACMG) recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet Med*. 2013;15(7):565–574.
29. Nussbaum RL, McInnes RR, Willard HF. *Thompson & Thompson Genetics in Medicine*. 8th ed. Saunders; 2015.
30. Boyle RJ. Effects of certain prenatal drugs on the fetus and newborn. *Pediatr Rev*. 2002;23(1):17–24.
31. Organization of Teratology Information Specialists. *Fact Sheets*; 2022. <https://www.mothersbaby.org>
32. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am J Hum Genet*. 2010;86:749–764.
33. Prasun, P., LoPiccolo, M.K., Ginevic, I. Long-chain hydroxyacyl-CoA dehydrogenase deficiency/trifunctional protein deficiency. 2022. GeneReviews. <https://www.ncbi.nlm.nih.gov/books/NBK583531/>.
34. El-Hattab AW, Almannai M, Scaglia F. *MELAS*; 2001. Last update 2018. GeneReviews. <https://www.ncbi.nlm.nih.gov/books/NBK1233/>

# Chapter 14

## Hematology

Joan Park, MD

 See additional content online.

 **Audio Case File 14.1** Hemophilia/emicizumab

### I. ANEMIA

#### A. Screening for Anemia

1. The American Academy of Pediatrics (AAP) recommends screening between 9 and 12 months with a repeat level in 6 months.
2. Screen yearly in high-risk children: history of prematurity or low birth weight, exposure to lead, exclusive breastfeeding without supplemental iron beyond 4 months, diet without iron-fortified cereals or foods naturally rich in iron, feeding problems, poor growth, inadequate nutrition<sup>1</sup>

#### B. Definition of Anemia


1. Anemia is defined as a reduction in hemoglobin (Hb) two standard deviations below the mean, based on age-specific norms.
2. See [Table 14.1](#) at the end of the chapter for age-specific blood cell indices.

#### C. Causes of Anemia

1. See [Fig. 14.1](#) for approach to anemia based on red blood cell (RBC) production, as measured by reticulocyte count and cell size. Note that normal ranges for Hb and mean corpuscular volume (MCV) are age dependent.
2. See [Tables 14.2 and 14.3](#) for more details regarding specific causes of nonhemolytic and hemolytic anemia.

#### D. Evaluation of Anemia

1. Useful equations in the evaluation of anemia:
  - a. **Mentzer index<sup>2</sup> = MCV/RBC**
    - (1) Index >13 suggests iron deficiency anemia (IDA).
    - (2) Index <13 suggests thalassemia trait.
  - b. **Reticulocyte index = % reticulocytes × patient hematocrit/normal hematocrit<sup>3</sup>**
    - (1) >2 is indicative of increased RBC production in appropriate response to anemia.
    - (2) <2 is evidence of hypoproliferative anemia.
2. Other useful indices and tests
  - a. **RBC distribution width (RDW):**
    - (1) Normal RDW favors thalassemia but can also be elevated.



**FIGURE 14.1**

Approach to anemia. *AEDs*, Antiepileptic drugs; *BM*, bone marrow; *CKD*, chronic kidney disease; *DAT*, direct antiglobulin test; *EPO*, erythropoietin; *Fe*, iron; *G6PD*, glucose-6-phosphate dehydrogenase; *GI*, gastrointestinal; *HUS*, hemolytic uremic syndrome; *LDH*, lactate dehydrogenase; *MAHA*, microangiopathic hemolytic anemia; *MCV*, mean corpuscular volume; *MMA*, methylmalonic acid; *PBS*, peripheral blood smear; *PK*, pyruvate kinase; *SC*, sickle cell; *SD*, standard deviation; *TIBC*, total iron binding capacity; *TTP*, thrombotic thrombocytopenic purpura. (Data from Wang, M. Iron deficiency and other types of anemia in infants and children. *Am Fam Physician*. 2016;93[4]:270–278; Orkin SH, Nathan DG, Ginsburg D, et al. *Nathan and Oski's Hematology and Oncology of Infancy and Childhood*. 8th ed. Saunders; 2015.)




FIGURE 14.1, cont'd

- (2) Increased in IDA and sideroblastic anemia
- b. **Mean cell hemoglobin concentration (MCHC):**
- (1) Allows for classification of anemia as hypochromic, normochromic, or hyperchromic
  - (2) Low MCHC in iron deficiency and thalassemia
  - (3) Elevated MCHC and spherocytes in hereditary spherocytosis and hemolytic disease of the newborn
- c. **Serum ferritin:**
- (1) Reflects total body iron stores after 6 months of age

TABLE 14.2

## NONHEMOLYTIC ANEMIA

## NUTRITIONAL DEFICIENCY

Iron deficiency anemia (IDA)	Causes: Poor intake, malnutrition, GI bleed, menstrual cycle, malabsorption (with celiac disease, <i>Helicobacter pylori</i> , IBD) Ferritin falls first. Low MCHC, elevated transferrin receptor, low reticulocyte Hb content. Usually normocytic; microcytic if severe or prolonged
------------------------------	--

## UNDERLYING DISEASE

Anemia of chronic disease	Typically secondary to prolonged/frequent infections, autoimmune conditions (SLE, JIA, IBD), vasculitis <sup>3</sup> Low iron, TIBC, transferrin. High ferritin, CRP, and ESR
Renal disease	Impaired erythropoietin production
Endocrine disease	Hypothyroidism, hyperthyroidism, panhypopituitarism, hyperparathyroidism (primary or secondary)

## TOXINS

Lead poisoning	Lead interferes with iron absorption and inhibits heme synthesis enzymes.
----------------	---

## BONE MARROW

## Acquired Failure

Primary red cell aplasia	Autoimmune disorder with autoantibody-mediated disruption of erythroid cell differentiation Bone marrow shows absent erythroblasts but is otherwise normal.
Secondary red cell aplasia	Causes: Infection (parvovirus B19, EBV, CMV, HHV-6, HIV, hepatitis), radiation, medications, collagen vascular disease Variable RBC size, variable platelet and WBC counts Aspirate bone marrow for evidence of dysfunction, neoplasm, infection.
Aplastic anemia	Causes: Infection (parvovirus B19, EBV, CMV), radiation, chemical exposure (benzene), medications (alkylating agents, chloramphenicol, gold, NSAIDs), autoimmune conditions, idiopathic or immune mediated Hypocellular bone marrow and peripheral cytopenia Severe: ANC $<500 \times 10^6/L$ , platelet $<20,000/\mu L$ , reticulocyte count $<60,000 \times 10^6/L$
Vitamin B <sub>12</sub> or folate deficiency	Typically secondary to malabsorption or inadequate intake
Myelophthitic anemia	Bone marrow fibrosis and infiltration by abnormal tissue Primary myelofibrosis: Clonal myeloproliferative disease with extramedullary hematopoiesis, ineffective erythropoiesis, bone marrow fibrosis, hepatosplenomegaly Secondary causes: Lymphoma, multiple myeloma, infiltrating metastatic cancer, autoimmune disease, granulomatous disease (sarcoidosis), hypo-/hyperparathyroidism Presentation: Pancytopenia

## Inherited Causes with Pure Anemia

Diamond-Blackfan anemia	Autosomal dominant mutations in multiple ribosomal protein genes identified Presentation: Infant (average 3 months) with RBC aplasia (sometimes with neutropenia and/or thrombocytosis) and congenital anomalies (30%–47% of patients): short stature, craniofacial abnormalities (cleft lip), skeletal (triphalaengeal thumb, short stature), genitourinary, cardiac abnormalities
-------------------------	--

TABLE 14.2

## NONHEMOLYTIC ANEMIA—CONT'D

## Inherited Causes with Pancytopenia

Fanconi anemia	Autosomal recessive or X-linked disorder Presentation: Child with pancytopenia, radial and thumb abnormalities, renal anomalies, microcephaly, short stature, skin findings (hyperpigmentation, café-au-lait spots)
Shwachman-Diamond syndrome	Autosomal recessive mutation in <i>SBDS</i> gene Presentation: Young child with neutropenia ± thrombocytopenia and macrocytic anemia, exocrine pancreatic dysfunction, bony abnormalities
Dyskeratosis congenita	Mutation in gene encoding telomerase complex components Presentation: Anemia, thrombocytopenia, abnormal skin reticular hyperpigmentation, nail dystrophy, oral leukoplakia

*ANC*, Absolute neutrophil count; *CMV*, cytomegalovirus; *CRP*, C-reactive protein; *EBV*, Epstein Barr virus; *ESR*, erythrocyte sedimentation rate; *GI*, gastroenterology; *Hb*, hemoglobin; *HHV-6*, human herpesvirus 6; *HIV*, human immunodeficiency virus; *IBD*, inflammatory bowel disease; *JIA*, juvenile idiopathic arthritis; *MCHC*, mean corpuscular hemoglobin concentration; *NSAID*, nonsteroidal antiinflammatory drug; *RBC*, red blood cell; *SBDS*, Shwachman-Bodian-Diamond syndrome gene; *SLE*, systemic lupus erythematosus; *TIBC*, total iron binding capacity; *WBC*, white blood cell.

Data from Orkin SH, Nathan DG, Ginsburg D, et al. *Nathan and Oski's Hematology and Oncology of Infancy and Childhood*. 8th ed. Saunders; 2015. Camaschella, C. Iron-deficiency anemia. *N Engl J Med*. 2015;372(19):1832–1843. Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med*. 2005;352(10):1011–1023. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. *Blood Rev*. 2010;24(3):101–122. Hartung HD, Olson TS, Bessler M. Acquired aplastic anemia in children. *Pediatr Clin North Am*. 2013;60(6):1311–1336.

TABLE 14.3

## HEMOLYTIC ANEMIA

## EXTRINSIC HEMOLYTIC ANEMIA

## DAT –

Microangiopathic hemolytic anemia (MAHA): HUS, TTP, DIC	Anemia due to RBC shearing with passage through microthrombi in microvasculature Diagnosis: Intravascular hemolysis, thrombocytopenia, schistocytes on peripheral smear
Hemoglobin disorders: Sickle cell disease, unstable hemoglobin	Denaturation of hemoglobin causes precipitation in RBC and reduces deformability. Diagnosis: Smear with Heinz bodies, bite or blister cells

## DAT +

Warm autoimmune hemolytic anemia	Diagnosis: Jaundice ± splenomegaly, +anti-IgG and/or +anti-C3 Treatment: Corticosteroids (first line; prednisone), rituximab, IVIG, and other immunosuppressants, splenectomy Transfuse for severe anemia with cardiovascular compromise (i.e., Hb <5 g/dL) or reticulocytopenia
Cold autoimmune hemolytic anemia	Diagnosis: Acrocyanosis, hemoglobinuria, +anti-IgM autoantibodies Treatment: Cold avoidance

Continued

TABLE 14.3

## HEMOLYTIC ANEMIA—CONT'D

Secondary autoimmune hemolytic anemia	Causes: Infections, <sup>a</sup> drug-associated, <sup>b</sup> malignancy (Hodgkin lymphoma), systemic lupus erythematosus, autoimmune lymphoproliferative syndrome, common variable immunodeficiency, posttransplant (stem cell or solid organ)
Transfusion reactions (ABO or Rh incompatibility)	See Table 14.19 for presentation of transfusion reactions.
<b>INTRINSIC HEMOLYTIC ANEMIA</b>	
<b>Membrane Disorders</b>	
Neonatal hemolytic disease	Maternal antibodies to incompatible fetal RBC antigens (Rh, A, B) cause hemolytic disease in utero and in neonatal period. Diagnosis: Mild anemia to hydrops fetalis, early jaundice Treatment: Intensive phototherapy, exchange transfusion
Hereditary spherocytosis	Inheritance: 75% AD. 25% spontaneous mutation or AR RBC membrane protein defect → membrane instability → RBC destruction via extravascular hemolysis Diagnosis: Family history with clinical suspicion and spherocytes on smear, osmotic fragility or EMA flow cytometry if unclear clinical picture Treatment: Folate supplementation if moderate-severe hemolysis, anticipatory guidance, splenectomy (for severe disease), cholecystectomy if needed for symptomatic cholelithiasis
Hereditary elliptocytosis	Inheritance: Typically AD Diagnosis: Elliptocytes on smear Treatment: Same as for hereditary spherocytosis
<b>Enzyme Deficiencies</b>	
G6PD deficiency	Inheritance: X-linked disorder Enzyme deficiency predisposes to intravascular hemolysis with oxidative stress (e.g., with infections/illness, fava beans, medications) Diagnosis: G6PD assay when well (may be falsely elevated immediately after hemolytic episode) Treatment: Avoid oxidative triggers, transfuse for severe anemia.
Pyruvate kinase (PK) deficiency	Inheritance: AR disorder of <i>PKLR</i> or <i>PKM</i> genes causes chronic hemolysis. Diagnosis: Measure PK activity in RBCs. Treatment: Transfuse if symptomatic. Consider splenectomy if severe transfusion-dependent anemia.

<sup>a</sup>Infections include EBV, CMV, mycoplasma, pneumococcus, parvovirus.<sup>b</sup>Causative drugs include penicillin, cephalosporins, quinine/quinidine, amphotericin B, NSAIDs, procainamide, IVIG.

ABO, Blood type; AD, autosomal dominant; AR, autosomal recessive; CMV, cytomegalovirus; DAT, direct antiglobulin test; DIC, disseminated intravascular coagulation; EBV, Epstein-Barr virus; EMA, eosin-5-maleimide; G6PD, glucose-6-phosphate dehydrogenase; Hb, hemoglobin; HUS, hemolytic uremic syndrome; Ig, immunoglobulin; IVIG, intravenous immunoglobulin; NSAID, nonsteroidal antiinflammatory drug; RBC, red blood cell; Rh, rhesus factor; TTP, thrombotic thrombocytopenic purpura.

Data from Noronha SA. Acquired and congenital hemolytic anemia. *Pediatr Rev.* 2016;37(6):235–246. Orkin SH, Nathan DG, Ginsburg D, et al. *Nathan and Oski's Hematology and Oncology of Infancy and Childhood.* 8th ed. Saunders; 2015.

- (2) It is the first value to fall in early iron deficiency and is elevated with inflammation or infection.
- d. **Coombs test<sup>4</sup>:**
- (1) Direct (direct antiglobulin testing [DAT]): Detects antibody/complement bound to patient's RBCs by mixing prepared nonspecific antihuman globulin with patient's blood. RBC agglutination = positive test
  - (2) Indirect (indirect antiglobulin testing): Detects antibodies to RBC antigens in patient's plasma by mixing reagent RBCs with patient's serum. RBC agglutination = positive test
- e. **Hemoglobin electrophoresis:**
- (1) Involves separation of Hb variants based on molecular charge and size. All positive sickle preparations and solubility tests for sickle Hb (e.g., Sickledex) should be confirmed with electrophoresis or isoelectric focusing (component of mandatory newborn screening in many states).
  - (2) See [Table 14.4](#) for neonatal Hb electrophoresis patterns.
  - (3) See [Fig. 14.2](#) for changes in Hb polypeptide over time in a normal fetus/infant.


**TABLE 14.4****NEONATAL HEMOGLOBIN ELECTROPHORESIS PATTERNS**

FA	Fetal Hb and adult normal Hb; the normal newborn pattern
FAV	Indicates presence of both HbF and HbA, but an anomalous band (V) is present that does not appear to be any of the common Hb variants
FAS	Indicates fetal Hb, adult normal HbA, and HbS, consistent with benign sickle cell trait
FS	Fetal and sickle HbS without detectable adult normal HbA. Consistent with clinically significant homozygous sickle Hb genotype (S/S) or sickle $\beta^0$ -thalassemia, with manifestations of sickle cell disease during childhood
FC <sup>a</sup>	Designates presence of HbC without adult normal HbA. Consistent with clinically significant homozygous HbC genotype (C/C), resulting in a mild hematologic disorder presenting during childhood
FSC	HbS and HbC present. This heterozygous condition could lead to manifestations of sickle cell disease during childhood.
FAC	HbC and adult normal HbA present, consistent with benign HbC trait
FSA	Heterozygous HbS/ $\beta^+$ -thalassemia, a clinically significant sickling disorder
F <sup>a</sup>	Fetal HbF is present without adult normal HbA. May indicate delayed appearance of HbA, but is also consistent with homozygous $\beta$ -thalassemia major or homozygous hereditary persistence of fetal HbF
FV <sup>a</sup>	Fetal HbF and an anomalous Hb variant (V) are present.
AF	May indicate prior blood transfusion. Submit another filter paper blood specimen when infant is 4 months of age, at which time the transfused blood cells should have been cleared.

<sup>a</sup>Repeat blood specimen should be submitted to confirm original interpretation.

Hemoglobin variants are reported in order of decreasing abundance; for example, FA indicates more fetal than adult hemoglobin.

**NOTE:** HbA:  $\alpha_2\beta_2$ ; HbF:  $\alpha_2\gamma_2$ ; HbA<sub>2</sub>:  $\alpha_2\delta_2$ .



**FIGURE 14.2**

Neonatal hemoglobin electrophoresis patterns. (From Chandrakasan S, Kamat D. An overview of hemoglobinopathies and the interpretation of newborn screening results. *Pediatr Ann.* 2013;42[12]:502–508.)

f. **Blood smear interpretation**<sup>3</sup>

- (1) Howell-Jolly bodies = Impaired splenic function, postsplenectomy
- (2) Target cells = Hemoglobinopathies (HbSS, HbSC, HbC, thalassemias), liver disease, postsplenectomy
- (3) Bite cells, Heinz bodies = G6PD deficiency (during hemolysis)
- (4) Toxic granulation of neutrophils, bandemia, atypical lymphocytes = Infection
- (5) Pencil poikilocytes = IDA, thalassemia
- (6) Basophilic stippling = Lead poisoning, sideroblastic anemia
- (7) Pappenheimer bodies = Sideroblastic anemia
- (8) Hypersegmented neutrophils = Vitamin B<sub>12</sub>, folate deficiencies
- (9) Blasts = Leukemia, lymphoma
- (10) Schistocytes (RBC fragments) = Microangiopathic hemolytic anemia (MAHA), burns, valve hemolysis
- (11) Spherocytes = Autoimmune hemolytic anemia, hereditary spherocytosis, ABO incompatibility/hemolytic disease of the newborn
- (12) Elliptocytes = Hereditary elliptocytosis, severe IDA
- (13) Teardrop cells = Myelofibrosis (and other bone marrow infiltrating processes), thalassemia
- (14) Echinocytes (burr cells) = Frequent artifact finding; uremia, pyruvate kinase deficiency

- (15) Acanthocytes (spur cells) = Liver disease, abetalipoproteinemia, hypothyroidism, vitamin E deficiency, severe malnutrition
- (16) See [eFigs. 14.1 to 14.12](#) for examples of peripheral smears.


## E. Management of Anemia

### 1. Iron deficiency anemia


- a. Oral iron (ferrous sulfate)
  - (1) Empirically treat children with microcytic anemia and history of poor dietary iron.<sup>5</sup>
  - (2) In anemia of chronic disease, only use iron supplementation if evidence of absolute iron deficiency and ferritin <100 ng/mL.<sup>5</sup>
  - (3) After initiation of iron supplementation, expect reticulocyte count to increase within the first week with a 1 g/dL increase in Hb in 4 weeks (if severe anemia with Hb <9 g/dL, a response should be seen in 2 weeks).<sup>1</sup>
- b. Iron infusion (low-molecular-weight iron dextran<sup>6</sup> or iron sucrose<sup>7</sup>) is appropriate for children with iron malabsorption (PPI use, short bowel syndrome, primary malabsorption), poor response to oral iron therapy, inability to tolerate oral iron therapy, and hemodialysis-dependent patients receiving erythropoietin.

### 2. Sickle cell anemia


- a. **Etiology:** Caused by a genetic defect in  $\beta$ -globin that leads to HbS polymerization and RBC sickling with deoxygenation, leading to hemolysis, adherence to blood vessel endothelium, and vaso-occlusive ischemia.
- b. **Most common subtypes:** HbSS (sickle cell anemia) and HbS $\beta^0$  (sickle- $\beta^0$ -thalassemia) are most severe. HbSC (sickle-hemoglobin C disease) and HbS $\beta^+$  (sickle- $\beta^+$ -thalassemia) are often milder.
- c. **Diagnosis:** Often made on newborn screen with Hb electrophoresis. The sickle preparation and Sickledex are rapid tests that are positive in all sickle hemoglobinopathies. False-negative test results may be seen in neonates and other patients with a high percentage of fetal Hb.
- d. **Complications:** See [Table 14.5](#). A hematologist should be consulted.
- e. **Acute management of anemia in sickle cell disease<sup>8</sup>:**
  - (1) Baseline lab values including CBC, reticulocyte, hemoglobin electrophoresis (percent HbF), creatinine, BUN, urinalysis, liver function tests, fractionated bilirubin should be collected to compare with those during acute illness.
  - (2) RBC exchange transfusions: Indicated for patients with stroke, acute chest syndrome (ACS) with rapid progression or clinical deterioration, and multisystem organ failure. May be indicated for hepatic sequestration, intrahepatic cholestasis, and refractory priapism. Also indicated for children with prior stroke or transcranial Doppler reading >200 cm/sec.<sup>8</sup> Replace with HbS-negative cells. Follow Hct carefully with goal Hct <30% to avoid hyperviscosity.<sup>9</sup>

**eFIGURE 14.1**


Normal smear. Round red blood cells with central pallor about one-third of the cell's diameter, scattered platelets, occasional white blood cells.

**eFIGURE 14.2**


Iron deficiency. Hypochromic/microcytic red blood cells, poikilocytosis, plentiful platelets, occasional ovalocytes, and target cells.

**eFIGURE 14.3**


Spherocytosis. Microspherocytes (densely stained red blood cells with no central pallor) are a hallmark.

**eFIGURE 14.4**


Basophilic stippling as a result of precipitated RNA throughout the cell; seen with heavy metal intoxication, thalassemia, iron deficiency, and other states of ineffective erythropoiesis.

**eFIGURE 14.5**


Sickle cell disease (hemoglobin SS disease). Sickled cells, target cells, hypochromia, poikilocytosis, Howell–Jolly bodies; nucleated red blood cells common (not shown).

**eFIGURE 14.6**


Sickle-hemoglobin C disease (hemoglobin SC disease). Target cells, boat cells, poikilocytosis; sickle forms rarely seen.

**eFIGURE 14.7**


Microangiopathic hemolytic anemia. Red blood cell fragments, anisocytosis, polychromasia, decreased platelets.

**eFIGURE 14.8**


Toxic granulations. Prominent dark blue primary granules; commonly seen with infection and other toxic states (e.g., Kawasaki disease).

**eFIGURE 14.9**


Howell–Jolly body. Small, dense nuclear remnant in a red blood cell; suggests splenic dysfunction or asplenia.

**eFIGURE 14.10**

Leukemic blasts showing large nucleus-to-cytoplasm ratio.

**eFIGURE 14.11**

Polychromatophilia. Diffusely basophilic because of RNA staining; seen with early release of reticulocytes from the marrow.

**eFIGURE 14.12**

Malaria. Intraerythrocytic parasites.

TABLE 14.5

## SICKLE CELL DISEASE COMPLICATIONS

Complication	Presentation	Additional Testing	Disposition/Treatment
Fever	>101°F or 38.3°C	Blood cultures CXR Blood and urine cultures Throat and CSF cultures, if indicated	Admit if ill-appearing, temperature $\geq 40^{\circ}\text{C}$ , infiltrate on CXR or abnormal $\text{SpO}_2$ , WBCs $>30,000/\mu\text{L}$ or $<5,000/\mu\text{L}$ , platelets $<100,000/\mu\text{L}$ , Hb $<5$ g/dL, history of sepsis. Antibiotics: Ceftriaxone, add IV Vancomycin if meningitis suspected or if severe illness. Clindamycin or levofloxacin if cephalosporin allergy. <sup>47</sup> Consider additional disease-specific coverage. If outpatient, return in 24 hr for second ceftriaxone dose.
Vaso-occlusive crisis	Dactylitis in $<2$ years old; unifocal or multifocal pain in $>2$ years old	Type and screen	Admit if signs of complications or pain not managed in outpatient setting. Recommendations for home pain control: <ul style="list-style-type: none"> <li>• Mild-moderate pain: NSAIDs</li> <li>• Moderate-severe pain: Oxycodone, morphine, hydrocodone</li> </ul> Recommendations for emergency department or inpatient pain control: <ul style="list-style-type: none"> <li>• Use IV opioids (morphine, hydromorphone). Use fentanyl if renal or hepatic dysfunction.</li> <li>• Use PCA and provide as-needed doses for breakthrough pain. Schedule pain medication if not using PCA.<sup>35</sup></li> <li>• Ketamine may be appropriate if poor response to opioids.<sup>36</sup></li> </ul> IV fluids as needed for dehydration. Evidence-based guidelines regarding amount or type of fluids are lacking. <sup>37</sup> Use incentive spirometry to reduce risk of ACS. Avoid transfusion unless other indication.
Acute chest syndrome	Fever, cough, chest pain, respiratory distress, hypoxia + new pulmonary infiltrate	CXR Type and screen Blood cultures	Admit IV antibiotics: IV cephalosporin + oral macrolide <sup>32</sup> $\text{O}_2$ as needed for goal $\text{SpO}_2 >95\%$ , incentive spirometry Analgesia, IV fluids (see above) Simple transfusion or partial exchange for moderate illness High-dose dexamethasone use is controversial. <sup>33</sup>

Splenic sequestration	Acutely enlarged spleen, Hb $\geq 2$ g/dL below baseline	Type and screen	Admit for serial abdominal exams, IV fluid resuscitation. Simple transfusion if severe anemia. <sup>a</sup>
Aplastic crisis	Acute illness (often viral, commonly parvovirus B19) + Hb < baseline, low reticulocyte count	Type and screen Parvovirus serology and PCR	Admit to isolated bed. IV fluids Simple transfusion with RBCs
Stroke	Focal neurologic signs May be precipitated by ACS, parvovirus, acute anemic events	MRI, TCD to detect increased velocities with stenosis	Emergency exchange transfusion preferable to simple transfusion, if possible <sup>39</sup> Chronic transfusion to maintain sickle Hb to <30% in patients with abnormal TCD US findings or history of stroke
Acute renal failure	Hematuria, proteinuria, hypertension	Urine spot protein, 24-hr collection	Monitor renal function. Avoid nephrotoxic drugs/contrast. Consult nephrology and initiate replacement therapy (hemodialysis) if necessary.
Avascular necrosis	Pain at site that worsens with activity, reduced range of motion. Hip most commonly involved, then shoulder and other joints	XR of affected joint, MRI if necessary	Analgesics, physical therapy Consult orthopedic surgery for assessment for possible decompression.
Priapism	Sustained painful erection lasting >4 hr	Not necessary	Oral and/or IV analgesia (as per VOC recommendations) Hydration with oral or IV fluids Consider supplemental oxygen. Consult urology for possible aspiration and irrigation of corpus cavernosum (if does not self-resolve).

<sup>a</sup>Be cautious with transfused volume and use 5- to 10-mL/kg aliquots if hemodynamically stable as autotransfusion from spleen can cause rebound increase in Hb and viscosity.

ACS, Acute chest syndrome; CSF, cerebrospinal fluid; CXR, chest x-ray; Hb, hemoglobin; IV, intravenous; MRI, magnetic resonance imaging; NSAIDs, nonsteroidal antiinflammatory drugs; PCA, patient-controlled analgesia; PCR, polymerase chain reaction test; PRN, as needed; RBCs, red blood cells; SpO<sub>2</sub>, peripheral oxygen saturation; TCD, transcranial Doppler; US = ultrasound; VOC, vaso-occlusive crisis; WBC, white blood cell; XR, X-ray. Data from National Heart, Lung, and Blood Institute. *Evidence-Based Management of Sickle Cell Disease: Expert Panel Report*, 2014. National Heart, Lung, and Blood Institute; 2014.

(3) Do not transfuse for asymptomatic anemia unless concern for aplastic crisis (low reticulocyte count).

f. **Chronic management and health maintenance**<sup>8</sup>: See Table 14.6.

Ongoing consultation and clinical involvement with a pediatric hematologist and/or sickle cell program are essential. Bone marrow transplant is the only current curative therapy.

### 3. **Thalassemia**

a. **Etiology**: Defects in  $\alpha$ - or  $\beta$ -globin production lead to precipitation of excess chains, causing ineffective erythropoiesis and shortened survival of mature RBCs.

b.  **$\alpha$ -Thalassemia**:

(1) Silent carriers ( $\alpha\text{--}/\alpha\alpha$ ): Not anemic; Hb electrophoresis usually normal

(2)  $\alpha$ -Thalassemia trait ( $\alpha\text{--}/\alpha\text{--}$ ) or ( $\alpha\alpha/\text{--}$ ): Causes mild microcytosis with or without mild anemia from birth; Hb electrophoresis usually normal. Hb Barts can be seen transiently in infancy (e.g., on state newborn screens) in patients with  $\alpha$ -thalassemia trait.

(3) HbH disease ( $\beta_4$ ) ( $\alpha\text{--}/\text{--}$ ): Causes mild to moderate anemia from birth; higher levels of Hb Barts seen on newborn screen with transition to HbH ( $\beta$ -tetramer) on subsequent electrophoresis.

(4) Hb Barts/hydrops fetalis ( $\text{--}/\text{--}$ ): Hb Barts ( $\gamma_4$ ) cannot deliver oxygen; usually fatal in utero or in neonatal period.

c.  **$\beta$ -Thalassemia**: Ineffective erythropoiesis is more severe in  $\beta$ -thalassemia than  $\alpha$ -thalassemia. Patients often develop more severe iron overload from increased enteral absorption and transfusions. Adult Hb electrophoresis with decreased Hb A, increased Hb A<sub>2</sub>, and increased HbF.

(1) Thalassemia trait/thalassemia minor ( $\beta/\beta+$ ) or ( $\beta/\beta 0$ ): Mildly decreased  $\beta$ -globin production. Usually asymptomatic with mild anemia.

(2) Thalassemia intermedia ( $\beta+/\beta+$ ): Markedly decreased  $\beta$ -globin production. Presents by 2 years of age with moderate compensated anemia (Hb 7 to 10 g/dL). Wide variability in presentation that may include features noted in thalassemia major.

(3) Thalassemia major/Cooley anemia ( $\beta 0/\beta 0$ ,  $\beta+/\beta 0$ , or  $\beta+/\beta+$ ): Minimal to no  $\beta$ -globin production. Presence of anemia within first 6 months of life requiring regular transfusions.

Overstimulation of bone marrow, ineffective erythropoiesis, and iron overload results in jaundice, growth failure, hypersplenism, gallstones, skeletal abnormalities, liver cirrhosis, and cardiac impairment.

d. **Management**<sup>10</sup>

(1) Patients with thalassemia major are transfusion dependent. Patients with thalassemia intermedia may need occasional transfusions.

TABLE 14.6

## SICKLE CELL DISEASE HEALTH MAINTENANCE

Medications	Penicillin	Twice daily in children with HbSS and HbS $\beta$ 0 under 5 years old <sup>a</sup>
	Hydroxyurea <sup>40</sup>	Offer in children with HbSS or HbS $\beta$ 0 >9 months. <sup>b</sup> Treatment goal: HbF >20% <sup>41</sup> Maximum dose parameters: ANC $\geq$ 2000–4000/ $\mu$ L, Hb $\geq$ 8 g/dL without transfusion, platelet $\geq$ 80,000/ $\mu$ L, absolute reticulocyte count $\geq$ 80–100,000/ $\mu$ L Continue in acute hospitalization or illness. Discontinue in pregnant and breastfeeding women.
	Hormonal contraception	Progestin-only contraception (pills, injection, implant), levonorgestrel IUDs, and barrier methods preferred over estrogen-containing methods due to increased risk of blood clots
Immunizations <sup>42</sup>	Pneumococcal vaccine	13-valent conjugate vaccine per routine childhood schedule. 23-valent polysaccharide vaccine at 2 years old with second dose 5 years later
	Meningococcal vaccine	Give MenACWY-CRM (Menveo) at 2, 4, 6, 12 months. If over 2 years old, administer 2-dose series of MenACWY-CRM or MenACWY-D. Give meningococcal B vaccine in patients 10 years or older.
	Influenza vaccine	Yearly starting at 6 months Give to all household members and close contacts.
Imaging and labs	Transcranial doppler	Screen annually from 2 to 16 years old in HbSS or HbS $\beta$ <sup>0</sup> Not necessary to screen in HbS $\beta$ + or HbSC
	Spot urine test	Screen for proteinuria by age 10; repeat annually. Refer those with microalbuminuria (>300 mg in 24 hr) to nephrologist.
Other	Ophthalmology	Annual exam starting at age 10 to evaluate for retinopathy

<sup>a</sup>Prophylaxis may be discontinued by age 5 years if patient has had no prior severe pneumococcal infections or splenectomy and has documented pneumococcal vaccinations, including second 23-valent vaccination. May be continued based on family preference. May be considered for children with HbSC/HbS $\beta$ +, especially after splenectomy.<sup>8,34</sup> Practice patterns vary.

<sup>b</sup>Increases levels of fetal Hb and decreases HbS polymerization in cells. Has been shown to significantly decrease episodes of vaso-occlusive crises, dactylitis, acute chest syndrome, number of transfusions, and hospitalizations. May decrease mortality in adults. Consider in HbSC/HbS $\beta$ + if recurrent sickle cell-associated pain interfering with daily activities or quality of life.<sup>40,43</sup>

ANC, Absolute neutrophil count; HbF, hemoglobin F level; HbS $\beta$ +, sickle cell beta thalassemia disease; HbSS, Homozygous sickle cell disease; HbSC, hemoglobin SC disease; IUD, intrauterine device.

Data from National Heart, Lung, and Blood Institute. *Evidence-Based Management of Sickle Cell Disease: Expert Panel Report*, 2014. National Heart, Lung, and Blood Institute; 2014. <http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines/>

- (2) Transfuse every 3 to 5 weeks to maintain Hb >9 to 10.5 mg/dL.
- (3) Avoid hypertransfusion to Hb >14 to 15 g/dL due to risk of hyperviscosity-related symptoms, including stroke.
- (4) Treat iron overload with chelation (deferasirox or deferiprone PO, deferoxamine SQ or rarely IV), which should be initiated in thalassemia major after 10 to 20 transfusions or when ferritin >1000 µg/L.
- (5) Bone marrow transplant is curative.

## II. ERYTHROCYTOSIS<sup>12,48</sup>

### A. Definition of Erythrocytosis

1. Erythrocytosis is defined as number of RBCs (cells per volume) two standard deviations above the mean, based on age-specific norms.
2. See [Table 14.1](#) at the end of the chapter for age-specific blood cell indices.
  - a. Relative erythrocytosis: A reduction in plasma volume without an increase in RBC mass (e.g., dehydration due to diuretic use, vomiting, or diarrhea)
  - b. Absolute erythrocytosis: An increase in RBC mass

### B. Causes of Erythrocytosis

1. **Primary erythrocytosis:** Independently increased production of RBC (e.g., familial erythrocytosis, polycythemia vera)
2. **Secondary erythrocytosis:** Increased erythropoietin (EPO), with resultant increased RBC production
  - a. Cardiopulmonary disease (e.g., congenital heart disease, chronic pulmonary disease, obstructive sleep apnea): Systemic hypoxia triggers increased EPO.
  - b. Renal disease (e.g., renal artery stenosis): Kidneys sense less oxygen and produce EPO. Also seen after renal transplant.
  - c. Tumors (e.g., renal, hepatic, CNS, or endocrine): Autonomous EPO synthesis by the tumor.
  - d. Exposure to androgens (testosterone), anabolic steroids
  - e. Congenital causes

### C. Evaluation of Erythrocytosis

1. CBC ± blood smear should be obtained to evaluate RBC morphology and concurrent presence of leukocyte and platelet abnormalities.
2. Measure serum EPO, electrolytes, kidney and liver function tests, and urinalysis.

### D. Management of Erythrocytosis

1. Treatment is directed at the underlying cause (e.g., hydration, addressing cardiopulmonary process) and consideration of hematocrit reduction (e.g. phlebotomy or partial exchange transfusion). Discuss use of a cytoreductive agent with a hematologist.
2. If patient has a stroke or chest pain, emergent hydration and/or phlebotomy is indicated.
3. Symptoms such as pruritus, erythromelalgia, bleeding, and gout should be managed accordingly.

### III. NEUTROPENIA

#### A. Definition of Neutropenia

1. Neutropenia is defined as an absolute neutrophil count (ANC)  $<1500/\mu\text{L}$ . Severe neutropenia is defined as an ANC  $<500/\mu\text{L}$ .
2. See [Table 14.7](#) at the end of the chapter for age-specific leukocyte differentials.
3. Repeat CBC 2 to 3 weeks later to determine if transient (e.g., secondary to a medication, infection) or persistent.<sup>11</sup>

#### B. Causes and Evaluation of Neutropenia<sup>11</sup>

1. CBC  $\pm$  blood smear should be obtained to evaluate neutrophil morphology and concurrent presence of anemia or thrombocytopenia.
2. If pancytopenic, consider bone marrow aspiration and biopsy with cytogenetics.
3. If persistent neutropenia for more than 2 to 4 weeks, consider further workup based on potential etiologies ([Table 14.8](#)).

#### C. Management of Neutropenia

##### 1. Additional diagnostic testing<sup>12</sup>:

- a. Repeat CBC 2 $\times$ /week for 6 to 8 weeks for cyclic neutropenia.
- b. Reticulocyte index with anemia to differentiate between destructive processes and marrow failure
- c. Blood smear for morphologic abnormalities
- d. Immunologic testing (Coombs test, antineutrophil and antiplatelet antibodies) for autoimmune or alloimmune processes
- e. IgG, IgA, IgM for immunodeficiency

##### 2. Treatment:

- a. Myeloid-specific cytokine granulocyte colony-stimulating factor (G-CSF; filgrastim)
  - (1) Indications for continuous use: Severe congenital neutropenia, cyclic neutropenia, glycogen storage disease 1b, bone marrow failure (e.g., aplastic anemia, Shwachman Diamond-Oski syndrome)<sup>12,13</sup>
  - (2) Indications for intermittent use: Life-threatening infection or history of recurrent or serious infections in patients with neutropenia<sup>12</sup>
  - (3) Side effects: Bone pain, headache, rash
- b. Stem cell transplant: Indicated for bone marrow failure (e.g., Fanconi anemia), poor response to G-CSF, severe congenital neutropenia with high risk of myelodysplasia or acute myeloid leukemia<sup>12</sup>

##### 3. Complications: See [Chapter 22](#) for management of neutropenic fever and typhlitis.

##### 4. Anticipatory guidance<sup>11</sup>:

- a. Maintain good oral hygiene and skin care to prevent local infections.
- b. Avoid rectal temperatures, rectal examinations, or rectal medications due to risk of mucosal trauma and bacteremia.
- c. No live or attenuated-live vaccines for patients with impaired T-/B-lymphocyte function.

TABLE 14.8

## CAUSES OF NEUTROPENIA

	Cause	Mechanism	Presentation
<b>ACQUIRED</b>			
Infections	Viruses (EBV, CMV, parvovirus, HHV-6, HIV, viral hepatitis) Bacteria (typhoid fever, Brucellosis) Protozoa ( <i>Leishmania</i> , malaria), Rickettsial infections, etc.	Bone marrow suppression, viral-induced immune neutropenia, redistribution to marginated pools	Occurs early in illness, persists 3–8 days and resolves spontaneously and/or with effective treatment of underlying illness
Medications	Many: Sulfasalazine, antipsychotics (clozapine, phenothiazines), thionamides, antimicrobials (TMP/SMX)	Direct marrow suppression (more common) or drug-induced immune-mediated destruction	Hypersensitivity reaction: fever, lymphadenopathy, rash. May have +ANA
Nutritional	Vitamin B <sub>12</sub> deficiency Folic acid deficiency Copper deficiency	Ineffective hematopoiesis due to impaired DNA processing and nuclear maturation (with B <sub>12</sub> /folate deficiency)	Mostly seen in chronically ill children, especially with malabsorption Hypersegmented neutrophils, megaloblastic anemia with B <sub>12</sub> /folate deficiency High MMA and HcY in B <sub>12</sub> deficiency vs. high HcY in folate deficiency
Hypersplenism	Inflammation, neoplasm, storage disorder, hemolytic anemia	Sequestration of WBCs in spleen	Concurrent anemia, thrombocytopenia. Rarely associated with infections

Autoimmune	Neonatal alloimmune neutropenia	Transfer of maternal IgG alloantibodies against fetus neutrophil antigens that were produced in response to fetal cells in maternal circulation	Severe neutropenia with fever, infection. Transient, resolves after 6–8 weeks
	Primary autoimmune neutropenia	Antineutrophil antibodies cross-react with antigen on neutrophil surface resulting in neutrophil destruction	Typically child 5–15 months old without recurrent infections despite severe neutropenia. +ANA. Marrow with myeloid hyperplasia and normal to increased mature neutrophils
	Secondary autoimmune neutropenia	Secondary to systemic disease: Systemic lupus erythematosus, Evans syndrome, rheumatoid arthritis/ Felty syndrome, systemic sclerosis, infections (HIV, EBV)	Presents with signs/symptoms of systemic autoimmune disease
	Pure white cell aplasia	Associated with thymoma, drug reactions, antiglomerular basement membrane antibody disease	At risk of severe, recurrent infections. Disappearance of granulocytopoietic tissue from bone marrow. +Antibodies (e.g., GM-CFU inhibitory activity)
Acquired bone marrow disorders	Leukemia, lymphoma, solid tumor infiltration, myelofibrosis, granulomatous infections, aplastic anemia	Impaired production of all cell lines due to bone marrow infiltration	Typically associated with anemia and/or thrombocytopenia. Bone marrow biopsy diagnostic
<b>INHERITED<sup>a</sup></b>			
Severe congenital neutropenia	Severe congenital neutropenia	AD mutation in <i>ELANE</i> or <i>GFI1</i> genes results in rapid apoptosis of myeloid precursors, arrest at promyelocyte development stage Risk of myelodysplastic syndrome and acute myelogenous leukemia	Recurrent infections: Mouth ulcers, gingivitis, otitis media, respiratory infections, skin cellulitis, abscesses Often with oncocytosis, eosinophilia, anemia, thrombocytosis Bone marrow: myeloid maturation arrest, normal/ increased promyelocytes

TABLE 14.8

## CAUSES OF NEUTROPENIA—CONT'D

Cause	Mechanism	Presentation
Kostmann syndrome	Severe form of SCN AR mutation in <i>HAX1</i> gene results in absent myeloid progenitors	Recurrent infections as above typically with monocytosis, eosinophilia
Cyclic neutropenia	AD mutation in <i>ELANE</i> gene	Periodic ~21-day cycles of neutropenia, typically associated with fever, oral ulcerations, ± gingivitis, pharyngitis, skin infections
Benign ethnic neutropenia	<i>DARC</i> gene polymorphism reducing Duffy antigen expression	Mild neutropenia in patient of West Indian, Yemenite, African, Greek, or Arab descent without increased infection incidence or severity
Bone marrow failure syndromes	Fanconi anemia Diamond-Blackfan anemia	See Table 14.2 Pancytopenia

<sup>a</sup>This is not an exhaustive list of all inherited causes of neutropenia.

*AD*, Autosomal dominant; *ANA*, antinuclear antibody; *AR*, autosomal recessive; *CMV*, cytomegalovirus; *DARC*, Duffy antigen/chemokine receptor; *EBV*, Epstein-Barr virus; *GM-CFU*, granulocyte-macrophage colony-forming unit; *HcY*, homocysteine; *HHV-6*, human herpesvirus 6; *HIV*, human immunodeficiency virus; *MMA*, methylmalonic acid; *SCN*, severe congenital neutropenia; *TMP/SMX*, trimethoprim-sulfamethoxazole; *WBC*, white blood cell. Data from Segel GB, Halterman JS. Neutropenia in pediatric practice. *Pediatr Rev.* 2008;29(1):12–24. Moerdler S, LaTuga MS. Neonatal neutropenia. *NeoReviews.* 2018;19(1):e22–e28. Orkin SH, Nathan DG, Ginsburg D, et al. *Nathan and Oski's Hematology and Oncology of Infancy and Childhood.* 8th ed. Saunders; 2015.

- d. Otherwise follow usual vaccination schedule.
- e. If fever  $>38.4^{\circ}\text{C}$ , seek emergent care for CBC, blood culture, and empiric antibiotics.
- f. Children with mild-moderate neutropenia can attend school/daycare, if they avoid obviously ill children.

## IV. LEUKOCYTOSIS<sup>12</sup>

### A. Definition of Leukocytosis

1. Leukocytosis is defined as number of WBCs (cells per volume) two standard deviations above mean, based on age-specific norms.
2. See [Chapter 22](#) for complications from hyperleukocytosis.
3. See [Table 14.7](#) at the end of the chapter for age-specific leukocyte differentials.

### B. Causes of Neutrophilia

1. Normal variation: Siblings and parents may also have neutrophilia.
2. Leukemoid reactions:
  - a. Infection (bacteria, some viruses): May see increased neutrophil granule size, Döhle bodies, cytoplasmic vacuoles in neutrophils on blood smear
  - b. Chronic inflammation (e.g. juvenile idiopathic arthritis, Kawasaki disease)
  - c. Acute inflammation (e.g. stress, burns, massive trauma)
  - d. Medications (e.g. catecholamines, glucocorticoids, myeloid growth factors, lithium, cyclophosphamide): Neutrophilia resolves soon after medication is stopped.
  - e. Endocrine abnormalities (e.g. thyroid storm, hypercortisolism)
  - f. Nonhematologic malignancy
  - g. Genetic disorders (e.g. leukocyte adhesion deficiency, Down syndrome)

### C. Causes of Eosinophilia

1. Premature birth: Eosinophilia may be seen in about 75% of low-birth-weight infants.
2. Infection (e.g. parasitic infections, infectious mononucleosis)
3. Allergic disorders (e.g. sensitization to mites and fungal infections, drug reaction, atopic dermatitis)
4. Pulmonary disorders (e.g. asthma, Loeffler syndrome, tropical pulmonary eosinophilia, polyarteritis nodosa, sarcoidosis)
5. Neoplasms
6. Other: Vascular occlusion of kidney, eosinophilic gastroenteritis, Addison disease

### D. Causes of Monocytosis

1. Occasionally reported with tuberculosis, syphilis, subacute bacterial endocarditis. Noted early in course of infection and again on recovery, particularly if associated with granulocytopenia
2. Malignancy (e.g. juvenile myelomonocytic leukemia, lymphoma)

### E. Causes of Basophilia

1. Allergic responses (along with eosinophilia), states of chronic inflammation (e.g. rheumatoid arthritis)
2. Has been reported in some chronic and acute infections

## V. THROMBOCYTOPENIA AND IMPAIRED PLATELET FUNCTION

### A. Definition of Thrombocytopenia

1. Defined as platelet count  $<150,000/\mu\text{L}$
2. See [Table 14.1](#) for age-specific values.

### B. Bleeding Risk With Thrombocytopenia

1. Risk of clinically significant bleeding is related to both platelet function and number. Unlikely with platelet counts  $>30,000/\mu\text{L}$  in the absence of other complicating factors<sup>14</sup>
2. Risk of severe bleeding (CNS hemorrhage, gross hematuria, melena/hematochezia, hematemesis) increases with platelet counts  $<10,000/\mu\text{L}$ .<sup>14</sup>

### C. Evaluation of Thrombocytopenia<sup>15,16</sup>

1. Platelet size: Large = mean platelet volume (MPV)  $>11$  fL, normal = MPV 7 to 11 fL, small = MPV  $<7$  fL
  - a. Large platelets suggest increased marrow production in destructive processes (e.g., immune thrombocytopenia [ITP]) or some congenital disorders.
  - b. Small platelets suggest production defects, typically seen in congenital disorders.
2. Peripheral blood smear: Confirm platelet count, evaluate size and morphology, and rule out pseudothrombocytopenia (i.e., spuriously low platelet count due to aggregation in EDTA tube only).
3. Immature platelet fraction: Correlates with measure of reticulated platelets, which reflects thrombopoiesis. Increases with peripheral destruction; is normal/low with bone marrow failure
4. Bone marrow aspiration: Obtain if systemic symptoms concerning for underlying malignancy, involvement of other cell lines, and/or blasts on smear. Differentiates decreased production versus increased destruction

### D. Causes of Thrombocytopenia and Impaired Platelet Function

1. See [Table 14.9](#) for an approach to the differential of thrombocytopenia.
2. See [Table 14.10](#) for differential of abnormal platelet function.

### E. Management of Thrombocytopenia

1. ITP<sup>17</sup>
  - a. Pathophysiology: Immune-mediated destruction of circulating platelets
  - b. Presentation: Otherwise healthy child with sudden bruising or bleeding after recent mild illness or vaccination, isolated thrombocytopenia (platelets  $<100,000/\mu\text{L}$ ), and peripheral smear with thrombocytopenia and reticulated large platelets

TABLE 14.9

## APPROACH TO THROMBOCYTOPENIA

ACQUIRED		
Destructive <ul style="list-style-type: none"> <li>• Smear: Large platelets</li> <li>• Increased IPF</li> <li>• Bone marrow: Normal-increased megakaryocytes</li> </ul>	Immune-mediated	Immune thrombocytopenia (ITP) Evans syndrome: ITP + autoimmune hemolytic anemia Autoimmune disorders (antiphospholipid antibody syndrome, systemic lupus erythematosus) Drug-induced thrombocytopenia (heparin-induced thrombocytopenia) Neonatal alloimmune thrombocytopenia <sup>a</sup> Neonatal autoimmune thrombocytopenia <sup>a</sup>
	Platelet consumption	Thrombotic microangiopathies (TMAs; e.g., HUS, TTP) Disseminated intravascular coagulation (DIC) Kasabach-Merritt syndrome (giant cavernous hemangioma, other vascular malformation) Major surgery/trauma/burn
	Mechanical destruction	Extracorporeal membrane oxygenation (ECMO) Hemodialysis
Impaired platelet production <ul style="list-style-type: none"> <li>• Smear: Normal-sized platelets</li> <li>• Low/normal IPF</li> <li>• Infiltration of bone marrow or reduced megakaryocytes</li> </ul>	Sequestration	Hypersplenism (sickle cell disease, malaria)
	Infection	EBV, CMV, parvovirus, varicella, rickettsia, HIV, sepsis (DIC), congenital infection
	Nutritional deficiency	Folate, vitamin B <sub>12</sub> , iron deficiency
	Acquired bone marrow failure	Aplastic anemia, myelodysplastic syndromes, medications (chemotherapy), radiation
	Inherited bone marrow failure	Fanconi anemia, Shwachman-Diamond syndrome
Infiltrative bone marrow disease	Leukemia, lymphoma, infectious granulomas, storage diseases	
CONGENITAL		
Impaired platelet production	Small platelets	Wiskott-Aldrich syndrome <sup>b</sup> X-linked thrombocytopenia
	Large/giant platelets	Bernard-Soulier syndrome <sup>b</sup> Gray platelet syndrome <sup>b</sup> MYH9-related disorders <sup>b</sup> Type 2B von Willebrand disease <sup>b</sup> Paris-Trousseau-Jacobsen syndrome DiGeorge syndrome
	Normal platelets	Congenital amegakaryocytic thrombocytopenia (CAMT) Thrombocytopenia with absent radius (TAR) syndrome <sup>b</sup> Amegakaryocytic thrombocytopenia with radioulnar synostosis Autosomal dominant thrombocytopenia

<sup>a</sup>Neonatal alloimmune thrombocytopenia occurs when maternal IgG antiplatelet antibodies cross the placenta and destroy fetal platelets expressing a “foreign” antigen inherited from father. Neonatal autoimmune thrombocytopenia occurs in children of mothers with antiplatelet antibodies, often related to autoimmune disorders (e.g., immune thrombocytopenic purpura or systemic lupus erythematosus).

<sup>b</sup>These disorders typically also have disordered platelet function.

CMV, Cytomegalovirus; EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; HUS, hemolytic uremic syndrome; TTP, thrombotic thrombocytopenic purpura.

Data from Buchanan GR. Thrombocytopenia during childhood: what the pediatrician needs to know. *Pediatr Rev.* 2005;26(11):401–409. Israels SJ, Kahr WH, Blanchette VS, et al. Platelet disorders in children: a diagnostic approach. *Pediatr Blood Cancer.* 2011;56(6):975–983.

**TABLE 14.10****CAUSES OF PLATELET DYSFUNCTION**

Medications	NSAIDs, Beta-lactam antibiotics, SSRIs
Underlying disease	Uremia, myeloproliferative disorders, myelodysplastic disorders
Inherited disorders	Glanzmann thrombasthenia
	von Willebrand disease
	Bernard-Soulier syndrome
	Storage pool diseases: Wiskott-Aldrich syndrome, thrombocytopenia with absent radii syndrome, Chediak-Higashi syndrome, Hermansky-Pudlak syndrome

NSAIDs, Nonsteroidal antiinflammatory drugs; SSRIs, selective serotonin reuptake inhibitors.

Data from Israels SJ, Kahr WH, Blanchette VS, et al. Platelet disorders in children: a diagnostic approach. *Pediatr Blood Cancer*. 2011;56(6):975–983.

- c. Diagnostic testing: No additional testing needed if presentation consistent with ITP. If concerning features/risk factors present, consider evaluation for: infection [human immunodeficiency virus (HIV), hepatitis C, *Helicobacter pylori* infection], autoimmune disorders (lupus), immunodeficiencies (common variable immunodeficiency, DiGeorge syndrome). If a second autoimmune cytopenia is present (Evans syndrome), consider evaluation for autoimmune lymphoproliferative syndrome (ALPS).<sup>18</sup>
  - d. Management: Observation if no or mild bleeding (e.g., skin manifestations). Treat if mucosal or other significant bleeding or for situations with higher bleeding risk (e.g., perioperative, trauma) with intravenous immunoglobulin (IVIg), steroids, or anti-Rh (D) immune globulin in consultation with a hematologist.<sup>18</sup> Only transfuse platelets if life-threatening bleed, often with IVIg and high-dose steroids. May require emergent splenectomy. Second-line agents for chronic or refractory ITP include rituximab, thrombopoietin (TPO) mimetics, and other immunomodulatory agents.
2. **Thrombotic thrombocytopenic purpura (TTP)**<sup>19</sup>
    - a. Pathophysiology: Decreased ADAMTS13 activity results in impaired processing of von Willebrand factor (vWF) multimers, which causes microthrombi.
    - b. Presentation: Microangiopathic hemolytic anemia (MAHA), thrombocytopenia, acute kidney injury, fever, and fluctuating neurologic symptoms (headache, altered mental status, seizure, stroke).
    - c. Management: Early plasma exchange with fresh frozen plasma (FFP) and glucocorticoids. If high clinical suspicion, treat emergently before ADAMTS13 testing results.
  3. **Hemolytic-uremic syndrome (HUS)**
    - a. Pathophysiology: Due to Shiga toxin–producing *Escherichia coli* O157:H7 or *Shigella* diarrhea; sometimes *Streptococcus pneumoniae*, HIV<sup>20</sup>

- b. Presentation: Early abdominal pain and bloody diarrhea, MAHA, late thrombocytopenia and renal failure
  - c. Management: Supportive care with early/aggressive hydration, RBC/platelet transfusions as needed, antihypertensives, and neurologic monitoring<sup>21</sup>
4. **Complement-mediated (“atypical HUS,” aHUS)**
- a. Pathophysiology: Uncontrolled activation of complement on cell membranes<sup>21</sup>
  - b. Presentation: Same as HUS without associated above illnesses
  - c. Diagnostic testing: Complement panel (not highly sensitive), complement factor H antibodies (seen in a subset of aHUS), consider genetic testing for complement protein gene variants
  - d. Management: Eculizumab with or without concurrent plasma exchange and immunomodulating therapy (corticosteroids, cyclophosphamide, rituximab, mycophenolate mofetil, azathioprine)
5. **Drug-induced thrombocytopenia**<sup>22</sup>
- a. Presentation: Lightheadedness, chills, fever, nausea/vomiting, purpura, petechiae ~7 days after starting medication (onset variable)
  - b. Diagnostic testing: For heparin-induced thrombocytopenia: +anti-PF4/heparin antibodies, +serotonin release assay. For other drugs: Flow cytometric detection of drug-dependent platelet antibodies
  - c. Management: Discontinue medication permanently, transfuse if severe thrombocytopenia to prevent intracranial or intrapulmonary hemorrhage.
6. **Neonatal alloimmune thrombocytopenia**<sup>23</sup>
- a. Pathophysiology: Maternal IgG antibodies (usually against paternally inherited PLA-1/HPA-1a) cross placenta and cause neonatal platelet destruction.
  - b. Presentation: Severe thrombocytopenia, intracranial hemorrhage (ICH)—most often occurring in utero
  - c. Diagnostic testing: Identify antibodies to paternal platelet antigens in maternal or infant blood sample, or potential mismatch between mother and infant on platelet antigen typing.
  - d. Management: Head ultrasound to screen for ICH, transfuse platelets if  $<30,000/\mu\text{L}$  or signs of bleeding, consider IVIG if poor response to platelet transfusion.

## VI. THROMBOCYTOSIS<sup>12</sup>

### A. Definition of Thrombocytosis

1. Thrombocytosis is defined as a platelet count greater than two standard deviations above mean, based on age-specific norms.
2. See [Table 14.1](#) for age-specific values.

### B. Causes of Thrombocytosis

1. See [Table 14.11](#) for differential of thrombocytosis.

TABLE 14.11

## ETIOLOGY OF THROMBOCYTOSIS

	Cause	Presentation
Secondary	Anemia	Iron deficiency Chronic hemolytic anemias Vitamin E deficiency Acute hemorrhage “Rebound” following thrombocytopenia
	Infection	Acute Chronic (e.g. TB, hepatitis, osteomyelitis)
	Inflammation	Rheumatoid arthritis Inflammatory bowel disease Ankylosing spondylitis Sarcoidosis Acute rheumatic fever Kawasaki syndrome
	Drug-induced	Vinca alkaloids Corticosteroids Epinephrine
	Neoplastic diseases	Lymphoma Neuroblastoma Solid tumors
	Asplenia	Surgical Congenital Afunctional
	Miscellaneous	Exercise Surgery (may persist for 1–2 weeks) Caffey disease
Primary (rare in pediatrics)		5q-syndrome Essential thrombocythemia Polycythemia vera Chronic myelogenous leukemia Primary myelofibrosis Acute megakaryoblastic leukemia Familial thrombocytosis

Adapted from Orkin SH, et al. *Nathan and Oski's Hematology and Oncology of Infancy and Childhood*. 8th ed. Philadelphia: Saunders; 2015.

### C. Evaluation of Thrombocytosis

1. CBC and blood smear should be obtained to evaluate platelet morphology and concurrent presence of anemia, leukemic blasts, or leukoerythroblastic features.
2. Patients with unexplained vasomotor symptoms (erythromelalgia, flushing, pruritus), constitutional symptoms, thrombosis at unusual or multiple sites, and/or splenomegaly should be evaluated for potential myeloproliferative neoplasm.

### D. Management of Thrombocytosis


1. Treatment is targeted at underlying etiology.

2. Patients with extreme thrombocytosis in the setting of myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN) are prone to both hemorrhage and thrombosis. Both should be managed according to the nature and severity of event.

## VII. COAGULATION

### A. Evaluation of Coagulation and Platelet Function

1. Coagulation
  - a. See Fig. 14.3 for coagulation cascade.
  - b. **Activated partial thromboplastin time (aPTT):** Measures intrinsic system (factors VIII, IX, XI, XII) and common pathway (fibrinogen, prothrombin, factors V and X)
  - c. **Prothrombin time (PT):** Measures extrinsic pathway (factor VII) and common pathway
  - d. **Thrombin time (TT):** Measures conversion of fibrinogen to fibrin. Prolonged with low or dysfunctional fibrinogen, anticoagulants (heparin, low-molecular-weight heparin, direct thrombin inhibitors), or specimen contamination from heparinized line, but not with common pathway abnormalities
  - e. **Reptilase time (RT):** Normal with heparin or direct thrombin inhibitors, but prolonged with fibrinogen abnormalities
  - f. **Mixing study:** Used in patients with abnormal clotting (i.e., prolonged PT, aPTT, or TT) to determine presence of factor deficiency (corrects with addition of normal plasma) or factor inhibitor (no correction would occur)
  - g. **Dilute Russell viper venom time (dRVVT):** Russell viper activates factor X directly and is sensitive to inhibition by antiphospholipid antibodies. Prolonged dRVVT that corrects with addition of phospholipid to assay suggests presence of antiphospholipid antibodies (Lupus anticoagulant).<sup>24</sup>
  - h. **Fibrinogen:** Low levels (<50 to 100 mg/dL) cause impaired clot formation and prolong PT and aPTT. Decreased in disseminated intravascular coagulation (DIC), liver disease, traumatic hemorrhage
  - i. **D-dimer:** Fibrin degradation product increased with recent/ongoing fibrinolysis (e.g., deep vein thrombosis, pulmonary embolism, DIC, and many other clinical scenarios)
  - j. **Thromboelastography (TEG):** Whole blood test that rapidly measures time parameters of clot formation and overall clot strength, detects increased fibrinolysis. Useful for identification of coagulopathy and to guide transfusion in cardiac surgery and trauma<sup>25</sup>
2. Platelet function<sup>12</sup>
  - a. Always assess platelet number and use of platelet inhibitors (e.g., nonsteroidal antiinflammatory drugs [NSAIDs]) before platelet function testing.
  - b. **Light transmission or whole blood impedance platelet aggregometry:** Measures platelet aggregation in vitro<sup>16</sup>



**FIGURE 14.3**

Coagulation cascade and differential diagnosis of bleeding disorders. *aPTT*, Activated partial thromboplastin time; *AT*, antithrombin; *DIC*, disseminated intravascular coagulation; *PT*, prothrombin time; *TFPI*, tissue factor pathway inhibitor; *TT*, thrombin time. (Adapted from Rodriguez V, Warad D. Pediatric coagulation disorders. *Pediatr Rev*. 2016;37[7]:279–290. Adaptation courtesy James Casella and Clifford Takemoto.)

- c. **Platelet function analyzer-100 (PFA-100):** Measures primary hemostasis (platelet adhesion, activation, and aggregation) in vitro<sup>16</sup>
- d. **Bleeding time (BT):** Evaluates clot formation, including platelet number/function and vWF, in vivo. Technically challenging to perform and has been largely replaced by above-mentioned tests

## B. Definition of Abnormal Coagulation

1. An incorrect anticoagulant-to-blood ratio (e.g., in under-filled lab tubes) will give inaccurate results.
2. Table 14.12 lists normal hematologic values for coagulation testing.

## C. Causes and Management of Coagulopathy

### 1. Medications

- a. Heparin affects aPTT, thrombin time, dRVVT, and mixing studies.
- b. Warfarin affects PT, may mildly affect aPTT, and interferes with dRVVT by reducing the activity of vitamin K–dependent factors (II, VII, IX, X, protein C and S).

### 2. Disseminated intravascular coagulation

- a. Tissue damage (e.g., due to sepsis, trauma, malignancy) results in tissue factor release and systemic activation of coagulation system, consumption of coagulation factors and platelets, increased fibrin formation and fibrinolysis, MAHA, bleeding, and microthromboses.<sup>26</sup>
- b. Diagnosis: May have prolonged PT and aPTT, decreased fibrinogen, thrombocytopenia, increased D-dimer, increased fibrin degradation products, and/or presence of schistocytes on peripheral smear
- c. Treatment: Address underlying condition and supportive care. May require FFP, cryoprecipitate, and/or platelet transfusions if active bleeding or high bleeding risk

### 3. Liver disease

- a. The liver is the major site of synthesis of factors V, VII, IX, X, XI, XII, XIII.
- b. It is also involved in the synthesis of prothrombin, plasminogen, fibrinogen, proteins C and S, and antithrombin.

### 4. Vitamin K deficiency

- a. Often secondary to liver or biliary disease, pancreatic insufficiency, malabsorption, exclusive breastfeeding, prolonged antibiotic use, malignancy
- b. Necessary for synthesis of factors II, VII, IX, X, protein C, and protein S<sup>12</sup>
- c. Treatment: Parenteral vitamin K corrects PT in 2 to 6 hours (IV administration can be associated with hypersensitivity reactions). Oral form corrects in 6–8 hours.<sup>27</sup> Give FFP if evidence of severe bleeding. Prothrombin complex concentrate can be given in cases of life-threatening hemorrhage, including ICH.

### 5. Hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency)<sup>28</sup>

- a. Etiology: X-linked recessive disorders. Females can be symptomatic carriers.
- b. Diagnosis: Prolonged aPTT that corrects with mixing study, normal PT, low specific factor assays. Mild forms can have normal aPTT.
- c. Classification of disease severity<sup>28</sup>:
  - (1) Severe: <1% factor activity; spontaneous bleeding (hemarthrosis, hematoma, bruising) without trauma

TABLE 14.12

## AGE-SPECIFIC COAGULATION VALUES

Coagulation Test	Preterm Infant (30–36 Weeks), Day of Life 1 <sup>a</sup>		Term Infant, Day of Life 1					
	Day of Life 1 <sup>a</sup>	Day of Life 1	Day of Life 3	1 Month–1 Year	1–5 Years	6–10 Years	11–16 Years	Adult
PT (s)	13.0 (10.6–16.2)	15.6 (14.4–16.4)	14.9 (13.5–16.4)	13.1 (11.5–15.3)	13.3 (12.1–14.5)	13.4 (11.7–15.1)	13.8 (12.7–16.1)	13.0 (11.5–14.5)
INR		1.26 (1.15–1.35)	1.20 (1.05–1.35)	1.00 (0.86–1.22)	1.03 (0.92–1.14)	1.04 (0.87–1.20)	1.08 (0.97–1.30)	1.00 (0.80–1.20)
aPTT (s) <sup>b</sup>	53.6 (27.5–79.4)	38.7 (34.3–44.8)	36.3 (29.5–42.2)	39.3 (35.1–46.3)	37.7 (33.6–43.8)	37.3 (31.8–43.7)	39.5 (33.9–46.1)	33.2 (28.6–38.2)
Fibrinogen (g/L)	2.43 (1.50–3.73)	2.80 (1.92–3.74)	3.30 (2.83–4.01)	2.42 (0.82–3.83)	2.82 (1.62–4.01)	3.04 (1.99–4.09)	3.15 (2.12–4.33)	3.1 (1.9–4.3)
Bleeding time (min) <sup>a</sup>					6 (2.5–10)	7 (2.5–13)	5 (3–8)	4 (1–7)
Thrombin time (s)	14 (11–17)	12 (10–16) <sup>a</sup>		17.1 (16.3–17.6)	17.5 (16.5–18.2)	17.1 (16.1–18.5)	16.9 (16.2–17.6)	16.6 (16.2–17.2)
Factor II (U/mL)	0.45 (0.20–0.77)	0.54 (0.41–0.69)	0.62 (0.50–0.73)	0.90 (0.62–1.03)	0.89 (0.70–1.09)	0.89 (0.67–1.10)	0.90 (0.61–1.07)	1.10 (0.78–1.38)
Factor V (U/mL)	0.88 (0.41–1.44)	0.81 (0.64–1.03)	1.22 (0.92–1.54)	1.13 (0.94–1.41)	0.97 (0.67–1.27)	0.99 (0.56–1.41)	0.89 (0.67–1.41)	1.18 (0.78–1.52)
Factor VII (U/mL)	0.67 (0.21–1.13)	0.70 (0.52–0.88)	0.86 (0.67–1.07)	1.28 (0.83–1.60)	1.11 (0.72–1.50)	1.13 (0.70–1.56)	1.18 (0.69–2.00)	1.29 (0.61–1.99)
Factor VIII (U/mL)	1.11 (0.50–2.13)	1.82 (1.05–3.29)	1.59 (0.83–2.74)	0.94 (0.54–1.45)	1.10 (0.36–1.85)	1.17 (0.52–1.82)	1.20 (0.59–2.00)	1.60 (0.52–2.90)
vWF (U/mL) <sup>a</sup>	1.36 (0.78–2.10)	1.53 (0.50–2.87)			0.82 (0.47–1.04)	0.95 (0.44–1.44)	1.00 (0.46–1.53)	0.92 (0.5–1.58)
Factor IX (U/mL)	0.35 (0.19–0.65)	0.48 (0.35–0.56)	0.72 (0.44–0.97)	0.71 (0.43–1.21)	0.85 (0.44–1.27)	0.96 (0.48–1.45)	1.11 (0.64–2.16)	1.30 (0.59–2.54)
Factor X (U/mL)	0.41 (0.11–0.71)	0.55 (0.46–0.67)	0.60 (0.46–0.75)	0.95 (0.77–1.22)	0.98 (0.72–1.25)	0.97 (0.68–1.25)	0.91 (0.53–1.22)	1.24 (0.96–1.71)
Factor XI (U/mL)	0.30 (0.08–0.52)	0.30 (0.07–0.41)	0.57 (0.24–0.79)	0.89 (0.62–1.25)	1.13 (0.65–1.62)	1.13 (0.65–1.62)	1.11 (0.65–1.39)	1.12 (0.67–1.96)
Factor XII (U/mL)	0.38 (0.10–0.66)	0.58 (0.43–0.80)	0.53 (0.14–0.80)	0.79 (0.20–1.35)	0.85 (0.36–1.35)	0.81 (0.26–1.37)	0.75 (0.14–1.17)	1.15 (0.35–2.07)
PK (U/mL) <sup>a</sup>	0.33 (0.09–0.57)	0.37 (0.18–0.69)			0.95 (0.65–1.30)	0.99 (0.66–1.31)	0.99 (0.53–1.45)	1.12 (0.62–1.62)
HMWK (U/mL) <sup>a</sup>	0.49 (0.09–0.89)	0.54 (0.06–1.02)			0.98 (0.64–1.32)	0.93 (0.60–1.30)	0.91 (0.63–1.19)	0.92 (0.50–1.36)

Factor XIIIa (U/mL) <sup>a</sup>	0.70 (0.32–1.08)	0.79 (0.27–1.31)			1.08 (0.72–1.43)	1.09 (0.65–1.51)	0.99 (0.57–1.40)	1.05 (0.55–1.55)
Factor XIIIs (U/mL) <sup>a</sup>	0.81 (0.35–1.27)	0.76 (0.30–1.22)			1.13 (0.69–1.56)	1.16 (0.77–1.54)	1.02 (0.60–1.43)	0.97 (0.57–1.37)
D-dimer		1.47 (0.41–2.47)	1.34 (0.58–2.74)	0.22 (0.11–0.42)	0.25 (0.09–0.53)	0.26 (0.10–0.56)	0.27 (0.16–0.39)	0.18 (0.05–0.42)
FDPs <sup>a</sup>								Borderline titer = 1:25–1:50 Positive titer <1:50
<b>COAGULATION INHIBITORS</b>								
ATIII (U/mL) <sup>a</sup>	0.38 (0.14–0.62)	0.63 (0.39–0.97)			1.11 (0.82–1.39)	1.11 (0.90–1.31)	1.05 (0.77–1.32)	1.0 (0.74–1.26)
$\alpha_2$ -M (U/mL) <sup>a</sup>	1.10 (0.56–1.82)	1.39 (0.95–1.83)			1.69 (1.14–2.23)	1.69 (1.28–2.09)	1.56 (0.98–2.12)	0.86 (0.52–1.20)
C1-Inh (U/mL) <sup>a</sup>	0.65 (0.31–0.99)	0.72 (0.36–1.08)			1.35 (0.85–1.83)	1.14 (0.88–1.54)	1.03 (0.68–1.50)	1.0 (0.71–1.31)
$\alpha_2$ -AT (U/mL) <sup>a</sup>	0.90 (0.36–1.44)	0.93 (0.49–1.37)			0.93 (0.39–1.47)	1.00 (0.69–1.30)	1.01 (0.65–1.37)	0.93 (0.55–1.30)
Protein C (U/mL)	0.28 (0.12–0.44)	0.32 (0.24–0.40)	0.33 (0.24–0.51)	0.77 (0.28–1.24)	0.94 (0.50–1.34)	0.94 (0.64–1.25)	0.88 (0.59–1.12)	1.03 (0.54–1.66)
Protein S (U/mL)	0.26 (0.14–0.38)	0.36 (0.28–0.47)	0.49 (0.33–0.67)	1.02 (0.29–1.62)	1.01 (0.67–1.36)	1.09 (0.64–1.54)	1.03 (0.65–1.40)	0.75 (0.54–1.03)
<b>FIBRINOLYTIC SYSTEM<sup>a</sup></b>								
Plasminogen (U/mL)	1.70 (1.12–2.48)	1.95 (1.60–2.30)			0.98 (0.78–1.18)	0.92 (0.75–1.08)	0.86 (0.68–1.03)	0.99 (0.7–1.22)
TPA (ng/mL)					2.15 (1.0–4.5)	2.42 (1.0–5.0)	2.16 (1.0–4.0)	4.90 (1.40–8.40)
$\alpha_2$ -AP (U/mL)	0.78 (0.4–1.16)	0.85 (0.70–1.0)			1.05 (0.93–1.17)	0.99 (0.89–1.10)	0.98 (0.78–1.18)	1.02 (0.68–1.36)
PAI (U/mL)					5.42 (1.0–10.0)	6.79 (2.0–12.0)	6.07 (2.0–10.0)	3.60 (0–11.0)

<sup>a</sup>Data from Andrew M, Paes B, Milner R, et al. Development of the human anticoagulant system in the healthy premature infant. *Blood*. 1987;70:165–172; Andrew M, Paes B, Milner R, et al. Development of the human anticoagulant system in the healthy premature infant. *Blood*. 1988;72(5):1651–1657; and Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. *Blood*. 1992;8:1998–2005.

<sup>b</sup>aPTT values may vary depending on reagent.

$\alpha_2$ -AP,  $\alpha_2$ -Antiplasmin;  $\alpha_2$ -AT,  $\alpha_2$ -antitrypsin;  $\alpha_2$ -M,  $\alpha_2$ -macroglobulin; aPTT, activated partial thromboplastin time; ATIII, antithrombin III; FDPs, fibrin degradation products; HMMWK, high-molecular-weight kininogen; INR, international normalized ratio; PAI, plasminogen activator inhibitor; PK, prekallikrein; PT, prothrombin time; TPA, tissue plasminogen activator; VIII, factor VIII procoagulant; vWF, von Willebrand factor.

Adapted from Monagle P, Barnes C, Ignjatovic, V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. *Thromb Haemost*. 2006;95:362–372.

- (2) Moderate: 1% to 5% factor activity; bleeding after minor trauma
  - (3) Mild: 5% to 40% factor activity; bleeding with surgery or significant trauma
- d. Bleeding prophylaxis:
- (1) Home prophylaxis: Regular administration of intravenous (IV) factor replacement to maintain factor level >1 IU/dL to prevent spontaneous bleeds and preserve joint function. Initiate before onset of frequent bleeding, typically in 1- to 3-year-olds with severe hemophilia.<sup>29</sup> Emicizumab-kxwh is a bispecific antibody that is delivered subcutaneously (SQ) and can be used for prophylaxis in hemophilia A.
  - (2) Surgical prophylaxis: Factor replacement to goal factor level 80 to 100 IU/dL (major procedure) or 50 to 80 IU/dL (minor procedure) preoperatively and through postoperative period of bleeding risk.<sup>28</sup> Consult hematologist before any diagnostic or therapeutic procedure, including dental, endoscopy with biopsy, arterial blood gas, etc.
- e. Treatment of acute bleeds:
- (1) Always remember: **“Factor first!”** Do not delay administration of first dose when suspicion for bleed or recent injury (e.g., do not wait for imaging or lab results).
  - (2) Bolus dose factor VIII or factor IX concentrate. May require additional doses
  - (3) Consult hematologist for all major bleeding.
  - (4) See [Table 14.13](#) for desired factor replacement level and dosing.
  - (5) Half-life of factor VIII: 8 to 12 hours. Half-life factor IX: 18 to 24 hours<sup>28</sup>

**TABLE 14.13****DESIRED FACTOR REPLACEMENT IN HEMOPHILIA**

Dose calculation:	
1. Units of factor VIII needed = weight (kg) × desired % replacement × 0.5	
2. Units of factor IX needed = weight (kg) × desired % replacement × 1.0 or 1.2	
Bleeding Site	Desired Level (%)
Minor soft tissue bleeding	20–30
Joint	40–70
Simple dental extraction	50
Major soft tissue bleeding	80–100
Serious oral bleeding	80–100
Head injury	100+
Major surgery (dental, orthopedic, other)	100+

**NOTE:** A hematologist should be consulted for all major bleeding and before surgery.

Round to the nearest vial; do not exceed 200%.

Dosing adapted from Nathan D, Oski FA. *Hematology of Infancy and Childhood*. WB Saunders; 1998.

- (6) If suspected intracranial bleed, replete 100% factor level immediately on presentation and **before** additional diagnostic testing (e.g., CT scan).
- (7) Alternative treatments:
  - (a) Desmopressin (DDAVP) can be used in mild hemophilia A only.
  - (b) Antifibrinolytic agents (tranexamic acid, aminocaproic acid) may be appropriate for minor mucosal bleeding.
- (8) Cryoprecipitate (for hemophilia A only) or FFP are used in settings where no factor concentrate is available.
- f. Factor inhibitors: IgG antibodies that develop with repeat factor exposure and complicate treatment. Patients with severe hemophilia A are at the highest risk.
  - (1) Screen for inhibitors with inhibitor assay if poor clinical response to factor. Consider screening during initiation of factor treatment and preoperatively.
  - (2) In the presence of inhibitors, patients may require higher doses of factor (only beneficial for low titer inhibitors), recombinant FVIIa concentrate, or activated prothrombin complex concentrates.
- g. Healthcare maintenance
  - (1) Vaccinations: Given per routine schedule. Give prophylactic factor for intramuscular vaccines or give vaccine SQ with 23-gauge or smaller needle without factor prophylaxis and hold pressure at site for 2 minutes.<sup>28</sup>
  - (2) Physical activity: Avoid high-contact (e.g., soccer, hockey) and high-velocity (e.g., skiing) activities.<sup>28</sup>
  - (3) Medications to avoid: Aspirin, NSAIDs, anticoagulants
  - (4) Many younger children will need a central venous catheter for factor delivery and must therefore follow strict fever guidelines.

## 6. von Willebrand disease (vWD)

- a. Pathophysiology: Most common inherited bleeding disorder. Abnormal platelet adhesion and aggregation, can have low factor VIII<sup>30</sup>
- b. Diagnosis: Low circulating von Willebrand factor antigen (VWF:Ag) and/or low vWF function on ristocetin-based platelet aggregation study (VWF:RCo) or vW GP1bM binding assay, low or normal factor VIII activity, prolonged PFA-100. May require additional evaluation. Notably, the African American population may have an artifactually low ristocetin cofactor assay from a common D1472H von Willebrand polymorphism.
- c. Classification<sup>30</sup>:
  - (1) Type 1 (75% to 80% cases): Partial quantitative deficiency of vWF
  - (2) Type 2 (20% to 25%): Qualitative dysfunction of vWF

- (3) Type 3 (rare): Absence or near absence of vWF + markedly low factor VIII activity (can resemble hemophilia A patient on labs and presentation)
- d. Treatment<sup>30</sup>:
- (1) Desmopressin (DDAVP): Stimulates vWF release. Given IV, intranasal (1.5 mg/mL concentration only), or SQ (rarely). May be used as prophylaxis for minor surgeries or treatment for mild bleeding. Ineffective in type 3, variable effect in type 2. Patients should be tested for DDAVP response before using as prophylaxis.
  - (2) vWF-containing concentrates (Humate-P or Wilate): Replaces vWF and factor VIII, derived from blood donors. Recombinant vWF available (VONVENDI). Used for severe bleeding events and surgery
  - (3) Cryoprecipitate for life-threatening situations only if vWF concentrate unavailable
  - (4) Alternative therapies: IV or oral antifibrinolytic therapy (tranexamic acid and aminocaproic acid) can be used to prevent or treat mild mucocutaneous bleeding alone or in conjunction with other therapies.

#### D. Causes of Hypercoagulability

1. Most thrombotic events are due to an acquired condition; however, an inherited thrombophilia is more likely if there is a family history, an unusual thrombus location, absence of an inciting factor, and/or recurrent thromboses.
2. See [Table 14.14](#) for etiologies and evaluation of hypercoagulable states.
3. Acquired conditions associated with venous thromboembolism include endothelial damage (vascular catheters, sepsis, smoking, diabetes, hypertension, surgery, hyperlipidemia), disturbed blood flow (central venous lines, congenital heart disease), hyperviscosity (macroglobulinemia, erythrocytosis, sickle cell disease), platelet activation (essential thrombocytosis, heparin-induced thrombocytopenia), malignancy, inflammatory bowel disease, parenteral nutrition, nephrotic syndrome, paroxysmal nocturnal hemoglobinuria, estrogen-containing hormonal therapy.

#### E. Thrombus Management

1. See [Table 14.15](#) for anticoagulant use.
2. See Formulary for dosing and adjustment based on monitoring protocols.
3. **NOTE:** Children receiving anticoagulation therapy should be protected from trauma. The use of antiplatelet agents should be avoided.
4. See [Table 14.16](#) for warfarin-reversal guidelines.
5. Consult a hematologist regarding interruption of anticoagulation for procedures and surgeries.

TABLE 14.14

## HYPERCOAGULABLE STATES

Hypercoagulable Condition	Cause	Risk of VTE (Compared to General Population; Odds Ratio)	Associated Test
Factor V Leiden (activated protein C resistance)	AD Factor V Leiden mutation	3.77 (heterozygote)	Activated protein C resistance assay (screening test) Factor V Leiden (DNA-based PCR assay)
Factor VIII, IX, XI abnormalities <sup>a</sup>	Inherited or acquired elevated factor levels	6.7 (Factor VIII)	Factor VIII, IX, XI
Protein C and S deficiency <sup>a</sup>	AD. Homozygous more severe than heterozygous	7.72 (protein C); 5.77 (protein S)	Protein C and S activity
Antithrombin III deficiency <sup>a</sup>	AD. Type I: Low level and activity (homozygous not compatible with life). Type II: Low activity or dysfunction	9.44	Antithrombin III activity
Hyperhomocystinemia <sup>a</sup>	AR alteration in <i>MTHFR</i> gene	1.27	Homocysteine level (fasting) <i>MTHFR</i> genetic testing if homocysteine elevated
Prothrombin mutation	AD mutation in G20210A	2.64 (heterozygote)	DNR-based PCR assay
Antiphospholipid antibodies <sup>a</sup>	Rarely inherited. Typically sporadic: Spontaneous (primary) or secondary to autoimmune disorder (e.g., SLE) or infections	High	Phospholipid-based clotting assays (aPTT, dRVVT) that correct with phospholipid addition ELISA assays: cardiolipin and $\beta$ 2-glycoprotein antibodies
High lipoprotein(a)	Levels determined by genetics and environment	4.49	Lipoprotein(a) level
Plasminogen deficiency	Inherited hypoplasminogenemia (type I) or dysplasminogenemia (type II)		Plasminogen activity <sup>b</sup>

<sup>a</sup>These conditions may be inherited or acquired.

<sup>b</sup>Also consider testing tissue plasminogen activator (tPA) antigen and plasminogen activator inhibitor-1 (PAI-1) activity. Low tPA decreases fibrinolysis. Increased PAI-1 causes excess inhibition of tPA. A hematologist should be consulted if initiating this workup.

AD, Autosomal dominant; aPTT, activated partial thromboplastin time; AR, autosomal recessive; dRVVT, dilute Russell viper venom time; ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction; SLE, systemic lupus erythematosus; VTE, venous thromboembolism.

Data from Rodriguez V, Warad D. Pediatric coagulation disorders. *Pediatr Rev.* 2016;37(7):279–290. Young G, Albisetti M, Bonduel M, et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. *Circulation.* 2008;118(13):1373–1382.

TABLE 14.15

## ANTICOAGULANTS

Medication	Indication	Contraindications and Adverse Effects	Monitoring	Reversal
Heparin/UFH (IV)	Acute treatment for VTE, acute ischemic stroke (AIS), cerebral venous sinus thrombosis (CVST) without ICH Prevention of thrombosis with cardiac catheterization, cardiopulmonary bypass surgery, extracorporeal circuits	Heparin hypersensitivity, major active or high-risk bleeding, platelets <50,000, known/suspected HIT, concurrent epidural therapy Cautious use in patients with high bleeding risk or platelets <50,000/mm <sup>3</sup> Avoid IM injections and concurrent use of drugs affecting platelet function (NSAIDs, aspirin, clopidogrel).	Anti-Xa level (goal 0.3–0.7 U/mL) or aPTT (1.5–2.5 times the control aPTT) The aPTT range in seconds (~50–80 sec) should be calibrated to anti-Xa of 0.3–0.7 U/mL	Protamine sulfate
LMWH/enoxaparin (SQ)	Initial or ongoing therapy for VTE, CVST, AIS with cardioembolic source, recurrent AIS Patients with history or risks for HIT	HIT (lower risk than UFH) Chronic use (>6 months) may decrease bone density.	Anti-Xa activity (goal 0.5–1 U/mL for thrombosis, 0.1–0.3 U/mL for prophylaxis)	Protamine sulfate (partial neutralization)
Warfarin (PO)	Long-term anticoagulation after bridge from UFH or LMWH for VTE, CVST, AIS Recurrent idiopathic VTE	Interactions with diet and medications (see <a href="#">eTable 14.1</a> ) Adjust dose in liver dysfunction, avoid in severe liver failure. Limited safety and efficacy data in newborns <3 months Warfarin-induced skin necrosis has been reported in patients initiated without bridging anticoagulation. Teratogenic	INR (2–3 with target 2.5, except with prosthetic cardiac valves) measured every 1–4 weeks	Vitamin K (see <a href="#">Table 14.18</a> )

**DIRECT THROMBIN INHIBITORS**

Argatroban (IV)	Alternative to heparin in patients with HIT	Avoid or alter dose in patients with hepatic impairment.	aPTT 1.5–2.5× baseline	None
Bivalirudin (IV)	Inpatient treatment of VTE and prevention of thrombus during cardiac catheterization in patients with HIT	Adjust dose with renal impairment.	aPTT 1.5–2.5× baseline	None
Dabigatran (PO) <sup>a</sup>	Approved in adults to treat DVT/PE, reduce embolic risk in nonvalvular AF	<i>Studies ongoing for safety and efficacy in pediatric patients.</i>	None required	Idarucizumab

**FACTOR XA INHIBITORS**

Fondaparinux (SQ) <sup>a</sup>	Approved in adults to treat and prevent DVT/PE. Can be used in patients with HIT.	Adjust dose with renal impairment.	Anti-Xa level 0.5–1 mg/L	None
Apixaban (PO) <sup>a</sup>	Approved in adults to treat and prevent DVT/PE, reduce embolic risk in AF.	<i>Studies ongoing for safety and efficacy in pediatric patients.</i>	Can measure anti-Xa level	Andexanet alfa
Rivaroxaban (PO) <sup>a</sup>	Approved in adults to treat and prevent recurrent DVT/PE, prevent nonvalvular AF embolic complications.			

<sup>a</sup>These medications are undergoing Phase II/III trials for use in children and should not be used as first-line therapy.<sup>44,45</sup>

AF, Atrial fibrillation; aPTT, activated partial thromboplastin time; DVT, deep venous thrombosis; HIT, heparin-induced thrombocytopenia; INR, international normalized ratio; IV, intravenous; LMWH, low-molecular-weight heparin; NSAID, nonsteroidal antiinflammatory drug; PE, pulmonary embolism; PO, oral; SQ, subcutaneous; UFH, unfractionated heparin; VTE, venous thromboembolism.

Data from Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *CHEST*. 2012;141(2):e737S–e801S. Young G. Anticoagulation therapies in children. *Pediatr Clin North Am*. 2017;64(6):1257–1269.

**eTABLE 14.1****MEDICATIONS THAT INFLUENCE WARFARIN THERAPY.**

Significant Increase in INR	Significant Decrease in INR
Amiodarone	Amobarbital
Anabolic steroids	Aprepitant
Bactrim (TMP/SMZ)	Butabarbital
Chloramphenicol	Carbamazepine
Disulfiram	Dicloxacillin
Fluconazole	Griseofulvin
Isoniazid	Methimazole
Metronidazole	Phenobarbital
Miconazole	Phenytoin
Phenylbutazone	Primidone
Quinidine	Propylthiouracil
Sulfinpyrazone	Rifabutin
Sulfisoxazole	Rifampin
Tamoxifen	Secobarbital
Moderate Increase in INR	Moderate Decrease in INR
Cimetidine	Atazanavir
Ciprofloxacin	Efavirenz
Clarithromycin	Nafcillin
Delavirdine	Ritonavir
Efavirenz	
Itraconazole	
Lovastatin	
Omeprazole	
Propafenone	

Numerous medications not listed in this table can affect warfarin administration.

*INR*, International normalized ratio; *TMP/SMZ*, trimethoprim/sulfamethoxazole.

TABLE 14.16

## MANAGEMENT OF EXCESSIVE WARFARIN ANTICOAGULATION

INR and Bleeding	Intervention
INR 4–4.5 without serious bleeding	Hold or lower next warfarin dose. Recheck INR daily. For patients with high bleeding risk, consider standard dose of oral vitamin K. <sup>a</sup> When INR approaches therapeutic range, resume warfarin therapy.
INR $\geq$ 4.5 but $<$ 10 without serious bleeding	Hold warfarin. Recheck INR every 24 hr until $<$ 4. If high risk for bleeding, give standard dose of oral vitamin K. <sup>a</sup> When INR approaches therapeutic range, resume warfarin at a lower dose.
INR $\geq$ 10 without serious bleeding	Hold warfarin. Recheck INR every 12 hr. Give high-dose oral vitamin K every 12–24 hr as necessary. <sup>b</sup> When INR approaches therapeutic range, resume warfarin at a lower dose.
Minor bleeding at any INR elevation	Hold warfarin. Monitor INR every 12–24 hr depending on bleeding severity. Give standard-dose oral vitamin K and repeat as necessary if bleeding continues and INR not corrected at 24 hr. <sup>a</sup> Restart warfarin when INR approaches therapeutic range and when clinically appropriate at a lower dose.
Significant or life-threatening bleeding at any INR	Hold warfarin. Monitor INR every 4–6 hr. Administer high-dose vitamin K IV, repeat as needed. <sup>b</sup> Transfusion of FFP (10–15 mL/kg IV), consider prothrombin complex concentrate; consult blood bank and/or hematology for dosing. Restart warfarin when INR approaches therapeutic range and when clinically appropriate at a lower dose.

<sup>a</sup>Standard-dose vitamin K: 0.03 mg/kg PO for patients  $<$ 40 kg in weight; 1–2.5 mg PO for patients  $\geq$ 40 kg. For rapid reversal, 0.5–2.5 mg IV slow infusion over 30 minutes. Expect INR reduction at 24–48 hr with oral dosing, and at 12–14 hr with IV dosing.

<sup>b</sup>High-dose vitamin K: 0.06 mg/kg PO for patients  $<$ 40 kg in weight; 5–10 mg for patients  $\geq$ 40 kg. For emergent situations, 5–10 mg IV slow infusion over 30 minutes.

**NOTE:** Always evaluate for bleeding risks and potential drug interactions. Do not give intramuscular vitamin K to children on anticoagulants.

FFP, Fresh frozen plasma; INR, international normalized ratio; IV, intravenous; PO, by mouth.

The Johns Hopkins Hospital Children's Center pediatric policies, procedures, and protocols general care (Policy Number MDU043): Baltimore, 2019.

Adapted from Holbrook A, Schulman S, Witt DM, et al. *Evidence-Based Management of Anticoagulation Therapy. Antithrombotic Therapy and Prevention of Thrombosis*, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *CHEST*. 2012;141(2):e152S–e184S. Bolton-Maggs P, Brook L. The use of vitamin K for reversal of over-warfarinization in children. *Br J Haematol*. 2002;118:924–925.

**TABLE 14.17****ESTIMATED BLOOD VOLUME**

Age	Total Blood Volume (mL/kg)
Preterm infants	90–105
Term newborns	78–86
1–12 months	73–78
1–3 years	74–82
4–6 years	80–86
7–18 years	83–90
Adults	68–88

Data from Nathan D, Oski FA. *Hematology of Infancy and Childhood*. WB Saunders; 1998.

**VIII. BLOOD COMPONENT REPLACEMENT****A. Calculating Estimated Blood Volume (Table 14.17)****B. Indications for and Expected Response Following Blood Transfusions**

1. See Table 14.18.
2. See Section X, Online Content, for information on directed-donor transfusions.

**C. Diagnosis and Management of Transfusion Reactions (Table 14.19)****D. Infectious Risks of Blood Transfusion**

1. Per-unit risk for transfusion recipients<sup>31,32</sup>
  - a. HIV: 1 in 2,941,176
  - b. Human T-lymphotropic virus (HTLV): 1 in 4,364,000
  - c. Hepatitis B: 1 in 1,470,588
  - d. Hepatitis C: 1 in 3,333,333
  - e. Cytomegalovirus (CMV), Epstein-Barr virus (EBV), hepatitis A, parasites, and tickborne infections may also be transmitted by blood products.
2. Sepsis related to bacterial contamination
  - a. Risk of transmission of bacteria in RBCs is 1 in 5 million units.
  - b. Risk of transmission in platelets is 1 in 107,000 units.
  - c. Risk is higher in platelets because they are stored at room temperature.

TABLE 14.18

## BLOOD PRODUCTS

Product	Contains	Indications	Dose	Volume of 1 Unit (U)	Change in blood count
PRBCs	Concentrated RBCs w/Hct 55%–70%	Generally Hb <7 g/dL, <sup>a</sup> but consider clinical picture. Use typed and crossmatched products when possible. O— can be provided emergently without crossmatch if transfusion cannot be delayed. See <a href="#">Section X, Online Content</a> , for specific types of PRBCs.	10–15 mL/kg (at max 2–4 mL/kg/hr) RBCs must be transfused within 4 hours of leaving blood bank.	300–350 mL after processing	To determine volume necessary for desired Hct: PRBC volume (mL) = (EBV [mL] × [desired Hct — actual Hct])/Hct of PRBCs <sup>b</sup>
Platelets		Severe (<10,000/μL) thrombocytopenia, symptomatic thrombocytopenia, to achieve platelets >50,000/μL before minor or >100,000/μL before major surgery or intracranial operation Transfusion indications for neonates: Platelets <20,000/μL; platelets <30,000/μL + weight <1 kg, age <1 week, clinically unstable, history major bleed (e.g., IVH), current bleed, coagulopathy/DIC, preprocedure; platelets >50,000/μL only if significant bleed	Children ≤30 kg <sup>c</sup> : 5–10 mL/kg or 1 equivalent unit per 5–10 kg Children >30 kg: 1 apheresis unit Transfuse as rapidly as able.	300 mL for 1 apheresis unit, 50 mL for 1 equivalent unit	10 mL/kg increases platelets by 50,000/μL.
FFP	Physiologic quantities all coagulation factors <sup>d</sup>	Treat severe clotting factor deficiencies with active bleeding (DIC, vitamin K deficiency with active bleeding, TTP) or before invasive procedure. Combine with vitamin K for emergency reversal of warfarin.	15 mL/kg; repeat PRN	250–300 mL	1 unit activity of all factors except V and VIII

Cryoprecipitate	Enriched factors VIII and XIII, vWF, fibrinogen, fibronectin	For hypofibrinogenemia, dysfibrinogenemia	Children <5 kg: 1 single donor unit. Children 5–50 kg: 1 unit per 5–10 kg. Children >50 kg: 1–2 pools (5–10 units)	10–15 mL for 1 unit, 50–100 mL for a pool	1 unit contains approximately 80 units factor VIII, 150 mg fibrinogen. <sup>e</sup>
-----------------	--	---	--	---	---

<sup>a</sup>Restrictive transfusion protocol with Hb threshold 7 g/dL associated with fewer transfusions without differences in clinical outcomes.

<sup>b</sup>Hct of PRBCs is typically 55% to 70% depending on storage anticoagulant.

<sup>c</sup>1 unit of apheresis platelets is derived from a single donor and contains  $>3 \times 10^{11}$  platelets/mL. 1 equivalent unit is  $\sim 1/5$ th– $1/6$ th an apheresis unit. Single-donor platelet concentrates are derived from a single donor and contain  $>5.5 \times 10^{10}$  platelets in approximately 50 mL. 4–6 equivalent units or platelet concentrates can be pooled to make equivalent of 1 apheresis unit.

<sup>d</sup>FFP does not include platelets or fibrinogen. Does include anticoagulant factors (antithrombin III, proteins C/S). **NOTE:** FFP unlikely to have significant effect when INR  $\leq 1.6$ .<sup>46</sup>

<sup>e</sup>This is an estimation. 1 unit of cryoprecipitate is derived from 500 mL of blood from 1 donor. A pool is 5 individual donor units pooled together.

*DIC*, Disseminated intravascular coagulation; *EBV*, estimated blood volume; *FFP*, fresh frozen plasma; *Hb*, hemoglobin; *Hct*, Hb/hematocrit; *PRBCs*, packed red blood cells; *PRN*, as needed; *RBCs*, red blood cells; *TTP*, thrombotic thrombocytopenic purpura; *vWF*, von Willebrand factor.

Data from Bachowski G, Borge D, Brunner PAR, et al. *A Compendium of Transfusion Practice Guidelines*. 3rd ed. American Red Cross; 2017. Behrman RE, Kliegman RM, Jenson AH. *Nelson Textbook of Pediatrics*. 17th ed. Saunders; 2004.

TABLE 14.19

## TRANSFUSION REACTIONS

Reaction	Timeline	Pathophysiology	Signs/Symptoms	Labs	Treatment
Acute hemolytic transfusion reaction	Immediate	Blood group incompatibility results in intravascular hemolysis, acute renal failure, DIC	Fevers, chills, flank pain, tachycardia, hypotension, shock, hematuria, bleeding	ABO, CBC hemolysis labs: DAT, haptoglobin, LDH, bilirubin +/- DIC labs: PT/aPTT, fibrinogen, D-dimer Urinalysis (evaluate for hemoglobinuria)	Stop transfusion. Notify blood bank. Supportive measures: IV normal saline to achieve UOP >1 mL/kg/hr, vasopressors as needed, nephrology consult if necessary for acute renal failure
Febrile nonhemolytic reaction	1–6 hr	Either cytokines from donor WBCs in product or recipient anti-neutrophil or anti-HLA antibodies against WBCs in donor product	Fever, chills, diaphoresis	Exclude alternative reactions (AHTR, sepsis)	Decreased incidence with leukoreduced products Stop transfusion. Notify blood bank. Antipyretics Consider future premedication with antipyretics (little evidence supporting practice).
Urticarial reaction	Immediate	Reaction to donor plasma proteins	Urticarial rash, respiratory distress	Possible formation IgE anti-IgA antibody	Stop transfusion. Notify blood bank. Epinephrine/steroids for respiratory compromise Antihistamines Resolved mild (cutaneous only) allergic reaction is the only time that a transfusion may be resumed with remainder of product.

Delayed transfusion reaction	>24 hr posttransfusion (up to 30 days)	Minor blood group antigen incompatibility results in extravascular hemolysis	Fatigue, jaundice, dark urine	Anemia +DAT Evidence of hemolysis New RBC Abs	Monitor Hb level closely. Supportive care
------------------------------	--	--	-------------------------------	--	--

*ABO*, Blood type; *Abs*, antibodies; *AHTR*, acute hemolytic transfusion reaction; *aPTT*, activated partial thromboplastin time; *CBC*, complete blood count; *DAT*, direct antiglobulin test; *DIC*, disseminated intravascular coagulation; *Hb*, hemoglobin; *HLA*, human leukocyte antigen; *IV*, intravenous; *LDH*, lactate dehydrogenase; *PRBCs*, packed red blood cells; *PT*, prothrombin time; *RBC*, red blood cell; *UOP*, urine output; *WBCs*, white blood cells. Data from Delaney M, Wendel S, Bercovitz RS, et al. Transfusion reactions: prevention, diagnosis, and treatment. *Lancet*. 2016;388(10061):2825–2836. Bachowski G, Borge D, Bruner PAR, et al. *A Compendium of Transfusion Practice Guidelines*. 3rd ed. American Red Cross; 2017.

TABLE 14.1

## AGE-SPECIFIC BLOOD CELL INDICES

Age	Hb (g/dL) <sup>a</sup>	HCT (%) <sup>a</sup>	MCV (fL) <sup>a</sup>	MCHC (g/dL RBC) <sup>a</sup>	Reticulocytes	WBCs ( $\times 10^3/\text{mL}$ ) <sup>b</sup>	Platelets ( $10^3/\text{mL}$ ) <sup>b</sup>
26–30 weeks <sup>c</sup> gestation <sup>c</sup>	13.4 (11)	41.5 (34.9)	118.2 (106.7)	37.9 (30.6)	—	4.4 (2.7)	254 (180–327)
28 weeks	14.5	45	120	31.0	(5–10)	—	275
32 weeks	15.0	47	118	32.0	(3–10)	—	290
Term <sup>d</sup> (cord)	16.5 (13.5)	51 (42)	108 (98)	33.0 (30.0)	(3–7)	18.1 (9–30) <sup>e</sup>	290
1–3 days	18.5 (14.5)	56 (45)	108 (95)	33.0 (29.0)	(1.8–4.6)	18.9 (9.4–34)	192
2 weeks	16.6 (13.4)	53 (41)	105 (88)	31.4 (28.1)	—	11.4 (5–20)	252
1 month	13.9 (10.7)	44 (33)	101 (91)	31.8 (28.1)	(0.1–1.7)	10.8 (4–19.5)	—
2 months	11.2 (9.4)	35 (28)	95 (84)	31.8 (28.3)	—	—	—
6 months	12.6 (11.1)	36 (31)	76 (68)	35.0 (32.7)	(0.7–2.3)	11.9 (6–17.5)	—
6 months–2 years	12.0 (10.5)	36 (33)	78 (70)	33.0 (30.0)	—	10.6 (6–17)	(150–350)
2–6 years	12.5 (11.5)	37 (34)	81 (75)	34.0 (31.0)	(0.5–1.0)	8.5 (5–15.5)	(150–350)
6–12 years	13.5 (11.5)	40 (35)	86 (77)	34.0 (31.0)	(0.5–1.0)	8.1 (4.5–13.5)	(150–350)
<b>12–18 YEARS</b>							
Male	14.5 (13)	43 (36)	88 (78)	34.0 (31.0)	(0.5–1.0)	7.8 (4.5–13.5)	(150–350)
Female	14.0 (12)	41 (37)	90 (78)	34.0 (31.0)	(0.5–1.0)	7.8 (4.5–13.5)	(150–350)
<b>ADULT</b>							
Male	15.5 (13.5)	47 (41)	90 (80)	34.0 (31.0)	(0.8–2.5)	7.4 (4.5–11)	(150–350)
Female	14.0 (12)	41 (36)	90 (80)	34.0 (31.0)	(0.8–4.1)	7.4 (4.5–11)	(150–350)

<sup>a</sup>Data are mean ( $-2$  SD).<sup>b</sup>Data are mean ( $\pm 2$  SD).<sup>c</sup>Values are from fetal samplings.<sup>d</sup>Until 1 month of age, capillary hemoglobin exceeds venous: 1 hour: 3.6-g difference; 5 days: 2.2-g difference; 3 weeks: 1.1-g difference.<sup>e</sup>Mean (95% confidence limits).

Hb, Hemoglobin; HCT, hematocrit; MCHC, mean cell hemoglobin concentration; MCV, mean corpuscular volume; RBC, red blood cell; WBC, white blood cell.

Data from Forestier F, Dattos F, Galacteros F, et al. Hematologic values of 163 normal fetuses between 18 and 30 weeks of gestation. *Pediatr Res*. 1986;20:342; Oski FA, Naiman JL. *Hematological Problems in the Newborn Infant*. WB Saunders; 1982; Nathan D, Oski FA. *Hematology of Infancy and Childhood*. WB Saunders; 1998; Matoth Y, Zaizor K, Varsano I, et al. Postnatal changes in some red cell parameters. *Acta Paediatr Scand*. 1971;60:317; and Wintrobe MM. *Clinical Hematology*. Williams & Wilkins; 1999.

TABLE 14.7

## AGE-SPECIFIC LEUKOCYTE DIFFERENTIAL

Age	Total Leukocytes <sup>a</sup>	Neutrophils <sup>b</sup>		Lymphocytes		Monocytes		Eosinophils	
	Mean (Range)	Mean (Range)	%	Mean (Range)	%	Mean	%	Mean	%
Birth	18.1 (9–30)	11 (6–26)	61	5.5 (2–11)	31	1.1	6	0.4	2
12 hr	22.8 (13–38)	15.5 (6–28)	68	5.5 (2–11)	24	1.2	5	0.5	2
24 hr	18.9 (9.4–34)	11.5 (5–21)	61	5.8 (2–11.5)	31	1.1	6	0.5	2
1 week	12.2 (5–21)	5.5 (1.5–10)	45	5.0 (2–17)	41	1.1	9	0.5	4
2 weeks	11.4 (5–20)	4.5 (1–9.5)	40	5.5 (2–17)	48	1.0	9	0.4	3
1 month	10.8 (5–19.5)	3.8 (1–8.5)	35	6.0 (2.5–16.5)	56	0.7	7	0.3	3
6 months	11.9 (6–17.5)	3.8 (1–8.5)	32	7.3 (4–13.5)	61	0.6	5	0.3	3
1 year	11.4 (6–17.5)	3.5 (1.5–8.5)	31	7.0 (4–10.5)	61	0.6	5	0.3	3
2 years	10.6 (6–17)	3.5 (1.5–8.5)	33	6.3 (3–9.5)	59	0.5	5	0.3	3
4 years	9.1 (5.5–15.5)	3.8 (1.5–8.5)	42	4.5 (2–8)	50	0.5	5	0.3	3
6 years	8.5 (5–14.5)	4.3 (1.5–8)	51	3.5 (1.5–7)	42	0.4	5	0.2	3
8 years	8.3 (4.5–13.5)	4.4 (1.5–8)	53	3.3 (1.5–6.8)	39	0.4	4	0.2	2
10 years	8.1 (4.5–13.5)	4.4 (1.5–8.5)	54	3.1 (1.5–6.5)	38	0.4	4	0.2	2
16 years	7.8 (4.5–13.0)	4.4 (1.8–8)	57	2.8 (1.2–5.2)	35	0.4	5	0.2	3
21 years	7.4 (4.5–11.0)	4.4 (1.8–7.7)	59	2.5 (1–4.8)	34	0.3	4	0.2	3

<sup>a</sup>Numbers of leukocytes are  $\times 10^3/\mu\text{L}$ ; ranges are estimates of 95% confidence limits; percentages refer to differential counts.

<sup>b</sup>Neutrophils include band cells at all ages and a small number of metamyelocytes and myelocytes in the first few days of life.

Adapted from Cairo MS, Brahuo F. Blood and blood-forming tissues. In: Randolph AM, ed. *Pediatrics*. 21st ed. McGraw-Hill; 2003.

## IX. ADDITIONAL RESOURCES

**A. Medications to Avoid With G6PD Deficiency:** <https://www.g6pd.org/en/G6PDDeficiency/SafeUnsafe.aspx>

**B. Medications Associated With Thrombocytopenia:** <https://www.ouhsc.edu/platelets/ditp.html>

**C. Anemia Algorithm App: Created for Adult Patients but Provides Useful Framework for Anemia Differential**

## REFERENCES

A complete list of references can be found online.

## X. ONLINE CONTENT

### A. Specific PRBC Types

1. Leukoreduced RBCs: 99.9% white blood cells (WBCs) removed to reduce risks of pathogen transmission (e.g., CMV), HLA alloimmunization, and febrile nonhemolytic transfusion reaction
2. Washed RBCs: Removal of plasma proteins in products for recipients with history of anaphylactic transfusion reactions or complete IgA deficiency
3. CMV-safe RBCs: Leukoreduced units likely comparable to low transmission risk with CMV-seronegative units (from donors with negative CMV serology). Preferred for vulnerable populations: CMV-negative bone marrow transplant or solid organ recipients, immunodeficient patients, premature or low-birth-weight infants, intrauterine transfusions, pregnant women
4. Irradiated blood products: Inactivated donor lymphocytes capable of causing transfusion-associated graft-versus-host disease (GVHD).<sup>33</sup> Used for susceptible patients: leukemia, lymphoma, BMT, solid organ transplant, intensive chemotherapy, known/suspected immune deficiency, intrauterine transfusions, neonate transfusions, patients receiving T-cell suppressive therapy. Also necessary in directed donation from a relative

### B. Directed-Donor Transfusions

1. When to consider directed donor:
  - a. Chronic transfusion programs (e.g., “blood buddy” programs), where donors provide antigen-matched red cells repetitively for the same patient requiring frequent transfusions (e.g., thalassemia, sickle cell disease)
  - b. Neonatal alloimmune thrombocytopenia (NAIT), where maternal platelets lack causative antigens and represent optimal therapy
2. Reasons to not consider directed donor:
  - a. Practice not often feasible. Specific screening, donation, product testing, and processing causes delays (2 to 3 days or more) when compatible blood is often readily available.
  - b. Directed donor may not be compatible: must be at least ABO/RhD compatible and may require other RBC antigen compatibility if recipient has antibodies.
  - c. Directed donors may be less likely to be truthful in donor screening due to motivation and social pressure to donate, causing potential increased infection risk.
  - d. Products from a relative require irradiation due to increased risk of transfusion-associated GVHD
  - e. If RBC donor is also a potential bone marrow transplant donor for recipient, donation increases risk of development of donor-directed human leukocyte antigen (HLA) antibodies in recipient, which may cause graft failure.

## REFERENCES

1. Baker RD, Greer FR. The Committee on Nutrition. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). *Pediatrics*. 2010;126(5):1–11.
2. Demir A, Yarali N, Fisgin T, et al. Most reliable indices in differentiation between thalassemia trait and iron deficiency anemia. *Pediatr Int*. 2002;44:612–616.
3. Loscalzo J, et al. *Harrison's Principles of Internal Medicine*. 21st ed. McGraw Hill Education; 2022.
4. Noronha SA. Acquired and congenital hemolytic anemia. *Pediatr Rev*. 2016;37(6):235–246.
5. Wang M. Iron deficiency and other types of anemia in infants and children. *Am Fam Physician*. 2016;93(4):270–278.
6. Plummer ES, Crary SE, McCavit TL, et al. Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. *Pediatr Blood Cancer*. 2013;60(11):1747–1752.
7. Crary SE, Hall K, Buchanan GR. Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. *Pediatr Blood Cancer*. 2011;56(4):615–619.
8. National Heart, Lung, and Blood Institute. *Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014*. National Institutes of Health; 2014.
9. Davis BA, Allard S, Qureshi A, et al. Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects. *Br J Haematol*. 2016;176(2):179–191.
10. Cappellini MD, et al. *2021 Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)*. 4th ed. Thalassaemia International Federation; 2021.
11. Walkovich K, Boxer LA. How to approach neutropenia in childhood. *Pediatr Rev*. 2013;34(4):173–184.
12. Orkin SH, et al. *Nathan and Oski's Hematology and Oncology of Infancy and Childhood*. 8th ed. Philadelphia: Saunders; 2015.
13. Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up of patients in the severe chronic neutropenia international Registry. *Am J Hematol*. 2003;72:82–93.
14. Arnold DM. Bleeding complications in immune thrombocytopenia. *Hematology Am Soc Hematol Educ Program*. 2015;2015(1):237–242.
15. Israels SJ, Kahr WH, Blanchette VS, et al. Platelet disorders in children: a diagnostic approach. *Pediatr Blood Cancer*. 2011;56:975–983.
16. Favaloro EJ, Lippi G, Franchini M. Contemporary platelet function testing. *Clin Chem Lab Med*. 2010;48(5):579–598.
17. Neunert C, Terrell DR, Arnold DM, et al. The American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv*. 2019;3(23):3829–3866.
18. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. *Blood*. 2010;115:168–186.
19. Loirat C, Girma JP, Desconclois C, et al. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. *Pediatr Nephrol*. 2009;24:19–29.
20. George JN, Nester CM. Syndromes of thrombotic microangiopathy. *N Engl J Med*. 2014;371:654–656.

21. Loirat C, Fakhouri F, Ariceta G, Besbas N, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. *Pediatr Nephrol*. 2016;31:15–39.
22. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. *N Engl J Med*. 2007;357(6):580–587.
23. Morrone K. Thrombocytopenia in the newborn. *NeoReviews*. 2018;19(1):e34–e41.
24. Briones M, Abshire T. Lupus anticoagulants in children. *Curr Opin Hematol*. 2003;10:375–379.
25. Curry NS, Davenport R, Pavord S, et al. The use of viscoelastic haemostatic assays in the management of major bleeding. *Br J Haematol*. 2018;182(6):789–806.
26. Oren H, Cingoz I, Duman M, et al. Disseminated intravascular coagulation in pediatric patients: clinical and laboratory features and prognostic factors influencing the survival. *Pediatr Hematol Oncol*. 2005;22:679–688.
27. Morley SL. Management of acquired coagulopathy in acute paediatrics. *Arch Dis Child Educ Pract*. 2011;96:49–60.
28. Srivastava A, Santagostino E, Dougall A, et al. *WFH Guidelines for the Management of Hemophilia*. Haemophilia; 2020.
29. Medical and Scientific Advisory Council. *MASAC Recommendation Concerning Prophylaxis*. (MASAC Document #241); 2016. <https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendation-Concerning-Prophylaxis>
30. Nichols WL, Hultin MB, James AH, et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) expert panel report. *Haemophilia*. 2008;14(2):171–232.
31. Bachowski G, Brunner P, Goldberg C, et al. *A Compendium of Transfusion Practice Guidelines*. 4th ed. American Red Cross; 2021.
32. *Red Book. 2021-2024 Report of the Committee on Infectious Diseases*. 32nd ed. American Academy of Pediatrics; 2021.
33. Strouse JJ, Takemoto CM, Keefer JR, et al. Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. *Pediatr Blood Cancer*. 2008;50:1006–1012.
34. Rankine-Mullings AE, Owusu Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. *Cochrane Database Syst Rev*. 2021 Mar 8;3(3):CD003427. <https://doi.org/10.1002/14651858.CD003427.pub5>.
35. Field JJ, Knight-Perry JE, DeBaun MR. Acute pain in children and adults with sickle cell disease: management in the absence of evidence-based guidelines. *Curr Opin Hematol*. 2009;16(3):173–178.
36. Zempsky WT, Loiselle KA, Corsi JM, et al. Use of low-dose ketamine infusion for pediatric patients with sickle cell disease-related pain: a case series. *Clin J Pain*. 2010;26(2):163–167.
37. Okomo U, Meremikwu MM. Fluid replacement therapy for acute episodes of pain in people with sickle cell disease. *Cochrane Database Syst Rev*. 2012;(6):CD005406.
38. Deleted in proofs
39. Hulbert ML, Scothorn DJ, Panepinto JA, et al. Exchange blood transfusion for first overt stroke is associated with a lower risk of subsequent stroke than simple transfusion: a retrospective cohort of 137 children with sickle cell anemia. *J Pediatr*. 2006;149:710–712.

40. Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) for sickle cell disease. *Cochrane Database of Systematic Reviews*. 2022;(9). <https://doi.org/10.1002/14651858.CD002202.pub3>. Art. No.: CD002202
41. Estep JH, Smeltzer MP, Kang G, et al. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. *Am J Hematol*. 2017;92:1333–1339.
42. *Vaccine Recommendations and Guidelines of the ACIP*. Accessed April 1, 2022. <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html>
43. Wang WC, Ware RE, Miller ST. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicenter, randomized, controlled trial (BABY-HUG). *Lancet*. 2011;377:1663–1672.
44. Von Vajna E, Alam R, So TY. Current clinical trials on the use of direct oral anticoagulants in the pediatric population. *Cardiol Ther*. 2016;5:19–41.
45. Ko RH, Michieli C, Lira JL. FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events. *Thromb Res*. 2014;134(3):643–647.
46. Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results. *Am J Clin Pathol*. 2006;126(1):133–139.
47. Shaw KN, Bachur RG. *Fleisher & Ludwig's Textbook of Pediatric Emergency Medicine*. 8th ed. Wolters Kluwer Health; 2020.
48. Cario H, McMullin MF, Bento C, et al. Erythrocytosis in children and adolescents-classification, characterization, and consensus recommendations for the diagnostic approach. *Pediatr Blood Cancer*. 2013;60(11):1734–1738.

# Chapter 15

## Immunology and Allergy

*Samantha E. Leong, MD, PhD*

 See additional content online.

### I. ALLERGIC RHINITIS<sup>1-6</sup>

#### A. Epidemiology

1. Most common pediatric chronic medical condition: Prevalence in children up to 40%
2. Increases risk for recurrent otitis media, asthma, and acute and chronic sinusitis
3. Risk factors: Atopic family history, higher socioeconomic status, infant exposure to maternal smoking in utero and during early childhood, early personal history of atopic dermatitis and/or food allergy

#### B. Diagnosis

##### 1. History:

- a. Allergen-driven mucosal inflammation leading to cyclical exacerbations or persistent symptoms
- b. Symptoms: Nasal (congestion, rhinorrhea, pruritus), ocular (pruritus, tearing), and postnasal drip (sore throat, cough)
- c. Patterns: Seasonal (depending on local allergens) versus perennial (year-round, often with seasonal peaks)
- d. Coexisting atopic diseases common (eczema, asthma, food allergy)

##### 2. Physical examination:

- a. Allergic facies with shinners, mouth breathing, transverse nasal crease (“allergic salute”), accentuated lines below lower eyelids (Dennie-Morgan lines)
- b. May have swollen nasal turbinates
- c. Injected sclera with or without clear discharge, conjunctival cobblestoning

##### 3. Diagnostic studies:

- a. Diagnosis can be made on clinical grounds; however, skin tests or allergen-specific IgE testing can identify specific sensitivities.
- b. Total IgE, peripheral blood eosinophil count, and imaging studies are not recommended due to poor specificity.

#### C. Differential Diagnosis

Vasomotor/nonallergic rhinitis (e.g., hypersensitivity to scents, alcohol, changes in climate), infectious rhinitis, adenoid hypertrophy, rhinitis medicamentosa (rebound rhinitis from prolonged use of nasal vasoconstrictors), sinusitis, nonallergic rhinitis with eosinophilia syndrome, nasal polyps

## D. Management

### 1. Allergen avoidance:

- Relies on identification of triggers, most common of which are pollens, fungi, dust mites, insects, and animals
- High efficiency particulate air (HEPA) filter may be useful when animal allergens are a concern.
- Thorough housecleaning and allergy-proof bed coverings can be useful.

### 2. Nasal irrigation with hypertonic saline: Use distilled, sterile, or boiled water (at least 3 minutes) for homemade solutions.

### 3. Pharmacotherapy (Table 15.1)

**TABLE 15.1**

#### PHARMACOTHERAPY FOR MANAGEMENT OF ALLERGIC RHINITIS

Class of Agents (Examples)	Use	Adverse Effects
<b>Oral antihistamines</b> (e.g., cetirizine, levocetirizine, fexofenadine, loratadine, desloratadine)	First-line for mild or episodic symptoms or patients who cannot tolerate or refuse nasal sprays	Sedation and anticholinergic effects (second-generation preparations preferable to first-generation due to reduced central nervous system side effects)
<b>Oral leukotriene inhibitors</b> (e.g., montelukast)	Consider in patients not effectively treated with or intolerant of other therapies. More effective in combination with antihistamines	Serious neuropsychiatric events (e.g., suicidal thoughts and actions) have been reported.
<b>Intranasal antihistamines</b> (e.g., azelastine, olopatadine)	Effective for acute symptoms; faster onset of action than glucocorticoid nasal spray	Bitter taste, systemic absorption with potential for sedation
<b>Intranasal corticosteroids</b> (e.g., fluticasone, mometasone, budesonide, flunisolide, ciclesonide, and triamcinolone)	First-line for persistent or moderate-to-severe symptoms, as it is the most effective monotherapy for nasal congestion and ocular symptoms. Maximal therapeutic benefit when used over several days or weeks. No effect with as-needed use. Administration: Clear mucus crusting, point head slightly down, and direct nozzle away from septum aiming towards the side of the nostril.	Nasal irritation, sneezing, bleeding, and potential risk of reduced growth velocity and adrenal suppression at high doses, especially in patients on multiple steroid preparations. Growth monitoring recommended

TABLE 15.1

## PHARMACOTHERAPY FOR MANAGEMENT OF ALLERGIC RHINITIS—CONT'D

Class of Agents (Examples)	Use	Adverse Effects
<b>Intranasal combination agents</b> (e.g., azelastine/ fluticasone)	Useful for moderate-to-severe allergic rhinitis Additional efficacy in rapidity of onset and magnitude of symptom relief	As above for individual preparations
<b>Ophthalmic agents:</b> <b>Mast cell stabilizers</b> (e.g., cromolyn sodium, lodoxamide-tromethamine, nedocromil, pemirolast)	Allergic conjunctivitis	Avoid use of steroids unless directed by an ophthalmologist.
<b>H1-antagonists and mast cell stabilizers</b> (e.g., alcaftadine, azelastine HCl, bepotastine, emedastine, epinastine, ketotifen fumarate, olopatadine)		

4. **Immunotherapy:**


- a. Success rate is high when patients are chosen carefully and when performed by an allergy specialist.
- b. Consider when symptoms are inadequately controlled with medications and allergen avoidance.
- c. In addition to traditional subcutaneous immunotherapy, sublingual products have now been approved for several allergens.
- d. Not recommended for patients with poor adherence to therapy or those with poorly controlled asthma
- e. Not well studied in children younger than 5 years
- f. May reduce risk for future development of asthma, and treatment of allergic rhinitis may improve asthma control

**II. FOOD ALLERGY<sup>7-18</sup>****A. Epidemiology**

1. Prevalence is 6% to 8% in young children and 3% to 4% in adolescence with increasing worldwide prevalence.
2. Most common allergens in children: Milk, eggs, peanuts, tree nuts (e.g., cashew, walnut), soy, fish, shellfish, and wheat

**B. Diagnosis (Fig. 15.1)**1. **History:**

- a. Identify specific foods and whether fresh vs. cooked.
- b. Establish timing and nature of reactions. Symptoms typically occur within minutes to hours of ingesting food.

**FIGURE 15.1**

Evaluation and management of food allergy. *IgE*, Immunoglobulin E; *PRN*, as needed; *Sxs*, symptoms. (Data from Wood RA. The natural history of food allergy. *Pediatrics*. 2003;111:1631–1637.)

## 2. Physical examination:

- a. Often a combination of several syndromes
- b. **Anaphylaxis:** See [Chapter 1](#).
- c. **Skin syndromes:**
  - (1) **Urticaria/angioedema:**
    - (a) Chronic urticaria is rarely related to food allergy.
    - (b) Acute urticaria due to food allergy may be a risk factor for future anaphylaxis.
  - (2) **Atopic dermatitis/eczema:**
    - (a) Food allergy is more common in patients with atopic dermatitis.

(b) Even if not apparent by history, at least one-third of children with moderate to severe atopic dermatitis have IgE-mediated food allergies.

d. **Gastrointestinal syndromes:**

(1) **Oral allergy syndrome:**

- (a) Pollen-associated food allergy caused by cross-reactivity of antibodies to pollens (e.g., apple and tree pollen)
- (b) Pruritus of oral mucosa after ingestion of certain fresh fruits and vegetables in patients with pollen allergies. Rarely results in edema of oral mucosa or progresses beyond mouth/throat
- (c) Inciting antigens are usually denatured by cooking.

(2) **Allergic eosinophilic gastroenteritis, esophagitis:** See [Chapter 12](#).

(3) **Food protein–induced enterocolitis syndrome (FPIES):**

- (a) Presents in infancy
- (b) Vomiting and diarrhea (may contain blood); when severe, may lead to lethargy, dehydration, hypotension, acidosis
- (c) Most commonly associated with milk and soy but may occur with a wide variety of foods (e.g., rice, oat, fruits, and vegetables)

(4) **Infantile proctocolitis:**

- (a) Confined to distal colon and can present with diarrhea or blood-streaked and mucus-containing stools
- (b) Symptoms usually resolve within 72 hours of stopping offending agent; rarely leads to anemia

3. **Diagnostic studies:**

a. Testing can demonstrate sensitization (allergen-specific IgE). A positive result only means sensitization and not necessarily allergy (must correlate with clinical history and exam).

b. **Skin testing:**

- (1) Skin-prick test has poor positive predictive value but very good negative predictive value.
- (2) Patient must not be taking antihistamines during week of testing.
- (3) Widespread skin conditions (e.g., dermatographism, urticaria, severe eczema) may limit ability to perform skin tests.

c. **Measurement of allergen-specific IgE:**

- (1) Similar to skin tests, it has poor positive predictive value and excellent negative predictive value.
- (2) Levels above a certain range (variable among different antigens) have increasing positive predictive value.
- (3) Useful in patients with dermatologic conditions that preclude skin testing
- (4) Not affected by use of antihistamines
- (5) Component testing (measuring IgE to specific food proteins rather than crude extracts) may improve diagnostic accuracy for peanut, hazelnut, and possibly other foods.

d. **Oral food challenges:**

- (1) Can verify clinical reactivity to a specific food allergen or document that a food allergy has been outgrown

- (2) Must be performed under close medical supervision with emergency medications readily available
- (3) Patient must not be taking antihistamines during week of testing
- (4) Most accurate when double-blinded using graded doses of disguised food

e. **Trial elimination diet:**

- (1) Helpful if improvement with removal of food from diet
- (2) Especially useful in infants and essential for non-IgE-mediated food allergy

### C. Differential Diagnosis

1. **Food intolerance:** Nonimmunologic, based on toxins or other properties of foods leading to adverse effects
2. **Malabsorption syndromes:**
  - a. Cystic fibrosis, celiac disease (see [Chapter 12](#)), and lactase deficiency
  - b. Gastrointestinal malformations

### D. Management

1. **Allergen avoidance:**
  - a. Most important intervention for all types of food allergy
  - b. Patients must pay close attention to food ingredients. Implement an *“If you can’t read it, you can’t eat it”* approach to avoid risky unlabeled foods.
  - c. Nutritional counseling and regular growth monitoring are recommended.
2. **Anaphylaxis:**
  - a. See [Chapter 1](#) for management of anaphylaxis.
  - b. Prescribe epinephrine autoinjector for all at-risk patients.
  - c. Counsel families to always have epinephrine autoinjectors readily available. Counsel to call 9-1-1 if using.
  - d. Counsel on possibility of symptom recurrence after initial resolution, which may require a second dose. Autoinjector two-packs should not be divided between locations (e.g., households, school).
  - e. Develop Anaphylaxis Action Plan indicating specific allergies, symptoms for which to observe, and medications to be administered.
  - f. Make school aware of Anaphylaxis Action Plan and ensure they can administer lifesaving medications.
3. **Non-anaphylactic angioedema/urticaria:**
  - a. Antihistamines or corticosteroids, based on severity and duration of symptoms
  - b. Omalizumab approved for treatment of chronic urticaria
4. **Atopic dermatitis:** Symptomatic control (see [Chapter 8](#))
5. **Food-specific immunotherapy:**
  - a. Used to induce clinical desensitization to specific allergens
  - b. Oral immunotherapy (OIT): Exposure to gradually increased quantity of ingested food (e.g., Palforzia is the first FDA-approved OIT for peanut allergy)
  - c. Other strategies (sublingual, epicutaneous, use of monoclonal antibody drugs as adjuncts or monotherapy) are under investigation.

### E. Natural History

1. About 50% of milk, egg, soy, and wheat allergies are outgrown by school age.
2. Peanut, tree nut, and shellfish allergies are outgrown only in 10% to 20%.
3. Skin tests and allergen-specific IgE may remain positive, even though symptoms resolve.

### F. Prevention

1. For introducing new foods to infants with high-risk atopic disease, there is no evidence that delaying or avoiding common allergenic foods prevents atopic disease.
2. Based on studies that showed early, sustained introduction of peanut reduced peanut allergy frequency, AAP recommends early introduction of peanut-based foods (e.g., thinned peanut butter, peanut snacks, peanut flour, peanut butter powder) at 4 to 6 months in highest-risk infants (severe eczema and/or egg allergy) after testing.
3. Emerging evidence suggests that early introduction of other common allergenic foods may be protective against the development of food allergies.

## III. DRUG ALLERGY<sup>19-21</sup>

### A. Definition


1. **Drug allergy:** Immunologically mediated response to an agent in a sensitized person
2. **Drug intolerance:** Undesirable pharmacologic effect
3. Although 10% of patients report penicillin allergy, after evaluation, about 90% of these individuals can tolerate penicillin.

### B. Diagnosis

1. Cutaneous manifestations are the most common presentation for drug allergic reactions.
2. **Diagnostic studies:** Penicillin is the only drug for which standardized skin testing reagents and procedures have been validated. Skin testing or supervised graded dose challenge may be done with caution for other medications, but results must be carefully considered in the context of the clinical picture, as both false positive and false negative results are common.

### C. Management (Fig. 15.2)

1. **Avoidance:** When able, use alternative therapy.
2. **Desensitization:** Progressive administration of an allergenic substance to render immune system less reactive
3. **Graded challenge:** Administration of progressively increasing doses of a drug until full dose is reached; does not modify a patient's response to the drug but is used to optimize safety when the history and test results are not completely reassuring

**FIGURE 15.2**

Evaluation and management of penicillin allergy. *ICU*, Intensive care unit; *IgE*, immunoglobulin E; *PCN*, penicillin. (Adapted from Mirakian R, Leech SC, Krishna MT, et al. Management of allergy to penicillins and other beta-lactams. *Clin Exp Allergy*. 2015;45:300.)

## IV. IMMUNODEFICIENCY<sup>22-27</sup>

### A. Clinical Presentation

1. Increased susceptibility to infection
  - a. Chronic/recurrent infections
    - (1) Four or more new ear infections within 1 year

- (2) Two or more serious sinus infections within 1 year
- (3) Two or more pneumonias within 1 year
- (4) Recurrent tissue or organ abscesses
- (5) Persistent thrush in mouth or fungal infection of skin
- b. Severe infections
  - (1) Bacterial meningitis
  - (2) Pneumonia with empyema
  - (3) Sepsis in the absence of a known risk (e.g., indwelling vascular catheter)
  - (4) Two or more months of antibiotics with little effect
  - (5) Need for intravenous antibiotics to clear infections
- c. Opportunistic infections
  - (1) *Pneumocystis jirovecii*
  - (2) *Mycobacterium avium* cellulare
2. Autoimmune or inflammatory diseases
  - a. Defects in immunity may also impair ability to discriminate self and non-self, manifesting as autoimmunity.
  - b. May be limited to single target cells (e.g., hemolytic anemia, immune thrombocytopenia) or organs (e.g., thyroiditis)
  - c. May involve multiple target organs or systems (e.g., systemic lupus erythematosus, vasculitis, arthritis)
3. Syndrome complex
  - a. Wiskott-Aldrich syndrome: Thrombocytopenia, eczema
  - b. DiGeorge syndrome: Congenital heart disease, facial dysmorphism, hypoparathyroidism
4. Other considerations
  - a. Failure to gain weight or grow normally
  - b. Family history of immunodeficiency or unexplained early deaths
  - c. Lymphopenia in infancy
  - d. Complications from a live vaccine

## B. Evaluation (Table 15.2)

## V. IMMUNOGLOBULIN THERAPY<sup>28-34</sup>

### A. Intravenous Immunoglobulin (IVIG)

#### 1. Indications:

- a. Replacement therapy for antibody-deficient disorders:
  - (1) Children with severe hypogammaglobulinemia (<100 mg/dL) may benefit from a higher total *loading* dose in two separate doses a few days apart, followed by standard dosing every 3 to 4 weeks
  - (2) Useful in human immunodeficiency virus (HIV), antibody deficiency (IgG concentration <400 mg/dL from failure to form antibodies to common antigens), recurrent serious bacterial infections, or prior to measles prophylaxis

TABLE 15.2

## EVALUATION OF SUSPECTED IMMUNODEFICIENCY

Suspected Functional Abnormality	Clinical Findings	Initial Tests	More Advanced Tests
Humoral (e.g., common variable immunodeficiency, X-linked agammaglobulinemia, IgA deficiency)	Sinopulmonary and systemic infections (pyogenic bacteria) Enteric infections (enterovirus, other viruses, <i>Giardia</i> spp.) Autoimmune diseases (immune thrombocytopenia, hemolytic anemia, inflammatory bowel disease)	Immunoglobulin levels (IgG, IgM, IgA) Antibody levels to T-cell-dependent protein antigens (e.g., tetanus or pneumococcal conjugate vaccines) Antibody levels to T-cell-independent polysaccharide antigens in a child $\geq 2$ years (e.g., pneumococcal polysaccharide vaccine, such as Pneumovax)	B-cell enumeration Immunofixation electrophoresis
Cell-mediated immunity (e.g., severe combined immunodeficiency, DiGeorge syndrome)	Pneumonia (pyogenic bacteria, fungi, <i>Pneumocystis jiroveci</i> , viruses)	TRECs newborn screening <sup>a</sup> Total lymphocyte counts HIV ELISA/Western blot/PCR	T-cell enumeration (CD3, CD4, CD8) In vitro T-cell proliferation to mitogens, antigens, or allogeneic cells Chromosomal microarray or FISH 22q11 for DiGeorge deletion
Phagocytosis (e.g., chronic granulomatous disease [CGD], leukocyte adhesion deficiency, Chédiak-Higashi syndrome)	Cutaneous infections, abscesses, lymphadenitis (staphylococci, enteric bacteria, fungi, mycobacteria) Poor wound healing	WBC/neutrophil count and morphology	CGD: Nitroblue tetrazolium (NBT) test or dihydro-rhodamine (DHR) reduction test Chemotactic assay Phagocytic assay
Spleen	Bacteremia/hematogenous infection (pneumococcus, other streptococci, <i>Neisseria</i> spp.)	Peripheral blood smear for Howell-Jolly bodies Hemoglobin electrophoresis (HbSS)	Technetium-99 spleen scan or sonogram
Complement	Bacterial sepsis and other bloodborne infections (encapsulated bacteria, especially <i>Neisseria</i> spp.) Lupus, glomerulonephritis Angioedema	CH50 (total hemolytic complement)	Alternative pathway assay (AH50) Mannose-binding lectin level Individual complement component assays

<sup>a</sup>Newborn screening using TRECs has now been implemented in multiple states. TRECs identify lymphopenia in children and prompt further testing for SCID or other immunodeficiencies associated with lymphopenia. *ELISA*, Enzyme-linked immunosorbent assay; *FISH*, fluorescent in situ hybridization; *HIV*, human immunodeficiency virus; *PCR*, polymerase chain reaction; *TRECs*, T-cell receptor excision circles; *WBC*, white blood cell. From Lederman HM. Clinical presentation of primary immunodeficiency diseases. In: McMillan J, ed. *Oski's Pediatrics*. Lippincott Williams & Wilkins; 2006:2441–2444.

- b. Immune thrombocytopenic purpura (see [Chapter 14](#)):
  - (1) Initially given on a single day or in divided doses over 2 to 5 consecutive days
  - (2) Maintenance dose given every 3 to 6 weeks based on clinical response and platelet count
- c. Bone marrow transplantation:
  - (1) Adjust dosing to maintain trough IgG level of at least 400 mg/dL.
  - (2) May decrease incidence of infection and death but not acute graft-versus-host disease
- d. Other indications:
  - (1) Kawasaki disease (see [Chapter 7](#)).
  - (2) Multi-system inflammatory syndrome in children (MIS-C) (see [Chapter 7](#)).
  - (3) Guillain-Barré syndrome
  - (4) Refractory dermatomyositis and polymyositis
  - (5) Chronic inflammatory demyelinating polyneuropathy

## 2. **Precautions and adverse reactions:**

- a. Severe systemic symptoms (hemodynamic changes, respiratory difficulty, and anaphylaxis)
- b. Less-severe systemic reactions (headache, myalgia, fever, chills, nausea, and vomiting)
  - (1) Decrease infusion rate and/or pre-medicate with intravenous corticosteroids and/or antipyretics.
  - (2) Can progress to aseptic meningitis syndrome
- c. Acute renal failure (increased risk with preexisting renal insufficiency and with sucrose-containing IVIG)
- d. Acute venous thrombosis (increased risk with sucrose-containing IVIG)
- e. Use with caution in patients with confirmed undetectable IgA levels (e.g., patients with partial B-cell immunodeficiencies or familial IgA deficiency), as antibodies against IgA may trigger anaphylactic reaction.

## **B. Intramuscular Immunoglobulin (IMIG)**

- 1. **Prophylaxis indications:** Hepatitis A, measles, rubella, rabies, and varicella-zoster (see [Chapter 16](#))
- 2. **Administration:**
  - a. No more than 5 mL should be given at one site in large child/adolescent, and 1 to 3 mL for smaller children/infants.
  - b. Administration of greater than 15 mL at one time is essentially never warranted.
  - c. Peak serum levels achieved by 48 hours; immune effect lasts 3 to 4 weeks.
- 3. **Precautions and adverse reactions:**
  - a. Similar to IVIG (discussed previously)
  - b. Local reaction at injection site increases with repeated use

- c. Intravenous or intradermal use of IMIG is absolutely contraindicated due to high risk for anaphylactoid reactions.

### C. Subcutaneous Immunoglobulin

1. **Indication:** Replacement therapy for antibody deficiency
2. **Administration:**
  - a. See the Formulary for dosages and administration instructions.
  - b. Larger doses can be given simultaneously in multiple sites or more frequently than once weekly.
  - c. Using the same areas for injections improves tolerability.
  - d. **Considerations:** Does not require venous access or special nursing (parents can administer), but may require multiple needlesticks in larger children, depending on the volume to be infused
3. **Precautions and adverse reactions:**
  - a. Systemic side effects are rare because of the small volumes given and the slow absorption rate.
  - b. Local redness and swelling are expected and generally decrease with every infusion.

### D. Specific Immunoglobulins

1. Hyperimmune globulins:
  - a. Prepared from donors with high titers of specific antibodies
  - b. Includes hepatitis B immune globulin, varicella-zoster immune globulin, cytomegalovirus immune globulin, Rho(D) immune globulin, botulism immune globulin, and others
2. **Monoclonal antibody preparations** (rituximab, palivizumab, and others)

### E. Vaccination Timing

See [Chapter 16](#) for discussion of timing of routine vaccination after immunoglobulin administration.

## VI. IMMUNOLOGIC REFERENCE VALUES

- A. Serum IgG, IgM, IgA, and IgE Levels (Table 15.3)
- B. Serum IgG, IgM, IgA, and IgE Levels for Low Birth Weight Preterm Infants (Table 15.4)
- C. Lymphocyte Enumeration (Table 15.5)
- D. Serum Complement Levels (Table 15.6)

**TABLE 15.3****SERUM IMMUNOGLOBULIN LEVELS<sup>a</sup>**

Age	IgG (mg/dL)	IgM (mg/dL)	IgA (mg/dL)	IgE (IU/mL)
Cord blood (term)	1121 (636–1606)	13 (6.3–25)	2.3 (1.4–3.6)	0.22 (0.04–1.28)
1 month	503 (251–906)	45 (20–87)	13 (1.3–53)	
6 weeks				0.69 (0.08–6.12)
2 months	365 (206–601)	46 (17–105)	15 (2.8–47)	
3 months	334 (176–581)	49 (24–89)	17 (4.6–46)	0.82 (0.18–3.76)
4 months	343 (196–558)	55 (27–101)	23 (4.4–73)	
5 months	403 (172–814)	62 (33–108)	31 (8.1–84)	
6 months	407 (215–704)	62 (35–102)	25 (8.1–68)	2.68 (0.44–16.3)
7–9 months	475 (217–904)	80 (34–126)	36 (11–90)	2.36 (0.76–7.31)
10–12 months	594 (294–1069)	82 (41–149)	40 (16–84)	
1 year	679 (345–1213)	93 (43–173)	44 (14–106)	3.49 (0.80–15.2)
2 years	685 (424–1051)	95 (48–168)	47 (14–123)	3.03 (0.31–29.5)
3 years	728 (441–1135)	104 (47–200)	66 (22–159)	1.80 (0.19–16.9)
4–5 years	780 (463–1236)	99 (43–196)	68 (25–154)	8.58 (1.07–68.9) <sup>b</sup>
6–8 years	915 (633–1280)	107 (48–207)	90 (33–202)	12.89 (1.03–161.3) <sup>c</sup>
9–10 years	1007 (608–1572)	121 (52–242)	113 (45–236)	23.6 (0.98–570.6) <sup>d</sup>
14 years				20.07 (2.06–195.2)
Adult	994 (639–1349)	156 (56–352)	171 (70–312)	13.2 (1.53–114)

<sup>a</sup>Numbers in parentheses are the 95% confidence intervals (CIs).

<sup>b</sup>IgE data for 4 years.

<sup>c</sup>IgE data for 7 years.

<sup>d</sup>IgE data for 10 years.

Data from Kjellman NM, Johansson SG, Roth A. Serum IgE levels in healthy children quantified by a sandwich technique (PRIST). *Clin Allergy*. 1976;6:51–59; Jolliff CR, Cost KM, Stivrins PC, et al. Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. *Clin Chem*. 1982;28:126–128; Zetterström O, Johansson SG. IgE concentrations measured by PRIST in serum of healthy adults and in patients with respiratory allergy: a diagnostic approach. *Allergy*. 1981;36:537–547.

TABLE 15.4

## SERUM IMMUNOGLOBULIN LEVELS FOR LOW BIRTH WEIGHT PRETERM INFANTS

Age (months)	Plasma Ig Concentrations in 25- to 28-Weeks' Gestation Infants			Plasma Ig Concentrations in 29- to 32-Weeks' Gestation Infants		
	IgG (mg/dL) <sup>a</sup>	IgM (mg/dL) <sup>a</sup>	IgA (mg/dL) <sup>a</sup>	IgG (mg/dL) <sup>a</sup>	IgM (mg/dL) <sup>a</sup>	IgA (mg/dL) <sup>a</sup>
0.25	251 (114–552)	7.6 (1.3–43.3)	1.2 (0.07–20.8)	368 (186–728)	9.1 (2.1–39.4)	0.6 (0.04–1.0)
0.5	202 (91–446)	14.1 (3.5–56.1)	3.1 (0.09–10.7)	275 (119–637)	13.9 (4.7–41)	0.9 (0.01–7.5)
1.0	158 (57–437)	12.7 (3.0–53.3)	4.5 (0.65–30.9)	209 (97–452)	14.4 (6.3–33)	1.9 (0.3–12.0)
1.5	134 (59–307)	16.2 (4.4–59.2)	4.3 (0.9–20.9)	156 (69–352)	15.4 (5.5–43.2)	2.2 (0.7–6.5)
2.0	89 (58–136)	16.0 (5.3–48.9)	4.1 (1.5–11.1)	123 (64–237)	15.2 (4.9–46.7)	3.0 (1.1–8.3)
3	60 (23–156)	13.8 (5.3–36.1)	3.0 (0.6–15.6)	104 (41–268)	16.3 (7.1–37.2)	3.6 (0.8–15.4)
4	82 (32–210)	22.2 (11.2–43.9)	6.8 (1.0–47.8)	128 (39–425)	26.5 (7.7–91.2)	9.8 (2.5–39.3)
6	159 (56–455)	41.3 (8.3–205)	9.7 (3.0–31.2)	179 (51–634)	29.3 (10.5–81.5)	12.3 (2.7–57.1)
8–10	273 (94–794)	41.8 (31.1–56.1)	9.5 (0.9–98.6)	280 (140–561)	34.7 (17–70.8)	20.9 (8.3–53)

<sup>a</sup>Geometric mean (numbers in parentheses are  $\pm 2$  SD).

From Ballow M, Cates KL, Rowe JC, et al. Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. *Pediatr Res*. 1986;9:899–904.

**TABLE 15.5****T AND B LYMPHOCYTES IN PERIPHERAL BLOOD**

Age	CD3 (Total T Cell) Count <sup>a</sup> (%) <sup>b</sup>	CD4 Count <sup>a</sup> (%) <sup>b</sup>	CD8 Count <sup>a</sup> (%) <sup>b</sup>	CD19 (B Cell) Count <sup>a</sup> (%) <sup>b</sup>
0–3 months	2.50–5.50 (53–84)	1.60–4.00 (35–64)	0.56–1.70 (12–28)	0.30–2.00 (6–32)
3–6 months	2.50–5.60 (51–77)	1.80–4.00 (35–56)	0.59–1.60 (12–23)	0.43–3.00 (11–41)
6–12 months	1.90–5.90 (49–76)	1.40–4.30 (31–56)	0.50–1.70 (12–24)	0.61–2.60 (14–37)
1–2 years	2.10–6.20 (53–75)	1.30–3.40 (32–51)	0.62–2.00 (14–30)	0.72–2.60 (16–35)
2–6 years	1.40–3.70 (56–75)	0.70–2.20 (28–47)	0.49–1.30 (16–30)	0.39–1.40 (14–33)
6–12 years	1.20–2.60 (60–76)	0.65–1.50 (31–47)	0.37–1.10 (18–35)	0.27–0.86 (13–27)
12–18 years	1.00–2.20 (56–84)	0.53–1.30 (31–52)	0.33–0.92 (18–35)	0.11–0.57 (6–23)
Adult <sup>c</sup>	0.70–2.10 (55–83)	0.30–1.40 (28–57)	0.20–0.90 (10–39)	

<sup>a</sup>Absolute counts (number of cells per microliter  $\times 10^{-3}$ ).

<sup>b</sup>Normal values (10th to 90th percentile).

<sup>c</sup>From Comans-Bitter WM, de Groot R, van den Beemd R, et al. Immunotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. *J Pediatr.* 1997;130:388–393.

From Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. *J Allergy Clin Immunol.* 2003;112:973–980.

**TABLE 15.6****SERUM COMPLEMENT LEVELS<sup>a</sup>**

Age	C3 (mg/dL)	C4 (mg/dL)
Cord blood (term)	83 (57–116)	13 (6.6–23)
1 month	83 (53–124)	14 (7.0–25)
2 months	96 (59–149)	15 (7.4–28)
3 months	94 (64–131)	16 (8.7–27)
4 months	107 (62–175)	19 (8.3–38)
5 months	107 (64–167)	18 (7.1–36)
6 months	115 (74–171)	21 (8.6–42)
7–9 months	113 (75–166)	20 (9.5–37)
10–12 months	126 (73–180)	22 (12–39)
1 year	129 (84–174)	23 (12–40)
2 years	120 (81–170)	19 (9.2–34)
3 years	117 (77–171)	20 (9.7–36)
4–5 years	121 (86–166)	21 (13–32)
6–8 years	118 (88–155)	20 (12–32)
9–10 years	134 (89–195)	22 (10–40)
Adult	125 (83–177)	28 (15–45)

<sup>a</sup>Numbers in parentheses are the 95% confidence intervals (CIs).

Modified from Jolliff CR, Cost KM, Stivirins PC, et al. Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. *Clin Chem.* 1982;28:126–128.

**REFERENCES**

A complete list of references can be found online.

## REFERENCES

1. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. *J Allergy Clin Immunol*. 2020;146:721–767.
2. Tharpe CA, Kemp SF. Pediatric allergic rhinitis. *Immunol Allergy Clin North Am*. 2015;35:185–198.
3. Wong AG, Lomas JM. Allergy testing and immunotherapy. *Pediatr Rev*. 2019;40:219–228.
4. Gentile D, Bartholow A, Valovirta E, Scadding G, Skoner D. Current and future directions in pediatric allergic rhinitis. *J Allergy Clin Immunol Pract*. 2013;1:214–226; quiz 27.
5. Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. *N Engl J Med*. 2015;372:456–463.
6. Rajaei A, Masquelin ME, Pohlgeers KM. Pediatric allergy: an overview. *Prim Care*. 2021;48:517–530.
7. Jones SM, Burks AW. Food allergy. *N Engl J Med*. 2017;377:1168–1176.
8. Cosme-Blanco W, Arroyo-Flores E, Ale H. Food allergies. *Pediatr Rev*. 2020;41:403–415.
9. Sampson HA, Aceves S, Bock SA, et al. Food allergy: a practice parameter update-2014. *J Allergy Clin Immunol*. 2014;134:1016–1025. e43.
10. Nowak-Wegrzyn A. Food protein-induced enterocolitis syndrome and allergic proctocolitis. *Allergy Asthma Proc*. 2015;36:172–184.
11. Sicherer SH, Wood RA. American Academy of Pediatrics Section on A, Immunology. Allergy testing in childhood: using allergen-specific IgE tests. *Pediatrics*. 2012;129:193–197.
12. Greenhawt M, Shaker M, Wang J, et al. Peanut allergy diagnosis: a 2020 practice parameter update, systematic review, and GRADE analysis. *J Allergy Clin Immunol*. 2020;146:1302–1334.
13. Burks AW, Jones SM, Boyce JA, et al. NIAID-sponsored 2010 guidelines for managing food allergy: applications in the pediatric population. *Pediatrics*. 2011;128:955–965.
14. Greer FR, Sicherer SH, Burks AW, Committee on Nutrition, Section on Allergy and Immunology. The effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, hydrolyzed formulas, and timing of introduction of allergenic complementary foods. *Pediatrics*. 2019;143:e20190281.
15. Savage J, Sicherer S, Wood R. The natural history of food allergy. *J Allergy Clin Immunol Pract*. 2016;4:196–203; quiz 4.
16. Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. *N Engl J Med*. 2015;372:803–813.
17. Du Toit G, Sayre PH, Roberts G, et al. Effect of avoidance on peanut allergy after early peanut consumption. *N Engl J Med*. 2016;374:1435–1443.
18. Togias A, Cooper SF, Acebal ML, et al. Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases—sponsored expert panel. *World Allergy Organ J*. 2017;10:1.
19. Joint Task Force on Practice P, American Academy of Allergy A, Immunology, et al. Drug allergy: an updated practice parameter. *Ann Allergy Asthma Immunol*. 2010;105:259–273.
20. Castells M, Khan DA, Phillips EJ. Penicillin allergy. *N Engl J Med*. 2019;381:2338–2351.

21. Fox SJ, Park MA. Penicillin skin testing is a safe and effective tool for evaluating penicillin allergy in the pediatric population. *J Allergy Clin Immunol Pract*. 2014;2:439–444.
22. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. *J Allergy Clin Immunol*. 2015;136:1186–1205.e1–78.
23. Lederman HM. Clinical presentation of primary immunodeficiency diseases. In: McMillan JAF, Ralph D, DeAngelis C, Jones MD, eds. *Oski's Pediatrics: Principles & Practice*. 4th ed. Lippincott Williams & Wilkins; 2006:2441–2449.
24. Hernandez-Trujillo VP. Approach to children with recurrent infections. *Immunol Allergy Clin North Am*. 2015;35:625–636.
25. Ballow M. Approach to the patient with recurrent infections. *Clin Rev Allergy Immunol*. 2008;34:129–140.
26. Chinn IK, Orange JS. Immunodeficiency disorders. *Pediatr Rev*. 2019;40:229–242.
27. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee. *J Clin Immunol*. 2020;40:24–64.
28. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. *J Allergy Clin Immunol*. 2017;139:S1–S46.
29. Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin replacement therapy in children. *Immunol Allergy Clin North Am*. 2008;28:833–849, ix.
30. Balch A, Wilkes J, Thorell E, Pavia A, Sherwin CMT, Enioutina EY. Changing trends in IVIG use in pediatric patients: a retrospective review of practices in a network of major USA pediatric hospitals. *Int Immunopharmacol*. 2019;76:105868.
31. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. *N Engl J Med*. 2012;367:2015–2025.
32. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. *Arthritis Rheumatol*. 2020;72:1791–1805.
33. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. *J Allergy Clin Immunol*. 2008;122:1238–1239.
34. Shapiro RS. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics. *Pediatr Allergy Immunol*. 2013;24:49–53.

# Chapter 16

## Immunoprophylaxis

Lindsay Sheets, MD, MPH

 See additional content online.

### I. COMMON TYPES OF VACCINES ADMINISTERED TO CHILDREN<sup>1</sup>

#### A. Inactivated Vaccines

1. Killed version of pathogen
2. Do not provide immunity as robust or long-lasting as live vaccines, so may require several doses over time
3. Examples: Hepatitis A, influenza, injectable polio, rabies

#### B. Live, Attenuated Vaccines

1. Weakened (or attenuated) form of pathogen
2. Creates a robust and long-lasting immune response
3. Examples: Measles, mumps, rubella (MMR), rotavirus, smallpox, varicella, yellow fever, oral polio (no longer used in United States)

#### C. Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines

1. Uses specific components of pathogen, such as protein, sugar, or capsid
2. Robust immune response but booster may be required for ongoing protection
3. Examples: *Haemophilus influenzae*, hepatitis B virus, human papillomavirus, *Bordetella pertussis* (pertussis), pneumococcal polysaccharide and conjugate vaccines, meningococcal polysaccharide and conjugate vaccines

#### D. Toxoid Vaccines

1. Use toxin from pathogen to create immunity to parts of pathogen that cause disease, instead of to entire pathogen itself.
2. May need booster shots
3. Examples: *Corynebacterium diphtheriae* (diphtheria), *Clostridium tetani* (tetanus)

#### E. mRNA Vaccines<sup>2,3</sup>

1. Messenger RNA enters host cell and is translated by ribosomes so that host cells produce proteins and subsequently induce antibody response.
  - a. Example: Spike protein against SARS-CoV-2 virus
2. Noninfectious, nonintegrating platform. mRNA degrades quickly.

## II. IMMUNIZATION SCHEDULES

### A. Routine Vaccines for Children in the United States

1. [Table 16.1](#): Routine Vaccines for Children and Adolescents in the United States<sup>4</sup>
2. All schedules: website—<https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html>; phone app—<https://www.cdc.gov/vaccines/schedules/hcp/schedule-app.html#download>
3. Schedules updated annually and put forth by Advisory Committee on Immunization Practices (ACIP)<sup>5</sup> and approved by Centers for Disease Control and Prevention (CDC) and American Academy of Pediatrics (AAP)
4. For the most recent guidelines on COVID-19 vaccination in pediatric patients, see: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html>

### B. Nonroutine Vaccines for Children in the United States<sup>6</sup>

1. For details on vaccines not routinely administered in the United States, including bacille Calmette-Guérin (BCG; tuberculosis vaccine), Japanese encephalitis, rabies, typhoid, and yellow fever, see [Table 16.2](#).
2. For information on other vaccines licensed but not routinely distributed, including anthrax and smallpox, see <https://emergency.cdc.gov/bioterrorism/>

## III. IMMUNIZATION GUIDELINES

### A. Vaccine Informed Consent

1. The most recent Vaccine Information Statements (VISs) should be provided to patient (nonminor) or parent/guardian, with documentation of version date and date of administration.
2. VISs can be found at the following:  
<https://www.cdc.gov/vaccines/hcp/vis/current-vis.html>
3. Multi-vaccine VISs for DTaP, *Haemophilus influenzae* type b (Hib), HepB, polio, and PCV13 can be used when two or more of these vaccines are administered during the same visit.

### B. Vaccine Administration

1. For information on vaccine storage, handling, and administration, see <https://www.cdc.gov/vaccines/hcp/admin/>
2. See [Chapter 4](#) for details on intramuscular and subcutaneous administration procedures.
3. Simultaneous administration
  - a. Routine childhood vaccines are safe and effective when administered simultaneously at different sites. There is no maximum number of vaccines that can be administered during the same visit.
  - b. Spread them out in location on the body, at least 1 cm apart.
4. Combination vaccines reduce number of injections.

TABLE 16.1

## ROUTINE VACCINES FOR CHILDREN AND ADOLESCENTS IN THE UNITED STATES

Disease	Vaccine Description	Dose and Administration	Side Effects <sup>a</sup>
Diphtheria, tetanus, pertussis	DTaP: Diphtheria and tetanus toxoids with acellular pertussis vaccine (preferred vaccine for children <7 years) DT: Diphtheria and tetanus toxoids without pertussis vaccine	0.5 mL IM × 5 doses (2, 4, 6, 15–18 months, and 4–6 years) <ul style="list-style-type: none"> <li>• If at least 6 months have passed since dose #3, dose #4 may be given as early as 12 months of age.</li> <li>• If dose #4 inadvertently given ≥4 months but &lt;6 months after dose #3 to a child ≥12 months old, it does NOT need to be repeated.</li> <li>• If dose #4 administered when child was ≥4 years old, dose #5 not necessary.</li> </ul> <p>Use DT for age &lt;7 years if pertussis vaccine is contraindicated.</p>	Mild: Injection site reaction (common), fever ≥38.0°C, drowsiness, fussiness/inconsolable crying, decreased appetite Severe: Allergic reactions, persistent crying >3 hours, hypotonic-hyporesponsive episode, seizures, and body temperature >40.5°C (all rare with DTaP)
	Tdap: Tetanus and diphtheria toxoids with acellular pertussis vaccine Td: Tetanus toxoid with reduced dose of diphtheria toxoid	0.5 mL IM Tdap × 1 dose at 11–12 years, then booster with Tdap or Td every 10 years after <ul style="list-style-type: none"> <li>• Tdap may be administered regardless of interval since last tetanus and diphtheria toxoid-containing vaccine.</li> <li>• 1 dose during each pregnancy (ideally 27–36 weeks' gestation)</li> </ul> <p>Use Td for age ≥7 years if pertussis vaccine is contraindicated.</p>	
<i>Haemophilus influenzae</i> type B (Hib)	Hib PRP-OMP: Capsular polysaccharide antigen conjugated to outer membrane protein of <i>Neisseria meningitidis</i> Hib PRP-T: Capsular polysaccharide antigen conjugated to tetanus toxoid	0.5 mL IM × 3–4 doses depending on which formulation used <ul style="list-style-type: none"> <li>• Recommend 4 doses of PRP-T (2, 4, 6 and 12–15 months) or 3 doses of PRP-OMP (2, 4 and 12–15 months)</li> <li>• Should not be given prior to 6 weeks of age</li> </ul>	Local injection site reaction (common), drowsiness, fussiness, restlessness, decreased appetite

TABLE 16.1

## ROUTINE VACCINES FOR CHILDREN AND ADOLESCENTS IN THE UNITED STATES—CONT'D

Disease	Vaccine Description	Dose and Administration	Side Effects <sup>a</sup>
Hepatitis A (HepA)	Inactivated virus purified from human fibroblast cultures	<ul style="list-style-type: none"> <li>No need to use same formulation for entire series</li> <li>See Section V.B.1 for children with high-risk conditions.</li> </ul> 0.5 mL IM × 2 doses (12–23 months with minimum 6-month interval between doses) Use 1 mL IM per dose if age ≥19 years. Adolescents ≥18 years eligible for combination Hep A/Hep B vaccine series International travel for unvaccinated children: <ul style="list-style-type: none"> <li>Age 6–11 months: 1 dose before departure and revaccinate with 2 doses starting at 12 months</li> <li>Age ≥12 months: 1 dose before departure</li> </ul>	Local injection site reaction (common), fever ≥38.0°C, drowsiness, irritability, headache
Hepatitis B (HepB)	Produced by recombinant DNA technology; monovalent formulations may be used interchangeably	0.5 mL IM × 3 doses (birth, 1–2 months, 6–18 months) <ul style="list-style-type: none"> <li>All term newborns should receive monovalent HepB vaccine within 24 hours of birth.</li> <li>4 doses acceptable if combined vaccines used after birth dose</li> <li>See Section V.C for details regarding preterm infants.</li> </ul> Use 1 mL IM per dose if age ≥20 years or giving 2-dose adolescent series (age 11–15 years). <ul style="list-style-type: none"> <li>Adolescents ≥18 years eligible for combination Hep A/Hep B vaccine series</li> </ul>	Pain at injection site, fatigue, fever ≥38.0°C

Human papilloma virus (HPV)	<p>HPV9: Protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58</p> <p>HPV4 and bivalent HPV vaccines not distributed in United States</p>	<p>0.5 mL IM <math>\times</math> 2 doses (separated by 6–12 months) at age 11–12 years</p> <ul style="list-style-type: none"> <li>Series may be started at age 9; consider if history of sexual abuse or assault.</li> <li>If first dose at age <math>\geq</math>15 years or immunocompromised, give 3 doses at intervals of 0, 1–2, and 6 months.</li> </ul>	<p>Pain and local injection site reaction (common), headache.</p> <p>Recommended to observe for syncope for 15 min after administration</p>
<p>Influenza vaccine</p> <p>NOTE: Influenza vaccine recommendations change annually; see CDC for up-to-date recommendations<sup>42</sup></p>	<p>LAIV4: Intranasal live, attenuated quadrivalent vaccine for healthy children age <math>\geq</math>2 years</p> <p>IIV4: Subvirion or purified surface-antigen quadrivalent vaccines for age <math>\geq</math>6 months</p> <p>ccIIV4: Cell culture-based quadrivalent vaccine for age <math>\geq</math>4 years</p> <p>RIV4: Recombinant quadrivalent vaccine for age <math>\geq</math>18 years</p>	<p>0.2 mL intranasally (0.1 mL per nare)</p> <p>0.25–0.5 mL IM if age 6–35 months (see manufacturer recommendations)</p> <p>0.5 mL IM if age <math>\geq</math>3 years</p> <ul style="list-style-type: none"> <li>Give annually starting at age 6 months</li> <li>Children <math>\leq</math>8 years who have not previously received <math>\geq</math>2 total doses (regardless of interval) should receive 2 doses separated by <math>\geq</math>4 weeks.</li> </ul>	<p>Local injection site reaction, fever within 24 hr after immunization in children <math>&lt;</math>2 years, drowsiness, irritability, myalgia, headache, GI symptoms</p> <p>Possible association with GBS (rare: 1–2 cases per million doses)</p>
Measles, mumps, rubella (MMR)	Combination vaccine composed of live, attenuated viruses	<p>0.5 mL SQ <math>\times</math> 2 doses (12–15 months, 4–6 years)</p> <ul style="list-style-type: none"> <li>Required minimum 4-week interval between doses</li> <li>Children <math>&gt;</math>12 years old not eligible for vaccine</li> </ul> <p>International travel:</p> <ul style="list-style-type: none"> <li>Age 6–11 months: 1 dose prior to departure, then revaccinate with 2 doses—dose #1 at 12–15 months, dose #2 <math>\geq</math>4 weeks later</li> <li>Age <math>\geq</math>12 months (and unvaccinated): 2 doses at least 4 weeks apart prior to departure</li> </ul>	<p>High fever (<math>&gt;</math>39.4°C) usually 6–12 days after immunization, and may last <math>\leq</math>5 days; febrile seizures may occur 5–12 days after the first dose (rare)</p> <p>Other reactions include transient rash transient thrombocytopenia (1 in 22,000–40,000), encephalitis, and encephalopathy (<math>&lt;</math>1 in 1 million)</p>

Continued

TABLE 16.1

## ROUTINE VACCINES FOR CHILDREN AND ADOLESCENTS IN THE UNITED STATES—CONT'D

Disease	Vaccine Description	Dose and Administration	Side Effects <sup>a</sup>
<i>N. meningitidis</i> (Meningococcal)	MenACWY-D (Menactra): Quadrivalent (serogroups A, C, Y, W) polysaccharide diphtheria toxoid conjugate for age $\geq 9$ months	0.5 mL IM $\times$ 2 doses (11–12 years, 16 years) <ul style="list-style-type: none"> <li>• If dose #1 not given until age <math>\geq 16</math> years, dose #2 not needed</li> <li>• See Section V.B.2 for children with high-risk conditions.</li> </ul>	Local injection site reaction, sleepiness, malaise, headache, nausea, diarrhea
	MenACWY-CRM (Menveo): Quadrivalent (serogroups A, C, Y, W) oligosaccharide diphtheria conjugate for age $\geq 2$ months	International travel: See CDC website for recommendations based on vaccine formulation and age of patient.	
	MenB-4C (Bexero): Serogroup B vaccine for age 10–25 years	0.5 mL IM $\times$ 2 doses (preferred age 16–18 years) <ul style="list-style-type: none"> <li>• Recommend shared decision-making for adolescents aged 16–23 years who are not at increased risk.</li> <li>• Dose intervals (vaccines not interchangeable): MenB-4C—1 month; MenB-FHbp—6 months</li> <li>• See Section V.B.2 for children with high-risk conditions.</li> </ul>	Local injection-site reaction, headache, myalgia, arthralgia, nausea
	MenB-FHbp (Trumemba): Serogroup B vaccine for age 10–25 years		
Polio	IPV: Inactivated injectable vaccine containing 3 types of poliovirus NOTE: OPV, a live, attenuated oral vaccine, is no longer available in the United States; see <a href="#">Table 16.2</a>	0.5 mL IM/SQ $\times$ 4 doses (2, 4, 6–18 months, 4–6 years) <ul style="list-style-type: none"> <li>• If 4 or more doses of IPV are administered before the fourth birthday due to use of combination vaccines, it is still recommended that an additional dose be given after the fourth birthday <math>\geq 6</math> months after the previous dose.</li> </ul>	Local injection site reaction, fever $\geq 38.0^{\circ}\text{C}$ , irritability, tiredness, loss of appetite

Rotavirus	RV5: Pentavalent live, attenuated oral vaccine containing five reassortant human and bovine rotavirus strains	<p>2 mL PO × 3 doses (2, 4, 6 months)</p> <ul style="list-style-type: none"> <li>• If any dose RV5 (RotaTeq) or unknown, 3 doses should be given</li> <li>• First dose must be given before 15 weeks. Cannot give final dose after 8 months old.</li> <li>• Do NOT readminister if infant spits out or vomits dose.</li> </ul>	<p>Diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm (uncommon) Small risk of intussusception (1 excess case per 30,000–100,000 vaccinated infants), usually within 1 week of vaccination</p>
	RV1: Monovalent live, attenuated oral vaccine	<p>1 mL PO × 2 doses (2, 4 months)</p> <ul style="list-style-type: none"> <li>• First dose must be given before 15 weeks. Cannot give final dose after 8 months old.</li> <li>• If infant spits out or vomits dose, 1 replacement dose can be given at same visit.</li> </ul>	
<i>Streptococcus pneumoniae</i> (Pneumococcal)	PCV13: Pneumococcal conjugate vaccine containing 13 purified capsular polysaccharides of <i>S. pneumoniae</i> , each coupled to a variant of diphtheria toxin: PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) + additional serotypes (1, 3, 5, 6A, 7F, and 19A) for age ≥6 weeks	<p>0.5 mL IM × 4 doses (2, 4, 6, 12–15 months)</p> <ul style="list-style-type: none"> <li>• See Section V.B.3 for children with high-risk conditions.</li> <li>• PCV13 and PPSV23 should not be administered during the same visit.</li> </ul>	Local injection site reaction, irritability, decreased appetite, decreased sleep, increased sleep, fever
	PPSV23: Purified capsular polysaccharide from 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) for age ≥2 years	<p>0.5 mL IM/SQ</p> <ul style="list-style-type: none"> <li>• See Section V.B.3 for children with high-risk conditions.</li> <li>• When both PCV13 and PPSV23 are indicated, administer PCV13 first.</li> </ul>	

Continued

TABLE 16.1

## ROUTINE VACCINES FOR CHILDREN AND ADOLESCENTS IN THE UNITED STATES—CONT'D

Disease	Vaccine Description	Dose and Administration	Side Effects <sup>a</sup>
Varicella	Cell-free live, attenuated varicella virus vaccine for age $\geq 12$ months	0.5 mL SQ $\times$ 2 doses (12–15 months, 4–6 years) <ul style="list-style-type: none"> <li>• Dose #2 may be given as early as 3 months after dose #1.</li> <li>• If dose #2 inadvertently given <math>&lt; 3</math> months but <math>\geq 4</math> weeks after dose #1, it is still valid.</li> </ul>	Local injection site reaction, fever Mild varicelliform rash within 5–26 days of vaccine administration may occur, though not all postimmunization rashes are attributable to vaccine; vaccine rash is often mild, but patient may be infectious.

<sup>a</sup>Unless otherwise indicated, side-effect profiles for vaccines are derived from vaccine-specific package inserts. Prevalence of each potential side effect differs depending on which vaccine formulation used. More information available at <https://www.immunize.org/fda/>.<sup>43</sup>

CDC, Centers for Disease Control and Prevention; *DT*, Diphtheria and tetanus vaccine; *DTaP*, diphtheria, tetanus, acellular pertussis vaccine; *GBS*, Guillain-Barré syndrome; *Hib*, *Haemophilus influenzae* type b; *IIV*, inactivated influenza vaccine; *IM*, intramuscular; *IPV*, inactivated polio vaccine; *LAIV*, live, attenuated influenza vaccine; *OPV*, oral polio vaccine; *PCV13*, pneumococcal 13-valent conjugate vaccine; *PO*, per os; *PPSV23*, pneumococcal 23-valent polysaccharide vaccine; *SQ*, subcutaneous; *Td*, tetanus and diphtheria vaccine; *Tdap*, tetanus, diphtheria, acellular pertussis vaccine.

TABLE 16.2

## NONROUTINE VACCINES FOR CHILDREN AND ADOLESCENTS

Disease	Indication	Type	Dose and Administration	Side Effects <sup>a</sup>
Japanese encephalitis (JE)	<p>≥1-month travel in endemic areas (most rural areas of Asia) during the JE season</p> <p>May also be considered for shorter-term travel with higher exposure risk (i.e., during epidemic or time outdoors in rural areas)</p>	JE-VC: Inactivated cell culture–derived JE vaccine for age ≥2 months	<p>0.25 mL IM × 2 doses for age 2 months–2 years</p> <p>0.5 mL IM × 2 doses for age ≥3 years</p> <ul style="list-style-type: none"> <li>• For children &lt;18 years, 4-week interval between doses</li> <li>• For adolescents ≥18 years, can reduce interval between doses to 7 days</li> <li>• If exposure ongoing, annual booster recommended</li> </ul>	Fever, irritability, and diarrhea in young children; injection site pain and headache in adolescents and adults
Polio	<p>Oral polio vaccine not available in the United States but is used worldwide</p> <p>Trivalent vaccine: Protective against all 3 poliovirus types in &gt;95% of recipients</p> <p>In 2016 most countries switched to the bivalent vaccine.</p>	<p>Bivalent (bOPV): Live, attenuated vaccine against wild types 1 and 3, but not 2</p> <p>Trivalent (tOPV): Live, attenuated vaccine against wild types 1, 2, and 3</p>	<p>3 doses at minimum 4-week intervals starting at age 6 weeks</p> <ul style="list-style-type: none"> <li>• Give additional OPV at birth in countries with endemic polio or high risk of importation.</li> <li>• Give ≥1 IPV dose, starting at 14 weeks (can be administered with OPV).</li> </ul>	Rare vaccine-associated paralytic poliomyelitis occurs for ~1 in 2.4 million doses.
Rabies	<p>High-risk groups: Veterinarians, animal handlers, laboratory workers, children living in high-risk environments, those traveling to high-risk areas, spelunkers</p> <p>Postexposure prophylaxis (see Table 16.5)</p>	<p>HDCV: Inactivated virus cultured in human diploid cells</p> <p>PCECV: Inactivated virus cultured in purified chicken embryo cells</p>	<p>Pre-exposure: 1 mL IM × 3 doses (Days 0, 7, and 21 or 28)</p> <p>Postexposure: 1 mL IM × 4 doses (Days 0, 3, 7, 14)</p> <ul style="list-style-type: none"> <li>• Administer in deltoid (children and adolescents) or anterolateral thigh (small children and infants), NOT in gluteal area.</li> </ul>	<p>Uncommon in children; in adults, local injection site reactions, mild systemic reactions</p> <p>Arthus-like reaction (urticaria, arthralgia, angioedema, vomiting, fever, malaise)</p>

Continued

TABLE 16.2

## NONROUTINE VACCINES FOR CHILDREN AND ADOLESCENTS—CONT'D

Disease	Indication	Type	Dose and Administration	Side Effects <sup>a</sup>
			<ul style="list-style-type: none"> <li>• Should be administered to body part distant from where RIG was injected</li> <li>• Follow serum Ab titers at 6-month intervals for those at continuous risk and at 2-year intervals for those at risk of frequent exposure.</li> <li>• Give booster doses only if titers are nonprotective.</li> </ul>	prophylaxis recipients at 2–21 days after booster.
Respiratory Syncytial Virus (RSV) <sup>36</sup>	<p>Preterm infants:</p> <ul style="list-style-type: none"> <li>• Born &lt;29 WGA and &lt;12 months at the start of RSV season</li> <li>• Chronic lung disease of prematurity in first year of life or requiring ongoing medical support in second year of life</li> </ul> <p>Children &lt;12 months with:</p> <ul style="list-style-type: none"> <li>• Anatomic pulmonary abnormality or neuromuscular disorder impairing upper airway clearance</li> <li>• Moderate-to- severe pulmonary hypertension</li> <li>• Hemodynamically significant heart disease (discuss with cardiologist)</li> </ul> <p>Children &lt;2 years with:</p> <ul style="list-style-type: none"> <li>• Cardiac transplant</li> <li>• Profound immunocompromise</li> </ul>	Palivizumab: Humanized mouse IgG1 monoclonal antibody to RSV	<p>15 mg/kg IM</p> <p>Give every 28-30 days during RSV season for up to 5 doses</p> <ul style="list-style-type: none"> <li>• First dose should be given prior to the beginning of RSV season</li> <li>• Children who develop an RSV infection should discontinue use of Palivizumab</li> </ul>	Fever and rash (local skin reaction)

Tuberculosis (TB)	1 dose of BCG should only be considered in the United States if a child is frequently exposed to someone with pulmonary TB that is untreated, ineffectively treated, or resistant to treatment, and the child cannot be given long-term primary preventive therapy. Children should be HIV-negative and those $\geq 2$ months should have a negative purified protein derivative (PPD).	BCG: Live, attenuated vaccine prepared from <i>Mycobacterium bovis</i> About $\leq 80\%$ effective	Reconstitute 1 vial of vaccine (50 mg) in 1 mL sterile water (2 mL if age $< 1$ month) Give 0.2–0.3 mL of reconstituted vaccine percutaneously with a multiple puncture device in the deltoid region.	In 1%–2%, axillary or cervical lymphadenopathy and pustule formation at injection site can occur.
Typhoid	Travel to areas with risk of exposure to <i>Salmonella</i> serotype Typhi, people with frequent close contact with a documented carrier, laboratory workers in contact with <i>Salmonella</i> serotype Typhi, and people living in areas with endemic infection	ViCPS: Vi capsular polysaccharide vaccine for age $\geq 2$ years Ty21a: Oral live, attenuated vaccine for age $\geq 6$ years	0.5 mL IM Give 1 dose $\geq 2$ weeks prior to exposure; booster every 2 years 1 capsule by mouth every other day for a total of 4 doses $\geq 1$ week prior to exposure; booster every 5 years	Local injection site reaction, subjective fever, decreased activity Mild reactions including abdominal pain, nausea, diarrhea, vomiting, fever, or headache
Yellow fever	Travel to endemic areas including parts of sub-Saharan Africa and South America Required by some countries as a condition of entry	YF-Vax: Live, attenuated (17D strain) vaccine approved for age $\geq 9$ months	0.5 mL SQ Give 1 dose $\geq 10$ days prior to travel. No booster doses indicated unless immunocompromised or at increased risk due to location or duration of exposure (e.g., prolonged travel or lab workers)	Rare viscerotropic disease (multiple-organ system failure) and neurotropic disease (encephalitis, meningitis) Increased risk of adverse events in adults $> 65$ years and persons with thymic dysfunction; increased risk of postvaccine encephalitis in ages $< 9$ months

<sup>a</sup>Unless otherwise indicated, side-effect profiles for vaccines are derived from vaccine-specific package inserts: <https://www.immunize.org/fda/43>

Ab, Antibody; BCG, bacille Calmette-Guérin; HDCV, human diploid cell vaccine; IM, intramuscular; IPV, inactivated polio vaccine; PCECV, purified chick embryo cell vaccine; RIG, rabies immune globulin; SQ, subcutaneous;

- a. MMR-Varicella (ProQuad)<sup>7</sup> can be used for children 12 months to 12 years of age. There is increased risk of febrile seizures if ProQuad is used as first dose for ages 12 to 47 months.

### C. Live, Attenuated Vaccines

1. Certain vaccines have live components that must replicate to produce immunity: influenza (intranasal), MMR, oral polio vaccine (OPV), BCG, typhoid (oral), varicella, yellow fever.
2. Systemic adverse reactions following these vaccines are usually mild and usually occur 3 to 21 days after vaccine administration.
3. Special consideration must be taken when administering these vaccines to patients with certain underlying medical conditions (see Section V).

### D. Timing and Spacing of Vaccine Doses

1. For information on recommended timing and spacing of vaccines, see <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html>
2. If patient is “behind” on a vaccine series, there is no maximum interval between doses that would require restarting entire series, except for oral typhoid vaccine.
3. Combination vaccines
  - a. Minimum age for administration of vaccine is oldest age required for administration of any of vaccine’s individual components.  
Example: For DTaP/HepB/IPV vaccine, HepB series starts at birth, but DTaP and IPV start at 6–8 weeks, so this combination vaccine should not be administered to children <6 weeks. In fact, all HepB-containing<sup>8</sup> combination vaccines should not be administered to infants <6 weeks because of other components.
  - b. Minimum interval between doses is equal to greatest required interval of any vaccine’s individual components.
4. Live, attenuated vaccines
  - a. If live vaccines are not administered at the same visit, they should be separated by interval of 28 days.

### E. Contraindications and Precautions

1. Contraindication: A condition, often temporary, that increases likelihood of vaccine recipient having serious adverse reaction to vaccine; vaccination should not occur while contraindication is present
2. Precaution: A condition that may increase likelihood or severity of adverse reaction in vaccine recipient, may cause diagnostic confusion, or may compromise vaccine’s ability to induce immunity. Vaccination usually should be deferred when precaution present, unless benefit of protection from vaccine outweighs vaccine risk.
3. [Table 16.3](#): Contraindications and precautions to select vaccines
4. [Table 16.4](#): Conditions incorrectly perceived as contraindications or precautions to vaccination (vaccines may be administered under these conditions)
5. For full details, see <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html>

TABLE 16.3

CONTRAINDICATIONS AND PRECAUTIONS TO SELECT VACCINES<sup>9-11,44,45</sup>

Vaccine	Contraindication	Precaution
All vaccines	Severe (life-threatening) allergic reaction after 1 dose or to any vaccine component (see package inserts)	Moderate-severe acute illness (wait until after recovery, if possible) Latex allergy: <a href="https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/latex-table.pdf">https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/latex-table.pdf</a>
Live vaccines	Most forms of altered immunocompetence (see Section V.A for exceptions) Solid organ transplant Pregnancy: Wait until after pregnancy; avoid becoming pregnant for $\geq 1$ month after vaccine.	Patients on corticosteroids: See Table 16.6 HSCT patients: Delay $\geq 3$ months after immunosuppressive therapy has been discontinued. See Table EC 16.2 Patients on biologic response modifier therapies: Contraindicated during therapy and for weeks to months after its discontinuation or if patient has received other live vaccines in past 4 weeks.
Diphtheria, tetanus, pertussis	Encephalopathy (including coma or status epilepticus) within 7 days of administration of prior dose of DTaP/Tdap not attributable to another identifiable cause	Evolving/progressive neurologic disorder, including uncontrolled seizures: Defer DTaP/Tdap temporarily until disorder stabilized; use DT or Td instead in children age $\geq 1$ year, reconsider pertussis immunization at each visit (i.e., if condition stabilized) GBS within 6 weeks of previous dose History of Arthus-type hypersensitivity reaction (including severe pain or swelling) after tetanus or diphtheria toxoid-containing vaccine: Defer vaccination for 10 years after last administration.
Hepatitis A	Anaphylaxis to neomycin	
Hepatitis B	Anaphylaxis/hypersensitivity to yeast	Defer for infants $< 2000$ g if mother HBsAg negative; see Fig. 16.1 for details
HPV	Anaphylaxis to yeast	Pregnancy: Delay vaccination until after pregnancy.
Influenza (IIV)		History of GBS within 6 weeks after a previous dose Egg allergy other than hives (administer in a supervised medical setting) <sup>46</sup>
Influenza (LAIV)	Contacts of severely immunocompromised patients requiring care in protective environment Children $< 5$ years with existing diagnosis of asthma or history of wheezing in past 12 months Receiving aspirin or aspirin-containing products Persons with active communications/leaks	History of GBS within 6 weeks after a previous dose Asthma in children $\geq 5$ years Medical conditions that might be at higher risk of complications from influenza Egg allergy other than hives (administer in a supervised medical setting) <sup>46</sup>

Continued

TABLE 16.3

CONTRAINDICATIONS AND PRECAUTIONS TO SELECT VACCINES<sup>9-11,44,45</sup>—CONT'D

Vaccine	Contraindication	Precaution
	between CSF and oropharyngeal space Presence of cochlear implant (consult specialist if no other influenza vaccine available) Use of influenza antiviral therapy in past 2–17 days, depending on which antiviral used (may interfere with immunogenicity)	
Japanese encephalitis	Anaphylaxis to protamine sulfate	
MenACWY	Anaphylaxis to yeast	History of preterm birth
MenB		Pregnancy Latex sensitivity
MMR		History of thrombocytopenia or TTP Recent blood product administration (within 3–11 months, depending on product and dose). See <a href="#">Table EC 16.4</a> Need for TB testing (PPD or interferon- $\gamma$ release assay testing may be done on day of immunization but otherwise should be postponed 4–6 weeks) Personal or family history of seizures (MMRV only)
Pneumococcal	PCV13: Anaphylaxis to any vaccine containing diphtheria toxoid or yeast	
Polio <sup>47</sup>	IPV: Anaphylaxis to neomycin, streptomycin, polymyxin B, 2-phenoxyethanol, and formaldehyde OPV: Immunocompromised patients and close/household contacts	Pregnancy: No evidence of harm, but avoid or give prior to pregnancy if possible
Rabies	Severe allergic reaction to prior dose—switch to PCECV if there is a reaction to HDCV (and vice versa)	
Rotavirus	SCID History of intussusception	Concern for immunocompromise, pre-existing chronic gastrointestinal disease, spina bifida, or bladder exstrophy
Tuberculosis (BCG) <sup>48</sup>	Immunocompromised, including HIV infection, or likelihood that patient will receive immunosuppressive therapy soon	

	Pregnancy: No evidence of harm, but avoid or give prior to pregnancy if possible	
Typhoid (Ty21a only) <sup>43</sup>		Certain antibiotics or antimalarials that would be active against <i>Salmonella</i> serovar Typhi or interfere with immunogenicity
Varicella <sup>49</sup>	Anaphylaxis to neomycin or gelatin	On aspirin or aspirin-containing products; avoid using salicylates for 6 weeks after vaccination Recent blood product administration (within 3–11 months, depending on product and dose, see Table EC 16.4) Other live vaccines in past 4 weeks Receipt of antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination; avoid for 14 days after vaccination
Yellow fever <sup>43,50</sup>	Anaphylaxis to eggs Symptomatic HIV infection or CD4 <sup>+</sup> count <200/mm <sup>3</sup> (or <15% for age <6 years) Age <6 months Thymus disorder	Age 6–8 months: Risk of vaccine-associated encephalitis Pregnant or breastfeeding: Rare cases of in utero or breastfeeding transmission of the vaccine virus Asymptomatic HIV infection with CD4 <sup>+</sup> count 200–499/mm <sup>3</sup> (or 15%–24% for age <6 years)

*BCG*, bacille Calmette-Guérin; *CSF*, cerebral spinal fluid; *DT*, Diphtheria and tetanus vaccine; *DTaP*, diphtheria, tetanus, acellular pertussis vaccine; *GBS*, Guillain-Barré syndrome; *HBsAg*, Hepatitis B surface antigen; *HDCV*, human diploid cell vaccine; *HIV*, human immunodeficiency virus; *HPV*, human papilloma virus; *HSCT*, hematopoietic stem cell transplant; *IIV*, inactivated influenza vaccine; *IPV*, inactivated poliovirus vaccine; *LAIV*, live, attenuated influenza vaccine; *MMR*, measles, mumps, rubella; *MMRV*, measles, mumps, rubella, varicella; *OPV*, oral poliovirus vaccine; *PCECV*, purified chick embryo cell vaccine; *PPD*, purified protein derivative; *SCID*, severe combined immunodeficiency; *Td*, tetanus and diphtheria vaccine; *Tdap*, tetanus, diphtheria, acellular pertussis vaccine; *TTP*, thrombotic thrombocytopenic purpura.

Modified from Table 4.1, Centers for Disease Control and Prevention. “Contraindications and Precautions.” Vaccine Recommendations and Guidelines of the ACIP. Last updated October 18, 2022 <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html>

#### IV. POSTEXPOSURE PROPHYLAXIS (TABLE 16.5)

#### V. SPECIAL PATIENT POPULATIONS<sup>9</sup>

##### A. Altered Immunocompetence<sup>10,11</sup>

1. For full details, see <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html>
2. General principles
  - a. Primary immunodeficiency: Congenital and usually inherited conditions defined by inherent absence or deficiency in cellular or humoral components that provide immunity
  - b. Secondary immunodeficiency: Acquired loss or deficiency in cellular or humoral immune components as a consequence of disease process or its therapy

TABLE 16.4

**CONDITIONS INCORRECTLY PERCEIVED AS CONTRAINDICATIONS OR PRECAUTIONS TO VACCINATION**<sup>9-11,44,45</sup>

Vaccine	NOT Contraindication/Precaution
All vaccines	Mild acute illness with or without fever Mild-moderate local reaction (i.e., swelling, redness, soreness); low-grade or moderate fever after previous dose Recent exposure to an infectious disease Current antimicrobial therapy (Exceptions: oral typhoid, varicella) Convalescent phase of illness Breastfeeding Preterm birth (Exception: hepatitis B vaccine in specific circumstances; see Fig. 16.1) History of penicillin allergy, other nonvaccine allergies, relatives with allergies, or receiving allergen extract immunotherapy History of GBS (Exception: within 6 weeks of influenza or tetanus toxoid-containing vaccine)
COVID-19 (SARS-CoV-2)	Pregnancy HIV or other altered immunocompetence
DTaP/Tdap	Fever within 48 hours of previous dose of DTaP/DTP Personal or family history of seizures, including seizures after previous dose of DTaP: Consider antipyretic use for 24 hours after vaccination. Collapse or shock-like state within 48 hours of a previous dose Persistent, inconsolable crying lasting $\geq 3$ hours within 48 hours of a previous dose Stable neurologic conditions (e.g., cerebral palsy, well-controlled seizures, or developmental delay)
Hepatitis B	Autoimmune disease
HPV	Evidence of active or prior HPV infection, such as abnormal Pap smear, history of genital warts, or positive HPV DNA test
Influenza (IIV)	Non-severe allergy to egg or latex Pregnancy: Give regardless of trimester Use of warfarin or aminophylline
Influenza (LAIV)	Contacts of persons with chronic disease or altered immunocompetence not requiring care in protected environment Breastfeeding
MMR	Family member or household contact who is pregnant or immunodeficient Patient female of child-bearing age Positive tuberculin skin test or interferon- $\gamma$ release assay Anaphylaxis to egg
Polio (IPV)	Previous receipt of $\geq 1$ dose of OPV
PPSV23	History of invasive pneumococcal disease or pneumonia
Rotavirus	Prematurity (give at hospital discharge)
Varicella	Family member or household contact who is pregnant or immunodeficient

(Exception: If patient experiences presumed vaccine-related rash 7–25 days after vaccination, patient should avoid direct contact with immunocompromised persons for duration of rash.)

Humoral immunodeficiency (e.g., agammaglobulinemia)

*DNA*, Deoxyribonucleic acid; *DTaP*, diphtheria, tetanus, acellular pertussis vaccine; *GBS*, Guillain-Barré syndrome; *HPV*, human papilloma virus; *IIV*, inactivated influenza vaccine; *IPV*, inactivated polio vaccine; *LAIV*, live, attenuated influenza vaccine; *OPV*, oral polio vaccine; *PPD*, purified protein derivative; *PPSV23*, pneumococcal 23-valent polysaccharide vaccine; *RA*, rheumatoid arthritis; *SLE*, systemic lupus erythematosus.

Modified from Table 4.2, Centers for Disease Control and Prevention. “Contraindications and Precautions.” Vaccine Recommendations and Guidelines of the ACIP. Last updated August 5, 2021. <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.pdf>

- (1) In general, inactivated vaccines should be administered at least 2 weeks and live vaccines at least 4 weeks before initiation of immunosuppression or transplantation.
- c. See Chapter 15 for specific information about immunodeficiencies.
- d. See Table EC 16.1 for specific vaccine recommendations and contraindications in patients with immunodeficiency.
3. Primary immunodeficiency
  - a. Live vaccines generally contraindicated, except for most complement deficiencies
  - b. Non-live vaccines should be administered according to routine schedule. Immune response may vary.
  - c. For immunodeficiencies that cause increased incidence/severity of some vaccine-preventable diseases, additional vaccination(s) may be recommended.
  - d. Passive immunoprophylaxis with immunoglobulin therapy may be indicated.
    - (1) See Chapter 15 for specific details.
    - (2) See Table 16.5 for postexposure prophylaxis guidelines.
  - e. Routine immunization of household contacts recommended
4. **Functional or anatomic asplenia (including sickle cell disease)**
  - a. Penicillin prophylaxis: See Chapter 14 for details.
  - b. See Section V.B for Hib, meningococcal, and pneumococcal vaccination recommendations.
  - c. Do not administer live attenuated influenza vaccine (LAIV).
  - d. Children  $\geq 2$  years undergoing elective splenectomy
    - (1) Administer pneumococcal and meningococcal vaccines  $\geq 2$  weeks before surgery for optimal immune response.
    - (2) If Hib immunization not previously completed, administer 1 dose  $\geq 2$  weeks before surgery.
5. **Known or suspected human immunodeficiency virus (HIV) disease**
  - a. See Section V.B for Hib, meningococcal, and pneumococcal vaccination recommendations.
  - b. CD4 count-dependent vaccines: Give to all HIV-infected children without evidence of severe immunocompromise (i.e., age 1–13 years

eTABLE 16.1

VACCINE INFORMATION FOR PATIENTS WITH IMMUNODEFICIENCIES<sup>9-11,44</sup>

Specific Immunodeficiency	Contraindicated Vaccines	Risk-Specific Recommended Vaccines	Effectiveness and Comments
<b>B LYMPHOCYTE (HUMORAL)</b>			
Severe antibody deficiencies (e.g., X-linked agammaglobulinemia, CVID)	OPV <sup>a</sup> Smallpox LAIV BCG Ty21a Yellow fever MMR MMRV	Pneumococcal Hib	Vaccine effectiveness is uncertain and dependent on humoral response.
Less severe antibody deficiencies (e.g., IgA deficiency, IgG subclass deficiency)	OPV <sup>a</sup> BCG Yellow fever <sup>8</sup> Other live vaccines appear to be safe.	Pneumococcal Hib	Vaccines likely effective; immune response might be attenuated
<b>T LYMPHOCYTE (CELL MEDIATED AND HUMORAL)</b>			
Complete defects (e.g., SCID, complete DiGeorge syndrome)	All live vaccines <sup>b</sup>	Pneumococcal Hib	Vaccines likely effective
Partial defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich)	All live vaccines <sup>b</sup>	Pneumococcal Meningococcal Hib	Vaccine effectiveness dependent on degree of immune suppression
IFN- $\gamma$ /IL-12 axis deficiencies	All live bacterial vaccines (All live vaccines contraindicated in IFN- $\gamma$ or IFN- $\alpha$ deficiencies)	None	
<b>COMPLEMENT</b>			
Persistent complement, properdin, or factor B deficiency	None	Pneumococcal Meningococcal Hib	Vaccines likely effective
Eculizumab (Soliris) therapy	None	Meningococcal	
<b>PHAGOCYtic FUNCTION</b>			
Chronic granulomatous disease	All live bacterial vaccines <sup>b</sup>	None	Live viral vaccines likely safe and effective

Phagocytic deficiencies that are undefined or accompanied by defects in T- and NK cell dysfunction (e.g., Chediak-Higashi syndrome, leukocyte adhesion deficiency)	MMR MMRV Varicella OPV <sup>a</sup> Smallpox BCG LAIV Ty21a Yellow fever and bacterial vaccines <sup>b</sup>	Pneumococcal	All inactivated vaccines safe and likely effective
--	--	--------------	--

**SECONDARY IMMUNODEFICIENCY**

HIV/AIDS	OPV <sup>a</sup> Smallpox BCG LAIV MMRV Withhold MMR and varicella in severely immunocompromised persons. Yellow fever vaccine may have contraindication or precaution depending on clinical parameters of immune function. (For details, see <a href="https://www.cdc.gov/yellowfever/healthcareproviders/vaccine-info.html">https://www.cdc.gov/yellowfever/healthcareproviders/vaccine-info.html</a> )	Pneumococcal Hib HepB MenACWY	MMR and varicella vaccine (in patients with mild immunocompromise—see Section V.A.5. for details), rotavirus, and all inactivated vaccines, including IIV as per routine vaccination schedule, may be effective.
----------	---	--	--

Generalized malignant neoplasm, transplantation, immuno-suppressive or radiation therapy	Live viral and bacterial, <sup>b</sup> depending on immune status	Pneumococcal Hib	Vaccine effectiveness dependent on degree of immune suppression
--	---	---------------------	---

Asplenia	LAIV	Pneumococcal Meningococcal Hib	Vaccines likely effective
----------	------	--------------------------------------	---------------------------

eTABLE 16.1

**VACCINE INFORMATION FOR PATIENTS WITH IMMUNODEFICIENCIES<sup>9-11,44</sup>—CONT'D**

Specific Immunodeficiency	Contraindicated Vaccines	Risk-Specific Recommended Vaccines	Effectiveness and Comments
Chronic renal disease	None	Pneumococcal HepB (indicated based on risk from dialysis-based blood-borne transmission)	Vaccines likely effective

<sup>a</sup>OPV is no longer available in the United States.

<sup>b</sup>Live bacterial vaccines: BCG, adenovirus, and oral Ty21a *Salmonella typhi* vaccine; live viral vaccines: MMR, MMRV, OPV, LAIV, yellow fever, zoster, rotavirus, varicella, and vaccinia (smallpox). Nonemergency smallpox vaccination is not recommended for children <18 years old or the general public.

*AIDS*, Acquired immunodeficiency syndrome; *BCG*, bacille Calmette-Guérin; *CDC*, Centers for Disease Control and Prevention; *CVID*, common variable immunodeficiency; *HepB*, hepatitis B; *Hib*, *Haemophilus influenzae* type b; *HIV*, human immunodeficiency virus; *IFN*, interferon; *IgA*, immunoglobulin A; *IgG*, immunoglobulin G; *IL*, interleukin; *LAIV*, live, attenuated influenza vaccine; *MMR*, measles, mumps, rubella; *MMRV*, measles, mumps, rubella, varicella; *OPV*, oral polio vaccine; *SCID*, severe combined immunodeficiency.

Modified from Appendix A from Centers for Disease Control and Prevention. *Epidemiology and Prevention of Vaccine-Preventable Diseases*. In: Hall E, Wodi A, Hamborsky J, Morelli V, Schillie S, eds. 14th ed. Public Health Foundation; 2021. <https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/a/immuno-table.pdf>

TABLE 16.5

## POSTEXPOSURE PROPHYLAXIS (PEP)

Disease	Prophylaxis Type	Indication/Administration Details <sup>a</sup>
COVID-19 (SARS CoV-2)	Monoclonal Ab	For the latest information on agents available and criteria to qualify, visit the U.S. Food and Drug Administration website.
Hepatitis A	Vaccine <sup>37</sup> IMIG <sup>51</sup>	Indicated for children $\geq 12$ months if $\leq 2$ weeks since exposure OR if $> 2$ weeks since exposure and exposure ongoing For children $< 12$ months if $\leq 2$ weeks since exposure Immunocompromised children with exposure Children with chronic liver disease with exposure Dosing: 0.1 mL/kg IM
Hepatitis B See Table 16.7 for details on percutaneous exposure to blood.	Vaccine  HBIG: Prepared from plasma containing high-titer anti-HBsAg antibodies	Give series to any previously unimmunized person with percutaneous/mucosal exposure to HBsAg-positive bodily fluids. Give within 12 hours after birth to any infant with maternal HBsAg status positive/unknown. Give within 12 hours after birth to infants with maternal HBsAg status positive; see Fig. 16.1 for guidance when maternal HBsAg unknown. Give to any previously unimmunized person or known nonresponder with percutaneous/mucosal exposure to HBsAg-positive blood/bodily fluids. Dosing: <ul style="list-style-type: none"> <li>• 0.5 mL IM for infants <math>&lt; 12</math> months</li> <li>• 0.06 mL/kg IM for children <math>\geq 12</math> months</li> </ul>
Hib (invasive)	Vaccine  Chemoprophylaxis	Invasive Hib $\leq 24$ months: Initiate 1 month after acute illness and continue immunization series as if previously unimmunized  Not required if invasive Hib disease develops in children $> 24$ months For any child who contracts invasive Hib disease after completing immunization series, consider immunologic workup. Exposure only: Rifampin prophylaxis recommended for household contacts in certain circumstances (see Table 3.9 of the 2021 Red Book for details <sup>52</sup> )

TABLE 16.5

## POSTEXPOSURE PROPHYLAXIS (PEP)—CONT'D

Disease	Prophylaxis Type	Indication/Administration Details <sup>a</sup>
Influenza NOTE: Recommendations vary by season; see CDC for up-to-date recommendations <sup>42</sup>	Chemoprophylaxis	<p>Most commonly used: Neuraminidase inhibitors (e.g., oseltamivir) given the high resistance to adamantanes (e.g., amantadine)</p> <p>For the following groups, give within 7 days of exposure:</p> <ul style="list-style-type: none"> <li>• Unimmunized high-risk children, including those for whom the vaccine is contraindicated or children immunized &lt;2 weeks before exposure</li> <li>• Unimmunized individuals in close contact with high-risk individuals</li> <li>• Immunodeficient individuals unlikely to have protective response to vaccine</li> <li>• Control of outbreaks in a closed setting</li> <li>• Immunized high-risk individuals if vaccine strain different from circulating strain</li> </ul> <p>Delay for ≥2 weeks if LAIV has been given</p> <p>Not a substitute for immunization</p>
Measles	Vaccine IMIG  IVIG	<p>Intervention of choice for measles outbreak; prevents or modifies disease if given within 72 hours of exposure</p> <p>Indicated in children &lt;1 year or nonimmune individuals who cannot receive the vaccine</p> <p>Prevents or modifies disease if given within 6 days of exposure</p> <p>Recommended for nonimmune pregnant women and severely immunocompromised hosts (including HIV-infected children) regardless of immunization status</p> <p>Additional therapy not required if given within 3 weeks before exposure</p>
Mumps	Vaccine	Persons ≥12 months who previously received ≤2 doses of MMR and are identified by public health authorities to be at increased risk during a mumps outbreak should receive 1 dose of MMR <sup>53</sup>
Meningococcal	Vaccine Chemoprophylaxis	<p>Adjunct to chemoprophylaxis when an outbreak is caused by a vaccine-preventable serogroup</p> <p>Indications:</p> <ul style="list-style-type: none"> <li>• Direct exposure to an infected person's oral secretions (including unprotected healthcare workers)</li> </ul>

- Close contact in the 7 days prior to onset of disease (e.g., child care, preschool, and household contacts and passengers seated next to the index patient during airline flights  $\geq 8$  hours)

Initiate within 24 hours of index patient diagnosis

See Table 3.36 of the *2021 Red Book* for details.<sup>52</sup>

Pertussis	Vaccine Chemoprophylaxis	Immunize all unimmunized or partially immunized close contacts based on the recommended schedule. Azithromycin, erythromycin, or clarithromycin recommended for household contacts and other close contacts. Alternatives include TMP-SMX (see Table 3.44 of the <i>2021 Red Book</i> for details <sup>52</sup> ).
Rabies See Table 16.8 for details based on type of exposure. NOTE: PEP indicated for bites, scratches, or contamination of open wound or mucous membrane with infectious material of potentially rabid animal or human	Vaccine  RIG: Antirabies Ig prepared from plasma of donors hyperimmunized with rabies vaccine  Other management	If unimmunized: give vaccine on Days 0, 3, 7, and 14 with $1 \times$ RIG on day 0. If immunosuppressed, give a fifth dose on day 28, and monitor response by checking neutralizing Ab levels 714 days after series completion. If RIG is unavailable, give vaccine alone. If previously immunized: booster doses on days 0 and 3 If unimmunized: <ul style="list-style-type: none"> <li>• Give <math>1 \times</math> RIG on day 0 with vaccine</li> <li>• If no vaccine, give RIG alone</li> <li>• May be given within 7 days after initiating immunization</li> </ul> Do not give RIG if previously immunized. Dosing: 20 units/kg; infiltrate around the wound, give remainder IM Consider tetanus prophylaxis and antibiotics, if indicated. General wound management: <ul style="list-style-type: none"> <li>• Clean immediately with soap and water and flush thoroughly.</li> <li>• Avoid suturing wound unless indicated for functional or cosmetic reasons.</li> </ul> Report all patients suspected of rabies infection to public health authorities.
Rubella	Rubella Ig	Does not prevent infection or viremia Routine use of rubella Ig in susceptible pregnant individuals with known exposure is not recommended.
Tetanus	Vaccine TIG	See Table 16.9 for details. Give to any child with HIV infection or other severe immunodeficiency for any tetanus-prone wound, regardless of vaccination status. Dosing: $1 \times 250$ units IM

TABLE 16.5

## POSTEXPOSURE PROPHYLAXIS (PEP)—CONT'D

Disease	Prophylaxis Type	Indication/Administration Details <sup>a</sup>
Varicella <sup>b</sup>	Vaccine	Vaccinate immunocompetent, nonimmune people $\geq 12$ months as soon as possible after exposure, preferably within 5 days. Do not give vaccine concurrently with or for 5 months after VariZIG. Avoid antivirals for 21 days after vaccination.
	VariZIG: Prepared from plasma containing high-titer antivari-cella antibodies	Give as soon as possible within 10 days of significant exposure in individuals with no immunity and a high likelihood of complications from infection, including: <ul style="list-style-type: none"> <li>• Immunocompromise</li> <li>• Pregnant women</li> <li>• Certain newborn infants</li> </ul> Dosing (weight-based, IM, 125 units = 1 vial): <ul style="list-style-type: none"> <li>• 62.5 units for <math>\leq 2</math> kg</li> <li>• 125 units for 2.1–10 kg</li> <li>• 250 units for 10.1–20 kg</li> <li>• 375 units for 20.1–30 kg</li> <li>• 500 units for 30.1–40 kg</li> <li>• 625 units for <math>&gt;40</math> kg</li> </ul>
	IVIg	May be used if VariZIG is not available Dosing: 400 mg/kg IV
	Chemoprophylaxis	If VariZIG or IVIg are not available, consider prophylaxis with 7 days of acyclovir or valacyclovir beginning 7–10 days after exposure in immunocompromised, nonimmune patients.

<sup>a</sup>Unless otherwise indicated, postexposure prophylaxis recommendations are derived from pathogen-specific chapters in Section 3 of American Academy of Pediatrics. *Red Book: 2021–2024 Report of the Committee on Infectious Diseases*. 32nd ed. AAP; 2021.

<sup>b</sup>See Fig 3.17 of the 2021 *Red Book* for specifics.<sup>52</sup>

CDC, Centers for Disease Control and Prevention; HBIG, hepatitis B immune globulin; HBsAg, hepatitis B surface antigen; Hib, *Haemophilus influenzae* type b; HIV, human immunodeficiency virus; Ig, immunoglobulin; IM, intramuscular; IMiG, intramuscular immunoglobulin; IViG, intravenous immunoglobulin; LAIV, live, attenuated influenza vaccine; MMR, measles, mumps, rubella; RIG, rabies immune globulin; TIG, tetanus immune globulin; TMP-SMX, trimethoprim-sulfamethoxazole; VariZIG, varicella zoster immune globulin.

with CD4<sup>+</sup> ≥15% for ≥6 months OR age ≥14 years with CD4<sup>+</sup> count ≥200 cells/mm for ≥6 months).

- (1) Varicella
  - (2) MMR
- c. Do not administer the following vaccines:
- (1) MMR-varicella combined vaccine
  - (2) LAIV
  - (3) OPV and/or BCG, unless in areas where infection risk outweighs possibility of vaccine-associated disease
- d. Consider passive immunoprophylaxis or chemoprophylaxis after exposures (see [Table 16.5](#)).

## 6. Malignancy

- a. Recommendations vary based on patient's specific treatment regimen. Always consult with patient's oncologist first.
- b. General strategies include the following:
  - (1) Defer routine immunization, except for Inactivated influenza vaccine (IIV), during chemotherapy.
  - (2) Presume loss of immunity with chemotherapy, and revaccinate per CDC catch-up immunization schedule after treatment completion.
- c. Timing of resumption of immunization varies based on patient's specific treatment regimen (from 3 months to ≥24 months).
  - (1) Inactivated vaccines and live vaccines are generally delayed until ≥3 months postcompletion of chemotherapy. However, if regimen included anti-B cell antibodies, all vaccines should be delayed until ≥6 months postcompletion of chemotherapy.
  - (2) Inactivated influenza vaccine (IIV) should be given annually, even during chemotherapy (except during treatment with intensive chemotherapy or anti-B-cell antibodies).

## 7. Hematopoietic stem cell transplant (HSCT) recipients

- a. After transplant, HSCT recipients are considered to no longer have immunity to previously received vaccines. Reimmunize against all vaccine-preventable illnesses.
  - (1) Inactivated vaccines are safe to administer 6 to 12 months after HSCT. Reasonable to consider pneumococcal series at 6 months and remainder at 12 months.
  - (2) Give IIV 6 months post-HSCT.

NOTE: During community outbreak, IIV may be given as early as 4 months post-HSCT.
  - (3) Do not administer live vaccines during first 24 months posttransplant.
  - (4) Do not administer live vaccines to patients with graft-versus-host-disease or ongoing immunosuppression, even if 24 months posttransplant.
  - (5) For specific vaccine recommendations, see [Table EC 16.2](#).
- b. Consider passive immunoprophylaxis or chemoprophylaxis after exposures (see [Table 16.5](#)).

eTABLE 16.2

VACCINATIONS AFTER HSCT<sup>11,54-57</sup>

Vaccine	Earliest Timing Posttransplant (# of recommended doses) <sup>a</sup>
DTaP, DT, Td, Tdap	Age <7 years: 6 months (3 doses of DTaP) Age ≥7 years: 6 months (3 doses of DTaP OR 1 dose of Tdap, followed by 2 doses of either DT or Td)
HepA	6 months (2 doses)
HepB	6 months (3 doses)
Hib	3 months (3 doses)
HPV	Age 11–26 years: 6 months (3 doses)
IIV	6 months, or 4 months during outbreak (1 dose annually; 2 doses if age 6 months–8 years and receiving for first time or if given prior to 6 months post-HSCT)
IPV	3 months (3 doses)
LAIV <sup>b</sup>	Contraindicated
Meningococcal	Age 11–18 years: 6 months (2 doses; booster at 16–18 years if first posttransplant dose given at age 11–15 years)
MMR <sup>b</sup>	24 months (2 doses) <sup>c</sup>
PCV13	3 months (3 doses; a fourth dose should be added at 14 months instead of PPSV23 in patients with chronic GVHD)
PPSV23	12 months if no chronic GVHD
Rotavirus <sup>b</sup>	Contraindicated
Varicella <sup>b</sup>	24 months (2 doses) <sup>c</sup>

<sup>a</sup>Some variation in recommended timing of administration post-HSCT. These recommendations reflect the IDSA Guidelines. Our center often will start vaccine series later than the “earliest timing” listed above.

<sup>b</sup>Do not administer live vaccines to patients with active GVHD or ongoing immunosuppression.

<sup>c</sup>Should only be administered to patients without ongoing immunosuppression, no chronic GVHD, and 8–12 months after last dose of IVIG.

*DT*, Diphtheria and tetanus vaccine; *DTaP*, diphtheria, tetanus, acellular pertussis vaccine; *GVHD*, graft-versus-host disease; *HepA*, hepatitis A; *HepB*, hepatitis B; *Hib*, *Haemophilus influenzae* type b; *HPV*, human papilloma virus; *IIV*, inactivated influenza vaccine; *IPV*, inactivated polio vaccine; *LAIV*, live, attenuated influenza vaccine; *MMR*, measles, mumps, rubella; *PCV13*, pneumococcal 13-valent conjugate vaccine; *PPSV23*, pneumococcal 23-valent polysaccharide vaccine; *Td*, tetanus and diphtheria vaccine; *Tdap*, tetanus, diphtheria, acellular pertussis vaccine.

Adapted from Table 16.4, “Vaccinations Prior to or After Allogeneic or Autologous Hematopoietic Stem Cell Transplant” in 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host.<sup>11</sup>

- c. Household contacts should receive routine immunizations. Only exception is LAIV if the HSCT recipient's level of immunocompromise is severe (e.g., HSCT in last 3 months). HSCT recipients should avoid contact with body fluids or skin eruptions of household contact who received rotavirus or varicella vaccines, respectively.

#### 8. **Solid organ transplant recipients**

- a. See Section V.B.3 for pneumococcal vaccination recommendations.
- b. Before transplant: Give all routinely recommended vaccines. Give live vaccines  $\geq 4$  weeks prior to transplantation.
  - (1) Children 6–11 months can receive MMR if not immunosuppressed and if transplant is  $\geq 4$  weeks away.
  - (2) Children 6 to 11 months (or without evidence of varicella immunity) can receive varicella vaccine if not immunosuppressed and if transplant is  $\geq 4$  weeks away.
- c. After transplant: Inactivated vaccines, including those indicated for immunocompromised hosts, should resume 2 to 6 months after transplant. Live vaccines are generally not administered after transplant. For specific vaccine recommendations, see [Table EC 16.3](#).

#### 9. **Patients on corticosteroids**

- a. Only live vaccines are potentially contraindicated.
- b. See [Table 16.6](#) for details.

#### 10. **Patients on biologic response modifiers**

- a. See Table 1.18 of the *2021 Red Book* for details.
- b. Antibodies to proinflammatory cytokines or proteins that bind to cytokine receptors (e.g., tumor necrosis factor [TNF]- $\alpha$  inhibitors) are considered highly immunosuppressive.
- c. Prior to initiating therapy:
  - (1) Perform serologic testing for hepatitis B virus and vaccinate/revaccinate if hepatitis B surface antibody (HBsAb) is  $< 10$  mIU/mL.
  - (2) Give inactivated vaccines (including IIV)  $\geq 2$  weeks prior to starting therapy.
  - (3) Give live-virus vaccines  $\geq 4$  weeks prior, unless contraindicated by condition or other therapies.
- d. During/after therapy:
  - (1) Live-virus vaccines: Contraindicated during therapy. Interval after therapy for safe administration has not been established.
  - (2) Inactivated vaccines (including IIV): Administer according to schedule.

#### 11. **Patients treated with immunoglobulin or other blood products**

- a. See [Table EC 16.4](#) for suggested intervals between blood product and MMR or varicella administration.

### **B. Disease-Specific Considerations**

#### 1. **Children at high risk of Hib**<sup>12,13</sup>

**eTABLE 16.3****VACCINATIONS AFTER SOLID ORGAN TRANSPLANT**<sup>11,56-59</sup>

Vaccine	Administration Recommendations (Starting 2–6 Months Posttransplant)
DTaP, DT, Td, Tdap	Routine schedule
HepA	Routine schedule
HepB	Routine schedule
Hib	Routine schedule
HPV	Routine schedule
IIV	Routine schedule (can be administered $\geq 1$ month after transplant during outbreak)
IPV	Routine schedule
LAIV	Contraindicated
Meningococcal	Routine schedule
MMR	Contraindicated
MMRV	Contraindicated
PCV13	Recommended, if not given pretransplant (high risk for pneumococcal disease)
PPSV23	Recommended for age $\geq 2$ years, if not given pretransplant (high risk for pneumococcal disease)
Rotavirus	Contraindicated
Varicella	Contraindicated <sup>a</sup>

<sup>a</sup>Exception: Select nonimmune patients with renal or liver transplant receiving minimal or no immunosuppression and without recent graft rejection.

NOTE: Vaccination should not be withheld because of concern about transplant rejection.

*DT*, Diphtheria and tetanus vaccine; *DTaP*, diphtheria, tetanus, acellular pertussis vaccine; *HepA*, hepatitis A; *HepB*, hepatitis B; *Hib*, *Haemophilus influenzae* type b; *HPV*, human papilloma virus; *IIV*, inactivated influenza vaccine; *IPV*, inactivated polio vaccine; *LAIV*, live, attenuated influenza vaccine; *MMR*, measles, mumps, rubella; *MMRV*, measles, mumps, rubella, varicella; *PCV13*, pneumococcal 13-valent conjugate vaccine; *PPSV23*, pneumococcal 23-valent polysaccharide vaccine; *Td*, tetanus and diphtheria vaccine; *Tdap*, tetanus, diphtheria, acellular pertussis vaccine.

Adapted from Table 16.5, “Vaccinations Prior to or After Solid Organ Transplant” in 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host.<sup>11</sup>

**eTABLE 16.4****RECOMMENDED INTERVALS BETWEEN ADMINISTRATION OF ANTIBODY-CONTAINING PRODUCTS AND MMR/VARICELLA VACCINES**

Product/Indication (Dosing)	Interval (Months)
<b>BLOOD TRANSFUSION (ALL 10 ML/KG IV)</b>	
Washed RBCs	0
RBCs, adenine-saline added	3
Packed RBCs	6
Whole blood	6
Plasma/platelet products	7
<b>INTRAMUSCULAR IMMUNOGLOBULIN</b>	
Hepatitis A IgG (0.1–0.2 mL/kg IM)	6
Hepatitis B IgG (HBIG) (0.06 mL/kg IM)	3
Tetanus IgG (TIG) (250 units IM)	3
Rabies IgG (RIG) (20 units/kg IM)	4
Palivizumab (RSV monoclonal Ab) (15 mg/kg IM)	0
Varicella IgG (VariZIG) (125 units/10 kg IM; max 625 units)	5
Measles prophylaxis IgG (immunocompetent contacts; 0.5 mL/kg IM)	6
<b>INTRAVENOUS IMMUNOGLOBULIN</b>	
Cytomegalovirus IVIG (150 mg/kg max)	6
Botulinum IVIG (BabyBIG) (1.0 mL/kg IV)	6
IVIG	
• Replacement therapy for immune deficiencies (300–400 mg/kg)	8
• Postexposure measles prophylaxis (immunocompromised contacts) (400 mg/kg)	8
• Postexposure varicella prophylaxis (400 mg/kg)	8
• ITP treatment (400 mg/kg)	8
• ITP treatment (1000 mg/kg)	10
• Kawasaki disease (2 g/kg)	11

*IM*, Intramuscular; *ITP*, immune; *IV*, intravenous; *IVIG*, intravenous immunoglobulin; *RBCs*, red blood cells; *RSV*, respiratory syncytial virus.

Modified from Appendix A from Centers for Disease Control and Prevention *Epidemiology and Prevention of Vaccine-Preventable Diseases*. In: Hall E, Wodi A, Hamborsky J, Morelli V, Schillie S, eds. 14th ed. Public Health Foundation; 2021. <https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/a/recommended-intervals-between-administration.pdf>

**TABLE 16.6****LIVE VACCINE IMMUNIZATION FOR PATIENTS RECEIVING CORTICOSTEROID THERAPY**

Steroid Dose	Recommended Guidelines
Topical, inhaled, or local injection of steroids Low-dose steroids (<2 mg/kg/day or <20 mg/day of prednisone equivalent <sup>a</sup> ) Physiologic maintenance doses	Live vaccines can generally be given unless there is clinical evidence of immunosuppression.
High-dose steroids (≥2 mg/kg/day or ≥20 mg/day of prednisone equivalent <sup>a</sup> ), duration of therapy <14 days	Live vaccines may be given immediately after cessation of therapy (but consider 2-week delay).
High-dose steroids (≥2 mg/kg/day or ≥20 mg/day of prednisone equivalent <sup>a</sup> ), duration of therapy ≥14 days	Delay live vaccines until 4 weeks after discontinuation of therapy.
Systemic or local steroids in patients with underlying disease affecting immune response (e.g., lupus) or receiving other immunosuppressant medication	Do not administer live vaccines.

<sup>a</sup>20 mg/day cutoff for children weighing more than 10 kg.

Adapted from pages 81–82 of the *2021 Red Book*.<sup>52</sup>

**TABLE 16.7****HEPATITIS B VIRUS PROPHYLAXIS FOR NON-HEALTHCARE PROVIDERS AFTER PERCUTANEOUS EXPOSURE TO BLOOD**

Exposed Person	HBsAg Status of Source of Blood		
	Positive	Negative	Unknown
Unimmunized	HBIG and HBV series	HBV series	HBV series
Previously immunized	Give 1 dose HBV booster.	No treatment	No treatment

HBIG, hepatitis B immune globulin; HBsAg, hepatitis B surface antigen; HBV, hepatitis B vaccine.

Adapted from Table 16.6 in Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. *MMWR Recomm Rep*. 2018;67(1):1–31.<sup>8</sup>

- a. Indications: Functional or anatomic asplenia (including sickle cell disease), HIV infection, immunoglobulin deficiency, early component complement deficiency, or chemotherapy/radiation
- b. Age <12 months: Administer primary series.
- c. Age 12–59 months:
  - (1) Received 0–1 dose(s) <12 months: Administer 2 doses at 8-week intervals.
  - (2) Received ≥2 doses <12 months: Administer 1 additional dose at least 8 weeks after previous dose.
  - (3) If patient undergoing chemotherapy or radiation, only readminister vaccine posttreatment if most recent dose was given <2 weeks prior to starting chemotherapy or radiation.
- d. Age ≥5 years with asplenia or HIV and not fully immunized: Administer 1 dose at least 8 weeks after previous dose.

## 2. Children at high risk of meningococcal disease<sup>14-18</sup>

TABLE 16.8

## RABIES POSTEXPOSURE PROPHYLAXIS BASED ON ANIMAL

Animal Type	Evaluation and Disposition of Animal	Postexposure Prophylaxis Recommendations
Dog, cat, ferret	Healthy and available for 10 days <sup>a</sup> observation	Do not begin prophylaxis unless animal develops signs of rabies.
	Rabid or suspected rabid: euthanize animal and test brain	Provide immediate immunization and RIG. <sup>a</sup>
	Unknown (escaped)	Consult public health officials.
Skunk, raccoon, bat, <sup>b</sup> fox, woodchuck, most other carnivores	Regard as rabid unless geographic area is known to be free of rabies or until animal is euthanized and proven negative by testing	Provide immediate immunization and RIG. <sup>a</sup>
Livestock, rodents, rabbit, other mammals	Consider individually	Consult public health officials; these bites rarely require treatment.

<sup>a</sup>Treatment may be discontinued if animal fluorescent antibody is negative.

<sup>b</sup>In the case of direct contact between a human and a bat, consider prophylaxis even if a bite, scratch, or mucous membrane exposure is not apparent.

RIG, Rabies immune globulin.

Adapted from Table 3.49 of the 2021 Red Book.<sup>52</sup>

TABLE 16.9

## INDICATIONS FOR TETANUS PROPHYLAXIS

Prior Tetanus Toxoid Doses	Clean, Minor Wounds		All Other Wounds	
	Tetanus Vaccine <sup>a</sup>	TIG	Tetanus Vaccine <sup>a</sup>	TIG
Unknown or <3	Yes	No	Yes	Yes
≥3, last <5 years ago	No	No	No	No
≥3, last 5–10 years ago	No	No	Yes	No
≥3, last ≥10 years ago	Yes	No	Yes	No

<sup>a</sup>DTaP preferred under age 7 years; Tdap preferred over Td for children ≥7 years if patient is underimmunized or hasn't received Tdap previously; otherwise, either one is acceptable. DT or Td if pertussis is contraindicated.

DT, Diphtheria and tetanus vaccine; DTaP, diphtheria, tetanus, acellular pertussis vaccine; Td, tetanus and diphtheria vaccine; Tdap, tetanus, diphtheria, acellular pertussis vaccine; TIG, tetanus immune globulin.

Adapted from Table 3.68 of the 2021 Red Book.<sup>52</sup>

- a. Indications: Functional or anatomic asplenia, HIV infection, persistent complement deficiency (including eculizumab use), travel to or residence in areas with hyperendemic or epidemic meningococcal disease, or residence in community with meningococcal outbreak
- b. Age <2 years:
  - (1) MenACWY-CRM (Menveo): If age 8 weeks–6 months, administer 4 doses at 2, 4, 6, and 12 months. If age 7–23 months and unvaccinated, administer 2 doses, with second dose ≥12 weeks after first dose and after first birthday.
  - (2) MenACWY-D (Menactra): Before age 2 years, can use for persistent complement component deficiency or travel but

**not** for anatomic/functional asplenia, sickle cell disease, or HIV infection before. If age 9–23 months, give two doses 12 weeks apart.

- c. Age  $\geq 2$  years:
  - (1) Administer two doses of Menactra or Menveo (minimum 8-week interval) to children at increased risk due to medical condition.
  - (2) Only one dose is needed for children at increased risk due to traveling, living in hyperendemic regions, or outbreak.
  - (3) Administer Menactra  $\geq 4$  weeks after completing PCV13 series.
- d. Age  $\geq 10$  years with asplenia or persistent complement deficiency:
  - (1) Administer MCV4 series.
  - (2) Administer two-dose MenB-4C (Bexsero) series or three-dose MenB-FHbp (Trumenba) series. The two MenB vaccines are **not** interchangeable; use the same product for all doses in series.
- e. Boosters:
  - (1) MCV4 series
    - (a) Most recent dose administered when child  $< 7$  years old: Administer one booster dose 3 years after completion of primary series, then every 5 years thereafter.
    - (b) Most recent dose administered when child  $\geq 7$  years old: Administer one booster dose every 5 years.
  - (2) MenB series
    - (a) Ongoing risk due to disease process: Administer one booster dose 1 year after completion of primary series, then every 2–3 years thereafter.
    - (b) Ongoing risk due to outbreak: Consider one booster dose 1 year after completion of primary series.

### 3. **Children at high risk for pneumococcal disease**<sup>19-21</sup>

- a. Indications:
  - (1) Immunocompromised: Functional or anatomic asplenia (including sickle cell disease), primary immunodeficiencies, HIV infection, malignancy, immunosuppressive or radiation therapy, solid organ transplant, chronic renal failure, or nephrotic syndrome
  - (2) Other chronic conditions: Chronic heart disease, chronic lung disease, diabetes mellitus, cerebrospinal fluid leak, cochlear implant, chronic liver disease, or alcoholism
- b. See [Fig. 16.2](#) for recommendations.


## C. Preterm Infants

### 1. **Immunize according to chronologic age, using regular vaccine dose.**


NOTE: Due to limited evidence regarding risk for nosocomial transmission of rotavirus following vaccine in hospitalized patients, individual institutions may decide whether to administer rotavirus vaccine to infants during hospitalization. Otherwise, administer at time of discharge.

### 2. **Hepatitis B:** See [Fig. 16.1](#).

### 3. **Respiratory syncytial virus (RSV)** immunoprophylaxis: See [Table 16.2](#).

**FIGURE 16.1**

Management of neonates born to mothers with unknown or positive hepatitis B surface antigen (*HBsAg*) status. <sup>a</sup>Only single antigen vaccine should be used. <sup>b</sup>Reimmunization may be required based on anti-HBs; test for HBsAg and anti-HBs at age 9 to 12 months or 1 to 2 months after completion of HepB series if delayed. HBsAg-negative infants with anti-HBs levels  $\geq 10$  mIU/mL are protected. HBsAg-negative infants with anti-HBs levels  $< 10$  mIU/mL should be reimmunized with a fourth dose and retested. If still  $< 10$  mIU/mL, two additional doses should be given. If after six doses the levels are  $< 10$  mIU/mL, no additional doses of HepB vaccine are indicated. *BW*, Birth weight; *HBIG*, hepatitis B immune globulin; *HepB*, hepatitis B. (Modified from American Academy of Pediatrics. *Red Book: 2021-2024 Report of the Committee on Infectious Diseases*. 32nd ed. AAP; 2021.)



**FIGURE 16.2**

Pneumococcal immunization recommendations for children at high risk of pneumococcal disease. (Adapted from Table 3.65 in American Academy of Pediatrics. *Red Book: 2021-2024 Report of the Committee on Infectious Diseases*. 32nd ed. AAP; 2021.)

## D. Pregnant Women

1. **Tdap (tetanus, diphtheria, acellular pertussis):** Give during each pregnancy, preferably at 27–36 weeks' gestation, regardless of prior immunization status.
2. **Give IIV** regardless of trimester. Do not administer LAIV.
3. **Other inactivated vaccines:** Considered precautionary and generally deferred until after the pregnancy, unless specific disease-risk/indication for vaccine present.
4. **Live vaccines:** Generally contraindicated during pregnancy

## E. Immigration, Emigration, and Travel

1. **Travelers:**
  - a. See CDC's Travelers' Health site for destination-specific recommendations: <https://www.cdc.gov/travel/destinations/list>
  - b. Consider referral to a travel clinic.
2. **Immigrants from outside the United States:** See CDC's Immigrant and Refugee Health site for recommendations for immigrants, refugees, and international adoptees: <https://www.cdc.gov/immigrantrefugeehealth/>

## VI. COUNSELING AND COMMUNICATION ABOUT VACCINES<sup>22-34</sup>

### A. Vaccine Hesitant versus Vaccine Refusal<sup>33</sup>

1. **Vaccine hesitant:** Not dichotomous, but a continuum. For example, parents may delay but eventually accept vaccines or accept some vaccines and refuse others. 20% of children in United States have a vaccine-hesitant parent.
2. **Vaccine refusal:** Parents refuse all or some vaccines. 1.3% of toddlers in United States are completely unvaccinated; there has been increased vaccine refusal in last decade.
3. AAP recommends continued engagement with vaccine-hesitant/refusal parents while providing other health services and attempting to modify opposition to vaccines.<sup>26</sup>
4. **Determinants of vaccine acceptance**
  - a. The 3C Model: Confidence, Complacency, Convenience. Key determinants of vaccine acceptance in global populations as determined by the World Health Organization SAGE Working Group on Vaccine Hesitancy.<sup>25</sup> See Section VIII, Online Content, for more details.
  - b. Parental concerns about vaccines, including concerns about vaccine safety, vaccine necessity, and freedom of choice. See [eBox 16.1](#) for details.

### B. Countering Vaccine Hesitancy<sup>26</sup>

1. General principles
  - a. Factor with greatest influence on parental decision to vaccinate is one-on-one conversation with child's pediatrician.
  - b. Acknowledge and address parent and/or patient-specific concerns, while correcting misconceptions in nonconfrontational manner. Emphasize mutual desire to do what is best for the child.

**eBOX 16.1****PARENTAL CONCERNS ABOUT VACCINES****Vaccine Safety**

Too many vaccines  
Development of autism  
Vaccine additives (thimerosal, aluminum)  
Overload of the immune system  
Serious adverse reactions  
Potential for long-term adverse events  
Inadequate research performed before licensure  
May cause pain to the child  
May make the child sick

**Necessity of Vaccines**

Disease is more “natural” than vaccine.  
Parents do not believe diseases being prevented are serious.  
Vaccine-preventable diseases have disappeared.  
Not all vaccines are needed.  
Vaccines do not work.

**Freedom of Choice**

Parents have the right to choose whether to immunize their child.  
Parents know what’s best for their child.  
Do not trust organized medicine, public health  
Do not trust government health authorities  
Do not trust pharmaceutical companies  
Ethical, moral, or religious reasons

Adapted from Table 16.2 of Edwards KM, Hackell JM, AAP Committee on Infectious Diseases, The Committee on Practice and Ambulatory Medicine. Countering vaccine hesitancy. *Pediatrics*. 2016;138(3):e20162146.<sup>26</sup>

## BOX 16.1

## COMMUNICATION STRATEGIES TO INCREASE VACCINE UPTAKE

- Presumptive > Participatory Approach<sup>26</sup>
  - Participatory: Would you like to vaccinate your child today? What do you think about vaccines?
  - Presumptive: Your child is due for three vaccines, so we will plan to give those during today's visit.
- CASE Approach<sup>41</sup>
  - Example statement of patient/guardian vaccine hesitancy: I've heard the MMR vaccine causes autism, so I don't want my child to get that one.
  - **Corroborate:** Acknowledge parental concern and find a point on which you can agree to set tone for respectful, successful discussion.
    - Example: That makes sense! There's lots of buzz on the news and internet about vaccines and autism. If the MMR vaccine caused autism, I wouldn't want your child to get it either.
  - **About Me:** Describe efforts you have made to build knowledge base and expertise. Consider including personal anecdotes, narratives, etc.
    - Example: I've been studying this claim for many years and have read many studies about the MMR vaccine, as well as about autism. I always want to make sure I have the most up-to-date information on this topic to give families.
  - **Science:** Present data (i.e., autism, Tdap in pregnancy, safety of ingredients)
    - Example: Dozens of studies have looked for a connection between the vaccine and autism, but no association has been identified. In fact, studies on autism show that children with autism display signs long before they receive the MMR vaccine. On the other hand, the MMR vaccine prevents measles, and I have seen how serious measles can be: one in three children become so sick they have to be hospitalized. Some even die.
  - **Explain/Advise:** Based on information you have presented, then give your strong recommendation.
    - Example: Choosing not to vaccinate will not protect your child from autism, but choosing to vaccinate will protect her from multiple dangerous diseases so that she can live a long and healthy life. I strongly recommend your child receive these vaccines today.

- c. Present vaccination as default practice (opt-out, **not** opt-in).
- d. Effective approaches to counseling on vaccine hesitancy include aspects of storytelling, anecdotes, and science-based messaging. Storytelling/anecdotes often play larger role in parents' decision to vaccinate, rather than data.<sup>34</sup>
- e. Gain versus loss: framed messaging<sup>34</sup>
  - (1) Though fear-based messaging has been effective in anti-vaccination movement, studies show it is ineffective for promoting vaccines.
  - (2) Emphasize what patients/families will gain from vaccination, rather than what they might lose from not vaccinating.
  - (3) Explain that vaccines benefit individual children and communities through herd immunity.

2. Specific strategies and resources
  - a. See [Box 16.1](#) for examples of specific communication strategies.
  - b. See Section VIII, Online Content, and [eBox 16.2](#) for more information on interventions and online provider resources.

## VII. WEB RESOURCES<sup>35-40</sup>

- Advisory Committee on Immunization Practices (ACIP) Vaccine Recommendations and Guidelines: <https://www.cdc.gov/vaccines/hcp/acip-recs/index.html>
- Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book): <https://www.cdc.gov/vaccines/pubs/pinkbook/index.html>
- AAP Report of the Committee on Infectious Diseases (Red Book): <https://redbook.solutions.aap.org/>
- CHOP Vaccine Education Center: <https://www.chop.edu/centers-programs/vaccine-education-center>
- WHO Immunization, Vaccines and Biologicals: <https://www.who.int/teams/immunization-vaccines-and-biologicals>
- VaxView: <https://www.cdc.gov/vaccines/vaxview/index.html>
- Data for ACIP-recommended vaccine coverage across the United States
- Vaccine Adverse Event Report System: <https://vaers.hhs.gov/>  
National vaccine safety surveillance program run by the CDC and U.S. Food and Drug Administration that collects information about postvaccination adverse events
- Vaccines for Children Program: <https://www.cdc.gov/vaccines/programs/vfc/about/index.html>  
Provides vaccines to children whose parents/guardians may not be able to afford them
- Centers for Disease Control and Prevention Vaccine Shortages and Delays: <https://www.cdc.gov/vaccines/hcp/clinical-resources/shortages.html>

## REFERENCES

A complete list of references can be found online.

## VIII. ONLINE CONTENT

### A. Additional Vaccine Information

1. Vaccine information for patients with immunodeficiencies (eTable 16.1)
2. Vaccinations after HSCT (eTable 16.2)
3. Vaccinations after solid organ transplant (eTable 16.3)
4. Recommended intervals between administration of antibody-containing products and MMR/varicella vaccines (eTable 16.4)

### B. The 3C Model: Key Barriers to Vaccine Use Worldwide<sup>22</sup>

1. Confidence: Trust in healthcare professionals, vaccines, and their effectiveness. Includes concerns regarding vaccine safety, quality of interactions with healthcare providers, religious beliefs, and media influence
2. Complacency: Low awareness of the risks of vaccine-preventable diseases and the importance of vaccines. Includes resistance to introduction of new vaccines, resistance to mode of vaccine delivery, and lack of knowledge about the risks of now-uncommon diseases
3. Convenience: Availability of and accessibility to vaccines and healthcare services (rural areas, low-middle income countries). Includes vaccine supply issues, lack of education or medical literacy, geographic barriers, political conflicts and instability, and immigration

### C. Provider Resources for Vaccine Communication: See eBox 16.2.

#### eBOX 16.2

##### ONLINE PROVIDER RESOURCES FOR ADDRESSING VACCINE-HESITANT PATIENTS AND FAMILIES

Safety of Vaccines Used for Routine Immunization of US Children: A Systematic Review: <https://pediatrics.aappublications.org/content/early/2014/06/26/peds.2014-1079.full.pdf+html>

Vaccine conversations with parents: <https://www.cdc.gov/vaccines/hcp/conversations/conv-materials.html>

List of public health, policy, and clinical studies for helping providers increase vaccination rates in their communities: <https://www.cdc.gov/vaccines/hcp/admin/reminder-sys.html>

AAP refusal to vaccinate form: <https://www.aap.org/en/patient-care/immunizations/implementing-immunization-administration-in-your-practice/refusal-to-vaccinate/>  
 Navigating Vaccine Hesitancy: [https://www.aap.org/en-us/Documents/immunization\\_hesitancy.pdf](https://www.aap.org/en-us/Documents/immunization_hesitancy.pdf) (will be available soon)

##### Education

Challenging Cases: Vaccine Hesitancy: <https://bit.ly/cc-vaccinehesitancy>. This module is the educational component of the clinical report.

AAP Immunization website: <https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/immunization/Pages/default.aspx>. Specific pages within this site include the following: Parental Refusal Resource Page, Vaccine-Hesitant Parents, Information for families, Common Parental Concerns.

Provider Resources for Vaccine Conversations With Parents: <https://www.cdc.gov/vaccines/hcp/conversations/conv-materials.html>

Immunization Action Coalition: <https://www.immunize.org/>

**eBOX 16.2—CONT'D**

Children's Hospital of Philadelphia: <https://www.chop.edu/service/vaccine-education-center/home.html>

**Red Book**

---

Discussing Vaccines With Patients and Parents (p. 7)

Addressing Parents' Questions About Vaccine Safety and Effectiveness (pp. 7–8)

Common Misconceptions About Immunizations and the Institute of Medicine Findings (pp. 8–10)

Resources for Optimizing Communications With Parents About Vaccines (pp. 10–11)

Parental Refusal of Immunizations (pp. 11–12)

Childhood Immunization: When Physicians and Parents Disagree: [https://www.pediatrics.aappublications.org/content/128/Supplement\\_4/S167.full](https://www.pediatrics.aappublications.org/content/128/Supplement_4/S167.full)

Adapted from Table 16.5 of Edwards KM, Hackell JM, AAP Committee on Infectious Diseases, The Committee on Practice and Ambulatory Medicine. Countering vaccine hesitancy. *Pediatrics*. 2016;138(3):e20162146.<sup>26</sup>

## REFERENCES

1. American Academy of Pediatrics. Active immunization. In: Kimberlin D, Barnett E, Lynfield R, Sawyer M, eds. *Red Book: 2021-2024 Report of the Committee on Infectious Diseases*. 32nd ed. American Academy of Pediatrics; 2021.
2. Li D-D, Li Q-H. SARS-COV-2: vaccines in the pandemic era. *Military Med Res*. 2021;8(1). <https://doi.org/10.1186/s40779-020-00296-y>
3. Modalities: mRNA vaccines, therapeutics, and immuno-oncology. mRNA Vaccines, Therapeutics, and Immuno-Oncology. Published 2021. Accessed March 2021. <https://www.modernatx.com/modalities-mrna-vaccines-therapeutics-and-immuno-oncology>
4. Centers for Disease Control and Prevention. *Recommended Immunization Schedules for Persons Aged 0 through 18 Years—United States*; 2021. <http://www.cdc.gov/vaccines/schedules>
5. Robinson CL, Romero JR, Kempe A, Pellegrini C, Szilagyi P. Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger United States, 2018. *MMWR Morb Mortal Wkly Rep*. 2018;67:156–157.
6. Centers for Disease Control and Prevention. *List of Vaccines Used in United States*; 2018. <https://www.cdc.gov/vaccines/vpd/vaccines-list.html>
7. Marin M, Broder KR, Temte JL, et al. Centers for disease control and prevention. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the advisory committee on immunization practices. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*. 2010;59:3.
8. Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*. 2018;67(No. RR-1):1–31.
9. American Academy of Pediatrics. Immunization in special clinical circumstances. In: Kimberlin D, Barnett E, Lynfield R, Sawyer M, eds. *Red Book: 2021-2024 Report of the Committee on Infectious Diseases*. 32nd ed. American Academy of Pediatrics; 2021.
10. Centers for Disease Control and Prevention. “Altered Immunocompetence.” Vaccine Recommendations and Guidelines of the ACIP. Last updated September 8, 2022 <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html>
11. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis*. 2014;58:e44–e100.
12. American Academy of Pediatrics. Haemophilus influenzae Infections. In: Kimberlin D, Barnett E, Lynfield R, Sawyer M, eds. *Red Book: 2021-2024 Report of the Committee on Infectious Diseases*. 32nd ed. American Academy of Pediatrics; 2021.
13. Briere EC, Rubin L, Moro PL, et al. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*. 2014;63(1):1–14.
14. American Academy of Pediatrics Committee on Infectious Diseases. Updated recommendations on the use of meningococcal vaccines. *Pediatrics*. 2014;134:400–403.
15. Folaranmi T, Rubin L, Martin SW, et al. Centers for Disease Control and Prevention. Use of serogroup B meningococcal (menb) vaccines in persons

- aged  $\geq 10$  years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices. *MMWR Morb Mortal Wkly Rep.* 2015;64:608–612.
16. MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW. Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons advisory committee on immunization practices. *MMWR Morb Mortal Wkly Rep.* 2016;65:1189–1194, 2016.
  17. Mbaeyi S, Bozio C, Duffy J, et al. Centers for disease control and prevention meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(9):1–41.
  18. American Academy of Pediatrics. Meningococcal infections. In: Kimberlin D, Barnett E, Lynfield R, Sawyer M, eds. *Red Book: 2021-2024 Report of the Committee on Infectious Diseases.* 32nd ed. American Academy of Pediatrics; 2021.
  19. AAP Committee on Infectious Diseases. Immunization for streptococcus pneumoniae infections in high-risk children. *Pediatrics.* 2014;134:1230–1233.
  20. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the advisory committee on immunization practices. *MMWR Morb Mortal Wkly Rep.* 2013;62(25):521–524.
  21. American Academy of Pediatrics. Streptococcus pneumoniae (pneumococcal) infections. In: Kimberlin D, Barnett E, Lynfield R, Sawyer M, eds. *Red Book: 2021-2024 Report of the Committee on Infectious Diseases.* 32nd ed. American Academy of Pediatrics; 2021.
  22. World Health Organization. *Addressing Vaccine Hesitancy. Immunization, Vaccines and Biologicals;* 2018. <http://www.who.int/immunization/en/>
  23. SAGE Vaccine Hesitancy Working Group. *Report of the SAGE Working Group on Vaccine Hesitancy.* Geneva: World Health Organization; 2014.
  24. Jarrett C, Wilson R, O’Leary M, Eckersberger E, Larson HJ. SAGE Working group on vaccine hesitancy. strategies for addressing vaccine hesitancy—a systematic review. *Vaccine.* 2015;33(34):4180–4190.
  25. Dubé E, Gagnon D, MacDonald NE. SAGE Working Group on Vaccine Hesitancy. Strategies intended to address vaccine hesitancy: review of published reviews. *Vaccine.* 2015;33(34):4191–4203.
  26. Edwards KM, Hackell JM. Committee on infectious diseases; the committee on practice and ambulatory medicine. countering vaccine hesitancy. *Pediatrics.* 2016;138(3).
  27. Dubé E, Gagnon D, Nickels E, Jeram S, Schuster M. Mapping vaccine hesitancy—country-specific characteristics of a global phenomenon. *Vaccine.* 2014;32(49):6649–6654.
  28. Kaufman J, Ryan R, Walsh L, et al. Face-to-face interventions for informing or educating parents about early childhood vaccination. *Cochrane Database Syst Rev.* 2018;5:CD010038.
  29. Ames HM, Glenton C, Lewin S. Parents’ and informal caregivers’ views and experiences of communication about routine childhood vaccination: a synthesis of qualitative evidence. *Cochrane Database Syst Rev.* 2017;2:CD011787.
  30. Saeterdal I, Lewin S, Austvoll-Dahlgren A, Glenton C, Munabi-Babigumira S. Interventions aimed at communities to inform and/or educate about early childhood vaccination. *Cochrane Database Syst Rev.* 2014;11:CD010232.

31. Getman R, Helmi M, Roberts H, Yansane A, Cutler D, Seymour B. Vaccine hesitancy and online information: the influence of digital networks. *Health Educ Behav.* 2018;45(4):599–606.
32. Hwang J, Shah DV. Health information sources, perceived vaccination benefits, and maintenance of childhood vaccination schedules. *Health Commun.* 2018:1–10.
33. Natbony J, Genies M. Vaccine hesitancy and refusal. *Pediatr Rev.* 2019;40(Supplement 1):22–23. <https://doi.org/10.1542/pir.2019-0072>
34. Olson O, Berry C, Kumar N. Addressing parental vaccine hesitancy towards childhood vaccines in the United States: a systematic literature review of communication interventions and strategies. *Vaccines.* 2020;8(4):590. <https://doi.org/10.3390/vaccines8040590>
35. Kroger AT, Duchin J, Vázquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices. Last updated March 15, 2022 <http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html>
36. Centers for Disease Control and Prevention. *ACIP Vaccine Recommendations and Guidelines*; 2021. <http://www.cdc.gov/vaccines/hcp/acip-recs/index.html>
37. Centers for Disease Control and Prevention. Hall E, Wodi A, Hamborsky J, Morelli V, Schillie S, eds. *Epidemiology and Prevention of Vaccine-Preventable Diseases*. 14th ed. Public Health Foundation; 2021. <http://www.cdc.gov/vaccines/pubs/pinkbook/index.html>
38. Centers for Disease Control and Prevention. Hall E, Wodi A, Hamborsky J, Morelli V, Schillie S, eds. *Epidemiology and Prevention of Vaccine-Preventable Diseases*. 14th ed. Supplement: Public Health Foundation; 2021.
39. The Children’s Hospital of Philadelphia. Vaccine education center. 2022. <https://www.chop.edu/centers-programs/vaccine-education-center>
40. World Health Organization. Immunization, vaccines, and biologicals. 2021. <https://www.who.int/teams/immunization-vaccines-and-biologicals>
41. Jacobson RM, Van Etta L, Bahta L. The C.A.S.E. approach: guidance for talking to vaccine-hesitant parents. *Minn Med.* 2013;96(4):49–50. PMID: 23926833.
42. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2018-19 influenza season. *MMWR Morb Mortal Wkly Rep.* 2018;67(3):1–20.
43. Immunization Action Coalition. Package inserts & FDA product approvals, Last updated November 30, 2021. <http://www.immunize.org/fda/>
44. Centers for Disease Control and Prevention. Contraindications and precautions. vaccine recommendations and guidelines of the ACIP. Last updated November 17, 2022 <http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html>
45. Immunization Action Coalition. Guide to contraindications and precautions to commonly used vaccines. Last updated October 14, 2022 <https://www.immunize.org/catg.d/p3072a.pdf>
46. Centers for Disease Control and Prevention. Flu vaccine and people with egg allergies. Last updated August 25, 2022 <https://www.cdc.gov/flu/prevent/egg-allergies.htm>
47. Centers for Disease Control and Prevention. Contraindications and precautions for polio vaccination. Last updated August 8, 2022 <https://www.cdc.gov/vaccines/vpd/polio/hcp/contraindications-precautions.html>

48. Centers for Disease Control and Prevention. Atlanta, GA: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; 2011. <https://www.cdc.gov/tb/publications/factsheets/prevention/BCG.pdf>
49. Marin M, Guris D, Chaves SS, et al. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the advisory committee on immunization practices. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*. 2007;56(4):1–40.
50. Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the advisory committee on immunization practices. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*. 2010;59(7):1–27.
51. Young M. The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles. *Hum Vaccin Immunother*. 2019;15(9):2060–2065.
52. American Academy of Pediatrics. In: Kimberlin D, Barnett E, Lynfield R, Sawyer M, eds. *Red Book: 2021-2024 Report of the Committee on Infectious Diseases*. 32nd ed. American Academy of Pediatrics; 2021.
53. Centers for Disease Control and Prevention. Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*. 2001;50(12):1–23.
54. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant*. 2009;15:1143.
55. Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. *Blood*. 2016;127(23):2824–2832.
56. Tsang V. Vaccination recommendations for the hematology and oncology and post-stem cell transplant populations. *J Adv Pract Oncol*. 2012;3(2):71–83.
57. L’Huillier AG, Kumar D. Immunizations in solid organ and hematopoietic stem cell transplant patients: a comprehensive review. *Hum Vaccin Immunother*. 2015;11(12):2852–2863.
58. Kotton CN, Hibberd PL. Travel medicine and the solid organ transplant recipient. *Am J Transplant*. 2009;9(suppl 4):S273.
59. Danziger-Isakov L, Kumar D, AST Infectious Diseases Community of Practice. Vaccination in solid organ transplantation. *Am J Transplant*. 2013;13(suppl 4):311–317.

# Chapter 17

## Microbiology and Infectious Disease

*Amali Gunawardana, MD and Ashley Wallace Wu, MD*

 See additional content online.

 **Audio Case File 17.1** Resistance mechanisms in gram-negative rods

### I. COMMON NEONATAL AND PEDIATRIC INFECTIONS: GUIDELINES FOR DIAGNOSIS AND INITIAL MANAGEMENT

Tables 17.1 to 17.6 and Figs. 17.1 to 17.3 present the most common neonatal and pediatric infections, organized by site of infection or by organism, when applicable. These recommendations are based on national guidelines and recent literature. They are not meant to replace clinical judgment.

For recommendations on preliminary identification of bacteria and antibiotic selection based on spectrum of activity for commonly used antibiotics, please see Sections II and III. Please note that local resistance patterns should guide antibiotic selection. Follow published institutional guidelines and culture results for individual patients and infections. When possible, always use the agent with the narrowest spectrum of activity, particularly when organism susceptibilities are known.

**A. Congenital, Perinatal, and Neonatal Infections (Table 17.1)**

**B. Pediatric Infections by System (Table 17.2)**

**C. Pediatric Viral Illnesses (Table 17.3)**


**D. Pediatric Tickborne Diseases (Table 17.4)**

**E. Pediatric Parasitic Infections (Table 17.5)**

**F. Pediatric Fungal Infections (Table 17.6)**

**G. Febrile Infants**


1. Etiology
  - a. Bacterial infections (urinary tract infection [UTI], bacteremia, meningitis) should be considered in all febrile infants. Risk is significant even if well-appearing without a clear source. Most bacterial infections in age <90 days are UTIs.
  - b. 0–28 days: *Escherichia coli*, group B streptococcal (GBS) disease. Rarely, *Listeria* spp.
  - c. 29+ days: Invasive infections resulting from *Haemophilus influenzae* type B and *Streptococcus pneumoniae* have declined significantly since the introduction of conjugate vaccines.

**FIGURE 17.1**

Example of categorical risk factor assessment for infants  $\geq 35$  weeks' gestation. The risk of infection is highly variable among newborn infants, depending on the gestational age, duration of membrane rupture, and timing and content of administered intrapartum antibiotics. This approach likely results in empiric treatment of many relatively low-risk infants. Newer, multivariate approaches are available online. (From Puopolo KM, Lynfield R, Cummings JJ. Committee on Infectious Diseases. Management of infants at risk for Group B streptococcal disease. *Pediatrics*. 2019;144[2]:e20191881.)

- d. *Staphylococcus aureus* is a significant cause of infection in the neonatal intensive care unit population.
- e. Fever following immunization is common (40% chance of fever within 48 hours).<sup>1</sup>

2. Workup and initial therapy (continued on page 491)



**FIGURE 17.2**

Algorithm for management of a previously healthy term infant 8 to 60 days with a fever without localizing signs. This algorithm is a suggested but not exhaustive approach. *CSF*, Cerebrospinal fluid; *HSV*, herpes simplex virus; *IM*, inflammatory marker; *LP*, lumbar puncture; *UA*, urinalysis. (Based on Pantell RH, Roberts KR, Adams WG, et al. Evaluation and management of well-appearing febrile infants 8 to 60 days old. *Pediatrics*. 2021;148[2].)

TABLE 17.1

## CONGENITAL, PERINATAL, AND NEONATAL INFECTIONS

	Presentation	Etiology	Diagnosis	Treatment
Cytomegalovirus (CMV) <sup>2</sup>	<p><b>Congenital:</b> 90% asymptomatic at birth. Diagnosed within 3 weeks of birth. IUGR, jaundice, thrombocytopenia, petechiae, hepatosplenomegaly, transaminitis, microcephaly, intracranial calcifications, sensorineural hearing loss, and retinitis</p> <p><b>Postnatal:</b> Sepsis-like syndrome, thrombocytopenia, pneumonitis, hepatitis, typically in preterm and very-low-birth-weight infants</p>	<p>Human herpesvirus. Congenital infection is transmitted in utero. Postnatal infection may be acquired via birth canal or breastmilk. Persists in leukocytes and tissue</p>	<p>PCR or rapid viral culture of saliva, urine, blood, or CSF</p> <p>Variable practices for screening infants (urine or saliva). May target those who fail newborn hearing screen or those with low birth weight</p>	<p>Congenital: IV ganciclovir or PO valganciclovir for 6 months if symptomatic</p> <p>Hearing tests at regular intervals</p> <p>Postnatal: IV ganciclovir for 2–3 weeks. Follow CMV serum viral load and ANC during treatment.</p>
<i>Chlamydia trachomatis</i> <sup>2</sup>	Ophthalmia (onset 5–12 days), afebrile pneumonia (onset 2–19 weeks), nasal stuffiness and otitis media, asymptomatic colonization	Obligate intracellular bacteria Affects 50% of infants born vaginally to affected moms	NAAT (gold standard), culture, or DFA of conjunctival cells and nasopharynx Test for gonorrhea.	Oral erythromycin ×14 days or oral azithromycin ×3 days Saline irrigation Erythromycin ointment NOT effective for ophthalmia prophylaxis
Gonorrhea <sup>2</sup>	Ophthalmia (onset 2–5 days), scalp abscess at electrode site, disseminated disease (sepsis, arthritis, meningitis)	Intracellular gram-negative diplococcus	Culture and Gram stain of exposed sites (conjunctiva, vagina, rectum, oropharynx) NAAT superior but not approved for conjunctival swab Gonococcal ophthalmia warrants hospitalization and workup for disseminated disease. Test for <i>Chlamydia trachomatis</i> .	Ceftriaxone or cefotaxime (if available) (single dose for ophthalmia, 7 days for scalp abscess/disseminated, 10–14 days for meningitis) Erythromycin ointment effective for ophthalmia prophylaxis

TABLE 17.1

## CONGENITAL, PERINATAL, AND NEONATAL INFECTIONS—CONT'D

	Presentation	Etiology	Diagnosis	Treatment
Group B streptococcal disease (GBS) <sup>27</sup>	<p><b>Early onset (0–6 days):</b> 95% present within 48 hours. Most commonly pneumonia, bacteremia, or meningitis. 2% case fatality in term infants, 20% in preterm infants</p> <p><b>Late onset (7–89 days):</b> Typically presents between 3–4 weeks. Most commonly bacteremia or meningitis. Also septic arthritis, osteomyelitis, UTI, and cellulitis.</p>	<p>Transmitted by mother with genitourinary GBS colonization OR maternal infection (bacteremia, endometritis, chorioamnionitis)</p> <p>Intrapartum antibiotics decrease transmission (at least 1 dose <math>\geq</math> 4 hr prior to delivery) and early-onset disease.</p>	<p>Multiple accepted approaches for risk assessment among infants born &gt;35 weeks of gestation. Example of common, categorical approach shown in Fig. 17.1. Newer, multivariate risk assessment (Neonatal Early-Onset Sepsis Calculator) is available at: <a href="https://neonatalespsiscalculator.kaiserpermanente.org/">https://neonatalespsiscalculator.kaiserpermanente.org/</a>.</p> <p>Diagnosis made by culture</p>	<p><b>Intrapartum antibiotic prophylaxis:</b> Penicillin G preferred, ampicillin as alternative</p> <p><b>Presumptive early-onset GBS sepsis:</b> ampicillin and gentamicin</p> <p><b>Empiric treatment for late-onset GBS meningitis:</b> ampicillin and ceftazidime (or cefotaxime, if available)</p> <p>Ceftriaxone if &gt;30 days. Consider inclusion of vancomycin for drug-resistant <i>Streptococcus pneumoniae</i> meningitis.</p>
Hepatitis B virus (HBV) <sup>2</sup>	<p>90% of infants infected perinatally or in first year of life develop chronic HBV infection, leading to:</p> <ol style="list-style-type: none"> <li>1. Chronic low-grade hepatitis</li> <li>2. Progression to cirrhosis and hepatocellular carcinoma</li> <li>3. Risk of reactivation and acute hepatitis</li> </ol>	<p>Hepadnavirus usually transmitted perinatally (rather than in utero), from mother with acute or active chronic infection.</p> <p>95% of transmission prevented with appropriate immunoprophylaxis at birth<sup>29</sup></p>	<p>If mother HBsAg-positive, test infant for HBsAg and anti-HBsAg between 9 and 12 months (or 1–2 months after final HBV vaccine).</p> <p>Monitor HBV DNA and ALT in chronic HBV. Infection cleared at <math>\sim</math>1% per year.</p> <p>See Table 17.7 for interpretation of serologies.</p>	<p>See Chapter 16 for immunoprophylaxis with HBV vaccine and hepatitis B immunoglobulin (HBIG).</p> <p>Breastfeeding is safe with appropriate immunoprophylaxis.</p> <p>Refer for treatment if active HBV replication with elevated ALT for 6 months.</p>
Hepatitis C virus (HCV) <sup>2</sup>	<p>80% of acute infections become chronic. Syndrome less pronounced than in hepatitis B</p>	<p>Flavivirus transmitted in utero or perinatally from about 5% of infected (RNA-positive) mothers</p>	<p>HCV antibody at 18 months for definitive diagnosis (maternal HCV antibodies persist 12+ months). Monitor ALT every 6 months.</p>	<p>Rapidly evolving field</p> <p>New oral antiviral regimens approved for age &gt;3 years old.</p> <p>Breastfeeding safe. Consider pausing if nipples bleeding.</p>

Herpes simplex virus (HSV) <sup>2</sup>	Presents within first 4 weeks as: 1. Localized to skin, eyes, and mouth (45%) 2. Localized to CNS (30%) 3. Disseminated (25%) with sepsis, pneumonitis, hepatitis, consumptive coagulopathy, and CNS involvement	Herpesvirus transmitted most commonly via maternal genital tract with active HSV lesions. Less commonly ascending (in utero) and postnatal (via caregivers) transmission. >75% of cases born to mothers without known history of HSV	Surface culture or PCR from active vesicles, mouth, nasopharynx, conjunctivae, and anus PCR or culture of blood and CSF LFTs Viremia can be seen in nondisseminated disease.	IV acyclovir: 14 days for skin, eye, and mouth disease; 21 days for CNS or disseminated disease. CSF clearance must be proven. Treat eye involvement with additional topical antiviral. All types receive 6 months PO acyclovir prophylaxis.
Parvovirus <sup>2</sup>	Fetal hydrops, IUGR, isolated pleural/pericardial effusions, death in 2%–6%, highest risk in 1st half of pregnancy	Small single-stranded DNA virus, replicates in erythrocyte precursors	IgM for diagnosis of acute infection PCR aids in diagnosis of hydrops fetalis.	Supportive care. Some success with intrauterine blood transfusion for hydrops fetalis
Rubella <sup>2</sup>	IUGR, cataracts, glaucoma, cardiac anomalies (patent ductus arteriosus and peripheral pulmonic stenosis), deafness, “blueberry muffin rash”	Togavirus transmitted via primary maternal infection (85% chance of transmission if maternal infection before 12 weeks gestation)	IgM at birth. Level typically would increase within first 6 months of life. Diagnosis can be confirmed by stable or increasing IgG level over first 7 to 11 months. RNA PCR and viral culture also used.	Supportive care, with evaluation by ophthalmology and cardiology Safe to vaccinate breastfeeding moms
Syphilis <sup>2</sup>	May be asymptomatic at birth Oro/nasopharyngeal secretions (“snuffles”), mucocutaneous lesions, maculopapular rash, hepatosplenomegaly, hemolytic anemia, thrombocytopenia If untreated, late disease affects CNS, bones/joints/teeth, eyes, and skin	<i>Treponema pallidum</i> is a spirochete transmitted in utero at any stage of maternal syphilis or at delivery.	If maternal nontreponemal serology positive (RPR or VDRL), obtain maternal serum treponemal test and screen infant using nontreponemal tests. Reverse sequence testing is also practiced. Full evaluation includes: CBC with differential, transaminases, CSF analysis, chest x-ray, long-bone x-rays, abdominal US, neuroimaging,	<b>Proven or highly probable</b> (abnormal exam, RPR or VDRL titer fourfold greater than maternal titer, or positive darkfield or PCR test): IV aqueous penicillin G or IM procaine penicillin G for 10 days. <b>If possible</b> (normal exam, RPR/VDRL $\leq$ fourfold maternal titer, AND one of the following: 1) mother not treated, inadequately treated, not documented, 2) mother treated with non-penicillin

TABLE 17.1

## CONGENITAL, PERINATAL, AND NEONATAL INFECTIONS—CONT'D

Presentation	Etiology	Diagnosis	Treatment
		ophthalmologic exam, auditory brainstem response testing. Refer to Red Book for interpretation of screening tests, diagnostic approach, and treatment algorithms.	regimen, or 3) mother treated <4 weeks before delivery): IV aqueous penicillin G for 10 days <b>If less likely</b> (normal exam, RPR/VDRL $\leq$ fourfold maternal titer, mother adequately treated >4 weeks before delivery, and no evidence of reinfection/relapse): IM benzathine penicillin G single dose <b>If unlikely</b> (normal exam, RPR/VDRL $\leq$ fourfold maternal titer, mother treated before pregnancy, and maternal titer low and stable before and throughout pregnancy): ensure titer returns to negative. Some experts give benzathine penicillin G single dose. Breastfeeding is safe in absence of breast chancre.
Toxoplasmosis <sup>2</sup>	May be asymptomatic at birth Severe manifestations: chorioretinitis, cerebral calcifications, hydrocephalus Other: IUGR, microcephaly, seizures, hearing loss, strabismus, petechial rash, cytopenias	Intracellular parasite transmitted via primary infection during pregnancy (contracted from cat feces or undercooked meat)	Pyrimethamine + sulfadiazine with folinic acid for at least 12 months Monitor ANC. Regular eye exams every 3–6 months
		Serologies and PCR. Positive IgM after 5 days or IgA after 10 days or IgG after 12 months is diagnostic. Positive PCR in CSF, blood, or urine is diagnostic. Eye exam for chorioretinitis CT is most sensitive for cerebral calcifications.	

Varicella <sup>2</sup>	<p><b>Congenital infection:</b> Varicella embryopathy (limb hypoplasia, cutaneous scarring, eye/CNS damage)</p> <p><b>Perinatal infection:</b> Disseminated infection. Highest risk with maternal disease onset at 5 days before through 2 days after delivery. High mortality because of lack of sufficient maternal antibodies</p>	<p>Herpesvirus transmitted via primary maternal infection, most commonly during 1st or early 2nd trimester.</p> <p>Also via active lesions peripartum</p>	<p>PCR of vesicle or scab contents is gold standard.</p> <p>PCR of saliva is less sensitive</p>	<p>Acyclovir ×10 days in disseminated disease</p> <p>Immunoprophylaxis with VariZIG (or IVIG) when:</p> <ol style="list-style-type: none"> <li>1. Mother develops primary varicella between 5 days prepartum and 2 days postpartum.</li> <li>2. Hospitalized preterm infants with known exposure<sup>30</sup></li> </ol>
Zika virus <sup>31</sup>	<p>Microcephaly, CNS or ocular anomalies, deafness, congenital contractures</p>	<p>Flavivirus transmitted in utero after primary maternal infection</p>	<p>Workup: RNA PCR of blood/urine, IgM in serum, and neuroimaging. If obtaining CSF, can check RNA PCR and IgM.</p> <p>Test if:</p> <ol style="list-style-type: none"> <li>1. Clinical findings with possible maternal infection in pregnancy based on stay in endemic areas</li> <li>2. Lab-proven maternal infection in pregnancy, even without clinical findings</li> </ol>	<p>Supportive. Head ultrasound, audiology evaluation, and full ophthalmologic exam by 1 month. See Red Book and latest WHO/CDC algorithms.</p>

*ALT*, Alanine aminotransferase; *ANC*, absolute neutrophil count; *CBC*, complete blood count; *CDC*, Centers for Disease Control and Prevention; *CNS*, central nervous system; *CRP*, C-reactive protein; *CSF*, cerebrospinal fluid; *CT*, computed tomography; *DFA*, direct fluorescent antibody; *DNA*, deoxyribonucleic acid; *FNA*, fine needle aspiration; *HBsAg*, hepatitis B surface antigen; *Ig*, immunoglobulin; *IM*, intramuscular; *IUGR*, intrauterine growth restriction; *IV*, intravenous; *IVIG*, intravenous immunoglobulin; *NAAT*, nucleic acid amplification test; *PCR*, polymerase chain reaction; *PO*, by mouth; *RNA*, ribonucleic acid; *RPR*, rapid plasma regain; *UTI*, urinary tract infection; *VDRRL*, venereal disease research laboratory test; *WHO*, World Health Organization.

TABLE 17.2

## PEDIATRIC INFECTIONS BY SYSTEM

	Presentation	Etiology	Diagnosis	Treatment
<b>CENTRAL NERVOUS SYSTEM</b>				
Meningitis <sup>32,33</sup>	<p><b>Infant:</b> Ill-appearing, fever, hypothermia, lethargy, vomiting, poor feeding, seizures, bulging fontanelle</p> <p><b>Child and adolescent:</b> Fever, headache, altered mental status, nuchal rigidity, photophobia, nausea, vomiting. Can be progressive or acute and fulminant</p>	<p><b>&lt;1 month:</b> Group B <i>Streptococcus</i>, <i>Escherichia coli</i>, <i>Listeria</i></p> <p><b>1–23 months:</b> <i>Streptococcus pneumoniae</i>, <i>Neisseria meningitidis</i>, <i>S. agalactiae</i> (GBS), <i>Haemophilus influenzae</i></p> <p><b>2+ years:</b> <i>S. pneumoniae</i>, <i>N. meningitidis</i>, <i>Haemophilus influenzae</i></p> <p>Brain abscess: <i>Streptococcus anginosus</i>, other <i>Streptococcus</i> spp., anaerobes, <i>Staphylococcus aureus</i></p>	<p>Indication for head CT prior to LP: immunocompromised, known CNS disease, papilledema, focal neurologic deficit</p> <p>LP for Gram stain, culture, and CSF analysis. See <a href="#">Table 17.8</a>.</p>	<p>Initiate antibiotics as soon as the possibility of bacterial meningitis is considered; do not delay antibiotics for head CT or LP.</p> <p><b>&lt;1 month:</b> ampicillin + ceftazidime (or cefotaxime, if available)</p> <p><b>1+ month:</b> vancomycin + ceftriaxone</p> <p>Adjunctive dexamethasone (administered at the initiation of antibiotic treatments) may reduce hearing loss in children &gt;6 weeks with <i>H. influenzae</i> type B meningitis; has also been found to improve mortality, decrease hearing loss, and decrease neurologic complications in adults with pneumococcal meningitis; therefore, some experts recommend adjunctive dexamethasone in children/adolescents with pneumococcal meningitis.</p> <p>Brain abscess: vancomycin + ceftriaxone + metronidazole</p>
CNS hardware infection <sup>33</sup>	Similar to meningitis	<i>Staphylococcus epidermidis</i> , <i>S. aureus</i> , gram-negative bacilli including <i>Pseudomonas</i> spp., <i>Cutibacterium acnes</i>	MRI with gadolinium CSF analysis, Gram stain, and culture (shunt sampling/tap or LP)	Vancomycin and cefepime Removal of all infected hardware with placement of an external ventriculostomy preferred over shunt externalization

## HEAD AND NECK

Conjunctivitis <sup>34</sup>	Foreign body sensation, itching, burning, photophobia, hyperemia	Infectious: Most commonly viral (especially adenovirus), <i>S. pneumoniae</i> , <i>H. influenzae</i> , <i>Neisseria</i> spp., <i>Chlamydia trachomatis</i> , <i>Staphylococcus</i> spp. Noninfectious: allergic, toxic, inflammatory, dry eyes	Clinical diagnosis is nonspecific, and individual symptoms are unreliable. Allergic: Watery, pruritic Viral: Fever, bilateral conjunctivitis, lymphadenopathy Bacterial: Fever, purulent discharge, pain, adherence of eyelids upon awakening, lack of itching	<b>Viral:</b> Supportive care. <b>Bacterial:</b> Ophthalmic polymyxin B/TMP drops for bacterial infection. Ointments preferred in young children. Conjunctivitis secondary to gonorrhea/chlamydia requires systemic antibiotic treatment in addition to topical therapy. Conjunctivitis in contact lens wearers should always be treated. Ophthalmology consult if photophobia, vision loss, severe pain, recurrent episodes, or suspected gonorrhea
Acute otitis media <sup>35</sup>	Nonspecific symptoms and signs, including fever, irritability, apathy, poor feeding, vomiting, and diarrhea. May have ear pain and/or rubbing	<i>S. pneumoniae</i> , <i>H. influenzae</i> , <i>Moraxella catarrhalis</i>	Moderate-to-severe bulging of the tympanic membrane, mild bulging with signs of inflammation, or new-onset otorrhea	High-dose amoxicillin × 10 days if <2 years old OR if severe symptoms regardless of age; 7 days if 2–5 years old, 5 days if 6 years or older If received amoxicillin in past 30 days, give amoxicillin/clavulanate. Consider watchful waiting if: 6–23 months—unilateral AOM without otorrhea or severe symptoms (toxic-appearing, T ≥39°C, otalgia >48 hr) 24+ months—unilateral or bilateral AOM without otorrhea or severe symptoms If treatment failure after 48–72 hr: amoxicillin-clavulanate × 10 days or IM ceftriaxone × 1–3 days

Continued

## PEDIATRIC INFECTIONS BY SYSTEM—CONT'D

	Presentation	Etiology	Diagnosis	Treatment
Mastoiditis <sup>36</sup>	Complication of acute otitis media Tender mastoid, protruding auricle	<i>S. pneumoniae</i> , <i>Streptococcus pyogenes</i> , <i>S. aureus</i> , <i>H. influenzae</i>	Clinical. Contrast CT or MRI if complications suspected (CNS signs, ill-appearing, treatment failure)	Empiric ceftriaxone and vancomycin Often requires surgical management
Otitis externa <sup>37</sup>	Ear pain, pruritus, discharge, auricle and tragus tenderness and erythema	<i>Pseudomonas</i> spp., <i>S. aureus</i>	Culture in severe cases.	Otic drops × 7 days: ciprofloxacin or polymyxin-neomycin Wick if outer canal swollen.
Group A streptococcal pharyngitis <sup>19</sup>	Classic signs: Fever, tonsillar exudates, lymphadenopathy, absence of cough Higher concern between age 3 and 15 Scarlet fever (from exotoxin production) involves diffuse, finely papular, erythematous rash 24–48 hr after onset of symptoms	<i>S. pyogenes</i>	Rapid antigen detection test or nucleic acid test (NAT). If negative, confirm with culture. IDSA recommends testing if 3+ years old, without viral symptoms (cough, rhinorrhea, hoarseness, oral ulcers).	Amoxicillin × 10 days or benzathine penicillin IM × 1 dose Nonsevere PCN allergy: cephalexin × 10 days PCN-allergic: clindamycin × 10 days Second line: azithromycin × 5 days
Peritonsillar abscess <sup>38,39</sup>	Sore throat, trismus, uvular deviation Can be bilateral Most common in adolescents	Often polymicrobial: <i>S. pyogenes</i> , viridans group streptococci, <i>S. aureus</i> , <i>Haemophilus</i> spp., oral anaerobes	Clinical. Consider imaging if diagnosis unclear.	Ampicillin/sulbactam or ceftriaxone/cefotaxime (if available) + clindamycin Often requires aspiration or I&D
Retropharyngeal/parapharyngeal abscess <sup>38,39</sup>	Sore throat, fever, dysphagia, neck stiffness, medial deviation of wall of oropharynx (parapharyngeal abscess) Most common at age 2–4 years	Often polymicrobial: <i>S. pyogenes</i> , viridans group streptococci, <i>S. aureus</i> , <i>Haemophilus</i> spp., oral anaerobes	Clinical. Consider imaging if diagnosis unclear.	Ampicillin/sulbactam or ceftriaxone/cefotaxime (if available) + clindamycin If no airway compromise, can trial antibiotics × 48–72 hr, prior to obtaining CT and surgical management

Ludwig angina (submandibular cellulitis) <sup>40</sup>	Rapidly progressive, bilateral cellulitis, often originating as dental infection Causes elevation of the tongue, risk of airway compromise	Often polymicrobial: viridans group Streptococci, <i>S. aureus</i> , oral anaerobes	Clinical. Consider imaging if diagnosis unclear.	Ampicillin/sulbactam or ceftriaxone + metronidazole (if PCN allergic: levofloxacin + metronidazole) Add vancomycin to above regimens if concern for MRSA. Consider surgical drainage.
Lemierre syndrome <sup>41</sup>	Thrombophlebitis of internal jugular vein seeded from primary oropharyngeal infection, bacteremia, or distant site(s) of infection. High-grade fever (>39.5C), neck swelling/tenderness, exudative tonsillitis, or grayish pseudomembranes	<i>Fusobacterium necrophorum</i> , oral Streptococci	WBC count, CRP, and ESR often are markedly elevated. CT with contrast is most useful imaging modality An unremarkable oropharyngeal appearance at the time of septicemia does not rule out Lemierre syndrome.	Aqueous penicillin G AND metronidazole Surgical management often required
Preseptal cellulitis <sup>42</sup>	May follow external trauma, spread from sinuses or hematogenous infection	<i>S. aureus</i> , <i>Streptococcus</i> spp.	Clinical	Amoxicillin/clavulanate × 7 days
Orbital cellulitis <sup>42</sup>	Proptosis, ophthalmoplegia, pain on extraocular movements, and blurred vision	<i>Streptococcus</i> spp., <i>S. aureus</i> , <i>H. influenzae</i> , <i>M. catarrhalis</i> Most commonly extension of rhinosinusitis Immunocompromised or diabetic—consider fungal (e.g. Mucorales)	CT with contrast; ophthalmology and ENT consultation	Ceftriaxone or cefotaxime (if available) + vancomycin OR ampicillin/sulbactam + vancomycin (if no concern for CNS involvement) Often requires abscess drainage

Continued

## PEDIATRIC INFECTIONS BY SYSTEM—CONT'D

	Presentation	Etiology	Diagnosis	Treatment
Sinusitis (bacterial) <sup>43</sup>	Rhinorrhea, inflammation of septum and turbinates, tenderness over sinuses	<i>S. pneumoniae</i> , <i>H. influenzae</i> (nontypeable), <i>M. catarrhalis</i> If chronic, also <i>S. aureus</i> , anaerobes	Clinical: Persistent sinusitis 10+ days without improvement, worsening course after initial improvement, or severe symptoms (purulent discharge, fever $\geq 39^{\circ}\text{C}$ ) for 3+ days	Amoxicillin/clavulanate $\times$ 10–14 days. Some experts recommend only 7 days of antibiotic treatment. If mild but persistent symptoms >10 days, can opt to observe with close follow-up. In chronic sinusitis, consider culture to guide antibiotics.
Cervical lymphadenitis <sup>2,44–46</sup>	Distinguished from reactive lymphadenopathy by fluctuance, warmth, overlying erythema	<b>Acute (&lt;2 weeks):</b> Unilateral: most commonly <i>S. aureus</i> , <i>S. pyogenes</i> Bilateral: Consider EBV, CMV. <b>Chronic (&gt;2 weeks):</b> Consider <i>Bartonella henselae</i> (cat scratch disease), nontuberculous mycobacterium (NTM), Toxoplasmosis, HIV, TB	Consider ultrasound if diagnosis unclear. Consider FNA and culture if no improvement in 48–72 hr. If >2 weeks, consider tuberculin skin test.	PO: Cephalexin or amoxicillin/clavulanate or clindamycin empirically. Definitive treatment is based on culture and susceptibility. Duration $\times$ 7–14 days If no response to PO/severe disease: cefazolin, clindamycin, or vancomycin Bartonella: Azithromycin $\times$ 5 days shown to have mild effect. Needle aspiration as needed for relief of symptoms only, because disease is self-limited and spontaneously resolves in 2–4 months. NTM: Curative management—surgical excision, if incomplete or recurrence, antibiotics can be used (macrolide + rifampin)
Oral candidiasis (thrush)	White plaques on tongue, buccal mucosa, and/or palate	<i>Candida albicans</i> is most common.	Clinical	Nystatin swish and swallow or clotrimazole troches for 7–14 days. Nystatin for infants

**PULMONARY**Community-acquired pneumonia<sup>47</sup>

Fever, respiratory distress, cough  
 On exam, tachypnea, hypoxia, diminished breath sounds, crackles, asymmetric breath sounds

Bacterial: *S. pneumoniae*, nontypeable *H. influenzae*, *M. catarrhalis*.  
*Mycoplasma pneumoniae* and *Chlamydia pneumoniae* may be considered in subacute presentations.  
 Viral: Influenza, parainfluenza, human metapneumovirus, adenovirus

Clinical diagnosis for mild disease.  
 Chest x-ray if hypoxic, respiratory distress, or hospitalized.  
 CBC or inflammatory markers (CRP, ESR, procalcitonin) are not reliable to differentiate bacterial vs viral pneumonia.  
 Blood culture not required for mild disease

**Outpatient:** High-dose amoxicillin × 5 days.  
**Inpatient:** Ampicillin × 5 days.  
**ICU:** Ceftriaxone plus coverage for MRSA empirically (e.g., TMP/SMX, vancomycin, clindamycin). Vancomycin not preferred due to poor lung penetration. Some experts discontinue MRSA coverage based on negative MRSA nares screening.  
 Small parapneumonic effusions treated with antibiotics alone

Pertussis<sup>2</sup>

Mild URI symptoms (catarrhal stage). Progresses to whooping cough (paroxysmal stage)  
 Duration 6–10 weeks  
 Atypical presentation in neonates with cyanosis, gasping and posttussive emesis

*Bordetella pertussis*.  
 Droplet transmission.  
 Incubation 7–10 days

NAAT performed on posterior nasopharynx specimen

Azithromycin × 5 days.  
 Alternative: TMP-SMX.  
 Treatment during paroxysmal stage unlikely to affect clinical course but reduces transmission.  
 Postexposure prophylaxis recommended for household and other close contacts (including children in daycare) = also azithromycin × 5 days

## Tuberculosis

See [Section 1.H](#)

**GASTROINTESTINAL**Appendicitis<sup>48</sup>

Right lower quadrant pain, anorexia, fever  
 More difficult to diagnose in females or those <3 years of age

Enteric pathogens + anaerobes

Clinical diagnosis  
 Imaging (ultrasound, otherwise CT with contrast or MRI)

Ceftriaxone + metronidazole + source control  
 Nonoperative management only considered if symptoms <48 hr and no abscess or fecalith

TABLE 17.2

## PEDIATRIC INFECTIONS BY SYSTEM—CONT'D

	Presentation	Etiology	Diagnosis	Treatment
Gastroenteritis <sup>2,49,50</sup>	Typically mild disease that does not require hospitalization Worrisome signs include: age <3 months, underlying disease, persistent vomiting, high-output diarrhea (>8×/day), family reported signs of severe dehydration.	Etiologies without treatment: toxin-mediated <i>S. aureus</i> , <i>Bacillus cereus</i> , <i>Clostridium perfringens</i> ; viral: norovirus, rotavirus, astrovirus, adenovirus	If suspect inflammatory bacterial enteritis: stool culture or bacterial NAAT panel. Depending on exposures and chronicity, consider stool for ova and parasites.	Enteral rehydration is preferred to intravenous regardless of etiology.
		Nontyphoid <i>Salmonella</i> spp. <sup>51</sup>		If <3 months, immunocompromised, hemoglobinopathy, or severe disease, treat with ceftriaxone or azithromycin. Optimal treatment duration unknown, range 3–14 days. Consider longer duration (7 days) in immunocompromised hosts, infants, and those with invasive disease (bacteremia), where evaluating for focal infection is often warranted to guide management and treatment duration.
		<i>Shigella</i> spp.		If <3 months, immunocompromised, or severe disease, treat with ceftriaxone × 2–5 days, azithromycin × 3 days, or ciprofloxacin × 3 days.

*Campylobacter* spp.

If severe disease, age <3 months, relapse, immunocompromised: azithromycin × 3 days or erythromycin × 5 days or ciprofloxacin × 3–5 days. Most patients do not require antimicrobial therapy.

*E. coli*

In most cases there is no need for antibiotics. Azithromycin × 3 days or fluoroquinolone × 3 days if severe or prolonged (>14 days); no antibiotics for STEC O157:H7, as antibiotics may increase risk of hemolytic uremic syndrome<sup>52</sup>

*Clostridioides difficile* colitis<sup>53</sup>

Diarrhea, pseudomembranous colitis with fever and abdominal pain. Fulminant disease can present with shock, ileus, or megacolon. Asymptomatic colonization is common in infants <12 months old.

Stool *C. difficile* toxin gene NAAT

Do not test unless ≥3 unformed stools within 24 hr. Make sure patient is not receiving laxatives.

Discontinue antibiotics if possible.

**Non-severe:** PO vancomycin (preferred) or PO metronidazole

**Severe:** PO vancomycin or PO fidaxomicin

**Fulminant** (shock, ileus, or toxic megacolon):

PO vancomycin + IV metronidazole  
If ileus: rectal vancomycin + IV metronidazole

*Giardia*<sup>2</sup>

Intermittent cramps, watery diarrhea that becomes foul-smelling, greasy, fatty  
Can be asymptomatic, acute, or chronic

Flagellate protozoan  
Fecal-oral transmission of cysts  
Incubation period 1–3 weeks

Stool EIA or DFA  
Stool NAAT panel if available

Metronidazole × 5–7 days

Alternatives: nitazoxanide × 3 days or tinidazole × 1 dose, paromomycin preferred in pregnancy

*Continued*

TABLE 17.2

## PEDIATRIC INFECTIONS BY SYSTEM—CONT'D

	Presentation	Etiology	Diagnosis	Treatment
<i>Helicobacter pylori</i> <sup>54,55</sup>	<p>Chronic gastritis, duodenal ulcer. Can often be asymptomatic. Warning signs include severe chronic abdominal pain, anorexia and failure to thrive, occult blood in stool, nighttime waking with pain, or persistent vomiting.</p> <p>Associations: iron deficiency anemia, short stature, and chronic immune thrombocytopenia</p>	<p>Fecal-oral transmission</p> <p>Up to 90% prevalent in resource-poor countries</p>	<p>Diagnosis should aim to find the underlying cause of symptoms and not solely look for <i>H. pylori</i> infection.</p> <p>Diagnostic testing for <i>H. pylori</i> not recommended in children with functional abdominal pain.</p> <p>Gold standard: gastric biopsy with culture (also yields susceptibilities).</p> <p>Test of cure (stool EIA or urea breath test) 4–6 weeks after treatment</p>	<p>Regimen selection should preferentially be guided by susceptibilities.</p> <p>If unknown susceptibilities, the following regimens may be initiated:</p> <p>Triple therapy options: PPI + amoxicillin + clarithromycin × 14 days or PPI + amoxicillin + metronidazole × 14 days</p> <p>Quadruple therapy options: PPI + bismuth + amoxicillin + metronidazole (if &lt;8 years old) × 14 days or PPI + bismuth + metronidazole + tetracycline (if at least 8 years old) × 14 days</p>

## GENITOURINARY

Cystitis (UTI) <sup>56,57</sup>	<p>Dysuria, urgency, frequency, new-onset enuresis, suprapubic pain</p> <p>Foul-smelling urine is not sensitive for UTI.</p>	<p><i>E. coli</i> (&gt;80%), <i>Klebsiella</i> spp., <i>Enterococcus</i> spp.</p> <p>The following are not considered pathogens in healthy children: <i>Lactobacillus</i> spp., coagulase-negative staphylococci, and <i>Corynebacterium</i> spp.</p>	<p>Diagnosis requires pyuria (<math>\geq 10</math> WBCs/hpf) and culture demonstrating <math>\geq 50,000</math> CFU/mL of a uropathogen for catheterized specimens or <math>\geq 100,000</math> CFU/mL of a uropathogen for clean-catch samples</p>	<p>PO cephalexin, cefadroxil, or nitrofurantoin: 3 days</p>
---------------------------------	--	---	---	---

Pyelonephritis<sup>56,58</sup>

Symptoms of cystitis, plus fever, flank pain, nausea/vomiting

All nonverbal infants and toddlers presenting with systemic symptoms and evidence of UTI are considered to have pyelonephritis. Risk factors for infants less than 2 years:  
Temp >39°C  
Uncircumcised male  
Fever >2 days  
Young age (<12 mo)  
Risk factors for all ages:  
bladder-bowel dysfunction, congenital anomalies of the kidney and urinary tract (including vesicoureteral reflux)

See cystitis.

See cystitis.

In infants, bagged urine specimen can be used for screening urinalysis, and if positive, should send catheterized sample for culture and repeat urinalysis.

If tolerating PO, not ill-appearing, and no concerns regarding adherence, PO can be considered. Cephalexin or cefadroxil is reasonable first line.

If not tolerating PO or ill-appearing, IV cefazolin or ceftriaxone

Pseudomonas coverage if history of prior pseudomonas or catheter dependent  
Transition to oral antibiotics once clinically improving. Consider renal US if no improvement/persistent fever after 72 hours of antibiotics.

Duration: 7 days. Longer treatment up to 14 days can be considered in certain circumstances.

In young (<2 years) patients with 1st time febrile UTI: renal bladder ultrasound; VCUG if abnormal. If US normal and recurrent UTI occurs, obtain VCUG.<sup>59</sup>

Sexually transmitted infections

See Chapter 5.

*Continued*

TABLE 17.2

## PEDIATRIC INFECTIONS BY SYSTEM—CONT'D

	Presentation	Etiology	Diagnosis	Treatment
<b>OSTEOARTICULAR</b>				
Osteomyelitis <sup>60,61</sup>	Majority in long bones: Pain, limping, swelling, erythema, fever Spinal infection in infants involving the discs: Gradual irritability, refusal to crawl/sit Spinal infection involving vertebra in adolescents: Back pain	Hematogenous spread <i>S. aureus</i> (>80% cases), GAS, <i>S. pneumoniae</i> , GBS (<3 months), <i>Kingella kingae</i> (<5 years), <i>Salmonella</i> spp. (if history of sickle cell disease)	Blood cultures, consider bone cultures. Inflammatory markers: CRP Imaging: x-ray, MRI If feasible, withhold antibiotics prior to obtaining invasive diagnostic testing (Gram stain/culture of fluid/aspirate/bone). If patient is ill appearing, do not withhold antibiotics.	Consider empiric coverage based on local resistance patterns. For children <5 years: (cefazolin or oxacillin) ± (TMP/SMX or clindamycin if concern for MRSA) For children >5 years: Cefazolin (TMP/SMX or clindamycin if concern for MRSA). If unstable or ill-appearing, IV vancomycin preferred. Switch to oral therapy when clinically improved. Duration 3–4 weeks for acute infection
Hardware-associated bone infection <sup>60</sup>	Pain, limping, swelling, erythema, fever	Coagulase-negative staphylococci, <i>S. aureus</i> , <i>C. acnes</i> , gram-negative bacilli including <i>Pseudomonas</i> spp.	Same as osteomyelitis	Cefepime and vancomycin empirically; add rifampin if <i>S. aureus</i> , but need to confirm susceptibility. Prolonged duration of treatment
Septic arthritis <sup>2,62</sup>	Pain, swelling of joint, inability to bear weight, gait abnormality, fever	<i>S. aureus</i> (>80% cases) GAS, <i>S. pneumoniae</i> , <i>K. kingae</i> (<5 years), <i>Salmonella</i> (if history of sickle cell disease) <i>Borrelia burgdorferi</i> (Lyme arthritis; if subacute	Kocher criteria used to differentiate septic joint from transient synovitis. Designed for hips, but often applied to knee/ankle If 3 of 4 criteria met, 93% chance of septic joint:	Early drainage relieves discomfort, prevents synovial damage. Consider empiric coverage based on local resistance patterns. For children <5 years: Cefazolin ± (TMP/SMX or clindamycin if concern for MRSA).

presentation involving large joint).  
*Neisseria gonorrhoeae*  
 (adolescents with migratory arthritis)

1. Non-weight bearing
2. Fever
3. ESR >40 mm/hr
4. WBC >12,000/mm<sup>3</sup>

If criteria met or high-risk:

Knee—x-ray

Hip—ultrasound

Joint aspiration suggests septic arthritis if >50,000 WBC/mm<sup>3</sup>.

For Lyme arthritis: two-tier test with serology and confirmation western blot and/or PCR from joint fluid

For children >5 years: cefazolin or clindamycin or TMP/SMX

If unstable or ill-appearing, IV vancomycin preferred

Lyme arthritis: Ceftriaxone, then step down to amoxicillin or doxycycline

*N. gonorrhoeae*: ceftriaxone. Should also treat for chlamydia and test for other STIs.

Duration 3–4 weeks for acute infection. Switch to oral therapy when clinically improved.

## SKIN AND SOFT TISSUE

Nonpurulent cellulitis/erysipelas <sup>63</sup>	Intact skin, erythema, warmth, swelling, tenderness, nonpurulent	Beta-hemolytic <i>streptococci</i> . Less common <i>S. aureus</i>	Clinical Blood or wound culture not routinely recommended	Cephalexin or Cefadroxil × 5 days
Purulent cellulitis/abscess <sup>63</sup>	Erythema, warmth, fever, tenderness, fluctuance, induration, history of purulent drainage	<i>S. aureus</i>	Clinical Ultrasound can confirm drainable collection. Wound cultures for hospitalized or immunocompromised children	<b>Mild</b> (no systemic signs of infection): I&D. One study demonstrated benefit of TMP/SMX or clindamycin regardless of abscess size, but must weigh with side effects. <sup>64</sup> <b>Moderate</b> (systemic signs of infection: fever, tachycardia, tachypnea, abnormal WBC count): I&D + antibiotics (cefazolin, clindamycin, TMP/SMX, or doxycycline) <b>Severe</b> (systemic signs of infection with failed I&D + antibiotics, immunocompromised): I&D + vancomycin

## PEDIATRIC INFECTIONS BY SYSTEM—CONT'D

	Presentation	Etiology	Diagnosis	Treatment
Animal/human bites <sup>63</sup>	Higher-risk injury with puncture wounds	Often polymicrobial: <i>S. aureus</i> , streptococci, <i>Pasteurella multocida</i> (animal), <i>Capnocytophaga</i> spp. (animal), oral anaerobes, <i>Eikenella corrodens</i> (human)	Clinical: Puncture vs. nonpuncture	Antibiotic prophylaxis is indicated if moderate/severe wound especially of hand or face, immunocompromise, possible penetration of periosteum or joint capsule, or edema of the area. Prophylaxis: amoxicillin/clavulanate × 5 days. See Chapter 2 for additional management. See Chapter 16 for postexposure prophylaxis recommendations for tetanus and rabies.
Dermatophyte (tinea) infections <sup>2</sup>	<p><b>Tinea capitis:</b> Multiple scaly patches with alopecia and patches of alopecia with black dots at follicular orifices that represent broken hairs. May also present with widespread scaling, kerion, or favus</p> <p><b>Tinea pedis</b> (athlete's foot): Interdigital hyperkeratotic or vesiculopustular eruption</p> <p><b>Tinea cruris</b> (jock itch): Involving the inguinal fold, groin, pubic/perianal area, or upper thighs</p> <p><b>Tinea corporis:</b> Dermatophyte infection occurring in sites other than feet, groin, face, or hand</p>	Dermatophytes	<p>Tinea capitis, pedis, cruris, corporis: Clinical</p> <p>Can confirm with skin scrapings in 10% potassium hydroxide (KOH) or fungal culture</p>	<p>Tinea capitis: Oral griseofulvin or terbinafine × 4–8 weeks or 2 weeks after clinical resolution</p> <p>Fungal shedding decreased with selenium sulfide or ketoconazole shampoo</p> <p>Tinea pedis, cruris, corporis: Topical antifungal</p> <p>Tinea pedis: 2–4 weeks</p> <p>Tinea cruris: 4–6 weeks</p> <p>Tinea corporis: 4–6 weeks</p>

**Tinea unguium**

(onychomycosis): White or yellow discoloration of finger- or toenail, often with thickening, splitting, or deformity

Tinea unguium: Confirm with nail clippings in 10% KOH or culture/staining.

Topical ciclopirox 8% twice daily for 4–48 weeks preferred (no lab monitoring)  
Alternative: Oral terbinafine 6 weeks if fingernail; 12 weeks if toenail

**BLOODSTREAM**

Catheter-related bloodstream infections<sup>65</sup>

Fever, erythema around catheter site; pain or hemodynamic instability with infusion

*S. aureus*, gram-negative bacilli including *Pseudomonas* spp., coagulase-negative staphylococci (usually requires two positive cultures to exclude contaminant), *Enterococcus* spp.

Two sets of cultures (one peripheral, one from suspected catheter) prior to antibiotics  
If unable to draw peripheral culture, draw two sets from lumen(s) several minutes apart.

Vancomycin and cefepime  
Remove line whenever possible.  
If line removal is not possible, infection is uncomplicated, and no sign of exit site or tunnel infection, can consider central line lock therapy with antibiotics or HCl to salvage line. Should be used in conjunction with systemic antimicrobial therapy.  
If candidemia, line removal is indicated. Refer to IDSA guidelines for further management.  
Consultation with infectious disease specialist is recommended.

Malaria<sup>2,66</sup>

Paroxysmal fevers and malaise  
Severe malaria: 5+% parasitemia, CNS involvement, shock, hypoglycemia, anemia, thrombocytopenia, acidosis

*Plasmodium falciparum*, *vivax*, *ovale*, *malariae*, *knowlesi*  
*P. vivax* and *ovale* form hypnozoites in liver, difficult to eradicate.  
Incubation period 7 to 30 days  
*P. vivax* and *ovale* can recur weeks to years later because of reemergence of hepatic hypnozoites.

Thick and thin blood smears  
If high suspicion with negative smears, repeat every 12–24 hr for 72 hr (minimum 3 smears).  
Rapid antigen detection tests exist.  
Speciation is performed by microscopy, with

Severe: IV artesunate, followed by full course of oral regimen  
Nonsevere (chloroquine-resistant or unknown resistance): artemether-lumefantrine × 3 days or atovaquone-proguanil × 3 days or mefloquine  
Nonsevere (chloroquine-sensitive) or *P. malariae/knowlesi*: chloroquine or hydroxychloroquine

TABLE 17.2

## PEDIATRIC INFECTIONS BY SYSTEM—CONT'D

Presentation	Etiology	Diagnosis	Treatment
		confirmation by PCR in specialized labs.	<i>P. vivax</i> or <i>P. ovale</i> : Add anti-relapse treatment with primaquine phosphate × 14 days; perform G6PD testing prior to initiation. Travel prophylaxis varies by region due to chloroquine resistance. See CDC Yellow Book for resistance info and specific regimens.
<b>OTHER</b>			
Fever of unknown origin <sup>67,68</sup>	Defined as temperature greater than 38°C for >8 days without a clear source	Localized or systemic infections are most commonly identified etiology.  Other etiologies include: rheumatologic, neoplastic, collagen vascular disease (e.g., juvenile idiopathic arthritis), drug fever, and Kawasaki disease. Often an uncommon presentation of a common disease	No specific guidelines exist; stepwise approach is recommended.  First line: CBC, BMP, LFTs, UA, urine and blood cultures.  Further studies targeted per history and physical/initial workup.
			Consider discontinuing all nonessential medications to aid in diagnosis. Treatment depends on etiology identified.

AAP, American Academy of Pediatrics; ANA, antinuclear antibody; AOM, acute otitis media; AUA, American Urologic Association; BMP, basic metabolic panel; CBC, complete blood count; CDC, Centers for Disease Control and Prevention; CFU, colony-forming unit; CMV, cytomegalovirus; CN, cranial nerve; CNS, central nervous system; CRP, C-reactive protein; CSF, cerebrospinal fluid; CT, computed tomography; DFA, direct fluorescent antibody; EBV, Epstein-Barr virus; EIA, enzyme immunoassay; ENT, ear-nose-throat physician (otolaryngologist); ESR, erythrocyte sedimentation rate; FNA, fine-needle aspiration; GBS, group B streptococcus; HIV, human immunodeficiency virus; hpf, high-power field; ICU, intensive care unit; I&D, incision and drainage; IDSA, Infectious Disease Society of America; IM, intramuscular; IV, intravenous; LFTs, liver function tests; LP, lumbar puncture; MRI, magnetic resonance imaging; MRSA, methicillin-resistant *Staphylococcus aureus*; NAAT, nucleic acid amplification test; PCN, penicillin; PCR, polymerase chain reaction; PO, by mouth; RIVUR, randomized intervention for children with vesicoureteral reflux; STEC, Shiga toxin-producing *Escherichia coli*; T, temperature; TB, tuberculosis; TMP, trimethoprim; TMP/SMX, trimethoprim sulfamethoxazole; UA, urinalysis; URI, upper respiratory infection; UTI, urinary tract infection; VCUG, voiding cystourethrography; VP, ventriculoperitoneal; WBC, white blood cell.

TABLE 17.3

## PEDIATRIC VIRAL ILLNESSES

	Presentation	Transmission and Incubation	Diagnosis	Treatment
Cytomegalovirus (CMV) <sup>2</sup>	<p>Children: most commonly asymptomatic</p> <p>Adults/adolescents: infectious mononucleosis-like syndrome with fever and hepatitis</p> <p>Immunocompromised: pneumonia, retinitis, colitis, leukopenia, thrombocytopenia</p> <p>See Table 17.1 for congenital CMV.</p>	<p>Primary infection from respiratory droplets or vertical transmission. Can also be transmitted via non-leukodepleted blood transfusion, solid organ transplant, or hematopoietic stem cell transplant.</p> <p>Persists after primary infection with intermittent shedding</p>	<p>CMV DNA PCR to determine presence of infection (i.e., viral replication)—quantitative preferred. Histopathology required for definitive diagnosis of tissue invasive disease.</p> <p>IgG to screen for risk of reactivation (e.g., organ transplant donors and recipients); not useful for diagnosing active infection/disease</p>	<p>Immunocompetent children: no treatment</p> <p>Immunocompromised children (e.g., HSCT, SOT): preemptive therapy for CMV viremia to prevent CMV disease OR treatment of CMV disease:</p> <p>Preferred: ganciclovir IV or valganciclovir PO</p> <p>Alternatives: foscarnet IV or cidofovir IV (more nephrotoxic)</p> <p>Universal prophylaxis in serodiscordant SOT recipients with valganciclovir PO</p>
Dengue <sup>2</sup>	<p>Febrile phase (2–7 days) with myalgias, arthralgias, retro-orbital headache. Critical phase (24–48 hr) follows defervescence with increased vascular permeability. Convalescent phase with gradual improvement</p> <p>Severe dengue (hemorrhagic fever): severe abdominal pain, bleeding, shock</p>	<p>Four virus subtypes; severe dengue more common with second or subsequent infections</p> <p>Transmitted by <i>Aedes</i> mosquitoes</p> <p>Incubation period 3–14 days</p>	<p>RT-PCR or anti-dengue virus IgM EIA</p>	<p>Supportive. Avoid NSAIDs (bleeding risk)</p>

## PEDIATRIC VIRAL ILLNESSES—CONT'D

	Presentation	Transmission and Incubation	Diagnosis	Treatment
Epstein-Barr virus (EBV) <sup>2</sup>	Infectious mononucleosis: Fever, pharyngitis with petechiae or exudates, hepatosplenomegaly, atypical lymphocytosis. Variable presentation in young children. Associated with post-transplant lymphoproliferative disease, Burkitt lymphoma, nasopharyngeal carcinoma, and other malignancies	Transmitted via oral secretions or sexual contact. Incubation period 30–50 days	Heterophile antibody positive by 2 weeks postexposure; though low sensitivity in children under 4 years. IgM/IgG to viral capsid antigen if heterophile negative and suspicion high. See Fig. 17.3.	Supportive. No strenuous activity or contact sports × 21 days, or until symptoms and splenomegaly resolve. Steroids if tonsillar swelling threatens airway, massive splenomegaly, myocarditis, hemolytic anemia, or HLH
Human immunodeficiency virus (HIV)	See Section I. 1.			
Influenza <sup>2</sup>	Often abrupt onset of systemic symptoms (fever, myalgias, chills, headache, malaise, anorexia) with URI, croup, bronchiolitis, pneumonia. Complications include AOM, secondary bacterial pneumonia (especially <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> ); rarely myositis, myocarditis, or CNS complications, including encephalitis, myelitis, Guillain-Barré syndrome	Incubation 1–4 days	Clinical diagnosis; lab confirmation should be performed given overlapping presentation with SARS-CoV-2. Multiple rapid antigen and PCR tests exist.	Oseltamivir for 5 days. Alternatives include inhaled zanamivir, IV peramivir, and PO baloxavir. Most effective within 48 hr of onset of symptoms. Treat all patients who are hospitalized, have severe illness, or are at high risk for complications. Consider treating patients who could transmit to elderly or unvaccinated contacts. Counsel families on influenza vaccination.

				Avoid aspirin/salicylate-containing products due to risk of Reye syndrome. Recommendations change yearly. See <a href="http://www.cdc.gov/flu">http://www.cdc.gov/flu</a> .
Measles <sup>2</sup>	Fever, cough, coryza, conjunctivitis, Koplik spots, descending maculopapular rash At risk for acute encephalitis and subacute sclerosing panencephalitis	Droplet and airborne precautions Incubation period 8–12 days	RT-PCR from throat swab or urine or serum IgM (ideally, obtain all 3, as this will increase likelihood of achieving a diagnosis)	Supportive Counsel families on measles vaccination. Vitamin A reduces morbidity and mortality.
Mumps <sup>2</sup>	Swelling of 1+ salivary glands, often parotid Orchitis more common after puberty	Droplet precautions until 5 days after onset of parotid swelling Incubation period 12–25 days	RT-PCR from buccal swab	Supportive
Parvovirus B19 (Fifth disease) <sup>2</sup>	Mild viral syndrome followed by slapped cheek rash with circumoral pallor Symmetric, macular, reticular rash on trunk, spreads peripherally Polyarthropathy Transient aplastic crisis Can cause chronic infection and anemia in immunocompromised	Droplet precautions Incubation period 4–14 days	Serum IgM PCR required if immunocompromised	Supportive RBC transfusion in aplastic crisis IVIg used in infections of immunodeficient patients

Continued

TABLE 17.3

## PEDIATRIC VIRAL ILLNESSES—CONT'D

	Presentation	Transmission and Incubation	Diagnosis	Treatment
Rubella <sup>2</sup>	Descending, erythematous, maculopapular rash, lymphadenopathy, low-grade fever. Often asymptomatic See Table 17.1 for congenital rubella.	Droplet precautions until 7 days after onset of the rash Incubation period 12–23 days	Serum IgM	Supportive
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) <sup>69</sup>	Many children with SARS-CoV-2 may be asymptomatic or with mild to moderate symptoms including fever, cough, and pharyngeal erythema. <sup>28</sup> In contrast with infected adults, most infected children appear to have a milder clinical course. <sup>70</sup>	Aerosol and respiratory droplet transmission. Shedding can start 1–2 days prior to symptoms and continue >2 weeks. Incubation period: 5 days (2–14) Virus detected in stool with implications for fecal-oral transmission.	Nasopharyngeal swab for PCR per CDC criteria Respiratory tract specimen NAAT, antigen tests also available but less sensitive <sup>73,74</sup>	Recommendations for SARS-CoV-2 are constantly evolving as new data become available; refer to <a href="https://www.covid19treatmentguidelines.nih.gov/">https://www.covid19treatmentguidelines.nih.gov/</a> for most up-to-date recommendations. Refer to website above for currently recommended therapeutics for non-hospitalized children at risk for progression to severe disease. Prophylaxis: Vaccination is recommended for those eligible and is currently authorized for use in children ages 6 months and older.

<p>Varicella zoster virus (VZV)<sup>2</sup></p>	<p>Primary varicella (chickenpox): pruritic macules that progress to vesicles, plus fever and malaise</p> <p>Herpes zoster: painful, vesicular, dermatomal rash</p> <p>See <a href="#">Table 17.1</a> for congenital VZV.</p>	<p>Airborne spread or direct contact</p> <p>Incubation period 10–21 days</p> <p>Reactivation of latent VZV from sensory ganglia</p>	<p>Clinical</p> <p>PCR of vesicular fluid</p>	<p>Supportive care if healthy host</p> <p>Treat with acyclovir/valacyclovir if chronic skin or lung disease, unvaccinated and 12+ years old, or immunocompromised.</p>
---	---	---	---	--

*DNA*, Deoxyribonucleic acid; *EIA*, enzyme immunoassay; *HLH*, hemophagocytic lymphohistiocytosis; *Ig*, immunoglobulin; *IVIg*, intravenous immunoglobulin; *NSAIDs*, nonsteroidal antiinflammatory drugs; *RBC*, red blood cell; *RT-PCR*, reverse-transcriptase polymerase chain reaction.

TABLE 17.4

## PEDIATRIC TICKBORNE DISEASES

	Presentation	Etiology	Diagnosis	Treatment
Lyme disease <sup>2,75</sup>	<p>Early localized: &lt;1 month after tick bite. Erythema migrans</p> <p>Early disseminated: 3–10 weeks after bite. Secondary erythema migrans with multiple smaller target lesions, cranioneuropathy (especially facial nerve palsy), systemic symptoms, rarely carditis with heart block or aseptic meningitis</p> <p>Late disease: 2–12 months after bite. Pauciarticular arthritis of large joints, peripheral neuropathy, encephalopathy</p>	<p>Spirochete <i>Borrelia burgdorferi</i> (<i>B. afzelii</i> and <i>B. garinii</i> in Europe and Asia)</p> <p>Requires 24–48 hr of tick attachment</p> <p>Incubation 3–32 days (median 11 days)</p> <p>Most common in New England and mid-Atlantic. Less common in upper Midwest and Northwest</p> <p>Can have coinfection with <i>Borrelia miyamotoi</i>, Babesiosis, Anaplasma</p>	<p>Early: Clinical. No testing indicated.</p> <p>Early disseminated and late disease: EIA or IFA for antibodies. If positive, Western blot to confirm</p> <p>IgM detectable for first 30 days. (Consider false positive if &gt;4 wk after symptom onset)</p> <p>IgG detectable by week 4–6.</p> <p>False positives occur with viral infections, other spirochetes, and autoimmune disease.</p> <p>Perform LP as clinically indicated for CNS involvement.</p>	<p>Erythema migrans/early Lyme disease: amoxicillin (14 days) or cefuroxime (14 days) or doxycycline (10 days).</p> <p>Lyme carditis: ceftriaxone or doxycycline or amoxicillin or cefuroxime × 14–21 days</p> <p>Lyme arthritis: doxycycline or amoxicillin × 28 days</p> <p>Lyme facial nerve palsy: doxycycline × 14–21 days</p> <p>Lyme meningitis (neuroborreliosis): ceftriaxone or doxycycline × 14–21 days (in patients with parenchymal involvement of the brain or spinal cord, IV ceftriaxone therapy is preferred over PO doxycycline therapy)</p> <p>In high-risk areas, can consider one-time dose of prophylactic doxycycline following removal of engorged tick for children of any age.</p> <p>Doxycycline traditionally avoided in children &lt;8 years old; however, evidence suggests low risk of teeth staining.</p>

Rocky Mountain spotted fever <sup>2</sup>	Initial symptoms can be nonspecific. Rash initially erythematous and macular, progresses to maculopapular and petechial. Classically spreads proximally from ankles and wrists, involves palms and soles. Peripheral and periorbital edema, anemia, leukopenia, thrombocytopenia, elevated LFTs, hyponatremia Can progress to meningismus, AMS, DIC, digital necrosis, shock	<i>Rickettsia rickettsii</i> Incubation 3–12 days Widespread; most common in South Atlantic, Southeastern, and South Central United States Case fatality 20%–80%	Clinical, with lab confirmation Gold standard is indirect fluorescent antibody; IgG and IgM increase around 7–10 days. Serum PCR if available Negative result (PCR or antibody testing) does not rule out the diagnosis.	Doxycycline recommended for children of any age. Should be started as soon as the diagnosis is suspected Duration: Continue until patient is afebrile for ≥3 days, with clinical improvement.
Ehrlichiosis <sup>2</sup>	Systemic febrile illness Rash common around day 5. Leukopenia, thrombocytopenia, elevated LFTs, CSF pleocytosis More severe disease: Pulmonary infiltrates, bone marrow hypoplasia, respiratory failure, encephalopathy, meningitis, DIC, spontaneous hemorrhage, and renal failure	<i>Ehrlichia chaffeensis</i> and <i>Ehrlichia ewingii</i> Incubation period 5–14 days Southeastern, south central, East Coast, and midwestern United States Coinfection with <i>Anaplasma</i> and other tickborne diseases common	Identification of DNA by PCR from whole blood is highly sensitive and specific. Paired acute and convalescent indirect fluorescent antibody are most commonly used tests. Peripheral smear with morulae	Doxycycline for at least 3 days after defervescence, for a minimum total course of 7–14 days.
Anaplasmosis <sup>2</sup>	Same as <i>Ehrlichia</i>	<i>Anaplasma phagocytophilum</i> Incubation 5–21 days Upper Midwest and Northeastern United States, northern California	Same as <i>Ehrlichia</i>	Same as <i>Ehrlichia</i>

TABLE 17.4

## PEDIATRIC TICKBORNE DISEASES—CONT'D

	Presentation	Etiology	Diagnosis	Treatment
Babesiosis <i>2,76</i>	>50% children asymptomatic or mild presentation <sup>77</sup> Systemic febrile illness, hemolytic anemia Severe cases with ARDS, DIC, shock, splenic rupture	<i>Babesia microti</i> (less commonly <i>B. duncani</i> or <i>divergens</i> ) Vector-borne (tick) or blood transfusion Incubation 1–5 wk for vector-borne. Can be longer for transfusion related Northeast and upper midwestern US Half are coinfectd with <i>B. burgdorferi</i> .	Blood smear (Giemsa or Wright stain). Monitor smears during/after treatment.	Oral Atovaquone + Azithromycin for 7–10 days. Longer course of IV antibiotics if immunocompromised Limited data for exchange transfusion; may be of benefit in severe disease.

CDC, Centers for Disease Control and Prevention; CNS, central nervous system; DIC, disseminated intravascular coagulation; DNA, deoxyribonucleic acid; EIA, enzyme immunoassay; hr, hour; IFA, immunofluorescent assay; IgG, immunoglobulin G; IgM, immunoglobulin M; LFTs, liver function tests; LP, lumbar puncture; PCN, penicillin; PCR, polymerase chain reaction.

TABLE 17.5

## PEDIATRIC PARASITIC INFECTIONS: UNITED STATES

	Presentation	Transmission and Incubation	Diagnosis	Treatment
American trypanosomiasis (Chagas disease) <sup>2</sup>	<p>Acute period (2–3 months). Most asymptomatic or mild febrile illness. Can have rash, myalgia, lymphadenopathy, hepatosplenomegaly, meningoencephalitis, acute myocarditis, unilateral eye edema (Romaña sign), or local inflammatory reaction of the skin (chagoma).</p> <p>In chronic course, 20%–40% develop complications: cardiomyopathy with conduction abnormalities, colonic or esophageal dilation.</p> <p>Congenital presentation includes prematurity, low birth weight, hepatosplenomegaly, fever, neurologic abnormalities, anasarca, and petechiae.</p>	<p><i>Trypanosoma cruzi</i> parasite</p> <p>Transmitted in feces of the Triatome (“kissing”) bug, congenitally (transmission rate 50% in acute Chagas, 2%–5% in chronic disease), solid organ transplant or transfusion.</p> <p>Vector-borne spread primarily in Mexico and Central/South America</p> <p>Incubation 1–2 wk</p>	<p>Acute: Giemsa</p> <p>Chronic: IgG (check two different assays for improved sensitivity)</p> <p>Direct microscopy or PCR available</p>	<p>Benznidazole (age &gt;2 year old) or Nifurtimox (birth to 18 years old)</p> <p>Treatment not recommended for cardiomyopathy due to adverse drug profile without clinical benefit.</p> <p>Donated blood is screened.</p>
Cyclosporiasis <sup>2</sup>	<p>Profuse, protracted watery diarrhea. Low-grade fevers in 50%. Biliary disease</p> <p>Affects immunocompetent and immunocompromised hosts</p>	<p><i>Cyclospora cayatanensis</i>, protozoan</p> <p>Spread via fecal oral route via oocysts, which become infectious after days/weeks in cool moist environment.</p> <p>Incubation period 2–14 days</p>	<p>Oocyst identification in stool, intestinal fluid aspirate, or intestinal biopsy. Variably acid fast</p> <p>PCR available</p>	<p>Trimethoprim-sulfamethoxazole for 7–10 days. Alternative is nitazoxanide.</p>

TABLE 17.5

## PEDIATRIC PARASITIC INFECTIONS: UNITED STATES—CONT'D

	Presentation	Transmission and Incubation	Diagnosis	Treatment
Cysticercosis <sup>2</sup>	<p>Neurocysticercosis can manifest as seizures, headaches, obstructive hydrocephalus, other neurologic signs.</p> <p>In endemic areas, it is responsible for up to 30% of epilepsy cases.</p>	<p><i>Taenia solium</i>. Fecal-oral spread or undercooked pork containing larval cysts</p> <p>Prevalent in parts of Latin America, Asia, and sub-Saharan Africa</p> <p>Incubation period is typically several years.</p>	<p>Neuroimaging: (CT) identifies calcifications, MRI identifies extraparenchymal cysts and parasites</p> <p>Antibody assays to confirm diagnosis (poor sensitivity and specificity).</p>	<p>Albendazole (&gt;1 year old) +/- praziquantel (off label) and corticosteroids (for host inflammatory response with cysticercidal medications)</p> <p>Anticonvulsant until radiographic and symptomatic resolution</p> <p>May require surgical management</p>
Toxocariasis	<p>Most infections are asymptomatic with persistent eosinophilia.</p> <p>Visceral disease (often age 2–7 years old) includes fever, cough, wheezing, abdominal pain, rash, myocarditis.</p> <p>Ocular disease (older children and adolescents) with isolated unilateral vision loss</p> <p>Neurotoxocariasis can present with seizures secondary to meningoencephalitis, space occupying lesions, cerebral vasculitis, etc.</p>	<p><i>Toxocara canis</i> or <i>Toxocara cati</i>, roundworms of dogs and cats</p> <p>5% seroprevalence in US. More common in southern US</p> <p>Unclear incubation period</p>	<p>ELISA (CDC laboratory).</p> <p>Cannot distinguish past and present infections. Less sensitive for ocular disease</p> <p>Liver imaging for visceral disease</p>	<p>Albendazole (&gt;1 year old) or mebendazole</p> <p>Add corticosteroids for myocarditis, CNS involvement, or ocular disease.</p>
Toxoplasmosis <sup>2</sup> See Table 17.1 for perinatal disease.	<p>&gt;50% of children asymptomatic</p> <p>Immunocompetent children present with mono-like illness.</p>	<p><i>Toxoplasma gondii</i>, an obligate intracellular parasite</p> <p>Many infectious forms.</p> <p>Tachyzoites cause symptoms;</p>	<p>IgG peaks at 3–5 months, remains positive indefinitely.</p> <p>IgM detectable by 1 week, peaks at 1 month, undetectable by 6–9 months.</p>	<p>Treat if immunocompromised, pregnant, infant, ocular involvement, or severe/persistent symptoms.</p>

<p>More severe manifestations include chorioretinitis, meningoencephalitis, myocarditis, myositis, ADEM.</p> <p>Brain abscess and shock may occur in immunocompromised, particularly in seropositive HSCT (R+) and seronegative cardiac transplant recipients (D+/R-).</p>	<p>tissue cysts form latent infections in brain, eye, cardiac, skeletal muscle tissue.</p> <p>Seropositivity in US is 11%. Half of infected individuals do not have identified risk factor.</p> <p>Incubation period 4–21 days</p>	<p>PCR for body fluid/tissue. Cannot differentiate between acute, reactivation, and latent infection</p>	<p>Pyrimethamine + folinic acid + sulfadiazine</p> <p>Add prednisone for chorioretinitis.</p> <p>Prophylaxis with trimethoprim-sulfamethoxazole for children with HIV, recurrent chorioretinitis, or other high-risk immunocompromising conditions</p>
--	--	--	--

Trichomoniasis

See [Chapter 5](#).

This table includes parasitic infections denoted by Centers for Disease Control and Prevention (CDC) to be present in the United States.

*ADEM*, acute disseminated encephalomyelitis; *CDC*, Centers for Disease Control and Prevention; *CNS*, central nervous system; *CT*, computed tomography; *ELISA*, enzyme-linked immunosorbent assay; *HSCT*, hematopoietic stem cell transplant; *Ig*, immunoglobulin; *MRI*, magnetic resonance imaging; *PCR*, polymerase chain reaction.

TABLE 17.6

## PEDIATRIC FUNGAL INFECTIONS

	Presentation	Transmission and Incubation	Diagnosis	Treatment
Aspergillosis <sup>2,78</sup>	Ubiquitous in environment Immunocompromised patients at risk for invasive pulmonary aspergillosis, sinusitis, and CNS disease. Can be complicated by angioinvasion, dissemination, thrombosis, and hemorrhage Allergic bronchopulmonary aspergillosis (ABPA) in children with asthma or cystic fibrosis: wheezing, productive cough, fever, eosinophilia, pulmonary infiltrates	<i>Aspergillus fumigatus</i> (>75%), <i>flavus</i> , <i>terreus</i> , <i>nidulans</i> , <i>niger</i> Inhalation of spores from environment Incubation period unknown	Characteristic hyphae on KOH or silver nitrate stain of tissue or BAL fluid. Fungal biomarker (serum or BAL galactomannan) can aid in early diagnosis. Serum galactomannan is less sensitive in non-neutropenic hosts (solid organ transplant and immunodeficiency) when compared to neutropenic hosts (hematologic malignancy and HSCT).	<b>Invasive aspergillosis:</b> Voriconazole is drug of choice, alternatives include isavuconazole, posaconazole, and polyenes. Highly variable voriconazole pharmacokinetics in children, monitor troughs, goal 1–6 mcg/mL Serial serum galactomannan can aid in monitoring progression of disease. <b>ABPA:</b> Steroids are the primary treatment. For steroid-refractory ABPA, add itraconazole.
Blastomycosis <sup>2,79</sup>	Asymptomatic in 50%. Productive cough with variable radiographic appearance (consolidation, pneumonitis, infiltrate, nodules). Dissemination in 25% of symptomatic cases (cutaneous lesions common, CNS infection less common)	<i>Blastomyces</i> spp. Inhalation of infectious conidia from environment Ohio and Mississippi river region, southeastern US, Great Lakes region	Characteristic broad-based budding yeast on KOH or silver stain of sputum, tracheal aspirate, BAL, CSF, urine, or biopsy Urine antigen testing more useful than serologic testing	All cases in children should be treated. <b>Severe:</b> Amphotericin B (1–2 weeks) + itraconazole (6–12 months) <b>CNS infection:</b> Amphotericin B (4–6 weeks) + Itraconazole (12 months) <b>Mild/moderate:</b> Itraconazole (6–12 months)

Candidiasis<sup>2,80</sup>

Mucocutaneous disease in immunocompetent patients. Concern for immunodeficiency if recurrent/chronic

Esophageal/laryngeal plaque in immunocompromised

Disseminated/candidemia in preterm neonates, immunocompromised and ICU patients with central lines

*Candida* species. *Candida albicans* most common, but other species account for >50% of invasive infections and have different resistance patterns. Budding yeast with pseudohyphae. Incubation period unknown

Mucocutaneous: clinical diagnosis. Yeast and pseudohyphae on KOH or Gram, calcofluor white, or fluorescent antibody stains

Imaging and endoscopy can support diagnosis.

Culture 70% sensitive for detecting candidemia and 50% sensitive for detecting invasive candidiasis without candidemia.

Once positive culture identified, rapid tests available (PNA FISH probes and PCR). Beta-D-glucan not recommended to be sent in children; poor sensitivity and specificity.

LP, brain imaging, dilated retinal exam for neonate with candidemia or candiduria

**Mucocutaneous:** oral (mucosal) or topical (cutaneous) nystatin, clotrimazole, miconazole. If refractory or immunocompromised host, use fluconazole. Breastfeeding should be continued.

**Vulvovaginal:** See Chapter 5.

**Esophagitis:** Oral fluconazole

**Asymptomatic candiduria:** Remove catheter.

**Neonatal invasive disease:** Amphotericin B for >3 weeks.

Avoid lipid formulation due to poor urinary penetration.

**Child with invasive disease or candidemia:** Echinocandin or fluconazole (if susceptible) × 14 days from first negative blood culture

*Cryptococcus*<sup>2,81</sup>

Often asymptomatic/mild. Cough, chest pain, constitutional symptoms, pulmonary masses, consolidation, or interstitial changes. Severe manifestations include ARDS, meningitis, fungemia.

Patients with defects in T-lymphocyte mediated immunity most at risk (e.g., patients with HIV/AIDS)

*Cryptococcus neoformans* and *gattii*. Inhalation from environment (soil, bird droppings)

British Columbia, Canada, Pacific Northwest US, Australia, Papua New Guinea

Incubation 8–13 months

Cryptococcal antigen testing of serum or CSF

Definitive diagnosis with isolation of encapsulated yeast on India ink (best for BAL fluid)

Mass spectrometry and PCR

Amphotericin B and oral flucytosine for >2 weeks, then fluconazole for >8 weeks


Follow up LP at 2 weeks.

Treat increased ICP and immune reconstitution inflammatory syndrome as needed.

## PEDIATRIC FUNGAL INFECTIONS—CONT'D

	Presentation	Transmission and Incubation	Diagnosis	Treatment
Histoplasmosis <sup>2,82</sup>	<p>95% asymptomatic</p> <p>Pulmonary or disseminated, acute or chronic, primary or reactivation</p> <p>Acute pulmonary presentation with fever, chills, dry cough, hilar/mediastinal adenopathy. Resolves in 2–3 weeks</p> <p>Severe infection can cause hypoxemia ARDS, airway compromise, pericarditis.</p> <p>Disseminated presentation (typically age &lt;2 years old or immunocompromised) with prolonged fever, failure to thrive, hepatosplenomegaly, pancytopenia, DIC, GI bleeding, CNS involvement</p>	<p>Histoplasma, a dimorphic fungi</p> <p>Transmitted primarily via inhalation of conidia from environment, vertically, or horizontally (transplant, exposure to cutaneous lesion)</p> <p>Present in most of world, particularly central/eastern US</p> <p>Incubation 1–3 weeks</p>	<p>Antigen testing of serum, urine, BAL is used for diagnosis and monitoring of treatment response.</p> <p>Antibody testing for subacute/chronic disease and CNS involvement</p> <p>Definitive diagnosis with culture</p>	<p><b>Mild acute infection</b> often self-limited. If no improvement in 4 weeks, give itraconazole for 6–12 weeks.</p> <p><b>Disseminated infection</b> requires amphotericin B +/- steroids for 1–2 weeks, then 12 weeks of itraconazole.</p> <p><b>Chronic pulmonary infection</b> treated with 1–2 years of itraconazole</p>
<i>Pneumocystis</i> pneumonia	<p>In immunocompromised host, dyspnea, tachypnea, hypoxemia, cough, fever/chills. Diffuse interstitial/alveolar changes on CXR. Mortality 5%–40% when treated, 100% when untreated</p>	<p><i>Pneumocystis jirovecii</i>, an atypical fungus. No latency/reactivation. Airborne transmission. Incubation unknown (~53 days in transplant recipients)</p>	<p>Evaluation of BAL fluid (stain for cysts, sporozoites, and trophozoites). PCR sensitive but not FDA approved. Beta-D-glucan may be useful if bronchoscopy not able to be performed.</p>	<p>IV trimethoprim-sulfamethoxazole × 21 days. Alternative is pentamidine. Other drug combinations studied in adults. First-line prophylaxis with trimethoprim-sulfamethoxazole. Alternative is atovaquone, dapsone, or aerosolized pentamidine.</p>

ARDS, acute respiratory distress syndrome; BAL, bronchoalveolar lavage; CNS, central nervous system; CSF, cerebrospinal fluid; CXR, chest X-ray; DIC, disseminated intravascular coagulation; FDA, Food and Drug Administration; GI, gastrointestinal; HIV/AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome; ICP, intracranial pressure; LP, lumbar puncture; ICU, intensive care unit; PCR, polymerase chain reaction; PNA FISH, Fluorescence in situ hybridization using peptide nucleic acid probes.



**FIGURE 17.3**

Graphic representation of the development of antibodies to Epstein-Barr virus antigens as a function of time from infection. Antibody titers are calculated as geometric mean values expressed as reciprocals of the serum dilution. The immunoglobulin M (*IgM*) response to viral capsid antigen (*VCA*) varies according to age of the patient. *IgG*, Immunoglobulin G. (From Jenson HB. Epstein-Barr virus. In: Kliegman RE, Stanton B, St Geme J, et al, eds. *Nelson Textbook of Pediatrics*. 20th ed. Elsevier; 2016.)

- a. Any ill-appearing or otherwise high-risk infant requires a full sepsis workup. Unimmunized infants, premature infants, infants with complicated neonatal courses, or infants who received antibiotics recently are at higher risk for serious bacterial infection.
- b. For well-appearing febrile infants, there are many established approaches, including the Rochester, Philadelphia, and Boston criteria and the Step-by-Step approach. In 2021 the AAP released guidelines for febrile infants 8–60 days. An adapted approach is outlined in [Fig. 17.2](#).

## H. Tuberculosis: Diagnosis and Treatment<sup>2,3</sup>

### 1. Diagnosis

- a. See [Box 17.1](#) for screening guidelines and [Box 17.2](#) for information on interpretation of tuberculin skin tests (TSTs). Interferon gamma release assays (IGRAs, namely T-SPOT-TB and QuantiFERON-TB Gold In-Tube) offer high specificity and can be used in children  $\geq 2$  years old.<sup>4</sup>
- b. If positive screening test, obtain chest x-ray.

**BOX 17.1****TUBERCULOSIS SCREENING GUIDELINES<sup>2</sup>**

The American Academy of Pediatrics recommends treatment for at-risk individuals. Clinicians should complete at-risk assessment questionnaire at first well-child visit, then every 6 months in 1st year of life, and then routine care (at least annually). Screening to identify at-risk individuals:

- Born outside the United States in countries with endemic infection
- Traveled outside United States in countries with endemic infection<sup>84</sup>
- Family member with positive tuberculin skin test (TST)
- Exposed to someone who had tuberculosis disease
- Children on immunosuppressive therapies (e.g., tumor necrosis factor blockers/antagonists)
- Depending on local epidemiology: children who spend time with individuals who have spent time in jail/prison/shelter, use illegal drugs, or are HIV positive, children who consume unpasteurized milk/products, household members who were born or have recently traveled/arrived from countries with endemic infection (outside the United States)

**BOX 17.2****DEFINITIONS OF POSITIVE TUBERCULIN SKIN TESTING<sup>2</sup>****Induration  $\geq 5$  mm**

- Children in close contact with known or suspected contagious cases of TB disease
- Children suspected to have active or previous TB disease based on clinical or radiographic findings
- Children on immunosuppressive therapy or with immunosuppressive conditions (including HIV infection)

**Induration  $\geq 10$  mm**

- Children at increased risk for dissemination based on young age (<4 years) or with other medical conditions (cancer, diabetes mellitus, chronic renal failure, or malnutrition)
- Children with increased exposure: Those born in or with travel to endemic countries; those exposed to HIV-infected adults, homeless persons, those with substance use disorder, nursing home residents, or incarcerated or institutionalized persons

**Induration  $\geq 15$  mm**

- Children  $\geq 4$  years without any risk factors

*HIV*, Human immunodeficiency virus; *TB*, tuberculosis.

- c. If symptoms indicate active tuberculosis (TB) disease, determine source.
  - (1) Consider pediatric protocol chest CT over x-ray when available.<sup>5</sup>
  - (2) Specimen sources include sputum, bronchial washings, gastric aspirates (morning aspirate before feeding/ambulation  $\times 3$ )

**TABLE 17.7**  
**INTERPRETATION OF THE SEROLOGIC MARKERS OF HEPATITIS B IN COMMON SITUATIONS**

Serologic Marker				Interpretation
HBsAg	Total HBcAb	IgM HBcAb	HBsAb	
—	—	—	—	No prior infection, not immune
—	—	—	+	Immune after hepatitis B vaccination (if concentration $\geq 10$ IU/mL) or passive immunization from HBIG administration
—	+	—	+	Immune after recovery from HBV infection
+	+	+	—	Acute HBV infection
+	+	—	—	Chronic HBV infection

*HBcAb*, antibody to hepatitis B core antigen; *HBsAb*, antibody to hepatitis B surface antigen; *HBsAg*, Hepatitis B surface antigen; *HBIG*, hepatitis B immune globulin; *HBV*, hepatitis B virus; *IgM*, immunoglobulin M.

From Davis AR, Rosenthal P. Hepatitis B in children. *Pediatr Rev.* 2008;29(4):111–120.

specimens), pleural fluid, cerebrospinal fluid, urine, tissue biopsy.

- (3) Acid-fast smear and/or nucleic acid amplification testing may provide rapid diagnosis. The latter may also detect rifampin resistance. Solid media culture can take as long as 10 weeks, liquid media 1 to 6 weeks.
  - d. Lumbar puncture is recommended in children less than 12 months with confirmed TB. In children older than 12 months, lumbar puncture should be considered only if neurologic signs and symptoms are present.
2. Treatment of latent TB infection
    - a. Rule out active TB.
    - b. Treatment regimens:
      - (1) Rifampin is preferred, especially for children  $\leq 5$  years
      - (2) 12 weeks of weekly isoniazid and rifapentine (preferred regimen if  $\geq 2$  years of age)
      - (3) Rifampin daily for 4 months (preferred regimen if isoniazid-resistant)
      - (4) Isoniazid plus rifampin daily for 3 months
      - (5) 6 or 9 months of isoniazid daily (twice-weekly dosing regimen available)
    - c. Treat all children  $< 5$  years or immunocompromised if exposed to an individual with TB disease, even if testing (TST/IGRA) is negative. Some experts would discontinue treatment in immunocompetent children if repeat testing is negative at 8–10 weeks.
  3. Treatment of active TB
    - a. High rates of resistance in endemic countries. Treatment should be initiated in consultation with an infectious disease specialist.
    - b. Drug-susceptible pulmonary TB: 6-month regimen, including 2 months RIPE (rifampin, isoniazid, pyrazinamide, ethambutol),

followed by 4 months of rifampin/isoniazid. Rifampin is preferred, especially for children  $\leq 5$  years.

- c. Extrapulmonary or drug-resistant TB: Consult infectious disease specialist.
- d. Pyridoxine supplementation if breastfed, meat-/milk-deficient diet, symptomatic HIV, or pregnant

### I. Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome<sup>6</sup>

Please see the National Institutes of Health (NIH) guidelines on the diagnosis and management of children with HIV infection at <https://www.aidsinfo.nih.gov/> for the most up-to-date recommendations.

#### 1. Diagnosis

- a. Perinatal: See [Table 17.9](#) for diagnosis in perinatal period.<sup>7,8</sup>
- b. Infants and children<sup>8,10</sup>: HIV nucleic acid testing must be used under 18 months to avoid confounding from maternal antibodies. Antigen/antibody testing can be performed after 18 months. If concern for breastmilk exposure, test immediately, then at 4 to 6 weeks, 3 months, and 6 months after breastfeeding is discontinued.
- c. Adolescents<sup>10</sup>: Fourth-generation HIV antigen/antibody assay with opt-out consent as part of routine clinical care. If positive, confirm with HIV-1/HIV-2 differentiation immunoassay; if indeterminate, HIV-1 nucleic acid testing.

#### 2. Management<sup>7,11</sup>

- a. See [Table 17.9](#) for management during perinatal period.
- b. Initiation of therapy for all children with HIV is recommended by the Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents and the World Health Organization (WHO).

**TABLE 17.8**

#### CEREBROSPINAL FLUID ANALYSIS IN SUSPECTED MENINGITIS

	Bacterial Meningitis	Viral Meningitis	No CNS Infection
WBC (cells/mm <sup>3</sup> )	>10; typically >100, but wide range	10–100	<10
Cell type	PMN predominance (80+%)	Mononuclear	Mononuclear
Protein (mg/dL)	>100	60–100	<60
Glucose (mg/dL)	<40	40–80	40–80

CNS, Central nervous system; PMN, polymorphonuclear neutrophil; WBC, white blood cell.

Modified from Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis*. 2004;39(9):1267-1284. doi:10.1086/425368. Analysis of cerebrospinal fluid is necessary to differentiate various types of meningitis. Initial studies such as cell counts and Gram stain can be helpful, but culture of cerebrospinal fluid remains diagnostic. Opening pressure is generally in the range of 200 to 500 mm H<sub>2</sub>O, although values may be lower in neonates, infants, and children with acute bacterial meningitis. Neonates tend to have higher baseline WBC and protein in the CSF. For additional data on normal WBC and protein concentrations in infants <60 days old, please reference Table 2 in Thompson J, et al. Cerebrospinal fluid reference values for young infants undergoing lumbar puncture. *Pediatrics*. 2018;141(3). or Table 2 in Pantell, Robert H, et al. Evaluation and management of well-appearing febrile infants 8 to 60 days old. *Pediatrics*. 2021;148:2.

TABLE 17.9

DIAGNOSIS AND MANAGEMENT FOR INFANTS WITH *IN UTERO* HIV EXPOSURE<sup>B</sup>

Age	Laboratory Tests <sup>a</sup>	Next Steps
Prenatal/labor	Opt-out testing of all pregnant women HIV antibody testing in first trimester, with repeat testing before 36 weeks' gestation preferred if high risk Rapid HIV testing with confirmation if unknown HIV status during labor	Start ART in mother. If viral load RNA >1000 copies/mL or unknown at labor, start IV zidovudine (ZDV) and consider cesarean section if greater than 38 weeks' gestation.
Newborn	HIV nucleic acid test (DNA and RNA) if maternal status unknown, or high risk of infection Baseline CBC with differential	Start ZDV within 6 hr of delivery. If low risk (mother who received ART during pregnancy with viral level <50 near delivery), continue ZDV for 4 weeks. If high risk, presumptive HIV therapy using zidovudine, lamivudine, and either nevirapine or raltegravir from birth to 6 weeks; expert consultation recommended. Two-drug ARV prophylaxis with zidovudine and nevirapine can be considered on a case-by-case basis but should be in consultation with a pediatric infectious disease specialist. In the US, HIV+ mothers should be counseled against breastfeeding. If breastfeeding is desired, an HIV specialist should be consulted. <sup>15</sup>
2–3 weeks	HIV nucleic acid test (DNA > RNA) CBC with differential	Check ZDV dosing and administration. Assess psychosocial needs, consider case management referral.
4–6 weeks	HIV nucleic acid test (DNA or RNA) CBC with differential	Discontinue ZDV monotherapy regardless of PCR result (ZDV monotherapy is used during first 6 weeks for prophylaxis only). If positive, start ART according to guidelines, and start <i>Pneumocystis jirovecii</i> pneumonia prophylaxis, such as TMP-SMX Presumptively exclude HIV infection if results of ≥2 weeks PCR and ≥4 weeks PCR both negative.

*Continued*

TABLE 17.9

DIAGNOSIS AND MANAGEMENT FOR INFANTS WITH *IN UTERO* HIV EXPOSURE<sup>8</sup>—CONT'D

Age	Laboratory Tests <sup>a</sup>	Next Steps
2 months		Discontinue TMP-SMX if DNA or RNA testing negative.
4–6 months	HIV nucleic acid test (DNA or RNA)	Definitively exclude HIV infection: two negative PCRs at $\geq 1$ month and $\geq 4$ months OR two negative HIV-antibody tests from separate specimens obtained at $\geq 6$ months of age, as long as no signs/symptoms of HIV infection.
18–24 months	Antibody testing may be performed to confirm clearance of maternal HIV antibodies. If present, need to use nucleic acid testing.	

<sup>a</sup>Any abnormal result requires prompt pediatric HIV specialist consultation.

ART, Antiretroviral therapy; CBC, complete blood cell count; DNA, deoxyribonucleic acid; HIV, human immunodeficiency virus; IV, intravenous; PCR, polymerase chain reaction; RNA, ribonucleic acid; TMP-SMX, trimethoprim-sulfamethoxazole; ZDV, zidovudine.

Modified from Department of Health and Human Services guidelines for pediatric and perinatal HIV infection (see <https://www.aidsinfo.nih.gov> for more detailed information). National Perinatal HIV Hotline: 1-888-448-8765.

- c. Therapy: Combination antiretroviral therapy (ART) of at least three drugs from at least two different classes. Consider consultation with an infectious disease specialist.
3. Monitoring<sup>6,9</sup>
    - a. At diagnosis: CD4 count, plasma HIV RNA viral load, genotype resistance. If starting therapy, HLA-B\*5701 (screening for hypersensitivity to abacavir), tropism testing, hepatitis B serology (HBsAb, HBsAg, HBcAb total), hepatitis C screening (HCV Ab, or, if indicated, HCV RNA), basic chemistry, ALT, AST, total bilirubin, CBC with differential, lipid profile, glucose, urinalysis (UA), pregnancy test if applicable
    - b. Follow-up: At 1 to 2 weeks to evaluate for adverse effects and provide support for adherence. At 2 to 4 weeks after initiation or switching therapy: CD4, viral load, and labs according to possible toxicities of ART. Then similar testing as above every 3 to 6 months
    - c. Once viral suppression achieved, CD4 improved, good adherence, and otherwise stable for 2 to 3 years, can space labs to every 6 to 12 months
    - d. Children infected with HIV should have latent TB skin testing starting at age 3 to 12 months, and then annually.
    - e. Vaccines<sup>2</sup> (see [Chapter 16](#) and Red Book for details)
  4. Preexposure prophylaxis (PrEP)<sup>15</sup>
    - a. Common indications
      - (1) Men who have sex with men: HIV-positive partner, bacterial sexually transmitted infection (STI, e.g. gonorrhea, chlamydia, syphilis) in past 6 months, history of inconsistent or condomless anal intercourse with an unknown status or nonmonogamous partner, commercial (or exchange) sex, history of high number of sex partners
      - (2) Heterosexual men and women: HIV-positive partner, bacterial STI in past 6 months, history of inconsistent condom use, commercial (or exchange) sex, history of high number of sex partners, living in a high HIV prevalence setting
    - b. Initiation
      - (1) Labs: Fourth-generation HIV test, syphilis, gonorrhea, chlamydia, hepatitis B virus (HBV), hepatitis C virus (HCV, if history of IV drug use), urinalysis, and renal function. Pregnancy test if indicated. Counsel on condom use.
      - (2) Use emtricitabine/tenofovir alafenamide (Descovy) for biological males. Effective only after 7 days. Emtricitabine/tenofovir disoproxil (Truvada) for biological females and males. Effective only after 21 days. Consult infectious disease specialist for initiation of PrEP unless provider has extensive experience.
      - (3) Descovy and Truvada are FDA approved for adolescents >35 kg. Descovy is not approved to prevent transmission via vaginal intercourse.

- c. Follow-up
  - (1) Every 3 months: HIV test; renal function (if normal at 3 months, can be spaced to every 6 months); syphilis/gonorrhea/chlamydia testing if patient is symptomatic, engaging in anal intercourse, has prior history of STIs, or has multiple partners. Counsel on condom use at every visit.
  - (2) Every 6 months: Same as above, plus routine STI screening (including oral and/or anal testing, if applicable)
- 5. Postexposure prophylaxis (PEP)<sup>13-15</sup>
  - a. Indications for occupational PEP: Consider with percutaneous, mucosal, or skin exposure to blood or bodily fluids from a patient with known HIV or in whom there is high suspicion. See Section IV for further information.
  - b. Indications for nonoccupational PEP (nPEP): Unprotected vaginal/anal intercourse, oral sex with ejaculation or blood exposure, needle sharing, or injuries with blood exposure from an individual with known HIV or unknown status
  - c. Labs: Fourth-generation HIV test, HBV surface antigen and antibody, HCV antibody, renal function, liver enzymes. Consider tetanus prophylaxis, STI testing, and pregnancy testing, if applicable.
  - d. Regimen: Initiate as soon as possible (lower likelihood of efficacy after 72 hours); three-drug (or more) ART regimen for 28 days. Regimens for children >2 years old and adolescents: tenofovir and emtricitabine in combination with one of the following integrase inhibitors: bictegravir, elvitegravir, dolutegravir, raltegravir. Regimen for infants/children <2 years old: zidovudine and lamivudine in combination with one of the following integrase inhibitors: raltegravir, dolutegravir. Consult infectious disease expert for any initiation of PEP.
  - e. Follow-up testing can occur at 6 weeks, 12 weeks, and 6 months; for occupational exposures, if fourth-generation testing available, follow-up testing can be done at 6 weeks and 4 months.
  - f. Clinicians' PEP Line: 1-888-448-4911

## II. MICROBIOLOGY

### A. Collection of Specimens for Blood Culture

1. Preparation: To minimize contamination, clean venipuncture site with 70% isopropyl ethyl alcohol. Apply tincture of iodine or 10% povidone-iodine and allow skin to dry for at least 1 minute, or scrub site with 2% chlorhexidine for 30 seconds and allow skin to dry for 30 seconds. Clean blood culture bottle injection site with alcohol only.
2. Collection: Two sets of cultures from two different sites of equal blood volume should be obtained for each febrile episode, based on patient weight: less than 8 kg, 1 to 3 mL; 8 to 13 kg, 4 to 5 mL; 14 to 25 kg, 5 to 6 mL; greater than 25 kg, 10 mL. Peripheral sites preferred. If concern for central line infection, collect one from central access site, second from peripheral. Consider anaerobic blood cultures if concern for the following:

head and neck infections, intra-abdominal infections, immunodeficiency, trauma, or pressure sore.<sup>16,17</sup>

### B. Rapid Microbiologic Identification of Common Aerobic Bacteria (Fig. 17.4) and Anaerobic Bacteria (Fig. 17.5)


**NOTE:** Molecular assays for identification of bacteria and antibiotic resistance are increasingly available.

## III. ANTIBIOTIC THERAPY AND STEWARDSHIP

### A. Spectra of Activity for Commonly Used Antibiotics (Fig. 17.6)


## REFERENCES

A complete list of references can be found online.




**FIGURE 17.4**

Algorithm demonstrating identification of aerobic bacteria.



**FIGURE 17.4**

cont'd.

**FIGURE 17.5**

Algorithm demonstrating identification of anaerobic bacteria.

	Gram-positive					Gram-negative														
	VRE	<i>E. faecalis</i>	MRSA	MSSA	CoNS	beta-hemolytic strep	<i>S. pneumoniae</i>	Viridans strep	<i>H. influenzae</i>	<i>E. coli</i>	<i>Klebsiella</i> spp.	<i>Neisseria</i> spp.	<i>Proteus</i> spp.	<i>Serratia</i> spp.	Enterobacter spp.	<i>Pseudomonas</i> spp.	Oral anaerobes	Abdominal anaerobes	Atypicals	
Penicillin																				Hypersensitivity; cross reactivity w/ other $\beta$ -lactams
Ampicillin																				Hypersensitivity; cross reactivity w/ other $\beta$ -lactams
Ampicillin/sulbactam																				Hypersensitivity; cross reactivity w/ other $\beta$ -lactams
Oxacillin																				Hypersensitivity; cross reactivity w/ other $\beta$ -lactams
Piperacillin/tazobactam																				Hypersensitivity; cross reactivity w/ other $\beta$ -lactams
Cefazolin																				Hypersensitivity; cross reactivity w/ other $\beta$ -lactams
Ceftriaxone																				Hyperbilirubinemia in neonates; hypersensitivity; cross reactivity w/ $\beta$ -lactams
Cefepime																				Hypersensitivity; cross reactivity w/ other $\beta$ -lactams
Aztreonam																				No cross reactivity w/ $\beta$ -lactams
Ertapenem																				Decreases valproic acid levels
Meropenem																				Decreases valproic acid levels
Moxifloxacin																				QTc prolongation; precipitation w/ calcium or magnesium; achilles tendon rupture
Ciprofloxacin																				QTc prolongation; precipitation w/ calcium or magnesium; achilles tendon rupture
*Azithromycin																				QTc prolongation
Gentamicin/tobramycin																				Renal toxicity; phototoxicity
Vancomycin																				Nephrotoxicity; red man syndrome; neutropenia
Linezolid																				Bone marrow suppression, polyneuropathy (chronic use), serotonin syndrome
Daptomycin																				Myopathy; eosinophilic pneumonia
Trimethoprim/Sulfamethoxazole																				Stevens-Johnson syndrome; myelosuppression
*Clindamycin																				<i>C. difficile</i> –associated diarrhea
Doxycycline																				Tooth discoloration and enamel hypoplasia; photosensitivity; avoid <8 yo
Metronidazole																				Disulfiram-like reaction w/alcohol; peripheral neuropathy (chronic use)

\*Used in select situations for treatment of enteric gram-negative infections #Rates of clindamycin-resistant *S. aureus* have gone up in several regions in the United States

*C. difficile*, Clostridium difficile; CoNS, coagulase-negative Staphylococcus; *E. coli*, Escherichia coli; *E. faecalis*, Enterococcus faecalis; *H influenzae*, Haemophilus influenzae; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; *S. pneumoniae*, Streptococcus pneumoniae; VRE, vancomycin-resistant Enterococcus

FIGURE 17.6

Approximation for the spectrum of activity for commonly used antibiotics and common pediatric infections. Exact sensitivities will change with different local resistance patterns. For antibiotic recommendations for specific infections, refer to relevant part of Section I.

## B. ANTIBIOTIC STEWARDSHIP

Antibiotic resistance is a growing public health threat and is increasingly responsible for morbidity and mortality in children. Antibigrams outlining rates of organism resistance to common antibiotics are typically available at the local and hospital level. Providers should consult their local infectious diseases specialist for questions regarding antibiotic stewardship and resistant organisms.

## C. RESISTANCE IN COMMON ORGANISMS

1. Gram positive:
  - a. MRSA (Methicillin-resistant *Staphylococcus aureus*). Check local antibiogram. TMP/SMX generally >90% susceptibility, clindamycin up to 40% resistant. Consider doxycycline in those >8 years of age; generally >90% susceptible. Vancomycin is preferred for bacteremia, endocarditis, and meningitis; it penetrates poorly into the lung parenchyma and bones/joints. Linezolid can be considered if other anti-MRSA agents cannot be used.<sup>18</sup>
  - b. Group A *Streptococcus*: Penicillin or amoxicillin are treatment of choice. Alternative is narrow-spectrum cephalosporin (e.g., cephalexin) or clindamycin (~1% resistance in the United States).<sup>19</sup> Macrolide resistance has ~5% prevalence in the United States, varies by region, and can be associated with clindamycin and streptogramin resistance.<sup>20</sup>
  - c. *Streptococcus pneumoniae*: Penicillin resistance minimal, can overcome by using high-dose amoxicillin; macrolide resistance remains a concern, azithromycin not recommended empirically<sup>20</sup>
  - d. VRE (Vancomycin-resistant enterococci) (i.e., *E. faecium*): Increasing in pediatrics.<sup>20</sup> Empiric therapy with daptomycin or linezolid
  - e. Viridans group streptococci: Penicillin and ceftriaxone resistance seen in hematologic malignancy and hematopoietic stem cell transplant recipients, empiric coverage with vancomycin warranted
2. Gram negative:
  - a. ESBL (Extended-spectrum beta-lactamase)–producing organisms: Common in *Escherichia coli*, *Klebsiella pneumoniae*, *K. oxytoca*, and *Proteus mirabilis*. Carbapenems are drugs of choice; found to be superior to piperacillin/tazobactam. Treatment options: Ertapenem, meropenem, imipenem/cilastatin, ciprofloxacin, levofloxacin, or trimethoprim-sulfamethoxazole. Nitrofurantoin can be used for uncomplicated cystitis.<sup>21</sup>
  - b. CRE (Carbapenem-resistant Enterobacterales): Defined by resistance to at least one carbapenem antibiotic; 50% of CREs produce a carbapenemase. Treatment options: Ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilastatin/relebactam, cefiderocol, ciprofloxacin, levofloxacin, TMP/SMX. Extended infusion of meropenem can be considered if ertapenem resistant, meropenem susceptible, with no carbapenemase gene detected.<sup>21</sup>

- c. AmpC beta-lactamase-producing organisms: Organisms with highest risk of clinically significant AmpC production are *Enterobacter cloacae*, *Klebsiella (Enterobacter) aerogenes*, and *Citrobacter freundii*. Avoid third-generation cephalosporins, even if initial results indicate they are susceptible. Cefepime is treatment of choice if cefepime minimum inhibitory concentration (MIC) is 2 mCg/mL or less; alternative is carbapenem if cefepime MIC is  $\geq 4$  mCg/mL due to high likelihood of ESBL coproduction.<sup>22</sup>
3. Atypical
  - a. *Mycoplasma*: ~13% resistance to macrolides in the United States, greater in other countries, such as China<sup>20</sup>

#### IV. EXPOSURES TO BLOODBORNE PATHOGENS AND PROPHYLAXIS

##### A. General Practice<sup>23</sup>

1. Regardless of status of patient, if you experience a needlestick or splash exposure, immediately wash with soap/water, irrigate, report to supervisor, and seek medical assistance. Vaccination history should be reviewed and if needed, tetanus vaccination should be administered.
2. There is an increased risk of transmission with larger volume of blood, prolonged exposure, high viral titer, deep injury, or if patient has advanced disease.
3. Source should be tested for HIV, hepatitis C antibody, and hepatitis B surface antigen. Exposed person should be tested for HIV, hepatitis C antibody, hepatitis B surface antibody, and hepatitis B surface antigen.

##### B. Disease-Specific Postexposure Management

1. Hepatitis B<sup>24,25</sup>: High risk of transmission if surface antigen and e-antigen positive. Lower risk of transmission if surface antigen positive, e-antigen negative. Postexposure management includes hepatitis B immune globulin and initiation of hepatitis B vaccine series, depending on immune status. For details, see [Chapter 16](#).
2. Hepatitis C<sup>24,26</sup>: Lower risk of transmission. No preventative therapy is currently recommended, but this is an evolving field. Follow-up testing essential
3. See Section I.I for information on postexposure management for HIV.

## REFERENCES

1. Pantell RH, et al. Evaluation and management of well-appearing febrile infants 8-60 days old. *Pediatrics*. 2021;148(2). <https://doi.org/10.1542/peds.2021-052228>
2. American Academy of Pediatrics. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. *Red Book®: 2021 Report of the Committee on Infectious Diseases*. American Academy of Pediatrics; 2021.
3. Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. *Pediatrics*. 2004;114(S4):1175–1201.
4. Ahmed, et al. Interferon- $\gamma$  Release Assays in Children <15 Years of Age. *Pediatrics*. 2020;145(1):e20191930. PMID: 31892518.
5. Jain SK, Andronikou S, Goussard P, et al. Advanced imaging tools for childhood tuberculosis: potential applications and research needs. *Lancet Infect Dis*. 2020;20(11):e289–e297.
6. NIH. Clinical guidelines. Clinical Info HIV.gov. <https://clinicalinfo.hiv.gov/en/guidelines> Accessed December 6, 2021.
7. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf>
8. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. Available at <https://clinicalinfo.hiv.gov/en/guidelines/perinatal>. Accessed December 6, 2021.
9. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV Infection. <https://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf>
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>
11. Seeborg FO, Paul ME, Shearer WT. Human immunodeficiency virus and acquired immunodeficiency syndrome. In: Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ, eds. *Feigin and Cherry's Textbook of Pediatric Infectious Diseases*. 7th ed. Elsevier; 2014.
12. Biondi EA, Mischler M, Jerardi KE, et al. Blood culture time to positivity in febrile infants with bacteremia. *JAMA Pediatr*. 2014;168(9):844–849.
13. Dominguez KL, Smith DK, Vasavi T, et al. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. CDC; April 2016.
14. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. *Infect Control Hosp Epidemiol*. 2013;34(9):875–892.
15. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Published July 2021. Accessed December 5, 2021. <https://apps.who.int/iris/bitstream/handle/10665/342899/9789240031593-eng.pdf>

16. Connell TG, Rele M, Cowley D, Buttery JP, Curtis N. How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. *Pediatrics*. 2007;119:891–896.
17. Baron EJ, Miller JM, Weinstein MP, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 Recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)a. *Clin Infect Dis*. 2013;57:e22–e121.
18. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis*. 2011;52(3):e18–e55. <https://doi.org/10.1093/cid/ciq146>
19. Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2012;55(10):1279–1282.
20. Medernach RL, Logan LK. The growing threat of antibiotic resistance in children. *Infect Dis Clin N Am*. 2018;32(1):1–17. <https://doi.org/10.1016/j.idc.2017.11.001>
21. Tamma PD, Aitken S, Bonomo RA, et al. Infectious diseases Society of America guidance on the treatment of Extended-spectrum  $\beta$ -lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and *Pseudomonas aeruginosa* with Difficult-to-treat resistance (DTR-*P. aeruginosa*). *Clin Infect Dis*. 2021;72(7):e169–e183. <https://doi.org/10.1093/cid/ciaa1478>
22. Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America guidance on the treatment of antimicrobial-resistant gram-negative infections: Version 2.0: a focus on AmpC  $\beta$ -lactamase-producing Enterobacterales, carbapenem-resistant *Acinetobacter baumannii*, and *Stenotrophomonas maltophilia* infections. Infectious Diseases Society of America. Published March 31, 2022. Accessed August 29, 2022. <https://www.idsociety.org/practice-guideline/amr-guidance-2.0/>
23. Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for isolation precautions: prevention transmission of infectious agents in healthcare settings. <http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf>
24. U.S. Public Health Service. Updated U.S. Public Health Service Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*. 2001;50(RR–11):1–52.
25. Schillie S, Murphy TV, Sawyer M, et al. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*. 2013;62(RR-10):1–19.
26. Moorman AC, de Perio MA, Goldschmidt R, et al. Testing and clinical management of health care personnel potentially exposed to hepatitis C Virus - CDC guidance, United States, 2020. *MMWR Recomm Rep (Morb Mortal Wkly Rep)*. 2020;69(6):1–8. Published July 24, 2020. doi:10.15585/mmwr.rr6906a1.
27. Puopolo KM, Lynfield R, Cummings JJ. COMMITTEE ON FETUS AND NEWBORN; COMMITTEE ON INFECTIOUS DISEASES. Management of Infants at Risk for Group B Streptococcal Disease [published correction appears in *Pediatrics*. 2019 Oct;144(4):]. *Pediatrics*. 2019;144(2):e20191881. <https://doi.org/10.1542/peds.2019-1881>
28. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. *N Engl J Med*. 2020;382(17):1663-1665. <https://doi.org/10.1056/NEJMc2005073>

29. Wong VC, Reesink HW, Lelie PN, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin: double-blind randomized placebo-controlled study. *Lancet*. 1984;1:921–926.
30. Centers for Disease Control and Prevention. Updated recommendations for use of variZIG—United States, 2013. *MMWR Morb Mortal Wkly Rep*. 2013;62(28):574–576.
31. World Health Organization. *WHO Toolkit for the Care and Support of People Affected by Complications Associated with Zika Virus*. World Health Organization; 2017.
32. Tunkel AR, Hartman BJ, Kaplan SL, et al. 2017 Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis*. 2004;39(9):1267–1284.
33. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. *Clin Infect Dis*. 2017.
34. Azari Amir A, Barney, Neal P. Conjunctivitis: a systematic review of diagnosis and treatment. *J Am Med Assoc*. 2013;310(16):1721–1730.
35. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. *Pediatrics*. 2013;131(3):e964–e999.
36. Kordeluk S, Kraus M, Leibovitz E. Challenges in the management of acute mastoiditis in children. *Curr Infect Dis Rep*. 2015;17(5):479.
37. Rosenfeld RM, Schwartz SR, Cannon CR, et al. Clinical practice guideline: acute otitis externa executive summary. *Otolaryngol Head Neck Surg*. 2014;150(2):161–168.
38. Brook I. Microbiology and management of peritonsillar, retropharyngeal, and parapharyngeal abscesses. *J Oral Maxillofac Surg*. 2004 Dec;62(12):1545–1550.
39. Bochner RE, Gangar M, Belamarich PF. A clinical approach to tonsillitis, tonsillar hypertrophy, and peritonsillar and retropharyngeal abscesses. *Pediatr Rev*. 2017;38(2):81–92.
40. Bridwell R, Gottlieb M, Koyfman A, et al. Diagnosis and management of Ludwig’s angina: an evidence-based review. *Am J Emerg Med*. 2021;41:1–5.
41. Hagelskjaer Kristensen L, Prag J. Human necrobacillosis, with emphasis on Lemierre’s syndrome. *Clin Infect Dis*. 2000;31(2):524–532.
42. Hauser A, Fogarasi S. Periorbital and orbital cellulitis. *Pediatr Rev*. 2010;31(6):242–249. <https://doi.org/10.1542/pir.31-6-242>
43. Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. *Pediatrics*. 2013;132(1):e262–e280. PMID: 23796742.
44. Leung AK, Davies HD. Cervical lymphadenitis: etiology, diagnosis, and management. *Curr Infect Dis Rep*. 2009;11(3):183–189.
45. Thorell EA. Cervical lymphadenitis and neck infections. In: Long SS, Prober CG, Fischer M. *Principles and Practice of Pediatric Infectious Diseases*. 5th ed. Elsevier; Vol. 2018:17/136–148. Accessed December 12, 2021. <https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323401814000177?indexOverride=GLOBAL>
46. Weinstock MS, Patel NA, Smith LP. Pediatric cervical lymphadenopathy. *Pediatr Rev*. 2018;39(9):433–443. <https://doi.org/10.1542/pir.2017-0249>
47. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. *Clin Infect Dis*. 2011;53(7):e25–e76.
48. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. *Clin Infect Dis*. 2010;50(2):133–164.

49. Alfredo G, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for pediatric infectious diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. *J Pediatr Gastroenterol Nutr.* 2014;59(1):132–152. PMID: 24739189.
50. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. *Clin Infect Dis.* 2017;65(12):e45–e80. <https://doi.org/10.1093/cid/cix669>
51. Wen SC, Best E, Nourse C. Non-typhoidal Salmonella infections in children: review of literature and recommendations for management. *J Paediatr Child Health.* 2017;53(10):936–941.
52. Wong CS, Mooney JC, Brandt JR, et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. *Clin Infect Dis.* 2012;55(1).
53. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis.* 2018;66(7):e1–e48. <https://doi.org/10.1093/cid/cix1085>
54. Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. *J Pediatr Gastroenterol Nutr.* 2011;53(2):230–243. <https://doi.org/10.1097/MPG.0b013e3182227e90>
55. Korotkaya Y, Shores D. *Helicobacter pylori* in pediatric patients. *Pediatr Rev.* 2020;41(11):585–592.
56. Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. *Pediatrics.* 2011;128(3):595–610.
57. Michael M, Hodson EM, Craig JC, et al. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. *Cochrane Database Syst Rev.* 2003;(1):CD003966. <https://doi.org/10.1002/14651858.CD003966>
58. Mattoo TK, Sheikh N, Nelson CP. Contemporary management of urinary tract infection in children. 2021;147(2):e2020012138. <https://doi.org/10.1542/peds.2020-012138>
59. Julian W, Skoog SJ, Hulbert WC, et al. Section on urology response to new guidelines for the diagnosis and management of UTI. *Pediatrics.* 2012;129(4):e1051–e1053.
60. Schmitt SK. Osteomyelitis. *Infect Dis Clin.* 2017;31(2):325–338.
61. Woods CR, Bradley JS, Chatterjee A, et al. Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics. *J Pediatric Infect Dis Soc.* 2021;10(8):801–844. <https://doi.org/10.1093/jpids/piab027>
62. Kocher MS, Mandiga R, Zurakowski D, et al. Validation of a clinical prediction rule for the differentiation between septic arthritis and transient synovitis of the hip in children. *J Bone Joint Surg Am.* 2004;86-A(8):1629–1635.
63. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2014;59(2):e10–e52.
64. Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess. *N Engl J Med.* 2016;374(9):823–832. <https://doi.org/10.1056/NEJMoa1507476>

65. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;49(1):1–45.
66. Centers for Disease Control and Infection. Guidelines for treatment of malaria in the United States. Published October 1, 2019. Accessed December 5, 2021. [https://www.cdc.gov/malaria/resources/pdf/Malaria\\_Treatment\\_Table\\_120419.pdf](https://www.cdc.gov/malaria/resources/pdf/Malaria_Treatment_Table_120419.pdf)
67. Rigante D, Esposito S. A roadmap for fever of unknown origin in children. *Int J Immunopathol Pharmacol*. 2013;26(2):315–326. <https://doi.org/10.1177/039463201302600205>
68. Antoon JW, Potisek NM, Lohr JA. Pediatric fever of unknown origin. *Pediatr Rev*. 2015;36(9):380–391. doi:10.1542/pir.36-9-380.
69. NIH. COVID-19 treatment guidelines. Updated January 14, 2022. Accessed January 15, 2022. <https://www.covid19treatmentguidelines.nih.gov/>
70. Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. *Pediatrics*. 2020;58(4):712–713. doi: 10/1542/peds.2020-0702.
71. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat Med*. 2020;26(4):502–505. <https://doi.org/10.1038/s41591-020-0817-4>
72. Talan DA, Moran GJ, Krishnadasan A, et al. Subgroup Analysis of Antibiotic Treatment for Skin Abscesses. *Ann Emerg Med*. 2018;71(1):21–30. <https://doi.org/10.1016/j.annemergmed.2017.07.483>
73. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. *Pediatr Pulmonol*. 2020;55(5):1169–1174. <https://doi.org/10.1002/ppul.24718>
74. Li W, Cui H, Li K, Fang Y, Li S. Chest computed tomography in children with COVID-19 respiratory infection. *Pediatr Radiol*. 2020;50(6):796–799. <https://doi.org/10.1007/s00247-020-04656-7>
75. Lantos PM, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. *Clin Infect Dis*. 2021;72(1):e1–e48. <https://doi.org/10.1093/cid/ciaa1215>
76. Krause PJ, Auwaerter PG, Bannuru RR, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis. *Clin Infect Dis*. 2021;72(2):e49–e64.
77. Parija SC, Kp D, Venugopal H. Diagnosis and management of human babesiosis. *Trop Parasitol*. 2015;5(2):88–93. <https://doi.org/10.4103/2229-5070.162489>
78. Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2016;63(4):e1–e60.
79. Clinical practice guidelines for the management of blastomycosis. 2008 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2008;46(12):1801–1812.
80. Pappas PG, Kauffman CA, Andes DR, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2016;62(4):409–417. <https://doi.org/10.1093/cid/civ1194>
81. Perfect JR, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2010;50(3):291–322. <https://doi.org/10.1086/649858>

82. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2007;45(7):807–825. <https://doi.org/10.1086/521259>
83. Centers for Disease Control and Prevention. US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. Published March 2018. Accessed August 29, 2022. <https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf>
84. Salazar-Austin N, Ordonez AA, Hsu A, et al. Extensively drug-resistant tuberculosis in a young child after travel to India. *Lancet Infect Dis*. 2015;15:1485–1491. PMID: 26607130.
85. Daum RS, Miller LG, Immergluck L, et al. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. *N Engl J Med*. 2017;376(26):2545–2555. <https://doi.org/10.1056/NEJMoa1607033>

# Chapter 18

## Neonatology

*Elizabeth Lee, MD*

 See additional content online.

 **Audio Case File 18.1** Ventilation strategies in the neonatal ICU

### I. NEWBORN RESUSCITATION

#### A. Algorithm for Neonatal Resuscitation (Fig. 18.1)

1. Essential functional equipment: Radiant warmer, prewarmed blankets, hat, bag-mask/NeoPIP ventilator, appropriately sized laryngoscope, appropriately sized endotracheal tube (ETT) ± stylet, suction device and bulb syringe, emergency medications, and vascular access supplies
2. Meconium-stained fluids: Routine intrapartum oropharyngeal/nasopharyngeal suctioning and endotracheal intubation are not recommended for vigorous and nonvigorous infants.<sup>1</sup>
3. Cord clamping should be delayed for at least 30 to 60 seconds for vigorous term and preterm infants, given no maternal or fetal indications for immediate clamping. See eBox 18.1 for exclusions. Cord milking should NOT be used for infants less than 28 weeks of gestation given link with intraventricular hemorrhage. There is insufficient evidence to support or refute use of umbilical cord milking for infants born at 32 weeks of gestation or more, including term.<sup>2</sup>

#### B. Endotracheal Tube Size and Depth of Insertion (Table 18.1)

1. Quick estimations:
  - a. ETT size: 2.5 mm for infants <30 weeks gestational age (wGA); 3.0 mm for 30 to 34 wGA; 3.5 mm for >35 wGA.
  - b. ETT depth: Infant's weight (kg) + 6 cm

#### C. Vascular Access (See Chapter 4 for Umbilical Venous/Artery Catheter Placement)

**NOTE:** During emergent placement, an umbilical venous catheter (UVC) may be inserted just far enough to obtain blood return; no measurement or verified placement is needed prior to emergent use.

**eBOX 18.1****EXCLUSION CRITERIA FOR DELAYED CORD CLAMPING****Absolute Exclusions Prior to Birth<sup>1,2</sup>****Fetal**

- Monochorionic twins
- Discordant twins >25%
- IUGR <3rd percentile with reversed end-diastolic flow
- Poorly controlled maternal diabetes
- Congenital diaphragmatic hernia
- Abdominal wall defects
- Infant requiring immediate resuscitation


**Maternal**

- Known carrier of G6PD
- Placental abruption
- Velamentous cord insertion
- Incision through placenta
- Uterine rupture
- Placental delivery prior to infant

**Individualized Considerations—Not Absolute Exclusions**

- Hydrops fetalis
- RBC alloimmunization
- History of sibling with double volume exchange transfusion

NOTE: Presence of meconium-stained amniotic fluid does not automatically exclude delayed cord clamping.



**FIGURE 18.1**

Overview of resuscitation in the delivery room. CPAP, Continuous positive airway pressure; HR, heart rate; IV, intravenous; PPV, positive pressure ventilations. (From American Academy of Pediatrics [AAP], American Heart Association. *Textbook of Neonatal Resuscitation [NRP]*. 8th ed. American Academy of Pediatrics; 2021.)

**TABLE 18.1****PREDICTED ENDOTRACHEAL TUBE SIZE AND DEPTH BY BIRTH WEIGHT AND GESTATIONAL AGE**

Gestational Age (Weeks)	Weight (g)	ETT Size (mm)	ETT Depth of Insertion (cm From Upper Lip)
23–24	500–600	2.5	5.5
25–26	700–800	2.5	6
27–29	900–1000	2.5	6.5
30–32	1100–1400	2.5–3.0	7
33–34	1500–1800	3.0	7.5
35–37	1900–2400	3.0–3.5	8
38–40	2500–3100	3.5	8.5

ETT, Endotracheal tube.

Data from Peterson J, Johnson N, Deakins K, et al. Accuracy of the 7-8-9 rule for endotracheal tube placement in the neonate. *J Perinatol.* 2006;26:333–336.

## II. ROUTINE NEWBORN CARE OF A TERM INFANT


### A. General Care for the Full-Term Healthy Newborn With Uncomplicated Delivery

**NOTE:** Protocols vary by hospital.

1. Drying, removal of wet blankets. Then, preferably, skin-to-skin contact with mother<sup>3</sup> or otherwise placed under warmer
2. Feeding: Breastfeeding soon after birth and on demand thereafter. Breastfed newborns should feed 8 to 12 times daily. Formula-fed newborns should be offered a bottle soon after birth.
3. Vitamin K IM injection for prevention of hemorrhagic disease of the newborn.
4. Antibiotic ophthalmic ointment for prophylaxis against gonococcal infection.
5. Monitor clinically for jaundice, accounting for newborn's risk factors for hyperbilirubinemia. Transcutaneous bilirubin monitoring may be useful as a screening tool but does not replace plasma level.<sup>4</sup> Obtain plasma total bilirubin level if warranted. See [Section IX](#) for further management.
6. Consider blood glucose monitoring if infant is at increased risk or is symptomatic of hypoglycemia (see [Fig. 18.2](#) for management).
7. Monitor for stool/urine output. Most infants should have 1 void and 1 meconium stool within first 24 hours.<sup>5</sup>
8. Monitor for excessive weight loss (>10% loss).

### B. Prior to Discharge<sup>6</sup>

1. Newborn metabolic screening: First screen typically performed within first 72 hours of life, at least 24 hours after initiation of feeding (see [Chapter 13](#))
2. Vaccinations: Hepatitis B vaccine (see [Chapter 16](#))
3. Critical congenital heart disease screening: Measure pre- and/or postductal oxygen saturation (see [Chapter 7](#)).
4. Newborn hearing screening
5. Document bilateral ophthalmic red reflex.
6. Establish primary care.

**FIGURE 18.2**

Screening for and management of postnatal glucose homeostasis. *D10W*, 10% Dextrose in water; *glc*, glucose; *IDM*, infant of diabetic mother; *IV*, intravenous; *LGA*, large for gestational age; *SGA*, small for gestational age; *WGA*, weeks' gestational age. (Modified from Adamkin D, Committee on the Fetus and Newborn. Postnatal glucose homeostasis in late-preterm and term infants. *Pediatrics*. 2011;127:575–579.)

### III. NEWBORN ASSESSMENT

#### A. Vital Signs and Birth Weight

1. **Mean arterial blood pressure (MAP):** Related to birth weight, gestational age
2. **Birth weight:**
  - a. Extremely low birth weight (ELBW):  $< 1000$  g, very low birth weight (VLBW):  $< 1500$  g, low birth weight (LBW):  $< 2500$  g
  - b. Small for gestational age (SGA):  $< 10\%$  for gestational age
  - c. Large for gestational age (LGA):  $> 90\%$  for gestational age

#### B. APGAR Scores (Table 18.2)

Assess at 1 and 5 minutes. Repeat at 5-minute intervals if score at 5 minutes is  $< 7$ .<sup>7</sup>

TABLE 18.2

## APGAR SCORES

Score	0	1	2
Heart rate	Absent	<100 bpm	>100 bpm
Respiratory effort	Absent, irregular	Slow, crying	Good
Muscle tone	Limp	Some flexion of extremities	Active motion
Reflex irritability (nose suction)	No response	Grimace	Cough or sneeze
Color	Blue, pale	Acrocyanosis	Completely pink

Data from Apgar V. Proposal for a new method of evaluation of the newborn infant. *Anesth Analg.* 1953;32:260.

### C. Gestational Age Estimation

If obstetric dating by Ultrasound (US) or Last Menstrual Period (LMP) is not available, Ballard scoring can be utilized for gestational age estimation. The Ballard score is most accurate at approximately 24 hours and estimates gestational age based on neuromuscular and physical maturity ratings (eFig. 18.1).

1. Posture: Observe infant quiet and supine. Score 0 for arms, legs extended; 1 for starting to flex hips and knees, arms extended; 2 for stronger flexion of legs, arms extended; 3 for arms slightly flexed, legs flexed and abducted; and 4 for full flexion of arms and legs.
2. Square window: Flex infant's hand on forearm enough to obtain fullest possible flexion without wrist rotation. Measure angle between hypothenar eminence and ventral aspect of forearm.
3. Arm recoil: With infant supine, flex infant's forearms for 5 seconds, fully extend by pulling on hands, then release. Measure the angle of elbow flexion to which arms recoil.
4. Popliteal angle: Hold infant supine with infant's pelvis flat, infant's thigh held in knee-chest position. Extend infant's leg by gentle pressure and measure popliteal angle.
5. Scarf sign: With infant supine, pull infant's hand across the neck toward opposite shoulder. Determine how far elbow will reach across. Score 0 if elbow reaches opposite axillary line, 1 if past midaxillary line, 2 if past midline, and 3 if elbow unable to reach midline.
6. Heel-to-ear maneuver: With baby supine, draw infant's foot as near to head as possible without forcing it. Observe distance between foot and head and degree of extension at knee.

### D. Birth Trauma

1. **Extradural fluid collections:** See Table 18.3 and Fig. 18.3.
2. **Fractured clavicle:** Possible crepitus/deformity/decreased movement on day 1 ± swelling/discomfort on day 2.
3. **Brachial plexus injuries:** See Section XI.

### E. Selected Anomalies, Syndromes, and Malformations (see Chapter 13 for genetic disorders)

1. **Infant of a diabetic mother:** Frequently at risk of hypoglycemia, polycythemia, transient tachypnea of the newborn (TTN). Other associated defects include sacral agenesis, femoral hypoplasia, cardiac

Neuromuscular maturity

Neuromuscular maturity sign	Score							Record score here
	-1	0	1	2	3	4	5	
Posture								
Square window (wrist)	> 90°	90°	60°	45°	30°	0°		
Arm recoil		180°	140–180°	110–140°	90–110°	<90°		
Popliteal angle	180°	160°	140°	120°	100°	90°	<90°	
Scarf sign								
Heel to ear								
TOTAL NEUROMUSCULAR MATURITY SCORE								

Physical maturity

Physical maturity sign	Score							Record score here
	-1	0	1	2	3	4	5	
Skin	Sticky, friable, transparent	Gelatinous, red, translucent	Smooth, pink, visible veins	Superficial peeling and/or rash, few veins	Cracking, pale areas, rare veins	Parchment, deep cracking, no vessels	Leathery, cracked, wrinkled	
Lanugo	None	Sparse	Abundant	Thinning	Bald areas	Mostly bald		
Plantar surface	Heel-toe: 40–50 mm: -1 <40 mm: -2	>50 mm, no crease	Faint red marks	Anterior transverse crease only	Creases anterior two thirds	Creases over entire sole		
Breast	Imperceptible	Barely perceptible	Flat areola, no bud	Stippled areola, 1–2 mm bud	Raised areola, 3–4 mm bud	Full areola, 5–10 mm bud		
Eye/ear	Lids fused: loosely: -1 tightly: -2	Lids open, pinna flat, stays folded	Sl. curved pinna, soft, slow recoil	Well-curved pinna, soft but ready recoil	Formed and firm, instant recoil	Thick cartilage, ear stiff		
Genitals (male)	Scrotum flat, smooth	Scrotum empty, faint rugae	Testes in upper canal, rare rugae	Testes descending, few rugae	Testes down, good rugae	Testes pendulous, deep rugae		
Genitals (female)	Clitoris prominent and labia flat	Prominent clitoris and small labia minora	Prominent clitoris and enlarging minora	Majora and minora equally prominent	Majora large, minora small	Majora cover clitoris and minora		
TOTAL PHYSICAL MATURITY SCORE								

Score	Maturity rating													Gestational age (weeks)		
Neuromuscular _____	Score	-10	-5	0	5	10	15	20	25	30	35	40	45	50	By dates _____	
Physical _____	Weeks	20	22	24	26	28	30	32	34	36	38	40	42	44	By ultrasound _____	
Total _____															By exam _____	


eFIGURE 18.1

Neuromuscular and physical maturity (New Ballard Score). (Modified from Ballard JL, et al. New Ballard Score, expanded to include extremely premature infants. *J Pediatr.* 1991;119:417–423.)

**TABLE 18.3****BIRTH-RELATED EXTRADURAL FLUID COLLECTIONS**

	<b>Caput Succedaneum</b>	<b>Cephalohematoma</b>	<b>Subgaleal Hemorrhage</b>
Location	At point of contact; can extend across sutures	Usually over parietal bones; does not cross sutures	Beneath epicranial aponeurosis; may extend to orbits or nape of neck
Findings	Vaguely demarcated; pitting edema, shifts with gravity	Distinct margins; initially firm, more fluctuant after 48 hr	Firm to fluctuant, ill-defined borders; may have crepitus or fluid waves
Timing	Maximal size/firmness at birth; resolves in 48–72 hr	Increases after birth for 12–24 hr; resolution over weeks	Progressive after birth; resolution over weeks
Severity	Minimal	Rarely severe	May be severe, especially in the setting of associated coagulopathy

Data from Davis DJ. Neonatal subgaleal hemorrhage: diagnosis and management. *CMAJ*. 2001;164:1452.

**FIGURE 18.3**

Types of extradural fluid collections seen in newborn infants.

defects, cleft palate/lip, preaxial radial defects, microtia, microphthalmia, holoprosencephaly, microcephaly, anencephaly, spina bifida, cauda equina, hemivertebrae, urinary tract defects, and polydactyly.

2. **VACTERL association:** **V**ertebral defects, **A**nal atresia, **C**ardiac defects, **T**racheo-**E**sophageal fistula, **R**enal anomalies, and **L**imb abnormalities
3. **CHARGE syndrome:** **C**oloboma, **H**eart disease, choanal **A**tresia, **R**etarded growth and development (may include central nervous system anomalies), **G**enital anomalies (may include hypogonadism), and **E**ar abnormalities or deafness

## IV. FLUIDS, ELECTROLYTES, AND NUTRITION

### A. Fluids

1. **Fluid requirements of newborns (Table 18.4).** Of note, insensible water loss increases with greater degree of prematurity through immature skin and renal losses.

TABLE 18.4

## ESTIMATED MAINTENANCE FLUID REQUIREMENTS OF NEWBORNS

Birth Weight (g)	Fluid Requirements (mL/kg/24 hr) by Age			
	Day 1	Day 2	Days 3–6	Days 7+
<750	100–140	120–160	140–200	140–160
750–1000	100–120	100–140	130–180	140–160
1000–1500	80–100	100–120	120–160	150
>1500	60–80	80–120	120–160	150

Data from Gleason CA, Juul SE, eds. *Avery's Diseases of the Newborn*. 10th ed. Elsevier; 2018.

## B. Glucose

1. **Glucose infusion rate (GIR):** Preterm neonates require approximately 5 to 6 mg/kg/min of glucose (40 to 100 mg/dL).<sup>8</sup> Term neonates require approximately 3 to 5 mg/kg/min of glucose. Calculate as follows:

$$\text{GIR (mg/kg/min)} = 0.167 \times [\text{dextrose concentration}] \left[ \text{infusion rate} \left( \frac{\text{mL}}{\text{hr}} \right) \right] / [\text{Weight (kg)}]$$

2. **Management of hyperglycemia and hypoglycemia:** Table 18.5 and Fig. 18.2 (see Chapters 1 and 10).

## C. Electrolytes, Minerals, and Vitamins

1. **Electrolyte requirements** (Table 18.6)
2. **Mineral and vitamin requirements:**
  - a. Infants born at <34 weeks' gestation have higher calcium, phosphorus, sodium, iron, and vitamin D requirements and require breastmilk fortifier or special preterm formulas with iron. Fortifier is generally added to breastmilk after the second week of life.
  - b. Iron: Preterm infants tolerating full enteral feeds require an elemental iron supplement of 2 to 6 mg/kg/day. Timing of initiation remains controversial, generally after age 10–14 days.<sup>9</sup>
  - c. Vitamin D: 400 IU/day is recommended for all infants from birth to 12 months of age regardless of mode of feeding.<sup>10</sup>
  - d. ADEK: Indicated for infants with malabsorption and/or cholestasis tolerating full enteral feeds.

## D. Nutrition

1. **Growth and caloric requirements:** Table 18.7
2. **Total parenteral nutrition** (see Chapter 21)

## V. CYANOSIS IN THE NEWBORN

### A. Differential Diagnosis

1. **General:** Hypothermia, hypoglycemia, sepsis
2. **Cardiac:** Congestive heart failure, congenital cyanotic heart disease
3. **Respiratory:** Persistent pulmonary hypertension of the newborn (PPHN), diaphragmatic hernia, pulmonary hypoplasia, choanal atresia,

TABLE 18.5

## MANAGEMENT OF HYPERGLYCEMIA AND HYPOGLYCEMIA

	Hypoglycemia	Hyperglycemia
Definition	Serum glucose <40 mg/dL in term and late preterm infants	Serum glucose >125 mg/dL in term infants, >150 mg/dL in preterm infants
Differential diagnosis	Insufficient glucose delivery Decreased glycogen stores Increased circulating insulin (e.g., infant of a diabetic mother, maternal drugs, Beckwith-Wiedemann syndrome, tumors) Endocrine and metabolic disorders Sepsis or shock Hypothermia, polycythemia, or asphyxia	Excess glucose administration Sepsis Hypoxia Hyperosmolar formula Neonatal diabetes mellitus Medications
Evaluation	Assess for symptoms and calculate glucose delivery to infant. Confirm bedside glucose with laboratory serum glucose. Consider other laboratory evaluations: Complete blood cell count with differential; electrolytes; blood, urine, ± cerebrospinal fluid cultures; urinalysis; insulin and C-peptide levels	
Management	See Fig. 18.2. If glucose <40 and symptomatic, treat with intravenous glucose (dose = 200 mg/kg, which is equivalent to dextrose 10% at 2 mL/kg). Change dextrose infusion rates gradually. Generally, no more than 2 mg/kg/min in a 2-hr interval (see Chapter 1)  Monitor glucose levels every 30–60 min until normal.	Gradually decrease glucose infusion rate if receiving >5 mg/kg/min. Monitor glucosuria. Consider insulin infusion for persistent hyperglycemia.

Modified from Paul S, et al. Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. *J Pediatr.* 2015;167(2):238–245.

TABLE 18.6

## ELECTROLYTE REQUIREMENTS

	Before 24 hr of Life	Transitional, After 24 hr of Life <sup>a</sup>	Growing Premature Infant	Growing Term Infant
Sodium (mEq/kg/day)	0–1	2–5	3–5	2–4
Potassium (mEq/kg/day)	0	0–2	2–3	2–3

<sup>a</sup>Pending postnatal diuresis has been established. Period to physiologic and metabolic stability generally occurring between 2 and 7 days.

pneumothorax, respiratory distress syndrome (RDS), TTN, pneumonia, meconium aspiration

4. **Neurologic:** Central apnea, central hypoventilation, intraventricular hemorrhage (IVH), meningitis

TABLE 18.7

## AVERAGE CALORIC REQUIREMENTS AND GROWTH FOR PRETERM AND TERM INFANTS

	Preterm Infant	Term Infant
Caloric requirements (kcal/kg/day) [parental/enteral]	PN: 85–110 EN: 105–130 Up to 150 for infants with cardiac conditions or BPD <sup>a</sup>	PN: 90–100 EN: 100–120
Growth after 10 days of life	<2 kg: 15–20 g/kg/day >2 kg: 25–35 g/day	20–30 g/day

<sup>a</sup>Signifies an exception for infants with cardiac conditions or BPD.

BPD, Bronchopulmonary dysplasia; EN, enteral nutrition or feeds into stomach; PN, parenteral nutrition or IV nutrition.

5. **Hematologic:** Polycythemia, methemoglobinemia
6. **Medications:** Respiratory depression from maternal medications (e.g., magnesium sulfate, narcotics, general anesthesia)

## B. Evaluation

1. **Physical examination:** Note central vs. peripheral and persistent vs. intermittent cyanosis, respiratory effort, single vs. split S<sub>2</sub>, presence of heart murmur. Acrocyanosis is a normal finding in newborns.
2. **Clinical tests:** Preductal/postductal arterial blood gases or pulse oximetry to assess for right-to-left shunt, and transillumination of chest for possible pneumothorax, hyperoxia test (see [Chapter 7](#)).
3. **Other data:** Complete blood cell count (CBC) with differential, serum glucose, lactate, chest radiograph, echocardiography. Consider blood, urine, and cerebrospinal fluid cultures if sepsis is suspected.

## VI. RESPIRATORY DISEASES

### A. General Respiratory Considerations

1. **Exogenous surfactant therapy:**
  - a. Indications: RDS in preterm infants. Consider in meconium/blood/amniotic fluid aspiration, pneumonia, persistent pulmonary hypertension of newborn (PPHN).
  - b. Administration: If newborn is gestational age (GA) ≤26 weeks, first dose is typically given in delivery room or as soon as stabilized in NICU; repeat dosing can be considered based on oxygen requirements and level of respiratory support.
  - c. Complications: Pneumothorax, pulmonary hemorrhage
2. **Supplemental O<sub>2</sub>:** Adjust inspired oxygen to maintain O<sub>2</sub> saturation. Ideal target oxygen saturations vary based on factors such as gestational age, chronologic age, and underlying conditions, and aim to minimize adverse outcomes from hypoxemia and hyperoxemia. Higher targets (>94%) can be used when the retinas are mature (see [Section XIII](#)) and in cases of pulmonary hypertension.<sup>11</sup>

**B. Respiratory Distress Syndrome (RDS)**

1. **Etiology:** Deficiency of pulmonary surfactant resulting in increased surface tension and alveolar collapse. Surfactant is produced in increasing quantities after 32 weeks' gestation.
2. **Prevention:**
  - a. Antenatal maternal steroids have been shown to decrease neonatal morbidity and mortality.<sup>12</sup>
  - b. Optimal timing: First course at >24 hours and <7 days prior to anticipated preterm delivery
  - c. Repeat course: Considered in women at gestational age (GA) <34 weeks and whose prior steroid course was administered >14 days prior. Serial courses not currently recommended.
3. **Incidence:** Table 18.8
4. **Risk factors:** Prematurity, maternal diabetes, cesarean section without antecedent labor, perinatal asphyxia, second twin, previous infant with RDS. Of note, certain maternal factors may accelerate lung maturity including: hypertension, sickle cell disease, narcotic addiction, intrauterine growth retardation, prolonged rupture of the membranes, and fetal stress.
5. **Clinical presentation:**
  - a. Respiratory distress (e.g., increased work of breathing, desaturations) worsens during first few hours of life, progresses over 48 to 72 hours, and subsequently improves.
  - b. Recovery is accompanied by brisk diuresis.
  - c. CXR consistent with hypoinflation along with diffuse and symmetric “ground glass” appearance See Chapter 26 for imaging findings.
6. **Management:**
  - a. Ventilatory and oxygenation support
  - b. Surfactant therapy

**C. Persistent Pulmonary Hypertension of the Newborn (PPHN)**

1. **Etiology:** Idiopathic or secondary to conditions leading to increased pulmonary vascular resistance, vasoconstriction, and right-to-left shunting

**TABLE 18.8****INCIDENCE OF RESPIRATORY DISTRESS SYNDROME BY GESTATIONAL AGE AND ANTE-NATAL STEROID ADMINISTRATION<sup>12,32-34</sup>**

Gestational Age (Week)	Antenatal Steroids Administered	Antenatal Steroids Not Administered
<30	35%	60%
30–34	10%	25%
34–36	1.4% <sup>a</sup> ; 5.5%	2.3% <sup>a</sup> ; 6.4%
>37	2.6%	5.4%

<sup>a</sup>Neonates with severe respiratory distress syndrome.

NOTE: The use of antenatal corticosteroids in >34 weeks' gestational age is controversial because of inconsistent data regarding efficacy and limited data regarding long-term effects.

2. **Risk factors:** Most commonly seen in term or postterm newborns, those born by cesarean section, and newborns with a history of fetal distress and low APGAR scores. Other risk factors are: hypoxemia and acidosis leading to vasoconstriction, interstitial pulmonary disease (meconium aspiration syndrome, pneumonia), hyperviscosity syndrome (polycythemia), and pulmonary hypoplasia, either primary or secondary to congenital diaphragmatic hernia or renal agenesis
3. **Diagnostic features: PPHN usually presents within 12 to 24 hours of birth**
  - a. Severe hypoxemia ( $P_{aO_2} < 35$  to  $45$  mmHg in  $100\% O_2$ ) disproportionate to radiologic changes
  - b. Structurally normal heart with right-to-left shunt at foramen ovale and/or ductus arteriosus; pre/postductal oxygenation gradient ( $\geq 7$  to  $15$  mmHg is significant)
  - c. Critically important to distinguish from cyanotic heart disease. If little to no improvement in oxygenation with oxygen therapy, perform detailed cardiac exam and hyperoxia test (see [Chapter 7](#) for interpretation), and consider echocardiogram.
4. **Principles of therapy:**
  - a. **Improve oxygenation:** Supplemental oxygen administration and optimization of oxygen-carrying capacity with blood transfusions as indicated
  - b. **Minimize pulmonary vasoconstriction:**
    - (1) Minimal handling of infant or noxious procedures. Sedation and occasionally paralysis of intubated neonates may be necessary.
    - (2) Avoid severe hyperventilation-associated hypocarbia ( $PCO_2 < 30$  mmHg), which can be associated with myocardial ischemia and decreased cerebral blood flow. Hyperventilation may result in barotrauma and predispose to chronic lung disease. Consider high-frequency ventilation.
  - c. **Maintenance of systemic blood pressure and perfusion:** Reversal of right-to-left shunt through volume expanders and/or inotropes
  - d. **Consider pulmonary vasodilator therapy:** see [Chapter 1](#)
    - (1) Inhaled nitric oxide (iNO): Reduces pulmonary vascular resistance (PVR). Typical starting dose is 20 parts per million (ppm), though research suggests lower doses in premature neonates (10 ppm) may be sufficient. Unlikely to have additional benefit at  $>40$  ppm. Complications include methemoglobinemia (reduce NO dose for methemoglobin  $>4\%$ ),  $NO_2$  poisoning (reduce NO dose for  $NO_2$  concentration  $>1$  to  $2$  ppm).
    - (2) Prostacyclin analog (e.g., epoprostenol): Pulmonary vasodilator, normally produced by lung when lung vessels are constricted
    - (3) Sildenafil: Cyclic cGMP-specific phosphodiesterase type 5 (PDE5) inhibitor; results in pulmonary vasodilation
  - e. **Consider extracorporeal membrane oxygenation (ECMO):** Reserved for cases of severe cardiovascular instability, oxygenation index (OI)  $>40$  for  $>3$  hour, or alveolar-arterial gradient ( $A-aO_2$ )  $\geq 610$  for 8 hours (see [Chapter 1](#) for OI and A-a gradient equations). Infants typically need to

be >2000 g and at gestation >34 weeks to be ECMO candidates. Obtain head ultrasound and consider EEG before initiating ECMO.

#### D. Transient Tachypnea of the Newborn

1. **Etiology:** Incomplete or delayed resorption of amniotic fluid from the lungs
  - a. Immaturity of respiratory epithelial  $\text{Na}^+$  transport
2. **Risk factors:** Birth by cesarean section, male sex, macrosomia, lower gestational age, maternal diabetes, maternal asthma, maternal smoking
3. **Diagnostic features:**
  - a. Symptoms present within first 6 hours of delivery and resolve within first postnatal week, usually within 72 hours.
  - b. Tachypnea: Greater than 60 breaths/min, often in the range of 80 to 100 breaths/min
  - c. Retractions, grunting, or nasal flaring may be present. Cyanosis and hypoxia are rare.
  - d. CXR consistent with retained fluid: Congestion, perihilar streaking, fluid in the interlobar fissure
  - e. Exclusion of other diagnoses: For example, pneumonia, aspiration, congenital malformations, subarachnoid hemorrhage, hypoxic-ischemic encephalopathy (HIE), pneumothorax, acidosis, RDS
4. **Management:**
  - a. NPO with gavage feedings or 10% dextrose-containing fluids via IV for persistent tachypnea
  - b. Supplemental oxygen and/or CPAP as indicated
  - c. No proven benefit of adjuncts, including diuretics or racemic epinephrine


#### E. Pneumothorax

1. Seen in 1% to 2% of normal newborns
2. Associated with use of high ventilatory pressures and underlying diseases such as RDS, meconium aspiration, and pneumonia
3. Consider monitoring in a neonatal intensive care unit (NICU).
4. If concern exists for tension pneumothorax, consider needle thoracostomy and/or chest tube placement (see [Chapter 4](#)).

## VII. APNEA AND BRADYCARDIA

### A. Apnea

1. **Definition:** Respiratory pause >20 seconds or a shorter pause associated with cyanosis, pallor, hypotonia, or bradycardia <100 bpm. May be central (no diaphragmatic activity), obstructive (upper airway obstruction), or mixed
2. **Etiology:** See [Fig. 18.4](#). Apnea of prematurity occurs in most infants born at <28 weeks' gestation, ~20% of infants born at 34 weeks' gestation, and <10% of infants born beyond 34 weeks' gestation. Usually resolves by 34 to 36 weeks postmenstrual age but may persist after term in infants born at <25 weeks' gestation.<sup>13</sup>

**FIGURE 18.4**

Causes of apnea in the newborn. *CNS*, Central nervous system; *PDA*, patent ductus arteriosus. (From Klaus MH, Fanaroff AA. *Care of the High-Risk Neonate*. 5th ed. WB Saunders; 2001:268.)

### 3. Management:

- Consider pathologic causes for apnea (e.g., meningitis, seizures).
- Pharmacotherapy with caffeine or other stimulants
- Continuous positive airway pressure or mechanical ventilation (see [Chapter 1](#)).

### B. Bradycardia Without Central Apnea

Etiologies include obstructive apnea, mechanical airway obstruction, gastroesophageal reflux, increased intracranial pressure, increased vagal tone (defecation, yawning, rectal stimulation, and placement of nasogastric [NG] tube), electrolyte abnormalities, heart block

## VIII. CARDIAC DISEASES

### A. Patent Ductus Arteriosus

- Definition:** Failure of ductus arteriosus to close in first 72 hours of life or reopening after functional closure. Typically results in left-to-right shunting of blood once PVR has decreased. If PVR remains high, blood may be shunted right to left, resulting in hypoxemia.
- Diagnosis:**
  - Examination: Systolic murmur may be continuous and best heard at the left upper sternal border or left infraclavicular area. Bounding peripheral pulses with widened pulse pressure if large shunt. Hyperactive precordium and palmar pulses may be present.
  - Chest radiograph: May show cardiomegaly and increased pulmonary vascular markings, depending on size of shunt
  - Echocardiogram
  - ECG: Normal to moderate left ventricular hypertrophy in small to moderate patent ductus arteriosus (PDA); biventricular hypertrophy in large PDA

### 3. Management:

- a. Indications for treatment, timing of intervention, and best management strategy remain controversial.<sup>14</sup>
- b. Current treatment options: ibuprofen, indomethacin, acetaminophen, watchful waiting
  - (1) Ibuprofen is as effective as indomethacin but fewer renal adverse effects and risk of necrotizing enterocolitis.<sup>14</sup>
  - (2) Complications
    - (a) Renal: Transient decrease in glomerular filtration rate and decreased urine output
    - (b) GI: Transient gastrointestinal bleeding (no increased incidence of necrotizing enterocolitis [NEC]). Spontaneous isolated intestinal perforations (SIP) are seen with indomethacin use. Rates are higher with concomitant hydrocortisone use.
    - (c) Heme: Prolonged bleeding time, and disturbed platelet function for 7 to 9 days independent of platelet count (no increased incidence of intracranial hemorrhage)
- c. Acetaminophen is emerging as a newer treatment modality with continued evolving research. It appears to be as similarly effective as oral ibuprofen without above effects on kidneys and platelets.<sup>14</sup>
- d. Surgical ligation of the duct
- e. Transcatheter closure of PDA

## B. Cyanotic Heart Disease (See Chapter 7)

## IX. HEMATOLOGIC DISEASES

### A. Unconjugated Hyperbilirubinemia in the Newborn<sup>15,16</sup>

#### 1. Overview:

- a. During first 3 to 4 days of life, total serum bilirubin (TSB) increases to  $6.5 \pm 2.5$  mg/dL.
- b. Maximum rate of bilirubin increase for normal infants with nonhemolytic hyperbilirubinemia: 5 mg/dL/24 hr or 0.2 mg/dL/hr
- c. Always consider clinical jaundice or TSB >5 mg/dL in first 24 hours as pathologic.
- d. Risk factors: Birth weight <2500 g, exclusive breastfeeding, prematurity, ABO incompatibility, cephalohematoma or significant bruising, predischarge total bilirubin in high-risk zone, observed jaundice in first 24 hours, infant of a diabetic mother, previous sibling requiring phototherapy, low albumin, infection, race

#### 2. Evaluation:

- a. Maternal prenatal testing: ABO and Rh (D) typing and serum screen for isoimmune antibodies
- b. Infant or cord blood: Blood and Rh typing (if maternal blood type is O or Rh negative, or prenatal blood typing was not performed). Consider hemoglobin, reticulocyte count, blood smear, glucose-6-phosphate dehydrogenase (G6PD) testing, direct Coombs test.


### 3. Management:

- a. Phototherapy: Ideally, intensive phototherapy produces a TSB decline of 1 to 2 mg/dL within 4 to 6 hours, with further subsequent decline. Guidelines:
  - (1) Preterm newborn (Table 18.9)
  - (2) Term newborn (Fig. 18.5)
- b. Intravenous immunoglobulin (IVIG): In isoimmune hemolytic disease, IVIG administration (0.5 to 1 g/kg over 2 hours) is recommended if TSB is rising despite intensive phototherapy or TSB is within 2 to 3 mg/dL of exchange transfusion level (see Chapter 15 for discussion of IVIG).

**TABLE 18.9**
**GUIDELINES FOR MANAGEMENT OF HYPERBILIRUBINEMIA IN PRETERM INFANTS AGED <1 WEEK**

Gestational Age (Weeks)	Phototherapy (mg/dL)	Consider Exchange Transfusion (mg/dL)
<28 0/7	5–6	11–14
28 0/7–29 6/7	6–8	12–14
30 0/7–31 6/7	8–10	13–16
32 0/7–33 6/7	10–12	15–18

Data from Maisels MJ, Watchko JF, Bhutani V. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. *J Perinatol.* 2012;32(9):660–664.




- Use total bilirubin. Do not subtract direct reacting or conjugated bilirubin.
- Risk factors: Isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin <3.0 g/dL (if measured)
- For well infants 35–37 6/7 wk, can adjust TSB levels for intervention around the medium risk line. It is an option to intervene at lower TSB levels for infants closer to 35 wk and at higher TSB levels for those closer to 37 6/7 wk.
- It is an option to provide conventional phototherapy in hospital or at home at TSB levels 2–3 mg/dL (35–50 μmol/L) below those shown, but home phototherapy should not be used in any infant with risk factors.

**FIGURE 18.5**

Guidelines for phototherapy in infants born at 35 weeks of gestation or more. *G6PD*, Glucose-6-phosphate dehydrogenase; *TSB*, total serum bilirubin.

- c. Neonatal double-volume exchange transfusion (see [Table 18.9](#) and [Fig. 18.6](#)):
- (1) Volume: Exchange volume is generally twice the infant's blood volume, generally 160 mL/kg for full-term infant, 200 mL/kg for preterm infant. Can consider single volume based on clinical stability
  - (2) Route: During exchange, blood is removed through umbilical arterial catheter (UAC) and an equal volume is infused through UVC. If UAC is unavailable, use a peripheral arterial line or single venous catheter.
  - (3) Procedure: Replaces up to 85% of infant's circulation. Exchange in 15-mL aliquots for full-term infants. Exchange at 2 to 3 mL/kg/min in premature/less stable infants to avoid hemolysis.
  - (4) Complications: Emboli, thromboses, hemodynamic instability, electrolyte disturbances (e.g. hypocalcemia), coagulopathy, infection, death

**NOTE:** CBC, reticulocyte count, peripheral smear, bilirubin,  $\text{Ca}^{2+}$ , glucose, total protein, infant blood type, Coombs test, and newborn screen should be performed on a preexchange sample of blood; they are of no diagnostic value with postexchange blood. **If indicated, save preexchange blood for serologic or genetic studies.**



- The dashed lines for the first 24 hours indicate uncertainty due to a wide range of clinical circumstances and a range of responses to phototherapy.
- Immediate exchange transfusion is recommended if infant shows signs of acute bilirubin encephalopathy (hypertonia, arching, retrocollis, opisthotonos, fever, high-pitched cry) or if TBS is  $\geq 5$  mg/dL ( $85 \mu\text{mol/L}$ ) above these lines.
- Risk factors: Isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis.
- Measure serum albumin and calculate B/A ratio.
- Use total bilirubin. Do not subtract direct reacting or conjugated bilirubin.
- If infant is well and 35–37 6/7 wk (median risk), can individualize TSB levels for exchange based on actual gestational age.

**FIGURE 18.6**

Guidelines for exchange transfusion in infants born at 35 weeks of gestation or more. *B/A*, Bilirubin/albumin; *G6PD*, glucose-6-phosphate dehydrogenase; *TSB*, total serum bilirubin.

## B. Conjugated Hyperbilirubinemia (See Chapter 12)

1. **Definition:** Direct bilirubin >2.0 mg/dL and >10% of TSB
2. **Etiology:** Biliary obstruction/atresia, choledochal cyst, hyperalimentation,  $\alpha_1$ -antitrypsin deficiency, hepatitis, sepsis, infections (especially urinary tract infections), hypothyroidism, inborn errors of metabolism, cystic fibrosis, red blood cell abnormalities
3. **Management:** Ursodiol for infants on full feeds; consider supplementation with fat-soluble vitamins (A, D, E, K); otherwise depends on etiology. Phototherapy is not contraindicated but poses the risk for “bronze baby” syndrome or transient dark, gray-brown discoloration of the skin, serum, and urine. This transient effect should be weighed against risk of continued rise and need for exchange transfusion.

## C. Polycythemia

1. **Definition:** Venous hematocrit >65% confirmed on two consecutive samples. May be falsely elevated when obtained by heel stick or falsely lower when obtained by arterial stick<sup>17</sup>
2. **Etiologies:** Twin-twin transfusion, maternal-fetal transfusion, intrauterine hypoxia, maternal diabetes, delayed cord clamping, neonatal thyrotoxicosis, congenital adrenal hyperplasia, trisomies, Beckwith-Wiedemann syndrome
3. **Clinical findings:** Plethora, respiratory distress, tachypnea, hypoglycemia, irritability, lethargy, seizures, apnea, jitteriness, poor feeding, thrombocytopenia, hyperbilirubinemia, cardiac failure
4. **Complications:** Hyperviscosity predisposes to venous thrombosis and CNS injury. Hypoglycemia may result from increased erythrocyte utilization of glucose.
5. **Management:** Partial-volume exchange transfusion for symptomatic infants, with isovolemic replacement (80 mL/kg at term, or 100 mL/kg for preterm) of blood with isotonic fluid. Blood is exchanged in 10- to 20-mL increments with goal to reduce hematocrit to <55%.

## X. GASTROINTESTINAL DISEASES

### A. Necrotizing Enterocolitis

1. **Definition:** Serious intestinal inflammation and injury thought to be multifactorial, including bowel ischemia, immaturity, and infection. Occurs principally in infants who have been fed
2. **Risk factors:** Prematurity, RDS, hypoxic ischemic encephalopathy (HIE), polycythemia–hyperviscosity syndrome, umbilical vessel catheterization, exchange transfusion, bacterial and viral pathogens, enteral feeds, PDA, congestive heart failure, cyanotic heart disease, intrauterine cocaine exposure
3. **Clinical findings:** See [eTable 18.1](#).
  - a. Systemic: Temperature instability, apnea, bradycardia, metabolic acidosis, hypotension, disseminated intravascular coagulopathy

**eTABLE 18.1****MODIFIED BELL'S STAGING SYSTEM FOR NECROTIZING ENTEROCOLITIS**

Stage	Findings
IA (NEC suspected)	Temperature instability, apnea, bradycardia, lethargy, mild abdominal distention, gastric residuals, poor feeding, bilious emesis, occult blood in stool, x-ray findings: normal to mild ileus
IB (NEC suspected)	As for stage IA, but with gross blood in stool
IIA (definite NEC, mildly ill)	As for stage IB with pneumatosis intestinalis, absent bowel sounds $\pm$ abdominal tenderness
IIB (definite NEC, moderately ill)	As for stage IIA with metabolic acidosis, mild thrombocytopenia; definite abdominal tenderness; $\pm$ abdominal cellulitis or right lower quadrant mass; $\pm$ ascites or portal venous gas
IIIA (advanced NEC, severely ill infant, bowel intact)	As for stage IIB, but with hypotension, bradycardia, apnea, metabolic and respiratory acidosis, neutropenia, disseminated intravascular coagulation, peritonitis, abdominal distention and tenderness, abdominal erythema; definite ascites
IIIB (severely ill, perforated bowel)	As for stage IIIA with pneumoperitoneum

*NEC*, Necrotizing enterocolitis.

Data from Cunningham FG, Leveno KJ, et al. Prenatal diagnosis. In: *Williams Obstetrics*. 25th ed. McGraw-Hill Education; 2018.

- b. Intestinal: Blood in stool, absent bowel sounds, and/or abdominal tenderness or mass. Elevated pregavage residuals in the absence of other clinical symptoms rarely raise a suspicion of NEC.
  - c. Radiologic: Ileus, intestinal pneumatosis, portal vein gas, ascites, pneumoperitoneum (see [Chapter 26](#))
4. **Management:** Nothing by mouth, NG tube decompression, maintain adequate hydration and perfusion, broad spectrum antibiotics for 7 to 10 days based on hospital antibiogram, surgical consultation. Surgery is performed for signs of perforation or necrotic bowel.
  5. **Minimizing risk of NEC:**
    - a. The exclusive use of human milk, including donor breastmilk, has been shown to decrease the risk of NEC and associated mortality.<sup>18</sup>
    - b. Several studies link the use of probiotics and a decreased risk of NEC.<sup>19</sup> However, variations among formulations of probiotics, dosing, and lack of long-term studies on outcome have prevented the standard use of probiotics in the NICU.<sup>20</sup>
    - c. There have been additional studies on supplements including L-arginine, glutamine, and lactoferrin,<sup>21</sup> but data remain insufficient to support a practice recommendation.<sup>22</sup>

## B. Bilious Emesis

See [eTable 18.2](#) and [Chapter 12](#).

1. **Etiologies:**
  - a. **Proximal:** Duodenal atresia, annular pancreas, malrotation with or without volvulus, jejunal obstruction/atresia; generally abdominal distention not prominent
  - b. **Distal:** Ileal atresia, meconium ileus, colonic atresia, meconium plus, hypoplastic left colon syndrome, Hirschsprung disease; generally with abdominal distention
  - c. **Functional (i.e., poor motility):** NEC, electrolyte abnormalities, sepsis
2. **Workup:** Abdominal x-ray, upper gastrointestinal series, contrast enema, sweat test, mucosal rectal biopsy

**NOTE:** Must eliminate malrotation as an etiology because volvulus is a surgical emergency

## C. Abdominal Wall Defects ([Table 18.10](#))

## D. Gastroesophageal Reflux Disease (See [Chapter 12](#))

# XI. NEUROLOGIC DISEASES

## A. Neonatal Hypoxic-Ischemic Encephalopathy

1. **Initial management:** Passive cooling, detailed Sarnat exam<sup>23</sup>
2. **Therapeutic hypothermia (TH):** Infants with evidence of hypoxic-ischemic encephalopathy (HIE) shortly after birth who are at gestation >35 weeks should be considered for therapeutic hypothermia. TH protocol should be initiated within 6 hours of delivery.

**eTABLE 18.2****CONSIDERATIONS IN BILIOUS EMESIS**

	<b>Proximal Intestinal Obstruction</b>	<b>Distal Intestinal Obstruction</b>
Differential diagnosis	Duodenal atresia Annular pancreas Malrotation with or without volvulus Jejunal obstruction/atresia	Ileal atresia Meconium ileus Colonic atresia Meconium plug—hypoplastic left colon syndrome Hirschsprung disease
Physical exam	Abdominal distention not prominent	Abdominal distention
Diagnosis	Abdominal x-ray: “Double bubble” Upper gastrointestinal series	Abdominal x-ray: Dilated loops of bowel Contrast enema Sweat test Mucosal rectal biopsy

Modified data from Shields TM, Lightdale JR. Vomiting in children. *Pediatr Rev.* 2018;39:342–358.

3. **Criteria for hypothermia include one or more of the following:**
  - a. Cord gas or blood gas in the first hour of life with a pH <7.0 or base deficit >16
  - b. For newborns with a pH 7.01 to 7.15 or base deficit 10 to 15.9, additional criteria should be met (e.g., significant perinatal event).
    - (1) 10-minute APGAR  $\leq$ 5
      - (a) Evidence of moderate to severe encephalopathy
      - (2) Need for assisted ventilation at birth for at least 10 minutes
4. **Severity and outcome of HIE in full-term neonate:** [Table 18.11](#).

## B. Intraventricular Hemorrhage

1. **Definition:** IVH usually arises in the germinal matrix and periventricular regions of the brain.
2. **Incidence<sup>24,25</sup>:**
  - a. 30% to 40% of infants <1500 g; 50% to 60% of infants <1000 g
  - b. Highest incidence within first 72 hours of life: 50% within 24 hours, 90% within 96 hours

**TABLE 18.10**

### DIFFERENCES BETWEEN OMPHALOCELE AND GASTROSCHISIS

	Omphalocele	Gastroschisis
Position	Central abdominal	Right paraumbilical
Hernia sac	Present	Absent
Umbilical ring	Absent	Present
Umbilical cord insertion	At the vertex of the sac	Normal
Herniation of other viscera	Common	Rare
Extraintestinal anomalies	Frequent	Rare
Intestinal infarction, atresia	Less frequent	More frequent

**TABLE 18.11**

### SEVERITY AND OUTCOME OF HYPOXIC-ISCHEMIC ENCEPHALOPATHY IN FULL-TERM NEONATE

	Mild	Moderate	Severe
Level of consciousness	Increased irritability, hyperalert	Lethargic	Stupor or coma
Seizures	Rare	Common	Uncommon
Primitive reflexes	Exaggerated	Suppressed	Absent
Brain stem dysfunction	Rare	Rare	Common
Elevated intracranial pressure	Rare	Rare	Variable
Duration	<24 hr	>24 hr (variable)	>5 days
Poor outcome (%) <sup>a</sup>	0	20–40	100

<sup>a</sup>Poor outcome is defined by presence of intellectual disability, cerebral palsy, or seizures.

Data from MacDonald M, Mullett M. Severity and outcome of hypoxic-ischemic encephalopathy in full term neonate. In: *Avery's Neonatology*. 6th ed. Lippincott Williams & Wilkins; 2005.

### 3. **Diagnosis and classification**<sup>25</sup>:

- a. Ultrasonography; grade is based on maximum amount of hemorrhage seen by age 2 weeks:
  - (1) Grade I: Hemorrhage in germinal matrix only
  - (2) Grade II: IVH without ventricular dilation
  - (3) Grade III: IVH with ventricular dilation
  - (4) Grade IV: Periventricular hemorrhagic infarct with or without IVH

**NOTE:** Many institutions use descriptive data (as opposed to the grading system) to denote severity of IVH.

4. **Screening:** Indicated in infants <32 weeks' gestational age or birth weight <1500 g within 72 hours of birth; repeat in 1 to 2 weeks
5. **Outcome:** Increased risk for neurodevelopmental (ND) disabilities and posthemorrhagic hydrocephalus follows grade III–IV IVH. More subtle learning/ND disabilities may occur with grade II IVH.

### C. **Periventricular White Matter Injury**<sup>24</sup>

1. **Definition and ultrasound findings:** Ischemic necrosis of periventricular white matter, characterized by CNS depression within first week of life and later findings of cysts on ultrasound with or without ventricular enlargement (caused by cerebral atrophy) or noncystic white matter injury visualized by MRI
2. **Incidence:** More common in preterm infants but also occurs in term infants
3. **Etiology:** Primarily ischemia-reperfusion injury, infectious, hypoxia, acidosis, acute hypotension, low cerebral blood flow, hypoglycemia
4. **Outcome:** Commonly associated with cerebral palsy with or without sensory and cognitive deficits

### D. **Neonatal Seizures (See Chapter 20)**

### E. **Neonatal Abstinence Syndrome**<sup>26</sup>

1. Assess in utero drug exposure (IUDE) to maternal substance use and medications; consider potential polypharmacy.
2. Onset of symptoms usually occurs within first 24 to 72 hours from birth (methadone may delay symptoms until 96 hours or later). Symptoms may last weeks to months. [Box 18.1](#) shows signs and symptoms of opioid withdrawal.
3. Treatment:
  - a. Nonpharmacologic: Includes rooming in, breastfeeding, skin-to-skin, swaddling, and environmental controls such as decreased disruptions
  - b. Pharmacologic: Target to known IUDE

### F. **Peripheral Nerve Injuries**

1. **Etiology:** Result from lateral traction on shoulder (vertex deliveries) or head (breech deliveries)
2. **Clinical features** ([Table 18.12](#))
3. **Management:** Evaluate for associated trauma (clavicular and humeral fractures, shoulder dislocation, facial nerve injury, cord injuries). Full recovery is seen in 85% to 95% of cases in first year of life.

**BOX 18.1****SIGNS AND SYMPTOMS OF OPIOID WITHDRAWAL**

W	Wakefulness
I	Irritability, insomnia
T	Tremors, temperature variation, tachypnea, twitching (jitteriness)
H	Hyperactivity, high-pitched cry, hiccups, hyperreflexia, hypertonia
D	Diarrhea (explosive), diaphoresis, disorganized suck
R	Rub marks, respiratory distress, rhinorrhea, regurgitation
A	Apnea, autonomic dysfunction
W	Weight loss
A	Alkalosis (respiratory)
L	Lacrimation (photophobia), lethargy
S	Seizures, sneezing, stuffy nose, sweating, sucking (nonproductive)

**TABLE 18.12****BRACHIAL PLEXUS INJURIES**

Plexus Injury	Spinal Level Involved	Clinical Features
Erb-Duchenne palsy (90% of cases)	C5–C6 Occasionally involves C4	Adduction and internal rotation of arm. Forearm is pronated; wrist is flexed. Diaphragm paralysis may occur if C4 is involved.
Total palsy (8%–9% of cases)	C5–T1 Occasionally involves C4	Upper arm, lower arm, and hand involved. Horner syndrome (ptosis, anhidrosis, and miosis) exists if T1 is involved.
Klumpke paralysis (<2% of cases)	C7–T1	Hand flaccid with little control. Horner syndrome if T1 is involved.

**XII. UROLOGIC DISORDERS****A. Lower Urinary Tract Obstruction**

- Definition:** Rare birth defects caused by partial or complete blockage of the urethra. Common causes include posterior urethral valves (PUV), urethral atresia, and triad syndrome (constricted narrowing in mid-portion of urethra). More common in males
- Diagnosis and evaluation:** Fetal anatomy ultrasound (18 to 24 weeks) with visualization of markedly distended bladder, often with a thickened wall (2 mm).<sup>27,28</sup> A “keyhole” sign representing dilation of the PUV proximal to the obstruction may be seen but is not specific.
  - Other tests include fetal MRI, echocardiogram, vesicocentesis, and karyotype to rule out coexisting abnormalities and determine gender.

3. **Clinical findings:** Pulmonary hypoplasia, renal dysplasia, oligohydramnios, ureterectasis, caliectasis, hydronephrosis, clubfeet, Potter facies
4. **Management:** Consultation with pediatric urology and nephrology to review prenatal and postnatal options. Prenatally, elective termination or expectant management should be offered for fetuses with poor prognostic profiles. Postnatal interventions include dialysis, vesicostomy, and transplantation.

### B. Bladder Exstrophy-Epispadias-Cloacal Exstrophy Complex

1. **Definition:** Anomalies involving urinary tract eversion; with genitourinary, musculoskeletal, and occasionally gastrointestinal malformations. See [eTable 18.3](#) for comparison.
2. **Diagnosis:** Fetal anatomy ultrasound showing abnormality of bladder filling, low-set umbilical cord, abdominal mass that increases in size throughout pregnancy, separation of pubic bones and small genitals
3. **Management:** Reconstructive surgery that aims to establish bladder continence, preserve renal function, repair epispadias and genitalia, and close the pelvic bones

## XIII. RETINOPATHY OF PREMATURETY<sup>29</sup>

### A. Definition

Interruption of normal progression of retinal vascularization

### B. Etiology

Exposure of the immature retina to high oxygen concentrations can result in vasoconstriction and obliteration of the retinal capillary network, followed by abnormal vasoproliferation. Risk is correlated to degree of prematurity.

### C. Diagnosis

Dilated funduscopic examination should be performed in the following patients:

1. All infants born  $\leq 30$  weeks' gestation or with birth weight  $< 1500$  g
2. Infants born  $> 30$  weeks' gestation with unstable clinical course, including those requiring cardiorespiratory support

### D. Timing of Screening<sup>30</sup>


1. All infants born  $\leq 27$  weeks' gestation, initial retinopathy of prematurity (ROP) screening examination performed at 31 weeks' postmenstrual age
2. All infants born  $\geq 28$  weeks' gestation, initial ROP screening examination performed at 4 weeks' chronologic age
3. Infants born before 25 weeks' gestation, consider earlier screening at 6 weeks' chronologic age (even if before 31 weeks' postmenstrual age) based on the severity of comorbidities to enable earlier detection and treatment of aggressive posterior ROP (a severe form of rapidly progressive ROP).

### E. Classification

1. **Stage** of ROP ([Fig. 18.7](#))

**eTABLE 18.3****COMPARISON OF BLADDER EXSTROPHY-EPISPADIAS-CLOACAL EXSTROPHY COMPLEX DISORDERS**


	<b>Epispadias</b>	<b>Bladder Exstrophy</b>	<b>Cloacal Exstrophy</b>
Severity	Mild, least severe	Intermediate	Most severe
Definition/ symptoms	Defect/opening in the urethra only Males: Urethra is short and split with meatus present on dorsum of penis. Females: Urethra develops too anteriorly with opening located between split clitoris and labia minora.	Defect in the urethra and the bladder. The posterior vesical wall everts through an opening in abdominal wall.	Defect in the urethra, bladder and rectum. Bladder divided in two halves with penis split in two halves in males, or clitoris divided in two halves in females
Incidence	Males: 1 in 112,000 births Females: 1 in 400,00 births	1 in 10,000 to 1 in 50,000 births. Males affected 2–3 times more than females	1 in 400,000 births
Associations		Vesicoureteral reflux, urinary incontinence, widening of pubic bones, displacement of umbilicus	Omphalocele, imperforate anus, spinal abnormalities (OEIS)



**FIGURE 18.7**

Retinopathy of prematurity: Stages and plus disease. (From Hellström A, Smith L EH, Dammann O. Retinopathy of prematurity. *Lancet*. 2013;382[9902]:1445–1457. Copyright 2013, Elsevier.)

- a. Stage 1: Demarcation line separates avascular from vascularized retina.
- b. Stage 2: Ridge forms along demarcation line.
- c. Stage 3: Extraretinal, fibrovascular proliferation tissue forms on ridge.
- d. Stage 4: Partial retinal detachment
- e. Stage 5: Total retinal detachment



**FIGURE 18.8**

Zones of the retina. (From American Academy of Pediatrics. Screening examination of premature infants for retinopathy of prematurity, AAP policy statement. *Pediatrics*. 2018 [6];142:1–9.)

**NOTE:** Stage 0 is equivalent to no evidence of ROP on fundoscopic exam.

2. **Zone of retina** (Fig. 18.8)

3. **Plus disease:** Abnormal dilation and tortuosity of posterior retinal blood vessels in two or more quadrants of retina; may be present at any stage

4. **Number of clock hours or 30-degree sectors involved**

#### F. Management<sup>29-30</sup>

1. **Type 1 ROP:** Peripheral retinal ablation should be considered. Anti-VEGF treatment may be as effective for Zone I disease. Type 1 ROP classified as:

- Zone I: Any stage ROP with plus disease
- Zone I: Stage 3 ROP without plus disease
- Zone II: Stage 2 or 3 ROP with plus disease

2. **Type 2 ROP:** Serial examinations rather than retinal ablation should be considered. Type 2 ROP classified as:

- Zone I: Stage 1 or 2 ROP without plus disease
- Zone II: Stage 3 ROP without plus disease

3. **Follow-up (eTable 18.4):** Serial fundoscopic exams through at least term-corrected age and based on degree of ROP disease present

## XIV. COMMONLY USED MEDICATIONS IN THE NEONATAL INTENSIVE CARE UNIT

See Table 18.13. For neonatal specific drug dosing, refer to Chapter 30, Formulary.

**eTABLE 18.4****SUGGESTED SCHEDULE FOR FOLLOW-UP OPHTHALMOLOGIC EXAMINATION IN RETINOPATHY OF PREMATURITY**

≤1 Week	1–2 Weeks	2 Weeks	2–3 Weeks
Zone I: Stage 1 or 2 ROP Zone II: Stage 3 ROP	Zone II: Stage 2 ROP	Zone II: Stage 1 ROP	Zone III: Stage 1 or 2 ROP
Zone I: Immature vascularization, no ROP	Posterior zone II: Immature vascularization	Zone II: No ROP, immature vascularization	Zone III: Regressing ROP
Immature retina extends into posterior zone II near boundary of zone I	Zone I: Unequivocally regressing ROP	Zone II: Unequivocally regressing ROP	
Suspected presence of aggressive posterior ROP			

NOTE: The presence of plus disease in zone I or II indicates that peripheral ablation rather than observation is appropriate. ROP, Retinopathy of prematurity.

From American Academy of Pediatrics. Screening examination of premature infants for retinopathy of prematurity, AAP policy statement. *Pediatrics*. 2018;142(6):1–9.

**TABLE 18.13****DOSING OF COMMONLY USED ANTIMICROBIALS IN THE NEONATAL INTENSIVE CARE UNIT, BASED ON POSTMENSTRUAL AND POSTNATAL AGE**

Drug	Dosing (IV)
Acyclovir	HSV infection: 20 mg/kg/dose
Ampicillin	Typical dosing: 25–50 mg/kg/dose; GBS meningitis: ≤7 postnatal days: 300 mg/kg/day divided Q8 hr ≥8 postnatal days: 300 mg/kg/day divided Q6 hr
Cefotaxime	Sepsis/meningitis: 50 mg/kg/dose Gonococcal infections: 25 mg/kg/dose
Ceftazidime	Sepsis/meningitis: 30–50 mg/kg/dose Consider use of ceftazidime for neonatal sepsis in the absence of cefotaxime due to drug shortages, and in whom ceftriaxone is contraindicated.
Fluconazole <sup>a</sup>	Invasive candidiasis: Loading 12–25 mg/kg/dose; maintenance 6–12 mg/kg/dose
Gentamicin	See chart below. See Formulary for recommendations for therapeutic monitoring.
Metronidazole	Loading dose: 15 mg/kg/dose; maintenance dose: see chart below
Oxacillin	25–50 mg/kg/dose; use higher dose for meningitis
Piperacillin/tazobactam	100 mg/kg/dose
Vancomycin	Bacteremia: 10 mg/kg/dose; meningitis: 15 mg/kg/dose See Formulary for recommendations for therapeutic monitoring.

Dosing Interval Chart: Ampicillin, Oxacillin			Dosing Interval Chart: Vancomycin			Dosing Interval Chart: Metronidazole		
PMA (Weeks)	Postnatal (Days)	Interval (Hours)	PMA (Weeks)	Postnatal (Days)	Interval (Hours)	PMA (Weeks)	Maintenance Dose (mg/kg)	Interval (Hours)
≤29 <sup>a</sup>	0–28	12	≤29	0–14	18	24–25	7.5	24
	>28	8		>14	12			
30–36	0–14	12	30–36	0–14	12	26–27	10	24
	>14	8		>14	8			
37–44	0–7	12	37–44	0–7	12	28–33	7.5	12
	>7	8		>7	8			
≥45	All	6	≥45	All	6	34–40	7.5	8
						>40	7.5	6

Dosing Interval Chart: Gentamicin				Dosing Interval Chart: Fluconazole			Dosing Interval Chart: Acyclovir		
PMA (Weeks)	Postnatal (Days)	Dose (mg/kg)	Interval (Hours)	Gest. Age (Weeks)	Postnatal (Days)	Interval (Hours)	PMA (Weeks)	Postnatal (Days)	Interval (Hours)
≤29	0–7	5	48	≤29	0–14	48		All	
	8–28	4	36		>14	24			
	≥29	4	24						
30–34	0–7	4.5	36	≥30	0–7	48	<30		8–12
	≥8	4	24	>7	24	≥30	All	8	
≥35	All	4	24 <sup>e</sup>						

Continued

**DOSING OF COMMONLY USED ANTIMICROBIALS IN THE NEONATAL INTENSIVE CARE UNIT, BASED ON POSTMENSTRUAL AND POSTNATAL AGE—CONT'D****Dosing Interval Chart: Piperacillin/Tazobactam, Ceftazidime**

PMA (weeks)	Postnatal (Days)	Interval (Hr)
≤29	0–28	12
	>28	8
30–36	0–14	12
	>14	8
37–44	0–7	12
	>7	8
≥45	All	8

**Dosing Interval Chart: Cefotaxime**

GA (Weeks)	Sepsis		Meningitis <sup>b,c</sup>	
	Postnatal (Days)	Interval (Hr)	Postnatal (Days)	Interval (Hr)
All weeks	<7	12	0–7	8–12
<32	≥7	8	>7	6–8
≥32	≥7	6		

<sup>a</sup>Thrush = 6 mg/kg/dose on day 1, then 3 mg/kg/dose orally (PO) Q24 hr, regardless of gestational or postnatal age.

<sup>b</sup>Consider smaller doses and longer intervals for very low–birth-weight neonates (less than 2 kg).

<sup>c</sup>Usual dose same for bone and joint, genitourinary, intraabdominal, lower respiratory tract, or skin and skin structure infections.

<sup>d</sup>Use every 36 hr dosing for patients undergoing therapeutic hypothermia.

See Online NeoFax: <http://neofax.micromedexsolutions.com/neofax/neofax.php?strTitle=Neofax&area=1&subarea=0>

GBS, Group B *Streptococcus*; GA, gestational age; GC, gonococcus; IV, intravenous; PDA, patent ductus arteriosus; PMA, postmenstrual age.

**XV. WEB RESOURCES**

- Extremely Preterm Birth Outcomes Tool: <https://www.nichd.nih.gov/research/supported/EPBO/use>
- Premature growth chart and calculator: <http://peditools.org/fenton2013>
- Bilitool (for gestational age (GA) >35 weeks): <https://bilitool.org>
- Premie BiliRecs (GA 27–34 weeks): <https://pbr.stanfordchildrens.org>
- NeoFax: <https://neofax.micromedexsolutions.com/neofax>
- Neonatal sepsis calculator: <https://neonatalesepsiscalculator.kaiserpermanente.org/>
- 8th edition, Neonatal Resuscitation Program (NRP) algorithm: [https://nrplearningplatform.com/instructor-toolkit/assets/Instructor\\_ToolKit/RESOURCES/DocumentsAndForms/resources/NRP%208th-Ed%20ITK%20Algorithm%20w%20logos.pdf](https://nrplearningplatform.com/instructor-toolkit/assets/Instructor_ToolKit/RESOURCES/DocumentsAndForms/resources/NRP%208th-Ed%20ITK%20Algorithm%20w%20logos.pdf)

**REFERENCES**

A complete list of references can be found online.

## XVI. PRENATAL ASSESSMENT OF FETAL HEALTH

### A. Fetal Anomaly Screening

#### 1. Fetal screening:

- Chorionic villus sampling (CVS): Segment of placenta obtained at 8 to 11 weeks' gestation. Detects chromosomal abnormalities and metabolic disorders; however, it cannot detect neural tube defects or measure  $\alpha$  fetoprotein (AFP). Complications include pregnancy loss (0.7% to 2%), maternal infection, increased risk for feto-maternal hemorrhage, and fetal limb and jaw malformations.
- Amniocentesis: 20 to 30 mL of amniotic fluid is withdrawn under ultrasound guidance after 16 to 18 weeks' gestation. Detects chromosomal abnormalities, metabolic disorders, and neural tube defects. Complications include pregnancy loss (0.06% to 1.0%), leakage of amniotic fluid (1.7%), chorioamnionitis, vertical transmission to infant in mothers with chronic viral infections, and fetal scarring or dimpling of the skin.
- Cell free DNA: A noninvasive prenatal screening test available for common trisomies and fetal sex determination. However, there are still limitations to this testing, and further diagnostic testing is typically recommended for positive results.<sup>31</sup>

2. **Anatomy ultrasound:** Performed at 18 to 20 weeks' gestation

3. **Maternal AFP:** (eBox 18.2)

### B. Fetal Health

#### 1. Amniotic fluid volume estimation and amniotic fluid index (AFI):

(eBox 18.3). AFI is calculated using ultrasound by adding together width of amniotic fluid pockets in four quadrants.

2. **Biophysical profile test:** (eTable 18.5)

#### eBOX 18.2

##### MATERNAL $\alpha$ -FETOPROTEIN ASSOCIATIONS

Elevated (>2.5 multiples of the median)	Low (<0.75 multiples of the median)
Incorrect gestational dating	Underestimation of gestational age
Neural tube defects	Intrauterine growth retardation
Anencephaly	Trisomy 13
Multiple pregnancy	Trisomy 18
Turner syndrome	Trisomy 21
Omphalocele	
Cystic hygroma	
Epidermolysis bullosa	
Renal agenesis	

Data from Cunningham FG, Leveno KJ, et al. Prenatal diagnosis. In: *Williams Obstetrics*. 25th ed. McGraw-Hill Education; 2018.

## eBOX 18.3

## AMNIOTIC FLUID VOLUME ESTIMATION AND AMNIOTIC FLUID INDEX

## Oligohydramnios

(&lt;500 mL)/(AFI &lt;5)

- Renal and urologic anomalies:
- Potter syndrome
- Lung hypoplasia
- Limb deformities
- Premature rupture of membranes
- Placental insufficiency

## Polyhydramnios (&gt;2 L)/(AFI &gt;25)

- GI anomalies: Gastroschisis, duodenal atresia, tracheoesophageal fistula, diaphragmatic hernia, esophageal atresia ± tracheoesophageal fistula
- CNS anomalies: those associated with impaired swallowing (anencephaly, holoprosencephaly), neuromuscular disorders such as myotonic dystrophy, spinomuscular atrophy
- Chromosomal trisomies
- Maternal diabetes
- Cystic adenomatoid malformation of the lung

AFI, Amniotic fluid index.

Data from Cunningham FG, Leveno KJ, et al. Amniotic fluid. In: *Williams Obstetrics*. 25th ed. McGraw-Hill Education; 2018.

3. Intrapartum fetal heart rate (FHR) monitoring:
  - a. **Normal baseline FHR:** 120 to 160 beats/min (bpm). Mild bradycardia is 100 to 120 bpm. Severe bradycardia is <90 bpm.
  - b. **Normal beat-to-beat variability:** Deviation from baseline of >6 bpm. Absence of variability is <2 bpm from baseline and is a sign of potential fetal distress, particularly when combined with variable or late decelerations.
  - c. **Accelerations:** Associated with fetal movements, are benign, and indicate fetal well-being
  - d. **Decelerations:**
    - (1) Early decelerations: Begin with onset of contractions. Heart rate reaches nadir at peak of contraction and returns to baseline as contraction ends. Early decelerations occur secondary to changes in vagal tone after brief hypoxic episodes or head compression and are benign.
    - (2) Variable decelerations: Represent umbilical cord compression and have no uniform temporal relationship to the onset of a contraction. Variable decelerations are considered severe when heart rate drops to <60 bpm for about 60 seconds, with a slow recovery to baseline.
    - (3) Late decelerations: Occur after peak of contraction, persist after contraction stops, and show a slow return to baseline. Late decelerations result from uteroplacental insufficiency and indicate fetal distress.

eTABLE 18.5

## THE BIOPHYSICAL PROFILE

Biophysical Variable	Normal (Score = 2)	Abnormal (Score = 0)
Fetal breathing movements	1 or more episodes of $\geq 20$ sec within 30 min	Absent or no episode of $\geq 20$ sec within 30 min
Gross body movements	2 or more discrete body/limb movements within 30 min (episodes of active continuous movement considered as a single movement)	$< 2$ episodes of body/limb movements within 30 min
Fetal tone	1 or more episodes of active extension with return to flexion of fetal limb(s) or trunk (opening and closing of hand considered normal tone)	Slow extension with return to partial flexion, movement of limb in full extension, absent fetal movement, or partially open fetal hand
Reactive fetal heart rate	2 or more episodes of acceleration of $\geq 5$ bpm and of $> 15$ sec associated with fetal movement within 20 min	1 or more episodes of acceleration of fetal heart rate or acceleration of $< 15$ bpm within 20 min
Qualitative amniotic fluid volume	1 or more pockets of fluid measuring $\geq 2$ cm in vertical axis	Either no pockets or largest pocket $< 2$ cm in vertical axis

bpm, Beats per minute.

Modified from Gearhart et al. Biophysical profile, ultrasound. Emedicine. Published 2005. <https://www.emedicine.com>

### C. Estimation of Gestational Age

1. **Last menstrual period (LMP):** Naegele rule gives most accurate determination of gestational age

$$\text{Estimation due date} = (\text{LMP} - 3 \text{ months}) + 7 \text{ days}$$

2. **Ultrasound:** Crown-rump length obtained between 6 and 12 weeks' gestation predicts gestational age  $\pm 3$  to 4 days. After 12 weeks, the biparietal diameter is accurate within 10 days; beyond 26 weeks, accuracy diminishes to  $\pm 3$  weeks.
3. **Postmenstrual age:** Gestational age + chronologic age in weeks. Used in perinatal period during hospitalization and until 2 years of age.
4. **Expected birth weight by gestational age (see Table 18.1)**

## REFERENCES

1. Aziz K, Lee H, Escobedo M, et al. Part 5: neonatal resuscitation 2020 American heart association Guidelines for Cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation*. 2021;147:S161–S190.
2. Delayed umbilical cord clamping after birth. *Obstetr Gynecol*. 2020;136(6):1238–1239.
3. Moore ER, Anderson GC, Bergman N, et al. Early skin-to-skin contact for mothers and their healthy newborn infants. *Cochrane Database Syst Rev*. 2012;5:CD003519. <https://doi.org/10.1102/14651858.CD003519.pub3>
4. Bosschaart N, Kok J, Newsum A, et al. Limitations and opportunities of transcutaneous bilirubin measurements. *Pediatrics*. 2012;129:689–694.
5. Laing I. General care. In: MacDonald M, Mullett M, Seshia M, eds. *Avery's Neonatology*. 6th ed. Lippincott Williams and Wilkins; 2005.
6. Benitz WE, AAP Committee on Fetus and Newborn. Hospital stay for healthy term newborn infants. *Pediatrics*. 2015;135(5):948–953.
7. Apgar V. A proposal for a new method of evaluation of the newborn infant. *Anesth Analg*. 1953;32:260–267.
8. Adamkin D. Committee on the Fetus and Newborn. Postnatal glucose homeostasis in late-preterm and term infants. *Pediatrics*. 2011;127:575–579.
9. McCarthy EK, Dempsey EM, Kiely ME. Iron supplementation in preterm and low-birth-weight infants: a systematic review of intervention studies. *Nutr Rev*. 2019;77(12):865–877.
10. Munns CF, Shaw N, Kiely M, et al. Global Consensus recommendations on prevention and management of nutritional Rickets. *J Clin Endocrinol Metab*. 2016;101(2):394–415. <https://doi.org/10.1210/jc.2015-2175>.
11. Cummings JJ, Polin RA, AAP Committee on Fetus and Newborn. Oxygen targeting in extremely low birth weight infants. *Pediatrics*. 2016;138(2); e20161576.
12. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev*. 2017;3:CD004454.
13. Erickson G, Dobson NR, Hunt CE. Immature control of breathing and apnea of prematurity: the known and unknown. *J Perinatol*. 2021;41:2111–2123.
14. Mitra S, Florez ID, Tamayo ME, et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. *JAMA*. 2018;319(12):1221–1238. <https://doi.org/10.1001/jama.2018.1896>.
15. American Academy of Pediatrics: Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics*. 2004;114(1):297–316. *Erratum in Pediatrics*. 2004;114(4):1138.
16. Wolf MF, Childers J, Gray KD, et al. Exchange transfusion safety and outcomes in neonatal hyperbilirubinemia. *J Perinatol*. 2020;40(10):1506–1512. <https://doi.org/10.1038/s41372-020-0642-0>.
17. Pappas A, Delaney-Black V. Differential diagnosis and management of polycythemia. *Pediatr Clin North Am*. 2004;51(4):1063–1086 x-xi, <https://doi.org/10.1016/j.pcl.2004.03.012>. PMID: 15275989.
18. American Academy of Pediatrics Section on Breastfeeding. Breastfeeding and the use of human milk. *Pediatrics*. 2012;129:e827–e841.

19. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. *Cochrane Database Syst Rev.* 2014;4:CD005496. <https://doi.org/10.1002/14651858.CD005496.pub4>.
20. Neu J. Routine probiotics for premature infants: let's be careful. *J Pediatr.* 2011;158(4):672–674.
21. Manzoni P, Meyer M, Stolfi I, et al. Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial. *Early Hum Dev.* 2014;90(suppl 1):S60–S65.
22. El-Shimi MS, Awad HA, Abdelwahed MA, Mohamed MH, Khafagy SM, Saleh G. Enteral l-arginine and glutamine supplementation for prevention of NEC in preterm neonates. *Int J Pediatr.* 2015;2015; 856091.
23. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress: a clinical and electroencephalographic study. *Arch Neurol.* 1976;33(10):696–705. <https://doi.org/10.1001/archneur.1976.00500100030012>.
24. Dorner RA, Burton VJ, Allen MC, Robinson S, Soares. Preterm neuroimaging and neurodevelopmental outcome: a focus on intraventricular hemorrhage, post-hemorrhagic hydrocephalus, and associated brain injury. *J Perinatol.* 2018;38(11):1431–1443. <https://doi.org/10.1038/s41372-018-0209-5>
25. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. *J Pediatr.* 1978;92(4):529–534. [https://doi.org/10.1016/s0022-3476\(78\)80282-0](https://doi.org/10.1016/s0022-3476(78)80282-0)
26. Zankl A, Martin J, Davey JG, Osborn DA. Opioid treatment for opioid withdrawal in newborn infants. *Cochrane Database Syst Rev.* 2021;7:CD002059. <https://doi.org/10.1002/14651858.CD002059.pub4>.
27. Anumba DO, Scott JE, Plant ND, Robson SC. Diagnosis and outcome of fetal lower urinary tract obstruction in the northern region of England. *Prenat Diagn.* 2005;25:7–13.
28. Irfan A, O'Hare E, Jelin EB. Fetal interventions for congenital renal anomalies. *Transl Pediatr.* 2021;10(5):1506–1517. <https://doi.org/10.21037/tp-2020-fs-05>
29. Good WV. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. *Arch Ophthalmol.* 2003;121:1684–1694.
30. Fierson WM. American Academy of Pediatrics section on Ophthalmology, American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. *Pediatrics.* 2018;142(6):1–9.
31. Cell-free DNA screening for fetal aneuploidy. Committee Opinion No. 640. American College of Obstetricians and Gynecologists. *Obstet Gynecol.* 2015;126:e31–e37.
32. Gyamfi-Bannerman C. Antenatal late preterm steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. *Am J Obstet Gynecol.* 2016;214:S2.
33. Saccone G, Berghella V. Antenatal corticosteroids for maturity of term or near term fetuses: systemic review and meta-analysis of randomized controlled trials. *BMJ.* 2016;355:i5044:27733360.
34. Sotiriadis A, Makrydimas G, Papatheodorou S, et al. Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term. *Cochrane Database Syst Rev.* 2018;8:CD006614, 30075059.

# Chapter 19

## Nephrology

Ryan Handoko, MD

 See additional content online.

### I. URINALYSIS<sup>1</sup>: SEE TABLE 19.1

- A. Common indications include infectious workup (urinary tract infection [UTI], pyelonephritis), abdominal trauma, suspected diabetes or renal disease, rhabdomyolysis, edema, failure to thrive.
- B. Best if urine specimen is evaluated within 1 hour of voiding, otherwise should be kept at 4°C
- C. Annual screening urinalysis (UA) is not recommended by the American Academy of Pediatrics (AAP), unless patient is at high risk of chronic kidney disease.

### II. KIDNEY FUNCTION TESTS

#### A. Tests of Glomerular Function

1. **Glomerulogenesis is complete at 36 weeks' gestation.** Glomerular filtration rate (GFR) increases over the first 2 years of life related to glomerular maturation.
2. **Normal GFR values**, as measured by inulin clearance (gold standard), are shown in [Table 19.2](#).
3. **Creatinine clearance (CCr):** Closely approximates inulin clearance in the normal range of GFR. When GFR is low, CCr overestimates GFR. May be inaccurate in children with obstructive uropathy or problems with bladder emptying secondary to challenges getting complete timed urine collections.

$$\text{CCr (mL / min / 1.73 m}^2\text{)} = [\text{U} \times (\text{V} / \text{P})] \times 1.73 / \text{BSA}$$

where  $U$  (mg/dL) = urinary creatinine concentration;  $V$  (mL/min) = total urine volume (mL) divided by the duration of the collection (min) (24 hours = 1440 minutes);  $P$  (mg/dL) = serum creatinine concentration (may average two levels); and  $BSA$  (m<sup>2</sup>) = body surface area.

4. **Estimated GFR (eGFR) from plasma creatinine:** Varies related to body size/muscle mass. If body habitus is markedly abnormal or a precise measurement of GFR is needed, consider other methods. Creatinine must be in steady state to estimate GFR; use caution in the setting of acute kidney injury. Three methods to calculate estimated GFR:

TABLE 19.1

## URINALYSIS COMPONENTS

Test	Purpose	Normal Findings	Special Notes
Appearance	General impression	Colorless to amber. Cloudy/turbid urine can be normal.	Causes of turbid urine: <ul style="list-style-type: none"> <li>• Uric acid crystals in acidic urine</li> <li>• Phosphate crystals in alkaline urine</li> <li>• Cellular and infectious material</li> </ul> Causes of red/orange urine: Foods, drugs (propofol, chlorpromazine, thioridazine, rifampin), hemoglobinuria, porphyrias
Specific gravity	Correlates with kidney's ability to concentrate urine; surrogate of osmolality and hydration status	Between 1.003 and 1.030	Isosthenuria: Urine with osmolality equal to plasma (specific gravity of 1.010). May indicate disease affecting ability to concentrate/dilute urine Falsely elevated by: Glucose, high protein, iodine-based contrast, ketoacids
pH	Evaluate renal tubule hydrogen ion maintenance	pH 4.5–8, average range of 5–6	Influenced by serum pH Alkaline urine may indicate UTI with urea-splitting organisms or certain types of stones
Protein	Evaluate for proteinuria	Dipstick values: Negative Trace 1+ (~30 mg/dL) 2+ (~100 mg/dL) 3+ (~300 mg/dL) 4+ (>1000 mg/dL)	Confirm and quantify significant proteinuria with random urine protein/creatinine ratio or 24-hr urine collection Evaluate for postural proteinuria with first morning void Concentrated urine can lead to false-positive result.
Glucose	Detect glucose in urine	Glucosuria is always abnormal	Glucosuria typically seen when blood glucose >160–180 mg/dL Consider diabetes mellitus, proximal renal tubular disease, pregnancy Dipstick only measures glucose; reduction tests (Clinitest) will detect other sugars for suspected inborn errors of metabolism

Ketones	Detect breakdown of fatty acids	Negative to trace	Suggests diabetes mellitus or starvation-induced catabolism Neonatal ketoacidosis may indicate inborn error of metabolism
Nitrite	Detect Gram-negative bacterial metabolism	Negative	Specific (90%–100%), but not sensitive (15%–82%) for UTI False-positive from phenazopyridine
Leukocyte esterase	Detect presence of WBCs	Negative	Indicates pyuria Sensitive (67%–84%), but less specific (64%–92%) for UTI
Hemoglobin	Detect presence of RBCs or hemoglobin	Negative	Indicates hematuria or hemoglobinuria False-positive on dipstick: Myoglobin (e.g., crush injury, rhabdomyolysis, vigorous exercise), contamination with blood outside the urinary tract
Bilirubin, urobilinogen	Evaluate for hyperbilirubinemia	Negative	Positive with indirect hyperbilirubinemia Urobilinogen may be present in low amounts; increased in all cases of hyperbilirubinemia
Red blood cells	Differentiate hemoglobinuria from intact RBCs	Centrifuged urine normally contains <5 RBCs/hpf	RBC morphology suggests location of bleeding; dysmorphic RBCs suggest a glomerular origin, normal RBCs suggest lower tract bleeding
White blood cells	Detect inflammation/infection	Centrifuged urine normally contains <5 WBCs/hpf	Consider UTI, sterile pyuria, inflammatory disorders (e.g., Kawasaki).
Epithelial cells	Index of possible contamination	<5 squamous epithelial cells/hpf	15–20 squamous epithelial cells/hpf suggests contamination, although any amount may indicate contamination
Sediment	Investigate for formed elements: casts, cells, crystals	None	Hyaline casts: may be normal (e.g., dehydration). Other possibly pathologic casts include RBC, WBC, tubular epithelial, and granular casts.

RBC, Red blood cell; UTI, urinary tract infection; WBC, white blood cell.

**TABLE 19.2****NORMAL VALUES OF GLOMERULAR FILTRATION RATE**

Age (Sex)	Mean GFR $\pm$ SD (mL/min/1.73 m <sup>2</sup> )
1 week (M and F)	41 $\pm$ 15
2–8 weeks (M and F)	66 $\pm$ 25
>8 weeks (M and F)	96 $\pm$ 22
2–12 years (M and F)	133 $\pm$ 27
13–21 years (M)	140 $\pm$ 30
13–21 years (F)	126 $\pm$ 22

F, Female; M, male; SD, standard deviation.

Modified from Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Chronic Kidney Disease in Children and Adolescents: evaluation, classification, and stratification. *Pediatrics*. 2003;111:1416.

- a. **Bedside chronic kidney disease in children (CKiD) cohort:** Only applicable if creatinine measured by enzymatic assay. Recommended for eGFR determination in children aged 1 to 16 years. Estimated GFRs of  $\geq 75$  mL/min/1.73 m<sup>2</sup> determined by this equation likely represent normal kidney function; clinical correlation is recommended with GFR estimation.<sup>2</sup>

$$\text{eGFR (mL / min / 1.73 m}^2\text{)} = 0.413 \times (L / \text{Pcr})$$

where 0.413 is the proportionality constant,  $L$  = height (cm), and  $\text{Pcr}$  = plasma creatinine (mg/dL).

- b. **Schwartz equation:** Historical equation for eGFR in children. However, laboratories are increasingly shifting to enzymatic assays to determine creatinine; use of enzymatically determined creatinine (vs. Jaffe method) with the Schwartz equation leads to overestimation of GFR and should be considered when applying clinically:

$$\text{eGFR (mL / min / 1.73 m}^2\text{)} = kL/\text{Pcr}$$

where  $k$  = proportionality constant (Table 19.3);  $L$  = height (cm); and  $\text{Pcr}$  = plasma creatinine (mg/dL).

**TABLE 19.3****PROPORTIONALITY CONSTANT FOR CALCULATING GLOMERULAR FILTRATION RATE**

Age	k-Values
Low birth weight during first year of life	0.33
Term AGA during first year of life	0.45
Children and adolescent girls	0.55
Adolescent boys	0.70

AGA, Appropriate for gestational age.

Data from Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. *Pediatr Clin North Am*. 1987;34:571.

- c. **Modification of diet in renal disease (MDRD) and chronic kidney disease epidemiology collaboration (CKD-EPI):** Used to calculate GFR in those >18 years old, recently updated in 2021 to omit race.<sup>3</sup> Available at National Kidney Disease Education Program (NKDEP) website and National Kidney Foundation (NKF) website (see [Section XII](#)).

5. **Other measurements of GFR:** May be used when more precise determination of GFR is needed (e.g., dosing of chemotherapy). These methods include iothalamate, diethylenetriaminepentaacetic acid (DTPA), and iohexol. Cystatin C is a low molecular protein that can also be used to estimate GFR and is more accurate than serum creatinine in individuals with conditions that significantly impact muscle mass, the source of creatinine.

## B. Tests of Kidney Tubular Function

### 1. Proximal tubule and solute handling:

- a. **Proximal tubule reabsorption:** Proximal tubule is responsible for reabsorption of electrolytes, glucose, and amino acids. Studies to evaluate proximal tubular function compare urine and blood levels of specific compounds, arriving at a percentage of tubular reabsorption (Tx):

$$Tx = 1 - [(Ux / Px) / (UCr / PCr)] \times 100$$

where  $Ux$  = concentration of compound in urine;  $Px$  = concentration of compound in plasma;  $Ucr$  = concentration of creatinine in urine; and  $Pcr$  = concentration of creatinine in plasma. This formula can be used for amino acids, electrolytes, calcium, and phosphorus. It is commonly used to calculate tubular reabsorption of phosphate (TRP). In a patient with hypophosphatemia and preserved proximal tubular function, the tubular reabsorption of phosphate would be expected to be near 100%.

- b. **Fractional excretion of sodium (FENa)<sup>4</sup>:** Commonly used to assess tubular function. Must consider sodium and volume status. May be inaccurate with recent diuretic use.

$$FENa = [(UNa / PNa) / (UCr / PCr)] \times 100$$

where  $UNa$  = concentration of sodium in urine; and  $PNa$  = concentration of sodium in plasma. FENa is usually <1% in prerenal azotemia or glomerulonephritis, and >1% (usually >3%) in acute tubular necrosis (ATN) or postrenal azotemia. Infants have diminished ability to reabsorb sodium; FENa in volume-depleted infants is <3%.

- (1) **Fractional excretion of urea (FEurea):** May be useful in certain clinical scenarios, including patients on diuretics. Use FENa equation above, substituting urea for sodium. FEurea is usually <35% in prerenal azotemia and >50% in ATN.<sup>4</sup>

- (2) **Fractional excretion of bicarbonate (FEHCO<sub>3</sub>):** May help differentiate the types of renal tubular acidosis (RTA). The majority of bicarb reabsorption occurs in proximal tubule.

$$FEHCO_3 = [(UHCO_3 / PHCO_3) / (UCr / PCr)] \times 100$$

Normal FEHCO<sub>3</sub> is <5%. Distal RTA is usually <5%. >15% suggests proximal (type II) RTA.

2. **Distal tubule and pH balance:**

- a. **Urine anion gap (UAG):** Used as an indirect measure of ammonium production in the distal nephron.

$$UAG = UNa + UK - UCl$$

where *UNa* = concentration of sodium in urine; *UK* = concentration of potassium in urine; and *UCl* = concentration of chloride in urine. Positive UAG (usually >20) suggests a distal RTA. Negative UAG (usually <-20) suggests high urinary NH<sub>4</sub><sup>+</sup> (e.g., secondary to diarrhea).

- b. **Urine pH:** A urine acidification defect (distal RTA) should be suspected when random urine pH values are >6 in the presence of moderate systemic metabolic acidosis. Confirm acidification defects by simultaneous venous or arterial pH, plasma bicarbonate concentration, and determination of the pH of fresh urine.
- c. **Urine osmolality:** Urine is concentrated distally in the kidney tubules. Urine osmolality, ideally on a first morning urine specimen, may be used to evaluate capacity to concentrate urine. If osmolality is >600 mOsm/L, then tubular dysfunction, including disease states such as diabetes insipidus leading to inappropriate water loss, is unlikely. For more formal testing, see the water deprivation test in [Chapter 10](#).
- d. **Urine calcium:** Hypercalciuria may be seen with distal RTA, vitamin D intoxication, hyperparathyroidism, immobilization, excessive calcium intake, use of steroids or loop diuretics, or an idiopathic cause. Diagnosis is as follows:
- (1) 24-hour urine: Calcium >4 mg/kg/24 hr (gold standard)
  - (2) Spot urine: Determine calcium/creatinine (Ca/Cr) ratio. Normal urine Ca/Cr ratio does not rule out hypercalciuria. Correlate clinically and follow elevated spot urine Ca/Cr ratio with a 24-hr urine calcium determination if indicated ([Table 19.4](#)).<sup>5</sup>

**TABLE 19.4**

**AGE-ADJUSTED CALCIUM/CREATININE RATIOS**

Age	Ca <sup>2+</sup> /Cr Ratio (mg/mg) (95th Percentile for Age)
<7 months	0.86
7–18 months	0.60
19 months to 6 years	0.42
Adults	0.22

From Sargent JD, Stukel TA, Kresel J, et al. Normal values for random urinary calcium-to-creatinine ratios in infancy. *J Pediatr.* 1993;123:393.

**III. BLOOD PRESSURE (BP) AND CHRONIC HYPERTENSION<sup>6-11</sup>**

**NOTE:** See Chapter 1 for the management of acute hypertension.

See Tables 19.5 and 19.6 for normal BP values (systolic blood pressure [SBP], diastolic blood pressure [DBP]) by age.<sup>9,11</sup>

**A. Definition**

Hypertension is defined as the sustained elevation of BP at or above the 95th percentile for those <13 years or  $\geq 130/80$  for those  $\geq 13$  years. Any BP that is >90th percentile or  $\geq 120/80$  should be repeated at a clinic visit; if persistently elevated when confirmed by manual auscultation, the child should return for a repeat measurement for confirmation (see Section III.E for management).

**B. Measurement of Blood Pressure in Children**

1. All children  $\geq 3$  years should have BP measured annually. Children  $\geq 3$  years should have BP measured at **all** visits if at increased risk for hypertension: obesity, taking medications known to increase BP, renal disease, history of aortic arch obstruction/coarctation, diabetes.
2. Children aged <3 years with risk factors should have BP measured at all well child care visits. Risk factors include history of prematurity <32 weeks' gestation or small for gestational age, very low birth weight, congenital heart disease, kidney/urologic disease or family history of kidney disease, recurrent UTIs, malignancy, solid organ or bone marrow transplant, taking medications known to increase BP, systemic illness associated with hypertension, and evidence of increased intracranial pressure.
3. BP should be measured in a seated position in an upper extremity after 5 minutes of rest with feet/back/arm supported and mid-cuff at heart level; auscultation is preferred. Appropriate cuff size has a bladder width at least 40% of upper arm circumference at midway point. Bladder length should cover 80% to 100% of arm circumference. Cuffs that are too small may result in falsely elevated BPs. Choose a larger-sized cuff if there is a choice between two.

**C. Etiologies of Hypertension in Neonates, Infants, and Children (Table 19.7)**

Drugs causing hypertension include glucocorticoids, calcineurin inhibitors, sympathomimetics, oral contraceptives, stimulants (methylphenidate), ephedrine, erythropoietin, NSAIDs, caffeine, tobacco, ethanol, cocaine, and amphetamines.

**D. Evaluation of Chronic Hypertension**

1. Rule out factitious causes of hypertension (improper cuff size or measurement technique [e.g., manual vs. oscillometric]), nonpathologic causes of hypertension (e.g., fever, pain, anxiety, muscle spasm), and iatrogenic mechanisms (e.g., medications, excessive fluid administration).
2. **History:** Headache, blurred vision, dyspnea on exertion, edema, obstructive sleep apnea symptoms (including poor sleep quality or duration), endocrine symptoms (e.g., diaphoresis, flushing, constipation, weakness), history of neonatal intensive care unit stay; rule out

TABLE 19.5

## BLOOD PRESSURE LEVELS FOR THE 50TH, 90TH, 95TH, AND 99TH PERCENTILES OF BLOOD PRESSURE FOR GIRLS AGED 1–17 YEARS BY PERCENTILES OF HEIGHT

Age (years)	BP Percentile	SBP (mmHg) Height Percentile or Measured Height							DBP (mmHg) Height Percentile or Measured Height						
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
1	Height (in)	29.7	30.2	30.9	31.8	32.7	33.4	33.9	29.7	30.2	30.9	31.8	32.7	33.4	33.9
	Height (cm)	75.4	76.6	78.6	80.8	83	84.9	86.1	75.4	76.6	78.6	80.8	83	84.9	86.1
	50th	84	85	86	86	87	88	88	41	42	42	43	44	45	46
	90th	98	99	99	100	101	102	102	54	55	56	56	57	58	58
	95th	101	102	102	103	104	105	105	59	59	60	60	61	62	62
	95th + 12 mmHg	113	114	114	115	116	117	117	71	71	72	72	73	74	74
2	Height (in)	33.4	34	34.9	35.9	36.9	37.8	38.4	33.4	34	34.9	35.9	36.9	37.8	38.4
	Height (cm)	84.9	86.3	88.6	91.1	93.7	96	97.4	84.9	86.3	88.6	91.1	93.7	96	97.4
	50th	87	87	88	89	90	91	91	45	46	47	48	49	50	51
	90th	101	101	102	103	104	105	106	58	58	59	60	61	62	62
	95th	104	105	106	106	107	108	109	62	63	63	64	65	66	66
	95th + 12 mmHg	116	117	118	118	119	120	121	74	75	75	76	77	78	78
3	Height (in)	35.8	36.4	37.3	38.4	39.6	40.6	41.2	35.8	36.4	37.3	38.4	39.6	40.6	41.2
	Height (cm)	91	92.4	94.9	97.6	100.5	103.1	104.6	91	92.4	94.9	97.6	100.5	103.1	104.6
	50th	88	89	89	90	91	92	93	48	48	49	50	51	53	53
	90th	102	103	104	104	105	106	107	60	61	61	62	63	64	65
	95th	106	106	107	108	109	110	110	64	65	65	66	67	68	69
	95th + 12 mmHg	118	118	119	120	121	122	122	76	77	77	78	79	80	81
4	Height (in)	38.3	38.9	39.9	41.1	42.4	43.5	44.2	38.3	38.9	39.9	41.1	42.4	43.5	44.2
	Height (cm)	97.2	98.8	101.4	104.5	107.6	110.5	112.2	97.2	98.8	101.4	104.5	107.6	110.5	112.2
	50th	89	90	91	92	93	94	94	50	51	51	53	54	55	55
	90th	103	104	105	106	107	108	108	62	63	64	65	66	67	67
	95th	107	108	109	109	110	111	112	66	67	68	69	70	70	71
	95th + 12 mmHg	119	120	121	121	122	123	124	78	79	80	81	82	82	83

Age (years)	BP Percentile	SBP (mmHg) Height Percentile or Measured Height							DBP (mmHg) Height Percentile or Measured Height						
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
5	Height (in)	40.8	41.5	42.6	43.9	45.2	46.5	47.3	40.8	41.5	42.6	43.9	45.2	46.5	47.3
	Height (cm)	103.6	105.3	108.2	111.5	114.9	118.1	120	103.6	105.3	108.2	111.5	114.9	118.1	120
	50th	90	91	92	93	94	95	96	52	52	53	55	56	57	57
	90th	104	105	106	107	108	109	110	64	65	66	67	68	69	70
	95th	108	109	109	110	111	112	113	68	69	70	71	72	73	73
	95th + 12 mmHg	120	121	121	122	123	124	125	80	81	82	83	84	85	85
6	Height (in)	43.3	44	45.2	46.6	48.1	49.4	50.3	43.4	44	45.2	46.6	48.1	49.4	50.3
	Height (cm)	110	111.8	114.9	118.4	122.1	125.6	127.7	110	111.8	114.9	118.4	122.1	125.6	127.7
	50th	92	92	93	94	96	97	97	54	54	55	56	57	58	59
	90th	105	106	107	108	109	110	111	67	67	68	69	70	71	71
	95th	109	109	110	111	112	113	114	70	71	72	72	73	74	74
	95th + 12 mmHg	121	121	122	123	124	125	126	82	83	84	84	85	86	86
7	Height (in)	45.6	46.4	47.7	49.2	50.7	52.1	53	45.6	46.4	47.7	49.2	50.7	52.1	53
	Height (cm)	115.9	117.8	121.1	124.9	128.8	132.5	134.7	115.9	117.8	121.1	124.9	128.8	132.5	134.7
	50th	92	93	94	95	97	98	99	55	55	56	57	58	59	60
	90th	106	106	107	109	110	111	112	68	68	69	70	71	72	72
	95th	109	110	111	112	113	114	115	72	72	73	73	74	74	75
	95th + 12 mmHg	121	122	123	124	125	126	127	84	84	85	85	86	86	87
8	Height (in)	47.6	48.4	49.8	51.4	53	54.5	55.5	47.6	48.4	49.8	51.4	53	54.5	55.5
	Height (cm)	121	123	126.5	130.6	134.7	138.5	140.9	121	123	126.5	130.6	134.7	138.5	140.9
	50th	93	94	95	97	98	99	100	56	56	57	59	60	61	61
	90th	107	107	108	110	111	112	113	69	70	71	72	72	73	73
	95th	110	111	112	113	115	116	117	72	73	74	74	75	75	75
	95th + 12 mmHg	122	123	124	125	127	128	129	84	85	86	87	87	87	87

Continued

TABLE 19.5

**BLOOD PRESSURE LEVELS FOR THE 50TH, 90TH, 95TH, AND 99TH PERCENTILES OF BLOOD PRESSURE FOR GIRLS AGED 1–17 YEARS BY PERCENTILES OF HEIGHT—CONT'D**

Age (years)	BP Percentile	SBP (mmHg) Height Percentile or Measured Height							DBP (mmHg) Height Percentile or Measured Height						
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
9	Height (in)	49.3	50.2	51.7	53.4	55.1	56.7	57.7	49.3	50.2	51.7	53.4	55.1	56.7	57.7
	Height (cm)	125.3	127.6	131.3	135.6	140.1	144.1	146.6	125.3	127.6	131.3	135.6	140.1	144.1	146.6
	50th	95	95	97	98	99	100	101	57	58	59	60	60	61	61
	90th	108	108	109	111	112	113	114	71	71	72	73	73	73	73
	95th	112	112	113	114	116	117	118	74	74	75	75	75	75	75
	95th + 12 mmHg	124	124	125	126	128	129	130	86	86	87	87	87	87	87
10	Height (in)	51.1	52	53.7	55.5	57.4	59.1	60.2	51.1	52	53.7	55.5	57.4	59.1	60.2
	Height (cm)	129.7	132.2	136.3	141	145.8	150.2	152.8	129.7	132.2	136.3	141	145.8	150.2	152.8
	50th	96	97	98	99	101	102	103	58	59	59	60	61	61	62
	90th	109	110	111	112	113	115	116	72	73	73	73	73	73	73
	95th	113	114	114	116	117	119	120	75	75	76	76	76	76	76
	95th + 12 mmHg	125	126	126	128	129	131	132	87	87	88	88	88	88	88
11	Height (in)	53.4	54.5	56.2	58.2	60.2	61.9	63	53.4	54.5	56.2	58.2	60.2	61.9	63
	Height (cm)	135.6	138.3	142.8	147.8	152.8	157.3	160	135.6	138.3	142.8	147.8	152.8	157.3	160
	50th	98	99	101	102	104	105	106	60	60	60	61	62	63	64
	90th	111	112	113	114	116	118	120	74	74	74	74	74	75	75
	95th	115	116	117	118	120	123	124	76	77	77	77	77	77	77
	95th + 12 mmHg	127	128	129	130	132	135	136	88	89	89	89	89	89	89

Age (years)	BP Percentile	SBP (mmHg) Height Percentile or Measured Height							DBP (mmHg) Height Percentile or Measured Height						
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
12	Height (in)	56.2	57.3	59	60.9	62.8	64.5	65.5	56.2	57.3	59	60.9	62.8	64.5	65.5
	Height (cm)	142.8	145.5	149.9	154.8	159.6	163.8	166.4	142.8	145.5	149.9	154.8	159.6	163.8	166.4
	50th	102	102	104	105	107	108	108	61	61	61	62	64	65	65
	90th	114	115	116	118	120	122	122	75	75	75	75	76	76	76
	95th	118	119	120	122	124	125	126	78	78	78	78	79	79	79
	95th + 12 mmHg	130	131	132	134	136	137	138	90	90	90	90	91	91	91
13	Height (in)	58.3	59.3	60.9	62.7	64.5	66.1	67	58.3	59.3	60.9	62.7	64.5	66.1	67
	Height (cm)	148.1	150.6	154.7	159.2	163.7	167.8	170.2	148.1	150.6	154.7	159.2	163.7	167.8	170.2
	50th	104	105	106	107	108	108	109	62	62	63	64	65	65	66
	90th	116	117	119	121	122	123	123	75	75	75	76	76	76	76
	95th	121	122	123	124	126	126	127	79	79	79	79	80	80	81
	95th + 12 mmHg	133	134	135	136	138	138	139	91	91	91	91	92	92	93
14	Height (in)	59.3	60.2	61.8	63.5	65.2	66.8	67.7	59.3	60.2	61.8	63.5	65.2	66.8	67.7
	Height (cm)	150.6	153	156.9	161.3	165.7	169.7	172.1	150.6	153	156.9	161.3	165.7	169.7	172.1
	50th	105	106	107	108	109	109	109	63	63	64	65	66	66	66
	90th	118	118	120	122	123	123	123	76	76	76	76	77	77	77
	95th	123	123	124	125	126	127	127	80	80	80	80	81	81	82
	95th + 12 mmHg	135	135	136	137	138	139	139	92	92	92	92	93	93	94
15	Height (in)	59.7	60.6	62.2	63.9	65.6	67.2	68.1	59.7	60.6	62.2	63.9	65.6	67.2	68.1
	Height (cm)	151.7	154	157.9	162.3	166.7	170.6	173	151.7	154	157.9	162.3	166.7	170.6	173
	50th	105	106	107	108	109	109	109	64	64	64	65	66	67	67
	90th	118	119	121	122	123	123	124	76	76	76	77	77	78	78
	95th	124	124	125	126	127	127	128	80	80	80	81	82	82	82
	95th + 12 mmHg	136	136	137	138	139	139	140	92	92	92	93	94	94	94

Continued

TABLE 19.5

**BLOOD PRESSURE LEVELS FOR THE 50TH, 90TH, 95TH, AND 99TH PERCENTILES OF BLOOD PRESSURE FOR GIRLS AGED 1–17 YEARS BY PERCENTILES OF HEIGHT—CONT'D**

Age (years)	BP Percentile	SBP (mmHg) Height Percentile or Measured Height							DBP (mmHg) Height Percentile or Measured Height						
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
16	Height (in)	59.9	60.8	62.4	64.1	65.8	67.3	68.3	59.9	60.8	62.4	64.1	65.8	67.3	68.3
	Height (cm)	152.1	154.5	158.4	162.8	167.1	171.1	173.4	152.1	154.5	158.4	162.8	167.1	171.1	173.4
	50th	106	107	108	109	109	110	110	64	64	65	66	66	67	67
	90th	119	120	122	123	124	124	124	76	76	76	77	78	78	78
	95th	124	125	125	127	127	128	128	80	80	80	81	82	82	82
	95th + 12 mmHg	136	137	137	139	139	140	140	92	92	92	93	94	94	94
17	Height (in)	60.0	60.9	62.5	64.2	65.9	67.4	68.4	60.0	60.9	62.5	64.2	65.9	67.4	68.4
	Height (cm)	152.4	154.7	158.7	163.0	167.4	171.3	173.7	152.4	154.7	158.7	163.0	167.4	171.3	173.7
	50th	107	108	109	110	110	111	111	64	64	65	66	66	66	67
	90th	120	121	123	124	124	125	125	76	76	77	77	78	78	78
	95th	125	125	126	127	128	128	128	80	80	80	81	82	82	82
	95th + 12 mmHg	137	137	138	139	140	140	140	92	92	92	93	94	94	94

BP, Blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.

From Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*. 2017;e20171904; <https://doi.org/10.1542/peds.2017-1904>

**TABLE 19.6**
**BLOOD PRESSURE LEVELS FOR THE 50TH, 90TH, 95TH, AND 99TH PERCENTILES OF BLOOD PRESSURE FOR BOYS AGED 1 TO 17 YEARS BY PERCENTILES OF HEIGHT**

Age (years)	BP Percentile	SBP (mmHg) Height Percentile or Measured Height							DBP (mmHg) Height Percentile or Measured Height						
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
1	Height (in)	30.4	30.8	31.6	32.4	33.3	34.1	34.6	30.4	30.8	31.6	32.4	33.3	34.1	34.6
	Height (cm)	77.2	78.3	80.2	82.4	84.6	86.7	87.9	77.2	78.3	80.2	82.4	84.6	86.7	87.9
	50th	85	85	86	86	87	88	88	40	40	40	41	41	42	42
	90th	98	99	99	100	100	101	101	52	52	53	53	54	54	54
	95th	102	102	103	103	104	105	105	54	54	55	55	56	57	57
	95th + 12 mmHg	114	114	115	115	116	117	117	66	66	67	67	68	69	69
2	Height (in)	33.9	34.4	35.3	36.3	37.3	38.2	38.8	33.9	34.4	35.3	36.3	37.3	38.2	38.8
	Height (cm)	86.1	87.4	89.6	92.1	94.7	97.1	98.5	86.1	87.4	89.6	92.1	94.7	97.1	98.5
	50th	87	87	88	89	89	90	91	43	43	44	44	45	46	46
	90th	100	100	101	102	103	103	104	55	55	56	56	57	58	58
	95th	104	105	105	106	107	107	108	57	58	58	59	60	61	61
	95th + 12 mmHg	116	117	117	118	119	119	120	69	70	70	71	72	73	73
3	Height (in)	36.4	37	37.9	39	40.1	41.1	41.7	36.4	37	37.9	39	40.1	41.1	41.7
	Height (cm)	92.5	93.9	96.3	99	101.8	104.3	105.8	92.5	93.9	96.3	99	101.8	104.3	105.8
	50th	88	89	89	90	91	92	92	45	46	46	47	48	49	49
	90th	101	102	102	103	104	105	105	58	58	59	59	60	61	61
	95th	106	106	107	107	108	109	109	60	61	61	62	63	64	64
	95th + 12 mmHg	118	118	119	119	120	121	121	72	73	73	74	75	76	76

*Continued*

TABLE 19.6

**BLOOD PRESSURE LEVELS FOR THE 50TH, 90TH, 95TH, AND 99TH PERCENTILES OF BLOOD PRESSURE FOR BOYS AGED 1 TO 17 YEARS BY PERCENTILES OF HEIGHT—CONT'D**

Age (years)	BP Percentile	SBP (mmHg) Height Percentile or Measured Height							DBP (mmHg) Height Percentile or Measured Height						
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
4	Height (in)	38.8	39.4	40.5	41.7	42.9	43.9	44.5	38.8	39.4	40.5	41.7	42.9	43.9	44.5
	Height (cm)	98.5	100.2	102.9	105.9	108.9	111.5	113.2	98.5	100.2	102.9	105.9	108.9	111.5	113.2
	50th	90	90	91	92	93	94	94	48	49	49	50	51	52	52
	90th	102	103	104	105	105	106	107	60	61	62	62	63	64	64
	95th	107	107	108	108	109	110	110	63	64	65	66	67	67	68
	95th + 12 mmHg	119	119	120	120	121	122	122	75	76	77	78	79	79	80
5	Height (in)	41.1	41.8	43.0	44.3	45.5	46.7	47.4	41.1	41.8	43.0	44.3	45.5	46.7	47.4
	Height (cm)	104.4	106.2	109.1	112.4	115.7	118.6	120.3	104.4	106.2	109.1	112.4	115.7	118.6	120.3
	50th	91	92	93	94	95	96	96	51	51	52	53	54	55	55
	90th	103	104	105	106	107	108	108	63	64	65	65	66	67	67
	95th	107	108	109	109	110	111	112	66	67	68	69	70	70	71
	95th + 12 mmHg	119	120	121	121	122	123	124	78	79	80	81	82	82	83
6	Height (in)	43.4	44.2	45.4	46.8	48.2	49.4	50.2	43.4	44.2	45.4	46.8	48.2	49.4	50.2
	Height (cm)	110.3	112.2	115.3	118.9	122.4	125.6	127.5	110.3	112.2	115.3	118.9	122.4	125.6	127.5
	50th	93	93	94	95	96	97	98	54	54	55	56	57	57	58
	90th	105	105	106	107	109	110	110	66	66	67	68	68	69	69
	95th	108	109	110	111	112	113	114	69	70	70	71	72	72	73
	95th + 12 mmHg	120	121	122	123	124	125	126	81	82	82	83	84	84	85
7	Height (in)	45.7	46.5	47.8	49.3	50.8	52.1	52.9	45.7	46.5	47.8	49.3	50.8	52.1	52.9
	Height (cm)	116.1	118	121.4	125.1	128.9	132.4	134.5	116.1	118	121.4	125.1	128.9	132.4	134.5
	50th	94	94	95	97	98	98	99	56	56	57	58	58	59	59
	90th	106	107	108	109	110	111	111	68	68	69	70	70	71	71
	95th	110	110	111	112	114	115	116	71	71	72	73	73	74	74
	95th + 12 mmHg	122	122	123	124	126	127	128	83	83	84	85	85	86	86

Age (years)	BP Percentile	SBP (mmHg) Height Percentile or Measured Height							DBP (mmHg) Height Percentile or Measured Height						
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
8	Height (in)	47.8	48.6	50	51.6	53.2	54.6	55.5	47.8	48.6	50	51.6	53.2	54.6	55.5
	Height (cm)	121.4	123.5	127	131	135.1	138.8	141	121.4	123.5	127	131	135.1	138.8	141
	50th	95	96	97	98	99	99	100	57	57	58	59	59	60	60
	90th	107	108	109	110	111	112	112	69	70	70	71	72	72	73
	95th	111	112	112	114	115	116	117	72	73	73	74	75	75	75
	95th + 12 mmHg	123	124	124	126	127	128	129	84	85	85	86	87	87	87
9	Height (in)	49.6	50.5	52	53.7	55.4	56.9	57.9	49.6	50.5	52	53.7	55.4	56.9	57.9
	Height (cm)	126	128.3	132.1	136.3	140.7	144.7	147.1	126	128.3	132.1	136.3	140.7	144.7	147.1
	50th	96	97	98	99	100	101	101	57	58	59	60	61	62	62
	90th	107	108	109	110	112	113	114	70	71	72	73	74	74	74
	95th	112	112	113	115	116	118	119	74	74	75	76	76	77	77
	95th + 12 mmHg	124	124	125	127	128	130	131	86	86	87	88	88	89	89
10	Height (in)	51.3	52.2	53.8	55.6	57.4	59.1	60.1	51.3	52.2	53.8	55.6	57.4	59.1	60.1
	Height (cm)	130.2	132.7	136.7	141.3	145.9	150.1	152.7	130.2	132.7	136.7	141.3	145.9	150.1	152.7
	50th	97	98	99	100	101	102	103	59	60	61	62	63	63	64
	90th	108	109	111	112	113	115	116	72	73	74	74	75	75	76
	95th	112	113	114	116	118	120	121	76	76	77	77	78	78	78
	95th + 12 mmHg	124	125	126	128	130	132	133	88	88	89	89	90	90	90
11	Height (in)	53	54	55.7	57.6	59.6	61.3	62.4	53	54	55.7	57.6	59.6	61.3	62.4
	Height (cm)	134.7	137.3	141.5	146.4	151.3	155.8	158.6	134.7	137.3	141.5	146.4	151.3	155.8	158.6
	50th	99	99	101	102	103	104	106	61	61	62	63	63	63	63
	90th	110	111	112	114	116	117	118	74	74	75	75	75	76	76
	95th	114	114	116	118	120	123	124	77	78	78	78	78	78	78
	95th + 12 mmHg	126	126	128	130	132	135	136	89	90	90	90	90	90	90

Continued

**TABLE 19.6**

**BLOOD PRESSURE LEVELS FOR THE 50TH, 90TH, 95TH, AND 99TH PERCENTILES OF BLOOD PRESSURE FOR BOYS AGED 1 TO 17 YEARS BY PERCENTILES OF HEIGHT—CONT'D**

Age (years)	BP Percentile	SBP (mmHg) Height Percentile or Measured Height							DBP (mmHg) Height Percentile or Measured Height						
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
12	Height (in)	55.2	56.3	58.1	60.1	62.2	64	65.2	55.2	56.3	58.1	60.1	62.2	64	65.2
	Height (cm)	140.3	143	147.5	152.7	157.9	162.6	165.5	140.3	143	147.5	152.7	157.9	162.6	165.5
	50th	101	101	102	104	106	108	109	61	62	62	62	62	63	63
	90th	113	114	115	117	119	121	122	75	75	75	75	75	76	76
	95th	116	117	118	121	124	126	128	78	78	78	78	78	79	79
	95th + 12 mmHg	128	129	130	133	136	138	140	90	90	90	90	90	91	91
13	Height (in)	57.9	59.1	61	63.1	65.2	67.1	68.3	57.9	59.1	61	63.1	65.2	67.1	68.3
	Height (cm)	147	150	154.9	160.3	165.7	170.5	173.4	147	150	154.9	160.3	165.7	170.5	173.4
	50th	103	104	105	108	110	111	112	61	60	61	62	63	64	65
	90th	115	116	118	121	124	126	126	74	74	74	75	76	77	77
	95th	119	120	122	125	128	130	131	78	78	78	78	80	81	81
	95th + 12 mmHg	131	132	134	137	140	142	143	90	90	90	90	92	93	93
14	Height (in)	60.6	61.8	63.8	65.9	68.0	69.8	70.9	60.6	61.8	63.8	65.9	68.0	69.8	70.9
	Height (cm)	153.8	156.9	162	167.5	172.7	177.4	180.1	153.8	156.9	162	167.5	172.7	177.4	180.1
	50th	105	106	109	111	112	113	113	60	60	62	64	65	66	67
	90th	119	120	123	126	127	128	129	74	74	75	77	78	79	80
	95th	123	125	127	130	132	133	134	77	78	79	81	82	83	84
	95th + 12 mmHg	135	137	139	142	144	145	146	89	90	91	93	94	95	96

Age (years)	BP Percentile	SBP (mmHg) Height Percentile or Measured Height							DBP (mmHg) Height Percentile or Measured Height						
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
15	Height (in)	62.6	63.8	65.7	67.8	69.8	71.5	72.5	62.6	63.8	65.7	67.8	69.8	71.5	72.5
	Height (cm)	159	162	166.9	172.2	177.2	181.6	184.2	159	162	166.9	172.2	177.2	181.6	184.2
	50th	108	110	112	113	114	114	114	61	62	64	65	66	67	68
	90th	123	124	126	128	129	130	130	75	76	78	79	80	81	81
	95th	127	129	131	132	134	135	135	78	79	81	83	84	85	85
	95th + 12 mmHg	139	141	143	144	146	147	147	90	91	93	95	96	97	97
16	Height (in)	63.8	64.9	66.8	68.8	70.7	72.4	73.4	63.8	64.9	66.8	70.7	70.7	72.4	73.4
	Height (cm)	162.1	165	169.6	174.6	179.5	183.8	186.4	162.1	165	169.6	174.6	179.5	183.8	186.4
	50th	111	112	114	115	115	116	116	63	64	66	67	68	69	69
	90th	126	127	128	129	131	131	132	77	78	79	80	81	82	82
	95th	130	131	133	134	135	136	137	80	81	83	84	85	86	86
	95th + 12 mmHg	142	143	145	146	147	148	149	92	93	95	96	97	98	98
17	Height (in)	64.5	65.5	67.3	69.2	71.1	72.8	73.8	64.5	65.5	67.3	69.2	71.1	72.8	73.8
	Height (cm)	163.8	166.5	170.9	175.8	180.7	184.9	187.5	163.8	166.5	170.9	175.8	180.7	184.9	187.5
	50th	114	115	116	117	117	118	118	65	66	67	68	69	70	70
	90th	128	129	130	131	132	133	134	78	79	80	81	82	82	83
	95th	132	133	134	135	137	138	138	81	82	84	85	86	86	87
	95th + 12 mmHg	144	145	146	147	149	150	150	93	94	96	97	98	98	99

BP, Blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.

From Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*. 2017;e20171904; <https://doi.org/10.1542/peds.2017-1904>

TABLE 19.7

## CAUSES OF HYPERTENSION BY AGE GROUP

Age	Most Common	Less Common
Neonates/infants	Renal artery thrombosis after umbilical artery catheterization Coarctation of aorta Renal artery stenosis Bronchopulmonary dysplasia or chronic lung disease	Medications Patent ductus arteriosus Intraventricular hemorrhage
1–10 years	Renal parenchymal disease Coarctation of aorta Bronchopulmonary dysplasia or chronic lung disease Essential hypertension	Renal artery stenosis Hypercalcemia Neurofibromatosis Neurogenic tumors Pheochromocytoma Mineralocorticoid excess Hyperthyroidism Transient hypertension Immobilization-induced Sleep apnea Essential hypertension Medications
11 years to adolescence	Renal parenchymal disease Coarctation of aorta Essential hypertension	All diagnoses listed in this table

Modified from Sinaiko A. Hypertension in children. *N Engl J Med.* 1996;335:26; Viera AJ, Neutze D. Diagnosis of secondary hypertension: an age-based approach. *Am Fam Physician.* 2010;82:12; Gupta-Malhotra M, Banker A, Shete S, et al. Essential hypertension vs. secondary hypertension among children. *Am J Hypertens.* 2015;28:1.

pregnancy, history of UTIs, history of medications and supplements, illicit drug use, or any family history of kidney dysfunction or hypertension.

3. **Physical examination:** Four-extremity pulses and BP, endocrine disease stigmata, edema, hypertrophied tonsils, skin lesions, abdominal mass, or abdominal bruit
4. **Clinical evaluation of confirmed hypertension:**
  - a. Laboratory studies:
    - (1) All patients: Urinalysis (UA), serum electrolytes, creatinine, blood urea nitrogen (BUN), lipid profile
    - (2) Obese patients: Hgb A1c, AST/ALT, fasting lipid panel
    - (3) Consider on basis of history and exam: Fasting serum glucose, thyroid stimulating hormone, drug screen, polysomnography, complete blood count
  - b. Clinical practice guidelines recommend 24-hour ambulatory blood pressure monitoring (ABPM) be conducted in all children with persistently elevated blood pressure to confirm the diagnosis of hypertension. Other at-risk populations (e.g., coarctation of the aorta status–post repair, CKD, history of hypertension) should also have this monitoring done yearly regardless of clinic blood pressure.

- c. Imaging:
  - (1) Renal ultrasound in patients <6 years old or those with abnormal UA or renal function
  - (2) Echocardiography to evaluate for left ventricular hypertrophy if pharmacologic treatment considered
  - (3) Consider renovascular imaging if renal artery stenosis is suspected.
- d. Patients  $\geq 6$  years of age do not require extensive evaluation for secondary causes if they have a strong family history of hypertension (HTN), are overweight, and do not have any evidence of secondary causes on history and physical exam.

### E. Classification and Treatment of Hypertension (Table 19.8)

Target: SBP and DBP to <90th percentile and <130/80 mmHg in adolescents  $\geq 13$  years old. Consider target 50th percentile in those with CKD.

1. **Nonpharmacologic:** Aerobic exercise, sodium restriction, smoking cessation, and weight loss indicated in all patients with hypertension. Reevaluate BP after lifestyle interventions, and begin pharmacologic therapy if hypertension persists.
2. **Pharmacologic:** Indications include secondary hypertension, symptomatic hypertension, stage 2 hypertension without a clearly modifiable factor (e.g., obesity), diabetes mellitus, and persistent hypertension despite nonpharmacologic measures.
3. **Treatment monitoring:** Repeat echocardiogram every 6 to 12 months in those with cardiac end organ damage or those at high risk. Repeated 24-hour ABPM can be used to assess treatment effectiveness as needed.

### F. Antihypertensive Drugs for Outpatient Management of Primary Hypertension in Children 1 to 17 Years of Age

Clinical guidelines recommend angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, thiazide diuretics, or long-acting calcium channel blockers as first-line medications for management of chronic hypertension in children.<sup>9</sup> Medication choice may be impacted by underlying comorbidities, contraindications, and side effects. Providers should familiarize themselves with existing guidelines, medication contraindications, and side effects. A list of medications and common side effects is found in Table 19.9.

## IV. URINARY TRACT INFECTIONS<sup>12-17</sup>

### A. History

Highly dependent on patient age. Inquire about fever, dysuria, frequency, urgency, and back/abdominal pain. Obtain voiding history (stool, urine), stream characteristics in toilet-trained children, sexual activity, sexual abuse, circumcision status, prolonged/bubble baths or swimming, evaluation of growth curve, recent antibiotic use, and family history of vesicoureteral reflux (VUR), recurrent UTIs, or chronic kidney disease.

### B. Physical Examination

Vital signs, abdominal examination for tenderness, flank masses, bowel distention, evidence of impaction, meatal stenosis or circumcision in males,

TABLE 19.8

**CLASSIFICATION OF HYPERTENSION IN CHILDREN AND ADOLESCENTS AND MANAGEMENT RECOMMENDATIONS**

	Ages 1–13 Years	Ages ≥13 Years	Frequency of BP Measurement	Pharmacologic Therapy (in Addition to Lifestyle Modifications)
Normal BP	<90th percentile	<120/<80	Annually (or sooner if at increased risk; see <a href="#">Section III.B</a> )	None
Elevated BP	90th to <95th percentile <i>OR</i> 120/80 to <95th percentile, whichever is lower	120/<80 to 129/<80	Recheck in 6 months; if persistent over 2 additional visits, conduct ABPM and diagnostic evaluation	None, unless compelling indications: CKD, DM
Stage 1 hypertension	95th to 95th percentile plus 12 mmHg <i>OR</i> 130/80 to 139/89, whichever is lower	130/80 to 139/89	Recheck in 1–2 weeks; if persistently elevated over 2 additional visits, conduct ABPM and diagnostic evaluation	Initiate therapy, especially if symptomatic, end-organ damage is present, CKD, DM, persistent hypertension despite nonpharmacologic measures
Stage 2 hypertension	≥95th percentile plus 12 mmHg <i>OR</i> ≥140/90, whichever is lower	≥140/90	Evaluate and refer within 1 week, or immediately if the patient is symptomatic	Initiate therapy

All blood pressures expressed in mmHg.

ABPM, Ambulatory blood pressure monitoring; CKD, chronic kidney disease; DBP, diastolic blood pressure; DM, diabetes mellitus; SBP, systolic blood pressure.

Modified from Flynn JT, Kaelber DC, Baker-Smith CM, et al, and AAP Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*. 2017;140(3):e20171904.

vulvovaginitis or labial adhesions in females, neurologic examination of lower extremities, perineal sensation and reflexes, and rectal and sacral examination (for anteriorly placed anus).

### C. Risk Factors

2011 AAP guidelines,<sup>12</sup> reaffirmed in 2016,<sup>13</sup> for children 2 to 24 months provide resources to help clinicians stratify the risk of UTI in the absence of

TABLE 19.9

## ANTIHYPERTENSIVE DRUGS FOR OUTPATIENT MANAGEMENT OF HYPERTENSION IN CHILDREN 1 TO 17 YEARS OF AGE

Class	Drug	Comments
Angiotensin-converting enzyme (ACE) inhibitor	Benazepril	Blocks conversion of angiotensin I to angiotensin II Decreases proteinuria while preserving renal function <b>Contraindicated:</b> Pregnancy, compromised renal perfusion (e.g., renal artery stenosis) Check serum potassium and creatinine periodically to monitor for hyperkalemia and uremia. Monitor for cough and angioedema.
	Captopril	
	Enalapril	
	Fosinopril	
	Lisinopril	
	Ramipril Quinapril	
Angiotensin-II receptor blocker (ARB)	Candesartan	<b>Contraindicated:</b> Pregnancy Check serum potassium and creatinine periodically to monitor for hyperkalemia and uremia.
	Irbesartan	
	Losartan	
	Olmesartan	
	Valsartan	
$\alpha$ - and $\beta$ -blockers	Labetalol	Cause decreased peripheral resistance and decreased heart rate <b>Contraindicated:</b> Asthma, heart failure, insulin-dependent diabetes Heart rate is dose-limiting. May impair athletic performance
	Carvedilol	
$\beta$ -blocker	Atenolol	Decreases heart rate, cardiac output, and renin release Noncardioselective agents (e.g., propranolol) are contraindicated in asthma and heart failure. Metoprolol and atenolol are $\beta_1$ selective. Heart rate is dose-limiting. May impair athletic performance Should not be used in insulin-dependent diabetics
	Esmolol	
	Metoprolol	
	Propranolol	
Calcium channel blocker	Amlodipine	Acts on vascular smooth muscles Renal perfusion/function is minimally affected; generally few side effects Amlodipine and isradipine can be compounded into suspensions.
	Felodipine	
	Isradipine	
	Extended-release nifedipine	May cause tachycardia
Central $\alpha$ -agonist	Clonidine	Stimulates brainstem $\alpha_2$ receptors and decreases peripheral adrenergic drive May cause dry mouth and/or sedation ( $\downarrow$ opiate withdrawal) Transdermal preparation also available Sudden cessation of therapy can lead to severe rebound hypertension.
Loop diuretics	Furosemide Bumetanide	Side effects are hyponatremia, hypokalemia, and ototoxicity.
Thiazide diuretics	Hydrochlorothiazide Chlorthalidone Chlorothiazide	Side effects are hypokalemia, hypercalcemia, hyperuricemia, and hyperlipidemia.

Continued

TABLE 19.9

**ANTIHYPERTENSIVE DRUGS FOR OUTPATIENT MANAGEMENT OF HYPERTENSION IN CHILDREN 1 TO 17 YEARS OF AGE—CONT'D**

Class	Drug	Comments
Potassium-sparing diuretics	Spironolactone Triamterene Amiloride	Useful as add-on therapy in patients being treated with drugs from other drug classes Potassium-sparing diuretics are modest antihypertensives. They may cause severe hyperkalemia, especially if given with ACE inhibitor or ARB.
Peripheral $\alpha$ -antagonist	Doxazosin Prazosin Terazosin	May cause hypotension and syncope, especially after first dose
Vasodilator	Hydralazine	Directly acts on vascular smooth muscle and is very potent Tachycardia, sodium retention, and water retention are common side effects.
	Minoxidil	Used in combination with diuretics or $\beta$ -blockers Minoxidil is usually reserved for patients with hypertension resistant to multiple drugs.

Modified from Flynn JT, Kaelber DC, Baker-Smith CM, et al, and AAP Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*. 2017;140(3):e20171904.

another source of infection in a febrile child. (This was reassessed in 2021<sup>14</sup> for improper use of race as a factor in disease risk; new AAP guidance forthcoming.)

1. Females are at higher risk for UTI than males.
2. Uncircumcised males are at higher risk than circumcised males.
3. Other risk factors include fever  $\geq 39^\circ\text{C}$  and fever  $>1$  to 2 days.

#### D. Methods of Urine Collection

1. **If a child is 2 months to 2 years old, has a fever, and appears sufficiently ill to warrant immediate antibiotics**, obtain UA and urine culture by transurethral catheterization. **Suprapubic percutaneous aspiration** may be useful in critically ill children, is generally very safe, and is similar to bladder catheterization in sensitivity and specificity.
2. **If a child is 2 months to 2 years old, has a fever, and does not appear ill enough to warrant immediate antibiotics**, obtain urine by catheterization or the most convenient method available. **Bag or absorbent pad** may be helpful when UTI is unlikely (to rule out infection), but both have very high false-positive rates ( $>75\%$  of cultures positive) and should not be sent for culture.<sup>12</sup> If UA does not suggest UTI, it is reasonable to avoid antimicrobial therapy. If UA does suggest UTI, urine culture should be obtained by catheterization.
3. **If a child is  $>2$  years old and toilet trained**, may provide midstream clean-catch urine specimen.

## E. Diagnosis

To establish the diagnosis of UTI, both UA results suggestive of infection and positive urine culture are recommended.

1. Nitrite test:
  - a. Detects products of reduction of dietary nitrates by urinary Gram-negative bacterial species (especially *Escherichia coli*, *Klebsiella*, and *Proteus*)
  - b. Sensitivity 15% to 82% and specificity 90% to 100% for UTI<sup>12</sup>
  - c. Special circumstances: False-negative (low sensitivity) results commonly occur with insufficient time (<4 hours) for conversion of urinary nitrates to nitrites (age-dependent voiding frequency) and inability of bacteria to reduce nitrates to nitrites (many Gram-positive organisms such as *Enterococcus*, *Mycobacterium* spp., and fungi).
2. Leukocyte esterase test:
  - a. Detects esterase released from leukocyte lysis
  - b. Sensitivity 67% to 84% and specificity 64% to 92% for UTI<sup>12</sup>
3. Pyuria is defined at a threshold of  $\geq 5$  WBCs/hpf. Absence of pyuria is rare if a true UTI is present.
4. Urine culture:
  - a. Transurethral catheterization or suprapubic aspiration:  $>50,000$  colony-forming units (CFU) per mL diagnostic of UTI. Some sources suggest  $>10,000$  CFU/mL in the presence of fever, symptoms, and pyuria may also be diagnostic.<sup>15</sup>
  - b. Clean catch:  $>100,000$  CFU/mL necessary to diagnose a UTI
  - c. Bagged specimen: Should not be used to collect urine culture
  - d. Catheter-associated (indwelling urethral or suprapubic): No specific data for pediatric patients. Adult Infectious Diseases Society of America guidelines define it as presence of symptoms and signs compatible with UTI and  $>1000$  CFU/mL of one or more bacterial species in a single catheter urine specimen or in a midstream voided urine specimen from a patient whose catheter has been removed within previous 48 hours.<sup>16</sup>

## F. Classification

Pyelonephritis (upper UTI), rather than cystitis (lower UTI), is suggested by fever  $\geq 38.5^{\circ}\text{C}$  (especially if lasting  $>48$  hours after initiating appropriate antibiotics), systemic symptoms, costovertebral angle tenderness, elevated C-reactive protein (CRP), leukocytosis.

## G. Imaging




1. **Renal and bladder ultrasound (RBUS):** Evaluates for anatomic abnormalities and abscesses. Indications include children 2 to 24 months with first UTI, recurrent or atypical UTIs, or if no response to treatment within 48 hours. If there is clinical improvement  $<48$  hours and follow-up is reliable, RBUS should be done after full recovery. If there is no response to treatment or follow-up is uncertain, then RBUS during illness is indicated.

2. **Voiding cystourethrography (VCUG):** Evaluates bladder anatomy, emptying, and looks for signs of vesicoureteral reflux (VUR). Should not be obtained routinely after first febrile UTI. Indications include children 2 to 24 months with abnormal RBUS findings (hydronephrosis, scarring, or other findings suggestive of either high-grade VUR or obstructive uropathy), complicated or recurrent pyelonephritis.<sup>12</sup> Consider if family history of VUR. Optimal time is 2 to 6 weeks after infection.

## H. Treatment of Culture-Positive Urinary Tract Infection

For empiric therapy, see [Chapter 17](#).

1. **Organisms:**
  - a. *E. coli* is the most common cause of pediatric UTI.
  - b. Other common pathogens: *Klebsiella*, *Proteus* spp., *Staphylococcus saprophyticus*, and *Staphylococcus aureus*.
  - c. Neonatal UTI: Group B streptococci and other bloodborne pathogens
  - d. *Enterococcus* and *Pseudomonas* are more prevalent in abnormal hosts (e.g., recurrent UTI, abnormal anatomy, neurogenic bladder, hospitalized patients, or those with frequent bladder catheterizations). Consider blood cultures if urine grows uncommon organism or *Staphylococcus*.
2. **Treatment considerations and duration:**
  - a. Route: Parenteral antibiotics for children who are toxic, dehydrated, or unable to tolerate oral medication because of vomiting or noncompliance
  - b. Duration: 3 to 5 days for uncomplicated cases<sup>17</sup>; 7 to 14 days for toxic children and those with pyelonephritis
3. **Inadequate response to therapy:** Consider renal abscess or urinary obstruction; RBUS and repeat urine culture is indicated. Repeat cultures should also be considered in patients with recurrent UTIs to rule out persistent bacteriuria.
4. **Management of VUR:**
  - a. Classification of VUR: [Fig. 19.1](#)
  - b. Antibiotic prophylaxis: Evidence suggests that prophylactic trimethoprim-sulfamethoxazole reduces the risk of UTI recurrence by 50%, but with no significant difference in renal scarring. Some experts suggest that recent studies are insufficiently powered to detect a difference in the relatively rare outcomes of renal scarring and thus recommend shifting guideline recommendations from “no prophylaxis” to “selective prophylaxis” in certain groups of patients.<sup>18</sup>
  - c. Surgical intervention: Monitor persistence/grade of VUR annually, often in consultation with a pediatric urologist. Spontaneous resolution may occur, although less likely with higher grade. Higher-grade VUR that persists as the child grows may ultimately require surgical intervention.
5. **Asymptomatic bacteriuria:** Defined as bacteria in urine on microscopy and Gram stain in an afebrile, asymptomatic patient without pyuria. Antibiotics not necessary if voiding habits and urinary tract are normal.

Grade I	Grade II	Grade III	Grade IV	Grade V
				
Ureter only	Ureter, pelvis, calyces; no dilatation, normal calyceal fornices	Mild or moderate dilatation and/or tortuosity of ureter; mild or moderate dilatation of the pelvis, but no or slight blunting of the fornices	Moderate dilatation and/or tortuosity of the ureter; mild dilatation of renal pelvis and calyces; complete obliteration of sharp angle of fornices, but maintenance of papillary impressions in majority of calyces	Gross dilatation and tortuosity of ureter; gross dilatation of renal pelvis and calyces; papillary impressions are no longer visible in majority of calyces

**FIGURE 19.1**

International classification of vesicoureteral reflux. (Modified from Rushton H. Urinary tract infections in children: epidemiology, evaluation, and management. *Pediatr Clin North Am.* 1997;44:5; International Reflux Committee. Medical vs. surgical treatment of primary vesicoureteral reflux: report of the International Reflux Study Committee. *Pediatrics.* 1981;67:392.)

- Referral to pediatric urology:** Consider in children with abnormal voiding patterns based on history or imaging, neurogenic bladder, abnormal anatomy, recurrent UTI, or poor response to appropriate antibiotics.

## V. PROTEINURIA<sup>19-21</sup>

### A. Definitions

- Orthostatic proteinuria:** Excretion of significant amounts of protein while in the upright position. A benign condition and common cause of proteinuria in children and adolescents
- Fixed proteinuria:** Proteinuria found on first morning urine void over several consecutive days. Suggestive of kidney disease

3. **Microalbuminuria:** Presence of albumin in urine below detectable range of dipsticks. In adults, defined as 30 to 300 mg/g creatinine. Most often used in screening for kidney disease secondary to diabetes
4. **Significant proteinuria:** Urine protein to urine creatinine (UPr:UCr) ratio 0.2 to 2.0 mg/mg or 4 to 40 mg/m<sup>2</sup>/hr in a 24-hour collection
5. **Nephrotic-range proteinuria:** UPr:UCr ratio >2 mg/mg or >40 mg/m<sup>2</sup>/hr in a 24-hour collection. In adults, 24-hour urine protein excretion of 3000 mg/24 hours
6. **Nephrotic syndrome:** Nephrotic-range proteinuria, hypoalbuminemia, edema, and hyperlipidemia (cholesterol >200 mg/dL)

## B. Methods of Detection

1. **Urinalysis** (see [Table 19.1](#)): Proteinuria on a urine dipstick should be verified by a urine protein/creatinine ratio in an appropriately collected first morning urine specimen. Urine samples collected immediately upon rising in the morning help distinguish the contribution of benign orthostatic proteinuria to the proteinuria detected on dipstick or randomly timed spot urine collection.
2. **First morning urine protein/creatinine ratio:**
  - a. Approximates 24-hour urine collections well
  - b. Appropriate collection is essential for accurate results. A child must empty the bladder before going to bed. If the child gets up during the night, the bladder should be emptied before returning to bed. When the child wakes up in the morning, the urine sample should be provided immediately.
  - c. Normal ratios:
    - (1) <2 years old: <0.5 mg/mg
    - (2) >2 years old: <0.2 mg/mg
  - d. Abnormal ratios (mg/mg): Significant proteinuria detected on a first morning protein/creatinine ratio should prompt verification of appropriate collection. Repeat specimen should be analyzed within 1 to 2 weeks, or sooner based on clinical scenario (e.g., edema, hypertension, or symptom of concern would prompt a more expedited workup).
3. **24-hour urine protein:** May have a contribution from benign orthostatic proteinuria, which cannot be ruled out without a fractional urine collection. Protein level >4 mg/m<sup>2</sup>/hr is considered significant.

## C. Etiologies ([Box 19.1](#))

## D. Evaluation<sup>20</sup>

Further evaluation is necessary if proteinuria is significant/symptomatic and not secondary to orthostatic proteinuria ([Box 19.2](#)).

## E. Nephrotic Syndrome<sup>21</sup>

1. **Epidemiology:** Idiopathic nephrotic syndrome of childhood is the most common form, representing approximately 90% of cases in children between the ages of 1 and 10 years. *Minimal change disease* is the most common renal pathology found among children with idiopathic nephrotic

**BOX 19.1****CAUSES OF PROTEINURIA**

**Transient proteinuria:** Fever, exercise, dehydration, cold exposure, congestive heart failure, seizure, stress, recent use of epinephrine

**Orthostatic proteinuria**

**Glomerular diseases characterized by isolated proteinuria:** Idiopathic (minimal change) nephrotic syndrome, focal segmental glomerulosclerosis, secondary causes of nephrotic syndrome, mesangial proliferative glomerulonephritis, membranous nephropathy, membranoproliferative glomerulonephritis, amyloidosis, diabetic nephropathy, sickle cell nephropathy

**Glomerular diseases with proteinuria as a prominent feature:** Acute postinfectious glomerulonephritis (streptococcal, endocarditis, hepatitis B or C virus, HIV), immunoglobulin A nephropathy, Henoch-Schönlein purpura nephritis, lupus nephritis, serum sickness, Alport syndrome, vasculitic disorders, reflux nephropathy

**Tubular disease:** Cystinosis, Fanconi syndrome, Wilson disease, Lowe syndrome, Dent disease (X-linked recessive nephrolithiasis), galactosemia, tubulointerstitial nephritis, acute tubular necrosis, renal dysplasia, polycystic kidney disease, reflux nephropathy, renal transplant rejection, drugs (aminoglycosides, cisplatin, penicillamine, lithium, NSAIDs, cyclosporine), heavy metals (lead, gold, mercury)

Modified from Kliegman RM, St. Geme JW III, Blum NJ, et al. *Nelson Textbook of Pediatrics*. 21st ed. Elsevier; 2020.

**BOX 19.2****BASIC EVALUATION OF SIGNIFICANT (NEPHROTIC AND NONNEPHROTIC) PROTEINURIA**

Complete metabolic panel with phosphorus

C3 and C4

Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)

Antinuclear antibody, anti-double-stranded DNA antibody

Hepatitis B, C, and HIV in high-risk populations

Antineutrophil antibodies (c- and p-ANCA)

Lipid panel

Renal and bladder ultrasonography

Referral to nephrologist

syndrome in this age group. Nephrotic syndrome may be a manifestation of a primary kidney disease, a systemic disorder resulting in glomerular injury, or rarely medication.

2. **Clinical manifestations:** Hypoalbuminemia and decrease in oncotic pressure results in generalized edema. Initial swelling commonly occurs on the face (especially periorbital), as well as in the pretibial area. Eye swelling is often mistaken for allergic reactions or seasonal allergies (Box 19.3).
3. **Etiologies:** See Table 19.10.

**BOX 19.3****FACTORS SUGGESTING DIAGNOSIS OTHER THAN IDIOPATHIC MINIMAL CHANGE NEPHROTIC SYNDROME**

Age <1 year or >10 years  
 Family history of kidney disease  
 Extrarenal disease (arthritis, rash, anemia)  
 Chronic disease of another organ or systemic disease  
 Symptoms due to intravascular volume expansion (hypertension, pulmonary edema)  
 Kidney failure  
 Active urine sediment (red blood cell casts)

**TABLE 19.10****ETIOLOGIES OF NEPHROTIC SYNDROME**

<b>Primary Causes (90%)</b>	<b>Secondary Causes (10%)</b>
Minimal change nephrotic syndrome (MCNS): 85% of idiopathic causes in children	Infections (HIV, hepatitis B, hepatitis C)
Focal segmental glomerulosclerosis (FSGS)	Systemic lupus erythematosus
Membranous nephropathy	Diabetes mellitus
IgA nephropathy	Drugs
Genetic disorders involving the slit diaphragm	Malignancy (leukemias, lymphomas)

4. **Investigations at first presentation:** UA and microscopy (microhematuria present in 30% and is not prognostic); urine P/Cr ratio; serum albumin, total protein, cholesterol, creatinine; infectious workup (consider tuberculosis, HIV, hepatitis B, hepatitis C, as indicated)
5. **Management of idiopathic nephrotic syndrome of childhood:** Empirical corticosteroid treatment without kidney biopsy is recommended for children without atypical features. Hospitalization recommended for children with overwhelming edema or infection. Home monitoring of proteinuria would include frequent first-morning dipsticks, with duration determined by provider.
  - a. Steroid-responsive: Approximately 95% of patients with minimal change disease (MCD) and 20% with focal segmental glomerulosclerosis (FSGS) achieve remission within 4 to 8 weeks of starting prednisone. Response to corticosteroids is the best prognostic indicator, including the likelihood of underlying MCD.
    - (1) Although duration of therapy varies, one common regimen includes prednisone 60 mg/m<sup>2</sup> daily or 2 mg/kg/day (maximum dose 60 mg/day) for 6 weeks, followed by 40 mg/m<sup>2</sup> or 1.5 mg/kg on alternate days for 6 weeks.<sup>21,22</sup>

- (2) Relapses of idiopathic nephrotic syndrome are treated with a shorter duration of corticosteroids, which also vary according to the center and the consensus body. Commonly, prednisone 60 mg/m<sup>2</sup> or 2 mg/kg/day (maximum dose 60 mg/day) until urine protein is negative for 3 consecutive days, followed by 40 mg/m<sup>2</sup> or 1.5 mg/kg on alternate days for 4 weeks
- b. Frequently relapsing: Defined as two or more relapses within 6 months of initial response, or four or more relapses in any 12-month period
  - c. Steroid-dependent: Defined as two consecutive relapses during tapering or within 14 days of cessation of steroids. Some patients can be managed with low-dose steroids, given daily or on alternate days, but many will relapse. Second-line treatments for frequently relapsing and steroid-dependent nephrotic syndrome: Cyclophosphamide, mycophenolate mofetil (MMF), calcineurin inhibitors, levamisole, or rituximab
  - d. Steroid-resistant: Lack of remission or partial remission after 8 weeks of corticosteroids. Second-line agents, including calcineurin inhibitors or MMF, are often introduced once steroid resistance is confirmed.
  - e. Indications for renal biopsy: Macroscopic hematuria, age <12 months or >12 years, systemic or syndromic findings, persistent creatinine elevation >1 to 2 weeks, low complement levels, and persistent proteinuria after 4 to 8 weeks of adequate steroid treatment<sup>23</sup>
6. **Complications:**
- a. AKI; thromboembolic disease; potentially life-threatening infection. See [Chapter 16](#) for vaccine recommendations.
  - b. Chronic systemic steroids: Cushingoid skin changes, cataracts, accelerated atherosclerosis, osteoporosis, gastric ulcer, mood swings, insomnia, insulin resistance, immunosuppression

## VI. HEMATURIA<sup>19,24</sup>

### A. Definition

1. **Microscopic hematuria:** >5 RBCs/hpf on centrifuged urine. Not visible to the naked eye
2. **Macroscopic (gross) hematuria:** Visible blood in urine
3. **Acute nephritic syndrome:** Classically tea or cola-colored urine, facial or body edema, hypertension, and oliguria

### B. Etiologies: See [Table 19.11](#)

### C. Evaluation ([Fig. 19.2](#))

**Differentiate glomerular and extraglomerular hematuria:** Examine urine sediment, looking for RBC casts and protein.

1. Glomerular hematuria
  - a. Usually hypertensive; dysuria usually absent; edema, fever, pharyngitis, rash, and arthralgia may suggest glomerular disease


TABLE 19.11

## CAUSES OF HEMATURIA IN CHILDREN

Upper urinary tract disease	Isolated renal disease	IgA nephropathy; Alport syndrome; thin glomerular basement membrane nephropathy; postinfectious/poststreptococcal glomerulonephritis; membranous nephropathy; membranoproliferative glomerulonephritis; rapidly progressive glomerulonephritis; focal segmental glomerulosclerosis; antiglomerular basement membrane disease; hereditary angiopathy with nephropathy, aneurysms, muscle cramps (HANAC)
	Multisystem disease	Systemic lupus erythematosus nephritis, Henoch-Schönlein purpura nephritis, granulomatosis with polyangiitis, polyarteritis nodosa, Goodpasture syndrome, hemolytic-uremic syndrome, sickle cell glomerulopathy, HIV nephropathy
	Tubulointerstitial disease	Pyelonephritis, interstitial nephritis, papillary necrosis, acute tubular necrosis
	Vascular disorders	Arterial or venous thrombosis, malformations (aneurysms, hemangiomas), nutcracker syndrome, hemoglobinopathy (sickle cell trait/disease), crystalluria
	Anatomic disorders	Hydronephrosis, cystic-syndromic kidney disease, polycystic kidney disease, multicystic dysplasia, tumor (Wilms tumor, rhabdomyosarcoma, angiomyolipoma, medullary carcinoma), trauma
Lower urinary tract disease		Inflammation (infectious and noninfectious) Cystitis Urethritis Urolithiasis Trauma Coagulopathy Heavy exercise Bladder tumor Factitious syndrome, factitious syndrome by proxy


Data from Kliegman RM, St. Geme JW III, Blum NJ, et al. *Nelson Textbook of Pediatrics*. 21st ed. Elsevier; 2020.

- b. Laboratory: Dysmorphic RBCs and casts on UA, complete blood cell count (CBC) with differential and smear, serum electrolytes with calcium, BUN/creatinine, serum protein/albumin, and other testing driven by history and exam, including ANA, hepatitis B and C serologies, HIV, audiology screen, if indicated
  - c. Consider other studies to determine underlying diagnosis: C3/C4, antineutrophil antibody (c- and p-antineutrophil cytoplasmic antibodies), anti-double-stranded DNA
2. Extraglomerular hematuria
    - a. Rule out infection: Urine culture, gonorrhea, chlamydia
    - b. Rule out trauma: History, consider imaging of abdomen/pelvis



**FIGURE 19.2**

Diagnostic strategy for hematuria. *GN*, Glomerulonephritis; *HIV*, human immunodeficiency virus; *MPGN*, membranoproliferative glomerulonephritis; *NSAIDs*, nonsteroidal antiinflammatory drugs; *PSGN*, poststreptococcal glomerulonephritis; *RBC*, red blood cell; *SBE*, subacute bacterial endocarditis; *SLE*, systemic lupus erythematosus.

**FIGURE 19.3**

Management algorithm for hematuria. ANA, antinuclear antibody; BP, blood pressure; ASO, antistreptolysin O; BUN, blood urea nitrogen; CBC, complete blood count; PE, physical exam; SLE, systemic lupus erythematosus. (Data from Hay WM, Levin MJ, Deterding RR, et al. *CURRENT Diagnosis & Treatment Pediatrics*. 21st ed. <https://www.accessmedicine.com>, Fig. 24.1.)

- c. Investigate other potential causes: Urine Ca/Cr ratio or 24-hour urine for kidney stone risk analysis, sickle cell screen, renal/bladder ultrasound. Consider serum electrolytes with calcium, coagulation studies.

#### D. Management (Fig. 19.3)

### VII. ACUTE KIDNEY INJURY<sup>25,26</sup>

#### A. Definition

Sudden decline in kidney function; clinically represented by rising creatinine, with or without changes in urine output

**B. Etiology (Table 19.12)**

Causes are generally subdivided into three categories:

1. **Prerenal:** Impaired perfusion of kidneys, the most common cause of acute kidney injury (AKI) in children. Volume depletion is a common cause of prerenal AKI.
2. **Renal:**
  - a. Parenchymal disease due to vascular or glomerular lesions
  - b. Acute tubular necrosis: Diagnosis of exclusion when no evidence of renal parenchymal disease is present and prerenal and postrenal causes have been eliminated, if possible
3. **Postrenal:** Obstruction of the urinary tract, commonly resulting from inherited anatomic abnormalities in children

**TABLE 19.12****ETIOLOGIES OF ACUTE KIDNEY INJURY**

Prerenal	<p><b>Decreased true intravascular volume:</b> Hemorrhage, volume depletion, sepsis, burns</p> <p><b>Decreased effective intravascular volume:</b> Congestive heart failure, hepatorenal syndrome</p> <p><b>Altered glomerular hemodynamics:</b> NSAIDs, ACE inhibitors (when renal perfusion is already low)</p>
Intrinsic renal	<p><b>Acute tubular necrosis:</b> Hypoxic/ischemic insults Drug-induced—aminoglycosides, amphotericin B, acyclovir, chemotherapeutic agents (ifosfamide, cisplatin) Toxin-mediated—endogenous toxins (myoglobin, hemoglobin); exogenous toxins (ethylene glycol, methanol)</p> <p><b>Interstitial nephritis:</b> Drug-induced—<math>\beta</math>-lactams, NSAIDs (may be associated with high-grade proteinuria), sulfonamides, PPIs Idiopathic</p> <p><b>Uric acid nephropathy:</b> Tumor lysis syndrome</p> <p><b>Glomerulonephritis:</b> In most severe degree, presents as rapidly progressive glomerulonephritis (RPGN)</p> <p><b>Vascular lesions:</b> Renal artery thrombosis, renal vein thrombosis, cortical necrosis, hemolytic uremic syndrome</p> <p><b>Hypoplasia/dysplasia:</b> Idiopathic or exposure to nephrotoxic drugs in utero</p>
Postrenal	<p>Obstruction in a solitary kidney Bilateral ureteral obstruction Urethral obstruction Bladder dysfunction</p>

ACE, Angiotensin-converting enzyme; NSAIDs, nonsteroidal antiinflammatory drugs; PPIs, proton pump inhibitors. Data from Andreoli SP. Acute kidney injury in children. *Pediatr Nephrol*. 2009;24:253–263.

### C. Clinical Presentation

Pallor, decreased urine output, systemic and pulmonary edema, hypertension, vomiting, and lethargy. The hallmark of early kidney failure is often oliguria.

1. **Oliguria:** Urine output  $<0.5$  mL/kg/hr (for at least 6 hours). May reflect intrinsic or obstructive kidney disease. Always interpret urine output in the context of physical exam, clinical scenario, and fluid delivery. For example, low urine output may be appropriate (physiologic response to water depletion in a prerenal state) and “normal” urine output may be inappropriate in a volume-depleted patient (potentially representing kidney tubular damage or another pathologic state). Laboratory differentiation of oliguria is found in [Table 19.13](#).
2. **Blood urea nitrogen/creatinine (BUN/Cr) ratio (both in mg/dL):** Interpret ratios with caution in small children with low serum creatinine.
  - a. 10 to 20 (normal ratio): Suggests intrinsic renal disease in the setting of oliguria
  - b.  $>20$ : Suggests volume depletion, prerenal azotemia, or gastrointestinal bleeding
  - c.  $<5$ : Suggests liver disease, starvation, or inborn error of metabolism

### D. Acute Tubular Necrosis

Clinically defined by three phases:

1. **Oliguric phase:** Period of severe oliguria that may last days. If oliguria or anuria persists for longer than 3 to 6 weeks, kidney recovery from ATN is less likely.
2. **High urine output phase:** Begins with increased urine output and progresses to passage of large volumes of isosthenuric urine containing sodium levels of 80 to 150 mEq/L
3. **Recovery phase:** Signs and symptoms usually resolve rapidly, but polyuria may persist for days to weeks.

### E. Treatment Considerations

1. Careful monitoring of volume status (daily weights, strict input/output). Consider placement of indwelling catheter to monitor urine output.
2. Prerenal and postrenal factors should be addressed or excluded.
3. Intravascular volume resuscitation and maintenance with appropriate fluids in consultation with a pediatric nephrologist

**TABLE 19.13**

#### LABORATORY DIFFERENTIATION OF OLIGURIA

Test	Prerenal	Renal
FENa	$\leq 1\%$	$> 3\%$
BUN/Cr ratio	$> 20:1$	$< 10:1$
Urine specific gravity	$> 1.015$	$< 1.010$

*BUN*, Blood urea nitrogen; *Cr*, creatinine; *FENa*, fractional excretion of sodium.

4. Monitor metabolic/electrolyte abnormalities, discontinue unnecessary nephrotoxic medications and follow drug levels closely when available, adjust dosing of medications based on creatinine clearance (see [Chapter 31](#)), monitor blood pressure closely, and maintain appropriate nutrition (low phosphorus, low potassium).
5. See [Section IX](#) for indications for acute dialysis.

### F. Complications

1. Dependent on clinical severity
2. Usually includes fluid overload (hypertension, congestive heart failure [CHF], or pulmonary edema), electrolyte disturbances (hyperkalemia), metabolic acidosis, hyperphosphatemia, and uremia

### G. Radiographic Imaging Considerations in AKI/CKD

1. Clinical significance of contrast-induced nephropathy (CIN) is uncertain in both adults and children, including those with mild-moderate CKD. Postcontrast AKI should be used instead of CIN when cause of AKI postcontrast exposure is uncertain.<sup>27,28</sup>
2. If patient at high risk for CIN, such as those with AKI or CKD, consider radiographic studies that do not require administration of radiographic iodinated contrast media (RICM), weighing risks and benefits.
3. If RICM is required, use of low or iso-osmolality contrast media is preferred.<sup>28</sup>
4. Recent trial suggests no hydration to be noninferior to hydration in adult CKD patients with eGFR 30 to 59 mL/min per 1.73 m<sup>2</sup>.<sup>29</sup>
5. Recent trial suggests no benefit to either sodium bicarbonate or acetylcysteine in preventing CIN.<sup>30</sup>
6. Gadolinium and nephrogenic systemic fibrosis: Newer group II gadolinium-based contrast agents (GBCAs) are thought to have minimal or negligible risk of causing nephrogenic systemic fibrosis, unlike older group I agents, which are contraindicated in patients with GFR <30 mL/min per 1.73 m<sup>2</sup>. Thus, screening of renal function prior to administration of a group II GBCA is optional.<sup>31</sup>

## VIII. CHRONIC KIDNEY DISEASE<sup>32,33</sup>

### A. Definition

Kidney damage for >3 months, as defined by structural or functional abnormalities, with or without decreased GFR. Classified as:

Stage I: Kidney injury with normal or increased GFR

Stage II: GFR 60 to 89 mL/min/1.73 m<sup>2</sup>

Stage III: GFR 30 to 59 mL/min/1.73 m<sup>2</sup>

Stage IV: GFR 15 to 29 mL/min/1.73 m<sup>2</sup>

Stage V: GFR <15 mL/min/1.73 m<sup>2</sup> or dialysis

### B. Etiology

1. Children <5 years: Most commonly due to congenital anomalies of the kidney and urinary tract (see [Chapter 18](#), Section XII).

2. Older children: More commonly acquired glomerular diseases (e.g., glomerulonephritis, FSGS) or hereditary disorders (e.g., Alport syndrome).

### C. Clinical Manifestations (Table 19.14)

### D. General Management

1. **Nutrition:** Growth should be monitored closely; supplemental nutrition should be considered if not reaching caloric goals, which are higher in children with CKD. Potassium and sodium restriction may be required in advanced CKD. Growth hormone therapy may be considered in consultation with pediatric nephrology/endocrinology.
2. **Anemia:** Evaluate with CBC and iron studies. Iron deficiency is common and should be treated with oral (preferred) or IV iron. Consider erythropoietin-stimulating agents in consultation with pediatric nephrology.
3. **CKD–mineral and bone disorder:** Characterized by phosphate retention, decreased free calcium, and decreased 1,25 hydroxyvitamin D. Serum calcium, phosphate, alkaline phosphatase, vitamin D, and parathyroid hormone should be regularly monitored. Control phosphate with phosphate binders, supplement with calcium and vitamin D, as indicated.
4. **Cardiovascular:** Regularly monitor blood pressure and lipid panel. Treating hypertension slows the progression of CKD.

## IX. DIALYSIS<sup>34-36</sup>

### A. Indications for Acute Dialysis

Acute dialysis is indicated when metabolic or fluid derangements are not controlled by aggressive medical management alone. Should be initiated in consultation with a nephrologist. Generally accepted criteria include the following:

1. **Acidosis:** Intractable metabolic acidosis
2. **Electrolyte abnormalities:** Hyperkalemia  $>6.5$  mEq/L despite restriction of delivery and medical management; calcium and phosphorus imbalance (e.g., hypocalcemia with tetany, seizures in the presence of a very high serum phosphate level); derangements implicated in neurologic abnormalities
3. **Ingestion or accumulation of dialyzable toxins or poisons:** Lithium, ammonia, alcohol, barbiturates, ethylene glycol, isopropanol, methanol, salicylates, theophylline. Consult poison control experts when available.
4. **Volume overload:** Evidence of pulmonary edema or hypertension
5. **Uremia:** BUN  $>150$  mg/dL (lower if rising rapidly), uremic pericardial effusion, neurologic symptoms, platelet dysfunction

### B. Techniques

1. **Peritoneal dialysis (PD):** Requires catheter to access peritoneal cavity, as well as adequate peritoneal perfusion. May be used acutely or chronically. Contraindications: Abdominal wall defects (omphalocele,

TABLE 19.14

## CLINICAL MANIFESTATIONS OF CHRONIC KIDNEY DISEASE

Manifestation	Mechanisms
Edema	Accumulation of Na <sup>+</sup> and water Decreased oncotic pressure Reduced cardiac output Mineralocorticoid excess
Uremia	Decline in GFR
Acidosis	Urinary bicarbonate wasting Decreased excretion of NH <sub>4</sub> and acid
Sodium wasting	Solute diuresis, tubular damage Aldosterone resistance
Sodium retention	Nephrotic syndrome CHF Reduced GFR
Urinary concentrating defect	Solute diuresis, tubular damage ADH resistance
Hyperkalemia	Decline in GFR, acidosis Aldosterone resistance
Renal osteodystrophy	Impaired production of 1,25(OH) vitamin D Decreased intestinal calcium absorption Impaired phosphorus excretion Secondary hyperparathyroidism
Growth retardation	Protein-calorie deficiency Renal osteodystrophy Acidosis Anemia Inhibitors of insulin-like growth factors
Anemia	Decreased erythropoietin production Low-grade hemolysis Bleeding, iron deficiency Decreased erythrocyte survival Inadequate folic acid intake Inhibitors of erythropoiesis
Bleeding tendency	Thrombocytopenia Defective platelet function
Infection	Defective granulocyte function Glomerular loss of immunoglobulin/opsonins
Neurologic complaints	Uremic factors
Gastrointestinal ulceration	Gastric acid hypersecretion/gastritis Reflux Decreased motility
Hypertension	Sodium and water overload Excessive renin production
Hypertriglyceridemia	Diminished plasma lipoprotein lipase activity
Pericarditis and cardiomyopathy	Unknown
Glucose intolerance	Tissue insulin resistance

ADH, Antidiuretic hormone; CHF, congestive heart failure; GFR, glomerular filtration rate; NH<sub>4</sub>, ammonium.  
Modified from Brenner BM. *Brenner and Rector's The Kidney*. 11th ed. Elsevier; 2019.

gastroschisis, bladder exstrophy, diaphragmatic hernia), severe inflammatory bowel disease, or infectious source in the abdomen<sup>34</sup>

2. **Intermittent hemodialysis (HD):** Requires placement of special vascular access catheters. May be method of choice for certain toxins (e.g., ammonia, uric acid, poisons) or when there are contraindications to peritoneal dialysis
3. **Continuous arteriovenous hemofiltration/hemodialysis (CAVH/D) and continuous venovenous hemofiltration/hemodialysis (CVVH/D):** Requires special vascular access catheter. Lower efficiency of solute removal compared with intermittent hemodialysis, but higher efficiency is not necessary because of the continuous nature of this form of dialysis. Sustained nature of dialysis allows for more gradual removal of volume/solutes, which is ideal for patients with hemodynamic or respiratory instability.

### C. Complications (Table 19.15)

**TABLE 19.15**

#### COMPLICATIONS OF DIALYSIS

PD	HD	CAVH/D, CVVH/D
PD catheter leaks: Confirm leakage of PD fluid with glucose dipstick. Discontinue PD for 7 to 10 days or lower dialysate volume.	Intradialytic hypotension: Causes include rapid fluid removal, predialysis antihypertensive medication, bradykinin release, hypotonic dialysate. Reduce or pause ultrafiltration.	Intradialytic hypotension
PD associated peritonitis (PDAP): Acute clouding of dialysate, abdominal pain/distention, vomiting. Culture peritoneal fluid and start empiric intraperitoneal antibiotics in consultation with nephrology. Refer to published ISPD Consensus Guidelines for treatment recommendations. <sup>35</sup>	HD fistula complications include vascular stenosis and thrombosis.	Use of citrate for anticoagulation can cause citrate overload (metabolic alkalosis), citrate accumulation (metabolic acidosis), hypocalcemia, and hypomagnesemia.

CAVH/D, continuous arteriovenous hemofiltration/hemodialysis; CVVH/D, continuous venovenous hemofiltration/hemodialysis; HD, hemodialysis; ISPD, International Society of Peritoneal Dialysis; PD, peritoneal dialysis  
 Modified from Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. *Perit Dial Int.* 2012;32:S29–S86; Sigwalt F, Bouteleux A, Dambricourt F, et al. Clinical complications of continuous renal replacement therapy. *Contrib Nephrol.* 2018;194:109–117.

## X. TUBULAR DISORDERS

### A. Renal Tubular Acidosis (Table 19.16)<sup>37</sup>

1. A group of transport defects resulting in abnormal urine acidification; result of defects in reabsorption of bicarbonate ( $\text{HCO}_3^-$ ), excretion of hydrogen ions ( $\text{H}^+$ ), or both

TABLE 19.16

## RENAL TUBULAR ACIDOSIS BIOCHEMICAL AND CLINICAL CHARACTERISTICS

	Type 1 (Distal)	Type 2 (Proximal)	Type 4 (Hypoaldosteronism)
Mechanism	Impaired distal acidification	Impaired bicarbonate absorption	Decreased aldosterone secretion or aldosterone effect
Etiology	Hereditary Sickle cell disease Toxins/drugs Cirrhosis Obstructive uropathy Connective tissue disorder	Hereditary Metabolic disease Fanconi syndrome Prematurity Toxins/heavy metals Amyloidosis PNH	Absolute mineralocorticoid deficiency Adrenal failure CAH DM Pseudohypoaldosteronism Interstitial nephritis
Minimal urine pH	>5.5	<5.5 (urine pH can be >5.5 with a bicarbonate load)	<5.5
Fractional excretion of bicarbonate (FeHCO <sub>3</sub> )	↓ (<5%)	↑ (>15%)	↓ (<5%)
Plasma K <sup>+</sup> concentration	Normal or ↓	Usually ↓	↑
Urine anion gap	Positive	Positive or negative	Positive
Nephrocalcinosis/nephrolithiasis	Common	Rare	Rare
Treatment	1–3 mEq/kg/day of HCO <sub>3</sub> <sup>-</sup> (5–10 mEq/kg/day if bicarb wasting)	5–20 mEq/kg/day of HCO <sub>3</sub> <sup>-</sup>	1–5 mEq/kg/day of HCO <sub>3</sub> <sup>-</sup> May add fludrocortisone and potassium binders

CAH, Congenital adrenal hyperplasia; DM, diabetes mellitus; PNH, paroxysmal nocturnal hemoglobinuria.

Modified from Avner ED, Harmon WE, Niaudet P, et al. *Pediatric Nephrology*. Springer-Verlag Berlin Heidelberg; 2016.

- Results in a persistent normal anion gap hyperchloremic metabolic acidosis
- RTA syndromes have a normal GFR and often do not progress to kidney failure.
- Clinical presentation may be characterized by failure to thrive, polyuria, constipation, vomiting, and dehydration.
- Fractional excretion of bicarbonate (FeHCO<sub>3</sub>) should be checked after a HCO<sub>3</sub> load.** Can help differentiate the types of RTA. See [Section II.B](#) for equation.
- Urine anion gap (UAG) is also useful;** however, it should not be used when a patient is volume depleted or has an anion-gap metabolic acidosis. See [Section II.B](#) for equation.

### B. Fanconi Syndrome

- Generalized dysfunction of the proximal tubule resulting not only in bicarbonate loss but also in variable wasting of phosphate, glucose, and amino acids

2. May be hereditary, as in cystinosis and galactosemia, or acquired through toxin injury and other immunologic factors
3. Clinically characterized by rickets and impaired growth

### C. Nephrogenic Diabetes Insipidus

1. **Water conservation is dependent on antidiuretic hormone (ADH) and its effects on the distal renal tubules.** Polyuria (urine output  $>5$  mL/kg/hr or  $>2$  L/day), a hallmark of nephrogenic diabetes insipidus (NDI), is due to diminished or lack of response of the ADH receptor in the distal renal tubules. Hereditary defects of ADH receptor or acquired insults (e.g., interstitial nephritis, sickle cell disease, lithium toxicity, CKD) may underlie NDI.
2. **Must be differentiated from other causes of polyuria:** Central diabetes insipidus (ADH deficiency that may be idiopathic or acquired through infection or pituitary trauma; see [Chapter 10](#)), diabetes mellitus, psychogenic polydipsia, cerebral salt wasting

## XI. NEPHROLITHIASIS<sup>38-44</sup>

### A. Risk Factors

Male sex; history of UTI (especially those  $<5$  years); congenital and structural urologic abnormalities (urinary stasis), neurogenic bladder, hypercalciuria, hyperoxaluria/oxalosis, hypocitraturia, other metabolic abnormalities; family history of stones, renal failure, consanguinity

### B. Presentation

1. Microscopic hematuria (90%), flank/abdominal pain (50% to 75%), gross hematuria (30% to 55%), and concomitant UTI in up to 20%
2. Have higher likelihood than adults of having asymptomatic stones, especially younger children

### C. Diagnostic Imaging

1. Ultrasonography is an effective and preferred modality, particularly at centers with expertise, given benefit of avoiding radiation exposure (75% sensitive for renal stones).<sup>40</sup>
2. Noncontrast CT may be preferred to improve diagnostic sensitivity (e.g., with radiolucent stones such as uric acid stones, ureteral stones, lack of ultrasonographic expertise).

### D. Management

1. **Pain control, urine culture, hydration.** Some centers initiate  $\alpha$ -blockers to facilitate stone passage, although evidence of benefit in children is equivocal.<sup>41-43</sup>
2. **Antibiotics:** Should be considered in treatment of all stones, especially if fever and/or pyuria present, because of the high association with UTI
3. **Urologic intervention** (e.g., extracorporeal shock wave lithotripsy, ureteroscopy, percutaneous nephrolithotomy): Consider with unremitting pain, urinary obstruction, increasing stone size, size  $\geq 7$  mm, or cystine/struvite stone, especially in the setting of AKI or at-risk patients (e.g., solitary kidney, anatomic anomalies).<sup>43</sup>

4. **Strain urine to collect stone; analyze stone composition to aid in prevention of future stones.**

### E. Workup

1. Up to 75% of children with a kidney stone will have a metabolic abnormality (e.g., hypercalciuria, hyperoxaluria, hyperuricosuria, cystinuria).
2. Workup should include analysis of the stone (if possible); UA; basic metabolic panel; and serum calcium, phosphate, magnesium, and uric acid levels. If evidence of elevated calcium or phosphate, obtain parathyroid hormone (PTH) level and consider checking 25- and 1,25(OH) vitamin D levels.
3. After symptoms have resolved, a 24-hour urine collection should be obtained. Risk factors for stone formation should be analyzed: urine volume, osmolarity, sodium, calcium, urate, oxalate, citrate, and cystine. This test is also referred to as a “stone risk analysis.”

### F. Prevention

1. **All children with history of stones should increase fluid intake** (e.g., at least 2 L/day in those aged >10 years old).
2. **Targeted interventions of any identified metabolic abnormalities** (e.g., low-sodium diet in those with hypercalciuria). Pharmacologic interventions are also available in certain scenarios (e.g., citrate supplementation).
3. **Dietary modifications:** Long-term adherence (5 years) to normal calcium, low-sodium diet may decrease recurrence of stones in people with idiopathic hypercalciuria with recurrent nephrolithiasis.<sup>44</sup>

## XII. WEB RESOURCES

- International Pediatric Nephrology Association: <https://theipna.org/>
- National Kidney Disease Education Program: <https://www.niddk.nih.gov/health-information/communication-programs/nkdep>
- National Kidney Foundation: [https://www.kidney.org/professionals/kdoqi/gfr\\_calculator](https://www.kidney.org/professionals/kdoqi/gfr_calculator)

## REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Shenoy MA, Webb NJA. Clinical evaluation of the child with suspected renal disease. In: Avner ED, Harmon WE, Niaudet P, et al., eds. *Pediatric Nephrology*. Springer Berlin Heidelberg; 2016:595–612.
2. Schwartz GJ, Munoz A, Schneider MF. New equations to estimate GFR in children with CKD. *J Am Soc Nephrol*. 2009;20:629–637.
3. Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. *N Engl J Med*. 2021. <https://doi.org/10.1056/NEJMoa2102953>
4. Carmody JB. Focus on diagnosis: urine electrolytes. *Pediatr Rev*. 2011;32:65–68.
5. Sargent JD, Stukel TA, Kresel J, et al. Normal values for random urinary calcium to creatinine ratios in infancy. *J Pediatr*. 1993;123:393–397.
6. Sinaiko A. Hypertension in children. *N Engl J Med*. 1996;335:26.
7. Viera AJ, Neutze D. Diagnosis of secondary hypertension: an age-based approach. *Am Fam Physician*. 2010;82:12.
8. Gupta-Malhotra M, Banker A, Shete S, et al. Essential hypertension vs. secondary hypertension among children. *Am J Hypertens*. 2015;28:1.
9. Flynn JT, Kaelber DC, Baker-Smith CM, et al. AAP subcommittee on screening and management of high blood pressure in children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*. 2017;140(3):e20171904.
10. Starr MC, Flynn JT. Neonatal hypertension: cases, causes, and clinical approach. *Pediatr Nephrol*. 2018:1–13.
11. Zubrow AB, Hulman S, Kushner H, et al. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia neonatal blood pressure study group. *J Perinatol*. 1995;15:470–479.
12. Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management. Urinary tract infection: clinical practice guidelines for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. *Pediatrics*. 2011;128:595–610.
13. Subcommittee on Urinary Tract Infection. Reaffirmation of AAP clinical practice guideline: the diagnosis and management of the initial urinary tract infection in febrile infants and young children 2–24 months of age. *Pediatrics*. 2016;138(6), e20163026.
14. American Academy of Pediatrics, American Academy of Pediatrics Board of Directors and Executive Committee. Race-based medicine. *Pediatrics*. 2021;6. <https://doi.org/10.1542/peds.2021-053829>
15. Tzimenatos L, Mahajan P, Dayan PS, et al. Accuracy of the urinalysis for urinary tract infections in febrile infants 60 days and younger. *Pediatrics*. 2018;141: e20173068.
16. Hooton T, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infections in adults: 2009 international clinical practice guidelines from the Infectious Disease Society of America. *Clin Infect Dis*. 2010;50:625–663.
17. Michael M, Hodson EM, Craig JC, et al. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. *Cochrane Database Syst Rev*. 2003;1:CD003966. <https://doi.org/10.1002/14651858>
18. RIVUR Trial Investigators, Hoberman A, Greenfield SP, et al. Antimicrobial prophylaxis for children with vesicoureteral reflux. *N Engl J Med*. 2014;370(25):2367–2376.

19. Kliegman RM, St. Geme III JW, Blum NJ, et al. *Nelson Textbook of Pediatrics*. 21st ed. Elsevier; 2020.
20. Cruz C, Spitzer A. When you find protein or blood in urine. *Contemp Pediatr*. 1998;15:89.
21. Gipson DS, Massengill SF, Yao L, et al. Management of childhood-onset nephrotic syndrome. *Pediatrics*. 2009;124:747–757.
22. Zotta F, Vivarelli M, Emma F. Update on the treatment of steroid-sensitive nephrotic syndrome. *Pediatr Nephrol*. 2021. <https://doi.org/10.1007/s00467-021-04983-3>
23. Lombel RM, Hodson EM, Gipson DS. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. *Pediatr Nephrol*. 2013;28:409–414.
24. Massengill SF. Hematuria. *Pediatr Rev*. 2008;29:342–348.
25. Whyte DA, Fine RN. Acute renal failure in children. *Pediatr Rev*. 2008;29:299–306.
26. Andreoli SP. Acute kidney injury in children. *Pediatr Nephrol*. 2009;24:253–263.
27. Rudnick MR, Leonberg-Yoo AK, Litt HI, et al. The controversy of contrast-induced nephropathy with intravenous contrast: what is the risk? *Am J Kidney Dis*. 2019;75(1):105–113.
28. Maloney E, Iyer RS, Phillips GS, et al. Practical administration of intravenous contrast media in children: screening, prophylaxis, administration and treatment of adverse reactions. *Pediatr Radiol*. 2019;49:433–447.
29. Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. *Lancet*. 2017;389:1312–1322.
30. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. *N Engl J Med*. 2018;378:603–614.
31. Mathur M, Jones JR, Weinreb JC. Gadolinium deposition and nephrogenic systemic fibrosis: a radiologist's primer. *RadioGraphics*. 2020;40:153–162.
32. Whyte DA, Fine RN. Chronic kidney disease in children. *Pediatr Rev*. 2008;29:335–341.
33. Brenner BM. *Brenner and Rector's The Kidney*. 11th ed. Elsevier; 2019.
34. Al-Natour M, Thompson D. Peritoneal dialysis. *Semin Intervent Radiol*. 2016;33(1):3–5.
35. Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. *Perit Dial Int*. 2012;32:S29–S86.
36. Sigwalt F, Bouteleux A, Dambricourt F, et al. Clinical complications of continuous renal replacement therapy. *Contrib Nephrol*. 2018;194:109–117.
37. Soriano JR. Renal tubular acidosis: the clinical entity. *J Am Soc Nephrol*. 2002;13:2160–2170.
38. Tanaka ST, Pope 4th JC. Pediatric stone disease. *Curr Urol Rep*. 2009;10:138–143.
39. McKay CP. Renal stone disease. *Pediatr Rev*. 2010;31:179–188.
40. Passerotti C, Chow JS, Silva A, et al. Ultrasound versus computerized tomography for evaluating urolithiasis. *J Urology*. 2009;182(4):1829–1834.
41. Chu DI, Tasian GE, Copelovitch L. Pediatric kidney stones—avoidance and treatment. *Curr Treat Options Pediatrics*. 2016;2(2):104–111.
42. Shet KR, White JT, Perez-Orozco AF, et al. Evaluating natural history and follow up strategies for nonobstructive urolithiasis in pediatric population. *Front Pediatr*. 2018;6:353.

43. Telli O, Hamidi N, Bagci U, et al. What happens to asymptomatic lower pole kidney stones smaller than 10mm in children during watchful waiting? *Pediatr Nephrol.* 2017;32(5):853–857.
44. Escribano J, Balaguer A, Roqué i Figuls M, et al. Dietary interventions for preventing complications in idiopathic hypercalciuria. *Cochrane Database Syst Rev.* 2014;2:CD006022.

# Chapter 20

## Neurology

*Hannah E. Edelman, MD, PhD and Maera J. Stratton, MD*

 See additional content online.

 **Audio Case File 20.1** Seizure mimics: an age-based approach

### I. NEUROLOGIC EXAMINATION

#### A. Mental Status: Alertness, Orientation (Person, Place, Time, Situation), Language, Cognition

1. Infants: Observe “cuteness” and ability to dynamically engage caretakers.
2. Toddlers: Bring toys. Observe and engage in play.
3. School age: Ask children to draw or describe school or friends.

#### B. Cranial Nerves (eTable 20.1)

1. For a quick assessment of cranial nerves for all patients, observe:
  - a. (II) Visual response to objects in each visual quadrant
  - b. (III, IV, VI) Conjugate gaze at full lateral and vertical positions, nystagmus, ptosis
  - c. (VII) Symmetry and expressiveness of face at rest and with emotive activation
  - d. (VIII) Finger rub, or response to and localization of sound for infants
  - e. (IX, X, XII) Quality of phonation and articulation; ask about feeding, chewing, swallowing

#### C. Motor

1. **Muscle bulk:** Atrophy or pseudohypertrophy is a red flag.
2. **Tone:** Spasticity, rigidity, hypotonia
  - a. Infants: Observe infant undressed to assess resting posture (varies with age). Active tone: Traction response, axillary stability (slip-through), posture in horizontal suspension. Passive tone (resistance of movements of the joints): Flap hands/feet, scarf sign
  - b. Red flags: Scissoring, toe-walking, inability to supinate hand, clasped thumb or grasp
3. **Strength:**
  - a. Younger children: Observe ease of normal functions: rising from floor, standing broad jump, running, climbing onto chair or exam table. Note presence of accommodations child is making to execute movements (e.g., shoulder shrug or trunk tilt to raise arm).
  - b. Older children: Confrontation testing, pronator drift
  - c. For conventional rating scale, see [Box 20.1](#).
4. **Involuntary movements:** Fasciculations, tics, dystonia, chorea, athetosis, myoclonus, tremor

eTABLE 20.1

## CRANIAL NERVES

Function	Cranial Nerve and Test
Smell	<b>I. Olfactory</b>
Vision	<b>II. Optic.</b> Visual acuity and fundus ( <i>Infants:</i> Fix and follow, red reflex; <i>Older children:</i> Snellen chart, fundoscopic exam)
Pupillary reflex	<b>II. Optic.</b> Detection of light and/or visual stimulus <b>III. Oculomotor.</b> Control of pupil size in response to light, accommodation
Eye movements and eyelids	<b>III. Oculomotor.</b> Eyelid elevation, eye adduction and elevation. Palsy—"down and out," ptosis <b>IV. Trochlear.</b> Eye depression and intorsion. Palsy—head tilt <b>VI. Abducens.</b> Lateral gaze NOTE: Nystagmus can be physiologic or pathologic (intoxication, lesions in vestibular system, brainstem, or cerebellum)
Sensation	<b>V. Trigeminal.</b> Facial sensation, corneal reflex
Mastication	<b>V. Trigeminal.</b> Clench teeth
Facial movement	<b>VII. Facial.</b> Observation of emotional expressions and facial symmetry, eyebrow elevation, eye closure, smile, puffing out cheeks
Hearing	<b>VIII. Vestibulocochlear.</b> Localize sound, finger rub, audiologic testing
Vestibular	<b>VIII. Vestibulocochlear.</b> Sense of balance, horizontal nystagmus, reading with passive head movement, Romberg, tandem gait
Oropharynx	<b>IX. Glossopharyngeal.</b> Palate elevation, gag reflex <b>X. Vagus.</b> Soft palate elevation, muscles of pharynx and larynx. Unilateral palsy—soft, hoarse voice; bilateral—respiratory distress
Head control	<b>XI. Accessory.</b> Lateral head turn, shoulder shrug
Tongue	<b>XII. Hypoglossal.</b> Tongue protrusion, push tongue against inner cheek

**BOX 20.1****STRENGTH RATING SCALE**

0/5: No movement (i.e., no palpable tension at tendon)

1/5: Flicker of movement

2/5: Movement in a gravity-neutral plane

3/5: Movement against gravity but not resistance

4/5: Subnormal strength against resistance (requires accommodation to execute movement)

5/5: Normal strength against resistance (motion is smooth, comfortably executed, without accommodation)

**D. Sensory**


1. Primarily important if any concern for spinal cord defect or peripheral nerve injury
2. Focus initial investigation along three axes for meaningful lesion localization:
  - a. Distal deficit with preserved (or less impaired) proximal sensation suggests **polyneuropathy**.
    - (1) Pain/temperature deficit: Small fiber polyneuropathy/anterior spinal cord
    - (2) Position/vibration deficit: Large fiber polyneuropathy/posterior spinal cord
  - b. Lower body more affected than upper body suggests **spinal cord injuries**.
    - (1) See [Fig. 20.1](#) for dermatomes.
    - (2) Ask about continence, assess rectal tone.
  - c. If difference between left and right, concern for **unilateral brain or spinal cord lesion**

**E. Reflexes**

1. **Tendon reflexes:** Gradation ([Box 20.2](#)) and localization ([eTable 20.2](#)). Helpful in localizing abnormalities including upper versus lower motor neuron pathology, especially in presence of weakness or asymmetry ([eTable 20.3](#)). Compare right to left, upper to lower extremities, and distal to proximal reflexes. Generalized high or low reflexes are of little significance in the setting of normal strength and coordination.
2. **Primitive reflexes:** Expected during specific time windows ([Table 20.1](#))

**F. Coordination and Gait**

1. **Evaluate coordination while watching age-appropriate activities.**
2. **Tests for cerebellar function:** Rapid alternating movements, finger-to-nose, heel-to-shin, walking, running

**FIGURE 20.1**

Dermatomes. (From Athreya BH, Silverman BK. *Pediatric Physical Diagnosis*. Appleton-Century-Crofts; 1985:238–239.)

**BOX 20.2****REFLEX RATING SCALE**

- 0: None
- 1+: Diminished (need use of clasped hands/gritting teeth to engage reflex)
- 2+: Normal
- 3+: Increased (reflexes cross neighboring joint or cross to other side)
- 4+: Hyperactive with clonus

**II. NEUROLOGIC EMERGENCIES****A. Stroke<sup>1-4</sup>**

1. Presentation and etiology
  - a. 50% ischemic, 50% hemorrhagic overall in pediatric stroke, but approximately 80% ischemic in perinatal stroke. Strokes have many mimics which are more common, which means strokes themselves are frequently missed (Box 20.3). Perinatal stroke

**eTABLE 20.2****MUSCLE STRETCH REFLEXES**

Reflex	Site
Biceps	C5, C6
Brachioradialis	C5, C6
Triceps	C7, C8
Knee	L2-L4
Ankle	S1, S2

C, Cervical spinal root; L, lumbar spinal root; S, sacral spinal root.

**eTABLE 20.3****UPPER AND LOWER MOTOR NEURON FINDINGS**

On Examination	Upper	Lower
Power	Decreased	Decreased
Tendon reflexes	Increased	Decreased
Tone	Increased ( <i>Infants</i> : decreased)	Normal or decreased
Babinski	Upgoing (expected in infants until 1–2 years of age)	Downgoing (normal)
Fasciculations	Absent	Present
Muscle wasting	Absent	Present

TABLE 20.1

## PRIMITIVE REFLEXES

Reflex	Appears	Extinguishes
Palmar grasp	28 WGA	2–3 months
Moro	28 WGA	5–6 months
Rooting	32 WGA	1 month
Tonic neck	35 WGA	6–7 months
Parachute	7–8 months	Remains for life

WGA, Weeks' gestational age.

Modified from Schor NF. Neurologic evaluation, Chapter 608. In: Kliegman RM, St. Geme J, ed. *Nelson Textbook of Pediatrics*. 21st ed. Elsevier; 2020.

## BOX 20.3

## STROKE MIMICS PRESENTING WITH ACUTE-ONSET FOCAL NEUROLOGIC DEFICIT

1. Migraine
2. Seizure ± postictal (Todd) paralysis
3. Functional disorders
4. Mass lesion
5. Infection
6. Drug toxicity (e.g., methotrexate)
7. Posterior reversible encephalopathy syndrome (PRES)
8. Metabolic abnormality
9. Demyelinating lesion

(28 weeks' gestational age to 28 days postnatal) rarely presents with focal symptoms; presentation most likely to include seizures, altered level of consciousness, feeding difficulties, early handedness. Even in childhood stroke (28 days to 18 years), seizure and headache are far more common presenting symptoms than in adults. It is important to consider stroke on the differential for acute neurologic changes.

- b. Etiologies vary by age (eTable 20.4).<sup>1</sup> Patients with increased risk of recurrent stroke: history of cardiac disease and cardiac surgery, cerebral arteriopathy, sickle cell disease, thrombophilias
2. Management
  - a. **Stroke team activation** (where available) or **urgent neurology consultation**, along with transfer to a tertiary care center with expertise in childhood stroke.
  - b. **Supportive care and neurologic monitoring:** Maintain normoglycemia, maintain normothermia (avoid fevers), maintain oxygenation, prompt seizure treatment. Monitor for signs of increased intracranial pressure.
  - c. **Optimize cerebral perfusion pressure:** Ensure adequate fluid volume and maintenance of median blood pressure (BP) for age, allow permissive hypertension in cases of ischemic stroke.
  - d. **Reperfusion therapies:** Thrombolytic therapy with intravenous tissue plasminogen activator (tPA) or mechanical thrombectomy may be considered under appropriate circumstances in centers with extensive

eTABLE 20.4

RISK FACTORS AND INITIAL INVESTIGATIONS FOR CHILDHOOD STROKE<sup>1</sup>

	Perinatal Arterial Ischemic Stroke (Occurring From 20 Weeks' Gestational Age to 28 Days Old)	Childhood Arterial Ischemic Stroke	Cerebral Venous Thrombosis
Risk factors	Not fully understood. Combination of maternal and fetal factors, both ante- and peripartum	<p>Cardiac (congenital or acquired heart diseases, arrhythmia, surgeries)</p> <p>Cerebral arteriopathy (moyamoya, arterial dissection, focal cerebral arteriopathy [including VZV-associated], CNS vasculitis)</p> <p>Hypercoagulable state (genetic anticoagulant deficiencies, rheumatologic conditions, malignancies)</p> <p>Hematologic disorders (sickle cell disease, iron deficiency anemia, thrombocytosis, malignancies)</p> <p>Infections (meningitis, varicella)</p> <p>Drugs (asparaginase, estrogen, cocaine, methamphetamines)</p> <p>Inflammatory/autoimmune (SLE, RA, systemic vasculitis)</p>	<p>Inherited thrombophilia (genetic anticoagulant deficiencies)</p> <p>Drugs (asparaginase, estrogen)</p> <p>Infections (sinusitis, otitis media, mastoiditis, oropharyngeal infections)</p> <p>Inflammatory/autoimmune (SLE, IBD)</p> <p>Dehydration</p> <p>Nephrotic syndrome</p> <p>Malignancies</p> <p>Sickle cell disease</p> <p>Trauma</p>
Initial workup	<p>Diagnosis by neuroimaging: MRI more sensitive than CT, obtain DWI, FLAIR, SWI/GRE, and MRA sequences</p> <p>Thrombophilia workup unlikely to change management</p> <p>Consider echocardiogram. Manage symptomatology.</p>	<p>Diagnosis by neuroimaging: MRI more sensitive than CT (especially in acute phase), obtain DWI, FLAIR, SWI/GRE, and MRA sequences</p> <p>Consider echocardiogram, ECG.</p> <p>Laboratory studies based on suspected etiology (start with CBC, PT/INR, PTT, ESR, CRP, electrolytes, antithrombin III activity, lupus anticoagulant, toxicology screen)</p> <p>Consider CSF studies (may include VZV DNA PCR).</p> <p>Consider digital subtraction angiography.</p>	<p>Diagnosis by neuroimaging: MRI more sensitive than CT, obtain MRV or CTV</p> <p>Laboratory studies (CBC, electrolytes, BUN, creatinine, glucose, PT, PTT, ESR, antithrombin III activity, pregnancy test)</p>

*BUN*, blood urea nitrogen; *CBC*, complete blood count; *CNS*, central nervous system; *CRP*, C-reactive protein; *CSF*, cerebrospinal fluid; *CT*, computed tomography; *DWI*, diffusion-weighted imaging; *ESR*, erythrocyte sedimentation rate; *FLAIR*, fluid-attenuated inversion recovery; *GRE*, gradient echo; *IBD*, inflammatory bowel disease; *MRA/MRV*, magnetic resonance angiography/venography; *MRI*, magnetic resonance imaging; *PCR*, polymerase chain reaction; *PT/INR*, prothrombin time/international normalized ration; *PTT*, partial thromboplastin time; *RA*, rheumatoid arthritis; *SLE*, systemic lupus erythematosus; *SWI*, susceptibility-weighted imaging; *VZV*, varicella zoster virus.

pediatric stroke experience, although not recommended in the perinatal period for arterial ischemic stroke (American Heart Association guidelines).

- e. **Early rehabilitation** with physical, occupational, and speech therapy as needed.
- f. **Children with sickle cell disease:** Consult a hematologist. Hydration and emergent exchange transfusion to reduce sickle hemoglobin (see [Chapter 14](#))

## B. Status Epilepticus and Breakthrough Seizures

1. **Definition**<sup>5,6</sup>: Status epilepticus is defined as continuous clinical or electrographic seizure activity lasting  $\geq 5$  minutes or two or more discrete seizures without return of consciousness between them. See [Chapter 1](#) for management algorithm.
2. **Breakthrough seizures (ED assessment):** Assess for missed medications or significant weight gain, lack of sleep, stress, drugs/alcohol, physical exertion, illness, dehydration, flickering lights, menses, and drug interactions that can lower seizure threshold (e.g. tricyclic antidepressants, certain antibiotics, over-the-counter cold preparations, diphenhydramine, herbal supplements). Consider antiseizure medication levels (see [Table 20.2](#) for therapeutic drug levels).

## C. Encephalopathy<sup>7-10</sup>

1. **Definitions:**
  - a. Encephalopathy: Diffuse neuronal dysfunction manifesting as acute or chronic altered mental status
  - b. Encephalitis: Inflammation of brain parenchyma secondary to infection or inflammatory response
2. **Selected causes of encephalopathy:** [Box 20.4](#)
3. **Diagnosis:** Targeted based on clinical scenario and associated symptoms. See [Chapter 1](#) for possible etiologies and workup considerations. May require serum and/or CSF studies for infectious/inflammatory/metabolic markers, EEG, neuroimaging (e.g., MRI or PET)
4. **Treatment:** Dependent on etiology. See [Chapter 1](#) for emergency management of acute altered level of consciousness. See [Chapter 17](#) for treatment of meningitis.

## D. Hydrocephalus with Increased Intracranial Pressure<sup>11-13</sup>

1. **Etiology:** Communicating (abnormal CSF reabsorption) versus noncommunicating (obstruction of CSF flow); congenital versus acquired (postinfectious, posthemorrhagic, mass lesions)
2. **Diagnosis**
  - a. Clinical signs: Macrocephaly, increasing head circumference (HC), bulging/tense fontanelle, splayed sutures, headaches, blurry/spotty vision, diplopia, decreased level of consciousness, “setting-sun” eye sign due to upward gaze paresis, vomiting, Cushing’s triad (hypertension, bradycardia, irregular respirations), papilledema, CN palsies (III, IV, VI)

TABLE 20.2

## COMMONLY USED ANTISEIZURE MEDICATIONS

Antiseizure Medication (Trade Name)	Standard Therapeutic Levels <sup>a</sup>	IV Preparation Available?	Side Effects
Brivaracetam (Briviact)	-	-	Somnolence/sedation, dizziness, fatigue, nausea/vomiting
Cannabidiol (Epidiolex)	-	-	Hepatotoxicity, somnolence, decreased appetite, diarrhea, fatigue, insomnia, infections. Can interact with other antiseizure drugs (e.g. clobazam)
Carbamazepine (Tegretol/Carbatrol)	4–12 mg/L	-	Black box: TEN/SJS in patients with HLA-B*1502 allele, aplastic anemia, agranulocytosis. Other: sedation, ataxia, diplopia, hyponatremia, hepatotoxicity, may worsen generalized seizures
Clobazam (Onfi)	30–300 mCg/L	-	Sedation, dizziness
Clonazepam (Klonopin)	20–70 mCg/L	-	Sedation, drooling, dependence
Diazepam (Diastat, Valium)	-	Yes, 1:1 conversion	Sedation, dry mouth, respiratory depression
Eslicarbazepine acetate (Aptiom)	10–35 mg/L	-	Hyponatremia, dizziness, somnolence, vomiting, headache, diplopia, vertigo, ataxia, tremor
Ethosuximide (Zarontin)	40–100 mg/L	-	GI upset
Felbamate (Felbatol)	30–60 mg/L	-	Black box: aplastic anemia (rare), liver failure. Other: sleep disturbances, weight loss
Fenfluramine (Fintepla)	-	-	Risk of cardiac valve abnormalities (recommend echo every 6 months), weight loss
Gabapentin (Neurontin)	2–20 mg/L	-	Weight gain, leg edema, dizziness
Lacosamide (Vimpat)	5–10 mg/L	Yes, 1:1 conversion	Sedation, reduced benefit with sodium channel drugs, increased PR interval
Lamotrigine (Lamictal)	2.5–15 mg/L	-	Black box: SJS/TEN (risk greater in pediatric patients, increased risk in combination with valproate). OCPs significantly decrease level. Other: fatigue, ataxia, diarrhea
Levetiracetam (Keppra)	12–46 mg/L	Yes, 1:1 conversion	Abnormal behavior, irritability, rare psychosis
Oxcarbazepine (Trileptal)	3–35 mg/L (10-hydroxycarbazepine level)	-	Hyponatremia, weight gain, dizziness

Perampanel (Fycompa)	-	-	Black box: psychiatric/behavioral reactions (hostility). Other: dizziness, headache
Phenobarbital (Luminal)	10–40 mg/L	Yes, 1:1 conversion	Somnolence, syncope, erythroderma
Phenytoin (Dilantin)	10–20 mg/L	Yes, 1:1 conversion	Ataxia, hirsutism, gingival hyperplasia, teratogenicity, morbilliform rash, purple-glove syndrome with infusion
Pregabalin (Lyrica)	2–5 mg/L	-	Peripheral edema, weight gain, constipation, dizziness, ataxia, sedation
Rufinamide (Banzel)	5–30 mg/L	-	Shortened QT interval, nausea, dizziness, sedation, headache. Interacts with other antiepileptic drugs
Tiagabine (Gabitril)	20–200 mCg/L	-	Can worsen generalized seizures
Topiramate (Topamax)	5–20 mg/L	-	Cognitive side effects, weight loss, renal stones, metabolic acidosis, glaucoma
Valproic acid (Depakote, Depakene)	50–100 mg/L	Yes, 1:1 conversion (Use total PO daily dose divided Q6 hr, see Formulary)	Black box: hepatotoxicity. Other: thrombocytopenia, weight gain, alopecia, pancreatitis, PCOS, teratogenicity
Vigabatrin (Sabril)	0.8–36 mg/L	-	Black box: permanent peripheral visual field defects. Other: rash, weight gain, irritability, dizziness, sedation
Zonisamide (Zonegran)	10–40 mg/L	-	Renal stones, weight loss; rare: SJS, aplastic anemia

<sup>a</sup>Draw level immediately before an oral dose for ideal sampling time.

GI, gastrointestinal; HLA, human leukocyte antigen; IV, intravenous; mCg, microgram; MHD, 10-monohydroxy metabolite; OCP, oral contraceptive pill; PCOS, polycystic ovarian syndrome; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.

Data from Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommittee on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. *Epilepsia*. 2008;49(7):1239–1276; Jacob S, Nair AB. An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. *Drugs R D*. 2016;16(4):303–316.

**BOX 20.4****DIFFERENTIAL DIAGNOSIS OF ENCEPHALOPATHY**

1. Infectious and parainfectious: meningitis, encephalitis, ADEM
2. Autoimmune: NMDAR, VGKC-complex, Hashimoto's thyroiditis-associated
3. Trauma
4. Seizure-related: status epilepticus, postictal, epileptic encephalopathy
5. Toxins: medications, drugs, heavy metals, carbon monoxide
6. Metabolic: uremia, hyperammonemia, hyper- or hypoglycemia, lactic acidosis
7. Hypertension, posterior reversible encephalopathy syndrome (PRES)
8. Hypoxic-ischemic: neonatal, drowning, cardiorespiratory arrest, vascular
9. Intracranial hemorrhage
10. Malignancy
11. Genetic: leukoencephalopathy, mitochondrial, ADANE

*ADANE*, Autosomal-dominant acute necrotizing encephalitis; *ADEM*, acute disseminated encephalomyelitis; *NMDAR*, N-methyl-D-aspartate receptor; *VGKC*, voltage-gated potassium channel.

- b. In infants, obtain serial measurements of HC. Obtain neuroimaging if significant increase in HC percentile or if patient is symptomatic.
- c. Imaging: Ultrafast MRI (or similar protocol) preferred to CT where available; can consider venous imaging if high suspicion of cerebral sinus venous thrombosis

**3. Treatment****a. Medical:**

- (1) Emergently manage acute increase of intracranial pressure (ICP; see [Chapter 1](#)).
- (2) Slowly progressive hydrocephalus: Acetazolamide and furosemide may provide temporary relief by decreasing the rate of CSF production.

**b. Surgical:** CSF shunting versus endoscopic third ventriculostomy (ETV)

- (1) Ventriculoperitoneal shunts used most commonly.
- (2) Patients with shunt dysfunction often present with signs of increased ICP. Causes include infection, obstruction (clogging or kinking), disconnection, migration of proximal or distal tips, valve programming.
- (3) Evaluation of shunt integrity: See [Chapter 26](#) for discussion of imaging. Consult pediatric neurosurgery (if available).

**E. Weakness****1. Botulism**<sup>14,15</sup>

- a. **Etiology:** May result from colonization of the colon by *Clostridium botulinum* bacteria, ingestion of botulinum toxin in food, or by wound colonization and toxin production. Botulinum toxin irreversibly cleaves the protein complex necessary for acetylcholine vesicle release into the neuromuscular junction. Predominantly affects those <1 year of age (most commonly <6 months) secondary to immaturity of the gut flora; however, foodborne botulism affects children of all ages.
- b. **Clinical features and diagnosis:** Subacute onset weakness of skeletal muscles diffusely, concentrating in eye, face, and bulbar muscles early. Dilated and poorly reactive pupils are common and specific when

present (note that normal pupil size in infants is smaller than in older children;  $\leq 4$  mm). Presenting symptoms in infants may be constipation for days to weeks before onset of weakness, poor feeding, and weak cry. At high risk for respiratory failure secondary to respiratory and bulbar muscle weakness. Tachycardia is common. Confirm diagnosis by toxin assay of stool (not culture) performed by state lab or CDC; may use sterile saline enema for specimen collection. Electromyography and nerve conduction studies can help confirm diagnosis.

- c. **Treatment:** Assess and stabilize airway; approximately 25% of children require intubation/advanced airway. Treat with one-time dose of human botulism immune globulin (BabyBIG or BIG-IV), available through Infant Botulism Treatment and Prevention Program (<http://www.infantbotulism.org/>). Prompt treatment is key—do not wait for confirmatory testing. With appropriate treatment, prognosis for full recovery is excellent. See [Chapter 16](#) for recommended interval before measles or varicella vaccination after botulism immune globulin administration.

## 2. Guillain-Barré syndrome (GBS)<sup>16-18</sup>

- a. **Etiology:** Presumed immune attack against peripheral nerve myelin. In some cases, triggered by illness (e.g., *Campylobacter jejuni* infection, Zika virus, SARS-CoV2 virus)
- b. **Clinical features:** Ascending weakness and sensory loss with rapid decline reaching greatest disability often less than 2 weeks after onset. Respiratory status can be compromised, ~20% of patients require mechanical ventilation. Often with autonomic instability. Poorly localized pain, ataxia often prominent in children
- c. **Diagnosis:** Elevated spinal fluid protein without cellular infiltrate (“albuminocytologic dissociation”) present in 50% to 70% of patients. Nerve conduction studies and MRI (nerve root enhancement) can be helpful.
- d. **Treatment:** Patients should be hospitalized at presentation to monitor respiratory stability. Acute phase treatment with IVIG (0.4 g/kg daily for 5 days), or plasmapheresis (200–250 mL plasma/kg for 5 sessions) helpful if initiated early. Combined or repeat treatments do not offer additional benefit. Supportive care. Recovery tends to require months to years.
- e. **Variants or differential diagnosis of GBS**
  - (1) Acute: Miller Fisher syndrome (ataxia, ophthalmoplegia, and areflexia), acute motor axonal neuropathy (AMAN)
  - (2) Chronic: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a similar but slower progressive autoimmune disorder that often requires chronic immunosuppressive therapy.

## F. Ataxia<sup>19,20</sup>

1. Impaired coordination of movement and balance; broad-based gait
2. Differential diagnosis of acute ataxia ([Box 20.5](#))
3. Evaluation ([Box 20.6](#))

**BOX 20.5****DIFFERENTIAL DIAGNOSIS OF ACUTE ATAXIA (IN NO PARTICULAR ORDER)**

1. Ingestion (e.g., antiseizure medications, antipsychotics, sedatives, hypnotics) or intoxication (e.g., alcohol, hydrocarbon fumes, heavy metals)
2. Postinfectious: acute cerebellar ataxia, cerebellitis (e.g., viral causes), acute disseminated encephalomyelitis
3. Head trauma: cerebellar contusion or hemorrhage, posterior fossa hematoma, vertebrobasilar dissection, postconcussion syndrome
4. Basilar migraine
5. Benign paroxysmal vertigo
6. Intracranial mass lesion: tumor, vascular malformation
7. Opsoclonus–myoclonus ataxia syndrome: Chaotic eye movements combined with ataxia and myoclonus. Postinfectious or paraneoplastic (neuroblastoma/neural crest tumors) etiology
8. Hydrocephalus
9. Infection: labyrinthitis, abscess
10. Seizure: ictal or postictal
11. Vascular events: cerebellar hemorrhage or stroke
12. Guillain-Barré syndrome or Miller-Fisher variant (ataxia, ophthalmoplegia, and areflexia). Warning: If bulbar signs present, patient may lose ability to protect airway.
13. Rare inherited paroxysmal ataxias
14. Inborn errors of metabolism
15. Multiple sclerosis
16. Somatic symptom/functional neurologic disorder

**BOX 20.6****CONSIDERATIONS FOR INITIAL EVALUATION OF ACUTE ATAXIA**

1. Complete blood cell count, electrolytes, urine and serum toxicology
2. Imaging (CT or MRI)
3. Lumbar puncture
4. EEG
5. If neuroblastoma is suspected (opsoclonus–myoclonus ataxia syndrome), obtain urine vanillylmandelic acid and homovanillic acid, as well as MRI or CT of chest and abdomen.

*CT*, Computed tomography; *EEG*, electroencephalogram; *MRI*, magnetic resonance imaging.

**III. CHRONIC OR GRADUALLY PROGRESSIVE CONDITIONS****A. Headaches<sup>21-33</sup>****1. Classification of headaches**

- a. **Primary headaches:** Migraine, tension type, cluster, trigeminal autonomic cephalalgias (TACs), other primary headache disorders
- b. **Secondary headaches:** Trauma, infection, substance use or withdrawal, vascular disorder, neurologic disorder, increased intracranial pressure

- c. **Differential diagnosis:** Acute (Box 20.7) and chronic (Box 20.8)

## 2. Evaluation of headaches

- a. Obtain history (Box 20.9) and physical exam (eTable 20.5)
- b. Evaluate for red flags (Box 20.10).
- c. If red flags are present, obtain appropriate imaging (CT for hemorrhage, MRI/MRA/MRV for vascular abnormalities).
- d. Perform lumbar puncture (LP) if concern for infection or increased intracranial pressure (Box 20.11). *If no red flags are present and normal neurologic exam, imaging and LP are not recommended.*

## 3. Migraine headache

- a. Migraines can be throbbing, pulsatile, or pressure-like in children. Usually bifrontal in children and unilateral in adolescents and adults. There are many potential triggers (e.g., stress, caffeine, menses, sleep disruption). See Box 20.12 for diagnostic criteria.

### BOX 20.7

#### DIFFERENTIAL DIAGNOSIS OF ACUTE HEADACHE

Evaluation of the first acute headache should consider pathologic causes listed here on the differential along with more common etiologies.

1. Increased intracranial pressure (ICP): Trauma, hemorrhage, tumor, hydrocephalus, idiopathic intracranial hypertension, abscess, arachnoid cyst, cerebral edema
2. Decreased ICP: Ventriculoperitoneal shunt placement, lumbar puncture, cerebrospinal fluid leak
3. Meningeal inflammation: Meningitis, leukemia, subarachnoid or subdural hemorrhage
4. Vascular: Vasculitis, arteriovenous malformation, hypertension, cerebrovascular accident
5. Bone, soft tissue: Referred pain from scalp, eyes, ears, sinuses, nose, teeth, pharynx, cervical spine, temporomandibular joint
6. Infection: Systemic, encephalitis, sinusitis
7. Medication or intoxicant exposure (e.g., stimulants, steroids, drugs of abuse)
8. First primary headache

### BOX 20.8

#### DIFFERENTIAL DIAGNOSIS OF RECURRENT OR CHRONIC HEADACHES

1. Migraine (with or without aura)
2. Tension
3. Analgesic rebound
4. Caffeine withdrawal
5. Sleep deprivation or chronic hypoxia (e.g., sleep apnea)
6. Tumor
7. Psychogenic: Conversion disorder, malingering, depression, acute stress, mood disorder
8. Cluster headache
9. New daily persistent headache

**BOX 20.9****IMPORTANT HISTORICAL INFORMATION IN EVALUATING HEADACHE**

1. When did the headaches begin?
2. How did the headache begin? Associated trauma, social stressors (school, home)?
3. What is the frequency and duration of the headaches?
  - a. Headache pattern (e.g., intermittent, progressive, chronic)
  - b. Time of day
4. Where is the pain, what is it like, and does it radiate? Focal occipital pain is concerning for secondary headaches.
5. Associated symptoms? What do you do during the headache?
  - a. Aura or prodrome
  - b. Constitutional symptoms (weight changes), vision changes, or any other neurologic symptoms (weakness, tingling, photophobia, phonophobia)
  - c. Triggers and alleviating/exacerbating factors
6. Other history (e.g., health problems, medications, family history of migraine)
7. How do the headaches affect your ability to function? Ask about school absences.

- b. **Classification<sup>21</sup>**: With or without aura. An aura is any neurologic symptom that occurs prior to onset of a migraine (e.g., visual aberrations, paresthesias, numbness, dysphasia).
- c. **Precursors to migraines and close associations**: Cyclic vomiting, abdominal migraines, recurrent abdominal pain, paroxysmal vertigo of childhood, paroxysmal torticollis of infancy, and motion sickness
- d. **Treatment**: Combination of acute and prophylactic treatment
  - (1) **Symptomatic treatment**: Avoid medication overuse as it can lead to rebound headaches. Optimal acute therapy can prevent progression to chronic migraines.
    - (a) Outpatient setting:
      - (i) Dark, quiet room and sleep
      - (ii) Nonsteroidal antiinflammatory drugs (NSAIDs; e.g., naproxen, ibuprofen, ketorolac) and/or acetaminophen. Limit to 3 days per week or 14 days per month.
      - (iii) Caffeine (e.g., coffee, tea, soda)
      - (iv) Triptans. Only effective at migraine onset. Limit to 9 days per month.
      - (v) Antidopaminergics have antiemetic properties, and may be effective even if nausea is not a prominent symptom. Prochlorperazine shown to be superior to metoclopramide<sup>22</sup>
    - (b) Emergency department (ED)/inpatient setting:
      - (i) Often helpful to combine medications and administer intravenous (IV) “migraine cocktail” (see Fig. 20.2 for example ED algorithm)
      - (ii) Steroids (e.g., methylprednisolone) may be useful in intractable cases, although evidence is lacking.
      - (iii) Dihydroergotamine may be considered.

**eTABLE 20.5****PHYSICAL AND NEUROLOGIC EXAMINATION OF THE CHILD WHO HAS HEADACHES**

<b>Feature</b>	<b>Significance</b>
Growth parameters	Chronic illness may affect linear growth Hypothalamic-pituitary dysfunction may disturb growth
Head circumference	Increased intracranial pressure before fusion of the sutures may accelerate head growth
Skin	Evidence of trauma or a neurocutaneous disorder
Blood pressure	Hypertension
Neurologic exam	Signs of increased intracranial pressure Focal abnormality on neurologic exam. Key areas: Fundoscopic exam (for optic nerve edema), extraocular movements, asymmetric reflexes, asymmetric strength/weakness/motor exam, coordination (cerebellar signs), abnormal gait
Cranial bruits	May reflect an intracranial arteriovenous malformation
Fundoscopy exam	Papilledema may reflect elevated intracranial pressure or pseudotumor cerebri.

**BOX 20.10****RED FLAGS IN HEADACHE EVALUATION**

1. Progressively worsening headaches
2. “Thunderclap” headache (less than 5 minutes from onset to maximal intensity)
3. Altered mental status
4. New-onset focal neurologic symptoms
5. Optic nerve edema
6. Nuchal rigidity
7. Seizures
8. Visual symptoms not typical of migraines (e.g., colorful, hallucinatory, short duration), diplopia, decreased visual acuity, visual field deficits
9. Concurrent fever (especially if accompanied by other red flags)
10. Headache worse with supine position or Valsalva (cough, straining)
11. Association with persistent emesis
12. Immunocompromised or on anticoagulation
13. Signs of endocrine pathology (e.g., short stature, obesity, polyuria, sluggishness, constipation, virilization)

**BOX 20.11****LUMBAR PUNCTURE**

1. See [Chapter 4](#) for indications, contraindications, and procedure.
2. Standard tests: Cell counts + differential, Gram stain, cerebrospinal fluid (CSF) culture, protein, glucose. Consider viral studies (e.g., herpes simplex virus, enterovirus).
3. Manometer for opening pressure (OP) if concern for increased intracranial pressure. Performed in a lateral decubitus position. OP of <28 cm H<sub>2</sub>O generally considered normal; however, interpret results in conjunction with other clinical and examination findings.
4. There is inconsistent evidence regarding correction factors for CSF white blood cell counts in the setting of blood-contaminated CSF from a traumatic lumbar puncture.
5. Xanthochromia: Yellow or pink discoloration of CSF due to breakdown of hemoglobin. Suspect subarachnoid hemorrhage.

Data from Fishman RA. *Cerebrospinal Fluid in Diseases of the Nervous System*. 2<sup>nd</sup> ed. Saunders; 1992:190; Avery RA. Interpretation of lumbar puncture opening pressure measurements in children. *J Neuro Ophthalmol*. 2014;34(3):284–287.

**(2) Preventative treatment:**

- (a) Lifestyle modification is a mainstay<sup>23</sup>:
  - (i) adequate sleep<sup>30</sup>
  - (ii) meals
  - (iii) hydration
  - (iv) regular
  - (v) exercise

**BOX 20.12****DIAGNOSTIC CRITERIA FOR PEDIATRIC MIGRAINE WITHOUT AURA**<sup>21,24,25</sup>

At least five attacks fulfilling the following criteria:

1. Headache 2–72 hours in children younger than 18 years (untreated or unsuccessfully treated)
2. At least two of the following characteristics:
  - a. Unilateral or bilateral
  - b. Pulsating quality
  - c. Moderate to severe in intensity
  - d. Aggravated by or causing avoidance of routine physical activities
3. At least one of the following occurs during the headache:
  - a. Nausea and/or vomiting
  - b. Photophobia and phonophobia (which may be inferred from behavior)
4. Not better accounted for by another diagnosis

(vi) weight loss if overweight

(vii) Avoid triggers, stress, caffeine withdrawal, tobacco exposure

(b) Consider prophylactic medications (eTable 20.6) in any of the following situations:

- (i) Migraines occur more than once per week or affect quality of life.
- (ii) Frequent ED visits
- (iii) Complicated migraines
- (iv) Migraines not responsive to abortive medications


(2) **Alternative/complementary therapies:**

- (a) Cognitive behavioral therapy
- (b) Biofeedback
- (c) Physical therapy
- (d) Acupuncture

Clinicians may use PedMIDAS scale<sup>31</sup> to determine disability associated with migraine. Recent systematic review of migraine prophylaxis in children suggests that preventative medication may be no more effective than placebo.<sup>23</sup> New biologic (anti-calcitonin gene-related peptide or CGRP)<sup>32,33</sup> was approved in adults in 2018; there are no studies yet in the pediatric population.

**B. Seizures**<sup>5,6,34-48</sup>

1. **Differential diagnosis of recurrent events that mimic epilepsy in childhood** (Table 20.3)
2. **Seizures: First and recurrent**
  - a. **Definition:** Paroxysmal, transient, synchronized discharge of cortical neurons resulting in alteration of function (motor, sensory, cognitive)
  - b. **Causes of seizures**
    - (1) Diffuse brain dysfunction: Fever, metabolic compromise, toxin or drugs, hypertension

**FIGURE 20.2**

Emergency department management of migraine headaches at Johns Hopkins Children's Center. H&P, history and physical.

(2) Focal brain dysfunction: Stroke, neoplasm, focal cortical dysgenesis, trauma

c. **Febrile seizure**<sup>34-36</sup>

(1) Simple febrile seizure: Primary generalized seizure associated with fever in a child 6 to 60 months of age that is nonfocal, lasts for <15 minutes, and does not recur in a 24-hour period

(a) Management: Identify the source of fever. No further workup (neuroimaging, EEG, or bloodwork) or antiseizure medications are necessary for a simple febrile seizure in a well-appearing, fully immunized child with a normal neurologic examination and no meningeal signs

eTABLE 20.6

PREVENTATIVE THERAPIES FOR MIGRAINE<sup>a</sup>

Medications	Adverse Effects	Consider in Patients With the Following Comorbidities
<b>VITAMINS</b>		
Riboflavin, magnesium, CoQ10	Low side effect profile, limited data of efficacy in children	Poor nutritional intake
<b>ANTIHISTAMINES</b>		
Cyproheptadine (Periactin)	Sedation, increased appetite, hepatitis	Seasonal allergies, poor appetite, insomnia
<b>β-BLOCKERS</b>		
Propranolol (Inderal)	Hypotension, bronchospasm, masks hypoglycemia, bradyarrhythmia	Hypertension
<b>ANTIDEPRESSANTS</b>		
Amitriptyline (Elavil)	Black box: suicidal thoughts. Other: sedation, constipation, weight gain	Depression, insomnia, underweight
Nortriptyline (Pamelor)	Black box: suicidal thoughts. Other: constipation	Depression
<b>ANTISEIZURE MEDICATIONS</b>		
Topiramate (Topamax)	Cognitive changes, weight loss, sensory changes, paresthesia, kidney stones	Obesity, epilepsy
Divalproex sodium (Depakote)	Black box: hepatotoxicity. Other: dizziness, drowsiness, weight gain, gastrointestinal upset, teratogenicity	Bipolar disorder, epilepsy, underweight

<sup>a</sup>See Formulary for specific dosing.

CoQ10, Coenzyme Q10.

**TABLE 20.3****DIFFERENTIAL DIAGNOSIS OF RECURRENT EVENTS THAT MIMIC EPILEPSY IN CHILDHOOD**

Event	Differentiation From Epilepsy
<b>SYNCOPE AND ANOXIC EVENTS</b>	
Breath-holding spells (18 mo–3 yr)	Loss of consciousness and generalized convulsions, always provoked by an event that makes child upset
Vasovagal syncope	Triggers: Postural change, heat, emotion. Preceded by dizziness, diaphoresis, nausea, and vision changes. Slow collapse, rapid return to awareness; may have associated convulsions and brief confusion after event
Cardiogenic syncope	Triggers: Exercise, strong emotion, water immersion. Abnormal ECG/Holter monitor finding. No consistent convulsive movements
Cough syncope	Prolonged cough spasm during sleep in asthmatic, leading to loss of consciousness, often with urinary incontinence
<b>BEHAVIORAL, PSYCHOLOGICAL, AND PSYCHIATRIC DISORDERS</b>	
Psychogenic nonepileptic seizure (PNES)	Also known as pseudoseizures. No EEG changes except movement artifact during event. Thrashing, proximal truncal movements. Eye closure with resistance to opening. Guards face with hand drop. Brief/absent postictal period. Often exacerbated by psychological stressor
<b>SLEEP-RELATED CONDITIONS</b>	
Narcolepsy	Excessive daytime sleepiness, cataplexy (sudden atonia triggered by emotion), sleep paralysis, sudden-onset REM on EEG
<b>PAROXYSMAL MOVEMENT DISORDERS</b>	
Tics	Involuntary, nonrhythmic, repetitive movements not associated with impaired consciousness. Strong urge to perform movement but temporarily suppressible
Stereotypies (mannerisms)	Repetitive movements or vocalizations (e.g., rocking, head banging)
Paroxysmal dyskinesias	Dystonia, choreoathetosis in response to specific triggers (e.g., startle, movement). Often familial
<b>MIGRAINE-ASSOCIATED DISORDERS</b>	
Migraine	Headache or visual changes that may precede attack. Autonomic or sensory changes can mimic focal seizure. Family history of migraines. EEG with regional area of slowing during attack
Paroxysmal vertigo (toddler)	Episode of vertigo, vomiting, staggering, and falling in a child. May become anxious, no loss of awareness; may have associated nystagmus
<b>MISCELLANEOUS EVENTS</b>	
Sandifer syndrome	GER in infancy. Paroxysmal dystonic posturing (back arching) associated with meals
Myoclonus	Involuntary muscle jerking or twitch

ECG, Electrocardiography; EEG, electroencephalography; GER, gastroesophageal reflux; REM, rapid eye movement.

Data from Fine A, Wirrell EC. Seizures in children. *Pediatr Rev.* 2020;41(7):321–347. doi:10.1542/pir.2019-0134; Glauser TA, Loddenkemper T. Management of childhood epilepsy. *Continuum.* 2013;19(3, Epilepsy):656–681; *Epilepsy imitators.* ILAE 2018: <https://www.epilepsydiagnosis.org/epilepsy-imitators.html>

- (b) Indications for lumbar puncture: Meningeal signs, incomplete or unknown *Haemophilus influenzae* or *Streptococcus pneumoniae* immunization status, or if pretreated with antibiotics (which can mask signs and symptoms of meningitis)
- (2) Complex febrile seizure: Seizure associated with a fever that is focal, lasts for >15 minutes, or recurs within 24 hours
  - (a) Management: Identify the source of fever; treat as per status epilepticus guidelines if seizure continues (see [Chapter 1](#)). Obtain EEG. Consider nonemergent MRI (to evaluate for associated focal lesion), LP if concern for CNS infection. Consider prescribing rectal diazepam for home emergency use. Slightly increased risk of developing epilepsy at a later age
- d. **Evaluation of unprovoked seizure**<sup>37,38</sup>
  - (1) Rule out provocative factors: Obtain vitals. Consider obtaining glucose, electrolytes, blood urea nitrogen, creatinine, complete blood cell count, toxicology screen.
  - (2) EEG is recommended in all children with first unprovoked seizure to evaluate for an epilepsy syndrome; however, it does not have to be emergently obtained.<sup>37</sup> Interictal EEGs may be normal, particularly in children with focal seizures. Repeat EEGs, prolonged EEG monitoring with video as clinically indicated
  - (3) Imaging: High-resolution MRI can assist with identification of underlying brain malformation, although it is not routinely indicated when evaluating a first-time seizure. CT is not recommended.
- e. **Epilepsy:** Recurrent, unprovoked seizures, a single seizure with an abnormal EEG, or diagnosis of genetic syndrome characterized by recurrent seizures. Assess seizure type, epilepsy classification ([eTable 20.7](#)),<sup>38-42</sup> and severity of disorder. See [Table 20.4](#) for selected epilepsy syndromes of childhood.
- f. **Treatment**<sup>38,43,44,46-48</sup>
  - (1) First seizure, nonfocal, and with return to baseline: No antiseizure medication typically indicated. Overall recurrence rate approximately 50% in 2 to 5 years. Epileptiform abnormalities on EEG indicate a higher chance of recurrence; clinician can consider antiseizure therapy after first seizure if EEG abnormalities.
  - (2) Educate parents and patient regarding seizure safety.<sup>44</sup> Review seizure first aid and precautions, including supervision during bathing or swimming. Be aware of driver's license laws in the state (<https://www.epilepsy.com/driving-laws>). Advocate for teacher and school awareness; provide seizure plan. Consider home abortive therapy.
  - (3) Pharmacotherapy (see [Table 20.2](#)): Initiate if known etiology of seizure (diagnosis of epilepsy syndrome), recurrent unprovoked seizure (risk of recurrent seizure >80% after second unprovoked

**eTABLE 20.7****INTERNATIONAL CLASSIFICATION OF SEIZURES AND EPILEPSY SYNDROMES<sup>39-42</sup>**

Seizure Type Nomenclature	Classification of Epilepsies
<b>I. FOCAL ONSET</b>	1. Seizure types (see left column)
1. Aware (previously termed simple partial)	a. Focal, generalized, or unknown
a. With motor onset <sup>a</sup>	b. Takes into account etiology
b. With nonmotor onset <sup>a</sup>	2. Epilepsy type (predisposition to seizures)
2. Impaired awareness (previously termed complex partial)	a. Focal, generalized, combined generalized and focal, unknown
a. With motor onset <sup>a</sup>	b. Takes into account seizure types, comorbidities, and etiologies
b. With nonmotor onset <sup>a</sup>	3. Epilepsy syndrome (e.g., genetic syndrome known to cause epilepsy); takes into account seizure types, epilepsy types, and etiologies
<b>II. GENERALIZED ONSET</b>	
1. Motor	
a. Tonic-clonic	
b. Other motor	
2. Nonmotor (Absence)	
<b>III. UNKNOWN ONSET</b>	
1. Motor	
a. Tonic-clonic	
b. Other motor	
2. Nonmotor	
3. Unclassified	

<sup>a</sup>May further characterize focal aware or impaired awareness seizures by the first prominent sign or symptoms during the seizure (motor or nonmotor).

TABLE 20.4

SELECTED EPILEPSY SYNDROMES<sup>38,40,42-44</sup>

Syndrome	Etiology	Evaluation	Treatment	Comments
Neonatal seizures (broad category encompassing a spectrum from benign to morbid syndromes)	Brain malformation, HIE, intracranial hemorrhage, inborn errors of metabolism, CNS infection, cerebral infarction, hypoglycemia, hypocalcemia, hypomagnesemia. Consider benign neonatal seizures (“fifth day fits”).	Screen for electrolyte and metabolic abnormalities, pyridoxine deficiency, and sepsis. Obtain LP, head ultrasound, CT or MRI, EEG.	Treat underlying abnormality, consider pyridoxine ± EEG, phenobarbital, levetiracetam (± additional agents). No treatment needed for benign neonatal seizures	Occur within first 28 days of life; may be myoclonic, tonic, clonic, or subtle Presents as blinking, chewing, bicycling, or apnea Distinguished from jitteriness by vital sign changes and inability to provoke or suppress movements
Early infantile epileptic encephalopathy (Ohtahara syndrome) and early myoclonic encephalopathy	Structural malformations, metabolic disorders (glycine encephalopathy, pyridoxine dependent epilepsy, mitochondrial mutations), genetic mutations	EEG with burst suppression pattern	Trial of pyridoxine, antiseizure medications, ketogenic diet Seizures are difficult to control. If due to metabolic disorder, treat appropriately.	Tonic and myoclonic seizures with onset in neonatal period Can progress to infantile spasms and/or Lennox-Gastaut Poor neurodevelopmental outcome

*Continued*

Syndrome	Etiology	Evaluation	Treatment	Comments
Infantile spasms	Unclear; often early insult (HIE, postnatal hemorrhage), structural, genetic (tuberous sclerosis complex, Down syndrome), or metabolic abnormalities	EEG with interictal hypsarrhythmia, MRI	High-dose steroids (oral prednisolone) or ACTH; vigabatrin (particularly for tuberous sclerosis), ketogenic diet	Onset after age 2 mos, peak onset 4–6 mos Highly variable appearance (flexor, extensor, mixed) often upon awakening and in clusters Overall poor long-term outcomes, especially if known etiology. Early recognition and treatment can improve this.
Lennox-Gastaut syndrome	Multifactorial etiology. Often progression from other epileptic encephalopathy	EEG with slow spike-wave discharges and intermittent runs of multiple spikes or fast activity	Clobazam, felbamate, lamotrigine, rufinamide, topiramate, valproic acid, ketogenic diet, cannabidiol	Multiple seizure types, cognitive impairment, and characteristic EEG findings Significant secondary morbidity associated with atonic seizures
Childhood absence seizures	Suspected to be genetic	EEG with sudden generalized 3–4 Hz spike-and-wave discharges Hyperventilation precipitates seizure.	Ethosuximide, lamotrigine, valproic acid	Onset 4–10 years Staring spells with diminished awareness, ± automatisms (eye blinking, mouth movements) Often resolves by adolescence, with good neurologic outcome
Childhood epilepsy with centrotemporal spikes (BECTS, benign Rolandic epilepsy)	Suspected to be genetic	EEG with spike wave discharges in centrotemporal regions, increased with sleep	Treatment is not always necessary. If frequent or distressing, may use levetiracetam or oxcarbazepine	Onset 4–11 years Seizures often nocturnal and upon awakening, with paresthesia of mouth or tongue, motor phenomena of ipsilateral face occasionally with generalization Seizure remission typically by puberty

Dravet syndrome	Most cases associated with <i>SCN1A</i> mutation	Genetic testing, EEG nonspecific	Clobazam, levetiracetam, stiripentol, valproate, fenfluramine, cannabidiol	Seizures starting in infancy or early childhood, often associated with heat Developmental regression, prolonged (often myoclonic) seizures
Juvenile myoclonic epilepsy	Suspected to be genetic	Clinical history, sleep-deprived EEG (reveals generalized spike and wave discharges with normal background activity)	Lamotrigine, levetiracetam, valproate, zonisamide	Adolescent onset often with absence seizures Develop myoclonus upon awakening and GTCs. Triggers: sleep deprivation, excessive alcohol intake, photic stimulation Full remission rare, majority require lifelong antiseizure medications.
Panayiotopoulos syndrome (early onset childhood occipital epilepsy)	Unknown	EEG with shifting multifocal spikes (often occipital spikes)	Often not treated Occasionally intermittent benzodiazepines, levetiracetam, oxcarbazepine	Onset 3–6 years Characteristic autonomic component (e.g., vomiting, pallor, hypersalivation, thermoregulatory or cardiorespiratory irregularities) Typically resolves 2–3 years after onset or by puberty

*BECTS*, Benign epilepsy with centrotemporal spikes; *CNS*, central nervous system; *CT*, computed tomography; *EEG*, electroencephalography; *GTC*, generalized tonic-clonic; *HIE*, hypoxic-ischemic encephalopathy; *LP*, lumbar puncture; *MRI*, magnetic resonance imaging.

- seizure). Choose therapy according to seizure type. Consider rectal diazepam (children older than 2), diazepam nasal spray (children >6), midazolam nasal spray (children >12) if seizures are prolonged (>5 minutes) or if there is hemodynamic instability.
- (4) Ketogenic diet<sup>48</sup>:
    - (a) High-fat, low-carbohydrate therapy typically used for intractable seizures
    - (b) Should be managed by trained providers
    - (c) Urine/serum ketones can be monitored to assess compliance.
    - (d) Side effects include transient GI upset and hyperlipidemia, chronic metabolic acidosis, kidney stones, decreased growth.
    - (e) Factor in carbohydrate content of formulations when prescribing medications to a child on a ketogenic diet.
    - (f) Avoid dextrose-containing intravenous fluids.
  - (5) Surgical therapies considered for children with identified seizure focus located in noneloquent cortex and/or those who have failed antiseizure medications.
    - (a) Device implantation: Vagus nerve stimulation, deep brain stimulation, responsive neurostimulation (NeuroPace; not yet approved in children)
    - (b) Resections: Hemispherectomy, focal resection (e.g., temporal lobectomy), corpus callosotomy

### C. Neuromuscular Disorders<sup>49-57</sup>

#### 1. Spinal muscular atrophy (SMA)<sup>49,50</sup>

- a. **Etiology:** Motor neuron degeneration caused by autosomal recessive mutations in *SMN1* gene with resulting insufficient levels of SMN protein. Severity correlates inversely with copy number of *SMN2*.
- b. **Clinical features:** Varying degrees of symmetric and progressive muscle weakness (proximal > distal) with preserved cognition. Diaphragm preserved. Patients with severe forms do not survive past early childhood without treatment; cause of death is generally respiratory failure. May be identified on newborn screening
- c. **Treatment:** Evaluation of weak/hypotonic infant for possible SMA is urgent, as effective treatment (nusinersen [Spinraza], onasemnogene abeparvovec-xioi [Zolgensma], risdiplam [Evrysdi]) is possible, but magnitude of benefit decreases with time.

#### 2. Duchenne or Becker muscular dystrophies (DMD/BMD)<sup>51-53</sup>

- a. **Etiology:** X-linked mutation in *DMD* gene, encoding dystrophin, causes disruption of muscular cytoskeleton. Primarily affects males. Duchenne form is more severe and caused by complete disruption of dystrophin; partial function causes milder Becker form.
- b. **Clinical features:** Delayed motor milestones and progressive proximal symmetric muscle weakness starting in early childhood leading to wheelchair use for mobility by age 13. Elevated serum CK levels

- c. **Treatment:** Corticosteroids (prednisone or deflazacort [Emflaza]) are mainstay.<sup>52</sup> Exon-skipping therapies for patients with susceptible *DMD* mutations (eteplirsen [Exondys 51], viltolarsen [Viltepso], golodirsen [Vyondys 53], casimersen [Amondys 45]).<sup>53</sup> Patients require multidisciplinary management: At high risk for cardiomyopathy, respiratory, and orthopedic complications

### 3. Myasthenia gravis<sup>54-58</sup>

- a. **Etiology:** Autoantibodies binding the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) impair neuromuscular junction function. Subtypes include transient neonatal myasthenia (resulting from transplacental transfer of maternal antibodies from mother with myasthenia), congenital myasthenic syndrome (genetic defects of neuromuscular junction proteins), and juvenile myasthenia gravis (classic autoimmune disease in children).
- b. **Clinical features:** A key feature is fatigable, variable weakness. Often concentrates in orbital muscles (double vision, ptosis, ophthalmoplegia), or bulbar weakness (slurred/nasal voice, difficulty chewing, swallowing, talking). Can also manifest with generalized weakness of limbs and trunk. Triggers include illness, fever, heat, and some medications. Weakness can worsen with illness and compromised respiratory status. A good bedside test for respiratory function is the single breath count. Ask the patient to count as high as possible in a single breath; the result correlates with vital capacity and <20 suggests impairment.<sup>57</sup> For bedside assessment of bulbar muscle fatigue, use the “slurp test.”<sup>58</sup> Ask patient to drink 4 ounces of water through a straw quickly: if slows after 1 or 2 ounces, at risk of bulbar decompensation; if marked slowing or times especially prolonged, at risk for respiratory failure.
- c. **Treatment:** Refer to/consult specialist for management.
- (1) Myasthenic crisis/rapid onset of symptoms: plasmapheresis, IVIG, and IV neostigmine. Evaluate the need to secure definitive airway.
  - (2) Obtain thymic imaging nonemergently.
  - (3) Avoid use of common medications that can exacerbate myasthenia gravis (Box 20.13).<sup>54,56</sup>
  - (4) Chronic management:
    - (a) Cholinesterase inhibitor (e.g., pyridostigmine)
    - (b) Prednisolone (caution about paradoxical worsening with large initial dose)
    - (c) Immunosuppressive, steroid-sparing medications (e.g., azathioprine, mycophenolate, rituximab)
    - (d) Consider thymectomy in patients with AChR antibodies

### D. Functional Neurologic Disorders (FNDs)<sup>59-62</sup>

1. **Definition:** The DSM-5 defines functional neurologic disorders (FNDs; previously known as conversion disorders) as:
  - a. One or more symptoms of altered voluntary motor or sensory function

**BOX 20.13****MEDICATIONS TO AVOID IN MYASTHENIA GRAVIS**

1. Anesthetic: succinylcholine
2. Antibiotic: aminoglycosides (e.g., amikacin, gentamycin, streptomycin), fluoroquinolones (e.g., ciprofloxacin, levofloxacin), and tetracyclines (e.g., doxycycline, minocycline, tetracycline)
3. Antimalarial: chloroquine, hydroxychloroquine
4. Antipsychotic: chlorpromazine, risperidone
5. Cardiac: beta-blocker (e.g., propranolol, sotalol, metoprolol), calcium-channel blocker (e.g., verapamil, amlodipine), antiarrhythmic (e.g., procainamide, quinidine)
6. Immunotherapy: checkpoint inhibitor
7. Other: botulinum toxin, desferrioxamine, magnesium, penicillamine

- b. Clinical findings provide evidence of incompatibility between the symptom and recognized neurologic or medical conditions.
  - c. The symptom or deficit is not better explained by another medical or mental disorder.
  - d. The symptom or deficit causes clinically significant distress or impairment in social, occupational, or other important areas of functioning or warrants medical evaluation.
2. **Etiology:** FNDs can present as changes in sensory, motor, or cognitive function but without a known physiologic cause (e.g., negative imaging, LP, and EEG; and/or nonfocal or inconsistent neurologic exam). Although the etiology is currently unknown, recent research using functional MRIs and other imaging modalities has found differences in neural networks, brain connections, and levels of brain activity during tasks between those with and without FNDs.
  3. **Diagnosis:** Once thought to be a diagnosis of exclusion, *FNDs do not necessarily need negative imaging or EEG to confirm*. If there are localizing signs, concern for true seizure, or concern for infection, imaging, EEG, and LP respectively should be obtained as functional overlay is common with other neurologic syndromes. Otherwise, many signs can lead to the diagnosis of FND without further diagnostic studies:
    - a. Hoover's sign: weakness of hip extension that returns to normal with contralateral hip flexion against resistance
    - b. Breakaway/give-way weakness
    - c. Variability in frequency of tremor
    - d. No falls, even with excessive swaying or imbalance
    - e. Forced closure of eyes during seizure-like activity
    - f. Dystonia with fixed-jaw deviation in one direction
  4. **Discussions with family:** See [eTable 20.8](#) for examples of ways to explain FNDs and their treatment to patients and families.
  5. **Management:** Current mainstays of treatment include physical therapy rehabilitation and cognitive behavioral therapy in either an inpatient or comprehensive outpatient setting. When treating FNDs, use a

eTABLE 20.8

PHRASES HELPFUL FOR EXPLAINING FUNCTIONAL NEUROLOGIC DISORDERS TO FAMILIES<sup>59</sup>

FND Problem	Example Phrasing
General	“FND is a problem with the functioning of the nervous system. A problem with the software rather than the hardware.” Or, for patients that aren’t as computer literate: “It’s like a piano that is out of tune—not broken, but just not working properly.”
Overcoming dualism	Patient: “So, are you saying it’s in my mind or brain?” Healthcare professional: “FND is a condition that shows that the mind and the brain are one and the same thing.”
Limb weakness	“Did you see how your leg returned briefly to normal when I did that test (Hoover’s sign). That shows us that there is a problem with the way your brain is sending the signal to your leg (voluntary movement), but the automatic movements are still okay.”
Prognosis	“This is not an easy problem to put right, but it does have the potential to improve and many people do make a good recovery.”
Psychiatry/psychology	“It’s common in FND for people to have problems like anxiety and depression. This can be a consequence of having the symptoms but, in many, it is already there for other reasons. FND symptoms make people fearful of falling and being injured and of being embarrassed. For some, there are things that have happened that may explain why your brain is vulnerable to going wrong in this way and could be worth exploring. I think a psychiatric/psychological assessment could be helpful. What do you think?”

FND, Functional neurologic disorder.

<sup>59</sup>Table excerpt from Bennett et al. 2021.

multidisciplinary approach involving PT, OT, speech therapy, psychology, psychiatry, and neurology and tailor the treatment to the individual's specific needs.

#### IV. WEB RESOURCES

- American Academy of Neurology Practice Guidelines: <https://www.aan.com/Guidelines>
- American Migraine Foundation: <https://www.americanmigrainefoundation.org>
- Child Neurology Foundation: <https://www.childneurologyfoundation.org>
- Child Neurology Society: <https://www.childneurologysociety.org>
- Epilepsy Diagnosis (with videos): <https://www.epilepsydiagnosis.org>
- Epilepsy Foundation: <https://www.epilepsy.com>
- Headache resource (from Children's Mercy Kansas): <https://www.headachereliefguide.com>
- International League Against Epilepsy: <https://www.ilae.org>
- Muscular Dystrophy Association: <https://www.mda.org>

#### REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Amlie-Lefond C. Evaluation and acute management of ischemic stroke in infants and children. *Continuum*. 2018;24(1, Child Neurology):150–170.
2. Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012;141(suppl 2):e737S–e801S.
3. Roach ES, Golomb M, Adams R, et al. Management of stroke in infants and children: a scientific statement from a special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. *Stroke*. 2008;39:2644–2691.
4. Ferriero DM, Fullerton HJ, Bernard TJ, et al. on behalf of the American Heart Association Stroke Council and Council on Cardiovascular and Stroke Nursing. Management of stroke in neonates and children: a scientific statement from the American Heart Association/American Stroke Association. *Stroke*. 2019;50:e51–e96.
5. Brophy GM, Bell R, Claassen J, et al. on behalf of the Neurocritical Care Society status epilepticus guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. *Neurocrit Care*. 2012;17(1):3–23.
6. Smith DM, McGinnis EL, Walleigh DJ, et al. Management of status epilepticus in children. *J Clin Med*. 2016;5(4):47. <https://doi.org/10.3390/jcm5040047>
7. Davies E, Connolly DJ, Mordekar SR. Encephalopathy in children: an approach to assessment and management. *Arch Dis Child*. 2010;97(5):452–458.
8. Dean NP, Carpenter JL, Campos JM, et al. A systematic approach to the differential diagnosis of encephalitis in children. *J Pediatric Infect Dis Soc*. 2014;3(2):175–179.
9. Lim M, Gorman M. Autoimmune neurologic disorders in children. *Handb Clin Neurol*. 2016;133:485–510.
10. Pillai SC, Hachohen Y, Tantsis E, et al. Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome. *Pediatrics*. 2015;135(4):e974–e984.
11. Wright Z, Larrew TW, Eskandari R. Pediatric hydrocephalus: current state of diagnosis and treatment. *Pediatr Rev*. 2016;37(11):478–490.
12. Tekes A, Senglaub SS, Ahn ES, Huisman TAGM, Jackson EM. Ultrafast brain MRI can be used for indications beyond shunted hydrocephalus in pediatric patients. *AJNR Am J Neuroradiol*. 2018;39(8):1515–1518.
13. Mazzola CA, Choudri AF, Auguste KI, et al. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 2: management of posthemorrhagic hydrocephalus in premature infants. *J Neurosurg Pediatr*. 2014;14(suppl 1):8–23.
14. Sakunonju A, Crawford TO. Acquired presynaptic neuromuscular junction disorders, Chapter 25. In: Darras BT, Jones RH, Ryan MM, et al., eds. *Neuromuscular Disorders of Infancy, Childhood and Adolescence*. 2nd ed. Academic Press London; 2015:445–455.
15. Griese SE, Kisselburgh HM, Bartenfeld MT, et al. Pediatric botulism and use of equine botulinum antitoxin in children: a systematic review. *Clin Infect Dis*. 2017;66(suppl\_1):S17–S29. <https://doi.org/10.1093/cid/cix812>
16. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. *Nat Rev Neurol*. 2019;15:671–683. <https://doi.org/10.1038/s41582-019-0250-9>

17. Ansar V, Valadi N. Guillain-Barré syndrome. *Prim Care Clin Office Pract.* 2015;42:189–193.
18. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. *Lancet.* 2016;388:717–727.
19. Overby P, Kapkalein M, Jacobson RI. Acute ataxia in children. *Pediatr Rev.* 2019;40(7):332–343. <https://doi.org/10.1542/pir.2017-0223>
20. Whelan HT, Verma S, Guo Y, et al. Evaluation of the child with acute ataxia: a systematic review. *Pediatr Neurol.* 2013;49(1):15–24. <https://doi.org/10.1016/j.pediatrneurol.2012.12.005>
21. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders. 3rd ed. *Cephalalgia.* 2018;38(1):1–211.
22. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. *Ann Emerg Med.* 1995;26(5):541–546.
23. Oskui M, Pringsheim T, Billingshurst L, et al. On behalf of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention. *Neurology.* 2019;93(11):500–509. <https://doi.org/10.1212/WNL.00000000000008105>
24. Blume HK. Childhood headache: a brief review. *Pediatr Ann.* 2017;46(4):e155–e165.
25. Gelfand AA. Pediatric and adolescent headache. *Continuum.* 2018;24(4, Headache):1108–1136.
26. Yonker M. Secondary headaches in children and adolescents: what not to miss. *Curr Neurol Neurosci Rep.* 2018;18(9):61.
27. Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update: acute treatment of migraine in children and adolescents: report of the guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology.* 2019;93(11):487–499.
28. Lewis DW, Ashwal S, Dahl G, et al. On behalf of the Practice Committee of the Child Neurology Society. Practice parameter: evaluation of children and adolescents with recurrent headaches: report of the quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology.* 2002;59(4):490–498.
29. Fishman RA. *Cerebrospinal Fluid in Diseases of the Nervous System.* 2nd ed. Saunders; 1992:190.
30. Paruthi S, Brooks LJ, D’Ambrosio C, et al. Consensus statement of the American Academy of Sleep Medicine on the recommended amount of sleep for healthy children: methodology and discussion. *J Clin Sleep Med.* 2016;12(11):1549–1561.
31. Hershey AD, Powers SW, Vockell AL, et al. PedMIDAS: Development of a questionnaire to assess disability of migraines in children. *Neurology.* 2001;57:2034–2039.
32. Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. *N Engl J Med.* 2017;377(22):2123–2132.
33. Szperka CL, VanderPluym J, Orr SL, et al. Recommendations on the use of Anti-CGRP monoclonal antibodies in children and adolescents. *Headache.* 2018;58(10):1658–1669.
34. Capovilla G, Mastrangelo M, Romeo A, et al. Recommendations for the management of “febrile seizures”: Ad Hoc Task Force of LICE guidelines commission. *Epilepsia.* 2009;50(suppl 1):2–6.

35. Subcommittee on Febrile Seizures of the American Academy of Pediatrics. Clinical practice guideline—febrile seizures: guideline for the neurodiagnostic evaluation of the child with a simple febrile seizure. *Pediatrics*. 2011;127(2):389–394. <https://doi.org/10.1542/peds.2010-3318>
36. Patel AD, Vidaurre J. Complex febrile seizures: a practical guide to evaluation and treatment. *J Child Neurol*. 2013;28(6):762–767. <https://doi.org/10.1177/0883073813483569>
37. Hirtz D, Berg A, Bettis D, et al. Practice parameter: treatment of the child with a first unprovoked seizure: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology*. 2003;60(2):166–175.
38. Fine A, Wirrell EC. Seizures in children. *Pediatr Rev*. 2020;41(7):321–347. <https://doi.org/10.1542/pir.2019-0134>
39. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):512–521.
40. Fisher RS, Cross HJ, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):522–530.
41. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. *Epilepsia*. 2014;55(4):475–482.
42. Pearl PL. Epilepsy syndromes in childhood. *Continuum*. 2018;24(1, Child Neurology):186–209.
43. Dang LT, Silverstein FS. Drug treatment of seizures and epilepsy in newborns and children. *Pediatr Clin North Am*. 2017;64(6):1291–1308.
44. Glauser TA, Loddenkemper T. Management of childhood epilepsy. *Continuum*. 2013;19(3, Epilepsy):656–681.
45. Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. *Epilepsia*. 2008;49(7):1239–1276.
46. Joshi SM, Singh RK, Shellhaas RA. Advanced treatments for childhood epilepsy: beyond antiseizure medications. *JAMA Pediatr*. 2013;167(1):76–83.
47. Jacob S, Nair AB. An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. *Drugs R*. 2016;16(4):303–316.
48. Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group. *Epilepsia Open*. 2018;3(2):175–192.
49. Arnold ES, Fischbeck KH. Handbook of Clinical Neurology, chapter 38. *Spinal muscular atrophy*. 2018;148(3):591–601.
50. Michelson D, Cialfoni E, Ashwal S, et al. Evidence in focus: nusinersen use in spinal muscular atrophy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018;91(20):923–933. <https://doi.org/10.1212/WNL.0000000000006502>
51. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol*. 2018;17(3):251–267.
52. Gloss D, Moxley 3rd RT, Ashwal S, et al. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2016;86(5):465–472.

53. Sheikh O, Yokota T. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies. *Expert Opin Investig Drugs*. 2021;30(2):167–176. <https://doi.org/10.1080/13543784.2021.1868434>
54. O’Connell K, Ramdas S, Palace J. Management of juvenile myasthenia gravis. *Front Neurol*. 2020;11:743. <https://doi.org/10.3389/fneur.2020.00743>
55. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. *Neurology*. 2016;87(4):419–425. <https://doi.org/10.1212/WNL.0000000000002790>
56. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. *Neurology*. 2021;96(3):114–122. <https://doi.org/10.1212/WNL.00000000000011124>
57. Elsheikh B, Arnold WD, Charibshahi S, et al. Correlation of single-breath count test and neck flexor muscle strength with spirometry in myasthenia gravis. *Muscle Nerve*. 2016;53(1):134–136. <https://doi.org/10.1002/mus.24929>
58. Hudspeth MP, Holden KR, Crawford TO. The “slurp” test: bedside evaluation of bulbar muscle fatigue. *Pediatrics*. 2006;118:e530–e533.
59. Bennett K, Diamond C, Hoeritzauer I, et al. A practical review of functional neurologic disorder (FND) for the general physician. *Clin Med*. 2021;21(1):28–36.
60. Gilmour G, Nielsen G, Teodoro T, et al. Management of functional neurologic disorder. *J Neurol*. 2020;267:2165–2172.
61. Feinstein A. Conversion disorder. *Continuum*. 2018;24(3):861–872.
62. Espay AJ, Aybek S, Carson A, et al. Current concepts in diagnosis and treatment of functional neurologic disorders. *JAMA Neurol*. 2018;75(9):1132–1141.

# Chapter 21

## Nutrition and Growth

*Audrey Companiony Hopkins, MD*

 See additional content online.

 **Audio Case File 21.1** Pediatric food insecurity

### I. ASSESSMENT OF GROWTH

#### A. Types of Growth Charts

1. Child <24 months: World Health Organization (WHO) international growth charts<sup>1</sup>
2. Child ≥2 years: Centers for Disease Control and Prevention (CDC) growth charts<sup>1</sup>
3. Growth charts for premature infants
  - a. Corrected age = infant's chronologic age – number of weeks of prematurity (using 40 weeks as full-term gestation) and should be used up to 3 years<sup>2,3</sup>
  - b. Chronologic age should be used if child's growth “catches up” before 3 years.<sup>4</sup>
  - c. Oslen, Bertino, and Fenton growth charts can be used to assess growth in premature infants up to 41 weeks (Oslen) to 50 weeks (Fenton).<sup>5</sup> After 4 to 8 weeks postterm, the WHO growth chart can be used.<sup>6</sup>
  - d. The choice of growth chart has some variability across practice sites and preferences.<sup>6</sup>
4. Special populations<sup>7,8</sup>
  - a. WHO or CDC growth charts are recommended in all cases due to limited reference data for condition-specific growth charts.
  - b. Condition-specific growth charts can show families how a specific condition can alter growth potential.
  - c. Growth charts have been created for Down syndrome, Prader-Willi syndrome, Williams syndrome, Cornelia de Lange syndrome, Turner syndrome, and Marfan syndrome.

#### B. Interpretation of Growth Charts<sup>9,10</sup>

1. Stunting/short stature: Length or height <5th percentile
2. Underweight:
  - a. Children <2 years: Weight for length/height <5th percentile
  - b. Children ≥2 years: Body mass index (BMI) for age <5th percentile or BMI <18.5 kg/m<sup>2</sup>

3. Healthy weight: BMI for age 5th percentile to <85th percentile or BMI 18.5 to 24.9 kg/m<sup>2</sup>
4. Overweight:
  - a. Children <2 years: Weight for length/height >95th percentile
  - b. Children ≥2 years: BMI for age ≥85th to <95th percentile or BMI 25 to 29.9 kg/m<sup>2</sup>
5. Obese:
  - a. Children <2 years: No consensus definition exists.
  - b. Children ≥2 years: BMI for age ≥95th percentile or BMI ≥30 kg/m<sup>2</sup>
  - c. Extended growth charts have been created for children with obesity. These growth charts track modified z-scores (BMI z and %BMI p95) that are based on a fixed SC (one-half the distance between 0 and 2 z-scores), which eliminate the failure of the BMI z-score to track the BMI of children who are persistently greater than the 95th percentile.<sup>11</sup>

### C. General Guidelines Regarding Appropriate Growth<sup>12,13</sup>

1. Term infants usually lose approximately 5% to 10% of their birth weight but regain the weight within 2 weeks.
2. Infants should gain 20 to 30 g/day from birth to 3 months, 15 to 22 g/day from 3 to 9 months, and 6 to 11 g/day from 9 to 12 months.
3. Term infants double their birth weight in 4 to 5 months and triple it by 1 year of age.
4. Height doubles from birth to age 3 to 4 years of age.
5. The average size of a 4-year-old is 40 inches and 35 lb.
6. From age 3 to 10 years of age, children grow an average of 2.5 inches per year.

## II. MANAGEMENT OF OVERWEIGHT AND OBESE CHILDREN

### A. AAP Recommendations for the Prevention of Obesity<sup>14-16</sup>

1. Exclusive breastfeeding until 6 months of age and then breastfeeding maintenance until at least 12 months
2. Daily breakfast and family mealtimes
3. Limit sugary beverages, fast food, and energy-dense foods, and encourage fruits and vegetables.
4. Develop a family media plan with limits and technology-free zones. For infants less than 18 months, no media other than video chatting. If media used with toddlers 18 to 24 months, parents should watch and engage with children during use. For children 2 to 5 years, a max of 1 hour of high-quality programming a day with co-viewing when possible
5. Recommend 60 minutes of moderate-to-vigorous exercise per day.

### B. Prevention and Management of Obesity in the Primary Care Setting (Table 21.1)

### C. Conditions Associated With Obesity<sup>14</sup>

1. Endocrine:
  - a. Polycystic ovarian syndrome

TABLE 21.1

## MANAGEMENT AND MONITORING STRATEGIES FOR CHILDREN BASED ON BODY MASS INDEX

BMI	Initial Management	Monitoring—Follow-up
Normal BMI	<ul style="list-style-type: none"> <li>• Praise child and family.</li> <li>• Screen for genetic dyslipidemia with nonfasting lipid profile between ages 9–11 and 18–21.</li> <li>• Maintain weight velocity.</li> </ul>	Next well child visit
Normal BMI that is increasing percentiles (crossing two percentile lines is a risk factor for obesity)	<ul style="list-style-type: none"> <li>• Screen for genetic dyslipidemia as above</li> <li>• Patient education</li> </ul>	Next well child visit
Overweight BMI	<ul style="list-style-type: none"> <li>• Patient education</li> <li>• If health risk factors, obtain fasting glucose, hemoglobin A1c or oral glucose tolerance test, lipid profile, ALT, and AST.</li> </ul>	2–4 weeks
Obese BMI	<ul style="list-style-type: none"> <li>• Patient education</li> <li>• Obtain fasting glucose, hemoglobin A1c or oral glucose tolerance test, lipid profile, ALT, and AST.</li> <li>• Some specialist clinics screen for vitamin D deficiency and insulin resistance (i.e., measure fasting insulin), but their clinical utility and cost effectiveness is unclear.</li> <li>• No guidelines on which age to start laboratory screening, but some experts start at 2 years of age</li> <li>• Consider other labs (e.g., thyroid studies, cortisol) based on clinical picture.</li> </ul>	2–4 weeks

Further follow-up and management for those who are overweight or obese:

(a) At each follow-up, record weight, measure blood pressure, and use an empathetic and empowering counseling style (e.g., motivational interviewing).

(b) Establish goals: Positive behavior change, weight maintenance, or decrease in BMI velocity. Children aged 2 to 5 years who have obesity should not lose more than 1 pound/month; older children and adolescents with obesity should not lose more than an average of 2 pounds/week.

(c) If no improvement after 3 to 6 months, refer to structured weight management program. If no improvement after 3 to 6 months, the next step is a comprehensive, multidisciplinary approach. If no improvement, refer for evaluation at a tertiary care center for medication management and weight reduction surgery.

*ALT*, Alanine aminotransferase; *AST*, aspartate aminotransferase; *BMI*, body mass index.

- b. Precocious puberty
- c. Prediabetes/type 2 diabetes
2. Gastrointestinal:
  - a. Cholelithiasis
  - b. Gastroesophageal reflux
  - c. Nonalcoholic fatty liver disease
3. Neurologic: Pseudotumor cerebri
4. Orthopedic:
  - a. Blount disease
  - b. Slipped capital femoral epiphysis (SCFE)
5. Behavioral health:
  - a. Anxiety
  - b. Binge eating disorder
  - c. Depression

### III. MALNUTRITION IN INFANTS AND CHILDREN

#### A. Defining Malnutrition<sup>15</sup>

**NOTE:** Also called growth failure or under-nutrition; previously called failure to thrive

1. Condition of under-nutrition generally identified in the first 3 years of life
2. Can be described by the following growth scenarios:
  - a. Primary indicators when single data point available:
    - (1) Weight for length/height z-score
    - (2) BMI for age z-score
    - (3) Length/height for age z-score
    - (4) Wasting or mid-upper arm circumference (MUAC)
    - (5) Presence of nutritional edema
  - b. Primary indicators when two or more data points available:
    - (1) Weight gain velocity (<2 years old)
    - (2) Degree of weight loss (2 to 20 years of age)
    - (3) Deceleration in weight for length/height z-score
    - (4) Inadequate nutrient intake

#### B. Classifying the Degree to Which a Patient Is Malnourished (Table 21.2)<sup>16</sup>

1. Acute (duration <3 months)
2. Chronic or stunting (duration >3 months); suggested by height/length for age

#### C. Resources for Determining Z-scores<sup>17</sup>

1. PediTools (<https://www.peditools.org>)
2. Standardized height and weight calculator (<https://www.quesgen.com/BMIPedsCalc.php>)
3. CDC website (<https://www.cdc.gov/growthcharts/zscore.htm>)
4. WHO website ([https://www.who.int/childgrowth/standards/chart\\_catalogue](https://www.who.int/childgrowth/standards/chart_catalogue))

TABLE 21.2

## DEFINITIONS FOR CATEGORY OF MALNUTRITION

	Mild	Moderate	Severe
Weight for height and BMI	−1 to −1.9 z-score	−2 to −2.9 z-score	−3 or greater z-score
Mid-upper arm circumference z-score <sup>a</sup>	≥ −1 to −1.9	≥ −2 to −2.9	≥ −3
Weight gain velocity (<2 years)	Less than 75% of the norm for expected weight gain	Less than 50% of the norm for expected weight gain	Less than 25% of the norm for expected weight gain
Weight loss (2–20 years)	5% usual body weight	7.5% usual body weight	10% usual body weight
Deceleration in weight for length/height z-score	Decline of 1 z-score	Decline of 2 z-scores	Decline of 3 z-scores
Inadequate nutritional intake	51%–75% estimated energy/protein need	26%–50% estimated energy/protein need	<26% estimated energy/protein need

<sup>a</sup>See Section III C for how to calculate z-score.

*BMI*, Body mass index.

Modified from Becker P, Carney LN, Corkins MR, et al. Primary indicators when 2 or more data points available. Consensus statement of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: indicators recommended for the identification and documentation of pediatric malnutrition. *Nutr Clin Pract*. 2015;30(10):147–161.

#### D. Differential Diagnosis of Malnutrition<sup>18</sup>

1. Secondary to disease/injury
2. Decreased intake (e.g., fluid restriction, cardiac failure, anorexia nervosa, food insecurity, food aversions)
3. Increased requirement/hypermetabolism (e.g., burns, malignancy, diabetes mellitus, inborn errors of metabolism)
4. Excessive loss (e.g., chronic diarrhea, burn, proteinuria)
5. Malabsorption (e.g., Crohn disease, cystic fibrosis)

#### E. Physical Exam Findings Consistent With Malnutrition<sup>19-21</sup>

1. Fat loss (e.g., orbital, buccal, triceps, ribs)
2. Muscle wasting (e.g., temporalis, pectoralis, deltoid, latissimus dorsi, quadriceps)
3. Edema
4. Functional limitations (e.g., hand grip strength)
5. Micronutrient deficiencies
  - a. Iron
    - (1) Exam findings: Koilonychias, pale conjunctiva and nail beds
    - (2) Risk factors: Low birth weight, feeding problems, poor growth, exclusive breastfeeding >6 months
  - b. Vitamin C
    - (1) Exam findings: Perifollicular hemorrhage, scorbutic tongue, bleeding gum, bruising

- (2) Risk factors: Limited diet, infant on cow's milk, dialysis, malabsorption
- c. Vitamin A
  - (1) Exam findings: Bitot spot, follicular hyperkeratosis
  - (2) Risk factors: Limited diet, fat malabsorption, alcoholism, cystic fibrosis, short bowel
- d. Vitamin B<sub>6</sub>
  - (1) Exam findings: Seborrheic dermatitis, angular palpebritis, hypertrophied papillae
  - (2) Risk factors: Dialysis, sickle cell disease, malabsorption; diuretic, anticonvulsant, contraceptive, and isoniazid use
- e. Zinc
  - (1) Exam findings: Dermatitis, vesicobullous lesions, diaper rash
  - (2) Risk factors: Prematurity, parenteral nutrition (PN), cholestasis, diarrhea, high phytate intake, celiac or Crohn disease, AIDS, liver or renal disease, alcoholism, trauma, burn, sleeve gastrectomy, diuretic and valproate use
- f. Vitamin D<sup>22</sup>
  - (1) Exam findings: Widening of the wrists and ankles, genu varum or valgum, prominence of the costochondral junctions (rachitic rosary), delayed closure of fontanelles, craniotabes, and frontal bossing
  - (2) Risk factors: Exclusive breastfeeding beyond 3 to 6 months, prematurity, maternal vitamin D deficiency, strict vegetarian diets/cult diets, malabsorption disorders (cystic fibrosis, Crohn disease, cholestatic hepatopathies)

## F. Diagnostic Evaluation of Malnutrition<sup>23-26</sup>

1. There is no consensus on workup algorithm.
2. Routine labs and imaging are often low yield and generally not recommended; workup should be guided by clinical suspicion.
3. If warranted, reasonable initial testing could include complete blood count, complete metabolic panel, urinalysis, and erythrocyte sedimentation rate.
4. If the child's length has decelerated and is below 50%, can screen for hypothyroidism and growth hormone deficiency
5. If recurrent or severe upper respiratory or opportunistic infections, consider testing for human immunodeficiency and tuberculosis and measuring immunoglobulin and complement levels.
6. Based on clinical suspicion, can consider celiac screening, sweat chloride testing, echocardiogram, hepatitis serology, stool studies
7. Consider hospitalization for observed feeding if the child fails outpatient management, suspicion for abuse/neglect or traumatic injury, severe psychological caregiver impairment, serious malnutrition, or at risk for re-feeding.

## G. Red Flags That Suggest a Medical Cause of Malnutrition<sup>27</sup>

1. Developmental delay or dysmorphic features

2. Cardiac findings (e.g., murmur, edema, jugular venous distention)
3. Failure to gain weight despite adequate calories
4. Organomegaly or lymphadenopathy
5. Recurrent or severe respiratory, mucocutaneous, or urinary infections
6. Recurrent vomiting, diarrhea, or dehydration

#### H. Approach to the Management of Malnourished Patients<sup>28,29</sup> (Box 21.1)

1. Address the etiology of malnutrition.
2. Approximately 20% to 30% more energy may be required to achieve catch-up growth in children. This should continue until the previous growth percentiles are regained.
3. Catch-up linear growth may lag several months behind weight.
4. See Box 21.1 for instructions on the calculation of catch-up growth requirements.
5. Screen for food insecurity and offer social work and community resources.
6. Pharmacotherapy (e.g., cyproheptadine, megestrol) may be helpful for patients with significant underlying diseases (e.g., cancer, cystic fibrosis).

### IV. RE-FEEDING SYNDROME

#### A. Patients at Risk of Developing Re-feeding Syndrome<sup>19</sup>

1. Chronic malnutrition (e.g., prolonged fasting  $\geq 5$  days, malignancy)
2. Renal/endocrine (e.g., chronic diuretic use, diabetic hyperglycemic hyperosmolar syndrome)
3. Gastrointestinal loss (e.g., inflammatory bowel disease, chronic pancreatitis, short bowel)
4. Infectious (e.g., AIDS, tuberculosis)
5. Cardiac (e.g., congenital heart disease)
6. Pulmonary (e.g., cystic fibrosis)

#### BOX 21.1

##### DETERMINING CATCH-UP GROWTH REQUIREMENTS

1. Plot the child's height and weight on the appropriate growth charts.
2. Determine recommended calories required for age [recommended dietary allowances (RDA)].
3. Determine the ideal weight (50th percentile) for child's height.
4. Multiply the RDA calories by ideal body weight for height (kg).
5. Divide this value by the child's actual weight (kg). For example, for a 12-month-old boy whose weight is 7 kg and length is 72 cm, RDA for age would be 98 kcal/kg/day, and ideal body weight for height is 9 kg (50th percentile weight for height); thus his catch-up growth requirement would be as follows:

$$98 \text{ kcal/kg/day} \times (9 \text{ kg} / 7 \text{ kg}) = 126 \text{ kcal/kg/day}$$

Modified from Nestle Health Science. Calorie and protein requirements. Pediatric nutrition helpful hints: Specialized nutrition for your most vulnerable patients. <https://www.nestlehealthscience.us/asset-library/documents/resources/pediatric%20helpful%20hints.pdf>; and Corrales KM, Utter SL. Failure to thrive. In: Samour PQ, Helm KK, Lang CE, eds. *Handbook of Pediatric Nutrition*. 2nd ed. Aspen Publishers; 1999:406.

7. Psychiatric (e.g., anorexia nervosa, chronic alcohol use)
8. Social (e.g., child abuse/neglect, homelessness, food insecurity)

### B. Management of Re-feeding Syndrome<sup>20</sup>

1. Maintain continuous cardiorespiratory monitoring or check vital signs every 4 hours, depending on level of concern.
2. Ensure strict intake and output monitoring with calorie count and daily weights.
3. Obtain at least daily basic metabolic panel with phosphorous and magnesium. Obtain more frequently if electrolyte replacement needed, or if there are concerning trends.
4. Measure pre-albumin, albumin, zinc.
5. Consider giving thiamine 100 to 300 mg PO daily (or 50 to 100 mg IV) × 3 days before feeding. There is some debate whether this is required.
6. Give a multivitamin daily.
7. Feeding should not proceed without appropriate supplementation.
8. Recommendations vary, but start at  $\frac{1}{4}$  to  $\frac{1}{2}$  of estimated caloric needs depending on degree of risk.
9. Dietary advancement over 3 to 7 days with caloric increases of 10% to 25% per day until recommended caloric goals achieved.
10. Enteral feeding is preferred over parenteral feeding.

## V. NUTRITIONAL NEEDS OF HEALTHY CHILDREN

### A. Dietary Allowances for Carbohydrates and Protein (Table 21.3)

### B. Fat Requirements (Table 21.4)

### C. Vitamin Requirements (Tables 21.5 and 21.6)

1. Vitamin D<sup>21-23</sup>

**TABLE 21.3**

**RECOMMENDED DIETARY ALLOWANCES: CALORIE AND PROTEIN REQUIREMENTS<sup>a</sup>**

Category	Age (years)	kcal/kg	Protein g/kg
Infants	0–0.5	108	2.2
	0.5–1	98	1.6
Children	1–3	102	1.2
	4–6	90	1.1
	7–10	70	1.0
Males	11–14	55	1.0
	15–18	45	0.9
	19–24	40	0.8
Females	11–14	47	1.0
	15–18	40	0.8
	19–24	38	0.8

<sup>a</sup>This recommended dietary allowance (RDA) by definition meets the needs of 97% of healthy children. This is a quick reference to estimate calorie and protein needs, but further estimation may be required, using various other energy and protein need equations and factors, typically used by a registered dietitian.

Data from Nestle Health Science. Calorie and protein requirements. Pediatric nutrition helpful hints: Specialized nutrition for your most vulnerable patients. <https://www.nestlehealthscience.us/asset-library/documents/resources/pediatric%20helpful%20hints.pdf>; and National Academy of Sciences. *Recommended Dietary Allowances*. 10th ed. National Academy Press; 1989:33–36.

**TABLE 21.4****FAT REQUIREMENTS: ADEQUATE INTAKE<sup>a</sup>**

Age	Total Fat (g/day)	Linoleic Acid (g/day)	$\alpha$ -Linolenic Acid (g/day)
0–6 months	31	4.4 (n-6 PUFA)	0.5 (n-3 PUFA)
7–12 months	30	4.6 (n-6 PUFA)	0.5 (n-3 PUFA)
1–3 years	<sup>b</sup>	7	0.7
4–8 years	<sup>b</sup>	10	0.9
9–13 years, boys	<sup>b</sup>	12	1.2
9–13 years, girls	<sup>b</sup>	10	1.0
14–18 years, boys	<sup>b</sup>	16	1.6
14–18 years, girls	<sup>b</sup>	11	1.1
Pregnancy	<sup>b</sup>	13	1.4
Lactation	<sup>b</sup>	13	1.3

<sup>a</sup>If sufficient scientific evidence is not available to establish a recommended dietary allowance (RDA), an adequate intake (AI) is usually developed. For healthy breastfed infants, the AI is the mean intake. The AI for other life stage and gender groups is believed to cover the needs of all healthy individuals in the group, but a lack of data or uncertainty in the data prevents specifying with confidence the percentage of individuals covered by this intake.

<sup>b</sup>No AI, estimated average requirement (EAR), or RDA established.

PUFA, Polyunsaturated fatty acid.

From Otten JJ, Hellwig JP, Meyers LD, eds. *Dietary Reference Intakes: The Essential Guide to Nutrient Requirements*. National Academies Press; 2006.

- a. Breastfed and partially breastfed infants should be supplemented with 400 international units (IU) per day beginning in the first few days of life until 12 months.
  - b. Formula-fed infants should be supplemented until the infant is taking 34 oz of formula per day.
  - c. For preterm infants tolerating full enteral feeds and weighing >1500–2000 g, supplement with 400 IU/day. Supplement with 200–400 IU/day for infants <1500 g.
  - d. Supplement children and adolescents with 600 IU/day if the child is ingesting <1000 mL (34 oz) per day of vitamin D fortified milk or not taking that amount through fortified foods.
  - e. At-risk children (e.g., cystic fibrosis) and those with laboratory confirmed vitamin D insufficiency/deficiency should also be supplemented.
  - f. See [Table 21.6](#) for interpreting vitamin D levels.
2. Folate<sup>24,25</sup>
    - a. All women capable of becoming pregnant should consume 400 mCg from supplements or diet.
    - b. This should continue as women enter prenatal care.
    - c. If a woman had a prior pregnancy with a neural tube defect and is planning another pregnancy, she should consume 4 mg of folic acid daily (requires a prescription) at least 4 weeks before becoming pregnant and continue through the first 12 weeks of pregnancy.

#### D. Mineral Requirements ([Table 21.7](#))

1. Iron<sup>26</sup>

TABLE 21.5

## DIETARY REFERENCE INTAKES: RECOMMENDED INTAKES FOR INDIVIDUALS—VITAMINS

Life Stage	Vit. A <sup>a</sup> (IU)	Vit. C (mg/day)	Vit. D <sup>b,c</sup> (IU)	Vit. E <sup>d</sup> (IU)	Vit. K (mCg/day)	Thiamin (mg/day)	Riboflavin (mg/day)	Niacin <sup>e</sup> (mg/day)	Vit. B <sub>6</sub> (mg/day)	Folate <sup>f</sup> (mCg/day)	Vit. B <sub>12</sub> (mCg/day)	Pantothenic Acid (mg/day)	Biotin (mCg/day)	Choline <sup>g</sup> (mg/day)
<b>INFANTS</b>														
0–6 months	1333	40*	400*	4*	2.0	0.2*	0.3*	2*	0.1*	65*	0.4*	1.7*	5*	125*
7–12 months	1666	50*	400*	5*	2.5	0.3*	0.4*	4*	0.3*	80*	0.5*	1.8*	6*	150*
<b>CHILDREN</b>														
1–3 years	1000	15	600*	6	30	0.5	0.5	6	0.5	150	0.9	2*	8*	200*
4–8 years	1333	25	600*	7	55	0.6	0.6	8	0.6	200	1.2	3*	12*	25*
<b>MALES</b>														
9–13 years	2000	45	600*	11	60	0.9	0.9	12	1.0	300	1.8	4*	20*	375*
14–18 years	3000	75	600*	15	75	1.2	1.3	16	1.3	400	2.4	5*	25*	550*
19–30 years	3000	90	600*	15	120	1.2	1.3	16	1.3	400	2.4	5*	30*	550*
<b>FEMALES</b>														
9–13 years	2000	45	600*	11	60	0.9	0.9	12	1.0	300	1.8	4*	20*	375*
14–18 years	2333	65	600*	15	75	1.0	1.0	14	1.2	400	2.4	5*	25*	400*
19–30 years	2333	75	600*	15	90	1.1	1.1	14	1.3	400	2.4	5*	30*	425*

Continued

TABLE 21.5

## DIETARY REFERENCE INTAKES: RECOMMENDED INTAKES FOR INDIVIDUALS—VITAMINS—CONT'D

Life Stage	Vit. A <sup>a</sup> (IU)	Vit. C (mg/day)	Vit. D <sup>b,c</sup> (IU)	Vit. E <sup>d</sup> (IU)	Vit. K (mCg/day)	Thiamin (mg/day)	Riboflavin (mg/day)	Niacin <sup>e</sup> (mg/day)	Vit. B <sub>6</sub> (mg/day)	Folate <sup>f</sup> (mCg/day)	Vit. B <sub>12</sub> (mCg/day)	Pantothenic Acid (mg/day)	Biotin (mCg/day)	Choline <sup>g</sup> (mg/day)
<b>PREGNANCY</b>														
≤18 years	<b>2500</b>	<b>80</b>	600*	15	<b>75*</b>	1.4	1.4	18	1.9	<b>600</b>	2.6	6*	30*	450*
19–30 years	<b>2567</b>	<b>85</b>	600*	15	<b>90*</b>	1.4	1.4	18	1.9	<b>600</b>	2.6	6*	30*	450*
<b>LACTATION</b>														
≤18 years	<b>4000</b>	<b>115</b>	600*	19	<b>75*</b>	1.4	1.6	17	2.0	<b>500</b>	2.8	7*	35*	550*
19–30 years	<b>4333</b>	<b>120</b>	600*	19	<b>90*</b>	1.4	1.6	17	2.0	<b>500</b>	2.8	7*	35*	550*

<sup>a</sup>One international unit (IU) = 0.3 mCg retinol equivalent.

<sup>b</sup>One mCg cholecalciferol = 40 IU vitamin D.

<sup>c</sup>In the absence of adequate exposure to sunlight.

<sup>d</sup>One IU = 1 mg vitamin E.

<sup>e</sup>As niacin equivalents (NE). 1 mg of niacin = 60 mg of tryptophan; 0 to 6 months = preformed niacin (not NE).

<sup>f</sup>As dietary folate equivalents (DFE). 1 DFE = 1 mCg food folate = 0.6 mCg of folic acid from fortified food or as a supplement consumed with food = 0.5 mCg of a supplement taken on an empty stomach.

<sup>g</sup>Although AIs have been set for choline, there are few data to assess whether a dietary supply of choline is required at all life stages, and it may be that the choline requirement can be met by endogenous synthesis at some of these stages.

**NOTE:** This table presents recommended dietary allowances (RDAs) in **bold type** and adequate intakes (AIs) in regular type followed by an asterisk (\*). RDAs and AIs may both be used as goals for individual intake. RDAs are set to meet the needs of almost all (97% to 98%) individuals in a group. For healthy breastfed infants, the AI is the mean intake. The AI for other life stage and gender groups is believed to cover needs of all individuals in the group, but lack of data or uncertainty in the data prevents specifying with confidence the percentage of individuals covered by this intake.

Modified from Otten JJ, Hellwig JP, Meyers LD, eds. *Dietary Reference Intakes: The Essential Guide to Nutrient Requirements*. National Academies Press; 2006. <http://www.nap.edu>

TABLE 21.6

## VITAMIN D LABORATORY INTERPRETATION

25-Hydroxy Vitamin D	Value (ng/mL)
Severe deficiency	<10
Deficiency	<10–20
Insufficiency	>20–<30
Optimal level	≥30 <sup>a</sup>

<sup>a</sup>Cutoff values are not yet well defined. Controversy exists regarding the optimal 25-hydroxy vitamin D level. Some experts recommend a level of 20 to 30 ng/mL as being sufficient. These are the Johns Hopkins Hospital Pediatrics guidelines used for dosing.

**NOTE:** 1,25-dihydroxy vitamin D is the physiologically active form, but 25-hydroxy vitamin D is the value to monitor for vitamin D deficiency as it approximates body stores of vitamin D.

- a. Breastfed term infants should receive 1 mg/kg/day of an oral iron supplement beginning at 4 months of age, preferably from iron-fortified cereal or, alternatively, elemental iron.
  - b. Breastfed preterm infants should receive 2 mg/kg/day by 1 month of age, which should continue until the infant is weaned to iron-fortified formula or begins eating complementary foods.
  - c. Formula-fed term infants receive adequate iron from fortified formula.
  - d. Formula-fed preterm infants need 2 mg/kg/day, which is the amount supplied by iron-fortified formulas.
2. Fluoride<sup>30</sup>
- a. Consider fluoride supplementation for those patients who use bottled water or home filtration systems. Some home water treatment systems can reduce fluoride levels.
  - b. For infants and children at high risk for the development of caries, fluoride supplementation ranging from 0.25 to 1 mg/day is recommended, according to the American Dental Association's schedule.
  - c. Fluoridated toothpaste is recommended for all children starting at tooth eruption, using a smear (grain-of-rice-sized) until age 3 and then a pea-sized amount after that time.

### E. Fiber Requirements (Table 21.8)

## VI. BREASTFEEDING AND THE USE OF HUMAN MILK

### A. Benefits of Breast Milk<sup>31</sup>

1. Decreased risk of infections (e.g., otitis media, respiratory), necrotizing enterocolitis, inflammatory bowel, sudden infant death syndrome (SIDS)
2. Decreased incidence of atopic conditions, obesity, and diabetes

### B. Contraindications to Breastfeeding<sup>31</sup> (Box 21.2)

1. Tobacco smoking is not contraindicated but is strongly discouraged because of an association with increased risks of SIDS, respiratory disease, and infections in exposed infants.

TABLE 21.7

## DIETARY REFERENCE INTAKES: RECOMMENDED INTAKES—ELEMENTS

Life Stage	Calcium (mg/day)	Chromium (mCg/day)	Copper (mCg/day)	Fluoride (mg/day)	Iodine (mCg/day)	Iron (mg/day)	Magnesium (mg/day)	Manganese (mg/day)	Molybdenum (mCg/day)	Phosphorus (mg/day)	Selenium (mCg/day)	Zinc (mg/day)
<b>INFANTS</b>												
0–6 months	200*	0.2*	200*	0.01*	110*	0.27*	30*	0.003*	2*	100*	15*	2*
7–12 months	260*	5.5*	220*	0.5*	130*	11	75*	0.6*	3*	275*	20*	3
<b>CHILDREN</b>												
1–3 years	700	11*	340	0.7*	90	7	80	1.2*	17	460	20	3
4–8 years	1000	15*	440	1.0*	90	10	130	1.5*	22	500	30	5
<b>MALES</b>												
9–13 years	1300	25*	700	2*	120	8	240	1.9*	34	1250	40	8
14–18 years	1300	35*	890	3*	150	11	410	2.2*	43	1250	55	11
19–30 years	1000	35*	900	4*	150	8	400	2.3*	45	700	55	11
<b>FEMALES</b>												
9–13 years	1300	21*	700	2*	120	8	240	1.6*	34	1250	40	8
14–18 years	1300	24*	890	3*	150	15	360	1.6*	43	1250	55	9
19–30 years	1000	25*	900	3*	150	18	310	1.8*	45	700	55	8
<b>PREGNANCY</b>												
≤18 years	1300	29*	1000	3*	220	27	400	2.0*	50	1250	60	13
19–30 years	1000	30*	1000	3*	220	27	350	2.0*	50	700	60	11
<b>LACTATION</b>												
≤18 years	1300	44*	1300	3*	290	10	360	2.6*	50	1250	70	14
19–30 years	1000	45*	1300	3*	290	9	310	2.6*	50	700	70	12

**NOTE:** This table presents recommended dietary allowances (RDAs) in **bold type** and adequate intakes (AIs) in regular type followed by an asterisk (\*). RDAs and AIs may both be used as goals for individual intake. RDAs are set to meet the needs of almost all (97% to 98%) individuals in a group. For healthy breastfed infants, the AI is the mean intake. The AI for other life stage and gender groups is believed to cover needs of all individuals in the group, but lack of data or uncertainty in the data prevents specifying with confidence the percentage of individuals covered by this intake.

Modified from Otten JJ, Hellwig JP, Meyers LD, eds. *Dietary Reference Intakes: The Essential Guide to Nutrient Requirements*. National Academies Press; 2006. Includes updates from Ross AC, Taylor CL, Yaktine AL, Del Valle HB, eds. *Dietary Reference Intakes for Calcium and Vitamin D*. National Academies Press; 2011.

**TABLE 21.8****FIBER REQUIREMENTS: ADEQUATE INTAKE<sup>a</sup>**

Age	Total Fiber (g/day)
0–12 months	Not determined
1–3 years	19
4–8 years	25
9–13 years, boys	31
9–13 years, girls	26
14–18 years, boys	38
14–18 years, girls	26
Pregnancy	28
Lactation	29

<sup>a</sup>Adequate intake (AI). If sufficient scientific evidence unavailable to establish recommended dietary allowance (RDA), an AI is usually developed. For healthy breastfed infants, the AI is the mean intake. AI for other life-stage and gender groups is believed to cover the needs of all healthy individuals in the group, but a lack of data or uncertainty in the data prevents specifying with confidence the percentage of individuals covered by this intake.

g, Grams.

Modified from Otten JJ, Hellwig JP, Meyers LD, eds. *Dietary Reference Intakes: The Essential Guide to Nutrient Requirements*. National Academies Press; 2006.

**BOX 21.2****CONTRAINDICATIONS TO BREASTFEEDING**

Infant galactosemia  
 Maternal human T-cell lymphotropic virus I/II infection  
 Maternal untreated brucellosis  
 Maternal HIV (developed countries)  
 Maternal active, untreated tuberculosis (may give expressed BM)  
 Maternal active HSV lesions on breast (may give expressed BM)  
 Maternal varicella infection 5 days before through 2 days after delivery (may give expressed BM)  
 Maternal use of diagnostic or therapeutic radioactive isotopes, antimetabolites, or chemotherapeutic agents  
 Illicit street drugs such as cannabis, cocaine, phencyclidine, etc.

BM, Breast milk; HIV, human immunodeficiency virus; HSV, herpes simplex virus.

Modified from American Academy of Pediatrics, Section on Breastfeeding. Policy Statement—Breastfeeding and the Use of Human Milk. *Pediatrics*. 2012;129:e827–e841.

- Alcohol should be limited to the occasional intake of 2 oz of liquor, 8 oz of wine, or two beers for the average 60 kg woman >2 hours prior to the onset of nursing.
- Methadone and buprenorphine are not contraindications, if the mother is in a stable maintenance program and not using street drugs.

**C. Use of Milk Bank Donor Human Milk<sup>32</sup>**

- Most commonly used in low-birth-weight infants (<1.5 kg)
- Can be considered in infants with intestinal disease with documented intolerance to specialized infant formulas

### D. Safe Handling of Breast Milk<sup>33</sup>

1. Freshly expressed or pumped milk can be stored at room temperature for up to 4 hours, in the refrigerator for up to 4 days, in the freezer for approximately 6 months (up to 12 months), and in an insulated cooler bag with frozen packs up to 24 hours while traveling.
2. Once breast milk is thawed to room temperature or warmed, it should be used within 2 hours.

### E. Breastfeeding Resources

See [Section IX.C](#).

## VII. ENTERAL NUTRITION

### A. Feeding the Healthy Infant

1. Recommended formula amount by age<sup>34</sup>
  - a. 1st days of life: 1 to 2 ounces every 2 to 3 hours
  - b. 1st month: 2 to 4 ounces every 3 to 4 hours
  - c. 2nd month: 5 to 6 ounces every 4 to 5 hours
  - d. 3rd to 5th month: 6 to 7 ounces every 4 to 5 hours
  - e. 6th to 8th month: 24 to 32 ounces in 24 hours
  - f. 8th to 10th month: 16 to 32 ounces in 24 hours
  - g. 10th to 12th month: 12 to 24 ounces in 24 hours
2. Properties of formula options for healthy infants and toddlers ([Table 21.9](#))
3. Appropriate preparation and fortification of formulas ([Table 21.10](#))
4. Methods to further increase calories, protein, carbohydrate, fat, or a combination ([Table 21.11](#))

### B. Available Formulas for Patients With Specific Clinical Conditions or for Those Requiring Special Diets ([Tables 21.12 and 21.13](#))

### C. Use of Enteral Tube Feeds<sup>35</sup>

1. Insufficient oral intake (e.g., anorexia nervosa, food aversion, malabsorption, increased needs)
2. As a primary therapy (e.g., metabolic or inflammatory bowel disease, fasting intolerance)
3. Oral motor dysfunction (e.g., prematurity, neuromuscular and neurologic disease)
4. Abnormal gastrointestinal tract (e.g., congenital malformations, esophageal stenosis, intestinal pseudo-obstruction)
5. Injury/critical illness (e.g., burn, trauma, surgery, sepsis, malignancy)

### D. Features of the Most Common Oral Rehydration Solutions ([Table 21.14](#))

## VIII. PARENTERAL NUTRITION

### A. Indications for the Use of Parenteral Nutrition<sup>36-38</sup>

1. Inability to feed enterally or when alimentation via gastrointestinal tract is restricted >3 to 5 days (or earlier for premature infants and neonates)
2. Chronic gastrointestinal dysfunction and/or malabsorption
3. Increased gastrointestinal losses or requirements

TABLE 21.9

## PROPERTIES OF FEEDING OPTIONS FOR HEALTHY INFANTS AND CHILDREN

Examples	Calories (kcal/oz)	Carbohydrate Source	Protein Source	Unique Properties	Indications
Human milk	20	Lactose	Human milk	See Section VI.A	Preferred for most infants
Cow's milk–based formulas Enfamil Infant, Similac Advance, Similac Sensitive, Gerber Good Start Gentle	20	Lactose	Cow's milk		Typical term infant
Toddler/child Boost Kids Essential, Carnation Instant Breakfast Essential, Compleat Pediatric, Nutren Junior, Pediasure Enteral, Pediasure	20–45	Lactose	Cow's milk	Milk-based Contain added iron, vitamin C, E, and zinc, DHA/AA, calcium	Age 1 year to 10–13 years

AA, Amino acids; DHA, docosahexaenoic acid; kcal, kilocalorie; oz, ounce.

Data from O'Connor N. Infant formula. *Am Fam Phys.* 2009;79(7):565–570, Table 21.9; and Comparison of breast milk and available infant formulas: <https://www.aafp.org/afp/2009/0401/p565.html>, Table 1.

**TABLE 21.10****PREPARATION OF INFANT FORMULAS FOR MOST FULL-TERM STANDARD AND SOY FORMULAS<sup>a</sup>**

Formula Type	Desired Caloric Concentration (kcal/oz)	Amount of Formula 13 oz = 1 can	Water (oz)	Approximate Final Volume (oz)
Liquid concentrates (40 kcal/oz)	20	13 oz	13 oz	26 oz
	22	13 oz	11 oz	24 oz
	24	13 oz	9 oz	22 oz
	26	13 oz	7 oz	20 oz
	27	13 oz	6 oz (3/4 cup)	19 oz
Powder (approx 44 kcal/scoop) <sup>b</sup>	30	13 oz	4.3 oz	17.3 oz
	20	1 scoop	2 oz	2 oz
	22	3 scoop	5.5 oz	6 oz
	24	3 scoops	5 oz	5.5 oz
	26	6 scoops	9 oz	10 oz
	27	6 scoops	8.5 oz	10 oz
	30	6 scoops	7.5 oz	9 oz

<sup>a</sup>Does not apply to Enfacare, Neocate Infant, Alfamino Infant, or NeoSure. Of note, Enfamil A.R. and Similac for Spit-Up is not recommended to be concentrated greater than 24 kcal/oz. Use a packed measure for Nutramigen and Pregestimil; all others unpacked powder.

<sup>b</sup>Slight variations in brands, range 40 to 45 kcal/scoop.

*kcal*, Kilocalorie; *oz*, ounce.

Modified from University of Michigan Hospitals & Health Centers. Powdered and liquid concentrate recipe chart. <https://www.med.umich.edu/1libr/pa/FormulaAdjustmentstandard.pdf>

**TABLE 21.11****COMMON CALORIC MODULARS<sup>a</sup>**

Component	Calories
<b>PROTEIN</b>	
Beneprotein (powder)	25 kcal/scoop (6 g protein)
ProSource protein powder	30 kcal/scoop (6 g protein)
Complete Amino Acid Mix (powder)	3.28 kcal/g (0.82 g protein) 2.9 g/teaspoon (9.5 kcal, 2.38 g protein)
Abbott Liquid Protein Fortifier	0.67 kcal/mL (0.167 g protein/mL)
<b>CARBOHYDRATE</b>	
SolCarb	3.75 kcal/g; 23 kcal/tbsp
Polycal	3.84 kcal/g; 28 kcal/tbsp; 20 kcal/scoop
<b>FAT</b>	
MCT oil <sup>b</sup>	7.7 kcal/mL
Vegetable oil	8.3 kcal/mL
Microlipid (emulsified LCT)	4.5 kcal/mL
Liquigen (emulsified MCT) <sup>b</sup>	4.5 kcal/mL
<b>FAT AND CARBOHYDRATE</b>	
Duocal (powder)	42 kcal/tbsp; 25 kcal/scoop (59% carb, 41% fat, 35% fat as MCT)

<sup>a</sup>Use these caloric supplements when you want to increase protein, carbohydrate, or fat; or when you have reached the maximum concentration tolerated and wish to further increase caloric density.

<sup>b</sup>Medium-chain triglyceride (MCT) oil is unnecessary unless there is fat malabsorption.

*Carb*, Carbohydrate; *g*, grams; *kcal*, kilocalorie; *LCT*, long chain-triglyceride; *MCT*, medium chain-triglyceride; *mL*, milliliter; *tbsp*, tablespoon.

TABLE 21.12

## FORMULA PROPERTIES AND INDICATIONS FOR SPECIFIC CONDITIONS

	Examples	Calories (kcal/oz)	Carbohydrate Source	Protein Source	Unique Properties	Indications
Human milk fortifiers					Contain protein, carbohydrates, fat, vitamins, and minerals	Preterm infants, especially <1500 g who are receiving human milk
Preterm formulas	Enfamil Premature, Similac Special Care Advance	24	Lactose	Cow's milk	Higher protein, calcium, magnesium, phosphorous, and vitamin A and D Contain taurine	Generally use until infant weighs 1800–2000 g or until 34 weeks corrected gestational age
Enriched or transitional formula	Enfamil Enfacare, Similac Neosure	22	Lactose	Cow's milk	Higher protein, calcium, magnesium, and phosphorous	Transition from preterm to enriched as described above until age 6–12 months
Cow's milk–based formulas	Enfamil Infant, Similac Advance, Similac Sensitive	20	Lactose	Cow's milk		Typical term infant
Soy formulas	America's Store Brand Soy, Enfamil ProSobee, Gerber Good Start Soy, Similac Soy Isomil, Similac for Diarrhea	20	Corn-based	Soy	Contain higher protein concentration and supplemental amino acids	Galactosemia, congenital lactase deficiency, strict vegan families Should NOT be used for preterm infants (increased risk of poor growth, osteopenia of prematurity)

Continued

TABLE 21.12

## FORMULA PROPERTIES AND INDICATIONS FOR SPECIFIC CONDITIONS—CONT'D

	Examples	Calories (kcal/oz)	Carbohydrate Source	Protein Source	Unique Properties	Indications
						Avoided in infants with milk protein intolerance given association with soy allergy
Hydrolyzed casein	Alimentum, Nutramigen, Pregestimil	20	Corn or sucrose	Casein	Easier to digest Hypoallergenic	IgE-mediated milk protein allergy Fat malabsorption
Partially hydrolyzed whey	Gerber Good Start Gentle, Gerber Good Start Soothe, Similac Pro-Total Comfort	20	Corn or sucrose	Hydrolyzed whey + casein or 100% whey	Reduced lactose content	May reduce risk of developing allergic diseases (especially eczema), improve gastric emptying, decrease colic, but data limited and may differ between products
Amino acid	Neocate Infant and Junior, Elecare Infant and Junior, Alfamino Infant and Junior, PurAmino Infant and Junior	20	Corn or sucrose	Amino acids	Easier to digest Nonallergenic	Milk protein allergy Severe malabsorption

g, Grams; kcal, kilocalorie; oz, ounce.

Data from O'Connor N. Infant formula. *Am Fam Phys*. 2009;79(7):565–570; Comparison of breast milk and available infant formulas: <https://www.aafp.org/afp/2009/0401/p565.html>. Additional sources listed in references.

**TABLE 21.13****ADDITIONAL FORMULAS FOR SPECIAL CLINICAL CIRCUMSTANCES****INFANTS**

Severe carbohydrate intolerance	MJ3232A Ross Carbohydrate Free (RCF)
---------------------------------	---

Requiring lower calcium and phosphorus	Similac PM 60/40
--	------------------

**TODDLERS AND YOUNG CHILDREN AGED 1–10 YEARS**

Vegetarian, lactose intolerance, or milk protein intolerance	Bright Beginnings Soy Pediatric Drink
--	---------------------------------------

Protein allergy/intolerance and/or fat malabsorption	PediaSure Peptide (and Peptide 1.5) Pepdite Junior Peptamen Junior (with and without Prebio) Vivonex Pediatric EleCare Junior Neocate Junior Neocate Splash Alfamino Junior PurAmino Junior
--	---

Fat malabsorption, intestinal lymphatic obstruction, chylothorax	Monogen Enfaport
Increased caloric needs	Boost Kids Essentials Carnation Instant Breakfast Essentials Nutren Junior (also with fiber) PediaSure (also with fiber)

Requiring clear liquid diet	Resource Breeze Ensure Clear
-----------------------------	---------------------------------

Intractable epilepsy	KetoCal (3:1 and 4:1)
----------------------	-----------------------

Blended formulas (using real foods) <sup>a</sup>	Pediasure Harvest Compleat Pediatric Compleat Organic Blends Compleat Pediatric Organic Blends Nourish Liquid Hope Kate Farms (Standard 1.0, Pediatric Standard 1.2, Peptide 1.5 and Pediatric Peptide 1.5)
--	---

**OLDER CHILDREN AND ADULTS****Enteral Nutrition (Tube Feeding)**

For malabsorption of protein and/or fat	Peptamen, Peptamen w/Prebio, Peptamen 1.0 and 1.5 Pediasure Peptide 1.0 and 1.5 Vital Peptide 1.5 Perative Tolerex Vital High Protein Vital 1.0 Cal and AF 1.2 Cal, 1.5 Cal Vivonex Plus and Vivonex T.E.N.
---	--

For critically ill and/or malabsorption	Pulmocare Pivot 1.5 Cal Perative
---	--

For impaired glucose tolerance	Glucerna Glytrol Store-brand diabetic nutritional drink
--------------------------------	---

*Continued*

TABLE 21.13

## ADDITIONAL FORMULAS FOR SPECIAL CLINICAL CIRCUMSTANCES—CONT'D

For dialysis patients	Magnacal Renal Nepro NutriRenal
For patients with acute renal failure not on dialysis	Renalcal Suplena
<b>Increased Caloric Needs (Oral)</b>	
With a normal gastrointestinal (GI) tract	Boost, Boost with fiber Boost Plus, Boost High Protein Carnation Instant Breakfast Essentials with whole milk Ensure Original NUTRA Shake
For clear liquid diet	Resource Breeze Ensure Clear
For patients with cystic fibrosis (CF)	Scandishake with whole milk

<sup>a</sup>Some blended formulas can also be used for older children and adults. Tube bore size (French) and gravity versus bolus feeding recommendations vary; review each formula company's recommendations. Calories and nutrient information vary among formulas. Gradually changing from a nonblended formula may allow for optimal tolerance.

TABLE 21.14

## ORAL REHYDRATION SOLUTIONS

Solution	Kcal/mL (kcal/oz)	Carbohydrate (g/L)	Na (mEq/L)	K (mEq/L)	Osmolality (mOsm/kg H <sub>2</sub> O)
CeraLyte-50	0.16 (4.9)	Rice digest (40)	50	20	N/A
CeraLyte-70	0.16 (4.9)	Rice digest (40)	70	20	N/A
CeraLyte-90	0.16 (4.9)	Rice digest (40)	90	20	N/A
Enfalyte	0.12 (3.7)	Rice syrup solids (30)	50	25	160
Oral Rehydration Salts (WHO)	0.06 (2)	Dextrose (20)	90	20	330
Pedialyte (unflavored)	0.1 (3)	Dextrose (25)	45	20	250

*g*, Gram; *kcal*, kilocalorie; *kg*, kilogram; *L*, liter; *mL*, milliliter; *mOsm*, milliosmole; *oz*, ounce.

**B. Starting and Advancing Parenteral Nutrition (Table 21.15)**

**C. Frequency of Monitoring Growth Parameters and Laboratory Studies in Patients on Parenteral Nutrition (Table 21.16)**

**D. Recommended Formulations of Parenteral Nutrition (Table 21.17)**

**TABLE 21.15****INITIATION AND ADVANCEMENT OF PARENTERAL NUTRITION FOR INFANTS THROUGH ADOLESCENTS<sup>a,b</sup>**

Nutrient	Initial Dose	Advancement	Goals
Glucose	3.5%–10%	1%–5%/day	5–12 (max 14–18) mg/kg/min (rate of infusion)
Protein	0.8–3 g/kg/day	1 g/kg/day	0.8–4 g/kg/day 10%–16% of calories
Fat <sup>c</sup>	1–2 g/kg/day	0.5–1 g/kg/day	1–3.5 g/kg/day <sup>d</sup> 0.17 g/kg/hr (maximum rate of infusion)

<sup>a</sup>Acceptable osmolarity of parenteral nutrition through a peripheral line varies between 900 and 1050 osm/L by institution. An estimate of the osmolarity of parenteral nutrition can be obtained with the following formula: Estimated osmolarity = (dextrose concentration × 50) + (amino acid concentration × 100) + (mEq of electrolytes × 2). Consult individual pharmacy for hospital limitations.

<sup>b</sup>In general, infants require the higher concentration and/or rate of glucose, protein, and fat compared to older children and adolescents.

<sup>c</sup>Essential fatty acid deficiency may occur in fat-free parenteral nutrition within 2 to 4 weeks in infants and children and as early as 2 to 14 days in neonates. A minimum of 2% to 4% of total caloric intake as linoleic acid and 0.25% to 0.5% as linolenic acid is necessary to meet essential fatty acid requirements.

<sup>d</sup>If parenteral nutrition–associated cholestasis occurs, lipid minimization and/or use of fish oil or composite lipids should be considered.

*g*, Gram; *hr*, hour; *kg*, kilogram; *L*, liter; *mg*, milligram; *min*, minute; *osm*, osmole.

Modified from Corkins M, Balint J, Plogsted S, eds. *The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum*. American Society for Parenteral and Enteral Nutrition; 2010; Table 34.4.

**TABLE 21.16****MONITORING SCHEDULE FOR PATIENTS RECEIVING PARENTERAL NUTRITION<sup>a</sup>**

Variable	Initial Period <sup>b</sup>	Later Period <sup>c</sup>
<b>GROWTH</b>		
Weight	Daily	2 times/week
Height	Weekly (infants) Monthly (children)	Monthly
Head circumference (infants)	Weekly	Monthly <sup>d</sup>
<b>LABORATORY STUDIES</b>		
Electrolytes and glucose	Daily ×3 or until stable	1–2× weekly
BUN/creatinine	Daily ×3 or until stable	1–2× weekly
Albumin or prealbumin	Weekly	Weekly
Ca <sup>2+</sup> , Mg <sup>2+</sup> , P	Daily ×3 or until stable	Weekly
ALT, AST, ALP	Weekly	Weekly
Total and direct bilirubin	Weekly	Weekly
CBC with differential	Daily ×3 or until stable	1–2× weekly
Triglycerides	Daily until stable	Weekly
Vitamins	—	As indicated
Trace minerals	—	As indicated

<sup>a</sup>For patients on long-term parenteral nutrition, monitoring every 24 weeks is adequate in most cases.

<sup>b</sup>The period before nutritional goals are reached or during any period of instability.

<sup>c</sup>When stability is reached, no changes in nutrient composition.

<sup>d</sup>Weekly in preterm infants.

*ALP*, Alkaline phosphatase; *ALT*, alanine transaminase; *AST*, aspartate transaminase; *BUN*, blood urea nitrogen; *CBC*, complete blood cell count; *Ca*, calcium; *Mg*, magnesium; *P*, phosphorous.

Modified from Worthington P, Balint J, Bechtold M, et al. When is parental nutrition appropriate? *J Parent Enter Nutr*. 2017;41(3); Table 13.2.

**TABLE 21.17****PARENTERAL NUTRITION FORMULATION RECOMMENDATIONS**

Electrolyte	Preterm	Term Infants/Children	Adolescents and Children >50 mg
Sodium (mEq/kg)	2–5	2–5	1–2
Potassium (mEq/kg)	2–4	2–4	1–2
Calcium	2–4 mEq/kg	0.5–4 mEq/kg	10–20 mEq/day
Phosphorus	1–2 mmol/kg	0.5–2 mmol/kg	10–40 mmol/day
Magnesium	0.3–0.5 mEq/kg	0.3–0.5 mEq/kg	10–30 mEq/day
Acetate and chloride	As needed for acid base balance		

Trace Element	Preterm Neonates <3 kg (mCg/kg/day)	Term Neonates 3–10 kg (mCg/kg/day)	Children 10–40 kg (mCg/kg/day)	Adolescents >40 kg (per day)
Zinc	400	50–250	50–125	2–5 mg
Copper <sup>a</sup>	20	20	5–20	200–500 mg
Manganese <sup>a</sup>	1	1	1	40–100 mCg
Chromium	0.05–0.2	0.2	0.14–0.2	5–15 mCg
Selenium	1.5–2	2	1–2	40–60 mCg

<sup>a</sup>Copper and manganese needs may be lowered in cholestasis.

From Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. *J Parenter Enteral Nutr.* 2004;28(6):S29–S70; and Corkins M, Balint J, Plogsted S, eds. *The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum.* American Society for Parenteral and Enteral Nutrition; 2010, Tables 34.5 and 34.7.

**IX. WEB RESOURCES****A. Professional and Government Organizations**

- Growth charts and nutrition information: [https://www.cdc.gov/growthcharts/cdc\\_charts.htm](https://www.cdc.gov/growthcharts/cdc_charts.htm)
- American Academy of Pediatrics (AAP) children's health topics: <http://www.healthychildren.org>
- Academy of Nutrition and Dietetics: <http://www.eatright.org>
- American Society for Parenteral and Enteral Nutrition: <http://www.nutritioncare.org>
- U.S. Department of Agriculture Healthy Eating Guidelines: <http://www.choosemyplate.gov>
- Bright Futures: Nutrition and Pocket Guide: <https://downloads.aap.org/AAP/PDF/Bright%20Futures/BFNutrition3rdEdPocketGuide.pdf>
- AAP Committee on Nutrition: <https://www.aap.org/en/community/aap-committees/committee-on-nutrition/>

**B. Infant and Pediatric Formula Company Websites**

- Enfamil, Enfacare, Nutramigen, and Pregestimil: <http://www.meadjohnson.com>
- Carnation, Good Start, Nutren, Peptamen, Vivonex, Boost, Alfamino, and Resource: <https://www.nestlehealthscience.us/> and <http://medical.gerber.com/>

- Alimentum, EleCare, Ensure, NeoSure, PediaSure, Pedialyte, and Similac: <https://www.abbottnutrition.com/content/dam/an/abbottnutrition/pdf/product-guides/Pediatric%20Nutrition%20Handbook%202022Q3.pdf>
- Bright Beginnings: <http://www.brightbeginnings.com>
- America's Store Brand: <http://www.storebrandformula.com>
- KetoCal, Neocate, and Pepdite: <http://www.nutricia-na.com>
- Liquid Hope and Nourish: <https://www.functionalformularies.com/>
- Kate Farms: <https://www.katefarms.com/>

### C. Breastfeeding Resources

- LactMed is an online resource from the National Library of Medicine/ National Institutes of Health (N/IIH) that provides information on the safety of maternal medications and breastfeeding: <https://www.ncbi.nlm.nih.gov/books/NBK501922/>
- Video instruction on breastfeeding techniques from Stanford Newborn Nursery: <http://newborns.stanford.edu/Breastfeeding/FifteenMinuteHelper.html>
- Academy of Breastfeeding Medicine Protocols for the Care of Breastfeeding Mothers and Infants. Management of common breastfeeding-related challenges discussed: <https://www.bfmed.org/protocols>
- National Institute of Child Health and Human Development—Breastfeeding: <https://www.nichd.nih.gov/health/topics/breastfeeding/Pages/default.aspx>
- La Leche League is an international organization that provides mother-to-mother support, encouragement, information, and education. This organization hosts free lactation consultant-led support groups to connect mothers locally. While there are some excellent articles and the support groups can provide access to a lactation consultant, this group does support co-sleeping, and anticipatory guidance regarding the danger of co-sleeping and SIDS is necessary when providing parents with this resource: <https://www.llli.org/>

## REFERENCES

A complete list of references can be found online.

## REFERENCES

1. National Center for Health Statistics. Growth charts. January 26, 2023. <https://www.cdc.gov/growthcharts/>
2. Bernbaum JC, Campbell DE, Imaizumi SO. Follow-up care of the graduate from the neonatal intensive care unit. In: McInerny T, ed. *American Academy of Pediatrics Textbook of Pediatric Care*. American Academy of Pediatrics; 2009:867–882. [https://doi.org/10.1542/9781581106411-5-section\\_3\\_chapter04](https://doi.org/10.1542/9781581106411-5-section_3_chapter04). Published: March 18, 2008.
3. Age terminology during the perinatal period. *Pediatrics*. 2004;114:1362. <http://pediatrics.aappublications.org/content/pediatrics/114/5/1362.full.pdf>. <https://doi.org/10.1542/peds.2004-1915>. Published: Nov 2004.
4. Deleted in proofs.
5. Bhatia J. Growth curves: how to best measure growth of the premature infant. *J Pediatr*. 2013;162(3):S2–S6. <https://doi.org/10.1016/j.jpeds.2012.11.047>. Published: March 2013.
6. Griffin I. *Growth Management in Preterm Infants*. Uptodate; 2018.
7. MCHB Training Module—Using the CDC growth charts: use of the CDC growth charts for children with special health care needs. <http://depts.washington.edu/growth/cshcn/text/page6a.htm>
8. Deleted in proofs.
9. Centers for Disease Control and Prevention. Defining childhood obesity BMI for children and teens. <https://www.cdc.gov/obesity/childhood/defining.html>. Published: December 4, 2022.
10. Deleted in proofs.
11. Freedman DS, Berenson GS. Tracking of BMI z scores for severe obesity. *Pediatrics*. 2017;140(3):e20171072. <https://doi.org/10.1542/peds.2017-1072>. Published: September 1, 2017.
12. Brayden RM, Daley MF, Brown JM. Ambulatory and community pediatrics. In: Hay Jr WW, Levin MJ, Sondheimer JM, Deterding RR, eds. *Current Diagnosis and Treatment in Pediatrics*. 18th ed. McGraw Hill; 2007:225–245.
13. Dawson P. Normal growth and revised growth charts. *Pediatr Rev*. 2002;23(7). <http://pedsinreview.aappublications.org/content/23/7/255>. Published: July 1, 2002.
14. Algorithm for the Assessment and Management of Childhood Obesity in Patients 2 Years and Older Published by the American Academy of Pediatrics Section on Obesity Edited by Christopher F. Bolling and Victoria W. Rogers Published on 9/2019. <https://doi.org/10.1542/9781610023559>. ISBN: 978-1-61002-354-2
15. Becker P, Carney L, Corkins M, et al. Consensus statement of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: indicators recommended for identification and documentation of pediatric malnutrition (under nutrition). *Nutr Clin Pract*. 2015;30(1):147–161.
16. Deleted in proofs.
17. Deleted in proofs.
18. Mehta NM, Corkins MR, Lyman B, et al. Defining pediatric malnutrition: a paradigm shift toward etiology-related definitions. *J Parenter Enteral Nutr*. 2013;37(4):460–481.
19. Pulcini C, Zettle S, Srinath A. Refeeding syndrome. *Pediatr Rev*. 2016;37(12). <http://pedsinreview.aappublications.org/content/37/12/516>
20. Wang J, Zhao Q, Chen B, Sun J, Huang J, Meng J, Li S, Yan W, Ren C, Hao L. Risk factors for metabolic bone disease of prematurity: A meta-analysis. *PLoS One*. 2022 Jun 13;17(6):e0269180. <https://doi.org/10.1371/journal.pone.0269180>. PMID: 35696368; PMCID: PMC9191712.

21. Golden NH, Abrams SA, APP Committee on Nutrition. Optimizing bone health in children and adolescents. *Pediatrics*. 2014;134:e1229–e1243.
22. Misra Madhusmita, Pacaud Daniele, Anna Petryk, et al. On behalf of the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. *Pediatrics*. 2008;122(2):398–417. <https://doi.org/10.1542/peds.2007-1894>
23. Abrams S. Calcium and vitamin D requirements of enterally fed preterm infants. *Pediatrics*. 2013;131(5):1676–1683.
24. Centers for Disease Control and Prevention. Folic acid. Published 2018. <https://www.cdc.gov/ncbddd/folicacid/recommendations.html>
25. Centers for Disease Control. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. *MMWR Morb Mortal Wkly Rep*. 1992;41.
26. Baker RD, Greer FR, AAP Committee on Nutrition. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children 0 through 3 years. *Pediatrics*. 2010;126:1040–1050.
27. Cole S, Lanham J. Failure to thrive: an update. *Am Fam Physician*. 2011;83(7):829–834. Published: April, 1 2011.
28. Corrales KM, Utter SL. Growth failure. In: Samour PQ, King K, eds. *Handbook of Pediatric Nutrition*. Jones and Bartlett Publishers; 2005:391–406.
29. Deleted in proofs.
30. Clark MB, Slayton RL, AAP Section on Oral Health. Fluoride use in caries prevention in primary care setting. *Pediatrics*. 2014;134:626–633.
31. Joan Younger Meek, Lawrence Noble, Section on Breastfeeding. Policy Statement: Breastfeeding and the Use of Human Milk. *Pediatrics*. July 2022;150(1):e2022057988. <https://doi.org/10.1542/peds.2022-057988>
32. Deleted in proofs.
33. Donor human milk for the high risk infant: preparation, safety, and usage options in the United States. *Pediatrics*. 2017;139(1).
34. Centers for Disease Control and Prevention. Proper Storage and Preparation of Breast Milk. <https://www.cdc.gov/breastfeeding/recommendations/handling-breastmilk.htm>. Access date 1/12/2023
35. Johns Hopkins Medicine. Feeding guide for the first year. [https://www.hopkinsmedicine.org/healthlibrary/conditions/pediatrics/feeding\\_guide\\_for\\_the\\_first\\_year\\_90](https://www.hopkinsmedicine.org/healthlibrary/conditions/pediatrics/feeding_guide_for_the_first_year_90). P02209 Published. July 26, 2019.
36. Singhal S, Baker S, Bojczuk G, Baker R. Tube feeding in children. *Pediatr Rev*. 2017.
37. American Society for Parenteral and Enteral Nutrition (ASPEN). Safe practices for parenteral nutrition. *J Parenter Enteral Nutr*. 2004;28(6):S39–S70. <http://pediatrics.aappublications.org/content/139/1/e20163440http://www.ashp.org/DocLibrary/Bestpractices/2004ASPEN.aspx>
38. Becker P, Carney LN, Corkins MR, et al. Consensus statement of the academy of nutrition and dietetics/American society for parenteral and enteral nutrition: indicators recommended for the identification and documentation of pediatric malnutrition. *Nutr Clin Pract*. 2015;30(10):147–161.

# Chapter 22

## Oncology

Lawrence Gersz, MD, MBA and Rebecca Xi, MD

 See additional content online.

 **Audio Case File 22.1** Initial presentation and workup of acute lymphoblastic leukemia

### I. NONSPECIFIC SYMPTOMS IN THE PRIMARY CARE SETTING (TABLE 22.1)<sup>1,2</sup>

TABLE 22.1

#### RED FLAGS FOR MALIGNANCY<sup>1,2</sup>

Finding	Red Flags
Lymphadenopathy	<ul style="list-style-type: none"><li>• Nontender</li><li>• Rubbery or hard</li><li>• Increase in size over 2–4 weeks or persisting &gt;6 weeks</li><li>• &gt;2 cm or &gt;1 cm in supraclavicular fossa</li><li>• Associated fever, night sweats, weight loss, orthopnea</li></ul>
Joint/bone pain	<ul style="list-style-type: none"><li>• Pain causing awakening from sleep</li><li>• Pain worse at night</li><li>• Back pain causing neurologic deficits</li><li>• Persisting &gt;2 weeks</li><li>• Associated with swelling</li><li>• Palpable mass</li><li>• Limping or refusal to walk</li><li>• Lack of improvement with NSAIDs</li><li>• Pathologic fracture</li></ul>
Headache	<ul style="list-style-type: none"><li>• New onset</li><li>• Pain causing awakening from sleep</li><li>• Pain worse with lying down</li><li>• Persistent morning headaches</li><li>• Associated emesis</li><li>• Occipital region</li><li>• Vision changes with or without papilledema</li><li>• Cranial nerve palsies</li><li>• Associated personality changes</li><li>• Altered gait or frequent falls</li></ul>
Hepatosplenomegaly or palpable abdominal mass	<ul style="list-style-type: none"><li>• Always investigate</li><li>• Associated with pain, anorexia, fever, vomiting</li></ul>

NSAIDs, Nonsteroidal antiinflammatory drugs.

II. PEDIATRIC HEMATOLOGIC MALIGNANCIES (TABLE 22.2)<sup>3-4</sup>

TABLE 22.2

COMMON PEDIATRIC HEMATOLOGIC MALIGNANCIES<sup>1,2</sup>

Malignancy	Clinical Presentation	Initial Workup	Epidemiology, Prognosis
<b>ALL, AML</b>	<p>Fever, pallor, petechiae/ecchymoses, lethargy, malaise, anorexia, bone/joint pain</p> <p><b>Exam:</b> Lymphadenopathy, hepatosplenomegaly, abnormal neurologic exam, testicular enlargement</p> <p><b>AML</b> may include subcutaneous nodules, gingival hyperplasia, chloromas (solid collection of leukemic cells)</p> <p><b>T-cell ALL</b> commonly presents with anterior mediastinal mass</p>	<p>CBC with differential, peripheral smear; CMP with phosphate, uric acid, LDH</p> <p>important to assess for tumor lysis</p> <p>CXR to assess for mediastinal mass</p> <p>Blood and urine cultures if febrile</p> <p>Definitive diagnosis requires lumbar puncture (evaluate for CNS involvement), bone marrow biopsy, flow cytometry</p>	<p><b>ALL:</b> Most common pediatric cancer (approximately 25% in &lt;15 years). Peaks at age 2–5 years. Overall 5-year survival rate exceeds 90%.</p> <p><b>AML:</b> Peaks in first year of life, risk increases again after adolescence. Survival rate ~60%–70%; acute promyelocytic leukemia best prognosis</p>
<b>Lymphoma</b> HD, NHL	<p>Painless, firm lymphadenopathy (often supraclavicular or cervical nodes)</p> <p>Cough, shortness of breath, “B symptoms” (fevers, night sweats, weight loss)</p>	<p>CBC with differential, peripheral smear, electrolytes, include CRP, UA, LDH</p> <p>CXR to assess for mediastinal mass</p> <p>Diagnosis made through lymph node biopsy and/or in some cases, fluid sampling. Full staging with PET/CT</p>	<p>15% of childhood malignancies</p> <p>HD peak incidence occurs in bimodal distribution (15–34 years old and &gt;55 years)</p> <p>NHL incidence increases with age, more common in second decade of life</p> <p>Prognosis: HD highly curable (95% survival with stage I disease and 75% for stage IV); NHL prognosis varies with histology and stage</p>
<b>Histiocytic Disease</b> Nonmalignant proliferation of monocytes, macrophages, or dendritic cells	<p>Scaly rash, long bone pain, fever, weight loss, diarrhea, dyspnea, painless lymphadenopathy, polydipsia, polyuria</p>	<p>Triglycerides, fibrinogen, ferritin, urine osmolality</p> <p>Imaging to detect lytic lesions: Skeletal survey, followed by CT/MRI, bone scan/PET</p>	<p><b>Langerhans Cell Histiocytosis:</b> Median age at presentation 30 months</p> <p><b>Rosai Dorfman:</b> Higher incidence among African Americans in first 2 decades of life</p>

NOTE: Laboratory testing and imaging suggestions are meant as a guide for evaluation of a potential malignancy. Patients warranting definitive testing should be referred to an oncologist.

ALL, Acute lymphocytic leukemia; AML, acute myeloid leukemia; CBC, complete blood count; CMP, complete metabolic panel; CNS, central nervous system; CRP, c-reactive protein; CT, computed tomography; CXR, chest x-ray; HD, Hodgkin disease; IV, intravenous; LDH, lactate dehydrogenase; MRI, magnetic resonance imaging; NHL, non-Hodgkin lymphoma; PET, positron emission tomography; UA, urinalysis.

### III. PEDIATRIC SOLID TUMOR MALIGNANCIES (TABLE 22.3)<sup>3-4</sup>

TABLE 22.3

PEDIATRIC SOLID TUMOR MALIGNANCIES<sup>1,2</sup>

Malignancy	Clinical Presentation	Initial Workup	Epidemiology, Prognosis
<b>Neuroblastoma:</b> Malignant tumor of neural crest cell origin	Abdominal pain and/or mass (hard, nontender), periorbital ecchymosis, spinal cord compression, Horner syndrome, Paraneoplastic syndromes (secretory diarrhea, diaphoresis, opsoclonus-myoclonus)	Abdominal ultrasound Definitive diagnosis requires CT chest/abdomen/pelvis, urine catecholamines (HVA/VMA), MIBG scan, biopsy	Most common malignancy in infancy; median age of diagnosis 17 months 8% childhood malignancies, 15% of deaths caused by childhood malignancy <b>Prognosis:</b> Favorable prognosis if age of diagnosis <1 year, Stage I, II, IV-S, absence of N-myc amplification
<b>Wilms tumor</b> (Nephroblastoma)	Abdominal mass with or without abdominal pain May see hypertension, hematuria, anemia (bleeding within the tumor)	Liver and renal function tests, urinalysis Abdominal ultrasound, chest/abdominal CT or MRI Diagnosis requires biopsy	Peaks at age 3–4 years Survival rate 90% (poorer prognosis with diffuse anaplasia)
<b>Bone tumors:</b> Osteosarcoma, Ewing sarcoma	<b>Osteosarcoma:</b> Bone pain or mass (typically in epiphysis/metaphysis of long bones) not relieved with conservative treatment <b>Ewing sarcoma:</b> Bone pain and swelling, most commonly in femur or pelvis	X-ray of primary site, followed by MRI Metastasis evaluation: CT of chest, PET scan	<b>Osteosarcoma:</b> Peaks in adolescence during maximum growth velocity <b>Ewing:</b> Peaks between 10 and 20 years <b>Prognosis:</b> Cure rate for localized disease: 60%–70% Poor prognosis with metastatic disease, primary tumor of axial skeleton, poor necrosis at time of resection (osteosarcoma)
<b>Rhabdomyosarcoma:</b> Soft tissue malignant tumor of skeletal muscle origin	Rapidly growing mass, may be painful Symptoms based on location <b>HEENT:</b> Periorbital swelling, proptosis, chronic otitis	CT or MRI of primary site Diagnosis requires tissue biopsy, immunohistochemical staining	Peak at 2–6 years and in adolescence <b>Prognosis:</b> Based on stage, extent of surgical resection, and histopathology (alveolar histopathology poorer prognosis than

Malignancy	Clinical Presentation	Initial Workup	Epidemiology, Prognosis
	<p>media, dysphagia, neck mass</p> <p><b>GU tract:</b></p> <p>Paratesticular swelling, hematuria, urinary frequency/retention</p>		<p>embryonal); favorable prognostic factors include localized disease, &gt;90% tumor necrosis at resection, age between 1 and 10 years at presentation</p>
<b>Retinoblastoma (Rb)</b>	<p>Leukocoria (retrolental mass), strabismus, hyphema, irregular pupil(s)</p>	<p>Ophthalmology referral</p> <p>MRI brain to evaluate pineal gland if bilateral</p>	<p>Peaks at age 2 years</p> <p>Survival at 5 years &gt;90%</p> <p>66%–75% tumors are unilateral</p> <p><i>Rb1</i> mutations carry risk for second malignancies (osteosarcoma, soft tissue sarcoma, malignant melanoma)</p>
<b>Hepatic tumors:</b> Hepatoblastoma, Hepatocellular carcinoma (HCC)	<p>Painless abdominal mass, anorexia, emesis, abdominal pain, fever</p> <p>Hepatoblastoma may be associated with anemia, thrombocytosis</p>	<p>CBC, LFTs, AFP, hepatitis B and C titers</p> <p>Abdominal ultrasound</p>	<p>Hepatoblastoma peaks at age &lt;3 years</p> <p>HCC peaks after 10 years of age (associated with hepatitis B and C)</p> <p><b>Prognosis:</b></p> <p>Hepatoblastoma favorable prognosis pending tumor resection at diagnosis; HCC carries poor prognosis</p>
<b>Gonadal/germ cell tumors</b>	<p><b>Testicular tumors:</b></p> <p>Nontender scrotal mass, hydrocele</p> <p><b>Ovarian tumors:</b></p> <p>Typically asymptomatic until quite large</p> <p><b>Hormone-producing tumors:</b></p> <p>Amenorrhea, precocious puberty, hirsutism</p>	<p>AFP, <math>\beta</math>-hCG, CXR, abdominal ultrasound, followed by CT or MRI</p>	<p>Peaks &lt;4 years, then again in adolescence</p> <p>Overall cure rate &gt;80%</p> <p>Favorable prognostic factors include &lt;12 years of age, lack of thoracic involvement</p>

NOTE: Laboratory testing and imaging suggestions are meant as a guide for evaluation of a potential malignancy. Patients warranting definitive testing should be referred to an oncologist.

*AFP*,  $\alpha$ -Fetoprotein;  *$\beta$ -hCG*, beta human chorionic gonadotropin; *CBC*, complete blood cell count; *CT*, computed tomography; *CXR*, chest x-ray; *GU*, genitourinary; *HEENT*, head eyes ears nose throat; *HVA/VMA*, homovanillic acid/vanillylmandelic acid (urine catecholamines); *LFTs*, liver function tests; *MIBG*, metaiodobenzylguanidine; *MRI*, magnetic resonance imaging; *PET*, positron emission tomography.

## IV. PEDIATRIC CENTRAL NERVOUS SYSTEM (CNS) TUMORS<sup>3-4,7-10</sup>

### (TABLE 22.4)

#### A. Epidemiology

1. Most common solid tumors in children
2. Leading cause of childhood cancer deaths
3. Highest incidence in infants and children under 5 years old

#### B. Clinical Presentation

1. Early/generalized symptoms: Headache, lethargy/fatigue, nausea/emesis, gait abnormalities; increased head circumference in infants
2. Later symptoms related to tumor location: Seizures, altered language, encephalopathy, hemiplegia/hemi-sensory deficit, facial weakness, neuroendocrine effects (precocious/delayed puberty, diabetes insipidus), visual changes, abnormal movements, back pain, sphincter disturbance

#### C. Initial Workup

1. Thorough neurologic exam, including fundoscopic exam
2. Neurosurgery/neurooncology consultation
3. Labs: Presurgical tests (complete blood count [CBC], electrolytes, blood type, coagulation factors, crossmatching); endocrine tests for suprasellar tumors;  $\alpha$  fetoprotein (AFP) and  $\beta$  human chorionic gonadotropin ( $\beta$ -hCG) if germinoma suspected
4. Imaging: Magnetic resonance imaging (MRI) of brain (sometimes spine) with and without intravenous (IV) contrast

#### D. Management Principles

1. High-dose dexamethasone: Often administered to reduce tumor-associated edema
2. Consider seizure prophylaxis for those at high risk of seizures or seizure history.

## V. ONCOLOGIC EMERGENCIES<sup>4,11-18,19</sup>

#### A. Fever and Neutropenia (Fig. 22.1)

1. **Etiology:** Fever with temperature  $\geq 38.0^{\circ}\text{C}$  (some centers and medical associations also use  $38.0^{\circ}\text{C}$  sustained over an hour to define fever) in the setting of neutropenia (absolute neutrophil count [ANC]  $< 500$  cells/ $\mu\text{L}$  or  $< 1000$  cells/ $\mu\text{L}$  but expected to drop to  $< 500$  cells/ $\mu\text{L}$  in the next 48 hours). Presumed serious infection in a neutropenic host. While fevers may be caused by other etiologies including medications, presume infection until proven otherwise.
2. **Presentation:** May appear ill with fatigue, lethargy, or localized pain. Can also appear well yet have subtle signs of compensated shock, including chills, rigors, tachypnea, or tachycardia. May deteriorate after initial doses of antibiotics
3. **Management:** Broad-spectrum antibiotics with anti-pseudomonal coverage should be administered within 60 minutes of presentation to medical facility. NOTE: Antibiotic administration may lead to clinical

TABLE 22.4

PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS<sup>1-2,5-7</sup>


Tumor (Incidence)	Epidemiology	Location	Prognosis
<b>Glioma</b> (40%)	<b>Low-grade:</b> Average age of diagnosis: 6.5–9 years; male predominance <b>High-grade:</b> 9–10 years; 1:1 male-female ratio	Occur throughout the CNS Low-grade astrocytomas commonly occur in cerebellum, hypothalamic, third ventricular region, optic nerve	Low-grade: 50%–100% depending on ability to resect
<b>Embryonal tumor:</b> Most commonly medulloblastoma (20%)	Most common group of malignant CNS tumors Bimodal distribution, peaking at 3–4 years, then again between 8–10 years	Commonly located in the midline cerebellar vermis Older patients can present in cerebellar hemisphere	5-year survival 50%–80% Poorer outcome if presents under 4 years of age given general avoidance of radiation if possible
<b>Ependymoma:</b> Derived from ependymal lining of ventricular system (10%)	Median age 6 years	~70% occur in the posterior fossa Can occur in supratentorial region, spinal cord Usually noninvasive, can extend into ventricular lumen	Long-term survival ~40% after undergoing gross total resection
<b>Craniopharyngioma:</b> Arise from embryonic remnant of Rathke pouch (5%–10%)	In childhood, peaks between 8–10 years of age Rarely occurs in infancy	Occur in suprasellar region adjacent to optic chiasm Minimally invasive	5 year survival 70%–90% Associated with significant morbidity (panhypopituitarism, growth failure, visual loss)
<b>Germ cell tumor</b> (3%–5%)	Peak incidence 10–12 years of age	Commonly arise in midline locations (pineal and suprasellar region)	5-year survival 40%–70%

CNS, Central nervous system.

sepsis secondary to release of endotoxin from Gram-negative bacteria. May consider early discharge (prior to ANC recovery) at 48 to 72 hours in certain low-risk populations

## B. Hyperleukocytosis/Leukostasis

- 1. Etiology:** Elevated white blood cell (WBC) count (usually  $>100,000/\mu\text{L}$ ) in patients with newly diagnosed leukemia, which leads to leukostasis in the microcirculation and diminished tissue perfusion (notably in CNS,

**FIGURE 22.1**

Algorithm for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem cell transplantation. NOTE: Some centers and medical associations also use 38.0°C sustained over an hour to define fever. *Abx*, Antibiotics; *ALL*, acute lymphocytic leukemia; *AML*, acute myeloid leukemia; *ANC*, absolute neutrophil count; *CBC*, complete blood cell count; *CT*, computed tomography; *CXR*, chest x-ray; *diff*, differential; *GN*, Gram-negative; *GP*, Gram-positive; *HSCT*, hematopoietic stem cell transplantation; *LFTs*, liver function tests; *MRSA*, methicillin-resistant *Staphylococcus aureus*. (Data from Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. *J Clin Oncol*. 2017;35:2082–2094.)

kidneys, and lungs). Leukostasis occurs more commonly and at lower WBC counts in acute myeloid leukemia (AML) than in acute lymphocytic leukemia (ALL).

2. **Presentation:** Hypoxia, tachypnea, dyspnea, and pulmonary hemorrhage from pulmonary leukostasis. Mental status changes, headaches, seizures, and papilledema from cerebral leukostasis. May also see gastrointestinal bleeding, abdominal pain, renal insufficiency, priapism, and/or intracranial hemorrhage. Hyperleukocytosis may be asymptomatic.
3. **Management:**
  - a. Prompt initiation of chemotherapy is the most effective approach.
  - b. Consider leukapheresis or exchange transfusion only if evidence of symptomatic leukostasis (although any improvement will be short term).
  - c. Transfuse platelets to keep count above at least 20,000/ $\mu$ L to prevent hemorrhage.<sup>3</sup>
  - d. Avoid red blood cell (RBC) transfusions if possible, which increase viscosity. If required, consider partial exchange transfusion.
  - e. Hydration and allopurinol should be initiated, as hyperleukocytosis increases the risk of tumor lysis syndrome.
  - f. Treat coagulopathy aggressively.

### C. Tumor Lysis Syndrome

1. **Etiology:** Rapid lysis of tumor cells releases intracellular contents into the bloodstream spontaneously before treatment or during early stages of chemotherapy (especially Burkitt lymphoma, T-cell leukemia/lymphoma, acute leukemias with hyperleukocytosis).
2. **Presentation:** Hyperuricemia, hyperkalemia, hyperphosphatemia (with secondary hypocalcemia). Can lead to acute kidney injury. Usually asymptomatic, but may present with nausea, anorexia, diarrhea, dark and/or decreased urine output, muscle cramps, heart palpitations
3. **Diagnosis:** CBC, basic metabolic panel (BMP), phosphorus, uric acid, lactate dehydrogenase (LDH), electrocardiogram (ECG)
4. **Prevention and management:**
  - a. Hydration: IV fluids (without potassium, calcium, phosphate or bicarbonate) at twice maintenance rate. Keep urine-specific gravity  $<1.010$  and urine output  $>100$  mL/ $m^2$ /hr. Alkalinization is no longer recommended, given increased risk of calcium phosphate precipitation.
  - b. Hyperuricemia: Allopurinol inhibits formation of uric acid and should only be given PO (see Formulary for dosing). Rasburicase converts uric acid to the more soluble allantoin and should be used if *two* of the following criteria are met: uric acid  $\geq 8$  mg/dL, WBC  $>50,000/\mu$ L, LDH  $>2\times$  ULN (upper limit of normal), creatinine  $>1.5\times$  ULN, CHF/pulmonary edema **OR** if uric acid  $\geq 8$  mg/dL despite 48 hours of allopurinol. Do not use rasburicase with patients with known G6PD deficiency, as it may result in methemoglobinemia.

- c. Monitor potassium, calcium, phosphorus, uric acid, and urinalysis closely (up to Q2 hr for high-risk patients). There is an increased risk of calcium phosphate precipitation when  $\text{Ca} \times \text{Phos} > 60$ . Consider early use of sevelamer.
- d. See [Chapter 11](#) for management of abnormal electrolytes and [Chapter 19](#) for dialysis indications.

#### D. Spinal Cord Compression

1. **Etiology:** Intrinsic or extrinsic compression of spinal cord. Occurs most commonly with metastases from brain tumors, spinal tumors, soft tissue sarcomas, neuroblastoma, lymphoma
2. **Presentation:** Back pain (localized or radicular), weakness, sensory loss, bowel or bladder dysfunction, gait abnormalities. Prognosis for recovery based on duration and level of disability at presentation
3. **Diagnosis:** MRI (preferred) or computed tomography (CT) scan of spine. Spine radiography is less sensitive.
4. **Management:**
  - a. In the presence of neurologic abnormalities, strong history, and/or rapid progression of symptoms, consider immediate dexamethasone. NOTE: Steroids may prevent accurate diagnosis/staging of leukemia/lymphoma; plan diagnostic procedure and LP as soon as possible.
  - b. If tumor type is known and chemosensitive, emergent chemotherapy is indicated.
  - c. If tumor type is unknown or debulking may remove most/all of tumor, emergent neurosurgery consultation may be indicated to decompress the spine in select cases. Emergent radiotherapy (RT) may also be considered.

#### E. Increased Intracranial Pressure (ICP)

1. **Etiology:** Ventricular obstruction or impaired cerebral spinal fluid (CSF) flow. Most commonly seen with brain tumors but also with intracranial hemorrhage, thrombosis, meningeal involvement by tumor, or infection.
2. **Presentation:** Headaches, altered mental status, irritability, lethargy, nuchal rigidity, emesis, abnormal vision; Cushing triad and pupillary changes are late and ominous findings
3. **Diagnosis:**
  - a. Evaluate for vital sign changes (i.e., Cushing triad [ $\downarrow$  heart rate,  $\uparrow$  systolic blood pressure, irregular respirations]).
  - b. Funduscopic evaluation for papilledema
  - c. Obtain CT/ultrafast MRI or MRI of the head (MRI preferred for diagnosis of posterior fossa tumors).
4. **Management:**
  - a. See [Chapter 1](#) for management principles.
  - b. Obtain emergent neurosurgical consultation.
  - c. If tumor is the cause, start IV dexamethasone (see Formulary for dosing).

## F. Other Neurologic Emergencies: Cerebrovascular Accident (CVA), Seizures

1. **CVA etiology:** Hyperleukocytosis, coagulopathy, thrombocytopenia, radiation (fibrosis) or chemotherapy-related (e.g., L-asparaginase–induced hemorrhage or thrombosis, methotrexate). Most common in patients with AML or any form of leukemia with hyperleukocytosis
2. **Seizure etiology:** Most common in primary CNS tumors with supratentorial location, tumors metastatic to CNS, meningeal leukemia, or chemotherapy-related (intrathecal [IT] cytarabine, IT/IV methotrexate)
3. See [Chapters 1 and 20](#) for diagnosis and management.

## G. Superior Vena Cava Syndrome/Superior Mediastinal Syndrome

1. **Etiology:** Compression of venous drainage and trachea, most commonly caused by mediastinal mass. Usually seen with T-lymphoblastic lymphoma, Hodgkin lymphoma, mature B-cell lymphoma, and germ cell tumors
2. **Presentation:** Dyspnea, cough, wheeze, stridor, orthopnea, headaches, facial swelling or plethora, dizziness
3. **Diagnosis:** Two-view chest radiograph. If mediastinal mass present, obtain CT or MRI to further assess. Avoid sedation, high risk for airway obstruction
4. **Management:**
  - a. Control airway (mass usually too distal for intubation), place in upright position, and administer supplemental oxygen.
  - b. Diagnosis through least invasive means necessary, including peripheral blood flow cytometry, percutaneous node biopsy, and/or effusion drainage
  - c. Empiric therapy: Radiotherapy, steroids, chemotherapy.

**NOTE:** Steroids can confound diagnosis and/or staging.

## H. Typhlitis (Neutropenic Enterocolitis)

1. **Etiology:** Inflammation of bowel wall, typically localized to cecum. Associated with bacterial or fungal invasion. Associated with prolonged neutropenia
2. **Presentation:** Right lower quadrant abdominal pain, nausea/emesis, diarrhea, fever (may be absent early in course). Risk for perforation
3. **Diagnosis:**
  - a. Careful serial abdominal examinations
  - b. Abdominal ultrasound may be considered (may show pneumatosis intestinalis, bowel wall edema), although CT abdomen with IV and PO contrast is most sensitive form of imaging.
4. **Management:**
  - a. Bowel rest: NPO on IV fluids; consider nasogastric decompression
  - b. Broad anaerobic and Gram-negative antibiotic coverage
  - c. Surgical consultation

### I. Cytokine Release Syndrome (CRS)

1. **Etiology:** Newer immunologic agents (e.g., chimeric antigen receptor T [CAR-T] therapy and specific antibodies) can provoke release of cytokines causing systemic inflammation and hemodynamic instability.
2. **Presentation:** Early symptoms include fever, headache, myalgia, or mild evidence of hemodynamic instability (tachycardia) that can progress quickly to cardiovascular collapse and multiorgan dysfunction.
3. **Diagnosis:** Based on clinical features. Consider obtaining CRP and ferritin, although nondiagnostic.
4. **Management:**
  - a. Place on continuous monitor, closely watch for hypotension, institute supportive care measures (acetaminophen, cold packs), obtain blood cultures, and administer appropriate antibiotics based on ANC and clinical status.
  - b. Treat hypotension with IV fluids (although use cautiously since patients are at risk of capillary leak). If refractory, may require vasopressors and intensive care unit-level care
  - c. Administer tocilizumab: Recombinant humanized monoclonal antibody targeting the IL-6 receptor
  - d. Closely monitor neurologic status. Patient should be on seizure prophylaxis.
  - e. For mild/moderate CRS, avoid use of glucocorticoids as they can deplete or eradicate CAR-T cell therapy. Severe CRS may require the use of tocilizumab in combination with glucocorticoids.

## VI. COMMONLY USED CHEMOTHERAPEUTIC DRUGS, ASSOCIATED ACUTE AND LONG-TERM TOXICITIES (TABLE 22.5)

**TABLE 22.5**

### COMMONLY USED CHEMOTHERAPEUTIC DRUGS AND ASSOCIATED ACUTE TOXICITIES

Drug Name (By Class)	Toxicity <sup>a</sup>	Acute Monitoring and Care	Long-Term Toxicity
<b>ALKYLATORS</b>	<b>Significant myelosuppression, severe nausea, impaired fertility</b>	<b>Myelosuppression supportive care, aggressive antiemetics, pretreatment fertility consult</b>	<b>Gonadal dysfunction, delayed/arrested puberty, infertility, secondary AML/ myelodysplasia</b>
Busulfan	Seizures, SOS/VOD, acute/chronic lung injury	Monitor weight, abdominal girth, bilirubin; seizure prophylaxis	Pulmonary fibrosis, cataracts
Carmustine	Hypotension, chronic lung injury	Slow infusion, PFTs	Pulmonary fibrosis
Cyclophosphamide		Hyperhydration and <b>mesna</b> to prevent	Urinary tract toxicity, bladder malignancy

Drug Name (By Class)	Toxicity <sup>a</sup>	Acute Monitoring and Care	Long-Term Toxicity
	Myocardial necrosis, hemorrhagic cystitis, SIADH	hemorrhagic cystitis; ECG	
Ifosfamide	Mental status changes, encephalopathy (rarely progressing to death), renal tubular damage, hemorrhagic cystitis, Fanconi syndrome	Monitor creatinine, magnesium, phosphate, potassium; hyperhydration and <b>mesna</b> to prevent hemorrhagic cystitis; methylene blue for neurotoxicity	Renal toxicity, hypertension
Lomustine	Disorientation, fatigue		Pulmonary fibrosis
Melphalan	Severe mucositis, pulmonary fibrosis	Aggressive oral hygiene, ophthalmologic examination	
Procarbazine	Encephalopathy; adverse effects with tyramine-rich foods, ethanol, MAOIs, meperidine, and many other drugs	Avoid serotonergic agents/modulators, diet low in tyramine (avoid aged cheese/meats, beer, pickled food, soy sauce)	
Temozolomide	Headache, seizures, thrombocytopenia		
Thiotepa	Encephalopathy, rash, burns, desquamation of skin, lower extremity weakness	Frequent bathing	
<b>NUCLEOTIDE ANALOGS</b>	<b>Myelosuppression, mucositis, transaminitis</b>	<b>Supportive care, monitor LFTs</b>	
Clofarabine	Capillary leak syndrome, SOS/VOD, nephrotoxicity, hyperbilirubinemia	Monitor creatinine; monitor weight, abdominal girth, bilirubin	
Cytarabine (Ara-C)	Ara-C syndrome (maculopapular rash, fever), conjunctivitis, severe mucositis, ataxia, respiratory distress rapidly progressing to pulmonary edema	Corticosteroid eye drops; coverage for viridans streptococci with fever, systemic steroids for Ara-C syndrome	High dose: Neurocognitive deficits (executive function, attention, memory, fine motor dexterity), clinical leukoencephalopathy (spasticity, ataxia, dysarthria, seizure)

Continued

TABLE 22.5

## COMMONLY USED CHEMOTHERAPEUTIC DRUGS AND ASSOCIATED ACUTE TOXICITIES—CONT'D

Drug Name (By Class)	Toxicity <sup>a</sup>	Acute Monitoring and Care	Long-Term Toxicity
Fludarabine	Transaminitis, neurotoxicity, immunosuppression (nonmyelosuppressive)	Monitor creatinine (decreased clearance results in increased risk of neurotoxicity)	
Mercaptopurine (6-MP)	Hepatotoxicity (increased risk in TPMT deficiency), pancreatitis	LFTs, hepatic dysfunction, VOD	
Thioguanine	Hepatotoxicity (increased risk in TPMT deficiency), SOS	LFTs, hepatic dysfunction, VOD	
<b>DNA MODIFYING AGENTS</b>			
Bleomycin (DNA strand breaker)	Anaphylaxis, pneumonitis, pulmonary fibrosis	PFTs	Interstitial pneumonitis, pulmonary fibrosis
Carboplatin (DNA cross-linker)	Nephrotoxicity, ototoxicity, peripheral neuropathy	Monitor creatinine, adjust dose based on creatinine clearance, audiology evaluation	Sensorineural hearing loss, tinnitus, vertigo, peripheral sensory neuropathy, renal toxicity, hypertension
Cisplatin (DNA cross-linker)	Nephrotoxicity (related to cumulative dose), severe emesis, hypomagnesemia, hypophosphatemia, ototoxicity	Monitor creatinine, magnesium, phosphorous; audiology evaluation; aggressive antiemetic regimen	Peripheral sensory neuropathy, renal toxicity, hypertension
Etoposide (topoisomerase inhibitor)	Anaphylaxis (rare), hypotension, hyperbilirubinemia, transaminitis, secondary malignancy (AML)	Slow infusion if hypotension; change formulation to etoposide phosphate if anaphylaxis; monitor bilirubin and LFTs	AML
<b>OTHER CHEMOTHERAPEUTIC AGENTS</b>			
Asparaginase (Enzyme)	Pancreatitis, hypersensitivity reaction (acute and delayed), coagulopathy (thrombosis and bleeding), hyperammonemia	Monitor serum asparaginase activity levels, high index of suspicion for clots/bleeds, consider amylase/lipase with abdominal pain	No known long-term effects

Drug Name (By Class)	Toxicity <sup>a</sup>	Acute Monitoring and Care	Long-Term Toxicity
Dactinomycin (antibiotic)	Rash, hypocalcemia, radiation recall (rash), SOS	Monitor calcium; monitor weight, abdominal girth, bilirubin	No known long-term effects
Daunorubicin and doxorubicin, mitoxantrone (adriamycin) (anthracyclines)	Arrhythmia, cardiomyopathy/heart failure (related to cumulative dose), severe mucositis, severe emesis, red urine and bodily fluids (dauno/doxo), blue-green urine (mitoxantrone), radiation recall	Limit cumulative dose; echocardiogram; consider <b>dexrazoxane</b> for cardioprotection	AML, cardiomyopathy, arrhythmias, subclinical left ventricular dysfunction
Methotrexate (MTX) (folate antagonist)	Mucositis, diarrhea, renal dysfunction, encephalopathy, chemical arachnoiditis (intrathecal), photosensitivity, leukoencephalopathy, osteoporosis	<b>Leucovorin</b> to reduce mucositis with high-dose therapy; oral hygiene; monitor neurologic exam and developmental milestones	Reduced bone mineral density, renal toxicity, hypertension, hepatic dysfunction High dose: Neurocognitive deficits (executive function, attention, memory, fine motor dexterity), clinical leukoencephalopathy (spasticity, ataxia, dysarthria, seizure)
Vinblastine, vincristine, and vinorelbine ( <i>Microtubule inhibitors</i> )	Constipation, bone and jaw pain, peripheral and autonomic sensory and motor neuropathy, foot drop, SIADH (rare), hyperbilirubinemia, transaminitis	Bowel regimen; monitor for neuropathy; fatal if given intrathecally; bilirubin, and LFTs	Peripheral sensory or motor neuropathy (areflexia, weakness, paresthesias, foot drop), vasospastic attacks (Raynaud phenomenon)

**MOLECULARLY TARGETED AGENTS**

Alemtuzumab (Campath) (monoclonal Ab binds CD52 on mature lymphocytes)	Severe infusion reactions (hypotension, bronchospasm, ARDS, anaphylaxis), infections	Antimicrobial prophylaxis	
Blinatumomab (bi-specific T-cell engager)	CRS, neurotoxicity	Dexamethasone	
Brentuximab (chimeric monoclonal Ab binds CD30)	Peripheral neuropathy, diarrhea		

Continued

TABLE 22.5

## COMMONLY USED CHEMOTHERAPEUTIC DRUGS AND ASSOCIATED ACUTE TOXICITIES—CONT'D

Drug Name (By Class)	Toxicity <sup>a</sup>	Acute Monitoring and Care	Long-Term Toxicity
CAR-T cells (immune cells genetically modified to bind tumor-specific antigens)	CRS, neurotoxicity (headache, confusion, encephalopathy, seizure), HLH	<b>Tocilizumab</b> (anti-IL- 6R), steroids if severe/refractory	
Dinutuximab (monoclonal Ab binds GD-2; for use in neuroblastoma)	Rash/hives, rigors, severe pain, neuropathy, hyponatremia, hepatotoxicity, hypocalcemia, capillary leak syndrome, ocular neurologic disorders	Monitor sodium, calcium, LFTs; aggressive pain management	
Imatinib (Gleevec), dasatinib, nilotinib (tyrosine kinase inhibitors)	Congestive heart failure, edema, pleural effusions, rash, night sweats, myelosuppression	ECG, serial echocardiograms	
Nivolumab (PD-1 checkpoint inhibitor) and pembrolizumab (CTLA-4 checkpoint inhibitor)	Autoimmune manifestations (colitis, dermatitis, hepatitis, nephritis, pneumonitis, etc.)		
Rituximab (Rituxan) (chimeric monoclonal Ab binds CD20 on B cells)	Infusion reaction, urticaria	Hep B testing before use, slow infusion for first dose, immune reconstitution may be very delayed post therapy	

<sup>a</sup>All chemotherapeutic medications may cause nausea, vomiting, fever, immunosuppression, mucositis, gastrointestinal upset.

*AML*, Acute myeloid leukemia; *ARDS*, acute respiratory distress syndrome; *CAR-T cell therapy*, chimeric antigen receptor T-cell; *CRS*, cytokine release syndrome; *ECG*, electrocardiogram; *LFTs*, liver function tests; *MAOIs*, monoamine oxidase inhibitors; *PFTs*, pulmonary function tests; *SIADH*, syndrome of inappropriate antidiuretic hormone; *SOS*, sinusoidal obstruction syndrome; *TPMT*, thiopurine S-methyltransferase; *VOD*, venoocclusive disease.

Data from *Physician's Desk Reference*. 71st ed. Medical Economics; 2017; and Taketomo CK, Hodding JH, Kraus DM. *American Pharmaceutical Association Pediatric Dosage Handbook* 16th ed. Lexi-Comp, *Pediatric & Neonatal Dosage Handbook*, 25th ed.; and Micromedex 2.0 (2018).

## VII. COMMON CHEMOTHERAPY COMPLICATIONS AND SUPPORTIVE CARE<sup>3,13</sup>

### A. Cytopenias: Anemia, Thrombocytopenia, Neutropenia

1. **Etiology:** Chemotherapy, medication, radiation, marrow infiltration, blood loss, hemolysis, consumptive coagulopathy
2. **Management:**
  - a. See [Chapter 14](#) for details on transfusion.
  - b. Anemia: Hemoglobin thresholds for pRBC transfusions in cancer patients are based on clinical status and symptoms (often  $\leq 8$  g/dL).
  - c. Thrombocytopenia: In general, maintain platelet count above 10,000/ $\mu$ L. Patients with active bleeding, fever, or before selected procedures (e.g., lumbar puncture, intramuscular injection) may require higher thresholds. Consider maintaining at higher levels for patients who have brain tumors, recent brain surgery, or history of stroke.
  - d. Neutropenia:
    - (1) Broad-spectrum antibiotics with concomitant fever (see [Fig. 22.1](#)).
    - (2) Granulocyte colony-stimulating factor (GCSF) to assist in recovery of neutrophils may be considered in some patient populations and regimens.
3. Transfuse only irradiated and leukoreduced packed red blood cells (pRBCs) and single-donor platelets; cytomegalovirus (CMV)-negative or leukofiltered pRBCs/platelets for CMV-negative patients. Use leukofiltered pRBCs/platelets for those who may undergo transplant in the future to prevent alloimmunization or for those who have had nonhemolytic febrile transfusion reactions. Many oncology patients have nonhemolytic reactions (fever, rash, hypotension, respiratory distress) to pRBCs and/or platelet transfusion and should subsequently be premedicated with diphenhydramine and/or acetaminophen.

### B. Mucositis

1. **Etiology:** Damage to endothelial cells of the GI tract from chemotherapy, leading to breakdown of the mucosa. Typically peaks in the first 1 to 2 weeks after chemotherapy
2. **Presentation:** Oropharyngeal pain, abdominal pain, nausea, vomiting, diarrhea, intolerance of oral intake
3. **Prevention and management:** Supportive care aimed at pain control and nutrition. Local pain control with lidocaine-containing mouthwashes and bicarbonate rinses. Systemic pain control often requires patient-controlled analgesia (PCA) infusion. Total parenteral nutrition (TPN) is commonly required. Low threshold to evaluate for contributing viral infection (e.g., herpes simplex virus)

### C. Nausea and Emesis

1. **Etiology:** Chemotherapy side effect. Also suspect opiate therapy, GI and CNS radiotherapy, obstructive abdominal process, elevated ICP, certain antibiotics, or hypercalcemia.

2. **Presentation:** Can be acute (within 24 hours of chemotherapy initiation), delayed (beyond 24 hours), or anticipatory in subsequent cycles
3. **Therapy:** Hydration plus one or more antiemetic medications (Table 22.6; see Formulary for dosing)

**TABLE 22.6****ANTIEMETIC THERAPIES<sup>3</sup>**

Antiemetic Classes	Common Agents	Common Adverse Effects
Serotonin (5-HT <sub>3</sub> ) antagonists	Ondansetron, granisetron	QT prolongation, QRS widening, constipation
Histamine-1 antagonist	Diphenhydramine, scopolamine	Sedation, urinary retention, blurred vision
Benzodiazepines	Lorazepam	Sedation
Dopamine antagonists	Metoclopramide, prochlorperazine, promethazine	Sedation, extrapyramidal effects, QT prolongation; rarely, seizures or neuroleptic malignant syndrome Consider diphenhydramine to reduce risk of extrapyramidal symptoms.
Substance P receptor antagonists	Aprepitant, fosaprepitant	Exercise caution with agents metabolized by CYP3A4.
Steroids (helpful in patients with brain tumors and prophylaxis for delayed nausea/vomiting)	Dexamethasone	Hypertension, hyperglycemia, bradycardia, osteoporosis/osteonecrosis
Cannabinoids (also an appetite stimulant)	Dronabinol	Hallucinations, dizziness
Antipsychotics (useful in patients with refractory vomiting, can help comorbid depression)	Olanzapine	Weight gain, sedation, insulin resistance, QT prolongation; extrapyramidal side effects (rare)

## VIII. ANTIMICROBIAL PROPHYLAXIS IN ONCOLOGY PATIENTS<sup>20-22</sup>

(TABLE 22.7)

NOTE: Treatment length and dosage may vary per protocol.

**TABLE 22.7****ANTIMICROBIAL PROPHYLAXIS IN ONCOLOGY PATIENTS<sup>3,20-22</sup>**

Organism	Medication	Indication
<i>Pneumocystis jirovecii</i>	TMP-SMX: 2–3 consecutive days per week Alternatives: atovaquone, dapson, or pentamidine	Patients receiving chemotherapy and/or HSCT; and usually at least 3–6 months after therapy completion
HSV, CMV, VZV	Acyclovir or valacyclovir (dosing is different for zoster, varicella, and mucocutaneous HSV)	At risk for prolonged neutropenia (HSCT, AML, induction chemotherapy for high-risk leukemia, or reinduction therapy for relapsed leukemia)

Organism	Medication	Indication
<i>Candida albicans</i>	Fluconazole Alternatives: voriconazole or micafungin	Patients with leukemia or after HSCT (usually at least 28 days)
Gram-positive and Gram-negative organisms	Levofloxacin	HSCT or leukemias with prolonged severe neutropenia until counts normalize

*AML*, Acute myeloid leukemia; *CMV*, cytomegalovirus; *HSCT*, hematopoietic stem cell transplantation; *HSV*, herpes simplex virus; *TMP-SMX*, trimethoprim–sulfamethoxazole; *VZV*, varicella zoster virus.

## IX. HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) (ALSO CALLED BONE MARROW OR STEM CELL TRANSPLANTATION)<sup>3,4,23</sup>

### A. Goal

Administer healthy functioning hematopoietic stem cells from the bone marrow, peripheral blood, or umbilical cord blood to a patient whose bone marrow is diseased (e.g., hematologic malignancy) or depleted (after treatment with intense myeloablative chemotherapy). HSCT is also used for some congenital and acquired hematologic, immunologic, and metabolic disorders.

### B. Preparative Regimens

1. **Myeloablative:** Elimination of recipient's diseased marrow with high-dose chemotherapy or chemotherapy plus total body irradiation (TBI) before stem cell infusion. Generally, provides greater anticancer activity but carries a higher risk of treatment-related organ injury
2. **Nonmyeloablative:** Reduced-intensity conditioning regimen in which marrow is not fully ablated, allowing recovery of autologous hematopoiesis if patient fails to engraft. Associated with decreased treatment-related morbidity and mortality but higher incidence of graft rejection

### C. Types of HSCT

1. Allogeneic
  - a. Recipient receives donor stem cells from a genetically similar but nonidentical donor, following a preparative regimen that includes chemotherapy ± radiation ± serotherapy. Donors undergo human leukocyte antigen (HLA) typing to determine if they are an adequate “match” to the recipient. Possible donors include HLA-matched siblings, fully or partially HLA-matched unrelated donors, umbilical cord blood units, and HLA-haploidentical (half-matched) related donors.
  - b. Increased level of mismatch between donor and recipient increases the risk for graft-versus-host disease (GVHD) but may offer greater graft-versus-leukemia (GVL) immunologic treatment effect.

- c. Used commonly for leukemias, myelodysplastic syndrome, hemophagocytic lymphohistiocytosis, and a number of nonmalignant hematologic, immunologic, and metabolic disorders
2. Autologous
    - a. Donor is recipient. Stem cells are harvested from the patient, stored, and given back after the patient has received myeloablative doses of chemotherapy.
    - b. Generally, lacks GVHD or GVL effect
    - c. Used for high-risk neuroblastoma, lymphoma, and various high-risk solid tumors, which have demonstrated improved disease control after higher intensity chemotherapy that would otherwise be limited by excessive marrow suppression

#### D. Engraftment

1. Recipient's bone marrow is repopulated with donor stem cells that proliferate and mature.
2. Usually starts within 2 to 4 weeks from graft infusion and may present with an inflammatory response but can be significantly delayed with certain conditions such as drug toxicity or infection
3. Defined as an ANC more than 500/ $\mu$ L for 3 consecutive days

## X. COMPLICATIONS OF HSCT<sup>3,4,23-26</sup>

### A. Graft-Versus-Host Disease (GVHD)

1. **Etiology:** Donor T-cell-mediated reaction to unique host antigens. Risk factors include HLA disparity, source of stem cells (peripheral blood > bone marrow > umbilical cord blood), magnitude of conditioning-related tissue injury, and posttransplant infections.
2. **Presentation:** Acute GVHD most commonly occurs within 6 weeks of transplantation, typically within 100 days of transplantation; rarely, it may occur or persist beyond this time. Chronic GVHD traditionally presents >100 days after transplant but may occur earlier and persist.
  - a. Maculopapular skin rash. Can progress to bullous lesions resembling toxic epidermal necrolysis
  - b. GI symptoms: Anorexia, dyspepsia, nausea, vomiting, abdominal cramping, secretory diarrhea
  - c. Liver: Direct hyperbilirubinemia  $\pm$  transaminitis
  - d. Chronic GVHD can involve nearly any organ. Can include sclerodermatous or lichenoid skin changes, cholestasis/hepatitis, lung involvement (restrictive or obstructive), and/or dry eyes and mouth
3. **Diagnosis:** Triad of rash, abdominal cramping with diarrhea, hyperbilirubinemia. Tissue biopsy of skin or mucosa can provide histologic confirmation, demonstrating lymphocytic infiltration and apoptosis. See Section XIII (EC [Table 22.1](#)) for clinical staging.
4. **Prevention and management:**

- a. Prophylaxis: Immunosuppression with posttransplant cyclophosphamide, cyclosporine, mycophenolate mofetil, tacrolimus, and/or sirolimus; adjuvants include methotrexate and prednisone
- b. First-line treatment: Grade 1 and 2 acute GVHD may be treated locally with topical steroids (skin) or nonabsorbable enteral steroids (gut). First-line systemic treatment of acute and chronic GVHD is corticosteroids, often with an additional immunosuppressant
- c. NOTE: Patients with chronic cGVHD are functionally asplenic and significantly immunosuppressed, requiring antimicrobial prophylaxis.

## **B. Sinusoidal Obstructive Syndrome (SOS); Previously Known as Venooclusive Disease (VOD)**

1. **Etiology:** Injury to endothelial cells leads to activation of the clotting cascade in liver sinusoids, causing erythrocyte congestion and occlusive fibrosis of terminal intrahepatic venules and sinusoids. Occurs as a consequence of hematopoietic cell transplantation, hepatotoxic chemotherapy, and/or high-dose liver radiation. Typically occurs within 3 weeks of the insult, most common at the end of the first week after transplant
2. **Presentation:** Tender hepatomegaly, hyperbilirubinemia, edema, ascites, unexplained weight gain, thrombocytopenia refractory to transfusions
3. **Diagnosis:** Based upon the Cairo/Cooke revised criteria<sup>26</sup> with any two of the following:
  - a. Elevated bilirubin (>2 mg/dL)
  - b. Unexpected weight gain (>5% compared to baseline weight pre-HSCT)
  - c. Excessive platelet transfusions consistent with refractory thrombocytopenia post-HSCT
  - d. Hepatomegaly for age or increased size over pre-HSCT
  - e. Right upper quadrant pain
  - f. Ascites confirmed by physical exam and/or imaging studies
  - g. Reversal of portal venous flow (hepatofugal flow) by Doppler ultrasoundOR
  - h. Any one of the following criteria following HSCT:
    - (1) Hepatic biopsy consistent with SOS/VOD
    - (2) Unexplained elevated portal venous wedge pressure
4. **Prevention and treatment:**
  - a. Prevention: Ursodeoxycholic acid from conditioning through 90 days posttransplant
  - b. Treatment: Mild/moderate SOS can be managed with supportive care, including fluid and sodium restriction and diuretics. Defibrotide is the only approved pharmacologic treatment modality, with improved outcomes with earlier initiation and a 50% response rate. Criteria for defibrotide use include renal or pulmonary dysfunction and severe SOS/VOD. Maintain coagulation factors, platelets, and RBCs in a stable range secondary to consumption.

**XI. CANCER SURVIVORSHIP<sup>5,27-29</sup>****A. Understand the Diagnosis**

Obtain comprehensive treatment summary from oncologist summarizing diagnosis, chemotherapeutic agents, radiation, surgeries, history of HSCT, and adverse drug reactions.

**B. Monitoring**

1. Determine any potential toxicities by organ system based upon treatments received and devise a plan for routine evaluation.
2. See [Table 22.5](#) and <https://www.survivorshipguidelines.org> for common late effects of therapy.
3. Multidisciplinary follow-up with clinician, social work, physical therapist, occupational therapist, neuropsychology/neuropsychiatry, nutritionist, and dentist.

**A. VACCINATIONS IN ONCOLOGY AND HSCT PATIENTS: SEE CHAPTER 16****XII. FERTILITY PRESERVATION<sup>30</sup>**

All newly diagnosed patients should be evaluated and counseled early on after treatment plans are made for the risk of infertility. It is important to identify which, if any, gonadotoxic therapies will be used for oncologic treatment. Different fertility preservation options are available depending on a patient's risk category (low, intermediate, high).

The choice of fertility preservation methodology is dependent on age and location of cancer. Among the chemotherapeutic drugs, alkylating agents have been shown to be associated with ovarian damage. Other risk factors for infertility include radiation to the abdomen and pelvis and surgery removing part or all reproductive organs.

For females, options include oocyte or ovarian cryopreservation, ovarian suppression, and ovarian transposition. For males, the primary option is sperm cryopreservation, though an experimental option of testicular tissue cryopreservation is available for prepubertal males.

**A. Resources for Patients and Families**

1. Fertility Hope (Livestrong): <http://www.fertilehope.org>
2. ASCO Survivorship Guidelines for Fertility Preservation: <https://ascopubs.org/doi/abs/10.1200/JOP.18.00160>
3. NCCN Adolescent & Young Adult Guidelines: <https://www.nccn.org/guidelines>

**XIII. WEB RESOURCES**

- National Cancer Institute (NCI): <https://www.cancer.gov/cancertopics/pdq/pediatric/treatment>
- NCI Clinical Trial Database: <https://www.cancer.gov/clinicaltrials>

- Surveillance, Epidemiology, and End Results (SEER) from NCI: <http://seer.cancer.gov/>
- Children's Oncology Group: <https://www.childrensoncologygroup.org>
- Long-term follow-up guidelines for survivors of pediatric cancer: <http://www.survivorshipguidelines.org/>
- Children's Oncology Camping Association, International: <https://www.cocai.org/>

## REFERENCES

A complete list of references can be found online.

## XIV. ONLINE CONTENT

### A. Complications of HSCT<sup>3,4,22-24,29-35</sup>

#### 1. Graft-versus-host disease (GVHD)

See eTable 22.1 for grading of acute GVHD.

Acute GVHD should be graded weekly through day +100. If systemic treatment is started, it should be graded twice weekly while on treatment.

#### 2. Engraftment syndrome

- Etiology:** Occurs several days prior to donor cell engraftment and in days following white blood cell recovery owing to endothelial injury and activated granulocytes in the setting of proinflammatory cytokines. Occurs in approximately 20% of HSCT patients
- Presentation:** Fever and rash; can have pulmonary infiltrates, diarrhea, or signs of shock
- Diagnosis:** Similar presentation to GVHD and infection. Imperative to rule out infection while treating empirically with antibiotics. Often mild and self-limited. However, if symptoms continue for  $\geq 48$  hours or are severe, consider initiation of corticosteroids. If insufficient steroid response after 72 hours, can biopsy for alternative diagnoses
- Treatment:** Treatment with supportive care and corticosteroids; optimization of GVHD prophylaxis. If biopsy confirms immune-mediated pathology, can treat with additional immunosuppressive agents

#### 3. Transplant-associated thrombotic microangiopathy (TA-TMA)

- Etiology:** Associated with immunosuppressants (e.g., cyclosporine, tacrolimus) and infection
- Presentation:** Microangiopathic hemolytic anemia and consumptive thrombocytopenia. Often associated with renal insufficiency/failure; may be associated with neurologic symptoms

**eTABLE 22.1**

### CLINICAL STAGING AND GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE

#### CLINICAL STAGING

Stage	Skin (Rash)	Liver (Bilirubin)	GI System (Diarrhea) <sup>a</sup>
1	<25% of BSA	2.1–3 mg/dL	500–1000 mL/day (10–19.9 mL/kg/day); OR severe nausea/vomiting
2	25%–50% of BSA	3.1–6 mg/dL	1001–1500 mL/day (20–30 mL/kg/day)
3	>50% of BSA	6.1–15 mg/dL	>1500 mL/day (or >30 mL/kg/day)
4	Erythroderma with bullous formation	>15 mg/dL	Severe abdominal pain and/or ileus

#### CLINICAL GRADE (BASED ON HIGHEST INDIVIDUAL TARGET ORGAN STAGING)

I	Skin only (stage 1–2)
II	Stage 3 skin OR stage 1 liver OR stage 1 GI
III	Stage 2–3 liver OR stage 2–4 GI
IV	Stage 4 skin OR stage 4 liver

<sup>a</sup>Measured in mL/day if  $\geq 50$  kg or mL/kg/day if  $< 50$  kg.

BSA, Body surface area; GI, gastrointestinal.

- c. **Diagnosis:** Anemia and thrombocytopenia on CBC, schistocytes on peripheral blood smear, hematuria, proteinuria, casts on urinalysis, elevated LDH, decreased haptoglobin, impaired renal function, elevated D-dimer on coagulation panel
- d. **Treatment:** Supportive care with blood products, fluid management, and dialysis. Address underlying etiology—consider alternative immunosuppressant and treat any underlying infection. For progressive or severe TA-TMA, consider neutralization of complement with eculizumab.<sup>36</sup>

#### 4. Hemorrhagic cystitis

- a. **Etiology:** Pretransplant conditioning regimens (specifically those that include cyclophosphamide, pelvic or total body irradiation [TBI]) or viral reactivation (adenovirus, BK virus)
- b. **Presentation:** Hematuria, dysuria, difficulty voiding as a result of clots
- c. **Diagnosis:** Urine polymerase chain reaction (PCR) assay for adenovirus and BK virus, bacterial cultures, bladder ultrasound, CBC, coagulation studies
- d. **Treatment:** Hydration, analgesics, platelet transfusion, treatment of any underlying infections. For obstruction, Foley catheter with bladder irrigation

#### 5. Idiopathic pneumonia syndrome

- a. **Etiology:** Widespread alveolar injury in the absence of infection or other known etiology. Thought to occur from a variety of insults, including toxic effects of the conditioning regimen, immunologic cell-mediated injury, and inflammation secondary to cytokine release following engraftment. Most commonly occurs within the first 120 days after transplant
- b. **Presentation:** Rapidly progressive dry cough, dyspnea, hypoxemia, diffuse radiographic opacities; may progress to ARDS
- c. **Diagnosis:** Imaging; bronchoalveolar lavage with transbronchial biopsy, if tolerated
- d. **Prevention and management:** Supportive care together with broad-spectrum antibiotics while infectious studies pending. IV corticosteroids and tumor necrosis factor- $\alpha$  inhibitor etanercept if no infection identified<sup>37</sup>

## REFERENCES

1. Allen-Rhoades W, Steuber CP. Clinical assessment and differential diagnosis of the child with suspected cancer. In: Pizzo P, Poplack DG, eds. *Principles and Practice of Pediatric Oncology*. 7th ed. Lippincott Williams & Wilkins; 2016:101.
2. American Cancer Society. Signs and symptoms of cancer in children. <https://www.cancer.org/cancer/cancer-in-children/finding-childhood-cancers-early.html>
3. Pizzo P, Poplack D. *Principles and Practice of Pediatric Oncology*. 7th ed. Wolters Kluwer; 2016.
4. Kliegman R, Stanton B, St Geme S, et al. *Nelson Textbook of Pediatrics*. 20th ed. Elsevier; 2015.
5. Crawford J. Childhood brain tumors. *Pediatr Review*. 2013;34:1–7.
6. Wilne S, et al. Presentation of childhood CNS tumours: a systematic review and meta-analysis. *Lancet Oncol*. 2007;8(3):685–695.
7. Udaka Y, Packer R. Pediatric brain tumors. *Neurol Clin*. 2018;36:533–556.
8. Thorp N, Taylor R. Management of central nervous system tumours in children. *J Clin Oncol*. 2014;26:438–445.
9. Prusakowski M, Cannone D. Pediatric oncologic emergencies. *Hematol Oncol Clin N Am*. 2017;31:959–980.
10. Henry M, Sung L. Supportive care in pediatric oncology: oncologic emergencies and management of fever and neutropenia. *Pediatr Clin N Am*. 2015;62:27–46.
11. Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. *J Clin Oncol*. 2017;35:2082–2094.
12. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2011;52:e56–e93.
13. Taplitz R, Kennedy E, Bow E, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Disease Society of America clinical guideline update. *J Clin Oncol*. 2018;36:1443–1453.
14. Jones G, Andre W, Jackson G, et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. *Br J Haematol*. 2015;169:661–671.
15. Pehlivan K, Duncan B, Lee D. CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease. *Curr Hematol Malig Rep*. 2018. <https://doi.org/10.1007/s11899-018-0470-x>
16. Porter D, Frey N, Wood P, et al. Grading of cytokine release syndrome associated with the CAR-T cell therapy tisagenlecleuel. *J Hematol Oncol*. 2018;11(1):35. <https://doi.org/10.1186/s13045-018-0571-y>
17. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. 2014;124(2):188–195. <https://doi.org/10.1182/blood-2014-05-552729>
18. Science M, Robinson P, MacDonald T, et al. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. *Pediatr Blood Cancer*. 2014;61:393–400.
19. Lighter-Fisher J, Stanley K, Phillips M, et al. Preventing infections in children with cancer. *Pediatr Rev*. 2016;37:247–258.
20. Pickering LK, American Academy of Pediatrics. *Red Book: 2012 Report of the Committee on Infectious Diseases*. 29th ed. AAP; 2012.

21. Bishop MR, ed. *Hematopoietic Stem Cell Transplantation*. Springer; 2009.
22. Militano O, Ozkaynak MF, Mehta B, et al. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients. *Pediatr Blood Cancer*. 2018;65:e27091.
23. Gatza E, Choi SW. Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation. *Int J Hematol Oncol*. 2015;4:113–126.
24. Cairo MS, Cooke KR, Lazarus HM, Chao N. Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. *Br J Haematol*. 2020;190(6):822–836. <https://doi.org/10.1111/bjh.16557>
25. Children's Oncology Group. *Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Version 4.0*. Children's Oncology Group. Published 2013. <https://www.survivorshipguidelines.org>
26. Landier W, Skinner R, Wallace W, et al. Surveillance for late effects in childhood cancer survivors. *J Clin Oncol*. 2018;36:2216–2222.
27. Chow EJ, Anderson L, Baker KS, et al. Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: a children's oncology group report. *Biol Blood Marrow Transplant*. 2016;22:782–795.
28. Johnson EK, Finlayson C, Rowell EE, et al. Fertility preservation for pediatric patients: current state and future possibilities. *J Urol*. 2017;198(1):186–194.
29. Corbacioglu S, Carreras E, Ansari M, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. *Bone Marrow Transplant*. 2018;53:138–145.
30. Bajwa RPS, Mahadeo KM, Taragin BH, et al. Consensus report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Consortium Joint Working Committees: supportive care guidelines for management of veno-occlusive disease in children and adolescents, part 1: focus on investigations, prophylaxis, and specific treatment. *Biol Blood Marrow Transplant*. 2017;23:1817–1825.
31. Richardson PG, Triplett BM, Ho VT, et al. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. *Expert Rev Clin Pharmacol*. 2018;11:113–124.
32. Cornell RF, Hari P, Drobyski WR. Engraftment syndrome after autologous stem cell transplantation: an update unifying the definition and management approach. *Biol Blood Marrow Trans*. 2015;21:2061–2068.
33. Cario M, et al. VOD Consensus Panel; 2018. [https://c.peerview.com/live/programs/150205417-1-2/downloads/PVI\\_slides\\_VODSOS.pdf](https://c.peerview.com/live/programs/150205417-1-2/downloads/PVI_slides_VODSOS.pdf)
34. Jodele S, Fukuda T, Vinks A, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplant-associated thrombotic microangiopathy. *Biol Blood Marrow Transplant*. 2014;20(4):518–525.
35. Yanik G, Grupp S, Pulsipher M. TNF receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome (IPS). *Biol Blood Marrow Transplant*. 2015;21(1):67–73.

# Chapter 23

## Palliative Care

Sapna Desai, MD

See additional content online.

**Audio Case File 23.1** End of life decision making in the adolescent palliative care patient

### I. INTRODUCTION TO HOSPICE AND PALLIATIVE MEDICINE

#### A. Definition of Palliative Care<sup>1,2</sup>


1. Palliative care is the active total care of the child's body, mind, and spirit with the intent to prevent and relieve suffering, with a special focus on symptom control.
2. Palliative medicine supports the best quality of life for the child and family. It can be provided along with disease-directed treatment from the time of diagnosis of serious illness.
3. See [Fig. 23.1](#) for the current accepted model for palliative care.

#### B. Definition of Hospice

1. Hospice care is an insurance benefit that may be initiated for patients who have a terminal illness with a life expectancy estimated to be 6 months or less.
2. It specializes in care at the end of life to promote a child's comfort and to support loved ones in their bereavement.

#### C. Concurrent Care for Children<sup>3</sup>

1. Prior to the Affordable Care Act, Medicaid would only provide either curative treatment or hospice services to those who qualified.
2. Now, children living with life-limiting or life-threatening conditions who are enrolled in Medicaid (and some other insurance providers) can receive both curative/life-prolonging treatments and hospice services.



**FIGURE 23.1**

Current accepted model for palliative care.

### D. Team Composition

1. Hospice and palliative care teams are robust and interdisciplinary.
2. They may include physicians, nurses, nurse practitioners, physician assistants, psychologists, counselors, social workers, child life specialists, pastoral care, patient care coordinators, and bereavement coordinators.

### E. Timing of Palliative Care Consults

1. Palliative care teams can become involved at any point during a child's life, but it is best to involve them as early as possible.
2. Prenatal consults may be done with parents to help them with planning, decision making, and development of a birth plan.

## II. COMMUNICATION AND DECISION-MAKING

### A. Decision-Making Tools<sup>4</sup>

1. Provide framework for discussion with families regarding medical issues, quality of life, family goals, preferences, and other contextual preferences, such as spirituality and culture.
2. **Advance directives:**
  - a. Adolescents 18 years and older can name another adult to make healthcare decisions if they cannot speak for themselves.
  - b. Children younger than 18 years can participate in decision-making with tools such as “Five Wishes” and “Voicing My Choices.”

### B. Structuring Family Meetings<sup>5</sup>

1. Make sure all necessary individuals are present and understand the meeting's purpose.
2. A pre-meeting with the healthcare team is helpful to make sure all clinicians agree about the patient's condition and recommendations.
3. Identify who will facilitate the meeting.
4. **Choose a private location with minimal distraction.**
5. Always have water and tissues available.
6. Begin by introducing all participants and the meeting's purpose.
7. Assess what the family knows and expects regarding the patient's condition.
8. Describe the clinical situation, providing the big picture and then asking family members if they would like or are ready for more details.
9. Encourage each family member to express concerns and questions.
10. Explore the patient's and family's values and how they influence decision making.
11. Propose goals for the patient's care that reflect the stated values.
12. Provide a concrete follow-up plan.

### C. Breaking Bad News<sup>6</sup>

1. Prepare yourself: Know the medical information, know what you will say, ask the patient/family if they want someone specific present with them for the discussion.
2. Prepare the family/patient: Give a brief, calm statement that leads into the news.

3. State the news: Do this clearly, concisely, and as definitively as possible.
4. Wait for the patient/family's reaction: Resist the urge to say more, allowing others to speak first.
5. Reflect the response back: "This news is clearly very upsetting to you."
6. Legitimize the reaction: "It is understandable that you would be upset."
7. Explore: "What upsets you most about this news?"
8. Provide realistic hope.
9. Discuss next steps (if appropriate at this time): "May I address your concerns now and talk about the next steps for treatment, or would you like more time?"

#### **D. Other Tools for Difficult Conversations**

1. Assess spirituality according to the "FICA" tool<sup>7</sup>:
  - a. **F**aith and belief: "Do you consider yourself spiritual or religious?"
  - b. **I**mportance in life: "What importance does your faith or belief system have in your life?"
  - c. **C**ommunity: "Are you a part of a spiritual or religious community?"
  - d. **A**ddress in care: "How would you like me, your healthcare provider, to address these issues in your healthcare?"
2. "Ask-tell-ask"<sup>8</sup>
  - a. **Ask** the patient/family to describe their understanding of the situation or issue.
  - b. **Tell** them what you need to communicate in a straightforward manner.
  - c. **Ask** them questions to assess their understanding.
3. "Hope together" with the patient/family while also preparing for all possible outcomes.

### **III. CARE OF THE DYING CHILD**

#### **A. Limiting Interventions**

The following options should be considered.

1. Do not attempt resuscitation (DNAR)/allow natural death (AND):  
Foregoing cardiopulmonary resuscitation (CPR) and other resuscitative interventions as part of a care plan that emphasizes comfort and quality of living
2. Do not intubate (DNI): Although, if clinically appropriate, may still allow the initiation of continuous positive-pressure ventilation or may help in managing symptoms
3. Do not escalate treatment: The choice to forego changes in treatment, even as a patient's condition worsens, because death is expected  
Examples include the following:
  - a. Do not increase the dose of current medications (e.g., vasopressors).
  - b. Do not add new medications (e.g., antibiotics).
  - c. Do not initiate new interventions (e.g., dialysis, mechanical ventilation).
  - d. However, one may still initiate and increase interventions to treat pain and reduce suffering.

4. Discontinuing current interventions: The option of discontinuing interventions that prolong the dying process must also be discussed.
5. Medical orders for life-sustaining treatment (MOLST) and physician orders for life-sustaining treatment (POLST) forms:
  - a. These are portable and enduring medical order forms completed by patients or their authorized decision-makers and are signed by a physician.
  - b. They contain orders regarding CPR and other life-sustaining treatments.
  - c. If a state offers one of these forms, the orders are valid for emergency medical service providers as well as healthcare providers and facilities within that state.
  - d. A copy must be provided to the patient or authorized decision maker within 48 hours of completion or sooner if the patient is to be transferred.
  - e. Refer to your state's laws prior to completing any documentation.
  - f. Additional information for US providers can be found at <https://www.polst.org>.

### B. Involving the Child in Conversations About Death<sup>9-12</sup>

1. See [Table 23.1](#) for the development of death concepts in children.<sup>13</sup>
2. A minor child has the capacity to meaningfully participate in medical decision making if he or she demonstrates the ability to do all of the following:
  - a. Communicate understanding of the medical information
  - b. State his or her preference
  - c. Communicate understanding of the consequences of decisions

**TABLE 23.1**

#### CONCEPTUALIZATION OF DEATH IN CHILDREN

Age Range	Characteristics	Concepts of Death	Interventions
0–2 years	Achieve object permanence May sense something is wrong	None	Provide maximal comfort with familiar persons and favorite toys.
2–6 years	Magical thoughts	Believe death is temporary Do not personalize death Believe death can be caused by thoughts	Minimize separation from parents, correct perceptions that the illness is punishment.
6–12 years	Concrete thoughts	Understand death can be personal Interested in details of death	Be truthful, evaluate fears, provide concrete details if requested, allow participation in decision making.
12–18 years	Reality becomes objective Capable of self-reflection	Search for meaning, hope, purpose, and value of life	Be truthful, allow expression of strong feelings, allow participation in decision making.

3. Helpful documents are available for purchase from the nonprofit Aging with Dignity (see Section IV.B).
  - a. Five Wishes: This is a legal advance directive with versions tailored for adolescents.
  - b. Voicing My Choices: A workbook for adolescents intended to complement Five Wishes
  - c. My Wishes: A simple booklet for younger children to help them share their preferences

### C. Outpatient Care

1. Provide continuity of care and advanced symptom management.
2. Focus on both patient and caregiver stress and support.

### D. Supporting Patients Throughout the Dying Process<sup>13-16, 22</sup>

1. See [Table 23.2](#) for normal changes that occur as death approaches and their recommended management.
2. See [Table 23.3](#) for appropriate dosing of recommended medications. (NOTE: Doses may be different for other indications.)
3. Integrative therapies can be utilized. For example, aromatherapy can be used for comfort and symptoms such as nausea, vomiting, pain, and anxiety.

**TABLE 23.2**

#### SYMPTOMATIC MANAGEMENT OF THE DYING PATIENT

System	Changes as Death Approaches	Interventions
Neurologic	Pain Overactive senses (hearing last to diminish) Increased need for sleep with occasional surge of energy to play or socialize	Morphine as needed Dim lights and reduce noise, provide soft background music
Cardiovascular	Heart rate increases, blood pressure decreases, pulse weakens, and skin becomes cooler	Inform family that death is near
Respiratory	Increased secretions Air hunger	Turn every few hours, elevate head of bed, frequent mouth care (avoid deep suctioning) Hyoscyamine Positive pressure through handheld fan Supplemental room air or oxygen as needed Morphine
Gastrointestinal	Nausea and vomiting Decreased appetite, preference for liquids Natural dehydration, fevers	Ondansetron or prochlorperazine Ice chips, moist mouth swabs Antipyretics per rectum
Dermatologic	Pruritus	Diphenhydramine
Psychiatric	Decreased interactions with outside world as thoughts and emotions are increasingly directed inward Agitation or delirium	Provide reassurance to family Frequently orient child to surroundings, surround with family and speak calmly Lorazepam and haloperidol if needed

TABLE 23.3

DOSING FOR MEDICATIONS USED IN PALLIATIVE CARE<sup>13,20, 22-24</sup>

Indication	Medication	Initial Regimen
Pain	Morphine	0.2–0.4 mg/kg/dose PO, SC, SL, PR Q2–4 hr <sup>a</sup> 0.1–0.2 mg/kg/dose IV Q2–4 hr <sup>a</sup> <b>NOTE:</b> Morphine should be titrated to symptomatic relief.
	Hydromorphone <sup>b</sup>	0.03–0.08 mg/kg/dose PO Q2–4 hr 0.015–0.02 mg/kg/dose IV, SC Q2–4 hr
	Oxycodone	0.1 mg/kg/dose PO 4hr (adult dose 5-10 mg)
Neuropathic pain	Gabapentin <sup>b</sup>	3–5 mg/kg/dose QHS day 1, BID day 2, then TID day 3 (titrate to effect, max dose per day 3600 mg)
Dyspnea	Morphine	0.1–0.25 mg/kg/dose PO, SC, SL, PR Q2–4 hr 0.05–0.1 mg/kg/dose IV Q2–4 hr
	Lorazepam	0.02–0.05 mg/kg/dose PO, IV, SL, PR Q4–8 hr
Agitation	Haloperidol	0.01–0.02 mg/kg/dose PO, IM, SC, IV Q8–12 hr
	Diphenhydramine	0.5–1 mg/kg/dose PO, IV Q6–8 hr
Pruritus	Diphenhydramine	0.5–1 mg/kg/dose PO, IV Q6–8 hr
Nausea/Vomiting	Prochlorperazine	0.1–0.15 mg/kg/dose PO, PR Q6–8 hr
	Ondansetron	0.15 mg/kg/dose PO, IV Q6–8 hr (max dose 8 mg)
	Granisetron	0.01 mg/kg IV/PO Q12hr (max 1 mg/dose)
	Olanzapine	0.1 mg/kg PO once daily (max 10 mg, titrate down in cases of oversedation)
Seizures	Diazepam	0.3–0.5 mg/kg/dose PR Q2–4 hr
	Lorazepam	0.05–0.1 mg/kg/dose SC, SL, IV Q2–4 hr
Secretions	Glycopyrrolate	0.04–0.1 mg/kg PO (max 8 mg/day) 0.004–0.01 mg/kg (4–10 mCg/kg) IV, SC

NOTE: For *adult*-sized patients, see Formulary for adult dosing recommendations.

<sup>a</sup>Infants <6 months should receive one-third to one-half the dose. For adolescents, consider starting adult dosing of 10 to 30 mg/dose PO, 2 to 15 mg/dose IV.

<sup>b</sup>Medication has not been studied in neonates.

*BID*, Twice daily; *IV*, intravenous; *PO*, oral; *PR*, rectal; *QHS*, nightly; *SC*, subcutaneous; *SL*, sublingual; *TID*, three times daily.

#### 4. Management of refractory distress

- Palliative sedation therapy is rarely required in pediatrics.
- The intent of palliative sedation therapy is relief of intolerable suffering from refractory symptoms by decreasing level of consciousness through sedation.
- Medications are titrated to symptom relief.
- Ensure that all appropriate symptom management strategies have been attempted, including expert consultation and nonpharmacologic approaches. Expert advice from palliative medicine experts is strongly recommended.

### E. Pronouncing Death<sup>17</sup>

#### 1. Preparation

- Know the child's name and gender.
- Be prepared to answer simple, pertinent questions from family and friends.
- Consult with nursing staff for relevant information, such as recent events and family dynamics.

- d. Determine the need and call for interdisciplinary support, such as social work, child life, pastoral care, and/or a bereavement coordinator.
2. Entering the room
  - a. Enter quietly and respectfully along with the primary nurse.
  - b. **Introduce yourself and identify your role.**
  - c. Determine the relationship of those in the room.
  - d. Inform the family of the purpose of your visit (“I am here to examine your child”) and invite them to remain in the room.
3. Procedure for pronouncement
  - a. Check ID bracelet and pulse.
  - b. Respectfully check response to tactile stimuli.
  - c. Check for spontaneous respirations for a minimum of 1 minute.
  - d. Check for heart sounds for a minimum of 1 minute.
  - e. Record the time of death.
  - f. Inform the family of death (“[Child’s name] has died”).
  - g. Remember to convey sympathy (“I’m so sorry for your loss”).
  - h. Offer to contact other family members.
4. Documentation of death in the chart
  - a. Write date, time of death, and the provider pronouncing the death.
  - b. Document absence of pulse, respirations, and heart sounds.
  - c. Identify family members who were present and informed of death.
  - d. Document notification of the attending physician.

## F. Explaining Autopsies<sup>18</sup>

1. Definitions
  - a. **Autopsy:** Definitive examination of a deceased patient to determine the cause of death
  - b. **Forensic autopsy:** Legally mandated examination to determine cause of death in a criminal investigation
  - c. **Rapid autopsy:** Urgent removal of tissues for research uses
2. Answers to frequently asked questions
  - a. A voluntary autopsy can look at all parts of a patient’s body or only some.
  - b. An autopsy will not affect the patient’s body cosmetically and should not affect funeral or viewing arrangements.
  - c. An autopsy takes 2 to 4 hours to perform and should not delay funeral/burial arrangements.
3. Benefits of autopsy
  - a. For families:
    - (1) May provide closure regarding diagnosis
    - (2) May help identify possible genetic or other etiologies for unexplained death
  - b. For providers: Clarifies potential diagnostic errors and uncertainties

## G. Organ Donation

1. Most hospitals have a special third-party team that coordinates organ donations.

2. Inform family members, if they are interested, that this team may be visiting soon to explain the process.

#### H. Completing Death Certificates<sup>17</sup>

1. Locate a copy of a sample death certificate for reference.
2. Cardiopulmonary arrest or respiratory arrest is NOT an acceptable primary cause of death.
3. For specific instructions for your state and/or institution, contact the Office of Decedent Affairs at your institution.
4. If you are completing a handwritten death certificate:
  - a. Use BLACK INK ONLY and complete *Physician sections*.
  - b. DO NOT use abbreviations (e.g., May 1 not 5/1).
  - c. DO NOT cross out or use correction fluid; you must begin again if mistakes are made.

#### I. Interacting with Loved Ones After a Child's Death

1. It is appropriate to send condolence cards, contact families, or attend funerals after a child has died. These are all appropriate physician activities that are deeply valued by bereaved families. Families want to know that their children are not forgotten.
2. Numerous services are available for families, including pastoral care, social work, bereavement coordinators, community support groups, counseling services, and bereavement follow-up programs.

### IV. WEB RESOURCES

- Center to Advance Palliative Care: <https://www.capc.org>
- Aging With Dignity: <https://agingwithdignity.org/>
- The American Academy of Hospice and Palliative Medicine: <https://www.aahpm.org>
- The National Hospice and Palliative Care Organization: <https://www.nhpco.org>

### REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Sepulveda C, Marlin A, Yoshida T, et al. Palliative care: World Health Organization's global perspective. *J Pain Symptom Manage*. 2002;24:91–96.
2. Nelson R. Palliative care for children: policy statement. *Pediatrics*. 2007;119:351–357.
3. Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-148, 124 Stat. 119 (2010).
4. Hays RM, Valentine J, Haynes G, et al. The Seattle Pediatric Palliative Care Project: effects on family satisfaction and health-related quality of life. *J Palliat Med*. 2006;9:716–728.
5. Back A, Arnold R, Tulsky J. *Mastering Communication With Seriously Ill Patients: Balancing Honesty With Empathy and Hope*. Cambridge University Press; 2009:85–88.
6. Cole SA, Bird J. *The Medical Interview: The Three Function Approach*. 3rd. ed. Elsevier, Saunders; 2014.
7. Puchalski CM. Spirituality and end-of-life care: a time for listening and caring. *J Palliat Med*. 2002;5:289–294.
8. Back AL, Arnold RM, Baile WF, et al. Approaching difficult communication tasks in oncology. *CA Cancer J Clin*. 2005;55(3):164–177. <https://doi.org/10.3322/canjclin.55.3.164>
9. Sourkes BM. *Armfuls of Time: The Psychological Experience of Children with Life-Threatening Illnesses*. University of Pittsburgh Press; 1995.
10. Corr CA. Children's understanding of death: striving to understand death. In: Doka KJ, ed. *Children Mourning, Mourning Children*. Hospice Foundation of America; 1995:8–10.
11. Corr CA, Balk DE, eds. *Handbook of Adolescent Death and Bereavement*. Springer; 1996.
12. Faulkner K. Children's understanding of death. In: Armstrong-Dailey A, Zarbock S, eds. *Hospice Care for Children*. 2nd ed. Oxford University Press; 2001:9–22.
13. Himelstein BP, Hilden JM, Boldt AM, et al. Pediatric palliative care. *N Engl J Med*. 2004;350:1752–1762.
14. Sigrist D. *Journey's End: A Guide to Understanding the Final Stages of the Dying Process*. Hospice of Rochester and Hospice of Wayne and Seneca Counties, Genesee Region Home Care; 1995.
15. Stewart M, Misra S, Weydert J, et al. Integrative therapies to support pediatric palliative care: the current evidence. *Pediatr Palliat Care*. 2018;6:150–157.
16. de Graeff A, Dean M. Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards. *J Palliat Med*. 2007;10(1):67–85. <https://doi.org/10.1089/jpm.2006.0139>
17. Bailey A. *The Palliative Response*. Menasha Ridge Press; 2003.
18. Sandeep Jauhar. Bring back the autopsy. *The New York Times*; 2016.
19. Deleted in proofs.
20. Flank J, Schechter T, Gibson P, et al. Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study. *Support Care Cancer*. 2018;26(2):549–555.
21. Deleted in proofs.
22. Wolfe J, Goldstein R. *Pediatrics: Evidence-Based Practice of Palliative Medicine*. Elsevier; Saunders; 2013:383.

23. Flank J, Robinson PD, Holdsworth M, et al. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. *Pediatr Blood Cancer*. 2016;63(7):1144–1451.
24. Kliegman RM, St. Geme JW. *Nelson Textbook of Pediatrics*. Elsevier; 2020.

# Chapter 24

## Psychiatry

*Jelina Marie V. Castillo, MD, MPH*

 See additional content online.

### I. OVERVIEW

#### A. General Approach

1. Screening:
  - a. Surveillance for mental health issues should occur at all well child visits from early childhood through adolescence.
  - b. The Pediatric Symptom Checklist (PSC) is a general mental health checklist that screens for a broad array of disorders ([Table 24.1](#)).<sup>1</sup>
2. See the *Diagnostic and Statistical Manual of Mental Disorders*, fifth edition (DSM-5), for a full list of psychiatric diagnoses.<sup>2</sup>
3. Pharmacotherapy for many disorders may be managed or monitored by the pediatrician.<sup>3</sup>

#### B. Mental Status Exam

1. General appearance: Dress, self-care, demeanor, attitude, behavior, developmental milestones
2. Motor activity: Activity level (restless, fidgety, stereotyped, or ritualized movements)
3. Speech and language: Fluency, comprehension, rate, rhythm, volume, expressive and receptive skills
4. Mood and affect: Stated by patient and observed by clinician
5. Thought form: Goal directed nature of thoughts, coherence, organization
6. Thought content:
  - a. What patient is thinking about
  - b. Mood, suicidal ideation, homicidal ideation, delusions
7. Abnormal perceptual phenomena: Illusions, hallucinations
8. Insight, judgment, cognition developmentally appropriate

#### C. Behavioral Interventions

1. Brief behavioral interventions can be done based on primary presenting problem or symptoms prior to escalation of care ([Table 24.4](#)).

### II. POSTPARTUM DEPRESSION

#### A. Diagnosis

1. Depression occurring in the 12-month period after birth
2. Maternal depression is important to identify and treat given the substantial impact on the health of the developing infant. Impaired

**TABLE 24.1****MENTAL HEALTH SCREENING TOOLS BY DIAGNOSIS**

Suspected Diagnosis	Screening Test	Age Group	Administration Time	Completed By
General psychosocial screening	Pediatric Symptom Checklist (PSC)	Ages 4–16 >11 years for child/adolescent self-report <sup>a</sup>	5 min	Different versions can be completed by parent or child/adolescent.
Postpartum depression	Edinburgh Postnatal Depression Scale	All postpartum mothers until child is 12 months of age	5 min	Mother
Attention-deficit/hyperactivity disorder (ADHD)	Vanderbilt Diagnostic Rating Scales	6–12 years <sup>a</sup>	10 min	Parent and teacher
Anxiety	Generalized Anxiety Disorder-7 (GAD-7)	>12 years <sup>a</sup>	5 min	Parent or child/adolescent
Depression	Patient Health Questionnaire-2 (PHQ-2) and Patient Health Questionnaire-9 (PHQ-9)	>12 years <sup>b</sup>	10 min	Child/adolescent
Eating disorders	Eating Disorder Screen for Primary Care (ESP)	Any age	1 min	Child/adolescent

<sup>a</sup>Recommendation based on validated age for screening tool, however can screen at any age if clinical suspicion

<sup>b</sup>Recommendation based on US Preventative Services Task Force (USPTF), however can screen at any age if clinical suspicion

Listed are the most common screening tools; however, more are available via The American Academy of Pediatrics. Mental health tools for pediatrics. In: *Addressing Mental Health Concerns in Pediatrics: A Practical Resource Toolkit for Clinicians*. 2nd ed. 2021.<sup>1</sup>

**TABLE 24.2****BRIEF INTERVENTIONS FOR COMMON PEDIATRIC PRIMARY CARE PROBLEMS**

Presenting Problem Area	Most Common Elements of Related Evidence-Based Practices
Anxiety	Graded exposure, modeling
ADHD and oppositional problems	Tangible rewards, praise for child and parent, help with monitoring, time-out, effective commands and limit setting, response cost
Low mood	Cognitive and/or coping methods, problem-solving strategies, activity scheduling, behavioral rehearsal, social skills building

Modified from Wissow LS, et al. Integrating children's mental health into primary care.<sup>4</sup>

maternal attachment may compromise the social, cognitive, and behavioral development of the infant.<sup>5</sup>

3. Differential diagnosis: Postpartum blues, other postpartum mood disorders such as bipolar mood disorder, postpartum psychosis

### **B. Epidemiology**

1. According to CDC analysis of Pregnancy Risk Assessment Monitoring System, 13.2% of women self-reported depressive symptoms postpartum in 2018.<sup>6</sup>

### **C. Evaluation**

1. Universal screening is recommended for all postpartum women.
2. A history of depression doubles the risk of postpartum depression and should prompt careful assessment for postpartum symptoms.<sup>7</sup>
3. Screening can be done using The Edinburgh Postnatal Depression Scale.

### **D. Management**

1. Referral to mother's primary care physician or a mental health expert is preferred.<sup>8</sup>

## **III. COMMON PSYCHIATRIC CONDITIONS OF CHILDREN AND ADOLESCENTS**

### **A. Attention-Deficit/Hyperactivity Disorder (ADHD)**

1. Diagnosis:
  - a. DSM-5 diagnostic criteria:
    - (1) Inattention, impulsivity/hyperactivity that are more frequent and severe than typically observed in children of the same developmental age
    - (2) Symptoms must persist for 6 months or more, occur before the age of 12 years, and should be evident in two or more settings (e.g., home and school).<sup>2</sup>
    - (3) Persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development
    - (4) Subtypes: Combined, predominantly inattentive, or predominantly hyperactive/impulsive

- b. If the medical history is unremarkable, no further laboratory or testing is required. Psychological and neuropsychological testing is not required for diagnosis but is recommended if other academic or developmental concerns are present.
  - c. Differential diagnosis: Conduct disorder, oppositional defiant disorder, anxiety, depression, or learning disorder. Vanderbilt Diagnostic Rating Scale scoring can help differentiate between these diagnoses.
  - d. Adverse childhood events (ACE) or trauma exposure can also contribute to an ADHD-like presentation, so referral for therapy can also be useful in this context. See [Chapter 9](#) for more information on ACE and trauma.
2. Epidemiology:
- a. According to the National Survey of Children's Health, prevalence of ADHD for 2- to 17- year-olds was 9.4%, with boys being more likely and earlier to be diagnosed than girls.<sup>9</sup>
  - b. Most affected children continue to meet the diagnostic criteria for ADHD through adolescence.
3. Evaluation:
- a. Evaluate all children who have academic and/or behavioral concerns for ADHD using Vanderbilt Diagnostic Rating Scales for parent and teacher. Vanderbilt can also be used to monitor changes in behavior and efficacy of interventions<sup>10</sup> (see [Table 24.1](#)).
4. Management:
- a. Pharmacologic treatment works best with behavioral therapy as an adjunct.<sup>10</sup>
  - b. Refer to [Table 24.2](#) for brief behavioral interventions.
  - c. Referral for behavioral therapy may be tried alone in preschool-age children (4 to 5 years old).
  - d. Before starting stimulant medication, take a history to exclude cardiac symptoms, Wolff-Parkinson-White syndrome, a family history of sudden death, hypertrophic cardiomyopathy, and long QT syndrome. If there is a cardiac history, referral for further testing to a cardiologist is recommended prior to initiating treatment. Screening electrocardiography is not required if there is no personal or family history of cardiac disease.<sup>11</sup>
  - e. See [Table 24.3](#) for pharmacologic treatment. The ADHD Medication guide (<https://www.adhdmedicationguide.com>) provides visual information.
  - f. Titrate medications to maximal symptom control with minimal side effects. Symptom control is expected within 1 week of medication initiation.
  - g. Common side effects of stimulants include appetite suppression, abdominal pain, headaches, palpitations, and sleep disturbance.<sup>10</sup>
  - h. If the first stimulant is ineffective, consider an alternative class of stimulant. Second-line options as alternative therapy or as an

TABLE 24.3

## COMMONLY USED PSYCHOTROPIC MEDICATIONS

Class	Drug Name	FDA Approved Ages	Starting Dose	Titration	Maximum Dose
Antidepressant/ Anxiolytics	Fluoxetine (Prozac)	7+ years (OCD)	10 mg	10 mg weekly	20 mg/24 hr
	Sertraline (Zoloft)	8+ years (MDD)	≤12 yo	≤12 yo	200 mg/24 hr
		6+ years (OCD)	12.5	25 mg weekly	
			≥13 yo	≥13 yo	
Escitalopram (Lexapro)	12+ years (MDD)	10 mg	10 mg after 3 weeks	20 mg/24 hr	
Methylphenidate Preparations	Methylphenidate (Ritalin)	6+ years	0.3 mg/kg/dose (or 2.5–5mg)	0.1 mg/kg (or 5–10 mg) weekly	2 mg/kg/24 hr or 60 mg/24 hr for <50 kg or 100 mg/24 hr for >50 kg
	Methylphenidate (Concerta)	6+ years	18 mg	18 mg weekly	6–12 yo: 54 mg/24 hr 13–17 yo: 72 mg/24 hr
	Dexmethylphenidate (Focalin)	6+ years	6–17 yo Immediate: 2.5 mg ER: 5 mg ≥18 yo Immediate: 2.5 mg ER: 20 mg/24 hr	6–17 yo Immediate: 2.5–5 mg ER: 5 mg weekly ≥18 yo Immediate: 2.5–5 mg ER: 10 mg weekly	6–17yo Immediate: 20 mg/24 hr ER: 30 mg/24 hr ≥18 yo Immediate: 20 mg/24 hr ER: 40 mg/24 hr
Amphetamine Preparations	Lisdexamfetamine (Vyvanse)	6+ years	<18 yo	10–20 mg weekly	70 mg/24 hr
			20 mg		
	Dextroamphetamine + amphetamine (Adderall)	3+ years (IR) 6+ years (ER)	30 mg	3–5 yo 2.5 mg weekly ≥6 yo 5 mg	3–5 yo 2.5 mg weekly ≥6 yo 5 mg weekly
3–5 yo					
2.5 mg					

<b>Non-stimulant options</b>	Clonidine extended release (Kapvay)	6+ years	≤45 kg 0.05 mg >45 kg 0.1 mg	≤45 kg 0.05 mg every 3–7 days >45 kg 0.1 mg every 3–7 days	27–40.5 kg 0.2 mg/24 hr 40.5–45 kg 0.3 mg/24 hr >45 kg 0.4 mg/24 hr
	Guanfacine immediate-release (Tenex)	12+ years	≤45 kg 0.5 mg >45 kg 1 mg	≤45 kg 0.5 mg every 3–4 days >45 kg 1 mg every 3–4 days	27–40.5 kg 2 mg/24 hr 40.5–45 kg 3 mg/24 hr >45 kg 4 mg/24 hr
	Guanfacine extended release (Intuniv)	6+ years	1 mg	1 mg weekly	6–12 yo 4 mg/24 hr >12 yo 7 mg/24 hr
	Atomoxetine (Strattera)	6+ years	≤70 kg 0.5 mg/kg/24 hr >70 kg 40 mg	≤70 kg 1.2 mg/kg/24 hr After 3 days >70 kg 80 mg After 3 days	≤70 kg 1.4 mg/kg/24 hr or 100 mg >70 kg 100 mg
<b>Antipsychotic for Acute Agitation</b>	Haloperidol (Haldol IM)	Not established	6–12 yo 1–3 mg >12 yo 2–5 mg	6–12 yo Q4–8 hr PRN >12 yo Q1 hr PRN	0.15 mg/kg/24 hr

*IR*, Immediate Release; *ER*, Extended Release; ASD, Autism spectrum disorder; GAD, generalized anxiety disorder; MDD, major depressive disorder; OCD, obsessive-compulsive disorder. Modified from the Centers for Medicare and Medicaid Services factsheets (<https://www.CMS.gov>) and the U.S. Food and Drug Administration.

augmenting agent to stimulant therapy include guanfacine, clonidine, and atomoxetine.<sup>3,10</sup> If multiple medication trials prove ineffective, consultation with a psychiatrist is suggested.

## B. Oppositional Defiant Disorder (ODD)

1. Diagnosis:
  - a. DSM-5 diagnostic criteria: Angry/irritable mood with argumentative/defiant behavior and vindictiveness for 6 or more months
  - b. Behavior must be present with at least one non-sibling.
2. Epidemiology:
  - a. According to the National Survey of Children's Health, prevalence of ODD for 3- to 17-year-olds was 4.6% in 2007. Prevalence of these disorders was twice as high among boys as among girls. Age of onset approximately 6 years of age, frequently comorbid with ADHD.<sup>12</sup>
3. Evaluation:
  - a. Many screening tools are available, including the Vanderbilt Assessment Scale (see [Table 24.1](#)).<sup>13</sup>
4. Management:
  - a. No evidence for pharmacologic intervention as first-line therapy for ODD
  - b. Refer to [Table 24.2](#) brief behavioral interventions.
  - c. Combination of cognitive behavioral therapy (CBT) and parent management training (PMT) may be most effective as first-line intervention.<sup>14</sup>


## C. Anxiety Disorders

1. Diagnosis:
  - a. A group of disorders characterized by excessive fear, anxiety, and related behavioral disturbances. May present with fear or worry and without recognizing that their fear or anxiety is unreasonable
  - b. Commonly presents as somatic complaints of headache and abdominal pain. Patients with many primary care visits for such complaints may benefit from formal anxiety screening.
  - c. Fear/anxiety may affect school performance or manifest as school avoidance.
  - d. Crying, irritability, angry outbursts, and disruptive behavior are expressions of fear and an effort to avoid anxiety-provoking stimuli.
  - e. Consider screening for adverse childhood experiences (ACE) or trauma exposure (see [Chapter 9](#) for more information).
  - f. DSM-5 diagnostic criteria vary based on the specific disorder<sup>2</sup>: (1) generalized anxiety disorder, (2) separation anxiety disorder, (3) social anxiety disorder, (4) selective mutism, (5) specific phobia, (6) panic disorder, (7) agoraphobia
  - g. Differential diagnosis: Obsessive-compulsive disorder, posttraumatic stress disorder

2. Epidemiology:
  - a. According to the National Survey of Children's Health, prevalence of anxiety diagnosis for 6- to 17-year-olds per parent report was 6.4% in 2011–2012, increased from 5.5% in 2007.<sup>15</sup>
  - b. There are ongoing studies on the effect of the COVID-19 pandemic on prevalence of anxiety in youth related to the social isolation and increase in social stressors. Meta-analysis of global data suggests increase of clinically elevated anxiety symptoms by 20.5%.<sup>16</sup>
3. Evaluation:
  - a. Multiple tools, such as the Generalized Anxiety Disorder-7 (GAD-7) and Self-Report for Childhood Anxiety Related Emotional Disorders (SCARED), are available (see [Table 24.1](#)).
4. Management ([Fig. 24.1](#)):
  - a. CBT with or without pharmacotherapy ([Table 24.3](#)) based on the disorder and its severity<sup>17</sup>
  - b. Refer to [Table 24.2](#) for brief behavioral interventions.<sup>4</sup>

#### D. Depressive and Mood Disorders

1. Diagnosis:
  - a. A group of disorders characterized by mood changes as well as somatic and cognitive symptoms that disrupt functioning
  - b. DSM-5 major depressive disorder diagnostic criteria:
    - (1) Five or more of the following symptoms for 2 or more weeks: Must include either depressed mood/irritability OR anhedonia; changes in appetite/weight, sleep, or activity; fatigue or loss of energy; guilt/worthlessness; decreased concentration; suicidality
    - (2) Symptoms cause significant impairment in functioning.
    - (3) Symptoms not due to substance use or a medical condition
    - (4) No history of manic episodes<sup>19</sup>
  - c. Other depressive disorders are defined by their own diagnostic criteria<sup>2</sup>:
    - (1) Disruptive mood dysregulation disorder
    - (2) Persistent depressive disorder (dysthymia)
    - (3) Premenstrual dysphoric disorder
  - d. Differential diagnosis: Bipolar disorder, adjustment disorder, demoralization
2. Epidemiology:
  - a. According to the National Survey of Children's Health, prevalence of depression diagnosis for 6- to 17-year-olds per parent report was 4.9% in 2011–2012.<sup>15</sup>
  - b. There are ongoing studies on the effect of the COVID-19 pandemic on the prevalence of depression in youth related to the social isolation and increase in social stressors. Meta-analysis of global data suggests increase of clinically elevated depressive symptoms by 25.2%.<sup>16</sup>
  - c. Common comorbid conditions: Anxiety disorders, disruptive behavior disorders, ADHD, substance use

**FIGURE 24.1**


Management of anxiety.

<sup>a</sup>There is no reason to believe sertraline is superior to other SSRIs such as fluoxetine or escitalopram. Sertraline recommendation based on Child/Adolescent Anxiety Multimodal Study (CAMS) 2010.<sup>18</sup>

3. Evaluation:
  - a. Routine screening is recommended for patients 12 years of age or older according to United States Preventative Services Taskforce (USPSTF); however, may consider younger if clinical concern
  - b. Multiple screening tools are available (see [Table 24.1](#)). The Patient Health Questionnaire (PHQ-2) is a brief but effective tool for use in adolescents.<sup>20</sup>
  - c. All patients with suspected depressive symptoms should be screened for suicidal ideation and referred for emergency evaluation if serious thoughts and/or action plans are endorsed (see [Section IV.A](#)).
4. Management ([Fig. 24.2](#))
  - a. Refer to [Table 24.2](#) for brief behavioral interventions.<sup>4</sup>
  - b. Selective serotonin reuptake inhibitors (SSRIs) may be initiated in the primary care setting.
  - c. Referral to subspecialist may be required depending on severity or in the case of treatment failure (see [Fig. 24.2](#)).
  - d. Antidepressant medications ([Table 24.3](#)) and CBT combined are recommended as studies show these will have benefit earlier than medication or CBT alone.<sup>21</sup>
  - e. Counsel patients that SSRIs may take up to 4 to 6 weeks for peak effect.
  - f. SSRIs have a black box warning from the US Food and Drug Administration (FDA) concerning a possible increase in suicidal thoughts or behaviors after initiation of medication.
    - (1) The basis of this warning was a large meta-analysis that found no increase in completed suicides but a small increase in suicidal ideation.<sup>22</sup>
    - (2) Professional mental health groups support the continued use of SSRIs in treating depression in children and adolescents because the benefits outweigh potential risks.<sup>22</sup>

## E. Eating Disorders

1. Diagnosis<sup>2</sup>:
  - a. Anorexia nervosa
    - (1) Restricted energy intake and low weight (body mass index [BMI] <18.5 kg/m<sup>2</sup>; severity stratified by BMI)
    - (2) Fear of gaining weight
    - (3) Disturbance in perception of body weight or shape
  - b. Bulimia nervosa
    - (1) Recurrent episodes of binge eating that occur at least once a week for 3 months
    - (2) Recurrent inappropriate compensatory mechanisms to prevent weight gain (e.g., diuretic or laxative use, exercise) or purging (self-induced vomiting)
    - (3) Self-evaluation excessively influenced by body shape or weight

**FIGURE 24.2**

Management of depressive disorders.

<sup>a</sup>There is no reason to believe fluoxetine is superior to other SSRIs such as sertraline or escitalopram. Fluoxetine recommendation based on The Treatment for Adolescents with Depression Study (TADS) Study 2008.<sup>21</sup>

2. Epidemiology:
  - a. According to the National Comorbidity Survey Adolescent Supplement, in the United States the lifetime prevalence of eating disorders was 2.7%; twice as prevalent among females (3.8%) than males (1.5%).<sup>23</sup>
  - b. Common comorbidities: Mood and anxiety disorders
3. Evaluation:
  - a. Many screening tools available, including the Eating Disorder Screen for Primary Care (ESP), the SCOFF (Sick, Control, One, Fat, Food) Questionnaire, and the Eating Attitudes Test (EAT-26) (see [Table 24.1](#))<sup>1</sup>
4. Management:
  - a. Aimed at nutritional rehabilitation, therapy (family-based or as a component of day treatment programs) and treatment of comorbid psychiatric illness. Hospitalization may be needed in cases of medical instability. See [Chapter 21](#) for management of refeeding syndrome.
  - b. SSRIs indicated in the treatment of bulimia nervosa (see [Table 24.3](#)). No medications have been approved for use in anorexia nervosa.<sup>24</sup>


## F. Substance Use Disorders

1. Epidemiology:
  - a. According to the National Survey on Drug Use and Health, 4.7% of adolescents ages 12 to 17 reported illicit drug use in the past year. Interviews from 2001 to 2004 for the National Comorbidity Survey Replication Adolescent Supplement estimated 8.3% prevalence of substance use disorder.<sup>12</sup>
  - b. Common comorbid conditions: ADHD, disruptive behavior disorders, mood disorders, anxiety disorders
2. For more information on diagnosis, evaluation, and management, please see [Chapter 5](#).

## IV. PSYCHIATRIC EMERGENCIES

### A. Suicide

1. Diagnosis:
  - a. Thoughts or plans to end one's life or not wanting to live anymore. Screening must be done to ensure safety of patient.
2. Epidemiology:
  - a. In 2019 suicide was the second leading cause of death among 10- to 34-year-olds.<sup>25</sup>
3. Evaluation:
  - a. Inpatient, outpatient, and emergency department settings: Use the Ask Suicide-Screening Questions (ASQ) ([Table 24.4](#)). This tool is validated for identifying pediatric patients at risk for suicide.
4. Management: (see [Table 24.4](#))

**FIGURE 24.3**

Suicide screening and assessment.

- a. Goal is to determine disposition (inpatient versus outpatient) and develop a safety plan with caregivers (see [Table 24.4](#)).
- b. Any positive reply to a screening question warrants further evaluation by the pediatrician and consideration of referral to a psychiatrist or other mental health professional.

## B. Aggression or Impulsivity<sup>26,27</sup>

### 1. Diagnosis:

- a. Agitation can be defined as disruptive behavior occurring during periods of emotional distress.
- b. Manifestations include:
  - (1) Excessive motor activity: Pacing, fidgeting
  - (2) Verbal aggression: Yelling, shouting, rapid pressured speech, threats
  - (3) Physical aggression: Hitting, throwing things

**TABLE 24.4****SUICIDE SAFETY PLAN AND SCREENING**

Validated for identifying pediatric patients at risk for suicide.

1. In the past few weeks, have you wished you were dead?
2. In the past few weeks, have you felt that you or your family would be better off if you were dead?
3. In the past week, have you been having thoughts about killing yourself?
4. Have you ever tried to kill yourself?


Any affirmative response constitutes a positive screen.

**COMPONENTS OF SAFETY PLAN**

1. Understanding warning signs that crisis may be developing
2. Coping strategies
3. People or social settings that can provide distraction
4. People who can be reached for help
5. Referral to professional agencies or Suicide and Crisis Lifeline 988 during crisis, or saving these numbers into personal phone
6. Making the environment safe, ensuring means of suicide such as weapons or medications are not readily available

Data from the Ask Suicide-Screen Questions (ASQ) Toolkit. National Institute of Mental Health, National Institutes of Health. Available from: <http://www.nimh.nih.gov/labs-at-nimh/asq-toolkit-materials/index.shtml>; and the Stanley-Brown Safety Plan <https://suicidesafetyplan.com/forms/>

- c. Acute aggression and impulsivity can occur as a manifestation of psychiatric illness, substance intoxication or withdrawal, grief, or organic disease.
2. Management:
  - a. Determine the etiology by reviewing vital signs, presenting history, past diagnoses, past episodes of aggression (Fig. 24.4). Attempt to rule out underlying medical cause (e.g., ingestion, traumatic brain injury).
  - b. Nonpharmacologic
    - (1) Low-stimulation environment (e.g., dim lights, move child away from busy areas, avoid unnecessary interventions)
    - (2) Communicate in a calm, neutral, empathetic tone at eye level using simple language.
    - (3) Utilize distraction techniques and Child Life Services if available.
  - c. Pharmacologic: Therapy choice should target the etiology of agitation (see Fig. 24.4).
  - d. Restraints and seclusion: Reserved for cases where both nonpharmacologic and pharmacologic interventions fail. Regulations and requirements for use vary by state.
    - (1) Close monitoring required
    - (2) Frequent reassessment of necessity of restraints

**FIGURE 24.4**

Agitation management algorithm.

## V. WEB RESOURCES

- ADHD Medication Guide: <https://www.adhdmedicationguide.com>
- AAP Mental Health Toolkit: <https://publications.aap.org/toolkits/pages/mental-health-toolkit>
- Template for Creating a Safety Plan: <https://suicidesafetyplan.com/forms/>

## REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Mental Health Toolkit, AAP Toolkits, AAP Point-of-Care-Solutions. Accessed August 12, 2021. <https://toolkits.solutions.aap.org/mental-health/home#>
2. Association AP. *Diagnostic and Statistical Manual of Mental Disorders (DSM-5®)*. American Psychiatric Pub; 2013.
3. Riddle MA. *Psychopharmacology for Primary Care: 3rd Edition*. American Academy Of Pediatrics; 2021.
4. Wissow LS, van Ginneken N, Chandna J, Rahman A. Integrating children's mental health into primary care. *Pediatr Clin North Am*. 2016;63(1):103.
5. Brummelte S, Galea LAM. Postpartum depression: etiology, treatment and consequences for maternal care. *Horm Behav*. 2016;77:153–166. <https://doi.org/10.1016/j.yhbeh.2015.08.008>
6. Bauman BL. Vital signs: postpartum depressive symptoms and provider discussions about perinatal depression — United States, 2018. *MMWR Morb Mortal Wkly Rep*. 2020;69. <https://doi.org/10.15585/mmwr.mm6919a2>
7. Banti S, Mauri M, Oppo A, et al. From the third month of pregnancy to 1 year postpartum. Prevalence, incidence, recurrence, and new onset of depression. Results from the perinatal depression-research & screening unit study. *Compr Psychiatry*. 2011;52(4):343–351. <https://doi.org/10.1016/j.comppsy.2010.08.003>
8. Olin S-CS, Kerker B, Stein REK, et al. Can postpartum depression be managed in pediatric primary care? *J Womens Health* 2002. 2016;25(4):381–390. <https://doi.org/10.1089/jwh.2015.5438>
9. Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, Blumberg SJ. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. *J Clin Child Adolesc Psychol*. 2018;47(2):199–212. <https://doi.org/10.1080/15374416.2017.1417860>
10. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents, American Academy of Pediatrics. <https://pediatrics.aappublications.org/content/144/4/e20192528> Accessed August 12, 2021.
11. American Academy of Pediatrics/American Heart Association. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. *J Dev Behav Pediatr*. 2008;29(4):335. <https://doi.org/10.1097/DBP.0b013e31818185dc14>
12. Mental Health Surveillance Among Children—United States, 2005–2011. Accessed August 17, 2021. [https://www.cdc.gov/mmwr/preview/mmwrhtml/su6202a1.htm?s\\_cid=su6202a1\\_w](https://www.cdc.gov/mmwr/preview/mmwrhtml/su6202a1.htm?s_cid=su6202a1_w)
13. Riley M, Ahmed S, Locke A. Common questions about oppositional defiant disorder. *Am Fam Physician*. 2016;93(7):586–591.
14. Dulcan MK. *Dulcan's Textbook of child and adolescent psychiatry*. 2nd ed. American Psychiatric Association Publishing; 2016. <https://doi.org/10.1176/appi.books.9781615370306>
15. Bitsko RH, Holbrook JR, Ghandour RM, et al. Epidemiology and impact of health care provider-diagnosed anxiety and depression among US children. *J Dev Behav Pediatr*. 2018;39(5):395–403. <https://doi.org/10.1097/DBP.0000000000000571>
16. Racine N, McArthur BA, Cooke JE, Eirich R, Zhu J, Madigan S. Global prevalence of depressive and anxiety symptoms in children and adolescents

- during COVID-19: a meta-analysis. *JAMA Pediatr*. Published August 9, 2021. <https://doi.org/10.1001/jamapediatrics.2021.2482>
17. Connolly SD, Bernstein GA, Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. *J Am Acad Child Adolesc Psychiatry*. 2007;46(2):267–283. <https://doi.org/10.1097/01.chi.0000246070.23695.06>
  18. Compton SN, Walkup JT, Albano AM, et al. Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods. *Child Adolesc Psychiatry Ment Health*. 2010;4:1. <https://doi.org/10.1186/1753-2000-4-1>
  19. Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. *J Am Acad Child Adolesc Psychiatry*. 2007;46(11):1503–1526. <https://doi.org/10.1097/chi.0b013e318145ae1c>
  20. Richardson LP, Rockhill C, Russo JE, et al. Evaluation of the PHQ-2 as a brief screen for detecting major depression among adolescents. *Pediatrics*. 2010;125(5):e1097–1103. <https://doi.org/10.1542/peds.2009-2712>
  21. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. *JAMA*. 2004;292(7):807–820. <https://doi.org/10.1001/jama.292.7.807>
  22. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. *Arch Gen Psychiatry*. 2006;63(3):332–339. <https://doi.org/10.1001/archpsyc.63.3.332>
  23. Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication—Adolescent Supplement (NCS-A). *J Am Acad Child Adolesc Psychiatry*. 2010;49(10):980–989.
  24. Rosen DS, American Academy of Pediatrics Committee on Adolescence. Identification and management of eating disorders in children and adolescents. *Pediatrics*. 2010;126(6):1240–1253. <https://doi.org/10.1542/peds.2010-2821>
  25. WISQARS Data Visualization. Accessed August 17, 2021. <https://wisqars-viz.cdc.gov:8006/lcd/home>
  26. Wilson MP, Pepper D, Currier GW, Holloman GH, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup. *West J Emerg Med*. 2012;13(1):26–34. <https://doi.org/10.5811/westjem.2011.9.6866>
  27. Gerson R, Malas N, Mroczkowski MM. Crisis in the emergency department: the evaluation and management of acute agitation in children and adolescents. *Child Adolesc Psychiatr Clin N Am*. 2018;27(3):367–386. <https://doi.org/10.1016/j.chc.2018.02.002>

# Chapter 25

## Pulmonology and Sleep Medicine

*Saskia Groenewald, MD*

 See additional content online.

### I. EVALUATION OF PULMONARY GAS EXCHANGE

#### A. Pulse Oximetry<sup>1-3</sup>

1. Noninvasive and indirect measurement of arterial O<sub>2</sub> saturation (SaO<sub>2</sub>) estimated by light absorption characteristics of oxygenated and deoxygenated hemoglobin in peripheral blood.
2. Limitations:
  - a. Measures oxygen saturation, not O<sub>2</sub> delivery to tissues
  - b. Insensitive to hyperoxia. See [eFig. 25.1](#) for oxyhemoglobin dissociation curve.
  - c. Artificially increased by: Carboxyhemoglobin levels >1% to 2%
  - d. Artificially decreased by: Intravenous dyes, opaque nail polish, and methemoglobin levels >1%
  - e. Unreliable when pulse signal is poor: Hypothermia, hypovolemia, shock, edema, movement artifact

#### B. Capnography<sup>4,5</sup>


1. Measures CO<sub>2</sub> concentration of expired gas by infrared or mass spectroscopy
2. End-tidal CO<sub>2</sub> (ETCO<sub>2</sub>) correlates with PaCO<sub>2</sub> (usually within 5 mmHg in healthy subjects).
3. Used to evaluate proper placement of an endotracheal tube, to monitor ventilation in mechanically ventilated patients, to assess effectiveness of CPR, and during polysomnography

#### C. Blood Gases<sup>6-8</sup>

1. Arterial blood gas (ABG): Most accurate way to assess oxygenation (PaO<sub>2</sub>), ventilation (PaCO<sub>2</sub>), and acid–base status (pH and HCO<sub>3</sub><sup>-</sup>). See [Chapter 28](#) for normal mean values.
2. Venous blood gas (VBG): PvCO<sub>2</sub> averages 6 to 8 mmHg higher than PaCO<sub>2</sub>; venous pH is slightly lower than arterial pH.
3. Capillary blood gas (CBG): Correlation with ABG is generally best for pH, moderate for PCO<sub>2</sub>, and worst for PO<sub>2</sub>.

#### D. Analysis of Acid–Base Disturbances<sup>9-11</sup>

Determine primary disturbance (metabolic versus respiratory), then assess for mixed disorder by calculating expected compensatory response. See [Chapter 11](#) for details.

**eFIGURE 25.1**

Oxyhemoglobin dissociation curve. (A) Curve shifts to the left as pH increases. (B) Curve shifts to the left as temperature decreases. (Modified from Boron WF. Transport of oxygen and carbon dioxide by the blood. In: *Medical Physiology*. 4th ed. 2016; 647–659.e1.)

## II. PULMONARY FUNCTION TESTS (PFT)

Provide objective and reproducible measurements of airway function and lung volumes. Used to characterize disease, assess severity, and follow response to therapy

### A. Peak Expiratory Flow Rate (PEFR)<sup>12,13</sup>

Maximal flow rate generated during a forced expiratory maneuver.

1. Used to follow the course of asthma and response to therapy by comparing current PEFR with the previous “personal best” and the normal predicted value
2. Limitations: Measurement is effort dependent and can be difficult to determine normal values based on patient factors. Cannot be done reliably by many young children
3. Normal predicted PEFR values for children (Table 25.1)

### B. Maximal Inspiratory and Expiratory Pressures<sup>14,15</sup>

Maximal pressure generated during inhalation and exhalation against a fixed obstruction. Used as a measure of respiratory muscle strength

1. Maximal inspiratory pressure (MIP) is in the range of 80 to 120 cm H<sub>2</sub>O at all ages. A low MIP may be an indication for ventilatory support.
2. Maximum expiratory pressure (MEP) increases with age and is greater in males. A low MEP correlates with decreased effectiveness of coughing.

### C. Spirometry (for Children ≥6 Years)<sup>16,17</sup>

Plot of airflow versus time during rapid, forceful, and complete expiration from total lung capacity (TLC) to residual volume (RV) is useful to characterize different patterns of airway obstruction (Fig. 25.1). Usually performed before and after bronchodilation to assess response to therapy or after bronchial challenge to assess airway hyperreactivity.


**TABLE 25.1**

**PREDICTED AVERAGE PEAK EXPIRATORY FLOW RATES FOR NORMAL CHILDREN**


Height in Inches (cm)	PEFR (L/min)	Height in Inches (cm)	PEFR (L/min)
43 (109)	147	56 (142)	320
44 (112)	160	57 (145)	334
45 (114)	173	58 (147)	347
46 (117)	187	59 (150)	360
47 (119)	200	60 (152)	373
48 (122)	214	61 (155)	387
49 (124)	227	62 (157)	400
50 (127)	240	63 (160)	413
51 (130)	254	64 (163)	427
52 (132)	267	65 (165)	440
53 (135)	280	66 (168)	454
54 (137)	293	67 (170)	467
55 (140)	307		

PEFR, Peak expiratory flow rate.

Data from Voter KZ. Diagnostic tests of lung function. *Pediatr Rev.* 1996;17:53–63.



A Expired vital capacity (%)




B

**FIGURE 25.1**

(A) Normal flow–volume curve. Maximal inspiratory flow (MIF). (B) Obstructive pattern seen in asthma or cystic fibrosis; restrictive pattern seen in interstitial lung disease. (B, Data from Baum GL, Wolinsky E. *Textbook of Pulmonary Diseases*. 5th ed. Little, Brown; 1994.)

1. Important definitions (Fig. 25.2)
  - a. Forced vital capacity (FVC): Maximum volume of air exhaled from the lungs after a maximum inspiration
  - b. Forced expiratory volume in 1 second ( $FEV_1$ ): Volume exhaled during the first second of the FVC maneuver
2. Interpretation of spirometry and lung volume readings<sup>18</sup> (Table 25.2).

**FIGURE 25.2**

Lung volumes.  $FEF_{25-75}$ , Forced expiratory flow between 25% and 75% of FVC;  $FEV_1$ , forced expiratory volume in 1 second;  $FVC$ , forced vital capacity.

**TABLE 25.2****INTERPRETATION OF SPIROMETRY AND LUNG VOLUME READINGS**

	<b>Obstructive Disease (Asthma, Cystic Fibrosis)</b>	<b>Restrictive Disease (Interstitial Fibrosis, Scoliosis, Neuromuscular Disease)</b>
<b>SPIROMETRY</b>		
$FVC^a$	Normal or reduced	Reduced
$FEV_1^a$	Reduced	Reduced <sup>d</sup>
$FEV_1/FVC^b$	Reduced	Normal
$FEF_{25-75}$	Reduced	Normal or reduced <sup>d</sup>
$PEFR^a$	Normal or reduced	Normal or reduced <sup>d</sup>
<b>LUNG VOLUMES</b>		
$TLC^a$	Normal or increased	Reduced
$RV^a$	Increased	Reduced
$RV/TLC^c$	Increased	Unchanged
$FRC$	Increased	Reduced

<sup>a</sup>Normal range:  $\pm 20\%$  of predicted.

<sup>b</sup>Normal range:  $>85\%$ .

<sup>c</sup>Normal range:  $20 \pm 10\%$ .

<sup>d</sup>Reduced proportional to FVC.

$FEF_{25-75}$ , forced expiratory flow between 25% and 75% of FVC;  $FEV_1$ , forced expiratory volume in 1 second;  $FRC$ , functional residual capacity;  $FVC$ , forced vital capacity;  $PEFR$ , peak expiratory flow rate;  $RV$ , residual volume;  $TLC$ , total lung capacity.

**III. ASTHMA** <sup>12-13,19</sup>**A. Definition**

A chronic inflammatory disease with reversible constriction of airway smooth muscles, mucus production, and edema that lead to obstruction and air trapping. Commonly manifests as recurrent episodes of wheezing, breathlessness, chest tightness, and cough. The inflammation causes increased

airway hyperreactivity to a variety of stimuli: viral infections, cold air, exercise, emotions, environmental allergens, and pollutants.

### B. Clinical Presentation

1. Cough, increased work of breathing (tachypnea, retractions, accessory muscle use), wheezing, hypoxemia, and variable expiratory airflow limitation. Crackles may also be present with asthma exacerbations.
2. No audible wheezing may indicate very poor air movement and severe bronchospasm.
3. Radiographic findings: Peri-bronchial thickening, hyperinflation, patchy atelectasis

### C. Treatment

1. See [Chapter 1](#) for acute management of status asthmaticus.
2. The National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group of the National Heart, Lung, and Blood Institute recently published its 2020 Focused Updates to the Asthma Management Guidelines:
  - a. Stepwise management recommendations summarized in [Figs. 25.3 to 25.8](#)
  - b. In children ages 0 to 4 years with intermittent asthma (recurrent wheezing triggered only by URIs), recommend short course inhaled corticosteroids (ICS) along with short-acting beta-agonist (SABA) at onset of infection.
  - c. The preferred treatment for ages 5 to 11 and 12+ with moderate to severe persistent asthma (steps 3 and 4) already taking low- or medium-dose ICS is a single inhaler with ICS-formoterol (referred to as single maintenance and reliever therapy, or “SMART”) used both daily and as needed.
  - d. For ages 12+: Addition of a long-acting muscarinic antagonist (LAMA) as an add-on therapy (preferred step 5, option in step 3+).
  - e. A biologic (omalizumab for ages  $\geq 5$ , additional options for ages 12+) should be considered for steps 5 and 6.
  - f. In children  $\geq 5$  years with mild/moderate asthma and allergen sensitization, the use of subcutaneous immunotherapy as an adjunct treatment to standard pharmacotherapy is recommended in steps 2 through 4.
  - g. Fractional exhaled nitric oxide (FeNO) is a biomarker that can be measured and used used to predict the level of inflammation in the lungs.
  - h. Using FeNO measurement as an adjunct to the evaluation process in individuals  $\geq 5$  years is recommended if further diagnostic clarification is needed but should not be used to predict risk of future exacerbations or severity.
    - i. In children with asthma who do not have sensitization to specific indoor allergens, the allergen-mitigation interventions is NOT recommended as part of routine asthma management.<sup>13</sup>
3. Initial classification and initiation of treatment for ages 0 to 4, 5 to 11, and  $\geq 12$  years ([Figs. 25.3, 25.4, and 25.5](#)).

### Classifying asthma severity and initiating treatment in children 0–4 years of age

Classifying severity in children who are not currently taking long-term control medication.

Components of severity		Classification of asthma severity (0–4 years of age)			
		Intermittent	Persistent		
			Mild	Moderate	Severe
Impairment	Symptoms	≤2 days/week	>2 days/week but not daily	Daily	Throughout the day
	Nighttime awakenings	0	1–2×/month	3–4×/month	>1×/week
	Short-acting β <sub>2</sub> -agonist use for symptom control (not prevention of EIB)	≤2 days/week	>2 days/week but not daily	Daily	Several times per day
	Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited
Risk	Exacerbations requiring oral systemic corticosteroids	0–1/year	≥2 exacerbations in 6 months requiring oral systemic corticosteroids, or ≥4 wheezing episodes/1 year lasting >1 day AND risk factors for persistent asthma		
		← Consider severity and interval since last exacerbation. Frequency and severity may fluctuate over time. → Exacerbations of any severity may occur in patients in any severity category.			

- Level of severity is determined by both impairment and risk. Assess impairment domain by caregiver's recall of previous 2–4 weeks. Assign severity to the most severe category in which any feature occurs.
- At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. For treatment purposes, patients who had ≥2 exacerbations requiring oral corticosteroids in the past 6 months, or ≥4 wheezing episodes in the past year, and who have risk factors for persistent asthma may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.

#### FIGURE 25.3

Guidelines for classifying asthma severity and initiating treatment in infants and young children (aged 0–4 years). (Modified from National Asthma Education and Prevention Program [NAEPP]—Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. August 2007.)

4. Stepwise approach to continued management for ages 0 to 4, 5 to 11, and ≥12 years (Figs. 25.6, 25.7, and 25.8)
5. Additional management guidelines available from the Global Initiative for Asthma<sup>19</sup>

#### D. Prevention of Exacerbations<sup>19</sup>

1. Ensure up-to-date immunizations, including influenza and COVID-19.
2. Create an asthma action plan.
3. Identify and minimize asthma triggers and environmental exposures.
4. Assess symptom control, inhaler technique, and medication adherence with regular clinical evaluations.

### CLASSIFYING ASTHMA SEVERITY AND INITIATING TREATMENT IN CHILDREN 5–11 YEARS OF AGE

Assessing severity and initiating therapy in children who are not currently taking long-term control medication

Components of severity		Classification of asthma severity (5–11 years of age)			
		Intermittent	Persistent		
			Mild	Moderate	Severe
Impairment	Symptoms	≤2 days/week	>2 days/week but not daily	Daily	Throughout the day
	Nighttime awakenings	≤2×/month	3–4×/month	>1×/week but not nightly	Often 7×/week
	Short-acting $\beta_2$ -agonist use for symptom control (not prevention of EIB)	≤2 days/week	>2 days/week but not daily	Daily	Several times per day
	Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited
	Lung function	• Normal FEV <sub>1</sub> between exacerbations • FEV <sub>1</sub> >80% predicted • FEV <sub>1</sub> /FVC >85%	• FEV <sub>1</sub> >80% predicted • FEV <sub>1</sub> /FVC >80%	• FEV <sub>1</sub> = 60%–80% predicted • FEV <sub>1</sub> /FVC = 75%–80%	• FEV <sub>1</sub> <60% predicted • FEV <sub>1</sub> /FVC <75%
Risk	Exacerbations requiring oral systemic corticosteroids	0–1/year (see note)	≥2/year (see note) →		
		← Consider severity and interval since last exacerbation. Frequency and severity may fluctuate over time → for patients in any severity category.			
		Relative annual risk of exacerbations may be related to FEV <sub>1</sub> .			

Key: EIB, exercise-induced bronchospasm; FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids

#### Notes

- The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs.
- Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous 2–4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs.
- At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (e.g., requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had ≥2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.

**FIGURE 25.4**

Guidelines for classifying asthma severity and initiating treatment in children 5 to 11 years of age. (Modified from National Asthma Education and Prevention Program [NAEPP]—Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. August 2007.)

### CLASSIFYING ASTHMA SEVERITY AND INITIATING TREATMENT IN YOUTHS $\geq 12$ YEARS OF AGE

Assessing severity and initiating treatment for patients who are not currently taking long-term control medications

Components of severity		Classification of asthma severity $\geq 12$ years of age			
		Intermittent	Persistent		
			Mild	Moderate	Severe
<b>Impairment</b>  <b>Normal FEV<sub>1</sub>/FVC:</b> 8–19 yr 85% 20–39 yr 80% 40–59 yr 75% 60–80 yr 70%	Symptoms	$\leq 2$ days/week	$> 2$ days/week but not daily	Daily	Throughout the day
	Nighttime awakenings	$\leq 2$ $\times$ /month	3–4 $\times$ /month	$> 1$ $\times$ /week but not nightly	Often 7 $\times$ /week
	Short-acting $\beta_2$ -agonist use for symptom control (not prevention of EIB)	$\leq 2$ days/week	$> 2$ days/week but not daily, and not more than 1 time on any day	Daily	Several times per day
	Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited
	Lung function	<ul style="list-style-type: none"> <li>• Normal FEV<sub>1</sub> between exacerbations</li> <li>• FEV<sub>1</sub> <math>&gt; 80\%</math> predicted</li> <li>• FEV<sub>1</sub>/FVC normal</li> </ul>	<ul style="list-style-type: none"> <li>• FEV<sub>1</sub> <math>&gt; 80\%</math> predicted</li> <li>• FEV<sub>1</sub>/FVC normal</li> </ul>	<ul style="list-style-type: none"> <li>• FEV<sub>1</sub> <math>&gt; 60\%</math> but <math>&lt; 80\%</math> predicted</li> <li>• FEV<sub>1</sub>/FVC reduced 5%</li> </ul>	<ul style="list-style-type: none"> <li>• FEV<sub>1</sub> <math>&lt; 60\%</math> predicted</li> <li>• FEV<sub>1</sub>/FVC reduced <math>&gt; 5\%</math></li> </ul>
<b>Risk</b>	Exacerbations requiring oral systemic corticosteroids	0–1/year (see note)	$\geq 2$ /year (see note) $\rightarrow$		
		Consider severity and interval since last exacerbation. $\leftarrow$ Frequency and severity may fluctuate over time $\rightarrow$ for patients in any severity category.			
		Relative annual risk of exacerbations may be related to FEV <sub>1</sub> .			

Key: FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity; ICU, intensive care unit

#### Notes

- The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs.
- Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous 2–4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs.
- At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (e.g., requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had  $\geq 2$  exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.

**FIGURE 25.5**

Guidelines for classifying asthma severity and initiating treatment in youths 12 years and older. (Modified from National Asthma Education and Prevention Program [NAEPP]—Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. August 2007.)

## Stepwise approach for management of asthma in individuals ages 0–4 years

		Intermittent asthma	Management of persistent asthma in individuals ages 0–4 years			
Treatment	Step 1	Step 2	Step 3	Step 4	Step 5	Step 6
<b>Preferred</b>	PRN SABA and At the start of RTI: Add short course daily ICS <sup>a</sup>	Daily low-dose ICS and PRN SABA	Daily medium-dose ICS and PRN SABA	Daily medium-dose ICS-LABA and PRN SABA	Daily high-dose ICS-LABA and PRN SABA	Daily high-dose ICS-LABA + oral systemic corticosteroid and PRN SABA
<b>Alternative</b>		Daily montelukast* or Cromolyn,* and PRN SABA		Daily medium-dose ICS + montelukast* and PRN SABA	Daily high-dose ICS + montelukast* and PRN SABA	Daily high-dose ICS + montelukast* + oral systemic corticosteroid and PRN SABA
			For children age 4 years only, see step 3 and step 4 on management of persistent asthma in individuals ages 5–11 years diagram.			
<b>Assess control</b>						
<ul style="list-style-type: none"> <li>• First check adherence, inhaler technique, environmental factors,<sup>a</sup> and comorbid conditions.</li> <li>• <b>Step up</b> if needed; reassess in 4–6 weeks</li> <li>• <b>Step down</b> if possible (if asthma is well controlled for at least 3 consecutive months)</li> </ul> <p>Consult with asthma specialist if step 3 or higher is required. Consider consultation at step 2.</p> <p>Control assessment is a key element of asthma care. This involves both impairment and risk. Use of objective measures, self-reported control, and health care utilization are complementary and should be employed on an ongoing basis, depending on the individual's clinical situation.</p>						

**Abbreviations:** ICS, inhaled corticosteroid; LABA, long-acting beta<sub>2</sub>-agonist; SABA, inhaled short-acting beta<sub>2</sub>-agonist; RTI, respiratory tract infection; PRN, as needed

<sup>a</sup> Updated based on the 2020 guidelines.

\* Cromolyn and montelukast were not considered for this update and/or have limited availability for use in the United States. The FDA issued a boxed warning for montelukast in March 2020.

**FIGURE 25.6**

Stepwise approach for managing asthma in infants and young children (aged 0–4 years). (Modified from National Asthma Education and Prevention Program [NAEPP]—2020 Focused Updates to the Asthma Management Guidelines. December 2020.)

## Ages 5–11 years: Stepwise approach for management of asthma

		Intermittent asthma	Management of persistent asthma in individuals ages 5–11 years			
Treatment	Step 1	Step 2	Step 3	Step 4	Step 5	Step 6
<b>Preferred</b>	PRN SABA	Daily low-dose ICS and PRN SABA	Daily and PRN combination low-dose ICS-formoterol <sup>▲</sup>	Daily and PRN combination medium-dose ICS-formoterol <sup>▲</sup>	Daily high dose ICS-LABA and PRN SABA	Daily high-dose ICS-LABA + oral systemic corticosteroids and PRN SABA
<b>Alternative</b>		Daily LTRA,* or Cromolyn,* or Nedocromil,* or Theophylline,* and PRN SABA	Daily medium-dose ICS and PRN SABA or Daily low-dose ICS-LABA, or daily low-dose ICS + LTRA,* or daily low-dose ICS + Theophylline,* and PRN SABA	Daily medium-dose ICS-LABA and PRN SABA or Daily medium-dose ICS + LTRA* or daily medium-dose ICS + Theophylline,* and PRN SABA	Daily high-dose ICS + LTRA* or daily high-dose ICS + Theophylline,* and PRN SABA	Daily high-dose ICS + LTRA* + oral systemic corticosteroid or daily high-dose ICS + Theophylline* + oral systemic corticosteroid, and PRN SABA
		Steps 2–4: Conditionally recommend the use of subcutaneous immunotherapy as an adjunct treatment to standard pharmacotherapy in individuals ≥ 5 years of age whose asthma is controlled at the initiation, buildup, and maintenance phases of immunotherapy <sup>▲</sup>			Consider omalizumab <sup>***</sup>	
<b>Assess control</b>						
<ul style="list-style-type: none"> <li>• First check adherence, inhaler technique, environmental factors, <sup>▲</sup> and comorbid conditions.</li> <li>• <b>Step up</b> if needed; reassess in 2–6 weeks</li> <li>• <b>Step down</b> if possible (if asthma is well controlled for at least 3 consecutive months)</li> </ul> Consult with asthma specialist if step 4 or higher is required. Consider consultation at step 3. <p>Control assessment is a key element of asthma care. This involves both impairment and risk. Use of objective measures, self-reported control, and health care utilization are complementary and should be employed on an ongoing basis, depending on the individual's clinical situation.</p>						

FIGURE 25.7

Stepwise approach for managing asthma in children 5 to 11 years. Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LTRA, leukotriene receptor antagonist; SABA, inhaled short-acting beta2-agonist. Updated based on the 2020 guidelines. \* Cromolyn, Nedocromil, LTRAs including montelukast, and Theophylline were not considered in this update and/or have limited availability for use in the United States, and/or have an increased risk of adverse consequences and need for monitoring that make their use less desirable. The FDA issued a Boxed Warning for montelukast in March 2020. \*\* Omalizumab is the only asthma biologic currently FDA-approved for this age range. (Modified from National Asthma Education and Prevention Program [NAEPP]— 2020 Focused Updates to the Asthma Management Guidelines. December 2020.)

**Quick-relief medications**

- Use SABA as needed for symptoms. The intensity of treatment depends on severity of symptoms: Up to 3 treatments at 20-minute intervals as needed.
- In steps 3 and 4, the preferred option includes the use of ICS-formoterol 1 to 2 puffs as needed up to a maximum total daily maintenance and rescue dose of 8 puffs (36 mcg).<sup>▲</sup>
- **Caution:** Increasing use of SABA or use >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and may require a step up in treatment.

**Each step:** Assess environmental factors, provide patient education, and manage comorbidities.<sup>▲</sup>

- In individuals with sensitization (or symptoms) related to exposure to pests<sup>‡</sup>: Conditionally recommend integrated pest management as a single or multicomponent allergen-specific mitigation intervention.<sup>▲</sup>
- In individuals with sensitization (or symptoms) related to exposure to identified indoor allergens, conditionally recommend a multi-component allergen-specific mitigation strategy.<sup>▲</sup>
- In individuals with sensitization (or symptoms) related to exposure to dust mites, conditionally recommend impermeable pillow/mattress covers only as part of a multicomponent allergen-specific mitigation intervention, but not as a single component intervention.<sup>▲</sup>

**Notes**

- The terms ICS-LABA and ICS-formoterol indicate combination therapy with both an ICS and a LABA, usually and preferably in a single inhaler.
- Where formoterol is specified in the steps, it is because the evidence is based on studies specific to formoterol.
- In individuals ages 5–11 years with persistent allergic asthma in which there is uncertainty in choosing, monitoring, or adjusting anti-inflammatory therapies based on history, clinical findings, and spirometry, FeNO measurement is conditionally recommended as part of an ongoing asthma monitoring and management strategy that includes frequent assessment.

FIGURE 25.7 CONT'D

## Stepwise approach for management of asthma in individuals ages 12 years and older

		Management of persistent asthma in individuals ages 12+ years					
		Step 1	Step 2	Step 3	Step 4	Step 5	Step 6 <sup>a</sup>
Treatment	Intermittent asthma						
	Preferred	PRN SABA	Daily low-dose ICS and PRN SABA or PRN concomitant ICS and SABA <sup>Δ</sup>	Daily and PRN combination low-dose ICS-formoterol <sup>Δ</sup>	Daily and PRN combination medium-dose ICS-formoterol <sup>Δ</sup>	Daily medium-high dose ICS-LABA + LAMA and PRN SABA <sup>Δ</sup>	Daily high-dose ICS-LABA + oral systemic corticosteroids + PRN SABA
Alternative	Preferred						
	Alternative	Daily LTRA <sup>*</sup> and PRN SABA or Cromolyn, <sup>*</sup> or Nedocromil, <sup>*</sup> or Zileuton, <sup>*</sup> or Theophylline, <sup>*</sup> and PRN SABA	Daily medium-dose ICS and PRN SABA or Daily low-dose ICS-LABA, or daily low-dose ICS + LAMA, <sup>Δ</sup> or daily low-dose ICS + LTRA, <sup>*</sup> and PRN SABA or Daily low-dose ICS + Theophylline <sup>*</sup> or Zileuton, <sup>*</sup> and PRN SABA	Daily medium-dose ICS-LABA or daily medium-dose ICS + LAMA, and PRN SABA <sup>Δ</sup> or Daily medium-dose ICS + LTRA, <sup>*</sup> or daily medium-dose ICS + Theophylline, <sup>*</sup> or daily medium-dose ICS + Zileuton, <sup>*</sup> and PRN SABA	Daily medium-high dose ICS-LABA or daily high-dose ICS + LTRA, <sup>*</sup> and PRN SABA		
		Steps 2–4: Conditionally recommend the use of subcutaneous immunotherapy as an adjunct treatment to standard pharmacotherapy in individuals ≥ 5 years of age whose asthma is controlled at the initiation, buildup, and maintenance phases of immunotherapy <sup>Δ</sup>				Consider adding asthma biologics (e.g., anti-IgE, anti-IL5, anti-IL5R, anti-IL4/IL13)**	
<b>Assess control</b>							
<ul style="list-style-type: none"> <li>• First check adherence, inhaler technique, environmental factors, <sup>Δ</sup> and comorbid conditions.</li> <li>• <b>Step up</b> if needed; reassess in 2–6 weeks</li> <li>• <b>Step down</b> if possible (if asthma is well controlled for at least 3 consecutive months)</li> </ul> <p>Consult with asthma specialist if step 4 or higher is required. Consider consultation at step 3.</p> <p>Control assessment is a key element of asthma care. This involves both impairment and risk. Use of objective measures, self-reported control, and health care utilization are complementary and should be employed on an ongoing basis, depending on the individual's clinical situation.</p>							

**FIGURE 25.8**

Stepwise approach for managing asthma in youths 12 years and older. (Modified from National Asthma Education and Prevention Program [NAEPP]— 2020 Focused Updates to the Asthma Management Guidelines. December 2020.)

**Abbreviations:** ICS, inhaled corticosteroid; LABA, long-acting beta<sub>2</sub>-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; SABA, inhaled short-acting beta<sub>2</sub>-agonist

- ▲ Updated based on the 2020 guidelines.
- \* Cromolyn, Nedocromil, LTRAs including Zileuton and montelukast, and Theophylline were not considered for this update, and/or have limited availability for use in the United States, and/or have an increased risk of adverse consequences and need for monitoring that make their use less desirable. The FDA issued a boxed warning for montelukast in March 2020.
- \*\* The AHRQ systematic reviews that informed this report did not include studies that examined the role of asthma biologics (e.g. anti-IgE, anti-IL5, anti-IL5R, anti-IL4/IL13). Thus, this report does not contain specific recommendations for the use of biologics in asthma in steps 5 and 6.
- Data on the use of LAMA therapy in individuals with severe persistent asthma (step 6) were not included in the AHRQ systematic review and thus no recommendation is made.

### Notes for individuals ages 12+ years diagram

<b>Quick-relief medications</b>	<ul style="list-style-type: none"> <li>• Use SABA as needed for symptoms. The intensity of treatment depends on the severity of symptoms: Up to 3 treatments at 20-minute intervals as needed.</li> <li>• In steps 3 and 4, the preferred option includes the use of ICS-formoterol 1 to 2 puffs as needed up to a maximum total daily maintenance and rescue dose of 12 puffs (54 mcg).▲</li> <li>• <b>Caution:</b> Increasing use of SABA or use &gt;2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and may require a step up in treatment.</li> </ul>
<b>Each step:</b> Assess environmental factors, provide patient education, and manage comorbidities ▲	<ul style="list-style-type: none"> <li>• In individuals with sensitization (or symptoms) related to exposure to pests‡: Conditionally recommend integrated pest management as a single or multicomponent allergen-specific mitigation intervention.▲</li> <li>• In individuals with sensitization (or symptoms) related to exposure to identified indoor allergens, conditionally recommend a multi-component allergen-specific mitigation strategy.▲</li> <li>• In individuals with sensitization (or symptoms) related to exposure to dust mites, conditionally recommend impermeable pillow/mattress covers only as part of a multicomponent allergen-specific mitigation intervention, but not as a single component intervention.▲</li> </ul>
<b>Notes</b>	<ul style="list-style-type: none"> <li>• The terms ICS-LABA and ICS-formoterol indicate combination therapy with both an ICS and a LABA, usually and preferably in a single inhaler.</li> <li>• Where formoterol is specified in the steps, it is because the evidence is based on studies specific to formoterol.</li> <li>• In individuals ages 12 years and older with persistent allergic asthma in which there is uncertainty in choosing, monitoring, or adjusting antiinflammatory therapies based on history, clinical findings, and spirometry, FeNO measurement is conditionally recommended as part of an ongoing asthma monitoring and management strategy that includes frequent assessment.</li> <li>• Bronchial thermoplasty was evaluated in step 6. The outcome was a conditional recommendation against the therapy.</li> </ul>

FIGURE 25.8 CONT'D

5. Consider specialist referral for formal PFT's, monitoring, and indoor allergen-mitigation strategies for sensitized children.

## **IV. BRONCHIOLITIS**<sup>20-27</sup>

### **A. Definition**

1. Lower respiratory tract infection common in infants and children aged 2 years and younger
2. Characterized by acute inflammation, edema, and necrosis of airway epithelium, leading to increased mucus production and bronchospasm
3. Most commonly caused by respiratory syncytial virus (RSV) but can also be seen with other viruses, including human rhinovirus, parainfluenza, adenovirus, mycoplasma, and human metapneumovirus

### **B. Clinical Presentation**

1. Rhinitis and cough, which may progress to tachypnea, wheezing, rales, use of accessory muscles, and/or nasal flaring. Transient apnea may also be seen.
2. Radiographic findings: Hyperinflation and atelectasis
3. Radiographs and viral testing should NOT be routinely obtained.

### **C. Treatment**

Mainstay is supportive care.

1. Assess risk factors for severe disease, such as age less than 12 weeks, a history of prematurity, underlying cardiopulmonary disease, or immunodeficiency.
2. Clinicians should NOT administer albuterol, epinephrine, systemic corticosteroids, or chest physiotherapy to previously healthy infants and children with a first-time diagnosis of bronchiolitis. Antibiotics should be administered only for concomitant bacterial infection.
3. Nebulized hypertonic saline may be considered for hospitalized patients but should not be administered as a therapy in emergency department settings.
4. Clinicians may choose to not give supplemental oxygen therapy if saturations are greater than 90% or use continuous pulse oximetry for monitoring if not requiring oxygen therapy.
5. Nasogastric or intravenous fluid is necessary when infant is unable to maintain oral hydration.
6. There is insufficient evidence to recommend or go against nasal suctioning as a way to clear upper airway obstruction resulting from mucus production. Deep suctioning can cause airway trauma and is not recommended because of the potential to lengthen hospitalization.<sup>23</sup>
7. Heated humidified high-flow nasal cannula oxygen may decrease work of breathing and need for escalation of care in children at risk for progression to respiratory failure, but conflicting data exist.<sup>22,27</sup>
8. RSV immunoprophylaxis with palivizumab is recommended for high-risk infants (see [Chapter 16](#)).

**V. BRONCHOPULMONARY DYSPLASIA (BPD)<sup>28-33</sup>****A. Definition**

1. Also known as chronic lung disease of prematurity or neonatal chronic lung disease and is due to disruption of pulmonary development
2. Chronic pulmonary condition that usually evolves after premature birth, characterized by the need for oxygen supplementation >21% for at least 28 days after birth
3. Thought to be a result of airway inflammation, damage from hyperoxia, hypoxia, or mechanical ventilation; results in interference with normal lung alveolar, airway, and vascular development
4. Risk factors: Prematurity, IUGR, maternal smoking, perinatal infection, mechanical ventilation, supplemental oxygen requirement

**B. Clinical Presentation**

Children with BPD may have persistent respiratory symptoms, airway hyperreactivity, and supplemental oxygen requirements, especially during intercurrent illness. Respiratory disease may persist into adulthood for a subset of individuals.

**C. Diagnosis**

Severity based on oxygen requirement at time of assessment and characterized as mild if on room air, moderate if requiring <30% oxygen, or severe if requiring >30% oxygen and/or positive pressure.

1. If gestational age at birth <32 weeks: Assess infant at 36 weeks' postmenstrual age or at discharge to home, whichever comes first.
2. If gestational age at birth >32 weeks: Assess infant at 28 to 56 days postnatal age or at discharge to home, whichever comes first.

**D. Treatment**

1. Children with BPD often require some combination of the following for their lung disease: Bronchodilators, antiinflammatory agents (corticosteroids), supplemental oxygen therapy, diuretics, tracheostomy and prolonged mechanical ventilation for severe cases, RSV prophylaxis (see [Chapter 16](#) for indications).
2. Minimize further lung damage and promote healing by ensuring adequate nutrition given increased caloric needs, carefully monitor fluid status, use low tidal volumes with mechanical ventilation, set oxygen goals per gestational age, and prioritize weaning respiratory support.
3. Children with BPD need close monitoring for complications, which can affect additional organ systems: Pulmonary or systemic hypertension, electrolyte abnormalities, nephrocalcinosis (from chronic diuretics), neurodevelopmental or growth delay, sleep-disordered breathing, aspiration from dysphagia and/or GER, more severe infections with RSV or influenza.

**VI. CYSTIC FIBROSIS (CF)**<sup>34-46</sup>**A. Definition**

Autosomal recessive disorder in which mutations of the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene reduce the function of a chloride channel that usually resides on the surface of epithelial cells in the airways, pancreatic ducts, biliary tree, intestine, vas deferens, and sweat glands, resulting in progressive obstructive pulmonary disease and pancreatic exocrine insufficiency

**B. Clinical Manifestations (Fig. 25.9)****C. Diagnosis (Fig. 25.10)**

Diagnosing CF is a multistep process; a complete evaluation involves the following:


1. Newborn screening (NBS): Utilizes blood immunoreactive trypsinogen (IRT) level and/or *CFTR* gene mutation analysis
2. Quantitative pilocarpine iontophoresis (sweat chloride) test: Gold standard for diagnosis. False-positive results can be seen in untreated adrenal insufficiency, glycogen storage disease type 1, fucosidosis, hypothyroidism, nephrogenic diabetes insipidus, ectodermal dysplasia, malnutrition, mucopolysaccharidosis, and panhypopituitarism.
3. Genetic analysis: Over 2500 *CFTR* gene mutations have been described. *CFTR* gene sequencing can be performed if a variant is not identified on the *CFTR* mutation screening pane.
4. Comprehensive medical history, family history, and physical exam.

**D. Treatment**


Patients with CF should be managed within a CF Foundation–accredited care center. Current annual care recommendations are four office visits, four respiratory cultures, and two PFTs.

**1. Pulmonary**

- a. Airway clearance therapy to mobilize airway secretions and facilitate expectoration: Often manual/mechanical percussion and postural drainage. Older children may use high-frequency chest wall oscillation, mechanical chest percussors, or oscillatory positive expiratory pressure (PEP) handheld devices.
- b. Aerosolized medications to enhance mucociliary clearance: Recombinant human DNAase (dornase alfa) and aerosolized hypertonic saline to hydrate airway mucus and stimulate cough.
- c. Chronic antibiotics: If *Pseudomonas aeruginosa* is persistently present in airway cultures, consider chronic aerosolized antibiotic. Chronic azithromycin therapy has been shown to decrease exacerbations.
- d. *CFTR* modulator therapy: Effective for patients with specific mutations that produce *CFTR* protein. Can be used in combination. See [Table 25.3](#) and Formulary for dosing.

**FIGURE 25.9**

Clinical manifestations of cystic fibrosis. (Modified from Kliegman R. *Nelson Essentials of Pediatrics*. Elsevier Saunders; 2019.)

**FIGURE 25.10**

Diagnosis of cystic fibrosis. *CF*, Cystic fibrosis; *CFTR*, cystic fibrosis transmembrane conductance regulator; *ICM*, intestinal current measurement; *MVCC*, mutation of varying clinical consequence; *NBS*, newborn screen; *NPD*, nasal potential difference. (Modified from Farrell DW, White TB, Ren CL, et al. Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation. *J Pediatr*. 2017;181S:S4-S15.e1. <https://doi.org/10.1016/j.jpeds.2016.09.064>)

- e. Intermittent use of IV antibiotics when hospitalized for exacerbations. Common bacteria that cause exacerbations include *P. aeruginosa* and *Staphylococcus aureus*. No current consensus regarding antibiotic choice, dosing, or duration
- f. Allergic bronchopulmonary aspergillosis (ABPA) treatment: Oral corticosteroids, antifungal therapy can be a helpful adjunct therapy
- g. Lung transplantation

TABLE 25.3

## CFTR MODULATORS

CFTR Modulator	Indications	Therapeutic Approach
Kalydeco (ivacaftor tablets and oral granules)	Patients at least 4 months or older Must have one mutation in the <i>CFTR</i> gene or one of 97 specified mutations, as noted in the prescribing information	CFTR Potentiator
Orkambi (lumacaftor/ivacaftor tablets)	Patients at least 2 years of age or older Must be homozygous for F508del mutation in the <i>CFTR</i> gene	Corrector + Potentiator
Symdeko (tezacaftor/ivacaftor and ivacaftor tablets)	Patients at least age 6 years or older Must be homozygous for the F508del mutation or have one of 154 specified mutations as noted in the prescribing information	Corrector + Potentiator
Trikafda (elexacaftor/tezacaftor/ivacaftor and ivacaftor tablets)	Patients aged 6 years and older Must have at least one copy of the F508del mutation or one of 177 specified mutations as noted in the prescribing information	Potentiator + Corrector + Corrector

*CFTR*, Cystic fibrosis transmembrane conductance regulator.

Data from prescriber information from Trikafta, Kalydeco, Orkambi, Symdeko (<sup>44,45,46</sup>).

## 2. Extrapulmonary

- a. Pancreatic and liver disease
  - (1) Pancreatic enzyme replacement therapy prior to meals to improve digestion and intestinal absorption of dietary protein and fat
  - (2) Fat-soluble vitamin A, D, E, and K supplementation
  - (3) Nutritional supplementation to maintain body mass index (BMI)  $\geq$ 50th percentile
  - (4) Monitoring for CF-related diabetes or liver disease
- b. Infertility
  - (1) Men have absence of the vas deferens; however, assisted fertilization is possible using aspiration of viable sperm from testes.
  - (2) Women who are healthy have relatively normal fertility.
- c. Decreased life expectancy. Survival continues to improve, and median predicted survival age is more than 48 years.

## VII. OBSTRUCTIVE SLEEP APNEA SYNDROME (OSAS)<sup>47-53</sup>

### A. Definition

Disorder of breathing during sleep characterized by prolonged partial upper airway obstruction and/or intermittent complete obstruction that disrupts normal ventilation during sleep and normal sleep patterns

## B. Clinical Presentation

1. Nighttime symptoms: Habitual snoring  $\pm$  intermittent pauses in breathing, increased respiratory effort, sleepwalking, enuresis, and/or sweating
2. Daytime symptoms: Inattention, learning problems, and behavioral issues. Young children rarely present with daytime sleepiness.
3. Long-term complications: Neurocognitive impairment, behavioral problems, poor growth, cardiac dysfunction, systemic and pulmonary hypertension
4. Risk factors: Adenotonsillar hypertrophy, obesity, family history of OSAS, craniofacial or laryngeal anomalies, prematurity, nasal/pharyngeal inflammation, cerebral palsy, neuromuscular disease

## C. Diagnosis

1. All children and adolescents should be routinely screened for snoring.
2. If a child snores on a regular basis and has any of the complaints or findings shown in [Box 25.1](#), clinicians should obtain a polysomnogram or, if polysomnography is not available, refer the patient to a sleep specialist or otolaryngologist for more extensive evaluation.
3. Polysomnography criteria for OSAS diagnosis (one of the following):
  - a. One or more obstructive or mixed apnea or hypopnea events per hour (AHI  $\geq 1$ ).

### BOX 25.1

#### SYMPTOMS AND SIGNS OF OBSTRUCTIVE SLEEP APNEA SYNDROME

##### I. History

Frequent snoring ( $\geq 3$  nights/week)  
 Labored breathing during sleep  
 Gaspings/snorting noises or observed episodes of apnea  
 Mouth breathing  
 Sleep enuresis (especially secondary enuresis)  
 Sleeping in a seated position or with the neck hyperextended  
 Cyanosis  
 Headache on awakening  
 Daytime sleepiness  
 Attention-deficit/hyperactivity disorder  
 Learning problems

##### II. Physical Examination

Underweight or overweight  
 Tonsillar hypertrophy  
 Adenoidal facies  
 Micrognathia/retrognathia  
 High-arched palate  
 Failure to thrive  
 Hypertension

Modified from Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics*. 2012;130:575–584.

- b. Obstructive hypoventilation ( $\text{PaCO}_2 > 50$  mmHg) for  $> 25\%$  of sleep time coupled with snoring, paradoxical thoracoabdominal movement, or flattening of nasal airway pressure waveform
4. No standard severity classifications but commonly classified as mild, moderate, or severe based on number of AHI events

#### D. Treatment

1. Adenotonsillectomy is recommended as first-line treatment of patients with OSAS documented with an overnight polysomnogram, especially adenotonsillar hypertrophy present. Patients should be reevaluated postoperatively to determine whether further treatment is required.
  - a. High-risk children warrant a more comprehensive evaluation and postoperative admission for monitoring.
2. Watchful waiting for up to 6 months can be considered for otherwise healthy children with mild/moderate OSAS along with supportive care (sleep hygiene practices, nasal saline spray, treatment for allergies)
3. Continuous positive airway pressure is recommended as treatment if adenotonsillectomy is not performed or if OSAS persists postoperatively.
4. Weight loss for patients who are overweight or obese
5. Intranasal corticosteroids may be considered for children with mild OSAS. Follow-up is needed to assess symptoms and monitor possible adverse effects of long-term intranasal steroids. Oral leukotriene inhibitor (e.g., montelukast) can also be considered.
6. Rapid maxillary expansion (RME) and use of a mandibular advancement device can be used to increase upper airway patency in children with certain orofacial features.
7. Craniofacial surgery and tracheostomy are reserved for severe cases in children with syndromic craniofacial abnormalities.

### VIII. INFANT AND CHILD SLEEP<sup>53-54</sup>

#### A. Sleep Duration

1. Recommended average sleep duration varies by age (Table 25.4).
2. Sleep concerns are common in childhood. Inadequate or poor-quality sleep can have negative impacts on health, behavior, and learning.
  - a. Chronic sleep insufficiency is associated with increased risk of obesity, depression, hypertension, diabetes, and poor academic performance.
3. See online content for a discussion of common childhood sleep disorders.

#### B. Sleep-Related Infant Death<sup>55-58</sup>

##### 1. Definition

- a. Sleep-related infant death: Sudden unexplained infant death (SUID) that occurs during an observed or unobserved sleep period
- b. Sudden infant death syndrome (SIDS): Cause assigned to infant death that cannot be explained after thorough case investigation

##### 2. Epidemiology

- a. In 2020, the SUID rate was 92.9 deaths per 100,000 live births. Disproportionately affects African-American and Native American populations<sup>57</sup>

**TABLE 25.4****RECOMMENDED AVERAGE SLEEP DURATION**

Age Group	Duration of Sleep (Per 24 Hours)
Infants (4–12 months)	12–16 hours <sup>a</sup>
Toddlers (1–2 years)	11–14 hours <sup>a</sup>
Preschool-aged children (3–5 years)	10–13 hours <sup>a</sup>
School-aged children (6–12 years)	9–12 hours
Teenagers (13–18 years)	8–10 hours

<sup>a</sup>Recommended sleep duration in 24-hour period includes naps.

Modified from Paruthi S, Brooks LJ, D'Ambrosio C, et al. Recommended amount of sleep for pediatric populations: a consensus statement of the American Academy of Sleep Medicine. *J Clin Sleep Med.* 2016;12(6):785–786.

- b. Peak incidence at 1 to 4 months, with 90% occurring before 6 months

### 3. Safe infant sleep

Most recent evidence-based safe infant sleep recommendations to reduce the risk of sleep-related infant death from the 2016 AAP guidelines include<sup>56</sup>:

- a. Back to sleep during every episode of sleep until age 1 year
- b. Using a firm sleep surface without soft objects or loose bedding
- c. Room-sharing with the infant on a separate surface, ideally for the first year of life, but at least for the first 6 months
- d. Avoidance of overheating and head covering
- e. Avoidance of alcohol, illicit drugs, and smoke exposure during pregnancy and after birth
- f. Protective factors that should be recommended: Regular prenatal care, breastfeeding, routine immunizations, offering pacifier at sleep times
- g. Modeling of safe sleep by healthcare providers/staff, daycare provides, and in advertising
- h. Home cardiorespiratory monitors should not be used as a strategy to reduce the risk of SIDS

## IX. BRIEF RESOLVED UNEXPLAINED EVENT (BRUE)<sup>58-59</sup>


### A. Definition

Formerly termed an *apparent life-threatening event (ALTE)*, a BRUE is defined as an event occurring in an infant younger than 1 year when the observer reports a sudden, brief (<1 minute), and now-resolved episode of at least one of the following:

1. Cyanosis or pallor
2. Absent, decreased, or irregular breathing
3. Marked change in tone (hyper- or hypotonia)
4. Altered level of responsiveness

### B. Differential Diagnosis

Differential diagnoses that should be evaluated for during the history and physical exam include gastroesophageal reflux (GER), seizure, nonaccidental

**FIGURE 25.11**

Algorithm for diagnosis, risk stratification, and management of BRUE. *CHD*, Congenital heart disease; *CPR*, cardiopulmonary resuscitation; *ECG*, electrocardiogram; *ED*, emergency department. (Modified from Tieder JS, Bonkowsky JL, Etzel RA, et al. AAP Clinical Practice Guideline: brief resolved unexplained events [formerly apparent life-threatening events] and evaluation of lower-risk infants. May 2016.)

trauma, cardiac arrhythmia, inborn errors of metabolism, and lower respiratory tract infection. If an explanation for the event is identified, then it is not a BRUE.

### C. Management

Algorithm for diagnosis, risk stratification, and management of patients with BRUE (Fig. 25.11)

## X. WEB RESOURCES

- American Lung Association: <https://www.lung.org>
- Cystic Fibrosis Foundation: <https://www.cff.org>

- American Academy of Allergy, Asthma and Immunology: <https://www.aaaai.org>
- National Heart Lung and Blood Institute: National Asthma Education and Prevention Program: <https://www.nhlbi.nih.gov>
- American Thoracic Society: <https://www.thoracic.org>
- American Academy of Sleep Medicine: <https://www.aasm.org>

## REFERENCES

A complete list of references can be found online.

**XI. ONLINE CONTENT****A. Evaluation of Pulmonary Gas Exchange**

Oxyhemoglobin dissociation curve (eFig. 25.1)

**B. Asthma**

Dosing of inhaled corticosteroids (eTable 25.1)

**C. Childhood Sleep Disorders<sup>44,45</sup>****1. Insomnia**

- a. Difficulty falling asleep, staying asleep, or both
- b. In younger children, the common behavioral insomnias of childhood include limit-setting (bedtime resistance) and sleep-onset association disorder (night wakings). Treatment includes bedtime limits and appropriate sleep hygiene.
- c. In older children, psychosocial or primary insomnia is characterized by excessive worry about sleep and the consequences of inadequate sleep. Managed with behavioral interventions.
- d. Insomnia can be secondary to another sleep or medical disorder. A comprehensive evaluation is required. Referral to a sleep specialist or behavioral psychologist may be useful.

**2. Nighttime fears**

- a. Common condition that is part of normal development and stems from cognitive development
- b. Characterized by tearful, fearful behavior at bedtime
- c. Relieved by sleeping with member of household
- d. Treatment involves reassurance, teaching coping skills, and security objects. Consider evaluation for anxiety disorder in older children/adolescents.

**3. Nightmares**

- a. Frightening dreams that result in awakening from sleep
- b. Part of normal development
- c. Peak at age 6 to 10 years
- d. May be reduced by reducing stressors, avoiding exposure to frightening images, and ensuring adequate sleep

**4. Delayed sleep phase syndrome**

- a. A circadian rhythm with a persistent, intractable shift in the sleep–wake cycle. Patients move to a late bedtime and late awakening.
- b. Seen most commonly in adolescent and young adults
- c. Patients have daytime sleepiness and tardiness/absenteeism when unable to sleep during the day.
- d. Treatment includes behavioral therapy, bright light exposure, and melatonin. Consider evaluation by a sleep specialist.

**5. Parasomnias**

- a. Common and benign disorders of arousal
- b. Include sleepwalking, night terrors, and confusional arousals
- c. Onset typically at age 4 to 6 years and usually disappear by adolescence
- d. Characterized by agitation and confusion. Child avoids comfort and does not recall event.
- e. Usually occur in the first few hours of the night
- f. Treatment involves keeping child safe, ensuring adequate sleep, and avoiding triggers. Discourage parental intervention during an episode.

eTABLE 25.1

## ESTIMATED COMPARATIVE DAILY DOSAGES FOR INHALED CORTICOSTEROIDS

ICS	Strength	<12 Years Old			≥12 Years Old		
		Low Dose	Medium Dose	High Dose	Low Dose	Medium Dose	High Dose
Beclomethasone/QVar MDI	40 mCg	2–4 puffs/day	5–8 puffs/day	>8 puffs/day	2–6 puffs/day	7–12 puffs/day	>12 puffs/day
	80 mCg	1–2 puffs/day	3–4 puffs/day	>4 puffs/day	1–3 puffs/day	3–6 puffs/day	>6 puffs/day
Budesonide/Pulmicort DPI Flexhaler	90 mCg	2–4 puffs/day	4–8 puffs/day	>8 puffs/day	2–6 puffs/day	7–12 puffs/day	>12 puffs/day
	180 mCg	1–2 puffs/day	2–4 puffs/day	>4 puffs/day	1–3 puffs/day	4–6 puffs/day	>6 puffs/day
Ciclesonide	80 mCg/actuation	<i>See Formulary remarks for ciclesonide</i>			1 puff BID	2 puffs BID	4 puffs BID
	160 mCg/actuation	<i>See Formulary remarks for ciclesonide</i>			N/A	1 puff BID	2 puffs BID
Budesonide/Pulmicort Respule	0.25 mg neb	2 nebs/day	4 nebs/day	8 nebs/day	N/A	N/A	N/A
	0.5 mg neb	1 neb/day	2 nebs/day	4 nebs/day	N/A	N/A	N/A
Flunisolide/Aerospan MDI	80 mCg	2 puffs/day	4 puffs/day	>8 puffs/day	4 puffs/day	5–8 puffs/day	>8 puffs/day
	250 mCg	2–3 puffs/day	4–5 puffs/day	>5 puffs/day	2–4 puffs/day	5–8 puffs/day	>8 puffs/day
Fluticasone/Flovent MDI	44 mCg	2–4 puffs/day	5–8 puffs/day	>8 puffs/day	2–6 puffs/day	7–10 puffs/day	>10 puffs/day
	110 mCg	1 puff/day	2–3 puffs/day	>3 puffs/day	1–2 puffs/day	3–4 puffs/day	>4 puffs/day
	220 mCg	N/A	1 puff/day	>1 puff/day	1 puff/day	2 puffs/day	>2 puffs/day
Fluticasone/Flovent Diskus DPI	50 mCg	2–4 puffs/day	5–8 puffs/day	>8 puffs/day	2–6 puffs/day	7–10 puffs/day	>10 puffs/day
	100 mCg	1–2 puffs/day	2–4 puffs/day	>4 puffs/day	1–3 puffs/day	4–5 puffs/day	>5 puffs/day
	250 mCg	N/A	1 puff/day	>1 puff/day	1 puff/day	2 puffs/day	>2 puffs/day
Mometasone/Asmanex Twisthaler	220 mCg	N/A	N/A	N/A	1 puff	2 puffs	>2 puffs
<b>COMBINATION DRUGS: ICS + LABA<sup>a</sup></b>							
Fluticasone/Salmeterol MDI (Advair)	45/21 mCg	2 puffs/day	2–3 puffs/day	4 puffs/day	2 puffs/day	3–4 puffs/day	
	115/21 mCg		2 puffs/day	2–4 puffs/day	2 puffs/day	2 puffs/day	3–4 puffs/day
	230/21 mCg			2–4 puffs/day			3–4 puffs/day

TABLE 25.1

## ESTIMATED COMPARATIVE DAILY DOSAGES FOR INHALED CORTICOSTEROIDS—CONT'D

ICS	Strength	<12 Years Old			≥12 Years Old		
		Low Dose	Medium Dose	High Dose	Low Dose	Medium Dose	High Dose
Fluticasone/Salmeterol Diskus DPI (Advair)	100/50 mCg	1 puff/day	2 puffs/day	2 puffs/day		2 puffs/day	
	250/50 mCg			2 puffs/day		1 puff/day	2 puffs/day
	500/50 mCg			2 puffs/day			2 puffs/day
Budesonide/Formoterol (Symbicort)	80/4.5 mCg MDI	1–2 puffs/day	2–4 puffs/day		1–3 puffs/day	4 puffs/day	
	160/4.5 mCg MDI		1–2 puffs/day	2–4 puffs/day		2 puffs/day	4 puffs/day
Mometasone/Formoterol (Dulera)	100 mCg mometasone + 5 mcg formoterol	<i>No dosing information currently available for &lt;12 yr</i>			N/A	2 puffs BID	N/A
	200 mCg mometasone + 5 mCg formoterol	<i>No dosing information currently available for &lt;12 yr</i>			N/A	N/A	2 puffs BID

\*For ICS + LABA combination drugs, patient should not take more than two puffs per dose of the MDI, one puff per dose of the DPI, or two doses per day.

DPI, Dry powder inhaler; ICS, inhaled corticosteroid; LABA, long-acting  $\beta$ -agonist; MDI, metered-dose inhaler.

Data from Expert Panel Report III. Guidelines for the diagnosis and management of asthma—full report 2007; National Institutes of Health Pub. No. 08-4051. National Asthma Education and Prevention Program; 2007.

## REFERENCES

1. Murray CB, Loughlin GM. Making the most of pulse oximetry. *Contemp Pediatr*. 1995;12:45–52, 55–57, 61–62.
2. Salyer JW. Neonatal and pediatric pulse oximetry. *Respir Care*. 2003;48:386–396; discussion 397–398.
3. Taussig L. *Pediatric Respiratory Medicine*. 2nd ed. Mosby; 2008.
4. Falk JL, Rackow EC, Weil MH. End-tidal carbon dioxide concentration during cardiopulmonary resuscitation. *N Engl J Med*. 1988;318:607–611.
5. Ornato JP, Shipley JB, Racht EM, et al. Multicenter study of a portable, hand-size colorimetric end-tidal carbon dioxide detection device. *Ann Emerg Med*. 1992;21:518–523.
6. Malatesha G, Singh NK, Bharija A, et al. Comparison of arterial and venous pH, bicarbonate, PCO<sub>2</sub> and PO<sub>2</sub> in initial emergency department assessment. *Emerg Med J*. 2007;24:569–571.
7. Courtney SE, Weber KR, Breakie LA, et al. Capillary blood gases in the neonate: a reassessment and review of the literature. *Am J Dis Child*. 1990;144(2):168–172.
8. Yöldözda D, Yapöcöoğlu H, Yölmaz HL, et al. Correlation of simultaneously obtained capillary, venous, and arterial blood gases of patients in a paediatric intensive care unit. *Arch Dis Child*. 2004;89:176–180.
9. Schrier RW. *Renal and Electrolyte Disorders*. 7th ed. Wolters Kluwer/Lippincott Williams & Wilkins; 2010.
10. Brenner BM, ed. *Brenner & Rector's the Kidney*. 8th ed. Saunders; 2007.
11. Lambertsen CJ. Transport of oxygen, CO<sub>2</sub>, and inert gases by the blood. In: Mountcastle VB, ed. *Medical Physiology*. 14th ed. Mosby; 1980.
12. National Asthma Education and Prevention Program (NAEPP)—Expert Panel Report 3. *Guidelines for the Diagnosis and Management of Asthma*; 2007. <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>
13. Expert Panel Working Group of the National Heart, Lung and Blood Institute. 2020 Focused updates to the asthma management guidelines: a report from the National asthma Education and prevention Program Coordinating Committee Expert Panel working Group. *J Allergy Clin Immunol*. 2020;146:1217–1270.
14. Yoos HL, Kitzman H, McMullen A, et al. Symptom monitoring in childhood asthma: a randomized clinical trial comparing peak expiratory flow rate with symptom monitoring. *Ann Allergy Asthma Immunol*. 2002;88:283–291.
15. Panitch HB. The pathophysiology of respiratory impairment in pediatric neuromuscular diseases. *Pediatrics*. 2009;123(suppl 4):S215–S218.
16. Domènech-Clar R, López-Andreu JA, Compte-Torrero L, et al. Maximal static respiratory pressures in children and adolescents. *Pediatr Pulmonol*. 2003;35:126–132.
17. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J*. 2005;26:319.
18. Hyatt RE, Scanlon PD, Nakamura M. *Interpretation of Pulmonary Function Tests. A Practical Guide*. 4th ed. Lippincott Williams & Wilkins; 2004.
19. Global Initiative for Asthma. *Global Strategy for Asthma Management and Prevention*; 2021. <https://www.ginasthma.org>
20. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. *Pediatrics*. 2014;134:e1474–e1502.
21. Silver AH, Nazif JM. Bronchiolitis. *Pediatr Rev*. 2019;40(11):568–576.

22. Riese J, Porter T, Fierce J, Riese A, et al. Clinical outcomes of bronchiolitis after implementation of a general ward high flow nasal cannula guideline. *Hosp Pediatr*. 2017;7(4):197–203.
23. Mussman GM, Parker MW, Statile A, et al. Suctioning and length of stay in infants hospitalized with bronchiolitis. *JAMA Pediatr*. 2013;167(5):414–421. <https://doi.org/10.1001/jamapediatrics.2013.36>
24. Zhang L, Mendoza-Sassi RA, Wainwright C, et al. Nebulized hypertonic saline solution for acute bronchiolitis in infants. *Cochrane Database Syst Rev*. 2008;4:CD006458.
25. Florin TA, Shaw KN, Kittick M, et al. Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial. *JAMA Pediatr*. 2014;168(7):664–670.
26. Sharma BS, Gupta MK, Rafik SP. Hypertonic (3%) saline vs 0.93% saline nebulization for acute viral bronchiolitis: a randomized controlled trial. *Indian Pediatr*. 2013;50(8):743–747.
27. Franklin D, Babl FE, Schlapbach LJ, et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. *N Engl J Med*. 2018;378(12):L1121–L1131.
28. Kair L, Leonard D, Anderson J. Bronchopulmonary dysplasia. *Pediatr Rev*. 2012;33(6):255–264.
29. Jobe A, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med*. 2001;163:1723–1729.
30. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. *J Pediatr*. 2005;116:1353–1360.
31. Davidson LM, Berkelhamer SK. Bronchopulmonary dysplasia: chronic lung disease of infancy and long-term pulmonary outcomes. *J Clin Med*. 2017;6(1):4. <https://doi.org/10.3390/jcm6010004>
32. Abman SH, Collaco JM, Shepherd EG, et al. Bronchopulmonary dysplasia collaborative. Interdisciplinary care of children with severe bronchopulmonary dysplasia. *J Pediatr*. 2017;181:12–28.e1. <https://doi.org/10.1016/j.jpeds.2016.10.082>
33. Higgins RD, Jobe AH, Koso-Thomas M, et al. Bronchopulmonary dysplasia: executive summary of a workshop. *J Pediatr*. 2018;197:300–308. <https://doi.org/10.1016/j.jpeds.2018.01.043>
34. Dickinson KM, Collaco JM. Cystic fibrosis. *Pediatr Rev*. 2021;42(2):55–67.
35. Farrell DW, White TB, Ren CL, et al. Diagnosis of cystic fibrosis: Consensus guidelines from the cystic fibrosis foundation. *J. Pediatr*. 2017;181S:S4–S15.e1. <https://doi.org/10.1016/j.jpeds.2016.09.064>
36. Mogayzel Jr PJ, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. *Am J Respir Crit Care Med*. 2013;187:680–689.
37. Flume PA, Mogayzel Jr PK, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. *Am J Respir Crit Care Med*. 2009;80:802–808.
38. Grasemann H. CFTR modulator therapy for cystic fibrosis. *N Engl J Med*. 2017;377(21):2085–2088.
39. Ren CL, Morgan RL, Oermann C, et al. Cystic fibrosis pulmonary guidelines: use of CFTR modulator therapy in patients with cystic fibrosis. *Ann Am Thorac Soc*. 2018;15:271–280.
40. Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. *Thorax*. 2016;71:1–22.

41. Borowitz D, Baker RD, Stallings V, et al. Consensus report on nutrition for pediatric patients with cystic fibrosis. *J Pediatr Gastroenterol Nutr.* 2002;35:246–259.
42. Cystic Fibrosis Foundation. *Cystic Fibrosis Foundation Patient Registry.* 2018 Annual Data Report; 2020.
43. US Food and Drug Administration. Highlights of prescribing information for Trikafta, 10/2021. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/212273s008lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s008lbl.pdf)
44. US Food and Drug Administration. Highlights of prescribing information for Kalydeco (ivacaftor), 12/2020. [https://pi.vrtx.com/files/uspi\\_ivacaftor.pdf](https://pi.vrtx.com/files/uspi_ivacaftor.pdf)
45. US Food and Drug Administration. Highlights of prescribing information for SYMDEKO, 12/2020. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/210491s007lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210491s007lbl.pdf)
46. US Food and Drug Administration. Highlights of prescribing information for Orkambi (lumacaftor/ivacaftor), Published 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/206038s007lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206038s007lbl.pdf)
47. American Academy of Sleep Medicine. *ICSD-3, International Classification of Sleep Disorders: Diagnostic and Coding Manual.* 3rd ed. 2014.
48. Dehlink E, Tan HL. Update on paediatric obstructive apnoea. *J Thorac Dis.* 2016;8:224–235.
49. Fehrm J, Nerfeldt P, Browaldh N, Friberg D. Effectiveness of adenotonsillectomy vs watchful waiting in young children with mild to moderate obstructive sleep apnea: a randomized clinical trial. *JAMA Otolaryngol Head Neck Surg.* 2020;146(7):647–654. <https://doi.org/10.1001/jamaoto.2020.0869>
50. Giuca MR, Carli E, Lardani L, et al. Pediatric obstructive sleep apnea syndrome: emerging evidence and treatment approach. *Sci World J.* 2021;2021:5591251. <https://doi.org/10.1155/2021/5591251>
51. Bitners AC, Arens R. Evaluation and management of children with obstructive sleep apnea syndrome. *Lung.* 2020;198(2):257–270. <https://doi.org/10.1007/s00408-020-00342-5>
52. AAP Clinical Practice Guideline. Diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics.* 2012;130:576–584.
53. Paruthi S, Brooks LJ, D'Ambrosio C, et al. Recommended amount of sleep for pediatric populations: a consensus statement of the American Academy of Sleep Medicine. *J Clin Sleep Med.* 2016;12(6):785–786.
54. Bhargava S. Diagnosis and management of common sleep problems in children. *Pediatr Rev.* 2011;32:91–98.
55. Mindel JA, Owens JA. *A Clinical Guide to Pediatric Sleep: Diagnosis and Management of Sleep Problems.* Lippincott Williams & Wilkins; 2003.
56. Task Force on Sudden Infant Death Syndrome, Moon RY. SIDS and other sleep-related infants deaths: evidence base for 2016 updated recommendations for a safe infant sleeping environment. *Pediatrics.* 2016;138:e20162940.
57. Centers for Disease Control and Prevention. 2020. *Sudden Unexpected Infant Death (SUID).* 2020. Centers for Disease Control and Prevention.
58. Behnam-Terneus M, Clemente M. SIDS, BRUE, and safe sleep guidelines. *Pediatr Rev.* 2019;40(9):443–455. <https://doi.org/10.1542/pir.2017-0259>
59. AAP Clinical Practice Guideline. Brief resolved unexplained events (formerly apparent life-threatening events) and evaluation of lower-risk infants. *Pediatrics.* 2016. <https://doi.org/10.1542/peds.2016-0591>

# Chapter 26

## Radiology

Urveel Mukesh Shah, MD

 See additional content online.

### I. GENERAL PEDIATRIC PRINCIPLES

#### A. Use Imaging Judiciously

1. Ionizing radiation is a carcinogen. Children are at increased risk of its effects given their potentially greater lifetime exposure, small size leading to greater penetration, and higher rates of cell division.<sup>1</sup>
2. Use evidence-based guidelines to inform appropriate imaging choice.<sup>1</sup>
3. See [Table 26.1](#) for relative radiation by imaging study.
4. Choose appropriate modality to obtain a diagnostic image while reducing unnecessary patient exposure to ionizing radiation.
5. Limit imaging to indicated areas to improve resolution and minimize unnecessary radiation exposure.
6. Provide adequate clinical background when ordering imaging studies to assist radiologist.

#### B. Terminology

1. Radiographs and computed tomography (CT): Fewer x-rays penetrate dense structures than structures that are less dense. In terms of density, air/gas < fat < fluid < soft tissue < bone < metal. Structures that are less dense than surrounding tissue appear darker on the radiograph (more

**TABLE 26.1**

#### COMPARATIVE RADIATION EXPOSURE

Radiation Source	mSv	Equivalent Chest X-Rays	Equivalent Flight Hours	Equivalent Background Radiation
CXR (single view)	0.01	1	3	1 day
Abdominal XR (2 views)	0.05	5	17	5 days
Chest CT	3	300	1000	12 months
Head CT	4	400	1300	16 months
Abdominal CT	5	500	1670	20 months

CT, Computed tomography; CXR, chest x-ray;

Data from Zitelli BJ, McIntire SC, Nowalk AJ, Garrison J. *Zitelli and Davis' Atlas of Pediatric Physical Diagnosis*. 8th ed. Elsevier; 2023; Image Gently. *What Parents Should Know About CT Scans for Children*. 2016; Flight Radiation Calculator. (n.d.). Updated January 10, 2023. <https://www.omnicalculator.com/other/flight-radiation>

x-rays pass through them). Structures that are denser than surrounding tissues appear whiter. More dense structures are referred to as higher in attenuation.

2. **Ultrasound:** Described with ability to reflect sound waves (echogenicity) compared to the tissue around them. The more echoes a structure demonstrates, the more sound waves are reflected. Anechoic (without echoes) structures are darker than hypoechoic structures, which are darker than hyperechoic structures. Fluid transmits sound well, so a bladder filled with urine can appear anechoic because the fluid transmits sound waves better than the soft tissues that surround the bladder. Air and gas have characteristically bright echoes because the air reflects sound waves.

## II. CHOOSING THE RIGHT STUDY

1. See [Table 26.2](#) for descriptions of imaging modalities.
2. **CT versus magnetic resonance imaging (MRI):** CT is often more readily available, can be performed quickly, and in most cases does not require sedation; however, CT raises safety concerns regarding radiation exposure. MRI uses nonionizing radiation and may require sedation due to longer imaging time.<sup>1</sup>
3. **Contrast:** Helps distinguish selected body areas from surrounding tissue. Oral and rectal contrast is used for bowel opacification. Intravenous contrast is used to opacify vessels and solid organs and can be helpful in cases of suspected infection/inflammation, malignancy, and trauma.

## III. HEAD

**Head ultrasound (HUS)** can be used for infants with open anterior fontanelles (up until about 6 months of age). **CT** is preferred for acute situations (e.g., trauma, hemorrhage) and for evaluating bone structure or calcifications. **MRI** offers better soft-tissue contrast and visualization of brain anatomy and is, therefore, preferred for most nontraumatic intracranial pathology. **MRI fast sequences** (such as ultrafast [UF] MRI) uses shorter sequences targeted for anatomic assessment of ventricular size and shunt position without requiring sedation. Does not allow for adequate delineation and diagnosis of other brain pathology<sup>1</sup>

### A. Head Trauma

1. **Preferred imaging:** Noncontrast head CT. Use the Pediatric Emergency Care Applied Research Network (PECARN) rules to decide whether imaging is indicated (see [Chapter 2](#)).<sup>2,3</sup>

### B. CSF Shunt Malfunction

1. **Preferred imaging:** Ultrafast brain MRI (UF MRI) and shunt series (radiographs evaluating shunt tubing course)
2. **Other imaging:** CT if UF MRI is not available or contraindicated

TABLE 26.2

## OVERVIEW OF IMAGING MODALITIES

Modality/Description	Ionizing Radiation	Advantages	Disadvantages/Limitations	Relative Cost
Conventional radiographs (CR) Uses x-rays to create 2D images based on density	Yes	Fast, portable, readily available	2D only, limited soft-tissue contrast	+
Ultrasound (US) Uses high-frequency sound waves to produce image, can evaluate blood flow with Doppler or contrast	No	Portable, real-time imaging, multiplanar	Operator dependent, limited in obese patients, poor penetration of air-filled viscera and bone, may require preparation (e.g., fasting or full bladder)	++
Computed tomography (CT) Uses multiple x-rays to produce cross-sectional image, delineates bones, soft tissue, calcifications	Yes	Fast, cross sectional, more detailed than CR, multiplanar capabilities	Uses ionizing radiation, rare potential side effects from intravenous contrast if used (anaphylaxis, nephrotoxicity)	+++
Magnetic resonance imaging (MRI) Uses motion of protons in magnetic fields, field gradients, and radio waves to produce detailed cross-sectional images	No	High resolution of soft tissue, multiplanar capabilities, dynamic applications	Lengthy, image quality may be degraded by motion, may require sedation in some patients, contraindicated for certain implantable devices	++++
Fluoroscopy Uses x-rays and contrast to evaluate dynamic processes	Yes	Real-time imaging	Requires contrast, high radiation dose	++
Nuclear medicine (commonly PET, Meckel scan, SPECT) Uses radioactive tracer to delineate patterns of concentration or elimination of tracer, can be superimposed with MRI or CT	Yes	Functional, dynamic capabilities, various studies may be paired with CT or MRI for improved spatial resolution	Uses ionizing radiation, may require sedation	++++

2D, Two dimensional; PET, positron emission tomography; SPECT, single photon emission computed tomography. Modified from Zitelli BJ, McIntire SC, Nowalk AJ, Garrison J. *Zitelli and Davis' Atlas of Pediatric Physical Diagnosis*. 8th ed. Elsevier; 2023.

### C. Orbital Cellulitis

1. **Preferred imaging:** Orbital contrast-enhanced CT (eFig. 26.1)<sup>4</sup>

## IV. NECK AND AIRWAY


**Conventional radiography (CR)** (anteroposterior (AP) and lateral neck views) are preferred initial imaging.<sup>5,6</sup>

### A. Normal Anatomy

1. Normal anatomy (Figs. 26.1 and 26.2)
2. Reading lateral C-spine radiographs
  - a. Must visualize skull base, C1 to C7, top of T1
  - b. Assess alignment on lateral radiograph by evaluating four curvilinear contour lines: anterior vertebral, posterior vertebral, spinolaminar, tips of spinous process (Fig. 26.3).
  - c. Evaluate vertebral bodies for fractures, displacement, subluxation, dislocations. Vertebral bodies should be similar/slightly increasing in height when descending below C2 (eFig. 26.2).
  - d. Evaluate prevertebral soft tissues.


### B. Cervical Spine Trauma

1. **Initial imaging:** CR, lateral and AP
2. **Other imaging:** MRI if high clinical suspicion of C-spine injury without CR findings




**FIGURE 26.1**

Anteroposterior neck radiograph with normal anatomy. Note, the vocal cords have a normal convex impression upon the subglottic airway resulting in rounded shoulders (arrow). (Modified from Blickman JG, Van Die L. *Pediatric Radiology: The Requisites*. 3rd ed. Elsevier; 2009, Fig. 2.17B.)




**eFIGURE 26.1**

Preseptal and postseptal cellulitis. (A) Axial contrast-enhanced computed tomography (CT) of orbits shows inflammation of the right preseptal soft tissues (*arrow*). There is also involvement of the medial extraconal postseptal soft tissues (*white arrowhead*). The medial rectus muscle is enlarged (*black arrowhead*) due to reactive myositis. Note partial ethmoid sinus (*black arrow*). (B) Coronal contrast-enhanced CT of a different patient also showing right medial postseptal cellulitis with a peripherally enhancing subperiosteal collection compatible with an abscess (*arrow*). Note again ethmoid sinusitis as the cause of orbital cellulitis. (From Donnelly LF. *Fundamentals of Pediatric Imaging*. 3rd ed. Elsevier; 2022, p. 308, Fig. 8.144.)

**eFIGURE 26.2**


Cervical spine fracture examples. Burst fracture of C5 in a 16-year-old girl. Lateral cervical spine radiograph shows a compression fracture of the body. There is demonstrated vertebral height loss, especially anteriorly, with deformity of inferior endplate and anterior aspect of the vertebral body. (Courtesy of Jonathan Martin, MD.)

**FIGURE 26.2**


Normal soft tissue lateral neck radiograph. The adenoids (*A*) are seen at the base of the skull and are adjacent to the nasopharyngeal airway (*N*). More distally is the pharynx (*P*). The epiglottis (*solid white arrow*) is bounded superiorly by air in the vallecula. The aryepiglottic folds are paired structures extending posteriorly from the epiglottis (*dotted white arrow*). The laryngeal ventricle (*black arrow*) separates the false vocal cords above from the true cords below. The trachea (*T*) starts below the true cords. The normal prevertebral soft tissue thickness is less than one-half the width of the adjacent vertebral body above *C3/C4* (\*) and less than the width of the adjacent vertebral body below *C3/C4* (\*\*). (Modified from Herring W. *Learning Radiology: Recognizing the Basics*. 3rd ed. Elsevier; 2016, Fig. 28.12.)

### C. Classic Findings of Upper Airway Conditions on Conventional Radiographs


1. Croup: AP and lateral radiographs with subglottic airway narrowing (*steep sign*) and dilation of hypopharynx. Evaluate for possible foreign bodies or subglottic airway masses (eFig. 26.3).
2. Epiglottitis: Enlarged, indistinct epiglottis on lateral radiograph (*thumbprint sign*) (eFig. 26.4)
3. Retropharyngeal abscess or pharyngeal mass: Soft tissue air or enlargement of prevertebral soft tissues not explained by neck flexion (eFig. 26.5)

**eFIGURE 26.3**


Croup. (A) Frontal radiograph showing marked vocal cord inflammation resulting in subglottic airway narrowing (*arrows*) and loss of normal shouldering, “steeple sign.” (B) Lateral radiograph showing subglottic narrowing (*arrow*) and distension of hypopharynx. Note normal-appearing epiglottis (*arrowhead*) and thin aryepiglottic folds. Also note enlarged adenoids (*A*) and palatine (*P*) tonsils. (From Donnelly LF. *Fundamentals of Pediatric Imaging*. 2nd ed. Elsevier; 2017, p. 2, Fig. 2.1.)

**eFIGURE 26.4**

Epiglottitis. (A) Lateral radiograph of neck soft tissues in a fourteen-month-old shows abnormal thickening of epiglottis (*asterisk*) and aryepiglottic folds (*arrow*). (B) Eight-year-old with lateral radiograph showing thickening of epiglottis (*asterisk*) and soft tissue density completely occluding subglottic airway. This patient required emergency intubation for airway protection. (From Walters MM, Robertson RL. *Pediatric Radiology: The Requisites*. 4th ed. Elsevier; 2017, Fig. 2.14.)

**eFIGURE 26.5**

Retropharyngeal abscess. (A) Lateral radiograph showing marked thickening of the prevertebral soft tissues (A), which are wider in the anterior-posterior dimension than the adjacent vertebral bodies. Note the anterior convexity of soft tissues. (B and C) Contrast-enhanced computed tomography in sagittal and axial planes shows a peripherally-enhancing, retropharyngeal fluid collection (A), compatible with a drainable abscess. (From Donnelly LF. *Fundamentals of Pediatric Imaging*. 2nd ed. Elsevier; 2017, p. 12, Fig. 2.7.)



**FIGURE 26.3**

Normal lateral cervical spine radiograph. Four curvilinear lines drawn along normal landmarks can be used to help evaluate alignment: anterior vertebral line (AV), posterior vertebral line (PV), spinolaminar line (SL), posterior spinous line (PS).

#### D. Foreign Body

1. **Preferred imaging:** CR, AP and lateral of neck and chest. With suspicion of foreign body in airways, obtain both expiratory and inspiratory radiographs. Bilateral decubitus for younger children who cannot hold breath on command<sup>7</sup>
2. **Findings:** Radiopaque foreign bodies visualized. *Indirect signs:* Persistent hyperinflation of affected lung on expiratory and decubitus radiographs, atelectasis/consolidation distal to obstruction<sup>7</sup>

#### E. Tracheoesophageal Fistula and Esophageal Atresia

1. **Initial imaging:** CR; upper GI (UGI) rarely needed
2. **Findings:** Distended air-filled pharyngeal pouch and failure to pass esophagogastric tube indicates esophageal atresia (EA). Presence of distal bowel gas indicates concurrent distal TEF.<sup>8</sup>

## F. Vascular Rings, Aortic Arch Variants, and Pulmonary Sling

1. **Preferred imaging:** Contrast-enhanced CT angiography (CTA) or MR angiography (MRA) for diagnosis
2. **Other imaging:** Echocardiography (ECHO) in neonates and infants may be able to directly visualize vascular ring.<sup>9</sup> Radiographs and fluoroscopic studies may suggest need for cross-sectional imaging. Neck and chest CR may show displacement or compression of tracheal air column. Fluoroscopic esophagram may show extrinsic compression of esophagus.<sup>7</sup>


## V. CHEST

**CR** used for initial imaging. **CT** useful for evaluating lung parenchyma, pleura, and osseous thorax; important for identifying oncologic disease.<sup>1,6</sup> **US** can evaluate pleura, lung parenchyma, and diaphragmatic motion.<sup>6</sup>


### A. Normal Anatomy (Fig. 26.4 and eFig. 26.6)

### B. Pulmonary Infections


1. **Preferred imaging:** CR, PA and lateral when possible
2. **Other imaging:** CT with IV contrast for suspected complications, including pulmonary abscess, empyema, bronchopleural fistula, lung necrosis, or recurrent infection. US for parapneumonic effusions, empyema, and evaluating feasibility of percutaneous drainage<sup>6,9</sup>
3. **Lower airway inflammation:** Examples include asthma and bronchiolitis. Chest radiographs in asthma and bronchiolitis are most often normal. They can demonstrate nonspecific findings that often overlap with other infections such as bilateral pulmonary opacities, peribronchial thickening (cuffing), hyperinflation, subsegmental atelectasis (eFig. 26.7).<sup>9</sup>
4. **Pneumonia:** Difficult to distinguish between bacterial and nonbacterial with imaging alone (both can be present)
  - a. **CXR findings:** Pneumonia can demonstrate alveolar consolidation and air bronchograms (eFig. 26.8).<sup>9,10</sup> Viral pneumonia may be accompanied by hyperinflation, air trapping, and atelectasis. Bacterial pneumonia may have lobar or segmental airway opacification and expansion.
  - b. Localizing pneumonia on CXR:
    - (1) *Silhouette sign:* Loss of normal borders between thoracic structures of same density; used to localize lung pathology (Table 26.3).<sup>10</sup>
    - (2) *Spine sign:* Vertebral bodies of thoracic spine normally become more radiolucent upon visual inspection inferiorly from the thoracic inlet to the diaphragm. Soft tissue or fluid density involving posterior lower lobe adds density, causing spine to become more radiopaque, which can suggest a consolidation.<sup>1,10</sup>

**eFIGURE 26.6**

Normal thymus. (A) Radiograph shows prominent but normal thymus with triangular contour of the right thymus which abuts the minor fissure “sail sign” (*black arrows*). (B) One aid in identifying the thymus gland is that it is frequently lobulated in appearance (*white arrows*). Although the thymus gland will usually involute with age, it may still be normally visible in children as old as 3 years of age on conventional radiographs. (A, Adapted from Herring W. *Learning Radiology: Recognizing the Basics*. 3rd ed. Elsevier; 2016, Fig. 28.19; B, From Donnelly LF. *Fundamentals of Pediatric Imaging*. 2nd ed. Elsevier; 2017, p. 58, Fig. 3.44.)


**eFIGURE 26.7**

Chest radiograph of a child with viral bronchiolitis. CXR shows hyperinflated lungs with scattered areas of subsegmental atelectasis, most pronounced in the right upper and left lower lungs, as well as thickening of the peribronchial structures.



**eFIGURE 26.8**

Pneumonia. Chest radiograph shows right upper lobe pneumonia with inferior bulging of the minor fissure (*arrowheads*) and air bronchograms (*arrows*).

**FIGURE 26.4**

Normal lung and cardiac anatomy as seen on anteroposterior (A) and lateral (B) chest radiograph. *AoA*, Aortic arch; *RPA*, right pulmonary artery; *LPA*, left pulmonary artery; *RA*, right atrium; *RV*, right ventricle; *LA*, left atrium; *LV*, left ventricle; *black arrow*, posterior wall of bronchus intermedius; *white arrow*, left upper lobe airway; *RUL*, right upper lobe, *RML*, right middle lobe; *RLL*, right lower lobe; *LUL*, left upper lobe; *LLL*, left lower lobe.


**TABLE 26.3****USING THE SILHOUETTE SIGN TO HELP LOCALIZE PNEUMONIA**

Silhouetted Structure	Lobe
Ascending aorta	Right upper lobe
Right heart border	Right middle lobe
Right diaphragm	Right lower lobe
Descending aorta	Left upper or lower lobe
Left heart border	Lingula of left upper lobe
Left diaphragm	Left lower lobe

from Herring W. *Learning Radiology: Recognizing the Basics*. 4th ed. Elsevier; 2020, Table 9.4.

### C. Neonatal Lung Disease

1. Respiratory distress syndrome (RDS, or hyaline membrane disease): Most common in preterm newborns. Hypoinflation, symmetrical hazy or granular pulmonary opacities, prominent air bronchograms, poor definition of pulmonary vessels<sup>6-8</sup> (Fig. 26.5)
2. Transient tachypnea of the newborn (TTN): Most common in term newborns. Interstitial edema, small pleural effusions, increased vascular markings, mildly enlarged cardiothymic silhouette, hyperinflation<sup>6,7</sup>
3. Meconium aspiration syndrome: Most common in term and postterm newborns, often with history of meconium. Bilateral, coarsened, and asymmetric opacities often described as “rope-like” and extending from the bilateral hila. Also with asymmetric areas of hyperinflation and atelectasis. Can be associated with pneumothorax, pneumomediastinum, or pleural effusions<sup>7,8</sup>
4. Neonatal pneumonia: Can occur in preterm and term newborns. Appear as symmetric, bilateral, diffuse pulmonary opacities with hyperinflation.<sup>7</sup> Can appear similar to RDS. Often associated with pleural effusions (whereas RDS are less likely to be associated with pleural effusions)

**FIGURE 26.5**

Infant respiratory distress syndrome. (A) Initial chest radiograph in a premature newborn with respiratory distress; demonstrates hypoinflated lungs and diffuse hazy granular opacities. (B) After intubation and surfactant administration, aeration in lungs has improved. (From Walters MM, Robertson RL. *Pediatric Radiology: The Requisites*. 4th ed. Elsevier; 2017. Fig 2.67.)

## D. Mediastinal Masses

1. **Differential diagnosis** (Table 26.4)<sup>1</sup>
2. **Preferred imaging:** CR followed by contrast-enhanced CT
3. **Findings:** Middle mediastinal masses silhouetting the heart border and aorta<sup>1</sup>

## VI. HEART

See Chapter 7. **ECHO** is the first-line imaging modality. Dynamic **cardiac MR (CMR)** evaluates cardiac and extracardiac anatomy; gold standard for quantifying ventricular volume, mass, and ejection fraction; creates a three-dimensional reconstruction of complex congenital heart disease (CHD) without ionizing radiation. **Cardiac CT** is alternative if CMR is contraindicated (see Fig. 26.4 for normal cardiac findings on CXR).<sup>1,8</sup>

## VII. ABDOMEN

**CR** used for initial workup for most suspected abdominal pathologies; two-view studies (supine and upright) may be necessary to further evaluate in some clinical situations (e.g., intestinal obstruction or free air). Decubitus and cross-table lateral views can help localize free air, foreign bodies, and enteric tubes.<sup>7</sup> **US** is the initial modality of choice for suspected abdominal masses, ascites, appendicitis, abscesses, and biliary pathology.<sup>1</sup> **CT** is preferred for trauma and intestinal obstruction.<sup>1</sup> **MRI** is becoming more frequently utilized, including magnetic resonance cholangiopancreatography (**MRCP**) for evaluating pancreaticobiliary obstructions not directly visualized on ultrasound, abnormal pancreaticobiliary anatomy, and trauma. Magnetic resonance enterography (**MRE**) in known or suspected inflammatory bowel disease can be used to assess disease activity, extent of bowel involvement, and extra-intestinal complications.<sup>1</sup> **Cross-sectional imaging** (US, CT, or MR) may be necessary for suspected inflammation, infection, tumors, and lymphadenopathy, especially if large and/or invasive. **Upper GI (UGI) series** can assess

**TABLE 26.4**

### MEDIASTINAL MASS DIFFERENTIAL DIAGNOSIS

Anterior compartment	Thymus (normal, hyperplasia, cyst, thymoma, carcinoma), teratoma, dermoid, lymphoma, ectopic thyroid, lymphatic malformation, lipoma
Middle compartment	Lymph nodes, lymphoma, foregut abnormalities (bronchopulmonary malformations, cysts), prominent vessels/dilations/aneurysms, pericardial abnormalities
Posterior compartment	Neurogenic tumors (ganglioneuroma, neuroblastoma, ganglioneuroblastoma), nerve sheath tumors (schwannoma, neurofibroma, malignant peripheral nerve sheath tumor), congenital lesions (bronchogenic or neurenteric cysts, sequestration)
Superior compartment	Lymphatic malformation, cystic hygroma, bronchogenic cyst, neurogenic tumors

Modified from Walters MM, Robertson RL. *Pediatric Radiology: The Requisites*. 4th ed. Elsevier; 2017, Box 2.1 and Ranganath SH, Lee EY, Restrepo R, Eisenberg RL. Mediastinal masses in children. *AJR Am J Roentgenol*. 2012 Mar;198(3):W197-216. doi: 10.2214/AJR.11.7027.


for proximal (esophagus to duodenojejunal junction) obstruction in neonates, malrotation, anatomic malformations, and motility problems.<sup>7</sup>

### A. Normal Abdominal X-Ray and Bowel Gas Pattern

1. Neonatal bowel gas pattern: Gas should be present in stomach immediately after birth and in colon by 24 hours (eFig. 26.9).<sup>6,11</sup> Bowel loops resemble polygons or honeycombs, and there should be uniform distribution and spacing between them.<sup>5</sup>
2. After infancy, pockets of gas should be visualized in small bowel, colon, and rectum.
3. Small bowel seen if contains gas, located centrally, has valvulae (extends across bowel) (Fig. 26.6)
4. Large bowel contains gas and stool, located peripherally, has haustra (extends partially across bowel) (see Fig. 26.6).


### B. Pneumoperitoneum (Free Intraoperative Air)

1. **Preferred imaging:** CR including upright imaging (cross-table or lateral decubitus if patient unable to stand or sit)
2. **Other imaging:** CT can confirm diagnosis and may be used to identify source of abnormal bowel or perforation, detects small amounts of air not seen on CR.<sup>10</sup>



**FIGURE 26.6**

Normal abdominal x-ray and free intraperitoneal air. A normal abdominal radiograph (A) with evenly distributed gas throughout nondilated loops of small and large bowel. An anteroposterior supine abdominal radiograph (B) in a baby with necrotizing enterocolitis and free air demonstrated generalized lucency throughout the abdomen. Note that free air outlines the falciform ligament (“football sign”) (*arrow*), and air is seen on both sides of the bowel wall (“Rigler sign”) (*double arrows*). (From Walters MM, Robertson RL. *Pediatric Radiology: The Requisites*. 4th ed. Elsevier; 2017, p. 93, Fig 4.1 image A only and Fig 4.4, labeled as B.)

**eFIGURE 26.9**

Normal bowel gas progression in neonates as seen on abdominal radiograph at 2 hours of life (A) and 24 hours of life (B). Note that by 12 hours of life air should have progressed through small bowel and by 24 hours of life (B) air can be visualized in the rectum.

### 3. Findings:


- a. *Continuous diaphragm sign*: Air outlines inferior aspect of diaphragm, including underneath heart silhouette.
- b. *Falciform ligament sign*: Ability to visualize the typically indistinct falciform ligament as free air surrounds it (and displaces surrounding soft tissue) (see Fig. 26.6)
- c. *Football sign*: Oval appearance of abdominal cavity outlined by gas with visualization of falciform ligament, seen in massive pneumoperitoneum (see Fig. 26.6)<sup>10</sup>

### C. Neonatal Enterocolitis (NEC, see Chapter 18)


1. **Initial imaging**: CR, include cross-table lateral or left decubitus views to evaluate for free air<sup>7</sup>
2. **CR findings**: *Nonspecific signs*: Diffuse gaseous distention, a nonspecific, but common finding, or persistence of focally/asymmetrically dilated bowel loop (fixed loop sign) may indicate an ileus, which is often the earliest radiographic sign. *Pathognomonic signs*: In the setting of clinically suspected necrotizing enterocolitis, radiographic signs of pneumatosis and portal venous gas are DIAGNOSTIC. (Fig. 26.7).<sup>7</sup>
3. **Other imaging**: Intestinal US if high clinical suspicion for NEC and CR nonspecific or inconclusive, as can depict changes in bowel motion, bowel distension, free abdominal fluid, organized fluid collections, bowel wall thickness, pneumatosis, pneumoperitoneum and bowel wall perfusion<sup>12</sup>

### D. Neonatal Intestinal Obstruction

1. Difficult to distinguish small from large bowel in neonates on radiographs<sup>5</sup>
2. **Initial imaging**: CR to decipher high obstruction (stomach to proximal ileum) from low obstruction (distal ileum to colon)
3. **Further imaging**: UGI series (obstruction proximal to ligament of Treitz), UGI series with small bowel follow-through (ligament of Treitz to ileocecal junction), contrast enema (distal colon to ileocecal junction)<sup>5,7,9</sup>
4. High intestinal obstruction
  - a. **CR findings**: Few dilated loops of bowel may indicate a proximal obstruction.
  - b. Duodenal obstruction: Double bubble on CR (eFig. 26.10), reflecting gas in dilated stomach and proximal duodenum with absence of gas distally. Obstruction may be partial or complete, due to duodenal atresia, stenosis, web, malrotation with midgut volvulus, or annular pancreas. If partial obstruction, UGI series may help with further differentiation.<sup>7</sup>
  - c. Malrotation with midgut volvulus: Abnormal rotation of the duodenojejunal loop resulting in a short mesenteric root and malposition of the duodenojejunal junction (normally located at or more superior to the level of the duodenal bulb and to the left of the spine). UGI series is the gold standard and can evaluate for duodenal

**eFIGURE 26.10**

Partial duodenal obstruction in a newborn infant. Radiograph shows air-filled, dilated stomach (*S*) and dilated duodenal bulb (*D*), giving the appearance of a double bubble. (From Donnelly LF. *Fundamentals of Pediatric Imaging*. 2nd ed. Elsevier; 2017, p. 95, Fig. 5.8.)





**FIGURE 26.7**

Necrotizing enterocolitis (NEC) in a premature infant. Radiography shows multiple dilated bowel loops with multiple areas of circumferential lucency (*arrows*) along the bowel wall, consistent with pneumatosis. Note portal venous gas (*arrowheads*) as branching, tubular lucencies overlying the liver. (From Donnelly LF. *Fundamentals of Pediatric Imaging*. 2nd ed. Elsevier; 2017, p. 92, Fig. 5.1.)

obstruction (either from Ladd bands or from volvulus).<sup>5,7</sup> CT may be performed for identification in older children (eFig. 26.11).

5. Low intestinal obstruction (Table 26.5)

- a. **CR findings:** Multiple dilated loops of bowel can indicate a distal obstruction; assess further with contrast enema.
- b. Ileal atresia: Contrast enema opacifies microcolon (diffusely small caliber large bowel). Rectum is normally distensible. Contrast refluxes into distal ileum at point of atresia as it is unable to reflux further. Bowel proximal to the obstruction in the distal ileum is gas filled and dilated.
- c. Hirschsprung disease: Contrast enema shows “transition zone” between nondilated aganglionic distal colon and distended, proximal colon with normal ganglion cells.<sup>7</sup>

**eFIGURE 26.11**

Malrotation without volvulus. (A) shows normal fixation of intestines with normal mesenteric root (*dashed line*) and (B) shows intestinal malrotation with short mesenteric root. Ladd bands (abnormal intraperitoneal fibrous bands) that cross the duodenum and which may cause duodenal obstruction. (C) shows an upper GI series with the duodenojejunal junction in the midline instead of its normal position to the left of a left-sided spinous pedicle. (From Walters MM, Robertson RL. *Pediatric Radiology: The Requisites*. 4th ed. Elsevier; 2017, p. 220, Figures 4.20 and 4.21.)

TABLE 26.5

## LOW INTESTINAL OBSTRUCTION

	Dilated Segment	Nondilated Segment
Ileal atresia	Proximal to point of atresia (no opacification on contrast enema because it cannot pass point of atresia)	Distal to point of atresia (microcolon)
Hirschsprung disease	Proximal, dilated, normal bowel with ganglion cells (will opacify with contrast enema)	Distal aganglionic bowel
Meconium ileus	Proximal to terminal ileum (will opacify with contrast enema)	Terminal ileum (microcolon) with filling defects (meconium pellets)

- d. Meconium ileus: Contrast enema opacifies a microcolon. Contrast refluxes into nondilated terminal ileum, which contains impacted meconium pellets. Bowel proximal to terminal ileum is dilated<sup>5,7</sup> (eFig. 26.12). Meconium ileus is seen almost exclusively in children with cystic fibrosis.

### E. Pyloric Stenosis

1. Commonly presents with forceful, nonbilious “projectile” emesis between 2 to 6 weeks old, rare after 3 months of age unless preterm child
2. **Preferred imaging:** Pylorus US
3. **Findings:** Abnormal wall thickness of pyloric muscularis ( $\geq 3$  mm) and elongation of pyloric channel ( $>15$  to 17 mm)<sup>10</sup>

### F. Intussusception


1. **Preferred imaging:** Abdominal US<sup>1</sup>
2. **Findings:** Donut or target sign, indicating a mass with bowel-in-bowel configuration<sup>1</sup>
3. **Treatment:** Pneumatic or water soluble contrast enema reduction under fluoroscopic guidance<sup>1</sup>

### G. Ileus


1. **Preferred imaging:** CR
2. **Findings:** Small and large bowel distention.<sup>1,10</sup> May not be able to identify transition point on radiographs

### H. Bowel Obstruction

1. **Initial imaging:** CR. Supine view for identifying gas pattern or paucity of bowel gas. Upright/erect, cross-table lateral, or lateral decubitus can identify free air and air-fluid levels in the appropriate clinical scenario (eFig. 26.13).
2. **Other imaging:** CT with IV and, ideally oral contrast helps determine obstruction site and detect complications such as ischemia.<sup>10</sup> *NOTE: CR has limited sensitivity for localizing bowel obstruction; therefore, CT should be obtained if obstruction clinically suspected.*
3. **Findings:** Dilated loops of bowel proximal to obstruction, little to no air in rectum<sup>1</sup>

**eFIGURE 26.12**

Meconium ileus. (A) Abdominal radiograph showing dilated loops of bowel suggestive of a low intestinal obstruction. (B) Contrast enema showing microcolon, contrast reflux proximal to terminal ileum, and filling defects in nondilated terminal ileum, suggestive of meconium ileus. (From Walters MM, Robertson RL. *Pediatric Radiology: The Requisites*. 4th ed. Elsevier; 2017, p. 220, Figure 4.14.)



**eFIGURE 26.13**

Pediatric small bowel obstruction with air fluid levels. Decubitus radiograph of patient with air-fluid levels, dilated bowel, and gas bubble in right chest in an 8-month-old status post liver transplant, found to have incarcerated right-sided diaphragmatic hernia. (From Truman, M. et al. Small bowel obstruction after pediatric liver transplantation: the unusual is the usual. *J Am Coll Surg.* 2011;212[1]:62–67.)

**I. Appendicitis**

1. **Preferred imaging:** Abdominal US
2. **Other imaging:** MRI if high suspicion for appendicitis and US unable to visualize appendix. CT if benefits of obtaining diagnostic image outweigh the risks of exposure to ionizing radiation, patient unstable, or MRI unavailable/patient cannot tolerate MRI<sup>1,7</sup>
3. **US findings:** Fluid-filled, noncompressible, blind-ending tubular structure greater than 6 mm in diameter with wall thickening/hyperemia, and surrounding inflammatory changes.<sup>1,7</sup> May also see appendicolith and sonographic evidence for perforation (disrupted appendix and/or fluid collections). If US able to visualize a normal appendix in its entirety with no signs of inflammation in abdomen, likely no further imaging is indicated.

**J. Esophageal Foreign Bodies**

1. **Preferred imaging:** CR (for a radiodense foreign body), evaluate entire GI tract (neck, chest, abdomen)
2. **Other imaging:** Esophagram with water-soluble contrast if suspicion high but CR negative and suspected radiolucent foreign body<sup>7</sup>
3. **Findings:** Most commonly lodged at thoracic inlet. May see mass effect on adjacent structures from swelling caused by foreign body
  - a. Coins (most common): Flat object on frontal view with radiodense edge visualized on lateral
  - b. Disk batteries (or button batteries): Metallic disk with peripheral lucent rim and step-off, best seen along its short axis. Must identify as may cause serious electrical burn or chemical injury<sup>7</sup>

**K. Abdominal Trauma**


1. **Preferred imaging:** CT with IV contrast
2. **Other imaging:** If hemodynamically unstable, rapid bedside US using focused assessment with sonography for trauma (FAST) protocol to evaluate for free fluid.<sup>7</sup> FAST evaluates bilateral upper quadrants, bilateral pericolic gutters, pelvis, and pericardium<sup>1</sup> (eFig. 26.14).

**L. Gallbladder Disease**

1. **Preferred imaging:** RUQ US. Patients should fast for 6 hours prior to allow for gallbladder filling.<sup>1</sup>
2. **Findings:** Mobile, echogenic structures with posterior acoustic shadowing in cholelithiasis. Sludge may appear mobile or adherent. Gallbladder wall thickening (>3 mm), positive sonographic Murphy sign (localized tenderness with transducer palpation over gallbladder), sludge, and pericholecystic fluid with cholelithiasis in acute cholecystitis.<sup>1</sup> Biliary tree dilation may indicate inflammation and/or obstruction (including choledochal cysts/congenital abnormalities in young patients) in appropriate clinical setting.

**M. Pancreatitis**

1. **Initial imaging:** US
2. **Other imaging:** CT with IV contrast to evaluate for potential complications. MRCP for detecting choledocholithiasis and biliary/pancreatic duct anomalies<sup>13</sup>

**eFIGURE 26.14**

FAST exam (Focused Assessment with Sonography for Trauma) consists of ultrasound examination of the pericardium, right upper quadrant, left upper quadrant, and pouch of Douglas for free fluid. (From Rozycki GS, Ochsner MG, Schmidt JA, et al. A prospective study of surgeon-performed ultrasound as the primary adjuvant modality for injured patient assessment. *J Trauma*. 1995;39:492–498.)

3. **US findings:** Abnormal pancreatic echogenicity, peripancreatic fluid, or fluid collection.<sup>1,7</sup> Pancreatic ductal dilation can indicate chronicity.

## VIII. GENITOURINARY TRACT

**Renal and bladder ultrasound (RBUS):** Generally acceptable first-line imaging modality; evaluates kidneys, ureters, and bladder; can assess calculi, urinary tract dilation. **Fluoroscopic voiding cystourethrogram (VCUG), radionuclide cystourethrography (RNC), and contrast-enhanced voiding urosonography (ceVUS)** assess for vesicoureteral reflux. **Nuclear renal scintigraphy (Mag-3 scan)** assesses renal perfusion, function, and excretion. **Cross-sectional imaging** (CT, MR, MR urography) assesses genitourinary (GU) tract anatomy, tumors, or obstruction. Additionally, MR urography can evaluate renal perfusion and excretion. Unenhanced CT can assess collecting system calculi.<sup>7</sup> See Chapter 19 for additional detail.

### A. Urinary Tract Infection

See Chapter 19.

### B. Nephrolithiasis/Urolithiasis

1. **Preferred imaging:** US or noncontrast CT<sup>1,7</sup>
2. **US findings:** Usually echogenic, shadowing foci<sup>7</sup>
3. **CT findings:** Radiodense stones, dilated ureteral or collection system, ureteral wall thickening, asymmetric enlargement, or edema of kidney<sup>1</sup>

### C. Testicular Pathology

1. **Preferred imaging:** US scrotum and testicles<sup>1</sup>
2. **Testicular torsion findings:** Affected testicle is frequently enlarged with heterogeneous echogenicity, and with diminished/absent blood flow. Torsed spermatic cord may be visualized.<sup>1</sup>
3. **Acute epididymo-orchitis findings:** Enlarged epididymis with increased blood flow in epididymis and testicle, scrotal thickening, reactive hydrocele<sup>1</sup>

### D. Ovarian Pathology

1. **Preferred imaging:** Pelvic US
2. **Ovarian cyst findings:** Well-circumscribed anechoic structures arising from ovary measuring more than 3 cm in diameter. Hyperechoic material or thin, lace-like septations within cyst indicate possible hemorrhage.<sup>9</sup>
3. **Ovarian torsion findings:** Variable appearance, usually asymmetrically enlarged solid ovary with multiple peripheral follicles<sup>9</sup> and edematous ovarian parenchyma. Absence or presence of flow on duplex not a reliable indicator of torsion<sup>7</sup>

### E. Congenital Hydronephrosis

1. Normally first detected on fetal US, defined as AP renal pelvis diameter greater than 4 mm in second trimester and greater than 7 mm in third trimester
2. **Preferred imaging:** US to confirm postnatally, as can resolve spontaneously. Do not perform until at least 48 hours after delivery given

risk of false negatives or underestimation of severity due to relative dehydration and low glomerular filtration rate.<sup>1</sup>

- Findings:** Dilation of the renal pelvis (>10 mm), calyces, and/or ureters especially with with abnormal sonographic appearance of the kidneys, clinical suspicion for obstruction or reflux, or family history may warrant further evaluation with VCUG and followup US between 1 and 6 months to confirm resolution.<sup>1,14</sup>

## IX. MUSCULOSKELETAL

**CR** is the primary initial imaging modality for assessment in trauma, infection, and suspected bone lesions.<sup>7</sup> **MRI** provides superior contrast resolution of soft tissue and bone marrow; preferred for internal derangement, infection, and tumors of bone and soft tissue. Use IV contrast to delineate inflammation, ischemia, suspected vascular anomalies, and masses.<sup>1</sup> **US** used for superficial soft-tissue masses, vascular anomalies, and suspected joint effusions.


### A. Fractures and Trauma

- Preferred imaging:** CR. For long bones, obtain at least two projections. For joints, obtain at least three projections and evaluate proximal and distal joint. Fractures may not be seen on initial CR; consider repeat CRs in 7 to 10 days, which may show evidence of healing.<sup>1,7</sup>
- Findings:** Abrupt disruption of the cortex or acute angulation of smooth contour of normal bone.<sup>10</sup> *Indirect signs:* Soft-tissue swelling, joint effusion, periosteal reaction (if subacute or healing)
- Describing fractures<sup>10</sup>:
  - Location:** Laterality, location on bone, relation to joint (intra-articular, extra-articular), involvement of growth plate (Table 26.6)
  - Type:** Complete (through whole cortex), incomplete (retains some continuity [e.g., plastic, bowing, torus, greenstick]),

**TABLE 26.6**

### SALTER-HARRIS CLASSIFICATION OF GROWTH PLATE INJURY

Class I	Class II	Class III	Class IV	Class V
Fracture along growth plate	Fracture along growth plate with metaphyseal extension	Fracture along growth plate with epiphyseal extension	Fracture across growth plate, including metaphysis and epiphysis	Crush injury to growth plate without obvious fracture



- c. **Number of fragments:** Simple (two fragments) or comminuted (>2)
  - d. **Orientation of fracture lines:** Transverse (perpendicular to long axis), oblique (diagonal in orientation relative to long axis), spiral
  - e. **Relationship** between fracture fragments: Displacement (amount distal fragment is offset relative to proximal fragment), angulation (angle between fragments), apposition (amount of contact between fragments), shortening (amount of overlap between fragments, change in bone length), distraction (distance fragments are separated in longitudinal axis), rotation (orientation of joint at one end of fracture relative to joint at other end)
  - f. **Open versus closed:** Open or compound (communication between fracture and outside atmosphere), closed or simple
  - g. **Common pediatric fracture patterns:** See [Chapter 2](#).
4. Elbow XRs
- a. **Anterior humeral line:** Line drawn tangential to anterior humeral cortex should bisect middle third of capitellum. If line more anterior, supracondylar fracture should be suspected ([Figs. 26.8 and 26.9](#)).<sup>10</sup> Of note, children under 4 years old can normally have tangential line cross the anterior one-third of capitellum.
  - b. **Radiocapitellar line:** Line drawn through the center and parallel to long axis of radius should pass through the center of capitellum. If it does not, dislocation should be suspected (see [Figs. 26.8 and 26.9](#)).<sup>14</sup>
  - c. **Ossification centers:** Mnemonic CRITOE commonly used to remember sequential order of appearance ([eTable 26.1](#) and [eFig. 26.15](#)).<sup>15</sup>
  - d. **Fat pad:** Normal lateral view of flexed elbow shows only anterior fat pad (lucency). Elevated anterior fat pad and visible posterior fat pad indicate intra-articular injury and possible radial neck or supracondylar humerus fracture (*positive fat-pad sign*) ([Fig. 26.10](#)).<sup>12</sup>
  - e. **Hourglass sign** (“figure-of-eight”): On a true lateral view, an hourglass or figure-of-eight configuration can be visualized on the distal humerus (see [Fig. 26.10](#)).

## B. Osteomyelitis


1. **Initial imaging:** CR. Findings often lag 7 to 14 days after symptom onset; however, may identify alternative diagnosis such as fractures or tumors.<sup>1</sup>
2. **Preferred imaging:** MRI. Findings can be seen as early as 24 to 48 hours after symptom onset.<sup>1,16</sup>
3. **Findings:** Metaphysis of long bones most frequently affected. CR: Soft tissue swelling, bony destruction or demineralization, cortical loss, periosteal reaction<sup>16</sup>

## C. Hip Disorders


1. Developmental dysplasia of the hip
  - a. **Preferred imaging:** US, typically around 6 weeks of age
  - b. **Other imaging:** Once femoral heads ossify (within 3 to 6 months), CR more helpful<sup>7</sup>

**eTABLE 26.1****ELBOW OSSIFICATION CENTERS USING MNEMONIC “CRITOE”**

<b>Ossification Center</b>	<b>Age at Which Appears (Highly Variable)</b>
Capitellum	1–2
Radial head	3–4
Internal (medial) epicondyle	5–6
Trochlea	7–8
Olecranon	9–10
External (lateral) epicondyle	11–12

**eFIGURE 26.15**

Ossification centers of normal elbow of 14-year-old boy. Anteroposterior (A) and lateral (B) radiographs. C, Capitellum; L, lateral epicondyle; M, medial epicondyle; O, olecranon; R, radial head; T, trochlea. (From Coley BD. *Caffey's Pediatric Diagnostic Imaging*. 13th ed. Elsevier; 2019, p. 1438, Fig. 142.17.)




**FIGURE 26.8**

Normal elbow alignment on lateral radiograph. The anterior humeral line (*black arrow*) is drawn along the anterior cortex of the humerus and should intersect the middle third of the capitellum (*asterisk*). The radiocapitellar line (*white arrow*) is drawn along the axis of the radius. (Modified from Coley BD. *Caffey's Pediatric Diagnostic Imaging*. 13th ed. Elsevier; 2019, p. 1439, Fig. 142.19.)

2. Idiopathic avascular necrosis of femoral head (Legg-Calvé-Perthes disease)
  - a. **Initial imaging:** CR, AP pelvis, and frog-leg lateral hip
  - b. **Other imaging:** MRI, more sensitive for early disease (especially cartilaginous changes), useful if CR is nondiagnostic<sup>7</sup>
  - c. **Findings:** Sclerotic femoral head, widened joint space, curvilinear subchondral lucency from subchondral fracture (*crescent sign*)<sup>7</sup>
3. Slipped capital femoral epiphysis (SCFE)
  - a. **Initial imaging:** CR, AP and frog-leg lateral views of pelvis
  - b. **Other imaging:** MRI is helpful in evaluation for early changes of SCFE and of contralateral hip.
  - c. **Findings:** Asymmetric widening, irregularity, and/or lucency of proximal femoral physis, posterior and inferomedial displacement of femoral head relative to femoral neck (ice cream falling off cone). SCFE can lead to femoral head avascular necrosis. Can assess femoral head position by drawing line along lateral aspect of the femoral neck (Klein's line), which should intersect the capital femoral epiphysis in normal anatomy (eFig. 26.16)<sup>7</sup>

**eFIGURE 26.16**

Slipped capital femoral epiphysis. (A) Anteroposterior radiograph of the pelvis shows asymmetric physeal widening on the left (*double arrows*). The Klein line (*dotted lines*) does not cross the epiphysis on the affected side. (B) Frog-leg lateral image confirms inferomedial slip of the femoral head relative to the proximal femoral metaphysis. (From Walters MM, Robertson RL. *Pediatric Radiology: The Requisites*. 4th ed. Elsevier; 2017, p. 220, Figure 7.60.)

**FIGURE 26.9**

(A) Abnormal anterior humeral line seen in a supracondylar humeral fracture. The anterior humeral line (*dashed line*) courses anterior to the capitellum (*white arrow*) in a minimally displaced fracture of the supracondylar humerus (*black arrow*). (B) Abnormal radiocapitellar line in a radial head dislocation. Radiocapitellar line (*white line*) drawn along the axis of the radius courses superior to the capitellum instead of intersecting the capitellum.



**FIGURE 26.10**

Lateral radiograph of elbow demonstrates visible posterior fat pad (*white arrow*), “positive fat-pad sign.” Note the “hourglass sign” (*dashed line*).

#### D. Scoliosis


1. **Initial imaging:** CR, upright PA view. Sitting or supine reserved for nonambulatory patients. Lateral view not necessary for initial screening; include if known scoliosis<sup>9</sup>
2. **Findings:** Lateral spinal curvature greater than 10 degrees as measured by Cobb method<sup>9</sup>

#### E. Bone Lesions

1. **Initial imaging:** CR, usually diagnostic<sup>1</sup>
2. **Other imaging:** MRI defines extent of lesion and staging of malignant lesions<sup>1</sup>
3. **Findings:** *Benign lesions:* Well-demarcated from normal bone, sclerotic margin around lesion, nonaggressive growth pattern. *Pathologic lesions:* Not well demarcated from surrounding normal bone, possible accompanying soft tissue mass, periosteal reaction, destructive bone changes (eFig. 26.17 to eFig. 26.21)<sup>1</sup>

#### F. Skeletal Survey in Suspected Nonaccidental Trauma

1. **Imaging:** CR at presentation and 2 weeks after presentation. Follow-up surveys may identify new or healing fractures (eFig. 26.22).<sup>5</sup>

**eFIGURE 26.17**

(A) Sessile osteochondroma (*arrows*) of proximal humeral diaphysis in a 16-year-old patient. (B) Pedunculated osteochondroma of the right distal femoral metaphysis in a 16-year-old patient. (From Coley BD. *Caffey's Pediatric Diagnostic Imaging*. 13th ed. Elsevier; 2019, p. 1375, Figs. 138.14–138.15.)

**eFIGURE 26.18**

Nonossifying fibroma in a 12-year-old patient. The lesion is well defined, with a "soap bubble" appearance and sclerotic margins (*arrow*). (From Coley BD. *Caffey's Pediatric Diagnostic Imaging*. 13th ed. Elsevier; 2019, p. 1382, Fig. 138.30.)

**eFIGURE 26.19**


Osteoid osteoma of tibia in a 15-year-old patient. Radiograph shows cortical thickening posteriorly. Lucent nidus is faintly seen (*arrow*). (From Coley BD. *Caffey's Pediatric Diagnostic Imaging*. 13th ed. Elsevier; 2019, p. 1387, Fig. 138.38.)

**eFIGURE 26.20**

Proximal tibial osteosarcoma. Radiograph demonstrates osteoblastic osteosarcoma with osteoid matrix (*arrow*) and "sunburst" periostitis (*arrowhead*). (Modified from Coley BD. *Caffey's Pediatric Diagnostic Imaging*. 13th ed. Elsevier; 2019, p. 1390, Fig. 138.41.)

**eFIGURE 26.21**

Anteroposterior (A) and lateral (B) radiographs of femur of a 6-year-old child show Ewing sarcoma arising from mid-diaphysis. Lamellar periosteal reaction and new bone formation are present, with Codman triangles at proximal and distal ends of tumor. Faint periosteal new bone extends perpendicularly into soft-tissue component of tumor. Medulla is not expanded. (From Slovis TL. *Caffey's Pediatric Diagnostic Imaging*. 11th ed. Mosby; 2008.)

**eFIGURE 26.22**

Frontal (A) and oblique (B) radiographs show healing fractures (*black arrows*) of right third, fourth, fifth, and sixth ribs. There are acute fractures (*white arrows*) of the posterior left fifth, sixth, seventh, eighth, and ninth ribs. Fractures are better appreciated on the oblique view. Note subacute healing left clavicular fracture (*arrowhead*). (From Donnelly LF. *Fundamentals of Pediatric Imaging*. 2nd ed. Elsevier; 2017, p. 56, Fig. 3.39.)

2. Evaluate for fractures inconsistent with history or developmental stage or other findings suspicious for nonaccidental trauma (NAT) (see [Chapter 2](#)).

## X. CONFIRMING TUBE PLACEMENT AND LINE INSERTION

### A. Central Venous Catheter

1. *Upper extremity*: Tip in superior vena cava (SVC) at cavoatrial junction or proximal atrium ([Fig. 26.11](#))
2. *Lower extremity*: Tip in inferior vena cava (IVC) within 1 cm of diaphragm

### B. Umbilical Lines ([Fig. 26.12](#))


1. Umbilical artery catheter (UAC): *High-lying (preferred)*: Tip above diaphragm between T6 and T9. *Low-lying*: Tip just above bifurcation of aorta between L3 and L4
2. Umbilical venous catheter (UVC): Tip near inferior cavoatrial junction
3. UACs distinguished from UVCs by initial downward course from umbilicus into internal iliac artery and subsequent ascent into the common iliac artery and aorta. UVCs extend immediately superior from umbilicus. UVC is more anteriorly located than UAC on lateral view radiographs.

### C. Nasogastric Tube

1. Tip below diaphragm in stomach, overlying gastric bubble


### D. Nasoduodenal Tube

1. Tube should pass through stomach, cross midline to the right abdomen into duodenal bulb, and end into the duodenum.



**FIGURE 26.11**

Central line placement on anteroposterior chest radiograph for line inserted in arm or neck. *Arrow* indicates termination of catheter at junction of superior vena cava and right atrium.

**FIGURE 26.12**

Umbilical catheters. Umbilical venous catheter (UVC) terminates at inferior cavoatrial junction (*arrows*). The umbilical arterial catheter (UAC) first descends the iliac artery before it ascends the aorta and terminates in a typical “high” position, at T7 (*arrowheads*).

### E. Endotracheal Tube

1. Tip between T1 and the carina.

### XI. WEB RESOURCES

- American College of Radiology Appropriateness Criteria: <http://www.acr.org/Clinical-Resources/ACR-Appropriateness-Criteria>
- Image Gently Alliance: <http://www.imagegently.org>
- Society for Pediatric Radiology: <http://www.pedrad.org>

### REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Zitelli BJ, McIntire SC, Nowalk AJ, Garrison J. *Zitelli and Davis' Atlas of Pediatric Physical Diagnosis*. 8th ed. Elsevier; 2023.
2. Kuppermann N, Holmes JF, Dayan PS, Hoyle Jr JD, Atabaki SM, et al. Pediatric Emergency Care Applied Research Network (PECARN). Identification of children at very low-risk of clinically-important brain injuries after head trauma: a prospective cohort study. *Lancet*. 2009;374(9696):1160–1170.
3. Nigrovic LE, Schunk JE, Foerster A, et al. Traumatic Brain Injury Group for the Pediatric Emergency Care Applied Research Network. The effect of observation on cranial computed tomography utilization for children after blunt head trauma. *Pediatrics [Internet]*. 2011;127(6):1067–1073.
4. Eustis HS, Mafee MF, Walton C, Mondonca J. MR imaging and CT of orbital infections and complications in acute rhinosinusitis. *Radiol Clin North Am*. 1998;36:1165.
5. Iyer RS, Chapman T. *Pediatric Imaging: The Essentials*. Wolters Kluwer; 2016.
6. Siegel MJ, Coley BD. *Core Curriculum: Pediatric Imaging*. Lippincott Williams & Wilkins; 2006.
7. Walters M, Robertson RL, Blickman JG. *Pediatric Radiology: The Requisites*. 4th ed. Elsevier; 2017.
8. Donnelly LF. *Fundamentals of Pediatric Imaging*. 3rd ed. Elsevier; 2022.
9. Coley BD. *Caffey's Pediatric Diagnostic Imaging*. 13th ed. Elsevier; 2019.
10. Herring W. *Learning Radiology: Recognizing the Basics*. 4th ed. Elsevier; 2020.
11. Swischuk LE. *Imaging of the Newborn, Infant, and Young Child*. Lippincott Williams & Wilkins; 2004.
12. Epelman M, Daneman A, Navarro OM, et al. Necrotizing enterocolitis: review of state-of-the-art imaging findings with pathologic correlation. *Radiographics*. 2007;27:285–305.
13. Restrepo R, Hagerott HE, Kulkarni S, Yasrebi M, Lee EY. Acute pancreatitis in pediatric patients: demographics, etiology, and diagnostic imaging. *Am J Roentgenol*. 2016;206:632–644.
14. Choi YH, Cheon J-E, Kim WS, Kim I-O. Ultrasonography of hydronephrosis in the newborn: a practical review. *Ultrasonography*. 2016;35:198–211. <https://doi.org/10.14366/usg.15073>
15. Grayson DE. The elbow: radiographic imaging pearls and pitfalls. *Semin Roentgenol*. 2005;40(3):223–247.
16. Jaramillo D, Dormans JP, Delgado J, Laor T, St Geme 3rd JW. Hematogenous osteomyelitis in infants and children: imaging of a changing disease. *Radiology*. 2017;283(3):629–643.

# Chapter 27

## Rheumatology

*Emma Vaimberg, MD*

 See additional content online.

 **Audio Case File 27.1** A systematic approach to differentiating the various childhood arthritic conditions

### I. BRIEF OVERVIEW OF CLINICAL CHARACTERISTICS OF RHEUMATOLOGIC DISEASES

#### A. Juvenile Idiopathic Arthritis (JIA)<sup>1-4</sup>

1. Most common rheumatologic condition in children
2. Classification criteria
  - a. Arthritis of one or more joints defined as: joint swelling, limitation in range of motion, and/or tenderness
  - b. Symptoms lasting at least 6 weeks
  - c. Symptom onset less than 16 years of age
3. See [Table 27.1](#) for information by JIA subtypes.<sup>5</sup>
4. Treatment varies based on JIA subtype, but can include:
  - a. Nonspecific therapies: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), corticosteroids
  - b. Disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, leflunomide, azathioprine
  - c. Biologic agents, such as antitumor necrosis factor (anti-TNF), anti-interleukin 1 (IL-1), anti-interleukin 6 (IL-6), abatacept, and ustekinumab
5. Macrophage activation syndrome (MAS)<sup>6</sup>
  - a. A severe disorder that develops in 7% to 17% of patients with systemic JIA
  - b. Clinical features: Persistent fever, mental status changes, lymphadenopathy, hepatosplenomegaly
  - c. Associated lab findings include severe and precipitous cytopenias with associated coagulopathies and hepatic dysfunction, marked hyperferritinemia with precipitous or paradoxical drop in erythrocyte sedimentation rate (ESR) and fibrinogen, elevated lactate dehydrogenase (LDH), and triglycerides, evidence of hemophagocytic macrophages in bone marrow or other tissue.
  - d. MAS can also complicate other diseases, such as systemic lupus erythematosus and Kawasaki disease.
  - e. First-line therapy includes pulse dose IV corticosteroids, IL-1 and IL-6 blockade. Cyclosporine A and Janus kinase (JAK) inhibitors can also be used in refractory disease.

TABLE 27.1

CLASSIFICATION OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)<sup>1,5</sup>

ILAR JIA Subtype (% of Total Patients)	Demographics	Arthritis Characteristics	Definition	Other Features
Oligoarticular (40%–50%)	<ul style="list-style-type: none"> <li>• F &gt; M predominance</li> <li>• Peak age of onset: 2–4 years</li> </ul>	Typically lower extremity large joints: knees and ankles	1–4 joint involvement within the first 6 months of disease Two subtypes: <ul style="list-style-type: none"> <li>• Persistent: Affects ≤4 joints for entire clinical course</li> <li>• Extended: Involves &gt;4 joints after first 6 months of disease</li> </ul>	60%–70% ANA positive Uveitis is common with an overall prevalence of 30%. Prevalence of uveitis in persistent oligoarticular JIA and extended oligoarticular JIA is 16% and 25%, respectively.
Polyarticular-rheumatoid factor negative (20%–35%)	<ul style="list-style-type: none"> <li>• F &gt; M predominance</li> <li>• Peak age of onset: 2–4 years and 10–14 years</li> </ul>	Involves small and large joints, can be symmetric or asymmetric	≥5 joints involved within the first 6 months of disease	50% ANA positive 10% HLA-B27 positive Uveitis prevalence: 4%
Polyarticular-rheumatoid factor positive (<10%)	<ul style="list-style-type: none"> <li>• F &gt; M predominance</li> <li>• Peak age of onset: 9–12 years</li> </ul>	Symmetric polyarthritis	≥5 joints involved within the first 6 months of disease	40% ANA positive 10%–15% HLA-B27 positive Rheumatoid nodules: Nontender subcutaneous nodules found on bony prominences, extensor surfaces, or adjacent to joints Uveitis prevalence: 2%
Systemic (5%–15%)	<ul style="list-style-type: none"> <li>• M = F predominance</li> <li>• Peak age of onset: 1–5 years</li> </ul>	Oligo- or polyarticular, usually involves knees, wrists, and ankles.	Arthritis with daily (quotidian) fevers for ≥2 weeks with 1 or more associated features.	20% ANA positive 5%–10% HLA-B27 positive Uveitis prevalence: 1%

Continued

TABLE 27.1

CLASSIFICATION OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)<sup>1,5</sup>—CONT'D

ILAR JIA Subtype (% of Total Patients)	Demographics	Arthritis Characteristics	Definition	Other Features
		The cervical spine can also be involved.	<ul style="list-style-type: none"> <li>• Evanescent erythematous rash</li> <li>• Generalized lymphadenopathy</li> <li>• Hepatomegaly and/or splenomegaly</li> <li>• Serositis</li> </ul> Macrophage activation syndrome (MAS) most commonly associated with systemic JIA	
Enthesitis-related arthritis (10%–15%)	<ul style="list-style-type: none"> <li>• M &gt; F predominance</li> <li>• Peak age of onset: 9–12 years</li> </ul>	Mostly lower extremity small and large joints. Can involve axial skeleton	Both arthritis and enthesitis OR Arthritis or enthesitis with at least 2 additional features: <ul style="list-style-type: none"> <li>• Axial spine involvement (including sacroiliitis)</li> <li>• HLA-B27 positive</li> <li>• Arthritis onset in males older than 6 years old</li> <li>• Symptomatic Anterior uveitis</li> <li>• First-degree relative with HLA-B27 associated disease</li> </ul>	20% ANA positive 60%–80% HLA-B27 positive Uveitis prevalence: 7% Uveitis is typically acute symptomatic type
Psoriatic arthritis (5%–10%)	<ul style="list-style-type: none"> <li>• F &gt; M predominance</li> <li>• Peak age of onset: 2–4 years and 9–11 years</li> </ul>	Involves wrists and small joints of the hands and feet initially but can progress to larger joints without effective treatment	Both arthritis and psoriasis OR Arthritis with at least 2 additional features: <ul style="list-style-type: none"> <li>• Dactylitis</li> <li>• Nail pitting or onycholysis</li> <li>• Psoriasis in first-degree relative</li> </ul>	40% ANA positive 20% HLA-B27 positive Uveitis prevalence: 10%

Undifferentiated (5%)	Arthritis that does not meet criteria for the above subtypes, or fulfills criteria for 2 or more subtypes	30% ANA positive 25% HLA-B27 positive Uveitis prevalence: 11%
--------------------------	---	--

*ANA*, Antinuclear antibodies; *F*, female; *HLA*, human leukocyte antigen; *ILAR*, International League of Associations for Rheumatology; *M*, male; *RF*, rheumatoid factor; *TMJ*, temporomandibular joint.

## B. Systemic Lupus Erythematosus (SLE)<sup>1,2,7-10</sup>

1. Epidemiology
  - a. 90% female, typically during reproductive years. However, F:M ratio closer to 5:1 for childhood onset disease
  - b. Childhood onset accounts for up to 20% of cases
  - c. Average age of onset: 12 years
  - d. Higher prevalence in non-Caucasian individuals
2. Heterogeneous clinical manifestations. Patients with SLE may not fit all of the classification criteria. However, these classification criteria can be used to support a clinical diagnosis.
  - a. American College of Rheumatology (ACR) criteria: Positive diagnosis **requires at least four** of the following:
    - (1) Malar rash, discoid rash, photosensitivity, oral ulcers, arthritis, serositis (pleuritis or pericarditis), renal disorder (persistent proteinuria or cellular casts), neurologic disorder (seizures, psychosis), hematologic disorder (hemolytic anemia, leukopenia, lymphopenia, thrombocytopenia), positive antinuclear antibody (ANA), other immunologic disorder (positive anti-double-stranded DNA [dsDNA], anti-Smith or antiphospholipid antibodies)
  - b. Systemic Lupus International Collaborating Clinics (SLICC) criteria: Positive diagnosis requires four items (at least one clinical and one immunologic) OR biopsy-proven lupus nephritis with positive ANA or anti-dsDNA.
    - (1) Clinical: Acute cutaneous, chronic cutaneous, oral ulcers, alopecia, synovitis, serositis, renal disorder, neurologic disorder, hemolytic anemia, leukopenia, thrombocytopenia
    - (2) Positive immunologic testing: ANA, anti-dsDNA, anti-Smith, antiphospholipid, low C3/C4 complements or CH50, direct Coombs test in the absence of hemolytic anemia
3. Other clinical symptoms: Unexplained recurrent fever, weight loss, fatigue, anorexia, myalgia, arthralgia

4. Common autoantibodies
  - a. ANAs are present in >99% of children with SLE.
  - b. anti-dsDNA and anti-Smith are highly specific for SLE.
  - c. anti-Ro (SSA) and anti-La (SSB) can be seen in SLE and can be associated with Sjögren syndrome and neonatal lupus (see Neonatal SLE).
5. Renal involvement
  - a. 20% to 75% of children under 18 years will have renal involvement.
  - b. 18% to 50% progress to end-stage kidney disease.
  - c. Kidney biopsy can be helpful for both disease management and prognostication.
6. Treatment varies depending on disease severity and end-organ system involvement.
  - a. NSAIDs
  - b. Corticosteroids
  - c. Hydroxychloroquine
  - d. Methotrexate
  - e. Azathioprine
  - f. Leflunomide
  - g. Cyclophosphamide
  - h. Mycophenolate mofetil
  - i. Biologics such as rituximab and belimumab
  - j. Adjunctive therapy with antihypertensives and renoprotective agents

### **C. Drug-Induced SLE<sup>11</sup>**

1. Some inciting drugs include: hydralazine, minocycline, procainamide, quinidine, isoniazid, interferon-alfa, chlorpromazine, ethosuximide, carbamazepine, anti-TNF therapy.
2. Usually with milder disease than idiopathic SLE
3. Presenting symptoms: Arthralgias, myalgias, fever, weight loss, serositis, polyarthritis
4. Rarely involves renal disorders and neuropsychiatric symptoms
5. More common lab findings: Positive ANA, anti-histone, anti-dsDNA
6. Treatment involves removal of the offending agent and, for severe disease, can include short-term immunosuppressive therapies.

### **D. Neonatal SLE<sup>12-14</sup>**

1. Neonates born to mothers with positive anti-Ro (anti-SSA) or anti-La (anti-SSB) can develop a transient lupus-like syndrome due to transplacental passage of these autoantibodies.
2. Frequently, the mothers are healthy and do not have known autoimmune disease. The mothers may have isolated positive anti-Ro or anti-La, primary Sjögren syndrome, or SLE.
3. Clinical features in the neonate include: rash (annular erythema on eyelids and scalp, papular or plaque-like lesions), hepatomegaly, thrombocytopenia, hemolytic anemia, congenital atrioventricular heart block (1st, 2nd, or 3rd degree), and hydrops fetalis.
4. Neonates with heart block may require permanent pacemaker and are at continued risk for cardiac dysfunction later in life.

5. Other inflammatory features in the neonate resolve as maternal autoantibodies are cleared. Often within 6 months
6. Treatment for neonatal lupus is dependent on presenting symptoms and cardiac involvement.
7. Treatment may include steroids, cardiac pacing, and IVIG.

### E. Vasculitis<sup>1,2,15,16</sup>

1. Refer to [Table 27.2](#).
2. Treatment
  - a. Note that treatment recommendations are largely based on adult studies because of limited clinical trials in pediatric patients.
  - b. Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) initiative first-line treatment recommendations for most severe vasculitis may include corticosteroids, cyclophosphamide, and/or plasma exchange. Rituximab may also be used.
    - (1) In [Table 27.2](#), this is referred to as “first-line vasculitis therapy.”

### F. Sarcoidosis<sup>2,26,27</sup>

1. Epidemiology
  - a. Prepubertal: Very rare
  - b. During puberty and postpuberty: Peak onset at 13 to 15 years; males and females are equally affected
2. Multisystem, infiltrative, noncaseating granulomatous disease of unknown etiology; lung is the most commonly involved organ
  - a. Pulmonary: Bilateral hilar adenopathy, restrictive and obstructive disease
  - b. Ocular: Anterior uveitis, conjunctival granulomas
  - c. Cutaneous: Erythema nodosum, plaques, alopecia
  - d. CNS: Bilateral or unilateral Bell palsy (more common in postpubertal children), seizures (more common in prepubertal children), aseptic meningitis
3. Definitive diagnosis with lymph node biopsy; elevated angiotensin-converting enzyme (ACE) levels can be helpful but not diagnostic
4. Blau syndrome and early-onset sarcoidosis are two monogenic forms of sarcoidosis characterized by polyarthritis, uveitis, and dermatitis; symptom onset <4 years
5. Systemic immune suppression is often needed for treatment.

### G. Scleroderma<sup>2,28</sup>

1. Both juvenile localized scleroderma and juvenile systemic sclerosis typically present in mid-childhood between 6 and 11 years of age, with a female predominance
2. In children, localized scleroderma is more common than systemic sclerosis and involves skin, muscle, and bone.
3. Treatment of localized scleroderma includes topical and systemic therapies such as corticosteroids, methotrexate, tacrolimus, imiquimod, and phototherapy.
4. Systemic sclerosis: Diffuse and limited disease; diffuse disease characterized by severe Raynaud syndrome, resulting in digital ulcers,

TABLE 27.2

CHILDHOOD VASCULITIS SYNDROMES<sup>1,2,15,16</sup>

Vasculitis	Involved Vessels	Epidemiology	Clinical Manifestations	Treatment
Takayasu arteritis <sup>17</sup>	Large arteries	Predominantly young adult women. If childhood onset, more likely in adolescence but can be seen in all age groups	Aneurysms, thrombosis, and stenosis of large arteries, hypertension is common	<ul style="list-style-type: none"> <li>• First-line vasculitis therapy</li> <li>• Therapy will also likely include hypertension management, which may be medically managed or require revascularization procedures</li> <li>• Maintenance therapy may include: methotrexate, azathioprine, or mycophenolate mofetil or other biologics</li> </ul>
Kawasaki disease	Medium-sized arteries	Children <5 years old	Fever, rash, lymphadenopathy, conjunctival injection, peripheral edema. See <a href="#">Chapter 7</a> for diagnostic criteria.	<ul style="list-style-type: none"> <li>• First-line: IVIG, aspirin</li> <li>• Treatment refractory options: corticosteroids, infliximab</li> </ul>
Polyarteritis nodosa <sup>17,18</sup>	Medium-sized arteries Histopathology with inflammatory infiltrates of vessel walls and fibrinoid necrosis	Slight female predominance, most cases presenting at 9–10 years of age, but there is wide age spectrum	<ul style="list-style-type: none"> <li>• Typical presentation with fever and weight loss</li> <li>• Commonly associated symptoms include: skin involvement (livedo reticularis, tendon nodules, infarcts, purpura), myalgia, kidney involvement (hypertension), and peripheral neuropathy.</li> </ul>	<ul style="list-style-type: none"> <li>• For mild disease: corticosteroids ± NSAIDs</li> <li>• For severe disease: first-line vasculitis therapy</li> <li>• For treatment of refractory disease, can consider: TNF blockade, B-cell depleting therapy, or IL-6 blockade</li> </ul>

Immunoglobulin A (IgA) vasculitis (Henoch-Schönlein purpura) <sup>17,19</sup>	Arterioles and venules, IgA-containing immune deposits seen on biopsy	Most common pediatric vasculitis, typically presents between 3 and 12 years old, Chronic renal disease develops in 1%–2% of children	Palpable purpura involving buttocks and lower extremities, colicky abdominal pain, subcutaneous or scrotal edema, migratory arthralgias/arthritis, renal disease, glomerulonephritis, intussusception (frequently ileoileal)	<ul style="list-style-type: none"> <li>• First-line: Supportive care</li> <li>• Corticosteroids can be used in the setting of severe GI disease.</li> <li>• Chronic corticosteroids, azathioprine, or mycophenolate mofetil may be used in refractory disease.</li> </ul>
Microscopic polyangiitis (MPA) <sup>20-22</sup>	Necrotizing vasculitis of arterioles, venules, and capillaries	Very rare in pediatrics	Necrotizing glomerulonephritis and pulmonary capillaritis leading to alveolar hemorrhage and hemoptysis	<ul style="list-style-type: none"> <li>• First-line vasculitis therapy</li> <li>• Refractory disease: Consider B cell-depleting biologic therapies.</li> </ul>
Granulomatosis with polyangiitis (GPA) <sup>20,22</sup>	Necrotizing small and medium-size vessel vasculitis with granulomatous inflammation	Most common ANCA-associated vasculitis in pediatrics	Diagnosis with at least 3 of the following: <ul style="list-style-type: none"> <li>• Histopathology with granulomatous inflammation</li> <li>• Upper airway involvement: epistaxis, sinusitis, otitis media, and hearing loss</li> </ul>	<ul style="list-style-type: none"> <li>• First-line vasculitis therapy</li> <li>• Refractory disease: Consider B cell-depleting biologic therapies.</li> </ul>

Continued

TABLE 27.2

CHILDHOOD VASCULITIS SYNDROMES<sup>1,2,15,16</sup>—CONT'D

Vasculitis	Involved Vessels	Epidemiology	Clinical Manifestations	Treatment
			<ul style="list-style-type: none"> <li>• Pulmonary involvement: nodules, infiltrates, hemorrhage</li> <li>• ANCA positive</li> <li>• Renal Involvement: glomerulonephritis</li> <li>• Laryngotracheobronchial stenoses</li> </ul>	
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) <sup>22</sup>	Necrotizing vasculitis of small arteries and veins	Very rare in pediatrics	Associated with asthma, nasal polyps, and allergic rhinitis	<ul style="list-style-type: none"> <li>• First-line vasculitis therapy</li> <li>• Mepolizumab (anti IL-5 monoclonal antibody) may also be used.</li> </ul>
Behcet disease <sup>23</sup>	Occlusive vasculitis in arterioles and veins	M = F prevalence in childhood, Males more frequently with severe vasculitis and uveitis, Females more frequently with genital ulcers and erythema nodosum, peak age of onset 8–12 years, often associated with HLA-B51	Defined by the presence of oral ulcers (at least 3 in a year), along with two of the following: recurrent genital ulcers, ocular disease, skin lesions, and a positive pathergy test (traumatic injury to skin results in development of a sterile pustule in 24–48 hours)	<ul style="list-style-type: none"> <li>• For oral/genital ulcers and anterior uveitis: Topical corticosteroids</li> <li>• For disease refractory to topical steroids OR as a first-line agent for posterior uveitis and retinal vasculitis: Systemic corticosteroids</li> <li>• Colchicine can be used for prevention of recurrent ulcers.</li> <li>• Alternative options for severe disease: Anti-TNF agents, azathioprine, cyclophosphamide, cyclosporine A</li> </ul>

Raynaud phenomenon<sup>24,25</sup>

Exaggerated vasoconstriction dictated by vascular, neural, and intravascular abnormalities

More common in women  
Can be idiopathic or associated with disorders such as SLE, mixed connective tissue disease, scleroderma, antiphospholipid antibody syndrome

Response to cold or emotional stress: Sudden onset color change in digits with demarcated skin pallor due to constricted blood flow, followed by cyanotic skin, and finally erythema with reperfusion; similar findings can be seen at sites other than digits; ischemic disease more likely to be seen in patients with a secondary cause

- First line for primary Raynaud syndrome: supportive care and education
- Pharmacologic management: calcium-channel blockers
- Management of critical digital ulcers: hospitalization with intensive vasodilator therapy and anti-platelet therapy (aspirin). If no improvement with initial management in a few hours, escalation to heparin and more intensive vasodilation is recommended.

*GI*, Gastrointestinal; *URI*, upper respiratory infection. *NSAID*, Non-Steroidal Anti-Inflammatory Drug; *TNF*, Tumor Necrosis Factor; *IVIG*, Intravenous Immunoglobulin; *IL*, Interleukin; *ANCA*, Anti-Neutrophil Cytoplasmic Antibodies; *SLE*, Systemic Lupus Erythematosus

pulmonary arterial hypertension (PAH), pulmonary fibrosis, esophageal dysmotility, renal disease

5. Treatment of systemic sclerosis involves management of the symptoms and underlying systemic inflammation.
  - a. Raynaud syndrome: Nifedipine or PDE-5 inhibitors
  - b. PAH: Endothelin receptor antagonist, PDE-5 inhibitors, riociguat, epoprostenol
  - c. Skin and lung disease: Methotrexate, cyclophosphamide, and biologic therapy
  - d. GI disease: Proton pump inhibitors, prokinetic medications
  - e. Renal disease: ACE inhibitors

#### H. Sjögren Syndrome<sup>2,29</sup>

1. Female-to-male ratio 5:1 in children, age of onset 7 to 14 years old
2. Widespread lymphocytic infiltration of salivary and lacrimal glands with secondary atrophy and obliteration of secretory acini
3. Keratoconjunctivitis sicca: Dry eyes secondary to decreased tear production by lacrimal glands
4. Xerostomia: Dry mouth from decreased salivary gland production
5. May present as parotid gland swelling in children
6. Other possible system involvement: MSK, pulmonary, neurologic, renal
7. Treatment focuses mostly on symptomatic relief and management of chronic glandular changes.
  - a. Keratoconjunctivitis sicca: Artificial tears
  - b. Xerostomia: Sugar-free hard candies or chewing gum
  - c. Systemic immune modulation and suppressing medications such as hydroxychloroquine, corticosteroids, methotrexate, and biologic therapy

#### I. Juvenile Dermatomyositis (JDM)<sup>2,30</sup>

1. More common in females (up to 2.5:1 female:male)
2. Median age of onset: 7 years old
3. Typically symmetric muscle weakness, involves more central musculature
4. Cutaneous findings: Gottron papules overlying knuckles and knees (91%), heliotrope rash (83%), malar rash (42%)
5. Treatment options depend on disease severity and prognosis and include the use of systemic immune modulation and suppressing medications such as intravenous immunoglobulins (IVIG), hydroxychloroquine, corticosteroids, methotrexate, mycophenolate mofetil, and biologic agents.

#### J. Other Rheumatologic Disorders<sup>2,31,32</sup>

##### 1. Reactive arthritis

- a. Sterile inflammatory arthritis in response to a preceding (<4 weeks) bacterial infection, particularly of the gastrointestinal or genitourinary tracts
- b. Common triggers: *Salmonella*, *Yersinia*, *Campylobacter*, *Shigella*, *Chlamydia trachomatis*

- c. Involves acute asymmetrical oligoarticular arthritis of larger joints, often the lower extremities
- d. Can be associated with fever, weight loss, fatigue, tendinitis, bursitis, anterior uveitis, conjunctivitis, erythema nodosum, urethritis, and cervicitis
- e. Therapies include treatment of the precipitating infection, if needed, and supportive care for arthritis symptoms with NSAIDs. Can consider intraarticular or systemic steroids for NSAID-refractory arthritis

## 2. **Reactive arthritis after a streptococcal infection**

- a. Acute rheumatic fever (ARF)
  - (1) Clinical features: Arthritis, carditis, erythema marginatum, nodules, Sydenham chorea
  - (2) Pathogenesis: M protein from Group A *Streptococcus* induces production of autoimmune antibodies that are cross-reactive.
  - (3) Typically occurs 2 to 3 weeks after tonsillopharyngitis infection
  - (4) Treatment: Arthritis is responsive to NSAIDs, transient, and migratory.
    - (a) Poststreptococcal reactive arthritis
      - (i) Does not meet diagnostic criteria for ARF
      - (ii) Typically occurs sooner after streptococcal infection (7–10 days)
      - (iii) Can involve large and small joints and axial skeleton
      - (iv) Arthritis is less responsive to NSAIDs, persistent, and additive.
      - (v) Cardiac involvement is less common but can occur.

## **K. Multisystem Inflammatory Syndrome in Children (MIS-C)**<sup>33-35</sup>

1. Emergence of MIS-C co-occurred with the 2019 SARS-CoV-2 pandemic. MIS-C is a postinfectious inflammatory syndrome after symptomatic or asymptomatic infection with the SARS-CoV-2 virus.
2. It is a rare complication of SAR-CoV-2 virus infection.
3. Case Definition for MIS-C was derived by the Centers for Disease Control and Prevention (CDC):  
An individual aged <21 years who presents with fever (>38.0° C for >24 hours, or subjective fever lasting >24 hours), laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization affecting multiple organ systems (>2) **AND** without other plausible diagnosis **AND** positive for current or recent SARS-CoV-2 infection by reverse transcription polymerase chain reaction, serology, or antigen test or confirmed COVID-19 case within 4 weeks of onset of symptoms
4. Common clinical features include: fever, mucocutaneous lesions, conjunctivitis, mucositis, peripheral edema, lymphadenopathy, diarrhea, vomiting, abdominal pain, coronary artery aneurysm, myocarditis and cardiac dysfunction, altered mental status, seizures, focal neurologic deficits, respiratory failure, hypotension, and shock. Some develop acute renal failure and pancreatitis.

5. Common laboratory findings: Evidence of systemic inflammation including cytopenia, elevated ESR, C-reactive protein (CRP), elevated ferritin, coagulopathy with prolonged PTT/PT, and elevated d-dimer. Evidence of cardiac involvement with elevated pro-BNP and troponin
6. MIS-C can be complicated by macrophage activation syndrome (see section on Juvenile Idiopathic Arthritis).
7. The American College of Rheumatology provides continued guidance on evaluation and management of MIS-C.
  - a. Suggested workup includes: complete blood count (CBC), comprehensive metabolic panel (CMP), PTT, PT, INR, CRP, ESR, ferritin, fibrinogen, d-dimer, troponin, Pro-BNP, EKG, echocardiogram.
  - b. Evaluation for infectious and noninfectious causes during workup for MIS-C is recommended.
  - c. Treatment includes: IVIG, systemic steroids, biologic therapy with agents such as anakinra (IL-1 blockade), or TNF inhibition with infliximab.
  - d. Adjunctive therapies include: antiplatelet and anticoagulation with aspirin, enoxaparin, or warfarin for coronary artery involvement. Anticoagulation in patient with MIS-C and coronary artery aneurysms may be guided by the American Heart Association recommendations for Kawasaki disease (see [Chapter 7](#) for a full discussion of cardiac involvement in MIS-C and Kawasaki disease). MIS-C patients with thrombosis should be on anticoagulation (low-dose aspirin and therapeutic) for 3 months or depending on resolution of thrombi on imaging at 4 to 6 weeks postdiagnosis.
8. Treatment teams should include input from Rheumatology, Cardiology, Infectious Disease, and Hematology, and if other organ systems involved, may also include: Nephrology, Neurology, Gastroenterology/Hepatology.

## II. INTERPRETATION OF LAB STUDIES USED IN THE DIAGNOSIS AND MONITORING OF RHEUMATOLOGIC DISORDERS<sup>1</sup>

Most laboratory studies used to diagnose rheumatic diseases are nonspecific, and results must be interpreted within the context of the full clinical picture. Once a diagnosis is established, however, some studies may be used to follow the clinical course, indicating flares or remission of the disease.

### **A. Acute Phase Reactants: Indicate presence of inflammation when elevated. Elevation is nonspecific and can result from trauma, infection, rheumatologic disorder or malignancy**

1. Erythrocyte sedimentation rate (ESR)<sup>36,37</sup>
  - a. Measure of the rate of fall of red blood cells in the first 1 hour after collection in anticoagulated blood within a vertical tube; reflects level of rouleaux formation caused by acute-phase reactants
  - b. Can be falsely lowered in afibrinogenemia, polycythemia, and hemoglobinopathies

- c. Increased levels can be seen in pregnancy, obesity, increasing age, and anemia
- 2. C-reactive protein (CRP)<sup>38,39</sup>
  - a. It is a nonspecific marker of inflammation; however:
    - (1) In most active-phase rheumatologic diseases CRP will increase to 1–10 mg/dL.
    - (2) CRP >10 mg/dL raises concern for bacterial infection or systemic vasculitis.
      - (a) Increases and decreases rapidly owing to short half-life (~ 19 hours)
      - (b) Not a useful marker of inflammation in SLE

### **B. Autoantibodies (See Table 27.3 for Association With Rheumatologic Diseases)<sup>36,39-43</sup>**

- 1. Antinuclear autoantibodies (ANA)
  - a. Can be useful in the diagnosis of SLE
  - b. Can be positive in other autoimmune diseases such as scleroderma (systemic and local), JIA, and JDM
  - c. Can be used to stratify risk of uveitis in patients with JIA
  - d. Can be positive in up to 33% of asymptomatic individuals, depending on cut-off titers used
- 2. Anti-dsDNA (double-stranded DNA)
  - a. Highly specific for SLE
  - b. Associated with lupus nephritis
- 3. Anti-centromere antibodies
  - a. Highly specific for systemic sclerosis (>99%)
  - b. Is not a sensitive test for the diagnosis of systemic sclerosis (19%)
- 4. Anti-Scl 70
  - a. Antibodies against topoisomerase I
  - b. In adulthood it is not very sensitive (43%) but highly specific (90%) for systemic sclerosis
  - c. Can predict increased risk for pulmonary involvement in systemic sclerosis
- 5. Anti-Neutrophil Cytoplasmic Antibodies (ANCA)
  - a. cANCA/PR3-ANCA: Mostly associated with GPA
  - b. pANCA/MPO-ANCA: Mostly associated with MPA, polyarteritis nodosa, SLE
- 6. Rheumatoid factor (RF)
  - a. IgM to the Fc portion of IgG
  - b. Can be used in the classification of specific subtypes of JIA
  - c. Can also be seen in Sjögren syndrome, SLE, sarcoidosis, systemic sclerosis
- 7. Anticyclic citrullinated peptide antibodies (anti-CCP)
  - a. Highly specific for rheumatoid arthritis in adults
  - b. In the pediatric population, primarily seen in polyarticular RF+ JIA
  - c. Associated with more aggressive disease

TABLE 27.3

## COMMON RHEUMATOLOGIC DISEASES AND AUTOANTIBODIES

Disease	Associated Antibody	Interpretation of Results	Clinical Considerations
SLE	ANA Anti-double-stranded DNA Anti-Smith Antiphospholipids	ANA sensitivity >95% Anti-dsDNA specificity is 97% Anti-Smith specificity 55%–100%	Most patients with positive ANA do not have SLE, but almost all patients with SLE have a positive ANA. Measure anti-dsDNA when ANA positive. Anti-phospholipids present in up to 50% of SLE patients; associated with thrombosis and fetal loss
Juvenile idiopathic arthritis	ANA	ANA positive in 80% of those with oligoarticular type	Typically RF and CCP negative; when positive, may indicate erosive disease
Vasculitis	ANCA-cytoplasmic/PR3 (proteinase-3) ANCA-perinuclear/MPO (myeloperoxidase)	90% of patients with active GPA and MPA are ANCA positive	c-ANCA associated with GPA p-ANCA associated with MPA and Churg-Strauss
Dermatomyositis/polymyositis	ANA Anti-Jo-1	Specificity of Anti-Jo-1 99% ANA may be normal	Anti-Jo-1 associated with polymyositis with interstitial lung disease and JDM
Mixed connective tissue disease	Anti-RNP	The presence of antibodies to RNP is required for diagnosis	Also present in SLE, systemic sclerosis
Scleroderma	ANA Anticentromere Anti-Scl-70	ANA sensitivity >85% Anticentromere specificity >98%	Anti-Scl-70 associated with diffuse systemic sclerosis, while anticentromere with limited disease
Sjögren syndrome	Anti-Ro/SS-A Anti-La/SS-B	Anti-Ro sensitivity 75%	Associated with neonatal cutaneous lupus Incidence of congenital heart block increased for infants born to mothers with high titers of anti-Ro and anti-La
Drug-induced SLE	Antihistone	Sensitivity >95%	Antihistone antibodies do not distinguish drug-induced lupus from SLE.

ANA, Antinuclear antibody; ANCA, antineutrophil cytoplasmic antibodies; CCP, cyclic citrullinated peptide; GPA, granulomatosis with polyangiitis; JDM, juvenile dermatomyositis; MPA, microscopic polyangiitis; SLE, systemic lupus erythematosus.

Data from Stone JH. *Current Diagnosis & Treatment in Rheumatology*. 4th ed. McGraw-Hill Medical; 2021.

**C. Complement:** The complement system is composed of a series of plasma proteins and cellular receptors that function together to mediate host defense and inflammation. Inflammatory processes may increase the synthesis or consumption of these proteins.

1. Total hemolytic complement level (CH<sub>50</sub>)
  - a. Assay that assesses the complement pathway as a whole
  - b. Low levels indicate reduced function or low levels of complement proteins.
  - c. Typically low values are seen in SLE, acute poststreptococcal glomerulonephritis, and subacute bacterial endocarditis.
2. C3/C4
  - a. Commonly measured in the diagnosis and clinical monitoring of SLE
  - b. Low levels indicate high levels of immune complex deposition.

### III. MEDICATIONS: MECHANISMS OF ACTION, TOXICITIES, AND RECOMMENDED SURVEILLANCE<sup>2</sup> (SEE TABLE 27.4)

#### IV. Primary Care Management of Rheumatologic Diseases<sup>54-57</sup>

##### A. Vaccination (See Chapter 16)

1. Patients on immunosuppressive therapies cannot receive live vaccines but can receive killed/inactivated vaccines.
2. Special considerations should be made for immunocompromised patients on biologics and other immunosuppressive therapy.
3. Patients who have received IVIG should not have live vaccines for up to 11 months following the IVIG administration.

##### B. Weight Management

1. As a result of chronic inflammation, malnutrition can be a common comorbidity in children with rheumatologic conditions.
2. Obesity is a common concern given the frequent use of corticosteroids.

##### C. Bone and Skin Health

1. Chronic steroid use, presence of arthritis, and many medications used in the maintenance therapy of rheumatologic diseases increase the risk for osteopenia. Ensure adequate calcium and vitamin D intake and weight-bearing activities.
2. Patients with SLE and dermatomyositis are particularly vulnerable to ultraviolet radiation. It is recommended that patients use broad-spectrum sunscreen with a high sun-protection factor (SPF) and not use tanning booths.

##### D. Reproductive Health

1. Many medications used in the treatment of rheumatologic diseases are teratogenic.
2. The American College of Rheumatology provides recommendations for the use of contraceptives and reproductive assistance (see Chapter 5 for more information regarding contraception).

**TABLE 27.4****COMMON MEDICATIONS USED IN PEDIATRIC RHEUMATOLOGY**<sup>2,44-53</sup>

Medication	Mechanism of Action	Side Effects	Recommended Surveillance
<b>NONSPECIFIC THERAPIES</b>			
Nonsteroidal antiinflammatory drugs (NSAIDs): naproxen, ibuprofen, celecoxib, meloxicam, acetylsalicylic acid	Cyclooxygenase (COX) inhibitor	Nephrotoxic, GI bleed	No specific surveillance recommendations. However, periodic evaluation for medication side effects is advised.
Corticosteroids: prednisone, prednisolone, methylprednisolone	Antiinflammatory and immunosuppressive, predominant effects on T-cells	Growth suppression, osteoporosis, avascular necrosis, Cushing syndrome, CNS: mood and behavioral disturbance, cataracts, glaucoma, hypertension	No specific surveillance recommendations. However, periodic evaluation for medication side effects is advised.
Intravenous immunoglobulins (IVIG)	Multiple proposed mechanisms of action	Infusion reaction, anaphylactoid reactions, aseptic meningitis	Labs: Immunoglobulin levels prior to initiation
<b>DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs)</b>			
Methotrexate	Folic acid analogue, targets dihydrofolate reductase (DHFR) and thymidylate synthetase (TYMS) to decrease de novo purine synthesis	GI upset, hepatotoxicity, hematologic toxicity (macrocytic anemia, leukopenia, thrombocytopenia, pancytopenia), teratogenicity	<ul style="list-style-type: none"> <li>• Labs: CBC, liver enzymes, creatinine</li> <li>• Timing: At initiation, 4–8 weeks after initiation, then every 12 weeks once stable</li> </ul>
Hydroxychloroquine	Exact mechanism of action is unknown. A number of proposed mechanisms exist: inhibit self-antigen binding, inhibit neutrophil function, decrease effect of prostaglandins on end-	Retinal toxicity, GI upset, headache, anxiety	Obtain baseline ophthalmology exam within first month of therapy and then annually.

		targets, decrease production of inflammatory molecules (TNF, IL-6, IFN- $\gamma$ ).	
Sulfasalazine	Exact mechanism of action is unknown. A number of proposed mechanisms exist: Decrease enzyme activity involved in the formation of leukotrienes and prostaglandins, impacts gut bacterial growth, which may have an impact in spondyloarthropathies.	Photosensitivity, oral ulcer, Steven-Johnson syndrome	<ul style="list-style-type: none"> <li>• Labs: CBC with differential, liver enzymes, creatinine, urine analysis</li> <li>• Timing: At initiation, every 1–2 weeks with dose adjustments, then every 3 months while on stable dose</li> <li>• Consider testing for G6PD deficiency on initiation.</li> <li>• Obtain immunoglobulins every 6 months.</li> </ul>
Leflunomide	Inhibits de novo pyrimidine synthesis	GI upset, hepatotoxicity, alopecia, teratogenicity	<ul style="list-style-type: none"> <li>• Labs: CBC with differential, liver enzymes, creatinine</li> <li>• Timing: At initiation, every 2–4 weeks with dose adjustments, then every 3 months while on stable dose</li> </ul>
<b>CYTOTOXIC AGENTS</b>			
Azathioprine	Purine analog that inhibits de novo purine synthesis	Common: GI upset Rare: hepatotoxicity, interstitial pneumonitis, maculopapular rash, cytopenias	<ul style="list-style-type: none"> <li>• CBC with differential at initiation, every 1–2 weeks with dose adjustments, then every 4–12 weeks while on stable dose</li> <li>• Liver enzymes, BUN, creatinine at initiation, every 4 weeks with dose adjustments, then every 12 weeks while on stable dose</li> <li>• TPMT genotype and/or activity at initiation</li> </ul>
Mycophenolate	Inhibits monophosphate dehydrogenase to inhibit de novo guanine synthesis	GI upset, cytopenias, opportunistic infections, teratogenic	<ul style="list-style-type: none"> <li>• Labs: CBC with differential every 4–12 weeks</li> </ul>

TABLE 27.4

COMMON MEDICATIONS USED IN PEDIATRIC RHEUMATOLOGY<sup>2,44-53</sup>—CONT'D

Medication	Mechanism of Action	Side Effects	Recommended Surveillance
Cyclophosphamide	Alkylating agent	Hemorrhagic cystitis, GI upset, alopecia, leukopenia, thrombocytopenia, infertility	<ul style="list-style-type: none"> <li>• Vitals when administering IV formulation (ensure pretreatment with Mesna and intravenous fluids)</li> <li>• Close urine output and urine specific gravity monitoring</li> <li>• Labs: CBC with differential on day 7–10 postinfusion</li> </ul>
Cyclosporine	Calcineurin inhibitor	Hypertension, hepatotoxicity, nephrotoxicity	<ul style="list-style-type: none"> <li>• Labs: CBC with differential, liver enzymes, BUN, creatinine, urine analysis</li> <li>• Timing: At initiation, continued until desired cyclosporine trough level is reached, and then monthly</li> <li>• Blood pressure monitoring</li> </ul>
<b>BIOLOGIC AGENTS</b>			
Antitumor necrosis factor-alpha agents (anti-TNF- $\alpha$ ) <sup>44</sup>	<ul style="list-style-type: none"> <li>• Etanercept: Small protein with anti-TNF ligand bound to Fc portion of human IgG</li> <li>• Adalimumab: Binds soluble and membrane-bound TNF</li> <li>• Infliximab: Binds soluble and membrane-bound TNF</li> </ul>	<p>Common: Infection, infusion-related reaction, GI upset, headache</p> <p>Rare: Hepatotoxic, hematologic malignancy</p>	<ul style="list-style-type: none"> <li>• Labs: CBC with differential, liver enzymes</li> <li>• Timing: At initiation, then every 12 weeks</li> <li>• Screen for viral hepatitis and tuberculosis prior to initiation</li> </ul>
Rituximab <sup>45</sup>	Anti-CD20 monoclonal antibody	<p>Common: Infection, GI upset, anemia, peripheral edema, headache, muscle spasms</p> <p>Rare: Infusion-related reaction, HBV reactivation, progressive multifocal leukoencephalopathy</p>	<ul style="list-style-type: none"> <li>• Labs: CBC, liver enzymes, GGT</li> <li>• Timing: At initiation, then every 4–12 weeks</li> <li>• Screen for viral hepatitis and tuberculosis prior to initiation</li> <li>• Assess Immunoglobulin levels every 3 months</li> <li>• Assess B-cell CD19/20 depletion 1 month before and after infusion</li> </ul>

Tocilizumab <sup>46</sup>	IL-6 receptor monoclonal antibody	Infection, headache, hypertension, hepatotoxic, injection site reactions	<ul style="list-style-type: none"> <li>• Labs: CBC with differential, liver enzymes, lipid panel</li> <li>• Timing: At initiation, time of second infusion, then every 2–4 weeks, lipid screening 4–8 weeks after initiation, then every 6 months</li> <li>• Screen for viral hepatitis and tuberculosis prior to initiation.</li> </ul>
Canakinumab <sup>47</sup>	Binds to IL-1 $\beta$	GI upset, headache, infection, vertigo	<ul style="list-style-type: none"> <li>• Labs: CBC with differential, liver enzymes, lipid panel</li> <li>• Timing: At initiation, then every 12 weeks, lipid panel after 2–3 months of therapy</li> <li>• Screen for latent tuberculosis prior to initiation: Tuberculosis testing.</li> </ul>
Anakinra	IL-1 receptor antagonist	Injection-site reactions	<ul style="list-style-type: none"> <li>• Labs: CBC with differential, liver enzymes, lipid panel</li> <li>• Timing: At initiation, then every 12 weeks, lipid panel 2–3 months after starting therapy</li> <li>• Screen for viral hepatitis and tuberculosis prior to initiation and intermittently during use.</li> </ul>
Janus kinase (JAK) inhibitors: Tofacitinib <sup>48</sup> , baricitinib <sup>49</sup> , ruxolitinib	Numerous subtypes of JAK proteins exist; small molecule drugs inhibit the dimerization of JAK proteins to prevent further downstream signaling.	Risk of serious bacterial, mycobacterial, and fungal infections, anemia, thrombocytopenia, neutropenia, hepatotoxicity, thrombosis	<ul style="list-style-type: none"> <li>• Labs: CBC with differential, liver enzymes, lipid panel</li> <li>• Timing: At initiation, every 4–8 weeks with dose adjustments, then every 3 months once at stable dose</li> <li>• Close monitoring of heart rate and blood pressure</li> <li>• Screen for viral hepatitis and latent tuberculosis prior to initiation.</li> </ul>

Continued

TABLE 27.4

COMMON MEDICATIONS USED IN PEDIATRIC RHEUMATOLOGY<sup>2,44-53</sup>—CONT'D

Medication	Mechanism of Action	Side Effects	Recommended Surveillance
Abatacept <sup>50</sup>	Fusion protein that inhibits T-cell activation	GI upset, fever, teratogenicity, infusion reaction	<ul style="list-style-type: none"> <li>• Labs: CBC with differential, liver enzymes</li> <li>• Timing: At initiation, then every 12 weeks</li> <li>• Screen for viral hepatitis and tuberculosis prior to initiation.</li> <li>• Close monitoring of vital signs during infusion (every 30 minutes)</li> </ul>
Ustekinumab <sup>51-53</sup>	IgG antibody that inhibits downstream effects of inflammatory molecules, such as IL-12 and IL-23	Nasopharyngitis, upper respiratory tract infections, headache, cardiovascular events seen in adult studies (myocardial infarction, stroke)	<ul style="list-style-type: none"> <li>• Screen for hepatitis and tuberculosis prior to initiation.</li> <li>• Labs: CBC with differential, complete metabolic panel</li> <li>• Timing: At initiation, every 3–6 months</li> <li>• Measure trough concentrations in between infusions</li> <li>• Monitor for signs of posterior reversible encephalopathy syndrome (PRES)</li> </ul>

*BUN*, Blood urea nitrogen; *CBC*, complete blood count; *CMP*, comprehensive metabolic panel; *DMARD*, disease-modifying antirheumatic drug; *GI*, gastrointestinal; *IV*, intravenous; *LFT*, liver function test; *SIADH*, syndrome of inappropriate antidiuretic hormone; *s/p*, status post; *TB*, tuberculosis; *TNF*, tumor necrosis factor.

**E. Ophthalmologic**

1. Individuals with JIA should have regular ophthalmology screenings.
  - a. Screening intervals are dependent on uveitis risk, presence of disease, and current therapy.

**F. Laboratory Monitoring**

1. As a primary care provider, be aware that multiple medications require frequent monitoring. Ensure the patient has adequate follow-up with their primary rheumatologist.

**REFERENCES**

A complete list of references can be found online.

## REFERENCES

1. Kliegman R. *Nelson Textbook of Pediatrics*. 21st ed. Elsevier; 2020.
2. Petty R, Laxer R, Lindsley C, et al. *Textbook of Pediatric Rheumatology*. 8th ed. Elsevier; 2021.
3. Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision. edmonton; 2001. *J Rheumatol*. 2004;31:390–392.
4. Macaubas C, Nguyen K, Milojevic D, Park JL, Mellins ED. Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. *Nature Rev Rheumatol*. 2009;5(11):616–626.
5. Heiligenhaus A, Heinz C, Edelsten C, Kotaniemi K, Minden K. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. *Ocular Immunol Inflammation*. 2013;21(3):180–191.
6. Crayne C, Cron RQ. Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg. *Eur J Rheumatol*. 2020;7(suppl 1):S13.
7. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*. 1997;40:1725.
8. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum*. 2012;64(8):2677–2686.
9. Johnson SR, Khanna D, Daikh D, et al. Use of consensus methodology to determine candidate items for systemic lupus erythematosus classification criteria. *J Rheumatol*. 2019;46(7):721–726.
10. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options: part II. *J Am Acad Dermatol*. 2011;65(6):e179–e193.
11. Rubin RL. Drug-Induced Lupus. In: Tsokos GC, ed. *Systemic Lupus Erythematosus (Second Edition)*. Academic Press. 2021.
12. Klein-Gitelman MS. Neonatal lupus: what we have learned and current approaches to care. *Curr Rheumatol Rep*. 2016;18:60.
13. Saxena A, Izmirly PM, Bomar RP, et al. Factors associated with long-term cardiac dysfunction in neonatal lupus. *Ann Rheum Dis*. 2020;79(2):217–224. <https://doi.org/10.1136/annrheumdis-2019-215900>
14. Rivera TL, Izmirly PM, Birnbaum BK, et al. Disease progression in mothers of children enrolled in the Research Registry for neonatal lupus. *Ann Rheum Dis*. 2009;68(6):828–835.
15. de Graeff N, Groot N, Brogan P, et al. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides—the SHARE initiative. *Rheumatology*. 2019;58(4):656–671.
16. Özen S, Sönmez HE, Demir S. Pediatric forms of vasculitis. *Best Pract Res Clin Rheumatol*. 2018;32(1):137–147.
17. Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. *Ann Rheum Dis*. 2010;69(5):798–806.
18. Chung SA, Gorelik M, Langford CA, et al. American College of Rheumatology/ Vasculitis Foundation guideline for the management of polyarteritis nodosa. *Arthr Rheumatol*. 2021;73(8):1384–1393.
19. Piram M, Mahr A. Epidemiology of immunoglobulin A vasculitis (Henoch–Schönlein): current state of knowledge. *Curr Opin Rheumatol*. 2013;25(2):171–178.

20. Iudici M, Quartier P, Terrier B, et al. Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. *Orphanet J Rare Dis*. 2016;11(1):1–12.
21. Li Q, Yu LC, Li FX, et al. The clinical and pathological features of children with microscopic polyangiitis. *Front Pediatr*. 2021;9.
22. Jariwala MP, Laxer RM. Primary vasculitis in childhood: GPA and MPA in childhood. *Front Pediatr*. 2018;6:226.
23. Yıldız M, Köker O, Adrovic A, et al. Pediatric Behçet's disease—clinical aspects and current concepts. *Eur J Rheumatol*. 2020;7(suppl 1):S38.
24. Bakst R, Merola JF, Franks Jr AG, Sanchez M. Raynaud's phenomenon: pathogenesis and management. *J Am Acad Dermatol*. 2008;59(4):633–653.
25. Goundry B, Bell L, Langtree M, Moorthy A. Diagnosis and management of Raynaud's phenomenon. *BMJ*. 2012;344.
26. Fretzayas A, Moustaki M, Vougiouka O. The puzzling clinical spectrum and course of juvenile sarcoidosis. *World J Pediatr*. 2011;7(2):103–110.
27. Baumann R, Robertson W. Neurosarcoid presents differently in children than in adults. *Pediatrics*. 2003;112:e480–e486.
28. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis*. 2017;76(8):1327–1339.
29. Flaitz CM. Parotitis as the initial sign of juvenile Sjogren's syndrome. *Pediatr Dent*. 2001;23(2):140–142.
30. Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. *Rheum Dis Clin*. 2002;28(4):833–857.
31. Hannu T. Reactive arthritis. *Best Pract Res Clin Rheumatol*. 2011;25:347–357.
32. Mackie SL, Keat A. Poststreptococcal reactive arthritis: what is it and how do we know? *Rheumatology*. 2004;43(8):949–954.
33. *Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C)*. CDC; 2021. [https://www.cdc.gov/mis/mis-c/hcp/index.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmis%2Fhcp%2Findex.html](https://www.cdc.gov/mis/mis-c/hcp/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmis%2Fhcp%2Findex.html)
34. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 2. *Arthr Rheumatol*. 2021;73(4):e13–e29.
35. Consiglio CR, Cotugno N, Sardh F, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. *Cell*. 2020;183(4):968–981.
36. Laboratory Mehta J. Testing in pediatric rheumatology. *Pediatr Clin North Am*. 2012;59:263–284.
37. Bray C, Bell LN, Liang H, et al. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. *Wis Med J*. 2016;115(6):317–321.
38. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. *J Clin Invest*. 2013;111(12):1805–1812.
39. Wener MH. Laboratory testing. In: Stone JH, ed. *Current Diagnosis & Treatment: Rheumatology*. 4th ed. McGraw Hill; 2021. <https://accessmedicine.mhmedical.com/content.aspx?bookid=3017&sectionid=253713713>
40. Solomon DH, Kavanaugh AJ, Schur PH. American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. *Arthritis Care Res*. 2002;47(4):434–444.

41. Malleson PN, Mackinnon MJ, Sailer-Hoeck M, Spencer CH. Review for the generalist: the antinuclear antibody test in children—When to use it and what to do with a positive titer. *Pediatr Rheumatol*. 2010;8(1):1–6.
42. Reveille JD, Solomon DH. American College of Rheumatology Ad Hoc Committee on immunologic testing guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. *Arthritis Care Res*. 2003;49(3):399–412.
43. Yasui K, Sakata S, Ochi H, et al. Onset of polyarticular juvenile idiopathic arthritis with both anti-cyclic citrullinated peptide antibodies and rheumatoid factor in a 3-year-old girl. *Pediatr Rheumatol Online J*. 2012;10(1):41. <https://doi.org/10.1186/1546-0096-10-41>
44. American College of Rheumatology. *Medication Guide: Infliximab (Remicade)*. Published February 2020. <https://www.rheumatology.org/Learning-Center/Medication-Guides/Medication-Guide-Infliximab-Remicade>
45. American College of Rheumatology. *Medication Guide: Rituximab (Rituxan)*. Published February 2020. <https://www.rheumatology.org/Learning-Center/Medication-Guides/Medication-Guide-Rituximab-Rituxan>
46. American College of Rheumatology. *Medication Guide: Tocilizumab (Actemra)*. Published February 2020. <https://www.rheumatology.org/Learning-Center/Medication-Guides/Medication-Guide-Tocilizumab-Actemra>
47. ILARIS [prescribing information]. Novartis; September 2016.
48. XELJANZ [prescribing information]. Pfizer; October 2020.
49. Oluminant [prescribing information]. Eli Lilly and Company; July 2020.
50. Orencia [prescribing information]. Bristol-Meyers Squibb Company; June 2020.
51. Stelara [prescribing information]. Janssen Biotech; 2019.
52. Ustekinumab: Medication Safety. *Micromedex* [electronic version]. Accessed December 14, 2021, from <https://www.micromedexsolutions.com/>
53. Emer JJ, Frankel A, Zeichner JA. A practical approach to monitoring patients on biological agents for the treatment of psoriasis. *J Clin Aesthetic Dermatol*. 2010;3(8):20.
54. Spencer CH, Patwardhan A. Pediatric rheumatology for the primary care clinicians—recognizing patterns of disease. *Curr Problems Pediatr Adolesc Health Care*. 2015;45(7):185–206. <https://doi.org/10.1016/j.cppeds.2015.04.002>
55. Milojevic DS, Ilowite NT. Treatment of rheumatic diseases in children: special considerations. *Rheum Dis Clin North Am*. 2002;28(3):461–482. [https://doi.org/10.1016/s0889-857x\(02\)00009-1](https://doi.org/10.1016/s0889-857x(02)00009-1)
56. Sammaritano LR, Bermas BL, Chakravarty EE. American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. *Arthritis Care Res*. 2020;72(4):461–488.
57. Angeles-Han ST, Ringold S, Beukelman T. American College of Rheumatology/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis—associated uveitis. *Arthritis Rheumatol*. 2019;71(6):864–877.

This page intentionally left blank

# PART III

## REFERENCE



This page intentionally left blank

# Chapter 28

## Blood Chemistry and Body Fluids

*Camille C. Anderson, MD*

 See additional content online.

Determining normal reference ranges of laboratory studies in pediatric patients poses some major challenges. Available literature is often limited due to small sample sizes of patients used to derive these suggested reference ranges.

The following values have been compiled from both published literature and the Johns Hopkins Hospital Department of Pathology. Reference range values vary with the analytic method used. Consult your laboratory for its analytic method and range of reference values, and for less commonly used parameters that are beyond the scope of this text. **Additional reference laboratory values may be found in Chapter 10 (Endocrinology), Chapter 14 (Hematology), and Chapter 15 (Immunology and Allergy).**

Special thanks to Lori Sokoll, PhD, and Nadia Ayala-Lopez, PhD, for their guidance in preparing this chapter.

### I. REFERENCE VALUES

(Table 28.1)

### II. EVALUATION OF BODY FLUIDS

- A. Evaluation of Cerebrospinal Fluid: See Table 28.2.
- B. Evaluation of Urine: See Table 28.3.
- C. Evaluation of Transudate/Exudate: See eTable 28.1.
- D. Evaluation of Synovial Fluid: See eTable 28.2.

### III. CONVERSION FORMULAS

#### A. Temperature

1. To convert degrees Celsius to degrees Fahrenheit:

$$[(9 / 5) \times \text{Celsius}] + 32$$

2. To convert degrees Fahrenheit to degrees Celsius:

$$(\text{Fahrenheit} - 32) \times (5 / 9)$$

#### B. Length and Weight

1. **Length:** To convert inches to centimeters, multiply by 2.54.
2. **Weight:** To convert pounds to kilograms, divide by 2.2.

**eTABLE 28.1****EVALUATION OF TRANSUDATE VERSUS EXUDATE (PLEURAL, PERICARDIAL, OR PERITONEAL FLUID)**

Measurement <sup>a</sup>	Transudate	Exudate <sup>b</sup>
Protein (g/dL)	<3.0	≥3.0
Fluid/serum protein ratio	<0.5	≥0.5
LDH (IU/L)	<200	≥200
Fluid/serum LDH ratio	<0.6	≥0.6
WBCs (cells/mm <sup>3</sup> ) <sup>c</sup>	<10,000	>50,000
Glucose (mg/dL)	≥60	<60
pH <sup>d</sup>	≥7.2	<7.2

<sup>a</sup>Always obtain serum glucose, LDH, protein, amylase, etc. for comparison.

<sup>b</sup>All of the following criteria do not have to be met for consideration as an exudate.

<sup>c</sup>In peritoneal fluid, WBC count ≥250 cells/mm<sup>3</sup> suggests peritonitis.

<sup>d</sup>Collect anaerobically in a heparinized syringe.

LDH, Lactate dehydrogenase; RBCs, red blood cells; WBCs, white blood cells.

From Kliegman RM, St Geme JW, et al. *Nelson Textbook of Pediatrics*. 21st ed. Elsevier; 2020.

**eTABLE 28.2****CHARACTERISTICS OF SYNOVIAL FLUID**

Group	Clarity	Color	WBC Count (WBC/mL)	PMN (%)	RBC Present	Glucose, Blood/Synovial Fluid Difference (mg/dL)
Normal	Transparent	Yellow	<150	<25	No	0–10
Noninflammatory	Transparent	Xanthochromic	<3,000	<30	No	0–10
Inflammatory	Transparent to opaque	Xanthochromic, white, or bloody	3,000–75,000	>50	No	0–40
Infectious	Opaque	White	50,000–200,000	>90	Yes	20–100
Hemorrhagic	Opaque	Red-brown or xanthochromic	50–10,000	<50	Yes	0–20

PMN, Polymorphonuclear leukocyte; RBC, red blood cell; WBC, white blood cell.

From McPherson RA, Pincus, MR. *Henry's Clinical Diagnosis and Management by Laboratory Methods*. 24th ed. Elsevier; 2022.

**TABLE 28.1****REFERENCE VALUES**

	Conventional Units	SI Units
<b>ALANINE AMINOTRANSFERASE (ALT)<sup>1</sup></b>		
0 to <1 year	5–33 U/L	5–33 U/L
1 to <13 years	9–25 U/L	9–25 U/L
13–19 years (male)	9–24 U/L	9–24 U/L
13 to <19 years (female)	8–22 U/L	8–22 U/L
<b>ALBUMIN<sup>a,1</sup></b>		
0–14 days	3.3–4.5 g/dL	33–45 g/L
15 days to <1 year	2.8–4.7 g/dL	28–47 g/L
1 to <8 years	3.8–4.7 g/dL	38–47 g/L
8 to <15 years	4.1–4.8 g/dL	41–48 g/L
15 to <19 years (male)	4.1–5.1 g/dL	41–51 g/L
15 to <19 years (female)	4.0–4.9 g/dL	40–49 g/L
<b>ALKALINE PHOSPHATASE<sup>1</sup></b>		
0–14 days	90–273 U/L	90–273 U/L
15 days to <1 year	134–518 U/L	134–518 U/L
1 to <10 years	156–369 U/L	156–369 U/L
10 to <13 years	141–460 U/L	141–460 U/L
13 to <15 years (male)	127–517 U/L	127–517 U/L
13 to <15 years (female)	62–280 U/L	62–280 U/L
15 to <17 years (male)	89–365 U/L	89–365 U/L
15 to <17 years (female)	54–128 U/L	54–128 U/L
17 to <19 years (male)	59–164 U/L	59–164 U/L
17 to <19 years (female)	48–95 U/L	48–95 U/L
<b>AMMONIA<sup>2</sup></b>		
0–14 days	0–161.8 mCg/dL	0–95 mcmol/L
15 days to 6 years	0–115.8 mCg/dL	0–68 mcmol/L
>6 years	0–122.6 mCg/dL	0–72 mcmol/L
<b>AMYLASE<sup>1</sup></b>		
0–14 days	3–10 U/L	3–10 U/L
15 days to <13 weeks	2–22 U/L	2–22 U/L
13 weeks to <1 year	3–50 U/L	3–50 U/L
1 year to <19 years	25–101 U/L	25–101 U/L
<b>ANTISTREPTOLYSIN-O TITER<sup>1</sup></b>		
0 to <6 months	0 IU/mL	0 IU/mL
6 months to <1 year	0–30 IU/mL	0–30 IU/mL
1 to <6 years	0–104 IU/mL	0–104 IU/mL
6 to <19 years	0–331 IU/mL	0–331 IU/mL
<b>ASPARTATE AMINOTRANSFERASE (AST)<sup>1</sup></b>		
0–14 days	32–162 U/L	32–162 U/L
15 days to <1 year	20–67 U/L	20–67 U/L
1 to <7 years	21–44 U/L	21–44 U/L
7 to <12 years	18–36 U/L	18–36 U/L
12 to <19 years (male)	14–35 U/L	14–35 U/L
12 to <19 years (female)	13–26 U/L	13–26 U/L

**BICARBONATE**<sup>1</sup>

0–14 days	5–20 mEq/L	5–20 mmol/L
15 days to <1 year	10–24 mEq/L	10–24 mmol/L
1 to <5 years	14–24 mEq/L	14–24 mmol/L
5 to <15 years	17–26 mEq/L	17–26 mmol/L
Male 15 to <19 years	18–28 mEq/L	18–28 mmol/L
Female 15 to <19 years	17–26 mEq/L	17–26 mmol/L

**BILIRUBIN (TOTAL)**<sup>1</sup>

See Chapter 18 for more complete information about neonatal hyperbilirubinemia.

0–14 days	0.19–16.60 mg/dL	3.3–283.8 mcmmol/L
15 days to <1 year	0.05–0.68 mg/dL	0.8–11.7 mcmmol/L
1 to <9 years	0.05–0.40 mg/dL	0.8–6.8 mcmmol/L
9 to <12 years	0.05–0.55 mg/dL	0.8–9.4 mcmmol/L
12 to <15 years	0.10–0.70 mg/dL	1.7–11.9 mcmmol/L
15 to <19 years	0.10–0.84 mg/dL	1.7–14.4 mcmmol/L

**BILIRUBIN (DIRECT)**<sup>1</sup>

0–14 days	0.33–0.71 mg/dL	5.7–12.1 mcmmol/L
15 days to <1 year	0.05–0.30 mg/dL	0.8–5.2 mcmmol/L
1 to <9 years	0.05–0.20 mg/dL	0.8–3.4 mcmmol/L
9 to <13 years	0.05–0.29 mg/dL	0.8–5.0 mcmmol/L
13 to <19 years (female)	0.10–0.39 mg/dL	1.7–6.7 mcmmol/L
13 to <19 years (male)	0.11–0.42 mg/dL	1.9–7.1 mcmmol/L

**BLOOD GAS, ARTERIAL (BREATHING ROOM AIR)**<sup>3</sup>

	pH	PaO <sub>2</sub> (mmHg)	PaCO <sub>2</sub> (mmHg)
Cord blood (umbilical artery)	7.18–7.38	5.7–30.5	42–74 <sup>4</sup>
Newborn (birth)	7.11–7.36	8–24	27–40
5–10 min	7.09–7.30	33–75	27–40
30 min	7.21–7.38	31–85	27–40
60 min	7.26–7.49	55–80	27–40
1 day	7.29–7.45	54–95	27–40
Child/adult	7.35–7.45	83–108	32–48

**NOTE:** Venous blood gases can be used to assess acid-base status, not oxygenation. PvCO<sub>2</sub> is 2–8 mmHg higher than PaCO<sub>2</sub>, and pH is slightly lower. Peripheral venous samples are strongly affected by the local circulatory and metabolic environment. Arterialized capillary blood gases correlate better than venous samples with arterial pH and PaCO<sub>2</sub>.<sup>3</sup>

**C-REACTIVE PROTEIN (HIGH SENSITIVITY)**<sup>1</sup>

0–14 days	0.3–6.1 mg/L	0.3–6.1 mg/L
15 days to <15 years	0.1–1.0 mg/L	0.1–1.0 mg/L
15 to <19 years	0.1–1.7 mg/L	0.1–1.7 mg/L

**CALCIUM (IONIZED)**<sup>2</sup>

0 to <1 month	4.4–5.4 mg/dL	1.10–1.35 mmol/L
1 month to adult	4.44–5.2 mg/dL	1.11–1.30 mmol/L

**CALCIUM (TOTAL)**<sup>1</sup>

0 to <1 year	8.5–11.0 mg/dL	2.1–2.7 mmol/L
1 year to <19 years	9.2–10.5 mg/dL	2.3–2.6 mmol/L

*Continued*

**TABLE 28.1****REFERENCE VALUES—CONT'D****CARBON MONOXIDE (CARBOXYHEMOGLOBIN)<sup>5</sup>**

Nonsmoker	<2% of total hemoglobin
Smoker	<10% of total hemoglobin

**CHLORIDE (SERUM)<sup>6</sup>**

3–5 years	100–107 mEq/L	100–107 mmol/L
6–11 year	101–107 mEq/L	101–107 mmol/L
12–29 years (male)	101–106 mEq/L	101–106 mmol/L
12–29 years (female)	100–107 mEq/L	100–107 mmol/L

**CHOLESTEROL**

(See LIPIDS, further on)

**COPPER<sup>7</sup>**

6 months to 2 years	72–178 mCg/dL	11.3–28.0 mcmol/L
3–4 years	80–160 mCg/dL	12.6–25.2 mcmol/L
5–6 years	76–167 mCg/dL	12.0–26.3 mcmol/L
7–8 years	79–147 mCg/dL	12.4–23.1 mcmol/L
9–10 years	84–154 mCg/dL	13.2–24.2 mcmol/L
11–12 years	73–149 mCg/dL	11.5–23.4 mcmol/L
13–14 years	66–137 mCg/dL	10.4–21.6 mcmol/L
15–16 years	60–132 mCg/dL	9.4–20.8 mcmol/L
17–18 years	59–146 mCg/dL	9.3–23.0 mcmol/L

**CREATINE KINASE<sup>8</sup>**

6 months to 2 years (male)	50–272 U/L	50–272 U/L
6 months to 2 years (female)	38–260 U/L	38–260 U/L
3–5 years (male)	59–296 U/L	59–296 U/L
3–5 years (female)	42–227 U/L	42–227 U/L
6–8 years (male)	54–275 U/L	54–275 U/L
6–8 years (female)	50–231 U/L	50–231 U/L
9–11 years (male)	55–324 U/L	55–324 U/L
9–11 years (female)	52–256 U/L	52–256 U/L
12–14 years (male)	63–407 U/L	63–407 U/L
12–14 years (female)	45–257 U/L	45–257 U/L
15–17 years (male)	68–914 U/L	68–914 U/L
15–17 years (female)	45–458 U/L	45–458 U/L

**CREATININE (SERUM) (ENZYMATIC)<sup>1</sup>**

0–14 days	0.32–0.92 mg/dL	29–82 mcmol/L
15 days to <2 years	0.10–0.36 mg/dL	9–32 mcmol/L
2 to <5 years	0.20–0.43 mg/dL	18–38 mcmol/L
5 to <12 years	0.31–0.61 mg/dL	27–54 mcmol/L
12 to <15 years	0.45–0.81 mg/dL	40–72 mcmol/L
15 to <19 years (male)	0.62–1.08 mg/dL	55–96 mcmol/L
15 to <19 years (female)	0.49–0.84 mg/dL	43–74 mcmol/L

**ERYTHROCYTE SEDIMENTATION RATE (ESR)<sup>9</sup>**

0 to <1 month	≤2 mm/hr
1 month–12 years	≤20 mm/hr

>12 years (male)	≤15 mm/hr
------------------	-----------

>12 years (female)	≤20 mm/hr
--------------------	-----------

**FERRITIN<sup>1</sup>**

4 to <15 days	100–717 ng/mL	224–1611 pmol/L
---------------	---------------	-----------------

15 days to <6 months	14–647 ng/mL	31–1454 pmol/L
----------------------	--------------	----------------

6 months to <1 year	8–182 ng/mL	19–409 pmol/L
---------------------	-------------	---------------

1 to <5 years	5–100 ng/mL	12–224 pmol/L
---------------	-------------	---------------

5 to <14 years	14–79 ng/mL	31–177 pmol/L
----------------	-------------	---------------

14 to <19 years (female)	6–67 ng/mL	12–152 pmol/L
--------------------------	------------	---------------

14 to <16 years (male)	13–83 ng/mL	28–186 pmol/L
------------------------	-------------	---------------

16 to <19 years (male)	11–172 ng/mL	25–386 pmol/L
------------------------	--------------	---------------

**FOLATE (RBC)<sup>2</sup>**

	≥366 ng/mL	≥829 nmol/L
--	------------	-------------

**FOLATE (SERUM)<sup>2</sup>**

Deficient	≤3.9 ng/mL	≤8.8 nmol/L
-----------	------------	-------------

Indeterminate	4.0–5.8 ng/mL	9.1–13.1 nmol/L
---------------	---------------	-----------------

Normal	≥5.9 ng/mL	≥13.4 nmol/L
--------	------------	--------------

**GAMMA-GLUTAMYL TRANSFERASE (GGT)<sup>1</sup>**

0–14 days	23–219 U/L	23–219 U/L
-----------	------------	------------

15 days to <1 year	8–127 U/L	8–127 U/L
--------------------	-----------	-----------

1 to <11 years	6–16 U/L	6–16 U/L
----------------	----------	----------

11 to <19 years	7–21 U/L	7–21 U/L
-----------------	----------	----------

**GLUCOSE**

See Chapter 10.

**HAPTOGLOBIN<sup>1</sup>**

0–14 days	0–10 mg/dL	0–0.10 g/L
-----------	------------	------------

15 days to <1 year	7–221 mg/dL	0.07–2.21 g/L
--------------------	-------------	---------------

1 to <12 years	7–163 mg/dL	0.07–1.63 g/L
----------------	-------------	---------------

12 to <19 years	7–179 mg/dL	0.07–1.79 g/L
-----------------	-------------	---------------

**HEMOGLOBIN A1c**

See Chapter 10.

**HEMOGLOBIN F, % TOTAL HEMOGLOBIN<sup>2</sup>**

0–1 month	45.8–91.7
-----------	-----------

2 months	32.7–85.2
----------	-----------

3 months	14.5–73.7
----------	-----------

4 months	4.2–56.9
----------	----------

5 months	1.0–38.1
----------	----------

6–8 months	0.9–19.4
------------	----------

9–12 months	0.6–11.6
-------------	----------

13–23 months	0.0–8.5
--------------	---------

2 years and older	0.0–2.1
-------------------	---------

**IRON<sup>1</sup>**

0 to <14 years	16–128 mCg/dL	2.8–22.9 mcmol/L
----------------	---------------	------------------

14–19 years (male)	31–168 mCg/dL	5.5–30.0 mcmol/L
--------------------	---------------	------------------

14–19 years (female)	20–162 mCg/dL	3.5–29.0 mcmol/L
----------------------	---------------	------------------

Continued

**TABLE 28.1****REFERENCE VALUES—CONT'D**

<b>LACTATE</b> <sup>10</sup>			
0–90 days	9–32 mg/dL		1.0–3.5 mmol/L
3–24 months	9–30 mg/dL		1.0–3.3 mmol/L
2–18 years	9–22 mg/dL		1.0–2.4 mmol/L
<b>LACTATE DEHYDROGENASE</b> <sup>1</sup>			
0–14 days	309–1222 U/L		309–1222 U/L
15 days to <1 year	163–452 U/L		163–452 U/L
1 to <10 years	192–321 U/L		192–321 U/L
10 to <15 years (male)	170–283 U/L		170–283 U/L
10 to <15 years (female)	157–272 U/L		157–272 U/L
15 to <19 years	130–250 U/L		130–250 U/L
<b>LEAD</b>			
See <a href="#">Chapter 3</a> .			
<b>LIPASE</b> <sup>1</sup>			
0 to <19 years	4–39 U/L		4–39 U/L
<b>LIPIDS</b> <sup>11</sup>			
	<b>Desirable</b>	<b>Borderline</b>	<b>High</b> <sup>b</sup>
Total cholesterol	<170 mg/dL (4.4 mmol/L)	170–199 mg/dL (4.4–5.1 mmol/L)	≥200 mg/dL (5.2 mmol/L)
LDL	<110 mg/dL (2.8 mmol/L)	110–129 mg/dL (2.8–3.3 mmol/L)	≥130 mg/dL (3.4 mmol/L)
Non-HDL	<120 mg/dL (3.1 mmol/L)	120–144 mg/dL (3.1–3.7 mmol/L)	≥145 mg/dL (3.8 mmol/L)
HDL	>45 mg/dL (1.2 mmol/L)	40–45 mg/dL (1.0–1.2 mmol/L)	<40 mg/dL (1.0 mmol/L)
Triglycerides (0–9 years)	<75 mg/dL (0.8 mmol/L)	75–99 mg/dL (0.8–1.1 mmol/L)	≥100 mg/dL (1.1 mmol/L)
Triglycerides (10–19 years)	<90 mg/dL (1.0 mmol/L)	90–129 mg/dL (1.0–1.5 mmol/L)	≥130 mg/dL (1.5 mmol/L)
	<b>Conventional Units</b>		<b>SI Units</b>
<b>MAGNESIUM</b> <sup>1</sup>			
0–14 days	1.99–3.94 mg/dL		0.82–1.62 mmol/L
15 days to <1 year	1.97–3.09 mg/dL		0.81–1.27 mmol/L
1 to <19 years	2.09–2.84 mg/dL		0.86–1.17 mmol/L
<b>OSMOLALITY</b> <sup>2</sup>			
0–16 years	271–296 mOsm/kg		271–296 mmol/kg
17 years and older	280–303 mOsm/kg		280–303 mmol/kg
<b>PHOSPHORUS</b> <sup>1</sup>			
0–14 days	5.6–10.5 mg/dL		1.8–3.4 mmol/L
15 days to <1 year	4.8–8.4 mg/dL		1.5–2.7 mmol/L
1 to <5 years	4.3–6.8 mg/dL		1.4–2.2 mmol/L
5 to <13 years	4.1–5.9 mg/dL		1.3–1.9 mmol/L

13 to <16 years (male)	3.5–6.2 mg/dL	1.1–2.0 mmol/L
13 to <16 years (female)	3.2–5.5 mg/dL	1.0–1.8 mmol/L
16 to <19 years	2.9–5.0 mg/dL	0.9–1.6 mmol/L
<b>PORCELAIN<sup>12</sup></b>		
0 to <1 year	10.11–20.22 mg/dL	6.20–19.56 mmol/L
1 to <19 years	6.30–20.21 mg/dL	11.09–20.22 mmol/L
<b>POTASSIUM<sup>3</sup></b>		
Preterm	3.0–6.0 mEq/L	3.0–6.0 mmol/L
Newborn	3.7–5.9 mEq/L	3.7–5.9 mmol/L
Infant	4.1–5.3 mEq/L	4.1–5.3 mmol/L
3–5 years	3.9–4.6 mEq/L	3.9–4.6 mmol/L
6 years and older	3.8–4.9 mEq/L	3.8–4.9 mmol/L
<b>PREALBUMIN<sup>1</sup></b>		
0–14 days	2–12 mg/dL	0.02–0.12 g/L
15 days to <1 year	5–24 mg/dL	0.05–0.24 g/L
1 to <5 years	12–23 mg/dL	0.12–0.23 g/L
5 to <13 years	14–26 mg/dL	0.14–0.26 g/L
13 to <16 years	18–31 mg/dL	0.18–0.31 g/L
16 to <19 years (male)	20–35 mg/dL	0.20–0.35 g/L
16 to <19 years (female)	17–33 mg/dL	0.17–0.33 g/L
<b>RHEUMATOID FACTOR<sup>1</sup></b>		
0–14 days	9.0–17.1 IU/mL	9.0–17.1 IU/mL
15 days to <19 years	0–9.0 IU/mL	0–9.0 IU/mL
<b>SODIUM<sup>6</sup></b>		
3–5 years	135–142 mEq/L	135–142 mmol/L
6–15 years	136–143 mEq/L	136–143 mmol/L
16–49 years (male)	137–143 mEq/L	137–143 mmol/L
16–49 years (female)	137–142 mEq/L	137–142 mmol/L
<b>TOTAL IRON-BINDING CAPACITY (TIBC)<sup>2</sup></b>		
0–2 months	59–175 mCg/dL	11–31 mcmol/L
3 months to 17 years	250–400 mCg/dL	45–72 mcmol/L
18 years and older	240–450 mCg/dL	43–81 mcmol/L
<b>TOTAL PROTEIN<sup>1</sup></b>		
0–14 days	5.3–8.3 g/dL	53–83 g/L
15 days to <1 year	4.4–7.1 g/dL	44–71 g/L
1 to <6 years	6.1–7.5 g/dL	61–75 g/L
6 to <9 years	6.4–7.7 g/dL	64–77 g/L
9 to <19 years	6.5–8.1 g/dL	65–81 g/L
<b>TRANSFERRIN<sup>1</sup></b>		
0 to <9 weeks	104–224 mg/dL	1.04–2.24 g/L
9 weeks <1 year	107–324 mg/dL	1.07–3.24 g/L
1 to <19 years	220–337 mg/dL	2.2–3.37 g/L

Continued

**TABLE 28.1****REFERENCE VALUES—CONT'D**

<b>TRIGLYCERIDES</b>		
(See LIPIDS, earlier)		
<b>UREA NITROGEN<sup>1</sup></b>		
0–14 days	2.8–23.0 mg/dL	1.0–8.2 nmol/L
15 days to <1 year	3.4–16.8 mg/dL	1.2–6.0 nmol/L
1 to <10 years	9.0–22.1 mg/dL	3.2–7.9 nmol/L
10 to <19 years (male)	7.3–21 mg/dL	2.6–7.5 nmol/L
10 to <19 years (female)	7.3–19 mg/dL	2.6–6.8 nmol/L
<b>URIC ACID<sup>1</sup></b>		
0–14 days	2.8–12.7 mg/dL	164–757 mcmol/L
15 days to <1 year	1.6–6.3 mg/dL	94–377 mcmol/L
1 to <12 years	1.8–4.9 mg/dL	106–289 mcmol/L
12 to <19 years (male)	2.6–7.6 mg/dL	156–454 mcmol/L
12 to <19 years (female)	2.6–5.9 mg/dL	153–349 mcmol/L
<b>VITAMIN A (RETINOL)<sup>1</sup></b>		
0 to <1 year	8.0–53.6 mg/dL	0–2 mcmol/L
1 to <11 years	27.5–44.4 mg/dL	1–2 mcmol/L
11 to <16 years	24.9–55.0 mg/dL	1–2 mcmol/L
16 to <19 years	28.7–75.1 mg/dL	1–3 mcmol/L
<b>VITAMIN B<sub>1</sub> (THIAMINE), WHOLE BLOOD<sup>3</sup></b>		
	90–140 nmol/L	90–140 nmol/L
<b>VITAMIN B<sub>2</sub> (RIBOFLAVIN)<sup>3</sup></b>		
	4–24 mCg/dL	106–638 nmol/L
<b>VITAMIN B<sub>12</sub> (COBALAMIN)<sup>1</sup></b>		
5 days to <1 year	259–1576 pg/mL	191–1163 pmol/L
1 to <9 years	283–1613 pg/mL	209–1190 pmol/L
9 to <14 years	252–1125 pg/mL	186–830 pmol/L
14 to <17 years	244–888 pg/mL	180–655 pmol/L
17 to <19 years	203–811 pg/mL	150–599 pmol/L
<b>VITAMIN C (ASCORBIC ACID)<sup>3</sup></b>		
	0.4–1.5 mg/dL	23–85 mcmol/L
<b>VITAMIN D (1,25-DIHYDROXY-VITAMIN D)<sup>13</sup></b>		
0 to <1 year	32–196 pg/mL	77–471 pmol/L
1 to <3 years	47–151 pg/mL	113–363 pmol/L
3 to <19 years	45–102 pg/mL	108–246 pmol/L
<b>VITAMIN D (25-HYDROXY-VITAMIN D)<sup>14,15</sup></b>		
Deficient	<12 ng/mL	<30 nmol/L
Insufficient	12–20 ng/mL	30–50 nmol/L
Sufficient <sup>c</sup>	>20 ng/mL	>50 nmol/L
Excess	>50–60 ng/mL	>125–150 nmol/L
<b>VITAMIN E (α-TOCOPHEROL)<sup>1</sup></b>		
0 to <1 year	0.2–2.1 mg/dL	5.0–50.0 mcmol/L
1 to <19 years	0.6–1.4 mg/dL	14.5–33.0 mcmol/L

**ZINC<sup>7</sup>**

6 months to 2 years	56–125 mCg/dL	8.6–19.1 mcmol/L
3–4 years	60–120 mCg/dL	9.2–18.4 mcmol/L
5–6 years	64–117 mCg/dL	9.8–17.9 mcmol/L
7–8 years	65–125 mCg/dL	9.9–19.1 mcmol/L
9–10 years	66–125 mcg/dL	10.1–19.1 mcmol/L
11–12 years	66–127 mCg/dL	10.1–19.4 mcmol/L
13–14 years	69–124 mCg/dL	10.6–19.0 mcmol/L
15–16 years	62–123 mCg/dL	9.5–18.8 mcmol/L
17–18 years	62–133 mCg/dL	9.5–20.3 mcmol/L

<sup>a</sup>Assay with bromocresol green.

<sup>b</sup>It is important to note that these values have not been validated to demonstrate increased risk of atherosclerosis or cardiovascular events.

<sup>c</sup>Controversy exists regarding optimal 25-hydroxyvitamin D level. Some experts recommend a level  $\geq 30$  ng/mL as sufficient.<sup>16</sup>

**TABLE 28.2****EVALUATION OF CEREBROSPINAL FLUID**

<b>WBC</b>		
<b>Age</b>	<b>Count/mcL (median)</b>	<b>95th Percentile</b>
0–28 days <sup>17</sup>	0–12 <sup>a</sup> (4)	16
29–60 days <sup>17</sup>	0–8 <sup>a</sup> (2)	11
Child <sup>19</sup>	0–7	
<b>GLUCOSE</b>		
<b>Age</b>	<b>Median</b>	<b>5th Percentile</b>
0–28 days <sup>17</sup>	45 mg/dL	35 mg/dL
29–60 days <sup>17</sup>	47 mg/dL	37 mg/dL
	<b>Conventional Units</b>	<b>SI Units</b>
Infant, child <sup>3</sup>	60–80 mg/dL	3.3–4.4 mmol/L
Adult <sup>3</sup>	40–70 mg/dL	2.2–3.9 mmol/L
<b>PROTEIN</b>		
<b>Age</b>	<b>Median</b>	<b>95th Percentile</b>
0–28 days <sup>17</sup>	66 mg/dL	118 mg/dL
29–60 days <sup>17</sup>	49 mg/dL	91 mg/dL
	<b>Conventional Units</b>	<b>SI Units</b>
6 months to 2 years <sup>18</sup>	6–25 mg/dL	60–250 mg/L
2–6 years <sup>18</sup>	5–25 mg/dL	50–250 mg/L
6–12 years <sup>18</sup>	5–28 mg/dL	50–280 mg/L
12–18 years <sup>18</sup>	6–34 mg/dL	60–340 mg/L
<b>OPENING PRESSURE (LATERAL RECUMBENT POSITION<sup>19,20</sup>)</b>		
1–18 years	11.5–28 cm H <sub>2</sub> O <sup>a</sup>	
Respiratory variations	0.5–1 cm H <sub>2</sub> O	

<sup>a</sup>10th to 90th percentiles.

WBC, White blood cell.

**TABLE 28.3****EVALUATION OF URINE**

Urine Analyte	Reference Range
<b>ALBUMIN<sup>3,19</sup></b>	
Random (first morning urine)	
Male	<22 mg urine albumin/g creatinine
Female	<30 mg urine albumin/g creatinine
24-hr collection	
4–16 years (male)	3.35–13.15 mg/1.73 m <sup>2</sup> /day
4–16 years (female)	3.75–18.34 mg/1.73 m <sup>2</sup> /day
<b>CALCIUM<sup>10</sup></b>	
Random	
1 month–1 year	0.03–0.81 mg/mg creatinine
1–2 years	0.03–0.56 mg/mg creatinine
2–3 years	0.02–0.5 mg/mg creatinine
3–5 years	0.02–0.41 mg/mg creatinine
5–7 years	0.01–0.3 mg/mg creatinine
7–10 years	0.01–0.25 mg/mg creatinine
10–14 years	0.01–0.24 mg/mg creatinine
14–17 years	0.01–0.24 mg/mg creatinine
24-hr collection	
2–18 years (male)	0.75–3.79 mg/kg/day
2–18 years (female)	0.73–3.41 mg/kg/day
<b>CHLORIDE<sup>3,21</sup></b>	
Random	
Male	25–253 mmol/g creatinine
Female	39–348 mmol/g creatinine
24-hr collection	
Infant	2–10 mmol/day
Child <6 years	15–40 mmol/day
6–10 years (male)	36–110 mmol/day
6–10 years (female)	18–74 mmol/day
10–14 years (male)	64–176 mmol/day
10–14 years (female)	36–173 mmol/day
Adult	110–250 mmol/day
<b>CREATININE<sup>3</sup></b>	
Random	
3–5 years	15–152 mg/dL
6–11 years	14–196 mg/dL
12–13 years	21–215 mg/dL
14–29 years	19–305 mg/dL
24-hr collection	
Infant	8–20 mg/kg/day
Child	8–22 mg/kg/day
Adolescent	8–30 mg/kg/day
Adult (male)	14–26 mg/kg/day
Adult (female)	11–20 mg/kg/day

**POTASSIUM**<sup>3,21</sup>

## Random

Male 13–116 mmol/g creatinine

Female 8–129 mmol/g creatinine

## 24-hr collection

6–10 years (male) 17–54 mmol/day

6–10 years (female) 8–37 mmol/day

10–14 years (male) 22–57 mmol/day

10–14 years (female) 18–58 mmol/day

Adult 25–125 mmol/day

**PROTEIN**<sup>5,19</sup>

## Random

6 months to 24 months &lt;0.5 mg protein/mg creatinine

&gt;2 years &lt;0.2 mg protein/mg creatinine

## 24-hr collection

At rest 50–80 mg/day

After intense exercise &lt;250 mg/day

**SODIUM**<sup>3,21</sup>

## Random

Male 23–229 mmol/g creatinine

Female 26–297 mmol/g creatinine

## 24-hr collection

6–10 years (male) 41–115 mmol/day

6–10 years (female) 20–69 mmol/day

10–14 years (male) 63–177 mmol/day

10–14 years (female) 48–168 mmol/day

Adult (male) 40–220 mmol/day

Adult (female) 27–287 mmol/day

**UREA NITROGEN**<sup>3,21</sup>

## Random

Male 102–352 mmol/g creatinine

Female 112–416 mmol/g creatinine

## 24-hr collection

10–20 g/day

**URINE OSMOLALITY**<sup>21</sup>

## Random

50–1,200 mOsm/kg H<sub>2</sub>O, depending on fluid intake

## On average fluid intake

300–900 mOsm/kg H<sub>2</sub>O

## After 12-hr fluid restriction

>850 mOsm/kg H<sub>2</sub>O

## 24-hr collection

~ 300–900 mOsm/kg H<sub>2</sub>O**REFERENCES**

A complete list of references can be found online.

## REFERENCES

1. Adeli K, Higgins V, Trajcevski K, White-Al Habeeb N. The Canadian laboratory initiative on pediatric reference intervals: a Caliper white paper. *Crit Rev Clin Lab Sci*. 2017;54(6):359–413.
2. ARUP Laboratories. A national reference laboratory. Accessed November 21, 2021. <https://www.aruplab.com/testing>
3. Rifai N. *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics*. 6th ed. Elsevier; 2018.
4. White C, Doherty D, Henderson J, et al. Benefits of introducing universal cord blood gas and lactate analysis into an obstetric unit. *Austr N Z J Obstetr Gynaecol*. 2010;50:318–328.
5. Kliegman RM, St Geme JW. *Nelson Textbook of Pediatrics*. 21st ed. Elsevier; 2020.
6. Adeli K, Higgins V, Nieuwesteeg, et al. Biochemical marker reference values across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures Survey. *Clin Chem*. 2015;61(8):1049–1062.
7. Lin CN, Wilson A, Church BB, et al. Pediatric reference intervals for serum copper and zinc. *Clin Chim Acta*. 2012;413(5–6):612–615.
8. Clifford SM, Bunker AM, Jacobsen JR, Roberts WL. Age and gender specific pediatric reference intervals for aldolase, amylase, ceruloplasmin, creatine kinase, pancreatic amylase, prealbumin, and uric acid. *Clin Chim Acta*. 2011;412(9–10):788–790.
9. Ramsay ES, Lerman MA. How to use the erythrocyte sedimentation rate in paediatrics. *Arch Dis Child Educ Pract Ed*. 2015;100:30–36.
10. Wong ECC, Brugnara C, Straseski JA, Kellogg MD, Adeli K. *Pediatric Reference Intervals*. 8th ed. Academic Press; 2020.
11. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. *Pediatrics*. 2011;128(suppl 5):S213–S256.
12. Anderson CC, Kapoor S, Mark TE. *The Perfect Storm: Our Chief Year Manifesto*. Johns Hopkins University Press; 2022-2023.
13. Higgins V, Truong D, White-Al Habeeb N, et al. Pediatric reference intervals for vitamin 1,25-dihydroxyvitamin D using the Diasorin LIASON XL assay in the healthy CALIPER cohort. *Clin Chem Lab Med*. 2018;56(6):964–972.
14. Office of Dietary Supplements—Vitamin D. Accessed November 21, 2021. <https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/>
15. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin d from the institute of medicine: what clinicians need to know. *J Clin Endocrinol Metab*. 2011;96(1):53–58. <https://doi.org/10.1210/jc.2010-2704>
16. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96(7):1911–1930. <https://doi.org/10.1210/jc.2011-0385>
17. Thomson J, Sucharew H, Cruz AT, et al. Cerebrospinal fluid reference values for young infants undergoing lumbar puncture. *Pediatrics*. 2018;141(3):e20173405.
18. Kahlmann V, Roodbal J, van Leeuwen, et al. Validated age-specific reference values for CSF total protein levels in children. *Eur J Paediatr Neurol*. 2017;21:654–660.

19. McMillan JA. *Oski's Pediatrics: Principles and Practice*. 4th ed. JB Lippincott; 2006.
20. Avery RA. Reference range for cerebrospinal fluid opening pressure in children: historical overview and current data. *Neuropediatrics*. 2014;45:206–211.
21. Wu AHB. *Tietz Clinical Guide to Laboratory Tests*. 4th ed. WB Saunders; 2006.

# Chapter 29

## Biostatistics and Evidence-Based Medicine

*Michael R. Rose, MD, MPH*

 See additional content online.


 **Audio Case File 29.1** Evidence based medicine: a discussion on race based in clinical practice guideline

### I. BIostatISTICS AND EVIDENCE-BASED MEDICINE (EBM)<sup>1-3</sup>

Evidence-based medicine is perhaps best encapsulated by Sackett's classic definition (and the accompanying Venn diagram, see [Fig. 29.1](#)): “the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients. The practice of evidence-based medicine means integrating individual clinical expertise with the best available external clinical evidence from systematic research.”<sup>1</sup>

1. **Formulate the clinical question (PICO process):** e.g., “Should I choose D5 0.9% saline or D5 0.45% saline for maintenance fluids for this 6-month-old with bronchiolitis and poor oral intake?”
  - a. **Patient, population, and/or problem:** Decide what question you seek to answer and for whom (i.e., infants requiring maintenance IV fluids).
  - b. **Intervention:** Describe the intervention under investigation (i.e., D5 0.9% saline)
  - c. **Compare:** Compare the intervention with alternative or current standard of care (i.e., D5 0.45% saline).
  - d. **Outcomes:** Formulate outcome(s) of interest for your question. (i.e., rates of electrolyte derangements, acute kidney injury, length of stay).
2. Search for evidence to answer the question.
  - a. **Define search terms** that fit the clinical questions (i.e., isotonic vs. hypotonic fluids in pediatrics).
  - b. **Develop search strategy** using primary sources such as PubMed or secondary sources such as Cochrane, UpToDate, ClinicalKey, or society guidelines. These strategies are not mutually exclusive and often used best in conjunction.
3. Critical appraisal of the evidence It is important to assess studies for both internal validity (study was conducted in an unbiased fashion) and external validity (study results are applicable in the “real world”).
  - a. Studies investigating an intervention are almost always best answered with randomized controlled trials (RCTs) given their ability to eliminate residual confounding (i.e., confounding we cannot anticipate, identify, and control for in nonrandomized studies). Key questions to ask:

## What is evidence-based medicine?

**FIGURE 29.1**

Venn diagram of evidence-based medicine. (Modified from Sackett DL, Rosenberg WMC, Gray JAM, et al. Evidence based medicine: what it is and what it isn't. *BMJ*. 1996;312:71. <https://doi.org/10.1136/bmj.312.7023.71>)

- (1) Were participants (truly) randomized?
- (2) Was the control/comparator group appropriate? (Beware of “straw man” comparators, e.g., new chemotherapeutic trialed against out-of-date standard of care.)
- (3) Were the participants/investigators blinded? (When not feasible, think how this may affect the outcome.)
  - (a) **Placebo effect:** Treatment benefit due to perception of treatment
  - (b) **Nocebo effect:** Adverse effects due to perception of treatment
  - (c) **Hawthorne effect:** Participant change of behavior from being studied
  - (d) **Observer-expectancy bias:** Researcher’s belief in efficacy of a treatment affects their actions
- (4) Was the analysis appropriate?
  - (a) **Intention to treat (ITT):** Analyzing outcomes based on initial group assignment regardless of receipt of intervention (almost always the proper analysis to minimize bias)
  - (b) **As-treated analysis:** Analyzing outcomes based on receipt of intervention, not initial assignment (almost always incorrect due to participant crossover not being random)
- (5) Were the outcomes clinically important (or a reasonable proxy to infer clinical relevance)?
- (6) Was the study properly powered? Were power calculations performed prospectively?

- (a) **Underpowered study:** May statistically miss clinically meaningful benefits and harms. Smaller studies can miss important but uncommon harms
  - (b) **Overpowered study:** May find statistically significant outcomes that are clinically insignificant
  - (c) Beware of the use of composite outcomes to increase statistical power, which may come at the consequence of clinical relevance if power increase is driven by a nonclinically important outcome.
- b. Studies investigating diagnosis (i.e., JAMA rational clinical exam, lab test characteristics, imaging modality comparisons)
- (1) Was the test compared with the appropriate reference standard? (Ideally this should be the “gold standard” test.)
  - (2) Was the test assessed in the appropriate population? (This is an especially important in extrapolating results from adults to pediatric patients.)
- c. Studies investigating prognosis
- (1) Where were patients in their course at the start of the study?
  - (2) Were they followed up over sufficient time to detect the outcomes of interest?
  - (3) Beyond the point estimate, how precise is the prognosis?
- d. Factors that increase the likelihood of causality between variable and outcome
- (1) The relationship is temporal.
  - (2) The association is strong.
  - (3) The relationship is dose dependent.
  - (4) The findings were replicated.
  - (5) The findings have bio-plausibility.
  - (6) The association fades with cessation of intervention.
  - (7) The findings are consistent with prior knowledge.
- e. **Bias:** Consider the many known types of bias and how they may affect the results.
- (1) **Selection biases:** Caused by a nonrandom or dissimilar sample (between cases/controls or exposed/unexposed) from a population. This is mitigated by randomization and selection of participants who are representative of the target population.
    - (a) **Sampling bias:** The sample studied is not representative of population results that are extrapolated to (e.g., RCT performed in healthy volunteers but results inform treatment of sicker patients).
    - (b) **Loss to follow-up bias:** The patients who are lost to follow-up are not randomly distributed (i.e., patients experiencing severe side effects were more likely to drop out of study, leaving only those who tolerated treatment).
    - (c) **Exclusion bias:** Certain populations (e.g., children) were excluded from a study limiting external validity of results.
  - (2) **Information bias:** Caused by flawed collection of information about exposures and outcomes. Mitigated by blinding

researchers and participants (see above) and standardizing data collection

- (a) **Recall bias:** Awareness of disorder alters recall by subjects.
  - (b) **Lead-time bias:** Early detection is confused with increased survival.
- (3) Other important biases
- (a) **Confounding:** A variable associated with both the disease and the exposure (risk factor), leading to detection of a false relationship between the disease and exposure if the researchers do not control for the confounder. Can be controlled for by adjustment, matching, and/or blinding, but best controlled for by randomization (e.g., ice cream sales increase violence is confounded by hot weather)
  - (b) **Effect modifier (interaction):** A variable that modifies the observed effect of an exposure on disease (e.g., a new drug is effective in female children but not male children, then sex is an effect modifier). Can be controlled for by stratification
  - (c) Directed acyclic graphs (DAGs) can be drawn to help assessment for confounders, effect modifiers, colliders, and other biases.
  - (d) A more complete list of common biases can be found at <https://catalogofbias.org/biases/>
- f. Assess value: Value is broadly defined as outcomes per cost. Ask whether the intervention is likely to be of high value, low value, or no value.<sup>4</sup>
- (1) **High-value care:** The intervention either improves outcomes, decreases cost, or both.
    - (a) Expensive interventions can be high value if they have large benefit.
    - (b) Low-cost interventions can be low value if they have negligible or no benefit.
    - (c) High-value interventions may still increase the overall cost of care.
    - (d) The cutoff between high and low value care is subjective and decided based on a society's values and resources.
  - (2) **Low-value care:** There is some benefit, but it is not worth the cost (or its savings are not worth how much it worsens outcomes).
  - (3) **No-value care:** The intervention adds no clinical benefit. Also known as a "Things We Do For No Reason"
- g. Apply evidence: If the evidence is scientifically valid and clinically important, integrate it with your clinical expertise and the patient's values and preferences.

## II. BIOSTATISTICS AND EPIDEMIOLOGY

### A. Statistical Tests

The following statistical tests are used to determine whether observed differences are statistically significant (Table 29.1).<sup>5-7</sup>

1. **Parametric tests** are used when data follow a particular distribution (e.g., a normal distribution—a bell-shaped distribution where the median, mean, and mode are all equal). These tests are generally more powerful.

**TABLE 29.1**  
**COMMONLY USED STATISTICAL TESTS**

Purpose of Test	Parametric Test	Nonparametric Test	Example
Compares two independent samples	Two-sample (unpaired) <i>t</i> test	Mann-Whitney <i>U</i> test	To compare girls' heights with boys' heights
Compares two sets of observations on a single sample	One-sample (paired) <i>t</i> test	Wilcoxon matched pairs test	To compare weight of infants before and after a feeding
Compares three or more sets of observations made on a single sample	One-way analysis of variance ( <i>F</i> test) using total sum of squares	Kruskal-Wallis analysis of variance by ranks	To determine whether plasma glucose level is higher 1 hr, 2 hr, or 3 hr after a meal
As above, but tests the influence (and interaction) of two different variables	Two-way analysis of variance (ANOVA)	Two-way analysis of variance by ranks	In the above example, to determine whether the results differ in male and female subjects
Tests the null hypothesis that the distribution of a categorical variable is the same in two (or more) independent samples	$\chi^2$ (chi square) test	Fisher exact test	To assess whether acceptance into medical school is more likely if the applicant was born in Britain
Assesses the strength of the straight-line association between two continuous variables	Product moment correlation coefficient (Pearson <i>r</i> )	Spearman rank correlation coefficient ( $r_s$ )	To assess whether and to what extent plasma HbA1C concentration is related to plasma triglyceride concentration in patients with diabetes
Describes the numeric relation between two quantitative variables, allowing one value to be predicted from the other	Regression by least squares method	Nonparametric regression (various tests)	To see how peak expiratory flow rate varies with height
Describes the numerical relationship between a dependent variable and several predictor variables (covariates)	Multiple regression by least squares method	Nonparametric regression (various tests)	To determine whether and to what extent a person's age, body fat, and sodium intake determine his or her blood pressure

Modified from Greenhalgh T. How to read a paper: Statistics for the non-statistician. I: Different types of data need different statistical tests. *BMJ*. 1997;315(7104):364–366.

2. **Nonparametric tests** are used when a particular distribution cannot be assumed. They rank data rather than taking absolute differences into account.
3. **Unpaired tests** compare values from independent samples.
4. **Paired tests** are performed on paired data. For example, where the same parameter is measured on each patient before and after an intervention.
5. **Two-tailed tests** should be used when an intervention could potentially lead to either an increase or decrease of the outcome.
6. **One-tailed tests** should be used when an intervention can have only one plausible effect on the outcome.

## B. Statistical Terminology

1.  **$\alpha$  (Alpha): Significance level of a statistical test<sup>5,8</sup>**

  - a.  **$\alpha$** : Probability of making a **type I error**; the probability of rejecting the null hypothesis (i.e., no effect exists) when the null hypothesis is true (i.e., a difference is seen by chance alone).
  - b.  **$\alpha$** , the preset level of significance, is typically set at less than 0.05 in medical research, which allows interpretation with 95% certainty that a detected association is true.
  - c. The  **$P$  value** is the probability of obtaining the observed values if the null hypothesis is true. For example, if  $P = 0.01$ , there is a 1 in 100 chance of the values being from chance alone. The  $P$  value is judged against  **$\alpha$** , the preset level of significance. If  $P$  is less than the significance level  **$\alpha$** , the detected association is considered significant. Even if a  $P$  value is significant, it can still turn out to not be true. A  $P$  value can also be statistically significant but not clinically significant (e.g., a trial of a new antiviral shortens viral URI symptoms by one hour compared to placebo).

2.  **$\beta$  (Beta): Power of a statistical test**

  - a.  **$\beta$** : Probability of making a **type II error**; the probability of accepting the null hypothesis when the alternative hypothesis is true (i.e., no difference is seen even though there is one). Power is influenced by sample size, effect size, and variance.
  - b. **Power = 1 –  $\beta$** : Probability of correctly rejecting the null hypothesis (i.e., finding a difference when there truly is one)
  - c. **Power** is typically set at a minimum of 0.80, which allows interpretation with 80% certainty that a detected lack of association is true.

3. **Sample size**: The number of subjects required in a study to detect an effect with a predetermined power and  **$\alpha$** .
4. **95% confidence interval**: Describes the values between which there is a 95% chance that the true population value falls. When confidence intervals for groups overlap, they have no statistically significant difference.

## C. Types of Study Designs<sup>9</sup> (see Table 29.2)

## D. Measurement of Disease Occurrence and Treatment Effects<sup>5</sup>

See Table 29.3 for equations in this section.

TABLE 29.2

## STUDY DESIGN COMPARISON

Design Type	Cross-Sectional	Case-Control (Retrospective)	Cohort (Usually Prospective, Occasional Retrospective)	Clinical Trial (Experimental)	Systematic Reviews/ Meta-Analysis
Definition	In study population, concurrently measure outcome (disease) and risk factor  Compare proportion of diseased group with risk factor to proportion of nondiseased group with risk factor	Define cases (with outcome of interest) and controls (without outcome)  Compare proportion of cases with exposure (risk factor) to proportion of controls with exposure (risk factor)	In study population, define exposed group (with risk factor) and nonexposed group (without risk factor)  Over time, compare proportion of exposed group with outcome (disease) to proportion of nonexposed group with outcome (disease)	In study population, randomly assign subjects to receive intervention or receive no intervention  Compare rate of outcomes between intervention and control groups	Combine data from multiple independent studies to maximize precision and power in testing for statistical significance
Advantages	Defines prevalence Short time to complete Inexpensive	Good for rare diseases/outcomes Small sample size Shorter study times Less expensive Can study association of multiple exposures with outcome	Defines incidence Stronger evidence for causality Decreases biases (sampling, measurement, reporting) Can study association of exposure with multiple outcomes	Randomized controlled trial is gold standard Randomization reduces confounding Best evidence for causality	Higher statistical power Can control for interstudy variation
Disadvantages	Selection bias Weak evidence for causality	Highest potential for biases Weak evidence for causality Unable to determine prevalence, incidence	Expensive Long study times May not be feasible for rare diseases/outcomes Factors related to exposure and outcome may falsely alter effect of exposure on outcome (confounding)	Expensive Risks of experimental treatments in humans Longer study time Not suitable for rare diseases/outcomes	Publication bias. Only as good as the studies included in the analysis.

Modified from Hulley SB, Cummings SR, Browner WS, et al. *Designing Clinical Research*. 4th ed. Lippincott Williams & Wilkins; 2013:84–207.

TABLE 29.3

GRID FOR CALCULATIONS IN CLINICAL STUDIES

Exposure or Risk Factor or Treatment	Disease or Outcome	
	Positive	Negative
Positive	A	B
Negative	C	D

Also known as a contingency table.

1. **Prevalence:** Proportion of population who has a disease at a point in time. Obtained in cross-sectional studies

$$\text{Prevalence} = \frac{\text{Number of total cases}}{\text{Population size}}$$

2. **Incidence:** Rate of people developing a disease in the population during a defined time period. Obtained in cohort studies and clinical trials

$$\text{Incidence} = \frac{\text{Number of new cases}}{\text{Population size}} \text{ per unit of time}$$

3. **Relative risk (RR):** The ratio of incidence of disease among people with an exposure to incidence of disease among people without the exposure. Obtained in cohort studies and clinical trials. RR cannot be obtained in case-control studies

$$\text{RR} = \frac{\frac{A}{A+B}}{\frac{C}{C+D}}$$

- a. RR = 1: No effect of exposure or treatment on outcome
  - b. RR <1: Exposure or treatment protective against outcome
  - c. RR >1: Exposure or treatment increases the outcome
  - d. The **relative risk reduction (RRR)**, which measures the strength of the impact of an exposure or treatment, is equal to 1 – RR.
4. **Odds ratios (ORs):** The ratio of the odds of an exposed person developing a disease to the odds of a nonexposed person developing the disease. OR are obtained in case-control studies, cohort studies, and clinical trials.

$$\text{OR} = \frac{\frac{A}{B}}{\frac{C}{D}} = \frac{A \times D}{B \times C}$$

- a. OR approximates RR when the disease is rare (incidence <0.10).
  - b. OR =1: No association between risk factor and disease
  - c. OR <1: Suggests that risk factor is protective against disease
  - d. OR >1: Suggests positive association between risk factor and disease
5. **Risk difference:** The difference between the risk of the outcome in control and the risk of the outcome in treatment group. If the risk of the outcome is decreased by the treatment, **absolute risk reduction (ARR)** is used. If the risk of the outcome is increased by the treatment, **absolute risk increase (ARI)** is used.

$$\text{ARR} = \frac{C}{(C + D)} - \frac{A}{(A + B)}$$

$$\text{ARI} = \frac{A}{(A + B)} - \frac{C}{(C + D)}$$

6. **Number needed to treat (NNT):** Number of patients who need to be treated to prevent one undesired outcome, expressed as the inverse of ARR.

$$\text{NNT} = \frac{1}{\text{ARR}}$$

7. **Number needed to harm (NNH):** Number of patients who need to be treated to cause one additional patient harm, expressed as the inverse of ARI.

$$\text{NNH} = \frac{1}{\text{ARI}}$$

### E. Measurements of Test Performance<sup>5</sup>

See [Table 29.4](#) for equations in this section.

1. **Validity:** The ability of a test to indicate which patients have or do not have disease. Intrinsic to the test—not affected by disease prevalence
  - a. **Sensitivity:** Proportion of all patients with disease who have a positive test. Measures the ability of the test to correctly identify those who have the disease. Use a highly sensitive test to help rule out a disease.

$$\text{Sensitivity} = \frac{\text{TP}}{\text{TP} + \text{FN}}$$

- b. **Specificity:** Proportion of all patients without disease who have a negative test. Measures the ability of the test to correctly identify those who do not have the disease. Use a highly specific test to help confirm a disease.

$$\text{Specificity} = \frac{\text{TN}}{\text{TN} + \text{FP}}$$

TABLE 29.4

GRID FOR EVALUATING A CLINICAL TEST

Test Result	Disease Status	
	Has Disease	Does Not Have Disease
Positive	TP (true positive)	FP (false positive)
Negative	FN (false negative)	TN (true negative)

## 2. Predictive value

- a. **Positive predictive value (PPV):** Proportion of those with positive tests who truly have disease. PPV is increased with higher disease prevalence.

$$PPV = \frac{TP}{TP + FP}$$


3. **Negative predictive value (NPV):** Proportion of those with negative tests who truly do not have disease. NPV is increased with lower disease prevalence.

$$NPV = \frac{TN}{TN + FN}$$

4. **Likelihood ratio (LR):** Incorporates the validity of a test (sensitivity and specificity) to determine the magnitude of the effect of a test result on changing the pretest probability. Used with Bayes nomogram (Fig. 29.2) to estimate posttest probability of a disease based on a given test result. Tests that provide the greatest impetus to changing clinical management are those with an LR  $\geq 10$  (for positive tests) or LR  $\leq 0.1$  (for negative tests). LR is unaffected by disease prevalence.

$$LR \text{ for positive test} = \frac{\text{Sensitivity}}{1 - \text{Specificity}}$$

$$LR \text{ for negative test} = \frac{1 - \text{Sensitivity}}{\text{Specificity}}$$



**FIGURE 29.2**

Bayes nomogram: draw a line connecting the baseline probability (pretest probability) with the value for the likelihood ratio for the test used. Extend this line to the right to find the posttest probability. (Modified from Fagan TJ. Nomogram for Bayes Theorem. *N Engl J Med.* 1975;293[5]:257.)

### III. WEB RESOURCES

#### A. Evidence-Based Resources

- Agency for Healthcare Research and Quality: <https://www.ahrq.gov/research/findings/evidence-based-reports/index.html>
- Centre for Evidence Based Medicine: <https://www.cebm.net>
- Cochrane Reviews: <https://www.cochranelibrary.com>
- JAMA evidence: <https://jamaevidence.mhmedical.com/>
- JAMA The Rational Clinical Examination: <https://jamanetwork.com/collections/6257/the-rational-clinical-examination>
- NICE Guidance: <https://www.nice.org.uk/guidance>
- PubMed: <https://www.ncbi.nlm.nih.gov/pubmed>
- U.S. Preventive Services Task Force: <https://www.uspreventiveservicestaskforce.org/uspstf/>

#### B. Biostatistics and Epidemiology Resources

- BMJ Statistics at Square One: <https://www.bmj.com/collections/statsbk/index.dtl>
- Centers for Disease Control and Prevention Epi Info: <https://www.cdc.gov/epiinfo/>
- JAMA Users' Guide to the Medical Literature: <https://jamanetwork.com/collections/44069/users-guide-to-the-medical-literature>

### REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Sackett DL, Rosenberg WMC, Gray JAM, et al. Evidence based medicine: what it is and what it isn't. *BMJ*. 1996;312:71. <https://doi.org/10.1136/bmj.312.7023.71>
2. Straus SE, Glasziou P, Richardson WS, Haynes RB. *Evidence-Based Medicine: How to Practice and Teach EBM*. 5th ed. Elsevier; 2019.
3. Celentano D, Szklo M. *Gordis Epidemiology*. 6th ed. Elsevier; 2018.
4. Pandya A. Adding cost-effectiveness to define low-value care. *JAMA*. 2018;319(19):1977–1978. <https://doi.org/10.1001/jama.2018.2856>
5. Rosner B. *Fundamentals of Biostatistics*. 8th ed. Cengage Learning; 2016:211–632.
6. Greenhalgh T. How to read a paper: statistics for the non-statistician. I: different types of data need different statistical tests. *BMJ*. 1997;315(7104):364–366.
7. Greenhalgh T. How to read a paper: statistics for the non-statistician. II: “Significant” relations and their pitfalls. *BMJ*. 1997;315(7104):422–425.
8. Motulsky H. *Introduction to P Values. Intuitive Biostatistics*. Oxford University Press; 1995:91–152.
9. Hulley SB, Cummings SR, Browner WS, et al. *Designing Clinical Research*. 4th ed. Lippincott Williams & Wilkins; 2013:84–207.

This page intentionally left blank

# PART IV

## FORMULARY



This page intentionally left blank

# Chapter 30

## Drug Dosages

*Carlton K.K. Lee, PharmD, MPH*

### I. NOTE TO READER

The author has made every attempt to check dosages and medical content for accuracy. Because of the incomplete data on pediatric dosing, many drug dosages will be modified after the publication of this text. We recommend that the readers check product information and published literature for changes in dosing, especially for newer medicines. The US Food and Drug Administration (FDA) provides the following pediatric drug information data sources:

- New Pediatric Labeling Information: <https://www.fda.gov/science-research/pediatrics/pediatric-labeling-changes>
- Drug Safety Report Updates: <https://www.fda.gov/advisory-committees/pediatric-advisory-committee/pediatric-advisory-recommendations-and-updates>
- Ongoing and completed clinical research study information of pediatric medicines in development is located in <https://www.clinicaltrials.gov/>

To prevent prescribing errors, the use of abbreviations has been greatly discouraged. The following is a list of abbreviations that The Joint Commission considers prohibited for use.

## THE JOINT COMMISSION

Official “Do Not Use” List<sup>a</sup>

Do Not Use	Potential Problem	Use Instead
U (unit)	Mistaken for “0” (zero), the number “4” (four) or “cc”	Write “unit”
IU (International Unit)	Mistaken for IV (intravenous) or the number 10 (ten)	Write “International Unit”
Q.D., QD, q.d., qd (daily)	Mistaken for each other	Write “daily”
Q.O.D., QOD, q.o.d, qod (every other day)	Period after the Q mistaken for “I” and the “O” mistaken for “I”	Write “every other day”
Trailing zero (X.0 mg) <sup>b</sup>	Decimal point is missed	Write X mg
Lack of leading zero (.X mg)	Decimal point is missed	Write 0.X mg
MS	Can mean morphine sulfate or magnesium sulfate	Write “morphine sulfate” Write “magnesium sulfate”
MSO <sub>4</sub> and MgSO <sub>4</sub>	Confused for one another	

<sup>a</sup>Applies to all orders and all medication-related documentation that is handwritten (including free-text computer entry) or on preprinted forms.

<sup>b</sup>Exception: A “trailing zero” may be used only where required to demonstrate the level of precision of the value being reported, such as for laboratory results, imaging studies that report size of lesions, or catheter/tube sizes. It may not be used in medication orders or other medication-related documentation.

## ADDITIONAL ABBREVIATIONS, ACRONYMS, AND SYMBOLS (FOR POSSIBLE FUTURE INCLUSION IN THE OFFICIAL “DO NOT USE” LIST)

Do Not Use	Potential Problem	Use Instead
> (greater than) < (less than)	Misinterpreted as the number “7” (seven) or the letter “L” Confused for one another	Write “greater than” Write “less than”
Abbreviations for drug names	Misinterpreted due to similar abbreviations for multiple drugs	Write drug names in full
Apothecary units	Unfamiliar to many practitioners Confused with metric units	Use metric units
@	Mistaken for the number “2” (two)	Write “at”
cc	Mistaken for U (units) when poorly written	Write “mL” or “ml” or “milliliters” (“mL” is preferred)
μg	Mistaken for mg (milligrams), resulting in one thousand-fold overdose	Write “mCg” or “micrograms”

## II. SAMPLE ENTRY

**Pharmacogenomics:** Indicates need for assessing patient genotype or genetic polymorphism affecting dosing, drug selection, or anticipated pharmacological effects.

**Liver:** Indicates need for caution or need for dose adjustment in hepatic impairment.

**Kidney:** Indicates need for caution or need for dose adjustment in renal impairment (see also Chapter 31).

**Breast:** Refer to explanation of breast-feeding categories (see p. 764).

**Pregnancy:** Refer to explanation of pregnancy categories (see p. 764).

**How Supplied****ALLOPURINOL**

Generic name

Zyloprim, Aloprim, and generics

Trade name and other names

**Uric acid lowering agent, xanthine oxidase inhibitor**

Drug category

**Tabs:** 100, 300 mg

**Oral suspension:** 20 mg/mL

**Injection (Aloprim and generics):** 500 mg

Contains ~ 1.45 mEq Na/500 mg drug

**For use in tumor lysis syndrome, see Chapter 22 for additional information.**



C



2



Yes



Yes



Yes

**Mortar and pestle:** Indicates need for extemporaneous compounding by a pharmacist

**Child:**

**Oral:** 10 mg/kg/24 hr PO ÷ BID–QID; **max. dose:** 800 mg/24 hr

**Injectable:** 200 mg/m<sup>2</sup>/24 hr IV ÷ Q6–12 hr; **max. dose:** 600 mg/24 hr

**Adult:**

**Oral:** 200–800 mg/24 hr PO ÷ BID–TID

**Injectable:** 200–400 mg/m<sup>2</sup>/24 hr IV ÷ Q6–12 hr; **max. dose:** 600 mg/24 hr

**Drug dosing**

Discontinue use at the first appearance of skin rash or other signs of an allergic reaction. **Avoid** use in individuals with HLA-B\*58:01 allele as they are at significant risk for developing severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome and TEN).

Side effects include rash, neuritis, hepatotoxicity, renal function impairment, GI disturbance, bone marrow suppression, and drowsiness.

**Adjust dose in renal insufficiency (see Chapter 31).** Must maintain adequate urine output and alkaline urine.

**Drug interactions:** increases serum theophylline level; may increase the incidence of rash with ampicillin and amoxicillin; increased risk of toxicity with azathioprine, didanosine, and mercaptopurine; and increased risk of hypersensitivity reactions with ACE inhibitors and thiazide diuretics. Use with didanosine is **contraindicated** due to increased risk for didanosine toxicity. Rhabdomyolysis has been reported with clarithromycin use.

IV dosage form is very alkaline and must be **diluted to a minimum concentration** of 6 mg/mL and infused over 30 min.

The manufacturer advises not to breastfeed during treatment with allopurinol for one week after the last dose as limited data indicate a maternal dose of 300 mg daily can provide near-therapeutic dose and plasma levels in an exclusively breastfed infant.

**Brief remarks about side effects, drug interactions, precautions, therapeutic monitoring, and other relevant information**



**III. EXPLANATION OF BREASTFEEDING CATEGORIES**


See sample entry on previous page.

- 1** Compatible
- 2** Use with caution
- 3** Unknown with concerns
- X** Contraindicated
- ?** Safety not established

**IV. EXPLANATION OF PREGNANCY CATEGORIES**

- A** Adequate studies in pregnant women have not demonstrated a risk to the fetus in the first trimester of pregnancy, and there is no evidence of risk in later trimesters.
- B** Animal studies have not demonstrated a risk to the fetus, but there are no adequate studies in pregnant women; or animal studies have shown an adverse effect, but adequate studies in pregnant women have not demonstrated a risk to the fetus during the first trimester of pregnancy, and there is no evidence of risk in later trimesters.
- C** Animal studies have shown an adverse effect on the fetus, but there are no adequate studies in humans; or there are no animal reproduction studies and no adequate studies in humans.
- D** There is evidence of human fetal risk, but the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks.
- X** Studies in animals or humans demonstrate fetal abnormalities or adverse reaction; reports indicate evidence of fetal risk. The risk of use in pregnant women clearly outweighs any possible benefit.
- ?** Pregnancy category not established

## V. NOMOGRAM AND EQUATION FOR BODY SURFACE AREA



Alternative (Mosteller's formula):

$$\text{Surface area (m}^2\text{)} = \sqrt{\frac{\text{Height (cm)} \times \text{Weight (kg)}}{3600}}$$

**FIGURE 30.1**

Nomogram and equation for body surface area. (From Kliegman RM, Stanton BF, Schor NF, et al., eds. *Nelson Textbook of Pediatrics*. 20th ed. Elsevier; 2016.)

## VI. DRUG INDEX

Trade Name(s)	Generic Name
1,25-dihydroxycholecalciferol	Calcitriol
2-PAM <sup>a</sup>	Pralidoxime Chloride
3TC <sup>a</sup>	Lamivudine
5-aminosalicylic acid	Mesalamine
5-ASA	Mesalamine
5-FC <sup>a</sup>	Flucytosine
5-Fluorocytosine <sup>a</sup>	Flucytosine
8-Arginine Vasopressin <sup>a</sup>	Vasopressin
9-Fluorohydrocortisone <sup>a</sup>	Fludrocortisone Acetate
27% Elemental Ca	Calcium Chloride
A-200	Pyrethrins
Abelcet	Amphotericin B Lipid Complex
Absorica	Isotretinoin
Abstra	Fentanyl
Accolate	Zafirlukast
AccuNeb (prediluted nebulized solution)	Albuterol
Accutane	Isotretinoin
Acetadote	Acetylcysteine
Acticin	Permethrin
Actigall	Ursodiol
Actiq	Fentanyl
Activase	Alteplase
Acular, Acular LS	Ketorolac
Acuvail	Ketorolac
Aczone	Dapsone
Adalat CC	Nifedipine
Adderall, Adderall XR	Dextroamphetamine + Amphetamine
Adenocard	Adenosine
Adoxa	Doxycycline
Adrenaline	Epinephrine HCl
Advair Diskus, Advair HFA	Fluticasone Propionate and Salmeterol
Advil, Children's Advil	Ibuprofen
Aerospan	Flunisolide
Afrin	Oxymetazoline
AK-Poly-Bac Ophthalmic	Bacitracin + Polymyxin B
AK-Sulf	Sulfacetamide Sodium Ophthalmic
AKTob	Tobramycin
AK-Tracin Ophthalmic	Bacitracin
Albuminar	Albumin, Human
Albutein	Albumin, Human
Aldactone	Spironolactone
Aleve [OTC]	Naproxen/Naproxen Sodium
Allegra, Allegra ODT	Fexofenadine
Allegra-D 12 Hour, Allegra-D 24 Hour	Fexofenadine + Pseudoephedrine
Allergen Ear Drops	Antipyrine and Benzocaine
Aloprim	Allopurinol
Almacone, Almacone II Double Strength	Aluminum Hydroxide with Magnesium Hydroxide

Trade Name(s)	Generic Name
Alsuma	Sumatriptan Succinate
AlternaGEL	Aluminum Hydroxide
Alu-Cap	Aluminum Hydroxide
Alvesco	Ciclesonide
AmBisome	Amphotericin B, Liposomal
Amicar	Aminocaproic Acid
Amikin	Amikacin Sulfate
Amnesteem	Isotretinoin
Amoclan	Amoxicillin-Clavulanic Acid
Amoxil	Amoxicillin
Amphadase	Hyaluronidase
Amphocin	Amphotericin B
Amphojel	Aluminum Hydroxide
Anacin	Aspirin
Anaprox	Naproxen/Naproxen Sodium
Ancef	Cefazolin
Ancobon	Flucytosine
Anectine	Succinylcholine
Antilirium	Physostigmine Salicylate
Antipyrine and Benzocaine Otic	Antipyrine and Benzocaine
Antizol	Fomepizole
Anzemet	Dolasetron
Apresoline	Hydralazine Hydrochloride
Apriso	Mesalamine
Aquachloral Suppettes	Chloral Hydrate
Aquasol A	Vitamin A
Aquasol E	Vitamin E
Aquavit-E	Vitamin E
Aralen	Chloroquine HCl/Phosphate
Aranesp	Darbepoetin Alfa
Arbinox	Carbinoxamine
Arestin	Minocycline
Aridol	Mannitol
Aristospan	Triamcinolone
ASA <sup>a</sup>	Aspirin
Asacol, Asacol HD	Mesalamine
Asmanex Twisthaler	Mometasone Furoate
Aspirin Free Anacin	Acetaminophen
Astelin	Azelastine
Astepro	Azelastine
Astragraf XL	Tacrolimus
Ativan	Lorazepam
AtroPen	Atropine Sulfate
Atrovent	Ipratropium Bromide
Augmentin, Augmentin ES-600, Augmentin XR	Amoxicillin-Clavulanic Acid
Auralgan (available in Canada)	Antipyrine and Benzocaine
Auro Ear Drops	Carbamide Peroxide
Avinza	Morphine Sulfate
Avita	Tretinoin
Ayr Saline	Sodium Chloride—Inhaled Preparations

Trade Name(s)	Generic Name
Azactam	Aztreonam
Azasan	Azathioprine
Azasite	Azithromycin
Azo-Standard [OTC]	Phenazopyridine HCl
Azulfidine, Azulfidine EN-Tabs	Sulfasalazine
Baciguent Topical	Bacitracin
Bactrim	Sulfamethoxazole and Trimethoprim
Bactroban, Bactroban Nasal	Mupirocin
BAL <sup>a</sup>	Dimercaprol
Beconase AQ	Beclomethasone Dipropionate
Benadryl	Diphenhydramine
Benzac AC Wash 2½, 5, 10; Benzac 5, 10	Benzoyl Peroxide
Beta-Val	Betamethasone
Bethkis	Tobramycin
Biaxin, Biaxin XL	Clarithromycin
Bicillin C-R, Bicillin C-R 900/300	Penicillin G Preparations—Penicillin G Benzathine and Penicillin G Procaine
Bicillin L-A	Penicillin G Preparations—Benzathine
Bio-Statin	Nystatin
Bloxiverz	Neostigmine
Bleph-10	Sulfacetamide Sodium Ophthalmic
Brevibloc	Esmolol HCl
Brevoxyl Creamy Wash	Benzoyl Peroxide
Brisdelle	Paroxetine
British anti-Lewisite	Dimercaprol
Bufferin	Aspirin
Bumex	Bumetanide
Buminate	Albumin, Human
Cafcit	Caffeine Citrate
Cafergot	Ergotamine Tartrate + Caffeine
Calcidol	Ergocalciferol
Caldolor	Ibuprofen
Calan, Calan SR	Verapamil
Calciferol	Ergocalciferol
Calcijex	Calcitriol
Calcionate	Calcium Glubionate
Calciquid	Calcium Glubionate
Cal-Citrate	Calcium Citrate
Calcium disodium versenate	Edetate (EDTA) Calcium Disodium
Cal-Glu	Calcium Gluconate
Cal-Lac	Calcium Lactate
Calphron	Calcium Acetate
Camphorated opium tincture	Paregoric
Canasa	Mesalamine
Cancidas	Caspofungin
Cankaid	Carbamide Peroxide
Capoten	Captopril
Carafate	Sucralfate
Carbatrol	Carbamazepine
Cardene, Cardene SR	Nicardipine

Trade Name(s)	Generic Name
Cardizem, Cardizem SR, Cardizem CD, Cardizem LA	Diltiazem
Carnitor	Carnitine
Catapres, Catapres TTS	Clonidine
Cathflo Activase	Alteplase
Cayston	Aztreonam
Ceclor, Ceclor CD	Cefaclor
Cecon	Ascorbic Acid
Cefotan	Cefotetan
Ceftin	Cefuroxime Axetil
Cefzil	Cefprozil
Celestone	Betamethasone
CellCept	Mycophenolate Mofetil
Cephulac	Lactulose
Ceptaz	Ceftazidime
Cerebyx	Fosphenytoin
Chemet	Succimer
Chloromycetin	Chloramphenicol
Chlor-Trimeton	Chlorpheniramine Maleate
Cholestyramine Light	Cholestyramine
Chronulac	Lactulose
Ciloxan ophthalmic	Ciprofloxacin
Cipro, Cipro XR, Ciprodex, Cipro HC Otic	Ciprofloxacin
Citracal	Calcium Citrate
Claforan	Cefotaxime
Claravis	Isotretinoin
Claritin, Claritin Children's Allergy, Claritin RediTabs	Loratadine
Claritin-D 12 Hour, Claritin-D 24 Hour	Loratadine + Pseudoephedrine
Cleocin-T, Cleocin	Clindamycin
Cogentin	Benzotropine Mesylate
Colace	Docusate
Colocort	Hydrocortisone
CoLyte	Polyethylene Glycol—Electrolyte Solution
Compazine	Prochlorperazine
Concerta	Methylphenidate HCl
Copegus	Ribavirin
Cordarone	Amiodarone HCl
Cordron-D NR, Cordron-D	Carbinoxamine + Pseudoephedrine
Coreg, Coreg CR	Carvedilol
Cortef	Hydrocortisone
Cortenema	Hydrocortisone
Cortifoam	Hydrocortisone
Cortisporin Otic	Polymyxin B Sulfate, Neomycin Sulfate, Hydrocortisone
Co-Trimoxazole	Sulfamethoxazole and Trimethoprim
Coumadin	Warfarin
Covera-HS	Verapamil
Cozaar	Losartan
Crolom	Cromolyn
Cruex	Clotrimazole
Cuprimine	Penicillamine

Trade Name(s)	Generic Name
Curosurf	Surfactant, Pulmonary/Poractant Alfa
Cutivate	Fluticasone Propionate
Cuvposa	Glycopyrrolate
Cyanoject	Cyanocobalamin/Vitamin B <sub>12</sub>
Cyclogyl	Cyclopentolate
Cyclomydril	Cyclopentolate with Phenylephrine
Cyomin	Cyanocobalamin/Vitamin B <sub>12</sub>
Cytovene	Ganciclovir
D-3, D3-5, D3-50	Cholecalciferol
Dantrium	Dantrolene
Daraprim	Pyrimethamine
Daytrana	Methylphenidate HCl
DDAVP <sup>a</sup>	Desmopressin Acetate
DDS <sup>a</sup>	Dapsone
D Drops	Cholecalciferol
Debrox	Carbamide Peroxide
Decadron	Dexamethasone
Deltasone	Prednisone
Delzicol	Mesalamine
Deodorized tincture of opium	Opium Tincture
Depacon	Valproic Acid
Depakene	Valproic Acid
Depakote, Depakote ER	Divalproex Sodium
Depen	Penicillamine
Depo-Medrol	Methylprednisolone
Depo-Provera	Medroxyprogesterone
Depo-Sub Q Provera 104	Medroxyprogesterone
Desquam-E 5, Desquam-E 10	Benzoyl Peroxide
Desyrel (previously available as)	Trazodone
Dexedrine Spansules	Dextroamphetamine
DexFerrum	Iron—Injectable Preparations (iron dextran)
Dexpak Taperpak	Dexamethasone
DextroStat	Dextroamphetamine ± Amphetamine
Di-5-ASA <sup>a</sup>	Olsalazine
Dialume	Aluminum Hydroxide
Diaminodiphenyl sulfone	Dapsone
Diamox	Acetazolamide
Diastat, Diastat AcuDial	Diazepam
Dificid	Fidaxomicin
Diflucan and others	Fluconazole
Digibind, DigiFab	Digoxin Immune Fab (Ovine)
Digitek	Digoxin
Dilacor XR	Diltiazem
Dilantin, Dilantin Infatab	Phenytoin
Dilaudid, Dilaudid-HP	Hydromorphone HCl
Di-mesalazine	Olsalazine
Dimetapp Children's Cold and Allergy	Brompheniramine with Phenylephrine
Diovan	Valsartan
Dipentum	Olsalazine

Trade Name(s)	Generic Name
Diprolene, Diprolene AF	Betamethasone
Diprosone	Betamethasone
DisperMox	Amoxicillin
Ditropan, Ditropan XL	Oxybutynin Chloride
Diuril	Chlorothiazide
DMSA [dimercaptosuccinic acid] <sup>a</sup>	Succimer
Dobutrex (previously available as)	Dobutamine
Dolophine	Methadone HCl
Doryx	Doxycycline
Doxidan	Bisacodyl
Dramamine, Children's Dramamine	Dimenhydrinate
Drisdol	Ergocalciferol
Dulcolax	Bisacodyl
Dulera	Mometasone Furoate + Formoterol Fumarate
Duraclon	Clonidine
Duragesic	Fentanyl
Duramist 12-Hr Nasal	Oxymetazoline
Duricef	Cefadroxil
Dycill	Dicloxacillin Sodium
Dymista	Azelastrine and Fluticasone
Dynacin	Minocycline
Dyrenium	Triamterene
EC-Naprosyn	Naproxen
Efidac/24-Pseudoephedrine	Pseudoephedrine
Elavil	Amitriptyline
Elidel	Pimecrolimus
Elimite	Permethrin
Eliphos	Calcium Acetate
Elitek	Rasburicase
Elixophyllin	Theophylline
Elocon	Mometasone Furoate
Enfamil D-Vi-Sol	Cholecalciferol
EMLA, Eutectic mixture of lidocaine and prilocaine	Lidocaine and Prilocaine
E-Mycin	Erythromycin Preparations
Enbrel	Etanercept
Endocet	Oxycodone and Acetaminophen
Endodan	Oxycodone and Aspirin
Enemeez	Docusate
Enlon	Edrophonium Chloride
Entocort EC	Budesonide
Enulose	Lactulose
Epaned	Enalapril Maleate
EpiPen	Epinephrine HCl
Epitol	Carbamazepine
Epivir, Epivir-HBV	Lamivudine
Epogen	Epoetin Alfa
Epsom salts	Magnesium Sulfate
Ergomar	Ergotamine Tartrate
Ery-Ped	Erythromycin

Trade Name(s)	Generic Name
Erythrocin, Pediamycin, E-Mycin, Ery-Ped	Erythromycin
Erythropoietin	Epoetin Alfa
Eryzole	Erythromycin Ethylsuccinate and Acetylsulfisoxazole
Exalgo	Hydromorphone HCl
Extina	Ketoconazole
Famvir	Famciclovir
Fansidar	Pyrimethamine + Sulfadoxine
Felbatol	Felbamate
Fentora	Fentanyl
Feosol	Iron—Oral Preparations (Ferrous sulfate)
Fergon	Iron—Oral Preparations (Ferrous sulfate)
Fer-In-Sol	Iron—Oral Preparations (Ferrous gluconate)
Ferrlecit	Iron—Injectable Preparations (Ferric gluconate)
Fetroja	Cefiderocol
Feverall	Acetaminophen
Fiberall	Psyllium
First-Lansoprazole	Lansoprazole
First-Omeprazole	Omeprazole
FK506	Tacrolimus
Flagyl, Flagyl ER	Metronidazole
Flebogamma DIF	Immune Globulin
Fleet BabyLax	Glycerin
Fleet Laxative, Fleet Bisacodyl	Bisacodyl
Fleet Mineral Oil	Mineral Oil
Fleet, Fleet Phospho-Soda	Sodium Phosphate
Fletcher's Castoria	Senna/Sennosides
Flonase HFA	Fluticasone Propionate
Florinef Acetate	Fludrocortisone Acetate
Flovent Diskus	Fluticasone Propionate
Floxin, Floxin Otic	Ofloxacin
Flumadine	Rimantadine
Fluohydrisone	Fludrocortisone Acetate
Fluoritab	Fluoride
Focalin, Focalin XR	Dexmethylphenidate
Folvite	Folic Acid
Foradil Aerolizer	Formoterol
Fortamet	Metformin
Fortaz	Ceftazidime
Fortical Nasal Spray	Calcitonin—Salmon
Foscavir	Foscarnet
Fulvicin U/F, Fulvicin P/G	Griseofulvin
Fungizone	Amphotericin B
Furadantin	Nitrofurantoin
Gabitril	Tiagabine
Gablofen	Baclofen
Galzin	Zinc Salts, Systemic
Gammaplex	Immune Globulin

Trade Name(s)	Generic Name
Gamma benzene hexachloride <sup>a</sup>	Lindane
Gammaked	Immune Globulin
Garamycin	Gentamicin
Gastrocrom	Cromolyn
Gas-X	Simethicone
Gengraf	Cyclosporine Modified
GlucaGen, Glucagon Emergency Kit	Glucagon HCl
Glucophage, Glucophage XR	Metformin
Gly-Oxide	Carbamide Peroxide
Glycate	Glycopyrrolate
GoLYTELY	Polyethylene Glycol—Electrolyte Solution
Gralise	Gabapentin
Granisol	Granisetron
Grifulvin V	Griseofulvin
Grisactin	Griseofulvin
Gris-PEG	Griseofulvin
Gyne-Lotrimin 3, Gyne-Lotrimin	Clotrimazole
H.P. Acthar Gel	Corticotropin
Haldol, Haldol Decanoate 50, Haldol Decanoate 100	Haloperidol
Hecoria	Tacrolimus
Hexadrol	Dexamethasone
Horizant	Gabapentin
Humatin	Paromomycin Sulfate
Hydro-Tussin CBX	Carbinoxamine + Pseudoephedrine
Hylenex	Hyaluronidase
Hypersal	Sodium Chloride—Inhaled Preparations
Imitrex	Sumatriptan Succinate
Imodium, Imodium AD	Loperamide
Imuran	Azathioprine
Inapsine	Droperidol
Inderal, Inderal LA	Propranolol
Indocin, Indocin SR, Indocin IV	Indomethacin
Infasurf	Surfactant, Pulmonary/Calfactant
INFeD	Iron—Injectable Preparations (iron dextran)
INH <sup>a</sup>	Isoniazid
Intal (previously available as)	Cromolyn
Intropin (previously available as)	Dopamine
Intuniv	Guanfacine
Invanz	Ertapenem
Iosat	Potassium Iodide
Iquix	Levofloxacin
Isentress, Isentress HD	Raltegravir
IsonaRif	Isoniazid
Isoptin SR	Verapamil
Isopto Carpine	Pilocarpine HCl
Isopto Hyoscine	Scopolamine Hydrobromide
Isuprel	Isoproterenol
Jantoven	Warfarin
Kadian	Morphine Sulfate

Trade Name(s)	Generic Name
Kantrex	Kanamycin
Kaopectate	Bismuth Subsalicylate
Kao-Tin	Bismuth Subsalicylate
Kapvay	Clonidine
Kayexalate	Sodium Polystyrene Sulfonate
Keflex	Cephalexin
Kemstro	Baclofen
Kenalog	Triamcinolone
Keppra, Keppra XR	Levetiracetam
Ketalar	Ketamine
Kionex	Sodium Polystyrene Sulfonate
Klonopin	Clonazepam
Klout	Pyrethrins with Piperonyl Butoxide
Kondremul	Mineral Oil
Konsyl	Psyllium
K-PHOS Neutral	Phosphorus Supplements
Kristalose	Lactulose
Kytril	Granisetron
Lamictal, Lamictal ODT, Lamictal XR	Lamotrigine
Laniazid	Isoniazid
Lanoxin	Digoxin
Lariam	Mefloquine HCl
Lasix	Furosemide
Lax-Pills	Senna/Sennosides
Lazanda	Fentanyl
L-Carnitine	Carnitine
Levaquin, Quixin, Iquix	Levofloxacin
Levocarnitine	Carnitine
Levophed and others	Norepinephrine Bitartrate
Lialda	Mesalamine
Licide	Pyrethrins with Piperonyl Butoxide
Lidoderm	Lidocaine
Lioresal	Baclofen
Liquid Pred	Prednisone
Lithobid	Lithium
L-M-X	Lidocaine
Loniten (previously available as)	Minoxidil
Lopressor, Toprol-XL	Metoprolol
Lotrimin AF	Clotrimazole
Lotrimin AF	Miconazole
Lovenox	Enoxaparin
Luminal	Phenobarbital
Luride	Fluoride
Luvox CR	Fluvoxamine
Maalox, Maalox Maximum Strength Liquid	Aluminum Hydroxide with Magnesium Hydroxide
Macrobid	Nitrofurantoin
Macrochantin	Nitrofurantoin
Mag-200, Mag-Ox 400, Uro-Mag	Magnesium Oxide
Marinol	Dronabinol

Trade Name(s)	Generic Name
Maxidex	Dexamethasone
Maxipime	Cefepime
Maxivate	Betamethasone
Maxolon	Metoclopramide
Medrol, Medrol Dosepack	Methylprednisolone
Mefoxin	Cefoxitin
Mephyton	Phytonadione/Vitamin K <sub>1</sub>
Mepron	Atovaquone
Merrem	Meropenem
Mestinon	Pyridostigmine Bromide
Metadate ER	Methylphenidate HCl
Metamucil	Psyllium
Methadose	Methadone HCl
Methylin, Methylin ER	Methylphenidate HCl
Metozolv	Metoclopramide
MetroCream	Metronidazole
MetroGel, MetroGel-Vaginal	Metronidazole
MetroLotion	Metronidazole
Miacalcin, Miacalcin Nasal Spray	Calcitonin—Salmon
Micatin	Miconazole
Microzide	Hydrochlorothiazide
Milk of Magnesia	Magnesium Hydroxide
Millipred	Prednisolone
Minocin	Minocycline
Mintezol	Thiabendazole
Mintox	Aluminum Hydroxide with Magnesium Hydroxide
MiraLax	Polyethylene Glycol—Electrolyte Solution
Monistat	Miconazole
Motrin, Children's Motrin	Ibuprofen
MS Contin	Morphine Sulfate
Mucomyst	Acetylcysteine
Mucosol	Acetylcysteine
Murine Ear	Carbamide Peroxide
Myambutol	Ethambutol HCl
Mycamine	Micafungin Sodium
Mycelex, Mycelex-7	Clotrimazole
Mycobutin	Rifabutin
Mycostatin	Nystatin
Myfortic	Mycophenolate Sodium
Mylanta Gas	Simethicone
Mylanta, Mylanta Extra Strength	Aluminum Hydroxide with Magnesium Hydroxide
Mylicon	Simethicone
Myorisan	Isotretinoin
Mysoline	Primidone
Nallpen	Nafcillin
Naprelan	Naproxen/Naproxen Sodium
Narcan	Naloxone
Nasacort AQ	Triamcinolone

Trade Name(s)	Generic Name
Nasalcrom	Cromolyn
Nasarel	Flunisolide
Nascobal	Cyanocobalamin/Vitamin B <sub>12</sub>
Nasonex	Mometasone Furoate
Nebcin	Tobramycin
NebuPent	Pentamidine Isethionate
Nembutal	Pentobarbital
NeoBenz Micro	Benzoyl Peroxide
Neo-fradin	Neomycin Sulfate
Neo-Polycin	Neomycin/Polymyxin B/Bacitracin
NeoProfen (IV)	Ibuprofen
Neoral	Cyclosporine
Neosporin, Neosporin Ophthalmic, Neo To Go	Neomycin/Polymyxin B/Bacitracin
Neosporin GU Irrigant	Neomycin/Polymyxin B
Neo-Synephrine	Phenylephrine HCl
Neo-Synephrine 12-Hr Nasal	Oxymetazoline
Nephron	Epinephrine, Racemic
Neupogen, G-CSF	Filgrastim
Neurontin	Gabapentin
Neut	Sodium Bicarbonate
Nexiclon XR	Clonidine
Nexium	Esomeprazole
Nexterone	Amiodarone HCl
Niacor	Niacin (Vitamin B <sub>3</sub> )
Niaspan	Niacin (Vitamin B <sub>3</sub> )
Nicotinic acid	Niacin (Vitamin B <sub>3</sub> )
Nifediac CC	Nifedipine
Niferex	Iron—Oral Preparations
Nilstat	Nystatin
Nipride (previously available as)	Nitroprusside
Nitro-Bid	Nitroglycerin
Nitro-Dur	Nitroglycerin
Nitro-Mist	Nitroglycerin
Nitropress	Nitroprusside
Nitrostat	Nitroglycerin
Nitro-Time	Nitroglycerin
Nix	Permethrin
Nizoral, Nizoral A-D	Ketoconazole
Noritrate	Metronidazole
Normal Serum Albumin (Human)	Albumin, Human
Normodyne	Labetalol
Noroxin	Norfloxacin
Norvasc	Amlodipine
Nostrilla	Oxymetazoline
NuCort	Hydrocortisone
NuLYTELY	Polyethylene Glycol—Electrolyte Solution
Nutr-E-Sol	Vitamin E/α-Tocopherol
NVP <sup>a</sup>	Nevirapine
Nydrazid	Isoniazid
OCL <sup>a</sup>	Polyethylene Glycol—Electrolyte Solution

Trade Name(s)	Generic Name
Ocean	Sodium Chloride—Inhaled Preparations
Ocuflox	Ofloxacin
Ocusulf-10	Sulfacetamide Sodium Ophthalmic
Omnaris	Ciclesonide
Ofirmev	Acetaminophen
Omeprazole and Syrspend SF Alka	Omeprazole
Omnicef	Cefdinir
Omnipaque 140, Omnipaque 180, Omnipaque 240, Omnipaque 300, and Omnipaque 350	Iohexol
Omnipen	Ampicillin
Onfi	Clobazam
Onmel	Itraconazole
Opticrom	Cromolyn
Optivar	Azelastine
Oralone	Corticosteroid
Oramorph SR	Morphine Sulfate
Orapred, Orapred ODT	Prednisolone
Oraqix	Lidocaine and Prilocaine
Orasone	Prednisone
OraVerse	Phentolamine Mesylate
Orazinc	Zinc Salts, Systemic
Os-Cal	Calcium Carbonate
Osmitrol	Mannitol
OsmoPrep	Sodium Phosphate
Oxtellar	Oxcarbazepine
Oxy-5, Oxy-10	Benzoyl Peroxide
OxyContin	Oxycodone
Oxytrol	Oxybutynin Chloride
Pacerone	Amiodarone HCl
Palgic	Carbinoxamine
Pamelor	Nortriptyline Hydrochloride
Pamix	Pyrantel Pamoate
Panadol	Acetaminophen
Paracetamol	Acetaminophen
Pataday	Olopatadine
Patanase	Olopatadine
Patanol	Olopatadine
Pathocil	Dicloxacillin Sodium
Paxil, Paxil CR	Paroxetine
Pediaflor	Fluoride
Pedia-Lax	Glycerin
Pediamycin	Erythromycin Preparations
Pediapred	Prednisolone
Pediazole	Erythromycin Ethylsuccinate and Acetylsulfisoxazole
PediOtic	Polymyxin B Sulfate, Neomycin Sulfate, Hydrocortisone
Pentam 300	Pentamidine Isethionate
Pentasa	Mesalamine

Trade Name(s)	Generic Name
Pepcid, Pepcid AC [OTC], Maximum Strength Pepcid AC [OTC], Pepcid Complete [OTC], Pepcid RPD	Famotidine
Pepto-Bismol	Bismuth Subsalicylate
Percocet	Oxycodone and Acetaminophen
Percodan	Oxycodone and Aspirin
Perforomist	Formoterol
Periactin (previously available as)	Cyproheptadine
Periostat	Doxycycline
Pexeva	Paroxetine
Pfizerpen	Penicillin G Preparations—Aqueous Potassium and Sodium
PGE <sub>1</sub> <sup>a</sup>	Alprostadil
Phazyme	Simethicone
Phenergan	Promethazine
Phenytek	Phenytoin
PhosLo	Calcium Acetate
Phoslyra	Calcium Acetate
Pilopine HS	Pilocarpine HCl
Pima	Potassium Iodide
Pin-Rid	Pyrantel Pamoate
Pin-X	Pyrantel Pamoate
Pipracil	Piperacillin
Pitressin	Vasopressin
Plaquenil	Hydroxychloroquine
Plasbumin	Albumin, Human
Polymox	Amoxicillin
Polysporin Ophthalmic	Bacitracin + Polymyxin B
Polysporin Topical	Bacitracin + Polymyxin B
Polytrim Ophthalmic Solution	Polymyxin B Sulfate and Trimethoprim Sulfate
Posture-D	Calcium Phosphate, Tribasic
Potassium Phosphate	Phosphorus Supplements
Pradaxa	Dabigatran etexilate mesylate
Precedex	Dexmedetomidine
Prelone	Prednisolone
Prevacid, Prevacid SoluTab	Lansoprazole
Prevalite	Cholestyramine
Prilosec, Prilosec OTC	Omeprazole
Primacor	Milrinone
Primaxin IV	Imipenem and Cilastatin
Principen	Ampicillin
Prinivil	Lisinopril
Privigen	Immune Globulin
ProAir HFA	Albuterol
Procardia, Procardia XL	Nifedipine
ProCentra	Dextroamphetamine Sulfate
Procrit	Epoetin Alfa
Proglycem	Diazoxide
Prograf	Tacrolimus
Pronestyl	Procainamide

Trade Name(s)	Generic Name
Pronto	Pyrethrins
Prostaglandin E <sub>1</sub>	Alprostadil
Prostigmin	Neostigmine
Prostin VR Pediatric	Alprostadil
Protonix	Pantoprazole
Protopam	Pralidoxime Chloride
Protopic	Tacrolimus
Protostat	Metronidazole
Proventil, Proventil HFA (aerosol inhaler)	Albuterol
Provera	Medroxyprogesterone
Prozac, Prozac Weekly	Fluoxetine Hydrochloride
Pseudo Carb Pediatric	Carbinoxamine + Pseudoephedrine
PTU <sup>a</sup>	Propylthiouracil
Pulmicort Respules, Pulmicort Flexhaler	Budesonide
Pulmozyme	Dornase Alfa/DNase
Pyrazinoic acid amide	Pyrazinamide
Pyridium	Phenazopyridine HCl
Pyrinyl	Pyrethrins
Qnasl	Beclomethasone Dipropionate
Quelicin, Quelicin-1000	Succinylcholine
Questran, Questran Light	Cholestyramine
Quinidex	Quinidine
Quixin	Levofloxacin
QVAR <sup>a</sup>	Beclomethasone Dipropionate
Raniclor	Cefaclor
Rapamune	Sirolimus
Rayos	Prednisone
Rebetol	Ribavirin
Reese's Pinworm	Pyrantel Pamoate
Regitine	Phentolamine Mesylate
Reglan	Metoclopramide
Regonal	Pyridostigmine Bromide
Renova	Tretinoin
Resectisol	Mannitol
Restasis	Cyclosporine, Cyclosporine Microemulsion, Cyclosporine Modified
Retin-A, Retin-A Micro	Tretinoin
Retrovir, AZT	Zidovudine
Revatio	Sildenafil
Reversol	Edrophonium Chloride
Revonto	Dantrolene
R-Gene 10	Arginine Chloride
Rhinaris	Sodium Chloride—Inhaled Preparations
Rhinocort Aqua Nasal Spray	Budesonide
Ribasphere	Ribavirin
RID	Pyrethrins
Rifadin	Rifampin
Rifamate	Isoniazid + Rifampin
Rifater	Pyrazinamide + Isoniazid + Rifampin
Rimactane	Rifampin

Trade Name(s)	Generic Name
Riomet	Metformin
Risperdal, Risperdal M-Tab, Risperdal Consta	Risperidone
Ritalin, Ritalin SR, Ritalin LA	Methylphenidate HCl
Robinul	Glycopyrrolate
Rocaltrol	Calcitriol
Rocephin	Ceftriaxone
Rogaine, Men's Rogaine Extra Strength	Minoxidil
Romazicon	Flumazenil
Rowasa, SfRowasa	Mesalamine
Roxanol	Morphine Sulfate
Roxicet	Oxycodone and Acetaminophen
Roxicodone	Oxycodone
Roxilox	Oxycodone and Acetaminophen
RuLox Plus	Aluminum Hydroxide with Magnesium Hydroxide
S-2 Inhalant	Epinephrine, Racemic
Sabril	Vigabatrin
Salagen	Pilocarpine HCl
Salicylazosulfapyridine	Sulfasalazine
Sal-Tropine	Atropine Sulfate
Sancuso	Granisetron
Sandimmune	Cyclosporine
Sandostatin, Sandostatin LAR Depot	Octreotide Acetate
Sani-Supp	Glycerin
Sarafem	Fluoxetine Hydrochloride
SAS <sup>a</sup>	Sulfasalazine
Saxenda	Liraglutide
Scopace	Scopolamine Hydrobromide
Selsun and others	Selenium Sulfide
Senna-Gen	Senna/Sennosides
Senokot	Senna/Sennosides
Septra	Sulfamethoxazole and Trimethoprim
Serevent Diskus	Salmeterol
Sildec	Carbinoxamine + Pseudoephedrine
Silvadene	Silver Sulfadiazine
Simply Saline	Sodium Chloride—Inhaled Preparations
Singulair	Montelukast
Slo-Niacin	Niacin (Vitamin B <sub>3</sub> )
Slow FE	Iron—Oral Preparations
Sodium Phosphate	Phosphorus Supplements
Solodyn	Minocycline
Solu-cortef	Hydrocortisone
Solu-Medrol	Methylprednisolone
Soluspan	Betamethasone
Sporanox	Itraconazole
SPS <sup>a</sup>	Sodium Polystyrene Sulfonate
SSD Cream, SSD AF Cream	Silver Sulfadiazine
SSKI <sup>a</sup>	Potassium Iodide
Stadol	Butorphanol
Stavzor	Valproic Acid
Stimate	Desmopressin Acetate

Trade Name(s)	Generic Name
Stomach Relief, Stomach Relief Max St, Stomach Relief Plus	Bismuth Subsalicylate
Strattera	Atomoxetine
Streptase	Streptokinase
Sublimaze	Fentanyl
Sudafed	Pseudoephedrine
Sulfatrim	Sulfamethoxazole and Trimethoprim
Sulfazine, Sulfazine EC	Sulfasalazine
Sunkist Vitamin C	Ascorbic Acid
Suprax	Cefixime
Surfak	Docusate
Surfaxin	Surfactant, Pulmonary/Lucinactant
Survanta	Surfactant, Pulmonary/Beractant
Symbicort	Budesonide and Formoterol
Symmetrel	Amantadine Hydrochloride
Synagis	Palivizumab
Synercid	Quinupristin and Dalfopristin
Synthroid	Levothyroxine T <sub>4</sub>
Tambocor	Flecainide Acetate
Tamiflu	Oseltamivir Phosphate
Tapazole	Methimazole
Tazicef	Ceftazidime
Tazidime	Ceftazidime
Tegretol, Tegretol-XR	Carbamazepine
Tempra	Acetaminophen
Tenex	Guanfacine
Tenormin	Atenolol
Tensilon	Edrophonium Chloride
Tetrahydrocannabinol	Dronabinol
THC <sup>a</sup>	Dronabinol
Theo-24	Theophylline
Theochron	Theophylline
Thera-Ear	Carbamide Peroxide
Thermazene	Silver Sulfadiazine
Thorazine	Chlorpromazine
ThyroSafe	Potassium Iodide
ThyroShield	Potassium Iodide
Tiazac	Diltiazem
Tigan	Trimethobenzamide HCl
Timentin	Ticarcillin and Clavulanate
Tinactin	Tolnaftate
Tirosint	Levothyroxine
Tisit	Pyrethrins
TMP-SMX <sup>a</sup>	Sulfamethoxazole and Trimethoprim
TOBI, TOBI Podhaler	Tobramycin
Tobrex	Tobramycin
Tofranil, Tofranil-PM	Imipramine
Topamax	Topiramate
Topiragen	Topiramate
Toprol-XL	Metoprolol
Totacillin	Ampicillin

Trade Name(s)	Generic Name
tPA <sup>a</sup>	Alteplase
Trandate	Labetalol
Transderm Scop	Scopolamine Hydrobromide
Trianex	Corticosteroid
Triaz	Benzoyl Peroxide
Triderm	Corticosteroid
Trileptal	Oxcarbazepine
Trilisate and others	Choline Magnesium Trisalicylate
TriLyte	Polyethylene Glycol—Electrolyte Solution
Trimethoprim-Sulfamethoxazole	Sulfamethoxazole and Trimethoprim
Trimox	Amoxicillin
Trokendi XR	Topiramate
Tums	Calcium Carbonate
Tylenol	Acetaminophen
Tylenol #1, #2, #3, #4	Codeine and Acetaminophen
Tylox	Oxycodone and Acetaminophen
Uceris	Budesonide
Unasyn	Ampicillin/Sulbactam
Unithroid, Unithroid Direct	Levothyroxine
Urecholine	Bethanechol Chloride
Uro-KP-Neutral	Phosphorus Supplements
Urolene Blue	Methylene Blue
Urso 250, Urso Forte	Ursodiol
Vagistat-3	Miconazole
Valcyte	Valganciclovir
Valium	Diazepam
Valtrex	Valacyclovir
Vancocin	Vancomycin
Vantin	Cefpodoxime Proxetil
VariZig	Varicella-Zoster Immune Globulin (Human)
Vasotec	Enalapril Maleate
Vasotec IV	Enalaprilat
Veetids	Penicillin V Potassium
Venofer	Iron—Injectable Preparations (iron sucrose)
Ventolin HFA	Albuterol
Veramyst	Fluticasone Propionate
Verelan, Verelan PM	Verapamil
Veripred	Prednisolone
Vermox	Mebendazole
Versed (previously available as)	Midazolam
VFEND	Voriconazole
Viagra	Sildenafil
Vibramycin	Doxycycline
Victoza	Liraglutide
Vimpat	Lacosamide
Viramune, Viramune XR	Nevirapine
Virazole	Ribavirin
Visicol	Sodium Phosphate
Visine LR	Oxymetazoline
Vistaril	Hydroxyzine

Trade Name(s)	Generic Name
Vistide	Cidofovir
Vitamin B <sub>1</sub>	Thiamine
Vitamin B <sub>2</sub>	Riboflavin
Vitamin B <sub>12</sub>	Cyanocobalamin/Vitamin B <sub>12</sub>
Vitamin B <sub>3</sub>	Niacin/Vitamin B <sub>3</sub>
Vitamin B <sub>6</sub>	Pyridoxine
Vitamin C	Ascorbic Acid
Vitrase	Hyaluronidase
Vitrasert	Ganciclovir
VoSpire ER	Albuterol
Vyvanse	Lisdexamfetamine
VZIG	Varicella-Zoster Immune Globulin (Human)
WinRho-SDF	Rh <sub>0</sub> (D) Immune Globulin Intravenous (Human)
Wycillin	Penicillin G Preparations—Procaine
Wymox	Amoxicillin
Xarelto, Xarelto Starter Pack	Rivaroxaban
Xolegel	Ketoconazole
Xopenex, Xopenex HFA	Levalbuterol
Xylocaine	Lidocaine
Zarontin	Ethosuximide
Zaroxolyn	Metolazone
Zegerid	Omeprazole
Zemuron	Rocuronium
Zenatane	Isotretinoin
Zenzedi	Dextroamphetamine Sulfate
Zerbaxa	Ceftolozane with Tazobactam
Zestril	Lisinopril
Zetonna	Ciclesonide
Zinacef	Cefuroxime
Zirgan	Ganciclovir
Zithromax, Zithromax TRI-PAK, Zithromax Z-PAK, Zmax	Azithromycin
Zoderm	Benzoyl Peroxide
Zofran	Ondansetron
Zolicef	Cefazolin
Zoloft	Sertraline HCl
Zonegran	Zonisamide
ZORprin	Aspirin
Zosyn	Piperacillin with Tazobactam
Zovirax	Acyclovir
Zyloprim	Allopurinol
Zyrtec, Children's Zyrtec	Cetirizine
Zyrtec-D 12 Hour	Cetirizine + Pseudoephedrine
Zyvox	Linezolid

<sup>a</sup>Common abbreviation or other name (not recommended for use when writing a prescription).

TABLE 30.1

## EXAMPLES OF INDUCERS AND INHIBITORS OF CYTOCHROME P450 SYSTEM

Isoenzyme	Substrates (Drugs Metabolized by Isoenzyme)	Inhibitors <sup>a</sup>	Inducers
CYP1A2	Caffeine, theophylline, estradiol, propranolol	Cimetidine, quinolones, fluvoxamine, ketoconazole, lidocaine	Carbamazepine, smoking, phenobarbital, rifampin
CYP2B6	Cyclophosphamide, efavirenz, propofol	Paroxetine, sertraline	Carbamazepine, (fos)phenytoin, phenobarbital, rifampin
CYP2C9/10	Warfarin, phenytoin, tolbutamide, fluoxetine, sulfamethoxazole, fosphenytoin	Amiodarone, fluconazole, ibuprofen, indomethacin, nicardipine	Carbamazepine, (fos)phenytoin, rifampin, phenobarbital
CYP2C19	Diazepam, PPIs, phenytoin, desogestrel, ifosfamide, phenobarbital, sertraline, voriconazole	Cimetidine fluvoxamine, fluconazole, isoniazid, PPIs, sertraline	Carbamazepine, (fos)phenytoin, rifampin
CYP2D6	Captopril, codeine, haloperidol, dextromethorphan, tricyclic antidepressants, hydrocodone, oxycodone, phenothiazines, metoprolol, propranolol, paroxetine, venlafaxine, risperidone, flecainide, sertraline, aripiprazole, fluoxetine, lidocaine, fosphenytoin, ritonavir	Chlorpromazine, cinacalcet, dexmedetomidine, cocaine, cimetidine, quinidine, ritonavir, fluoxetine, sertraline, amiodarone	None known
CYP2E1	Acetaminophen, alcohol, isoniazid, theophylline, isoflurane	Disulfiram	Alcohol
CYP3A4	Amlodipine, aripiprazole, budesonide, cocaine, clonazepam, diltiazem, efavirenz, erythromycin, estradiol, fentanyl, fluticasone, nifedipine, verapamil, cyclosporine, carbamazepine, cisapride, tacrolimus, midazolam, alfentanil, diazepam, ifosfamide, imatinib, itraconazole, ketoconazole, cyclophosphamide, PPIs, haloperidol, lidocaine, medroxyprogesterone, methadone, methylprednisolone, salmeterol, theophylline, quetiapine, ritonavir, indinavir, sildenafil, ivacaftor	Erythromycin, cimetidine, clarithromycin, isoniazid, ketoconazole, itraconazole, metronidazole, sertraline, ritonavir, indinavir, imatinib, nicardipine, propofol, quinidine	Rifampin, (fos)phenytoin, phenobarbital, carbamazepine, dexamethasone, lumacaftor

**NOTE:** The cytochrome P450 enzyme system is composed of different isoenzymes. Each isoenzyme metabolizes a unique group of drugs or substrates. When an inhibitor of a particular isoenzyme is introduced, the serum concentration of any drug or substrate metabolized by that particular isoenzyme will increase. When an inducer of a particular isoenzyme is introduced, the serum concentration of drugs or substrates metabolized by that particular isoenzyme will decrease.

PPI, Proton pump inhibitor.

<sup>a</sup>Only strong and some moderate inhibitors are listed here. Weak inhibitors also exist.

Data from Taketomo CK, Hodding JH, Kraus DM. *American Pharmaceutical Association Pediatric Dosage Handbook* 16th ed. Lexi-Comp; 2009; Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. *Clin Pharmacokinet*. 1999;36:425–438; Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. *Am Fam Physician*. 1998;57:107–116.

## REFERENCES

1. Daily Med: Current Medication Information. National Library of Medicine. National Institutes of Health. <https://dailymed.nlm.nih.gov/dailymed/index.cfm>
2. Drugs and Lactation Database (LactMed). United States National Library of Medicine, Toxicology Data Network. <https://www.ncbi.nlm.nih.gov/books/NBK501922/?report=reader>
3. Pickering LK, ed. *Red Book: 2015 Report of the Committee on Infectious Diseases*. 30th ed. American Academy of Pediatrics; 2015. <https://publications.aap.org/redbook>
4. AIDSinfo: Information on HIV/AIDS Treatment, Prevention, and Research. U.S. Department of Health and Human Services. <https://hivinfo.nih.gov/home-page>
5. Young TE, Mangum OB. Pediatrics and Neofax [electronic version]. Thomson Healthcare.
6. McEvoy GK, Snow EK, eds. *AHFS Drug Information*. Stat!Ref electronic version. American Society of Health-System Pharmacists. <https://www.ahfsdruginformation.com/>
7. Micromedex® Healthcare Series 2.0. electronic database. Thomson Healthcare USA. Updated periodically. <https://www.micromedexsolutions.com/micromedex2/librarian>
8. Takemoto CK, Hodding JH, Kraus DM. *Pediatric Dosage Handbook*, electronic intranet database. Lexi-Comp, Inc. Updated periodically. <https://www.crlonline.com/lco/action/home>
9. National Institutes of Health: National Heart, Lung and Blood Institute –Expert Panel. *Clinical practice guidelines: Guidelines for the Diagnosis and Management of Asthma*. <https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma>
10. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Disease Society and the Infectious Diseases Society of America. *Clin Infect Dis*. 2011;53(7):617–630.
11. Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics*. 2014;134(2):415–420.
12. National high blood pressure education program working group on high blood pressure in children and adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics*. 2004;114:555–576.
13. Flynn JT, Daniels SR. Pharmacologic treatment of hypertension in children and adolescents. *J Pediatr*. 2006;149:746–754.
14. Lande MB, Flynn JT. Treatment of hypertension in children and adolescents. *Pediatr Nephrol*. 2009;24:1939–1949.
15. Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). *Chest*. 2012;141(suppl 2):e737S–e801S.
16. Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 – Rationale and perspectives. *Thromb Res*. 2007;120:1–10.
17. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. *Am J Respir Crit Care Med*. 2000;161:1376–1395.
18. Food and Drug Administration Drug Safety Labeling Changes. <https://www.fda.gov/safety/medical-product-safety-information/drug-safety-related-labeling-changes>

19. Abrams SA, The Committee on Nutrition. Clinical report: calcium and vitamin D requirements of enterally fed preterm infants. *Pediatrics*. 2013;131:e1676–e1683.
20. Registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. U.S. National Institute of Health. <https://www.clinicaltrials.gov/>
21. New Pediatric Drug Labeling Database. U.S. Food and Drug Administration. <https://www.fda.gov/science-research/pediatrics/pediatric-labeling-changes>

## A

**ACETAMINOPHEN**

Tylenol, Tempra, Panadol, FeverAll, Anacin Asprin  
Free, Mapap, Paracetamol, Ofirmev, and many  
others

**Analgesic, antipyretic**



C 1 Yes Yes No

**Tabs [OTC]:** 325, 500 mg

**Chewable tabs [OTC]:** 80, 160 mg; some may contain phenylalanine

**Child suspension/syrup [OTC]:** 160 mg/5 mL; may contain sodium benzoate and propylene glycol

**Oral liquid [OTC]:** 160 mg/5 mL; may contain sodium benzoate and propylene glycol

**Elixir [OTC]:** 160 mg/5 mL; may contain sodium benzoate and propylene glycol

**Extended release tabs [OTC]:** 650 mg

**Capsules [OTC]:** 325, 500 mg

**Dispersible tabs (Tylenol Children's Meltaways) [OTC]:** 80, 160 mg; contain sucralose

**Suppositories (FeverAll and generics) [OTC]:** 80, 120, 325, 650 mg; contain polysorbate 80

**Injection:**

**Ofirmev and generics:** 10 mg/mL (100 mL); preservative free

**PO/PR (maximum daily doses include all routes of acetaminophen administration and DO NOT exceed 5 doses in 24 hours):**



**Term neonate:** 10–15 mg/kg/dose PO/PR Q4–6 hr; **max. dose:** 75 mg/kg/24 hr. Some advocate loading doses of 20–25 mg/kg/dose for PO dosing or 30 mg/kg/dose for PR dosing.

**Pediatric:** 10–15 mg/kg/dose PO/PR Q4–6 hr; **max. dose:** 75 mg/kg/24 hr or 4 g/24 hr. For rectal dosing, some may advocate a 40–45 mg/kg/dose loading dose.

**Dosing by weight (preferred) or age (PO/PR Q4–6 hr; DO NOT exceed 5 doses in 24 hours):**

Weight (lbs)	Weight (kg)	Age	Dosage (mg)
6–11	2.7–5	0–3 mo	40
12–17	5.1–7.7	4–11 mo	80
18–23	7.8–10.5	1–2 yr	120
24–35	10.6–15.9	2–3 yr	160
36–47	16–21.4	4–5 yr	240
48–59	21.5–26.8	6–8 yr	320 to 325
60–71	26.9–32.3	9–10 yr	325 to 400
72–95	32.4–43.2	11 yr	480 to 500

**Adult:** 325–650 mg/dose

**Max. dose:** 4 g/24 hr, 5 doses/24 hr

**IV (maximum daily doses include all routes of acetaminophen administration):**

**Neonate (≥32 weeks' gestation) and infant:**

≤28 days old: 12.5 mg/kg/dose Q6 hr IV up to a **maximum** of 50 mg/kg/24 hr

≥29 days old to <2 yr: 15 mg/kg/dose Q6 hr IV up to a **maximum** of 60 mg/kg/24 hr

**Child (≥2–12 yr) and adolescent (≥13 yr)/adult:** 15 mg/kg/dose Q6 hr, **OR** 12.5 mg/kg/dose Q4 hr IV up to the following **maximum** dose by patient weight:

<50 kg: 75 mg/kg/24 hr up to 3750 mg/24 hr with a **maximum** single dose of 15 mg/kg/dose up to 750 mg

≥50 kg: 75 mg/kg/24 hr up to 4000 mg/24 hr with a **maximum** single dose of 15 mg/kg/dose up to 1000 mg

*Continued*

ACETAMINOPHEN *continued*

**Adolescent (≥13 yr) and adult (≥50 kg):** 1000 mg Q6 hr, **OR** 650 mg Q4 hr up to a **maximum** of 4000 mg/24 hr with a **maximum** single dose of 1000 mg/dose

Does not possess antiinflammatory activity. Safety and efficacy for acute pain and fever in children ≥2 years old are supported by controlled clinical trials. **Use with caution** in patients with known G6PD deficiency.



**T<sub>1/2</sub>:** 1–3 hr, 2–5 hr in neonates; metabolized in the liver; see [Chapter 3](#) and acetylcysteine for management of drug overdose.

Some preparations contain alcohol (7%–10%) and/or phenylalanine; all suspensions should be shaken before use.

May be used for the treatment of patent ductus arteriosus when standard NSAID is contraindicated or has failed. Most commonly reported dosage is 15 mg/kg dose Q6 hr IV/PO for 3 days (may be given up to 7 days or with a repeated 3-day course).

May decrease the activity of lamotrigine and increase the activity/toxicity of busulfan, warfarin, and zidovudine. Barbiturates, phenytoin, rifampin, and anticholinergic agents (e.g., scopolamine) may decrease the effect of acetaminophen. Increased risk for hepatotoxicity may occur with barbiturates, carbamazepine, phenytoin, carmustine (with high acetaminophen doses), chronic alcohol use, and inducers of CYP 450 2E1 (e.g., isoniazid). **Adjust dose in renal failure (see Chapter 31).**

**FOR IV USE:** Administer dose undiluted over 15 min. Most common side effects with IV use include nausea, vomiting, constipation, pruritus, agitation, and atelectasis in children; and nausea, vomiting, headache, and insomnia in adults. Rare risk of serious skin reactions (e.g., SJS, TEN) has been reported.

**ACETAZOLAMIDE**

Various generics; previously available as Diamox  
**Carbonic anhydrase inhibitor, diuretic**



C



1



Yes



Yes



No

**Tabs:** 125, 250 mg

**Oral suspension:** 25 mg/mL 

**Capsules (extended release):** 500 mg

**Injection (sodium):** 500 mg

Contains 2.05 mEq Na/500 mg drug

**Diuretic (PO, IV)**

**Child:** 5 mg/kg/dose once daily or every other day

**Adult:** 250–375 mg/dose once daily or every other day

**Glaucoma**

**Child:**

**PO:** 8–30 mg/kg/24 hr ÷ Q6–8 hr; **max. dose:** 1000 mg/24 hr

**IM/IV:** 20–40 mg/kg/24 hr ÷ Q6 hr; **max. dose:** 1000 mg/24 hr

**Adult:**

**PO (Simple chronic; open angle):** 1000 mg/24 hr ÷ Q6 hr

**IV (Acute secondary; closed angle):** For rapid decrease in intraocular pressure, administer 500 mg/dose IV.

**Seizures (extended release product not recommended):**

**Child and adult:** 8–30 mg/kg/24 hr ÷ Q6–12 hr PO; **max. dose:** 1 g/24 hr

**Urine alkalization:**

**Adult:** 5 mg/kg/dose PO repeated BID-TID over 24 hr



ACETAZOLAMIDE *continued*

**Management of hydrocephalus (see remarks):** Start with 20 mg/kg/24 hr ÷ Q8 hr PO/IV; may increase to 100 mg/kg/24 hr up to a **max. dose** of 2 g/24 hr.

**Pseudotumor cerebri (PO; see remarks):**

**Child:** Start with 25 mg/kg/24 hr ÷ once daily-QID; increase by 25 mg/kg/24 hr until clinical response or as tolerated up to a **maximum** of 100 mg/kg/24 hr.

**Adolescent:** Start with 1 g/24 hr ÷ once daily-QID; increase by 250 mg/24 hr until clinical response or as tolerated up to a **maximum** of 4 g/24 hr.

**Contraindicated** in hepatic failure, severe renal failure (GFR <10 mL/min), and hypersensitivity to sulfonamides. 

**T<sub>1/2</sub>:** 2–6 hr; **do not use** sustained release capsules in seizures; **IM** injection may be painful; bicarbonate replacement therapy may be required during long-term use (see [Citrate Mixtures](#) or [Sodium Bicarbonate](#)). For use in pseudotumor cerebri, doses of 60 mg/kg/24 hr may be required. Possible side effects (more likely with long-term therapy) include GI irritation, paresthesias, sedation, hypokalemia, acidosis, reduced urate secretion, aplastic anemia, polyuria, and development of renal calculi.

May increase toxicity of carbamazepine and cyclosporine. Aspirin may increase toxicity of acetazolamide. May decrease the effects of salicylates, lithium, and phenobarbital. False-positive urinary protein may occur with several assays. **Adjust dose in renal failure (see Chapter 31).**

**ACETYLCYSTEINE**

Various generics, Acetadote; previously available as Mucomyst

**Mucolytic, antidote for acetaminophen toxicity**



B



?



No



Yes



No

**Solution for inhalation or oral use:** 100 mg/mL (10%) (4, 10, 30 mL) or 200 mg/mL (20%) (4, 10, 30 mL); may contain EDTA

**Injectable (Acetadote and generics):** 200 mg/mL (20%) (30 mL); may contain EDTA 0.5 mg/mL. Preservative-free versions of the inhalation and oral solutions and injectable forms exist.

**Acetaminophen poisoning (see Chapter 3 for additional information):** 

**PO:** 140 mg/kg (**max.** 15 g/dose) × 1, followed by 70 mg/kg/dose (**max.** 7.5 g/dose) Q4 hr for a total of 17 doses. Repeat dose if vomiting occurs with 1 hr of administration.

**IV (see remarks):** 150 mg/kg (**max.** 15 g/dose) × 1 diluted in D<sub>5</sub>W or D<sub>5</sub>W 1/2 NS administered over 60 min, followed by 50 mg/kg (**max.** 5 g/dose) diluted in D<sub>5</sub>W administered over 4 hr, then 100 mg/kg (**max.** 10 g/dose) diluted in D<sub>5</sub>W administered over 16 hr. Recommended weight-based drug dilution volumes:

Weight (kg)	Volume of D <sub>5</sub> W or D <sub>5</sub> W 1/2 NS for 150 mg/kg Loading Dose Administered Over 60 min	Volume of D <sub>5</sub> W for 50 mg/kg Second Dose Administered Over 4 hr	Volume of D <sub>5</sub> W for 100 mg/kg Third Dose Administered Over 16 hr
≤20	3 mL/kg	7 mL/kg	14 mL/kg
>20 to ≤40	100 mL	250 mL	500 mL
>40	200 mL	500 mL	1000 mL

**Nebulizer:**

**Infant:** 1–2 mL of 20% solution (diluted with equal volume of H<sub>2</sub>O, or sterile saline to equal 10%), or 2–4 mL of 10% solution; administer TID-QID

*Continued*

ACETYLCYSTEINE *continued*

**Child:** 3–5 mL of 20% solution (diluted with equal volume of H<sub>2</sub>O, or sterile saline to equal 10%), or 6–10 mL of 10% solution; administer TID-QID

**Adolescent:** 5–10 mL of 10% or 20% solution; administer TID-QID

**Distal intestinal obstruction syndrome in cystic fibrosis:**

**Adolescent and adult:** 10 mL of 20% solution (diluted in a sweet drink) PO QID with 100 mL of 10% solution PR as an enema once daily-QID

**Use with caution** in asthma. For nebulized use, give inhaled bronchodilator 10–15 min before use and follow with postural drainage and/or suctioning after acetylcysteine administration. Prior hydration is essential for distal intestinal obstruction syndrome treatment.



May induce bronchospasm, stomatitis, drowsiness, rhinorrhea, nausea, vomiting, and hemoptysis.

Serious hypersensitivity reactions have been reported with IV use in children. Be aware of potential fluid overload resulting in hyponatremia with IV volume dilution; reduce diluent volume if needed.

For IV use, elimination T<sub>1/2</sub> is longer in newborns (11 hr) than in adults (5.6 hr). T<sub>1/2</sub> is increased by 80% in patients with severe liver damage (Child-Pugh score of 7–13) and biliary cirrhosis (Child-Pugh score of 5–7). A 2-bag IV administration method for acetaminophen poisoning has been associated with less cutaneous and systemic nonallergic anaphylactic reactions with similar efficacy (≥12 yr: 200 mg/kg infused IV over 4 hr followed by 100 mg/kg infused over 16 hr; **max. total dose:** 30 g).

For oral administration, chilling the solution and mixing with carbonated beverages, orange juice, or sweet drinks may enhance palatability.

**ACTH**

See [Corticotropin](#).

**ACYCLOVIR**

Zovirax, Avaclyr, and generics

**Antiviral**



B



2



Yes



No



No

**Capsules:** 200 mg

**Tabs:** 400, 800 mg

**Oral suspension:** 200 mg/5 mL (473 mL); may contain parabens

**Ointment:** 5% (5, 15, 30 g)

**Cream:** 5% (5 g); may contain propylene glycol

**Ophthalmic ointment (Avaclyr):** 3% (3.5 g)

**Injection in solution (with sodium):** 50 mg/mL (10, 20 mL)

Contains 4.2 mEq Na/1 g drug

**IMMUNOCOMPETENT:**

**Neonatal (HSV and HSV encephalitis; birth–3 mo):**

**Initial IV therapy (duration of therapy: 14 days for cutaneous/mucous membrane infection or 21 days for CNS/disseminated infection):**

**<34 wk postmenstrual age:** 40 mg/kg/24 hr ÷ Q12 hr IV

**≥34 wk postmenstrual age:** 60 mg/kg/24 hr ÷ Q8 hr IV

**Oral therapy for HSV suppression and neurodevelopment following treatment with IV acyclovir for**

**14–21 days:** 300 mg/m<sup>2</sup>/dose Q8 hr PO × 6 mo

**HSV encephalitis (duration of therapy: 14–21 days):**

**Birth–3 mo:** Use aforementioned IV dosage.

**3 mo–12 yr:** 60 mg/kg/24 hr ÷ Q8 hr IV

**≥12 yr:** 30 mg/kg/24 hr ÷ Q8 hr IV



ACYCLOVIR *continued***Mucocutaneous HSV (including genital, ≥12 yr):****Initial infection:**

**IV:** 15 mg/kg/24 hr or 750 mg/m<sup>2</sup>/24 hr ÷ Q8 hr × 5–7 days

**PO:** 1000–1200 mg/24 hr ÷ 3–5 doses per 24 hr × 7–10 days. For pediatric dosing, use 40–80 mg/kg/24 hr ÷ Q6–8 hr × 5–10 days (**max. pediatric dose:** 1000 mg/24 hr)

**Recurrence (≥12 yr):**

**PO:** 1000 mg/24 hr ÷ 5 doses per 24 hr × 5 days, or 1600 mg/24 hr ÷ Q12 hr × 5 days, or 2400 mg/24 hr ÷ Q8 hr × 2 days

**Chronic suppressive therapy (≥12 yr):**

**PO:** 800 mg/24 hr ÷ Q12 hr for up to 1 yr

**Zoster:**

**IV (all ages):** 30 mg/kg/24 hr or 1500 mg/m<sup>2</sup>/24 hr ÷ Q8 hr × 7–10 days

**PO (≥12 yr):** 4000 mg/24 hr ÷ 5×/24 hr × 5–7 days

**Varicella:**

**IV (≥2 yr):** 30 mg/kg/24 hr or 1500 mg/m<sup>2</sup>/24 hr ÷ Q8 hr × 7–10 days

**PO (≥2 yr):** 80 mg/kg/24 hr ÷ QID × 5 days (begin treatment at earliest signs/symptoms); **max. dose:** 3200 mg/24 hr

**Max. dose** of oral acyclovir in children = 80 mg/kg/24 hr

**IMMUNOCOMPROMISED:****HSV:**

**IV (all ages):** 750–1500 mg/m<sup>2</sup>/24 hr ÷ Q8 hr × 7–14 days

**PO (≥2 yr):** 1000 mg/24 hr ÷ 3–5 times/24 hr × 7–14 days; **max. dose** for child: 80 mg/kg/24 hr

**HSV prophylaxis:**

**IV (all ages):** 750 mg/m<sup>2</sup>/24 hr ÷ Q8 hr during risk period

**PO (≥2 yr):** 600–1000 mg/24 hr ÷ 3–5 times/24 hr during risk period; **max. dose** for child: 80 mg/kg/24 hr

**Varicella or zoster:**

**IV (all ages):** 1500 mg/m<sup>2</sup>/24 hr ÷ Q8 hr × 7–10 days

**PO (consider using valacyclovir or famciclovir for better absorption):**

**Infant and child:** 20 mg/kg/dose (**max.** 800 mg) Q6 hr × 7–10 days

**Adolescent and adult:** 20 mg/kg/dose (**max.** 800 mg) 5 times daily × 7–10 days

**Max. dose** of oral acyclovir in children = 80 mg/kg/24 hr

**TOPICAL:****Cream (see remarks):**

**Herpes labialis (≥12 and adult):** Apply to affected areas 5 times a day × 4 days.

**Ointment:**

**Immunocompromised genital or mucocutaneous HSV:** Apply 1/2-inch ribbon of 5% ointment for 4-inch square surface area 6 times a day × 7 days.

**OPHTHALMIC:**

**Herpes simplex keratitis (≥2 yr and adolescent):** Apply 1 cm (1/2-inch) ribbon onto the lower eyelid of affected eye(s) 5 times a day while awake (~Q3 hr) until corneal ulcer heals, then reduce dosage to TID for 7 days.

See most recent edition of the AAP Red Book for further details. Use with **caution** in patients with preexisting neurologic or **renal impairment (adjust dose; see Chapter 31)** or dehydration. Adequate hydration and slow (1 hr) IV administration are essential to prevent crystallization in renal tubules. **Do not use** topical product on the eye or for the prevention of recurrent HSV infections. Oral absorption is unpredictable (15%–30%); consider using valacyclovir or famciclovir for better absorption. Use ideal body weight for obese patients when calculating dosages. Resistant strains of HSV and VZV have been reported in immunocompromised patients (e.g., advanced HIV infection).



*Continued*

ACYCLOVIR *continued*

Inflammation or phlebitis at the injection site and transient elevations of sCr and BUN are the most frequent IV use side effects. Can cause renal impairment and has been associated with headache, vertigo, insomnia, encephalopathy, GI tract irritation, elevated liver function tests, rash, urticaria, arthralgia, fever, and adverse hematologic effects. Probenecid decreases acyclovir renal clearance. Acyclovir may increase the concentration of tenofovir, and meperidine and its metabolite (normeperidine).

Topical cream acyclovir 5% in combination with hydrocortisone 1% (Xerese) is indicated for herpes labialis ( $\geq 6$  yr and adults) at a dosage of 5 applications per day for 5 days. Use a finger cot or rubber glove when applying topical cream or ointment.

**Ophthalmic ointment:** Patient should close their eyes for 1–2 min after each application and wipe away any excess ointment. Most common side effects include stinging, punctate keratitis, and follicular conjunctivitis. Blepharitis and hypersensitivity reactions have been reported. Do not use contact lenses during therapy.

**ADAPALENE ± BENZOYL PEROXIDE**

Differin and generics

In combination with benzoyl peroxide: Epiduo, Epiduo Forte

**Synthetic retinoic acid derivative; topical acne product**



C

?

No

No

No

**Topical cream:** 0.1% (45 g)

**Topical gel:** 0.1% [OTC] (15, 45 g), 0.3% (45 g); some preparations may contain parabens and propylene glycol

**Topical lotion:** 0.1% (59 mL); some preparations may contain parabens and propylene glycol

**Topical solution as a swab:** 0.1% (1.2 g per swab; 14 swabs per box)

**In combination with benzoyl peroxide:**

**Topical gel:**

**Epiduo and generics:** 0.1% adapalene + 2.5% benzoyl peroxide (45 g)

**Epiduo Forte:** 0.3% adapalene + 2.5% benzoyl peroxide (45, 60 g)

**Topical gel as a swab:** 0.1% adapalene + 2.5% benzoyl peroxide (1.2 g per swab; 14 swabs per box)

**Adapalene ( $\geq 12$  yr and adult; see remarks):** Apply a thin film of cream, gel, or lotion to affected areas of cleansed and dried skin QHS. Limited data in children 7 to  $\leq 12$  yr



**Adapalene and benzoyl peroxide (see remarks):** Apply a thin film to affected areas of cleansed and dried skin once daily.

**Epiduo:** Indicated for children  $\geq 9$  yr and adults with limited data in children 7 to  $< 9$  yr

**Epiduo Forte:** Indicated for children  $\geq 12$  yr and adults

**Avoid** contact with eyes, mucous membranes, abraded skin, and open wounds; excessive sun exposure; and use of other irritating topical products. A mild, transitory warm or stinging sensation of the skin may occur during the first 4 wk of use. Clean and dry the skin before each use.



**ADAPALENE:** Onset of therapeutic benefits seen in 8–12 wk. Common side effects include dry skin, erythema, and scaly skin. When compared with tretinoin in clinical trials for acne vulgaris, adapalene was as effective and had a more rapid onset of clinical effects with less skin irritation.

**ADAPALENE + BENZOYL PEROXIDE: Contraindicated** in patients with a history of benzoyl peroxide hypersensitivity reactions. **Avoid** or minimize exposure to artificial (e.g., tanning beds) or natural light to prevent photosensitivity reactions; sunscreen products and protective apparel use are recommended. Onset of therapeutic benefits seen in 4–8 wk. Side effects reported in placebo-controlled studies include dry skin, erythema, skin irritation, and contact dermatitis. When

ADAPALENE ± BENZOYL PEROXIDE *continued*

compared with isotretinoin in a clinical trial for nodulocystic acne, adapalene + benzoyl peroxide plus doxycycline was not inferior to isotretinoin and was less effective in reducing the number of total lesions (nodules, papules/pustules, and comedones).

**ADDERALL**

See [Dextroamphetamine ± Amphetamine](#).

**ADENOSINE**

Generics; previously available as Adenocard

**Antiarrhythmic**



C



?



No



No



No

**Injection:** 3 mg/mL (2, 4 mL); preservative free

**Supraventricular tachycardia (follow each dose with NS flush; see remarks):**

**Neonate:** 0.05–0.1 mg/kg by rapid IV push over 1–2 sec; may increase dose by 0.05–0.1 mg/kg increments every 2 min to a **max. single dose** of 0.3 mg/kg or until termination of SVT

**Child:** 0.1 mg/kg (**initial max. dose:** 6 mg) by rapid IV/IO push over 1–2 sec; may repeat in 2 min at 0.2 mg/kg IV/IO, then 0.3 mg/kg IV/IO after 2 min (**all subsequent max. single doses:** 12 mg), or until termination of SVT

**Adolescent and adult ≥50 kg:** 6 mg rapid IV push over 1–2 sec; if no response after 1–2 min, give 12 mg rapid IV push. May repeat a second 12 mg dose after 1–2 min if required. **Max. single dose:** 12 mg



**Contraindicated** in 2nd and 3rd degree AV block or sick-sinus syndrome unless pacemaker placed. **Use with caution** in combination with digoxin (enhanced depressant effects on SA and AV nodes). If necessary, doses may be administered IO.  $T_{1/2}$ : <10 sec.



May precipitate bronchoconstriction, especially in asthmatics. Side effects include transient asystole, facial flushing, headache, shortness of breath, dyspnea, nausea, chest pain, and lightheadedness. Carbamazepine and dipyridamole may increase the effects/toxicity of adenosine. Methylxanthines (e.g., caffeine and theophylline) may decrease the effects of adenosine.

**ALBUMIN, HUMAN**

Albuked, Albumin-ZLB, Albutein, Kedbumin, Plasbumin, and many others

**Blood product derivative, plasma volume expander**



C



?



No



No



No

**Injection:** 5% (50 mg/mL) (50, 100, 250, 500 mL); 25% (250 mg/mL) (20, 50, 100 mL); both concentrations contain 130–160 mEq Na/L

**Hypoalbuminemia:**

**Child:** 0.5–1 g/kg/dose (**max. dose:** 25 g/dose) IV over 30–120 min; repeat Q1–2 days PRN

**Adult:** 25 g/dose IV over 30–120 min; repeat Q1–2 days PRN

**Max. dose:** 2 g/kg/24 hr

**Hypovolemia:**

**Child:** 0.5–1 g/kg/dose IV rapid infusion; after 15–30 min, may repeat PRN



*Continued*

ALBUMIN, HUMAN *continued*

**Adult:** 12.5–25 g/dose IV rapid infusion; after 15–30 min, may repeat PRN

**Contraindicated** in cases of CHF or severe anemia; rapid infusion may cause fluid overload; hypersensitivity reactions may occur; may cause rapid increase in serum sodium levels. Recommended maximum infusion rates:



Product Concentration	Patients With Normal Plasma	
	Volume	Patients With Hypoproteinemia
5%	2–4 mL/min	5–10 mL/min
25%	1 mL/min	2–3 mL/min

**Caution:** 25% concentration is considered **contraindicated** in preterm infants due to risk of IVH. Use product-specific recommended in-line filter size. Both 5% and 25% products are isotonic but differ in oncotic effects. Dilutions of the 25% product should be made with D<sub>5</sub>W or NS; **avoid sterile water as a diluent.**

**ALBUTEROL**

ProAir HFA, Proventil HFA, Ventolin HFA (aerosol inhaler); ProAir RespiClick, ProAir Digihaler (breath activated aerosol powder inhaler); AccuNeb (prediluted nebulized solution); and many generics

***β<sub>2</sub> adrenergic agonist***



C



1



No



No



No

**Tabs:** 2, 4 mg

**Oral solution:** 2 mg/5 mL (473 mL)

**Aerosol inhaler (HFA):** 90 mCg/actuation

**ProAir HFA:** (200 actuations/inhaler) (8.5 g)

**Proventil HFA:** (200 actuations/inhaler) (6.7 g)

**Ventolin HFA:** (60 actuations/inhaler) (8 g), (200 actuations/inhaler) (18 g)

**Generic:** (6.7, 8.5, 18 g)

**Breath-activated aerosol powder inhaler:**

**ProAir RespiClick and ProAir Digihaler:** 90 mCg/actuation (200 actuations/inhaler) (0.65 g); contains milk proteins and small amounts of lactose. ProAir Digihaler contains an electronic event monitor that detects, records, and stores data on inhaler use events, including peak inspiratory flow rate.

**Nebulization solution (dilution required):** 0.5% (5 mg/mL) (0.5, 20 mL); some preparations may be preservative free (see remarks)

**Prediluted nebulized solution:** 0.63 mg in 3 mL NS, 1.25 mg in 3 mL NS, and 2.5 mg in 3 mL NS (0.083%); some preparations may be preservative free (see remarks)

**Inhalations (nonacute use; see remarks):**

**Aerosol (HFA):** 2 puffs (90 mCg/puff) Q4–6 hr PRN

**Breath-activated aerosol (see remarks):**

**>4 yr:** 2 inhalations (90 mCg/inhalation) Q4–6 hr PRN

**Nebulization:**

**<1 yr:** 0.05–0.15 mg/kg/dose Q4–6 hr

**1–5 yr:** 1.25–2.5 mg/dose Q4–6 hr

**5–12 yr:** 2.5 mg/dose Q4–6 hr

**>12 yr:** 2.5–5 mg/dose Q4–8 hr

**For use in acute exacerbations, more aggressive dosing may be used.**



ALBUTEROL *continued***Exercise-induced bronchospasm (administered 15–30 min before exercise):****Aerosol (HFA):** 2 puffs (90 mCg/puff)**Breath-activated aerosol (see remarks):** 2 inhalations (90 mCg/inhalation)**Oral (highly discouraged—see remarks):****2–6 yr:** 0.3 mg/kg/24 hr PO ÷ TID; **max. dose:** 12 mg/24 hr**6–12 yr:** 6 mg/24 hr PO ÷ TID; **max. dose:** 24 mg/24 hr**>12 yr and adult:** 2–4 mg/dose PO TID-QID; **max. dose:** 32 mg/24 hr

Inhaled doses may be given more frequently than indicated. In such cases, consider cardiac monitoring and monitoring of serum potassium (hypokalemia). Systemic effects are dose related. Verify the concentration of the nebulization solution used. Continuous nebulization treatment with an albuterol product containing the benzalkonium chloride preservative has been reported to have a longer duration of treatment and need for additional respiratory support when compared to a preservative-free albuterol product.



Safety and efficacy for the treatment of symptoms or bronchospasms associated with obstructive airway disease have not been demonstrated for children <4 yr of age (either dose studied was not optimal in this age or drug is not effective in this age group).

Use of oral dosage form is discouraged due to increased side effects and decreased efficacy compared with inhaled formulations.

Possible side effects include tachycardia, palpitations, tremor, insomnia, nervousness, nausea, and headache.

The use of tube spacers or chambers may enhance efficacy of the HFA metered dose inhalers and have been proven to be just as effective and sometimes safer than nebulizers. **Do not** use a spacer device with any of the breath-activated inhaler dosage forms. Breath-activated dosage forms require patients to generate a minimum inspiratory flow rate of  $\geq 30$  L/min for proper dose activation. **Do not** wash or place any part of the ProAir RespiClick or ProAir Digihaler inhaler in water.

**ALLOPURINOL**

Zyloprim, Aloprim, and generics

**Uric acid lowering agent, xanthine oxidase inhibitor**

C



3



Yes



Yes



Yes

**Tabs:** 100, 300 mg**Oral suspension:** 20 mg/mL **Injection (Aloprim and generics):** 500 mg

Contains ~1.45 mEq Na/500 mg drug

For use in tumor lysis syndrome, see [Chapter 22](#) for additional information. See remarks for genomic considerations.

**Child:****Oral:** 10 mg/kg/24 hr PO ÷ BID-QID; **max. dose:** 800 mg/24 hr**Injectable:** 200 mg/m<sup>2</sup>/24 hr IV ÷ Q 6–12 hr; **max. dose:** 600 mg/24 hr**Adult:****Oral:** 200–800 mg/24 hr PO ÷ BID-TID**Injectable:** 200–400 mg/m<sup>2</sup>/24 hr IV ÷ Q 6–12 hr; **max. dose:** 600 mg/24 hr

Discontinue use at the first appearance of skin rash or other signs of an allergic reaction.

**Avoid** use in individuals with HLA-B\*58:01 allele as they are at significant risk for developing severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome and TEN).



Side effects include rash, neuritis, hepatotoxicity, renal function impairment, GI disturbance, bone marrow suppression, and drowsiness.

*Continued*

ALLOPURINOL *continued*

**Adjust dose in renal insufficiency (see Chapter 31).** Must maintain adequate urine output and alkaline urine.

**Drug interactions:** Increases serum theophylline level; may increase the incidence of rash with ampicillin and amoxicillin; increased risk of toxicity with azathioprine, didanosine, and mercaptopurine; and increased risk of hypersensitivity reactions with ACE inhibitors and thiazide diuretics. Use with didanosine is **contraindicated** due to increased risk for didanosine toxicity. Rhabdomyolysis has been reported with clarithromycin use.

IV dosage form is very alkaline and must be **diluted to a minimum concentration** of 6 mg/mL and infused over 30 min.

The manufacturer advises not to breastfeed during treatment with allopurinol for 1 week after the last dose as limited data indicate a maternal dose of 300 mg daily can provide near-therapeutic dose and plasma levels in an exclusively breastfed infant.

**ALMOTRIPTAN MALATE**

Generics; previously available as Axert

**Antimigraine agent, selective serotonin agonist**



C



3



Yes



Yes



No

**Tabs:** 6.25, 12.5 mg

**Treatment of acute migraines with or without aura:**

**Oral (safety of an average of >4 headaches in a 30-day period has not been established; see remarks):**

**Child ≥12 and adult:** Start with 6.25–12.5 mg PO × 1. If needed in 2 hr, a second dose may be administered. **Max. daily dose:** 2 doses/24 hr and 25 mg/24 hr

**Contraindicated** in ischemic/vasospastic coronary artery disease, significant underlying cardiovascular disease, cerebrovascular syndromes, peripheral vascular disease, uncontrolled hypertension, or hemiplegic/basilar migraine. **Do not** administer with any ergotamine-containing medication or ergot-type medication, any other 5-HT<sub>1</sub> agonist (e.g., triptans), methylene blue, or with/within 2 wk of discontinuing an MAO inhibitor or linezolid.

FDA-labeled indication for adolescents is acute migraine treatment in patients with a history of migraine lasting ≥4 hr when left untreated. Efficacy for the treatment of migraine-associated symptoms of nausea, photophobia, and phonophobia was not established for adolescents.

Most common side effects include dizziness, somnolence, headache, paresthesia, nausea, and vomiting. Reported serious adverse effects include coronary artery spasm, ischemia (myocardial, gastrointestinal, peripheral vascular), cerebral/subarachnoid hemorrhage, cerebrovascular accident/disease, and vision loss.

Use with **caution** in renal impairment (CrCl ≤30 mL/min) or hepatic impairment; use initial dose of 6.25 mg dose with a **max. daily dose** of 12.5 mg/24 hr.

Almotriptan is a minor substrate for CYP 450 2D6 and 3A4. Use lower initial single dose of 6.25 mg with **maximum daily dose** of 12.5 mg if receiving a potent CYP 450 3A4 inhibitor (e.g., itraconazole, ritonavir). **Do not use** almotriptan in the presence of renal or hepatic impairment and receiving a potent CYP 3A4 inhibitor.

Doses may be administered with or without food.

**ALPROSTADIL**

Prostin VR Pediatric, and generics, prostaglandin E<sub>1</sub>, PGE<sub>1</sub>

**Prostaglandin E<sub>1</sub>, vasodilator**



?



?



No



No



No

ALPROSTADIL *continued*

**Injection:** 500 mCg/mL (1 mL); contains dehydrated alcohol

**Neonate:**

**Initial:** 0.05–0.1 mCg/kg/min. Advance to 0.2 mCg/kg/min if necessary.

**Maintenance:** When increase in PaO<sub>2</sub> is noted, decrease immediately to lowest effective dose. Usual dosage range: 0.01–0.4 mCg/kg/min; doses >0.4 mCg/kg/min not likely to produce additional benefit.

**To prepare infusion:** See p. iii.

For palliation only. Continuous vital sign monitoring essential. May cause apnea (10%–12%; especially in those weighing <2 kg at birth), fever, seizures, flushing, bradycardia, hypotension, diarrhea, gastric outlet obstruction, and reversible cortical proliferation of long bones (with prolonged use). May decrease platelet aggregation.

**ALTEPLASE**

Activase, Cathflo Activase, tPA

**Thrombolytic agent, tissue plasminogen activator**



C



2



Yes



Yes



No

**Injection:**

**Cathflo Activase:** 2 mg

**Activase:** 50 mg (29 million unit), 100 mg (58 million unit)

**All products contain:** L-arginine and polysorbate 80

**Occluded IV catheter:**

**Aspiration method:** Use 1 mg/1 mL concentration as follows:

**Central venous line (dosage per lumen, treating one lumen at a time):**

**<30 kg:** Instill a volume equal to 110% of internal lumen volume of the catheter **NOT exceeding** 2 mg.

**≥30 kg:** 2 mg each lumen

**Subcutaneous port:** Instill a volume equal to 110% of internal lumen and line volume of the port **NOT exceeding** 2 mg.

Instill into catheter over 1–2 min and leave in place for 2 hr before attempting blood withdrawal.

After 2 hr, attempts to withdraw blood may be made every 2 hr for 3 attempts. Dose may be repeated once in 24 hr using a longer catheter dwell time of 3–4 hr. After 3–4 hr (repeat dose), attempts to withdraw blood may be made every 2 hr for 3 attempts. **DO NOT** infuse into patient.

**Systemic thrombolytic therapy (limited data, use in consultation with a hematologist; see remarks):**

**Low-dose initial infusion:**

**<90 days old:** 0.06 mg/kg/hr; **max. dose:** 2 mg/hr

**≥90 days old–21 yr:** 0.03 mg/kg/hr; **max. dose:** 2 mg/hr

**High-dose initial infusion:** 0.1–0.5 mg/kg/hr; **max. dose:** 25 mg/hr

Dosage regimens ranging from lower dosages (0.01 mg/kg/hr) to higher dosages (0.1–0.6 mg/kg/hr) have been reported (*Chest* 2008;133:887–968S). The length of continuous infusion is variable as patients may respond to longer or shorter courses of therapy.

Current use in the pediatric population is limited. May cause bleeding, rash, angioedema, and increased prothrombin time. Rare fatal hypersensitivity reaction has been reported.

**THROMBOLYTIC USE:** History of stroke, transient ischemic attacks, other neurologic disease, and hypertension are **contraindications for adults** but considered **relative contraindications for children**. Monitor fibrinogen, thrombin clotting time, PT, and aPTT when used as a thrombolytic. For systemic thrombosis therapy, efficacy has been reported at 40%–97% with the risk for bleeding at

*Continued*

ALTEPLASE *continued*


3%–27%. Poor efficacy in VTE in children has been recently reported. **Use with caution** in severe hepatic or renal dysfunction (systemic use only).

Newborns have reduced plasminogen levels (~50% of adult values), which decrease the thrombolytic effects of alteplase. Plasminogen supplementation may be necessary.

**ALUMINUM HYDROXIDE**

Various generics; previously available as Amphojel

**Antacid, phosphate binder**



**Oral suspension [OTC]:** 320 mg/5 mL (473 mL)

Each 5 mL suspension contains <0.13 mEq Na.

**Antacid (see remarks):**

**Child:** 320–960 mg PO 1–3 hr PC and QHS PRN

**Adult:** 640 mg PO 1–3 hr PC and QHS PRN; **max. dose:** 3840 mg/24 hr

**Hyperphosphatemia (administer all doses with meals and titrate to normal serum phosphorus):**

**Child:** 50–150 mg/kg/24 hr ÷ Q4–6 hr PO

**Adult:** 300–600 mg TID PO with meals

**Max. dose (all ages):** 3000 mg/24 hr



**AVOID** long-term use. Chronic antacid use is not recommended for children with GERD.

**Use with caution** in patients with renal failure and upper GI hemorrhage.

Interferes with the absorption of several orally administered medications, including digoxin, ethambutol, indomethacin, isoniazid, naproxen, mycophenolate, tetracyclines, fluoroquinolones (e.g., ciprofloxacin), and iron. In general, **do not** take oral medications within 1–2 hr of taking aluminum dose unless specified.

May cause constipation, decreased bowel motility, encephalopathy, and phosphorus depletion.

**ALUMINUM HYDROXIDE WITH MAGNESIUM HYDROXIDE**

Mylanta Maximum Strength, Almacone Antacid Antigas, Almacone Double Strength, and many other generics (see remarks); previously available as Maalox

**Antacid**



**Chewable tabs [OTC]:** (Al [OH]<sub>3</sub>: Mg [OH]<sub>2</sub>)

Almacone and generics: 200 mg AlOH, 200 mg MgOH, and 25 mg simethicone

**Oral suspension [OTC] (see remarks):**

Almacone Antacid Antigas, and generics: each 5 mL contains 200 mg AlOH, 200 mg MgOH, and 20 mg simethicone (150, 360, 720 mL); some preparations may contain 0.2% alcohol, benzyl alcohol, or propylene glycol

Mylanta Maximum Strength, Almacone Double Strength, and generics: each 5 mL contains 400 mg AlOH, 400 mg MgOH, and 40 mg simethicone (360, 480 mL); some preparations may contain benzyl alcohol

Many other combinations exist.

Contains 0.03–0.06 mEq Na/5 mL

**Antacid (mL volume dosages are based on the 200 mg AlOH, 200 mg MgOH, and 20 mg simethicone per 5 mL oral suspension concentration):**



ALUMINUM HYDROXIDE WITH MAGNESIUM HYDROXIDE *continued*

**Child ≤12 yr:** 0.5–1 mL/kg/dose (**max. dose:** 20 mL/dose) PO 1–3 hr PC and HS PRN

**>12 yr and adult:** 10–20 mL PO 1–3 hr PC and HS PRN; **max. dose:** 80 mL/24 hr

Chronic antacid use is not recommended for children with GERD. May have laxative effect.

May cause hypokalemia. **Use with caution** in patients with renal insufficiency (magnesium), gastric outlet obstruction. **Do not use** for hyperphosphatemia.

Interferes with the absorption of the benzodiazepines, chloroquine, digoxin, naproxen, mycophenolate, phenytoin, quinolones (e.g., ciprofloxacin), tetracyclines, and iron. In general, do not take oral medications within 1–2 hr of taking antacid dose unless specified.

**DO NOT use** Maalox Total Relief (bismuth subsalicylate), Mylanta New Tonight Soothing Liquid (calcium carbonate + magnesium hydroxide + simethicone), Maalox Regular Strength or Children's Chewable Tablets and Children's Mylanta Chewable Tablets (calcium carbonate), Maalox Maximum Strength Chewable (calcium carbonate and simethicone), and Mylanta Gas (simethicone), as these products do not contain aluminum hydroxide and magnesium hydroxide.

**AMANTADINE HYDROCHLORIDE**

Immediate release dosage forms: generics; previously available as Symmetrel

Extended release dosage forms: Gocovri, Osmolex ER

**Antiviral agent**



C



3



Yes



Yes



No

**Capsule:** 100 mg

**Tab:** 100 mg

**Extended release capsule (Gocovri; see remarks):** 68.5, 137 mg

**Extended release tabs (Osmolex ER; see remarks):** 129, 193 mg

**Oral solution:** 50 mg/5 mL (480 mL); may contain parabens

**Influenza A prophylaxis and treatment (for treatment, it is best to initiate therapy immediately after the onset of symptoms; within 2 days; use immediate release dosage forms and see remarks):**



**1–9 yr:** 5 mg/kg/24 hr PO ÷ BID; **max. dose:** 150 mg/24 hr

**≥10 yr:**

**<40 kg:** 5 mg/kg/24 hr PO ÷ BID; **max. dose:** 200 mg/24 hr

**≥40 kg:** 200 mg/24 hr PO ÷ BID

**Duration of therapy:**

**Prophylaxis:**

**Single exposure:** At least 10 days

**Repeated/uncontrolled exposure:** Up to 90 days

Use with influenza A vaccine when possible.

**Symptomatic treatment:**

Continue for 24–48 hr after disappearance of symptoms.

**Traumatic brain injury (limited data; use immediate release dosage forms):**

**≥6 yr to <16 yr:** 4–6 mg/kg/24 hr PO ÷ BID with the suggested **maximum** dosage:

**<10 yr or <40 kg:** 150 mg/24 hr

**≥10 yr or ≥40 kg:** 200 mg/24 hr

**≥16 yr:** 100 mg PO BID x 14 days, then increase to 150 mg PO BID. If needed, may increase dose to 200 mg PO BID only after 3 weeks from the initiation of therapy.

The CDC has reported resistance to influenza A and does not recommend its use for treatment and prophylaxis. Check with local microbiology laboratories and the CDC for seasonal



*Continued*

AMANTADINE HYDROCHLORIDE *continued*

susceptibility/resistance. Individuals immunized with live attenuated influenza vaccine should not receive amantadine prophylaxis for 14 days after the vaccine.

Preliminary studies in traumatic brain injury suggest improved cognition in children that were more recently injured (<2 years after injury).

**Do not use** in the first trimester of pregnancy. **Use with caution** in patients with liver disease, seizures, renal disease, congestive heart failure, peripheral edema, orthostatic hypotension, history of recurrent eczematoid rash, and in those receiving CNS stimulants. **Adjust dose in patients with renal insufficiency (see Chapter 31).**

Extended release capsule and tablet dosage forms are indicated for the treatment of dyskinesia in patients with Parkinson disease receiving levodopa-based therapy.

May cause dizziness, anxiety, depression, mental status change, rash (livedo reticularis), nausea, orthostatic hypotension, edema, CHF, and urinary retention. Impulse control disorder has been reported. Neuroleptic malignant syndrome has been reported with abrupt dose reduction or discontinuation (especially if patient is receiving neuroleptics).

**AMIKACIN SULFATE**

Various generics; previously available as Amikin

**Antibiotic, aminoglycoside**



D



1



Yes



No



No

**Injection:** 250 mg/mL (2, 4 mL); may contain sodium bisulfite

Initial empirical dosage; patient-specific dosage defined by therapeutic drug monitoring (see remarks).



**Neonate:** See the following table.

Postconceptional			
Age (wk)	Postnatal Age (days)	Dose (mg/kg/dose)	Interval (hr)
≤29 <sup>a</sup>	0–7	18	48
	8–28	15	36
	>28	15	24
30–34	0–7	18	36
	>7	15	24
≥35	ALL	15	24 <sup>b</sup>

<sup>a</sup>Or significant asphyxia, PDA, indomethacin use, poor cardiac output, reduced renal function.

<sup>b</sup>Use Q36 hr interval for HIE patients receiving whole-body therapeutic cooling.

**Infant and child:** 15–22.5 mg/kg/24 hr ÷ Q8 hr IV/IM; infants and patients requiring higher doses (e.g., cystic fibrosis) may receive initial doses of 30 mg/kg/24 hr ÷ Q8 hr IV/IM

**Cystic fibrosis (if available, use patient's previous therapeutic mg/kg dosage):**

**Conventional Q8 hr dosing:** 30 mg/kg/24 hr ÷ Q8 hr IV

**High-dose extended interval (once daily) dosing (limited data):** 30–35 mg/kg/24 hr Q24 hr IV

**Nontuberculous mycobacterium (part of a multiple drug regimen):**

**Infant and child:** 15–30 mg/kg/dose Q24 hr IV; **max. dose:** 1500 mg/24 hr

**Adolescent:** 10–15 mg/kg/dose Q24 hr IV; **max. dose:** 1500 mg/24 hr

**Adult:** 15 mg/kg/24 hr ÷ Q8–12 hr IV/IM

**Initial max. dose:** 1.5 g/24 hr, then monitor levels

Use with **caution** in preexisting renal, vestibular, or auditory impairment; concomitant anesthesia or neuromuscular blockers, neurotoxic; concomitant neurotoxic, ototoxic, or nephrotoxic drugs; sulfite sensitivity; and dehydration. **Adjust dose in renal failure**



AMIKACIN SULFATE *continued*

(see Chapter 31). Longer dosing intervals may be necessary for neonates receiving indomethacin for PDAs and for all patients with poor cardiac output. Rapidly eliminated in patients with cystic fibrosis or burns, and in febrile neutropenic patients. CNS penetration is poor beyond early infancy.

**Therapeutic Drug Monitoring Goals:**

Dosing Method/ Indication	Peak Level	Trough Level	Recommended Serum Sampling Time
Conventional dosing	20–30 mg/L; 25–30 mg/L for CNS, pulmonary, bone, life-threatening, <i>Pseudomonas</i> infections and febrile neutropenia	5–10 mg/L	Trough within 30 min before the third consecutive dose and peak 30–60 min after the administration of the third consecutive dose (at steady state)
High-dose extended interval (Q24 hr) for cystic fibrosis	80–120 mg/L	<10 mg/L	Trough within 30 min before the 2nd dose and peak 30–60 min after administration of 2nd dose
Extended interval (Q24 hr) for nontuberculous mycobacterium	20–40 mg/L	<10 mg/L	Trough within 30 min before the 2nd dose and peak 30–60 min after administration of 2nd dose

For initial dosing in obese patients, use an adjusted body weight (ABW).  $ABW = \text{ideal body weight} + 0.4 (\text{total body weight} - \text{ideal body weight})$ .

May cause ototoxicity, nephrotoxicity, neuromuscular blockade, and rash. Loop diuretics may potentiate the ototoxicity of all aminoglycoside antibiotics.

A liposomal inhalation product, Arikayce, is currently approved in adults as part of a multi-drug treatment regimen for *Mycobacterium avium complex* (MAC) lung disease.

**AMINOCAPROIC ACID**

Amicar and generics

**Hemostatic agent**

C



?



Yes



No



No

**Tabs:** 500, 1000 mg**Oral liquid/syrup:** 250 mg/mL (240, 480 mL); may contain 0.2% methylparaben and 0.05% propylparaben**Injection:** 250 mg/mL (20 mL); may contain 0.9% benzyl alcohol**Child (IV/PO):****Loading dose:** 100–200 mg/kg**Maintenance:** 50–100 mg/kg/dose Q4–6 hr; **max. dose:** 24–30 g/24 hr**Adult (IV/PO):** 4–5 g during the first hour, followed by 1 g/hr × 8 hr or until bleeding is controlled.**Max. dose:** 30 g/24 hr*Continued*

AMINOCAPROIC ACID *continued*

**Contraindications:** DIC, hematuria. **Use with caution** in patients with cardiac or renal disease. 

Should not be given with factor IX complex concentrates or antiinhibitor coagulant concentrates because of risk for thrombosis. Dose should be reduced by 75% in oliguria or end stage renal disease. Hypercoagulation may be produced when given in conjunction with oral contraceptives.

May cause nausea, diarrhea, malaise, weakness, headache, decreased platelet function, hypotension, and false increase in urine amino acids. Elevation of serum potassium may occur, especially in patients with renal impairment. Prolonged use may increase risk for skeletal muscle weakness and rhabdomyolysis.

**AMINOPHYLLINE**

Various generics

**Bronchodilator, methylxanthine**



C



1



No



Yes



No

**Injection:** 25 mg/mL (79% theophylline) (10, 20 mL)

**Note:** Pharmacy may dilute IV dosage forms to enhance accuracy of neonatal dosing.

**Neonatal apnea:**

**Loading dose:** 5–6 mg/kg IV

**Maintenance dose:** 1–2 mg/kg/dose Q6–8 hr, IV

**Asthma exacerbation and reactive airway disease:**

**IV loading:** 6 mg/kg IV over 20 min (each 1.2 mg/kg dose raises the serum theophylline concentration 2 mg/L)

**IV maintenance: Continuous IV drip:**

**Neonate:** 0.2 mg/kg/hr

**6 wk–6 mo:** 0.5 mg/kg/hr

**6 mo–1 yr:** 0.6–0.7 mg/kg/hr

**1–9 yr:** 1–1.2 mg/kg/hr

**9–12 yr and young adult smoker:** 0.9 mg/kg/hr

**>12 yr healthy nonsmoker:** 0.7 mg/kg/hr

The above total daily doses may also be administered IV ÷ Q4–6 hr.

Consider milligrams of theophylline available when dosing aminophylline. For oral route of administration, use theophylline. 

Monitoring serum levels is essential, especially in infants and young children. Intermittent dosing for infants and children 1–5 yr may require Q4 hr dosing regimen due to enhanced metabolism/clearance. Side effects: restlessness, GI upset, headache, tachycardia, seizures (may occur in absence of other side effects with toxic levels)

Therapeutic level (as theophylline): for asthma, 10–20 mg/L; for neonatal apnea, 6–13 mg/L

Recommended guidelines for obtaining levels:

IV bolus: 30 min after infusion

IV continuous: 12–24 hr after initiation of infusion

PO liquid, immediate release tab (theophylline product):

*Peak:* 1 hr post dose

*Trough:* just before dose

PO sustained release (theophylline product):

*Peak:* 4 hr post dose

*Trough:* just before dose

Ideally, obtain levels after steady state has been achieved (after at least 1 day of therapy). Liver impairment, cardiac failure, and sustained high fever may increase theophylline levels. See [Theophylline](#) for drug interactions.

AMINOPHYLLINE *continued*

Use in breastfeeding may cause irritability to infant. It is recommended to avoid breastfeeding for 2 hr after IV or 4 hr after immediate release oral intermittent dose.

**AMIODARONE HCL**

Pacerone, Nexterone, and generics

**Antiarrhythmic, Class III**



D



3



Yes



Yes



No

**Tabs (Pacerone and generics):** 100, 200, 400 mg

**Oral suspension:** 5 mg/mL 

**Injection:** 50 mg/mL (3, 9, 18 mL) (contains 20.2 mg/mL benzyl alcohol and 100 mg/mL polysorbate 80 or Tween 80)

**Premixed injection (Nexterone):** 1.5 mg/mL (100 mL) (iso-osmotic solution, each 1 mL contains 15 mg sulfbutylether  $\beta$ -cyclodextrin [SBECD; see remarks], 0.362 mg citric acid, 0.183 mg sodium citrate, and 42.1 mg dextrose), 1.8 mg/mL (200 mL) (iso-osmotic solution, each 1 mL contains 18 mg SBECD, 0.362 mg citric acid, 0.183 mg sodium citrate, and 41.4 mg dextrose)

Contains 37.3% iodine by weight

See algorithms in **front of book** for arrest dosing.

**Child PO for tachyarrhythmia:**

**<1 yr:** 600–800 mg/1.73 m<sup>2</sup>/24 hr  $\div$  Q12–24 hr  $\times$  4–14 days and/or until adequate control achieved, then reduce to 200–400 mg/1.73 m<sup>2</sup>/24 hr

**$\geq$ 1 yr:** 10–15 mg/kg/24 hr  $\div$  Q12–24 hr  $\times$  4–14 days and/or until adequate control achieved, then reduce to 5 mg/kg/24 hr  $\div$  Q12–24 hr if effective

**Child IV for tachyarrhythmia (limited data):**

5 mg/kg (**max. dose:** 300 mg) over 30–60 min followed by a continuous infusion starting at 5 micrograms (mCg)/kg/min; infusion may be increased up to a **max. dose** of 15 mCg/kg/min or 20 mg/kg/24 hr or 2200 mg/24 hr

**Adult PO for ventricular arrhythmias:**

**Loading dose:** 800–1600 mg/24 hr  $\div$  Q8–12 hr for 1–3 wk

**Maintenance:** 600–800 mg/24 hr  $\div$  Q12–24 hr  $\times$  1 mo, then 200 mg Q12–24 hr

**Use lowest effective dose to minimize adverse reactions.**

**Adult IV for ventricular arrhythmias:**

**Loading dose:** 150 mg over 10 min (15 mg/min) followed by 360 mg over 6 hr (1 mg/min); followed by a maintenance dose of 0.5 mg/min. Supplemental boluses of 150 mg over 10 min may be given for breakthrough VF or hemodynamically unstable VT, and the maintenance infusion may be increased to suppress the arrhythmia. **Max. dose:** 2.1 g/24 hr

Used in the resuscitation algorithm for ventricular fibrillation/pulseless ventricular tachycardia (**see front of book** for arrest dosing and **back cover** for PALS algorithm).

Overall use of this drug may be limited due to its potentially life-threatening side effects and the difficulties associated with managing its use.

**Contraindicated** in severe sinus node dysfunction, marked sinus bradycardia, second- and third-degree AV block. **Use with caution** in hepatic impairment.

Long elimination half-life (IV single dose: 9–36 days, chronic oral dosing: 40–55 days). Major metabolite N-desethylamiodarone is active with a long half-life (IV single dose: 9–30 days; chronic oral dosing: 61 days). Use of premixed injection (Nexterone) is not recommended in renal insufficiency due to accumulation of cyclodextrin excipient.

Increases cyclosporine, digoxin, phenytoin, tacrolimus, warfarin, calcium channel blockers, theophylline, and quinidine levels. Amiodarone is a CYP P450 3A3/4 substrate and inhibits CYP 3A3/4, 2C9, and 2D6. Risk of rhabdomyolysis is increased when used with simvastatin at doses greater than 20 mg/24 hr and lovastatin at doses greater than 40 mg/24 hr. Serious symptomatic bradycardia has been reported when used with sofosbuvir.

*Continued*

AMIODARONE HCL *continued*

Proposed therapeutic level with chronic oral use: 1–2.5 mg/L

Asymptomatic corneal microdeposits should appear in all patients. Alters liver enzymes, thyroid function. Pulmonary fibrosis reported in adults. May cause worsening of preexisting arrhythmias with bradycardia and AV block. May also cause hypotension, anorexia, nausea, vomiting, dizziness, paresthesias, ataxia, tremor, SIADH, and hypothyroidism or hyperthyroidism. Drug rash with eosinophilia and systemic symptoms (DRESS), acute respiratory distress syndrome, and anaphylactic reactions have been reported. IV administration at much higher concentrations and rates of infusion has been reported to increase the risk for hepatic injury.

Correct hypokalemia, hypocalcemia, or hypomagnesemia whenever possible before use as these conditions may exaggerate QTc prolongation.


Intravenous continuous infusion concentration for peripheral administration **should not exceed** 2 mg/mL (minimizes the risk for phlebitis) and **must be** diluted with D<sub>5</sub>W. The intravenous dosage form can leach out plasticizers such as DEHP. It is recommended to reduce the potential exposure to plasticizers in pregnant women and children at the toddler stages of development and younger by using alternative methods of IV drug administration.

Oral administration should be consistent with regard to meals because food increases the rate and extent of oral absorption.

**AMITRIPTYLINE**

Generics; previously available as Elavil

**Antidepressant, tricyclic (TCA)**



C

2

No

Yes

Yes

**Tabs:** 10, 25, 50, 75, 100, 150 mg

**Oral suspension:** 10 mg/mL , 20 mg/mL 

**Oral syrup:** 1 mg/mL 

**See remarks for genomic considerations.**



**Antidepressant:**

**Child:** Start with 1 mg/kg/24 hr ÷ TID PO for 3 days; then increase to 1.5 mg/kg/24 ÷ TID. Dose may be gradually increased to a **max. dose** of 5 mg/kg/24 hr if needed. Monitor ECG, BP, and heart rate (HR) for doses >3 mg/kg/24 hr.

**Adolescent:** 10 mg TID PO and 20 mg QHS; dose may be gradually increased up to a **max. dose** of 200 mg/24 hr if needed.

**Adult:** 40–100 mg/24 hr ÷ QHS-BID PO; dose may be gradually increased up to 300 mg/24 hr if needed; gradually decrease dose to lowest effective dose when symptoms are controlled.

**Augment analgesia for chronic pain:**

**Child:** Initial: 0.1 mg/kg/dose QHS PO; increase as needed and tolerated over 2–3 wk to 0.5–2 mg/kg/dose QHS.

**Migraine prophylaxis (limited data):**

**Child:** Initial 0.1–0.25 mg/kg/dose QHS PO; increase as needed and tolerated every 2 wk by 0.1–0.25 mg/kg/dose up to a **max. dose** of 2 mg/kg/24 hr or 75 mg/24 hr. For doses >1 mg/kg/24 hr, divide daily dose BID and monitor ECG.

**Adult:** Initial 10–25 mg/dose QHS PO; reported range of 10–400 mg/24 hr

**Contraindicated** in narrow-angle glaucoma, seizures, severe cardiac disorders, and patients who received MAO inhibitors within 14 days. See [Chapter 3](#) for management of TCA toxic ingestion.



$T_{1/2}$  = 9–25 hr in adults. **Maximum** antidepressant effects may not occur for 2 wk or more after initiation of therapy. **Do not abruptly discontinue therapy in patients receiving high doses for prolonged periods.**

Therapeutic levels (sum of amitriptyline and nortriptyline): 100–250 ng/mL. Recommended serum sampling time: obtain a single level 8 hr or more after an oral dose (following 4–5 days of

AMITRIPTYLINE *continued*

continuous dosing). Amitriptyline is a substrate for CYP 450 1A2, 2C9, 2C19, 2D6, and 3A3/4 and inhibitor for CYP 450 1A2, 2C19, 2C9, 2D6, and 2E1. Rifampin can decrease amitriptyline levels. Amitriptyline may increase side effects of tramadol.

Pharmacogenomic dosing considerations for CYP 2D6 and 2C19 phenotype (*Clinical Pharmacology and Therapeutics*. 2016;102[1]:37–44):

Phenotype	CYP 2D6 Ultra-Rapid Metabolizer	CYP 2D6 Normal Metabolizer	CYP 2D6 Intermediate Metabolizer	CYP 2D6 Poor Metabolizer
<b>CYP 2C19 Ultra-rapid or Rapid Metabolizer</b>	Avoid use, use alternative therapy	Consider alternative therapy not metabolized by CYP 2C19	Consider alternative therapy not metabolized by CYP 2C19	Avoid use; use alternative therapy
<b>CYP 2C19 Normal Metabolizer</b>	Avoid use but if use necessary, titrate to higher target dose	Use recommended initial dose	Consider a 25% initial dose reduction	Avoid use but if use necessary, consider 50% initial dose reduction
<b>CYP 2C19 Intermediate Metabolizer</b>	Avoid use; use alternative therapy	Use recommended initial dose	Consider a 25% initial dose reduction	Avoid use but if use necessary, consider 50% initial dose reduction
<b>CYP 2C19 Poor Metabolizer</b>	Avoid use; use alternative therapy	Avoid use but if use necessary, consider 50% initial dose reduction	Avoid use; use alternative therapy	Avoid use; use alternative therapy

Side effects include sedation, urinary retention, constipation, dry mouth, dizziness, drowsiness, liver enzyme elevation, and arrhythmia. May discolor urine (blue/green). QHS dosing during first weeks of therapy will reduce sedation. Monitor ECG, BP, CBC at start of therapy and with dose changes. Decrease dose if PR interval reaches 0.22 sec, QRS reaches 130% of baseline, HR rises greater than 140/min, or if BP is >140/90. Tricyclics may cause mania. **For antidepressant use, monitor for clinical worsening of depression and suicidal ideation/behavior following the initiation of therapy or after dose changes.**

**AMLODIPINE**

Norvasc, Norliqva, Katerzia, and generics

**Calcium channel blocker, antihypertensive**



C



2



No



Yes



No

Continued

AMLODIPINE *continued*

**Tabs:** 2.5, 5, 10 mg

**Oral solution (Norliqva):** 1 mg/mL (150 mL); contains 4% v/v alcohol

**Oral suspension:** 1 mg/mL 

**Katerzia:** 1 mg/mL (150 mL); contains polysorbate 80 and sodium benzoate

**Hypertension:****Child:**

**<6 yr:** Start with 0.1 mg/kg/dose (**max. dose:** 5 mg) PO once daily—BID; dosage may be gradually increased to a **max. dose** of 0.6 mg/kg/24 hr up to 5 mg/24 hr.

**≥6—17 yr:** Start with 2.5 mg PO once daily; dosage may be gradually increased to a **max. dose** of 10 mg/24 hr.

**Adult:** 5—10 mg/dose once daily PO; use 2.5 mg/dose once daily PO in patients with hepatic insufficiency. **Max. dose:** 10 mg/24 hr



**Use with caution** in combination with other antihypertensive agents. Younger children (<6 yr) may require higher mg/kg doses than older children and adults. A BID dosing regimen may provide better efficacy in children.



Reduce dose in hepatic insufficiency. Allow 5—7 days of continuous initial dose therapy before making dosage adjustments because of the drug's gradual onset of action and lengthy elimination half-life. Amlodipine is a substrate for CYP 450 3A4 and **should be used with caution** with 3A4 inhibitors such as protease inhibitors and azole antifungals (e.g., fluconazole and ketoconazole). May increase levels and toxicity of cyclosporine, tacrolimus, and simvastatin.

Dose-related side effects include edema, dizziness, flushing, fatigue, and palpitations. Other side effects include headache, nausea, abdominal pain, and somnolence.

Limited data report amlodipine present in breast milk at low levels, undetectable in infant plasma with no adverse effects to breastfed infants.

**AMMONUL**

See [Sodium Phenylacetate + Sodium Benzoate](#).

**AMOXICILLIN**

Various generics; previously available as Amoxil and Trimox

**Antibiotic, aminopenicillin**



B



1



Yes



No



No

**Oral suspension:** 125, 250 mg/5 mL (80, 100, 150 mL); and 200, 400 mg/5 mL (50, 75, 100 mL)

**Caps:** 250, 500 mg

**Tablets:** 500, 875 mg

**Chewable tabs:** 125, 250 mg; may contain phenylalanine

**Neonate — ≤3 mo:** 20—30 mg/kg/24 hr ÷ Q12 hr PO

**Child:**

**Standard dose:** 25—50 mg/kg/24 hr ÷ Q8—12 hr PO

**High dose (resistant *Streptococcus pneumoniae*; see remarks):** 80—90 mg/kg/24 hr ÷ Q8—12 hr PO

**Max. dose:** 2—3 g/24 hr; some experts recommend a **maximum** dosage up to 4 g/24 hr

**Adult:**

**Mild/moderate infections:** 250 mg/dose Q8 hr PO OR 500 mg/dose Q12 hr PO

**Severe infections:** 500 mg/dose Q8 hr PO OR 875 mg/dose Q12 hr PO

**Max. dose:** 2—3 g/24 hr



AMOXICILLIN *continued*

**Tonsillitis/pharyngitis (*S. pyogenes*):** 50 mg/kg/24 hr ÷ Q12 hr PO × 10 days; **max. dose:** 1 g/24 hr

**SBE prophylaxis:** Administer dose 30–60 min before procedure.

**Child:** 50 mg/kg PO × 1; **max.** 2 g/dose

**Adult:** 2 g PO × 1

**Early Lyme disease:**

**Child:** 50 mg/kg/24 hr ÷ Q8 hr PO × 14–21 days; **max. dose:** 1.5 g/24 hr

**Adult:** 500 mg/dose Q8 hr PO × 14–21 days

Renal elimination. **Adjust dose in renal failure (see Chapter 31).** Serum levels about twice those achieved with equal dose of ampicillin. Fewer GI effects, but otherwise similar to ampicillin. Side effects: rash and diarrhea. Rash may develop with concurrent EBV infection. May increase warfarin's effect by increasing INR.

High-dose regimen is recommended in respiratory infections (e.g., CAP), acute otitis media, and sinusitis, owing to increasing incidence of penicillin-resistant pneumococci. **Chewable tablets may contain phenylalanine and should not be used by patients with phenylketonuria.**

**AMOXICILLIN-CLAVULANIC ACID**

Augmentin, Augmentin ES-600, and generics

**Antibiotic, aminopenicillin with  $\beta$ -lactamase inhibitor**



B



1



Yes



No



No

**Tabs:**

**For TID dosing:** 250, 500 mg (with 125 mg clavulanate)

**For BID dosing:** 875 mg amoxicillin (with 125 mg clavulanate)

**Extended release tabs (previously available as Augmentin XR):** 1 g amoxicillin (with 62.5 mg clavulanate)

**Chewable tabs:**

**For BID dosing (7:1 amoxicillin:clavulanate):** 200, 400 mg amoxicillin (28.5 and 57 mg clavulanate, respectively); contains saccharin and aspartame

**Oral suspension:**

**For TID dosing (4:1 amoxicillin:clavulanate):** 125, 250 mg amoxicillin/5 mL (31.25 and 62.5 mg clavulanate/5 mL, respectively) (75, 100, 150 mL); contains saccharin

**For BID dosing:**

**7:1 amoxicillin:clavulanate:** 200, 400 mg amoxicillin/5 mL (28.5 and 57 mg clavulanate/5 mL, respectively) (50, 75, 100 mL)

**14:1 amoxicillin:clavulanate (Augmentin ES-600 and generics):** 600 mg amoxicillin/5 mL; contains 42.9 mg clavulanate/5 mL (75, 125, 200 mL); contains saccharin and/or aspartame

Contains 0.63 mEq K<sup>+</sup> per 125 mg clavulanate (Augmentin ES-600 contains 0.23 mEq K<sup>+</sup> per 42.9 mg clavulanate)

**Dosage based on amoxicillin component (see remarks for resistant *S. pneumoniae*).**

**Infant 1–<3 mo:** 30 mg/kg/24 hr ÷ Q12 hr PO (recommended dosage form is 125 mg/5 mL suspension)

**Child ≥3 mo:**

**Non–high-dose amoxicillin regimens:**

**<40 kg:**

**TID dosing (see remarks):** 20–40 mg/kg/24 hr ÷ Q8 hr PO

**BID dosing (see remarks):** 25–45 mg/kg/24 hr ÷ Q12 hr PO

**≥40 kg:** Use adult dosage.

**High-dose amoxicillin regimens:**



*Continued*

AMOXICILLIN-CLAVULANIC ACID *continued*

≥3 mo and <40 kg (use 14:1 amoxicillin:clavulanate dosage form, Augmentin ES-600, or generic oral suspension): 90 mg/kg/24 hr ÷ Q8–12 hr PO; Q8 hr recommended for CAP, orbital cellulitis, and severe infections

≥40 kg: Use adult dosage.

**Adult:** 250–500 mg/dose Q8 hr PO or 875 mg/dose Q12 hr PO for more severe and respiratory infections

**Extended release tablet:**

≥16 yr and adult: 2 g Q12 hr PO × 10 days for acute bacterial sinusitis, 7–10 days for community-acquired pneumonia, or 5–10 days for acute otitis media

See [Amoxicillin](#) for additional comments. **Adjust dose in renal failure (see Chapter 31).**

**Contraindicated** in patients with a history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin-clavulanic acid. Extended release tablet dosage form is **contraindicated** in patients with CrCl <30 mL/min.

Clavulanic acid extends the activity of amoxicillin to include β-lactamase–producing strains of *Haemophilus influenzae*, *Moraxella catarrhalis*, *Neisseria gonorrhoeae*, and some *Staphylococcus aureus* and may increase the risk for diarrhea.

The BID dosing schedule is associated with less diarrhea. For BID dosing, the 875 mg, 1 g tablets, the 200 mg, 400 mg chewable tablets or the 200 mg/5 mL, 400 mg/5 mL, 600 mg/5 mL suspensions should be used. These BID dosage forms contain phenylalanine and **should not be used** by patients with phenylketonuria. For TID dosing, the 250 mg, 500 mg tablets, the 125 mg, 250 mg chewable tablets, or the 125 mg/5 mL, 250 mg/5 mL suspensions should be used.

Higher doses of 80–90 mg/kg/24 hr (amoxicillin component) have been recommended for resistant strains of *S. pneumoniae* in acute otitis media and pneumonia (use BID formulations containing 7:1 or 14:1 ratio of amoxicillin to clavulanic acid or Augmentin ES-600, respectively).

The 250 or 500 mg tablets **cannot** be substituted for Augmentin XR tablets.

**AMPHETAMINE**

Evekeo, Evekeo ODT, Adzenys XR-ODT, Dyanavel XR

**CNS stimulant**



C



3



No



No



No

**Tabs, immediate release:**

**Evekeo and generics:** 5, 10 mg; both tablets are scored

**Immediate release dispersible tabs:**

**Evekeo ODT:** 5, 10, 15, 20 mg

**Extended release dispersible tabs:**

**Adzenys XR-ODT:** 3.1, 6.3, 9.4, 12.5, 15.7, 18.8 mg

**Extended release oral suspension:**

**Dyanavel XR:** 2.5 mg/mL (464 mL); contains parabens and polysorbate 80

**DO NOT substitute** extended release formulations for other amphetamine products on a milligram per milligram basis due to differences in potency and pharmacokinetic profiles. If converting from other amphetamine products, discontinue that treatment first and titrate new dosage form as indicated in the drug dosage section.

**Attention-deficit/hyperactivity disorder:**

**Immediate release tabs (Evekeo and generics) and dispersible tabs (Evekeo ODT) (PO):**

**3–5 yr:** 2.5 mg/24 hr QAM; increase by 2.5 mg/24 hr at weekly intervals until desired response. Incremental dosages may be administered BID-TID with the first dose at awakening and subsequent doses spaced at 4–6 hr intervals. Doses rarely exceed 40 mg/24 hr.

AMPHETAMINE *continued*

**≥6 yr and adolescent:** 5 mg once daily or BID; increase by 5 mg/24 hr at weekly intervals until desired response. Incremental dosages may be administered BID-TID with the first dose at awakening and subsequent doses spaced at 4–6 hr intervals. Doses rarely exceed 40 mg/24 hr.

**Extended release suspension (Dyanavel XR; PO):**

**≥6 yr and adolescent:** Start at 2.5 or 5 mg/24 hr QAM; increase by 2.5–10 mg/24 hr every 4–7 days until desired response up to a **maximum dose** of 20 mg/24 hr.

**Extended release dispersible tabs (see how-supplied section, earlier; Adzenys XR-ODT; PO):**

**6–17 yr:** 6.3 mg/24 hr QAM; increase by 3.1 or 6.3 mg/24 hr at weekly intervals until desired response. **Max. dose:** 6–12 yr: 18.8 mg/24 hr; 13–17 yr: 12.5 mg/24 hr

**Adult:** 12.5 mg/24 hr QAM

If converting from Adderall XR, see dosage equivalent information in Adzenys XR-ODT product information.

**Narcolepsy:****Immediate release tabs (Evekeo and generics; PO):**

**6–12 yr:** 5 mg QAM; increase by 5 mg/24 hr at weekly intervals until desired response. Incremental doses may be administered with the first dose at awakening and subsequent doses (5 or 10 mg) spaced at 4–6 hr intervals. Usual daily dosage range: 5–60 mg/24 hr in divided doses

**≥13 yr and adult:** 10 mg QAM; increase by 10 mg/24 hr at weekly intervals until desired response. Incremental doses may be administered with the first dose at awakening and subsequent doses (5 or 10 mg) spaced at 4–6 hr intervals. Usual daily dosage range: 5–60 mg/24 hr in divided doses

**Use with caution** in presence of hypertension or cardiovascular disease. **Avoid use** in known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may increase risk of sympathomimetic effects of amphetamines (sudden death, stroke, and MI have been reported).

**Contraindicated** with MAO inhibitors, including linezolid and IV methylene blue, as a hypertensive crisis may occur if used within 14 days of discontinuance of MAO inhibitor. Serotonin syndrome may occur when used in combination with MAO inhibitors, SSRIs, serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, TCAs, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's wort.

Amphetamine is a minor substrate of CYP 450 2D6. Alkalinizing agents should be **avoided** as they can increase the effects/toxicity of amphetamine by decreasing its secretion.

Not recommended for patients <3 yr of age. Medication should generally not be used in children <5 yr, because diagnosis of ADHD in this age group is extremely difficult (use in consultation with a specialist). Interrupt administration occasionally to determine need for continued therapy.

Common side effects include headache, insomnia, anorexia (monitor growth), abdominal pain, anxiety, mood swings, and agitation. Psychotic disorder, peripheral vascular disease (including Raynaud phenomenon), intestinal ischemia, and cerebrovascular accident have been reported.

Evekeo has an additional labeled indication for the treatment of exogenous obesity in ≥12 yr and adults. Doses may be administered with or without food. **Do not** crush or chew the extended release dispersible tabs (Adzenys XR-ODT). Shake oral suspension bottle (Dyanavel XR) well before dispensing and administering each dose.

**AMPHOTERICIN B DEOXYCHOLATE (CONVENTIONAL)**

Various generics; previously available as

Fungizone

**Antifungal, polyene**



B



?



Yes



Yes



No

*Continued*

AMPHOTERICIN B DEOXYCHOLATE (CONVENTIONAL) *continued*

**Injection:** 50 mg vials

**IV:** Mix with D<sub>5</sub>W to concentration 0.1 mg/mL (peripheral administration) or 0.25 mg/mL (central line only). pH >4.2. Infuse over 2–6 hr.



**Optional test dose:** 0.1 mg/kg/dose IV up to **max. dose** of 1 mg (followed by remaining initial dose)

**Initial dose:** 0.5–1 mg/kg/24 hr; if test dose NOT used infuse first dose over 6 hr and monitor frequently during the first several hours.

**Increment:** Increase as tolerated by 0.25–0.5 mg/kg/24 hr once daily or every other day. Use larger dosage increment (0.5 mg once daily) for critically ill patients.

**Usual maintenance:**

**Once daily dosing:** 0.5–1 mg/kg/24 hr once daily

**Every other day dosing:** 1.5 mg/kg/dose every other day

**Max. dose:** 1.5 mg/kg/24 hr

**Intrathecal (limited data):** 25–100 mCg Q48–72 hr. Increase to 500 mCg as tolerated. Dosages as high as 1500 mCg have been recommended by the 2018 AAP Red Book.

**Bladder irrigation for urinary tract mycosis (limited data):** 5–15 mg in 100 mL sterile water for irrigation at 100–300 mL/24 hr. Instill solution into bladder, clamp catheter for 1–2 hr, then drain; repeat TID–QID for 2–5 days.

Monitor renal, hepatic, electrolyte, and hematologic status closely. Hypercalciuria, hypokalemia, hypomagnesemia, RTA, renal failure, acute hepatic failure, hypotension, and phlebitis may occur. **For dosing information in renal failure, see Chapter 31.**



Common infusion-related reactions include fever, chills, headache, hypotension, nausea, and vomiting; may premedicate with acetaminophen and diphenhydramine 30 min before and 4 hr after infusion. Meperidine useful for chills. Hydrocortisone, 1 mg/mg ampho (**max.:** 25 mg) added to bottle may help to prevent immediate adverse reactions. Use total body weight for obese patients when calculating dosages.

Salt loading with 10–15 mL/kg of NS infused prior to each dose may minimize the risk of nephrotoxicity. Maintaining sodium intake of >4 mEq/kg/24 hr in premature neonates may also reduce risk for nephrotoxicity. Nephrotoxic drugs such as aminoglycosides, chemotherapeutic agents, and cyclosporine may result in synergistic toxicity. Hypokalemia may increase the toxicity of neuromuscular blocking agents and cardiac glycosides.

Although there are no breastfeeding data for amphotericin, many experts believe it is compatible since the drug is highly protein bound, has a large molecular weight, and is not absorbed orally.

**AMPHOTERICIN B LIPID COMPLEX**

Abelcet, ABLC

**Antifungal, polyene**



B



?



Yes



Yes



No

**Injection:** 5 mg/mL (20 mL)

(Formulated as a 1:1 molar ratio of amphotericin B to lipid complex composed of dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol)

**IV:** 5 mg/kg/24 hr once daily

**Candidiasis:**

**IV:** 3–5 mg/kg/24 hr once daily

**Cryptococcal meningitis:**

**IV:** 5 mg/kg/24 hr once daily; use in combination with flucytosine or fluconazole for HIV  
Mix with D<sub>5</sub>W to concentration 1 or 2 mg/mL for fluid-restricted patients.



AMPHOTERICIN B LIPID COMPLEX *continued*

**Infusion rate:** 2.5 mg/kg/hr; shake the infusion bag every 2 hr if total infusion time exceeds 2 hr. **Do not** use an in-line filter.

Monitor renal, hepatic, electrolyte, and hematologic status closely. Thrombocytopenia, anemia, leukopenia, hypokalemia, hypomagnesemia, diarrhea, respiratory failure, skin rash, nephrotoxicity, and increases in liver enzymes and bilirubin may occur. See Conventional [Amphotericin B](#) for drug interactions.

Highest concentrations achieved in spleen, lung, and liver from human autopsy data from one heart transplant patient. CNS/CSF levels are lower than amphotericin B, liposomal (AmBisome). In animal models, concentrations are higher in the liver, spleen, and lungs but the same in the kidneys when compared with conventional amphotericin B. Pharmacokinetics in renal and hepatic impairment have not been studied.

Common infusion-related reactions include fever, chills, rigors, nausea, vomiting, hypotension, and headache; may premedicate with acetaminophen, diphenhydramine, and meperidine (see Conventional [Amphotericin B](#) remarks).

**AMPHOTERICIN B, LIPOSOMAL**

AmBisome and generics

**Antifungal, polyene**

B



?



Yes



Yes



No

**Injection:** 50 mg (vials); contains soy, 900 mg sucrose

(Formulated in liposomes composed of hydrogenated soy phosphatidylcholine, cholesterol, distearoylphosphatidylglycerol, and  $\alpha$ -tocopherol)

**Systemic fungal infections:** 3–5 mg/kg/24 hr IV once daily; an upper dosage limit of 10 mg/kg/24 hr has been suggested based on pharmacokinetic endpoints and risk for hypokalemia. However, dosages as high as 15 mg/kg/24 hr have been used. Dosages as high as 10 mg/kg/24 hr have been used in patients with *Aspergillus*.

**Empiric therapy for febrile neutropenia:** 3 mg/kg/24 hr IV once daily

**Cryptococcal meningitis in HIV:** 6 mg/kg/24 hr IV once daily

**Leishmaniasis (a repeat course may be necessary if infection does not clear):**

**Immunocompetent:** 3 mg/kg/24 hr IV on days 1 to 5, 14, and 21

**Immunocompromised:** 4 mg/kg/24 hr IV on days 1 to 5, 10, 17, 24, 31, and 38

Mix with D<sub>5</sub>W to concentration 1–2 mg/mL (0.2–0.5 mg/mL may be used for infants and small children).

**Infusion rate:** Administer dose over 2 hr; infusion may be reduced to 1 hr if well tolerated. A  $\geq$ 1-micron inline filter may be used.

Closely monitor renal, hepatic, electrolyte, and hematologic status. Thrombocytopenia, anemia, leukopenia, tachycardia, hypokalemia, hypomagnesemia, hypocalcemia, hyperglycemia, diarrhea, dyspnea, skin rash, low back pain, nephrotoxicity, and increases in liver enzymes and bilirubin may occur. Rhabdomyolysis has been reported. Safety and effectiveness in neonates have not been established as lipid-based formulations may have reduced tissue penetration as compared with conventional formulations in neonates. See [Conventional Amphotericin B](#) for drug interactions. Compared with conventional amphotericin B, higher concentrations are found in the liver and spleen; and similar concentrations found in the lungs and kidney. CNS/CSF concentrations are higher than other amphotericin B products. Pharmacokinetics in renal and hepatic impairment have not been studied. Common infusion-related reactions include fever, chills, rigors, nausea, vomiting, hypotension, and headache; may premedicate with acetaminophen, diphenhydramine, and meperidine (see [Conventional Amphotericin B](#) remarks).

*Continued*

AMPHOTERICIN B, LIPOSOMAL *continued*

False elevations of serum phosphate have been reported with the PHOSm assay (used in Beckman Coulter analyzers).

**AMPICILLIN**

Many generics

**Antibiotic, aminopenicillin**



B



1



Yes



No



No

**Caps:** 500 mg

**Injection:** 125, 250, 500 mg; 1, 2, 10 g

Contains 3 mEq Na/1 g IV drug

**Neonate (IM/IV):**

**≤34 wk gestation:**

**Postnatal age ≤7 days old:** 100 mg/kg/24 hr ÷ Q12 hr

**Postnatal age 8—<28 days old:** 150 mg/kg/24 hr ÷ Q12 hr

**>34 wk gestation:**

**Postnatal age ≤28 days old:** 150 mg/kg/24 hr ÷ Q8 hr

**Group B streptococcal meningitis (independent of gestational age):**

**Postnatal age ≤7 days old:** 300 mg/kg/24 hr ÷ Q8 hr

**Postnatal age 8—<28 days old:** 300 mg/kg/24 hr ÷ Q6 hr

**Infant/child (see remarks):**

**Mild-moderate infections:**

**IM/IV:** 100—200 mg/kg/24 hr ÷ Q6 hr; **max dose:** 8 g/24 hr

**PO:** 50—100 mg/kg/24 hr ÷ Q6 hr; **max. PO dose:** 2 g/24 hr

**Severe infections:** 300—400 mg/kg/24 hr ÷ Q4—6 hr IM/IV; **max. dose:** 12 g/24 hr

**Community-acquired pneumonia in a fully immunized patient (IV/IM):**

***S. pneumoniae* penicillin MIC ≤2.0 or *H. influenzae* (β-lactamase negative):** 150—200 mg/kg/24 hr ÷ Q6 hr

***S. pneumoniae* penicillin MIC ≥4.0:** 300—400 mg/kg/24 hr ÷ Q6 hr

**Max. IV/IM dose:** 12 g/24 hr

**Adult:**

**IM/IV:** 500—3000 mg Q4—6 hr; **max. dose:** 14 g/24 hr

**PO:** 250—500 mg Q6 hr

**SBE prophylaxis (when PO administration is not feasible):**

**Moderate-risk patients:**

**Child:** 50 mg/kg/dose (**max. dose:** 2 g/dose) × 1 IV/IM 30 min before procedure

**Adult:** 2 g/dose × 1 IV/IM 30 min before procedure

**High-risk patients with GU and GI procedures:** Aforementioned doses PLUS gentamicin 1.5 mg/kg × 1 (**max. dose:** 120 mg) IV within 30 min of starting procedure. Followed by ampicillin 25 mg/kg/dose IV (or PO amoxicillin) × 1, 6 hr later.

Use higher doses with shorter dosing intervals to treat CNS disease and severe infection.

CSF penetration occurs only with inflamed meninges. **Adjust dose in renal failure (see Chapter 31).**

Produces the same side effects as penicillin, with cross-reactivity. Rash commonly seen at 5—10 days and rash may occur with concurrent EBV infection or allopurinol use. May cause interstitial nephritis, diarrhea, and pseudomembranous enterocolitis. Chloroquine reduces ampicillin's oral absorption.



**AMPICILLIN/SULBACTAM**

Unasyn and generics

**Antibiotic, aminopenicillin with  $\beta$ -lactamase inhibitor**

B 1 Yes Yes No

**Injection:**

1.5 g = ampicillin 1 g + sulbactam 0.5 g

3 g = ampicillin 2 g + sulbactam 1 g

15 g = ampicillin 10 g + sulbactam 5 g

Contains 5 mEq Na per 1.5 g drug combination

**Dosage based on ampicillin component:****Neonate:****Premature (based on pharmacokinetic data):** 100 mg/kg/24 hr  $\div$  Q12 hr IM/IV**Full term:** 100 mg/kg/24 hr  $\div$  Q8 hr IM/IV**Infant  $\geq$ 1 mo and child (see remarks):****Mild/moderate infections:** 100–200 mg/kg/24 hr  $\div$  Q6 hr IM/IV; **max. dose:** 2 g ampicillin/dose**Meningitis/severe infections:** 200–400 mg/kg/24 hr  $\div$  Q4–6 hr IM/IV; **max. dose:** 2 g ampicillin/dose**Adult:** 1–2 g Q6–8 hr IM/IV; **max. dose:** 8 g ampicillin/24 hr

Similar spectrum of antibacterial activity to ampicillin with the added coverage of  $\beta$ -lactamase-producing organisms. Total sulbactam dose **should not exceed** 4 g/24 hr.


Use higher doses with shorter dosing intervals to treat CNS disease and severe infection. Hepatic dysfunction (e.g., hepatitis and cholestatic jaundice) and allergic reaction resulting in acute myocardial ischemia have been reported. Monitor hepatic function in patients with hepatic impairment.

**Adjust dose in renal failure (see Chapter 31).** Similar CSF distribution and side effects to ampicillin.

Postmarketing adverse reactions reported include abdominal pain, melena, gastritis, stomatitis, dyspepsia, black hairy tongue, dizziness, dyspnea, TEN, and urticaria.

**ANTIPYRINE AND BENZOCAINE (OTIC)**

Antipyrine and Benzocaine Otic and generics; previously available as Auralgan

**Otic analgesic, cerumenolytic**

C 2 No No No

**Otic solution:** antipyrine 5.4%, benzocaine 1.4% (15 mL); may contain oxyquinoline sulfate**Otic analgesia:** Fill external ear canal (2–4 drops) Q1–2 hr PRN. After instillation of the solution, a cotton pledget should be moistened with the solution and inserted into the meatus.**Cerumenolytic:** Fill external ear canal (2–4 drops) TID for 2–3 days.

Benzocaine sensitivity may develop; not intended for prolonged use. **Contraindicated** if tympanic membrane perforated or PE tubes in place. Local reactions (e.g., burning, stinging) and hypersensitivity reactions may occur. Risk of benzocaine-induced methemoglobinemia may be increased in infants aged  $\leq$ 3 mo.

**ARGININE HYDROCHLORIDE—INJECTABLE PREPARATION**

R-Genex 10

**Metabolic alkalosis agent, urea cycle disorder treatment agent, growth hormone diagnostic agent**

B ? Yes Yes No

Continued

ARGININE HYDROCHLORIDE—INJECTABLE PREPARATION *continued*

**Injection:** 10% (100 mg/mL) arginine hydrochloride, contains 47.5 mEq chloride per 100 mL (300 mL)

**Osmolality:** 950 mOsmol/L

**Used as a secondary alternative agent for patients that are unresponsive or unable to receive sodium chloride and potassium chloride.**



**Correction of hypochloremia (IV):** Arginine chloride dose in milliequivalents (mEq) =  $0.2 \times \text{patient's weight (kg)} \times (103 - \text{patient's serum chloride in mEq/L})$ . Administer  $\frac{1}{2}$  to  $\frac{2}{3}$  of the calculated dose and reassess.

**Drug administration:** Do not exceed an IV infusion rate of 1 g/kg/hr (4.75 mEq/kg/hr). Drug may be administered without further dilution but should be diluted to reduce risk of tissue irritation.

**Hyperammonemia in metabolic disorders:** See [Chapter 13](#).

**Contraindicated** in renal or hepatic failure. Use with **extreme caution** as overdosages may result in hyperchloremic metabolic acidosis, cerebral edema, and death. Hypersensitivity reactions, including anaphylaxis, and hematuria have been reported.



Arginine hydrochloride is metabolized to nitrogen-containing products for renal excretion. Excess arginine increases the production of nitric oxide (NO) to cause vasodilation/hypotension. Closely monitor acid/base status. Hyperglycemia, hyperkalemia, GI disturbances, IV extravasation, headache, and flushing may occur.

In addition to its use for chloride supplementation, arginine is used in urea cycle disorder therapy (increase arginine levels and prevent breakdown of endogenous proteins) and as a diagnostic agent for growth hormone (stimulates pituitary release of growth hormone).

**ARIPIPIRAZOLE**

Abilify, Abilify Maintena, Abilify MyCite (Starter or Maintenance Kit), and generics

**Atypical antipsychotic (2nd generation)**



C



3



No



No



Yes

**Tabs:** 2, 5, 10, 15, 20, 30 mg

**Abilify MyCite:** 2, 5, 10, 15, 20, 30 mg; contains an ingestible event marker sensor inside the tablet to monitor adherence

**Starter Kit:** Each respective strength starter kit comes with 30 tablets, one MYCITE pod device, and 7 MYCITE adhesive strips.

**Maintenance Kit:** Each respective strength maintenance kit comes with 30 tablets and 7 MYCITE adhesive strips.

**Tabs, orally disintegrating (ODT):** 10, 15 mg; contains phenylalanine

**Oral solution:** 1 mg/mL (150 mL); may contain parabens

**Intramuscular suspension for injection (extended release):**

**Abilify Maintena:** 300, 400 mg

**Irritability Associated With Autistic Disorder:**



**6–17 yr:** Start at 2 mg PO once daily  $\times$  7 days, then increase to 5 mg PO once daily. If needed, dose may be increased in 5 mg increments  $\geq$  7 days in duration up to a **maximum** dose of 15 mg/24 hr. Patients should be periodically evaluated to determine the continued need for maintenance treatment.

**Schizophrenia:**

**13–17 yr:** Start at 2 mg PO once daily  $\times$  2 days, followed by 5 mg PO once daily  $\times$  2 days, then to the recommended target dose of 10 mg PO once daily. If necessary, dose may be increased in 5 mg increments up to a **maximum** of 30 mg/24 hr (30 mg/24 hr was not shown to be more effective than 10 mg/24 hr in clinical trials). Patients should be periodically evaluated to determine the continued need for maintenance treatment.

ARIPRAZOLE *continued***Bipolar 1 Disorder (monotherapy or adjunctive therapy):**

**10–17 yr:** Start at 2 mg PO once daily  $\times$  2 days, followed by 5 mg PO once daily  $\times$  2 days, then to the recommended target dose of 10 mg PO once daily. If necessary, dose may be increased in 5 mg increments up to a **maximum** of 30 mg/24 hr.

**Tourette Disorder:**

**6–18 yr (patients should be periodically evaluated to determine the continued need for maintenance treatment):**

**<50 kg:** Start at 2 mg PO once daily  $\times$  2 days, then increase to the target dose of 5 mg PO once daily. If necessary after 7 days, dose may be increased to 10 mg PO once daily.

**$\geq$ 50 kg:** Start at 2 mg PO once daily  $\times$  2 days, followed by 5 mg PO once daily  $\times$  5 days, and then 10 mg PO once daily. If necessary after 7 days, dose may be increased in 5 mg increments of  $\geq$  7 days in duration **up to** a **maximum** of 20 mg/24 hr.

Monitor for clinical worsening of depression and suicidal ideation/behavior after initiation of therapy or after dose changes. **Avoid** use of extended-release IM injection with CYP 450 inducers, including carbamazepine, for  $>$ 14 days. Higher cumulative doses and longer treatment duration may increase risk for irreversible tardive dyskinesia.



Weight gain, constipation, GI discomfort, akathisia, dizziness, extrapyramidal symptoms, headaches, insomnia, sedation, blurred vision, and fatigue are common. May cause leukopenia, neutropenia, agranulocytosis, hiccups, hyperthermia, neuroleptic malignant syndrome, hyperglycemia, orthostatic hypotension (risk for falls), and prolongation of the QT interval (use considered contraindicated with other medications prolonging the QT interval). Rare impulse-control problems (e.g., compulsive or uncontrollable urges to gamble, binge eat, shop, and to have sex), oculogyric crisis, and DRESS have been reported.

Primarily metabolized by the CYP 450 2D6 and 3A4 enzymes. Dosage reduction for using half of the usual dose has been recommended for those who are either known CYP 450 2D6 poor metabolizers; or nonpoor CYP 450 2D6 metabolizers taking strong CYP 450 2D6 (e.g., quinidine, fluoxetine, paroxetine) or 3A4 (e.g., itraconazole, clarithromycin) inhibitors. Use of  $\frac{1}{4}$  the usual dose has been recommended for known CYP 2D6 poor metabolizers taking either a strong 2D6 or 3A4 inhibitor; or nonpoor CYP 450 2D6 metabolizers taking both strong 2D6 AND 3A4 inhibitors.

Consult with a pediatric psychiatrist for use in ADHD, conduct disorder, and PDD-NOS. Oral doses may be administered with or without meals. Do not split orally disintegrating tablet dosage form.

**ARNUIITY ELLIPTA**

See [Fluticasone Preparations](#).

**ASCORBIC ACID**

Vitamin C; many brands and generics

**Water-soluble vitamin**



A/C



1



No



No



No

**Tabs [OTC]:** 100, 250, 500 mg, 1 g

**Chewable tabs [OTC]:** 100, 250, 500 mg; some may contain aspartame

**Tabs (timed release) [OTC]:** 0.5, 1.5 g

**Caps [OTC]:** 500, 1000 mg

**Extended release caps [OTC]:** 500 mg

**Injection:** 500 mg/mL (50 mL); may contain sodium hydrosulfite or edetate disodium

**Oral liquid [OTC]:** 500 mg/5 mL (120, 236, 473 mL); may contain propylene glycol, saccharin, sodium benzoate

*Continued*

ASCORBIC ACID *continued*

**Oral crystals or powder [OTC]:** 1 g per 1/4 teaspoonful (120 g, 480 g)

Some products may contain approximately 5 mEq Na/1 g ascorbic acid.

**Scurvy (PO/IM/IV/SC):**

**Child:** 100–300 mg/24 hr ÷ once daily-BID for at least 2 wk

**Adult:** 100–250 mg once daily-BID for at least 2 wk

**U.S. Recommended Daily Allowance (RDA):**

See [Chapter 21](#).



Adverse reactions: nausea, vomiting, heartburn, flushing, headache, faintness, dizziness, and hyperoxaluria. Use high doses with **caution** in G6PD patients. May cause false-negative and false-positive urine glucose determinations with glucose oxidase and cupric sulfate tests, respectively. May increase the enteral absorption of aluminum hydroxide and iron; and increase the adverse/toxic effects of deferoxamine. 200 mg oral vitamin C per 30 mg iron has been recommended to enhance enteral iron absorption. May reduce the effects of amphetamines.



Oral dosing is preferred with or without food. IM route is the preferred parenteral route. Protect the injectable dosage form from light.

Pregnancy Category changes to “C” if used in doses greater than the RDA.

**ASPIRIN**

ASA, various trade names and generics

**Nonsteroidal antiinflammatory agent, antiplatelet agent, analgesic**



D



2



Yes



Yes



No

**Tabs/caplet [OTC]:** 325, 500 mg

**Tabs, enteric coated [OTC]:** 81, 325, 650 mg

**Tabs, time release [OTC]:** 81, 325 mg

**Tabs, buffered [OTC]:** 325, 500 mg; may contain magnesium, aluminum, and/or calcium

**Caplet, buffered [OTC]:** 500 mg; may contain calcium

**Tabs, chewable [OTC]:** 81 mg

**Suppository [OTC]:** 300 mg (12s)

**Analgesic/antipyretic:** 10–15 mg/kg/dose PO/PR Q4–6 hr up to total of 60–80 mg/kg/24 hr

**Max. dose:** 4 g/24 hr

**Antiinflammatory:** 60–100 mg/kg/24 hr PO ÷ Q6–8 hr

**Kawasaki disease (see remarks):** 80–100 mg/kg/24 hr PO ÷ QID for during febrile phase (up to 14 days) until defervesces for 48–72 hr, then decrease to 3–5 mg/kg/24 hr PO QAM. Continue for at least 8 wk or until both platelet count and ESR are normal. Alternatively, a lower initial febrile phase dosage of 30–50 mg/kg/24 hr PO ÷ QID is used in Japan and Western Europe because there are no data to suggest this or the higher 80–100 mg/kg/24 hr dosage regimen is superior.



**Do not use in children <16 yr** for treatment of varicella or flu-like symptoms (risk for Reye syndrome), in combination with other NSAIDs, or in severe renal failure. **Use with caution** in bleeding disorders, renal dysfunction, gastritis, and gout. May cause GI upset, allergic reactions, liver toxicity, and decreased platelet aggregation.



Drug interactions: May increase effects of methotrexate, valproic acid, and warfarin, which may lead to toxicity (protein displacement). Buffered dosage forms may decrease absorption of ketoconazole and tetracycline. GI bleeds have been reported with concurrent use of SSRIs (e.g., fluoxetine, paroxetine, sertraline).

Therapeutic levels: antipyretic/analgesic: 30–50 mg/L, antiinflammatory: 150–300 mg/L. Tinnitus may occur at levels of 200–400 mg/L. Recommended serum sampling time at steady state: Obtain

ASPIRIN *continued*

trough level just prior to dose following 1–2 days of continuous dosing. Peak levels obtained 2 hr (for nonsustained release dosage forms) after a dose may be useful for monitoring toxicity. **Adjust dose in renal failure (see Chapter 31).**

For breastfeeding considerations:

High-dose aspirin regimens: Use of an alternative drug is recommended.


Low-dose (75–162 mg/24 hr) aspirin regimens: Avoid breastfeeding for 1–2 hr after a dose.

For pregnancy considerations: Low-dose regimens are currently recommended for certain pregnancy-related conditions such as the prevention of preeclampsia. However, **DO NOT** use non-low-dose regimens at >20 weeks' gestation as it may cause problems to the unborn child or complications during delivery.

**ATENOLOL**

Tenormin and generics

$\beta_1$  selective adrenergic blocker



D 2 Yes No No

**Tab:** 25, 50, 100 mg

**Oral suspension:** 2 mg/mL 

**Hypertension:**

**Child and adolescent:** 0.5–1 mg/kg/dose PO once daily–BID; **max. dose:** 2 mg/kg/24 hr up to 100 mg/24 hr 

**Adult:** 25–100 mg/dose PO once daily–BID; **max. dose:** 100 mg/24 hr

**Infantile hemangioma (limited data):**

**Infant and child <2 yr:** 1 mg/kg/dose PO once daily x 6 mo

**Contraindicated** in pulmonary edema and cardiogenic shock. May cause bradycardia, hypotension, second- or third-degree AV block, dizziness, fatigue, lethargy, and headache. 


**Use with caution** in diabetes and asthma. Wheezing and dyspnea have occurred when daily dosage exceeds 100 mg/24 hr. Postmarketing evaluation reports a temporal relationship for causing elevated LFTs and/or bilirubin, hallucinations, psoriatic rash, thrombocytopenia, visual disturbances, and dry mouth. **Avoid** abrupt withdrawal of the drug. Does not cross the blood-brain barrier; lower incidence of CNS side effects compared with propranolol. Neonates born to mothers receiving atenolol during labor or while breastfeeding may be at risk for hypoglycemia.

Use with disopyramide, amiodarone, or digoxin may enhance bradycardic effects. **Adjust dose in renal impairment (see Chapter 31).**

**ATOMOXETINE**

Strattera and generics

Norepinephrine reuptake inhibitor, ADHD agent



C 3 No Yes Yes

**Capsules:** 10, 18, 25, 40, 60, 80, 100 mg

**Child ≥6 yr and adolescent ≤70 kg (see remarks):**

Start with 0.5 mg/kg/24 hr PO QAM and increase after a minimum of 3 days to approximately 1.2 mg/kg/24 hr PO ÷ QAM or BID (morning and late afternoon/early evening). 

**Max. daily dose:** 1.4 mg/kg/24 hr or 100 mg, whichever is less

**If used with a strong CYP 450 2D6 inhibitor (e.g., fluoxetine, paroxetine, quinidine) or in patients with reduced CYP 450 2D6 activity:** Maintain aforementioned initial dose for 4 wk and increase to a **max.** of 1.2 mg/kg/24 hr only if symptoms **do not** improve and initial dose is tolerated.

**Child ≥6 yr and adolescent >70 kg (see remarks):**

*Continued*

ATOMOXETINE *continued*

Start with 40 mg PO QAM and increase after a minimum of 3 days to approximately 80 mg/24 hr PO ÷ QAM or BID (morning and late afternoon/early evening). After 2–4 wk, dose may be increased to a **max.** of 100 mg/24 hr if needed.

**If used with a strong CYP 450 2D6 inhibitor (e.g., fluoxetine, paroxetine, quinidine) or in patients with reduced CYP 450 2D6 activity:** Maintain aforementioned initial dose for 4 wk and increase to 80 mg/24 hr only if symptoms **do not** improve and initial dose is tolerated.

**Contraindicated** in patients with narrow-angle glaucoma, pheochromocytoma, and severe cardiac disorders. **Do not** administer with or within 2 wk after discontinuing an MAO inhibitor; fatal reactions have been reported. **Use with caution** in hypertension, tachycardia, cardiovascular or cerebrovascular diseases, or with concurrent albuterol therapy. Increased risk of suicidal thinking has been reported; closely monitor for clinical worsening, agitation, aggressive behavior, irritability, suicidal thinking or behaviors, and unusual changes in behavior when initiating (first few months) or at times of dose changes (increases or decreases). Patients with bipolar disorders may be at increased risk for developing mania or mixed episodes.



Atomoxetine is a CYP 450 2D6 substrate; poor 2D6 metabolizers compared with normal have been reported to have higher rates of adverse effects (insomnia, weight loss, constipation, depression, tremor, and excoriation), greater improvement of ADHD symptoms with lower final dose requirements.

Doses >1.2 mg/kg/24 hr in patients ≤70 kg have not been shown to be of additional benefit. Reduce dose (initial and target doses) by 50% and 75% for patients with moderate (Child-Pugh Class B) and severe (Child-Pugh Class C) hepatic insufficiency, respectively.

Major side effects include GI discomfort, vomiting, fatigue, anorexia, dizziness, and mood swings. Hypersensitivity reactions, aggression, irritability, psychotic or manic symptoms, priapism, allergic reactions, severe liver injury, alopecia, and hyperhidrosis have also been reported. Consider interrupting therapy in patients who are not growing or gaining weight satisfactorily.

Doses may be administered with or without food. Atomoxetine can be discontinued without tapering.

**ATOVAQUONE**

Mepron and generics

**Antiprotozoal**



C



3



Yes



Yes



No

**Oral suspension:** 750 mg/5 mL (210 mL); contains benzyl alcohol

***Pneumocystis jiroveci* (carinii) pneumonia (PCP):****Treatment (21-day course):**

**Child:** 30–40 mg/kg/24 hr PO ÷ BID with fatty foods; **max. dose:** 1500 mg/24 hr. Infants 4–24 mo may require higher doses of 45 mg/kg/24 hr.

**Adult:** 750 mg/dose PO BID

**Prophylaxis (1st episode and recurrence):**

**Child 1–3 mo or >24 mo:** 30 mg/kg/24 hr PO once daily; **max. dose:** 1500 mg/24 hr

**Child 4–24 mo:** 45 mg/kg/24 hr PO once daily; **max. dose:** 1500 mg/24 hr

**Adult:** 1500 mg/dose PO once daily

***Toxoplasma gondii:*****Child:**

**First episode prophylaxis and recurrence prophylaxis:** Use *P. jiroveci* prophylaxis dosages ± pyrimethamine 1 mg/kg/dose (**max.** 25 mg/dose) PO once daily PLUS leucovorin 5 mg PO Q3 days.

**Adult:**

**Treatment:** 1500 mg/dose PO BID ± (sulfadiazine 1000–1500 mg PO Q6 hr or pyrimethamine PLUS leucovorin) for a minimum of 6 weeks

ATOVAQUONE *continued*

**First episode prophylaxis:** 1500 mg/dose PO once daily ± pyrimethamine 25 mg PO once daily PLUS leucovorin 10 mg PO once daily

**Recurrence prophylaxis:** 750 mg/dose PO Q6–12 hr ± pyrimethamine 25 mg PO once daily PLUS leucovorin 10 mg PO once daily

**Not recommended** in the treatment of severe *P. jiroveci* (lack of clinical data). Patients with GI disorders or severe vomiting and who cannot tolerate oral therapy should consider alternative IV therapies. Rash, pruritus, sweating, GI symptoms, LFT elevation, dizziness, headache, insomnia, anxiety, cough, and fever are common. Anemia, Stevens-Johnson syndrome, hepatitis, renal/urinary disorders, and pancreatitis have been reported.



Metoclopramide, rifampin, rifabutin, and tetracycline may decrease atovaquone levels. Shake oral suspension well before dispensing all doses. Take all doses with high-fat foods to maximize absorption.

**ATROPINE SULFATE**

AtroPen, Isopto Atropine, and many generics

**Anticholinergic agent**



C



2



No



No



No

**Injection (vials):** 0.4, 1 mg/mL

**Injection (prefilled syringe):** 0.25 mg/5 mL, 0.5 mg/5 mL, 1 mg/10 mL

**Injection (autoinjector for IM use):**

**AtroPen 0.25 mg:** Delivers a single 0.25 mg (0.3 mL) dose (yellow-colored pen)

**AtroPen 0.5 mg:** Delivers a single 0.5 mg (0.7 mL) dose (blue-colored pen)

**AtroPen 1 mg:** Delivers a single 1 mg (0.7 mL) dose (dark red-colored pen)

**AtroPen 2 mg:** Delivers a single 2 mg (0.7 mL) dose (green-colored pen)

**Ophthalmic Dosage Forms:**

**Ointment:** 1% (3.5 g)

**Solution:**

**Isopto Atropine:** 1% (5 mL); contains benzalkonium chloride

**Generics:** 1% (2, 5, 15 mL)

**Preintubation dose (use 1 mg/mL concentration for IM route; see remarks):**

**Neonate:** 0.01–0.02 mg/kg/dose IV (over 1 min)/IM prior to other premedications

**Child:** 0.02 mg/kg/dose IV/IO/IM; **max. dose:** 0.5 mg/dose

**Adult:** 0.5 mg/dose IV/IM



**Cardiopulmonary resuscitation/bradycardia (see remarks):**

**Child:** 0.02 mg/kg/dose IV/IO/IM (use 1 mg/mL for IM) Q5 min × 2–3 doses PRN; **max. single dose:** 0.5 mg in children, 1 mg in adolescents; **max total dose:** 1 mg children, 2 mg adolescents

**ET tube administration:** 0.04–0.06 mg/kg (dilute with NS to volume of 1–2 mL and follow dose with 1 mL NS); may repeat once if needed

**Adult:** 0.5–1 mg/dose IV Q5 min; **max. total dose:** 3 mg

**Bronchospasm:** 0.025–0.05 mg/kg/dose (**max. dose:** 2.5 mg/dose) in 2.5 mL NS Q6–8 hr via nebulizer

**Nerve agent and insecticide poisoning for muscarinic symptoms (organophosphate or carbamate poisoning) (IV/IO/IM/ET; dilute in 1–2 mL NS for ET administration):**

**Child:** 0.05–0.1 mg/kg Q 5–10 min until bronchial or oral secretions terminate

**Adolescent:** 1–3 mg/dose Q 3–5 min until bronchial or oral secretions terminate

**Adult:** 2–5 mg/dose Q3–5 min until bronchial or oral secretions terminate

*Continued*

ATROPINE SULFATE *continued*

**AtroPen device (IM route):** Inject as soon as exposure is known or suspected. Give one dose for mild symptoms and two additional doses (total three doses) in rapid succession 10 min after the first dose for severe symptoms as follows:

**Child <6 mo (<7 kg):** 0.25 mg

**Child 6 mo–4 yr (7–18 kg):** 0.5 mg

**Child 4–10 yr (18–41 kg):** 1 mg

**Child >10 yr and adult (>41 kg):** 2 mg

**Ophthalmic (uveitis; see remarks):**

**Child:** (0.5% solution; prepared by diluting equal volume of the 1% atropine ophthalmic solution with artificial tears) 1–2 drops in each eye once daily—TID

**Adult:** (1% solution) 1–2 drops in each eye once daily—BID

**Contraindicated** in glaucoma, obstructive uropathy, tachycardia, and thyrotoxicosis, except for severe or life-threatening muscarinic symptoms. Use with **caution** in patients sensitive to sulfites. 

Use in neonatal bradycardia is no longer recommended. Data suggest the use of a minimum 0.1 mg dose may not be warranted for the preintubation indication. Use of the minimum 0.1 mg dose could result in an overdose in younger patients.

Side effects include: dry mouth, blurred vision, fever, tachycardia, constipation, urinary retention, CNS signs (dizziness, hallucinations, restlessness, fatigue, headache).

Use injectable solution for nebulized use; can be mixed with albuterol for simultaneous administration.

AtroPen dosage form is designed for IM administration to the outer thigh.

Ophthalmic use is not recommended for children less than 3 mo of age due to risk for systemic absorption.

**AURALGAN**

See [Antipyrine and Benzocaine](#).

**AZATHIOPRINE**

Imuran, Azasan, and generics

**Immunosuppressant**



D

2

Yes

Yes

Yes

**Oral suspension:** 50 mg/mL 

**Tabs:**

**Imuran and generics:** 50 mg (scored)

**Azasan and generics:** 75, 100 mg (scored)

**Injection:** 100 mg

**Immunosuppression (see remarks for genomic considerations):** 

**Child and adult:**

**Initial:** 3–5 mg/kg/24 hr IV/PO once daily

**Maintenance:** 1–3 mg/kg/24 hr IV/PO once daily

Increased risk for hepatosplenic T-cell lymphoma has been reported in adolescents and young adults. Toxicity: Bone marrow suppression, rash, stomatitis, hepatotoxicity, alopecia, arthralgias, and GI disturbances. 

Use  $\frac{1}{4}$ – $\frac{1}{3}$  dose when given with xanthine oxidase inhibitors (e.g., allopurinol). Patients with low or absent thiopurine methyl transferase (TPMT) or nucleotide diphosphatase (NUDT15) may be at increased risk for severe and life-threatening myelotoxicity. Consider alternative therapy in patients

AZATHIOPRINE *continued*

with homozygous TPMT or NUDT15 deficiency and reduced dosages in patients with heterozygous deficiency. Individuals with the low-functioning alleles for NUDT15 are common among Asian ancestry and Hispanic ethnicity.

Severe anemia has been reported when used in combination with captopril or enalapril. Monitor CBC, platelets, total bilirubin, alkaline phosphatase, BUN, and creatinine. Pancytopenia and bone marrow suppression have been reported with concomitant use of pegylated interferon and ribavirin in patients with hepatitis C. Progressive multifocal leukoencephalopathy (PML) has been reported.

**Adjust dose in renal failure (see Chapter 31).**

Administer oral doses with food to minimize GI discomfort. To minimize infant exposure via breastmilk, avoid breastfeeding for 4–6 hr after administering a maternal dose.

**AZELASTINE**

Generics; previously available as Astepro and Opitvar

**Antihistamine**



C



?



No



No



No

**Nasal spray (generics; previously available as Astepro):**

0.1% (delivers 137 mCg/spray) (200 actuations per 30 mL); contains benzalkonium chloride and EDTA

0.15% (delivers 205.5 mCg/spray) (200 actuations per 30 mL); contains benzalkonium chloride and EDTA

**Ophthalmic drops (generics; previously available as Opitvar):** 0.05% (0.5 mg/mL) (6 mL); contains benzalkonium chloride

**Seasonal allergic rhinitis:****0.1% strength:**

**Child 2–11 yr:** 1 spray each nostril BID

**≥12 yr and adult:** 1–2 sprays each nostril BID

**0.15% strength:**

**Child 6–12 yr:** 1 spray each nostril BID

**≥12 yr and adult:** 1–2 sprays each nostril BID or 2 sprays each nostril once daily

**Perennial allergic rhinitis:****0.1% strength:**

**≥6 mo—<12 yr:** 1 spray each nostril BID

**0.15% strength:**

**6—<12 yr:** 1 spray each nostril BID

**≥12 yr and adult:** 2 sprays each nostril BID

**Ophthalmic:**

**≥3 yr and adult:** Instill 1 drop into each affected eye BID.



**NASAL USE:** Drowsiness may occur despite nasal route of administration (**avoid** concurrent use of alcohol or CNS depressants). Bitter taste, nausea, nasal burning, pharyngitis, weight gain, fatigue, nasal sores, and epistaxis may also occur. Also available in combination with fluticasone as Dymista with labeled dosing information of 1 spray each nostril BID for seasonal allergic rhinitis (≥6 yr and adult).



**OPHTHALMIC USE:** Eye burning and stinging have been reported in about 30% of patients receiving the ophthalmic dosage form. **Should not be used** to treat contact lens–related irritation. Soft contact lens users should wait at least 10 min after dose instillation before they insert their lenses.

**AZELASTINE AND FLUTICASONE**

Dymista and generics

**Intranasal antihistamine and corticosteroid combination**



C



?



No



No



No

*Continued*

AZELASTINE AND FLUTICASONE *continued*

**Nasal spray:** 137 mcg azelastine and 50 mcg fluticasone per spray (23 g delivers 120 doses); contains benzalkonium chloride, EDTA, and polysorbate 80

**Seasonal allergic rhinitis:**

**Child >6 yr, adolescent, and adult:** 1 spray each nostril BID



May cause drowsiness. **Avoid use** with recent nasal ulcers, nasal surgery, or nasal trauma.

Use with ketoconazole, ritonavir, or other strong CYP 450 3A4 inhibitors may increase fluticasone levels and result in systemic corticosteroid effects, including Cushing syndrome and adrenal suppression. Monitor growth velocity in children with prolonged use. See azelastine and fluticasone preparations for remarks on intranasal route of administration for additional information.

**AZITHROMYCIN**

Zithromax, Zithromax TRI-PAK, Zithromax Z-PAK, AzaSite, and generics

**Antibiotic, macrolide**



B



2



Yes



Yes



No

**Tablets:** 250, 500, 600 mg

**TRI-PAK and generics:** 500 mg (3s as unit dose pack)

**Z-PAK and generics:** 250 mg (6s as unit dose pack)

**Oral suspension:** 100 mg/5 mL (15 mL), 200 mg/5 mL (15, 22.5, 30 mL)

**Oral powder (sachet):** 1 g (3s, 10s)

**Injection:** 500 mg; contains 9.92 mEq Na/1 g drug

**Ophthalmic solution (AzaSite):** 1% (2.5 mL); contains benzalkonium chloride

**Infant and child (see remarks):**

**Community acquired pneumonia (≥3 mo):**

**Tablet or oral suspension (mild infection or step-down therapy):** 10 mg/kg (**max. dose:** 500 mg) PO on day 1, followed by 5 mg/kg/24 hr (**max. dose:** 250 mg/24 hr) PO once daily on days 2–5

**IV and PO regimen (severe infection):** 10 mg/kg/dose (**max. dose:** 500 mg/dose) IV once daily for at least 2 days followed by 5 mg/kg/dose (**max. dose:** 250 mg/dose) PO once daily to complete a 5-day course

**Pharyngitis/tonsillitis (Group A streptococcal; 2–15 yr):** 12 mg/kg/24 hr PO once daily × 5 days (**max. dose:** 500 mg/24 hr)

**Acute sinusitis (≥6 mo):** 10 mg/kg/dose (**max. dose:** 500 mg) PO once daily × 3 days

**Pertussis:**

**1–<6 mo:** 10 mg/kg/dose PO once daily × 5 days

**≥6 mo:** 10 mg/kg/dose (**max. dose:** 500 mg) PO × 1, followed by 5 mg/kg/dose (**max. dose:** 250 mg) PO once daily on days 2–5

**Mycobacterium avium complex in HIV (see [www.aidsinfo.nih.gov/guidelines](http://www.aidsinfo.nih.gov/guidelines) for most current recommendations):**

**Prophylaxis for first episode:** 20 mg/kg/dose PO Q7 days (**max. dose:** 1200 mg/dose); alternatively, 5 mg/kg/24 hr PO once daily (**max. dose:** 250 mg/dose) with or without rifabutin

**Prophylaxis for recurrence:** 5 mg/kg/24 hr PO once daily (**max. dose:** 250 mg/dose), plus ethambutol 15 mg/kg/24 hr (**max. dose:** 900 mg/24 hr) PO once daily with or without rifabutin 5 mg/kg/24 hr (**max. dose:** 300 mg/24 hr)

**Treatment:** 10–12 mg/kg/24 hr PO once daily (**max. dose:** 500 mg/24 hr) × 1 mo or longer, plus ethambutol 15–25 mg/kg/24 hr (**max. dose:** 1 g/24 hr) PO once daily with or without rifabutin 10–20 mg/kg/24 hr (**max. dose:** 300 mg/24 hr)

**Endocarditis prophylaxis:** 15 mg/kg/dose (**max. dose:** 500 mg) PO × 1, 30–60 min before procedure



AZITHROMYCIN *continued***Antiinflammatory agent in cystic fibrosis:**

**<18 kg:** 10 mg/kg/dose PO every Mondays, Wednesdays, and Fridays

**18—<36 kg:** 250 mg PO every Mondays, Wednesdays, and Fridays

**≥36 kg:** 500 mg PO every Mondays, Wednesdays, and Fridays

**Adolescent and adult:**

**Pharyngitis, tonsillitis, skin, and soft tissue infection:** 500 mg PO day 1, then 250 mg/24 hr PO on days 2–5

**Mild/moderate bacterial COPD exacerbation:** Aforementioned 5-day dosing regimen OR 500 mg PO once daily × 3 days

**Community acquired pneumonia:**

**Tablets (outpatient regimen):** 500 mg PO day 1, then 250 mg/24 hr PO on days 2–5

**IV and tablet regimen (inpatient regimen):** 500 mg IV once daily × 3 days followed by 500 mg PO once daily to complete a 7- to 10-day regimen (IV and PO)

**Sinusitis:**

**Tablets:** 500 mg PO once daily × 3 days

**Uncomplicated chlamydial cervicitis or urethritis:** Single 1 g dose PO

**Gonococcal cervicitis or urethritis:** Single 2 g dose PO

**Acute PID (chlamydia):** 500 mg IV once daily × 1–2 days followed by 250 mg PO once daily to complete a 7-day regimen (IV and PO)

***Mycobacterium avium* complex in HIV (see [www.aidsinfo.nih.gov/guidelines](http://www.aidsinfo.nih.gov/guidelines) for most recent recommendations):**

**Prophylaxis for first episode:** 1200 mg PO Q7 days with or without rifabutin 300 mg PO once daily

**Prophylaxis for recurrence:** 500 mg PO once daily, plus ethambutol 15 mg/kg/dose PO once daily, with or without rifabutin 300 mg PO once daily

**Treatment:** 500–600 mg PO once daily with ethambutol 15 mg/kg/dose PO once daily with or without rifabutin 300 mg PO once daily

**Endocarditis prophylaxis:** 500 mg PO × 1, 30–60 min before procedure

**Antiinflammatory agent in cystic fibrosis:** Use same dosing in children.

**Ophthalmic:**

**≥1 yr and adult:** Instill one drop into the affected eye(s) BID, 8–12 hr apart, × 2 days, followed by one drop once daily for the next 5 days

No longer recommended for otitis media due to increased resistant pathogens.

**Contraindicated** in hypersensitivity to macrolides and history of cholestatic jaundice/

hepatic dysfunction associated with prior use. **Use with caution** in impaired hepatic function, GFR <10 mL/min (limited data), hypokalemia, hypomagnesemia, bradycardia, arrhythmias, prolonged QT intervals, and receiving medications that can cause the aforementioned conditions of caution. May cause increase in hepatic enzymes, cholestatic jaundice, GI discomfort, and pain at injection site (IV use). Compared with other macrolides, less risk for drug interactions. Nelfinavir may increase azithromycin levels; monitor for liver enzyme abnormalities and hearing impairment. Vomiting, diarrhea, and nausea have been reported at higher frequency in otitis media with 1-day dosing regimen. Exacerbations of myasthenia gravis/syndrome, serious skin reactions (e.g., SJS and TEN), infantile hypertrophic pyloric stenosis, decreased lymphocytes, and elevated bilirubin, BUN, and creatinine have been reported. CNS penetration is poor.

Aluminum- and magnesium-containing antacids decrease absorption. Tablet and oral suspension dosage forms may be administered with or without food. Extended release oral suspension should be taken on an empty stomach (at least 1 hr before or 2 hr following a meal). Intravenous administration is over 1–3 hr; **do not** give as a bolus or IM injection.

**Ophthalmic Use:** **Do not** wear contact lenses. Eye irritation is the most common side effect.



**AZTREONAM**

Azactam, Cayston, and generic intravenous products

**Antibiotic, monobactam****Injection:** 1, 2 g; each 1 g drug contains approximately 780 mg L-arginine**Nebulizer solution (Cayston):** 75 mg powder to be reconstituted with the supplied diluent of 1 mL 0.17% sodium chloride (28-day course kit contains 84 sterile vials of Cayston and 88 ampules of sterile diluent)**Neonate:****30 mg/kg/dose IV/IM (higher doses may be necessary for meningitis):****Gestational age <34 wk:**

≤7 days old: Q12 hr

&gt;7 days old: Q8 hr

**Gestational age ≥34 wk:**

≤7 days old: Q8 hr

&gt;7 days old: Q6 hr

**Child:** 90–120 mg/kg/24 hr ÷ Q6–8 hr IV/IM; **max. dose:** 2 g/dose and 8 g/24 hr**Cystic fibrosis:** 150–200 mg/kg/24 hr ÷ Q6–8 hr IV/IM (**max. dose:** 8 g/24 hr). Alternatively, higher doses have been used at 200–300 mg/kg/24 hr ÷ Q6 hr IV/IM (**max. dose:** 12 g/24 hr)**Adult:** Moderate infections: 1–2 g/dose Q8–12 hr IV/IM**Severe infections:** 2 g/dose Q6–8 hr IV/IM**Max. dose:** 8 g/24 hr**Inhalation:****Cystic fibrosis prophylaxis therapy:**

≥7 yr and adult: 75 mg TID (minimum 4 hr between doses) administered in repeated cycles of 28 days on drug followed by 28 days off drug. Administer each dose with the Altera Nebulizer System.

Typically indicated in multidrug resistant aerobic gram-negative infections when β-lactam therapy is contraindicated. Well-absorbed IM. **Use with caution** in arginase deficiency.Low cross-allergenicity between aztreonam and other β-lactams. Adverse reactions: thrombophlebitis, eosinophilia, leukopenia, neutropenia, thrombocytopenia, elevation of liver enzymes, hypotension, seizures, and confusion. Good CNS penetration. Probenecid and furosemide increase aztreonam levels. **Adjust dose in renal failure (see Chapter 31).****INHALATIONAL USE:** Cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain, and vomiting may occur. Bronchospasm has been reported. Use the following order of administration: bronchodilator first, chest physiotherapy, other inhaled medications (if indicated), and aztreonam last. Cayston vials and diluent ampules should be stored in the refrigerator (2–8° C), but once they are removed from the refrigerator, they can be stored at room temperature for up to 28 days. Cayston vials should be protected from light.**B****BACITRACIN ± POLYMYXIN B**

Various ophthalmic and topical generic products

In combination with polymyxin B: AK-Poly-Bac

Ophthalmic, Polycin, Double Antibiotic Topical,

Polysporin Topical and others

**Antibiotic, topical****BACITRACIN:****Ophthalmic ointment:** 500 units/g (3.5 g)**Topical ointment (OTC):** 500 units/g (1, 14, 15, 28, 30, 454 g)

BACITRACIN ± POLYMYXIN B *continued***BACITRACIN IN COMBINATION WITH POLYMYXIN B:**

**Ophthalmic ointment (AK-Poly-Bac Ophthalmic, Polycin, and generics):** 500 units bacitracin +10,000 units polymyxin B/g (3.5 g)

**Topical ointment (OTC):** 500 units bacitracin +10,000 units polymyxin B/g (15, 30 g)

**BACITRACIN:****Child and adult:**

**Topical:** Apply to affected area once daily—TID.

**Ophthalmic:** Apply 0.25- to 0.5-inch ribbon into the conjunctival sac of the infected eye(s) Q3—12 hr; frequency depends on severity of infection. Administer Q3—4 hr × 7—10 days for mild/moderate infections.

**BACITRACIN + POLYMYXIN B:****Child and adult:**

**Topical:** Apply ointment to affected area once daily—TID.

**Ophthalmic:** Apply 0.25- to 0.5-inch ribbon into the conjunctival sac of the infected eye(s) Q3—12 hr; frequency depends on severity of infection. Administer Q3—4 hr × 7—10 days for mild/moderate infections.

Hypersensitivity reactions to bacitracin and/or polymyxin B can occur. **Do not use** topical ointment for the eyes or for a duration of >7 days. Side effects may include rash, itching, burning, and edema.

Ophthalmic dosage form may cause temporary blurred vision and retard corneal healing. For ophthalmic use, wash hands before use and **avoid contact** of tube tip with skin or eye.

For neomycin-containing products, see [Neomycin/Polymyxin B/± Bacitracin](#).

**BACLOFEN**

Lioresal, Gablofen, Lyvispah, Ozobax, Fleqsuvy, and generics

**Centrally acting skeletal muscle relaxant**



C



2



Yes



No



No

**Tabs:** 5, 10, 20 mg

**Oral granules (Lyvispah):** 5, 10, 20 mg (90 packets); contains saccharin

**Oral suspension:** 5, 10 mg/mL

**Fleqsuvy:** 5 mg/mL (120, 300 mL); contains propylene glycol and sodium benzoate

**Oral solution (Ozobax and generics):** 1 mg/mL (473 mL); may contain parabens

**Injection:**

**Gablofen:** 50 mCg/mL (1 mL), 0.5 mg/mL (20 mL), 1 mg/mL (20 mL), 2 mg/mL (20 mL); preservative free

**Lioresal:** 50 mCg/mL (1 mL), 0.5 mg/mL (20 mL), 2 mg/mL (5, 20 mL); preservative free

**Generics:** 0.5 mg/mL (20 mL), 1 mg/mL (20 mL), 2 mg/mL (20 mL); preservative free

**Oral: Dosage increments, if tolerated, are made at 3-day intervals until desired effect**

**or max. dose is achieved.** Initiate first dosage level at QHS, followed by Q12 hr and then Q8 hr. Dosage increments are made by first increasing the QHS dosage, followed by the morning dosage and then the remaining mid-day dosage.

**Child (PO, see remarks):**

**<20 kg:** Start at 2.5 mg QHS, increase in 2.5 mg increments, if needed, up to the recommended **max. dose**, below.

**≥20—50 kg:** Start at 5 mg QHS, increase in 5 mg increments, if needed, up to the recommended **max. dose**, below.

**>50 kg:** Start at 10 mg QHS, increase in 10 mg increments, if needed, up to the recommended **max. dose**, below.

*Continued*

BACLOFEN *continued***Recommended max. PO dose:**

2 yr—&lt;8 yr: 60 mg/24 hr

8—16 yr: 80 mg/24 hr

&gt;16 yr: 120 mg/24 hr

**Adult (PO):**Start at 5 mg TID, increase in 5 mg increments, if needed, up to a **maximum** of 80 mg/24 hr.**Intrathecal continuous infusion maintenance therapy (not well established):**

&lt;12 yr: Average dose of 274 mCg/24 hr (range: 24—1199 mCg/24 hr) has been reported.

≥12 yr and adult: Most required 300—800 mCg/24 hr (range: 12—2003 mCg/24 hr with limited experience at doses &gt;1000 mCg/24 hr).

**Avoid** abrupt withdrawal of drug. **Use with caution** in patients with seizure disorder or impaired renal function. Approximately 70%—80% of the drug is excreted in the urine unchanged. Administer oral doses with food or milk.



Adverse effects: Drowsiness, fatigue, nausea, vertigo, psychiatric disturbances, rash, urinary frequency, and hypotonia. **Avoid** abrupt withdrawal of intrathecal therapy to prevent potential life-threatening events (rhabdomyolysis, multiple organ system failure, and death).

Cases of intrathecal mass at the tip of the implanted catheter leading to withdrawal symptoms have been reported. Inadvertent subcutaneous injection may occur with improper access of the reservoir refill septum and may result in an overdose. Sterile techniques must be used with intrathecal use, accounting for all nonsterile external surfaces.

Usual maintenance oral dosage range observed from a collection of smaller prospective and retrospective studies suggests the following (see dosage section for initial dose titration):

<2 yr: 10—20 mg/24 hr ÷ Q8 hr to a **maximum** of 40 mg/24 hr2—7 yr: 20—40 mg/24 hr ÷ Q8 hr to a **maximum** of 60 mg/24 hr≥8 yr: 30—40 mg/24 hr ÷ Q8 hr to a **maximum** of 200 mg/24 hr

**Caution:** Multiple concentrations of the oral liquid dosage form exist (e.g., 1, 5, 10 mg/mL). This is important to consider when completing the medication reconciliation process for needing to determine the dosage in milligrams and NOT the dosage volume that may result in an under- or overdose when using the incorrect medication concentration.

Oral granules dosage form may be administered directly into the mouth or mixed into liquids or soft foods (e.g., applesauce, yogurt, or pudding). Recommended enteral feeding tube size for administering granules: nasogastric (>8 FR), gastrostomy (>12 FR), percutaneous endoscopic gastrostomy (>14 FR), and gastrojejunostomy (>16 FR); see product information for additional details with feeding tube administration.

**BALOXAVIR MARBOXIL**

Xofluza

**Antiviral, endonuclease inhibitor**

C



?



No



No



No

**Tabs:** 40, 80 mg (1 tablet blister card)**Oral suspension:** 2 mg/mL (20 mL)**Treatment of influenza (initiate therapy within 48 hr of onset of symptoms):****Child 1—<12 yr (limited data):**

&lt;20 kg: 2 mg/kg/dose PO once

≥20 kg: 40 mg PO once

**≥12 yr and adult:**

&lt;80 kg: 40 mg PO once

≥80 kg: 80 mg PO once



BALOXAVIR MARBOXIL *continued*

Pediatric phase 3 comparison trial with oseltamivir (MINISONE-2) showed comparable efficacy and baloxavir was well tolerated. May be used for influenza postexposure prophylaxis for children  $\geq 12$  yr and adults using the same treatment dosage; data are limited for  $< 12$  yr old for this indication. Human pregnancy information currently not available.

Adverse effects reported in clinical trials include diarrhea, bronchitis, nasopharyngitis, headache, and nausea.

Baloxavir marboxil is a prodrug that is rapidly converted to the active baloxavir following oral administration. No clinically meaningful pharmacokinetics differences with moderate hepatic impairment (Child-Pugh class B) or with creatinine clearances  $\geq 50$  mL/min. Pharmacokinetics have not been evaluated in severe hepatic and/or severe renal impairment.

Primarily metabolized by UGT1A3 with minor contribution from CYP3A4. May reduce the efficacy of intranasal live attenuated influenza vaccine.

Dose may be administered with or without food. **Avoid** coadministration with dairy products, calcium, aluminum, magnesium, multivitamins with minerals, iron, selenium, or zinc, because decreased absorption of baloxavir may occur. Oral suspension dosage form must be administered within 10 hours after reconstitution.

**BECLOMETHASONE DIPROPIONATE**

QVAR Redihaler, Beconase AQ, Qnasl Children's, Qnasl

**Corticosteroid**



C



2



No



Yes



No

**Breath-activated inhalation aerosol, oral:**

**QVAR Redihaler:** 40 mCg/inhalation (10.6 g provides 120 inhalations), 80 mCg/inhalation (10.6 g provides 120 inhalations)

**Inhalation aerosol, nasal:**

**Qnasl Children's:** 40 mCg/inhalation (6.8 g provides 60 metered doses)

**Qnasl:** 80 mCg/inhalation (10.6 g provides 120 metered doses)

**Inhalation suspension, nasal:**

**Beconase AQ:** 42 mCg/inhalation (25 g provides 180 metered doses); contains benzalkonium chloride

**Oral inhalation (QVAR Redihaler) (patient requires an inspiratory flow rate of approximately 30 L/min for optimal drug delivery; see remarks):****Asthma maintenance therapy:**

**4–11 yr:** Start at 40 mCg BID. If response is inadequate after 2 wk, may increase dose to the recommended **maximum dose** of 80 mCg BID.

 **$\geq 12$  yr and adult:**

**Corticosteroid naïve:** Start at 40–80 mCg BID; **max. dose:** 320 mCg BID

**Previous corticosteroid use:** Start at 40–160 mCg BID; **max. dose:** 320 mCg BID

**Nasal inhalation for allergic rhinitis:****Beconase AQ:**

**6–12 yr:** Start with 1 spray (42 mCg) each nostril BID, may increase to the **maximum dose** of 2 sprays each nostril BID if needed. Once symptoms are controlled, decrease dose to 1 spray each nostril BID.

**>12 yr and adult:** 1–2 spray(s) (42–84 mCg) each nostril BID

**Maximum dose (>6 yr and adult):** 2 sprays each nostril BID or 336 mCg/24 hr

**Qnasl Children's:**

**4–11 yr:** 1 spray (40 mCg) each nostril once daily; **max. dose:** 2 sprays total (80 mCg)/24 hr

*Continued*

BECLOMETHASONE DIPROPIONATE *continued***Qnasl:**

**12 yr and adult:** 2 sprays (160 mCg) each nostril once daily; **max. dose:** 4 sprays (320 mCg)/24 hr

**Not recommended** for children <4 yr with oral inhalation and <6 yr (Beconase AQ) or <4 yr (Qnasl Children's) with the nasal administration because of unknown safety and efficacy.

Dose should be titrated to lowest effective dose. **Avoid** using higher-than-recommended doses.

**Avoid** use of nasal dosage form in recent nasal ulcers, nasal surgery, or nasal trauma. Nasal septal perforation has been reported with nasal product. Psychiatric and behavioral changes have been reported in children with the oral inhalation product. Routinely monitor growth of pediatric patients with chronic use of all dosage forms.

For mild asthma exacerbation in patients with mild/moderate disease, no history of life-threatening exacerbations, and a good asthma self-management plan, limited data in adolescents and adults suggest a temporary quadrupling of the maintenance dosage when asthma control starts to deteriorate. Revert back to baseline maintenance dose after symptoms stabilize or up to a **maximum** of 14 days of the quadrupled dose; whichever comes first. **DO NOT** use this management strategy for children <12 years of age due to the lack of efficacy and increased risk for decreasing linear growth.

When converting from fluticasone to beclomethasone for oral inhalation use, consider the following:

Fluticasone MDI (Flovent HFA)	Fluticasone DPI (Flovent Diskus)	Beclomethasone BAI (QVAR Redihaler)
44 mCg: 2 puffs BID	50 mCg: 2 inhalations BID	40 mCg: 1 puff BID
110 mCg: 2 puffs BID	100 mCg: 2 inhalations BID	40 mCg: 2 puffs BID
220 mCg: 2 puffs BID	250 mCg: 2 inhalations BID	80 mCg: 2 puffs BID

BAI, Breath-activated inhaler; DPI, dry powder inhaler; MDI, metered dose inhaler.

CYP 450 3A4 inhibitors (e.g., ketoconazole, erythromycin, and protease inhibitors) or significant hepatic impairment may increase systemic exposure of beclomethasone.


Monitor for hypothalamic, pituitary, adrenal, or growth suppression, and hypercorticism. Rinse mouth and gargle with water after oral inhalation; may cause thrush.

QVAR Redihaler is a breath-activated inhaler device and requires the patient to have a minimum inspiratory flow rate of 30 L/min for proper dose activation and does not require priming. **Do not** shake the Redihaler device with the cap open, and **do not use** it with a tube spacer or volume holding chamber.

**BENZOYL PEROXIDE**

BP Gel, BP Wash, Oxy-5, Oxy-10, PanOxyl, and many other products

**Topical acne product**



C

?

No

No

No

**Liquid wash [OTC]:** 2.5% (240 mL), 5% (120, 150, 240 mL), 7% (480 mL), 10% (120, 150, 240 mL)

**Liquid cream wash [OTC]:** 4% (170 g), 7% (180 g)

**Bar [OTC]:** 10% (113 g)

**Lotion [OTC]:** 5% (30, 120 mL), 8% (297 g), 10% (30, 120 mL)

**Cream [OTC]:** 5% (3, 30 g), 10% (30 g)

**Gel [OTC]:** 2.5% (60 g), 5% (42.5, 60, 90 g), 6.5% (113 g), 8% (113 g), 10% (42.5, 60, 90 g)

**NOTE:** Some preparations may contain alcohol and come in combination packs of cleansers and creams at various strengths.

BENZOYL PEROXIDE *continued***Combination product with erythromycin (Benzamycin and generics):**

**Gel:** 30 mg erythromycin and 50 mg benzoyl peroxide per g (23.3, 46 g); some preparations may contain 20% alcohol.

**Combination product with clindamycin:**

**Gel:** 10 mg clindamycin and 50 mg benzoyl peroxide per g (25, 35, 50 g), 12 mg clindamycin and 25 mg benzoyl peroxide per g (50 g), 12 mg clindamycin and 50 mg benzoyl peroxide per g (45 g); some preparations may contain methylparaben.

**Acanya:** 12 mg clindamycin and 25 mg benzoyl peroxide per g (50 g); contains propylene glycol

**Neuac:** 12 mg clindamycin and 50 mg benzoyl peroxide per g (45 g); contains parabens

**Onexton:** 12 mg clindamycin and 37.5 mg benzoyl peroxide per g (3.5, 50 g); contains propylene glycol

**Combination product with adapalene:** See [Adapalene ± Benzoyl Peroxide](#).

**Acne (child ≥12 yr and adult, see remarks):**

**Cleansers (liquid wash, or bar):** Wet affected area prior to application. Apply and wash once daily—BID; rinse thoroughly, and pat dry. Modify dose frequency or concentration to control the amount of drying or peeling.

**Lotion, cream, or gel:** Cleanse skin, and apply small amounts over affected areas once daily initially; increase frequency to BID—TID, if needed. Modify dose frequency or concentration to control drying or peeling.

**Combination products (these products have not been evaluated beyond 12 weeks of use):**

**Generics:** Apply once daily to affected areas after washing and drying skin. The 10 mg clindamycin and 50 mg benzoyl peroxide per g product may be administered BID (morning and evening).

**Acanya and Onexton:** Apply pea-sized amount to affected areas once daily after washing and drying skin.

**Neuac:** Apply a thin layer QHS to affected areas after washing and drying skin.

**Contraindicated** in known history of hypersensitivity to product's components (benzoyl peroxide, clindamycin, or erythromycin). **Avoid** contact with mucous membranes and eyes. May cause skin irritation, stinging, dryness, peeling, erythema, edema, and contact dermatitis. Anaphylaxis has been reported with products containing clindamycin and benzoyl peroxide.

Concomitant topical acne therapy should be used with caution due to possible cumulative irritancy effect. Concurrent use with tretinoin (Retin-A) will increase risk of skin irritation. Products containing clindamycin and erythromycin should not be used in combination.

Any single application resulting in excessive stinging or burning may be removed with mild soap and water. Lotion, cream, and gel dosage forms should be applied to dry skin.

Data are limited for use <12 yr of age.

**BENZTROPINE MESYLATE**

Generics; previously available as Cogentin

**Anticholinergic agent, drug-induced dystonic reaction antidote, anti-Parkinson agent**



?



?



No



No



No

**Injection:** 1 mg/mL (2 mL)

**Tabs:** 0.5, 1, 2 mg

**Drug-induced extrapyramidal symptoms (PO/IM/IV; see remarks):**

**>3 yr:** 0.02–0.05 mg/kg/dose once daily—BID

**Adult:** 1–4 mg/dose once daily—BID

*Continued*

BENZTROPINE MESYLATE *continued***Acute dystonic reactions (IM/IV; see remarks):****Child:** 0.02 mg/kg/dose (**max. dose:** 1 mg) × 1**Adult:** 1–2 mg/dose × 1

**Contraindicated** in myasthenia gravis, GI/GU obstruction, untreated narrow-angle glaucoma, and peptic ulcer. Use IV route **only** when PO and IM routes are not feasible. May cause anticholinergic side effects, especially constipation and dry mouth. Drug interactions include: potentiate CNS depressant effects when used with CNS depressants; enhance CNS side effects of amantadine; and inhibit the response of neuroleptics. This medication has not been formally assigned a pregnancy category by the FDA. The Australian pregnancy ratings have deemed use in pregnancy to a limited number of women without an increase in frequency of malformation or other direct/indirect harmful effects.



Onset of action: 15 min for IV/IM and 1 hr for PO.

Oral doses should be administered with food to decrease GI upset.

**BERACTANT**See [Surfactant, pulmonary](#).**BETAMETHASONE****Injection:** Celestone Soluspan and generics**Topical:** Diprolene, Luxiq, Sernivo, and generics**Corticosteroid**

C



3



No



No



No

**Na Phosphate and Acetate:****Injection suspension (Celestone Soluspan and generics):** 6 mg/mL (3 mg/mL Na phosphate +3 mg/mL betamethasone acetate) (5 mL); may contain benzalkonium chloride and EDTA**Dipropionate:****Topical cream:** 0.05% (15, 45 g)**Topical emulsion (Sernivo):** 0.05% (120 mL); contains parabens**Topical lotion:** 0.05% (60 mL); may contain 46.8% alcohol and propylene glycol**Topical ointment:** 0.05% (15, 45 g)**Valerate:****Topical cream:** 0.1% (15, 45 g)**Topical foam (Luxiq and generics):** 1.2 mg/g (50, 100 g); may contain 60.4% ethanol, cetyl alcohol, stearyl alcohol, and propylene glycol**Topical lotion:** 0.1% (60 mL); may contain 47.5% isopropyl alcohol**Topical ointment:** 0.1% (15, 45 g)**Dipropionate augmented:****Topical cream:** 0.05% (15, 50 g); contains propylene glycol**Topical gel:** 0.05% (15, 50 g); contains propylene glycol**Topical lotion:** 0.05% (60 mL); contains 30% isopropyl alcohol**Topical ointment (Diprolene and generics):** 0.05% (15, 45, 50 g); contains propylene glycol**All dosages should be adjusted based on patient response and severity of condition**

(see remarks).

**Antiinflammatory:****Child:****IM:** 0.0175–0.125 mg/kg/24 hr or 0.5–7.5 mg/m<sup>2</sup>/24 hr Q6–12 hr

BETAMETHASONE *continued***Adolescent and adult:**

**IM:** 0.6–9 mg/24 hr ÷ Q12–24 hr

**Topical (use smallest amount for shortest period of time to avoid adrenal suppression, and reassess diagnosis if no improvement is achieved after 2 wk; see remarks):**

**Valerate and dipropionate forms:**

**Child and adult:** Apply to affected areas once daily—BID.

**Dipropionate augmented forms (see remarks):**

**≥13 yr—adult:** Apply to affected areas once daily—BID.

**Max. dose:** 14 days and the following specific dosage form maximum amount

**Cream, ointment, and gel:** 50 g/wk

**Lotion:** 50 mL/wk

**Use with caution** in hypothyroidism, cirrhosis, ulcerative colitis, and history of allergic reactions to corticosteroids. See [Chapter 8](#) for relative steroid potencies and doses based on body surface area. Betamethasone is inadequate when used alone for adrenocortical insufficiency because of its minimal mineralocorticoid properties. Like all steroids, may cause hypertension, pseudotumor cerebri, acne, Cushing syndrome, adrenal axis suppression, GI bleeding, hyperglycemia, and osteoporosis.

Betamethasone is a substrate for CYP 450 3A4, and use with a strong inhibitor (e.g., ketoconazole and itraconazole) may lead to increased exposure and side effects of betamethasone.

Na phosphate and acetate injectable suspension recommended for IM, intra-articular, intrasynovial intralesional, soft tissue use only; but **not** for IV use. Topical betamethasone dipropionate augmented (Diprolene and Diprolene AF) is **not recommended** in children ≤12 yr owing to the higher risk for adrenal suppression.

Injectable IM dosage form is used in premature labor to stimulate fetal lung maturation.

**BICITRA**

See [Citrate Mixtures](#).

**BISACODYL**

Dulcolax, Ducodil, Bisacodyl EC, Fleet Bisacodyl, and various other names

**Laxative, stimulant**



B



1



No



No



No

**Tabs (enteric coated) [OTC]:** 5 mg

**Suppository [OTC]:** 10 mg

**Enema (Fleet Bisacodyl) [OTC]:** 10 mg/30 mL (37.5 mL)

**Delayed release tabs [OTC]:** 5 mg

**Oral (administered 6 hr before desired effect):**

**Child (3–10 yr):** 5 mg once daily

**>10 yr and adolescent:** 5–10 mg once daily

**Adult:** 5–15 mg once daily

**Rectal suppository (see remarks):**

**2–10 yr:** 5 mg once daily

**>10 yr and adolescent:** 5–10 mg once daily

**Adult:** 10 mg once daily



*Continued*

BISACODYL *continued***Rectal enema (as a single dose):**

2–10 yr: 5 mg (15 mL) × 1

&gt;10–18 yr: 5–10 mg (15–30 mL) × 1

**Adult:** 10 mg (30 mL) × 1

**Do not use** in newborn period. Instruct patient/parent that tablets should be swallowed whole, **not** chewed or crushed; **not** to be given within 1 hr of antacids or milk. May cause abdominal cramps, nausea, vomiting, and rectal irritation. Oral usually effective within 6–10 hr; rectal usually effective within 15–60 min.

Antacids may decrease the effect of bisacodyl and may cause the premature release of the delayed release formulation prior to reaching the large intestine. Use of suppository should be retained in the rectum for 15–20 min.

**BISMUTH SUBSALICYLATE**

Pepto-Bismol, Bismatrol, Pink Bismuth, Stomach Relief, Stomach Relief Extra Strength, and many others (see remarks)

**Antidiarrheal, gastrointestinal ulcer agent**



D



3



Yes



No



No

**Liquid [OTC]:**

**Pepto-Bismol, Bismatrol, Pink Bismuth, Stomach Relief, and others:** 262 mg/15 mL (240, 360, 480 mL)

**Stomach Relief Extra Strength:** 525 mg/15 mL (237 mL)

**Chewable tabs [OTC]:** 262 mg; may contain aspartame

Contains 102 mg salicylate per 262 mg tablet; or 129 mg salicylate per 15 mL of the 262 mg/15 mL liquid

**Diarrhea:**

**Child:** 100 mg/kg/24 hr ÷ 5 equal doses for 5 days; **max. dose:** 4.19 g/24 hr

**Dosage by age:** Give following dose Q30 min to 1 hr PRN up to a **max. dose** of 8 doses/24 hr:

**3–5 yr:** 87.3 mg (1/3 tablet or 5 mL of 262 mg/15 mL)

**6–8 yr:** 174.7 mg (2/3 tablet or 10 mL of 262 mg/15 mL)

**9–11 yr:** 262 mg (1 tablet or 15 mL of 262 mg/15 mL)

**≥12 yr—adult:** 524 mg (2 tablets or 30 mL of 262 mg/15 mL)

**Helicobacter pylori gastric infection** (as part of a 3 or 4 drug combination therapy; doses not well established for children):

**Child:** 8 mg/kg/24 hr PO ÷ BID × 10–14 days, or 262 mg PO QID × 7–14 days has been reported.

**Adult:** 300 mg PO QID × 10–14 days

**Generally not recommended** in children <16 yr with chicken pox or flu-like symptoms (risk for Reye syndrome), in combination with other nonsteroidal antiinflammatory drugs, anticoagulants, or oral antidiabetic agents, or in severe renal failure. **Use with caution** in bleeding disorders, renal dysfunction, gastritis, and gout. May cause darkening of tongue and/or black stools, GI upset, impaction, and decreased platelet aggregation.

Drug combination appears to have antisecretory and antimicrobial effects with some antiinflammatory effects. Absorption of bismuth is negligible, whereas approximately 80% of the salicylate is absorbed. Decreases absorption of tetracycline. The salicylate component may increase the effects/toxicity of antiplatelet, anticoagulant, and blood glucose—lowering medications and increase nephrotoxicity risk when used with ACE inhibitors.

**DO NOT use** Children's Pepto (calcium carbonate) because it does not contain bismuth subsalicylate. **Avoid use in renal failure** (see [Chapter 31](#)).

**BOSENTAN**

Tracleer and generics

**Endothelin receptor antagonist**

X



3



No



Yes



No

**Tabs:** 62.5, 125 mg**Dispersible tabs (to be dissolved in water to make an oral suspension):**

Tracleer: 32 mg (scored); contains aspartame

**Oral suspension:** 6.25 mg/mL **Pulmonary arterial hypertension (see remarks):****2015 AHA/ATS Pediatric Pulmonary Hypertension Guidelines:**

&lt;10 kg: Start at 1 mg/kg/dose PO BID, then increase to 2 mg/kg/dose PO BID.

10–20 kg: Start at 15.625 mg PO BID, then increase to 31.25 mg PO BID.

&gt;20–40 kg: Start at 31.25 mg PO BID, then increase to 62.5 mg PO BID.

&gt;40 kg: Start at 62.5 mg PO BID, then increase to 125 mg PO BID.

**Alternative FDA-labeled dosing by age and weight (PO):**

Age	Weight (kg)	Dosage (PO)
≤12 yr	4–8	16 mg BID
	>8–16	32 mg BID
	>16–24	48 mg BID
	>24–40	64 mg BID
>12 yr	≤40	62.5 mg BID
	>40	62.5 mg BID × 4 wk, then 125 mg BID

**Dosage Modification for Transaminase Elevation:**

ALT/AST Levels	Dosage Adjustment
>3 to ≤5 × ULN	Reconfirm by another aminotransferase test; if confirmed, modify dosage regimen (always reassess aminotransferase levels within 3 days and Q2 wk thereafter to any dosage reintroduction or reduction): ≤12 yr, and >12 yr and ≤40 kg: Interrupt therapy. If aminotransferase returns to pretreatment levels, reintroduce with dosage prior to interruption. >12 yr and >40 kg, and adult: Reduce dosage to 62.5 mg PO BID; or interrupt therapy and monitor aminotransferase levels Q2 wk (if aminotransferase levels return to pretreatment levels, continue with most recent dosage or 62.5 mg PO BID).
>5 to ≤8 × ULN	Reconfirm by another aminotransferase test; if confirmed, stop treatment and monitor aminotransferase at least Q2 wk. Once aminotransferase returns to pretreatment levels, consider reintroduction of bosentan and reassess aminotransferase within 3 days and Q2 wk thereafter to any dosage reintroduction or reduction: ≤12 yr, and >12 yr and ≤40 kg: Dosage prior to discontinuing >12 yr and >40 kg, and adult: 62.5 mg PO BID
>8 × ULN	All ages: Discontinue treatment permanently

ULN, Upper limit of normal.

Continued

BOSENTAN *continued*

**Contraindicated** in women who are or may become pregnant and with concurrent use of cyclosporine (increases bosentan concentrations) or glyburide (increases risk for hepatotoxicity). Due to these risks, bosentan is available only through the Tracleer REMS program, where prescribers and pharmacies need to be certified. See [www.BosentanREMSProgram.com](http://www.BosentanREMSProgram.com) or call 1-866-359-2612 for more information.



Baseline and monthly monitoring of serum aminotransferases and bilirubin; and pregnancy tests for females of reproductive potential (two forms of birth control required) are required. Use should be **avoided** in patients with preexisting hepatic impairment (baseline aminotransferases >3 times the usual normal limit).

May cause respiratory tract infections, anemia (dose related), edema, increased liver aminotransferases (see dosage modification; higher incidence in adults), and pyrexia. Decreased sperm counts, liver cirrhosis, liver failure, DRESS, thrombocytopenia, and sinusitis have been reported.

Bosentan is substrate for the CYP2C9 and 3A4 enzymes, and OATP1B1/SLC01B1 transporter. It also induces CYP2C9 and 3A4; may decrease sildenafil levels. Reduces the effectiveness of hormonal contraceptives.

Doses may be administered orally with or without food.

**BREO ELLIPTA**

See [Fluticasone Furoate + Vilanterol](#).

**BROMPHENIRAMINE WITH PHENYLEPHRINE**

Children's Dimetapp Cold and Allergy, Rynex PE, Ru-Hist D, and many other products

**Antihistamine + decongestant**



C



3



No



No



No

**Oral liquid/syrup (Children's Dimetapp Cold and Allergy, Rynex PE, and others) [OTC]:**

Brompheniramine 1 mg + phenylephrine 2.5 mg/5 mL (118, 237 mL); contains propylene glycol and sodium benzoate

**Tabs (Ru-Hist D) [OTC]:** Brompheniramine 4 mg + phenylephrine 10 mg

**NOTE:** Other combination products exist, using the Dimetapp name; always check the specific ingredients and their concentration (amount) with each specific product.

**All doses based on brompheniramine component** (see remarks).

**2 to <6 yr:** 1 mg Q4 hr PRN PO up to a **max. dose** of 6 mg/24 hr

**6–12 yr:** 2 mg Q4 hr PRN PO up to a **max. dose** of 12 mg/24 hr

**≥12 yr and adult:** 4 mg Q4 hr PRN PO up to a **max. dose** of 24 mg/24 hr

**Alternatively, dosing based on specific dosage forms/products. CAUTION:** These products may be available in different concentrations (see remarks).

**Oral, liquid/syrup (Children's Dimetapp Cold and Allergy and Rynex PE):**

**6 to <12 yr:** 10 mL Q4 hr PRN PO up to a **max. dose** of 60 mL/24 hr

**≥12 yr and adult:** 20 mL Q4 hr PRN PO up to a **max. dose** of 120 mL/24 hr

**Oral, tab (Ru-Hist D):**

**6 to <12 yr:** 0.5 tab Q4 hr PRN PO **not to exceed** 3 tablets/24 hr

**≥12 yr and adult:** 1 tab Q4 hr PRN PO **not to exceed** 6 tablets/24 hr



**Generally not recommended** for treating URIs for infants. No proven benefit for infants and young children with URIs. Over-the-counter (OTC or nonprescription) use of this product is **not recommended** for children <6 yr old due to reports of serious adverse effects (cardiac and respiratory distress, convulsions, and hallucinations) and fatalities (from unintentional overdoses, including combined use of other OTC products containing the same active ingredients).



BROMPHENIRAMINE WITH PHENYLEPHRINE *continued*

**Contraindicated** with use of MAO inhibitors (concurrent use and within 14 days after discontinuing MAO inhibitor). **Use with caution** in narrow-angle glaucoma, bladder neck obstruction, asthma, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, hypertension, coronary artery disease, diabetes mellitus, and thyroid disease. Discontinue use 48 hr prior to allergy skin testing. May cause drowsiness, fatigue, CNS excitation, xerostomia, blurred vision, and wheezing.

**BUDESONIDE**

Pulmicort Respules, Pulmicort Flexhaler, Ortikos, Tarpeyo, Uceris, and generics; previously available as Rhinocort Allergy Nasal Spray and Entocort EC

**Corticosteroid**

B/C



2/?



No



Yes



No

**Nasal spray (generics; previously available as Rhinocort Allergy) [OTC]:** 32 mCg/actuation (8.43 mL delivers 120 sprays); may contain disodium EDTA and polysorbate 80

**Nebulized inhalation suspension (Pulmicort Respules and generics):** 0.25 mg/2 mL, 0.5 mg/2 mL, 1 mg/2 mL (30s); may contain disodium EDTA and polysorbate 80

**Oral breath-activated inhalation powder (Pulmicort Flexhaler):** 90 mCg/metered dose (165 mg, delivers 60 doses), 180 mCg/metered dose (225 mg, delivers 120 doses); contains lactose

**Delayed or extended release capsule:**

**Tarpeyo:** 4 mg

**Ortikos:** 6, 9 mg

**Enteric coated granules in a capsule (generics; previously available as Entocort EC):** 3 mg

**Extended release tablet (Uceris and generics):** 9 mg

**Rectal foam (Uceris):** 2 mg per metered dose (33.4 g, delivers 14 doses; 2 canisters per kit)

**Nebulized inhalation suspension (see remarks):****Child 1–8 yr:**

**No prior steroid use:** 0.5 mg/24 hr ÷ once daily—BID; **max. dose:** 0.5 mg/24 hr

**Prior inhaled steroid use:** 0.5 mg/24 hr ÷ once daily—BID; **max. dose:** 1 mg/24 hr

**Prior oral steroid use:** 1 mg/24 hr ÷ once daily—BID; **max. dose:** 1 mg/24 hr

**NIH Asthma Guideline 2007 recommendations (divide daily doses once daily—BID):****Child 0–4 yr:**

**Low dose:** 0.25–0.5 mg/24 hr

**Medium dose:** >0.5–1 mg/24 hr

**High dose:** >1 mg/24 hr

**Child 5–11 yr:**

**Low dose:** 0.5 mg/24 hr

**Medium dose:** 1 mg/24 hr

**High dose:** 2 mg/24 hr

**Oral inhalation (see remarks):**

**Pulmicort Flexhaler (patient requires an inspiratory flow rate of approximately 60 L/min for optimal drug delivery):**

**Child ≥6–17 yr:** Start at 180 mCg BID; **max. dose:** 720 mCg/24 hr.

**≥18 yr and adult:** Start at 180–360 mCg BID; **max. dose:** 1440 mCg/24 hr.

**NIH Asthma Guideline 2007 recommendations (divide daily doses BID):****Child 5–11 yr:**

**Low dose:** 180–400 mCg/24 hr

**Medium dose:** >400–800 mCg/24 hr

**High dose:** >800 mCg/24 hr

*Continued*

BUDESONIDE *continued*

**Child  $\geq 12$  and adolescent:**

**Low dose:** 180–600 mCg/24 hr

**Medium dose:** >600–1200 mCg/24 hr

**High dose:** >1200 mCg/24 hr

**Nasal inhalation:**

**$\geq 6$  to  $< 12$  yr:** Start at 1 spray (32 mCg) in each nostril once daily. If needed, increase to 2 sprays (64 mCg) each nostril once daily. Then reduce dose back to initial dose when symptoms improve. Max. nasal dose: 128 mCg/24 hr (4 sprays/24 hr).

**$\geq 12$  yr to adult:** Start at 2 sprays (64 mCg) in each nostril once daily. When symptoms improve, reduce dose to 1 spray (32 mCg) each nostril once daily. Usual max. dose is 128 mCg/24 hr (4 sprays/24 hr) but some may require 256 mCg/24 hr (8 sprays/24 hr) initially with a subsequent reduced dosage to improve symptoms.

**Crohn disease:**

**Child  $\geq 6$  yr (see remarks):** Data are limited; only the following dosages have been reported. Additional studies are needed.

**Active disease:** 9 mg/24 hr PO once daily or  $\div$  Q8 hr  $\times$  7–8 wk

**Maintenance of remission:** 6 mg PO once daily  $\times$  3–4 wk

In addition, a report in 10–19 yr old children demonstrated higher remission rates with an induction dose of 12 mg PO once daily  $\times$  4 wk, followed by 9 mg PO once daily  $\times$  3 wk, followed by 6 mg PO once daily  $\times$  3 wk.

**Adult:**

**Active disease:** 9 mg PO QAM  $\times$  8 wk; if remission is not achieved, a second 8-wk course may be given.

**Maintenance of remission:** 6 mg PO once daily for up to 3 mo. If symptom control is maintained at 3 mo, taper dosage to compete cessation. Remission therapy beyond 3 mo has not shown to provide substantial clinical benefit.

**Ulcerative colitis, induction of remission (Uceris and generics):**

**Adult:**

**Extended release oral tablet:** 9 mg PO QAM for up to 8 wk

**Rectal foam:** 2 mg PR BID  $\times$  2 wk followed by 2 mg PR once daily  $\times$  4 wk

Reduce maintenance dose to as low as possible to control symptoms. May cause pharyngitis, cough, epistaxis, nasal irritation, and HPA-axis suppression. Rinse mouth after each use via the oral inhalation route. Nebulized budesonide has been shown effective in mild to moderate croup at doses of 2 mg  $\times$  1. Ref: *N Engl J Med.* 331(5):285.

For mild asthma exacerbation in patients with mild/moderate disease, no history of life-threatening exacerbations, and a good asthma self-management plan, limited data in adolescents and adults suggest a temporary quadrupling of the maintenance dosage when asthma control starts to deteriorate. Revert back to baseline maintenance dose after symptoms stabilize or up to a **maximum** of 14 days of the quadrupled dose, whichever comes first. **DO NOT** use this management strategy for children  $< 12$  years of age due to the lack of efficacy and increased risk for decreasing linear growth.

Hypersensitivity reactions, including anaphylaxis, have been reported with the inhaled route.

Anaphylactic reactions, rectal bleeding, peripheral edema, mood swings, increased blood pressure, rash, and benign intracranial hypertension have been reported with oral route of administration.

Safety and effectiveness for mild/moderate Crohn disease have been established for children 8–17 yr old weighing  $\geq 25$  kg. Safety and efficacy have NOT been established in pediatric patients for the maintenance of clinical remission of mild/moderate Crohn disease. Although the reported safety profile in pediatric Crohn disease is consistent with adults, there may be increased risk for decreased growth velocity due to higher systemic absorption of corticosteroids in children with Crohn disease.



## BUDESONIDE *continued*

CYP 450 3A4 inhibitors (e.g., ketoconazole, erythromycin, protease inhibitors) or significant hepatic impairment may increase systemic exposure of budesonide (inhalation and PO routes). Onset of action for oral inhalation and nebulized suspension is within 1 day and 2–8 days, respectively, with peak effects at 1–2 wk and 4–6 wk, respectively.

For nasal use, onset of action is seen after 1 day with peak effects after 3–7 days of therapy.

Discontinue therapy if no improvement in nasal symptoms after 3 wk of continuous therapy.

Pulmicort Flexhaler is a breath-activated device that requires the patient to have an inspiratory flow rate of approximately 60 L/min for optimal drug delivery.

Pregnancy category is “B” for inhalation routes of administration and “C” for the oral and rectal routes.

**Breastfeeding category is “2” for inhalation routes and “?” for the rectal route.** Breastfeeding with the oral route of administration may result in budesonide exposure to the infant up to 10 times higher than that by the inhalation route. **Do not** crush or chew the oral capsule dosage form.

### BUDESONIDE AND FORMOTEROL

Symbicort and generics

**Corticosteroid and long-acting  $\beta_2$  adrenergic agonist**



#### Aerosol inhaler:

80 mCg budesonide + 4.5 mCg formoterol fumarate dihydrate (6.9 g delivers 60 inhalations, 10.2 g delivers approximately 120 inhalations)

160 mCg budesonide + 4.5 mCg formoterol fumarate dihydrate (6 g delivers 60 inhalations, 10.2 g delivers approximately 120 inhalations)

#### Asthma maintenance therapy:

**5–11 yr (NIH Asthma Guideline 2007 recommendations) and 6 to <12 yr (FDA labeling);**

**see remarks:** Two inhalations BID of 80 mCg budesonide + 4.5 mCg formoterol; **max. dose:** 4 inhalations/24 hr

**≥12 yr and adult (see remarks):**

**No prior inhaled steroid use:** Start with two inhalations BID of 80 mCg budesonide + 4.5 mCg formoterol **OR** 160 mCg budesonide + 4.5 mCg formoterol, depending on severity.

**Prior low to medium doses of inhaled steroid use:** Start with two inhalations BID of 80 mCg budesonide + 4.5 mCg formoterol.

**Prior medium to high doses of inhaled steroid use:** Start with two inhalations BID of 160 mCg budesonide + 4.5 mCg formoterol.

**Max. dose:** 2 inhalations of 160 mCg budesonide + 4.5 mCg formoterol BID

See [Budesonide](#) and [Formoterol](#) for remarks. Should only be used for patients not adequately controlled on other asthma-controller medications (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity requires the use of two maintenance therapies. Titrate to the lowest effective strength after asthma is adequately controlled.

Reported side effects at ≥3% and more frequently compared with budesonide alone include URI, pharyngitis, headache, and rhinitis.

As-needed rescue combination low-dose inhaled corticosteroid (ICS) and formoterol is preferred over short-acting beta-agonists (SABA) for adolescent and adult patients with asthma for all asthma severity levels (2022 GINA guidelines; see [www.ginasthma.org/gina-reports](http://www.ginasthma.org/gina-reports) for the latest updates). Significant reduction in ED visits/hospitalizations with PRN ICS-formoterol compared to daily ICS and PRN SABA; and greater reduction in severe asthma exacerbations in adults and adolescents previously taking SABA alone with PRN ICS-formoterol compared with daily ICS and PRN SABA were also reported. **DO NOT** substitute formoterol with a slower onset, long-acting beta-agonist (LABA) such as salmeterol.

*Continued*

BUDESONIDE AND FORMOTEROL *continued*

Proper patient education including dosage administration technique is essential; see patient package insert for detailed instructions. Rinse mouth after each use.

**BUMETANIDE**

Bumex and generics

**Loop diuretic**

C

?

No

Yes

No

**Tabs:** 0.5, 1, 2 mg**Injection:** 0.25 mg/mL (4, 10 mL); some preparations may contain 1% benzyl alcohol**Edema:****Neonate and infant (see remarks):** PO/IM/IV

≤6 mo: 0.01–0.05 mg/kg/dose once daily or every other day

**Infant and child:** PO/IM/IV>6 mo: 0.015–0.1 mg/kg/dose once daily–QID; **max. dose:** 10 mg/24 hr**Adult:****PO:** 0.5–2 mg/dose as a single dose. If needed, repeat dose(s) in 4–5 hour intervals up to two additional doses.**IM/IV:** 0.5–1 mg (over 1–2 min for IV). May give additional doses Q2–3 hr PRN**Max. dose (PO/IM/IV):** 10 mg/24 hr

Cross-allergenicity may occur in patients allergic to sulfonamides. Dosage reduction may be necessary in patients with hepatic dysfunction. Administer oral doses with food.

Side effects include cramps, dizziness, hypotension, headache, electrolyte losses (hypokalemia, hypocalcemia, hyponatremia, hypochloremia), and encephalopathy. May also lead to metabolic alkalosis. Serious skin reactions (e.g., Stevens-Johnson, TEN) have been reported.

Drug elimination has been reported to be slower in neonates with respiratory disorders compared with neonates without. May displace bilirubin in critically ill neonates. **Maximal** diuretic effect for infants ≤6 mo has been reported at 0.04 mg/kg/dose with greater efficacy seen at lower dosages.

**BUTORPHANOL**

Generics; previously available as Stadol

**Narcotic, analgesic**

C

3

Yes

Yes

No

**Injection:** 1 mg/mL (1 mL), 2 mg/mL (1, 2 mL)**Nasal solution:** 10 mg/mL (2.5 mL); 1 mg per spray

**Child (limited data):** 0.01–0.02 mg/kg/dose (**max. dose:** 2 mg/dose) IV Q3–4 hr PRN. Use of a single dose of 0.03 mg/kg IV has been reported in postoperative patients.

**Adult:****IV:** 1 mg/dose Q3–4 hr PRN; usual dosage range: 0.5–2 mg Q3–4 hr PRN**IM:** 2 mg/dose Q3–4 hr PRN; usual dosage range: 1–4 mg Q3–4 hr PRN

**Intranasal:** 1 spray (1 mg) in one nostril × 1; an additional 1 mg dose may be given at 1–1.5 hr if needed. This 2-dose sequence may be repeated in 3–4 hr if needed. Alternatively, the patient may receive 2 mg initially (1 mg in each nostril) only if they remain recumbent if drowsiness or dizziness occurs; an additional dose may be given 3–4 hr later.



BUTORPHANOL *continued*

A synthetic mixed agonist/antagonist opioid analgesic used when alternative treatment options are ineffective or not tolerated. **Contraindicated** in patients hypersensitive to benzethonium chloride. **Use with caution** in hypotension, thyroid dysfunction, renal or hepatic impairment, and concomitant CNS depressants. **Suggested dosage reduction** in renal impairment (IV/IM): 75% of usual dose for GFR 10–50 mL/min and 50% of usual dose for GFR <10 mL/min with an increase in dosage interval based on duration of clinical effects. A 50% IV/IM dosage reduction with increased dosage interval has been recommended in hepatic dysfunction. Reduced dosage for intranasal administration for both renal and hepatic impairment: initial dose should not exceed 1 mg.



Butorphanol is a P450 3A4 substrate. Cytochrome P450 3A4 inhibitors may increase butorphanol's effects and toxicity (fatal respiratory depression).

Common side effects include drowsiness, dizziness, insomnia (nasal spray), nausea, vomiting, nasal congestion (nasal spray). Severe respiratory depression has been reported with use of nasal solutions.

**Onset of action:** 5–10 min (IV); 0.5–1 hr (IM); and within 15 min (intranasal). **Duration:** 3–4 hr (IV/IM) and 4–5 hr (intranasal).

## C

## CAFFEINE CITRATE

Cafcit and generics

**Methylxanthine, respiratory stimulant**



C

2

Yes

Yes

No

**Injection:** 20 mg/mL (3 mL)

**Oral liquid:** 20 mg/mL (3 mL), also available as powder for compounding 10 or 20 mg/mL



20 mg/mL caffeine citrate salt = 10 mg/mL caffeine base

**Doses expressed in mg of caffeine citrate.**

**Apnea of prematurity:**

**Loading dose:** 20–25 mg/kg IV/PO  $\times$  1

**Maintenance dose:** 5–10 mg/kg/dose PO/IV Q24 hr, to begin 24 hr after loading dose



**Avoid** use in symptomatic cardiac arrhythmias. **Do not use** caffeine benzoate formulations in neonates; it has been associated with kernicterus. **Use with caution** in impaired renal or hepatic function; monitor serum concentration to prevent toxicity.



**Therapeutic levels:** 5–25 mg/L. Cardiovascular, neurologic, or GI toxicity reported at serum levels >50 mg/L. Recommended serum sampling time: obtain trough level within 30 min prior to a dose. Steady state is typically achieved 3 wk after initiation of therapy. Levels obtained prior to steady state are useful for preventing toxicity.

For IV administration, give loading dose over 30 min and maintenance dose over 10 min.

## CALCITONIN—SALMON

Miacalcin and generics; previously available as

Fortical and Miacalcin as nasal sprays

**Hypercalcemia antidote, antiosteoporotic**



C

?

No

No

No

**Injection (Miacalcin and generics):** 200 U/mL (2 mL); contains phenol

*Continued*

CALCITONIN—SALMON *continued*

**Nasal spray:** 200 U/metered dose (3.7 mL provides at least 30 doses); may contain benzalkonium chloride or chlorobutanol

**Osteogenesis imperfecta:**

**>6 mo—adolescent:** 2 U/kg/dose IM/SC 3 times per week

**Hypercalcemia (see remarks):**

**Adult:** Start with 4 U/kg/dose IM/SC Q12 hr; if response is unsatisfactory after 1 or 2 days, may increase dose to 8 U/kg/dose Q12 hr. If response remains unsatisfactory after 2 more days, increase to a **max. dose** of 8 U/kg/dose Q6 hr.

**Paget disease (see remarks):**

**Adult:** Start with 100 U IM/SC once daily initially, followed by lower maintenance dose of 50 U 3 times per week if sufficient.

**Contraindicated** in patients sensitive to salmon protein or gelatin. Because of hypersensitivity risk (e.g., bronchospasm, airway swelling, anaphylaxis), skin test is recommended before initiating IM/SC therapy. For skin test, prepare a 10-U/mL dilution with normal saline (NS), administer 0.1 mL intradermally, and observe for 15 min for wheal or significant erythema. Tachyphylaxis has been reported after 2–3 days of use for the treatment of hypercalcemia of malignancy.

Nausea, abdominal pain, diarrhea, flushing, and inflammation/urticaria at the injection site have been reported with IM/SC route of administration. May decrease lithium levels via enhanced urinary clearance. Hypocalcemia and increased risk for malignancies have been reported in a meta-analysis.

Intranasal use currently indicated for postmenopausal osteoporosis in adults. Nasal irritation (alternate nostrils to reduce risk), rhinitis, and epistaxis may occur with the intranasal product. Tremors have been reported with both intranasal and injectable routes of administration. If the injection volume exceeds 2 mL, use IM route and multiple sites of injection.

**CALCITRIOL**

1,25-dihydroxycholecalciferol, Rocaltrol, and generics

**Active form vitamin D, fat soluble**



C



2



No



No



No

**Caps (Rocaltrol and generics):** 0.25, 0.5 mCg; may contain parabens

**Oral solution (Rocaltrol and generics):** 1 mCg/mL (15 mL)

**Injection (generics; previously available as Calcijex):** 1 mCg/mL (1 mL); contains EDTA

**Neonatal hypocalcemia:** 0.25–1 mCg/dose PO once daily

**Hypoparathyroidism (evaluate dosage at 2- to 4-wk intervals and note the different mCg/dose vs. mCg/kg/dose per respective age group below):**

**Child >1 yr and adult:** Initial dose of 0.25 mCg/dose PO once daily. May increase daily dosage by 0.25 mCg at 2- to 4-wk intervals. Usual maintenance dosage as follows:

**<1 yr (limited data):** 0.02–0.06 mCg/kg/dose PO once daily

**1–5 yr:** 0.25–0.75 mCg/dose PO once daily

**>6 yr and adult:** 0.5–2 mCg/dose PO once daily

**Renal failure:** See the National Kidney Foundation guidelines at <https://kdigo.org/guidelines/ckd-mbd/>

Most potent vitamin D metabolite available. Should not be used to treat 25-OH vitamin D deficiency; use cholecalciferol or ergocalciferol. Monitor serum calcium and phosphorus, and parathyroid hormone (PTH) in dialysis patients. **Avoid** concomitant use of Mg<sup>2+</sup>-containing antacids. IV dosing applies if patient is undergoing hemodialysis.

CALCITRIOL *continued*

**Contraindicated** in patients with hypercalcemia or vitamin D toxicity. Side effects include: weakness, headache, vomiting, constipation, hypotonia, polydipsia, polyuria, myalgia, metastatic calcification, etc. Allergic reactions, including anaphylaxis, have been reported. May increase serum creatinine in predialysis patients.

**CALCIUM ACETATE**

Calphron, Phoslyra, and generics; previously available as PhosLo; 25% elemental Ca

**Calcium supplement, phosphorus-lowering agent**



C



2



Yes



No



No

**Tabs (Calphron [OTC] and generics):** 667 mg (169 mg elemental Ca)

**Capsules (Generics; previously available as PhosLo):** 667 mg (169 mg elemental Ca)

**Oral solution (Phoslyra):** 667 mg/5 mL (473 mL) (169 mg elemental Ca per 5 mL); contains methylparabens and propylene glycol

Each 1 g of salt contains 12.7 mEq or 6.34 mmol (250 mg) elemental Ca.

**Doses expressed in mg of calcium acetate.**

**Hyperphosphatemia (see remarks):**

**Child and adolescent:** Start with 667–1000 mg PO with each meal. If needed, dosage may be titrated every 2–4 wk up to the recommended limits from the KDOQI guidelines:

**Calcium intake as phosphate binders:** 1500 mg elemental calcium/24 hr

**Total calcium intake from all sources:** 2000 mg elemental calcium/24 hr

**Adult:** Start with 1334 mg PO with each meal. Dosage may be increased gradually every 2–3 wk to bring serum phosphorus levels below 6 mg/dL, as long as hypercalcemia does not occur. Most patients require 2001–2668 mg PO with each meal.

**Contraindicated** in ventricular fibrillation. **Use with caution** in renal impairment, as hypercalcemia may develop in end-stage renal failure. Nausea and hypercalcemia may occur. Approximately 40% of dose is systemically absorbed under fasting conditions and up to 30% in nonfasting conditions. May reduce absorption of fluoroquinolones, tetracyclines, and iron and effectiveness of polystyrene sulfonate. May potentiate effects of digoxin.

1 g calcium acetate binds to 45 mg phosphorus.

Administer with meals and plenty of fluids for use as a phosphorus-lowering agent. Calcium is excreted in breast milk and is not expected to harm the infant, provided maternal serum calcium is appropriately monitored.

**CALCIUM CARBONATE**

Tums, Children's Pepto, Maalox Children's, and many others including generics; 40% elemental Ca

**Calcium supplement, antacid**



C



2



Yes



No



No

**Tab, chewable [OTC]:** 500, 750, 1000, 1250 mg; may contain aspartame

**Children's Pepto, Maalox Children's [OTC]:** 400 mg

**Tab [OTC]:** 648, 1250, 1500 mg

**Oral suspension [OTC]:** 1250 mg/5 mL (473 mL); may contain parabens

**Powder [OTC]:** 800 mg/2 g (480 g)

Each 1 g of salt contains 20 mEq or 10 mmol (400 mg) elemental Ca.

Some products may be combined with vitamin D; check package labeling.



*Continued*

CALCIUM CARBONATE *continued*

**Hypocalcemia: (Doses expressed in mg of elemental calcium. To convert to mg of salt, divide elemental dose by 0.4.)**

**Neonate:** 50–150 mg/kg/24 hr ÷ Q4–6 hr PO; **max. dose:** 1 g/24 hr

**Child:** 45–65 mg/kg/24 hr PO ÷ QID

**Adult:** 1–2 g/24 hr PO ÷ TID–QID

**Antacid: (Doses expressed in mg of calcium carbonate; chronic use NOT recommended in GERD.)**

**2–5 yr and ≥10.9 kg:** 375–400 mg PO as symptoms occur; **max. dose:** 1500 mg/24 hr

**>6–11 yr:** 750–800 mg PO as symptoms occur; **max. dose:** 3000 mg/24 hr

**>11 yr and adult:** 500–3000 mg PO as symptoms occur; **max. dose:** 7500 mg/24 hr

See [Calcium Acetate](#) for **contraindications, precautions,** and drug interactions. Side effects: constipation, hypercalcemia, hypophosphatemia, hypomagnesemia, nausea, vomiting, headache, and confusion. Some products may contain trace amounts of sodium. Administer with plenty of fluids. For use as a phosphorus-lowering agent, administer with meals. Calcium is excreted in breast milk and is not expected to harm the infant, provided maternal serum calcium is appropriately monitored.

**CALCIUM CHLORIDE**

Various generics; 27% elemental Ca

**Calcium supplement**



C



2



Yes



No



No

**Injection:** 100 mg/mL (10%) (1.36 mEq Ca/mL) (10 mL)

**Prefilled syringe for injection:** 100 mg/mL (10%) (1.36 mEq Ca/mL) (10 mL)

Each 1 g of salt contains 13.6 mEq or 6.8 mmol (273 mg) elemental Ca.

**Doses expressed in mg of calcium chloride.**

**Cardiac arrest or calcium channel blocker toxicity (see remarks):**

**Neonate, infant, and child:** 20 mg/kg/dose (**max. dose:** 1000 mg/dose) IV/IO Q10 min PRN; if effective, an infusion of 20–50 mg/kg/hr may be used

**Adult:** 500–1000 mg/dose IV Q10 min PRN

**MAXIMUM IV ADMINISTRATION RATES (in mg of calcium chloride):**

**IV push:** Do not exceed 100 mg/min (over 10–20 sec in cardiac arrest).

**IV infusion:** Do not exceed 45–90 mg/kg/hr with a **max. concentration** of 20 mg/mL.



**Contraindicated** in ventricular fibrillation. **Not recommended** for asystole and electromechanical dissociation. **Use with caution** in renal impairment, as hypercalcemia may develop in end-stage renal failure. May potentiate effects of digoxin. Routine use in cardiac arrest is NOT recommended due to the lack of improved survival.



**Use IV with extreme caution.** Extravasation may lead to necrosis. Hyaluronidase may be helpful for extravasation. Central line administration is preferred IV route of administration. **Do not use** scalp veins. **Do not administer IM or SC routes.**

Rapid IV infusion associated with bradycardia, hypotension, and peripheral vasodilation. May cause hyperchloremic acidosis.

Calcium is excreted in breast milk and is not expected to harm the infant, provided maternal serum calcium is appropriately monitored.

**CALCIUM CITRATE**

Calcitrate, Citracal Petites, Citracal Maximum Plus, Citracal Gummies, Viactiv Calcium and Bone Strengthening, and generics; 21% elemental Ca

**Calcium supplement**



C



2



Yes



No



No

CALCIUM CITRATE *continued***Tabs:**

**Calcitrate and generics [OTC]:** 950 mg (200 mg elemental Ca)

**Generics [OTC]:** 1040 mg (218 mg elemental Ca)

**Caplets:**

**Citracal Petites [OTC]:** 200 mg elemental Ca and 250 IU vitamin D<sub>3</sub> with 2.5 mg sodium

**Citracal Maximum Plus [OTC]:** 325 mg elemental Ca and 500 IU vitamin D<sub>3</sub> with 2.75 mg zinc, 0.225 mg copper, 0.575 mg manganese, and 2.5 mg sodium

**Some products may be combined with vitamin D; check package labeling.**

**Chewable tabs:**

**Citracal Gummies [OTC]:** 250 mg elemental Ca and 500 IU vitamin D<sub>3</sub> with 105 mg phosphorus and 12.5 mg sodium

**Viactiv Calcium and Bone Strengthening [OTC]:** 650 mg elemental Ca and 500 IU vitamin D<sub>3</sub> with 40 mCg vitamin K, and 10 mg sodium

Each 1 g of salt contains 10.5 mEq or 5.25 mmol (211 mg) elemental Ca.

**Doses expressed as mg of elemental calcium. To convert to mg of salt, divide elemental dose by 0.21.**

**Hypocalcemia:**

**Neonate:** 50–150 mg/kg/24 hr ÷ Q4–6 hr PO; **max. dose:** 1 g/24 hr

**Child:** 45–65 mg/kg/24 hr PO ÷ QID

**Adult:** 1–2 g/24 hr PO ÷ BID–TID

See [Calcium Acetate](#) for **contraindications, precautions,** and drug interactions. Side effects: constipation, hypercalcemia, hypophosphatemia, hypomagnesemia, nausea, vomiting, headache, and confusion.




Administer with meals for use as a phosphorus-lowering agent. For hypocalcemia, do not administer with or before meals/food and take plenty of fluids.

Calcium is excreted in breast milk and is not expected to harm the infant, provided maternal serum calcium is appropriately monitored.

**CALCIUM GLUCONATE**

Cal-Glu and generics, 9.3% elemental Ca

**Calcium supplement**



C

2

Yes

No

No

**Tabs [OTC]:** 50 mg

**Caps (Cal-Glu) [OTC]:** 500 mg

**Injection:** 100 mg/mL (10%) (0.465 mEq Ca/mL) (10, 50, 100 mL); may contain up to 512 mCg aluminum per 1000 mL (0.512 mCg per 100 mg calcium gluconate); see remarks

**Ready to use injection in sodium chloride:** 20 mg/mL (0.093 mEq Ca/mL) (50, 100 mL); contains 0.675% NaCl and may contain up to 100 mCg aluminum per 1000 mL (0.5 mCg per 100 mg calcium gluconate); see remarks

Each 1 g of salt contains 4.65 mEq or 2.33 mmol (93 mg) elemental Ca.

**Doses expressed in mg calcium gluconate.**

**Maintenance/hypocalcemia:**

**Neonate:** IV: 200–800 mg/kg/24 hr ÷ Q6 hr

**Infant:**

**IV:** 200–500 mg/kg/24 hr ÷ Q6 hr

**PO:** 400–800 mg/kg/24 hr ÷ Q6 hr

**Child:** 200–500 mg/kg/24 hr IV or PO ÷ Q6 hr

**Adult:** 0.5–8 g/24 hr IV or PO ÷ Q6 hr

*Continued*

CALCIUM GLUCONATE *continued***For cardiac arrest (see remarks):**

**Infant and child:** 60 mg/kg/dose (**max.** 3000 mg/dose) IV Q10–20 min PRN

**Adult:** 1.5–3 g/dose IV Q10 min PRN

**Max. dose:** 3 g/dose

**For tetany:**

**Neonate, infant, child:** 100–200 mg/kg dose IV over 5–10 min; repeat dose 6 hr later if needed; **max. dose:** 500 mg/kg/24 hr

**Adult:** 0.5–2 g IV over 10–30 min; repeat dose 6 hr later if needed.

**MAXIMUM IV ADMINISTRATION RATES:**

**IV push:** **Do not exceed** 100 mg/min (over 10–20 sec in cardiac arrest).

**IV infusion:** **Do not exceed** 200 mg/min with a **maximum** concentration of 50 mg/mL.

**Contraindicated** in ventricular fibrillation. **Use with caution** in renal impairment, as hypercalcemia may develop in end-stage renal failure. **Avoid** peripheral infusion because extravasation may cause tissue necrosis. IV infusion associated with hypotension and bradycardia. Also associated with arrhythmias in digitalized patients. May reduce absorption of fluoroquinolones, tetracyclines, iron, and effectiveness of polystyrene sulfonate with oral route of administration. Routine use in cardiac arrest is not recommended due to lack of improved survival. Use of calcium chloride IV may be preferred due to its more rapid increase of ionized calcium in critically ill children.



**Do not administer** IV dosage form via scalp veins and the IM or SC routes. IV dosage form may precipitate when mixed with bicarbonate or ceftriaxone. IV dosage form may also contain aluminum (see how-supplied section), and for patients with renal impairment (including premature infants), receipt of >4–5 mCg/kg/24 hr aluminum has been associated with CNS and bone toxicities. Calcium is excreted in breast milk and is not expected to harm the infant, provided maternal serum calcium is appropriately monitored.

**CALCIUM LACTATE**

Cal-Lac and various generics; 13% elemental Ca

**Calcium supplement**



C



2



Yes



No



No

**Tabs [OTC]:** 100, 654 mg

**Caps (Cal-Lac and generics) [OTC]:** 500 mg

Each 1 g salt contains 6.48 mEq or 3.24 mmol (130 mg) elemental Ca.

**Doses expressed in mg of calcium lactate.****Hypocalcemia:**

**Neonate/Infant:** 400–500 mg/kg/24 hr PO ÷ Q4–6 hr

**Child:** 500 mg/kg/24 hr PO ÷ Q6–8 hr

**Adult:** 1.5–3 g PO Q8 hr

**Max. dose:** 9 g/24 hr



See [Calcium Acetate](#) for **contraindications**, **precautions**, and drug interactions. May cause constipation, headache, and hypercalcemia.



Administer with or following meals and with plenty of fluids. **Do not** dissolve tablets in milk.

Calcium is excreted in breast milk and is not expected to harm the infant, provided maternal serum calcium is appropriately monitored.

**CALFACTANT**

See [Surfactant, pulmonary](#).

**CANNABIDIOL**

Epidiolex

**Anticonvulsant**



C



3



No



Yes



No

**Oral solution:** 100 mg/mL (60, 100 mL); contains ethanol and sesame oil

**Lennox-Gastaut syndrome or Dravet syndrome (see remarks for therapy discontinuation):**

**Child ≥2 yr and adult:** Start at 2.5 mg/kg/dose PO BID × 1 wk, dosage may be increased to a maintenance dose of 5 mg/kg/dose PO BID. Dose may be further increased after 1 wk if needed and tolerated at weekly increments of 2.5 mg/kg/dose BID (5 mg/kg/24 hr) up to the **maximum** of 20 mg/kg/24 hr. Those requiring a more rapid titration from 10 mg/kg/24 hr to 20 mg/kg/24 hr may be titrated no more frequently than Q48 hr.

**Dosage reduction in moderate and severe hepatic impairment prior to initiation of therapy (slower dose titration has been suggested):**

**Child-Pugh**

Category for Hepatic Impairment	Initial PO Dose (mg/kg/dose BID)	Maintenance PO Dose (mg/kg/dose BID)	Maximum PO Dose (mg/kg/dose BID)
B (moderate)	1.25	2.5	5
C (severe)	0.5	1	2

Cannabidiol is no longer a controlled substance (FDA: April 6, 2020). Common side effects include somnolence, decreased appetite, diarrhea, elevated transaminase (dose related or with concomitant valproic acid and clobazam use), fatigue, malaise and asthenia, rash, insomnia, and sleep disorder. Suicidal behavior and ideation, hypersensitivity reactions, elevated serum creatinine, respiratory failure, and increase risk for pneumonia with concomitant clobazam have been reported.

Monitor ALT, AST, and total bilirubin at baseline and 1, 3, 6 mo initially and periodically thereafter. More frequent monitoring is recommended with concurrent valproic acid or clobazam. Reduce dose or discontinue use in the presence of hepatic impairment.

Cannabidiol is a substrate for CYP 450 2C19 and 3A4; other moderate/strong inducers or inhibitors for these enzymes may affect its overall exposure. May increase the effects/toxicity of clobazam and diazepam because it may inhibit CYP 450 1A2, 2B6, 2C8, 2C9, and 2C19 and UGT 1A9 and 2B7 transporters. May also inhibit P-glycoprotein transporters to increase effects/toxicity of sirolimus, tacrolimus, digoxin, and other P-glycoprotein substrates.

Teratogen data limited only to animal studies with evidence of developmental toxicities at similar exposure concentrations in humans receiving therapeutic doses. Patients exposed to cannabidiol during pregnancy are encouraged to register with the North American Antiepileptic Drug Pregnancy Registry at [www.aedpregnancyregistry.org](http://www.aedpregnancyregistry.org).

Administration with high-fat or high-calorie meals may increase absorption. Gradually taper when discontinuing medication; **avoid** abrupt discontinuation to reduce risk for increased seizures.

Use the supplied oral dosing syringe and bottle adapter and store the bottle of oral solution in the original bottle in the upright position at 59–86°F. Discard the unused portion of each bottle 12 wk after first opening.

**CAPTOPRIL**

Various generics; previously available as Capoten

**Angiotensin-converting enzyme inhibitor,  
antihypertensive**

D



1



Yes



No



No

**Tabs:** 12.5, 25, 50, 100 mg**Oral suspension:** 1 mg/mL **Hypertension:****Neonate:** 0.01–0.05 mg/kg/dose PO Q8–12 hr**Infant:** Initially 0.05–0.3 mg/kg/dose PO BID–TID; titrate upward if needed; **max. dose:** 6 mg/kg/24 hr**Child:** Initially, 0.3–0.5 mg/kg/dose PO BID–TID; titrate upward if needed; **max. dose:** 6 mg/kg/24 hr up to 450 mg/24 hr**Adolescent and adult:** Initially, 12.5–25 mg/dose PO BID–TID; increase weekly if necessary by 25 mg/dose to **max. dose:** 450 mg/24 hr. Usual dosage range: 25–100 mg/24 hr ÷ BID

Onset within 15–30 min of administration. Peak effect within 1–2 hr. **Adjust dose with renal failure (see Chapter 31).** Should be administered on an empty stomach 1 hr before or 2 hr after meals. Titrate to minimal effective dose. Lower doses should be used in patients with sodium and water depletion because of diuretic therapy.



**Use with caution** in collagen vascular disease and concomitant potassium-sparing diuretics. **Avoid use** with dialysis with high-flux membranes as anaphylactoid reactions have been reported. May cause rash, proteinuria, neutropenia, cough, angioedema (head, neck, and intestine), hyperkalemia, hypotension, or diminution of taste perception (with long-term use). Known to decrease aldosterone and increase renin production. **Do not** coadminister with angiotensin receptor blockers or aliskiren as use has been associated with increased risks for hypotension, hyperkalemia, and acute renal failure. Captopril is a CYP 450 2D6 substrate. Use with sirolimus, everolimus, temsirolimus, or sacubitril may increase risk for angioedema.

Captopril should be discontinued as soon as possible when pregnancy is detected.

**CARBAMAZEPINE**

Epitol, Tegretol, Tegretol-XR, Carbatrol, Equetro, and various generics

**Anticonvulsant**

D



2



Yes



Yes



Yes

**Tabs:** 200 mg**Chewable tabs:** 100 mg**Extended release tabs (Tegretol-XR and generics):** 100, 200, 400 mg**Extended release caps (Carbatrol, Equetro, and generics):** 100, 200, 300 mg**Oral suspension:** 100 mg/5 mL (450 mL); may contain propylene glycol**Seizures (see remarks regarding specific dosage form dosing interval and pharmacogenomic considerations):****<6 yr:****Initial:** 10–20 mg/kg/24 hr PO ÷ BID–TID (QID for oral suspension)**Increment:** Q5–7 days up to **max. dose** of 35 mg/kg/24 hr PO**6–12 yr:****Initial:** 10 mg/kg/24 hr PO ÷ BID (QID for oral suspension) up to **max. dose:** 100 mg/dose BID (50 mg/dose QID for oral suspension)

CARBAMAZEPINE *continued*

**Increment:** 100 mg/24 hr at 1-wk intervals ( $\div$  TID—QID) until desired response is obtained

**Maintenance:** 20–30 mg/kg/24 hr PO  $\div$  BID–QID; usual maintenance dose is 400–800 mg/24 hr;

**max. dose:** 1000 mg/24 hr

**>12 yr and adult:**

**Initial:** 200 mg PO BID (100 mg/dose QID for oral suspension)

**Increment:** 200 mg/24 hr at 1-wk intervals ( $\div$  BID–QID) until desired response is obtained

**Maintenance:** 800–1200 mg/24 hr PO  $\div$  BID—QID

**Max. dose:**

**Child 12–15 yr:** 1000 mg/24 hr

**Child >15 yr:** 1200 mg/24 hr

**Adult:** 1.6–2.4 g/24 hr

**Contraindicated** for patients taking monoamine oxidase (MAO) inhibitors or who are sensitive to tricyclic antidepressants. Should not be used in combination with clozapine, owing to increased risk for bone marrow suppression and agranulocytosis. Increased risk for severe dermatologic reactions (e.g., Stevens-Johnson syndrome [SJS] and toxic epidermal necrolysis [TEN]) has been associated with the HLA-B\*1502 (prevalent among Asian descent) and HLA-A\*3101 (prevalent among Japanese, Native American, Southern Indian, and some Arabic ancestry) alleles.



Erythromycin, diltiazem, verapamil, cefixime, cimetidine, itraconazole, aprepitant, and INH may increase serum levels. Carbamazepine may decrease activity of warfarin, direct-acting oral anticoagulants (e.g., rivaroxaban, apixaban), doxycycline, oral contraceptives, cyclosporine, theophylline, phenytoin, benzodiazepines, ethosuximide, and valproic acid. Carbamazepine is a CYP 450 3A3/4 substrate and inducer of CYP 450 1A2, 2C, and 3A3/4. The enzyme-inducing effects may increase effects/toxicity of cyclophosphamide. CYP 450 3A4 inhibitors may increase carbamazepine levels/toxicity.

Suggested dosing intervals for specific dosage forms: extended release tabs or caps (BID); chewable and immediate release tabs (BID—TID); oral suspension (TID—QID).

Doses may be administered with food. **Do not** crush or chew extended release dosage forms. Shake bottle well prior to dispensing oral suspension dosage form, and **do not** administer simultaneously with other liquid medicines or diluents.

Drug metabolism typically increases after the first month of therapy initiation due to hepatic autoinduction.

Therapeutic blood levels for seizures: 4–12 mg/L. Recommended serum sampling time: obtain trough level within 30 min prior to an oral dose. Steady state is typically achieved 1 mo following the initiation of therapy (following enzymatic autoinduction). Levels obtained prior to steady state are useful for preventing toxicity. Blood trough levels of 7–10 mg/L have been recommended for bipolar disorders.

Side effects include sedation, dizziness, diplopia, aplastic anemia, neutropenia, urinary retention, nausea, SIADH, and SJS. Suicidal behavior or ideation, hypogammaglobulinemia, and onychomadesis have been reported. Approximately one-third of patients who had hypersensitivity reactions will also experience the hypersensitivity to oxcarbazepine. Pretreatment complete blood counts (CBCs) and liver function tests (LFTs) are suggested. Patient should be monitored for hematologic and hepatic toxicity. Most common side effects with the IV route: dizziness, somnolence, blurred vision, diplopia, headache, infusion-related reaction, infusion site pain, and anemia.

**Adjust dose in renal impairment (see Chapter 31).**

**CARBAMIDE PEROXIDE**

Otic solution: Debrox, Auraphene-B, Clearcanal  
Earwax Softener, GoodSense Ear Wax Removal,  
and many generic products

Oral liquid: Gly-Oxide

***Cerumenolytic, topical oral analgesic***



?



1



No



No



No

**Otic solution (OTC):** 6.5% (15 mL); may contain propylene glycol or alcohol

**Oral liquid (OTC):** 10% (Gly-Oxide) (15 mL)

**Cerumenolytic:**

**<12 yr:** Tilt head sideways and instill 1–5 drops (according to patient size) into affected ear; retain drops in ear for several minutes. Remove wax by gently flushing the ear with warm water, using a soft rubber bulb ear syringe. Dose may be repeated BID PRN for up to 4 days.

**≥12 yr:** Following the same instructions as aforementioned, instill 5–10 drops into affected ear BID PRN for up to 4 days.

**Oral analgesic (see remarks):**

**≥2 yr (able to follow instructions):** Instill several drops of the oral liquid to affected area and expectorate after 2–3 min, *OR* place 10 drops on tongue and mix with saliva, swish for several minutes, and expectorate. Administer up to QID, after meals and QHS, for **up to 7 days**.

**Otic solution:** Contraindicated if tympanic membrane perforated; following otic surgery; ear discharge, drainage, pain, irritation, or rash; or PE tubes in place. Tip of applicator should not enter ear canal when used as a cerumenolytic.

**Oral liquid:** Prolonged use may result in fungal overgrowth. **Do not** rinse the mouth or drink for at least 5 min when using oral preparation.

Pregnancy category has not been formally assigned by the FDA.

**CARBINOXAMINE**

Karbinal ER, RyVent, and many generics

***Antihistamine***



C



3



No



No



No

**Oral liquid:** 4 mg/5 mL (118 mL); may contain propylene glycol

**Extended release oral suspension (Karbinal ER):** 4 mg/5 mL (480 mL); contains parabens and metasulfite

**Tabs:** 4, 6 mg

RyVent: 6 mg

**Child (PO; see remarks):**

**Immediate release dosage forms:** 0.2–0.4 mg/kg/24 hr PO ÷ TID–QID; alternative dosing by age (**do not exceed** 0.4 mg/kg/24 hr):

**2–5 yr:** 1–2 mg TID–QID

**6–11 yr:** 2–4 mg TID–QID

**≥12 yr:** 4–8 mg TID–QID

**Extended release oral suspension (Karbinal ER; approximately 0.2–0.4 mg/kg/24 hr):**

**2–3 yr:** 3–4 mg Q12 hr

**4–5 yr:** 3–8 mg Q12 hr

**6–11 yr:** 6–12 mg Q12 hr

**≥12 yr:** 6–16 mg Q12 hr

CARBINOXAMINE *continued***Adult (PO):**

**Immediate release dosage forms:** 4–8 mg TID–QID

**Extended release oral suspension (Karbinal ER):** 6–16 mg Q12 hr

Generally not recommended for treating upper respiratory tract infections (URIs) for infants.

No proven benefit for infants and young children with URIs. **The FDA does not recommend use for URIs in children <2 yr because of reports of increased fatalities.** Karbinal ER use is **contraindicated** in children <2 yr and in nursing mothers.

**Contraindicated** in acute asthma, hypersensitivity with other ethanolamine antihistamines, MAO inhibitors (prolongs and intensifies anticholinergic effects), severe hypertension, narrow-angle glaucoma, severe coronary artery disease, and urinary retention. Be aware that combination products containing a decongestant may exist.

May cause drowsiness, vertigo, dry mucus membranes, and headache. Paradoxical excitation reactions more likely in younger children. Contact dermatitis and CNS excitation have been reported.

**CARNITINE**

Levocarnitine, Carnitor, Carnitor SF, L-Carnitine, and generics

**Nutritional supplement, amino acid**



B



?



Yes



No



No

**Tabs (Carnitor and generics):** 330 mg

**Caps:** 250 mg

**Oral solution:** 100 mg/mL (118 mL); contains methylparabens and propylparabens; Carnitor SF is a sugar-free product

**Injection:** 200 mg/mL (5 mL); preservative free

**Primary carnitine deficiency:****Oral:**

**Child:** 50–100 mg/kg/24 hr PO ÷ Q8–12 hr; increase slowly as needed and tolerated to **max. dose** of 3 g/24 hr

**Adult:** 330 mg to 1 g/dose BID–TID PO; **max. dose:** 3 g/24 hr

**Secondary carnitine deficiency:****IV:**

**Child and adult:** 50 mg/kg as loading dose; may follow with 50 mg/kg/24 hr IV infusion (for severe cases); maintenance: 50 mg/kg/24 hr ÷ Q4–6 hr; increase to **max. dose** of 300 mg/kg/24 hr if needed

May cause nausea, vomiting, abdominal cramps, diarrhea, and body odor. Seizures have been reported in patients with or without a history of seizures.

Safety in end-stage renal disease (ESRD) has not been established. High doses to severely compromised renal function or ESRD on dialysis may result in accumulation of potentially toxic metabolites (trimethylamine and trimethylamine-*N*-oxide). Serious hypersensitivity reactions, including anaphylaxis, have been reported with IV use mostly in ESRD patients undergoing dialysis. Give bolus IV infusion over 2–3 min.

**CARVEDILOL**

Coreg, Coreg CR, and generics

**Adrenergic antagonist ( $\alpha$  and  $\beta$ ), antihypertensive**



C



?



Yes



Yes



No

Continued

CARVEDILOL *continued*

**Tabs:** 3.125, 6.25, 12.5, 25 mg

**Extended release caps (Coreg CR and generics):** 10, 20, 40, 80 mg

**Oral suspension:** 0.1, 1.25, 1.67 mg/mL 

**Heart failure:**

**Immediate release dosage forms (tablets and oral suspension; see remarks):**

**Infant, child, adolescent (2013 Canadian Cardiovascular Society Guidelines):**

**<62.5 kg:** Start at 0.1 mg/kg/24 hr PO ÷ Q12 hr. Dose may be doubled every 2 wk if needed and tolerated up to 0.8–1 mg/kg/24 hr ÷ Q12 hr. Due to altered pharmacokinetics divide daily dosage by Q8 hr if child is <4 yr old.

**≥62.5 kg:** Start at 3.125 mg PO BID. Dose may be doubled every 2 wk if needed and tolerated up to 25 mg BID. 25 mg PO TID may be needed for patients weighing >75 kg.

**Adult:** Start at 3.125 mg PO BID × 2 wk; if needed and tolerated, may increase to 6.25 mg BID. Dose may be doubled every 2 wk if needed to the following **max. doses:**

**<85 kg:** 25 mg BID

**≥85 kg:** 50 mg BID

**Extended release capsules:**

**Adult:** Start at 10 mg PO once daily × 2 wk; if needed and tolerated, double the dose every 2 wk up to the **maximum** of 80 mg once daily.

**Hypertension:**

**Adult:**

**Immediate release dosage forms:** Start at 6.25 mg PO BID; dose may be doubled every 1–2 wk up to a **maximum** of 25 mg PO BID.

**Extended release capsules:** Start at 20 mg PO once daily × 1–2 wk; if needed and tolerated, increase to 40 mg PO once daily. If needed, dose may be further increased in 2-wk intervals up to a **maximum** of 80 mg/24 hr.

Immediate release and extended release products are NOT interchangeable on a mg-to-mg basis. **Contraindicated** in asthma or related bronchospastic disease, sick sinus syndrome, 2nd- or 3rd-degree heart block, severe bradycardia, cardiogenic shock, decompensated cardiac failure requiring IV inotropic therapy, and severe hepatic impairment (Child-Pugh class C).

**Use with caution** mild/moderate hepatic impairment (Child-Pugh class A or B), renal insufficiency, thyrotoxicosis, ischemic heart disease, diabetes, and cataract surgery. **Avoid abrupt withdrawal** of medication.

Children <3½ yr old may have faster carvedilol clearance and may require higher dosages or TID dosing. Carvedilol is a CYP 450 2D6 substrate. Digoxin, disopyramide, and dipyridamole may increase bradycardic effects.

Bradycardia, postural hypotension, peripheral edema, weight gain, hyperglycemia, diarrhea, dizziness, and fatigue are common. Hypersensitivity reactions have been reported. Chest pain, headache, vomiting, edema, and dyspnea have also been reported in children. Administering doses with food can reduce risk for orthostatic hypotension.

**CASPOFUNGIN**

Cancidas and generics

**Antifungal, echinocandin**



C



?



No



Yes



No

**Injection:** 50, 70 mg; contains sucrose (39 mg in 50 mg vial and 54 mg in 70 mg vial) and mannitol (26 mg in 50 mg vial and 36 mg in 70 mg vial)

CASPOFUNGIN *continued***Preterm neonate to <3 mo infant:**

**BSA dosing (based on a small pharmacokinetic study, achieving similar plasma exposure as seen in adults receiving 50 mg/24 hr):** 25 mg/m<sup>2</sup>/dose IV once daily

**Weight-based dosing (based on prospective, randomized, double-blinded, controlled, and case series data):** 2 mg/kg/dose IV once daily for at least 2 wk after first negative blood culture and resolution of signs/symptoms for invasive candidiasis has been reported to be more efficacious with fewer side effects than conventional amphotericin B.

**3 mo infant—17 yr (see remarks):** 70 mg/m<sup>2</sup>/dose IV loading dose on day 1 followed by 50 mg/m<sup>2</sup>/dose IV once-daily maintenance dose. Increase the maintenance dose to 70 mg/m<sup>2</sup>/dose if response is inadequate or if the patient is receiving an enzyme-inducing medication (see remarks).

**Maximum loading and maintenance dose:** 70 mg/dose

**Adult (see remarks):**

**Loading dose:** 70 mg IV × 1

**Maintenance dose:**

**Usual:** 50 mg IV once daily. If tolerated and response is inadequate or if patient is receiving an enzyme-inducing medication (see remarks), increase to 70 mg IV once daily.

**Moderate hepatic insufficiency (Child-Pugh score 7—9):** 35 mg IV once daily is recommended in the FDA label. However, several pharmacokinetic evaluations suggest the reduced dosage may result in subtherapeutic levels for these patients.

**Use with caution** in hepatic impairment and concomitant enzyme-inducing drugs. Higher maintenance doses (70 mg/m<sup>2</sup>/dose [not to exceed 70 mg] in children and 70 mg in adults) are recommended for concomitant use of enzyme inducers such as carbamazepine, dexamethasone, phenytoin, nevirapine, efavirenz, or rifampin. Use Mosteller formula for calculating body surface area (BSA).

Most common adverse effects (>10%) in children include fever, diarrhea, rash, elevated aspartate transaminase/alanine transaminase (ALT/AST), hypokalemia, hypotension, and chills. May also cause facial swelling, nausea/vomiting, headache, infusion site phlebitis, and LFT elevation. Anaphylaxis, TEN, SJS, and possible histamine-related reactions (angioedema, bronchospasm, and warmth sensation) have been reported. Hepatobiliary adverse effects have been reported in pediatric patients with serious underlying medical conditions.

Despite the FDA labeling recommendation for reducing the daily maintenance dose by 30% in moderate hepatic impairment (Child-Pugh score 7—9), several pharmacokinetic evaluations suggest this dose reduction may result in subtherapeutic levels.

Use with cyclosporine may cause transient increase in LFTs and caspofungin level elevations. May decrease tacrolimus levels.

Administer doses by slow IV infusion over 1 hr. **Do not** mix or co-infuse with other medications, and **avoid** using dextrose-containing diluents (e.g., D<sub>5</sub>W).

**CEFACLOR**

Generics; previously available as Ceclor

**Antibiotic, cephalosporin (second generation)**



B



1



Yes



No



No

**Caps:** 250, 500 mg

**Extended release tabs:** 500 mg

**Oral suspension:** 125 mg/5 mL (150 mL); 250 mg/5 mL (150 mL); 375 mg/5 mL (100 mL)

**Child >1 mo old (use regular release dosage forms):** 20—40 mg/kg/24 hr PO ÷ Q8 hr;  
**max. dose:** 1 g/24 hr

**Q12 hr dosage interval option for pharyngitis (use oral suspension dosage form):** 20 mg/kg/24 hr  
PO ÷ Q12 hr; **max. dose:** 1 g/24 hr

*Continued*

CEFACLOR *continued***Adult:** 250–500 mg/dose PO Q8 hr**Extended release tablets:** 500 mg/dose PO Q12 hr

Not recommended for otitis media or pharyngitis/tonsillitis. **Use with caution** in patients with penicillin allergy or renal impairment. Side effects include elevated LFTs, bone marrow suppression, and moniliasis. Probenecid may increase cefaclor concentrations. May cause positive Coombs test or false-positive test for urinary glucose (e.g., Clinitest, Benedict's solution, or Fehling's solution). Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended. Serum sickness reactions have been reported in patients receiving multiple courses of cefaclor.



**Do not crush, cut, or chew** extended release tablets. Doses should be given on an empty stomach.

**Extended release tablets not recommended for children. Adjust dose in renal failure (see Chapter 31).**

**CEFADROXIL**

Generics; previously available as Duricef

**Antibiotic, cephalosporin (first generation)**

B



1



Yes



No



No

**Oral suspension:** 250 mg/5 mL (100 mL), 500 mg/5 mL (75, 100 mL)**Tabs:** 1 g**Caps:** 500 mg**Infant and child:** 30 mg/kg/24 hr PO ÷ Q12 hr; **max. dose:** 2 g/24 hr

**Group A β-hemolytic streptococci pharyngitis/tonsillitis:** 30 mg/kg/24 hr PO ÷ Q12–24 hr; **max. dose:** 1 g/24 hr



**Adolescent and adult:** 1–2 g/24 hr PO ÷ Q12–24 hr (administer Q12 hr for complicated UTIs); **max. dose:** 2 g/24 hr

**Group A β-hemolytic streptococci pharyngitis/tonsillitis:** 1 g /24 hr PO ÷ Q12–24 hr; **max. dose:** 1 g/24 hr

See **Cephalexin** for **precautions** and interactions. Rash, nausea, vomiting, and diarrhea are common. Transient neutropenia and vaginitis have been reported. **Adjust dose in renal failure (see Chapter 31).**

**CEFAZOLIN**

Generics; previously available as Ancef

**Antibiotic, cephalosporin (first generation)**

B



1



Yes



Yes



No

**Injection:** 0.5, 1, 10, 100 g

**Frozen injection:** 1 g/50 mL (contains 2 g dextrose to make an iso-osmotic solution), 2 g/100 mL (contains 4 g dextrose to make an iso-osmotic solution)

Contains 2.1 mEq Na/g drug

**Neonate (IM/IV):****Postnatal age ≤7 days:**

≤2000 g: 50 mg/kg/24 hr ÷ Q12 hr

&gt;2000 g: 100 mg/kg/24 hr ÷ Q12 hr

**Postnatal age >7–28 days:**

≤2000 g: 75 mg/kg/24 hr ÷ Q8 hr

&gt;2000 g: 150 mg/kg/24 hr ÷ Q8 hr

**Infant >1 mo and child (IM/IV):****Mild/moderate infection:** 25–100 mg/kg/24 hr ÷ Q6–8 hr; **max. dose:** 6 g/24 hr

CEFAZOLIN *continued*

**Severe infection:** 100–150 mg/kg/24 hr ÷ Q6–8 hr (**max. dose:** 12 g/24 hr); 150 mg/kg/24 hr ÷ Q6–8 hr has been recommended for bone/joint infections

**Adult:** 1–2 g/dose Q8 hr IV/IM; **max. dose:** 12 g/24 hr

**Bacterial endocarditis prophylaxis for dental and upper respiratory procedures:**

**Infant and child:** 50 mg/kg IV/IM (**max. dose:** 1 g) 30–60 min before procedure

**Adult:** 1 g IV/IM 30–60 min before procedure

**Use with caution** in renal impairment or in penicillin-allergic patients. Does not penetrate well into cerebrospinal fluid (CSF). May cause phlebitis, leukopenia, thrombocytopenia, transient liver enzyme elevation, and false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution) and Coombs test. Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended.

For dosing in obese patients, use higher end of the dosing recommendation. **Adjust dose in renal failure (see Chapter 31).**

**CEFDINIR**

Generics; previously available as Omnicef

**Antibiotic, cephalosporin (third generation)**



B



1



Yes



Yes



No

**Caps:** 300 mg

**Oral suspension:** 125 mg/5 mL (60, 100 mL), 250 mg/5 mL (60, 100 mL)

**6 mo–12 yr:**

**Otitis media, sinusitis (not recommended as empiric monotherapy), pharyngitis/tonsillitis:**

14 mg/kg/24 hr PO ÷ Q12–24 hr; **max. dose:** 600 mg/24 hr

**Uncomplicated skin infections (see remarks):** 14 mg/kg/24 hr PO ÷ Q12 hr; **max. dose:** 600 mg/24 hr

**≥13 yr and adult:**

**Bronchitis, sinusitis, pharyngitis/tonsillitis:** 600 mg/24 hr PO ÷ Q12–24 hr

**Community-acquired pneumonia, UTI, uncomplicated skin infections (see remarks):** 600 mg/24 hr PO ÷ Q12 hr



**Use with caution** in penicillin-allergic patients or in presence of renal impairment. Good Gram-positive cocci activity but may be inadequate for penicillin-resistant pneumococci. May cause diarrhea (especially in children <2 yr), headache, vaginitis, and false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution) and Coombs test. Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended. Eosinophilia and abnormal LFTs have been reported with higher-than-usual doses.

Once-daily dosing has not been evaluated in pneumonia and skin infections. Probenecid increases serum cefdinir levels. **Avoid** concomitant administration with iron and iron-containing vitamins and antacids containing aluminum or magnesium (space 2 hr apart) to reduce the risk for decreasing antibiotic's absorption. May cause red stools when administered with iron and iron-containing products. Doses may be taken without regard to food. **Adjust dose in renal failure (see Chapter 31).**

**CEFEPIME**

Generics; previously available as Maxipime

**Antibiotic, cephalosporin (fourth generation)**



B



1



Yes



Yes



No

**Injection:** 0.5, 1, 2, 100 g

**Premixed injection:** 1 g/50 mL, 2 g/100 mL (iso-osmotic dextrose solutions)

Each 1 g drug contains 725 mg L-arginine.

*Continued*

CEFEPIME *continued***Neonate (IV/IM):****<14 days old:** 60 mg/kg/24 hr ÷ Q12 hr**≥14 days old:** 100 mg/kg/24 hr ÷ Q12 hr**Meningitis or *Pseudomonas* infections:****<1 kg and 0–14 days old, or 1–2 kg and <0–7 days old:** 100 mg/kg/24 hr ÷ Q12 hr**<1 kg and >14 days old, or 1–2 kg and >7 days old, or >2 kg and 0–30 days old:** 150 mg/kg/24 hr ÷ Q8 hr**Child ≥2 mo (IV/IM):** 100 mg/kg/24 hr ÷ Q12 hr; **max. dose:** 4 g/24 hr**Meningitis, fever, and neutropenia, or serious infections:** 150 mg/kg/24 hr ÷ Q8 hr; **max. dose:** 2 g/single dose or 6 g/24 hr**Cystic fibrosis:** 150 mg/kg/24 hr ÷ Q8 hr IV/IM, up to a **max. dose** of 6 g/24 hr. Higher dose of 200 mg/kg/24 hr ÷ Q6 hr (**max. dose:** 8 g/24 hr) has been recommended for resistant *Pseudomonas* isolates.**Adult:** 1–4 g/24 hr ÷ Q12 hr IV/IM**Severe infections:** 6 g/24 hr ÷ Q8 hr IV/IM**Max. dose:** 6 g/24 hr**Use with caution** in patients with penicillin allergy or renal impairment. Good activity against *Pseudomonas aeruginosa* and other Gram-negative bacteria plus most Gram-positives (methicillin-sensitive *Staphylococcus aureus*). Extended/continuous infusion administration is an option for treating resistant isolates.May cause thrombophlebitis, GI discomfort, transient increases in liver enzymes, and false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution) and Coombs test. Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended. Probenecid increases serum cefepime levels. Encephalopathy, myoclonus, seizures (including nonconvulsive status epilepticus), aphasia, transient leukopenia, neutropenia, agranulocytosis, and thrombocytopenia have been reported. Reported neurotoxicity (e.g., encephalopathy, aphasia, myoclonus, and seizures) may be attributed to cefepime's concentration-dependent GABA inhibitory effects. **Adjust dose in renal failure (see Chapter 31).****CEFIDEROCOL**

Fetroja

**Antibiotic, cephalosporin (siderophore type)**

?



1



Yes



Yes



No

**Injection:** 1 g; contains sucrose

Contains 3.7 mEq Na/g drug

**Infant <3 mo (limited data based on pharmacokinetic allometric scaling techniques to replicate similar adult exposure levels; infuse doses IV over 1 hr):****<2 mo:****<32 wk gestation:** 30 mg/kg/dose IV Q8 hr**≥32 wk gestation:** 40 mg/kg/dose IV Q8 hr**2–<3 mo:****<32 wk gestation:** 40 mg/kg/dose IV Q8 hr**≥32 wk gestation:** 60 mg/kg/dose IV Q8 hr**Child 3 mo–<18 yr (current dosage being evaluated in clinical trials for suspected or confirmed Gram-negative bacterial infections; infuse doses IV over 3 hr):****<34 kg:** 60 mg/kg/dose IV Q8 hr**≥34 kg:** 2 g IV Q8 hr

CEFIDEROCOL *continued***Adult:**

**Hospital-acquired pneumonia, ventilator-associated pneumonia, and UTI (infuse doses IV over 3 hr):** 2 g IV Q8 hr

Possesses a unique mechanism of action for having a catechol side chain that chelates with iron to enable iron transport systems to deliver cefiderocol to the outer membrane of Gram-negative aerobic bacteria. Its cephalosporin moiety then exerts its bactericidal properties by binding to penicillin-binding proteins.

**Use with caution** in penicillin, cephalosporin, or beta-lactam allergic patients or in the presence of renal impairment (**adjust dose in renal failure; see Chapter 31**). Common side effects include injection site reaction, rash, increased LFTs, hypokalemia, diarrhea, constipation, GI disturbance, and headache. Hypomagnesemia, hypersensitivity reactions, atrial fibrillation, seizures, and increase in mortality in patients with carbapenem-resistant Gram-negative bacterial infections have been reported in adults. May cause false-positive results for urine dipstick tests (urine protein, ketones, or occult blood) and Coombs test.

**CEFIXIME**

Suprax and generics

**Antibiotic, cephalosporin (third generation)**

**Oral suspension:** 100 mg/5 mL (50 mL), 200 mg/5 mL (50, 75 mL), 500 mg/5 mL (10, 20 mL); may contain sodium benzoate

**Chewable tabs:** 100, 200 mg; contain aspartame

**Caps:** 400 mg

**Infant (>6 mo) and child:** 8 mg/kg/24 hr ÷ Q12–24 hr PO; **max. dose:** 400 mg/24 hr

**Alternative dosing for acute UTI:** 16 mg/kg/24 hr ÷ Q12 hr on day 1, followed by 8 mg/kg/24 hr Q24 hr PO × 13 days. **Max. dose:** 400 mg/24 hr

**Adolescent and adult:** 400 mg/24 hr ÷ Q12–24 hr PO

**Uncomplicated cervical, urethral, or rectal infections due to *Neisseria gonorrhoeae* (not recommended as first-line cephalosporin by the CDC; ceftriaxone is preferred, use only when ceftriaxone is not available):** 800 mg × 1 PO plus doxycycline 100 mg PO BID × 7 days

**Use with caution** in patients with penicillin allergy or renal failure. Adverse reactions include diarrhea (16% incidence reported in clinical trials), abdominal pain, nausea, and headaches. Transient increase in AST/ALT has been reported. Activity is inadequate against penicillin-resistant pneumococci.

Because of reduced bioavailability, do not use tablets for the treatment of otitis media. Probenecid increases serum cefixime levels. Unlike most cephalosporins, drug is excreted unchanged in the bile (5%–10%) and urine (50%). May increase carbamazepine serum concentrations. May cause false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution), Coombs test, and nitroprusside test for ketones. Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended. **Adjust dose in renal failure (see Chapter 31).**

**CEFOTAXIME**

Generics; previously available as Claforan

**Antibiotic, cephalosporin (third generation)**

**Injection:** 1, 2 g

Contains 2.2 mEq Na/g drug

*Continued*

CEFOTAXIME *continued***Neonate, IV/IM:****Postnatal age ≤7 days (all weights):** 100 mg/kg/24 hr ÷ Q12 hr**Postnatal age 8–28 days:**

&lt;1000 g:

8–14 days postnatal: 100 mg/kg/24 hr ÷ Q12 hr

15–28 days postnatal: 150 mg/kg/24 hr ÷ Q8 hr

≥1000 g: 150 mg/kg/24 hr ÷ Q8 hr

**Meningitis (minimum 21 days of therapy):****Postnatal age ≤7 days and ≥2 kg:** 100–150 mg/kg/24 hr ÷ Q8–12 hr**Postnatal age >7 days and ≥2 kg:** 150–200 mg/kg/24 hr ÷ Q6–8 hr**Infant and child (1 mo–12 yr and <50 kg):** 150–200 mg/kg/24 hr ÷ Q6–8 hr IV/IM. Higher doses of 150–225 mg/kg/24 hr ÷ Q6–8 hr have been recommended for infections outside the CSF due to penicillin-resistant pneumococci.**Meningitis:** 200 mg/kg/24 hr ÷ Q6 hr IV/IM. Higher doses of 225–300 mg/kg/24 hr ÷ Q6–8 hr (some recommend 300 mg/kg/24 hr ÷ Q4–6 hr), in combination with vancomycin (dosed at CNS target levels), have been recommended for meningitis due to penicillin-resistant pneumococci.**Max. dose:** 12 g/24 hr**Child (>12 yr or ≥50 kg) and adult:** 1–2 g/dose Q6–8 hr IV/IM**Severe infection:** 2 g/dose Q4–6 hr IV/IM**Max. dose:** 12 g/24 hr**Use with caution** in penicillin allergy and renal impairment (reduce dosage). Toxicities similar to other cephalosporins: allergy, neutropenia, thrombocytopenia, eosinophilia, false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution) and Coombs test, elevated BUN, creatinine, and liver enzymes. Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended. Probenecid increases serum cefotaxime levels. Good CNS penetration. **Adjust dose in renal failure (see Chapter 31).****CEFOTETAN**

Generics; previously available as Cefotan

**Antibiotic, cephalosporin (second generation)**

B



1



Yes



Yes



No

**Injection:** 1, 2 g

Contains 3.5 mEq Na/g drug

**Infant and child (IV/IM, limited data):****Mild/moderate infection:** 60 mg/kg/24 hr ÷ Q12 hr; **max. single dose:** 2 g/dose**Severe infection:** 100 mg/kg/24 hr ÷ Q12 hr; **max. single dose:** 2–3 g/dose**Intra-abdominal infection:** 40–80 mg/kg/24 hr ÷ Q12 hr; **max. dose:** 6 g/24 hr**Adolescent and adult:** 2–4 g/24 hr ÷ Q12 hr IV/IM; **max. dose:** 6 g/24 hr**PID:** 2 g Q12 hr IV × 24–48 hr after clinical improvement. Doxycycline 100 mg Q12 hr PO/IV × 14 days is also initiated at the same time.**Max. dose (all ages):** 6 g/24 hr**Preoperative prophylaxis (30–60 min before procedure; may repeat dose in 6 hr if lengthy procedure or excessive blood loss):****Child:** 40 mg/kg/dose (**max. dose:** 2 g/dose) IV**Adult:** 1–2 g IV**Use with caution** in penicillin-allergic patients or in presence of renal impairment. May cause disulfiram-like reaction with ethanol and increase effects/toxicities of anticoagulants,


CEFOTETAN *continued*

false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution), and false elevations of serum and urine creatinine (Jaffe method). Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended. Hemolytic anemia and liver enzyme elevations have been reported. Good anaerobic activity but poor CSF penetration. **Adjust dose in renal failure (see Chapter 31).**

**CEFOXITIN**

Generics; previously available as Mefoxin

**Antibiotic, cephalosporin (second generation)**



B 1 Yes Yes No

**Injection:** 1, 2, 10 g

**Frozen injection:** 1 g/50 mL 4% dextrose, 2 g/50 mL 2.2% dextrose (iso-osmotic solutions)

Contains 2.3 mEq Na/g drug

**Neonate:**

**<32 wk gestation:**

≤7 days old: 70 mg/kg/24 hr ÷ Q12 hr IM/IV

>7 days old: 105 mg/kg/24 hr ÷ Q8 hr IM/IV

≥32 wk gestation: 105 mg/kg/24 hr ÷ Q8 hr IM/IV

**Infant and child:**

**Mild/moderate infections:** 80–100 mg/kg/24 hr ÷ Q6–8 hr IM/IV

**Severe infections:** 100–160 mg/kg/24 hr ÷ Q4–6 hr IM/IV

**Adult:** 1–2 g/dose Q6–8 hr IM/IV

**Mild/moderate acute PID:** 2 g IM x 1 and probenecid 1 g PO x 1, plus doxycycline 100 mg Q12 hr PO and metronidazole 500 mg Q12 hr PO × 14 days

**Severe acute PID:** 2 g IV Q6 hr × 24–48 hr after clinical improvement. Doxycycline 100 mg Q12 hr PO/IV × 14 days is also initiated at the same time.

**Max. dose (all ages):** 12 g/24 hr

**Preoperative prophylaxis (30–60 min before procedure; may repeat dose in 2 hr for lengthy procedure or excessive blood loss):**

**Child:** 40 mg/kg/dose (max. dose: 2 g/dose) IV

**Adult:** 2 g IV

**Use with caution** in penicillin-allergic patients or in presence of renal impairment. Has good anaerobic activity but poor CSF penetration. May cause injection site reaction and thrombophlebitis. Transient increases in LFTs have been reported.

Probenecid increases serum cefoxitin levels. May cause false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution) and false elevations of serum and urine creatinine (Jaffe and KDA methods). Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended.

**Adjust dose in renal failure (see Chapter 31).**

**CEFPODOXIME PROXETIL**

Generics; previously available as Vantin

**Antibiotic, cephalosporin (third generation)**



B 1 Yes Yes No

**Tabs:** 100, 200 mg

**Oral suspension:** 50, 100 mg/5 mL (50, 100 mL)

*Continued*

CEFPODOXIME PROXETIL *continued***2 mo–11 yr:****Otitis media:** 10 mg/kg/24 hr PO ÷ Q12 hr × 5–10 days; **max. dose:** 400 mg/24 hr**Pharyngitis/tonsillitis:** 10 mg/kg/24 hr PO ÷ Q12 hr × 5–10 days; **max. dose:** 200 mg/24 hr**Acute maxillary sinusitis:** 10 mg/kg/24 hr PO ÷ Q12 hr × 10 days; **max. dose:** 400 mg/24 hr**≥12 yr—adult:****Exacerbation of chronic bronchitis, community-acquired pneumonia, and sinusitis:** 400 mg/24 hr PO ÷ Q12 hr × 10 days (14 days for pneumonia)**Pharyngitis/tonsillitis:** 200 mg/24 hr PO ÷ Q12 hr × 5–10 days**Skin/skin structure infection:** 800 mg/24 hr PO ÷ Q12 hr × 7–14 days**Uncomplicated UTI:** 200 mg/24 hr PO ÷ Q12 hr × 5–7 days

**Use with caution** in penicillin-allergic patients or in presence of renal impairment. May cause diarrhea, nausea, vomiting, vaginal candidiasis, and false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution) and Coombs test. Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended. Transient elevation of ALT/SGPT has been reported in clinical trials.



Tablets should be administered with food to enhance absorption. Suspension may be administered without regard to food. High doses of antacids or H<sub>2</sub> blockers may reduce absorption. Probenecid increases serum cefpodoxime levels.

Cefpodoxime proxetil is a prodrug that is deesterified in the GI tract to the active cefpodoxime. **Adjust dose in renal failure (see Chapter 31).**

**CEFPROZIL**

Generics; previously available as Cefzil

**Antibiotic, cephalosporin (second generation)**

B



1



Yes



Yes



No

**Tabs:** 250, 500 mg**Oral suspension:** 125 mg/5 mL, 250 mg/5 mL (50, 75, 100 mL); contains aspartame and phenylalanine**Otitis media:****6 mo–12 yr:** 30 mg/kg/24 hr PO ÷ Q12 hr; **max. dose:** 1 g/24 hr**Pharyngitis/tonsillitis:****2–12 yr:** 15 mg/kg/24 hr PO ÷ Q12 hr; **max. dose:** 1 g/24 hr**≥13 yr:** 500 mg PO Q24 hr**Acute sinusitis:****6 mo–12 yr:** 15–30 mg/kg/24 hr PO ÷ Q12 hr; **max. dose:** 1 g/24 hr**>12 yr:** 250 or 500 mg PO Q12 hr**Uncomplicated skin infections:****2–12 yr:** 20 mg/kg/24 hr PO Q24 hr; **max. dose:** 500 mg/dose**>12 yr:** 250 mg PO Q12 hr or 500 mg PO Q12–24 hr**UTI:****2–24 mo:** 30 mg/kg/24 hr PO ÷ Q12 hr

**Use with caution** in penicillin-allergic patients or in presence of renal impairment. Oral suspension contains aspartame and phenylalanine and should not be used by phenylketonurics. May cause nausea, vomiting, diarrhea, liver enzyme elevations, and false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution) and Coombs test. Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended. Probenecid increases serum cefprozil levels. Absorption is not affected by food. **Adjust dose in renal failure (see Chapter 31).**



**CEFTAROLINE FOSAMIL**

Teflaro

**Antibiotic, cephalosporin (fifth generation)**

B



1



Yes



Yes



No

**Injection:** 400, 600 mg; contains L-arginine**Child (2 mo—<18 yr):****Acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP):****Infant <2 mo (ABSSSI indication only):** 6 mg/kg/dose IV Q8 hr**2 mo—<2 yr:** 8 mg/kg/dose IV Q8 hr**≥2 yr—<18 yr:**

≤33 kg: 12 mg/kg/dose IV Q8 hr

&gt;33 kg: 400 mg IV Q8 hr or 600 mg IV Q12 hr

**Adult:** 600 mg IV Q12 hr**Cystic fibrosis (limited data):****Child ≥6 yr and adolescent:** 15 mg/kg/dose IV Q8 hr (**max. dose:** 600 mg/dose) infused over 2 hr in 7 patients (mean age: 20.3 ± 8.0) achieved the targeted serum concentration time greater than the MIC of 60%.**Adult:** Pharmacokinetic simulations in 8 patients revealed dosages of 600 mg IV Q8 hr infused over 1 hr or 600 mg IV Q12 hr infused over 3 hr would achieve the targeted serum concentration time greater than the MIC of 60%.**Use with caution** in penicillin allergy and renal impairment. Common side effects from pediatric trials include diarrhea, rash, vomiting, pyrexia, and nausea. Leukopenia and liver enzyme elevations have been reported.

Probenecid increases serum ceftaroline levels. Direct Coombs test seroconversion has been reported with use.

**Adjust dose in renal failure (see Chapter 31).****CEFTAZIDIME**

Tazicef and generics; previously available as Fortaz

**Antibiotic, cephalosporin (third generation)**

B



1



Yes



Yes



No

**Injection:** 1, 2, 6 g**Frozen injection:** 1 g/50 mL 4.4% dextrose, 2 g/50 mL 3.2% dextrose (iso-osmotic solutions)

Contains 2.3 mEq Na/g drug

**Neonate (IV/IM):****Postnatal age ≤7 days:** 50 mg/kg/dose Q12 hr**Postnatal age >7—28 days:**

&lt;1000 g:

**Postnatal age 8—14 days:** 50 mg/kg/dose Q12 hr**Postnatal age 15—28 days:** 50 mg/kg/dose Q8 hr

≥1000 g: 50 mg/kg/dose Q8 hr

**Meningitis:****Postnatal age ≤7 days:** 50 mg/kg/dose Q8—12 hr**Postnatal age >7 days:** 50 mg/kg/dose Q8 hr**Infant (>1 mo), child and adolescent (IV/IM):****Mild/moderate infection:** 100—150 mg/kg/24 hr ÷ Q8 hr; **max. dose:** 6 g/24 hr**Meningitis:** 150—200 mg/kg/24 hr ÷ Q8 hr (**max. dose:** 6 g/24 hr)

Continued

CEFTAZIDIME *continued*

**Serious *Pseudomonas* infections:** 200–300 mg/kg/24 hr ÷ Q8 hr (**max. dose:** 12 g/24 hr)

**Cystic fibrosis:** 200–400 mg/kg/24 hr ÷ Q6–8 hr (**max. dose:** 12 g/24 hr)

**Adult (IV/IM):** 1–2 g/dose Q8–12 hr; **max. dose:** 6 g/24 hr

**Use with caution** in penicillin-allergic patients or in presence of renal impairment. Good *Pseudomonas* coverage and CSF penetration. May cause rash, liver enzyme elevations, and false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution) and Coombs test. Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended. Probenecid increases serum ceftazidime levels. **Adjust dose in renal failure (see Chapter 31).** Nonconvulsive status epilepticus, neuromuscular excitability, and myoclonia may occur with elevated levels of ceftazidime.

**CEFTAZIDIME WITH AVIBACTAM**

Avycaz

**Antibiotic, cephalosporin (third generation with  $\beta$ -lactamase inhibitor)**



?



1



Yes



Yes



No

**Injection:** 2 g ceftazidime and 0.5 g avibactam

Contains 3.2 mEq Na/g ceftazidime

**All doses based on ceftazidime component and are infused over 2 hr.**

**Complicated UTI (including pyelonephritis; treat for 7–14 days):**

≥3 mo—<6 mo: 40 mg/kg/dose IV Q8 hr

≥6 mo, child, and adolescent: 50 mg/kg/dose (**max.** 2 g/dose) IV Q8 hr

**Adult:** 2 g IV Q8 hr

**Complicated intra-abdominal infections:** Use same dosage for complicated UT in combination with metronidazole and treat for 5–14 days.

**Nosocomial pneumonia (including VAP):**

**Adult:** 2 g IV Q8 hr × 7–14 days

See [Ceftazidime](#) for additional remarks. Avibactam is a novel  $\beta$ -lactamase inhibitor of serine  $\beta$ -lactamases to improve ceftazidime's susceptibility to Enterobacteriaceae.

Clinical trial safety profiles in children and adults are similar, which include common side effects of vomiting, diarrhea, rash, and infusion site reactions. May cause false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution) and Coombs test. Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended.

**Adjust dose in renal failure (see Chapter 31).** Australian Therapeutic Goods Administration reports animal reproductive toxicity without evidence of teratogenic effects with avibactam. Human studies of ceftazidime/avibactam are incomplete.

**CEFTOLOZANE WITH TAZOBACTAM**

Zerbaxa

**Antibiotic, cephalosporin with  $\beta$ -lactamase inhibitor**



?



1



Yes



Yes



No

**Injection:** 1 g ceftolozane and 0.5 g tazobactam; contains 600 mg L-arginine

Contains 8.3 mEq Na/g ceftolozane

**All doses based on ceftolozane component and are infused over 1 hr.**

**Neonate (limited data based on a single-dose pharmacokinetic [PK] evaluation where PK**

**profiles in 13 neonates and infants <3 mo were comparable to older children receiving a single**



CEFTOLOZANE WITH TAZOBACTAM *continued*

**IV dose; <32 wk gestation and >7 days old [N = 6] and >32 wk gestation and >7 days old [N = 7]:**

**UTI:** 20 mg/kg/dose IV Q8 hr

**Severe infections:** 40 mg/kg/dose IV Q8 hr

**Infant, child, and adolescent:**

**Complicated intra-abdominal infection and complicated UTI (including pyelonephritis):** 20 mg/kg/dose (**max. dose:** 1 g/dose) IV Q8 hr for 5–14 days for intra-abdominal infection and 7–14 days for UTI

**Severe infections:** 40 mg/kg/dose (**max. dose:** 2 g/dose) IV Q8 hr

**Adult:**

**Complicated intra-abdominal infection and UTI (including pyelonephritis):** 1 g IV Q8 hr for 4–14 days for intra-abdominal infection and 7 days for UTI

**Hospital-acquired pneumonia and ventilator-associated pneumonia:** 2 g IV Q8 hr for 8–14 days

Use is reserved for multi-drug-resistant Gram-negative bacterial infections, including *Pseudomonas aeruginosa* and *E. coli*. Tazobactam irreversibly inhibits certain  $\beta$ -lactamases, penicillinases, and cephalosporinases to extend ceftolozane's spectrum of activity. Safety and efficacy in children with hospital-acquired and ventilator-associated pneumonia are currently being evaluated.



**Use with caution** in penicillin, cephalosporin, or  $\beta$ -lactam allergic patients or in the presence of renal impairment (**adjust dose in renal failure; see Chapter 31**). Decreased efficacy has been reported in adults with baseline eGFR of 30–50 mL/min/1.73 m<sup>2</sup> in both intra-abdominal and UTI trials (monitor for changing renal function and adjust dosage accordingly). The manufacturer does not recommend use in children with an eGFR <50 mL/min/1.73 m<sup>2</sup> due to insufficient clinical data. Common side effects in pediatric trials include thrombocytopenia, diarrhea, pyrexia, leukopenia, abdominal pain, vomiting, increased AST, and anemia. Common side effects in adult UTI trials include nausea, diarrhea, headache, and pyrexia. Increased hepatic transaminases, renal impairment, and diarrhea were observed in adult pneumonia trials.

**CEFTRIAXONE**

Generics; previously available as Rocephin

**Antibiotic, cephalosporin (third generation)**



B



1



Yes



Yes



No

**Injection:** 0.25, 0.5, 1, 2, 10 g

**Frozen injection:** 1 g/50 mL 3.8% dextrose, 2 g/50 mL 2.4% dextrose (iso-osmotic solutions)

Contains 3.6 mEq Na/g drug

**Neonate:**

**Gonococcal ophthalmia or prophylaxis:** 25–50 mg/kg/dose IM/IV  $\times$  1; **max. dose:** 250 mg/dose



**Infant (>1 mo) and child:**

**Mild/moderate infections:** 50–75 mg/kg/24 hr  $\div$  Q12–24 hr IM/IV; **max. dose:** 2 g/24 hr

**Severe infections/meningitis (including penicillin-resistant pneumococci):** 100 mg/kg/24 hr IM/IV  $\div$  Q12 hr; **max. dose:** 2 g/dose and 4 g/24 hr

**Penicillin-resistant pneumococci outside of the CSF:** 80–100 mg/kg/24 hr  $\div$  Q12–24 hr (**max. dose:** 2 g/dose and 4 g/24 hr)

**Lyme disease:** 50–75 mg/kg/dose (**max. dose:** 2 g/dose) IV once daily

**Acute otitis media:** 50 mg/kg IM/IV (**max. dose:** 1 g)  $\times$  1; for persistent or relapse cases use 50 mg/kg IM/IV (**max. dose:** 1 g) Q24 hr  $\times$  3 doses

**Adult:** 1–2 g/dose Q12–24 hr IV/IM; **max. dose:** 2 g/dose and 4 g/24 hr

*Continued*

CEFTRIAXONE *continued***Uncomplicated gonorrhea:**

&lt;150 kg: 500 mg IM × 1

≥150 kg: 1 g IM × 1

**PID (see latest CDC Sexually Transmitted Infections Treatment Guidelines):****Mild/moderate acute:** 0.5–1 g IM × 1 (following the above uncomplicated gonorrhea dosage), plus doxycycline 100 mg Q12 hr PO and metronidazole 500 mg Q12 hr PO × 14 days**Severe acute:** 1 g IV once daily, plus doxycycline 100 mg Q12 hr IV/PO and metronidazole 500 mg Q12 hr IV/PO to complete a 14-day course; convert to oral therapy after clinical improvement with IV therapy.**Bacterial endocarditis prophylaxis for dental and upper respiratory procedures:****Infant and child:** 50 mg/kg IV/IM (max. dose: 1 g) 30–60 min before procedure**Adult:** 1 g IV/IM 30–60 min before procedure

**Contraindicated** in neonates with hyperbilirubinemia. **Do not** administer with IV calcium-containing solutions or products (mixed or administered simultaneously via different lines) in neonates (<28 days old) because of risk of precipitation of ceftriaxone-calcium salt. Cases of fatal reactions with calcium-ceftriaxone precipitates in lung and kidneys in preterm and full-term neonates have been reported. **Do not** administer simultaneously with IV calcium-containing solutions via a Y-site for any age group. IV calcium-containing products may be administered sequentially only when the infusion lines are thoroughly flushed between infusions with a compatible fluid.



**Use with caution** in penicillin allergy; patients with gallbladder, biliary tract, liver, or pancreatic disease; presence of renal impairment; or in neonates with continuous dosing (risk for hyperbilirubinemia). In neonates, consider using an alternative third-generation cephalosporin with similar activity. Unlike other cephalosporins, ceftriaxone is significantly cleared by the biliary route (35%–45%).

Rash, injection site pain, diarrhea, and transient increase in liver enzymes are common. May cause reversible cholelithiasis, sludging in gallbladder, and jaundice. Reversible neurologic reactions (e.g., encephalopathy, seizures, myoclonus) have been reported in post-marketing reports. May interfere with serum and urine creatinine assays (Jaffe method) and cause false-positive urinary protein and urinary reducing substances (e.g., Clinitest, Benedict's solution, or Fehling's solution). Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended.

For IM injections, dilute drug with either sterile water for injection or 1% lidocaine to a concentration of 250 or 350 mg/mL (250 mg/mL has lower incidence of injection site reactions). Assess the potential risk/benefit for using lidocaine as a diluent; see [Lidocaine](#) for additional remarks, especially risk for methemoglobinemia.

**CEFUROXIME (IV, IM)/CEFUROXIME AXETIL (PO)**

IV: Generics; previously available as Zinacef

PO: Generics; previously available as Ceftin

**Antibiotic, cephalosporin (second generation)**

B



1



Yes



Yes



No

**Injection:** 0.75, 1.5 g

Injectable dosage forms contain 2.4 mEq Na/g drug.

**Tabs:** 250, 500 mg**IM/IV:****Neonate:****Postnatal age ≤7 days:** 100 mg/kg/24 hr ÷ Q12 hr**Postnatal age >7 days:**

&lt;1 kg:

**8 to ≤14 days old:** 100 mg/kg/24 hr ÷ Q12 hr

CEFUROXIME (IV, IM)/CEFUROXIME AXETIL (PO) *continued*

≥15 days old: 150 mg/kg/24 hr ÷ Q8 hr

≥1 kg: 150 mg/kg/24 hr ÷ Q8 hr

**Infant (>3 mo)/child:**

**Mild/moderate infection:** 75–100 mg/kg/24 hr ÷ Q8 hr; **max. dose:** 1500 mg/dose

**Severe infection:** 100–200 mg/kg/24 hr ÷ Q6–8 hr; **max. dose:** 1500 mg/dose

**Adult:** 750–1500 mg/dose Q8 hr; **max. dose:** 9 g/24 hr

**PO (see remarks):**

**Child (3 mo–12 yr):**

**Pharyngitis and tonsillitis (oral suspension):** 20 mg/kg/24 hr ÷ Q12 hr; **max. dose:** 500 mg/24 hr

**Impetigo (oral suspension):** 30 mg/kg/24 hr ÷ Q12 hr; **max. dose:** 1 g/24 hr

**Otitis media and sinusitis:**

**Oral suspension:** 30 mg/kg/24 hr ÷ Q12 hr; **max. dose:** 1 g/24 hr

**Oral tablet:** 250 mg BID

**Lyme disease (alternative to doxycycline or amoxicillin):**

**Oral suspension:** 30 mg/kg/24 hr (**max. dose:** 1 g/24 hr) ÷ Q12 hr × 14–28 days

**Child (≥13 yr):**

**Sinusitis, otitis media, pharyngitis, and tonsillitis:**

**Tab:** 250 mg Q12 hr

**Adult:** 250–500 mg BID; **max. dose:** 1 g/24 hr

**Use with caution** in penicillin-allergic patients or in presence of renal impairment. May cause GI discomfort; thrombophlebitis at the infusion site; false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution) and Coombs test; and may interfere with serum and urine creatinine determinations by the alkaline picrate method. Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended. Transient increases in liver enzymes have been reported. Not recommended for meningitis.

Oral suspension dosage form currently not available. Tablets and oral suspension are NOT bioequivalent and CANNOT be substituted on a mg/mg basis. Concurrent use of antacids, H<sub>2</sub> blockers, and proton pump inhibitors may decrease oral absorption. **Adjust dose in renal failure (see Chapter 31).**



**CELECOXIB**

Celebrex, Elyxyb, and generics

**Nonsteroidal antiinflammatory agent (COX-2 selective)**



C/X



2



Yes



Yes



Yes

**Capsules (Celebrex and generics):** 50, 100, 200, 400 mg

**Oral solution (Elyxyb):** 120 mg/4.8 mL (4.8 mL); contains alcohol, cremophor, and levomenthol

**Juvenile rheumatoid arthritis (JRA; ≥2 yr and adolescent; see remarks for dosage**

**adjustment considerations):**

**10–25 kg:** 50 mg PO BID

**>25 kg:** 100 mg PO BID

**Adult (see remarks for dosage adjustment considerations):**

**Analgesia:** 100–200 mg PO BID

**Acute migraine with or without aura (Elyxyb):** 120 mg PO × 1; **max. dose:** 120 mg/24 hr

**Contraindicated** for perioperative pain with coronary artery bypass graft (CABG) surgery. **Use with caution** in patients with systemic-onset JRA due to risk for serious adverse reactions



*Continued*

CELECOXIB *continued*

(e.g., disseminated intravascular coagulation). In adults, serious cardiovascular and GI risks reported include thrombosis, myocardial infarction (MI), stroke, GI bleed, GI ulceration, and GI perforation. Common adverse effects include headache, diarrhea, nausea, and hypertension. DRESS, TEN, SJS, acute kidney injury, and hyperkalemia have also been reported.

Celecoxib is a substrate of CYP 450 2C9. Poor metabolizers of 2C9 should start with half the lowest recommended dose and use with caution, or consider alternative therapy. Angiotensin-converting enzyme (ACE) inhibitors, loop diuretics, and sodium phosphates may increase risk for renal dysfunction. Oral corticosteroids, antiplatelet drugs (e.g., aspirin), anticoagulants, SSRIs, smoking, alcohol use, older age, and poor health status may increase risk for GI bleeds with prolonged treatment courses. Celecoxib may reduce the antihypertensive effects of ACE inhibitors and increase the levels/toxicity of lithium, metoprolol, and methotrexate.

**Not recommended** for use in severe renal dysfunction and severe hepatic impairment (Child-Pugh Class C). Reduce dose by 50% and monitor patient closely in moderate hepatic impairment (Child-Pugh Class B).

Pregnancy category is “C” for prior to 30 weeks’ gestation and “X” for 30 weeks and greater. **Avoid use** at  $\geq 30$  weeks’ gestation due to increased risk for premature closure of the fetal ductus arteriosus. Limit dose and duration of use at 20–30 weeks’ gestation for concerns of fetal renal dysfunction. If patient is unable to swallow capsules whole, contents of the capsule may be added to applesauce (stable for up to 6 hr refrigerated) and ingested with water.

**CEPHALEXIN**

Generics; previously available as Keflex

**Antibiotic, cephalosporin (first generation)**



B



1



Yes



Yes



No

**Caps:** 250, 500, 750 mg

**Tabs:** 250, 500 mg

**Oral suspension:** 125 mg/5 mL, 250 mg/5 mL (100, 200 mL)

**Infant and child:**

**Mild/moderate infection:** 25–50 mg/kg/24 hr PO  $\div$  Q6 hr; **max. dose:** 2 g/24 hr. Less frequent dosing (Q8–12 hr) may be used for uncomplicated infections.

**Severe infection:** 75–100 mg/kg/24 hr PO  $\div$  Q6 hr; **max. dose:** 4 g/24 hr

**Streptococcal pharyngitis and skin infections:** 25–50 mg/kg/24 hr PO  $\div$  Q6–12 hr. Total daily dose may be divided Q12 hr for streptococcal pharyngitis ( $>1$  yr).

**UTI:** 25 mg/kg/dose PO Q6–8 hr; **max. dose:** 1 g/dose

**Adult:** 1–4 g/24 hr PO  $\div$  Q6 hr

**Max. dose (all ages):** 4 g/24 hr

**Bacterial endocarditis prophylaxis for dental and upper respiratory procedures:**

**Infant and child:** 50 mg/kg PO (**max. dose:** 2 g) 30–60 min before procedure

**Adult:** 2 g PO 30–60 min before procedure

Some cross-reactivity with penicillins. **Use with caution** in renal insufficiency. May cause GI discomfort, false-positive urine-reducing substance (e.g., Clinitest, Benedict's solution, or Fehling's solution) and Coombs test; false elevation of serum theophylline levels (HPLC method); and false urinary protein test. Enzymatic glucose oxidase urinary glucose tests (e.g., Clinistix or Tes-Tape) are recommended. Hemolytic anemia and slight increases in AST and ALT have been reported. Probenecid increases serum cephalexin levels, and concomitant administration with cholestyramine may reduce cephalexin absorption. May increase the effects of metformin.

Administer doses on an empty stomach; 2 hr prior to or 1 hr after meals. **Adjust dose in renal failure** (see [Chapter 31](#)).

**CETIRIZINE ± PSEUDOEPHEDRINE**

Zyrtec, Zyrtec Allergy, Zyrtec Children's Allergy,

Zerviate, and many generics

In combination with pseudoephedrine:

Zyrtec-D 12 hr and generics

**Antihistamine, less-sedating**

B/C



2



Yes



Yes



No

**Oral solution or syrup (OTC):** 5 mg/5 mL (120, 473 mL); contains parabens**Tabs (OTC):** 5, 10 mg**Chewable tabs (OTC):** 2.5, 5, 10 mg**Capsule (liquid filled; OTC):** 10 mg**Dispersible/disintegrating tabs (OTC):** 10 mg**Ophthalmic solution (Zerviate):** 2.4 mg/1 mL (0.2 mL; 5 or 30 single-use vials per box; and 5, 7.5 mL multidose bottles); contains benzalkonium chloride and polyethylene glycol**In combination with pseudoephedrine (PE):****Extended release tabs (OTC):** 5 mg cetirizine + 120 mg PE**Cetirizine (see remarks for dosing in hepatic impairment):****6 mo and <2 yr:** 2.5 mg PO once daily; dose may be increased for children 12–23 mo to a **max. dose** of 2.5 mg PO Q12 hr**2–5 yr: Initial dose:** 2.5 mg PO once daily; if needed, may increase dose to a **max. dose** of 5 mg/24 hr once daily or divided BID**≥6 yr—adult:** 5–10 mg PO once daily**Ophthalmic use:****≥2 yr and adult:** Instill 1 drop to affected eye(s) BID (approximately 8 hr apart).**Cetirizine in combination with pseudoephedrine (PE) (see remarks for dosing in hepatic impairment):****≥12 yr and adult:****Zyrtec-D 12 hr:** 1 tablet PO BID

Generally not recommended for treating URIs for infants. No proven benefit for infants and young children with URIs. The FDA does not recommend use for URIs in children &lt;2 yr because of reports of increased fatalities.

May cause headache, pharyngitis, GI symptoms, dry mouth, and sedation. Aggressive reactions and convulsions have been reported. Has NOT been implicated in causing cardiac arrhythmias when used with other drugs that are metabolized by hepatic microsomal enzymes (e.g., ketoconazole, erythromycin).

**In hepatic impairment, the following doses have been recommended:****Cetirizine:****<6 yr:** Use not recommended**6–11 yr:** <2.5 mg PO once daily**≥12 yr—adult:** 5 mg PO once daily**Cetirizine in combination with pseudoephedrine (Zyrtec-D 12 and generics):****≥12 yr—adult:** 1 tablet PO once dailyDoses may be administered without regard to food. For Zyrtec-D 12 Hr, see [Pseudoephedrine](#) for additional remarks. Pregnancy category is “B” for cetirizine and “C” when combined with pseudoephedrine. **Dosage adjustment is recommended in renal impairment (see [Chapter 31](#)).****OPHTHALMIC USE:** Common side effects include application site pain, ocular hyperemia, and reduced visual acuity. Oculogyric crisis has been reported. Do not touch dropper tip to anything, and remove contact lenses prior to administration (wait 10 min before reinserting lenses).

**CHARCOAL, ACTIVATED**

See Chapter 3.

**CHLORAMPHENICOL**

Generics

**Antibiotic**

C



3



Yes



Yes



No

**Injection:** 1 g

Contains 2.25 mEq Na/g drug

**Neonate IV (see remarks for therapeutic drug monitoring):****Loading dose:** 20 mg/kg**Maintenance dose (first dose should be given 12 hr after loading dose):**

≤7 days: 25 mg/kg/24 hr Q24 hr

&gt;7 days:

≤2 kg: 25 mg/kg/24 hr Q24 hr

&gt;2 kg: 50 mg/kg/24 hr ÷ Q12 hr

**Infant/child/adult (see remarks for therapeutic drug monitoring):** 50–75 mg/kg/24 hr IV ÷ Q6 hr**Meningitis:** 75–100 mg/kg/24 hr IV ÷ Q6 hr**Max. dose (all ages):** 4 g/24 hr

Dose recommendations are just guidelines for therapy; monitoring of blood levels is essential.

Follow hematologic status for dose-related or idiosyncratic marrow suppression. “Gray baby” syndrome may be seen with levels >50 mg/L. **Use with caution** in G6PD deficiency, renal or hepatic dysfunction, and neonates.

Concomitant use of phenobarbital and rifampin may lower chloramphenicol serum levels.

Phenytoin may increase chloramphenicol serum levels. Chloramphenicol may increase the effects/toxicity of phenytoin, chlorpropamide, cyclosporine, tacrolimus, and oral anticoagulants and decrease absorption of vitamin B<sub>12</sub>. Chloramphenicol is an inhibitor of CYP 450 2C9.

Therapeutic levels: Peak: 15–25 mg/L for meningitis and 10–20 mg/L for other infections. Trough: 5–15 mg/L for meningitis and 5–10 mg/L for other infections. Recommended serum sampling time: trough within 30 min prior to next dose; peak 30 min after the end of infusion. Time to achieve steady state: 2–3 days for newborns; 12–24 hr for children and adults.

**CHLOROQUINE PHOSPHATE**

Generics; previously available as Aralen

**Amebicide, antimalarial**

C



2



Yes



Yes



No

**Tabs:** 250, 500 mg as phosphate (150, 300 mg base, respectively)**Oral suspension:** 16.67 mg/mL as phosphate (10 mg/mL base), 15 mg/mL as phosphate (9 mg/mL base) **Doses expressed in mg of chloroquine base:****Malaria prophylaxis (start 1–2 wk prior to exposure and continue for 4 wk after leaving endemic area):****Infant and child:** 5 mg/kg/dose PO every week on the same day of the week; **max. dose:** 300 mg/dose**Adult:** 300 mg/dose PO every week on the same day of the week

CHLOROQUINE PHOSPHATE *continued***Malaria treatment (chloroquine sensitive strains):**

For treatment for malaria, consult with ID specialist or see the latest edition of the AAP Red Book.

**Infant and child:** 10 mg/kg/dose (**max. dose:** 600 mg/dose) PO  $\times$  1; followed by 5 mg/kg/dose (**max. dose:** 300 mg/dose) 6, 24, and 48 hr after the initial dose

**Adult:** 600 mg/dose PO  $\times$  1; followed by 300 mg/dose 6, 24, and 48 hr after the initial dose

**Contraindicated** in the presence of retinal or visual field changes and known hypersensitivity to 4-aminoquinoline compounds. **Use with caution** in liver disease, preexisting auditory damage or seizures, G6PD deficiency, psoriasis, porphyria, or concomitant hepatotoxic drugs. May cause nausea, vomiting, electrocardiogram (ECG) abnormalities, prolonged QT interval, blurred vision, retinal and corneal changes (reversible corneal opacities), headaches, confusion, skeletal muscle weakness, increased liver enzymes, and hair depigmentation. SJS, TEN, anaphylactic reactions, and maculopathy and macular degeneration have been reported. False-positive test for urine amphetamine screen may occur.



Antacids, ampicillin, and kaolin may decrease the absorption of chloroquine (allow 4-hr interval between these drugs and chloroquine). Cimetidine may increase effects/toxicity of chloroquine. May increase serum cyclosporine levels. Coadministration with mefloquine may increase risk of convulsions. May reduce the antibody response to intradermal human diploid-cell rabies vaccine. Monitor CBCs periodically with therapies of prolonged duration. **Adjust dose in renal failure (see Chapter 31).**

**CHLOROTHIAZIDE**

Diuril and generics

**Thiazide diuretic**



C/D



2



Yes



Yes



No

**Oral suspension:** 250 mg/5 mL (237 mL); contains 0.5% alcohol, 0.12% methylparaben, 0.02% propylparaben, and 0.1% benzoic acid

**Injection:** 500 mg; contains 5 mEq Na/1 g drug

**<6 mo:**

**PO:** 20–40 mg/kg/24 hr  $\div$  Q12 hr

**IV:** Start at 5–10 mg/kg/24 hr  $\div$  Q12 hr; may increase to 20–40 mg/kg/24 hr  $\div$  Q12 hr if needed

**$\geq$ 6 mo:**

**PO:** 10–40 mg/kg/24 hr  $\div$  Q12 hr; **maximum PO** dose by age:

**6 mo–<2 yr:** 375 mg/24 hr

**2–12 yr:** 1 g/24 hr

**>12 yr:** 2 g/24 hr

**IV:** Start at 5–10 mg/kg/24 hr  $\div$  Q12–24 hr, may increase to 20 mg/kg/24 hr  $\div$  Q12 hr if needed

**Adult:** 500–2000 mg/24 hr  $\div$  Q12–24 hr IV; alternative IV dosing, some may respond to intermittent dosing on alternate days or on 3–5 days each week

**Adjunct therapy for neonatal hyperinsulinemia/hypoglycemia (limited data):** 7–10 mg/kg/24 hr  $\div$  BID PO with diazoxide PO

**Contraindicated** in anuria. **Use with caution** in liver and severe renal disease and sulfonamide hypersensitivity. May increase serum calcium, bilirubin, glucose, and uric acid. May cause alkalosis, pancreatitis, dizziness, hypokalemia, and hypomagnesemia.



**Avoid IM or subcutaneous administration.**

Pregnancy category changes to “D” if used in pregnancy-induced hypertension.

**CHLORPHENIRAMINE MALEATE**

Chlor-Trimeton and generics

*Antihistamine*

B



3



No



No



No

**Tabs [OTC]:** 4 mg**Sustained release tabs [OTC]:** 12 mg**Syrup [OTC]:** 2 mg/5 mL (120, 473 mL); may contain 5% alcohol and/or parabens**Doses may be administered as scheduled or PRN (see remarks).****Child <12 yr:** 0.35 mg/kg/24 hr PO ÷ Q4–6 hr or dose based on age as follows:2–5 yr: 1 mg/dose PO Q4–6 hr; **max. dose:** 6 mg/24 hr6–11 yr: 2 mg/dose PO Q4–6 hr; **max. dose:** 12 mg/24 hr≥12 yr—adult: 4 mg/dose Q4–6 hr PO; **max. dose:** 24 mg/24 hr

Sustained release: 12 mg PO Q12 hr

**Use with caution** in asthma. May cause sedation, dry mouth, blurred vision, urinary retention, polyuria, and disturbed coordination. Young children may be paradoxically excited.Found in many combinations, over-the-counter (OTC) cough and cold products are **not recommended** for children <6 yr old due to reports of serious adverse effects (cardiac and respiratory distress, convulsions, and hallucinations) and fatalities (from unintentional overdosages, including combined use of other OTC products containing the same active ingredients).Administer doses with food. Sustained release forms are **NOT** recommended in children <6 yr and should **NOT** be crushed, chewed, or dissolved.**CHLORPROMAZINE**

Generics; previously available as Thorazine

*Antiemetic, antipsychotic, phenothiazine derivative*

C



3



No



No



No

**Tabs:** 10, 25, 50, 100, 200 mg**Oral liquid concentrate:** 30 mg/mL (120 mL), 100 mg/mL (240 mL) **Injection:** 25 mg/mL (1, 2 mL); may contain sodium metabisulfite and sodium sulfite**Psychosis (gradually taper doses when discontinuing therapy to prevent withdrawal symptoms and minimize risk of relapse):****Child >6 mo:****PO:** 2.5–6 mg/kg/24 hr ÷ Q4–6 hr; **max. PO dose:** 500 mg/24 hr**IM/IV:** 2.5–4 mg/kg/24 hr ÷ Q6–8 hr**Max. IM/IV dose:**

&lt;5 yr: 40 mg/24 hr

5–12 yr: 75 mg/24 hr

**Adult:****PO:** 10–25 mg/dose Q4–6 hr; **max. dose:** 1–2 g/24 hr**IM/IV:** Initial: 25 mg; repeat with 25–50 mg/dose; if needed, Q1–4 hr up to a **max. dose** of 400 mg/dose Q4–6 hr**Antiemetic:****Child (≥6 mo):****IV/IM/PO:** 0.5–1 mg/kg/dose Q6–8 hr PRN**Max. IM/IV/PO dose:**

&lt;5 yr or &lt;22.7 kg: 40 mg/24 hr

5–12 yr or 22.7–45.5 kg: 75 mg/24 hr

CHLORPROMAZINE *continued***Adult:**

**IV/IM:** 25–50 mg/dose Q4–6 hr PRN; **max. dose:** 300 mg/24 hr

**PO:** 10–25 mg/dose Q4–6 hr PRN; **max. dose:** 150 mg/24 hr

Adverse effects include drowsiness, jaundice, lowered seizure threshold, extrapyramidal/anticholinergic symptoms, hypotension (more with IV), arrhythmias, agranulocytosis, and neuroleptic malignant syndrome. May potentiate effect of narcotics, sedatives, and other drugs. Monitor BP closely. ECG changes include prolonged PR interval, flattened T waves, and ST depression; **do not use** in combination with fluoxetine, haloperidol, citalopram, and other drugs that can prolong the QT interval. **Do not administer oral liquid dosage form simultaneously with carbamazepine oral suspension;** an orange, rubbery precipitate may form.

**CHOLECALCIFEROL**

D–3, D3–5, D3–50, Decara, D Drops, Emfamil

D-Vi-Sol, Replesta, and many others

**Vitamin D<sub>3</sub>**



A/D



1



No



No



No

**Tablet (OTC):** 400; 1000; 2000; 3000; 5000; 50,000 IU

**Caps (OTC):** 1000; 2000; 5000; 10,000; 50,000 IU

**D3–5:** 5000 IU

**Decara:** 5,000, 25,000 IU

**D3–50:** 50,000 IU

**Chewable tablet (OTC):** 400; 1000; 2000 IU

**Chewable wafer (Replesta; OTC):** 14,000 (8), 50,000 IU (4)

**Oral drops (D Drops and others) [OTC]:** 400 IU/drop (2.5, 10.3 mL), 600 IU/drop (2.8 mL), 1000 IU/drop (5, 10.3 mL), 2000 IU/drop (5, 10.3 mL), 4000 IU/drop (10.3 mL), 6000 IU/drop (10.3 mL)

**Oral liquid (OTC):** 400, 5000 IU/mL

**Emfamil D-Vi-Sol (OTC):** 400 IU/mL (50 mL)

**Conversion:** 1000 IU is equivalent to 25 mCg of cholecalciferol

**Dietary supplementation (see Chapter 21 for additional information):**

**Preterm:** 200–400 IU/24 hr PO

**Infant (<1 yr):** 400 IU/24 hr PO

**Neonate and infant (breastfed and/or receiving <32 oz of formula):** 400 IU/24 hr PO

**Child (≥1 yr) and adolescent:** 400–600 IU/24 hr PO

**Cystic fibrosis:** See specific cystic fibrosis specialty multivitamin product (e.g., DEKA Plus, MVW Complete, ADEK) for recommended dosages.

**Vitamin D insufficiency and deficiency (PO):**

**Patients without cystic fibrosis or malabsorptive conditions:**

**Vitamin D (25-OH) Level**

Age	12–<20 ng/mL (Insufficiency)	<12 ng/mL (Deficiency)
<1 yr	1000 IU once daily	2000–4000 IU once daily
≥1 yr	2000 IU once daily	5000–6000 IU once daily OR 50,000 IU once weekly

*Continued*

CHOLECALCIFEROL *continued*

Patients with non-cystic fibrosis malabsorptive conditions:

Age	Vitamin D (25-OH) Level	
	12—<20 ng/mL (Insufficiency)	<12 ng/mL (Deficiency)
<10 yr	2000 IU once daily	5000 IU once daily
≥10 yr	4000—6000 IU once daily	10,000 IU once daily OR 50,000 IU once weekly

Patients with cystic fibrosis:

Age	Vitamin D (25-OH) Level	
	20—<30 ng/mL (Insufficiency)	<20 ng/mL (Deficiency)
<1 yr	2000 IU once daily	5000 IU once daily
1—<10 yr	6000 IU once daily	50,000 IU once daily × 1 mo followed by either 10,000 IU once daily OR 50,000 IU once weekly
≥10 yr	10,000 IU once daily	50,000 IU once daily × 1 mo followed by either 10,000 IU once daily OR 50,000 IU once weekly

**Rickets (with calcium supplementation; decrease to maintenance dosage when radiologically proven healing is achieved):**

**Infant:** 2000 IU PO once daily × ≥3 mo, followed by 400 IU once daily maintenance

**Child:** 3000—6000 IU PO once daily × ≥3 mo, followed by 600 IU once daily maintenance

**Adolescent:** 6000 IU PO once daily × ≥3 mo, followed by 600 IU once daily maintenance

**Renal failure (CKD stages 2—5) and 25-OH vitamin D levels ≤30 ng/mL (monitor serum 25-OH vitamin D and corrected calcium/phosphorus 1 mo after initiation and Q3 mo thereafter):**

**Child (PO):**

**25-OH vitamin D <5 ng/mL:** 8000 IU/24 hr × 4 wk, followed by 4000 IU/24 hr × 2 mo; OR 50,000 IU weekly × 4 wk, followed by 50,000 IU twice monthly × 3 mo

**25-OH vitamin D 5—15 ng/mL:** 4000 IU/24 hr × 12 wk; OR 50,000 IU every other week × 12 wk

**25-OH vitamin D 16—30 ng/mL:** 2000 IU/24 hr × 3 mo; OR 50,000 IU monthly × 3 mo

**Maintenance dose (after repletion):** 200—1000 IU once daily

Biologic potency and oral absorption may be greater than ergocalciferol (vitamin D<sub>2</sub>). Requires activation by the liver (25-hydroxylation) and kidney (1-hydroxylation) to the active form, calcitriol. Recommended time period to recheck serum 25-OH vitamin D is 3 mo after initiation or change in dosage. 

**Monitor** serum Ca<sup>2+</sup>, PO<sub>4</sub>, 25-OH vitamin D (goal level for infant and child: ≥20 ng/mL) and alkaline phosphate. Serum Ca<sup>2+</sup>, PO<sub>4</sub> product should be <70 mg/dL to avoid ectopic calcification. Serum 25-OH vitamin D level of ≥35 ng/mL has been used in cystic fibrosis patients to decrease the risk of hyperparathyroidism and bone loss.

Serum 25-OH vitamin D levels ≥100 ng/mL are considered toxic. Toxic effects in infants may result in nausea, vomiting, constipation, abdominal pain, loss of appetite, polydipsia, polyuria, muscle weakness, muscle/joint pain, confusion, and fatigue; renal damage may also occur.

Pregnancy category changes to “D” if used in doses above the U.S. RDA.

**CHOLESTYRAMINE**

Questran, Questran Light, Cholestyramine Light,  
Prevalite, and generics

**Antilipemic, binding resin**



C



1



No



No



No

**Powder for oral suspension:**

**Questran and generics:** 4 g anhydrous resin per 9 g powder (9 g—box of 60 packets, 378 g can)

**Questran Light:** 4 g anhydrous resin per 5 g powder (5 g—box of 60 packets, 210 g can)

**Cholestyramine Light:** 4 g anhydrous resin per 5.7 g powder with aspartame (5.7 g—box of 60 packets, 239 g can)

**Prevalite:** 4 g anhydrous resin per 5.5 g powder with aspartame (5.5 g—box of 42 or 60 packets, 231 g can)

**All doses based in terms of anhydrous resin. Titrate dose based on response and tolerance.**

**Hypercholesterolemia:**

**Child and adolescent:** 240 mg/kg/24 hr ÷ TID PO; doses normally do not exceed 8 g/24 hr (higher doses do not provide additional benefit). Give PO as slurry in water, juice, or milk before meals for better efficacy.

**Adult:** 4 g once daily—BID PO; **max. dose:** 24 g/24 hr

**Pruritus associated with cholestasis:**

**Child:** 240 mg/kg/24 hr ÷ BID—TID PO; suggested **max. dose:**

≤10 yr: 4–10 g/24 hr; higher doses may cause steatorrhea

>10 yr and adolescent: 16 g/24 hr

**Adult:** 4 g once daily or BID PO; may gradually increase dose to 16 g/24 hr. **Max. dose:** 24 g/24 hr

In addition to the use for managing hypercholesterolemia, drug may be used for itching associated with elevated bile acids, and diarrheal disorders associated with excess fecal bile acids or *Clostridium difficile* (pseudomembranous colitis). May also be applied topically for diaper dermatitis by preparing a 5% or 10% topical product with hydrophilic topical ointment (Aquaphor); other compounded topical formulations exist (e.g., Butt paste: Cholestyramine, sucralfate, zinc oxide, and Eucerin).

May cause constipation, abdominal distention, vomiting, vitamin deficiencies (A, D, E, K), and rash. Hyperchloremic acidosis may occur with prolonged use.

Give other oral medications 4–6 hr after cholestyramine or 1 hr before dose to avoid decreased absorption. High doses or long-term systemic therapy may decrease the absorption of folic acid, fat-soluble vitamins, and iron.

**CICLESONIDE**

Alvesco, Omnaris, Zetonna

**Corticosteroid**



C



1



No



Yes



No

**Aerosol inhaler (Alvesco):** 80 mCg/actuation (6.1 g = 60 doses), 160 mCg/actuation (6.1 g = 60 doses)

**Nasal spray:**

**Omnaris (nasal suspension):** 50 mCg/actuation (12.5 g = 120 doses); contains sodium EDTA

**Zetonna (nasal aerosol solution):** 37 mCg/actuation (6.1 g = 60 doses)

**Intranasal (allergic rhinitis):**

**Omnaris:**

**2–11 yr (limited data):** 1 or 2 sprays (50 or 100 mCg) per nostril once daily. **Max. dose:** 200 mCg/24 hr

Continued

CICLESONIDE *continued*

**FDA labeled seasonal allergic rhinitis for children  $\geq 6$  yr:** 2 sprays (100 mCg) per nostril once daily

**$\geq 12$  yr and adult:** 2 sprays (100 mCg) per nostril once daily. **Max. dose:** 200 mCg/24 hr

**Zetonna:**

**$\geq 12$  yr and adult:** 1 spray (37 mCg) per nostril once daily. **Max. dose:** 74 mCg/24 hr

**Oral inhalation (asthma; Alvesco):**

**Dosage recommended by the Global Initiative for Asthma (GINA) guidelines (current FDA labeled dosage information is for  $\geq 12$  yr and is listed below). All daily doses divided BID:**

Age	Low Dose (mCg/24 hr)	Medium Dose (mCg/24 hr)	High Dose (mCg/24 hr)
6–11 yr	80	>80–160	>160 up to 640 mCg/24 hr
$\geq 12$ yr and adult	80–160	>160–320	>320 up to 640 mCg/24 hr

**2–11 yr (limited data from randomized controlled studies in 4–11 and 2–6 yr of age, where efficacy could not be established):** 40, 80, or 160 mCg/dose BID

 **$\geq 12$  yr and adult (FDA labeling):**

**Prior use with bronchodilator only:** 80 mCg/dose BID; **max. dose:** 320 mCg/24 hr

**Prior use with inhaled corticosteroid:** 80 mCg/dose BID; **max. dose:** 640 mCg/24 hr

**Prior use with oral corticosteroid:** 320 mCg/dose BID; **max. dose:** 640 mCg/24 hr

Ciclesonide is a prodrug hydrolyzed to an active metabolite, des-ciclesonide via esterases in nasal mucosa and lungs; further metabolism via hepatic CYP3A4 and 2D6. Concurrent use with ketoconazole and other CYP 450 3A4 inhibitors may increase systemic des-ciclesonide levels.


**Use with caution** and monitor in hepatic impairment.

**Oral inhalation (asthma):** Rinse mouth after each use. May cause headache, arthralgia, nasal congestion, nasopharyngitis, and URIs. Routinely monitor growth of pediatric patients. Maximum therapeutic benefit may not be achieved until 4 wk after initiation; consider dose increase if response is inadequate 4 wk after initial dosage.

**Intranasal (allergic rhinitis):** Clear nasal passages prior to use. May cause otalgia, epistaxis, nasopharyngitis, and headache. Nasal septal perforation has been reported. Patients should be free of nasal disease, except for allergic rhinitis, before starting therapy. Monitor linear growth of pediatric patients routinely. Onset of action: 24–48 hr; further improvement observed over 1–2 wk in seasonal allergic rhinitis or 5 wk in perennial allergic rhinitis. Discontinue use if nasal erosion, ulceration, or perforation occurs.

**CIDOFOVIR**

Generics; previously available as Vistide

**Antiviral**

C

3

Yes

No

No

**Injection:** 75 mg/mL (5 mL); preservative free

**Safety and efficacy have not been established in children.**

**CMV retinitis:****Adolescent and adult:**

**Induction:** 5 mg/kg IV once weekly  $\times$  2 with probenecid and hydration

CIDOFOVIR *continued*

**Maintenance:** 5 mg/kg IV Q2 weeks with probenecid and hydration

**Adenovirus infection in immunocompromised oncology patients (limited data and other regimens exist; see remarks):**

**Child:**

**Induction:** 5 mg/kg/dose IV once weekly until PCR negative. Administer oral probenecid 1–1.25 g/m<sup>2</sup>/dose (rounded to the nearest 250-mg interval) 3 hr before and 1 hr and 8 hr after each dose of cidofovir. Also give IV NS via IV at maintenance fluid concentration, 3 times, 1 hr before and 1 hr after cidofovir, followed by 2 times maintenance fluid for an additional 2 hr. For patients with renal dysfunction (see remarks), give 1 mg/kg/dose IV three times weekly until PCR negative.

**Maintenance:** 5 mg/kg/dose IV Q2 weeks with probenecid and hydration

**Contraindicated** in hypersensitivity to probenecid or sulfa-containing drugs; sCr >1.5 mg/dL, CrCl ≤55 mL/min, urine protein ≥100 mg/dL (2+ proteinuria), direct intraocular injection of cidofovir, and concomitant nephrotoxic drugs. **Renal impairment is the major dose-limiting toxicity.** IV NS prehydration and probenecid must be used (unless not indicated) to reduce risk of nephrotoxicity. May also cause nausea, vomiting, headache, rash, metabolic acidosis, uveitis, decreased intraocular pressure, and neutropenia.

Reported criteria for defining renal dysfunction in children include a sCr >1.5 mg/dL, GFR <90 mL/min/1.73 m<sup>2</sup>, and >2+ proteinuria. For adults, reduce dose to 3 mg/kg if sCr increases 0.3–0.4 mg/dL from baseline. Discontinue therapy if sCr increases ≥0.5 mg/dL from baseline or development of ≥3+ proteinuria.

Administer doses via IV infusion over 1 hr at a concentration ≤8 mg/mL.

**CIPROFLOXACIN**

Cipro, Ciloxan ophthalmic, Cetraxal, Ciprodex, Cipro HC Otic, Otovel Otic, and generics

**Antibiotic, quinolone**



C



2



Yes



Yes



No

**Tabs:** 100, 250, 500, 750 mg

**Oral suspension:** 250 mg/5 mL (100 mL), 500 mg/5 mL (100 mL)

**Premixed injection:** 200 mg/100 mL 5% dextrose, 400 mg/200 mL 5% dextrose (iso-osmotic solutions)

**Ophthalmic solution:** 0.3% (2.5, 5, 10 mL); may contain benzalkonium chloride

**Ophthalmic ointment (Ciloxan):** 0.3% (3.5 g)

**Otic solution (Cetraxal and generics):** 0.5 mg/0.25 mL or 0.2% (14s)

**Otic suspension:**

**With dexamethasone (Ciprodex and generics):** 3 mg/mL (0.3%) ciprofloxacin + 1 mg/mL (0.1%) dexamethasone (7.5 mL); contains benzalkonium chloride

**With hydrocortisone (Cipro HC Otic):** 2 mg/mL (0.2%) ciprofloxacin + 10 mg/mL (1%) hydrocortisone (10 mL); contains benzyl alcohol

**With fluocinolone (Otovel Otic and generics):** 3 mg/mL (0.3%) ciprofloxacin + 0.25 mg/mL (0.025%) fluocinolone acetonide (0.25 mL; carton of 14s)

**Neonate:**

**32–37 weeks' gestation:** 10 mg/kg/dose IV Q12 hr

**≥38 weeks' gestation:** 15 mg/kg/dose IV Q12 hr

**Child:**

**PO:**

**Mild/moderate infection:** 20 mg/kg/24 hr ÷ Q12 hr; **max. dose:** 1 g/24 hr

**Severe infection:** 30–40 mg/kg/24 hr ÷ Q12 hr; **max. dose:** 1.5 g/24 hr



*Continued*

CIPROFLOXACIN *continued***IV:**

**Severe infection:** 10 mg/kg/dose Q8–12 hr; **max. dose:** 400 mg/dose

**Complicated UTI or pyelonephritis (× 10–21 days):**

**PO:** 20–40 mg/kg/24 hr ÷ Q12 hr; **max. dose:** 1.5 g/24 hr

**IV:** 18–30 mg/kg/24 hr ÷ Q8 hr; **max. dose:** 1.2 g/24 hr

**Cystic fibrosis:**

**PO:** 40 mg/kg/24 hr ÷ Q12 hr; **max. dose:** 2 g/24 hr

**IV:** 30 mg/kg/24 hr ÷ Q8 hr; **max. dose:** 1.2 g/24 hr

**Anthrax (see remarks):**

**Inhalational/systemic/cutaneous:** Start with 20–30 mg/kg/24 hr ÷ Q12 hr IV (**max. dose:** 800 mg/24 hr) and convert to oral dosing with clinical improvement at 20–30 mg/kg/24 hr ÷ Q12 hr PO (**max. dose:** 1 g/24 hr). Duration of therapy: 60 days (IV and PO combined)

**Postexposure prophylaxis:** 20–30 mg/kg/24 hr ÷ Q12 hr PO × 60 days; **max. dose:** 1 g/24 hr

**Adult:****PO:**

**Immediate release:** 250–750 mg/dose Q12 hr

**Extended release tabs (Cipro XR and generics):**

**Uncomplicated UTI/cystitis:** 500 mg/dose Q24 hr

**Complicated UTI/uncomplicated pyelonephritis:** 1000 mg/dose Q24 hr

**IV:** 400 mg/dose Q12 hr; 400 mg/dose Q8 hr for more severe/complicated infections

**Anthrax (see remarks):**

**Inhalational/systemic/cutaneous:** Start with 400 mg/dose Q12 hr IV and convert to oral dosing with clinical improvement at 500 mg/dose Q12 hr PO. Duration of therapy: 60 days (IV and PO combined)

**Postexposure prophylaxis:** 500 mg/dose Q12 hr PO × 60 days

**Ophthalmic solution:**

**≥1 yr and adult:** 1–2 drops Q2 hr while awake × 2 days, then 1–2 drops Q4 hr while awake × 5 days. Clinical efficacy for bacterial conjunctivitis has been demonstrated for neonates <31 days old in a randomized, double-blinded, multicenter, parallel-group clinical trial.

**Ophthalmic ointment:**

**≥2 yr and adult:** Apply 0.5-inch ribbon TID × 2 days, then BID × 5 days.

**Otic:****Cetraxal and generics:**

**Acute otitis externa (≥1 yr and adult):** 0.25 mL to affected ear(s) BID × 7 days

**Ciprodex:**

**Acute otitis media with tympanostomy tubes or acute otitis externa (≥6 mo and adult):** 4 drops to affected ear(s) BID × 7 days

**Cipro HC Otic:**

**Otitis externa (>1 yr and adult):** 3 drops to affected ear(s) BID × 7 days

**Otovel Otic:**

**Acute otitis media with tympanostomy tubes (≥6 mo):** 0.25 mL to affected ear(s) BID × 7 days

Systemic fluoroquinolones are associated with disabling and potentially permanent side effects of the tendons, muscles, joints, nerves, and central nervous system.



Can cause GI upset, renal failure, and seizures. GI symptoms, headache, restlessness, and rash are common side effects. Peripheral neuropathy, pseudotumor cerebri, severe hepatic necrosis, and psychiatric reactions have been reported. **Use with caution** in children <18 yr (like other quinolones, tendon rupture can occur during or after therapy, especially with concomitant corticosteroid use), alkalinized urine (crystalluria), seizures, excessive sunlight (photosensitivity), and renal dysfunction (**adjust systemic dose in renal failure; see Chapter 31**). Blood glucose

CIPROFLOXACIN *continued*

disturbances (hypoglycemia and hyperglycemia) have been reported in patients with diabetes who are receiving insulin or oral hypoglycemic agent.

**Do not use otic suspension with perforated tympanic membranes and with viral infections of the external ear canal.**

For dosing in obese patients, use an adjusted body weight (ABW).  $ABW = \text{ideal body weight} + 0.45 (\text{total body weight} - \text{ideal body weight})$

Combinational antimicrobial therapy is recommended for anthrax. For penicillin-susceptible strains, consider changing to high-dose amoxicillin (25–35 mg/kg/dose TID PO). See [www.bt.cdc.gov](http://www.bt.cdc.gov) for the latest information.

Inhibits CYP 450 1A2. Ciprofloxacin can increase effects and/or toxicity of caffeine, methotrexate, theophylline, warfarin, tizanidine (excessive sedation and dangerous hypotension), and cyclosporine. Probenecid increases ciprofloxacin levels.

**Do not administer antacids or other divalent salts** with or within 2–4 hr of oral ciprofloxacin dose.

**Do not** administer oral suspension through feeding tubes, because this dosage form adheres to the tube.

**CITRATE MIXTURES**

*Alkalinizing agent, electrolyte supplement*



?



?



Yes



No



No

**Oral liquid:**

Each mL of oral solution contains the following mEq of electrolyte:

	Na	K	Citrate or HCO <sub>3</sub>
Tricitrates <sup>a</sup> or Sodium Citrate/Potassium Citrate and Citric Acid (473 mL)	1	1	2
Potassium Citrate and Citric Acid <sup>a</sup> (473 mL)	0	2	2
Sodium Citrate and Citric Acid <sup>a</sup> (30, 473 mL)	1	0	1
Oracit (15, 30, 500 mL)	1	0	1

<sup>a</sup>Sugar free.

**Oral powder for oral solution:**

**Cytra-K:** Each packet of sugar-free powder contains 30 mEq each of potassium and citrate/HCO<sub>3</sub> (100 packets per box) and must be diluted in at least 6 ounces of cold water or juice.

**Dilute dose in water or juice.**

All mEq doses based on citrate.

**Systemic alkalinization:**

**Infant and child (PO):** 2–3 mEq/kg/24 hr ÷ Q6–8 hr or 5–15 mL/dose Q6–8 hr (after meals and before bedtime) and adjust dose to desired serum bicarbonate level

**Adult (PO):** 100–200 mEq/24 hr ÷ Q6–8 hr or 15–30 mL/dose Q6–8 hr (after meals and before bedtime)

**Contraindicated** in severe renal impairment and acute dehydration. **Use with caution** in

patients already receiving potassium supplements or who are sodium restricted. May have laxative effect and cause hypocalcemia and metabolic alkalosis. Patients with active UTIs may attenuate the ability to increase urinary citrate by bacterial enzymatic degradation of citrate. Also, the rise in urinary pH may promote bacterial growth.



*Continued*

CITRATE MIXTURES *continued*

Adjust dose to maintain desired pH. 1 mEq of citrate is equivalent to 1 mEq HCO<sub>3</sub> in patients, as citrate is converted to CO<sub>2</sub> via the citric acid cycle in the mitochondria.

Potassium citrate has a pregnancy category of “C”; otherwise the pregnancy category is unknown for the other components to this medication.

**CLARITHROMYCIN**

Generics; previously available as Biaxin and Biaxin XL

**Antibiotic, macrolide**



C



2



Yes



Yes



No

**Film tablets:** 250, 500 mg

**Extended release tablets:** 500 mg

**Granules for oral suspension:** 125, 250 mg/5 mL (50, 100 mL)

**Infant and child:**

**Acute otitis media, pharyngitis/tonsillitis, pneumonia, acute maxillary sinusitis, or uncomplicated skin infections:** 15 mg/kg/24 hr PO ÷ Q12 hr; **max. dose:** 1 g/24 hr

**Pertussis (≥1 mo):** 15 mg/kg/24 hr PO ÷ Q12 hr × 7 days; **max. dose:** 1 g/24 hr

**Bacterial endocarditis prophylaxis:** 15 mg/kg (**max. dose:** 500 mg) PO 30–60 min before procedure

**Helicobacter pylori:** 20 mg/kg/24 hr PO ÷ Q12 hr × 7–14 days; **max. dose:** 1 g/24 hr with amoxicillin and proton pump inhibitor with/without metronidazole

**Mycobacterium avium complex (MAC):**

**Prophylaxis (1st episode and recurrence):** 15 mg/kg/24 hr PO ÷ Q12 hr

**Treatment:** 15 mg/kg/24 hr PO ÷ Q12 hr with other antimycobacterial drugs

**Max. dose (prophylaxis and treatment):** 1 g/24 hr

**Adolescent and adult:**

**Pharyngitis/tonsillitis, acute maxillary sinusitis, bronchitis, pneumonia, or uncomplicated skin infections:**

**Immediate release:** 250–500 mg/dose Q12 hr PO

**Extended release tablet:** 1000 mg Q24 hr PO (currently not indicated for pharyngitis/tonsillitis or uncomplicated skin infections)

**Adult:**

**Pertussis:** 500 mg (immediate release)/dose Q12 hr PO × 7 days

**Bacterial endocarditis prophylaxis:** 500 mg PO 30–60 min before procedure

**MAC:**

**Prophylaxis (1st episode and recurrence):** 500 mg/dose Q12 hr PO

**Treatment:** 500 mg Q12 hr PO with other antimycobacterial drugs

**Helicobacter pylori GI infection:** 500 mg Q12 hr PO × 7–14 days with proton pump inhibitor (lansoprazole or omeprazole) and amoxicillin

**Contraindicated** in patients allergic to erythromycin and history of cholestatic jaundice/hepatic dysfunction with prior use. As with other macrolides, clarithromycin has been associated with QT prolongation (**avoid use** with other drugs known to prolong QT interval) and ventricular arrhythmias, including ventricular tachycardia and torsades de pointes. May cause cardiac arrhythmias in patients also receiving cisapride. Side effects: diarrhea, nausea, abnormal taste, dyspepsia, abdominal discomfort (less than erythromycin but greater than azithromycin), and headache. Anaphylaxis, angioedema, hepatic dysfunction, rhabdomyolysis, SJS, and TEN have been reported.

CLARITHROMYCIN *continued*

May increase effects/toxicity of carbamazepine, theophylline, cyclosporine, digoxin, ergot alkaloids, fluconazole, midazolam, selected oral hypoglycemic agents, tacrolimus, triazolam, quetiapine, and warfarin. Substrate and inhibitor of CYP 450 3A4, and inhibits CYP 1A2.

**Adjust dose in renal failure (see Chapter 31).** Doses, regardless of dosage form, may be administered with food.

**CLINDAMYCIN**

Cleocin, Cleocin-T, Clindagel, Evoclin, Clindesse, Xaciatto, and generics

**Antibiotic, lincomycin derivative**



B



2



Yes



Yes



No

**Caps:** 75, 150, 300 mg

**Oral solution:** 75 mg/5 mL (100 mL); may contain ethyl parabens

**Injection:** 150 mg/mL (2, 4, 6, 60 mL); contains 9.45 mg/mL benzyl alcohol

**Premixed injection in 5% dextrose or NS:** 300 mg/50 mL, 600 mg/50 mL, 900 mg/50 mL; contains edetate disodium and may contain benzyl alcohol

**Solution, topical:** 1% (30, 60 mL); may contain 50% isopropyl alcohol and propylene glycol

**Gel, topical (Cleocin-T, Clindagel, and generics):** 1% (30, 60 g); may contain methylparaben and propylene glycol

**Lotion, topical (Cleocin-T and generics):** 1% (60 mL); may contain methylparaben

**Foam, topical (Evoclin and generics):** 1% (50, 100 g); contains 58% ethanol

See [Benzoyl peroxide](#) for combination topical product (clindamycin and benzoyl peroxide).

See [Tretinoin](#) for combination topical product (clindamycin and tretinoin).

**Vaginal cream (Cleocin and generics):** 2% (40 g); may contain benzyl alcohol or parabens

**Clindesse:** 2% (5 g); contains parabens

**Vaginal gel (Xaciatto):** 2% (25 g); contains benzyl alcohol

**Vaginal suppository (Cleocin):** 100 mg (3s)

**Neonate (IV/IM):**

**≤32 wk postmenstrual age:** 5 mg/kg/dose Q8 hr

**33–40 wk postmenstrual age:** 7 mg/kg/dose Q8 hr

**>40 wk postmenstrual age:** 9 mg/kg/dose Q8 hr

**Child (>1 mo) and adolescent (see remarks for dosing in obesity):**

**PO:** 10–40 mg/kg/24 hr ÷ Q6–8 hr; **max. dose:** 1.8 g/24 hr

**IM/IV:** 20–40 mg/kg/24 hr ÷ Q6–8 hr; **max. dose:** 2.7 g/24 hr

**Adult:**

**PO:** 600–1800 mg/24 hr ÷ Q6–12 hr; **max. dose:** 2.4 g/24 hr

**IM/IV:** 1200–2700 mg/24 hr ÷ Q6–12 hr; **max. IV dose:** 4.8 g/24 hr. **Max. IM dose:** 600 mg/dose

**Topical for acne (≥12 yr and adult; administer after washing and fully drying the affected skin):**

**Solution, lotion, or gel (Cleocin-T and generics):** Apply to affected area BID.

**Clindagel or Evoclin (foam):** Apply to affected area once daily.

**Bacterial vaginosis (≥12 yr and adult):**

**Suppositories:** 100 mg/dose QHS × 3 days for nonpregnant patients

**Vaginal cream (2%):** 1 applicator dose (5 g) QHS for 3 or 7 days in nonpregnant patients and for 7 days in pregnant patients in second and third trimesters.

**Clindesse (2%):** 1 applicator dose (5 g) × 1 for nonpregnant patients

**Vaginal gel (2%; Xaciatto):** 1 applicator dose (5 g) × 1

Not indicated in meningitis; CSF penetration is poor. Clindamycin is no longer recommended for antibiotic prophylaxis for dental procedures.



*Continued*

CLINDAMYCIN *continued*

Pseudomembranous colitis may occur up to several weeks after cessation of therapy. May cause diarrhea, rash, granulocytopenia, thrombocytopenia, or sterile abscess at injection site. Anaphylaxis, DRESS, SJS, TEN, severe taste alterations including metallic taste (with high IV doses), and AKI have been reported with systemic use. The intravenous product contains benzyl alcohol. Eye pain and contact dermatitis have been reported with topical use.

Clindamycin may increase the neuromuscular blocking effects of tubocurarine and pancuronium. **Do not exceed** IV infusion rate of 30 mg/min because hypotension and cardiac arrest have been reported with rapid infusions. May diminish the effects of erythromycin when administered together. In vitro studies indicate clindamycin is a substrate and inhibitor for CYP 450 3A4.

Dosage reduction may be required in severe renal or hepatic disease but not necessary in mild/moderate conditions. Systemic clindamycin should be dosed based on total body weight regardless of obesity. Oral liquid preparation may not be palatable; consider use of oral capsules as a sprinkle onto applesauce or pudding.

**CLOBAZAM**

Onfi, Sympazan, and generics  
**Benzodiazepine, anticonvulsant**



C 3 No Yes Yes

**Tabs (Onfi and generics):** 10, 20 mg

**Oral film (Sympazan):** 5, 10, 20 mg (60s)

**Oral suspension (Onfi and generics):** 2.5 mg/mL (120 mL); contains parabens, polysorbate 80, and propylene glycol

**Lennox-Gastaut (adjunctive therapy; see remarks):**

**Child (≥2 yr) and adult (PO):** Dosage increments (if needed) should not be more rapid than every 7 days.



Weight (kg)	Initial Dose	Dose at Day 8, if Needed	Dose at Day 15, if Needed
≤30 kg	5 mg once daily	5 mg BID	10 mg BID (max. dose)
>30 kg	5 mg BID	10 mg BID	20 mg BID (max. dose)

**Dosage adjustment for mild/moderate hepatic impairment (Child-Pugh score 5–9) and individuals with poor CYP 450 2C19 activity (PO):**

Weight (kg)	Initial Dose	First Dose Increment, if Needed	Second Dose Increment, if Needed	Third Dose Increment, if Needed
≤30 kg	5 mg once daily	5 mg BID × ≥7 days	10 mg BID (max. dose)	N/A
>30 kg	5 mg once daily	5 mg BID × ≥7 days	10 mg BID × ≥7 days	20 mg BID (max. dose)

N/A, Not applicable.

CLOBAZAM *continued*

**Seizures (generalized or partial, as monotherapy or adjunctive therapy; limited data and prescribing information from Canada and the United Kingdom):**

**Infant and child (<2 yr):** Start at 0.5–1 mg/kg/24 hr (**max. dose:** 5 mg/24 hr) PO ÷ BID; if needed and tolerated, slowly increase dosage at 5- to 7-day intervals up to the **maximum** of 10 mg/24 hr.

**2–16 yr:** Start at 5 mg PO once daily; if needed and tolerated, slowly increase dosage at 5- to 7-day intervals up to the **maximum** of 40 mg/24 hr. Usual dosage range: 10–20 mg/24 hr or 0.3–1 mg/kg/24 hr ÷ BID

**Use with caution** in hepatic impairment (dose adjustment may be needed). **Do not** discontinue use abruptly, as seizures/withdrawal symptoms may occur. Common side effects include constipation, drooling, ataxia, drowsiness, insomnia, aggressive behavior, cough, and fever. SJS, TEN, urinary retention, hypothermia, leukopenia, and thrombocytopenia have been reported.



**Do not use in combination** with azelastine, olanzapine, sodium oxybate, and thioridazine; increases risk for adverse events. Proton pump inhibitors,azole antifungal agents (e.g., itraconazole and ketoconazole), St. John's wort, grapefruit juice, CNS depressants, cimetidine, calcium channel blockers, and strong/moderate CYP 2C19 inhibitors may increase the effects/toxicity of clobazam. Use with opioids may result in profound sedation, respiratory depression, coma, and mortality. Carbamazepine, rifamycin derivatives (e.g., rifampin), and theophylline may decrease the effects of clobazam. Clobazam is a major substrate for CYP 450 2C19 and P-glycoprotein, minor substrate for CYP 450 2B6 and 3A4, inhibitor of CYP 450 2D6, and inducer of CYP 3A4. Carefully review the patient's medication profile for other drug interactions each time clobazam is initiated or when a new drug is added to a regimen containing clobazam.

Doses may be taken with or without food. Tablets may be crushed and mixed with applesauce.

Oral film (Sympazan) uses same PO dosage with the following method for administration: Apply film on top of the tongue, allow it to dissolve, and swallow saliva in a normal manner. **Do not** chew, spit, or talk while film is dissolving. Doses may be taken with or without food but **do not** administer with liquids.

**CLONAZEPAM**

Klonopin and generics

**Benzodiazepine, anticonvulsant**



D



3



Yes



Yes



No

**Tabs:** 0.5, 1, 2 mg

**Disintegrating oral tabs:** 0.125, 0.25, 0.5, 1, 2 mg; contains phenylalanine

**Oral suspension:** 100 mCg/mL 

**Seizures:**

**Infant and child <10 yr or <30 kg:**

**Initial:** 0.01–0.03 mg/kg/24 hr PO ÷ BID–TID; **maximum initial dose:** 0.05 mg/kg/24 hr

**Increment:** 0.25–0.5 mg/24 hr Q3 days, up to a **maximum maintenance dose** of 0.2 mg/kg/24 hr ÷ TID

**Child ≥10 yr or ≥30 kg and adult:**

**Initial:** 1.5 mg/24 hr PO ÷ TID

**Increment:** 0.5–1 mg/24 hr Q3–7 days up to a **maximum maintenance dose** of 20 mg/24 hr



**Contraindicated** in severe liver disease and acute narrow-angle glaucoma. Drowsiness, behavior changes, increased bronchial secretions, GI, CV, GU, and hematopoietic toxicity (thrombocytopenia, leukopenia) may occur. Monitor for depression, suicidal behavior/ideation, and unusual changes in behavior/mood. **Use with caution** in patients with compromised respiratory function, porphyria, and renal impairment. **Do not discontinue abruptly.**



$T_{1/2}$  = 24–36 hr.

*Continued*

CLONAZEPAM *continued*

**Proposed therapeutic levels (not well established):** 20–80 ng/mL. Recommended serum sampling time: Obtain trough level within 30 min prior to an oral dose. Steady state is typically achieved after 5–8 days continuous therapy using the same dose.

Carbamazepine, phenytoin, and phenobarbital may decrease clonazepam levels and effect. Drugs that inhibit CYP-450 3A4 isoenzymes (e.g., erythromycin) may increase clonazepam levels and effects/toxicity.

**CLONIDINE**

Kapvay, Catapres TTS, Duraclon, and generics; previously available as Catapres

**Central  $\alpha$  adrenergic agonist, antihypertensive**



C



3



Yes



No



No

**Tabs:** 0.1, 0.2, 0.3 mg

**Extended release oral tabs:**

**Kapvay and generics (12 hr dosing):** 0.1 mg

**Oral suspension:** 20, 100 mCg/mL 

**Transdermal patch (Catapres TTS and generics):** 0.1, 0.2, 0.3 mg/24 hr (7-day patch; 4 patches per box); contains metallic components (see remarks)

**Injection, epidural (Duraclon and generics):** 100, 500 mCg/mL (10 mL); preservative free

**Neonatal abstinence syndrome, adjunctive therapy (use immediate release product;**

**limited data):** 0.5–1 mCg/kg/dose Q4–6 hr PO; use Q6 hr interval for preterm neonates



**ADHD (Child  $\geq$ 6 yr and adolescent):**

**Immediate release product (PO):**

**27–45 kg:** Start with 0.05 mg QHS; if needed, increase by 0.05 mg/24 hr every 3–7 days as increments with BID, TID, and then QID dosing up to the following **max. dose:**

**27–40.5 kg:** 0.2 mg/24 hr

**>40.5–45 kg:** 0.3 mg/24 hr

**>45 kg:** Start with 0.1 mg QHS; if needed, increase by 0.1 mg/24 hr every 3–7 days as increments with BID, TID, and then QID dosing up to the **max. dose** of 0.4 mg/24 hr.

**Extended release product (Kapvay and generics, PO):** Start with 0.1 mg QHS; if needed, increase by 0.1 mg every 7 days by administering the dose BID up to a **maximum** of 0.4 mg/24 hr. Depending on dosage level, BID dosing should be either the same amount or with the higher dosage given at bedtime. If therapy is to be discontinued, slowly reduce dosage at  $\leq$ 0.1 mg every 3 to 7 days to avoid withdrawal.

**Hypertension (use immediate release products unless noted):**

**Child (PO):** 2–5 mCg/kg/dose Q6–8 hr initially; if needed, increase at 5- to 7-day intervals up to 10 mCg/kg/dose Q6–8 hr; **max. dose:** 0.8 mg/24 hr

**$\geq$ 12 yr and adult (PO):** 0.1 mg BID initially; increase in 0.1 mg/24 hr increments at weekly intervals until desired response is achieved (usual range: adolescent: 0.2–0.6 mg/24 hr  $\div$  BID; adult: 0.1–0.8 mg/24 hr  $\div$  BID); **max. dose:** 2.4 mg/24 hr

**Transdermal patch (each patch lasts 7 days by rotating application sites, but more frequent patch change at every 5 days may be needed for children):**

**Child:** Conversion to patch only after establishing an optimal oral dose first. Use a transdermal dosage closest to the established total oral daily dose.

**Adult:** Initial 0.1 mg/24 hr patch for first week. May increase dose by 0.1 mg/24 hr at 1–2 wk intervals PRN. Usual range: 0.1–0.3 mg/24 hr. Doses  $>$ 0.6 mg/24 hr do not provide additional benefit.

**Side effects:** Dry mouth, dizziness, drowsiness, fatigue, constipation, anorexia, arrhythmias, and local skin reactions with patch. Somnolence, fatigue, URIs, irritability, throat pain, insomnia, nightmares, and emotional disorder were reported as common side effects in ADHD



CLONIDINE *continued*

clinical trials. May worsen sinus node dysfunction and AV block, especially for patients taking other sympatholytic drugs. **Do not abruptly discontinue**; signs of sympathetic overactivity may occur; taper gradually over >1 wk.

$\beta$ -blockers may exacerbate rebound hypertension during and following the withdrawal of clonidine. If patient is receiving both clonidine and a  $\beta$ -blocker and clonidine is to be discontinued, the  $\beta$ -blocker should be withdrawn several days prior to tapering the clonidine. If converting from clonidine over to a  $\beta$ -blocker, introduce the  $\beta$ -blocker several days after discontinuing clonidine (after taper).

Monitor heart rate when used with digitalis, calcium channel blockers, and  $\beta$ -blockers. Use with diltiazem or verapamil may result in sinus bradycardia. Use with neuroleptics may induce/exacerbate orthostatic hypotension, dizziness, and fatigue. Consider using lower dosages in renal impairment because the drug is primarily eliminated unchanged in the urine and signs of bradycardia, sedation, and hypotension may occur.

$T_{1/2}$ : 44–72 hr (neonate), 6–20 hr (adult). Onset of action (antihypertensive): 0.5–1 hr for oral route, 2–3 days for transdermal route. **Do not** use transdermal route while patient is undergoing a magnetic resonance imaging (MRI) procedure; transdermal patches contain metals and may result in serious patient burns when undergoing MRI.

**CLOTRIMAZOLE**

Alevazol, Lotrimin AF, Gyne-Lotrimin 3, Gyne-Lotrimin 7, and generics

**Antifungal, imidazole**



B/C



?



No



Yes



No

**Oral troche:** 10 mg

**Cream, topical (Lotrimin AF and generics; OTC):** 1% (15, 30, 45 g); may contain benzyl alcohol or parabens

**Ointment, topical (Alevazol; OTC):** 1% (56.7 g)

**Solution, topical (OTC):** 1% (10, 30 mL)

**Vaginal cream (OTC):**

**Gyne-Lotrimin 7 and generics:** 1% (45 g)

**Gyne-Lotrimin 3 and generics:** 2% (21 g)

**Topical (cream, ointment, or solution):**

**≥2 yr—adult:** Apply to affected skin areas BID; × 2 wk for cutaneous candidiasis, × 4–8 wk for tinea corporis/pedis.



**Vaginal cream (>12 yr and adult; in addition to intravaginal use, may also apply to external vaginal area BID × 7 days PRN for itching and irritation):**

1 applicator dose (5 g) of 1% cream intravaginally QHS × 7–14 days, or

1 applicator dose of 2% cream intravaginally QHS × 3 days

**Oropharyngeal candidiasis:**

**>3 yr—adult:** Dissolve slowly (15–30 min) one troche in the mouth 5 times/24 hr × 14 days.

**Systemic use: Do not use** troches for systemic infections. Liver enzyme elevation, nausea, and vomiting may occur with troches.



**Topical use:** May cause erythema, blistering, or urticaria with topical use. **Avoid use** of tampons, douches, spermicides, other vaginal products, condoms, and diaphragms with vaginal cream. Vaginal cream can weaken latex.

Pregnancy code is a “B” for topical and vaginal dosage forms and “C” for troches.

**CORTICOTROPIN**

Acthar Gel, Cortrophin Gel; ACTH

**Adrenocorticotropic hormone**

C

?

No

No

No

**Injection, repository gel:** 80 U/mL (5 mL); contains phenol

1 unit = 1 mg

**Infantile spasms (many regimens exist):**

20–40 U/24 hr IM once daily × 6 wk or 150 U/m<sup>2</sup>/24 hr ÷ BID for 2 wk, followed by a gradual 2 wk taper of 30 U/m<sup>2</sup>/dose QAM × 3 days, followed by 15 U/m<sup>2</sup>/dose QAM × 3 days, followed by 10 U/m<sup>2</sup>/dose QAM × 3 days and 10 U/m<sup>2</sup>/dose every other morning × 6 days

**Antiinflammatory:****≥2 yr and adolescent:** 0.8 U/kg/24 hr ÷ Q12–24 hr IM

**Contraindicated** in infants <2 yr with suspected congenital infections, acute psychoses, CHF, Cushing disease, primary adrenocortical insufficiency or adrenocortical hyperfunction, TB, peptic ulcer, ocular herpes, fungal infections, recent surgery, and sensitivity to porcine products. **Use with caution** in osteoporosis. Repository gel dosage form is only for IM route.



Hypersensitivity reactions and injection site reactions may occur. Cases of anaphylaxis have been reported. Similar adverse effects as corticosteroids. **Do not use** with live or live attenuated vaccines.

**CORTISONE ACETATE**

Various generics

**Corticosteroid**

C/D

?

No

No

No

**Tabs:** 25 mg**Antiinflammatory/immunosuppressive:****Child:** 2.5–10 mg/kg/24 hr ÷ Q6–8 hr PO**Adult:** 25–300 mg/24 hr ÷ Q12–24 hr PO

May produce glucose intolerance, Cushing syndrome, edema, hypertension, adrenal suppression, cataracts, hypokalemia, skin atrophy, peptic ulcer, osteoporosis, and growth suppression.



Pregnancy category changes to “D” if used in the first trimester.

**CO-TRIMOXAZOLE**See [Sulfamethoxazole and Trimethoprim](#).**CROMOLYN**

Nasal crom, Gastrocrom, and generics; previously available as Intal

**Antiallergic agent, mast cell stabilizer**

B

1

Yes

Yes

No

**Nebulized solution:** 10 mg/mL (2 mL)**Oral concentrate (Gastrocrom and generics):** 100 mg/5 mL (5 mL)**Ophthalmic solution:** 4% (10 mL)

CROMOLYN *continued*

**Nasal spray (NasalCrom and generics) [OTC]:** 4% (5.2 mg/spray) (100 sprays, 13 mL; 200 sprays, 26 mL); contains benzalkonium chloride and EDTA

**Nebulization:**

**Child  $\geq 2$  yr and adult:** 20 mg Q6–8 hr

**Exercise-induced asthma:** 20 mg  $\times$  1, 10–15 min prior to and no longer than 1 hr before exercise

**Nasal:**

**Child  $\geq 2$  yr and adult:** 1 spray each nostril TID–QID; **max. dose:** 1 spray 6 times/24 hr

**Ophthalmic:**

**Child  $> 4$  yr and adult:** 1–2 gtts 4–6 times/24 hr

**Food allergy/inflammatory bowel disease (taper to lowest effective dose once desired effect is achieved):**

**2–12 yr:** 100 mg PO QID; give 15–20 min AC and QHS; **max. dose:** 40 mg/kg/24 hr

**$> 12$  yr and adult:** 200–400 mg PO QID; give 15–20 min AC and QHS

**Systemic mastocytosis (taper to lowest effective maintenance dose once desired effect is achieved):**

**Infant and child  $< 2$  yr:** 20 mg/kg/24 hr  $\div$  QID PO; **max. dose:**  $< 6$  mo: 20 mg/kg/24 hr,  $\geq 6$  mo to  $< 2$  yr: 100 mg/dose or 40 mg/kg/24 hr

**2–12 yr:** 100 mg PO QID; give 30 min AC and QHS; **max. dose:** 40 mg/kg/24 hr

**$> 12$  yr and adult:** 200 mg PO QID; give 30 min AC and QHS; **max. dose:** 40 mg/kg/24 hr

May cause rash, cough, bronchospasm, and nasal congestion. May cause headache, diarrhea with oral use. **Use with caution** in patients with renal or hepatic dysfunction because cromolyn is equally excreted unchanged in the urine and feces (bile).

Therapeutic response often occurs within 2 wk; however, a 4- to 6-wk trial may be needed to determine maximum benefit. Oral concentrate can only be diluted in water. Nebulized solution can be mixed with albuterol nebs.

**CYANOCOBALAMIN/VITAMIN B<sub>12</sub>**

Dodex, Physicians EZ Use B-12, Vitamin Deficiency System B12, Nascobal, vitamin B<sub>12</sub>, and generics

**Vitamin (synthetic), water soluble**



A/C



1



Yes



No



No

**Tabs (OTC):** 100, 250, 500, 1000 mCg

**Extended release tabs:** 1000 mCg

**Sublingual tabs:** 2500 mCg

**Sublingual liquid:** 3000 mCg/mL (52 mL)

**Lozenges (OTC):** 50, 100, 250, 500 mCg

**Nasal spray (Nascobal):** 500 mCg/spray (1.3 mL delivers 4 doses); contains benzalkonium chloride

**Injection (Dodex and generics):** 1000 mCg/mL (1, 10, 30 mL); may contain benzyl alcohol

**Injection kit (Physicians EZ Use B-12, Vitamin Deficiency System B12, and generics):** 1000 mCg/mL (1 mL); may contain benzyl alcohol

Contains cobalt (4.35%), and some preparations may contain aluminum

**U.S. RDA:** See Chapter 21.

**Vitamin B<sub>12</sub> deficiency, treatment:**

**Child (IM or deep SC):** 100 mCg/24 hr  $\times$  10–15 days followed by 100 mCg once or twice weekly for several months

**Maintenance:** At least 60 mCg/mo

Continued

CYANOCOBALAMIN/VITAMIN B<sub>12</sub> *continued*

**Adult (IM or deep SC):** 100 mCg/24 hr × 6–7 days; if improvement, 100 mCg/dose every 3–4 days × 2–3 wk. Use maintenance dose when hematologic values return to normal.

**Maintenance:** 100 mCg/mo

**Pernicious anemia:**

**Child (IM or deep SC):** 30–50 mCg/24 hr for at least 14 days to a total dose of 1000–5000 mCg

**Maintenance:** 100 mCg/mo

**Adult (IM or deep SC):** 100 mCg/24 hr × 6–7 days; if improvement, 100 mCg/dose every 3–4 days × 2–3 wk. Use maintenance dose when hematologic values return to normal.

**Maintenance:**

**IM/deep SC:** 100 mCg/mo

**Intranasal:** 500 mCg in one nostril once weekly

**Sublingual:** 1000–2000 mCg/24 hr

**Contraindicated** in optic nerve atrophy. May cause hypokalemia, hypersensitivity (anaphylaxis shock and death reported with parenteral use), pruritus, and vascular thrombosis. Vitamin B<sub>12</sub> use may mask folate deficiency and unmask polycythemia vera.



Prolonged use of acid-suppressing medications may reduce cyanocobalamin oral absorption.

Pregnancy category changes to “C” if used in doses greater than the RDA or if administered by the intranasal route.

Protect product from light. Some products may contain aluminum and may accumulate in renal impairment. Oral route of administration is generally **not recommended** for pernicious anemia and B<sub>12</sub> deficiency due to poor absorption. IV route of administration is **NOT recommended** because of a more rapid elimination. See [Chapter 21](#) for multivitamin preparations.

**CYCLOPENTOLATE**

Cyclogyl and generics

**Anticholinergic, mydriatic agent**



C



?



No



No



No

**Ophthalmic solution:** 0.5% (15 mL), 1% (2, 5, 15 mL), 2% (2, 5, 15 mL); may contain benzalkonium chloride

**Administer dose approximately 40–50 min prior to examination/procedure.**



**Infant:** Use of cyclopentolate/phenylephrine (Cyclomydril) due to lower cyclopentolate concentration and reduced risk of systemic side effects

**Child and adolescent:** 1 drop of 0.5%–1% solution OU, followed by repeat drop, if necessary, in 5 min. Use 2% solution for heavily pigmented iris.

**Adult:** 1 drop of 1% solution OU, followed by another drop OU in 5 min. Use 2% solution for heavily pigmented iris.

**Do not use** in narrow-angle glaucoma. May cause a burning sensation, behavioral disturbance, tachycardia, and loss of visual accommodation. Psychotic reactions and behavioral disturbances have been reported in children. To minimize absorption, apply pressure over nasolacrimal sac for at least 2 min. CNS and cardiovascular side effects are common with the 2% solution in children. **Avoid** feeding infants within 4 hr of dosing to prevent potential feeding intolerance.



**Onset of action:** 15- to 60-min; duration of action: 6–24 hr; complete recovery of accommodation may take several days for some patients. Observe patient closely for at least 30 min after dose.

**CYCLOPENTOLATE WITH PHENYLEPHRINE**

Cyclomydril

**Anticholinergic/sympathomimetic, mydriatic agent**

C

?

No

No

No

**Ophthalmic solution:** 0.2% cyclopentolate and 1% phenylephrine (2, 5 mL); contains 0.1% benzalkonium chloride, EDTA, and boric acid

**Neonate (administer dose approximately 40–50 min prior to examination/procedure; see remarks):** 1 drop OU Q5–10 min; **max. dose:** 3 drops per eye

**Infant, child, and adolescent (administer dose at least 15 min prior to examination; see remarks):** 1 drop OU Q5–10 min PRN

Used to induce mydriasis. See [Cyclopentolate](#) for additional remarks.

Onset of action: 15–60 min. Duration of action: 4–12 hr.

Apply pressure over the nasolacrimal sac for 2–3 min after administration to minimize systemic absorption.

**CYCLOSPORINE, CYCLOSPORINE MICROEMULSION, CYCLOSPORINE MODIFIED**

Sandimmune, Gengraf, Neoral, Restasis, Verkazia, Cequa, and generics

**Immunosuppressant**

C

2

Yes

Yes

No

**CYCLOSPORINE (Sandimmune and generics):**

**Injection:** 50 mg/mL (5 mL); contains 32.9% alcohol and 650 mg/mL polyoxyethylated castor oil (Cremophor EL)

**Oral solution:** 100 mg/mL (50 mL); contains 12.5% alcohol

**Caps:** 25, 50, 100 mg; contains 12.7% alcohol

**CYCLOSPORINE MICROEMULSION (Neoral):**

**Caps:** 25, 100 mg

**Oral solution:** 100 mg/mL (50 mL)

All Neoral products contain 11.9% alcohol and propylene glycol.

**CYCLOSPORINE MODIFIED (Gengraf):**

**Caps:** 25, 100 mg; contains 12.8% alcohol and propylene glycol

**Oral solution:** 100 mg/mL (50 mL); contains propylene glycol

**Ophthalmic emulsion:**

**Restasis and generics:** 0.05% (0.4 mL as 30 or 60 single-use vials/box); preservative free and contains polysorbate 80

**Verkazia:** 0.1% (0.3 mL as 5 or 120 single-use vials/box); preservative free and contains poloxamer 188

**Ophthalmic solution/drops (Cequa):** 0.09% (0.25 mL in boxes of 60s); preservative free and contains Cremophor EL

**Transplantation rejection prophylaxis: Neoral manufacturer recommends a 1:1 conversion ratio with Sandimmune. Because of its better absorption, lower doses of Neoral and Gengraf may be required. Exact dosing will vary depending on transplant type.**

**Oral:** 15 mg/kg/24 hr as a single dose given 4–12 hr pretransplantation; give same daily dose ÷ Q12–24 hr for 1–2 wk posttransplantation, then reduce by 5% per week to 3–10 mg/kg/24 hr ÷ Q12–24 hr

Continued

CYCLOSPORINE, CYCLOSPORINE MICROEMULSION,  
CYCLOSPORINE MODIFIED *continued*

**IV:** 5–6 mg/kg/24 hr as a single dose given 4–12 hr pretransplantation; administer over 2–6 hr; give same daily dose posttransplantation until patient able to tolerate oral form

**Ophthalmic:****Keratoconjunctivitis sicca:****Ophthalmic emulsion (0.05%; Restasis and generics):**

≥16 yr and adult: Instill one drop onto affected eye(s) Q12 hr.

**Ophthalmic solution (0.09%; Cequa):**

≥18 yr: Instill one drop onto affected eye(s) Q12 hr.

**Severe vernal keratoconjunctivitis:****Ophthalmic emulsion:****Verkazia (0.1%):**

≥4 yr and adult: Instill one drop onto affected eye(s) QID until resolution.

**Restasis and generics (0.05%; limited data):**

≥5 yr–14 yr: Instill one drop onto affected eye(s) QID.

May cause nephrotoxicity, hepatotoxicity, hypomagnesemia, hyperkalemia, hyperuricemia, hypertension, hirsutism, acne, GI symptoms, tremor, leukopenia, sinusitis, gingival hyperplasia, and headache. Encephalopathy, convulsions, lower extremity pain, vision and movement disturbances, and impaired consciousness have been reported, especially in liver transplant patients. Psoriasis patients previously treated with PUVA and, to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy are at increased risk for skin malignancies when taking Neoral or Gengraf.



Opportunistic infections and activation of latent viral infections have been reported.

BK virus—associated nephropathy has been observed in renal transplant patients.

**Use caution** with concomitant use of other nephrotoxic drugs (e.g., amphotericin B, aminoglycosides, nonsteroidal antiinflammatory drugs, and tacrolimus).

Plasma concentrations increased with the use of boceprevir, telaprevir, fluconazole, ketoconazole, itraconazole, erythromycin, clarithromycin, voriconazole, nefazodone, diltiazem, verapamil, nifedipine, carvedilol, and corticosteroids. Plasma concentrations decreased with the use of carbamazepine, nafcillin, rifampin, oxcarbazepine, bosentan, phenobarbital, octreotide, and phenytoin. May increase bosentan, dabigatran, methotrexate, repaglinide, and anthracycline antibiotics (e.g., doxorubicin, mitoxantrone, daunorubicin) levels/effects/toxicity. Use with nifedipine may result in gingival hyperplasia. Cyclosporine is a substrate and inhibitor for CYP 450 3A4 and P-glycoprotein.

Children may require dosages 2–3 times higher than adults. Plasma half-life 6–24 hr.

Monitor trough levels (just prior to a dose at steady state). Steady state is generally achieved after 3–5 days of continuous dosing. Interpretation will vary based on treatment protocol and assay methodology (RIA monoclonal vs. RIA polyclonal vs. HPLC), as well as whole blood vs. serum sample. Additional monitoring and dosage adjustments may be necessary in renal and hepatic impairment or when changing dosage forms.

**For ophthalmic use:** Ocular burning may occur. Remove contact lens prior to use; lens may be inserted 15 min after dose administration. May be used with artificial tears but need to be separated by 15 min from one another.

**CYPROHEPTADINE**

Various generics; previously available as  
Periactin

**Antihistamine**

B



3



No



Yes



No

CYPROHEPTADINE *continued***Tabs:** 4 mg**Syrup:** 2 mg/5 mL (473 mL); may contain alcohol 5%**Antihistaminic uses:****Child:** 0.25 mg/kg/24 hr or 8 mg/m<sup>2</sup>/24 hr ÷ Q8–12 hr PO or by age:**2–6 yr:** 2 mg Q8–12 hr PO; **max. dose:** 12 mg/24 hr**7–14 yr:** 4 mg Q8–12 hr PO; **max. dose:** 16 mg/24 hr**≥15 yr:** 4 mg Q8 hr PO; usual range 12–16 mg/24 hr; **max. dose:** 0.5 mg/kg/24 hr**Adult:** Start with 12 mg/24 hr ÷ TID PO; dosage range: 12–32 mg/24 hr ÷ TID PO; **max. dose:** 0.5 mg/kg/24 hr**Migraine prophylaxis:** 0.25–0.4 mg/kg/24 hr ÷ BID–TID PO up to the following **max. doses:****2–6 yr:** 12 mg/24 hr**7–14 yr:** 16 mg/24 hr**Adult:** 0.5 mg/kg/24 hr or 32 mg/24 hr**Appetite stimulation (see remarks):****≥2 yr and adolescent:** 0.25 mg/kg/24 hr ÷ Q12 hr PO up to the following **max. dose** by age: 2–6 yr: 12 mg/24 hr, 7–14 yr: 16 mg/24 hr, ≥15 yr: 32 mg/24 hr**Alternative dosing by age:****4–8 yr (limited data):** 2 mg Q8 hr PO**>13 yr and adult:** Start with 2 mg Q6 hr PO; dose may be gradually increased to 8 mg Q6 hr over a 3-wk period.**Contraindicated** in neonates, patients currently on MAO inhibitors, and patients suffering from asthma, glaucoma, or GI/GU obstruction. May produce anticholinergic side effects including sedation and appetite stimulation. Consider reducing dosage with hepatic insufficiency.

Allow 4 to 8 wk of continuous therapy for assessing efficacy in migraine prophylaxis. For use as an appetite stimulant, a dosing cycle of 3 wk on therapy followed by 1 wk off of therapy may enhance efficacy.

**D****DABIGATRAN ETEXILATE MESYLATE**

Pradaxa and generics

**Anticoagulant, direct thrombin inhibitor**

C



?



Yes



No



No

**Oral pellets (Pradaxa):** 20, 30, 40, 50, 110, 150 mg (60 packets of pellets per carton)**Caps:****Pradaxa:** 75, 110, 150 mg; may contain carrageenan**Generics:** 75, 150 mg**Oral pellets and capsule dosage forms are NOT bioequivalent and are NOT interchangeable on a mg per mg basis.****Prevention and treatment of venous thromboembolic event (VTE; see remarks):****Child 3 mo—<2 yr (using oral pellets):**

Weight (kg)	Age (mo)	Dose (mg) PO BID
3—<4	3—<6	30
4—<5	3—<10	40
5—<7	3—<5	40

*Continued*

DABIGATRAN ETEXILATE MESYLATE *continued*

Weight (kg)	Age (mo)	Dose (mg) PO BID
	5—<24	50
7—<9	3—<4	50
	4—<9	60
	9—<24	70
9—<11	5—<6	60
	6—<11	80
	11—<24	90
11—<13	8—<18	100
	18—<24	110
13—<16	10—<11	100
	11—<24	140
16—<21	12—<24	140
21—<26	18—<24	180

**Child 2—12 yr (PO BID; using oral pellets):**

7—<9 kg: 70 mg  
 9—<11 kg: 90 mg  
 11—<13 kg: 110 mg  
 13—<16 kg: 140 mg  
 16—<21 kg: 170 mg  
 21—<41 kg: 220 mg  
 ≥41 kg: 260 mg

**Child 8—<18 yr (PO BID; using oral capsules):**

11—<16 kg: 75 mg  
 16—<26 kg: 110 mg  
 26—<41 kg: 150 mg  
 41—<61 kg: 185 mg  
 61—<81 kg: 220 mg  
 ≥81 kg: 260 mg

**Adult (PO BID; using oral capsules): 150 mg**

**Contraindicated** in mechanical prosthetic heart valves, active bleeding, and prior serious hypersensitivity reactions to dabigatran and any of its excipients. Use is **NOT** recommended in patients with triple-positive antiphospholipid syndrome due to the increase risk for recurrent thrombosis. Epidural or spinal hematomas may occur in patients receiving neuraxial anesthesia or undergoing spinal puncture and may result in paralysis.



Common side effects include esophagitis, gastritis, indigestion, GI hemorrhage, and hemorrhage. Alopecia, angioedema, neutropenia, and agranulocytosis have been reported. Idarucizumab is the reversal agent indicated for adults in situations of emergency surgery/urgent procedures and life-threatening/uncontrolled bleeding. Pediatric use of idarucizumab has not been established. Consider the use of an alternative anticoagulant to decrease the risk of thrombosis in situations where dabigatran is discontinued for reasons other than pathological bleeding or completion of a therapy course.

Safety and efficacy have been established in children 8—<18 years of age for the treatment and prophylaxis of venous thromboembolism. In a phase 3 pediatric treatment trial, site-specific bleeding rates were comparable to standard-of-care therapy (vitamin K antagonists, low molecular weight heparin, or fondaparinux) except for GI bleeds (5.7% vs. 1.8%). An open label study evaluating the safety of dabigatran prophylaxis following a treatment course of dabigatran noted

DABIGATRAN ETEXILATE MESYLATE *continued*

common side effects of dyspepsia, epistaxis, nausea, and menorrhagia. The adverse reaction profile for this pediatric trial was generally consistent with that of adult patients.

**Adjust dose in renal impairment (see Chapter 31);** pediatric renal impairment studies have not been completed. Dabigatran is a P-glycoprotein (P-gp)/ABCB1 substrate. **Avoid** use with rifampin (P-gp inducer). Use with a P-gp inhibitor in patients with renal impairment is likely to result in supratherapeutic/toxic effects.

BID dosing should be separated by Q12 hr when possible. **DO NOT** combine the capsule and pellet dosage forms as they are NOT bioequivalent. Capsules may be administered with or without food and **MUST NOT** be opened or chewed. Oral pellets are mixed with mashed carrot or banana, applesauce, or apple juice (see product information for specific instructions) for administration. **DO NOT** administer oral pellets via oral syringes or feeding tubes and **DO NOT** mix them with milk or any milk-containing products.

**DANTROLENE**

Dantrium, Revonto, Ryanodex, and generics

**Skeletal muscle relaxant**



C



?



No



Yes



No

**Cap:** 25, 50, 100 mg

**Oral suspension:** 5 mg/mL 

**Injection:**

**Dantrium, Revonto, and generics:** 20 mg; injectable solution containing 3 g mannitol per 20 mg drug

**Ryanodex :** 250 mg; injectable suspension containing 125 mg mannitol, 25 mg polysorbate 80, 4 mg povidone K12 per 250 mg drug

**Chronic spasticity:**

**Child (≥5 yr):**

**Initial:** 0.5 mg/kg/dose (**max. dose:** 25 mg/dose) PO BID

**Increment:** Increase frequency to TID—QID at 4- to 7-day intervals, then increase doses by 0.5 mg/kg/dose

**Max. dose:** 3 mg/kg/dose PO BID—QID, up to 400 mg/24 hr

**Malignant hyperthermia (infant, child, and adult):**

**Prevention:**

**PO:** 4–8 mg/kg/24 hr ÷ Q6 hr × 1–2 days before surgery with last dose administered 3–4 hr prior to surgery

**IV (see remarks for specific dosage form administration rates):** 2.5 mg/kg beginning 1.25 hr before anesthesia, additional doses PRN

**Treatment (see remarks for specific dosage form administration rates):** 1 mg/kg IV, repeat PRN to **maximum cumulative dose** of 10 mg/kg, followed by a post-crisis regimen of 4–8 mg/kg/24 hr PO ÷ Q6 hr for 1–3 days

**Contraindicated** in active hepatic disease. Monitor transaminases for hepatotoxicity. **Use with caution** with cardiac or pulmonary impairment. May cause change in sensorium, drowsiness, weakness, diarrhea, constipation, incontinence, and enuresis. Rare cardiovascular collapse has been reported in patients receiving concomitant verapamil. May potentiate vecuronium-induced neuromuscular block.

**Avoid** unnecessary exposure of medication to sunlight. **Avoid** extravasation into tissues. A decrease in spasticity sufficient to allow daily function should be therapeutic goal. Discontinue if benefits are not evident in 45 days.

*Continued*

DANTROLENE *continued*

IV administration rates for malignant hyperthermia:

Dosage Form	Prevention Use	Treatment Use
Injectable solution	Over 1 hr	IV push
Injectable suspension	Over at least 1 min	IV push

**DAPSONE**

Aczone, Diaminodiphenyl sulfone, DDS, and generics

**Antibiotic, sulfone derivative**



C



2



Yes



Yes



No

**Tab:** 25, 100 mg

**Oral suspension:** 2 mg/mL 

**Topical gel (Aczone and generics):** 5%, 7.5% (60, 90 g); contains methylparaben

***Pneumocystis jiroveci* (formerly *carinii*) treatment:**

**Child and adult:** 2 mg/kg/24 hr PO once daily (**max. dose:** 100 mg/24 hr) with trimethoprim 15 mg/kg/24 hr PO ÷ TID × 21 days

***P. jiroveci* (formerly *carinii*) prophylaxis (first episode and recurrence):**

**Child ≥1 mo:** 2 mg/kg/24 hr PO once daily; **max. dose:** 100 mg/24 hr. Alternative weekly dosing: 4 mg/kg/dose PO Q7 days; **max. dose:** 200 mg/dose

**Adult:** 100 mg/24 hr PO ÷ once daily—BID as monotherapy; OR 50 mg PO once daily with pyrimethamine 50 mg PO Q7 days and leucovorin 25 mg PO Q7 days; other combination regimens with pyrimethamine and leucovorin may be used (see <https://www.aidsinfo.gov>)

***Toxoplasma gondii* prophylaxis (prevent first episode):**

**Child ≥1 mo:** 2 mg/kg/24 hr (**max. dose:** 25 mg/24 hr) PO once daily with pyrimethamine 1 mg/kg/24 hr (**max. 25 mg/dose**) PO once daily and leucovorin 5 mg PO Q3 days

**Adolescent and adult:** 50 mg PO once daily with pyrimethamine 50 mg PO Q7 days and leucovorin 25 mg PO Q7 days; other combination regimens with pyrimethamine and leucovorin may be used (see <https://www.aidsinfo.gov>)

**Leprosy (see <http://www.who.int/en/> for the WHO latest recommendations, including combination regimens such as rifampin ± clofazimine):**

**Child:** 1–2 mg/kg/24 hr PO once daily; **max. dose:** 100 mg/24 hr

**Adult:** 100 mg PO once daily

**Acne vulgaris (topical gel; reevaluate patient if no improvement after 12 wk of therapy):**

**5% gel (≥12 yr old):** Apply small amount (pea size) of topical gel onto clean, acne-affected areas BID.

**7.5% gel (≥9 yr old):** Apply small amount (pea size) of topical gel onto clean, acne-affected areas once daily.

Patients with HIV, glutathione deficiency, or G6PD deficiency may be at increased risk for developing methemoglobinemia. Side effects include hemolytic anemia (dose related), agranulocytosis, methemoglobinemia, aplastic anemia, nausea, vomiting, hyperbilirubinemia, headache, nephrotic syndrome, and hypersensitivity reaction (sulfone syndrome). Cholestatic jaundice, hepatitis, peripheral neuropathy, and suicidal intent have been reported with systemic use.



Didanosine, rifabutin, and rifampin decrease dapson levels. Trimethoprim increases dapson levels.

Pyrimethamine, nitrofurantoin, primaquine, and zidovudine increase risk for hematological side effects.

Oral suspension may not be absorbed as well as tablets.

DAPSONE *continued*

**TOPICAL USE:** Dry skin, erythema, and peeling of the skin may occur. Use of topical gel, followed by benzoyl peroxide for acne, has resulted in temporary local discoloration (yellow/orange) of the skin and facial hair. **Avoid use** of topical gel in G6PD deficiency or congenital/idiopathic methemoglobinemia.

### DARBEPOETIN ALFA

Aranesp

*Erythropoiesis stimulating protein*



C

1

No

Yes

No

**Injection:** 25, 40, 60, 100, 200 mCg/1 mL (1 mL)

**Single-dose prefilled injection syringe (27 gauge 1/2-inch needle):** 10 mCg/0.4 mL (0.4 mL), 25 mCg/0.42 mL (0.42 mL), 40 mCg/0.4 mL (0.4 mL), 60 mCg/0.3 mL (0.3 mL), 100 mCg/0.5 mL (0.5 mL), 150 mCg/0.3 mL (0.3 mL), 200 mCg/0.4 mL (0.4 mL), 300 mCg/0.6 mL (0.6 mL), 500 mCg/1 mL (1 mL)

Both dosage forms contain polysorbate 80 (0.05 mg/mL) and mouse and/or hamster protein; albumin free and preservative free.

#### Anemia in chronic renal failure (see remarks):

**Receiving dialysis (initial dosage and adjust dose according to the table that follows;**

**IV route is recommended for patients on hemodialysis):**

**Infant, child, and adolescent:** Start with 0.45 mCg/kg/dose IV/SC once weekly.

**Adult:** Start with 0.45 mCg/kg/dose IV/SC once weekly, **OR** 0.75 mCg/kg/dose IV/SC once every 2 wk.

**Not receiving dialysis (initial dosage; adjust dose according to the table that follows):**

**Infant, child, and adolescent:** Start with 0.45 mCg/kg/dose IV/SC once weekly, **OR** 0.75 mCg/kg/dose IV/SC once every 2 wk.

**Adult:** Start with 0.45 mCg/kg/dose IV/SC once every 4 wk.



#### DARBEPOETIN ALFA DOSE ADJUSTMENT IN ANEMIA ASSOCIATED WITH CHRONIC RENAL FAILURE

Response to Dose	Dose Adjustment
<1 g/dL increase in hemoglobin and below target range after 4 wk of therapy	Increase dose by 25% not more frequently than once monthly. Further increases, if needed, may be done at 4-wk intervals. Among those who do not adequately respond over a 12-wk escalation period, further dose increase is unlikely to improve response and may increase risks.
>1 g/dL increase in hemoglobin in any 2-wk period, or if hemoglobin exceeds and approaches 11 g/dL	Decrease dose by 25% or more
Hemoglobin continues to increase despite dosage reduction	Discontinue therapy; reinstitute therapy at a 25% lower dose of the previous dose after the hemoglobin starts to decrease

#### Anemia associated with chemotherapy (patients with nonmyeloid malignancies):

**Child (limited data) and adult (see remarks):** Start with 2.25 mCg/kg/dose SC once weekly and adjust dose according to the table that follows:

*Continued*

DARBEPOETIN ALFA *continued***DARBEPOETIN ALFA DOSE ADJUSTMENT IN ANEMIA ASSOCIATED WITH CHEMOTHERAPY**

Response to Dose	Dose Adjustment
<1 g/dL increase in hemoglobin and remains below 10 g/dL after 6 wk of therapy	Increase dose to 4.5 mCg/kg/dose once weekly SC/IV
>1 g/dL increase in hemoglobin in any 2-wk period, or when hemoglobin reaches a level needed to avoid transfusion	Decrease dose by 40%
If hemoglobin exceeds a level needed to avoid transfusion	Hold therapy until hemoglobin approaches a level where transfusions may be required and restart at a reduced dose by 40%
Lack of response after 8 wk or completion of chemotherapy	Discontinue therapy

**Conversion from epoetin alfa to darbepoetin alfa (see table below):**

Previous Weekly Epoetin Alfa Dose (units/wk) <sup>a</sup>	Pediatric Weekly Darbepoetin Alfa Dose (mCg/wk) Administered SC/IV Once Weekly <sup>b</sup>	Adult Weekly Darbepoetin Alfa Dose (mCg/wk) Administered SC/IV Once Weekly <sup>b</sup>	Adult Once Every 2 wk Darbepoetin Alfa Dose (mCg Every 2 wk) Administered SC/IV Once Every 2 wk <sup>c</sup>
<1,500	Insufficient data	6.25	12.5
1,500–2,499	6.25	6.25	12.5
2,500–4,999	10	12.5	25
5,000–10,999	20	25	50
11,000–17,999	40	40	80
18,000–33,999	60	60	120
34,000–89,999	100	100	200
≥90,000	200	200	400

<sup>a</sup>200 units of epoetin alfa is equivalent to 1 mCg darbepoetin alfa.

<sup>b</sup>If patient was receiving epoetin alfa 2–3 times weekly, darbepoetin alfa should be administered once weekly.

<sup>c</sup>If patient was receiving epoetin alfa once weekly, darbepoetin alfa should be administered once every 2 wk.

**Contraindicated** in uncontrolled hypertension and patients hypersensitive to albumin/polysorbate 80 or epoetin alfa. Darbepoetin alfa is not intended for patients requiring acute correction of anemia. **Use with caution** in seizures and liver disease. Erythema multiforme, SJS, and TEN have been reported. Evaluate serum iron, ferritin, and TIBC; concurrent iron supplementation may be necessary. Red cell aplasia and severe anemia associated with neutralizing antibodies to erythropoietin have been reported.

**USE IN CHRONIC RENAL FAILURE:** Higher doses may be needed for pediatric patients being switched from epoetin alfa than those for naïve patients. May cause edema, fatigue, GI disturbances, headache, blood pressure changes, fever, cardiac arrhythmia/arrest, infections, and myalgia. Higher risk for mortality and serious cardiovascular events have been reported with higher targeted hemoglobin levels (>11 g/dL). If hemoglobin levels do not increase or reach targeted levels despite appropriate dose titrations over a 12-wk period, (1) **do not** administer higher doses; use the lowest dose that will maintain hemoglobin levels to avoid the need for recurrent blood transfusions; (2) evaluate and treat other causes of anemia; (3) always follow the dose adjustment instructions; and (4) discontinue use if patient remains transfusion dependent.



DARBEPOETIN ALFA *continued*


**USE IN CANCER:** Use only for anemia due to myelosuppressive chemotherapy; not effective in reducing the need for transfusions in patients with anemia not due to chemotherapy. Shortened survival and time to tumor progression have been reported in patients with various cancers. May cause fatigue, fever, edema, dizziness, headache, GI disturbances, arthralgia/myalgia, and rash. Use lowest dose to avoid transfusions and **do not exceed hemoglobin levels >12 g/dL**; increased frequency of adverse events, including mortality and thrombotic vascular events, have been reported.

**Prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense this drug to cancer patients.**

Monitor hemoglobin, BP, serum chemistries, and reticulocyte count. Increases in dose should not be made more frequently than once a month. For IV administration, infuse over 1–3 min.

**DEFEROXAMINE MESYLATE**

Desferal and generics

**Chelating agent**

C 2 Yes Yes No

**Injection:** 500, 2000 mg

**Acute iron poisoning (if using IV route, convert to IM as soon as the patient's clinical condition permits; see remarks):**

**Child:****IV:** 15 mg/kg/hr**IM:** 50 mg/kg/dose Q6 hr**Max. IV or IM dose:** 6 g/24 hr**Adult:****IV:** 15 mg/kg/hr**IM:** 1 g × 1, then 0.5 g Q4 hr × 2; may repeat 0.5 g Q4–12 hr**Max. dose:** 6 g/24 hr

**Chronic iron overload (see remarks):**

**Child and adolescent:****IV:** 20–40 mg/kg/dose over 8–12 hr once daily × 5–7 days per week; usual **max. dose:** 40 mg/kg/24 hr (child) or 60 mg/kg/24 hr (adolescent)**SC:** 20–40 mg/kg/dose once daily as infusion over 8–12 hr × 3–7 days per week; **max. dose:** 2 g/24 hr**Adult:****IV:** 40–50 mg/kg/dose over 8–12 hr once daily × 5–7 days per week; **max. dose:** 60 mg/kg/24 hr**IM:** 0.5–1 g/dose once daily; **max. dose:** 1 g/24 hr**SC:** 1–2 g/dose once daily as infusion over 8–24 hr

**Contraindicated** in severe renal disease or anuria. **Not approved** for use in primary hemochromatosis. May cause flushing, erythema, urticaria, hypotension, tachycardia, diarrhea, leg cramps, fever, cataracts, hearing loss, nausea, and vomiting. Iron mobilization may be poor in children <3 yr. Serum creatinine elevation, acute renal failure, renal tubular disorders, and hepatic dysfunction have been reported.

**Avoid** use if glomerular filtration rate (GFR) <10 mL/min and administer 25%–50% of usual dose if GFR is 10–50 mL/min or patient is receiving continuous renal replacement therapy (CRRT).

High doses and concomitant low ferritin levels have also been associated with growth retardation. Growth velocity may resume to pretreatment levels by reducing the dosage. Acute respiratory distress syndrome (ARDS) has been reported following treatment with excessively high IV doses in patients with acute iron intoxication or thalassemia. Toxicity risk has been reported with infusions >8 mg/kg/hr for >4 days for thalassemia, and with infusions of 15 mg/kg/hr for >1 day for acute iron toxicity. Pulmonary toxicity was not seen in 193 courses.

*Continued*

DEFEROXAMINE MESYLATE *continued*

For IV infusion, **maximum rate:** 15 mg/kg/hr. Infuse IV infusion over 6–12 hr for mild/moderate iron intoxication and over 24 hr for severe cases, then reassess. SC route is via a portable controlled-infusion device and is **not recommended** in acute iron poisoning.

**DESMOPRESSIN ACETATE**

DDAVP, Stimate, and generics

**Vasopressin analog, synthetic; hemostatic agent**

B



2



Yes



No



No

**Tabs:** 0.1, 0.2 mg**Injection:** 4 mCg/mL (1, 10 mL); contains 9 mg NaCl/mL and may contain chlorobutanol**Nasal spray:**

100 mCg/mL, 10 mCg/spray (50 sprays, 5 mL); contains 7.5 mg NaCl/mL and 0.2 mg benzalkonium chloride/mL

Stimate: 1500 mCg/mL, 150 mCg/spray (25 sprays, 2.5 mL); contains 7.5 mg NaCl/mL and 0.1 mg benzalkonium chloride/mL

**Conversion:** 100 mCg = 400 IU arginine vasopressin**Diabetes insipidus (see remarks):****Oral:****Child ≤12 yr:** Start with 0.05 mg/dose BID; titrate to effect; usual dose range: 0.1–0.8 mg/24 hr.**Child >12 yr and adult:** Start with 0.05 mg/dose BID; titrate dose to effect; usual dose range: 0.1–1.2 mg/24 hr ÷ BID–TID.**Nasal spray (titrate dose to achieve control of excessive thirst and urination. Morning and evening doses should be adjusted separately for diurnal rhythm of water turnover):****≥4–18 yr:** Start at 10 mCg once daily, may titrate up to 30 mCg/24 hr ÷ once daily or BID (20 mCg AM and 10 mCg PM).**Adult:** Start at 10 mCg once daily, may titrate up to 40 mCg/24 hr ÷ BID–TID.**Converting from IV dosage form:** Give 10 times the IV dose intranasally, rounding down to the nearest 10 mCg.**Converting from PO dosage form:** Intranasal dose is approximately 10- to 40-fold more potent than oral dose.**IV/SC:****<12 yr (limited data):** 0.1–1 mCg/24 hr ÷ once daily–BID; start with lower dose and increase as needed.**≥12 yr and adult:** 2–4 mCg/24 hr ÷ BID**Hemophilia A and von Willebrand disease:****Intranasal (≥11 mo, child and adolescent; using 150 mCg/spray product):****<50 kg:** 150 mcg (1 spray) 2 hr before procedure**≥50 kg:** 300 mcg (1 spray each nostril) 2 hr before procedure**IV (≥3 mo, child, adolescent):** 0.3 mCg/kg/dose over 15–30 min, administered 30 min before procedure**Nocturnal enuresis (≥6 yr; see remarks):****Oral:** 0.2 mg at bedtime; if needed, titrate to achieve desired effect by 0.2 mg Q3 days up to a **max. dose** of 0.6 mg/24 hr. Limit fluid intake to a minimum from 1 hr prior to desmopressin dosing until the next morning or at least 8 hr after dose administration.

**Use with caution** in hypertension, patients at risk for water intoxication with hyponatremia, and coronary artery disease. May cause headache, nausea, seizures, blood pressure changes, hyponatremia, nasal congestion, abdominal cramps, and hypertension.



DESMOPRESSIN ACETATE *continued*

Desmopressin is primarily excreted in the urine, and renal impairment may increase the elimination half-life (some consider use contraindicated when GFR is <50 mL/min).

**NOCTURNAL ENURESIS:** Intranasal formulations are no longer indicated by the FDA for primary **nocturnal enuresis** (children are susceptible for severe hyponatremia and seizures) or in patients with a history of hyponatremia. Patients using tablets should reduce their fluid intake to prevent potential water intoxication and hyponatremia, and have their therapy interrupted during acute illnesses that may lead to fluid and/or electrolyte imbalance.

Injection may be used SC or IV at approximately 10% of intranasal dose. Adjust fluid intake to decrease risk of water intoxication and monitor serum sodium.

If switching stabilized patient from intranasal route to IV/SC route, use 10% of intranasal dose. Peak effects: 1–5 hr with intranasal route; 1.5–3 hr with IV route; and 2–7 hr with PO route.

**DEXAMETHASONE**

Dexabliss, Dxevo, HiDex, TaperDex, ZCORT, Maxidex, and various generics; previously available as Decadron

**Corticosteroid**

C

3

No

No

No

**Tabs:** 0.5, 0.75, 1, 1.5, 2, 4, 6 mg

**Dexabliss, Dxevo:** 1.5 mg [39 tabs (11 days)]

**HiDex:** 1.5 mg [21 tabs (6 days)]

**TaperDex:** 1.5 mg [21 tabs (6 days), 27 tabs (7 days), 49 tabs (12 days)]

**ZCORT:** 1.5 mg [25 tabs (7 days)]

**Generic:** 1.5 mg [21 tabs (6 days), 35 tabs (10 days), 51 tabs (13 days)]

**Injection (sodium phosphate salt):** 4 mg/mL (1, 5, 30 mL), 10 mg/mL (1, 10 mL); some preparations contain benzyl alcohol or methyl/propyl parabens

**Oral elixir:** 0.5 mg/5 mL (237 mL); some preparations contain 5% alcohol

**Oral solution:** 0.1, 1 mg/mL; some preparations contain 30% alcohol

**Ophthalmic solution:** 0.1% (5 mL)

**Ophthalmic suspension (Maxidex):** 0.1% (5 mL)

**Airway edema/extubation:**

**Infant, child, and adolescent:** 0.5 mg/kg/dose (**max. dose:** 10 mg/dose) IV/IM/PO Q6 hr × 6 doses initiating therapy 6–12 hr prior to extubation

**Asthma exacerbation:**

**Infant, child, and adolescent:** 0.6 mg/kg/dose (**max. dose:** 16 mg/dose) PO/IV/IM Q24 hr × 1 or 2 doses; use beyond 2 days increases risk for metabolic adverse effects

**Croup:**

**Infant and child:** 0.6 mg/kg/dose PO/IV/IM ×1. **Usual max. dose:** 16 mg/dose

**Antiemetic (chemotherapy induced):**

**Initial:** 10 mg/m<sup>2</sup>/dose IV; **max. dose:** 20 mg

**Subsequent:** 5 mg/m<sup>2</sup>/dose Q6 hr IV

**Antiinflammatory:**

**Child:** 0.08–0.3 mg/kg/24 hr PO, IV, IM ÷ Q6–12 hr

**Adult:** 0.75–9 mg/24 hr PO, IV, IM ÷ Q6–12 hr

**Cerebral edema (infant, child, and adolescent; limited data):**

**Loading dose:** 1–2 mg/kg/dose IV/IM ×1

**Maintenance:** 1–2 mg/kg/24 hr ÷ Q4–6 hr; **max. dose:** 16 mg/24 hr

Continued

DEXAMETHASONE *continued***Ophthalmic use (infant, child, and adult):**

**Solution:** Instill 1–2 drops into the conjunctival sac(s) of the affected eye(s) Q1 hr during the day and Q2 hr during the night as initial therapy. When a favorable response is achieved, reduce dosage to Q3–4 hr. Further dose reduction to 1 drop TID–QID may be sufficient to control symptoms.

**Suspension:** Shake well before using. Instill 1–2 drops in the conjunctival sac(s) of the affected eye(s) up to 4–6 times/24 hr. For severe disease, drops may be used Q1 hr, being tapered to discontinuation as inflammation subsides. For mild disease, drops may be used  $\leq$ 4–6 times/24 hr.

**Not recommended** for systemic therapy in the prevention or treatment of chronic lung disease in infants with very low birth weight because of increased risk for adverse events.

Dexamethasone is a substrate of CYP P450 3A3/4 and P-glycoprotein, and a moderate inducer of CYP P450 3A4.

Compared to prednisone, dexamethasone has no mineralocorticoid effects with greater glucocorticoid effects. Consider use of alternative low glucocorticoid systemic steroid for patients with hyperglycemia. **Contraindicated** in active untreated infections and fungal, viral, and mycobacterial ocular infections.


Oral peak serum levels occur 1–2 hr and within 8 hr following IM administration. **For other uses, doses based on body surface area, and dose equivalence to other steroids, see Chapter 10.**

**OPHTHALMIC USE:** Use ophthalmic preparation only in consultation with an ophthalmologist. **Use with caution** in corneal/scleral thinning and glaucoma. Consider the possibility of persistent fungal infections of the cornea after prolonged use. Ophthalmic solution/suspension may be used in otitis externa.

**DEXMEDETOMIDINE**

Precedex and generics

$\alpha$  adrenergic agonist, sedative



C

?

No

Yes

No

**Injection (Precedex and generics):** 200 mCg/2 mL (2 mL); preservative free

**Multidose injection:** 400 mCg/4 mL (4 mL), 1000 mCg/10 mL (10 mL); contains methyl- and propylparabens

**Premixed injection in NS (Precedex and generics):** 80 mCg/20 mL (20 mL), 200 mCg/50 mL (50 mL), 400 mCg/100 mL (100 mL), 1000 mCg/250 mL (250 mL); preservative free

**NOTE:** Maintenance infusion rate dosing metric is mCg/kg/HR.

**ICU sedation:**

**Child (limited data):** 0.5–1 mCg/kg/dose IV  $\times$  1 over 10 min followed by 0.2–1 mCg/kg/hr infusion titrated to effect. Children <1 yr of age may require higher dosages.

**Adult:** 1 mCg/kg/dose IV  $\times$  1 over 10 min, followed by 0.2–0.7 mCg/kg/hr infusion and titrated to effect.

**Procedural sedation:****Child (limited data):**

**IV:** 2 mCg/kg/dose  $\times$  1 IV followed by 1.5 mCg/kg/hr was administered to children with autism/pervasive developmental disorders for sedation for electroencephalography (EEG).

**IM:** 1–4.5 mCg/kg/dose  $\times$  1 IM was administered to children for sedation for EEG. Extremely anxious, inconsolable, aggressive, and noncompliant children received doses >2.5 mCg/kg, and calm and relatively compliant children received doses  $\leq$ 2.5 mCg/kg. A second lower repeat dose ( $\sim$ 2 mCg/kg/dose IM) was administered when adequate sedation was not achieved after 10 min of the first dose.

**Intranasal route (limited data):** 1–2 mCg/kg/dose  $\times$  1 for premedication 30–60 min prior to anesthesia induction

**Adult:** 0.5–1 mCg/kg/dose IV  $\times$  1 over 10 min, followed by 0.6 mCg/kg/hr titrated to effect; dosage has ranged from 0.2–1 mCg/kg/hr

DEXMEDETOMIDINE *continued*

**Use with caution** with other vasodilating or negative chronotropic agents (additive pharmacodynamic effects), hepatic impairment (decrease drug clearance; consider dose reduction), advanced heart block, hypovolemia, diabetes mellitus, chronic hypertension, and severe ventricular dysfunction. Prolonged use >24 hr may be associated with tolerance and tachyphylaxis and dose-related side effects (ARDS, respiratory failure, and agitation). Withdrawal symptoms within 24 hr after discontinuing dexmedetomidine have been reported in ~5% of adults receiving the medication up to 7 days regardless of dosage; no withdrawal symptoms were seen in adults after discontinuing therapy lasting <6 hr in duration.

Hypotension and bradycardia are common side effects; may be more pronounced in hypovolemia, diabetes, or chronic hypertension. Transient hypertension has been observed during loading doses. QT prolongation, hypernatremia, sinus arrest, and polyuria have been reported. **Do not** abruptly withdraw therapy, as withdrawal symptoms (nausea, vomiting, and agitation) are possible; taper the dose when discontinuing use. May cause hyperthermia or pyrexia, which may be resistant to administration of cooled IV fluids and antipyretics; may require discontinuing dexmedetomidine.

Use with anesthetics, sedatives, hypnotics, and opioids may lead to enhanced effects; consider dosage reduction of dexmedetomidine. Dexmedetomidine is a CYP 450 2A6 substrate and a weak inhibitor of CYP 450 1A2, 2C9, and 3A4.

**Onset of action for procedural sedation:** IV or IM: 15 min, intranasal: 15–30 min. Duration of action for procedural sedation: IM: 1 hr, intranasal: 1–1.5 hr

This drug should be administered by individuals skilled in the management of patients in the ICU and OR. Concentrated IV solution (100 mcg/1 mL) must be diluted with NS to a concentration of 4 mcg/mL prior to administration. See [Chapter 6](#) for additional information.

**DEXMETHYLPHENIDATE**

Focalin, Focalin XR, and generics

**CNS stimulant**

C



3



No



No



No

**Tab, immediate release (Focalin and generics):** 2.5, 5, 10 mg

**Extended release caps (Focalin XR and generics):** 5, 10, 15, 20, 25, 30, 35, 40 mg

**Attention deficit/hyperactivity disorder:**

**METHYLPHENIDATE NAÏVE:**



Age/Dosage Form	Initial Dose	Dosage Increase at Weekly Intervals, if Needed	Daily Maximum Dose
<b>≥6 YR AND ADOLESCENT</b>			
Immediate release tabs <sup>a</sup>	2.5 mg PO BID	2.5–5 mg/24 hr	20 mg/24 hr (10 mg BID)
Extended release caps <sup>b</sup>	5 mg PO once daily	5 mg/24 hr	30 mg/24 hr (some may require and be able to tolerate up to 50 mg/24 hr)
<b>ADULT</b>			
Immediate release tabs <sup>a</sup>	2.5 mg PO BID	2.5–5 mg/24 hr	20 mg/24 hr (10 mg BID)
Extended release caps <sup>b</sup>	10 mg PO once daily	10 mg/24 hr	40 mg/24 hr

<sup>a</sup>BID dosing (at least 4 hr apart).

<sup>b</sup>Once-daily dosing.

*Continued*

DEXMETHYLPHENIDATE *continued***CONVERTING FROM METHYLPHENIDATE:**

**≥6 yr and adult:** Start at 50% of the total daily dose of racemic methylphenidate with the following **max. doses:**

**Immediate release tabs (BID dosing):** 20 mg/24 hr; some may require and be able to tolerate 50 mg/24 hr

**Extended release caps (once daily dosing):**

**≥6 yr—adolescent:** 30 mg/24 hr (some may require and be able to tolerate 50 mg/24 hr)

**Adult:** 40 mg/24 hr

**CONVERTING FROM IMMEDIATE RELEASE TABS (BID) TO EXTENDED RELEASE CAPS (ONCE DAILY) DEXMETHYLPHENIDATE:**

Use the equivalent mg dosage amount.

Dexmethylphenidate is the d-enantiomer of methylphenidate and accounts for the majority of clinical effects for methylphenidate. **Contraindicated** in glaucoma, anxiety disorders, motor tics, and Tourette syndrome. **Do not** use with monoamine oxidase (MAO) inhibitor; hypertensive crisis may occur if used within 14 days of discontinuance of MAO inhibitor. When used in combination with risperidone, any dosage change to either medication may increase the risk for extrapyramidal symptoms. See [Methylphenidate](#) for additional warnings and drug interactions.



Common side effects include abdominal pain, indigestion, appetite suppression, nausea, headache, insomnia, and anxiety. Peripheral vasculopathy, including Raynaud phenomenon, and priapism have been reported. Monitor for long-term growth suppression in children and assess for risk of abuse and dependence prior to prescribing.

Immediate release tablets are dosed BID (minimum 4 hr between doses), and extended release capsules are dosed once daily. Contents of the extended release capsule may be sprinkled on a spoonful of applesauce and consumed immediately for those who are unable to swallow capsules.

**DEXTROAMPHETAMINE ± AMPHETAMINE**

Dexedrine, ProCentra, Zenzedi, Xelstrym, and many generics

In combination with amphetamine: Adderall, Adderall XR, Mydayis, and generics

**CNS stimulant, amphetamine**



C



X



Yes



Yes



No

**Tabs, immediate release:**

**Generics:** 5, 10 mg

**Zenzedi:** 2.5, 5, 7.5, 10, 15, 20, and 30 mg

**Sustained release caps:**

**Generics:** 5, 10, 15 mg

**Dexedrine:** 10, 15 mg

**Oral solution (ProCentra and generics):** 1 mg/mL (473 mL); may contain benzoic acid and saccharin

**Transdermal patch (Xelstrym):** 4.5 mg/9 hr (4.76 cm<sup>2</sup> patch), 9 mg/9 hr (9.52 cm<sup>2</sup> patch), 13.5 mg/9 hr (14.29 cm<sup>2</sup> patch), and 18 mg/9 hr (19.02 cm<sup>2</sup> patch) (30s)

**In combination with amphetamine (Adderall):** Available as 1:1:1:1 mixture of dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate, and amphetamine sulfate salts (e.g., 5 mg tablet contains 1.25 mg dextroamphetamine sulfate, 1.25 mg dextroamphetamine saccharate, 1.25 mg amphetamine aspartate, and 1.25 mg amphetamine sulfate; 5 mg of the mixture is equivalent to 3.1 mg amphetamine base):

DEXTROAMPHETAMINE ± AMPHETAMINE *continued*

**Tabs (Adderall and generics):** 5, 7.5, 10, 12.5, 15, 20, 30 mg

**Caps, extended release:**

**Adderall XR and generics:** 5, 10, 15, 20, 25, 30 mg

**Mydayis:** 12.5, 25, 37.5, 50 mg

**Oral suspension:** 1 mg/mL 

Dosages are in terms of mg of dextroamphetamine when using dextroamphetamine alone OR in terms of mg of the total dextroamphetamine and amphetamine salts (e.g., Adderall, Mydayis, or generic equivalent).



**Attention deficit/hyperactivity disorder (PO):**

	Dextroamphetamine	Dextroamphetamine + Amphetamine
<b>Immediate release dosage forms<sup>a</sup></b>	<b>Zenzedi and generics</b>	<b>Adderall and generics</b>
3–5 yr	Start at 2.5 mg QAM; increase by 2.5 mg/24 hr at weekly intervals PRN to a <b>max. dose</b> of 40 mg/24 hr ÷ BID-TID (first dose in the morning)	Start at 2.5 mg QAM; increase by 2.5 mg/24 hr at weekly intervals PRN to a <b>max. dose</b> of 40 mg/24 hr ÷ QAM-TID (first dose in the morning)
6–17 yr	Start at 5 mg QAM or BID (first dose in the morning); increase by 5 mg/24 hr at weekly intervals PRN to a <b>max. dose</b> of 40 mg/24 hr ÷ BID-TID (first dose in the morning)	Start at 5 mg QAM or BID (first dose in the morning); increase by 5 mg/24 hr at weekly intervals PRN to a <b>max. dose</b> of 40 mg/24 hr ÷ QAM-TID (first dose in the morning). <b>Max. dose</b> of 60 mg/24 hr has been used in patients >50 kg.
<b>Extended/sustained release dosage forms<sup>b</sup></b>	<b>Dexedrine and generics</b>	<b>Adderall XR and generics</b>
6–12 yr	Start at 5 mg QAM or BID (first dose in the morning); increase by 5 mg/24 hr at weekly intervals PRN to a <b>max. dose</b> of 40 mg/24 hr ÷ QAM or BID (first dose in the morning). <b>Max. dose</b> of 60 mg/24 hr has been used in patients >50 kg.	Start at 5 or 10 mg QAM; increase by 5 or 10 mg/24 hr at weekly intervals PRN to a <b>max. dose</b> of 30 mg/24 hr. <b>Max. dose</b> of 60 mg/24 hr has been used in patients >50 kg.
13–17 yr	Similar dosing as 6–12 yr (see above)	Start at 10 mg QAM; if needed after 1 week, may increase to 20 mg QAM. <b>Max. dose:</b> 20 mg/24 hr. <b>Max. dose</b> of 60 mg/24 hr has been used in patients >50 kg.

<sup>a</sup>Usually given PO BID-TID; first dose upon awakening and subsequent doses at intervals of 4–6 hr later.

<sup>b</sup>Usually given PO once daily, sometimes BID (6–8 hr between doses).

*Continued*

DEXTROAMPHETAMINE ± AMPHETAMINE *continued***Mydayis (extended release capsules):**

**13–17 yr:** Start at 12.5 mg PO QAM; increase by 12.5 mg/24 hr PRN at weekly intervals to a **max. dose** of 25 mg/24 hr QAM.

**Adult:** Start at 12.5 mg PO QAM; increase by 12.5 mg/24 hr PRN at weekly intervals to a **max. dose** of 50 mg/24 hr QAM.

**Transdermal patch (Xelstrym; see remarks):** Apply to the hip, upper arm, chest, upper back, or flank 2 hr before the effect is desired and remove within 9 hr. Patch may be removed before 9 hr if shorter duration of effect is desired.

**6–17 yr:** Start with 4.5 mg/9 hr patch. Dose may be adjusted in weekly increments of 4.5 mg up to a **maximum** of 18 mg/9 hr.

**Adult:** Start with 9 mg/9 hr patch. **Maximum dose:** 18 mg/9 hr

**Narcolepsy (divide daily dosage once daily—TID for immediate release dosage form and once daily—BID for extended release dosage form; PO):**

**6–12 yr:** 5 mg/24 hr ÷ once daily-TID; increase by 5 mg/24 hr at weekly intervals to a **max. dose** of 60 mg/24 hr

**>12 yr and adult:** 10 mg/24 hr ÷ once daily-TID; increase by 10 mg/24 hr at weekly intervals to a **max. dose** of 60 mg/24 hr

**Use with caution** in presence of hypertension, cardiovascular disease, and renal or hepatic impairment (drug elimination may be decreased). **Avoid** use in known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may increase risk of sympathomimetic effects of amphetamines (sudden death, stroke, and MI have been reported). **Do not** give with MAO inhibitors (also within 14 days of discontinuance) or general anesthetics. Use with proton pump inhibitors (PPIs) may reduce the effectiveness of either dextroamphetamine or the combination with amphetamine.



DEXTROAMPHETAMINE AND AMPHETAMINE: Serotonin syndrome may occur when used with serotonergic neurotransmitter medications such as MAO inhibitors, SSRIs, serotonin and norepinephrine reuptake inhibitors (SNRIs), triptans, and TCAs. CYP 450 2D6 inhibitors may increase the effects/toxicity of the combination medication.

**Not recommended** for children <3 yr. Medication should generally **not** be used in children <5 yr old, as diagnosis of attention deficit and hyperactivity disorder (ADHD) in this age group is extremely difficult (use in consultation with a specialist). Interrupt administration occasionally to determine need for continued therapy. Many side effects, including insomnia (**avoid** dose administration within 6 hr of bedtime), restlessness/irritability, anorexia, psychosis, visual disturbances, headache, vomiting, abdominal cramps, dry mouth, and growth failure. Paranoia, mania, peripheral vasculopathy (including Raynaud phenomenon), priapism, bruxism, intestinal ischemia, and auditory hallucination have been reported. Assess for risk of abuse and dependence prior to prescribing. Tolerance develops. Same guidelines as for methylphenidate apply. See [Amphetamine](#) for amphetamine-containing products.

**DIAZEPAM**

Valium, Diastat, Diastat AcuDial, Valtoco, and generics

**Benzodiazepine; anxiolytic, anticonvulsant**



D



X



Yes



Yes



No

**Tabs:** 2, 5, 10 mg

**Oral solution:** 1 mg/mL, 5 mg/mL; contains 19% alcohol

**Injection:** 5 mg/mL (2, 10 mL); contains 40% propylene glycol, 10% alcohol, 5% sodium benzoate, and 1.5% benzyl alcohol

**Intramuscular auto-injector:** 5 mg/mL (2 mL); contains 40% propylene glycol, 10% alcohol, 5% sodium benzoate, and 1.5% benzyl alcohol

DIAZEPAM *continued***Rectal gel:**

**Pediatric rectal gel (Diastat and generics):** 2.5 mg (5 mg/mL concentration with 4.4 cm rectal tip delivery system; contains 10% alcohol, 1.5% benzyl alcohol, sodium benzoate, and propylene glycol); in twin packs

**Pediatric/Adult rectal gel (Diastat AcuDial and generics):**

**4.4 cm rectal tip delivery system (pediatric/adult):** 10 mg (5 mg/mL, delivers set doses of either 5, 7.5, or 10 mg); contains 10% alcohol, 1.5% benzyl alcohol, sodium benzoate, and propylene glycol; in twin packs

**6 cm rectal tip delivery system (adult):** 20 mg (5 mg/mL, delivers set doses of either 12.5, 15, 17.5, 20 mg); contains 10% alcohol, 1.5% benzyl alcohol, sodium benzoate, and propylene glycol; in twin packs

**Nasal spray:**

**Valtoco:** 5 mg/0.1 mL, 7.5 mg/0.1 mL, 10 mg/0.1 mL (in 2 individual blister packs with one nasal spray device in each blister pack); contains alcohol and benzyl alcohol

**Sedative/muscle relaxant:****Child:**

**IM or IV:** 0.05–0.2 mg/kg/dose Q6–12 hr; **max. dose:** 0.6 mg/kg within an 8-hr period

**PO:** 0.12–0.8 mg/kg/24 hr ÷ Q6–12 hr; **max. dose:** 10 mg/dose

**Adult:**

**IM or IV:** 5–10 mg/dose Q3–4 hr PRN

**PO:** 2–10 mg/dose Q6–8 hr PRN

**Status epilepticus:**

**Neonate (use only after failed therapy of other agents; note the excipients of the IV dosage forms):**

0.1–0.3 mg/kg/dose IV Q15–30 min × 2–3 doses up to **max. total dose** of 2 mg

**Child >1 mo–<5 yr:** 0.2–0.5 mg/dose IV Q2–5 min up to **max. total dose** of 5 mg. May repeat dosing in 2–4 hr as needed.

**Child ≥5 yr:** 1 mg/dose IV Q2–5 min up to **max. total dose** of 10 mg. May repeat dosing in 2–4 hr as needed.

**Adult:** 5–10 mg/dose IV Q10–15 min; **max. total dose:** 30 mg in an 8-hr period. May repeat dosing in 2–4 hr as needed.

**Acute seizures:**

**Nasal spray:** Administer one dose using the dosing table below. If needed, a second dose may be administered 4 hr after the first dose. **Max. dose:** 2 doses per single seizure episode. Do not use more than once every 5 days and no more than 5 times per month.

**Child >6 yr and adult:**

Dose Based on Age and Weight			Administration	
6–11 yr (0.3 mg/kg/dose) Weight (kg)	≥12 yr (0.2 mg/kg/dose) Weight (kg)	Dose (mg)	Number of Nasal Spray Devices	Number of Sprays
10–18	14–27	5	One 5 mg device	One spray in only one nostril
19–37	28–50	10	One 10 mg device	One spray in only one nostril
38–55	51–75	15	Two 7.5 mg devices	One spray in each nostril
56–74	>76	20	Two 10 mg devices	One spray in each nostril

*Continued*

DIAZEPAM *continued*

**Rectal dose (using IV dosage form):** 0.5 mg/kg/dose followed by 0.25 mg/kg/dose in 10 min PRN; **max. dose:** 20 mg/dose

**Rectal gel:** All doses rounded up to the nearest 2.5 mg increment; repeat dose in 4–12 hr PRN. **Do not use** more than once every 5 days and no more than 5 times per month.

**2–5 yr:** 0.5 mg/kg/dose

**6–11 yr:** 0.3 mg/kg/dose

**≥12 yr and adult:** 0.2 mg/kg/dose

**Max. dose (all ages):** 20 mg/dose

**Contraindicated** in myasthenia gravis, severe respiratory insufficiency, severe hepatic failure, and sleep apnea syndrome. Hypotension and respiratory depression may occur.

**Use with caution** in hepatic and renal dysfunction, glaucoma, shock, and depression.

**Do not** use in combination with protease inhibitors. Concurrent use with CNS depressants, cimetidine, erythromycin, itraconazole, and valproic acid may enhance the effects of diazepam. Use with opioids may result in profound sedation, respiratory depression, coma, and mortality. Diazepam is a substrate for CYP 450 2B6, 2C8, 2C9, and 3A5-7, and minor substrate and inhibitor for CYP 450 2C19 and 3A3/4. The active desmethyldiazepam metabolite is a CYP 450 2C19 substrate.

Nasal discomfort, dysgeusia, and epistaxis may occur with the intranasal route of administration.

Ataxia, headache, dizziness, sedation, and rash have been reported with use of the the rectal gel.

Administer the conventional IV product undiluted no faster than 2 mg/min and **do not** mix with IV fluids. **Do not** test or prime the nasal spray dosage form as each device sprays one time only.

In status epilepticus, diazepam must be followed by long-acting anticonvulsants. Onset of anticonvulsant effect: 1–3 min with IV route; 2–10 min with rectal route; and <5 min with intranasal route. **For management of status epilepticus, see Chapter 1.**

**DIAZOXIDE**

Proglycem and generics

**Antihypoglycemic agent**



C



?



Yes



No



No

**Oral suspension:** 50 mg/mL (30 mL); contains 7.25% alcohol

**Hyperinsulinemic hypoglycemia (due to insulin-producing tumors; start at the lowest dose; see remarks):**



**Newborn and infant:** Start at 5 mg/kg/24 hr ÷ Q8–12 hr PO and gradually titrate if needed; usual range of 8–15 mg/kg/24 hr with reported range of 5–20 mg/kg/24 hr ÷ Q8–12 hr

**Child and adolescent:** Start at 5 mg/kg/24 hr ÷ 8 hr PO and gradually titrate if needed; usual range: 3–8 mg/kg/24 hr ÷ Q8–12 hr PO

Hypoglycemia should be treated initially with IV glucose; diazoxide should be introduced only if refractory to glucose infusion. Should **not** be used in patients hypersensitive to thiazides unless benefit outweighs risk. Thiazides may enhance diazoxide's hyperglycemic effects.



**Use with caution** in renal impairment (clearance of drug is reduced); consider dosage reduction. Sodium and fluid retention is common in young infants and adults and may precipitate congestive heart failure (CHF) in patients with compromised cardiac reserve (usually responsive to diuretics). Hirsutism (reversible), GI disturbances, transient loss of taste, tachycardia, ketoacidosis, palpitations, rash, headache, weakness, and hyperuricemia may occur. Pulmonary hypertension in newborns/infants treated for hypoglycemia (especially at doses ≥10 mg/kg/24 hr) has been reported, and resolution/improvement of the condition was achieved after discontinuing diazoxide. Monitor BP closely for hypotension.

Hyperglycemic effect with PO administration occurs within 1 hr, with a duration of 8 hr.

**DIGOXIN**

Lanoxin, Lanoxin Pediatric, Digitek, and generics

**Antiarrhythmic agent, inotrope**

C



2



Yes



No



No

**Tabs:****Digitek:** 125, 250 mCg**Lanoxin and generics:** 62.5, 125, 250 mCg**Oral solution:** 50 mCg/mL (60 mL); may contain 10% alcohol**Injection:****Lanoxin Pediatric:** 100 mCg/mL (1 mL); may contain propylene glycol and alcohol**Lanoxin and generics:** 250 mCg/mL (2 mL); may contain propylene glycol and alcohol**Digitalizing:** Total digitalizing dose (TDD) and maintenance doses in mCg/kg/24 hr (see the following table):**DIGOXIN DIGITALIZING AND MAINTENANCE DOSES**

Age	TDD		Daily Maintenance	
	PO	IV/IM	PO	IV/IM
Premature neonate	20	15	5	3–4
Full-term neonate	30	20	8–10	6–8
1 mo—<2 yr	40–50	30–40	10–12	7.5–9
2–10 yr	30–40	20–30	8–10	6–8
>10 yr and <100 kg	10–15	8–12	2.5–5	2–3

TDD, Total digitalizing dose.

**Initial:**  $\frac{1}{2}$  TDD, then  $\frac{1}{4}$  TDD Q8–18 hr  $\times$  2 doses; obtain electrocardiogram (ECG) 6 hr after dose to assess for toxicity**Maintenance:****<10 yr:** Give maintenance dose  $\div$  BID. **$\geq$ 10 yr:** Give maintenance dose once daily.

**Contraindicated** in patients with ventricular dysrhythmias. Use should be **avoided** in patients with preserved left ventricular systolic function. **Use with caution** in renal failure, with calcium channel blockers (may result in heart block), and with adenosine (enhanced depressant effects on sinoatrial [SA] and atrioventricular [AV] nodes). May cause AV block or dysrhythmias. In patients treated with digoxin, cardioversion, or calcium infusion, may lead to ventricular fibrillation (pretreatment with lidocaine may prevent this). Patients with beri beri heart disease may not respond to digoxin if underlying thiamine deficiency is not treated concomitantly. Decreased serum potassium and magnesium, or increased magnesium and calcium may increase risk for digoxin toxicity. For signs and symptoms of toxicity, see [Chapter 3](#).



Excreted via the kidney; **adjust dose in renal failure (see Chapter 31)**. Therapeutic concentration: 0.8–2 ng/mL. Higher doses may be required for supraventricular tachycardia. Neonates, pregnant women, and patients with renal, hepatic, or heart failure may have falsely elevated digoxin levels due to the presence of digoxin-like substances.

Digoxin is a CYP450 3A4 and P-glycoprotein substrate. Calcium channel blockers, captopril, carvedilol, amiodarone, quinidine, cyclosporine, itraconazole, tetracycline, and macrolide antibiotics may increase digoxin levels. Use with  $\beta$ -blockers and ivabradine may increase risk for bradycardia.


Succinylcholine may cause arrhythmias in digitalized patients.

$T_{1/2}$ : Premature infants, 61–170 hr; full-term neonates, 35–45 hr; infants, 18–25 hr; and children, 35 hr. Recommended serum sampling at steady state: Obtain a single level from 6 hr postdose to just before the next scheduled dose following 5–8 days of continuous dosing. Levels obtained prior to steady state may be useful in preventing toxicity.

**DIGOXIN IMMUNE FAB (OVINE)**

DigiFab

*Antidigoxin antibody*



**Injection:** 40 mg; derived from the blood of healthy sheep immunized with digoxin derivative

**Dosing based on known amounts of digoxin acutely ingested:**

**First, determine total body digoxin load (TBL):**

$$\text{TBL (mg)} = \text{mg digoxin ingested} \times 0.8$$

**Then, calculate digoxin immune Fab dose:**

$$\text{Dose in number of digoxin immune Fab vials (DigiFab): } \# \text{ of vials} = \text{TBL} \div 0.5$$

**Dosing based on steady-state serum digoxin levels:**

DigiFab dose (mg) from steady-state digoxin levels



**Serum Digoxin Concentration (ng/mL)**

Patient Weight (kg)	1	2	4	8	12	16	20
1	0.4 mg <sup>a</sup>	1 mg <sup>a</sup>	1.5 mg <sup>a</sup>	3 mg <sup>a</sup>	5 mg	6.5 mg	8 mg
3	1 mg <sup>a</sup>	2.5 mg <sup>a</sup>	5 mg	10 mg	14 mg	19 mg	24 mg
5	2 mg <sup>a</sup>	4 mg	8 mg	16 mg	24 mg	32 mg	40 mg
10	4 mg	8 mg	16 mg	32 mg	48 mg	64 mg	80 mg
20	8 mg	16 mg	32 mg	64 mg	96 mg	128 mg	160 mg
40	20 mg	40 mg	80 mg	120 mg	200 mg	280 mg	320 mg
60	20 mg	40 mg	120 mg	200 mg	280 mg	400 mg	480 mg
70	40 mg	80 mg	120 mg	240 mg	360 mg	440 mg	560 mg
80	40 mg	80 mg	120 mg	280 mg	400 mg	520 mg	640 mg
100	40 mg	80 mg	160 mg	320 mg	480 mg	640 mg	800 mg

<sup>a</sup>Use 1 mg/mL DigiFab concentration for dose accuracy.

**Dosage administration:**

Reconstitute each vial with 4 mL NS for a 10 mg/mL concentration and infuse IV dose over 30 min. If an infusion rate reaction occurs, stop infusion and restart at a slower rate. In situations of cardiac arrest, DigiFab can be administered as a bolus injection, but expect an increased risk for infusion-related reactions. For smaller doses, vials may be reconstituted with 36 mL NS for a 1 mg/mL concentration.

**Contraindicated** if hypersensitive to sheep products. **Use with caution** in renal or cardiac failure. May cause rapidly developing severe hypokalemia, decreased cardiac output (from withdrawal of digoxin's inotropic effects), rash, edema, and phlebitis. Digoxin therapy may be reinstated in 3–7 days, when toxicity has been corrected. Digoxin-immune FAB will interfere with digitalis immunoassay measurements to result in misleading concentrations.



**DILTIAZEM**

Cardizem, Cardizem CD, Cardizem LA, Cartia XT, Matzim LA, Taztia XT, Tiazac, and many others including generics

*Calcium channel blocker, antihypertensive*



DILTIAZEM *continued*

**Tabs:** 30, 60, 90, 120 mg

**Extended release tabs (for Q24 hr dosing):**

Various generics: 180, 240, 300, 360, 420 mg

Cardizem LA: 120, 180, 240, 300, 360, 420 mg

Matzim LA: 180, 240, 300, 360, 420 mg

**Extended release caps (for Q12 hr dosing):** 60, 90, 120 mg

**Extended release caps (for Q24 hr dosing):**

Various generics: 120, 180, 240, 300, 360, 420 mg

Cardizem CD, Taztia XT: 120, 180, 240, 300, 360 mg

Cartia XT: 120, 180, 240, 300 mg

Tiazac: 120, 180, 240, 300, 360, 420 mg

**Oral liquid:** 12 mg/mL 

**Injection:** 5 mg/mL (5, 10, 25 mL)

**Hypertension:**

**Child:** 1.5–2 mg/kg/24 hr PO ÷ TID–QID; **max. dose:** 3.5 mg/kg/24 hr; alternative **max. dose** of 6 mg/kg/24 hr up to 360 mg/24 hr has been recommended 

**Adolescent and adult:**

**Immediate release:** 30–120 mg/dose PO TID–QID; usual range 180–360 mg/24 hr

**Extended release:** 120–360 mg/24 hr PO ÷ once daily–BID (BID dosing with Q12 hr extended release generic capsule; once daily dosing with extended release tab, Cardizem CD, Cartia XT, Cardizem LA, Matzim LA, Taztia XT, Tiazac, and Q24 hr generic extended release capsule or tab); **max. dose:** 540 mg/24 hr

**Contraindicated** in acute myocardial infarction (MI) with pulmonary congestion, second- or third-degree heart block, and sick sinus syndrome. **Use with caution** in CHF or renal and hepatic impairment. Dizziness, headache, edema, nausea, vomiting, heart block, and arrhythmias may occur. Acute hepatic injury and severe skin reactions have been reported. Monitor heart rate with concurrent clonidine use (sinus bradycardia has been reported). 

Diltiazem is a substrate and inhibitor of the CYP 450 3A4 enzyme system. May increase levels and effects/toxicity of buspirone, cyclosporine, carbamazepine, fentanyl, digoxin, ivabradine, quinidine, tacrolimus, benzodiazepines, and  $\beta$ -blockers. Cimetidine and statins may increase diltiazem serum levels. Rifampin may decrease diltiazem serum levels.

Maximal antihypertensive effect seen within 2 wk. Extended release dosage forms should be swallowed whole and NOT crushed or chewed. Cardizem immediate release tablets should be swallowed whole, as crushing or chewing them may alter their pharmacokinetics.

**DIMENHYDRINATE**

Dramamine, Driminate, and generics

**Antiemetic, antihistamine**



B



3



No



No



No

**Tabs (OTC):** 50 mg

**Chewable tabs (OTC):** 50 mg; contains 0.75 mg phenylalanine

**Injection:** 50 mg/mL; contains benzyl alcohol and propylene glycol

**Child (<12 yr):** 5 mg/kg/24 hr ÷ Q6 hr PO/IM/IV; alternative oral dosing by age: 

2–5 yr: 12.5–25 mg/dose Q6–8 hr PRN PO with the max. dosage below

*Continued*

DIMENHYDRINATE *continued*

**6–12 yr:** 25–50 mg/dose Q6–8 hr PRN PO with the max. dosage below

**≥12 yr and adult:** 50–100 mg/dose Q4–6 hr PRN PO/IM/IV

**MAX. PO DOSE:**

**2–5 yr:** 75 mg/24 hr

**6–12 yr:** 150 mg/24 hr

**≥12 yr and adult:** 400 mg/24 hr

**MAX. IM DOSE:**

**Child:** 300 mg/24 hr

Causes drowsiness and anticholinergic side effects. May mask vestibular symptoms and cause CNS excitation in young children. **Caution** when taken with ototoxic agents or history of seizures. **Use should be limited to management of prolonged vomiting of known etiology. Not recommended** in children <2 yr. Toxicity resembles anticholinergic poisoning.

**DIPHENHYDRAMINE**

Benadryl, many other brand names, and generics

**Antihistamine**



B



3



Yes



No



No

**Elixir (OTC):** 12.5 mg/5 mL; may contain 5.6% alcohol

**Oral liquid/solution (OTC):** 12.5 mg/5 mL

**Caps/tabs (OTC):** 25, 50 mg

**Chewable tabs (OTC):** 12.5 mg; contains aspartame, phenylalanine

**Injection:** 50 mg/mL (1, 10 mL)

**Topical cream (OTC):** 2% (28, 35, 42 g); may contain zinc acetate

**Topical gel (OTC):** 2% (103, 118 mL); contains parabens

**Topical stick (OTC):** 2% (14 mL); contains alcohol

**Severe allergic reaction (anaphylaxis) and dystonic reactions (including phenothiazine toxicity) (PO/IM/IV):**

**Child:** 1–2 mg/kg/dose Q6 hr; usual dose: 5 mg/kg/24 hr ÷ Q6 hr. **Max. dose:** 50 mg/dose and 300 mg/24 hr

**Adult:** 25–50 mg/dose Q4–8 hr; **max. dose:** 400 mg/24 hr

**Sleep aid (PO/IM/IV):** Administer dose 30 min before bedtime.

**2–11 yr:** 0.5–1 mg/kg/dose; **max. dose:** 50 mg/dose

**≥12 yr:** 25–50 mg

**Topical (cream, gel, stick):**

**≥2 yr—adult:** Apply to affected area no more than TID–QID.



**Contraindicated** with concurrent MAO inhibitor use, acute attacks of asthma, GI or urinary obstruction. **Use with caution** in infants and young children, and **do not use** in neonates due to potential CNS effects. Side effects include sedation, nausea, vomiting, xerostoma, blurred vision, and other reactions common to antihistamines. CNS side effects more common than GI disturbances. May cause paradoxical excitement in children. False-positive test for urine phencyclidine (PCP) screen may occur. **Adjust dose in renal failure (see Chapter 31).**



**TOPICAL USE:** Side effects include rash, urticaria, and photosensitivity.

**DIVALPROEX SODIUM**

Depakote, Depakote Sprinkles, Depakote ER, and generics

**Anticonvulsant**

D/X



2



No



Yes



Yes

**Delayed release tabs:** 125, 250, 500 mg**Extended release tabs (for Q24 hr dosing):****Depakote ER and generics:** 250, 500 mg**Sprinkle caps (Depakote Sprinkles and generics):** 125 mg**Dose:** See [Valproic Acid](#).

See [Valproic Acid](#). Preferred over valproic acid for patients on ketogenic diet. **Contraindicated** with known urea cycle disorders. Depakote ER is prescribed by a once-daily interval, whereas Depakote is typically prescribed BID. Depakote and Depakote ER are not bioequivalent; see package insert for dose conversion.



Efficacy was not established in separate randomized double-blinded, placebo-controlled trials for the treatment of pediatric bipolar disorder (10–17 yr old) and migraine prophylaxis (12–17 yr old). Pregnancy category is “X” when used for migraine prophylaxis and is “D” for all other indications.

**DOBUTAMINE**

Various generics; previously available as Dobutrex

**Sympathomimetic agent**

B



?



No



No



No

**Injection:** 12.5 mg/mL (20 mL); contains sulfites**Prediluted injection in D<sub>5</sub>W:** 1 mg/mL (250 mL), 2 mg/mL (250 mL), 4 mg/mL (250 mL)**Continuous IV infusion (all ages):** 2–20 mCg/kg/min**Recommended max. dose:** 40 mCg/kg/min**To prepare infusion:** See [page iii](#).

**Contraindicated** in idiopathic hypertrophic subaortic stenosis (IHSS). Tachycardia, arrhythmias (premature ventricular contractions [PVCs]), and hypertension may occasionally occur (especially at higher infusion rates). Correct hypovolemic states before use. Increases AV conduction and may precipitate ventricular ectopic activity.



Dobutamine has been shown to increase cardiac output and systemic pressure in pediatric patients of every age group. However, in premature neonates, dobutamine is less effective than dopamine in raising systemic blood pressure without causing undue tachycardia, and dobutamine has not been shown to provide any added benefit when given to such infants already receiving optimal infusions of dopamine.

Monitor BP and vital signs.  $T_{1/2}$ : 2 min. Peak effects in 10–20 min. Use with linezolid may potentially increase blood pressure. Use with catechol-O-methyltransferase (COMT) inhibitors (e.g., entacapone) may increase heart rate and risk for arrhythmias and changes in blood pressure.

**DOCUSATE**

Colace, DocuSol Kids, DocuSol Mini, Enemeez Mini, and many other brands

**Stool softener, laxative**

C



1



No



No



No

Continued

DOCUSATE *continued***Available as docusate sodium:****Caps (OTC):** 100, 250 mg; sodium content (100 mg cap: ~5 mg)**Tab (OTC):** 100 mg**Syrup (OTC):** 20 mg/5 mL (473 mL); may contain alcohol**Oral liquid (OTC):** 10 mg/mL (118, 473 mL); contains 1 mg/mL sodium**Rectal enema:****DocuSol Kids (OTC):** 100 mg/5 mL (5 mL); contains polyethylene glycol**Enemeez Mini, and DocuSol Mini (OTC):** 283 mg/5 mL (5 mL); DocuSol Plus product contains benzocaine**Available as docusate calcium:****Caps (OTC):** 240 mg**PO (take with liquids; see remarks):****<3 yr:** 10–40 mg/24 hr ÷ once daily—QID**3–6 yr:** 20–60 mg/24 hr ÷ once daily—QID**6–12 yr:** 40–150 mg/24 hr ÷ once daily—QID**>12 yr and adult:** 50–400 mg/24 hr ÷ once daily—QID**Rectal (see remarks):****2–<12 yr:** 100 mg/5 mL or 283 mg/5 mL PR once daily**≥12 yr and adult:** 283 mg/5 mL PR once daily—TID. Alternatively, 50–100 mg of oral liquid (not syrup) mixed in enema fluid (saline or oil retention enemas) may be used.

Oral dosage effective only after 1–3 days of therapy, whereas the enema has an onset of action in 2–15 min. Reassess therapy if no response seen after 7 days of continuous use.

Incidence of side effects is exceedingly low. Rash, nausea, and throat irritation have been reported.

Oral liquid is bitter; give with milk, fruit juice, or formula to mask taste.

A few drops of the 10 mg/mL oral liquid may be used in the ear as a cerumenolytic. Effect is usually seen within 15 min.

**DOLASETRON**

Anzemet

**Antiemetic agent, 5-HT<sub>3</sub> antagonist**

B

?

Yes

Yes

No

**Tab:** 50 mg**Oral suspension:** 10 mg/mL **Chemotherapy-induced nausea and vomiting prevention:**

**2 yr—adult:** 1.8 mg/kg/dose PO up to a **max. dose** of 100 mg. Administer PO dose 60 min prior to chemotherapy. IV route of administration is considered **contraindicated** for this indication due to increased risk for QTc prolongation and is no longer available.

May cause hypotension and prolongation of cardiac conduction intervals, particularly QTc interval (dose-dependent effect). Common side effects include dizziness, headache, sedation, blurred vision, fever, chills, and sleep disorders. Rare cases of sustained supraventricular and ventricular arrhythmias, fatal cardiac arrest, and MI have been reported in children and adolescents.

**Avoid** use in patients with congenital long QTc syndrome, hypomagnesemia, hypokalemia, or with concurrent use with other drugs that increase QTc interval (e.g., erythromycin, cisapride). Drug's active metabolite (hydrodolasetron) is a substrate for CYP 450 2D6 and 3A3/4 isoenzymes; concomitant use of enzyme inhibitors (e.g., cimetidine) may increase risk for side effects, and use of enzyme inducers (e.g., rifampin) may decrease dolasetron's efficacy. Serotonin syndrome has been associated with concurrent use of SSRIs (e.g., fluoxetine, sertraline), SNRIs (e.g., duloxetine, venlafaxine), MAO inhibitors, mirtazapine, fentanyl, lithium, tramadol, and IV methylene blue.

DOLASETRON *continued*

Although no dosage adjustments are necessary, hydrodolasetron's clearance decreases 42% with severe hepatic impairment and 44% with severe renal impairment.

ECG monitoring is recommended in patients with electrolyte abnormalities, CHF, bradyarrhythmias, or renal impairment.

**DOPAMINE**

Various generics; previously available as Intropin

**Sympathomimetic agent**



C ? No No No

**Injection:** 40 mg/mL (5, 10 mL)

**Prediluted injection in D<sub>5</sub>W:** 0.8, 1.6, 3.2 mg/mL (250, 500 mL)

**All ages:**

**Low dose:** 2–5 mCg/kg/min IV; increases renal blood flow; minimal effect on heart rate and cardiac output

**Intermediate dose:** 5–15 mCg/kg/min IV; increases heart rate, cardiac contractility, cardiac output, and to a lesser extent, renal blood flow

**High dose:** >15 mCg/kg/min IV;  $\alpha$  adrenergic effects are prominent; decreases renal perfusion

**Max. dose recommended:** 20–50 mCg/kg/min IV

**To prepare infusion:** See [page iii](#).



**Do not use** in pheochromocytoma, tachyarrhythmias, or hypovolemia. Monitor vital signs and blood pressure continuously. Correct hypovolemic states. Tachyarrhythmias, ectopic beats, hypertension, vasoconstriction, and vomiting may occur. **Use with caution** with phenytoin because hypotension and bradycardia may be exacerbated. Use with linezolid may potentially increase blood pressure.



Newborn infants may be more sensitive to the vasoconstrictive effects of dopamine. Children <2 yr of age clear dopamine faster, and high variability in neonates is exhibited.

Should be administered through a central line or large vein. Extravasation may cause tissue necrosis; treat with phentolamine. **Do not** administer into an umbilical arterial catheter.

**DORNASE ALFA/DNASE**

Pulmozyme

**Inhaled mucolytic**



B 1 No No No

**Inhalation solution:** 1 mg/mL (2.5 mL; in boxes of 30s)

**Cystic fibrosis:**

**Child 3 mo—<5 yr (limited data from 65 patients receiving 2 wk of therapy):** 2.5 mg via nebulizer once daily

**Child  $\geq$ 5 yr and adult:** 2.5 mg via nebulizer once daily. Some patients may benefit from 2.5 mg BID.



**Contraindicated** in patients with hypersensitivity to epoetin alfa. Voice alteration, pharyngitis, laryngitis may result. These are generally reversible without dose adjustment. Safety and efficacy have not been demonstrated in patients >1 yr of continuous use.



Has been used intranasally via the Pari Sinus device for chronic rhinosinusitis in cystic fibrosis (>5 yr and adult); 2.5 mg intranasally once daily (limited data).

**Do not** mix with other nebulized drugs. An inhaled  $\beta$ -agonist may be useful before administration to enhance drug distribution. Chest physiotherapy should be incorporated into treatment regimen. The following nebulizer compressor systems have been recommended for use: Pulmo-Aide, Pari-Proneb, Mobilaire, Porta-Neb, or PariBaby. Use of the “Sidestream” nebulizer cup can significantly reduce the medication administration time.

*Continued*

**DOXYCYCLINE**

Acticlate, Vibramycin, Doxy, Doryx, Monodox,

Oracea, many others, and generics

**Antibiotic, tetracycline derivative**

D



2



Yes



Yes



No

**Caps:** 50, 75, 100, 150 mg**Tabs (Acticlate and generics):** 20, 50, 75, 100, 150 mg**Delayed release caps (Oracea and generics):** 40 mg**Delayed release tabs (Doryx and generics):** 50, 75, 80, 100, 150, 200 mg**Syrup:** 50 mg/5 mL (473 mL); contains parabens and propylene glycol**Oral suspension:** 25 mg/5 mL (60 mL)**Injection (Doxy and generics):** 100 mg**General dosing, Lyme disease, rickettsial disease, Rocky Mountain spotted fever, and skin/soft tissue infection** (see remarks):**≤45 kg:** 2.2 mg/kg/dose BID PO/IV; **max. dose:** 200 mg/24 hr**>45 kg:** 100 mg/dose BID PO/IV**Max. dose:** 200 mg/24 hr**PID (see latest CDC STI treatment guidelines):****Inpatient:** 100 mg IV Q12 hr with cefotetan or ceftioxin, or ceftriaxone + metronidazole. Convert to oral therapy 24 hr after patient improves on IV to complete a 14-day total course (IV and PO).**Outpatient:** 100 mg PO Q12 hr × 14 days with ceftriaxone single IM dose with metronidazole, or ceftioxin single IM dose + probenecid single PO dose with metronidazole, or other parenteral third-generation cephalosporin with metronidazole**Anthrax (inhalation/systemic/cutaneous; see remarks):** Initiate therapy with IV route and convert to PO route when clinically appropriate. Duration of therapy is 60 days (IV and PO combined):**≤8 yr or ≤45 kg:** 2.2 mg/kg/dose BID IV/PO; **max. dose:** 200 mg/24 hr**>8 yr and >45 kg:** 100 mg/dose BID IV/PO**Malaria prophylaxis (start 1–2 days prior to exposure and continue for 4 wk after leaving endemic area):****≥8 yr:** 2.2 mg/kg/24 hr PO once daily; **max. dose:** 100 mg/24 hr and max. duration of 4 mo**Adult:** 100 mg PO once daily**Acne:****≥8 yr and adolescent:** 50-100 mg BID PO or 150 mg once daily PO**Periodontitis:****Adult:** 20 mg BID PO × ≤9 mo**Use with caution** in hepatic and renal disease. Generally **not recommended** for use in children <8 yr due to risk for tooth enamel hypoplasia and discoloration. However, the AAP Red Book recommends doxycycline as the drug of choice for rickettsial disease regardless of age and the use in children <8 yr for short treatment courses (≤21 days). May cause GI symptoms, photosensitivity, hemolytic anemia, rash, and hypersensitivity reactions. Increased intracranial pressure (pseudotumor cerebri), TEN, DRESS, erythema multiforme, and Stevens-Johnson syndrome have been reported.Doxycycline is approved for the treatment of anthrax (*Bacillus anthracis*) in combination with one or two other antimicrobials. If meningitis is suspected, consider using an alternative agent because of poor CNS penetration. Consider changing to high-dose amoxicillin (25–35 mg/kg/dose TID PO) for penicillin-susceptible strains. See [www.cdc.gov/anthrax/treatment/index.html](http://www.cdc.gov/anthrax/treatment/index.html) for the latest information.

Rifampin, barbiturates, phenytoin, and carbamazepine may increase clearance of doxycycline.

Doxycycline may enhance the hypoprothrombinemic effect of warfarin. See [Tetracycline](#) for additional drug/food interactions and remarks.Infuse IV over 1–4 hr. **Avoid** prolonged exposure to direct sunlight.

For periodontitis, take tablets ≥1 hr prior to or 2 hr after meals.



**DRONABINOL**

Marinol, Syndros, Tetrahydrocannabinol, THC,  
and generics

**Antiemetic**



C



X



No



Yes



Yes

**Caps (Marinol and generics):** 2.5, 5, 10 mg; may contain sesame oil

**Oral solution (Syndros):** 5 mg/mL (30 mL); contains alcohol (50% w/w), parabens, and polyethylene glycol

**Oral capsule and solution dosage forms are NOT bioequivalent and should not be used interchangeably.**

**ORAL CAPSULES:****Antiemetic:**

**Child and adult (PO capsules):** 5 mg/m<sup>2</sup>/dose 1–3 hr prior to chemotherapy, then Q2–4 hr up to a **max. dose** of 4–6 doses/24 hr; doses may be gradually increased by 2.5 mg/m<sup>2</sup>/dose increments up to a **max. dose** of 15 mg/m<sup>2</sup>/dose if needed and tolerated.

**Appetite stimulant:**

**Adult (PO capsules):** 2.5 mg BID 1 hr before lunch and dinner; if not tolerated, reduce dose to 2.5 mg once daily 1 hr before dinner or QHS. **Max dose:** 20 mg/24 hr (use **caution** when increasing doses because of increased risk of dose-related adverse reactions at higher dosages)

**ORAL SOLUTION:****Antiemetic:**

**Adult (PO oral solution):** 4.2 mg/m<sup>2</sup>/dose 1–3 hr prior to chemotherapy, then Q2–4 hr up to a **max. dose** of 4–6 doses/24 hr; doses may be gradually increased by 2.1 mg/m<sup>2</sup>/dose increments up to a **max. dose** of 12.6 mg/m<sup>2</sup>/dose if needed and tolerated.

**Appetite stimulant:**

**Adult (PO oral solution):** 2.1 mg BID 1 hr before lunch and dinner; if not tolerated, reduce dose to 2.1 mg once daily 1 hr before dinner or QHS. Dose may be gradually increased, if needed and tolerated, by increasing the pre-dinner dose to 4.2 mg 1 hr before dinner. Further increase to 4.2 mg BID 1 hr before lunch and dinner if needed and tolerated. **Max. dose:** 16.8 mg/24 hr

**Contraindicated** in patients with history of substance abuse and mental illness and allergy to sesame oil (capsules only). **Use with caution** in heart disease, seizures, hepatic disease (reduce dose if severe), and in patients who operate motor vehicles or dangerous machinery. Side effects: euphoria, dizziness, difficulty concentrating, anxiety, mood change, sedation, hallucinations, ataxia, paresthesia, hypotension, excessively increased appetite, and habit-forming potential. Exacerbation of mania, depression, schizophrenia, and seizures have been reported. **Avoid use** with other medications that can produce similar side effects.



Dronabinol is a substrate for CYP 450 2C9 and 3A4. Individuals with poor CYP 450 2C9 activity may have reduced clearance of dronabinol, which may increase effects/toxicity.

Onset of action: 0.5–1 hr; duration of psychoactive effects 4–6 hr, appetite stimulation 24 hr

**DROPERIDOL**

Generics; previously available as Inapsine

**Sedative, antiemetic**



C



3



Yes



Yes



No

**Injection:** 2.5 mg/mL (2 mL)

**Antiemetic/sedation:**

**Child:** 0.03–0.07 mg/kg/dose IM or IV over 2–5 min; if needed, may give 0.1–0.15 mg/kg/dose; **initial max. dose:** 0.1 mg/kg/dose and subsequent **max. dose:** 2.5 mg/dose



*Continued*

DROPERIDOL *continued***Dosage interval:****Antiemetic:** PRN Q4–6 hr**Sedation:** Repeat dose in 15–30 min if necessary.**Adult:** 2.5–5 mg IM or IV over 2–5 min; **initial max. dose** is 2.5 mg**Dosage interval:****Antiemetic:** PRN Q3–4 hr**Sedation:** Repeat dose in 15–30 min if necessary.

**Use with caution** in renal and hepatic impairment; 75% of metabolites are excreted renally, and drug is extensively metabolized in the liver. Side effects include hypotension, tachycardia, extrapyramidal side effects such as dystonia, feeling of motor restlessness, laryngospasm, and bronchospasm. May lower seizure threshold. **Fatal arrhythmias and QT interval prolongation have been associated with use.**



Onset in 3–10 min. Peak effects within 10–30 min. Duration of 2–4 hr. Often given as adjunct to other agents.

**DYMISTA**See [Azelastine and Fluticasone](#).**E****ELEXACAFTOR/TEZACAFTOR/IVACAFTOR**

Trikafta

***Cystic fibrosis transmembrane conductance regulator corrector and potentiator***

C



?



Yes



Yes



Yes

**Tabs:****Morning dose:****Light orange colored:** Elexacaftor 50 mg + tezacaftor 25 mg + ivacaftor 37.5 mg**Orange colored:** Elexacaftor 100 mg + tezacaftor 50 mg + ivacaftor 75 mg**Evening dose (light blue colored):** Ivacaftor 75 mg or 150 mg

Available as an 84-tablet carton containing 4 wallets for a 28-day supply; each wallet contains 14 morning-dose tablets and 7 evening-dose tablets for a 7-day supply of the following combinations: Light orange colored morning tablets (elexacaftor 50 mg + tezacaftor 25 mg + ivacaftor 37.5 mg) and light blue colored evening tablets (ivacaftor 75 mg)

Orange colored morning tablets (elexacaftor 100 mg + tezacaftor 50 mg + ivacaftor 75 mg) and light blue colored evening tablets (ivacaftor 150 mg)

**Morning and evening doses should be taken (PO) ~12 hr apart with fat-containing food; see remarks.**

**Child 6–11 yr weighing <30 kg:****Morning dose:** 2 morning-dose tablets (elexacaftor 50 mg + tezacaftor 25 mg + ivacaftor 37.5 mg each tablet) every morning**Evening dose:** 1 evening-dose tablet (75 mg ivacaftor) every evening**Child 6–11 yr weighing ≥30 kg, and child ≥12 yr and adult:****Morning dose:** 2 morning-dose tablets (elexacaftor 100 mg + tezacaftor 50 mg + ivacaftor 75 mg each tablet) every morning

ELEXACAFTOR/TEZACAFTOR/IVACAFTOR *continued*

**Evening dose:** 1 evening-dose tablet (150 mg ivacaftor) every evening

**Dose Adjustment for Hepatic Impairment:**

	Mild (Child-Pugh Class A)	<sup>a</sup> Moderate (Child-Pugh Class B)	Severe (Child-Pugh Class C)
Morning dose	Use regular dosage	Day 1: Use regular AM dosage (2 tablets) Day 2: Use one AM tablet Then continue alternating Day 1 and Day 2 dosing thereafter and closely monitor liver function tests	Should not be used
Evening dose	Use regular dosage	No evening dosage	Should not be used

<sup>a</sup>Use not recommended unless benefit exceeds risk.

**Dose Adjustment for Moderate CYP 450 3A inhibitors (e.g., fluconazole, erythromycin):** Administer all doses in the morning.

**Child 6–11 yr weighing <30 kg:**

**Day 1:** 2 morning-dose tablets of elexacaftor 50 mg + tezacaftor 25 mg + ivacaftor 37.5 mg each tablet (light orange tabs)

**Day 2:** 1 evening-dose tablet (ivacaftor 75 mg) in the morning

Then continue alternating Day 1 and Day 2 regimens QAM thereafter.

**Child 6–11 yr weighing ≥30 kg, and child ≥12 yr and adult:**

**Day 1:** 2 morning-dose tablets of elexacaftor 100 mg + tezacaftor 50 mg + ivacaftor 75 mg each tablet (orange tabs)

**Day 2:** 1 evening-dose tablet (ivacaftor 150 mg) in the morning

Then continue alternating Day 1 and Day 2 regimens QAM thereafter.

**Dose Adjustment for Strong CYP 450 3A inhibitors (e.g., ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, and clarithromycin):** Administer all doses in the morning twice weekly.

**Child 6–11 yr weighing <30 kg:**

**Day 1:** 2 morning-dose tablets of elexacaftor 50 mg + tezacaftor 25 mg + ivacaftor 37.5 mg each tablet (light orange tabs)

**Days 2 and 3:** No dose

**Day 4:** Use day 1 regimen (2 morning-dose tablets), then continue the same dosage twice a week (approximately 3–4 days apart).

**Child 6–11 yr weighing ≥30 kg, and child ≥12 yr and adult:**

**Day 1:** 2 morning-dose tablets of elexacaftor 100 mg + tezacaftor 50 mg + ivacaftor 75 mg each tablet (orange tabs)

**Days 2 and 3:** No dose

**Day 4:** Use Day 1 regimen (2 morning-dose tablets), then continue the same dosage twice a week (approximately 3–4 days apart).

Works on CFTR trafficking defects with two correctors (elexacaftor and tezacaftor) and a potentiator (ivacaftor). Indicated for individuals with at least one F508del CFTR mutation.



Common side effects include headache, URI, abdominal pain, diarrhea, rash, nasal congestion, rhinorrhea, rhinitis, influenza sinusitis, and increases in liver enzymes (ALT/AST, bilirubin) and serum creatine phosphokinase. Monitor baseline ALT/AST and bilirubin at baseline and repeat every 3 mo for the first year followed by annual assessments. Ocular exams should be obtained at baseline and annually as cataracts have been reported in children. May cause a false-positive urine drug screen for cannabinoids.

*Continued*

ELEXACAFTOR/TEZACAFTOR/IVACAFTOR *continued*

Do **not use** in severe hepatic impairment (Child-Pugh C) and use is not recommended, unless the benefit outweighs the risk, for moderate hepatic impairment (Child-Pugh B). Liver failure resulting in transplantation has been reported in a patient with cirrhosis and portal hypertension. Mental status changes (e.g., fogginess, memory issues) have been reported within the first 3 months of therapy. **Use with caution** with CrCl  $\leq 30$  mL/min and ESRD because of lack of data.

All three components of this medication are substrates of CYP 450 3A. **Avoid use** in combination with strong inducers of CYP 450 3A (e.g., rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, and St. John's wort). Use with moderate and strong CYP 3A inhibitors requires dose reductions; see dosing section. Elexacaftor/tezacaftor/ivacaftor may increase the effects/toxicity of digoxin, cyclosporine, everolimus, glimepiride, glipizide, glyburide, nateglinide, repaglinide, sirolimus, tacrolimus, and warfarin. Always evaluate the potential drug-drug interactions.

**Avoid** food or drink containing grapefruit or Seville oranges.

Administer all doses with high-fat foods to ensure absorption. If a dose is missed within 6 hr of a scheduled dose, administer the respective morning or evening dose immediately and resume usual dosing. However, if the missed dose is  $>6$  hr, the following are recommended:

Missed morning dose: Take missed dose as soon as possible and do not take evening dose for that day, then resume usual dosing the next day.

Missed evening dose: Do not take the missed dose, then resume usual dosing the next day.

Never take a double dose for a missed dose.

**EMLA**

See [Lidocaine and Prilocaine](#).

**ENALAPRIL MALEATE (PO), ENALAPRILAT (IV)**

Enalapril: Vasotec, Epaned, and generics

Enalaprilat: generics; previously available as Vasotec IV

**Angiotensin-converting enzyme inhibitor, antihypertensive**



D



2



Yes



No



No

**Enalapril:**

Tablets (Vasotec and generics): 2.5, 5, 10, 20 mg (scored)

Oral solution (Epaned and generics): 1 mg/mL (150 mL); may contain sodium benzoate

Oral suspension: 0.1, 1 mg/mL

**Enalaprilat:**

Injection: 1.25 mg/mL (1, 2 mL); contains benzyl alcohol

**Hypertension:****Infant and child:**

**PO:** 0.08 mg/kg/24 hr up to 5 mg/24 hr once daily; increase PRN over 2 wk

**Max. dose (higher doses have not been evaluated):** 0.58 mg/kg/24 hr up to 40 mg/24 hr

**IV:** 0.005–0.01 mg/kg/dose Q8–24 hr; **max. dose:** 1.25 mg/dose

**Adolescent and adult:**

**PO:** 2.5–5 mg/24 hr once daily initially to **max. dose** of 40 mg/24 hr  $\div$  once daily—BID

**IV:** 0.625–1.25 mg/dose IV Q6 hr; doses as high as 5 mg Q6 hr are reported to be tolerated for up to 36 hr

**Contraindicated** with hypersensitivity to ACE inhibitors and use in combination with a neprilysin inhibitor (e.g., sacubitril). **Use with caution** in bilateral renal artery stenosis.

**Avoid use** in dialysis with high-flux membranes because anaphylactoid reactions have been reported. Side effects: nausea, diarrhea, headache, dizziness, hyperkalemia, hypoglycemia, hypotension, and hypersensitivity. Cough is a reported side effect of ACE inhibitors.



ENALAPRIL MALEATE (PO), ENALAPRILAT (IV) *continued*

Risk for angioedema increases with enalapril and coadministration of rapamycin or sacubitril.

Enalapril (PO) is converted to its active form (Enalaprilat) by the liver. Administer IV over 5 min. **Adjust dose in renal impairment (see Chapter 31).**

Nitritoid reactions have been seen in patients receiving concomitant IV gold therapy. Enalapril/enalaprilat should be discontinued as soon as possible when pregnancy is detected. If oliguria or hypotension occurs in a neonate with in utero exposure with enalapril/enalaprilat, exchange transfusions or dialysis may be needed to reverse hypotension and/or support renal function.

**ENOXAPARIN**

Lovenox and generics

**Anticoagulant, low-molecular-weight heparin**



B



1



Yes



Yes



No

**Injection:** 100 mg/mL (3 mL); contains pork proteins and 15 mg/mL benzyl alcohol

**Injection (prefilled syringes with 27-gauge × 1/2-inch needle):** 30 mg/0.3 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL, 120 mg/0.8 mL, 150 mg/1 mL; preservative free and may contain pork proteins

**Approximate anti-factor Xa activity:** 100 IU per 1 mg

Initial empiric dosage; patient-specific dosage defined by therapeutic drug monitoring when indicated (see remarks)

**DVT treatment:**

**Premature neonate:** 2 mg/kg/dose Q12 hr SC

**Full-term neonate:** 1.7 mg/kg/dose Q12 hr SC

**1—<2 mo:** 1.5 mg/kg/dose Q12 hr SC

**≥2 mo—adult:** 1 mg/kg/dose Q12 hr SC; alternatively, 1.5 mg/kg/dose Q24 hr SC can be used in adults

**Dosage adjustment for DVT treatment to achieve target anti-factor Xa low-molecular-weight heparin (LMWH) levels of 0.5—1 units/mL (see the following table):**

Anti-factor Xa Level LMWH (units/mL)	Hold Next Dose?	Dose Change	Repeat Anti-factor Xa Level LMWH?
<0.4	No	Increase by 25%	4 hr after the second new dose
0.4	No	Increase by 10%	4 hr after the second new dose
0.5	No	No	4 hr after the next dose; if within therapeutic range recheck 1 wk later (4 hr after the dose)
0.6—0.7	No	No	1 wk later (4 hr after the dose)
0.8—1	No	No	4 hr after the next dose; if within therapeutic range recheck 1 wk later (4 hr after the dose)
1.1—1.5	No	Decrease by 20%	4 hr after the second new dose

*Continued*

ENOXAPARIN *continued*

Anti-factor Xa Level LMWH (units/mL)	Hold Next Dose?	Dose Change	Repeat Anti-factor Xa Level LMWH?
1.6–2	Hold dose for 3 hr and measure level (goal <0.5 units/mL) prior to next new dose.	Decrease by 30%	4 hr after the second new dose
>2	Hold dose until anti-factor Xa LMWH reaches 0.5 units/mL (levels can be measured Q12 hr until it reaches ≤0.5 units/mL).	When anti-factor Xa LMWH reaches ≤0.5 units/mL, dose may be restarted at a dose 40% less than the previous dose.	4 hr after the second new dose

**DVT prophylaxis:**

**Infant <2 mo:** 0.75 mg/kg/dose Q12 hr SC

**Infant ≥2 mo—child 18 yr:** 0.5 mg/kg/dose Q12 hr SC; **max. dose:** 30 mg/dose

**Patients with indwelling epidural catheters/neuraxial anesthesia (≥2 mo—child 18 yr):** 1 mg/kg/dose Q24 hr SC; **max. dose:** 40 mg/dose. Twice-daily dosing is contraindicated for these patients. See remarks.

**Adult:** 40 mg Q24 hr SC

**Dosage adjustment for DVT prophylaxis to achieve target anti—factor Xa low-molecular-weight heparin (LMWH) levels of 0.1–0.4 units/mL for all children (see the following table):**

Anti-Xa Level LMWH (units/mL)	Hold Next Dose?	Dose Change	Repeat Anti-factor Xa Level LMWH?
<0.1	No	Increase by 20%–30%	4 hr after the second new dose
0.1–0.4	No	No	1 wk later (4 hr after the dose)
0.5–0.7	No	Decrease by 20%	4 hr after the second new dose
0.7–1	No	Decrease by 30%–40%	4 hr after the second new dose
>1	Hold dose until anti-factor Xa LMWH is <0.5 units/mL.	When anti-factor Xa LMWH reaches <0.5 units/mL, dose may be restarted at a dose 40% less than the previous dose.	4 hr after the second new dose

Inhibits thrombosis by inactivating factor Xa without significantly affecting bleeding time, platelet function, PT, or aPTT at recommended doses. Dosages of enoxaparin, heparin, or other LMWHs **CANNOT** be used interchangeably on a unit-for-unit (or mg-for-mg) basis because of differences in pharmacokinetics and activity. Peak anti—factor Xa LMWH activity is achieved 4 hr after a SC dose. **Anti—factor Xa LMWH is NOT THE SAME as unfractionated heparin anti—factor Xa level (used for monitoring heparin therapy).**



ENOXAPARIN *continued*

**Contraindicated** in major bleeding, drug-induced thrombocytopenia, and pork hypersensitivity.

Relative contraindications include: platelets  $\leq 50,000/\text{mm}^3$  and IM injections. **Use with caution** in uncontrolled arterial hypertension, bleeding diathesis, history of recurrent GI ulcers, diabetic retinopathy, and severe renal dysfunction (reduce dose by increasing the dosage interval from Q12 hr to Q24 hr if GFR  $<30$  mL/min). Prophylactic use is not recommended in patients with prosthetic heart valves (especially in pregnant women) due to reports of fatalities in patients and fetuses.

**Concurrent use with spinal or epidural anesthesia or spinal puncture has resulted in long-term or permanent paralysis; potential benefits must be weighed against the risks.** May cause fever, confusion, edema, nausea, hemorrhage, thrombocytopenia (including heparin-induced thrombocytopenia  $\pm$  thrombosis [HIT/HITTS]), hypochromic anemia, and pain/erythema at injection site. Allergic reactions, headache, eosinophilia, alopecia, hepatocellular and cholestatic liver injury, and osteoporosis (long-term use) have been reported. **Protamine sulfate is the antidote**; 1 mg protamine sulfate neutralizes 1 mg enoxaparin.

DVT prophylaxis for patients with epidural catheters/neuraxial anesthesia: If placing needle, hold anticoagulation for 12 hr and restart dosing  $\geq 4$  hr after needle insertion. If removing catheter, hold anticoagulation for 12 hr and restart dosing  $\geq 2$  hr after catheter removal.

Recommended anti-factor Xa LMWH levels obtained 4 hr after subcutaneous dose after the third consecutive dose for children (anti-factor Xa LMWH response in children is highly variable compared to adults):

DVT treatment: 0.5–1 units/mL

DVT prophylaxis: 0.1–0.4 units/mL

Administer by deep SC injection by having the patient lie down. Alternate administration between the left and right anterolateral and left and right posterolateral abdominal wall. See package insert for detailed SC administration recommendations. To minimize bruising, do not rub the injection site. IM route of administration is not recommended.

For additional information, see *Chest* 2008;133:887–968 and *Regional Anesthesia and Pain Medicine* 2003;28(3):172–197.

**EPINEPHRINE HCL**

Adrenalin, EpiPen, Auvi-Q, Symjepi, Epinephrine SNAP, Primatene Mist, and generics

**Sympathomimetic agent**



C



2



No



No



No

**Injection:**

1:1000 (aqueous): 1 mg/mL (1, 30 mL); may contain chlorobutanol and metabisulfite

**Injection, in prefilled syringe:**

1:10,000 (aqueous): 0.1 mg/mL (10 mL prefilled syringes with either 18-G 3.5-inch or 20-G 1.5-inch needles)

**Autoinjector:**

EpiPen and generics: Delivers a single 0.3 mg (0.3 mL) dose (2 pack; EpiPen and some generic products include a training device)

EpiPen Jr and generics: Delivers a single 0.15 mg (0.3 mL) dose (2 pack; EpiPen Jr and some generic products include a training device)

Auvi-Q: Delivers a single 0.1 mg (0.1 mL) dose, 0.15 mg (0.15 mL) dose, or 0.3 mg (0.3 mL) dose (2 pack with training device; each unit provides voice instructions when activated)

Symjepi: Delivers a single 0.15 mg (0.3 mL) dose or 0.3 mg (0.3 mL) dose (1 or 2 pack)

**Syringe Kit for Anaphylaxis (for specific weight-based dosages for any size patient):**

EpinephrineSNAP: 1 mg/mL (1 mL single use vial in a box of 25 vials, 30 mL multi-use vial as a single vial or box of 10 vials)

*Continued*

EPINEPHRINE HCL *continued*

Many preparations may contain sulfites.

**Aerosol inhaler (HFA):**

Primatene Mist [OTC]: 0.125 mg per spray (160 sprays per inhaler) (11.7 g); contains 1% alcohol and polysorbate 80

**CARDIAC USE:****Neonate:**

**Asystole and bradycardia:** 0.01–0.03 mg/kg of 1:10,000 solution (0.1–0.3 mL/kg) IV/IO Q3–5 min PRN

**Infant and child:**

**Bradycardia/asystole and pulseless arrest:** See [page ii](#) and [PALS algorithms](#) in the [back of the book](#).

**Bradycardia, asystole, and pulseless arrest (see remarks):**

**First dose:** 0.01 mg/kg of 1:10,000 solution (0.1 mL/kg) IO/IV; **max. dose:** 1 mg (10 mL).

Subsequent doses Q3–5 min PRN should be the same. High-dose epinephrine after failure of standard dose has not been shown to be effective (see remarks). Must circulate drug with CPR. For ET route, see below.

**All ET doses:** 0.1 mg/kg (**max. dose:** 2.5 mg) of 1:1000 solution (0.1 mL/kg; **max. dose** 2.5 mL) ET Q3–5 min

**Adult:**

**Asystole:** 1 mg IV or 2–2.5 mg ET Q3–5 min

**IV drip (all ages):** 0.1–1 mcg/kg/min; titrate to effect; to prepare infusion, see [p. iii](#).

**HYPERSENSITIVITY/ANAPHYLACTIC REACTIONS:**

**Recommended IM administration via the anterolateral aspect of the thigh through clothing if necessary; see remarks for IV dosing.**

**Infant, child, and adolescent:** 0.01 mg/kg/dose IM (**max. dose:** 0.3 mg/dose for prepubertal child, 0.5 mg/dose for adolescent) Q5–15 min PRN

**Auvi-Q (administer the following dosage IM ×1; an additional dose may be repeated in 5–15 min):**

**7.5 to <15 kg:** 0.1 mg

**15 to <30 kg:** 0.15 mg

**≥30 kg:** 0.3 mg

**EpiPen/EpiPen Jr, Adrenaclick, Symjepi, or equivalent generic autoinjector (administer the following dosage IM ×1; an additional dose may be repeated in 5–15 min):**

**7.5 to <30 kg:** 0.15 mg

**≥30 kg:** 0.3 mg

**Adult:** Start with 0.2–0.5 mg IM Q5–15 min PRN. If using EpiPen, Adrenaclick, Symjepi, or equivalent generic autoinjector, use 0.3 mg IM ×1; an additional dose may be repeated in 5–15 min.

**RESPIRATORY BRONCHODILATOR USE:****SC Injection (use 1:1000 or 1 mg/mL aqueous injection):**

**Infant and child:** 0.01 mL/kg/dose SC (**max. single dose** 0.5 mL); repeat Q15 min × 3–4 doses or Q4 hr PRN

**Adult:** 0.3–0.5 mg (0.3–0.5 mL)/dose SC Q20 min × 3 doses

**Nebulization (alternative to racemic epinephrine):** 0.5 mL/kg of 1:1000 solution diluted in 3 mL NS;

**max. doses:** ≤4 yr: 2.5 mL/dose; >4 yr: 5 mL/dose

**Aerosol inhaler (Primatene Mist):**

**≥12 yr and adult:** 1 inhalation PO, may repeat 1 inhalation if needed one minute after the first dose.

Wait >4 hours between additional doses PRN; **max. dose:** 8 inhalations/24 hr

High-dose rescue therapy for in-hospital cardiac arrest in children after failure of an initial standard dose has been reported to be of no benefit compared to standard dose (*N Engl J Med* 2004;350:1722–1730).



EPINEPHRINE HCL *continued*

May produce arrhythmias, tachycardia, hypertension, headaches, nervousness, nausea, vomiting, and rare cases of stress cardiomyopathy. Necrosis may occur at site of repeated local injection. Rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis, have been reported with IM or deep SC injections.

Concomitant use of noncardiac selective  $\beta$ -blockers, MAO inhibitors, COMT inhibitors, levothyroxine, diphenhydramine, chlorpheniramine, clonidine, or tricyclic antidepressants may enhance epinephrine's pressor response. Chlorpromazine, diuretics, ergot alkaloids, nitrates, or  $\alpha$ -blockers may reverse the pressor response.  $\beta$ -blockers may antagonize epinephrine's cardiostimulating and bronchodilating effects. Cardiac arrhythmias may develop for those who receive epinephrine while concomitantly taking cardiac glycosides, diuretics, or anti-arrhythmics. **Do not** use products containing chlorobutanol for ophthalmic use, as it may be harmful to the corneal endothelium.

ETT doses should be diluted with NS to a volume of 3–5 mL before administration. Follow with several positive pressure ventilations.

**Hypersensitivity reactions:** For bronchial asthma and certain allergic manifestations (e.g., angioedema, urticaria, serum sickness, anaphylactic shock), use epinephrine SC. Patients with anaphylaxis may benefit from IM administration. The adult IV dose for hypersensitivity reactions or to relieve bronchospasm usually ranges from 0.1 to 0.25 mg injected slowly over 5–10 min Q5–15 min as needed. Neonates may be given a dose of 0.01 mg/kg body weight; for infants, 0.05 mg is an adequate initial dose, and this may be repeated at 20- to 30-min intervals in the management of asthma attacks.

Due to the inconsistent availability of autoinjector products, periodic reeducation of available device may be necessary. See respective autoinjector product for proper dose administration methods, including methods to prevent injury and/or inadvertent dose administration to the individual administering the dose. Accidental injection into the digits, hand, or feet may result in the loss of blood flow to the affected area. **Do not** inject into the buttock area.

**EPINEPHRINE, RACEMIC**

Asthmanefrin and S-2

**Sympathomimetic agent**

C 2 No No No

**Solution for inhalation (OTC):** 2.25% (1.25% epinephrine base) (0.5 mL) (30s)

Contains edetate disodium and may contain sulfites

**<4 yr:**

**Croup (using 2.25% solution):** 0.05 mL/kg/dose up to a **max. dose** of 0.5 mL/dose diluted to 3 mL with NS. Given via nebulizer over 15 min PRN but **not** more frequently than Q1–2 hr

**≥4 yr:** 0.5 mL/dose diluted to 3 mL with NS via nebulizer over 15 min Q3–4 hr PRN

Tachyarrhythmias, headache, nausea, palpitations have been reported. Rebound symptoms may occur. Cardiorespiratory monitoring should be considered if administered more frequently than Q1–2 hr.

**EPOETIN ALFA**

Epogen, Procrit, Retacrit, and Erythropoietin

**Recombinant human erythropoietin**

C 2 Yes No No

**Injection (single-dose, preservative-free vials):** 2000, 3000, 4000, 10,000, 40,000 U/mL (1 mL)

**Injection (multidose vials):** 10,000 U/mL (2 mL), 20,000 U/mL (1 mL); contains 1% benzyl alcohol

All dosage forms contain 2.5 mg albumin per 1 mL.

**NOTE:** Epoetin alfa-epbx (Retacrit) is a biosimilar product.

*Continued*

EPOETIN ALFA *continued*

Single-dose preservative-free vials: 2000, 3000, 4000, 10,000, 40,000 U/mL (1 mL) and contains phenylalanine

Multidose vials: 10,000 U/mL (2 mL), 20,000 U/mL (1 mL); contains benzyl alcohol

**Anemia in chronic renal failure (see remarks for dosage adjustment and withholding therapy):** SC/IV (IV preferred for hemodialysis patients)
**Initial dose:**

**Child and adolescent:** Start at 50 U/kg/dose 3 times per week. Reported dosage range for children (3 mo–20 yr) not requiring dialysis, 50–250 U/kg/dose 3 times per week. Reported dosage range for children receiving hemodialysis, 50–450 U/kg/dose 2–3 times per week

**Adult:** Start at 50–100 U/kg/dose 3 times per week.

**Maintenance dose:** Dose is individualized to achieve and maintain the lowest Hgb level sufficient to avoid transfusions and **not to exceed** the following levels:

**Child ≤16 yr (receiving or not receiving dialysis):** 12 g/dL

**>16 yr :**

**Receiving dialysis:** 11 g/dL

**Not receiving dialysis:** 10 g/dL

**Anemia in cancer (use until chemotherapy is completed; see remarks for dosage reduction and withholding therapy):**
**Initial dose:**

**Child (5–18 yr):** Start at 600 U/kg (**max. dose:** 40,000 U) IV once weekly.

**Adult:** Start at 150 U/kg/dose SC 3 times per week or 40,000 U SC once every week.

**Increasing doses (if needed):**

**Three-times-a-week dosing regimen (adult):** If no increase in Hgb >1 g/dL and Hgb remains <10 g/dL after initial 4 wk of therapy, increase dosage to 300 U/kg/dose 3 times per week.

**Weekly dosing regimen: If no increase in Hgb >1 g/dL and Hgb remains <10 g/dL after initial 4 wk of therapy:**

**Child:** Increase dose to 900 U/kg/dose IV (**max. dose:** 60,000 U) once weekly.

**Adult:** 60,000 U SC once weekly

For all ages, discontinue use after 8 wk of therapy if transfusions are still required or no hemoglobin response is observed.

**AZT-treated HIV patients (Hgb should not exceed 12 g/dL):** SC/IV

**Child:** Reported dosage range in children (≥3 mo–17 yr), 50–400 U/kg/dose 2–3 times per wk

**Adult (with serum erythropoietin ≤500 milliunits/mL and receiving ≤4200 mg AZT per week):** Start at 100 U/kg/dose 3 times per wk × 8 wk. If response is NOT satisfactory in reducing transfusion requirements or increasing Hgb levels after 8 wk of therapy, dose may be increased by 50–100 U/kg/dose given 3 times per wk and reevaluated every 4–8 wk thereafter. Patients are unlikely to respond to doses >300 U/kg/dose 3 times per wk.

For all ages, withhold therapy if Hgb >12 g/dL and resume therapy by decreasing dosage by 25% once Hgb falls below 11 g/dL. For adults, discontinue therapy if Hgb does not increase after 8 wk of the 300 U/kg/dose 3 times per wk dosage.

**Anemia of prematurity (many regimens exist):**

250 U/kg/dose SC 3 times per wk × 10 doses; alternatively, 200–400 U/kg/dose IV/SC 3–5 times per wk for 2–6 wk (total dose per wk is 600–1400 U/kg). Administer with supplemental iron at 3–6 mg elemental iron/kg/24 hr.

Use the lowest dose to avoid transfusions.

Increased risk for death, serious cardiovascular events, and thrombosis/stroke have been reported in patients treated with chronic kidney disease and hemoglobin levels >11 g/dL.

Increased risk for death, shortened survival and/or shortened time to tumor progression/regression, serious cardiovascular events, and thrombosis in various cancer patients, especially



with Hgb levels >12 g/dL, have been reported with epoetin alfa and other erythropoiesis-stimulating agents.

Evaluate serum iron, ferritin, TIBC before therapy. Iron supplementation recommended during therapy unless iron stores are already in excess. Monitor Hct, BP, clotting times, platelets, BUN, serum creatinine. Peak effect in 2–3 wk.

#### DOSAGE ADJUSTMENT FOR ANEMIA IN CHRONIC RENAL FAILURE:

**Reduce dose by ≥25%:** When Hgb increases >1 g/dL in any 2-wk period. Dose reductions can be made more frequently than once every 4 wk if needed.

**Increase dose by 25%:** When Hgb does not increase by 1 g/dL after 4 wk of therapy. Dosage increments should not be made more frequently than once every 4 wk.

**Withholding therapy:** When Hgb exceeds the age and dialysis-specific maximum level; restart therapy at a 25% lower dose after Hgb decreases below the age and dialysis-specific maximum level.

**Inadequate response after a 12-week dose escalation:** Use minimum effective dosage that will maintain hemoglobin levels to avoid the need for recurrent blood transfusions and evaluate other causes of anemia. Discontinue use if patient remains transfusion dependent.

#### DOSAGE REDUCTION ADJUSTMENT/WITHHOLDING THERAPY FOR ANEMIA IN CANCER:

**If Hgb exceeds a level needed to avoid blood transfusion:** Withhold dose and resume therapy at a reduced dosage by 25% when Hgb approaches a level where blood transfusions may be needed.

**If Hgb increases >1 g/dL in any 2-wk period or Hgb reaches a level to avoid blood transfusion:** Reduce dose by 25%.

May cause hypertension, seizure, hypersensitivity reactions, headache, edema, dizziness. SC route provides sustained serum levels compared to IV route. For IV administration, infuse over 1–3 min.

**Do not use** multidose vial preparation for neonates, infants, and pregnant/breastfeeding mothers because of concerns for benzyl alcohol.

#### EPOPROSTENOL

Flolan, Veletri, and generics, PGI<sub>2</sub>, PGX, prostacyclin

**Prostaglandin I<sub>2</sub>, vasodilator**



B



?



No



No



No

**Injection:** 0.5, 1.5 mg

**Flolan:** Reconstitute with provided pH 12 sterile diluent for Flolan (50 mL).

**Veletri (available only via designated specialty outpatient pharmacies):** Reconstitute with sterile water for injection or 0.9% sodium chloride.

**Generic:** Reconstitute with provided sterile diluent for epoprostenol sodium (50 mL) or with sterile water for injection or 0.9% sodium chloride (product specific).

#### Pulmonary Hypertension (limited data):

**IV Infusion via central-line and 0.22-micron filter:** Start at 1–2 **nanograms/kg/min** IV.

Increase by 0.5–2 **nanograms/kg/min** Q45 min as needed and tolerated. **Avoid** abrupt withdrawal, interruptions in delivery, or sudden large decreases in dosage.

#### Usual effective dose:

**Neonate:** 20–40 **nanograms/kg/min**

**Infant, child, and adolescent:** 40 to >150 **nanograms/kg/min** (average 80 **nanograms/kg/min**)

Down-titration of dosage is required in the presence of high-output state (hyperdynamic right ventricle).

#### Inhalation route (very limited data):

**Neonate:** 50 **nanograms/kg/min** via continuous nebulization at a rate of 8 mL/hr, OR 50 **nanograms/kg/min** diluted in 3 mL Q2 hr via intermittent nebulization has been reported.

**Child:** 20–50 **nanograms/kg/min** via continuous nebulization has been reported.



EPOPROSTENOL *continued*

**Contraindicated** in heart failure caused by decreased left ventricular ejection fraction. **Use with caution** in bleeding disorders; inhibits platelet aggregation.



Dose-dependent side effects of nausea, diarrhea, jaw pain, bone pain, and headaches are common. Other common side effects include hypotension, flushing, diarrhea, loss of appetite, and chest and musculoskeletal pain. Reported complications include sepsis, local site infection, and catheter dislodgement resulting in severe sepsis or rebound pulmonary hypertension (**avoid** abrupt dose withdrawal and monitor for IV line interruptions). Hypoxia, flushing, and tachycardia may suggest an overdose.

Use with medications exhibiting antiplatelet effects (e.g., SSRI antidepressants, desvenlafaxine, venlafaxine, duloxetine, NSAIDs, and anticoagulants) may increase risk for bleeding. May increase digoxin levels.

Systemic  $T_{1/2}$  is 2–5 min. Continuous IV infusion is administered via central venous catheter with a 0.22-micron filter. Medication temperature stability requirements and the use of icepacks are product specific; consult with a pharmacist.

**ERGOCALCIFEROL**

Calcitol, Drisdol, Ergocal, and generics  
**Vitamin D<sub>2</sub>**



A/C



2



No



No



No

**Caps:**

**Ergocal:** 2500 IU

**Drisdol and generics:** 50,000 IU (1.25 mg)

**Tabs [OTC]:** 400, 2000, 2400 IU

**Drops [OTC]:** 8000 IU/mL (200 mCg/mL) (60 mL); contain propylene glycol

**Conversion:** 1 mg = 40,000 IU vitamin D activity

**Dietary supplementation (see Chapter 21 for additional information):**

**Preterm neonate:** 200–400 IU/24 hr PO

**Term neonate and infant (<1 yr) (breastfed or receiving <32 oz formula):** 400 IU/24 hr PO

**Child (≥1 yr) and adolescent:** 400–600 IU/24 hr PO

**Renal failure (CKD stages 2–5) and 25-OH vitamin D levels <30 ng/mL (monitor serum 25-OH vitamin D and corrected calcium/phosphorus 1 mo after initiation and Q3 mo thereafter):**

**25-OH vitamin D <5 ng/mL:**

**Child:** 8000 IU/24 hr × 4 wk followed by 4000 IU/24 hr × 2 mo; or 50,000 IU weekly × 4 wk followed by 50,000 IU twice monthly for 2 mo

**25-OH vitamin D 5–15 ng/mL:**

**Child:** 4000 IU/24 hr PO × 12 wk or 50,000 IU every other wk × 12 wk

**25-OH vitamin D 16–30 ng/mL:**

**Child:** 2000 IU/24 hr PO × 3 mo or 50,000 IU every mo × 3 mo

**Vitamin D dependent rickets:**

**Child:** 3000–5000 IU/24 hr PO; **max. dose:** 60,000 IU/24 hr

**Nutritional rickets:**

**Child and adult with normal GI absorption:** 2000–5000 IU/24 hr PO × 6–12 wk

**Malabsorption:**

**Child:** 10,000–25,000 IU/24 hr PO

**Adult:** 10,000–300,000 IU/24 hr PO

**Vitamin D resistant rickets (with phosphate supplementation):**

**Child:** Initial dose 40,000–80,000 IU/24 hr PO; increase daily dose by 10,000–20,000 IU PO Q3–4 mo if needed

ERGOCALCIFEROL *continued*

**Adult:** 10,000–60,000 IU/24 hr PO

**Hypoparathyroidism (with calcium supplementation):**

**Child:** 50,000–200,000 IU/24 hr PO

**Adult:** 25,000–200,000 IU/24 hr PO

Consider using cholecalciferol instead; cholecalciferol has shown to be more biologically potent with better absorption than ergocalciferol. Vitamin D<sub>2</sub> is activated by 25-hydroxylation in liver and 1-hydroxylation in kidney to the active form, calcitriol.



Monitor serum Ca<sup>2+</sup>, PO<sub>4</sub>, 25-OH vitamin D (goal level for infant and child: ≥20 ng/mL), and alkaline phosphate. Serum Ca<sup>2+</sup>, PO<sub>4</sub> product should be <70 mg/dL to avoid ectopic calcification. Titrate dosage to patient response. Watch for symptoms of hypercalcemia: weakness, diarrhea, polyuria, metastatic calcification, nephrocalcinosis.

Serum 25-OH vitamin D level of ≥35 ng/mL has been suggested in cystic fibrosis patients to decrease the risk of hyperparathyroidism and bone loss.

Pregnancy category changes to “C” if used in doses above the U.S. RDA.

**ERGOTAMINE TARTRATE ± CAFFEINE**

Ergomar

In combination with caffeine: Cafergot, Migergot, and generics

**Ergot alkaloid**



X



X



Yes



Yes



No

**Sublingual tabs (Ergomar):** 2 mg

**In combination with caffeine:**

**Tabs (Cafergot and generics):** 1 mg and 100 mg caffeine

**Suppository (Migergot):** 2 mg and 100 mg caffeine (12s)

**ERGOTAMINE:**

**Adolescent and adult:**

**SL:** 2 mg at onset of migraine attack, then 2 mg Q30 min PRN up to **max. dose** of 6 mg/24 hr; **do not exceed** 10 mg/wk

**ERGOTAMINE PLUS CAFFEINE:**

Doses based on mg of ergotamine

**Oral tablet:**

**Adolescent and adult:** 1 or 2 mg PO at onset of migraine attack, then 1 mg Q30 min up to 6 mg per attack, **not to exceed** 10 mg/wk

**Suppository:**

**Adolescent:** 1 mg (0.5 suppository) at first sign of attack; follow with second 1 mg dose after 45 min if needed; **max. dose:** 2 mg per attack, 4 mg/24 hr, **not to exceed** 8 mg/wk

**Adult:** 2 mg at first sign of attack; follow with second 2 mg dose after 1 hr if needed; **max. dose:** 4 mg per attack, **not to exceed** 10 mg/wk

**Use with caution** in renal or hepatic disease. May cause paresthesias, GI disturbance, angina-like pain, rebound headache with abrupt withdrawal, or muscle cramps.



**Contraindicated** in pregnancy and has **not been recommended** in breastfeeding. Concurrent administration with protease inhibitors, clarithromycin, erythromycin, other CYP 450 3A4 inhibitors, and nitroglycerin are **contraindicated** owing to risk of ergotism (nausea, vomiting, vasospastic ischemia leading to cerebral and peripheral ischemia).

For sublingual administration, place tablet under the tongue and do not crush.

**ERTAPENEM**

Invanz and generics

**Antibiotic, carbapenem**

B

1

Yes

No

No

**Injection:** 1 g

Contains ~6 mEq Na/g drug

**≥1 mo—12 yr:** 15 mg/kg/dose IV/IM Q12 hr; **max. dose:** 1 g/24 hr**Adolescent and adult:** 1 g IV/IM Q24 hr**Recommended duration of therapy (all ages):****Complicated intra-abdominal infection:** 5–14 days or 4–7 days with source control**Complicated skin/subcutaneous tissue infections:** 7–14 days**Diabetic foot infection without osteomyelitis:** 14–28 days**Community-acquired pneumonia, complicated UTI/pyelonephritis:** 10–14 days**Acute pelvic infection:** 3–10 days**Surgical prophylaxis:****Child and adolescent:** 15 mg/kg (**max. dose:** 1 g/dose) IV 1 hr before procedure**Adult (colorectal surgery):** 1 g IV 1 hr before procedureErtapenem has poor activity against *P. aeruginosa*, *Acinetobacter*, MRSA, and Enterococcus.**Do not use** in meningitis due to poor CSF penetration. **Use with caution** with CNS disorders including seizures. **Adjust dosage in renal impairment; see Chapter 31.**

Diarrhea, infusion complications, nausea, headache, vaginitis, phlebitis/thrombophlebitis, and vomiting are common. Seizures (primarily with renal insufficiency and/or CNS disorders such as brain lesions and seizures), decreased consciousness, muscle weakness, gait disturbance, abnormal coordination, teeth staining, hypersensitivity vasculitis, and DRESS syndrome have been reported. Increased ALT, AST, and neutropenia have been reported in pediatric clinical trials. Decreases valproic acid levels. Probenecid may increase ertapenem levels.

IM route requires reconstitution with 1% lidocaine and **should not** be administered by IV. **Do not** reconstitute or co-infuse with dextrose-containing solutions.

**ERYTHROMYCIN PREPARATIONS**

Erythromycin, EES, EryPed, Ery-Tab, and generics

Ophthalmic ointment: Generics; previously available as Ilotycin

Topical gel: Ery, Erygel, and generics

**Antibiotic, macrolide**

B

2

Yes

Yes

No

**Erythromycin base:****Tabs:** 250, 500 mg**Delayed release tabs (Ery-Tab and generics):** 250, 333, 500 mg**Delayed release caps:** 250 mg**Topical gel (Erygel and generics):** 2% (30, 60 g); contains alcohol 92%**Topical solution:** 2% (60 mL); may contain 44%–66% alcohol**Topical pad/swab (Ery):** 2% (60s); may contain propylene glycol and alcohol**Ophthalmic ointment:** 0.5% (1, 3.5 g)**Erythromycin ethyl succinate (EES):****Oral suspension (EES, EryPed, and generics):** 200 mg/5 mL (100, 200 mL), 400 mg/5 mL (100 mL)**Tabs (EES and generics):** 400 mg**Erythromycin stearate (Erythrocin):****Tabs:** 250 mg

ERYTHROMYCIN PREPARATIONS *continued***Erythromycin lactobionate (Erythrocin and generics):**

**Injection:** 500 mg

**Oral:**

**Neonate (use EES preparation; see remarks for safety concerns):**

**<1.2 kg:** 20 mg/kg/24 hr ÷ Q12 hr PO

**≥1.2 kg:**

**0–7 days:** 20 mg/kg/24 hr ÷ Q12 hr PO

**>7 days:**

**1.2–2 kg:** 30 mg/kg/24 hr ÷ Q8 hr PO

**≥2 kg:** 30–40 mg/kg/24 hr ÷ Q6–8 hr PO

**Chlamydial conjunctivitis and pneumonia:** 50 mg/kg/24 hr ÷ Q6 hr PO × 14 days; **max. dose:** 2 g/24 hr

**Child (use base, EES, or stearate preparation):** 30–50 mg/kg/24 hr ÷ Q6–8 hr; **max. dose:** 4 g/24 hr

**Pertussis:** 40–50 mg/kg/24 hr ÷ Q6 hr PO × 14 days (**max. dose:** 2 g/24 hr); use azithromycin for infants <1 mo old

**Adult:** 2 g/24 hr ÷ Q6 hr PO × 14 days

**Parenteral:**

**Child and adult:** 15–20 mg/kg/24 hr ÷ Q6 hr IV; **max. dose:** 4 g/24 hr

**Ophthalmic:**

**Neonatal gonococcal ophthalmia prophylaxis:** Apply 1-cm ribbon to both eyes × 1.

**Conjunctivitis:**

**Infant, child, and adolescent:** Apply 1-cm ribbon to affected eye(s) several times a day up to 6 times daily.

**Preoperative bowel prep:** 20 mg/kg/dose (**max. dose:** 1000 mg/dose) PO erythromycin base × 3 doses, with neomycin, 1 day before surgery

**Prokinetic agent:**

**Infant and child:** 10–20 mg/kg/24 hr PO ÷ TID–QID (QAC or QAC and QHS)

**Topical (administer doses after washing skin with warm water and soap and patting it dry):**

**Acne (≥7 yr—adolescent; typically not used as monotherapy):**

**Topical gel:** Apply to affected area once daily—BID; discontinue use after 8 wk if no improvement or worsening of condition.

**Topical solution or pad:** Apply to affected area BID (morning and evening).

**Avoid** use in patients with known QT prolongation, proarrhythmic conditions (e.g., hypokalemia, hypomagnesemia, significant bradycardia), and receiving class IA or class III antiarrhythmic agents, HMG CoA reductase inhibitors metabolized by CYP 450 3A4 (e.g., lovastatin or simvastatin; increases risk for myopathy and rhabdomyolysis), cisapride, or pimozide. Hypertrophic pyloric stenosis in neonates receiving prophylactic therapy for pertussis; life-threatening episodes of ventricular tachycardia associated with prolonged QTc interval; and exacerbation of myasthenia gravis have been reported. May produce false-positive urinary catecholamines, 17-hydroxycorticosteroids, and 17-ketosteroids.

GI side effects common (nausea, vomiting, abdominal cramps). Cardiac dysrhythmia, anaphylaxis, interstitial nephritis, and hearing loss have been reported. Use with **caution** in liver disease. Estolate formulation may cause cholestatic jaundice, although hepatotoxicity is uncommon (2% of reported cases). Inhibits CYP 450 1A2, 3A3/4 isoenzymes. May produce elevated digoxin, theophylline, carbamazepine, clozapine, cyclosporine, and methylprednisolone levels. **Adjust dose in renal failure (see Chapter 31).** Use ideal body weight for obese patients when calculating doses.

*Continued*

ERYTHROMYCIN PREPARATIONS *continued*

Oral therapy should replace IV as soon as possible. Give oral doses after meals. Because of different absorption characteristics, higher oral doses of EES are needed to achieve therapeutic effects. **Avoid** IM route (pain, necrosis). For ophthalmic use, **avoid** contact of ointment tip with eye or skin.

## ERYTHROPOIETIN

See [Epoetin Alfa](#).

## ESCITALOPRAM

Lexapro and generics

**Antidepressant, selective serotonin reuptake inhibitor**



C



3



Yes



Yes



Yes

**Tabs:** 5, 10, 20 mg

**Oral solution:** 1 mg/mL (240 mL); contains parabens and propylene glycol

**Depression:**

**<12 yr:** Limited data, only one placebo-controlled RCT did not demonstrate efficacy

**≥12 yr and adolescent:** Start with 10 mg PO once daily. If needed after 3 wk, dose may be increased to 20 mg once daily.

**Adult:** Start with 10 mg PO once daily. If needed after 1 wk, dose may be increased to 20 mg once daily.

**Autism and pervasive developmental disorders (PDD; limited data)**

**6–17 yr:** A 10-wk open-label trial in which 28 subjects were given a weekly PRN increasing PO dosage regimen of 2.5, 5, 10, 15, and 20 mg/24 hr. Mean dosage of responders with significant improvement at  $11.1 \pm 6.5$  mg/24 hr. 25% of subjects responded at doses  $<10$  mg/24 hr, and 36% responded at doses  $\geq 10$  mg/24 hr. Seven of the 17 (41%) responders and 25% of all treated subjects could not tolerate the 10 mg/24 hr dose.

**Social Anxiety Disorder (limited data):**

**10–17 yr:** A 12-wk open-label trial in which 20 subjects were given an initial PO dosage of 5 mg once daily  $\times$  7 days followed by 10 mg once daily. If needed and tolerated, increase by 5 mg/24 hr at weekly intervals up to a **maximum** of 20 mg/24 hr. Two subjects did not complete the trial due to lack of efficacy and tolerability. Sixty-five percent of the remaining subjects met the response criteria with a mean final dose of  $13 \pm 4.1$  mg/24 hr. Common adverse events included somnolence (25%), insomnia (20%), flu symptoms (15%), increased appetite (15%), and decreased appetite (15%).

Increased risk for serotonin syndrome when used with MAO inhibitors (or within 14 days of discontinuance), linezolid, or methylene blue; concurrent use considered **contraindicated**.

**Do not use** with pimozide because of risk for increased QTc interval. **Use with caution** with hepatic or severe renal impairment; dosage adjustment may be needed. **Avoid** abrupt discontinuation to prevent withdrawal symptoms.

Diaphoresis, GI discomfort, xerostomia, dizziness, headache, insomnia, somnolence, sexual dysfunction, and fatigue are common side effects. Abnormal bleeding, depression, QTc prolongation, and suicidal ideation (especially during initiation of therapy and with any dosage change) have been reported.

Mixed/manic episode may occur when treating a depressive episode in patients with bipolar disorders. Primarily metabolized by the CYP 450 2C19 and 3A4 enzymes and is a weak inhibitor for CYP 450 2D6 enzyme. Consider an alternative medication (not significantly metabolized by CYP 450 2C19) for individuals with ultrarapid CYP 450 2C19 activity. Poor CYP450 2C19 metabolizers can either initiate therapy at 50% the usual dose and titrate to response or consider alternative therapy.



ESCITALOPRAM *continued*

Taking with other medications with QTc prolongation may further increase that risk. Omeprazole may increase the toxicity of escitalopram. Doses may be administered with or without food.

**ESMOLOL HCL**

Brevibloc and generics

**$\beta_1$  selective adrenergic blocking agent, anti-hypertensive agent, class II antiarrhythmic**



C



?



No



No



No

**Injection:** 10 mg/mL (10 mL); preservative free

**Injection, premixed infusion in iso-osmotic sodium chloride:** 2000 mg/100 mL (100 mL), 2500 mg/250 mL (250 mL); preservative free

**Injection, premixed infusion in iso-osmotic water for injection:** 2000 mg/100 mL (100 mL), 2500 mg/250 mL (250 mL); contains ethanol, propylene glycol

**Postoperative hypertension:** Titrate to response (limited information):

**Loading dose:** 500 mcg/kg IV over 1 min

**Maintenance dose:** 50–250 mcg/kg/min IV as infusion. Titrate doses upward 50–100 mcg/kg/min Q 5–10 min as needed. Heart surgery patients may require higher doses (~700 mcg/kg/min). Dosages as high as 1000 mcg/kg/min have been reported in children 1–12 yr.

**SVT:** Titrate to response (limited information).

**Loading dose:** 100–500 mcg/kg IV over 1 min

**Maintenance dose:** 25–100 mcg/kg/min IV as infusion. Titrate doses upward 50–100 mcg/kg/min Q5–10 min as needed. Dosages as high as 1000 mcg/kg/min have been reported.

**Contraindicated** in sinus bradycardia, >first-degree heart block, and cardiogenic shock or heart failure. Short duration of action;  $T_{1/2}$  = 2.9–4.7 min for children and 9 min for adults. May cause bronchospasm, congestive heart failure, hypotension (at doses >200 mcg/kg/min), nausea, and vomiting. May increase digoxin (by 10%–20%) and theophylline levels. Morphine may increase esmolol level by 46%. Theophylline may decrease esmolol's effects.

**Administer only in a monitored setting.** Concentration for administration is typically  $\leq 10$  mg/mL, but 20 mg/mL has been administered in pediatric patients.

**ESOMEPRAZOLE**

Nexium, Nexium 24HR, and generics

**Gastric acid proton pump inhibitor**



B/C



2



Yes



Yes



No

**Caps, delayed release (Nexium and generics):** 20, 40 mg; contains magnesium (some generic products may contain strontium instead)

**Nexium 24 HR [OTC]:** 20 mg

**Nexium 24 HR Clear Minis [OTC]:** 20 mg

**Tab, delayed release (Nexium 24HR; [OTC]):** 20 mg; contains magnesium

**Powder for oral suspension:**

**Nexium:** 2.5, 5, 10, 20, 40 mg packets (30s); contains magnesium

**Generics:** 10, 20, 40 mg packets (30s)

**Injection (Nexium and generics):** 40 mg; contains EDTA

**Child (PO):**

**GERD (use for 4–8 wk):**

**Weight-based dosage:** 0.7–3.3 mg/kg/24 hr once daily; **max. dose:** 40 mg/24 hr

**<20 kg:** 10 mg once daily

*Continued*

ESOMEPRAZOLE *continued*

≥20 kg: 20 mg once daily

**Erosive esophagitis in GERD:**

**Infant (1 mo to <1 yr; use for up to 6 wk):**

3–5 kg: 2.5 mg once daily

>5 to 7.5 kg: 5 mg once daily

>7.5 kg: 10 mg once daily

**1–11 yr (use for 8 wk):**

<20 kg: 10 mg once daily

≥20 kg: 10 or 20 mg once daily

**12–17 yr:** 20 or 40 mg once daily for 4–8 wk

**Child (IV):****GERD with erosive esophagitis:**

**Infant:** 0.5–1 mg/kg/dose once daily

**Child 1–17 yr:**

<55 kg: 10 mg once daily

≥55 kg: 20–40 mg once daily

**Adult (PO/IV):**

**GERD:** 20 mg once daily

**GERD with erosive esophagitis:** 20 or 40 mg once daily × 4–8 wk

**Prevention of NSAID-induced gastric ulcers:** 20 or 40 mg once daily for up to 6 mo

**Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome):** 40 mg BID; doses up to 240 mg/24 hr have been used

**Hepatic impairment:** Patients with severe hepatic function impairment (Child-Pugh class C) should not exceed 20 mg/24 hr (40 mg/24 hr for pathological hypersecretory conditions).

Cross-allergic reactions with other proton pump inhibitors (e.g., lansoprazole, pantoprazole, rabeprazole). **Use with caution** in liver impairment (see dosage adjustment recommendation in dosing section). GI disturbances and headache are common. Hypomagnesemia may occur with continuous use and may lead to hypocalcemia and/or hypokalemia. Anaphylaxis, angioedema, bronchospasm, acute interstitial nephritis, erythema multiforme, urticaria, Stevens-Johnson syndrome, TEN, pancreatitis, and fractures of the hip, wrist, and spine (in adults >50 yr old receiving high doses or prolonged therapy >1 yr) have been reported. Fundic gland polyps have been associated with long-term use of >1 yr.



Drug is a substrate and inhibitor of CYP 450 2C19 and substrate of CYP 450 3A4. May decrease the absorption or effects of atazanavir, clopidogrel, ketoconazole, itraconazole, mycophenolate mofetil, and iron salts. May increase the effect/toxicity of diazepam, midazolam, digoxin, carbamazepine, and warfarin. Voriconazole may increase the effects of esomeprazole.

May be used in combination with clarithromycin and amoxicillin for *Helicobacter pylori* infections. Pregnancy category is a “B” for the magnesium-containing product and a “C” for the strontium-containing product.

Administer all oral doses before meals and 30 min before sucralfate (if receiving). **Do not** crush or chew capsules. IV doses may be given as fast as 3 min or infused over 10–30 min.

**ETANERCEPT**

Enbrel, Enbrel SureClick, Enbrel Mini

**Antirheumatic, immunomodulatory agent, tumor necrosis factor receptor p75 Fc fusion protein**



B



?



No



Yes



No

ETANERCEPT *continued*

**Prefilled injection (single use):** 25 mg (0.5 mL), 50 mg (1 mL); contains sucrose, L-arginine (preservative free) (carton of 4 prefilled syringes)

**Injection (powder; multidose vial):** 25 mg with diluent (1 mL bacteriostatic water containing 0.9% benzyl alcohol); contains mannitol, sucrose, tromethamine (carton of 4 vials)

**Injection (single dose vial):** 25 mg (0.5 mL); contains sucrose, L-arginine (preservative free) (carton of 4 vials)

**Autoinjector:**

**Enbrel SureClick (single use):** 50 mg (1 mL); contains sucrose, L-arginine (preservative free) (carton of 4 autoinjectors)

**Prefilled injection cartridge to be used with Auto Touch reusable autoinjector device:**

**Enbrel Mini:** 50 mg (1 mL); contains sucrose, L-arginine (preservative free) (carton of 4 cartridges)

**Juvenile idiopathic arthritis:**

**Child 2—17 yr:** 0.4 mg/kg/dose SC twice weekly administered 72—96 hr apart; **max. dose:** 25 mg. Alternative once-weekly dose of 0.8 mg/kg/dose SC (**max. dose:** 50 mg/wk and **max. single injection site dose** of 25 mg) may be used.

**Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis:**

**Adult:** 25 mg SC twice weekly administered 72—96 hr apart. Alternative once weekly dose of 50 mg SC (**max. single injection site dose** of 25 mg) may be used.

**Plaque psoriasis:**

**Child and adolescent (4—17 yr):** 0.8 mg/kg/dose (**max. dose:** 50 mg) SC once weekly

**Adult:** Start with 50 mg SC twice weekly administered 72—96 hr apart × 3 mo, followed by a reduced maintenance dose of 50 mg SC per wk. Starting doses of 25 mg or 50 mg/wk have also been shown to be effective.

**Max. single injection site dose:** 25 mg

**Contraindicated** in serious infections, sepsis, or hypersensitivity to any of medication components. **Use with caution** in patients with history of recurrent infections (including hepatitis B) or underlying conditions that may predispose them to infections (including concomitant immunosuppressive therapy), CNS demyelinating disorders, malignancies, immune-related diseases, and latex allergy. Use in patients with granulomatosis with polyangiitis receiving immunosuppressive therapy is not recommended due to the risk for noncutaneous solid malignancies and no improved clinical outcomes.



Common adverse effects in children include headache, abdominal pain, vomiting, and nausea. Injection site reactions (e.g., discomfort, itching, swelling), rhinitis, dizziness, rash, depression, infections (varicella, aseptic meningitis, rare cases of TB, and fatal/serious infections and sepsis), bone marrow suppression (e.g., aplastic anemia), sarcoidosis, vertigo, and CNS demyelinating disorder have also been reported. Malignancies (some fatal and ~50% were lymphomas) have been reported in children and adolescents.

**Do not** administer live vaccines concurrently with this drug. In JRA, it is recommended that before initiating therapy, the patient be brought up to date with all immunizations in agreement with current immunization guidelines.

Onset of action is 1—4 wk, with peak effects usually within 3 mo.

Patients must be properly instructed on preparing and administering the medication (see specific product information). For multidose vial, reconstitute vial by gently swirling its contents with the supplied diluent (**do not** shake or vigorously agitate), as some foaming will occur. Reconstituted solutions should be clear and colorless; unused portions must be stored in the refrigerator and used within 14 days. Do not store Auto Touch autoinjector device in the refrigerator.

Drug is administered subcutaneously by rotating injection sites (thigh, abdomen, or upper arm) with a **max. single injection site dose** of 25 mg. Administer new injections ≥1 inch from an old site and NEVER where the skin is tender, bruised, red, or hard.

**ETHAMBUTOL HCL**

Myambutol and generics

**Antituberculosis drug**

C

2

Yes

Yes

No

**Tabs:** 100, 400 mg; 400 mg tabs may be scored**Oral suspension:** 50, 100 mg/mL **Tuberculosis (use in combination with other medications; see remarks):****Infant, child, adolescent, and adult (see latest CDC guidelines as additional dosing schedules exist):****<15 yr and <40 kg:** 15–25 mg/kg/dose (**max. dose:** 1 g/24 hr) PO once daily or 50 mg/kg/dose PO twice weekly (**max. dose:** 2.5 g/week)**<15 yr and ≥40 kg, or ≥15 yr:****40–55 kg:** 800 mg PO once daily or 5 times weekly**56–75 kg:** 1200 mg PO once daily or 5 times weekly**76–90 kg:** 1600 mg PO once daily or 5 times weekly**Nontuberculous mycobacterial infection; and *Mycobacterium avium* complex in AIDS (recurrence prophylaxis or treatment; use in combination with other medications):****Infant, and child:** 15–25 mg/kg/24 hr PO once daily; **max. dose:** 2.5 g/24 hr**Adolescent:** 15 mg/kg/24 hr PO once daily; **max. dose:** 2.5 g/24 hr

May cause reversible optic neuritis, especially with larger doses. Obtain baseline ophthalmologic studies before beginning therapy and then monthly. Follow visual acuity, visual fields, and (red-green) color vision. **Do not use** in optic neuritis and in children whose visual acuity cannot be assessed. **Discontinue** if any visual deterioration occurs. Monitor uric acid, liver function, heme status, and renal function. Hyperuricemia, GI disturbances, and mania are common. Erythema multiforme and hepatotoxicity have been reported.

Dosing should be based on lean body weight. Coadministration with aluminum hydroxide can reduce ethambutol's absorption; space administration by 4 hr. Give with food. **Adjust dose with renal failure (see Chapter 31).**

**ETHOSUXIMIDE**

Zarontin and generics

**Anticonvulsant**

D

2

Yes

Yes

No

**Caps:** 250 mg**Oral solution:** 250 mg/5 mL (473 mL); may contain sodium benzoate**Oral:****≤6 yr:****Initial:** 10 mg/kg/24 hr up to 250 mg/24 hr ÷ BID-TID; increase by 5–10 mg/kg/24 hr as needed Q4–7 days**Usual maintenance dose:** 15–40 mg/kg/24 hr ÷ BID-TID**>6 yr and adult:** 10 mg/kg/24 hr up to 500 mg/24 hr ÷ BID-TID; increase by 250 mg/24 hr as needed Q4–7 days**Usual maintenance dose:** 20–40 mg/kg/24 hr ÷ BID-TID**Max. dose (all ages):** The lesser of 60 mg/kg/24 hr or 2 g/24 hr

Drug of choice for absence seizures. **Use with caution** in hepatic and renal disease. Ataxia, anorexia, drowsiness, sleep disturbances, rashes, and blood dyscrasias are rare idiosyncratic reactions. May cause lupus-like syndrome; may increase frequency of grand mal seizures in patients with mixed-type seizures. Serious dermatological reactions (e.g., Stevens-Johnson and DRESS) and

ETHOSUXIMIDE *continued*

immune thrombocytopenia have been reported. May increase risk of suicidal thoughts/behavior.

Cases of birth defects have been reported; ethosuximide crosses the placenta.

Carbamazepine, phenytoin, primidone, phenobarbital, valproic acid, nevirapine, and ritonavir may decrease ethosuximide levels.

Therapeutic levels: 40–100 mg/L.  $T_{1/2}$  = 24–42 hr. Recommended serum sampling time at steady state: obtain trough level within 30 min prior to the next scheduled dose after 5–10 days of continuous dosing.

To minimize GI distress, may administer with food or milk. Abrupt withdrawal of drug may precipitate absence status.

**ETOMIDATE**

Amidate and generics

**General anesthetic**



C



2



Yes



No



No

**Injection:** 2 mg/mL (10, 20 mL); may be preservative free or contain propylene glycol

**Rapid Sequence Intubation (infuse dose over 30–60 sec):**

**Normotensive patient:** 0.3 mg/kg/dose IV/IO  $\times$  1; **max. dose:** 20 mg/dose

**Hypotensive patient (see remarks):** 0.15 mg/kg/dose IV/IO  $\times$  1; **max. dose:** 20 mg/dose



Not recommended for patients in septic shock due to transient adrenocortical suppression and increased risk for mortality. **Avoid use** with benznidazole and metronidazole due to the risk for disulfiram-like reaction. **Use with caution** in renal impairment (higher risk for toxicity) and in heart failure (may exacerbate condition).



Injection site pain, myoclonus (pretreatment with midazolam may reduce risk), nausea, and vomiting are reported common side effects for indications other than rapid-sequence intubation.

## F

**FAMCICLOVIR**

Generics; previously available as Famvir

**Antiviral**



B



?



Yes



Yes



No

**Tabs:** 125, 250, 500 mg

**Adult:**

**Herpes zoster:** 500 mg Q8 hr PO  $\times$  7–10 days; initiate therapy promptly as soon as diagnosis is made (initiation within 48 hr after rash onset is ideal; currently no data for starting treatment >72 hr after rash onset)

**Genital herpes (first episode):**

**Immunocompetent:** 250 mg Q8 hr PO  $\times$  7–10 days

**Immunocompromised:** 500 mg Q12 hr PO  $\times$  5–10 days

**Recurrent genital herpes (initiate therapy within 1 day of lesion onset):**

**Immunocompetent:** 1000 mg Q12 hr PO  $\times$  1 day or 125 mg Q12 hr PO  $\times$  5 days

**Immunocompromised:** 500 mg Q12 hr PO  $\times$  5–7 days

**Suppression of recurrent genital herpes (immunocompetent):** 250 mg Q12 hr PO up to 1 yr, then reassess for HSV infection recurrence



*Continued*

FAMCICLOVIR *continued***Recurrent herpes labialis:****Immunocompetent:** 1500 mg PO  $\times$  1**Immunocompromised:** 500 mg Q12 hr PO  $\times$  7 days**Recurrent mucocutaneous herpes in HIV:** 500 mg Q12 hr PO  $\times$  7 days

Drug is converted to its active form (penciclovir). Hepatic impairment may impair/reduce the conversion of famciclovir to penciclovir. Better absorption than PO acyclovir.




May cause headache, diarrhea, nausea, and abdominal pain. Serious skin reactions (e.g., TEN and Stevens-Johnson), angioedema, hypersensitivity vasculitis, seizure, palpitations, cholestatic jaundice, and abnormal LFTs have been reported. Concomitant use with probenecid and other drugs eliminated by active tubular secretion may result in decreased penciclovir clearance. **Reduce dose in renal impairment (see Chapter 31).**

Safety and efficacy in suppression of recurrent genital herpes have not been established beyond 1 yr. No efficacy data are available for children 1–<12 yr to support its use for genital herpes, recurrent herpes labialis, and varicella. Furthermore, efficacy has not been established for recurrent herpes labialis for children 12–<18 yr. May be administered with or without food.

**FAMOTIDINE**

Pepcid, Pepcid AC [OTC], Pepcid AC Maximum Strength [OTC], Pepcid Complete [OTC], Zantac 360 [OTC], Zantac 360 Maximum Strength [OTC], and generics

***Histamine-2-receptor antagonist***

B

1

Yes

No

No

**Injection:** 10 mg/mL (2, 4, 20 mL); multidose vials contain 0.9% benzyl alcohol**Premixed injection:** 20 mg/50 mL in iso-osmotic sodium chloride**Oral suspension:** 40 mg/5 mL (50 mL); may contain parabens and sodium benzoate**Tabs:****Pepcid AC, Zantac 360, and generics [OTC]:** 10 mg**Pepcid, Pepcid AC Maximum Strength, Zantac 360 Maximum Strength, and generics [OTC and by prescription]:** 20 mg**Pepcid and generics:** 40 mg**Chewable tabs:****Pepcid Complete (OTC):** 10 mg famotidine with 800 mg calcium carbonate and 165 mg magnesium hydroxide (25s, 50s, 100s)**Neonate and <3 mo:****IV:** 0.25–0.5 mg/kg/dose Q24 hr**PO:** 0.5–1 mg/kg/dose Q24 hr **$\geq$ 3 mo–1 yr (GERD):****IV (limited to PK data):** 0.25 mg/kg/dose Q12 hr**PO:** 0.5 mg/kg/dose Q12 hr**Child (1–12 yr):****IV:** Initial: 0.5–1 mg/kg/24 hr  $\div$  Q12 hr up to a **max.** of 40 mg/24 hr**PO:** Initial: 1–1.2 mg/kg/24 hr  $\div$  Q12 hr up to a **max.** of 40 mg/24 hr**Peptic ulcer:** 0.5–1 mg/kg/24 hr PO/IV QHS or  $\div$  Q12 hr up to a **max. dose** of 40 mg/24 hr**GERD:****IV:** 0.5–1 mg/kg/24 hr  $\div$  Q12 hr up to a **max. dose** of 40 mg/24 hr**PO:** 1–2 mg/kg/24 hr  $\div$  Q12 hr up to a **max. dose** of 80 mg/24 hr

FAMOTIDINE *continued***Adolescent and adult:****Duodenal ulcer:**

**PO:** 20 mg BID or 40 mg QHS × 4–8 wk, then maintenance therapy at 20 mg QHS

**IV:** 20 mg BID

**GERD:** 20 mg BID PO × 6 wk

**Esophagitis:** 20–40 mg BID PO × 12 wk

A Q12-hr dosage interval is generally recommended; however, infants and young children may require a Q8-hr interval because of enhanced drug clearance. Headaches, dizziness, constipation, diarrhea, and drowsiness have occurred. **Dosage adjustment is required in severe renal failure (see Chapter 31);** prolonged QT interval has been reported very rarely in patients with renal impairment whose dosage had not been adjusted appropriately. Rhabdomyolysis has been reported. Shake oral suspension well prior to each use. Oral doses may be administered with or without food.

**FELBAMATE**

Felbatol and generics

**Anticonvulsant**



C



3



Yes



Yes



No

**Tabs:** 400, 600 mg

**Oral suspension:** 600 mg/5 mL (240, 473 mL)

**Lennox-Gastaut for child 2–14 yr (adjunctive therapy):**

Start at 15 mg/kg/24 hr PO ÷ TID–QID; increase dosage by 15 mg/kg/24 hr increments at weekly intervals up to a **max. dose** of 45 mg/kg/24 hr or 3600 mg/24 hr (whichever is less).

See remarks for adjusting concurrent anticonvulsants.

**Child ≥14 yr—adult:**

**Adjunctive therapy:** Start at 1200 mg/24 hr PO ÷ TID–QID; increase dosage by 1200 mg/24 hr at weekly intervals up to a **max. dose** of 3600 mg/day. See remarks for adjusting concurrent anticonvulsants.

**Monotherapy (as initial therapy):** Start at 1200 mg/24 hr PO ÷ TID–QID. Increase dose under close clinical supervision at 600 mg increments Q2 wk to 2400 mg/24 hr. **Max. dose:** 3600 mg/24 hr

**Conversion to monotherapy:** Start at 1200 mg/24 hr ÷ PO TID–QID for 2 wk; then increase to 2400 mg/24 hr for 1 wk. At wk 3, increase to 3600 mg/24 hr. Reduce dose of other anticonvulsants by 33% at the initiation of felbamate, then an additional 33% of original dose at wk 2 and continue to reduce other anticonvulsants as clinically indicated at wk 3 and beyond.

Drug should be prescribed under strict supervision by a specialist. **Contraindicated** in blood dyscrasias or hepatic dysfunction (prior or current), and hypersensitivity to meprobamate. Aplastic anemia and hepatic failure leading to death have been associated with drug. May cause headache, fatigue, anxiety, GI disturbances, gingival hyperplasia, increased liver enzymes, and bone marrow suppression. Suicidal behavior or ideation have been reported. **Obtain serum levels of concurrent anticonvulsants.** Monitor liver enzymes, bilirubin, CBC with differential, platelets at baseline, and every 1–2 wk. Doses should be decreased by 50% in renally impaired patients. When initiating adjunctive therapy (all ages), reduce doses of other antiepileptic drugs (AEDs) by 20% to control plasma levels of concurrent phenytoin, valproic acid, phenobarbital, and carbamazepine. Further reductions of concomitant AED dosage may be necessary to minimize side effects caused by drug interactions.



When converting to monotherapy, reduce other AEDs by one-third at the start of felbamate therapy. Then after 2 wk and at the start of increasing the felbamate dosage, reduce other AEDs by an additional one-third. At wk 3, continue to reduce other AEDs as clinically indicated.

*Continued*

FELBAMATE *continued*

Carbamazepine levels may be decreased; however, phenytoin and valproic acid levels may be increased. Phenytoin and carbamazepine may increase felbamate clearance; valproic acid may decrease its clearance.

Doses can be administered with or without food.

**FENTANYL**

Sublimaze, Fentora, Actiq, generics; previously available as Duragesic

**Narcotic; analgesic, sedative**



C/D



2



Yes



No



No

**Injection:** 50 mCg/mL (1, 2, 5, 10, 20, 50 mL)

**SR transdermal patch:** 12.5, 25, 37.5, 50, 62.5, 75, 87.5, 100 mCg/hr (5s)

**Tabs for buccal administration:**

Fentora and generics: 100, 200, 400, 600, 800 mCg (28s)

**Lozenge on a stick:**

Actiq and generics: 200, 400, 600, 800, 1200, 1600 mCg (30s)

**Titrate dose to effect.**

**Neonate and younger infant:**

**Sedation/analgesia:** 1–4 mCg/kg/dose (**max. dose:** 100 mCg/dose) IV Q2–4 hr PRN

**Continuous IV infusion:** 1–5 mCg/kg/hr; tolerance may develop

**Older infant and child:**

**Sedation/analgesia:** 1–2 mCg/kg/dose (**max. dose:** 100 mCg/dose) IV/IM Q30–60 min PRN

**Continuous IV infusion:** 1 mCg/kg/hr; titrate to effect; usual infusion range 1–3 mCg/kg/hr

**To prepare infusion, use the following formula:**

$$50 \times \frac{\text{Desired dose (mCg/kg/hr)}}{\text{Desired infusion rate (mL/hr)}} \times \text{Wt (kg)} = \frac{\text{mCg Fentanyl}}{50 \text{ mL fluid}}$$

**Oral, breakthrough cancer pain for opioid-intolerant patients (see remarks):**

**Buccal tabs (≥18 yr NOT previously using Actiq):** Start with 100 mCg by placing tablet in the buccal cavity (above a rear molar, between the upper cheek and gum) and letting the tablet dissolve for 15–25 min. A second 100 mCg dose, if needed, may be administered 30 min after the start of the first dose. If needed, increase dose initially in multiples of 100 mCg tablets when patients require >1 dose per breakthrough pain episode for several consecutive episodes. Must wait at least 4 hr before treating another episode with buccal tabs. If titration requires >400 mCg/dose, use 200 mCg tabs.

**Lozenges (≥16 yr):** Start with 200 mCg by placing lozenge in the mouth between the cheek and lower gum. If needed, may repeat dose 15 min after the completion of the first dose (30 min after start of prior dose). If therapy requires >1 lozenge per episode, consider increasing the dose to the next higher strength. **Do not** give more than 2 doses for each episode of breakthrough pain and reevaluate long-acting opioid therapy if patient requires >4 doses/24 hr. **Must wait at least 4 hr before treating another episode with lozenges.**

**Transdermal (see remarks):** Safety has not been established in children <2 yr and should be administered in children ≥2 yr who are opioid tolerant. Use is **contraindicated** in acute or postoperative pain in opiate-naïve patients.

**Opioid-tolerant child receiving at least 60 mg morphine equivalents/24 hr:** Use 25 mCg/hr patch Q72 hr. Patch titration should not occur before 3 days of administration of the initial dose or more frequently than every 6 days thereafter.

See [Chapter 6](#) for equianalgesic dosing and PCA dosing.



FENTANYL *continued*

**Intranasal route for acute and pre-procedure analgesia (use IV dosage form; see remarks):**

≥1 yr—adolescent: 1–2 mCg/kg/dose intranasally via an automizer (**max. dose:** 100 mCg/dose) Q1 hr PRN

**Use with caution** in bradycardia, respiratory depression, and increased intracranial pressure. 

**Adjust dose in renal failure (see Chapter 31).** Fatalities and life-threatening respiratory depression have been reported with inappropriate use (overdoses, use in opioid-naïve patients, changing the patch too frequently, and exposing the patch to a heat source) of the transdermal route.

Highly lipophilic and may deposit into fat tissue. IV onset of action 1–2 min with peak effects in 10 min. IV duration of action 30–60 min. Give IV dose over 3–5 min. Rapid infusion may cause respiratory depression and chest wall rigidity. Respiratory depression may persist beyond the period of analgesia. Transdermal onset of action 6–8 hr with a 72-hr duration of action. See Chapter 6 for pharmacodynamic information with transmucosal and transdermal routes.

Buccal tabs and oral lozenges are indicated only for the management of breakthrough cancer pain in patients who are already receiving and who are tolerant to opioid therapy. Buccal tabs (Fentora), transdermal patches (Duragesic), and lozenge (Actiq) dosage forms are available through a restricted distribution program (REMS) and are **NOT bioequivalent** (see package insert for conversion).

Intranasal route of administration for analgesia has an onset of action at 10–30 min. Pediatric studies have demonstrated that the intranasal fentanyl is equivalent to and better than morphine (PO/IV/IM) and equivalent to intravenous fentanyl for providing analgesia.

Fentanyl is a substrate for the CYP 450 3A4 enzyme. Be aware of medications that inhibit or induce this enzyme, for they may increase or decrease the effects of fentanyl, respectively.

Pregnancy category changes to “D” if drug is used for prolonged periods or in high doses at term.

**FERRIC GLUCONATE**

See [Iron—Injectable Preparations](#).

**FERROUS SULFATE**

See [Iron—Oral Preparations](#).

**FEXOFENADINE ± PSEUDOEPHEDRINE**

Allegra [OTC], Children's Allegra Allergy [OTC], Allegra-D 12 Hour [OTC], Allegra-D 24 Hour [OTC], and generics

**Antihistamine, less-sedating ± decongestant**



C



2



Yes



No



No

**Tabs:** 60 mg [OTC], 180 mg [OTC]

**Tabs, orally disintegrating (Children's Allegra Allergy; ODT) [OTC]:** 30 mg; contains phenylalanine

**Oral suspension [OTC]:** 6 mg/mL (120, 240 mL); contains parabens

**Extended release tab in combination with pseudoephedrine (PE):**

**Allegra-D 12 Hour and generics [OTC]:** 60 mg fexofenadine + 120 mg pseudoephedrine

**Allegra-D 24 Hour and generics [OTC]:** 180 mg fexofenadine + 240 mg pseudoephedrine

**Fexofenadine:**

**6 mo—<2 yr:** 15–30 mg PO BID

**2–11 yr:** 30 mg PO BID

**≥12 yr—adult:** 60 mg PO BID; 180 mg PO once daily may be used in seasonal rhinitis



*Continued*

FEXOFENADINE ± PSEUDOEPHEDRINE *continued***Extended release tabs of fexofenadine and pseudoephedrine:**

≥12 yr—adult:

**Allegra-D 12 Hour:** 1 tablet PO BID**Allegra-D 24 Hour:** 1 tablet PO once daily

May cause drowsiness, fatigue, headache, dyspepsia, nausea, and dysmenorrhea. Has not been implicated in causing cardiac arrhythmias when used with other drugs that are metabolized by hepatic microsomal enzymes (e.g., ketoconazole, erythromycin). **Reduce dose to 15 mg PO once daily for child 6 mo—<2 yr, 30 mg PO once daily for child 6—11 yr old, and 60 mg PO once daily for ≥12 yr old for any degree of renal impairment. For use of Allegra-D 12 Hour and decreased renal function (CrCl <80 mL/min), an initial dose of 1 tablet PO once daily is recommended. Avoid use of Allegra-D 24 Hour in renal impairment. See Pseudoephedrine for additional remarks if using the combination product.**

Medication as the single agent may be administered with or without food. **Do not** administer antacids with or within 2 hr of fexofenadine dose. The extended release combination product should be swallowed whole without food.

**FIDAXOMICIN**

Difcid

**Antibiotic, macrolide**

B



?



No



No



No

**Oral suspension:** 40 mg/mL (136 mL); contains sodium benzoate**Tabs:** 200 mg; contains soybean lecithin**C. difficile treatment (PO):****Child >6 mo:** 16 mg/kg/dose (**max. dose:** 200 mg/dose) BID × 10 days; or alternative fixed dosage by weight:

4—&lt;7 kg: 80 mg BID

7—&lt;9 kg: 120 mg BID

9—&lt;12.5 kg: 160 mg BID

≥12.5 kg: 200 mg BID

**Adult:** 200 mg BID × 10 days

Minimally absorbable macrolide antibiotic with bactericidal activity against *C. difficile*; inhibits RNA polymerase sigma subunit resulting in inhibition of protein synthesis and cell death. Fidaxomicin use in children <18 yr is currently indicated as a second-line agent following recurrent courses of oral vancomycin, whereas it is the recommended first-line initial episode therapy for adults.

Acute hypersensitivity reactions such as angioedema, dyspnea, pruritus, and rash have been reported, and individuals with a history of macrolide allergies may be at risk. Common side effects include abdominal pain, nausea, vomiting, anemia, and neutropenia. Bowel obstruction and GI hemorrhage have been reported.

Fidaxomicin and its main metabolite (OP-118) are substrates of the P-gp efflux transporter in the GI tract. Use with cyclosporine, a P-gp inhibitor, may increase systemic levels of fidaxomicin and OP-118 without affecting the safety and efficacy for treating *C. difficile* in adult clinical trials.

Doses may be administered with or without food.

**FILGRASTIM**

Neupogen, G-CSF

**Colony-stimulating factor**

C



2



Yes



No



No

FILGRASTIM *continued*

**Injection (Neupogen):** 300 mCg/mL (1, 1.6 mL vials)

**Injection, prefilled syringes with 27-gauge 1/2-inch needles (Neupogen):** 600 mCg/mL (300 mCg per 0.5 mL and 480 mCg per 0.8 mL) (10s)

**All dosage forms contain polysorbate 80 and are preservative free.**

**NOTE:** The following biosimilar products are available (all contain polysorbate 80 and are preservative free).

**Single-dose vials [Nivestym (filgrastim-aafi), Granix (tbo-filgrastim), Releuko (filgrastim-ayow)]:** 300 mCg/1 mL and 480 mCg/1.6 mL (10s)

**Prefilled syringes [Nivestym (filgrastim-aafi), Zarxio (filgrastim-sndz), Releuko (filgrastim-ayow)]:** 300 mCg/0.5 mL and 480 mCg/0.8 mL (1 or 10s); may be attached with a 27-gauge, 1/2-inch needle

**Individual protocols may direct dosing.**

**Myelosuppressive chemotherapy recipients with non-myeloid malignancies:**

**IV/SC:** 5 mCg/kg/dose once daily  $\times$  14 days or until ANC  $>10,000/\text{mm}^3$ . Dosage may be increased by 5 mCg/kg/24 hr if desired effect is not achieved within 7 days.

Discontinue therapy when ANC  $>10,000/\text{mm}^3$ .

**Contraindicated** for patients sensitive to *E. coli*-derived proteins. **Avoid** simultaneous administration with chemotherapy and radiation and do not administer 24 hr before or after administration of chemotherapy. May cause bone pain, fever, and rash. Monitor CBC, uric acid, and LFTs. Aortitis, sickle cell crisis, serious allergic reactions, glomerulonephritis, and thrombocytopenia have been reported. Decreased bone density/osteoporosis has been reported in pediatric patients with severe chronic neutropenia. **Use with caution** in patients with malignancies with myeloid characteristics. Myelodysplastic syndrome and acute myeloid leukemia have been associated with the filgrastim in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer.

Safety and effectiveness have been established for nonmyeloid malignancies receiving myelosuppressive chemotherapy in children  $\geq 1$  mo— $<17$  yr old. The safety profile was similar to adults.

SC routes of administration are preferred because of prolonged serum levels over IV route. If used via IV route and G-CSF final concentration  $<15$  mCg/mL, add 2 mg albumin/1 mL of IV fluid to prevent drug adsorption to the IV administration set.

**FLECAINIDE ACETATE**

Generics; previously available as Tambocor

**Antiarrhythmic, class Ic**



C



2



Yes



Yes



Yes

**Tabs:** 50, 100, 150 mg

**Oral suspension:** 20 mg/mL 

**Child: Initial:** 1–3 mg/kg/24 hr  $\div$  Q8 hr PO; usual range: 3–6 mg/kg/24 hr  $\div$  Q8 hr PO, monitor serum levels to adjust dose if needed

**Adult:**

**Sustained V tach:** 100 mg PO Q12 hr; may increase by 50 mg Q12 hr (100 mg/24 hr) every 4 days to **max. dose** of 400 mg/24 hr

**Paroxysmal SVT/paroxysmal AF:** 50 mg PO Q12 hr; may increase dose by 50 mg Q12 hr every 4 days to **max. dose** of 300–400 mg/24 hr

May aggravate LV failure, sinus bradycardia, preexisting ventricular arrhythmias. May cause AV block, dizziness, blurred vision, dyspnea, nausea, headache, and increased PR or QRS intervals. **Reserve for life-threatening cases. Use with caution** in renal and/or hepatic impairment.

*Continued*

FLECAINIDE ACETATE *continued*

Flecainide is a substrate for the CYP P-450 2D6 enzyme. Be aware of medications that inhibit (e.g., certain SSRIs) or induce this enzyme, for it may increase or decrease the effects of flecainide, respectively. 50% and 25% dose reductions with ECG and serum level monitoring have been recommended for poor and intermediate CYP2D6 metabolizers, respectively.

**Therapeutic trough level:** 0.2–1 mg/L. Recommended serum sampling time at steady state: Obtain trough level within 30 min prior to the next scheduled dose after 2–3 days of continuous dosing for children; after 3–5 days for adults. **Adjust dose in renal failure (see Chapter 31).**

**FLUCONAZOLE**

Diffucan and generics  
**Antifungal agent**

C/D    2    Yes    Yes    No

**Tabs:** 50, 100, 150, 200 mg

**Injection:** 2 mg/mL (50, 100, 200 mL); contains 9 mEq Na/2 mg drug

**Oral suspension:** 10 mg/mL (35 mL), 40 mg/mL (35 mL)

**Neonate (IV/PO):**

**Loading dose:** 12–25 mg/kg

**Thrush:** 6 mg/kg

**Maintenance dose:** 6–12 mg/kg with the following dosing intervals (see following table); use higher doses for severe infections of *Candida* strains with MICs >4–8 mCg/mL.

**Thrush:** 3–6 mg/kg/dose with the following dosing intervals (see following table) for at least 2 wk



Postconceptional Age (wk)	Postnatal Age (days)	Dosing Interval (hr) and Time (hr) to Start First Maintenance Dose After Load
≤29	0–14	48
	>14	24
≥30	0–7	48
	>7	24

**Child ≥1 mo (IV/PO):**

Indication	Dosage Q24 hr	Maximum Dose
Oropharyngeal candidiasis	6–12 mg/kg	400 mg/dose
Esophageal candidiasis	6–12 mg/kg	600 mg/dose
Invasive systemic candidiasis (e.g., endocarditis) and cryptococcal meningitis	12 mg/kg	800 mg/dose
Suppressive therapy for HIV infected with cryptococcal meningitis	6 mg/kg	200 mg/dose

**Adult:**

**Oropharyngeal candidiasis:** Loading dose of 200 mg PO/IV followed by 100–200 mg Q24 hr (24 hr after load) for 7–14 days; doses up to 400 mg/24 hr have been used

**Esophageal candidiasis:** Loading dose of 400 mg PO/IV followed by 200–400 mg Q24 hr (24 hr after load); doses up to 800 mg/24 hr have been used

**Systemic candidiasis:** Loading dose of 800 mg PO/IV, followed by 400–800 mg Q24 hr (24 hr after load)

FLUCONAZOLE *continued*

**Bone marrow transplant prophylaxis:** 400 mg PO/IV Q24 hr

**Suppressive therapy in for HIV infected with cryptococcal meningitis:** 200–400 mg PO/IV Q24 hr

**Vaginal candidiasis:** 150 mg PO × 1

**Severe infection in immunocompromised:** 150 mg Q72 hr × 2–3 doses



Use with other medications known to prolong the QT interval and that are metabolized via the CYP 450 3A4 enzyme (e.g., erythromycin) are considered **contraindicated**. May cause nausea, headache, rash, vomiting, abdominal pain, hepatitis, cholestasis, and diarrhea. Neutropenia, agranulocytosis, thrombocytopenia, exfoliative skin disorders (e.g., SJS, TEN, DRESS), and adrenal insufficiency (reversible) have been reported. **Use with caution** in hepatic or renal dysfunction and in patients with hypokalemia, proarrhythmic conditions, or advanced cardiac failure.

Inhibits CYP 450 2C9/10 and CYP 450 3A3/4 (weak inhibitor). May increase effects, toxicity, or levels of cyclosporine, midazolam, phenytoin, rifabutin, tacrolimus, theophylline, warfarin, oral hypoglycemics, AZT, and medicines containing ivacaftor. Rifampin increases fluconazole metabolism. May increase the risk of myopathy and rhabdomyolysis when co-administered with HMG-CoA reductase inhibitors (statins); statin dosage reduction may be needed.

Consider using higher doses in morbidly obese patients. **Adjust dose in renal failure (see Chapter 31).**

Pregnancy category is “C” for single 150 mg use for vaginal candidiasis, but a Danish study reports a higher risk for miscarriages for during weeks 7–22 of gestation. Pregnancy category “D” is for all other indications (high-dose use during first trimester of pregnancy may result in birth defects).

**FLUCYTOSINE**

Ancobon, 5-FC, 5-Fluorocytosine, and generics

**Antifungal agent**



C



3



Yes



Yes



No

**Caps:** 250, 500 mg

**Oral suspension:** 10, 50 mg/mL 

**Neonate (monitor serum concentrations):**

**<1 kg:**

≤14 days old: 75 mg/kg/24 hr ÷ Q8 hr PO

15–28 days old: 75 mg/kg/24 hr ÷ Q6 hr PO

**1–2 kg:**

≤7 days old: 75 mg/kg/24 hr ÷ Q8 hr PO

8–28 days old: 75 mg/kg/24 hr ÷ Q6 hr PO

**>2 kg and ≤60 days old:** 75 mg/kg/24 hr ÷ Q6 hr PO

Dosages of 75–100 mg/kg/24 hr have been used in neonates (preterm and term) for candidal meningitis.

**Child and adult (monitor serum concentrations):** 50–150 mg/kg/24 hr ÷ Q6 hr PO

Monitor CBC, BUN, serum creatinine, alkaline phosphatase, AST, and ALT. Common side effects: nausea, vomiting, diarrhea, rash, CNS disturbance, anemia, leukopenia, and thrombocytopenia. **Use with caution** in hepatic and renal impairment and in hematologic disorders. Use is **contraindicated** in the first trimester of pregnancy.



**Therapeutic levels:** 25–100 mg/L. Recommended serum sampling time at steady state: Obtain peak level 2–4 hr after oral dose following 4 days of continuous dosing. Peak levels of 40–60 mg/L have been recommended for systemic candidiasis. Maintain trough levels above 25 mg/L. Prolonged levels above 100 mg/L can increase risk for bone marrow suppression. Bone marrow suppression in immunosuppressed patients can be irreversible and fatal.

Flucytosine interferes with creatinine assay tests using the dry-slide enzymatic method (Kodak Ektachem analyzer). **Adjust dose in renal failure (see Chapter 31).**

**FLUDROCORTISONE ACETATE**

Generics (previously available as Florinef);

9-fluorohydrocortisone

**Corticosteroid**

C

3

Yes

No

No

**Tabs:** 0.1 mg**Oral suspension:** 0.1 mg/mL **Infant and child:** 0.05–0.1 mg/24 hr once daily PO**Congenital adrenal hyperplasia:** 0.05–0.3 mg/24 hr once daily PO**Adult:** 0.05–0.2 mg/24 hr once daily PO**Contraindicated** in CHF and systemic fungal infections. Has primarily mineralocorticoid activity.**Use with caution** in hypertension, edema, or renal dysfunction. May cause hypertension, hypokalemia, acne, rash, bruising, headaches, GI ulcers, and growth suppression.Monitor BP and serum electrolytes. See [Chapter 10](#) for steroid potency comparison.**Drug interactions:** Drug's hypokalemic effects may induce digoxin toxicity; phenytoin and rifampin may increase fludrocortisone metabolism.

Doses 0.2–2 mg/24 hr have been used in the management of severe orthostatic hypotension in adults. Use a gradual dosage taper when discontinuing therapy.

**FLUMAZENIL**

Generics; previously available as Romazicon

**Benzodiazepine antidote**

C

?

No

Yes

No

**Injection:** 0.1 mg/mL (5, 10 mL); contains parabens**Benzodiazepine overdose (IV, see remarks):****Child and adolescent (limited data):** 0.01 mg/kg (**max. dose:** 0.2 mg) IV over 15 secondsQ1 minute PRN up to a **max. total cumulative dose** of 1 mg. As an alternative for repeat bolus doses, a continuous infusion of 0.005–0.01 mg/kg/hr has been used.**Adult:** Initial dose: 0.2 mg over 30 sec, if needed, give 0.3 mg 30 sec later over 30 sec. Additional doses of 0.5 mg given over 30 sec Q1 min PRN up to a cumulative dose of 3 mg (usual cumulative dose: 1–3 mg). Patients with only partial response to 3 mg may require additional slow titration to a total of 5 mg. Patients who have not responded 5 min after receiving a cumulative dose of 5 mg should be reassessed for other causes of sedation from non-benzodiazepines.**Reversal of benzodiazepine sedation (IV):****Child and adolescent:** Initial dose: 0.01 mg/kg (**max dose:** 0.2 mg) given over 15 sec; if needed after 45 sec, 0.01 mg/kg (**max. dose:** 0.2 mg) Q1 min to a **max. total cumulative dose** of 0.05 mg/kg or 1 mg, whichever is lower. Usual total dose: 0.08–1 mg (average 0.65 mg)**Adult:** Initial dose: 0.2 mg over 15 sec; if needed after 45 sec, give 0.2 mg Q1 min to a **max. total cumulative dose** of 1 mg. Doses may be repeated at 20 min interval (**max. dose** of 1 mg per 20 min interval) up to a **max. dose** of 3 mg in 1 hr.**Does not reverse narcotics.** Onset of benzodiazepine reversal occurs in 1–3 min. Reversal effects of flumazenil ( $T_{1/2}$  approximately 1 hr) may wear off sooner than benzodiazepine effects. If patient does not respond after cumulative 1–3 mg dose, suspect agent other than benzodiazepines.

May precipitate seizures, especially in patients taking benzodiazepines for seizure control or in patients with tricyclic antidepressant overdose. Fear and panic attacks in patients with history of panic disorders have been reported.


FLUMAZENIL *continued*

**Use with caution** in liver dysfunction; flumazenil's clearance is significantly reduced. Use normal dose for initial dose and decrease the dosage and frequency for subsequent doses.

See [Chapter 3](#) for complete management of suspected ingestions.

**FLUNISOLIDE**

Generics; previously available as Nasarel or Nasalide

**Corticosteroid**

**Nasal solution:** 25 mCg/spray (200 sprays/bottle) (25 mL); contains propylene glycol and benzalkonium chloride

**After symptoms are controlled, reduce to lowest effective maintenance dose (e.g., 1 spray each nostril once daily) to control symptoms.**

**Nasal solution:****Child (6–14 yr):**

**Initial:** 1 spray per nostril TID or 2 sprays per nostril BID; **max. dose:** 4 sprays per nostril/24 hr  
**≥15 yr and adult:**

**Initial:** 2 sprays per nostril BID; if needed in 4–7 days, increase to 2 sprays per nostril TID; **max. dose:** 8 sprays per nostril/24 hr


Nasal burning and stinging is common. Nasal congestion, sneezing, epistaxis, watery eyes, sore throat, nausea/vomiting, and headaches may also occur. May cause a reduction in growth velocity. Nasal septal perforations have been reported. Flunisolide is a minor substrate of CYP 450 3A4.



Shake nasal solution well before use and clear nasal passages before use. Priming of the nasal spray is recommended when using a new bottle or if the bottle has not been used for ≥5 days.

**FLUORIDE**

NaFrinse, Fluoritab, many others, and generics

**Mineral****Concentrations and strengths based on fluoride ion:****Oral drops/solution:**

**Fluoritab NaFrinse, and generics:** 0.125 mg/drop (30 mL)

**Generics:** 0.5 mg/mL (50 mL)

**Chewable tabs:**

**Fluoritab, NaFrinse, and generics:** 1 mg

**Generics:** 0.25, 0.5 mg

**All doses/24 hr (see table below):**

Recommendations from American Academy of Pediatrics and American Dental Association for prevention of dental caries.



Age	Concentration of Fluoride in Drinking Water (ppm)		
	<0.3	0.3–0.6	>0.6
Birth–6 mo	0	0	0
6 mo–3 yr	0.25 mg	0	0
3–6 yr	0.5 mg	0.25 mg	0
6–16 yr	1 mg	0.5 mg	0

*Continued*

FLUORIDE *continued*

**Contraindicated** in areas where drinking water fluoridation is  $>0.7$  ppm. **Acute overdose:**

GI distress, salivation, CNS irritability, tetany, seizures, hypocalcemia, hypoglycemia, and cardiorespiratory failure. Chronic excess use may result in mottled teeth or bone changes.

Take with food, but **not** milk, to minimize GI upset. The doses have been decreased owing to concerns over dental fluorosis.

**FLUOXETINE HYDROCHLORIDE**

Prozac and generics

**Antidepressant, selective serotonin reuptake inhibitor**



C

X

Yes

Yes

No

**Oral solution:** 20 mg/5 mL (120 mL); may contain alcohol

**Caps:** 10, 20, 40 mg

**Delayed release caps:** 90 mg

**Tab:** 10, 20, 60 mg

**All dosages are with immediate release dosage forms.**

**Depression:**

**Child, 8—<12 yr:** Start at 5 or 10 mg once daily PO. Usual dose: 10 mg once daily. May increase dose every 1–2 weeks as needed up to a **maximum dose** of 40 mg/24 hr (some patients may require higher doses)

**Adolescent  $\geq 12$  yr:** Start at 10 or 20 mg once daily PO. May increase by 10–20 mg increments every 1–2 weeks as needed up to a **maximum dose** of 60 mg/24 hr. Usual effective dose: 20–40 mg once daily

**Adult:** Start at 20 mg once daily in the morning PO. May increase after several weeks by 20 mg/24 hr increments to **max. dose** of 80 mg/24 hr. Doses  $>20$  mg/24 hr should be divided BID.

**Obsessive-compulsive disorder:**

**Child, 7–18 yr:**

**Lower-weight child:** Start at 5 or 10 mg once daily PO. May increase after several weeks. Usual dose range: 20–30 mg/24 hr. There is very minimal experience with doses  $>20$  mg/24 hr and no experience with doses  $>60$  mg/24 hr.

**Higher-weight child and adolescent:** Start at 10 mg once daily PO and increase dose to 20 mg/24 hr after 2 wk. May further increase dose after several weeks. Usual dose range: 20–60 mg/24 hr

**Bulimia:**

**Adolescent (PO; limited data):** 20 mg QAM  $\times$  3 days, then 40 mg QAM  $\times$  3 days, then 60 mg QAM

**Adult:** 60 mg QAM PO; it is recommended to titrate up to this dose over several days

**Contraindicated** in patients taking MAO inhibitors (e.g., linezolid) due to possibility of seizures, hyperpyrexia, and coma. **Use with caution** in patients with angle-closure glaucoma, receiving diuretics, or with liver (reduce dose with cirrhosis) or renal impairment. May increase the effects of tricyclic antidepressants. May cause headache, insomnia, nervousness, drowsiness, GI disturbance, sexual dysfunction, and weight loss. Increased bleeding diathesis with unaltered prothrombin time may occur with warfarin. Hyponatremia has been reported. Monitor for clinical worsening of depression and suicidal ideation/behavior following the initiation of therapy or after dose changes. May displace other highly protein-bound drugs. Inhibits CYP 450 2C19, 2D6, and 3A3/4 drug metabolism isoenzymes, which may increase the effects or toxicity of drugs metabolized by these enzymes. For example, use with pimozone or thioridazine may increase the risk for prolonged cardiac QTc interval and is considered **contraindicated**. Use with serotonergic drugs (e.g., triptans, methylene blue) and drugs that impair serotonin metabolism (MAOIs) may increase the risk for serotonin syndrome. Carefully review the patients' medication profile for potential interactions.



FLUOXETINE HYDROCHLORIDE *continued*

Delayed release capsule is currently indicated for depression and is dosed at 90 mg Q7 days. It is unknown if weekly dosing provides the same protection from relapse as does daily dosing. Breastfeeding is not recommended by the manufacturer, as adverse events to nursing infants have been reported. Fluoxetine and metabolite are variable and are higher when compared with other SSRIs. Maternal use of SSRIs during pregnancy and postpartum may result in more difficult breastfeeding. Infants exposed to SSRIs during pregnancy may also have an increased risk for persistent pulmonary hypertension of the newborn.

**FLUTICASONE FUROATE + VILANTEROL**

Breo Ellipta and generics

**Corticosteroid and long-acting  $\beta_2$  adrenergic agonist**

C



2



No



Yes



No

**Breath-activated aerosol powder for inhalation; contains lactose and milk proteins:**

100 mCg fluticasone furoate + 25 mCg vilanterol per actuation (28, 60 doses)

200 mCg fluticasone furoate + 25 mCg vilanterol per actuation (28, 60 doses)

For Fluticasone Furoate (Arnuity Ellipta) as a single agent, see [Fluticasone Preparations](#).

**Asthma (see remarks):**

**Adult:** One inhalation of 100 mCg fluticasone furoate + 25 mCg vilanterol OR 200 mCg fluticasone furoate + 25 mCg vilanterol once daily

**Max. dose:** One inhalation/24 hr for either dosage strength (25 mCg vilanterol/24 hr)



**Contraindicated** with hypersensitivity to milk proteins. See [Fluticasone Preparations](#) for remarks. Vilanterol is a long-acting  $\beta_2$  adrenergic agonist with a faster onset and longer duration of action compared to salmeterol.



Hypersensitivity reactions, hyperglycemia, muscle spasms, and tremor have been reported.

Titrate to the lowest effective strength after asthma is adequately controlled. This dosage form's breath-activated device requires a minimum inspiratory flow rate of 60 mL/min for proper dose activation. Proper patient education including dosage administration technique is essential; see patient package insert for detailed instructions. Rinse mouth after each use.

**FLUTICASONE PREPARATIONS**

Fluticasone propionate: Flonase, Flovent Diskus, Flovent HFA, ArmonAir Digihaler, and generics

Fluticasone furoate: Flonase Sensimist and Arnuity Ellipta

**Corticosteroid**

C



2



No



Yes



No

**FLUTICASONE PROPIONATE:**

**Nasal spray (Flonase and generics; OTC):** 50 mCg/actuation (9.9 mL = 60 doses, 15.8 mL = 120 doses); contains benzalkonium chloride and polysorbate 80

**Topical cream:** 0.05% (15, 30, 60 g)

**Topical ointment:** 0.005% (15, 30, 60 g)

**Topical lotion:** 0.05% (60 mL); contains parabens and propylene glycol

**Aerosol inhaler (MDI) (Flovent HFA and generics):** 44 mCg/actuation (10.6 g), 110 mCg/actuation (12 g), 220 mCg/actuation (12 g); each inhaler provides 120 metered inhalations

*Continued*

FLUTICASONE PREPARATIONS *continued*

**Dry-powder inhalation (DPI) (Flovent Diskus):** 50 mCg/dose, 100 mCg/dose, 250 mCg/dose; all strengths come in a package of 15 Rotadisks; each Rotadisk provides 4 doses for a total of 60 doses per package. Contains lactose.

**Breath-activated aerosol powder inhaler (ArmonAir Digihaler):** 55 mCg/inhalation, 113 mCg/inhalation, 232 mCg/inhalation; each inhaler contains 0.9 g of formulation and provides 60 doses. Contains lactose. Digihaler device contains a built-in electronic module that detects, records, and stores usage events, including peak inspiratory flow rate (L/min).

**FLUTICASONE FUROATE:**

**Nasal spray (Flonase Sensimist [OTC]):** 27.5 mCg/actuation (5.9 mL = 60 doses); contains benzalkonium chloride and polysorbate 80

**Breath-activated aerosol powder inhaler (Arnuity Ellipta):** 50 mCg/actuation, (30 doses), 100 mCg/actuation (14, 30 doses), 200 mCg/actuation dose (14, 30 doses); contains lactose

**Allergic rhinitis (Intranasal):****Fluticasone propionate (Flonase and generics):**

**≥4–11 yr:** 1 spray (50 mCg) per nostril once daily. Higher doses of 2 sprays (100 mCg) per nostril once daily may be needed for nonallergic rhinitis (≥4 yr and adolescent)

**≥12 yr and adult:** Initial 200 mCg/24 hr [2 sprays (100 mCg) per nostril once daily; OR 1 spray (50 mCg) per nostril BID]. Reduce to 1 spray per nostril once daily when symptoms are controlled.

**Max. dose (4 yr—adult):** 2 sprays (100 mCg) per nostril/24 hr

**Fluticasone furoate (Veramyst):**

**2–11 yr:** 1 spray (27.5 mCg) per nostril once daily. If needed, dose may be increased to 2 sprays each nostril once daily. Reduce to 1 spray per nostril once daily when symptoms are controlled.

**≥12 yr and adult:** 2 sprays (55 mCg) each nostril once daily. Reduce to 1 spray per nostril once daily when symptoms are controlled.

**Max. dose (2 yr—adult):** 2 sprays (55 mCg) per nostril/24 hr

**Asthma maintenance therapy (oral inhalation; see remarks):**

**Fluticasone propionate (Flovent HFA and Diskus):** Divide all 24 hr doses BID. If desired response is not seen after 2 wk of starting therapy, increase dosage. Then reduce to the lowest effective dose when asthma symptoms are controlled. Administration of MDI (HFA) with aerochamber enhances drug delivery.

Recommended dosages for asthma (see following table):



Age	Previous Use of Bronchodilators Only: (Max. Dose)	Previous Use of Inhaled Corticosteroid: (Max. Dose)	Previous Use of Oral Corticosteroid: (Max. Dose)
Child (4–11 yr)	MDI: 88 mCg/24 hr (176 mCg/24 hr) DPI: 100 mCg/24 hr (200 mCg/24 hr)	MDI: 88 mCg/24 hr (176 mCg/24 hr) DPI: 100 mCg/24 hr (200 mCg/24 hr)	Dose not available
≥12 yr and adult	MDI: 176 mCg/24 hr (880 mCg/24 hr) DPI: 200 mCg/24 hr (2000 mCg/24 hr)	MDI: 176–440 mCg/24 hr (880 mCg/24 hr) DPI: 200–500 mCg/24 hr (2000 mCg/24 hr)	MDI: 880 mCg/24 hr (1760 mCg/24 hr) DPI: 1000–2000 mCg/24 hr (2000 mCg/24 hr)

DPI, Dry-powder inhaler (breath activated); MDI, metered dose inhaler.

FLUTICASONE PREPARATIONS *continued***Fluticasone propionate (ArmonAir Digihaler; breath-activated aerosol powder inhaler):****≥12 yr and adult:****No prior inhaled corticosteroids:** Start with 55 mCg inhaled BID; **max. dose:** 232 mCg BID**Prior treatment with inhaled corticosteroids:** Start with low (55 mCg), medium (113 mCg), or high (232 mCg) inhaled BID based on the strength of previous inhaled corticosteroid and disease severity; **max. dose:** 232 mCg BID**Fluticasone furoate (Arnuity Ellipta; breath-activated inhaler aerosol powder inhaler):****5–11 yr:** Inhale 50 mCg once daily.**≥12 yr and adult:** Inhale 100–200 mCg once daily; **max. dose:** 200 mCg/24 hr**Eosinophilic esophagitis (limited data and other regimens exist; use oral fluticasone propionate HFA dosage form without spacer for PO administration as doses are swallowed):****Induction (short-term):****Child (1–10 yr):** 220 mCg QID × 4 wk, then 220 mCg TID × 3 wk, then 220 mCg BID × 3 wk, and 220 mCg once daily × 2 wk**Child ≥11 yr and adolescent:** 440 mCg QID × 4 wk, then 440 mCg TID × 3 wk, then 440 mCg BID × 3 wk, and 440 mCg once daily × 2 wk**Maintenance (long-term):****Child 2–4 yr:** 88 mCg BID**Child 5–10 yr:** 220 mCg BID**Child ≥11 yr and adolescent:** 440 mCg BID**Atopic dermatitis (topical fluticasone propionate; reassess diagnosis if no improvement in 2 wk):****Cream (see Chapter 8 for topical steroid comparisons):****≥3 mo and adult:** Apply thin film to affected areas once daily—BID; then reduce to a less potent topical agent when symptoms are controlled. Safety and efficacy have not been evaluated longer than 4 wk.**Lotion (see remarks):****≥3 mo and adult:** Apply thin film to affected areas once daily. Safety and efficacy have not been evaluated longer than 4 wk.**Ointment:****Adult:** Apply thin film to affected areas BID.

Fluticasone propionate and fluticasone furoate do not have equivalent potencies; follow specific dosing regimens for the respective products. 

For mild asthma exacerbation in patients with mild/moderate disease, no history of life-threatening exacerbations, and a good asthma self-management plan, limited data in adolescents (>16 yr) and adults suggest a temporary quadrupling of the maintenance dosage when asthma control starts to deteriorate. Revert back to baseline maintenance dose after symptoms stabilize or up to a maximum of 14 days of the quadrupled dose, whichever comes first. **DO NOT** use this management strategy for children <12 years of age due to the lack of efficacy and increased risk for decreasing linear growth.

Concurrent administration with ritonavir and other CYP 450 3A4 inhibitors may increase fluticasone levels, resulting in Cushing syndrome and adrenal suppression. **Use with caution** and monitor closely in hepatic impairment.

**Intranasal:** Clear nasal passages prior to use. May cause epistaxis and nasal irritation, which are usually transient. Taste and smell alterations, rare hypersensitivity reactions (angioedema, pruritis, urticaria, wheezing, dyspnea), and nasal septal perforation have been reported in postmarketing studies.

**Oral inhalation: DO NOT USE** a spacer or volume holding chamber with breath-activated dosage forms. Specific breath-activated dosage forms require the following minimum inspiratory flow rates for proper dose activation:

**Arnuity Ellipta:** 60 L/min*Continued*

FLUTICASONE PREPARATIONS *continued***ArmonAir Digihaler:** 30 L/min


Rinse mouth after each use. May cause dysphonia, oral thrush, and dermatitis. Esophageal candidiasis and hypersensitivity reactions have been reported. Compared to beclomethasone, has been shown to have less of an effect on suppressing linear growth in asthmatic children. Eosinophilic conditions may occur with the withdrawal or decrease of oral corticosteroids after the initiation of inhaled fluticasone.

**TOPICAL USE:** Irritation, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, hypertrichosis, miliaria, cataracts, and glaucoma have been reported. **Avoid** contact with topical dosage forms to the eyes.

**FLUTICASONE PROPIONATE AND SALMETEROL**

Advair Diskus, Advair HFA, AirDuo Digihaler, AirDuo RespiClick, and generics

**Corticosteroid and long-acting  $\beta_2$ -adrenergic agonist**

**Aerosol inhaler (MDI) (Advair HFA):**

45 mCg fluticasone propionate + 21 mCg salmeterol per inhalation (8 g delivers 60 doses, 12 g delivers 120 doses)

115 mCg fluticasone propionate + 21 mCg salmeterol per inhalation (8 g delivers 60 doses, 12 g delivers 120 doses)

230 mCg fluticasone propionate + 21 mCg salmeterol per inhalation (8 g delivers 60 doses, 12 g delivers 120 doses)

**Breath-activated DPI (Advair Diskus and generics; contains lactose and milk proteins):**

100 mCg fluticasone propionate + 50 mCg salmeterol per inhalation (14, 60 doses)

250 mCg fluticasone propionate + 50 mCg salmeterol per inhalation (14, 60 doses)

500 mCg fluticasone propionate + 50 mCg salmeterol per inhalation (14, 60 doses)

**Breath-activated aerosol powder inhaler (AirDuo Digihaler, AirDuo RespiClick and generics; contains lactose):**

55 mCg fluticasone propionate + 14 mCg salmeterol per inhalation (0.45 g delivers 60 doses)

113 mCg fluticasone propionate + 14 mCg salmeterol per inhalation (0.45 g delivers 60 doses)

232 mCg fluticasone propionate + 14 mCg salmeterol per inhalation (0.45 g delivers 60 doses)

Digihaler device contains a built-in electronic module that detects, records, and stores usage events, including peak inspiratory flow rate (L/min).

**Asthma:****Without prior inhaled steroid use:****Breath-activated (DPI; Advair Diskus; see remarks):**

**4–11 yr:** Start with one inhalation BID of 100 mCg fluticasone propionate + 50 mCg salmeterol.

**≥12 yr and adult:** Start with one inhalation BID of 100 mCg fluticasone propionate + 50 mCg salmeterol, OR 250 mCg fluticasone propionate + 50 mCg salmeterol; **max. dose:** one inhalation BID of 500 mCg fluticasone propionate + 50 mCg salmeterol

**Aerosol inhaler (MDI; Advair HFA):**

**≥12 yr and adult:** Start with 2 inhalations BID of 45 mCg fluticasone + 21 mCg salmeterol, OR 115 mCg fluticasone + 21 mCg salmeterol; **max. dose:** 2 inhalations BID of 230 mCg fluticasone + 21 mCg salmeterol

**Breath-activated aerosol powder inhaler (AirDuo Digihaler, AirDuo RespiClick; see remarks):**

**≥12 yr and adult:** Start with 1 inhalation BID of 55 mCg fluticasone + 14 mCg salmeterol; **max. dose:** one inhalation BID of 232 mCg fluticasone propionate + 14 mCg salmeterol



FLUTICASONE PROPIONATE AND SALMETEROL *continued*

With prior inhaled steroid use (conversion from other inhaled steroids; see following table and below):

Inhaled Corticosteroid	Current Daily Dose	Recommended Strength of Fluticasone Propionate + Salmeterol Diskus (DPI) (Advair Diskus) Administered at One Inhalation BID	Recommended Strength of Fluticasone Propionate + Salmeterol Aerosol Inhaler (MDI) (Advair HFA) Administered at Two Inhalations BID
Beclomethasone dipropionate (Qvar Redihaler)	160 mCg	100 mCg + 50 mCg	45 mCg + 21 mCg
	320 mCg	250 mCg + 50 mCg	115 mCg + 21 mCg
	640 mCg	500 mCg + 50 mCg	230 mCg + 21 mCg
Budesonide	≤400 mCg	100 mCg + 50 mCg	45 mCg + 21 mCg
	800–1200 mCg	250 mCg + 50 mCg	115 mCg + 21 mCg
	1600 mCg	500 mCg + 50 mCg	230 mCg + 21 mCg
Fluticasone propionate aerosol (HFA)	≤176 mCg	100 mCg + 50 mCg	45 mCg + 21 mCg
	440 mCg	250 mCg + 50 mCg	115 mCg + 21 mCg
	660–880 mCg	500 mCg + 50 mCg	230 mCg + 21 mCg
Fluticasone propionate dry powder (DPI)	≤200 mCg	100 mCg + 50 mCg	45 mCg + 21 mCg
	500 mCg	250 mCg + 50 mCg	115 mCg + 21 mCg
	1000 mCg	500 mCg + 50 mCg	230 mCg + 21 mCg
Mometasone furoate	220 mCg	100 mCg + 50 mCg	45 mCg + 21 mCg
	440 mCg	250 mCg + 50 mCg	115 mCg + 21 mCg
	880 mCg	500 mCg + 50 mCg	230 mCg + 21 mCg

DPI, Dry powder inhaler (breath activated); MDI, metered dose inhaler.

**Breath-activated aerosol powder inhaler (AirDuo Digihaler, AirDuo RespiClick):** Select low (55 mCg fluticasone + 14 mCg salmeterol), medium (113 mCg fluticasone + 14 mCg salmeterol), or high (232 mCg fluticasone + 14 mCg salmeterol) dose strength based on the previous inhaled corticosteroid product or the strength of the inhaled corticosteroid from a combination product and disease severity. All dosage strengths are administered as one inhalation BID.

**Max. doses:**

**Breath-activated (DPI; Advair Diskus):** One inhalation BID of 500 mCg fluticasone propionate + 50 mCg salmeterol

**Aerosol inhaler (MDI; Advair HFA):** Two inhalations BID of 230 mCg fluticasone propionate + 21 mCg salmeterol

**Breath-activated aerosol powder inhaler (AirDuo RespiClick):** One inhalation BID of 232 mCg fluticasone propionate + 14 mCg salmeterol

**Contraindicated** with hypersensitivity to milk proteins. See [Fluticasone Preparations and Salmeterol](#) for remarks. Titrate to the lowest effective strength after asthma is adequately controlled.



*Continued*

FLUTICASONE PROPIONATE AND SALMETEROL *continued*

**DO NOT USE** a spacer or volume holding chamber with breath-activated dosage forms. Specific breath-activated dosage forms require the following minimum inspiratory flow rates for proper dose activation:

**Advair Diskus:** 60 L/min

**AirDuo Digihaler, AirDuo RespiClick:** 30 L/min

Proper patient education including dosage administration technique is essential; see patient package insert to specific dosage form for detailed instructions. Rinse mouth after each use.

**FLUVOXAMINE**

Generics; previously available as Luvox and Luvox CR

**Antidepressant, selective serotonin reuptake inhibitor**



C



2



No



Yes



Yes

**Tabs:** 25, 50, 100 mg

**Extended release capsules:** 100, 150 mg

**Obsessive compulsive disorder (use immediate release tablets unless noted otherwise, see remarks):**



**Child 8–12 yr:** Start at 12.5–25 mg PO QHS. Dose may be increased by 25 mg/24 hr Q7–14 days (slower titration at Q2–4 wk may be used for minimizing behavioral side effects). Total daily doses >50 mg/24 hr should be divided BID. Female patients may require lower dosages compared to males.

**Max. dose:** Child: 8–11 yr: 200 mg/24 hr; and child 12 yr: 300 mg/24 hr

**Adolescent:** Start at 25–50 mg PO QHS. Dose may be increased by 25 mg/24 hr Q7–14 days (slower titration at Q2–4 wk may be used for minimizing behavioral side effects). Total daily doses >50 mg/24 hr should be divided BID with the larger dose at bedtime. **Max. dose:** 300 mg/24 hr

**Adult:** Start at 50 mg PO QHS. Dose may be increased by 50 mg/24 hr Q4–7 days up to a **max. dose** of 300 mg/24 hr. Total daily doses >100 mg/24 hr should be divided BID with larger dose at bedtime.

**Extended release capsule (adult):** Start at 100 mg PO QHS. Dose may be increased by 50 mg/24 hr Q7 days up to a **max. dose** of 300 mg/24 hr.

**Contraindicated** with coadministration of cisapride, pimozide, thioridazine, tizanidine, or MAO inhibitors. **Use with caution** in hepatic disease (dosage reduction may be necessary as drug is extensively metabolized by the liver) and in combination with serotonergic drugs (e.g., TCAs, triptans, fentanyl, lithium, tramadol, amphetamines, tryptophan, and St. John's wort). Monitor for clinical worsening of depression and suicidal ideation/behavior following the initiation of therapy or after dose changes.



Major substrate for CYP 450 1A2 and 2D6. Poor metabolizers of CYP 450 2D6 should consider an initial dose reduction of 25%–50% and titrate to response or use an alternative medication not metabolized by this enzyme.

Inhibits CYP 450 1A2, 2C19, 2C9, 2D6, and 3A3/4, which may increase the effects or toxicity of drugs metabolized by these enzymes. Dose-related use of thioridazine with fluvoxamine may cause prolongation of QT interval and serious arrhythmias. May increase warfarin plasma levels by 98% and prolong PT. May increase toxicity and/or levels of theophylline, caffeine, and tricyclic antidepressants. Side effects include: headache, insomnia, somnolence, nausea, diarrhea, dyspepsia, dry mouth, and sexual dysfunction.

Titrate to lowest effective dose. Use a gradual taper when discontinuing therapy to prevent withdrawal symptoms.

Consider the benefits to potential risk for maternal use in breastfeeding. Maternal use during pregnancy and postpartum may result in breastfeeding difficulties.

**FOLIC ACID**

FA-8 and many generics; previously available as

Folvite

**Water-soluble vitamin**

A/C



1



No



No



No

**Tabs [OTC]:** 0.4, 0.8, 1 mg**Caps:****FA-8:** 0.8 mg [OTC]**Generics:** 5 mg, 20 mg**Oral solution:** 0.05 mg/mL , 1 mg/mL **Injection:** 5 mg/mL (10 mL); contains 1.5% benzyl alcohol**For U.S. RDA, see Chapter 21.****Folic acid deficiency PO, IM, IV, SC:****Infant:** 0.1 mg/24 hr once daily**Child <4 yr:** 0.1–0.3 mg/24 hr once daily**Child ≥4 yr and adolescent:** 0.1–0.4 mg/24 hr once daily**Adult:** 0.4 mg/24 hr once daily**Pregnant and lactating women:** 0.8 mg/24 hr once daily**Normal levels:** See Chapter 28. May mask hematologic effects of vitamin B<sub>12</sub> deficiency but will not prevent progression of neurologic abnormalities. High-dose folic acid may decrease the absorption of phenytoin.

Women of childbearing age considering pregnancy should take at least 0.4 mg once daily before and during pregnancy to reduce risk of neural tube defects in the fetus. Pregnancy category changes to “C” if used in doses above the RDA.

**FOMEPIZOLE**

Generics; previously available as Antizol

**Antidote for ethylene glycol or methanol toxicity**

C



?



Yes



No



No

**Injection:** 1 g/mL (1.5 mL); preservative free**Child and adult not requiring hemodialysis (IV, all doses administered over 30 min):****Load:** 15 mg/kg/dose × 1**Maintenance:** 10 mg/kg/dose Q12 hr × 4 doses, then 15 mg/kg/dose Q12 hr until ethylene glycol or methanol level decreases to <20 mg/dL and the patient is asymptomatic with normal pH**Child and adult requiring hemodialysis (IV following the recommended doses at the intervals indicated here. Fomepizole is removed by dialysis. All doses administered IV over 30 min):****Dosing at the beginning of hemodialysis:****If <6 hr since last fomepizole dose:** DO NOT administer dose.**If ≥6 hr since last fomepizole dose:** Administer next scheduled dose upon beginning dialysis.**Dosing during hemodialysis:** Administer Q4 hr or, alternatively, 10–20 mg/kg loading dose, followed by a continuous infusion of 1–1.5 mg/kg/hr.**Dosing at the time hemodialysis is completed (based on the time between last dose and end of hemodialysis):****<1 hr:** DO NOT administer dose at end of hemodialysis.**1–3 hr:** Administer ½ of next scheduled dose at the end of hemodialysis.**>3 hr:** Administer next scheduled dose at the end of hemodialysis.

Continued

FOMEPIZOLE *continued*

**Maintenance dose off hemodialysis:** Give next scheduled dose 12 hr from last dose administered.

Works by competitively inhibiting alcohol dehydrogenase. Safety and efficacy in pediatrics have not been established. **Contraindicated** in hypersensitivity to any components or other pyrazole compounds. Most frequent side effects include headache, nausea, and dizziness. Fomepizole is extensively eliminated by the kidneys (**use with caution** in renal failure) and removed by hemodialysis.

Drug product may solidify at temperatures  $<25^{\circ}\text{C}$  ( $77^{\circ}\text{F}$ ); vial can be liquefied by running it under warm water (efficacy, safety, and stability are not affected). All doses must be diluted with at least 100 mL of D5W or NS to prevent vein irritation. **DO NOT** use polycarbonate syringe or polycarbonate-containing needles when diluting or administering this medication.

**FOSCARNET**

Foscavir and generics

**Antiviral agent**

C



3



Yes



No



No

**Injection:** 24 mg/mL (250 mL); preservative free

Contains 10 mEq Na/g drug

**HIV positive or exposed with the following infection (IV):****CMV disease:****Infant, child, and adolescent:**

**Induction:** 180 mg/kg/24 hr  $\div$  Q8–12 hr in combination with ganciclovir; continue until symptom improvement and convert to maintenance therapy

**Maintenance:** 90–120 mg/kg/dose Q24 hr

**CMV retinitis (disseminated disease; IV):****Infant and child:**

**Induction:** 180 mg/kg/24 hr  $\div$  Q8–12 hr  $\times$  14–21 days with or without ganciclovir

**Maintenance:** 90–120 mg/kg/24 hr once daily

**Adolescent and adult:**

**Induction:** 180 mg/kg/24 hr  $\div$  Q8–12 hr  $\times$  14–21 days

**Maintenance:** 90–120 mg/kg/24 hr once daily

**Acyclovir-resistant herpes simplex (limited data; IV):**

**Infant and child:** 40 mg/kg/dose Q8 hr or 60 mg/kg/dose Q12 hr for up to 3 wk or until lesions heal

**Adolescent and adult:** 40 mg/kg/dose Q8–12 hr  $\times$  14–21 days or until lesions heal

**Varicella zoster unresponsive to acyclovir (IV):**

**Infant and child:** 40–60 mg/kg/dose Q8 hr  $\times$  7–10 days

**Adolescent:** 90 mg/kg/dose Q12 hr

**Varicella zoster, progressive outer retinal necrosis (IV):**

**Infant, child, and adolescent:** 90 mg/kg/dose Q12 hr in combination with ganciclovir IV and intravitreal foscarnet with or without ganciclovir

**Intravitreal route for progressive outer retinal necrosis (HIV positive or exposed):**

**Child and adolescent:** 1.2 mg/0.05 mL or 2.4 mg/0.1 mL per dose 2–3 times weekly in combination with IV foscarnet and ganciclovir and/or intravitreal ganciclovir

**Use with caution** in patients with renal insufficiency and hypernatremia (large sodium content). **Discontinue** use in adults if serum Cr  $\geq 2.9$  mg/dL. **Adjust dose in renal failure** (see [Chapter 31](#)).

FOSCARNET *continued*

May cause peripheral neuropathy, seizures, neutropenia, esophageal ulceration, hallucinations, GI disturbance, increased LFTs, hypertension, chest pain, ECG abnormalities (QT interval prolongation has been reported), coughing, dyspnea, bronchospasm, and renal failure (adequate hydration and avoiding nephrotoxic medications may reduce risk). Hypocalcemia (increased risk if given with pentamidine), hypokalemia, and hypomagnesemia may also occur. Hypersensitivity reactions have been reported. Use with ciprofloxacin may increase risk for seizures.

Correction of dehydration and adequate hydration reduces the risk for nephrotoxicity. 10–20 mL/kg IV (**max. dose:** 1000 mL) of NS or D<sub>5</sub>W should be administered prior to the first dose and concurrently with subsequent doses. For lower foscarnet dosage regimens of 40–60 mg/kg, use 50% of the aforementioned hydration recommendations. Actual hydration may need to be reduced when clinically indicated. Oral hydration methods may also be considered in patients who are able to tolerate.

For peripheral line IV administration, the concentration must be diluted to 12 mg/mL in NS or D<sub>5</sub>W.

**FOSPHENYTOIN**

Cerebyx and generics

**Anticonvulsant**

D



2



Yes



Yes



Yes

**Injection:** 50 mg phenytoin equivalent (75 mg fosphenytoin)/1 mL (2, 10 mL)

1 mg phenytoin equivalent provides 0.0037 mmol phosphate

**All doses are expressed as phenytoin sodium equivalents (PE) (see remarks for dose administration information):**



**Neonate, child, and adolescent:** See [Phenytoin](#) and use the conversion of 1 mg phenytoin = 1 mg PE

**Adult:**

**Loading dose:**

**Status epilepticus:** 20 mg PE/kg IV (**max. dose:** 1500 mg PE/dose)

**Nonemergent loading:** 10–20 mg PE/kg IV/IM

**Nonemergent initial maintenance dose (initiated 12 hr after loading dose):** 4–7 mg PE/kg/24 hr IV/IM ÷ Q6–12 hr

All doses should be prescribed and dispensed in terms of mg phenytoin sodium equivalents (PE) to avoid medication errors. Safety in pediatrics has not been fully established.



**Contraindicated** in patients with history of phenytoin or other hydantoin hypersensitivity. **Use with caution** in patients with renal or hepatic impairment and porphyria (consider amount of phosphate delivered by fosphenytoin in patients with phosphate restrictions). Drug is also metabolized to liberate small amounts of formaldehyde, which is considered clinically insignificant with short-term use (e.g., 1 wk). Side effects: hypokalemia (with rapid IV administration), slurred speech, dizziness, ataxia, rash, exfoliative dermatitis (e.g., TEN, SJS; increased risk with patients with HLA-B\*1502 allele), nystagmus, diplopia, and tinnitus. Angioedema, macrocytosis, megaloblastic anemia, and pure red cell aplasia have been reported. Increased unbound phenytoin concentrations may occur in patients with renal disease or hypoalbuminemia; measure “free” or “unbound” phenytoin levels in these patients. Patients with reduced CYP 2C9 activity (CYP2C\*3) have decreased clearance of phenytoin, resulting in increased phenytoin levels.

Abrupt withdrawal may cause status epilepticus. BP and ECG monitoring should be present during IV loading dose administration. **Max. IV infusion rate:** 2 mg PE/kg/min up to a **max.** of 150 mg PE/min. Administer IM via 1 or 2 injection sites, and IM route is not recommended in status epilepticus. Therapeutic levels: 10–20 mg/L (free and bound phenytoin) OR 1–2 mg/L (free only). Recommended peak serum sampling times: 4 hr following an IM dose or 2 hr following an IV dose.

*Continued*

FOSPHENYTOIN *continued*

See [Phenytoin](#) remarks for drug interactions and additional side effects. Drug is more safely administered via peripheral IV than phenytoin.

**FUROSEMIDE**

Lasix and generics

**Loop diuretic**

C/D

3

Yes

Yes

No

**Tabs:** 20, 40, 80 mg**Injection:** 10 mg/mL (2, 4, 10 mL)**Oral solution:** 10 mg/mL (60, 120 mL), 40 mg/5 mL (500 mL)**IM, IV:****Neonate (see remarks):** 0.5–1 mg/kg/dose Q12–24 hr; **max. dose:** 2 mg/kg/dose**Infant and child:** 0.5–2 mg/kg/dose Q6–12 hr; **max. dose:** 6 mg/kg/dose not to exceed 200 mg/dose**Adult:** 20–40 mg/24 hr ÷ Q6–12 hr; **max. dose:** 200 mg/dose**PO:****Neonate:** Bioavailability by this route is poor; doses of 1–3 mg/kg/dose once daily to BID have been used.**Infant and child:** Start at 2 mg/kg/dose; may increase by 1–2 mg/kg/dose no sooner than 6–8 hr following the previous dose. **Max. dose:** 6 mg/kg/dose. Dosages have ranged from 1–6 mg/kg/dose Q12–24 hr.**Adult:** 20–80 mg/dose Q6–12 hr; **max. dose:** 600 mg/24 hr**Continuous IV infusion:****Infant and child:** 0.1 mg/kg IV bolus followed by 0.05–0.4 mg/kg/hr infusion and titrate to effect**Adult:** 40–100 mg IV bolus followed by 10–40 mg/hr infusion and titrate to effect**Contraindicated** in anuria and hepatic coma. **Use with caution** in hepatic disease (hepatic encephalopathy has been reported); cirrhotic patients may require higher than usual doses.

Ototoxicity may occur in presence of renal disease (especially when used with aminoglycosides and other nephrotoxic drugs), with rapid IV injection (do not infuse >4 mg/min in adults), or with hypoproteinemia. May cause hypokalemia, alkalosis, dehydration, hyperuricemia, and increased calcium excretion. Rash with eosinophilia and systemic symptoms and acute generalized exanthematous pustulosis have been reported. Prolonged use in premature infants and in children <4 yr may result in nephrocalcinosis. May increase risk for PDA in premature infants during the first week of life. Premature infants <31 wk post conceptual age receiving doses >1 mg/kg/24 hr may develop plasma levels that could be associated with potential ototoxicity.



Furosemide-resistant edema in pediatric patients may benefit with the addition of metolazone. Some of these patients may have an exaggerated response leading to hypovolemia, tachycardia, and orthostatic hypotension requiring fluid replacement. Severe hypokalemia has been reported with a tendency for diuresis persisting for up to 24 hr after discontinuing metolazone, prolonged use of laxatives, or concomitant use of corticosteroids, ACTH, and large amounts of licorice.

High doses of furosemide may inhibit binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones followed by an overall decrease in total thyroid hormone levels.

**Max. rate of intermittent IV dose:** 0.5 mg/kg/min. For patients receiving ECMO, **do not** administer IV doses directly into the ECMO circuit as the medication is absorbed in the circuit, which may result in diminished effects and the need for higher doses.

Pregnancy category changes to “D” if used in pregnancy-induced hypertension.

## G

**GABAPENTIN**

Neurontin, Gralise, Horizant, and generics

**Anticonvulsant**

C



2



Yes



No



No

**Caps:** 100, 300, 400 mg**Tabs:** 300, 600, 800 mg**Slow release/extended release tabs** (these dosage forms are **not interchangeable** with other gabapentin products due to different pharmacokinetic profiles affecting the dosing interval; see specific product information for specific indications for use and dosage):

Gralise: 300, 600 mg

Horizant (Gabapentin Enacarbil): 300, 600 mg

**Oral solution:** 250 mg/5 mL (470 mL)**Seizures, adjunctive therapy (maximum time between doses should not exceed 12 hr):****3—<12 yr (PO, see remarks):****Day 1:** 10–15 mg/kg/24 hr ÷ TID, then gradually titrate dose upward to the following dosages over a 3-day period:**3–4 yr:** 40 mg/kg/24 hr ÷ TID**≥5—<12 yr:** 25–35 mg/kg/24 hr ÷ TID

Dosages up to 50 mg/kg/24 hr have been well tolerated.

**≥12 yr and adult (PO, see remarks):** Start with 300 mg TID; if needed, increase dose up to 1800 mg/24 hr ÷ TID. Usual effective doses: 900–1800 mg/24 hr ÷ TID. Doses as high as 3.6 g/24 hr have been tolerated.**Neuropathic pain (see remarks):****Child (PO; limited data):****Day 1:** 5 mg/kg/dose (**max.** 300 mg/dose) at bedtime**Day 2:** 5 mg/kg/dose (**max.** 300 mg/dose) BID**Day 3:** 5 mg/kg/dose (**max.** 300 mg/dose) TID; then titrate dose to effect with TID schedule. A dosage range of 8–35 mg/kg/24 hr ÷ TID has been reported in patients taking concurrent analgesics.**Maximum daily dose of 3600 mg/24 hr has been suggested but not formally evaluated.****Adult (PO):****Day 1:** 300 mg at bedtime**Day 2:** 300 mg BID**Day 3:** 300 mg TID; then titrate dose to effect with TID schedule. Usual dosage range: 1800–2400 mg/24 hr; **max. dose:** 3600 mg/24 hr**Postherpetic neuralgia:** The above dosage regimen may be titrated up PRN for pain relief to a daily dose of 1800 mg/24 hr ÷ TID (efficacy has been shown from 1800 to 3600 mg/24 hr; however, no additional benefit has been shown for doses >1800 mg/24 hr). The Gralise dosage form is designed for once-daily administration with the evening meals, whereas the Horizant dosage form is dosed once daily—BID. These slow release/extended release dosage forms are NOT interchangeable due to different pharmacokinetic profiles. See specific product information for details.

Generally used as adjunctive therapy for partial and secondary generalized seizures, and neuropathic pain.

Somnolence, dizziness, ataxia, fatigue, and nystagmus were common when used for seizures (≥12 yr).

Viral infections, fever, nausea and/or vomiting, somnolence, and hostility have been reported in patients 3–12 yr receiving other antiepileptics. Dizziness, somnolence, and peripheral edema are



Continued

GABAPENTIN *continued*

common side effects in adults with postherpetic neuralgia. Suicidal behavior or ideation, agitation, and multiorgan hypersensitivity (e.g., anaphylaxis, angioedema, or drug reaction with eosinophilia and systemic symptoms [DRESS]) have been reported. Life-threatening or fatal respiratory depression in patients taking gabapentin with opioids or other CNS depressants, or with an underlying respiratory impairment, has been reported.

**Do not withdraw medication abruptly** (gradually over a minimum of 1 wk). Drug is not metabolized by the liver and is primarily excreted in the urine unchanged. Higher doses may be required for children <5 yr because of faster clearance in this age group.

May be taken with or without food. In TID dosing schedule, **interval between doses should not exceed 12 hr. Adjust dose in renal impairment (see Chapter 31).**

**GANCICLOVIR**

Cytovene, Zirgan, and generics

**Antiviral agent**

C



3



Yes



No



No

**Injection (Cytovene and generics):** 500 mg; contains 4 mEq Na per 1 g drug

**Injection in solution:** 500 mg/10 mL (10 mL)

**Premixed injection in 0.8% sodium chloride:** 500 mg/250 mL (250 mL); preservative free

**Ophthalmic gel (drops):**

Zirgan: 0.15% (5 g); contains benzalkonium chloride

**Cytomegalovirus (CMV) infections:**

**Neonate (congenital CMV):** 12 mg/kg/24 hr ÷ Q12 hr IV with transition to oral valganciclovir to complete a total 6 mo course

**Child >3 mo and adult:**

**Induction therapy (duration 14–21 days):** 10 mg/kg/24 hr ÷ Q12 hr IV

**IV maintenance therapy:** 5 mg/kg/dose once daily IV for 7 days/wk or 6 mg/kg/dose once daily IV for 5 days/wk

**Prevention of CMV in transplant recipients:**

**Child and adult:**

**Induction therapy (duration 5–7 days):** 10 mg/kg/24 hr ÷ Q12 hr IV

**IV maintenance therapy:** 5 mg/kg/dose once daily IV for 7 days/wk or 6 mg/kg/dose once daily IV for 5 days/wk for 100–120 days posttransplant

**CMV in HIV-infected individuals:** See [www.aidsinfo.nih.gov](http://www.aidsinfo.nih.gov) for latest recommendations and guidelines for CMV treatment and prophylaxis.

**Herpetic keratitis (ophthalmic gel/drops):**

**≥2 yr and adult:** Apply 1 drop onto affected eye(s) 5 times a day (~Q3 hr while awake) until corneal ulcer is healed, then 1 drop TID × 7 days.

Limited experience with use in children <12 yr old. **Contraindicated** in severe neutropenia (ANC <500/microliter) or severe thrombocytopenia (platelets <25,000/microliter). **Use with extreme caution. Reduce dose in renal failure (see Chapter 31).** Has not been evaluated in hepatic impairment. For oral route of administration, see [Valganciclovir](#).

Common side effects: neutropenia, thrombocytopenia, retinal detachment, and confusion. Drug reactions alleviated with dose reduction or temporary interruption. Ganciclovir may increase didanosine and zidovudine levels, whereas didanosine and zidovudine may decrease ganciclovir levels. Immunosuppressive agents may increase hematologic toxicities. Amphotericin B, cyclosporine, and tacrolimus increase risk for nephrotoxicity. Imipenem/cilastatin may increase risk for seizures. May cause female and male infertility.

Minimum dilution is 10 mg/mL and should be infused IV over ≥1 hr. IM and SC administration are **contraindicated** because of high pH of 11.

**GATIFLOXACIN**

Zymaxid and generics

**Antibiotic, quinolone**

C



2



No



No



No

**Ophthalmic solution:** 0.5% (2.5 mL); may contain benzalkonium chloride

Previously available as a 0.3% ophthalmic solution (Zymar)

**Conjunctivitis:**

≥1 yr—**adult:** Instill 1 drop to affected eye(s) Q2 hr while awake (up to 8 times/24 hr) for the first day, then 1 drop BID—QID while awake on days 2–7.



Worsening of conjunctivitis, decreased visual acuity, excessive tear production, and keratitis are common side effects. Conjunctival hemorrhage has been reported.



**Avoid** touching the applicator tip to eye, fingers, or other surfaces, and **do not** wear contact lenses during treatment of ocular infections. Apply pressure to the lacrimal sac during and for 1–2 min after dose administration to reduce risk of systemic absorption.

**GCSF**See [Filgrastim](#).**GENTAMICIN**

Gentak and generics; previously available as

Garamycin

**Antibiotic, aminoglycoside**

C/D



2



Yes



No



No

**Injection:** 10 mg/mL (2 mL, preservative free), 40 mg/mL (2, 20 mL); some products may contain sodium metabisulfite

**Premixed injection in NS:** 60 mg (50 mL), 80 mg (50, 100 mL), 100 mg (50, 100 mL), 120 mg (100 mL)

**Ophthalmic ointment (Gentak and generics):** 0.3% (3.5 g); may contain parabens

**Ophthalmic drops:** 0.3% (5 mL)

**Topical ointment:** 0.1% (15, 30 g)

**Topical cream:** 0.1% (15, 30 g)

**Initial empiric dosage; patient-specific dosage defined by therapeutic drug monitoring (see remarks).**



**Parenteral (IM or IV):**

**Neonate/Infant (see table below):**

**Postconceptional**

Age (wk)	Postnatal Age (days)	Dose (mg/kg/dose)	Interval (hr)
≤29 <sup>a</sup>	0–7	5	48
	8–28	4	36
	>28	4	24
30–34	0–7	4.5	36
	>7	4	24
≥35	ALL	4	24 <sup>b</sup>

<sup>a</sup>Or significant asphyxia, patent ductus arteriosus (PDA), indomethacin use, poor cardiac output, reduced renal function. Alternatively, dosing by levels may be necessary for situations of unstable renal function.

<sup>b</sup>Use Q36 hr interval for hypoxic-ischemic encephalopathy (HIE) patients receiving whole-body therapeutic cooling.

Continued

GENTAMICIN *continued*

**Child (eGFR >75 mL/min/1.73m<sup>2</sup>):** 7.5 mg/kg/24 hr ÷ Q8 hr

**Adult (eGFR >75 mL/min/1.73m<sup>2</sup>):** 3–6 mg/kg/24 hr ÷ Q8 hr

**Cystic fibrosis (eGFR >75 mL/min/1.73m<sup>2</sup>):** 7.5–10.5 mg/kg/24 hr ÷ Q8 hr

**Intrathecal/intraventricular (use preservative-free product only):**

**Newborn:** 1 mg once daily

**>3 mo:** 1–2 mg once daily

**Adult:** 4–8 mg once daily

**Ophthalmic ointment:** Apply 0.5-inch ribbon to the conjunctival sac of the affected eye(s) Q8–12 hr.

**Ophthalmic drops:** Instill 1–2 drops to affected eye(s) Q4 hr; up to 2 drops Q1 hr for severe infections.

**Topical cream or ointment:**

**>1 yr and adult:** Apply to affected area TID–QID.

**Use with caution** in patients receiving anesthetics or neuromuscular blocking agents and in patients with neuromuscular disorders. May cause nephrotoxicity and ototoxicity. Ototoxicity may be potentiated with the use of loop diuretics. Eliminated more quickly in patients with cystic fibrosis, neutropenia, and burns. **Adjust dose in renal failure (see Chapter 31).** Monitor peak and trough levels.



Therapeutic peak levels are 6–10 mg/L in general, and 8–10 mg/L in pulmonary infections, cystic fibrosis, neutropenia, osteomyelitis, and severe sepsis.

To maximize bactericidal effects, an individualized peak concentration to target a peak/minimal inhibitory concentration (MIC) ratio of 8–10:1 may be applied.

Therapeutic trough levels: <2 mg/L. Recommended serum sampling time at steady state: trough within 30 min prior to the 3rd consecutive dose and peak 30–60 min after the administration of the 3rd consecutive dose.

For initial dosing in obese patients, use an adjusted body weight (ABW).  $ABW = \text{Ideal Body Weight} + 0.4 (\text{Total Body Weight} - \text{Ideal Body Weight})$

Pregnancy category is a “C” for ophthalmic use, a “D” with IV use, and not classified for topical use.

**GLUCAGON HCL**

GlucaGen, Glucagon Emergency Kit, Gvoke, Baqsimi, and generics

**Antihypoglycemic agent**



B



1



No



No



No

**Injection:** 1 mg vial (requires reconstitution)

**Injection kit:**

**GlucaGen Hypokit and generics:** 1 mg vial with 1 mL syringe of sterile water for injection

**Gvoke Kit:** 1 mg/0.2 mL vial with syringe; for subcutaneous injection only

**Injection in prefilled syringe (Gvoke PFS):** 0.5 mg/0.1 mL (1 or 2 pack), 1 mg/0.2 mL (1 or 2 pack); for subcutaneous injection only

**Injection in autoinjector (Gvoke HypoPen):** 0.5 mg/0.1 mL (1 or 2 pack), 1 mg/0.2 mL (1 or 2 pack); for subcutaneous injection only

**Nasal powder (Baqsimi):** 3 mg/dose (1 or 2 pack); contains betadex and dodecylphosphocholine  
1 unit = 1 mg

**Hypoglycemia (see remarks):**

**Injectable route (IM, IV, SC; see remarks):**

**Neonate, infant, and child <20 kg:** 0.5 mg/dose (or 0.02–0.03 mg/kg/dose) Q15–20 min PRN

**Child ≥20 kg and adult:** 1 mg/dose Q15–20 min PRN

**Intranasal route (see remarks):**

**≥4 yr and adult:** Actuate 3 mg (1 actuation) intranasally into one nostril × 1. If no response after 15 min, an additional 3 mg dose may be given.



GLUCAGON HCL *continued***β-blocker or calcium channel blocker overdose (for hypotension that is unresponsive to fluid boluses; limited data):**

**Infant and child:** Load with 0.05 mg/kg IV × 1; if no response, may repeat dose. Some recommend initiating a continuous IV infusion of 0.05–0.1 mg/kg/hr at the time of the responsive dose.

**Adolescent:** Loading dose of 5–10 mg IV × 1, followed by a continuous IV infusion of 1–5 mg/hr

**Contraindicated** in insulinoma, pheochromocytoma, glucagonoma, and history of hypersensitivity to glucagon and components. Drug product is genetically engineered and identical to human glucagon. High doses have a cardiac stimulatory effect and have been used with some success in β-blocker and calcium channel blocker overdose. May increase myocardial oxygen demand, blood pressure, and pulse, which may be life-threatening in patients with cardiac disease. May cause nausea, vomiting, urticaria, and respiratory distress. Necrolytic migratory erythema (NME) has been reported with continuous IV infusion; assess benefit/risk for continued use.



**Do not delay** glucose infusion; dose for hypoglycemia is 2–4 mL/kg of dextrose 25%.

Glucagon may increase the effects/toxicity of warfarin. Indomethacin use may decrease the effects of glucagon.

Sufficient hepatic glycogen is necessary for effect; patients in states of starvation, with adrenal or chronic hypoglycemia, may not have adequate levels of glycogen. Onset of action: IM: 8–10 min; SC: ~10 min; IV: 1 min. Duration of action: IM: 12–27 min; SC: up to 90 min; IV: 9–17 min.

**INTRANASAL USE:** See product information for dose administration instructions. Dose does not need to be inhaled and can be administered if the patient has nasal congestion or the common cold. Common side effects include nausea, vomiting, headache, rhinorrhea, nasal discomfort/congestion, cough, epistaxis, and irritation to the eyes, nose, and throat. In type 1 pediatric diabetes trials, the time to increase glucose ≥20 mg/dL from nadir was 11–15 min, and peak plasma levels were achieved in 15–20 min with a median  $T_{1/2}$  of 21–31 min.

**GLYCERIN**

Pedia-Lax, Fleet Liquid Glycerin Supp, and others, including generics

**Osmotic laxative**



C



?



No



No



No

**Rectal liquid suppository [OTC]:**

**Pedia-Lax:** 4 mL with average 2.7 mL (2.8 g) dose delivered (6s)

**Fleet Liquid Glycerin:** 7.5 mL with average 5.4 mL (5.4 g) dose delivered (4s)

**Suppository [OTC]:****Infant/pediatric:**

Pedia-Lax and generics: 1 g (12s)

Generics: 1.2 g (12s, 25s)

**Adult:**

Generics: 2 g (12s, 25s, 50s, 100s)

**Constipation:**

**Neonate:** 0.5 mL/kg/dose rectal solution PR as an enema once daily PRN or sliver/chip of infant/pediatric suppository PR once daily PRN

**Child <6 yr:** 2–5 mL rectal solution PR as an enema or 1 infant/pediatric suppository PR once daily PRN

**>6 yr–adult:** 5–15 mL rectal solution PR as an enema or 1 adult suppository PR once daily PRN



*Continued*

GLYCERIN *continued*

**Onset of action:** 15–30 min. May cause rectal irritation, abdominal pain, bloating, and dizziness. Insert suppository high into rectum and retain for 15 min.

**GLYCOPYRROLATE**

Robinul, Glycate, Glyrx-PF, Cuvposa, and generics

**Anticholinergic agent**



B/C



3



Yes



Yes



No

**Tabs (Robinul, Glycate, and generics):** 1, 1.5, 2 mg

**Oral solution (Cuvposa and generics):** 1 mg/5 mL (473 mL); contains propylene glycol and parabens

**Injection (Glyrx-PF and generics):** 0.2 mg/mL (1, 2, 5, 20 mL); some multidose vials contain 0.9% benzyl alcohol

**Respiratory antisecretory:****IM/IV:**

**Child:** 0.004–0.01 mg/kg/dose TID–QID

**Adult:** 0.1–0.2 mg/dose TID–QID

**Max. dose:** 0.2 mg/dose or 0.8 mg/24 hr

**Oral:**

**Child:** 0.04–0.1 mg/kg/dose TID–QID

**Alternative dosage for 3–16 yr old with chronic severe drooling secondary to neurologic**

**conditions:** Start with 0.02 mg/kg/dose PO TID and titrate in increments of 0.02 mg/kg/dose every 5–7 days as needed and tolerated up to a **max. dose** of 0.1 mg/kg/dose TID not to exceed 1.5–3 mg/dose.

**Adult:** 1–2 mg/dose BID–TID

**Reverse neuromuscular blockade:**

**Child and adult:** 0.2 mg IV for every 1 mg neostigmine or 5 mg pyridostigmine

**Use with caution** in hepatic and renal disease, ulcerative colitis, asthma, glaucoma, ileus, or urinary retention. Atropine-like side effects: tachycardia, nausea, constipation, confusion, blurred vision, and dry mouth. These may be potentiated if given with other drugs with anticholinergic properties.

**Onset of action:** PO: within 1 hr; IM/SC: 15–30 min; IV: 1 min. Duration of antisialagogue effect: PO: 8–12 hr; IM/SC/IV: 7 hr. Oral doses should be administered 1 hr before and 2 hr after meals.

Pregnancy category is “B” for the injection and tablet dosage forms and “C” for the oral solution.

**GRANISETRON**

Sancuso, Sustol, and generics; previously available as Kytril

**Antiemetic agent, 5-HT<sub>3</sub> antagonist**



B



?



No



Yes



No

**Injection:** 1 mg/mL (1, 4 mL); 4 mL multidose vials contain benzyl alcohol

**Prefilled syringe for subcutaneous extended release injection (Sustol):** 10 mg/0.4 mL (0.4 mL); contains polyethylene glycol

**Tabs:** 1 mg

**Oral suspension:** 0.2 mg/mL , 50 mCg/mL 

**Transdermal patch (Sancuso):** 3.1 mg/24 hr

**Chemotherapy-induced nausea and vomiting prevention (used in combination with dexamethasone):**



GRANISETRON *continued***IV:**

**Child  $\geq 2$  yr and adult:** 10–20 mCg/kg/dose 15–60 min before chemotherapy; the same dose may be repeated 2–3 times at  $\geq 10$ -min intervals following chemotherapy (within 24 hr after chemotherapy) as a treatment regimen. **Max. dose:** 3 mg/dose or 9 mg/24 hr. Alternatively, a single 40 mCg/kg/dose 15–60 min before chemotherapy has been used.

**SC (Sustol, extended release):**

**Adult:** 10 mg at least 30 min prior to first dose of moderately emetogenic chemotherapy. **Do not** administer more frequently than Q7 days.

**PO:**

**Infant, child, and adolescent:** 40 mCg/kg/dose BID is recommended for moderately or low emetogenic chemotherapy; initiate first dose 1 hr prior to chemotherapy

**Adult:** 2 mg/24 hr  $\div$  once daily—BID; initiate first dose 1 hr prior to chemotherapy

**Postoperative nausea and vomiting prevention (dosed prior to anesthesia or immediately before anesthesia reversal) and treatment (IV; see remarks):**

**Adult:** 1 mg  $\times$  1

**Radiation-induced nausea and vomiting prevention:**

**Adult:** 2 mg once daily PO administered within 1 hr of radiation

**Transdermal patch (see remarks):**

**Prophylaxis for chemotherapy-induced nausea and vomiting (adult):** Apply 1 patch 24–48 hr prior to chemotherapy. Patch removal at a minimum of 24 hr after completion of chemotherapy. Patch may be worn up to 7 days, depending on the chemotherapy regimen duration.

**Use with caution** in liver disease, recent abdominal surgery, and preexisting cardiac conduction disorders and arrhythmias. May cause hypertension, hypotension, progressive ileus, gastric distention, arrhythmias, agitation, and insomnia. QT prolongation has been reported. Inducers or inhibitors of the CYP 450 3A3/4 drug metabolizing enzymes may increase or decrease, respectively, the drug's clearance. Serotonin syndrome has been reported with concomitant use of 5-HT<sub>3</sub> antagonists and other serotonergic drugs.



Safety and efficacy in pediatric patients for the prevention of postoperative nausea and vomiting have not been established due to lack of efficacy and QT prolongation in a prospective multicenter, randomized double-blinded trial in 157 patients aged 2–16 yr.

**Avoid** external heat sources (e.g., heating pads) on and around the transdermal patch dosage form as heat may increase the rate of drug release. Application site reactions of pain, pruritus, rash, irritation, vesicles, and discoloration have been reported with transdermal patch use. Covering the application site of the transdermal system with clothing (while wearing the patch and 10 days following removal) is recommended to prevent potential phototoxic skin reactions.

Onset of action: IV: 4–10 min. Duration of action: IV:  $\leq 24$  hr.

**GRISEOFULVIN**

**Microsize:** Generics; previously available as Grifulvin V, Griseofulvin Microsize

**Ultramicrosize:** Generics; previously available as Gris-PEG

**Antifungal agent**



X



3



No



Yes



No

**Microsize:**

**Tablets:** 250, 500 mg

**Oral suspension:** 125 mg/5 mL (120 mL); contains 0.2% alcohol, parabens, and propylene glycol

**Ultramicrosize:**

*Continued*

GRISEOFULVIN *continued*

Tabs: 125, 250 mg

250 mg ultramicrosize is approximately 500 mg microsize.

**Microsize:**

**Child >2 yr and adolescent:** 20–25 mg/kg/24 hr PO ÷ once daily—BID; give with milk, eggs, fatty foods

**Adult:** 500–1000 mg/24 hr PO ÷ once daily—BID

**Max. dose (all ages):** 1 g/24 hr

**Ultramicrosize:**

**Child >2 yr and adolescent:** 10–15 mg/kg/24 hr PO ÷ once daily—BID

**Adult:** 375 mg/dose PO once daily or BID

**Max. dose (all ages):** 750 mg/24 hr



**Contraindicated** in porphyria, pregnancy, and hepatic disease. Monitor hematologic, renal, and hepatic function. May cause leukopenia, rash, headache, paresthesias, and GI symptoms.

Severe skin reactions (e.g., Stevens-Johnson, TEN), erythema multiforme, LFT elevations (AST, ALT, bilirubin), and jaundice have been reported. Possible cross-reactivity in penicillin-allergic patients. Usual treatment period is 8 wk for tinea capitis and 4–6 mo for tinea unguium. Photosensitivity reactions may occur. May reduce effectiveness or decrease level of oral contraceptives, warfarin, and cyclosporine. Induces CYP 450 1A2 isoenzyme. Phenobarbital may enhance clearance of griseofulvin. Coadministration with fatty meals will increase the drug's absorption.



**GUANFACINE**

Intuniv and generics

$\alpha_2$  adenergetic agonist



B

3

Yes

Yes

No

Tabs: 1, 2 mg

Extended release tabs (Intuniv and generics): 1, 2, 3, 4 mg

**Attention-deficit hyperactivity disorder (see remarks):**

**Immediate release tab:**

**≥6 yr and adolescent:**

**≤45 kg:** Start at 0.5 mg QHS; if needed and tolerated, increase dose every 3–4 days at 0.5 mg/24 hr increments by increasing the dosing frequency to BID, TID, QID. **Max. dose:** 27–40.5 kg: 2 mg/24 hr and 40.5–45 kg: 3 mg/24 hr

**>45 kg:** Start at 1 mg QHS; if needed and tolerated, increase dose every 3–4 days at 1 mg/24 hr increments by increasing the dosing frequency to BID, TID, QID. **Max. dose:** 4 mg/24 hr

**Extended release tab:**

**6–17 yr:** Start at 1 mg Q24 hr; if needed and tolerated, increase dose no more than 1 mg per week up to the **max. dose** of 4 mg/24 hr for 6–12 yr and 7 mg/24 hr for 13–17 yr.

**Use with strong CYP 450 3A4 inhibitors or inducers:**



CYP 450 3A4 Characteristic	Adding Guanfacine With Respective CYP 450 3A4 Inducer/Inhibitor Already on Board	Adding Respective CYP 450 3A4 Inducer/Inhibitor With Guanfacine Already on Board
Strong inducer (e.g., carbamazepine, phenytoin, rifampin, St. John's wort)	Guanfacine may be titrated up to double the recommended target dose.	Consider increasing guanfacine dose up to double the recommended target dose over 1–2 wk

GUANFACINE *continued*

CYP 450 3A4 Characteristic	Adding Guanfacine With Respective CYP 450 3A4 Inducer/Inhibitor Already on Board	Adding Respective CYP 450 3A4 Inducer/Inhibitor With Guanfacine Already on Board
Strong inhibitor (e.g., clarithromycin, azole antifungals)	Decrease guanfacine dose to 50% of recommended target dose.	as tolerated. If the strong inducer is discontinued, decrease guanfacine dose to target dose over 1–2 wk. Decrease guanfacine dose to 50% of recommended target dose. If the strong inhibitor is discontinued, increase guanfacine dose to recommended target dose.

**Use with caution** in patients at risk for hypotension, bradycardia, heart block, and syncope.

A dose-dependent hypotension and bradycardia may occur. Somnolence, fatigue, insomnia, dizziness, and abdominal pain are common side effects. Orthostatic hypotension, hallucinations, syncope, and erectile dysfunction have been reported.



Drug is a substrate for CYP 450 3A4. See dosing section for dosage adjustment with inhibitors and inducers.

**Do not** abruptly discontinue therapy (may cause rebound hypertension); taper of no more than 1 mg Q3–7 days has been recommended. Dose reductions may be required with clinically significant renal or hepatic impairment. When converting from an immediate release tab to the extended release tab, **do not** covert on a mg per mg basis (due to differences in pharmacokinetic profiles) but discontinue the immediate release and titrate with the extended release product using the recommended dosing schedules.

## H

**HALOPERIDOL**

Haldol, Haldol Decanoate, and generics

**Antipsychotic agent**



C



3



Yes



Yes



Yes

**Injection (IM use only):**

Lactate: 5 mg/mL (1, 10 mL)

Decanoate (long acting): 50, 100 mg/mL (1, 5 mL); in sesame oil with 1.2% benzyl alcohol

**Tabs:** 0.5, 1, 2, 5, 10, 20 mg

**Oral solution:** 2 mg/mL (15, 120 mL)

**Child 3–12 yr (limited data; see remarks):**

**PO:** Initial dose at 0.5 mg/24 hr ÷ BID–TID. If necessary, increase daily dosage by 0.25–0.5 mg/24 hr Q5–7 days PRN. Benefits are not to be expected for doses beyond 6 mg/24 hr. Usual maintenance doses for specific indications include the following:

**Agitation:** 0.01–0.03 mg/kg/24 hr once daily PO

**Psychosis:** 0.05–0.15 mg/kg/24 hr ÷ BID–TID PO



*Continued*

HALOPERIDOL *continued*

**Tourette’s syndrome:** 0.05–0.075 mg/kg/24 hr ÷ BID–TID PO; may increase daily dose by 0.5 mg Q5–7 days

**IM, as lactate, for 6–12 yr:** 1–3 mg/dose Q4–8 hr; **max. dose:** 0.15 mg/kg/24 hr  
**>12 yr (limited data):**

**Acute agitation:** 2–5 mg/dose IM as lactate or 1–15 mg/dose PO; repeat in 1 hr PRN

**Psychosis:** 2–5 mg/dose Q4–8 hr IM PRN or 1–15 mg/24 hr ÷ BID–TID PO

**Tourette’s syndrome:** 0.5–2 mg/dose BID–TID PO; 3–5 mg/dose BID–TID PO may be used for severe symptoms

Contraindicated in severe toxic CNS depression, comas, Parkinson disease, and dementia Lewy bodies. **Use with caution** in patients with cardiac disease (risk of hypotension), cerebrovascular adverse reaction risk, renal or hepatic dysfunction, thyrotoxicosis, and in patients with epilepsy since the drug lowers the seizure threshold. Extrapyramidal symptoms, drowsiness, headache, tachycardia, ECG changes, nausea, and vomiting can occur. Higher-than-recommended doses are associated with a higher risk of QT prolongation and torsades de pointes. Leukopenia/neutropenia, including agranulocytosis and rhabdomyolysis (IM route), and transient dyskinetic signs (following abrupt withdrawal from maintenance therapies) have been reported.



Drug is metabolized by CYP 450 1A2, 2D6, and 3A3/4 isoenzymes. May also inhibit CYP 450 2D6 and 3A3/4 isoenzymes. Serotonin-specific reuptake inhibitors (e.g., fluoxetine) may increase levels and effects of haloperidol. Carbamazepine and phenobarbital may decrease levels and effects of haloperidol. Monitor for encephalopathic syndrome when used in combination with lithium.

For poor metabolizers of CYP 450 2D6, consider a 50% reduction of initial dose and titrate to response, OR use an alternative medication not metabolized by this enzyme system.

Acutely aggravated patients may require doses as often as Q60 min. **Decanoate salt is given every 3–4 wk in doses that are 10–15 times the individual patient’s stabilized oral dose.**

<b>HEPARIN SODIUM</b> Various generics <b>Anticoagulant</b>					
	C	1	No	Yes	No

**Injection:**

Porcine intestinal mucosa: 1000, 5000, 10,000, 20,000 U/mL (some products may be preservative free; multidosed vials contain benzyl alcohol)

**Lock flush solution (porcine based):** 10, 100 U/mL (some products may be preservative free or contain benzyl alcohol)

**Injection for IV infusion (porcine based):**

D<sub>5</sub>W: 40 U/mL (500 mL), 50 U/mL (250, 500 mL), 100 U/mL (100, 250 mL); contains bisulfite

NS (0.9% NaCl): 2 U/mL (500, 1000 mL)

0.45% NaCl: 50 U/mL (250, 500 mL), 100 U/mL (250 mL); contains EDTA

120 U = approximately 1 mg

**Anticoagulation empiric dosage:**

Continuous IV infusion (initial doses for goal unfractionated heparin [UFH] anti-Xa level of 0.3–0.7 units/mL):



Age	Loading Dose (IV) <sup>a</sup>	Initial IV infusion Rate (units/kg/hr)
Neonate and infant <1 yr	75 U/kg IV	28
Child age 1–18 yr	75 U/kg IV (max. dose: 8000 U)	20 (max. initial rate: 1650 U/hr)
>18 yr	70 U/kg IV (max. dose: 8000 U)	18 (max. initial rate: 1650 U/hr)

<sup>a</sup>Do not give loading dose for patients with stroke or significant bleeding risk and obtain aPPT 4 hr after loading dose.

HEPARIN SODIUM *continued***DVT or PE prophylaxis:**

**Adult:** 5000 U/dose SC Q8–12 hr until ambulatory

**Heparin flush (doses should be less than heparinizing dose):**

**Younger child:** Lower doses should be used to avoid systemic heparinization.

**Older child and adult:**

**Peripheral IV:** 1–2 mL of 10 U/mL solution Q4 hr

**Central lines:** 2–3 mL of 100 U/mL solution Q24 hr

**TPN (central line) and arterial line:** Add heparin to make final concentration of 0.5–1 U/mL.

**Contraindicated** in active major bleeding, known or suspected HIT, and concurrent epidural therapy. **Use with caution** if platelets  $<50,000/\text{mm}^3$ . **Avoid** IM injections and other medications affecting platelet function (e.g., NSAIDs and ASA). Toxicities include bleeding, allergy, alopecia, and thrombocytopenia. May increase serum aminotransferases (AST and ALT).



Adjust dose with one of the following laboratory goals:

Unfractionated heparin (UFH) anti-Xa level: 0.3–0.7 units/mL

aPTT level (reagent specific to reflect anti-Xa level of 0.3–0.7 units/mL): 50–80 sec

These laboratory measurements are best measured 4–6 hr after initiation or changes in infusion rate.

**Do not** collect blood levels from the heparinized line or same extremity as site of heparin infusion. If unfractionated heparin anti-Xa or aPTT levels are not available, a ratio of aPPT 1.5–2.5 times control value has been used in the past. Unfractionated heparin anti-Xa level is **NOT THE SAME** as low-molecular-weight heparin anti-Xa (used for monitoring low-molecular-weight heparin products such as enoxaparin).

Use with IV nitroglycerin may decrease the partial thromboplastin time (PTT) with subsequent rebound upon discontinuation of nitroglycerin. Antithrombin III (human) and NSAIDs may increase heparin's anticoagulant effects and bleeding risk.

Use preservative-free heparin in neonates. **Note:** Heparin flush doses may alter aPTT in smaller patients; consider using more dilute heparin in these cases. Multiple strengths of heparin exist, and **do not use** the more concentrated injectable product as flushes.

Use actual body weight when dosing obese patients. Due to recent regulatory changes to the manufacturing process, heparin products may exhibit decreased potency.

**Antidote: Protamine sulfate** (1 mg per 100 U heparin in previous 4 hr). For low-molecular-weight heparin (LMWH), see [Enoxaparin](#).

**HYALURONIDASE**

Amphadase, Hylenex, and Vitrase

**Antidote, extravasation**



C



?



No



No



No

**Injection:**

Amphadase: 150 U/mL (1 mL); bovine source; contains edetate disodium and thimerosal

Hylenex: 150 U/mL (1 mL); recombinant human source; contains 1 mg albumin, 1.5 mg L-methionine, and 0.2 mg polysorbate 80 per 150 U

Vitrax: 200 U/mL (1.2 mL); ovine source containing lactose, preservative free



Pharmacy can make a 15 U/mL dilution.

**Extravasation:**

**Infant and child:** Give 1 mL (150 U) by injecting 5 separate injections of 0.2 mL (30 U) at borders of extravasation site SC or intradermal using a 25- or 26-gauge needle. Alternatively, a diluted 15 U/mL concentration has been used with the same dosing instructions.



*Continued*

HYALURONIDASE *continued*

**Contraindicated** in dopamine and alpha-agonist extravasation and hypersensitivity to the respective product sources (bovine or ovine). May cause urticaria. Patients receiving large amounts of salicylates, cortisone, ACTH, estrogens, or antihistamines may decrease the effects of hyaluronidase (larger doses may be necessary). Administer as early as possible (minutes to 1 hr) after IV extravasation.

Hylenex product is chemically incompatible with sodium metabisulfite, furosemide, benzodiazepines, and phenytoin.

**HYDRALAZINE HYDROCHLORIDE**

Generics; previously available as Apresoline

**Antihypertensive, vasodilator**



C



1



Yes



No



Yes

**Tabs:** 10, 25, 50, 100 mg

**Injection:** 20 mg/mL (1 mL)

**Oral liquid:** 4 mg/mL

Some dosage forms may contain tartrazines or sulfites.

**Acute severe hypertension (may result in severe and prolonged hypotension; see Chapter 1, Table 1.7 for alternatives):**

**Child:** 0.1–0.2 mg/kg/dose IM or IV Q4–6 hr PRN; **max. dose:** 20 mg/dose. Usual IV/IM dosage range is 0.2–0.6 mg/kg/dose Q4–6 hr.

**Adult:** 10–20 mg IM or IV Q4–6 hr PRN; may increase to **max. dose** of 40 mg/dose if needed

**Chronic hypertension:**

**Infant and child:** Start at 0.75–1 mg/kg/24 hr PO ÷ Q6–12 hr (**max. initial dose:** 10 mg/dose). If necessary, increase dose over 3–4 wk up to a **max. dose** of 5 mg/kg/24 hr for infants and 7.5 mg/kg/24 hr for children; or 200 mg/24 hr.

**Adult:** 10–50 mg/dose PO QID; **max. dose:** 300 mg/24 hr

**Use with caution** in severe renal and cardiac disease. Slow acetylators, patients receiving high-dose chronic therapy, and those with renal insufficiency are at highest risk of lupus-like syndrome (generally reversible). May cause reflex tachycardia, palpitations, dizziness, headaches, and GI discomfort. MAO inhibitors and  $\beta$ -blockers may increase hypotensive effects. Indomethacin may decrease hypotensive effects.

Drug undergoes first-pass metabolism. Onset of action: PO: 20–30 min; IV: 5–20 min. Duration of action: PO: 2–4 hr; IV: 2–6 hr. **Adjust dose in renal failure (see Chapter 31).**

**HYDROCHLOROTHIAZIDE**

Generics; previously available as HydroDiuril and

Microzide

**Diuretic, thiazide**



B/D



2



Yes



No



No

**Tabs:** 12.5, 25, 50 mg

**Caps:** 12.5 mg

**Oral suspension:** 5 mg/mL , 10 mg/mL

**Edema:**

**Neonate and infant <6 mo:** 1–3 mg/kg/24 hr ÷ once daily–BID PO; **max. dose:** 37.5 mg/24 hr

**≥6 mo, child, and adolescent:** 1–2 mg/kg/24 hr ÷ once daily–BID PO; **max. dose:** <2 yr: 37.5 mg/24 hr, child 2–12 yr: 100 mg/24 hr, and adolescent: 200 mg/24 hr

**Adult:** 25–100 mg/24 hr ÷ once daily–BID PO; **max. dose:** 200 mg/24 hr

HYDROCHLOROTHIAZIDE *continued***Hypertension:**

**Infant and child:** Start at 1–2 mg/kg/24 hr ÷ once daily—BID PO; **max. dose:** <6 mo: 37.5 mg/24 hr, child ≥6 mo–12 yr: 100 mg/24 hr (37.5 mg/24 hr has been recommended by some experts)

**Adult:** 12.5–25 mg/dose once daily—BID PO; doses >50 mg/24 hr often result in hypokalemia

See [Chlorothiazide](#). May cause fluid and electrolyte imbalances and hyperuricemia. Drug may not be effective when creatinine clearance is less than 25–50 mL/min/1.73m<sup>2</sup>. Use with carbamazepine may result in symptomatic hyponatremia.

Hydrochlorothiazide is also available in combination with potassium-sparing diuretics (e.g., spironolactone), ACE inhibitors, angiotensin II receptor antagonists, hydralazine, methyldopa, reserpine, and β-blockers.

Pregnancy category is “D” if used in pregnancy-induced hypertension.

**HYDROCORTISONE**

Systemic dosage forms: Solu-Cortef, Cortef, Alkindi Sprinkle, and generics  
 Topical: Anusol HC, Cortifoam, Cortenema, MiCort-HC, NuCort, Proctocort, and many others including generics

**Corticosteroid**



C



2



No



No



No

**Hydrocortisone base:**

**Tabs (Cortef and generics):** 5, 10, 20 mg

**Oral granules in capsules (Alkindi sprinkle):** 0.5, 1, 2, 5 mg

**Oral suspension:** 2 mg/mL 

**Rectal cream:** 1% (30 g)

**Anusol HC and generics:** 2.5% (30 g)

**Rectal suspension as an enema (Cortenema):** 100 mg/60 mL; may contain parabens

**Topical ointment:** 0.5% [OTC], 1% [OTC], 2.5%

**Topical cream:** 0.5% [OTC], 1% [OTC], 2.5%

**Topical lotion:** 1% [OTC], 2%, 2.5%

**Na Succinate (Solu-Cortef):**

**Injection:** 100, 250, 500, 1000 mg/vial; contains benzyl alcohol

**Acetate:**

**Topical cream:** 1% [OTC]

**MiCort-HC:** 2.5% (4, 28.4 g); contains parabens

**Topical lotion (NuCort):** 2% (60 g); contains benzyl alcohol

**Suppository:**

**Anusol HC and generics:** 25 mg

**Proctocort and generics:** 30 mg

**Rectal foam aerosol (Cortifoam):** 10% (90 mg/dose) (15 g); may contain parabens

**Status asthmaticus:****Child:**

**Load (optional):** 4–8 mg/kg/dose IV; **max. dose:** 250 mg

**Maintenance:** 8 mg/kg/24 hr ÷ Q6 hr IV

**Adult:** 100–500 mg/dose Q6 hr IV

**Physiologic replacement:** See [Chapter 10](#) for dosing.

**Antiinflammatory/immunosuppressive:****Child:**

*Continued*

HYDROCORTISONE *continued***PO:** 2.5–10 mg/kg/24 hr ÷ Q6–8 hr**IM/IV:** 1–5 mg/kg/24 hr ÷ Q12–24 hr**Adolescent and adult:****PO/IM/IV:** 15–240 mg/dose Q12 hr**Acute adrenal insufficiency:** See [Chapter 10](#) for dosing.**Topical use:****Child and adult:** Apply to affected areas BID–QID, depending on severity and specific indication for use.**Ulcerative colitis, induction for mild/moderate case:****Child, adolescent, and adult:** Insert 1 application of 100 mg rectal enema once daily—BID × 2–3 wk.**Hemorrhoids:****Adult:****Rectal cream:** Apply sparingly up to BID with either 1% or 2.5% strength.**Suppository:** 25 or 30 mg PR BID × 2 wk**Use with caution** in immunocompromised patients, as they should avoid exposure to chickenpox or measles. Hypertrophic cardiomyopathy has been reported in premature infants.**Alkindi sprinkle product:** Administered by sprinkling the capsule's contents directly onto the tongue or mixed with soft food. **DO NOT** swallow capsules. Different hydrocortisone exposure may occur when converting to Alkindi sprinkle from other oral manipulated oral formulations (e.g., split or crushed tabs, compounded formulations).For potency comparisons of topical preparations, see [Chapter 8](#). For doses based on body surface area, see [Chapter 10](#).**HYDROMORPHONE HCL**

Dilaudid and generics

**Narcotic, analgesic**

C/D



3



Yes



Yes



No

**Tabs:** 2, 4, 8 mg**Extended release tabs:** 8, 12, 16, 32 mg**Injection:** 1, 2, 4 mg/mL (1 mL), 10 mg/mL (1, 5, 50 mL); may be preservative free**Prefilled injectable syringes:** 0.2 mg/mL (1 mL), 1 mg/mL (0.5, 1 mL), 2 mg/mL (1 mL)**Suppository:** 3 mg (6s)**Oral solution:** 1 mg/mL; may contain parabens and metasulfite**Analgesia, initial doses with immediate release dosage forms to opioid-naïve (titrate to effect):****Child (<50 kg):****IV:** 0.015 mg/kg/dose Q3–6 hr PRN**PO:** 0.03–0.08 mg/kg/dose Q3–4 hr PRN; **max. dose:** 5 mg/dose**Child and adolescent (≥50 kg; NOTE: doses are NOT weight based):****IV:** 0.2–0.6 mg/dose Q2–4 hr PRN**IM, SC (not preferred route; absorption is erratic):** 0.8–1 mg/dose Q4–6 hr PRN**PO:** 1–2 mg/dose Q3–4 hr PRN**PR:** 3 mg Q6–8 hr PRN**Adult:****IV:** 0.2–0.5 mg/dose Q2–4 hr PRN**IM, SC (not preferred route; absorption is erratic):** 0.2–0.5 mg/dose Q2–3 hr PRN**PO:** 1–2 mg/dose Q4–6 hr PRN**PR:** 3 mg Q6–8 hr PRN

HYDROMORPHONE HCL *continued*

Refer to **Chapter 6** for equianalgesic doses and for patient-controlled analgesia dosing. Less pruritus than morphine. Similar profile of side effects to other narcotics. **Use with caution** in infants and young children, and **do not use** in neonates due to potential CNS effects. Dose reduction recommended in renal insufficiency or severe hepatic impairment. Pregnancy category changes to “D” if used for prolonged periods or in high doses at term.

The FDA has assigned a Risk Evaluation and Mitigation Strategy (REMS) for this medication, which involves an education program for provision of safety information. See [www.opioidanalgesicrems.com](http://www.opioidanalgesicrems.com).

**HYDROXYCHLOROQUINE SULFATE**

Plaquenil and generics

**Antimalarial, antirheumatic agent**

?



2



Yes



Yes



No

**Tabs:** 200 mg (155 mg base)**Oral suspension:** 25 mg/mL (19.375 mg/mL base) **All doses expressed in mg of hydroxychloroquine base.****Malaria prophylaxis (start 2 wk prior to exposure and continue for 4 wk after leaving endemic area):****Child:** 5 mg/kg/dose PO once weekly; **max. dose:** 310 mg**Adult:** 310 mg PO once weekly**Malaria treatment (acute uncomplicated cases):**

For treatment of malaria, consult with ID specialist or see the latest edition of the AAP Red Book.

**Child:** 10 mg/kg/dose (**max. dose:** 620 mg) PO × 1 followed by 5 mg/kg/dose (**max. dose:** 310 mg) 6 hr later. Then 5 mg/kg/dose (**max. dose:** 310 mg) Q24 hr × 2 doses starting 24 hr after the first dose.**Adult:** 620 mg PO × 1 followed by 310 mg 6 hr later. Then 310 mg Q24 hr × 2 doses starting 24 hr after the first dose.**Systemic lupus erythematosus (limited data):****Child:** 3.1–5 mg/kg/24 hr (base) PO ÷ once daily—BID; **max. dose:** 310 mg/24 hr

**Contraindicated** in psoriasis, porphyria, retinal or visual field changes, and 4-aminoquinoline hypersensitivity. **Use with caution** in liver disease, G6PD deficiency, concomitant hepatic toxic drugs, renal impairment, metabolic acidosis, or hematologic disorders. Long-term use in children is **not recommended**. May cause headaches, myopathy, GI disturbances, skin and mucosal pigmentation, agranulocytosis, visual disturbances, and increased digoxin serum levels. Hypoglycemia, cardiomyopathy with phospholipidosis without inflammation, proximal myopathy/neuropathy, and suicidal behavior have been reported. Baseline ocular exam is recommended within the first year of initiating long-term therapy, as retinal damage has been reported.

Use with aurothioglucose may increase risk for blood dyscrasias. When used in combination with other immunosuppressive agents for SLE and JRA, lower doses of hydroxychloroquine can be used.

Pregnancy category has not been formally assigned by the FDA. The only situation where use is recommended during pregnancy is during the suppression or treatment of malaria, when the benefits outweigh the risks.

**HYDROXYZINE**

Vistaril and generics

**Antihistamine, anxiolytic, antiemetic**

C



3



No



Yes



No

**Tabs (HCl salt):** 10, 25, 50 mg**Caps (pamoate salt):** 25, 50, 100 mg*Continued*

HYDROXYZINE *continued*

**Oral syrup (HCl salt):** 10 mg/5 mL (120, 473 mL); may contain alcohol, parabens, and propylene glycol

**Oral solution (HCl salt):** 10 mg/5 mL (473 mL); may contain sodium benzoate

**Injection for IM use (HCl salt):** 25 mg/mL (1 mL), 50 mg/mL (1, 2 mL); may contain benzyl alcohol

**NOTE:** Pamoate and HCL salts are equivalent in regard to mg of hydroxyzine.

**Pruritus and anxiety:****Oral:**

**Child and adolescent:** 2 mg/kg/24 hr ÷ Q6–8 hr PRN; **max. single dose:** <6 yr: 12.5 mg, 6–12 yr: 25 mg, and >12 yr: 100 mg

**Alternative dosing by age:**

<6 yr: 50 mg/24 hr ÷ Q6–8 hr PRN

≥6 yr: 50–100 mg/24 hr ÷ Q6–8 hr PRN

**Adult:** 25–100 mg/dose TID–QID PRN

**IM:**

**Child and adolescent:** 0.5–1 mg/kg/dose Q4–6 hr PRN; **max. single dose:** 100 mg

**Adult:** 25–100 mg/dose Q4–6 hr PRN

**Antiemetic (excluding use during pregnancy):**

**Child and adolescent:** 1.1 mg/kg/dose IM; **max. single dose:** 100 mg

**Adult:** 25–100 mg IM

**Contraindicated** in prolonged QT interval. May potentiate barbiturates, meperidine, and other CNS depressants. **Use with caution** with concomitant use of other medications known to prolong the QT interval. May cause dry mouth, drowsiness, tremor, convulsions, blurred vision, and hypotension. May cause pain at injection site. Fixed drug eruptions have been reported with use of the oral dosage form.

Increase dosage interval to Q24 hr or longer in the presence of liver disease (e.g., primary biliary cirrhosis).

Onset of action within 15–30 min. Duration of action: 4–6 hr. IV administration is **NOT recommended**.

**IBUPROFEN**

PO: Motrin, Advil, Children's Advil, Children's Motrin, and generics

IV: NeoProfen, Caldolor

**Nonsteroidal antiinflammatory agent**



C/X



1



Yes



Yes



No

**Oral suspension [OTC]:** 100 mg/5 mL (120, 240, 473 mL); may contain propylene glycol and sodium benzoate

**Oral drops [OTC]:** 40 mg/mL (15, 30 mL); may contain sodium benzoate

**Chewable tabs [OTC]:** 100 mg; contains aspartame

**Caplets [OTC]:** 100, 200 mg

**Tablets [OTC]:** 200 [OTC], 400, 600, 800 mg

**Capsules [OTC]:** 200 mg

**Injection:**

**NeoProfen and generic (lysine salt):** 10 mg ibuprofen base/1 mL (2 mL); preservative-free

**Caldolor:**

IBUPROFEN *continued*

100 mg/mL (8 mL); contains 78 mg/mL arginine

Ready to use: 4 mg/mL (200 mL)

**PO:****Infant and child (≥6 mo):**

**Analgesic/antipyretic:** 5–10 mg/kg/dose Q6–8 hr PO; **max. dose:** the lesser of 40 mg/kg/24 hr or 3200 mg/24 hr (analgesic), or 2400 mg/24 hr (antipyretic)

**JRA (6 mo–12 yr):** 30–50 mg/kg/24 hr ÷ Q6 hr PO; **max. dose:** 800 mg/dose or 2400 mg/24 hr

**Adult:**

**Inflammatory disease:** 400–800 mg/dose Q6–8 hr PO; **max. dose:** 800 mg/dose or 3.2 g/24 hr

**Pain/fever/dysmenorrhea:** 200–400 mg/dose Q4–6 hr PRN PO; **max. dose:** 3.2 g/24 hr

**IV:****6 mo–<12 yr:**

**Analgesic and antipyretic:** 10 mg/kg/dose up to 400 mg/dose Q4–6 hr PRN; **max. dose:** the lesser of 40 mg/kg/24 hr or 2400 mg/24 hr

**12–17 yr:**

**Analgesic and antipyretic:** 400 mg/dose Q4–6 hr PRN; **max. dose:** 2400 mg/24 hr

**≥18 yr and adult:**

**Analgesic (see remarks):** 400–800 mg/dose Q6 hr PRN; **max. dose:** 3200 mg/24 hr

**Antipyretic (see remarks):** 400 mg/dose Q4–6 hr or 100–200 mg/dose Q4 hr PRN; **max. dose:** 3200 mg/24 hr

**Closure of ductus arteriosus:**

**<32 wks' gestation and 0.5–1.5 kg (use birth weight to calculate all doses and infuse all doses over 15 min; see remarks):** 10 mg/kg/dose IV × 1 followed by two doses of 5 mg/kg/dose each, 24 and 48 hr after the initial dose. Hold second or third dose if urinary output is <0.6 mL/kg/hr; dosing should resume when laboratory studies indicate the return of normal renal function. If the ductus arteriosus fails to close or reopens, a second course of ibuprofen, the use of IV indomethacin, or surgery may be necessary.



**Contraindicated** with active GI bleeding and ulcer disease. **Use caution** with aspirin hypersensitivity, hepatic/renal insufficiency, heart disease (risk for MI and stroke with prolonged use), or dehydration, and in patients receiving anticoagulants. GI distress (lessened with milk), rashes, ocular problems, hypertension, granulocytopenia, and anemia may occur. Inhibits platelet aggregation. Consumption of more than three alcoholic beverages per day or use with corticosteroids or anticoagulants may increase risk for GI bleeding. False-positive test for urine cannabinoid and phencyclidine (PCP) screen may occur.

May increase serum levels and effects of digoxin, methotrexate, and lithium. May decrease the effects of antihypertensives, aspirin (antiplatelet effects), furosemide, and thiazide diuretics.

Pregnancy category is “C” for prior to 30 wks' gestation and “X” for 30 wk and greater. **Avoid use** at >30 wks' gestation due to increased risk for premature closure of the fetal ductus arteriosus. Limit dose and duration of use at 20–30 wks' gestation for concerns of fetal renal dysfunction and oligohydramnios.

**IV USE for analgesia/antipyretic:** Hydrate patient well before use. Doses must be diluted to a concentration ≤4 mg/mL with NS, D<sub>5</sub>W, or LR and infused over ≥30 min for adults and ≥10 min for children. Most common reported side effects in clinical trials include nausea, flatulence, vomiting, and headache.

**IV USE for PDA:** Contraindicated in untreated infections, congenital heart diseases requiring a patent ductus arteriosus to facilitate satisfactory pulmonary and systemic blood flow, active intracranial or gastrointestinal bleeds, thrombocytopenia, coagulation defects, suspected/active NEC, and significant renal impairment. **Use with caution** in hyperbilirubinemia. Not indicated for IVH prophylaxis. Renal side effects are generally less frequent and severe when compared with IV indomethacin. NEC, GI perforation, and pulmonary hypertension have been reported. NeoProfen doses must be administered within 30 min of preparation and infused intravenously over 15 min.

**ILOPROST**Ventavis, synthetic PGI<sub>2</sub>**Prostaglandin I<sub>2</sub>, vasodilator**

C

3

Yes

Yes

No

**Inhalation solution:** 10 mCg/mL (1 mL), 20 mCg/mL (1 mL); contains ethanol and tromethamine**Pulmonary arterial hypertension (limited data):**

**Intermittent inhalation via nebulization:** Start at 2.5 mCg/dose (some recommend 1.25 mCg/dose for infant and small child). If tolerated, increase dose to 5 mCg/dose at intervals of 6 to 9 times daily (Q2–3 hr while awake; Q3–4 hr may be considered for patients with moderate/severe hepatic impairment).

**Use with caution** in bleeding disorders, respiratory diseases, and hypotension.

Headache, nausea, cough, flu-like symptoms, and flushing are common side effects.

Bronchospasm, hypotension, and AKI have been reported. May increase the effects/toxicity of anticoagulants and antiplatelet, antihypertensive, and vasodilating medications.

Administer by nebulization, which may take 10–15 min. **Avoid** contact with skin or eyes and do not ingest by mouth.**IMIPENEM AND CILASTATIN**

Primaxin IV and generics

**Antibiotic, carbapenem**

C

2

Yes

No

No

**Injection:** 250, 500 mg; each 1 mg drug contains 1 mg imipenem and 1 mg cilastatin

Contains 3.2 mEq Na/g drug

**Dosages based on imipenem component.****Neonate (see remarks):****<1 kg:**

≤14 days old: 40 mg/kg/24 hr ÷ Q12 hr IV

15–28 days old: 50 mg/kg/24 hr ÷ Q12 hr IV

**1–2 kg:**

≤7 days old: 40 mg/kg/24 hr ÷ Q12 hr IV

8–28 days old: 50 mg/kg/24 hr ÷ Q12 hr IV

**>2 kg:**

≤7 days old: 50 mg/kg/24 hr ÷ Q12 hr IV

8–28 days old: 75 mg/kg/24 hr ÷ Q8 hr IV

**Child (4 wk–3 mo):** 100 mg/kg/24 hr ÷ Q6 hr IV**Child (>3 mo):** 60–100 mg/kg/24 hr ÷ Q6 hr IV; **max. dose:** 4 g/24 hr**Cystic fibrosis:****Pulmonary exacerbation:** 100 mg/kg/24 hr ÷ Q6 hr IV; **max. dose:** 4 g/24 hr**Non-tuberculosis mycobacterium:** 30–40 mg/kg/24 hr ÷ Q12 hr IV; **max. dose:** 2 g/24 hr**Adult:** 0.5–1 g/dose Q6–8 hr IV; **max. dose:** 4 g/24 hr or 50 mg/kg/24 hr, whichever is less

For IV use, give slowly over 30–60 min at a concentration ≤5 mg/mL to reduce risk for nausea (lowering the rate may reduce severity). Adverse effects: thrombophlebitis, pruritus, urticaria, GI symptoms, seizures, dizziness, hypotension, elevated LFTs, blood dyscrasias, and penicillin allergy. Greater risk for seizures may occur with CNS infections, concomitant use with ganciclovir, higher doses, and renal impairment. CSF penetration is variable but best with inflamed meninges. Not recommended in CNS infections for neonates due to cilastatin accumulation and seizure risk.



IMIPENEM AND CILASTATIN *continued*

**Do not administer** with probenecid (increases imipenem/cilastatin levels) and ganciclovir (increased risk for seizures). May significantly reduce valproic acid levels.

**Adjust dose in renal insufficiency (see Chapter 31).**

**IMIPRAMINE**

Tofranil and generics

**Antidepressant, tricyclic**



C



2



Yes



Yes



Yes

**Tab (HCl):** 10, 25, 50 mg

**Caps (pamoate):** 75, 100, 125, 150 mg; strengths are expressed as imipramine HCl equivalent

**Antidepressant (see remarks):**

**Child (≥8 yr):**

**Initial:** 1.5 mg/kg/24 hr ÷ BID–TID PO; increase 1 mg/kg/24 hr Q3–4 days to a **max. dose** of 5 mg/kg/24 hr

**Adolescent:**

**Initial:** 25–50 mg/24 hr ÷ once daily–TID PO; **max. dose:** 200 mg/24 hr. Dosages exceeding 100 mg/24 hr are generally not necessary.

**Adult:**

**Initial:** 75–100 mg/24 hr ÷ TID PO

**Maintenance:** 50–300 mg/24 hr QHS PO; **max. dose:** 300 mg/24 hr

**Enuresis (≥6 yr):**

**Initial:** 10–25 mg QHS PO

**Increment if needed:** 10–25 mg/dose at 1- to 2-wk intervals until **max. dose** for age or desired effect achieved. Continue × 2–3 mo, then taper slowly.

**Max. dose:**

**6–12 yr:** The lesser of 2.5 mg/kg/24 hr or 50 mg/24 hr

**≥12 yr:** 75 mg/24 hr

**Augment analgesia for chronic pain:**

**Initial:** 0.2–0.4 mg/kg/dose QHS PO; increase 50% every 2–3 days PRN to a **max. dose** of 1–3 mg/kg/dose QHS PO

**Contraindicated** in narrow-angle glaucoma and patients who used MAO inhibitors within 14 days. See Chapter 3 for management of toxic ingestion. Monitor for clinical worsening of depression and suicidal ideation/behavior following the initiation of therapy or after dose changes.

**Use with caution** in renal or hepatic impairment. Side effects include sedation, urinary retention, constipation, dry mouth, dizziness, drowsiness, and arrhythmia. QHS dosing during first weeks of therapy will reduce sedation. Monitor ECG, BP, CBC at start of therapy and with dose changes.

Tricyclics may cause mania. False-positive test for urine PCP screen may occur.

Therapeutic reference range for depression (sum of imipramine and desipramine) = 150–250 ng/mL. Levels >1000 ng/mL are toxic; however, toxicity may occur at >300 ng/mL.

Recommended serum sampling times at steady-state: Obtain trough level within 30 min prior to the next scheduled dose after 5–7 days of continuous therapy.

Imipramine is a major substrate for CYP 450 2C19 and 2D6. See the remarks in amitriptyline for pharmacogenomic dosing considerations. Carbamazepine may reduce imipramine levels, and cimetidine, fluoxetine, fluvoxamine, labetalol, quinidine may increase imipramine levels.

Onset of antidepressant effects: 1–3 wk. **Do not discontinue** abruptly in patients receiving long-term high-dose therapy.

Pregnancy category has not been officially assigned by the FDA as congenital abnormalities have been reported in humans with the causal relationship not being established.



**IMMUNE GLOBULIN***Immune globulins*

C

?

Yes

No

No

**IM preparations:**

GamaSTAN: 150–180 mg/mL (2, 10 mL); contains 0.16–0.26 M glycine; preservative free

**IV preparations in solution (preservative free):**

Asceniv: 10% (100 mg/mL) (50 mL); contains polysorbate 80, 0.2–0.29 M glycine and <200 mCg/mL IgA; sucrose free

Bivigam: 10% (100 mg/mL) (50, 100 mL); contains polysorbate 80, 0.2–0.29 M glycine and <200 mCg/mL IgA; sucrose free

**Flebogamma DIF:**

5% (50 mg/mL) (10, 50, 100, 200, 400 mL); contains 50 mg/mL sorbitol, ≤3 mg/mL polyethylene glycol, and <50 mCg/mL IgA; sucrose free

10% (100 mg/mL) (50, 100, 200 mL); contains 50 mg/mL sorbitol, ≤6 mg/mL polyethylene glycol and <100 mCg/mL IgA; sucrose free

Gamunex-C: 10% (100 mg/mL) (10, 25, 50, 100, 200, 400 mL); contains 0.16–0.24 M glycine and ~46 mCg/mL IgA; sucrose free

Gammagard liquid: 10% (100 mg/mL) (10, 25, 50, 100, 200, 300 mL); contains 0.25 M glycine and ~37 mCg/mL IgA; sucrose free

Gammaked: 10% (100 mg/mL) (10, 25, 50, 100, 200 mL); contains 0.16–0.24 M glycine and ~46 mCg/mL IgA; sucrose free

**Gammaplex:**

5% (50 mg/mL) (100, 200, 400 mL); contains polysorbate 80, 50 mg/mL D-sorbitol, 6 mg/mL glycine, and <10 mCg/mL IgA; sucrose free

10% (100 mg/mL) (50, 100, 200 mL); contains polysorbate 80, 2–3 mM/mL glycine, and <20 mCg/mL IgA; sucrose free

Octagam: 5% (50 mg/mL) (20, 50, 100, 200, 500 mL), 10% (100 mg/mL) (20, 50, 100, 200, 300 mL); contains ~100 mg/mL maltose and ≤0.2 mg/mL IgA; sucrose free

Panzyga 10%: (100 mg/mL) (10, 25, 50, 100, 200, 300 mL); contains 15–19.5 mg/mL glycine and ~100 mCg/mL IgA; sucrose free

Privigen 10% (100 mg/mL) (50, 100, 200, 400 mL); contains 210–290 mmol/L L-proline and <25 mCg/mL IgA; sucrose free

**IV preparations in powder for reconstitution (sucrose and preservative free):**

Gammagard S/D: 5, 10 g (when diluted at 5% or 50 mg/mL, contains <1 mCg/mL of IgA, 3 mg/mL albumin, 22.5 mg/mL glycine, 20 mg/mL glucose, 2 mg/mL polyethylene glycol, 1 mCg/mL tri-n-butyl phosphate, 1 mCg/mL octoxynol 9, and 100 mCg/mL polysorbate 80); may be diluted to 5% or 10%

**Subcutaneous (SC) preparations (sucrose and preservative free):**

Hizentra: 20% (200 mg/mL) (5, 10, 20, 50 mL); contains 210–290 mmol/L L-proline, 8–30 mg/L polysorbate 80, and ≤50 mCg/mL IgA

Cutaquig: 16.9% (169 mg/mL) (6, 10, 12, 20, 24, 48 mL); contains 30 mEq/L sodium, polysorbate 80, and ~0.206 mg/mL IgA

Cuvitru: 20% (200 mg/mL) (5, 10, 20, 40, 50 mL); contains 0.25 M glycine, ~80 mCg/mL IgA, and polysorbate 80

Xembify: 20% (200 mg/mL) (5, 10, 20, 50 mL); contains 0.16–0.26 M glycine, 10–40 mCg/mL polysorbate 80, and IgA

IMMUNE GLOBULIN *continued***Intravenous (IV) preparations:**

**Kawasaki disease (should be initiated within first 10 days of symptoms):** 2 g/kg  $\times$  1 dose over 8–12 hr infusion. If signs and symptoms persist, infliximab monotherapy as second line therapy is recommended by a meta-analysis. If a second IVIG dose is used instead, consider using a different drug brand or lot number.

**Immune thrombocytopenia (ITP) (see RH<sub>0</sub>[D] immune globulin intravenous for Rh-positive patients):**

**Acute therapy:** 400–1000 mg/kg/dose once daily for 2–5 days for a total cumulative dose 2000 mg/kg

**Maintenance therapy:** 400–1000 mg/kg/dose Q3–6 wk based on clinical response

**Replacement therapy for antibody-deficient disorders:** Start at 400–500 mg/kg/dose Q4 wk and adjust dose based on clinical response and to maintain a trough IgG level  $\geq$ 500 mg/dL. For severe hypogammaglobulinemia (<100 mg/dL), patients may benefit with a loading dose of 400 mg/kg/dose once daily  $\times$  2, followed by 400–500 mg/kg/dose Q4 wk.

**Pediatric HIV with IgG <400 mg/dL:** See replacement therapy for antibody-deficient disorder from above.

**Bone marrow transplantation (may decrease risk for infection and death but not acute graft-versus-host disease):** Start at 400–500 mg/kg/dose to maintain IgG levels  $\geq$ 400 mg/dL resulting in dosage intervals ranging from once weekly to Q3–4 wk.

**Measles, postexposure prophylaxis for individuals with primary humoral immunodeficiency or without evidence of measles immunity (6–16 yr):** 400 mg/kg/dose as soon as possible and within 6 days after exposure.

**General guidelines for administration (see package insert of specific products):**

**IV:** Begin infusion at 0.01 mL/kg/min, double rate every 15–30 min, up to **max.** of 0.08 mL/kg/min. If adverse reactions occur, stop infusion until side effects subside and may restart at rate that was previously tolerated.

**Subcutaneous (SC) preparations:**

**Converting to SC route from previous IV dosage for patients receiving IV immune globulin (IVIG) infusions at regular intervals for at least 3 mo ( $\geq$ 2 yr):**

**Initial weekly dose (start 1 wk after last IV dose):**

SC Product	Dose Calculation (mg)	Dose Calculation (mL)
Hizentra	Dose (g) = 1.37 $\times$ Previous IVIG dose in grams (g) $\div$ number of weeks between IVIG doses	mL = multiply dose (g) by 5
Cutaquig	Dose (g) = 1.30 $\times$ Previous IVIG dose in grams (g) $\div$ number of weeks between IVIG doses	mL = multiply dose (g) by 6
Cuvitru	Dose (g) = 1.30 $\times$ Previous IVIG dose in grams (g) $\div$ number of weeks between IVIG doses	mL = multiply dose (g) by 5

Adjust dose over time by clinical response and serum IgG trough levels. Obtain a previous trough level from IVIG therapy prior to SC conversion and repeat trough level 2–3 mo after initiating the SC route. A goal trough with the SC route of  $\sim$ 290 mg/dL higher than a trough with the IV route has been recommended. A Q2 wk dosing interval may be used after establishing the patient individualized weekly dosage by multiplying the weekly dosage by 2.

**Measles, postexposure prophylaxis for high-risk patients:**

**Hizentra:** 0.2 g/kg/dose SC Q7 days  $\times$  2, or 0.4 g/kg/dose SC  $\times$  1

**SC administration:** Injection sites include the abdomen, thigh, upper arm, and/or lateral hip. Doses may be administered into multiple sites (spaced  $\geq$ 2 inches apart) simultaneously. See following table.

*Continued*

IMMUNE GLOBULIN *continued*

SC Product	Max. Simultaneous Injection Sites	Max. Infusion Rate	Max. Infusion Volume
Hizentra	8	<p>First infusion: 15 mL/hr per infusion site for primary immunodeficiency (PI) or 20 mL/hr per infusion site for chronic inflammatory demyelinating polyneuropathy (CIDP)</p> <p>Subsequent infusions: 25 mL/hr per infusion site for PI or 50 mL/hr per infusion site for CIDP</p>	<p>First infusion: 15 mL per infusion site for PI or 20 mL per infusion site for CIDP</p> <p>Subsequent infusions: 25 mL per infusion site for PI or 50 mL per infusion site for CIDP</p>
Cutaquig	6	<p><u>Child 2—&lt;18 yr:</u> First 2 infusions: ≤15 mL/hr per infusion site Subsequent infusions: Gradually increase as tolerated by 5–10 mL/hr per infusion site Q2–4 wk up to a <b>maximum rate</b> of 25 mL/hr per infusion site.</p> <p><u>18 yr and older:</u> First 2 infusions: ≤20 mL/hr per infusion site Subsequent infusions: Gradually increase as tolerated by 10 mL/hr per infusion site Q2–4 wk up to a <b>maximum rate</b> of 52 mL/hr per infusion site.</p>	<p><u>Child 2–6 yr:</u> First 2 infusions: ≤10 mL per infusion site Subsequent infusions: Gradually increase as tolerated by 5–10 mL per infusion site Q2–4 wk up to a <b>maximum</b> of 15.5 mL per infusion site.</p> <p><u>Child &gt;6—&lt;17 yr:</u> First 2 infusion: ≤15 mL per infusion site Subsequent infusions: Gradually increase as tolerated by 5–10 mL per infusion site Q2–4 wk up to a <b>maximum</b> of 29 mL per infusion site.</p> <p><u>17 yr and older:</u> First 2 infusion: ≤25 mL per infusion site Subsequent infusions: Gradually increase as tolerated by 10 mL per infusion site Q2–4 wk up to a <b>maximum</b> of 40 mL per infusion site.</p>
Cuvitru	4	<p>First 2 infusions: 10–20 mL/hr per infusion site Subsequent infusions: Gradually increase as tolerated to 60 mL/hr per infusion site.</p>	<p>First 2 infusions: &lt;40 kg: ≤20 mL per infusion site; ≥40 kg: ≤60 mL per infusion site Subsequent infusions (all weights): ≤60 mL per infusion site</p>

IMMUNE GLOBULIN *continued***Intramuscular (IM) preparations:**

Measles, postexposure prophylaxis for high-risk patients: 0.5 mL/kg/dose (**max. dose:** 15 mL) IM × 1 within 6 days of exposure

**IM administration:** Administer in the anterolateral aspects of the upper thigh or deltoid muscle of the upper arm. **Avoid** gluteal region due to risk of injury to sciatic nerve. Consider splitting doses for multiple injection sites to address age-specific maximum IM injection volumes.

**Use with caution** in patients with increased risk of thrombosis (e.g., hypercoagulable states, prolonged immobilization, indwelling catheters, estrogen use, thrombosis history, cardiovascular risks, and hyperviscosity) or hemolysis (e.g., non-O blood type, associated inflammatory conditions, and receiving high cumulative doses of immune globulins over several days).



May cause flushing, chills, fever, headache, and hypotension. Hypersensitivity reaction may occur when IV form is administered rapidly. Maltose-containing products may cause an osmotic diuresis. May cause **anaphylaxis** in IgA-deficient patients due to varied amounts of IgA. Some products are IgA depleted; consult a pharmacist.

To decrease risk of renal dysfunction, including acute renal failure, IV preparations containing sucrose should not be infused at a rate such that the amount of sucrose exceeds 3 mg/kg/min.

SC route provides higher serum trough levels, lower rate of adverse reactions, and shorter administration time when compared with the IV route. Use of adjusted body weight (ABW = Ideal Body Weight + 0.5 [Actual Body Weight – Ideal Body Weight]) for dosing in obese patients has been recommended.

Delay immunizations after immune globulin administration (see latest AAP Red Book for details).

**INDOMETHACIN**

Indocin, Tivorbex, and generics

**Nonsteroidal antiinflammatory agent**



C/X



1



Yes



Yes



No

**Caps:** 20, 25, 50 mg

Tivorbex: 20, 40 mg

**Sustained release caps:** 75 mg

**Oral suspension:** 25 mg/5 mL (237 mL); contains 1% alcohol

**Suppositories:** 50 mg (30s)

**Injection:** 1 mg; preservative free

**Antiinflammatory/rheumatoid arthritis:**

**Child (≥2 yr):**

**Immediate release:** Start at 1–2 mg/kg/24 hr ÷ TID–QID PO; **max. dose:** the lesser of 4 mg/kg/24 hr or 200 mg/24 hr

**Sustained release caps (≥15 yr):** Start with 75 mg once daily PO, may increase to 75 mg BID; **max. dose:** 150 mg/24 hr

**Adult (immediate release):** 50–150 mg/24 hr ÷ BID–QID PO; **max. dose:** 200 mg/24 hr

**Tivorbex:** 20 mg TID PO or 40 mg BID–TID PO

**Sustained release caps:** Start with 75 mg once daily PO, may increase to 75 mg BID; **max. dose:** 150 mg/24 hr



*Continued*

INDOMETHACIN *continued***Closure of ductus arteriosus:**

Infuse intravenously over 20–30 min:

Postnatal Age at Time of 1st Dose	Dose (mg/kg/dose Q12–24 hr) <sup>a</sup>		
	#1	#2	#3
<48 hr	0.2	0.1	0.1
2–7 days	0.2	0.2	0.2
>7 days	0.2	0.25	0.25

<sup>a</sup>Do not administer if urine output is <0.6 mL/kg/hr or anuric.

For infants &lt;1500 g, 0.1–0.2 mg/kg/dose IV Q24 hr may be given for an additional 3–5 days.

**Intraventricular hemorrhage prophylaxis:** 0.1 mg/kg/dose IV Q24 hr × 3 doses, initiated at 6–12 hr of age (give in consultation with a neonatologist)

**Contraindicated** in active bleeding, coagulation defects, necrotizing enterocolitis, and renal insufficiency (urine output <0.6 mL/kg/hr). **Use with caution** in cardiac dysfunction, hypertension, heart disease (risk for MI and stroke with prolonged use), and renal or hepatic impairment. May cause (especially in neonates) decreased urine output, thrombocytopenia, and decreased GI blood flow, and a reduction in the antihypertensive effects of  $\beta$ -blockers, hydralazine, and ACE inhibitors. **Fatal hepatitis reported in JRA treatment.** Pancreatitis has been reported. Thrombotic events have been observed in adults receiving high doses or prolonged duration of therapy. Monitor renal and hepatic function before and during use. False-positive test for urine cannabinoid screen may occur.

**Reduction in cerebral blood flow associated with rapid IV infusion;** infuse all IV doses over 20–30 min.

Sustained-release capsules are dosed once daily—BID.

Pregnancy category is “C” for prior to 30 wks’ gestation and “X” for 30 wk and greater. **Avoid use** at >30 wks’ gestation due to increased risk for premature closure of the fetal ductus arteriosus. Limit dose and duration of use at 20–30 wks’ gestation for concerns of fetal renal dysfunction and oligohydramnios.**INSULIN PREPARATIONS***Pancreatic hormone*

B



1



Yes



Yes



No

Many preparations, at concentrations of 100, 500 Units/mL. See [Chapter 10, Table 10.3](#).

Diluted concentrations of 1 Unit/mL or 10 Units/mL may be necessary for smaller doses in neonates and infants.

**Hyperkalemia:** See [Resuscitation Medications Table](#) in the front matter of the book.**DKA:** See [Chapter 10, Figure 10.1](#).

Accidental mix-ups between insulin products have been reported. Always check the insulin label before each use or injection.

When using insulin drip with new IV tubing, fill the tubing with the insulin infusion solution and wait for 30 min (before connecting tubing to the patient). Then flush the line and connect the IV line to the patient to start the infusion. This will ensure proper drug delivery. **Adjust dose in renal failure** (see [Chapter 31](#)). **Use with caution** and monitor closely in hepatic impairment.

**IODIDE**

See [Potassium Iodide](#).

**IODIXANOL**

Visipaque and generics

**Radiopaque agent, contrast media**



B



3



Yes



Yes



No

**Injection:** 270 mg/mL, 320 mg/mL (50, 100, 150, 200 mL); may contain EDTA and tromethamine (some products are preservative free)

**Consult with your local radiologist for specific dosing and administration recommendations.**

**IV contrast for CT scans:** Use Visipaque 320 mg/mL, check for contraindications, and all patients should be encouraged to drink extra fluids for 8 hr after the exam as allowed.

**eGFR  $\geq 60$  mL/min/1.73 m<sup>2</sup>:** 2 mL/kg/dose

**eGFR 30–60 mL/min/1.73 m<sup>2</sup>:** Administered a reduced dose with IV fluids + acetylcysteine to reduce risk for nephropathy

**eGFR  $< 30$  mL/min/1.73 m<sup>2</sup>:** **Avoid use** unless life-threatening situation where benefits outweigh the risk.

**PO contrast for CT scans:** See [Iohexol](#).

**Contraindicated** in children with prolonged fasting and the administration of a laxative before use. **Avoid use** via intrathecal route (serious life-threatening reactions may occur) and previous hypersensitivity reactions with contrast agents. **Use with caution** in asthma, hay fever, food allergy, congestive heart failure, severe liver or renal impairment, diabetic nephropathy, multiple myeloma, pheochromocytoma, hyperthyroidism, and sickle cell disease.

Common side effects include general discomfort, sensations of warmth, and pain. Cardiac arrest, dysrhythmia, heart failure, shock, severe dermatologic reactions (e.g., SJS, TEN), sickle cell crisis, thromboembolic disorder, acute kidney injury, and hypersensitivity reactions have been reported.

Children at higher risk for adverse events with contrast medium administration may include those having asthma, sensitivity to medication and/or allergens, congestive heart failure, or serum creatinine  $> 1.5$  mg/dL, and those aged  $< 12$  mo. Hypothyroidism or transient thyroid suppression following single or multiple exposures has been reported in children 0–3 yr old.

**Avoid use** with metformin as lactic acidosis and acute renal failure may occur. Postpone IV administration in patients who have recently received an oral cholecystographic contrast agent as renal toxicity may occur.

Visipaque 320 mg/mL has an osmolality of 290 mOsmol/kg than Omnipaque 350 mg/mL (884 mOsmol/kg) for a lower risk of contrast nephropathy. See product information for intravenous and intra-arterial administration guidelines.

**IOHEXOL**

Iohexol: Omnipaque 140, Omnipaque 180, Omnipaque 240, Omnipaque 300, Omnipaque 350, Omnipaque oral solution 9, Omnipaque oral solution 12, Oraltag

Iodixanol: see Visipaque

**Radiopaque agent, contrast media**



B



3



Yes



Yes



No

**Injection:**

Omnipaque 140: 302 mg iohexol equivalent to 140 mg iodine/mL (50 mL)

Continued

IOHEXOL *continued*

Omnipaque 180: 388 mg iohexol equivalent to 180 mg iodine/mL (10, 20 mL)

Omnipaque 240: 518 mg iohexol equivalent to 240 mg iodine/mL (10, 20, 50, 100, 150, 200 mL)

Omnipaque 300: 647 mg iohexol equivalent to 300 mg iodine/mL (10, 30, 50, 75, 100, 125, 150, 200, 500 mL)

Omnipaque 350: 755 mg iohexol equivalent to 350 mg iodine/mL (50, 75, 100, 125, 150, 200, 250, 500 mL)

**Oral solution:**

**Omnipaque, Oraltag:** 9 mg iodine/mL (19 mg/mL iohexol equivalent; 500 mL)

**Omnipaque:** 12 mg iodine/mL (26 mg iohexol equivalent; 500 mL)

All preparations contain tromethamine and edetate calcium disodium.

**Consult with your local radiologist for specific dosing and administration recommendations.**

**Oral contrast for CT scans:** Use oral Omnipaque 9 mg iodine/mL solution. If oral solution not available, mix 13 mL of the Omnipaque 350 injection with 500 mL of noncarbonated beverage to make an Omnipaque 9 mg iodine/mL solution. Administer dose all at once or over a period of up to 45 min. The more contrast the patient consumes, the better the CT study.

**1–7 kg:** 40–60 mL

**8–11 kg:** 110–160 mL

**12–15 kg:** 165–240 mL

**16–42 kg:** 250–360 mL

**>42 kg:** ≥480 mL

**IV contrast for CT scans:** See [Iodixanol](#).

Use in hysterosalpingography is **contraindicated** in pregnant women due to the potential risk to the fetus from an intrauterine procedure. **Avoid** use with history of severe cutaneous reactions to iohexol. **Use with caution** in dehydration, previous allergic reaction to a contrast medium, iodine sensitivity, asthma, hay fever, food allergy, congestive heart failure, severe liver or renal impairment, diabetic nephropathy, multiple myeloma, pheochromocytoma, hyperthyroidism, and sickle cell disease. Allergic reactions, arrhythmias, hypothyroidism, transient thyroid suppression, and nephrotoxicity have been reported.



Children at higher risk for adverse events with contrast medium administration may include those having asthma, sensitivity to medication and/or allergens, congestive heart failure, serum creatinine >1.5 mg/dL, or those aged <12 mo. Hypothyroidism or transient thyroid suppression following single or multiple exposures has been reported in children 0–3 yr old.

Use **NOT** recommended with drugs that lower seizure threshold (e.g., phenothiazines), amiodarone (increased risk of cardiotoxicity), and metformin (lactic acidosis and acute renal failure).

Many other uses exist; see package insert for additional information. Iohexol is particularly useful when barium sulfate is **contraindicated** in patients with suspected bowel perforation or those in whom aspiration of contrast medium is of concern. Oral dose is poorly absorbed from the normal GI tract (0.1%–0.5%); absorption increases with bowel perforation or bowel obstruction. Concentrations 302–755 mg iohexol/mL have osmolalities from 1.1 to 3 times that of plasma (285 mOsm/kg) and CSF (301 mOsm/kg) and may be hypertonic.

**IPRATROPIUM BROMIDE ± ALBUTEROL**

Atrovent HFA and generics

In combination with albuterol: Combivent

Respimat and generics; previously available as

DuoNeb

**Anticholinergic agent**



B/C



1



No



No



No

IPRATROPIUM BROMIDE ± ALBUTEROL *continued*

**Aerosol oral inhaler (Atrovent HFA):** 17 mCg/dose (200 actuations per canister, 12.9 g); contains alcohol

**Nebulized solution:** 0.02% (500 mCg/2.5 mL) (25s, 30s, 60s)

**Nasal spray:** 0.03% (21 mCg per actuation, 30 mL provides 345 sprays); 0.06% (42 mCg per actuation, 15 mL provides 165 sprays)

**In combination with albuterol:**

Nebulized solution (generic; previously available as DuoNeb): 0.5 mg ipratropium bromide and 2.5 mg albuterol in 3 mL (30s, 60s)

Inhalation spray (Combivent Respimat): 20 mCg ipratropium and 100 mCg albuterol per actuation (120 actuations per canister, 4 g); contains benzalkonium chloride

**Ipratropium:****Acute use in the ED or ICU for moderate/severe asthma exacerbations:****Nebulizer treatments:**

<12 yr: 250–500 mCg/dose Q20 min × 3, then Q2–4 hr PRN

≥12 yr: 500 mCg/dose Q20 min × 3, then Q2–4 hr PRN

**Inhaler:**

<12 yr: 4–8 puffs Q20 min PRN up to 3 hr

≥12 yr: 8 puffs Q20 min PRN up to 3 hr

**Nonacute use:****Inhaler:**

<12 yr: 1–2 puffs Q6 hr; **max. dose:** 12 puffs/24 hr

≥12 yr: 2–3 puffs Q6 hr; **max. dose:** 12 puffs/24 hr

**Nebulized treatments:**

**Infant:** 125–250 mCg/dose Q8 hr

**Child ≤12 yr:** 250–500 mCg/dose Q6–8 hr

**>12 yr and adult:** 250–500 mCg/dose Q6 hr

**Nasal spray:****0.03% strength (21 mCg/spray):**

**Allergic and nonallergic rhinitis (≥6 yr and adult):** 2 sprays (42 mCg) per nostril BID–TID

**0.06% strength (42 mCg/spray):**

**Rhinitis associated with common cold (use up to a total of 4 days; safety and efficacy have not been evaluated >4 days):**

**2–<5 yr (limited data):** 2 sprays (84 mCg) per nostril TID

**5–11 yr:** 2 sprays (84 mCg) per nostril TID

**12 yr–adult:** 2 sprays (84 mCg) per nostril TID–QID

**Rhinitis associated with seasonal allergies:**

**2–<5 yr (limited data):** 1 spray (42 mCg) per nostril TID × 14 days

**≥5 yr–adult:** 2 sprays (84 mCg) per nostril QID; use up to a total of 3 weeks (safety and efficacy have not been evaluated for >3 weeks)

**Ipratropium in combination with albuterol:****Acute use in the ED or ICU for severe asthma exacerbations:****Nebulizer treatments:**

<12 yr: 1.5 or 3 mL (0.25 mg ipratropium and 1.25 mg albuterol or 0.5 mg ipratropium and 2.5 mg albuterol) Q20 min × 3 then PRN for up to 3 hr

≥12 yr: 3 mL (0.5 mg ipratropium and 2.5 mg albuterol) Q20 min × 3 then PRN for up to 3 hr



*Continued*

IPRATROPIUM BROMIDE ± ALBUTEROL *continued***Inhalation spray (Combivent Respimat):**

<12 yr: 4–8 sprays Q20 min × 3 then PRN for up to 3 hr

≥12 yr: 8 sprays Q20 min × 3 then PRN for up to 3 hr

**Contraindicated** in atropine hypersensitivity. **Use with caution** in narrow-angle glaucoma or bladder neck obstruction, though ipratropium has fewer anticholinergic systemic effects than atropine. May cause anxiety, dizziness, headache, GI discomfort, and cough with inhaler or nebulized use. Epistaxis, nasal congestion, and dry mouth/throat have been reported with the nasal spray. Reversible anisocoria may occur with unintentional aerosolization of drug to the eyes, particularly with mask nebulizers. Proven efficacy of nebulized solution in pediatrics is currently limited to reactive airway disease management in the emergency room and intensive care unit areas.



Current aerosol inhaler product does not contain soy products. Combination ipratropium and albuterol products are currently approved for use only in adults and have not been formally studied in children. See [albuterol](#) for additional remarks if using the combination product.

Bronchodilation onset of action is 1–3 min with peak effects within 1.5–2 hr and duration of action of 4–6 hr.

Shake inhaler well prior to use with spacer. Nebulized solution may be mixed with albuterol (or use the combination product).

Pregnancy category is “C” for Combivent Respimat. Breastfeeding safety **extrapolated** from safety of atropine.

**IRON DEXTRAN**

See [Iron—Injectable Preparations](#).

**IRON—INJECTABLE PREPARATIONS**

Ferric gluconate: Ferrlecit and generics

Iron dextran: INFeD

Iron sucrose: Venofer

***Parenteral iron***

B/C



2



No



No



No

**Injection:**

Ferric gluconate (Ferrlecit and generics): 62.5 mg/mL (12.5 mg elemental Fe/mL) (5 mL); contains 9 mg/mL benzyl alcohol and 20% sucrose

Iron dextran (INFeD): 50 mg/mL (50 mg elemental Fe/mL) (2 mL); products containing phenol 0.5% are only for IM administration; products containing sodium chloride 0.9% can be administered via the IM or IV route

Iron sucrose (Venofer): 20 mg/mL (20 mg elemental Fe/mL) (2.5, 5, 10 mL); contains 300 mg/mL sucrose; preservative free

**FERRIC GLUCONATE (IV):**

**Iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoietin therapy (most require 8 doses at 8 sequential dialysis treatments to achieve a favorable response):**



**Child ≥6 yr:** 1.5 mg/kg elemental Fe (0.12 mL/kg) IV; **max. dose:** 125 mg elemental Fe/dose. Dilute dose in 25 mL NS and infuse over 1 hr.

**Adult:** 125 mg elemental Fe in 100 mL NS IV; infuse over 1 hr. Most require a minimum cumulative dose of 1 g elemental Fe administered over 8 sessions.

IRON—INJECTABLE PREPARATIONS *continued***IRON DEXTRAN (IV OR IM):****Iron deficiency anemia (≥4 mo, child, adolescent):****Test dose** (IV over 5 min or IM; may initiate treatment dose 1 hr after test dose):

&lt;10 kg: 10 mg

10–20 kg: 15 mg

≥20 kg: 25 mg

Total replacement dose of iron dextran (mL) =  $0.0442 \times \text{lean body wt (kg)} \times (\text{desired Hb [g/dL]} - \text{measured Hb [g/dL]}) + (0.26 \times \text{lean body wt [kg]})$ . For patients weighing 5–15 kg, use actual body weight instead lean body weight. Total replacement dose is divided into smaller daily doses if exceeds respective IV or IM daily **max. doses** (see below).

**Acute blood loss:** Total replacement dose of iron dextran (mL) =  $0.02 \times \text{blood loss (mL)} \times \text{hematocrit expressed as decimal fraction}$ . Assumes 1 mL of RBC = 1 mg elemental iron

If no reaction to test dose, give remainder of replacement dose ÷ over 2–3 daily doses.

**Max. daily IV dose:** 100 mg**Max. daily IM dose:**

&lt;5 kg: 0.5 mL (25 mg)

5–10 kg: 1 mL (50 mg)

&gt;10 kg: 2 mL (100 mg)

**IM administration:** Use “Z-track” technique.

**IV administration:** Dilute in NS at a **max. concentration** of 50 mg/mL and infuse over 1–6 hr at a **max. rate** of 50 mg/min.

**IRON SUCROSE (IV):****Test dose (optional):** Infuse 25% of first day dose up to a **max. of 25 mg undiluted over 30 min.****Iron deficiency anemia in patients with chronic kidney disease:****Child:**

**ESRD on hemodialysis:** (limited data from 14 children): 1 mg/kg/dialysis was adequate for correcting ferritin levels and 0.3 mg/kg/dialysis was successful in maintaining ferritin levels between 193 and 250 mCg/L. Doses were administered during the last hr of each dialysis and are recommended at a frequency of 3 times a week. A 10 mg test dose was administered.

**Nonrenal iron deficiency, refractory to PO therapy (limited data):** Calculate total iron replacement dose (mg) =  $0.6 \times \text{wt (kg)} \times (100 - [\text{measured Hb} \div \text{desired Hb} \times 100])$ . Replacement dose is administered by giving an initial dose of 5–7 mg/kg (**max. dose:** 100 mg/24 hr) followed by a maintenance dose of 5–7 mg/kg/dose (**max. dose:** 300 mg/24 hr) Q3–7 days until total iron replacement dose is achieved.

**Adult:**

**Hemodialysis-dependent:** 100 mg elemental Fe 1–3 times a wk during dialysis up to a total cumulative dose of 1000 mg. May continue to administer at lowest dose to maintain target Hb, Hct, and iron levels.

**Nonhemodialysis-dependent:** 200 mg elemental Fe on 5 different days over a 2 wk period (total cumulative dose: 1000 mg)

**IV administration:** May administer undiluted over 2–5 min. For an infusion, dilute each 100 mg with a **max.** of 100 mL NS and infuse over at least 15 min.

Oral therapy with iron salts is preferred; injectable routes are painful. Gluconate and sucrose salts may be better tolerated than iron dextran. Adverse effects include hypotension, GI disturbances, fever, rash, myalgia, arthralgias, cramps, and headaches. Hypersensitivity reactions have been reported for iron dextran and sucrose products; use of test dose prior to first therapeutic dose is recommended.



IRON—INJECTABLE PREPARATIONS *continued*

**IM administration is only possible with iron dextran salt product.** Follow infusion recommendations for specific product. Monitor vital signs during IV infusion. TIBC levels may not be meaningful within 3 wk after dosing.

Efficacy and safety of iron sucrose for maintenance therapy have been evaluated in children 2 yr and older with CKD and receiving erythropoietin therapy. Common side effects include headache, respiratory tract viral infection, peritonitis, vomiting, pyrexia, dizziness, and cough.

Pregnancy category is “B” for ferric gluconate and iron sucrose and “C” for iron dextran.


**IRON—ORAL PREPARATIONS**

Ferrous sulfate: Fer-In-Sol, Slow FE, Slow Iron, and many generics

Ferrous gluconate: Ferate and generics

Ferrous fumarate: Ferretts, Ferrimin 150, and generics

Polysaccharide-iron complex: EZFE 200, Poly-Iron 150, iFerex 150, NovaFerrum, NovaFerrum Pediatric Drops, and many other brands; previously available as Niferex

**Oral iron supplements****Ferrous sulfate (20% elemental Fe):**

Drops and oral solution (Fer-In-Sol and generics; OTC): 75 mg (15 mg Fe)/1 mL (50 mL); may contain 0.2% alcohol and sodium bisulfite

Oral elixir and liquid (OTC): 220 mg (44 mg Fe)/5 mL (473 mL); may contain 5% alcohol

Oral syrup (OTC): 300 mg (60 mg Fe)/5 mL

Tabs (OTC): 325 mg (65 mg Fe)

Extended release tabs (Slow FE, Slow Iron, and generics; OTC): 142 mg (45 mg Fe), 160 mg (50 mg Fe), 324 mg (65 mg Fe), and 325 mg (65 mg Fe)

**Ferrous gluconate (12% elemental Fe):**

Tabs (Ferate and generics; OTC): 240 mg (27 mg Fe), 324 mg (37.5 mg Fe)

**Ferrous fumarate (33% elemental Fe):**

Tabs (all OTC):

**Generics:** 90 mg (29.5 mg Fe), 324 mg (106 mg Fe)

**Ferretts:** 325 mg (106 mg Fe)

**Ferrimin 150:** 456 mg (150 mg Fe)

**Polysaccharide-iron complex and ferrous bis-glycinate chelate (expressed in mg elemental Fe):**

Caps (OTC): 50 mg (NovaFerrum 50), 150 mg (Poly-Iron 150, iFerex 150, and others), 200 mg (EZFE 200); 150 mg strength may contain 50 mg vitamin C

Oral liquid (NovaFerrum 125; OTC): 125 mg/5 mL (180 mL); contains sodium benzoate and 100 units cholecalciferol/5 mL

Oral drops (NovaFerrum Pediatric Drops; OTC): 15 mg/mL (120 mL); contains sodium benzoate

**Iron deficiency anemia, treatment:**

**Premature infant:** 2–4 mg elemental Fe/kg/24 hr ÷ once daily—BID PO; **max. dose:** 15 mg elemental Fe/24 hr

**Child:** 3–6 mg elemental Fe/kg/24 hr ÷ BID—TID PO

**Adult:** 60–100 mg elemental Fe BID PO up to 60 mg elemental Fe QID

**Prophylaxis:**

**Child:** Give dose below PO ÷ once daily—TID



IRON—ORAL PREPARATIONS *continued*

**Premature infant:** 2 mg elemental Fe/kg/24 hr; **max. dose:** 15 mg elemental Fe/24 hr

**Full-term infant:** 1–2 mg elemental Fe/kg/24 hr; **max. dose:** 15 mg elemental Fe/24 hr

**Child 2–12 yr:** 2 mg elemental Fe/kg/24 hr; **max. dose:** 30 mg elemental Fe/24 hr

**Adolescent and adult:** 60 mg elemental Fe/24 hr PO once daily

**Contraindicated** in hemolytic anemia and hemochromatosis. **Avoid** use in GI tract inflammation. May produce constipation, dark stools (false-positive guaiac is controversial), nausea, and epigastric pain. Iron and tetracycline inhibit each other's absorption. Antacids may decrease iron absorption. 

Iron preparations are variably absorbed. Less GI irritation when given with or after meals. Vitamin C, 200 mg per 30 mg iron, may enhance absorption. Liquid iron preparations may stain teeth. Give with dropper or drink through straw.

Pregnancy category is "A" for ferrous sulfate and is unknown for the other salt forms.

**IRON SUCROSE**

See [Iron—Injectable Preparations](#).

**ISONIAZID**

Generics, INH; previously available as Nydravid and Laniazid

**Antituberculous agent**



C



1



Yes



Yes



No

**Tabs:** 100, 300 mg

**Syrup:** 50 mg/5 mL (473 mL); contains parabens

**Injection:** 100 mg/mL (10 mL); contains 0.25% chlorobutanol

See most recent edition of the **AAP Red Book** for details and length of therapy. 

**TB Treatment (other dosing regimens exist; see remarks):**

**Infant and child:**

10–15 mg/kg (**max. dose:** 300 mg) PO once daily or 20–30 mg/kg (**max. dose:** 900 mg) per dose three times weekly with rifampin for uncomplicated pulmonary tuberculosis in compliant patients. Additional drugs are necessary in complicated disease.

**Adult:**

5 mg/kg (**max. dose:** 300 mg) PO once daily or 15 mg/kg (**max. dose:** 900 mg) per dose three times weekly with rifampin. Additional drugs are necessary in complicated disease.

**For INH-resistant TB:** Discuss with Health Department or consult ID specialist.

**Should not be used alone for treatment. Contraindicated** in acute liver disease and previous isoniazid-associated hepatitis. Peripheral neuropathy, optic neuritis, seizures, encephalopathy, psychosis, and hepatic side effects may occur with higher doses, especially in combination with rifampin. Severe liver injury has been reported in children and adults treated for latent TB. Follow LFTs monthly. Pancreatitis, toxic epidermal necrolysis, and DRESS have been reported. May cause false-positive urine glucose test. 

Supplemental pyridoxine (1–2 mg/kg/24 hr) is recommended for prevention of neurologic side effects. Inhibits CYP 450 1A2, 2C9, 2C19, and 3A3/4 microsomal enzymes; decrease dose of carbamazepine, diazepam, phenytoin, and prednisone. Prednisone may decrease isoniazid's effects. Also a substrate and inducer of CYP 450 2E1 and may potentiate acetaminophen hepatotoxicity. **Avoid** daily alcohol use to reduce risk for isoniazid-induced hepatitis.

*Continued*

ISONIAZID *continued*

May be given IM (same as oral doses) when oral therapy is not possible. Administer oral doses 1 hr prior to and 2 hr after meals. Aluminum salts may decrease absorption. **Adjust dose in renal failure (see Chapter 31).**

**ISOPROTERENOL**

Generics; previously available as Isuprel  
**Adrenergic agonist**



**Injection:** 0.2 mg/mL (1, 5 mL); preparations may be preservative free or contain disodium EDTA

**NOTE:** The dosage units for adults are in mCg/min, compared to mCg/kg/min for children.

**IV infusion:**


**Neonate—child:** 0.05–2 mCg/kg/min; start at minimum dose and increase every 5–10 min by 0.1 mCg/kg/min until desired effect or onset of toxicity; **max. dose:** 2 mCg/kg/min

**Adult:** 2–20 mCg/min; titrate to desired effect

**Use with caution** in diabetes, hyperthyroidism, renal disease, CHF, ischemia, or aortic stenosis. May cause flushing, ventricular arrhythmias, profound hypotension, anxiety, and myocardial ischemia. Monitor heart rate, respiratory rate, and blood pressure. **Not** for treatment of asystole or for use in cardiac arrests, unless bradycardia is due to heart block. Continuous infusion for bronchodilatation must be gradually tapered over a 24–48 hr period to prevent rebound bronchospasm. Tolerance may occur with prolonged use. Clinical deterioration, myocardial necrosis, congestive heart failure, and **death** have been reported with continuous infusion use in refractory asthmatic children.

**ISOTRETINOIN**

Absorica, Absorica LD, Accutane, Amnesteem, Claravis, Myorisan, Zenatane, and generics  
**Retinoic acid, vitamin A derivative**

**Caps, standard formulation (all products contain soybean oil):**

**Absorica:** 10, 20, 25, 30, 35, 40 mg

**Amnesteem:** 10, 20, 40 mg; contains EDTA

**Accutane, Claravis, Myorisan, Zenatane:** 10, 20, 30, 40 mg; may contain EDTA

**Generics:** 10, 20, 25, 30, 35, 40 mg

**Caps, micronized formulation (not substitutable with standard formulation due to different bioavailability):**

**Absorica LD:** 8, 16, 20, 24, 28, 32 mg; contains soybean oil and polysorbate 80

**Cystic acne/severe recalcitrant nodular acne (see remarks):****Child (>12 yr) and adult:**

**Standard formulation:** 0.5–2 mg/kg/24 hr ÷ BID PO × 15–20 wk or until the total cyst count decreases by 70%, whichever comes first. Dosages as low as 0.05 mg/kg/24 hr have been reported to be beneficial.

**Micronized formulation (Absorica LD):** 0.4–0.8 mg/kg/24 hr ÷ BID PO × 15–20 wk or until the total cyst count decreases by 70%, whichever comes first. Dosages as high as 1.6 mg/kg/24 hr ÷ BID have been used for severe cases in adults.

ISOTRETINOIN *continued*

Micronized (Absorica LD) and standard formulations are not bioequivalent and are **NOT substitutable**.

**Contraindicated during pregnancy; known teratogen. Use with caution** in females during childbearing years. May cause conjunctivitis, xerosis, pruritus, photosensitivity reactions (**avoid** exposure to sunlight and use sunscreen), epistaxis, anemia, hyperlipidemia, pseudotumor cerebri (especially in combination with tetracyclines; **avoid** this combination), cheilitis, bone pain, muscle aches, skeletal changes, lethargy, nausea, vomiting, elevated ESR, mental depression, aggressive/violent behavior, and psychosis. Serious skin reactions (e.g., Stevens-Johnson syndrome, TEN) have been reported.

Elevation of liver enzymes may occur during treatment; a dosage reduction or continued treatment may result in normalization. Discontinue use if liver enzymes do not normalize or if hepatitis is suspected.

To avoid additive toxic effects, **do not** take vitamin A concomitantly. Increases clearance of carbamazepine. Hormonal birth control (oral, injectable, and implantable) failures have been reported with concurrent use. Monitor CBC, ESR, triglycerides, and LFTs.

Prescribers, site pharmacists, patients, and wholesalers must register with the iPLEDGE system (a risk minimization program) at [www.ipledgeprogram.com](http://www.ipledgeprogram.com) or 1-866-495-0654 before doses are dispensed. Prescriptions may not be written for more than a 1-mo supply.

**ITRACONAZOLE**

Sporanox, Tolsura, and generics

**Antifungal agent**

C



3



Yes



Yes



No

**Caps:****Sporanox and generics:** 100 mg**Tolsura:** 65 mg

**Oral solution (Sporanox and generics):** 10 mg/mL (150 mL); contains hydroxypropyl- $\beta$ -cyclodextrin, propylene glycol, and saccharin

**Neonate (limited data in full-term neonates treated for tinea capitis):** 5 mg/kg/24 hr PO once daily  $\times$  6 wk



**Child (limited data):** 3–5 mg/kg/24 hr PO  $\div$  once daily–BID; dosages as high as 5–10 mg/kg/24 hr have been used for *Aspergillus* prophylaxis in chronic granulomatous disease. Population pharmacokinetic data in pediatric cystic fibrosis and bone marrow transplant patients suggest an oral liquid dosage of 10 mg/kg/24 hr PO  $\div$  BID or oral capsule dosage of 20 mg/kg/24 hr PO  $\div$  BID to be more reliable for achieving trough plasma levels between 500 and 2000 ng/mL.

**Prophylaxis for recurrence of opportunistic disease in HIV:*****Coccidioides* spp.:** 2–5 mg/kg/dose PO Q12 hr; **max. dose:** 400 mg/24 hr***Cryptococcal meningitis:*** 5 mg/kg/dose PO Q24 hr; **max. dose:** 200 mg/24 hr**Histoplasmosis:** 5–10 mg/kg/dose PO once daily; **max. dose:** 200 mg/dose**Treatment of opportunistic disease in HIV:****Candidiasis:** 5 mg/kg/24 hr PO  $\div$  Q12–24 hr; **max. dose:** 400 mg/24 hr***Coccidioides* spp. pneumonia:** 2–5 mg/kg/dose (**max. dose:** 200 mg/dose) PO TID  $\times$  3 days, followed by 2–5 mg/kg/dose PO BID; **max. dose:** 400 mg/24 hr***Cryptococcal meningitis:*** 2.5–5 mg/kg/dose (**max. dose:** 200 mg/dose) PO TID  $\times$  3 days, followed by 5–10 mg/kg/24 hr (**max. dose:** 400 mg/24 hr)  $\div$  once to twice daily for a minimum of 8 wk*Continued*

ITRACONAZOLE *continued*

**Histoplasmosis:** 2–5 mg/kg/dose (**max. dose:** 200 mg/dose) PO TID × 3 days, followed by 2–5 mg/kg/dose (**max. dose:** 200 mg/dose) PO BID × 12 mo

**Adult:**

**Blastomycosis and nonmeningeal histoplasmosis:** 200 mg PO TID × 3 days, followed by 200 mg PO once daily or BID depending on severity

**Aspergillosis and severe infections (use oral solution):** 600 mg/24 hr PO ÷ TID × 3–4 days, followed by 200–400 mg/24 hr ÷ BID; **max. dose:** 600 mg/24 hr ÷ TID

Oral solution and capsule dosage form should NOT be used interchangeably; oral solution is more bioavailable. Only the oral solution has been demonstrated effective for oral and/or esophageal candidiasis. **Contraindicated** in CHF and certain interacting drugs (see below). **Use with caution** in hepatic and/or renal impairment, cardiac dysrhythmias, and azole hypersensitivity. May cause GI symptoms, headaches, rash, liver enzyme elevation, hepatitis, and hypokalemia. Double/blurred vision, dizziness, and tremor have been reported.



Like ketoconazole, it inhibits the activity of the CYP450 3A4 drug metabolizing isoenzyme. Thus, the coadministration of cisapride, dofetilide, felodipine, methadone, nisoldipine, pimozide, quinidine, triazolam, lovastatin, simvastatin, ergot derivatives, and oral midazolam is contraindicated. May increase systemic hormone concentrations of oral contraceptives. See remarks in [Ketoconazole](#) for additional drug interaction information.

Steady-state serum concentrations of >0.25 mg/L itraconazole and >1 mg/L hydroxyitraconazole (metabolite) have been recommended. Recommended serum sampling time at steady state: any time after 2 wk after continuous dosing. Itraconazole has a 34–42-hour  $T_{1/2}$ .

Administer oral solution on an empty stomach but administer capsules with food. Oral capsule bioavailability has been shown to be reduced in immunocompromised patients. Achlorhydria reduces absorption of the drug. **Do not** use oral liquid dosage form in patients with GFR <30 mL/min because hydroxypropyl- $\beta$ -cyclodextrin excipient has reduced clearance with renal failure.

**IVACAFTOR**

Kalydeco

***Cystic fibrosis transmembrane conductance regulator potentiator***



B



?



Yes



Yes



Yes

**Oral granules:** 25 mg (56 packets), 50 mg (56 packets), 75 mg (56 packets)

**Tabs:** 150 mg (56 tabs)

**Cystic fibrosis (see remarks):**

4–<6 mo and  $\geq 5$  kg (use oral granules): 25 mg PO Q12 hr

$\geq 6$  mo and child <6 yr (use oral granules):

5–<7 kg: 25 mg PO Q12 hr

7–<14 kg: 50 mg PO Q12 hr

$\geq 14$  kg: 75 mg PO Q12 hr

$\geq 6$  yr, adolescent, and adult: 150 mg PO Q12 hr

**Dosage modification with hepatic impairment:**

**Child-Pugh class B:** Use above dosage with a once-daily dosage interval.

**Child-Pugh class C:** Studies have not been completed but exposure is expected to be higher than class B; use above dosage with caution once daily or with a less frequent dosage interval.

**Hepatotoxicity (ALT or AST > 5 × ULN) during therapy:** Hold doses and reinstate therapy after resolution of enzyme elevation if the benefits outweigh the risks.



IVACAFTOR *continued***Dosage modification when used with CYP 450 3A inhibitors:**

Age	Weight (kg)	Dosed With Strong CYP 450 3A Inhibitor (e.g., Ketoconazole, Itraconazole, Voriconazole, Posaconazole, Clarithromycin)	Dosed With Moderate CYP 450 3A Inhibitor (e.g., Erythromycin, Fluconazole)
4—<6 mo	≥5 kg	Use not recommended	Use not recommended
≥6 mo and <6 yr	5—<7 kg	25 mg PO twice weekly	25 mg PO once daily
	7—<14 kg	50 mg PO twice weekly	50 mg PO once daily
≥6 yr, adolescent, and adult	≥14 kg	75 mg PO twice weekly	75 mg PO once daily
	All	150 mg PO twice weekly	150 mg PO once daily

Works as a CFTR potentiator on class 3 CFTR mutations. Originally indicated for G551D CFTR mutation but has since been approved for many other mutations; see product information for list of approved mutations. Use is not recommended in children 4—<6 mo with hepatic impairment (due to variability of CYP enzyme maturation) and/or taking moderate or strong CYP 450 3A inhibitors.



Common side effects include rash, abdominal pain, diarrhea, nausea, dizziness, headache, nasal congestion, pharyngitis, and URIs. Increased liver enzymes and cataracts may occur; monitor baseline AST/ALT and ocular exam. Repeat AST/ALT every 3 months for the first year followed by annual assessments. Repeat ocular exams annually. May cause a false-positive urine drug screen test for cannabinoids. **Use with caution** in patients with CrCl ≤30 mL/min; has not been studied. Ivacaftor is CYP 450 3A substrate; see dose modification table in the dosing section. Use with strong CYP 450 3A inducers (e.g., rifampin, rifabutin, carbamazepine, St. John's wort) is not recommended. Ivacaftor may inhibit CYP 450 2C9 and increase the effects/toxicity of warfarin. Always evaluate potential drug-drug interactions; see <https://www.kalydecohcp.com/drug-interactions>. **Avoid** food or drink containing grapefruit or Seville oranges.

Administer all doses with high-fat foods to ensure absorption. Oral granules can be mixed with 5 mL of soft foods or liquids such as puréed fruits or vegetables, yogurt, applesauce, water, breast milk, infant formula, milk, or juice. Once mixed, it should be consumed within an hour. If a dose (all dosage forms) is missed within 6 hr of a scheduled dose, administer a dose immediately. However, if the missed dose is >6 hr, skip that dose and resume therapy at the next scheduled dose. Never take a double dose for a missed dose.

**IVERMECTIN**

Stromectol and generics; previously available as Sklice and Soolantra

**Anthelmintic**

C



2



No



No



No

**Tab (Stromectol and generics):** 3 mg

**Topical lotion (OTC and prescription; previously available as Sklice):** 0.5% (117 g); contains parabens

Continued

IVERMECTIN *continued*

**Topical cream (previously available as Soolantra):** 1% (45 g); contains cetyl alcohol, EDTA, parabens, and propylene glycol

**Systemic use:**

**Cutaneous lava migrans or strongyloidiasis:** 0.2 mg/kg/dose PO once daily  $\times$  1–2 days for cutaneous lava migrans and  $\times$  2 days for strongyloidiasis; dosing by body weight (see first table)

**Scabies:** 0.2 mg/kg/dose PO  $\times$  1, followed by repeat second dose in 7 or 10–14 days, dosing by body weight as follows:



Weight (kg)	Oral Dose
15–24	3 mg
25–35	6 mg
36–50	9 mg
51–65	12 mg
66–79	15 mg
$\geq 80$	0.2 mg/kg

**Onchocerciasis:** 0.15 mg/kg/dose PO  $\times$  1; may repeat dose every 6–12 mo until asymptomatic; dosing by body weight as follows:

Weight (kg)	Single Oral Dose
15–25	3 mg
26–44	6 mg
45–64	9 mg
65–84	12 mg
$\geq 85$	0.15 mg/kg

**Topical use:****Lotion:**

**Head lice infestation ( $\geq 6$  mo to adult):** Apply lotion to dry hair in sufficient amounts (up to one full tube) to thoroughly coat the hair and scalp for 10 min. Then rinse off with water.

**Cream:**

**Rosacea (Adult):** Apply cream to each affected area once daily.

**Systemic Use:** Rare fatal encephalopathy may occur in onchocerciasis with a concurrent heavy *Loa loa* infection. Reactions experienced with strongyloidiasis include diarrhea, nausea, vomiting, pruritus, rash, dizziness, and drowsiness. Adverse reactions experienced in onchocerciasis include cutaneous or systemic allergic/inflammatory reactions of varying severity (Mazzotti reaction) and ophthalmologic reactions. Neurotoxicity ranging from somnolence/drowsiness, stupor, and coma has been reported in patients without onchocerciasis or in patients with onchocerciasis in the absence of *Loa loa*. Specific reactions may include arthralgia/synovitis, lymph node enlargement and tenderness, pruritus, edema, fever, orthostatic hypotension, and tachycardia. Therapy for postural hypotension may include oral hydration, recumbency, IV normal saline, and/or IV steroids. Antihistamines or aspirin, or both, have been used for most mild-to-moderate cases.



Ivermectin may increase the effects/toxicity of warfarin. Administer oral doses on an empty stomach with water.

**Topical Use:** Safety and efficacy have not been established for children  $< 6$  mo. Common side effects include conjunctivitis, ocular hyperemia, eye irritation, dandruff, dry skin, and skin burning. Contact dermatitis has been reported. Not for oral, ophthalmic, or intravaginal use. Use of lotion for children should be supervised by an adult to prevent oral ingestion.

## K

## KALYDECO

See [Ivacaftor](#).

## KETAMINE

Ketalar and generics

**General anesthetic**

?



3



No



Yes



No

**Injection:** 10 mg/mL (20 mL), 50 mg/mL (10 mL), 100 mg/mL (5, 10 mL); contains benzethonium chloride

**Child (see remarks):****Sedation:****PO:** 5 mg/kg × 1**IV:** 0.5–1 mg/kg; **max. dose:** 150 mg/dose**IM:** 2–5 mg/kg × 1**Intranasal (≥3 mo; limited data):** 3–6 mg/kg × 1, administering half of total dose per nostril using a mucosal atomizer device**Adult:****Analgesia with sedation:****IV (see remarks):** 0.2–1 mg/kg**IM:** 0.5–4 mg/kg

**Contraindicated** in significant hypertension and known hypersensitivity to the drug. **Use with caution** in elevated ICP, aneurysms, thyrotoxicosis, CHF, angina, and psychotic disorders.



May cause hypertension, hypotension, emergence reactions, tachycardia, laryngospasm, respiratory depression, and stimulation of salivary secretions. Cystitis has been reported with chronic use/abuse. Intravenous use may induce general anesthesia. Hepatobiliary dysfunction with or without biliary obstruction has also been reported with recurrent use. Diplopia and nystagmus have been noted following IV administration. False-positive test for urine phencyclidine (PCP) screen may occur. Co-administration of an anticholinergic agent may be added in situations of clinically significant hypersalivation in patients with impaired ability to mobilize secretions. Benzodiazepine may be used in the presence of a ketamine-associated recovery reaction (prophylaxis use in adults may be beneficial). Ondansetron prophylaxis can slightly reduce vomiting. See *Ann Emerg Med*. 2001;57:449–461 for additional use information in the emergency department.

Drug is a substrate for CYP 450 2B6, 2C9, and 3A4 isoenzymes. Consider potential drug interactions with respective enzyme inhibitors and inducers, especially with prolonged use. Use with aminophylline or theophylline may increase risk for seizures. Use with sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine. Use with CNS depressants may result in profound sedation, respiratory depression, and coma.

Rate of IV infusion should **not** exceed 0.5 mg/kg/min and **should not** be administered in less than 60 sec. For additional information including onset and duration of action, see [Chapter 6](#).

## KETOCONAZOLE

Nizoral, Xolegel, Extina, Ketodan, and generics

**Antifungal agent, imidazole**

C



2



No



Yes



No

Continued

KETOCONAZOLE *continued***Tabs:** 200 mg**Oral suspension:** 100 mg/5 mL **Cream:** 2% (15, 30, 60 g); contains sulfites**Gel:** 2% [Xolegel] (45 g); contains 34% alcohol and polyethylene glycol**Topical foam:** 2% [Extina, Ketodan, and generics] (50, 100 g); contains alcohol and propylene glycol**Shampoo:**

1% [Nizoral (OTC)] (125, 200 mL)

2% [generics] (120 mL)

**Oral:****Child  $\geq 2$  yr and adolescent:** 3.3–6.6 mg/kg/24 hr once daily**Adult:** 200–400 mg/24 hr once daily**Max. dose** (all ages): 400 mg/24 hr**Topical ( $\geq 12$  yr; see remarks):****Cream:** 1 application to affected area once daily  $\times$  2–6 wk. For seborrheic dermatitis, use BID  $\times$  4 wk.**Gel (Xolegel):** 1 application to affected area once daily  $\times$  2 wk for seborrheic dermatitis**Foam:** 1 application to affected area BID  $\times$  4 wk for seborrheic dermatitis**Shampoo:****1% (Dandruff):** Apply to wet hair, generously lather, rinse thoroughly; use every 3–4 days for up to 8 wk PRN.**2% (Tinea versicolor):** Apply to wet hair and leave on for 5 minutes before rinsing  $\times$  1.

The systemic dosage form should NOT be first-line treatment for any fungal infection due to concerns of hepatotoxicity and adrenal gland effects (per the FDA).

Monitor LFTs in long-term use and adrenal function for patients at risk. Drugs that decrease gastric acidity will decrease absorption. May cause nausea, vomiting, rash, headache, pruritus, and fever. Hepatotoxicity (including fatal cases) has been reported; use with hepatic impairment is **contraindicated**. High doses may decrease adrenocortical function and serum testosterone levels. Hypersensitivity reactions (including anaphylaxis) have been reported with all dosage forms.

Safety and efficacy with topical use in seborrheic dermatitis for patients  $>12$  yr of age have been established. **Avoid** topical use on breast or nipples in nursing mothers.

Inhibits CYP 450 3A4. **Contraindicated** when used with cisapride, disopyramide, methadone, mefloquine, quinidine, terfenadine, pimozide, or any drug that can prolong the QT interval (because of risk for cardiac arrhythmias), and HMG-CoA reductase inhibitors (e.g., simvastatin and lovastatin). Excessive sedation and prolonged hypnotic effects with triazolam use (also **contraindicated**). May increase levels/effects of phenytoin, digoxin, cyclosporine, corticosteroids, nevirapine, protease inhibitors, and warfarin. Achlorhydria, phenobarbital, rifampin, isoniazid, H<sub>2</sub> blockers, antacids, and omeprazole can decrease levels of oral ketoconazole.

Administering oral doses with food or acidic beverages and 2 hr prior to antacids will increase absorption. For topical products, **avoid contact** with eyes and other mucous membranes.

To use shampoo, wet hair and scalp with water, apply sufficient amount to scalp, and gently massage for about 1 min. Rinse hair thoroughly, reapply shampoo and leave on the scalp for an additional 3 min, and rinse.

**KETOROLAC**

Many generics (previously available as Toradol),  
Acular, Acular LS, Acuvail

**Nonsteroidal antiinflammatory agent**

C/X



3



Yes



Yes



No

KETOROLAC *continued*

**Injection:** 15 mg/mL (1 mL), 30 mg/mL (1, 2 mL); contains 10% alcohol and tromethamine

**Tabs:** 10 mg; contains tromethamine

**Ophthalmic solution (all containing tromethamine):**

Acular and generics: 0.5% (3, 5, 10 mL); contains benzalkonium chloride and EDTA

Acular LS and generics: 0.4% (5 mL); contains benzalkonium chloride and EDTA

Acuvail: 0.45% (0.4 mL; 30s); preservative free

**Systemic use is not to exceed 3–5 days, regardless of systemic route of administration (IM, IV, PO).**

**IM/IV:**

**Child:** 0.5 mg/kg/dose IM/IV Q6–8 hr. **Max. dose:** 30 mg Q6 hr or 120 mg/24 hr

**Adult:** 30 mg IM/IV Q6 hr. **Max. dose:** 120 mg/24 hr

**PO:**

**Child 2–≤16 yr (limited data):** 1 mg/kg/dose Q4-6 hr; **max. dose:** 10 mg/dose and 40 mg/24 hr

**Child >16 yr and adult:** 10 mg PRN Q4-6 hr; **max. dose:** 40 mg/24 hr

**Ophthalmic (see remarks):****Postoperative cataract surgery:**

≥2 yr—adult (use 0.5%): 1 drop in each affected eye QID starting 24 hr after surgery × 2 wk

**Postoperative corneal refractive surgery:**

≥3 yr—adult (use 0.4%): 1 drop in each affected eye QID PRN for up to 4 days after surgery

**Seasonal allergic conjunctivitis:**

≥2 yr—adult (use 0.5%): 1 drop in each eye QID

May cause GI bleeding, nausea, dyspepsia, drowsiness, decreased platelet function, and interstitial nephritis. **Not recommended** in patients at increased risk of bleeding. **Do not use** in hepatic or renal failure. **Use with caution** in heart disease (risk for MI and stroke with prolonged use). False-positive test for urine cannabinoid screen may occur with systemic use.



Duration of therapy for ophthalmic use: 14 days after cataract surgery, and up to 4 days after corneal refractive surgery. Also indicated for ocular itching associated with seasonal allergic conjunctivitis. Bronchospasm or asthma exacerbations, allergic reactions, corneal erosion/perforation/thinning/melt, and epithelial breakdown have been reported with ophthalmic use. **Avoid** having the tip of the ophthalmic bottle touch the eye or surrounding structures to decrease risk for ocular infections.

Pregnancy category is “C” for prior to 30 wks’ gestation and “X” for 30 wk and greater. **Avoid use** at >30 wks’ gestation due to increased risk for premature closure of the fetal ductus arteriosus. Limit dose and duration of use at 20–30 wks’ gestation for concerns of fetal renal dysfunction and oligohydramnios.

## L

**LACOSAMIDE**

Vimpat and generics

**Anticonvulsant**



C



2



Yes



Yes



No

**Oral solution:** 10 mg/mL (200 mL); contains aspartame, parabens, and propylene glycol

**Tabs:** 50, 100, 150, 200 mg

**Injection:** 10 mg/mL (20 mL); preservative free

*Continued*

LACOSAMIDE *continued*

**Partial-onset seizures as monotherapy or adjunctive therapy:**

**Child (1 mo—<17 yr):**



Weight (kg)	Initial Dosage	Titration Regimen	Maintenance Dosage
<6	PO: 1 mg/kg/dose BID IV: 0.66 mg/kg/dose TID	PO: Increase by 1 mg/kg/dose BID every 7 days IV: Increase by 0.66 mg/kg/dose TID every 7 days	PO: 3.75–7.5 mg/kg/dose BID IV: 2.5–5 mg/kg/dose TID
6–<30	PO/IV: 1 mg/kg/dose BID	PO/IV: Increase by 1 mg/kg/dose BID every 7 days	PO/IV: 3–6 mg/kg/dose BID
30–<50	PO/IV: 1 mg/kg/dose BID	PO/IV Increase by 1 mg/kg/dose BID every 7 days	PO/IV: 2–4 mg/kg/dose BID
≥50	PO/IV: 50 mg BID	PO/IV: Increase by 50 mg BID every 7 days	PO/IV: Monotherapy: 150–200 mg BID Adjunctive therapy: 100–200 mg BID

**Primary generalized tonic-clonic seizures as adjunctive therapy:**

**Child (4 yr—<17 yr):**

Weight (kg)	Initial Dosage	Titration Regimen	Maintenance Dosage
11–<30	PO/IV: 1 mg/kg/dose BID	PO/IV: Increase by 1 mg/kg/dose BID every 7 days	PO/IV: 3–6 mg/kg/dose BID
30–<50	PO/IV: 1 mg/kg/dose BID	PO/IV Increase by 1 mg/kg/dose BID every 7 days	PO/IV: 2–4 mg/kg/dose BID
≥50	PO/IV: 50 mg BID	PO/IV: Increase by 50 mg BID every 7 days	PO/IV: Monotherapy: 150–200 mg BID Adjunctive therapy: 100–200 mg BID

**Partial-onset seizures as monotherapy or adjunctive therapy, and primary generalized tonic-clonic seizures as adjunctive therapy:**

**17 yr and adult:**

Initial Dosage (PO/IV)	Titration Regimen (PO/IV)	Maintenance Dosage (PO/IV)
Monotherapy: 100 mg BID <sup>a</sup> Adjunctive therapy: 50 mg BID <sup>a</sup>	Increase by 50 mg BID every 7 days	Monotherapy: 150–200 mg BID Adjunctive therapy: 100–200 mg BID Doses up to 300 mg BID may provide benefit for some patients for both indications

<sup>a</sup>Alternative initial dosage (under medical supervision due to increased risk for CNS side effects): 200 mg × 1 and start 12 hr later, 100 mg BID × 7 days then titrate to the respective monotherapy or adjunctive therapy goal.

LACOSAMIDE *continued*

**Converting from other single antiepileptic drug (AED) to lacosamide monotherapy:** administer lacosamide in combination with the established single AED for at least 3 days before tapering. Gradually withdrawing the concomitant AED over 6 wk is recommended.

**IV use:** Use same dose when converting from PO to IV and vice versa; except for pediatric patients <6 kg (see above table). IV use should be considered for short-term use as clinical treatment evaluations have been limited to 5 days of consecutive use.

**Use with caution** with known cardiac conduction problems (e.g., second-degree AV block), severe cardiac disease (e.g., MI or heart failure), concomitant use with drugs known to prolong PR interval, and renal (see [Chapter 31](#)) and hepatic impairment. Lacosamide undergoes 95% renal excretion; a reduction of 25% of the **maximum** dosage is recommended for adult and pediatric patients with severe renal impairment (CrCl <30 mL/min and ESRD), or with mild/moderate hepatic impairment. Use is **not recommended** in severe hepatic impairment. Dose reduction may be also necessary with concurrent strong inhibitor of CYP 450 3A4 or 2C9 medication. Patients with mild/moderate hepatic impairment should be observed closely during dose titration. Oral bioavailability is approximately 100%. 

Most common side effects in adults include diplopia, headache, dizziness, and nausea. Somnolence and irritability were frequently reported in pediatric studies. Patients should be advised of potential dizziness, ataxia, and syncope with use. Multiorgan hypersensitivity reactions (including DRESS, affecting the skin, kidney, and liver), worsening of seizures, agranulocytosis, and euphoria (high doses) have been reported. As with other AEDs, monitor for suicidal behavior and ideation.


Oral doses may be administered with or without food. Swallow tablets whole; **do not** cut tablets. IV doses should be administered over 30–60 min. **Do not** abruptly withdraw therapy; gradually taper to prevent potential seizures.

Lacosamide is present in human milk as increased sleepiness in breastfed infants has been reported.

**LABETALOL**

Generics; previously available as Normodyne and Trandate

**Adrenergic antagonist ( $\alpha$  and  $\beta$ ), antihypertensive**



C/D 2 No Yes No

**Tabs:** 100, 200, 300 mg

**Injection:** 5 mg/mL (4, 20, 40 mL); contains parabens

**Injection, premixed:**

In 0.72% NaCl: 1 mg/mL (100, 200, 300 mL)

In D<sub>5</sub>W: 1 mg/mL (200 mL)

**Oral suspension:** 10 mg/mL , 40 mg/mL 

**Child (see remarks):**

**PO:** Initial: 1–3 mg/kg/24 hr ÷ BID. May increase up to a **maximum** of 12 mg/kg/24 hr up to 1200 mg/24 hr 

**IV:** Hypertensive emergency (start at lowest dose and titrate to effect; see [Chapter 4](#) for additional information):

**Intermittent dose:** 0.2–1 mg/kg/dose Q10 min PRN; **max. dose:** 40 mg/dose

**Infusion (hypertensive emergencies):** 0.4–1 mg/kg/hr to a **max. dose** of 3 mg/kg/hr; may initiate with a 0.2–1 mg/kg bolus; **max. bolus:** 40 mg

**Adult (see remarks):**

**PO:** 100 mg BID, increase by 100 mg/dose Q2–3 days PRN to a **max. dose** of 2.4 g/24 hr. Usual range: 200–800 mg/24hr ÷ BID

*Continued*

LABETALOL *continued*

**IV:** Hypertensive emergency (start at lowest dose and titrate to effect with a **max. total dose** of 300 mg for both methods of administration):

**Intermittent dose:** 10–20 mg/dose Q10 min PRN; **max. dose:** 80 mg/dose

**Infusion:** 0.5–2 mg/min, increase to titrate to response; may initiate with a 10–20 mg bolus over 2 min

**Contraindicated** in asthma, pulmonary edema, cardiogenic shock, and heart block. May cause orthostatic hypotension, edema, CHF, bradycardia, AV conduction disturbances, bronchospasm, urinary retention, and skin tingling. **Use with caution** in hepatic disease (dose reduction may be necessary), diabetes, liver function test elevation, hepatic necrosis, and hepatitis. Cholestatic jaundice has been reported. Use with digitalis glycosides may increase risk for bradycardia. False-positive test for urine amphetamine screen may occur.

Patient should remain supine for up to 3 hr after IV administration. Pregnancy category changes to “D” if used in second or third trimesters.

Onset of action: PO: 1–4 hr; IV: 5–15 min

**LACTULOSE**

Constulose, Enulose, Generlac, Kristalose, and generics

**Ammonium detoxicant, hyperosmotic laxative**



B



?



No



No



No

**Oral syrup:** 10 g/15 mL (15, 30, 237, 473, 946 mL); contains galactose, lactose, and other sugars

**Crystals for reconstitution (Kristalose and generics):** 10 g (15s, 30s), 20 g (30s)

**Constipation:**

**Child:** 1.5–3 mL/kg/24 hr PO ÷ once daily–BID; **max. dose:** 90 mL/24 hr

**Adult:** 15–30 mL/24 hr PO once daily × 1–2 days; may increase to 60 mL/24 hr if needed

**Portal systemic encephalopathy (adjust dose to produce 2–3 soft stools/day):**

**Infant:** 2.5–10 mL/24 hr PO ÷ TID–QID

**Child and adolescent:** 40–90 mL/24 hr PO ÷ TID–QID

**Adult:** 30–45 mL/dose PO TID–QID; acute episodes 30–45 mL Q1–2 hr until 2–3 soft stools/day

**Rectal (adult):** 300 mL diluted in 700 mL water or NS in 30–60 min retention enema; may give Q4–8 hr

**Contraindicated** in galactosemia. **Use with caution** in diabetes mellitus. GI discomfort and diarrhea may occur. For portal systemic encephalopathy, monitor serum ammonia, serum potassium, and fluid status.

**Do not use** with antacids. Dissolve crystal dosage form with 4 ounces of water or juice. All doses may be administered with juice, milk, or water.

**LAMIVUDINE**

Epivir, Epivir-HBV, 3TC, and generics

**Antiviral agent, nucleoside analogue reverse transcriptase inhibitor**



C



2



Yes



Yes



No

**Tabs:**

**Epivir-HBV and generics:** 100 mg

**Epivir and generics:** 150, 300 mg

**Oral solution:**

**Epivir-HBV:** 5 mg/mL (240 mL) contains parabens

LAMIVUDINE *continued*

**Epivir and generics:** 10 mg/mL (240 mL); contains parabens

**HIV:** See <https://clinicalinfo.hiv.gov/en/guidelines>

HIV vertical transmission and presumptive treatment during high-risk situations (mothers who received no antepartum antiretroviral therapy, mothers who received only intrapartum antiretroviral therapy, mothers who receive antepartum antiretroviral therapy, but with suboptimal viral suppression ( $\geq 50$  copies/mL) within 4 weeks prior to delivery, or mothers with acute or primary HIV infection during pregnancy or breastfeeding (immediately discontinue breastfeeding). Transition to a treatment regimen if positive HIV diagnosis is confirmed and discontinue use after a negative diagnosis; see **Chapter 17** for additional information:

**Neonate  $\geq 32$  wks' gestation (use in combination with zidovudine and either raltegravir or nevirapine):** 2 mg/kg/dose PO BID within 6–12 hr after birth. Increase dose to 4 mg/kg/dose PO BID at 4 wk of age.

**Chronic hepatitis B, non—HIV exposed or infected (see remarks):**

**2–17 yr:** 3 mg/kg/dose PO once daily up to a **max. dose** of 100 mg/dose

**18 and adult:** 100 mg/dose PO once daily

See <https://clinicalinfo.hiv.gov/en/guidelines> for remarks for use in HIV. Oral tablet dosage form is preferred over oral solution for children  $\geq 14$  kg treated for HIV because subjects in the ARROW clinical trial receiving oral solution had lower rates of HIV viral suppression and lower plasma lamivudine exposure, and developed viral resistance more frequently.

May cause headache, fatigue, GI disturbances, rash, and myalgia/arthralgia. Lactic acidosis, severe hepatomegaly with steatosis, posttreatment exacerbations of hepatitis B and ALT elevations, pancreatitis, and emergence of resistant viral strains have been reported. Treatment should be suspended in any patient developing clinical or laboratory signs of lactic acidosis or hepatotoxicity.

**Avoid use** with sorbitol-containing medicines, as sorbitol reduces lamivudine exposure. Concomitant use with co-trimoxazole (TMP/SMX) may result in increased lamivudine levels.

**Use Epivir-HBV product for chronic hepatitis B** indication only. Safety and effectiveness beyond 1 yr have not been determined. If serum HBV DNA remains detectable after 24 wk of lamivudine monotherapy, consider switching to an alternative therapy. Patients with both HIV and hepatitis B should use the higher HIV doses along with an appropriate combination regimen.

May be administered with food. **Adjust dose in renal impairment (see Chapter 31).**

**LAMOTRIGINE**

Lamictal, Subvenite, Lamictal ODT, Lamictal XR, and generics

**Anticonvulsant**



C



2



Yes



Yes



No

**Tabs (Lamictal, Subvenite, and generics):** 25, 100, 150, 200 mg

**Extended release tabs (Lamictal XR and generics):** 25, 50, 100, 200, 250, 300 mg

**Chewable tabs (Lamictal and generics):** 5, 25 mg

**Orally disintegrated tabs (Lamictal ODT and generics):** 25, 50, 100, 200 mg

**Oral suspension:** 1 mg/mL

**Infant and child  $< 2$  yr adjunctive seizure therapy (limited data; use immediate release dosage forms):**

**WITH** enzyme-inducing AEDs (e.g., carbamazepine, phenytoin, phenobarbital, primidone) and **WITHOUT** valproic acid:

*Continued*

LAMOTRIGINE *continued*

**Wk 1 and 2:** 0.6 mg/kg/24 hr PO ÷ once daily—BID

**Wk 3 and 4:** 1.2 mg/kg/24 hr PO ÷ once daily—BID

**Usual maintenance dose (>wk 4):** Titrate dose to effect PRN by increasing dosage every week by no more than 1.2 mg/kg/24 hr up to a **maximum** of 15.6 mg/kg/24 hr ÷ TID **not to exceed** 400 mg/24 hr.

**WITH AEDs containing valproic acid or non-enzyme-inducing AEDs:**

**Wk 1 and 2:** 0.15 mg/kg/24 hr PO ÷ once daily—BID

**Wk 3 and 4:** 0.3 mg/kg/24 hr PO ÷ once daily—BID

**Usual maintenance dose (>wk 4):** Titrate dose to effect PRN by increasing dosage every week by no more than 0.3 mg/kg/24 hr up to a **maximum** of 5.1 mg/kg/24 hr ÷ TID **not to exceed** 200 mg/24 hr.

**Child 2–12 yr adjunctive seizure therapy (maintenance doses for patients <30 kg may need to be increased as much as 50%; use immediate release dosage forms; see remarks):**

**WITH AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid:**

**Wk 1 and 2:** 0.3 mg/kg/24 hr PO ÷ once daily—BID; rounded down to the nearest whole tablet

**Wk 3 and 4:** 0.6 mg/kg/24 hr PO ÷ BID; rounded down to the nearest whole tablet

**Usual maintenance dose (>wk 4):** 4.5–7.5 mg/kg/24 hr PO ÷ BID; titrate to effect. To achieve the usual maintenance dose, increase doses Q1–2 wk by 0.6 mg/kg/24 hr (rounded down to the nearest whole tablet) as needed.

**Max. dose:** 300 mg/24 hr ÷ BID

**WITH enzyme-inducing AEDs WITHOUT valproic acid:**

**Wk 1 and 2:** 0.6 mg/kg/24 hr PO ÷ BID; rounded down to the nearest whole tablet

**Wk 3 and 4:** 1.2 mg/kg/24 hr PO ÷ BID; rounded down to the nearest whole tablet

**Usual maintenance dose (>wk 4):** 5–15 mg/kg/24 hr PO ÷ BID; titrate to effect. To achieve the usual maintenance dose, increase doses Q1–2 wk by 1.2 mg/kg/24 hr (rounded down to the nearest whole tablet) as needed.

**Max. dose:** 400 mg/24 hr ÷ BID

**WITH AEDs WITH valproic acid:**

**Wk 1 and 2:** 0.15 mg/kg/24 hr PO ÷ once daily—BID; rounded down to the nearest whole tablet (see following table)

**Wk 3 and 4:** 0.3 mg/kg/24 hr PO ÷ once daily—BID; rounded down to the nearest whole tablet (see following table)

Weight (kg)	Weeks 1 and 2	Weeks 3 and 4
6.7–14	2 mg every other day	2 mg once daily
14.1–27	2 mg once daily	4 mg/24 hr ÷ once daily—BID
27.1–34	4 mg/24 hr ÷ once daily—BID	8 mg/24 hr ÷ once daily—BID
34.1–40	5 mg once daily	10 mg/24 hr ÷ once daily—BID

**Usual maintenance dose:** 1–5 mg/kg/24 hr PO ÷ once daily—BID; titrate to effect. To achieve the usual maintenance dose, increase doses Q1–2 wk by 0.3 mg/kg/24 hr (rounded down to the nearest whole tablet) as needed. If adding lamotrigine with valproic acid alone, usual maintenance dose is 1–3 mg/kg/24 hr.

LAMOTRIGINE *continued*

**Max. dose:** 200 mg/24 hr

**>12 yr and adult adjunctive therapy:**

**WITH AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproic acid (use immediate release dosage forms):**

**Wk 1 and 2:** 25 mg once daily PO

**Wk 3 and 4:** 50 mg once daily PO

**Usual maintenance dose (>wk 4):** 225–375 mg/24 hr ÷ BID PO; titrate to effect. To achieve the usual maintenance dose, increase doses Q1–2 wk by 50 mg/24 hr as needed.

**WITH enzyme-inducing AEDs WITHOUT valproic acid (use immediate release dosage forms):**

**Wk 1 and 2:** 50 mg once daily PO

**Wk 3 and 4:** 50 mg BID PO

**Usual maintenance dose (>wk 4):** 300–500 mg/24 hr ÷ BID PO; titrate to effect. To achieve the usual maintenance dose, increase doses Q1–2 wk by 100 mg/24 hr as needed. Doses as high as 700 mg/24 hr ÷ BID have been used.

**WITH AEDs WITH valproic acid: (use immediate release dosage forms)**

**Wk 1 and 2:** 25 mg every other day PO

**Wk 3 and 4:** 25 mg once daily PO

**Usual maintenance dose (>wk 4):** 100–400 mg/24 hr ÷ once daily–BID PO, titrate to effect. To achieve the usual maintenance dose, increase doses Q1–2 wk by 25–50 mg/24 hr as needed. If adding lamotrigene to valproic acid alone, usual maintenance dose is 100–200 mg/24 hr.

**Extended release dosage form (Lamictal XR):**

**≥13 yr and adult adjunctive therapy (dose increases at wk 8 or later should not exceed 100 mg/24 hr at weekly intervals; see remarks):**

	<b>Weeks 1 and 2</b>	<b>Weeks 3 and 4</b>	<b>Week 5</b>	<b>Week 6</b>	<b>Week 7</b>	<b>Maintenance Dose</b>
Patient NOT receiving enzyme-inducing drugs (e.g., carbamazepine) OR valproic acid	25 mg once daily	50 mg once daily	100 mg once daily	150 mg once daily	200 mg once daily	300–400 mg once daily
Patients receiving enzyme-inducing drugs (e.g., carbamazepine) WITHOUT valproic acid	50 mg once daily	100 mg once daily	200 mg once daily	300 mg once daily	400 mg once daily	400–600 mg once daily
Patients receiving valproic acid	25 mg every other day	25 mg once daily	50 mg once daily	100 mg once daily	150 mg once daily	200–250 mg once daily

*Continued*

LAMOTRIGINE *continued*

**Converting Adjunctive Therapy to Lamotrigine Monotherapy:**

	<b>Immediate Release Lamotrigine Dosage Form Regimen (≥16 Yr and Adult)</b>	<b>Extended Release Tabs (≥13 Yr and Adult)</b>
<p>Patient NOT receiving enzyme-inducing drugs (e.g., carbamazepine) OR valproic acid</p>	<p>No specific dosing guidelines provided</p>	<p>After achieving a maintenance dose of 250–300 mg/24 hr with the above recommendations, withdraw the concomitant AED by 20% decrements each week over a 4-wk period.</p>
<p>Patients receiving enzyme-inducing drugs (e.g., carbamazepine) WITHOUT valproic acid</p>	<p>After achieving a maintenance dose of 500 mg/24 hr with the above recommendations, withdraw the concomitant enzyme-inducing AED by 20% decrements each week over a 4-wk period.</p>	<p>After achieving a maintenance dose of 500 mg/24 hr with the above recommendations, withdraw the concomitant enzyme-inducing AED by 20% decrements each week over a 4-wk period. After 2 wk of the complete withdrawal of enzyme-inducing AED, lamotrigine may be decreased no faster than 100 mg/24 hr each week to the maintenance dose of 250–300 mg/24 hr.</p>
<p>Patients receiving valproic acid</p>	<p><i>Step 1:</i> Achieve maintenance dose of 200 mg/24 hr with the above recommendations. <i>Step 2:</i> Decrease valproic acid by decrements no greater than 500 mg/24 hr per week to reach 500 mg/24 hr and maintain for 1 wk. <i>Step 3:</i> Increase lamotrigine to 300 mg/24 hr and decrease valproic acid to 250 mg/24 hr; maintain both for 1 wk. <i>Step 4:</i> Increase lamotrigine by 100 mg/24 hr Q7 days until reaching maintenance dose of 500 mg/24 hr and discontinue valproic acid.</p>	<p><i>Step 1:</i> Achieve maintenance dose of 150 mg/24 hr with the above recommendations. <i>Step 2:</i> Decrease valproic acid by decrements no greater than 500 mg/24 hr per week to reach 500 mg/24 hr and maintain for 1 wk. <i>Step 3:</i> Increase lamotrigine to 200 mg/24 hr and decrease valproic acid to 250 mg/24 hr; maintain both for 1 wk. <i>Step 4:</i> Increase lamotrigine to 250–300 mg/24 hr and discontinue valproic acid.</p>

LAMOTRIGINE *continued*

Bipolar disease (use immediate release dosage forms; see remarks):

≥18 yr and adult (PO; see table below):

	Weeks 1 and 2	Weeks 3 and 4	Week 5	Weeks 6 and Thereafter
Patient NOT receiving enzyme-inducing drugs (e.g., carbamazepine) OR valproic acid	25 mg/24 hr	50 mg/24 hr ÷ once daily—BID	100 mg/24 hr ÷ once daily—BID	200 mg/24 hr ÷ once daily—BID (target dose); some patients may require 400 mg/24 hr
Patients receiving enzyme-inducing drugs (e.g., carbamazepine) WITHOUT valproic acid	50 mg/24 hr ÷ once daily—BID	100 mg/24 hr ÷ once daily—BID	200 mg/24 hr ÷ once daily—BID	Week 6: 300 mg/24 hr ÷ once daily—BID Week 7 and thereafter: may increase to 400 mg/24 hr ÷ once daily—BID <sup>a</sup>
Patients receiving valproic acid	25 mg every other day	25 mg once daily	50 mg/24 hr ÷ once daily—BID	100 mg/24 hr ÷ once daily—BID (target dose) <sup>b</sup>

<sup>a</sup>If carbamazepine or other enzyme-inducing drug is discontinued, maintain current lamotrigine dose for 1 wk, then decrease daily lamotrigine dose in 100 mg increments at weekly intervals until 200 mg/24 hr.

<sup>b</sup>If valproic acid is discontinued, increase by 50 mg at weekly intervals, up to 200 mg/24 hr.

Enzyme-inducing AEDs include carbamazepine, phenytoin, and phenobarbital. Stevens-Johnson syndrome, toxic epidermal necrolysis, and other potentially life-threatening rashes have been reported in children (0.3%–0.8%) and adults (0.08%–0.3%) for adjunctive therapy in seizures. Reported rates for adults treated for bipolar/mood disorders as monotherapy and adjunctive therapy are 0.08% and 0.13%, respectively. May cause fatigue, drowsiness, ataxia, rash (especially with valproic acid), headache, nausea, vomiting, and abdominal pain. Diplopia, nystagmus, aseptic meningitis, hemophagocytic lymphohistiocytosis, aggression, and alopecia have also been reported. False-positive test for urine phencyclidine (PCP) screen may occur.



Use during the first 3 mo of pregnancy may result in a higher chance for cleft lip or cleft palate in the newborn. Suicidal behavior or ideation has been reported. In vitro studies show lamotrigine having Class IB antiarrhythmic activity; access the benefit/risk for use in patients with clinically significant structural or functional heart disease, including cardiac channelopathies.

If converting from immediate release to extended release dosage form, match the initial dose of extended release to the total daily dose of the immediate release dosage and administer once daily. Adjust dose as needed with the recommended dosage guidelines.

Reduce maintenance dose in renal failure. Reduce all doses (initial, escalation, and maintenance) in liver dysfunction defined by the Child-Pugh grading system as follows:

Grade B: Moderate dysfunction; decrease dose by ~50%

Grade C: Severe dysfunction; decrease dose by ~75%

Withdrawal symptoms may occur if discontinued suddenly. A stepwise dose reduction over ≥2 wk (~50% per week) is recommended unless safety concerns require a more rapid withdrawal.

Continued

LAMOTRIGINE *continued*

Lamotrigine is metabolized by uridine 5'-diphospho-glucuronyl transferases (UGT). Strong and moderate inducers of CYP 450 3A4 are known to induce UGT to increase lamotrigine clearance. Acetaminophen, carbamazepine, oral contraceptives (ethinylestradiol), phenobarbital, primidone, phenytoin, and rifampin may decrease levels of lamotrigine. Valproic acid may increase levels. Use with sodium channel blockers may increase the risk of arrhythmias. False-positive urine drug screen for phencyclidine (PCP) has been reported.

Safety and efficacy for maintenance therapy for bipolar disorder in 10–17 yr olds were not established in an RCT with 301 subjects.

**LANSOPRAZOLE**

Prevacid, Prevacid SoluTab, First-Lansoprazole, and generics

**Gastric acid pump inhibitor**



B



?



Yes



Yes



Yes

**Caps, delayed release:** 15 mg (OTC and Rx), 30 mg

**Tab, disintegrating delayed release (Prevacid SoluTab and generics):** 15 mg (OTC and Rx), 30 mg; contains aspartame

**Oral suspension (First-Lansoprazole):** 3 mg/mL (90, 150, 300 mL); contains benzyl alcohol

**Neonate:** 0.5–1.5 mg/kg/24 hr PO ÷ once daily—BID

**Short-term treatment of GERD and erosive esophagitis, for up to 12 wk (see remarks):**

**Infant ≥3 mo:** 15 mg/24 hr PO ÷ once daily—BID

**Child 1–11 yr (initial dose using fixed dosing):**

≤30 kg: 15 mg PO once daily

>30 kg: 30 mg PO once daily

**Subsequent dosage increase (if needed):** May be increased up to 30 mg PO BID after ≥2 wk of therapy without response at initial dose level

**Alternative weight-based dosing:**

**Infant:** 1–2 mg/kg/24 hr PO once daily

**Child and adolescent:** 0.7–3 mg/kg/24 hr PO ÷ once daily—BID; **max. dose:** 30 mg/24 hr

**12 yr—adult:**

**GERD:** 15 mg PO once daily for up to 8 wk

**Erosive esophagitis:** 30 mg PO once daily × 8–16 wk; maintenance dose: 15 mg PO once daily

**Duodenal ulcer:** 15 mg PO once daily × 4 wk; maintenance dose: 15 mg PO once daily

**Gastric ulcer and NSAID-induced ulcer:**

**Prophylaxis:** 15 mg PO once daily for up to 12 wk

**Treatment:** 30 mg PO once daily for up to 8 wk

**Hypersecretory conditions:** 60 mg PO once daily; dosage may be increased up to 90 mg PO BID, where doses >120 mg/24 hr are divided BID

Common side effects include GI discomfort, headache, fatigue, rash, and taste perversion.

Hypersensitivity reactions may result in anaphylaxis, angioedema, severe cutaneous reactions, bronchospasm, interstitial nephritis, and urticaria. Prolonged use may result in vitamin B<sub>12</sub> deficiency (≥2 yr) or hypomagnesemia (>1 yr; sometimes leading to hypocalcemia, tetany, arrhythmias, and seizures). Microscopic colitis, resulting in watery diarrhea, has been reported, and switching to an alternative proton pump inhibitor may be beneficial in resolving diarrhea. Increased risk for fundic gland polyps has been associated with long-term use >1 yr.

Drug is a substrate for CYP 450 2C19 and 3A3/4. Ultrarapid metabolizers of CYP 450 2C19 may experience reduced efficacy and may require a 4-fold higher dosage. Lansoprazole may decrease levels of itraconazole, ketoconazole, iron salts, mycophenolate, nelfinavir, and ampicillin esters; and

LANSOPRAZOLE *continued*

increase the levels/effects of methotrexate, tacrolimus, and warfarin. Theophylline clearance may be enhanced. **Reduce dose in severe hepatic impairment.** May be used in combination with clarithromycin and amoxicillin for *H. pylori* infections.

A multicenter, double-blind, parallel-group study in infants (1 mo–1 yr) with GERD was no more effective than placebo.

Administer all oral doses before meals and 30 min prior to sucralfate. **Do not** crush or chew the granules (all dosage forms). Capsule may be opened and intact granules may be administered in an acidic beverage or food (e.g., apple or cranberry juice, applesauce). **Do not** break or cut the orally disintegrating tablets. Use of oral disintegrating tablets dissolved in water has been reported to clog and block oral syringes and feeding tubes (gastric and jejunostomy). For IV use, use a 1.2-micron in-line filter.

**LEVALBUTEROL**

Xopenex, Xopenex HFA, and generics

$\beta_2$  adrenergic agonist



C



1



No



No



No

**Prediluted nebulized solution:** 0.31 mg in 3 mL, 0.63 mg in 3 mL, 1.25 mg in 3 mL (30s)

**Concentrated nebulized solution:** 1.25 mg/0.5 mL (0.5 mL) (30s)

**Aerosol inhaler (MDI; Xopenex HFA and generics):** 45 mCg/actuation (15 g delivers 200 doses)

**Nonacute exacerbation symptom relief:****Nebulizer:**

**≤4 yr (limited data):** Start at 0.31 mg inhaled Q4–6 hr PRN; dose may be increased up to 1.25 mg Q4–6 hr PRN.

**5–11 yr:** Start at 0.31 mg inhaled Q8 hr PRN; dose may be increased to 0.63 mg Q8 hr PRN.

**≥12 yr and adult:** Start at 0.63 mg inhaled Q6–8 hr PRN; dose may be increased to 1.25 mg inhaled Q6–8 hr PRN.

**Aerosol inhaler (MDI):**

**≥4 yr and adult:** 2 puffs Q4–6 hr PRN

**For use in acute exacerbations, more aggressive dosing may be used.**

R-isomer of racemic albuterol. Side effects include tachycardia, palpitations, tremor, insomnia, nervousness, nausea, and headache.

Clinical data in children demonstrate levalbuterol is as effective as albuterol with fewer cardiac side effects at equipotent doses (0.31–0.63 mg levalbuterol ~2.5 mg albuterol). However, when higher doses of levalbuterol (1.25 mg) were compared to 2.5 mg albuterol, changes in heart rate were similar.

More frequent dosing may be necessary in asthma exacerbation.

**LEVETIRACETAM**

Keppra, Keppra XR, Elepsia XR, Roweepra, Spritam, and generics

**Anticonvulsant**



C



2



Yes



No



No

**Tabs:** 250, 500, 750, 1000 mg

**Extended release tabs (Q24 hr dosing; see remarks):**

**Keppra XR and generics:** 500, 750 mg

**Elepsia XR:** 1000, 1500 mg

**Tabs, disintegrating (Spritam; see remarks):** 250, 500, 750, 1000 mg

*Continued*


LEVETIRACETAM *continued*

**Oral solution:** 100 mg/mL (480 mL); dye free and contains parabens

**Injection:** 100 mg/mL (5 mL); contains 45 mg sodium chloride and 8.2 mg sodium acetate trihydrate per 100 mg drug

**Premixed injection:** 500 mg/100 mL in 0.82% sodium chloride, 1000 mg/100 mL in 0.75% sodium chloride, 1500 mg/100 mL in 0.54% sodium chloride

**Partial seizures (mono or adjunctive therapy; using immediate release dosage forms and IV):**



**Infant (1–5 mo):** Start at 7 mg/kg/dose PO/IV BID; increase by 7 mg/kg/dose BID every 2 wk as tolerated to the recommended dose of 21 mg/kg/dose BID. An average daily dose of 35 mg/kg/24 hr was reported in clinical trials.

**Infant ≥6 mo—child 3 yr (>20 kg):** Start at 10 mg/kg/dose PO/IV BID; increase by 10 mg/kg/dose BID every 2 wk as tolerated to the recommended dose of 25 mg/kg/dose BID. An average daily dose of 47 mg/kg/24 hr was reported in clinical trials.

**Child 4–15 yr:** Start at 10 mg/kg/dose PO/IV BID; increase by 10 mg/kg/dose BID every 2 wk as tolerated up to the recommended dose of 30 mg/kg/dose BID or up to a **max. dose** of 3000 mg/24 hr. An average daily dose of 44 mg/kg/24 hr was reported in clinical trials.

**Alternative dosing with oral tablets:**

**20–40 kg:** Start at 250 mg PO BID; increase by 250 mg BID every 2 wk as tolerated up to a **maximum** of 750 mg BID.

**>40 kg:** Start at 500 mg PO BID; increase by 500 mg BID every 2 wk as tolerated up to a **maximum** of 1500 mg BID.

**16 yr—adult:** Start at 500 mg PO/IV BID; may increase by 500 mg/dose BID every 2 wk as tolerated up to a **max. dose** of 1500 mg BID.

**Extended release tabs (>12 yr and adult):** Start at 1000 mg PO once daily; increase by 1000 mg/24 hr every 2 wk as tolerated up to a **maximum** of 3000 mg/24 hr once daily.

**Myoclonic seizure (adjunctive therapy; using immediate release dosage forms and IV):**

**≥12 yr and adult:** Start at 500 mg PO/IV BID; then increase dosage by 500 mg/dose BID every 2 wk as tolerated to reach the target dosage of 1500 mg BID.

**Tonic-clonic seizure (primary generalized, adjunctive therapy; use immediate release dosage forms and IV):**

**Child 6–15 yr:** Start at 10 mg/kg/dose PO/IV BID; increase by 10 mg/kg/dose BID every 2 wk as tolerated to reach the target dosage of 30 mg/kg/dose BID.

**Alternative fixed dosing with oral disintegrating tabs (Spritam):**

**20–40 kg:** Start at 250 mg PO BID; increase by 250 mg BID every 2 wk as tolerated up to a **maximum** of 750 mg BID.

**>40 kg:** Start at 500 mg PO BID; increase by 500 mg BID every 2 wk as tolerated up to a **maximum** of 1500 mg BID.

**16 yr—adult:** Start at 500 mg PO/IV BID; then increase dosage by 500 mg/dose BID every 2 wk as tolerated to reach the target dosage of 1500 mg BID.

**Refractory status epilepticus (limited data):**

**Infant, child, and adolescent:** 60 mg/kg (**max. dose:** 4500 mg/dose) IV/IO over 10 min × 1, then start maintenance therapy based on clinical response and seizure type

**Do not** abruptly withdraw therapy, to reduce risk for seizures. **Use with caution** in renal impairment (**reduce dose; see Chapter 31**), hemodialysis, and neuropsychiatric conditions.



May cause loss of appetite, vomiting, dizziness, headaches, somnolence, agitation, depression, and mood swings. Drowsiness, fatigue, nervousness, and aggressive behavior have been reported in children. Nonpsychotic behavioral symptoms reported in children are approximately 3 times greater than in adults (37.6% vs. 13.3%). Suicidal behavior or ideation, serious dermatologic reactions

LEVETIRACETAM *continued*

(e.g., Stevens-Johnson and TEN), hematologic abnormalities (e.g., anemia, leukopenia), reversible alopecia, hyponatremia, hypertension, and worsening of seizures have been reported. Levetiracetam may decrease carbamazepine's effects. Ginkgo may decrease levetiracetam's effects.

Drug has excellent PO absorption. For IV use, use similar immediate release PO dosages only when the oral route of administration is not feasible. Extended release tablet is designed for once-daily administration at similar daily dosage of the immediate release forms (e.g., 1000 mg once daily of the extended release tablet is equivalent to 500 mg BID of the immediate release tablet). Disintegrating tabs (Spritam) may be administered by allowing the tablet to disintegrate in the mouth when taken with a sip of liquid or made into a suspension (see package insert); **do not** swallow this dosage form whole.

## LEVOCARNITINE

See [Carnitine](#).

## LEVOFLOXACIN

Generics; previously available as Levaquin and Quixin

**Antibiotic, quinolone**



C



2



Yes



No



No

**Tabs:** 250, 500, 750 mg

**Oral solution:** 25 mg/mL (100, 200, 480 mL)

**Injection:** 25 mg/mL (20, 30 mL)

**Premixed injection in D<sub>5</sub>W:** 250 mg/50 mL, 500 mg/100 mL, 750 mg/150 mL

**Ophthalmic drops (generics previously available as Quixin):** 0.5% (5 mL)

## Child:

## General dosing:

**6 mo—<5 yr:** 10 mg/kg/dose IV/PO Q12 hr; **max. dose:** 500 mg/24 hr

**≥5 yr:** 10 mg/kg/dose IV/PO Q24 hr; **max. dose:** 750 mg/24 hr

**Recurrent or persistent acute otitis media (6 mo—<5 yr):** 10 mg/kg/dose PO Q12 hr × 10 days; **max. dose:** 500 mg/24 hr

## Community-acquired pneumonia (IDSA/Pediatric Infectious Disease Society):

**6 mo—<5 yr:** 8–10 mg/kg/dose PO/IV Q12 hr; **max. dose:** 750 mg/24 hr

**5–16 yr:** 8–10 mg/kg/dose PO/IV Q24 hr; **max. dose:** 750 mg/24 hr

## Inhalational anthrax (postexposure) and plague:

**≥6 mo and <50 kg:** 8 mg/kg/dose PO/IV Q12 hr; **max. dose:** 500 mg/24 hr

**>50 kg:** 500 mg PO/IV once daily

## Duration of therapy:

**Inhalational anthrax (postexposure):** 60 days

**Plague:** 10–14 days

## Adult:

**Community-acquired pneumonia:** 750 mg PO/IV Q24 hr × 5 days

**Complicated UTI/acute pyelonephritis:** 750 mg PO/IV Q24 hr × 5–7 days

**Acute bacterial sinusitis:** 500 mg PO/IV Q24 hr × 10–14 days; OR 750 mg PO/IV Q24 hr × 5 days

**Inhalational anthrax (postexposure):** 750 mg PO/IV Q24 hr × 60 days

**Plague:** 500 mg PO/IV Q24 hr × 10–14 days



*Continued*

LEVOFLOXACIN *continued***Conjunctivitis:**

≥1 yr and adult: Instill 1–2 drops of the 0.5% solution to affected eye(s) Q2 hr up to 8 times/24 hr while awake for the first 2 days, then Q4 hr up to 4 times/24 hr while awake for the next 5 days.

**Contraindicated** in hypersensitivity to other quinolones. **Avoid** in patients with history of QTc prolongation or taking QTc prolonging drugs, and excessive sunlight exposure. **Use with caution** in diabetes, seizures, myasthenia gravis, children <18 yr, and renal impairment (**adjust dose, see Chapter 31**). May cause GI disturbances, headache, and blurred vision with the ophthalmic solution. Musculoskeletal disorders (e.g., arthralgia, arthritis, tendinopathy, and gait abnormality) may occur. Peripheral neuropathy and uveitis have been reported. Safety in pediatric patients treated more than 14 days has not been evaluated. Like other quinolones, tendon rupture can occur during or after therapy (risk increases with concurrent corticosteroids). Psychiatric adverse events, increased intracranial pressure, seizures, and blood glucose disturbances have been reported. Use with NSAIDs may increase risk of CNS stimulation and seizures.

Infuse IV over 1–1.5 hr; **avoid** IV push or rapid infusion because of risk of hypotension. **Do not** administer antacids or other divalent salts with or within 2 hr of oral levofloxacin dose; otherwise may be administered with or without food.

**LEVOTHYROXINE (T<sub>4</sub>)**

Synthroid, Euthyrox, Levoxyl, Tirosint, Thyquidity, Tirosint-Sol, Unithroid, and generics

**Thyroid product**

A



1



No



No



No

**Tabs:** 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 mCg

**Caps (Tirosint):** 13, 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200 mCg

**Injection:** 100, 200, 500 mCg; preservative free

**Oral solution:**

**Thyquidity:** 100 mcg/5 mL (100 mL); contains parabens

**Tirosint-Sol:** 13, 25, 37.5, 44, 50, 62.5, 75, 88, 100, 112, 125, 137, 150, 175, 200 mCg/1 mL (30 ampules per box)

**Oral suspension:** 25 mCg/mL 

**Hypothyroidism:****Child PO dosing (see remarks):**

**1–3 mo:** 10–15 mCg/kg/dose once daily. If patient is at risk for developing cardiac failure, start with lower dose of 25 mCg/24 hr; and if patient has very low T<sub>4</sub> (<5 mCg/dL), use higher 12–17 mCg/kg/24 hr dose.

**>3–6 mo:** 8–10 mCg/kg/dose once daily

**>6–12 mo:** 6–8 mCg/kg/dose once daily

**1–5 yr:** 5–6 mCg/kg/dose once daily

**6–12 yr:** 4–5 mCg/kg/dose once daily

**>12 yr:**

**Incomplete growth and prepuberty:** 2–3 mCg/kg/dose once daily

**Complete growth and puberty:** 1.7 mCg/kg/dose once daily

**Child IM/IV dose:** 50%–75% of oral dose once daily

**Adult:**

**PO:** Start with 12.5–25 mCg/dose once daily. Increase by 12.5–25 mCg/24 hr at intervals of Q2–4 wk until euthyroid. Usual adult dose: 100–200 mCg/24 hr

**IM/IV dose:** 50% of oral dose once daily

LEVOTHYROXINE (T4) *continued***Myxedema coma or stupor:**

**Adult:** 300–500 mCg IV  $\times$  1, then 50–100 mCg IV once daily; convert to oral therapy once patient is stabilized

**Contraindications** include acute MI, thyrotoxicosis, and uncorrected adrenal insufficiency.

May cause hyperthyroidism, rash, growth disturbances, hypertension, worsening of diabetic control, decreased bone mineral density (primarily in postmenopausal females), arrhythmias, diarrhea, and weight loss. Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in children. Overtreatment may cause craniosynostosis in infants and premature closure of the epiphyses in infants who have not undergone complete closure of the fontanelles.

Total replacement dose may be used in children unless there is evidence of cardiac disease; in that case, begin with one-fourth of maintenance and increase weekly. Titrate dosage with clinical status and serum T<sub>4</sub> and TSH.

Increases the effects of warfarin. Phenytoin, rifampin, carbamazepine, iron and calcium supplements, antacids, grapefruit juice, and orlistat may decrease levothyroxine levels. Tricyclic antidepressants and SSRIs may enhance toxic effects. Use with ketamine may cause hypertension and tachycardia. High doses of propranolol or dexamethasone, and amiodarone may decrease the conversion of T<sub>4</sub> to T<sub>3</sub>.

**100 mCg levothyroxine = 65 mg thyroid USP.** Administer oral doses on an empty stomach and tablets with a full glass of water. Iron and calcium supplements and antacids may decrease absorption; **do not** administer within 4 hr of these agents. Excreted in low levels in breast milk; preponderance of evidence suggests no clinically significant effect in infants.

**LIDOCAINE**

Xylocaine, L-M-X, Lidoderm, Gen7T Plus, many different brands of topical products, and generics

**Antiarrhythmic class Ib, local anesthetic**



B



1



Yes



Yes



No

**Injection:** 0.5%, 1%, 1.5%, 2%, 4% (1% sol = 10 mg/mL)

**IV infusion (in D<sub>5</sub>W):** 0.4% (4 mg/mL) (250, 500 mL); 0.8% (8 mg/mL) (250 mL)

**Injection with epinephrine (some preparations may contain metasulfite and parabens or are preservative free):**

**Injection with 1:100,000 epinephrine:** 1%, 2% lidocaine

**Injection with 1:200,000 epinephrine:** 0.5%, 1%, 1.5%, 2% lidocaine

**Ointment:** 4% (50 g), 5% (30, 50 g)

**Cream, topical:** 3% (30, 85 g), 4% (L-M-X-4 and generics) [OTC] (5, 15, 30, 45 g), 5% (L-M-X-5 and generics) [OTC] (15, 30 g); may contain benzyl alcohol

**Cream, rectal:** 5% (L-M-X-5 and others; 15, 30 g); contains benzyl alcohol

**Gel (external):** 2% (5, 10, 20, 30 mL), 3% (10, 30 mL), 4% (10, 30, 113 g), 5% (10, 30, 113 g); may contain benzyl alcohol, EDTA

**Lotion:** 3% (118, 177 mL), 4% (88 mL)

**Solution (external):** 4% (50 mL); may contain parabens

**Aerosol spray (external):** 4% (104 mL)

**Transdermal patch:**

**Gen7T Plus and generics:** 3.5% (5s, 10s, 15s); may contain menthol

**Lidocaine Pain Relief and generics [OTC]:** 4% (5s, 10s); may contain menthol, capsaicin, and methyl salicylate

**Lidoderm and generics:** 5% (1s, 15s, 30s)

*Continued*

LIDOCAINE *continued*

**Oral solution (mouth/throat):** 2% (15, 100 mL), 4% (4 mL)

**Topical cream or gel 2.5% with 2.5% prilocaine:** See [Lidocaine and Prilocaine](#).

**Anesthetic:**

**Injection (local):** Use <2% concentration. Dosage varies with procedure, degree and duration of analgesia, tissue vascularity, and patient condition.

**Without epinephrine: max. dose** of 4.5 mg/kg/dose (up to 300 mg); do not repeat within 2 hr.

**With epinephrine: max. dose** of 7 mg/kg/dose (up to 500 mg); do not repeat within 2 hr.

**Topical:**

**Cream (child ≥2 yr and adult):** Apply to affected intact skin areas BID—QID; **max. dose:** 4.5 mg/kg/dose up to 300 mg/dose

**Gel, lotion, or ointment (child ≥2 yr and adult):** Apply to affected intact skin areas once daily—QID (BID—TID for lotion); **max. dose:** 4.5 mg/kg/dose up to 300 mg/dose

**Patch:**

**4% (≥12 yr and adult):** Apply patch to painful area and leave in place for up to 12 hr; **max. dose:** one patch/24 hr

**5% (adult):** Apply to most painful area with up to 3 patches at a time. Patch(es) may be left in place for up to 12 hr in any 24 hr period.

**Antiarrhythmic (infant, child, adolescent):**

**Bolus:** 1 mg/kg/dose (**max. dose:** 100 mg) slowly IV; may repeat in 10–15 min × 2; **max. total dose:** 3–5 mg/kg within the first hr. ETT dose = 2–3 × IV dose.

**Continuous infusion:** 20–50 mCg/kg/min IV/IO (**do not exceed** 20 mCg/kg/min for patients with shock, CHF, hepatic disease, or cardiac arrest); see inside cover for infusion preparation. Administer a 1 mg/kg bolus when infusion is initiated if bolus has not been given within previous 15 min.

**Oral use (2% viscous liquid):**

**Child (≥3 yr):** Up to the lesser of 4.5 mg/kg/dose or 300 mg/dose, swish and spit Q3 hr PRN up to a **max. dose** of 4 doses per 12 hr period

**Adult:** 15 mL, swish and spit Q3 hr PRN up to a **max. dose** 4.5 mg/kg/dose or 300 mg/dose up to 8 doses/24 hr

For cardiac arrest, amiodarone is the preferred agent over lidocaine; lidocaine may be used only when amiodarone is not available.

**Contraindicated** in Stokes-Adams or Wolff-Parkinson-White syndromes and SA, AV, or intraventricular heart block without a pacemaker. Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products. Side effects include hypotension, asystole, seizures, and respiratory arrest. Anaphylactic reactions have been reported. Local anesthetic use has been associated with methemoglobinemia.

CYP 450 2D6 and 3A3/4 substrate. **Use with caution** in severe liver or renal disease. Decrease dose in hepatic failure or decreased cardiac output. **Do not use** topically for teething. Prolonged infusion may result in toxic accumulation of lidocaine, especially in infants. **Do not use** epinephrine-containing solutions for treatment of arrhythmias.

Therapeutic levels 1.5–5 mg/L. Toxicity occurs at >7 mg/L. Toxicity in neonates may occur at >5 mg/L due to reduced protein binding of drug. Elimination  $T_{1/2}$ : premature infant: 3.2 hr, adult: 1.5–2 hr. When using the topical patch, **avoid** exposing the application site to external heat sources as this may increase the risk for toxicity.

**LIDOCAINE AND PRILOCAINE**

Many brand names, Oraqix, Eutectic mixture of lidocaine and prilocaine; previously available as EMLA

**Topical analgesic**



B



?



Yes



Yes



No



**Cream:** Lidocaine 2.5% + prilocaine 2.5% (5, 30 g)

**Peridontal gel (Oraqix):** Lidocaine 2.5% + prilocaine 2.5% (1.7 g in dental cartridges; 20s)

See [Chapter 6](#) for general use information.

**Neonate:**

**<37 wk gestation (limited data):**

**Painful procedures (e.g., IM injections):** 0.5 g/site for 60 min

**≥37 wk gestation and <5 kg:**

**Painful procedures (e.g., IM injections):** 1 g/site for 60 min. **Max. dose:** 1 g for all sites combined with a **max.** application area of 10 cm<sup>2</sup> and **max.** application time of 1 hr

**Circumcision:** 1–2 g and cover with occlusive dressing for 60–90 min

**Infant and child:** The following are the recommended **maximum doses** based on the child's age and weight.

Age and Weight	Maximum Total EMLA Dose (g)	Maximum Application Area (cm <sup>2</sup> )	Maximum Application Time
Birth—<3 mo or <5 kg	1	10	1 hr
3–12 mo and >5–10 kg <sup>a</sup>	12	20	4 hr
1–6 yr and >10 kg	10	100	4 hr
7–12 yr and >20 kg	20	200	4 hr

<sup>a</sup>If patient is >3 mo and is not >5 kg, use the **maximum** total dose which corresponds to the patient's weight. *EMLA*, Eutectic mixture of local anesthetics.

**Adolescent and adult:**

**Minor procedures:** 2.5 g/site over 20–25 cm<sup>2</sup> of skin for at least 60 min

**Painful procedures:** 2 g/10 cm<sup>2</sup> of skin for at least 2 hr

**Should not be used** in neonates <37 wk of gestation or in infants <12 mo old receiving treatment with methoglobin-inducing agents (e.g., sulfa drugs, acetaminophen, nitrofurantoin, nitroglycerin, nitroprusside, phenobarbital, phenytoin). **Use with caution** in patients with G6PD deficiency, patients treated with class I or III antiarrhythmic drugs (additive or toxic cardiac effects), and in patients with renal and hepatic impairment. Prilocaine has been associated with methemoglobinemia. Long duration of application, large treatment area, small patients, or impaired elimination may result in high blood levels.

Apply topically to intact skin and cover with occlusive dressing; **avoid** mucous membranes or the eyes. Wipe cream off before procedure.

**LINDANE**

Gamma benzene hexachloride and various generics

**Scabicide agent, pediculocide**



C



3



No



No



No

**Shampoo:** 1% (60 mL)

**Pediculosis capitis (second-line therapy; see remarks):**

**Child and adult:** Apply ≤30 mL (amount depends on length and density of hair; **max. dose:**

60 mL) shampoo to dry hair without adding water. Work shampoo thoroughly into hair and allow to remain in place for 4 min. Then add small amounts of water to the hair until a good lather forms. Immediately rinse all the lather away and **avoid** contact of lather to other body surfaces. Towel dry and comb hair with fine-tooth comb to remove nits. **Do not re-treat.**



Continued

LINDANE *continued*

Lindane is now considered a second-line therapy owing to side effect risk and reports of resistance. **Contraindicated** in premature infants and seizure disorders. **Use with caution** with drugs that lower seizure threshold. Systemically absorbed. Risk of toxic effects is greater in young children; use other agents (permethrin) in infants, young children (<2 yr), and during pregnancy. May cause a rash; rarely may cause seizures or aplastic anemia. For scabies, change clothing and bed sheets after starting treatment and treat family members. For pediculosis pubis, treat sexual contacts.

**Avoid** contact with face, urethral meatus, damaged skin, or mucous membranes. **Do not use** any covering that does not breathe (e.g., plastic lining or clothing) over the applied lindane.

**LINEZOLID**

Zyvox and generics

**Antibiotic, oxazolidinone**

C



2



Yes



Yes



No

**Tab:** 600 mg; contains ~0.45 mEq Na per 200 mg drug**Oral suspension:** 100 mg/5 mL (150 mL); contains phenylalanine and sodium benzoate and 0.8 mEq Na per 200 mg drug**Injection, premixed:** 200 mg in 100 mL, 600 mg in 300 mL; contains 1.7 mEq Na per 200 mg drug**Neonate:**

&lt;1 kg:

&lt;14 days old: 10 mg/kg/dose IV Q12 hr

≥14 days old: 10 mg/kg/dose IV Q8 hr

≥1–2 kg:

&lt;7 days old: 10 mg/kg/dose IV/PO Q12 hr

≥7–28 days old: 10 mg/kg/dose IV/PO Q8 hr

&gt;2 kg: 10 mg/kg/dose IV/PO Q8 hr

**Alternate dosing by gestational age:**

&lt;34 wk's gestation:

&lt;7 days old: 10 mg/kg/dose IV/PO Q12 hr

≥7–28 days old: 10 mg/kg/dose IV/PO Q8 hr

≥34 wk's gestation and 0–28 days old: 10 mg/kg/dose IV/PO Q8 hr

**Infant and child <12 yr old:****Pneumonia, bacteremia, bone/joint infections, septic thrombosis (MRSA), complicated skin/skin structure infections, vancomycin-resistant *E. faecium* (VRE) infections (including endocarditis):**

10 mg/kg/dose IV/PO Q8 hr

**Uncomplicated skin/skin structure infections:**

&lt;5 yr: 10 mg/kg/dose IV/PO Q8 hr

5–11 yr: 10 mg/kg/dose IV/PO Q12 hr

**Max. dose** for all indications <12 yr: 600 mg/dose

≥12 yr and adult: 600 mg Q12 hr IV/PO; 400 mg Q12 hr IV/PO may be used for adults with uncomplicated infection.



Most common side effects include diarrhea, headache, and nausea. Anemia, leukopenia, pancytopenia, and thrombocytopenia may occur in patients who are at risk for myelosuppression and who receive regimens >2 wk. Complete blood count monitoring is recommended in these individuals. Pseudomembranous colitis, neuropathy (peripheral and optic), hyponatremia, hypoglycemia, and severe cutaneous adverse reactions (e.g., TEN and SJS) have also been reported. CSF penetration is variable in patients with VP shunts.



LINEZOLID *continued*

**Do not use** with SSRIs (e.g., fluoxetine, paroxetine), tricyclic antidepressants, venlafaxine, and trazodone; may cause serotonin syndrome. **Avoid** use with monoamine oxidase inhibitors (e.g., phenelzine); and in patients with uncontrolled hypertension, pheochromocytoma, or thyrotoxicosis, and taking sympathomimetics or vasopressive agents (may elevate blood pressure). **Use caution** when consuming large amounts of foods and beverages containing tyramine; may increase blood pressure. Use in severe hepatic impairment (e.g., cirrhosis) or kidney impairment may increase risk for thrombocytopenia.

Protect all dosage forms from light and moisture. Oral suspension product must be gently mixed by inverting the bottle 3–5 times prior to each use (**do not shake**). All oral doses may be administered with or without food.

**LIRAGLUTIDE**

Saxenda, Victoza

**Antidiabetic agent, glucagon-like peptide-1 (GLP-1) receptor agonist**

**Subcutaneous pen-injector:**

**Saxenda and Victoza:** 18 mg/3 mL (3 mL); contains phenol, propylene glycol

**Type 2 diabetes mellitus (adjunctive therapy with diet and exercise):**

**Victoza (child >10 yr and adolescent):** Start with 0.6 mg SC once daily × 1 wk, if needed, increase by 0.6 mg increments on a weekly basis PRN up to a **maximum dose** of 1.8 mg/24 hr. In clinical trials, metformin was also prescribed with some receiving insulin (those receiving insulin had their insulin dose reduced by ~20%).

**Chronic weight management (adjunctive therapy with diet and exercise):**

**Saxenda (child >12 yr and adolescent):** Start with 0.6 mg SC once daily × 1 wk, then increase dose by 0.6 mg/24 hr at weekly increments up to the target dose of 3 mg once daily. If unable to tolerate 3 mg once daily, may reduce dose to 2.4 mg once daily (discontinue use if 2.4 mg dose is not tolerated). Pediatric patients who are unable to tolerate the dose escalation may use the lower dose, and the targeted escalation could take up to 8 wk. Discontinue therapy if the patient has a <1% reduction in BMI after 12 weeks of therapy.


A bioengineered analog of human GLP-1 in *Saccharomyces cerevisiae* and acts as a GLP-1 receptor agonist. **Contraindicated** in patients with a family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2.

Common side effects include hypoglycemia, constipation, diarrhea, nausea, vomiting, indigestion, and headache. Pancreatitis, cholelithiasis/cholecystitis, hypersensitivity reactions (e.g., anaphylaxis and angioedema), and acute renal failure have been reported. Use with **caution** with other medications that could cause hypoglycemia (e.g., sulfonylurea, insulin, fluoroquinolones, beta-blockers, and SSRIs).

Doses are injected subcutaneously in the abdomen, thigh, or upper arm any time of the day without regard to meals. Each new prefilled pen requires priming before the first injection. Use a new needle for each dose administration. **Do not share** pens between patients despite changing needles. **Do not mix** with insulin and **do not administer** adjacent to insulin. If a dose is missed more than 3 days, reinitiate the dosage titration at 0.6 mg/24 hr. **Never administer** extra or doubled doses.

**LISDEXAMFETAMINE**

Vyvanse

**CNS stimulant**

**Capsules:** 10, 20, 30, 40, 50, 60, 70 mg

**Chewable tabs:** 10, 20, 30, 40, 50, 60 mg; contains mannitol and sucralose

*Continued*

LISDEXAMFETAMINE *continued***Attention-deficit hyperactivity disorder:**

**Child ≥6 yr and adult:** Start with 20–30 mg PO QAM (adult, start at 30 mg). May increase dose by 10–20 mg/24 hr at weekly intervals if needed, up to a **max. dose** of 70 mg/24 hr. Lower maximum dosages for renal insufficiency include the following:

**GFR ≥30 mL/min/1.73 m<sup>2</sup>:** 70 mg/24 hr

**GFR 15–<30 mL/min/1.73 m<sup>2</sup>:** 50 mg/24 hr

**GFR <15 mL/min/1.73 m<sup>2</sup> or ESRD on hemodialysis:** 30 mg/24 hr

**Binge eating disorder (moderate to severe):**

**Adult:** Start with 30 mg PO once daily. Increase in increments of 20 mg at weekly intervals to achieve the recommended dosage of 50–70 mg PO once daily; **max. dose:** 70 mg/24 hr; discontinue use if no improvement.

Lisdexamfetamine is a prodrug of dextroamphetamine that requires activation by intestinal/hepatic metabolism.

**Contraindicated** in amphetamine or sympathomimetic hypersensitivity, symptomatic cardiovascular disease, moderate/severe hypertension, hyperthyroidism, glaucoma, agitated states, drug/alcohol abuse history, and MAO inhibitors (concurrent or use within 14 days). As with other CNS stimulant medications, serious cardiovascular events, including **death**, have been reported in patients with preexisting structural cardiac abnormalities or other serious heart problems. **Use with caution** in patients with hypertension, psychiatric conditions, and epilepsy. May cause insomnia, irritability, rash, appetite suppression/weight loss, growth suppression, dizziness, xerostomia, and GI disturbances. Dermatillomania, bruxism, intestinal ischemia, Stevens-Johnson syndrome, and TEN have been reported.

Urinary acidifying agents may reduce levels of amphetamines, and urinary alkalinizing agents may increase levels. May increase the effects of TCAs; increase or decrease the effects of guanfacine and phenytoin, and phenobarbital; and decrease the effects of adrenergic blockers, antihistamines, and antihypertensives. Norepinephrine may increase the effects of amphetamines.

Chewable tablets must be completely chewed before swallowing. Chewable tablet and capsule dosage forms can be converted on an equal mg-per-mg basis.

See [Dextroamphetamine ± Amphetamine](#) for additional remarks.

**LISINAPRIL**

Qbrelis, Zestril, and generics; previously available as Prinivil

**Angiotensin-converting enzyme inhibitor, antihypertensive**



X



3



Yes



Yes



No

**Tabs:** 2.5, 5, 10, 20, 30, 40 mg

**Oral solution (Qbrelis):** 1 mg/mL (150 mL); contains sodium benzoate

**Oral suspension:** 1 mg/mL

**Oral syrup:** 2 mg/mL

**Hypertension (see remarks):**

**Child (<6 yr; limited data):** Use 6–16 yr dosing below.

**6–16 yr:** Start with 0.07–0.1 mg/kg/dose PO once daily; **max. initial dose:** 5 mg/dose. If needed, titrate dose upward at 1–2 wk intervals to doses up to 0.61 mg/kg/24 hr or 40 mg/24 hr (higher doses have not been evaluated).

**Adult:** Start with 10 mg PO once daily (use 5 mg if using a diuretic). If needed, increase dose by 5–10 mg/24 hr at 1–2 wk intervals. Usual dosage range: 20–40 mg/24 hr; **max. dose:** 80 mg/24 hr.

LISINOPRIL *continued*

Use lower initial dose (50% of recommended dose) if using with a diuretic or with the presence of hyponatremia, hypovolemia, severe CHF, or decreased renal function.



**Contraindicated** in hypersensitivity and history of angioedema with other ACE inhibitors and in combination with a neprilysin inhibitor (e.g., sacubitril). **Do not use** with aliskiren in patients with diabetes. **Avoid** use with dialysis with high-flux membranes because anaphylactoid reactions have been reported. **Use with caution** in aortic or bilateral renal artery stenosis and hepatic impairment. Side effects include cough, dizziness, headache, hyperkalemia, hypotension (especially with concurrent diuretic or antihypertensive agent use), rash, and GI disturbances. Mood alterations, including depressive symptoms, have been reported.

Dual blockade of the renin-angiotensin system with lisinopril and angiotensin receptor antagonists (e.g., losartan) or aliskiren is associated with increased risk for hypotension, syncope, hyperkalemia, and renal impairment. Diabetic patients on lisinopril treated with oral antidiabetic agents should be monitored for hypoglycemia, especially during the first month of use. NSAIDs (e.g., indomethacin) may decrease lisinopril's effects. Use with mTOR inhibitors (e.g., sirolimus, everolimus) may increase risk for angioedema. **Adjust dose in renal impairment (see Chapter 31).**

Onset of action: 1 hr with maximal effect in 6–8 hr. Long-term blood pressure monitoring is recommended at Q2–4 wk until good control is achieved, followed by Q3–4 mo.

Additional indications with limited data in children include proteinuria associated with mild IgA nephropathy, and renal protection for diabetes or renal parenchymal disease.

Lisinopril should be discontinued as soon as possible when pregnancy is detected as it can cause fetal harm especially when used during the second and third trimesters.

**LITHIUM**

Lithobid and many generics; previously available as Eskalith

**Antimanic agent**



D



X



Yes



No



No

**Carbonate salt:**

300 mg carbonate = 8.12 mEq lithium

**Caps:** 150, 300, 600 mg

**Tab:** 300 mg

**Extended release tabs:** 300 mg (Lithobid and generics), 450 mg

**Citrate salt:**

**Syrup:** 8 mEq/5 mL (500 mL); 5 mL is equivalent to 300 mg lithium carbonate

**Child (see remarks):**

**Initial (immediate release dosage forms):** 15–60 mg/kg/24 hr ÷ TID–QID PO. Adjust as needed (weekly) to achieve therapeutic levels.



**Adolescent:** 600–1800 mg/24 hr ÷ TID–QID PO (divided BID–TID using extended-release tablets)

**Adult:**

**Initial:** 300 mg TID PO. Adjust as needed to achieve therapeutic levels. Usual dose is about 300 mg TID–QID with immediate release dosage form. For extended release tablets, 900–1800 mg/24 hr PO ÷ BID–TID

**Contraindicated** in severe cardiovascular disease (including Brugada syndrome) or renal disease. Decreased sodium intake, increased sodium wasting, or significant renal or cardiovascular disease may increase lithium levels, resulting in toxicity. May cause goiter, nephrogenic diabetes insipidus, hypothyroidism, arrhythmias, or sedation at therapeutic doses. Nephrotic syndrome and dermatologic reactions (e.g., alopecia, acne, psoriasis, and DRESS) have been reported.



*Continued*

LITHIUM *continued*

Coadministration with diuretics, metronidazole, ACE inhibitors, angiotensin receptor antagonists (e.g., losartan), or NSAIDs may increase risk for lithium toxicity. Use with iodine may increase risk for hypothyroidism. If used in combination with haloperidol, closely monitor neurologic toxicities because an encephalopathic syndrome followed by irreversible brain damage has been reported.

Safety and efficacy for monotherapy for acute mania or mixed episodes of bipolar I disorder and maintenance monotherapy of bipolar I disorder in children 7–17 yr have been established from a clinical trial. Common adverse effects observed in this study included nausea/vomiting, polyuria, thyroid abnormalities, tremor, polydipsia, dizziness, rash/dermatitis, ataxia/gait disturbance, anorexia, and blurry vision.

**Therapeutic levels:** 0.6–1.5 mEq/L. In either acute or chronic toxicity, confusion and somnolence may be seen at levels of 2–2.5 mEq/L. **Seizures or death** may occur at levels >2.5 mEq/L. Recommended serum sampling: trough level within 30 min prior to the next scheduled dose. Steady-state is achieved within 4–6 days of continuous dosing. **Adjust dose in renal failure (see Chapter 31).**

**LODOXAMIDE**

Alomide

**Antiallergic agent, mast cell stabilizer**

B



?



No



No



No

**Ophthalmic solution:** 0.1% (10 mL); contains benzalkonium chloride

**≥2 yr and adult:** Instill 1–2 drops to affected eye(s) QID for up to 3 mo.



Transient burning, stinging, or discomfort of the eye and headache are common side effects.

Itching/pruritus, blurred vision, dry eye, tearing, hyperemia, crystalline deposits, and foreign body sensation may also occur.



**Do not** wear soft contact lenses during treatment because medication contains benzalkonium chloride.

**LOPERAMIDE**

Imodium, Imodium A–D, and generics

**Antidiarrheal**

C



1



No



No



No

**Caps (OTC):** 2 mg

**Tabs (OTC):** 2 mg

**Oral solution (OTC):** 1 mg/7.5 mL (120, 240 mL); may contain propylene glycol and sodium benzoate; each 30 mL contains 16 mg of sodium

**Acute diarrhea (see remarks):**

**Child (initial doses within the first 24 hr):**

2–5 yr (13–<21 kg): 1 mg PO TID

6–8 yr (21–27 kg): 2 mg PO BID

9–11 yr (>27–43 kg): 2 mg PO TID

**Max. single dose:** 2 mg

Follow initial day's dose with 0.1 mg/kg/dose after each loose stool (not to exceed the aforementioned initial doses).

**≥12 yr and adult:** 4 mg/dose × 1, followed by 2 mg/dose after each stool up to **max. dose** of 8 mg/24 hr for 12–<18 yr and 16 mg/24 hr for adult



LOPERAMIDE *continued***Chronic diarrhea (see remarks):**

**Infant—child (limited data):** 0.08–0.24 mg/kg/24 hr PO ÷ BID–TID; **max. dose:** 2 mg/dose

**Contraindicated** in acute dysentery; acute ulcerative colitis; bacterial enterocolitis caused by *Salmonella*, *Shigella*, *Campylobacter*, and *Clostridium difficile*; and abdominal pain in the absence of diarrhea. **Avoid** use in children <2 yr due to reports of paralytic ileus associated with abdominal distention. Rare hypersensitivity reactions including anaphylactic shock have been reported. May cause nausea, rash, vomiting, constipation, cramps, dry mouth, and CNS depression. Use of higher than recommended dosages via abuse or misuse can cause serious cardiac events (e.g., Torsades de Pointes, arrhythmias, cardiac arrest, and QT prolongation).

**Discontinue use if no clinical improvement is observed within 48 hr.** Naloxone may be administered for CNS depression.

**LORATADINE ± PSEUDOEPHEDRINE**

Alavert, Claritin, Claritin Children's Allergy, Claritin RediTabs, many others and generics

In combination with pseudoephedrine:

Claritin-D 12 Hour, Claritin-D 24 Hour, Alavert D-12 Hour Allergy and Congestion, Loratadine-D 12 Hour, Loratadine-D 24 Hour, Allergy Relief-D, and generics

**Antihistamine, less sedating ± decongestant**



B/C



2



Yes



Yes



No

**Tabs [OTC]:** 10 mg

**Caps, liquid filled [OTC]:** 10 mg; contains polysorbate 80

**Chewable tabs (Claritin Children's Allergy and others) [OTC]:** 5 mg; contains aspartame

**Disintegrating tabs (Claritin RediTabs and others) [OTC]:** 5, 10 mg; contains aspartame

**Oral solution or syrup [OTC]:** 1 mg/mL (120 mL); contains propylene glycol and sodium benzoate; some preparations may contain metasulfite

**Time-release tabs in combination with pseudoephedrine (PE):**

**Claritin-D 12 Hour, Alavert D-12 Hour Allergy and Congestion, Loratadine-D 12 Hour, and generics [OTC]:** 5 mg loratadine + 120 mg PE

**Claritin-D 24 Hour, Loratadine-D 24 Hour, Allergy Relief-D and generics [OTC]:** 10 mg loratadine + 240 mg PE

**Loratadine:**

**2–5 yr:** 5 mg PO once daily

**≥6 yr and adult:** 10 mg PO once daily. Disintegrating tablet may be dosed at 5 mg PO BID or 10 mg PO once daily.

**Time-release tabs of loratadine and pseudoephedrine:**

**≥12 yr and adult (see remarks):**

**Claritin-D 12 Hour and generics:** 1 tablet PO BID

**Claritin-D 24 Hour and generics:** 1 tablet PO once daily

May cause drowsiness, fatigue, dry mouth, headache, bronchospasms, palpitations, dermatitis, and dizziness. Has not been implicated in causing cardiac arrhythmias when used with other drugs that are metabolized by hepatic microsomal enzymes (e.g., ketoconazole, erythromycin). May be administered safely in patients who have allergic rhinitis and asthma.

In hepatic and renal function impairment (GFR <30 mL/min), prolong loratadine (single agent) dosage interval to every other day. **Adjust dose in renal failure (see Chapter 31).**

For time-release tablets of the combination product (loratadine and pseudoephedrine), prolong dosage interval in renal impairment (GFR <30 mL/min) as follows: Claritin-D 12 Hour: 1 tablet PO once daily; Claritin-D 24 Hour: 1 tablet PO every other day. **Do not** use the combination product in hepatic

*Continued*

LORATADINE ± PSEUDOEPHEDRINE *continued*

impairment because drugs cannot be individually titrated. Pregnancy category changes to “C” for the combination product (loratadine and pseudoephedrine).

Administer doses on an empty stomach. For use of RediTabs, place tablet on tongue and allow it to disintegrate in the mouth with or without water. For Claritin-D products, also see remarks in [Pseudoephedrine](#).

**LORAZEPAM**

Ativan, Loreev XR, and generics

**Benzodiazepine anticonvulsant**



D



2



Yes



Yes



No

**Tabs:** 0.5, 1, 2 mg

**Extended release capsules (Loreev XR):** 1, 1.5, 2, 3 mg

**Injection:** 2, 4 mg/mL (1, 10 mL); each contains 2% benzyl alcohol and propylene glycol

**Oral solution:** 2 mg/mL (30 mL); some dosage forms may be alcohol and dye free, and contain propylene glycol

**DOSAGES ARE FOR IMMEDIATE RELEASE DOSAGE FORMS (TABS, INJECTION, AND ORAL SOLUTION):**



**Status epilepticus (IV route is preferred but may use IM route if IV is not available):**

**Neonate, infant, child, and adolescent:** 0.05–0.1 mg/kg/dose IV over 2–5 min. May repeat dose in 10–15 min. **Max. dose:** 4 mg/dose. If IV access not available, 0.1 mg/kg/dose (**max.** 4 mg/dose) may be administered intranasally.

**Adult:** 4 mg/dose IV given slowly over 2–5 min. May repeat in 10–15 min. Usual total **max. dose** in 12-hr period is 8 mg.

**Antiemetic adjunct therapy:**

**Child:** 0.025–0.05 mg/kg/dose IV Q6 hr PRN; **max. single dose:** 2 mg

**Anxiolytic/sedation:**

**Infant and child:** 0.05 mg/kg/dose Q4–8 hr PO/IV; **max. dose:** 2 mg/dose

May also give IM for preprocedure sedation

**Adult:** 0.5–2 mg/dose PO/IV Q4–6 hr PRN up to 10 mg/24 hr

**Contraindicated** in narrow-angle glaucoma and severe hypotension. **Use with caution** in renal insufficiency (glucuronide metabolite clearance is reduced), hepatic insufficiency (may worsen hepatic encephalopathy; decrease dose with severe hepatic impairment), compromised pulmonary function, and use of CNS depressant medications. May cause respiratory depression, especially in combination with opioids and other sedatives. May also cause sedation, dizziness, mild ataxia, mood changes, rash, and GI symptoms. Paradoxical excitation has been reported in children (10%–30% of patients <8 yr old).



When compared to diazepam for status epilepticus (3 mo–17 yr), lorazepam was found to be more sedating with a longer time to return to baseline mental status.

Significant respiratory depression and/or hypotension has been reported when used in combination with loxapine. Probenecid and valproic acid may increase the effects/toxicity of lorazepam, and oral contraceptive steroids may decrease lorazepam's effects.

Injectable product may be given rectally. Benzyl alcohol and propylene glycol may be toxic to newborns at higher doses.

**Onset of action for sedation:** PO, 20–30 min; IM, 30–60 min; IV, 1–5 min. Duration of action: 6–8 hr.

Extended release capsules (Loreev XR) may be swallowed whole or its content may be opened and sprinkled over a tablespoon of applesauce followed by drinking water; **DO NOT** crush or chew. See product information for dose conversion from immediate release dosage forms.

**Flumazenil is the antidote.**

**LOSARTAN**

Cozaar and generics

**Angiotensin II receptor antagonist**

X

3

Yes

Yes

No

**Tabs:** 25, 50, 100 mg**Oral suspension:** 2.5 mg/mL 

Contains 2.12 mg potassium per 25 mg drug

**Hypertension (see remarks):**

**6–16 yr:** Start with 0.7 mg/kg/dose (**max. dose:** 50 mg/dose) PO once daily. Adjust dose to desired blood pressure response and daily dose may be divided BID. **Max. dose** (higher doses have not been evaluated): 1.4 mg/kg/24 hr or 100 mg/24 hr

**≥17 yr and adult:** Start with 50 mg PO once daily (use lower initial dose of 25 mg PO once daily if patient receiving diuretics, experiencing intravascular volume depletion, or has hepatic impairment). Usual maintenance dose is 25–100 mg/24 hr PO ÷ once daily–BID.



**Use with caution** in angioedema (current or past), excessive hypotension (volume depletion), hepatic (use lower starting dose) or renal (contains potassium) impairment, hyperkalemia (including use with medications that can cause hyperkalemia), renal artery stenosis, and severe CHF. Not recommended in patients <6 yr or in children with GFR <30 mL/min/1.73 m<sup>2</sup>, owing to lack of data.



Discontinue use as soon as possible when pregnancy is detected because injury and death to developing fetus may occur; especially during the second and third trimesters.

Diarrhea, asthenia, dizziness, fatigue, and hypotension are common. Thrombocytopenia, rhabdomyolysis, hallucinations, and angioedema have been rarely reported.

Losartan is a substrate for CYP 450 2C9 (major) and 3A4. Fluconazole and cimetidine may increase losartan's effects/toxicity. Rifampin, phenobarbital, and indomethacin may decrease its effects. Losartan may increase the risk of lithium toxicity. **Do not use** with aliskiren in patients with diabetes or with renal impairment (GFR <60 mL/min). Dual blockade of the renin-angiotensin system with losartan and ACE inhibitors (e.g., captopril) or aliskiren is associated with increased risk for hypotension, syncope, hyperkalemia, and renal impairment.

**LOW-MOLECULAR-WEIGHT HEPARIN**See [Enoxaparin](#).**LUCINACTANT**See [Surfactant, pulmonary](#).**LUMACAFTOR AND IVACAFTOR**

Orkambi

**Cystic fibrosis transmembrane conductance regulator corrector and potentiator**

B

2

Yes

Yes

Yes

**Oral granules (Lumacaftor:lvacaftor):** 75 mg:94 mg (14 packets), 100 mg:125 mg (56 packets), 150 mg:188 mg (56 packets)

LUMACAFTOR AND IVACAFTOR *continued*

**Tabs (Lumacaftor:Ivacaftor):** 100 mg:125 mg (112 tabs), 200 mg:125 mg (112 tabs)

**Child 1—<2 yr:**

**7—<9 kg:** One lumacaftor 75 mg/ivacaftor 94 mg granule packet PO Q12 hr

**9—<14 kg:** One lumacaftor 100 mg/ivacaftor 125 mg granule packet PO Q12 hr

**≥14 kg:** One lumacaftor 150 mg/ivacaftor 188 mg granule packet PO Q12 hr

**Child ≥2—5 yr:**

**<14 kg:** One lumacaftor 100 mg/ivacaftor 125 mg granule packet PO Q12 hr

**≥14 kg:** One lumacaftor 150 mg/ivacaftor 188 mg granule packet PO Q12 hr

**Child ≥6—11 yr:** Two lumacaftor 100 mg/ivacaftor 125 mg tablets PO Q12 hr**Child ≥12, adolescent, and adult:** Two lumacaftor 200 mg/ivacaftor 125 mg tablets PO Q12 hr**Dosage modification for hepatic impairment:**

Level of Hepatic Impairment (Child-Pugh Class)	Age Group	Morning Dose	Evening Dose
A. Mild	1—5 yr	No dose adjustment; use usual dose	No dose adjustment; use usual dose
	≥6 yr	No dose adjustment; use usual dose	No dose adjustment; use usual dose
B. Moderate	1—5 yr	1 packet of granules	1 packet of granules every other day
	≥6 yr	2 tablets	1 tablet
C. Severe	1—5 yr	1 packet of granules <sup>a</sup>	No dose
	≥6 yr	1 tablet <sup>a</sup>	1 tablet <sup>a</sup>

<sup>a</sup>or less frequently as studies have not been conducted in severe hepatic impairment.

**Dosage modification when used with CYP 450 3A inhibitors:**

**Already taking Orkambi and initiating a strong CYP 450 3A inhibitor (e.g., itraconazole):** No dosage adjustment

**Already taking a strong CYP 450 3A inhibitor and initiating Orkambi:** Reduce Orkambi dosage to 1 tablet or 1 packet of granules every other day × the first week followed by the recommended daily dose. If Orkambi is interrupted for >1 wk and reinitiated while taking strong CYP 450 3A inhibitors, Orkambi should be reintroduced with the reduced dosage of 1 tablet or 1 packet of granules every other day × 1 wk followed by the recommended daily dose.

Works on CFTR trafficking defect by acting as a CFTR corrector (lumecaftor) and in combination with a CFTR potentiator (ivacaftor). Indicated for individuals with homozygous F508del CFTR mutation.



Respiratory events, such as chest discomfort, dyspnea, and abnormal respiration, may occur during the initiation of therapy and may vary from transient to severe (requiring discontinuation). Common side effects include rash, diarrhea, nausea, flatulence, fatigue, nasal discharge, and URIs. Increased liver enzymes and cataracts may occur; monitor AST/ALT and ocular exam at baseline. Repeat AST/ALT every 3 mo for the first year followed by annual assessments. Repeat ocular exams annually. Hypertension has been reported. May cause a false-positive urine drug screen for cannabinoids.

Use with **caution** with CrCl ≤30 mL/min and ESRD. Reduce dose with moderate/severe hepatic impairment (see dosage section) or when initiating therapy while taking a strong CYP 450 3A4 inhibitor.

LUMACAFITOR AND IVACAFITOR *continued*

Lumecaftor is a strong inducer of CYP 450 3A and ivacaftor is a CYP 450 3A substrate; see dose modification table in the dosage section. Use with strong CYP 450 3A inducers (e.g., rifampin, rifabutin, carbamazepine, St. John's wort) is not recommended. Lumecaftor/ivacaftor may reduce the efficacy of hormonal contraceptives and increase the incidence of menstruation-associated side effects (e.g., amenorrhea, dysmenorrhea, and irregular menses). Always evaluate potential drug-drug interactions; see <https://www.orkambihcp.com/drug-interactionsddi-tool>. **Avoid** food or drink containing grapefruit or Seville oranges.

Administer all doses with high-fat foods to ensure absorption. Oral granules can be mixed with 5 mL of soft foods or liquids, such as puréed fruits or vegetables, yogurt, applesauce, water, breast milk, infant formula, milk, or juice. Once mixed, it should be consumed within an hour. If a dose (all dosage forms) is missed within 6 hr of a scheduled dose, administer a dose immediately. However, if the missed dose is >6 hr, skip that dose and resume therapy at the next scheduled dose. Never take a double dose for a missed dose.

M

**MAGNESIUM CITRATE**

Various generics  
16.17% Elemental Magnesium  
**Laxative/cathartic**



**Oral solution (OTC):** 1.75 g/30 mL (300 mL); 5 mL = 3.9–4.7 mEq Mg

**Tabs:** 100 mg

**Constipation:**

**2–<6 yr:** 2–4 mL/kg/24 hr PO ÷ once daily–BID; **OR** 60–90 mL/24 hr PO ÷ once daily–BID

**6–12 yr:** 100–150 mL/24 hr PO ÷ once daily–BID

**>12 yr and adult:** 150–300 mL/24 hr PO ÷ once daily–BID

**Bowel prep:**

**Child >6 yr and adolescent:** 4–6 mL/kg/24 hr (**max.** 300 mL/24 hr) PO × 1 as a single or divided dose the day prior to surgery

**Use with caution** in renal insufficiency (monitor magnesium level) and patients receiving digoxin. May cause hypermagnesemia, diarrhea, muscle weakness, hypotension, and respiratory depression. Up to approximately 30% of dose is absorbed. May decrease absorption of H<sub>2</sub> antagonists, phenytoin, iron salts, tetracyclines, steroids, benzodiazepines, and quinolone antibiotics.

**MAGNESIUM HYDROXIDE**

Milk of Magnesia, Pedia-Lax, and various generics  
41.69% Elemental Magnesium  
**Antacid, laxative**



**Oral liquid (OTC):** 400 mg/5 mL (Milk of Magnesia and others) (355, 473 mL)

**Concentrated oral liquid (OTC):** 2400 mg/10 mL (Milk of Magnesia concentrate) (10 mL)

*Continued*

MAGNESIUM HYDROXIDE *continued*

**Chewable tabs (Pedia-Lax, see remarks [OTC]):** 400 mg

400 mg magnesium hydroxide is equivalent to 166.76 mg elemental magnesium.

**Combination product with aluminum hydroxide:** See [Aluminum Hydroxide](#).

**Laxative (all liquid mL doses based on 400 mg/5 mL magnesium hydroxide, unless noted otherwise):**

Dose/24 hr ÷ once daily—QID PO

<2 yr: 0.5 mL/kg

2–5 yr: 5–15 mL **OR** 400–1200 mg (1–3 chewable tabs)

6–11 yr: 15–30 mL **OR** 1200–2400 mg (3–6 chewable tabs)

≥12 yr and adult: 30–60 mL **OR** 2400–4800 mg (6–12 chewable tabs)

**Antacid:**

**Child:**

**Liquid:** 2.5–5 mL/dose once daily—QID PO

**Tabs:** 400 mg once daily—QID PO

**Adult:**

**Liquid:** 5–15 mL/dose once daily—QID PO

**Concentrated liquid (800 mg/5 mL):** 2.5–7.5 mL/dose once daily—QID PO

**Tabs:** 400–1200 mg/dose once daily—QID PO

See [Magnesium Citrate](#). **Use with caution** in renal insufficiency (monitor magnesium level) and patients receiving digoxin. Drink a full 8 oz of liquid with each dose of the chewable tablets.

Pedia-Lax chewable tablet is magnesium hydroxide. However, other dosage forms bearing the

Pedia-Lax name (e.g., oral liquid, suppository, and enema) contain different active ingredients.

**MAGNESIUM OXIDE**

Mag-200, Mag-Ox 400, and other generics

60.32% Elemental Magnesium

**Oral magnesium salt**



A?



1



Yes



No



No

**Tabs (OTC):** 100, 200, 250, 400, 420, 500 mg

**Caps (OTC):** 300, 500 mg

400 mg magnesium oxide is equivalent to 241.3 mg elemental Mg or 20 mEq Mg.

**Doses expressed in magnesium oxide salt.**

**Magnesium supplementation:**

**Child:** 5–10 mg/kg/24 hr ÷ TID—QID PO

**Adult:** 400–800 mg/24 hr ÷ BID—QID PO

**Hypomagnesemia:**

**Child:** 65–130 mg/kg/24 hr ÷ QID PO

**Adult:** 2000 mg/24 hr ÷ QID PO

See [Magnesium Citrate](#). **Use with caution** in renal insufficiency (monitor magnesium level) and patients receiving digoxin. **For dietary recommended intake (U.S. recommended daily**

**allowance [RDA]) for magnesium, see Chapter 21.**

Pregnancy category is an “A” for doses up to 400 mg/24 hr.

**MAGNESIUM SULFATE**

Epsom salts, many others, and generics

9.9% Elemental Magnesium

**Magnesium salt**



D



2



Yes



No



No

MAGNESIUM SULFATE *continued*

**Injection:** 500 mg/mL (4 mEq/mL) (2, 10, 20, 50 mL); must be diluted before use

**Injection, prediluted in sterile water for injection; ready to use:** 40 mg/mL (0.325 mEq/mL) (50, 100, 500, 1000 mL); 80 mg/mL (0.65 mEq/mL) (50 mL)

**Injection, prediluted in D<sub>5</sub>W; ready to use:** 10 mg/mL (0.081 mEq/mL) (100 mL)

**Granules (Epsom salts and generics):** Approx. 40 mEq Mg per 5 g (454, 1810 g)

500 mg magnesium sulfate is equivalent to 49.3 mg elemental Mg or 4.1 mEq Mg.

**All doses expressed in magnesium sulfate salt.****Cathartic:**

**Child:** 0.25 g/kg/dose PO Q4–6 hr

**Adult:** 10–30 g/dose PO Q4–6 hr

**Hypomagnesemia or hypocalcemia:**

**IV/IM:** 25–50 mg/kg/dose Q4–6 hr × 3–4 doses; repeat PRN. **Max. single dose:** 2 g

**PO:** 100–200 mg/kg/dose QID PO

**Daily maintenance for parenteral nutrition:**

30–60 mg/kg/24 hr or 0.25–0.5 mEq/kg/24 hr IV; **max. dose:** 1 g/24 hr

**Adjunctive therapy for moderate to severe reactive airway disease exacerbation (bronchodilation); some recommend an IV saline bolus prior to magnesium administration to prevent hypotension:**

**Child:** 25–75 mg/kg/dose (**max. dose:** 2 g) × 1 IV over 20 min

**Adult:** 2 g/dose × 1 IV over 20 min

When magnesium sulfate is given IV, **beware** of hypotension, bradycardia, respiratory depression, complete heart block, and/or hypermagnesemia. Calcium gluconate (IV) should be available as **antidote**. **Use with caution** in patients with renal insufficiency (monitor magnesium levels) and with patients on digoxin. **Serum level dependent toxicity** includes the following: >3 mg/dL: CNS depression; >5 mg/dL: decreased deep tendon reflexes, flushing, somnolence; and >12 mg/dL: respiratory paralysis, heart block.

**Max. IV intermittent infusion rate:**

Emergent situations: 1 mEq/kg/hr or 125 mg MgSO<sub>4</sub> salt/kg/hr

Asymptomatic hypomagnesemia: 0.1 mEq/kg/hr or 12.5 mg MgSO<sub>4</sub> salt/kg/hr

Pregnancy category is “D” because hypocalcemia, osteopenia, and fractures in the developing baby or fetus have been reported in pregnant women receiving magnesium >5–7 days for preterm labor.

**MANNITOL**

Osmitrol and generics; inhalation: Bronchitol

**Osmotic diuretic**



**Injection:** 100, 150, 200, 250 mg/mL (10%, 15%, 20%, 25%, respectively)

**Inhalation powder in capsules:**

**Bronchitol:** 40 mg (10s, 140s, 560s with 1, 1, and 4 inhalers, respectively)

**Oliguria (child and adult):**

**Test dose to assess renal function:** 0.2 g/kg/dose (**max. dose:** 12.5 g) IV over 3–5 min.

If there is no diuresis within 2 hr, discontinue mannitol.

**Initial:** 0.5–1 g/kg/dose IV over 2–6 hr

**Maintenance:** 0.25–2 g/kg/dose Q4–6 hr IV over 2–6 hr

**Intracranial pressure reduction (see remarks):** 0.25–1 g/kg/dose IV/IO over 20–30 min; may repeat dose if needed

**Inhalational use:**

**Cystic fibrosis maintenance (Bronchitol; after passing tolerance test):**

*Continued*

MANNITOL *continued*

Child  $\geq 6$  yr and adult (limited data  $< 18$  yr): Inhale the contents of 10 capsules (400 mg) BID (every morning and 2–3 hr before bedtime). Use an inhaled short-acting bronchodilator 5–15 min prior to each dose.

**Contraindicated** in severe renal disease, active intracranial bleed, dehydration (especially severe hypovolemia), prior hypersensitivity to mannitol, and pulmonary edema. May cause circulatory overload and electrolyte disturbances. For hyperosmolar therapy, keep serum osmolality at 310–320 mOsm/kg. **Do not use** with aminoglycosides as this may enhance nephrotoxicity risk. Larger doses may require fluid bolus to prevent hypotension. May cause hypovolemia, headache, acute kidney injury, and polydipsia. Reduction in ICP occurs in 15 min and lasts 3–6 hr.

**Caution:** Drug may crystallize at low temperatures with concentrations  $\geq 15\%$ ; redissolve crystals by warming solution up to  $70^\circ\text{C}$  with agitation. Use an in-line filter ( $\leq 5$  micron).

**INHALED USE (Bronchitol):** **Do not** puncture the capsule more than once and **do not** swallow capsule. Use an inhaled bronchodilator prior to each dose. Patients are instructed to exhale fully first, then place inhaler device in the mouth by closing the lips around the mouthpiece, and take a steady, deep breath, inhaling the contents of the capsule, followed by holding the breath for 5 sec before exhaling. Repeat the process again if powder is still left. Each inhaler device should be replaced after 7 days of use. Use of this product is **contraindicated** if the patient fails the Bronchitol Tolerance Test (BTT); see product information for testing procedure and passing criteria. Common side effects from the BTT include: nausea, retching, chest discomfort, dizziness, headache, cough, dyspnea, respiratory tract pain, nasal discharge, throat irritation, and wheezing. Common side effects during maintenance therapy include arthralgia, cough, throat pain, pulmonary bacterial infection (positive sputum), and fever.

**MEBENDAZOLE**

Emverm; previously available as Vermox

**Anthelmintic**

C



1



No



Yes



No

**Chewable tabs:** 100 mg (may be swallowed whole or chewed)

**Child ( $\geq 2$  yr) and adult:**

**Pinworms (*Enterobius*):** 100 mg PO  $\times$  1, repeat in 2 wk if not cured.

**Hookworms, roundworms (*Ascaris*), and whipworm (*Trichuris*):** 100 mg PO BID  $\times$  3 days. Repeat in 3–4 wk if not cured. Alternatively, may administer 500 mg PO  $\times$  1 and repeat in 3–4 wk if not cured.

**Capillariasis:** 200 mg PO BID  $\times$  20–30 days

**Visceral larva migrans (toxocariasis):** 100–200 mg PO BID  $\times$  5 days

**Trichinellosis (*Trichinella spiralis*):** 200–400 mg PO TID  $\times$  3 days, then 400–500 mg PO TID  $\times$  10 days; use with steroids for severe symptoms

**Eosinophilic enterocolitis:** 100 mg PO BID  $\times$  3 days

See latest edition of the AAP Red Book for additional information.

Experience in children  $< 2$  yr and pregnancy is limited. May cause rash, headache, diarrhea, and abdominal cramping in cases of massive infection. Liver function test elevations and hepatitis have been reported with prolonged courses; monitor hepatic function with prolonged therapy. Family may need to be treated as a group. Therapeutic effect may be decreased if administered to patients receiving aminoquinolones, carbamazepine, or phenytoin. Cimetidine may increase the effects/toxicity of mebendazole. **Avoid** taking with metronidazole as this may cause serious skin reactions. Administer with food. Tablet may be crushed and mixed with food, swallowed whole, chewed, or turned into a soft mass by adding 2–3 mL of water to a spoon, then placing the tablet into the water (which can then be swallowed).

**MEDROXYPROGESTERONE**

Depo-Provera, Provera, Depo-Sub Q Provera 104, and generics

**Contraceptive, progestin**



X



2



No



Yes



No

**Tabs (Provera and generics):** 2.5, 5, 10 mg

**Injection, suspension as acetate:**

**Depo-Provera and generics, for IM use only:** 150 mg/mL (1 mL and 1 mL prefilled syringe), 400 mg/mL (2.5 mL); may contain parabens and polyethylene glycol

**Injection, prefilled syringe as acetate:**

**Depo-Sub Q Provera 104, for SC use only:** 104 mg (0.65 mL of 160 mg/mL); contains parabens and polyethylene glycol

**Adolescent and adult:**

**Contraception:** Initiate therapy during the first 5 days after onset of a normal menstrual period; within 5 days postpartum if not breastfeeding; or if breastfeeding, at 6 wk postpartum.

When converting contraceptive method to Depo-Sub Q Provera, administer dose within 7 days after the last day of using the previous method (pill, ring, patch).

**IM (Depo-Provera and generics):** 150 mg Q3 mo (every 13 wk)

**SC (Depo-Sub Q Provera 104):** 104 mg Q3 mo (every 12–14 wk)

**Amenorrhea:** 5–10 mg PO once daily × 5–10 days

**Abnormal uterine bleeding:** 5–10 mg PO once daily × 5–10 days initiated on the 16th or 21st day of the menstrual cycle

**Endometriosis-associated pain (Depo-Sub Q Provera 104):** 104 mg SC Q3 mo. Do not use longer than 2 yr due to impact on bone mineral density.



Consider patient's risk for osteoporosis because of the potential for decrease in bone mineral density with long-term use. Contraception use >2 yr for is NOT recommended.



**Contraindicated** in pregnancy, breast or genital cancer, liver disease, missed abortion, thrombophlebitis, thromboembolic disorders, cerebral vascular disease, and undiagnosed vaginal bleeding. **Use with caution** in patients with family history of breast cancer, depression, diabetes, and fluid retention. May cause dizziness, headache, insomnia, fatigue, nausea, weight increase, appetite changes, amenorrhea, and breakthrough bleeding. Cholestatic jaundice, adrenal suppression, anaphylaxis, and increased intracranial pressure have been reported. Injection site reactions may include pain/tenderness, persistent atrophy/indentation/dimpling, lipodystrophy, sterile abscess, skin color change, and node/lump.

Drug is a substrate to CYP 450 3A4 isoenzyme. Aminoglutethimide may decrease medroxyprogesterone levels. May alter thyroid and liver function tests, prothrombin time, factors VII, VIII, IX, and X, and metyrapone test.

The WHO recommends the use of injectable depot medroxyprogesterone should not be used before 6 weeks postpartum.

**Do not** inject IM or SC product intravenously. Shake IM injection vial well before use, and administer in the upper arm or buttock. Administer SC injection product into the anterior thigh or abdomen. Administer oral doses with food.

**MEFLOQUINE HCL**

Generics; previously available as Lariam

**Antimalarial**



B



2



No



Yes



No

**Tabs:** 250 mg (228 mg base)

Continued

MEFLOQUINE HCL *continued*

Doses expressed in mg mefloquine HCl salt.

**Malaria prophylaxis (start 2 wk prior to exposure and continue for 4 wk after leaving endemic area; see remarks):**

**Child (PO, administered Q7 days):**

<10 kg: 5 mg/kg

10–19 kg: 62.5 mg (1/4 tablet)

20–30 kg: 125 mg (1/2 tablet)

31–45 kg: 187.5 mg (3/4 tablet)

>45 kg: 250 mg (1 tablet)

**Adult:** 250 mg PO Q7 days

**Malaria treatment (uncomplicated/mild infection, chloroquine-resistant *Plasmodium vivax*; used in combination with other agents):**

**Child ≥6 mo and >5 kg:** 15 mg/kg (max. dose: 750 mg) × 1 PO followed by 10 mg/kg (max. dose: 500 mg) × 1 PO 6–12 hr later

**Adult:** 750 mg × 1 PO followed by 500 mg × 1 PO 6–12 hr later

See latest edition of the Red Book for additional information.

**Contraindicated** in active or recent history of depression, anxiety disorders, psychosis or schizophrenia, seizures, or hypersensitivity to quinine or quinidine. **Use with caution** in cardiac dysrhythmias and neurologic disease. May cause dizziness, ringing of the ears, headache, syncope, psychiatric symptoms (e.g., anxiety, paranoia, depression, hallucinations, and psychotic behavior), seizures, ocular abnormalities, GI symptoms, leukopenia, and thrombocytopenia. If neurologic or psychiatric side effects occur, discontinue therapy and use an alternative medication. Most adverse events occur within 3 doses with prophylaxis use. Monitor liver enzymes and ocular exams for therapies >1 yr.

Mefloquine is a substrate and inhibitor of P-glycoprotein and may reduce valproic acid levels. ECG abnormalities may occur when used in combination with quinine, quinidine, chloroquine, halofantrine, and β-blockers. If any of the aforementioned antimalarial drugs is used in the initial treatment of severe malaria, initiate mefloquine at least 12 hr after the last dose of any of these drugs. **Do not** initiate halofantrine or ketoconazole within 15 days of the last dose of mefloquine. Use with chloroquine may increase risk for seizures. Rifampin may decrease mefloquine levels.

**Do not** take on an empty stomach. Administer with at least 240 mL (8 oz) water. Treatment failures in children may be related to vomiting of administered dose. If vomiting occurs less than 30 min after the dose, administer a second full dose. If vomiting occurs 30–60 min after the dose, administer an additional half-dose. If vomiting continues, monitor patient closely and consider alternative therapy.

**MEROPENEM**

Generics; previously available as Merrem

**Carbapenem antibiotic**



B



2



Yes



Yes



No

**Injection:** 0.5, 1 g; contains 3.92 mEq Na/g drug

**Injection, in a duplex chamber to be diluted in supplied sodium chloride for injection:**

500 mg in 50 mL; contains 10.7 mEq Na per 500 mg drug when diluted

1000 mg in 50 mL; contains 12.6 mEq Na per 1000 mg drug when diluted

**Neonate and infant <3 mo (IV):**

**Non-CNS general dosing (meropenem MIC <4):**

≤2 kg:

≤14 days old: 20 mg/kg/dose Q12 hr

MEROPENEM *continued*

15–28 days old: 20 mg/kg/dose Q8 hr

29–60 days old: 30 mg/kg/dose Q8 hr

>2 kg:

≤14 days old: 20 mg/kg/dose Q8 hr

15–60 days old: 30 mg/kg/dose Q8 hr

**Non-CNS infection with moderately resistant meropenem isolate (MIC 4–8 mCg/mL; from a single-dose PK simulation study):**

>30 wks' gestation and >7 days old: 40 mg/kg/dose IV Q8 hr

**Intra-abdominal infection (meropenem MIC <4 mCg/mL):**

<32 wks' gestation:

<14 days old: 20 mg/kg/dose Q12 hr

≥14 days old: 20 mg/kg/dose Q8 hr

≥32 wks' gestation:

<14 days old: 20 mg/kg/dose Q8 hr

≥14 days old: 30 mg/kg/dose Q8 hr

**Meningitis (limited data):**

≤2 kg:

≤14 days old: 40 mg/kg/dose Q12 hr

15–60 days old: 40 mg/kg/dose Q8 hr

>2 kg:

≤60 days old: 40 mg/kg/dose Q8 hr

1–3 mo, IV; recommendation from 2004 IDSA meningitis practice guidelines: 40 mg/kg/dose Q8 hr

**Infant (≥3 mo), child, and adolescent (IV):**

**Meningitis, severe infections, and cystic fibrosis pulmonary exacerbations:** 40 mg/kg/dose (max. dose: 2 g/dose) Q8 hr

**Complicated skin and skin structure infection:** 10 mg/kg/dose (max. dose: 500 mg/dose) Q8 hr. For severe or necrotizing infections or *Pseudomonas aeruginosa* infection (suspected or confirmed), use 20 mg/kg/dose (max. dose: 1 g/dose) Q8 hr.

**Intra-abdominal and mild/moderate infections, and fever/neutropenia empiric therapy:** 20 mg/kg/dose (max. dose: 1 g/dose) Q8 hr

**Adult (IV):**

**Skin and subcutaneous tissue infections:** 500 mg Q8 hr; use 1 g Q8 hr for suspected or confirmed *Pseudomonas aeruginosa*

**Intra-abdominal and mild/moderate infections; and fever/neutropenia empiric therapy:** 1 g Q8 hr

**Meningitis and severe infections:** 2 g Q8 hr

**Contraindicated** in patients sensitive to carbapenems, or with a history of anaphylaxis to  $\beta$ -lactam antibiotics. **Use with caution** in meningitis and CNS disorders (may cause seizures) and renal impairment (**adjust dose; see Chapter 31**). Drug penetrates well into the CSF.



May cause diarrhea, rash, nausea, vomiting, oral moniliasis, glossitis, pain and irritation at the IV injection site, and headache. Hepatic enzyme and bilirubin elevation, dermatologic reactions (including Stevens-Johnson, DRESS, and TEN), leukopenia, thrombocytopenia (in renal dysfunction), and neutropenia have been reported. Probenecid may increase serum meropenem levels. May reduce valproic acid levels.

Lengthening the IV drug administration time to 4 hr will improve the meropenem concentration time above the MIC and may be useful in situations of resistant organisms.

**MESALAMINE**

Apriso, Asacol HD, Canasa, Delzicol, Lialda, Pentasa, Rowasa, SfRowasa, and generics; 5-aminosalicylic acid, 5-ASA

**Salicylate, GI antiinflammatory agent**



B



2



Yes



Yes



No

**Caps, controlled release:**

**Pentasa and generics:** 250, 500 mg

**Delzicol and generics:** 400 mg

**Apriso and generics (for Q24 hr dosing):** 375 mg; contains aspartame

**Tab, delayed release:**

**Asacol HD and generics:** 800 mg

**Lialda and generics:** 1200 mg

**Suppository (Canasa and generics):** 1000 mg (1, 6s, 30s)

**Rectal suspension enema (Rowasa, SfRowasa, and generics):** 4 g/60 mL; contains sulfites (SfRowasa is sulfite free) and sodium benzoate

**Child and adolescent (ulcerative colitis):**

**Caps (controlled release) and tabs (delayed release):** 60–80 mg/kg/24 hr ÷ once daily—BID (defined by dosage form used); **max. dose:** 4.8 g/24 hr

**Delzicol (mild/moderate ulcerative colitis treatment for 6 wk; ≥5–18 yr; see remarks):**

**17–32 kg:** 800 mg QAM and 400 mg Q afternoon PO

**33–53 kg:** 1200 mg QAM and 800 mg Q afternoon PO

**54–90 kg:** 1200 mg QAM and Q afternoon PO

**Lialda (mild/moderate ulcerative colitis; child and adolescent ≥24 kg):**

**24–35 kg:** 2400 mg once daily PO × 8 weeks, then decrease to 1200 mg once daily PO

**>35–50 kg:** 3600 mg once daily PO × 8 weeks, then decrease to 2400 mg once daily PO

**>50 kg:** 4800 mg once daily PO × 8 weeks, then decrease to 2400 mg once daily PO

**Older child and adolescent (mild/moderate ulcerative colitis; see remarks):**

**Enema (Rowasa):** 25 mg/kg/dose (**max. dose:** 1 g/dose) PR once daily; doses greater than 1 g are not more effective

**Adult (mild/moderate ulcerative colitis; see remarks):****Caps, controlled release:**

**Initial therapy:** 1 g QID PO × 3–8 wk

**Delzicol:** 800 mg TID PO × 6 wk

**Maintenance therapy for remission:**

**Apriso:** 1.5 g QAM PO

**Delzicol:** 1.6 g/24 hr PO divided BID—QID

**Pentasa:** 1 g QID PO

**Tab, delayed release:****Initial therapy:**

**Asacol HD:** 1.6 g TID PO × 6 wk

**Lialda:** 2.4–4.8 g once daily PO up to 8 wk

**Maintenance therapy for remission:**

**Generic:** At least 2 g PO once daily

**Lialda:** 2.4 g PO once daily

**Suppository (ulcerative proctitis):** 1000 mg QHS PR × 3–6 wk; retain each dose in the rectum for 1–3 hr or longer, if possible

**Rectal suspension (ulcerative colitis or proctitis):** 60 mL (4 g) QHS × 3–6 wk, retaining each dose for about 8 hr; lie on left side during administration to improve delivery to the sigmoid colon



MESALAMINE *continued*

Generally **not recommended** in children <16 yr with chickenpox or flu-like symptoms (risk of Reye syndrome). **Contraindicated** in active peptic ulcer disease, severe renal failure, and salicylate hypersensitivity. Rectal suspension should not be used in patients with history of sulfite allergy. **Use with caution** in sulfasalazine hypersensitivity, impaired hepatic or renal function, pyloric stenosis, nephrotoxic medications, and concurrent thrombolytics. May cause headache, GI discomfort, pancreatitis, pericarditis, and rash. Angioedema, Stevens-Johnson syndrome, DRESS, fatal infections (e.g., sepsis and pneumonia; discontinue use), interstitial nephritis, renal failure, nephrolithiasis, and photosensitivity have been reported. May cause a false-positive urinary normetanephrine test.

Safety and efficacy of Delzicol in children 5–17 yr for mild/moderate acute ulcerative colitis have been established over a 6-wk period; safety and efficacy for maintenance of remission of ulcerative colitis in children have not been established. Safety and efficacy of Canasa suppositories have not been demonstrated for mild/moderate active ulcerative proctitis in a 6-wk open-label study in 49 patients 5–17 yr old.

**Do not** administer with lactulose or other medications that can lower intestinal pH. Use with myelosuppressive drugs (e.g., azathioprine, 6-mercaptopurine) may increase risk for blood disorders, bone marrow failure, and associated complications.

Two Delzicol 400-mg capsules have not been shown to be interchangeable or substitutable with one mesalamine 800-mg delayed release tablet. Oral capsules are designed to release medication throughout the GI tract, and oral tablets release medication at the terminal ileus and beyond. 400 mg PO mesalamine is equivalent to 1 g sulfasalazine PO. Tablets should be swallowed whole.

**METFORMIN**

Glumetza, Fortamet, Riomet, and generics; previously available as Glucophage and Glucophage XR

**Antidiabetic, biguanide**



B



2



Yes



Yes



No

**Tabs:** 500, 850, 1000 mg

**Tabs, extended release:**

**Generics:** 500, 750, 1000 mg

**Fortamet and Glumetza:** 500, 1000 mg

**Oral suspension (Riomet and generics):** 100 mg/mL (120, 480 mL); may contain saccharin and propylene glycol

**Type 2 diabetes:** Administer all doses with meals (e.g., BID: morning and evening meals).

**Child (10–16 yr; PO) (see remarks):**

**Immediate release dosage forms:** Start with 500 mg BID; may increase dose every 1–2 wk as tolerated by 500 mg/24 hr in 2 divided doses up to a **max. dose** of 2000 mg/24 hr.

**Extended release tabs:** Start with 500–1000 mg once daily  $\times$  7–14 days; may increase dose every 1–2 wk as tolerated by 500–1000 mg/24 hr as once daily or divided doses up to a **max. dose** of 2000 mg/24 hr.

**Child  $\geq$ 17 yr and adult (see remarks):**

**500 mg immediate release tabs:** Start with 500 mg PO BID; may increase dose weekly by 500 mg/24 hr in 2 divided doses up to a **max. dose** of 2500 mg/24 hr. Administer 2500 mg/24 hr doses by dividing daily dose TID with meals.

**850 mg immediate release tabs:** Start with 850 mg PO once daily with morning meal; may increase by 850 mg every 2 wk up to a **max. dose** of 2550 mg/24 hr (first dosage increment: 850 mg PO BID; second dosage increment: 850 mg PO TID).



*Continued*

METFORMIN *continued*

**Extended release tabs:** Start with 500 mg PO once daily with evening meal; may increase by 500 mg every week up to a **max. dose** of 2000 mg/24 hr (if glycemic control is not achieved at **max. dose**, divide dose to 1000 mg PO BID). If using Fortamet, **max. dose** is 2500 mg/24 hr. If a dose >2000 mg is needed, consider switching to non—extended release tablets in divided doses and increase dose to a **max. dose** of 2550 mg/24 hr.

Assess patient's eGFR prior to initiating therapy. **Contraindicated** in severe renal impairment (<30 mL/min/1.73 m<sup>2</sup>), hepatic impairment (increased risk for lactic acidosis), CHF, and metabolic acidosis and during radiology studies using iodinated contrast media. **Use with caution** when transferring patients from chlorpropamide therapy (potential hypoglycemia risk), excessive alcohol intake, hypoxemia, dehydration, surgical procedures, mild/moderate renal impairment, hepatic disease, anemia, and thyroid disease. 

**Fatal lactic acidosis** (diarrhea; severe muscle pain, cramping; shallow and fast breathing; unusual weakness and sleepiness) and decrease in vitamin B<sub>12</sub> levels have been reported. May cause GI discomfort (~50% incidence), anorexia, and vomiting. Transient abdominal discomfort or diarrhea has been reported in 40% of pediatric patients. Organic cationic transporter-2 (OCT2) and multidrug and toxin extrusion (MATE) inhibitors (e.g., cimetidine), furosemide, and nifedipine may increase the effects/toxicity of metformin. In addition to monitoring serum glucose and glycosylated hemoglobin, monitor renal function and hematologic parameters (baseline and annual).

Adult patients initiated on 500 mg PO BID may also have their dose increased to 850 mg PO BID after 2 wk.

**COMBINATION THERAPY WITH SULFONYLUREAS:** If patient has not responded to 4 wk of **maximum** doses of metformin monotherapy, consider gradual addition of an oral sulfonylurea with continued **maximum** metformin dosing (even if failure with sulfonylurea has occurred). Attempt to identify the minimum effective dosage for each drug (metformin and sulfonylurea) because the combination can increase risk for sulfonylurea-induced hypoglycemia. If patient does not respond to 1—3 mo of combination therapy with maximum metformin doses, consider discontinuing combination therapy and initiating insulin therapy.

Administer all doses with food.

**METHADONE HCL**

Methadose and generics; previously available as Dolophine

**Narcotic, analgesic**



C



2



Yes



Yes



No

**Tabs:** 5, 10 mg

**Tabs, dispersible (Methadose and generics):** 40 mg

**Oral solution:** 5 mg/5 mL (500 mL), 10 mg/5 mL (500 mL); contains 8% alcohol

**Concentrated oral solution (Methadose and generics):** 10 mg/mL (30 mL); may contain propylene glycol and parabens and may be sugar free

**Injection:** 10 mg/mL (20 mL), contains 0.5% chlorobutanol

**Analgesia (initial doses; see remarks):**

**Child:** 0.7 mg/kg/24 hr ÷ Q4—6 hr PO, SC, IM, or IV PRN pain; **max. dose:** 10 mg/dose

**Adult:** 2.5—10 mg/dose Q8—12 hr PO, SC, IM, or IV PRN pain

**Detoxification or maintenance:** See package insert.

Unintentional overdoses have resulted in fatalities and severe adverse events such as respiratory depression and cardiac arrhythmias. **Use with caution** in hepatic (**avoid** in severe cases) and biliary tract impairment. May cause respiratory depression, sedation, increased intracranial pressure, hypotension, and bradycardia. Cardiac QT interval prolongation and serious 

METHADONE HCL *continued*

arrhythmias have occurred mostly with higher doses; **avoid use** with other medications that may prolong QT interval. Nystagmus, strabismus, hypoglycemia, hypokalemia, hypomagnesemia, and weight gain have been reported.

Average  $T_{1/2}$ : Children 19 hr, and adults 35 hr. Duration of action PO is 6–8 hr initially and 22–48 hr after repeated doses. Respiratory effects last longer than analgesia. Accumulation may occur with continuous use, making it necessary to adjust dose.

Nevirapine may decrease serum levels of methadone. Fatalities have been reported with abuse in combination with benzodiazepines. Serotonin syndrome has been reported with use with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitor (SNRIs), TCAs, 5-HT<sub>3</sub> antagonists, MAO inhibitors, and drugs that affect the serotonergic neurotransmitter system (e.g., trazodone, tramadol). Methadone is a substrate for CYP 450 3A3/4, 2D6, and 1A2 and inhibitor of 2D6.

See [Chapter 6](#) for equianalgesic dosing and onset of action. **Adjust dose in renal failure (see Chapter 31).**

A Risk Evaluation and Mitigation Strategy (REMS) is required for healthcare providers to ensure the benefits outweigh the risks of addiction, abuse, and misuse. See [www.fda.gov/OpioidAnalgesicREMSBlueprint](http://www.fda.gov/OpioidAnalgesicREMSBlueprint) or call 1-800-503-0784.

**METHIMAZOLE**

Generics; previously available as Tapazole

**Antithyroid agent**



D 2 No Yes No

**Tabs:** 5, 10 mg

**Hyperthyroidism:****Child:**

**Initial:** 0.4–0.7 mg/kg/24 hr or 15–20 mg/m<sup>2</sup>/24 hr PO ÷ Q8 hr

**Maintenance:** 1/3–2/3 of initial dose PO ÷ Q8 hr

**Max. dose:** 30 mg/24 hr

**Adult:**

**Initial:** 15–60 mg/24 hr PO ÷ Q8 hr

**Maintenance:** 5–15 mg/24 hr PO ÷ Q8 hr



Readily crosses placental membranes and distributes into breast milk (maternal doses ≤20 mg/24 hr are considered safe, but there are insufficient data to support safe use with maternal doses >20 mg/24 hr). Blood dyscrasias, dermatitis, hepatitis, arthralgia, CNS reactions, pruritus, nephritis, hypoprothrombinemia, agranulocytosis, headache, fever, and hypothyroidism may occur. Acute hepatic failure and hepatitis have been reported.



May increase the effects of oral anticoagulants. When correcting hyperthyroidism, consider whether existing β-blocker, digoxin, and theophylline doses need to be reduced to avoid potential toxicities. Switch to maintenance dose when patient is euthyroid. Administer all doses with food.

**METHYLENE BLUE**

ProVayBlue and generics

**Antidote, drug-induced methemoglobinemia, and cyanide toxicity**



X ? Yes No No

**Injection:** 10 mg/mL (1%) (10 mL)

**Intravenous solution (ProVayBlue):** 50 mg/10 mL (2, 10 mL; see remarks)

*Continued*

METHYLENE BLUE *continued***Methemoglobinemia:**

**Child and adult:** 1–2 mg/kg/dose or 25–50 mg/m<sup>2</sup>/dose IV/IO over 5 min. May repeat in 30–60 min if needed.



At high doses, may cause methemoglobinemia. **Avoid** subcutaneous or intrathecal routes of administration. **Use with caution** in G6PD deficiency or renal insufficiency (methylene blue concentrations have increased in subjects with renal impairment). May cause nausea, vomiting, dizziness, headache, diaphoresis, stained skin, and abdominal pain. Causes blue-green discoloration of urine and feces.



Serotonin syndrome has been reported with the coadministration of SSRI, SNRI, or clomipramine. Use with bupropion, paroxetine, sertraline, duloxetine, vilazodone, venlafaxine, fluoxetine, or desipramine is considered **contraindicated**.

ProvayBlue (50 mg/10 mL) dosage form is hypotonic and may be diluted in 50 mL D<sub>5</sub>W to prevent local infusion pain. **Avoid** diluting in sodium chloride as this may reduce the solubility of methylene blue.

**METHYLPHENIDATE HCL**

Ritalin, Adhansia XR, Aptensio XR, Jornay PM, Methylin, Metadate ER, Methylin ER, Concerta, Relexxii, QuilliChew ER, Quillivant XR, Ritalin LA, Cotempla XR-ODT, Daytrana, and generics

**CNS stimulant**



C

2

No

Yes

No

**Tabs (Ritalin and generics):** 5, 10, 20 mg

**Chewable tabs (generics):** 2.5, 5, 10 mg; contains phenylalanine

**Extended release chewable tabs (dosed once daily in the morning):**

**QuilliChew ER:** 20, 30, 40 mg; contains phenylalanine

**Oral solution (Methylin and generics):** 1 mg/mL, 2 mg/mL; may contain propylene glycol

**Oral suspension, extended release (dosed once daily in the morning):**

**Quillivant XR:** 25 mg/5 mL (60, 120, 150, 180 mL); contains sodium benzoate

**Extended release tabs:**

**8-hr duration (Metadate ER):** 20 mg; dosed BID–TID

**24-hr duration:**

**Concerta and generics:** 18, 27, 36, 54 mg

**Relexxii and generics:** 72 mg

**Extended release oral disintegrating tabs:**

**Cotempla XR-ODT (dosed once daily in the morning):** 8.6, 17.3, 25.9 mg; contains polyethylene glycol

**Extended release caps:**

**24-hr duration:**

**Ritalin LA, and generics:** 10, 20, 30, 40, 50, 60 mg

**Adhansia XR:** 25, 35, 45, 55, 70, 85 mg

**Aptensio XR:** 10, 15, 20, 30, 40, 50, 60 mg

**Jornay PM:** 20, 40, 60, 80, 100 mg (dosed only in the evening)

**Transdermal patch (Daytrana and generics):** 10 mg/9 hr (each 12.5 cm<sup>2</sup> patch contains 27.5 mg), 15 mg/9 hr (each 18.75 cm<sup>2</sup> patch contains 41.3 mg), 20 mg/9 hr (each 25 cm<sup>2</sup> patch contains 55 mg), 30 mg/9 hr (each 37.5 cm<sup>2</sup> patch contains 82.5 mg) (30s)

**Attention-deficit/hyperactivity disorder (ADHD):**

**Immediate release oral dosage forms (Methylin, Ritalin; ≥6 yr):**



METHYLPHENIDATE HCL *continued*

**Initial:** 0.3 mg/kg/dose (or 2.5–5 mg/dose) given before breakfast and lunch. May increase by 0.1 mg/kg/dose PO (or 5–10 mg/24 hr) weekly until maintenance dose achieved. May give extra afternoon dose if needed.

**Maintenance dose range:** 0.3–1 mg/kg/24 hr

**Max. dose:** 2 mg/kg/24 hr or 60 mg/24 hr for those weighing ≤50 kg and 100 mg/24 hr >50 kg

**Extended release once-daily oral dosage form (Concerta; ≥6 yr):**

**Methylphenidate-naïve patients:** Start with 18 mg PO QAM for children and adolescents and 18–36 mg PO QAM for adults; dosage may be increased at weekly intervals at 18 mg increments up to the following **max. dose:**

**6–12 yr:** 54 mg/24 hr

**13–17 yr:** 72 mg/24 hr **not to exceed** 2 mg/kg/24 hr

**Patients weighing >50 kg:** Higher **max. dose** of 108 mg/24 hr may be used.

**Patients currently receiving methylphenidate:** See following table.

**RECOMMENDED DOSE CONVERSION FROM METHYLPHENIDATE REGIMENS TO CONCERTA**

Previous Methylphenidate Daily Dose	Recommended Concerta Dose
5 mg PO BID–TID or 20 mg SR PO once daily	18 mg PO QAM
10 mg PO BID–TID or 40 mg SR PO once daily	36 mg PO QAM
15 mg PO BID–TID or 60 mg SR PO once daily	54 mg PO QAM
20 mg PO BID–TID	72 mg PO QAM

After a week of receiving the above-recommended Concerta dose, dose may be increased in 18 mg increments at weekly intervals PRN up to a **maximum** of 54 mg/24 hr for 6–12 yr and 72 mg/24 hr (**not to exceed** 2 mg/kg/24 hr) for 13–17 yr.

**Other extended release oral dosage forms (see specific product information if converting from another product or dosage form):**

Product (Dosage Form)	Initial Dose (≥6 yr) <sup>a</sup>	Dosage Adjustment	Max. Dose
Adhansia XR (extended release caps)	25 mg PO once daily in the AM	Increase at 10–15 mg increments at intervals ≥5 days PRN	85 mg/24 hr but doses ≥70 mg/24 hr were associated with higher rate of side effects in children
Aptensio XR (extended release caps)	10 mg PO once daily in the AM	Increase at 10 mg increments Q7 days PRN	60 mg/24 hr
Cotempla XR-ODT (extended release oral disintegrating tabs) <sup>b</sup>	17.3 mg PO once daily in the AM	Increase at 8.6 or 17.3 mg increments Q7 days PRN	51.8 mg/24 hr
Jornay PM (extended release caps)	20 mg PO QHS (between 6:30 and 9:30 PM; 8:00 PM was the most optimal time for 6–12 yr in clinical trials)	Increase at 20 mg increments Q7 days PRN; administered QHS	100 mg/24 hr

*Continued*

METHYLPHENIDATE HCL *continued*

Product (Dosage Form)	Initial Dose ( $\geq 6$ yr) <sup>a</sup>	Dosage Adjustment	Max. Dose
Metadate CD (extended release caps)	20 mg PO once daily	Increase at 10–20 mg increments Q7 days PRN	$\leq 50$ kg: 60 mg/24 hr >50 kg: 100 mg/24 hr
Quillivant XR (extended release oral suspension) <sup>a</sup>	20 mg PO once daily	Increase at 10–20 mg increments Q7 days PRN	60 mg/24 hr
QuilliChew (extended release chewable tabs)	20 mg PO once daily	Increase by 10, 15, or 20 mg Q7 days PRN	Doses >60 mg/24 hr have not been studied
Relexxii (extended release tabs)	18 mg PO once daily in the AM	Increase by 18 mg Q7 days PRN	6–12 yr <sup>c</sup> : 54 mg/24 hr 13–<18 yr <sup>c</sup> : lesser of 72 mg/24 hr or 2 mg/kg/24 hr $\geq 18$ yr: 72 mg/24 hr
Ritalin LA (extended release caps)	20 mg PO once daily	Increase at 10 mg increments Q7 days PRN	$\leq 50$ kg: 60 mg/24 hr >50 kg: 100 mg/24 hr

<sup>a</sup>Quillivant XR dosing recommendations for children 6–12 yr.

<sup>b</sup>Cotempla XR ODT dosing recommendations for children 6–17 yr.

<sup>c</sup>Higher doses have not been studied for this age group.

**Metadate ER (8-hr duration of action):** Convert immediate release tabs when the 8-hr dosage corresponds to the available extended release tablet size. Usual **max. dose:** 60 mg/24 hr for children, but some patients >50 kg may tolerate doses up to 100 mg/24 hr with increased monitoring.

**Transdermal patch (Daytrana; see remarks):** Apply to the hip 2 hr before the effect is needed and remove 9 hr later. Patch may be removed before 9 hr if shorter duration of effect is desired or if late-day adverse effects appear.

**6–17 yr:** Start with 10 mg/9 hr patch once daily. Increase dose PRN Q7 days by increasing to the next dosage strength. Higher starting doses have been reported in patients converting from oral dosage forms >20 mg/24 hr.

**Contraindicated** in glaucoma, anxiety disorders, motor tics, and Tourette syndrome. Medication should generally not be used in children <5 yr old; diagnosis of ADHD in this age group is extremely difficult and should be done only in consultation with a specialist. Sudden death (children, adolescents, and adults), stroke (adults), and MI (adults) have been reported in patients with preexisting structural cardiac abnormalities or other serious heart problems. **Use with caution** in patients with hypertension, psychiatric conditions, and epilepsy. Insomnia, weight loss, anorexia, rash, nausea, emesis, abdominal pain, hypertension or hypotension, tachycardia, arrhythmias, palpitations, restlessness, headaches, fever, tremor, visual disturbances, and thrombocytopenia may occur. Abnormal liver function (ranging from transaminase elevation to severe hepatic injury), cerebral arteritis and/or occlusion, peripheral vasculopathy (including Raynaud phenomenon), leukopenia and/or anemia, hypersensitivity reactions, transient depressed mood, paranoia, mania, auditory hallucination, priapism, and scalp hair loss have been reported. Skin irritation, chemical leukoderma, and contact dermatitis have been reported with transdermal route. High doses may slow growth by appetite suppression. GI obstruction has been reported with Concerta.



METHYLPHENIDATE HCL *continued*


May increase serum concentrations/effects of tricyclic antidepressants, dopamine agonists (e.g., haloperidol), phenytoin, phenobarbital, and warfarin. May decrease the effects of antihypertensive drugs. Effect of methylphenidate may be potentiated by MAO inhibitors; hypertensive crisis may also occur if used within 14 days of discontinuance of the MAO inhibitor. When used with risperidone, any dosage adjustment (increase/decrease) to either medication can result in extrapyramidal symptoms.

**Extended/sustained release dosage forms have either an 8- or 24-hr dosage interval (as stipulated previously).** Concerta dosage form delivers 22.2% of its dose as an immediate release product with the remaining amounts as an extended release product (e.g., 18 mg strength: 4 mg as immediate release, and 14 mg as extended release). Jornay PM is dosed only in the evening and should **NOT** be taken in the morning. **Do not** consume alcohol with Ritalin LA dosage form, because it may result in a more rapid release of the drug. **Do not** expose transdermal application site to external heat sources (e.g., electric blankets, heating pads); this may increase drug release.

**METHYLPREDNISOLONE**

Medrol, Medrol Dosepack, Solu-Medrol, Depo-Medrol, and generics

**Corticosteroid**



**Tabs:** 2, 4, 8, 16, 32 mg

**Tabs, dose pack (Medrol Dosepack and generics):** 4 mg (21s)

**Injection, Na succinate (Solu-Medrol and generics):** 40, 125, 500, 1000 mg (IV or IM use); multidose vials contain benzyl alcohol

**Injection, acetate suspension (Depo-Medrol and generics; for IM, intrasynovial, and soft tissue injection):** 20 mg (5 mL), 40 mg (1, 5, 10 mL), 80 mg/mL (1, 5 mL); multidose vials contain benzyl alcohol

**Antiinflammatory/immunosuppressive:**

**PO/IM/IV (use succinate salt for IM/IV):** 0.5–1.7 mg/kg/24 hr ÷ Q6–12 hr

**Asthma exacerbations (2007 National Heart, Lung, and Blood Institute Guideline Recommendations; dose until peak expiratory flow reaches 70% of predicted or personal best):**

**Child ≤12 yr (IV/IM/PO; use succinate salt for IV/IM):** 1–2 mg/kg/24 hr ÷ Q12 hr (max. dose: 60 mg/24 hr). An alternative regimen for ≤5 yr old of 1 mg/kg/dose Q6 hr × 24 hr followed by oral corticosteroids to complete a 3–5 day course has been suggested.

**Child >12 yr and adult (IV/IM/PO; use succinate salt for IV/IM):** 40–80 mg/24 hr ÷ Q12–24 hr

**Outpatient asthma exacerbation burst therapy (longer durations may be necessary):**

**PO:**

**Child ≤12 yr:** 1–2 mg/kg/24 hr ÷ Q12–24 hr (max. dose: 60 mg/24 hr) × 3–10 days

**Child >12 yr and adult:** 40–60 mg/24 hr ÷ Q12–24 hr × 3–10 days

**IM (use methylprednisolone acetate product) for patients vomiting or with adherence issues:**

**Child ≤4 yr:** 7.5 mg/kg (max. dose: 240 mg) IM × 1

**Child >4 yr, adolescent, and adult:** 240 mg IM × 1

**Acute spinal cord injury:**

30 mg/kg IV over 15 min followed in 45 min by a continuous infusion of 5.4 mg/kg/hr × 23 hr

**See Chapter 10** for relative steroid potencies. Acetate form may also be used for intra-articular and intralesional injection and has longer times to max. effect and duration of action; it should **NOT** be given IV. **Use with caution** with systemic sclerosis. Like all steroids, may cause hypertension, leukocytosis, pseudotumor cerebri, acne, Cushing syndrome, adrenal axis suppression,

*Continued*

METHYLPREDNISOLONE *continued*

GI bleeding, hyperglycemia, and osteoporosis. Hypertrophic cardiomyopathy has been reported in premature infants.

Barbiturates, phenytoin, and rifampin may enhance methylprednisolone clearance. Erythromycin, itraconazole, and ketoconazole may increase methylprednisolone levels. Methylprednisolone may increase cyclosporine and tacrolimus levels.

**METOCLOPRAMIDE**

Reglan and generics

**Antiemetic, prokinetic agent**



B



2



Yes



No



No

**Tabs:** 5, 10 mg

**Tabs, orally disintegrating (ODT):** 5, 10 mg

**Injection:** 5 mg/mL (2 mL)

**Oral solution:** 5 mg/5 mL (473 mL)

**Gastroesophageal reflux (GER) or GI dysmotility:**

**Infant and child:** 0.1–0.2 mg/kg/dose up to QID IV/IM/PO; **max. dose:** 0.8 mg/kg/24 hr or 10 mg/dose

**Adult:** 10 mg/dose QAC and QHS IV/IM/PO

**Antiemetic for chemotherapy-induced nausea and vomiting (child and adolescent):** Premedicate with diphenhydramine to reduce extrapyramidal symptoms (EPS).

1–2 mg/kg/dose Q2–6 hr IV/IM/PO up to 5 doses/24 hr

**Postoperative nausea and vomiting:**

**Child (limited data):** 0.1–0.2 mg/kg/dose Q6–8 hr PRN IV; **max. dose:** 10 mg/dose  
**>14 yr and adult:** 10 mg Q6–8 hr PRN IV

**Contraindicated** in GI obstruction, seizure disorder, tardive dyskinesia, pheochromocytoma, or in patients receiving drugs likely to cause EPS. May cause EPS, especially at higher doses.

Sedation, headache, anxiety, depression, leukopenia, and diarrhea may occur. Neuroleptic malignant syndrome and tardive dyskinesia (increased risk with prolonged duration of therapy; **avoid use** >12 wk) have been reported.

Metoclopramide is a substrate for CYP 450 2D6; inhibitors to this enzyme may increase risk for metoclopramide toxicity. G6PD deficiency may increase risk for methemoglobinemia; **DO NOT** use methylene blue as it may cause a fatal hemolytic anemia.

For GER, give 30 min before meals and at bedtime. **Reduce dose in renal impairment (see Chapter 31).**

**METOLAZONE**

Generics; previously available as Zaroxolyn

**Diuretic, thiazide-like**



B



2



Yes



Yes



No

**Tabs:** 2.5, 5, 10 mg

**Oral suspension:** 0.25 mg/mL , 1 mg/mL 

**Dosage based on Zaroxolyn (for oral suspension, see remarks):****Child:**

**Edema:** 0.2–0.4 mg/kg/24 hr ÷ once daily—BID PO

**Adult:**

**Hypertension:** 2.5–5 mg once daily PO

**Edema:** 2.5–20 mg once daily PO

METOLAZONE *continued*

**Contraindicated** in patients with anuria, hepatic coma, or hypersensitivity to sulfonamides or thiazides. **Use with caution** in severe renal disease, impaired hepatic function, gout, lupus erythematosus, diabetes mellitus, and elevated cholesterol and triglycerides. Electrolyte imbalance, GI disturbance, hyperglycemia, marrow suppression, chills, hyperuricemia, chest pain, hepatitis, and rash may occur.



Oral suspensions have increased bioavailability; therefore lower doses may be necessary when using these dosage forms. More effective than thiazide diuretics in impaired renal function; may be effective in GFRs as low as 20 mL/min. Furosemide-resistant edema in pediatric patients may benefit with the addition of metolazone.

**METOPROLOL**

Lopressor, Toprol-XL, Kaspargo Sprinkle, and generics

**Adrenergic blocking agent ( $\beta_1$  selective), class II antiarrhythmic**



C



1



No



Yes



Yes

**Tabs:** 25, 37.5, 50, 75, 100 mg

**Extended release tabs (Toprol-XL and generics):** 25, 50, 100, 200 mg

**Extended release caps as sprinkles (Kaspargo Sprinkle):** 25, 50, 100, 200 mg; contains corn starch

**Oral liquid:** 10 mg/mL 

**Injection:** 1 mg/mL (5 mL)

**Hypertension:****Child  $\geq 1$  yr and adolescent:**

**Non—extended release oral dosage forms:** Start at 1–2 mg/kg/24 hr PO  $\div$  BID (**max. initial dose:** 25 mg/dose); if needed, adjust dose up to a **max. dose** of 6 mg/kg/24 hr **up to** 200 mg/24 hr.

**Extended release tabs or caps ( $\geq 6$  yr and adolescent):** Start at 1 mg/kg/dose (**max. dose:** 50 mg) PO once daily; if needed, adjust dose **up to** a **max. dose** of 2 mg/kg/24 hr or 200 mg/24 hr once daily (higher doses have not been evaluated).

**Adult:**

**Non—extended release tabs:** Start at 50–100 mg/24 hr PO  $\div$  once daily—BID; if needed, increase dosage at weekly intervals to desired blood pressure. Usual effective dosage range is 100–200 mg/24 hr. Doses  $>450$  mg/24 hr have not been studied. Patients with bronchospastic diseases should receive the lowest possible daily dose divided TID.

**Extended release tabs or caps:** Start at 25–100 mg/24 hr PO once daily; if needed, increase dosage at weekly intervals to desired blood pressure. Usual dosage range is 50–200 mg/24 hr. Doses  $>400$  mg/24 hr have not been studied.

**Contraindicated** in sinus bradycardia, heart block  $>1$ st degree, sick sinus syndrome (except with functioning pacemaker), cardiogenic shock, and uncompensated CHF. **Use with caution** in hepatic dysfunction, peripheral vascular disease, history of severe anaphylactic hypersensitivity drug reactions, pheochromocytoma, and concurrent use with verapamil, diltiazem, or anesthetic agents that may decrease myocardial function. Should not be used with bronchospastic diseases. Reserpine and other drugs that deplete catecholamines (e.g., MAO inhibitors) may increase the effects of metoprolol. Metoprolol is a CYP 450 2D6 substrate. Poor metabolizers and extensive metabolizers who concomitantly use CYP 2D6 inhibitors will have significant increases in metoprolol blood levels to decrease its cardioselectivity.



*Continued*

METOPROLOL *continued*

**Avoid** abrupt cessation of therapy in ischemic heart disease; angina, ventricular arrhythmias, and MI have occurred. Common side effects include bradyarrhythmia, heart block, heart failure, pruritus, rash, GI disturbances, dizziness, fatigue, and depression. Bronchospasm, dyspnea, and elevations in transaminase, alkaline phosphatase, and LDH have all been reported.

**METRONIDAZOLE**

Flagyl, First-Metronidazole, MetroGel, MetroLotion, MetroCream, Rosadan, Noritate, Vandazole, Nuvessa, and generics

**Antibiotic, antiprotozoal**



B



3



Yes



Yes



No

**Tabs:** 250, 500 mg

**Caps:** 375 mg

**Oral suspension:** 50 mg/mL 

**First-Metronidazole:** 50 mg/mL (150 mL); contains sodium benzoate and saccharin

**Ready-to-use injection:** 5 mg/mL (100 mL); contains 28 mEq Na/g drug

**Gel, topical:**

**Rosadan and generics:** 0.75% (45 g)

**MetroGel and generics:** 1% (55, 60 g)

**Lotion (MetroLotion and generics):** 0.75% (59 mL); contains benzyl alcohol

**Cream, topical:**

**MetroCream, Rosadan, and generics:** 0.75% (45 g); contain benzyl alcohol

**Noritate:** 1% (60 g); contains parabens

**Gel, vaginal:**

**Vandazole and generics:** 0.75% (each applicator delivers ~5 g of gel containing ~37.5 mg metronidazole); contains parabens (70 g with 5 applicators)

**Nuvessa:** 1.3%: (each applicator delivers ~5 g containing ~65 mg metronidazole); contains parabens and benzyl alcohol (1 prefilled applicator)

**Amebiasis:**

**Child:** 35–50 mg/kg/24 hr PO ÷ Q8 hr × 10 days; **max. dose:** 750 mg/dose

**Adult:** 500–750 mg/dose PO Q8 hr × 10 days



**Anaerobic infection (see remarks):**

**Neonate: PO/IV:**

**Loading dose (all ages):** 15 mg/kg × 1

**Maintenance dose based on postmenstrual age (PMA):**

**PMA 24–25 wk:** 7.5 mg/kg/dose Q24 hr

**PMA 26–27 wk:** 10 mg/kg/dose Q24 hr

**PMA 28–33 wk:** 7.5 mg/kg/dose Q12 hr

**PMA 34–40 wk:** 7.5 mg/kg/dose Q8 hr

**PMA >40 wk:** 7.5 mg/kg/dose Q6 hr

**Infant/child/adolescent:**

**PO:** 30–50 mg/kg/24 hr ÷ Q8 hr; **max. dose:** 2250 mg/24 hr

**IV:** 22.5–40 mg/kg/24 hr ÷ Q6–8 hr; **max. dose:** 4 g/24 hr

**Adult:**

**PO/IV:** 30 mg/kg/24 hr ÷ Q6–8 hr; **max. dose:** 4 g/24 hr. A 15 mg/kg/dose IV loading dose over 1 hr is administered 6 hr prior to the aforementioned maintenance dose for IV route.

**Bacterial vaginosis:**

**Child >45 kg, adolescent, and adult:**

METRONIDAZOLE *continued***PO:**

**Immediate release tabs:** 500 mg BID × 7 days

**Vaginal:**

**Vaginal gel 0.75% (Adolescent and adult):** ~37.5 mg (1 applicator full) QHS × 5 days

**Vaginal gel 1.3% (≥12 yr and adult):** ~65 mg (1 applicator full) at bedtime × 1

**Giardiasis:**

**Child:** 15–30 mg/kg/24 hr PO ÷ TID × 5–7 days; **max. dose:** 750 mg/24 hr

**Adult:** 250 mg PO TID × 5 days

**Trichomoniasis: Treat sexual contacts.**

**Child <45 kg:** 45 mg/kg/24 hr PO ÷ TID × 7 days; **max. dose:** 2000 mg/24 hr

**Child ≥45 kg, adolescent/adult:** 2 g PO × 1, or 500 mg PO BID × 7 days

**Clostridium difficile infection (IV may be less efficacious):**

**Child:** 30 mg/kg/24 hr ÷ Q6 hr PO/IV × 10–14 days; **max. dose:** 2000 mg/24 hr

**Severe fulminant infection (with oral or rectal vancomycin):** 30 mg/kg/24 hr ÷ Q8 hr IV × 10 days; **max. dose:** 500 mg/dose

**Adult:** 500 mg TID PO/IV × 10–14 days

**Severe fulminant infection (with oral or rectal vancomycin):** 500 mg IV Q8 hr

**Helicobacter pylori infection (use in combination with amoxicillin and acid-suppressing agent with/without clarithromycin):**

**Child:** 20 mg/kg/24 hr (**max. dose:** 1000 mg/24 hr) ÷ BID PO × 10–14 days

**Adult:** 250–500 mg TID–QID (QAC and QHS) PO × 10–14 days

**Topical use for rosacea:** Apply and rub a thin film to affected areas at the following frequencies specific to product concentration.

**0.75% cream:** BID

**1% cream:** Once daily

**Contraindicated** in Cockayne syndrome as fatal liver failure has been reported. **Avoid use** in first-trimester pregnancy. **Use with caution** in patients with CNS disease, blood dyscrasias, severe liver (reduce dose by 50% with Child-Pugh C) or **renal disease (GFR <10 mL/min; see Chapter 31)**. If using single 2 g dose in a breastfeeding mother, discontinue breastfeeding for 12–24 hr to allow excretion of the drug.



Nausea, diarrhea, urticaria, dry mouth, leukopenia, vertigo, metallic taste, and peripheral neuropathy may occur. Candidiasis may worsen. May discolor urine. Patients **should not** ingest alcohol for 24–48 hr after dose (disulfiram-type reaction). Peripheral neuropathy has been reported with topical use. May interfere with AST, ALT, triglycerides, glucose, and LDH testing.

Single-dose oral regimen no longer recommended in bacterial vaginosis due to poor efficacy. May increase levels or toxicity of phenytoin, lithium, and warfarin. Phenobarbital and rifampin may increase metronidazole metabolism. QT prolongation has been reported when used with other medications with the potential for prolonging the QT interval.

IV infusion must be given slowly over 1 hr. For intravenous use in all ages, some references recommend a 15 mg/kg loading dose.

**MICAFUNGIN SODIUM**

Mycamine and generics

**Antifungal, echinocandin**



C



?



Yes



Yes



No

**Injection:** 50, 100 mg; contains lactose

**Invasive candidiasis (see remarks):**



*Continued*

MICALFUNGIN SODIUM *continued*

**Neonate and infant (based on a multidose pharmacokinetic and safety trial in 13 neonates/infants >48 hr and <120 days old with suspected or invasive candidiasis; minimum of 4–5 days of therapy):**

**<1 kg:** 10 mg/kg/dose IV Q24 hr; additional data from another multidose trial in 12 preterm neonates (median birth weight: 775 g, 27 wks' gestation) suggest 15 mg/kg/dose IV Q24 hr will provide similar AUC drug exposure of approximately 5 mg/kg/dose in adults

**≥1 kg:** 7–10 mg/kg/dose IV Q24 hr; 10–12 mg/kg/dose IV Q24 hr may be needed for HIV-exposed/infected neonates

**Infant (≥1 mo), child, and adolescent:** 3 mg/kg/dose IV Q24 hr; **max. dose:** 100 mg/dose

**Adult:** 100–150 mg IV Q24 hr

**Esophageal candidiasis, invasive aspergillosis, candidal endocarditis (see remarks):**

**Infant (≥1 mo), child, and adolescent:** 4 mg/kg/dose IV Q24 hr; **max. dose:** 150 mg/24 hr

**Adult:** 150 mg IV Q24 hr

**Candida prophylaxis in hematopoietic stem cell transplant:**

**Infant (1 mo), child, and adult:** 1 mg/kg/dose IV Q24 hr; **max. dose:** 50 mg/dose

Prior hypersensitivity to other echinocandins (anidulafungin, casopofungin) increases risk; anaphylaxis with shock has been reported. **Use with caution** in hepatic and renal impairment.



No dosing adjustments are required based on race or gender, or in patients with severe renal dysfunction or mild to moderate hepatic function impairment. Effect of severe hepatic function impairment on micafungin pharmacokinetics has not been evaluated. Higher dosage requirements in premature and young infants may be attributed to the faster drug clearance due to lower protein binding. Higher treatment doses in infants and children have been reported at 8.6–12 mg/kg/dose IV once daily.

May cause GI disturbances, phlebitis, rash, hyperbilirubinemia, liver function test elevation, headache, fever, and rigor. Anemia, leukopenia, neutropenia, thrombocytopenia, TEN, Stevens-Johnson syndrome, and hemolysis have been reported. Micafungin is CYP 450 3A isoenzyme substrate and weak inhibitor. May increase the effects/toxicity of nifedipine and sirolimus.

Safety and efficacy in children ≤4 mo have been established in patients without meningoencephalitis and/or other dissemination. This is supported by adequate and well-controlled studies in children ≥4 mo with additional pharmacokinetic/safety data in children <4 mo.

**MICONAZOLE**

Topical products: Micatin, Desenex, Lotrimin AF, and other brands including generics

Vaginal products: Miconazole 7, Miconazole 3, Monistat, Vagistat-3, other brands & generics

Oral buccal tab: Oravig

**Antifungal agent**



C



2



No



No



No

**Cream (OTC):** 2% (15, 30, 57, 118 g); may contain benzoic acid

**Ointment (OTC):** 2% (56, 141 g)

**Topical solution (OTC):** 2% with alcohol (30 mL); may contain benzyl alcohol

**Powder (OTC):** 2% (43, 71, 85, 90 g)

**Spray, powder (OTC):** 2% (85, 113, 133 g); contains alcohol

**Vaginal cream (OTC):** 2% (45 g); contains benzoic acid

**Vaginal suppository (OTC):** 100 mg (7s), 200 mg (3s)

MICONAZOLE *continued***Vaginal combination packs:**

**Monistat 1 Combination Pack (OTC):** 1200 mg vaginal suppository (1) and 2% cream (9 g)

**Miconazole 3 Combo Pack, Monistat 3 Combo Pack, Vagistat-3 (OTC):** 200 mg (4%) vaginal suppository (3s); and 2% external cream (9 g)

**Monistat 7 Combo Pack (OTC):** 100 mg vaginal suppository (7s) and 2% cream (9 g)

**Oral buccal tab:**

**Oravig:** 50 mg; contains corn starch and milk proteins

**Topical (≥2 yr and adolescent):** Apply BID × 2–4 wk.

**Vaginal (≥12 yr and adult):**

**7-day regimen:** 1 applicator full of 2% cream or 100 mg suppository QHS × 7 days

**3-day regimen:** 1 applicator full of 4% cream or 200 mg suppository QHS × 3 days

**1-day regimen (Monistat 1):** 1200 mg suppository × 1 at bedtime or during the day

**Mild oropharyngeal candidiasis (adult):** Apply 1 tab (50 mg) to the upper gum once daily × 7–14 days.

**Use with caution** in hypersensitivity to other imidazole antifungal agents (e.g., clotrimazole, ketoconazole). Side effects include pruritus, rash, burning, phlebitis, headaches, and pelvic cramps.

Drug is a substrate and inhibitor of the CYP 450 3A3/4 isoenzymes. Vaginal use with concomitant warfarin use has also been reported to increase warfarin's effect. Vegetable oil base in vaginal suppositories may interact with latex products (e.g., condoms and diaphragms); consider switching to the vaginal cream.

**Avoid** contact with eyes.

**Do not** crush, chew, or swallow the buccal tabs. Apply buccal tabs in the morning after brushing teeth by placing the tablet against the upper gum above one of the incisor tooth and hold with slight pressure over the upper lip for 30 sec (alternate sides of the mouth with each application). Placement of the rounded side of the tablet against the gum may be more comfortable, and avoid chewing gum while tablet is in place. If tablet falls off within 6 hr of application, reposition the same tablet immediately. See product information for additional information. Oral discomfort, including mouth and tongue ulceration, dry mouth, toothache, and loss/altered taste, has been reported with use of buccal tabs.

**MIDAZOLAM**

Generics; previously available as

Versed; intranasal: Nayzilam

**Benzodiazepine**



D



2



Yes



Yes



No

**Injection:** 1 mg/mL (2, 5, 10 mL), 5 mg/mL (1, 2, 5, 10 mL); some preparations may contain 1% benzyl alcohol

**Oral syrup:** 2 mg/mL (118 mL); contains sodium benzoate

**Nasal solution (Nayzilam):** 5 mg per 0.1 mL (2s); contains propylene glycol

**Titrate to effect under controlled conditions (see remarks).**

See [Chapter 6](#) for additional routes of administration.

**Sedation for procedures:****Infant, child, and adolescent:**

**IM:** 0.1–0.15 mg/kg/dose 30–60 min prior to procedure. Higher dose of 0.5 mg/kg/dose has been used for anxious patients. **Max. dose:** 10 mg

*Continued*

MIDAZOLAM *continued***IV:**

**6 mo—5 yr:** 0.05—0.1 mg/kg/dose over 2—3 min. May repeat dose PRN in 2—3 min intervals up to a **max. total dose** of 6 mg. A total dose up to 0.6 mg/kg may be necessary for desired effect.

**6—12 yr:** 0.025—0.05 mg/kg/dose over 2—3 min. May repeat dose PRN in 2—3 min intervals up to a **max. total dose** of 10 mg. A total dose up to 0.4 mg/kg may be necessary for desired effect.

**>12—18 yr:** 0.5—2.5 mg over 2—3 min. May repeat in 2—3 min intervals up to **max. total dose** of 10 mg

**PO:**

**≥6 mo, child, and adolescent <16 yr:** 0.25—0.5 mg/kg/dose × 1; **max. dose:** 20 mg. Younger patients (6 mo—5 yr) may require higher doses of 1 mg/kg/dose, whereas older patients (6—15 yr) may require only 0.25 mg/kg/dose. Use 0.25 mg/kg/dose for patients with cardiac or respiratory compromise, concurrent CNS depressive drug, or high-risk surgery.

**Intranasal (limited data; using IV dosage form with nasal atomizer):**

**Infant, child, and adolescent:** 0.2—0.3 mg/kg/dose (**max.** 10 mg/dose) intranasally × 1. Higher doses of 0.4—0.5 mg/kg/dose (**max.** 10 mg/dose) have also been reported.

**Adult (Sedation for procedures):**

**IM:** 0.07—0.08 mg/kg/dose 30—60 min prior to procedure; usual dose is 5 mg

**IV:** 0.5—2 mg/dose over 2 min. May repeat PRN in 2—3 min intervals until desired effect. Usual total dose: 2.5—5 mg. **Max. total dose:** 5 mg

**Sedation with mechanical ventilation:****Intermittent:**

**Infant and child:** 0.05—0.15 mg/kg/dose IV Q1—2 hr PRN

**Continuous IV infusion (initial doses, titrate to effect):****Neonate:**

**<32-wks' gestation:** 0.5 mCg/kg/min

**≥32-wks' gestation:** 1 mCg/kg/min

**Infant and child:** 1—2 mCg/kg/min

**Refractory status epilepticus:**

**≥2 mo and child:** Load with 0.2 mg/kg IV × 1 followed by a continuous infusion of 1 mCg/kg/min; titrate dose upward Q5 min to effect (mean dose of 2.3 mCg/kg/min with a range of 1—18 mCg/kg/min has been reported).

**Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy:****Infant, child, and adolescent (intranasal using IV dosage form with nasal atomizer):**

Inhale 0.2—0.3 mg/kg/dose (**max. dose:** 10 mg/dose) intranasally by administering half of total dose into each nostril. If no response after 10 min, dose may be repeated once.

**≥12 yr and adult (Nayzilam intranasal; see remarks):** Administer one spray (5 mg) intranasally into one nostril. If no response in 10 min, administer an additional 5 mg spray into the alternative nostril. **Do not** administer the second dose if patient has trouble breathing or if there is excessive sedation that is uncharacteristic of the patient during a seizure episode. **Max. dose:** 10 mg/dose per episode; **not to exceed** one episode every 3 days and 5 episodes per month.

**Contraindicated** in patients with narrow-angle glaucoma and shock. **Use with caution** in CHF, renal impairment (**adjust dose; see Chapter 31**), pulmonary disease, hepatic dysfunction, and neonates. Causes respiratory depression, hypotension, and bradycardia. Cardiovascular monitoring is recommended. Use lower doses or reduce dose when given in combination with narcotics or in patients with respiratory compromise.



MIDAZOLAM *continued*

Higher recommended dosage for younger patients (6 mo–5 yr) is attributed to the water-soluble properties of midazolam and the higher percent body water for younger patients.

Drug is a substrate for CYP 450 3A4. Serum concentrations may be increased by cimetidine, clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, ranitidine, and protease inhibitors (**use contraindicated**). Sedative effects may be antagonized by theophylline. **Effects can be reversed by flumazenil.** For pharmacodynamic information, see [Chapter 6](#).

**Do not** prime Nayzilam intranasal dosage form, because this will promote drug loss.

**MILRINONE**

Generics; previously available as Primacor

**Inotrope, phosphodiesterase inhibitor**



C



?



Yes



No



No

**Injection:** 1 mg/mL (10, 20, 50 mL); single-dose use products are preservative free

**Premixed injection in D<sub>5</sub>W:** 200 mCg/mL (100, 200 mL); preservative free

**Infant, child, and adolescent (limited data):** Optional 50 mCg/kg IV loading dose over 15 min, followed by a continuous infusion of 0.25–0.75 mCg/kg/min and titrate to effect. Loading dose is **NOT recommended** by some due to the risk of hypotension.



**Adult:** Continuous infusion of 0.125–0.75 mCg/kg/min; titrate to the lowest dose for clinical effect. Prior use of loading dose is **NOT recommended** due to the risk of hypotension.

**Contraindicated** in severe aortic stenosis, severe pulmonic stenosis, and acute MI. May cause headache, dysrhythmias, hypotension, hypokalemia, nausea, vomiting, anorexia, abdominal pain, hepatotoxicity, and thrombocytopenia. Pediatric patients may require higher mCg/kg/min doses because of a faster elimination  $T_{1/2}$  and larger volume of distribution, when compared with adults. Hemodynamic effects can last up to 3–5 hr after discontinuation of infusion in children. **Reduce dose in renal impairment.**

**MINERAL OIL**

GoodSense Mineral Oil, Kondremul, Fleet Mineral Oil, and generics

**Laxative, lubricant**



C



2



No



No



No

**Liquid, oral (GoodSense Mineral Oil and generics; OTC):** 473, 946 mL

**Emulsion, oral (Kondremul; OTC):** 480 mL; each 5 mL Kondremul contains 2.5 mL mineral oil

**Rectal liquid (Fleet Mineral Oil and generics; OTC):** 133 mL bottle delivers approximately 120 mL

**Constipation:**

**Child 6–11 yr (see remarks):**

**Oral liquid:** 5–15 mL/24 hr ÷ once daily (QHS)—TID PO

**Oral emulsion (Kondremul):** 10–30 mL/24 hr ÷ once daily (QHS)—TID PO

**Rectal (2–11 yr):** ~60 mL (half-bottle) as single dose

**Child ≥12 yr and adult (see remarks):**

**Oral liquid:** 15–45 mL/24 hr ÷ once daily (QHS)—TID PO

**Oral emulsion (Kondremul):** 30–90 mL/24 hr ÷ once daily (QHS)—TID PO

**Rectal (≥12 yr and adult):** ~120 mL (full bottle) as single dose



May cause diarrhea, cramps, and lipid pneumonitis via aspiration. Use as a laxative **should not exceed** >1 wk. Onset of action is approximately 6–8 hr. Higher doses may be necessary to achieve desired effect. **DO NOT** give QHS dose and use with **caution** in children <5 yr to



*Continued*

MINERAL OIL *continued*

minimize risk of aspiration. May impair the absorption of fat-soluble vitamins, calcium, phosphorus, oral contraceptives, and warfarin. Emulsified preparations are more palatable and are dosed differently than the oral liquid preparation.

For disimpaction, doses up to 1 ounce (30 mL) per year of age (**max. dose** of 240 mL) BID can be given.

**MINOCYCLINE**

Minocin, CoreMino, Solodyn, Minolira, Ximino, Amzeeq, and generics

**Antibiotic, tetracycline derivative**



D

2

Yes

Yes

No

**Tabs:** 50, 75, 100 mg

**Caps:** 50, 75, 100 mg

**Extended release tabs (Q24 hr dosing):**

**Solodyn and generics:** 55, 65, 80, 105, 115 mg

**CoreMino:** 45, 90, 135 mg

**Minolira:** 105, 135 mg

**Other generics:** 45, 90, 135 mg

**Extended release caps (Q24 hr dosing):**

**Ximino and generics:** 45, 90, 135 mg

**Injection (Minocin):** 100 mg; may contain 2.2 mEq magnesium/100 mg drug

**Topical foam (dispensed in a pressurized container with butane, isobutane, and propane propellants):**

**Amzeeq:** 4% (30 g); contains alcohols

**General infections:**

**Child (8–12 yr):** 4 mg/kg/dose (**max. dose:** 200 mg/dose) × 1 IV/PO, then 2 mg/kg/dose Q12 hr IV/PO; **max. dose:** 200 mg/24 hr

**Adolescent and adult:** 200 mg/dose × 1 IV/PO, then 100 mg Q12 hr IV/PO

***Chlamydia trachomatis/Ureaplasma urealyticum:***

**Adolescent and adult:** 100 mg IV/PO Q12 hr × 7 days

**Acne (≥12 yr—adult):**

**Immediate release dosage forms:** 50–100 mg PO once daily—BID

**Extended release tabs:**

**Solodyn and generics:**

**45–49 kg:** 45 mg PO once daily

**50–59 kg:** 55 mg PO once daily

**60–71 kg:** 65 mg PO once daily

**72–84 kg:** 80 mg PO once daily

**85–96 kg:** 90 mg PO once daily

**97–110 kg:** 105 mg PO once daily

**111–125 kg:** 115 mg PO once daily

**126–136 kg:** 135 mg PO once daily

**Minolira:**

**45–59 kg:** 52.5 mg (half of 105 mg tab)

**60–89 kg:** 67.5 mg (half of 135 mg tab) PO once daily

**90–125 kg:** 105 mg PO once daily

**126–136 kg:** 135 mg PO once daily



MINOCYCLINE *continued***Extended release caps:****Ximino:**

45–59 kg: 45 mg PO once daily

60–90 kg: 90 mg PO once daily

91–136 kg: 135 mg PO once daily

**Topical foam (Amzeeq; moderate-to-severe acne vulgaris):**

≥9 yr and adult (see remarks): Apply a small amount to affected areas QHS until all areas are treated.



**Not recommended** for children <8 yr and during the last half of pregnancy due to risk of permanent tooth discoloration. **Use with caution** in renal failure; lower dosage may be necessary. High incidence of vestibular dysfunction (30%–90%). Nausea, vomiting, allergy, increased intracranial pressure (e.g., pseudotumor cerebri), photophobia, and injury to developing teeth may occur. Hepatitis, including autoimmune hepatitis, liver failure, hypersensitivity reactions (e.g., anaphylaxis, Stevens-Johnson syndrome, erythema multiforme), and serum sickness—like and lupus-like syndrome have been reported.

May increase effects/toxicity of warfarin and decrease the efficacy of live attenuated oral typhoid vaccine. May be administered with food but **NOT** with milk or dairy products. See [Tetracycline](#) for additional drug/food interactions and comments.

**TOPICAL USE:** Dosage form is flammable; **avoid** smoking during and immediately after application. Not for oral, ophthalmic, or intravaginal use. Headache is the most common side effect. Hyperpigmentation, erythema, dryness, itching, and headache have also been reported.

**MINOXIDIL**

Tabs: Generics; previously available as Loniten

Topical: Rogaine Men's/Women's, Minoxidil for Men/Women, Hair Regrowth Treatment Men,

Men's Rogaine Extra Strength

**Antihypertensive agent, hair growth stimulant**



C



2



Yes



Yes



No

**Tabs:** 2.5, 10 mg

**Topical solution:**

**Minoxidil for Men, Minoxidil for Women, Rogaine, and generics (OTC):** 2% (60 mL); contains alcohol and propylene glycol

**Hair Regrowth Treatment for Men, Men's Rogaine Extra Strength, Minoxidil Extra Strength for Men, and generics (OTC):** 5% (60, 120 mL); contains 30% alcohol

**Topical foam:**

**Rogaine Men's, Rogaine Women's, Rogaine Men's Extra Strength (OTC):** 5% (60 g); contains cetyl alcohol

**Hypertension:**

**Child <12 yr:** Start with 0.1–0.2 mg/kg/24 hr PO once daily; **max. dose:** 5 mg/24 hr. Dose may be increased in increments of 0.1–0.2 mg/kg/24 hr at 3-day intervals. Usual effective range: 0.25–1 mg/kg/24 hr PO ÷ once daily–TID; **max. dose:** 50 mg/24 hr

≥12 yr and adult: Start with 5 mg PO once daily. Dose may be gradually increased at 3-day intervals. Usual effective range: 10–40 mg/24 hr ÷ once daily–TID; **max. dose:** 100 mg/24 hr

**Topical (alopecia; see remarks):****Adult:**

**Solution (2% or 5%):** Apply 1 mL to affected areas of the scalp BID (QAM and QHS).

*Continued*

MINOXIDIL *continued***Foam:**

**Female:** Apply ½ capful to affected areas of the scalp once daily.

**Male:** Apply ½ capful to affected areas of the scalp BID.

**Contraindicated** in acute MI, dissecting aortic aneurysm, and pheochromocytoma. Concurrent use with a β-blocker and diuretic is recommended to prevent reflex tachycardia and reduce water retention, respectively. Use with **caution** in hepatic impairment as decrease in drug clearance has been reported in mild cirrhosis for adults. May cause drowsiness, dizziness, CHF, pulmonary edema, pericardial effusion, pericarditis, thrombocytopenia, leukopenia, Stevens-Johnson syndrome, TEN, and hypertrichosis (reversible) with systemic use. Neonatal hypertrichosis has been reported following use during pregnancy.

Concurrent use of guanethidine may cause profound orthostatic hypotension; use with other antihypertensive agents may cause additive hypotension. Patients with renal failure or receiving dialysis may require a dosage reduction. Antihypertensive onset of action within 30 min and peak effects within 2–8 hr.

**TOPICAL USE:** Local irritation, contact dermatitis may occur. **Do not use** in conjunction with other topical agents, including topical corticosteroids, retinoids or petrolatum, or agents that are known to enhance cutaneous drug absorption. Onset of hair growth is 4 mo. Wash hands thoroughly after each application. The 5% solution is flammable.

**MOMETASONE FUROATE ± FOMOTEROL FUMARATE**

Asmanex, Nasonex, and other generic nasal and topical products; previously available as Elocon (topical forms)

In combination with fomoterol: Dulera

**Corticosteroid**

C



2



No



Yes



No

**Nasal spray (Nasonex and generics):** 0.05%, 50 mCg per actuation (10 mL provides 60 doses [OTC]; 17 g, provides 120 doses)

**Aerosol for inhalation (Asmanex HFA):** 50 mCg per actuation (13 g, provides 120 actuations), 100 mCg per actuation (13 g, provides 120 actuations), 200 mCg per actuation (13 g, provides 120 actuations)

**Powder for inhalation, breath activated (Asmanex Twisthaler; see remarks):** 110 mCg per actuation (30 doses), 220 mCg per actuation (14, 30, 60, 120 doses); contains lactose and milk proteins

**Topical cream and ointment:** 0.1% (15, 45 g)

**Topical lotion:** 0.1% (30, 60 mL); contains isopropyl alcohol

**In combination with fomoterol:****Aerosol inhaler (Dulera):**

50 mCg mometasone furoate + 5 mCg fomoterol fumarate dihydrate per inhalation (13 g delivers 120 inhalations)

100 mCg mometasone furoate + 5 mCg fomoterol fumarate dihydrate per inhalation (8.8 g delivers 60 inhalations, 13 g delivers 120 inhalations)

200 mCg mometasone furoate + 5 mCg fomoterol fumarate dihydrate per inhalation (8.8 g delivers 60 inhalations, 13 g delivers 120 inhalations)

**MOMETASONE FUROATE:**

**Intranasal (allergic rhinitis):** Patients with known seasonal allergic rhinitis should initiate therapy 2–4 wk prior to anticipated pollen season.

**Child 2–11 yr:** 50 mCg (1 spray) each nostril once daily (100 mCg/24 hr)

**Child ≥12 yr and adult:** 100 mCg (2 sprays) each nostril once daily (200 mCg/24 hr)

MOMETASONE FUROATE ± FOMOTEROL FUMARATE *continued***Oral inhalation:****Asmanex HFA (aerosol for inhalation):****Child 5—<12 yr:** 2 inhalations (100 mCg) BID of 50 mCg inhaler (200 mCg/24 hr)**Child ≥12 yr and adult:** Max. effects may not be achieved until 2 wk. Titrate doses to lowest effective dose once asthma stabilized.**Previously treated with bronchodilators alone or medium-dose inhaled corticosteroids:**

2 inhalations (200 mCg) BID of 100 mCg inhaler (400 mCg/24 hr)

**Previously receiving high-dose inhaled or chronic oral corticosteroids:** 2 inhalations

(400 mCg) BID of 200 mCg inhaler (800 mCg/24 hr)

**Max. dose (all ages):** 800 mCg/24 hr**Asmanex Twisthaler (breath-activated powder for inhalation; see remarks):****Child 4—11 yr:** Start with 110 mCg (1 inhalation) QHS of the 110 mCg inhaler regardless of prior therapy; **max. dose:** 110 mCg/24 hr.**Child ≥12 yr and adult:** Max. effects may not be achieved until 1–2 wk or longer. Titrate doses to the lowest effective dose once asthma stabilized.**Previously treated with bronchodilators alone or with inhaled corticosteroids:** Start with 220 mCg (1 inhalation) QHS. Dose may be increased up to a **max. dose** of 440 mCg/24 hr ÷ QHS or BID.**Previously treated with oral corticosteroids:** Start with 440 mCg BID; **max. dose:** 880 mCg/24 hr.**Topical (see Chapter 8 for topical steroid comparisons):****Cream and ointment:****≥2 yr and adult:** Apply a thin film to affected area once daily. Safety and efficacy for >3 wk have not been established for pediatric patients.**Lotion:****≥12 yr and adult:** Apply a few drops to affected area and massage lightly into skin once daily until it disappears.**MOMETASONE FUROATE + FOMOTEROL FUMARATE (DULERA):****Child 5—<12 yr:** Two inhalations BID of 50 mCg mometasone + 5 mCg formoterol; **max. dose:** 2 inhalations BID**Child ≥12 yr and adult:** Two inhalations BID of either 100 mCg mometasone + 5 mCg formoterol or 200 mCg mometasone + 5 mCg formoterol based on prior asthma therapy (see the following table). If using the lower strength (100 mCg mometasone + 5 mCg formoterol), allow for 2 wk of therapy before increasing to the higher strength if no adequate response. **Max. dose:** Two inhalations BID of 200 mCg mometasone + 5 mCg formoterol.

Previous Therapy	Recommended Starting Dose	Recommended Maximum Daily Dose
Medium-dose inhaled corticosteroids	100 mCg mometasone + 5 mCg formoterol: 2 inhalations BID	400 mCg mometasone + 20 mCg formoterol
High-dose inhaled corticosteroids	200 mCg mometasone + 5 mCg formoterol: 2 inhalations BID	800 mCg mometasone + 20 mCg formoterol

Mometasone is a CYP 450 3A4 substrate; concurrent administration with ketoconazole and other CYP 450 3A4 inhibitors (e.g., protease inhibitors) may increase mometasone levels, resulting in Cushing syndrome and adrenal suppression. Blurred vision, cataracts, and glaucoma have been reported. Use with **caution** with hepatic impairment; increased drug exposure is possible.

*Continued*

MOMETASONE FUROATE ± FOMOTEROL FUMARATE *continued*

**INTRANASAL:** Clear nasal passages and shake nasal spray well before each use. Onset of action for nasal symptoms of allergic rhinitis has been shown to occur within 11 hr after the first dose. Nasal burning and irritation, and epistaxis may occur. Nasal septal perforation, localized *Candida* infections, adrenal suppression (using higher than recommended dosages), and taste and smell disturbances have been reported. Monitor linear growth in children; especially with long-term use. A clinical trial in children 6–17 yr old was not able to demonstrate effectiveness for treating nasal polyps. A combination intranasal product of mometasone and olopatadine (Ryaltris) is available for seasonal allergic rhinitis and currently indicated for children ≥12 yr and adults.

**ORAL INHALATION (all forms):** Rinse mouth after each use. Fever, allergic rhinitis, URI, UTI, GI discomfort, and sore throat have been reported in children. Musculoskeletal pain, oral candidiasis, arthralgia, and fatigue may occur. May potentially worsen tuberculosis, fungal, bacterial, viral or parasitic infection, or ocular herpes simplex. **Do not use** Asmanex Twisthaler if allergic to milk proteins. The Twisthaler dosage form requires a minimum 30–60 L/min inspiratory flow rate to ensure proper dose delivery. Breastfeeding information is currently unknown, but most experts consider use of inhaled corticosteroids acceptable.

**MOMETASONE + FOMOTEROL (Dulera):** Common side effects include nasopharyngitis, sinusitis, and headache. Angioedema, anaphylaxis, and arrhythmias have been reported. See [Formoterol](#) for additional remarks.

**TOPICAL USE:** HPA axis suppression and skin atrophy have been reported with cream and ointment use in infants 6–23 mo. **Avoid** application/contact to face, eyes, underarms, groin, and mucous membranes. Occlusive dressings and use in diaper dermatitis are not recommended.

**MONTELUKAST**

Singulair and generics

**Antiasthmatic, antiallergy, leukotriene receptor antagonist**

B



1



No



Yes



No

**Chewable tabs:** 4, 5 mg; contain phenylalanine**Tabs:** 10 mg**Oral granules:** 4 mg per packet (30s)**Asthma and allergic rhinitis:****Child:****6 mo–5 yr:** 4 mg (oral granules or chewable tablet) PO QHS; minimum age for use in asthma (per product label) is 12 mo**6–14 yr:** 5 mg (chewable tablet) PO QHS**Adolescent ≥15 yr and adult:** 10 mg PO QHS**Prevention of exercise-induced bronchospasm (administer dose at least 2 hr prior to exercise; additional doses should not be administered within 24 hr):****Child (6–14 yr):** 5 mg (chewable tablet) PO**≥15 yr and adult:** 10 mg PO

Chewable tablet dosage form is **contraindicated** in phenylketonuric patients. Side effects include: headache, abdominal pain, dyspepsia, fatigue, dizziness, cough, and elevated liver enzymes. Diarrhea, enuresis, epistaxis, pulmonary eosinophilia, thrombocytopenia, hypersensitivity reactions (including Stevens-Johnson and TEN), pharyngitis, nausea, otitis, sinusitis, and viral infections have been reported in children. Neuropsychiatric events, including aggression, anxiety, dream abnormalities, obsessive-compulsive symptoms, hallucinations, depression, suicidal behavior, and insomnia, have been reported.



MONTELUKAST *continued*

Drug is a substrate for CYP 450 3A4 and 2C9. Phenobarbital and rifampin may induce hepatic metabolism to increase the clearance of montelukast.

Doses may be administered with or without food.

**MORPHINE SULFATE**

Duramorph, MS Contin, Avinza, Kadian, and many generics

**Narcotic, analgesic**



C/D



2



Yes



Yes



No

**Oral solution:** 10 mg/5 mL, 20 mg/5 mL

**Concentrated oral solution:** 100 mg/5 mL

**Tabs:** 15, 30 mg

**Extended release tabs:**

**MS Contin and generics:** 15, 30, 60, 100, 200 mg

**Extended release caps:**

**Kadian:** 10, 20, 30, 40, 50, 60, 80, 100, 200 mg

**Generics:** 10, 20, 30, 45, 50, 60, 75, 80, 90, 100, 120 mg

**Combination immediate release and extended release caps:**

**Avinza (10% of dose as immediate release):** 30, 60, 90, 120 mg

**Rectal suppository:** 5, 10, 20, 30 mg (12s)

**Injection:** 0.5, 1, 2, 4, 5, 8, 10, 15, 25, 50 mg/mL

**Titrate to effect.**

**Neonate:**

**Analgesia/tetralogy (cyanotic) spells:** 0.05–0.1 mg/kg/dose IM, slow IV, SC Q4 hr

**Opiate withdrawal:** 0.04–0.2 mg/kg/dose PO Q3–4 hr PRN

**Infant 1–6 mo:**

**Analgesia:**

**PO:** 0.08–0.1 mg/kg/dose Q3–4 hr PRN

**IV:** 0.025–0.03 mg/kg/dose Q2–4 hr PRN

**Infant >6 mo and child:**

**Analgesia:**

**PO:** 0.2–0.5 mg/kg/dose (**initial max. dose:** 15–20 mg/dose) Q4–6 hr PRN (immediate release) or 0.3–0.6 mg/kg/dose Q12 hr PRN (controlled release)

**IM/IV/SC:** 0.1–0.2 mg/kg/dose Q2–4 hr PRN; **max. initial dose:** infant: 2 mg/dose, 1–6 yr: 4 mg/dose, 7–12 yr: 8 mg/dose, and adolescent: 10 mg/dose

**Adult (analgesia):**

**PO:** 10–30 mg Q4 hr PRN (immediate release) or 15–30 mg Q8–12 hr PRN (controlled release; see specific dosage form product information for additional instructions)

**IM/IV/SC:** 2–15 mg/dose Q2–6 hr PRN

**Continuous IV infusion and SC infusion:** Dosing ranges, titrate to effect.

**Neonate (IV route only):** 0.01–0.02 mg/kg/hr

**Infant and child:**

**Postoperative pain:** 0.01–0.04 mg/kg/hr

**Sickle cell and cancer:** 0.04–0.07 mg/kg/hr

**Adult:** 0.8–10 mg/hr



*Continued*

MORPHINE SULFATE *continued*

To prepare infusion for neonates, infants, and children, use the following formula:

$$50 \times \frac{\text{Desired dose (mg/kg/hr)}}{\text{Desired infusion rate (mL/hr)}} \times \text{Wt(kg)} = \frac{\text{mg morphine}}{50 \text{ mL fluid}}$$

Dependence, CNS and respiratory depression, nausea, vomiting, urinary retention, constipation, hypotension, bradycardia, increased ICP, miosis, biliary spasm, and allergy may occur. 

Be aware of concomitant medications with similar side effect profiles. **Naloxone may be used to reverse effects, especially respiratory depression.** Causes histamine release, resulting in itching and possible bronchospasm. Low-dose naloxone infusion may be used for itching. Inflammatory masses (e.g., granulomas) have been reported with continuous infusions via indwelling intrathecal catheters.


Dosage reduction may be necessary with liver cirrhosis. See [Chapter 6](#) for equianalgesic dosing. Pregnancy category changes to “D” if used for prolonged periods or in higher doses at term. Rectal dosing is same as oral dosing but is not recommended due to poor absorption. Controlled/sustained release oral tablets must be administered whole. Controlled release oral capsules may be opened and the entire contents sprinkled on applesauce immediately prior to ingestion. **Be aware** of the various oral solution concentrations; the concentrated oral solution (100 mg/5 mL) has been associated with accidental overdoses. **Adjust dose in renal failure (see Chapter 31).**

The FDA has assigned a REMS for Opioid Analgesia; see [www.fda.gov/OpioidAnalgesicREMSPCG](http://www.fda.gov/OpioidAnalgesicREMSPCG). The REMS strongly encourages the provider to (1) complete a REMS-compliant education program; (2) counsel patients/caregivers on prescription safe use, risks, storage, and disposal; (3) emphasize the importance of reading the Medication Guide provided by pharmacists at all times; and (4) consider other methods for improving patient, household, and community safety.

**MUPIROCIN**

Centany, Centany AT, and generics; previously available as Bactroban

**Topical antibiotic**



**Ointment (Centany, Centany AT, and generics):** 2% (15, 22, 30 g); contains propylene glycol  
**Cream (Generics):** 2% (15, 30 g); may contain benzyl alcohol

**Topical (see remarks):**

**≥3 mo—adult:** Apply small amount TID to affected area × 5–10 days. Topical ointment may be used in infants ≥2 mo for impetigo. 

**Intranasal for elimination of nasal colonization of *Staphylococcus aureus*, including MRSA (in the absence of the nasal ointment dosage form, use ointment dosage form):**

**Infant and child:** Apply small amount intranasally to both nostrils BID × 5–10 days.

**Child ≥12 yr and adult:** Apply approximately 500 mg intranasally to both nostrils using a cotton swab BID × 5–10 days.

**Avoid** contact with the eyes. Topical cream is not intended for use in lesions >10 cm in length or 100 cm<sup>2</sup> in surface area. **Do not use** topical ointment preparation on open wounds because of concerns about systemic absorption of polyethylene glycol. May cause minor local irritation and dry skin. Intranasal route may cause nasal stinging, taste disorder, headache, rhinitis, and pharyngitis. Severe allergic reactions (e.g., anaphylaxis, urticaria, angioedema, and rash) have been reported. 

If clinical response is not apparent in 3–5 days with topical use, reevaluate infection.

**MYCOPHENOLATE**

Mycophenolate mofetil: CellCept and generics

Mycophenolic acid: Myfortic and generics

**Immunosuppressant agent**

D



3



Yes



No



Yes

**Mycophenolate mofetil (CellCept and generics):****Caps:** 250 mg**Tab:** 500 mg**Oral suspension:** 200 mg/mL (160 mL); contains phenylalanine (0.56 mg/mL) and methylparabens**Injection:** 500 mg; may contain polysorbate 80**Mycophenolic acid:****Delayed release tabs (Myfortic and generics):** 180, 360 mg**Infant  $\geq 3$  mo, child, and adolescent (see remarks):****Heart and liver transplant (mycophenolate mofetil):****Suspension:** Start with 600 mg/m<sup>2</sup>/dose PO BID, if tolerated, may increase to 900 mg/m<sup>2</sup>/dose BID.**Max. dose:** 3000 mg/24 hr**Tab:** or **caps:****BSA 1.25—<1.5 m<sup>2</sup>:** Start with 750 mg PO BID; if tolerated, may increase dose with BID dosage interval up to a **maximum** of 3000 mg/24 hr.**BSA  $\geq 1.5$  m<sup>2</sup>:** Start with 1000 mg PO BID; if tolerated, may increase dose with BID dosage interval up to a **maximum** of 3000 mg/24 hr.**Renal transplant:****Caps, tabs, or suspension (mycophenolate mofetil):** 600 mg/m<sup>2</sup>/dose PO/IV BID up to a **max. dose** of 2000 mg/24 hr; alternatively, patients with BSAs  $\geq 1.25$  m<sup>2</sup> may be dosed as follows:**1.25—1.5 m<sup>2</sup>:** 750 mg PO BID**>1.5 m<sup>2</sup>:** 1000 mg PO BID**Delayed release tabs (Myfortic;  $\geq 5$  yr):** 400 mg/m<sup>2</sup>/dose PO BID; **max. dose:** 720 mg BID; this dosage form not recommended in patients with BSAs  $< 1.19$  m<sup>2</sup>. Alternatively, patients with BSAs  $\geq 1.19$  m<sup>2</sup> may be dosed as follows:**1.19—1.58 m<sup>2</sup>:** 540 mg PO BID**>1.58 m<sup>2</sup>:** 720 mg PO BID**Nephrotic syndrome:****Frequently relapsing:** 12.5—18 mg/kg/dose or 600 mg/m<sup>2</sup>/dose PO BID up to a **max. dose** of 2000 mg/24 hr for 1—2 yr and taper prednisone regimen**Steroid dependent:** 12—18 mg/kg/dose or 600 mg/m<sup>2</sup>/dose PO BID up to a **max. dose** of 2000 mg/24 hr for at least 12 mo**Adult (in combination with corticosteroids and cyclosporine; check specific transplantation protocol for specific dosage):****IV:** 1000—3000 mg/24 hr  $\div$  BID**Oral:****Caps, tabs, or suspension:** 500—1500 mg PO BID**Delayed release tabs (Myfortic):** 360—1080 mg PO BID

Check specific transplantation protocol for specific dosage. Mycophenolate mofetil is a prodrug for mycophenolic acid. Owing to differences in absorption, the delayed release tablets should **not** be interchanged with other oral dosage forms on an equivalent milligram-to-milligram basis. Increases risk of first trimester pregnancy loss and increased risk of congenital malformations (especially external ear and facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, and esophagus).



Continued

MYCOPHENOLATE *continued*

Common side effects may include headache, hypertension, diarrhea, vomiting, bone marrow suppression, anemia, fever, opportunistic infections, and sepsis. May cause drowsiness and increase the risk for bacterial, fungal, protozoal, and viral infections, and lymphomas or other malignancies. GI bleeds and increased risk for rejection in heart transplant patients switched from calcineurin inhibitors (e.g., cyclosporine and tacrolimus) and CellCept to sirolimus and CellCept have been reported. Cases of progressive multifocal leukoencephalopathy (PML), pure red cell aplasia (PRCA), posttransplant lymphoproliferative disorder (PTLD), acute inflammatory syndrome, and hypogammaglobulinemia have also been reported. The type and frequency of adverse reactions in pediatric heart or kidney transplant patients have been reported to be similar to those observed in pediatric renal transplant patients and in adults.

Use of mycophenolic acid (Myfortic) should be **avoided** in patients with hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency (e.g., Lesch-Nyhan and Kelley-Seegmiller syndrome) because it may exacerbate disease symptoms characterized by increased uric acid, leading to acute arthritis, tophi, nephrolithiasis/uroolithiasis, and renal failure.

**Use with caution** in patients with active GI disease or renal impairment (GFR <25 mL/min/1.73 m<sup>2</sup>) outside of the immediate posttransplant period. In adults with renal impairment, **avoid** doses >2 g/24 hr and observe carefully. Dose should be interrupted or reduced in the presence of neutropenia (ANC <1.3 × 10<sup>3</sup>/microliter). No dose adjustment is needed for patients experiencing delayed graft function postoperatively.

**Drug interactions:** (1) Displacement of phenytoin or theophylline from protein-binding sites will decrease total serum levels and increase free serum levels of these drugs. Salicylates displace mycophenolate to increase free levels of mycophenolate. (2) Competition for renal tubular secretion results in increased serum levels of acyclovir, ganciclovir, probenecid, and mycophenolate (when any of these are used together). (3) **Avoid** live and live attenuated vaccines (including influenza); decreases vaccine effectiveness. (4) Proton pump inhibitors, antacids, cholestyramine, cyclosporine, and telmisartan may reduce mycophenolate levels.

Administer oral doses on an empty stomach. Infuse intravenous doses over 2 hr. Oral suspension may be administered via NG tube with a minimum size of 8 Fr.

## N

**NAFCILLIN**

Generics; previously available as Nallpen

**Antibiotic, penicillin (penicillinase resistant)**



B



2



Yes



Yes



No

**Injection:** 1, 2, 10 g; contains 2.9 mEq Na/g drug

**Injection, premixed in iso-osmotic dextrose:** 1 g in 50 mL, 2 g in 100 mL

**Neonate (IM/IV):**

<1 kg:

≤14 days old: 50 mg/kg/24 hr ÷ Q12 hr

15–28 days old: 75 mg/kg/24 hr ÷ Q8 hr

1–2 kg:

≤7 days old: 50 mg/kg/24 hr ÷ Q12 hr

8–28 days old: 75 mg/kg/24 hr ÷ Q8 hr

>2 kg:

≤7 days old: 75 mg/kg/24 hr ÷ Q8 hr

8–28 days old: 100 mg/kg/24 hr ÷ Q6 hr



NAFCILLIN *continued*

**Meningitis:** Use twice the above mg/kg/24 hr dose with the same dosage interval.

**Infant and child (IM/IV):**

**Mild to moderate infections:** 100–150 mg/kg/24 hr ÷ Q6 hr

**Severe infections:** 150–200 mg/kg/24 hr ÷ Q4–6 hr; give 200 mg/kg/24 hr ÷ Q4–6 hr for staphylococcal endocarditis or meningitis

**Max. dose:** 12 g/24 hr

**Adult:**

**IV:** 1000–2000 mg Q4–6 hr

**IM:** 500–1000 mg Q4–6 hr

**Max. dose:** 12 g/24 hr

Allergic cross-sensitivity with penicillin. Solutions containing dextrose may be **contraindicated** in patients with known allergy to corn or corn products. High incidence of phlebitis with IV dosing. May cause rash, bone marrow suppression, and false-positive urinary and serum proteins. Hypokalemia has been reported. Acute interstitial nephritis is rare.



Cerebrospinal fluid (CSF) penetration is poor unless meninges are inflamed. **Use with caution** in patients with combined renal and hepatic impairment (reduce dose by 33%–50%). Nafcillin may increase elimination of cyclosporine and warfarin.

**NALOXONE**

Narcan, Kloxxado, Zimhi, and generics

**Narcotic antagonist**



C



?



No



No



No

**Injection:** 0.4 mg/mL (1, 10 mL); some preparations may contain parabens

**Injection, in prefilled syringe:**

**Generic:** 2 mg/2 mL (2 mL)

**Zimhi:** 5 mg/0.5 mL (0.5 mL)

**Injection in single-dose Carpuject:** 0.4 mg/mL (1 mL)

**Auto-injector:** 10 mg/0.4 mL single-dose prefilled auto-injector (box of 10)

**Nasal liquid:**

**Narcan and generics:** 4 mg/0.1 mL (1 or 2 each); may contain benzalkonium chloride and EDTA

**Kloxxado:** 8 mg/0.1 mL (2 each); contains 20% alcohol, EDTA, and propylene glycol

**Opiate intoxication (full reversal, IM/IV/IO/SC, use 2–10 times IV dose for ETT route; see remarks):**



**Neonate, infant, child ≤20 kg or ≤5 yr (IV/IO route is preferred for faster onset of action):**

0.1 mg/kg/dose. May repeat PRN Q2–3 min

**Child >20 kg or >5 yr (IV/IO route preferred):** 2 mg/dose. May repeat PRN Q2–3 min.

**Zimhi (≥12 yr):** 5 mg/dose × 1 IM/SC into the anterolateral aspect of the thigh, through clothing if necessary. May repeat PRN Q2–3 min

**Continuous infusion (child and adult):** 0.005 mg/kg loading dose followed by infusion of 0.0025 mg/kg/hr has been recommended. A range of 0.0025–0.16 mg/kg/hr has been reported. Taper gradually to avoid relapse.

**Adult:** 0.4–2 mg/dose. May repeat PRN Q2–3 min. Use 0.1 to 0.2 mg increments in opiate-dependent patients.

**Zimhi:** 5 mg/dose × 1 IM/SC into the anterolateral aspect of the thigh, through clothing if necessary. May repeat PRN Q2–3 min

**Auto-injector product (10 mg/0.4 mL) for suspected high-potency opiate intoxication:**

**Child ≥12 yr and adult:** Administer one dose (10 mg) into the anterolateral aspect of the thigh, through clothing if necessary, by pressing the device firmly until you hear a click and hiss sound and

*Continued*

NALOXONE *continued*

then hold in place for 5 seconds. If the patient symptoms relapse after the first dose, additional doses may be necessary.

**Intranasal route for opiate intoxication (full reversal):**

**All ages:** 4 or 8 mg of nasal liquid dosage form into one nostril Q2–3 min PRN in alternating nostrils.

**Opioid-dependent patient at risk for opioid withdrawal:** Use lower 2 mg of nasal liquid dosage form into one nostril Q2–3 min PRN in alternating nostrils. Alternatively, the 2 mg/2 mL intravenous (IV) syringe dosage form with nasal adapter may be used by administering 1 mg (1 mL) per nostril.

**Opiate-induced pruritus (limited data):** 0.25–2 mCg/kg/hr IV; a dose-finding study in 59 children suggests a minimal dose of 1 mCg/kg/hr when used as prophylactic therapy. Doses  $\geq 3$  mCg/kg/hr increase the risk for reduced pain control.

Short duration of action may necessitate multiple doses. For severe intoxication, doses of 0.2 mg/kg may be required. If no response is achieved after a cumulative dose of 10 mg, reevaluate diagnosis. **In the nonarrest situation, use the lowest dose effective (may start at 0.001 mg/kg/dose).** See [Chapter 6](#) for additional information.



Will produce narcotic withdrawal syndrome in patients with chronic dependence. Use with **caution** in patients with chronic cardiac disease. Abrupt reversal of narcotic depression may result in nausea, vomiting, diaphoresis, tachycardia, hypertension, and tremulousness. Aggressive behavior has been reported in abrupt reversal of an opioid overdose. False-positive test for urine opiates screen may occur.

IV administration is preferred for faster onset of action. Onset of action may be delayed with other routes of administration; the intranasal route is slightly delayed compared to IM or IV routes.

**NAPROXEN/NAPROXEN SODIUM**

Naprosyn, EC-Naprosyn, Anaprox DS, Naprelan, Aleve [OTC], and many others, including generics

**Nonsteroidal antiinflammatory agent**



C/X



3



Yes



Yes



No

**Naproxen:**

**Tabs:** 250, 375, 500 mg

**Delayed release tabs:**

**EC-Naprosyn:** 375, 500 mg

**Anaprox DS:** 550 mg

**Oral suspension (Naprosyn and generics):** 125 mg/5 mL; contains 0.34 mEq Na/1 mL and parabens

**Naproxen sodium:****Tabs:**

**Aleve and generics (OTC):** 220 mg (200 mg base); contains 0.87 mEq Na

**Generics:** 275 mg (250 mg base), 550 mg (500 mg base); contains 1 mEq, 2 mEq Na, respectively

**Controlled release tabs:**

**Naprelan and generics:** 412.5 mg (375 mg base), 550 mg (500 mg base), 825 mg (750 mg base)

**Anaprox DS:** 550 mg (500 mg base)

**All doses based on naproxen base.****Child >2 yr:**

**Analgesia:** 5–10 mg/kg/dose Q12 hr PO

**JRA:** 10–20 mg/kg/24 hr  $\div$  Q12 hr PO

**Usual max. dose:** 1000 mg/24 hr



NAPROXEN/NAPROXEN SODIUM *continued***Adolescent and adult:****Analgesia:**

**Over-the-counter dosage forms:** 200 mg Q8–12 hr PRN PO (400 mg initial dose may be needed).

**Max. dose:** 600 mg/24 hr

**Prescription-strength dosage forms:** 250 mg Q8–12 hr PRN (500 mg initial dose may be needed) or 500 mg Q12 hr PRN PO. **Max. dose:** 1250 mg/24 hr for first day, then 1000 mg/24 hr

**Rheumatoid arthritis, ankylosing spondylitis:**

**Immediate release forms:** 250–500 mg BID PO

**Delayed release tabs:**

**EC-Naprosyn:** 375–500 mg BID PO

**Anaprox DS:** 275–550 mg BID PO

**Controlled release tabs (Naprelan):** 750–1000 mg once daily PO. For patients converting from immediate and delayed release forms, calculate daily dose and administer Naprelan as a single daily dose.

**Max. dose (all dosage forms):** 1000–1500 mg/24 hr

**Dysmenorrhea:**

500 mg × 1, then 250 mg Q6–8 hr PRN PO or 500 mg Q12 hr PRN PO; **max. dose:** 1250 mg/24 hr for first day, then 1000 mg/24 hr

**Contraindicated** in treating perioperative pain for coronary artery bypass graft surgery. May cause GI bleeding, thrombocytopenia, heartburn, headache, drowsiness, vertigo, and tinnitus.



**Use with caution** in patients with GI disease, cardiac disease (risk for thrombotic events, myocardial infarction [MI], stroke), or renal or hepatic impairment, and those receiving anticoagulants. drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported. False-positive test for urine cannabinoid screen may occur.

Use is **NOT** recommended for moderate/severe renal impairment (CrCl <30 mL/min). See [Ibuprofen](#) for other side effects.

Pregnancy category is “C” for prior to 30 weeks’ gestation and “X” for 30 wk and greater. **Avoid use** at >30 weeks’ gestation due to increased risk for premature closure of the fetal ductus arteriosus.

Limit dose and duration of use at 20–30 weeks’ gestation for concerns of fetal renal dysfunction and oligohydramnios.

Administer doses with food or milk to reduce GI discomfort.

**NEO-POLYMYCIN OPHTHALMIC OINTMENT**

See [Neomycin/polymyxin B Ophthalmic Products](#).

**NEOSPORIN OPHTHALMIC SOLUTION**

See [Neomycin/polymyxin B Ophthalmic Products](#).

**NEO-POLYCIN HC**

See [Neomycin/polymyxin B Ophthalmic Products](#).

**NEOMYCIN SULFATE**

Generics

**Antibiotic, aminoglycoside; ammonium detoxicant**



D



2



Yes



No



No

*Continued*

NEOMYCIN SULFATE *continued***Tabs:** 500 mg**Oral solution:** 25 mg/mL ; contains parabens

125 mg neomycin sulfate is equivalent to 87.5 mg neomycin base.

**Enteric bacterial eradication (limited data):****Preterm (>1.2 kg) and newborn:** 50–100 mg/kg/24 hr ÷ Q6 hr PO for up to 2 wk**Hepatic encephalopathy (limited data):****Infant and child:** 50–100 mg/kg/24 hr ÷ Q6–8 hr PO × 5–6 days. **Max. dose:** 12 g/24 hr**Adult:** 4–12 g/24 hr ÷ Q4–6 hr PO × 5–6 days**Bowel prep (in combination with erythromycin base; many other regimens exist):****Child:** 90 mg/kg/24 hr PO ÷ Q4 hr × 2–3 days**Adult:** 1 g Q1 hr PO × 4 doses, then 1 g Q4 hr PO × 5 doses

**Contraindicated** in ulcerative bowel disease, intestinal obstruction, or aminoglycoside hypersensitivity. Monitor for nephrotoxicity and ototoxicity. Oral absorption is limited, but levels may accumulate. Consider dosage reduction in the presence of renal failure. May cause itching, redness, edema, colitis, candidiasis, or poor wound healing if applied topically. Prevalence of neomycin hypersensitivity has increased. May decrease absorption of penicillin V, vitamin B<sub>12</sub>, digoxin, and methotrexate. May potentiate oral anticoagulants and the adverse effects of other neurotoxic, ototoxic, or nephrotoxic drugs.

**NEOMYCIN/POLYMYXIN B OPHTHALMIC PRODUCTS****Neomycin/Polymyxin B + Bacitracin:**

Neo-Polycin and generics

**Neomycin/Polymyxin B + Dexamethasone:**

Maxitrol

**Neomycin/Polymyxin B + Gramicidin:**

Generics

**Neomycin/Polymyxin B + Hydrocortisone:**

Generics

**Neomycin/Polymyxin B + Bacitracin + Hydrocortisone:**

Neo-Polycin HC and generics

**Ophthalmic antibiotic ± corticosteroid**

C



2



No



No



No

**Neomycin/Polymyxin B + Bacitracin:****Ophthalmic ointment (Neo-Polycin Ophthalmic Ointment and generics):** 3.5 g neomycin, 10,000 U polymyxin B, and 400 U bacitracin per g ointment (3.5 g)**Neomycin/Polymyxin B + Dexamethasone:****Ophthalmic ointment (Maxitrol):** 3.5 mg neomycin, 10,000 U polymyxin B, and 1 mg dexamethasone per 1 g (3.5 g)**Ophthalmic suspension (Maxitrol):** 3.5 mg neomycin, 10,000 U polymyxin B, and 1 mg dexamethasone per 1 mL (5 mL); contains benzalkonium chloride**Neomycin/Polymyxin B + Gramicidin:****Ophthalmic solution:** 1.75 neomycin, 10,000 U polymyxin B, and 0.025 mg gramicidin per 1 mL (10 mL); contains propylene glycol, alcohol, and thimerosal**Neomycin/Polymyxin B + Hydrocortisone:****Ophthalmic suspension:** 3.5 mg neomycin, 10,000 U polymyxin B, and 10 mg hydrocortisone per 1 mL (7.5 mL)

NEOMYCIN/POLYMYXIN B OPHTHALMIC PRODUCTS *continued***Neomycin/Polymyxin B + Bacitracin + Hydrocortisone:**

**Ophthalmic ointment (Neo-Polycin HC and generics):** 3.5 mg neomycin, 10,000 U polymyxin B, 400 U bacitracin, and 10 mg hydrocortisone per 1 g (3.5 g)

**Neomycin/Polymyxin B + Bacitracin (Neo-Polycin and generics):**

**Child and adult:** Apply 0.5-inch ribbon to affected eye(s) Q3–4 hr for acute infections or BID–TID for mild/moderate infections × 7–10 days.

**Neomycin/Polymyxin B + Dexamethasone (Maxitrol):**

**Child (≥2 yr)—adult:**

**Ophthalmic suspension:** Instill 1–2 drops into the conjunctival sac of the affected eye(s) 4–6 times per day for mild/moderate infections. For severe infections, administer Q1 hr and taper to discontinuation as inflammation subsides. No more than 20 mL should be prescribed initially.

**Ophthalmic ointment:** Apply ~0.5-inch ribbon into the conjunctival sac of the affected eye(s) TID–QID. Reevaluate diagnosis if signs and symptoms do not improve in 48 hr. Do not dispense >8 g.

**Neomycin/Polymyxin B + Gramicidin:**

**Child and adult:** Instill 1–2 drops to affected eye(s) Q4 hr or 2 drops every hour for severe infections × 7–10 days.

**Neomycin/Polymyxin B + Hydrocortisone:**

**Child and adult:** Instill 1–2 drops to affected eye(s) Q3–4 hr. More frequent dosing has been used for severe infection in adults.

**Neomycin/Polymyxin B + Bacitracin + Hydrocortisone (Neo-Polycin HC and generics):**

**Child and adult (limited data):** Apply ointment sparingly to inside of lower lid of affected eye(s) Q3–4 hr. Reevaluate diagnosis if signs and symptoms do not improve in 48 hr. Monitor intraocular pressure if use is equal to or greater than 10 days.

**Contraindicated** if patient is hypersensitive to specific medications (e.g., neomycin, polymyxin B, gramicidin, bacitracin, or hydrocortisone) of respective product. **Use with caution** in glaucoma. Blurred vision, burning, and stinging may occur. Increased intraocular pressure and mycosis may occur with prolonged use. **Avoid** prolonged use with products containing corticosteroids.



**Ophthalmic solution/suspension:** Shake well before use and **avoid** contamination of tip of eye dropper. Apply finger pressure to lacrimal sac during and 1–2 min after dose application.

**Ophthalmic ointment:** Do not touch tube tip to eyelids or other surfaces to prevent contamination.

**NEOMYCIN/POLYMYXIN B/BACITRACIN**

Neosporin Original, Triple Antibiotic, and various generics

**Topical antibiotic**



C



?



No



No



No

**Ointment, topical (OTC):** 3.5 mg neomycin sulfate, 400 U bacitracin, 5000 U polymyxin B/g (1, 15, 30, 454 g)

For ophthalmic products, see [Neomycin/Polymyxin B Ophthalmic Products](#).

**Child and adult:** Apply to minor wounds and burns once daily—TID.



**Do not use** for extended periods. May cause superinfection, delayed healing. See [Neomycin](#) for additional remarks. Prevalence of neomycin hypersensitivity has increased.



**NEOSTIGMINE**

Bloxiverz and generics

**Anticholinesterase (cholinergic) agent**

C

2

Yes

No

No

**Injection (Bloxiverz and generics):** 0.5, 1 mg/mL (10 mL) (as methylsulfate); contains phenol**Prefilled syringe injection:** 1 mg/mL (3 mL); may contain phenol**Myasthenia gravis diagnosis:** Use with atropine (see remarks).**Child:** 0.025–0.04 mg/kg IM × 1**Adult:** 1.5 mg IM × 1**Treatment:****Child:** 0.01–0.04 mg/kg/dose IM/IV/SC Q2–4 hr PRN**Adult:** 0.5–2.5 mg/dose IM/IV/SC Q1–3 hr PRN up to **max. dose** of 10 mg/24 hr**Reversal of nondepolarizing neuromuscular blocking agents:** Administer with atropine or glycopyrrolate.**All ages:** 0.03–0.07 mg/kg/dose IV; **max. dose:** 5 mg/dose**Contraindicated** in GI and urinary obstruction. **Caution** in patients with asthma. May cause cholinergic crisis, bronchospasm, salivation, nausea, vomiting, diarrhea, miosis, diaphoresis, lacrimation, bradycardia, hypotension, fatigue, confusion, respiratory depression, and seizures. Titrate for each patient, but **avoid** excessive cholinergic effects.

For reversal of neuromuscular blockade, infants and small children may be at greater risk of complications from incomplete reversal of neuromuscular blockade due to decreased respiratory reserve.

For diagnosis of myasthenia gravis (MG), administer atropine 0.011 mg/kg/dose IV immediately before or IM (0.011 mg/kg/dose) 30 min before neostigmine. For treatment of MG, patients may need higher doses of neostigmine at times of greatest fatigue.

**Antidote:** Atropine 0.01–0.04 mg/kg/dose. Atropine and epinephrine should be available in the event of a hypersensitivity reaction.**Adjust dose in renal failure (see Chapter 31).****NEVIRAPINE**

Generics; previously available as Viramune, Viramune XR; NVP

**Antiviral, nonnucleoside reverse transcriptase inhibitor**

B

2

Yes

Yes

No

**Tabs:** 200 mg**Extended release tabs:** 100, 400 mg**Oral suspension:** 10 mg/mL (240 mL); contains parabens, propylene glycol, and polysorbate 80**HIV treatment:** See <https://clinicalinfo.hiv.gov/en/guidelines>**Prevention of HIV vertical transmission during high-risk situations (mothers who received no antepartum antiretroviral therapy, mothers who received only intrapartum antiretroviral therapy, mothers who receive antepartum antiretroviral therapy but with suboptimal viral suppression [ $>50$  copies/mL] within 4 weeks prior to delivery, or mothers with acute or primary HIV infection during pregnancy or breastfeeding [immediately discontinue breastfeeding]); see Chapter 17 for additional information:****Newborn: Use in combination with zidovudine within 6–12 hr after birth (discontinue this regimen and convert to presumptive treatment regimen if HIV diagnosis is obtained):** 3 doses (based on birth weight) in the first week of life; dose 1: within 48 hr of birth; dose 2: 48 hr after dose 1; dose 3: 96 hr after dose 2

NEVIRAPINE *continued*

**Birth weight 1.5–2 kg:** 8 mg/dose PO

**Birth weight >2 kg:** 12 mg/dose PO

**HIV vertical transmission and presumptive treatment during high-risk situations (see above). Use in combination with zidovudine and lamivudine initiated within 6–12 hr after birth; transition to a treatment regimen if positive HIV diagnosis is confirmed and discontinue use after a negative diagnosis (see Chapter 17 for additional information):**

**≥32–<34 weeks' gestation at birth (dosage based on pharmacokinetic modeling and simulation and has not been evaluated in clinical trials):**

**Birth to 2 wk old:** 2 mg/kg/dose PO BID; first dose within 6–12 hr after delivery

**2–4 wk old:** 4 mg/kg/dose PO BID

**4–6 wk old:** 6 mg/kg/dose PO BID

**>6 wk old (use this higher dose only if infant has a confirmed HIV diagnosis):** 200 mg/m<sup>2</sup>/dose PO BID

**≥34–<37 weeks' gestation at birth (dosage based on pharmacokinetic and safety data):**

**Birth to 1 week old:** 4 mg/kg/dose PO BID; first dose within 6–12 hr after delivery

**1–4 weeks old:** 6 mg/kg/dose PO BID

**>4 weeks old (use this higher dose only if infant has a confirmed HIV diagnosis):** 200 mg/m<sup>2</sup>/dose PO BID

**≥37 weeks' gestation at birth (dosage based on pharmacokinetic and safety data):**

**Birth to 4 wk old:** 6 mg/kg/dose PO BID; first dose within 6–12 hr after delivery

**>4 wk old (use this higher dose only if infant has a confirmed HIV diagnosis):** 200 mg/m<sup>2</sup>/dose PO BID

See <https://clinicalinfo.hiv.gov/en/guidelines> for additional remarks.



**Use with caution** in patients with hepatic or renal dysfunction. **Contraindicated** in

moderate/severe hepatic impairment (Child-Pugh Class B or C) and postexposure (occupational or nonoccupational) prophylactic regimens. Most frequent side effects with continuous therapy include skin rash (may be life threatening, including Stevens-Johnson syndrome and DRESS; permanently discontinue and never restart), fever, abnormal liver function tests, headache, and nausea.

**Discontinue therapy** if any of the following occurs: severe rash; rash with fever, blistering, oral lesions, conjunctivitis, or muscle aches. Permanently discontinue and do not restart therapy if symptomatic hepatitis, severe transaminase elevations, or hypersensitivity reactions occur.

**Life-threatening** hepatotoxicity has been reported primarily during the first 12 wk of continuous therapy. Patients with increased serum transaminase or a history of hepatitis B or C infection prior to nevirapine are at greater risk for hepatotoxicity. Women, including pregnant women, with CD<sub>4</sub> cell counts >250/mm<sup>3</sup> or men with CD<sub>4</sub> cell counts >400/mm<sup>3</sup> are at risk for hepatotoxicity. Monitor liver function tests (obtain transaminases immediately after development of hepatitis signs/symptoms, hypersensitivity reactions, or rash) and complete blood counts. Hypophosphatemia has been reported.

Nevirapine induces the CYP 450 3A4 drug metabolizing isoenzyme to cause an autoinduction of its own metabolism within the first 2–4 wk of therapy and has the potential to interact with many drugs.

**Carefully review the patient's drug profile for other drug interactions each time nevirapine is initiated or when a new drug is added to a regimen containing nevirapine.**

Doses can be administered with food and concurrently with didanosine.

**NIACIN/VITAMIN B<sub>3</sub>**

Niacor, Niaspan, Slo-Niacin, Nicotinic acid, Vitamin B<sub>3</sub>, and many generics

***Vitamin, water soluble***



A/C



2



Yes



Yes



No

*Continued*

NIACIN/VITAMIN B<sub>3</sub> *continued***Tabs:****Generics (OTC):** 50, 100, 250, 500 mg**Niacor:** 500 mg**Timed or extended release tabs:****Generics:** 250 (OTC), 500, 750, 1000 mg**Slo-Niacin (OTC):** 500, 750 mg**Niaspan:** 500, 750, 1000 mg; dosed QHS**Caps (OTC):** 100, 500, 1000 mg**Timed or extended release caps (OTC):** 250, 500 mg**Powder (OTC):** 100, 500, 1000 g**US recommended dietary allowance (RDA):** See [Chapter 21](#).**Pellagra (PO):** Usual treatment duration is 3–4 wk**Child:** 50–100 mg/dose TID**Adult:** 50–100 mg/dose TID–QID**Max. dose:** 500 mg/24 hr

**Contraindicated** in hepatic dysfunction, active peptic ulcer, and severe hypotension. **Use with caution** in unstable angina, acute MI (especially if patient is receiving vasoactive drugs), renal dysfunction, and in patients with history of jaundice, hepatobiliary disease, or peptic ulcer. Adverse reactions of flushing, pruritus, or GI distress may occur with oral administration. May cause hyperglycemia, hyperuricemia, blurred vision, abnormal liver function tests, dizziness, and headaches. Burning sensation of the skin, skin discoloration, acanthosis nigricans, hepatitis, and elevated creatine kinase have been reported. May cause false-positive urine catecholamines (fluorometric methods) and urine glucose (Benedict reagent).



Use with statins may increase the risk of myopathy/rhabdomyolysis. Bile acid sequestrants (e.g., cholestyramine) may bind to niacin and should be taken at least 4–6 hr before niacin administration.

Pregnancy category changes to “C” if used in doses above the RDA or for typical doses used for lipid disorders. Breastfeeding should be discontinued when used for the treatment of dyslipidemias for mothers as hepatotoxicity is a potential to the infant. **See Chapter 21 for multivitamin preparations.**

**NICARDIPINE**

Cardene IV and generics

**Calcium channel blocker, antihypertensive**

C



1



Yes



Yes



No

**Caps (immediate release):** 20, 30 mg**Injection:****Cardene IV:** 0.1 mg/mL (200 mL; premixed in isotonic dextrose or saline), 0.2 mg/mL (200 mL; premixed in isotonic saline)**Generic:** 2.5 mg/mL (10 mL); may contain sorbitol or benzoic acid**Child (see remarks):****Hypertension:****Continuous IV infusion for severe hypertension:** Start at 0.5–1 mCg/kg/min, dose may be increased as needed every 15–30 min up to a **max.** of 4–5 mCg/kg/min.**Adult (see remarks):****Hypertension:****Oral:** 20 mg PO TID; dose may be increased after 3 days to 40 mg PO TID if needed

NICARDIPINE *continued*

**Continuous IV infusion:** Start at 5 mg/hr, increase dose as needed by 2.5 mg/hr Q5–15 min up to a **max. dose** of 15 mg/hr. Following attainment of desired BP, decrease infusion to 3 mg/hr and adjust rate as needed to maintain desired response.

Reported use in children has been limited to a small number of preterm infants, infants, and children.



**Contraindicated** in advanced aortic stenosis. **Avoid** systemic hypotension in patients following an acute cerebral infarct or hemorrhage. Use with **caution** in hepatic or renal dysfunction by carefully titrating dose. The drug undergoes significant first-pass metabolism through the liver and is excreted in the urine (60%). Use **caution** when converting to another dosage form; they are NOT equivalent on a milligram-per-milligram basis.

May cause headache, dizziness, asthenia, peripheral edema, and GI symptoms. Nicardipine is a substrate for CYP 450 3A and inhibitor of CYP 450 2 C9/19. Cimetidine increases the effects/toxicity of nicardipine. Nicardipine may increase effect/toxicity of cyclosporine and tacrolimus. **See Nifedipine for additional drug and food interactions.**

Onset of action for orally administered drug is 20 min with peak effects in 0.5 to 2 hr. Onset of action of intravenously administered drug is 1 min. Duration of action following a single IV or PO dose is 3 hr. To reduce the risk for venous thrombosis, phlebitis, and vascular impairment with IV administration, do not use small veins (e.g., dorsum of hand or wrist). **Avoid** intra-arterial administration or extravasation. For additional information, **see Chapter 4.**

**NIFEDIPINE**

Procardia XL and many generics; previously available as Procardia and Adalat CC

**Calcium channel blocker, antihypertensive**



C



2



No



Yes



No

**Caps:** 10 mg (0.34 mL), 20 mg (0.45 mL)

**Sustained release tabs:** (Procardia XL, and generics): 30, 60, 90 mg

**Oral suspension:** 4 mg/mL 

**Child (see remarks for precautions):**

**Chronic hypertension:**

**Sustained release tabs:** Start with 0.2–0.5 mg/kg/24 hr (initial **max. dose:** 30–60 mg/24 hr) ÷ Q12–24 hr. May increase to **max. dose:** 3 mg/kg/24 hr up to 120 mg/24 hr



**Adult:**

**Chronic hypertension or angina:**

**Sustained release tabs:** Start with 30 or 60 mg PO once daily. May increase to **max. dose** of 120 mg/24 hr. Dosing above 90 mg/24 hr for angina is limited and should be used with caution.

Use of immediate release dosage form in children is controversial and has been abandoned by many. **Use with caution** in children with acute CNS injury due to increased risk for stroke, seizure, hepatic impairment, and altered level of consciousness. To prevent rapid decrease in blood pressure in children, an initial dose of  $\leq 0.25$  mg/kg is recommended.



**Use with caution** in patients with congestive heart failure (CHF), aortic stenosis, GI obstruction/narrowing (bezoar formation), and cirrhosis (reduced drug clearance). May cause severe hypotension, peripheral edema, flushing, tachycardia, headaches, dizziness, nausea, palpitations, and syncope. Acute generalized exanthematous pustulosis has been reported.

Although overall use in adults has been abandoned, the immediate release dosage form is **contraindicated** in adults with severe obstructive coronary artery disease or recent MI and in hypertensive emergencies.

*Continued*

NIFEDIPINE *continued*

Nifedipine is a substrate for CYP 450 3A3/4, and 3A5-7. **Do not administer** with grapefruit juice; may increase bioavailability and effects. Itraconazole and ketoconazole may increase nifedipine levels and/or effects. CYP 3A inducers (e.g., rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine) may reduce nifedipine's effects. Nifedipine may increase phenytoin, cyclosporine, and digoxin levels. For hypertensive emergencies, **see Chapter 4**.

For sublingual (SL) administration, capsule must be punctured and liquid expressed into the patient's mouth. A small amount is absorbed via the SL route. Most effects are due to swallowing and oral absorption. **Do not** crush or chew sustained release tablet dosage form.

**NITROFURANTOIN**

Macrochantin, Macrobid, and generics; previously available as Furadantin

**Antibiotic**



B/X



2



Yes



Yes



No

**Caps (macrocrystals; Macrochantin and generics):** 25, 50, 100 mg

**Caps (dual release; Macrobid and generics):** 100 mg (25 mg macrocrystal/75 mg monohydrate)

**Oral suspension:** 25 mg/5 mL (230 mL); may contain parabens, sorbitol, and saccharin

**Child (>1 mo; oral suspension or macrocrystals):**

**UTI treatment:** 5–7 mg/kg/24 hr ÷ Q6 hr PO; **max. dose:** 400 mg/24 hr

**UTI prophylaxis:** 1–2 mg/kg/dose QHS PO; **max. dose:** 100 mg/24 hr

**≥12 yr and adult:**

**UTI treatment:**

**Macrocrystals:** 50–100 mg/dose Q6 hr PO

**Dual release (Macrobid):** 100 mg/dose Q12 hr PO

**UTI prophylaxis (macrocrystals):** 50–100 mg/dose PO QHS



**Contraindicated** in severe renal disease, infants younger than 1 mo of age, glomerular filtration rate (GFR) below 60 mL/min (reduced drug distribution in the urine), active/previous cholestatic jaundice/hepatic dysfunction, and pregnant women at term. **Use with caution** in G6PD deficiency, anemia, lung disease, and peripheral neuropathy. May cause nausea, hypersensitivity reactions (including vasculitis), vomiting, cholestatic jaundice, headache, hepatotoxicity, polyneuropathy, and hemolytic anemia.

Anticholinergic drugs and high-dose probenecid may increase nitrofurantoin toxicity. Magnesium salts may decrease nitrofurantoin absorption. Causes false-positive urine glucose with Clinitest.

Administer doses with food or milk.

Pregnancy category changes to “X” at term (38–42 weeks' gestation). Breastfeeding in mothers receiving nitrofurantoin is not recommended for infants younger than 1 mo and those with G6PD deficiency; use in infants 1 mo and without G6PD deficiency is compatible.

**NITROGLYCERIN**

Nitro-Bid, Nitrostat, Nitro-Time, Nitro-Dur, Nitrolingual, Nitromist, Rectiv, and generics

**Vasodilator, antihypertensive**



C



?



Yes



Yes



No

**Injection:** 5 mg/mL (10 mL); contains alcohol or propylene glycol

**Prediluted injection in D<sub>5</sub>W:** 100 mCg/mL (250 mL), 200 mCg/mL (250 mL), 400 mCg/mL (250 mL); contains alcohol and propylene glycol

**Sublingual tabs (Nitrostat and generics):** 0.3, 0.4, 0.6 mg

NITROGLYCERIN *continued*

**Sustained release caps (Nitro-Time):** 2.5, 6.5, 9 mg

**Ointment, topical (Nitro-Bid):** 2% (1, 30, 60 g)

**Ointment, rectal (Rectiv):** 0.4% (30 g); contains propylene glycol

**Patch (Nitro-Dur and generics):** 2.5 mg/24 hr (0.1 mg/hr), 5 mg/24 hr (0.2 mg/hr), 7.5 mg/24 hr (0.3 mg/hr), 10 mg/24 hr (0.4 mg/hr), 15 mg/24 hr (0.6 mg/hr), 20 mg/24 hr (0.8 mg/hr) (30s, 100s)

**Spray, translingual (Nitrolingual and generics):** 0.4 mg per metered spray (4.9, 12 g; delivers 60 and 200 doses, respectively); contains 20% alcohol (flammable)

**Aerosol spray, translingual (Nitromist):** 0.4 g per spray (4.1, 8.5 g; delivers 90 and 230 doses, respectively); contains peppermint oil and menthol

**NOTE:** The IV dosage units for children are in mCg/kg/min, compared with mCg/min for adults (see remarks).

**Infant/child:**

**Continuous IV infusion:** Begin with 0.25–0.5 mCg/kg/min; may increase by 0.5–1 mCg/kg/min Q3–5 min PRN. Usual dose: 1–5 mCg/kg/min. **Max. dose:** 20 mCg/kg/min

**Treatment of sympathomimetic/vasopressor extravasation (alternative to phentolamine; very limited data):** Apply 4 mm/kg of the 2% ointment as a thin ribbon to the affected areas. If no improvement seen after 8 hr, apply another dose. Monitor patient's blood pressure for hypotension.

**Adult:**

**Continuous IV infusion:** 5 mCg/min IV, then increase Q3–5 min PRN by 5 mCg/min up to 20 mCg/min. If no response, increase by 10–20 mCg/min Q3–5 min PRN up to a **max.** of 200 mCg/min for hypertension and 400 mCg/min for acute angina.

**Acute angina:**

**Sublingual tabs:** 0.3–0.4 mg Q5 min. **Max.** of three doses in 15 min

**Angina prophylaxis:**

**Sustained release oral caps:** 2.5–6.5 mg TID–QID; up to 26 mg QID

**Sublingual tabs:** 0.3–0.4 mg 5–10 min before activity that might induce an attack

**Translingual spray (0.4 mg/spray):** 1–2 sprays 5–10 min before activity that might induce an attack

**Ointment:** Apply ½ inch upon rising in the morning and another ½ inch 6 hr later if needed, double the dose to 1 inch with the same dosing schedule the next day and subsequently to 2 inches if needed. **Max. recommended dose:** 2 doses/24 hr. Provide 10–12 hr/day of nitrate-free period to minimize tolerance.

**Patch:** 0.2–0.4 mg/hr initially, then titrate to 0.4–0.8 mg/hr; apply new patch daily (tolerance is minimized by removing patch for 10–12 hr/24 hr)

**Contraindicated** in glaucoma, with increased ICP, cerebral hemorrhage, traumatic brain injury, shock, severe anemia, concurrent phosphodiesterase-5 inhibitor (e.g., sildenafil), and concurrent guanylate cyclase stimulator (e.g., riociguat). In small doses (1–2 mCg/kg/min), acts mainly on systemic veins and decreases preload. At 3–5 mCg/kg/min, acts on systemic arterioles to decrease resistance. May cause headache, flushing, hypersensitivity reactions, hypotension, GI upset, blurred vision, and methemoglobinemia. **Use with caution** in severe renal impairment and hepatic failure. IV nitroglycerin may antagonize anticoagulant effect of heparin. Tachyphylaxis develops within 24–48 hr of continuous IV administration; 10–12 hr/day of nitrate-free period has been recommended to prevent tachyphylaxis in adults.



Decrease dose gradually in patients receiving drug for prolonged periods to avoid withdrawal reaction. Must use polypropylene infusion sets to avoid adsorption of drug to plastic tubing. Use in heparinized patients may result in a decrease of PTT with subsequent rebound effect on discontinuation of nitroglycerin.

*Continued*

NITROGLYCERIN *continued*

Onset (duration) of action: IV: 1–2 min (3–5 min); sublingual: 1–3 min (30–60 min); PO sustained release: 40 min (4–8 hr); topical ointment: 20–60 min (2–12 hr); and transdermal patch: 40–60 min (18–24 hr).

**NITROPRUSSIDE**

Nipride RTU and generics

**Vasodilator, antihypertensive**

C



X



Yes



Yes



No

**Injection:** 25 mg/mL (2 mL)**Prediluted injection in 0.9% sodium chloride:****Nipride RTU:** 0.2 mg/mL (100 mL), 0.5 mg/mL (100 mL)**Child, adolescent, and adult:** IV, continuous infusion**Dose:** Start at 0.3–0.5 mCg/kg/min, titrate to effect. Usual dose is 3–4 mCg/kg/min.**Max. dose:** 10 mCg/kg/min

**Contraindicated** in patients with decreased cerebral perfusion and in situations of compensatory hypertension (increased ICP). Monitor for hypotension and acidosis. Dilute with D<sub>5</sub>W and protect from light.



Pediatric efficacy is supported by a dose-ranging trial, an open-label trial, and adult trials. No novel safety issues were found in the aforementioned pediatric trials.

Nitroprusside is nonenzymatically converted to cyanide, which is converted to thiocyanate. Cyanide may produce metabolic acidosis and methemoglobinemia; thiocyanate may produce psychosis and seizures. Monitor thiocyanate levels if used for more than 48 hr or in a dose equal to or greater than 4 mCg/kg/min. **Thiocyanate levels should be less than 50 mg/L. Monitor cyanide levels (toxic levels >2 mCg/mL)** in patients with hepatic dysfunction and thiocyanate levels in patients with renal dysfunction.

Onset of action is 2 min with a 1- to 10-min duration of effect.

**NOREPINEPHRINE BITARTRATE**

Levophed and generics

**Adrenergic agonist**

C



?



Yes



No



No

**Injection:** 1 mg/mL as norepinephrine base (4 mL); may contain sulfites**Prediluted injection in D<sub>5</sub>W or normal saline:** 16 mCg/mL (250 mL), 32 mCg/mL (250 mL), 64 mCg/mL (250 mL); contains sulfites**NOTE:** The dosage units for children are in mCg/kg/min compared with mCg/min for adults.**Child:** Continuous IV infusion doses as norepinephrine base. Start at 0.05–0.1 mCg/kg/min.Titrate to effect. **Max. dose:** 2 mCg/kg/min**Adult:** Continuous IV infusion **doses as norepinephrine base.** Start at 8–12 mCg/min and titrate to effect. Usual maintenance dosage range: 2–4 mCg/min

May cause cardiac arrhythmias, hypertension, hypersensitivity, headaches, vomiting, uterine contractions, and organ ischemia. May cause decreased renal blood flow and urine output.



**Avoid** extravasation into tissues; may cause severe tissue necrosis. If this occurs, treat locally with phentolamine.

**NORTRIPTYLINE HYDROCHLORIDE**

Pamelor and generics

**Antidepressant, tricyclic**

D

2

No

Yes

Yes

**Caps:** 10, 25, 50, 75 mg; may contain benzyl alcohol, parabens, or EDTA**Oral solution:** 10 mg/5 mL (473 mL); contains up to 4% alcohol, benzoic acid, and sorbitol**Depression (see remarks):****Child 6–12 yr:** 1–3 mg/kg/24 hr ÷ TID–QID PO or 10–20 mg/24 hr ÷ TID–QID PO**Adolescent:** 1–3 mg/kg/24 hr ÷ TID–QID PO or 30–50 mg/24 hr ÷ TID–QID PO**Adult:** 75–100 mg/24 hr ÷ TID–QID PO**Max. dose** (all ages): 150 mg/24 hr**Nocturnal enuresis (see remarks):****6–7 yr (20–25 kg):** 10 mg PO QHS**8–11 yr (26–35 kg):** 10–20 mg PO QHS**>11 yr (36–54 kg):** 25–35 mg PO QHS

See imipramine for contraindications and common side effects. Also **contraindicated** with linezolid or IV methylene blue due to increased risk for serotonin syndrome. **Avoid** use in patients with Brugada syndrome. Fewer CNS and anticholinergic side effects than with amitriptyline. May cause mild pupillary dilation, which can lead to narrow angle glaucoma.

Lower doses and slower dose titration are recommended in hepatic impairment. Therapeutic antidepressant effects occur in 7–21 days. Monitor for clinical worsening of depression and suicidal ideation/behavior following the initiation of therapy or after dose changes. **Do not** discontinue abruptly. Nortriptyline is a substrate for the CYP 450 1A2 and 2D6 drug-metabolizing enzymes. Use and dosing considerations have been recommended based on the following CYP 450 2D6 phenotypes:

**Ultrarapid metabolizer:** Use of alternative drug not metabolized by CYP 2D6. If use is warranted, titrate to the highest target dose and monitor serum levels.

**Intermediate metabolizer:** Reduce recommended initial dose by 25% and monitor serum levels.

**Poor metabolizer:** **Avoid use** to prevent potential side effect and use alternative drug not metabolized by CYP 2D6. If use is warranted, reduce recommended initial dose by 50% and monitor serum levels.

Rifampin may increase the metabolism of nortriptyline.

Therapeutic nortriptyline levels for depression: 50–150 ng/mL. Recommended serum sampling time:

Obtain a single level 8 or more hours after an oral dose (following 4 days of continuous dosing for children and after 9–10 days for adults).

Administer with food to decrease GI upset.

**NYSTATIN**

Nyamyc, Nystop, and generics; previously available as Mycostatin and Nilstat

**Antifungal agent**

C

2

No

No

No

**Tabs:** 500,000 U**Oral suspension:** 100,000 U/mL (5, 60, 480 mL)**Topical cream and ointment:** 100,000 U/g (15, 30 g)**Topical powder (Nyamyc, Nystop, and generics):** 100,000 U/g (15, 30, 60 g)**Oropharyngeal candidiasis:****Preterm infant:** 0.5 mL (50,000 U) to each side of mouth QID

Continued

NYSTATIN *continued*

**Term infant:** 1–4 mL (100,000–400,000 U) to each side of mouth QID

**Child, adolescent, and adult:** 4–6 mL (400,000–600,000 U) swish and swallow QID

**Nonesophageal mucous membrane GI candidiasis:**

**Adult (oral tabs):** 500,000–1,000,000 U PO Q8 hr until 48 hr after clinical cure

**Topical (all topical dosage forms):**

**All ages:** Apply to affected areas BID-QID.

May produce diarrhea and GI side effects. Local irritation, contact dermatitis, and Stevens-Johnson syndrome have been reported. Treat until 48–72 hr after resolution of symptoms. Drug is poorly absorbed through the GI tract. Oral suspension should be swished about the mouth and retained in the mouth as long as possible before swallowing.



0

**OCTREOTIDE ACETATE**

Sandostatin, Sandostatin LAR Depot, and generics

**Somatostatin analog, antisecretory agent**



B



2



Yes



No



No

**Injection (amps and single dose vials):** 0.05, 0.1, 0.5 mg/mL (1 mL); preservative free

**Injection (multidose vials):** 0.2, 1 mg/mL (5 mL); contains phenol

**Injection, microspheres for suspension (Sandostatin LAR Depot; see remarks):** 10, 20, 30 mg (in kits with 2 mL diluent and 1.5-inch 20-gauge needles)

**Infant and child:**

**Intractable diarrhea (very limited data):**

**IV/SC:** 1–10 mCg/kg/24 hr ÷ Q12–24 hr. Dose may be increased within the recommended range by 0.3 mCg/kg/dose every 3 days as needed. **Max. dose:** 1500 mCg/24 hr

**IV continuous infusion:** Bolus of 1 mCg/kg/dose followed by 1 mCg/kg/hr; this has been used in diarrhea associated with graft-versus-host disease.

**Esophageal varices (limited data):** Bolus of 1–2 mCg/kg/dose followed by 1–2 mCg/kg/hr. Use was reported as safe and effective over a 2–5 day duration with major adverse effects in one subject each receiving higher dose or longer duration of therapy. Therapy is typically discontinued 24 hr after bleeding has ceased or when no clinical response is seen after 12 hr of use.



Cholelithiasis, hyperglycemia, hypoglycemia, hypothyroidism, nausea, diarrhea, abdominal discomfort, headache, dizziness, and pain at injection site may occur. Growth hormone suppression may occur with long-term use. Bradycardia, thrombocytopenia, and increased risk for pregnancy in patients with acromegaly and pancreatitis have been reported. Cyclosporine levels may be reduced in patients receiving this drug. May increase the effects/toxicity of bromocriptine.

Patients with severe renal failure requiring dialysis may require dosage adjustments due to an increase in half-life. Effects of hepatic dysfunction on octreotide have not been evaluated.

Octreotide may interfere with the efficacy of lutetium Lu 177 dotatate; discontinue octreotide at least 24 hr prior to each lutetium Lu 177 dotatate dose. May decrease the effects of cyclosporine and increase the effect/toxicity of bromocriptine. **Use with caution** with medications that are primarily metabolized via CYP 450 3A4 with low therapeutic index (e.g., quinidine) as somatostatin analogs may decrease CYP 450 activity via growth hormone suppression.

Sandostatin LAR Depot is administered once every 4 wk **only** by the IM route and is currently indicated for use in adults who have been stabilized on IV/SC therapy. See package insert for details.



**OFLOXACIN (OTIC AND OPHTHALMIC)**

Ocuflox, and generics; previously available as Floxin and Floxin Otic  
**Antibiotic, quinolone**



C



2



No



No



No

**Otic solution:** 0.3% (5, 10 mL); contains benzalkonium chloride

**Ophthalmic solution (Ocuflox and generics):** 0.3% (5, 10 mL); contains benzalkonium chloride

**Otic use:****Otitis externa (acute):**

**6 mo—12 yr:** 5 drops to affected ear(s) once daily × 7 days

**≥13 yr—adult:** 10 drops to affected ear(s) once daily × 7 days

**Chronic suppurative otitis media:**

**≥12 yr—adult:** 10 drops to affected ear(s) BID × 14 days

**Acute otitis media with tympanostomy tubes:**

**1—12 yr:** 5 drops to affected ear(s) BID × 10 days

**Ophthalmic use (>1 yr—adult):**

**Conjunctivitis:** 1—2 drops to affected eye(s) 2—4 hr while awake × 2 days, then QID × 5 additional days

**Corneal ulcer:** 1—2 drops to affected eye(s) Q30 min while awake and Q4—6 hr while asleep at night × 2 days, followed by Q1 hr while awake × 5 days, and then QID until treatment has been completed



Pruritus, local irritation, taste perversion, dizziness, and earache have been reported with otic use. Ocular burning/discomfort is frequent with ophthalmic use. Consult with ophthalmology in corneal ulcers.



When otic solution is being used, the solution should be warmed by holding the bottle in the hand for 1—2 min. The use of cold solutions may result in dizziness. For otitis externa, the patient should lie with the affected ear upward before instillation and remain in the same position after dose administration for 5 min to enhance drug delivery. For acute otitis media with tympanostomy tubes, the patient should lie in the same position prior to instillation and the tragus should be pumped

4 times after the dose to assist in drug delivery to the middle ear.

Systemic use of ofloxacin is typically replaced by levofloxacin, its S-isomer, which has a more favorable side effect profile than ofloxacin. See [Levofloxacin](#).

**OLANZAPINE**

Zyprexa, Zyprexa Zydis, Zyprexa Relprevv, and generics

**Antipsychotic, atypical second generation**



C



2



No



Yes



No

**Tabs:** 2.5, 5, 7.5, 10, 15, 20 mg

**Orally disintegrating tabs (Zyprexa Zydis and generics):** 5, 10, 15, 20 mg; contain phenylalanine and parabens

**IM injection:**

**Short-acting:** 10 mg; contains tartaric acid

**Long-acting pamoate salt (Zyprexa Relprevv):**

**Every 2 wk dosing:** 210, 300 mg; contains mannitol, polysorbate 80

**Every 4 wk dosing:** 405 mg; contains mannitol, polysorbate 80

Continued

OLANZAPINE *continued***PO DOSING**

**Severe or refractory agitation for psychiatric emergencies in developmental delay, autism, or oppositional defiant/conduct disorder (very limited data; oral disintegrating tab is preferred):**

**Child <12 yr:** 2.5 mg PO

**Child ≥12 yr and adolescent:** 5–10 mg PO

**Bipolar I disorder (manic or mixed episodes; not first-line therapy):**

**Child 4–6 yr of age (limited data, based on an open-label trial in 15 subjects):** Start at 1.25 mg PO once daily × 7 days, then increase dose Q7 days PRN as tolerated to a target dose of 10 mg once daily.

**Child 6–12 yr of age (limited data):** Start at 2.5 mg PO once daily × 7 days, then increase dose in 2.5 or 5 mg increments Q7 days to a target dose of 10 mg once daily. Suggested **max. dose:** 20 mg/24 hr

**Adolescent (see remarks):** Start at 2.5 or 5 mg PO once daily × 7 days, then increase dose in 2.5 or 5 mg increments Q7 days to a target dose of 10 mg once daily. Suggested **max. dose:** 20 mg/24 hr (doses >20 mg/24 hr have not been evaluated)

**Adult:** Start at 10 or 15 mg PO once daily (use 10 mg if used with lithium or valproate). If needed, increase or decrease dose by 5 mg daily at intervals not <24 hr. Maintenance dosage range: 5–20 mg/24 hr. Suggested **max. dose:** 20 mg/24 hr (doses >20 mg/24 hr have not been evaluated)

**Schizophrenia:**

**Child ≥8 yr of age and adolescent (see remarks):** Start with 2.5 or 5 mg PO once daily, then increase dose in 2.5 or 5 mg increments Q7 days to the target dose of 10 mg once daily (doses >20 mg/24 hr have not been evaluated).

**Adult:** Start with 5 or 10 mg PO once daily (use 5 mg for individuals who are debilitated, predisposed to hypotension, pharmacodynamically sensitive to olanzapine, or nonsmoking females ≥65 yr old) with a target dose of 10 mg once daily within 5–7 days. If needed, increase or decrease dose by 5 mg daily at weekly intervals. Usual dosage range: 10–15 mg once daily. Additional clinical assessment is recommended for doses >10 mg/24 hr (doses >20 mg/24 hr have not been evaluated).

**Chemotherapy-induced nausea and vomiting (refractory breakthrough; limited data):**

**Child ≥3 yr and adolescent:** 0.1–0.14 mg/kg/dose (rounded to the nearest 1.25 mg dosage increment) PO once daily—BID. Many report use in combination with other antiemetics such as aprepitant, dexamethasone, ondansetron, or granisetron.

**IM DOSING**

**Short-acting IM injection:**

**Severe or refractory agitation for psychiatric emergencies in developmental delay, autism, or oppositional defiant/conduct disorder (PO administration is preferred; limited data):**

**Child <12 yr:** 1.25–5 mg IM

**Child ≥12 yr and adolescent:** 5–10 mg IM; dose may be repeated after 2 hr if needed

**Acute agitation associated with bipolar I or schizophrenia:**

**Child and adolescent (limited retrospective data in 15 children and 35 adolescents):** ≤12 yr: 5 mg and adolescent (13–17 yr): 10 mg. Dosing frequencies and max. doses were not reported.

**Adult:** 10 mg (5 mg for geriatric patients and 2.5 mg for individuals who are debilitated, predisposed to hypotension, or pharmacodynamically sensitive to olanzapine). If needed, additional doses × 2 may be given; second dose 2 hr after the first dose and third dose 4 hr after the second dose. Recommended max. dose is 30 mg/24 hr (10 mg × 3 given 2–4 hr apart); safety of doses >30 mg/24 hr has not been evaluated.

OLANZAPINE *continued***Long-acting pamoate salt (Zyprexa Relprevv):**

**Schizophrenia (adult):** See remarks and package insert for specific dosage based on established oral dosage.

**Use with caution** in cardiovascular or cerebrovascular disease, hypotensive conditions, diabetes/hyperglycemia, elevated serum lipids and cholesterol, paralytic ileus, hepatic impairment, seizure disorders, narrow angle glaucoma, and prostatic hypertrophy. Medication exhibits anticholinergic effects.



Common side effects include orthostatic hypotension, peripheral edema, hypercholesterolemia, hyperprolactinemia, appetite stimulation, weight gain (greater in adolescents than adults; monitoring is recommended), hypertriglyceridemia, constipation, xerostomia, akathisia, asthenia, dizziness, somnolence, tremor, and personality disorder. Neuroleptic malignant syndrome, dystonia, cognitive and motor impairment, tardive dyskinesia (irreversible with cumulative high doses), neutropenia, leukopenia, agranulocytosis, suicidal intent, acute pancreatitis, pulmonary embolism, increases in liver function tests (ALT, AST, GGT), DRESS, salivary hypersecretion, and hyperthermia have been reported.

Olanzapine is a major substrate for CYP 450 1A2 and minor substrate for 2D6. It also is a weak inhibitor to CYP 450 1A2, 2C9/19. Do not use in combination with alcohol, benzodiazepines, or opiates due to increased risk for sedation and cardiopulmonary depression. Caution is also indicated with anticholinergic agents (e.g., azelastine, glycopyrrolate), as olanzapine may enhance the anticholinergic effects. Use with QTc-prolonging medications may further increase the risk for QTc prolongation. Metoclopramide may enhance neurologic side effects of olanzapine. Do not use oral disintegrating tablets in phenylketonuria.

$T_{1/2}$ : 37 hr for children and 21–54 hr for adults via PO route. Short-acting IM  $T_{1/2}$  in adults is similar to PO route, but long-acting IM  $T_{1/2}$  is ~30 days in adults.

Maintenance treatment for bipolar I disorder and schizophrenia has not been systematically evaluated in adolescents. Therefore it is recommended to utilize the lowest dose to maintain efficacy and to reassess the need for maintenance treatment periodically for this age group.

All oral dosages may be taken either with or without food. For orally disintegrating tabs, tablet must be placed in patient's mouth immediately after removing it from the foil pack (by peeling off the foil, not by pushing the tablet through the foil) and allowed to dissolve in saliva; then swallowed with or without liquids.

**Zyprexa Relprevv (long-acting IM injection):** Postinjection delirium and sedation syndrome have been reported with this dosage form. Patients must be observed by a healthcare provider at a healthcare facility for at least 3 hr after administration. The FDA REMS program requires prescribers, healthcare facilities, and pharmacies to register with the Zyprexa Relprevv Patient Care Program at 1-877-772-9390 for use of this product.

**OLOPATADINE**

Patanol, Pataday, Patanase, and generics

**Antihistamine**



C



2/?



No



No



No

**Ophthalmic solution (products may contain benzalkonium chloride):**

**Patanol, Pataday, and generics (OTC):** 0.1% (5 mL)

**Pataday and generics (OTC):** 0.2% (2.5 mL)

**Pataday:** 0.7% (2.5 mL)

**Nasal spray (Patanase and generics):** 0.6% (30.5 g provides 240 metered spray doses); contains benzalkonium chloride and EDTA

*Continued*

OLOPATADINE *continued***Ophthalmic use for allergic conjunctivitis ( ≥2 yr old and adult):**

**0.1% solution:** 1 drop in affected eye(s) BID (spaced 6–8 hr apart)

**0.2% or 0.7% solution:** 1 drop in affected eye(s) once daily

**Intranasal use of allergic rhinitis:**

**Patients 6–11 yr old:** Inhale 1 spray into each nostril BID.

**Patients ≥12 yr old and adult:** Inhale 2 sprays into each nostril BID.



**Ocular use: DO NOT** use while wearing contact lenses; wait at least 10 min after instilling drops before inserting lenses. Ocular side effects include burning or stinging, dry eye, foreign body sensation, hyperemia, keratitis, lid edema, and pruritus. May also cause headaches, asthenia, pharyngitis, rhinitis, and taste perversion. Use with caution in lactation with the ocular route of administration.



**Nasal use:** Common side effects include bitter taste and headaches. Somnolence, impaired mental alertness, nasal ulceration, epistaxis, nasal septal perforation, throat pain, and postnasal drip have been reported. Diarrhea was reported more frequently (9%) in an allergic rhinitis clinical trial for 2–5 yr old children compared to 6–11 yr old (<1%). Breastfeeding information is unknown with the intranasal route of administration.

To reduce the risk of drug being systemically absorbed with ophthalmic use, place pressure on the tear duct by the corner of the eye for ≥1 min, then remove the excess solution with an absorbent tissue. A combination intranasal product of olopatadine and mometasone (Ryaltris) is available for seasonal allergic rhinitis and currently indicated for children >12 yr and adults.

**OMEPRAZOLE**

Prilosec, Prilosec OTC, First-Omeprazole, and generics

In combination with sodium bicarbonate:

Zegerid, Zegerid OTC, and generics

**Gastric acid pump inhibitor**



C

2

Yes

Yes

Yes

**Caps, sustained release:** 10, 20, 40 mg; may contain magnesium

**Tabs, delayed release (Prilosec OTC and generics; OTC):** 20 mg; may contain magnesium

**Oral suspension:**

**First-Omeprazole:** 2 mg/mL (90, 150, 300 mL); contains benzyl alcohol

**Compounded formulation:** 2 mg/mL; contains ~0.5 mEq sodium bicarbonate per 1 mg drug



**Granules for oral suspension (Prilosec):** 2.5 and 10 mg packets (30s); contains magnesium

**In combination with sodium bicarbonate:**

**Powder for oral suspension (Zegerid and generics):** 20, 40 mg packets (30s); each packet (regardless of strength) contains 1680 mg (20 mEq) sodium bicarbonate

**Caps, immediate release (Zegerid, Zegerid OTC, and generics):** 20 mg (OTC), 40 mg; each capsule (regardless of strength) contains 1100 mg (13.1 mEq) sodium bicarbonate

**Chewable tabs (Zegerid):** 20 and 40 mg; each tab (regardless of strength) contains 600 mg (7.1 mEq) sodium bicarbonate and 700 mg magnesium hydroxide

**Infant and child:**

**Esophagitis, GERD, or ulcers:** Start at 1 mg/kg/24 hr PO ÷ once daily—BID (**max. dose:**

20 mg/24 hr). Reported effective range for GERD: 0.7–4 mg/kg/24 hr. Children 1–6 yr may require higher doses due to enhanced drug clearance. Alternative dosing by weight category:

**3–<5 kg:** 2.5 mg PO once daily

**5–<10 kg:** 5 mg PO once daily

**10–<20 kg:** 10 mg PO once daily

**20 kg and above:** 20 mg PO once daily



OMEPRAZOLE *continued***Adult:**

**Duodenal ulcer or GERD:** 20–40 mg/dose PO once daily  $\times$  4–8 wk; may give up to 12 wk for erosive esophagitis

**Gastric ulcer:** 20–40 mg/24 hr PO  $\div$  once daily–BID  $\times$  4–8 wk

**Pathologic hypersecretory conditions:** Start with 60 mg/24 hr PO once daily. If needed, dose may be increased up to 120 mg/24 hr PO  $\div$  TID. Daily doses  $>$ 80 mg should be administered in divided doses.

**Common side effects:** Headache, diarrhea, nausea, and vomiting. Allergic reactions (discontinue use immediately) including anaphylaxis, acute interstitial nephritis, severe skin reactions, hypomagnesemia, and vitamin B<sub>12</sub> deficiency (with prolonged use) have been reported. Fundic gland polyps have been associated with long-term use of PPIs. Has been associated with increased risk for *Clostridium difficile*–associated diarrhea.



Drug induces CYP 450 1A2 (decreases theophylline levels) and is also a substrate and inhibitor of CYP 2C19. Recommended dosage modification for ultrarapid metabolizers of CYP 2C19 is to increase the usual dose by threefold. Increases T<sub>1/2</sub> of citalopram, diazepam, phenytoin, and warfarin. May decrease the effects of itraconazole, ketoconazole, clopidogrel, iron salts, and ampicillin esters. St. John's wort and rifampin may decrease omeprazole effects. May be used in combination with clarithromycin and amoxicillin for *Helicobacter pylori* infections. Omeprazole may interfere with serum chromogranin A (CgA) diagnostic test for neuroendocrine tumors; discontinue use at least 14 days prior to testing.

Bioavailability may be increased with hepatic dysfunction or in patients of Asian descent. Safety and efficacy for GERD in children  $<$ 1 mo have not been established.

Administer all doses before meals. Administer 30 min prior to sucralfate. Capsules contain enteric-coated granules to ensure bioavailability. Do not chew or crush capsule. For doses unable to be divided by 10 mg, capsule may be opened and intact pellets may be administered in an acidic beverage (e.g., apple juice, cranberry juice) or applesauce. The extemporaneously compounded oral suspension product may be less bioavailable due to the loss of the enteric coating.

**OMNIPAQUE**

See [lohexol](#).

**ONDANSETRON**

Zofran, Zofran ODT, and generics

**Antiemetic agent, 5-HT<sub>3</sub> antagonist**



B



2



No



Yes



Yes

**Injection:** 2 mg/mL (2, 20 mL); single dose vials are preservative free and multidose vials contain parabens

**Tabs:** 4, 8, 24 mg

**Tabs, orally disintegrating (ODT):** 4, 8 mg; contain aspartame

**Oral solution:** 4 mg/5 mL (50 mL); contains sodium benzoate

**Preventing nausea and vomiting associated with chemotherapy:**

**Oral (give initial dose 30 min before chemotherapy):**

**Child ( $\geq$ 2 yr of age and adolescent), dose based on body surface area:**

**$<$ 0.3 m<sup>2</sup>:** 1 mg TID PRN nausea

**0.3–0.6 m<sup>2</sup>:** 2 mg TID PRN nausea

**0.6–1 m<sup>2</sup>:** 3 mg TID PRN nausea



*Continued*

ONDANSETRON *continued*

>1 m<sup>2</sup>: 4–8 mg TID PRN nausea

**Dose based on age:**

<4 yr of age: Use dose based on body surface area from preceding dosages

4–11 yr of age: 4 mg TID PRN nausea

>11 yr of age and adult: 8 mg TID or 24 mg once daily PRN nausea

**IV (child and adult):**

**Moderately emetogenic drugs:** 0.15 mg/kg/dose (**max. dose:** 8 mg/dose for child and 16 mg/dose adult) at 30 min before and 4 and 8 hr after emetogenic drugs. Then same dose Q4 hr PRN

**Highly emetogenic drugs:** 0.15 mg/kg/dose (**max. dose:** 16 mg/dose) 30 min before 4 and 8 hr after emetogenic drugs. Then 0.15 mg/kg/dose (**max. dose:** 16 mg/dose) Q4 hr PRN

**Preventing nausea and vomiting associated with surgery (additional doses for controlling nausea and vomiting may not provide any benefits):****IV/IM (administered prior to anesthesia over 2–5 min):****Child (1 mo–12 yr of age):**

<40 kg: 0.1 mg/kg/dose × 1

≥40 kg: 4 mg × 1

**Adult:** 4 mg × 1

**Oral:**

**Adult:** 16 mg × 1, 1 hr prior to induction of anesthesia

**Preventing nausea and vomiting associated with radiation therapy:**

**Child:** Use above dosage for preventing nausea and vomiting associated with chemotherapy and give initial dose 1–2 hr prior to radiation.

**Adult:**

**Total body irradiation:** 8 mg PO 1–2 hr prior to radiation once daily—BID

**Single high-dose fraction radiation to abdomen:** 8 mg PO 1–2 hr prior to radiation with subsequent doses Q8 hr after first dose × 1–2 days after completion of radiation

**Daily fractionated radiation to abdomen:** 8 mg PO 1–2 hr prior to radiation with subsequent doses Q8 hr after first dose for each day radiation is given

**Vomiting in acute gastroenteritis (oral route is preferred; use IV route when oral administration is not possible):****Oral (child 6 mo–10 yr old and weighing ≥8 kg; use oral disintegrating tablet):**

8–15 kg: 2 mg × 1

>15 and ≤30 kg: 4 mg × 1

>30 kg: 8 mg × 1

**IV (≥1 mo):** 0.15–0.3 mg/kg/dose × 1; **max. dose:** 8 mg/dose

**Avoid use** in congenital long-QTc syndrome. Bronchospasm, tachycardia, hypokalemia, seizures, headaches, lightheadedness, constipation, diarrhea, and transient increases in AST, ALT, and bilirubin may occur. Transient blindness (resolution within a few min up to 48 hr), arthralgia, Stevens-Johnson syndrome, TEN, hepatic dysfunction, masking of progressive ileus and gastric distention, myocardial ischemia (primarily with IV route) and rare/transient ECG changes (including QTc-interval prolongation) have been reported. Data limited for use in children below 3 yr of age. ECG monitoring is recommended in patients with electrolyte abnormalities, CHF, or bradyarrhythmias. Drug clearance is higher for surgical and cancer patients <18 yr as compared with adults.

Clearance is slower for children 1–4 mo old compared with children >4–24 mo old.

Ondansetron is a substrate for CYP 450 1A2, 2D6, 2E1, and 3A3/4 drug metabolizing enzymes. It is likely that the inhibition/loss of one of the previously listed enzymes will be compensated by others and may result in insignificant changes to the elimination of ondansetron, which may be affected by CYP 450 enzyme inducers. Ultrarapid metabolizers of CYP 450 2D6 are associated with decreased response, and use of an alternative drug not predominantly metabolized by CYP 2D6



ONDANSETRON *continued*

(e.g., granisetron) is recommended. Follow theophylline, phenytoin, or warfarin levels closely, if used in combination. Use with apomorphine may result in profound hypotension and loss of consciousness and is **contraindicated**.

To administer the oral film dosage form (Zuplenz), film must be placed on top of patient's tongue, allowed to dissolve completely in 4–20 sec, and swallowed with or without liquid.

**ORKAMBI**

See [Lumacaftor](#) and [Ivacaftor](#).

**OSELTAMIVIR PHOSPHATE**

Tamiflu and generics

**Antiviral, neurominidase inhibitor**

C 2 Yes Yes No

**Caps:** 30, 45, 75 mg

**Oral suspension:** 6 mg/mL (60 mL); may contain saccharin and sodium benzoate

May also be extemporaneously compounded from capsules (6 mg/mL)

**Treatment of influenza (initiate therapy within 2 days of onset of symptoms):**

**Preterm neonate (limited data):** Usual duration of therapy for 5 days

**Postmenstrual age (PMA) neonate <38 wk:** 1 mg/kg/dose PO BID

**PMA 38–40 wk:** 1.5 mg/kg/dose PO BID

**Full-term neonate (PMA >40 wk)—child 1 yr:** 3 mg/kg/dose PO BID × 5 days

**Child <1 yr alternative dosing based on age:** See following table.



Age (mo)	Dosage for 5 days	Volume of Oral Suspension (6 mg/mL)
<3	12 mg PO BID	2 mL
3–5	20 mg PO BID	3.33 mL
6–11	25 mg PO BID	4.2 mL

**Child ≥1–12 yr:** See following table.

Weight (kg)	Dosage for 5 days	Volume of Oral Suspension (6 mg/mL)
≤15	30 mg PO BID	5 mL
>15–23	45 mg PO BID	7.5 mL
>23–40	60 mg PO BID	10 mL
>40	75 mg PO BID	12.5 mL

**≥13 yr old and adult:** 75 mg PO BID × 5 days

**Prophylaxis of influenza (initiate therapy within 2 days of exposure; see remarks):**

**Child 3 mo—<1 yr:** 3 mg/kg/dose PO once daily; alternative dosage based on age:

**3–5 mo:** 20 mg PO once daily

**6–11 mo:** 25 mg PO once daily

*Continued*

OSELTAMIVIR PHOSPHATE *continued***Child 1–12 yr:**

≤15 kg: 30 mg PO once daily

16–23 kg: 45 mg PO once daily

24–40 kg: 60 mg PO once daily

&gt;40 kg: 75 mg PO once daily

≥13 yr old and adult: 75 mg PO once daily for a minimum of 7 days and up to 6 wk; initiate therapy within 2 days of exposure.

Currently indicated for the treatment of influenza A and B strains. Use in children <1 yr of age has not been recommended due to concerns of excessive CNS penetration and fatalities in 7-day-old rats.



Nausea and vomiting generally occur within the first 2 days and are the most common adverse effects. Insomnia, vertigo, seizures, hypothermia, neuropsychiatric events (may result in fatal outcomes), arrhythmias, rash, and toxic epidermal necrolysis have also been reported. If the glomerular filtration rate (GFR) is 10–30 mL/min, reduce treatment dose to 75 mg PO once daily × 5 days for adults. (See [Chapter 31](#).)

**PROPHYLACTIC USE:** Oseltamivir is not a substitute for annual flu vaccination. Safety and efficacy have been demonstrated for ≤6 wk of therapy; duration of protection lasts for as long as dosing is continued. Adjust prophylaxis dose if GFR is 10–30 mL/min by extending the dosage interval to once every other day.

Probenecid increases oseltamivir levels. Oseltamivir decreases the efficacy of the nasal influenza vaccine (live attenuated influenza vaccine, FluMist); **avoid** administration of vaccine within 2 wk before or 48 hr after oseltamivir administration unless medically indicated.

Dosage adjustments in hepatic impairment, severe renal disease, and dialysis have not been established for either treatment or prophylactic use. The safety and efficacy of repeated treatment or prophylaxis courses have not been evaluated. Doses may be administered with or without food.

**OXACILLIN**

Various generics

***Antibiotic, penicillin (penicillinase resistant)***

B



2



Yes



Yes



No

**Injection:** 1, 2, 10 g**Injection, premixed in iso-osmotic dextrose:** 1 g/50 mL, 2 g/50 mL

Injectable products contain 2.8–3.1 mEq Na per 1 g drug

**Neonate (IM/IV):****Usual dose:** 25 mg/kg/dose; following the dosage interval below**Meningitis or severe infection:** 50 mg/kg/dose; following the dosage interval below**Postmenstrual age:**

## ≤29 wk:

≤28 days old: Q12 hr

&gt;28 days old: Q8 hr

## 30–36 wk:

≤14 days old: Q12 hr

&gt;14 days old: Q8 hr

## 37–44 wk:

≤7 days old: Q12 hr

&gt;7 days old: Q8 hr

≥45 wk (all postnatal ages): Q6 hr



OXACILLIN *continued*

**Infant and child (IM/IV):** 100–200 mg/kg/24 hr ÷ Q4–6 hr (**max. dose:** 12 g/24 hr); use 200 mg/kg/24 hr for endocarditis and severe infections and Q4 hr dosing for severe/CNS infections

**Adult (IM/IV):** 250–2000 mg/dose Q4–6 hr; use higher dosage range for endocarditis or severe infections and Q4 hr dosing for severe/CNS infections

**Max. dose** (all ages): 12 g/24 hr

Rash and GI disturbances are common. Leukopenia, reversible hepatotoxicity, and acute interstitial nephritis have been reported. Hematuria and azotemia have occurred in neonates and infants with high doses. May cause false-positive urinary and serum proteins.

Probenecid increases serum oxacillin levels. Tetracyclines may antagonize the bactericidal effects of oxacillin.

CSF penetration is poor unless meninges are inflamed. Use the lower end of the usual dosage range for patients with creatinine clearances <10 mL/min. **Adjust dose in renal failure (see Chapter 31).**

**OXCARBAZEPINE**

Trileptal, Oxtellar XR, and generics

**Anticonvulsant**



C



2



Yes



Yes



Yes

**Tabs:** 150, 300, 600 mg

**Extended release tabs (Oxtellar XR):** 150, 300, 600 mg

**Oral suspension:** 300 mg/5 mL (250 mL); contains saccharin, ethanol, and propylene glycol

**Child (2–<4 yr old):**

**Adjunctive therapy for partial-onset seizures (limited data):** Start with 8–10 mg/kg/24 hr

PO ÷ BID up to a **max. dose** of 600 mg/24 hr. For children <20 kg, may consider using a starting dose of 16–20 mg/kg/24 hr PO ÷ BID; gradually increase the dose over a 2–4 wk period and **do not exceed** 60 mg/kg/24 hr ÷ BID.

**Child (4–16 yr old, see remarks):**

**Adjunctive therapy for partial-onset seizures:** Start with 8–10 mg/kg/24 hr PO ÷ BID up to a **max. dose** of 600 mg/24 hr. Then gradually increase the dose over a 2-wk period to the following maintenance doses:

**20–29 kg:** 900 mg/24 hr PO ÷ BID

**29.1–39 kg:** 1200 mg/24 hr PO ÷ BID

**>39 kg:** 1800 mg/24 hr PO ÷ BID

**Conversion to monotherapy for partial-onset seizures:** Start with 8–10 mg/kg/24 hr PO ÷ BID and simultaneously initiate dosage reduction of concomitant AEDs and withdrawal completely over 3–6 wk. Dose may be increased at weekly intervals, as clinically indicated, by a **maximum** of 10 mg/kg/24 hr to achieve the recommended monotherapy maintenance dose as described in the following table.

**Initiation of monotherapy for partial-onset seizures (with no concomitant AEDs):** Start with 8–10 mg/kg/24 hr PO ÷ BID. Then increase by 5 mg/kg/24 hr Q3 days up to the recommended monotherapy maintenance dose as described in the following table:

## RECOMMENDED MONOTHERAPY MAINTENANCE DOSES FOR CHILDREN BY WEIGHT

Weight (kg)	Daily Oral Maintenance Dose (mg/24 hr) Divided BID
20–<25	600–900
25–<35	900–1200

*Continued*

OXCARBAZEPINE *continued*

Weight (kg)	Daily Oral Maintenance Dose (mg/24 hr) Divided BID
35—<45	900—1500
45—<50	1200—1500
50—<60	1200—1800
60—<70	1200—2100
≥70	1500—2100

**Adult:**

**Adjunctive therapy for partial-onset seizures:** Start with 600 mg/24 hr PO ÷ BID. Dose may be increased at weekly intervals, as clinically indicated, by a **maximum** of 600 mg/24 hr. Usual maintenance dose is 1200 mg/24 hr PO ÷ BID. Doses ≥2400 mg/24 hr are generally not well tolerated due to CNS side effects.

**Conversion to monotherapy for partial-onset seizures:** Start with 600 mg/24 hr PO ÷ BID and simultaneously initiate dosage reduction of concomitant AEDs. Dose may be increased at weekly intervals as clinically indicated, by a **max** of 600 mg/24 hr to achieve a dose of 2400 mg/24 hr PO ÷ BID. Concomitant AEDs should be terminated gradually over approximately 3—6 wk.

**Initiation of monotherapy for partial-onset seizures:** Start with 600 mg/24 hr PO ÷ BID. Then increase by 300 mg/24 hr every 3 days up to 1200 mg/24 hr PO ÷ BID.

**EXTENDED RELEASE TABS (Oxtellar XR; see remarks):****Child 6—17 yr of age:**

**Adjunctive therapy for partial-onset seizures:** Start with 8—10 mg/kg/24 hr PO once daily up to a **max. dose** of 600 mg/24 hr. Then gradually increase at weekly intervals in increments of 8—10 mg/kg/24 hr (**max. dosage** increment: 600 mg) to the following maintenance doses:

**20—29 kg:** 900 mg PO once daily

**29.1—39 kg:** 1200 mg PO once daily

**>39 kg:** 1800 mg PO once daily

**Adult:**

**Adjunctive therapy for partial-onset seizures:** Start with 600 mg PO once daily (consider using 900 mg if patient is receiving concomitant enzyme-inducing AEDs). Then gradually increase at weekly intervals in 600 mg/24 hr increments to the maintenance dose of 1200—2400 mg once daily.

**Clinically significant hyponatremia may occur; generally seen within the first 3 mo of therapy.** May also cause headache, dizziness, drowsiness, ataxia, fatigue, nystagmus, urticaria, diplopia, abnormal gait, and GI discomfort. About 25%—30% of patients with carbamazepine hypersensitivity will experience a cross-reaction with oxcarbazepine. Serious dermatologic reactions (Stevens-Johnson syndrome [SJS] and TEN), multiorgan hypersensitivity reactions (e.g., DRESS), bone marrow depression, osteoporosis, pancreatitis, folic acid deficiency, hypothyroidism, rare cases of anaphylaxis and angioedema, and suicidal behavior or ideation have been reported. Increased risk for severe dermatologic reactions (e.g., SJS and TEN) has been associated with the HLA-B\*1502 (prevalent among persons of Asian descent) alleles.

Inhibits CYP 450 2C19 and induces CYP 450 3A4/5 drug metabolizing enzymes. Carbamazepine, cyclosporine, phenobarbital, phenytoin, rifampin, valproic acid, and verapamil may decrease oxcarbazepine levels. Oxcarbazepine may increase phenobarbital and phenytoin levels. Oxcarbazepine can decrease the effects of oral contraceptives, cyclosporine, felodipine, and lamotrigine.

If GFR <30 mL/min, adjust dosage by administering 50% of the normal starting dose (**max. dose:** 300 mg/24 hr) followed by a slower than normal increase in dose if necessary (**see Chapter 31**). No dosage adjustment is required in mild/moderate hepatic impairment. Use is **not recommended** in severe hepatic impairment due to lack of information.

Extended release and immediate release products are not bioequivalent, as higher doses of the extended release product may be necessary. Doses may be administered with or without food.



**OXYBUTYNIN CHLORIDE**

Ditropan XL, Oxytrol, Oxytrol for Women, and generics; previously available as Ditropan

**Anticholinergic agent, antispasmodic**



B



?



Yes



Yes



No

**Tabs:** 5 mg

**Tabs, extended release (Ditropan XL and generics):** 5, 10, 15 mg

**Syrup:** 1 mg/mL (473 mL); contains parabens

**Transdermal system (Oxytrol, Oxytrol for Women [OTC]):** Delivers 3.9 mg/24 hr (1, 4, 8s); contains 36 mg per system

**Child ≤5 yr:**

**Immediate release:** 0.2 mg/kg/dose BID–TID PO; **max. dose:** 15 mg/24 hr

**Child >5 yr:**

**Immediate release:** 5 mg/dose BID–TID PO; **max. dose:** 20 mg/24 hr

**Extended release (≥6 yr):** Start with 5 mg/dose once daily PO; if needed, increase as tolerated by 5 mg weekly increments up to a **maximum** of 20 mg/24 hr.

**Adult:**

**Immediate release:** 5 mg/dose BID–TID PO; **max. dose:** 5 mg QID

**Extended release (Ditropan XL):** 5–10 mg/dose once daily PO, adjust in 5-mg weekly increments if needed, up to a **max. dose** of 30 mg/dose once daily PO

**Transdermal system:**

**Female:** 1 patch (3.9 mg/24 hr) every 4 days

**Male:** 1 patch (3.9 mg/24 hr) every 3–4 days (twice weekly)

**Use with caution** in hepatic or renal disease, hyperthyroidism, GE reflux, IBD, concurrent use of bisphosphonates, or cardiovascular disease. Anticholinergic side effects may occur, including drowsiness, confusion, and hallucinations. **Contraindicated** in glaucoma, GI obstruction, megacolon, myasthenia gravis, severe colitis, hypovolemia, and GU obstruction. Memory impairment, angioedema, and QT-interval prolongation have been reported. Oxybutynin is a CYP 450 3A4 substrate; inhibitors and inducers of CYP 450 3A4 may increase and decrease the effects of oxybutynin, respectively. May antagonize the effects of metoclopramide.

Dosage adjustments for the extended release dosage form are at weekly intervals. The extended release tablets **should not** be crushed, chewed, or divided. Apply transdermal system on dry intact skin on the abdomen, hip, or buttock; rotate the site and avoiding same-site application within 7 days.

**OXYCODONE**

OxyContin, Roxicodone, RoxyBond, Oxaydo, Xtampza ER, and many others, including generics

**Narcotic, analgesic**



B/D



2



Yes



Yes



No

**Expressed as hydrochloride salt unless indicated otherwise.**

**Oral solution:** 1 mg/mL (5, 15, 473 mL); contains alcohol

**Concentrated oral solution:** 20 mg/mL (30 mL); may contain saccharin

**Tabs:**

**Generics:** 5, 10, 15, 20, 30 mg

**Roxicodone and RoxyBond:** 5, 15, 30 mg

**Oxaydo:** 5, 7.5 mg

**Controlled release tabs (OxyContin and generics):** 10, 15, 20, 30, 40, 60, 80 mg (80 mg strength for opioid-tolerant patients only)

Continued

OXYCODONE *continued***Caps:** 5 mg**Extended release caps (Xtampza ER):** 9, 13.5, 18, 27, 36 mg oxycodone base; equivalent to 10, 15, 20, 30, and 40 mg oxycodone hydrochloride salt, respectively**Opioid-naïve doses based upon oxycodone hydrochloride salt (limited data):****Infant ≤6 mo:** 0.025–0.05 mg/kg/dose Q4–6 hr PRN PO**Infant >6 mo, child, and adolescent <50 kg:** 0.05–0.15 mg/kg/dose Q4–6 hr PRN up to 5 mg/dose PO**Adolescent (≥50 kg) and adult:** 5–10 mg Q4–6 hr PRN PO; see remarks for use of controlled release tablets

There is a potential for abuse; CNS and respiratory depression, increased ICP, histamine release, constipation, and GI distress may occur. **Use with caution** in severe renal impairment (increases  $T_{1/2}$ ) and mild/moderate hepatic dysfunction (use of one-third to one-half of usual dose has been recommended). **Naloxone is the antidote.** See [Chapter 6](#) for equianalgesic dosing. Check dosages of acetaminophen or aspirin when using combination products (e.g., Percocet, Percodan). Oxycodone is metabolized by the CYP 450 3A4 (major) and 2D6 (minor) isoenzyme.



When controlled release tablets (e.g., Oxycontin) are being used, patient's total 24-hr requirement should be determined and divided by 2 to administer on a Q12 hr dosing interval. Oxycontin 80-mg tablet is **USED ONLY** for opioid-tolerant patients; this strength can cause fatal respiratory depression in opioid-naïve patients. Controlled release dosage form should not be used as a PRN analgesic and must be swallowed whole.

Pregnancy category changes to “D” if used for prolonged periods or in high doses at term.

The FDA has assigned a Risk Evaluation and Mitigation Strategy (REMS) for opioid analgesia; see [www.fda.gov/OpioidAnalgesicREMSPCG](http://www.fda.gov/OpioidAnalgesicREMSPCG). The REMS strongly encourages to (1) complete a REMS-compliant education program; (2) counsel patients/caregivers on prescription safe use, risks, storage, and disposal; (3) emphasize the importance of reading the medication guide provided by pharmacists at all times; and (4) consider other methods for improving patient, household, and community safety.

**OXYCODONE AND ACETAMINOPHEN**

Endocet, Percocet, Roxicet, Prolate, and many others, including generics

**Combination analgesic with a narcotic**

C



2



Yes



Yes



No

**Tabs (Percocet, Endocet, and others, including generics):****Most common strength:** Oxycodone HCl 5 mg + acetaminophen 325 mg**Other strengths:**

Oxycodone HCl 2.5 mg + acetaminophen 325 mg

Oxycodone HCl 7.5 mg + acetaminophen 325 mg

Oxycodone HCl 10 mg + acetaminophen 325 mg

**Oral solution:****Roxicet:** Oxycodone HCl 5 mg + acetaminophen 325 mg/5 mL (500 mL); contains 0.4% alcohol, EDTA, and saccharin**Prolate and generics:** Oxycodone HCl 10 mg + acetaminophen 300 mg/5 mL (120, 500 mL); contain EDTA, propylene glycol, and saccharinDose based on amount of oxycodone and acetaminophen. **Do not exceed** 4 g/24 hr of acetaminophen.

OXYCODONE AND ACETAMINOPHEN *continued*

See oxycodone and acetaminophen. Check dosages of acetaminophen and oxycodone when using these combination products.



The FDA has assigned a Risk Evaluation and Mitigation Strategy (REMS) for Opioid Analgesia; see [www.fda.gov/OpioidAnalgesicREMSPCG](http://www.fda.gov/OpioidAnalgesicREMSPCG). The REMS strongly encourages to (1) complete a REMS-compliant education program; (2) counsel patients/caregivers on prescription safe use, risks, storage and disposal; (3) emphasize the importance of reading the Medication Guide provided by pharmacists at all times; and (4) consider other methods for improving patient, household, and community safety.

**OXYCODONE AND ASPIRIN**

Various generics; previously available as Percodan and Endodan

**Combination analgesic (narcotic and salicylate)**



C



2



No



No



No

**Tab:** Oxycodone 4.8355 mg and aspirin 325 mg

Dose based on amount of oxycodone and aspirin. **Do not exceed** 4 g/24 hr of aspirin.



See oxycodone and aspirin. **Must not be used** in children <16 yr of age because of risk for Reye syndrome. Check dosages of aspirin and oxycodone when using these combination products.



The FDA has assigned a Risk Evaluation and Mitigation Strategy (REMS) for Opioid Analgesia; see [www.fda.gov/OpioidAnalgesicREMSPCG](http://www.fda.gov/OpioidAnalgesicREMSPCG). The REMS strongly encourages to (1) complete a REMS-compliant education program; (2) counsel patients/caregivers on prescription safe use, risks, storage and disposal; (3) emphasize the importance of reading the Medication Guide provided by pharmacists at all times; and (4) consider other methods for improving patient, household, and community safety.

**OXYMETAZOLINE**

Afrin 12 Hour, Vicks Sinex 12 Hour, Nostrilla, and many others, including generics

**Nasal decongestant, vasoconstrictor**



D



2



Yes



Yes



No

**Nasal spray (OTC):** 0.05% (15 mL); may contain benzalkonium chloride, EDTA, and propylene glycol

**Nasal decongestant (not to exceed 3 days in duration):**

**≥6 yr of age to adult:** 2–3 sprays or 2–3 drops in each nostril BID (separated by 10–12 hr). **Do not exceed** 2 doses/24 hr.



**Contraindicated** in patients on MAO inhibitor therapy. Rebound nasal congestion may occur with excessive use (>3 days) via the nasal route. Systemic absorption may occur.



Headache, insomnia, hypertension, transient burning, stinging, dryness, nasal mucosal ulceration, and sneezing have occurred.

Accidental ingestion in children <5 yr of age has been reported and required hospitalization for adverse events (nausea, vomiting, lethargy, tachycardia, respiratory depression, bradycardia, hypotension, hypertension, sedation, mydriasis, stupor, hypothermia, drooling, and coma).

## P

**PALIVIZUMAB**

Synagis

**Monoclonal antibody**

C



?



No



No



No

**Injection, solution:** 100 mg/mL (0.5, 1 mL; single use); contains glycine and histidine**RSV prophylaxis during RSV season for the following age and clinical criteria (see latest edition of Red Book for most recent indications).**Following recommendations are from *Pediatrics* 2014;134(2):415—420.**Candidates for recommended use:****<12 mo of age (one of the following):**

Born at &lt;29 wks' gestation; OR

With chronic lung disease (CLD) of prematurity (&lt;32 wks' gestation requiring &gt;21% oxygen for at least 28 days after birth); OR

With hemodynamically significant congenital heart disease

**<24 mo of age:**

Born at ≤32 wks' gestation with CLD requiring medical therapy (e.g., ≥28 days of supplemental oxygen, bronchodilator, diuretics, or chronic steroids) within 6 mo prior to start of RSV season

**Candidates for consideration:****<12 mo of age (one of the following):**

With congenital airway abnormalities or neuromuscular disorders that decrease ability to manage airway secretions; OR

With cystic fibrosis with clinical evidence of CLD and/or nutritional compromise

**≤24 mo of age (one of the following):**

With cystic fibrosis with severe lung disease (previous pulmonary exacerbation in first year of life or abnormal chest x-ray) or weight for length less than the 10th percentile; OR

Profoundly immunocompromised; OR

Undergoing cardiac transplantation during RSV season

**DOSE:****≤24 mo old:** 15 mg/kg/dose IM Q monthly just prior to and during the RSV season. **Maximum** of five doses per RSV season is recommended by the AAP. Therapy should be discontinued if child experiences breakthrough RSV hospitalization.

RSV season typically November through April in the northern hemisphere but may begin earlier or persist later in certain communities. This infection pattern was significantly altered in 2020—2022 due to the implementation of COVID-19 prevention strategies of masking and social distancing. Check with state and county health departments and the CDC for the current RSV activity in your region.



**IM** is currently the only route of administration, so **use with caution** in patients with thrombocytopenia or any coagulation disorder. The following adverse effects have been reported at slightly higher incidences when compared with placebo: rhinitis, rash, pain, increased liver enzymes, pharyngitis, cough, wheeze, diarrhea, vomiting, conjunctivitis, and anemia. Rare acute hypersensitivity reactions have been reported (first or subsequent doses).

Does not interfere with the response to routine childhood vaccines. May interfere with immunologic-based RSV diagnostic tests (some antigen detection—based assays and viral culture assays) but not with reverse transcriptase-polymerase chain reaction (PCR)—based assays.

Palivizumab is currently indicated for RSV prophylaxis in high-risk infants only. Efficacy and safety have not been demonstrated for treatment of RSV.


PALIVIZUMAB *continued*

Cardiopulmonary bypass and ECMO will significantly reduce serum concentrations; administer a dose immediately after the bypass procedure or ECMO even if it is <1 mo from the previous dose. Each dose should be administered IM in the anterolateral aspect of the thigh. It is recommended to divide doses with total injection volumes >1 mL. **Avoid** injection in the gluteal muscle because of risk for damage to the sciatic nerve.

**PANCRELIPASE/PANCREATIC ENZYMES**

Creon, Pancreaze, Pertzye, Ultresa, Viokace, and Zenpep

**Pancreatic enzyme**



**Delayed release enterically coated beads, microspheres, or minitabs in capsules (porcine derived):**

Product	Lipase (USP) Units	Amylase (USP) Units	Protease (USP) Units
<b>Creon<sup>a</sup></b>			
3	3,000	15,000	9,500
6	6,000	30,000	19,000
12	12,000	60,000	38,000
24	24,000	120,000	76,000
36	36,000	180,000	114,000
<b>Pancreaze<sup>b</sup></b>			
MT 2	2,600	15,200	8,800
MT 4	4,200	24,600	14,200
MT 10	10,500	61,500	35,500
MT 16	16,800	98,400	56,800
MT 20	21,000	83,900	54,700
MT 37	37,000	149,900	97,300
<b>Pertzye<sup>a,c</sup></b>			
4	4,000	15,125	14,375
8	8,000	30,250	28,750
16	16,000	60,500	57,500
24	24,000	90,750	86,250
<b>Zenpep<sup>d</sup></b>			
3	3,000	14,000	10,000
5	5,000	24,000	17,000
10	10,000	42,000	32,000
15	15,000	63,000	47,000
20	20,000	84,000	63,000
25	25,000	105,000	79,000
40	40,000	168,000	126,000

<sup>a</sup>Enteric coated microspheres.

<sup>b</sup>Enteric coated minitabs.

<sup>c</sup>Contains bicarbonate.

<sup>d</sup>Enteric coated beads.

*Continued*

For explanation of icons, see p. 763

PANCRELIPASE/PANCREATIC ENZYMES *continued*

**Tabs (porcine derived):**

Product	Lipase (USP) Units	Amylase (USP) Units	Protease (USP) Units
Viokace			
10	10,440	39,150	39,150
20	20,880	78,300	78,300

**Initial doses (actual requirements are patient specific):**

**Enteric coated microspheres and microtabs:**

**Infant:** 2000–4000 U lipase per 120 mL (formula or breast milk)

**Child <4 yr:** 1000 U lipase/kg/meal

**Child ≥4 yr and adult:** 500 U lipase/kg/meal

**Max. dose (child–adult):** 2500 U lipase/kg/meal, or 10,000 U lipase/kg/24 hr, or 4000 U lipase/g fat/24 hr

Total daily dose should include approximately three meals and two to three snacks per day. Snack doses are approximately half of meal doses, depending on the amount of fat and food consumed.

May cause occult GI bleeding, allergic reactions to porcine proteins, hyperuricemia, and hyperuricosuria with high doses. Dose should be titrated to eliminate diarrhea and to minimize steatorrhea. **Do not** chew microspheres or microtabs. Concurrent administration with H<sub>2</sub> antagonists or gastric acid pump inhibitors may enhance enzyme efficacy. Doses higher than 6000 U lipase/kg/meal have been associated with colonic strictures in children <12 yr. Non–enteric coated dosage forms (e.g., powder and tablet) are not preferred, owing to potential GI mucosal ulceration. Patients who are unable to swallow capsules intact may mix the contents with small amount of acidic soft foods (pH ≤4.5; such as applesauce), swallow immediately after mixing, and follow with infant formula, breast milk, or fluids to ensure complete ingestion of the medication.


**Avoid use** of generic pancreatic enzyme products because they have been associated with treatment failures. Products not approved by the FDA are no longer allowed to be distributed in the United States.

Patients requiring enzyme supplementation who receive enteral feeding via a feeding tube may alternatively use a digestive enzyme cartridge (RELIZORB).

**PANCURONIUM BROMIDE**

Generics; previously available as Pavulon

**Nondepolarizing neuromuscular blocking agent**



**Injection:** 1 mg/mL (10 mL); contains benzyl alcohol

**Intermittent dosing (see remarks):**

**Neonate:**

**Initial:** 0.02 mg/kg/dose IV

**Maintenance:** 0.05–0.1 mg/kg/dose IV Q0.5–4 hr PRN

**1 mo–adult:**

**Initial:** 0.04–0.1 mg/kg/dose IV

**Maintenance:** 0.015–0.1 mg/kg/dose IV Q30–60 min

**Continuous IV infusion (see remarks):**

**Neonate:** 0.02–0.04 mg/kg/hr

**Child:** 0.03–1 mg/kg/hr

PANCURONIUM BROMIDE *continued*

**Adolescent and adult:** 0.02–0.04 mg/kg/hr

Onset of action is 1–2 min. May cause tachycardia, salivation, and wheezing. Severe anaphylactic reactions have been reported; cross-reactivity between neuromuscular blocking agents has been reported. Hypoventilation and hypotension have been reported in mechanically ventilated infants. 

Drug effects may be accentuated by hypothermia, acidosis, neonatal age, decreased renal function, halothane, succinylcholine, hypokalemia, hyponatremia, hypocalcemia, clindamycin, tetracycline, and aminoglycoside antibiotics. Drug effects may be antagonized by alkalosis, hypercalcemia, peripheral neuropathies, diabetes mellitus, demyelinating lesions, carbamazepine, phenytoin, theophylline, anticholinesterases (e.g., neostigmine, pyridostigmine), and azathioprine. For obese patients, use of lean body weight for dose calculation has been recommended to prevent intense block of long duration and possible overdose.

**Antidote is neostigmine** (with atropine or glycopyrrolate). **Avoid** use in severe renal impairment (<10 mL/min). Patients with cirrhosis may require a high initial dose to achieve adequate relaxation, but muscle paralysis will be prolonged.

**PANTOPRAZOLE**

Protonix and generics

**Gastric acid pump inhibitor**



C



2



Yes



Yes



Yes

**Tab, delayed release:** 20, 40 mg

**Injection:** 40 mg; contains edetate sodium

**Oral suspension:** 2 mg/mL ; contains 0.25 mEq sodium bicarbonate per 1 mg drug

**Enterically coated granules for delayed release oral suspension:** 40 mg packets (30s); may contain polysorbate 80

**Child (see remarks):**

**GERD (limited data):**

**Infant, child, and adolescent:** 1–2 mg/kg/24 hr PO once daily; **max. dose:** 40 mg/24 hr × 4–8 weeks 

**GERD with erosive esophagitis:**

**1–5 yr (limited data):** 0.3, 0.6, or 1.2 mg/kg/24 hr PO once daily all improved GERD symptoms in an 8-wk multicenter, randomized placebo control trial for 60 subjects with GERD and histologic/erosive esophagitis

**≥5 yr (up to 8 wk of therapy):**

**15–<40 kg:** 20 mg PO once daily

**≥40 kg:** 40 mg PO once daily

**IV (when PO route not feasible; data limited to pharmacokinetic trials):**

**Infant, child, and adolescent:** Some doses ranging from 0.32–1.88 mg/kg/dose have been reported from three separate trials (total  $N = 31$ ; 0.01–16.4 yr). Patients with systemic inflammatory response syndrome (SIRS) cleared the drug more slowly, resulting in higher  $T_{1/2}$  and AUC, than patients without. Despite limited data, 1–2 mg/kg/24 hr ÷ Q12–24 hr have been used. Additional studies are needed.

**Adult:**

**GERD with erosive esophagitis:**

**PO:** 40 mg once daily × 8–16 wk

**IV:** 40 mg once daily × 7–10 days

**Peptic ulcer:** 40–80 mg PO once daily × 4–8 wk

*Continued*

PANTOPRAZOLE *continued***Hypersecretory conditions:**

**PO:** 40 mg BID; dose may be increased as needed up to a **max. dose** of 240 mg/24 hr

**IV:** 80 mg Q12 hr; dose may be increased as needed to Q8 hr (**max. dose:** 240 mg/24 hr). Therapy >7 days at 240 mg/24 hr has not been evaluated.

Convert from IV to PO therapy as soon as patient is able to tolerate PO. Common side effects include diarrhea and headache. May cause transient elevation in LFTs. Like other PPIs, may increase risk for *Clostridium difficile*—associated diarrhea. Hypomagnesemia has been reported with long-term use. Hypersensitivity reactions (e.g., anaphylaxis, shock, angioedema, bronchospasm, acute interstitial nephritis, TEN, DRESS, and urticaria), agranulocytosis, pancytopenia, hypomagnesemia, and taste disorders have been reported. Fundic gland polyps have been associated with long-term use of PPIs.

May interfere with serum chromogranin A (CgA) diagnostic test for neuroendocrine tumors; discontinue use at least 14 days prior to testing. False-positive test for urine cannabinoid screen may occur.

Drug is a substrate for CYP 450 2C19 (major), 2D6 (minor), and 3A3/4 (minor) isoenzymes.

Recommended dosage modification for ultrarapid metabolizers of CYP 2C19 is to increase the usual dose by fivefold. May decrease the absorption of itraconazole, ketoconazole, iron salts, and ampicillin esters. May increase the effect/toxicity of methotrexate. May cause false-positive elevated serum chromogranin A levels.

Children 1–2 yr of age have demonstrated more rapid clearance of pantoprazole in pharmacokinetic studies; this age group may require higher doses. All oral doses may be taken with or without food.

**Do not** crush or chew tablets. The extemporaneously compounded oral suspension may be less bioavailable owing to the loss of the enteric coating. Granules for delayed release oral suspension product may be mixed with 5 mL apple juice (administer immediately followed by rinsing container with more apple juice), or sprinkled on 1 teaspoonful of applesauce (administer within 10 min); see package insert for NG administration.

For IV infusion, doses may be administered over 15 min at a concentration of 0.4–0.8 mg/mL or over 2 min at a concentration of 4 mg/mL. Midazolam and zinc are **not compatible** with the IV dosage form. Parenteral routes other than IV are **not recommended**.

**PAROMOMYCIN SULFATE**

Humatin and generics

**Amebicide, antibiotic (aminoglycoside)**



C



1



No



No



No

**Caps:** 250 mg

**Intestinal amebiasis (*Entamoeba histolytica*), *Dientamoeba fragilis*, and *Giardia lamblia* infection:**

**Child and adult:** 25–35 mg/kg/24 hr PO ÷ Q8 hr × 5–10 days

**Cryptosporidial diarrhea with HIV:**

**Adult (limited data):** 500 mg PO QID for 14–21 days

**Contraindicated** in intestinal obstruction. **Use with caution** in ulcerative bowel lesions to avoid renal toxicity via systemic absorption. Drug is generally poorly absorbed and therefore not indicated for sole treatment of extraintestinal amebiasis. Side effects include GI disturbance, hematuria, rash, ototoxicity, and hypocholesterolemia. Bacterial overgrowth of nonsusceptible organisms, including fungi, may occur. May decrease the effects of digoxin.

**PAROXETINE**

Paxil, Pexeva, Paxil CR, and generics

**Antidepressant, selective serotonin reuptake inhibitor**

D



2



Yes



Yes



Yes

**Tabs (Paxil, Pexeva, and generics):** 10, 20, 30, 40 mg**Caps:** 7.5 mg**Controlled release tabs (Paxil CR and generics):** 12.5, 25, 37.5 mg**Oral suspension (Paxil and generics):** 10 mg/5 mL (250 mL); contains saccharin and parabens**Child:****Depression:** Well-controlled clinical trials have failed to demonstrate efficacy in children.

The FDA recommends paroxetine not be used for this indication.

**Obsessive-compulsive disorder (limited data, based on a 10-wk randomized controlled trial in 207 children 7–17 yr; mean age 11.1 + 3.03 yr):** Start with 10 mg PO once daily. If needed, adjust upward by increasing dose no more than 10 mg/24 hr no more frequently than Q7 days up to a **max. dose** of 60 mg/24 hr. Mean doses of 20.3 mg/24 hr (children) and 26.8 mg/24 hr (adolescents) were used.**Social anxiety disorder (limited data; 8–17 yr):** Start with 10 mg PO once daily. If needed, increase dose by 10 mg/24 hr no more frequently than Q7 days up to a **max. dose** of 50 mg/24 hr.**Adult:****Depression:****Immediate release dosage forms:** Start with 20 mg PO QAM × 4 wk. If no clinical improvement, increase dose by 10 mg/24 hr Q7 days PRN up to a **max. dose** of 50 mg/24 hr.**Controlled release tabs (Paxil CR and generics):** Start with 25 mg PO QAM × 4 wk. If no improvement, increase dose by 12.5 mg/24 hr Q7 days PRN up to a **max. dose** of 62.5 mg/24 hr.**Obsessive-compulsive disorder (immediate release):** Start with 20 mg PO once daily; increase dose by 10 mg/24 hr Q7 days PRN up to a **max. dose** of 60 mg/24 hr. Usual dose is 40 mg PO once daily. Rapid metabolizers may require doses as high as 100 mg/24 hr.**Panic disorder:****Immediate release dosage forms:** Start with 10 mg PO QAM; increase dose by 10 mg/24 hr Q7 days PRN up to a **max. dose** of 60 mg/24 hr.**Paxil CR:** Start with 12.5 mg PO QAM; increase dose by 12.5 mg/24 hr Q7 days PRN up to a **max. dose** of 75 mg/24 hr.**Contraindicated** in patients taking MAO inhibitors (within 14 days of discontinuing MAO inhibitors), linezolid, methylene blue, pimozide, or thioridazine. **Use with caution** in patients with history of seizures, renal or hepatic impairment, cardiac disease, suicidal concerns, mania/hypomania, concurrent use with other serotonergic drugs (e.g., triptans, fentanyl, lithium, tramadol, amphetamines, or St. John's wort), and diuretic use. Patients with severe renal or hepatic impairment should initiate therapy at 10 mg/24 hr and increase dose as needed up to a **max.** of 40 mg/24 hr.

Common side effects include anxiety, nausea, anorexia, sexual dysfunction, and decreased appetite.

Monitor for clinical worsening of depression and suicidal ideation/behavior following the initiation of therapy or after dose changes. Stevens-Johnson syndrome has been reported.

Paroxetine is an inhibitor and substrate for CYP 450 2D6. Ultrametabolizers of CYP 2D6 should avoid use of paroxetine and use an alternative medication not metabolized by this enzyme system. A 50% initial dose reduction for poor CYP 2D6 metabolizers has been recommended. May increase the effects/toxicity of tricyclic antidepressants, theophylline, and warfarin. May decrease the effects of tamoxifen. Cimetidine, ritonavir, MAO inhibitors (fatal serotonin syndrome), dextromethorphan, phenothiazines, and type 1C antiarrhythmics may increase the effect/toxicity of paroxetine.

Weakness, hyperreflexia, and poor coordination have been reported when taken with sumatriptan.

Continued

PAROXETINE *continued*

**Do not discontinue** therapy abruptly; may cause sweating, dizziness, confusion, and tremor. May be taken with or without food.

**PENICILLIN G PREPARATIONS—AQUEOUS POTASSIUM AND SODIUM**

Pfizerpen and generics

**Antibiotic, aqueous penicillin**



B



2



Yes



No



No

**Injection (K<sup>+</sup>):** 5, 20 million units (contains 1.7 mEq K and 0.3 mEq Na/1 million units penicillin G)

**Premixed frozen injection (K<sup>+</sup>):** 1 million units in 50 mL dextrose 4%; 2 million units in 50 mL dextrose 2.3%; 3 million units in 50 mL dextrose 0.7% (contains 1.7 mEq K and 0.3 mEq Na/1 million units penicillin G)

**Injection (Na<sup>+</sup>):** 5 million units (contains 2 mEq Na/1 million units penicillin G)

**Conversion:** 250 mg = 400,000 units

**Neonate (IM/IV; use higher end of dosage range for meningitis and severe infections):**

≤34 wks' gestation:

≤7 days old: 100,000–200,000 units/kg/24 hr ÷ Q12 hr

8–28 days old: 150,000–300,000 units/kg/24 hr ÷ Q8 hr

>34 wks' gestation:

≤7 days old:

**General dosing:** 100,000 units/kg/24 hr ÷ Q12 hr

**Meningitis and severe infection:** 300,000 units/kg/24 hr ÷ Q8 hr

8–28 days old:

**General dosing:** 150,000 units/kg/24 hr ÷ Q8 hr

**Meningitis and severe infection:** 400,000 units/kg/24 hr ÷ Q6 hr

**Group B streptococcal meningitis:**

≤7 days old: 450,000 units/kg/24 hr ÷ Q8 hr

8–28 days old: 500,000 units/kg/24 hr ÷ Q4–6 hr

**Congenital syphilis (total of 10 days of therapy; if >1 day of therapy is missed, restart the entire course):**

≤7 days old: 100,000 units/kg/24 hr ÷ Q12 hr IV; increase to the following dosage at day 8 of life

8–28 days old: 150,000 units/kg/24 hr ÷ Q8 hr IV

>28–60 days old: 200,000 units/kg/24 hr ÷ Q6 hr IV; if full-term neonate, may receive higher dose of 300,000 units/kg/24 hr ÷ Q4 hr IV

**Infant, child, and adolescent:**

**IM/IV (use higher end of dosage range and Q4 hr interval for meningitis and severe infections):**

100,000–400,000 units/kg/24 hr ÷ Q4–6 hr; **max. dose:** 24 million units/24 hr

**Neurosyphilis:**

**Infant and child:** 200,000–300,000 units/kg/24 hr ÷ Q4–6 hr IV × 10–14 days; **max. dose:** 24 million units/24 hr

**Adolescent:** 3–4 million units Q4 hr IV × 10–14 days; **max. dose:** 24 million units/24 hr

**Adult:**

**Moderate/severe infection (IM/IV):** 12–24 million units/24 hr ÷ Q4–6 hr; lower doses may be indicated for other indications

**Neurosyphilis:** 18–24 million units/24 hr ÷ Q4 hr IV × 10–14 days

Use penicillin V potassium for oral use. Side effects: anaphylaxis, urticaria, hemolytic anemia, interstitial nephritis, Jarisch-Herxheimer reaction (syphilis). Preparations containing potassium and/or sodium salts may alter serum electrolytes.  $T_{1/2} = 30$  min; may be prolonged by



## PENICILLIN G PREPARATIONS—AQUEOUS POTASSIUM AND SODIUM *continued*

concurrent use of probenecid. For meningitis, use higher daily dose at shorter dosing intervals. For the treatment of anthrax (*Bacillus anthracis*), see [www.bt.cdc.gov](http://www.bt.cdc.gov) for additional information.

**Adjust dose in renal impairment (see Chapter 31).**

Tetracyclines, chloramphenicol, and erythromycin may antagonize penicillin's activity. Probenecid increases penicillin levels. May cause false-positive or false-negative urinary glucose (Clinitest method), false-positive direct Coombs test, and false-positive urinary and/or serum proteins.

### PENICILLIN G PREPARATIONS—BENZATHINE

Bicillin L-A

**Antibiotic, penicillin (very-long-acting IM)**



B

2

Yes

No

No

**Injection:** 600,000 units/mL (1, 2, 4 mL); contains parabens and povidone  
**Injection should be IM only.**

#### Group A streptococci:

**Infant and child:** 25,000–50,000 units/kg/dose IM  $\times$  1. **Max. dose:** 1.2 million units/dose **OR:**

**>1 mo and <27 kg:** 600,000 units/dose IM  $\times$  1

**$\geq$ 27 kg and adult:** 1.2 million units/dose IM  $\times$  1

#### Rheumatic fever prophylaxis (Q3 wk administration is recommended for high-risk situations):

**Infant and child (>1 mo and <27 kg):** 600,000 units/dose IM Q3–4 wk

**Child  $\geq$ 27 kg and adult:** 1.2 million units/dose IM Q3–4 wk

#### Congenital syphilis (for cases of low probability of disease; aqueous penicillin is the drug of choice):

**Neonate:** 50,000 units/kg/dose IM  $\times$  1

#### Syphilis (if >1 day of therapy is missed, restart the entire course; divided total dose into two injection sites):

##### Infant and child:

**Primary, secondary, and early latent syphilis (<1-yr duration):** 50,000 units/kg/dose  $\times$  1

**Late latent syphilis or latent syphilis of unknown duration:** 50,000 units/kg/dose Q7 days  $\times$  3 doses

**Max. dose:** 2.4 million units/dose

##### Adult:

**Primary, secondary, and early latent syphilis:** 2.4 million units/dose IM  $\times$  1

**Late latent syphilis or latent syphilis of unknown duration:** 2.4 million units/dose IM Q7 days  $\times$  3 doses

Provides sustained levels for 2–4 wk. **Use with caution** in renal failure, asthma, G6PD deficiency (risk for methemoglobinemia), and cephalosporin hypersensitivity. Side effects and drug interactions same as for [Penicillin G Preparations—Aqueous Potassium and Sodium](#). Injection site reactions are common. Severe cutaneous reactions (e.g., SJS, TEN, and DRESS) have been reported.

**Deep IM administration only. Do not administer intravenously** (cardiac arrest and death may occur), and **do not inject** into or near an artery or nerve (may result in permanent neurologic damage and necrosis/sloughing at the injection site).

### PENICILLIN G PREPARATIONS—PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE

Bicillin C-R, Bicillin C-R 900/300

**Antibiotic, penicillin (very-long-acting IM)**



B

2

Yes

No

No

**Bicillin CR:** 300,000 units penicillin G procaine + 300,000 units penicillin G benzathine/mL to provide 600,000 units penicillin per 1 mL (2 mL Tubex syringe)

*Continued*

PENICILLIN G PREPARATIONS—PENICILLIN G BENZATHINE  
AND PENICILLIN G PROCAINE *continued*

**Bicillin CR (900/300):** 150,000 units penicillin G procaine + 450,000 units penicillin G benzathine/mL  
(2 mL Tubex syringe)

All preparations contain parabens and povidone.

**Injection should be for IM use only.**

**Dosage based on total amount of penicillin.**

**Group A streptococci (see remarks):**

**Infant and child (Bicillin CR):**

<14 kg: 600,000 units/dose IM × 1

14–27 kg: 900,000–1,200,000 units/dose IM × 1

**Child >27 kg and adult:**

**Bicillin C-R:** 2,400,000 units/dose IM × 1

**Bicillin C-R 900/300:** 1,200,000 units/dose IM × 1

**Pneumococcal infection (non-CNS):** Dosed Q2–3 days until afebrile for 48 hr (see remarks)

**Child (Bicillin C-R):** 600,000 units/dose IM

**Adult (Bicillin C-R or Bicillin C-R 900/300):** 1,200,000 units/dose IM

This preparation provides early peak levels in addition to prolonged levels of penicillin in the blood. **Do not use this product to treat syphilis; treatment failure can occur. Use with caution** in renal failure, asthma, significant allergies, G6PD deficiency (risk for methemoglobinemia), and cephalosporin hypersensitivity. Severe cutaneous reactions (e.g., SJS, TEN, and DRESS) have been reported. The addition of procaine penicillin has not been shown to be more efficacious than benzathine alone. However, it may reduce injection discomfort.

**Deep IM administration only. Do not administer intravenously** (cardiac arrest and death may occur), and **do not** inject into or near an artery or nerve (may result in permanent neurologic damage and necrosis/sloughing at the injection site).

Side effects and drug interactions same as for [Penicillin G Preparations—Aqueous Potassium and Sodium](#). Immune hypersensitivity reaction has been reported.

**PENICILLIN G PREPARATIONS—PROCAINE**

Generics; previously available as Wycillin

**Antibiotic, penicillin (long-acting IM)**



B

2

Yes

No

No

**Injection:** 600,000 units/mL (1, 2 mL); may contain parabens, phenol, povidone, and formaldehyde  
Contains 120 mg procaine per 300,000 units penicillin

**Injection should be for IM use only.**

**General dosing:**

**Newborn:** 50,000 units/kg/24 hr IM once daily

**Infant, child, adolescent:** 50,000 units/kg/24 hr ÷ Q12–24 hr IM. **Max. dose:** 1.2 million units/24 hr

**Adult:** 0.6–1 million units/24 hr ÷ Q12–24 hr IM

**Congenital syphilis, syphilis (if >1 day of therapy is missed, restart the entire course; see remarks):**

**Neonate, infant, child:** 50,000 units/kg/dose once daily IM × 10 days; **max. dose:** 2.4 million units/24 hr

**Neurosyphilis (see remarks):**

**Adolescent and adult:** 2.4 million units IM once daily and probenecid 500 mg Q6 hr PO × 10–14 days (both medications)

PENICILLIN G PREPARATIONS—PROCAINE *continued*

**Inhaled anthrax:** Postexposure prophylaxis (not the preferred drug of choice but total duration of therapy with all forms of therapy is 60 days; switch to an alternative form of therapy after 2 wk of procaine penicillin because of the risk for adverse effects; see remarks):

**Child and adolescent:** 25,000 units/kg/dose (**max. dose:** 1.2 million units/dose) IM Q12 hr

**Adult:** 1.2 million units IM Q12 hr

Provides sustained levels for 2–4 days. **Use with caution** in renal failure, asthma, significant allergies, cephalosporin hypersensitivity, G6PD deficiency (risk for methemoglobinemia), and neonates (higher incidence of sterile abscess at injection site and risk of procaine toxicity). Side effects and drug interactions similar to [Penicillin G Preparations—Aqueous Potassium and Sodium](#). In addition, may cause CNS stimulation and seizures. Immune hypersensitivity reaction has been reported.

**Deep IM administration only. Do not administer intravenously** (cardiac arrest and death may occur), and **do not inject** into or near an artery or nerve (may result in permanent neurologic damage). Large doses may be administered in two injection sites. No longer recommended for empiric treatment of gonorrhea due to resistant strains.

**PENICILLIN V POTASSIUM**

Generics; previously available as Veetids

**Antibiotic, penicillin**



B



2



Yes



No



No

**Tabs:** 250, 500 mg

**Oral solution:** 125 mg/5 mL, 250 mg/5 mL (100, 200 mL); may contain saccharin

Contains 0.7 mEq potassium/250 mg drug

**Conversion:** 250 mg = 400,000 units

**Infant and child:** 25–75 mg/kg/24 hr ÷ Q6–8 hr PO; **max. dose:** 2 g/24 hr

**Adolescent and adult:** 125–500 mg/dose PO Q6–8 hr

**Acute group A streptococcal pharyngitis (use BID dosing regimen ONLY if good compliance is expected):**

**Child <27 kg:** 250 mg PO BID–TID × 10 days

**Child ≥27 kg, adolescent, and adult:** 500 mg PO BID–TID × 10 days

**Rheumatic fever prophylaxis, and pneumococcal prophylaxis for sickle cell disease and functional or anatomic asplenia (regardless of immunization status):**

**2 mo–<3 yr:** 125 mg PO BID

**3–5 yr:** 250 mg PO BID; for sickle cell and asplenia, use may be discontinued after 5 yr of age if child received recommended pneumococcal immunizations and did not experience invasive pneumococcal infection

**Recurrent rheumatic fever prophylaxis:**

**Child and adult:** 250 mg PO BID

See [Penicillin G Preparations—Aqueous Potassium and Sodium](#) for side effects and drug interactions. GI absorption is better than penicillin G. **Note:** Must be taken 1 hr before or 2 hr after meals. Penicillin will prevent rheumatic fever if started within 9 days of the acute illness.

**Adjust dose in renal failure (see Chapter 31).**

**PENTAMIDINE ISETHIONATE**

Pentam 300, NebuPent, and generics

**Antibiotic, antiprotozoal**

C

3

Yes

No

No

**Injection (Pentam 300 and generics):** 300 mg**Inhalation (NebuPent and generics):** 300 mg**Treatment (child and adult):*****Pneumocystis jiroveci (carinii)*:** 4 mg/kg/24 hr IM/IV once daily × 14–21 days (IV is the preferred route)**Trypanosomiasis (*Trypanosoma gambiense*, *Trypanosoma rhodesiense* without CNS involvement):** 4 mg/kg/24 hr IM/IV once daily × 7–10 days**Visceral leishmaniasis (*Leishmania donovani*, *L. infantum*, *L. chagasi*):** 2–4 mg/kg/dose IM/IV once daily, or once every other day × 15–30 doses**Cutaneous leishmaniasis (*Leishmania [Viannia] panamensis*):** 2–4 mg/kg/dose IM/IV once or twice a week until lesions healed**Prophylaxis (child and adult):*****P. jiroveci (carinii)*:****IM/IV (IV is the preferred route):** 4 mg/kg/dose Q4 wk (Q2–4 wk for hematopoietic stem cell transplant); **max. single dose:** 300 mg**Inhalation (use with Respigard II nebulizer):****<5 yr:** 9 mg/kg (**max. dose:** 300 mg/dose) Q month**≥5 yr:** 300 mg Q month**Use with caution** in ventricular tachycardia, Stevens-Johnson syndrome, and daily doses >21 days. May cause hypoglycemia, hyperglycemia, hypotension (both IV and IM administration), nausea, vomiting, fever, mild hepatotoxicity, pancreatitis, megaloblastic anemia, nephrotoxicity, hypocalcemia, and granulocytopenia. Additive nephrotoxicity with aminoglycosides, amphotericin B, cisplatin, and vancomycin may occur. Aerosol administration may also cause bronchospasm, cough, oxygen desaturation, dyspnea, and loss of appetite. Infuse IV over 1–2 hr to reduce the risk of hypotension. Sterile abscess may occur at IM injection site.**Adjust dose in renal impairment (see Chapter 31) with systemic use.****PENTOBARBITAL**

Nembutal and generics

**Barbiturate**

D

3

No

Yes

No

**Injection:** 50 mg/mL (20, 50 mL); contains propylene glycol and 10% alcohol**Hypnotic****Child:****IM:** 2–6 mg/kg/dose. **Max. dose:** 100 mg**Adult:****IM:** 150–200 mg**Reduction in elevated ICP (adjunct therapy; patient must be intubated):** Barbiturate coma may be used if needed.**Child and adolescent:****IV/IO:** 1–3 mg/kg/dose**IM/PR:** 2–6 mg/kg/dose**Max. dose:** 100 mg/dose

PENTOBARBITAL *continued***Barbiturate coma****Child and adult:****IV:** Loading dose: 10–15 mg/kg given slowly over 1–2 hr**Maintenance:** Begin at 1 mg/kg/hr. Usual range: 0.5–5 mg/kg/hr as needed

**Contraindicated** in liver failure and history of porphyria. Use in preprocedure sedation has been replaced by other agents. **Use with caution** in hypovolemic shock, CHF, hypotension, and hepatic impairment. No advantage over phenobarbital for control of seizures. May cause drug-related isoelectric EEG. **Do not administer** for >2 wk in treatment of insomnia. May cause hypotension, arrhythmias, hypothermia, respiratory depression, and dependence.



Onset of action: IM: 10–15 min; IV: 1 min. Duration of action: IV: 15 min.

Administer IV at a rate of &lt;50 mg/min.

Therapeutic serum levels: sedation: 1–5 mg/L; hypnosis: 5–15 mg/L; coma: 20–40 mg/L (steady state is achieved after 4–5 days of continuous IV dosing).

**PERMETHRIN**

Nix and generics; previously available as Elimite

**Scabicial agent**

B



2



No



No



No

**Cream (generics):** 5% (60 g); contains 0.1% formaldehyde**Liquid cream rinse/lotion (Nix Lice-Killing Crème Rinse—OTC and generics) [OTC]:** 1% (59 mL with comb); may contain 20% isopropyl alcohol (1 or 2 bottles)**Additional OTC permethrin products for use on bedding, furniture, and garments include the following:****Liquid spray (Nix Lice Control Spray):** 0.25% (150 mL)**Spray (Rid Home Lice, Bedbug, and Dust Mite Spray):** 0.5% (141.8 g)***Pediculus humanus capitis*, *Phthirus pubis* (>2 mo, child, and adolescent):**

**Head lice:** Saturate hair and scalp and apply behind the ears and at the base of the neck with 1% cream rinse/lotion after shampooing, rinsing, and towel drying hair. Leave on for 10 min, then rinse. May repeat in 7 days. May be used for lice in other areas of the body (e.g., pubic lice) in same fashion. If the 1% cream rinse is resistant, the 5% cream may be used after shampooing, rinsing, and towel drying hair. Leave on for 8–14 hr overnight under a shower cap; then rinse off. May repeat in 7 days.

**Scabies:** Apply 5% cream from neck to toe (head to toe for infants and toddlers); wash off with water in 8–14 hr. May repeat in 14 days if mites appear. Use in full-term infants <1 mo is safe and effective when applied for a 6-hr period.

Ovicidal activity generally makes single-dose regimen adequate. However, resistance to permethrin has been reported. May cause pruritus, hypersensitivity, burning, stinging, erythema, and rash. For either lice or scabies, instruct patient to launder bedding and clothing. For lice, treat symptomatic contacts only. For scabies, treat all contacts even if asymptomatic.



**Avoid** contact with eyes during application. Shake well before using. **Do not use** near eyes, inside of nose, mouth, or vagina, or for lice in eyebrows/eyelashes. Topical cream dosage form contains formaldehyde. Dispense 60 g per one adult or two small children.

**PHENAZOPYRIDINE HCL**

Pyridium, Azo-Urinary Pain Relief [OTC], Azo-Urinary Pain Relief Maximum Strength [OTC], many other brands and generics

*Urinary analgesic*



B



3



Yes



Yes



No

**Tabs:** 95 mg [OTC] (12s, 30s), 99.5 mg [OTC] (24s, 72s), 100 mg, 200 mg

**Oral suspension:** 10 mg/mL 

**UTI (use with an appropriate antibacterial agent):**

**Child 6—<12 yr:** 12 mg/kg/24 hr ÷ TID PO until symptoms of lower urinary tract irritation are controlled or for 2 days. **Max. dose:** 200 mg/dose

**≥12 yr and adult:** 190—200 mg TID PO until symptoms are controlled or for 2 days



May cause pruritus, rash, GI distress, vertigo, and headache. Anaphylactoid-like reaction, methemoglobinemia, hemolytic anemia, and renal and hepatic toxicity have been reported, usually at overdosage levels. Colors urine orange; stains clothing. May also stain contact lenses and interfere with urinalysis tests based on spectrometry or color reactions. Give doses with or after meals.



**Avoid use in moderate/severe renal impairment; adjust dose in mild renal impairment (see Chapter 31).**

**PHENOBARBITAL**

Generics; previously available as Luminal

*Barbiturate*



D



2



Yes



Yes



No

**Tabs:** 15, 16.2, 30, 32.4, 60, 64.8, 97.2, 100 mg

**Oral elixir or solution:** 20 mg/5 mL (473 mL); may contain 15% alcohol

**Injection:** 65, 130 mg/mL (1 mL); may contain 10% alcohol and propylene glycol

**Status epilepticus:**

**Loading dose, IV:**

**Neonate, infant, and child:** 15—20 mg/kg/dose (**max. loading dose:** 1000 mg) in a single or divided dose. May give additional 5 mg/kg doses Q20 min to a **max. total** of 30 mg/kg

**Seizures maintenance therapy (PO/IV):** Monitor levels.

**Neonate:** 3—5 mg/kg/24 hr ÷ once daily—BID

**Infant:** 5—6 mg/kg/24 hr ÷ once daily—BID

**Child 1—5 yr:** 6—8 mg/kg/24 hr ÷ once daily—BID

**Child 6—12 yr:** 4—6 mg/kg/24 hr ÷ once daily—BID

**>12 yr:** 1—3 mg/kg/24 hr ÷ once daily—BID

**Hyperbilirubinemia (limited data; <12 yr):** 3—8 mg/kg/24 hr PO ÷ BID—TID. Doses up to 12 mg/kg/24 hr have been used. Not recommended for biliary cirrhosis.

**Preoperative sedation (child):** 1—3 mg/kg/dose IM/IV/PO × 1. Give 60—90 min before procedure.

**Contraindicated** in porphyria, severe respiratory disease with dyspnea, or obstruction. **Use with caution** in hepatic or renal disease (reduce dose). IV administration may cause respiratory arrest or hypotension. Side effects include drowsiness, cognitive impairment, ataxia, hypotension, hepatitis, rash, respiratory depression, apnea, megaloblastic anemia, and anticonvulsant hypersensitivity syndrome. Paradoxical reaction in children (not dose related) may cause hyperactivity, irritability, or insomnia. Induces several liver enzymes (CYP 450 1A2, 2A6, 2B6, 2C8/9, 3A4), P-glycoprotein, and glucuronidation (UGT1A1), and thus decreases blood levels of many drugs (e.g., anticonvulsants). **IV push not to exceed 1 mg/kg/min.**



PHENOBARBITAL *continued*

T<sub>1/2</sub> is variable with age: neonates, 45–100 hr; infants, 20–133 hr; children, 37–73 hr. Owing to long half-life, consider other agents for sedation for procedures.


Therapeutic levels: 15–40 mg/L. Recommended serum sampling time at steady state: trough level obtained within 30 min prior to the next scheduled dose after 10–14 days of continuous dosing.

Adjust dose in renal failure (see Chapter 31).

**PHENTOLAMINE MESYLATE**

OraVerse and generics; previously available as Regitine

**Adrenergic blocking agent ( $\alpha$ ); antidote, extravasation**



**Injection:** 5 mg vial; may contain mannitol

**Injection in solution for submucosal use:**

**OraVerse:** 0.4 mg/1.7 mL (1.7 mL in dental cartridges) (10s); contains edetate disodium

**Treatment of  $\alpha$ -adrenergic drug extravasation (most effective within 12 hr of extravasation):**

All doses are five doses administered SC around the site of extravasation within 12 hr of extravasation. Monitor for hypotension (BP) Q15 min  $\times$  4 then Q1 hr  $\times$  2. See the following table for weight-based dosing and recommended drug concentration.



Patient Weight	Drug Concentration (Diluted With Preservative-Free NS)	Dose for Each Syringe $\times$ 5 Syringes	Total Dose From All 5 Syringes
<2.5 kg	0.2 mg/mL	0.1 mL	0.1 mg
2.5–<5 kg	0.2 mg/mL	0.25 mL	0.25 mg
5–<10 kg	1 mg/mL	0.1 mL	0.5 mg
10–<20 kg	1 mg/mL	0.2 mL	1 mg
20–<30 kg	1 mg/mL	0.4 mL	2 mg
30–<40 kg	1 mg/mL	0.6 mL	3 mg
40–<50 kg	1 mg/mL	0.8 mL	4 mg
$\geq$ 50 kg	1 mg/mL	1 mL	5 mg

**Max. total dose:**

**Neonate:** 2.5 mg

**Infant, child, adolescent, and adult:** 0.1–0.2 mg/kg/dose or 5 mg

**Diagnosis of pheochromocytoma, IM/IV:**

**Child:** 0.05–0.1 mg/kg/dose up to a **max. dose** of 5 mg

**Adult:** 5 mg/dose

**Hypertension, prior to surgery for pheochromocytoma, IM/IV:**

**Child:** 0.05–0.1 mg/kg/dose up to a **max. dose** of 5 mg 1–2 hr **before** surgery, repeat Q2–4 hr PRN

**Adult:** 5 mg/dose 1–2 hr **before** surgery, repeat Q2–4 hr PRN

**Contraindicated** in MI, coronary insufficiency, and angina. **Use with caution** in hypotension, arrhythmias, and cerebral vascular spasm/occlusion.



For diagnosis of pheochromocytoma, patient should be resting in a supine position. A blood pressure reduction of more than 35 mm Hg systolic and 24 mm Hg diastolic is considered a positive test for pheochromocytoma. For treatment of extravasation, use 27- to 30-gauge needle with multiple small injections, and monitor site closely because repeat doses may be necessary.

**PHENYLEPHRINE HCL**

Vazculep, Neo-Syneprine, Biorphen, many others, and generics

**Adrenergic agonist**



C



3



No



No



No

**Injection:**

**Vazculep and generics:** 10 mg/mL (1%) (1, 5, 10 mL); may contain metasulfites

**Biorphen and generics:** 10 mg/mL (1%) (1 mL ampules); preservative and sulfite free

**Ready-to-use injection:**

**Biorphen:** 0.1 mg/mL (5 mL ampules); preservative and sulfite free

**Nasal spray/drops (OTC; may contain benzalkonium chloride):**

**0.125% (Little Remedies Decongestant Nose Drops):** 0.125% (15 mL)

**0.25% (Neo-Syneprine Mild Strength, Rhinall):** 0.25% (15, 30, 40 mL)

**0.5% (Neo-Syneprine Regular Strength):** 0.5% (15 mL)

**1% (4-Way Fast Acting, Nasal Four, Neo-Syneprine Extra Strength, and generics):** 1% (15, 30 mL)

**NOTE:** For Neo-Syneprine 12-hr Nasal, see [Oxymetazoline](#).

**Ophthalmic drops (Altafrin and generics):** 2.5% (2, 10, 15 mL), 10% (5 mL); contains benzalkonium chloride

**Tabs (Sudafed PE Sinus Congestion and others) [OTC]:** 10 mg

**Oral solution (Sudafed PE Children's) [OTC]:** 2.5 mg/5 mL (118 mL)

**Hypotension:**

To prepare infusion: See [p. iii](#).

**Child:**

**IV bolus:** 5–20 mCg/kg/dose (**initial max. dose:** 500 mCg/dose, **subsequent max. dose:** 1000 mCg/dose) Q10–15 min PRN

**IV drip:** Start at 0.1–0.5 mCg/kg/min; titrate to effect.

**IM/SC:** 0.1 mg/kg/dose Q1–2 hr PRN; **max. dose:** 5 mg

**Adult:**

**IV drip:** 0.5–6 mCg/kg/min; titrate to effect

**Pupillary dilation (see remarks):**

**<1 yr:** 2.5% ophthalmic solution; 1 drop in each eye 15–30 min before exam

**Child (≥1 yr) and adult:** 2.5% or 10% ophthalmic solution; 1 drop in each eye 10–60 min before exam

**Nasal decongestant (in each nostril; give up to 3 days):**

**Child 2–<6 yr:** 1–3 drops to each nostril of 0.125% solution Q4 hr PRN

**Child 6–12 yr:** 1–3 sprays/drops to each nostril of 0.25% solution Q4 hr PRN

**>12 yr—adult:** 1–3 sprays/drops to each nostril of 0.25%, 0.5%, or 1% solution Q4 hr PRN

**Oral decongestant (see remarks):**

**4–<6 yr:** 2.5 mg (5 mL) PO Q4 hr PRN, up to 15 mg (30 mL)/24 hr

**≥6–<12 yr:** 5 mg (10 mL) PO Q4 hr PRN up to 30 mg (60 mL)/24 hr

**≥12 yr and adult:** 10 mg PO Q4 hr PRN up to 60 mg/24 hr

**Use with caution** in presence of arrhythmias, hyperthyroidism, or hyperglycemia. May cause tremor, insomnia, or palpitations. Metabolized by MAO. **Contraindicated** in pheochromocytoma and severe hypertension. Injectable product may contain sulfites.

Nasal decongestants may cause rebound congestion with excessive use (>3 days). The 1% nasal spray can be used in adults with extreme congestion.

Oral phenylephrine is found in a variety of combination cough and cold products and has replaced pseudoephedrine and phenylpropanolamine. Over-the-counter (OTC or nonprescription) use of this product is **not recommended** for children younger than age 6; reports of serious adverse effects (cardiac and respiratory distress, convulsions, and hallucinations) and fatalities (from unintentional overdoses, including combined use of other OTC products containing the same active ingredients) have been made.



PHENYLEPHRINE HCL *continued*

**Ophthalmic use:** Apply pressure to the lacrimal sac during and 2 min after administering drops to minimize systemic absorption.

**PHENYTOIN**

Dilantin, Dilantin Infatab, Phenytoin Infatab, Phenytek, and generics

**Anticonvulsant, class Ib antiarrhythmic**



D



2



Yes



Yes



Yes

**Chewable tabs (Dilantin Infatab and generics):** 50 mg; may contain saccharin

**Extended release caps:**

**Dilantin:** 30, 100 mg

**Phenytek:** 200, 300 mg

**Generics:** 100, 200, 300 mg

**Oral suspension (Dilantin and generics):** 125 mg/5 mL (240 mL); contains ≤0.6% alcohol and sodium benzoate

**Injection:** 50 mg/mL (2, 5 mL); contains alcohol and sodium benzoate

**Status epilepticus:** See [Chapter 1](#) and remarks.

**Loading dose (all ages):** 20 mg/kg IV; **max. dose:** 1500 mg/24 hr

**Maintenance for seizure disorders (initiate 12 hr after administration of loading dose; use once-daily or BID dosing with extended release caps):**

**Neonate:** Start with 5 mg/kg/24 hr PO/IV ÷ Q12 hr; usual range 4–8 mg/kg/24 hr PO/IV ÷ Q8–12 hr

**Infant/child:** Start with 5 mg/kg/24 hr ÷ BID–TID PO/IV; usual dose range (doses divided BID–TID):

**6 mo–3 yr:** 8–10 mg/kg/24 hr

**4–6 yr:** 7.5–9 mg/kg/24 hr

**7–9 yr:** 7–8 mg/kg/24 hr

**10–16 yr:** 6–7 mg/kg/24 hr

**Adult:** Start with 100 mg/dose Q8 hr IV/PO and carefully titrate (if needed) by 100 mg increments Q2–4 wk to 300–600 mg/24 hr (or 6–7 mg/kg/24 hr) ÷ Q8–24 hr IV/PO.

**Contraindicated** in patients with heart block or sinus bradycardia; those who are receiving delavirdine (decrease virologic response); and history of hydantoin hypersensitivity. **Use with caution** in patients with pacemakers or cardiac dysrhythmias because of its class IB antiarrhythmic properties. IM administration is **not recommended** because of erratic absorption and pain at injection site; consider fosphenytoin. Side effects include gingival hyperplasia, hirsutism, dermatitis, blood dyscrasia, ataxia, lupus-like and Stevens-Johnson syndromes, lymphadenopathy, liver damage, and nystagmus. Suicidal behavior or ideation, bradycardia, cardiac arrest, red cell aplasia, and multiorgan hypersensitivity (DRESS) have been reported. An increased risk for serious skin reactions (e.g., TEN and Stevens-Johnson) may occur in patients with the HLA-B\*1502 allele; do not use this medication in individuals who carry this genotype.

Many drug interactions: Levels may be increased by cimetidine, chloramphenicol, INH, sulfonamides, trimethoprim, etc. Levels may be decreased by some antineoplastic agents. Phenytoin induces hepatic microsomal enzymes (CYP 450 1A2, 2C8/9/19, and 3A3/4), leading to decreased effectiveness of oral contraceptives, direct thrombin inhibitors (e.g., dabigatran, rivaroxaban), fosamprenavir (used without ritonavir), quinidine, lacosamide, valproic acid, theophylline, and other substrates to the previously listed CYP 450 hepatic enzymes. May increase levels of amprenavir when administered with fosamprenavir and ritonavir. May cause resistance to neuromuscular blocking action of nondepolarizing neuromuscular blocking agents (e.g., pancuronium, vecuronium,

*Continued*

PHENYTOIN *continued*

rocuronium, and cisatracurium) and decrease concentrations of T<sub>4</sub> and T<sub>3</sub> (typically without clinical hypothyroidism). May increase risk for hyperammonemia when used with valproic acid.

The following initial maintenance dose modifications for HLA-B\*1502 allele noncarriers and CYP 450 2C9 phenotypes have been recommended:

CYP 2C9 intermediate metabolizer: 25% reduction with therapeutic drug monitoring

CYP 2C9 poor metabolizer: 50% reduction with therapeutic drug monitoring

Some recommend avoiding use for those who are positive for HLA-B\*1502 or CYP2C9\*3 carriers.

Ideal body weight should be used for calculating dosages. Suggested dosing intervals for specific oral dosage forms: extended release caps (once daily—BID); chewable tablets, and oral suspension (TID).

Oral absorption reduced in neonates. T<sub>1/2</sub> is variable (7–42 hr) and dose dependent. Drug is highly protein bound; free fraction of drug will be increased in patients with hypoalbuminemia.

For seizure disorders, therapeutic levels: 10–20 mg/L (free and bound phenytoin) **OR** 1–2 mg/L (free only). Monitor free phenytoin levels in hypoalbuminemia or renal insufficiency. Recommended serum sampling times: trough level (PO/IV) within 30 min prior to the next scheduled dose; peak or postload level (IV) 1 hr after the end of IV infusion. Steady state is usually achieved after 5–10 days of continuous dosing. For routine monitoring, measure trough.

IV push/infusion rate: **Not to exceed** 0.5 mg/kg/min in neonates, or 1 mg/kg/min in infants, children, and adults with **maximum** of 50 mg/min; may cause cardiovascular collapse. Consider fosphenytoin in situations of tenuous IV access and risk for extravasation.

**PHOSPHORUS SUPPLEMENTS**

K-PHOS Neutral, Phospho-Trin 250 Neutral, Phospha 250 Neutral, PHOS-NaK, Sodium Phosphate, Potassium Phosphate, and many generics

**Electrolyte supplement**



C



2



Yes



No



No

**Oral:****Na and K phosphate:**

**PHOS-NaK and generics; powder:** 250 mg (8 mM) P, 6.96 mEq (160 mg) Na, 7.16 mEq (280 mg) K per packet of powder (100s); reconstitute with 75 mL water or juice per packet

**K-PHOS Neutral, Phospho-Trin 250 Neutral, Phospha 250 Neutral, and generics; tabs:** 250 mg P (8 mM), 13 mEq Na, 1.1 mEq K; administer each dose with a full glass of water

**K-PHOS No. 2; tabs:** 250 mg P (8 mM), 5.8 mEq Na, 2.3 mEq K; administer each dose with a full glass of water

**K phosphate:**

**K-Phos Original; tabs:** 500 mg potassium acid phosphate (114 mg phosphorus and 3.7 mEq K); dissolve each tab in 3–4 oz water

**Injection:**

**Na phosphate:** 3 mM (93 mg) P, 4 mEq Na/mL (5, 15, 50 mL)

**K phosphate:** 3mM (93 mg) P, 4.4 mEq K/mL (5, 15 mL)

**Conversion:** 31 mg P = 1 mM P

**Acute hypophosphatemia:** 0.16–0.32 mM/kg/dose (or 5–10 mg/kg/dose) IV over 6 hr

**Maintenance/replacement:****Child:**

**IV:** 0.5–1.5 mM/kg (or 15–45 mg/kg) over 24 hr

**PO:** 30–90 mg/kg/24 hr (or 1–3 mM/kg/24 hr) ÷ TID–QID



PHOSPHORUS SUPPLEMENTS *continued***Adult:****IV:** 50–65 mM (or 1.5–2 g) over 24 hr**PO:** 3–4.5 g/24 hr (or 100–150 mM/24 hr) ÷ TID–QID

**Recommended IV infusion rate:**  $\leq 0.1$  mM/kg/hr (or 3.1 mg/kg/hr) of phosphate. When potassium salt is used, the rate will be limited by the **max.** potassium infusion rate. **Do not** co-infuse with calcium-containing products.

May cause tetany, hyperphosphatemia, hyperkalemia, or hypocalcemia. **Use with caution** in patients with renal impairment. Be aware of sodium and/or potassium load when supplementing phosphate. IV administration may cause hypotension and renal failure, or arrhythmias, heart block, and cardiac arrest with potassium salt. PO dosing may cause nausea, vomiting, abdominal pain, or diarrhea. See [Chapter 21](#) for daily requirements and [Chapter 11](#) for additional information on hypophosphatemia and hyperphosphatemia.

**PHYSOSTIGMINE SALICYLATE**

Generics; previously available as Antilirium

**Cholinergic agent**

C



?



No



No



No

**Injection:** 1 mg/mL (2 mL); contains 2% benzyl alcohol and 0.1% sodium metabisulfite

**Reversal of toxic anticholinergic effects from antihistamine or anticholinergic agents:**

**Child:** 0.02 mg/kg/dose (**max. dose:** 0.5 mg/dose) IM or IV (administered no  $> 0.5$  mg/min), dose may be repeated every 5–10 min if no response or return of anticholinergic symptoms up to a **max. total** of 2 mg

**Adult:** 0.5–2 mg IM or IV (administered no  $> 1$  mg/min); if needed, repeat dose every 10–30 min until response is seen or when adverse effects occur



**Physostigmine antidote:** Atropine always should be available. **Contraindicated** in asthma, gangrene, diabetes, cardiovascular disease, GI or GU tract obstruction, any vagotonic state, and patients receiving choline esters or depolarizing neuromuscular blocking agents (e.g., decamethonium, succinylcholine). May cause seizures, arrhythmias, bradycardia, GI symptoms, and other cholinergic effects. Rapid IV administration can cause bradycardia and hypersalivation leading to respiratory distress and seizures.

**PHYTONADIONE/VITAMIN K<sub>1</sub>**

Mephyton and generics

**Vitamin, fat soluble**

C



2



No



No



No

**Tabs (Mephyton and generics):** 5 mg

**Oral suspension:** 1 mg/mL 

**Injection, emulsion (contains no more than 500 mCg/L aluminum):**

2 mg/mL (0.5 mL); some preparations may be preservative free but may contain propylene glycol  
10 mg/mL (1 mL); contains 0.9% benzyl alcohol

**Vitamin K deficiency bleeding (neonatal hemorrhagic disease):** Preservative-free dosage form is preferred.

**Prophylaxis (IM, administered 1 hr within 1 hr after birth):**

**<1 kg:** 0.5 mg/kg/dose  $\times$  1

**1–1.5 kg:** 0.5 mg  $\times$  1

**>1.5 kg:** 1 mg  $\times$  1

**Treatment:** 1–2 mg/24 hr IM/SC/IV

*Continued*

PHYTONADIONE/VITAMIN K1 *continued***Warfarin overdose (see remarks):****No significant bleeding:**

**INR 4–4.5:** Consider PO vitamin K at dosage indicated for INR >4.5—<10 below and monitor INR Q24 hr. Lower or hold warfarin dose.

**INR >4.5—<10:** Repeat INR and hold warfarin dose. Monitor INR Q24 hr until INR <4. Give PO vitamin K for patients with high bleeding risk:

**<40 kg:** 0.03 mg/kg PO × 1

**≥40 kg:** 1–2.5 mg PO × 1

**INR ≥10:** Repeat INR and hold warfarin dose. Monitor INR Q12 hr and give PO vitamin K (dose may be repeated Q12–24 hr PRN):

**<40 kg:** 0.06 mg/kg PO × 1

**≥40 kg:** 5–10 mg PO × 1

**Minor bleeding (any elevated INR):** Hold warfarin and monitor INR Q12–24 hr, administer single vitamin K dose and repeat vitamin K dose in 24 hr if full correction not achieved and bleeding persists.

**PO:**

**<40 kg:** 0.03 mg/kg × 1

**≥40 kg:** 1–2.5 mg × 1

**IV:** 0.5–2.5 mg × 1

**Significant or life-threatening bleeding (any elevated INR):** Hold warfarin and give vitamin K 5–10 mg IV × 1 in combination with FFP (10–15 mL/kg) or prothrombin complex concentrate (KCentra). Monitor INR Q4–6 hr, repeat vitamin K dose if full correction not achieved at 12–24 hr and bleeding persists.

**Vitamin K deficiency:**

**Liver disease (infant, child, and adolescent):** 2.5–5 mg/24 hr PO

**Cholestasis (infant, child, and adolescent):** 2.5–15 mg/24 hr PO

IV or IM doses may cause flushing, dizziness, cardiac/respiratory arrest, hypotension, and anaphylaxis. IV or IM administration is indicated only when other routes of administration are not feasible (or in emergency situations).



Monitor PT/PTT. Large doses (10–20 mg) in newborns may cause hyperbilirubinemia and severe hemolytic anemia. Blood coagulation factors increase within 6–12 hr after oral doses and within 1–2 hr following parenteral administration. Use of higher doses for warfarin overdose may cause warfarin resistance for ≥1 wk. Concurrent administration of oral mineral oil may decrease GI absorption of oral vitamin K.

IV injection rate **not to exceed** 3 mg/m<sup>2</sup>/min or 1 mg/min. Protect product from light. **See Chapter 21 for multivitamin preparations.**

**PILOCARPINE HCL**

Vuity, Salagen, and generics; previously available as Isopto Carpine

**Cholinergic agent**



C



3



No



Yes



No

**Ophthalmic solution:**

**Generics:** 1% (15 mL), 2% (15 mL), 4% (15 mL); may contain benzalkonium chloride

Vuity: 1.25% (2.5 mL); contains benzalkonium chloride

**Tab (Salagen and generics):** 5, 7.5 mg

**For elevated intraocular pressure:**

**Infant and child <2 yr:** Instill 1 drop of the 1% solution into each affected eye(s) TID.



PILOCARPINE HCL *continued*

**Child  $\geq 2$  yr, adolescent, and adult:** Instill 1–2 drop(s) in each affected eye up to 4 times a day; concentration and dosage frequency are dependent on the degree of elevated pressure and miotic response.

**Xerostomia:**

**Adult:** 5 mg/dose PO TID, dose may be titrated to 10 mg/dose PO TID in patients who do not respond to lower dose and who are able to tolerate the drug. 5 mg/dose PO QID has been used in Sjögren syndrome.

**OPHTHALMIC USE: Contraindicated** in acute iritis or anterior chamber inflammation and uncontrolled asthma. May cause transient blurred or dim/dark vision, stinging, burning, lacrimation, headache, and retinal detachment. **Use with caution** in patients with corneal abrasion or significant cardiovascular disease. Use with topical NSAIDs (e.g., ketorolac) may decrease topical pilocarpine effects.

**ORAL USE:** Sweating, nausea, rhinitis, chills, flushing, urinary frequency, dizziness, asthenia, and headaches have also been reported. Reduce oral dosing in the presence of mild hepatic insufficiency (Child-Pugh score of 5–6); **avoid use** in severe hepatic insufficiency.

**PIMECROLIMUS**

Elidel and generics

**Topical immunosuppressant, calcineurin inhibitor**

C



3



No



No



No

**Cream:** 1% (30, 60, 100 g); contains benzyl alcohol and propylene glycol

**Atopic dermatitis (second-line therapy):**

**Child  $\geq 2$  yr, adolescent, and adult (see remarks):** Apply a thin layer to affected area BID and rub in gently and completely. Reevaluate patient in 6 wk if lesions are not healed.

**Do not use** in children  $< 2$  yr (higher rate of upper respiratory infections), in immunocompromised patients, or with occlusive dressings (promotes systemic absorption).

**Avoid use** on malignant or premalignant skin conditions as rare cases of lymphoma and skin malignancy have been reported with topical calcineurin inhibitors. Approved as a second-line therapy for atopic dermatitis for patients who fail to respond, or do not tolerate, other approved therapies. Use medication for short periods of time by using the minimum amounts to control symptoms; long-term safety is unknown. **Avoid** contact with eyes, nose, mouth, and cut, infected, or scraped skin. Minimize and **avoid** exposure to natural and artificial sunlight, respectively.

Most common side effects include burning at the application site, headache, viral infections, and pyrexia. Skin discoloration, skin flushing associated with alcohol use, anaphylactic reactions, ocular irritation after application to the eyelids or near the eyes, angioneurotic edema, and facial edema have been reported. Drug is a CYP 450 3A3/4 substrate.

**PIPERACILLIN WITH TAZOBACTAM**

Zosyn and generics

**Antibiotic, penicillin (extended spectrum with  $\beta$ -lactamase inhibitor)**

B



2



Yes



No



No

**8:1 ratio of piperacillin to tazobactam:**

**Injection, powder:** 2 g piperacillin and 0.25 g tazobactam; 3 g piperacillin and 0.375 g tazobactam; 4 g piperacillin and 0.5 g tazobactam; 12 g piperacillin and 1.5 g tazobactam; 36 g piperacillin and 4.5 g tazobactam

*Continued*

PIPERACILLIN WITH TAZOBACTAM *continued*

**Injection, premixed in iso-osmotic dextrose:** 2 g piperacillin and 0.25 g tazobactam in 50 mL; 3 g piperacillin and 0.375 g tazobactam in 50 mL; 4 g piperacillin and 0.5 g tazobactam in 100 mL  
Contains 2.84 mEq Na/g piperacillin

**All doses based on piperacillin component.**

**Neonate and infant (IV; limited data):**

≤2 kg:

≤7 days old: 100 mg/kg/dose Q8 hr

8–28 days old:

≤30 wk postmenstrual age: 100 mg/kg/dose Q8 hr

>30 wk postmenstrual age: 80 mg/kg/dose Q6 hr

29–60 days old: 80 mg/kg/dose Q6 hr

>2 kg:

≤60 days old: 80 mg/kg/dose Q6 hr

**NOTE:** For patients with a postmenstrual age of >35 wk, a pharmacokinetic study suggests using 80 mg/kg/dose IV Q4 hr to achieve targeted drug concentration time above the MIC.

**Child and adolescent:**

**Severe infections and nosocomial pneumonia (lengthening the dose administration time to 4 hr [see remarks] may enhance the pharmacodynamic properties):**

2–9 mo: 80 mg/kg/dose IV Q6 hr

>9 mo, child, and adolescent: 100 mg/kg/dose (max. 4000 mg/dose) IV Q6 hr

**Max. dose (all ages):** 16 g/24 hr

**Appendicitis or peritonitis (dosing interval may be shortened to Q6 hr to enhance pharmacodynamic properties):**

2–9 mo: 80 mg/kg/dose IV Q8 hr

>9 mo—adolescent:

≤40 kg: 100 mg/kg/dose (max. 3000 mg/dose) IV Q8 hr

>40 kg: 3 g/dose IV Q6 hr

**Max. dose (all ages):** 16 g/24 hr

**Adult:**

**Intra-abdominal or soft tissue infections:** 3 g IV Q6 hr

**Nosocomial pneumonia:** 4 g IV Q6 hr

**Cystic fibrosis (antipseudomonal; see remarks):**

**All ages:** 350–600 mg/kg/24 hr IV ÷ Q4–6 hr; **max. dose:** 24 g/24 hr

Tazobactam is a  $\beta$ -lactamase inhibitor, thus extending the spectrum of piperacillin. Like other penicillins, CSF penetration occurs only with inflamed meninges. GI disturbances, pruritus, rash, and headaches are common. Abnormal platelet aggregation and prolonged bleeding, hemophagocytic lymphohistiocytosis, and serious skin reactions (e.g., Stevens-Johnson, DRESS, acute generalized exanthematous pustulosis, and TEN) have been reported. Cystic fibrosis patients have an increased risk for fever and rash. Increases in renal failure risk (in critically ill adults) and incidence of acute kidney injury (in combination with IV vancomycin) have been reported.

Coagulation parameters should be tested more frequently and monitored regularly with high doses of heparin, warfarin, or other drugs affecting blood coagulation or thrombocyte function. May falsely decrease aminoglycoside serum levels if the drugs are infused close to one another; allow a minimum of 2 hr between infusions to prevent this interaction. May prolong the neuromuscular blockade effects of vecuronium.

Prolonging the dose administration time to 4 hr will maximize the pharmacokinetic/pharmacodynamic properties by prolonging the time of drug concentration above the MIC; especially for pathogens with piperacillin MICs of 8–16 mCg/mL. **Adjust dose in renal impairment (see Chapter 31).**



## POLYCITRA


See [Citrate Mixtures](#).

## POLYETHYLENE GLYCOL—ELECTROLYTE SOLUTION

Bowel cleansing products: GoLYTELY, NuLYTELY, and generics

Laxative products: MiraLax, GaviLAX, GlycoLax, HealthyLax, and many others, including generics

**Bowel evacuant, osmotic laxative**



## Powder for oral solution:

## Bowel cleansing products:

**GoLYTELY and others:** Polyethylene glycol 3350 236 g; contains Na sulfate 22.74 g, Na bicarbonate 6.74 g, NaCl 5.86 g, KCl 2.97 g (mixed with water to 4 L). Contents vary somewhat. See package insert for specific contents of other products.

## Laxative products:

MiraLax [OTC], GaviLAX [OTC], Glycolax [OTC], HealthyLax [OTC], and generics [OTC and Rx]: Polyethylene glycol 3350 (17, 119, 238, 255, 510, 527, 765, 850 g)

**Bowel cleansing (using products containing supplemental electrolytes for bowel cleansing such as GoLYTELY, NuLYTELY, and generics; and patients should be NPO 3–4 hr prior to dosing):**



## Child:

**Oral/nasogastric:** 25–40 mL/kg/hr until rectal effluent is clear (usually in 4–10 hr)

## Adult:

**Oral:** 240 mL PO Q10 min up to 4 L or until rectal effluent is clear

**Nasogastric:** 20–30 mL/min (1.2–1.8 L/hr) up to 4 L or until rectal effluent is clear

**Bowel cleansing (using MiraLax or equivalent product):**

**≥2 yr and adolescent:** 1.5 g/kg/24 hr (**max. dose:** 100 g/24 hr) × 4 days

**Constipation (using MiraLax or equivalent product):**

**Child (limited data in 20 children with chronic constipation, 18 mo–11 yr; see remarks):** A mean effective dose of 0.84 g/kg/24 hr PO ÷ BID for 8 wk (range: 0.25–1.42 g/kg/24 hr) was used to yield 2 soft stools per day. Do not exceed 17 g/24 hr. If patient >20 kg, use adult dose.

**Adult:** 17 g (one heaping tablespoonful) mixed in 240 mL of water, juice, soda, coffee, or tea PO once daily

## Fecal impaction:

## GoLYTELY and others:

**≥2 yr (PO/NG tube):** 20 mL/kg/hr up to a **maximum** of 1 L/hr × 4 hr per 24 hr for 2 days

## Miralax and others:

**>3 yr:** 1–1.5 g/kg/24 hr (**max. dose:** 100 g/24 hr) PO × 3–6 days. Following disimpaction, give a maintenance dose of 0.4–1 g/kg/24 hr for ≥2 mo followed by a gradual decrease in dose.

**Contraindicated** in polyethylene glycol hypersensitivity. Monitor electrolytes, BUN, serum glucose, and urine osmolality with prolonged administration. Seizures resulting from electrolyte abnormalities have been reported.



**BOWEL CLEANSING (GoLYTELY and others):** Contraindicated in toxic megacolon, gastric retention, toxic colitis, ileus, and bowel perforation. **Use with caution** in patients prone to aspiration or with impaired gag reflex. **Do not mix** with starch-based thickeners as it may reduce their viscosity and increase the risk of choking and aspiration for patients who have trouble swallowing. Effect should occur within 1–2 hr. Solution generally more palatable if chilled.

Continued

POLYETHYLENE GLYCOL—ELECTROLYTE SOLUTION *continued*

**CONSTIPATION (MiraLax and others): Contraindicated** in bowel obstruction.

**Child:** Dilute powder using the ratio of 17 g powder to 240 mL of water, juice, or milk. An onset of action within 1 wk in 12 of 20 patients, with the remaining 8 patients reporting improvement during the second week of therapy. Side effects reported in this trial included diarrhea, flatulence, and mild abdominal pain. (See *J Pediatr* 2001;139[3]:428–432 for additional information.)

**Adult:** 2–4 days may be required to produce a bowel movement. Most common side effects include nausea, abdominal bloating, cramping, and flatulence. Use beyond 2 wk has not been studied.


**POLYMYXIN B SULFATE AND BACITRACIN**

See [Bacitracin ± Polymyxin B](#).

**POLYMYXIN B SULFATE AND TRIMETHOPRIM SULFATE**

Polytrim Ophthalmic Solution and generics

**Topical antibiotic (ophthalmic preparations listed)**



**Ophthalmic solution:** Polymyxin B sulfate 10,000 U/mL, and trimethoprim sulfate 1 mg/mL (10 mL); some preparations may contain 0.04 mg/mL benzalkonium chloride

**≥2 mo, child, adolescent, and adult:** Instill 1 drop in the affected eye(s) Q3 hr (max. of 6 doses/24 hr) × 7–10 days



Active against susceptible strains of *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Streptococcus pneumoniae*, *Streptococcus viridans*, *Haemophilus influenzae*, and *Pseudomonas aeruginosa*. **Not indicated** for the prophylaxis or treatment of ophthalmia neonatorum. Local irritation consisting of redness, burning, stinging, and/or itching is common. Hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash have been reported.




Apply finger pressure to lacrimal sac during and for 1–2 min after dose application.

**POLYMYXIN B SULFATE, NEOMYCIN SULFATE, HYDROCORTISONE OTIC**

Generics; previously available as Cortisporin Otic

**Topical otic antibiotic**



**Otic solution or suspension:** Polymyxin B sulfate 10,000 U/mL, neomycin sulfate 5 mg/mL (3.5 mg/mL neomycin base), hydrocortisone 10 mg/mL (10 mL); some preparations may contain thimerosal and metabisulfite

For ophthalmic suspension, see [Neomycin/Polymyxin B Ophthalmic Products](#).

**Otitis externa:**

**≥2 yr, child, and adolescent:** 3 drops TID–QID × 7–10 days. If preferred, a cotton wick may be saturated and inserted into ear canal. Moisten wick with antibiotic every 4 hr. Change wick Q24 hr.

**Adult:** 4 drops TID–QID × 7–10 days (otic suspension preferred)



**Contraindicated** in patients with active varicella and herpes simplex and in cases with perforated eardrum (possible ototoxicity). **Use with caution** in chronic otitis media and when the integrity of the tympanic membrane is in question. Metabisulfite-containing products may



POLYMYXIN B SULFATE, NEOMYCIN SULFATE,  
HYDROCORTISONE OTIC *continued*

cause allergic reactions to susceptible individuals. Hypersensitivity (itching, skin rash, redness, swelling, or other sign of irritation in or around the ear) may occur. Neomycin may cause sensitization. Prolonged treatment may result in overgrowth of nonsusceptible organisms and fungi. May cause cutaneous sensitization.

Shake suspension well before use. Warm the medication to body temperature prior to use.

## POLYSPORIN

See [Bacitracin ± Polymyxin B](#).

## POLYTRIM OPHTHALMIC SOLUTION

See [Polymyxin B Sulfate and Trimethoprim Sulfate](#).

## PORACTANT ALFA

See [Surfactant, pulmonary](#).

## POSACONAZOLE

Noxafil, Noxafil PowderMix, and generics  
*Antifungal agent*



C 3 Yes Yes No

**Delayed release tabs:** 100 mg

**Injection:** 300 mg/16.7 mL (16.7 mL); contains EDTA and sulfobutyl ether- $\beta$ -cyclodextrin (SBECD)

**Oral suspension:** 40 mg/mL (105 mL); contains polysorbate 80 and sodium benzoate

**Delayed release oral suspension (Noxafil PowderMix):** 300 mg powder packet to be mixed with 9 mL of mixing liquid to yield a 30 mg/mL oral suspension (8 powder packets); contains sorbitol

**Prophylaxis for invasive *Aspergillus* and *Candida* in severely immunocompromised (e.g., hematopoietic stem cell recipients with GVHD or those with hematologic malignancies with prolonged neutropenia); duration based on recovery from neutropenia or immunosuppression (see remarks):**



**Delayed release oral suspension (Noxafil PowderMIX):**

**≥2 yr and 10–40 kg:**

**10–<12 kg:** 90 mg (3 mL) PO BID × 1 day, followed by 90 mg PO once daily

**12–<17 kg:** 120 mg (4 mL) PO BID × 1 day, followed by 120 mg PO once daily

**17–<21 kg:** 150 mg (5 mL) PO BID × 1 day, followed by 150 mg PO once daily

**21–<26 kg:** 180 mg (6 mL) PO BID × 1 day, followed by 180 mg PO once daily

**26–<36 kg:** 210 mg (7 mL) PO BID × 1 day, followed by 210 mg PO once daily

**36–40 kg:** 240 mg (8 mL) PO BID × 1 day, followed by 240 mg PO once daily

**Delayed release tablet:**

**≥2–<18 yr (>40 kg) and adult:** 300 mg PO BID × 1 day, followed by 300 mg PO once daily

**Oral suspension:**

**≥13 yr and adult:** 200 mg PO TID

*Continued*

POSACONAZOLE *continued***IV:**

≥2—<18 yr: 6 mg/kg/dose (**max. dose:** 300 mg/dose) IV BID × 1 day, followed by 6 mg/kg/dose (**max. dose:** 300 mg/dose) IV once daily

**Adult:** 300 mg IV BID × 1 day, followed by 300 mg IV once daily

**Treatment of invasive aspergillosis:**

**IV or delayed release tablet (switching between these 2 dosage forms is acceptable):**

≥13 yr and adult: 300 mg IV/PO BID × 1 day, followed by 300 mg IV/PO once daily for 6–12 weeks

**Oropharyngeal candidiasis:****Oral suspension:**

≥13 yr and adult: 100 mg PO Q12 hr × 2 doses followed by 100 mg PO Q24 hr × 13 days

**Refractory oropharyngeal candidiasis (refractory to itraconazole/fluconazole):****Oral suspension:**

≥13 yr and adult: 400 mg PO Q12 hr. Duration of therapy based on severity and response

**Contraindicated** with use of ergot alkaloids (e.g., ergotamine); major substrates for CYP

450 3A4 (e.g., atorvastatin, lovastatin, simvastatin, sirolimus); or CYP 450 3A4

medications that prolong the QTc interval (e.g., pimozide and quinidine). Also **contraindicated** in patients with CLL or SLL who are treated with venetoclax during the initiation and ramp-up phase due to the potential for increased tumor lysis syndrome. **Use with caution** with electrolyte imbalances (correct prior to use), cardiac arrhythmias, and hepatic or renal impairment. Use of IV dosage form is not recommended for eGFR <50 mL/min due to the risk for accumulation of SBECB excipient.

The delayed release oral suspension (Noxafil PowderMix) is not recommended for patients weighing >40 kg (recommended dosage cannot be achieved with this dosage form) and is **contraindicated** for use in patients with hereditary fructose intolerance (dosage form contains sorbitol).

Hypokalemia, diarrhea, nausea, vomiting, headache, and fever are common side effects. Serious reactions include hypersensitivity reactions, arrhythmias, QTc prolongation, and hepatotoxicity (consider discontinuing therapy). Pseudoaldosteronism and pancreatitis have been reported.

Posaconazole is a substrate of UDP-glucuronosyltransferase 1–4 (UGT1A4) and P-gp efflux and strong inhibitor of CYP 450 3A4 (see earlier for contraindicated substrates for concurrent use). Use with vincristine has been associated with neurotoxicity, seizures, peripheral neuropathy, SIADH, and paralytic ileus.

Oral suspension dosage form is **NOT** substitutable with delayed release tablets or delayed release oral suspension. Use respective dosage form for specific indication. Administer delayed release tablets with food to enhance absorption. **Do not** crush or chew delayed release tablets. IV dosage information is currently limited in adults.

**POTASSIUM IODIDE**

Iosat, SSKI, ThyroShield, ThyroSafe, and others

**Antithyroid agent**



D



X



Yes



No



No

**Tabs:**

**Iosat [OTC]:** 65 mg (50 mg iodine), 130 mg

**ThyroSafe [OTC]:** 65 mg

**Oral solution:**

**ThyroShield [OTC] and generics:** 65 mg/mL (30 mL); contains parabens and saccharin

**Saturated solution (SSKI):** 1000 mg/mL (30, 240 mL); 10 drops = 500 mg potassium iodide

Potassium content is 6 mEq (234 mg) K<sup>+</sup>/g potassium iodide.

**Neonatal Graves disease:** 50–100 mg (about 1–2 drops of SSKI) PO once daily

**Thyrotoxicosis:**

**Child:** 50–250 mg (about 1–5 drops of SSKI) PO TID



POTASSIUM IODIDE *continued*

**Adult:** 50–500 mg (1–10 drops of SSKI) PO TID

**Cutaneous or lymphocutaneous sporotrichosis (treat for 4–6 wk after lesions have completely healed; increase dose until either max. dose is achieved or signs of intolerance appear):**

**Child and adolescent (limited data):** 50 mg PO TID. Dose may be gradually increased as tolerated to the **max. dose** of the lesser of 50 mg/kg/dose or 2000–2500 mg PO TID.

**Adult:** Start with 250 mg PO TID. Doses may be gradually increased as tolerated to the **max. dose** of 2000–2500 mg PO TID.

**Contraindicated** in pregnancy, hyperkalemia, iodine-induced goiter, and hypothyroidism.

**Use with caution** in cardiac disease and renal failure. GI disturbance, metallic taste, rash, salivary gland inflammation, headache, lacrimation, and rhinitis are symptoms of iodism. Give with milk or water after meals. Monitor thyroid function tests. Onset of antithyroid effects: 1–2 days. Lithium carbonate and iodide-containing medications may have synergistic hypothyroid activity.

Potassium-containing medications, potassium-sparing diuretics, and ACE inhibitors may increase serum potassium levels.

For use as a thyroid blocking agent in nuclear or radiation emergencies, see

<https://www.fda.gov/drugs/bioterrorism-and-drug-preparedness/radiation-emergencies>

**POTASSIUM SUPPLEMENTS**

Many brand names and generics

**Electrolyte**



C



1



Yes



No



No

**Potassium chloride (40 mEq K = 3 g KCl):**

**Sustained release caps:** 8, 10 mEq

**Sustained release tabs:** 8, 10, 15, 20 mEq

**Powder:** 20 mEq/packet (30s, 100s)

**Oral solution/liquid:** 10% (6.7 mEq/5 mL), 20% (13.3 mEq/5 mL) (473 mL)

**Concentrated injection:** 2 mEq/mL (5, 10, 15, 20 mL)

**Potassium gluconate (40 mEq K = 9.4 g K gluconate):**

**Tabs:** 465 mg (2 mEq), 581 mg (2.5 mEq)

**Caps [OTC as K-99]:** 595 mg (2.56 mEq)

**Potassium acetate (40 mEq K = 3.9 g K acetate):**

**Concentrated injection:** 2 mEq/mL (20, 50 mL)

**Potassium bicarbonate/citric acid (10 mEq K = 1 g K bicarbonate):**

**Effervescent tab for oral solution (Effer-K):** 10, 20, 25 mEq; each 10 mEq K contains 0.84 g citric acid

**Potassium phosphate:**

See [Phosphorus Supplements](#).

**Normal daily requirements:** See [Chapter 21](#).

**Replacement:** Determine based on maintenance requirements, deficit, and ongoing losses.

See [Chapter 11](#).

**Hypokalemia:**

**Oral (mild/moderate hypokalemia):**

**Child:** 1–4 mEq/kg/24 hr ÷ BID–QID. Monitor serum potassium.

**Adult:** 40–100 mEq/24 hr ÷ BID–QID. Limit single doses by 20–25 mEq to minimize GI side effects.

**IV (severe hypokalemia):** MONITOR SERUM K CLOSELY.

**Child:** 0.5–1 mEq/kg/dose given as an infusion of 0.5 mEq/kg/hr × 1–2 hr



*Continued*

POTASSIUM SUPPLEMENTS *continued*

**Max. IV infusion rate:** 1 mEq/kg/hr. This may be used in critical situations (i.e., hypokalemia with arrhythmia).

**Adult:**

**Serum K  $\geq$ 2.5 mEq/L:** Replete at rates up to 10 mEq/hr. **Total dosage not to exceed** 200 mEq/24 hr.

**Serum K  $<$ 2.5 mEq/L:** Replete at rates up to 40 mEq/hr. **Total dosage not to exceed** 400 mEq/24 hr.

**Max. peripheral IV solution concentration:** 40 mEq/L

**Max. concentration for central line administration:** 150–200 mEq/L

PO administration may cause GI disturbance and ulceration. Oral liquid supplements should be diluted in water or fruit juice prior to administration. Sustained release tablets must be swallowed whole and **NOT** dissolved in the mouth or chewed.



**Do not administer** IV potassium undiluted. IV administration may cause irritation, pain, and phlebitis at the infusion site. **Rapid or central IV infusion may cause cardiac arrhythmias.** Patients receiving infusion  $>0.5$  mEq/kg/hr ( $>20$  mEq/hr for adults) should be placed on an ECG monitor.

**PRALIDOXIME CHLORIDE + ATROPINE**

Protopam, 2-PAM, and generics

In combination with atropine: Duodote, ATNAA

**Antidote, organophosphate poisoning**



C



?



Yes



Yes



No

**Injection (Protopam):** 1000 mg

**In combination with atropine (Duodote, ATNNA):**

**Injection for intramuscular injection in autoinjector device:** 600 mg/2 mL of pralidoxime and 2.1 mg/0.7 mL of atropine; contains benzyl alcohol. Duodote or ATNNA must be administered by emergency medical services personnel who have had adequate training in the recognition and treatment of nerve agent or insecticide intoxication.

**Organophosphate poisoning (use with atropine):**

**Child:**

**IV intermittent:** 20–50 mg/kg/dose (**max. dose:** 2000 mg)  $\times$  1 IV. May repeat in 1–2 hr if muscle weakness is not relieved, then at Q10–12 hr PRN if cholinergic signs reappear.

**IV continuous infusion:** Loading dose of 20–50 mg/kg/dose (**max. dose:** 2000 mg) IV over 15–30 min followed by 10–20 mg/kg/hr (**max. dose:** 500 mg/hr)

**IM (use when IV route not feasible):**

**$<40$  kg:** 15 mg/kg/dose  $\times$  1 IM. May repeat Q15 min PRN up to a **max. total dose** of 45 mg/kg for mild symptoms; may repeat twice in rapid succession for severe symptoms (**max. total dose** of 45 mg/kg). For persistent symptoms, may repeat another maximum 45 mg/kg series (in 3 divided doses) approximately 1 hr after the last injection.

**$\geq 40$  kg:** 600 mg  $\times$  1 IM. May repeat Q15 min PRN up to a **max. total dose** of 1800 mg for mild symptoms; may repeat twice in rapid succession for severe symptoms (**max. total dose** of 1800 mg). For persistent symptoms, may repeat another **max.** 1800 mg series (in 3 divided doses) approximately 1 hr after the last injection.

**Adult:**

**IV intermittent:** 1–2 g/dose  $\times$  1 IV. May repeat in 1–2 hr if muscle weakness is not relieved, then at Q10–12 hr PRN if cholinergic signs reappear.

**IM:** Use aforementioned  $\geq 40$  kg child IM dosage.

**In combination with atropine (Duodote, ATNNA; see remarks for description of symptoms):**

**Child and adult  $>41$  kg:**

PRALIDOXIME CHLORIDE + ATROPINE *continued*

**Mild symptoms of nerve agent or insecticide exposure:** Inject one prefilled syringe IM  $\times$  1 and wait 10–15 min for effect. If severe symptoms emerge at any time after the first dose, inject 2 additional prefilled syringes IM in rapid succession.

**Severe symptoms of nerve agent or insecticide exposure:** Inject three prefilled syringes IM in rapid succession.

**Contraindicated** in poisonings due to phosphorus, inorganic phosphates, or organic phosphates without anticholinesterase activity. **Do not use** as an antidote for carbamate classes of pesticides. Removal of secretions and maintaining a patent airway are critical. May cause muscle rigidity, laryngospasm, and tachycardia after rapid IV infusion. Drug is generally ineffective if administered 36–48 hr after exposure. Additional doses may be necessary.



For IV administration, dilute to 50 mg/mL or less and infuse over 15–30 min (**not to exceed** 200 mg/min). Reduce dosage in renal impairment since 80%–90% of the drug is excreted unchanged in the urine 12 hr after administration. Severe hepatic impairment may require less frequent doses after the initial dose for both IV and IM routes.

**Pralidoxime and atropine combination (Duodote):** Signs of atropine effects/toxicity may occur earlier than when atropine is used alone. Safety and efficacy data are only available for children and adults >41 kg (90 lb). Duodote product information description of mild and severe symptoms:

Mild symptoms: Increased airway secretions, blurred vision, bradycardia, breathing difficulties, chest tightness, drooling, miosis, nausea, vomiting, runny nose, salivation, stomach cramps (acute onset), tachycardia, teary eyes, tremors/muscular twitching, wheezing/coughing

Severe symptoms: Breathing difficulties (severe), confused/strange behavior, convulsions, copious secretions from lung or airways, involuntary urination/defecation, muscular twitching/generalized weakness (severe), unconsciousness

IM injection is via the midlateral thigh.

**PREDNISOLONE**

Oral products:

Orapred ODT, Pediapred, and generics; previously available as Prelone

Ophthalmic products:

Pred Forte, Pred Mild, Econopred, and generics

**Corticosteroid**



C/D

2

No

No

No

**Tabs:** 5 mg

**Oral solution (generics):** 15 mg/5 mL (240 mL); may contain alcohol and saccharin

**Tablets, orally disintegrating (as Na phosphate) (Orapred ODT and generics):** 10, 15, 30 mg

**Oral solution/syrup (as Na phosphate):**

**Pediapred and generics:** 5 mg/5 mL (120 mL); alcohol and dye free

**Generics:** 10 mg/5 mL (237 mL), 15 mg/5 mL (237 mL), 20 mg/5 mL (237 mL), 25 mg/5 mL (237 mL); may contain parabens, alcohol; some preparations may be dye free

**Ophthalmic suspension (as acetate; both strengths contain benzalkonium chloride and may contain bisulfites):**

**Pred Mild:** 0.12% (5, 10 mL)

**Econopred:** 0.125% (5, 10 mL)

**PredForte, Econopred Plus, and generics:** 1% (5, 10, 15 mL)

**Ophthalmic solution (as Na phosphate):** 1% (10 mL); may contain benzalkonium chloride

See [Prednisonone](#) for systemic oral dosing (equivalent dosing).

**Ophthalmic (consult ophthalmologist before use; see remarks):**



*Continued*

PREDNISOLONE *continued***Ophthalmic suspension:**

**Child (limited data) and adult:** 1–2 drops to the conjunctival sac of the affected eye(s) BID–QID (dosage frequency may be increased during initial 24–48 hr if needed). Reevaluate patient if signs and symptoms do not improve after 2 days.

**Ophthalmic solution:**

**Child and adult:** Start with 1–2 drops Q1 hr during the day and Q2 hr during the night until favorable response, then reduce dose to 1 drop Q4 hr. Dose may be further reduced to 1 drop TID–QID.

See [Prednisone](#) for remarks. See [Chapter 10](#) for relative steroid potencies. Pregnancy category changes to “D” if used in the first trimester.



**OPHTHALMIC USE: Contraindicated** in viral (e.g., herpes simplex, vaccinia, and varicella), fungal, and mycobacterial infections of the cornea and conjunctiva. Increase in intraocular pressure, cataract formation, eye pain, and delayed wound healing may occur.

**PREDNISONE**

Deltasone, Rayos, and generics

**Corticosteroid**

C/D



2



No



Yes



No

**Tabs (Deltasone and generics):** 1, 2.5, 5, 10, 20, 50 mg

**Delayed release tabs (Rayos):** 1, 2, 5 mg

**Oral solution:** 1 mg/mL (120, 500 mL); may contain 5% alcohol and saccharin

**Concentrated solution (Prednisone Intensol):** 5 mg/mL (30 mL); contains 30% alcohol

**Acute asthma:**

**Child:** 2 mg/kg/24 hr PO ÷ once daily–BID × 5–7 days; **max. dose:** 80 mg/24 hr.

Patients may benefit from tapering if therapy exceeds 5–7 days.

**Acute exacerbation in emergency care or hospital (2007 National Heart, Lung, and Blood Institute [NHLBI] Guideline Recommendations; dose until peak expiratory flow reaches 70% of predicted or personal best):**

**Child ≤12 yr:** 1–2 mg/kg/24 hr PO ÷ Q12 hr (**max. dose:** 60 mg/24 hr)

**Child >12 yr and adult:** 40–80 mg/24 hr PO ÷ Q12–24 hr

**Outpatient asthma exacerbation burst therapy (2007 NHLBI guidelines; therapy should be continued until symptoms resolve or until peak expiratory flow reaches 80% of personal best; usual therapy duration 3–10 days [average ~5 days]; longer durations may be necessary):**

**Child ≤12 yr:** 1–2 mg/kg/24 hr PO ÷ Q12–24 hr (**max. dose:** 60 mg/24 hr)

**Child >12 yr and adult:** 40–60 mg/24 hr PO ÷ Q12–24 hr

**Acute exacerbation in primary care or acute care facility (2020 Global Initiative for Asthma [GINA] Guidelines):**

**Infant and child:** 1–2 mg/kg/24 hr PO once daily × 3–5 days with the following **maximum dose** by age:

**Infant and child ≤2 yr:** 20 mg/24 hr

**Child 3–5 yr:** 30 mg/24 hr

**Child 6–11 yr:** 40 mg/24 hr

**Child >12 yr and adolescent:** 1 mg/kg/24 hr (**max. dose:** 50 mg/24 hr) PO once daily × 5–7 days

**Antiinflammatory/immunosuppressive:**

**Child:** 0.5–2 mg/kg/24 hr PO ÷ once daily–BID

**Nephrotic syndrome:**

PREDNISONE *continued*

**Child (use ideal body weight for obese patients):** Starting dose of 2 mg/kg/24 hr PO (max. dose: 60 mg/24 hr) ÷ once daily—TID is recommended. Further treatment plans are individualized. Consult a nephrologist.

See Chapter 10 for physiologic replacement, relative steroid potencies, and doses based on body surface area.

Despite requiring hepatic metabolism to its active form (prednisolone), patients with liver disease have reported higher prednisolone levels than that of normal patients. Methylprednisolone or prednisolone may be preferable in hepatic disease.

Side effects may include: mood changes, seizures, hyperglycemia, diarrhea, nausea, abdominal distension, GI bleeding, HPA axis suppression, osteopenia, cushingoid effects, and cataracts with prolonged use. Prednisone is a CYP 450 3A3/4 substrate and inducer. Barbiturates, carbamazepine, phenytoin, rifampin, and isoniazid may reduce the effects of prednisone, whereas estrogens may enhance the effects. Pregnancy category changes to “D” if used in the first trimester.

## PRIMAQUINE PHOSPHATE

Various generics

**Antimalarial**



X



3



No



No



No

**Tab:** 26.3 mg (15 mg base)

**Oral suspension:** 10.52 mg (6 mg base)/5 mL



**Doses expressed in mg of primaquine base:**

**Malaria:**

**Prevention of relapses for *Plasmodium vivax* or *Plasmodium ovale* only (initiate therapy during the last 2 wk of, or following a course of, suppression with chloroquine or comparable drug):**

**Child:** 0.5 mg/kg/dose (max. dose: 30 mg/dose) PO once daily × 14 days

**Adult:** 30 mg PO once daily × 14 days

**Prevention of chloroquine-resistant strains (initiate 1 day prior to departure and continued until 7 days after leaving endemic area):**

**Child:** 0.5 mg/kg/dose PO once daily; max. dose: 30 mg/24 hr

**Adult:** 30 mg PO once daily

***P. jirovecii* (carinii) pneumonia (in combination with clindamycin):**

**Child:** 0.3 mg/kg/dose (max. dose: 30 mg/dose) PO once daily × 21 days

**Adult:** 30 mg PO once daily × 21 days

**Contraindicated** in granulocytopenia (e.g., rheumatoid arthritis, lupus erythematosus)

and bone marrow suppression. **Avoid use** with quinacrine and with other drugs that have a potential for causing hemolysis or bone marrow suppression. **Use with caution** in patients with G6PD and NADH methemoglobin-reductase deficiency due to increased risk for hemolytic anemia and leukopenia, respectively. Monitor ECG for QTc prolongation in patients with cardiac disease, history of arrhythmias, uncorrected hypokalemia and/or hypomagnesemia, bradycardia, and receiving concomitant QTc prolonging medications. Use in pregnancy is **not recommended** by the AAP Red Book. Cross sensitivity with iodoquinol.

May cause headache, visual disturbances, nausea, vomiting, and abdominal cramps. Hemolytic anemia, leukopenia, cardiac arrhythmia, QTc interval prolongation, and methemoglobinemia have been reported. Administer all doses with food to mask bitter taste.

**PRIMIDONE**

Mysoline and generics

**Anticonvulsant, barbiturate**



D

2

Yes

Yes

No

**Tabs:** 50, 250 mg

**Neonate:** 12–20 mg/kg/24 hr PO ÷ BID–QID; initiate therapy at the lower dosage range and titrate upward.

**Child, adolescent, and adult:**



Day of Therapy	<8 Yr	≥8 Yr and Adult
Days 1–3	50 mg PO QHS	100–125 mg PO QHS
Days 4–6	50 mg PO BID	100–125 mg PO BID
Days 7–9	100 mg PO BID	100–125 mg PO TID
Day 10 and thereafter	125–250 mg PO TID or 10–25 mg/kg/ 24 hr ÷ TID–QID	250 mg PO TID–QID; <b>max. dose:</b> 2 g/24 hr

**Use with caution** in renal or hepatic disease and pulmonary insufficiency. Primidone is metabolized to phenobarbital and has the same drug interactions and toxicities (see [Phenobarbital](#)). In addition, primidone may cause vertigo, nausea, leukopenia, malignant lymphoma-like syndrome, diplopia, nystagmus, and systemic lupus-like syndrome. Monitor for suicidal behavior or ideation. Acetazolamide may decrease primidone absorption. **Adjust dose in renal failure (see Chapter 31).**



Monitor both primidone and phenobarbital levels. Therapeutic levels: 5–12 mg/L of primidone and 15–40 mg/L of phenobarbital. Recommended serum sampling time at steady state: trough level obtained within 30 min prior to the next scheduled dose after 1–4 days of continuous dosing.

**PROBENECID**

Various generics

**Penicillin therapy adjuvant, uric acid–lowering agent**



B

?

Yes

No

No

**Tabs:** 500 mg

**To prolong penicillin levels.**

**Child (2–14 yr):** 25 mg/kg PO × 1, then 40 mg/kg/24 hr ÷ QID; **max. single dose:** 500 mg/dose. Use adult dose if >50 kg.

**Adult:** 500 mg PO QID

**Hyperuricemia with gout:**

**Adult:** 250 mg PO BID × 1 wk, then 500 mg PO BID; may increase by 500 mg increments Q4 wk PRN up to a **max. dose** of 2–3 g/24 hr ÷ BID

**Gonorrhea, antibiotic adjunct (administer just prior to antibiotic):**

≤45 kg: 23 mg/kg/dose PO × 1

>45 kg: 1 g PO × 1

**Prevention of nephrotoxicity from cidofovir:** See [Cidofovir](#).

**Use with caution** in patients with peptic ulcer disease. **Contraindicated** in children <2 yr and patients with renal insufficiency. **Do not use** if GFR <30 mL/min.




PROBENECID *continued*

Increases uric acid excretion. Inhibits renal tubular secretion of acyclovir, ganciclovir, ciprofloxacin, levofloxacin, nalidixic acid, moxifloxacin, organic acids, penicillins, cephalosporins, AZT, dapsone, methotrexate, nonsteroidal antiinflammatory agents, and benzodiazepines. Salicylates may decrease probenecid's activity. Alkalinize urine in patients with gout. May cause headache, GI symptoms, rash, anemia, and hypersensitivity. False-positive glucosuria with Clinitest may occur.

**PROCHLORPERAZINE**

Compro and generics; previously available as Compazine

**Antiemetic, phenothiazine derivative**



C

2

No

No

No

**Tabs (as maleate):** 5, 10 mg

**Suppository (Compro and generics):** 25 mg (12s)

**Injection (as edisylate):** 5 mg/mL (2 mL); may contain benzyl alcohol

**Antiemetic doses:**

**Child (≥2 yr and ≥9 kg):**

**PO or PR:** 0.4 mg/kg/24 hr ÷ TID—QID PRN (**max. dose:** 10 mg/dose) or alternative dosing by weight:

**9–13 kg:** 2.5 mg once daily—BID PRN; **max. dose:** 7.5 mg/24 hr

**>13–18 kg:** 2.5 mg BID—TID PRN; **max. dose:** 10 mg/24 hr

**>18–39 kg:** 2.5 mg TID or 5 mg BID PRN; **max. dose:** 15 mg/24 hr

**>39 kg:** Use adult dose.

**IM:** 0.1–0.15 mg/kg/dose BID—TID PRN; **max. dose:** 10 mg/single dose or 40 mg/24 hr

**Adult:**

**PO:** 5–10 mg/dose TID—QID PRN; **max. dose:** 40 mg/24 hr

**PR:** 25 mg/dose BID PRN

**IM:** 5–10 mg/dose Q3–4 hr PRN

**IV:** 2.5–10 mg/dose; may repeat Q3–4 hr PRN

**Max. IM/IV dose:** 40 mg/24 hr

**Psychoses:**

**Child 2–12 yr and >9 kg:**

**PO:** Start with 2.5 mg BID—TID with a **max. first-day dose** of 10 mg/24 hr. Dose may be increased as needed to 20 mg/24 hr for children 2–5 yr and 25 mg/24 hr for 6–12 yr.

**IM:** 0.13 mg/kg/dose × 1 and convert to PO immediately

**Adult:**

**PO:** 5–10 mg TID—QID; may be increased as needed to a **max. dose** of 150 mg/24 hr

**IM:** 10–20 mg Q2–4 hr PRN; convert to PO immediately

**Intractable migraines:**

**Child (5–18 yr, limited data):** 0.15 mg/kg/dose (**max. dose:** 10 mg/dose) IV over 10 min was effective in migraine headaches presenting in the emergency departments (see *Ann Emerg Med.* 2004;43:256–262).

Toxicity as for other phenothiazines (see [Chlorpromazine](#)). Extrapyramidal reactions (reversed by diphenhydramine) or orthostatic hypotension may occur. May mask signs and symptoms of overdose of other drugs and may obscure the diagnosis and treatment of conditions such as intestinal obstruction, brain tumor, and Reye syndrome. May cause false-positive test for phenylketonuria, urinary amylase, uroporphyrins, and urobilinogen. **Do not use** IV route in children. Use only in management of prolonged vomiting of known etiology.



**PROMETHAZINE**

Phenergan, Promethegan, and generics

**Antihistamine, antiemetic, phenothiazine derivative**

C



3



No



No



No

**Tabs:** 12.5, 25, 50 mg**Oral solution/syrup:** 6.25 mg/5 mL (473 mL); contains alcohol and may contain parabens, sodium benzoate, or phenol (many formulations exist)**Suppository (Phenadoz, Promethegan, and generics):** 12.5, 25, 50 mg (12s)**Injection:** 25, 50 mg/mL (1 mL); may contain edetate disodium, sulfites, and phenol**Antihistaminic:****Child ≥2 yr:** 0.1 mg/kg/dose (**max. dose:** 12.5 mg/dose) Q6 hr PO during the day hours and 0.5 mg/kg/dose (**max. dose:** 25 mg/dose) QHS PO PRN**Adult:** 6.25–12.5 mg PO/PR TID and 25 mg QHS**Nausea and vomiting PO/IM/IV/PR (see remarks):****Child ≥2 yr:** 0.25–1 mg/kg/dose Q4–6 hr PRN; **max. dose:** 25 mg/dose**Adult:** 12.5–25 mg Q4–6 hr PRN**Motion sickness:** (1st dose 0.5–1 hr before departure):**Child ≥2 yr:** 0.5 mg/kg/dose Q12 hr PO/PR PRN; **max. dose:** 25 mg/dose**Adult:** 25 mg PO Q8–12 hr PRN

**Avoid** use in children <2 yr because of risk for fatal respiratory depression. Toxicity similar to other phenothiazines (see [Chlorpromazine](#)). **Do not** administer SC or intra-arterially because of severe local reactions. IV route of administration is **not recommended** (IM preferred) due to severe tissue injury (tissue necrosis and gangrene). If using IV route, dilute 25 mg/mL strength product with 10–20 mL NS and administer over 10–15 min, consider lower initial doses, administer through a large-bore vein and check patency of line before administering, administer through an IV line at the port farthest from the patient's vein, and monitor for burning or pain during or after injection. Administer oral doses with meals to decrease GI irritation.

May cause profound sedation, blurred vision, respiratory depression (use lowest effective dose in children and **avoid** concomitant use of respiratory depressants), and dystonic reactions (reversed by diphenhydramine). Cholestatic jaundice and neuroleptic malignant syndrome has been reported. May interfere with pregnancy tests (immunologic reactions between hCG and anti-hCG). **For nausea and vomiting, use only in management of prolonged vomiting of known etiology.**

**PROPRANOLOL**

Inderal, Inderal LA, Hemangeol, and generics

**Adrenergic blocking agent (β), class II antiarrhythmic**

C/D



1



Yes



Yes



No

**Tabs:** 10, 20, 40, 60, 80 mg**Extended release caps (Inderal LA and others, including generics):** 60, 80, 120, 160 mg**Oral solution:** 20 mg/5 mL, 40 mg/5 mL; contains parabens and saccharin**Hemangeol:** 4.28 mg/mL (120 mL); alcohol, sugar and paraben free; contains saccharin**Injection:** 1 mg/mL (1 mL)**Arrhythmias:****Child:****IV:** 0.01–0.1 mg/kg/dose IV push over 10 min, repeat Q6–8 hr PRN; **max. dose:** 1 mg/dose for infant; 3 mg/dose for child

PROPRANOLOL *continued*

**PO:** Start at 0.5–1 mg/kg/24 hr ÷ Q6–8 hr; increase dosage Q3–5 days PRN. Usual dosage range: 2–4 mg/kg/24 hr ÷ Q6–8 hr; **max. dose:** 60 mg/24 hr or 16 mg/kg/24 hr

**Adult:**

**IV:** 1 mg/dose Q5 min up to total 5 mg

**PO:** 10–30 mg/dose TID–QID; increase PRN. Usual range 30–160 mg/24 hr ÷ TID–QID

**Hypertension (as alternative therapy):****Child:**

**PO:** Initial: 0.5–1 mg/kg/24 hr ÷ Q6–12 hr. May increase dose Q5–7 days PRN; **max. dose:** 8 mg/kg/24 hr

**Adult:**

**PO:** 40 mg/dose PO BID or 60–80 mg/dose (sustained release capsule) PO once daily. May increase 10–20 mg/dose Q3–7 days; **max. dose:** 640 mg/24 hr

**Migraine prophylaxis:****Child:**

**<35 kg:** Start with 10 mg PO once daily and increase dose PRN weekly intervals at 10 mg increments. Usual dosage range: 10–20 mg PO TID

**≥35 kg:** 20–40 mg PO TID

**Adult:** 80 mg/24 hr ÷ Q6–8 hr PO; increase dose by 20–40 mg/dose Q3–4 wk PRN. Usual effective dose range: 160–240 mg/24 hr

**Tetralogy spells:**

**IV:** 0.15–0.25 mg/kg/dose slow IV push. May repeat in 15 min × 1. See also [Chapter 7](#).

**PO:** Start at 2–4 mg/kg/24 hr ÷ Q6 hr PRN. Usual dose range: 4–8 mg/kg/24 hr ÷ Q6 hr PRN. Doses as high as 15 mg/kg/24 hr have been used with careful monitoring.

**Thyrotoxicosis:**

**Neonate:** 0.5–2 mg/kg/24 hr PO ÷ Q6–12 hr

**Infant and child:** 0.5–2 mg/kg/24 hr PO ÷ Q8 hr; **max. dose:** 40 mg/dose

**Adolescent and adult:**

**IV:** 1–3 mg/dose over 10 min. May repeat in 4–6 hr

**PO:** 10–40 mg/dose PO Q6 hr

**Infantile hemangioma (see remarks):**

**Infant (5 wk–5 mo and ≥2 kg; labeled dosing information for Hemangeol product):** 0.6 mg/kg/dose BID PO (at least 9 hr apart) × 7 days, then increase to 1.1 mg/kg/dose BID PO × 14 days, followed by 1.7 mg/kg/dose BID PO × 6 mo

**Alternative dosing:** Start at 1 mg/kg/24 hr ÷ Q8 hr PO. If tolerated after 1 day, increase dose to 2 mg/kg/24 hr ÷ Q8 hr PO

**Contraindicated** in asthma, Raynaud syndrome, heart failure, and heart block. **Not indicated** for the treatment of hypertensive emergencies. **Use with caution** in presence of obstructive lung disease, diabetes mellitus, or renal or hepatic disease. May cause hypoglycemia, hypotension, nausea, vomiting, depression, weakness, impotence, bronchospasm, and heart block. Cutaneous reactions, including Stevens-Johnson, TEN, exfoliative dermatitis, erythema multiforme, and urticaria have been reported. Acute hypertension has occurred after insulin-induced hypoglycemia in patients on propranolol.



Therapeutic levels for beta-blockade: 50–100 ng/mL; ventricular arrhythmia: 40–85 ng/mL. Drug is metabolized by CYP 450 1A2, 2C18, 2C19, and 2D6 isoenzymes. Concurrent administration with barbiturates, indomethacin, or rifampin may cause decreased activity of propranolol. Concurrent administration with cimetidine, hydralazine, flecainide, quinidine, chlorpromazine, or verapamil may lead to increased activity of propranolol. **Avoid** IV use of propranolol with calcium channel blockers; may increase effect of calcium channel blocker. Use with amiodarone may increase negative chronotropic effects.

*Continued*

PROPRANOLOL *continued*

For infantile hemangioma, monitor BP and HR 2 hr after initiating therapy and after dose increases. To reduce risk of hypoglycemia, administer doses during or right after a feeding; hold doses if child is not eating or is vomiting. Infants <6 mo must be fed every 4 hr. Common adverse effects (>10%) reported in clinical trials with Hemangeol include sleep disorders, aggravated respiratory tract infections (e.g., bronchitis and bronchiolitis) associated with cough/fever, diarrhea, and vomiting. Readjust dose periodically with changes (increases) in child's body weight.

Successful use in infantile hepatic hemangiomas has also been reported.

Pregnancy category changes to "D" if used in second or third trimesters.

**PROPYLTHIOURACIL**

PTU and generics

**Antithyroid agent**



D



2



Yes



Yes



No

**Tabs:** 50 mg

**Oral suspension:** 5 mg/mL 

100 mg PTU = 10 mg methimazole

**Dosages should be adjusted as required to achieve and maintain T<sub>4</sub>, TSH levels in normal ranges.**



**Neonate:** 5–10 mg/kg/24 hr ÷ Q8 hr PO

**Child:**

**Initial:** 5–7 mg/kg/24 hr ÷ Q8 hr PO, OR by age:

**6–10 yr:** 50–150 mg/24 hr ÷ Q8 hr PO

**>10 yr:** 150–300 mg/24 hr ÷ Q8 hr PO

**Maintenance:** Generally begins after 2 mo. Usually 1/3–2/3 the initial dose in divided doses (Q8–12 hr) when the patient is euthyroid

**Adult:**

**Initial:** 300–400 mg/24 hr ÷ Q6–8 hr PO; some may require larger doses of 600–900 mg/24 hr

**Maintenance:** 100–150 mg/24 hr ÷ Q8 hr PO

Generally reserved for patients who are unable to tolerate methimazole and for whom radioactive iodine or surgery is not appropriate. May be the antithyroid treatment of choice during or just prior to the first trimester of pregnancy because of risk of fetal abnormalities associated with methimazole.



May cause blood dyscrasias, fever, liver disease, dermatitis, urticaria, malaise, CNS stimulation or depression, and arthralgias. Glomerulonephritis, severe liver injury/failure, agranulocytosis, severe vasculitis, interstitial pneumonitis, exfoliative dermatitis, and erythema nodosum have also been reported. May decrease the effectiveness of warfarin. Monitor thyroid function. A dose reduction of  $\beta$ -blocker may be necessary when the hyperthyroid patient becomes euthyroid.

For neonates, crush tablets, weigh appropriate dose, and mix in formula/breast milk. **Adjust dose in renal failure (see Chapter 31).**

**PROSTAGLANDIN E<sub>1</sub>**

See [Alprostadil](#).

**PROTAMINE SULFATE**

Various generics

**Antidote, heparin**



C



?



No



No



No

PROTAMINE SULFATE *continued*

**Injection:** 10 mg/mL (5, 25 mL); preservative free

**Heparin antidote, IV:**

1 mg protamine will neutralize 115 U porcine intestinal heparin, or 100 U (1 mg) low-molecular-weight heparin

**Consider time since last heparin dose:**

**If <0.5 hr:** Give 100% of specified dose.

**If within 0.5–1 hr:** Give 50%–75% of aforementioned dose.

**If within 1–2 hr:** Give 37.5%–50% of aforementioned dose.

**If ≥2 hr:** Give 25%–37.5% of aforementioned dose.

**Max. dose:** 50 mg/dose IV

**Max. infusion rate:** 5 mg/min

**Max. IV concentration:** 10 mg/mL

**If heparin was administered by deep SC injection, give 1–1.5 mg protamine per 100 U heparin as follows:**

Load with 25–50 mg via slow IV infusion followed by the rest of the calculated dose via continuous infusion over 8–16 hr or the expected duration of SC heparin absorption.

**Enoxaparin overdose, IV (see remarks):** Approximately 1 mg protamine will neutralize 1 mg enoxaparin.

**Consider time since last enoxaparin dose:**

**If <8 hr:** Give 100% of aforementioned dose.

**If within 8–12 hr:** Give 50% of aforementioned dose.

**If >12 hr:** Protamine not required but if serious bleeding is present, give 50% of aforementioned dose.

If aPTT remains prolonged 2–4 hr after the first protamine dose or if bleeding continues, a second infusion of 0.5 mg protamine per 1 mg enoxaparin may be given.

**Max. dose:** 50 mg/dose. See aforementioned heparin antidote IV dosage for **max.** administration concentration and rate.

Risk factors for protamine hypersensitivity include known hypersensitivity to fish and exposure to protamine-containing insulin or prior protamine therapy.

May cause hypotension, bradycardia, dyspnea, and anaphylaxis. Monitor aPTT or ACT. Heparin rebound with bleeding has been reported to occur 8–18 hr later.

Use in enoxaparin overdose may not be complete despite using multiple doses of protamine.

**PSEUDOEPHEDRINE**

Sudafed, Sudafed 12 Hour, Sudafed 24 Hour, and generics

**Sympathomimetic, nasal decongestant**



C



2



Yes



No



No

**Tabs (OTC):** 30, 60 mg

**Extended release tab (OTC):**

**Sudafed 12 Hour and generics:** 120 mg

**Sudafed 24 Hour:** 240 mg

**Oral liquid (OTC):** 15 mg/5 mL (120 mL); may contain sodium benzoate

Purchases of OTC products are limited to behind the pharmacy counter sales with monthly sale limits due to the methamphetamine epidemic.

**Child <12 yr:** 4 mg/kg/24 hr ÷ Q6 hr PO or by age:

**<4 yr:** 4 mg/kg/24 hr ÷ Q6 hr PO; **max. dose:** 60 mg/24 hr

**4–5 yr:** 15 mg/dose Q4–6 hr PO; **max. dose:** 60 mg/24 hr

**6–12 yr:** 30 mg/dose Q4–6 hr PO; **max. dose:** 120 mg/24 hr

*Continued*

PSEUDOEPHEDRINE *continued***Child ≥12 yr and adult:**

**Immediate release:** 60 mg/dose Q4–6 hr PO; **max. dose:** 240 mg/24 hr

**Sustained release:**

**Sudafed 12 Hour and generics:** 120 mg PO Q12 hr

**Sudafed 24 Hour:** 240 mg PO Q24 hr

**Contraindicated** with MAO inhibitor drugs and in severe hypertension and severe coronary artery disease. **Use with caution** in mild/moderate hypertension, hyperglycemia, hyperthyroidism, and cardiac disease. May cause dizziness, nervousness, restlessness, insomnia, and arrhythmias. Pseudoephedrine is a common component of OTC cough and cold preparations and is combined with several antihistamines; these products are not recommended for children <6 yr. Since drug and active metabolite are primarily excreted renally, **doses should be adjusted in renal impairment**. May cause false-positive test for amphetamines (EMIT assay).

**PSYLLIUM**

Metamucil, Konsyl, Mucilin, and many others, including some generics

**Bulk-forming laxative**



B



1



No



No



No

**Check specific product label for amount of psyllium per unit of measurement.**

**Granules [OTC]:**

Konsyl: 4.3 g psyllium per rounded teaspoon or 6 g of granules (300 g); contains maltodextrin and 35 mg potassium for each 6 g dose; sugar and gluten free

**Powder [OTC]:**

Metamucil: 3.4 g psyllium per rounded teaspoon; contains 5 mg sodium, 30 mg potassium, and 25 mg phenylalanine for each teaspoon. Other products may contain sucrose or maltodextrin instead of phenylalanine.

3.4 g psyllium hydrophilic mucilloid is equivalent to 2 g soluble fiber

**Constipation (granules or powder must be mixed with a full glass [240 mL] of water or juice):**

**<6 yr:** 1.25–2.5 g/dose PO once daily–TID; **max. dose:** 7.5 g/24 hr

**6–11 yr:** 2.5–3.75 g/dose PO once daily–TID; **max. dose:** 15 g/24 hr

**≥12 yr and adult:** 2.5–7.5 g/dose PO once daily–TID; **max. dose:** 30 g/24 hr



**Contraindicated** in cases of fecal impaction or GI obstruction. **Use with caution** in patients with esophageal strictures and rectal bleeding. Phenylketonurics should be aware that certain preparations may contain aspartame. Should be taken or mixed with a full glass (240 mL) of liquid. Onset of action: 12–72 hr.

**PYRANTEL PAMOATE**

Reese's Pinworm Medicine, Pin-Away, and many other generics

**Anthelmintic**



C



2



No



Yes



No

**Oral suspension (OTC):** 50 mg/mL pyrantel base (144 mg/mL pyrantel pamoate) (30, 60, 473 mL); may contain sodium benzoate, parabens, and saccharin

**Tabs (OTC):** 62.5 mg pyrantel base (180 mg pyrantel pamoate); scored tablet

**All doses expressed in terms of pyrantel base.**



PYRANTEL PAMOATE *continued***Child (≥2 yr), adolescent, and adult:****Ascaris (roundworm) and Trichostrongylus:** 11 mg/kg/dose PO × 1**Enterobius (pinworm):** 11 mg/kg/dose PO × 1. Repeat same dose 2 wk later.**Hookworm or eosinophilic enterocolitis:** 11 mg/kg/dose PO once daily × 3 days**Moniliformis:** 11 mg/kg/dose PO Q2 wk × 3 doses**Max. dose (all indications):** 1 g/dose

**Use with caution** in liver dysfunction. **Do not use** in combination with piperazine because of antagonism. May cause nausea, vomiting, anorexia, transient AST elevations, headaches, rash, and muscle weakness. Limited experience in children <2 yr. May increase theophylline levels. Drug may be mixed with milk or fruit juice and may be taken with food.

**PYRAZINAMIDE**

Pyrazinoic acid amide and generics

**Antituberculous agent**

C



2



Yes



Yes



No

**Tabs:** 500 mg**Oral suspension:** 100 mg/mL **In combination with isoniazid and rifampin (Rifater):****Tabs:** 300 mg with 50 mg isoniazid and 120 mg rifampin; contains povidone and propylene glycol

**Tuberculosis:** Use as part of a multidrug regimen for tuberculosis. See latest edition of the AAP Red Book for recommended treatment for tuberculosis.

**Child:****<40 kg:****Daily dose regimen:** 30–40 mg/kg/24 hr PO once daily; **max. dose:** 2 g/24 hr**Twice-weekly dose regimen:** 50 mg/kg/dose PO 2× per week; **max. dose:** 2 g/dose**≥40 kg:** Use adult dosage below.**Adult:****Daily dose regimen:****40–55 kg:** 1000 mg PO once daily**56–75 kg:** 1500 mg PO once daily**76–90 kg:** 2000 mg PO once daily**Twice-weekly dose regimen:****40–55 kg:** 2000 mg PO 2× per week**56–75 kg:** 3000 mg PO 2× per week**76–90 kg:** 4000 mg PO 2× per week

See latest edition of the AAP Red Book for recommended treatment for tuberculosis.

**Contraindicated** in severe hepatic damage and acute gout. The CDC and ATS **do not recommend** the combination of pyrazinamide and rifampin for latent TB infections.

**Use with caution** in patients with renal failure (dosage reduction has been recommended), gout, or diabetes mellitus. Monitor liver function tests (baseline and periodic) and serum uric acid.

Hepatotoxicity is most common dose-related side effect; doses ≤30 mg/kg/24 hr minimize effect. Hyperuricemia, maculopapular rash, arthralgia, fever, acne, porphyria, dysuria, and photosensitivity may occur. Severe hepatic toxicity may occur with rifampin use. May decrease isoniazid levels.



**PYRETHRINS WITH PIPERONYL BUTOXIDE**

A-200, Pronto Plus, RID, and many others

**Pediculicide**

C

2

No

No

No

**All products are available OTC without a prescription.****Shampoo (RID, Pronto Plus, A-200):** 0.33% pyrethrins and 4% piperonyl butoxide (60, 120, 240 mL); may contain alcohol**Pediculosis ( $\geq 2$  yr and adult):** Apply to dry hair or affected body area for 10 min, then wash thoroughly and comb with fine-tooth comb or nit-removing comb; repeat in 7–10 days.**Contraindicated** in ragweed hypersensitivity; drug is derived from the chrysanthemum flowers. For topical use only. **Avoid** use in and around the eyes, mouth, nose, or vagina.**Avoid** repeat applications in <24 hr. Low ovicidal activity requires repeat treatment. Dead nits require mechanical removal. Wash bedding and clothing to eradicate infestation.

Local irritation, including erythema, pruritus, urticaria, edema, and eczema, may occur.

**PYRIDOSTIGMINE BROMIDE**

Mestinon, Regonol, and generics

**Cholinergic agent**

C

1

Yes

No

No

**Oral syrup (Mestinon):** 60 mg/5 mL (473 mL); contains 5% alcohol and sodium benzoate**Tabs (Mestinon and generics):** 30, 60 mg**Sustained release tab (Mestinon and generics):** 180 mg; scored tablet**Injection (Regonol):** 5 mg/mL (2 mL); may contain 1% benzyl alcohol**Myasthenia gravis:****Neonate:****PO:** 1 mg/kg/dose Q4 hr; **max. dose:** 7 mg/kg/24 hr**IM/IV:** 0.05–0.15 mg/kg/dose Q4–6 hr; **max.** single IM/IV dose: 10 mg**Child:****PO:** 7 mg/kg/24 hr in 5–6 divided doses**IM/IV:** 0.05–0.15 mg/kg/dose Q4–6 hr; **max.** single IM/IV dose: 10 mg**Adult:****PO (immediate release):** 60 mg TID; increase Q48 hr PRN. Usual effective dose: 60–1500 mg/24 hr**PO (sustained release):** 180–540 mg once daily–BID**IM/IV (use when PO therapy is not practical):** Give 1/30 of the usual PO**Contraindicated** in mechanical intestinal or urinary obstruction. **Use with caution** in patients with epilepsy, asthma, bradycardia, hyperthyroidism, arrhythmias, or peptic ulcer. May cause nausea, vomiting, diarrhea, rash, headache, and muscle cramps. Pyridostigmine is mainly excreted unchanged by the kidney. Therefore, lower doses titrated to effect in renal disease may be necessary. Changes in oral dosages may take several days to show results. **Atropine is the antidote.****PYRIDOXINE**Vitamin B<sub>6</sub> and various names including generics**Vitamin, water soluble**

A/C

1

No

No

No

**Tabs (HCl) [OTC]:** 25, 50, 100, 250, 500 mg**Oral solution (HCl):** 1 mg/mL

PYRIDOXINE *continued*

**Injection (HCl):** 100 mg/mL (1 mL); some products may contain aluminum and 0.5% chlorobutanol

**Deficiency, IM/IV/PO (PO preferred):**

**Child:** 5–25 mg/24 hr × 3 wk, followed by 2.5–5 mg/24 hr as maintenance therapy (via multivitamin preparation)

**Adolescent and adult:** 10–20 mg/24 hr × 3 wk, followed by 2–5 mg/24 hr as maintenance therapy (via multivitamin preparation)

**Drug-induced neuritis (PO):****Prophylaxis:**

**Child:** 1 mg/kg/24 hr or 10–50 mg/24 hr

**Adolescent and adult:** 25–50 mg/24 hr

**Treatment (optimal dose not established):**

**Child:** 50–200 mg/24 hr

**Adolescent and adult:** 50–300 mg/24 hr

**Pyridoxine-dependent seizures:****Neonate and infant:**

**Initial:** 50–100 mg/dose IM or rapid IV × 1

**Maintenance:** 50–100 mg/24 hr PO

**Recommended daily allowance:** See [Chapter 21](#).

**Use caution** with concurrent levodopa therapy. Chronic administration has been associated with sensory neuropathy. Nausea, headache, increased AST, decreased serum folic acid level, and allergic reaction may occur. May lower phenobarbital and phenytoin levels.

See [Chapter 20](#) for management of neonatal seizures.

Pregnancy category changes to “C” if dosage exceeds U.S. RDA.

**PYRIMETHAMINE**

Daraprim and generics

**Antiparasitic agent**



C 2 Yes Yes No

**Tab:** 25 mg; scored tablet (see remarks for outpatient prescription process)

**Oral suspension:** 2 mg/mL

**Congenital toxoplasmosis (administer with sulfadiazine and leucovorin; see remarks):**

**Load:** 2 mg/kg/24 hr PO ÷ Q12 hr × 2 days

**Maintenance:** 1 mg/kg/24 hr PO once daily × 2–6 mo, then 1 mg/kg/24 hr 3× per wk to complete total 12 mo of therapy

**Toxoplasmosis (administer with sulfadiazine or trisulfapyrimidines, and leucovorin):****Child:**

**Load:** 2 mg/kg/24 hr PO ÷ BID (**max. dose:** 100 mg/24 hr) with the following duration:

**Non–HIV exposed/positive:** 2 days

**HIV exposed/positive:** 3 days

**Maintenance:**

**Non–HIV exposed/positive:** 1 mg/kg/24 hr PO once daily (**max. dose:** 25 mg/24 hr) × 6 mo, followed by 1 mg/kg/dose (**max. dose:** 25 mg/24 hr) 3 times per week to complete a total 12 mo therapy

**HIV exposed/positive:** 1 mg/kg/24 hr PO once daily (**max. dose:** 25 mg/24 hr) ≥6 wk

**Adult:**

**Non–HIV exposed/positive:** 50–75 mg/24 hr PO × 1–3 wk. Depending on tolerance and response, additional therapy at a 50% reduced dosage is continued × 4–5 wk.

**HIV exposed/positive:** 200 mg PO × 1 followed by 50–75 mg/24 hr once daily × ≥6 wk

*Continued*

PYRIMETHAMINE *continued*

Pyrimethamine is a folate antagonist. Supplementation with folic acid leucovorin at 5–15 mg/24 hr is recommended. **Contraindicated** in megaloblastic anemia secondary to folate deficiency. **Use with caution** in G6PD deficiency, malabsorption syndromes, alcoholism, pregnancy, and renal or hepatic impairment. Pyrimethamine can cause glossitis, bone marrow suppression, seizures, rash, and photosensitivity. For congenital toxoplasmosis, see *Clin Infect Dis* 1994;18:38–72. Zidovudine and methotrexate may increase risk for bone marrow suppression. Aurothioglucose, trimethoprim, and sulfamethoxazole may increase risk for blood dyscrasias. Administer doses with meals. Most cases of acquired toxoplasmosis do not require specific antimicrobial therapy.


Outpatient prescriptions may need to be processed through a specialty pharmacy program via the manufacturer; see <http://www.daraprimdirect.com/healthcare-providers>.



Q

**QUETIAPINE**

Seroquel, Seroquel XR, and generics  
**Antipsychotic, second generation**



C 2 No Yes No

**Tabs:** 25, 50, 100, 200, 300, 400 mg

**Extended release tabs (Seroquel XR and generics):** 50, 150, 200, 300, 400 mg

**Oral suspension:** 10, 40 mg/mL

**Bipolar mania (continue therapy at lowest dose to maintain efficacy and periodically assess maintenance treatment needs; PO):**



**Immediate release dosage forms:**

Age	Dose Titration	Usual Effective Dose	Maximum Dose
Child ≥10 yr and adolescent (monotherapy)	Day 1: 25 mg BID Day 2: 50 mg BID Day 3: 100 mg BID Day 4: 150 mg BID Day 5: 200 mg BID ≥Day 6: If needed, additional increases should be ≤100 mg/24 hr up to 600 mg/24 hr. Total daily doses may be divided TID based on response and tolerability.	400–600 mg/24 hr	600 mg/24 hr
Adult (monotherapy or in combination with lithium or divalproex)	Day 1: 50 mg BID Day 2: 100 mg BID Day 3: 150 mg BID Day 4: 200 mg BID ≥Day 5: If needed, additional increases ≤200 mg/24 hr up to 800 mg/24 hr by day 6.	400–800 mg/24 hr	800 mg/24 hr

QUETIAPINE *continued***Extended release tabs (see remarks):**

Age	Dose Titration	Usual Effective Dose	Maximum Dose
Child $\geq$ 10 yr and adolescent (monotherapy)	Day 1: 50 mg QHS Day 2: 100 mg QHS Day 3–5: Increase by 100 mg/24 hr increments each day until 400 mg once daily is achieved on day 5.	400–600 mg once daily	600 mg/24 hr
Adult (monotherapy or in combination with lithium or divalproex)	Day 1: 300 mg QHS Day 2: 600 mg QHS Day 3: Adjust dose to 400–800 mg once daily based on efficacy and tolerance.	400–800 mg once daily	800 mg/24 hr (some may require 1200 mg/24 hr)

**Schizophrenia (continue therapy at lowest dose to maintain efficacy and periodically assess maintenance treatment needs; PO):****Immediate release dosage forms:**

Age	Dose Titration	Usual Effective Dose	Maximum Dose
Adolescent (13–17 yr)	Day 1: 25 mg BID Day 2: 50 mg BID Day 3: 100 mg BID Day 4: 150 mg BID Day 5: 200 mg BID $\geq$ Day 6: If needed, additional increases should be $\leq$ 100 mg/24 hr up to 800 mg/24 hr. Total daily doses may be divided TID based on response and tolerability.	400–800 mg/24 hr	800 mg/24 hr
Adult	Day 1: 25 mg BID Day 2 and 3: Increase in increments of 25–50 mg divided 2–3 doses daily to 300–400 mg/24 hr divided BID–TID by day 4. If needed, increase dose by 50–100 mg/24 hr at intervals of at least 2 days.	150–750 mg/24 hr	750 mg/24 hr

**Extended release tabs (see remarks):**

Age	Dose Titration	Usual Effective Dose	Maximum Dose
Adolescent (13–17 yr)	Day 1: 50 mg once daily Day 2: 100 mg once daily Day 3: 200 mg once daily	400–800 mg once daily	800 mg/24 hr

*Continued*

QUETIAPINE *continued*

Age	Dose Titration	Usual Effective Dose	Maximum Dose
	Day 4: 300 mg once daily Day 5: 400 mg once daily		
Adult	Day 1: 300 mg QHS If needed, increase dose in increments of up to 300 mg/24 hr.	400–800 mg once daily	800 mg/24 hr

**Avoid** use in patients with history of cardiac arrhythmias or prolonged QTc syndrome, concurrent medications that can prolong the QTc interval, and alcohol use. **Use with caution** in hypovolemia and diabetes mellitus.



Suicidal ideation/behavior or worsening depression may occur, especially in children and young adults during the first few months of therapy or during dosage changes.

Common side effects in children include hypertension, hyperglycemia, hyperprolactinemia, and significant weight gain. Other common side effects include orthostatic hypotension, tachycardia, hypercholesterolemia, hypertriglyceridemia, abdominal pain, GI disturbances, increased appetite, xerostomia, increased serum transaminases, EPS, headache, dizziness, agitation, and fatigue. Anaphylactic reactions, DRESS, SJS, TEN, SIADH, cardiomyopathy, priapism, DKA, pancreatitis, eosinophilia, agranulocytosis, leukopenia, neutropenia, cataracts, hypothyroidism, neuroleptic malignant syndrome, and seizures have been reported. Anticholinergic side effects (e.g., constipation, urinary retention) may occur due to norquetiapine, its active metabolite, and may be enhanced with concurrent use of anticholinergic medications.

**Do not** abruptly discontinue medication as acute withdrawal symptoms occur. Dosage adjustment in hepatic impairment may be necessary as it is primarily hepatically metabolized. Quetiapine is a major substrate for CYP 450 3A4 and minor substrate for 2D6. Opioids and other CNS depressants may enhance CNS depressant effects. Carbamazepine may decrease the effects of quetiapine. Quetiapine may decrease dopamine agonist effects (e.g., anti-Parkinson agents) but may enhance the anticholinergic and QTc prolongation effects to those medications processing these risks. Always check for drug interactions as effects can be mild to severe.

Non—extended release dosage forms may be administered with or without food. Extended release tabs must be swallowed whole and administered preferably in the evening without food (a light meal of ≤300 calories is allowed). May convert patients from immediate release to extended release tablets at the equivalent total daily dose and administer once daily; individual dosage adjustments may be necessary.

**QUINIDINE**

Various generics

**Class 1a antiarrhythmic, antimalarial agent**

				
C	2	Yes	Yes	No

**As gluconate (62% quinidine):**

**Slow-release tabs:** 324 mg

**As sulfate (83% quinidine):**

**Tabs:** 200, 300 mg

**Oral suspension:** 10 mg/mL 

**Equivalents:** 200 mg sulfate = 267 mg gluconate

**NOTE:** The intravenous dosage form is no longer available in the United States. Contact the CDC Malaria Hotline at (770) 488-7788 or (855) 856-4713 for an alternative therapy.

QUINIDINE *continued*

All doses are expressed as salt forms.

**Antiarrhythmic (not first line):**

**Child (as sulfate):** 15–60 mg/kg/24 hr 24 hr PO ÷ Q6 hr; **max. dose:** 2400 mg/24 hr

**Adult:**

**As sulfate:** Start at 200 mg/dose Q6 hr and titrate cautiously to desired effect up to 600 mg PO Q6–12 hr.

**As gluconate:** 324–648 mg PO Q8–12 hr

**Malaria:**

**Child and adult (give intravenously as gluconate; see remarks):**

**Loading dose:** 10 mg/kg/dose IV (**max. dose:** 600 mg) over 1–2 hr followed by maintenance dose. Omit or decrease load if patient has received quinine or mefloquine.

**Maintenance dose:** 0.02 mg/kg/min IV as continuous infusion until oral therapy can be initiated. If more than 48 hr of intravenous therapy is required, reduce dose by 30%–50%.

Test dose is given to assess for idiosyncratic reaction to quinidine. Toxicity indicated by increase of QRS interval by  $\geq 0.02$  sec (skip dose or stop drug). May cause gastrointestinal (GI) symptoms, hypotension, tinnitus, TTP, rash, heart block, and blood dyscrasias. When used alone, may cause 1:1 conduction in atrial flutter leading to ventricular fibrillation. Patients may develop idiosyncratic ventricular tachycardia with low levels, especially when therapy is being initiated.

Quinidine is a substrate of CYP 450 3A3/4 and 3A5–7 enzymes, and an inhibitor of CYP 450 2D6 and 3A3/4 enzymes. Can cause increase in digoxin levels. Quinidine potentiates the effect of neuromuscular blocking agents,  $\beta$ -blockers, anticholinergics, and warfarin. Amiodarone, antacids, delavirdine, diltiazem, grapefruit juice, saquinavir, ritonavir, verapamil, or cimetidine may enhance the drug's effect. Barbiturates, phenytoin, cholinergic drugs, nifedipine, sucralfate, or rifampin may reduce quinidine's effect. **Use with caution** in renal insufficiency (15%–25% of drug is eliminated unchanged in the urine), myocardial depression, sick sinus syndrome, G6PD deficiency, and hepatic dysfunction.

**Therapeutic levels (antiarrhythmic):** 3–7 mg/L. Recommended serum sampling times at steady state: trough level obtained within 30 min prior to the next scheduled dose after 1–2 days of continuous dosing (steady state).

**MALARIA USE:** Continuous monitoring of electrocardiogram, blood pressure, and serum glucose is recommended, especially in pregnant women and young children.

**QUINUPRISTIN AND DALFOPRISTIN**

Synercid

**Antibiotic, streptogramin**



B



2



No



Yes



No

**Injection:** 500 mg (150 mg quinupristin and 350 mg dalfopristin)

**Doses expressed in mg of combined quinupristin and dalfopristin.**

**Vancomycin-resistant *Enterococcus faecium* (VREF) and severe infections:**

**Child <16 yr (limited data),  $\geq 16$  yr, and adult:** 7.5 mg/kg/dose IV Q8 hr

**VERF endocarditis duration of therapy:** Minimum of 8 weeks

**Complicated skin infections:**

**Child <16 yr (limited data),  $\geq 16$  yr, and adult:** 7.5 mg/kg/dose IV Q12 hr for at least 7 days

**Not active** against *Enterococcus faecalis*. **Use with caution** in hepatic impairment; dosage reduction may be necessary. Most common side effects include pain, burning, inflammation and edema at the intravenous infusion site, thrombophlebitis and thrombosis, GI disturbances,

*Continued*

QUINUPRISTIN AND DALFOPRISTIN *continued*

rash, arthralgia, myalgia, increased liver enzymes, hyperbilirubinemia, and headache. Dose frequency reductions (Q8 hr—Q12 hr) or discontinuation can improve severe cases of arthralgia and myalgia. Use total body weight for obese patients when calculating dosages.

Drug is an inhibitor to the CYP 450 3A4 isoenzyme. **Avoid use** with CYP 450 3A4 substrates, which can prolong QTc interval. May increase the effects/toxicity of cyclosporine, tacrolimus, sirolimus, delavirdine, nevirapine, indinavir, ritonavir, diazepam, midazolam, carbamazepine, methylprednisolone, vinca alkaloids, docetaxel, paclitaxel, quinidine, and some calcium channel blockers.


**Pediatric (<16 yr old) pharmacokinetic studies are incomplete.** Reduce dose for patients with hepatic cirrhosis (Child-Pugh A or B).

Drug is compatible with D<sub>5</sub>W and incompatible with saline and heparin. Infuse each dose over 1 hr using the following **max. IV concentrations**: peripheral line: 2 mg/mL, central line: 5 mg/mL. If injection site reaction occurs, dilute infusion to <1 mg/mL.

## R

**RALTEGRAVIR**

Isentress and Isentress HD

**Antiretroviral agent, integrase inhibitor**

C

2

No

Yes

No

**Tabs:****Isentress:** 400 mg**Isentress HD:** 600 mg**Chewable tabs:** 25, 100 mg; contains aspartame (100 mg tab is scored)**Oral powder for suspension:** 100 mg (60 packets); contains polyethylene glycol**HIV treatment:** See <https://clinicalinfo.hiv.gov/en/guidelines>

**HIV vertical transmission and presumptive treatment during high-risk situations (mothers who received no antepartum antiretroviral therapy, mothers who received only intrapartum antiretroviral therapy, mothers who receive antepartum antiretroviral therapy but with suboptimal viral suppression [ $>50$  copies/mL] within 4 weeks prior to delivery, or mothers with acute or primary HIV infection during pregnancy or breastfeeding [immediately discontinue breastfeeding]). Transition to a treatment regimen if positive HIV diagnosis is confirmed and discontinue use after a negative diagnosis; see **Chapter 17** for additional information:**

**$\geq 37$  weeks' gestation at birth and  $\geq 2$  kg (use 10 mg/mL oral suspension dosage form in combination with zidovudine and lamivudine administered from birth up to 6 weeks; delay first dose of raltegravir 24–48 hr after birth if mother received raltegravir 2 to 24 hours prior to delivery, but initiate zidovudine and lamivudine immediately):**

**<7 days old:** 1.5 mg/kg/dose PO once daily or by the following weight categories:

**2–<3 kg:** 4 mg PO once daily

**3–<4 kg:** 5 mg PO once daily

**4–<5 kg:** 7 mg PO once daily

**1–4 weeks old:** 3 mg/kg/dose PO BID or by the following weight categories:

**2–<3 kg:** 8 mg PO BID

**3–<4 kg:** 10 mg PO BID

**4–<5 kg:** 15 mg PO BID



RALTEGRAVIR *continued*

**4–6 weeks old:** 6 mg/kg/dose PO BID or by the following weight categories:

**3–<4 kg:** 25 mg PO BID

**4–<6 kg:** 30 mg PO BID

**6–<8 kg:** 40 mg PO BID



Common side effects include nausea, headache, increased ALT and other liver enzymes, insomnia, and fatigue. Severe and life-threatening skin reactions (e.g., SJS, TEN), hypersensitivity reactions characterized by rash, organ dysfunction (including hepatic failure), immune reconstitution syndrome, hyperglycemia, rhabdomyolysis, and autoimmune disorders (e.g., Graves disease and Guillain-Barré syndrome) have been reported.

Raltegravir is ~83% protein bound and primarily metabolized via the UGT1A1 glucuronidation pathway. UGT1A1 activity is low at birth and increases rapidly during the next 4–6 weeks of life. No dosing information is currently available for preterm infants or infants weighing <2 kg at birth and for severe hepatic impairment. Use with antacids containing aluminum or magnesium salts may reduce raltegravir levels and is not recommended. Medications containing polyvalent cations (e.g., supplements containing iron, calcium or magnesium, sucralfate, and laxatives) should be spaced apart by administering raltegravir at least 2 hours before or 6 hours after the administration of polyvalent cation medicine. Use with fosamprenavir may result in reduced levels of amprenavir and raltegravir. Other medications that could decrease raltegravir levels and effects include rifampin, orlistat, and etravirine. Omeprazole may increase raltegravir levels.

Each dosage form has a different pharmacokinetic profile; dosage forms are not interchangeable. Oral tablets must be swallowed whole, and the chewable tablet may be crushed and mixed with ~5 mL of water, juice, or breast milk. The oral suspension must be administered within 30 min after reconstitution. Doses may be administered with or without food; however, the effect of food on the oral suspension has not been evaluated.

**RASBURICASE**

Elitek

**Antihyperuricemic agent**



C



?



No



No



Yes

**Injection:** 1.5, 7.5 mg; contains mannitol and L-alanine

**Hyperuricemia (all ages; see remarks):** 0.1–0.2 mg/kg/dose (rounded down to the nearest whole 1.5 mg multiple) IV over 30 min × 1. Patients generally respond to one dose, but if needed dose may be repeated Q24 hr for up to four additional doses.



**Contraindicated** in G6PD deficiency (risk for acute hemolytic anemia) or history of hypersensitivity, hemolytic reactions, or methemoglobinemia with rasburicase. **Use with caution** in asthma, allergies, hypersensitivity with other medications, and children <2 yr of age (decreased efficacy and increased risk for rash, vomiting, diarrhea, and fever).



Common side effects include nausea, vomiting, abdominal pain, discomfort, diarrhea, constipation, mucositis, fever, and rash. Serious and fatal hypersensitivity reactions have been reported in <1% of patients, including anaphylaxis, and can occur at any time; discontinue use immediately and permanently.

During therapy, uric acid blood samples must be sent to the laboratory immediately. Blood should be collected in prechilled tubes containing heparin and placed in an ice-water bath to avoid potential falsely low uric acid levels (degradation of plasma uric acid occurs in the presence of rasburicase at room temperature). Centrifugation in a precooled centrifuge (4°C) is indicated. Plasma samples must be assayed within 4 hr of sample collection.

**RH<sub>0</sub> (D) IMMUNE GLOBULIN INTRAVENOUS (HUMAN)**

WinRho-SDF, Rhophylac, HyperRHO S/D  
Mini-Dose, HyperRHO S/D Full Dose, RhoGAM Ultra-Filtered Plus, MICRhoGAM Ultra-Filtered Plus

*Immune globulin*



**Injection (WinRho-SDF):** 1500 IU (1.3 mL), 2500 IU (2.2 mL), 5000 IU (4.4 mL), 15,000 IU (13 mL); may contain polysorbate 80

**Prefilled injection for IV or IM administration:**

**Rhophylac:** 1500 IU (2 mL); preservative free

**Prefilled injection for IM administration:**

**HyperRHO S/D Mini-Dose:** 250 IU

**HyperRHO S/D Full Dose:** 1500 IU

**MICRhoGAM Ultra-Filtered Plus:** 250 IU; contains polysorbate 80

**RhoGAM Ultra-Filtered Plus:** 1500 IU; contains polysorbate 80

**Conversion:** 1 mCg = 5 IU

**IM route and IM dosage forms:** Indicated for prevention of Rh hemolytic disease of newborn by administering to Rh<sub>0</sub>(D) negative mother or prevention of isoimmunization in Rh<sub>0</sub>(D)-negative individuals who have been transfused with Rh<sub>0</sub>(D)-positive blood/cell components.

**All doses based on international units (IU)**

**Immune thrombocytopenic purpura (nonsplenectomized Rh<sub>0</sub>[D]-positive patients; see remarks):**



**WinRho-SDF (child, adolescent, and adult; see remarks):**

**Initial dose (may be given in two divided doses on separate days or as a single dose):**

**Hemoglobin ≥10 mg/dL:** 250 IU/kg/dose IV × 1

**Hemoglobin 8–<10 mg/dL:** 125–200 IU/kg/dose IV × 1

**Hemoglobin <8 mg/dL:** Use alternative therapy.

**Subsequent doses (actual dose and frequency of administration is determined by the patient's clinical response and subsequent hemoglobin level):**

**Hemoglobin <8 g/dL:** Use alternative therapy.

**Hemoglobin 8–10 g/dL:** 125–200 IU/kg/dose IV × 1

**Hemoglobin >10 g/dL:** 250–300 IU/kg/dose IV × 1

**Rhophylac (child, adolescent, and adult; see remarks):** 250 IU/kg/dose IV × 1

**Contraindicated** in IgA deficiency. **Use with caution** with history of atherosclerosis, known/suspected hyperviscosity, coagulation disorders, and other thrombotic risks. Adverse events associated with ITP indication include headache, chills, fever, and reduction in hemoglobin (due to the destruction of Rh<sub>0</sub>[D] antigen-positive red cells). Intravascular hemolysis resulting in anemia and renal insufficiency has been reported. May interfere with immune response to live virus vaccines (e.g., MMR, varicella).



Clinical response for ITP therapy requires monitoring of platelet counts, RBC, Hgb, and reticulocyte count. Rh<sub>0</sub>(D)-positive patients should be monitored for signs and symptoms of intravascular hemolysis, anemia, and renal insufficiency.

**Recommended IV administration rate:**

WinRho-SDF: Over 3–5 min

Rhophylac: Each 1500 IU (2 mL) per 15–60 sec

**RIBAVIRIN**

Oral: Generics; previously available as Rebetol

Inhalation: Virazole and generics

*Antiviral agent*



RIBAVIRIN *continued***Oral caps:** 200 mg**Tabs:** 200, 400, 600 mg**Aerosol (Virazole and generics):** 6 g

**Hepatitis C (PO, see remarks):** Hepatitis C combination therapy is dependent on HCV genotype and treatment status. Specific treatment recommendations are dynamic with newer therapies; see the most recent American Association for the Study of Liver Diseases/Infectious Disease Society of America (AASLD/IDSA) treatment recommendations at [www.hcvguidelines.org](http://www.hcvguidelines.org)



**Child:** In combination with sofosbuvir for patients with genotypes 2 or 3 with/without cirrhosis:

**Child <12 yr and ≥35 kg, child ≥12 yr and adolescent (see remarks):**

**<47 kg:** 15 mg/kg/24 hr PO ÷ BID

**47–49 kg:** 600 mg/24 hr PO ÷ BID

**50–65 kg:** 800 mg/24 hr PO ÷ BID

**66–80 kg:** 1000 mg/24 hr PO ÷ BID

**>80 kg:** 1200 mg/24 hr PO ÷ BID

**Duration of therapy:**

**Genotype 2:** 12 weeks

**Genotype 3:** 24 weeks

**Adult (see remarks):**

**Oral capsules or solution as part of a recommended combination therapy:**

**<75 kg:** 500 mg PO BID

**≥75 kg:** 600 mg PO BID

**Inhalation (see remarks):**

**Continuous:** Administer 6 g by aerosol over 12–18 hr once daily for 3–7 days. The 6 g ribavirin vial is diluted in 300 mL preservative-free sterile water to a final concentration of 20 mg/mL. Must be administered with Viratek Small Particle Aerosol Generator (SPAG-2).

**Intermittent (for nonventilated patients):** Administer 2 g by aerosol over 2 hr TID for 3–7 days. The 6 g ribavirin vial is diluted in 100 mL preservative-free sterile water to a final concentration of 60 mg/mL. The intermittent use is not recommended in patients with endotracheal tubes.

**ORAL RIBAVIRIN: Contraindicated** in pregnancy, significant or unstable cardiac disease, autoimmune hepatitis, hepatic decompensation (Child-Pugh score >6; class B or C), hemoglobinopathies, and creatinine clearance <50 mL/min. **Use with caution** in preexisting cardiac disease, pulmonary disease, and sarcoidosis. Anemia (most common), insomnia, depression, irritability, and suicidal behavior (higher in adolescent and pediatric patients) have been reported with the oral route.



Combination therapy with peginterferon for Hep C is no longer recommended due to poor efficacy. Tinnitus, hearing loss, vertigo, severe hypertriglyceridemia, and homicidal ideation have been reported in combination with interferon. Suicidal ideation or attempts have been reported more frequently among adolescents compared to adults (2.4% vs. 1%) during treatment and off-therapy follow up. Pancytopenia has been reported in combination with interferon and azathioprine. Increased risk for hepatic decompensation with cirrhotic chronic hepatitis C patients treated with  $\alpha$  interferons or with HIV coinfection receiving HAART and interferon alfa-2a. Growth inhibition (delays in weight and height increases) was observed in children (5–17 years old) receiving combination therapy for up to 48 weeks.

May decrease the effects of zidovudine and stavudine and increase the risk for lactic acidosis with nucleoside analogues. **Reduce or discontinue dosage for toxicity as follows:**

Patient with no cardiac disease:

*Hgb* <10 g/dL and ≥8.5 g/dL:

*Child:* 12 mg/kg/dose PO once daily; may further reduce to 8 mg/kg/dose PO once daily

*Continued*

RIBAVIRIN *continued*

*Adult:* 600 mg PO once daily (capsules or solution) or 200 mg PO QAM and 400 mg PO QPM (tablets)

*Hgb <8.5 g/dL:* Discontinue therapy permanently.

Patient with cardiac disease:

$\geq 2$  mg/dL decrease in Hgb during any 4-week period during therapy:

*Child:* 12 mg/kg/dose PO once daily; may further reduce to 8 mg/kg/dose PO once daily (monitor weekly)

*Adult:* 600 mg PO once daily (capsules or solution) or 200 mg PO QAM and 400 mg PO QPM (tablets)

*Hgb <12 g/dL after 4 weeks of reduced dose:* Discontinue therapy permanently.

**INHALED RIBAVIRIN:** Use of ribavirin for RSV is controversial and not routinely indicated. Aerosol therapy may be considered for selected infants and young children at high risk for serious RSV disease (see most recent edition of the AAP *Red Book*). Most effective if begun early in course of RSV infection; generally in the first 3 days. May cause worsening respiratory distress, rash, conjunctivitis, mild bronchospasm, hypotension, anemia, and cardiac arrest. **Avoid** unnecessary occupational exposure to ribavirin due to its teratogenic effects. Drug can precipitate in the respiratory equipment.

**RIBOFLAVIN**

Vitamin B<sub>2</sub> and various brands and generics

**Water-soluble vitamin**



A/C



1



No



No



No

**Tabs [OTC]:** 25, 50, 100 mg

**Caps [OTC]:** 400 mg

**Riboflavin deficiency:**

**Child:** 2.5–10 mg/24 hr ÷ once daily—BID PO

**Adult:** 5–30 mg/24 hr ÷ once daily—BID PO

**U.S. RDA requirements:** See [Chapter 21](#).

**Migraine prophylaxis (limited data):**

**Child  $\geq 8$  yr and adolescent:** 200–400 mg PO once daily

Hypersensitivity may occur. Administer with food. Causes yellow to orange discoloration of urine. For multivitamin information, see [Chapter 21](#).

Pregnancy category changes to “C” if used in doses above the RDA.

**RIFABUTIN**

Mycobutin and generics

**Antituberculous agent**



B



2



Yes



Yes



No

**Caps:** 150 mg

**Oral suspension:** 20 mg/mL

**MAC primary prophylaxis for first episode of opportunistic disease in HIV (see remarks for interactions and [www.aidsinfo.nih.gov/guidelines](http://www.aidsinfo.nih.gov/guidelines)):**

**Child >5 yr, adolescent, and adult:** 300 mg PO once daily; doses may be administered as 150 mg PO BID if gastrointestinal (GI) upset occurs

**MAC secondary prophylaxis for recurrence of opportunistic disease in HIV (in combination with ethambutol and a macrolide antibiotic [clarithromycin or azithromycin]):**

RIFABUTIN *continued*

**Infant and child:** 5 mg/kg/24 hr PO once daily; **max. dose:** 300 mg/24 hr

**Adolescent and adult:** 300 mg PO once daily; doses may be administered 150 mg PO BID if GI upset occurs

**MAC treatment:**

**Child:** 10–20 mg/kg/24 hr PO once daily; **max. dose:** 300 mg/24 hr as part of a multidrug regimen for severe disease

**Adult:** 300 mg PO once daily; may be used in combination with azithromycin and ethambutol

**Use in combination with HIV antiretroviral agents:** See product information for dosage recommendations.

**Should not be used** for MAC prophylaxis with active TB. May cause GI distress, discoloration of skin and body fluids (brown-orange color), and marrow suppression. Rash, eosinophilia, and bronchospasm have been reported. **Use with caution** in renal and liver impairment. **Adjust dose in renal impairment (see Chapter 31).** May permanently stain contact lenses. Uveitis can occur when using high doses (>300 mg/24 hr in adults) in combination with macrolide antibiotics.


Rifabutin is an inducer of CYP 450 3A enzyme and is structurally similar to rifampin (similar drug interactions, see [Rifampin](#)). Clarithromycin, fluconazole, itraconazole, nevirapine, and protease inhibitors increase rifabutin levels. Efavirenz may decrease rifabutin levels. May decrease effectiveness of dapson, delavirdine, nevirapine, amprenavir, indinavir, nelfinavir, saquinavir, itraconazole, warfarin, oral contraceptives, digoxin, cyclosporine, ketoconazole, and narcotics.

Doses may be administered with food if patient experiences GI intolerance.

**RIFAMPIN**

Rifadin and generics

**Antibiotic, antituberculous agent, rifamycin**



**Caps:** 150, 300 mg

**Oral suspension:** 10, 25 mg/mL

**Injection (Rifadin and generics):** 600 mg; contains formaldehyde sulfoxylate

**Staphylococcus aureus infections (as part of synergistic therapy with other antistaphylococcal agents):**

**Neonate, infant, child, and adolescent:** 10–20 mg/kg/24 hr ÷ Q12 hr IV/PO; **max. dose:** 600 mg/24 hr

**Prosthetic valve endocarditis:**

**Early infection (≤1 yr surgery):** 20 mg/kg/24 hr ÷ Q8 hr IV/PO; **max. dose:** 900 mg/24 hr

**Late infection (>1 yr surgery):** 15–20 mg/kg/24 hr ÷ Q12 hr IV/PO; **max. dose:** 600 mg/24 hr

**MRSA infection:** 15 mg/kg/24 hr ÷ Q8 hr IV/PO; **max. dose:** 900 mg/24 hr

**Adult:** 600 mg once daily, or 300–450 mg Q12 hr IV/PO

**Prosthetic valve endocarditis:** 300 mg Q8 hr IV/PO for a minimum of 6 weeks in combination with antistaphylococcal penicillin with or without gentamicin for first 2 weeks

**Tuberculosis (see latest edition of the AAP Red Book for duration of therapy and combination therapy):** Twice-weekly therapy may be used after 1–2 months of daily therapy.

**Infant, child, and adolescent (as part of a combination therapy):**

**Daily therapy:** 10–20 mg/kg/24 hr ÷ Q12–24 hr IV/PO; higher dose of 20–30 mg/kg/24 hr ÷ Q12–24 hr has been recommended for infants and toddlers and for central nervous system (CNS) and disseminated disease. **Max. dose:** 600 mg/24 hr

**Twice-weekly therapy:** 15–20 mg/kg/24 hr PO twice weekly; higher dose of 20–30 mg/kg/24 hr twice weekly has been recommended for infants and toddlers and for CNS and disseminated disease. **Max. daily dose:** 600 mg/24 hr

*Continued*

RIFAMPIN *continued***Adult:****Daily therapy:** 10 mg/kg/24 hr IV/PO once daily**Twice-weekly therapy:** 10 mg/kg/24 hr IV/PO once daily twice weekly**Max. daily dose:** 600 mg/24 hr**TB meningitis (all ages):****PO:** 20 mg/kg/dose Q24 hr; **max. dose:** 1200 mg/dose**IV:** 15 mg/kg/dose Q24 hr; **max. dose:** 900 mg/dose**Prophylaxis for *Neisseria meningitidis* (see latest edition of the AAP Red Book for additional information):****0—<1 mo:** 10 mg/kg/24 hr ÷ Q12 hr PO × 2 days**≥1 mo:** 20 mg/kg/24 hr ÷ Q12 hr PO × 2 days**Adult:** 600 mg PO Q12 hr × 2 days**Max. dose (all ages):** 1200 mg/24 hr

**Never** use as monotherapy except when used for prophylaxis. Patients with latent tuberculosis infection should NOT be treated with rifampin and pyrazinamide because of the risk of severe liver injury. Use is **NOT recommended** in porphyria. **Use with caution** in diabetes.



May cause GI irritation, allergy, headache, fatigue, ataxia, muscle weakness, confusion, fever, hepatitis, transient LFT abnormalities, blood dyscrasias, interstitial nephritis, and elevated BUN and uric acid. Causes red discoloration of body secretions such as urine, saliva, and tears (which can permanently stain contact lenses). Pulmonary toxicity, hepatotoxicity, bleeding, and vitamin K—dependent coagulation disorders have been reported.

Induces several hepatic enzymes and transporters (CYP 450 2C9, 2C19, and 3A4; UGT1A1, P-glycoprotein, and OATP1B1/1B3), which may decrease plasma concentration of digoxin, corticosteroids, buspirone, benzodiazepines, fentanyl, calcium channel blockers, β-blockers, cyclosporine, tacrolimus, itraconazole, ketoconazole, oral anticoagulants, barbiturates, and theophylline. May reduce the effectiveness of oral contraceptives and anti-retroviral agents (protease inhibitors and nonnucleoside reverse transcriptase inhibitors). **Use is contraindicated** with praziquantel due to decreased praziquantel levels; rifampin should be discontinued 4 weeks prior to initiating praziquantel, and rifampin can be restarted 1 day after completion of praziquantel. Hepatotoxicity is a greater concern when used in combination with pyrazinamide and ritonavir-boosted saquinavir (**use is contraindicated**).

**Adjust dose in renal failure (see Chapter 31).** Reduce dose in hepatic impairment. Give oral doses 1 hr before or 2 hr after meals. Patients should abstain from alcohol, hepatotoxic medications, or herbal products while taking rifampin.

For *Haemophilus influenzae* type b prophylaxis, see latest edition of the Red Book.

**RIFAXIMIN**

Xifaxan

**Antibiotic, rifamycin derivative**

C



?



No



Yes



No

**Tabs:** 200, 550 mg; may contain edetate disodium**Oral suspension:** 20 mg/mL **Small intestinal bacterial overgrowth (SIBO; limited data):****Child 3—<8 yr:** 200 mg PO TID × 7—14 days**Child ≥8 yr and adolescent:** 200—550 mg PO TID × 7—14 days**Adult:** 550 mg PO TID × 14 days**Irritable bowel syndrome with diarrhea:****Child ≥8 yr and adolescent (limited data):** 10—30 mg/kg/24 hr PO ÷ TID; **max. dose:** 1200 mg/24 hr

RIFAXIMIN *continued*

**Adult:** 550 mg PO TID  $\times$  14 days; may repeat up to two times with the same dosage regimen

**Travelers' diarrhea (caused by noninvasive strains of *Escherichia coli*):**

**Child  $\geq 3$ –11 yr (limited data):** 100 mg PO QID for up to 5 days

**Child  $\geq 12$  yr and adult:** 200 mg PO TID  $\times$  3 days

**Recurrent or subsequent *Clostridium difficile* diarrhea (initiated after a 10-day course of oral vancomycin):**

**Child  $< 12$  yr (limited data):** 15–30 mg/kg/24 hr PO  $\div$  TID  $\times$  20 days; **max. dose:** 1200 mg/24 hr

**Child  $\geq 12$  yr and adult:** 400 mg PO TID  $\times$  20 days

**Contraindicated** with rifamycin hypersensitivity. **Avoid use** in diarrhea complicated by fever or blood in the stool. **Use with caution** in severe hepatic impairment (Child-Pugh class C).



Severe cutaneous reactions (e.g., SJS, TEN) have been reported with use in patients with cirrhosis. Common side effects include peripheral edema, abdominal pain, nausea, ascites, dizziness, headache, and fatigue. Anaphylaxis, angioedema, rhabdomyolysis, and exfoliative dermatitis have been reported.

Substrate and inhibitor of OATP1A2/SLCOA2 transporter and substrate of P-glycoprotein ABCB1 and OATP1B1/1B3. May decrease the effects of warfarin and immunological effects of cholera and BCG vaccines. P-glycoprotein inhibitors (e.g., cyclosporine) may increase the effects/toxicity of rifaximin. Doses may be administered with or without food.

**RIMANTADINE**

Generics; previously available as Flumadine

**Antiviral agent**



C



3



Yes



Yes



No

**Tabs:** 100 mg

**Oral suspension:** 10 mg/1 mL 

**Influenza A prophylaxis (for at least 10 days after known exposure; usually for 6–8 weeks during influenza A season or local outbreak):**



**Child:**

**1–9 yr:** 5 mg/kg/24 hr PO once daily—BID; **max. dose:** 150 mg/24 hr

**$\geq 10$  yr:**

**$< 40$  kg:** 5 mg/kg/24 hr PO  $\div$  BID; **max. dose:** 150 mg/24 hr

**$\geq 40$  kg:** 100 mg per dose PO BID

**Adult:** 100 mg PO BID

**Influenza A treatment (within 48 hr of illness onset; NOT to be used in areas with high resistance rates):**

Use the aforementioned prophylaxis dosage  $\times$  7 days.

Resistance to influenza A and recommendations against the use for treatment and prophylaxis have been reported by the Centers for Disease Control (CDC). Check with local microbiology laboratories and the CDC for seasonal susceptibility/resistance.



Preferred over amantadine for influenza due to lower incidence of adverse events. Individuals immunized with live attenuated influenza vaccine (e.g., FluMist) should not receive rimantadine prophylaxis for 14 days after the vaccine. Chemoprophylaxis does not interfere with immune response to inactivated influenza vaccine.

May cause GI disturbance, xerostomia, dizziness, headache, and urinary retention. CNS disturbances are less than with amantadine. **Contraindicated** in amantadine hypersensitivity. **Use with caution** in renal or hepatic insufficiency; dosage reduction may be necessary. A dosage reduction of 50% has been recommended in severe hepatic or renal impairment. Subjects with severe renal impairment have been reported to have an 81% increase in systemic exposure.

**RISPERIDONE**

Risperdal, Risperdal Consta, Perseris, and generics

**Atypical antipsychotic, serotonin (5-HT<sub>2</sub>) and dopamine (D<sub>2</sub>) antagonist**

C



3



Yes



Yes



No

**Tabs:** 0.25, 0.5, 1, 2, 3, 4 mg**Oral solution:** 1 mg/mL (30 mL); may contain benzoic acid**Orally disintegrating tabs:** 0.25, 0.5, 1, 2, 3, 4 mg; contain phenylalanine**IM injection (Risperdal Consta):** 12.5, 25, 37.5, 50 mg (prefilled syringe with 2 mL diluent; includes one 21-gauge 1-in needle for deltoid administration and one 20-gauge 2-in needle for gluteal administration); for IM administration only**Subcutaneous extended release injection (Perseris):** 90, 120 mg (prefilled syringe that includes a 18-gauge, 5/8 inch needle)**Irritability associated with autistic disorder:****5–17 yr (PO daily doses may be administered once daily—BID; patients experiencing somnolence may benefit from QHS or BID dosing or dose reduction):****Initial dose:****<20 kg:** 0.25 mg/24 hr PO for a minimum of 4 days; use with caution if <15 kg as dosing recommendation is not established**≥20 kg:** 0.5 mg/24 hr PO for a minimum of 4 days**Dose increment (if needed) after 4 days of initial dose:****<20 kg:** 0.5 mg/24 hr PO for a minimum of 14 days; if additional increments needed, increase dose by 0.25 mg/24 hr at intervals of at least 14 days**≥20 kg:** 1 mg/24 hr PO for a minimum of 14 days; if additional increments needed, increase dose by 0.5 mg/24 hr at intervals of at least 14 days**Max. daily dose for plateau of therapeutic effect (from one pivotal clinical trial):****<20 kg:** 1 mg/24 hr**≥20–45 kg:** 2.5 mg/24 hr**>45 kg:** 3 mg/24 hr**Bipolar mania:** Oral doses may be administered once or twice daily; patients experiencing somnolence may benefit from QHS or BID dosing or dose reduction. Long-term use beyond 3 weeks and doses (all ages) >6 mg/24 hr have not been evaluated.**Child (10–17 yr):** Start with 0.5 mg/24 hr PO once daily (QAM or QHS). If needed, increase dose at intervals ≥24 hr in increments of 0.5 or 1 mg/24 hr, as tolerated, up to a recommended dose of 2.5 mg/24 hr. Although efficacy has been demonstrated between 0.5 and 6 mg/24 hr, no additional benefit was seen above 2.5 mg/24 hr. Higher doses were associated with more adverse effects.**Adult:** Start with 2–3 mg PO once. Dosage increases or decreases of 1 mg/24 hr can be made at 24-hr intervals. Dosage range: 4–6 mg/24 hr. **Usual max. dose:** 8 mg/24 hr**Schizophrenia:** Oral doses may be administered once daily—BID and patients experiencing somnolence may benefit from BID dosing (see remarks).**Adolescent (13–17 yr):** No data are available to support long-term use of >8 wk.**PO:** Start with 0.5 mg once daily (QAM or QHS). If needed, increase dose at intervals ≥24 hr in increments of 0.5 to 1 mg/24 hr, as tolerated, to a recommended dose of 3 mg/24 hr. Although efficacy has been demonstrated between 1–6 mg/24 hr, no additional benefit and greater side effects were seen above 3 mg/24 hr. Doses >6 mg/24 hr have not been studied.**Adult:****PO:** Start with 1 mg BID on day 1; if tolerated, increase to 2 mg BID on day 2 and to 3 mg BID thereafter. Dosage increases or decreases of 1–2 mg can be made on a weekly basis if needed. Usual effective dose: 2–8 mg/24 hr. Doses above 16 mg/24 hr have not been evaluated.

RISPERIDONE *continued*

**IM:** Start with 25 mg Q2 wk; if no response, dose may be increased to 37.5 mg or 50 mg at 4-week intervals. **Max. IM dose:** 50 mg Q2 wk. PO risperidone should also be administered with the initial IM dose and continued  $\times$  3 weeks and discontinued to provide adequate plasma concentrations during the initial IM dosing period.

**Subcutaneous extended release injection (Perseris; establish tolerability with oral therapy first before using this dosage form):** 90 or 120 mg SC once every month. 90 mg dose corresponds to a 3 mg/24 hr PO risperidone and 120 mg dose to 4 mg/24 hr PO risperidone. No loading dose nor supplemental oral doses are recommended.

**Use with caution** in cardiovascular disorders, diabetes, renal or hepatic impairment

(dose reduction necessary), hypothermia or hyperthermia, seizures, breast cancer or other prolactin-dependent tumors, and dysphagia. Common side effects include abdominal pain and other GI disturbances, arthralgia, anxiety, dizziness, headache, insomnia, somnolence (use QHS dosing), EPS, cough, fever, pharyngitis, rash, rhinitis, sexual dysfunction, tachycardia, and weight gain. Weight gain, somnolence, and fatigue were common side effects reported in the autism studies. Priapism, QTc prolongation, neuroleptic malignant syndrome, hypothermia, sleep apnea syndrome, sleepwalking, ileus, urinary retention, diabetes mellitus, and hypoglycemia have been reported. Very rare cases of anaphylaxis have been reported with use of the IM dosage form in patients who have previously tolerated the oral dosage form.



In the presence of severe renal or hepatic impairment or risk for hypotension, the following adult dosing has been recommended: Start with 0.5 mg PO BID. Increase dose, if needed and tolerated, in increments no more than 0.5 mg BID. Increases to doses  $>1.5$  mg BID should occur at intervals of at least 1 week; slower titration may be required in some patients.

Limited studies in pediatric related Tourette syndrome, schizophrenia, and aggressive behavior in psychiatric disorders are reported. Autistic disorder safety and efficacy in children  $<5$  years of age have not been established. If therapy has been discontinued for a period of time, therapy should be reinitiated with the same initial titration regimen.

Drug is a CYP 450 2D6 and 3A4 isoenzyme substrate. Concurrent use of isoenzyme inhibitors (e.g., fluoxetine, paroxetine, sertraline, cimetidine) and inducers (e.g., carbamazepine, rifampin, phenobarbital, phenytoin) may increase and decrease the effects of risperidone, respectively. Alcohol, CNS depressants, and St. John's wort may potentiate the drug's side effect. Risperidone may enhance the hypotensive effects of levodopa and dopamine agonists. When used with methylphenidate, an increase risk for extrapyramidal symptoms may occur whenever a dosage change is made to either medication.

Oral dosage forms may be administered with or without food. Oral solution can be mixed in water, coffee, orange juice, or low-fat milk but is incompatible with cola or tea. **Do not** split or chew the orally disintegrating tablet. Use IM suspension preparation within 6 hr after reconstitution.

**RIVAROXABAN**

Xarelto, Xarelto Starter Pack

**Anticoagulant, direct thrombin inhibitor**



C



?



Yes



Yes



No

**Tabs:** 2.5, 10, 15, 20 mg

**Xarelto Starter Pack:** 15 mg (42 tabs) and 20 mg (9 tabs); provides 30 days of therapy

**Oral suspension:** 1 mg/mL (155 mL); contains sodium benzoate

**Prevention and treatment venous thromboembolic event (VTE):**

**Child from birth ( $\geq 37$  weeks' gestation and  $\geq 2.6$  kg) to  $<18$  yr:** Prevention and treatment dosages are similar. Initiate therapy after a minimum of 5 days of initial IV anticoagulation therapy.



*Continued*

RIVAROXABAN *continued*

Neonates and infants <6 months old should have had at least 10 days of oral feedings. Use only the oral suspension dosage form for patients <30 kg and either oral suspension or tablets for patients >30 kg (2.5 mg tablet not recommended in children due to incomplete pharmacokinetic/pharmacodynamic and clinical data). Monitor patient weight regularly (especially those <12 kg) and review dosage level regularly to maintain a therapeutic dose. Administer all doses with feeds or food for VTE treatment but optional for VTE prevention.

**2.6–2.9 kg:** 0.8 mg PO Q8 hr

**3–3.9 kg:** 0.9 mg PO Q8 hr

**4–4.9 kg:** 1.4 mg PO Q8 hr

**5–6.9 kg:** 1.6 mg PO Q8 hr

**7–7.9 kg:** 1.8 mg PO Q8 hr

**8–8.9 kg:** 2.4 mg PO Q8 hr

**9–9.9 kg:** 2.8 mg PO Q8 hr

**10–11.9 kg:** 3 mg PO Q8 hr

**12–29.9 kg:** 5 mg PO Q12 hr

**30–49.9 kg:** 15 mg PO Q24 hr

**≥50 kg:** 20 mg PO Q24 hr

**Duration of therapy:**

**All patients (except for <2 yr old with catheter-related thrombosis):** 3–12 months

**<2 yr old with catheter-related thrombosis:** 1–3 months

**Adult:** Administer all doses with food for VTE treatment but optional for VTE prevention.

**VTE Treatment:** 15 mg PO BID × 21 days followed by 20 mg PO once daily

**VTE Prevention:** 10 mg PO once daily

**Thromboprophylaxis following Fontan procedure:**

**Child ≥2–<18 yr:** Use only the oral suspension dosage form for patients <50 kg and either oral suspension or tablets for patients >50 kg (2.5 mg tablet not recommended in children due to incomplete pharmacokinetic/pharmacodynamic and clinical data). Doses may be administered with or without feeds or food.

**7–7.9 kg:** 1.1 mg PO Q12 hr

**8–9.9 kg:** 1.6 mg PO Q12 hr

**10–11.9 kg:** 1.7 mg PO Q12 hr

**12–19.9 kg:** 2 mg PO Q12 hr

**20–29.9 kg:** 2.5 mg PO Q12 hr

**30–49.9 kg:** 7.5 mg PO Q24 hr

**≥50 kg:** 10 mg PO Q24 hr

**Contraindicated** in active pathological bleeding and severe hypersensitivity to rivaroxaban and its excipients. **AVOID** use in moderate/severe hepatic impairment (Child-Pugh classes B and C); in those who develop acute renal failure with use; children with moderate/severe renal impairment (eGFR <50 mL/min); adults with severe renal impairment (eGFR <15 mL/min); use with medications that are p-glycoprotein (P-gp) and strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, and St. John's wort), or use with medications that are P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, lopinavir/ritonavir, ritonavir, indinavir/ritonavir). Use is not recommended in triple-positive antiphospholipid syndrome; patients with prosthetic heart valves or transcatheter aortic valve replacement; and with HIV protease inhibitors.

Common side effects include gastroenteritis (13% in children), vomiting (11%–14% in children), cough (16% in children), heavy menstrual bleeding (27% in adolescents), and hemorrhage (5%–36% in children and adults). Spinal hematoma or epidural hemorrhage may occur in patients receiving neuraxial anesthesia or undergoing spinal puncture; if needed, discontinue use of rivaroxaban 72 hours prior to neuraxial intervention and consider checking anti-factor Xa level.



RIVAROXABAN *continued*

Rivaroxaban is a major CYP450 3A4 and minor P-gp/ABC1 and BCRP/ABCG2 substrate. See above for medications to avoid and always assess for other drug interactions.

Administer all dosages with food or feeds as indicated. If anticoagulation needs to be discontinued prior to surgery or other procedures with bleeding risk, discontinue rivaroxaban at least 24 hr before the procedure. If converting from or to another anticoagulant medication, see product information for recommendations. Adjust dosage in renal impairment (see [Chapter 31](#)).

**RIZATRIPTAN BENZOATE**

Maxalt, Maxalt-MLT, and generics

*Antimigraine agent, selective serotonin agonist*



C

3

Yes

Yes

No

**Tabs:**

**Generics:** 5, 10 mg (12s, 18s)

**Maxalt:** 10 mg (18s)

**Orally disintegrating tabs (ODT):**

**Generics:** 5, 10 mg (9s, 12s, 18s); contain aspartame

**Maxalt-MLT:** 10 mg (18s); contains aspartame

**Treatment of acute migraines with or without aura (tabs and ODT):**

**Child 6–17 yr (efficacy and safety with >1 dose within 24 hr has not been established):**

<40 kg: 5 mg PO × 1

≥40 kg: 10 mg PO × 1

**≥18 yr and adult (safety in an average of >4 headaches in a 30-day period has not been established; see remarks):** 5–10 mg PO × 1. If needed in 2 hr, a second dose may be administered. **Max. daily dose:** 30 mg/24 hr

**Dosage adjustment if receiving propranolol:**

**Child 6–17 yr:**

<40 kg: **DO NOT USE**

≥40 kg: 5 mg PO × 1; **max. dose:** 5 mg/24 hr period

**≥18 yr and adult:** 5 mg PO up to a **maximum** of three doses at 2-hr intervals; **max. dose:** 15 mg/24 hr period

**Contraindicated** in hemiplegic or basilar migraine, coronary artery vasospasm, uncontrolled hypertension, ischemic bowel or coronary artery disease, peripheral vascular disease, history of stroke or transient ischemic attack (TIA), and current or recent use (within 2 weeks) of an MAO inhibitor.

**Do not** administer within 24 hr with any ergotamine-containing or ergot-type agent, any other 5-HT<sub>1</sub> agonist (e.g., triptans), methylene blue, or linezolid.

Use with **caution** in renal and hepatic impairment, as a 44% increase in AUC for patients receiving hemodialysis and a 30% increase in plasma concentration for patients with moderate hepatic dysfunction were reported.

Common adverse effects include nausea, asthenia, dizziness, somnolence, and fatigue. Serious adverse effects include chest pain, coronary artery spasm, hypertension, myocardial infarction (MI), peripheral ischemia, ventricular arrhythmia, ischemic colitis, anaphylaxis, angioedema, cerebrovascular accident, and serotonin syndrome. Transient and permanent vision loss have been reported.

When the ODT is being used, place the whole tablet on the tongue, allow the tablet to dissolve, and swallow with saliva. Administration with liquids is optional. Do not break the ODT tablet.

**ROCURONIUM**

Generics; previously available as Zemuron

**Nondepolarizing neuromuscular blocking agent**

C

?

No

Yes

No

**Injection:** 10 mg/mL (5, 10 mL); may be preservative free**Surgical tracheal intubation; use of a peripheral nerve stimulator to monitor drug effect is recommended.****Infant:****IV:** 0.5 mg/kg/dose; may repeat Q20–30 min PRN**Child (3 mo–14 yr):****IV:** 0.6 mg/kg/dose  $\times$  1; if needed, give maintenance doses of 0.075–0.125 mg/kg/dose Q20–30 min PRN when neuromuscular blockade returns to 25% of control. Alternatively, a maintenance continuous intravenous infusion may be used starting at 7–12 mCg/kg/min when neuromuscular blockade returns to 10% of control.**Adolescent and adult:****IV:** Start with 0.6–1.2 mg/kg/dose  $\times$  1; if needed, maintenance doses at 0.1–0.2 mg/kg/dose Q20–30 min PRN. Alternatively, a maintenance continuous intravenous infusion may be used starting at 10–12 mCg/kg/min (range: 4–16 mCg/kg/min).**Use with caution** in hepatic impairment and history of anaphylaxis with other neuromuscular blocking agents. Hypertension, hypotension, arrhythmia, tachycardia, nausea, vomiting, bronchospasm, wheezing, hiccups, rash, and edema at the injection site may occur. Myopathy after long-term use in an intensive care unit (ICU) and QT interval prolongation in pediatric patients receiving general anesthetic agents have been reported. Severe anaphylactic reactions and malignant hypothermia have been reported. Increased neuromuscular blockade may occur with concomitant use of aminoglycosides, clindamycin, tetracycline, magnesium sulfate, quinine, quinidine, succinylcholine, and inhalation anesthetics (for continuous infusion, reduce infusion by 30%–50% at 45–60 min after intubating dose).

Caffeine, calcium, carbamazepine, phenytoin, phenylephrine, azathioprine, and theophylline may reduce neuromuscular blocking effects.

Use must be accompanied by adequate anesthesia or sedation. Peak effects occur in 0.5–1 min for children and in 1–3.7 min for adults. Duration of action: 30–40 min in children and 20–94 min in adults (longer in geriatrics). Recovery time in children 3 months to 1 year of age is similar to that in adults. To prevent residual paralysis, extubate patient **only** after the patient has sufficiently recovered from neuromuscular blockade. In obese patients, use actual body weight for dosage calculation.**RUFINAMIDE**

Banzel and generics

**Anticonvulsant, triazole derivative**

C

3

Yes

Yes

No

**Tabs:** 200, 400 mg**Oral suspension:** 40 mg/mL (460 mL); contains parabens and propylene glycol**Lennox-Gastaut syndrome (adjunctive therapy; it is not known if doses lower than the targeted dosages are effective; see remarks):****Child 1–<17 yr (see remarks):** Start at 10 mg/kg/24 hr PO  $\div$  BID, then increase dose by  $\sim$  10 mg/kg/24 hr every other day up to the **maximum** targeted dose of 45 mg/kg/24 hr  $\div$  BID **not to exceed** 3200 mg/24 hr.

RUFINAMIDE *continued*

**Child ≥17 yr and adult:** Start at 400–800 mg/24 hr PO ÷ BID, then increase dose by 400–800 mg/24 hr every other day up to the **maximum** targeted dose of 3200 mg/24 hr ÷ BID.

**Use with concurrent valproate therapy:** Use lower initial dosages; <10 mg/kg/24 hr for child 1–<17 yr and <400 mg/24 hr for ≥17 yr and adult.

**Contraindicated** in familial short QT syndrome. Use is **not recommended** in severe hepatic impairment (Child-Pugh 10–15). Use with **caution** when taking other medications that can shorten the QT interval, performing tasks requiring mental alertness, and in mild/moderate hepatic impairment (Child-Pugh 5–9). 

Common side effects include fatigue, blurred vision, diplopia, ataxia, dizziness, headache, somnolence, nausea, vomiting, and shortening of cardiac QT interval. Serious side effects of leukopenia, severe dermatologic reactions (e.g., Stevens-Johnson syndrome), multiorgan hypersensitivity reactions (e.g., DRESS), and suicidal ideation have been reported.

Rufinamide is a weak inhibitor of CYP 450 2E1 and weak inducer of 3A4. May decrease levels/effects of nifedipine, nimodipine, piperazine, calcifediol, clozapine, carbamazepine, lamotrigine, triazolam, orlistat, and hormonal contraceptives. May increase the levels/effects of phenytoin and phenobarbital. Primidone, phenobarbital, phenytoin, and carbamazepine may decrease the levels/effects of rufinamide, whereas valproic acid may increase the levels/effects of rufinamide.

The effectiveness data for 1- to 4-year-old children are based on bridging pharmacokinetic (PK) and safety data as their PK and safety data are similar to children ≥4 years old and adults.

Consider dose adjustment for drug loss in patients receiving hemodialysis (rufinamide is dialyzable). For therapy discontinuation, reduce dose by ~25% every 2 days. Tablets may be crushed and all doses may be administered with or without food.

## S

**SALMETEROL**

Serevent Diskus

*β<sub>2</sub> adrenergic agonist (long acting)*

C



1



No



Yes



No

**Dry powder inhalation (DPI; Diskus):** 50 mCg/inhalation (60 inhalations); contains lactose and milk protein

**In combination with fluticasone:** See [Fluticasone Propionate and Salmeterol](#).

**Persistent asthma (see remarks):**

≥4 yr and adult: 1 inhalation (50 mCg) Q12 hr 

**Prevention of exercise-induced bronchospasm:**

≥4 yr and adult: 1 inhalation 30 to 60 min before exercise. Additional doses should not be used for another 12 hr. Patients who are already using 12-hr dosing for persistent asthma should NOT use additional salmeterol doses for this indication and use alternative therapy (e.g., albuterol) prior to exercise.

For long-term asthma control, should be used in combination with inhaled corticosteroids. 

**Should not be used to relieve symptoms of acute asthma.** It is long acting and has its onset of action in 10 to 20 min with a peak effect at 3 hr. May be used at QHS (1 inhalation of the dry powder inhaler [DPI]) for nocturnal symptoms. Salmeterol is a chronic medication and is not used in similar fashion to short-acting β agonists (e.g., albuterol). Patients already receiving salmeterol every 12 hr should not use additional doses for prevention of exercise-induced bronchospasm; consider alternative therapy. Asthma exacerbations or hospitalizations were reported to be lower when this medication was used with an inhaled corticosteroid.

*Continued*

SALMETEROL *continued*

**WARNING: Long-acting  $\beta_2$ -agonists as monotherapy increase the risks of asthma-related death** and asthma-related hospitalizations. Monotherapy without concomitant use of an inhaled corticosteroid is **contraindicated** in asthma. Use salmeterol only as additional therapy for patients not adequately controlled on other asthma-controller medications (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity clearly requires initiation of treatment with two maintenance therapies. **Contraindicated** in milk allergies; contains milk proteins.

**Should not be used** in conjunction with an inhaled, long-acting  $\beta_2$ -agonist and is not a substitute for inhaled or systemic corticosteroid. Use with strong CYP450 3A4 inhibitors (e.g., ketoconazole, HIV protease inhibitors, clarithromycin, itraconazole, nefazodone, and telithromycin) is **not recommended** due to risk for cardiovascular adverse events (e.g., QTc prolongation, tachycardia). Salmeterol is a CYP 450 3A4 substrate.

Proper patient education is essential. This dosage form's breath activated device requires a minimum inspiratory flow rate of 60 mL/min for proper dose delivery. Use with caution in hepatic impairment. Side effects are similar to those of albuterol. Hypertension and arrhythmias have been reported. See [Chapter 24](#) for recommendations for asthma controller therapy.

**SCOPOLAMINE HYDROBROMIDE**

Transderm Scop and generics

**Anticholinergic agent**

C



2



Yes



Yes



No

**Transdermal patch:****Transderm Scop:** 1 mg/3 days patch (10s and 24s); delivers ~1 mg over 3 days**Generics:** 1 mg/3 days patch (4s, 10s, and 24s); delivers ~1 mg over 3 days

**Prevention of postoperative nausea and vomiting (apply patch behind the ear, the evening before surgery and remove patch the morning of the first postoperative day; limited data):**

**Child <2 yr:**  $\frac{1}{4}$  patch**Child 2–6 yr:**  $\frac{1}{2}$  patch**Child 6–12 yr:**  $\frac{1}{2}$  –1 patch**Child 12 yr and adolescent:** 1 patch**Adult indications:****Motion sickness:** Apply 1 patch behind the ear at least 4 hr prior to exposure to motion; remove after 72 hr. If additional therapy is needed, apply 1 new patch behind the other ear.**Prevention of postoperative nausea and vomiting (excluding cesarean section):** Apply 1 patch behind the ear the evening before surgery. Remove patch 24 hr after surgery.**Antiemetic prior to cesarean section:** Apply 1 patch behind the ear 1 hr prior to surgery to minimize infant exposure. Remove patch 24 hr after surgery.

Toxicities similar to those of atropine. **Contraindicated** in closed-angle glaucoma and hypersensitivity to belladonna alkaloids. **Use with caution** in hepatic or renal dysfunction, GI and urinary disorders (discontinue use if there is difficulty in urination), cardiac disease, seizures, or psychosis. May cause dry mouth, drowsiness, and blurred vision. Generalized rash and erythema may indicate hypersensitivity to the medication or other ingredients in the formulation. Hallucinations, amblyopia and mydriasis have been reported in children.

Drug withdrawal symptoms (nausea, vomiting, headache, and vertigo) have been reported following removal of transdermal patch in patients using the patch for more than 3 days. For perioperative use, the patch should be kept in place for 24 hr following surgery.

SCOPOLAMINE HYDROBROMIDE *continued*


Concurrent use with medications with known CNS adverse reactions or that have anticholinergic properties may potentiate scopolamine's CNS effects. Use of this medication may delay the rate of orally administered drugs and will interfere with the gastric secretion test (discontinue use 10 days prior to testing).

REMOVE transdermal patch before undergoing an MRI; patch contains aluminum.

**SELENIUM SULFIDE**

Selsun Blue and generics

**Topical antiseborrheic agent**

**Shampoo:**

**1% (Selsun Blue and others; OTC):** 207, 325, 400, 420 mL; some products are available in combination with a conditioner. Be aware of different active ingredients in the Selsun Blue product line.

**2.25%:** 180 mL; may contain parabens and propylene glycol

**2.3%:** 180 mL; may contain parabens and propylene glycol

**Topical lotion:** 2.5% (120 mL)

**≥2 yr and adult:****Seborrhea/dandruff:**

**Lotion:** Massage 5 to 10 mL into wet scalp and leave on scalp for 2 to 3 min. Rinse thoroughly and repeat. Use twice weekly for 2 weeks for control and may be followed by a less frequent maintenance application of once every 1 to 4 wk.

**Shampoo:** Massage shampoo into wet scalp then rinse thoroughly. Shampoo at least twice weekly.

**Pityriasis (tinea) versicolor:** Apply 2.5% lotion to affected areas of skin. Allow to remain on skin for 10 min. Rinse thoroughly. Repeat once daily for 7 days. Follow with weekly or monthly applications for 3 mo to prevent recurrences.


Rinse hands and body well after treatment. May cause local irritation, hair loss, and hair discoloration. **Avoid** eyes, genital areas, and skin folds. Shampoo may be used for tinea capitis to reduce risk of transmission to others (does not eradicate tinea infection).

For tinea versicolor, 15% to 25% sodium hyposulfite or thiosulfate (Tinver lotion) applied to affected areas twice daily for 2 to 4 wk is an alternative. Topical antifungals (e.g., clotrimazole, miconazole) may be used for small focal infections. **Do not use** for tinea versicolor during pregnancy.

**SENNA/SENNOSIDES**

Senokot, Senna-Lax, Ex-Lax, Genexa Kids Senna Laxative, and many others

**Laxative, stimulant**

**Based on mg of senna (all products are OTC):**

**Oral syrup:** 176 mg/5 mL, 218 mg/5 mL (60 mL, 240 mL); may contain parabens and propylene glycol

**Tabs:** 187, 217, 374 mg

187 mg senna extract is approximately 8.6 mg sennosides.

**Based on mg of sennosides (all products are OTC):**

**Oral syrup:** 8.8 mg/5 mL (237 mL); may contain parabens and propylene glycol

**Tabs:** 8.6, 12, 15, 17.2, 25 mg

*Continued*

SENNA/SENNOSIDES *continued*

**Chewable tabs:** 8.6 mg

**Genexa Kids Senna Laxative:** 3 mg

8.6 mg sennosides is approximately 187 mg senna extract.

**Constipation (a second-line agent for short-term use; other agents are preferred for maintenance therapy):**



**Dosing based on mg senna:**

**Child:**

**Oral:** 10–20 mg/kg/dose PO QHS (**max. dose:** as shown below) or dosage by age:

**1 mo–1 yr:** 55–109 mg PO QHS to **max. dose:** 218 mg/24 hr

**1–5 yr:** 109–218 mg PO QHS to **max. dose:** 436 mg/24 hr

**5–15 yr:** 218–436 mg PO QHS to **max. dose:** 872 mg/24 hr

**Adult:**

**Oral powder:** ½ to 1 tsp PO once or twice daily

**Syrup:** 436–654 mg PO at bedtime; **max. dose:** 654 mg (15 mL) BID

**Tabs:** 374 mg PO at bedtime; **max. dose:** 748 mg BID

**Dosing based on mg sennosides:**

**Child ≤12 yr:**

**Syrup:**

**1 mo–2 yr:** 2.2–4.4 mg (1.25–2.5 mL) PO QHS to **max. dose:** 8.8 mg/24 hr

**2–5 yr:** 4.4–6.6 mg (2.5–3.75 mL) PO QHS to **max. dose:** 6.6 mg BID

**6–12 yr:** 8.8–13.2 mg (5–7.5 mL) PO QHS to **max. dose:** 13.2 mg BID

**Tabs or chewable tabs (8.6 mg):**

**2–5 yr:** 4.3 mg PO QHS to **max. dose:** 8.6 mg BID

**6–12 yr:** 8.6 mg PO QHS to **max. dose:** 17.2 mg BID

**Chewable tabs (Genexa Kids Senna Laxative; 3 mg):**

**2–5 yr:** 3 mg PO once daily or BID

**6–12 yr:** 6 mg PO once daily or BID

**>12 yr and adult:**

**Granules:** 15 mg PO QHS to **max. dose:** 30 mg BID

**Syrup:** 17.6–26.4 mg (10–15 mL) PO QHS to **max. dose:** 26.4 mg BID

**Tabs:** 17.2 mg PO QHS to **max. dose:** 34.4 mg BID

Effects occur within 6 to 24 hr after oral administration. Prolonged use (>1 wk) should be **avoided** as it may lead to dependency. May cause nausea, vomiting, diarrhea, and abdominal cramps. Active metabolite stimulates the Auerbach plexus. Syrup may be administered with juice or milk or mixed with ice cream.

**SERTRALINE HCL**

Zoloft and generics

**Antidepressant (selective serotonin reuptake inhibitor)**



C



2



Yes



Yes



Yes

**Tabs:** 25, 50, 100 mg; tablets may be scored

**Caps:** 150, 200 mg

**Oral concentrate solution:** 20 mg/mL (60 mL); may contain 12% alcohol and propylene glycol

**Depression (see remarks):**

**Child 6–12 yr:** Start at 12.5–25 mg PO once daily. May increase dosage by 12.5–25 mg at weekly intervals up to a **max. dose** of 200 mg/24 hr



SERTRALINE HCL *continued*

**Child ≥13 yr and adult:** Start at 25–50 mg PO once daily. May increase dosage by 25–50 mg at weekly intervals up to a **max. dose** of 200 mg/24 hr

**Obsessive compulsive disorder (see remarks):**

**Child 6–12 yr:** Start at 25 mg PO once daily. May increase dosage by 25–50 mg at weekly intervals up to a **max. dose** of 200 mg/24 hr

**Child ≥13 yr and adult:** Start at 50 mg PO once daily. May increase dosage by 50 mg at weekly intervals up to **max. dose** of 200 mg/24 hr

Drug is **contraindicated** in combination (or within 14 days of discontinuing use) with a monoamine oxidase (MAO) inhibitor (e.g., linezolid or intravenous methylene blue) or pimozide (increases adverse/toxic effects of pimozide). **Use with caution** in patients with abnormal bleeding, syndrome of inappropriate diuretic hormone (SIADH) secretion, and hepatic or renal impairment. Adverse effects include nausea, diarrhea, tremor, sexual dysfunction, and increased sweating. Hyponatremia, diabetes mellitus, rhabdomyolysis, trismus, and platelet dysfunction have been reported. A positive correlation with length of QTc interval and serum sertraline and N-desmethylsertraline levels has been reported.



Monitor for clinical worsening of depression and suicidal ideation/behavior following the initiation of therapy or after dose changes. Use during the late third trimester of pregnancy may increase risk for withdrawal symptoms and persistent pulmonary hypertension in the newborn.

Use with drugs that interfere with hemostasis (e.g., NSAIDs, aspirin, warfarin) may increase risk for GI bleeds. Use with warfarin may increase PT. Inhibits the CYP 450 2D6 drug metabolizing enzyme. Serotonin syndrome may occur when taken with selective serotonin reuptake inhibitors (e.g., amitriptyline, amphetamines, buspirone, dihydroergotamine, sumatriptan, sympathomimetics).

Sertraline is a substrate for CYP 450 2B6, 2C9, 2C19, 2D6, and 3A4. Poor metabolizers of CYP 450 2C19 should initiate therapy at 50% of the recommended dosage and titrate to desired effect *or* consider using an alternative medication not predominantly metabolized by this enzyme. Ultrarapid 2C19 metabolizers should initiate therapy at the recommended starting dose and titrate to the recommended maintenance dosage *or* consider using a drug not predominantly metabolized by this enzyme.

**Do not** abruptly discontinue use; gradually taper dose (4–6 wk has been recommended) to reduce risk for withdrawal symptoms.

Mix oral concentrate solution with 4 oz of water, ginger ale, lemon/lime soda, lemonade, or orange juice. After mixing, a slight haze may appear; this is normal. This dosage form should be **used cautiously** in patients with latex allergy because the dropper contains dry natural rubber.

**SILDENAFIL**

Revatio, Viagra, and generics

**Phosphodiesterase type-5 (PDE5) inhibitor**



B



2



Yes



Yes



No

**Tabs:**

**Revatio and generics:** 20 mg

**Viagra and generics:** 25, 50, 100 mg

**Oral suspension:** 2.5 mg/mL 

**Revatio and generics:** 10 mg/mL (112 mL); may contain sodium benzoate

**Injection:**

**Revatio and generics:** 0.8 mg/mL (12.5 mL)

**Pulmonary hypertension:**

**Neonate (limited data from case reports and small clinical trials):**



*Continued*

SILDENAFIL *continued*

**PO:** Several dosages have been reported and have ranged from 0.5 to 3 mg/kg/dose Q6–12 hr PO. A single dose of ~0.3 mg/kg PO has been used in select patients to facilitate weaning from inhaled nitric oxide.

**IV (case report from 4 neonates >34 weeks' gestation and <72 hr old):** Start with 0.4 mg/kg/dose IV over 3 hr followed by a continuous infusion of 1.6 mg/kg/24 hr (0.067 mg/kg/hr) for up to 7 days.

**Infant and child (limited data):**

**PO:** Start at 0.25 mg/kg/dose Q6 hr or 0.5 mg/kg/dose Q8 hr; if needed, titrate dose up to 1–2 mg/kg/dose Q6–8 hr. A single dose of ~0.4 mg/kg PO has been used in select patients to facilitate weaning from inhaled nitric oxide.

**Child 1–17 yr (higher doses and long-term use are associated with increased risk for mortality; see remarks):**

**PO:**

≥8–20 kg: 10 mg TID

>20–45 kg: 20 mg TID

>45 kg: 40 mg TID

**Pulmonary arterial hypertension:****Adult:**

**PO:** 20 mg TID (take at least 4–6 hr apart)

**IV:** 10 mg TID

**Contraindicated** with concurrent use of nitrates (e.g., nitroglycerin) and other nitric oxide donors; potentiates hypotensive effects. **Use with caution** in sepsis (high levels of cGMP may potentiate hypotension), hypotension, sickle cell anemia (use not established), and with concurrent CYP 450 3A4 inhibiting medications (see discussion that follows) and anti-hypertensive medications. Hepatic insufficiency or severe renal impairment (glomerular filtration rate [GFR] <30 mL/min) significantly reduces sildenafil clearance. 

Findings from the dose-ranging study in 1- to 17-yr-olds with pulmonary arterial hypertension found an association of increased mortality risk with long-term use (>2 yr). Headache, pyrexia, upper respiratory tract infections (URTIs), vomiting, and diarrhea were the most frequently reported side effects in this study. Optimal dosing based on age and body weight still needs to be determined. Hazard ratios for mortality were 3.95 (95% CI: 1.46–10.65) for high versus low doses and 1.92 (95% CI: 0.65–5.65) for medium versus low doses in follow-up study for those receiving therapy for ≥3 yr. A subsequent extension open-label study on the same population for an additional 16 weeks reported a greater hazard ratio for mortality with high- versus low-dose therapy ( $P = 0.007$ ).

In adults, a transient impairment of color discrimination may occur; this effect could increase risk of severe retinopathy of prematurity in neonates. Common side effects reported in adults have included flushing, rash, diarrhea, indigestion, headache, abnormal vision, and nasal congestion. Hearing loss has been reported.

Sildenafil is substrate for CYP 450 3A4 (major) and 2C8/9 (minor). Azole antifungals, cimetidine, ciprofloxacin, clarithromycin, erythromycin, nicardipine, propofol, protease inhibitors, quinidine, verapamil, and grapefruit juice may increase the effects/toxicity of sildenafil. Bosentan, efavirenz, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's wort, and high-fat meals may decrease sildenafil effects.

**SILVER SULFADIAZINE**

Silvadene, Thermazene, SSD Cream, and generics

**Topical antibiotic**



B



3



Yes



Yes



No

SILVER SULFADIAZINE *continued*

**Cream:** 1% (20, 25, 50, 85, 400, 1000 g); contains methylparabens and propylene glycol


**Child (≥2 mo) and adult:** Cover affected areas completely once or twice daily. Apply cream to a thickness of 1/16 inch using sterile technique.

**Contraindicated** in premature infants and infants up to 2 mo of age due to concerns of kernicterus; also contraindicated in pregnancy (approaching term). **Use with caution** in G6PD and renal and hepatic impairment. Discard product if cream has darkened. Significant systemic absorption may occur in severe burns. Adverse effects include pruritus, rash, bone marrow suppression, hemolytic anemia, hepatitis, interstitial nephritis, and life-threatening cutaneous reactions (e.g., Stevens-Johnson syndrome/toxic epidermal necrolysis [TEN] and exfoliative dermatitis). **Avoid** contact with the eye. Dressing may be used but is not necessary. See [Chapter 4](#) for more information.



**SIMETHICONE**

Mylicon, Children's Mylicon, Phazyme, Mylanta Gas, Gas-X, and generics  
**Antiflatulent**



All dosage forms available OTC

**Oral drops and suspension:** 40 mg/0.6 mL (15, 30 mL); may contain sodium benzoate and polyethylene glycol

**Caps (Phazyme, Gas-X, and generics):** 125, 180, 250 mg

**Chewable tabs:** 80, 125 mg

**Children's Mylicon:** 40 mg; contains 400 mg calcium carbonate

**Strip, orally disintegrating (Gas-X):** 40 mg (16s), 62.5 mg (18s); may contain alcohol

**Infant and child <2 yr:** 20 mg PO QPC and QHS PRN; **max. dose:** 240 mg/24 hr

**2–12 yr:** 40 mg PO QPC and QHS PRN; **max. dose:** 480 mg/24 hr


**>12 yr and adult:** 40–125 mg PO QPC and QHS PRN; **max. dose:** 500 mg/24 hr

Efficacy has not been demonstrated for treating infant colic. **Avoid** carbonated beverages and gas-forming foods. Oral liquid may be mixed with water, infant formula, or other suitable liquids for ease of oral administration.



**SIROLIMUS**

Rapamune and generics  
**Immunosuppressant agent**



**Tabs:** 0.5, 1, 2 mg

**Oral solution:** 1 mg/mL (60 mL); contains 1.5%–2.5% ethanol, polysorbate 80, and propylene glycol

**Prophylaxis of organ rejection in renal transplantation:**

**Child ≥13 yr (tablet and oral solution dosage forms are NOT bioequivalent; see remarks):**

**<40 kg:** 3 mg/m<sup>2</sup>/dose PO given once immediately after transplantation, followed by 1 mg/m<sup>2</sup>/24 hr PO ÷ Q 12–24 hr on the next day. Adjust dose to achieve desired trough blood level.

**≥40 kg:** Use adult (low/moderate immunologic risk) ≥40 kg dosage below and adjust dose to achieve desired trough blood level.

**Adult (tablet and oral solution dosage forms are NOT bioequivalent; see remarks):**

**Patients at low/moderate immunologic risk:**



*Continued*

SIROLIMUS *continued***In combination with cyclosporine (adjust dose to achieve desired trough blood level):**

**<40 kg:** 3 mg/m<sup>2</sup>/dose PO given once immediately after transplantation followed by 1 mg/m<sup>2</sup>/dose PO once on the next day

**≥40 kg:** 6 mg PO once immediately after transplantation, followed by 2 mg PO once on the next day

**Patients at high immunologic risk:**

**In combination with cyclosporine (withdrawal of cyclosporine is not recommended):** 15 mg PO once immediately after transplantation, followed by 5 mg PO once on the next day. Adjust dose to achieve desired trough blood level.

Increased susceptibility to infection and development of lymphoma may result from immunosuppression. **Fatal** bronchial anastomotic dehiscence has been reported in lung transplantation. Excess mortality, graft loss, and hepatic artery thrombosis have been reported in liver transplantation when used with tacrolimus. Patients with the greatest amount of urinary protein excretion prior to sirolimus conversion were those whose protein excretion increased the most after conversion. Increased risk of BK virus—associated nephropathies has been reported. The following adverse effects have been reported when converting from a calcineurin inhibitor-based regimen to maintenance sirolimus:

Stable liver transplant: increased mortality

Kidney transplant: pneumonia, proteinuria, acute rejection, graft loss, and death

Monitor whole-blood trough levels (just prior to a dose at steady state); especially with pediatric patients; hepatic impairment; concurrent use of CYP 450 3A4 and/or P-gp inducers and inhibitors; and/or if cyclosporine dosage is markedly changed or discontinued. Steady-state is generally achieved after 5 to 7 days of continuous dosing. **Interpretation will vary based on specific treatment protocol and assay methodology (HPLC vs. immunoassay vs. LC/MS/MS). Younger children may exhibit faster sirolimus clearance compared with adolescents.**

Sirolimus is a substrate for CYP 450 3A4 and P-gp. Bromocriptine, cannabidiol, cyclosporine, diltiazem, metoclopramide, protease inhibitors, erythromycin, grapefruit juice, and other inhibitors of CYP 3A4 (e.g., calcium channel blockers) may increase the toxicity of sirolimus. Phenobarbital, carbamazepine, phenytoin, and St John's wort may decrease the effects of sirolimus. Strong inhibitors (e.g., azole antifungals and clarithromycin) and strong inducers (e.g., rifamycins) are **not recommended**.

Hypertension, peripheral edema, increased serum creatinine, dyspnea, epistaxis, headache, anemia, thrombocytopenia, hyperlipidemia, hypercholesterolemia, and arthralgia may occur. Progressive multifocal leukoencephalopathy (PML), diabetes mellitus, posterior reversible encephalopathy syndrome, ovarian cysts, and menstrual disorders have been reported. Urinary tract infections have been reported in pediatric renal transplant patients with high immunologic risk.

Two milligrams of the oral solution have been demonstrated to be clinically equivalent to the 2-mg tablets. However, it is not known whether they are still therapeutically equivalent at higher doses. Reduce maintenance dosage by one-third in the presence of hepatic function impairment. Administer doses consistently with or without food. When administered with cyclosporine, give dose 4 hr after cyclosporine. **Do not** crush or split tablets. Measure the oral liquid dosage form with an amber oral syringe and dilute in a cup with 60 mL of water or orange juice only. Take dose immediately after mixing, add/mix additional 120 mL diluent into the cup, and drink immediately after mixing.

**SODIUM BICARBONATE**

Generics

**Alkalinizing agent, electrolyte**



C



?



Yes



No



No

**Injection:** 4.2% (0.5 mEq/mL) (5, 10 mL), 7.5% (0.89 mEq/mL) (50 mL), 8.4% (1 mEq/mL) (10, 50 mL)

**Tabs:** 325 mg (3.8 mEq), 650 mg (7.6 mEq)

SODIUM BICARBONATE *continued*

**Powder:** 1, 120, 500 g; contains 30 mEq Na<sup>+</sup> per 1/2 teaspoon  
Each 1 mEq bicarbonate provides 1 mEq Na<sup>+</sup>.

**Cardiac arrest:** See [inside front cover](#).

**Correction of metabolic acidosis:** Calculate patient's dose with the following formulas.

**Neonate, infant, and child:**

$$\text{HCO}_3^- \text{ (mEq)} = 0.3 \times \text{weight (kg)} \times \text{base deficit (mEq/L)}, \text{ OR}$$

$$\text{HCO}_3^- \text{ (mEq)} = 0.5 \times \text{weight (kg)} \times [24 - \text{serum HCO}_3^- \text{ (mEq/L)}]$$

**Adult:**

$$\text{HCO}_3^- \text{ (mEq)} = 0.2 \times \text{weight (kg)} \times \text{base deficit (mEq/L)}, \text{ OR}$$

$$\text{HCO}_3^- \text{ (mEq)} = 0.5 \times \text{weight (kg)} \times [24 - \text{serum HCO}_3^- \text{ (mEq/L)}]$$

**Urinary alkalization (titrate dose accordingly to urine pH):**

**Child:** 84–840 mg (1–10 mEq)/kg/24 hr PO ÷ QID

**Adult:** 4 g (48 mEq) × 1 followed by 1–2 g (12–24 mEq) PO Q4 hr. Doses up to 16 g (192 mEq)/24 hr have been used.

**Contraindicated** in respiratory alkalosis, hypochloremia, and inadequate ventilation during cardiac arrest. **Use with caution** in congestive heart failure (CHF), renal impairment, cirrhosis, hypocalcemia, hypertension, and concurrent corticosteroids. Maintain high urine output. Monitor acid-base balance and serum electrolytes. May cause hypernatremia (contains sodium), hypokalemia, hypomagnesemia, hypocalcemia, hyperreflexia, edema, and tissue necrosis (extravasation). Oral route of administration may cause GI discomfort and gastric rupture from gas production. For direct intravenous administration (cardiac arrest) in neonates and infants, use the 0.5 mEq/mL (4.2%) concentration or dilute the 1 mEq/mL (8.4%) concentration 1:1 with sterile water for injection and infuse at a rate **no greater than** 10 mEq/min. The 1 mEq/mL (8.4%) concentration may be used in children and adults for direct intravenous administration.

For intravenous infusions (for all ages), dilute to a **max. concentration** of 0.5 mEq/mL in dextrose or sterile water for injection and infuse over 2 hr using a **max. rate** of 1 mEq/kg per hr.

Sodium bicarbonate should not be mixed with or be in contact with calcium, norepinephrine, or dobutamine.

**SODIUM CHLORIDE—INHALED PREPARATIONS**

Hypersal, Nebusal, PulmoSal, Simply Saline, Ocean, Ayr Saline, Ayr Nasal Mist Allergy/Sinus, many other brands, and generics

**Electrolyte, inhalation**



C



1



No



No



No

**Nebulized solution (generics):** 0.9% (3, 5, 15 mL), 3% (4, 15 mL), 7% (4 mL), 10% (4, 15 mL)

**Hypersal (preservative-free):** 3.5% (4 mL), 7% (4 mL)

**Nebusal:** 3% (4 mL), 6% (4 mL)

**PulmoSal:** 7% (4 mL)

**Nasal solution spray/drops/mist (OTC):** 0.65% (15, 30, 45 mL), 2.65% (50 mL); may contain benzalkonium chloride

**Intranasal as moisturizer (use 0.65% concentration):**

**Child and adult:**

**Spray/Mist:** 2–6 sprays into each nostril Q2 hr PRN

**Drops:** 2–6 drops into each nostril Q2 hr PRN

**Cystic fibrosis (Pretreatment with albuterol is recommended to prevent bronchospasms; see remarks):**

*Continued*

SODIUM CHLORIDE—INHALED PREPARATIONS *continued*

≥2 yr and adult: Nebulize 4 mL of 7% solution once or twice daily. If patient is unable to tolerate the 7% strength, lower strengths of 3%, 3.5%, or 5% may be used.

**Acute viral bronchiolitis (for hospitalized patients only; pretreatment with albuterol is recommended to prevent bronchospasms; see remarks):**

**Infant (>34 weeks' gestation up to 18 mo old):** Nebulize 4 mL of 3% solution Q2 hr for three doses followed by Q4 hr for five doses followed by Q6 hr dosing until discharge.

**INTRANASAL USE:** May be used as a nasal wash for sinuses, to restore moisture, to thin nasal secretions, or to relieve dry, crusted, and inflamed nasal membranes from colds, low humidity, allergies, nasal decongestant overuse, minor nosebleeds, and other irritations. Nasal administration instructions:

**Nasal drops:** Tilt head back and hold bottle upside down.

**Nasal spray:** Hold head in upright position and give short, firm squeezes into each nostril. Sniff deeply.

**NEBULIZATION:** Hypertonic solutions lowers sputum viscosity and enhances mucociliary clearance.

**Cystic fibrosis:** Improves FEV<sub>1</sub> and reduces pulmonary exacerbation frequency. May cause bronchospasm, cough, pharyngitis, hemoptysis, and acute decline in pulmonary function (administer first dose in a medical facility). It is recommended to withhold therapy in the presence of massive hemoptysis.

**Acute viral bronchiolitis:** Use not recommended in the emergency department but may be administered in hospitalized patients. Reported reduction in length of hospitalization when compared to normal saline is controversial. May cause acute bronchospasm and local irritation.

**SODIUM PHENYLACETATE AND SODIUM BENZOATE**

Ammonul and generics

**Ammonium detoxicant, urea cycle disorder treatment agent**



C

?

Yes

Yes

Yes

**Injection:** 100 mg sodium phenylacetate and 100 mg sodium benzoate per 1 mL (50 mL)

**IV via central line (administered with IV arginine, continue infusion until ammonia levels are in the normal range):** See [Chapter 13](#) for dosing information.

Indicated for hyperammonemia due to enzyme deficiencies of the urea cycle (e.g., carbamoyl phosphate synthetase [CPS] and ornithine transcarbamylase deficiency). **Use with caution** in renal and hepatic impairment. Significant amounts of sodium may be administered with prolonged durations of therapy. Ammonia clearance is most efficient with hemodialysis.

Side effects include hypotension, hypokalemia, hyperglycemia, injection site reaction, nausea/vomiting, altered mental status, fever, metabolic acidosis, cerebral edema, seizures, anemia, and disseminated intravascular coagulation. CNS side effects are more frequent with ornithine transcarbamylase (OTC) and CPS. Blood and lymphatic system disorders and hypotension are common in patients 30 days old or younger, whereas nausea, vomiting, and diarrhea are common in patients more than 30 days old. Monitor blood chemistry profiles, blood pH and pCO<sub>2</sub> for hyperventilation and metabolic acidosis.

Although no formal drug interaction studies have been completed, penicillin antibiotics and probenecid may increase serum concentrations of sodium phenylacetate and sodium benzoate by competing for renal tubular secretion. Use of valproic acid or corticosteroids may increase plasma ammonia levels.

Must be diluted and administered IV via central line; peripheral line administration may result in burning and extravasation.

**SODIUM PHOSPHATE**

Fleet Enema, Fleet Pedia-Lax, Fleet Enema Extra, GoodSense Enema, LaCrosse Complete, OsmoPrep, and generics

*Laxative, enema/oral*



C



2



Yes



No



No

**Enema [OTC]:**

7 g dibasic sodium phosphate and 19 g monobasic sodium phosphate/118 mL; contains 4.4 g sodium per 118 mL

**Pediatric size (Fleet Pedia-Lax):** 66 mL

**Adult size (Fleet Enema, GoodSense Enema, LaCrosse Complete, and generics):** 133 mL

7 g dibasic sodium phosphate and 19 g monobasic sodium phosphate/197 mL; contains 4.4 g sodium per 197 mL

**Fleet Enema Extra:** 230 mL

**Oral tablets (OsmoPrep):** 1.5 g (1.102 g monobasic sodium and 0.398 g per tablet); gluten free

**Injection:** See [Phosphorus Supplements](#).

**Not to be used for phosphorus supplementation (see [Phosphorus Supplements](#))**



**Enema (see remarks):**

**2–4 yr:** 33 mL enema (half of Fleet Pedia-Lax) × 1

**5–11 yr:** 66 mL enema (Fleet Pedia-Lax) × 1

**≥12 yr and adult:** 133 mL enema (Fleet Enema or generics) **OR** 230 mL enema (Fleet enema Extra) × 1

**Bowel prep prior to colonoscopy:**

**Adult (PO):**

**Evening prior to colonoscopy:** 4 tabs (OsmoPrep) with 8 ounces of clear liquids Q15 min up to a total of 5 doses (20 tabs with 40 oz of clear liquids)

**Day of colonoscopy, 3 to 5 hr prior to procedure:** 4 tabs (OsmoPrep) with 8 oz of clear liquids Q15 min up to a total of three doses (12 tabs with 24 oz of clear liquids)

**Contraindicated** in patients with severe renal failure, megacolon, bowel obstruction, and CHF.



May cause hyperphosphatemia, hypernatremia, hypocalcemia, hypotension, dehydration, and acidosis. **Avoid** retention of enema solution and **do not exceed** recommended doses, as this may lead to severe electrolyte disturbances due to enhanced systemic absorption. **Use with caution** in cardiac arrhythmias. Colonic mucosal aphthous ulceration should be considered when interpreting colonoscopy findings with use in patients with known or suspected irritable bowel disease (IBD).

Correct electrolyte abnormalities prior to use to minimize electrolyte side effects.

**Onset of action:** PR, 2–5 min

**SODIUM POLYSTYRENE SULFONATE**

SPS, and generics; previously available as Kayexalate and Kionex

*Potassium-removing resin*



C



1



Yes



No



No

**Powder:** 15, 454 g

**Oral suspension:** 15 g/60 mL (60, 120, 473, 500 mL); contains 21.5 mL sorbitol per 60 mL and 0.1%–0.3% alcohol

Contains 4.1 mEq Na<sup>+</sup>/g drug

**Hyperkalemia: Note:** Oral suspension may be given PO or PR (PO route is more effective).

Practical exchange ratio is 1 mEq K per 1 g resin. May calculate dose according to desired exchange (see remarks).



*Continued*

SODIUM POLYSTYRENE SULFONATE *continued***Infant and child:**

**PO:** 1 g/kg per dose (**max. dose:** 15 g per dose) Q6 hr

**PR:** 1 g/kg per dose Q2–6 hr; **max. dose:** 30–50 g per dose. Dosing by practical exchange (1 mEq K per 1 g resin) has been recommended for infants and smaller children.

**Adult:**

**PO:** 15 g once daily—QID

**PR:** 30–50 g Q6 hr

**Contraindicated** in obstructive bowel disease, neonates with reduced gut motility, and oral administration in neonates. **Use cautiously** in presence of renal failure, CHF, hypertension, or severe edema. May cause hypokalemia, hypernatremia, hypomagnesemia, and hypocalcemia. Cases of colonic necrosis, GI bleeding, ischemic colitis, and perforation have been reported with the concomitant use of sorbitol in patients with GI risk factors (prematurity, history of intestinal disease or surgery hypovolemia, and renal insufficiency/failure). Use in neonates generally **not recommended** due to complication concerns for hypernatremia and NEC.

1 mEq Na delivered for each mEq K removed. **Do not administer** with antacids or laxatives containing  $Mg^{2+}$  or  $Al^{3+}$ . Systemic alkalosis may result. May reduce absorption of other orally administered medication; administer other oral medications at least 3 hr before or 3 hr after sodium polystyrene sulfonate (patients with gastroparesis may require a 6-hr separation). Enema should be retained in the colon for at least 30–60 min.

**SPIRONOLACTONE**

Aldactone, CaroSpir, and generics

**Diuretic, potassium sparing**



C/D



1



Yes



Yes



No

**Tab:** 25, 50, 100 mg

**Oral suspension:** 1, 5, 25 mg/mL 

**CaroSpir:** 25 mg/5 mL (118, 473 mL); contains saccharin

**Diuretic:**

**Neonate:** 1–3 mg/kg/24 hr ÷ once or twice daily PO

**Child:** 1–3 mg/kg/24 hr ÷ BID–QID PO; **max. dose by indication:**

**Hypertension:** The lesser of 3.3 mg/kg/24 hr or 100 mg/24 hr

**Edema:** The lesser of 4–6 mg/kg/24 hr or 400 mg/24 hr

**Adult:** 25–200 mg/24 hr ÷ once daily—BID PO (see remarks); **max. dose:** 200 mg/24 hr

**Diagnosis of primary aldosteronism:**

**Child:** 125–375 mg/m<sup>2</sup>/24 hr ÷ once or twice daily PO

**Adult:** 400 mg once daily PO × 4 days (short test) or 3–4 wk (long test), then 100–400 mg once or twice daily maintenance

**Hirsutism in women:**

**Adult:** 50–200 mg/24 hr ÷ once or twice daily PO

**Contraindicated in Addison disease, hyperkalemia, use with eplerenone, or severe renal failure (see Chapter 31). Use with caution** in dehydration, hyponatremia, and renal or hepatic dysfunction. Precipitation of impaired neurologic function, worsening hepatic encephalopathy, and coma may occur with hepatic disease with cirrhosis and ascites. May cause hyperkalemia (especially with severe heart failure), GI distress, rash, lethargy, dizziness, and gynecomastia. May potentiate ganglionic blocking agents and other antihypertensives. Monitor potassium levels and be aware of other K<sup>+</sup> sources, K<sup>+</sup>-sparing diuretics, and angiotensin-

converting enzyme inhibitors (ACEIs) (all of which can increase K<sup>+</sup>).

SPIRONOLACTONE *continued*

**Do not use** with other medications known to cause hyperkalemia (e.g., ACEIs, angiotensin II antagonists, aldosterone blockers, and other potassium-sparing diuretics). Hyperkalemic metabolic acidosis has been reported with concurrent cholestyramine use. May cause false elevation in serum digoxin levels measured by radioimmunoassay.

Although TID—QID regimens have been recommended, data suggest once- or twice-daily dosing to be adequate. Pregnancy category changes to “D” if used in pregnancy-induced hypertension.

**STREPTOMYCIN SULFATE**

Generics

**Antibiotic, aminoglycoside, antituberculous agent**

D

2

Yes

No

No

Powder for injection: 1 g

**MDR tuberculosis:** Use as part of multidrug regimen (see latest edition of AAP *Red Book*).

IM route is preferred. Monitor levels.

**Infant, child, and adolescent (<15 yr or ≤40 kg):****Daily therapy:** 20–40 mg/kg/24 hr IM/IV once daily**Max. daily dose:** 1 g/24 hr**Twice weekly therapy (under direct observation):** 25–30 mg/kg/dose IM/IV twice weekly**Max. daily dose:** 1 g/24 hr**Child, adolescent, and adult (≥15 yr or >40 kg):****Daily therapy:** 15 mg/kg/24 hr IM/IV once daily; **max. daily dose:** 1 g/24 hr**Twice-weekly therapy (under direct observation):** 15 mg/kg/dose IM/IV twice weekly; **max. daily dose:** 1 g/24 hr**Brucellosis, tularemia, plague, and rat bite fever:** See latest edition of the *Red Book*.

**Contraindicated** with aminoglycoside and sulfite hypersensitivity. **Use with caution** in preexisting vertigo, tinnitus, hearing loss, and neuromuscular disorders. Drug is administered via deep IM injection **only**. Follow auditory status. May cause CNS depression, other neurologic problems, myocarditis, serum sickness, nephrotoxicity, and ototoxicity. Concomitant neurotoxic, ototoxic, or nephrotoxic drugs and dehydration may increase risk for toxicity.

Therapeutic levels: peak 15–40 mg/L; trough: <5 mg/L. Recommended serum sampling time at steady state: trough within 30 min prior to the third consecutive dose and peak at 30–60 min (60 min for IM) after the administration of the third consecutive dose. Therapeutic levels are not achieved in cerebrospinal fluid (CSF).

**Adjust dose in renal failure (see Chapter 31).****SUCCIMER**

Chemet, DMSA [dimercaptosuccinic acid]

**Chelating agent**

C

3

Yes

Yes

No

**Cap:** 100 mg**Lead chelation, child:**10 mg/kg/dose (or 350 mg/m<sup>2</sup>/dose) PO Q8 hr × 5 days, then 10 mg/kg/dose (or 350 mg/m<sup>2</sup>/dose) PO Q12 hr × 14 days. **Max. dose:** 500 mg per dose

Manufacturer recommendation (see following table):

*Continued*

SUCCIMER *continued*

Weight (kg)	Dose (mg) Q8 hr × 5 Days Followed by Same Dose Q12 hr × 14 Days
8–15	100
16–23	200
24–34	300
35–44	400
≥45	500

**Use caution** in patients with compromised renal or hepatic function. Repeated courses may be necessary. Follow serum lead levels. Allow a minimum of 2 wk between courses unless blood levels require more aggressive management. Side effects: GI symptoms, increased negative liver function tests (LFTs) (10%), rash, headaches, and dizziness. Allergic reactions, such as urticaria and angioedema, and neutropenia have been reported. May cause false-positive urinary ketone readings with nitroprusside reagent tests such as Ketostix and can falsely lower measured serum uric acid and creatine phosphokinase (CPK). **Coadministration with other chelating agents is not recommended.**

Serum transaminases should be monitored at baseline and weekly during therapy. Treatment of iron deficiency is recommended as well as environmental remediation. Contents of capsule may be sprinkled on food for those who are unable to swallow a capsule.

**SUCCINYLCHOLINE**

Anectine, Quelicin, and generics

**Neuromuscular blocking agent**

C



?



No



Yes



Yes

**Injection:****Anectine, Quelicin, and generics:** 20 mg/mL (10 mL); may contain parabens**Prefilled syringe injection:****Generics:** 100 mg/5 mL (5 mL); preservative free**Paralysis for intubation (see remarks):****Infant, child, and adolescent:****Initial:****IV:****Infant:** 2–3 mg/kg/dose × 1**Child:** 1–2 mg/kg/dose × 1**Adolescent:** 1–1.5 mg/kg/dose × 1**IM:****Infant <6 mo:** 4–5 mg/kg/dose × 1**Infant ≥6 mo and child:** 4 mg/kg/dose × 1; **max. dose:** 150 mg per dose**Adolescent:** 3–4 mg/kg/dose × 1; **max. dose:** 150 mg per dose**Adult:****Initial:****IV:** 0.3–1.1 mg/kg/dose × 1**IM:** 3–4 mg/kg/dose × 1; **max. dose:** 150 mg/dose**Maintenance for long surgical procedures:** 0.04–0.07 mg/kg/dose IV Q5–10 min PRN.

Continuous infusion not recommended.

**Contraindicated** after the acute phase of an injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury because severe

SUCCINYLCHOLINE *continued*

hyperkalemia and subsequent **cardiac arrest** may occur. Individuals carrying the *RYR1* or *CACNA1S* gene have an increased risk for developing malignant hyperthermia with succinylcholine or halogenated volatile anesthetics; use in these individuals is **contraindicated**. Succinylcholine should be **avoided** in patients who are susceptible to malignant hyperthermia.

Pretreatment with atropine is recommended to reduce incidence of bradycardia. For rapid sequence intubation, see [Chapter 1](#).

**Cardiac arrest** has been reported in children and adolescents primarily with skeletal muscle myopathies (e.g., Duchenne muscular dystrophy). Identify developmental delays suggestive of a myopathy prior to use. Predose creatine kinase may be useful for identifying patients at risk. Monitoring of the electrocardiogram (ECG) for peaked T waves may be useful in detecting early signs of this adverse effect.

May cause malignant hyperthermia (use dantrolene to treat), bradycardia, hypotension, arrhythmia, and hyperkalemia. Severe anaphylactic reactions have been reported; **use caution** if previous anaphylactic reaction to other neuromuscular blocking agents. **Use with caution** in patients with severe burns, paraplegia, or crush injuries and in patients with preexisting hyperkalemia. Beware of prolonged depression in patients with liver disease, malnutrition, pseudocholinesterase deficiency, hypothermia and those receiving aminoglycosides, phenothiazines, quinidine,  $\beta$  blockers, amphotericin B, cyclophosphamide, diuretics, lithium, acetylcholine, and anticholinesterases. Diazepam may decrease neuromuscular blocking effects. Prior use of succinylcholine may enhance the neuromuscular blocking effect of vecuronium and its duration of action.

Duration of action 4–6 min IV, 10–30 min IM. Must be prepared to intubate within 1 min.

**SUCRALFATE**

Carafate and generics

**Oral antiulcer agent**

B



1



Yes



No



No

**Tabs:** 1 g**Oral suspension:** 100 mg/mL (420 mL); contains sorbitol and parabens**Child:****Duodenal or gastric ulcer:** 40–80 mg/kg/24 hr  $\div$  Q6 hr PO; **max. dose:** 1000 mg/dose**Stomatitis:** 5–10 mL (500–1000 mg of suspension), swish and spit or swish and swallow QID**Adult:****Duodenal ulcer:****Treatment:** 1 g PO QID (1 hr before meals and QHS) or 2 g PO BID  $\times$  4–8 wk**Maintenance/prophylaxis:** 1 g PO BID**Stress ulcer:****Prophylaxis:** 1 g PO QID**Stomatitis:** 10 mL (1000 mg of suspension), swish and spit or swish and swallow QID**Proctitis (use oral suspension as rectal enema):** 20 mL (2 g) PR once or twice daily for at least 4 wk or resolution of symptoms

May cause vertigo, constipation, and dry mouth. Hypersensitivity, including anaphylactic reactions, and hyperglycemia in patients with diabetes have been reported. Aluminum may accumulate in patients with renal failure. This may be augmented by the use of aluminum-containing antacids. **Use with caution** in patients with dysphagia or other conditions that may alter gag or cough reflexes or diminish oropharyngeal coordination/motility who are receiving the oral tablet dosage form; cases of tablet aspiration with respiratory complications have been reported.

*Continued*

SUCRALFATE *continued*

Decreases absorption of phenytoin, digoxin, theophylline, cimetidine, fat-soluble vitamins, ketoconazole, omeprazole, quinolones, and oral anticoagulants. Administer these drugs at least 2 hr before or after sucralfate doses.

Drug requires an acidic environment to form a protective polymer coating for damaged GI tract mucosa. Administer oral doses on an empty stomach (1 hr before meals and QHS).

**SUGAMMADEX**

Bridion

**Neuromuscular blockade reversal agent**

?

1

Yes

Yes

No

**Injection:** 100 mg/1 mL (2, 5 mL); may be diluted with NS to a concentration of 10 mg/mL to increase the accuracy of smaller doses

**Routine reversal of rocuronium-induced moderate blockade (see remarks):**

**Infant, child (<2 yr; limited data):** 2 or 4 mg/kg/dose IV once over 10 sec; some suggest administering over slow intravenous push to reduce risk for bradycardia or asystole

**Reversal rocuronium or vecuronium-induced neuromuscular blockade (see remarks):**

**Child ≥2 yr, adolescent, and adult (use actual body weight):**

**Deep block (spontaneous recovery of twitch response reaching 1 to 2 post-tetanic counts with no twitch responses to train-of-four stimulation):** 4 mg/kg/dose IV × 1 over 10 seconds

**Moderate block (spontaneous recovery of reappearance of the second twitch in response of train-of-four stimulation):** 2 mg/kg/dose IV × 1 over 10 seconds

**Reversal of neuromuscular blockade 3 min after rocuronium 1.2 mg/kg:**

**Adult (use actual body weight):** 16 mg/kg/dose IV × 1. The recovery to T<sub>1</sub> of 10% baseline (relative to the time of administration of rocuronium or succinylcholine) was faster with rocuronium/sugammadex than with succinylcholine alone. This dose has not been evaluated for vecuronium-induced neuromuscular blockade.

Sugammadex is a modified gamma cyclodextrin that binds to rocuronium and vecuronium for reduced neuromuscular blockade.

Use is **not recommended** for GFR <30 mL/min or on dialysis. **Use with caution** in hepatic impairment, especially in the presence of coagulopathy or severe edema.

Common side effects include nausea, vomiting, and headache. Serious effects include bradycardia, prolonged QTc interval, hypersensitivity reactions/anaphylaxis, increased creatine kinase, and respiratory arrest. Bronchospasm, laryngospasm, dyspnea, wheezing, and pulmonary edema have been reported. May increase the effects/toxicity of anticoagulants and decrease the effects of hormonal contraceptives. Fusidic acid and toremifene may decrease sugammadex activity.

Limited data in children (especially <2 yr) and dosing in a multicenter, randomized, parallel-group, dose-finding study in 63 children (28 days to 17 yr of age) and 28 adult surgical patients. Doses were well tolerated across all ages with dose-response relationship for those 2 yr of age or older. All had a median recovery time of 1.1 to 1.2 min after a 2 mg/kg dose (*Anesthesiology*. 2009;110:284–294).

**SULFACETAMIDE SODIUM OPHTHALMIC**

Generics; previously available as Bleph-10

**Ophthalmic antibiotic, sulfonamide derivative**

C

?

No

No

No

**Ophthalmic solution:** 10% (5, 15 mL); may contain thimerosal or benzalkonium chloride

**Ophthalmic ointment:** 10% (3.5 g)

SULFACETAMIDE SODIUM OPHTHALMIC *continued***Conjunctivitis (usual duration of therapy for ophthalmic use is 7–10 days):****≥2 mo and adult:****Ointment:** Apply 0.5-in ribbon into conjunctival sac Q3–4 hr and QHS initially, and reduce the dosing frequency with adequate response.**Drops:** 1–2 drops to affected eye(s) Q2–3 hr initially and reduce the dosing frequency with adequate response

Hypersensitivity reactions between different sulfonamides can occur regardless of route of administration. May cause local irritation, stinging, burning, conjunctival hyperemia, excessive tear production, and eye pain. Rare toxic epidermal necrolysis and Stevens-Johnson syndrome have been reported. Sulfacetamide preparations are incompatible with silver preparations. To reduce risk of systemic absorption with ophthalmic solution, apply finger pressure to lacrimal sac during and 1–2 min after instillation.

**SULFADIAZINE**

Various generics

**Antibiotic, sulfonamide derivative**

C/D



3



Yes



Yes



Yes

**Tabs:** 500 mg**Oral suspension:** 100, 200 mg/mL **General dosing:****Infant ≥2 mo, child, and adolescent:** 75 mg/kg/dose or 2000 mg/m<sup>2</sup>/dose PO × 1, followed by 150 mg/kg/24 hr or 4000 mg/m<sup>2</sup>/24 hr ÷ Q4–6 hr (**max. dose:** 6000 mg/24 hr)**Adult:** 2–4 g/dose × 1, followed by 2–4 g/24 hr PO ÷ Q4–8 hr**Congenital toxoplasmosis (administer with pyrimethamine and folinic acid; see [Pyrimethamine](#) for dosage information):****Infant:** 100 mg/kg/24 hr PO ÷ BID × 12 mo**Acquired toxoplasmosis (administer with pyrimethamine and folinic acid; see [Pyrimethamine](#) for dosage information):****Infant ≥2 mo and child:** 100–200 mg/kg/24 hr ÷ Q6 hr PO for at least 4–6 wk; **max. dose:** 6000 mg/24 hr**Adult:** 4–6 g/24 hr PO ÷ Q6 hr for at least 4–6 wk**Rheumatic fever secondary prophylaxis (≥2 mo):****≤27 kg:** 500 mg PO once daily**>27 kg:** 1000 mg PO once daily

Most cases of acquired toxoplasmosis do not require specific antimicrobial therapy.

**Contraindicated** in porphyria and hypersensitivity to sulfonamides. **Use with caution** in premature infants and infants below 2 mo of age, because of risk of hyperbilirubinemia, and in hepatic or renal dysfunction (30%–44% eliminated in urine). Maintain hydration. May cause fever, rash, hepatitis, systemic lupus erythematosus (SLE)–like syndrome, vasculitis, bone marrow suppression, and hemolysis in patients with G6PD deficiency, and Stevens-Johnson syndrome.

May cause increased effects of warfarin, methotrexate, thiazide diuretics, uricosuric agents, and sulfonyleureas due to drug displacement from protein binding sites. Large quantities of vitamin C or acidifying agents (e.g., cranberry juice) may cause crystalluria. Pregnancy category changes from C to D if administered near term. Administer on an empty stomach with plenty of water.

**SULFAMETHOXAZOLE AND TRIMETHOPRIM**

Trimethoprim-sulfamethoxazole, Co-Trimoxazole, TMP-SMX, Bactrim, Bactrin DS, Sulfatrim Pediatric Suspension, and generics; previously available as Septra

**Antibiotic, sulfonamide derivative**



D



2



Yes



Yes



Yes

**Tabs (may contain sodium benzoate):**

**Reg. strength (Bactrim and generics):** 80 mg TMP/400 mg SMX

**Double strength (Bactrim DS and generics):** 160 mg TMP/800 mg SMX

**Oral suspension (Sulfatrim Pediatric Suspension and generics):** 40 mg TMP/200 mg SMX per 5 mL (100, 480 mL)

**Injection:** 16 mg TMP/mL and 80 mg SMX/mL (5, 10, 30 mL); some preparations may contain propylene glycol and benzyl alcohol

**Doses based on TMP component.****Minor/moderate infections (PO or IV):**

**Child:** 8–12 mg/kg/24 hr ÷ BID; **max. dose:** 160 mg/dose

**Adult (>40 kg):** 160 mg/dose BID

**Severe infections (PO or IV):**

**Child and adult:** 20 mg/kg/24 hr ÷ Q6–8 hr

**UTI prophylaxis:**

**Child:** 2–4 mg/kg/24 hr PO once daily

***Pneumocystis jiroveci* (carinii) pneumonia (PCP):**

**Treatment (≥2 mo and adult, PO or IV):** 15–20 mg/kg/24 hr ÷ Q6–8 hr × 21 days

**Prophylaxis (PO or IV):**

≥1 mo and child: 150 mg/m<sup>2</sup>/24 hr ÷ BID for 3 consecutive days per wk; **max. dose:** 320 mg/24 hr; see [Chapter 17](#) for use criteria for perinatal HIV PCP prophylaxis.

**Adolescent and adult:** 80 or 160 mg once daily or 160 mg 3 days per wk

**Not recommended** for use in infants below 2 mo of age (excluding PCP prophylaxis).

**Contraindicated** in patients with sulfonamide or trimethoprim hypersensitivity, megaloblastic anemia due to folate deficiency, and those who are taking dofetilide. May cause kernicterus in newborns; may cause blood dyscrasias, crystalluria, glossitis, renal or hepatic injury, GI irritation, rash, Stevens-Johnson syndrome, or hemolysis in patients with G6PD deficiency. Severe hyponatremia may occur during treatment of *Pneumocystis jiroveci* pneumonia. Hyperkalemia may appear in HIV/AIDS patients. **Use with caution** in renal and hepatic impairment and in G6PD deficiency. QT prolongation resulting in ventricular tachycardia has been reported. Slow acetylators may be prone to idiosyncratic reactions to sulfonamides. Intravenous dosage form contains propylene glycol and benzyl alcohol, which may result in adverse toxic effects when used at higher dosages, especially in neonates. Use of an adjusted body weight ([ABW] ABW = ideal body weight + 0.4 × [total body weight – ideal body weight]) has been recommended for determining doses for obese patients.

Discontinue use if significant electrolyte abnormality, renal insufficiency, or reduction in CBC occurs. Epidemiologic studies suggest that use during pregnancy may be associated with increased risk of congenital malformations (particularly neural tube defects), cardiovascular malformations, urinary tract defects, oral clefts, and clubfoot.

Sulfamethoxazole is a CYP 450 2C9 substrate and inhibitor. Trimethoprim is a CYP 450 2C9, 3A4 substrate and an inhibitor or CYP 450 2C8 and OCT2 transporter. **Avoid use** with drugs that are substrates of CYP2C8 and 2C9 or OCT2. **Reduce dose in renal impairment** (see [Chapter 31](#)).

**SULFASALAZINE**

Azulfidine, Azulfidine EN-tabs, Salicylazosulfapyridine, and generics

**Anti-inflammatory agent**

B/D



2



Yes



Yes



Yes

**Tabs (Azulfidine and generics):** 500 mg**Delayed release tabs (Azulfidine EN-tabs and generics):** 500 mg**Oral suspension:** 100 mg/mL **Inflammatory bowel disease:****Child ≥6 yr:****Initial dosing:****Mild:** 40–50 mg/kg/24 hr ÷ Q6 hr PO**Moderate/severe:** 50–75 mg/kg/24 hr ÷ Q4–6 hr PO**Max. initial dose:** 4 g/24 hr**Maintenance:** 30–70 mg/kg/24 hr ÷ Q4–8 hr PO; **max. dose:** 4 g/24 hr**Adult:****Initial:** 3–4 g/24 hr ÷ Q4–8 hr PO**Maintenance:** 2 g/24 hr ÷ Q6 hr PO**Max. dose:** 6 g/24 hr**Juvenile idiopathic arthritis:****Child 6–16 yr:** Start with 10 mg/kg/24 hr ÷ BID PO and increase by 10 mg/kg/24 hr Q7 days until planned maintenance dose is achieved. Usual maintenance dose is 30–50 mg/kg/24 hr ÷ BID PO up to a **max.** of 2 g/24 hr.**Contraindicated** in sulfa or salicylate hypersensitivity, porphyria, and GI or genitourinary (GU) obstruction. Discontinue use if a serious infection or renal function deterioration developswhile on therapy. **Use with caution** in renal impairment, blood dyscrasias, or asthma. Maintain hydration. May cause orange-yellow discoloration of urine and skin. May permanently stain contact lenses. May cause photosensitivity, hypersensitivity (which may result in hepatitis and nephritis), blood dyscrasias, CNS changes, nausea, vomiting, anorexia, diarrhea, and renal damage.

Hepatotoxicity/hepatic failure, anaphylaxis, angioedema, severe drug rash with eosinophilia and systemic symptoms (DRESS), and interstitial lung disease have been reported. May cause hemolysis in patients with G6PD deficiency. Pseudomonucleosis, myocarditis, folate deficiency (decreases folic acid absorption), nephrolithiasis, and oropharyngeal pain have been reported.

Reduces serum digoxin and cyclosporine levels. Slow acetylators may require lower dosage due to accumulation of active sulfapyridine metabolite. May cause false-positive test for urinary normetanephrine if using liquid chromatography methods.

Pregnancy category changes to “D” if drug is administered near term. Bloody stools or diarrhea have been reported in breastfed infants of mothers receiving sulfasalazine.

**SUMATRIPTAN SUCCINATE**

Imitrex, Imitrex STAT dose, Sumavel Dose Pro, Zembrace SymTouch, Tosymra, Onzetra Xsail, and generics

In combination with naproxen:

Treximet and generics

**Antimigraine agent, selective serotonin agonist**

C



2



Yes



Yes



No

**Injection, for subcutaneous use:**

Zembrace SymTouch: 3 mg/0.5 mL (0.5 mL)

Continued

SUMATRIPTAN SUCCINATE *continued*

Imitrex, Imitrex STAT dose, Sumavel DosePro, and generics: 4 mg/0.5 mL (0.5 mL), 6 mg/0.5 mL (0.5 mL)

**Tabs:** 25, 50, 100 mg

**Oral suspension:** 5 mg/mL 

**Nasal spray (as a unit-dose spray device):**

**Imitrex and generics:** 5 mg dose in 100 microliters (six units per pack); 20 mg dose in 100 microliters (six units per pack)

**Tosymra:** 10 mg dose in 100 microliters (six units per pack)

**Nasal powder (Onzetra Xsail):** 11 mg capsule with nasal inhalation nosepiece (two each per pouch; box of eight pouches)

**In combination with naproxen:**

**Tab (Treximet and generics):** 85 mg sumatriptan and 500 mg naproxen sodium (nine tabs)

**Child <18 yr:**

**PO/SC/Nasal:** Incomplete clinical trials to establish efficacy with concerns of serious side effects; see remarks 

**Adolescent ≥18 yr and adult (see remarks):**

**PO:** 25, 50, or 100 mg as soon as possible after onset of headache. If no relief in 2 hr, give 25–100 mg Q2 hr up to a daily **max.** of 200 mg. Safety of treating more than four headaches in a 30-day period has not been established.

**Max. single dose:** 100 mg/dose

**Max. daily dose:** 200 mg/24 hr (with exclusive PO dosing or with an initial SC dose and subsequent PO dosing)

**SC:** 3, 4, or 6 mg × 1 as soon as possible after onset of headache. If no response, may give an additional dose 1 hr later; **max. daily dose:** 12 mg/24 hr. Use lower subsequent dose if side effects occur.

**Nasal (safety of treating more than four headaches in a 30-day period has not been established):**

**Nasal spray (Imitrex, Tosymra, and generics):** 5, 10, or 20 mg per dose into one nostril or divided into each nostril after onset of headache. Dose may be repeated in 2 hr up to a **max.** of 40 mg/24 hr.

**Nasal powder (Onzetra Xsail):** Inhale 22 mg (11 mg per nostril) after onset of headache. Dose may be repeated in 2 hr up to a **max.** of 44 mg/24 hr. If using a combination of different dosage forms, the **max. dose** is one dose of Onzetra Xsail (22 mg) and one dose of another sumatriptan product.

**In combination with naproxen sodium:**

**Treximet and generics:**

**Child 12–17 yr:** 1 tablet (85 mg sumatriptan + 500 mg naproxen sodium) after the onset of headache × 1; **max. dose:** 1 tab/24 hr. Safety of treating more than two headaches in a 30-day period has not been established.

**Adult:** 1 tablet (85 mg sumatriptan + 500 mg naproxen sodium) after the onset of headache × 1; if response is unsatisfactory in 2 hr, a second dose may be administered. **Max. dose:** 2 tabs/24 hr. Safety of treating more than five headaches in a 30-day period has not been established.

**Contraindicated** with concomitant administration of ergotamine derivatives, MAO inhibitors (and use within the past 2 wk), other vasoconstrictive drugs, or history of TIA or stroke. 

**Not** for migraine prophylaxis. **Use with caution** in renal or hepatic impairment. **A max. single**

PO dose of 50 mg has been recommended in adults with hepatic dysfunction. Acts as selective agonist for serotonin receptor. Induration and swelling at the injection site; flushing; dizziness; as well as chest, jaw, and neck tightness may occur with SC administration. Weakness, hyperreflexia, incoordination, and serotonin syndrome (may be life-threatening) have been reported with use in combination with selective serotonin reuptake inhibitors (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline).

May cause coronary vasospasm if administered intravenously. **Use injectable form SC only!** Onset of action is 10–120 min SC, 60–90 min PO, and 15–120 min intranasal.


SUMATRIPTAN SUCCINATE *continued*

PO, nasal, and SC efficacy studies were not conclusive in clinical trials for children. Some do not recommend use in patients less than 18 yr of age owing to poor efficacy and reports of serious adverse events (e.g., stroke, visual loss, and death) in both children and adults with all dosage forms.

To minimize infant exposure to sumatriptan, **avoid** breastfeeding for 12 hr after treatment. See [Naproxen](#) remarks if using the combination sumatriptan and naproxen dosage form.

**SURFACTANT, PULMONARY/BERACTANT**

Survanta

**Bovine lung surfactant**

**Suspension for inhalation:** 25 mg/mL phospholipids (4, 8 mL); contains 0.5–1.75 mg triglycerides, 1.4–3.5 mg free fatty acids, and <1 mg protein per 1 mL drug

**Prophylactic therapy:** 4 mL/kg/dose intratracheally as soon as possible; up to four doses may be given at intervals no shorter than Q6 hr PRN during the first 48 hr of life

**Rescue therapy (treatment):** 4 mL/kg/dose intratracheally immediately following the diagnosis of respiratory distress syndrome (RDS). May repeat dose as needed Q6 hr PRN to a **max.** of four total doses during the first 48 hr of life


**Method of administration for previously listed therapies (see remarks):** Suction infant prior to administration. Each dose is divided into four aliquots of 1 mL/kg each; administer 1 mL/kg in each of four different positions (slight downward inclination with head turned to the right, head turned to the left; slight upward inclination with the head turned to the right, head turned to the left).

Transient bradycardia, O<sub>2</sub> desaturation, pallor, vasoconstriction, hypotension, endotracheal tube blockage, hypercarbia, hypercapnea, apnea, and hypertension may occur during the administration process. Other side effects may include pulmonary interstitial emphysema, pulmonary air leak, and posttreatment nosocomial sepsis. Monitor heart rate and transcutaneous O<sub>2</sub> saturation during dose administration and arterial blood gases for postdose hyperoxia and hypocarbia after administration.

All doses are administered intratracheally via a 5-french feeding catheter. If the suspension settles during storage, gently swirl the contents; **do not shake**. Drug is stored in the refrigerator, protected from light, and must be warmed by standing at room temperature for at least 20 min or warmed in the hand for at least 8 min. Artificial warming methods should **NOT** be used.

**SURFACTANT, PULMONARY/CALFACTANT**

Infasurf

**Bovine lung surfactant**

**Intratracheal suspension:** 35 mg/mL phospholipids (3, 6 mL); contains 26 mg phosphatidylcholine, 0.7 mg protein, and 0.26 mg surfactant protein B per 1 mL

**Prophylactic therapy:** 3 mL/kg/dose intratracheally as soon as possible; up to a total of three doses may be given Q12 hr

**Rescue therapy (treatment; see remarks):** 3 mL/kg/dose intratracheally immediately after the diagnosis of RDS. May repeat dose as needed Q12 hr to **max.** of 3 doses total

**Method of administration for previously listed therapies (see remarks):** Suction infant prior to administration. Manufacturer recommends administration through a side-port adapter into the endotracheal tube with two attendants (one to instill drug and another to monitor and position patient). Each dose is divided into two aliquots of 1.5 mL/kg each; administer 1.5 mL/kg in each of

*Continued*

SURFACTANT, PULMONARY/CALFACTANT *continued*

two different positions (infant positioned with either the right or left side dependent). Drug is administered while ventilation is continued over 20 to 30 breaths for each aliquot, with small bursts timed only during the inspiratory cycles. A pause followed by evaluation of respiratory status and repositioning should separate the two aliquots. The drug has also been administered by divided dose into four equal aliquots and administered with repositioning in the prone, supine, right, and left lateral positions.

Common adverse effects include cyanosis, airway obstruction, bradycardia, reflux of surfactant into the endotracheal (ET) tube, requirement for manual ventilation, and reintubation. Monitor O<sub>2</sub> saturation and lung compliance after each dose such that oxygen therapy and ventilator pressure are adjusted as necessary.



All doses administered intratracheally via a 5-French feeding catheter. If suspension settles during storage, gently swirl the contents; **do not shake**. Drug is stored in the refrigerator, protected from light, and does not need to be warmed before administration. Unopened vials that have been warmed to room temperature (once only) may be refrigerated within 24 hr and stored for future use. For rescue therapy, repeat doses may be administered as early as 6 hr after the previous dose for a total of up to four doses if the infant is still intubated and requires at least 30% inspired oxygen to maintain a PaO<sub>2</sub> ≥80 torr.

**SURFACTANT, PULMONARY/PORACTANT ALFA**

Curosurf

***Porcine lung surfactant***

?

?

No

No

No

**Intratracheal suspension:** 80 mg/mL (1.5, 3 mL): contains 76 mg phospholipids, 1 mg protein (0.45 mg surfactant protein B, and 0.59 mg surfactant protein C) per 1 mL drug

**Rescue therapy (treatment):** 2.5 mL/kg/dose (use birth weight) × 1 intratracheally, immediately following the diagnosis of RDS. May administer 1.25 mL/kg/dose Q12 hr × 2 doses as needed up to a **max. total dose** of 5 mL/kg



**Method of administration (see remarks):** Suction infant prior to administration. Each dose is divided into two aliquots, with each aliquot administered into one of the two main bronchi by positioning the infant with either the right or left side dependent. After the first aliquot is administered, remove the catheter from the ET tube and manually ventilate the infant with 100% oxygen at a rate of 40–60 breaths/min for 1 min. When the infant is stable, reposition the infant and administer the second dose with the same procedures. Then remove the catheter without flushing.

Currently approved by the US Food and Drug Administration (FDA) for the treatment (rescue therapy) of RDS. Transient episodes of bradycardia, decreased oxygen saturation, reflux of surfactant into the ET tube, and airway obstruction have occurred during dose administration. Monitor O<sub>2</sub> saturation and lung compliance after each dose and adjust oxygen therapy and ventilator pressure as necessary. Pulmonary hemorrhage has been reported.



All doses administered intratracheally via a 5-french feeding catheter. Suction infant prior to administration and 1 hr after surfactant instillation (unless signs of significant airway obstruction). Drug is stored in the refrigerator and protected from light. Each vial of drug should be slowly warmed to room temperature and gently turned upside down for uniform suspension (**do not shake**) before administration. Unopened vials that have been warmed to room temperature (once only) may be refrigerated within 24 hr and stored for future use.

**SYMDEKO**

See [Tezacaftor and Ivacaftor](#).

## T

**TACROLIMUS**

Prograf, Astagraf XL, Envarsus XR, Protopic, FK506, and generics

**Immunosuppressant**



C



2



Yes



Yes



Yes

**Caps (Prograf and generics):** 0.5, 1, 5 mg

**Extended release caps (Astagraf XL):** 0.5, 1, 5 mg (Q24 hr dosing; see remarks)

**Extended release tabs (Envarsus XR):** 0.75, 1, 4 mg (Q24 hr dosing; see remarks)

**Oral suspension:** 0.5, 1 mg/mL 

**Injection (Prograf):** 5 mg/mL (1 mL); contains alcohol and polyoxyl 60 hydrogenated castor oil (cremophor)

**Topical ointment (Protopic and generics):** 0.03%, 0.1% (30, 60, 100 g)

**SYSTEMIC USE:**

**Infant, child, and adolescent (initial immediate release doses; titrate to therapeutic levels and convert IV to PO as soon as possible; see remarks):**

**Liver transplantation:**

**IV:** 0.03–0.05 mg/kg/24 hr by continuous infusion

**PO:** 0.15–0.2 mg/kg/24 hr ÷ Q12 hr

**Renal transplantation:**

**IV:** 0.06 mg/kg/24 hr by continuous infusion

**PO:** 0.2–0.3 mg/kg/24 hr ÷ Q12 hr

**Astagraf XL (in combination with other immunosuppressants):** 0.15–0.3 mg/kg/24 hr PO Q24 hr; initial dose and post-reperfusion times vary with or without basiliximab induction

**Cardiac transplantation:**

**IV:** 0.01–0.03 mg/kg/24 hr by continuous infusion

**PO:** 0.1–0.3 mg/kg/24 hr ÷ Q12 hr; use lower initial dose for those receiving cell depleting induction therapy

**Adult (initial immediate release doses; titrate to therapeutic levels):**

**IV:**

**Liver or kidney transplantation:** 0.03–0.05 mg/kg/24 hr by continuous infusion

**Cardiac transplantation:** 0.01 mg/kg/24 hr by continuous infusion

**PO:**

**Liver transplantation:** 0.1–0.15 mg/kg/24 hr PO ÷ Q12 hr

**Kidney transplantation:** 0.1–0.2 mg/kg/24 hr PO ÷ Q12 hr

**Cardiac transplantation:** 0.075 mg/kg/24 hr PO ÷ Q12 hr

**TOPICAL USE:**

**Atopic dermatitis (discontinue treatment when symptoms resolve and reconsider diagnosis if no improvement seen after 6 weeks; see remarks):**

**Child ≥2 to 15 yr old:** Apply a thin layer of the 0.03% ointment to the affected skin areas BID and rub in gently and completely.

**Adolescent ≥16 yr and adult:** Apply a thin layer of the 0.03% or 0.1% ointment to the affected skin areas BID and rub in gently and completely.

**Avoid** use in patients with prolonged cardiac QT intervals. IV dosage form **contraindicated** in patients allergic to polyoxyl 60 hydrogenated castor oil (cremophor). Experience in pediatric kidney transplantation is limited. Pediatric patients may require higher mg/kg doses than adults. For BMT use (beginning 1 day before BMT), dose and therapeutic levels similar to those in liver transplantation have been used.



Continued

TACROLIMUS *continued*

Major adverse events include tremor, headache, insomnia, diarrhea, constipation, hypertension, nausea, and renal dysfunction (increased risk with use of other nephrotoxic medications and with CYP 450 3A inhibitors). Hypokalemia, hypomagnesemia, hyperglycemia, confusion, depression, infections, lymphoma, liver enzyme elevation, optic neuropathy, and coagulation disorders may also occur. GI perforation, agranulocytosis, HUS, TTP, and hemolytic anemia have been reported.

Tacrolimus is a substrate of the CYP 450 3A4 drug metabolizing enzyme and P-gp transporter. A 1.5–2-fold higher initial standard dose up to a max. dose of 0.3 mg/kg/24 hr has been recommended for intermediate or extensive metabolizers for CYP 450 3A5. Calcium channel blockers, imidazole antifungals (ketoconazole, itraconazole, fluconazole, clotrimazole, posaconazole), macrolide antibiotics (erythromycin, clarithromycin, troleandomycin), cisapride, cimetidine, cyclosporine, danazol, herbal products containing schisandra sphenanthera extracts, methylprednisolone, grapefruit juice, Seville oranges, and severe diarrhea can increase tacrolimus serum levels. In contrast, carbamazepine, caspofungin, phenobarbital, phenytoin, rifampin, rifabutin, and sirolimus may decrease levels. Use with sirolimus may increase risk for hepatic artery thrombosis. **Avoid use** of live, attenuated vaccines. Use with other CYP 450 3A inhibitors and substrates has the potential to prolong the cardiac QT interval. Reduce dose in renal or hepatic insufficiency.

Monitor trough levels (just prior to a dose at steady state). Steady state is generally achieved after 2–5 days of continuous dosing. Interpretation will vary based on treatment protocol and assay methodology (whole blood ELISA vs. MEIA vs. HPLC). Whole blood trough concentrations of 5–20 ng/mL have been recommended in liver transplantation at 1–12 mo. Trough levels of 7–20 ng/mL (whole blood) for the first 3 mo and 5–15 ng/mL after 3 mo have been recommended in renal transplantation. African Americans may need to be titrated to higher dosages. Patients with liver function changes during direct-acting antiviral therapy related to hepatitis C may alter tacrolimus pharmacokinetics, therefore requiring enhanced monitoring.

Tacrolimus therapy generally should be initiated 6 hr or more after transplantation. PO is the preferred route of administration, and all PO dosage forms should be administered on an empty stomach (1 hr before and 2 hr after meals).

**Astagraf XL (extended release capsule):** Safety and efficacy have been established for de novo and stable (receiving immediate release dosage form) pediatric kidney transplant patients. A mg-per-mg conversion from immediate release dosage form to Astagraf XL has been recommended.

**Envarsus XR (extended release tablet):** Currently labeled for use in adult kidney transplant patients (de novo and stable on immediate release tacrolimus). When converting to Envarsus XR from immediate release dosage form, initiate at 80% of the established immediate release dosage form. All extended release formulations are NOT interchangeable. IV infusions should be administered at concentrations between 0.004 and 0.02 mg/mL diluted with NS or D<sub>5</sub>W.

**TOPICAL USE:** Not recommended for use in patients with skin conditions with a skin barrier defect with the potential for systemic absorption. **Do not use** in children <2 yr, immunocompromised patients, or with occlusive dressings (promotes systemic absorption). Approved as a second-line therapy for short-term and intermittent treatment of atopic dermatitis for patients who fail to respond, or do not tolerate, other approved therapies. Long-term safety is unknown. Skin burn sensation, pruritus, flu-like symptoms, allergic reaction, skin erythema, headache, and skin infection are the most common side effects. Application site edema has been reported. Although the risk is uncertain, the FDA has issued an alert about the potential cancer risk with the use of this product.

See [www.fda.gov/medwatch](http://www.fda.gov/medwatch) for the latest information.

**TAZAROTENE**

Arazlo, Fabior, Tazorac, and generics

**Topical retinoid acid prodrug, keratolytic agent for acne or psoriasis**

X



3



No



No



No

**Topical cream:****Tazorac and generics:** 0.05%, 0.1% (30, 60 g); contains benzyl alcohol**Topical foam:****Fabior and generics:** 0.1% (50, 100 g)**Topical gel:****Tazorac and generics:** 0.05%, 0.1% (30, 100 g); contains benzyl alcohol**Topical lotion:****Arazlo:** 0.045% (45 g); contains EDTA and parabens**Acne:****0.045% topical lotion (Tazorac):****>9 yr and adult:** Apply a thin layer of the lotion to affected areas once daily.**0.01% topical cream, foam, or gel:****≥12 yr and adult:** Apply a small amount of 0.1% strength dosage forms to affected areas QHS. Use thin film (2 mg/cm<sup>2</sup>) for cream or gel dosage form and small amount for foam dosage form.**Psoriasis:****≥12 yr and adult:** Apply a small amount of 0.05% gel (2 mg/cm<sup>2</sup>) to affected areas QHS initially. If needed and tolerated, increase to 0.1% gel QHS. The cream dosage form may also be used the same way as the gel, but it is currently labeled for use in adults (≥18 yr).**Contraindicated** in pregnancy. Pregnancy testing 2 wk prior to use and initiation of use during menstrual period have been recommended. **Avoid** use in abraded or eczematous skin or with other medications or cosmetics with drying effects, or medications that can cause photosensitivity. Tazarotene is a retinoid prodrug that is converted to its active form, the cognate carboxylic acid of tazarotene (AGN 190299), by rapid deesterification in animals and humans.

Common side effects include erythema, dry skin, skin irritation/pain (including blistering and skin desquamation), pruritus, and worsening of psoriasis.

**Avoid** contact with mucous membranes. The foam dosage form is flammable; **avoid** fire, flame, or smoking during or immediately after use.**TERBINAFINE**

Previously available as Lamisil, Lamisil AT, and generics

**Antifungal**

B



2



Yes



Yes



No

**Tabs:** 250 mg**Oral suspension:** 25 mg/mL **Topical cream:****Lamisil AT and generics [OTC]:** 1% (12, 15, 30 g); contains benzyl alcohol**Topical spray:****Lamisil AT [OTC]:** 1% (15 mL); contains alcohol and propylene glycol**Tinea capitis:****Child:** 4–6 mg/kg/dose (**max. dose:** 250 mg) PO once daily, OR by the following once-daily dosage by weight category:**10–20 kg:** 62.5 mg**20–40 kg:** 125 mg

Continued

TERBINAFINE *continued***>40 kg:** 250 mg**Duration of therapy:** *Trichophyton tonsurans*: 2–6 wk; *Microsporum canis*: 8–12 wk**Adult:** 250 mg PO once daily × 4–6 wk**Onychomycosis:****Child and adolescent (limited data):** PO once daily by weight category:**10–20 kg:** 62.5 mg**20–40 kg:** 125 mg**>40 kg:** 250 mg**Adult:** 250 mg PO once daily**Duration of therapy:****Fingernail infection:** 6 wk**Toenail infection:** 12 wk**Topical use for dermal mycosis:****≥12 yr:****Tinea pedis:** Apply topically (cream or spray) interdigitally BID × 1 wk; if needed, apply the cream to the bottom or sides of the foot BID × 2 wk.**Tinea cruris/tinea corporis:** Apply topically (cream or spray) to affected area once daily × 1 wk.**Pityriasis (tinea) versicolor:** Apply spray to affected area once daily × 1 wk.

**SYSTEMIC USE:** Contraindicated in chronic or acute liver disease. Common side effects include headache, fever, cough, diarrhea, taste disorder, increased LFTs, GI disturbances, and rash. Severe dermatological reactions (e.g., SJS, TEN), hearing loss, neutropenia, thrombotic microangiopathy, and liver failure (some fatal) have been reported. Monitor AST/ALT at baseline and repeat with CBC if therapy is >6 wk. Signs and symptoms of liver disease may include persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, or jaundice. Discontinue use immediately if biochemical or clinical evidence of liver injury develops.



**Use with caution** in renal impairment as terbinafine's clearance has been shown to decrease by ~50% in adults with CrCl ≤50 mL/min. Terbinafine inhibits CYP 450 2D6, thus increasing the effects/toxicity of 2D6 substrates such as amphetamines, risperidone, and fluoxetine.

Doses may be administered with or without food.

**TOPICAL USE:** Do not use on/in the eyes, mouth, nails, scalp, or vaginal areas. Local irritation, skin rash, xeroderma, pruritus, and contact dermatitis may occur. Apply to clean and dry affected area, and wash hands after each use. If using topical spray, hold spray 4–6 inches from the affected area during dose administration.

**TERBUTALINE**

Various generics; previously available as Brethine

***β*<sub>2</sub> adrenergic agonist**

C



2



Yes



No



No

**Tabs:** 2.5, 5 mg**Oral suspension:** 1 mg/mL **Injection:** 1 mg/mL (1 mL)**Acute asthma exacerbation:****SC injection:****≤12 yr:** 0.005–0.01 mg/kg/dose (**max. dose:** 0.4 mg/dose) Q15–20 min × 3; if needed, Q2–6 hr PRN**>12 yr and adult:** 0.25 mg/dose Q20 min PRN × 3; **max. total dose:** 0.75 mg

TERBUTALINE *continued*

**Continuous infusion, IV:** 2–10 mCg/kg loading dose followed by infusion of 0.1–0.4 mCg/kg/min. May titrate in increments of 0.1–0.2 mCg/kg/min Q30 min depending on clinical response. Doses as high as 10 mCg/kg/min have been used. To prepare infusion: See [p. iii](#).

**Nebulization (use IV dosage form):**

<2 yr: 0.5 mg in 2.5 mL NS Q4–6 hr PRN

2–9 yr: 1 mg in 2.5 mL NS Q4–6 hr PRN

>9 yr: 1.5–2.5 mg in 2.5 mL NS Q4–6 hr PRN

**Prevention and reversal of bronchospasms with asthma:****Oral:**

≤12 yr: **Initial:** 0.05 mg/kg/dose Q8 hr, increase as required. **Max. dose:** 0.15 mg/kg/dose Q8 hr or total of 5 mg/24 hr

>12 yr and adult: 2.5–5 mg/dose PO Q6–8 hr

**Max. dose:**

12–15 yr: 7.5 mg/24 hr

>15 yr: 15 mg/24 hr

**Use of the IV and PO route should not be used for the prevention or prolonged treatment of preterm labor because of the potential for serious maternal cardiac events and even death.**

Nervousness, tremor, headache, nausea, tachycardia, arrhythmias, and palpitations may occur. Paradoxical bronchoconstriction may occur with excessive use; if it occurs, discontinue drug immediately. Injectable product may be used for nebulization. For acute asthma, nebulizations may be given more frequently than Q4–6 hr.

Monitor heart rate, blood pressure, respiratory rate, and serum potassium when using the continuous IV infusion route of administration. **Adjust dose in renal failure (see Chapter 31).**

**TETRACYCLINE HCL**

Various generics; previously available as Sumycin

**Antibiotic**



D



2



Yes



Yes



No

**Caps:** 250, 500 mg

**Oral suspension:** 25 mg/mL 

**Do not use in children <8 yr.**

**Child ≥8 yr:** 25–50 mg/kg/24 hr PO ÷ Q6 hr; **max. dose:** 3 g/24 hr

**Acne:** 500 mg PO BID

**Adult:** 250–500 mg PO Q6 hr or 500 mg PO Q12 hr



**Not recommended** in patients <8 yr owing to tooth staining and decreased bone growth.

Also **not recommended** for use in pregnancy because these side effects may occur in the fetus. The risk for these adverse effects is highest with long-term use. May cause nausea, GI upset, hepatotoxicity, stomatitis, rash, fever, and superinfection. Photosensitivity reaction may occur. **Avoid** prolonged exposure to sunlight.

**Never use outdated tetracyclines** because they may cause Fanconi-like syndrome. **Do not** give with dairy products or with any divalent cations (i.e.,  $Fe^{2+}$ ,  $Ca^{2+}$ ,  $Mg^{2+}$ ). Give 1 hr before or 2 hr after meals.

May decrease the effectiveness of oral contraceptives, increase serum digoxin levels, and increase effects of warfarin. Use with methoxyflurane increases risk for nephrotoxicity, and use with isotretinoin is associated with pseudotumor cerebri. **Adjust dose in renal failure (see Chapter 31).** Short-term maternal use is not likely to cause harm to breastfeeding infants.



**TEZACAFTOR AND IVACAFTOR**

Symdeko

*Cystic fibrosis transmembrane conductance regulator corrector and potentiator*



B

?

Yes

Yes

Yes

**Tabs (4-week supply in 4 weekly blister packs):**

Tezacaftor 50 mg and ivacaftor 75 mg (white tabs; 28 tabs) and ivacaftor 75 mg (light blue tabs; 28 tabs)

Tezacaftor 100 mg and ivacaftor 150 mg (yellow tabs; 28 tabs) and ivacaftor 150 mg (light blue tabs; 28 tabs)

**Child 6 to <12 yr:**

**<30 kg:** One tezacaftor 50 mg/75 mg ivacaftor PO QAM and one ivacaftor 75 mg PO every evening administered ~12 hr apart

**≥30 kg:** One tezacaftor 100 mg/150 mg ivacaftor PO QAM and one ivacaftor 150 mg PO every evening administered ~12 hr apart

**Child ≥12 yr—adult:** One tezacaftor 100 mg/150 mg ivacaftor PO QAM and one ivacaftor 150 mg PO every evening administered ~12 hr apart

**Dosage modification with hepatic impairment:**



Child-Pugh Class	Morning Dose		Evening Dose
	Age 6 to <12 yr and <30 kg:	Age 6 to <12 yr and ≥30 kg, and ≥12 yr—adult:	All patients
Class A	No adjustment	No adjustment	No adjustment
Class B	One tablet of tezacaftor 50 mg/ivacaftor 75 mg PO QAM	One tablet of tezacaftor 100 mg/ivacaftor 150 mg PO QAM	No ivacaftor
Class C	One tablet of tezacaftor 50 mg/ivacaftor 75 mg PO QAM or less frequently	One tablet of tezacaftor 100 mg/ivacaftor 150 mg PO QAM or less frequently	No ivacaftor

**Dosage modification with CYP 450 3A4 inhibitors:**

**Moderate inhibitors (e.g., fluconazole, erythromycin):** Do not administer any evening doses.

**Child 6 to <12 yr and <30 kg:** Administer the following tablet PO on the following days only in the morning:

Tablet	Day 1	Day 2	Day 3	Day 4 <sup>a</sup>
Tezacaftor 50 mg/ivacaftor 75 mg tab	One tablet		One tablet	
Ivacaftor 75 mg tab		One tablet		One tablet

<sup>a</sup>Continue dosing with tezacaftor 50 mg/ivacaftor 75 mg or ivacaftor 75 mg on alternate days.

**Child 6 to <12 yr and ≥30 kg, and ≥12 yr—adult:** Administer the following tablet PO on the following days only in the morning:

Tablet	Day 1	Day 2	Day 3	Day 4 <sup>a</sup>
Tezacaftor 100 mg/ivacaftor 150 mg tab	One tablet		One tablet	
Ivacaftor 150 mg tab		One tablet		One tablet

<sup>a</sup>Continue dosing with tezacaftor 100 mg/ivacaftor 150 mg or ivacaftor 150 mg on alternate days.

TEZACAFTOR AND IVACAFTOR *continued*

**Strong inhibitors (e.g., ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, and clarithromycin):** Do not administer any evening doses.

**Child 6 to <12 yr and <30 kg:** One tezacaftor 50 mg/ivacaftor 75 mg PO in the morning on days 1 and 4, then continue with the same one tablet twice weekly (administered 3–4 days apart).

**Child 6 to <12 yr and ≥30 kg, and ≥12 yr—adult:** One tezacaftor 100 mg/ivacaftor 150 mg PO in the morning on days 1 and 4, then continue with the same one tablet twice weekly (administered 3–4 days apart).

Works on CFTR trafficking defect by acting as a CFTR corrector (tezacaftor) and in combination with a CFTR potentiator (ivacaftor). Indicated for individuals with homozygous F508del CFTR mutation or who have at least one CFTR mutation that is responsive to this drug based on in vitro data and/or clinical evidence. 

Common side effects include headache, nausea, sinus congestion, and dizziness. Increased liver enzymes and cataracts may occur; monitor baseline AST/ALT and ocular exam at baseline. Repeat AST/ALT every 3 months for the first year followed by annual assessments. Repeat ocular exams annually. May cause a false-positive urine drug screen for cannabinoids.

**Use with caution** with CrCl ≤30 mL/min and ESRD. Reduce dose with moderate/severe hepatic impairment or when initiating therapy while taking a CYP 450 3A4 inhibitor (see dosing section). Tezacaftor and ivacaftor are substrates for CYP 450 3A4/3A5. Use with strong CYP 450 3A inducers (e.g., rifampin, rifabutin, carbamazepine, phenobarbital, phenytoin, St. John's wort) is not recommended. Tezacaftor and ivacaftor may increase the effects/toxicity of cyclosporine, digoxin, everolimus, sirolimus, tacrolimus, and warfarin. Always evaluate potential drug-drug interactions; see <https://www.symdekohcp.com/drug-interactions>. **Avoid** food or drink containing grapefruit or Seville oranges.

Administer all doses with high-fat foods to ensure absorption. If a dose (all dosage forms) is missed within 6 hr of a scheduled dose, administer a dose immediately. However, if the missed dose is >6 hr, skip that dose and resume therapy at the next scheduled dose. Never take a double dose for a missed dose.

**THEOPHYLLINE**

Theo-24, Elixophyllin, and generics

**Bronchodilator, methylxanthine**



C



2



No



Yes



No

**Other dosage forms may exist.**

**Immediate release:**

**Oral elixir/solution (Elixophyllin and generics):** 80 mg/15 mL (473 mL); may contain up to 20% alcohol (alcohol-free preparations may be available)

**Sustained/extended release (see remarks):**

**Tab:**

**Q12 hr dosing (generics):** 300, 450 mg

**Q24 hr dosing (generics):** 400, 600 mg

**Caps (Q24 hr dosing: Theo-24 and generics):** 100, 200, 300, 400 mg

Sustained release forms should **not** be chewed or crushed. Capsules may be opened and contents may be sprinkled on food.

**Dosing intervals are for immediate release preparations.**

For sustained release preparations, divide daily dose >Q8–24 hr based on product. 

**Neonatal apnea:**

**Loading dose:** 5 mg/kg/dose PO × 1

**Maintenance:** 3–6 mg/kg/24 hr PO ÷ Q6–8 hr

*Continued*

THEOPHYLLINE *continued*

**Bronchospasm; PO:**

**Loading dose:** 1 mg/kg/dose for each 2 mg/L desired increase in serum theophylline level

**Maintenance, infant (<1 yr):**

**Preterm:**

<24 days old (postnatal): 1 mg/kg/dose PO Q12 hr

≥24 days old (postnatal): 1.5 mg/kg/dose PO Q12 hr

**Full-term up to 1 yr old:** Total daily dose (mg) = [(0.2 × age in weeks) + 5] × (kg body weight)

≤6 mo: Divide daily dose Q8 hr

>6 mo: Divide daily dose Q6 hr

**Maintenance, child >1 yr and adult without risk factors for altered clearance (see remarks):**

<45 kg: Begin therapy at 12–14 mg/kg/24 hr ÷ Q4–6 hr up to **max. dose** of 300 mg/24 hr. If needed based on serum levels, gradually increase to 16–20 mg/kg/24 hr ÷ Q4–6 hr. **Max. dose:** 600 mg/24 hr

≥45 kg: Begin therapy with 300 mg/24 hr ÷ Q6–8 hr. If needed based on serum levels, gradually increase to 400–600 mg/24 hr ÷ Q6–8 hr.

Drug metabolism varies widely with age, drug formulation, and route of administration. Most common side effects and toxicities are nausea, vomiting, anorexia, abdominal pain, gastroesophageal reflux, nervousness, tachycardia, seizures, and arrhythmias.



Serum levels should be monitored. Therapeutic levels: bronchospasm: 10–20 mg/L; apnea: 7–13 mg/L. Half-life is age dependent: 30 hr (newborns); 6.9 hr (infants); 3.4 hr (children); 8.1 hr (adults). See [Aminophylline](#) for guidelines for serum level determinations. Liver impairment, cardiac failure, and sustained high fever may increase theophylline levels. Theophylline is a substrate for CYP 450 1A2. Levels are increased with allopurinol, alcohol, ciprofloxacin, cimetidine, clarithromycin, disulfiram, erythromycin, estrogen, isoniazid, propranolol, thiabendazole, and verapamil. Levels are decreased with carbamazepine, isoproterenol, phenobarbital, phenytoin, and rifampin. May cause increased skeletal muscle activity, agitation, and hyperactivity when used with doxapram, and increase quinine levels/toxicity.

Use ideal body weight in obese patients when calculating dosage because of poor distribution into body fat. Risk factors for increased clearance include: smoking, cystic fibrosis, hyperthyroidism, and high-protein diet. Factors for decreased clearance include CHF, correction of hyperthyroidism, fever, viral illness, sepsis, and high-carbohydrate diet.

**Suggested dosage intervals for sustained release products (see following table):**

**THEOPHYLLINE SUSTAINED RELEASE PRODUCTS**

Trade Name	Available Strengths	Dosage Interval
<b>CAPSULES:</b>		
Theo-24	100, 200, 300, 400 mg	Q24 hr
<b>TABLETS:</b>		
Theochron and generics	100, 200, 300, 450 mg	Q12 hr
Generics	400, 600 mg	Q24 hr

**THIAMINE**

Vitamin B<sub>1</sub>, many generic products

**Water-soluble vitamin**



A/C 1 No No No

**Tabs (OTC):** 50, 100, 250 mg

**Caps (OTC):** 50, 100, 500 mg

**Oral suspension:** 25, 100 mg/mL

THIAMINE *continued*

**Injection:** 100 mg/mL (2 mL); may contain benzyl alcohol

For US RDA, see [Chapter 21](#).

**Beriberi (thiamine deficiency):**

**Child:** 10–25 mg/dose IM/IV once daily (if critically ill) or 10–50 mg/dose PO once daily × 2 wk, followed by 5–10 mg/dose once daily × 1 mo

**Adult:** 10–20 mg/dose IM/IV TID (if critically ill) × 2 wk, followed by 5–30 mg/24 hr PO ÷ once daily or TID × 1 mo

**Wernicke's encephalopathy syndrome:**

**Adult:** 100 mg IV × 1, then 50–100 mg IM/IV once daily until patient resumes a normal diet. Initiate thiamine before starting glucose infusion.


**Refeeding syndrome:** see [Chapter 11](#)

Multivitamin preparations contain amounts meeting RDA requirements. Allergic reactions and anaphylaxis may occur, primarily with IV administration. Therapeutic range: 1.6–4 mg/dL. High-carbohydrate diets or IV dextrose solutions may increase thiamine requirements. Large doses may interfere with serum theophylline assay. Pregnancy category changes to “C” if used in doses above the RDA.

**THIORIDAZINE**

Various generics; previously available as Mellaril

**Antipsychotic, phenothiazine derivative**



C

3

No

Yes

No

**Tabs:** 10, 25, 50, 100 mg

**Refractory schizophrenia:**

**Child ≥6 yr—adolescent:** Start with 0.5 mg/kg/24 hr PO ÷ BID–TID (**initial max.:**

50 mg/dose); dosage range: 0.5–3 mg/kg/24 hr PO ÷ BID–TID. **Max. dose:** 3 mg/kg/24 hr

**Adult:** Start with 150–300 mg/24 hr PO ÷ TID. Then gradually increase PRN to **max. dose** 800 mg/24 hr ÷ BID–QID.

Indicated for schizophrenia unresponsive to standard therapy. **Contraindicated** in severe CNS depression, brain damage, narrow-angle glaucoma, blood dyscrasias, and severe liver or cardiovascular disease. **DO NOT** co-administer with drugs that may inhibit the CYP 450 2D6 isoenzymes (e.g., SSRIs such as fluoxetine, fluvoxamine, paroxetine; and β-blockers such as propranolol and pindolol); drugs that may widen the QTc interval (e.g., disopyramide, procainamide, quinidine); and in patients with known reduced activity of CYP 450 2D6.


May cause drowsiness, extrapyramidal reactions, autonomic symptoms, ECG changes (QTc prolongation in a dose-dependent manner), arrhythmias, paradoxical reactions, and endocrine disturbances. Long-term use may cause tardive dyskinesia. Pigmentary retinopathy may occur with higher doses; a periodic eye exam is recommended. More autonomic symptoms and less extrapyramidal effects than chlorpromazine. Concurrent use with epinephrine can cause hypotension. Increased cardiac arrhythmias may occur with tricyclic antidepressants.

In an overdose situation, monitor ECG and avoid drugs that can widen QTc interval.

**TIAGABINE**

Gabitril and generics

**Anticonvulsant**



C

?

No

Yes

No

**Tabs:** 2, 4, 12, 16 mg

*Continued*

TIAGABINE *continued*Oral suspension: 1 mg/mL **Adjunctive therapy for refractory seizures (see remarks):** 

**Child  $\geq 2$  yr (limited data from a safety and tolerability study in 52 children 2–17 yr, mean 9.3 + 4.1):** Initial dose of 0.25 mg/kg/24 hr PO  $\div$  TID  $\times$  4 wk. Dosage was increased at 4-wk intervals to 0.5, 1, and 1.5 mg/kg/24 hr until an effective and well-tolerated dose was established. Criteria for dose increase required tolerance of the current dosage level and  $<50\%$  reduction in seizures. Patients receiving enzyme-inducing antiepileptic drugs (AEDs) received a **max. daily dose** of 0.73 + 0.44 mg/kg/24 hr, and patients receiving non-enzyme-inducing AEDs received a **max.** of 0.61 + 0.32 mg/kg/24 hr.

**Adjunctive therapy for partial seizures (dosage based on use with enzyme-inducing AEDs; see remarks). NOTE:** Patients receiving non-enzyme-inducing AEDs had tiagabine blood levels about two times higher than patients receiving enzyme-inducing AEDs.

**$\geq 12$  yr and adult:** Start at 4 mg PO once daily  $\times$  7 days. If needed, increase dose to 8 mg/24 hr PO  $\div$  BID. Dosage may be increased further by 4–8 mg/24 hr at weekly intervals (daily doses may be divided BID–QID) until a clinical response is achieved or up to specified **max. dose**.

**Max. dose:**

12–18 yr: 32 mg/24 hr

Adult: 56 mg/24 hr

**Use with caution** in hepatic insufficiency (may need to reduce dose and/or increase dosing interval). Most common side effects include dizziness, somnolence, depression, confusion, and asthenia. Nervousness, tremor, nausea, abdominal pain, confusion, and difficulty in concentrating may also occur. Cognitive/neuropsychiatric symptoms resulting in nonconvulsive status epilepticus requiring subsequent dose reduction or drug discontinuation have been reported. Suicidal behavior or ideation, bullous dermatitis, and blurred vision have been reported. **Off-label use in patients WITHOUT epilepsy is discouraged** due to reports of seizures in these patients. 

Tiagabine's clearance is increased by concurrent hepatic enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, and barbiturates), and St. John's wort. Lower doses or a slower titration for clinical response may be necessary for patients receiving non-enzyme-inducing drugs (e.g., valproate, gabapentin, and lamotrigine). **Avoid** abrupt discontinuation of drug.

TID dosing schedule may be preferred since BID schedule may not be well tolerated. Doses should be administered with food.

**TIOTROPIUM**

Spiriva HandiHaler, Spiriva Respimat

**Anticholinergic agent, long-acting**

C



2



Yes



No



No

**Aerosol inhaler:****Spiriva Respimat:**

**For asthma:** 1.25 mCg/actuation (each cartridge weighs 4 g and provides either 28 or 60 actuations/inhaler); contains benzalkonium chloride and disodium EDTA

**For COPD:** 2.5 mCg/puff (each cartridge weighs 4 g and provides either 10, 28, or 60 actuations/inhaler); contains benzalkonium chloride and disodium EDTA

**Inhalational capsules:**

Spiriva HandiHaler: 18 mCg (boxes of 5s, 30s, or 90s with one HandiHaler device); contains milk protein

**Asthma (maintenance therapy, see remarks):** 

TIOTROPIUM *continued***Child ≥6 yr, adolescent, and adult:**

**Spiriva Respimat:** Inhale two 1.25 mCg actuations once daily; **max. dose:** 2.5 mCg/24 hr

**Contraindicated** in patients with ipratropium hypersensitivity reactions (e.g., angioedema, itching, or rash). Common side effects include headache, constipation, xerostomia, UTI, bronchitis, cough, pharyngitis, sinusitis, and URI. Bowel obstruction, angle-closure glaucoma, urinary retention, and bronchospasm have been reported. The pediatric adverse reaction profile is similar to adults.



Use as an add-on maintenance therapy for asthma along with inhaled corticosteroid. Maximum benefits may take up to 4–8 wk of continuous use. Doses >2.5 mCg/24 hr were not associated with greater efficacy in FEV<sub>1</sub> for adults with asthma.

Monitor for anticholinergic side effects in patients with moderate/severe renal impairment (eGFR <60 mL/min).

Administration of Spiriva Respimat 1.25 mCg × 2 delivered with the AeroChamber Plus Flow-Vu holding chamber with/without facemask by an in vitro study utilizing inspiratory flow rates for children 6–12 mo, 2–5 yr, and >5 yr has been shown to deliver a comparable adult dose on a mCg-per-body-weight basis. Despite a report of similar adverse reaction profile to adolescents and adults from a 12-wk placebo control trial (2.5 mCg/24 hr) in children 1–5 yr, the clinical efficacy and safety have not been fully established for children <6 years of age with asthma.

**TOBRAMYCIN**

Tobrex, TOBI, TOBI Podhaler, Bethkis, Kitabis Pak, and generics; previously available as Nebcin

**Antibiotic, aminoglycoside**



B/D



2



Yes



No



No

**Injection:** 10 mg/mL (2 mL), 40 mg/mL (2, 30, 50 mL); may contain phenol and bisulfites

**Powder for injection:** 1.2 g; preservative free

**Ophthalmic ointment (Tobrex):** 0.3% (3.5 g); contains 0.5% chlorobutanol

**In combination with dexamethasone (TobraDex):** 0.3% tobramycin with 0.1% dexamethasone (3.5 g); contains 0.5% chlorobutanol

**Ophthalmic solution (Tobrex and generics):** 0.3% (5 mL)

**In combination with dexamethasone as an ophthalmic suspension (both products contain 0.01% benzalkonium chloride and EDTA):**

**TobraDex and generics:** 0.3% tobramycin with 0.1% dexamethasone (2.5, 5, 10 mL)

**TobraDex ST:** 0.3% tobramycin with 0.05% dexamethasone (5 mL)

**Nebulizer solution:**

**Bethkis:** 300 mg/4 mL (56s); preservative free

**TOBI, Kitabis Pak, and generics:** 300 mg/5 mL (56s); preservative free

170 mg/3.4 mL (mixed in 0.45% NS, preservative free, use with eFlow/Trio nebulizer) 

**Powder for inhalation:**

**TOBI Podhaler:** 28 mg capsules (224 capsules in 4 weekly packs with 2 Podhaler inhalation devices)

**Initial empiric dosage; patient-specific dosage defined by therapeutic drug monitoring (see remarks)**



*Continued*

TOBRAMYCIN *continued*

Neonate/infant, IM/IV (see following table):

Postconceptional age (wk)	Postnatal age (days)	Dose (mg/kg/dose)	Interval (hr)
≤29 <sup>a</sup>	0–7	5	48
	8–28	4	36
	>28	4	24
30–34	0–7	4.5	36
	>7	4	24
≥35	ALL	4	24 <sup>b</sup>

<sup>a</sup>Or significant asphyxia, PDA, indomethacin use, poor cardiac output, reduced renal function.<sup>b</sup>Use Q36 hr interval for HIE patients receiving whole-body therapeutic cooling.**Child:** 7.5 mg/kg/24 hr ÷ Q8 hr IV/IM**Cystic fibrosis (if available, use patient's previous therapeutic mg/kg dosage):****Conventional Q8 hr dosing:** 7.5–10.5 mg/kg/24 hr ÷ Q8 hr IV**High-dose extended interval (once daily) dosing:** 10–12 mg/kg/dose Q24 hr IV**Adult:****Conventional Q8 hr dosing:** 3–6 mg/kg/24 hr ÷ Q8 hr IV/IM**High-dose extended interval:** 4–7 mg/kg/dose Q24 hr IV/IM**Ophthalmic:****Tobramycin:****Child and adult:****Ophthalmic ointment:** Apply 0.5-inch ribbon into conjunctival sac(s) BID–TID; for severe infections, apply Q3–4 hr initially, then reduce dose frequency.**Ophthalmic drop:** Instill 1–2 drops of solution to affected eye(s) Q4 hr; for severe infections, instill 2 drops Q30–60 min initially, then reduce dosing frequency.**Tobramycin with dexamethasone:****≥2 yr and adult:****Ophthalmic ointment:** Apply 0.5-inch ribbon of ointment into conjunctival sac(s) TID–QID.**Ophthalmic drop:****TobraDex:** Instill 1–2 drop(s) of solution to affected eye(s) Q2 hr × 24–48 hr, then 1–2 drop(s) Q4–6 hr; increase dosing interval when signs and symptoms improve.**TobraDex ST:** Instill 1 drop of solution to affected eye(s) Q2 hr × 24–48 hr, then 1 drop Q4–6 hr; increase dosing interval when signs and symptoms improve.**Inhalation:****Cystic fibrosis prophylaxis therapy:****≥6 yr and adult:****TOBI, Bethkis, Kitabis Pak, and generic nebs:** 300 mg Q12 hr administered in repeated cycles of 28 days on drug followed by 28 days off drug**Use with eFlow/Trio nebulizer:** 170 mg Q12 hr administered in repeated cycles of 28 days on drug followed by 28 days off drug**TOBI Podhaler:** Inhale four 28-mg capsules (112 mg) Q12 hr administered in repeated cycles of 28 days on drug followed by 28 days off drug.

**Use with caution** in combination with neurotoxic, ototoxic, or nephrotoxic drugs; anesthetics or neuromuscular blocking agents; pre-existing renal, vestibular, or auditory impairment; and in patients with neuromuscular disorders. May cause ototoxicity, nephrotoxicity, and neuromuscular blockade. Serious allergic reactions, including anaphylaxis, and dermatologic reactions, including exfoliative dermatitis, toxic epidermal necrolysis, erythema multiforme, and Stevens-Johnson syndrome, have been reported rarely. **Ototoxic effects synergistic with furosemide.**



TOBRAMYCIN *continued*

Higher doses are recommended in patients with cystic fibrosis, neutropenia, or burns. **Adjust dose in renal failure (see Chapter 31).** Monitor peak and trough levels.

**Therapeutic peak levels with conventional Q8 hr dosing:**

6–10 mg/L in general

8–10 mg/L in pulmonary infections, neutropenia, osteomyelitis, and severe sepsis

**Therapeutic trough levels with conventional Q8 hr dosing:** <2 mg/L. Recommended serum sampling time at steady state: trough within 30 min prior to the third consecutive dose and peak 30–60 min after the administration of the third consecutive dose.

**Therapeutic peak and trough goals for high-dose extended-interval dosing for cystic fibrosis:**

**Peak:** 20–40 mg/L; recommended serum sampling time at 30–60 min after the administration of the first dose

**Trough:** <1 mg/L; recommended serum sampling time within 30 min before the second dose

Serum levels should be rechecked with changing renal function, poor clinical response, and at a minimum of once weekly for prolonged therapies.

To maximize bactericidal effects, an individualized peak concentration to target a peak/MIC ratio of 8–10:1 may be applied.

For initial dosing in obese patients, use an adjusted body weight (ABW).  $ABW = \text{Ideal Body Weight} + 0.4 (\text{Total Body Weight} - \text{Ideal Body Weight})$

**INHALATIONAL USE:** Transient voice alteration, bronchospasm, dyspnea, pharyngitis, and increased cough may occur. Transient tinnitus, decreased appetite, and hearing loss have been reported with nebulized dosage forms. Aphonia, discolored sputum, and malaise have been reported with the powder for inhalation. Use is not recommended with nephrotoxic, neurotoxic, or ototoxic medications, or when intravenous antibiotic therapy is prescribed. When used with other inhaled medications in cystic fibrosis, use the following order of administration: bronchodilator first, chest physiotherapy, other inhaled medications (if indicated), and tobramycin last. For TOBI Podhaler, inhale the entire contents of each capsule. To improve adherence with prophylactic inhalation therapy, initiate each 28-day inhalation cycle on the first day of an odd- or even-numbered month.

Pregnancy category is a “D” for injection and inhalation routes of administration and a “B” for the ophthalmic route.

**TOLNAFTATE**

Tinactin, many other brands and generics

**Antifungal agent**



?



?



No



No



No

**Topical aerosol liquid [OTC]:** 1% (150 g); may contain 29% vol/vol or 41% wt/wt alcohol

**Aerosol powder [OTC]:** 1% (133 g); contains 11% vol/vol alcohol and talc

**Cream [OTC]:** 1% (15, 30, 114 g)

**Topical powder [OTC]:** 1% (45 g)

**Topical solution [OTC]:** 1% (10, 15, 30 mL); may contain propylene glycol and/or parabens

**Child (≥2 yr), adolescent, and adult:**

**Topical for tinea pedis, tinea corporis, and tinea cruris:** Apply 1–3 drops of solution, or small amount of liquid, cream, or powder to affected areas BID for 2–4 wk.



May cause mild irritation and sensitivity. Contact dermatitis has been reported. **Avoid eye contact. Do not use** for nail or scalp infections. Discontinue use if sensitization develops.



Pregnancy category not formally assigned by FDA.

**TOPIRAMATE**

Topamax, Topamax Sprinkle, Trokendi XR, Qudexy XR, Eprontia, and generics

**Anticonvulsant**

D



2



Yes



Yes



No

**Caps, sprinkle:****Topamax Sprinkle and generics:** 15, 25 mg**Tab:****Topamax and generics:** 25, 50, 100, 200 mg**Extended release caps, sprinkle (Q24 hr dosing; see remarks):****Qudexy XR and generics:** 25, 50, 100, 150, 200 mg**Extended release caps (Q24 hr dosing; see remarks):****Trokendi XR:** 25, 50, 100, 200 mg**Oral solution:****Eprontia:** 25 mg/mL (473 mL); contains parabens and polyethylene glycol**Oral suspension: 6, 14, 20 mg/mL** **Adjunctive therapy for partial onset seizures or Lennox-Gastaut syndrome (immediate release dosage forms):****Child 2–16 yr:** Start with 1–3 mg/kg/dose (**max. dose:** 25 mg/dose) PO QHS  $\times$  7 days, then increase by 1–3 mg/kg/24-hr increments at 1- to 2-wk intervals (divided daily dose BID) to response. Usual maintenance dose is 5–9 mg/kg/24 hr PO  $\div$  BID; **max. dose:** 400 mg/24 hr **$\geq$ 17 yr and adult:** Start with 25–50 mg PO QHS  $\times$  7 days, then increase by 25–50 mg/24 hr increments at 1-wk intervals until adequate response. Doses  $>$ 50 mg should be divided BID. Usual maintenance dose: 100–200 mg BID. Doses above 1600 mg/24 hr have not been studied.**Adjunctive therapy for primary generalized tonic-clonic seizures (immediate release dosage forms):****Child 2–16 yr:** Use above initial dose and slower titration rate by reaching 6 mg/kg/24 hr by the end of 8 weeks. **$\geq$ 17 yr and adult:** Use above initial dose and slower titration rate by reaching 200 mg BID by the end of 8 weeks; **max. dose:** 1600 mg/24 hr**Monotherapy for partial onset seizures or primary generalized tonic-clonic seizures (immediate release dosage forms):****Child 2 to  $<$ 10 yr:** Start with 25 mg PO QHS  $\times$  7 days; if needed and tolerated, may increase dose to 25 mg PO BID. May further increase by 25–50 mg/24 hr at weekly intervals over 5–7 wk up to the lower end of the following daily target maintenance dosing range (if needed and tolerated, increase to higher end of dosing range by increasing by 25–50 mg/24 hr at weekly intervals): **$\leq$ 11 kg:** 150–250 mg/24 hr  $\div$  BID**12–22 kg:** 200–300 mg/24 hr  $\div$  BID**23–31 kg:** 200–350 mg/24 hr  $\div$  BID**32–38 kg:** 250–350 mg/24 hr  $\div$  BID **$>$ 38 kg:** 250–400 mg/24 hr  $\div$  BID**Child  $\geq$ 10 yr and adult:** Start with 25 mg PO BID  $\times$  7 days, then increase by 50 mg/24 hr increments at 1-wk intervals up to a **max. dose** of 100 mg PO BID at wk 4. If needed, dose may be further increased at weekly intervals by 100 mg/24 hr up to a recommended **max. dose** of 200 mg PO BID.**Migraine prophylaxis:****Child 6 to  $<$ 12 yr and  $\geq$ 20 kg (limited data):** Start with 15 mg PO once daily  $\times$  7 days, then increase to 25 mg PO BID  $\times$  7 days, then gradually increase dose to effect up to a target dose of 2–3 mg/kg/24 hr  $\div$  BID (**max. dose:** 200 mg/24 hr).**Child  $\geq$ 12 yr and adult:** Titrate dosage to 50 mg PO BID with the following schedule:

TOPIRAMATE *continued*

	Morning PO Dose	Evening PO Dose
Week 1	None	25 mg
Week 2	25 mg	25 mg
Week 3	25 mg	50 mg
Week 4 and beyond	50 mg	50 mg

Use clinical outcome to guide dose and titration. Longer intervals between dose adjustments can be used.

**Use with caution** in renal and hepatic dysfunction (decreased clearance) and sulfa hypersensitivity. **Reduce dose by 50% when creatinine clearance is <70 mL/min.**



Common side effects (incidence lower in children) include ataxia, cognitive dysfunction, dizziness, nystagmus, paresthesia, sedation, visual disturbances, nausea, dyspepsia, and kidney stones (higher urinary calcium/citrate ratio; incidence higher in children). Secondary angle closure glaucoma characterized by ocular pain, acute myopia, and increased intraocular pressure has been reported and may lead to blindness if left untreated. Patients should be instructed to seek immediate medical attention if they experience blurred vision or periorbital pain. Oligohidrosis and hyperthermia have been reported primarily in children and should be monitored, especially during hot weather and with use of drugs that predispose patients to heat-related disorders (e.g., carbonic anhydrase inhibitors and anticholinergics). Low serum bicarbonate levels, negative effects on growth (height and weight) in children, increased serum creatinine and glucose in children, and decreased bone mineral density have been reported in clinical trials. Hyperchloremic, non-anion gap metabolic acidosis, hyperammonemia (with or without encephalopathy), suicidal behavior or ideation, serious skin reactions (e.g., SJS and TEN), and false-positive sweat chloride test for cystic fibrosis have been reported.

Drug is metabolized by and inhibits the CYP 450 2C19 isoenzyme. Phenytoin, valproic acid, and carbamazepine may decrease topiramate levels. Topiramate may decrease valproic acid, digoxin, warfarin, and ethinyl estradiol (to decrease oral contraceptive efficacy) but may increase phenytoin levels/effects. Alcohol and CNS depressants may increase CNS side effects. Carbonic anhydrase inhibitors (e.g., acetazolamide) may increase risk of metabolic acidosis, nephrolithiasis, or paresthesia. Use with valproic acid may result in the development of hyperammonemia.

Safety and efficacy in migraine prophylaxis in pediatrics have not been established; an increase in serum creatinine has been reported in a clinical trial.

Qudexy XR and Trokendi XR are not bioequivalent and should not be interchanged. Doses may be administered with or without food. Capsule may be opened and sprinkled on small amount of food (e.g., 1 teaspoonful of applesauce) and swallowed whole (do not chew). Maintain adequate hydration to prevent kidney stone formation. If discontinuing therapy, gradually taper dosage.

**TRAZODONE**

Generics; previously available as Desyrel  
**Antidepressant, serotonin reuptake inhibitor/  
antagonist, triazolopyridine-derivative**



C



2



Yes



Yes



No

**Tabs:** 50, 100, 150, 300 mg

**Oral suspension:** 10 mg/mL 

**Insomnia with comorbid psychiatric disorders (limited data):**

**18 mo to <3 yr:** Start at 1–2 mg/kg/dose (**max. dose:** 25 mg) PO QHS. If needed, increase by 12.5–25 mg Q2 wk up to a **max.** of 100 mg/24 hr.



*Continued*

TRAZODONE *continued*

**3–5 yr:** Start at 1–2 mg/kg/dose (**max. dose:** 50 mg) PO QHS; if needed, increase by 12.5–25 mg Q2 wk up to a **max.** of 150 mg/24 hr.

**5 yr—adolescent:** 25–50 mg PO QHS; if needed, increase by 12.5–25 mg Q2 wk up to a **max.** of 200 mg/24 hr. Daily dose may be divided BID—TID when used for palliative care.

**Use with caution** in pre-existing cardiac disease, initial recovery phase of MI, in patients receiving antihypertensive medications, renal and hepatic impairment (has not been evaluated), and electroconvulsive therapy. Common side effects include dizziness, drowsiness, dry mouth, and diarrhea. May cause angle-closure glaucoma in patients with anatomically narrow angles who do not have an iridectomy. Seizures, tardive dyskinesia, EPS, arrhythmias, priapism, blurred vision, neuromuscular weakness, anemia, orthostatic hypotension, and rash have been reported. Monitor for clinical worsening of depression and suicidal ideation/behavior following the initiation of therapy or after dose changes.

Trazodone is a CYP 450 3A4 isoenzyme substrate (may interact with inhibitors and inducers) and may increase digoxin levels and increase CNS effects of alcohol, barbiturates, and other CNS depressants. **Max.** antidepressant effect is seen at 2–6 wk.

**TREPROSTINIL**

Remodulin, Tyvaso, Tyvaso DPI, Orenitram, and generics

**Prostaglandin I<sub>2</sub> analogue, vasodilator**



C



?



Yes



Yes



No

**Injection:**

**Remodulin and generics:** 1 mg/mL (20 mL), 2.5 mg/mL (20 mL), 5 mg/mL (20 mL), 10 mg/mL (20 mL); contains metacresol

**Inhalation solution:**

**Tyvaso:** 0.6 mg/mL (2.9 mL; 4s and 28s); use with Tyvaso inhalation system

**Powder for inhalation:**

**Tyvaso DPI:** 16, 32, 48, 64 mCg (16 cartridges with 2 inhaler devices, 112 cartridges with 5 inhaler devices)

**Extended release tab:**

**Orenitram:** 0.125, 0.25, 1, 2.5, 5 mg

**Pulmonary arterial hypertension (PAH):****IV/SC infusion:**

**Child (limited data):** Initial dose of 2 nanogram/kg/min has been recommended with careful titration. Stable doses have been reported at 50–80 nanogram/kg/min with an unknown maximum dosage. Dosages as high as 350 and 170 nanogram/kg/min have been reported with the SC and IV routes, respectively.

**Adult:** Start at 1.25 nanogram/kg/min. If not tolerated, reduce to 0.625 nanogram/kg/min. If needed, increase dose at increments of 1.25 nanogram/kg/min per wk for the first 4 wk followed by 2.5 nanogram/kg/min per wk thereafter. Usual target dose: 40–80 nanogram/kg/min

**Inhalation:**

**Child (limited data):** 1–9 (6–54 mCg) patient-activated breaths Q6 hr. A retrospective report of 29 children with PAH receiving background therapy initially received 3 breaths (18 mCg) via oral inhalation QID and titrated doses weekly as tolerated to a **maximum** of 9 breaths (54 mCg) QID for ≥6 wk. Nineteen of 29 children had WHO functional class improvement (significant improvements in exercise tolerance and peak oxygen consumption). Four children had to discontinue therapy for reasons of O<sub>2</sub> desaturation (1), progression of PAH (1), and chest tightness with bronchospasms (2).



TREPROSTINIL *continued*

**Adult:** Start at 3 breaths (18 mCg) via oral inhalation Q4 hr four times a day during waking hours. Reduce dose to 1 or 2 breaths if not tolerated and subsequently increase to 3 breaths. If tolerated, increase dose by 3 additional inhalations at ~1–2 wk intervals to the target and **maximum** maintenance dose of 9 breaths (54 mCg) QID.

**Use with caution** in liver or renal impairment by titrating doses slowly. **Avoid use** with the oral dosage form in Child-Pugh class B and C. Treprostinil is primarily metabolized by the liver via CYP 450 2C8, and its metabolites are excreted primarily via the urinary route. Inhibitors (e.g., gemfibrozil) and inducers (e.g., rifampin) may increase and decrease treprostinil effects, respectively.



Flushing, muscle pain (especially with SC route), headaches, and diarrhea are common side effects with injectable routes. Central line Gram-negative catheter infections have been reported with the IV route. Recommendations for reducing this risk include using watertight seals in the drug delivery system and closed-hub systems, replacing the diluent with the diluent used for epoprostenol, and using the SC route. Thrombocytopenia has been reported with SC administration. Worsening of reactive airway symptoms, bronchospasm, cough, dizziness, muscle, bone or jaw pain, headache, syncope, and flushing may occur with the inhaled route. Headache, diarrhea, nausea, and flushing are common side effects with the oral dosage form in clinical trials.

Treprostinil has a longer  $T_{1/2}$  than epoprostenol with better room temperature stability (depending on specific diluent used).

**Do not** abruptly withdraw therapy, and have a backup plan for interruptions with IV/SC continuous therapies (e.g., backup pumps and medications).

**TRETINOIN—TOPICAL PREPARATIONS**

Retin-A, Retin-A Micro, Altreno, Atralin, Avita, Renova, Refissa, and many others

In combination with clindamycin: Veltin, Ziana, and generics

In combination with benzoyl peroxide: Twyneo

**Retinoic acid derivative, topical acne product**



C



2



No



No



No

**Cream (all strengths may contain parabens, benzyl alcohol, and edetate disodium):**

**0.02% (20, 40, 60 g):** Renova

**0.025% (20, 45 g):** Avita, Retin-A, and generics

**0.05% (20, 40, 45 g):** Refissa and generics

**0.1% (20, 45 g):** Generics

**Topical gel (all strengths may contain 90% alcohol, benzyl alcohol, propylene glycol, and trolamine):**

**0.01% (15, 45 g):** Retin-A and generics

**0.025% (15, 20, 45 g):** Avita and generics

**0.04% (20, 45, 50 g):** Retin-A Micro and generics

**0.05% (45 g):** Atralin and generics

**0.06% and 0.08% (50 g):** Retin-A Micro

**0.1% (20, 45, 50 g):** Retin-A Micro and generics

**Lotion (Altreno):**

0.05% (20, 45 g), contains benzyl alcohol, parabens, and trolamine

**In combination with clindamycin:**

**Topical gel (Veltin, Ziana, and generics):** 0.025% tretinoin and 1.2% clindamycin (30, 60 g); may contain parabens, tromethamine, and propylene glycol

*Continued*

TRETINOIN—TOPICAL PREPARATIONS *continued***In combination with benzoyl peroxide:**

**Topical cream (Twynéo):** 0.1% tretinoin and 3% benzoyl peroxide (50 g)

**Topical for acne:**

**Child ≥12 yr and adult (may be used as young as 8 yr as reported in the literature and specific product labeling; see remarks):** Gently wash face with a mild soap, pat the skin dry, and wait 20 to 30 min before use. Initiate therapy with lower strengths (0.02% or 0.025% cream, or 0.01% gel) and apply a small pea-size amount to the affected areas of the face QHS or on alternate days. See remarks.

**In combination with clindamycin:**

**Child ≥12 yr and adult:** Gently wash face with a mild soap, pat the skin dry, and wait 20 to 30 min before use. Apply a pea-size amount to entire face QHS.

**In combination with benzoyl peroxide:**

**Child ≥9 yr and adult:** Apply a thin layer to affected areas once daily on clean and dry skin.

**Contraindicated** in sunburns. **Avoid** excessive sun exposure. If stinging or irritation occurs, decrease frequency of administration to every other day. **Avoid** contact with eyes, ears, nostrils, mouth, or open wounds. Local adverse effects include irritation, erythema, excessive dryness, blistering, crusting, hyperpigmentation or hypopigmentation, and acne flare-ups. Concomitant use of other topical acne products may lead to significant skin irritation. Onset of therapeutic benefits may be experienced within 2–3 wk with optimal effects in 6 wk. The gel dosage form is flammable and should not be exposed to heat or temperatures >120°F.

**Lower minimum age (<12 yr) for use by specific product labeling:**

**Atralin gel:** ≥10 yr

**Altreno lotion:** ≥9 yr

Retin-A Micro 0.04% topical gel has been used in children ≥8 yr as reported in the literature.

**In combination with clindamycin (additional remarks from above):** **Contraindicated** in regional enteritis, ulcerative colitis, or history of antibiotic-associated colitis. Prolonged use may result in fungal and bacterial superinfection, including *C. difficile*—associated diarrhea. Common side effects include burning sensation, desquamation, erythema, and xeroderma. See [Clindamycin](#) (topical use) for additional information.

**In combination with benzoyl peroxide (additional remarks from above):** **Contraindicated** with a history of hypersensitivity reactions to either components. Common side effects include pain at application site, application-site scaling, erythema, dry skin, pruritus, and irritation. See [Benzoyl Peroxide](#) for additional information.

**TRIAMCINOLONE**

Nasal preparations: Nasacort Allergy 24HR, Nasal Allergy 24 Hour, and generics

Topical preparations: Triderm, Kenalog, Oralone, Trianex, Tritocin, and generics

Injection preparations: Kenalog-10, Kenalog-40, Kenalog-80, generics, and others in kits

**Corticosteroid****Nasal spray:**

**Nasacort Allergy 24HR, Nasal Allergy 24 Hour, and generics [OTC]:** 55 mCg/actuation (60 actuations per 10.8 mL, 120 actuations per 16.9 mL); contains benzalkonium chloride, polysorbate 80, and EDTA

TRIAMCINOLONE *continued***Cream:**

**Triderm and generics:** 0.1% (15, 28.4, 30, 80, 454 g); contains propylene glycol

**Generics:** 0.025% (15, 80, 454 g), 0.5% (15 g)

**Ointment:**

**Generics:** 0.025%, 0.1% (15, 80, 454 g), 0.5% (15 g)

**Trianex, Tritocin, and generics:** 0.05% (110, 430 g)

**Lotion:** 0.025%, 0.1% (60 mL)

**Topical aerosol:**

**Kenalog and generics:** 0.2 mg/2 second spray; each g of spray contains 0.147 mg triamcinolone acetate (63, 100 g); contains 10.3% alcohol

**Dental paste:**

**Oralone and generics:** 0.1% (5 g)

See [Chapter 10](#) for potency rankings and sizes of topical preparations.

**Injection as acetamide:** 10 mg/mL (Kenalog-10 and generics) (5 mL), 40 mg/mL (Kenalog-40 and generics) (1, 5, 10 mL), 80 mg/mL (Kenalog-80) (1, 5 mL); all strengths contains benzyl alcohol and polysorbate 80

**Kits (all contain benzyl alcohol and polysorbate 80):**

P-Care K40, Pod-Care 100K: 40 mg/mL (1 × 1 mL)

P-Care K80, Pro-C-Dure 5: 40 mg/mL (2 × 1 mL)

Pro-C-Dure 6: 40 mg/mL (3 × 1 mL)

**Intranasal (titrate to lowest effective dose after symptoms are controlled; discontinue use if no relief of symptoms occurs after 3 wk of use):**

**Child 2–5 yr:** 1 spray in each nostril once daily (110 mCg/24 hr; starting and **max. dose**)

**Child 6–11 yr:** Start with 1 spray in each nostril once daily (110 mCg/24 hr). If no benefit in 1 wk, dose may be increased to the **max. dose** of 2 sprays in each nostril once daily (220 mCg/24 hr). Decrease dose back to 1 spray each nostril when symptoms are controlled.

**≥12 yr and adult:** 2 sprays in each nostril once daily (220 mCg/24 hr; starting and **max. dose**). Decrease dose to 1 spray each nostril when symptoms are controlled.

**Topical cream or ointment:**

**Infant, child, and adult:** Apply a thin film to affected areas BID–TID for topical concentrations of 0.1% or 0.5% and BID–QID for 0.025% or 0.05%.

**Topical spray or lotion:**

**Infant, child, and adult:** Spray or apply to affected area TID–QID.

**SYSTEMIC USE (see remarks):****Anti-inflammatory and allergic condition:**

**Child and adolescent (use 40 or 80 mg/mL strength, deep IM into gluteal muscle):** 0.11–1.6 mg/kg/24 hr IM ÷ TID–QID

**Intralesional for dermatosis:**

**≥12 yr and adult (use 10 mg/mL strength):** Inject up to 1 mg/site × 1 and may be repeated × 1 or more times weekly. May give separate doses in sites ≥1 cm apart, **not to exceed** 30 mg.

**NASAL USE:** Rare reports of bone mineral density loss and osteoporosis have been reported with prolonged use of inhaled dosage form. Nasal preparations may cause epistaxis, cough, fever, nausea, throat irritation, dyspepsia, and fungal infections (rarely). Shake intranasal dosage forms before each use.



**TOPICAL USE:** Topical preparations may cause dermal atrophy, telangiectasias, and hypopigmentation. HPA axis suppression, Cushing syndrome, and intracranial hypertension have been reported in children with topical use. Topical steroids should be used with caution on the face and in intertriginous areas. See [Chapter 8](#). **Avoid** spraying the eye or inhaling the topical aerosol dosage form. Aerosol dosage form is flammable.

*Continued*

TRIAMCINOLONE *continued*

**INJECTABLE USE:** Anaphylaxis has been reported with use of the injectable dosage form. Dosage adjustment for hepatic failure with systemic use may be necessary. Triamcinolone is a substrate of the CYP 450 3A4 enzyme; inhibitors of this enzyme may increase risk for side effects. **Use with caution** in thyroid dysfunction, respiratory TB, ocular herpes simplex, peptic ulcer disease, osteoporosis, hypertension, CHF, myasthenia gravis, ulcerative colitis, and renal dysfunction. With systemic use, pregnancy category changes to “D” if used in the first trimester. **Avoid IV** administration with injectable dosage forms. Injectable forms contain benzyl alcohol.

**TRIAMTERENE**

Dyrenium and generics

**Diuretic, potassium sparing**

C/D



?



Yes



Yes



No

**Caps:** 50, 100 mg**Hypertension:**

**Child:** 1–2 mg/kg/24 hr PO ÷ BID. May increase up to a **max.** of 3–4 mg/kg/24 hr up to 300 mg/24 hr

**Adult:** 50–100 mg/24 hr ÷ once daily—BID PO; **max. dose:** 300 mg/24 hr



**Do not use** if GFR <10 mL/hr or in severe hepatic disease. **Adjust dose in renal impairment** (see [Chapter 31](#)) and cirrhosis. Monitor serum electrolytes. May cause hyperkalemia,

hyponatremia, hypomagnesemia, and metabolic acidosis. Interstitial nephritis, thrombocytopenia, and anaphylaxis have been reported.



Concurrent use of ACE inhibitors may increase serum potassium. **Use with caution** when administering medications with high potassium load (e.g., some penicillins) and in patients with hepatic impairment or on high-potassium diets. Cimetidine may increase effects. This drug is also available as a combination product with hydrochlorothiazide; erythema multiforme and toxic epidermal necrolysis have been reported with this combination product. Administer doses with food to minimize GI upset. Pregnancy category changes to “D” if used in pregnancy-induced hypertension.

**TRIFLURIDINE**

Generics; previously available as Viroptic

**Antiviral, ophthalmic**

C



?



No



No



No

**Ophthalmic solution:** 1% (7.5 mL); contains thimerosal**Herpes keratoconjunctivitis:**

**≥6 yr, adolescent, and adult:** Instill 1 drop into affected eye(s) Q2 hr while awake up to a **maximum** of 9 drops/24 hr. Reduce dose when there is re-epithelialization of the corneal ulcer to 1 drop Q4 hr (**minimum** 5 drops/24 hr) × 7 days. If improvement does not occur in 7–14 days, consider alternative therapy. **DO NOT EXCEED** 21 days of treatment.



Burning sensation in eyes and palpebral edema are common side effects. Rare cross sensitivity with idoxuridine, increased intraocular pressure, keratoconjunctivitis, and ocular hyperemia have been reported.



**Avoid** touching the applicator tip to eye, fingers, or other surfaces, and do not wear contact lenses during treatment of ocular infections. Apply pressure to the lacrimal sac during and for 1–2 min after dose administration to reduce risk of systemic absorption.

TRIFLURIDINE *continued*


Store medication in the refrigerator (2–8°C). Storage at room temperature will result in a decrease in pH to cause stinging and ocular discomfort when in use.

**TRIKAFTA**

See [Elexacaftor/Tezacaftor/Ivacaftor](#).

**TRIMETHOBENZAMIDE HCL**

Tigan and generics  
**Antiemetic**



**Caps:** 300 mg  
**Injection (Tigan):** 100 mg/mL (2 mL)

**Nausea/Vomiting:**

**Child (PO):** 15–20 mg/kg/24 hr ÷ TID–QID  
**Alternative dosing:**  
 <13.6 kg: 100 mg TID–QID  
 13.6–40 kg: 100–200 mg/dose TID–QID  
 >40 kg: 300 mg/dose TID–QID

**Adult:**

**PO:** 300 mg/dose TID–QID  
**IM:** 200 mg/dose TID–QID



**Do not use** in premature or newborn infants. **Avoid** use in patients with hepatotoxicity, acute vomiting, medications with CNS depressant effects, or allergic reaction. CNS disturbances are common in children (extrapyramidal symptoms, drowsiness, confusion, dizziness). Hypotension, especially with IM use, may occur. **IM not recommended in children.** Consider reducing dosage in the presence of renal impairment since a significant amount of drug is excreted and eliminated by the kidney.




**TRIMETHOPRIM AND SULFAMETHOXAZOLE**

See [Sulfamethoxazole and Trimethoprim](#).

**U**

**URSODIOL**

Urso 250, Urso Forte, Reltone, and generics; previously available as Actigall  
**Gallstone solubilizing agent, cholelitholytic agent**



**Oral suspension:** 20, 25, 50, 60 mg/mL

**Caps:**

**Generics:** 200, 300, 400 mg  
**Reltone:** 200, 400 mg

*Continued*

URSODIOL *continued***Tabs:****Urso 250 and generics:** 250 mg**Urso Forte and generics:** 500 mg**Biliary atresia:****Infant and child (limited data):** 10–20 mg/kg/24 hr ÷ BID–TID PO; higher doses of 20–36 mg/kg/24 hr have been reported in neonates and infants receiving the Kasai procedure**Pruritus from cholestasis:****Infant, child, and adolescent (limited data):** 15–30 mg/kg/24 hr ÷ once daily–BID PO**TPN-induced cholestasis:****Infant and child (limited data):** 10–30 mg/kg/24 hr ÷ TID PO**Cystic fibrosis (to improve fatty acid metabolism in liver disease; limited data):****Child:** 15–30 mg/kg/24 hr ÷ BID–TID PO**Gallstone dissolution:****Adult:** 8–10 mg/kg/24 hr ÷ BID–TID PO

**Contraindicated** in calcified cholesterol stones, radiopaque stones, bile pigment stones, or stones >20 mm in diameter. **Use with caution** in patients with nonvisualizing gallbladder and chronic liver disease. May cause GI disturbance, rash, arthralgias, anxiety, headache, and elevated liver enzymes (elevated ALT, AST, alkaline phosphatase, bilirubin, GGT). Monitor LFTs every month for the first 3 months after initiating therapy and every 6 months thereafter. Thrombocytopenia has been reported in clinical trials.

Aluminum-containing antacids, cholestyramine, and oral contraceptives decrease ursodiol effectiveness. Dissolution of stones may take several months. Stone recurrence occurs in 30% to 50% of patients within 5 yr.

**V****VALACYCLOVIR**

Valtrex and generics

**Antiviral agent**

B



1



Yes



Yes



No

**Tabs/caplets:** 500, 1000 mg**Oral suspension:** 50 mg/mL 

**Child:** Recommended dosages based on steady-state pharmacokinetic data in immunocompromised children. Efficacy data are incomplete.

**To mimic an IV acyclovir regimen of 250 mg/m<sup>2</sup>/dose or 10 mg/kg/dose TID:****30 mg/kg/dose PO TID OR alternatively by weight:**

4–12 kg: 250 mg PO TID

13–21 kg: 500 mg PO TID

22–29 kg: 750 mg PO TID

≥30 kg: 1000 mg PO TID

**To mimic a PO acyclovir regimen of 20 mg/kg/dose 4 or 5 times a day:****20 mg/kg/dose PO TID OR alternatively by weight:**

6–19 kg: 250 mg PO TID

20–31 kg: 500 mg PO TID

≥32 kg: 750 mg PO TID

VALACYCLOVIR *continued*

**Varicella zoster (chickenpox; immunocompetent patient; initiate therapy at earliest signs or symptoms, within 24 hr of rash onset):**

**Infant  $\geq 3$  mo, child, and adolescent:** 20 mg/kg/dose PO TID  $\times$  5 days; **max. dose:** 1 g/dose TID

**HSV genital herpes (immunocompetent):**

**Child  $\geq 3$  mo—11 yr (limited data):**

**Initial episode:** 20 mg/kg/dose PO Q12 hr (**max. dose:** 1000 mg/dose)  $\times$  7–10 days or longer if lesions are not completely healed

**Recurrent episodes:** 20 mg/kg/dose PO Q12 hr (**max. dose:** 1000 mg/dose)  $\times$  5–10 days; most effective when therapy is initiated within 1 day of lesion appearance

**Suppressive therapy:** 20 mg/kg/dose PO Q24 hr (**max. dose:** 1000 mg/dose)

**Adolescent and adult:**

**Initial episode:** 1 g/dose PO BID  $\times$  10 days or longer if lesions are not completely healed

**Recurrent episodes:** 500 mg/dose PO BID  $\times$  3 days or 1000 mg PO once daily  $\times$  5 days

**Suppressive therapy:**

**Immunocompetent patient:** 500–1000 mg/dose PO once daily  $\times$  1 year, then reassess for recurrences. Patients with  $<9$  recurrences per yr may be dosed at 500 mg/dose PO once daily  $\times$  1 yr.

**Herpes zoster (shingles, immunocompetent; initiate therapy within 48–72 hr of onset of rash; see remarks):**

**Child  $\geq 2$  yr and adolescent:** 20 mg/kg/dose PO Q8 hr; **max. dose:** 1000 mg/dose for a minimum of 7–10 days and until lesions have crusted over

**Adult (immunocompetent):** 1 g/dose PO Q8 hr for a minimum of 7–10 days and until lesions have crusted over

**Herpes labialis (cold sores; initiated at earliest symptoms):**

**$\geq 12$  yr and adult:**

**Immunocompetent:** 2 g/dose PO Q12 hr  $\times$  2 doses (1 day)

**HIV positive:** 1 g/dose PO Q12 hr  $\times$  5–10 days. For chronic suppressive therapy, 500 mg PO Q12 hr

This pro-drug is metabolized to acyclovir and L-valine with better oral absorption than acyclovir. **Use with caution in hepatic or renal insufficiency (adjust dose; see Chapter 31).**

Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) has been reported in patients with advanced HIV infection and in bone marrow and renal transplant recipients. Probenecid or cimetidine can reduce the rate of conversion to acyclovir. Headache, nausea, and abdominal pain are common adverse events in adults. Headache is common in children. See [Acyclovir](#) for additional drug interactions and adverse effects.

For initial episodes of genital herpes, therapy is most effective when initiated within 48 hr of symptom onset. Therapy should be initiated immediately after the onset of symptoms in recurrent episodes (no efficacy data when initiating therapy  $>24$  hr after onset of symptoms). Data are not available for use as suppressive therapy for periods  $>1$  yr.

Valacyclovir **CANNOT** be substituted for acyclovir on a one-to-one basis. Doses may be administered with or without food.

**VALGANCICLOVIR**

Valcyte and generics

**Antiviral agent**



C



3



Yes



Yes



No

**Tabs:** 450 mg

**Oral solution:** 50 mg/mL (88 mL); contains saccharin and sodium benzoate

**Oral suspension:** 60 mg/mL 

*Continued*

VALGANCICLOVIR *continued***Neonate and infant:****Symptomatic congenital CMV (from pharmacokinetic [PK] data in 8 infants 4–90 days**

**old [mean: 20 days] and 24 neonates 8–34 days old):** 16 mg/kg/dose PO Q12 hr produced similar levels to IV ganciclovir 6 mg/kg/dose BID. A comparison of 6 weeks vs. 6 months of therapy in 96 neonates (>32 wk gestation and  $\geq 1.8$  kg) showed modest improvement in long-term hearing and developmental outcomes at 1–2 yr of age with the longer duration of therapy of 6 months.

**Child (1 mo–16 yr):****CMV treatment for mild/moderate infection for solid organ transplant recipients (see remarks):**

Q12 hr PO dosage calculated with the following equation:

mg dose (**max. dose:** 900 mg) =  $7 \times \text{BSA} \times \text{CrCl}$ . BSA is determined by the Mosteller equation and CrCl is determined by a modified Schwartz equation (**max. value:** 150 mL/min/1.73m<sup>2</sup>).

**Mosteller BSA (m<sup>2</sup>) equation:** square root of [(height [cm]  $\times$  weight [kg])  $\div$  3600]

**Modified Schwartz (mL/min/1.73 m<sup>2</sup>) equation (max. value: 150 mL/min/1.73 m<sup>2</sup>):**  $k \times \text{height (cm)} \div \text{serum creatinine (mg/dL)}$ ; where  $k = 0.33$  if patient is <1 yr old with low birth weight for gestational age;  $k = 0.45$  if patient is <1 yr old with birth weight appropriate for gestational age or if patient is 1 to <2 yr old;  $k = 0.55$  for males 2 to <13 yr old and females aged 2 to <16 yr old; or  $k = 0.7$  if male 13–16 yr old

**Duration of therapy for treatment regimen:** Minimum of 2 weeks until symptoms resolve, and until 1 or 2 consecutive weekly CMV viral loads are undetectable or below a test-specific threshold level

**CMV prophylaxis in kidney (4 mo–16 yr), heart (1 mo–16 yr), or liver (4 mo–16 yr)**

**transplantation (see remarks):** Q24 hr PO dosage initiated within 10 days of transplantation is calculated with the following equation:

Daily mg dose (**max. dose:** 900 mg) =  $7 \times \text{BSA} \times \text{CrCl}$ . BSA is determined by the Mosteller equation and CrCl is determined by a modified Schwartz equation (**max. value:** 150 mL/min/1.73 m<sup>2</sup>).

**Mosteller BSA (m<sup>2</sup>) equation:** square root of [(height [cm]  $\times$  weight [kg])  $\div$  3600]

**Modified Schwartz (mL/min/1.73 m<sup>2</sup>) equation (max. value: 150 mL/min/1.73 m<sup>2</sup>):**  $k \times \text{height (cm)} \div \text{serum creatinine (mg/dL)}$ ; where  $k = 0.33$  if patient is <1 yr old with low birth weight for gestational age;  $k = 0.45$  if patient is <1 yr old with birth weight appropriate for gestational age or if patient is 1 to <2 yr old;  $k = 0.55$  for males 2 to <13 yr old and females aged 2 to <16 yr old; or  $k = 0.7$  for males 13–16 yr old

**Duration of therapy for prophylaxis:**

**Kidney transplantation ( $\geq 4$  mo to 16 yr):** 200 days

**Heart transplantation ( $\geq 1$  mo to 16 yr):** 100 days

**Liver transplantation ( $\geq 4$  mo to 16 yr):** 100–200 days; limited data

**Adolescent (>16 yr) and adult:****CMV retinitis:**

**Induction therapy:** 900 mg PO BID  $\times$  14–21 days with food

**Maintenance therapy:** 900 mg PO once daily with food for a minimum of 3–6 mo

**CMV treatment of mild/moderate infection in solid organ transplant recipients:** 900 mg PO BID for a minimum of 2 wk until symptoms resolve and until 1 or 2 consecutive weekly CMV viral load is undetectable or below a test-specific threshold level

**CMV prophylaxis in heart, kidney, and kidney-pancreas transplantation:** 900 mg PO once daily starting within 10 days of transplantation until 100 days post heart or kidney-pancreas transplantation; or until 200 days post kidney transplantation

This pro-drug is metabolized to ganciclovir with better oral absorption than ganciclovir.

**Contraindicated** with hypersensitivity to valganciclovir/ganciclovir; ANC <500 mm<sup>3</sup>; platelets <25,000 mm<sup>3</sup>; hemoglobin <8 g/dL; and patients on hemodialysis. **Use with caution in renal insufficiency (adjust dose; see Chapter 31)**, preexisting bone marrow suppression, or receiving



VALGANCICLOVIR *continued*

myelosuppressive drugs or irradiation. Has not been evaluated in hepatic impairment. May cause headache, insomnia, peripheral neuropathy, diarrhea, vomiting, neutropenia, anemia, and thrombocytopenia. Neutropenia incidence is greater at day 200 vs. day 100 in pediatric kidney transplant patients.

Use effective contraception during and for at least 90 days after therapy; may impair fertility in men and women. See [Ganciclovir](#) for drug interactions and additional adverse effects.

Monitor CBC with differential, platelets, and serum creatinine at baseline and periodically during therapy. Consider changes in serum creatinine and body changes to height and body weight for prophylaxis dosing.

Valganciclovir **CANNOT** be substituted for ganciclovir on a one-to-one basis. All doses are administered with food. **Avoid** direct skin or mucous membrane contact with broken or crushed tablets.

**VALPROIC ACID/VALPROATE SODIUM**

Generics; previously available as Depakene (PO) and Depacon (IV)

Depakote: See [Divalproex Sodium](#)

**Anticonvulsant**



D/X



2



No



Yes



Yes

**VALPROIC ACID:**

**Caps:** 250 mg

**Oral solution:** 250 mg/5 mL (473 mL); may contain parabens

**VALPROATE SODIUM:**

**Injection:** 100 mg/mL (5 mL); contains EDTA

**Dosages based on valproic acid or valproate sodium. See remarks regarding use of extended release dosage forms such as Depakote ER.**

**Seizures (PO):**

**Initial:** 10–15 mg/kg/24 hr ÷ once daily—TID

**Increment:** 5–10 mg/kg/24 hr at weekly intervals to **max. dose** of 60 mg/kg/24 hr

**Maintenance:** 30–60 mg/kg/24 hr ÷ BID—TID. Due to drug interactions, higher doses (up to 100 mg/kg/24 hr ÷ TID—QID) may be required in children on other anticonvulsants. If using divalproex sodium (Depakote or Depakote Sprinkle), divide daily dose BID.

**Intravenous route (use only when PO is not possible):**

Use same PO daily dose ÷ Q6 hr. Convert back to PO as soon as possible.

**Rectal route (use syrup diluted 1:1 with water, given PR as a retention enema; limited data):**

**Load:** 20 mg/kg/dose

**Maintenance:** 10–15 mg/kg/dose Q8 hr

**Migraine prophylaxis:**

**Child (limited data):** Start at 10–15 mg/kg/24 hr PO ÷ BID (**max. initial dose:** 250 mg/dose). If needed, increase dose over 4–6 wk to 40–45 mg/kg/24 hr PO ÷ BID up to a **maximum** of 1000 mg/24 hr. Alternative dosing for adolescent ≥17 yr is 250 mg PO BID initially titrated up to a **maximum** of 1000 mg/24 hr.

**Adult:** Start with 500 mg/24 hr ÷ PO BID. Dose may be gradually increased to a **max.** of 1000 mg/24 hr ÷ PO BID. If using divalproex sodium extended release tablets, administer daily dose once daily.

**Contraindicated** in hepatic disease, pregnancy (for migraine indication), urea cycle disorders (e.g., OTC deficiency), mitochondrial disorders with mutations in DNA polymerase  $\gamma$  (e.g., Alpers-Huttenlocher syndrome), and children <2 yr suspected of the aforementioned



*Continued*

VALPROIC ACID/VALPROATE SODIUM *continued*

mitochondrial disorder. May cause GI, liver, blood, and CNS toxicity; weight gain; transient alopecia; pancreatitis (potentially life-threatening); nausea; sedation; vomiting; headache; thrombocytopenia (dose-related); platelet dysfunction; rash (especially with lamotrigine); and hyperammonemia. Hepatic failure has occurred especially in children <2 yr (especially those receiving multiple anticonvulsants, with congenital metabolic disorders, with severe seizure disorders with mental retardation, and with organic brain disease). Idiosyncratic life-threatening pancreatitis has been reported in children and adults. Hyperammonemic encephalopathy has been reported in patients with urea cycle disorders. Suicidal behavior or ideation, male infertility, elevated testosterone, decreased bone mineral density, DRESS, encephalopathy without elevated ammonia levels, hair texture/color changes, and nail/nail bed disorders have been reported.

Valproic acid is a substrate for CYP 450 2C19 isoenzyme and an inhibitor of CYP 450 2C9, 2D6, and 3A3/4 (weak). It increases amitriptyline/nortriptyline, rufinamide, phenytoin, propofol, diazepam, and phenobarbital levels. Concomitant estrogen-containing contraceptives, phenytoin, phenobarbital, topiramate, meropenem, cholestyramine, and carbamazepine may decrease valproic acid levels. Amitriptyline or nortriptyline may increase valproic acid levels. May interfere with urine ketone and thyroid tests.

**Do not give** syrup with carbonated beverages. Use of IV route has not been evaluated for >14 days of continuous use. Infuse IV over 1 hr up to a **max. rate** of 20 mg/min. Depakote and Depakote ER are **NOT** bioequivalent; see package insert for dose conversion. Depakote ER is intended for once daily administration and may require higher daily doses when converting from other dosage forms.

**Therapeutic levels:** 50–100 mg/L. Recommendations for serum sampling at steady state: Obtain trough level within 30 min prior to the next scheduled dose after 2–3 days of continuous dosing. Levels of 50–60 mg/L and as high as 85 mg/L have been recommended for bipolar disorders. Monitor CBC and LFTs prior to and during therapy.

Valproic acid and divalproex should not be used in pregnant women. Increased risk of neural tube defects, decreased child IQ scores, craniofacial defects, and cardiovascular malformations have been reported in babies exposed to valproic acid and divalproex sodium.

Pregnancy category is “X” when used for migraine prophylaxis and is “D” for all other indications.

**VALSARTAN**

Diovan and generics

**Angiotensin II receptor blocker, antihypertensive agent**



D



3



Yes



Yes



No

**Tabs:** 40, 80, 160, 320 mg

**Oral solution:** 4 mg/mL (120, 473 mL); may contain parabens and propylene glycol

**Oral suspension:** 4 mg/mL 

**Hypertension (see remarks):**

**Infant ≥6 mo and ≥6 kg (limited data):** Start at 1 mg/kg/dose PO once daily; if needed, increase dose every 2 weeks up to a **maximum** of 4 mg/kg/24 hr. Usual range: 0.25–4 mg/kg/dose once daily

**Child 1–16 yr:** Start at 1 or 2 mg/kg/dose PO once daily (**max. dose:** 40 mg/24 hr). Usual dosage range: 1–4 mg/kg/dose once daily; **max. dose:** 4 mg/kg/24 hr up to 160 mg/24 hr

**Alternative dosage for child 1–5 yr (≥8 kg; limited data):** A reported range of 0.4–3.4 mg/kg/dose PO once daily with the following **maximum doses:**

<18 kg: 40 mg/24 hr

≥18 kg: 80 mg/24 hr



VALSARTAN *continued*

**Adolescent ≥17 yr and adult (non-volume-depleted status):** Start 80 or 160 mg PO once daily; usual dose range is 80–320 mg once daily. **Max. dose:** 320 mg/24 hr

**Contraindicated** with aliskiren use in patients with diabetes. Discontinue use immediately when pregnancy is detected. **Use with caution** in renal (CrCl <30 mL/min) and liver insufficiency, heart failure, post-myocardial infarction, renal artery stenosis, renal function changes, and volume depletion.




Hypotension, dizziness, headache, cough, and increases in BUN and sCr are common side effects. Hyperkalemia (most commonly reported in children <6 yr with underlying renal disease in clinical trials; also consider salt substitutes, foods, and medications which may increase potassium levels), bullous dermatitis, angioedema, acute renal failure, and dysgeusia have been reported. May increase lithium levels resulting in toxicity for those receiving concurrent lithium therapy; monitor lithium levels closely.

Onset of initial antihypertensive effects is 2 hr with maximum effects after 2–4 wk of chronic use. Patients may require higher doses of oral tablet dosage form than with the oral suspension due to increased bioavailability with the oral suspension.

**VANCOMYCIN**

Vancocin, Firvanq, and generics  
**Antibiotic, glycopeptide**



**Injection:** 0.5, 0.75, 1, 1.5, 5, 10 g

**Premixed injection:**

**In D<sub>5</sub>W or NS:** 500 mg/100 mL, 750 mg/150 mL, 1000 mg/200 mL

**In NS:** 1250 mg/300 mL, 1500 mg/300 mL

**Caps (Vancocin and generics):** 125, 250 mg

**Oral solution:** 25 mg/mL

**Firvanq and generics:** 25 mg/mL (80, 150, 300 mL); may contain sodium benzoate

**Firvanq:** 50 mg/mL (150, 210, 300 mL); may contain sodium benzoate

**Initial empiric dosage; patient-specific dosage defined by therapeutic drug monitoring (see remarks)**



**Neonate, IV (see following table for dosage interval):**

**Bacteremia:** 10 mg/kg/dose

**Meningitis, pneumonia:** 15 mg/kg/dose

Postmenstrual Age (Weeks) <sup>a</sup>	Postnatal Age (Days)	Dosage Interval (hr)
≤29	0–14	18
	>14	12
30–36	0–14	12
	>14	8
37–44	0–7	12
	>7	8
≥45	All	6

<sup>a</sup>Postmenstrual age = gestational age + postnatal age.

*Continued*

VANCOMYCIN *continued*

## Infant, child, adolescent, and adult, IV:

Age	General Dosage	CNS Infections, Endocarditis, Osteomyelitis, Pneumonia, and Septic Arthritis
1 mo–12 yr	15 mg/kg/dose Q6 hr	20 mg/kg/dose Q6 hr
Adolescent (>12 to <18 yr) <sup>a</sup>	15 mg/kg/dose Q6–8 hr	20 mg/kg/dose Q6–8 hr
Adult (≥18 yr)	15 mg/kg/dose Q8–12 hr	20 mg/kg/dose (max. 2 g) Q8–12 hr

<sup>a</sup>Use Q8 hr dosing interval for older adolescent.

***Clostridium difficile* colitis (PR route of administration may be preferable for complete ileus):**

**Child:** 40–50 mg/kg/24 hr ÷ Q6 hr PO × 7–10 days

**Max dose:** 500 mg/24 hr; higher maximum of 2 g/24 hr have also been used for severe/fulminant disease

**Adult:** 125 mg/dose PO Q6 hr × 7–10 days; dosages as high as 2 g/24 hr ÷ Q6–8 hr have also been used for severe/fulminant disease

**Endocarditis prophylaxis for GU or GI (excluding esophageal) procedures (complete all antibiotic dose infusion[s] within 30 min of starting procedure):****Moderate-risk patients allergic to ampicillin or amoxicillin:**

**Child:** 20 mg/kg/dose (max. 1 g/dose) IV over 1–2 hr × 1

**Adult:** 1 g/dose IV over 1–2 hr × 1

**High-risk patients allergic to ampicillin or amoxicillin:**

**Child and adult:** Same vancomycin IV dose as moderate-risk patients plus gentamicin 1.5 mg/kg/dose (max. dose: 120 mg/dose) IV/IM × 1

Ototoxicity and nephrotoxicity may occur and may be exacerbated with concurrent aminoglycoside use. Greater nephrotoxicity risk has been associated with higher therapeutic serum trough concentrations (≥15 mg/mL), concurrent piperacillin/tazobactam therapy, and receiving furosemide in the intensive care unit. **Adjust dose in renal failure (see Chapter 31).** Use total body weight for obese patients when calculating dosages. Low concentrations of the drug may appear in CSF with inflamed meninges. Nausea, vomiting, and drug-induced erythroderma are common with IV use. Vancomycin infusion reaction is associated with rapid IV infusion. Infuse over 60 min (may infuse over 120 min if 60-min infusion is not tolerated). **NOTE:** Diphenhydramine is used to reverse the infusion reaction. Allergic reactions (including drug rash with eosinophilia and systemic symptoms [DRESS]), neutropenia, and immune-mediated thrombocytopenia have been reported. Serious skin reactions (e.g., SJS, TEN) have been reported in association with use of both IV and oral routes of administration.

Although current extrapolated adult guidelines suggest measuring only trough levels, an additional post-distributional level may be useful in characterizing enhanced/alterd drug clearance for quicker dosage modification to attain target levels; this may be useful for infants with known faster clearance and patients in renal compromise. Consult a pharmacist.

The following therapeutic trough level recommendations are based on the assumption that the pathogen's vancomycin MIC is ≤1 mg/L.

Indication	Goal Trough Level
Uncomplicated skin and soft tissue infection, uncomplicated bacteremia, febrile neutropenia, sepsis	10–14 mg/L
CNS infections, endocarditis, pneumonia, osteomyelitis, septic arthritis	14–17 mg/L

VANCOMYCIN *continued*

Peak level measurement (20–50 mg/L) has also been recommended for patients with burns, clinically nonresponsiveness in 72 hr of therapy, persistent positive cultures, and CNS infections ( $\geq 30$  mg/L).

**Recommended serum sampling time at steady state:** Trough within 30 min prior to the fourth consecutive dose and peak 60 min after the administration of the fourth consecutive dose. Infants with faster elimination (shorter  $T_{1/2}$ ) may be sampled around the third consecutive dose.

Recent evidence strongly suggests moving away from serum trough vancomycin monitoring to a pharmacokinetic/pharmacodynamics (PK/PD) target of area under the curve (AUC) to MIC ratio. An  $AUC_{[24]}$  of 400–600 mg $\cdot$ h/L is associated with clinical efficacy and reduced risk for AKI. Vancomycin therapeutic monitoring guidelines were revised in 2020 by the IDSA in collaboration with PIDS, SIDP, and ASHP. Consult with an ID specialist and pharmacist to see how this monitoring method is best operationalized at your institution.

**ORAL USE for *C. difficile*:** Vancomycin (PO) or metronidazole (PO) is currently the recommended first-line therapy for children, whereas vancomycin (PO) or fidaxomicin is recommended for adults. See *Clinical Infectious Diseases* 66(7):e1–e48 for the 2017 IDSA/SHEA Clinical Practice Guidelines. Common adverse effects with oral vancomycin capsules in adults include nausea, abdominal pain, and hypokalemia.

Pregnancy category “C” for the intravenous route and “B” for the oral route of administration.

**VARICELLA-ZOSTER IMMUNE GLOBULIN (HUMAN)**

VariZig, VZIG

***Hyperimmune globulin, varicella-zoster***

C 2 No No No

**Injection:** 125 Units (1.2 mL); contains 10% maltose, 0.03% polysorbate 80, and <40 mCg/mL IgA; preservative free. May contain low levels of anti-protein S antibodies

**Infant, child, and adolescent:** Dose should be given within 48 hr of varicella exposure and no later than 96 hr postexposure. **IM administration:**

&lt;2 kg: 62.5 Units

2.1–10 kg: 125 Units

10.1–20 kg: 250 Units

20.1–30 kg: 375 Units

30.1–40 kg: 500 Units

&gt;40 kg: 625 Units

**Max. dose:** 625 Units/dose

If patient is high risk and re-exposed to varicella for more than 3 weeks after a prior dose, another full dose may be given.

**Contraindicated** in severe thrombocytopenia due to IM injection, immunoglobulin A deficiency (anaphylactic reactions may occur), and known immunity to varicella zoster virus.

See [Chapter 16](#) for indications. Local discomfort, redness, and swelling at the injection site and headache may occur.

Hyperviscosity of the blood may increase risk for thrombotic events. Interferes with immune response to live virus vaccines such as measles, mumps, and rubella; defer administration of live vaccines 6 mo or longer after VZIG dose. See latest AAP *Red Book* for additional information.

**Avoid** IM injection into the gluteal region due to risk for sciatic nerve damage and **do not exceed** age-specific **single max. IM injection** volume.

**VASOPRESSIN**

Vasostrict and generics, 8-Arginine Vasopressin;  
previously available as Pitressin

**Antidiuretic hormone analog**



C



2



No



Yes



No

**Injection:**

**Vasostrict and generics:** 20 Units/mL (aqueous) (1, 10 mL); may contain 0.5% chlorobutanol

**Premixed injection in D<sub>5</sub>W:**

**Vasostrict:** 0.2, 0.4, 0.6 Units/mL (100 mL)

**Diabetes insipidus:** Titrate dose to effect (see remarks).

**SC/IM:**

**Child:** 2.5–10 Units BID–QID

**Adult:** 5–10 Units BID–TID

**Continuous infusion (child and adult; limited data):** Start at 0.5 milliunit/kg/hr (0.0005 Units/kg/hr). Increase dosage by 0.5 milliunit/kg/hr every 10 min PRN up to **max. dose** of 10 milliunit/kg/hr (0.01 Units/kg/hr).

**GI hemorrhage (IV; NOTE: dosage metric is Units/kg/min for children and Units/min for adults):**

**Child (limited data):** Start at 0.002–0.005 Units/kg/min. Increase dose as needed to **max. dose** of 0.01 Units/kg/min.

**Adult:** Start at 0.2–0.4 Units/min. Increase dose as needed to **max. dose** of 0.8 Units/min.

**Cardiac arrest, ventricular fibrillation, and pulseless ventricular tachycardia (limited data):**

**Child (use following 2 doses of epinephrine; limited data):** 0.4 Units/kg IV × 1

**Vasodilatory shock with hypotension (unresponsive to fluids and pressors; NOTE: dosage metric is Units/kg/min for children and Units/min for adults):**

**Infant, child, adolescent (various reports; limited data):** 0.00017–0.008 Units/kg/min via continuous IV infusion in combination with pressors

**Adult:** 0.01–0.04 Units/min via continuous IV infusion in combination with pressors

**Use with caution** in seizures, migraine, asthma, and renal, cardiac, or vascular diseases.

Side effects include tremor, sweating, vertigo, abdominal discomfort, nausea, vomiting, urticaria, anaphylaxis, hypertension, and bradycardia. May cause vasoconstriction, water intoxication, bronchoconstriction, and decreased cardiac index. Drug interactions: lithium, demeclocycline, heparin, and alcohol reduces activity; carbamazepine, tricyclic antidepressants, fludrocortisone, and chlorpropamide increases activity. Hemodynamic monitoring is recommended when used with catecholamines, indomethacin, ganglionic blocking agents, and medications that may cause SIADH (e.g., SSRIs, TCAs, carbamazepine, and oxcarbazepine).

**Do not** abruptly discontinue IV infusion (taper dose). Patients with variceal hemorrhage and hepatic insufficiency may respond to lower dosages. Monitor fluid intake and output, urine specific gravity, urine and serum osmolality, plasma osmolality, and sodium.

**VECURONIUM BROMIDE**

Various generics; previously available as  
Norcuron

**Nondepolarizing neuromuscular blocking agent**



C



?



Yes



Yes



No

**Injection:** 10, 20 mg; contains mannitol

**Neonate:**

**Initial:** 0.1 mg/kg/dose IV

**Maintenance:** 0.03–0.15 mg/kg/dose IV Q1–2 hr PRN

VECURONIUM BROMIDE *continued***Infants (>7 wk to 1 yr) (see remarks):**

**Initial:** 0.08–0.1 mg/kg/dose IV; reduce dose to 0.04–0.06 mg/kg/dose IV if used in combination with succinylcholine

**Maintenance:** 0.05–0.1 mg/kg/dose IV Q1 hr PRN; may administer via continuous infusion at 0.06–0.09 mg/kg/hr IV

**>1 yr—adult (see remarks):**

**Initial:** 0.08–0.1 mg/kg/dose IV; reduce dose to 0.04–0.06 mg/kg/dose IV if used in combination with succinylcholine

**Maintenance:** 0.05–0.1 mg/kg/dose IV Q1 hr PRN; may administer via continuous infusion at 0.09–0.15 mg/kg/hr IV

**Use with caution** in patients with renal or hepatic impairment, and neuromuscular disease.

Dose reduction may be necessary in hepatic insufficiency. Infants (7 wk to 1 yr) are more sensitive to the drug and may have a longer recovery time. Children (1–10 yr) may require higher doses and more frequent supplementation than adults. Enflurane, isoflurane, aminoglycosides,  $\beta$ -blockers, calcium channel blockers, clindamycin, furosemide, magnesium salts, quinidine, procainamide, and cyclosporine may increase the potency and duration of neuromuscular blockade. Calcium, caffeine, carbamazepine, phenytoin, steroids (chronic use), acetylcholinesterases, and azathioprine may decrease effects. May cause arrhythmias, rash, and bronchospasm. Severe anaphylactic reactions have been reported.

**Neostigmine, pyridostigmine, or edrophonium is an antidote.** Onset of action within 1–3 min. Duration is 30–40 min. **See Chapter 1 for rapid sequence intubation.**

**VERAPAMIL**

Calan SR, Verelan, Verelan PM, and generics; previously available as Calan

**Calcium channel blocker**



C



2



Yes



Yes



No

**Tabs:** 40, 80, 120 mg

**Extended/sustained release tabs (Calan SR and generics):** 120, 180, 240 mg

**Extended/sustained release caps (for Q24 hr dosing):**

**Verelan:** 120, 180, 240, 360 mg

**Verelan PM:** 100, 200, 240, 300, 360 mg

**Generics:** 100, 120, 180, 200, 240, 300, 360 mg

**Injection:** 2.5 mg/mL (2, 4 mL)

**Oral suspension:** 50 mg/mL 

**IV for dysrhythmias:** Give over 2–3 min. May repeat once after 30 min.

**1–16 yr, for PSVT:** 0.1–0.3 mg/kg/dose IV  $\times$  1 may repeat dose in 30 min; **max. dose:** 5 mg first dose, 10 mg second dose

**Adult, for SVT:** 5–10 mg (0.075–0.15 mg/kg) IV  $\times$  1 may administer second dose of 10 mg (0.15 mg/kg) 15–30 min later

**Hypertension (PO):**

**Adult:**

**Immediate release dosage forms:** 120–360 mg/24 hr PO  $\div$  TID

**Sustained release dosage forms:** 200–480 mg/24 hr PO once daily. **Max. dose:** 480 mg/24 hr (400 mg/24 hr for Verelan PM)

No longer recommended as an antihypertensive agent for children. **Contraindications** include hypersensitivity, cardiogenic shock, severe CHF, sick sinus syndrome, or AV block. **Use with caution** in hepatic and renal (reduce dose in renal insufficiency; see Chapter 31) impairment.

*Continued*

VERAPAMIL *continued*

Owing to negative inotropic effects, verapamil should not be used to treat SVT in an emergency setting for infants. Avoid IV use in neonates and young infants due to apnea, bradycardia, and hypotension. May cause constipation, headache, dizziness, edema, and hypotension. EPS has been reported.

Monitor ECG. Have calcium and isoproterenol available to reverse myocardial depression. May decrease neuromuscular transmission in patients with Duchenne muscular dystrophy, and worsen myasthenia gravis.

Drug is a substrate of CYP 450 1A2 and 3A3/4, and an inhibitor of CYP 3A4 and P-gp transporter. Barbiturates, sulfapyrazone, phenytoin, vitamin D, and rifampin may decrease serum levels/effects of verapamil; erythromycin, quinidine, and grapefruit juice may increase serum levels/effects. Verapamil may increase effects/toxicity of  $\beta$ -blockers (severe myocardial depression), carbamazepine, cyclosporine, sirolimus, everolimus, digoxin, ethanol, fentanyl, lithium, nondepolarizing muscle relaxants, prazosin, and tizanidine. Use with telithromycin has resulted in hypotension, bradyarrhythmias, and lactic acidosis. Bradycardia has been reported with concurrent use of clonidine, and increased bleeding times have been reported with use with aspirin.

Do not crush or chew extended release dosage forms.

<p><b>VIGABATRIN</b> Sabril, Vigadrone, and generics <b>Anticonvulsant</b></p>	 C	 2	 Yes	 Yes	 No
--	---	--	--	--	---

**Tabs (Sabril and generics):** 500 mg

**Powder for oral solution (Sabril, Vigadrone, and generics):** 500 mg per packet to be dissolved in 10 mL water (50s)

**Infantile spasms (1 mo–2 yr; see remarks for discontinuation of therapy):** Start at 50 mg/kg/24 hr  $\div$  BID PO; if needed and tolerated, may titrate dosage upward by 25–50 mg/kg/24 hr increments Q3 days up to a **maximum** of 150 mg/kg/24 hr  $\div$  BID. Gradually withdraw therapy if no clinical benefit is seen in 2–4 wk.



**Adjunctive therapy for refractory complex partial seizures (gradually withdraw therapy if no clinical benefit is seen in 3 mo; see remarks for discontinuation of therapy):**

**Child  $\geq 2$  yr and  $\geq 10$  kg, and adolescent  $\leq 16$  yr and  $\leq 60$  kg:** If needed and tolerated, increase starting dose at weekly intervals to the recommended maintenance dose.

Weight (kg)	Starting Daily Dose (mg/24 hr $\div$ BID)	Recommended Daily Maintenance Dose (mg/24 hr $\div$ BID)
10–15	350	1050
>15–20	450	1300
>20–25	500	1500
>25–60	500	2000

**Adolescent ( $\geq 17$  yr) and adult (see remarks for discontinuation of therapy):** Start at 500 mg BID PO; if needed and tolerated, increase daily dose by 500-mg increments at 7-day intervals. Usual recommended dose: 1500 mg BID; **max. dose:** 6000 mg/24 hr. Doses  $>3$  g/24 hr have not been shown to provide additional benefit and are associated with more side effects.

**Use with caution** in renal impairment (**reduce dose; see Chapter 31**) and other CNS depressants (enhanced effects). Can cause progressive and permanent vision loss (risk increases with dose and duration); periodic vision testing is required. Common side effects in children and adults include rash, weight gain, GI disturbances, arthralgia, visual disturbances,



VIGABATRIN *continued*

vertigo, sedation, headache, confusion, and URIs. Liver failure, anemia, psychotic disorder, angioedema, Stevens-Johnson syndrome, TEN, alopecia, and suicidal ideation have been reported. Abnormal MRI signal changes (T2 signal and restricted diffusion in a symmetric pattern) and intramyelinic edema (in postmortem exams) have been reported in infants treated for infantile spasms. Ketorolac, naproxen, and mefloquine may decrease the effect of vigabatrin. Vigabatrin may decrease the effects/levels of phenytoin but increase the levels/toxicity of carbamazepine.

Use in adjunctive therapy for refractory complex partial seizure has labeled indication for ≥10-yr-old patients when potential benefits outweigh the risk of vision loss.

**DO NOT** rapidly withdraw therapy. Dosage needs to be tapered when discontinuing therapy to minimize increased seizure frequency. The following tapering guidelines have been recommended:

**Infant:** Decrease by 25–50 mg/kg every 3–4 days.

**Child:** Decrease dose by  $\frac{1}{3}$  every 7 days for 3 weeks.

**Adult:** Decrease by 1 g/24 hr every 7 days.

Doses may be administered with or without food. Access to this medication is restricted to prescribers and pharmacies registered under a special restricted distribution program (SABRIL REMS Program) in the United States. Call 888-457-4273 or see [www.SabriIREMS.com](http://www.SabriIREMS.com) for more information.

**VITAMIN A**

Aquasol A and many generics

**Vitamin, fat soluble**



A/X



2



No



No



No

**Caps [OTC]:** 7500, 8000, 10,000, 25,000 IU

**Tabs [OTC]:** 10,000, 15,000 IU

**Oral drops [OTC]:** 750 mCg/0.3 mL (2500 IU/0.3 mL) (30 mL)

**Sublingual tabs [OTC]:** 5000 IU

**Injection for IM use (Aquasol A):** 50,000 IU/mL (2 mL); contains polysorbate 80 and chlorobutanol

**Conversion:** 10,000 IU is equivalent to 3000 mCg vitamin A.

**US RDA:** See [Chapter 21](#).

**Supplementation in measles (a third dose may be administered 2–4 wk after the second dose if patient has ocular signs of vitamin A deficiency or is severely malnourished; see remarks):**

**<6 mo:** 50,000 IU/dose once daily PO × 2 days

**Infant 6 mo to <1 yr:** 100,000 IU/dose once daily PO × 2 days

**Child 1–5 yr:** 200,000 IU/dose once daily PO × 2 days

**Malabsorption syndrome prophylaxis:**

**Child >8 yr and adult:** 10,000–50,000 IU/dose once daily PO of water miscible product

**Cystic fibrosis (usually dosed in cystic fibrosis specific multivitamins, but those with liver disease may require higher doses; monitor serum concentrations):**

**Infant:** 1500 IU/dose once daily PO

**Child 1–3 yr:** 5000 IU/dose once daily PO

**Child 4–8 yr:** 5000–10,000 IU/dose once daily PO

**Child ≥9 yr and adolescent:** 10,000 IU/dose once daily PO

**High doses above the US RDA are teratogenic (category X).** The use of vitamin A in measles is recommended in children 6 mo–2 yr of age who are either hospitalized or who have any of the following risk factors: immunodeficiency, ophthalmologic evidence of vitamin A deficiency, impaired GI absorption, moderate to severe malnutrition, and recent immigration from areas with high measles mortality. May cause GI disturbance, rash, headache, increased ICP (pseudotumor cerebri), papilledema, and irritability. Large doses may increase the effects of warfarin. Mineral oil, cholestyramine, and neomycin will reduce vitamin A absorption. **Do not** assess vitamin A levels during an acute inflammatory condition as falsely low levels have been reported.

**VITAMIN B<sub>1</sub>**

See [Thiamine](#).

**VITAMIN B<sub>2</sub>**

See [Riboflavin](#).

**VITAMIN B<sub>3</sub>**

See [Niacin](#).

**VITAMIN B<sub>6</sub>**

See [Pyridoxine](#).

**VITAMIN B<sub>12</sub>**

See [Cyanocobalamin](#).

**VITAMIN C**

See [Ascorbic Acid](#).

**VITAMIN D<sub>2</sub>**

See [Ergocalciferol](#).

**VITAMIN D<sub>3</sub>**

See [Cholecalciferol](#).

**VITAMIN E/ $\alpha$ -TOCOPHEROL**

Aqueous Vitamin E, Nutr-E-Sol, and many others including generics

***Vitamin, fat soluble***



A/C



2



No



No



No

**Tabs [OTC]:** 100, 200, 400 IU

**Caps [OTC]:** 100, 200, 400, 1000 IU

**Oral solution (Aqueous Vitamin E and generics [OTC]):** 50 IU/mL (12, 30 mL); may contain propylene glycol, polysorbate 80, and saccharin

**Oral liquid (Nutr-E-sol) [OTC]:** 400 IU/15 mL (473 mL)

**Conversion:** 400 IU is equivalent to 180 mg of vitamin E

**US RDA:** See [Chapter 21](#).



VITAMIN E/ $\alpha$ -TOCOPHEROL *continued*

**Vitamin E deficiency and liver disease, PO:** Monitor levels closely and use water miscible form (especially with malabsorption).

**Neonate:** 25–50 IU/kg/24 hr

**Infant, child, and adolescent:** 10–50 IU/kg/24 hr

**Cystic fibrosis supplementation (use water miscible form; usually dosed in cystic fibrosis specific multivitamins):** 5–10 IU/kg/24 hr PO once daily; **max. dose:** 400 IU/24 hr

Adverse reactions include GI distress, rash, headache, gonadal dysfunction, decreased serum thyroxine and triiodothyronine, and blurred vision. Necrotizing enterocolitis has been associated with large doses (>200 units/24 hr) of a hyperosmolar product administered to low birth weight infants. May increase hypoprothrombinemic response of oral anticoagulants (e.g., warfarin), especially in doses >400 IU/24 hr.

In malabsorption, water miscible preparations are better absorbed. Therapeutic levels: 6–14 mg/L. Pregnancy category changes to “C” if used in doses above the US RDA.



## VITAMIN K

See [Phytonadione](#).

## VORICONAZOLE

Vfend and generics

**Antifungal, triazole**



D



3



Yes



Yes



Yes

**Tab:** 50, 200 mg; contains povidone

**Oral suspension:** 40 mg/mL (75 mL); may contain sodium benzoate

**Injection:** 200 mg; contains 3200 mg sulfobutyl ether  $\beta$ -cyclodextrin (SBECD) (see remarks)

**Empiric doses; consider drug interactions and pharmacogenomic based recommendations (see remarks). Between-patient and inter-occasion pharmacokinetic variability is high.**

**Monitor trough level and adjust dose accordingly.**

**Infant and child <2 yr (limited data):** Start with 9 mg/kg/dose IV/PO Q12 hr; monitor levels and adjust dose. Median dose of 31.5 mg/kg/24 hr  $\div$  12 hr (range: 12–71 mg/kg/24 hr) has been reported to achieve target trough levels.

**Child 2– $\leq$ 12 yr and 12–14 yr weighing <50 kg:**

**Invasive aspergillosis, candidemia (nonneutropenic), other deep tissue *Candida* infections, or other rare molds (e.g., *Scedosporium* and *Fusarium*):**

**Loading dose:** 9 mg/kg/dose IV Q12 hr  $\times$  2 followed by maintenance dose

**Maintenance dose:** 8 mg/kg/dose IV Q12 hr and convert to the oral suspension dosage form after significant clinical improvement at a dose of 9 mg/kg/dose PO Q12 hr (**max. dose:** 350 mg Q12 hr). The oral suspension dosage form was used in clinical trials, and the bioequivalence of this dosage form and tablets has not been evaluated in children. Dosage increments and decrements of 1 mg/kg (or 50 mg) steps have been recommended for those with inadequate response and who are unable to tolerate their dosage level, respectively.

**Esophageal candidiasis:**

**Treatment:**

**IV:** 4 mg/kg/dose Q12 hr

**PO:** 9 mg/kg/dose Q12 hr; **max. dose:** 350 mg Q12 hr

**Prophylaxis for candidiasis in high-risk AML, ALL, and allogeneic HSCT patients (limited data):**

**IV:** 9 mg/kg/dose Q12 hr  $\times$  2 doses followed by 8 mg/kg/dose Q12 hr

**PO (oral suspension):** 9 mg/kg/dose Q12 hr; **max. dose:** 350 mg/dose



*Continued*

VORICONAZOLE *continued*

**Child 12—<15 yr weighing ≥50 kg, >15 yr (any weight), and adult:**

**Invasive aspergillosis, candidemia (nonneutropenic), fusariosis, scedosporiosis, or other serious fungal infections:**

**Loading dose:** 6 mg/kg/dose IV Q12 hr × 2 doses followed by maintenance dose

**Maintenance dose:**

**Candidemia (nonneutropenic):** 3–4 mg/kg/dose IV Q12 hr

**Invasive aspergillosis, fusariosis, scedosporiosis, or other serious fungal infections:** 4 mg/kg/dose IV Q12 hr; if patient unable to tolerate, reduce dose to 3 mg/kg/dose IV Q12 hr

**PO maintenance dose:** Initial dose may be increased to the maximum dose when response is inadequate; if dose is not tolerated, reduce dose by 50 mg decrements, until tolerated, with minimum of the initial recommended dose.

**<40 kg:** 100 mg Q12 hr

**≥40 kg:** 200 mg Q12 hr

**Esophageal candidiasis (secondary therapy; treat for a minimum of 14 days and until 7 days after resolution of symptoms):** Initial dose may be increased to the maximum dose when response is inadequate by 50 mg increments for patients <40 kg and by 100 mg increments for ≥40 kg. If a titrated dose is not tolerated, reduce dose by 50 mg decrements until tolerated with the minimum of the initial recommended dose.

**<40 kg:** 100 mg Q12 hr

**≥40 kg:** 200 mg Q12 hr

**Contraindicated** with concomitant administration with rifampin, carbamazepine, long-acting barbiturates, ritonavir, efavirenz, rifabutin, ergot alkaloids, or St. John's wort (decreases voriconazole levels); and with terfenadine, astemizole, cisapride, pimozide, naloxegol, tolvaptan, quinidine, or sirolimus (voriconazole increases levels of these drugs to increase side effects). **Use with caution** in proarrhythmic conditions (e.g., congenital/acquired QTc prolongation, cardiomyopathy, and sinus bradycardia), severe hepatic disease, and galactose intolerance. Concurrent use with CYP 450 3A4 substrates that can lead to prolonged QTc interval (e.g., cisapride, ivabradine, pimozide, and quinidine) is **contraindicated**.

Drug is a substrate and inhibitor for CYP 450 2C9, 2C19 (major substrate), and 3A4 isoenzymes.

Always check for interactions for risk of potential toxicities and use recommendation when used with other medications that have similar CYP 450 substrate characteristics. Specific CYP 2C19 phenotype and use recommendation for children and adults are as follows:

### CYP 450 2C19

Phenotype	Pediatric Use Recommendation	Adult Use Recommendation
Ultrarapid metabolizer	Use alternative medication <sup>a</sup>	Use alternative medication <sup>a</sup>
Rapid metabolizer	Initiate with standard dosing with TDM <sup>b</sup>	Use alternative medication <sup>a</sup>
Intermediate metabolizer	Initiate with standard dosing with TDM <sup>b</sup>	Initiate with standard dosing with TDM <sup>b</sup>
Poor metabolizer	Use alternative medication <sup>a</sup> ; if voriconazole must be used, use a lower dose with TDM <sup>b</sup>	Use alternative medication <sup>a</sup> ; if voriconazole must be used, use a lower dose with TDM <sup>b</sup>

<sup>a</sup>Alternative medication should not be dependent on CYP 2C19 metabolism and may include agents such as isavuconazole, liposomal amphotericin B, and posaconazole.

<sup>b</sup>TDM = therapeutic drug monitoring

VORICONAZOLE *continued*

Currently approved for use in invasive aspergillosis; candidemia, and disseminated candidiasis in skin, abdomen, kidney, bladder wall, and wounds; candidal esophagitis; and serious infections caused by *Fusarium* species and *Scedosporium apiospermum* in children  $\geq 2$  yr of age.

Common side effects include GI disturbances, fever, headache, hepatic abnormalities, photosensitivity (higher incidence in children; **avoid** direct sunlight and use protective measures), rash (6%), and visual disturbances (30%). Use with drugs associated with UV reactivation (e.g., methotrexate) increases risk for photosensitivity. Discontinue therapy with a dermatological follow up for those who develop photosensitivity reactions as squamous cell carcinoma and melanoma have been reported in those who experience this adverse reaction, especially with long-term use. Serious but rare side effects include anaphylaxis, liver or renal failure, and Stevens-Johnson syndrome. DRESS has been reported. Pancreatitis has been reported in children. Monitoring serum transaminase and bilirubin levels weekly for the first month of therapy followed by reduced frequency has been recommended. Higher frequency of LFT elevations has been reported with children.

Correct potassium, magnesium, and calcium levels before and during voriconazole therapy. **Adjust dose in hepatic impairment** by decreasing only the maintenance dose by 50% for patients with a Child-Pugh class A or B. **Do not use** IV dosage form for patients with GFR  $< 50$  mL/min because of accumulation of the cyclodextrin excipient; switch to oral therapy if possible. Patients receiving concurrent phenytoin should increase their voriconazole maintenance doses (IV: 5 mg/kg/dose Q12 hr; PO: double the usual dose).

Inter-occasion pharmacokinetic variability is high, thus requiring serum level monitoring. Therapeutic levels: trough: 1–5.5 mg/L. Levels  $< 1$  mg/L have resulted in treatment failures and levels  $> 5.5$  mg/L have resulted in neurotoxicity such as encephalopathy. Recommended serum sampling time: obtain trough within 30 min prior to a dose. Steady state is typically achieved after 5–7 days of initiating therapy.

Oral bioequivalence of the oral suspension and tablet has not been evaluated in children. Administer IV over 1–2 hr with a **max. rate** of 3 mg/kg/hr at a concentration  $\leq 5$  mg/mL. Administer oral doses 1 hr before and after meals.

## W

## WARFARIN

Jantoven and generics; previously available as Coumadin

**Anticoagulant**



D/X



1



Yes



Yes



Yes

**Tabs:** 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg

**Infant and child (see remarks):** To achieve an INR between 2 and 3.5 directed by specific indication



**Loading dose on day 1:**

**Baseline INR  $\leq 1.3$ :** 0.2 mg/kg/dose PO; **max. dose:** 7.5 mg/dose

**Liver dysfunction, baseline INR  $> 1.3$ , cardiopulmonary bypass within previous 10 days, NPO status/poor nutrition, receiving broad spectrum antibiotics, receiving medications that significantly inhibit CYP 450 2C9, or slow metabolizers of warfarin (see remarks):** 0.05–0.1 mg/kg/dose PO; **max. dose:** 5 mg/dose

**Immediate postoperative period after a Fontan procedure:** 0.05 mg/kg/dose PO; **max. dose:** 2.5 mg/dose

**Loading dose on days 2–4:**

*Continued*

WARFARIN *continued*

Day 2		Days 3 & 4	
INR Level	Dose Adjustment	INR Level	Dose Adjustment
1.1–1.3	Repeat day 1 loading dose	1.1–1.4	Increase previous dose by 20%–50%
1.4–1.9	Decrease day 1 loading dose by 50%	1.5–1.9	Continue current dose
≥2	Hold dose for 24 hr, then give 50% of day 1 loading dose on day 3	2–3	Use 25%–50% of day 1 loading dose
		3.1–3.5	Use 25% of day 1 loading dose
		>3.5	Hold dose until INR <3.5, then restart at ≤25% of day 1 loading dose

**Maintenance dose (therapy day ≥5):**

Goal INR 2–3		Goal INR 2.5–3.5	
INR	Dose Adjustment	INR	Dose Adjustment
1.1–1.4	Increase previous dose by 20%	1.1–1.9	Increase previous dose by 20%
1.5–1.9	Increase previous dose by 10%	2–2.4	Increase previous dose by 10%
2–3	No change	2.5–3.5	No change
3.1–3.5	Decrease previous dose by 10%	3.6–4	Decrease previous dose by 50% for one dose, then restart at a dose (prior to 50% dose decrease) decreased by 20% the next day
>3.5	Hold dose until INR <3.5, then restart at 20% less than the last dose	>4	Hold dose for 1 day, then restart at a dose decreased by 20% of the last dose

**Usual maintenance dose for INR goal of 2–3 (see remarks):** ~0.1 mg/kg/24 hr PO once daily; range: 0.05–0.34 mg/kg/24 hr. Reported average dosages include the following:

**Infant <1 yr:** 0.33 mg/kg/24 hr PO once daily

**Adolescent 11–18 yr:** 0.09 mg/kg/24 hr PO once daily

**Adult (see remarks):** 2.5–10 mg PO once daily × 2–3 days. Adjust dose to achieve the desired INR or PT. Maintenance dose range: 2–10 mg/24 hr PO once daily

**Contraindicated** in severe liver or kidney disease, uncontrolled bleeding, GI ulcers, and malignant hypertension. Acts on vitamin K–dependent coagulation factors II, VII, IX, and X. Side effects include fever, skin lesions, skin necrosis (especially in protein C deficiency), anorexia, nausea, vomiting, diarrhea, hemorrhage, and hemoptysis.



Warfarin is a substrate for CYP 450 1A2, 2C8, 2C9, 2C18, 2C19, and 3A3/4. Amiodarone, azole antifungals (e.g., fluconazole, voriconazole), broad spectrum antibiotics (e.g., cefepime, meropenem, piperacillin/tazobactam), chloramphenicol, chloral hydrate, cimetidine, corticosteroids, delavirdine, fluoroquinolones (e.g., ciprofloxacin, levofloxacin), fluoxetine, metronidazole, indomethacin, large doses of vitamins A or E, nonsteroidal anti-inflammatory agents, omeprazole, oxandrolone, quinidine, salicylates, SSRIs (e.g., fluoxetine, paroxetine, sertraline), sulfonamides, and zafirlukast may increase warfarin's effect. Ascorbic acid, barbiturates, carbamazepine, cholestyramine, dicloxacillin, griseofulvin, oral contraceptives, nafcillin, ribavirin, rifampin, spironolactone, sucralfate, and vitamin K (including foods with high content) may decrease warfarin's effect.

WARFARIN *continued*

Younger children generally require higher doses to achieve desired effect. Children receiving Fontan cardiac surgery may require smaller doses than children with either congenital heart disease (without Fontan) or no congenital heart disease. (See *Chest* 2004;126:645–687S and *Blood* 1999;94 [9]:3007–3014 for additional information.)


Lower doses should be considered for patients with pharmacogenetic variations in CYP 2C9 (e.g., \*2 and \*3 alleles) and VKORC1 (e.g., 1639G>A allele) enzymes, especially in European ancestry. Elderly and/or debilitated patients, and patients with a potential to exhibit greater than expected PT/INR response to warfarin should also consider using lower doses.

Z

**ZIDOVUDINE**

Retrovir, AZT, and generics

**Antiviral agent, nucleoside analogue reverse transcriptase inhibitor**



C 2 Yes Yes No

**Caps:** 100 mg

**Tab:** 300 mg

**Oral syrup:** 50 mg/5 mL (240 mL); contains 0.2% sodium benzoate

**Injection:** 10 mg/mL (20 mL); preservative-free solution (vial stoppers may contain latex)

**In combination with lamivudine (3TC) as Combivir and generics:**

**Tab:** 300 mg zidovudine + 150 mg lamivudine

**In combination with abacavir and lamivudine (3TC) as Trizivir and generics:**

**Tab:** 300 mg zidovudine + 300 mg abacavir + 150 mg lamivudine

**HIV:** See <https://clinicalinfo.hiv.gov/en/guidelines>



**Prevention of HIV vertical transmission (low- and high-risk cases) and presumptive treatment:**

**14–34 weeks of pregnancy (maternal dosing):**

**Until labor (see perinatal guidelines for currently recommended combination antiretroviral therapies, which may or may not include zidovudine):** 600 mg/24 hr PO ÷ BID–TID

**During labor (maternal dosing; dosage based on maternal total body weight):** 2 mg/kg/dose IV over 1 hour followed by 1 mg/kg/hr IV infusion for 2 hours. For scheduled cesarean delivery, initiate this regimen 3 hr prior to surgery.

**Neonate and infant (initiate therapy within 6–12 hr of birth):**

Gestational Age (wk)	Oral (PO) Dosage	Intravenous (IV) Dosage <sup>a</sup>
<30	<b>Birth to 4 wk of age:</b> 2 mg/kg/dose Q12 hr	<b>Birth to 4 wk of age:</b> 1.5 mg/kg/dose Q12 hr
	<b>4 to 8–10 wk of age:</b> 3 mg/kg/dose Q12 hr	<b>4 to 8–10 wk of age:</b> 2.25 mg/kg/dose Q12 hr
	<b>&gt;8–10 wk of age<sup>b</sup>:</b> 12 mg/kg/dose Q12 hr	<b>&gt;8–10 wk of age<sup>b</sup>:</b> 9 mg/kg/dose Q12 hr

*Continued*

ZIDOVUDINE *continued*

Gestational Age (wk)	Oral (PO) Dosage	Intravenous (IV) Dosage <sup>a</sup>
30—34	<p><b>Birth to 2 wk of age:</b> 2 mg/kg/dose Q12 hr</p> <p><b>2 to 6—8 wk of age:</b> 3 mg/kg/dose Q12 hr</p> <p><b>&gt;6—8 wk of age<sup>b</sup>:</b> 12 mg/kg/dose Q12 hr</p>	<p><b>Birth to 2 wk of age:</b> 1.5 mg/kg/dose Q12 hr</p> <p><b>2 to 6—8 wk of age:</b> 2.25 mg/kg/dose Q12 hr</p> <p><b>&gt;6—8 wk of age<sup>b</sup>:</b> 9 mg/kg/dose Q12 hr</p>
≥35	<p><b>Birth to 4 wk of age:</b> 4 mg/kg/dose Q12 hr</p> <p><b>&gt;4 wk of age<sup>b</sup>:</b> 12 mg/kg/dose Q12 hr</p>	<p><b>Birth to 4 wk of age:</b> 3 mg/kg/dose Q12 hr</p> <p><b>&gt;4 wk of age<sup>b</sup>:</b> 9 mg/kg/dose Q12 hr</p>

<sup>a</sup>Convert to PO route when possible.

<sup>b</sup>Make this dose increase only for infants with confirmed HIV infection.

**HIV postexposure prophylaxis (all therapies to begin within 2 hr of exposure if possible for a total of 28 days):** See <https://clinicalinfo.hiv.gov/en/guidelines> for the most recent preferred and alternative regimens. Zidovudine is dosed using HIV treatment doses and used in combination with lamivudine and additional antiretroviral agent(s).

See <https://clinicalinfo.hiv.gov/en/guidelines> for additional remarks.



**Use with caution** in patients with impaired renal or hepatic function. Dosage reduction is recommended in severe renal impairment and may be necessary in hepatic dysfunction. Drug penetrates well into the CNS. Most common side effects include: anemia, granulocytopenia, nausea, and headache (dosage reduction, erythropoietin, filgrastim/GCSF, or discontinuance may be required depending on event). Seizures, confusion, rash, myositis, myopathy (use >1 yr), hepatitis, and elevated liver enzymes have been reported. Macrocytosis is noted after 4 wk of therapy and can be used as an indicator of compliance. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported. Neutropenia and severe anemia have been reported in advanced HIV disease. Use of injectable dosage form may cause allergic reactions in latex-sensitive individuals.

**Do not use** in combination with stavudine because of poor antiretroviral effect. Effects of interacting drugs include: increased toxicity (acyclovir, trimethoprim-sulfamethoxazole); increased hematological toxicity (ganciclovir, interferon-alpha, marrow suppressive drugs); and granulocytopenia (drugs that affect glucuronidation). Methadone, atovaquone, cimetidine, valproic acid, probenecid, and fluconazole may increase levels of zidovudine, whereas rifampin, rifabutin, and clarithromycin may decrease levels.

**Do not administer IM.** IV form is incompatible with blood product infusions and should be infused over 1 hr (intermittent IV dosing). Despite manufacturer recommendations of administering oral doses 30 min prior to or 1 hr after meals, doses may be administered with food.

<p><b>ZINC SALTS, SYSTEMIC</b> Galzin, Orazinc, and generics <i>Trace mineral</i></p>					
	A/C	2	Yes	No	No

**Sulfate salt (23% elemental Zn):**

**Tab as sulfate (Orazinc and generics) [OTC]:** 66, 110, 220 mg

ZINC SALTS, SYSTEMIC *continued*

**Caps as sulfate (Orazinc and generics) [OTC]:** 220 mg

**Liquid as sulfate:** 10 mg elemental Zn/mL 

**Injection as sulfate; preparations may be preservative free:**

1 mg elemental Zn/mL (10 mL)

3 mg elemental Zn/mL (10 mL)

5 mg elemental Zn/mL (5 mL)

**Acetate salt (30% elemental Zn):**

**Caps as acetate (Galzin):** 25, 50 mg elemental per capsule

**Liquid as acetate:** 5 mg elemental Zn/mL, 10 mg elemental Zn/mL 

**Chloride salt (48% elemental Zn):**

**Injection as chloride:** 1 mg elemental Zn/mL (10 mL)

**Zinc deficiency (see remarks):**

**Infant and child:** 0.5–2 mg elemental Zn/kg/24 hr PO ÷ once daily—TID

**Adult:** 25–50 mg elemental Zn/dose (100–220 mg Zn sulfate/dose) PO TID



**Wilson disease:**

**Child ≥5–<10 yr:** 75 mg elemental Zn /24 hr PO ÷ TID

**Child ≥10 yr and adolescent:** 75–150 mg elemental Zn /24 hr PO ÷ TID

**US RDA:** See [Chapter 21](#).

For supplementation in parenteral nutrition, see [Chapter 21](#).

Nausea, vomiting, GI disturbances, leukopenia, and diaphoresis may occur. Gastric ulcers, hypotension, and tachycardia may occur at high doses. Patients with excessive losses (burns) or impaired absorption require higher doses. Therapeutic levels: 70–130 mCg/dL.



Parenteral products may contain aluminum; **use with caution** in renal impairment. May decrease the absorption of penicillamine, tetracycline, and fluoroquinolones (e.g., ciprofloxacin). Drugs that increase gastric pH (e.g., H<sub>2</sub> antagonists and proton pump inhibitors) can reduce the absorption of zinc. Excessive zinc administration can cause copper deficiency.

Approximately 20%–30% of oral dose is absorbed. Oral doses may be administered with food if GI upset occurs. Pregnancy category is “A” for zinc acetate and “C” for all other salt forms.

**ZOLMITRIPTAN**

Zomig and generics previously available as Zomig ZMT

**Antimigraine agent, selective serotonin agonist**



C 3 Yes Yes No

**Tabs:**

**Zomig and generics:** 2.5 mg (scored), 5 mg

**Oral disintegrating tabs (ODT):**

**Generics:** 2.5, 5 mg; contains aspartame

**Nasal spray:**

**Zomig and generics:** 2.5 mg single unit nasal spray (6s), 5 mg single unit nasal spray (1s, 6s)

**Treatment of acute migraines with or without aura:**

**Nasal (safety of an average of >4 headaches in a 30-day period has not been established; see remarks):**



**≥12 yr and adult:** Start with 2.5 mg inhaled into a single nostril × 1. If needed in 2 hr, a second dose may be administered. Dose may be increased to a **maximum** single dose of 5 mg if needed.

**Max. daily dose:** 10 mg/24 hr

*Continued*

ZOLMITRIPTAN *continued*

**Patients receiving concurrent cimetidine:** Limit maximum doses to 2.5 mg as the **max. single dose** and **do not exceed** 5 mg in any 24 hr period.

**Oral (use not recommended in children; safety and efficacy in children have not been established with the oral route. One randomized placebo-controlled trial in 696 adolescents 12–17 yr old did not establish efficacy and had similar adverse events as seen in adult trials):**

**Adult (safety of an average of >3 headaches in a 30-day period has not been established; see remarks):**

**PO tabs:** Start with 1.25 or 2.5 mg PO × 1. If needed in 2 hr, a second dose may be administered. Dose may be increased to a **maximum** single dose of 5 mg if needed. **Max. daily dose:** 10 mg/24 hr

**ODT tabs:** Use the same dosage recommendation for PO tabs but with a 2.5 mg initial dose.

**Patients receiving concurrent cimetidine:** Limit **maximum** doses to 2.5 mg as the **max. single dose** and **do not exceed** 5 mg in any 24 hr period for both PO and ODT tabs.

**Contraindicated** in ischemic bowel disease; ischemic coronary artery disease; uncontrolled hypertension; peripheral vascular disease; history of stroke or TIA, arrhythmias, hemiplegic, or basilar migraine; significant cardiovascular disease; and coronary artery vasospasm.



**Do not administer** with any ergot-containing medications, any other 5-HT<sub>1</sub> agonist (e.g., triptans), methylene blue, or within 2 wk of discontinuing an MAO inhibitor or linezolid. Cimetidine may increase the zolmitriptan levels; see dosage section for reduced maximum dosage. Patients with multiple cardiovascular risk factors and negative cardiovascular evaluation should have their first dose administered in a medically supervised facility.

Use **not** recommended in moderate/severe hepatic impairment. Severe renal impairment (CrCl 5–25 mL/min) reduces zolmitriptan clearance by 25%.

Common adverse reactions for all dosage forms unless otherwise indicated include nausea, taste alteration (nasal route), xerostomia, dizziness, hyperesthesia (nasal route), paresthesia, somnolence, sensation of hot and cold, throat pain, and asthenia (oral route). Hypertension, coronary artery spasm, MI, cerebral hemorrhage, and headaches have been reported.

For intranasal use, blow nose gently prior to dosing. Block opposite nostril while administering dose by breathing in gently.

When using the ODT, place the whole tablet on the tongue, allow the tablet to dissolve, and swallow with saliva. Administration with liquids is optional. **Do not** break the ODT tablet.

**ZONISAMIDE**

Zonegran, Zonisade, and generics

**Anticonvulsant**



C



3



Yes



Yes



No

**Caps:**

**Zonegran:** 25, 100 mg

**Generics:** 25, 50, 100 mg

**Oral suspension:**

**Zonisade:** 20 mg/mL (150 mL); contains sodium benzoate

**Oral syrup:** 10 mg/mL 

**Infant, child, and adolescent <16 yr:**

**Adjunctive therapy for partial seizures (limited data):**

**<5 yr:** Start with 1–2 mg/kg/24 hr PO ÷ BID. Increase dosage by 0.5–1 mg/kg/24 hr Q2 wk to the usual dosage range of 5–8 mg/kg/24 hr PO ÷ BID.



ZONISAMIDE *continued*

**5—<16 yr:** Start with 0.5—1 mg/kg/24 hr PO ÷ once daily—BID. Increase dosage by 0.5—1 mg/kg/24 hr ÷ BID Q2 wk to the usual dosage range of 5—8 mg/kg/24 hr PO ÷ once daily—BID.

Suggested maximum dose: 12 mg/kg/24 hr or 500 mg/24 hr; whichever is less

**Infantile spasms (regimen that was effective in a small study from Japan; additional studies**

**needed):** Start with 2—4 mg/kg/24 hr PO ÷ BID. Then increase by 2—5 mg/kg/24 hr every 2—4 days until seizures disappear, up to a **maximum** of 20 mg/kg/24 hr.

**Adolescent ≥16 yr—adult:**

**Adjunctive therapy for partial seizures:** 100 mg PO once daily × 2 wk. Dose may be increased to 200 mg PO once daily × 2 wk. Additional dosage increments of 100 mg/24 hr can be made at 2-wk intervals to allow attainment of steady-state levels. Effective doses have ranged from 100—600 mg/24 hr ÷ once daily—BID (BID dosing may provide better efficacy). No additional benefit has been shown for doses >400 mg/24 hr.

Because zonisamide is a sulfonamide, it is **contraindicated** in patients allergic to sulfonamides (may result in Stevens-Johnson syndrome or TEN). Common side effects of drowsiness (especially at higher doses), ataxia, anorexia, gastrointestinal discomfort, headache, rash, and pruritus usually occur early in therapy and can be minimized with slow dose titration. Children are at increased risk for hyperthermia and oligohydrosis, especially in warm or hot weather. Suicidal behavior or ideation, acute pancreatitis, urolithiasis, metabolic acidosis (more frequent and severe in younger patients), DRESS/multiorgan hypersensitivity, rhabdomyolysis, metabolic acidosis, hyperammonemia/encephalopathy, acute myopia, glaucoma, and elevated creatinine phosphokinase have been reported.



Although not fully delineated, therapeutic serum levels of 20—30 mg/L have been suggested as higher rates of adverse reactions have been seen at levels >30 mg/L.

Zonisamide is a CYP 450 3A4 substrate. Phenytoin, carbamazepine, and phenobarbital can decrease levels of zonisamide.

**Use with caution** in renal or hepatic impairment; slower dose titration and more frequent monitoring is recommended. **Do not use** if GFR is <50 mL/min. **Avoid** abrupt discontinuation or radical dose reductions. Swallow capsules whole and **do not** crush or chew.

# Chapter 31

## Drugs in Kidney Failure

*Elizabeth A.S. Goswami, PharmD and  
Katherine Hapgood, PharmD*

 See additional content online.

### I. DOSE ADJUSTMENT METHODS

#### A. Maintenance Dose

In patients with kidney insufficiency, the dose may be adjusted using the following methods:

1. Lengthen intervals between individual doses, keeping normal dose.
2. Reduce number of individual doses, keeping interval between doses normal. For this method, percentage of usual dose is shown. For some medications and indications, specific dosing is provided.
3. A combination of the above

NOTE: Dose adjustments in these tables do not apply to patients in the neonatal period. For neonatal renal dosing, please consult a neonatal dosage reference (see [Chapter 18](#)). Dose modifications given are only approximations and may not be appropriate for all patients or indications. Recommendations for dose adjustments with reduced glomerular filtration rate (GFR) are often based on chronic kidney disease populations; it may not be appropriate to extrapolate these adjustments to acute kidney injury. **Each patient must be monitored closely for signs of drug toxicity, and serum levels must be measured when available; drug doses and intervals should be adjusted accordingly.** When in doubt, always consult a pharmacist and/or nephrologist who has expertise in renal dosing.

#### B. Dialysis

General recommendations are provided when available. However, factors such as patient age, indication for use, residual native kidney function, specific peritoneal dialysis (PD) or intermittent hemodialysis (IHD) prescription, and so on, will affect the medication dosing needs of each individual patient. Doses for IHD generally assume standard, thrice-weekly dialysis sessions with limited residual native kidney function. **Consult with a nephrologist or pharmacist who is familiar with medication dosing in dialysis before prescribing medications for a dialysis patient.**

#### C. Glomerular Filtration Rate Estimation

Estimated GFR (eGFR) in children may be calculated using the bedside CKiD equation<sup>1</sup>:  $0.413 \times \text{height (cm)} / \text{serum creatinine}$ . Changes in serum creatinine lag changes in kidney function, and estimations may be inaccurate if serum creatinine is not at steady state. Additionally, in patients with reduced

muscle mass or malnutrition, this equation may overestimate GFR. Other information such as trend in serum creatinine or presence of oliguria (<0.5 mL/kg/hr urine × 6 hr) or anuria may help interpret the appropriateness of the calculated eGFR. When in doubt, consult a nephrologist to help determine an accurate eGFR range for medication dosing.

## II. ANTIMICROBIALS REQUIRING ADJUSTMENT IN KIDNEY FAILURE

(Table 31.1)

**TABLE 31.1**

### ANTIMICROBIALS REQUIRING ADJUSTMENT IN KIDNEY FAILURE

Medication	Adjustments Kidney Failure			
	eGFR (mL/min/1.73 m <sup>2</sup> )	Percentage of Usual Dose	Interval	
Acyclovir (IV) <sup>2</sup>	25–50	100%	Q12 hr	
	10–25	100%	Q24 hr	
	<10/IHD <sup>a</sup> /PD	50%	Q24 hr	
Amantadine <sup>b,3</sup>	30–50	50%	Q24 hr	
	NOTE: On day 1, give normal dose, then decrease subsequent doses based on renal function.	15–29	50%	Q48 hr
	<15/IHD/PD	100%	Q7 days	
Amikacin <sup>4</sup>	<60/IHD/PD	Administer a standard, one-time dose. Determine the appropriate interval for redosing based on serum concentrations. For IHD, redose based on concentrations. Optimal pharmacokinetic targets may be difficult to reach in patients with impaired kidney function; consider alternative agents.		
Amoxicillin <sup>5,6</sup>	10–29	50%–100%	Q12 hr	
	NOTE: Do not administer 875 mg immediate-release tablets with eGFR <30 mL/min/1.73 m <sup>2</sup> .	<10/IHD <sup>a</sup> /PD	50%–100% Q24 hr	
Amoxicillin/clavulanate <sup>5-7</sup>	10–29	50%–100%	Q12 hr	
	NOTE: Do not administer 875 mg immediate-release or 1000 mg XR extended-release tablet with eGFR <30 mL/min/1.73 m <sup>2</sup> .	<10/IHD <sup>a</sup> /PD	50%–100% Q24 hr	
Amphotericin B	No guidelines established.			
Ampicillin (IV) <sup>5</sup>	10–29	100%	Q8 hr	
	<10/IHD <sup>a</sup> /PD	100%	Q12 hr	
Ampicillin/sulbactam <sup>8</sup>	15–29	100%	Q12 hr	
	<15/IHD <sup>c</sup> /PD	100%	Q24 hr	
Aztreonam <sup>b,5,9</sup>	10–30	50%–66%	Q6–8 hr	
	NOTE: Administer full dose for initial dose, then adjust subsequent doses for kidney function.	<10/IHD/PD	25%–33% Q6–8 hr	
	IHD: Administer 12% of the full dose as an additional supplemental dose after dialysis in severe infections.			

Continued

TABLE 31.1

## ANTIMICROBIALS REQUIRING ADJUSTMENT IN KIDNEY FAILURE—CONT'D

Medication	Adjustments Kidney Failure		
	eGFR (mL/min/1.73 m <sup>2</sup> )	Percentage of Usual Dose	Interval
Cefaclor <sup>5</sup>	<10/IHD <sup>c</sup> /PD	50%	Q8–12 hr
Cefadroxil <sup>5</sup>	10–29/IHD <sup>a</sup>	100%	Q24 hr
	<10/PD	100%	Q36 hr
Cefazolin <sup>5,10</sup>	11–34	50%	Q12 hr
NOTE: Administer full dose for initial dose, then adjust subsequent doses for kidney function.	≤10	50%	Q24 hr
	IHD <sup>a</sup> /PD	25 mg/kg	Q24 hr
Cefdinir <sup>11</sup>	<30	7 mg/kg (max 300 mg)	Q24 hr
	IHD <sup>c</sup> /PD	7 mg/kg (max 300 mg)	Q48 hr
Cefepime <sup>12</sup>	30–60	100%	Q12 hr
NOTE: Administer full dose for initial dose, then adjust subsequent doses for kidney function.	10–29	100%	Q24 hr
	<10/PD/IHD <sup>a</sup>	50%	Q24 hr
cefiderocol	>120	100%	Q6h
	30–59	75%	Q8h
	15–29	50%	Q8h
	<15/HDa/PD	38%	Q12h
Cefixime <sup>b,14</sup>	21–60/IHD	75%	Q12–24 hr
	<20/PD	50%	Q12–24 hr
Cefotaxime <sup>5</sup>	30–50	100%	Q8–12 hr
	10–29	100%	Q12 hr
	<10/IHD <sup>a</sup> /PD	100%	Q24 hr
Cefotetan <sup>5,15</sup>	10–30	50%	Q12 hr
	<10/IHD <sup>a</sup> /PD	50%	Q24 hr
Cefoxitin <sup>16</sup>	30–50	100%	Q8 hr
	10–30	100%	Q12 hr
	<10/IHD <sup>c</sup> /PD	100%	Q24 hr
Cefpodoxime <sup>17</sup>	<30	100%	Q24 hr
	IHD	Administer thrice weekly after dialysis sessions.	
Cefprozil <sup>18</sup>	<30/IHD <sup>a</sup> /PD	50%	Q12–24 hr
Ceftaroline <sup>19</sup>	31–50	66%	Q8–12 hr
	15–30	50%	Q8–12 hr
	<15/IHD <sup>a</sup> /PD	33%	Q8–12 hr
Ceftazidime <sup>5,20</sup>	31–50	100%	Q12 hr
NOTE: Administer full dose for initial dose, then adjust subsequent doses for kidney function. <sup>4</sup>	10–30	100%	Q24 hr
	<10/IHD <sup>a</sup> /PD	50%	Q24 hr

Ceftozolane/tazobactam <sup>21</sup>	30–50	50%	
NOTE: the manufacturer recommends against the use in pediatric patients with eGFR below 50 mL/min/1.73 m <sup>2</sup> . Doses based on adult recommendations.	15–29	25%	
	<15/HD	50–75%	
		THEN	
		10–15%	
Cefuroxime (IV) <sup>22</sup>	10–20	100%	Q12 hr
	<10/IHD <sup>c</sup> /PD	100%	Q24 hr
Cephalexin <sup>5</sup>	30–50	100%	Q8 hr
	10–29	100%	Q12 hr
	<10/IHD <sup>a</sup> /PD	100%	Q24 hr
Ciprofloxacin <sup>5</sup>	10–29	100%	Q18 hr
	<10/IHD <sup>a</sup> /PD	100%	Q24 hr
Clarithromycin <sup>23</sup>	<30/IHD <sup>a</sup> /PD	50%	Q12 hr
Ertapenem <sup>b,24</sup>	≤30/IHD/PD	50%	Q12–24 hr
	IHD: If administered within 6 hr before dialysis, administer 30% of the normal daily dose as a supplemental dose after dialysis.		
Erythromycin <sup>5,25-26</sup>	Prophylaxis: no adjustment required		
	Treatment:		
	<10/IHD/PD: Hearing loss has been seen with normal doses in renal insufficiency, particularly in the elderly. Some recommend 50%–75% Q6–12 hr for treatment. Dose reduction may result in failure to achieve pharmacodynamic targets. Consider alternate therapy when possible. Weigh risks/benefits and individualize dose if required to treat serious infections.		
Ethambutol <sup>b,27</sup>	<30, IHD <sup>a</sup>	100%	3 times weekly
	PD	Data are not available. Begin with IHD dosing. Monitor closely and consider therapeutic drug monitoring.	
Famciclovir <sup>b,28</sup>	Dose adjustments recommended for adult patients vary by indication. See package insert.		
Fluconazole <sup>5,4,6</sup>	10–50	50%	Q24 hr
NOTE: No adjustment required for single-dose regimen.	<10/PD	50%	Q48 hr
Administer 100% of initial loading dose.	IHD	100%	After each dialysis session
Flucytosine <sup>29-30</sup>	21–40	100%	Q12 hr
NOTE: If available, therapeutic drug monitoring should be used to guide optimal dosing. Use extreme caution in children with kidney impairment.	10–20	100%	Q24 hr
	<10	100%	Q48 hr
	IHD	100%	After each dialysis session
Foscarnet <sup>31</sup>	Dose adjustments vary by indication. See package insert for adjustments for induction and maintenance.		
Ganciclovir <sup>32</sup>	INDUCTION IV		
	50–69	2.5 mg/kg	Q12 hr
	25–49	2.5 mg/kg	Q24 hr
	10–24	1.25 mg/kg	Q24 hr
	<10/PD/IHD <sup>a</sup>	1.25 mg/kg	Thrice weekly

Continued

TABLE 31.1

## ANTIMICROBIALS REQUIRING ADJUSTMENT IN KIDNEY FAILURE—CONT'D

Medication	Adjustments Kidney Failure		
	eGFR (mL/min/1.73 m <sup>2</sup> )	Percentage of Usual Dose	Interval
	MAINTENANCE IV		
	50–69	2.5 mg/kg	Q24 hr
	25–49	1.25 mg/kg	Q24 hr
	10–24	0.625 mg/kg	Q24 hr
	<10/PD/IHD <sup>a</sup>	0.625 mg/kg	Thrice weekly
Gentamicin <sup>4</sup>	<50/IHD/PD	Administer standard initial dose. Determine appropriate interval for redosing based on serum concentrations. Optimal pharmacokinetic targets may be difficult to reach in patients with impaired kidney function. Consider alternative agents.	
Imipenem/cilastatin <sup>b,33</sup>	60–89	75–80%	Q6–8 hr
NOTE: Patients with eGFR ≤15 should not receive imipenem/cilastatin unless dialysis will be initiated within 48 hr. Seizure risk increased with decreased kidney function.	30–59	50–60%	Q6 hr
	10–29	40–50%	Q6–12 hr
	<10/IHD <sup>a</sup>	50%	Q24 hr
Isoniazid <sup>6</sup>	IHD <sup>a</sup>	100%	Q24 hr
Lamivudine <sup>b,34</sup>	30–50	100%	Q24 hr
NOTE: Administer full dose for initial dose, then adjust subsequent doses for kidney function. If eGFR <5 or IHD, administer 33% of full dose as initial dose.	15–29	66%	Q24 hr
	5–14	33%	Q24 hr
	<5/IHD <sup>a</sup> /PD	17%	Q24 hr
Levofloxacin <sup>5,35</sup>	Q12 hr dosing		
NOTE: Administer full dose for initial dose, then adjust subsequent doses for kidney function.	10–29	100%	Q24 hr
	<10/IHD/PD	100%	Q48 hr
	Q24 hr dosing		
	10–29	100%	Q48h
	<10/IHD/PD	67%	Q48 hr
Meropenem <sup>b,36–37</sup>	30–50	100%	Q12 hr
Note: For GFR <30, maximum dose is 1000 mg	10–29	50%	Q12 hr
	<10/PD	50%	Q24 hr
	IHD <sup>a</sup>	25 mg/kg	Q24 hr
Metronidazole <sup>5,38</sup>	<10/IHD <sup>c</sup> /PD	Renally eliminated metabolites may accumulate and lead to adverse events. Monitor patient. Though no dose adjustment is recommended by the manufacturer, some recommend a dose of 4 mg/kg at standard intervals. We prefer standard dosing with careful monitoring.	

Oseltamivir <sup>b,39</sup>	INFLUENZA TREATMENT		
	31–60	50%	Q12 hr
	11–30	50%	Q24 hr
	IHD	50%	Once, then after each dialysis session
	PD	50%	Once
	INFLUENZA PROPHYLAXIS		
	31–60	50%	Q24 hr
	10–30	50%	Q48 hr
	IHD	50%	Once, then after every-other dialysis session
	PD	50%	Weekly for duration of prophylaxis
Penicillin G—aqueous (K <sup>+</sup> , Na <sup>+</sup> ) (IV) <sup>5</sup>	10–50	75%	Q4–6 hr
NOTE: Administer full dose for initial dose, then adjust subsequent doses for kidney function.	<10/IHD <sup>a</sup> /PD	50%	Q4–6 hr
Penicillin V K <sup>+</sup> (PO) <sup>40</sup>	<10/IHD <sup>a</sup> /PD	100%	Q8 hr
NOTE: No dose adjustment required for twice-daily prophylaxis dosing. The manufacturer makes no recommendations for renal dose adjustments. Extending the interval has been suggested.			
Pentamidine <sup>5</sup>	10–30	100%	Q36 hr
NOTE: Adjustment is not required for monthly prophylaxis.	<10/IHD <sup>a</sup> /PD	100%	Q48 hr
Piperacillin/tazobactam <sup>41</sup>	20–40	70%	Q6 hr
	<20	50%	Q6 hr
	IHD <sup>a</sup> /PD	50%	Q8 hr
Posaconazole <sup>42</sup>	<50	Consider risks and benefits of use of the IV product as solubilizing agent may accumulate. Monitor SCr and consider changing to PO if signs of toxicity. With PO products, exposure may vary, and breakthrough infections may occur.	
Rifabutin <sup>43</sup>	<30	50%–100%	Q24 hr
Streptomycin sulfate <sup>b,5,44</sup>	10–50	100%	Q24–72 hr
NOTE: Determine appropriate interval for redosing based on serum concentration when available. Patients with impaired kidney function are at risk for severe neurotoxicities, and a single dose may result in high levels for several days.	<10	100%	Q72–96 hr
	IHD/PD	100%	Administer 2–3 times weekly after dialysis.

Continued

**TABLE 31.1**  
**ANTIMICROBIALS REQUIRING ADJUSTMENT IN KIDNEY FAILURE—CONT'D**

Medication	Adjustments Kidney Failure		
	eGFR (mL/min/1.73 m <sup>2</sup> )	Percentage of Usual Dose	Interval
Sulfamethoxazole/trimethoprim <sup>45</sup>	<30/IHD <sup>a</sup> /PD	50%	Q8–12 hr
NOTE: No adjustment recommended for 2–3 times weekly prophylaxis dosing. The manufacturer recommends against use with GFR <15.			
Tetracycline <sup>b,5</sup>	10–50	100%	Q12–24 hr
	<10	100%	Q24 hr
Tobramycin <sup>4</sup>	<60	Administer standard initial dose. Determine appropriate interval for redosing based on serum concentrations. Optimal pharmacokinetic targets may be difficult to reach in patients with impaired kidney function. Consider alternative agents.	
Valacyclovir <sup>b,46–47</sup> NOTE: For IHD for all indications, dose for eGFR <10 and administer dose after dialysis. For PD for all indications, administer 500 mg Q48 hr.	HERPES ZOSTER (ADULTS)		
	30–49	100%	Q12 hr
	10–29	100%	Q24 hr
	<10/IHD <sup>a</sup>	50%	Q24 hr
	GENITAL HERPES (ADOLESCENTS/ADULTS): INITIAL EPISODE		
	10–29	100%	Q24 hr
	<10	50%	Q24 hr
	GENITAL HERPES (ADOLESCENTS/ADULTS): RECURRENT EPISODE		
	<30	100%	Q24 hr
	GENITAL HERPES (ADOLESCENTS/ADULTS): SUPPRESSIVE		
	<30	500 mg OR	Q24 hr (for usual dose of 1 g Q24 hr)
		500 mg	Q48 hr (for usual dose of 500 mg Q24 hr)
HERPES LABIALIS (ADOLESCENTS/ADULTS)			
30–49	50%	Q12 hr ×2 doses	
10–29	25%	Q12 hr ×2 doses	
<10	25%	Single dose	
Valganciclovir <sup>6,48–49</sup> NOTE: For dosing in children, a maximum eGFR value of 150 mL/min/1.73 m <sup>2</sup> should be used to calculate the dose. Calculate eGFR = k × height (cm) /	CHILDREN		
	Normal dosing accounts for kidney function: Once daily dose (mg) = 7 × body surface area × creatinine clearance.		
ADULTS—INDUCTION			
40–59	450 mg	Q12 hr	

creatinine. Consider use of $k = 0.413$ when enzymatic creatinine assays are used. Original labeling includes the following when SCr calculated via Jaffe method: $k = 0.33$ in infants aged <1 year, with low birth weight for gestational age, $0.45$ in infants aged <1 year, with birth weight appropriate for gestational age, $0.45$ in children aged 1 to <2 years, $0.55$ in boys aged 2 to <13 years and girls aged 2 to <16 years, and $0.7$ in boys aged 13–16 years.	25–39	450 mg	Q24 hr
	10–24	450 mg	Q48 hr
	<10/IHD <sup>a</sup> (limited data; consider ganciclovir)	200 mg	Thrice weekly
	ADULTS—MAINTENANCE		
	40–59	450 mg	Q24 hr
	25–39	450 mg	Q48 hr
	10–24	450 mg	Twice weekly
	<10/IHD <sup>a</sup> (limited data; consider ganciclovir)	100 mg	Thrice weekly

Vancomycin <sup>4</sup>	<50	Administer standard initial dose. Determine appropriate interval for redosing based on serum concentrations.
	IHD/PD	Administer standard initial dose. Obtain serum concentration after dialysis to determine need to redose. Obtain levels 4–6 hr after dialysis to allow for redistribution from peripheral compartment. If patient is unstable, may obtain sooner with knowledge that concentration may be lower than steady state.

<sup>a</sup>For IHD administer after dialysis on dialysis days.

<sup>b</sup>In adults; guidelines not established in children.

<sup>c</sup>Administer a supplemental dose after dialysis.

*eGFR*, Estimated glomerular filtration rate; *HIV*, human immunodeficiency virus; *hr*, hour; *IHD*, intermittent hemodialysis; *IM*, intramuscular; *IV*, intravenous;  $K^+$ , potassium;  $Na^+$ , sodium; *PD*, peritoneal dialysis; *PO*, oral; *Q*, every.

### III. NON-ANTIMICROBIALS REQUIRING ADJUSTMENT IN KIDNEY FAILURE

(Table 31.2)

**TABLE 31.2**

#### NON-ANTIMICROBIALS REQUIRING ADJUSTMENT IN KIDNEY FAILURE

Medication	eGFR	Adjustments in Kidney Failure	
		Dose	Percentage of Usual Interval
Acetaminophen <sup>5</sup>	10–50	100%	Q6 hr
	<10/IHD/PD	100%	Q8 hr
Acetazolamide <sup>5</sup>	10–50	100%	Q12 hr
	<10/IHD/PD	Avoid use.	

*Continued*

TABLE 31.2

## NON-ANTIMICROBIALS REQUIRING ADJUSTMENT IN KIDNEY FAILURE—CONT'D

Medication	eGFR	Adjustments in Kidney Failure	
		Dose	Interval
Allopurinol <sup>5</sup>	10–50	50%	Q6–24 hr
	<10/IHD/PD	30%	Q6–24 hr
Aminocaproic acid <sup>b,50–51</sup> Use with caution in patients with renal dysfunction. Can cause renal failure.	<60/Oliguria/ ESRD IHD	12%–25%  No reduction needed	Q4–6 hr,  continuous
Aspirin <sup>5</sup>	10–50	100%	Q4–24 hr
	IHD <sup>a</sup>	100%	Q24 hr
	<10/PD	Avoid use for analgesia and anti-inflammatory indications.	
Atenolol <sup>5</sup>	30–50	1 mg/kg up to 50 mg	Q24 hr
	10–29	1 mg/kg up to 50 mg	Q48 hr
	<10/IHD <sup>a</sup> /PD	1 mg/kg up to 25 mg	Q48 hr
Azathioprine <sup>5,52</sup>	10–50	75%	Q24 hr
	<10/IHD <sup>a</sup> /PD	50%	Q24 hr
Bismuth subsalicylate <sup>b,52</sup>	<50/IHD/PD	Avoid use in patients with renal failure.	
Bosentan <sup>53</sup>	Dose adjustment not required. Significant clearance by dialysis is not expected.		
Calcium supplements	<25	May require dosage adjustment depending on calcium level.	
Captopril <sup>4,52</sup>	10–50	75%	Q6–8 hr
	<10/IHD <sup>a</sup> /PD	50%	Q6–8 hr
Carbamazepine <sup>5</sup>	<10/IHD <sup>a</sup> /PD	75%	Q8–12 hr
Cetirizine <sup>5,6,52</sup>	10–29/IHD/PD	50%	Q24 hr
	≤10	Use not recommended. Some consider 50% Q24 hr in this population.	
Chloroquine <sup>5,6</sup> NOTE: Dose adjustment recommended for long-term use.	<10/IHD/PD	50%	Depends on indication
Chlorothiazide <sup>52,54</sup>	<30	May be ineffective	
	<10	Use not recommended	
Clobazam <sup>55</sup>	<30	Use with caution; has not been studied	
Dabigatran <sup>56</sup>	<50	Avoid use.	
Desloratadine <sup>b,57</sup>	<50	100%	Q48 hr
Digoxin <sup>5</sup>	DIGITALIZING DOSE		
	ESRD	50%	NA
	MAINTENANCE DOSE		
	30–50	75%	Q12–24 hr

	10–29	50%	Q12–24 hr
		OR 100%	Q36 hr
	<10/IHD/PD	25%	Q12–24 hr
		OR 100%	Q48 hr
Disopyramide <sup>b,58</sup>	30–40	100%	Q8 hr
NOTE: Avoid continuous release product with eGFR <40.	15–30	100%	Q12 hr
	<15	100%	Q24 hr
EDTA calcium disodium <sup>b,59</sup>	IV: ADULT SERUM CREATININE-BASED DOSING		
NOTE: Do not administer in patients with anuria or severe oliguria.	≤2 mg/dL	1 g/m <sup>2</sup>	Q24 hr ×5 days
	2–3 mg/dL	500 mg/m <sup>2</sup>	Q24 hr ×5 days
	3–4 mg/dL	500 mg/m <sup>2</sup>	Q48 hr ×3 doses
	>4 mg/dL	500 mg/m <sup>2</sup>	Once weekly
Enalapril/Enalaprilat <sup>5,52,60</sup>	10–50	75%	Q12–24 hr
NOTE: Manufacturer does not recommend in pediatric patients GFR <30 mL/min/1.73 m <sup>2</sup> .	<10/IHD <sup>a</sup> /PD	50%	Q12–24 hr
Enoxaparin <sup>b,6,52</sup>	<30 IHD/PD	100%	Q24 hr
		Serious bleeding complications may occur. Avoid use. If used, reduce dose and monitor anti-Xa activity.	
Epoprostenol <sup>61</sup>	Manufacturer does not recommend renal dose reduction. Titrate to clinical effect.		
Famotidine <sup>5,62</sup>	30–50	100%	Q24 hr
	10–29	50%	Q24 hr
	<10/IHD/PD	25%	Q24 hr
Felbamate <sup>b,5,52,63</sup>	<50/IHD <sup>a</sup>	50%	Q6–8 hr
Fentanyl <sup>5,52,64–68</sup>	INJECTION		
	<50	Manufacturer does not recommend dose reduction. Titrate to clinical effect.	
	PATCH		
	Limit use to non-opioid-naïve adult patients. Titrate after 72 hr from initial transdermal exposure.		
	Mild–moderate impairment <sup>b</sup>	12.5–25 mcg patch	Q72 hr
	Severe impairment	Not recommended by manufacturer	
Fexofenadine <sup>5,52</sup>	<50/IHD/PD	100%	Q24 hr
Flecainide <sup>b,69</sup>	<35	50%	Q12 hr
Furosemide	Avoid use in oliguria.		
Gabapentin <sup>5,70</sup>	30–59	75%	Q12 hr
	15–29	75%	Q24 hr
	<15/IHD <sup>c</sup> /PD	75%	Q48 hr
Hydralazine <sup>d,5,6</sup>	10–50	100%	Q8 hr
	<10/IHD/PD	100%	Q12–24 hr
Iloprost <sup>b,71</sup>	IHD/PD	Dose adjustment not required. Use with caution; has not been studied.	
Insulin (regular) <sup>e,5,52</sup>	10–50	75%	No change
	<10/IHD/PD	50%	No change
Ivacaftor <sup>72</sup>	<30	Use with caution, not studied.	

Continued

TABLE 31.2

## NON-ANTIMICROBIALS REQUIRING ADJUSTMENT IN KIDNEY FAILURE—CONT'D

Medication	eGFR	Adjustments in Kidney Failure	
		Dose	Interval
Lacosamide <sup>b,73</sup>	<30	75%	Q12 hr
		Maximum adult dose: 300 mg/24-hr period	
	IHD	Administer 50% dose supplementation after 4-hr dialysis session.	
Levetiracetam <sup>5,74,75</sup>	CHILDREN		
	<50	50%	Q12 hr
	IHD <sup>f</sup> /PD	50%	Q24 hr
	ADULTS — IMMEDIATE RELEASE		
	50–80	500–1000 mg	Q12 hr
	30–50	250–750 mg	Q12 hr
	<30	250–500 mg	Q12 hr
	IHD <sup>f</sup> /PD	500–1000 mg	Q24 hr
	ADULTS — EXTENDED RELEASE		
	50–80	1000–2000 mg	Q24 hr
	30–50	500–1500 mg	Q24 hr
	<30	500–1000	Q24 hr
	IHD <sup>f</sup> /PD	Use of immediate release product recommended	
Lisinopril <sup>b,76</sup>	10–50	50%	Q24 hr
	<10/IHD <sup>a</sup> /PD	25%	Q24 hr
Lithium <sup>5,52,77–78</sup>	10–50	50%–75%	Q8–12 hr
NOTE: Monitor serum concentrations.	<10	25%–50%	Q8–12 hr
Lithium concentrations rebound after dialysis.	IHD <sup>a</sup> /PD	25%–50%	Q8–12 hr
Loratadine <sup>5</sup>	<10/IHD/PD	100%	Q24–48 hr
Lumacaftor + Ivacaftor <sup>79</sup>	<30	Use with caution.	
Meperidine <sup>5,6,52,80</sup>	10–50	75%	Avoid use, especially repeat administrations.
NOTE: Accumulation of normeperidine can lead to tremors and seizures. Limit duration to ≤48 hr in all patients. Avoid use in patients with kidney dysfunction.	<10	50%	Avoid use, especially repeat administrations.
	IHD/PD	Avoid use.	
Methadone <sup>5,52</sup>	<10/IHD/PD	50%–75%	Q8–12 hr
Metoclopramide <sup>5</sup>	30–50	75%	No change
	10–30	50%	No change
	<10/IHD/PD	25%	No change

Midazolam <sup>5,81</sup>	<10	50%	No change
NOTE: Metabolite $\alpha$ -hydroxymidazolam can accumulate in kidney failure, leading to prolonged sedation after midazolam is discontinued.			
Milrinone <sup>82–83</sup>	50		0.43 mCg/kg/min
NOTE: Initial doses suggested by manufacturer. Interpatient variability is common.	40		0.38 mCg/kg/min
	30		0.33 mCg/kg/min
	20		0.28 mCg/kg/min
Individualized doses and titration to hemodynamic and clinical response may be necessary.	10		0.23 mCg/kg/min
	5		0.2 mCg/kg/min
Morphine <sup>5,66–68,84</sup>	10–50	75%	No change
NOTE: Consider other agents in patients with moderate to severe renal dysfunction or who receive dialysis. Glucuronide metabolites may accumulate, increasing risk of respiratory depression and sedation.	<10/IHD/PD	50%	No change
Neostigmine <sup>b,5,52</sup>	10–50	50%	No change
	<10	25%	No change
Oxcarbazepine <sup>b,85–86</sup>	IMMEDIATE-RELEASE		
	<30	Initial dose: 50%. Titrate slowly.	Q12 hr
	EXTENDED-RELEASE		
	<30	Initial adult dose: 300 mg	Q24 hr
Pancuronium bromide <sup>5,52,87</sup>	10–50	50%	No change
	<10/IHD/PD	Avoid use. Prolonged neuromuscular blockade may result; half-life is doubled in renal failure.	
Phenazopyridine <sup>52</sup>	50–80	100%	Q8–16 hr
	<50	Contraindicated. Risk of nephrotoxicity, methemoglobinemia, and hemolytic anemia	
Phenobarbital <sup>5,52,88</sup>	<10/IHD <sup>f</sup> /PD	100%	Q12–24 hr
NOTE: Therapeutic drug monitoring encouraged. Titrate to level and therapeutic effect.			
Primidone <sup>5</sup>	10–50	100%	Q12–24 hr
NOTE: Due to complex metabolism, it is preferred to use other options when available for patients with kidney failure.	<10/IHD <sup>a</sup>	100%	Q24 hr
Quinidine <sup>5,52</sup>	<10/IHD <sup>a</sup> /PD	75%	Q6–12 hr
Sodium phenylacetate and sodium benzoate <sup>89</sup>	<50		Use with caution and close monitoring.
Spirolactone <sup>5,52</sup>	30–50	100%	Q24 hr
	<30		Avoid use due to risk of hyperkalemia.

Continued

**TABLE 31.2**  
**NON-ANTIMICROBIALS REQUIRING ADJUSTMENT IN KIDNEY FAILURE—CONT'D**

Medication	eGFR	Adjustments in Kidney Failure	
		Percentage of Usual Dose	Interval
Terbutaline <sup>52,90–91</sup>	<50	Renally eliminated; use with caution. No specific dose adjustment available	
Tezacaftor + Ivacaftor <sup>92</sup>	<30	Use with caution.	
Treprostinil <sup>93–94</sup>	Manufacturer does not recommend dose reduction. Use with caution and titrate slowly as increased exposure is expected.		
Triamterene <sup>5,52</sup>	<50/IHD/PD	Do not use due to risk of hyperkalemia.	
Verapamil <sup>95–96</sup>	<10	Dose reduction may be needed; use caution. Monitor blood pressure, ECG for PR prolongation, and other signs of overdose.	
Vigabatrin <sup>97</sup>	50–80	75%	Q12 hr
	30–50	50%	Q12 hr
	10–30	25%	Q12 hr

<sup>a</sup>For IHD administer after dialysis on dialysis days.

<sup>b</sup>In adults; guidelines not established in children.

<sup>c</sup>Administer supplemental dose after every 4 hours of dialysis, based on daily dose as follows (daily dose/recommended supplemental dose): 100 mg/125 mg; 125 mg/150 mg; 150 mg/200 mg; 200 mg/250 mg; 300 mg/350 mg.

<sup>d</sup>Dose interval varies for rapid and slow acetylators with normal and impaired renal function.

<sup>e</sup>Renal failure may cause hyposensitivity or hypersensitivity to insulin. Empiric dosing recommendations may not be appropriate for all patients; adjust to clinical response and blood glucose.

<sup>f</sup>Administer a supplemental dose after dialysis.

*D*, Dose reduction; *ECG*, electrocardiogram; *EDTA*, ethylenediaminetetraacetic acid; *eGFR*, estimated glomerular filtration rate; *ESRD*, end-stage renal disease; *GI*, gastrointestinal; *I*, interval extension; *IHD*, intermittent hemodialysis; *IM*, intramuscular; *IV*, intravenous; *MHD*, 10-monohydroxy metabolite; *NA*, not applicable; *PD*, peritoneal dialysis; *PO*, oral; *Q*, every; *SubQ*, subcutaneous; *t*<sub>1/2</sub>, half-life.

## REFERENCES

A complete list of references can be found online.

## REFERENCES

1. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. *J Am Soc Nephrol*. 2009;20:629–637.
2. Zovirax® (acyclovir sodium) for injection [package insert]. GlaxoSmithKline; Published 2003. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2004/18603slr027\\_zovirax\\_lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18603slr027_zovirax_lbl.pdf)
3. Symmetrel® (amantadine hydrochloride, USP) tablets and syrup [package insert]. Endo Pharmaceuticals; Published 2009. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/016023s041,018101s016lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016023s041,018101s016lbl.pdf)
4. Veltri M, Neu AM, Fivush B, et al. Dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients. *Paediatr Drugs*. 2004;6:45–66.
5. Aronoff GR, Bennett WM, Berns JS, et al. *Drug Prescribing in Renal Failure: Dosing Guidelines for Adults*. 5th ed. American College of Physicians; 2007.
6. Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online. [electronic database]. Lexi-Comp, Inc; Published 2022. <http://www.crlonline.com>
7. Augmentin® (amoxicillin/clavulanate potassium) [package insert]. Dr. Reddy's Laboratories, Inc; Published 2013. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf)
8. Unasyn® (ampicillin sodium/sulbactam sodium) [package insert]. Pfizer; Published 2007. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/050608s029lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050608s029lbl.pdf)
9. Aztreonam [package insert]. Bristol-Myers Squibb Company; 2018. [https://packageinserts.bms.com/pi/pi\\_azactam.pdf](https://packageinserts.bms.com/pi/pi_azactam.pdf)
10. Ancef® cefazolin for injection [package insert]. GlaxoSmithKline; Published 2004. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2004/50461slr139\\_ancef\\_lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50461slr139_ancef_lbl.pdf)
11. Omnicef® (cefdinir) [package insert]. Lupin Pharmaceuticals, Inc.; Published 2009. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2c3705f2-0b44-4d38-a7f9-4b392d0a1a45&type=display>
12. Maxipime® (cefepime hydrochloride, USP) for injection [package insert]. Hospira; Published 2012. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/050679s036lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050679s036lbl.pdf)
13. Fetroja® (cefiderocol) for injection [package insert]. Shionogi Inc.; Published 2021. <https://www.shionogi.com/content/dam/shionogi/si/products/pdf/fetroja.pdf>
14. Suprax® [package insert]. Lupin Pharma; Published 2008. <https://www.lupin.com/US/pdf/09/SUPRAX%20Common%20PI%20.pdf>
15. Cefotan (cefotetan for injection, USP) [package insert]. Teligent Pharma, Inc; Published 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/050588s032lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050588s032lbl.pdf)
16. Mefoxin® (cefoxitin for injection) [package insert]. Mylan Institutional, LLC; Published 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/050517s053lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050517s053lbl.pdf)
17. Vantin® tablets and oral suspension [package insert]. Pharmacia and Upjohn Company; Published 2013. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2013/050674s015,050675s018lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050674s015,050675s018lbl.pdf)
18. Cefzil (cefprozil) tablets 250 mg and 500 mg [package insert]. Bristol-Myers Squibb; Published 2007. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2007/050664s024,050665s024lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050664s024,050665s024lbl.pdf)

19. *Telfaro*<sup>TM</sup> (ceftaroline fosamil) injection for intravenous use [package insert]. Forest Laboratories; Published 2010. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2011/200327s001lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200327s001lbl.pdf)
20. *Fortaz*<sup>®</sup> (ceftazidime for injection) [package insert]. Teligent Pharma, Inc; Published 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/050578s061,050634s028lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050578s061,050634s028lbl.pdf)
21. *Zerbaxa*<sup>®</sup> (ceftolozane and tazobactam) for injection [package insert]. Merck & Co., Inc.; Published 2022. [https://www.merck.com/product/usa/pi\\_circulars/z/zerbaxa/zerbaxa\\_pi.pdf](https://www.merck.com/product/usa/pi_circulars/z/zerbaxa/zerbaxa_pi.pdf)
22. *Zinacef*<sup>®</sup> (cefuroxime for injection) [package insert]. GlaxoSmithKline; Published 2001. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2001/50643s11lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/50643s11lbl.pdf)
23. *Biaxin*<sup>®</sup> (clarithromycin filmtabs, USP) [package insert]. AbbVie, Inc; Published 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/050662s058,050698s038,050775s026lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050662s058,050698s038,050775s026lbl.pdf)
24. *Invanz*<sup>®</sup> (ertapenem for injection) for intravenous (IV) or intramuscular (IM) use [package insert]. Merck & Co., Inc; Published 2011. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/021337s038lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021337s038lbl.pdf)
25. *Erythrocin*<sup>®</sup> Lactobionate (erythromycin lactobionate), injection [package insert]. Hospira; Published 2006. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/050609s025lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050609s025lbl.pdf)
26. Czock D, Spitaletta M, Keller F. Suboptimal antimicrobial drug exposure in patients with renal impairment. *Int J Clin Pharm*. 2015;37:906–916.
27. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Disease Society of America Clinical Practice Guidelines: Treatment of drug-susceptible tuberculosis. *Clin Infect Dis*. 2016;63:e147–e195.
28. *Famvir*<sup>®</sup> (famciclovir) tablets [package insert]. Novartis Pharmaceuticals Corporation; Published 2011. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2011/020363s037lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020363s037lbl.pdf)
29. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the Prevention and Treatment of Opportunistic Infection in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Disease Society of America. Accessed January 6, 2023. <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf>
30. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Accessed January 6, 2023. <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/guidelines-pediatric-oi.pdf>
31. *Foscavir*<sup>®</sup> (foscarnet sodium) injection [package insert]. Fresenius Kabi Austria GmbH; Published 2011. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/020068s018lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020068s018lbl.pdf)
32. *Ganciclovir* injection, for intravenous use [package insert]. Elexa Pharma Sciences; Published 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/209347lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209347lbl.pdf)
33. *Primaxin*<sup>®</sup> (Imipenem and Cilastatin) for Injection [package insert]. Merck & Co; Published 2016. <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf>

34. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Accessed January 14, 2022. <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf>
35. *Levaquin® levofloxacin [package insert]*. Ortho-McNeil-Janssen Pharmaceuticals, Inc; Published 2008. <https://www.fda.gov/files/drugs/published/Levaquin-Label.pdf>
36. *Merrem® IV (meropenem for injection) [package insert]*. Astra-Zeneca; Published 2016. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/050706s037lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s037lbl.pdf)
37. Goldstein SL, Murry DJ, May S, et al. Meropenem pharmacokinetics in children and adolescents receiving hemodialysis. *Pediatr Nephrol*. 2001;16:1015–1018.
38. *Flagyl® (metronidazole) tablets [package insert]*. Pfizer Inc; Published 2021. <http://labeling.pfizer.com/showlabeling.aspx?id=570>
39. *Tamiflu® (oseltamivir phosphate) [package insert]*. Genentech, Inc; Published 2019. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/021087s071,021246s054lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021087s071,021246s054lbl.pdf)
40. Penicillin V. In: *IBM Micromedex® DRUGDEX [database on the Internet]*; Published 2022. Accessed January 14, 2022. <http://www.micromedexsolutions.com>. Subscription required to view
41. *Zosyn® (piperacillin and tazobactam for injection, for intravenous use [package insert])*. Pfizer; Published 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/050684s88s89s90\\_050750s37s38s39lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050684s88s89s90_050750s37s38s39lbl.pdf)
42. *Noxafil® (posaconazole) [package insert]*. Merck & Co., Inc; Published 2015. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf)
43. *Mycobutin® rifabutin capsules, USP [package insert]*. Pharmacia & Upjohn Company; Published 2007. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/050689s016lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050689s016lbl.pdf)
44. *Streptomycin for injection, USP [package insert]*. X-Gen Pharmaceuticals; Published 2011. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/064210s009lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064210s009lbl.pdf)
45. *Bactrim™ (sulfamethoxazole and trimethoprim) injection, for intravenous use [package insert]*. Sun Pharmaceutical Industries, Inc; Published 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/018374s025lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018374s025lbl.pdf)
46. Stathoulopoulou F, Dhillon S, Thodis H, Stathakis C, Vargemezis V. Evaluation of valacyclovir dosage reduction in continuous ambulatory peritoneal dialysis patients. *Nephron*. 2002;91:164–166.
47. *Valtrex® (valacyclovir hydrochloride) caplets [package insert]*. GlaxoSmithKline; Published 2008. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/020487s014lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020487s014lbl.pdf)
48. *Valcyte® (valganciclovir hydrochloride) [package insert]*. Genentech USA, Inc; Published 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/021304s012,022257s007lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021304s012,022257s007lbl.pdf)
49. Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine association of the Infectious Diseases Society of America. *Clin Infect Dis*. 2014;59:e96–138.
50. Haug 3rd MT, Mauro VF, Davis HH. Effect of renal failure and hemodialysis on aminocaproic acid plasma concentrations. *DICP*. 1989;23(11):922–923. <https://doi.org/10.1177/106002808902301116>

51. Pitts TO, Spero JA, Bontempo FA, Greenberg A. Acute renal failure due to high-grade obstruction following therapy with epsilon-aminocaproic acid. *Am J Kidney Dis.* 1986;8(6):441–444. [https://doi.org/10.1016/s0272-6386\(86\)80172-x](https://doi.org/10.1016/s0272-6386(86)80172-x)
52. Golightly LK, Teitelbaum I, Kiser TH, et al. *Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys.* Springer; 2013.
53. *Tracleer® (bosentan) tablets [package insert].* Actelion Pharmaceuticals US, Inc; Published 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/209279s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf)
54. *Diuril® (chlorthiazide) oral suspension [package insert].* Salix Pharmaceuticals, Inc; Published 2008. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/011870s040lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/011870s040lbl.pdf)
55. *Onfi® (clobazam) tablets [package insert].* Lundbeck; Published 2021. [https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/onfi\\_pi\\_us\\_en.pdf](https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/onfi_pi_us_en.pdf)
56. *Pradaxa® (dabigatran etexilate mesylate) oral capsules [package insert].* Boehringer Ingelheim Pharmaceuticals, Inc; Published 2015. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/022512s028lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdf)
57. *Clarinox® (desloratadine) [package insert].* Merck & Co, Inc; Published 2014. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf)
58. *Norpace® disopyramide phosphate [package insert].* G.D. Searle LLC; Published 2006. [https://cdn.pfizer.com/pfizercom/products/uspi\\_norpace.pdf](https://cdn.pfizer.com/pfizercom/products/uspi_norpace.pdf)
59. *Calcium disodium versenate (edetate calcium disodium injection, USP) [package insert].* Graceway Pharmaceuticals; Published 2009. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/008922s016lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/008922s016lbl.pdf)
60. *Epaned (enalapril maleate) [package insert].* Silvergate Pharmaceuticals, Inc; Published 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/204308s006lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204308s006lbl.pdf)
61. *Veletri (epoprostenol) for injection [package insert].* Actelion Pharmaceuticals US, Inc; Published 2012. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/022260s005lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022260s005lbl.pdf)
62. *Pepcid® (famotidine) oral tablets [package insert].* Valeant Pharmaceuticals North America, LLC; Published 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/019462s039lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf)
63. *Felbatol® (felbamate) [package insert].* MEDA Pharmaceuticals, Inc. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/020189s022lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020189s022lbl.pdf)
64. *Duragesic(R) (fentanyl transdermal system) [package insert].* Janssen Pharmaceuticals, Inc; Published 2009. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/019813s069lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019813s069lbl.pdf)
65. Niscola P, Scaramucci L, Vischini G, et al. The use of major analgesics in patients with renal dysfunction. *Curr Drug Targets.* 2010;11(6):752–758. <https://doi.org/10.2174/138945010791170879>
66. Koncicki HM, Unruh M, Schell JO, et al. Pain management in CKD: a guide for nephrology providers. *Am J Kidney Dis.* 2017;69(3):451–460.
67. Reis A, Luecke C, Davis TK, Kakajiwala A, et al. Pain Management in Pediatric Chronic Kidney Disease. *J Pediatr Pharmacol Ther.* 2018;23(3):192–202. <https://doi.org/10.5863/1551-6776-23.3.192>
68. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ, et al. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. *J Pain Palliat Care Pharmacother.* 2007;21(2):5–16.
69. *Flecainide acetate tablets, USP [package insert].* Roxane Laboratories, Inc; Published 2014. [https://docs.boehringer-ingelheim.com/Prescribing%](https://docs.boehringer-ingelheim.com/Prescribing%20Flecainide%20Acetate%20Tablets%20USP.pdf)

- 20Information/PIs/Roxane/Flecainide%20Acetate/Flecainide%20Acetate%  
20Tablets.pdf
70. *Nerutontin*® (*gabapentin*) [package insert]. Pfizer; Published 2020. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/020235s068,020882s049,021129s049lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020235s068,020882s049,021129s049lbl.pdf)
  71. *Ventavis*® (*iloprost*) *inhalation solution* [package insert]. Actelion Pharmaceuticals US, Inc; Published 2009. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/021779s009lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021779s009lbl.pdf)
  72. *Kayldeco*® (*ivacaftor*) [package insert]. Vertex Pharmaceuticals, Inc; Published 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/203188s0221\\_207925s003lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203188s0221_207925s003lbl.pdf)
  73. *Vimpat*® (*lacosamide*) [package insert]. UBC, Inc; Published 2008. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/022253lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf)
  74. *Keppra*® (*levetiracetam*) [package insert]. UBC, Inc; Published 2009. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/021035s078s080%2C021505s021s024lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021035s078s080%2C021505s021s024lbl.pdf)
  75. *Keppra XR*® *extended-release tablets* [package insert]. UBC, Inc; Published 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/022285s025lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022285s025lbl.pdf)
  76. *Zestril*® (*lisinopril*) [package insert]. AstraZeneca; Published 2008. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/019777s054lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019777s054lbl.pdf)
  77. Hausmann R, Bauer M, von Bonin S, Grof P, Lewitzka U. Treatment of lithium intoxication: facing the need for evidence. *Int J Bipolar Disord.* 2015;3(1):23.
  78. McGrane IR, Omar FA, Morgan NF, Shuman MD. Lithium therapy in patients on dialysis: A systematic review. *Int J Psychiatry Med.* 2022;57(3):187–201. <https://doi.org/10.1177/00912174211028544>.
  79. *Orkambi*® (*lumacaftor/ivacaftor*) *tablets* [package insert]. Vertex Pharmaceuticals, Inc; Published 2015. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/206038orig1s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038orig1s000lbl.pdf)
  80. Institute for Safe Medication Practice (ISMP). High alert medication feature: reducing patient harm from opiates. Published February 22, 2007. Accessed January 21, 2022. <https://www.ismp.org/resources/high-alert-medication-feature-reducing-patient-harm-opiates>
  81. Bauer TM, Ritz R, Haberthur C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. *Lancet.* 1995;346:145–147.
  82. *Milrinone lactate injection* [package insert]. Hospira, Inc; Published 2021. <https://labeling.pfizer.com/ShowLabeling.aspx?id=7388>
  83. Gist KM, Mizuno T, Goldstein SL, Vinks A. Retrospective evaluation of milrinone pharmacokinetics in children with kidney injury. *Ther Drug Monit.* 2015;37:792–796.
  84. Niesters M, Overdyk F, Smith T, Arts L, Dahan A. Opioid-induced respiratory depression in paediatrics: a review of case reports. *Br J Anaesth.* 2013;110:175–182.
  85. *Trileptal*® (*oxcarbazepine*) *oral suspension* [package insert]. Novartis Pharmaceuticals Corporation; Published 2014. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/021014s033,021285s027lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021014s033,021285s027lbl.pdf)
  86. *Oxtellar XR*®. *oxcarbazepine*) *extended-release* [package insert]. Supernus Pharmaceuticals, Inc; Published 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/202810s010lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202810s010lbl.pdf)
  87. *Pancuronium bromide injection, USP* [package insert]. Hospira, Inc; Published 2019. <https://labeling.pfizer.com/ShowLabeling.aspx?id=4562>
  88. Porto I, John EG, Heiliczer J. Removal of phenobarbital during continuous cycling peritoneal dialysis in a child. *Pharmacotherapy.* 1997;17(4):832–835.

89. *Ammonul*® (sodium phenylacetate and sodium benzoate) injection [package insert]. Ucylyd Pharma Inc; Published 2005. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2005/020645lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020645lbl.pdf)
90. *Terbutaline sulfate injection* [package insert]. Bedford Laboratories; Published 2011. [https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue\\_Bedford%20Labs/55390-101-10%20TBT%201MG/5539010110](https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Ben%20Venue_Bedford%20Labs/55390-101-10%20TBT%201MG/5539010110)
91. Bastiansen A, Eggert S, Pedersen E. Pharmacokinetics of terbutaline in chronic kidney disease. *Eur J Clin Pharmacol*. 2013;69:1951–1954.
92. *Symdeko*® (tezacaftor/ivacaftor) tablets [package insert]. Vertex Pharmaceuticals Inc; Published 2020. [https://pi.vrtx.com/files/uspi\\_tezacaftor\\_ivacaftor.pdf](https://pi.vrtx.com/files/uspi_tezacaftor_ivacaftor.pdf)
93. *Orenitram*™ (treprostinil) oral extended-release tablets [package insert]. United Therapeutics Corp; Published 2013. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2013/203496s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203496s000lbl.pdf)
94. *Remodulin*® (treprostinil) subcutaneous injection [package insert]. United Therapeutics Corp; Published 2011. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2011/021272s015lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021272s015lbl.pdf)
95. *Calan*® (verapamil hydrochloride) injection [package insert]. Pfizer; Published 2009. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2010/018925s007,019038s003lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018925s007,019038s003lbl.pdf)
96. *Verelan*® (verapamil hydrochloride) sustained release capsules [package insert]. Alkermes Gaineville, LLC; Published 2014. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/019614s050lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019614s050lbl.pdf)
97. *Sabril*® (vigabatrin) [package insert]. Lundbeck; Published 2013. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2013/020427s010s011s012,022006s011s012s013lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020427s010s011s012,022006s011s012s013lbl.pdf)

*Note:* Page numbers followed by “f” indicate figures “t” indicate tables and “b” indicate boxes.

## A

- A-200. See Pyrethrins with piperonyl butoxide
- AAP. See American Academy of Pediatrics
- Abacavir, 119
- Abatacept, for pediatric rheumatology, 726t–730t
- Abbott Liquid Protein Fortifier, calories of, 610t
- Abdomen, acute, 319–320, 320t
- Abdominal imaging, CT with IV contrast, 46–47, 46f
- Abdominal injury, 44–45
- Abdominal pain, acute, 320t
- Abdominal trauma, 701, 701.e1f  
blunt, 44–45
- Abdominal wall defects, 520
- Abelcet. See Amphotericin B lipid complex
- ABG. See Arterial blood gas
- Abilify. See Aripiprazole
- Abilify Maintena. See Aripiprazole
- Abilify MyCite. See Aripiprazole
- Abrasion, corneal, 53
- Absolute risk increase (ARI), 754
- Absolute risk reduction (ARR), 754
- Absorbable sutures, characteristics of, 105t
- Absorica. See Isotretinoin
- Absorica LD. See Isotretinoin
- Abstinence syndrome, neonatal, 522
- Abstral. See Fentanyl
- Abuse  
physical, 62–64, 63.e1f, 63.e2f  
sexual, 64–65
- Acanthocytes (Spur cells), 373
- AccuNeb. See Albuterol
- Accutane. See Isotretinoin
- Acetadote. See Acetylcysteine
- Acetaminophen (Tylenol, Tempra, Panadol, FeverAll, Anacin Aspirin Free, Mapap, Paracetamol, Ofirmev), 767, 771–772, 777–778, 780–782, 784–785  
adjustment in kidney failure, 1203t–1208t  
analgesic properties of, 156  
overdose, 69t–70t, 71
- Acetate, formulation recommendations for, 616t
- Acetate salt, 119
- Acetazolamide (Diamox), 770, 786–787, 1104  
adjustment in kidney failure, 1203t–1208t  
for hydrocephalus, 577
- Acetone, in toxicology, 67.e1t–67.e3t
- Acetylcysteine (Acetadote, Mucomyst, Mucosol), 766, 775, 787–788
- Acetylsalicylic acid, for pediatric rheumatology, 726t–730t
- Achondroplasia, 361
- Acid-base disturbances, 308–315  
analysis of, 663  
anion gap, 310–311  
delta gap, 311–312  
derangement, 315, 316f  
determining pH, 308–310  
etiology of, 315, 315b, 316f  
expected compensatory response, 314, 315t  
osmolal gap, 313–314
- Acidemia, 310  
isovaleric, 341t–342t  
metabolic, 310  
methylmalonic, 341t–342t  
propionic, 341t–342t  
respiratory, 310
- Acidosis  
chronic kidney disease and, 565t  
fatal lactic, 1024  
metabolic, evaluation of, 337
- ACIP. See Advisory Committee on Immunization Practices
- Acne  
benzoyl peroxide for, 889  
doxycycline for, 908  
neonatal, 227  
treatment of, 888  
vulgaris, 222–225
- Acne vulgaris, dapsone for, 888
- Acquired bone marrow disorders, neutropenia and, 380t–382t
- Acquired heart disease, 190–202
- Acquired immunodeficiency syndrome (AIDS), 494–498  
vaccine information for, 1t–3t
- Acquired nail disorders, 233
- Acquired toxoplasmosis, 1114, 1147
- ACTH. See Adrenocorticotropin hormone
- Acthar Gel. See Corticotropin
- Acticlate. See Doxycycline
- Actigall. See Ursodiol
- Actiq. See Fentanyl
- Activase. See Alteplase
- Activated charcoal, 67  
contraindications to, 67  
for ingestions, 67–71
- Activated partial thromboplastin time (aPTT), 389
- Activated protein C resistance, 397t
- Activities, HEEADSSS assessment, 118
- Activities of daily living (ADLs), 236
- Acular. See Ketorolac
- Acular LS. See Ketorolac

- Acute abdomen, 319–320, 320t  
Acute abdominal pain, 320t  
Acute agitation, 960, 1062  
Acute ataxia, 579b  
Acute bacterial skin and skin structure infection (ABSSSI), 857  
Acute blood loss, iron and, 979  
Acute chest syndrome, 374t–375t  
Acute diarrhea, treatment for, 1010  
Acute dystonic reactions, benzotropine mesylate for, 828  
Acute Guillain-Barré syndrome, 578  
Acute headache, 580b  
Acute kidney injury (AKI), 560–563  
    clinical presentation of, 562  
    complications for, 563  
    definition of, 560  
    etiology of, 561, 561t  
    radiographic imaging considerations in, 563  
    treatment considerations for, 562–563  
Acute liver failure, 329–331, 331t  
Acute lymphocytic leukemia (ALL), 619t  
Acute maxillary sinusitis, 856, 874  
Acute migraine, 794, 861, 1129, 1193  
Acute myeloid leukemia (AML), 619t  
Acute nephrotic syndrome, 557  
Acute otitis externa, 872  
Acute otitis media, 462t–476t  
    treatment of, 806  
Acute pancreatitis, 333–334, 333t  
Acute paronychia, 233.e1f  
Acute pelvic infection, treatment of, 992  
Acute phase reactants, rheumatologic diseases and, 722–723  
Acute renal failure, 613t–614t  
    in sickle cell disease, 374t–375t  
Acute rheumatic fever (ARF), 721  
Acute sinusitis, azithromycin for, 820  
Acute spinal cord injury, 1029  
Acute tubular necrosis, 562  
Acute viral bronchiolitis, 1140  
Acuvail. *See* Ketorolac  
Acyclovir (Zovirax, Avaclyr), 783, 790, 1175  
    adjustment in kidney failure, 1197t–1203t  
    for herpes simplex virus, 214, 457t–461t  
    neonatal dosing, 527t–528t  
    for oncology patients, 634t–635t  
    for varicella, 457t–461t  
    for VZV, 477t–481t  
Aczone. *See* Dapsone  
Adalat CC. *See* Nifedipine  
Adapalene (Differin), 790–791  
    combination product with, 827  
    formulations and concentrations, 224.e1t  
Adapalene ± benzoyl peroxide (Epiduo, Epiduo Forte), 790  
Adaptive skills, 236, 238t–242t  
Adderall, 766, 791. *See also*  
    Dextroamphetamine + amphetamine  
Adderall XR. *See* Dextroamphetamine + amphetamine  
Addison disease, 276–277  
Adenocard. *See* Adenosine  
Adenoid hypertrophy, 408  
Adenosine (Adenocard), 6t–7t, 766, 791, 901  
Adenotonsillectomy, for obstructive sleep apnea, 683  
Adenovirus infection, 871  
Adhansia XR, 1026. *See also* Methylphenidate HCl  
ADHD. *See* Attention-deficit/hyperactivity disorder  
Adhesives, tissue, for laceration repair, 107–108  
Adjunctive therapy, for tapering, 162–163  
Adjuvants, PCA and, 162  
ADLs. *See* Activities of daily living  
Adolescence, defined, 115  
Adolescent medicine, 115–152  
    confidentiality in, 115.e1–117  
    contraception, 140–149  
    health maintenance, 116–128  
    physical examination, 124–128  
    transitioning into adult care, 150  
    web resources of, 150  
Adolescents, 115  
    advance directives for, 641  
    gastrointestinal bleeding in, 319t  
    health maintenance elements unique to, 116–128  
    HIV infection in, 494  
    pain assessment in, 152  
    psychiatric conditions of  
        anxiety disorders, 654–655  
        attention-deficit/hyperactivity disorder, 650–654  
        depressive and mood disorders, 655–657  
        eating disorders, 657–659  
        oppositional defiant disorder, 654  
        substance use disorders, 659  
    psychosocial development of, 1t  
    sexual health of, 127–150  
    structural factors impacting, health and, 115–116  
    theory of, 115  
    transitioning, into adult care, 150  
    vomiting in, 321t  
Adoxa. *See* Doxycycline  
Adrenal crisis, 275  
Adrenal gland, 272–279  
    diagnosis of, 274, 275t  
    laboratory findings of, 274  
    treatment of, 277–278, 277t  
Adrenal hyperplasia, congenital, 274  
Adrenal insufficiency, 272–278  
    acute, 937, 964  
    diagnosis of, 274, 275t  
    laboratory findings in, 274  
    primary, 274  
    treatment of, 277–278  
Adrenal medulla, 279  
Adrenalin. *See* Epinephrine HCl

- Adrenergic agonist  
 isoproterenol, 982  
 norepinephrine bitartrate, 1058  
 phenylephrine HCl, 1088
- $\alpha_2$ -Adrenergic agonist  
 dexmedetomidine, 8941  
 with PCA, 163
- $\beta_2$ -Adrenergic agonist  
 albuterol, 792  
 levalbuterol, 999  
 salmeterol, 1131  
 terbutaline, 1156
- Adrenocorticotrophic hormone (ACTH), 880.  
*See also* Corticotropin  
 stimulation test, 274, 276b
- Adriamycin, 628t–632t. *See also* Doxorubicin
- Adults, formulas for, 613t–614t
- Advair Diskus. *See* Fluticasone propionate and salmeterol
- Advair HFA. *See* Fluticasone propionate and salmeterol
- Advance directives, 641
- Adverse Childhood Experiences (ACEs), 257–259
- Advil. *See* Ibuprofen
- Advisory Committee on Immunization Practices (ACIP), immunization schedules by, 424
- Adzenys XR-ODT. *See* Amphetamine
- Aerobic bacteria, 499, 499f
- Aerosol inhaler. *See* Albuterol
- Aerosolized medications, for cystic fibrosis, 678
- Aerospan. *See* Flunisolide
- Affordable Care Act, 640
- AFI. *See* Amniotic fluid index
- Afrin 12 Hour. *See* Oxymetazoline
- Agammaglobulinemia, X-linked, 417t
- Ages and Stages Questionnaire (ASQ), 245t
- Aggression, 243t–244t, 660–661  
 diagnosis of, 660–661  
 management of, 661, 662f
- Aging with Dignity, 644, 647
- Agitation  
 acute, 960, 1062  
 definition of, 660  
 management of, algorithm for, 660, 662f  
 medications for palliative care, 645t  
 treatment of, 807
- AIDS. *See* Acquired immunodeficiency syndrome
- AirDuo Digihaler. *See* Fluticasone propionate and salmeterol
- AirDuo RespiClick. *See* Fluticasone propionate and salmeterol
- Airway  
 lower, inflammation, 693  
 Mallampati classification system, 165, 165f  
 normal anatomy of, 690, 690f–691f  
 in procedural sedation, 166
- Airway (*Continued*)  
 radiology for, 690–693  
 supplies, 9–10  
 surgical, 10  
 upper, conditions on conventional radiographs, 691
- Airway clearance therapy, for cystic fibrosis, 678
- Airway disease, reactive, 800, 978
- Airway edema, dexamethasone for, 893
- Airway obstruction, patterns of, 664–665, 665f
- Airway patency, 8
- Airway-pressure-release ventilation (APRV), 14
- AKI. *See* Acute kidney injury
- AK-Poly-Bac Ophthalmic. *See* Bacitracin  $\pm$  polymyxin B
- Alanine aminotransferase (ALT), 329, 330t  
 reference values of, 736t–743t
- Alavert. *See* Loratadine
- Alavert D-12 Hour Allergy and Congestion. *See* Loratadine + pseudoephedrine
- Albuked. *See* Albumin
- Albumin (Albuked, Albumin-ZLB, Albutein, Kedbumin, Albuminar, Buminat, Plasbumin, Normal Serum Albumin), 766, 791–792  
 reference values for, 736t–743t  
 solution, 297t  
 in urine, 744t–745t
- Albuminar. *See* Albumin
- Albumin-ZLB. *See* Albumin
- Albutein. *See* Albumin
- Albuterol (VoSpire ER, ProAir HFA, Proventil HFA, Ventolin HFA, ProAir RespiClick, ProAir Digihaler, AccuNeb), 766, 792–793  
 for allergic emergencies, 19  
 for hyperkalemia, 311f  
 for status asthmaticus, 22t–23t
- Alcaftadine (Lastacaft), 409t–410t
- Alclometasone dipropionate, 230t
- Alcohol, odor, in toxicology, 67.e1t–67.e3t
- Aldactone. *See* Spironolactone
- Aldosterone, 277t
- Aldosteronism, 1142
- Alemtuzumab (Campath), 628t–632t
- Alevazol. *See* Clotrimazole
- Aleve. *See* Naproxen/naproxen sodium
- Alf amino Junior formulas, 611t–614t
- Alimentum, 611t–612t
- Alkalemia, 310  
 metabolic, 310  
 respiratory, 310
- Alkaline phosphatase, 330t  
 reference values for, 736t–743t
- Alkalosis  
 metabolic, 310, 316f  
 respiratory, 310, 316f
- Alkindi Sprinkle. *See* Hydrocortisone
- Alkylator, 628t–632t
- ALL. *See* Acute lymphocytic leukemia

- Allegra. *See* Fexofenadine ± pseudoephedrine  
Allegra-D 12 Hour. *See* Fexofenadine ± pseudoephedrine  
Allegra-D 24 Hour. *See* Fexofenadine ± pseudoephedrine  
Allergen, 413  
Allergen-specific IgE, 412  
Allergic bronchopulmonary aspergillosis (ABPA), in cystic fibrosis, 680  
Allergic conjunctivitis, seasonal, treatment for, 989  
Allergic dermatitis, 228  
Allergic dermatologic conditions, 228–233  
Allergic enteropathy, diarrhea vs., 328t  
Allergic eosinophilic gastroenteritis, 412  
Allergic lesions, 235.e1  
Allergic reactions  
    to drugs, 414  
    to foods, 414  
    severe, diphenhydramine for, 839, 904  
Allergic rhinitis (AR), 408–410  
    nasal inhalation for, 825  
    perennial, 408  
    seasonal, 408, 819–820  
    treatment of, 825, 1042, 1064  
"Allergic salute", 408  
Allergy, 408–422  
Allergy Relief-D. *See* Loratadine + pseudoephedrine  
Allogeneic hematopoietic stem cell transplantation, 635–636  
Alloimmune thrombocytopenia, neonatal (NAIT), 387  
Allopurinol (Zyloprim, Alopim), 763, 766, 793–794, 1160  
    adjustment in kidney failure, 1203t–1208t  
    for hyperuricemia, 625  
Almacone Antacid Antigas. *See* Aluminum hydroxide with magnesium hydroxide  
Almacone Double Strength. *See* Aluminum hydroxide with magnesium hydroxide  
Almotriptan malate (Axert), 794  
Alomide. *See* Lodoxamide  
Alopecia, treatment of, 886  
Alopecia areata, 222  
Aloprim. *See* Allopurinol  
α (Alpha), 751  
Alprostadil (Prostin VR Pediatric), 778–779, 794  
ALT. *See* Alanine aminotransferase  
ALTE. *See* Apparent life-threatening event  
Alteplase (Activase, Cathflo Activase), 766, 769, 795–796  
Altered immunocompetence, 437–445  
Altered level of consciousness  
    definition of, 28–30  
    emergency management of, 28–31  
    management of, 30–31  
Altered mental status, 574  
Altreno. *See* Tretinoin; topical preparations  
Alu-Cap. *See* Aluminum hydroxide  
Aluminum hydroxide (AlternaGEL, Alu-Cap, Amphojel, Dialume), 766–767, 796–797  
Aluminum hydroxide with magnesium hydroxide (Maalox, Maalox Maximum Strength Liquid, Mintox, Mylanta, Mylanta Maximum Strength, RuLox Plus, Almacone, Almacone Antacid Antigas, Almacone Double Strength), 766, 775, 796  
Aluminum/magnesium hydroxide/simethicone, 159t  
Alvesco. *See* Ciclesonide  
Amantadine hydrochloride (Symmetrel, Gocovri, Osmolex ER), 781, 797–798  
    adjustment in kidney failure, 1197t–1203t  
Ambiguous genitalia, 287–291  
AmBisome. *See* Amphotericin B; liposomal  
Amcinonide, 230t  
Amebiasis, 1032  
    intestinal, paromomycin sulfate for, 1032  
Amebicide  
    chloroquine phosphate, 864–865  
    paromomycin sulfate, 773, 1078  
Amenorrhea, 287, 1019  
    lactational, 141f  
American Academy of Hospice and Palliative Medicine, 647  
American Academy of Pediatrics (AAP), 163–164, 356  
    immunization schedules by, 424  
    recommendations for prevention of obesity, 595  
American Association of Poison Control Centers, 66  
American Diabetes Association, 264t, 293  
American Heart Association (AHA), Pediatric Advanced Life Support (PALS), 37  
American Society of Anesthesiologists (ASA), 163–164  
    Physical Status Classification, 165, 166t  
American trypanosomiasis, 485t–487t  
Americans with Disabilities Act (ADA), 255  
Amicar. *See* Aminocaproic acid  
Amidate. *See* Etomidate  
Amikacin sulfate (Amikin), 767, 798–799  
    adjustment in kidney failure, 1197t–1203t  
Amikin. *See* Amikacin sulfate  
Amiloride, 549t–550t  
Amino acid, in formulas, 611t–612t  
Amino acid 8.5% (Travasol), 297t  
Amino acid-based formulas, components of, 297t  
Aminoacidopathies, 341t–342t  
    γ-aminobutyric acid (GABA) receptor mutations, 345t  
Aminocaproic acid (Amicar), 767, 799–800  
    adjustment in kidney failure, 1203t–1208t  
Aminoglycoside  
    amikacin sulfate, 798–799  
    gentamicin, 953–954

- Aminoglycoside (*Continued*)  
 neomycin sulfate, 1049–1050  
 paromomycin sulfate, 1078  
 streptomycin sulfate, 1143  
 tobramycin, 1163–1164
- Aminopenicillin  
 amoxicillin, 804–805  
 amoxicillin-clavulanic acid, 805–806  
 ampicillin, 810  
 ampicillin/sulbactam, 811
- Aminophylline, 800–801  
 for status asthmaticus, 22t–23t
- Amiodarone HCl (Cordarone, Pacerone, Nexterone), 6t–7t, 769, 801–802
- Amitriptyline (Elavil), 771, 802–803  
 for migraine, 584.e1t
- AML. *See* Acute myeloid leukemia
- Amlodipine (Norvasc, Norliqva, Katerzia), 776, 803–804  
 for hypertension, 549t–550t
- Ammonia, 330t  
 reference values for, 736t–743t
- Ammonium detoxicant  
 lactulose, 992–993  
 neomycin sulfate, 1049–1050
- Ammonul, 804, 1140. *See also* Sodium phenylacetate and sodium benzoate for metabolic disease, 345–346
- Amnesteem. *See* Isotretinoin
- Amniocentesis, 528.e1
- Amniotic fluid index (AFI), 528.e1, 528.e2b
- Amniotic fluid volume, 528.e1, 528.e2b
- Amoclan. *See* Amoxicillin-clavulanic acid
- Amoxicillin (Amoxil, Polymox, Trimox, Wymox, Moxatag), 767, 771, 804–805  
 for acute otitis media, 462t–476t  
 adjustment in kidney failure, 1197t–1203t  
 combined with metronidazole, 858  
 for Lyme disease, 482t–484t  
 for strep pharyngitis, 462t–476t
- Amoxicillin + clarithromycin, for *Helicobacter pylori*, 462t–476t
- Amoxicillin + metronidazole, for *Helicobacter pylori*, 462t–476t
- Amoxicillin-clavulanic acid (Augmentin), 767, 805–806  
 for acute otitis media, 462t–476t  
 adjustment in kidney failure, 1197t–1203t  
 for animal/human bites, 462t–476t  
 for cervical lymphadenitis, 462t–476t  
 for preseptal cellulitis, 462t–476t  
 for sinusitis, 462t–476t
- Amoxil. *See* Amoxicillin
- AmpC beta-lactamase-producing organisms, resistance in, 502.e2
- Amphadase. *See* Hyaluronidase
- Amphetamine (Evekeo, Evekeo ODT, Adzenys XR-ODT, Dyanavel XR), 806–807  
 overdose, 69t–70t
- Amphocin. *See* Amphotericin B
- Amphojel. *See* Aluminum hydroxide
- Amphotericin B (Amphocin), 766–767  
 adjustment in kidney failure, 1197t–1203t  
 liposomal (AmBisome), 767, 809–810
- Amphotericin B deoxycholate (Fungizone), 807–808
- Amphotericin B lipid complex (Abelcet), 766, 808–809
- Ampicillin (Omnipen, Principen, Totacillin), 777, 810–811  
 adjustment in kidney failure, 1197t–1203t  
 for community-acquired pneumonia, 462t–476t  
 for group B streptococcal (GBS) disease, 457t–461t  
 neonatal dosing, 527t–528t
- Ampicillin + cefotaxime, for meningitis, 462t–476t
- Ampicillin + gentamicin, for fever in infant, 457t–461t
- Ampicillin/sulbactam (Unasyn), 782, 811–812  
 adjustment in kidney failure, 1197t–1203t  
 for Ludwig angina, 462t–476t  
 for orbital cellulitis, 462t–476t  
 for peritonsillar abscess, 462t–476t  
 for retropharyngeal/parapharyngeal abscess, 462t–476t
- Amylase, reference values for, 736t–743t
- Amzeeq. *See* Minocycline
- ANA. *See* Antinuclear autoantibodies
- Anacin. *See* Aspirin
- Anacin Aspirin Free. *See* Acetaminophen
- Anaerobic bacteria, 499, 501f
- Anakinra, for pediatric rheumatology, 726t–730t
- Anal intercourse, receptive, screening guidelines by, 129
- Analgesia, 75, 154–161, 861, 964  
 acetaminophen, 785–786, 1072–1073  
 aspirin, 814–815, 1073–1074  
 for burn, 60  
 butorphanol, 836–837  
 carbamide peroxide, 846–847  
 fentanyl, 932–933  
 hydromorphone HCl, 770, 964–965  
 lidocaine and prilocaine, 1004–1005  
 local anesthetics, 158, 159t  
 medications to avoid in children, 154–156  
 methadone HCl, 1024–1025  
 morphine sulfate, 1043–1044  
 nonopioid, 156  
 nonpharmacologic measures of pain relief and, 158–161  
 opioids and, 156–158, 157t  
 oxycodone, 1071–1072  
 oxycodone and acetaminophen, 1072–1073  
 for pancreatitis, 334  
 patient-controlled, 161–162  
 phenazopyridine HCl, 1086–1087  
 procedural sedation, example protocols, 171t  
 protocols of, 170.e1t

- Analgesia (*Continued*)  
topical oral, 846–847  
web resources, 171
- Analysis of variance (ANOVA)  
Kruskal-Wallis, 750t  
one-way (F test), 750t  
two-way, 750t
- Anaphylaxis  
emergency management of, 19–20  
treatment of, 413
- Anaplasmosis, 477t–481t
- Anaprox DS. *See* Naproxen/naproxen sodium
- ANCA. *See* Antineutrophil cytoplasmic antibodies
- ANCA-cytoplasmic/PR3 (proteinase-3), 724t
- ANCA-perinuclear/MPO (myeloperoxidase), 724t
- Ancef. *See* Cefazolin
- Ancobon. *See* Flucytosine
- Androstenedione, 291.e2t
- Anectine. *See* Succinylcholine
- Anemia, 365–378  
aplastic, 368t–369t  
causes of, 365, 366f, 368t–370t  
in chemotherapy patients, 633  
of chronic disease, 368t–369t  
chronic kidney disease and, 565t  
Cooley, 376  
definition of, 365, 406t  
Diamond-Blackfan, 368t–369t  
evaluation of, 365–373  
Fanconi, 368t–369t  
hemolytic, 365, 406t  
nonhemolytic, 365  
pernicious, 882  
of prematurity, 918  
screening for, 365  
sickle cell, 369t–370t  
treatment of  
in cancer, 919  
in chronic renal failure, 919  
darbepoetin alfa for, 889–890
- Anesthetics  
fasting recommendations for, 164t  
inhaled, for status asthmaticus, 22t–23t  
local, 158  
injectable, 158, 160t  
topical, 158, 159t  
toxicity of, 158, 160f
- Aneuploidy, 356–357
- Angelman syndrome, 359
- Angina, treatment for, 1055
- Angioedema  
food allergy, 411  
non-anaphylactic, 413
- Angiotensin-converting enzyme (ACE)  
inhibitors  
captopril, 844–845  
enalapril maleate, 912–913  
for hypertension, 549t–550t  
lisinopril, 1008–1009
- Angiotensin-II receptor blocker (ARB)  
for hypertension, 549t–550t  
losartan, 1013–1014  
valsartan, 1178–1179
- Angiotensin-receptor blockers, 549t–550t
- Animal bites, 55–56, 462t–476t  
antibiotic prophylaxis, 55  
decision to suture, 56  
high infection risk, 55  
imaging of, 56  
physical exam assessment of, 56  
rabies postexposure prophylaxis, 55  
tetanus postexposure prophylaxis, 55
- Anion gap (AG)  
calculation of, 310–311  
metabolic acidosis, 311–312  
nonelevated anion gap metabolic acidosis, 311–312
- Anion gap metabolic acidosis (AGMA), in toxicology, 67.e1t–67.e3t
- Ankle stirrup splint, 98f, 99–100
- Ankylosing spondylitis, treatment of, 927, 1049
- Annular lesions, 210
- Anogenital warts, 136t–138t
- Anorchia, 291
- Anorexia nervosa, 657
- ANOVA. *See* Analysis of variance
- Antacids  
aluminum hydroxide, 796–797  
with magnesium hydroxide, 796–797  
calcium carbonate (Tums, Children's Pepto), 839–840  
magnesium hydroxide, 796–797
- Anterior humeral line, 704
- Anthracyclines, chemotherapeutic agents, 628t–632t
- Anthrax  
doxycycline for, 908  
inhaled, penicillin G for, 1082–1083  
post exposure prophylaxis against, 1083
- Antiarrhythmics  
adenosine, 791  
amiodarone HCl, 801–802  
digoxin, 901  
esmolol HCl, 925  
flecainide acetate, 935–936  
lidocaine, 1003–1004  
metoprolol, 1031–1032  
phenytoin, 949–950  
propranolol, 1089–1090  
quinidine, 1116–1117
- Antibiotic resistance, 502.e1
- Antibiotics  
for acne vulgaris, 223t, 224, 224.e2t  
amikacin sulfate, 798–799  
amoxicillin, 804–805  
amoxicillin-clavulanic acid, 805–806  
ampicillin, 810  
ampicillin/sulbactam, 811  
azithromycin, 820–821  
aztreonam, 822  
bacitracin ± polymyxin B, 822–823

Antibiotics (*Continued*)

cefaclor, 849–850  
 cefadroxil, 850  
 cefazolin, 850–851  
 cefdinir, 851  
 cefepime, 851–852  
 cefiderocol, 852–853  
 cefixime, 853  
 cefotaxime, 853–854  
 cefotetan, 854–855  
 ceftazidime, 855  
 ceftazidime proxetil, 855–856  
 ceftazidime with avibactam, 858  
 ceftazidime with avibactam, 858  
 ceftazidime with avibactam, 858–859  
 ceftazidime with avibactam, 858  
 ceftazidime with avibactam, 858–859  
 ceftriaxone, 859–860  
 cefuroxime, 860–861  
 cephalixin, 862  
 chemotherapeutic agents, 628t–632t  
 chloramphenicol, 864  
 chronic, for cystic fibrosis, 678  
 ciprofloxacin, 871–873  
 clarithromycin, 874–875  
 clindamycin, 875–876  
 dapson, 888–889  
 doxycycline, 908  
 ertapenem, 922  
 erythromycin, 922–924  
 fidaxomicin, 934  
 gatifloxacin, 953  
 gentamicin, 953–954  
 imipenem and cilastatin, 968–969  
 levofloxacin, 1001–1002  
 linezolid, 1006–1007  
 meropenem, 1020–1021  
 metronidazole, 1032–1033  
 minocycline, 1038–1039  
 mupirocin, 1044  
 nafcillin, 1046–1047  
 neomycin sulfate, 1049–1050  
 neomycin/polymyxin B + bacitracin,  
 1050–1051  
 nitrofurantoin, 1056  
 ofloxacin, 1061  
 oxacillin, 1068–1069  
 paromomycin sulfate, 1078  
 penicillin G benzathine, 1081–1082  
 penicillin G benzathine and penicillin G  
 procaine, 1081–1082  
 penicillin G preparations-aqueous  
 potassium and sodium,  
 1080–1081  
 penicillin G procaine, 1081–1082  
 penicillin V potassium, 1083  
 pentamidine isethionate, 1084  
 piperacillin with tazobactam, 1093–1094  
 polymyxin B sulfate, neomycin sulfate,  
 hydrocortisone otic, 1096–1097  
 polymyxin B sulfate and trimethoprim  
 sulfate, 1096

Antibiotics (*Continued*)

prophylaxis, 55  
 quinupristin and dalfopristin, 1117–1118  
 rifampin, 1123–1124  
 rifaximin, 1124–1125  
 silver sulfadiazine, 1136–1137  
 stewardship, 502.e1  
 streptomycin sulfate, 1143  
 sulfacetamide sodium ophthalmic,  
 1146–1147  
 sulfadiazine, 1147  
 sulfamethoxazole and trimethoprim, 1148  
 tetracycline HCl, 1157  
 tobramycin, 1163–1165  
 vancomycin, 1179–1181

Antibodies, 491f  
 Antibody deficiency  
 evaluation for, 417t  
 replacement therapy for, 416, 419  
 severe, vaccine information for, 1t–3t  
 Antibody-deficient disorders, replacement  
 therapy for, 971  
 Anti-CCP. *See* Anticyclic citrullinated peptide  
 antibodies  
 Anti-centromere antibodies, 723, 724t  
 Anticholinergics  
 atropine sulfate, 817–818  
 benzotropine mesylate, 827–828  
 cyclopentolate, 882  
 glycopyrrolate, 956  
 ipratropium bromide ± albuterol, 976–978  
 oxybutynin chloride, 1071  
 scopolamine hydrobromide, 1132–1133  
 tiotropium, 1162–1163  
 toxicology with, 69t–70t  
 Anticholinesterase overdose, 69t–70t  
 Anticoagulants  
 dabigatran etexilate mesylate, 885–886  
 enoxaparin, 913–915  
 heparin sodium, 960–961  
 rivaroxaban, 1127–1129  
 warfarin, 1189–1191  
 Anticoagulation, empiric dosage for, 960  
 Anticonvulsants  
 cannabidiol, 843  
 carbamazepine, 844–845  
 clobazam, 876–877  
 clonazepam, 877–878  
 diazepam, 898–900  
 divalproex sodium, 905  
 ethosuximide, 928–929  
 felbamate, 931–933  
 fosphenytoin, 949–950  
 gabapentin, 951–952  
 lacosamide, 989–990  
 lamotrigine, 993–998  
 levetiracetam, 999–1001  
 lorazepam, 1012  
 oxcarbazepine, 1069–1070  
 phenytoin, 1089–1090  
 primidone, 1104  
 rufinamide, 1130–1131

Anticonvulsants (*Continued*)

tiagabine, 1161–1162  
topiramate, 1166–1167  
valproic acid, 1177–1178  
vigabatrin, 1184–1185  
zonisamide, 1194–1195

Anticyclic citrullinated peptide antibodies (anti-CCP), rheumatologic diseases and, 723

## Antidepressants

escitalopram, 924–925  
fluoxetine hydrochloride, 940–941  
fluvoxamine, 946  
for migraine, 584.e1t  
sertraline HCl, 1134–1135  
trazodone, 1167–1168

Anti-DNA antibody, 724t

Antidopaminergics, for migraine, 581

Antidotes, 67–71

Anti-dsDNA (double-stranded DNA), 723, 724t

## Antiemetic therapy, 634t

chlorpromazine, 8666–867  
dimenhydrinate, 903–904  
dolasetron, 906–907  
dronabinol, 909  
droperidol, 909–910  
granisetron, 956–957  
hydroxyzine, 965–966  
metoclopramide, 1030  
ondansetron, 1065–1067  
prochlorperazine, 1105  
promethazine, 1106  
trimethobenzamide HCl, 1173

Antifibrinolytic therapy, for von Willebrand (vW) disease, 396

## Antifungal agent

amphotericin B, liposomal, 809–810  
amphotericin B deoxycholate, 807–808  
amphotericin B lipid complex, 808–809  
casposfungin, 848–849  
clotrimazole, 879  
fluconazole, 936–937  
flucytosine, 937  
griseofulvin, 957–958  
itraconazole, 983–984  
ketoconazole, 987–988  
micafungin sodium, 1033–1034  
miconazole, 1034–1035  
nystatin, 1059–1060  
posaconazole, 1097–1098  
terbinafine, 1155–1156  
tolnaftate, 1165  
voriconazole, 1187–1189

## Antihistamines

azelastine, 819  
azelastine and fluticasone, 819–820  
brompheniramine with phenylephrine, 832–833  
carbinoxamine, 846–847  
cetirizine ± pseudoephedrine, 863  
chlorpheniramine maleate, 866

Antihistamines (*Continued*)

cyproheptadine, 884–885  
dimenhydrinate, 903–904  
diphenhydramine, 904  
fexofenadine ± pseudoephedrine, 933–934  
intranasal, 409t–410t  
loratadine ± pseudoephedrine, 1011–1012  
for migraine, 584.e1t  
olopatadine, 1063–1064  
oral, 409t–410t  
for atopic dermatitis (eczema), 229  
poisoning with, 69t–70t  
promethazine, 1106  
sedating, properties of, 167b–168b

Antihistone, 724t

Antihypertensive drugs, 549t–550t

amlodipine, 803–804  
carvedilol, 847–848  
clonidine, 878–879  
diltiazem, 902–903  
enalapril maleate, 912–913  
esmolol HCl, 925  
hydralazine hydrochloride, 962  
labetalol, 991–992  
lisinopril, 1008–1009  
minoxidil, 1039–1040  
nicardipine, 1054–1055  
nifedipine, 1055–1056  
nitroglycerin, 1056–1058  
nitroprusside, 1058  
valsartan, 1178–1179

Antiinflammatory agents

corticotropin, 880  
cortisone acetate, 880  
hydrocortisone, 963–964  
methylprednisolone, 1029–1030

Anti-Jo-1, 724t

Anti-La/SS-B, 724t

Antilirium. *See* Physostigmine salicylate

Antimalarial drugs

chloroquine phosphate, 864–865  
hydroxychloroquine sulfate, 965  
mefloquine HCl, 1019–1020  
primaquine phosphate, 1103  
quinidine, 1116–1117

Antimicrobials

neutropenia and, 380t–382t  
prophylaxis, in oncology patients, 634t–635t

Antimigraine agent

almotriptan malate, 794  
rizatriptan benzoate, 1229  
sumatriptan succinate, 1149–1151  
zolmitriptan, 1193–1194

Antineutrophil cytoplasmic antibodies (ANCA), rheumatologic diseases and, 723

Antinuclear autoantibodies (ANA), 723  
in SLE, 724t

Antiphospholipid antibodies, 397t

Antiprogestins, 148

- Antiprotozoals  
  atovaquone, 816–817  
  metronidazole, 1032–1033  
  pentamidine isethionate, 1084
- Antipsychotics, 634t  
  aripiprazole, 812–813  
  chlorpromazine, 866–867  
  haloperidol, 959–960  
  neutropenia and, 380t–382t  
  olanzapine, 1061–1062  
  quetiapine, 1114–1115  
  risperidone, 1126–1127  
  thioridazine, 1161
- Antipyrine and benzocaine (Allergen Ear  
  Drops, Antipyrine and benzocaine  
  Otic, Auralgan), 766–767, 811
- Antirheumatic drugs  
  etanercept, 926–927  
  hydroxychloroquine sulfate, 965
- Anti-RNP, 724t
- Anti-Ro/SS-A, 724t
- Anti-Scl-70, 723, 724t
- Antiseizure medications, 575t–576t  
  for migraine, 584.e1t
- Anti-Smith antibody, 724t
- Antistreptolysin O titer, 736t–743t
- Antithrombin III deficiency, 397t
- Antituberculous agent  
  isoniazid, 981–982  
  pyrazinamide, 1111  
  rifabutin, 1122–1123  
  rifampin, 1123–1124  
  streptomycin sulfate, 1143
- Antitumor necrosis factor-alpha agents (anti-  
  TNF- $\alpha$ ), for pediatric rheumatology,  
  726t–730t
- Antivirals  
  acyclovir, 788–789  
  amantadine hydrochloride, 797–798  
  baloxavir marboxil, 824–825  
  cidofovir, 870–871  
  famciclovir, 929–930  
  foscarnet, 948–949  
  ganciclovir, 952  
  lamivudine, 992–993  
  nevirapine, 1052–1053  
  oseltamivir phosphate, 1067–1068  
  ribavirin, 1120–1121  
  rimantadine, 1125–1126  
  trifluridine, 1172–1173  
  valacyclovir, 1174–1175  
  valganciclovir, 1175–1176  
  zidovudine, 1191–1192
- Antizol. *See* Fomepizole
- Anuria, 1031
- Anxiety  
  disorders of  
    diagnosis of, 654  
    epidemiology of, 655  
    evaluation of, 655  
    management of, 650t, 655, 656f  
    treatment of, 924
- Anxiety (*Continued*)  
  screening for, 245t, 649t  
  separation, 243t–244t  
  stranger, 243t–244t  
  treatment of, 966
- Anxiolysis, 163
- Anxiolytics  
  diazepam, 898–899  
  hydroxyzine, 965–966
- Anzemet. *See* Dolasetron
- Aortic arch variants, radiology for, 693
- Aortic dissection, 44
- Aortic stenosis (AS), 191t–192t
- Apgar scores, 506, 507t
- Apixaban, 398t–399t
- Aplastic crisis, 374t–375t
- Apnea  
  definition of, 514  
  etiology of, 514, 515f  
  in newborns, 514–515, 515f  
  obstructive sleep, 681–683  
    clinical presentation of, 682  
    daytime symptoms of, 682  
    definition of, 681  
    diagnosis of, 682–683  
    long-term complications of, 682  
    nighttime symptoms of, 682  
    polysomnography criteria for,  
      682–683  
    risk factors for, 682  
    symptoms and signs of, 682b  
    treatment of, 683  
  of prematurity, 514
- Apparent life-threatening event (ALTE), 684
- Appendicitis, 462t–476t  
  imaging for, 701  
  piperacillin with tazobactam for,  
  1093–1094
- Appetite stimulation, 885
- Apple juice, 299t
- Aprepitant, 634t
- Apriso. *See* Mesalamine
- Aptensio XR, 1026–1027
- Aptiom. *See* Eslicarbazepine acetate
- Aquasol A. *See* Vitamin A
- Aqueous penicillin, 1081–1082
- Aqueous Vitamin E. *See* Vitamin E
- Aralen. *See* Chloroquine phosphate
- Aranesp. *See* Darbepoetin alfa
- Arazlo. *See* Tazarotene
- Arbinox. *See* Carbinoxamine
- ARF. *See* Acute rheumatic fever
- Arginine hydrochloride, 811–812  
  injectable preparation (R-Gen 10),  
  811–812  
  for MELAS stroke-like episode, 346
- 8-Arginine Vasopressin. *See* Vasopressin
- ARI. *See* Absolute risk increase
- Aripiprazole (Abilify, Abilify Maintena, Abilify  
  MyCite), 812–813
- Aristospan. *See* Triamcinolone
- Arm recoil, 507, 507.e1f

- ArmonAir Digihaler. *See* Fluticasone propionate
- Arnuity Ellipta. *See* Fluticasone furoate
- ARR. *See* Absolute risk reduction
- Array CGH, 350t–351t
- Artemether, for malaria, 462t–476t
- Arterial blood gas (ABG), 663  
reference values for, 736t–743t
- Arterial blood pressure, 506
- Arterial catheter, umbilical, 88
- Arterial switch, 204t
- Artesunate, for malaria, 462t–476t
- Arthritis  
rheumatoid, treatment of, 927  
septic, 462t–476t  
vancomycin for, 1179–1181
- Arthrocentesis, knee, 101
- As treated analysis, 747
- ASA. *See* American Society of Anesthesiologists
- Asacol HD. *See* Mesalamine
- Ascaris*  
mebendazole for, 1018  
pyrantel pamoate for, 1110–1111
- Asceniv, preparations for, 970
- Ascorbic acid (Cecon, Sunkist Vitamin C, vitamin C), 769, 781, 783, 813–814  
recommended intakes, 603t–604t
- Ask Suicide-Screening Questions (ASQ), 659
- Ask-Tell-Ask method, 642
- Asmanex. *See* Mometasone furoate
- Asparaginase, 628t–632t
- Aspartate aminotransferase (AST), 329, 330t, 736t–743t
- Aspergillosis, 488t–490t  
allergic bronchopulmonary, in cystic fibrosis, 680  
invasive, 1034, 1098  
itraconazole for, 983–984  
voriconazole for, 1187–1189
- Aspergillus*, prophylaxis for, 983
- Aspiration  
foreign body, 21–22  
suprapubic bladder, 94–96
- Aspirin (ASA, Anacin, Bufferin, ZORprin), 767, 771, 778, 783, 814–815  
adjustment in kidney failure, 1203t–1208t  
analgesic properties of, 156  
for Kawasaki disease, 199–200, 200.e1t
- Asplenia, vaccine information for, 1t–3t
- ASQ. *See* Ask Suicide-Screening Questions
- Assessment  
newborn, 506–508  
pain, 151–154  
tools for, 237
- AST. *See* Aspartate aminotransferase
- Astagraf XL. *See* Tacrolimus
- Astelin. *See* Azelastine
- Astepro. *See* Azelastine
- Asthma, 666–676, 800, 825  
acute, prednisone for, 1102–1103  
beclomethasone dipropionate for, 825–826  
budesonide and formoterol for, 835–836  
clinical presentation of, 667  
definition of, 666–667  
exacerbations  
aminophylline for, 800  
dexamethasone for, 893–894  
prevention of, 668–676  
therapy for, 1102  
guidelines for, 668f–670f  
obstructive pattern seen in, 665f  
spirometry and lung volume readings in, 666t  
stepwise approach for, 671f–672f, 674f  
treatment of, 667–668, 944
- Asthmanefrin. *See* Epinephrine; racemic
- Asymptomatic bacteriuria, 552
- Asystole, treatment of, 840, 916
- Ataxia, 578  
acute, 579b  
in toxicology, 67.e1t–67.e3t
- Atenolol (Tenormin), 781, 815–816  
adjustment in kidney failure, 1203t–1208t  
for hypertension, 549t–550t
- Ativan. *See* Lorazepam
- ATNAA. *See* Pralidoxime chloride + atropine
- Atomoxetine (Strattera), 652t–653t, 781, 815–816
- Atopic dermatitis (eczema), 229–231  
with allergic rhinitis, 408  
food allergy, 411–412  
pimecrolimus for, 1093  
treatment of, 413
- Atovaquone (Mepron), 775, 816–817  
for oncology patients, 634t–635t
- Atovaquone-proguanil, for malaria, 462t–476t
- Atralin. *See* Tretinoin; topical preparations
- Atrial enlargement, 180, 181f
- Atrial fibrillation, 182t–183t
- Atrial flutter, 182t–183t
- Atrial septal defect (ASD), 191t–192t
- Atrioventricular septal defects, 191t–192t
- AtroPen. *See* Atropine sulfate
- Atropine, 6t–7t  
ketazolam (ketamine + midazolam + atropine), 171t  
for procedural sedation, 171t
- Atropine sulfate (AtroPen, Isopto Atropine, Sal-Tropine), 767, 780, 817–818
- Atrovent HFA. *See* Ipratropium bromide
- Attention-deficit/hyperactivity disorder (ADHD), 208, 650–654  
diagnosis of, 650–651  
epidemiology of, 651  
evaluation of, 651  
guanfacine for, 958–959  
management of, 650t, 651–654, 652t–653t  
Medication Guide, 651

- Attention-deficit/hyperactivity disorder (ADHD)  
(*Continued*)  
  screening for, 245t, 649t  
  treatment for, 806, 1026
- Atypical HUS, 387
- Augmentative and Alternative Communication, 250.e4t
- Augmentin. *See* Amoxicillin-clavulanic acid
- Augmentin ES-600. *See* Amoxicillin-clavulanic acid
- Aura, 581  
  acute migraine with, 794
- Auralgan. *See* Antipyrine and benzocaine
- Auraphene-B. *See* Carbamide peroxide
- Auro Ear Drops. *See* Carbamide peroxide
- Autism, 252–254  
  screening tests, 245t  
  treatment of, 924
- Autism speaks, 260
- Autism spectrum disorders (ASDs), 252–254  
  definition of, 252–253  
  diagnosis of, 253  
  epidemiology of, 252–253  
  interventions/treatment for, 253–254  
  screening for, 245t, 253
- Autistic disorder, 252
- Autoantibodies  
  diabetes, 263  
  rheumatologic diseases and, 723, 724t
- Autoeczematization reaction. *See* Id reaction
- Autoimmune dermatologic conditions, 228–233
- Autoimmune lesions, 235.e1
- Autologous hematopoietic stem cell transplantation, 636
- Autopsies, 646
- Auvi-Q. *See* Epinephrine HCl
- Avaclyr. *See* Acyclovir
- Avascular necrosis, in sickle cell disease, 374t–375t
- Avinza. *See* Morphine sulfate
- Avita. *See* Tretinoin; topical preparations
- AVPU mnemonic, 29
- Avulsion, 48–51  
  fractures, 48
- Avycaz. *See* Ceftazidime with avibactam
- Axert. *See* Almotriptan malate
- Axial contrast-enhanced computed tomography (CT), of neck and airway, 690.e1f
- Ayr Nasal Mist Allergy/Sinus. *See* Sodium chloride
- Ayr Saline. *See* Sodium chloride
- Azactam. *See* Aztreonam
- Azasan. *See* Azathioprine
- AzaSite. *See* Azithromycin
- Azathioprine (Imuran, Azasan), 768, 773, 818–819  
  adjustment in kidney failure, 1203t–1208t  
  for pediatric rheumatology, 726t–730t
- Azelaic acid, for acne vulgaris, 224
- Azelastine (Astelin, Astepro, Optivar), 767, 771, 777, 819  
  for allergic rhinitis, 409t–410t
- Azelastine and fluticasone (Dymista), 771, 819–820
- Azithromycin, oral, for neonatal exudative conjunctivitis, 457t–461t
- Azithromycin (AzaSite, Zithromax, Zithromax TRI-PAK, Zithromax Z-PAK, Zmax), 768, 783, 820–821  
  for cervical lymphadenitis, 462t–476t  
  for chancroid, 136t–138t  
  for chlamydia, 130t–134t  
  for gastroenteritis, 462t–476t  
  for gonorrhea, 130t–134t  
  for pertussis, 462t–476t  
  for strep pharyngitis, 462t–476t
- Azo-Urinary Pain Relief. *See* Phenazopyridine HCl
- Azo-Urinary Pain Relief Maximum Strength. *See* Phenazopyridine HCl
- AZT. *See* Zidovudine
- Aztreonam (Azactam, Cayston), 768–769, 822–823  
  adjustment in kidney failure, 1197t–1203t
- Azulfidine. *See* Sulfasalazine
- Azulfidine EN-tabs. *See* Sulfasalazine
- B**
- B lymphocyte, vaccine information for, 1t–3t
- B6-dependent seizures, 345t
- Bacille Calmette-Guérin (BCG), 424
- Bacitracin (AK-Tracin Ophthalmic, Baciguent Topical), 766, 768, 776
- Bacitracin ± polymyxin B (AK-Poly-Bac Ophthalmic, Polycin, Double Antibiotic Topical, Polysporin Topical), 766, 822–823
- Baclofen (Lioresal, Gablofen, Lyvispah, Ozobax, Fleqsuvy, Kemstro), 772, 774, 823–824
- Bacteremia  
  treatment for, 1006  
  vancomycin for, 1179–1180
- Bacteria  
  aerobic, 499, 499f  
  anaerobic, 499, 501f  
  neutropenia and, 380t–382t
- Bacterial endocarditis prophylaxis, 832, 851, 860, 874
- Bacterial infection, of skin, 220–221
- Bacterial overgrowth, small bowel, diarrhea vs., 328t
- Bacterial pneumonia, community-acquired (CABP), 857
- Bacterial skin and skin structure infection, acute (ABSSSI), 857
- Bacterial superinfection, 231
- Bacterial vaginosis  
  diagnostic features of, 134t–136t

- Bacterial vaginosis (*Continued*)  
management of, 134t–136t  
treatment of, 875, 1032
- Bactrim. *See* Sulfamethoxazole and trimethoprim
- Bactrim DS. *See* Sulfamethoxazole and trimethoprim
- Bactroban. *See* Mupirocin
- Bad news, breaking, 641–642
- Bag or absorbent pad, for urine collection, 550
- Bag-mask ventilation, 91–92
- Ballard score, 507
- Baloxavir, for influenza, 477t–481t
- Baloxavir marboxil (Xofluza), 824–825
- Bandemia, 372
- Banzel. *See* Rufinamide
- Baqsimi. *See* Glucagon HCl
- Barbiturates, 169t  
pentobarbital, 1084–1085  
phenobarbital, 1086–1087  
primidone, 1104  
properties of, 167b–168b
- Baricitinib, for pediatric rheumatology, 726t–730t
- Barrier methods, 147
- Basophilia, causes of, 384
- Basophilic stippling, 372, 373.e1f
- Bayes nomogram, 755, 756f
- BCG. *See* Bacille Calmette-Guérin
- Becker muscular dystrophy (BMD), 590–591
- Beclomethasone dipropionate (QVAR)  
Redihaler, Beconase AQ, Qnasl  
Children's, Qnasl), 768, 779,  
825–826  
estimated comparative daily dosages for,  
3t–4t
- Beconase AQ. *See* Beclomethasone dipropionate
- BECTS. *See* Benign epilepsy with centrotemporal spikes
- Bedside chronic kidney disease in children (CKiD) cohort, 532
- Behavior  
age-appropriate issues, 243t–244t  
guidelines for, 237  
screening for problems, 245t
- Behavioral history, 246t–247t
- Behavioral modifications, for constipation, 326
- Behavioral response, of infant, in pain  
assessment, 151, 153t
- Behcet disease, 711t–713t
- Bell's staging system, for necrotizing enterocolitis, 519.e1t
- Benadryl. *See* Diphenhydramine
- Benazepril, 549t–550t
- Beneprotein, calories of, 610t
- Benign epilepsy with centrotemporal spikes (BECTS), 587t–589t
- Benign ethnic neutropenia, 380t–382t
- Benign heart murmurs, 173
- Benzathine penicillin G (Bicillin L-A), 1081  
for strep pharyngitis, 462t–476t  
for syphilis, 130t–134t
- Benzodiazepines, 169t, 634t  
clobazam, 876–877  
clonazepam, 877–878  
diazepam, 898–900  
lorazepam, 1012  
poisoning or overdose, 69t–70t  
properties of, 167b–168b
- Benzoyl peroxide (Benzac AC Wash 2<sup>1</sup>/<sub>2</sub>, 5, 10; Benzac 5, 10, Brevoxyl Creamy Wash, Desquam-E 5, Desquam-E 10, NeoBenz Micro, Oxy-5, Oxy-10, PanOxyl, Triaz, Zoderm), 768, 770, 776–777, 782–783, 826–827  
for acne vulgaris, 223t, 224
- Benztropine mesylate (Cogentin), 769, 827–828
- Bepotastine (Bepreve), 409t–410t
- Beractant (Survanta), 1151
- β (Beta), 751
- Betamethasone (Beta-Val, Celestone Soluspan, Diprolene, Diprosone, Luxiq, Sernivo, Maxivate), 768–769, 771, 775, 780, 828–829  
potency, 230t
- Beta-Val. *See* Betamethasone
- Bethanechol chloride (Urecholine), 782
- Bethkis. *See* Tobramycin
- Bias, 748–749
- Biaxin. *See* Clarithromycin
- Biaxin XL. *See* Clarithromycin
- Bicarbonate, reference values for, 736t–743t
- Bicillin L-A. *See* Benzathine penicillin G
- Bicitra, 829
- Bidirectional Glenn shunt, 204t
- Bile, 301t
- Bilevel positive airway pressure (BiPAP), 13
- Biliary obstruction, hyperbilirubinemia vs., 332t
- Biliary system, laboratory studies for, 329
- Bilious emesis, 520, 520.e1t
- Bilirubin, 332  
reference values for, 736t–743t  
unconjugated hyperbilirubinemia in the newborn and, 516  
in urinalysis, 530t–531t
- Billing, confidentiality and, 117
- Binge eating disorder, treatment for, 1008
- Biologic agents, for pediatric rheumatology, 726t–730t
- Biologic response modifiers, vaccinations for, 445
- Biophysical profile test, 528.e1, 528.e3t
- Biopsy, 323
- Biorphen. *See* Phenylephrine HCl
- Biostatistics, 749–755
- Biotin, recommended intakes, 603t–604t
- “Biphasic anaphylaxis”, 19–20

- Bipolar 1 disorder, aripiprazole for, 813
- Bipolar disease, treatment for, 997
- Bipolar mania, 1114  
treatment for, 1126
- Birth control, nonhormonal, forms of, 147
- Birth trauma, 507
- Birth weight, 506  
predicted endotracheal tube size and depth by, 505t
- Birth-related extradural fluid collection, 508f, 508t
- Bisacodyl (Doxidan, Dulcolax, Ducodyl, Bisacodyl EC, Fleet Bisacodyl, Fleet Laxative), 771–772, 829–830  
for constipation, 1t
- Bisacodyl EC. *See* Bisacodyl
- Bismatrol. *See* Bismuth subsalicylate
- Bismuth subsalicylate (Kao-Tin, Kaopectate, Pepto-Bismol, Stomach Relief, Stomach Relief Max St, Stomach Relief Plus), 774, 781
- Bismuth subsalicylate (Pepto-Bismol, Geri-Pectate, Bismatrol, Kao-Tin, Stomach Relief, Stomach Relief Max St), 778, 781  
adjustment in kidney failure, 1203t–1208t
- Bi-specific T-cell engager, 628t–632t
- Bite cells, 372
- Bites  
animal, 55–56, 462t–476t  
antibiotic prophylaxis, 55  
decision to suture, 56  
high infection risk, 55  
imaging of, 56  
physical exam assessment of, 56  
rabies postexposure prophylaxis, 55  
tetanus postexposure prophylaxis, 55  
human, 462t–476t
- Bitter almond odor, in toxicology, 67.e1t–67.e3t
- Bivalirudin, 398t–399t
- Bivigam, preparations for, 970
- BK virus-associated nephropathy, 884
- Black dot, tinea capitis and, 218
- Bladder exstrophy-epispadias-cloacal exstrophy complex, 524, 524.e1t
- Bladder irrigation, for urinary tract mycosis, 808
- Blaschkoid dyspigmentation, 234, 234.e1f
- Blastomycosis, 488t–490t  
itraconazole for, 983–984
- Blasts, 372, 373.e3f
- Blau syndrome, 715
- Bleeding, 47  
abnormal uterine, 1019  
chronic kidney disease and, 565t  
gastrointestinal, 318, 319t  
prophylaxis, 394, 394t
- Bleeding diathesis, 77
- Bleeding time (BT), 390
- Bleomycin, 628t–632t
- Blinatumomab, 628t–632t
- $\alpha$ -blockers, for hypertension, 549t–550t
- $\beta$ -blockers  
for hypertension, 549t–550t  
for Kawasaki disease, 200.e1t  
for migraine, 584.e1t  
overdose, glucagon HCl for, 954–955  
poisoning or overdose, 69t–70t
- Blood cell indices, 406t
- Blood chemistry, 735–746  
conversion formulas in, 735  
length and weight, 735  
temperature, 735  
reference values of, 735, 736t–743t
- Blood component replacement, 401
- Blood culture, specimen collection for, 498–499
- Blood gases, 663  
arterial, 663, 736t–743t  
arterial, reference values for, 736t–743t  
capillary, 663  
venous, 663
- Blood lead level, 73, 74t
- Blood pressure (BP), 172, 535–547  
abnormalities in, 172  
arterial, 506  
assessment of, 3  
diastolic, 4, 541t–545t  
in headaches, 581.e1t  
normal values, 172  
screening of, for adolescents, 119t  
systolic, 536t–540t
- Blood products, 402t–403t
- Blood smear, interpretation, 372–373
- Blood tests, 66–67
- Blood transfusions  
exchange, 513  
infectious risks of, 401  
recommended intervals between administration, 2t
- Blood urea nitrogen/creatinine (BUN/Cr) ratio, 562
- Bloodborne pathogens, exposures to, 502.e2  
disease-specific postexposure management of, 502.e2  
general practice of, 502.e2
- Bloxiverz. *See* Neostigmine
- Blunt trauma, 39
- BMI. *See* Body mass index
- BMJ Statistics at Square One, 757
- Body fluids, 735–746  
electrolyte composition of, 301t  
evaluation of, 735  
cerebrospinal fluid, 735, 743t  
synovial fluid, 735, 735.e1t  
transudate/exudate, 735, 735.e1t  
urine, 735, 744t–745t
- Body image, 1t
- Body mass index (BMI), management and monitoring strategies for children based on, 596t
- Bone, rheumatologic diseases and, 725

- Bone lesions, imaging for, 707, 707.e1f, 707.e1f, 707.e2f, 707.e2f, 707.e3f
- Bone marrow aspiration, in thrombocytopenia, 384
- Bone marrow failure syndromes, 380t–382t
- Bone marrow transplantation. *See* Hematopoietic stem cell transplantation
- Bone Strengthening. *See* Calcium citrate
- Boost Kids Essentials formulas, 609t, 613t–614t
- Boost Plus formula, 613t–614t
- Boost with fiber formula, 613t–614t
- Boosters, 448
- Bosentan (Tracleer), 831–832  
adjustment in kidney failure, 1203t–1208t
- Botulinum IVIG (BabyBIG), 2t
- Botulinum toxin, 577
- Botulism, 577–578
- Bowel gas pattern, 697f, 697, 697.e1f
- Bowel obstruction, 700, 700.e2f
- Boys, target height range for, 281
- BP Gel. *See* Benzoyl peroxide
- BP Wash. *See* Benzoyl peroxide
- BPD. *See* Bronchopulmonary dysplasia
- BPO. *See* Benzoyl peroxide
- Brachial plexus injuries, 507, 523t
- Bradycardia, 182t–183t  
atropine sulfate for, 817–818  
in newborns, 514–515  
treatment of, 916  
without central apnea, 515
- Bradypnea, in toxicology, 67.e1t–67.e3t
- Breach of confidentiality, 115.e1–117
- Breakthrough seizures, 574
- Breast milk  
benefits of, 605  
safe handling of, 608
- Breastfeeding, 605–608  
challenges of, 608  
contraindications to, 605–607, 607b  
in newborn care, 505
- Breasts  
examination of, 126, 127f  
in newborn, 507.e1f
- Breath-holding spells, 585t
- Breech deliveries, 522
- Brentuximab, 628t–632t
- Breo Ellipta. *See* Fluticasone furoate + vilanterol
- Brethine. *See* Terbutaline
- Brevibloc. *See* Esmolol HCl
- Bridion. *See* Sugammadex
- Brief resolved unexplained event (BRUE), 684–685  
definition of, 684  
differential diagnosis of, 684–685  
management of, 685, 685f
- Bright Beginnings formulas, 613t–614t
- Bright Futures, 260
- Bristol Stool Form Scale, 326f
- Brivaracetam (Briviact), for seizures, 575t–576t
- Briviact. *See* Brivaracetam
- Brompheniramine with phenylephrine (Dimetapp Children's Cold and Allergy), 770, 832–833
- Bronchiolitis, 676  
clinical presentation of, 676  
definition of, 676  
treatment of, 676
- Bronchitis, 825, 851, 856, 874, 1108
- Bronchopulmonary aspergillosis, allergic, in cystic fibrosis, 680
- Bronchopulmonary dysplasia (BPD), 677
- Bronchospasms, 793, 1011, 1157  
atropine sulfate for, 817–818  
exercise-induced, 793  
albuterol for, 792–793  
prevention of, 1131
- Brucellosis, 1143
- BRUE. *See* Brief resolved unexplained event
- Bruises, 62
- Budesonide (Pulmicort, Rhinocort Aqua Nasal Spray, Entocort EC, Uceris), 771, 779, 781–782, 833–834  
estimated comparative daily dosages for, 3t–4t
- Budesonide and formoterol (Symbicort), 781, 835–836  
estimated comparative daily dosages for, 3t–4t
- Bufferin. *See* Aspirin
- Bulimia nervosa, 657
- Bulla, 209
- Bullous diseases, autoimmune, 235.e1
- Bullous impetigo, 220
- Bumetanide (Bumex), 768, 836  
for hypertension, 549t–550t
- Bumex. *See* Bumetanide
- Buminate. *See* Albumin
- Bupivacaine, 160t
- Burns, 56–62  
assessment (modified Lund-Browder chart), 58f  
in children, 60  
classification of, 59t  
elective intubation and, 58–59  
electrolyte composition of, 301t  
fluid resuscitation in patients with, 59, 59f  
indications for transfer, 60  
management of, 56–61, 57f  
nonaccidental trauma, 62–63  
special considerations with, 61–62
- Busulfan, 628t–632t
- Butorphanol (Stadol), 780, 836–837
- Button batteries, poisoning or overdose, 69t–70t
- C**
- Café-au-lait spots, 224.e1f, 234
- Caffeine citrate (Cafcit), 768  
formulary entry, 837–838

- Calan. *See* Verapamil  
 Calan SR. *See* Verapamil  
 Calcidol. *See* Ergocalciferol  
 Calcijex. *See* Calcitriol  
 Calcineurin inhibitors  
   for nephrotic syndrome, 557  
   topical, for atopic dermatitis (eczema),  
     231  
 Calcionate. *See* Calcium glubionate  
 Calciquid. *See* Calcium glubionate  
 Calcitonin-salmon (Miacalcin, Fortical Nasal  
 Spray), 772, 837–838  
 Calcitrate. *See* Calcium citrate  
 Calcitriol (1,25-dihydroxycholecalciferol,  
 Rocaltrol, Calcijex), 766, 768, 780,  
 838–839  
 Calcium, 308  
   formulation recommendations for, 616t  
   recommended intakes, 606t  
   reference values for, 736t–743t  
   in urine, 744t–745t  
 Calcium acetate (Calphron, Eliphos, PhosLo,  
 Phoslyra), 768, 771, 778, 839  
 Calcium carbonate (Tums, Children's Pepto,  
 Maalox Children's, Os-Cal), 777, 782,  
 839–840  
 Calcium channel blockers  
   amlodipine, 803–804  
   diltiazem, 902–903  
   for hypertension, 549t–550t  
   nicardipine, 1054–1055  
   nifedipine, 1055–1056  
   poisoning or overdose, 69t–70t  
   verapamil, 1183–1184  
 Calcium chloride, 6t–7t, 766, 840  
 Calcium citrate (Calcitrate, Citracal Petites,  
 Citracal Maximum Plus, Citracal  
 Gummies, Viactiv Calcium, Bone  
 Strengthening), 768–769, 840–841  
 Calcium glubionate (Calcionate, Calciquid),  
 768  
 Calcium gluconate (Cal-Glu), 768  
   formulary entry, 841–842  
   for hyperkalemia, 311f  
 Calcium lactate (Cal-Lac), 768, 842  
 Calcium phosphate, tribasic (Posture-D), 778  
 Calcium supplements, 1203t–1208t  
 Caldolor. *See* Ibuprofen  
 Cal-Glu. *See* Calcium gluconate  
 Cal-Lac. *See* Calcium lactate  
 Caloric modulars, 610t  
 Calories  
   methods to increase, 608, 610t  
   newborn and, 511t  
 Calphron. *See* Calcium acetate  
 Campath (Alemtuzumab), 628t–632t  
 Canakinumab, for pediatric rheumatology,  
 726t–730t  
 Canasa. *See* Mesalamine  
 Cancer  
   darbepoetin alfa for, 889–890  
   survivorship, 638  
 Cancidas. *See* Caspofungin  
 Candesartan, 549t–550t  
*Candida*, prophylaxis for, 1034, 1097  
*Candida albicans*, 134t–136t  
   prophylaxis of, 634t–635t  
 Candidemia, voriconazole for, 1187  
 Candidiasis, 488t–490t  
   amphotericin B lipid complex for, 766,  
     808–809  
   esophageal, 936, 944  
     voriconazole for, 1187  
   invasive, 849, 1033–1034  
   itraconazole for, 1098  
   prophylaxis against, 1187  
   vulvovaginal, 134t–136t  
 Cankaid. *See* Carbamide peroxide  
 Cannabidiol (Epidiolex), 843  
   for seizures, 575t–576t  
 Cannabinoids, antiemetic agent, 634t  
 Capillariasis, 1018  
 Capillary blood gas (CBG), 663  
 Capnography, 663  
 Captopril (Capoten), 768  
   adjustment in kidney failure, 1203t–1208t  
   formulary entry, 844  
   for hypertension, 549t–550t  
 Capute Scales, 245t  
 CAR T-cells, 628t–632t  
 Carafate. *See* Sucralfate  
 Carbamazepine (Eptol, Tegretol, Tegretol-XR,  
 Carbatrol, Equetro), 768, 771,  
 844–845  
   adjustment in kidney failure, 1203t–1208t  
   for seizures, 575t–576t  
 Carbamide peroxide (Debrox, Auraphene-B,  
 Clearcanal Earwax Softener,  
 GoodSense Ear Wax Removal, Gly-  
 Oxide, Auro Ear Drops, Cankaid,  
 Murine Ear, Thera-Ear), 767–768,  
 770, 773, 775, 781, 846  
 Carbamoyl phosphate synthetase (CPS)  
   deficiency, 341t–342t  
 Carbapenem  
   ertapenem, 922  
   imipenem and cilastatin, 968–969  
   meropenem, 1020–1021  
 Carbapenem-resistant Enterobacterales (CRE),  
 resistance in, 502.e1  
 Carbatrol. *See* Carbamazepine  
 Carbinoxamine (Arbinoxa, Palgic, Karbinal ER,  
 RyVent), 767, 769, 777, 846–847  
 Carbinoxamine + pseudoephedrine (Cordron-  
 D NR, Cordron-D, Hydro-Tussin CBX,  
 Pseudo Carb Pediatric, Sildec), 769,  
 773, 779–780  
 Carbohydrate disorders, 341t–342t  
 Carbohydrate intolerance, 613t–614t  
 Carbohydrates  
   dietary allowances for, 601, 601t  
   methods to increase, 608, 610t  
 Carbon monoxide, reference values for,  
 736t–743t

- Carboplatin, 628t–632t  
Carboxyhemoglobin, reference values for, 736t–743t  
Cardene IV. *See* Nifedipine  
Cardiac arrest, 840  
    treatment of, 1139  
    vasopressin for, 1182  
Cardiac catheterization, 202–203, 205t  
Cardiac complaints, 204–207  
    nontraumatic chest pain, 204–205, 206f  
    syncope, 205–207  
Cardiac conditions, genetic conditions with, 348–349, 352t  
Cardiac defects, major syndromes associated with, 190t  
Cardiac diseases, 515–516  
Cardiac magnetic resonance (CMR), 696  
Cardiac output, medications to support, 18t  
Cardiac shunts, 203f  
Cardiac surgery, 202, 204t  
Cardiac system, changes as death approaches, 644t  
Cardiac tamponade, 43, 198  
Cardiogenic shock, 5, 16, 17t  
Cardiogenic syncope, 585t  
Cardiology, 172–212  
Cardiomyopathy, 349  
    chronic kidney disease and, 565t  
    dilated, 196  
    hypertrophic, 207.e1t  
    hypertrophic obstructive, 197  
    sports restrictions, 207.e1t  
Cardiopulmonary bypass, 1075, 1189  
Cardiopulmonary resuscitation (CPR), 642  
    extracorporeal, 5–8  
    high-quality, 3, 4b  
Cardiovascular effects, procedural sedation and, 167  
Cardiovascular procedures, 81–90  
    external jugular puncture and catheterization, 83–86, 85f–86f  
    heelstick and fingerstick, 82  
    intraosseous access, 86–88, 86f  
    peripheral intravenous access, 82–83  
    umbilical artery and umbilical vein catheterization, 88–90, 89f  
    vagal maneuvers for SVT, 81–90  
Cardiovascular screening, 208  
Cardioversion, 4–5  
Cardizem. *See* Diltiazem  
Cardizem CD. *See* Diltiazem  
Cardizem LA. *See* Diltiazem  
Carmustine, 628t–632t  
Carnation Instant Breakfast Essentials  
    formulas, 609t, 613t–614t  
Carnitine (Levocarnitine, Carnitor, Carnitor SF, L-Carnitine), 769, 774  
    deficiency, 847  
    formulary entry, 847  
    for metabolic disease, 345  
Carnitor. *See* Carnitine  
Carnitor SF. *See* Carnitine  
CaroSpir. *See* Spironolactone  
Carotid bruit (systolic), 174t  
Carotid sinus massage, for supraventricular tachycardia, 82  
CARP. *See* Confluent and reticulated papillomatosis  
Cartia XT. *See* Diltiazem  
Carvedilol (Coreg, Coreg CR), 769  
    formulary entry, 47–848  
    for hypertension, 549t–550t  
Casein, hydrolyzed, 611t–612t  
Caspofungin (Cancidas), 768, 848–849  
Catapres. *See* Clonidine  
Catapres TTS. *See* Clonidine  
Cataract surgery, postoperative, treatment for, 989  
Catch-up growth, requirements for, determining, 600, 600b  
Catecholamines  
    plasma, 279.e1t  
    urine, 279.e1t  
Cathartics, 1017  
Catheterization  
    external jugular puncture and, 83–86, 111.e1–111.e4, 111.e4f  
    radial artery puncture and, 83–86, 85f  
    umbilical artery and umbilical vein, 88–90, 89f  
    urinary bladder, 93–94  
Catheter-related bloodstream infections, 462t–476t  
Cathflo Activase. *See* Alteplase  
CAVH/D. *See* Continuous arteriovenous hemofiltration/hemodialysis  
Causton. *See* Aztreonam  
CBG. *See* Capillary blood gas  
CCr. *See* Creatinine clearance  
CDC. *See* Centers for Disease Control and Prevention  
Cefaclor (Ceclor), 769, 779  
    adjustment in kidney failure, 1197t–1203t  
    formulary entry, 849–850  
Cefadroxil (Duricef), 771  
    adjustment in kidney failure, 1197t–1203t  
    formulary entry, 850  
    for pyelonephritis, 462t–476t  
Cefazolin (Ancef, Zolicef), 767, 783  
    adjustment in kidney failure, 1197t–1203t  
    for cervical lymphadenitis, 462t–476t  
    formulary entry, 850–851  
    for osteomyelitis, 462t–476t  
    for pyelonephritis, 462t–476t  
    for septic arthritis, 462t–476t  
Cefdinir (Omnicef), 777  
    adjustment in kidney failure, 1197t–1203t  
    formulary entry, 851  
Cefepime (Maxipime), 775  
    adjustment in kidney failure, 1197t–1203t  
    for catheter-related bloodstream infections, 462t–476t  
    formulary entry, 851–852

- Cefepime (Maxipime) (*Continued*)  
 for hardware-associated bone infection, 462t–476t  
 for pyelonephritis, 462t–476t  
 for VP shunt infection, 462t–476t
- Cefiderocol (Fetroja), 772  
 formulary entry, 852–853
- Cefixime (Suprax), 781  
 adjustment in kidney failure, 1197t–1203t  
 formulary entry, 853  
 for gonorrhea, 130t–134t
- Cefotan. *See* Cefotetan
- Cefotaxime (Claforan), 769  
 adjustment in kidney failure, 1197t–1203t  
 for fever in infant, 457t–461t  
 formulary entry, 853–854  
 for gonorrhea, 130t–134t  
 for group B streptococcal (GBS) disease, 457t–461t  
 for meningitis, 462t–476t  
 neonatal dosing, 527t–528t  
 for neonatal exudative conjunctivitis, 457t–461t
- Cefotaxime + clindamycin  
 for peritonsillar abscess, 462t–476t  
 for retropharyngeal/parapharyngeal abscess, 462t–476t
- Cefotetan (Cefotan), 769  
 adjustment in kidney failure, 1197t–1203t  
 formulary entry, 854–855  
 for pelvic inflammatory disease, 130t–134t
- Cefoxitin (Mefoxin), 775  
 adjustment in kidney failure, 1197t–1203t  
 formulary entry, 855  
 for pelvic inflammatory disease, 130t–134t
- Cefpodoxime proxetil (Vantin), 782  
 adjustment in kidney failure, 1197t–1203t  
 formulary entry, 855–856
- Cefprozil (Cefzil), 769  
 adjustment in kidney failure, 1197t–1203t  
 formulary entry, 856
- Ceftaroline fosamil (Teflaro)  
 adjustment in kidney failure, 1197t–1203t  
 formulary entry, 857
- Ceftazidime (Ceptaz, Fortaz, Tazicef, Tazidime), 769, 772, 781  
 adjustment in kidney failure, 1197t–1203t  
 formulary entry, 857–858
- Ceftazidime with avibactam (Avycaz),  
 formulary entry, 858
- Ceftibuten (Cedax), 766t–783t
- Ceftin. *See* Cefuroxime
- Ceftolozane with tazobactam (Zerbaxa), 783  
 formulary entry, 858–859
- Ceftriaxone (Rocephin), 780  
 for acute otitis media, 462t–476t  
 for chancroid, 136t–138t  
 for community-acquired pneumonia, 462t–476t  
 for fever in infant, 457t–461t
- Ceftriaxone (Rocephin) (*Continued*)  
 for fever without localizing signs, 456f  
 formulary entry, 859–860  
 for gastroenteritis, 462t–476t  
 for gonorrhea, 130t–134t  
 for group B streptococcal (GBS) disease, 457t–461t  
 for mastoiditis, 462t–476t  
 for meningitis, 462t–476t  
 for neonatal exudative conjunctivitis, 457t–461t  
 for osteomyelitis, 462t–476t  
 for peritonsillar abscess, 462t–476t  
 for PID, 130t–134t  
 for pyelonephritis, 462t–476t  
 for septic arthritis, 462t–476t
- Ceftriaxone + metronidazole, for appendicitis, 462t–476t
- Cefuroxime (Zinacef, Ceftin), 769, 783  
 adjustment in kidney failure, 1197t–1203t  
 formulary entry, 860–861  
 for Lyme disease, 482t–484t
- Cefzil. *See* Cefprozil
- Celebrex. *See* Celecoxib
- Celecoxib (Celebrex, Elyxyb)  
 analgesic properties of, 156  
 formulary entry, 861–862  
 for pediatric rheumatology, 726t–730t
- Celestone. *See* Betamethasone
- Celestone Soluspan. *See* Betamethasone
- Celiac disease, 323  
 diarrhea vs., 328t
- Cell free DNA, 528.e1
- CellCept. *See* Mycophenolate mofetil
- Cellulitis  
 orbital, 462t–476t, 690  
 postseptal, 690.e1f  
 preseptal, 690.e1f  
 submandibular, 462t–476t
- Centany. *See* Mupirocin
- Centany AT. *See* Mupirocin
- Center to Advance Palliative Care, 647
- Centers for Disease Control and Prevention (CDC)  
 Acute Concussion Evaluation (ACE), 42  
 growth charts and, 594  
 HEADS UP website, 42  
 immunization schedules by, 424
- Central  $\alpha$ -agonists, for hypertension, 549t–550t
- Central nervous system (CNS)  
 local anesthetics and, 158  
 pediatric tumors, 622, 623t  
 procedural sedation and, 167
- Central venous catheter, placement of, 708, 708f
- Centre for Evidence Based Medicine, 757
- Cephalexin (Keflex), 774  
 adjustment in kidney failure, 1197t–1203t  
 for cervical lymphadenitis, 462t–476t  
 for cystitis, 462t–476t  
 formulary entry, 862

- Cephalexin (Keflex) (*Continued*)  
 for nonpurulent cellulitis/erysipelas, 462t–476t  
 for pyelonephritis, 462t–476t  
 for strep pharyngitis, 462t–476t
- Cephalosporin  
 cefaclor, 849–850  
 cefadroxil, 850  
 cefazolin, 850–851  
 cefdinir, 851  
 cefepime, 851–852  
 cefiderocol, 852–853  
 cefixime, 853  
 cefotaxime, 853–854  
 cefotetan, 854–855  
 ceftioxin, 855  
 cefpodoxime proxetil, 855–856  
 cefprozil, 856  
 ceftaroline fosamil, 857  
 ceftazidime, 857–858  
 ceftazidime with avibactam, 858  
 ceftolozane with tazobactam, 858–859  
 ceftriaxone, 859–860  
 cefuroxime, 860–861  
 cephalixin, 862
- Cequa. *See* Cyclosporine
- CeraLyte solutions, 614t
- Cerebellar function tests, 571
- Cerebral edema  
 dexamethasone for, 893–894  
 in diabetic ketoacidosis, 266
- Cerebral palsy (CP), 251–252  
 clinical presentation of, 251  
 definition of, 251  
 diagnosis of, 251–252, 252t  
 epidemiology of, 251  
 interventions/treatment of, 250.e4t, 252
- Cerebral Palsy Foundation, 260
- Cerebral perfusion pressure, 573
- Cerebrospinal fluid (CSF)  
 analysis of, in suspected meningitis, 494t  
 evaluation of, 735, 743t  
 shunting, 577
- Cerebrovascular accident (CVA), 627
- Cerebyx. *See* Fosphenytoin
- Cerumen impaction removal, 79
- Cerumenolytics, 79  
 antipyrine and benzocaine (otic), 767, 811  
 carbamide peroxide, 767–768, 846
- Cervical cancer, screening of, for adolescents, 119t
- Cervical infections, 853
- Cervical lymphadenitis, 462t–476t
- Cervical spine  
 fracture, 690.e2f  
 imaging, 39–41  
 normal anatomy of, 692f  
 trauma, 690
- Cetirizine (Zyrtec, Zyrtec Allergy, Zyrtec Children's Allergy, Zerviate), 783  
 adjustment in kidney failure, 1197t–1208t  
 for allergic rhinitis, 409t–410t  
 formulary entry, 863
- Cetirizine + pseudoephedrine (Zyrtec-D 12 Hour), 783, 863
- Cetralax. *See* Ciprofloxacin
- ceVUS. *See* Contrast-enhanced voiding urosonography
- CF. *See* Cystic fibrosis
- CFTR. *See* Cystic fibrosis transmembrane conductance regulator
- Chagas disease, 485t–487t
- Chancroid, 136t–138t  
 diagnostic features and management of, 136t–138t
- CHARGE syndrome, 508
- Chédiak-Higashi syndrome, 417t  
 vaccine information for, 1t–3t
- Chelation therapy, for lead poisoning, 73–74
- Chemet. *See* Succimer
- Chemotherapy  
 complications of, 633–634  
 drugs, 628t–632t  
 myeloablative, 635  
 nonmyeloablative, 635  
 supportive care in, 633–634
- Chemotherapy-induced nausea, 633–634
- Chest compressions, 3
- Chest pain, non-traumatic, 204–205, 206f
- $\chi^2$  (chi square) test, 750t
- Chickenpox, valacyclovir for, 1174–1175
- Childhood absence seizures, 587t–589t
- Childhood Autism Screening Test (CAST), 245t, 252–253
- Childhood-onset fluency disorder, 250
- Child-Pugh category, for hepatic impairment, 843
- Children  
 burns in, 60  
 with diabetes, web resources for, 293  
 dying, 642–647  
 concept of death on, 643, 643t  
 concurrent care for, 640  
 limiting interventions in, 642–643  
 outpatient care for, 644  
 support for, 644–645, 644t  
 fearful, attending to needs of, 75–76  
 HIV infection in, 494  
 malnutrition in, 597–600  
 medications to avoid in, 154–156  
 multisystem inflammatory syndrome in, 201–202  
 nutritional needs of healthy, 601–605  
 psychiatric conditions of, 650–659  
 anxiety disorders, 654–655  
 attention-deficit/hyperactivity disorder, 650–654  
 depressive and mood disorders, 655–657  
 eating disorders, 657–659

- Children (*Continued*)  
 oppositional defiant disorder, 654  
 substance use disorders, 659  
 recommended dietary allowances for, 601t  
 recommended element intakes, 606t  
 recommended vitamin intakes, 603t–604t  
 with significant neurological impairment,  
 pain assessment in, 152–154, 154t  
 sleep of, 683–684  
 traumatic fractures in, 48  
 unresponsive, approach to, 3–15  
 vaccines administered to, 423  
 inactivated, 423  
 live, attenuated, 423  
 mRNA, 423  
 nonroutine, 424, 431t–433t  
 routine, 424, 425t–430t  
 subunit, recombinant,  
 polysaccharide, and  
 conjugate, 423  
 toxoid, 423  
 Children's Advil. *See* Ibuprofen  
 Children's Allegra Allergy. *See* Fexofenadine ±  
 pseudoephedrine  
 Children's Dimetapp Cold and Allergy. *See*  
 Brompheniramine with  
 phenylephrine  
 Children's Motrin. *See* Ibuprofen  
 Children's Mylicon. *See* Simethicone  
 Children's Pepto. *See* Calcium carbonate  
 Chimeric monoclonal Ab binds CD20,  
 628t–632t  
 Chimeric monoclonal Ab binds CD30,  
 628t–632t  
 Chlamydia infections, evaluation and  
 management of, 130t–134t,  
 138–140  
 management of, 923  
*Chlamydia trachomatis*, 139, 1038  
 Chlamydial cervicitis, uncomplicated,  
 azithromycin for, 821  
 Chlamydial conjunctivitis, treatment of, 923  
 Chloral hydrate (Aquachloral Suppettes), 767  
 Chloramphenicol (Chloromycetin), 769  
 formulary entry, 864  
 Chloride  
 formulation recommendations for, 616t  
 reference values for, 736t–743t  
 in urine, 744t–745t  
 Chloride salt, 1193  
 Chloroquine phosphate (Aralen), 767  
 adjustment in kidney failure, 1203t–1208t  
 formulary entry, 864–865  
 for malaria, 462t–476t  
 Chlorothiazide (Diuril), 549t–550t, 771  
 adjustment in kidney failure, 1203t–1208t  
 formulary entry, 865  
 Chlorpheniramine maleate (Chlor-Trimeton),  
 769, 866  
 Chlorpromazine (Thorazine), 781, 866–867  
 Chlorthalidone, 549t–550t  
 Chlor-Trimeton. *See* Chlorpheniramine  
 maleate  
 Cholecalciferol (D-3, D3-5, D3-50, Decara, D  
 Drops, Enfamil D-Vi-Sol, Replesta),  
 770, 867–868  
 Cholestasis, pruritus associated with, 869  
 Cholesterol  
 low-density lipoprotein (LDL), 207  
 reference values for, 736t–743t  
 screening  
 for adolescents, 119t  
 recommendations for, 207  
 total, 207  
 Cholestyramine (Questran, Questran Light,  
 Cholestyramine Light, Prevalite), 769,  
 869  
 Cholestyramine Light. *See* Cholestyramine  
 Choline, 603t–604t  
 Choline magnesium trisalicylate (Trilisate), 782  
 Chondrodysplasia punctata, rhizomelic, 344t  
 Chorionic villus sampling (CVS), 528.e1  
 Chromium  
 formulation recommendations for, 616t  
 recommended intakes, 606t  
 Chromosomal abnormalities,  
 hyperbilirubinemia vs., 332t  
 Chronic bronchitis exacerbation, 856  
 Chronic disease, anemia of, 368t–369t  
 Chronic granulomatous disease, 417t  
 Chronic headaches, 580b  
 Chronic inflammatory demyelinating  
 polyneuropathy (CIDP), 578  
 Chronic ingestion, 71  
 Chronic iron overload, deferoxamine mesylate  
 for, 891  
 Chronic kidney disease (CKD), 563–564  
 clinical manifestations of, 565t  
 definition of, 563  
 etiology of, 563–564  
 general management of, 564  
 radiographic imaging considerations in,  
 563  
 Chronic kidney disease in epidemiology  
 collaboration (CKD-EPI), 533  
 Chronic pain, augment analgesia for, 802,  
 969  
 Chronic paronychia, 233.e1f  
 Chronic renal failure, anemia in, 889, 918  
 Chronic spasticity, dantrolene for, 887  
 Churg-Strauss syndrome, 711t–713t  
 Chvostek sign, 312t  
 in toxicology, 67.e1t–67.e3t  
 Chylothorax, 613t–614t  
 Ciclesonide (Alvesco, Omnaris, Zetonna), 767,  
 777  
 estimated comparative daily dosages for,  
 3t–4t  
 formulary entry, 869–870  
 Ciclopirox, for fungal infections, 462t–476t  
 Cidofovir (Vistide), 783  
 formulary entry, 870–871

- Cidofovir (Vistide) (*Continued*)  
nephrotoxicity from, prevention of,  
1104–1105
- CIDP. *See* Chronic inflammatory demyelinating  
polyneuropathy
- Ciliary dyskinesias, primary, 349
- Ciliopathies, 349
- Ciloxan ophthalmic. *See* Ciprofloxacin
- Cimetidine (Tagamet), 784  
formulary entry, 865
- Cipro. *See* Ciprofloxacin
- Ciprodex Cipro HC Otic. *See* Ciprofloxacin
- Ciprofloxacin (Cipro, Cipro XR, Ciloxan  
ophthalmic, Cetraxal, Ciprodex, Cipro  
HC Otic, Otovel Otic), 769  
adjustment in kidney failure,  
1197t–1203t  
formulary entry, 871–872  
for gastroenteritis, 462t–476t  
for otitis externa, 462t–476t
- Circulation  
assessment of, 3–8  
emergencies, allergic, 19  
management of, 3–8
- Circulation Airway, and Breathing (C-A-B)  
pathway, 3
- Cisgender, 122t
- Cisplatin, 628t–632t
- Citracal Gummies. *See* Calcium citrate
- Citracal Maximum Plus. *See* Calcium citrate
- Citracal Petites. *See* Calcium citrate
- Citrate mixtures, 873–874
- Citric acid, 801, 873
- Citrullinemia, 341t–342t
- CKD. *See* Chronic kidney disease
- CKD-EPI. *See* Chronic kidney disease in  
epidemiology collaboration
- Claforan. *See* Cefotaxime
- Claravis. *See* Isotretinoin
- Clarithromycin (Biaxin, Biaxin XL), 768  
adjustment in kidney failure, 1197t–1203t  
formulary entry, 874–875  
with metronidazole, 908
- Claritin. *See* Loratadine
- Claritin Children's Allergy. *See* Loratadine
- Claritin RediTabs. *See* Loratadine
- Claritin-D 12 Hour. *See* Loratadine +  
pseudoephedrine
- Classic Rett syndrome, 359
- Classic vibratory murmur (Still's murmur;  
systolic), 174t
- Clavicle, fractured, 507
- Clear liquid diet, 613t–614t
- Cleft lip and palate (CLP), 352
- Cleocin. *See* Clindamycin
- Cleocin-T. *See* Clindamycin
- Clindagel. *See* Clindamycin
- Clindamycin (Cleocin-T, Cleocin, Clindagel,  
Evoclin, Clindesse, Xaciato), 769  
for acne vulgaris, 224  
for bacterial vaginosis, 134t–136t  
for cervical lymphadenitis, 462t–476t
- Clindamycin (Cleocin-T, Cleocin, Clindagel, Evo-  
clin, Clindesse, Xaciato) (*Continued*)  
formulary entry, 875–876  
for malaria, 462t–476t  
for strep pharyngitis, 462t–476t
- Clindesse. *See* Clindamycin
- Clinical Adaptive Test (CAT), 245t
- Clinical diagnostic aids, 67.e1t–67.e3t
- Clinical Linguistic and Auditory Milestone Scale  
(CLAMS), 245t
- Clinical question, 746
- Clinical trial, 752t  
grid for calculations in, 753t  
grid for evaluating tests, 755t  
study design, 752t
- Clitoromegaly, 287
- Clobazam (Onfi, Sympazan)  
adjustment in kidney failure, 1203t–1208t  
formulary entry, 876–877  
for seizures, 575t–576t
- Clobetasol propionate, 230t
- Clocortolone pivalate, 230t
- Clofarabine, 628t–632t
- Clonazepam (Klonopin), 774  
formulary entry, 877–878  
for seizures, 575t–576t
- Clonidine (Catapres, Catapres TTS, Duraclon,  
Kapvay, Nexiclon XR), 162–163,  
652t–653t, 769, 771  
formulary entry, 878–879  
for hypertension, 549t–550t  
overdose, 69t–70t
- Clostridium difficile* colitis, 462t–476t
- Clostridium difficile* infection, treatment of,  
1033
- Clotrimazole (Alevazol, Cruex, Lotrimin AF,  
Gyne-Lotrimin 3, Gyne-Lotrimin 7,  
Mycelex, Mycelex-7), 769  
formulary entry, 879
- CLP. *See* Cleft lip and palate
- Clubbing, of nails, 233
- Clustered lesions, 210
- CMN. *See* Congenital melanocytic nevi
- CMV. *See* Cytomegalovirus
- CNS. *See* Central nervous system
- CNS infections, vancomycin for, 968
- Coagulation, 389–396  
abnormal, 391, 392t–393t  
causes and management of, 391–396  
evaluation of, 389–396
- Coagulation cascade, 390f
- Cobalamin (vitamin B<sub>12</sub>)  
recommended intakes, 603t–604t  
reference values of, 736t–743t
- Coca-cola, 299t
- Cocaine, overdose, 69t–70t
- Coccidioides* spp. pneumonia, itraconazole for,  
983
- Cochrane Reviews, 757
- Codeine, 154
- Codeine and acetaminophen (Tylenol),  
782

- Cogentin. *See* Benztropine mesylate
- Cognitive development, screening tests for, 245t
- Cohort studies, 752t
- Colace. *See* Docusate
- Cold autoimmune hemolytic anemia, 369t–370t
- Cold sores, valacyclovir for, 1175
- Cold stimulus, to face, for supraventricular tachycardia, 82
- Colic, 243t–244t
- Colitis  
    infantile proctocolitis, 412  
    infectious, diarrhea vs., 328t  
    ulcerative, 323
- Colocort. *See* Hydrocortisone
- Colonoscopy, 1141
- Color, 507t
- Coma  
    emergency management of, 28  
    in toxicology, 67.e1t–67.e3t
- Combined hormonal methods, 145–147
- Comedone  
    closed, 223  
    open, 223
- Common variable immunodeficiency, 417t
- Communication, 641–642  
    Ask-Tell-Ask method, 642  
    breaking bad news in, 641–642  
    family meetings, 641  
    tools for difficult conversations, 642
- Communication and Symbolic Behavior Scales and Developmental Profile (CSBS DP), 245t
- Communication disorders, 250
- Community-acquired pneumonia, 462t–476t  
    azithromycin for, 768, 820–821  
    exacerbation of, 856  
    treatment of, 810, 851, 856, 922
- Community-acquired bacterial pneumonia (CABP), 857
- Compartment syndrome, 47
- Compazine. *See* Prochlorperazine
- Compensated, shock, 15–16
- Compleat formulas, 613t–614t
- Compleat Organic Blends formulas, 613t–614t
- Compleat Pediatric, 609t
- Compleat Pediatric Organic blends formulas, 613t–614t
- Complement  
    immunodeficiency and, 417t  
    vaccine information for, 1t–3t
- Complement system, rheumatologic diseases and, 725
- Complete Amino Acid Mix, calories of, 610t
- Complete defects, vaccine information for, 1t–3t
- Complex molecules, disorders of, 337t, 339, 344t
- Compression, direct, for epistaxis, 81
- Compro. *See* Prochlorperazine
- Computed tomography (CT), 687–688  
    for abdomen, 696–697  
    advantages and disadvantages of, 689t  
    head, 688  
    magnetic resonance imaging vs, 688
- Concerta. *See* Methylphenidate HCl
- Concussions, 42  
    evaluation of, 42
- Conduction blocks, 186f
- Confidence intervals, 751
- Confidentiality, 115.e1–117  
    breach of, 115.e1–117  
    consent laws, 116  
    documentation and billing, 117
- Confluent and reticulated papillomatosis (CARP), 235
- Confounding, 749
- Congenital adrenal hyperplasia (CAH), 274, 276f  
    diagnosis of, 276  
    newborn screening for, 274–275
- Congenital dermal melanocytosis, 227
- Congenital heart disease, 348, 352t, 189, 207.e1t  
    acyanotic, 191t–192t  
    cyanotic, 193t–194t  
    exercise recommendations for, 207  
    newborn screening for, 505  
    syndromes associated with, 189
- Congenital ingrown nails, 233.e2f
- Congenital melanocytic nevi (CMN), 233–234
- Congenital nail disorders, 233
- Congenital syphilis, penicillin G for, 1080–1082
- Congenital toxoplasmosis, 1113–1114
- Conjugate vaccines, 423
- Conjugated hyperbilirubinemia, 519
- Conjunctivitis, 457t–476t, 923, 953  
    gatifloxacin for, 953  
    treatment for, 923
- Connective tissue disorders, 352–353
- Conscious sedation, 163
- Consciousness, altered level of, emergency management of, 28–31, 30t
- Consent, 75  
    of genetic testing, 361–363  
    of minor, 116
- Constipation, 324–326, 992  
    definitions of, 324  
    diagnosis of, 325, 326f  
    differential diagnosis of, 325t  
    functional, 1t, 324  
    glycerin for, 955–956  
    in infants, 326  
    maintenance therapy for, 325–326, 327b  
    management of, 1t, 325–326, 327b  
    nonfunctional, 324  
    polyethylene glycol for, 1095–1096  
    psyllium for, 1110  
    Rome criteria for, 1t, 324  
    treatment of, 955, 1096
- Constitutional growth delay, 282t, 283f
- Contact dermatitis, 228

- Continuous arteriovenous hemofiltration/  
hemodialysis (CAVH/D), 566, 566t
- Continuous diaphragm sign, of  
pneumoperitoneum, 698
- Continuous positive airway pressure (CPAP),  
13
- Continuous venovenous hemofiltration/  
hemodialysis (CVVH/D), 566, 566t
- Contraception, 140–149  
barrier methods, 147  
combined hormonal methods, 145–147  
depot medroxyprogesterone acetate,  
144–146  
emergency, 141f, 146–149  
fertility awareness-based methods, 147  
follow-up recommendations for, 149  
hormonal, 140–143  
initiation of, 140–143  
intrauterine device, 141–145  
long-acting reversible, 141  
methods of, 141f, 143  
nonhormonal birth control, 147  
oral, 146  
progestin-only pills, 147  
quick start, 143, 144f, 145b  
selection and initiation of, 140–143  
selection of, 140–143  
for sickle cell disease, 377t  
special considerations in adolescents, 141  
subdermal implant, 141–147  
transdermal, 146  
vaginal ring, 145–147
- Contrast-enhanced voiding urosonography  
(ceVUS), 702
- Controlled ventilation, 13–14
- Conventional radiographs (CR)  
for abdomen, 696–697  
advantages and disadvantages of, 689t  
for musculoskeletal, 703
- Conversion, for tapering, 162
- Conversion disorders. *See* Functional  
neurologic disorders
- Cooley anemia, 376
- Coombs test, 379  
direct, 371  
indirect, 371
- Coordination, gait and, 571
- Copper  
deficiency, neutropenia and, 380t–382t  
formulation recommendations for, 616t  
IUD, 148, 143  
recommended intakes, 606t  
reference values for, 736t–743t
- Copy number variation (deletions and  
duplications), 357–358
- CoQ10, for migraine, 584.e1t
- Cord clamping, 503, 503.e1b
- Cordarone. *See* Amiodarone HCl
- Cordron-D. *See* Carbinoxamine +  
pseudoephedrine
- Coreg. *See* Carvedilol
- Coreg CR. *See* Carvedilol
- CoreMino. *See* Minocycline
- Corneal abrasion, 53
- Corneal refractive surgery, postoperative,  
treatment for, 989
- Coronal contrast-enhanced computed  
tomography (CT), of neck and airway,  
690.e1f
- Cortef. *See* Hydrocortisone
- Cortenema. *See* Hydrocortisone
- Corticosteroids, 777, 782  
for allergic emergencies, 19  
for allergic rhinitis, 409t–410t  
budesonide and formoterol, 835–836  
fluticasone furoate + vilanterol, 941  
fluticasone propionate and salmeterol,  
944–946  
for graft-*versus*-host disease, 636–637  
for hemangioma, 212  
inhaled, dosing of, 686.e1  
intranasal, for obstructive sleep apnea,  
683  
live vaccine immunization for, 446t  
for nephrotic syndrome, 556–557  
for pediatric rheumatology, 726t–730t  
topical, 230t  
vaccinations and, 445
- Corticotropin (Acthar Gel, ACTH), 773, 880
- Cortifoam. *See* Hydrocortisone
- Cortisol, potency of, 277t
- Cortisone acetate  
formulary entry, 880  
potency of, 277t
- Cortisporin Otic. *See* Polymyxin B sulfate
- Cotempla XR-ODT, 1026–1029. *See also*  
Methylphenidate HCl
- Co-Trimoxazole. *See* Sulfamethoxazole and  
trimethoprim
- Cough syncope, 585t
- Coumadin. *See* Warfarin
- Counseling  
contraception, 141  
options, 149
- COVID-19 (SARS CoV-2), postexposure  
prophylaxis for, 440t–443t
- Cow's milk-based formulas, 609t, 611t–612t
- Cozaar. *See* Losartan
- C-peptide, 262
- CPS. *See* Carbamoyl phosphate synthetase
- CR. *See* Conventional radiographs
- CRAFFT questionnaire, 120, 120b
- Cranial bruits, 581.e1t
- Cranial nerves, examination, 570,  
570.e1t
- Craniofacial surgery, for obstructive sleep  
apnea, 683
- Craniopharyngioma, 623t
- CRE. *See* Carbapenem-resistant  
Enterobacterales
- C-reactive protein (CRP), 723  
reference values for, 736t–743t
- Creatine kinase, reference values for,  
736t–743t

- Creatinine  
   reference values for, 736t–743t  
   in urine, 744t–745t
- Creatinine clearance (CCr), 529
- Creon. *See* Pancrelipase
- Cricoid pressure (Sellick maneuver), 9
- Cricothyrotomy, needle, 90–91
- Cri-du-chat syndrome, 358
- Crisaborole, for atopic dermatitis (eczema), 231
- Critical care  
   management, 3–35  
   reference data, 35
- CRITOE mnemonic, 704, 704.e1t
- Crohn disease, 323  
   budesonide for, 833–835
- Cromolyn (Nasal crom, Gastrocrom, Opticrom, Intal, Crolom), 769, 773  
   for allergic rhinitis, 409t–410t  
   formulary entry, 880–881
- Cross-sectional imaging, for abdomen, 696–697
- Cross-sectional studies, 752t
- Croup, 691, 691.e1f  
   dexamethasone for, 893–894  
   emergency management of, 20–21  
   treatment of, 893
- CRP. *See* C-reactive protein
- CRS. *See* Cytokine release syndrome
- Cruex. *See* Clotrimazole
- Crust, 209
- Cryoprecipitate, 402t–403t  
   for von Willebrand (vW) disease, 396
- Cryptococcal meningitis  
   amphotericin B, liposomal for, 809–810  
   amphotericin B lipid complex for, 808–809  
   itraconazole for, 983–984
- Cryptococcus*, 488t–490t
- Cryptorchidism, 291–292
- Cryptosporidial diarrhea, paromomycin sulfate for, 1078
- CSF. *See* Cerebrospinal fluid; shunting
- CSF shunt malfunction, radiology for, 688
- CT. *See* Computed tomography
- CTLA-4 checkpoint inhibitor, 628t–632t
- Cushing disease, 283f
- Cushing syndrome, 278–279
- Cutaneous lava migrans, ivermectin for, 986
- Cutaneous leishmaniasis, pentamidine isethionate for, 1084
- Cutaquig, preparations for, 970–972
- Cuvitru, preparations for, 970–972
- Cuvposa. *See* Glycopyrrolate
- CVA. *See* Cerebrovascular accident
- CVS. *See* Chorionic villus sampling
- CVVH/D. *See* Continuous venovenous hemofiltration/hemodialysis
- Cyanocobalamin/vitamin B<sub>12</sub> (Cyanject, Cyomin, Dodex, Physicians EZ Use B-12, Vitamin Deficiency System B12, Nascobal, vitamin B<sub>12</sub>), 770, 776, 881–882
- Cyanject. *See* Cyanocobalamin/vitamin B<sub>12</sub>
- Cyanosis  
   in newborns, 509–511  
   in toxicology, 67.e1t–67.e3t
- Cyanotic heart disease, 516
- Cyanotic lesions, 189
- Cyanotic spells, 1043
- Cyclic neutropenia, 380t–382t
- Cyclogyl. *See* Cyclopentolate
- Cyclomydril. *See* Cyclopentolate with phenylephrine
- Cyclopentolate (Cyclogyl), 770, 882
- Cyclopentolate with phenylephrine (Cyclomydril), 770, 883
- Cyclophosphamide, 628t–632t  
   for nephrotic syndrome, 557  
   for pediatric rheumatology, 726t–730t
- Cyclosporiasis, 485t–487t
- Cyclosporine (Sandimmune, Gengraf, Neoral, Restasis, Verkazia, Cequa), 773, 776, 779–780  
   for atopic dermatitis (eczema), 231  
   formulary entry, 883–884  
   for pediatric rheumatology, 726t–730t
- Cyomin. *See* Cyanocobalamin/vitamin B<sub>12</sub>
- Cyproheptadine (Periactin), 778  
   formulary entry, 884–885  
   for migraine, 584.e1t
- Cystatin C, 533
- Cystic acne, isotretinoin for, 982
- Cystic fibrosis (CF), 678–681, 798, 822  
   amikacin sulfate for, 798–799  
   antiinflammatory agent in, 821  
   clinical manifestations of, 678, 679f  
   definition of, 678  
   diagnosis of, 678, 680f  
   diarrhea vs., 328t  
   dornase alfa for, 907  
   formulas for, 613t–614t  
   ivacaftor for, 910–911  
   obstructive pattern seen in, 665f  
   piperacillin with tazobactam for, 1093–1094  
   pulmonary exacerbations, 1021  
   spirometry and lung volume readings in, 666t  
   therapy for, 822, 984  
   treatment of, 678–681  
   vitamin A for, 1185  
   vitamin E for, 1186–1187
- Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, 678, 681t
- Cystic kidneys, nonmotile ciliopathies and, 349
- Cysticercosis, 485t–487t
- Cystitis, 462t–476t, 551  
   hemorrhagic, 1091  
   management of, 987
- Cytarabine (Ara-C), 628t–632t

- Cytochrome P450 system, examples of inducers and inhibitors of, 784
- Cytokine release syndrome (CRS), 628
- Cytomegalovirus (CMV) infection, 457t–461t, 477t–481t
- antimicrobial prophylaxis against, 634t–635t
  - ganciclovir for, 948
  - retinitis, 870, 948
  - valganciclovir for, 952
- Cytotoxic agents, for pediatric rheumatology, 726t–730t
- Cytovene. *See* Ganciclovir
- D**
- Dabigatran, 398t–399t
- adjustment in kidney failure, 1203t–1208t
- Dabigatran etexilate mesylate (Pradaxa), 778, 885–887
- Dactinomycin, 628t–632t
- Dandruff, 988
- Dantrium. *See* Dantrolene
- Dantrolene (Dantrium, Revonto, Ryanodex), 770, 779, 887–888
- Dapsone (Aczone, diaminodiphenylsulfone, DDS), 770, 776, 888–889
- for oncology patients, 634t–635t
- Daraprim. *See* Pyrimethamine
- Darbepoetin alfa (Aranesp), 767, 889–891
- Dasatinib, 628t–632t
- Daunorubicin, 628t–632t
- Daytrana. *See* Methylphenidate HCl
- DDAVP. *See* Desmopressin acetate
- D-dimer, 389
- D Drops. *See* Cholecalciferol
- DDS. *See* Dapsone
- Deafness, 353
- Death
- changes as death approaches, 644
  - concepts of, 643, 643t
  - documentation of, 646
- Death certificates, 647
- Death pronouncement, 645–646
- preparation for, 645–646
  - procedure for, 646
- Debridement, of burn, 61
- Debrox. *See* Carbamide peroxide
- Decadron. *See* Dexamethasone
- Decanoate, 959–960
- Decara. *See* Cholecalciferol
- Decision making, 641–642
- child participation in, 643–644
- Decision-making tools (DMTs), 641
- Decompensated, shock, 16
- Decontamination, 67
- Deep dermal suture, 104f
- Deep sedation, 163
- Deep-vein thrombosis (DVT)
- prophylaxis of, 914–915
  - treatment of, 915
- Deferoxamine mesylate (Desferal), 891–892
- Defibrillation, 4
- Defibrotide, for sinusoidal obstructive syndrome, 637
- Deficit repletion, 300t
- Dehydration
- clinical observations in, 296t
  - hypernatremic, 306b–307b
  - hyponatremic, 303–305, 304b
  - isonatremic, 300b
  - volume replacement strategy for, 298, 300t, 300b, 301t
- Dehydroepiandrosterone sulfate (DHEA-S), 290t
- Delayed puberty, 288f
- Delayed sleep phase syndrome, 1
- Delayed transfusion reaction, 404t–405t
- Delirium, in toxicology, 67.e1t–67.e3t
- Delivery room, 504f
- Delta gap, calculation of, 308–315
- Deltasone. *See* Prednisone
- Delzicol. *See* Mesalamine
- Dengue, 477t–481t
- Dennie-Morgan lines, 408
- Dental injuries, 48–51
- avulsion, 48–51
  - luxation, 51
  - subluxation, 51
  - tooth fracture, 51, 51t
- Dental procedures, bacterial endocarditis prophylaxis for, 851, 860, 862, 874
- Dental trauma, 48–52
- anticipatory guidance following, 51–52
  - components of tooth, 48, 49f
  - dental injuries, 48–51
    - avulsion, 48–51
    - luxation, 51
    - subluxation, 51
    - tooth fracture, 51, 51t
- differences between primary and permanent teeth, 48, 50f
- Dentition, examination of, 126
- Deoxycorticosterone (DCC) acetate, potency of, 277t
- Depacon. *See* Valproic acid
- Depakene. *See* Valproic acid
- Depakote. *See* Divalproex sodium
- Depakote ER. *See* Divalproex sodium
- Depakote Sprinkles. *See* Divalproex sodium
- Depigmentation, 234
- Depo-Medrol. *See* Methylprednisolone
- Depo-Provera. *See* Medroxyprogesterone
- Depo-Sub Q Provera 104. *See* Medroxyprogesterone
- Depot medroxyprogesterone acetate (DMPA, [Depo-Provera]), 144–146
- Depression, 803, 924
- adolescents and, 123–125
  - paroxetine for, 1079–1080
  - respiratory, procedural sedation and, 167
  - screening for, 245t, 649t
  - in toxicology, 67.e1t–67.e3t
  - treatment for, 1059, 1079

- Depressive disorders, 655–657  
 diagnosis of, 655  
 epidemiology of, 655  
 evaluation of, 657  
 management of, 650t, 657, 658f
- Dermal melanocytosis, congenital, 227
- Dermalon, characteristics of, 105t
- Dermatitis  
 allergic, 228  
 atopic (eczema), 229–231, 408, 413  
 contact, 228  
 diaper, 227–228  
 irritant, 228  
 seborrheic, 227
- Dermatologic changes, as death approaches, 644t
- Dermatology, 209–242  
 acne vulgaris and, 222–225  
 autoimmune and allergic dermatologic conditions, 228–233  
 atopic dermatitis (eczema), 229–231  
 autoimmune bullous diseases, 235.e1  
 contact dermatitis, 228  
 nail disorders, 233  
 papular urticaria, 231–232  
 pigmentation disorders, 233–234  
 Stevens-Johnson syndrome, 232–233  
 unknown rashes, 234–235  
 hair loss and, 221–222  
 neonatal dermatologic conditions, 225–228  
 congenital dermal melanocytosis, 227  
 diaper dermatitis, 227–228  
 erythema toxicum neonatorum, 225  
 milia, 225–227  
 miliaria (heat rash), 225  
 neonatal acne, 227  
 seborrheic dermatitis, 227  
 transient neonatal pustular melanosis, 225  
 skin findings, evaluation and clinical descriptions of, 209–210  
 skin infections, 212–221  
 bacterial, 220–221  
 fungal, 218–220  
 parasitic, 215–218  
 viral, 212–215  
 vascular anomalies, 210–212  
 malformations, 212, 212.e1t  
 tumors, 210–212, 212.e1t
- Dermatomal lesions, 209
- Dermatomes, 572f
- Dermatomyositis, associated antibody in, 724t
- Dermatophytid reaction. *See* Id reaction
- Desenex. *See* Miconazole
- Desensitization, 414
- Desferal. *See* Deferoxamine mesylate
- Desired factor replacement, in hemophilia, 394t
- Desloratadine, 1203t–1208t
- Desmopressin (DDAVP), for von Willebrand (vW) disease, 396
- Desmopressin acetate (DDAVP, Stimate), 770, 892–893
- Desonide, 230t
- Desoximetasone, 230t
- Desyrel. *See* Trazodone
- Detergent pods, 69t–70t
- Development, 236–267  
 abnormal, 237  
 definition of, 236–237  
 delay, 237  
 guidelines for, 237  
 milestones, 238t–242t  
 red flags, 246t  
 streams, 236  
 web resources, 260
- Developmental delay, 353
- Developmental disability, 236–267
- Developmental disorders, 237–244  
 diagnosis of, 249  
 longitudinal care of children with, 254–255  
 red flags, 246t  
 transition domains for, 255, 256t  
 transition from pediatric to adult care, 255
- Developmental evaluation, 238t–242t, 249t
- Developmental history, 246t–247t
- Developmental night waking, 243t–244t
- Developmental quotient (QI), 236–237
- Developmental screening, 237–244  
 guidelines for, 237  
 standardized, 237  
 tests and tools, 237, 245t
- Developmental surveillance, 237
- Deviancy, 237
- Dexabliss. *See* Dexamethasone
- Dexamethasone (Decadron, Dexabliss, Dxevo, HiDex, TaperDex, ZCORT, Maxidex, Hexadrol), 19, 634t, 770, 773, 775, 893–894  
 for croup, 21  
 for meningitis, 462t–476t  
 potency of, 277t  
 for spinal cord compression, 626  
 for status asthmaticus, 22t–23t  
 supression test, 279
- Dexamethasone with ciprofloxacin (Ciprodex), 893–894
- Dexedrine. *See* Dextroamphetamine
- Dexmedetomidine (Precedex), 163, 778, 784, 894–895  
 properties of, 167b–168b
- Dexmethylphenidate (Focalin), 652t–653t, 772, 895–896
- Dexrazoxane, 628t–632t
- Dextroamphetamine (Dexedrine, ProCentra, Zenedi, Xelstryl), 770, 778, 898
- Dextroamphetamine + amphetamine (Adderall, Adderall XR, Mydayis, DextroStat), 770, 896–898

- Dextroamphetamine sulfate (Zenzedi), 778, 783
- Dextrose solution, 6t–7t  
for altered level of consciousness, 31  
composition of, 297t  
for hyperglycemia and hypoglycemia, 510t  
for hyperkalemia, 311f
- Diabetes, 261–268  
autoantibodies to, 263  
diagnosis of, 261  
etiology of, 261–262, 262t  
increased risk of, 261  
management of, 263–265  
monitoring for, 265  
monogenic, 261–262  
neonatal, 262  
polygenic, 261  
screening of, for adolescents, 119t  
symptoms of, 261
- Diabetes insipidus (DI), 280–281  
desmopressin acetate for, 770, 780, 892–893  
diagnosis of, 281t  
nephrogenic, 281t  
normal (psychogenic), 281t  
vasopressin for, 1182
- Diabetes mellitus, type, 261–262, 262t
- Diabetic foot infection, treatment of, 922
- Diabetic ketoacidosis (DKA), 265–266, 267f
- Diabetic neuropathy, screening for, 266t
- Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, for substance use disorders, 121, 122t
- Dialume. *See* Aluminum hydroxide
- Dialysis, 564–566  
acute, indications for, 564  
complications of, 566t  
formulas for, 613t–614t  
hemodialysis, for ingestions, 67  
techniques for, 564–566
- Diaminodiphenylsulfone. *See* Dapsone
- Diamond-Blackfan anemia, 368t–369t, 380t–382t
- Diamox. *See* Acetazolamide
- Diaper dermatitis, 227–228
- Diarrhea, 328–329  
bismuth subsalicylate for, 774, 781, 830  
differential diagnosis of, 328, 328t  
electrolyte composition of, 301t  
management of, 329  
osmotic, 328  
secretory, 328
- Diastat. *See* Diazepam
- Diastat AcuDial. *See* Diazepam
- Diastolic sounds, 172
- Diathesis, bleeding, 77
- Diazepam (Valium, Diastat, Diastat AcuDial, Valtoco), 169t, 770, 782, 898–900  
for palliative care, 645t  
for seizures, 575t–576t  
for status epilepticus, 32t–33t
- Diazoxide (Proglycem), 778, 900
- Diclofenac, 156
- Dicloxacillin sodium (Dycill, Pathocil), 771, 777
- Dientamoeba fragilis*, paromomycin sulfate for, 1078
- Diet  
for constipation, 326  
for diarrhea, 329  
for eosinophilic esophagitis, 322  
for gastrointestinal reflux disease, 322
- Dietary reference intakes (DRIs), 603t–604t, 606t
- Dietary supplementation, 867
- Differin. *See* Adapalene
- Difcid. *See* Fidaxomicin
- Diflorasone diacetate, 230t
- Diflucan. *See* Fluconazole
- DiGeorge syndrome, 357–358  
evaluation for, 417t  
vaccine information for, 1t–3t
- DigiFab. *See* Digoxin immune Fab
- Digitek. *See* Digoxin
- Digoxin (Lanoxin, Lanoxin Pediatric, Digitek), 770, 774, 901  
adjustment in kidney failure, 1203t–1208t  
maintenance doses and, 901–902
- Digoxin immune Fab (Ovine, Digibind, DigiFab), 770, 902
- Dihydrotestosterone (DHT), 291.e1t
- 1,25-Dihydroxycholecalciferol. *See* Calcitriol
- Dilantin. *See* Phenytoin
- Dilantin Infatab. *See* Phenytoin
- Dilated cardiomyopathy, 196
- Dilated fundoscopic examination, 524
- Dilaudid. *See* Hydromorphone HCl
- Diltiazem (Cardizem, Cardizem SR, Cardizem CD, Cardizem LA, Cartia XT, Matzim LA, Taztia XT, Tiazac), 769–770, 781, 902–903
- Dilute Russell viper venom time (dRVVT), 389
- Dimenhydrinate (Dramamine, Draminate), 771, 903–904
- Dimercaprol (BAL), for lead poisoning, 74
- Dimercaprol (British anti-Lewisite), 768
- Dinutuximab, 628t–632t
- Diovan. *See* Valsartan
- Diphenhydramine (Benadryl), 634t, 768  
for allergic emergencies, 19  
for palliative care, 645t  
properties of, 159t, 167b–168b
- Diphtheria and tetanus toxoids with acellular pertussis vaccine (DTaP), 425t–430t  
after HSCT, 1t  
after solid organ transplant, 1t  
contraindications and precautions to, 435t–437t  
incorrectly perceived as contraindications or precautions to, 438t–439t
- Diphtheria and tetanus toxoids without pertussis vaccine (DT), 425t–430t  
after HSCT, 1t

- Diphtheria and tetanus toxoids without pertussis vaccine (DT) (*Continued*)  
after solid organ transplant, 1t
- Diprolene. *See* Betamethasone
- Dipropionate. *See* Betamethasone
- Diprosone. *See* Betamethasone
- Direct compression, for epistaxis, 81
- Directed donor transfusions, 407.e1
- Disability Programs and Services (website), 260
- Discharge, prior to, routine newborn care, 505
- Discharge criteria, for procedural sedation, 168
- Discontinuing interventions, 643
- Disease-modifying antirheumatic drugs (DMARDs), 726t–730t
- Disimpaction, 325
- Dislocation reduction, of finger/toe, 100–101
- Disopyramide, 1197t–1203t
- Displacement of the ETT, Obstruction, Pneumothorax, or Equipment failure (DOPE), 10
- Disseminated gonococcal infection, 139
- Disseminated intravascular coagulation, 391
- Dissociation, 237
- Dissociative sedation, 163
- Distal tubule, pH balance and, 534
- Distress, 8
- Distributive shock, 16, 17t
- Ditropan. *See* Oxybutynin chloride
- Ditropan XL. *See* Oxybutynin chloride
- Diuretics, 298–300  
acetazolamide, 770  
for hypertension, 549t–550t
- Diuril. *See* Chlorothiazide
- Divalproex sodium (Depakote), 770, 905  
for migraine, 584.e1t
- DMARDs. *See* Disease-modifying antirheumatic drugs
- DMD. *See* Duchenne muscular dystrophy
- DMSA (dimercaptosuccinic acid). *See* Succimer
- DNA cross-linker, 628t–632t
- DNA strand breaker, 628t–632t
- Do Not Attempt Resuscitation (DNAR) orders, 642
- Do Not Escalate Treatment requests, 642
- Dobutamine (Dobutrex), 771, 905
- Dobutrex. *See* Dobutamine
- Documentation, 75  
adolescents and, 116  
confidentiality and, 117  
of death, 646
- Docosate (Colace, DocuSol Kids, DocuSol Mini, Enemeez, Surfak), 769, 771, 905–906
- DocuSol Kids. *See* Docosate
- DocuSol Mini. *See* Docosate
- Dolasetron (Anzemet), 767, 906–907
- Dopamine (Intropin), 773, 907  
plasma, 279.e1t  
urine, 279.e1t
- Dopamine antagonists, 634t
- Dopamine disorders, 345t
- Dopa-responsive dystonia, 345t
- Doppler ultrasound  
in sickle cell disease, 377t  
transcranial (TCD), 377t
- Dornase alfa (DNase, Pulmozyme), 779, 907
- Doryx. *See* Doxycycline
- Dose adjustment methods, 1196–1197
- Double Antibiotic Topical. *See* Bacitracin ± polymyxin B
- Double-volume exchange transfusion, 517t, 518, 518f
- Down syndrome (Trisomy 21), 356
- Doxapram HCl (Dopram), 1160
- Doxazosin, 549t–550t
- Doxidan. *See* Bisacodyl
- Doxorubicin (adriamycin), 628t–632t
- Doxycycline (Adoxa, Acticlate, Vibramycin, Doxy, Doryx, Monodox, Oracea), 766, 771, 778, 782, 908  
for acne vulgaris, 224.e2t  
for chlamydia, 130t–134t  
for ehrlichiosis, 477t–481t  
for epididymitis, 130t–134t  
for Lyme disease, 482t–484t  
for malaria, 462t–476t  
for nongonococcal urethritis, 130t–134t  
for PID, 130t–134t, 908  
for Rocky Mountain spotted fever, 482t–484t
- Dramamine. *See* Dimenhydrinate
- Dravet syndrome, 587t–589t
- Driminate. *See* Dimenhydrinate
- Drisdol. *See* Ergocalciferol
- Dronabinol (Marinol, Syndros, tetrahydrocannabinol, THC), 774, 781, 909
- Droperidol (Inapsine), 773, 909–910
- Drug allergy, 414  
management of, 414
- Drug intolerance, 414
- Drug-induced extrapyramidal symptoms, benzotropine mesylate for, 827
- Drug-induced neuritis, pyridoxine for, 1113
- Drug-induced systemic lupus erythematosus (SLE), 714  
associated antibody in, 724t
- Drug-induced thrombocytopenia, 387
- Drugs  
dosages, 761–1195  
additional abbreviations, acronyms, and symbols, 762  
examples of inducers and inhibitors of cytochrome P450 system, 784  
explanation of breastfeeding categories, 764  
explanation of pregnancy categories, 764  
The Joint Commission, 761  
nomogram and equation for body surface area, 765

- Drugs (*Continued*)  
 note to reader, 761–762  
 sample entry, 763  
 dose adjustment methods for, 1196–1197  
 HEEADSSS assessment, 117–121  
 hyperbilirubinemia and, 332t  
 index, 766  
 in kidney failure, 1196–1208  
 for palliative care, 645t
- Drugs, Infection, Metabolic, and Structural causes (DIMS), 30
- DSM-5. *See* Diagnostic and Statistical Manual of Mental Disorders
- DT. *See* Diphtheria and tetanus toxoids without pertussis
- DTaP. *See* Diphtheria and tetanus toxoids with acellular pertussis
- Duchenne muscular dystrophy (DMD), 590–591
- Ducodyl. *See* Bisacodyl
- Ductus arteriosus, closure of, 786, 794
- Dulcolax. *See* Bisacodyl
- Dulera. *See* Mometasone furoate + formoterol fumarate
- Duocal, calories of, 610t
- Duodenal atresia, 698.e1f
- Duodenal ulcer, 931, 998  
 treatment for, 1145
- Duodote. *See* Pralidoxime chloride + atropine
- DuoNeb. *See* Ipratropium bromide
- Dupilumab, for atopic dermatitis (eczema), 231
- Duraclon. *See* Clonidine
- Duragesic. *See* Fentanyl
- Duramorph. *See* Morphine sulfate
- Duricef. *See* Cefadroxil
- Dxevo. *See* Dexamethasone
- Dyanavel XR. *See* Amphetamine
- Dycill. *See* Dicloxacillin sodium
- Dymista. *See* Azelastine and fluticasone
- Dyrenium. *See* Triamterene
- Dysfunctional pain, 152t
- Dyskeratosis congenita, 368t–369t
- Dyskinesias, ciliary, primary, 349
- Dysmenorrhea, treatment for, 967, 1049
- Dysmorphology, 347–348  
 etiologies of, 349f, 356–361  
 exam findings, examples of, 348t  
 family history of, 347  
 genetic testing for, 348, 349f, 350t–351t  
 history of, 347  
 major anomalies of, 347, 348t  
 minor anomalies of, 347, 348t  
 patterns of inheritance of, 347  
 physical examination of, 347  
 workup in, 347–348
- Dysmotility, gastrointestinal reflux disease and, 321
- Dysphoria, gender, 122t
- Dyspigmentation, 234
- Dysplasia, Greenberg, 344t
- Dyspnea, 645t
- Dystonia, dopa-responsive, 345t
- Dystonic reactions, diphenhydramine for, 904
- E**
- Ear  
 foreign body removal from, 79–80  
 newborn, 507.e1f
- Early childhood, 243t–244t
- Early Head Start, 255
- Early infantile epileptic encephalopathy (Ohtahara syndrome), 587t–589t
- Early intervention services, 254
- Early myoclonic encephalopathy, 587t–589t
- Eating, HEEADSSS assessment, 118, 119t
- Eating Disorder Screen for Primary Care (ESP), 649t
- Eating disorders, 657–659  
 diagnosis of, 657  
 epidemiology of, 659  
 evaluation of, 659  
 management of, 659  
 screening test for, 649t
- EBV. *See* Epstein-Barr virus
- Echinocandin  
 caspofungin, 768, 848–849  
 micafungin sodium, 775, 1033–1034
- Echinocytes (Burr cells), 372
- Echocardiography, 696, 187t–188t, 201, 201, 202.e1t
- ECMO. *See* Extracorporeal membrane oxygenation
- EC-Naprosyn. *See* Naproxen/naproxen sodium
- Econopred. *See* Prednisolone
- Ecstasy overdose, 69t–70t
- Eculizumab (Soliris) therapy, vaccine information for, 1t–3t
- Eczema. *See* Atopic dermatitis
- Eczema herpeticum superinfection, 231
- ED. *See* Emergency department
- Edema  
 airway, dexamethasone for, 893  
 angioedema, 411  
 bumetanide for, 768, 836  
 cerebral, 266  
 chronic kidney disease and, 565t  
 treatment of, 836, 962–963
- Edate (EDTA) calcium disodium, 768  
 for lead poisoning, 73–74
- Edinburgh Postnatal Depression Scale, 649t
- Edrophonium chloride (Enlon, Reversol, Tensilon), 771, 779
- EDS. *See* Ehlers-Danlos syndrome
- Educational history, 246t–247t
- Education/employment, HEEADSSS assessment, 118
- Edwards syndrome (Trisomy 18), 357
- EEG. *See* Electroencephalography
- EES. *See* Erythromycin
- Effect modifier (interaction), 749
- eGFR. *See* Estimated glomerular filtration rate
- Ehlers-Danlos syndrome (EDS), 360

- Ehrlichiosis, 477t–481t
- Elavil. *See* Amitriptyline
- Elbow, radiology of, 704, 704.e1t, 704.e2f, 705f, 706f, 707f
- ELBW. *See* Extremely low birth weight
- EleCare formulas, 613t–614t
- EleCare Infant and Junior, 611t–612t
- Electrocardiography (ECG), 66, 174–189
  - complexes, 174
  - lead placement, 174, 176f
  - principles, 174–180
  - systematic approach for evaluating, 175–180, 178f
    - axis, 176, 177t, 179f
    - intervals, 176, 177t
    - rate, 175
    - rhythm, 176
- Electroencephalography (EEG), for seizures, 586
- Electrolyte disturbances, in toxicology, 67.e1t–67.e3t
- Electrolyte management, 300–308
- Electrolytes, newborn and, 508–509, 510t
- Elements, 606t
- Elepsia XR. *See* Levetiracetam
- Elevated blood pressure (BP), management of, 548t
- Elexacaftor/tezacaftor/ivacaftor (Trikafta), 910–911
- Elidel. *See* Pimecrolimus
- Elimination diets, trial, 413
- Elimite. *See* Permethrin
- Eliphos. *See* Calcium acetate
- Elitek. *See* Rasburicase
- Elixophyllin. *See* Theophylline
- Elliptocytes, 372
- Elyxyb. *See* Celecoxib
- Embryonal tumor, 623t
- Emedastine (Emadine), 409t–410t
- Emergencies, gastrointestinal, 318–320
  - acute abdomen, 319–320, 320t
  - gastrointestinal bleeding, 318, 319t
- Emergency contraception (EC), 141f, 146–149
- Emergency department (ED), management, of
  - migraine headaches, 584f
- Emergency management, 3–35
  - of airway, 8–15
  - of altered level of consciousness, 28–31
  - of anaphylaxis, 19–20
  - of breathing, 8–15
  - of circulation, 3–8
  - of hypercyanotic crisis, 28, 29t
  - of hypertensive crisis, 24–26
  - of increased intracranial pressure, 32–35
  - of pulmonary hypertensive crisis, 24–26
  - of upper airway obstruction, 20–22
- Emergency plan, 165–166
- Emesis, in chemotherapy patients, 633–634
- Emfamil D-Vi-Sol. *See* Cholecalciferol
- Emigration, immunoprophylaxis for, 451
- EMLA. *See* Eutectic mixture of local anesthetics; Lidocaine and prilocaine
- Empiric antibiotic treatment, 55, 55t
- Empiric therapy, for febrile neutropenia, 809, 1021
- Employment, HEEADSSS assessment, 118
- Emverm. *See* Mebendazole
- Enalapril maleate (Vasotec, Epaned), 771, 782
  - adjustment in kidney failure, 1197t–1203t
  - formulary entry, 912–913
  - for hypertension, 549t–550t
- Enalaprilat (Vasotec IV), 782
  - adjustment in kidney failure, 1197t–1203t
  - formulary entry, 912–913
- Enbrel. *See* Etanercept
- Enbrel Mini. *See* Etanercept
- Enbrel SureClick. *See* Etanercept
- Encephalitis, definition of, 574
- Encephalopathy, 574
  - differential diagnosis of, 577b
  - hypoxic-ischemic, 520–521, 521t
- Endocarditis, 190–196
  - bacterial prophylaxis, 196, 196b, 851, 860, 862, 874
  - vancomycin for, 782
- Endocet. *See* Oxycodone and acetaminophen
- Endocrine disease, 368t–369t
- Endocrinology, 261–299
  - web resources, 293
- Endodan. *See* Oxycodone and aspirin
- Endometriosis-associated pain, 1019
- Endoscopic third ventriculostomy (ETV), 577
- Endothelial damage, 396
- Endothelin receptor antagonist, for pulmonary hypertensive crisis, 26
- Endotracheal intubation, 9–10
- Endotracheal tube (ETT), 5
  - Displacement of the ETT, Obstruction, Pneumothorax, or Equipment failure (DOPE), 10
  - placement of, 709
  - size and depth of, 503, 505t
- End-tidal CO<sub>2</sub> (EtCO<sub>2</sub>), 4
  - quantitative, 9
- Enemas
  - for constipation, 1t
  - mesalamine, 1022–1023
- Enemeez Mini. *See* Docusate
- Enfalyte solutions, 614t
- Enfamil Enfacare, 611t–612t
- Enfamil Infant, 609t, 611t–612t
- Enfamil Premature, 611t–612t
- Enfamil ProSobee, 611t–612t
- Enfaport formula, 613t–614t
- Engraftment, in hematopoietic stem cell transplantation, 636
- Engraftment syndrome, 639.e1
- Enlon. *See* Edrophonium chloride
- Enoxaparin (Lovenox), 398t–399t, 774
  - adjustment in kidney failure, 1203t–1208t
  - formulary entry, 913–915
- Enoxaparin overdose, 1109
- Enriched formulas, 611t–612t
- Ensure Clear formula, 613t–614t

- Ensure formulas, 613t–614t  
Ensure Original formula, 613t–614t  
*Entamoeba histolytica*, paromomycin sulfate  
for, 1078  
Enteral nutrition, 608, 613t–614t  
formulas for, 613t–614t  
Enteral tube feeds, use of, 608, 613t–614t  
Enteric bacterial eradication, treatment for,  
1050  
*Enterobius* (pinworm)  
mebendazole for, 782, 1018  
pyrantel pamoate for, 777–778,  
1110–1111  
Enterocolitis  
eosinophilic, 943–944  
food protein-induced, 412  
Enterohepatic recirculation, hyperbilirubinemia  
vs., 332t  
Enthesitis-related arthritis, 711t–713t  
Entocort EC. *See* Budesonide  
Enulose. *See* Lactulose  
Enuresis, imipramine for, 969  
Envarsus XR. *See* Tacrolimus  
Environmental exposures, teratogens and,  
362t  
Environmental information, toxicology and, 66  
Environmental/neighborhood disparities,  
adolescents and, 116  
Enzyme deficiencies, anemia, 369t–370t  
Enzymes, chemotherapeutic agents,  
628t–632t  
EOE. *See* Eosinophilic esophagitis  
Eosinophilia, 408  
causes of, 383  
Eosinophilic enterocolitis, 1018, 1111  
pyrantel pamoate for, 777, 1110–1111  
Eosinophilic esophagitis (EOE), 322  
Eosinophilic gastroenteritis, allergic, 412  
Eosinophilic granulomatosis with polyangiitis,  
711t–713t  
Eosinophils, 407t  
Epaned. *See* Enalapril maleate  
Ependymoma, 623t  
Epidermal melanosis, 234  
Epididymitis, evaluation and management of,  
130t–134t  
Epidiolex. *See* Cannabidiol  
Epigenetics, disorders of, 358–359  
Epiglottitis, 691, 691.e1f  
emergency management of, 20  
Epilepsy, 586  
classification of, 586.e1t  
intractable, formulas for, 613t–614t  
recurrent events that mimic, 585t  
syndromes, 587t–589t  
Epinastine (Elestat), 409t–410t  
Epinephrine, 6t–7t, 18t, 160t  
LET (lidocaine, epinephrine, tetracaine),  
159t  
plasma, 279.e1t  
racemic, 21  
Epinephrine (*Continued*)  
racemic (Asthmanefrin, S-2 Inhalant),  
776, 780  
formulary entry, 917  
for status asthmaticus, 22t–23t  
topical, 159t  
urine, 279.e1t  
Epinephrine HCl (Adrenalin, EpiPen, Auvi-Q,  
Symjepi, Epinephrine SNAP,  
Primatene Mist), 766, 771  
formulary entry, 915–917  
hypersensitivity/anaphylactic reaction of,  
916  
respiratory bronchodilator use of,  
916  
Epinephrine SNAP. *See* Epinephrine HCl  
EpiPen. *See* Epinephrine HCl  
Epistaxis, management of, 81  
Epithelial cells, in urinalysis, 530t–531t  
Epitol. *See* Carbamazepine  
Epivir. *See* Lamivudine  
Epivir-HBV. *See* Lamivudine  
Epoetin alfa (Epogen, Procrit, Retacrit,  
Erythropoietin), 767, 771–772  
formulary entry, 889–891  
Epogen. *See* Epoetin Alfa  
Epoprostenol (Flolan, Veletri, PGI2, PGX,  
prostacyclin)  
adjustment in kidney failure, 1203t–1208t  
formulary entry, 919–920  
Eprontia. *See* Topiramate  
Epstein-Barr virus (EBV), 477t–481t, 491f  
Equetro. *See* Carbamazepine  
Equipment, for endotracheal intubation, 9  
Erb-Duchenne palsy, 523t  
Ergocal. *See* Ergocalciferol  
Ergocalciferol (Calcidol, Drisdol, Ergocal), 768,  
771, 920–921  
Ergomar. *See* Ergotamine tartrate  
Ergotamine tartrate (Ergomar), 771  
Ergotamine tartrate + caffeine (Cafergot,  
Migergot), 768, 921  
Erosion, 209  
Erosive esophagitis  
in GERD, 926  
pantoprazole for, 1077–1078  
treatment for, 998  
Errors  
type I, 751  
type II, 751  
Ertapenem (Invanz), 773  
adjustment in kidney failure, 1197t–1203t  
formulary entry, 922  
EryPed. *See* Erythromycin  
Ery-Tab. *See* Erythromycin  
Erythema, reactive, 215, 216f  
Erythema infectiosum ("fifth disease"), 214  
Erythema toxicum neonatorum, 225  
Erythrocyte sedimentation rate (ESR),  
722–723, 736t–743t  
Erythrocytosis, 378

- Erythromycin (Erythrocin, Pediamycin, EES, E-Mycin, EryPed, Ery-Tab, PCE, Erygel), 771–772, 777, 845  
 for acne vulgaris, 224  
 adjustment in kidney failure, 1197t–1203t  
 for chlamydia, 130t–134t  
 for neonatal exudative conjunctivitis, 457t–461t
- Erythromycin ethyl succinate (EES), 922
- Erythromycin ethylsuccinate and acetylsulfisoxazole (Eryzole, Pediazole), 772, 777
- Erythromycin lactobionate (Erythrocin), 923
- Erythromycin stearate (Erythrocin), 922
- Erythropoietin. *See* Epoetin alfa
- ESBL. *See* Extended-spectrum beta-lactamase
- Escitalopram (Lexapro), 652t–653t  
 formulary entry, 924–925
- Eskalith. *See* Lithium
- Eslicarbazepine acetate (Aptiom), for seizures, 575t–576t
- Esmolol HCl (Brevibloc), 768  
 formulary entry, 925  
 for hypertension, 549t–550t
- Esomeprazole (Nexium), 776, 925–926
- Esophageal atresia, radiology for, 692
- Esophageal candidiasis, 936–937, 1034  
 voriconazole for, 1187–1188
- Esophagitis  
 eosinophilic, 322  
 erosive, pantoprazole for, 1077–1078  
 food allergy, 412
- ESP. *See* Eating Disorder Screen for Primary Care
- ESR. *See* Erythrocyte sedimentation rate
- Estimated blood volume, 401t
- Estimated glomerular filtration rate (eGFR), 529–533
- Estradiol, 286t
- Etanercept (Enbrel, Enbrel SureClick, Enbrel Mini), 771  
 formulary entry, 926–927
- Ethambutol HCl (Myambutol), 775  
 adjustment in kidney failure, 1197t–1203t  
 formulary entry, 928
- Ethanol, overdose, 69t–70t
- Ethilon, characteristics of, 105t
- Ethinyl estradiol, 148
- Ethosuximide (Zarontin), 783, 928–929  
 for seizures, 575t–576t
- Ethylene glycol/methanol poisoning, 69t–70t
- Etomidate (Amidate), formulary entry, 929
- Etoposide, 628t–632t
- ETT. *See* Endotracheal tube
- ETV. *See* Endoscopic third ventriculostomy
- Eutectic mixture of local anesthetics (EMLA), 159t
- Euthyrox. *See* Levothyroxine
- Evekeo. *See* Amphetamine
- Evekeo ODT. *See* Amphetamine
- Evidence-based medicine (EBM), 746–757, 747f
- Evoclin. *See* Clindamycin
- Ewing sarcoma, 620t–621t, 707.e3f
- Exacerbation  
 in asthma, prevention of, 668–676  
 symptom relief for, 999
- Exalgo. *See* Hydromorphone HCl
- Exchange transfusion  
 double-volume, 518  
 in infants, 518, 518f
- Excitation, in toxicology, 67.e1t–67.e3t
- Exclusion bias, 748
- Excoriation, 209
- Exercise recommendations, 207.e1t
- Exercise-induced bronchospasm, 793, 1042, 1131  
 albuterol for, 792–793
- Ex-Lax. *See* Senna
- Expiratory pressure, maximum, 664
- Exposure history, 66
- Extended-spectrum beta-lactamase (ESBL), resistance in, 502.e1
- External jugular puncture, catheterization and, 83–86, 111.e1–111.e4, 111.e4f
- Extina. *See* Ketoconazole
- Extracorporeal membrane oxygenation (ECMO), 513–514
- Extradural fluid collection, birth-related, 507, 508f, 508t
- Extraglomerular hematuria, 558–560
- Extravasation, in peripheral intravenous access, 83
- Extremely low birth weight (ELBW), of infants, 506
- Extrinsic hemolytic anemia, 369t–370t
- Exudate, evaluation of, 735, 735.e1t
- Eye, of newborn, 507.e1f
- Eyelid laceration, 54
- EZFE 200. *See* Polysaccharide-iron complex
- F**
- F test, 750t
- FA-8. *See* Folic acid
- Fabior. *See* Tazarotene
- Fabry disease, 344t
- FACES pain scale revised (FPS-R), 151, 153f
- Factor B deficiency, vaccine information for, 1t–3t
- Factor IX, abnormalities, 392t–393t, 397t
- Factor V Leiden, 392t–393t, 397t
- Factor VIII, abnormalities, 392t–393t, 397t
- Factor X, abnormalities, 392t–393t
- Factor XI, abnormalities, 397t
- Failure, kidney  
 antimicrobials requiring adjustment in, 1197, 1197t–1203t  
 dose adjustment methods for, 1196–1197  
 drugs in, 1196–1208  
 non-antimicrobials requiring adjustment in, 1203, 1203t–1208t

- Falciform ligament sign, of  
pneumoperitoneum, 697f, 698
- Famciclovir (Famvir), 722  
adjustment in kidney failure, 1197t–1203t  
formulary entry, 929–930
- Familial genetic information, professional  
disclosure of, 363
- Familial short stature, 282t, 283f
- Family acceptance, adolescents and, 124
- Family history, 246t–247t
- Family meetings, 641
- Family planning, adolescents and, 124
- Famotidine (Pepcid, Pepcid AC, Pepcid AC  
Maximum Strength, Pepcid  
Complete, Zantac 360, Zantac 360  
Maximum Strength), 778  
adjustment in kidney failure, 1203t–1208t  
formulary entry, 930–931
- Famvir. *See* Famciclovir
- Fanconi anemia, 368t–369t
- Fanconi syndrome, 567–568
- FAO. *See* Fatty acid oxidation
- FAST. *See* Focused assessment with  
sonography for trauma
- Fasting recommendations, for anesthesia, 164t
- Fat  
initiation and advancement of, 615t  
methods to increase, 608, 610t
- Fat malabsorption, 613t–614t
- Fat pad, of elbow, 704, 707f
- Fat requirements, 602t
- Fatty acid oxidation (FAO) disorders, 343t
- Fatty liver disease, nonalcoholic, 331
- Febrile neutropenia, empiric therapy for, 809
- Febrile seizures, 584–586
- Fecal impaction, polyethylene glycol for, 1095,  
1110
- Feeding  
in newborn care, 505  
trained night feeding, 243t–244t
- FEHCO<sub>3</sub>. *See* Fractional excretion of  
bicarbonate
- Felbamate (Felbatol), 772  
adjustment in kidney failure, 1203t–1208t  
formulary entry, 931–932  
for seizures, 575t–576t
- Felbatol. *See* Felbamate
- Felodipine, 549t–550t
- Females  
recommended dietary allowances for,  
601t  
recommended element intakes, 606t  
recommended vitamin intakes, 603t–604t
- FENa. *See* Fractional excretion of sodium
- Fenfluramine (Fintepla), for seizures,  
575t–576t
- FeNO measurement, for asthma, 667
- Fentanyl (Abstral, Actiq, Duragesic, Fentora,  
Lazanda, Sublimaze), 157t, 766,  
771–772, 774, 781  
adjustment in kidney failure, 1203t–1208t  
formulary entry, 932–933
- Fentanyl (Abstral, Actiq, Duragesic, Fentora,  
Lazanda, Sublimaze) (*Continued*)  
for PCA, 161t  
for procedural sedation, 171t
- Ferate. *See* Ferrous gluconate
- Fer-In-Sol. *See* Ferrous sulfate
- Ferretts. *See* Ferrous fumarate
- Ferric gluconate (Ferrlecit), 772, 933, 978
- Ferrimin 150. *See* Ferrous fumarate
- Ferritin, reference values of, 736t–743t
- Ferrlecit. *See* Iron; injectable
- Ferrous fumarate (Ferretts, Ferrimin 150),  
980
- Ferrous gluconate (Ferate), 772, 980
- Ferrous sulfate (Fer-In-Sol, Slow FE, Slow Iron,  
Feosol, Fergon), 772, 933, 980  
for iron-deficiency anemia, 373
- Fertility, adolescents and, 124
- Fertility awareness-based methods, of  
pregnancy prevention, 147
- Fertility preservation, in oncology patients, 638
- Fetal anomaly screening, 528.e1
- Fetal health, prenatal assessment of,  
528.e1–528.e3
- Fetal heart rate (FHR), intrapartum, 528.e2
- Fetal screening, 528.e1
- Fetroja. *See* Cefiderocol
- FEurea. *See* Fractional excretion of urea
- FEV<sub>1</sub>. *See* Forced expiratory volume in 1  
second
- Fever, 622–623  
empiric therapy for, 1021  
etiology of, 622  
in infant, 457t–461t  
management of, 622–623, 624f, 1042  
presentation of, 622  
in sickle cell disease, 374t–375t  
of unknown origin, 462t–476t  
without localizing signs, 456f
- FeverAll. *See* Acetaminophen
- Fexofenadine, 766, 1203t–1208t
- Fexofenadine ± pseudoephedrine (Allegra,  
Children's Allegra Allergy, Allegra-D  
12 Hour, Allegra-D 24 Hour), 766,  
933–934
- FHR. *See* Fetal heart rate
- Fiber requirements, 605, 607t
- Fibrinogen, 389
- Fibroma, 707.e1f
- FICA acronym, 642
- Fidaxomicin (Dificid), 770, 934
- Fifth disease, 477t–481t
- Filgrastim (Neupogen, G-CSF, Nivestym,  
Granix, Releuko, Zarxio), 776,  
934–935
- Filiform lesions, 209
- Fine-motor skills, 236
- Fingerstick, 82
- Finger/toe dislocation reduction, 100–101
- Fintepla. *See* Fenfluramine
- First morning urine protein/creatinine ratio, for  
proteinuria, 554

- First-Lansoprazole. *See* Lansoprazole  
 First-Metronidazole. *See* Metronidazole  
 First-Omeprazole. *See* Omeprazole  
 Firvanq. *See* Vancomycin  
 FISH. *See* Fluorescence in situ hybridization  
 Fissure, 209  
 Five Wishes, 644  
 5-FC. *See* Flucytosine  
 5-fluorocytosine. *See* Flucytosine  
 5p-syndrome, 358  
 Fixed proteinuria, 553  
 FK506. *See* Tacrolimus  
 FLACC pain assessment, 151, 153t  
 Flagyl. *See* Metronidazole  
 Flail chest, 44  
 Flebogamma, preparations for, 772  
 Flecainide acetate (Tambocor), 781  
     adjustment in kidney failure, 1203t–1208t  
     formulary entry, 935–936  
 Fleet Bisacodyl. *See* Bisacodyl  
 Fleet Enema. *See* Sodium phosphate  
 Fleet Enema Extra. *See* Sodium phosphate  
 Fleet Laxative. *See* Bisacodyl  
 Fleet Liquid Glycerin Supp. *See* Glycerin  
 Fleet Mineral Oil. *See* Mineral oil  
 Fleet Pedia-Lax. *See* Sodium phosphate  
 Fleqsuvy. *See* Baclofen  
 Flolan. *See* Epoprostenol  
 Flonase. *See* Fluticasone propionate  
 Flonase Sensimist. *See* Fluticasone furoate  
 Florinef. *See* Fludrocortisone acetate  
 Flovent Diskus. *See* Fluticasone propionate  
 Flovent HFA. *See* Fluticasone propionate  
 Floxin. *See* Ofloxacin  
 Floxin Otic. *See* Ofloxacin  
 Fluconazole (Diflucan), 770  
     adjustment in kidney failure, 1197t–1203t  
     formulary entry, 936–937  
     neonatal dosing, 527t–528t  
     for oncology patients, 634t–635t  
     for vulvovaginal candidiasis, 134t–136t  
 Flucytosine (Ancobon, 5-FC, 5-fluorocytosine), 766–767  
     adjustment in kidney failure, 1197t–1203t  
     formulary entry, 937  
 Fludarabine, 628t–632t  
 Fludrocortisone, 277t  
 Fludrocortisone acetate (Florinef Acetate, 9-fluorohydrocortisone, Fluohydrisone), 766, 772, 938  
 Fluid and electrolyte management  
     deficit repletion, 300t  
     maintenance fluid choice, 296, 298b  
     normal electrolyte composition, 301t  
     ongoing losses, 300t  
     volume replacement strategy, 298  
 Fluid resuscitation, 294–298  
     calculation of fluids for, 294–295  
     in diabetic ketoacidosis, 267f  
     in patients with burn, 59, 59f  
     rapid, 300t  
 Fluid resuscitation (*Continued*)  
     sample calculations, 300b  
 Fluids, new born and, 508, 509t  
 Fluids and electrolytes, 294–317  
     calculating maintenance fluid volume, 294  
 Flumadine. *See* Rimantadine  
 Flumazenil (Romazicon), 780, 938–939  
     for procedural sedation reversal, 168  
 Flunisolide (Aerospan, Nasarel, Nasalide), 766, 776, 939  
     estimated comparative daily dosages for, 3t–4t  
 Fluocinolone acetonide, 230t  
 Fluocinolone with ciprofloxacin (Otovel Otic), 871  
 Fluocinonide, 230t  
 Fluocinonide acetonide, 230t  
 Fluorescence in situ hybridization (FISH), 350t–351t  
 Fluoridated toothpaste, 605  
 Fluoride (NaFrinse, Fluoritab, Luride), 772, 774, 777  
     formulary entry, 939–940  
     recommended intakes, 605, 606t  
 Fluoride (Pediaflor), 772, 774, 777  
 Fluoritab. *See* Fluoride  
 Fluoroscopic voiding cystourethrogram (VCUG), 702  
 Fluoroscopy, advantages and disadvantages of, 689t  
 Fluoxetine hydrochloride (Prozac, Prozac Weekly, Sarafem), 779–780, 940–941  
 Flushing, in toxicology, 67.e1t–67.e3t  
 Fluticasone furoate (Flonase Sensimist, Arnuity Ellipta), formulary entry, 942  
 Fluticasone furoate + vilanterol (Breo Ellipta), formulary entry, 941  
 Fluticasone propionate (Flonase, Flovent Diskus, Flovent HFA, ArmonAir Digihaler, Veramyst), 766, 770, 772, 941  
     for allergic rhinitis, 409t–410t  
     formulary entry, 944–945  
     potency, 230t  
 Fluticasone propionate and salmeterol (Advair Diskus, Advair HFA, AirDuo Digihaler, AirDuo RespiClick), 766, 944–946  
     estimated comparative daily dosages for, 3t–4t  
 Fluvoxamine (Luvox, Luvox CR), 774, 946  
 FNDs. *See* Functional neurologic disorders  
 Focalin. *See* Dexmethylphenidate  
 Focused assessment with sonography for trauma (FAST), 45  
     for abdominal trauma, 701, 701.e1f  
 Focused patient history, for sedation, 164  
 Folate  
     recommended intakes, 602, 603t–604t  
     reference values for, 736t–743t

- Folate antagonist, 628t–632t  
Folic acid (FA-8, Folvite), 772  
    formulary entry, 947  
Folic acid deficiency, neutropenia and,  
    380t–382t  
Follicle-stimulating hormone, 285t  
Folvite. *See* Folic acid  
Fomepizole (Antizol), 767, 947–948  
Fondaparinux, 398t–399t  
Fontan procedure, 204t, 1128  
Food allergy, 410–414  
    diagnosis of, 410–413, 411f  
Food challenges, oral, 412–413  
Food intolerance, 413  
Food-specific immunotherapy, 413  
Football sign, of pneumoperitoneum, 697f,  
    698  
Forced expiratory volume in 1 second (FEV<sub>1</sub>),  
    665, 666f, 666t  
Forced vital capacity (FVC), 665, 666f, 666t  
Foreign body removal  
    from ear, 79–80  
    from nose, 80  
Foreign-body aspiration (FBA), 21–22  
Forensic autopsy, 646  
Formoterol (Foradil Aerolizer, Perforomist),  
    772, 778, 781, 835–836  
Formula-fed newborns, 505  
Formulas  
    preparation and fortification of, 608, 610t  
    properties of, 608, 609t  
    recommended amount of, 608  
    for specific clinical conditions, 608,  
    611t–614t  
Fortaz. *See* Ceftazidime  
Fortical Nasal Spray. *See* Calcitonin-salmon  
Fosaprepitant, 634t  
Foscarnet (Foscavir), 772  
    adjustment in kidney failure, 1197t–1203t  
    for CMV, 477t–481t  
    formulary entry, 948–949  
Foscavir. *See* Foscarnet  
Fosinopril, 549t–550t  
Fosphenytoin (Cerebyx), 769  
    formulary entry, 949–950  
    for status epilepticus, 32t–33t  
FPS-R. *See* FACES pain scale revised  
Fractional excretion of bicarbonate (FEHCO<sub>3</sub>),  
    534  
Fractional excretion of sodium (FENa), 533  
Fractional excretion of urea (FEurea), 533  
Fractures  
    clavicle, 507  
    imaging, 703–704  
    with outpatient referral to orthopedics, 48,  
    49t  
    requiring urgent orthopedic surgeon  
    consultation, 48  
Fragile X syndrome, 359–360  
Free and appropriate public education (FAPE),  
    254  
Free water deficit (FWD), 305  
Fresh frozen plasma (FFP), 402t–403t  
Fructose intolerance, hereditary, 341t–342t  
Full-term healthy newborn, with  
    uncomplicated delivery, 505  
Functional neurologic disorders (FNDs), 591,  
    592.e1t  
Fundoscopy exam, in headaches, 581.e1t  
Fundoscopic examination, dilated, 524  
Fungal infections, 462t–476t, 488t–490t  
    of skin, 218–220  
Fungizone. *See* Amphotericin B deoxycholate  
Furadantin. *See* Nitrofurantoin  
Furosemide (Lasix), 774  
    adjustment in kidney failure, 1203t–1208t  
    formulary entry, 950  
    for hydrocephalus, 577  
    for hypertension, 549t–550t  
FVC. *See* Forced vital capacity  
Fycompa. *See* Perampanel
- G**  
G2, 299t  
G6PD. *See* Glucose-6-phosphate  
    dehydrogenase (G6PD) assay  
GABA. *See*  $\gamma$ -aminobutyric acid  
Gabapentin (Neurontin, Gralise, Horizant),  
    645t, 773, 776, 951–952  
    adjustment in kidney failure, 1203t–1208t  
    for seizures, 575t–576t  
Gabitril. *See* Tiagabine  
Gablofen. *See* Baclofen  
GAD-7. *See* Generalized Anxiety Disorder-7  
Gait, coordination and, 571  
Galactosemia, 341t–342t  
Gallbladder disease, 701  
Galzin. *See* Zinc salts  
GamaSTAN, preparations for, 970  
Gamma benzene hexachloride. *See* Lindane  
Gamma globulin, 197  
Gammagard liquid, preparations for, 970  
Gamma-glutamyl transferase (GGT), 329, 330t  
    reference values of, 736t–743t  
Gammaked, preparations for, 970  
Gammaplex, preparations for, 970  
Gamunex-C, preparations for, 970  
Ganciclovir (Cytovene, Zirgan, Vitrasert), 770,  
    783, 952  
    adjustment in kidney failure, 1197t–1203t  
    for CMV, 457t–461t, 477t–481t  
Garamycin. *See* Gentamicin  
Garlic odor, in toxicology, 67.e1t–67.e3t  
Gastric fluid, 301t  
Gastric ulcer, 998  
    treatment for, 998  
Gastrocrom. *See* Cromolyn  
Gastroenteritis, 462t–476t  
    allergic eosinophilic, 412  
Gastroenterology, 318–337  
    web resources, 334–335  
Gastroesophageal reflux (GER), 321  
    treatment of, 1030

- Gastroesophageal reflux disease (GERD), 321–322, 520  
 pantoprazole for, 1077–1078  
 treatment of, 998
- Gastrointestinal (GI) bleeding, 318, 319t
- Gastrointestinal (GI) conditions  
 as death approaches, 644t  
 food allergy, 412
- Gastrointestinal (GI) diseases, in newborns, 519–520
- Gastrointestinal (GI) emergencies, 318–320  
 acute abdomen, 319–320, 320t  
 allergic, 19  
 gastrointestinal bleeding, 318, 319t
- Gastrointestinal (GI) procedures, 92–93  
 gastrostomy tube replacement, 92–93  
 nasogastric tube placement, 92
- Gastrointestinal (GI) tract  
 conditions of, 320–329  
 celiac disease, 323  
 constipation, 1t, 324–326, 325t, 326f, 327b  
 diarrhea, 328–329, 328t  
 eosinophilic esophagitis, 322  
 gastrointestinal reflux disease, 321–322  
 inflammatory bowel disease, 323–324  
 vomiting, 320–321, 321t  
 normal, 613t–614t
- Gastrointestinal ulceration, chronic kidney disease and, 565t
- Gastroschisis, omphalocele vs., 521t
- Gastrostomy tube replacement, 92–93
- Gas-X. *See* Simethicone
- Gatifloxacin (Zymar), 953
- Gatorade, 299t
- Gaucher disease, 344t
- GaviLAX. *See* Polyethylene glycol
- GBS. *See* Guillain-Barré syndrome
- GCSF. *See* Granulocyte colony stimulating factor
- G-CSF. *See* Filgrastim
- Gen7T Plus. *See* Lidocaine
- Gender  
 HEEDSSS assessment, 120–124  
 terminology and definitions, 122t
- Gender affirmation, for transgender and gender-diverse youth, 124t
- Gender dysphoria, 122t
- Gender expression, 122t
- Gender identity, 122t
- Gender nonbinary, 122t
- Gender nonconforming, 122t
- Gender-diverse youth  
 gender affirmation for, 124t  
 screening guidelines of, 129
- Genderqueer, 122t
- Generalized Anxiety Disorder-7 (GAD-7), 649t
- Generalized malignant neoplasm, vaccine information for, 1t–3t
- Generalized seizures, 951
- Generlac. *See* Lactulose
- Genetic disorders, hyperbilirubinemia vs., 332t
- Genetic testing  
 consent and disclosure of, 361–363  
 for cystic fibrosis, 678  
 diagnostic, clinical considerations and, 350t–351t  
 for dysmorphology, 348, 349f  
 ethics of, in pediatrics, 361–362
- Genetics, 336–365  
 conditions, patterns of, with distinctive appearance, 348–356  
 dysmorphology and, 347–348  
 metabolism and, 336–346  
 newborn metabolic screening and, 346  
 web resources, 363–364
- Genexa Kids Senna Laxative. *See* Senna
- Gengraf. *See* Cyclosporine
- Genital examination, adolescent, 125–128
- Genital herpes, 136t–138t  
 diagnostic features and management of, 136t–138t
- Genital ulcers, diagnostic features and management of, 136t–138t, 141
- Genitalia  
 ambiguous, 287–291  
 examination of, 125–128  
 female, 119t, 127f, 128  
 male, 126–128, 127f  
 of newborn, 507.e1f
- Genitourinary infections, 130t–134t
- Genitourinary procedures, 93–96  
 suprapubic bladder aspiration, 94–96, 95f–96f  
 urinary bladder catheterization, 93–94
- Genitourinary tract, radiology for, 702–703
- Gentak. *See* Gentamicin
- Gentamicin (Gentak, Garamycin), 773, 953–954  
 adjustment in kidney failure, 1197t–1203t  
 for gonorrhea, 130t–134t  
 for group B streptococcal (GBS) disease, 457t–461t  
 neonatal dosing, 527t–528t  
 for PID, 130t–134t
- Geographic lesions, 210
- GER. *See* Gastroesophageal reflux
- Gerber Good Start Gentle, 609t, 611t–612t
- Gerber Good Start Soothe, 611t–612t
- Gerber Good Start Soy, 611t–612t
- GERD. *See* Gastroesophageal reflux disease
- Germ cell tumor, 623t
- Gesell block skills, 246t–247t, 249.e2, 249.e3t
- Gestational age  
 estimation of, 507, 528.e3  
 incidence of respiratory distress syndrome by, 512t  
 predicted endotracheal tube size and depth by, 505t
- GFR. *See* Glomerular filtration rate
- GGT. *See* Gamma-glutamyl transferase
- GI hemorrhage, vasopressin for, 886, 1182
- Gianotti-Crosti syndrome, 235

- Giardia*, 462t–476t  
*Giardia lamblia*, paromomycin sulfate for, 1078  
Giardiasis, 1033  
Ginger ale, 299t  
GIR. *See* Glucose infusion rate  
Girls, target height range for, 281  
Glasgow Coma Scale, 29, 29t  
Glaucoma, acetazolamide for, 786  
Glioma, 623t  
Globe, of eyes, ruptured, 52–53  
Glomerular disease, with proteinuria, cause of, 555b  
Glomerular filtration rate (GFR), 529  
    normal values of, 529, 532t  
    proportionality constant for calculating, 532t  
Glomerular function, tests of, 529–533  
Glomerular hematuria, 557–558  
GlucaGen. *See* Glucagon HCl  
Glucagon Emergency Kit. *See* Glucagon HCl  
Glucagon HCl (GlucaGen, Glucagon Emergency Kit, Gvoke, Baqsimi), 773, 954–955  
Glucagon stimulation test, 292  
Glucerna formulas, 613t–614t  
Glucocorticoids, stress dose, 278  
Glucose  
    in cerebrospinal fluid, 743t  
    for hyperglycemia and hypoglycemia, 506f, 510t  
    for hypoglycemia, 292  
    initiation and advancement of, 615t  
    newborn and, 509  
    reference values for, 736t–743t  
    in urinalysis, 530t–531t  
Glucose infusion rate (GIR), 509  
Glucose intolerance, chronic kidney disease and, 565t  
Glucose tolerance  
    impaired, 613t–614t  
    oral glucose tolerance test (OGTT), 261  
Glucose-6-phosphate dehydrogenase (G6PD) assay, 369t–370t  
Glycate. *See* Glycopyrrolate  
Glycemic control, 265  
Glycerin, for constipation, 1t, 326  
Glycerin (Pedia-Lax, Fleet Liquid Glycerin Supp, Fleet BabyLax, Sani-Supp), 772, 777, 780, 955–956  
Glycogen storage disorders, 343t  
GlycoLax. *See* Polyethylene glycol  
Glycopyrrolate, 645t  
Glycopyrrolate (Robinul, Glycate, Glyrx-PF, Cuvposa), 770, 772, 780, 956  
Gly-Oxide. *See* Carbamide peroxide  
Glyrx-PF. *See* Glycopyrrolate  
Glytrol formula, 613t–614t  
Gocovri. *See* Amantadine hydrochloride  
GoLYTELY. *See* Polyethylene glycol  
Gonadal/germ cell tumors, 620t–621t  
Gonococcal ophthalmia, 859, 923  
Gonorrhea infections  
    evaluation and management of, 130t–134t, 138–140  
    probenecid for, 1104–1105  
GoodSense Enema. *See* Sodium phosphate  
GoodSense Mineral Oil. *See* Mineral oil  
Got transition, web resources for, 260  
Gottron papules, 720  
Gout, probenecid for, 1104–1105  
GPA. *See* Granulomatosis with polyangiitis  
Graded challenge, 414  
Graft-versus-host disease (GVHD), 636–637, 639.e1  
    acute, clinical staging and grading, 639.e1t  
Graft-versus-leukemia (GVL), 635  
Gralise. *See* Gabapentin  
Gram negative bacteria, resistance in, 502.e1–502.e2  
Gram positive bacteria, resistance in, 502.e1  
Granisetron (Sancuso, Sustol, Kytril, Granisol), 634t, 645t, 773–774, 780, 956–957  
Granix. *See* Filgrastim  
Granulocyte colony stimulating factor (GCSF), 953, 1192  
Granulomatosis with polyangiitis (GPA), 711t–713t  
Granulomatous disease, chronic, vaccine information for, 1t–3t  
Graves disease, potassium iodide for, 1098–1099  
Gray patch, tinea capitis and, 218  
Greenberg dysplasia, 344t  
Grifulvin V. *See* Griseofulvin  
Griseofulvin (Grifulvin V, Griseofulvin Microsize, Gris-PEG, Grisactin, Fulvicin U/F, Fulvicin P/G), 772–773, 957–958  
    for fungal infections, 462t–476t  
    for tinea capitis, 218–219  
Gris-PEG. *See* Griseofulvin  
Gross motor skills, 236, 238t–242t  
Group A *Streptococcus*, resistance in, 502.e1  
Group B streptococcal (GBS) disease, 455f, 457t–461t  
Group B streptococcal meningitis, penicillin G for, 810, 1080  
Growth, 281–284, 594–617  
    assessment of, 594–595  
    catch-up, requirements for, 600, 600b  
    estimate velocity, 281, 281t, 281.e1f, 281.e2f  
    general guidelines regarding, 595  
    web resources for, 616–617  
Growth charts  
    interpretation of, 594–595  
    types of, 594  
Growth delay, constitutional, 282t, 283f  
Growth failure, 597  
Growth hormone deficiency, 282  
Growth parameters, 581.e1t  
Growth plate injury, Salter-Harris classification of, 703t

- Growth retardation, chronic kidney disease and, 565t
- Guanfacine (Tenex, Intuniv), 652t–653t, 773, 781, 958–959
- Guillain-Barré syndrome (GBS), acute, 578
- Gums, examination of, 126
- GVHD. *See* Graft-versus-host disease
- GVL. *See* Graft-versus-leukemia
- Gvoke. *See* Glucagon HCl
- Gynecomastia, physiologic, in males, 126
- Gyne-Lotrimin 3. *See* Clotrimazole
- Gyne-Lotrimin 7. *See* Clotrimazole
- H**
- H2 receptor antagonists (H2Ras), for  
gastrointestinal reflux disease, 322
- Haemophilus ducreyi*, 136t–138t
- Haemophilus influenzae* type B (Hib) vaccines, 425t–430t  
after HSCT, 1t  
after solid organ transplant, 1t  
children at high risk of, 445–446  
postexposure prophylaxis of, 440t–443t
- Hair apposition technique, for laceration repair, 108
- Hair loss, 221–222
- Hair pulling, 222
- Hair Regrowth Treatment for Men. *See* Minoxidil
- Halcinonide, 230t
- Haldol. *See* Haloperidol
- Haldol Decanoate. *See* Haloperidol
- Halobetasol propionate, 230t
- Haloperidol (Haldol, Haldol Decanoate), 652t–653t, 773  
formulary entry, 959–960  
for palliative care, 645t
- Hand, foot, and mouth disease, 215
- Hand-eye coordination, 236
- Haptoglobin, reference values for, 736t–743t
- Hardware-associated bone infection, 462t–476t
- Hawthorne effect, 747
- HbsAg. *See* Hepatitis B surface antigen
- HCC. *See* Hepatocellular carcinoma
- HCTZ. *See* Hydrochlorothiazide
- HD. *See* Intermittent hemodialysis
- Head  
circumference, 581.e1t  
radiology for, 688–690
- Head imaging, in trauma, 39, 40f
- Head lice  
ivermectin for, 985–986  
permethrin for, 41085
- Head Start, 255
- Head trauma, 39–42  
acute, 32  
radiology for, 688
- Head ultrasound (HUS), 688
- Headaches, 579–583  
acute, 580b  
chronic, 580b
- Headaches (*Continued*)  
important historical information, 581b  
in malignancy, 618t  
migraine, 580–583, 585t  
emergency department management of, 584f  
precursors to, 581  
preventive therapies for, 584.e1t  
physical and neurologic examination for, 581.e1t  
red flags in, 582b
- Healthy weight, 595
- HealthyLax. *See* Polyethylene glycol
- Hearing, hard of, 353
- Heart block  
first-degree, 185t  
second-degree, 185t  
third-degree, 185t
- Heart disease  
acquired, 190–202  
congenital, 348, 352t, 189, 207, 207.e1t  
radiological contours of, 203f  
rheumatic, 202, 202b
- Heart failure, 848
- Heart murmurs, 173–174, 174t  
benign, 173  
diastolic, 175b  
grading of, 173  
pathologic, 174  
systolic, 175b
- Heart rate (HR)  
Apgar scores, 507t  
assessment of, 3  
systematic approach for evaluating ECGs, 175–180
- Heart rhythm, assessment of, 3
- Heart sounds, 172, 173b
- Heat rash. *See* Miliaria
- HEEADSSS assessment, 116–125
- Heelstick, 82
- Heel-to-ear maneuver, 507, 507.e1f
- Height, 281  
assessing, 281  
target range, 281
- Heinz bodies, 372
- Helicobacter pylori*, 462t–476t  
gastric infection, bismuth subsalicylate for, 830  
infection, 830, 874, 926, 1033  
testing for, 318
- Heliox  
for croup, 21  
for status asthmaticus, 22t–23t
- Helium, for croup, 21
- Hemangeol. *See* Propranolol
- Hemangioma, infantile, 210–212, 211t  
atenolol for, 815  
propranolol for, 1106–1108
- Hematocrit (Hct), 406t
- Hematologic diseases, in newborns, 516–519
- Hematologic malignancies, pediatric, 619t
- Hematology, 365–411

- Hematoma blocks, 101–102
- Hematopoietic stem cell transplantation (HSCT), 635–636
- allogeneic, 635–636
  - autologous, 636
  - Candida* prophylaxis in, 1034
  - complications of, 636–637
  - engraftment in, 636
  - goal of, 635
  - preparative regimens for, 635
  - types of, 635–636
  - vaccinations after, 1t, 444–445
- Hematuria, 557–560
- causes of, in children, 558t
  - definition of, 557
  - diagnostic strategy for, 558f
  - management algorithm for, 560f
- Hemi-Fontan (3–6 months), 204t
- Hemochromatosis, 341t–342t
- Hemodialysis, for ingestions, 67
- Hemoglobin (Hb)
- age-specific values, 406t
  - disorders, 369t–370t
  - in urinalysis, 530t–531t
- Hemoglobin A (HbA), interpreting, 261
- Hemoglobin A1c, reference values for, 736t–743t
- Hemoglobin Bart/hydrops fetalis, 376
- Hemoglobin electrophoresis, 371, 371t
- Hemoglobin F, reference values for, 736t–743t
- Hemoglobin H (HbH) disease, 376
- Hemoglobin SC disease, 373.e2f
- Hemoglobin SS disease, 373.e2f
- Hemolytic anemia, 365, 369t–370t, 406t
- neutropenia and, 380t–382t
- Hemolytic disorders, hyperbilirubinemia vs., 332t
- Hemolytic-uremic syndrome (HUS), 386–387
- Hemophilia A (factor VIII deficiency)
- coagulation and, 391
  - desmopressin acetate for, 892–893
- Hemophilia B (factor IX deficiency), coagulation and, 391
- Hemorrhage, intraventricular, 521–522
- Hemorrhagic cystitis, 639.e2
- Hemorrhoids, 964
- Hemostatic agent
- aminocaproic acid, 799–800
  - desmopressin acetate, 892–893
- Henoch-Schönlein purpura, 711t–713t
- HepA. *See* Hepatitis A
- Heparin, 398t–399t
- Heparin flush, 961
- Heparin sodium, formulary entry, 960–961
- Hepatic impairment, 794, 825, treatment of
- Child-Pugh category for, 843
  - dosage modification with, 984
  - treatment for, 1068, 1085
- Hepatitis A (HepA) vaccine, 425t–430t
- after HSCT, 1t
  - after solid organ transplant, 1t
- Hepatitis A (HepA) vaccine (*Continued*)
- contraindications and precautions to, 435t–437t
  - postexposure prophylaxis of, 440t–443t
- Hepatitis A virus (HAV), recommended intervals between administration, 2t
- Hepatitis B, 457t–461t, 502.e2
- serologic markers of, 493t
  - treatment for, 993
- Hepatitis B immune globulin (HBIG), recommended intervals between administration, 2t
- Hepatitis B surface antigen (HbsAg), 449f
- Hepatitis B (HepB) vaccine, 425t–430t
- after solid organ transplant, 1t
  - contraindications and precautions to, 435t–437t
  - incorrectly perceived as contraindications or precautions to, 438t–439t
  - postexposure prophylaxis of, 440t–443t
  - for preterm infants, 448, 449f
- Hepatitis B virus prophylaxis, for non-healthcare providers after percutaneous exposure to blood, 446t
- Hepatitis C, 457t–461t, 502.e2
- treatment for, 1121
- Hepatoblastoma, 620t–621t
- Hepatocellular carcinoma (HCC), 620t–621t
- Hepatosplenomegaly, in malignancy, 618t
- HepB. *See* Hepatitis B
- Hereditary elliptocytosis, 369t–370t
- Hereditary fructose intolerance (HFI), 341t–342t
- Hereditary nail disorders, 233
- Hereditary spherocytosis, 369t–370t
- Herpes
- diagnostic features and management of, 136t–138t
  - evaluation and management of, 130t–134t
  - genital, 136t–138t
  - management of, 130t–134t
- Herpes labialis, valacyclovir for, 1175
- Herpes simplex keratitis, acyclovir for, 789
- Herpes simplex virus (HSV) infection, 213–214, 457t–461t
- acyclovir for, 788–790
  - antimicrobial prophylaxis against, 634t–635t
  - eczema herpeticum superinfection, 231
  - with eczema herpeticum superinfection, 231
  - valacyclovir for, 1174–1175
- Herpes zoster
- valacyclovir for, 1174–1175
- Herpetic keratitis, ganciclovir for, 952
- Herpetiform lesions, 210
- Hexadrol. *See* Dexamethasone
- HFI. *See* Hereditary fructose intolerance
- Hib. *See* *Haemophilus influenzae* type B
- HiDex. *See* Dexamethasone

- HIE. *See* Hypoxic-ischemic encephalopathy
- High lipoprotein, 397t
- High urine output phase, of acute tubular necrosis, 562
- High-flow nasal cannula (HFNC), 13
- High-flow oxygen, in foreign body removal from nose, 80
- High-flow systems, 10
- High-frequency oscillatory ventilation (HFOV), 14
- High-value care, 749
- Hip disorders, 704–705
- Hirschsprung disease, 699  
diarrhea vs., 328t
- Hirsutism, 884, 900
- Histamine receptor antagonist, for allergic emergencies, 19
- Histamine-1 antagonist, 634t
- Histocytic disease, 619t
- Histoplasmosis, 488t–490t  
itraconazole for, 983–984
- History  
behavioral, 246t–247t  
developmental, 246t–247t  
educational, 246t–247t  
exposure, 66  
family, 246t–247t  
medical, 116–125  
menstrual, 125  
sexual, 123
- HIV. *See* Human immunodeficiency virus
- Hizentra, preparations for, 970–971
- Holliday-Segar method, 294, 295t, 295b  
sample calculations, 295b
- Holt-Oram syndrome, 352t
- Home, HEEADSSS assessment, 117
- Homeostasis, postnatal glucose, screening for and management of, 506f
- Homovanillic acid, 279.e1t
- Hookworms, 1
- Horizant. *See* Gabapentin
- Horizontal mattress suture, 104f
- Hormonal contraception, 140–143
- Hormonal therapy, oral, for acne vulgaris, 223t, 224–225
- Hospice, 640
- Hourglass sign, 704, 707f
- Household bleach, poisoning or overdose, 69t–70t
- Howell-Jolly bodies, 372, 373.e2f, 373.e3f
- HPV. *See* Human papillomavirus
- HR. *See* Heart rate
- HSCT. *See* Hematopoietic stem cell transplantation
- HSV. *See* Herpes simplex virus
- Human bites, 462t–476t
- Human immunodeficiency virus (HIV)  
infection, 477t–481t, 494–498  
with antibody deficiency, 416  
diagnosis of, 494, 494t  
evaluation and management of, 130
- Human immunodeficiency virus (HIV) infection  
(*Continued*)  
management of, 494–497, 495t–496t, 983  
monitoring of, 497  
postexposure prophylaxis, 498, 983  
pre-exposure prophylaxis, 497–498  
prevention of vertical transmission of, 1052  
screening guidelines by, 130  
treatment for, 821, 983, 993, 1053  
vaccine information for, 439–444
- Human milk  
bank donor, use of, 607  
properties of, 609t  
use of, 605–608
- Human milk fortifiers, 611t–612t
- Human papillomavirus (HPV) infection, 136t–138t
- Human papillomavirus (HPV) vaccine, 425t–430t  
after HSCT, 1t  
after solid organ transplant, 1t  
contraindications and precautions to, 435t–437t  
incorrectly perceived as contraindications or precautions to, 438t–439t
- Humatin. *See* Paromomycin sulfate
- Hunter syndrome, 344t
- Hurler syndrome, 344t
- HUS. *See* Head ultrasound
- Hyaline membrane disease. *See* Respiratory distress syndrome
- Hyaluronidase (Amphadase, Hydase, Hylenex, Vitrase), 767, 773, 783, 961–962
- Hydase. *See* Hyaluronidase
- Hydralazine hydrochloride (Apresoline), 767  
adjustment in kidney failure, 1203t–1208t  
formulary entry, 962–963  
for hypertension, 549t–550t
- Hydration, for tumor lysis syndrome, 625
- Hydrocarbon odor, in toxicology, 67.e1t–67.e3t
- Hydrocephalus, 574–577
- Hydrochlorothiazide (HydroDiuril, Microzide), 775  
formulary entry, 962–963  
for hypertension, 549t–550t
- Hydrocortisone (Solu-Cortef, Cortef, Alkindi Sprinkle, Anusol HC, Cortifoam, Cortenema, MiCort-HC, NuCort, Proctocort, Colocort), 769, 777, 780  
for adrenal insufficiency, 278  
formulary entry, 963–964  
potency, 230t, 277t
- Hydrocortisone with ciprofloxacin (Cipro HC Otic), 871–872
- Hydrolyzed casein, 611t–612t
- Hydrolyzed whey, partially, 611t–612t
- Hydromorphone, 157t, 645t  
for PCA, 161t

- Hydromorphone HCl (Dilaudid, Exalgo), 770, 772  
formulary entry, 964–965
- Hydronephrosis, congenital, imaging for, 702–703
- Hydro-Tussin CBX. *See* Carbinoxamine + pseudoephedrine
- Hydroxychloroquine (Plaquenil), 778  
formulary entry, 965  
for pediatric rheumatology, 726t–730t
- Hydroxyprogesterone, 275t
- Hydroxyurea, 377t
- Hydroxyzine (Vistaril), 782  
formulary entry, 965–966  
properties of, 167b–168b
- Hylenex. *See* Hyaluronidase
- Hyoscyamine, 644t
- Hyperammonemia  
evaluation of, 338, 339f  
in metabolic disorders, 812
- Hyperandrogenism, 287
- Hyperbilirubinemia, 332, 517t  
conjugated, 519  
differential diagnosis of, 332t  
phenobarbital for, 1086–1087  
unconjugated, 516–518
- Hypercalcemia, 308  
etiology of, 312t  
treatment of, 838
- Hypercalciuria, 534
- Hypercholesterolemia, 869, 1063
- Hypercoagulability, 396, 397t
- Hypercyanotic crisis, emergency management of, 28, 29t
- Hyperglycemia, management of, 509, 510t
- Hyperglycinemia, nonketotic, 345t
- Hypergonadotropic hypogonadism, 288f
- Hyperhomocystinemia, 397t
- Hyperimmune globulins, 419
- Hyperinsulinemia, 292–293
- Hyperinsulinemic hypoglycemia, diazoxide for, 900
- Hyperkalemia, 308, 311f, 812, 884, 974  
causes of, 310t  
chronic kidney disease and, 565t  
ECG changes in, 189  
insulin for, 974
- Hyperleukocytosis, 623–625
- Hyperlipidemia, 302  
screening for, 266t
- Hypermagnesemia, 308  
etiology of, 313t
- Hypernatremia, 279, 302, 305t
- Hypernatremic dehydration  
sample calculations, 306b  
severe, 307b
- Hypernatremic hypovolemia, 303
- Hyperoxia test, 189
- Hyperphosphatemia, 308, 314t, 796  
aluminum hydroxide for, 796–797
- Hyperpigmentation, 233–234  
postinflammatory, 229.e1f
- Hyperproteinemia, 302
- Hyperpyrexia, in toxicology, 67.e1t–67.e3t
- HyperRHO S/D Full Dose. *See* RH<sub>0</sub> (D)  
immune globulin intravenous (human)
- HyperRHO S/D Mini Dose. *See* RH<sub>0</sub> (D)  
immune globulin intravenous (human)
- Hypersal. *See* Sodium chloride
- Hypersecretory conditions  
pantoprazole for, 1077–1078  
treatment for, 998
- Hypertension (HTN), 172  
acute severe, 962  
amlodipine for, 803–804  
antihypertensive drugs for, 547, 549t–550t  
atenolol for, 815  
causes of, by age group, 546t  
chronic, 535–547  
chronic kidney disease and, 565t  
classification of, 547, 548t  
clinical evaluation of, 546–547  
definition of, 535  
diltiazem for, 902–903  
etiologies of, 535  
evaluation of, 535–547  
persistent pulmonary hypertension of the newborn, 512–514  
phentolamine mesylate for, 1087  
physical examination for, 546  
propranolol for, 1106–1108  
screening for, 266t  
in toxicology, 67.e1t–67.e3t  
treatment of, 547, 815, 844, 848, 903, 912, 962, 1172  
postoperative, 925  
pulmonary, 831, 919  
valsartan for, 1178–1179  
verapamil for, 1183–1184
- Hypertensive crisis, 807, 896, 1026  
emergency management of, 26, 27t
- Hypertensive emergency, 26
- Hypertensive urgency, 26
- Hyperthermia, malignant, dantrolene for, 1145
- Hyperthyroidism, 270–272, 272t  
treatment of, 1025
- Hypertonic saline (HTS), 303  
for increased intracranial pressure, 34  
nasal irrigation with, 409  
nebulized, for bronchiolitis, 676
- Hypertriglyceridemia, chronic kidney disease and, 565t
- Hypertrophic cardiomyopathy, sports restrictions, 207.e1t
- Hypertrophic obstructive cardiomyopathy (HOCM), 197
- Hyperuricemia  
management of, 625, 1119  
probenecid for, 1104–1105  
treatment for, 1104

- Hyperviscosity, 396
- Hyperviscosity syndrome, 513
- Hypnotic agents, 167, 169t  
properties of, 167b–168b  
toxicology with, 68t
- Hypoalbuminemia, albumin for, 791
- Hypocalcemia, 308  
etiology of, 312t  
treatment of, 840, 842
- Hypocarbica, 513
- Hypogammaglobulinemia, severe, 416
- Hypoglycemia  
definition of, 292  
evaluation of, 338, 340f  
glucagon HCl for, 954–955  
management of, 506f, 509, 510t  
neonatal evaluation of, 292–293  
in toxicology, 67.e1t–67.e3t  
treatment of, 954
- Hypogonadotropic hypogonadism, 288f
- Hypokalemia, 308, 309t  
potassium supplements for, 1099–1101
- Hypomagnesemia, 308, 313t  
treatment of, 1016–1017
- Hyponatremia, 31, 301–303, 302t
- Hyponatremic dehydration, 303–305  
sample calculations, 304b  
severe symptomatic, 304b
- Hypoparathyroidism, treatment of, 8, 921
- Hypoperfusion, in toxicology, 67.e1t–67.e3t
- Hypophosphatemia, 308, 314t  
acute, phosphorus supplements for, 1090–1091
- Hypopigmentation, 234
- Hypopigmented macules, 234, 234.e1f
- Hypopituitarism, 292
- Hypoproliferative anemia, 365
- Hypotension, 3, 16  
phenylephrine HCl for, 1088–1089  
in toxicology, 67.e1t–67.e3t
- Hypothermia  
criteria for, 521  
therapeutic, 520  
in toxicology, 67.e1t–67.e3t
- Hypothyroidism, 270, 271t  
differential diagnosis of, 283f  
newborn screening for, 270  
treatment for, 1002
- Hypotonia, 353
- Hypotonic fluid, 294
- Hypovolemia  
albumin for, 791–792  
hyponatremic, 303
- Hypovolemic shock, 16, 17t
- Hypoxia, in toxicology, 67.e1t–67.e3t
- Hypoxic-ischemic encephalopathy (HIE), 520–521, 521t
- I  
IBIH. *See* Insect bite-induced hypersensitivity
- Ibuprofen (Advil, Motrin, NeoProfen, Caldolor), 766, 768, 775–776, 966–967  
analgesic properties of, 156
- Ibuprofen (Advil, Motrin, NeoProfen, Caldolor)  
(Continued)  
for pediatric rheumatology, 726t–730t
- ICP. *See* Intracranial pressure
- Id reaction, fungal skin infections and, 220
- Identity, 1t
- Idiopathic pneumonia syndrome, 639.e2
- IDM. *See* Infant of diabetic mother
- iFerex 150. *See* Polysaccharide-iron complex
- Ifosfamide, 628t–632t
- IgG antibodies, in hemophilia, 395
- IIV. *See* Inactivated influenza vaccine
- Ileal atresia, 699, 700t
- Ileostomy fluid, 301t
- Ileus, 700
- Iloprost (Ventavis), 968  
adjustment in kidney failure, 1203t–1208t
- Image optimization, of ultrasound, 76
- Imaging  
for altered level of consciousness, 31  
cardiac, 202  
of head, 39, 40f  
modalities, 689t  
of neck, 39–41  
specific studies, 41–42
- Imatinib (Gleevec), 628t–632t
- Imipenem and cilastatin (Primaxin), 778, 968–969  
adjustment in kidney failure, 1197t–1203t
- Imipramine (Tofranil), 781, 969
- Imitrex. *See* Sumatriptan succinate
- Imitrex STAT dose. *See* Sumatriptan succinate
- Immature platelet fraction, in thrombocytopenia, 384
- Immigration  
adolescents and, 116  
immunoprophylaxis for, 451
- Immune globulin A (IgA) deficiency, 417t
- Immune globulin E (IgE) allergen-specific, 412
- Immune globulins, 772–773, 778, 782–783, 970–973  
intramuscular, 418–419, 973  
intravenous, 416–418, 971  
for ITP, 384–386  
subcutaneous, 419, 970  
vaccinations and, 445
- Immune thrombocytopenic purpura (ITP), 384–386, 418  
immune globulin for, 1120  
treatment for, 971
- Immunizations. *See also* Vaccines  
administration of, 102–103  
guidelines for, 424–434  
live vaccines, for corticosteroid therapy, 446t  
online content for, 1b–2b, 451  
recommended intervals between administration, 2t  
schedules of, 424  
screening of, for adolescents, 119t
- Immunodeficiency, 415–416  
evaluation for, 417t
- Immunoglobulin A (IgA) vasculitis, 711t–713t
- Immunology, 408–422

- Immunoprophylaxis, 423–460
- Immunosuppressant agent
- azathioprine, 818–819
  - cortisone acetate, 880
  - cyclosporine, 883–884
  - mycophenolate, 1045–1046
  - pimecrolimus, 1093
  - sirolimus, 1137–1138
  - tacrolimus, 1153–1154
- Immunosuppressives, vaccine information for, 1t–3t
- Immunotherapy
- for allergic rhinitis, 410
  - food-specific, 413
- Imodium. *See* Loperamide
- Impetigo, 220
- treatment of, 861
- Implants, subdermal, 141–147
- Impulsivity, 660–661
- diagnosis of, 660–661
  - management of, 661, 662f
- Imuran. *See* Azathioprine
- In utero forces, 361
- Inactivated influenza vaccine (IIV), 425t–430t
- after HSCT, 1t
  - after solid organ transplant, 1t
  - contraindications and precautions to, 435t–437t
  - incorrectly perceived as contraindications or precautions to, 438t–439t
  - for pregnant women, 451
- Inactivated poliovirus (IPV) vaccines, 425t–430t
- after HSCT, 1t
  - after solid organ transplant, 1t
  - contraindications and precautions to, 435t–437t
  - incorrectly perceived as contraindications or precautions to, 438t–439t
  - for pregnant women, 451
- Inactivated vaccines, 423
- Inapsine. *See* Droperidol
- Incidence, 753
- Incidental findings, disclosure of, 363
- Incision and drainage, of abscess, 108–111, 109f
- Independence, 1t
- Inderal. *See* Propranolol
- Inderal LA. *See* Propranolol
- Individualized Education Program (IEP), 254
- Individuals with Disabilities Education Improvement Act (IDEA), 254–255
- web resources for, 260
- Indocin. *See* Indomethacin
- Indomethacin (Indocin, Tivorbex), 773, 793–794
- Infant formulas, 613t–614t
- enteral nutrition components, 613t–614t
- Infant of diabetic mother (IDM), hypoglycemia and, 506f
- Infant Toddler Checklist (CSBS DP), 245t
- Infantile hemangioma
- atenolol for, 815
  - propranolol for, 1106–1108
- Infantile proctocolitis, 412
- Infantile spasms, 587t–589t
- treatment of, 880, 1195
  - vigabatrin for, 780, 1184–1185
- Infants
- age-appropriate behavioral issues, 243t–244t
  - caloric requirements, 511t
  - categorical risk factor assessment for, 455f
  - constipation in, 326
  - febrile, 456f, 491
  - with fever without localizing signs, algorithm for management of, 456f
  - formulas for, 613t–614t
  - gastrointestinal bleeding in, 319t
  - healthy, feeding, 608
  - HIV infection in, 494, 495t–496t
  - large-for-gestational-age, 506, 506f
  - malnutrition in, 597–600
  - mean TSH and T<sub>4</sub> values, 269t
  - pain assessment in, 151
  - recommended dietary allowances for, 601t
  - recommended element intakes, 606t
  - recommended vitamin intakes, 603t–604t
  - routine newborn care of, 505
  - sleep of, 683–684
  - small-for-gestational-age, 506, 506f
  - sodium and, 510t
  - very low-birth-weight, 506
  - vomiting in, 321t
- Infections
- altered level of consciousness and, 31
  - amoxicillin for, 804–805
  - anaerobic, 1032
  - chronic kidney disease and, 565t
  - complicated intra-abdominal, 858–859
  - complicated skin and skin structure, 1021
  - hyperbilirubinemia vs., 332t
  - intra-abdominal, 854, 859, 1021
  - intrauterine, 362t
  - mild/moderate, 857, 859, 861–862, 871
  - serious, 852, 858, 1149
  - severe, 804, 810, 822, 851, 859, 1047
  - piperacillin with tazobactam for, 1093–1094
  - skin, 212–221, 851
  - bacterial, 220–221
  - fungal, 218–220
  - parasitic, 215–218
  - viral, 212–215
  - treatment of, 1172
- Infectious colitis, diarrhea vs., 328t
- Infectious disease, 454–499
- antibiotics for, 502f, 502.e1
  - congenital, perinatal, neonatal, 454, 457t–461t

- Infectious disease (*Continued*)
- pediatric infections by system, 454, 462t–476t
  - pediatric tick-borne infections, 454, 482t–484t
  - pediatric viral illnesses, 454, 477t–481t
  - screening of, for adolescents, 119t
  - tuberculosis, 491–494, 492b
- Infectious rhinitis, 408
- INFeD. *See* Iron dextran
- Infertility, 681
- Infiltration, in peripheral intravenous access, 83
- Inflammation, neutropenia and, 380t–382t
- Inflammatory bowel disease (IBD), 323–324, 881, 1149
- Influenza, 477t–481t
- baloxavir marboxil for, 824–825
  - postexposure prophylaxis for, 440t–443t
- Influenza A, treatment for, 797, 1068
- Influenza vaccine, 377t
- Information bias, 748–749
- Informed consent
- of genetic testing, 362t, 363
  - vaccine, 424
- Ingestions, 67–71
- altered level of consciousness and, 31
- Ingrown nails, congenital, 233.e2f
- Inhalational anthrax
- penicillin G for, 1080–1081
  - treatment for, 1001
- Inhaled  $\beta_2$  agonist, 19
- Inhaled corticosteroids, dosing of, for asthma, 3t–4t, 686.e1
- Inhaled nitric oxide (iNO), 513
- Inhalers, metered-dose, use of, 90
- Injectable local anesthetics, 158, 160t
- Injections
- intramuscular, 103
  - subcutaneous, 102–103
- Injury
- dental, 48–51
    - avulsion, 48–51
    - luxation, 51
    - subluxation, 51
  - head, 39–42
  - traumatic, 36–67
- iNO. *See* Inhaled nitric oxide
- Insect bite-induced hypersensitivity (IBIH), 231
- Insecticide poisoning, atropine sulfate for, 817
- Insomnia, 1
- Inspiratory pressure, maximal, 664
- Instrumentation, 79
- in foreign body removal from nose, 80
- Insulin, 263
- adjustment in kidney failure, 1203t–1208t
  - for diabetic ketoacidosis, 267f
  - dosage of, 264t
  - for hyperkalemia, 311f
  - preparations for, 974
- Insulin (*Continued*)
- regular (Humulin 70/30), 1203t–1208t
  - subcutaneous, 264t
- Insulin-like growth factor 1 (IGF-1), 284t
- Insulin-like growth factor-binding protein (IGF-BP3), 282.e1t
- Intal. *See* Cromolyn
- Intellectual disability (ID), 250, 353
- diagnostic criteria for, 250
  - severity levels for, 250.e1
  - web resources for, 260
- Intention to treat (ITT), 747
- Intermittent hemodialysis (HD), 566, 566t
- Intermittent mandatory ventilation (IMV), 14
- International Society for Pediatric and Adolescent Diabetes, 293
- Interstitial fibrosis, spirometry and lung volume readings in, 666t
- Interventions
- discontinuing, 643
  - limiting, 642–643
- Intestinal amebiasis, paromomycin sulfate for, 1078
- Intestinal obstruction
- formulas for, 613t–614t
  - high, 699.e1f
  - low, 699–700, 700t
  - neonatal, 698–700, 698.e1f
- Intoxication
- acetaminophen, 71
  - disorders, 337t, 339, 341t–342t
- Intra-abdominal infection, 854, 859
- treatment of, 1021
- Intracranial pressure (ICP), increased, 76–77, 574–577, 626
- Intraerythrocytic parasites, 373.e3f
- Intramuscular immunoglobulin (IMIG), 418–419
- recommended intervals between administration, 2t
- Intramuscular (IM) injections, 103
- Intranasal antihistamines, 409t–410t
- Intranasal combination agents, 409t–410t
- Intranasal corticosteroids
- for allergic rhinitis, 409t–410t
  - for obstructive sleep apnea, 683
- Intraocular pressure, elevated, pilocarpine HCl for, 1092
- Intraosseous (IO) access, 86–88, 86f
- Intrathecal continuous infusion maintenance therapy, baclofen and, 824
- Intrathoracic trauma, 42–47
- assessment and management pearls, 42–45
  - imaging studies to consider, 45–47
- Intrauterine device (IUD), 141–145
- Intrauterine infections, 362t
- Intrauterine medication exposure, 362t
- Intrauterine substance exposure, 362t
- Intravenous access, peripheral, 82–83
- infiltration and extravasation, 83
  - ultrasound-guided procedure, 83

- Intravenous immunoglobulin (IVIG), 416–418  
for ITP, 386  
for pediatric rheumatology, 726t–730t  
recommended intervals between administration, 2t  
for unconjugated hyperbilirubinemia in the newborn, 517
- Intraventricular hemorrhage (IVH), 521–522
- Intrinsic hemolytic anemia, 369t–370t
- Intropin. *See* Dopamine
- Intubation  
in procedural sedation, 166  
rapid sequence, 9–10
- Intuniv. *See* Guanfacine
- Intussusception, 700
- Invanz. *See* Ertapenem
- Invasive aspergillosis, 1034, 1187
- Invasive candidiasis, 1033–1034
- Iodide, 975
- Iodine, recommended intakes, 606t
- Iodixanol (Visipaque), 975
- Iohexol (Omnipaque, Oraltag), 777, 975–976
- Iosat. *See* Potassium iodide
- Ipratropium bromide (Atrovent), 767, 977  
for status asthmaticus, 22t–23t
- Ipratropium bromide ± albuterol (Combivent Respimat), 976–978
- IPV. *See* Inactivated poliovirus
- Irbesartan, 549t–550t
- Iron  
for infants, 509  
injectable preparations, 978–980  
ferric gluconate (Ferrlecit), 772, 978  
iron dextran (INFeD), 770, 979  
iron sucrose (Venofer), 782, 979  
for iron-deficiency anemia, 373  
oral preparations (Niferex), 772, 980–981  
ferrous fumarate (Ferretts, Ferrimin 150), 980  
ferrous gluconate (Ferlate), 772, 980  
ferrous sulfate (Fer-In-Sol, Slow FE, Slow Iron, Feosol, Fergon), 772, 980  
polysaccharide-iron complex (EZFE 200, Poly-Iron 150, iFerex 150, NovaFerrum, NovaFerrum Pediatric Drops), 980  
overdose, 69t–70t  
recommended intakes, 602–605, 606t  
reference values for, 736t–743t
- Iron deficiency, malnutrition and, 598
- Iron deficiency anemia (IDA), 368t–369t  
management of, 373  
treatment of, 980
- Iron dextran (INFeD), 770, 773, 979
- Iron poisoning, acute, deferoxamine mesylate for, 891
- Iron sucrose (Venofer), 782, 979
- Irrigation, 79  
wound, 103
- Irritability, associated with autistic disorder  
aripiprazole for, 812–813  
treatment for, 322
- Irritable bowel syndrome  
diarrhea vs., 328t  
treatment for, 1124
- Irritant dermatitis, 228
- Isentress. *See* Raltegravir
- Isentress HD. *See* Raltegravir
- Isonatremic dehydration  
deficit replacement strategy for, 300b  
sample calculations, 300b
- Isoniazid (INH, Nydrazid, Laniazid, IsonaRif), 773–774, 776, 981–982  
adjustment in kidney failure, 1197t–1203t  
for hyperkalemia, 311f  
for TB, 493
- Isoniazid + rifampin (Rifamate), 779
- Isoproterenol (Isuprel), 773, 982
- Isopto Atropine. *See* Atropine sulfate
- Isopto Carpine. *See* Pilocarpine HCl
- Isotretinoin (Absorica, Absorica LD, Accutane, Amnesteem, Claravis, Myorisan, Zenatane), 766–767, 769, 783, 982–983  
oral, for acne vulgaris, 223t, 225
- Isovaleric acidemia, 341t–342t
- Isradipine, 549t–550t
- Isuprel. *See* Isoproterenol
- ITP. *See* Immune thrombocytopenic purpura
- Itraconazole (Sporanox, Tolsura, Onmel), 777, 780, 983–984
- ITT. *See* Intention to treat
- IUD. *See* Intrauterine device
- IV antibiotics, intermittent use of, for cystic fibrosis, 680
- Ivacaftor (Kalydeco), 681t, 984–985  
adjustment in kidney failure, 1203t–1208t
- Ivermectin (Stromectol, Sklice, Soolantra), 985–986  
for scabies, 217
- IVH. *See* Intraventricular hemorrhage
- IVIG. *See* Intravenous immunoglobulin
- J**
- J depression, 180f
- JAK. *See* Janus kinase
- Jantoven. *See* Warfarin
- Janus kinase (JAK) inhibitors, for pediatric rheumatology, 726t–730t
- Japanese encephalitis (JE) vaccine (JE-VC), 431t–433t  
contraindications and precautions to, 435t–437t
- Jaundice, in toxicology, 67.e1t–67.e3t
- JDM. *See* Juvenile dermatomyositis
- JE-VC. *See* Japanese encephalitis vaccine
- JIA. *See* Juvenile idiopathic arthritis
- Joint/bone pain, in malignancy, 618t

- Jornay PM, 1026–1029. *See also*  
Methylphenidate HCl
- Jugular puncture, external, catheterization  
and, 83–86, 111.e1–111.e4, 111.e4f
- Juvenile dermatomyositis (JDM), 720
- Juvenile idiopathic arthritis (JIA), 710, 927  
associated antibody in, 724t  
classification of, 711t–713t  
treatment of, 1149
- Juvenile myoclonic epilepsy, 587t–589t
- Juvenile rheumatoid arthritis (JRA), 861
- K**
- Kadian. *See* Morphine sulfate
- Kalydeco. *See* Ivacaftor
- Kanamycin (Kantrex), 774
- Kaopectate. *See* Bismuth subsalicylate
- Kao-Tin. *See* Bismuth subsalicylate
- Kaspargo Sprinkle. *See* Metoprolol
- Kapvay. *See* Clonidine
- Karbinal ER. *See* Carbinoxamine
- Karyotype, 350t–351t
- Kate farms formulas, 613t–614t
- Katerzia. *See* Amlodipine
- Kawasaki disease, 198–201, 716t–719t  
aspirin for, 814  
guidelines for treatment and follow-up,  
200.e1t  
immune globulin for, 971  
incomplete, 198–199, 200f  
IVIG for, 418
- Kearns-Sayre syndrome, 345t
- Kedbumin. *See* Albumin
- Keflex. *See* Cephalexin
- Kemstro. *See* Baclofen
- Kenalog. *See* Triamcinolone; topical  
preparations
- Kenalog-10. *See* Triamcinolone; injection  
preparations
- Kenalog-40. *See* Triamcinolone; injection  
preparations
- Kenalog-80. *See* Triamcinolone; injection  
preparations
- Keppra. *See* Levetiracetam
- Keppra XR. *See* Levetiracetam
- Keratoconjunctivitis sicca, 720
- Keratolytics, for viral skin infections, 213
- Kerion, 218
- Ketamine (Ketalar), 162, 774, 987  
for procedural sedation, 171t  
properties of, 167b–168b  
for status asthmaticus, 22t–23t
- Ketamine + midazolam + atropine  
("ketazolam"), 171t
- Ketoacidosis, diabetic, 265–266
- KetoCal formulas, 613t–614t
- Ketoconazole (Nizoral, Xolegel, Extina,  
Ketodan), 772, 776, 783, 987–988
- Ketodan. *See* Ketoconazole
- Ketogenic diet, 590
- Ketones, in urinalysis, 530t–531t
- Ketorolac (Toradol, Acular, Acular LS, Acuvail),  
766, 988–989  
analgesic properties of, 156
- Ketotifen fumarate (Zaditor), 409t–410t
- Kidney failure  
antimicrobials requiring adjustment in,  
1197, 1197t–1203t  
dose adjustment methods for, 1196–1197  
drugs in, 1196–1208  
non-antimicrobials requiring adjustment  
in, 1203, 1203t–1208t
- Kidney function tests, 529–534
- Kitabis Pak. *See* Tobramycin
- Klinefelter syndrome, 357
- Klonopin. *See* Clonazepam
- Kloxxado. *See* Naloxone
- Klumpke paralysis, 523t
- Knee arthrocentesis, 101
- Koilonychia, 233, 233.e2f
- Kondremul. *See* Mineral oil
- Konsyl. *See* Psyllium
- Kostmann syndrome, 380t–382t
- K-PHOS Neutral. *See* Phosphorus  
supplements
- Krabbe disease, 344t
- Kristalose. *See* Lactulose
- Kruskal-Wallis analysis of variance by ranks,  
750t
- Kytril. *See* Granisetron
- L**
- Labetalol (Normodyne, Trandate), 776, 782  
formulary entry, 991–992  
for hypertension, 549t–550t
- Laboratory studies, liver, 329, 330t
- Laceration repair, 103–108  
hair apposition technique, 108  
skin staples, 107  
suturing, 103–107, 104f, 105t  
tissue adhesives, 107–108  
wound irrigation, 103
- Lacerations, of eyelid, 54
- Lacosamide (Vimpat), 782  
adjustment in kidney failure, 1203t–1208t  
formulary entry, 989–991  
for seizures, 575t–576t
- LaCrosse Complete. *See* Sodium phosphate  
Lactate, 959  
reference values for, 736t–743t
- Lactate dehydrogenase, reference values for,  
736t–743t
- Lactated Ringers, 297t
- Lactation  
recommended element intakes, 606t  
recommended vitamin intakes, 603t–604t
- Lactational amenorrhea (LAM), 141f
- Lactic acidosis  
fatal, 1024  
mitochondrial encephalomyopathy, 345t
- Lactose intolerance, 613t–614t
- Lactose malabsorption, diarrhea vs., 328t

- Lactulose (Constulose, Enulose, Generlac, Kristalose, Cephulac, Chronulac), 769, 771, 774, 992  
for constipation, 1t, 326
- LAIV. See Live, attenuated influenza vaccine
- LAM. See Lactational amenorrhea
- LAMA. See Long-acting muscarinic antagonist
- Lamictal. See Lamotrigine
- Lamictal ODT. See Lamotrigine
- Lamictal XR. See Lamotrigine
- Lamisil. See Terbinafine
- Lamisil AT. See Terbinafine
- Lamivudine (EpiVir, EpiVir-HBV, 3TC), 766, 771  
adjustment in kidney failure, 1197t–1203t  
formulary entry, 992–993  
zidovudine with abacavir and lamivudine (Trizivir), 1191  
zidovudine with lamivudine (Combivir), 1191
- Lamotrigine (Lamictal, Subvenite, Lamictal ODT, Lamictal XR), 774  
formulary entry, 993–998  
for seizures, 575t–576t
- Language, 236  
development, 238t–242t, 245t
- Laniazid. See Isoniazid
- Lanoxin. See Digoxin
- Lanoxin Pediatric. See Digoxin
- Lansoprazole (Prevacid, Prevacid SoluTab, First-Lansoprazole), 772, 778, 998–999
- Lanugo, 507.e1f
- LARC. See Long-acting reversible contraception
- Large for gestational age (LGA), 506, 506f
- Lariam. See Mefloquine HCl
- Laryngeal mask airway (LMA), 9
- Lasix. See Furosemide
- LAST. See Local Anesthetic Systemic Toxicity
- Last menstrual period (LMP), 528.e3
- Laxatives  
bisacodyl, 829–830  
for constipation, 1t  
docusate, 905–906  
glycerin, 955–956  
magnesium citrate, 1015  
magnesium hydroxide, 1015–1016  
mineral oil, 1037–1038  
polyethylene glycol, 1095  
psyllium, 1110  
senna, 1133–1134  
sodium phosphate, 1141
- Lazanda. See Fentanyl
- LCAHD. See Long-chain L-3 hydroxyacyl-CoA dehydrogenase
- L-Carnitine. See Carnitine
- Lead, reference values for, 736t–743t
- Lead poisoning, 69t–70t, 72–74, 368t–369t  
management of, 73t
- Lead-time bias, 749
- Learning disabilities (LDs), 250–251
- Least restrictive environment (LRE), 254
- Leflunomide, for pediatric rheumatology, 726t–730t
- Left bundle-branch block (LBBB), 186t
- Legg-Calvé-Perthes disease, imaging for, 705
- Leigh disease, 345t
- Leishmania chagasi*, pentamidine isethionate for, 1084
- Leishmania donovani*, pentamidine isethionate for, 1084
- Leishmania infantum*, pentamidine isethionate for, 1084
- Leishmania (Viannia) panamensis*, pentamidine isethionate for, 1084
- Leishmaniasis  
amphotericin B, liposomal for, 809  
cutaneous, pentamidine isethionate for, 1084
- Lemierre syndrome, 462t–476t
- Length, conversion formulas for, 735
- Lennox-Gastaut syndrome, 587t–589t, 843, 1130  
therapy for, 1166
- Leprosy, dapsone for, 888
- LET (lidocaine, epinephrine, tetracaine), 159t
- Lethargy, emergency management of, 28
- Leucovorin, 628t–632t
- Leukocyte adhesion deficiency, 417t  
vaccine information for, 1t–3t
- Leukocyte esterase test, 530t–531t, 551
- Leukocytes, 407t
- Leukocytosis, 383–384
- Leukostasis, 623–625
- Levalbuterol (Xopenex, Xopenex HFA), 783, 999
- Levaquin. See Levofloxacin
- Levetiracetam (Keppra, Keppra XR, Elepsia XR, Roweepra, Spritam), 774, 999–1001  
adjustment in kidney failure, 1203t–1208t  
for seizures, 575t–576t  
for status epilepticus, 32t–33t
- Levocarnitine. See Carnitine
- Levofloxacin (Levaquin, Quixin, Iquix), 773–774, 779  
adjustment in kidney failure, 1197t–1203t  
formulary entry, 1001–1002  
for oncology patients, 634t–635t
- Levonorgestrel, 148
- Levophed. See Norepinephrine bitartrate
- Levothyroxine (Synthroid, Euthyrox, Levoxyl, Tirosint, Thyquidity, Tirosint-Sol, Unithroid), 781–782, 1002–1004
- Levoxyl. See Levothyroxine
- Lexapro. See Escitalopram
- LGA. See Large for gestational age
- LGV. See Lymphogranuloma venereum
- Lialda. See Mesalamine
- Lichenification, 209
- Lidocaine, epinephrine, tetracaine (LET), 159t
- Lidocaine (Xylocaine, L-M-X, Lidoderm, Gen7T Plus), 6t–7t, 160t, 774, 783  
for analgesia and sedation, 159t

- Lidocaine (Xylocaine, L-M-X, Lidoderm, Gen7T Plus) (*Continued*)  
 formulary entry, 1003–1004  
 for mucositis pain control, 633  
 topical, 159t  
 viscous, 159t
- Lidocaine and prilocaine (Oraqix, EMLA), 777, 1004–1005
- Lidoderm. *See* Lidocaine
- Lifestyle, gastrointestinal reflux disease and, 322
- Lifestyle modification, for migraine headache, 582–583
- Light transmission aggregometry (LTA), 389
- Likelihood ratio (LR), 755
- Limb conditions, 353–354
- Limit setting, 243t–244t
- Limiting interventions, 642–643
- Lindane (gamma benzene hexachloride), 773, 1005–1006
- Linear lesions, 209
- Linezolid (Zyvox), 783, 1006–1007
- Lioresal. *See* Baclofen
- Lipase, reference values for, 736t–743t
- Lipids  
 recommendations for monitoring, 207  
 reference values for, 736t–743t  
 screening, 207
- Liquid hope formulas, 613t–614t
- Liquigen, calories of, 610t
- Liraglutide (Saxenda, Victoza), formulary entry, 780, 782, 1007
- Lisdexamfetamine (Vyvanse), 652t–653t, 783, 1007–1008
- Lisinopril (Prinivil, Qbrelis, Zestril), 778, 783  
 adjustment in kidney failure, 1203t–1208t  
 formulary entry, 1008–1009  
 for hypertension, 549t–550t
- Lithium (Lithobid, Eskalith), 774  
 adjustment in kidney failure, 1203t–1208t  
 formulary entry, 1009–1010
- Lithobid. *See* Lithium
- Live, attenuated influenza vaccine (LAIV)  
 after HSCT, 1t  
 after solid organ transplant, 1t  
 contraindications and precautions to, 435t–437t  
 incorrectly perceived as contraindications or precautions to, 438t–439t
- Live, attenuated vaccines, 423  
 contraindications and precautions to, 435t–437t  
 guidelines for, 434  
 for pregnant women, 451
- Live vaccine immunization, for corticosteroid therapy, 446t
- Liver  
 conditions of, 329–332  
 acute liver failure, 329–331, 331t  
 hyperbilirubinemia, 332, 332t  
 nonalcoholic fatty liver disease, 331  
 laboratory studies, 329, 330t
- Liver cell injury, 329
- Liver disease, 681  
 coagulation and, 391  
 genetics and, 354  
 vitamin E for, 1187
- Liver dysfunction, warfarin for, 1189
- Liver failure  
 in acetaminophen overdose, 71  
 acute, 329–331, 331t
- Live-virus vaccines, during biologic response modifiers, 445
- LMP. *See* Last menstrual period
- L-M-X. *See* Lidocaine
- Local Anesthetic Systemic Toxicity (LAST), checklist for treatment of, 158, 160f
- Local anesthetics, 158  
 injectable, 158, 160t  
 topical, 158, 159t  
 toxicity of, 158, 160f
- Locomotion, 236
- Lodoxamide (Alomide), formulary entry, 1010
- Lodoxamide-tromethamine, 409t–410t
- Lomefloxacin (LMX), 159t
- Lomustine, 628t–632t
- Long arm posterior splint, 97, 98f
- Long bone trauma, 47–48
- Long QT disorders, 349
- Long QT syndrome, 205, 207.e1t
- Long-acting  $\beta_2$ -adrenergic agonist  
 budesonide and formoterol, 835–836  
 fluticasone furoate + vilanterol, 941  
 fluticasone propionate and salmeterol, 944–946  
 salmeterol, 1131–1132
- Long-acting muscarinic antagonist (LAMA), 667
- Long-acting reversible contraception (LARC), 141
- Long-chain L-3 hydroxyacyl-CoA dehydrogenase (LCAHD) deficiency, 343t
- Loop diuretics  
 bumetanide, 836  
 furosemide, 950  
 for hypertension, 549t–550t
- Loperamide (Imodium, Imodium A-D), 773, 1010–1011
- Lopressor. *See* Metoprolol
- Loratadine (Alavert, Claritin, Claritin Children's Allergy, Claritin RediTabs), 769  
 adjustment in kidney failure, 1203t–1208t  
 formulary entry, 1011–1012
- Loratadine + pseudoephedrine (Claritin-D 12 Hour, Claritin-D 24 Hour, Alavert D-12 Hour Allergy and Congestion, Loratadine-D 12 Hour, Loratadine-D 24 Hour, Allergy Relief-D), 769, 1011–1012
- Loratadine-D 12 Hour. *See* Loratadine + pseudoephedrine
- Loratadine-D 24 Hour. *See* Loratadine + pseudoephedrine

Lorazepam (Ativan, Loreev XR), 169t, 767  
 formulary entry, 1012  
 for palliative care, 645t  
 for status epilepticus, 32t–33t  
 Loreev XR. *See* Lorazepam  
 Losartan (Cozaar), 769  
 formulary entry, 1013  
 for hypertension, 549t–550t  
 Loss to follow-up bias, 748  
 Lotrimin AF. *See* Clotrimazole; Miconazole  
 Lovenox. *See* Enoxaparin  
 Low-birth-weight (LBW) infants, 506  
 serum immunoglobulin levels, 421t  
 Low-density lipoprotein (LDL) cholesterol, 207  
 Lower motor neuron findings, 572.e1t  
 Lower urinary tract obstruction, 523–524  
 Low-flow systems, 10  
 Low-molecular-weight heparin (LMWH)  
 enoxaparin, 913–915  
 for thrombosis, 398t–399t  
 Low-value care, 749  
 LR. *See* Likelihood ratio  
 Ludwig angina, 462t–476t  
 Lumacaftor and ivacaftor (Orkambi), 681t,  
 1013–1015  
 Lumbar puncture, 76–79  
 in lateral position, 78f  
 perform, 582b  
 in sitting position, 77, 78f  
 for TB, 493  
 ultrasound-guided, 111.e1, 111.e2f,  
 111.e3f, 111.e3f  
 LUMBAR syndrome, 210–211  
 Luminal. *See* Phenobarbital  
 Lung volumes, 665, 666f, 666t  
 Luteinizing hormone, 285t  
 Luvox. *See* Fluvoxamine  
 Luvox CR. *See* Fluvoxamine  
 Luxation, 51  
 Luxiq. *See* Betamethasone  
 Lyme disease, 482t–484t  
 early, amoxicillin for, 805  
 treatment of, 861  
 Lymphadenopathy, in malignancy, 618t  
 Lymphocytes, atypical, 372  
 Lymphogranuloma venereum (LGV), 139  
 Lymphoma, 619t  
 Lyrica. *See* Pregabalin  
 Lyvispah. *See* Baclofen

## M

Maalox. *See* Aluminum hydroxide with  
 magnesium hydroxide  
 Maalox Children's. *See* Calcium carbonate  
 MAC. *See* Mycobacterium avium complex  
 Macrobid. *See* Nitrofurantoin  
 Macrochantin. *See* Nitrofurantoin  
 Macrolides  
 azithromycin, 820–821  
 clarithromycin, 874–875  
 erythromycin, 922–924

Macrolides (*Continued*)  
 fidaxomicin, 934  
 for neonatal pneumonia, 457t–461t  
 Macrophage activation syndrome (MAS), 710  
 Macroscopic (gross) hematuria, 557  
 Macule, 209  
 hypopigmented, 234, 234.e1f  
 Mag-200. *See* Magnesium oxide  
 Magnacal Renal formula, 613t–614t  
 Magnesium  
 formulation recommendations for, 616t  
 for migraine, 584.e1t  
 recommended intakes, 606t  
 reference values for, 736t–743t  
 Magnesium citrate, 1015  
 for constipation, 1t  
 Magnesium disturbances, 308  
 Magnesium hydroxide (Milk of Magnesia,  
 Pedia-Lax), 775, 1015–1020  
 Magnesium oxide (Mag-200, Mag-Ox 400,  
 Uro-Mag), 774, 1016  
 Magnesium sulfate (MgSO<sub>4</sub>, Epsom salts),  
 6t–7t, 762, 771, 1016–1017  
 for status asthmaticus, 22t–23t  
 Magnetic resonance  
 cholangiopancreatography (MRCP),  
 696–697  
 Magnetic resonance enterography (MRE),  
 696–697  
 Magnetic resonance imaging (MRI), 688  
 advantages and disadvantages of, 689t  
 computed tomography vs, 688  
 fast sequences, 688  
 for musculoskeletal, 703  
 ultrafast, 577  
 Mag-Ox 400. *See* Magnesium oxide  
 Malabsorption  
 differential diagnosis of, 283f  
 lactose, diarrhea vs., 328t  
 syndromes, 413  
 treatment of, 920, 1187  
 Malabsorption syndrome, vitamin A for, 1185  
 Malaria, 462t–476t, 1117  
 acute, 965  
 chloroquine-resistant, 1020, 1103  
 doxycycline for, 908  
 primaquine phosphate for, 1103  
 prophylaxis, 864, 908, 965, 1020  
 treatment of, 865, 965, 1020  
 Males  
 recommended dietary allowances for,  
 601t  
 recommended element intakes, 606t  
 recommended vitamin intakes, 603t–604t  
 Malignancy  
 immunoprophylaxis for, 444  
 red flags for, 618t  
 Malignant hyperthermia, dantrolene for,  
 887  
 Malignant neoplasm, generalized, vaccine  
 information for, 1t–3t  
 Mallampati classification system, 165f

- Malnutrition  
 approach to management of, 600, 600b  
 chronic, re-feeding syndrome and, 600  
 definitions for, 597, 598t  
 diagnostic evaluation of, 599  
 differential diagnosis of, 598  
 in infants and children, 597–600  
 physical exam findings consistent with, 598–599  
 red flags, 599–600
- Manganese  
 formulation recommendations for, 616t  
 recommended intakes, 606t
- Mannerisms. *See* Stereotypies
- Mannitol (Aridol, Osmitol, Resectisol), 767, 777, 779  
 formulary entry, 1017–1018  
 for increased intracranial pressure, 34
- Mann-Whitney U test, 750t
- Manual removal/instrumentation, 79
- Mapap. *See* Acetaminophen
- Maple syrup urine disease, 341t–342t
- Marfan syndrome, 360
- Marinol. *See* Dronabinol
- Maroteaux-Lamy syndrome, 344t
- MAS. *See* Macrophage activation syndrome
- Mass, 209
- Mast cell stabilizers, 409t–410t
- Mastoiditis, 462t–476t
- Maternal AFP, 528.e1, 528.e1b
- Maternal medical conditions, teratogens and, 362t
- Matzim LA. *See* Diltiazem
- Maxalt. *See* Rizatriptan benzoate
- Maxalt-MLT. *See* Rizatriptan benzoate
- Maxidex. *See* Dexamethasone
- Maxillary sinusitis  
 acute, 856, 874
- Maximal inspiratory pressure (MIP), 664
- Maximum expiratory pressure (MEP), 664
- Maxipime. *See* Cefepime
- Maxitrol. *See* Neomycin/polymyxin B + dexamethasone
- Maxivate. *See* Betamethasone
- MCAD. *See* Medium-chain acyl-CoA dehydrogenase
- MDRD. *See* Modification of diet in renal disease
- Mean arterial pressure (MAP), 172
- Mean cell hemoglobin concentration (MCHC), 367, 406t
- Mean corpuscular volume (MCV), 406t
- Measles, 477t–481t  
 immune globulin for, 971, 973  
 postexposure prophylaxis of, 440t–443t  
 supplementation in, 1185
- Measles, mumps, rubella (MMR)  
 immunoprophylaxis, 418  
 recommended intervals between administration, 2t
- Measles, mumps, rubella (MMR) vaccines, 425t–430t  
 after HSCT, 1t  
 after solid organ transplant, 1t  
 contraindications and precautions to, 435t–437t  
 incorrectly perceived as contraindications or precautions to, 438t–439t
- Mebendazole (Emverm, Vermox), 782, 1018
- Mechanical ventilation, 1036  
 sedation with, 1036
- Meconium aspiration syndrome, 695
- Meconium ileus, 700, 700t, 700.e1f
- MECP2* mutations, 359
- Mediastinal mass, 696  
 differential diagnosis of, 696t
- Medical history, of adolescents, 116–125  
 other aspects of, 125
- Medical Orders for Life-Sustaining Treatment (MOLST) forms, 643
- Medication  
 for addiction treatment, 121  
 administration of, 102–103  
 adolescents and, 125  
 coagulation and, 391  
 for constipation, 326
- Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, 343t
- Medium-chain triglyceride (MCT) oil, calories of, 610t
- Medrol. *See* Methylprednisolone
- Medroxyprogesterone (Depo-Provera, Provera, Depo-Sub Q Provera 104), 770, 779, 1019
- Meetings, family, 641
- Mefloquine HCl (Lariam), 774, 1019–1020
- Mefoxin. *See* Cefoxitin
- Melanoma, 233–234
- MELAS. *See* Mitochondrial encephalomyopathy; lactic acidosis
- Meloxicam, for pediatric rheumatology, 726t–730t
- Melphalan, 628t–632t
- Membrane disorders, anemia, 369t–370t
- MenACWY. *See* Meningococcal vaccines
- MenB. *See* Meningococcal B vaccine
- Mendelian disorders, 360–361
- Meningitis, 462t–476t, 852  
 ampicillin/sulbactam for, 811  
 cerebrospinal fluid analysis in, 494t  
 treatment for, 811, 852, 854, 857, 1080  
 vancomycin for, 1179
- Meningococcal B vaccine (MenB), 425t–430t  
 after HSCT, 1t  
 after solid organ transplant, 1t  
 contraindications and precautions to, 435t–437t  
 postexposure prophylaxis of, 440t–443t
- Meningococcal disease, children at high risk of, 446–448

- Meningococcal vaccines (MenACWY),  
425t–430t  
after HSCT, 1t  
after solid organ transplant, 1t  
for children, with sickle cell disease,  
377t  
contraindications and precautions to,  
435t–437t  
MenACWY-CRM (Menveo), 447  
MenACWY-D (Menactra), 447–448  
postexposure prophylaxis of, 440t–443t
- Menkes, 341t–342t
- Mens Rogaine Extra Strength. *See* Minoxidil
- Menstrual history, of adolescents, 125
- Mental health disorders, screening tests for,  
245t
- Mental status exam, 570, 648
- Mentzer index, 365
- MEP. *See* Maximum expiratory pressure
- Meperidine, 156, 1203t–1208t
- Mephyton. *See* Phytonadione
- Mepro. *See* Atovaquone
- Mercaptopurine (6-MP), 628t–632t
- Meropenem (Merrem), 775  
adjustment in kidney failure, 1197t–1203t  
formulary entry, 1020–1021
- MERRF. *See* Myoclonic epilepsy with ragged  
red fibers
- Mesalamine (Apriso, Asacol HD, Canasa,  
Delzicol, Lialda, Pentasa, Rowasa,  
SfRowasa, 5-aminosalicylic acid,  
5-ASA), 766–768, 770, 774, 777,  
780, 1022–1023
- Messenger RNA vaccines, 423
- Mestinon. *See* Pyridostigmine bromide
- Meta-analysis, 752t
- Metabolic acidosis, 310, 871, 965,  
1139  
anion gap (AGMA), 308  
etiology of, 316f  
evaluation of, 337, 338f  
nonelevated anion gap, 311–312
- Metabolic alkalosis, 310  
etiology of, 316f
- Metabolic crisis, management of, 339–340
- Metabolic disease  
categories of, 336, 337t, 339  
commonly used medications of, 345–346  
laboratory tests of, 337  
subsequent evaluation for, 337
- Metabolic disorders  
hyperammonemia in, 812  
hyperbilirubinemia vs., 332t
- Metabolic function, laboratory studies for,  
329
- Metabolic screening, newborn, 346, 505
- Metabolism, 336–346  
clinical presentation of, 1f, 336–337,  
336b, 337t  
defects, 345t  
evaluation of, 337–338
- Metadate CD, 1028
- Metadate ER. *See* Methylphenidate HCl
- Metal disorders, 341t–342t
- Metamucil. *See* Psyllium
- Metanephrines  
plasma, 279  
urine, 279, 279.e1t
- Metered-dose inhalers, use of, 90
- Metered-dose spacer, use of, 90
- Metformin (Glumetza, Fortamet, Riomet,  
Glucophage, Glucophage XR),  
772–773, 780  
formulary entry, 1023–1024  
with sulfonyleureas, 1024
- Methadone, 157t
- Methadone HCl (Dolophine, Methadose), 771,  
775  
adjustment in kidney failure, 1203t–1208t  
formulary entry, 1024–1025
- Methemoglobinemia, 189.e1t
- Methicillin-resistant *Staphylococcus aureus*  
(MRSA), resistance in, 502.e1
- Methimazole (Tapazole), 781, 1025
- Methohexital, 169t
- Methotrexate (MTX), 628t–632t  
for atopic dermatitis (eczema), 231  
for pediatric rheumatology, 726t–730t
- Methylation  
analysis, 350t–351t  
disorders of, 358–359
- Methylene blue (ProvayBlue, Urolene Blue),  
782, 1025–1026
- Methylin. *See* Methylphenidate HCl
- Methylin ER. *See* Methylphenidate HCl
- Methylmalonic acidemia, 341t–342t
- Methylphenidate HCl (Ritalin, Adhansia XR,  
Aptensio XR, Jornay PM, Methylin,  
Metadate ER, Methylin ER, Concerta,  
Relexxii, QuilliChew ER, Quillivant  
XR, Ritalin LA, Cotempla XR-ODT,  
Daytrana), 652t–653t, 769–770,  
775, 780  
formulary entry, 1026–1029
- Methylprednisolone (Medrol, Medrol  
Dosepack, Solu-Medrol, Depo-  
Medrol), 770, 775, 780  
for allergic emergencies, 19  
formulary entry, 1029–1030  
for pediatric rheumatology, 726t–730t  
potency, 277t  
for status asthmaticus, 22t–23t
- Metoclopramide (Reglan, Metozolv, Maxolon),  
775, 779  
adjustment in kidney failure, 1203t–1208t  
formulary entry, 1030
- Metolazone (Zaroxolyn), 783, 1030–1031
- Metoprolol (Lopressor, Toprol-XL, Kapsargo  
Sprinkle), 774, 781  
formulary entry, 1031–1032  
for hypertension, 549t–550t
- MetroCream. *See* Metronidazole
- MetroGel. *See* Metronidazole
- MetroLotion. *See* Metronidazole

- Metronidazole (Flagyl, First-Metronidazole, MetroGel, MetroLotion, MetroCream, Rosadan, Noritate, Vandazole, Nuversa), 772, 775–776  
 adjustment in kidney failure, 1197t–1203t  
 for bacterial vaginosis, 134t–136t  
 for *Clostridium difficile* colitis, 462t–476t  
 formulary entry, 1032–1033  
 for Giardia, 462t–476t  
 for Lemierre syndrome, 462t–476t  
 for Ludwig angina, 462t–476t  
 for meningitis, 462t–476t  
 neonatal dosing, 527t–528t  
 for PID, 130t–134t  
 for trichomoniasis, 134t–136t
- MgSO<sub>4</sub>. See Magnesium sulfate
- Miacalcin. See Calcitonin-salmon
- Micafungin sodium (Mycamine), 775  
 formulary entry, 1033–1034  
 for oncology patients, 634t–635t
- Micatin. See Miconazole
- Miconazole (Micatin, Desenex, Lotrimin AF, Miconazole 7, Miconazole 3, Monistat, Vagistat-3, Oravig), 774–775, 782, 1034–1035
- Miconazole 3. See Miconazole
- Miconazole 7. See Miconazole
- MiCort-HC. See Hydrocortisone
- MICRhoGAM Ultra-Filtered Plus. See RH<sub>0</sub> (D) immune globulin intravenous (human)
- Microalbuminuria, 554
- Microangiopathic hemolytic anemia (MAHA), 369t–370t, 373.e2f
- Microarray, 350t–351t
- Microbiology, 454–499
- Microlipid, calories of, 610t
- Micronutrient deficiencies, malnutrition and, 598–599
- Micropenis, 287
- Microscopic hematuria, 557
- Microscopic polyangiitis (MPA), 711t–713t
- Microtubule inhibitors, 628t–632t
- Microzide. See Hydrochlorothiazide
- Midazolam (Versed), 782  
 adjustment in kidney failure, 1203t–1208t  
 for analgesia and sedation, 169t  
 formulary entry, 1035–1037  
 ketamine + midazolam + atropine ("ketazolam"), 171t  
 for procedural sedation, 171t  
 for status epilepticus, 32t–33t
- Migraine  
 acute, almotriptan malate for, 794  
 intractable, prochlorperazine for, 1105  
 prophylaxis, 802, 885, 1107, 1122, 1166  
 propranolol for, 1107  
 treatment for, 1193  
 valproic acid for, 1177
- Migraine headaches, 580–583, 585t  
 emergency department management of, 584f
- Migraine headaches (*Continued*)  
 precursors to, 581  
 preventive therapies for, 584.e1t  
 without aura, 583b
- Mild sedation (anxiolysis), 163
- Milia, 225–227
- Miliaria (heat rash), 225
- Milk, 299t
- Milk bank donor human milk, use of, 607
- Milk of Magnesia. See Magnesium hydroxide
- Milk protein intolerance, 613t–614t
- Milrinone (Primacor), 18t, 778  
 adjustment in kidney failure, 1203t–1208t  
 formulary entry, 1037
- Mineral oil (GoodSense Mineral Oil, Kondremul, Fleet Mineral Oil), 772, 774  
 formulary entry, 1037–1038
- Mineral oil enemas, for constipation, 1t, 325
- Mineralocorticoid, dosing, 277t
- Minerals  
 newborn and, 509  
 requirements of, for healthy children, 602–605
- Minocin. See Minocycline
- Minocycline (Minocin, CoreMino, Solodyn, Minolira, Ximino, Amzeeq, Arestin, Dynacin), 767, 771, 775, 780  
 for acne vulgaris, 224.e2t  
 formulary entry, 1038–1039
- Minolira. See Minocycline
- Minoxidil, for hypertension, 549t–550t
- Minoxidil (Loniten, Rogaine Men's/Women's, Minoxidil for Men, Hair Regrowth Treatment for Men, Mens Rogaine Extra Strength), 774, 780, 1039–1040
- Minoxidil for Men. See Minoxidil
- Miosis, in toxicology, 67.e1t–67.e3t
- MIP. See Maximal inspiratory pressure
- MiraLax. See Polyethylene glycol
- MIS-C. See Multisystem inflammatory syndrome in children
- Mitochondrial disorders, 337t, 339, 345t
- Mitochondrial encephalomyopathy, lactic acidosis (MELAS), 345t
- Mitoxantrone (anthracyclines), 628t–632t
- Mixed connective tissue disease, associated antibody in, 724t
- Mixing study, 389
- MMR. See Measles; mumps; rubella
- Mobitz type I (Wenckebach) heart block, 185t
- Mobitz type II (Wenckebach) heart block, 185t
- Moderate sedation, 163
- Modification of diet in renal disease (MDRD), 533
- Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F), 245t, 253
- Modified Fontan, 204t
- Modified Valsalva maneuver, for supraventricular tachycardia, 82
- Molds, voriconazole for, 1187

- Molluscum contagiosum, 213  
Molybdenum, recommended intakes, 606t  
Mometasone, estimated comparative daily dosages for, 3t–4t  
Mometasone furoate (Asmanex, Nasonex, Elocon, Twisthaler), 767, 771, 776, 1040  
    potency, 230t  
Mometasone furoate + formoterol fumarate (Dulera), 771, 1040–1042  
    estimated comparative daily dosages for, 3t–4t  
*Moniliformis*, pyrantel pamoate for, 1111  
Monistat. *See* Miconazole  
Monitoring, of chest compressions, 4  
Monoclonal Ab binds CD52, 628t–632t  
Monoclonal Ab binds GD-2, 628t–632t  
Monoclonal antibodies, 419  
Monocryl, characteristics of, 105t  
Monocytes, 407t  
Monocytosis, causes of, 383  
Monodox. *See* Doxycycline  
Monogen formula, 613t–614t  
Montelukast (Singulair), 780  
    for allergic rhinitis, 409t–410t  
    formulary entry, 1042–1043  
Mood disorders, 655–657  
Morbilliform lesions, 210  
Morphine, 157t  
    adjustment in kidney failure, 1203t–1208t  
    analgesic properties of, 156  
    for palliative care, 645t  
    for PCA, 161t  
Morphine sulfate (Duramorph, MS Contin, Avinza, Kadian), 767, 775, 1043–1044  
Morquio syndrome, 344t  
Motion sickness, 1106, 1132  
    promethazine for, 1106  
Motor development, 245t  
Motor examination, 570  
Motrin. *See* Ibuprofen  
MPA. *See* Microscopic polyangiitis  
MRCP. *See* Magnetic resonance cholangiopancreatography  
MRE. *See* Magnetic resonance enterography  
MRI. *See* Magnetic resonance imaging  
MS Contin. *See* Morphine sulfate  
MTX. *See* Methotrexate  
Mucilin. *See* Psyllium  
Mucolytics  
    acetylcysteine, 787–788  
    dornase alfa, 907  
Mucomyst. *See* Acetylcysteine  
Mucopolysaccharidoses, 344t  
Mucosal emergencies, allergic, 19  
Mucositis, 633  
Mucosol. *See* Acetylcysteine  
Multiple gene panels, 350t–351t  
Multiple ingestion, 71  
Multisystem inflammatory syndrome in children (MIS-C), 201–202, 721–722  
Mumps, 477t–481t  
    postexposure prophylaxis of, 440t–443t  
Mupirocin (Centany, Centany AT, Bactroban), 768, 1044  
Murine Ear. *See* Carbamide peroxide  
Murmurs, 173–174, 174t  
    benign, 173  
    diastolic, 175b  
    grading of, 173  
    pathologic, 174  
    systolic, 175b  
Muscarinic antagonist, long-acting, 667  
Muscle bulk, 570  
Muscle stretch reflexes, 572.e1t  
Muscle tone, 507t, 570  
Muscle weakness, 577–578  
Musculoskeletal procedures, 96–102  
    basic splinting, 96–97  
    finger/toe dislocation reduction, 100–101  
    hematoma blocks, 101–102  
    knee arthrocentesis, 101  
    radial head subluxation (nursemaid's elbow) reduction, 100  
    selected splints and indications, 97–100, 98f  
    ankle stirrup splint, 99–100  
    long arm posterior splint, 97  
    posterior ankle splint, 99  
    sugar tong forearm splint, 99  
    thumb spica splint, 99  
    ulnar gutter splint, 99  
    volar splint, 99  
Musculoskeletal system, radiology for, 703–708  
My Wishes, 644  
Myambutol. *See* Ethambutol HCl  
Myasthenia gravis, 591  
    medications to avoid in, 592b  
    pyridostigmine bromide for, 1112  
    treatment for, 1052  
Mycamine. *See* Micafungin sodium  
*Mycobacterium avium* complex (MAC), 799  
    in AIDS, treatment of, 928  
    azithromycin for, 820–821, 874  
    prophylaxis of, 874  
    treatment of, 874  
Mycobutin. *See* Rifabutin  
Mycophenolate, 726t–730t, 1045–1046  
Mycophenolate mofetil (CellCept), 769  
    formulary entry, 1045–1046  
    for nephrotic syndrome, 557  
Mycophenolate sodium (Myfortic), 775  
Mycophenolic acid (Myfortic), 1045–1046  
*Mycoplasma*, resistance in, 502.e2  
*Mycoplasma genitalium*, evaluation and management of, 130t–134t, 139–141  
Mycosis, urinary tract, bladder irrigation for, 808  
Mycostatin. *See* Nystatin

- Mydayis. *See* Dextroamphetamine + amphetamine
- Mydriasis, in toxicology, 67.e1t–67.e3t
- Myeloablative chemotherapy, 635
- Myeloid-specific cytokine granulocyte colony-stimulating factor (G-CSF), 379
- Myelophthisic anemia, 368t–369t
- Mylanta. *See* Aluminum hydroxide with magnesium hydroxide
- Mylanta Gas. *See* Simethicone
- Mylanta Maximum Strength. *See* Aluminum hydroxide with magnesium hydroxide
- Mylicon. *See* Simethicone
- Myocardial disease, 196–197
- Myocardial infarction (MI), 190, 195f, 195b
- Myocarditis, 197
- Myoclonic epilepsy with ragged red fibers (MERRF), 345t
- Myoclonus, 585t
- Myorisan. *See* Isotretinoin
- Mysoline. *See* Primidone
- Myxedema coma, treatment for, 1003
- N**
- Na Succinate (Solu-Cortef), 963
- N*-acetylcysteine, for acetaminophen overdose, 71
- NAEPP. *See* National Asthma Education and Prevention Program
- Nafcillin (Nallpen), 775, 1046–1047
- NaFrinse. *See* Fluoride
- Nail clubbing, 233
- Nail disorders, 233
- Nail dystrophy, congenital, 233
- Nallpen. *See* Nafcillin
- Naloxone (Narcan, Kloxxado, Zimhi, Evzio), 6t–7t, 31, 162, 168, 170b, 775, 1047–1048
- Naprelan. *See* Naproxen/naproxen sodium
- Naprosyn. *See* Naproxen/naproxen sodium
- Naproxen/naproxen sodium (Naprosyn, Ec-Naprosyn, Anaprox DS, Naprelan, Aleve), 766–767, 775  
analgesic properties of, 156  
formulary entry, 1048–1049  
for pediatric rheumatology, 726t–730t
- Narcan. *See* Naloxone
- Narcolepsy, 585t  
amphetamine for, 807  
dextroamphetamine for, 898
- Narcotics  
butorphanol, 836–837  
fentanyl, 932–933  
hydromorphone HCl, 964–965  
methadone HCl, 1024–1025  
morphine sulfate, 1043–1044  
oxycodone, 1071–1072
- Nasacort Allergy 24HR. *See* Triamcinolone; nasal preparations
- Nasal Allergy 24 Hour. *See* Triamcinolone; nasal preparations
- Nasal packing, for epistaxis, 81
- Nasal polyps, 408
- Nasal crom. *See* Cromolyn
- Nasalide. *See* Flunisolide
- Nasarel. *See* Flunisolide
- Nascobal. *See* Cyanocobalamin/vitamin B<sub>12</sub>
- Nasoduodenal tube, placement of, 708
- Nasogastric tube (NGT), 9  
placement, 92, 708
- Nasonex. *See* Mometasone furoate
- Nasopharyngeal airway, 9
- National Asthma Education and Prevention Program (NAEPP), 668f–672f, 674f
- National Center for Learning Disabilities, 260
- National disasters, adolescents and, 125
- National Early Childhood Technical Assistance Center, 260
- National Heart, Lung, and Blood Institute (NHLBI), 1029, 1102
- National Hospice and Palliative Care Organization, 647
- National Institutes of Health (NIH), on HIV infection, 494–498
- National Kidney Foundation guidelines for renal failure, 838
- Nausea and vomiting  
chemotherapy-induced, 633–634  
dolasetron for, 906  
granisetron for, 957  
medications for palliative care, 645t  
postoperative, treatment of, 957  
promethazine for, 1106
- Nebulized hypertonic saline, for bronchiolitis, 676
- NebuPent. *See* Pentamidine isethionate
- Nebusal. *See* Sodium chloride
- NEC. *See* Neonatal enterocolitis
- Neck  
normal anatomy of, 690f–691f  
radiology for, 690–693  
trauma, 39–42
- Necrotizing enterocolitis  
minimizing risk of, 520  
modified Bell's staging system for, 519.e1t  
in newborns, 519–520
- Nedocromil (Alocril), for allergic rhinitis, 409t–410t
- Needle cricothyrotomy, 90–91
- Needle thoracostomy, 91
- Negative predictive value (NPV), 755
- Neighborhood disparities, adolescents and, 116
- Neisseria gonorrhoeae* infections, 139  
treatment of, 853
- Neisseria meningitis*, prophylaxis for, 1124
- Nembutal. *See* Pentobarbital
- NeoBenz Micro. *See* Benzoyl peroxide
- Neocate Junior formulas, 611t–614t
- Neocate Splash formulas, 613t–614t
- Neomycin/polymyxin B ophthalmic products, 1050–1051
- Neomycin/polymyxin B (Neosporin GU Irrigant), 776

- Neomycin/polymyxin B + bacitracin (Neo-Polycin, Neosporin, Neosporin Ophthalmic, Neo To Go), 776, 1050–1051
- Neomycin/polymyxin B + bacitracin + hydrocortisone (Neo-polycin HC), 1050–1051
- Neomycin/polymyxin B + dexamethasone (Maxitrol), 1050–1051
- Neomycin/polymyxin B + gramicidin, 1050–1051
- Neomycin/polymyxin B + hydrocortisone, 1050–1051
- Neomycin sulfate (Neo-fradin), 776, 1049–1050
- Neonatal abstinence syndrome, 522, 878
- Neonatal acne, 227
- Neonatal alloimmune neutropenia, 380t–382t
- Neonatal alloimmune thrombocytopenia (NAIT), 387
- Neonatal dermatology, conditions, 225–228
  - congenital dermal melanocytosis, 227
  - diaper dermatitis, 227–228
  - erythema toxicum neonatorum, 225
  - milia, 225–227
  - miliaria (heat rash), 225
  - neonatal acne, 227
  - seborrheic dermatitis, 227
  - transient neonatal pustular melanosis, 225
- Neonatal diabetes (NDM), 262
- Neonatal enterocolitis (NEC), 698, 699f
- Neonatal exudative conjunctivitis, 457t–461t
- Neonatal hemoglobin electrophoresis, 372f
- Neonatal hemolytic disease, 369t–370t
- Neonatal hyperinsulinemia, treatment of, 865
- Neonatal hypocalcemia, 838
- Neonatal hypoglycemia evaluation, 292–293
- Neonatal hypoxic-ischemic encephalopathy, 520–521
- Neonatal Infant Pain Scale (NIPS), 151
- Neonatal infections, pneumonia, 457t–461t
- Neonatal intensive care unit (NICU), commonly used medications in, 526, 527t–528t
- Neonatal lung disease, 695, 695f
- Neonatal rashes, evaluation of, 226f
- Neonatal seizures, 522, 587t–589t
  - evaluation of, 338
- Neonatal thyrotoxicosis, 270–272
- Neonates, sucrose for, 158–161
- Neonatology, 503–534
- Neoplasm
  - generalized malignant, vaccine information for, 1t–3t
  - neutropenia and, 380t–382t
- Neo-polycin. *See* Neomycin/polymyxin B + bacitracin
- Neo-polycin HC. *See* Neomycin/polymyxin B ophthalmic products
- Neo-polymyxin ophthalmic ointment, 1049
- NeoProfen. *See* Ibuprofen
- Neoral. *See* Cyclosporine
- Neosporin. *See* Neomycin/polymyxin B + bacitracin
- Neosporin ophthalmic solution. *See* Neomycin/polymyxin B ophthalmic products
- Neostigmine (Prostigmin, Bloxiverz), 768, 779, 1052
  - adjustment in kidney failure, 1203t–1208t
- Neo-Synephrine. *See* Phenylephrine HCl
- Nephrogenic diabetes insipidus, 281t, 568
- Nephrolithiasis, 568–569
  - diagnostic imaging for, 568
  - imaging for, 702
  - management of, 568–569
  - presentation of, 568
  - prevention of, 569
  - risk factors of, 568
  - workup for, 569
- Nephrology, 529–569
- Nephrotic syndrome, 554–557
  - clinical manifestations of, 555, 556b
  - complications of, 557
  - epidemiology of, 554–555
  - etiologies of, 556t
  - idiopathic, management of, 556–557
  - investigations at first presentation of, 556
  - management of, 1045
  - prednisone for, 1102
- Nephrotic-range proteinuria, 554
- Nepro formula, 613t–614t
- Nervous system instability, in toxicology, 67.e1t–67.e3t
- Neupogen. *See* Filgrastim
- Neuralgia, postherpetic, gabapentin for, 951
- Neuroblastoma, 620t–621t
- Neurocutaneous melanosis, 234
- Neurogenic shock, 17t
- Neurologic complaints, chronic kidney disease and, 565t
- Neurologic disease, in newborns, 520–522
- Neurologic emergencies, 572–578
- Neurologic examination, 570–571
  - in headaches, 581.e1t
- Neurologic monitoring, for stroke, 573
- Neurologic procedures, 76–79
- Neurologic system, changes as death approaches, 644t
- Neurology, 570–600
  - chronic or gradually progressive conditions, 579
  - functional neurologic disorders, 591
  - headaches, 579–583
  - neuromuscular disorders, 590–591
  - seizures, 583–590
- emergencies, 572–578
  - ataxia, 578
  - encephalopathy/altered mental status, 574
  - increased intracranial pressure, 574–577
  - muscle weakness, 577–578

- Neurology (*Continued*)
- status epilepticus and breakthrough seizures, 574
  - stroke, 572–574, 573b
- examination, 570–571
- coordination and gait, 571
  - cranial nerves, 570, 570.e1t
  - mental status, 570
  - motor, 570
  - reflexes, 571
  - sensory, 571
- web resources for, 593
- Neuromuscular blockade, reversal of
- glycopyrrolate for, 956
  - neostigmine for, 1052
- Neuromuscular disease, spirometry and lung volume readings in, 666t
- Neuromuscular disorders, 590–591
- Neuromuscular maturity, 507.e1f
- Neurontin. *See* Gabapentin
- Neuropathic pain, 152t
- gabapentin for, 951
  - medications, for palliative care, 645t
- Neuropathy, screening for, 266t
- Neurosyphilis, penicillin G for, 1080, 1082
- Neurotransmitter disorders, 339, 345t
- Neurovascular assessment, 47
- Neutropenia, 379–383, 622–623
- causes and evaluation of, 379, 380t–382t
  - in chemotherapy patients, 633
  - definition of, 379, 407t
  - differential diagnosis of, 407t
  - empiric therapy for, 809
  - etiology of, 622
  - febrile, empiric therapy for, 809
  - management of, 379–383, 622–623, 624f
  - presentation of, 622
  - severe, 379
  - treatment for, 852
- Neutropenic enterocolitis, 627
- Neutrophilia, causes of, 383
- Neutrophils
- hypersegmented, 372
  - toxic granulation of, 372, 373.e2f
- Nevirapine (Viramune, Viramune XR, NVP), 776, 782, 1052–1053
- Newborn care
- exchange transfusion, 517t, 518, 518f
  - exogenous surfactant therapy, 511
  - fluid, electrolytes, and nutrition, 508–509
  - in hyperglycemia and hypoglycemia, 506f, 509, 510t
  - medications in neonatal intensive care unit, 526, 527t–528t
  - phototherapy, 517, 517f, 517t
  - respiratory considerations, 511
  - routine, 505
  - supplemental O<sub>2</sub>, 511
  - vaccinations, 505
- Newborn resuscitation, 503
- algorithm for, 503, 504f
- Newborn screening (NBS), for congenital adrenal hyperplasia, 274–275
- Newborns
- assessment, 506–508
  - cardiac diseases in, 515–516
  - cyanosis in, 509–511
  - electrolyte requirements of, 509, 510t
  - extradural fluid collection in, 508f, 508t
  - gastrointestinal bleeding in, 319t
  - gastrointestinal diseases in, 519–520
  - glucose and, 509
  - hematologic diseases in, 516–519
  - metabolic screening for, 346
  - mineral requirements for, 509
  - neurologic diseases in, 520–522
  - peripheral nerve injuries in, 522
  - persistent pulmonary hypertension of, 512–514
  - respiratory diseases in, 511–514
  - respiratory distress syndrome in, 512, 512t
  - transient tachypnea of, 514
  - vitamin requirements, 509
  - vomiting in, 321t
- Nexiclon XR. *See* Clonidine
- Nexium. *See* Esomeprazole
- Nexium 24HR. *See* Esomeprazole
- Nexplanon, 141–147
- Nexterone. *See* Amiodarone HCl
- Next-generation sequencing, 350t–351t
- NEXUS criteria, 41
- Niacin (vitamin B<sub>3</sub>, Niacor, Niaspan, Slo-Niacin, Nicotinic acid), 776, 780, 783
- formulary entry, 1053–1054
  - recommended intakes, 603t–604t
- Niacor. *See* Niacin
- Niaspan. *See* Niacin
- Nicardipine (Cardene IV), 768, 1054–1055
- Nicotine poisoning, 69t–70t
- Nicotinic acid. *See* Niacin
- NICU. *See* Neonatal intensive care unit
- Niemann-Pick disease, 344t
- Nifedipine (Procardia XL, Procardia Adalat CC), 766, 778
- extended-release, 549t–550t
  - formulary entry, 1055–1056
- Niferex. *See* Iron; oral preparations
- Night feeding, trained, 243t–244t
- Night terrors, 243t–244t
- Night waking, 243t–244t
- Nightmares, 1, 243t–244t
- Nighttime fears, 1
- NIH. *See* National Institutes of Health
- Nilotinib, 628t–632t
- Nilstat. *See* Nystatin
- 9-fluorohydrocortisone. *See* Fludrocortisone acetate
- Nipride RTU. *See* Nitroprusside
- Nitazoxanide, for Giardia, 462t–476t
- Nitric oxide, inhaled, 513

- Nitrite test, 530t–531t, 551
- Nitro-Bid. *See* Nitroglycerin
- Nitro-Dur. *See* Nitroglycerin
- Nitrofurantoin (Macrochantin, Macrobid, Furadantin), 772, 774  
for cystitis, 462t–476t  
formulary entry, 1056
- Nitroglycerin (Nitro-Bid, Nitrostat, Nitro-Time, Nitro-Dur, Nitrolingual, Nitromist, Rectiv), 776, 1056–1058
- Nitrolingual. *See* Nitroglycerin
- Nitromist. *See* Nitroglycerin
- Nitroprusside (Nipride, Nitropress), 776, 1058
- Nitrostat. *See* Nitroglycerin
- Nitro-Time. *See* Nitroglycerin
- Nivestym. *See* Filgrastim
- Nivolumab, 628t–632t
- Nix. *See* Permethrin
- Nizoral. *See* Ketoconazole
- NKH. *See* Nonketotic hyperglycinemia
- NNH. *See* Number needed to harm
- NNT. *See* Number needed to treat
- Nocebo effect, 747
- Nociceptive pain, 152t
- Nocturnal enuresis  
desmopressin acetate for, 892–893  
treatment for, 1059
- Nodal escape/junctional rhythm, 182t–183t
- Nodule, 209
- Nonabsorbable sutures, characteristics of, 105t
- Nonaccidental trauma, 62–65
- Nonalcoholic fatty liver disease, 331
- Nonalcoholic steatohepatitis (NASH), screening for, 266t
- Nonallergic rhinitis with eosinophilia syndrome (NARES), 408
- Nonbinary, gender, 122t
- Nonbullous impetigo, 220
- Non-cystic fibrosis, 868
- Nonelevated anion gap metabolic acidosis (NAGMA), 311–312
- Nonesophageal mucous membrane GI candidiasis, treatment for, 1060
- Nongonococcal urethritis (NGU), evaluation and management of, 130t–134t
- Nonhemolytic anemia, 365
- Nonhormonal birth control, forms of, 147
- Noninvasive positive pressure ventilation (NIPPV), 13
- Nonketotic hyperglycinemia (NKH), 345t
- Nonmotile ciliopathies, 349
- Nonmyeloablative chemotherapy, 635
- Nonopioid analgesics, 156
- Nonparametric tests, 751
- Nonpharmacologic measures, of pain relief, 158–161
- Nonpurulent cellulitis/erysipelas, 462t–476t
- Nonroutine vaccines, for children, in United States, 424, 431t–433t
- Nonsteroidal antiinflammatory drugs (NSAIDs), 69t–70t  
analgesic properties of, 156  
aspirin, 814–815  
for dengue, 477t–481t  
for migraine, 581  
for pediatric rheumatology, 726t–730t
- Nontraumatic chest pain, 204–205, 206f
- Nontuberculous mycobacterial infection, treatment of, 928
- Nontuberculous mycobacterium, amikacin sulfate for, 798
- Nonventricular arrhythmias, 180, 182t–183t
- Nonventricular conduction disturbances, 180, 185t
- Noonan syndrome, 352t
- Norcuron. *See* Vecuronium bromide
- Norepinephrine, 18t  
normal plasma levels, 279.e1t  
normal urine levels, 279.e1t
- Norepinephrine bitartrate (Levophed), 774  
formulary entry, 1058
- Norfloxacin (Noroxin), 776
- Noritate. *See* Metronidazole
- Norliqva. *See* Amlodipine
- Normal blood pressure (BP), management of, 548t
- Normal saline (NS)  
composition of, 297t  
for hypernatremic dehydration, 307b
- Normal Serum Albumin. *See* Albumin
- Normetanephrines, 279.e1t
- Normodyne. *See* Labetalol
- Nortriptyline hydrochloride (Pamelor), 777  
formulary entry, 1059  
for migraine, 584.e1t
- Norvasc. *See* Amlodipine
- Norwood procedure, stage 1 (neonatal period), 204t
- Nose, foreign body removal from, 80
- Nosebleed, simple, 81
- Nosocomial pneumonia, 858  
piperacillin with tazobactam for, 1094
- Nostrilla. *See* Oxymetazoline
- Nourish formulas, 613t–614t
- NovaFerrum. *See* Polysaccharide-iron complex
- NovaFerrum Pediatric Drops. *See* Polysaccharide-iron complex
- No-value care, 749
- Noxafil. *See* Posaconazole
- Noxafil PowderMix. *See* Posaconazole
- NPV. *See* Negative predictive value
- NSAID-induced ulcer, treatment for, 998
- NSAIDs. *See* Nonsteroidal antiinflammatory drugs
- Nuclear medicine, advantages and disadvantages of, 689t
- Nuclear renal scintigraphy (Mag-3 scan), 702
- Nucleoside analogue reverse transcriptase inhibitor  
lamivudine, 992–993  
zidovudine, 1191–1192

- Nucleoside analogue reverse transcriptase inhibitor (*Continued*)  
 zidovudine and, 1191–1192
- Nucleotide analogs, 628t–632t
- NuCort. *See* Hydrocortisone
- NuLYTELY. *See* Polyethylene glycol
- Number needed to harm (NNH), 754
- Number needed to treat (NNT), 754
- Nummular/discoid lesions, 210
- Nurolon, characteristics of, 105t
- Nursemaid's elbow reduction, 100
- NUTRA Shake, 613t–614t
- Nutramigen, 611t–612t
- Nutren Junior formulas, 609t, 613t–614t
- Nutr-E-Sol. *See* Vitamin E
- NutriRenal formula, 613t–614t
- Nutrition, 594–617  
 enteral, 608, 613t–614t  
 needs of healthy children, 601–605  
 newborn and, 508–509  
 pancreatitis and, 334  
 parenteral, 608–614  
     frequency of monitoring growth  
     parameters and laboratory  
     studies in, 614, 615t  
     indications for, 608  
     recommended formulations of, 614,  
     616t  
     starting and advancing, 608, 615t  
     web resources for, 616–617
- Nutritional rickets, 920
- Nuversa. *See* Metronidazole
- NVP. *See* Nevirapine
- Nyamyc. *See* Nystatin
- Nydravid. *See* Isoniazid
- Nylon, characteristics of, 105t
- Nystagmus, in toxicology, 67.e1t–67.e3t
- Nystatin (Nyamyc, Nystop, Mycostatin, Nilstat),  
 775–776, 1059–1060
- Nystop. *See* Nystatin
- O**
- Obesity, 595  
 conditions associated with, 595–597  
 hypothyroidism and, 270  
 management of, 595–597  
 prevention and management of, in  
 primary care setting, 595, 596t
- Observer-expectancy bias, 747
- Obsessive-compulsive disorder (OCD), 940  
 paroxetine for, 1079
- Obstruction, lower urinary tract, 523–524
- Obstructive disease, spirometry and lung  
 volume readings in, 666t
- Obstructive shock, 16, 17t
- Obstructive sleep apnea (OSAS), 681–683  
 clinical presentation of, 682  
 daytime symptoms of, 682  
 definition of, 681  
 diagnosis of, 682–683  
 long-term complications of, 682  
 nighttime symptoms of, 682
- Obstructive sleep apnea (OSAS) (*Continued*)  
 polysomnography criteria for, 682–683  
 risk factors for, 682  
 screening for, 266t  
 symptoms and signs of, 682b  
 treatment of, 683
- Ocean. *See* Sodium chloride
- OCPs. *See* Oral contraceptive pills
- Octagam, preparations for, 970
- Octreotide acetate (Sandostatin, Sandostatin  
 LAR Depot), 780  
 formulary entry, 1060
- Ocuflox. *See* Ofloxacin
- ODD. *See* Oppositional defiant disorder
- Odds ratio (OR), 753
- Ofirmev. *See* Acetaminophen
- Ofloxacin (Ocuflox, Floxin, Floxin Otic), 772,  
 777  
 formulary entry, 1061
- Ohtahara syndrome. *See* Early infantile  
 epileptic encephalopathy
- Oil of wintergreen odor, in toxicology,  
 67.e1t–67.e3t
- Olanzapine (Zyprexa, Zyprexa Zydis, Zyprexa  
 Relprev), 634t, 645t  
 formulary entry, 1061–1063
- Oligochromosomal microarray, 350t–351t
- Oliguria, 562, 1017  
 laboratory differentiation of, 562t
- Olmesartan, 549t–550t
- Olopatadine (Patanol, Pataday, Patanase), 777  
 for allergic rhinitis, 409t–410t  
 formulary entry, 1063–1064
- Olsalazine (Di-5-ASA, Di-mesalazine,  
 Dipentum), 770
- Omalizumab, for asthma, 667
- Omeprazole (Prilosec, Prilosec OTC, First-  
 Omeprazole), 772, 778  
 formulary entry, 1064–1065
- Omeprazole with sodium bicarbonate (Zegerid,  
 Zegerid OTC), 783  
 formulary entry, 1064–1065
- Omnaris. *See* Ciclesonide
- Omnicef. *See* Cefdinir
- Omnipaque. *See* Iohexol
- Omnipaque 140. *See* Iohexol
- Omnipaque 180. *See* Iohexol
- Omnipaque 240. *See* Iohexol
- Omnipaque 300. *See* Iohexol
- Omnipaque 350. *See* Iohexol
- Omnipaque oral solution 9. *See* Iohexol
- Omnipaque oral solution 12. *See* Iohexol
- Omnipen. *See* Ampicillin
- Omphalocele, gastroschisis vs., 521t
- Onchocerciasis, ivermectin for, 986
- Oncologic conditions, genetics and, 354
- Oncologic emergencies, 622–628
- Oncology, 618–639  
 antiemetic therapies in, 634t  
 antimicrobial prophylaxis in, 634t–635t  
 cancer survivorship, 638  
 chemotherapeutic drugs, 628t–632t

- Oncology (*Continued*)  
chemotherapy complications and  
supportive care, 633–634  
emergencies in, 622–628  
fertility preservation in, 638  
hematopoietic stem cell transplantation,  
635–636  
pediatric central nervous system tumors,  
623t  
pediatric hematologic malignancies, 619t  
pediatric solid tumor malignancies,  
620t–621t
- Ondansetron (Zofran, Zofran ODT), 634t, 783  
formulary entry, 1065–1067  
for palliative care, 645t
- 1p36 Deletion syndrome, 358
- One-sample (paired) *t* test, 750t
- One-tailed tests, 751
- Onfi. *See* Clobazam
- Onzetra Xsail. *See* Sumatriptan succinate
- Ophthalmic agents, 409t–410t
- Ophthalmic conjunctivitis, treatment of, 1061
- Ophthalmologic examination, follow-up,  
526.e1t
- Ophthalmologic trauma, 52–55  
chemical injury to eye, 52  
corneal abrasion, 53  
eyelid laceration, 54  
orbital floor fractures, 54–55  
other instances requiring, 55  
ruptured globe, 52–53  
superglue to eye, 53–54
- Ophthalmology  
rheumatology diseases and, 731  
in sickle cell disease, 377t
- Opiate intoxication, naloxone for, 1047–1048
- Opiate-induced pruritus, naloxone for, 1048
- Opioid withdrawal, signs and symptoms of,  
523b
- Opioids, 69t–70t, 156–158, 157t  
properties of, 167b–168b  
tapering, 162–163  
examples of, 163, 163.e1b  
indications of, 162  
recommendations for, 162–163  
withdrawal of, 162  
toxicology with, 68t
- Opium tincture (deodorized tincture of opium),  
770
- Opportunistic disease, treatment of, 983
- Oppositional defiant disorder (ODD),  
654  
diagnosis of, 654  
epidemiology of, 654  
evaluation of, 654  
management of, 650t, 654
- Opticrom. *See* Cromolyn
- Optivar. *See* Azelastine
- Oracea. *See* Doxycycline
- Oral allergy syndrome, 412
- Oral azithromycin, for neonatal exudative  
conjunctivitis, 457t–461t
- Oral contraceptive pills (OCPs), combined  
hormonal, 146
- Oral food challenges, 412–413
- Oral glucose tolerance test (OGTT), 261
- Oral griseofulvin, for fungal infections,  
462t–476t
- Oral intercourse, screening guidelines by, 129
- Oral leukotriene inhibitors, 409t–410t
- Oral polio vaccine, 431t–433t  
contraindications and precautions to,  
435t–437t
- Oral regimen, for tapering, 162
- Oral rehydration solutions, features of, 608,  
614t
- Oral rehydration therapy (ORT)  
composition of fluids, 299t  
for diarrhea, 329  
fluids not recommended for, 299t
- Oralone. *See* Triamcinolone; topical  
preparations
- Oraltag. *See* Iohexol
- Orange juice, 299t
- Orapred ODT. *See* Prednisolone
- Oraqix. *See* Lidocaine and prilocaine
- OraVerse. *See* Phentolamine mesylate
- Oravig. *See* Miconazole
- Orazinc. *See* Zinc salts
- Orbital cellulitis, 462t–476t  
, imaging for, 690
- Orbital floor fractures, 54–55
- Orenitram. *See* Treprostinil
- Organ donation, 646–647
- Organic acidemias, 341t–342t
- Organophosphate poisoning, pralidoxime  
chloride for, 1100
- Organophosphates, 69t–70t
- Orkambi. *See* Lumacaftor and ivacaftor
- Ornithine transcarbamylase (OTC) deficiency,  
341t–342t
- Oropharyngeal airway, 9
- Oropharyngeal candidiasis, treatment for, 936,  
1059–1060, 1098
- ORT. *See* Oral rehydration therapy
- Orthostatic proteinuria, 553
- Ortikos. *See* Budesonide
- OSAS. *See* Obstructive sleep apnea
- Oseltamivir phosphate (Tamiflu), 781  
adjustment in kidney failure, 1197t–1203t  
formulary entry, 1067–1068  
for influenza, 477t–481t
- Osmitol. *See* Mannitol
- Osmolal gap, calculation of, 313–314
- Osmolality, 301  
reference values for, 736t–743t  
serum, 301
- Osmolex ER. *See* Amantadine hydrochloride
- OsmoPrep. *See* Sodium phosphate
- Osmotic diarrhea, 328
- Osmotic laxative, for constipation, 1t
- Ossification centers, of normal elbow, 704.e1t,  
704.e2f
- Osteochondroma, sessile, 707.e1f

- Osteogenesis imperfecta, 838  
 Osteoid osteoma, 707.e2f  
 Osteomyelitis, 462t–476t  
   imaging for, 704  
   vancomycin for, 1180  
 Osteosarcoma, 620t–621t  
   proximal tibial, 707.e2f  
 OTC. *See* Ornithine transcarbamylase  
 Otitis externa, 462t–476t  
   polymyxin B sulfate for, 1096  
   treatment of, 872  
 Otitis media  
   acute, 462t–476t, 805–8006  
   treatment of, 856  
 Otolaryngologic procedures, 79–81  
   cerumen impaction removal, 79  
   foreign body removal  
     from ear, 79–80  
     from nose, 80  
   management of epistaxis, 81  
 Otovel Otic. *See* Ciprofloxacin  
 Ovaries  
   pathology of, imaging for, 702  
   polycystic, 287  
 Overgrowth, genetics and, 354–355  
 Overpowered study, 748  
 Overweight, 595  
   management of, 595–597  
 Ovine. *See* Digoxin immune fab  
 Oxacillin  
   formulary entry, 1068–1069  
   neonatal dosing, 527t–528t  
 Oxaydo. *See* Oxycodone  
 Oxcarbazepine (Trileptal, Oxtellar XR), 777, 782  
   adjustment in kidney failure, 1203t–1208t  
   formulary entry, 1069–1070  
   for seizures, 575t–576t  
 Oxtellar XR. *See* Oxcarbazepine  
 Oxy-5. *See* Benzoyl peroxide  
 Oxy-10. *See* Benzoyl peroxide  
 Oxybutynin chloride (Ditropan XL, Oxytrol, Oxytrol for Women, Ditropan), 771, 777  
   formulary entry, 1071  
 Oxycodone, 645t  
   analgesic properties of, 157t  
 Oxycodone (OxyContin, Roxicodone, RoxyBond, Oxaydo, Xtampza ER), 777, 780, 1071–1072  
 Oxycodone and acetaminophen (Endocet, Percocet, Roxicet, Prolate), 771, 778, 780, 1072–1073  
 Oxycodone and aspirin (Percodan, Endodan), 771, 778, 1073  
 OxyContin. *See* Oxycodone  
 Oxygen challenge test, 189.e1t  
 Oxygen delivery systems, 10–13  
 Oxygen mixture, for croup, 21  
 Oxygen therapy, for newborns, 513  
 Oxygenation, 10–15  
 Oxyhemoglobin dissociation curve, 1f, 663  
 Oxymetazoline (Afrin 12 Hour, Vicks Sinex 12 Hour, Nostrilla, Duramist 12-Hr Nasal, Neo-Synephrine 12-Hr Nasal, Visine LR), 766, 771, 776, 782, 1073  
 Oxytrol. *See* Oxybutynin chloride  
 Oxytrol for Women. *See* Oxybutynin chloride  
 Ozobax. *See* Baclofen
- P**  
*P* value, 751  
 P wave, 174, 176  
 Pacerone. *See* Amiodarone HCl  
 Packed red blood cells (PRBCs), 402t–403t  
   recommended intervals between administration, 2t  
   specific, 407.e1  
 Paget disease, 838  
 Pain  
   acute abdominal, 320t  
   endometriosis-associated, 1019  
   medications, for palliative care, 645t  
   neuropathic/dysfunctional, 152t  
   nociceptive, 152t  
   types of, 151, 152t  
 Pain assessment, 151–154  
   in adolescent, 152  
   in children with significant neurological impairment, 152–154, 154t  
   FACES pain scale revised (FPS-R), 151, 153f  
   FLACC scale, 151, 153t  
   in infant, 151  
   in preschooler, 151, 153f  
   in school-age children, 152  
 Pain relief, nonpharmacologic measures of, 158–161  
 Paired tests, 751  
 Palgic. *See* Carbinoxamine  
 Palivizumab (Synagis), 419, 781, 1074–1075  
   recommended intervals between administration, 2t  
 Palliative care, 640–647  
   definition of, 640  
   medications for symptomatic relief in, 645t  
   model for, 640f  
   web resources, 647  
 Palliative systemic-to-pulmonary artery shunts, 204t  
 Pamelor. *See* Nortriptyline; Nortriptyline hydrochloride  
 Panadol. *See* Acetaminophen  
 Panayiotopoulos syndrome, 587t–589t  
 Pancreatic disease, 681  
 Pancreatic enzymes, 1075–1076  
 Pancreatic fluid, 301t  
 Pancreatitis, 333–334, 333t, 701–702  
   acute, 333–334, 333t  
   chronic, 334, 334t  
 Pancreaze. *See* Pancrelipase

- Pancrelipase (Creon, Pancreaze, Pertzye, Ultresa, Viokace, and Zenpep), 1075–1076
- Pancuronium bromide (Pavulon), 1076–1077  
adjustment in kidney failure, 1203t–1208t
- Pandemics, adolescents and, 125
- Panic disorder, paroxetine for, 1079
- PanOxyl. *See* Benzoyl peroxide
- Pantoprazole (Protonix), 779, 1077–1078
- Pantothenic acid, recommended intakes, 603t–604t
- Panzyga, preparations for, 970
- Pappenheimer bodies, 372
- Papular urticaria, 231–232
- Papule, 209
- Paracetamol. *See* Acetaminophen
- Paragard, 145
- Paralysis  
for intubation, 1144  
Klumpke, 523t  
in toxicology, 67.e1t–67.e3t
- Parametric tests, 749, 750t
- Parapharyngeal abscess, 462t–476t
- Parasitic infections, 485t–487t  
of skin, 215–218
- Parasomnias, 1
- Parathyroid, 272
- Parathyroid hormone (PTH), 272
- Paregoric (camphorated opium tincture), 768
- Parent kiss, in foreign body removal from nose, 80
- Parenteral nutrition, 608–614  
frequency of monitoring growth  
parameters and laboratory  
studies in, 614, 615t  
indications for, 608  
recommended formulations of, 614, 616t  
starting and advancing, 608, 615t
- Parenteral rehydration fluids, composition of, 297t
- Parents Evaluation of Developmental Status (PEDS), 245t
- Paromomycin sulfate (Humatin), 773, 1078
- Paronychia, 233, 233.e1f
- Paroxetine (Paxil, Pexeva, Brisdelle), 777–778, 1079–1080
- Paroxysmal dyskinesias, 585t
- Paroxysmal vertigo (toddler), 585t
- Partial defects, vaccine information for, 1t–3t
- Partial seizures  
adjunctive therapy for, 1162, 1194–1195  
treatment of, 1000
- Partially hydrolyzed whey, in formulas, 613t–614t
- Parvovirus B19, 477t–481t
- Pataday. *See* Olopatadine
- Patanase. *See* Olopatadine
- Patanol. *See* Olopatadine
- Patau syndrome (Trisomy 13), 357
- Patch, 209
- Patent ductus arteriosus (PDA), 191t–192t, 515–516, 515f
- Pathocil. *See* Dicloxacillin sodium
- Patient Health Questionnaire-2 (PHQ-2), 649t, 657
- Patient Health Questionnaire-9 (PHQ-9), 649t
- Patient-controlled analgesia (PCA), 161–162  
adjuvants, 162  
agents of, 161, 161t  
definition of, 161  
indications of, 161  
for mucositis pain control, 633  
orders of, 161t  
routes of administration of, 161  
side effects of, 162
- Pavulon. *See* Pancuronium bromide
- Paxil. *See* Paroxetine
- Paxil CR. *See* Paroxetine
- PCA. *See* Patient-controlled analgesia
- PCV13. *See* Pneumococcal conjugate vaccine
- PD. *See* Peritoneal dialysis
- PD-1 checkpoint inhibitor, 628t–632t
- PDA. *See* Patent ductus arteriosus
- Peak expiratory flow rate (PEFR), 664, 664t
- Pear odor, in toxicology, 67.e1t–67.e3t
- Pearson *r* (product moment correlation coefficient), 750t
- PECARN algorithm, 39, 40f
- Pedia-Lax. *See* Glycerin
- Pedialyte, 299t, 614t
- Pediapred. *See* Prednisolone
- PediaSure, 609t
- PediaSure Enteral, 609t
- PediaSure formulas, 613t–614t
- PediaSure Harvest formulas, 613t–614t
- PediaSure Peptide 1.0 and 1.5 formulas, 613t–614t
- PediaSure Peptide formulas, 613t–614t
- Pediatric Advanced Life Support (PALS), 37
- Pediatric asthma score, 24t
- Pediatric Endocrine Society, 293
- Pediatric Symptom Checklist (PSC), 648, 649t
- Pediatrics, ethics of genetic testing in, 361–362
- Pediculosis, pyrethrins with piperonyl butoxide for, 1112
- Pediculosis capitis, 217–218  
treatment for, 1005
- Pediculus humanus capitis*, 217  
permethrin for, 1085
- Pedigree construction, 1f, 336
- Peers, 1t
- PEFR. *See* Peak expiratory flow rate
- PEG. *See* Polyethylene glycol
- Pellagra, treatment for, 1054
- Pelvic fracture, unstable, 45
- Pelvic inflammatory disease (PID), evaluation and management of, 130t–134t, 140
- Pelvic trauma, 42–47  
assessment and management pearls, 42–45

- Pelvic trauma (*Continued*)  
 imaging studies to consider, 45–47
- Pembrolizumab, 628t–632t
- Pemrolast (Alamast), 409t–410t
- Pemphigus vulgaris, 235.e1, 235.e1f
- Pencil poikilocytes, 372
- Penetrative penile intercourse, screening  
 guidelines by, 129
- Penicillamine (Cuprimine, Depen), 769–770
- Penicillin  
 allergy, 414, 415f  
 for sickle cell disease, 377t  
 for syphilis, 136t–138t
- PenicillinG  
 adjustment in kidney failure, 1197t–1203t  
 aqueous potassium and sodium  
 preparations (Pfizerpen-G), 778,  
 1080–1081  
 benzathine (Bicillin L-A), 768, 1081  
 for syphilis, 130t–134t  
 for group B streptococcal (GBS) disease,  
 457t–461t  
 for Lemierre syndrome, 462t–476t  
 for Ludwig angina, 462t–476t  
 penicillin G benzathine and penicillin  
 procaine, 1081–1082  
 procaine (Wycillin), 783, 1082–1083  
 for syphilis, 457t–461t
- Penicillin V potassium (Veetids), 782, 1083  
 adjustment in kidney failure, 1197t–1203t
- Penile length, 290t
- Pentam 300. *See* Pentamidine isethionate
- Pentamidine isethionate (Pentam 300,  
 NebuPent), 776–777, 1084  
 adjustment in kidney failure, 1197t–1203t  
 for oncology patients, 634t–635t
- Pentasa. *See* Mesalamine
- Pentobarbital (Nembutal), 776, 1084–1085  
 properties of, 169t
- PEP. *See* Postexposure prophylaxis
- Pepcid. *See* Famotidine
- Pepcid AC. *See* Famotidine
- Pepcid AC Maximum Strength. *See* Famotidine
- Pepcid Complete. *See* Famotidine
- Pepdite Junior formulas, 613t–614t
- Peptamen formulas, 613t–614t
- Peptamen Junior formulas, 613t–614t
- Peptic ulcer, pantoprazole for, 1077
- Pepto-Bismol. *See* Bismuth subsalicylate
- Peramivir, for influenza, 477t–481t
- Perampanel (Fycompa), for seizures,  
 575t–576t
- Perative formulas, 613t–614t
- Percocet. *See* Oxycodone and acetaminophen
- Percodan. *See* Oxycodone and aspirin
- Percutaneous exposure, to blood, hepatitis B  
 virus prophylaxis for, 446t
- Perennial allergic rhinitis, 408  
 azelastine for, 819
- Perfusion  
 assessment of, 3  
 poor, 3
- Periactin. *See* Cyproheptadine
- Pericardial disease, 197–198
- Pericardial effusion, 198
- Pericardial fluid, 735.e1t
- Pericarditis, 197–198  
 chronic kidney disease and, 565t
- Perinatal period, HIV infection in, 494
- Periodontitis, doxycycline for, 908
- Peripheral  $\alpha$ -antagonist, for hypertension,  
 549t–550t
- Peripheral blood  
 smear, in thrombocytopenia, 384  
 T and B lymphocytes in, 422t
- Peripheral intravenous access, 82–83  
 infiltration and extravasation, 83  
 ultrasound-guided procedure, 83
- Peripheral nerve injuries, 522
- Peritoneal dialysis (PD), 564–566, 566t
- Peritoneal fluid, 735.e1t
- Peritonitis, piperacillin with tazobactam for,  
 1094
- Peritonsillar abscess, 462t–476t
- Periventricular white matter injury, 522
- Permanent teeth, differences between primary  
 and, 48, 50f
- Permethrin (Acticin, Elimite, Nix), 766, 771,  
 776, 1085  
 for scabies, 217
- Pernicious anemia, 882
- Peroxisomal disorders, 344t
- Perseris. *See* Risperidone
- Persistent complement, vaccine information  
 for, 1t–3t
- Persistent pulmonary hypertension, 189.e1t
- Persistent pulmonary hypertension of the  
 newborn (PPHN), 512–514
- Personal-social skills, 236, 238t–242t
- Personnel, in procedural sedation, 166
- Pertussis, 462t–476t  
 azithromycin for, 820  
 treatment for, 820  
 vaccine, postexposure prophylaxis of,  
 440t–443t
- Pertzye. *See* Pancrelipase
- Pervasive development disorders (PDD),  
 treatment of, 924
- Pervasive developmental disorder not  
 otherwise specified (PDD-NOS),  
 252
- Pexeva. *See* Paroxetine
- Pfizerpen. *See* Penicillin G, aqueous potassium  
 and sodium
- PFT. *See* Pulmonary function tests
- PGI2. *See* Epoprostenol
- PGX. *See* Epoprostenol
- pH  
 determination of, 308–310  
 in urinalysis, 530t–531t
- PHACES syndrome, 210–211
- Phagocytic function, vaccine information for,  
 1t–3t
- Phagocytosis, 417t

- Pharmacology, in endotracheal intubation, 10, 11t–12t
- Pharmacotherapy  
for diarrhea, 329  
for eosinophilic esophagitis, 322  
for gastrointestinal reflux disease, 322  
for malnutrition, 600  
in resuscitation, 5  
for seizures, 586–590
- Pharyngeal mass, 691, 691.e2f
- Pharyngitis  
amoxicillin for, 805  
azithromycin for, 820–821  
strep, 462t–476t  
streptococcal, 862, 1083  
treatment of, 820
- Phase 1, of intoxication, 71
- Phase 2, of intoxication, 71
- Phase 3, of intoxication, 71
- Phase 4, of intoxication, 71
- Phazyme. *See* Simethicone
- Phenazopyridine HCl (Pyridium, Azo-Urinary Pain Relief, Azo-Urinary Pain Relief Maximum Strength), 768, 779, 1086  
adjustment in kidney failure, 1203t–1208t
- Phenergan. *See* Promethazine
- Phenobarbital (Luminal), 774, 1086–1087  
adjustment in kidney failure, 1203t–1208t  
for seizures, 575t–576t  
for status epilepticus, 32t–33t
- Phenothiazine derivative  
chlorpromazine, 866–867  
prochlorperazine, 1105  
promethazine, 1106  
thioridazine, 1161
- Phentolamine mesylate (OraVerse, Regitine), 777, 779, 1087
- Phenylephrine, 18t
- Phenylephrine HCl (Vazculep, Neo-Synephrine, Biorphen), 776, 1088–1089
- Phenylketonuria (PKU), 341t–342t
- Phenytek. *See* Phenytoin
- Phenytoin (Dilantin, Dilantin Infatab, Phenytoin Infatab, Phenytek), 770, 778, 1089–1090  
for seizures, 575t–576t  
for status epilepticus, 32t–33t
- Phenytoin Infatab. *See* Phenytoin
- Pheochromocytoma, 279
- PhosLo. *See* Calcium acetate
- Phoslyra. *See* Calcium acetate
- PHOS-NaK. *See* Phosphorus supplements
- Phospha 250 Neutral. *See* Phosphorus supplements
- Phosphate disturbances, 308
- Phosphodiesterase type-5 inhibitors, for pulmonary hypertensive crisis, 25
- Phosphorus  
formulation recommendations for, 616t  
recommended intakes, 606t  
reference values for, 736t–743t
- Phosphorus supplements (K-PHOS Neutral, Av-Phos 250 Neutral, Phospha 250 Neutral, PHOS-NaK, Sodium Phosphate, Potassium Phosphate), 774, 778, 780, 1090–1091
- Phospho-Trin 250 Neutral. *See* Phosphorus supplements
- Phototherapy, 517, 517f, 517t  
for atopic dermatitis (eczema), 231
- PHQ-2. *See* Patient Health Questionnaire-2
- PHQ-9. *See* Patient Health Questionnaire-9
- Phthirus pubis*, permethrin for, 1085
- Physeal fractures, 48
- Physical abuse, 62–64, 63.e1f, 63.e1f, 63.e2f, 63.e2f
- Physical examination  
in adolescents, 124–128  
in cyanosis, 511  
in food allergy, 411–412  
primary survey, 41  
for sedation, 165, 165f
- Physical maturity, 507, 507.e1f
- Physical Status Classification, 165, 166t
- Physician Orders for Life-Sustaining Treatment (POLST) forms, 643
- Physicians EZ Use B-12. *See* Cyanocobalamin/vitamin B<sub>12</sub>
- Physiologic gynecomastia, in males, 126
- Physiologic response, of infant, in pain assessment, 151
- Physostigmine salicylate (Antilirium), 767, 1091
- Phytonadione (vitamin K<sub>1</sub>, Mephyton), 775, 1091–1092  
recommended intakes, 603t–604t
- PICO process, 746
- PID. *See* Pelvic inflammatory disease
- Pigmentation, disorders of, 233–234
- Pilocarpine HCl (Isopto Carpine, Vuity, Salagen, Pilopine HS), 773, 778, 780, 1092–1093
- Pimecrolimus (Elidel), 771, 1093
- Pin-Away. *See* Pyrantel pamoate
- Pink Bismuth. *See* Bismuth subsalicylate
- Pinworms, 1018
- Piperacillin (Pipracil), 778  
adjustment in kidney failure, 1197t–1203t
- Piperacillin with tazobactam (Zosyn), 783, 1093–1094  
adjustment in kidney failure, 1197t–1203t
- Pitressin. *See* Vasopressin
- Pityriasis lichenoides chronica (PLC), 234–235
- Pityriasis lichenoides et varioliformis acuta (PLEVA), 234–235
- Pityriasis rosea, 214–215
- Pityriasis versicolor. *See* Tinea versicolor
- Pityriasis (tinea) versicolor, 1133, 1156
- Pivot 1.5 Cal formula, 613t–614t
- Placebo effect, 747
- Plague, 1001  
treatment for, 1001

- Plantar surface, 507.e1f
- Plantar warts, 213
- Plaque, 209
- Plaque psoriasis, treatment of, 927
- Plaquenil. *See* Hydroxychloroquine
- Plasbumin. *See* Albumin
- Plasmanate, 297t
- Plasma/platelet products, 2t
- Plasminogen deficiency, 397t
- Plastic fractures, 48
- Platelet function
  - evaluation of, 389–390
  - impaired, 384–387
    - causes of, 384, 385t–386t
- Platelet Function Analyzer-100 (PFA-100) system, 390
- Platelet size, in thrombocytopenia, 384
- Platelet transfusions, recommended intervals
  - between administration, 2t
- Platelets, 402t–403t
  - age-specific values, 406t
  - aggregation of, 390
- PLC. *See* Pityriasis lichenoides chronica
- Pleural fluid, 735.e1t
- PLEVA. *See* Pityriasis lichenoides et varioliformis acuta
- Plexus injuries, brachial, 523t
- Plus disease, 526
- PNES. *See* Psychogenic nonepileptic seizure
- Pneumatosis intestinalis, 698, 699f
- Pneumococcal conjugate vaccine (PCV13), 425t–430t
  - after HSCT, 1t
  - after solid organ transplant, 1t
  - contraindications and precautions to, 435t–437t
- Pneumococcal disease, children at high risk for, 448, 450f
- Pneumococcal infection, penicillin-resistant, 1083
- Pneumococcal polysaccharide vaccine (PPSV23), 425t–430t
  - after HSCT, 1t
  - after solid organ transplant, 1t
  - incorrectly perceived as contraindications or precautions to, 438t–439t
- Pneumococcal vaccines, for sickle cell disease, 377t
- Pneumocystis*, 488t–490t
- Pneumocystis jirovecii*
  - atovaquone for, 816
  - dapsone for, 888
  - pentamidine isethionate for, 1084
  - primaquine phosphate for, 1103
  - prophylaxis of, 634t–635t
- Pneumonia, 488t–490t
  - community-acquired
    - azithromycin for, 820
    - exacerbation of, 856
  - community-acquired bacterial, 857
  - imaging for, 693, 693.e3f, 695t
  - neonatal, 695
- Pneumonia (*Continued*)
  - Pneumocystis jirovecii* (*carinii*), atovaquone for, 816
  - treatment of, 874
  - vancomycin for, 1180
- Pneumoperitoneum, 697–698
- Pneumothorax, in newborns, 514
- Poison control, 66
- Poison ivy, 228
- Polio vaccine, 425t–430t
  - contraindications and precautions to, 435t–437t
- Polyarteritis nodosa, 716t–719t
- Polyarticular-rheumatoid factor negative, 711t–713t
- Polyarticular-rheumatoid factor positive, 711t–713t
- Polycal, calories of, 610t
- Polychromatophilia, 373.e3f
- Polycin. *See* Bacitracin ± polymyxin B
- Polycitra, 1095–1096
- Polycystic ovary cysts, 287
- Polycystic ovary syndrome (PCOS), 287
  - screening for, 266t
- Polycythemia, 519
- Polyethylene glycol (PEG)-electrolyte solution
  - bowel cleansing products (GoLYTELY, CoLyte, NuLYTELY, TriLyte), 1095–1096
  - for constipation, 1t, 325
- Poly-Iron 150. *See* Polysaccharide-iron complex
- Polymorphism, single nucleotide, 350t–351t
- Polymox. *See* Amoxicillin
- Polymyositis, associated antibody in, 724t
- Polymyxin B, for conjunctivitis, 462t–476t
- Polymyxin B sulfate
  - bacitracin (AK-Poly-Bac Ophthalmic, Double Antibiotic Topical, Polysporin Topical), 41096
  - neomycin sulfate, hydrocortisone (Cortisporin Otic, AK-Spore H.C. Otic, PediOtic, Polytrim Ophthalmic Solution), 769, 777, 1096–1097
  - trimethoprim sulfate and (Polytrim Ophthalmic Solution), 778, 1096
- Polymyxin-neomycin, for otitis externa, 462t–476t
- Polypropylene, characteristics of, 105t
- Polysaccharide vaccines, 423
- Polysaccharide-iron complex (EZFE 200, Poly-Iron 150, iFerex 150, NovaFerrum, NovaFerrum Pediatric Drops), 980–981
- Polysomnography criteria, for obstructive sleep apnea, 682–683
- Polysporin, 1097
- Polysporin Topical. *See* Bacitracin ± polymyxin B
- Popliteal angle, 507, 507.e1f

- Poractant alfa (Curosurf), 770, 1097, 1152  
Porcelain, reference values for, 736t–743t  
Portal systemic encephalopathy, treatment for, 992  
Posaconazole (Noxafil, Noxafil PowderMix), 1097–1098  
    adjustment in kidney failure, 1197t–1203t  
Positioning, in endotracheal intubation, 10  
Positive predictive value (PPV), 755  
Positive pressure ventilation, noninvasive (NIPPV), 13  
Positive stress, 258  
Postcardiac arrest care, 8  
Posterior ankle splint, 98f, 99  
Postexposure prophylaxis (PEP), 440t–443t, 498  
    rabies, based on animal, 447t  
Postherpetic neuralgia, gabapentin for, 952  
Postmenstrual age, 528.e3  
Postnatal glucose homeostasis, screening for and management of, 506f  
Postpartum depression, 648–650  
    diagnosis of, 648–650  
    epidemiology of, 650  
    evaluation of, 650  
    management of, 650  
    screening test for, 649t  
Postseptal cellulitis, 690.e1f  
Poststreptococcal reactive arthritis, 721  
Posture, 236  
    of newborn, 507, 507.e1f  
Potassium (K+), 308  
    for diabetic ketoacidosis, 267f  
    formulation recommendations for, 616t  
    newborn and, 510t  
    reference values for, 736t–743t  
    in urine, 744t–745t  
Potassium acetate, 1099  
Potassium bicarbonate, 1099  
Potassium chloride, 1099  
Potassium gluconate, 1099  
Potassium iodide (Iosat, SSKI, ThyroShield, ThyroSafe), 766–783, 1098  
Potassium phosphate. *See* Phosphorus supplements  
Potassium supplements, 1099–1100  
Potassium-sparing diuretics  
    for hypertension, 549t–550t  
    spironolactone, 1143  
    triamterene, 1172  
Powerade, 299t  
PPHN. *See* Persistent pulmonary hypertension of the newborn  
PPIs. *See* Proton-pump inhibitors  
PPSV23. *See* Pneumococcal polysaccharide vaccine  
PPV. *See* Positive predictive value  
Pradaxa. *See* Dabigatran etexilate mesylate  
Prader-Willi syndrome, 358  
Pralidoxime chloride (Protopam, 2-PAM), 766, 779  
Pralidoxime chloride + atropine (Duodote, ATNAA), 1100–1101  
Prazosin, 549t–550t  
Prealbumin, reference values for, 736t–743t  
Precedex. *See* Dexmedetomidine  
Precocious puberty, 285t, 287, 289f  
Pred Forte. *See* Prednisolone  
Pred Mild. *See* Prednisolone  
Prednicarbate, 230t  
Prednisolone  
    ophthalmic products (Pred Forte, Pred Mild, Econopred), 1101–1102  
    oral products (Orapred ODT, Pediapred, Prelone, Millipred, Veripred), 777, 1101–1102  
    for pediatric rheumatology, 726t–730t  
    potency of, 277t  
    for status asthmaticus, 22t–23t  
Prednisone  
    for pediatric rheumatology, 726t–730t  
    potency of, 277t  
    stress-dose, 278  
Prednisone (Deltasone, Rayos, Liquid ), 770, 774, 779, 1102–1103  
    for nephrotic syndrome, 557  
    for status asthmaticus, 22t–23t  
Preexposure prophylaxis (PrEP), 497–498  
Pregabalin (Lyrica), for seizures, 575t–576t  
Pregestimil, 611t–612t  
Pregnancy  
    of adolescent, 148–150  
    immunoprophylaxis for, 451  
    recommended element intakes, 606t  
    recommended vitamin intakes, 603t–604t  
    screening guidelines of, 129  
Prelone. *See* Prednisolone  
Premature atrial contraction (PAC), 182t–183t  
Premature infants, growth charts for, 594  
Premature ventricular contraction (PVC), 184t  
Prenatal testing, 149  
Preoperative prophylaxis, 854–855  
Preoxygenation, 9  
PrEP. *See* Preexposure prophylaxis  
Preschooler  
    gastrointestinal bleeding in, 319t  
    pain assessment in, 151, 153f  
    vomiting in, 321t  
Preseptal cellulitis, 690.e1f, 462t–476t  
Pressure support (PS), 14  
Pressure-controlled ventilation (PCV), 14  
Preterm formulas, 611t–612t  
Preterm infants  
    caloric requirements, 511t  
    glucose and, 509  
    guidelines for management of hyperbilirubinemia in, 517t  
    hypoglycemia in, 506f  
    immunoprophylaxis for, 448  
    iron and, 509  
Prevacid. *See* Lansoprazole

- Prevacid SoluTab. *See* Lansoprazole
- Prevalence, 753
- Prevalite. *See* Cholestyramine
- Priapism, in sickle cell disease, 374t–375t
- Prilocaine, 159t
- Prilosec. *See* Omeprazole
- Prilosec OTC. *See* Omeprazole
- Primacor. *See* Milrinone
- Primaquine phosphate, 1103  
for malaria, 462t–476t
- Primary autoimmune neutropenia, 380t–382t
- Primary carnitine deficiency, 847
- Primary survey, 36–39
- Primatene Mist. *See* Epinephrine HCl
- Primaxin IV. *See* Imipenem and cilastatin
- Primidone (Mysoline), 775, 1104  
adjustment in kidney failure, 1203t–1208t
- Primitive reflexes, 247t–248t, 571, 573t
- Principen. *See* Ampicillin
- Prinivil. *See* Lisinopril
- Privigen, preparations for, 778, 970
- ProAir Digihaler. *See* Albuterol
- ProAir HFA. *See* Albuterol
- ProAir RespiClick. *See* Albuterol
- Probe selection, of ultrasound, 76
- Probenecid, 1104–1105
- Probiotics  
for diarrhea, 329  
in NICU, 520
- Procainamide (Procanbid, Pronestyl),  
6t–7t
- Procarbazine, 628t–632t
- Procardia. *See* Nifedipine
- Procedural sedation, 163–170  
definitions of, 163  
discharge criteria of, 168  
goal of, 167  
monitoring of, 166  
pharmacologic agents of, 157t, 167–168,  
167b–168b, 169t  
preparation of, 163–166, 164t  
protocols of, 170, 170.e1t, 171t  
web resources, 171
- Procedures, 75–111  
cardiovascular, 81–90  
gastrointestinal, 92–93  
general guidelines for, 75–76  
genitourinary, 93–96  
musculoskeletal, 96–102  
neurologic, 76–79  
otolaryngologic, 79–81  
pulmonary, 90–92  
skin/dermatologic, 102–111  
ultrasound for, 76
- ProCentra. *See* Dextroamphetamine
- Prochlorperazine (Compro, Compazine), 634t,  
769, 1105  
for palliative care, 645t
- Procrit. *See* Epoetin Alfa
- Proctitis, 1145
- Proctocolitis, infantile, 412
- Proctocort. *See* Hydrocortisone
- Product moment correlation coefficient  
(Pearson *r*), 750t
- Progestin-only pills, 147
- Proglycem. *See* Diazoxide
- Prograf. *See* Tacrolimus
- Prolate. *See* Oxycodone and acetaminophen
- Prolene, characteristics of, 105t
- Promethazine (Phenergan, Promethegan),  
778, 1106
- Promethegan. *See* Promethazine
- Pronto Plus. *See* Pyrethrins with piperonyl  
butoxide
- Properdin, vaccine information for, 1t–3t
- Prophylaxis, postexposure, 440t–443t  
rabies, based on animal, 447t
- Propionic acidemia, 341t–342t
- Propofol, properties of, 167b–168b
- Propranolol (Inderal, Inderal LA, Hemangeol),  
773, 1106–1108  
for hypertension, 549t–550t  
for infantile hemangioma, 211  
for migraine, 584.e1t
- Propylthiouracil (PTU), 779, 1108
- ProSource protein powder, calories of,  
610t
- Prostacyclin. *See* Epoprostenol
- Prostacyclin analogs, synthetic, for pulmonary  
hypertensive crisis, 25
- Prostaglandin E<sub>1</sub>, 794–795, 1108
- Prostaglandin I<sub>2</sub>  
epoprostenol, 919–920  
treprostinil, 1168–1169
- Prosthetic valve endocarditis, treatment for,  
1123
- Prostin VR Pediatric. *See* Alprostadil
- Protamine sulfate, 915  
formulary entry, 1108–1109
- Protein  
allergy/intolerance, 613t–614t  
in cerebrospinal fluid, 743t  
dietary allowances for, 601, 601t  
initiation and advancement of, 615t  
methods to increase, 608, 610t  
in transudate/exudate, 735.e1t  
in urinalysis, 530t–531t  
in urine, 744t–745t
- Protein C deficiency, 397t
- Proteinuria, 553–557  
basic evaluation of, 555b  
causes of, 555b  
definitions of, 553–554  
methods of detection of, 554  
significant, 554
- Prothrombin mutation, 397t
- Prothrombin time (PT), 389
- Protonix. *See* Pantoprazole
- Proton-pump inhibitors (PPIs), for  
gastrointestinal reflux disease, 322
- Protopam. *See* Pralidoxime chloride + atropine
- Protopic. *See* Tacrolimus
- Protozoa, neutropenia and, 380t–382t
- Proventil HFA. *See* Albuterol

- Provera. *See* Medroxyprogesterone
- Proximal tibial osteosarcoma, 707.e2f
- Proximal tubule
- reabsorption, 533
  - tests, 533–534
- Prozac. *See* Fluoxetine hydrochloride
- Pruritus, associated with cholestasis, 869
- Pruritus control, 934
- medications for palliative care, 645t
- Pseudo Carb Pediatric. *See* Carbinoxamine + pseudoephedrine
- Pseudoephedrine (Efidac/24-Pseudoephedrine, Sudafed), 771, 781, 1109–1110
- Pseudomonas infection, treatment of, 852, 858
- Pseudotumor cerebri, acetazolamide for, 787
- Psoriatic arthritis, 711t–713t
- treatment of, 927
- Psychiatry, 648–662
- approach to, 648, 649t
  - changes as death approaches, 644t
  - conditions of children and adolescents, 650–659
    - anxiety disorders, 654–655
    - attention-deficit/hyperactivity disorder, 650–654
    - depressive and mood disorders, 655–657
    - eating disorders, 657–659
    - oppositional defiant disorder, 654
    - substance use disorders, 659  - emergencies in, 659–661
    - aggression or impulsivity, 660–661
    - suicide, 659–660  - mental status exam in, 648
  - pediatric primary care problems, brief interventions for, 648, 650t
  - postpartum depression, 648–650
    - diagnosis of, 648–650
    - epidemiology of, 650
    - evaluation of, 650
    - management of, 650
- Psychogenic headaches, 580b
- Psychogenic nonepileptic seizure (PNES), 585t
- Psychoses, prochlorperazine for, 1105
- Psychosis
- in toxicology, 67.e1t–67.e3t
  - treatment of, 866–867
- Psychosocial development, of adolescents, 1t
- Psychosocial screening tests, 649t
- Psychotropic medications, 652t–653t
- Psyllium (Metamucil, Konsyl, Mucilin, Fiberall), 772, 774–775, 1110
- Puberty
- delayed, 287, 288f
  - precocious, 287, 289f
- Pulmicort. *See* Budesonide
- Pulmicort Flexhaler. *See* Budesonide
- Pulmicort Respules. *See* Budesonide
- Pulmocare formulas, 613t–614t
- Pulmonary arterial hypertension, 831136
- bosentan for, 831
  - iloprost for, 968
- Pulmonary disease, oxygen challenge test findings in, 189.e1t
- Pulmonary ejection murmur (systolic), 174t
- Pulmonary embolism, 26–28
- Pulmonary flow murmur of newborn (systolic), 174t
- Pulmonary function tests (PFT), 664–665
- Pulmonary gas exchange, evaluation of, 663
- Pulmonary hypertension, 919, 1135–1136
- persistent, 189.e1t
  - of newborn, 512–514
  - treatment of, 919
- Pulmonary hypertensive crisis, 25
- Pulmonary hypertensive crisis, emergency management of, 24–26
- Pulmonary procedures, 90–92
- bag-mask ventilation, 91–92
  - metered-dose inhalers and spacer, 90
  - needle cricothyrotomy, 90–91
  - needle thoracostomy, 91
- Pulmonary sling, radiology for, 693
- Pulmonary stenosis (PS), 191t–192t
- Pulmonary vasoconstriction, minimize, 513
- Pulmonary vasodilators
- inhaled, for pulmonary hypertensive crisis, 25
  - for persistent pulmonary hypertension of the newborn, 513
- Pulmonology, 663–687
- web resources for, 685–686
- PulmoSal. *See* Sodium chloride
- Pulmozyme. *See* Dornase alfa
- Pulse
- assessment of, 3
  - palpable, 4–5
- Pulse oximetry, 1f, 663
- for congenital heart disease, 189
- Pulse pressure, 172
- Pulseless ventricular tachycardia, 1182
- vasopressin for, 1182
- Pulsus paradoxus, 172
- Pupillary dilation, phenylephrine HCl for, 1088
- PurAmino Junior formulas, 611t–614t
- Pure white cell aplasia, 380t–382t
- Purulent cellulitis/abscess, 462t–476t
- Pustule, 209
- Pyelonephritis, 462t–476t, 551
- treatment of, 858
  - uncomplicated, 872
- Pyloric stenosis, 700
- Pyogenic granuloma, 212
- Pyrantel pamoate (Reese's Pinworm, Pin-Rid, Pin-X, Pamix), 777–779, 1110–1111
- Pyrazinamide (pyrazinoic acid amide), 779, 1111
- Pyrazinamide + isoniazid + rifampin (Rifater), 779
- Pyrazinoic acid amide. *See* Pyrazinamide

- Pyrethrins with piperonyl butoxide (A-200, Pronto, RID, Klout, Licide, Pynyl), 774, 1112
- Pyridium. *See* Phenazopyridine HCl
- Pyridostigmine bromide (Mestinon, Regonol), 775, 779, 1112
- Pyridoxine (vitamin B<sub>6</sub>), 783, 1112–1113
- Pyridoxine-dependent seizures, pyridoxine for, 1113
- Pyrimethamine (Daraprim), 770, 1113–1114
- Pyrimethamine + sulfadiazine with folinic acid, for toxoplasmosis, 457t–461t
- Pyrimethamine + sulfadoxine (Fansidar), 772
- Pyruvate kinase (PK) deficiency, 369t–370t
- Q**
- Q waves, 179, 180f
- Qbrelis. *See* Lisinopril
- Qnasl. *See* Beclomethasone dipropionate
- Qnasl Children's. *See* Beclomethasone dipropionate
- QRS complex, 174, 176  
wide, in toxicology, 67.e1t–67.e3t
- QTc interval, 176
- Qualifying disabilities, 254
- Quantitative pilocarpine iontophoresis (sweat chloride) test, for cystic fibrosis, 678
- Qudexy XR. *See* Topiramate
- Quelicin. *See* Succinylcholine
- Questions, clinical, 746
- Questran. *See* Cholestyramine
- Questran Light. *See* Cholestyramine
- Quetiapine (Seroquel, Seroquel XR), formulary entry, 1114–1116
- Quick start contraception, 143, 144f, 145b
- QuilliChew, 1026–1029
- QuilliChew ER. *See* Methylphenidate HCl
- Quillivant XR, 1026–1029. *See also* Methylphenidate HCl
- Quinapril, 549t–550t
- Quinidine, 779, 1116–1117  
adjustment in kidney failure, 1203t–1208t  
for malaria, 462t–476t
- Quinine plus doxycycline, for malaria, 462t–476t
- Quinolone  
ciprofloxacin, 871–873  
gatifloxacin, 953  
levofloxacin, 1001–1002  
ofloxacin, 1061
- Quinupristin and dalfopristin (Synercid), 781, 1117–1118
- Quixin. *See* Levofloxacin
- QVAR Redihaler. *See* Beclomethasone dipropionate
- R**
- R wave, 176–179
- Rabies immune globulin (RIG), 2t
- Rabies vaccine, 431t–433t  
contraindications and precautions to, 435t–437t  
postexposure prophylaxis based on animal, 447t  
postexposure prophylaxis of, 440t–443t
- Racism, adolescents and, 115
- Radial artery puncture, 83–86  
catheter placement in, 84, 85f  
ultrasound-guided procedure, 84–85, 86f
- Radial head subluxation (nursemaid's elbow) reduction, 100
- Radiation, exposure, comparative, 687t
- Radiation therapy, vaccine information for, 1t–3t
- Radiocapitellar line, 704
- Radiograph, small opacities on, in toxicology, 67.e1t–67.e3t
- Radiology, 687–729  
for abdomen, 696–702  
  appendicitis, 701  
  bowel obstruction, 700, 700.e2f  
  esophageal foreign bodies, 701  
  gallbladder disease, 701  
  ileus, 700  
  intussusception, 700  
  neonatal enterocolitis, 698, 699f  
  normal, x-ray, 697, 697f  
  pancreatitis, 701–702  
  pneumoperitoneum, 697–698  
  pyloric stenosis, 700  
  trauma, 701, 701.e1f  
for chest, 693–696  
  mediastinal masses, 696, 696t  
  neonatal lung disease, 695, 695f  
  normal anatomy, 693, 693.e1f, 694f  
  pulmonary infections, 693, 693.e2f, 693.e3f, 695t  
choosing the right study, 688, 689t  
for confirming tube placement and line insertion, 708–709  
  in central venous catheter, 708, 708f  
  in endotracheal tube, 709  
  in nasoduodenal tube, 708  
  in nasogastric tube, 708  
  in umbilical line, 708, 709f  
general pediatric principles of, 687–688, 687t  
for genitourinary tract, 702–703  
  congenital hydronephrosis, 702–703  
  nephrolithiasis, 702  
  ovarian pathology, 702  
  testicular pathology, 702  
  urinary tract infection, 702  
  urolithiasis, 702  
for head, 688–690  
  CSF shunt malfunction, 688  
  orbital cellulitis, 690  
  trauma, 688  
for heart, 694f, 696  
musculoskeletal, 703–708

- Radiology (*Continued*)  
bone lesions, 707, 707.e1f, 707.e2f, 707.e3f  
fractures and trauma, 703–704, 703t  
hip disorders, 704–705  
osteomyelitis, 704  
scoliosis, 707  
in suspected nonaccidental trauma, 707–708, 707.e4f  
for neck and airway, 690–693  
aortic arch variants, 693  
cervical spine trauma, 690  
foreign body in, 692  
normal anatomy of, 690f–691f  
pulmonary sling, 693  
tracheoesophageal fistula and esophageal atresia, 692  
vascular rings, 693
- Radionuclide cystourethrography (RNC), 702
- Raltegravir (Isentress, Isentress HD), formulary entry, 773, 1118–1119
- Raniclur. *See* Cefaclor
- Ranitidine HCl (Zantac, Zantac 75, Zantac 150 Maximum Strength), 766t–783t
- Rapamune. *See* Sirolimus
- Rapid autopsy, 646
- Rapid maxillary expansion (RME), for obstructive sleep apnea, 683
- Rapid sequence intubation (RSI), 9–10, 929, 1183
- Rasburicase (Elitek), 771  
formulary entry, 1119  
for hyperuricemia, 625
- Rashes  
neonatal, 226f  
of unknown or inflammatory etiology, 234–235
- Rat bite fever, 1143
- Raynaud phenomenon, 711t–713t, 720
- Rayos. *See* Prednisone
- RBC distribution width (RDW), 365–367
- RBC exchange transfusions, for sickle cell anemia, 373
- RBUS. *See* Renal and bladder ultrasound
- RCDP. *See* Rhizomelic chondrodysplasia punctata
- RCF formula, 613t–614t
- RDS. *See* Respiratory distress syndrome
- Reach Out and Read, web resources, 260
- Reactive airway disease, 800  
aminophylline for, 800
- Reactive arthritis, 720–721
- Reactive erythema, 215, 216f
- Rebetol. *See* Ribavirin
- Recall bias, 749
- Receptive anal intercourse, screening guidelines by, 129
- Receptive vaginal intercourse, screening guidelines by, 127–129
- Receptive/expressive language disorder, 250
- Recombinant vaccines, 423
- Recovery phase, of acute tubular necrosis, 562
- Recovery position, in spontaneous respirations, 8
- Rectal enema, 830, 906
- Rectal foam aerosol (Cortifoam), 963
- Rectal infections, 853
- Rectal suppository, 829, 1043
- Rectiv. *See* Nitroglycerin
- Red blood cells (RBCs)  
recommended intervals between administration, 2t  
in urinalysis, 530t–531t
- Red cell aplasia, 368t–369t
- Reduced fasting tolerance, disorders of, 337t, 339, 343t
- Reese's Pinworm. *See* Pyrantel pamoate
- Re-feeding syndrome, 600–601  
management of, 601  
patients at risk of developing, 600–601
- Reference values, 735, 736t–743t
- Refissa. *See* Tretinoin; topical preparations
- Reflex irritability, 507t
- Reflexes  
muscle stretch, 572.e1t  
primitive, 247t–249t, 571, 573t  
rating scale for, 572b  
tendon, 571
- Refractory complex partial seizures, adjunctive therapy for, 1184
- Refractory distress, management of, 645
- Refractory status epilepticus, treatment for, 1000, 1036
- Regitine. *See* Phentolamine mesylate
- Regonol. *See* Pyridostigmine bromide
- Regression  
by least squares, 750t  
multiple, 750t  
nonparametric, 750t
- Rehabilitation, early, for stroke, 574
- Rehabilitation Act, 255
- Rehydralyte, 299t
- Rehydration fluids, 299t  
oral  
for diarrhea, 329  
features of, 608, 614t
- Relative risk (RR), 753
- Relative risk reduction (RRR), 753
- Releuko. *See* Filgrastim
- Rellexii, 1026–1029. *See also* Methylphenidate HCl
- Reltone. *See* Ursodiol
- Remodulin. *See* Treprostinil
- Renal and bladder ultrasound (RBUS), 551, 702
- Renal disease, 368t–369t  
chronic, vaccine information for, 1t–3t
- Renal failure  
guidelines for, 10030  
patients with, opioids for, 156  
treatment of, 920

- Renal osteodystrophy, chronic kidney disease and, 565t
- Renal transplant, 1045
- Renal tubular acidosis, 566–567  
biochemical and clinical characteristics of, 567t
- Renalcal formula, 613t–614t
- Renova. *See* Tretinoin; topical preparations
- Repeat expansion, 350t–351t, 359–360
- Reperfusion therapies, for stroke, 573–574
- Replacement therapy  
for antibody-deficient disorders, 416  
antibody-deficient disorders for, 971  
volume replacement strategy, 298
- Replesta. *See* Cholecalciferol
- Reproductive health, rheumatologic diseases and, 725
- Reproductive justice, adolescents and, 116
- Reptilase time (RT), 389
- Rescue therapy, 1151–1152
- Research  
clinical question, 746  
evidence-based medicine, 746–749  
grid for calculations in clinical studies, 753t  
study design, 752t
- Resectisol. *See* Mannitol
- Resistance, in common organisms, 502.e1–502.e2
- Resource Breeze formulas, 613t–614t
- Respiration  
adequacy of, 8  
spontaneous, 8
- Respiratory acidosis, 310  
etiology of, 316f
- Respiratory alkalosis, 310  
etiology of, 316f
- Respiratory depression, procedural sedation and, 167
- Respiratory diseases, in newborns, 511–514
- Respiratory distress syndrome (RDS), 512, 512t, 695, 695f
- Respiratory effort, 507t
- Respiratory emergencies, allergic, 19
- Respiratory syncytial virus (RSV)  
immunoprophylaxis for, 2t, 431t–433t, 448, 10030
- Respiratory system, changes as death approaches, 644t
- Restasis. *See* Cyclosporine
- Restrictive cardiomyopathy, 197
- Restrictive disease, spirometry and lung volume readings in, 666t
- Resuscitation, 5, 6t–7t  
DNAR orders, 642  
fluids, 5  
neonatal, 503  
algorithm for, 503, 504f
- Retacrit. *See* Epoetin Alfa
- Reticulated lesions, 210
- Reticulocyte index, 365
- Reticulocytes, age-specific counts, 406t
- Retin-A. *See* Tretinoin; topical preparations
- Retina, zone of, 526f
- Retin-A Micro. *See* Tretinoin; topical preparations
- Retinitis, CMV, 870, 948, 1176
- Retinoblastoma (Rb), 620t–621t
- Retinoic acid derivative  
adapalene ± benzoyl peroxide, 790–791  
isotretinoin, 982  
tretinoin, 1169–1170
- Retinoids, topical  
for acne vulgaris, 223t, 224  
formulations and concentrations, 224.e1t
- Retinol. *See* Vitamin A
- Retinopathy, screening for, 266t
- Retinopathy of prematurity (ROP), 524–526  
stages of, 524–526, 525f  
suggested schedule for follow-up  
ophthalmologic examination, 526.e1t  
type 1, 526  
type 2, 526
- Retropharyngeal abscess, 691, 691.e2f, 462t–476t
- Retrovir. *See* Zidovudine
- Return-to-play, 42, 43t
- Return-to-school, 42, 43t
- Revatio. *See* Sildenafil
- Reversal agents, in procedural sedation, 166, 168
- Reverse neuromuscular blockade, glycopyrrolate for, 956
- Reversol. *See* Edrophonium chloride
- Revonto. *See* Dantrolene
- RF. *See* Rheumatoid factor
- r-FLACC scale, 153–154, 155t
- R-Gene 10. *See* Arginine hydrochloride
- RH<sub>0</sub> (D) immune globulin intravenous (human) (WinRho-SDF, Rhophylac, HyperRHO S/D Mini-Dose, HyperRHO S/D Full Dose, RhoGAM Ultra-Filtered Plus, MICRhoGAM Ultra-Filtered Plus), 783, 1120
- Rhabdomyosarcoma, 620t–621t
- Rheumatic fever  
penicillin G for, 1081  
penicillin V potassium for, 1083  
secondary prophylaxis, 1147
- Rheumatoid arthritis  
indomethacin for, 973  
juvenile, treatment of, 861  
treatment of, 1049
- Rheumatoid factor (RF)  
reference values for, 736t–743t  
rheumatologic diseases and, 723
- Rheumatoid nodules, 711t–713t
- Rheumatology, 710–731  
diseases  
clinical characteristics of, 710–722  
laboratory studies for, 722–725  
primary care management of, 725  
medications, 725–731, 726t–730t

- Rhinitis  
infectious, 408  
nonallergic, with eosinophilia syndrome (NARES), 408  
vasomotor/nonallergic, 408
- Rhinitis medicamentosa, 408
- Rhinocort Allergy Nasal Spray. *See* Budesonide
- Rhinocort Aqua Nasal Spray. *See* Budesonide
- Rhinorrhea, 408
- Rhizomelic chondrodysplasia punctata (RCDP), 344t
- RhoGAM Ultra-Filtered Plus. *See* RH<sub>0</sub> (D) immune globulin intravenous (human)
- Rhophylac. *See* RH<sub>0</sub> (D) immune globulin intravenous (human)
- Rib fractures, 44
- Ribavirin (Copegus, Rebetol, Virazole, Ribasphere), 769, 779, 782, 1120–1122
- Riboflavin (vitamin B<sub>2</sub>), 783  
deficiency, 1122  
formulary entry, 1122  
for migraine, 584.e1t  
recommended intakes, 603t–604t  
reference values of, 736t–743t
- Rickets, 868
- RID. *See* Pyrethrins with piperonyl butoxide
- Rifabutin (Mycobutin), 775  
adjustment in kidney failure, 1197t–1203t  
formulary entry, 1122–1123
- Rifadin. *See* Rifampin
- Rifampin (Rifadin, Rimactane), 779  
formulary entry, 1123–1124  
for hardware-associated bone infection, 462t–476t  
for TB, 493
- Rifamycin derivative  
rifampin, 1123–1124  
rifaximin, 1124–1125
- Rifapentine, for TB, 493
- Rifaximin (Xifaxan), formulary entry, 1124–1125
- Right bundle-branch block (RBBB), 186t
- "Rigler sign", 697f
- Rimantadine (Flumadine), 772, 1125
- Risk, relative, 753
- Risk reduction  
absolute, 754  
relative, 753
- Risks, in procedures, 75
- Risperdal. *See* Risperidone
- Risperdal Consta. *See* Risperidone
- Risperidone (Risperdal, Risperdal Consta, Perseris), 780, 1126–1127
- Ritalin. *See* Methylphenidate HCl
- Ritalin LA, 1026–1029. *See also* Methylphenidate HCl
- Rituximab (Rituxan), 419, 628t–632t  
for nephrotic syndrome, 557  
for pediatric rheumatology, 726t–730t
- Rivaroxaban (Xarelto, Xarelto Starter Pack), 398t–399t, 783, 1127–1129
- Rizatriptan benzoate (Maxalt, Maxalt-MLT), formulary entry, 1129
- RME. *See* Rapid maxillary expansion
- RNC. *See* Radionuclide cystourethrography
- Robinul. *See* Glycopyrrolate
- Rocaltrol. *See* Calcitriol
- Rocky Mountain spotted fever, 482t–484t
- Rocuronium (Zemuron), 783, 1130
- Rocuronium-induced moderate blockade, 1146
- Romazicon. *See* Flumazenil
- Rome criteria, for constipation, 1t, 324
- ROP. *See* Retinopathy of prematurity
- Rosadan. *See* Metronidazole
- Roseola infantum, 215
- Ross procedure ("switch procedure"), 204t
- Rotavirus vaccine, 425t–430t  
after HSCT, 1t  
after solid organ transplant, 1t  
contraindications and precautions to, 435t–437t  
incorrectly perceived as contraindications or precautions to, 438t–439t
- Round red blood cells, 373.e1f
- Roundworms, 1018, 1111
- Routine vaccines, for children, in United States, 424, 425t–430t
- Rowasa. *See* Mesalamine
- Roweepra. *See* Levetiracetam
- Roxicet. *See* Oxycodone and acetaminophen
- Roxicodone. *See* Oxycodone
- Roxilox. *See* Oxycodone and acetaminophen
- RoxyBond. *See* Oxycodone
- RR. *See* Relative risk
- RRR. *See* Relative risk reduction
- RSI. *See* Rapid sequence intubation
- RSV. *See* Respiratory syncytial virus
- Rubella, 457t–461t, 477t–481t  
prophylaxis, 418
- Rubella vaccines  
measles, mumps, rubella (MMR) vaccine  
recommended intervals between administration, 2t  
postexposure prophylaxis of, 440t–443t
- Rufinamide (Banzel)  
formulary entry, 1130–1131  
for seizures, 575t–576t
- Ru-Hist D. *See* Brompheniramine with phenylephrine
- RuLox. *See* Aluminum hydroxide with magnesium hydroxide
- Rumack-Matthew nomogram, 71, 72f
- Ruxolitinib, for pediatric rheumatology, 726t–730t
- Ryanodex. *See* Dantrolene
- Rynex PE. *See* Brompheniramine with phenylephrine
- RyVent. *See* Carbinoxamine

## S

- Sabril. *See* Vigabatrin
- Safe infant sleep, 684
- Safety, HEEADSSS assessment, 125
- Salagen. *See* Pilocarpine HCl
- Salicylates, 69t–70t
- Salicylazosulfapyridine. *See* Sulfasalazine
- Saline  
for constipation, 325  
nebulized hypertonic, for bronchiolitis, 676
- Salmeterol (Serevent Diskus), 944–946, 8780
- Salter-Harris classification, of growth plate injury, 703t
- Sal-Tropine. *See* Atropine Sulfate
- Sample size, 751
- Sampling bias, 748
- Sancuso. *See* Granisetron
- Sandifer syndrome, 585t
- Sandimmune. *See* Cyclosporine
- Sandostatin. *See* Octreotide acetate
- Sandostatin LAR Depot. *See* Octreotide acetate
- Sanfilippo syndrome, 344t
- Sarcoidosis, 715
- Saxenda. *See* Liraglutide
- SBIRT. *See* Screening, brief intervention, and referral to treatment
- Scabies, 215–217  
ivermectin for, 986  
permethrin for, 1085
- Scale, 209
- Scandishakes, 613t–614t
- Scar, 209
- Scarf sign, 507, 507.e1f
- Scarlet fever, 221
- SCFE. *See* Slipped capital femoral epiphysis
- Schistocytes (RBC fragments), 372
- Schizophrenia, 1062  
aripiprazole for, 812  
treatment for, 1115, 1126
- School-age children  
gastrointestinal bleeding in, 319t  
pain assessment in, 152  
vomiting in, 321t
- Schwartz equation, 532, 532t
- Scleroderma, 715–720  
associated antibody in, 724t
- SCN1A mutations, 355
- Scoliosis, 707  
spirometry and lung volume readings in, 666t
- Scopolamine, 634t
- Scopolamine hydrobromide (Isopto Hyoscine, Scopace, Transderm Scop), 773, 780, 782  
formulary entry, 1132–1133
- SCRATCH principles, 232
- Screening  
in adolescents, 116–125  
cardiovascular, 208.e1  
developmental, 237–244  
lipids, 207
- Screening (*Continued*)  
metabolic, newborn, 346  
newborn, for congenital adrenal hyperplasia, 274–275  
tests, 245t  
for type 2 diabetes mellitus, 262–263
- Screening, brief intervention, and referral to treatment (SBIRT), 119–121
- Seasonal allergic conjunctivitis, treatment for, 989
- Seasonal allergic rhinitis, 408, 819–820  
azelastine for, 819
- "Seatbelt sign", 45
- Seborrhea, 1133
- Seborrheic dermatitis, 227
- Secondary autoimmune hemolytic anemia, 369t–370t
- Secondary autoimmune neutropenia, 380t–382t
- Secondary red cell aplasia, 368t–369t
- Secondary survey, 37, 38f
- Secretions, medications for palliative care, 645t
- Secretory diarrhea, 328
- Sedation, 75, 987, 1035  
common, 167, 167b–168b, 169t  
conscious, 163  
deep, 163  
dexmedetomidine, 894–895  
dissociative, 163  
droperidol, 909–910  
fentanyl, 932–933  
with mechanical ventilation, 1036  
mild, 163  
moderate, 163  
procedural, 163–170  
definitions of, 163  
discharge criteria of, 168  
goal of, 167  
monitoring of, 166  
pharmacologic agents of, 157t, 167–168, 167b–168b, 169t  
preparation of, 163–166, 164t  
protocols of, 170, 170.e1t, 171t  
web resources, 171  
toxicology with, 68t
- Sediment, in urinalysis, 530t–531t
- Seizures, 583–590, 627  
acetazolamide for, 786  
acute, diazepam for, 899  
adjunctive therapy for, 877, 951  
B6-dependent, 345t  
breakthrough, 574  
caused by ingestions, 67.e1t–67.e3t  
classification of, 586.e1t  
conditions associated with, 355  
gabapentin for, 951  
generalized, 877  
medications for, 645t  
monotherapy for, 877, 1070  
myoclonic, adjunctive therapy for, 877, 951

- Seizures (*Continued*)  
  neonatal, 522  
    evaluation of, 338  
  partial onset  
    adjunctive therapy for, 1069–1070, 1194  
    monotherapy for, 1166  
  pharmacotherapy for, 586–590  
  phenobarbital for, 1086  
  refractory complex partial, adjunctive therapy for, 1162  
  tonic-clonic, adjunctive therapy for, 1166  
  in toxicology, 67.e1t–67.e3t  
  valproic acid for, 1177
- Seldinger technique, 84, 85f
- Selection biases, 748
- Selective serotonin agonist  
  almotriptan malate, 794  
  rizatriptan benzoate, 1129  
  sumatriptan succinate, 1149–1151  
  zolmitriptan, 1193–1194
- Selective serotonin reuptake inhibitors (SSRIs)  
  for depressive disorders, 665  
  escitalopram, 924–925  
  fluoxetine hydrochloride, 940–941  
  fluvoxamine, 946  
  paroxetine, 1079–1080  
  sertraline HCl, 1134–1135  
  trazodone, 1167–1168
- Selenium  
  formulation recommendations for, 616t  
  recommended intakes, 606t
- Selenium sulfide (Selsun Blue), 780, 1133
- Selenium sulfide 2.5%, shampoo, for tinea capitis, 218–219
- Self-help skills, 236
- Self-removal, in foreign body removal from nose, 80
- Sellick maneuver (cricoid pressure), 9
- Selsun Blue. *See* Selenium sulfide
- Senna (Senokot, Senna-Lax, Ex-Lax, Genexa Kids Senna Laxative, Fletcher's Castoria, Lax-Pills), 772, 774  
  for constipation, 1t  
  formulary entry, 1133–1134
- Senna-Lax. *See* Senna
- Senokot. *See* Senna
- Sensitivity, 754
- Sensory examination, 571
- Separation anxiety, 243t–244t
- Sepsis, in newborns, 509
- Septic arthritis, 462t–476t  
  vancomycin for, 1180
- Septic shock, 5, 17t
- Septic thrombosis, treatment for, 1006
- Serevent Diskus. *See* Salmeterol
- Sernivo. *See* Betamethasone
- Seroquel. *See* Quetiapine
- Seroquel XR. *See* Quetiapine
- Serotonergic agents  
  overdose, 69t–70t  
  toxicology with, 68t
- Serotonin (5-HT<sub>3</sub>) antagonists, 634t  
  dolasetron, 906–907  
  granisetron, 956–957  
  ondansetron, 634t  
  risperidone, 1126
- Serpiginous lesions, 210
- Sertraline HCl (Zoloft), 652t–653t, 783, 1134–1135
- Serum acetaminophen, 71
- Serum complement levels, 422t
- Serum ferritin, 367–371
- Serum immunoglobulin levels, 420t
- Serum osmol gap, in toxicology, 67.e1t–67.e3t
- Serum osmolality, 301
- Serum osmolar gap, 313–314
- Sessile osteochondroma, 707.e1f
- 7q11.23 Deletion, 352t
- Severe combined immunodeficiency, 417t
- Severe congenital neutropenia, 380t–382t
- Severe recalcitrant nodular acne, isotretinoin for, 982–983
- Sex assigned at birth, 122t
- Sexual abuse, 64–65
- Sexual development, 284–292
- Sexual health  
  of adolescents, 127–150  
  contraception, 140–149  
  pregnancy, 148–150  
  screening of, for adolescents, 119t  
  sexually transmitted infection  
    evaluation and management, 129–141, 130t–138t  
    screening guidelines by sexual behaviors, 127–130
- Sexual history, of adolescents, 123
- Sexual Maturity Rating, 126, 127f
- Sexual orientation, 122t
- Sexuality  
  HEEADSSS assessment, 120–124  
  terminology and definitions of, 122t
- Sexually transmitted infections (STIs), 462t–476t  
  concern for recent exposure to, 130  
  evaluation and management of, 129–141, 130t–134t, 136t–138t  
  screening guidelines by sexual behaviors, 127–130  
  testing, 64–65
- SfRowasa. *See* Mesalamine
- SGA. *See* Small for gestational age
- Shingles, valacyclovir for, 1175
- Shock  
  definition of, 15–16  
  etiology of, 16  
  management of, 15–19, 17t  
  risk of, 60
- Short stature, 282–284  
  differential diagnosis of, 283f  
  familial, 282t, 283f  
  pathologic, 282
- Shwachman-Diamond syndrome, 368t–369t
- Siblings, 243t–244t

- SIBO. *See* Small intestinal bacterial overgrowth
- Sickle cell anemia, management of, 373–376
- Sickle cell disease, 369t–370t  
 acute management of anemia in, 373–376  
 children with, 574  
 complications of, 374t–375t  
 health maintenance, 377t  
 immunoprophylaxis and, 439
- Significance level, 751
- Significant neurological impairment (SNI), children with, pain assessment in, 152–154, 154t
- Sildec. *See* Carbinoxamine + pseudoephedrine
- Sildenafil (Revatio, Viagra), 779, 782, 1135–1136
- Silhouette sign, of pneumonia, 693, 695t
- Silvadene. *See* Silver sulfadiazine
- Silver sulfadiazine (Silvadene, Thermazene, SSD Cream), 780–781, 1136–1137
- Simethicone (Mylicon, Children's Mylicon, Phazyme, Mylanta Gas, Gas-X), 773, 775, 778, 1137
- Similac Advance, 609t, 611t–612t
- Similac for Diarrhea, 611t–612t
- Similac formulas, 613t–614t
- Similac Neosure, 611t–612t
- Similac Pro-Total Comfort, 611t–612t
- Similac Sensitive, 609t, 611t–612t
- Similac Soy Isomil, 611t–612t
- Similac Special Care Advance, 611t–612t
- Simple febrile seizure, 584–586
- Simple interrupted suture, 104f
- Simply Saline. *See* Sodium chloride
- Single gene disorders, 360–361
- Single gene testing, 350t–351t
- Single maintenance and reliever therapy (SMART), for asthma, 667
- Single nucleotide polymorphism (SNP), 350t–351t
- Sinus rhythm, 176
- Sinusitis, 462t–476t  
 acute, 820, 856  
 acute maxillary, 856, 874  
 azithromycin for, 821  
 differential diagnosis of, 408  
 exacerbation of, 10030  
 treatment of, 861
- Sinusoidal obstructive syndrome (SOS), 637
- Sirolimus (Rapamune), 779, 1137–1138
- Sjögren syndrome, 720  
 associated antibody in, 724t
- Skeletal survey, 63
- Skin  
 examination of, 126  
 in headaches, 581.e1t  
 of newborn, 507.e1f  
 rheumatologic diseases and, 725
- Skin infections, 212–221  
 bacterial, 220–221  
 fungal, 218–220
- Skin infections (*Continued*)  
 parasitic, 215–218  
 treatment of, 862  
 uncomplicated, 851, 856, 874  
 viral, 212–215
- Skin lesions  
 autoimmune and allergic, 235.e1  
 primary, 209  
 secondary, 209  
 shapes and arrangement of, 209–210
- Skin pigmentation alterations, 355
- Skin staples, for laceration repair, 107
- Skin syndromes, 411–412
- Skin testing  
 for drug allergy, 414  
 for food allergy, 412  
 tuberculin, 111
- Skin/dermatologic procedures, 102–111  
 basic laceration repair, 103–108, 104f, 105t  
 immunization and medication administration, 102–103  
 incision and drainage of abscess, 108–111, 109f  
 tick removal, 111  
 tuberculin skin test placement, 111
- Sklice. *See* Ivermectin
- SLE. *See* Systemic lupus erythematosus
- Sleep, infant and child, 683–684
- Sleep apnea, obstructive, 681–683  
 clinical presentation of, 682  
 daytime symptoms of, 682  
 definition of, 681  
 diagnosis of, 682–683  
 long-term complications of, 682  
 nighttime symptoms of, 682  
 polysomnography criteria for, 682–683  
 risk factors for, 682  
 symptoms and signs of, 682b  
 treatment of, 683
- Sleep disorders, childhood, 686.e1
- Sleep duration, 683, 684t
- Sleep medicine, 663–687  
 web resources for, 685–686
- Sleep-related infant death, 683–684  
 definition, 683  
 epidemiology of, 683–684  
 safe infant sleep, 684
- Slipped capital femoral epiphysis (SCFE), imaging for, 705.e1f, 705
- Slo-Niacin. *See* Niacin
- Slow dose decrease, for tapering, 162
- Slow Iron. *See* Ferrous sulfate
- Small bowel bacterial overgrowth, diarrhea vs., 328t
- Small bowel fluid, 301t
- Small for gestational age (SGA), 506, 506f
- Small intestinal bacterial overgrowth (SIBO), treatment for, 1124
- SMART. *See* Single maintenance and reliever therapy
- Smith-Lemli-Opitz syndrome, 344t

- SNI. *See* Significant neurological impairment
- SNP. *See* Single nucleotide polymorphism
- Social anxiety disorder  
  escitalopram for, 924  
  paroxetine for, 1079
- Social media, 118
- Social skills, 238t–242t
- Sociocontextual factors, adolescents and, 125
- Sodium, 301–307  
  formulation recommendations for, 616t  
  newborn and, 510t  
  reference values for, 736t–743t  
  regulation, disorders of, 280–281, 280t  
  in urine, 744t–745t
- Sodium benzoate  
  for metabolic disease, 345–346  
  for nonketotic hyperglycinemia, 346
- Sodium bicarbonate (NaHCO<sub>3</sub>, Neut), 6t–7t, 776, 1138–1139  
  for hyperkalemia, 311f  
  rehydration fluids, 297t
- Sodium channel defects (*SCN1A* mutations), 355
- Sodium chloride, inhaled preparations  
  (Hypersal, Nebusal, PulmoSal, Simply Saline, Ocean, Ayr Saline, Ayr Nasal Mist Allergy/Sinus), 767, 773, 777, 780
- Sodium docusate, for constipation, 1t
- Sodium phenylacetate, for metabolic disease, 345–346
- Sodium phenylacetate and sodium benzoate (Ammonul)  
  adjustment in kidney failure, 1203t–1208t  
  formulary entry, 1140
- Sodium phosphate. *See* Phosphorus supplements
- Sodium phosphate (Fleet Enema, Fleet Pedia-Lax, Fleet Enema Extra, GoodSense Enema, LaCrosse Complete, OsmoPrep), 772, 777  
  for constipation, 1t  
  formulary entry, 1141
- Sodium polystyrene resin, for hyperkalemia, 311f
- Sodium polystyrene sulfonate (SPS, Kayexalate and Kionex), 774, 780, 1141–1142
- Sodium retention, chronic kidney disease and, 565t
- Sodium wasting, chronic kidney disease and, 565t
- Soft tissue infection, azithromycin for, 821
- SolCarb, calories of, 610t
- Solid organ transplant, vaccinations after, 1t, 445
- Solodyn. *See* Minocycline
- Solu-Cortef. *See* Hydrocortisone
- Solu-Medrol. *See* Methylprednisolone
- Soluspan. *See* Betamethasone
- Solute fluid deficit (SFD), 305
- Soolantra. *See* Ivermectin
- SOS. *See* Sinusoidal obstructive syndrome
- Soy formulas, 610t–612t
- Spacer, metered-dose, use of, 90
- Specific gravity, in urinalysis, 530t–531t
- Specificity, 754
- Specimen collection, for blood culture, 498–499
- Speech sound disorders, 250
- Spherocytes, 372
- Spherocytosis, 373.e1f
- Sphingolipidoses, 344t
- Spinal cord compression, 626
- Spinal cord injuries, 571  
  acute, 1029
- Spine sign, of pneumonia, 693
- Spiriva HandiHaler. *See* Tiotropium
- Spiriva Respimat. *See* Tiotropium
- Spirometry, for children, 664–665, 665f  
  definitions, 665, 666f  
  interpretation of, 665, 666t
- Spirolactone (Aldactone, CaroSpir), 766  
  adjustment in kidney failure, 1203t–1208t  
  formulary entry, 1142–1143  
  for hypertension, 549t–550t
- Spleen, immunodeficiency and, 417t
- Splenic sequestration, 374t–375t
- Splinting  
  ankle stirrup, 98f, 99–100  
  basic, 96–97  
  long arm posterior, 97, 98f  
  posterior ankle, 98f, 99  
  postsplint care, 97  
  sugar tong forearm, 98f, 99  
  thumb spica, 98f, 99  
  ulnar gutter, 98f, 99  
  volar, 98f, 99
- Spooning, of nails, 233
- Sporanox. *See* Itraconazole
- Sporotrichosis, potassium iodide for, 1099
- Sports  
  allowances for cardiac lesions, 208  
  cardiovascular screening, 208
- Spot urine, 534  
  test, 377t
- Spritam. *See* Levetiracetam
- SPS. *See* Sodium polystyrene sulfonate
- Square window, 507, 507.e1f
- SSD Cream. *See* Silver sulfadiazine
- SSKI. *See* Potassium iodide
- SSRIs. *See* Selective serotonin reuptake inhibitors
- Stadol. *See* Butorphanol
- Staph scalded skin syndrome, 220–221
- Staphylococcal endocarditis, treatment for, 1047
- Staphylococcus aureus* infections, treatment for, 1123
- Staples, skin, for laceration repair, 107
- Statistical tests, 749–751, 750t  
  power of, 751  
  significance level, 751  
  terminology, 751

- Stature  
 conditions, 353–354  
 short, 282–284
- Status asthmaticus, 963  
 emergency management of, 22–24, 22t–23t
- Status epilepticus, 574  
 diazepam for, 899  
 emergency management of, 32, 32t–33t  
 phenobarbital for, 1086  
 phenytoin for, 1089  
 refractory, 1000, 1036  
 treatment for, 899
- Stem cell transplant, 379. *See also*  
 Hematopoietic stem cell  
 transplantation
- Stepwise approach, for asthma, 671f–672f, 674f
- Stereotypies (mannerisms), 585t
- Steroids  
 antiemetic agent, 634t  
 for eosinophilic esophagitis, 322  
 for migraine, 581  
 stress-dose, 278, 278t, 278b  
 topical, for atopic dermatitis (eczema), 229–231
- Sterol synthesis disorders, 344t
- Stevens-Johnson syndrome, 232–233
- Stimate. *See* Desmopressin acetate
- Stimulant laxatives, for constipation, 1t
- STIs. *See* Sexually transmitted infections
- Stomach Relief. *See* Bismuth subsalicylate
- Stomach Relief Extra Strength. *See* Bismuth subsalicylate
- Stomach Relief Max St. *See* Bismuth subsalicylate
- Stomatitis, 1145
- Stool osmolar gap, 328
- Stool softeners, for constipation, 1t
- Storage disorder, neutropenia and, 380t–382t
- Store-brand diabetic nutritional drink formula, 613t–614t
- Stranger anxiety, 243t–244t
- Strattera. *See* Atomoxetine
- Strength  
 motor examination and, 570  
 rating scale, 571b
- Strep pharyngitis, 462t–476t
- Streptococcal pharyngitis, 862, 1083
- Streptococcus pneumoniae*, resistance in, 502.e1
- Streptokinase (Streptase), 781
- Streptomycin sulfate, 1143  
 adjustment in kidney failure, 1197t–1203t
- Stress ulcer, 1145
- Stroke, 572–574, 573b  
 risk factors and initial investigations for, 573.e1t  
 in sickle cell disease, 374t–375t
- Stromectol. *See* Ivermectin
- Strongyloidiasis, ivermectin for, 986
- ST-segment, 179, 180f
- Study designs, 752t
- Stupor  
 emergency management of, 29  
 treatment for, 1003
- Stuttering, 250
- Subcutaneous immunotherapy, for asthma, 667
- Subcutaneous injections, 102–103
- Subcutaneous tissue infections, 922  
 treatment of, 1021
- Subdermal implant, 141–147
- Sublimaze. *See* Fentanyl
- Subluxation, 51  
 radial head, 100
- Submandibular cellulitis, 462t–476t
- Substance identification, toxicology and, 66
- Substance P receptor antagonists, 634t
- Substance use  
 disorders, 121, 122t, 659  
 history, 1t
- Subunit vaccines, 423
- Subvenite. *See* Lamotrigine
- Succimer (Chemet, DMSA [dimercaptosuccinic acid]), 769, 771  
 formulary entry, 1143–1144  
 for lead poisoning, 73
- Succinylcholine (Anectine, Quelicin), 767, 779, 1144–1145
- Sucralfate (Carafate), 768, 1145–1146
- Sucrose (Sweet-Ease), for neonates, 158–161
- Sudafed. *See* Pseudoephedrine
- Sugammadex (Bridion), formulary entry, 1146
- Sugar tong forearm splint, 98f, 99
- Suicide, 659–660  
 diagnosis of, 659  
 epidemiology of, 659  
 HEEADSSS assessment, 123–125  
 safety plan for, 661t  
 screening and assessment of, 660f
- Sulfacetamide sodium ophthalmic (AK-Sulf, Bleph-10, Ocusulf-10), 766, 768, 777, 1146–1147
- Sulfadiazine, formulary entry, 1147
- Sulfamethoxazole and trimethoprim (Trimethoprim-sulfamethoxazole, Co-Trimoxazole, TMP-SMX, Bactrim, Bactrim DS, Sulfatrim Pediatric Suspension, Septa), 768–769, 780–782  
 for acne vulgaris, 224  
 adjustment in kidney failure, 1197t–1203t  
 formulary entry, 1148  
 for oncology patients, 634t–635t
- Sulfasalazine (Azulfidine, Azulfidine EN-tabs, Salicylazosulfapyridine), 768, 780  
 formulary entry, 1149  
 neutropenia and, 380t–382t  
 for pediatric rheumatology, 726t–730t
- Sulfate salt, 1192
- Sulfatrim Pediatric Suspension. *See* Sulfamethoxazole and trimethoprim
- Sulfite oxidase deficiency, 345t

- Sulfonamide derivative  
  sulfacetamide sodium ophthalmic,  
    1146–1147  
  sulfadiazine, 1147  
  sulfamethoxazole and trimethoprim, 1148
- Sulfonylureas  
  with metformin, 1024  
  overdose, 69t–70t
- Sumatriptan succinate (Imitrex, Imitrex STAT  
  dose, Sumavel Dose Pro, Zembrace  
  SymTouch, Tosymra, Onzetra Xsail,  
  Alsuma), 767, 773, 1149–1151
- Sumavel Dose Pro. *See* Sumatriptan succinate
- Sumycin. *See* Tetracycline HCl
- Sunkist Vitamin C. *See* Ascorbic acid
- Superinfection, eczema herpeticum, 231
- Superior mediastinal syndrome, 627
- Superior vena cava syndrome, 627
- Suplena formulas, 613t–614t
- Supplemental O<sub>2</sub>, 511
- Support ventilation, 14
- Supportive care  
  for bronchiolitis, 676  
  for stroke, 573
- Suprapubic bladder aspiration, 94–96, 95f–96f
- Suprapubic percutaneous aspiration, for urine  
  collection, 550
- Supraventricular arrhythmias, 184f
- Supraventricular tachycardia (SVT), 182t–183t  
  adenosine for, 791  
  treatment of, 791  
  vagal maneuvers for, 81–82
- Suprax. *See* Cefixime
- Surfactant  
  beractant (Survanta), 781, 828, 1151  
  calfactant (Infasurf), 773, 843,  
    1151–1152  
  exogenous, for newborns, 511  
  lucinactant (Surfaxin), 781, 1013  
  poractant alfa (Curosurf), 770, 1097,  
    1152
- Surfak. *See* Docusate
- Surgery, for hydrocephalus, 577
- Surgical gut chromic, characteristics of, 105t
- Surgical gut plain, characteristics of, 105t
- Surgical prophylaxis, treatment of, 922
- Surgilene, characteristics of, 105t
- Surgilon, characteristics of, 105t
- Surveillance, developmental, 237
- Sustol. *See* Granisetron
- Suturing, 103–107  
  absorbable, 105t  
  basic, 103, 104f  
  guidelines for, 105t  
  nonabsorbable, 105t
- SVT. *See* Supraventricular tachycardia
- Sweat, 301t
- Sweat chloride test, for cystic fibrosis, 678
- Sweet-Ease, 158–161
- Symbicort. *See* Budesonide and formoterol
- Symdeko. *See* Tezacaftor and ivacaftor
- Symjepi. *See* Epinephrine HCl
- Symmetrel. *See* Amantadine hydrochloride
- Sympathomimetics, toxicology with, 68t
- Sympazan. *See* Clobazam
- Synagis. *See* Palivizumab
- Synchronized intermittent mandatory  
  ventilation (SIMV), 14
- Syncope, 585t
- Syndros. *See* Dronabinol
- Synercid. *See* Quinupristin and dalfopristin
- Synovial fluid, 735, 735.e1t
- Synthetic cannabinoids, 69t–70t
- Synthetic function, laboratory studies for, 329
- Synthroid. *See* Levothyroxine
- Syphilis, 457t–461t  
  evaluation and management of, 129–139,  
    130t–134t  
  management of, 130t–134t  
  penicillin G for, 1081  
  primary, 136t–138t  
    diagnostic features and management  
      of, 136t–138t
- Systemic fungal infections, amphotericin B,  
  liposomal for, 809
- Systemic juvenile idiopathic arthritis,  
  711t–713t
- Systemic lupus erythematosus (SLE), 713–714,  
  724t  
  ACR criteria of, 713  
  clinical manifestations of, 713  
  common autoantibodies of, 714  
  drug-induced, 714  
    associated antibody in, 724t  
  epidemiology of, 713  
  neonatal, 714–715  
  renal involvement of, 714  
  SLICC criteria of, 713  
  treatment for, 714  
  treatment of, 965
- Systemic mastocytosis, 881
- Systolic heart murmurs, 175b
- Systolic sounds, 172, 173b
- T**
- T lymphocyte, vaccine information for, 1t–3t
- t* test, 750t
- T wave, 174, 180t
- T4 (triiodothyronine), 269t
- Tachyarrhythmia, 4–5
- Tachycardia, 182t–183t  
  pulseless ventricular, vasopressin for,  
    1182  
  in toxicology, 67.e1t–67.e3t
- Tachypnea, in toxicology, 67.e1t–67.e3t
- Tacrolimus (Hecoria, Prograf, Astagraf XL,  
  Envarsus XR, Protopic, FK506), 761,  
  772–773, 778–779, 1153–1154
- Tagamet. *See* Cimetidine
- Takayasu arteritis, 716t–719t
- Tambocor. *See* Flecainide acetate
- Tamiflu. *See* Oseltamivir phosphate
- Tanner staging, 126, 127f

- TaperDex. *See* Dexamethasone
- Target cells, 372
- Targeted mutation analysis, 350t–351t
- Targeted screening, 207
- Targetoid lesions, 210
- Tarpeyo. *See* Budesonide
- Tay-Sachs disease, 344t
- Tazarotene (Arazlo, Fabior, Tazorac), 1155  
formulations and concentrations, 224.e1t
- Tazicef. *See* Ceftazidime
- Tazidime. *See* Ceftazidime
- Tazobactam, piperacillin with, 1093–1094
- Tazorac. *See* Tazarotene
- Taztia XT. *See* Diltiazem
- TB. *See* Tuberculosis
- TBI. *See* Total body irradiation
- Tdap. *See* Tetanus and diphtheria toxoids with acellular pertussis
- Teardrop cells, 372
- Teflaro. *See* Ceftaroline fosamil
- Tegretol. *See* Carbamazepine
- Tegretol-XR. *See* Carbamazepine
- Telogen effluvium, 221–222
- Temper tantrums, 243t–244t
- Temperature, conversion formulas for, 735
- Tempra. *See* Acetaminophen
- Tendon reflexes, 571
- Tenex. *See* Guanfacine
- Tenormin. *See* Atenolol
- Tensilon. *See* Edrophonium chloride
- Teratogen, 843, 983
- Terazosin, 549t–550t
- Terbinafine (Lamisil, Lamisil AT)  
formulary entry, 1155–1156  
for fungal infections, 462t–476t
- Terbutaline (Brethine)  
adjustment in kidney failure, 1203t–1208t  
formulary entry, 1156–1157  
for status asthmaticus, 22t–23t
- Terminal illness  
discontinuing interventions in, 643  
DNAR orders in, 642
- Testicles, pathology of, imaging for, 702
- Testosterone, 286t
- "TET spells", 28
- Tetanus and diphtheria toxoids with acellular pertussis vaccine (Tdap), 425t–430t  
after HSCT, 1t  
after solid organ transplant, 1t  
incorrectly perceived as contraindications or precautions to, 438t–439t  
for pregnant women, 451
- Tetanus immunoglobulin (TIG), recommended intervals between administration, 2t
- Tetanus vaccines  
indications for, 447t  
postexposure prophylaxis of, 440t–443t
- Tetany, 842
- Tetracaine, 159t
- Tetracycline derivative  
doxycycline, 908  
minocycline, 1038–1039
- Tetracycline HCl (Sumycin)  
adjustment in kidney failure, 1197t–1203t  
formulary entry, 1157
- Tetrahydrocannabinol. *See* Dronabinol
- Tetralogy spells, propranolol for, 1107
- Tezacaftor and ivacaftor (Symdeko), 681t  
adjustment in kidney failure, 1203t–1208t  
formulary entry, 1158–1159
- $\alpha$ -Thalassemia, 376
- $\beta$ -Thalassemia, 376
- Thalassemia, management of, 376–378
- Thalassemia intermedia, 376
- Thalassemia minor, 376
- $\alpha$ -Thalassemia trait, 376
- The Arc, 250
- The Joint Commission, 762
- Theo-24. *See* Theophylline
- Theochron. *See* Theophylline
- Theophylline (Theo-24, Theochron, Elixophyllin), 771, 781
- Thera-Ear. *See* Carbamide peroxide
- Thermazene. *See* Silver sulfadiazine
- Thiabendazole (Mintezol), 775
- Thiamine (vitamin B<sub>1</sub>), 31, 783  
formulary entry, 1160–1161  
recommended intakes, 603t–604t  
reference values of, 736t–743t
- Thiazide diuretics  
chlorothiazide, 865  
hydrochlorothiazide, 962–963  
for hypertension, 549t–550t  
metolazone, 1031
- Thioguanine, 628t–632t
- Thionamides, neutropenia and, 380t–382t
- Thioridazine (Mellaril), formulary entry, 1161
- Thiotepa, 628t–632t
- Thoracostomy, needle, 91
- Thorazine. *See* Chlorpromazine
- 3 Ps, 232
- 3C Model, of vaccine acceptance, 1, 451
- 3TC. *See* Lamivudine
- Thrombin time (TT), 389
- Thrombocytopenia, 384–387  
approach to, 385t  
bleeding risk with, 384  
causes of, 384  
in chemotherapy patients, 633  
definition of, 384  
evaluation of, 384  
immune, immune globulin for, 971  
management of, 384–387  
neonatal, 387  
neonatal alloimmune (NAIT), 387
- Thrombocytopenic purpura  
idiopathic (ITP), 384–386  
immune (ITP), 418  
thrombotic (TTP), 386
- Thrombocytosis, 387–389  
causes of, 387  
etiology of, 388t  
evaluation of, 388  
treatment of, 388–389

- Thromboelastography (TEG), 389  
Thrombolytic therapy, for stroke, 573–574  
Thrombotic thrombocytopenic purpura (TTP), 386  
Thrombus, management of, 396, 398t–399t  
Thumb spica splint, 98f, 99  
Thymus, normal, 693.e1f  
Thyquidity. *See* Levothyroxine  
Thyroid gland, 268–272  
    examination of, 126  
    function of, 268, 268t  
Thyroid storm, 270  
Thyroid test, 268–269  
    interpretation of, 269, 269t  
Thyroid-stimulating hormone (TSH), 269t  
ThyroSafe. *See* Potassium iodide  
ThyroShield. *See* Potassium iodide  
Thyrotoxicosis  
    potassium iodide for, 1098  
    propranolol for, 1107  
Thyroxine (T)  
    mean values in infants, 269t  
    normal values, 268t  
Thyroxine-binding globulin (TBG), 269t  
Tiagabine (Gabitril), 772  
    formulary entry, 1161–1162  
    for seizures, 575t–576t  
Tiazac. *See* Diltiazem  
Ticarcillin and clavulanate (Timentin), 781  
Tick removal, 111  
Tics, 585t  
Tigan. *See* Trimethobenzamide HCl  
Timolol, topical, for hemangioma, 212  
Tinactin. *See* Tolnaftate  
Tinea capitis, 218–219  
Tinea corporis, 219  
Tinea pedis, 219  
Tinea versicolor, 219–220  
    treatment for, 988  
Tinidazole, for *Giardia*, 462t–476t  
Tiotropium (Spiriva HandiHaler, Spiriva Respimat), formulary entry, 1162–1163  
Tirosint. *See* Levothyroxine  
Tirosint-Sol. *See* Levothyroxine  
Tissue adhesives, for laceration repair, 107–108  
Tissue transglutaminase (TTG), 323  
Tivorbex. *See* Indomethacin  
TMP-SMX. *See* Sulfamethoxazole and trimethoprim  
TOBI. *See* Tobramycin  
TOBI Podhaler. *See* Tobramycin  
Tobramycin (Tobrex, TOBI, TOBI Podhaler, Bethkis, Kitabis Pak, AKTob, Nebcin), 766, 768, 776, 781  
    adjustment in kidney failure, 1197t–1203t  
    formulary entry, 1163–1165  
Tobrex. *See* Tobramycin  
Tocilizumab, 628t–632t  
    for cytokine release syndrome, 628  
    for pediatric rheumatology, 726t–730t  
 $\alpha$ -tocopherol. *See* Vitamin E  
Toddlers, formulas for, 613t–614t  
Toe dislocation reduction, 100–101  
Tofacitinib, for pediatric rheumatology, 726t–730t  
Tofranil. *See* Imipramine  
Toilet training, 243t–244t  
Tolerable stress, 258  
Tolerex formula, 613t–614t  
Tolnaftate (Tinactin), 781, 1165  
Tolsura. *See* Itraconazole  
Tonicity, 301  
Tonsillitis, 805  
    amoxicillin for, 805  
    azithromycin for, 820–821  
Tooth fracture, 51, 51t  
Toothpaste, fluoridated, 605  
Topamax. *See* Topiramate  
Topamax Sprinkle. *See* Topiramate  
Topical acne product  
    adapalene  $\pm$  benzoyl peroxide, 790–791  
    benzoyl peroxide, 826–827  
    tretinoin, 1169–1170  
Topical calcineurin inhibitors, for atopic dermatitis (eczema), 231  
Topical corticosteroids, 230t  
Topical local anesthetics, 158, 159t  
Topical retinoids  
    for acne vulgaris, 223t, 224  
    formulations and concentrations of, 224.e1t  
Topical timolol, for hemangioma, 212  
Topical vasoconstriction, for epistaxis, 81  
Topiramate (Topamax, Topamax Sprinkle, Trokendi XR, Qudexy XR, Eprontia, Topiragen), 781–782  
    formulary entry, 1166–1167  
    for migraine, 584.e1t  
    for seizures, 575t–576t  
Topoisomerase inhibitor, 628t–632t  
Toprol-XL. *See* Metoprolol  
Toradol. *See* Ketorolac  
Tosymra. *See* Sumatriptan succinate  
Totacillin. *See* Ampicillin  
Total body irradiation (TBI), 635  
Total hemolytic complement level (CH<sub>50</sub>), 725  
Total parenteral nutrition (TPN), 633  
Tourette disorder, aripiprazole for, 813  
Tourette's syndrome, 960  
Toxic epidermal necrolysis, 232–233  
Toxic stress, 258  
Toxicity, of local anesthetics, 158  
Toxicology, 66–77  
    acetaminophen intoxication, 71  
    antidotes, 67–71  
    clinical diagnostic aids, 67  
    ingested agents in, 69t–70t  
    ingestions, 67–71  
    initial evaluation of, 66–67  
    web resources, 74  
Toxidromes, 67, 68t  
Toxocariasis, 1018

- Toxoid vaccines, 423
- Toxoplasma gondii  
   atovaquone for, 816–817  
   prophylaxis for, 888
- Toxoplasmosis, 457t–461t, 485t–487t  
   congenital, pyrimethamine for, 1113
- TPN. *See* Total parenteral nutrition
- Trace mineral, 1192–1193
- Tracheoesophageal fistula, radiology for, 692
- Tracheostomy, for obstructive sleep apnea, 683
- Tracleer. *See* Bosentan
- Traction alopecia, 222
- Trained night feeding, 243t–244t
- Tramadol, 156
- Trandate. *See* Labetalol
- Transaminase elevation, dosage modification for, 831
- Transcranial Doppler (TCD), 377t
- Transderm Scop. *See* Scopolamine hydrobromide
- Transdermal patch, 146, 878, 896, 898, 956–957, 1003, 1132
- Transferrin, reference values for, 736t–743t
- Transfusion, results affected by, 346
- Transfusion reactions (ABO or Rh incompatibility), 369t–370t
- Transgender, 122t  
   gender affirmation for, 124t  
   screening guidelines of, 129
- Transient neonatal jaundice,  
   hyperbilirubinemia vs., 332t
- Transient neonatal pustular melanosis, 225
- Transient proteinuria, cause of, 555b
- Transient tachypnea of the newborn (TTN), 514, 695
- Transition services, 254–255
- Transitional formula, 611t–612t
- Transplant-associated thrombotic microangiopathy (TA-TMA), 639.e1–639.e2
- Transplantation  
   kidney, management of, 1153, 1176  
   vaccine information for, 1t–3t
- Transudate, evaluation of, 735, 735.e1t
- Trauma  
   abdominal, 42–47  
   assessment, components of, 47  
   birth, 507  
   blunt thoracic and abdominal, 44–45  
   dental, 48–52  
     components of tooth, 48, 49f  
     dental injuries, 48–51  
     differences between primary and permanent teeth, 48, 50f  
   head, 39–42  
   intrathoracic, 42–47  
     assessment and management pearls, 42–45  
     imaging studies to consider, 45–47  
   long bone, 47–48  
   neck, 39–42
- Trauma (*Continued*)  
   nonaccidental, 62–65  
   ophthalmologic, 52–55  
     chemical injury to eye, 52  
     corneal abrasion, 53  
     eyelid laceration, 54  
     orbital floor fractures, 54–55  
     other instances requiring, 55  
     ruptured globe, 52–53  
     superglue to eye, 53–54  
   pelvic, 42–47  
     assessment and management pearls, 42–45  
     imaging studies to consider, 45–47
- Trauma-informed examination, to adolescent, 124–126
- Traumatic brain injury, amantadine hydrochloride for, 797
- Traumatic fractures, in children, 48
- Traumatic stress, 258
- Travasol (amino acid 8.5%), 297t
- Travel, immunoprophylaxis for, 451
- Traveler's diarrhea, treatment for, 1125
- Trazodone (Desyrel), 770, 1167–1168
- Treponema pallidum*, 130
- Treprostinil (Remodulin, Tyvaso, Tyvaso DPI, Orenitram)  
   adjustment in kidney failure, 1203t–1208t  
   formulary entry, 1168–1169
- Tretinoin  
   with benzoyl peroxide (Twynéo), 1169–1170  
   with clindamycin (Veltin, Ziana), 1169–1170  
   formulations and concentrations, 224.e1t  
   topical preparations (Retin-A, Retin-A Micro, Altreno, Atralin, Avita, Renova, Refissa), 767, 779
- Trial elimination diet, 413
- Triamcinolone  
   injection preparations (Kenalog-10, Kenalog-40, Kenalog-80), 774, 1170–1172  
   nasal preparations (Nasacort Allergy 24HR, Nasal Allergy 24 Hour), 775, 1170–1172  
   potency of, 277t  
   topical preparations (Triderm, Kenalog, Oralone, Trianex, Tritocin), 1170–1172
- Triamcinolone acetonide, potency, 230t
- Triamterene (Dyrenium), 771  
   adjustment in kidney failure, 1203t–1208t  
   formulary entry, 1172  
   for hypertension, 549t–550t
- Trianex. *See* Triamcinolone; topical preparations
- Trichinellosis, 1018
- Trichomonas vaginalis*, evaluation and management of, 130t–134t, 140

- Trichomoniasis, 134t–136t, 485t–487t, 1033  
evaluation and management of, 140  
*Trichostrongylus*, pyrantel pamoate for, 1111  
Trichotillomania, 222  
*Trichuris*, 1018  
Tricyclic antidepressants (TCAs)  
amitriptyline, 802–803  
imipramine, 969  
nortriptyline hydrochloride, 1059  
overdose, 69t–70t  
paroxetine, 1079–1080  
Triderm. See Triamcinolone; topical preparations  
Trifluridine (Viroptic), formulary entry, 1172–1173  
Triglycerides, reference values for, 736t–743t  
Trikafta, 681t. See also Elexacaftor/tezacaftor/ivacaftor  
Trileptal. See Oxcarbazepine  
Trimethobenzamide HCl (Tigan), 781, 1173  
Trimethoprim-sulfamethoxazole. See Sulfamethoxazole and trimethoprim  
Trimox. See Amoxicillin  
Triptans, for migraine, 581  
Trisomy 13. See Patau syndrome  
Trisomy 18. See Edwards syndrome  
Trisomy 21. See also Down syndrome  
differential diagnosis of, 283f  
Tritocin. See Triamcinolone; topical preparations  
Trokendi XR. See Topiramate  
Tromethamine-iodoxamide, 409t–410t  
Trousseau's sign, 312t  
in toxicology, 67.e1t–67.e3t  
*Trypanosoma gambiense*, pentamidine isethionate for, 1084  
*Trypanosoma rhodesiense*, pentamidine isethionate for, 1084  
Trypanosomiasis  
American, 485t–487t  
pentamidine isethionate for, 1084  
TST. See Tuberculin skin test  
TTG. See Tissue transglutaminase  
TTN. See Transient tachypnea of the newborn  
Tube feeding, formulas for, 613t–614t  
Tube feeds, enteral, use of, 608  
Tuberculin skin test (TST), 111, 492b  
Tuberculosis (TB), 462t–476t, 491–494  
diagnosis of, 491–493, 492b  
pyrazinamide for, 1111  
treatment of, 981  
for active, 493–494  
for latent, 493  
vaccines for, 431t–433t  
contraindications and precautions to, 435t–437t  
Tubular disease, cause of, 555b  
Tubular disorders, 566–568  
Tularemia, 1143  
Tumor lysis syndrome, 625–626  
Tumors, 209  
embryonal, 623t  
germ cell, 623t  
gonadal, 620t–621t  
pediatric central nervous system, 623t  
vascular, 210–212, 212.e1t  
Wilms, 620t–621t  
Tums. See Calcium carbonate  
Turner syndrome (45, X), 352t, 357  
differential diagnosis of, 283f  
24-hour urine protein, for proteinuria, 554  
22q11 Deletion syndrome, 357–358  
22q11.2 Deletion syndrome, 352t  
2-PAM. See Pralidoxime chloride + atropine  
Two-tailed tests, 751  
Twynéo. See Tretinoin; with benzoyl peroxide  
Tylenol. See Acetaminophen  
Tylox. See Oxycodone and acetaminophen  
Tympanostomy tubes, 872, 1061  
Type I error, 751  
Type II errors, 751  
Typhlitis, 627  
Typhoid, vaccines for, 431t–433t  
contraindications and precautions to, 435t–437t  
Tyrosine hydroxylase deficiency, 345t  
Tyrosine kinase inhibitors, 628t–632t  
Tyrosinemia (HT), 341t–342t  
Tyvaso. See Treprostinil  
Tyvaso DPI. See Treprostinil
- U**  
U wave, 174  
UAC. See Umbilical arterial catheter  
UAG. See Urine anion gap  
Uceris. See Budesonide  
Ulcer, 209  
Ulcerative colitis, 323  
budesonide for, 834  
mild/moderate, 964, 1022  
Ulcers  
genital, diagnostic features and management of, 136t–138t  
prophylaxis of, 1056  
Ulipristal, 148  
Ulnar gutter splint, 98f, 99  
Ultrasound (US), 688  
for abdomen, 696–697  
advantages and disadvantages of, 689t  
basics of, 76  
of bladder, 94, 96f  
for musculoskeletal, 703  
for procedures, 76  
of soft tissue cellulitis and abscess, 109f  
Ultresa. See Pancrelipase  
Umbilical arterial catheter (UAC), placement of, 708, 709f  
Umbilical artery catheterization, 88–90  
line, procedure for, 88–89, 89f  
Umbilical cord blood  
serum complement levels, 422t  
serum immunoglobulin levels, 420t

- Umbilical lines, placement of, 708, 709f
- Umbilical vein catheterization, 88–90  
line, procedure for, 89f, 90
- Umbilical venous catheter (UVC), placement of, 708, 709f
- Unasyn. *See* Ampicillin/sulbactam
- Uncomplicated chlamydial cervicitis, azithromycin for, 821
- Under-nutrition, 597
- Underpowered study, 748
- Underweight, 594
- Undifferentiated juvenile idiopathic arthritis, 711t–713t
- Unfractionated heparin (UFH), for thrombosis, 398t–399t
- Unithroid. *See* Levothyroxine
- Universal screening, 207
- Unpaired tests, 751
- Unstable hemoglobin, 369t–370t
- Upper airway obstruction, 20–22
- Upper motor neuron findings, 572.e1t
- Urea cycle disorders, 341t–342t
- Urea nitrogen  
reference values for, 736t–743t  
in urine, 744t–745t
- Ureaplasma urealyticum*, 1038
- Urecholine. *See* Bethanechol chloride
- Uremia, chronic kidney disease and, 565t
- Urethral infections, 853
- Urethritis  
azithromycin for, 821  
nongonococcal, evaluation and management of, 130t–134t
- Urgent neurology consultation, 573
- Urinalysis  
components of, 530t–531t  
for proteinuria, 554
- Urinary bladder catheterization, 93–94
- Urinary concentrating defect, chronic kidney disease and, 565t
- Urinary tract infections (UTIs), 547–553  
acute, 853  
classification of, 551  
complicated, 859  
culture-positive, treatment of, 552–553  
diagnosis of, 551  
history of, 547  
imaging for, 551–552, 702  
methods of urine collection in, 550  
physical examination for, 547–548  
risk factors of, 548–550  
treatment of, 1056  
uncomplicated, 856
- Urinary tract mycosis, bladder irrigation for, 808
- Urinary tract obstruction, lower, 523–524
- Urine  
calcium, 534, 534t  
evaluation of, 735, 744t–745t  
osmolality of, 534  
pH of, 534
- Urine anion gap (UAG), 534
- Urine culture, 551
- Urine osmolality, evaluation of, 744t–745t
- Urine output, assessment of, 3
- Urine toxicology screens, 67
- Urobilinogen, 530t–531t
- Urolithiasis, imaging for, 702
- Urologic disorders, 523–524
- Urso 250. *See* Ursodiol
- Urso Forte. *See* Ursodiol
- Ursodeoxycholic acid, for sinusoidal obstructive syndrome, 637
- Ursodiol (Actigall, Urso 250, Urso Forte, Reltone), 766, 782, 1173–1174
- Urticaria, food allergy, 411
- Urticarial reaction, 404t–405t
- US. *See* Ultrasound
- Ustekinumab, for pediatric rheumatology, 726t–730t
- Uterine bleeding, abnormal, 1019
- Uterine compression, 361
- UTIs. *See* Urinary tract infections
- UVC. *See* Umbilical venous catheter
- Uveitis, 711t–713t  
atropine sulfate for, 818
- V**
- Vaccination, rheumatologic diseases and, 725
- Vaccine acceptance, determinants of, 451
- Vaccine hesitancy, 451  
countering, 1b–2b, 451–453, 452b
- Vaccine Information Statements (VIS), 424
- Vaccine refusal, 451
- Vaccines  
additional information about, 1  
administration of, 424–434  
after solid organ transplant, 1t, 445  
for children, 423  
inactivated, 423  
live, attenuated, 423  
mRNA, 423  
nonroutine, 424, 431t–433t  
routine, 424, 425t–430t  
subunit, recombinant,  
polysaccharide, and conjugate, 423  
toxoid, 423  
contraindications and precautions of, 434, 435t–437t  
counseling and communication about, 451–453  
doses, timing and spacing of, 434  
informed consent, 424  
parental concerns about, 1b, 451
- VACTERL association, 508
- Vagal maneuvers, for SVT, 81–82
- Vaginal infections  
diagnostic features of, 134t–136t, 141  
management of, 134t–136t
- Vaginal intercourse, receptive, screening guidelines by, 127–129
- Vaginal ring, 145–147

- Vaginal swab, for gonorrhea, 128
- Vaginosis, bacterial, 875, 1032–1033
- Vagistat-3. *See* Miconazole
- Valacyclovir (Valtrex), 782, 1174–1175  
adjustment in kidney failure, 1197t–1203t  
for herpes, 130t–134t  
for herpes simplex virus, 214  
for oncology patients, 634t–635t  
for VZV, 477t–481t
- Valcyte. *See* Valganciclovir
- Valerate. *See* Betamethasone
- Valganciclovir (Valcyte), 782, 1175–1177  
adjustment in kidney failure, 1197t–1203t  
for CMV, 457t–461t, 477t–481t
- Validity, 754
- Valium. *See* Diazepam
- Valproate sodium, 1177–1178
- Valproic acid (Depakene, Depacon, Stavzor),  
770, 780, 1177–1178  
for seizures, 575t–576t  
for status epilepticus, 32t–33t
- Valsalva maneuver, for supraventricular  
tachycardia, 82
- Valsartan (Diovan), 549t–550t, 770,  
1178–1179
- Valtoco. *See* Diazepam
- Valtrex. *See* Valacyclovir
- Vancocin. *See* Vancomycin
- Vancomycin (Vancocin, Firvanq), 782,  
1179–1181  
adjustment in kidney failure, 1197t–1203t  
for catheter-related bloodstream  
infections, 462t–476t  
for *Clostridium difficile* colitis, 462t–476t  
for hardware-associated bone infection,  
462t–476t  
for mastoiditis, 462t–476t  
for meningitis, 462t–476t  
neonatal dosing, 527t–528t  
for osteomyelitis, 462t–476t  
for purulent cellulitis/abscess, 462t–476t  
for septic arthritis, 462t–476t  
for staph scalded skin syndrome, 221  
for VP shunt infection, 462t–476t
- Vancomycin + ceftriaxone + metronidazole, for  
meningitis, 462t–476t
- Vancomycin + metronidazole, for *Clostridium  
difficile* colitis, 462t–476t
- Vancomycin-resistant enterococci (VRE)  
infections  
resistance in, 502.e1  
treatment for, 1006, 1117
- Vandazole. *See* Metronidazole
- Vanderbilt Diagnostic Rating Scales, 649t, 651
- Vanillylmandelic acid, 279.e1t
- Vantin. *See* Cefpodoxime proxetil
- Varicella (chickenpox), 457t–461t
- Varicella vaccine, 425t–430t  
after HSCT, 1t  
after solid organ transplant, 1t  
contraindications and precautions to,  
435t–437t
- Varicella vaccine (*Continued*)  
incorrectly perceived as contraindications  
or precautions to, 438t–439t  
postexposure prophylaxis of, 440t–443t  
recommended intervals between  
administration of antibody-  
containing products and, 2t
- Varicella zoster virus (VZV), 477t–481t  
antimicrobial prophylaxis against,  
634t–635t  
vaccine (Varivax), recommended intervals  
between administration, 2t  
valacyclovir for, 1175
- Varicella-zoster immune globulin (human)  
(VariZig, VZIG), 782–783, 1181  
recommended intervals between  
administration, 2t
- VariZig. *See* Varicella-zoster immune globulin
- Vascular access, 503
- Vascular anomalies, 210–212, 355–356
- Vascular malformations, 212, 212.e1t
- Vascular rings, radiology for, 693
- Vascular tumors, 210–212, 212.e1t
- Vasculitis, 715, 716t–719t  
associated antibody in, 724t
- Vasoconstriction, pulmonary, minimize, 513
- Vasodilators  
alprostadil, 794–795  
epoprostenol, 919–920  
hydralazine hydrochloride, 962  
for hypertension, 549t–550t  
iloprost, 968  
nitroglycerin, 1056–1058  
nitroprusside, 1058  
pulmonary, 513  
treprostinil, 1168–1169
- Vasodilatory shock, vasopressin for, 1182
- Vasomotor/nonallergic rhinitis, 408
- Vaso-occlusive crisis, 374t–375t
- Vasopressin (Pitressin, Vasostriect, 8-Arginine  
Vasopressin), 766, 778, 1182
- Vasopressin test, 281t
- Vasostriect. *See* Vasopressin
- Vasotec. *See* Enalapril maleate
- Vasovagal syncope, 585t
- Vazculep. *See* Phenylephrine HCl
- VBG. *See* Venous blood gas
- VCUG. *See* Voiding cystourethrography
- Vecuronium bromide (Norcuron), 1182–1183
- Vecuronium-induced neuromuscular  
blockade, 1146
- Veetids. *See* Penicillin V potassium
- Vegetable oil, calories of, 610t
- Vegetarian formulas, 613t–614t
- Veletri. *See* Epoprostenol
- Velocardiofacial syndrome, 357–358
- Veltin. *See* Tretinoin; with clindamycin
- Venofer. *See* Iron sucrose
- Venoocclusive disease (VOD). *See* Sinusoidal  
obstructive syndrome
- Venous blood gas (VBG), 663
- Venous catheter, umbilical, 88

- Venous hum (continuous), 174t  
Venous thromboembolic event (VTE),  
    prevention and treatment of, 885,  
    1127  
Ventavis. *See* Iloprost  
Ventilation, 10–15  
    bag-mask, 8–9, 91–92  
    mechanical, 13–15  
        management of, 14–15  
        modes of, 13–14  
        parameters of, 13, 15t  
        sedation with, 1036  
    modes of, 13–14  
    noninvasive positive-pressure, 13  
Ventolin HFA. *See* Albuterol  
Ventricular arrhythmias, 180, 184t, 185f  
    adult IV for, 801  
Ventricular conduction disturbances, 180,  
    186t  
Ventricular fibrillation, 4, 184t  
    vasopressin for, 1182  
Ventricular hypertrophy  
    criteria for, 181b  
    ECG findings in, 180  
Ventricular septal defect (VSD), 191t–192t  
Ventricular tachycardia, 184t  
Ventriculoperitoneal shunts, infected,  
    462t–476t  
Veramyst. *See* Fluticasone furoate  
Verapamil (Calan, Calan SR, Verelan, Verelan  
    PM, Covera-HS, Isoptin SR),  
    768–769, 773, 782, 1183–1184  
    adjustment in kidney failure, 1203t–1208t  
Verelan. *See* Verapamil  
Verelan PM. *See* Verapamil  
Verkazia. *See* Cyclosporine  
Vertical mattress suture, 104f  
Very low birth weight (VLBW), in newborn  
    assessment, 506  
Very-long-chain acyl-CoA dehydrogenase  
    (VLCAD) deficiency, 343t  
Vesicle, 209  
Vesicoureteral reflux (VUR), 552  
    international classification of, 553f  
Vfend. *See* Voriconazole  
Viactiv Calcium. *See* Calcium citrate  
Viagra. *See* Sildenafil  
Vibramycin. *See* Doxycycline  
Vicks Sinex 12 Hour. *See* Oxymetazoline  
Vicryl, characteristics of, 105t  
Vicryl rapide, characteristics of, 105t  
Victoza. *See* Liraglutide  
Vigabatrin, 1184–1185  
Vigabatrin (Sabril), 780, 1184–1185  
    adjustment in kidney failure, 1203t–1208t  
    for seizures, 575t–576t  
Vigadron. *See* Vigabatrin  
Vimpat. *See* Lacosamide  
Vinblastine, 628t–632t  
Vincristine, 628t–632t  
Vinorelbine, 628t–632t  
Viokace. *See* Pancrelipase  
Violets, in toxicology, 67.e1t–67.e3t  
Viral bronchiolitis, 693.e2f  
Viral infections, of skin, 212–215  
Viramune. *See* Nevirapine  
Viramune XR. *See* Nevirapine  
Virazole. *See* Ribavirin  
Viridans group streptococci, resistance in,  
    502.e1  
Viroptic. *See* Trifluridine  
Viruses, neutropenia and, 380t–382t  
VIS. *See* Vaccine Information Statements  
Visceral larva migrans, 1018  
Visceral leishmaniasis, pentamidine  
    isethionate for, 1084  
Viscous lidocaine, 159t  
Visipaque. *See* Iodixanol  
Vistaril. *See* Hydroxyzine  
Vistide. *See* Cidofovir  
Visual-motor/problem-solving skills, 236,  
    238t–242t  
Vital 1.0 cal and AF 1.2 cal formulas,  
    613t–614t  
Vital High Protein formulas, 613t–614t  
Vital Peptide 1.5 formulas, 613t–614t  
Vital signs  
    monitoring of, in procedural sedation, 166  
    in newborn assessment, 506  
Vitamin A (Aquasol A), 767, 1185  
    for measles, 477t–481t  
    recommended intakes, 603t–604t  
    reference values of, 736t–743t  
Vitamin A deficiency in, malnutrition and,  
    599  
Vitamin B<sub>1</sub>. *See* Thiamine  
Vitamin B<sub>2</sub>. *See* Riboflavin  
Vitamin B<sub>3</sub>. *See* Niacin  
Vitamin B<sub>6</sub>. *See* Pyridoxine  
Vitamin B<sub>6</sub> deficiency, malnutrition and, 599  
Vitamin B<sub>12</sub>. *See* Cyanocobalamin/vitamin B<sub>12</sub>  
Vitamin B<sub>12</sub> deficiency, 881  
    neutropenia and, 380t–382t  
Vitamin B<sub>12</sub> folate, 368t–369t  
Vitamin C. *See also* Ascorbic acid  
    deficiency in, malnutrition and, 598  
Vitamin D, 272  
    deficiency, 273t  
    deficiency in, malnutrition and, 599  
    levels of, interpreting, 602, 605t  
    recommendations for, 603t–604t  
    recommended intake of, 601–602  
    reference values of, 736t–743t  
Vitamin D dependent rickets, 920  
Vitamin D resistant rickets, 920  
Vitamin D<sub>2</sub>, 1186  
Vitamin D<sub>3</sub>, 1186  
Vitamin E (α-tocopherol, Aqueous Vitamin E,  
    Nutr-E-Sol, Aquasol E, Aquavit-E),  
    767, 776, 1186–1187  
    recommended intakes, 603t–604t  
    reference values of, 736t–743t  
Vitamin E deficiency, 1187  
Vitamin K. *See* Phytonadione

Vitamin K deficiency  
 bleeding, phytonadione for, 1091  
 coagulation and, 391  
 Vitamin K<sub>1</sub>, 1091–1092  
 Vitamins  
 for migraine, 584.e1t  
 newborn and, 509  
 recommended intakes, 603t–604t  
 Vitrase. *See* Hyaluronidase  
 Vivonex Pediatric formulas, 613t–614t  
 Vivonex Plus formulas, 613t–614t  
 VLBW. *See* Very low birth weight  
 VLCAD. *See* Very-long-chain acyl-CoA  
 dehydrogenase  
 Voicing My Choices, 644  
 Voiding cystourethrography (VCUG), 552  
 Volar splint, 98f, 99  
 Volume replacement strategy, 298  
 Volume-controlled ventilation (VCV), 14  
 Vomiting, 320–321, 321t  
 dolasetron for, 906  
 granisetron for, 956  
 von Willebrand (vW) disease, 395–396  
 Voriconazole (Vfend), 782, 1187–1189  
 for oncology patients, 634t–635t  
 VoSpire ER. *See* Albuterol  
 VRE. *See* Vancomycin-resistant enterococci  
 VSV. *See* Varicella zoster virus  
 VTE. *See* Venous thromboembolic event  
 Vuity. *See* Pilocarpine HCl  
 Vulvovaginal candidiasis, 134t–136t  
 VUR. *See* Vesicoureteral reflux  
 VWF-containing concentrates, 396  
 Vyvanse. *See* Lisdexamfetamine  
 VZIG. *See* Varicella-zoster immune globulin  
 VZV. *See* Varicella zoster virus

**W**

Warfarin (Coumadin, Jantoven), 769, 773  
 anticoagulation, management of  
 excessive, 398t–399t  
 formulary entry, 1189–1191  
 for Kawasaki disease, 200.e1t  
 management of excessive, 400t  
 medications that influence, 399.e1t  
 overdose, 69t–70t  
 Warm autoimmune hemolytic anemia,  
 369t–370t  
 Warts, 212–213  
 diagnostic features and management of,  
 136t–138t, 141  
 Water, regulation of, disorders of, 280–281,  
 280t  
 Water deficits, free, 305  
 Water deprivation test, 280, 281t  
 WBCs. *See* White blood cells  
 Web resources  
 for adolescent medicine, 150  
 for biostatistics and epidemiology, 757  
 for cardiology, 208  
 for development, behavior, and mental  
 health, 260


Web resources (*Continued*)  
 for endocrinology, 293  
 for evidence-based medicine, 757  
 gastroenterology, 334–335  
 of immunoprophylaxis, 453  
 for neonatology, 528  
 for nephrology, 569  
 for neurology, 593  
 for palliative care, 647  
 for psychiatry, 662  
 for radiology, 709  
 for toxicology, 74  
 Weight  
 conversion formulas for, 735  
 healthy, 595  
 management, 10007  
 overweight, 595  
 rheumatologic diseases and, 725  
 underweight, 594  
 WES. *See* Whole exome sequencing  
 WGS. *See* Whole genome sequencing  
 Wheal, 209  
 Whipworm, 1018  
 White blood cells (WBCs)  
 age-specific values, 406t  
 in cerebrospinal fluid, 743t  
 in urinalysis, 530t–531t  
 WHO Solution, 299t  
 Whole blood, 2t  
 Whole bowel irrigation, 67  
 Whole exome sequencing (WES), 350t–351t  
 Whole genome sequencing (WGS), 350t–351t  
 Wilcoxon matched pairs test, 750t  
 Willebrand disease, desmopressin acetate for,  
 892  
 Williams syndrome, 352t  
 Wilms tumor, 620t–621t  
 Wilson disease, 341t–342t, 1193  
 WinRho-SDF. *See* RH<sub>0</sub> (D) immune globulin  
 intravenous (human)  
 Withdrawal, opioid, signs and symptoms of,  
 523b  
 Wolff-Parkinson-White (WPW), 186t  
 Wong-Baker FACES pain rating scale, 153f  
 World Health Organization (WHO), growth  
 charts and, 594  
 World Professional Association for Transgender  
 Health (WPATH), 123  
 Wound dressing, for burn, 61  
 Wound irrigation, 103  
 WPATH. *See* World Professional Association for  
 Transgender Health  
 Wymox. *See* Amoxicillin

**X**

Xanthochromia, 582b  
 Xarelto. *See* Rivaroxaban  
 Xarelto Starter Pack. *See* Rivaroxaban  
 Xelstrym. *See* Dextroamphetamine  
 Xembify, preparations for, 970  
 Xerostomia, 720  
 pilocarpine HCl for, 1093

- Xifaxan. *See* Rifaximin  
Ximino. *See* Minocycline  
X-linked adrenoleukodystrophy, 344t  
X-linked agammaglobulinemia, 417t  
Xofluza. *See* Baloxavir marboxil  
Xolegel. *See* Ketoconazole  
Xopenex. *See* Levalbuterol  
Xopenex HFA. *See* Levalbuterol  
Xtampza ER. *See* Oxycodone  
Xylocaine. *See* Lidocaine
- Y**
- Yellow fever, vaccines for, 431t–433t  
    contraindications and precautions to, 435t–437t  
Yuzpe regimen, 148
- Z**
- Zafirlukast (Accolate), 766  
Zanamivir, for influenza, 477t–481t  
Zantac 360. *See* Famotidine  
Zantac 360 Maximum Strength. *See* Famotidine  
Zarontin. *See* Ethosuximide  
Zaroxolyn. *See* Metolazone  
Zarxio. *See* Filgrastim  
ZCORT. *See* Dexamethasone  
Zegerid. *See* Omeprazole with sodium bicarbonate  
Zegerid OTC. *See* Omeprazole with sodium bicarbonate  
Zellweger syndrome, 344t  
Zembrace SymTouch. *See* Sumatriptan succinate  
Zemuron. *See* Rocuronium  
Zenatane. *See* Isotretinoin  
Zenpep. *See* Pancrelipase  
Zenedi. *See* Dextroamphetamine  
Zerbaxa. *See* Ceftolozane with tazobactam  
Zerviate. *See* Cetirizine  
Zestril. *See* Lisinopril  
Zetonna. *See* Ciclesonide  
Ziana. *See* Tretinoin; with clindamycin  
Zidovudine (Retrovir, AZT), 779, 1191–1192  
Zidovudine with abacavir and lamivudine (Trizivir), 1191  
Zidovudine with lamivudine (Combivir), 1191  
Zika virus, 457t–461t  
Zimhi. *See* Naloxone  
Zinacef. *See* Cefuroxime  
Zinc  
    deficiency, 1193  
    malnutrition and, 599  
    formulation recommendations for, 616t  
    recommended intakes, 606t  
    reference values of, 736t–743t  
Zinc salts (Galzin, Orazinc), 772, 777, 1192  
Zirgan. *See* Ganciclovir  
Zithromax. *See* Azithromycin  
Zithromax TRI-PAK. *See* Azithromycin  
Zithromax Z-PAK. *See* Azithromycin  
Zmax. *See* Azithromycin  
Zofran. *See* Ondansetron  
Zofran ODT. *See* Ondansetron  
Zolicef. *See* Cefazolin  
Zolmitriptan (Zomig), formulary entry, 1193  
Zoloft. *See* Sertraline; Sertraline HCl  
Zomig. *See* Zolmitriptan  
Zonegran. *See* Zonisamide  
Zonisamide (Zonegran, Zonisade), 783  
    formulary entry, 1194–1195  
    for seizures, 575t–576t  
ZORprin. *See* Aspirin  
Zoster virus, acyclovir for, 789  
Zosyn. *See* piperacillin with tazobactam  
Zovirax. *See* Acyclovir  
Z-scores, resources for determining, 597  
Zyloprim. *See* Allopurinol  
Zymaxid. *See* Gatifloxacin  
Zyprexa. *See* Olanzapine  
Zyprexa Relprev. *See* Olanzapine  
Zyprexa Zydis. *See* Olanzapine  
Zyrtec. *See* Cetirizine  
Zyrtec Allergy. *See* Cetirizine  
Zyrtec Children's Allergy. *See* Cetirizine  
Zyvox. *See* Linezolid

## Pediatric BLS Health Care Providers




### High-Quality CPR

- Rate of 100-120/min
- Compression depth to at least 1/3 anterior-posterior diameter of chest, about 1 1/2 inches (4 cm) in infants and 2 inches (5 cm) in children
- Allow complete chest recoil after each compression
- Minimize interruptions in chest compressions
- Avoid excessive ventilation

Pediatric BLS health care providers algorithm. (From Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2020;142[16\_suppl\_2]:S469–S523. <http://dx.doi.org/10.1161/CIR.0000000000000901>)

“Special thanks to Caitlin O’Brien MD, MPH for her expert guidance with the pediatric resuscitation algorithms.”




**Doses/Details**

**Synchronized Cardioversion:** Begin with 0.5–1 J/kg; if not effective, increase to 2 J/kg. Sedate if needed, but don't delay cardioversion.

**Adenosine IO/IV Dose:** First dose: 0.1 mg/kg rapid bolus (maximum: 6 mg). Second dose: 0.2 mg/kg rapid bolus (maximum second dose 12 mg).

Pediatric tachycardia algorithm. (From Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2020;142[16\_suppl\_2]:S469–S523. <http://dx.doi.org/10.1161/CIR.0000000000000901>)

## Pediatric Bradycardia With a Pulse and Poor Perfusion




**Doses/Details**

**Epinephrine IO/IV Dose:** 0.01 mg/kg (0.1 mg/mL concentration). Max dose: 1 mg (10 mL). Repeat every 3–5 minutes. If IO/IV access not available but endotracheal (ET) tube in place, may give ET dose: 0.1 mg/kg (1 mg/mL concentration, max 2.5 mg).

**Atropine IO/IV Dose:** 0.02 mg/kg. May repeat once after 5 min. Minimum dose 0.1 mg and maximum single dose 0.5 mg.

Pediatric bradycardia algorithm. (From Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2020;142[16\_suppl\_2]:S469-S523. <http://dx.doi.org/10.1161/CIR.0000000000000901>)

## Pediatric Cardiac Arrest



### CPR Quality

- Push hard ( $\geq \frac{1}{2}$  of anterior-posterior diameter of chest) and fast (100–120/min) and allow complete chest recoil
- Minimize interruptions in compressions
- Avoid excessive ventilation
- Rotate compressor every 2 minutes or sooner if fatigued
- If no advanced airway, 15:2 compression-ventilation ratio.

### Shock Energy for Defibrillation

First shock 2 J/kg, second shock 4 J/kg, subsequent shocks  $\geq 4$  J/kg, maximum 10 J/kg or adult dose.

### Drug Therapy

- **Epinephrine IO/IV Dose:** 0.01 mg/kg (0.1 mg/mL concentration). Max dose: 1 mg (10 mL). Repeat every 3–5 minutes. If no IO/IV access, may give endotracheal dose: 0.1 mg/kg (1 mg/mL concentration, max 2.5 mg).
- **Amiodarone IO/IV Dose:** 5 mg/kg bolus during cardiac arrest. Max dose: 300 mg. May repeat up to 3 total doses for refractory VF/pulseless VT.
- **Lidocaine IO/IV Dose:** Initial: 1 mg/kg loading dose. Max dose: 100 mg. Maintenance: 20–50 mcg/kg per minute infusion (repeat bolus dose if infusion initiated >15 min after initial bolus therapy).

### Advanced Airway

- Endotracheal intubation or supraglottic advanced airway
- Waveform capnography or capnometry to confirm and monitor endotracheal tube placement
- Once advanced airway in place give 1 breath every 2–3 seconds with continuous chest compressions

### Return of Spontaneous Circulation (ROSC)

- Pulse and blood pressure
- Spontaneous arterial pressure waves with intra-arterial monitoring

### Reversible Causes

- |                            |                         |
|----------------------------|-------------------------|
| – Hypovolemia              | – Tension pneumothorax  |
| – Hypoxia                  | – Tamponade, cardiac    |
| – Hydrogen ion (acidosis)  | – Toxins                |
| – Hypoglycemia             | – Thrombosis, pulmonary |
| – Hypokalemia/hyperkalemia | – Thrombosis, coronary  |
| – Hypothermia              |                         |

Pediatric cardiac arrest algorithm. (From Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2020;142 [16\_suppl\_2]:S469-S523. <http://dx.doi.org/10.1161/CIR.0000000000000901>)